<SEC-DOCUMENT>0001193125-21-198826.txt : 20210624
<SEC-HEADER>0001193125-21-198826.hdr.sgml : 20210624
<ACCEPTANCE-DATETIME>20210624171307
ACCESSION NUMBER:		0001193125-21-198826
CONFORMED SUBMISSION TYPE:	S-4/A
PUBLIC DOCUMENT COUNT:		96
FILED AS OF DATE:		20210624
DATE AS OF CHANGE:		20210624

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Consonance-HFW Acquisition Corp.
		CENTRAL INDEX KEY:			0001824893
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				981556622
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-256146
		FILM NUMBER:		211043709

	BUSINESS ADDRESS:	
		STREET 1:		1 PALMER SQUARE
		STREET 2:		SUITE 305
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540
		BUSINESS PHONE:		(609) 921-2333

	MAIL ADDRESS:	
		STREET 1:		1 PALMER SQUARE
		STREET 2:		SUITE 305
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4/A
<SEQUENCE>1
<FILENAME>d40894ds4a.htm
<DESCRIPTION>S-4/A
<TEXT>
<HTML><HEAD>
<TITLE>S-4/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on June&nbsp;24, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="right"><B><FONT STYLE="white-space:nowrap">No.&nbsp;333-256146</FONT> </B></P>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT
NO. 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-4</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP.* </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Cayman Islands*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>6770</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">98-1556622</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>1 Palmer Square, Suite 305 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Princeton, NJ 08540 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Tel.:
(609) <FONT STYLE="white-space:nowrap">921-2333</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of
registrant&#146;s principal executive offices) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Gad Soffer
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>1 Palmer Square, Suite 305 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Princeton, NJ 08540 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Tel.:
(609) <FONT STYLE="white-space:nowrap">921-2333</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code,
of agent for service) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies of all communications, including communications sent to agent for service, should be sent to: </I></B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Michael E. Tenta</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Barbara L. Borden</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Ryan M.
James</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>3175 Hanover Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Palo Alto, CA
94304</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Tel: (650) <FONT STYLE="white-space:nowrap">843-5000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Jocelyn M. Arel</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Jacqueline Mercier</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Yasin E.
Akbari</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Goodwin Procter LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>100 Northern Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Boston,
MA 02210</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Tel: (617) <FONT STYLE="white-space:nowrap">570-1000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="justify"><B>Approximate
date of commencement of proposed sale of the securities to the public</B>: As soon as practicable after this <B>registration statement is declared effective and all other conditions to the Business Combination described in the enclosed proxy
statement/prospectus have been satisfied or waived</B>. If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following
box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="justify">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the
Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="justify">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company,&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging growth company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="justify">If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction: </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="justify">Exchange Act Rule <FONT STYLE="white-space:nowrap">13e-4(i)</FONT> (Cross-Border Issuer Tender Offer)&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="justify">Exchange Act Rule <FONT STYLE="white-space:nowrap">14d-l(d)</FONT> (Cross-Border Third-Party Tender Offer)&nbsp;&nbsp;&#9744; </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of Each Class&nbsp;of<BR>Securities to be Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount<BR>to be<BR>Registered(4)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Maximum<BR>Offering Price<BR>Per Unit</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Maximum<BR>Aggregate<BR>Offering Price(1)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>Registration Fee</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">New Surrozen Common Stock(1)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">31,175,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$9.87(5)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$307,697,250</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$33,570 (8)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">New Surrozen Common Stock(2)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">3,211,334</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$11.50 (6)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$36,930,341</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$4,030 (8)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Warrants to purchase New Surrozen Common Stock(3)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">3,211,334</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$1.19 (7)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$3,821,488</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$417 (8)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">37,597,668</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$38,017 (8)(9)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="justify">The number of shares of common stock of New Surrozen (as defined below) being registered represents (i)
9,200,000 Class&nbsp;A ordinary shares underlying units issued in CHFW&#146;s initial public offering, (ii) 434,000 Class&nbsp;A ordinary shares underlying units issued in a private placement simultaneously with the closing of CHFW&#146;s initial
public offering, (iii) 1,541,000 Class&nbsp;B ordinary shares held by CHFW&#146;s initial shareholders and (iv) up to 20,000,000 shares of common stock of New Surrozen (the &#147;New Surrozen Common Stock&#148;), the maximum number of shares that
will be issued to the equityholders of Surrozen in connection with the Business Combination described in the proxy statement/prospectus forming part of this registration statement (the &#147;proxy statement/prospectus&#148;). </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="justify">Represents shares of New Surrozen Common Stock to be issued upon the exercise of (i) 3,066,667 warrants to
purchase Class&nbsp;A ordinary shares underlying units issued in CHFW&#146;s initial public offering (&#147;public warrants&#148;) and (ii) 144,667 warrants to purchase Class&nbsp;A ordinary shares underlying units issued in a private placement
simultaneously with the closing of CHFW&#146;s initial public offering (&#147;private placement warrants&#148; and, together with the public warrants, the &#147;warrants&#148;). The warrants will convert into warrants to acquire shares of New
Surrozen Common Stock in the Domestication. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="justify">The number of warrants to acquire shares of New Surrozen Common Stock being registered represents (i)
3,066,667 public warrants and (ii) 144,667 private placement warrants. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="justify">Pursuant to Rule 416(a) of Securities Act of 1933, as amended (the &#147;Securities Act&#148;), there are
also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="justify">Estimated solely for the purpose of calculating the registration fee, based on the average of the high and
low prices of the Class&nbsp;A ordinary shares of CHFW on the NYSE American LLC on May 10, 2021 ($9.87 per Class&nbsp;A ordinary share). This calculation is in accordance with Rule 457(f)(1) of the Securities Act. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="justify">Represents the exercise price of the warrants. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="justify">Estimated solely for the purpose of calculating the registration fee, based on the average of the high and
low prices of the CHFW public warrants on the NYSE American LLC on May 10, 2021 ($1.19 per warrant). This calculation is in accordance with Rule 457(f)(1) of the Securities Act. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="justify">Calculated by multiplying the proposed maximum aggregate offering price of securities to be registered by
0.0001091. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="justify">Immediately prior to the consummation of the Business Combination,
<FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., a Cayman Islands exempted company (&#147;CHFW&#148;), intends to effect a deregistration under the Cayman Islands Companies Act (2021 Revision) and a domestication under Part
XII of the Delaware General Corporation Law, pursuant to which CHFW&#146;s jurisdiction of incorporation will be changed from the Cayman Islands to the State of Delaware (the &#147;Domestication&#148;). All securities being registered will be issued
by the continuing entity following the Domestication, which will be renamed &#147;Surrozen, Inc.&#148; upon the consummation of the Domestication. As used herein, &#147;New Surrozen&#148; refers to CHFW after giving effect to the Domestication.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman; " ALIGN="justify">Registration fee has previously been paid. </P></TD></TR></TABLE>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="justify"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act or until the registration statement shall become
effective on such date as the SEC, acting pursuant to Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow" ALIGN="justify"><FONT COLOR="#ff4338"><B>The information in this preliminary proxy statement/prospectus is not
complete and may be changed. The registrant may not sell the securities described in this preliminary proxy statement/prospectus until the registration statement filed with the Securities and Exchange Commission is declared effective. This
preliminary proxy statement/prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>PRELIMINARY&#151;SUBJECT TO COMPLETION, DATED
JUNE&nbsp;24, 2021 </B></FONT></P>  <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT FOR </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>EXTRAORDINARY GENERAL MEETING OF <FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS FOR </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>34,386,334
SHARES OF COMMON STOCK AND 3,211,334 WARRANTS OF <FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(AFTER ITS
DOMESTICATION AS A CORPORATION INCORPORATED IN THE STATE OF DELAWARE, </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>WHICH WILL BE RENAMED SURROZEN, INC. IN CONNECTION WITH THE
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>DOMESTICATION DESCRIBED HEREIN) </B></P>
<P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify">The board of directors of <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., a Cayman Islands exempted company
(&#147;CHFW&#148;), has unanimously approved the transactions (collectively, the &#147;Business Combination&#148;) contemplated by that certain Business Combination Agreement, dated April&nbsp;15, 2021 (as may be amended, supplemented or otherwise
modified from time to time, the &#147;Business Combination Agreement&#148;), by and among CHFW, Perseverance Merger Sub Inc., Inc., a Delaware corporation (&#147;Merger Sub&#148;), and Surrozen, Inc., a Delaware corporation (&#147;Surrozen&#148;), a
copy of which is attached to this proxy statement/prospectus as Annex A, including the domestication of CHFW as a Delaware corporation (the &#147;Domestication&#148;). As described in this proxy statement/prospectus, CHFW&#146;s shareholders are
being asked to consider a vote upon each of the Domestication and the Business Combination, among other items. As used in this proxy statement/prospectus, &#147;New Surrozen&#148; refers to CHFW after giving effect to the consummation of the
Domestication and the Business Combination. </P>  <P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify">In connection with the Domestication, on the Closing Date, prior to the Effective Time (as
defined below): (i) each issued and outstanding Class&nbsp;A ordinary share, par value $0.0001 per share (the &#147;Class<U></U> A ordinary shares&#148;), and each issued and outstanding Class&nbsp;B ordinary share, par value $0.0001 per share (the
&#147;Class<U></U> B ordinary shares&#148;), of CHFW will be converted into one share of common stock, par value $0.0001 per share, of New Surrozen (the &#147;New Surrozen Common Stock&#148;); (ii) each issued and outstanding whole warrant to
purchase Class&nbsp;A ordinary shares of CHFW will automatically represent the right to purchase one share of New Surrozen Common Stock at an exercise price of $11.50 per share on the terms and conditions set forth in the CHFW warrant agreement;
(iii)&nbsp;the governing documents of CHFW will be replaced as contemplated by the Business Combination Agreement and become the certificate of incorporation and the bylaws of New Surrozen as described in this proxy statement/prospectus; and
(iv)&nbsp;CHFW&#146;s name will change to &#147;Surrozen, Inc.&#148; In connection with clauses (i)&nbsp;and (ii) of this paragraph, each issued and outstanding unit of CHFW that has not been previously separated into the underlying Class&nbsp;A
ordinary shares of CHFW and the underlying warrants of CHFW prior to the Domestication will be cancelled and will entitle the holder thereof to one share of New CHFW Common Stock and <FONT STYLE="white-space:nowrap">one-third</FONT> of one warrant
representing the right to purchase one share of New Surrozen Common Stock at an exercise price of $11.50 per share on the terms and subject to the conditions set forth in the CHFW warrant agreement. </P>
<P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify">On the date of Closing, promptly following the consummation of the Domestication, Merger Sub will merge with and into Surrozen (the
&#147;Merger&#148;), with Surrozen as the surviving company in the Merger and, after giving effect to the Merger, Surrozen will be a wholly-owned subsidiary of CHFW (the time that the Merger becomes effective being referred to as the &#147;Effective
Time&#148;). </P> <P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify">In accordance with the terms and subject to the conditions of the Business Combination Agreement, at the Effective Time, each
share and equity award (whether vested or unvested) of Surrozen outstanding as of immediately prior to the Effective Time will be exchanged for shares of New Surrozen Common Stock or comparable equity awards that are settled or are exercisable for
shares of New Surrozen Common Stock, as applicable, based on an implied Surrozen equity value of $200,000,000 and a $10.00 per share value of New Surrozen Common Stock The market value of the shares to be issued could vary significantly from the
market value as of the date of this proxy statement/prospectus. </P> <P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify">It is anticipated that, upon completion of the Business Combination,
(i)&nbsp;the Surrozen stockholders will own, collectively, approximately 53.5% of the outstanding New Surrozen Common Stock, and (ii)&nbsp;CHFW&#146;s initial shareholders will own (taking into account Sponsor&#146;s participation in the PIPE)
approximately 10.4% of the outstanding New Surrozen Common Stock, in each case, assuming that none of CHFW&#146;s outstanding public shares are redeemed in connection with the Business Combination, or approximately 65.5% and 12.7%, respectively,
assuming that all 7,900,000 of CHFW&#146;s redeemable outstanding public shares are redeemed in connection with the Business Combination (giving effect to agreements with holders of 1,300,000 public shares not to redeem such shares). These
percentages (i)&nbsp;assume that 20,000,000 shares of New Surrozen Common Stock are issued to the Surrozen equityholders at Closing (representing the maximum number of shares that could be issued at Closing); (ii) are based on 12,020,000 shares of
New Surrozen Common Stock to be issued in the PIPE Financing; (iii)&nbsp;do not take into account any exercise of public warrants or private placement warrants to purchase New Surrozen Common Stock that will be outstanding immediately following
Closing; and (iv)&nbsp;do not take into account any shares of New Surrozen Common Stock underlying option awards granted by New Surrozen immediately following Closing. If the actual facts are different than these assumptions, the ownership
percentages in New Surrozen will be different. </P> <P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify">This prospectus covers 34,386,334 shares of New Surrozen Common Stock (including shares
issuable upon exercise of the warrants described above and outstanding equity awards) and 3,211,334 warrants to acquire shares of New Surrozen Common Stock, all of which will be issued in connection with the Domestication and the Business
Combination. The number of shares of New Surrozen Common Stock that this prospectus covers represents the maximum number of shares that may be issued to holders of shares and outstanding equity awards of Surrozen in connection with the Business
Combination (as more fully described in this proxy statement/prospectus), together with the shares issued or issuable to the existing shareholders and warrant holders of CHFW in connection with the Business Combination. </P>
<P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify">CHFW&#146;s units, public shares and public warrants are currently listed on the NYSE American LLC (&#147;NYSE American&#148;) under the symbols
&#147;CHFW.U,&#148; &#147;CHFW&#148; and &#147;CHFW.W,&#148; respectively. On April 14, 2021, the last trading day before announcement of the execution of the merger agreement, the closing price of CHFW&#146;s units, public shares and public
warrants was $10.11, $9.88 and $1.32, respectively. On June&nbsp;22, 2021, the closing price of CHFW&#146;s units, public shares and public warrants was $10.30, $9.90 and $1.58, respectively. CHFW will apply for listing, to be effective at the time
of the Business Combination, of New Surrozen Common Stock and warrants on the Nasdaq Stock Market LLC (&#147;Nasdaq&#148;) under the proposed symbols &#147;SRZN&#148; and &#147;SRZNW,&#148; respectively. It is a condition of the consummation of the
Business Combination that CHFW receive confirmation from Nasdaq that New Surrozen has been conditionally approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that CHFW will obtain. If such listing
condition is not met or if such confirmation is not obtained, the Business Combination will not be consummated unless the Nasdaq condition set forth in the Business Combination Agreement is waived by the applicable parties. </P>
<P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><B>The accompanying proxy statement/prospectus provides shareholders of CHFW with detailed information about the Business Combination and other
matters to be considered at the extraordinary general meeting of CHFW. We encourage you to read the entire accompanying proxy statement/prospectus, including the Annexes and other documents referred to therein, carefully and in their entirety. You
should also carefully consider the risk factors described in &#147;</B><B><I><A HREF="#rom40894_28">Risk Factors</A> </I></B><B>&#148; beginning on page&nbsp;54 of the accompanying proxy statement/prospectus. </B></P>
<P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS
DESCRIBED IN THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS, PASSED UPON THE MERITS OR FAIRNESS OF THE BUSINESS COMBINATION OR RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THE ACCOMPANYING PROXY
STATEMENT/PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE. </B></P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>The
accompanying proxy statement/prospectus is dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>is first being mailed to CHFW&#146;s shareholders on or
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1 Palmer Square, Suite 305 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Princeton, New Jersey 08540 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dear <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. Shareholders: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You are cordially invited to attend the extraordinary general meeting (the &#147;extraordinary general meeting&#148;) of <FONT
STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., a Cayman Islands exempted company (&#147;CHFW&#148;), at&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.m., Eastern Time,
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, or at such other time and/or on such other date to which the meeting may be adjourned. The meeting will be held via live webcast at the
following address: https://www.cstproxy.com/consonancehfw/sm2021. You will need the <FONT STYLE="white-space:nowrap">12-digit</FONT> meeting control number that is printed on your proxy card to enter the extraordinary general meeting. CHFW
recommends that you log in at least 15 minutes before the extraordinary general meeting to ensure you are logged in when the extraordinary general meeting starts. Please note that you will not be able to attend the extraordinary general meeting in
person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As further described in the accompanying proxy statement/prospectus, in connection with the Domestication, on the Closing Date
prior to the Effective Time (as described below), among other things, (i)&nbsp;CHFW will change its name to &#147;Surrozen, Inc.,&#148; (ii) all of the outstanding shares of CHFW will be converted into common stock of a new Delaware corporation and
all of the outstanding CHFW warrants will be converted into warrants to purchase common stock of a new Delaware corporation, and (iii)&nbsp;the governing documents of CHFW will be replaced. As used in the accompanying proxy statement/prospectus,
&#147;New Surrozen&#148; refers to CHFW after giving effect to the Domestication and the Business Combination. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At the extraordinary
general meeting, CHFW shareholders will be asked to consider and vote upon a proposal, which is referred to herein as the &#147;Business Combination Proposal&#148; to approve and adopt the Business Combination Agreement, dated as of April&nbsp;15,
2021 (as may be amended, supplemented or otherwise modified from time to time, the &#147;Business Combination Agreement&#148;), by and among CHFW, Perseverance Merger Sub, Inc., a Delaware corporation (&#147;Merger Sub&#148;) and Surrozen, Inc., a
Delaware corporation (&#147;Surrozen&#148;), a copy of which is attached to the accompanying proxy statement/prospectus as Annex A, including the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As further described in the accompanying proxy statement/prospectus, subject to the terms and conditions of the Business Combination
Agreement, the following transactions will occur: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">On the Closing Date, prior to the Effective Time, CHFW will change its jurisdiction of incorporation by
deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware (the &#147;Domestication&#148;). In connection with the Domestication, CHFW will change its
name to &#147;Surrozen, Inc.&#148; (sometimes referred to as &#147;New Surrozen&#148;) (for further details, see &#147;<I>Proposal No. 2&#151;The Domestication Proposal</I>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Merger Sub will merge with and into Surrozen (the &#147;Merger&#148;), with Surrozen as the surviving
company in the Merger and, after giving effect to such Merger, Surrozen shall be a wholly-owned subsidiary of New Surrozen. In accordance with the terms and subject to the conditions of the Business Combination Agreement, at the Effective Time, each
share and equity award of Surrozen outstanding as of immediately prior to the Effective Time (whether vested or unvested) will be exchanged for shares of New Surrozen Common Stock or comparable vested equity awards that are settled or are
exercisable for shares of New Surrozen Common Stock, as applicable, based on an implied Surrozen equity value of $200,000,000. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with the foregoing and concurrently with the execution of the Business Combination Agreement, CHFW entered into Subscription
Agreements with certain investors (the &#147;Subscription Agreements&#148; and such investors, the &#147;PIPE Investors&#148;), pursuant to which the PIPE Investors have agreed to subscribe for and purchase, and CHFW has agreed to issue and sell to
the PIPE Investors, an aggregate of 12,020,000 units, each consisting of one share of New Surrozen Common Stock <FONT STYLE="white-space:nowrap">and&nbsp;one-third&nbsp;of</FONT> one redeemable warrant for one share of New Surrozen Common Stock (the
&#147;PIPE Warrants&#148;), for a purchase price of $10.00 per unit (the &#147;PIPE Units&#148;), for aggregate gross proceeds of $120,200,000 (the &#147;PIPE Financing&#148;). The PIPE Units were offered to facilitate the
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
subscriptions, however, the shares of New Surrozen Common Stock and the PIPE Warrants which comprise the PIPE Units are not attached and will trade separately without any instruction or
detachment obligations on the part of the investors, CHFW or the warrant agent. Each whole PIPE Warrant entitles the holder thereof to purchase one share of New Surrozen Common Stock at a price of $11.50 per share, subject to adjustment as described
in the form of warrant agreement attached to the form of Subscription Agreement, and only whole PIPE Warrants will be exercisable. The PIPE Warrants have substantially the same provisions as the public warrants issued in connection with CHFW&#146;s
initial public offering. The shares and warrants of New Surrozen Common Stock to be issued pursuant to the Subscription Agreements have not been registered under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) in reliance
upon the exemption provided in Section&nbsp;4(a)(2) of the Securities Act. CHFW will grant the PIPE Investors certain registration rights in connection with the PIPE Financing. The PIPE Financing is contingent upon, among other things, the
substantially concurrent closing of the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You will also be asked to consider and vote upon (a)&nbsp;the Domestication
(the &#147;Domestication Proposal&#148;), (b)&nbsp;a proposal to approve the replacement of CHFW&#146;s existing amended and restated memorandum and articles of association (the &#147;Existing Governing Documents&#148;) with a proposed new
certificate of incorporation (the &#147;Proposed Certificate of Incorporation) and proposed new bylaws (the &#147;Proposed Bylaws&#148; and, together with the Proposed Certificate of Incorporation, the &#147;Proposed Governing Documents&#148;) of
New Surrozen (the &#147;New Organizational Documents Proposal&#148;) (c)&nbsp;four (4) separate advisory, non-binding proposals to approve material differences between the Existing Governing Documents and the proposed new certificate of
incorporation of New Surrozen and the proposed new bylaws of New Surrozen upon the Domestication, copies of which are attached to the accompanying proxy statement/prospectus as Annexes&nbsp;C and D, respectively, including to approve the change in
the authorized share capital of CHFW from (i) $50,100 divided into 350,000,000 Class&nbsp;A ordinary shares, par value $0.0001 per share, 150,000,000 Class&nbsp;B ordinary shares, par value $0.0001 per share and 1,000,000 preference shares, par
value $0.0001 per share, to (ii) 300,000,000 shares of common stock, par value $0.0001 per share and 10,000,000 shares of preferred stock, par value $0.0001 per share (which proposals are referred to herein collectively as the &#147;Governing
Documents Proposals&#148;) (d) a proposal to approve, for purpose of complying with Nasdaq Listing Rule 5635, the issuance of New Surrozen Common Stock in connection with the Business Combination and the PIPE Financing, which is referred to herein
as the &#147;Share Issuance Proposal,&#148; (e) a proposal to approve and adopt the Surrozen, Inc. 2021 Equity Incentive Plan, a copy of which is attached to the accompanying proxy statement/prospectus as Annex&nbsp;J, which is referred to herein as
the &#147;Incentive Award Plan Proposal,&#148; (f) a proposal to approve and adopt the Surrozen, Inc. 2021 Employee Stock Purchase Plan, a copy of which is attached to the accompanying proxy statement/prospectus as Annex K, which is referred to
herein as the &#147;Employee Stock Purchase Plan Proposal,&#148; and (g)&nbsp;a proposal to adjourn the extraordinary general meeting to a later date or dates to the extent necessary, which is referred to herein as the &#147;Adjournment
Proposal.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Business Combination will be consummated only if the Business Combination Proposal, the Domestication Proposal, the
New Organizational Documents Proposal, the Share Issuance Proposal and the Incentive Award Plan Proposal, (collectively, the &#147;Condition Precedent Proposals&#148;) are approved at the extraordinary general meeting. The Employee Stock Purchase
Plan Proposal is conditioned on the approval of the Condition Precedent Proposals. The Adjournment Proposal is not conditioned upon the approval of any other proposal. Each of these proposals is more fully described in the accompanying proxy
statement/prospectus, which each shareholder is encouraged to read carefully and in its entirety. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Adjournment Proposal provides
for a vote to adjourn the extraordinary general meeting to a later date or dates (A)&nbsp;to the extent necessary to ensure that any required supplement or amendment to the accompanying proxy statement/prospectus is provided to CHFW shareholders or,
if as of the time for which the extraordinary general meeting is scheduled, there are insufficient CHFW ordinary shares represented (either in person or by proxy) to constitute a quorum necessary to conduct business at the extraordinary general
meeting, (B)&nbsp;in order to solicit additional proxies from CHFW shareholders in favor of one or more of the proposals at the extraordinary general meeting or (C)&nbsp;if CHFW shareholders redeem an amount of the public shares such that the
condition to consummation of the Business Combination that the aggregate cash proceeds to be received by CHFW from the trust account in connection with the Business Combination, together with the aggregate gross proceeds from the
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
PIPE Financing, equal no less than $100,000,000 after deducting certain agreed upon CHFW unpaid expenses and liabilities (such aggregate proceeds, the &#147;Aggregate Transaction Proceeds&#148;,
and such condition to the consummation of the Business Combination, the &#147;Aggregate Transaction Proceeds Condition&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
connection with the Business Combination, certain related agreements have been, or will be entered into upon or prior to the closing of the Business Combination, including the Subscription Agreements, the Company Stockholder Support Agreements, the
CHFW Shareholder Support Agreements, the Sponsor Letter Agreement and the Investor Rights Agreement (each as defined in the accompanying proxy statement/prospectus). See &#147;<I>Business Combination Proposal&#151;Related Agreements</I>&#148; in the
accompanying proxy statement/prospectus for more information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the Existing Governing Documents, a holder of CHFW&#146;s
public shares (a &#147;public shareholder&#148;) may request that CHFW redeem all or a portion of such public shares for cash if the Business Combination is consummated. Holders of units must elect to separate the units into the underlying public
shares and warrants prior to exercising redemption rights with respect to the public shares. If holders hold their units in an account at a brokerage firm or bank, holders must notify their broker or bank that they elect to separate the units into
the underlying public shares and warrants, or if a holder holds units registered in its own name, the holder must contact Continental Stock Transfer&nbsp;&amp; Trust Company (&#147;Continental&#148;), CHFW&#146;s transfer agent, directly and
instruct it to do so. The redemption rights include the requirement that a holder must identify itself in writing as a beneficial holder and provide its legal name, phone number and address to Continental in order to validly redeem its shares.
<B>Public shareholders (other than those who have agreed not to do so by executing an CHFW Shareholder Support Agreement) may elect to redeem their public shares even if they vote &#147;for&#148; the Business Combination Proposal. </B>If the
Business Combination is not consummated, the public shares will be returned to the respective holder, broker or bank. If the Business Combination is consummated, and if a public shareholder properly exercises its right to redeem all or a portion of
the public shares that it holds and timely delivers its shares to Continental, New Surrozen will redeem such public shares for a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the pro rata portion of the trust
account established at the consummation of CHFW&#146;s initial public offering, calculated as of two business days prior to the consummation of the Business Combination. For illustrative purposes, as of March&nbsp;31, 2021, this would have amounted
to approximately $10.00 per issued and outstanding public share. If a public shareholder exercises its redemption rights in full, then it will be electing to exchange its public shares for cash and will no longer own public shares. The redemption
will take place following the Domestication and, accordingly, it is shares of New Surrozen Common Stock that will be redeemed immediately after consummation of the Business Combination. See &#147;<I>Extraordinary General Meeting of
CHFW&#151;Redemption Rights</I>&#148; in the accompanying proxy statement/prospectus for a detailed description of the procedures to be followed if you wish to redeem your public shares for cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing, a public shareholder, together with any affiliate of such public shareholder or any other person with whom such
public shareholder is acting in concert or as a &#147;group&#148; (as defined in Section&nbsp;13(d)(3) of the Securities Exchange Act of 1934, as amended (&#147;Exchange Act&#148;)), will be restricted from redeeming its public shares with respect
to more than an aggregate of 15% of the public shares. Accordingly, if a public shareholder, alone or acting in concert or as a group, seeks to redeem more than 15% of the public shares, then any such shares in excess of that 15% limit would not be
redeemed for cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sponsor and each of Dr.&nbsp;Mitchell Blutt, Dr.&nbsp;Benny Soffer, Mr.&nbsp;Donald&nbsp;J. Santel,
Dr.&nbsp;Christopher Haqq and Ms.&nbsp;Jennifer Jarrett (collectively, the &#147;initial shareholders&#148;) have, pursuant to the Sponsor Letter Agreement, agreed to, among other things, vote all of their ordinary shares in favor of the proposals
being presented at the extraordinary general meeting and waive their anti-dilution rights with respect to their Class&nbsp;B ordinary shares in connection with the consummation of the Business Combination. Such shares will be excluded from the pro
rata calculation used to determine the <FONT STYLE="white-space:nowrap">per-share</FONT> redemption price. As of the date of the accompanying proxy statement/prospectus, the initial shareholders own approximately 22.9% of the issued and outstanding
ordinary shares. See &#147;<I>Business Combination Proposal&#151;Related Agreements&#151;Sponsor Letter Agreement</I>&#148; in the accompanying proxy statement/prospectus for more information related to the Sponsor Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Business Combination Agreement is subject to the satisfaction or waiver of certain other closing conditions as described in the
accompanying proxy statement/prospectus. There can be no assurance that the parties to the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Business Combination Agreement would waive any such provision of the Business Combination Agreement. In addition, in no event will CHFW redeem public shares in an amount that would cause New
Surrozen&#146;s net tangible assets (as determined in accordance with Rule <FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange Act) to be less than </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
$5,000,001 after giving effect to the transactions contemplated by the Business Combination Agreement and the PIPE Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW is providing the accompanying proxy statement/prospectus and accompanying proxy card to CHFW&#146;s shareholders in connection with the
solicitation of proxies to be voted at the extraordinary general meeting and at any adjournments of the extraordinary general meeting. Information about the extraordinary general meeting, the Business Combination and other related business to be
considered by CHFW&#146;s shareholders at the extraordinary general meeting is included in the accompanying proxy statement/prospectus. <B>Whether or not you plan to attend the extraordinary general meeting, all of CHFW&#146;s shareholders are urged
to read the accompanying proxy statement/prospectus, including the Annexes and other documents referred to therein, carefully and in their </B><B>entirety. You should also carefully consider the risk factors described in</B> &#147;<B><I>Risk
Factors</I></B>&#148; <B>beginning on page 49 of the accompanying proxy statement/prospectus</B>. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>After careful consideration, the
board of directors of CHFW has unanimously approved the Business Combination Agreement and the Transactions, including the Domestication, the New Organizational Documents Proposal and the Share Issuance Proposal, and unanimously recommends that
shareholders vote &#147;FOR&#148; the adoption of the Business Combination Agreement and approval of the Transactions, including the Domestication and the Share Issuance Proposal, and &#147;FOR&#148; all other proposals presented to CHFW&#146;s
shareholders in the accompanying proxy statement/prospectus. When you consider the recommendation of these proposals by the board of directors of CHFW, you should keep in mind that CHFW&#146;s directors and officers have interests in the Business
Combination that may conflict with your interests as a shareholder. See the section entitled &#147;</B><B><I>Business Combination Proposal&#151;Interests of CHFW&#146;s Directors and Executive Officers in the Business Combination</I></B><B>&#148; in
the accompanying proxy statement/prospectus for a further discussion of these considerations. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The approval of each of the
Domestication Proposal, the Governing Documents Proposal&nbsp;B, the Governing Documents Proposal&nbsp;C and the Governing Documents Proposal&nbsp;D requires a special resolution under Cayman Islands law, being the affirmative vote of at least a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> (2/3) majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter. The
approval of each of the Business Combination Proposal, the New Organizational Documents Proposal, the Governing Documents Proposal&nbsp;A, the Share Issuance Proposal, the Incentive Award Plan Proposal, the Employee Stock Purchase Plan Proposal and
the Adjournment Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of at least a majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the
extraordinary general meeting and entitled to vote on such matter. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B></B><B><I>Your vote is very important</I></B><B>. Whether or
not you plan to attend the extraordinary general meeting, please vote as soon as possible by following the instructions in the accompanying proxy statement/prospectus to make sure that your shares are represented at the extraordinary general
meeting. If you hold your shares in &#147;street name&#148; through a bank, broker or other nominee, you will need to follow the instructions provided to you by your bank, broker or other nominee to ensure that your shares are represented and voted
at the extraordinary general meeting. The Business Combination will be consummated only if the Condition Precedent Proposals are approved at the extraordinary general meeting. Each of the Condition Precedent Proposals is cross-conditioned on the
approval of each other. The Incentive Award Plan Proposal and the Employee Stock Purchase Plan Proposal are conditioned on the approval of the Condition Precedent Proposals. The Adjournment Proposal is not conditioned on the approval of any other
proposal set forth in the accompanying proxy statement/prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you sign, date and return your proxy card without indicating
how you wish to vote, your proxy will be voted FOR each of the proposals presented at the extraordinary general meeting. If you fail to return your proxy card or fail to instruct your bank, broker or other nominee how to vote, and do not attend the
extraordinary general meeting in person, the effect will be, among other things, that your shares will not be counted for purposes of determining whether a quorum is present at the extraordinary general meeting. If you are a shareholder of record
and you attend the extraordinary general meeting and wish to vote in person, you may withdraw your proxy and vote in person. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">TO EXERCISE YOUR REDEMPTION RIGHTS, YOU MUST DEMAND IN WRITING THAT YOUR PUBLIC SHARES ARE
REDEEMED FOR A PRO RATA PORTION OF THE FUNDS HELD IN THE TRUST ACCOUNT AND TENDER YOUR SHARES TO CHFW&#146;S TRANSFER AGENT AT LEAST TWO BUSINESS DAYS PRIOR TO THE VOTE AT THE EXTRAORDINARY GENERAL MEETING. IN ORDER TO EXERCISE YOUR REDEMPTION
RIGHT, YOU NEED TO IDENTIFY YOURSELF AS A BENEFICIAL HOLDER AND PROVIDE YOUR LEGAL NAME, PHONE NUMBER AND ADDRESS IN YOUR WRITTEN DEMAND. YOU MAY TENDER YOUR SHARES BY EITHER DELIVERING YOUR SHARE CERTIFICATE TO THE TRANSFER AGENT OR BY DELIVERING
YOUR SHARES ELECTRONICALLY USING THE DEPOSITORY TRUST COMPANY&#146;S DWAC (DEPOSIT WITHDRAWAL AT CUSTODIAN) SYSTEM. IF THE BUSINESS COMBINATION IS NOT COMPLETED, THEN THESE SHARES WILL BE RETURNED TO YOU OR YOUR ACCOUNT. IF YOU HOLD THE SHARES IN
STREET NAME, YOU WILL NEED TO INSTRUCT THE ACCOUNT EXECUTIVE AT YOUR BANK OR BROKER TO WITHDRAW THE SHARES FROM YOUR ACCOUNT IN ORDER TO EXERCISE YOUR REDEMPTION RIGHTS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On behalf of CHFW&#146;s board of directors, I would like to thank you for your support and look forward to the successful completion of the
Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sincerely, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mitchell Blutt </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Chairman </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS
DESCRIBED IN THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS, PASSED UPON THE MERITS OR FAIRNESS OF THE BUSINESS COMBINATION OR RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THE ACCOMPANYING PROXY
STATEMENT/PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accompanying proxy statement/prospectus is
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 and is first being mailed to shareholders on or
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1 Palmer Square, Suite 305 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Princeton, NJ 08540 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXTRAORDINARY GENERAL MEETING </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">TO THE SHAREHOLDERS OF <FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP.: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NOTICE IS HEREBY GIVEN that an extraordinary general meeting of the shareholders (the &#147;extraordinary general meeting&#148;) of <FONT
STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., a Cayman Islands exempted company (&#147;CHFW&#148;), will be held at&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.m., Eastern
Time, on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, via live webcast at the following address: https://www.cstproxy.com/consonancehfw/sm2021. You will need the <FONT
STYLE="white-space:nowrap">12-digit</FONT> meeting control number that is printed on your proxy card to enter the extraordinary general meeting. CHFW recommends that you log in at least 15 minutes before the Special Meeting to ensure you are logged
in when the extraordinary general meeting starts. Please note that you will not be able to attend the extraordinary general meeting in person. The extraordinary general meeting will be held for the following purposes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No. 1&#151;The Business Combination Proposal</B>&#151;<B>RESOLVED</B>, as an ordinary resolution,
that CHFW&#146;s entry into the Business Combination Agreement, dated as of April&nbsp;15, 2021 (as may be amended, supplemented or otherwise modified from time to time, the &#147;Business Combination Agreement&#148;), by and among CHFW,
Perseverance Merger Sub, Inc., a Delaware corporation (&#147;Merger Sub&#148;), and Surrozen, Inc., a Delaware corporation, which will change its name to Surrozen Operating, Inc. (&#147;Surrozen&#148;), a copy of which is attached to the proxy
statement/prospectus as Annex A, pursuant to which, among other things, following the <FONT STYLE="white-space:nowrap">de-registration</FONT> of CHFW as an exempted company in the Cayman Islands and the continuation and domestication of CHFW as a
corporation in the State of Delaware with the name &#147;Surrozen, Inc.,&#148; (a) Merger Sub will merge with and into Surrozen (the &#147;Merger&#148;), with Surrozen as the surviving company in the Merger and, after giving effect to such Merger,
Surrozen shall be a wholly-owned subsidiary of CHFW and (b)&nbsp;at the Effective Time, (i)&nbsp;each share and equity award (whether vested or unvested) of Surrozen outstanding as of immediately prior to the Effective Time will be exchanged for
shares of New Surrozen Common Stock or comparable vested or unvested equity awards that are settled or are exercisable for shares of New Surrozen Common Stock, as applicable, based on an implied Surrozen equity value of $200,000,000, on the terms
and subject to the conditions set forth in the Business Combination Agreement, certain related agreements (including the Subscription Agreements, the Company Stockholder Support Agreements, the CHFW Shareholder Transaction Support Agreements, the
Sponsor Letter Agreement and the Investor Rights Agreement, each in the form attached to the proxy statement/prospectus as Annex F, Annex H, Annex I, Annex E and Annex G, respectively), and the Transactions, be approved, ratified and confirmed in
all respects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No. 2&#151;The Domestication Proposal</B>&#151;<B>RESOLVED</B>, as a special resolution, that CHFW
be transferred by way of continuation to Delaware pursuant to Part XII of the Companies Act (as revised) of the Cayman Islands and Section&nbsp;388 of the General Corporation Law of the State of Delaware and, immediately upon being <FONT
STYLE="white-space:nowrap">de-registered</FONT> in the Cayman Islands, CHFW be continued and domesticated as a corporation under the laws of the state of Delaware and, conditional upon, and with effect from, the registration of CHFW as a corporation
in the State of Delaware, the name of CHFW be changed from <FONT STYLE="white-space:nowrap">&#147;Consonance-HFW</FONT> Acquisition Corp.&#148; to &#147;Surrozen, Inc.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No. 3&#151;New Organizational Documents Proposal&#151;RESOLVED</B>, as a special resolution, that
the Proposed Certificate of Incorporation and the Proposed Bylaws, copies of which are attached to the proxy statement/prospectus as Annex C and Annex D, respectively, be approved as the certificate of incorporation and bylaws, respectively, of New
Surrozen, effective upon the effectiveness of the Domestication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No. 4&#151;Governing Documents Proposals&#151;</B>to consider and vote, on an advisory,
non-binding basis, upon the following four&nbsp;(4) separate resolutions to approve that, upon the Domestication, the Existing Governing Documents be replaced in their entirety and the substitution in their place of the proposed new certificate of
incorporation, a copy of which is attached to the proxy statement/prospectus </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
as Annex&nbsp;C (the &#147;Proposed Certificate of Incorporation&#148;) and the proposed new bylaws, a copy of which is attached to the proxy statement/prospectus as Annex&nbsp;D (the
&#147;Proposed Bylaws&#148;) of &#147;Surrozen, Inc.&#148; upon the Domestication (such proposals, collectively, the &#147;Governing Documents Proposals&#148;): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT
STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No. 4&#151;Governing Documents Proposal&nbsp;A&#151;RESOLVED</B>, as an ordinary resolution, that
the change in the authorized share capital of CHFW from (i)&nbsp;350,000,000 Class A ordinary shares, par value $0.0001 per share, (ii)&nbsp;150,000,000 Class B ordinary shares, par value $0.0001 per share and (iii)&nbsp;1,000,000 preference shares,
par value $0.0001 per share, to (a)&nbsp;500,000,000 shares of common stock, par value $0.0001 per share, of New Surrozen and (b)&nbsp;10,000,000 shares of preferred stock, par value $0.0001 per share, of New Surrozen be approved.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT
STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No. 4&#151;Governing Documents Proposal&nbsp;B&#151;RESOLVED, </B>as a special resolution, that
the authorization to the New Surrozen Board to issue any or all shares of New Surrozen Preferred Stock in one or more classes or series, with such terms and conditions as may be expressly determined by the New Surrozen Board and as may be permitted
by the Delaware General Corporation Law be approved. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT
STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No. 4&#151;Governing Documents Proposal&nbsp;C&#151;RESOLVED, </B>as a special resolution, that
the removal of the ability of New Surrozen stockholders to take action by written consent in lieu of a meeting be approved. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT
STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No. 4&#151;Governing Documents Proposal&nbsp;D&#151;RESOLVED, </B>as a special resolution, that
the replacement of the Existing Governing Documents be approved and that all other immaterial changes necessary or, as mutually agreed in good faith by CHFW and Surrozen, desirable in connection with the replacement of Existing Governing Documents
with the Proposed Certificate of Incorporation and Proposed Bylaws as part of the Domestication (copies of which are attached to the proxy statement/prospectus as Annex C and Annex D, respectively), including (i)&nbsp;changing the post-Business
Combination corporate name from &#147;Consonance-HFW Acquisition Corp.&#148; to &#147;Surrozen, Inc.&#148; (which is expected to occur upon the consummation of the Domestication), (ii)&nbsp;making New Surrozen&#146;s corporate existence perpetual,
(iii)&nbsp;adopting Delaware as the exclusive forum for certain stockholder litigation and federal district courts of the United States of America as the exclusive forum for litigation arising out of the Securities Act of 1933, as amended and
(iv)&nbsp;removing certain provisions related to our status as a blank check company that will no longer be applicable upon consummation of the Business Combination be approved. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No. 5&#151;The Share Issuance Proposal</B>&#151;<B>RESOLVED</B>, as an ordinary resolution, that
for the purposes of complying with the applicable provisions of Nasdaq Stock Exchange Listing Rule 5635, the issuance of shares of New Surrozen Common Stock in the Merger and in the PIPE Financing be approved. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No. 6&#151;The Incentive Award Plan Proposal</B>&#151;<B>RESOLVED</B>, as an ordinary resolution,
that the Surrozen, Inc. 2021 Equity Incentive Plan, a copy of which is attached to the proxy statement/prospectus as Annex J, be adopted and approved. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No. 7&#151;The Employee Stock Purchase Plan Proposal</B>&#151;<B>RESOLVED</B>, as an ordinary
resolution, that the Surrozen, Inc. 2021 Employee Stock Purchase Plan, a copy of which is attached to the proxy statement/prospectus as Annex K, be adopted and approved. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No. 8&#151;The Adjournment Proposal</B>&#151;<B>RESOLVED</B>, as an ordinary resolution, that the
adjournment of the extraordinary general meeting to a later date or dates (A)&nbsp;to the extent necessary to ensure that any required supplement or amendment to the proxy statement/prospectus is provided to CHFW shareholders or, if as of the time
for which the extraordinary general meeting is scheduled, there are insufficient CHFW ordinary shares represented (either in person or by proxy) to constitute a quorum necessary to conduct business at the extraordinary general meeting, (B)&nbsp;in
order to solicit additional proxies from CHFW shareholders in favor of one or more of the proposals at the extraordinary general meeting or (C)&nbsp;if CHFW shareholders redeem an amount of the public shares such that the condition to consummation
of the Business Combination that the aggregate cash proceeds </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
to be received by CHFW from the trust account in connection with the Business Combination, together with aggregate gross proceeds from the PIPE Financing, equal no less than $100,000,000 after
deducting certain of CHFW&#146;s unpaid expenses and liabilities would not be satisfied, at the extraordinary general meeting be approved. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each of the Business Combination Proposal, the Domestication Proposal, the New Organizational Documents Proposal, the Incentive Award Plan
Proposal and the Share Issuance Proposal is conditioned on the approval and adoption of each of the other Condition Precedent Proposals. The Employee Stock Purchase Plan Proposal is conditioned on the approval of the Condition Precedent Proposals.
The Adjournment Proposal is not conditioned on any other proposal. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These items of business are described in this proxy
statement/prospectus, which we encourage you to read carefully and in its entirety before voting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Only holders of record of ordinary
shares at the close of business on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021 are entitled to notice of and to vote and have their votes counted at the extraordinary general meeting and any
adjournment of the extraordinary general meeting. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This proxy statement/prospectus and accompanying proxy card is being provided to
CHFW&#146;s shareholders in connection with the solicitation of proxies to be voted at the extraordinary general meeting and at any adjournment of the extraordinary general meeting. <B>Whether or not you plan to attend the extraordinary general
meeting, all of CHFW&#146;s shareholders are urged to read this proxy statement/prospectus, including the Annexes and the documents referred to herein carefully and in their entirety. You should also carefully consider the risk factors described in
&#147;</B><B><I><A HREF="#rom40894_28">Risk Factors</A></I></B>&#148; <B>beginning on page 51 of this proxy statement/prospectus.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>After careful consideration, the board of directors of CHFW has unanimously determined that the Business Combination Agreement and the
Transactions, including the Domestication and the Share Issuance Proposal, are advisable and fair to, and in the best interest of CHFW and its shareholders, approved the execution, delivery and performance by CHFW of the Business Combination
Agreement and the consummation of the Transactions and unanimously recommends that shareholders vote &#147;FOR&#148; the adoption of the Business Combination Agreement and approval of the Transactions, and &#147;FOR&#148; all other proposals
presented to CHFW&#146;s shareholders in this proxy statement/prospectus. When you consider the recommendation of these proposals by the board of directors of CHFW, you should keep in mind that CHFW&#146;s directors and officers have interests in
the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#147;</B><B><I>Business Combination Proposal&#151;Interests of CHFW&#146;s Directors and Executive Officers in the Business
Combination</I></B><B>&#148; in this proxy statement/prospectus for a further discussion of these considerations. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the
Existing Governing Documents, a public shareholder may request of CHFW that New Surrozen redeem all or a portion of its public shares for cash if the Business Combination is consummated. As a holder of public shares, you will be entitled to receive
cash for any public shares to be redeemed only if you: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hold public shares, or if you hold public shares through units, you elect to separate your units into the
underlying public shares and warrants prior to exercising your redemption rights with respect to the public shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submit a written request to Continental, CHFW&#146;s transfer agent, in which you (a)&nbsp;request that New
Surrozen redeem all or a portion of your public shares for cash, and (b)&nbsp;identify yourself as the beneficial holder of the public shares and provide your legal name, phone number and address; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deliver your public shares to Continental, CHFW&#146;s transfer agent, physically or electronically through
The Depository Trust Company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Holders must complete the procedures for electing to redeem their public shares in the
manner described above prior to 5:00 p.m., Eastern Time, on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 (two business days before the extraordinary general meeting) in order for their shares
to be redeemed. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Holders of units must elect to separate the units into the underlying public shares and
warrants prior to exercising redemption rights with respect to the public shares. If holders hold their units in an account at a brokerage firm or bank, holders must notify their broker or bank that they elect to separate the units into the
underlying public shares and warrants, or if a holder holds units registered in its own name, the holder must contact Continental, CHFW&#146;s transfer agent, directly and instruct them to do so. The redemption rights include the requirement that a
holder must identify itself in writing as a beneficial holder and provide its legal name, phone number and address to Continental in order to validly redeem its shares. Public shareholders (other than those who have agreed not to do so by executing
an CHFW Shareholder Support Agreement) may elect to redeem public shares regardless of if or how they vote in respect of the Business Combination Proposal. If the Business Combination is not consummated, the public shares will be returned to the
respective holder, broker or bank. If the Business Combination is consummated, and if a public shareholder properly exercises its right to redeem all or a portion of the public shares that it holds and timely delivers its shares to Continental,
CHFW&#146;s transfer agent, New Surrozen will redeem such public shares for a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the pro rata portion of the trust account established at the consummation of CHFW&#146;s
initial public offering (the &#147;trust account&#148;), calculated as of two business days prior to the consummation of the Business Combination. For illustrative purposes, as of March&nbsp;31, 2021, this would have amounted to approximately $10.00
per issued and outstanding public share. If a public shareholder exercises its redemption rights in full, then it will be electing to exchange its public shares for cash and will no longer own public shares. The redemption will take place following
the Domestication and, accordingly, it is shares of New Surrozen Common Stock that will be redeemed immediately after consummation of the Business Combination. See &#147;<I>Extraordinary General Meeting of CHFW&#151;Redemption Rights</I>&#148; in
this proxy statement/prospectus for a detailed description of the procedures to be followed if you wish to redeem your public shares for cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing, a public shareholder, together with any affiliate of such public shareholder or any other person with whom such
public shareholder is acting in concert or as a &#147;group&#148; (as defined in Section&nbsp;13(d)(3) of the Securities Exchange Act of 1934, as amended (&#147;Exchange Act&#148;)), will be restricted from redeeming its public shares with respect
to more than an aggregate of 15% of the public shares. Accordingly, if a public shareholder, alone or acting in concert or as a group, seeks to redeem more than 15% of the public shares, then any such shares in excess of that 15% limit would not be
redeemed for cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The initial shareholders have, pursuant to the Sponsor Letter Agreement, agreed to, among other things, vote all of
their ordinary shares in favor of the proposals being presented at the extraordinary general meeting and waive their anti-dilution rights with respect to their Class&nbsp;B ordinary shares in connection with the consummation of the Business
Combination. Such shares will be excluded from the pro rata calculation used to determine the <FONT STYLE="white-space:nowrap">per-share</FONT> redemption price. As of the date of this proxy statement/prospectus, the initial shareholders own
approximately 22.9% of the issued and outstanding ordinary shares. See &#147;<I>Business Combination Proposal&#151;Related Agreements&#151;Sponsor Letter Agreement</I>&#148; in the accompanying proxy statement/prospectus for more information related
to the Sponsor Letter Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Business Combination Agreement is subject to the satisfaction or waiver of certain other closing
conditions as described in the accompanying proxy statement/prospectus. There can be no assurance that the parties to the Business Combination Agreement would waive any such provision of the Business Combination Agreement. In addition, in no event
will CHFW redeem public shares in an amount that would cause New Surrozen&#146;s net tangible assets (as determined in accordance with Rule <FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange Act) to be less than $5,000,001 after
giving effect to the transactions contemplated by the Business Combination Agreement and the PIPE Financing. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The approval of the
Domestication Proposal, the New Organizational Documents Proposal, Governing Documents Proposal&nbsp;B, the Governing Documents Proposal&nbsp;C and the Governing Documents Proposal&nbsp;D requires a special resolution under Cayman Islands law, being
the affirmative vote of at least a <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and
entitled to vote on such matter. The approval of each of the Business Combination Proposal, the Governing Documents Proposal&nbsp;A, the Incentive Award Plan Proposal, the Employee Stock Purchase Plan Proposal, the Share Issuance Proposal and the
Adjournment Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of at least a majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the
extraordinary general meeting and entitled to vote on such matter. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B></B><B><I>Your vote is very important</I></B><B>. Whether or not you plan to attend the
extraordinary general meeting, please vote as soon as possible by following the instructions in this proxy statement/prospectus to make sure that your shares are represented at the extraordinary general meeting. If you hold your shares in
&#147;street name&#148; through a bank, broker or other nominee, you will need to follow the instructions provided to you by your bank, broker or other nominee to ensure that your shares are represented and voted at the extraordinary general
meeting. The Business Combination will be consummated only if the Condition Precedent Proposals are approved at the extraordinary general meeting. Each of the Condition Precedent Proposals is cross-conditioned on the approval of each other. The
Employee Stock Purchase Plan Proposal is conditioned on the approval of the Condition Precedent Proposals. The Adjournment Proposal is not conditioned on the approval of any other proposal set forth in this proxy statement/prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you sign, date and return your proxy card without indicating how you wish to vote, your proxy will be voted FOR each of the proposals
presented at the extraordinary general meeting. If you fail to return your proxy card or fail to instruct your bank, broker or other nominee how to vote, and do not attend the extraordinary general meeting in person, the effect will be, among other
things, that your shares will not be counted for purposes of determining whether a quorum is present at the extraordinary general meeting. If you are a shareholder of record and you attend the extraordinary general meeting and wish to vote in
person, you may withdraw your proxy and vote in person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Your attention is directed to the remainder of the proxy statement/prospectus
following this notice (including the Annexes and other documents referred to herein) for a more complete description of the proposed Business Combination and related transactions and each of the proposals. You are encouraged to read this proxy
statement/prospectus carefully and in its entirety, including the Annexes and other documents referred to herein. If you have any questions or need assistance voting your ordinary shares, please contact Okapi Partners LLC, our proxy solicitor, by
calling (844) <FONT STYLE="white-space:nowrap">203-3605,</FONT> or banks and brokers can call collect at (212) <FONT STYLE="white-space:nowrap">297-0720,</FONT> or by emailing info@okapipartners.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Thank you for your participation. We look forward to your continued support. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By Order of the Board of Directors of <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mitchell Blutt </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Chairman of
the Board of Directors </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO EXERCISE YOUR REDEMPTION RIGHTS, YOU MUST DEMAND IN WRITING THAT YOUR PUBLIC SHARES ARE REDEEMED FOR A
PRO RATA PORTION OF THE FUNDS HELD IN THE TRUST ACCOUNT AND TENDER YOUR SHARES TO CHFW&#146;S TRANSFER AGENT AT LEAST TWO BUSINESS DAYS PRIOR TO THE VOTE AT THE EXTRAORDINARY GENERAL MEETING. IN ORDER TO EXERCISE YOUR REDEMPTION RIGHT, YOU NEED TO
IDENTIFY YOURSELF AS A BENEFICIAL HOLDER AND PROVIDE YOUR LEGAL NAME, PHONE NUMBER AND ADDRESS IN YOUR WRITTEN DEMAND. YOU MAY TENDER YOUR SHARES BY EITHER DELIVERING YOUR SHARE CERTIFICATE TO THE TRANSFER AGENT OR BY DELIVERING YOUR SHARES
ELECTRONICALLY USING THE DEPOSITORY TRUST COMPANY&#146;S DWAC (DEPOSIT WITHDRAWAL AT CUSTODIAN) SYSTEM. IF THE BUSINESS COMBINATION IS NOT COMPLETED, THEN THESE SHARES WILL BE RETURNED TO YOU OR YOUR ACCOUNT. IF YOU HOLD THE SHARES IN STREET NAME,
YOU WILL NEED TO INSTRUCT THE ACCOUNT EXECUTIVE AT YOUR BANK OR BROKER TO WITHDRAW THE SHARES FROM YOUR ACCOUNT IN ORDER TO EXERCISE YOUR REDEMPTION RIGHTS. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_1">ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_2">TRADEMARKS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_3">SELECTED DEFINITIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_5">QUESTIONS AND ANSWERS FOR SHAREHOLDERS OF CHFW</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_6">SUMMARY OF THE PROXY STATEMENT/PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_7">The Parties to the Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_8">Proposals to be Put to the Shareholders of CHFW at the Extraordinary General Meeting
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_9">The CHFW Board&#146;s Reasons for the Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_10">Ownership of New Surrozen following Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_11">Date, Time and Place of Extraordinary General Meeting of CHFW&#146;s Shareholders
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_12">Voting Power; Record Date</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_13">Quorum and Vote of CHFW Shareholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_14">Redemption Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_15">Appraisal Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_16">Proxy Solicitation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_17">Interests of CHFW Directors and Executive Officers in the Business Combination
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_18">Recommendation to Shareholders of CHFW</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_19">U.S. Federal Income Tax Considerations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_20">Expected Accounting Treatment</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_21">Regulatory Approvals</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_22">Emerging Growth Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_23">Smaller Reporting Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_24">Risk Factors Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_25">SELECTED HISTORICAL FINANCIAL INFORMATION OF CHFW AND SURROZEN</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_26">SUMMARY UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_27">COMPARATIVE PER SHARE DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_28">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_29">Risks Related to New Surrozen&#146;s Business Following the Business Combination
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_30">Risks Related to Surrozen Intellectual Property</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_31">Risks Related to Government Regulation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_32">Risks Related to the Business Combination and CHFW</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_33">Risks Related to the Consummation of the Domestication</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_34">Risks Related to the Redemption</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_35">Risks if the Adjournment Proposal is Not Approved</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_36">Risks if the Domestication and the Business Combination are not
Consummated</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_37">EXTRAORDINARY GENERAL MEETING OF CHFW</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_38">General</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_39">Date, Time and Place</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_40">Purpose of the CHFW Extraordinary General Meeting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_41">Recommendation of the CHFW Board</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_42">Record Date; Who is Entitled to Vote</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_43">Quorum</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_44">Abstentions and Broker
<FONT STYLE="white-space:nowrap">Non-Votes</FONT></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_45">Vote Required for Approval</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_46">Voting Your Shares</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_48">Revoking Your Proxy </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_49">Who Can Answer Your Questions About Voting Your Shares </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_50">Redemption Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_51">Appraisal Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_52">Proxy Solicitation Costs</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_52"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_52"></A>140</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_52"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_53">CHFW Initial Shareholders&#146; Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_53"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_53"></A>140</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_53"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_54">BUSINESS COMBINATION PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_54"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_54"></A>141</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_54"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_55">Overview</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_55"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_55"></A>141</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_55"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_56">The Business Combination Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_56"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_56"></A>142</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_56"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_57">General; Structure of the Merger</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_57"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_57"></A>142</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_57"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_58">Effect of the Domestication on Existing CHFW Equity in the Business Combination
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_58"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_58"></A>143</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_58"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_59">Consideration to Surrozen Equityholders in the Business
Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_59"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_59"></A>143</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_59"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_60">Aggregate New Surrozen Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_60"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_60"></A>144</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_60"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_61">Closing and Effective Time of the Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_61"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_61"></A>144</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_61"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_62">Conditions to Closing of the Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_62"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_62"></A>145</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_62"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_63">Representations and Warranties</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_63"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_63"></A>147</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_63"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_64">Material Adverse Effect</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_64"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_64"></A>148</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_64"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_65">Covenants of the Parties</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_65"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_65"></A>150</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_65"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_66">Board of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_66"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_66"></A>154</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_66"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_67">Survival of Representations, Warranties and Covenants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_67"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_67"></A>155</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_67"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_68">Termination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_68"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_68"></A>155</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_68"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_69">Effect of Termination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_69"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_69"></A>156</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_69"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_70">Expenses</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_70"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_70"></A>156</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_70"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_71">Governing Law</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_71"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_71"></A>156</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_71"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_72">Amendments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_72"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_72"></A>156</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_72"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_73">Ownership of New Surrozen</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_73"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_73"></A>156</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_73"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_74">Related Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_74"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_74"></A>158</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_74"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_75">The CHFW Board&#146;s Reasons for the Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_75"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_75"></A>170</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_75"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_76">Satisfaction of 80% Test</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_76"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_76"></A>173</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_76"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_77">Interests of CHFW&#146;s Directors and Executive Officers in the Business Combination
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_77"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_77"></A>173</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_77"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_78">Expected Accounting Treatment of the Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_78"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_78"></A>176</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_78"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_79">Regulatory Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_79"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_79"></A>176</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_79"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_80">Vote Required for Approval</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_80"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_80"></A>176</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_80"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_81">Resolution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_81"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_81"></A>176</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_81"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_82">DOMESTICATION PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_82"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_82"></A>178</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_82"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_83">Overview</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_83"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_83"></A>178</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_83"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_84">Reasons for the Domestication</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_84"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_84"></A>178</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_84"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_85">Expected Accounting Treatment of the Domestication</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_85"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_85"></A>179</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_85"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_86">Vote Required for Approval</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_86"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_86"></A>180</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_86"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_87">Resolution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_87"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_87"></A>180</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_87"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_88">Recommendation of the CHFW Board</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_88"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_88"></A>180</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_88"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_89">GOVERNING DOCUMENTS PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_89"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_89"></A>182</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_89"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_90">Overview of Change in Authorized Shares</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_90"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_90"></A>184</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_90"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_91">Reasons for the Change in Authorized Shares</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_91"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_91"></A>185</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_91"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_92">Overview of Issuance of Preferred Stock by the Board</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_92"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_92"></A>185</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_92"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_93">Reasons for the Issuance of Preferred Stock by the Board</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_93"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_93"></A>185</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_93"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_94">Reasons for the Removal of Stockholder Action by Written
Consent</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_94"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_94"></A>185</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_94"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_95">Overview of Other Provisions of the Proposed Governance
Documents</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_95"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_95"></A>186</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_95"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_96">Reasons for the Other Provisions of the Proposed Governance
Documents</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_96"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_96"></A>187</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_96"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_97">Vote Required for Approval</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_97"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_97"></A>188</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_97"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_98">Resolution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_98"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_98"></A>189</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_98"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_99">Recommendation of the CHFW Board</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_99"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_99"></A>189</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_99"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_100">SHARE ISSUANCE PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_100"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_100"></A>190</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_100"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_101">Overview</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_101"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_101"></A>190</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_101"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_102">Reasons for the Approval for Purposes of Nasdaq Listing Rule
5635</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_102"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_102"></A>190</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_102"></A>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_103">Vote Required for Approval</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_103"></A>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><A HREF="#rom40894_103"></A>191</TD>
<TD NOWRAP VALIGN="bottom"><A HREF="#rom40894_103"></A>&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_104">Resolution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_105">Recommendation of the CHFW Board</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_106">INCENTIVE AWARD PLAN PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_107">Overview</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_108">General Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_109">Description of the 2021 Plan</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_110">U.S. Federal Income Tax Consequences</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_111">Tax Consequences to New Surrozen</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_112">New Plan&nbsp;Benefits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_113">Interests of CHFW&#146;s Directors and Officers in the Equity Incentive Plan&nbsp;Proposal
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_114">Vote Required for Approval</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_115">Resolution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_116">Recommendation of CHFW&#146;s Board</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_117">EMPLOYEE STOCK PURCHASE PLAN PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_118">Overview</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_119">Description of the ESPP</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_120">U.S. Federal Income Tax Consequences</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_121">New Plan&nbsp;Benefits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_122">Interests of CHFW&#146;s Directors and Officers in the Employee Stock Purchase
 Plan&nbsp;Proposal</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_123">Vote Required for Approval</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_124">Resolution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_125">Recommendation of CHFW&#146;s Board</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_126">ADJOURNMENT PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_127">Consequences if the Adjournment Proposal is Not Approved</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_128">Vote Required for Approval</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_129">Resolution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_130">Recommendation of the CHFW Board</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_131">CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_132">U.S. Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_133"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_134">Distributions on Shares of New Surrozen Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_135">Sale, Exchange or Other Disposition of Shares of New Surrozen Common Stock and
New Surrozen Public Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_136">Foreign Account Tax Compliance Act</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_137">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_138">UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET AS OF DECEMBER&nbsp;
31, 2020 </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_139">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS FOR THE YEAR ENDED
 DECEMBER&nbsp;31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_140">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_141">INFORMATION ABOUT CHFW</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_142">Financial Position</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_143">Effecting Our Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_144">Employees</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_145">Directors and Executive Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_146">Number and Terms of Office of Officers and Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_147">Committees of the Board of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_148">Code of Ethics</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_149">Section&nbsp;16(a) Beneficial Ownership Reporting Compliance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_150">Conflicts of Interest</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_151">Limitation on Liability and Indemnification of Officers and
Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_152">Executive Compensation and Director Compensation and Other
Interests</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_153">Director Independence</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_154">Legal Proceedings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_155">Properties</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_156">Competition</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_157">Periodic Reporting and Audited Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_158">CHFW&#146;S MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
 AND RESULTS OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_159">Overview</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_160">Proposed Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_161">Results of Operations and Known Trends or Future Events</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_162">Liquidity and Capital Resources</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_163">Contractual Obligations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_164">Critical Accounting Policies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_166"><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements; Commitments
 and Contractual Obligations; Quarterly Results</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_168">INFORMATION ABOUT SURROZEN</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_169">Overview</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_170">Fundamental Importance of the Wnt Pathway and Our Founders&#146; Roles in Its
 Discovery</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_171">Past Limitations in Targeting the Wnt Pathway for Drug
Discovery</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_172">Our Wnt Therapeutics Platform</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_173">Our Product Candidates and Research Programs</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_174">Our People</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_175">Our Strategy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_176">Intellectual Property</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_177">Competition</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_178">Government Regulation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_179">Other Healthcare Laws and Regulations and Legislative Reform</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_180">Employees and Human Capital Resources</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_181">Facilities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_182">Legal Proceedings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_183">SURROZEN&#146;S MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
 AND RESULTS OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_184">Overview</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_185">The Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_186">Key Trends, Opportunities and Uncertainties</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_187">Stanford License Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_188">UCSF License and Option Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_189">Distributed Bio Subscription Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_190">Components of Our Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_191">Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_192">Liquidity, Capital Resources and Requirements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_193">Funding Requirements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_194">Contractual Obligations and Commitments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_195">Critical Accounting Policies, Significant Judgments and Use of
Estimates</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_196">Emerging Growth Company Status</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_197">Recent Accounting Pronouncements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_198">Quantitative and Qualitative Disclosures About Market Risk</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_199">SURROZEN&#146;S EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_200">Summary Compensation Table</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_201">Employment Arrangements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_202"><FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_203">Outstanding Equity Awards as of December&nbsp;31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_204">Other Compensation and Benefits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_205">Employee Benefit and Stock Plans</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_206">Limitations of Liability and Indemnification Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_208">MANAGEMENT OF NEW SURROZEN FOLLOWING THE BUSINESS COMBINATION</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_209">Executive Officers and Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_210">Executive Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_211"><FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_212">Family Relationships</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_213">Composition of Our Board of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_214">Director Independence</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_215">Committees of Our Board of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_217">Compensation Committee Interlocks and Insider Participation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_218">Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_219">BENEFICIAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_220">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_221">Certain Relationships and Related Person
Transactions&#151;CHFW</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_222">Certain Relationships and Related Person
Transactions&#151;Surrozen</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_223">Preferred Stock Financings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_224">UCSF License and Option Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_225">Investors&#146; Rights Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_226">Voting Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_227">Indemnification Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_228">Policies and Procedures for Related Person Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_229">COMPARISON OF CORPORATE GOVERNANCE AND SHAREHOLDER RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_230">DESCRIPTION OF NEW SURROZEN SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_231">Authorized Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_232">Action by Written Consent</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_233">Anti-Takeover Provisions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_234">Limitations on Liability and Indemnification of Officers and
Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_235">Exclusive Jurisdiction of Certain Actions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_237">SECURITIES ACT RESTRICTIONS ON RESALE OF NEW SURROZEN COMMON
STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_238">Restrictions on the Use of Rule 144 by Shell Companies or Former Shell Companies
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_239">STOCKHOLDER PROPOSALS AND NOMINATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_240">Stockholder Proposals</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_241">Stockholder Director Nominees</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_242">SHAREHOLDER COMMUNICATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_243">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_244">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_245">DELIVERY OF DOCUMENTS TO SHAREHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_246">ENFORCEABILITY OF CIVIL LIABILITY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_247">TRANSFER AGENT AND REGISTRAR</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_248">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY
REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_249">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_250">ANNEX A</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_251">ANNEX B</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_252">ANNEX C</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">C-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_253">ANNEX D</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_254">ANNEX E</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">E-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_255">ANNEX F</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_256">ANNEX G</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_257">ANNEX H</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">H-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_258">ANNEX I</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">I-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_259">ANNEX J</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">J-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_260">ANNEX K</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">K-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom40894_261">EXHIBITS AND FINANCIAL STATEMENTS SCHEDULES </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">II-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_1"></A>ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>You may request copies of this proxy statement/prospectus and any other publicly available information concerning CHFW, without charge, by
written request to <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., 1 Palmer Square, Suite 350, Princeton, NJ 08540, or by telephone request at (609) <FONT STYLE="white-space:nowrap">921-2333;</FONT> or Okapi Partners LLC,
our proxy solicitor, by calling (844) <FONT STYLE="white-space:nowrap">203-3605,</FONT> or banks and brokers can call collect at <FONT STYLE="white-space:nowrap">(212)&nbsp;297-0720,</FONT> or by emailing info@okapipartners.com or from the SEC
through the SEC website at http://www.sec.gov. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>In order for CHFW&#146;s shareholders to receive timely delivery of the documents
in advance of the extraordinary general meeting of CHFW to be held on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, you must request the information no later than five business days prior to
the date of the extraordinary general meeting, by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_2"></A>TRADEMARKS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This document contains references to trademarks, trade names and service marks belonging to other entities. Solely for convenience,
trademarks, trade names and service marks referred to in this proxy statement/prospectus may appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or TM symbols, but such references are not intended to indicate, in any way,
that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies&#146; trade names, trademarks or service marks to imply
a relationship with, or endorsement or sponsorship of us by, any other companies. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_3"></A>SELECTED DEFINITIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless otherwise stated in this proxy statement/prospectus or the context otherwise requires, references to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Articles of Association&#148; are to the amended and restated articles of association of CHFW;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;CHFW,&#148; &#147;we,&#148; &#147;us&#148; or &#147;our&#148; are to
<FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., a Cayman Islands exempted company, prior to the consummation of the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;CHFW Acquisition Proposal&#148; means (a)&nbsp;any transaction or series of related transactions under
which CHFW or any of its controlled affiliates, directly or indirectly, (i)&nbsp;acquires or otherwise purchases any other person(s), (ii) engages in a business combination with any other person(s) or (iii)&nbsp;acquires or otherwise purchases all
or a material portion of the assets or businesses of any other Persons(s) (in the case of each of clause (i), (ii) and (iii), whether by merger, consolidation, recapitalization, purchase or issuance of equity securities, tender offer or otherwise)
or (b)&nbsp;any equity, debt or similar investment in CHFW or any of its controlled affiliates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;CHFW Board&#148; are to CHFW&#146;s board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Business Combination&#148; are to the Domestication, the Merger and other transactions contemplated by
the Business Combination Agreement, collectively, including the PIPE Financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Business Combination Agreement&#148; are to that certain Business Combination Agreement, dated
April&nbsp;15, 2021 (as may be amended, supplemented or otherwise modified from time to time), by and among CHFW, Merger Sub and Surrozen; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Cayman Islands Companies Act&#148; are to the Companies Act (2021 Revision) of the Cayman Islands as the
same may be amended from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Class&nbsp;A ordinary shares&#148; are to the Class&nbsp;A ordinary shares, par value $0.0001 per share,
of CHFW, which will automatically convert, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, into shares of New Surrozen Common Stock in connection with the Domestication; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Class&nbsp;B ordinary shares&#148; or &#147;founder shares&#148; are to the 2,300,000 Class&nbsp;B
ordinary shares, par value $0.0001 per share, of CHFW outstanding as of the date of this proxy statement/prospectus that were initially issued to our Sponsor in a private placement prior to our initial public offering and of which 90,000 were
transferred to Dr.&nbsp;Haqq, Mr.&nbsp;Santel and Ms.&nbsp;Jarrett (30,000 shares each) in November 2020, of which shares shall be contributed without consideration to CHFW in connection with the Domestication and the remaining shares in connection
with the Domestication, will automatically convert, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, into shares of New Surrozen Common Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Closing&#148; are to the closing of the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Closing Date&#148; means that date that is in no event later than the third (3rd) business day,
following the satisfaction (or, to the extent permitted by applicable law, waiver) of the conditions described under the section entitled <I>&#147;Business Combination Proposal&#151;The Business Combination Agreement&#151;Conditions to Closing of
the Business Combination,&#148; (other than those conditions that by their nature are to be satisfied at the Closing, but subject to satisfaction or waiver of such conditions) or at such other date as CHFW and Surrozen may agree in writing; </I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Condition Precedent Proposals&#148; are to the Business Combination Proposal, the Domestication
Proposal, the New Organizational Documents Proposal, the Incentive Award Plan Proposal and the Share Issuance Proposal, collectively; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Consonance Capital&#148; are to Consonance Capital Management LP, any existing and future entity in the
investment advisory business to which Mitchell Blutt, Benny Soffer or Kevin Livingston provides services and any affiliates of our Sponsor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Consonance Capital Management&#148; are to Consonance Capital Management LP, a Delaware limited
partnership; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Consonance Shareholders&#148; are to the Sponsor and the Consonance PIPE Investor;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Continental&#148; are to Continental Stock Transfer&nbsp;&amp; Trust Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Domestication&#148; are to the transfer by way of continuation and deregistration of CHFW from the
Cayman Islands and the continuation and domestication of CHFW as a corporation incorporated in the State of Delaware; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Effective Time&#148; means the time at which the Merger becomes effective; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;ESPP&#148; are to the New Surrozen 2021 Employee Stock Purchase Plan to be considered for adoption and
approval by the shareholders pursuant to the Employee Stock Purchase Plan Proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;extraordinary general meeting&#148; are to the extraordinary general meeting of CHFW
at&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a.m., Eastern Time, on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, via live webcast at the
following address https://www.cstproxy.com/consonancehfw/sm2021, or at such other time or on such other date to which the meeting may be adjourned; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Existing Governing Documents&#148; are to the memorandum of association and the articles of association
of CHFW; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Governing Documents Proposals&#148; are collectively, four (4)&nbsp;separate proposals to approve
material differences between CHFW&#146;s existing amended and restated memorandum and articles of association (the &#147;Existing Governing Documents&#148;) and the proposed new certificate of incorporation of New Surrozen and the proposed new
bylaws of New Surrozen upon the Domestication, copies of which are attached to the accompanying proxy statement/prospectus as Annexes&nbsp;C and D, respectively, including to approve the change in the authorized share capital of CHFW from
(i)&nbsp;$50,100 divided into 350,000,000 Class&nbsp;A ordinary shares, par value $0.0001 per share, 150,000,000 Class&nbsp;B ordinary shares, par value $0.0001 per share and 1,000,000 preference shares, par value $0.0001 per share, to
(ii)&nbsp;300,000,000 shares of common stock, par value $0.0001 per share and 10,000,000 shares of preferred stock, par value $0.0001 per share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Group Companies&#148; are to Surrozen and its subsidiaries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;initial public offering&#148; are to CHFW&#146;s initial public offering that was consummated on
November&nbsp;23, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Incentive Equity Plan&#148; are to the Surrozen, Inc. 2021 Equity Incentive Plan to be considered for
adoption and approval by the shareholders pursuant to the Incentive Award Plan Proposal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;initial shareholders&#148; are to Sponsor and each Dr.&nbsp;Mitchell Blutt, Dr.&nbsp;Benny Soffer,
Mr.&nbsp;Donald&nbsp;J. Santel, Dr.&nbsp;Christopher Haqq and Ms.&nbsp;Jennifer Jarrett; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Merger&#148; are to the merger of Merger Sub with and into Surrozen pursuant to the Business Combination
Agreement, with Surrozen (to be renamed Surrozen Operating, Inc.) as the surviving company in the Merger and, after giving effect to such Merger, Surrozen Operating, Inc. becoming a wholly-owned subsidiary of New Surrozen; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Merger Sub&#148; are to Perseverance Merger Sub, Inc., a Delaware corporation and wholly-owned
subsidiary of CHFW prior to the consummation of the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Nasdaq&#148; are to the Nasdaq Capital Market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;New Surrozen&#148; are to Surrozen, Inc. (f.k.a. <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT>
Acquisition Corp.) upon and after the Domestication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;New Surrozen Board&#148; are to the board of directors of New Surrozen; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;New Surrozen Common Stock&#148; are to the common stock, par value $0.0001 per share, of New Surrozen;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;ordinary shares&#148; are to our Class&nbsp;A ordinary shares and our Class&nbsp;B ordinary shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;PIPE Financing&#148; are to the transactions contemplated by the Subscription Agreements, pursuant to
which the PIPE Investors have collectively committed to subscribe for 12,020,000 units, each consisting of one share of New Surrozen Common Stock <FONT STYLE="white-space:nowrap">and&nbsp;one-third&nbsp;of</FONT> one redeemable warrant for one share
of New Surrozen Common Stock (the &#147;PIPE Warrants&#148;), for a purchase price of $10.00 per unit (the &#147;PIPE Units&#148;), for aggregate gross proceeds of $120,200,000; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;PIPE Investors&#148; are to the investors in the PIPE Financing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;private placement shares&#148; are to the Class&nbsp;A ordinary shares of CHFW that were issued to our
Sponsor as part of the private placement units; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;private placement units&#148; are to the private placement units that were issued to our Sponsor in a
private placement simultaneously with the closing of our initial public offering, which are identical to the units sold in our initial public offering, subject to certain limited exceptions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;private placement warrants&#148; are to the private placement warrants that were issued to our Sponsor
as part of the private placement units, which are substantially identical to the public warrants sold as part of the units in the initial public offering, subject to certain limited exceptions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;pro forma&#148; are to giving pro forma effect to the Business Combination, including the Merger and the
PIPE Financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Proposed Bylaws&#148; are to the proposed bylaws of New Surrozen to be effective upon the Domestication
attached to this proxy statement/prospectus as Annex D; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Proposed Certificate of Incorporation&#148; are to the proposed certificate of incorporation of New
Surrozen to be effective upon the Domestication attached to this proxy statement/prospectus as Annex&nbsp;C; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Proposed Governing Documents&#148; are to the Proposed Certificate of Incorporation and the Proposed
Bylaws; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;public shareholders&#148; are to holders of public shares, whether acquired in CHFW&#146;s initial
public offering or acquired in the secondary market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;public shares&#148; are to the Class&nbsp;A ordinary shares of CHFW issued in CHFW&#146;s initial public
offering, whether acquired in CHFW&#146;s initial public offering or acquired in the secondary market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;public warrants&#148; are to the redeemable warrants to purchase Class&nbsp;A ordinary shares of CHFW
that were issued by CHFW in its initial public offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;redemption&#148; are to each redemption of public shares for cash pursuant to the Existing Governing
Documents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;SEC&#148; are to the U.S. Securities and Exchange Commission; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Securities Act&#148; are to the Securities Act of 1933, as amended; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Sponsor&#148; are to Consonance Life Sciences, a Cayman Islands limited liability company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Subscription Agreements&#148; are to the subscription agreements, entered into by CHFW and each of the
PIPE Investors in connection with the PIPE Financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Surrozen&#148; are to Surrozen, Inc., a Delaware corporation, prior to the consummation of the Business
Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Surrozen Acquisition Proposal&#148; means (a)&nbsp;any transaction or series of related transactions
under which any person(s), directly or indirectly, (i)&nbsp;acquires or otherwise purchases Surrozen or any of its controlled affiliates or (ii)&nbsp;all or more than 15% in value of assets or businesses of Surrozen or any of its controlled
affiliates (in the case of each of clause (i)&nbsp;and (ii), whether by merger, consolidation, recapitalization, purchase or issuance of equity securities, tender offer or otherwise), or (b) 15% or more of any equity or similar investment in
Surrozen or any of its controlled affiliates other than Surrozen equity awards or shares issuable under the exercise or settlement of Surrozen equity awards (subject to exceptions for any of the Transactions); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Surrozen Stockholders&#148; are all of the stockholders of Surrozen; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Transactions&#148; means the transactions contemplated by the Business Combination Agreement, including
the Domestication and the Merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;transfer agent&#148; are to Continental, CHFW&#146;s transfer agent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;trust account&#148; are to the trust account established at the consummation of CHFW&#146;s initial
public offering that holds the proceeds of the initial public offering and is maintained by Continental, acting as trustee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;units&#148; are to the units of CHFW, each unit representing one Class&nbsp;A ordinary share and <FONT
STYLE="white-space:nowrap">one-third</FONT> of one warrant to acquire one Class&nbsp;A ordinary share, that were offered and sold by CHFW in its initial public offering and in its concurrent private placement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;warrants&#148; are to the public warrants and the private placement warrants. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain statements in this proxy statement/prospectus may constitute &#147;forward-looking statements&#148; for purposes of the federal
securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management team&#146;s expectations, hopes, beliefs, intentions or strategies regarding the future, including those relating to the
Business Combination. The information included in this proxy statement/prospectus in relation to Surrozen has been provided by Surrozen and its management, and forward-looking statements include statements relating to its and its management
team&#146;s expectations, hopes, beliefs, intentions or strategies regarding the future, including those relating to the Business Combination. In addition, any statements that refer to projections, forecasts or other characterizations of future
events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148;
&#147;expect,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;possible,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; and similar
expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this proxy statement/prospectus may include, for example, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to complete the Business Combination with Surrozen or, if we do not consummate such Business
Combination, any other initial business combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfaction or waiver of the conditions to the Business Combination including, (i)&nbsp;the approval by our
shareholders of the Condition Precedent Proposals being obtained; (ii)&nbsp;CHFW having at least $5,000,001 of net tangible assets (as determined in accordance with <FONT STYLE="white-space:nowrap">Rule&nbsp;3a51-1(g)(1)&nbsp;of</FONT> the Exchange
Act) after giving effect to the transactions contemplated by the Business Combination Agreement and the PIPE Financing; (iii)&nbsp;the Aggregate Transaction Proceeds Condition; (iv)&nbsp;the approval by Nasdaq of our initial listing application in
connection with the Business Combination; and (v)&nbsp;the consummation of the Domestication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the occurrence of any event, change or other circumstances, including the outcome of any legal proceedings
that may be instituted against CHFW and Surrozen following the announcement of the Business Combination Agreement and the transactions contemplated therein, that could give rise to the termination of the Business Combination Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to obtain and/or maintain the listing of New Surrozen Common Stock on Nasdaq, and the potential
liquidity and trading of such securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that the proposed Business Combination disrupts current plans and operations of Surrozen as a result
of the announcement and consummation of the proposed Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to recognize the anticipated benefits of the proposed Business Combination, which may be affected
by, among other things, the ability of Surrozen to pursue its business plan and retain its key employees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to the proposed Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in applicable laws or regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to raise financing in the future, if and when needed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our success in retaining or recruiting, or changes required in, our officers, key employees or directors
following the completion of the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our officers and directors allocating their time to other businesses and potentially having conflicts of
interest with our business or in approving the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of Surrozen&#146;s total addressable market, expenses, capital requirements and our needs for
additional financing;<B> </B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, cost, timing, progress and results of research and development activities, preclinical or and
clinical trials with respect to <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT STYLE="white-space:nowrap">SZN-043,</FONT> and potential future drug candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s ability to identify, develop and commercialize drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s ability to advance <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT
STYLE="white-space:nowrap">SZN-043,</FONT> or other future product candidates into, and successfully complete, preclinical studies and clinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s ability to obtain and maintain regulatory approval of
<FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT STYLE="white-space:nowrap">SZN-043,</FONT> or other future product candidates, and any related restrictions, limitations and/or warnings in the label of an approved drug candidate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s ability to develop and expand our drug discovery and development capabilities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s ability to identify product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s ability to obtain funding for our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s ability to obtain and maintain intellectual property protection for Surrozen&#146;s technology
and any of its product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s ability to successfully commercialize any of its product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of any of Surrozen&#146;s product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and international jurisdictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential liability lawsuits and penalties related to Surrozen&#146;s technology, product candidates and
current and future relationships with third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s ability to attract and retain key scientific and management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s ability to effectively manage the growth of its operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s ability to contract with third-party suppliers and manufacturers and their ability to perform
adequately under those arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s ability to compete effectively with existing competitors and new market entrants;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential effects of extensive government regulation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New Surrozen&#146;s expectations regarding the time during which it will be an emerging growth company under
the JOBS Act; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the volatility of the trading price of our common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You should not rely on forward-looking statements as predictions of future events. We and Surrozen have based the forward-looking statements
contained herein primarily on current expectations and projections about future events and trends that we and Surrozen believe may affect our business, financial condition, results of operation, business strategy and financial needs. The outcome of
the events described in these forward-looking statements is subject to risks and uncertainties These risks and uncertainties include, but are not limited to, those factors described under the heading &#147;<I>Risk Factors.</I>&#148; Should one or
more of these risks or uncertainties materialize, or should any of our or Surrozen&#146;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to
predict or identify all such risks. Moreover, Surrozen operates, and New Surrozen will operate, in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict
all risks and uncertainties that could have an impact on us. The results, events and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events or circumstances could differ materially from
those described in the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, statements that &#147;we believe&#148; or &#147;Surrozen believes&#148;
and similar statements reflect our or Surrozen&#146;s beliefs and opinions on the relevant subject. These statements are based on information available to us as of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
date hereof. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Such statements should not be read to indicate that
we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. We undertake no obligation to update any
forward-looking statements made herein to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We qualify all of the forward-looking statements included in this proxy statement/prospectus, or any amendments or supplements to this proxy
statement/prospectus, by these cautionary statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Before any shareholder grants its proxy or instructs how its vote should be cast or
vote on the proposals to be put to the extraordinary general meeting, such stockholder should be aware that the occurrence of the events described in the &#147;<I>Risk Factors</I>&#148; section and elsewhere in this proxy statement/prospectus may
adversely affect us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_5"></A>QUESTIONS AND ANSWERS FOR SHAREHOLDERS OF CHFW </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The questions and answers below highlight only selected information from this document and only briefly address some commonly asked
questions about the proposals to be presented at the extraordinary general meeting, including with respect to the proposed Business Combination. The following questions and answers do not include all the information that is important to CHFW&#146;s
shareholders. We urge shareholders to read this proxy statement/prospectus, including the Annexes and the other documents referred to herein, carefully and in their entirety to fully understand the proposed Business Combination and the voting
procedures for the extraordinary general meeting, which will be held at&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.m., Eastern Time,
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, via live webcast at the following address: https://www.cstproxy.com/consonancehfw/sm2021. </I></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Why am I receiving this proxy statement/prospectus? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">CHFW shareholders are being asked to consider and vote upon, among other proposals, a proposal to approve
and adopt the Business Combination Agreement and approve the Transactions. In accordance with the terms and subject to the conditions of the Business Combination Agreement, among other things, in connection with the Domestication, on the Closing
Date prior to the Effective Time, (i)&nbsp;CHFW will be renamed &#147;Surrozen, Inc.&#148; and (ii)&nbsp;each share and equity award (whether vested or unvested) of Surrozen outstanding as of immediately prior to the Effective Time will be exchanged
for shares of New Surrozen Common Stock or comparable vested equity awards that are settled or are exercisable for shares of New Surrozen Common Stock, as applicable, based on an implied Surrozen equity value of $200,000,000<B> </B>and a $10.00 per
share value for New Surrozen Common Stock. See &#147;<I>Business Combination Proposal</I>.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A copy of the Business
Combination Agreement is attached to this proxy statement/prospectus as Annex A and you are encouraged to read the Business Combination Agreement in its entirety. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The approval of each of the Business Combination Proposal, the Governing Documents Proposal&nbsp;A, the Incentive Award Plan Proposal, the
Employee Stock Purchase Plan Proposal, the Share Issuance Proposal and the Adjournment Proposal (each as defined below) requires an ordinary resolution under Cayman Islands law, being the affirmative vote of at least a majority of the votes cast by
the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter, and each of the Domestication Proposal, the New Organizational Documents Proposal, the
Governing Documents Proposal&nbsp;B, the Governing Documents Proposal&nbsp;C and the Governing Documents Proposal&nbsp;D (each as defined below) requires a special resolution under Cayman Islands law, being the affirmative vote of at least a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> (2/3) majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with the Domestication, on the Closing Date prior to the Effective Time, (i)&nbsp;each issued and outstanding Class&nbsp;A
ordinary share and each issued and outstanding Class&nbsp;B ordinary share of CHFW will convert automatically by operation of law, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, into shares of
New Surrozen Common Stock; (ii)&nbsp;each issued and outstanding warrant to purchase Class&nbsp;A ordinary shares of CHFW will automatically represent the right to purchase one share of New Surrozen Common Stock at an exercise price of $11.50 per
shares of New Surrozen Common Stock on the terms and conditions set forth in the warrant agreement; and (iii)&nbsp;each issued and outstanding unit of CHFW that has not been previously separated into the underlying Class&nbsp;A ordinary share and
underlying warrant upon the request of the holder thereof, will be cancelled and will entitle the holder thereof to one share of New Surrozen Common Stock and <FONT STYLE="white-space:nowrap">one-third</FONT> of one warrant to acquire one share of
New Surrozen Common Stock. See &#147;<I>Domestication Proposal</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The provisions of the Proposed Governing Documents will differ in certain material
respects from the Existing Governing Documents. Please see &#147;<I>What changes will be made to the current constitutional documents of CHFW?</I>&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THE VOTE OF SHAREHOLDERS IS IMPORTANT. SHAREHOLDERS ARE ENCOURAGED TO VOTE AS SOON AS POSSIBLE AFTER CAREFULLY REVIEWING THIS PROXY
STATEMENT/PROSPECTUS. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>What proposals are shareholders of CHFW being asked to vote upon? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">At the extraordinary general meeting, CHFW is asking holders of its ordinary shares to consider and vote
upon eight (8) separate proposals: </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a proposal to approve by ordinary resolution and adopt the Business Combination Agreement, including the
Merger, and the Transactions (the &#147;Business Combination Proposal&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a proposal to approve by special resolution the Domestication (the &#147;Domestication Proposal&#148;);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a proposal to approve the replacement of CHFW&#146;s existing amended and restated memorandum and articles of
association with a proposed new certificate of incorporation (the &#147;Proposed Certificate of Incorporation) and proposed new bylaws (the &#147;Proposed Bylaws&#148;) and, together with the Proposed Certificate of Incorporation, the &#147;Proposed
Governing Documents&#148;) of New Surrozen (the &#147;New Organizational Documents Proposal&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">four&nbsp;(4) separate advisory, non-binding proposals to approve material differences between CHFW&#146;s
existing amended and restated memorandum and articles of association (the &#147;Existing Governing Documents&#148;) and the proposed new certificate of incorporation of New Surrozen and the proposed new bylaws of New Surrozen upon the Domestication,
copies of which are attached to the accompanying proxy statement/prospectus as Annexes&nbsp;C and D, respectively, including to approve the change in the authorized share capital of CHFW from (i)&nbsp;$50,100 divided into 350,000,000 Class&nbsp;A
ordinary shares, par value $0.0001 per share, 150,000,000 Class&nbsp;B ordinary shares, par value $0.0001 per share and 1,000,000 preference shares, par value $0.0001 per share, to (ii)&nbsp;300,000,000 shares of common stock, par value $0.0001 per
share and 10,000,000 shares of preferred stock, par value $0.0001 per share (collectively, the &#147;Governing Documents Proposals&#148;): </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a proposal to approve by ordinary resolution shares of New Surrozen Common Stock in connection with the
Business Combination and the PIPE Financing in compliance with the Nasdaq Listing Rules (the &#147;Share Issuance Proposal&#148;); </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a proposal to approve and adopt by ordinary resolution the Equity Incentive Plan (the &#147;Incentive Award
Plan Proposal&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a proposal to approve and adopt by ordinary resolution the ESPP (the &#147;Employee Stock Purchase Plan
Proposal&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a proposal to approve by ordinary resolution the adjournment of the extraordinary general meeting to a later
date or dates, if necessary, to, among other things, permit further solicitation and vote of proxies in the event that there are insufficient votes for the approval of one or more proposals at the extraordinary general meeting (the &#147;Adjournment
Proposal&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Business Combination will be consummated only if the Condition Precedent Proposals
are approved at the extraordinary general meeting. The Employee Stock Purchase Plan Proposal is conditioned on the approval of the Condition Precedent Proposals. The Adjournment Proposal is not conditioned upon the approval of any other proposal.
Each of these proposals is more fully described in the accompanying proxy statement/prospectus, which each shareholder is encouraged to read carefully and in its entirety. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If our shareholders do not approve each of the Condition Precedent Proposals, then unless certain conditions in the Business
Combination Agreement are waived by the applicable parties to the Business Combination </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Agreement, the Business Combination Agreement could terminate and the Business Combination may not be consummated. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For more information, please see &#147;<I>Business Combination Proposal</I>,&#148; &#147;<I>Domestication Proposal</I>,&#148;
&#147;<I>Governing Documents Proposals</I>,&#148; &#147;<I>Share Issuance Proposal</I>,&#148; &#147;<I>Incentive Award Plan Proposal,</I>&#148; &#147;<I>Employee Stock Purchase Plan Proposal</I>&#148; and &#147;<I>Adjournment Proposal</I>.&#148;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW will hold the extraordinary general meeting to consider and vote upon these proposals. This proxy
statement/prospectus contains important information about the Business Combination and the other matters to be acted upon at the extraordinary general meeting. Shareholders of CHFW should read it carefully. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>After careful consideration, the CHFW Board has determined that the Business Combination Proposal, the Domestication
Proposal, the New Organizational Documents Proposal, each of the Governing Documents Proposals, the Share Issuance Proposal, the Incentive Award Plan Proposal, the Employee Stock Purchase Plan Proposal and the Adjournment Proposal are in the best
interests of CHFW and its shareholders and unanimously recommends that you vote or give instruction to vote &#147;FOR&#148; each of those proposals. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The existence of financial and personal interests of one or more of CHFW&#146;s directors may result in a conflict of interest
on the part of such director(s) between what he, she or they may believe is in the best interests of CHFW and its shareholders and what he, she or they may believe is best for himself or themselves in determining to recommend that shareholders vote
for the proposals. In addition, CHFW&#146;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#147;<I>Business Combination Proposal&#151;Interests of CHFW&#146;s
Directors and Executive Officers in the Business Combination</I>&#148; for a further discussion of these considerations. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Why is CHFW proposing the Business Combination? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">CHFW is a blank check company incorporated on August&nbsp;21, 2020 as a Cayman Islands exempted company and
incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Although CHFW may pursue an acquisition opportunity in any business,
industry, sector or geographical location for purposes of consummating an initial business combination, CHFW has focused on businesses in the life sciences industry. CHFW is not permitted under its Existing Governing Documents to effect a business
combination with a blank check company or a similar type of company with nominal operations. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW has
identified several criteria and guidelines it believes are important for evaluating acquisition opportunities. CHFW has sought to acquire companies that: possess multiple clinical and or <FONT STYLE="white-space:nowrap">pre-clinical</FONT> product
candidates in its pipeline, diversifying risk away from a single asset and providing multiple potential catalysts for value creation, business development or financing activities once public; have existing clinical or preclinical data, whether or
not generated by the target company, suggesting a validated biologic or mechanistic rationale for the most advanced product candidates in its pipeline; have <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical development programs
designed to address significant challenges in areas of high unmet need where opportunities exist for accelerated clinical development and registration due to the paucity of existing treatments or the limited safety or efficacy of current treatments;
have a valuation at acquisition suggesting an attractive risk/reward profile for investors; a management team with significant scientific, clinical, and operational expertise, with a track record of drug development giving us confidence that they
can execute against stated timelines; and would be funded well beyond significant value inflection points once the acquisition is complete, and would benefit from CHFW&#146;s experience and network to bring value to patients and shareholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on its due diligence investigations of Surrozen and the industry in which it operates, including the pipeline and other
information provided by Surrozen in the course of negotiations, the CHFW Board believes that Surrozen meets the criteria and guidelines listed above. However, there is no assurance of this. See &#147;<I>Business Combination Proposal&#151;The CHFW
Board&#146;s Reasons for the Business Combination</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although the CHFW Board believes that the Business Combination with Surrozen
presents a unique business combination opportunity and is in the best interests of CHFW and its shareholders, the board of directors did consider certain potentially material negative factors in arriving at that conclusion. These factors are
discussed in greater detail in the sections entitled &#147;<I>Business Combination Proposal&#151;The CHFW</I> <I>Board&#146;s Reasons for the Business Combination</I>&#148; and &#147;<I>Risk Factors&#151;Risks Related to CHFW&#146;s Business and to
New Surrozen&#146;s Business Following the Business Combination</I>.&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Did the CHFW Board obtain a third-party valuation or fairness opinion in determining whether or not to
proceed with the Business Combination? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">No. The CHFW Board did not obtain a third-party valuation or fairness opinion in connection with its
determination to approve the Business Combination. However, CHFW&#146;s management, the members of the CHFW Board and the other representatives of CHFW have substantial experience in evaluating the operating and financial merits of companies similar
to Surrozen and identified and evaluated approximately 100 potential business combination partners which CHFW&#146;s management and directors believed, based on their experience, could satisfy some or all the key criteria for a business combination
target described in the section titled &#147;<I>Business Combination Proposal&#151;Background to the Business Combination</I>.&#148; Accordingly, investors will be relying solely on the judgment of the CHFW Board in valuing Surrozen&#146;s business
and assuming the risk that the CHFW Board may not have properly valued such business. </P></TD></TR></TABLE>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>What will Surrozen&#146;s equityholders receive in return for the Business Combination with CHFW?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">On the date of Closing, promptly following the consummation of the Domestication, Merger Sub will merge with
and into Surrozen, with Surrozen as the surviving company in the Merger and, after giving effect to such Merger, Surrozen shall be a wholly-owned subsidiary of CHFW. In accordance with the terms and subject to the conditions of the Business
Combination Agreement, at the Effective Time, each share and equity award (whether vested or unvested) of Surrozen outstanding as of immediately prior to the Effective Time will be exchanged for shares of New Surrozen Common Stock or comparable
vested or unvested equity awards that are settled or are exercisable for shares of New Surrozen Common Stock, as applicable, based on an implied Surrozen equity value of $200,000,000<B> </B>and a $10.00 per share value for New Surrozen Common Stock.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>How will the combined company be managed following the business combination? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Business Combination Agreement provides that the current management of Surrozen will become the
management of New Surrozen, and the New Surrozen Board will consist of nine directors, which will be divided into three classes (Class I, II and III) with each class consisting of three directors. Pursuant to the Business Combination Agreement, the
New Surrozen Board will consist of eight individuals designated by Surrozen prior to the mailing of this proxy statement to CHFW shareholders (all of whom are existing members of Surrozen&#146;s board of directors) and one director designated by
CHFW prior to the mailing of this proxy statement to CHFW shareholders, to be reasonably acceptable to Surrozen&#146;s CEO. CHFW has nominated Mace Rothenberg, M.D., who was appointed to the Surrozen board on May&nbsp;6, 2021. Please see the section
entitled &#147;<I>Management of New Surrozen Following the Business Combination</I>&#148; for further information. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>What equity stake will current CHFW shareholders and current equityholders of Surrozen hold in New
Surrozen immediately after the consummation of the Business Combination? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">It is anticipated that, upon completion of the Business Combination and based on ownership as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021, the record date for the extraordinary general meeting, the CHFW shareholders (other than the PIPE Investors&#146; PIPE Financing) will retain
an ownership interest of approximately 21.3% in New Surrozen and the PIPE Investors (excluding the impact of PIPE subscriptions by certain Surrozen stockholders and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Sponsor), by virtue of the PIPE Financing, will own approximately 14.8% of New Surrozen (such that CHFW shareholders, including the PIPE Investors, will own approximately 36.1% in New Surrozen).
The ownership&nbsp;percentage with respect to New Surrozen following the Business Combination does not take into account (i)&nbsp;the redemption of any shares by the CHFW shareholders, or (ii)&nbsp;the issuance of any shares after the Closing under
the Equity Incentive Plan or the Employee Stock Purchase Plan. If the actual facts are different from these assumptions (which they are likely to be), the&nbsp;percentage ownership retained by CHFW&#146;s existing shareholder in New Surrozen will be
different. Please see the section titled &#147;<I>Management of New Surrozen Following the Business Combination</I>&#148; for further information. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Why is CHFW proposing the Domestication? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Our board of directors believes that there are significant advantages to us that will arise as a result of a
change of our domicile to Delaware. Further, our board of directors believes that any direct benefit that the Delaware General Corporation Law (the &#147;DGCL&#148;) provides to a corporation also indirectly benefits its stockholders, who are the
owners of the corporation. The board of directors believes that there are several reasons why transfer by way of continuation to Delaware is in the best interests of CHFW and its shareholders, including, (i)&nbsp;the prominence, predictability and
flexibility of the DGCL, (ii)&nbsp;Delaware&#146;s well-established principles of corporate governance and (iii)&nbsp;the increased ability for Delaware corporations to attract and retain qualified directors, each of the foregoing are discussed in
greater detail in the section titled &#147;<I>Domestication Proposal&#151;Reasons for the Domestication</I>.&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To effect the Domestication, we will file an application for deregistration with the Cayman Islands Registrar of Companies,
together with the necessary accompanying documents, and file a certificate of corporate domestication and a certificate of incorporation with the Secretary of State of the State of Delaware, under which we will be domesticated and continue as a
Delaware corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The approval of the Domestication Proposal is a condition to closing the Business Combination under
the Business Combination Agreement. The approval of the Domestication Proposal requires a special resolution under Cayman Islands law, being the affirmative vote of at least a <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) majority of the
votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes,</FONT>
while considered present for the purposes of establishing a quorum, will not count as votes cast at the extraordinary general meeting, and otherwise will have no effect on a particular proposal. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>What changes will be made to the current constitutional documents of CHFW? </B></P></TD></TR></TABLE>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The consummation of the Business Combination is conditioned on, among other things, the Domestication.
Accordingly, in addition to voting on the Business Combination, CHFW&#146;s shareholders also are being asked to consider and vote upon a proposal to approve the Domestication, and replace CHFW&#146;s Existing Governing Documents, in each case,
under Cayman Islands law with the Proposed Governing Documents, in each case, under the DGCL, which differ from the Existing Governing Documents in the following material respects: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="40%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Existing Governing Documents</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Proposed Governing Documents</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Authorized&nbsp;Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The share capital under the Existing Governing Documents is US$50,100 divided into 350,000,000 Class&nbsp;A ordinary shares
of par value US$0.0001 per share, 150,000,000 Class&nbsp;B ordinary shares of par value US$0.0001 per share and 1,000,000 preference shares of par value US$0.0001 per share.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents authorize 300,000,000 shares of New Surrozen Common Stock and 10,000,000 shares of New
Surrozen Preferred Stock.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See paragraph 8 of the Existing Governing Documents.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See Article IV subsection A of the Proposed Certificate of
Incorporation.</I></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="40%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Existing Governing Documents</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Proposed Governing Documents</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Authorize the</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Board&nbsp;of&nbsp;Directors</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to Issue Preferred</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Stock Without</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Stockholder</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Existing Governing Documents authorize the issuance of 1,000,000 preference shares with such designation, rights and
preferences as may be determined from time to time by our board of directors. Accordingly, the CHFW Board is empowered under the Existing Governing Documents, without shareholder approval, to issue preference shares with dividend, liquidation,
redemption, voting or other rights which could adversely affect the voting power or other rights of the holders of ordinary shares.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents authorize the board of directors to issue all or any shares of preferred stock in one or
more series to fix the number of shares and to determine or alter for each such series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such
qualifications, limitations, or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by the Board of Directors providing for the issuance of such shares and as may be permitted by the DGCL.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See paragraph 8 of the Existing Governing Documents and Article 3 of the Articles of Association.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See Article IV subsection B of the Proposed Certificate of Incorporation.</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Corporate&nbsp;Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Existing Governing Documents provide the name of the company is
<FONT STYLE="white-space:nowrap">&#147;Consonance-HFW</FONT> Acquisition Corp.&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents will provide that the name of the corporation will be &#147;Surrozen,
Inc.&#148;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See paragraph 1 of our Existing Governing Documents.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See Article I of the Proposed Certificate of Incorporation.</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Perpetual</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Existence</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Existing Governing Documents provide that if we do not consummate a business combination (as defined in the Existing
Governing Documents) by November&nbsp;23, 2022 (twenty-four months after the closing of CHFW&#146;s initial public offering), CHFW will cease all operations except for the purposes of winding up and will redeem the shares issued in CHFW&#146;s
initial public offering and liquidate its trust account.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents do not include any provisions relating to New Surrozen&#146;s ongoing existence; the
default under the DGCL will make New Surrozen&#146;s existence perpetual.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See Article 38 of our Articles of Association.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>This is the default rule under the DGCL.</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Shareholder/Stockholder Written Consent In Lieu of a Meeting</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Existing Governing Documents provide that resolutions may be passed by a vote in person, by proxy at a general meeting,
or by unanimous written resolution.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Certificate of Incorporation allows stockholders to vote in person or by proxy at a meeting of stockholders,
but prohibits the ability of stockholders to act by written consent in lieu of a meeting.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See Articles 14 and 15 of our Articles of Association.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Exclusive&nbsp;Forum</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Existing Governing Documents do not contain a provision adopting an exclusive forum for certain shareholder
litigation.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents adopt Delaware as the exclusive forum for certain stockholder litigation and the federal
district courts of the United Stated of America shall be the exclusive forum for litigation arising out of the Securities Act.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="40%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Existing Governing Documents</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Proposed Governing Documents</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See Article VII subsections A and B of the Proposed Certificate of Incorporation</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Provisions&nbsp;related</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to&nbsp;the&nbsp;Corporate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Opportunity</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Doctrine</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Existing Governing Documents do not address corporate opportunities under Cayman Law.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents provide a waiver of the obligation of nonemployee directors of New Surrozen to offer
certain corporate opportunities to New Surrozen unless the opportunity is acquired or become in the possession of the direct expressly and solely in connection with such individual&#146;s service on the board of New Surrozen.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See Article V of the Proposed Certificate of Incorporation.</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Provisions&nbsp;Related</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to Status as a</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Blank Check</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Existing Governing Documents set forth various provisions related to our status as a blank check company prior to the consummation of a business combination.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Proposed Governing Documents do not include such provisions related to our status as a blank check company, which no longer will apply upon consummation of the Business Combination, as we will cease to be a blank check company
at such time.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>See Article 38 of our Articles of Association.</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>How will the Domestication affect my ordinary shares, warrants and units? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In connection with the Domestication, on the Closing Date prior to the Effective Time, (i)&nbsp;each issued
and outstanding Class&nbsp;A ordinary share and each issued and outstanding Class&nbsp;B ordinary share of CHFW will convert automatically by operation of law, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, into shares of New Surrozen Common Stock; (ii)&nbsp;each issued and outstanding warrant to purchase Class&nbsp;A ordinary shares of CHFW will
automatically represent the right to purchase one share of New Surrozen Common Stock at an exercise price of $11.50 per shares of New Surrozen Common Stock on the terms and conditions set forth in the warrant agreement; and (iii)&nbsp;each issued
and outstanding unit of CHFW that has not been previously separated into the underlying Class&nbsp;A ordinary share and underlying warrant upon the request of the holder thereof, will be cancelled and will entitle the holder thereof to one share of
New Surrozen Common Stock and <FONT STYLE="white-space:nowrap">one-third</FONT> of one warrant to acquire one share of New Surrozen Common Stock. See &#147;<I>Domestication Proposal.</I>&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with the terms and subject to the conditions of the Business Combination Agreement, at the Effective Time, each
share and equity award (whether vested or unvested) of Surrozen outstanding as of immediately prior to the Effective Time will be exchanged for shares of New Surrozen Common Stock or comparable equity awards that are settled or are exercisable for
shares of New Surrozen Common Stock, as applicable, based on an implied Surrozen equity value of $200,000,000 and a $10.00 per share value for New Surrozen Common Stock. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>What are the U.S. federal income tax consequences of the Domestication? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">As discussed more fully under &#147;<I>U.S. Federal Income Tax Considerations</I>, <I>Risks Related to the
Consummation of the Domestication&#148;</I><B> </B>the Domestication should qualify as a <FONT STYLE="white-space:nowrap">tax-deferred</FONT> reorganization within the meaning of Section&nbsp;368(a)(1)(F) of the U.S. Internal Revenue Code of 1986,
as amended (the &#147;Code&#148;). However, due to the absence of direct guidance on the application of Section&nbsp;368(a)(1)(F) to a statutory conversion of a corporation holding only investment-type assets such as CHFW, this result is not
entirely clear. Accordingly, due to the absence of such guidance, it is not possible to predict whether the IRS or a court considering the issue would take a contrary position. If the Domestication qualifies as a
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
reorganization, certain U.S. Holders may be required to recognize gain under Section 367(b) of the Code . In addition, a s discussed under &#147;<I>Certain Material U.S. Federal Income Tax
Considerations</I>,&#148; CHFW believes it is likely that it qualified as a &#147;passive foreign investment company (&#147; PFIC&#148;) for the 2020 taxable year and will qualify as a PFIC for the short taxable year that will end on the date of the
Domestication. If CHFW is treated as a PFIC, proposed Treasury Regulations under Section 1291(f) of the Code that have a retroactive effective date, if finalized in their current form, would require U.S. Holders of public shares and public warrants
to recognize gain on the Domestication in certain circumstances. If, however, the Domestication fails to qualify as a reorganization under Section&nbsp;368(a)(1)(F) of the Code, a U.S. Holder (as defined under &#147;<I>U.S. Federal Income Tax
Considerations</I>&#148;) generally would recognize gain or loss with respect to its public shares or public warrants in an amount equal to the difference, if any, between the fair market value of the corresponding shares of New Surrozen Common
Stock or New Surrozen warrants received in the Domestication and the U.S. Holder&#146;s adjusted tax basis in its public shares and public warrants surrendered in exchange therefor. If the PFIC rules apply and the U.S. Holder has not made certain
elections with respect to its public shares, the character of the gain and the amount of tax required to be paid with respect to such gain may differ. For further discussion, see &#147;<I>Certain Material </I><I>U.S. Federal </I><I>Income Tax
Considerations.&#148;</I> </P></TD></TR></TABLE>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Do I have redemption rights? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If you are a holder of public shares, you have the right to request that we redeem all or a portion of your
public shares for cash provided that you follow the procedures and deadlines described elsewhere in this proxy statement/prospectus. <B>Public shareholders (other than those who have agreed not to do so by executing an CHFW Shareholder Support
Agreement) may elect to redeem all or a portion of the public shares held by them regardless of if or how they vote in respect of the Business Combination Proposal</B>. If you wish to exercise your redemption rights, please see the answer to the
next question: &#147;<I>How do I exercise my redemption rights?</I>&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing,
a public shareholder, together with any affiliate of such public shareholder or any other person with whom such public shareholder is acting in concert or as a &#147;group&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act), will be
restricted from redeeming its public shares with respect to more than an aggregate of 15% of the public shares. Accordingly, if a public shareholder, alone or acting in concert or as a group, seeks to redeem more than 15% of the public shares, then
any such shares in excess of that 15% limit would not be redeemed for cash. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The initial shareholders have agreed to waive
their redemption rights with respect to all of their ordinary shares in connection with the consummation of the Business Combination. Such shares will be excluded from the pro rata calculation used to determine the
<FONT STYLE="white-space:nowrap">per-share</FONT> redemption price. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>How do I exercise my redemption rights? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In connection with the proposed Business Combination, pursuant to the Existing Governing Documents,
CHFW&#146;s public shareholders (other than those who have agreed not to do so by executing an CHFW Shareholder Support Agreement) may request that CHFW redeem all or a portion of such public shares for cash if the Business Combination is
consummated. If you are a public shareholder and wish to exercise your right to redeem the public shares, you must: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">(a) hold public shares, or (b)&nbsp;if you hold public shares through units, you elect to separate your
units into the underlying public shares and public warrants prior to exercising your redemption rights with respect to the public shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">submit a written request to Continental, CHFW&#146;s transfer agent, in which you (i)&nbsp;request that we
redeem all or a portion of your public shares for cash, and (ii)&nbsp;identify yourself as the beneficial holder of the public shares and provide your legal name, phone number and address; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">deliver your public shares to Continental, our transfer agent, physically or electronically through The
Depository Trust Company (&#147;DTC&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Holders must complete the procedures for electing to
redeem their public shares in the manner described above prior to 5:00 p.m., Eastern Time, on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 (two business days before the extraordinary general
meeting) in order for their shares to be redeemed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The address of Continental, CHFW&#146;s transfer agent, is listed
under the question &#147;<I>Who can help answer my questions?</I>&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Holders of units must elect to separate
the units into the underlying public shares and public warrants prior to exercising redemption rights with respect to the public shares. If holders hold their units in an account at a brokerage firm or bank, holders must notify their broker or bank
that they elect to separate the units into the underlying public shares and public warrants, or if a holder holds units registered in its own name, the holder must contact Continental, our transfer agent, directly and instruct them to do so.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Public shareholders will be entitled to request that their public shares be redeemed for a pro rata portion of the
amount then on deposit in the trust account as of two business days prior to the consummation of the Business Combination including interest earned on the funds held in the trust account and not previously released to us (net of taxes payable). For
illustrative purposes, as of March&nbsp;31, 2021, this would have amounted to approximately $10.00 per issued and outstanding public share. However, the proceeds deposited in the trust account could become subject to the claims of our creditors, if
any, which could have priority over the claims of our public shareholders, regardless of whether such public shareholders vote or, if they do vote, irrespective of if they vote for or against the Business Combination Proposal. Therefore, the per
share distribution from the trust account in such a situation may be less than originally expected due to such claims. Whether you vote, and if you do vote irrespective of how you vote, on any proposal, including the Business Combination Proposal,
will have no impact on the amount you will receive upon exercise of your redemption rights. It is expected that the funds to be distributed to public shareholders electing to redeem their public shares will be distributed promptly after the
consummation of the Business Combination. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any request for redemption, once made by a holder of public shares, may be
withdrawn at any time up to the time the vote is taken with respect to the Business Combination Proposal at the extraordinary general meeting. If you deliver your shares for redemption to Continental, our transfer agent, and later decide prior to
the extraordinary general meeting not to elect redemption, you may request that our transfer agent return the shares (physically or electronically) to you. You may make such request by contacting Continental, our transfer agent, at the phone number
or address listed at the end of this section. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any corrected or changed written exercise of redemption rights must be
received by Continental, our transfer agent, prior to the vote taken on the Business Combination Proposal at the extraordinary general meeting. <B>No request for redemption will be honored unless the holder&#146;s public shares have been delivered
(either physically or electronically) to Continental, our transfer agent, at least two business days prior to the vote at the extraordinary general meeting.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a holder of public shares properly makes a request for redemption and the public shares are delivered as described above,
then, if the Business Combination is consummated, we will redeem the public shares for a pro rata portion of funds deposited in the trust account, calculated as of two business days prior to the consummation of the Business Combination. The
redemption takes place following the Domestication and, accordingly, it is shares of New Surrozen Common Stock that will be redeemed immediately after consummation of the Business Combination. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you are a holder of public shares and you exercise your redemption rights, such exercise will not result in the loss of any
warrants that you may hold. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>If I am a holder of units, can I exercise redemption rights with respect to my units?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">No. Holders of issued and outstanding units must elect to separate the units into the underlying public
shares and public warrants prior to exercising redemption rights with respect to the public shares. If you hold your units in an account at a brokerage firm or bank, you must notify your broker or bank that you elect to separate the units into the
underlying public shares and public warrants, or if you hold units registered in your own name, you must contact Continental, our transfer agent, directly and instruct them to do so. The redemption rights include the requirement that a holder must
identify itself in writing as a beneficial holder and provide its legal name, phone number and address to Continental in order to validly redeem its shares. You are requested to cause your public shares to be separated and delivered to Continental,
our transfer agent, by 5:00 p.m., Eastern Time, on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021 (two business days before the extraordinary general meeting) in order to exercise your
redemption rights with respect to your public shares. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>What are the U.S. federal income tax consequences of exercising my redemption rights?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">We expect that a U.S. Holder (as defined in &#147;<I>U.S. Federal Income Tax Considerations&#151;U.S.
Holders</I>&#148;) that exercises its redemption rights to receive cash from the trust account in exchange for its shares of New Surrozen Common Stock will generally be treated as selling such shares of New Surrozen Common Stock resulting in the
recognition of capital gain or capital loss. There may be certain circumstances in which the redemption may be treated as a distribution for U.S. federal income tax purposes depending on the amount of shares of New Surrozen Common Stock that such
U.S. Holder owns or is deemed to own (including through the ownership of warrants) prior to and following the redemption. For a more complete discussion of the U.S. federal income tax considerations of an exercise of redemption rights, see
&#147;<I>U.S. Federal Income Tax Considerations.</I>&#148; </P></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, because the Domestication
will occur immediately prior to the redemption by any public shareholder, U.S. Holders exercising redemption rights will take into account the potential tax consequences associated with the Domestication, including Section&nbsp;367(b) of the Code
and the rules relating to PFICs. The tax consequences of the exercise of redemption rights, including pursuant to Section&nbsp;367(b) of the Code and the PFIC rules, are discussed more fully below under &#147;<I>U.S. Federal Income Tax
Considerations&#151;U.S. Holders.</I>&#148; All holders of our public shares considering exercising their redemption rights are urged to consult their tax advisor on the tax consequences to them of an exercise of redemption rights, including the
applicability and effect of U.S. federal, state, local and foreign income and other tax laws. </P>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>What happens to the funds deposited in the trust account after consummation of the Business Combination?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Following the closing of our initial public offering, an amount equal to $92,000,000 ($10.00 per unit) of
the net proceeds from our initial public offering and the sale of the private placement units was placed in the trust account. As of March&nbsp;31, 2021, funds in the trust account totaled approximately $92.0&nbsp;million and were held in U.S.
treasury securities. These funds will remain in the trust account, except for the withdrawal of interest to pay taxes, if any, until the earliest of (i)&nbsp;the completion of a business combination (including the closing of the Business
Combination) or (ii)&nbsp;the redemption of all of the public shares if we are unable to complete a business combination by November&nbsp;23, 2022 (unless such date is extended in accordance with the Existing Governing Documents), subject to
applicable law. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If our initial business combination is paid for using equity or debt securities or not
all of the funds released from the trust account are used for payment of the consideration in connection with our initial business combination or used for redemptions or purchases of the public shares, we may apply the balance of the cash released
to us from the trust account for general corporate purposes, including for maintenance or expansion of operations of New Surrozen, the payment of principal or interest due on indebtedness incurred in completing our Business Combination, to fund the
purchase of other companies or for working capital. See <I>&#147;Summary of the Proxy Statement/Prospectus&#151;Sources and Uses of Funds for the Business Combination.&#148;</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>What happens if a substantial number of the public shareholders vote in favor of the Business Combination
Proposal and exercise their redemption rights? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Our public shareholders are not required to vote &#147;FOR&#148; the Business Combination in order to
exercise their redemption rights. Accordingly, the Business Combination may be consummated even though the funds available from the trust account and the number of public shareholders are reduced as a result of redemptions by public shareholders.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In no event will CHFW redeem public shares in an amount that would cause our net tangible assets (as
determined in accordance with Rule <FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange Act) to be less than $5,000,001 after giving effect to the transactions contemplated by the Business Combination Agreement and the PIPE
Financing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, as a result of redemptions, the trading market for the New Surrozen Common Stock may be less
liquid than the market for the public shares was prior to consummation of the Business Combination and we may not be able to meet the listing standards for Nasdaq or another national securities exchange. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>What conditions must be satisfied to complete the Business Combination? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The consummation of the Business Combination is conditioned upon, among other things, (i)&nbsp;the approval
by our shareholders of the Condition Precedent Proposals being obtained; (ii)&nbsp;CHFW having at least $5,000,001 of net tangible assets (as determined in accordance with Rule <FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange
Act) after giving effect to the transactions contemplated by the Business Combination Agreement and the PIPE Financing; (iii)&nbsp;the aggregate cash proceeds from CHFW&#146;s trust account, together with the proceeds from the PIPE Financing,
equaling no less than $100,000,000 (after deducting any amounts paid to CHFW shareholders who exercise their redemption rights in connection with the Business Combination, and net of certain CHFW unpaid transaction liabilities and expenses (the
&#147;Aggregate Transaction Proceeds Condition&#148;); (iv) the approval by Nasdaq of our initial listing application in connection with the Business Combination; and (v)&nbsp;the consummation of the Domestication. Therefore, unless these conditions
are waived by the applicable parties to the Business Combination Agreement, the Business Combination Agreement could terminate and the Business Combination may not be consummated. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For more information about conditions to the consummation of the Business Combination, see &#147;<I>Business Combination
Proposal&#151;Conditions to Closing of the Business Combination</I>.&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Are there any arrangements to help ensure that New Surrozen will have sufficient funds, together with the
proceeds in its trust account, to fund the Business Combination? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Yes. On April&nbsp;15, 2021, CHFW entered into Subscription Agreements with the PIPE Investors providing for
the issuance by CHFW of 12,020,000 PIPE Units (subject to certain conditions, including that all conditions precedent to the Closing will have been satisfied or waived (other than those conditions that are to be satisfied at the Closing), for gross
proceeds to CHFW of $120,200,000.<B> </B>In addition, CHFW entered into support agreements with holders of 1,300,000 public shares of CHFW pursuant to which such holders agreed not to exercise redemption rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent not utilized to consummate the Business Combination, New Surrozen anticipates that the proceeds from the trust
account and the PIPE Financing, together with its existing cash and cash equivalents and short term investments, will fund its operating expenses through the first half of 2024, which includes the following: (i)&nbsp;fund the development of SZN-1326
and SZN-043 through Phase&nbsp;1b clinical trials; (ii)&nbsp;identify additional lead product candidates and IND candidates; and (iii)&nbsp;the remaining proceeds to fund other ongoing research and discovery programs as well as for working capital
and other general corporate purposes. CHFW will agree that it (or its successor) will file with the SEC a registration statement registering the resale of the shares purchased in the PIPE Financing (including the shares underlying the PIPE Warrants)
and maintain an effective registration statement under the Securities Act covering such securities and certain other securities of New Surrozen. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>When do you expect the Business Combination to be completed? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">It is currently expected that the Business Combination will be consummated in the second half of 2021. This
date depends, among other things, on the approval of the proposals to be put to CHFW shareholders at the extraordinary general meeting. However, such extraordinary general meeting could be adjourned if the Adjournment Proposal is adopted by our
shareholders at the extraordinary general meeting and we elect to adjourn the extraordinary general meeting to a later date or dates to consider and vote upon a proposal to approve by ordinary resolution the adjournment of the extraordinary general
meeting to a later date or dates (A)&nbsp;to the extent necessary to ensure that any required supplement or amendment to the accompanying proxy statement/prospectus is provided to CHFW shareholders or, if as of the time for which the extraordinary
general meeting is scheduled, there are insufficient CHFW ordinary shares represented (either in person or by proxy) to constitute a quorum necessary to conduct business at the extraordinary general meeting, (B)&nbsp;in order to solicit additional
proxies from CHFW shareholders in favor of one or more of the proposals at the extraordinary general meeting or (C)&nbsp;if CHFW shareholders redeem an amount of public shares such that the Aggregate Transaction Proceeds Condition would not be
satisfied. For a description of the conditions for the completion of the Business Combination, see &#147;<I>Business Combination Proposal&#151;Conditions to Closing of the Business Combination</I>.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>What happens if the Business Combination is not consummated? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">CHFW will not complete the Domestication to Delaware unless all other conditions to the consummation of the
Business Combination have been satisfied or waived by the parties in accordance with the terms of the Business Combination Agreement. If CHFW is not able to consummate the Business Combination with Surrozen nor able to complete another business
combination by November&nbsp;23, 2022, in each case, as such date may be extended pursuant to our Existing Governing Documents, we will (i)&nbsp;cease all operations except for the purpose of winding up, (ii)&nbsp;as promptly as reasonably possible
but not more than ten business days thereafter, redeem the public shares, at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest (which
interest shall be net of taxes payable, and less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public shareholders&#146; rights as
shareholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders
and our board of directors, liquidate and dissolve, subject in each case to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable laws. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Do I have appraisal rights in connection with the proposed Business Combination and the proposed
Domestication? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">CHFW shareholders and warrant holders are not entitled to appraisal rights in connection with the Business
Combination or the Domestication under the Cayman Islands Companies Act or under the DGCL. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>What do I need to do now? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">We urge you to read this proxy statement/prospectus, including the Annexes and the documents referred to
herein, carefully and in their entirety and to consider how the Business Combination will affect you as a shareholder and/or warrant holder. Our shareholders should then vote as soon as possible in accordance with the instructions provided in this
proxy statement/prospectus and on the enclosed proxy card. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>How do I vote? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If you hold your shares in &#147;street name,&#148; which means your shares are held of record by a broker,
bank or nominee, and were a holder of record of ordinary shares on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, the record date for the
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
extraordinary general meeting, you may vote with respect to the proposals in person or virtually at the extraordinary general meeting, or by completing, signing, dating and returning the enclosed
proxy card in the postage-paid envelope provided. For the avoidance of doubt, the record date does not apply to CHFW shareholders that hold their shares in registered form and are registered as shareholders in CHFW&#146;s register of members. All
holders of shares in registered form on the day of the extraordinary general meeting are entitled to vote at the extraordinary general meeting. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>If my shares are held in &#147;street name,&#148; will my broker, bank or nominee automatically vote my
shares for me? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">No. If your shares are held in a stock brokerage account or by a bank or other nominee, you are considered
the &#147;beneficial holder&#148; of the shares held for you in what is known as &#147;street name.&#148; If this is the case, this proxy statement/prospectus may have been forwarded to you by your brokerage firm, bank or other nominee, or its
agent. As the beneficial holder, you have the right to direct your broker, bank or other nominee as to how to vote your shares. If you do not provide voting instructions to your broker on a particular proposal on which your broker does not have
discretionary authority to vote, your shares will not be voted on that proposal. This is called a &#147;broker <FONT STYLE="white-space:nowrap">non-vote.&#148;</FONT> Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes,</FONT> while
considered present for the purposes of establishing a quorum, will not count as votes cast at the extraordinary general meeting, and otherwise will have no effect on a particular proposal. If you decide to vote, you should provide instructions to
your broker, bank or other nominee on how to vote in accordance with the information and procedures provided to you by your broker, bank or other nominee. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>When and where will the extraordinary general meeting be held? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The extraordinary general meeting will be held
at&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.m., Eastern Time, on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, unless the meeting is
adjourned, via live webcast at the following address: https://www.cstproxy.com/consonancehfw/sm2021. You will need the <FONT STYLE="white-space:nowrap">12-digit</FONT> meeting control number that is printed on your proxy card to enter the
extraordinary general meeting. CHFW recommends that you log in at least 15 minutes before the extraordinary general meeting to ensure you are logged in when the extraordinary general meeting starts. Please note that you will not be able to attend
the extraordinary general meeting in person. </P></TD></TR></TABLE>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>How will the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impact <FONT
STYLE="white-space:nowrap">in-person</FONT> voting at the General Meeting? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">We intend to hold the extraordinary general meeting in person. However, we are sensitive to the public
health and travel concerns our shareholders may have and recommendations that public health officials may issue in light of the evolving coronavirus <FONT STYLE="white-space:nowrap">(COVID-19)</FONT> situation. As a result, we may impose additional
procedures or limitations on meeting attendees. We plan to announce any such updates in a press release filed with the SEC and on our proxy website at&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
and we encourage you to check this website prior to the meeting if you plan to attend. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Who is entitled to vote at the extraordinary general meeting? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">We have
fixed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 as the record date for the extraordinary general meeting. If you were a shareholder of CHFW at the close of business on the record date, you
are entitled to vote on matters that come before the extraordinary general meeting. However, a shareholder may only vote his or her shares if he or she is present in person or is represented by proxy at the extraordinary general meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>How many votes do I have? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">CHFW shareholders are entitled to one vote at the extraordinary general meeting for each ordinary share held
of record as of the record date. As of the close of business on the record date for the extraordinary general meeting, there were 11,934,000 ordinary shares issued and outstanding, of which 9,200,000 were issued and outstanding public shares.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>What constitutes a quorum? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A quorum of CHFW shareholders is necessary to hold a valid meeting. A quorum will be present at the
extraordinary general meeting if one or more shareholders who together hold not less than a majority of the issued and outstanding ordinary shares entitled to vote at the extraordinary general meeting are represented in person or by proxy at the
extraordinary general meeting. As of the record date for the extraordinary general meeting, 5,967,001 ordinary shares would be required to achieve a quorum. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>What vote is required to approve each proposal at the extraordinary general meeting?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The following votes are required for each proposal at the extraordinary general meeting:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B><I>Business Combination Proposal: </I></B>The approval of the Business Combination Proposal does not
require statutory approval under Cayman Islands law, but does require an ordinary resolution in accordance with CHFW&#146;s articles of association, being the affirmative vote of at least a majority of the votes cast by the holders of the issued
shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B><I>Domestication Proposal: </I></B>The approval of the Domestication Proposal does not require statutory
approval under Cayman Islands law but does require a special resolution in accordance with CHFW&#146;s Articles of Association, being the affirmative vote of at least a <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) majority of the votes
cast by the holders of the issued shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B><I>New Organizational Documents Proposal: </I></B>The approval of the replacement of CHFW&#146;s Existing
Governing Documents with the Proposed Governing Documents of New Surrozen. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B><I>Governing Documents Proposal: </I></B>The separate advisory, non-binding approval of each of the
Governing Documents Proposals does not require statutory approval under Cayman Islands law but does require a special resolution under Cayman Islands Law law, being the affirmative vote of at least a two-thirds (2/3) majority of the votes cast by
the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter, save for Governing Documents Proposal&nbsp;A, which proposes to alter CHFW&#146;s
authorized share capital and which will require an ordinary resolution, being the affirmative vote of holders of a majority of the ordinary shares represented in person or by proxy and entitled to vote thereon and who vote at the extraordinary
general meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B><I>Share Issuance Proposal: </I></B>The approval of the Share Issuance Proposal requires an ordinary
resolution under Cayman Islands law, being the affirmative vote of at least a majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote
on such matter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B><I>Incentive Award Plan Proposal: </I></B>We are seeking<B> </B>approval of the Incentive Award Plan
Proposal as an ordinary resolution which, under Cayman Islands law, requires the affirmative vote of at least a majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary
general meeting and entitled to vote on such matter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B><I>Employee Stock Purchase Plan Proposal: </I></B>We are seeking approval of the Employee Stock Purchase
Plan Proposal as an ordinary resolution which, under Cayman Islands law, requires the affirmative vote of a majority of the ordinary shares represented in person or by proxy and entitled to vote thereon and who vote at the extraordinary general
meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B><I>Adjournment Proposal: </I></B>The approval of the Adjournment Proposal requires an ordinary resolution
under Cayman Islands law, being the affirmative vote of at least a majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such
matter. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of the record date, CHFW had 11,934,000 Class A and Class B ordinary
shares issued and outstanding. CHFW shareholders are entitled to one vote at the extraordinary general meeting for each ordinary share held of record as of the record date. 1,300,000 Class&nbsp;A ordinary shares are subject to the CHFW Shareholder
Support Agreements, pursuant to which certain holders of CHFW&#146;s Class&nbsp;A ordinary shares agreed to vote all of their shares in favor of the Business Combination and 2,300,000 Class B ordinary shares are subject to Sponsor Letter Agreements
pursuant to which the holders of CHFW&#146;s Class B shares have agreed to vote all of their shares in favor of the Business Combination. 8,334,000 Class&nbsp;A ordinary shares are not subject to the CHFW Shareholder Support Agreements. For
additional information regarding the CHFW Shareholder Support Agreements, see &#147;<I>Business Combination Proposal&#151;Related Agreements&#151;Support Agreements</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Assuming all holders that are entitled to vote on such matter vote all of their ordinary shares in person or by proxy,
5,967,001 shares, of which 2,367,001 shares are not subject to either the CHFW Shareholder Support Agreements or the Sponsor Letter Agreement, will need to be voted in favor of each of the Business Combination Proposal, the Share Issuance Proposal,
the Incentive Award Plan Proposal, the Employee Stock Purchase Plan Proposal and the Adjournment Proposal in order to approve each of the Business Combination Proposal, the Share Issuance Proposal, the Incentive Award Plan Proposal, the Employee
Stock Purchase Plan Proposal and the Adjournment Proposal. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Assuming all holders that are entitled to vote on such
matter vote all of their ordinary shares in person or by proxy, 7,956,000 shares, of which 4,356,000 shares are not subject to either the CHFW Shareholder Support Agreements or the Sponsor Letter Agreement, will need to be voted in favor of the
Domestication Proposal, the New Organizational Documents Proposal, and each of the Governing Documents Proposals in order to approve the Domestication Proposal and each of the Governing Documents Proposals. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>What are the recommendations of the CHFW Board? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The CHFW Board believes that the Business Combination Proposal and the other proposals to be presented at
the extraordinary general meeting are in the best interest of CHFW and its shareholders and unanimously recommends that its shareholders vote &#147;FOR&#148; the Business Combination Proposal, &#147;FOR&#148; the Domestication Proposal,
&#147;FOR&#148; the New Organizational Documents Proposal, &#147;FOR&#148; each of the separate advisory, non-binding Governing Documents Proposals, &#147;FOR&#148; the Share Issuance Proposal, &#147;FOR&#148; the Incentive Award Plan Proposal,
&#147;FOR&#148; the Employee Stock Purchase Plan Proposal and &#147;FOR&#148; the Adjournment Proposal, in each case, if presented to the extraordinary general meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The existence of financial and personal interests of one or more of CHFW&#146;s directors may result in a conflict of interest
on the part of such director(s) between what he, she or they may believe is in the best interests of CHFW and its shareholders and what he, she or they may believe is best for himself or themselves in determining to recommend that shareholders vote
for the proposals. In addition, CHFW&#146;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#147;<I>Business Combination Proposal&#151;Interests of CHFW&#146;s
Directors and Executive Officers in the Business Combination</I>&#148; for a further discussion of these considerations. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>How do Sponsor and the other initial shareholders intend to vote their shares? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Unlike some other blank check companies in which the initial shareholders agree to vote their shares in
accordance with the majority of the votes cast by the public shareholders in connection with an initial business combination, our Sponsor and certain other shareholders have agreed to vote all their shares in favor of all the proposals being
presented at the extraordinary general meeting. As of the date of this proxy statement/prospectus, our Sponsor and such other shareholders own approximately 33.8% of the voting power of the issued and outstanding ordinary shares.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At any time at or prior to the Business Combination, during a period when they are not then aware of any
material nonpublic information regarding us or our securities, our initial shareholders, Surrozen and/or their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
directors, officers, advisors or respective affiliates may purchase public shares from institutional and other investors who vote, or indicate an intention to vote, against any of the Condition
Precedent Proposals, or execute agreements to purchase such shares from such investors in the future, or they may enter into transactions with such investors and others to provide them with incentives to acquire public shares or vote their public
shares in favor of the Condition Precedent Proposals. Such a purchase may include a contractual acknowledgement that such shareholder, although still the record or beneficial holder of our shares, is no longer the beneficial owner thereof and
therefore agrees not to exercise its redemption rights. In the event that our initial shareholders, Surrozen and/or their directors, officers, advisors or respective affiliates purchase shares in privately negotiated transactions from public
shareholders who have already elected to exercise their redemption rights, such selling shareholder would be required to revoke their prior elections to redeem their shares. The purpose of such share purchases and other transactions would be to
increase the likelihood of satisfaction of the requirements that (i)&nbsp;the Business Combination Proposal, the Governing Documents Proposal&nbsp;A, the Share Issuance Proposal, the Incentive Award Plan Proposal, the Employee Stock Purchase Plan
Proposal and the Adjournment Proposal are approved by the affirmative vote of at least a majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and
entitled to vote on such matter (ii)&nbsp;the Domestication Proposal, the Governing Documents Proposal&nbsp;B, the Governing Documents Proposal&nbsp;C and the Governing Documents Proposal&nbsp;D and the New Organizational Documents Proposal are
approved by the affirmative vote of at least a <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general
meeting and entitled to vote on such matter, (iii)&nbsp;otherwise limit the number of public shares electing to redeem and (iv)&nbsp;New Surrozen&#146;s net tangible assets (as determined in accordance with Rule
<FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange Act) being at least $5,000,001 after giving effect to the transactions contemplated by the Business Combination Agreement and the PIPE Financing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Entering into any such arrangements may have a depressive effect on the ordinary shares. For example, as a result of these
arrangements, an investor or holder may have the ability to effectively purchase shares at a price lower than market and may therefore be more likely to sell the shares he or she owns, either at or prior to the Business Combination. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If such transactions are effected, the consequence could be to cause the Business Combination to be consummated in
circumstances where such consummation could not otherwise occur. Purchases of shares by the persons described above would allow them to exert more influence over the approval of the proposals to be presented at the extraordinary general meeting and
would likely increase the chances that such proposals would be approved. We will file or submit a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to disclose any material arrangements entered into or significant purchases made by
any of the aforementioned persons that would affect the vote on the proposals to be put to the extraordinary general meeting or the redemption threshold. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any such report will include descriptions of any arrangements entered into or significant purchases by any of the
aforementioned persons. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>What happens if I sell my CHFW ordinary shares before the extraordinary general meeting?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The record date for the extraordinary general meeting is earlier than the date of the extraordinary general
meeting and earlier than the date that the Business Combination is expected to be completed. If you transfer your public shares after the applicable record date, but before the extraordinary general meeting, unless you grant a proxy to the
transferee, you will retain your right to vote at such general meeting. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>May I change my vote after I have mailed my signed proxy card? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Yes. Shareholders may send a later-dated, signed proxy card to us at our address set forth below so that it
is received by us prior to the vote at the extraordinary general meeting (which is scheduled to take place on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021) or attend the extraordinary general
meeting in person and vote. Shareholders also may </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
revoke their proxy by sending a notice of revocation to us, which must be received by us prior to the vote at the extraordinary general meeting. However, if your shares are held in &#147;street
name&#148; by your broker, bank or another nominee, you must contact your broker, bank or other nominee to change your vote. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>What happens if I fail to take any action with respect to the extraordinary general meeting?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If you fail to vote with respect to the extraordinary general meeting and the Business Combination is
approved by shareholders and the Business Combination is consummated, you will become a stockholder and/or warrant holder of New Surrozen. If you fail to vote with respect to the extraordinary general meeting and the Business Combination is not
approved, you will remain a shareholder and/or warrant holder of CHFW. However, if you fail to vote with respect to the extraordinary general meeting, you will nonetheless be able to elect to redeem your public shares in connection with the Business
Combination. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>What should I do if I receive more than one set of voting materials? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Shareholders may receive more than one set of voting materials, including multiple copies of this proxy
statement/prospectus and multiple proxy cards or voting instruction cards. For example, if you hold your shares in more than one brokerage account, you will receive a separate voting instruction card for each brokerage account in which you hold
shares. If you are a holder of record and your shares are registered in more than one name, you will receive more than one proxy card. Please complete, sign, date and return each proxy card and voting instruction card that you receive in order to
cast a vote with respect to all of your ordinary shares. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Who will solicit and pay the cost of soliciting proxies for the extraordinary general meeting?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">CHFW will pay the cost of soliciting proxies for the extraordinary general meeting. CHFW has engaged Okapi
Partners to assist in the solicitation of proxies for the extraordinary general meeting. CHFW has agreed to pay Okapi Partners a fee of $22,500, plus disbursements, and will reimburse Okapi Partners for its reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses and indemnify Okapi Partners and its affiliates against certain claims, liabilities, losses, damages and expenses. CHFW will also reimburse banks,
brokers and other custodians, nominees and fiduciaries representing beneficial owners of Class&nbsp;A ordinary shares for their expenses in forwarding soliciting materials to beneficial owners of Class&nbsp;A ordinary shares and in obtaining voting
instructions from those owners. CHFW&#146;s directors and officers may also solicit proxies by telephone, by facsimile, by mail, on the Internet or in person. They will not be paid any additional amounts for soliciting proxies.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Where can I find the voting results of the extraordinary general meeting? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The preliminary voting results will be announced at the extraordinary general meeting. CHFW will publish
final voting results of the extraordinary general meeting in a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> within four business days after the extraordinary general meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Who can help answer my questions? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If you have questions about the Business Combination or if you need additional copies of the proxy
statement/prospectus or the enclosed proxy card you should contact: </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Okapi Partners LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Banks and Brokers Call Collect: (212) <FONT STYLE="white-space:nowrap">297-0720</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">All Others Call Toll Free: (844) <FONT STYLE="white-space:nowrap">203-3605</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: info@okapipartners.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You also may obtain additional information about CHFW from documents filed with the SEC by
following the instructions in the section entitled <I>&#147;Where You Can Find More Information; Incorporation by Reference.&#148; </I>If you are a holder of public shares and you intend to seek redemption of your public shares, you will need to
deliver your public shares (either physically or electronically) to Continental, CHFW&#146;s transfer agent, at the address below prior to the extraordinary general meeting. <B>Holders must complete the procedures for electing to redeem their public
shares in the manner described above prior to 5:00 p.m., Eastern Time, on</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>, 2021 (two business days before the
extraordinary general meeting) in order for their shares to be redeemed.</B> If you have questions regarding the certification of your position or delivery of your stock, please contact: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Continental Stock Transfer&nbsp;&amp; Trust Company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 State Street 30th Floor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_6"></A>SUMMARY OF THE PROXY STATEMENT/PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>This summary highlights selected information from this proxy statement/prospectus and does not contain all of the information that is
important to you. To better understand the proposals to be submitted for a vote at the extraordinary general meeting, including the Business Combination, you should read this proxy statement/prospectus, including the Annexes and other documents
referred to herein, carefully and in their entirety. The Business Combination Agreement is the legal document that governs the Business Combination and the other transactions that will be undertaken in connection with the Business Combination. The
Business Combination Agreement is also described in detail in this proxy statement/prospectus in the section entitled &#147;Business Combination Proposal&#151;The Business Combination Agreement.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_7"></A>The Parties to the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>CHFW </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW is a
blank check company incorporated on August&nbsp;21, 2020, as a Cayman Islands exempted company and incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination
with one or more businesses. CHFW has neither engaged in any operations nor generated any revenue to date. Based on CHFW&#146;s business activities, it is a &#147;shell company&#148; as defined under the Exchange Act because it has no operations and
nominal assets consisting almost entirely of cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On November&nbsp;23, 2020, CHFW consummated an initial public offering of 8,000,000
units at an offering price of $10.00 per unit, and a private placement with the Sponsor of 410,000 private placement units at an offering price of $10.00 per unit. Each unit sold in the initial public offering and private placement consists of one
Class&nbsp;A ordinary share and <FONT STYLE="white-space:nowrap">one-third</FONT> of one redeemable warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On December&nbsp;1, 2020,
the underwriters fully exercised their over-allotment option, resulting in an additional 1,200,000 units issued at $10.00 per unit, generating gross proceeds of $12.0&nbsp;million. In connection with the underwriters&#146; full exercise of their
over-allotment option, the Company also consummated the sale of an additional 24,000 private placement units at $10.00 per private placement unit, generating additional gross proceeds of approximately $0.2&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the closing of CHFW&#146;s initial public offering, an amount equal to $92.0&nbsp;million of the net proceeds from its initial
public offering and the sale of the private placement units was placed in the trust account. The trust account may be invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in
United States Treasuries and meeting certain conditions under Rule <FONT STYLE="white-space:nowrap">2a-7</FONT> under the Investment Company Act of 1940, as amended, which invest only in direct U.S. government obligations. As of March&nbsp;31, 2021,
funds in the trust account totaled approximately $92.0&nbsp;million and were held in U.S. treasury securities. These funds will remain in the trust account, except for the withdrawal of interest to pay taxes, if any, until the earliest of
(i)&nbsp;the completion of CHFW&#146;s initial business combination, (ii)&nbsp;the redemption of any public shares properly tendered in connection with a shareholder vote to amend the Existing Governing Documents to modify the substance and timing
of our obligation to redeem 100% of the public shares if CHFW does not complete a business combination by November&nbsp;23, 2022, or (iii)&nbsp;the redemption of all of the public shares if CHFW is unable to complete a business combination by
November&nbsp;23, 2022 (unless such date is extended in accordance with the Existing Governing Documents), subject to applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW&#146;s units, public shares and public warrants are currently listed on NYSE American under the symbols &#147;CHFW.U,&#148;
&#147;CHFW&#148; and &#147;CHFW.W,&#148; respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW&#146;s principal executive office is located at 1 Palmer Square, Suite 350,
Princeton, NJ 08540, and its telephone number is (609) <FONT STYLE="white-space:nowrap">921-2333.</FONT> CHFW&#146;s corporate website address is <I>www.consonancehfw.com</I>. CHFW&#146;s </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
website and the information contained on, or that can be accessed through, the website is not deemed to be incorporated by reference in, and is not considered part of, this proxy
statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen is a Delaware corporation incorporated on August&nbsp;12, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen is discovering and developing biologic drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair,
in a broad range of organs and tissues. Building upon the seminal work of its founders and scientific advisors who discovered the Wnt gene and key regulators of the Wnt pathway, Surrozen has made breakthrough discoveries that it believes will
overcome previous limitations in harnessing the potential of Wnt biology. These breakthroughs enable Surrozen to rapidly and flexibly design tissue-targeted therapeutics that modulate Wnt signaling. As a result of its discoveries, Surrozen is
pioneering the selective activation of Wnt signaling, designing and engineering Wnt pathway mimetics, and advancing tissue-specific Wnt candidates. Surrozen&#146;s lead product candidates are multi-specific, antibody-based therapeutics that mimic
the roles of naturally occurring Wnt or <FONT STYLE="white-space:nowrap">R-spondin</FONT> proteins, both of which are involved in activation of the Wnt pathway. Given Wnt signaling is essential in tissue maintenance and regeneration throughout the
body, Surrozen has the potential to target a wide variety of severe diseases, including certain diseases that afflict the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas and central nervous system. In each of these areas,
Surrozen believes its approach has the potential to change the treatment paradigm for the disease and substantially impact patient outcomes. Surrozen&#146;s strategy is to exploit the full potential of Wnt signaling by identifying disease states
responsive to Wnt modulation, design tissue-specific therapeutics, and advance candidates into clinical development in targeted indications with high unmet need. Surrozen&#146;s unique approach and platform technologies have led to the discovery and
advancement of two lead product candidates. Surrozen is currently conducting preclinical studies and plans to initiate a Phase 1 clinical trial in 2022 for <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> Surrozen&#146;s candidate in development
for moderate to severe inflammatory bowel disease (&#147;IBD&#148;) with ulcerative colitis (&#147;UC&#148;) as Surrozen&#146;s first proposed indication. Furthermore, Surrozen plans to initiate a Phase 1 clinical trial in 2022 for <FONT
STYLE="white-space:nowrap">SZN-043,</FONT> Surrozen&#146;s candidate in development for severe alcoholic hepatitis (&#147;AH&#148;). Surrozen expects to nominate additional lead candidates and advance them into the clinic in 2023 and beyond. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s strategy is to develop a portfolio of product candidates that can repair tissue damage and regenerate functional tissues
for a variety of diseases. Consistent throughout Surrozen&#146;s strategy is its goal to activate Wnt signaling only within targeted diseased tissue, focusing on severe diseases, and mimicking the self-limiting physiologic repair process. Surrozen
plans to achieve this goal by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continuing to build on its pioneering research, insights and intellectual property in Wnt pathway modulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing <FONT STYLE="white-space:nowrap">SZN-1326</FONT> for the treatment of moderate to severe IBD;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing <FONT STYLE="white-space:nowrap">SZN-043</FONT> for treatment of severe AH; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing novel product candidates and expanding its platform technologies to further our leading position in
developing the Wnt signaling pathway modulators; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursuing strategic alliances to maximize the full potential of its pipeline. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s principal executive office is located at 171 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080, and its telephone
number is (650) <FONT STYLE="white-space:nowrap">489-9000.</FONT> Surrozen&#146;s corporate website address is <I>www.surrozen.com</I>. Surrozen&#146;s website and the information contained on, or that can be accessed through, the website is not
deemed to be incorporated by reference in, and is not considered part of, this proxy statement/prospectus. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Perseverance Merger Sub </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Merger Sub is a Delaware corporation and wholly-owned subsidiary of CHFW formed for the purpose of effecting the Business Combination. Merger
Sub owns no material assets and does not operate any business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Merger Sub&#146;s principal executive office is located at 1 Palmer Square,
Suite 350, Princeton, NJ 08540, and its telephone number is (609) <FONT STYLE="white-space:nowrap">921-2333.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_8">
</A>Proposals to be Put to the Shareholders of CHFW at the Extraordinary General Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following is a summary of the proposals
to be put to the extraordinary general meeting of CHFW and certain transactions contemplated by the Business Combination Agreement. Each of the proposals below, except the Adjournment Proposal, is cross-conditioned on the approval of each other. The
Adjournment Proposal is not conditioned upon the approval of any other proposal set forth in this proxy statement/prospectus. The transactions contemplated by the Business Combination Agreement will be consummated only if the Condition Precedent
Proposals are approved at the extraordinary general meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As discussed in this proxy statement/prospectus, CHFW is asking its
shareholders to approve by ordinary resolution the Business Combination Agreement, pursuant to which, among other things, on the date of Closing, promptly following the consummation of the Domestication, Merger Sub will merge with and into Surrozen,
with Surrozen as the surviving company in the Merger and, after giving effect to such Merger, Surrozen shall be a wholly-owned subsidiary of CHFW. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After consideration of the factors identified and discussed in the section entitled &#147;<I>Business Combination Proposal&#151;The CHFW
Board&#146;s Reasons for the Business Combination</I>,&#148; the CHFW Board concluded that the Business Combination met all of the requirements disclosed in the prospectus for CHFW&#146;s initial public offering, including that the businesses of
Surrozen had a fair market value of at least 80% of the balance of the funds in the trust account at the time of execution of the Business Combination Agreement. For more information about the transactions contemplated by the Business Combination
Agreement, see &#147;<I>Business Combination Proposal</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Consideration to Surrozen Equityholders in the Business Combination </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with the terms and subject to the conditions of the Business Combination Agreement, at the Effective Time, each share and equity
award of Surrozen (whether vested or unvested) outstanding as of immediately prior to the Effective Time will be exchanged for shares of New Surrozen Common Stock or comparable equity awards that are settled or are exercisable for shares of New
Surrozen Common Stock, as applicable, based on an implied Surrozen equity value of $200,000,000 and a $10.00 price per share for New Surrozen Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For further details, see &#147;<I>Business Combination Proposal&#151;Business Combination Consideration</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conditions to Closing of the Business Combination </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The consummation of the Business Combination is conditioned upon, among other things, (i)&nbsp;the approval by our shareholders of the
Condition Precedent Proposals being obtained; (ii)&nbsp;CHFW having at least $5,000,001 of net tangible assets (as determined in accordance with Rule <FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange Act) after giving effect to
the transactions contemplated by the Business Combination Agreement and the PIPE Financing; (iii)&nbsp;the Aggregate Transaction Proceeds Condition; (iv)&nbsp;the approval by Nasdaq of our initial listing application in connection with the Business
Combination; and (v)&nbsp;the consummation of the Domestication. Therefore, unless these conditions are waived by the applicable parties to the Business Combination Agreement, the Business Combination Agreement could terminate and the Business
Combination may not be consummated. For further details, see &#147;<I>Business Combination Proposal&#151;Conditions to Closing of the Business Combination</I>.&#148; </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Domestication Proposal </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As discussed in this proxy statement/prospectus, CHFW will ask its shareholders to approve by special resolution the Domestication Proposal. As
a condition to closing the Business Combination pursuant to the terms of the Business Combination Agreement, the board of directors of CHFW has unanimously approved the Domestication Proposal. The Domestication Proposal, if approved, will authorize
a change of CHFW&#146;s jurisdiction of incorporation from the Cayman Islands to the State of Delaware. Accordingly, while CHFW is currently incorporated as an exempted company under the Cayman Islands Companies Act, upon Domestication, New Surrozen
will be governed by the DGCL. There are differences between Cayman Islands corporate law and Delaware corporate law as well as the Existing Governing Documents and the Proposed Governing Documents. The approval of each of the Domestication Proposal,
the New Organizational Documents Proposal, the Governing Documents Proposal B, the Governing Documents Proposal C and the Governing Documents Proposal D requires a special resolution under Cayman Islands law, being the affirmative vote of holders at
least a <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such
matter. Accordingly, we encourage shareholders to carefully consult the information set out below under &#147;<I>Comparison of Corporate Governance and Shareholder Rights</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For further details, see &#147;<I>Domestication Proposal</I>&#148;, the &#147;<I>New Organizational Documents Proposal</I>,&#148; and
&#147;<I>Governing Documents Proposal</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>New Organizational Documents and Governing Documents Proposals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW will ask its shareholders to approve (which approval is, in the case of the Governing Documents Proposals, non-binding and advisory) by
special resolution (unless otherwise stated) the New Organizational Documents Proposal and four (4) separate Governing Documents Proposals in connection with the replacement of the Existing Governing Documents, under Cayman Islands law, with the
Proposed Governing Documents, under the DGCL. The CHFW Board has unanimously approved the New Organizational Documents Proposal and each of the Governing Documents Proposals and believes such proposals are necessary to adequately address the needs
of New Surrozen after the Business Combination. Approval of the New Organizational Documents Proposal is a condition to the consummation of the Business Combination. Summaries are qualified in their entirety by reference to the complete text of the
Proposed Governing Documents. The Proposed Governing Documents differ in certain material respects from the Existing Governing Documents, and we encourage shareholders to carefully consult the information set out in the section entitled
&#147;<I>Governing Documents Proposal</I>&#148; and the full text of the Proposed Governing Documents of New Surrozen, attached hereto as Annexes C and D. A&nbsp;brief summary of the New Organizational Documents Proposal and each of the Governing
Documents Proposals is set forth below. These summaries are qualified in their entirety by reference to the complete text of the Proposed Governing Documents. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>New Organizational Documents Proposal</I>&#151;to approve by special resolution the adoption and approval
of the proposed new certificate of incorporation and bylaws of New Surrozen, copies of which are attached to the accompanying proxy statement/consent solicitation statement/prospectus as Annex C and Annex D, respectively. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Governing Documents Proposal A</I>&#151;to authorize by way of ordinary resolution the change in the
authorized share capital of CHFW from (i) 350,000,000 Class A ordinary shares, par value $0.0001 per share, (ii) 150,000,000 Class B ordinary shares, par value $0.0001 per share and (iii) 1,000,000 preference shares, par value $0.0001 per share, to
(a) 500,000,000 shares of common stock, par value $0.0001 per share, of New Surrozen and (b) 10,000,000 shares of preferred stock, par value $0.0001 per share, of New Surrozen be approved. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Governing Documents Proposal B</I>&#151;to authorize the New Surrozen Board to issue any or all shares of
New Surrozen Preferred Stock in one or more classes or series, with such terms and conditions as may be expressly determined by the New Surrozen Board and as may be permitted by the DGCL. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Governing Documents Proposal C</I>&#151;to authorize the removal of the ability of New Surrozen
stockholders to take action by written consent in lieu of a meeting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Governing Documents Proposal D&#151;</I>to replace the Existing Governing Documents and authorize all other
changes necessary or, as mutually agreed in good faith by CHFW and Surrozen, desirable in connection with the replacement of Existing Governing Documents with the Proposed Governing Documents as part of the Domestication, including (i) changing the
post-Business Combination corporate name from &#147;Consonance-HFW Acquisition Corp.&#148; to &#147;Surrozen, Inc.&#148; (which is expected to occur after the consummation of the Domestication in connection with the Business Combination), (ii)
making New Surrozen&#146;s corporate existence perpetual, (iii) adopting Delaware as the exclusive forum for certain stockholder litigation and the federal district courts of the United States as the exclusive forum for litigation arising out of the
Securities Act and (iv) removing certain provisions related to our status as a blank check company that will no longer be applicable upon consummation of the Business Combination, all of which the CHFW Board believes is necessary to adequately
address the needs of New Surrozen after the Business Combination. </P></TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Share Issuance Proposal </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our shareholders are also being asked to approve, by ordinary resolution, the Share Issuance Proposal in order to be able to issue shares of
New Surrozen Common Stock to the Surrozen Stockholders in the Business Combination and in the PIPE Financing, including shares of New Surrozen Common Stock issuable upon the exercise of warrants pursuant to Nasdaq Listing Rule 5635 (the
&#147;Listing Application&#148;). Nasdaq Listing Rule 5635 requires shareholder approval for the issuance of common stock (or securities convertible into or exercisable for common stock) in connection with the acquisition of stock of another company
if the number of shares of common stock to be issued will be in excess of 20% of the number of shares of common stock outstanding before the issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For additional information, see &#147;<I>Share Issuance Proposal</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Incentive Award Plan Proposal </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our shareholders are also being asked to approve, by ordinary resolution, the Incentive Award Plan Proposal. Pursuant to the Equity Incentive
Plan, a number of shares of New Surrozen Common Stock equal to 10% of shares of New Surrozen Common Stock that are outstanding on an <FONT STYLE="white-space:nowrap">as-converted</FONT> and <FONT STYLE="white-space:nowrap">as-redeemed</FONT> basis
as of the date immediately following the consummation of the Business Combination will be reserved for issuance under the Incentive Award Plan<B> </B>as well as the shares of New Surrozen Common Stock that are underlying the vested and unvested
equity awards of Surrozen that are rolled over into New Surrozen awards in the Business Combination. The Equity Incentive Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each
January&nbsp;1, beginning on January&nbsp;1, 2022, by 5.0% of the outstanding number of shares of New Surrozen Common Stock on the immediately preceding December&nbsp;31, or such lesser amount as determined by the Board of New Surrozen. For
additional information, see &#147;<I>Incentive Award Plan Proposal</I>.&#148; The full text of the Incentive Award Plan is attached hereto as Annex J. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Employee Stock Purchase Plan Proposal </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our shareholders are also being asked to approve, by ordinary resolution, the Employee Stock Purchase Plan Proposal. A total number of shares
of New Surrozen Common Stock equal to one percent of the shares of New </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Surrozen Common Stock that are outstanding on (1)&nbsp;an <FONT STYLE="white-space:nowrap">as-converted</FONT> and <FONT STYLE="white-space:nowrap">(2)&nbsp;as-converted</FONT> and <FONT
STYLE="white-space:nowrap">as-redeemed</FONT> basis as of the date immediately following the consummation of the Business Combination will be reserved for issuance under the ESPP. Based upon a price per share of $10.00, the maximum aggregate market
value of the New Surrozen Common Stock that could potentially be issued under the ESPP at Closing is $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The ESPP provides that the number of shares reserved and available for issuance under the ESPP
will automatically increase each January&nbsp;1, beginning on January&nbsp;1, 2022, by 1.0% of the outstanding number of shares of New Surrozen Common Stock on the immediately preceding December&nbsp;31, or such lesser amount as determined by the
New Surrozen Board. For additional information, see &#147;<I>Employee Stock Purchase Plan Proposal</I>.&#148; The full text of the ESPP is attached hereto as Annex&nbsp;K. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Adjournment Proposal </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If, based on the tabulated vote, there are not sufficient votes at the time of the extraordinary general meeting to authorize CHFW to
consummate the Business Combination, the CHFW Board may submit a proposal to adjourn the extraordinary general meeting to a later date or dates to consider and vote upon a proposal to approve by ordinary resolution the adjournment of the
extraordinary general meeting to a later date or dates. For additional information, see &#147;<I>Adjournment Proposal</I>.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each
of the Business Combination Proposal, the Domestication Proposal, the New Organizational Documents Proposal, the Incentive Award Plan Proposal and the Share Issuance Proposal is conditioned on the approval and adoption of each of the other Condition
Precedent Proposals. The Employee Stock Purchase Plan Proposal is conditioned on the approval of the Condition Precedent Proposals. The Adjournment Proposal is not conditioned on any other proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_9"></A>The CHFW Board&#146;s Reasons for the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, share purchase, reorganization or similar
business combination with one or more businesses. The CHFW Board sought to do this by utilizing the networks and industry experience of both the Sponsor and the CHFW Board and management to identify, acquire and operate one or more businesses. The
members of the CHFW Board and management have extensive transactional experience, particularly in the healthcare and life sciences industries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In particular, the CHFW Board considered the following positive factors, although not weighted or in any order of significance, including but
not limited to, the following material factors in deciding to approve the Business Combination Proposal: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Pioneering, industry leading platform and technologies to harness a fundamental pathway in tissue
regeneration</I></B>. Surrozen is harnessing Wnt biology, one of the body&#146;s innate tissue repair mechanisms, to treat a broad array of diseases. The company&#146;s scientific <FONT STYLE="white-space:nowrap">co-founders</FONT> are among the
world&#146;s preeminent Wnt biologists and discovered the first mammalian Wnt gene. Surrozen possesses a deep, industry-leading understanding of the Wnt pathway as well as the internal antibody discovery capabilities to rapidly design and develop
precisely-targeted <FONT STYLE="white-space:nowrap">Wnt-directed</FONT> antibody therapeutics in tissue specific applications. Its two proprietary antibody technologies are designed to selectively activate Wnt signaling in specific tissues by
activation of physiologic Wnt signal with <FONT STYLE="white-space:nowrap">Wnt-mimetic</FONT> antibodies, or by amplification of endogenous Wnt with <FONT STYLE="white-space:nowrap">R-spondin</FONT> mimetic antibodies. The CHFW Board believes
Surrozen is well positioned to unlock the therapeutic potential of the Wnt pathway. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Broad therapeutic potential across a wide range of diseases.</I></B> The Wnt pathway holds broad
therapeutic potential in view of its ability to regulate stem cell renewal, proliferation and differentiation, and its central role in tissue repair and regeneration. Surrozen has worked to identify and characterize tissues where Wnt biology is
central to structure and function and has prioritized a </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
number of potential applications for its technologies, including diseases of the eye <FONT STYLE="white-space:nowrap">(age-related</FONT> macular degeneration (AMD) and diabetic retinopathy),
liver (alcoholic hepatitis and cirrhosis), lung (idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD)), gastrointestinal tract (IBD and short bowel syndrome), cochlea (sensorineural hearing loss), pancreas <FONT
STYLE="white-space:nowrap">(type-1</FONT> diabetes), kidney (polycystic kidney disease), and others. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Multiple, wholly-owned, pipeline programs in development in areas of high unmet medical need.</I></B>
Surrozen has established a diverse pipeline of wholly owned product candidates led by <FONT STYLE="white-space:nowrap">SZN-1326</FONT> for moderate to severe IBD and <FONT STYLE="white-space:nowrap">SZN-043</FONT> for severe alcoholic hepatitis. In
IBD, many patients fail to respond to available approved therapies which reduce inflammation but do not directly drive mucosal healing, whereas <FONT STYLE="white-space:nowrap">SZN-1326</FONT> may promote restoration of intestinal tissue
architecture and function. In severe alcoholic hepatitis, there are an estimated 100,000 hospitalizations annually in the United States, the overall <FONT STYLE="white-space:nowrap">90-day</FONT> mortality rate in hospitalized patients is
approximately 30%, and there are few treatment options available. If clinical trials with <FONT STYLE="white-space:nowrap">SZN-043</FONT> demonstrate the ability to stimulate proliferation of hepatocytes and improve liver function in these patients,
the data could support the potential for a rapid path to approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Differentiated <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data for lead programs demonstrating
potential for disease modifying effects.</I></B> In preclinical models used to evaluate treatments for IBD, <FONT STYLE="white-space:nowrap">SZN-1326</FONT> led to proliferation and differentiation of intestinal stem cells, restoration of intestinal
barrier function and tissue architecture, reduction in inflammation and reduced disease activity. Similarly, in animal models of alcoholic hepatitis, treatment with <FONT STYLE="white-space:nowrap">SZN-043</FONT> led to hepatocyte proliferation and
improved liver function. These effects, if demonstrated in human clinical trials, could signal the potential for disease modifying efficacy and support use as monotherapy or in combination with other approved agents. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Emerging ophthalmology programs bolster pipeline and may provide breakthrough potential. </I></B>The
Surrozen pipeline is supplemented by numerous ongoing research efforts in a diverse set of tissues, including ophthalmic applications such as wet AMD, dry AMD, diabetic retinopathy, Fuch&#146;s dystrophy and Sj&ouml;gren&#146;s dry eye. In
preclinical experiments, Surrozen has shown that activation of the Wnt pathway can potentially reverse vascular damage through a mechanism that is different from that of currently approved agents that target angiogenesis. Surrozen is developing an
agonist of a specific Fzd receptor found in retinal vasculature, which the company has shown in animal models can inhibit retinal pathology in the eye. Surrozen believes that the ability to deliver this agonist locally to the eye has the potential
to treat multiple ocular disorders with high unmet need by inducing repair of damaged tissue. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Multiple upcoming catalysts funded by proceeds from this transaction.</I></B> Surrozen expects to
initiate Phase 1a trials for <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043</FONT> in 2022, with Phase 1b trials in ulcerative colitis and severe alcoholic hepatitis patients expected in 2023. Each of
these programs is expected to yield clinical proof of concept data in patients from the Phase 1b trials in 2024. The company also expects to nominate additional lead candidates and advance them into the clinic in 2023 to explore the potential
breadth and utility of its product candidates in other clinical settings, including ophthalmology. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Opportunities for strategic alliances to support and fuel growth.</I></B> Given the breadth of
therapeutic applications enabled by targeting the Wnt pathway and Surrozen&#146;s ability to modulate Wnt biology in a tissue specific manner, we believe there may be opportunities for strategic alliances that further support the company&#146;s
capital needs and growth. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Experienced management team and Board of Directors.</I></B> The CHFW Board believes that Surrozen has a
proven and experienced team that will continue to lead the company after the Business Combination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Strong commitment from top tier US healthcare investors and existing Surrozen stockholders</I></B>.
Leading healthcare-focused and life sciences-dedicated investors, as well as current existing Surrozen </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
stockholders, including The Column Group, committed to investment of a total of $120,200,000 in the PIPE concurrent with the business combination. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The CHFW Board also considered a variety of uncertainties and risks and other potentially negative factors concerning the Business
Combination, including, but not limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Benefits Not Achieved.</I></B> The risk that the potential benefits of the Business Combination may not
be fully achieved, or may not be achieved within the expected timeframe. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Liquidation of CHFW.</I></B> The risks and costs to CHFW if the Business Combination is not completed,
including the risk of diverting management focus and resources from other businesses combination opportunities, which could result in CHFW being unable to effect a business combination by November&nbsp;19, 2022 and force CHFW to liquidate.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Exclusivity.</I></B> The fact that the Business Combination Agreement includes an exclusivity provision
that prohibits CHFW from soliciting other business combination proposals, which restricts CHFW&#146;s ability, so long as the Business Combination Agreement is in effect, to consider other potential business combinations prior to November&nbsp;19,
2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Shareholder Vote.</I></B> The risk that CHFW&#146;s shareholders may fail to provide the respective
votes necessary to effect the Business Combination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Closing Conditions.</I></B> The fact that completion of the Business Combination is conditioned on the
satisfaction of certain closing conditions that are not within CHFW&#146;s control. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Litigation.</I></B> The possibility of litigation challenging the Business Combination or that an
adverse judgment granting permanent injunctive relief could indefinitely enjoin consummation of the Business Combination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Fees and Expenses.</I></B> The fees and expenses associated with completing the Business Combination.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Other Risks.</I></B> Various other risks associated with the Business Combination, the business of CHFW
and the business of Surrozen described under the section entitled &#147;Risk Factors.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to considering
the factors described above, the CHFW Board also considered that certain of the officers and directors of CHFW may have interests in the Business Combination as individuals that are in addition to, and that may be different from, the interests of
CHFW&#146;s shareholders. CHFW&#146;s independent directors reviewed and considered these interests during the negotiation of the Business Combination and in evaluating and approving, as members of the CHFW Board, the Business Combination Agreement
and the transactions contemplated therein, including the Business Combination. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The CHFW Board concluded that the potential benefits that
it expected CHFW and its shareholders to achieve as a result of the Business Combination outweighed the potentially negative factors associated with the Business Combination. Accordingly, the CHFW Board determined that the Business Combination
Agreement, the Business Combination and the Merger, were advisable, fair to, and in the best interests of, CHFW and its shareholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For
more information about the CHFW Board&#146;s decision-making process concerning the Business Combination, please see the section entitled &#147;<I>The Business Combination Proposal&#151;the CHFW Board&#146;s Reasons for the Business
Combination</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Related Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This section describes certain additional agreements entered into or to be entered into in connection with the Business Combination Agreement.
For additional information, see &#147;<I>Business Combination Proposal&#151;Related Agreements</I>.&#148; </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>PIPE Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW entered into Subscription Agreements with the PIPE Investors to consummate the PIPE Financing, pursuant to which the PIPE Investors have
agreed to subscribe for and purchase, and CHFW has agreed to issue and sell to the PIPE Investors, an aggregate of 12,020,000 units, each consisting of one share of CHFW Common Stock <FONT STYLE="white-space:nowrap">and&nbsp;one-third&nbsp;of</FONT>
one redeemable warrant for one share of CHFW Common Stock (the &#147;PIPE Warrants&#148;), for a purchase price of $10.00 per unit (the &#147;PIPE Units&#148;), for aggregate gross proceeds of $120,200,000 in the PIPE Financing. The PIPE Units were
offered to facilitate the subscriptions, however, the shares of CHFW Common Stock and the PIPE Warrants which comprise the PIPE Units are not attached and will trade separately without any instruction or detachment obligations on the part of the
investors, CHFW or the warrant agent. Each whole PIPE Warrant entitles the holder thereof to purchase one share of CHFW Common Stock at a price of $11.50 per share, subject to adjustment as described in the form of warrant agreement attached to the
form of Subscription Agreement and only whole PIPE Warrants will be exercisable. The PIPE Warrants have substantially the same provisions as the public warrants issued in connection with CHFW&#146;s initial public offering. The PIPE Financing is
contingent upon, among other things, the substantially concurrent closing of the Business Combination. For additional information, see &#147;<I>Business Combination Proposal&#151;Related Agreements&#151;PIPE Financing</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Investor Rights Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At, and as a condition to, the closing of the Business Combination, CHFW, Sponsor, and certain other individuals will enter into an investor
rights agreement (the &#147;Investor Rights Agreement&#148;) pursuant to which, among other things, certain stockholders will agree not to effect any sale or distribution of CHFW equity securities during
<FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;period</FONT> as described therein, and will be granted certain customary registration rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The foregoing description of the Investor Rights Agreement is subject to and qualified in its entirety by reference to the full text of the
form of Investor Rights Agreement (filed as Exhibit 10.4 to CHFW&#146;s Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on April&nbsp;15, 2021). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen Company Support Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the Business Combination Agreement, certain stockholders of Surrozen, together holding more than 67% of the outstanding preferred
stock and voting power of Surrozen (collectively, the &#147;Surrozen Supporting Stockholders&#148;), each entered into a Company Support Agreement (the &#147;Support Agreements&#148;) with CHFW and Surrozen, pursuant to which the Surrozen Supporting
Stockholders have agreed to, among other things, (i)&nbsp;vote in favor of the Business Combination Agreement and the Transactions, (ii)&nbsp;irrevocably appoint Surrozen, and any designee thereof, and each of them individually, as such Surrozen
Stockholder&#146;s proxy <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">and&nbsp;attorney-in-fact&nbsp;to</FONT></FONT> deliver any action by written consent of the stockholders of Surrozen or attend any meeting of the
stockholders of Surrozen concerning the Business Combination and related stockholder proposals, and to include the Surrozen equity securities owned by the Surrozen Supporting Stockholders in any computation for purposes of establishing a quorum at
any such meeting, and to vote against any competing proposal and (iii)&nbsp;not transfer subject shares during the period prior to closing under or termination of the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The foregoing description of the Support Agreements is subject to and qualified in its entirety by reference to the full text of the form of
Support Agreement (filed as Exhibit 10.3 to CHFW&#146;s Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on April&nbsp;15, 2021). For additional information, see &#147;<I>Business Combination Proposal&#151;Related
Agreements&#151;Support Agreements</I>.&#148; </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>CHFW Shareholder Support Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Concurrently with the execution of the Subscription Agreements, CHFW, Surrozen and certain affiliates of Sponsor holding a total of 1,300,000
public Class&nbsp;A shares of CHFW entered into shareholder support agreements (the &#147;Shareholder Support Agreements&#148;) pursuant to which each such holder agreed (i)&nbsp;to vote at any meeting of the shareholders of CHFW all of its
Class&nbsp;A ordinary shares held of record or thereafter acquired in favor of the Business Combination and the other Transaction Proposals and (ii)&nbsp;not to redeem any such securities in connection with the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Sponsor Letter Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the Business Combination Agreement, CHFW, Consonance Life Sciences, a Cayman Islands limited liability company, (the
&#147;Sponsor&#148;), Donald J. Santel, Christopher Haqq, Jennifer Jarrett, who collectively hold 2,300,000 CHFW Class&nbsp;B ordinary shares, and Surrozen entered into the Sponsor Letter Agreement (the &#147;Sponsor Letter Agreement&#148;),
pursuant to which the Sponsor and each of Mr.&nbsp;Santel, Dr.&nbsp;Haqq and Ms.&nbsp;Jarrett, each as a holder of CHFW Class&nbsp;B ordinary shares, has agreed to: (i)&nbsp;vote in favor of the Business Combination and each of the Transaction
Proposals (as defined in the Business Combination Agreement), (ii) waive any adjustment to the conversion ratio set forth in the governing documents of CHFW or any other anti-dilution or similar protection with respect to the Class&nbsp;B ordinary
shares (whether resulting from the transactions contemplated by the Subscription Agreements (as defined below) or otherwise), (iii) be bound by certain other covenants and agreements related to the Business Combination, (iv)&nbsp;be bound by certain
transfer restrictions with respect to his, her or its shares in CHFW prior to the closing of the Business Combination, and (v)&nbsp;in the case of the Sponsor, effective as of the closing, contribute to CHFW 759,000 Class&nbsp;B ordinary shares, in
each case, for no consideration on the terms and subject to the conditions set forth in the Sponsor Letter Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The foregoing
description of the Sponsor Letter Agreement is subject to and qualified in its entirety by reference to the full text of the form of Support Agreement (filed as Exhibit 10.1 to CHFW&#146;s Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with
the SEC on April&nbsp;15, 2021). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_10"></A>Ownership of New Surrozen following Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of the date of this proxy statement/prospectus, there are 11,934,000 ordinary shares issued and outstanding, which includes the 2,300,000
Class&nbsp;B shares held by the Sponsor and certain directors of CHFW (before giving effect to the contribution of 759,000 Class&nbsp;B shares by the Sponsor to CHFW, for no consideration, that will be effective as of the closing), 434,000
Class&nbsp;A private placement shares and the 9,200,000 Class&nbsp;A public shares. As of the date of this proxy statement/prospectus, there is outstanding an aggregate of 3,211,334 warrants, which includes the 144,667 private placement warrants
held by the Sponsor and the 3,066,667 public warrants. Each whole warrant entitles the holder thereof to purchase one Class&nbsp;A ordinary share and, following the Domestication, will entitle the holder thereof to purchase one share of New Surrozen
common stock. Therefore, as of the date of this proxy statement/prospectus (without giving effect to the Business Combination) the CHFW fully diluted share capital would be 15,145,334. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is anticipated that, following the Business Combination (1)&nbsp;CHFW&#146;s public shareholders are expected to own approximately 21.3% of
the outstanding New Surrozen Common Stock (excluding the PIPE subscriptions by certain CHFW public shareholders), (2) Surrozen Stockholders (without taking into account any public shares held by Surrozen Stockholders prior to the consummation of the
Business Combination or shares of New Surrozen Common Stock issuable to holders of New Surrozen Awards, but taking into account the PIPE subscriptions by certain Surrozen Stockholders) are expected to own approximately 53.5% of the outstanding New
Surrozen Common Stock, (3)&nbsp;the Sponsor (taking into account Sponsor&#146;s PIPE subscription) is expected to own approximately 10.4% of the outstanding New Surrozen Common Stock and (4)&nbsp;the PIPE Investors
</P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
(excluding subscriptions from Surrozen Stockholders and from the Sponsor) are expected to own approximately 14.8% of the outstanding New Surrozen Common Stock. These&nbsp;percentages assume
(i)&nbsp;that no public shareholders exercise their redemption rights in connection with the Business Combination, (ii)&nbsp;no exercise of the public warrants or issuance of any shares of New Surrozen Common Stock, (iii)&nbsp;that (x)&nbsp;New
Surrozen issues or reserves 20,000,000 shares of New Surrozen Common Stock to Surrozen Stockholders and holders of vested and unvested Surrozen equity awards as part of the merger consideration pursuant to the Business Combination Agreement and
(y)&nbsp;New Surrozen issues 12,020,000 shares of New Surrozen Common Stock to the PIPE Investors pursuant to the PIPE Investment. If the actual facts are different from these assumptions, the&nbsp;percentage ownership retained by current CHFW
shareholders and Surrozen Stockholders will be different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table illustrates varying ownership levels in New Surrozen
immediately following the consummation of the Business Combination based on the assumptions above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share Ownership in New Surrozen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma Combined<BR>(Assuming No Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma Combined<BR>(Assuming Maximum<BR>Redemptions)<SUP STYLE="font-size:85%; vertical-align:top">5</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Ownership<SUP STYLE="font-size:85%; vertical-align:top">6</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Ownership<SUP STYLE="font-size:85%; vertical-align:top">6</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surrozen stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,122,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,122,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CHFW&#146;s public shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,200,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsor and certain directors of CHFW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,472,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,472,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Investors (excluding Surrozen stockholders and Sponsor)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,400,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,195,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,295,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Includes 20,000,000 shares issuable to Surrozen equityholders as Merger consideration per the terms of the
Business Combination Agreement, and 3,122,500 PIPE shares subscribed for by Surrozen stockholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Includes 1,000,000 shares purchased by affiliates of Consonance Capital Management in the CHFW IPO. Does not
reflect impact of any PIPE shares subscribed for by CHFW public shareholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Calculated as the sum of the following: (1) 1,541,000 founder&#146;s shares (which number is net of the
forfeiture of 759,000 founder&#146;s shares); (2) 434,000 shares underlying the private placement units; and (3) 2,497,500 shares subscribed for by Sponsor in the PIPE. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">12,020,000 PIPE shares, less subscriptions from existing Surrozen stockholders (3,122,500 shares) and
Sponsor (2,497,500 shares) </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">This scenario assumes the redemption of 7,900,000 public shares, equal to the number of public shares not
covered by CHFW Shareholder Support Agreements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Columns may not sum to 100% due to rounding. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_11"></A>Date, Time and Place of Extraordinary General Meeting of CHFW&#146;s Shareholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The extraordinary general meeting of CHFW will be held
at&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a.m., Eastern Time, on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021, via live webcast at the
following address: https://www.cstproxy.com/consonancehfw/sm2021. You will need the <FONT STYLE="white-space:nowrap">12-digit</FONT> meeting control number that is printed on your proxy card to enter the extraordinary general meeting. CHFW
recommends that you log in at least 15 minutes before the extraordinary general meeting to ensure you are logged in when the extraordinary general meeting starts. Please note that you will not be able to attend the extraordinary general meeting in
person, to consider and vote upon the proposals to be put to the extraordinary general meeting, including if necessary, the Adjournment Proposal, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the
extraordinary general meeting, each of the Condition Precedent Proposals have not been approved. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_12"></A>Voting Power; Record Date </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW shareholders will be entitled to vote or direct votes to be cast at the extraordinary general meeting if they owned ordinary shares at the
close of business on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, which is the &#147;record date&#148; for the extraordinary general meeting. Shareholders will have one vote for each
ordinary share owned at the close of business on the record date. If your shares are held in &#147;street name&#148; or are in a margin or similar account, you should contact your broker to ensure that votes related to the shares you beneficially
own are properly counted. Our warrants do not have voting rights. As of the close of business on the record date, there were 11,934,000 ordinary shares issued and outstanding, of which 9,200,000 were issued and outstanding public shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_13"></A>Quorum and Vote of CHFW Shareholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A quorum of CHFW shareholders is necessary to hold a valid meeting. A quorum will be present at the extraordinary general meeting if one or
more shareholders who together hold not less than a majority of the issued and outstanding ordinary shares entitled to vote at the extraordinary general meeting are represented in person or by proxy at the extraordinary general meeting. As of the
record date for the extraordinary general meeting, 5,967,001 ordinary shares would be required to achieve a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The initial
shareholders have, pursuant to the Sponsor Letter Agreement, agreed to, among other things, vote all of their ordinary shares in favor of the proposals being presented at the extraordinary general meeting. As of the date of this proxy
statement/prospectus, the initial shareholders own approximately 22.9% of the issued and outstanding ordinary shares. See &#147;<I>Business Combination Proposal&#151;Related Agreements&#151;Sponsor Letter Agreement</I>&#148; in the accompanying
proxy statement/prospectus for more information related to the Sponsor Letter Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The proposals presented at the extraordinary
general meeting require the following votes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B><I>Business Combination Proposal: </I></B>The approval of the Business Combination Proposal requires an
ordinary resolution under Cayman Islands law, being the affirmative vote of at least a majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and
entitled to vote on such matter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B><I>Domestication Proposal: </I></B>The approval of the Domestication Proposal requires a special
resolution under Cayman Islands law, being the affirmative vote of at least a <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy
at the extraordinary general meeting and entitled to vote on such matter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B><I>New Organizational Documents Proposal:</I></B> The approval of the replacement of CHFW&#146;s Existing
Governing Documents with the Proposed Governing Documents of New Surrozen; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B><I>Governing Documents Proposal: </I></B>The separate advisory, non-binding approval of each of the
Governing Documents Proposals requires a special resolution under Cayman Islands law, being the affirmative vote of at least a <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) majority of the votes cast by the holders of the issued ordinary
shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter, save for Governing Documents Proposal A, which proposes to alter CHFW&#146;s authorized share capital and which will require
an ordinary resolution, being the affirmative vote of holders of a majority of the ordinary shares represented in person or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B><I>Share Issuance Proposal: </I></B>The approval of the Share Issuance Proposal requires an ordinary
resolution under Cayman Islands law, being the affirmative vote of at least a majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote
on such matter. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B><I>Incentive Award Plan Proposal: </I></B>The approval of the Incentive Award Plan Proposal requires an
ordinary resolution under Cayman Islands law, being the affirmative vote of at least a majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and
entitled to vote on such matter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B><I>Employee Stock Purchase Plan Proposal: </I></B>The approval of the Employee Stock Purchase Plan
Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of a majority of the ordinary shares represented in person or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B><I>Adjournment Proposal: </I></B>The approval of the Adjournment Proposal requires an ordinary resolution
under Cayman Islands law, being the affirmative vote of at least a majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such
matter. </P></TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_14"></A>Redemption Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the Existing Governing Documents, a public shareholder may request of CHFW that New Surrozen redeem all or a portion of its public
shares for cash if the Business Combination is consummated. As a holder of public shares, you will be entitled to receive cash for any public shares to be redeemed only if you: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">(a) hold public shares, or (b)&nbsp;if you hold public shares through units, you elect to separate your
units into the underlying public shares and warrants prior to exercising your redemption rights with respect to the public shares; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">submit a written request to Continental, CHFW&#146;s transfer agent, in which you (i)&nbsp;request that New
Surrozen redeem all or a portion of your public shares for cash, and (ii)&nbsp;identify yourself as the beneficial holder of the public shares and provide your legal name, phone number and address; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">deliver your public shares to Continental, CHFW&#146;s transfer agent, physically or electronically through
DTC. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Holders must complete the procedures for electing to redeem their public shares in the manner described above
prior to 5:00 p.m., Eastern Time, on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 (two business days before the extraordinary general meeting) in order for their shares to be redeemed.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Holders of units must elect to separate the units into the underlying public shares and public warrants prior to exercising
redemption rights with respect to the public shares. If holders hold their units in an account at a brokerage firm or bank, holders must notify their broker or bank that they elect to separate the units into the underlying public shares and public
warrants, or if a holder holds units registered in its own name, the holder must contact Continental, CHFW&#146;s transfer agent, directly and instruct them to do so. The redemption rights include the requirement that a holder must identify itself
in writing as a</B> <B>beneficial holder and provide its legal name, phone number and address to Continental in order to validly</B> <B>redeem its shares. Public shareholders (other than those who have agreed not to do so by executing an CHFW
Shareholder Support Agreement) may elect to redeem all or a portion of the public shares held by them regardless of if or how they vote in respect of the Business Combination Proposal. </B>If the Business Combination is not consummated, the public
shares will be returned to the respective holder, broker or bank. If the Business Combination is consummated, and if a public shareholder properly exercises its right to redeem all or a portion of the public shares that it holds and timely delivers
its shares to Continental, CHFW&#146;s transfer agent, New Surrozen will redeem such public shares for a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the pro rata portion of the trust account, calculated as of
two business days prior to the consummation of the Business Combination. For illustrative purposes, as of March&nbsp;31, 2021, this would have amounted to approximately </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
$10.00 per issued and outstanding public share. If a public shareholder exercises its redemption rights in full, then it will be electing to exchange its public shares for cash and will no longer
own public shares. The redemption takes place following the Domestication and accordingly it is shares of New Surrozen Common Stock that will be redeemed immediately after consummation of the Business Combination. See &#147;<I>Extraordinary General
Meeting of CHFW&#151;Redemption Rights</I>&#148; in this proxy statement/prospectus for a detailed description of the procedures to be followed if you wish to redeem your public shares for cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing, a public shareholder, together with any affiliate of such public shareholder or any other person with whom such
public shareholder is acting in concert or as a &#147;group&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act), will be restricted from redeeming its public shares with respect to more than an aggregate of 15% of the public shares.
Accordingly, if a public shareholder, alone or acting in concert or as a group, seeks to redeem more than 15% of the public shares, then any such shares in excess of that 15% limit would not be redeemed for cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The initial shareholders have, pursuant to the Sponsor Letter Agreement, agreed to, among other things, vote all of their ordinary shares in
favor of the proposals being presented at the extraordinary general meeting and waive their anti-dilution rights with respect to their Class&nbsp;B ordinary shares in connection with the consummation of the Business Combination. Such shares will be
excluded from the pro rata calculation used to determine the <FONT STYLE="white-space:nowrap">per-share</FONT> redemption price. As of the date of this proxy statement/prospectus, the initial shareholders own approximately 22.9% of the issued and
outstanding ordinary shares. See &#147;<I>Business Combination Proposal&#151;Related Agreements&#151;Sponsor Letter Agreement</I>&#148; in the accompanying proxy statement/prospectus for more information related to the Sponsor Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Holders of the warrants will not have redemption rights with respect to the warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_15"></A>Appraisal Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither CHFW shareholders nor CHFW warrant holders have appraisal rights in connection with the Business Combination or the Domestication under
the Cayman Islands Companies Act or under the DGCL. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_16"></A>Proxy Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Proxies may be solicited by mail, telephone or in person. CHFW has engaged Okapi Partners to assist in the solicitation of proxies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a shareholder grants a proxy, it may still vote its shares in person if it revokes its proxy before the extraordinary general meeting. A
shareholder also may change its vote by submitting a later-dated proxy as described in the section entitled &#147;<I>Extraordinary General Meeting of CHFW&#151;Revoking Your Proxy</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_17"></A>Interests of CHFW Directors and Executive Officers in the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">When you consider the recommendation of the CHFW Board in favor of approval of the Business Combination Proposal, you should keep in mind that
the initial shareholders, including CHFW&#146;s directors and executive officers, have interests in such proposal that are different from, or in addition to, those of CHFW shareholders and warrant holders generally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table details the number of ordinary shares and warrants held by Sponsor, its affiliates and the directors and officers of CHFW,
and quantifies the purchase price and the current value of such securities. The </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
value of such securities could have significantly higher value at the time of, or following, the Business Combination. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Entity<SUP STYLE="font-size:85%; vertical-align:top">1</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value<SUP STYLE="font-size:85%; vertical-align:top">2</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Promote<BR>shares<SUP STYLE="font-size:85%; vertical-align:top">3</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IPO units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IPO PIPE<BR>units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PIPE</B><br><B>Financing </B><br><B>units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right">Consonance Capital</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="right">Management</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of ordinary shares</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,497,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,497,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of warrants</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">832,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,165,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Aggregate Purchase Price</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,975,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,975,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Estimated Current Value</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,223,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,723,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right">Consonance Life</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="right">Sciences, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of ordinary shares</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,451,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">434,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,885,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of warrants</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Aggregate Purchase Price</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,340,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,365,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Estimated Current Value</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,510,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,557,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,067,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="right">Donald Santel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of ordinary shares</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of warrants</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Aggregate Purchase Price</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Estimated Current Value</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="right">Christopher Haqq</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of ordinary shares</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of warrants</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Aggregate Purchase Price</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Estimated Current Value</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="right">Jennifer Jarrett</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of ordinary shares</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of warrants</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Aggregate Purchase Price</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Estimated Current Value</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>No. of ordinary shares</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,541,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,000,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>434,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,497,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,472,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>No. of warrants</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>333,333</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>144,667</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>832,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,310,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>Aggregate&nbsp;Purchase&nbsp;Price</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>25,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,000,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,340,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>24,975,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>39,340,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>Estimated Current Value</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>15,410,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,500,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,557,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>26,223,750</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>56,690,751</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="justify">Please see <I>Beneficial Ownership of Securities</I> for details regarding voting and dispositive power of
the securities held by the persons included in this table. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="justify">The Estimated Current Value assumes a $10.00 per share price and a $1.50 price per warrant. As of
June&nbsp;22, 2021, the trading price was $9.90 per CHFW Class A ordinary share and $1.58 per warrant. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="justify">Net of contributions for no consideration. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="justify">This number is net of (i) 90,000 shares transferred (in the aggregate) to the independent directors of the
CHFW Board, (ii) 759,000 founder shares which will be forfeited for no consideration at the closing of the Business Combination and (iii) 718,750 and 575,000 founder shares previously contributed back to CHFW for no consideration on October 8, 2020
and November 10, 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These interests also include, among other things, the interests listed below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that our initial shareholders have agreed not to redeem any Class&nbsp;A ordinary shares held by them
in connection with a shareholder vote to approve a proposed initial business combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that Sponsor and its affiliates has made a sizable investment in CHFW securities, which securities
would be worthless if a business combination is not consummated by November&nbsp;23, 2022 (unless such date is extended in accordance with the Existing Governing Documents) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the initial shareholders and CHFW&#146;s other current officers and directors have agreed to
waive their rights to liquidating distributions from the trust account, which, as of June&nbsp;22, 2021, included an amount of approximately $92&nbsp;million, with respect to any ordinary shares (other than public shares) held by them if CHFW fails
to complete an initial business combination by November&nbsp;23, 2022; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Investor Rights Agreement will be entered into by the initial shareholders;
</P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continued indemnification of CHFW&#146;s directors and officers and the continuation of CHFW&#146;s
directors&#146; and officers&#146; liability insurance after the Business Combination through the purchase of a six year tail policy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor and CHFW&#146;s officers and directors will lose their entire investment in CHFW and
will not be reimbursed for any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses if an initial business combination is not consummated by November&nbsp;23, 2022; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that CHFW will reimburse Sponsor for office space, secretarial and administrative services provided
to members of the CHFW founding team, in the amount of $55,000 per month, which payments will cease upon completion of the Business Combination; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that CHFW is entitled to designate one director of New Surrozen at closing and the Sponsor has the
right to replace the designated director with a new director during the first two years from the date of its extraordinary shareholders meeting to approve the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that if the trust account is liquidated, including in the event CHFW is unable to complete an initial
business combination by November&nbsp;23, 2022, the Sponsor has agreed to indemnify CHFW to ensure that the proceeds in the trust account are not reduced below $10.00 per public share, or such lesser per public share amount as is in the trust
account on the liquidation date, by the claims of prospective target businesses with which CHFW has entered into an acquisition agreement or claims of any third party for services rendered or products sold to CHFW, but only if such a vendor or
target business has not executed a waiver of any and all rights to seek access to the trust account; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that CHFW may be entitled to distribute or pay over funds held by CHFW outside the Trust Account to
the Sponsor or any of its Affiliates prior to the Closing. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June 22, 2021, Sponsor and its affiliates have
invested or committed to invest an aggregate of $39.3&nbsp;million, including its commitment with respect to the PIPE Financing and assuming consummation of the Business Combination (the &#147;Total Commitment&#148;). Assuming the issuance of all
securities underlying the Total Commitment and utilizing a per share price of $10.00 and a per warrant value of $1.50, the Total Commitment would have an approximate value of $56.7&nbsp;million. If the Business Combination is not consummated,
Sponsor and its affiliates will lose approximately $4.3&nbsp;million of their amounts already invested. Although Sponsor and its affiliates have committed considerable capital to CHFW, including through its participation in the CHFW IPO and its
contribution of a portion of the Promote for no consideration, if the Business Combination is consummated, taking into account the investments described above, including the Promote, it is possible that Sponsor and its affiliates could realize a
positive rate of return on such investments even if other CHFW shareholders experience a negative rate of return following the Business Combination. Except as described above, there are no outstanding loans or material fee or reimbursement
arrangements among CHFW, Sponsor, its affiliates, or the CHFW directors or officers. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The initial shareholders have, pursuant to the
Sponsor Letter Agreement, agreed to, among other things, vote all of their ordinary shares in favor of the proposals being presented at the extraordinary general meeting and waive their anti-dilution rights with respect to their Class&nbsp;B
ordinary shares in connection with the consummation of the Business Combination. Such shares will be excluded from the pro rata calculation used to determine <FONT STYLE="white-space:nowrap">the&nbsp;per-share&nbsp;redemption</FONT> price. As of the
date of this proxy statement/prospectus, the initial shareholders own approximately 22.9% of the issued and outstanding ordinary shares. See &#147;<I>Business Combination Proposal&#151;Related Agreements&#151;Sponsor Letter Agreement</I>&#148; in
the accompanying proxy statement/prospectus for more information related to the Sponsor Letter Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At any time at or prior to the
Business Combination, during a period when they are not then aware of any material nonpublic information regarding us or our securities, our initial shareholders, Surrozen and/or their directors, </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
officers, advisors or respective affiliates may purchase public shares from institutional and other investors who vote, or indicate an intention to vote, against any of the Condition Precedent
Proposals, or execute agreements to purchase such shares from such investors in the future, or they may enter into transactions with such investors and others to provide them with incentives to acquire public shares or vote their public shares in
favor of the Condition Precedent Proposals. Such a purchase may include a contractual acknowledgement that such shareholder, although still the record or beneficial holder of our shares, is no longer the beneficial owner thereof and therefore agrees
not to exercise its redemption rights. In the event that our initial shareholders, Surrozen and/or their directors, officers, advisors or respective affiliates purchase shares in privately negotiated transactions from public shareholders who have
already elected to exercise their redemption rights, such selling shareholder would be required to revoke their prior elections to redeem their shares. The purpose of such share purchases and other transactions would be to increase the likelihood of
satisfaction of the requirements that (i)&nbsp;the Business Combination Proposal, the Governing Documents Proposal A, the Share Issuance Proposal, the Incentive Award Plan Proposal, the Employee Stock Purchase Plan Proposal and the Adjournment
Proposal are approved by the affirmative vote of at least a majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter
(ii)&nbsp;the Domestication Proposal, the New Organizational Documents Proposal, the Governing Documents Proposal B, the Governing Documents Proposal C and the Governing Documents Proposal D are approved by the affirmative vote of at least <FONT
STYLE="white-space:nowrap">a&nbsp;two-thirds&nbsp;(2/3)</FONT> majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such
matter, (iii)&nbsp;otherwise limit the number of public shares electing to redeem and (iv)&nbsp;New Surrozen&#146;s net tangible assets (as determined in accordance with <FONT STYLE="white-space:nowrap">Rule&nbsp;3a51-1(g)(1)</FONT> of the Exchange
Act) being at least $5,000,001 after giving effect to the transactions contemplated by the Business Combination Agreement and the PIPE Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Entering into any such arrangements may have a depressive effect on the ordinary shares. For example, as a result of these arrangements, an
investor or holder may have the ability to effectively purchase shares at a price lower than market and may therefore be more likely to sell the shares he or she owns, either at or prior to the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If such transactions are effected, the consequence could be to cause the Business Combination to be consummated in circumstances where such
consummation could not otherwise occur. Purchases of shares by the persons described above would allow them to exert more influence over the approval of the proposals to be presented at the extraordinary general meeting and would likely increase the
chances that such proposals would be approved. We will file or submit a Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;to</FONT> disclose any material arrangements entered into or significant purchases made by any of the
aforementioned persons that would affect the vote on the proposals to be put to the extraordinary general meeting or the redemption threshold. Any such report will include descriptions of any arrangements entered into or significant purchases by any
of the aforementioned persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The existence of financial and personal interests of one or more of CHFW&#146;s directors may result in a
conflict of interest on the part of such director(s) between what he, she or they may believe is in the best interests of CHFW and its shareholders and what he, she or they may believe is best for himself, herself or themselves in determining to
recommend that shareholders vote for the proposals. In addition, CHFW&#146;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_18"></A>Recommendation to Shareholders of CHFW </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The CHFW Board believes that the Business Combination Proposal and the other proposals to be presented at the extraordinary general meeting are
in the best interest of CHFW and its shareholders and unanimously recommends that its shareholders vote &#147;FOR&#148; the Business Combination Proposal, &#147;FOR&#148; the Domestication Proposal, &#147;FOR&#148; the New Organizational Documents
Proposal, &#147;FOR&#148; each of the Governing Documents Proposals, &#147;FOR&#148; the Share Issuance Proposal, &#147;FOR&#148; the Incentive Award Plan Proposal, &#147;FOR&#148; the Employee </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Stock Purchase Plan Proposal and &#147;FOR&#148; the Adjournment Proposal, in each case, if presented to the extraordinary general meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The existence of financial and personal interests of one or more of CHFW&#146;s directors may result in a conflict of interest on the part of
such director(s) between what he, she or they may believe is in the best interests of CHFW and its shareholders and what he, she or they may believe is best for himself or themselves in determining to recommend that shareholders vote for the
proposals. In addition, CHFW&#146;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#147;<I>Business Combination Proposal&#151;Interests of CHFW&#146;s Directors
and Executive Officers in the Business Combination</I>&#148; for a further discussion of these considerations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Sources and Uses of
Funds for the Business Combination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables summarize the sources and uses for funding the Business Combination assuming a
Closing Date of June&nbsp;30, 2020, and (i)&nbsp;assuming that none of CHFW&#146;s outstanding public shares are redeemed in connection with the Business Combination and (ii)&nbsp;assuming that, giving effect to the CHFW Shareholder Transaction
Support Agreements entered into by certain CHFW public shareholders participating, all of CHFW&#146;s outstanding public shares are redeemed in connection with the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>No Redemption </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="4" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Source of Funds&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Uses&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing Cash held in trust
account&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">92,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares of New Surrozen Common Stock issued to Surrozen shareholders&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares of New Surrozen Common Stock issued to Surrozen shareholders&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated Transaction Fees and Expenses&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Financing&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remaining Cash on Balance
Sheet&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">190,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>412,200</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Uses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>412,200</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Sources and uses of funds excludes impact of Surrozen&#146;s balance sheet cash, cash equivalents and
short-term investments which, as of December&nbsp;31, 2020, totaled $49.2&nbsp;million. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">As of March&nbsp;31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Shares issued to Surrozen are at a deemed value of $10.00 per share. Assumes 20,000,000 shares are issued to
Surrozen shareholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Reflects impact of 12.02&nbsp;million shares underlying units sold in committed PIPE financing. Excludes any
impact of approximately 4&nbsp;million shares underlying warrants sold as part of PIPE financing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Estimated transaction fees and expenses includes deferred underwriting fee payable from CHFW IPO of
$3.2&nbsp;million, as well as total preliminary estimated transaction costs incurred by Surrozen and CHFW of approximately $18.8&nbsp;million for legal, financial advisory and other professional fees. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Does not include impact of CHFW warrants outstanding. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Maximum Redemption </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="4" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Source of Funds&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Uses&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing Cash held in trust
account&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">13,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares of New Surrozen Common Stock issued to Surrozen shareholders&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares of New Surrozen Common Stock issued to Surrozen shareholders&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated Transaction Fees and Expenses&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Financing&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remaining Cash on Balance
Sheet&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>333,200</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Uses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>333,200</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Sources and uses of funds excludes impact of Surrozen&#146;s balance sheet cash, cash equivalents and
short-term investments which, as of December&nbsp;31, 2020, totaled $49.2&nbsp;million. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">As of March&nbsp;31, 2021, assuming redemption of 7.9&nbsp;million CHFW public shares, the maximum number of
shares that may be redeemed taking into account CHFW Shareholder Transaction Support Agreements entered into by certain public shareholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Shares issued to Surrozen are at a deemed value of $10.00 per share. Assumes 20,000,000 shares are issued to
Surrozen shareholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Reflects impact of 12.02&nbsp;million shares underlying units sold in committed PIPE financing. Excludes any
impact of approximately 4&nbsp;million shares underlying warrants sold as part of PIPE financing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Estimated transaction fees and expenses includes deferred underwriting fee payable from CHFW IPO of
$3.2&nbsp;million, as well as total preliminary estimated transaction costs incurred by Surrozen and CHFW of approximately $18.8&nbsp;million for legal, financial advisory and other professional fees. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Does not include impact of CHFW warrants outstanding. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_19"></A>U.S. Federal Income Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For a discussion summarizing the U.S. federal income tax considerations of the Domestication and exercise of redemption rights, please see
&#147;<I>U.S. Federal Income Tax Considerations</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_20"></A>Expected Accounting Treatment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The Domestication </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There will be no accounting effect or change in the carrying amount of the consolidated assets and liabilities of CHFW as a result of the
Domestication. The business, capitalization, assets and liabilities and financial statements of New Surrozen immediately following the Domestication will be the same as those of CHFW immediately prior to the Domestication. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The Business Combination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen has been determined to be the accounting acquirer in the Business Combination based on the following predominate factors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s existing stockholders will have the greatest voting interest in the combined entity under the
no redemption and maximum redemption scenarios with over 50% of the voting interest in each scenario; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen will have the ability to nominate a majority of the members of the Board of Directors of the combined
entity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s senior management will be the senior management of the combined entity; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen is the larger entity based on historical operating activity and has the larger employee base.
</P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Business Combination is expected to be accounted for as a reverse recapitalization in
accordance with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;). Under this method of accounting, CHFW is treated as the acquired company and Surrozen is treated as the acquirer. Accordingly, for
accounting purposes, the Business Combination will be treated as the equivalent of Surrozen issuing stock for the net assets of CHFW, accompanied by a recapitalization. The net assets of CHFW will be stated at historical cost, with no goodwill or
other intangible assets recorded. Operations presented for the period prior to the Business Combination will be those of Surrozen. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_21">
</A>Regulatory Approvals </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Business Combination and the transactions contemplated by the Business Combination Agreement are not
subject to any additional regulatory requirement or approval, except for (i)&nbsp;filings with the Registrar of Companies of the Cayman Islands and Secretary of State of the State of Delaware necessary to effectuate the Domestication and
(ii)&nbsp;filings required with the SEC pursuant to the reporting requirements applicable to CHFW, and the requirements of the Securities Act and the Exchange Act, including the requirement to file the registration statement of which this proxy
statement/prospectus forms a part and to disseminate this proxy statement/prospectus to CHFW&#146;s shareholders. Based on the <FONT STYLE="white-space:nowrap">anticipated&nbsp;pro-forma&nbsp;voting</FONT> power of the Company, no filings are
required under the&nbsp;HSR Act&nbsp;in connection with the Business Combination; however, such a filing may be required to the extent the anticipated pro forma ownership changes. CHFW must comply with applicable U.S. federal and state securities
laws in connection with the Domestication, including the filing with NYSE American of a press release disclosing the Domestication, among other things. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_22"></A>Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the Jumpstart Our
Business Startups Act of 2012 (the &#147;JOBS Act&#148;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not
limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 (the &#147;Sarbanes-Oxley Act&#148;), reduced disclosure obligations regarding executive compensation in our
periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial
accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or
revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies
but any such election to opt out is irrevocable. CHFW has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, CHFW,
as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of CHFW&#146;s financial statements with certain other public companies difficult or
impossible because of the potential differences in accounting standards used. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will remain an emerging growth company until the earlier
of: (i)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the closing of CHFW&#146;s initial public offering, (b)&nbsp;in which we have total annual gross revenue of at least $1.07&nbsp;billion, or (c)&nbsp;in which we
are deemed to be a large accelerated filer, which means the market value of our common equity that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the last business day of its most recently completed
second fiscal quarter; and (ii)&nbsp;the date on which we have issued more than </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
$1.00&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. References herein to &#147;emerging growth company&#148; have the
meaning associated with it in the JOBS Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_23"></A>Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, we are a &#147;smaller reporting company&#148; as defined in Item 10(f)(1) of Regulation
<FONT STYLE="white-space:nowrap">S-K.</FONT> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller
reporting company until the last day of the fiscal year in which (i)&nbsp;the market value of our ordinary shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $250&nbsp;million as of the prior June&nbsp;30, or (ii)&nbsp;our
annual revenues exceeded $100&nbsp;million during such completed fiscal year and the market value of our ordinary shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June 30. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_24"></A>Risk Factors Summary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our shareholders should carefully read this proxy statement/prospectus and especially consider the factors discussed in the section entitled
&#147;<I>Risk Factors</I>&#148;, which include, but are not limited to, the following: The following is a summary of the&nbsp;principal&nbsp;risks&nbsp;we face: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen is a preclinical stage biopharmaceutical company with a history of losses. It expects to continue to
incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of New Surrozen Common Stock. In addition, Surrozen may be unable to continue as a going
concern. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s lead product candidates, <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT
STYLE="white-space:nowrap">SZN-043,</FONT> are in preclinical development and have never been tested in humans. Its product candidates may fail in clinical development or suffer delays that materially and adversely affect their commercial viability.
If either <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT STYLE="white-space:nowrap">SZN-043,</FONT> or any future product candidate is ever tested in humans, it may not demonstrate the safety, purity and potency, or efficacy, necessary to
become approvable or commercially viable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen may not be successful in applying its Wnt therapeutics platform to build a pipeline of product
candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen faces competition from entities that have developed or may develop product candidates for the
treatment of the diseases that Surrozen may target, including companies developing novel treatments and therapeutic platforms. If these companies develop therapeutics or product candidates more rapidly than Surrozen does, or if its therapeutics or
product candidates are more effective or have fewer side effects, Surrozen&#146;s ability to develop and successfully commercialize product candidates may be adversely affected. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen will need substantial additional funds to advance development of product candidates and its Wnt
therapeutics platform, and it cannot guarantee that it will have sufficient funds available in the future to develop and commercialize its current or potential future product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical development includes a lengthy and expensive process with an uncertain outcome, and results of
earlier studies and trials may not be predictive of future trial results. Surrozen may be unable to obtain U.S. or foreign regulatory approval and, as a result, be unable to commercialize <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT
STYLE="white-space:nowrap">SZN-043,</FONT> or potential future product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen relies, or will rely, and expect to continue to rely, on third parties to conduct the preclinical and
clinical trials for its product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing to comply with applicable regulatory requirements.
</P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The manufacturing of Surrozen&#146;s product candidates is complex. Surrozen and its third-party manufacturers
may encounter difficulties in production. If Surrozen encounters any such difficulties, its ability to supply its product candidates for clinical trials or, if approved, for commercial sale, could be delayed or halted entirely.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if any of Surrozen&#146;s product candidates is approved for marketing and commercialization in the
future, Surrozen may be unable to develop sales, marketing and distribution capabilities on its own or enter into agreements with third parties to perform these functions on acceptable terms. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If Surrozen is unable to obtain or protect intellectual property rights related to its technology and current
or future product candidates, or if its intellectual property rights are inadequate, it may not be able to compete effectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If Surrozen fails to comply with its obligations under any license, collaboration or other intellectual
property-related agreements, it may be required to pay damages and could lose intellectual property rights that may be necessary for developing, commercializing and protecting its current or future technologies or product candidates or it could lose
certain rights to grant sublicenses. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s principal stockholders and management will own a significant percentage of New Surrozen&#146;s
stock and will be able to exert significant control over matters subject to stockholder approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s business, operations and clinical development plans and timelines could be adversely affected
by the effects of health epidemics, including the recent <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on the manufacturing, preclinical studies, clinical trial and other business activities performed by it or by third parties with whom
Surrozen conducts business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New Surrozen does not know whether an active, liquid and orderly trading market will develop for its common
shares or what the market price of its common shares will be and, as a result, it may be difficult for you to sell your common shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The price of New Surrozen Common Stock may be volatile, and you could lose all or part of your investment.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Future sales and issuances of New Surrozen&#146;s Common Stock or rights to purchase New Surrozen Common
Stock, including pursuant to the Equity Incentive Plan, could result in additional dilution of the&nbsp;percentage ownership of New Surrozen stockholders and could cause New Surrozen&#146;s share price to fall. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New Surrozen does not intend to pay dividends on its Common Stock, so any returns will be limited to the value
of New Surrozen&#146;s Common Stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Risks related to CHFW and the Business Combination, including, among others, that: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CHFW&#146;s Sponsor, directors and officers have interests in the Business Combination which may be different
from or in addition to (and which may conflict with) the interests of its shareholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CHFW has no operating history and is subject to a mandatory liquidation and subsequent dissolution
requirement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Following the Closing, New Surrozen&#146;s only significant asset will be ownership of 100% of Surrozen
Operating, Inc. and such ownership may not be sufficient to pay dividends or make distributions or loans to enable it to pay any dividends on its Common Stock. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Business Combination is subject to conditions, including certain conditions that may not be satisfied on a
timely basis, if at all. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Neither the CHFW Board nor any committee thereof obtained a third-party valuation in determining whether or
not to pursue the Business Combination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we seek shareholder approval of our initial business combination, our Sponsor, directors, executive
officers, advisors and their affiliates may elect to purchase public shares or warrants, which may influence a vote on a proposed business combination and reduce the public &#147;float&#148; of our Class&nbsp;A ordinary shares or public warrants.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Domestication may result in adverse tax consequences for holders of public shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are not able to complete the Business Combination with Surrozen nor able to complete another business
combination by November&nbsp;23, 2022, in each case, as such date may be extended pursuant to our Existing Governing Documents, we would cease all operations except for the purpose of winding up and we would redeem our Class&nbsp;A ordinary shares
and liquidate the trust account, in which case our public shareholders may only receive approximately $10.00 per share and our warrants will expire worthless. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Risks related to the redemptions, including, among others, that: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ability of our public shareholders to exercise redemption rights with respect to a large number of our
public shares may not allow us to complete the most desirable business combination or optimize the capital structure of New Surrozen. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If CHFW&#146;s shareholders fail to comply with the redemption requirements specified in this proxy
statement/prospectus, they will not be entitled to redeem their shares of Class&nbsp;A Common Stock for a pro rata portion of the funds held in the trust account. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ability to execute CHFW&#146;s strategic plan for New Surrozen could be negatively impacted to the extent
a significant number of shareholders choose to redeem their shares in connection with the Business Combination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If third parties bring claims against us, the proceeds held in the trust account could be reduced and the per
share redemption amount received by shareholders may be less than $10.00 per share (which was the offering price in our initial public offering). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may redeem your unexpired warrants prior to their exercise at a time that is disadvantageous to you,
thereby making your warrants worthless. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Public Shareholders who wish to redeem their public shares for a pro rata portion of the trust account must
comply with specific requirements for redemption that may make it more difficult for them to exercise their redemption rights prior to the deadline. If shareholders fail to comply with the redemption requirements specified in this proxy
statement/prospectus, they will not be entitled to redeem their public shares for a pro rata portion of the funds held in the trust account. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If a public shareholder fails to receive notice of CHFW&#146;s offer to redeem public shares in connection
with the Business Combination, or fails to comply with the procedures for tendering its shares, such shares may not be redeemed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CHFW does not have a specified maximum redemption threshold. The absence of such a redemption threshold may
make it possible for us to complete the Business Combination with which a substantial majority of CHFW&#146;s shareholders do not agree. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The securities in which we invest the funds held in the trust account could bear a negative rate of interest,
which could reduce the value of the assets held in trust such that the <FONT STYLE="white-space:nowrap">per-share</FONT> redemption amount received by public shareholders may be less than $10.00 per share. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_25"></A>SELECTED HISTORICAL FINANCIAL INFORMATION OF SURROZEN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows selected historical financial information of Surrozen for the periods and as of the dates indicated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The selected historical financial information of Surrozen as of March 31, 2021, and for the three months ended March 31, 2021 and 2020 was
derived from the unaudited condensed interim financial statements of Surrozen included elsewhere in this proxy statement/prospectus. The selected historical financial information of Surrozen as of March 31, 2021, and for the three months ended March
31, 2021 and 2020 was derived from the unaudited interim financial statements of Surrozen included elsewhere in this proxy statement/prospectus. The selected historical financial information of Surrozen as of December&nbsp;31, 2020 and 2019, and for
the&nbsp;years ended December&nbsp;31, 2020 and 2019 was derived from the audited financial statements of Surrozen included elsewhere in this proxy statement/prospectus. As explained elsewhere in this proxy statement/prospectus, the financial
information contained in this section relates to Surrozen, prior to and without giving pro forma effect to the impact of the Business Combination and, as a result, the results reflected in this section may not be indicative of the results of
Surrozen going forward. See the section entitled &#147;<I>Unaudited Pro Forma Condensed Combined Financial Information</I>&#148; included elsewhere in this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following selected historical financial information should be read together with Surrozen&#146;s financial statements and accompanying
notes and &#147;<I>Surrozen&#146;s</I> <I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I>&#148; appearing elsewhere in this proxy statement/prospectus. The selected historical financial information in
this section is not intended to replace Surrozen&#146;s financial statements and the related notes. Surrozen&#146;s historical results are not necessarily indicative of Surrozen&#146;s future results. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended</B><br><B>March 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended</B><br><B>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(In thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statements of Operations and Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,031</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,361</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,807</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,022</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,362</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4.42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing net loss per share attributable to common stockholders,
basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,062,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,042,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,394,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,899,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt"><B>Balance Sheet Data:</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(98,245</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(85,804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELECTED HISTORICAL FINANCIAL INFORMATION OF CHFW </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW is providing the following selected historical financial data to assist you in your analysis of the financial aspects of the Business
Combination. Such data as of December 31, 2020 (as restated) and for the period from August 21, 2020 (inception) through December 31, 2020 (as restated) are derived from CHFW&#146;s audited financial statements included elsewhere in this proxy
statement/prospectus. Such data as of March 31, 2021 and for the three months ended March 31, 2021 are derived from CHFW&#146;s unaudited financial statements included elsewhere in this proxy statement/prospectus. The information below is only a
summary and should be read in conjunction with CHFW&#146;s consolidated financial statements and related notes and &#147;<I>CHFW&#146;s Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I>&#148; contained
elsewhere in this proxy statement/prospectus. CHFW&#146;s historical results are not necessarily indicative of future results, and the results for any interim period are not necessarily indicative of the results that may be expected for a full
fiscal year. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the</B><br><B>three&nbsp;months&nbsp;ended<BR>March&nbsp;31,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>August&nbsp;21,&nbsp;2020<BR>(inception) to<BR>December&nbsp;31,<BR>2020</B><br><B>(as restated)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,065,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">438,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(232,964</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,122,328</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding of Class&nbsp;A ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,186,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,181,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income per share, Class&nbsp;A ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding of Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,747,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,461,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share, Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.07</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.86</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the</B><br><B>three months ended</B><br><B>March 31,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B><br><B>(as restated)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Condensed Balance Sheet Data (At Period End):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">422,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,487,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93,435,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93,775,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,807,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,914,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the</B><br><B>three months ended</B><br><B>March 31,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>August&nbsp;21,&nbsp;2020<BR>(inception) to<BR>December&nbsp;31,<BR>2020</B><br><B>(as restated)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flow Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(212,256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(933,988</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(92,000,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93,921,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_26"></A>SUMMARY UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
INFORMATION </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following summary unaudited pro forma condensed combined financial data (the &#147;summary pro forma data&#148;)
gives effect to the Business Combination described in the section entitled <I>&#147;Unaudited Pro Forma Condensed Combined Financial Information.&#148;</I> The Business Combination is expected to be accounted for as a reverse recapitalization,
whereby CHFW will be treated as the acquired company and Surrozen is treated as the acquirer. Accordingly, for accounting purposes, the Business Combination will be treated as the equivalent of Surrozen issuing stock for the net assets of CHFW,
accompanied by a recapitalization. The net assets of CHFW will be stated at historical cost, with no goodwill or other intangible assets recorded. Subsequently, results of operations presented for the period prior to the Business Combination will be
those of Surrozen. The summary unaudited pro forma condensed combined balance sheet data as of March 31, 2021 gives the pro forma effect to the Business Combination as if it had occurred on March&nbsp;31, 2021. The summary unaudited pro forma
condensed combined statement of operations data for the three months ended March 31, 2021 and year ended December&nbsp;31, 2020 give the pro&nbsp;forma effect to the Business Combination as if it had been consummated on January&nbsp;1, 2020. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The summary pro forma data has been derived from, and should be read in conjunction with, the unaudited pro forma condensed combined
financial information of the combined company appearing elsewhere in this proxy statement/prospectus and the accompanying notes. The unaudited pro forma condensed combined financial information is based upon, and should be read in conjunction with,
the historical consolidated financial statements of Surrozen and CHFW and related notes included in this proxy statement/prospectus. The summary pro forma data has been presented for informational purposes only and is not necessarily indicative of
what the combined company&#146;s financial position or results of operations actually would have been had the Business Combination been completed as of the date indicated. In addition, the summary pro forma data does not purport to project the
future financial position or operating results of the combined company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table presents summary pro forma data after giving effect to the Business
Combination and related transactions, assuming two redemption scenarios as follows: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Assuming No Redemptions</I>: This presentation assumes that no CHFW shareholders exercise redemption rights
with respect to their public shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Assuming Maximum Redemptions</I>: This presentation assumes the redemption of 7,900,000 public shares,
equal to the number of public shares not covered by CHFW Shareholder Support Agreements. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Combined<BR>(Assuming No<BR>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Combined<BR>(Assuming<BR>Maximum<BR>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Summary Unaudited Pro Forma Condensed Combined</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations Data Three Months Ended March&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 13,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 13,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted weighted average shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,407,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,507,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Summary Unaudited Pro Forma Condensed Combined</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations Data Year Ended December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 33,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 33,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted weighted average shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,407,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,507,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Selected Unaudited Pro Forma Condensed Combined</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data as of March&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 242,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 163,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 16,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 16,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 226,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 147,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_27"></A>COMPARATIVE PER SHARE DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth selected historical comparative share information for Surrozen and CHFW and unaudited pro forma condensed
combined per share information after giving effect to the Business Combination, assuming two redemption scenarios as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Assuming No Redemptions</I>: This presentation assumes that no CHFW shareholders exercise redemption rights
with respect to their public shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Assuming Maximum Redemptions</I>: This presentation assumes the redemption of 7,900,000 public shares,
equal to the number of public shares not covered by CHFW Shareholder Support Agreements. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The pro forma book value
information reflects the Business Combination as if it had occurred on March&nbsp;31, 2021. The weighted average shares outstanding and net loss per share information give pro forma effect to the Business Combination as if it had occurred on
January&nbsp;1, 2020. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This information is only a summary and should be read together with the selected historical financial
information included elsewhere in this proxy statement/prospectus and the historical financial statements of Surrozen and CHFW and related notes that are included elsewhere in this proxy statement/prospectus. The unaudited pro forma combined per
share information of Surrozen and CHFW is derived from, and should be read in conjunction with, the unaudited pro forma condensed combined financial statements and related notes included elsewhere in this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The unaudited pro forma combined net loss per share information below does not purport to represent the net loss per share which would have
occurred had the companies been combined during the periods presented, nor net loss per share for any future date or period. The unaudited pro forma combined book value per share information below does not purport to represent what the value of
Surrozen and CHFW would have been had the companies been combined during the period presented. </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Combined Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Surrozen equivalent pro<BR>forma per share data (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Surrozen</B><br><B>(Historical)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CHFW</B><br><B>(Historical)&nbsp;(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Assuming</B><br><B>No</B><br><B>Redemption)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Assuming</B><br><B>Maximum</B><br><B>Redemption)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Assuming</B><br><B>No</B><br><B>Redemption)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Assuming</B><br><B>Maximum</B><br><B>Redemption)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of and for the Year Ended March&nbsp;31, 2021 (3)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Book value per share (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (10.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 5.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 4.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,062,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,747,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,407,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,507,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,212,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,212,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (1.62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.07</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.06</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.07</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of and for the Year Ended December&nbsp;31, 2020 (3)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,394,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,461,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,407,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,507,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,212,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,212,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (4.42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.86</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Book value per share&nbsp;=&nbsp;Total equity excluding preferred stock/shares outstanding excluding
preferred shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The equivalent pro forma basic and diluted per share data for Surrozen is based on the exchange ratio set
forth in the Business Combination Agreement. The weighted average shares outstanding includes Surrozen preferred stock, which will be converted into shares of New Surrozen Common Stock at the effective time of the Business Combination.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">There were no cash dividends declared in the period presented. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Net loss per share of common stock&#151;basic and diluted of CHFW represents the basic and diluted net loss
per share of non-redeembable ordinary shares of CHFW. Weighted average shares outstanding of common stock&#151;basic and diluted of CHFW represents the weighted average shares outstanding of non-redeembable ordinary shares of CHFW. Book value per
share of CHFW represents the book value per share of non-redeembable ordinary shares of CHFW. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc40894_16"></A><A NAME="rom40894_28"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>CHFW shareholders should carefully consider the following risk factors, together with all of the other information included in this proxy
statement/prospectus, before they decide whether to vote or instruct their vote to be cast to approve the relevant proposals described in this proxy statement/prospectus. These risk factors are not exhaustive and investors are encouraged to perform
their own investigation with respect to our business, financial condition and prospects</I>. <I>Unless the context otherwise requires, any reference in the below sections of</I> <I>this proxy statement/prospectus to the &#147;we,&#148;
&#147;us&#148; or &#147;our&#148; refers to CHFW prior to the consummation of the Business Combination and to New Surrozen following the Business Combination. The following discussion and analysis of our financial condition and results of operations
should be read in conjunction with our financial</I> <I>statements and accompanying notes, and other financial information included elsewhere within this proxy statement/prospectus. This discussion includes forward-looking information regarding our
business, results of operations and cash flows and contractual obligations and arrangements that involves risks, uncertainties and assumptions. Our actual results may differ materially from any future results expressed or implied by such
forward-looking statements as a result of various factors, including, but not limited to, those discussed in the sections of this proxy statement/prospectus entitled &#147;Cautionary Note Regarding Forward-Looking Statements&#148; and
&#147;CHFW&#146;s Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_29">
</A>Risks Related to New Surrozen&#146;s Business Following the Business Combination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>References to Surrozen in this section shall
be deemed to include references to New Surrozen when the context refers to operations following the Business Combination. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen is a preclinical stage biopharmaceutical company with a history of losses. Surrozen expects to continue to incur significant
losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of New Surrozen&#146;s common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen is a preclinical stage biopharmaceutical company with a history of losses. Since its inception, Surrozen has devoted substantially all
of its resources to research and development, preclinical studies, building its management team and building its intellectual property portfolio, and has incurred significant operating losses. Substantially all of Surrozen&#146;s losses have
resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations. To date, Surrozen has not generated any revenue from product sales, and has not sought
or obtained regulatory approval for any product candidate. Furthermore, Surrozen does not expect to generate any revenue from product sales for the foreseeable future, and Surrozen expects to continue to incur significant operating losses for the
foreseeable future due to the cost of research and development, preclinical studies and clinical trials and the regulatory approval process for its current and potential future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen expects its net losses to increase substantially as its lead product candidates, <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and
<FONT STYLE="white-space:nowrap">SZN-043,</FONT> advance into clinical development. However, the amount of New Surrozen&#146;s future losses is uncertain. Following the closing of the Business Combination, New Surrozen&#146;s ability to achieve or
sustain profitability, if ever, will depend on, among other things, successfully developing product candidates, obtaining regulatory approvals to market and commercialize product candidates, manufacturing any approved products on commercially
reasonable terms, entering into potential future alliances, establishing a sales and marketing organization or suitable third-party alternatives for any approved product and raising sufficient funds to finance business activities. If Surrozen, or
its potential future collaborators, is unable to commercialize one or more of its product candidates, or if sales revenue from any product candidate that receives approval is insufficient, New Surrozen will not achieve or sustain profitability,
which could have a material and adverse effect on its business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT STYLE="white-space:nowrap">SZN-1326</FONT> and
<FONT STYLE="white-space:nowrap">SZN-043</FONT> are in preclinical development and have never been tested in humans. One or both of <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043</FONT> may fail in
clinical development or suffer delays that materially and adversely affect their commercial viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen has no products on
the market or that have gained regulatory approval or that have entered clinical trials. None of Surrozen&#146;s product candidates has ever been tested in humans. New Surrozen&#146;s ability to achieve and sustain profitability will depend on
obtaining regulatory approvals for and successfully commercializing product candidates, either alone or with collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Before
obtaining regulatory approval for the commercial distribution of Surrozen&#146;s product candidates, Surrozen or a collaborator must conduct extensive preclinical studies, followed by clinical trials to demonstrate the safety, purity and potency, or
efficacy of Surrozen&#146;s product candidates in humans. There is no guarantee that the U.S. Food and Drug Administration, or the FDA, will permit Surrozen to conduct clinical trials. Further, Surrozen cannot be certain of the timely completion or
outcome of its preclinical studies and cannot predict if the FDA or other regulatory authorities will accept its proposed clinical programs, its clinical protocols or if the outcome of its preclinical studies will ultimately support the further
development of its preclinical programs or testing in humans. As a result, Surrozen cannot be sure that it will be able to submit Investigational New Drugs, or INDs, or similar applications for its proposed clinical programs on the timelines it
expects, if at all, and cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials for any of Surrozen&#146;s product candidates to begin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043</FONT> are in preclinical development and
Surrozen is subject to the risks of failure inherent in the development of product candidates based on novel approaches, targets and mechanisms of action. Although Surrozen anticipates initiating a Phase 1 clinical trial of <FONT
STYLE="white-space:nowrap">SZN-1326</FONT> for UC in 2022 and initiating a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">SZN-043</FONT> in healthy volunteers and in patients with impaired liver function in 2022, there is no guarantee
that Surrozen will be able to proceed with clinical development of either of these product candidates or that either product candidate will demonstrate a clinical benefit once Surrozen advances these candidates to testing in patients. Accordingly,
you should consider its prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by preclinical stage biopharmaceutical companies such as Surrozen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen may not be able to access the financial resources to continue development of, or to enter into any collaborations for, <FONT
STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT STYLE="white-space:nowrap">SZN-043</FONT> or any potential future product candidates. This may be exacerbated if Surrozen experiences any issues that delay or prevent regulatory approval of, or its
ability to commercialize, a product candidate, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative or inconclusive results from its preclinical or clinical trials or the clinical trials of others for
product candidates similar to Surrozen&#146;s, leading to a decision or requirement to conduct additional preclinical studies or clinical trials or abandon any or all of Surrozen&#146;s programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product-related side effects experienced by participants in its clinical trials or by individuals using drugs
or therapeutic antibodies similar to Surrozen&#146;s, including immunogenicity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in submitting IND applications or comparable foreign applications, or delays or failures to obtain the
necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions imposed by the FDA or other regulatory authorities regarding the scope or design of Surrozen&#146;s
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in enrolling research subjects in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">high <FONT STYLE="white-space:nowrap">drop-out</FONT> rates of research subjects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inadequate supply or quality of product candidate components or materials or other supplies necessary for the
conduct of its clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">chemistry, manufacturing and control, or CMC, challenges associated with manufacturing and scaling up biologic
product candidates to ensure consistent quality, stability, purity and potency among different batches used in clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater-than-anticipated clinical trial costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">poor potency or effectiveness of Surrozen&#146;s product candidates during clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable FDA or other regulatory authority inspection and review of a clinical trial or manufacturing site;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays as a result of the Coronavirus Disease 2019, or <FONT STYLE="white-space:nowrap">COVID-19,</FONT>
pandemic or events associated with the pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of Surrozen&#146;s third-party contractors or investigators to comply with regulatory requirements or
otherwise meet their contractual obligations in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays and changes in regulatory requirements, policies and guidelines; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other regulatory authorities interpreting Surrozen&#146;s data differently than it does.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, Surrozen and any potential future collaborator may never receive approval to market and commercialize any
product candidate. Even if Surrozen or a potential future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as were intended or desired or may require labeling
that includes significant use or distribution restrictions or safety warnings. Surrozen or a potential future collaborator may be subject to post-marketing testing requirements to maintain regulatory approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If either <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT STYLE="white-space:nowrap">SZN-043</FONT> or any future product
candidate is ever tested in humans, it may not demonstrate the safety, purity and potency, or efficacy, necessary to become approvable or commercially viable. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither <FONT STYLE="white-space:nowrap">SZN-1326</FONT> nor <FONT STYLE="white-space:nowrap">SZN-043</FONT> has ever been tested in humans.
Surrozen may ultimately discover that <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043</FONT> do not possess certain properties that Surrozen believes are helpful for therapeutic effectiveness and safety.
For example, although <FONT STYLE="white-space:nowrap">SZN-043</FONT> has exhibited encouraging results in animal studies, including improvement of liver function in multiple animal models of liver injury, it may not demonstrate the same properties
in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. As a result, Surrozen may never succeed in developing a marketable product based on <FONT STYLE="white-space:nowrap">SZN-1326</FONT> or <FONT
STYLE="white-space:nowrap">SZN-043.</FONT> If <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT STYLE="white-space:nowrap">SZN-043</FONT> or any of Surrozen&#146;s potential future product candidates prove to be ineffective, unsafe or
commercially unviable, its entire pipeline could have little, if any, value, which could require us to change its focus and approach to antibody-based discovery and development and materially and adversely affect its business, financial condition,
results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen may not be successful in its efforts to use and expand its Wnt therapeutics platform
to build a pipeline of product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A key element of Surrozen&#146;s strategy is to use and expand its Wnt therapeutics
platform to discover and develop a portfolio of Wnt product candidates that can facilitate the repair and/or regeneration of damaged tissue for patients suffering from a variety of severe diseases. Although Surrozen&#146;s research and development
efforts to date have resulted in the discovery and development of <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT STYLE="white-space:nowrap">SZN-043</FONT> and other potential product candidates, its current product candidates may not be
safe or effective therapeutics and it may not be able to develop any successful product candidates. Surrozen&#146;s platform is evolving and may not reach a state at which building a pipeline of product candidates is possible. Even if Surrozen is
successful in building its pipeline of product candidates, the potential product candidates that Surrozen identifies may not be suitable for clinical development or generate acceptable clinical data, including as a result of being shown to have
unacceptable toxicity or other characteristics that indicate that they are unlikely to be products that will receive marketing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
approval from the FDA or other regulatory authorities or achieve market acceptance. If Surrozen does not successfully develop and commercialize product candidates, Surrozen will not be able to
generate product revenue in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Although Surrozen intends to explore other therapeutic opportunities, in addition to the
product candidates that Surrozen is currently developing, Surrozen may fail to identify viable new product candidates for clinical development for a number of reasons. If Surrozen fails to identify additional potential product candidates,
Surrozen&#146;s business could be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although a substantial amount of Surrozen&#146;s efforts will focus on the
planned clinical trials and potential approval of its existing product candidates and other potential product candidates Surrozen is evaluating, a key element of its strategy is to discover, develop and potentially commercialize additional products
beyond its current product candidates to treat various conditions and in a variety of therapeutic areas. Surrozen&#146;s intends to do so by investing in its own drug discovery efforts, exploring potential strategic alliances for the development of
new products and <FONT STYLE="white-space:nowrap">in-licensing</FONT> technologies. Identifying new investigational medicines requires substantial technical, financial and human resources, whether or not any investigational medicines are ultimately
identified. Even if Surrozen identifies investigational medicines that initially show promise, Surrozen may fail to successfully develop and commercialize such products for many reasons, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the research methodology used may not be successful in identifying potential investigational medicines;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitors may develop alternatives that render its investigational medicines obsolete;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investigational medicines it develops may nevertheless be covered by third parties&#146; patents or other
exclusive rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investigational medicine may, on further study, be shown to have harmful side effects or other
characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may take greater human and financial resources than Surrozen will possess to identify additional
therapeutic opportunities for its product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting its ability to develop, diversify and expand its product portfolio. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investigational medicine may not be capable of being produced in commercial quantities at an acceptable
cost, or at all; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an approved product may not be accepted as safe and effective by trial participants, the medical community or
third-party payors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because Surrozen has limited financial and human resources, Surrozen intends to initially focus on
research programs and product candidates for a limited set of indications. As a result, Surrozen may forgo or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential
or a greater likelihood of success. Surrozen&#146;s resource allocation decisions may cause it to fail to capitalize on viable commercial products or profitable market opportunities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accordingly, there can be no assurance that Surrozen will ever be able to identify additional therapeutic opportunities for Surrozen&#146;s
product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect Surrozen&#146;s future growth and prospects. Surrozen may focus its efforts and resources on potential
product candidates or other potential programs that ultimately prove to be unsuccessful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The market may not be receptive to Surrozen&#146;s current or potential future product
candidates, and Surrozen may not generate any revenue from the sale or licensing of its product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if regulatory
approval is obtained for a product candidate, including <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043,</FONT> Surrozen may not generate or sustain revenue from sales of approved products. Market
acceptance of Surrozen&#146;s current and potential future product candidates, if approved, will depend on, among other factors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of its receipt of any marketing and commercialization approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any approvals and the countries in which approvals are obtained; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the safety and efficacy of its product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any adverse side effects associated with its product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations or warnings contained in any labeling approved by the FDA or other regulatory authority;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">relative convenience and ease of administration of its product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of its physician education programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of coverage and adequate government and third-party payor reimbursement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing of its products, particularly as compared to alternative treatments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability of alternative effective treatments for the disease indications its product candidates are
intended to treat and the relative risks, benefits and costs of those treatments. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If any product candidate Surrozen
commercializes fails to achieve market acceptance, it could have a material and adverse effect on Surrozen&#146;s business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT STYLE="white-space:nowrap">SZN-043</FONT> or any potential future product
candidate begins clinical trials or receives marketing approval and Surrozen or others later identify undesirable side effects caused by the product candidate, Surrozen&#146;s ability to market and derive revenue from the product candidate could be
compromised. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Undesirable side effects caused by <FONT STYLE="white-space:nowrap">SZN-1326,</FONT>
<FONT STYLE="white-space:nowrap">SZN-043</FONT> or any potential future product candidate could cause regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of
regulatory approval by the FDA or other regulatory authorities. While Surrozen has not yet initiated clinical trials for <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT STYLE="white-space:nowrap">SZN-043,</FONT> or any other product
candidate, it is likely that there will be side effects associated with their use. Results of Surrozen&#146;s clinical trials could reveal a high and unacceptable severity and prevalence of these side effects. In such an event, Surrozen&#146;s
trials could be suspended or terminated and the FDA or other regulatory authorities could order Surrozen to cease further development of or deny approval of a product candidate for any or all targeted indications. Such side effects could also affect
patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. For example, certain researchers have noted that therapeutics targeting the Wnt pathway may lead to tumor formation or
proliferation as a result of the downstream impacts of Wnt signaling. To date, Surrozen&#146;s has not observed any such tumor formation in Surrozen&#146;s preclinical studies, but there can be no guarantee that Surrozen&#146;s current or future
product candidates will not result in tumor formation. Any of these occurrences may materially and adversely affect Surrozen&#146;s business and financial condition and impair Surrozen&#146;s ability to generate revenues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited
duration of exposure, rare and severe side effects of a product candidate may only be uncovered when a significantly larger number of patients are exposed to the product candidate or when patients are exposed for a longer period of time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that any of Surrozen&#146;s current or potential future product candidates receive regulatory approval and Surrozen or others
identify undesirable side effects caused by one of these products, any of the following adverse </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
events could occur, which could result in the loss of significant revenue to Surrozen and materially and adversely affect its results of operations and business: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw their approval of the product or seize the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen may be required to recall the product or change the way the product is administered to patients;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing
processes for the product or any component thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen may be subject to fines, injunctions or the imposition of civil or criminal penalties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require the addition of labeling statements, such as a &#147;black box&#148;
warning or a contraindication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen may be required to create a Medication Guide outlining the risks of such side effects for
distribution to patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen could be sued and held liable for harm caused to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product may become less competitive; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen will need substantial additional funds to advance development of product candidates and its Wnt therapeutics platform, and
Surrozen cannot guarantee that it will have sufficient funds available in the future to develop and commercialize its current or potential future product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The development of biopharmaceutical product candidates is capital-intensive. If <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT
STYLE="white-space:nowrap">SZN-043</FONT> or potential future product candidates enter and advance through preclinical studies and clinical trials, Surrozen will need substantial additional funds to expand its development, regulatory, manufacturing,
marketing and sales capabilities. Surrozen has used substantial funds to develop its Wnt therapeutics platform, <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT STYLE="white-space:nowrap">SZN-043</FONT> and other product candidates and
Surrozen will require significant funds to continue to develop Surrozen&#146;s platform and conduct further research and development, including preclinical studies and clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s future capital requirements and the period for which it expects existing resources to support its operations may vary
significantly from what it expects. Surrozen&#146;s monthly spending levels vary based on new and ongoing research and development and other corporate activities. Because the length of time and activities associated with successful research and
development of product candidates is highly uncertain, Surrozen is unable to estimate the actual funds Surrozen will require for development and any approved marketing and commercialization activities. The timing and amount of Surrozen&#146;s
operating expenditures will depend largely on: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and progress of preclinical and clinical development of
<FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT STYLE="white-space:nowrap">SZN-043</FONT> and other potential future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and progress of its development of its Wnt therapeutics platform; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price and pricing structure that it is able to obtain from its third-party contract manufacturers to
manufacture its preclinical study and clinical trial materials and supplies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and scope of preclinical and clinical programs it decides to pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its ability to maintain its current licenses, research and development programs and to establish new
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of the development efforts of parties with whom it may in the future enter into collaboration and
research and development agreements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs involved in obtaining, maintaining, enforcing and defending patents and other intellectual property
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on its business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of regulatory approvals; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its efforts to enhance operational systems and hire additional personnel, including personnel to support
development of its product candidates and satisfy New Surrozen&#146;s obligations as a public company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To date,
Surrozen has primarily financed its operations through the sale of equity securities. Surrozen may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations, strategic
alliances, licensing arrangements, grants and other marketing and distribution arrangements. Surrozen cannot assure you that it will be successful in acquiring additional funding at levels sufficient to fund its operations or on terms favorable to
it. If Surrozen is unable to obtain adequate financing when needed, it may have to delay, reduce the scope of or suspend one or more of its preclinical studies, clinical trials, research and development programs or commercialization efforts. Because
of the numerous risks and uncertainties associated with the development and commercialization of Surrozen&#146;s current and potential future product candidates and the extent to which it may enter into collaborations with third parties to
participate in their development and commercialization, it is unable to estimate the amounts of increased capital outlays and operating expenditures associated with its current and anticipated preclinical studies and clinical trials. To the extent
that Surrozen raises additional capital through collaborations, strategic alliances or licensing arrangements with third parties, it may have to relinquish valuable rights to its current and potential future product candidates, future revenue
streams or research programs or to grant licenses on terms that may not be favorable to it. If Surrozen does raise additional capital through public or private equity or convertible debt offerings, the ownership interest of its existing stockholders
will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect Surrozen&#146;s stockholders&#146; rights. If Surrozen raises additional capital through debt financing, Surrozen may be subject to
covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen does not expect to realize revenue from product sales or royalties from licensed products for the foreseeable future, if at all, and
unless and until Surrozen&#146;s current and potential future product candidates are clinically tested, approved for commercialization and successfully marketed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen may expend its limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may
be more profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because Surrozen has limited financial and managerial
resources, it intends to focus its efforts on specific research and development programs, including clinical development of <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043.</FONT> As a result, Surrozen
may forgo or delay pursuit of other opportunities, including with potential future product candidates that later prove to have greater commercial potential. Surrozen&#146;s resource allocation decisions may cause it to fail to capitalize on viable
commercial product candidates or profitable market opportunities. Surrozen&#146;s spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product
candidates. If Surrozen does not accurately evaluate the commercial potential or target market for a particular product candidate, it may relinquish valuable rights to that product candidate through collaborations, licensing or other royalty
arrangements in cases in which it would have been more advantageous for it to retain sole development and commercialization rights to such product candidate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Interim, topline and preliminary data from Surrozen&#146;s clinical trials that it announces or publishes from time to time may change
as more patient data become available or as additional analyses are conducted, and as the data are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, Surrozen may publicly disclose interim, preliminary or topline data from its preclinical studies and clinical trials, which
is based on a preliminary analysis of then-available data, and the results and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular trial. Surrozen also makes assumptions, estimations,
calculations and conclusions as part of its analyses of data, and Surrozen may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, preliminary or topline results that Surrozen reports may
differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures
that may result in the final data being materially different from the preliminary data Surrozen previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, Surrozen may also
disclose interim, preliminary or topline data from its clinical studies. Interim, topline or preliminary data from clinical trials that Surrozen may complete are subject to the risk that one or more of the clinical outcomes may materially change as
patient enrollment continues and more patient data become available. Adverse differences between preliminary, topline or interim data and final data could significantly harm Surrozen&#146;s business prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, others, including regulatory agencies, may not accept or agree with Surrozen&#146;s assumptions, estimates, calculations, conclusions
or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and the value of Surrozen in
general. In addition, the information Surrozen chooses to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what Surrozen determines is the
material or otherwise appropriate information to include in its disclosure, and any information Surrozen determines not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise
regarding a particular product, product candidate or its business. If the topline data that Surrozen reports differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, Surrozen&#146;s ability
to obtain approval for, and commercialize, Surrozen&#146;s product candidates may be harmed, which could harm Surrozen&#146;s business, operating results, prospects or financial condition </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen may not be able to enter into strategic transactions on acceptable terms, if at all, which could adversely affect
Surrozen&#146;s ability to develop and commercialize current and potential future product candidates, impact Surrozen&#146;s cash position, increase Surrozen&#146;s expense, and present significant distractions to Surrozen&#146;s management.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, Surrozen considers strategic transactions, such as collaborations, acquisitions of companies, asset purchases,
joint ventures and <FONT STYLE="white-space:nowrap">out-</FONT> or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of product candidates or technologies. For example, Surrozen will evaluate and, if strategically attractive, seek to enter into
collaborations, including with biotechnology or biopharmaceutical companies or hospitals. The competition for collaborators is intense, and the negotiation process is time-consuming and complex. If Surrozen is not able to enter into strategic
transactions, it may not have access to required liquidity or expertise to further develop its potential future product candidates or its Wnt therapeutics platform. Any such collaboration, or other strategic transaction, may require Surrozen to
incur <FONT STYLE="white-space:nowrap">non-recurring</FONT> or other charges, increase its near- and long-term expenditures and pose significant integration or implementation challenges or disrupt its management or business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen also may acquire additional technologies and assets, form strategic alliances or create joint ventures with third parties that it
believes will complement or augment its existing business, but it may not be able to realize the benefit of acquiring such assets. Conversely, any new collaboration that Surrozen enters into may be on terms that are not optimal for Surrozen or its
product candidates. These transactions would entail numerous operational and financial risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exposure to unknown liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruption of Surrozen&#146;s business and diversion of its management&#146;s time and attention in order to
manage a collaboration or develop acquired products, product candidates or technologies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or
costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">higher-than-expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or
impairment charges, increased amortization expenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty and cost in facilitating the collaboration or combining the operations and personnel of any
acquired business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to
changes in management and ownership; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to retain key employees of any acquired business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accordingly, although there can be no assurance that Surrozen will undertake or successfully complete any transactions of the nature described
above, any transactions that it does complete may be subject to the foregoing or other risks and its business could be materially harmed by such transactions. Conversely, any failure to enter any collaboration or other strategic transaction that
would be beneficial to Surrozen could delay the development and potential commercialization of Surrozen&#146;s product candidates and have a negative impact on the competitiveness of any product candidate that reaches market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, to the extent that any future collaborators terminate a collaboration agreement, Surrozen may be forced to independently develop
Surrozen&#146;s current and future product candidates, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and maintaining, enforcing and defending intellectual property rights, or, in certain
instances, abandon product candidates altogether, any of which could result in a change to its business plan and materially harm its business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen relies on third parties to conduct its preclinical studies, and plans to rely on third parties to conduct clinical trials, and
those third parties may not perform satisfactorily. If third parties on which Surrozen intends to rely to conduct certain preclinical and clinical studies do not perform as contractually required, fail to satisfy regulatory or legal requirements or
miss expected deadlines, Surrozen&#146;s development program could be delayed with material and adverse impacts on its business and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen relies on third-party clinical investigators, contract research organizations, or CROs, clinical data management organizations and
consultants to design, conduct, supervise and monitor certain preclinical studies and any clinical trials. Because Surrozen intends to rely on these third parties and will not have the ability to conduct certain preclinical studies or clinical
trials independently, Surrozen will have less control over the timing, quality and other aspects of such preclinical studies and clinical trials than Surrozen would have had it conducted them on its own. These investigators, CROs and consultants
will not be Surrozen&#146;s employees and it will have limited control over the amount of time and resources that they dedicate to Surrozen&#146;s programs. Some of these third parties may terminate their engagements with Surrozen at any time.
Surrozen also expects to have to negotiate budgets and contracts with CROs, clinical trial sites and CMOs and may not be able to do so on favorable terms, which may result in delays to its development timelines and increased costs. If Surrozen needs
to enter into alternative arrangements with, or replace or add any third parties, it would involve substantial cost and require extensive management time and focus, or involve a transition period, and may delay Surrozen&#146;s drug development
activities, as well as materially impact its ability to meet its desired clinical development timelines. These third parties may have contractual relationships with other entities, some of which may be Surrozen&#146;s competitors, which may draw
time and resources from its programs. The third parties with which Surrozen may contract might not be diligent, careful or timely in conducting Surrozen&#146;s preclinical studies or clinical trials, resulting in the preclinical studies or clinical
trials being delayed or unsuccessful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s reliance on these third parties for such drug development activities will reduce
Surrozen&#146;s control over these activities. As a result, Surrozen will have less direct control over the conduct, timing and completion </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if Surrozen were relying entirely upon its
own staff. Nevertheless, Surrozen is responsible for ensuring that each of its studies and trials is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards, including good laboratory practice, or
GLP, good clinical practice, or GCP and current good manufacturing practice, or cGMP, and Surrozen&#146;s reliance on third parties does not relieve Surrozen of its regulatory responsibilities. For example, Surrozen will remain responsible for
ensuring that each of its clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA and other regulatory authorities require Surrozen to comply with GCP standards, regulations for
conducting, recording and reporting the results of clinical trials to assure that data and reported results are reliable and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities
enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If Surrozen or any of its CROs fail to comply with applicable GCP requirements, the clinical data generated in Surrozen&#146;s
clinical trials may be deemed unreliable and the FDA, European Medicines Agency, or EMA, or other regulatory authorities may require Surrozen to perform additional clinical trials before approving its marketing applications. There can be no
assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of Surrozen&#146;s clinical trials substantially comply with GCP regulations. In addition, Surrozen&#146;s clinical trials must be
conducted with product candidates produced under cGMP regulations and will require a large number of test patients. Surrozen&#146;s failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of
patients, may require it to repeat clinical trials, which would delay the regulatory approval process. Moreover, Surrozen&#146;s business may be implicated if any of these third parties violates FDA regulatory requirements as well as federal or
state healthcare laws and regulations or healthcare privacy and security laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If these third parties do not successfully carry out their
contractual duties, meet expected deadlines or conduct Surrozen&#146;s clinical trials in accordance with regulatory requirements or Surrozen&#146;s stated protocols, or if these third parties need to be replaced, they will not be able to obtain, or
may be delayed in obtaining, marketing approvals for Surrozen&#146;s product candidates and will not be able to, or may be delayed in its efforts to, successfully commercialize its product candidates. As a result, Surrozen&#146;s financial results
and the commercial prospects for its product candidates would be harmed, its costs could increase and its ability to generate revenue could be delayed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen and its collaborators may not achieve projected discovery and development milestones and other anticipated key events in the
time frames that Surrozen such collaborators announce, which could have an adverse impact on Surrozen&#146;s business and could cause New Surrozen&#146;s stock price to decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, Surrozen expects that it will make public statements regarding the expected timing of certain milestones and key events,
such as the commencement and completion of preclinical and <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies in Surrozen&#146;s internal drug discovery programs as well as the commencement and completion of Surrozen&#146;s planned
clinical trials. The actual timing of these events can vary dramatically due to a number of factors such as delays or failures in Surrozen&#146;s or any future collaborators&#146; drug discovery and development programs, the amount of time, effort
and resources committed by Surrozen and any future collaborators, and the numerous uncertainties inherent in the development of drugs. As a result, there can be no assurance that Surrozen or any future collaborators&#146; programs will advance or be
completed in the time frames it or they announce or expect. If Surrozen or any collaborators fail to achieve one or more of these milestones or other key events as planned, Surrozen&#146;s business could be materially adversely affected and the
price of New Surrozen Common Stock could decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Clinical trials are expensive, time-consuming and difficult to design and
implement. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous
regulatory requirements. Because Surrozen&#146;s current and potential future product candidates are based on new technologies and discovery approaches, it expects that they will require extensive research and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
development and have substantial manufacturing and processing costs. In addition, because of the limited number of drug candidates that target the Wnt pathway, the FDA or other regulatory
authorities may require Surrozen to perform additional testing before commencing clinical trials and be hesitant to allow Surrozen to enroll patients impacted with its targeted disease indications in its planned Phase 1 trials. If Surrozen is unable
to enroll patients impacted by its targeted disease indications in Surrozen&#146;s planned Phase 1 trials, Surrozen would be delayed in obtaining potential
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data in humans, which could extend Surrozen&#146;s development timelines. In addition, costs to treat patients and to treat potential side effects that
may result from Surrozen&#146;s product candidates may be significant. Accordingly, Surrozen&#146;s clinical trial costs are likely to be high and could have a material and adverse effect on its business, financial condition, results of operations
and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If Surrozen encounters difficulties enrolling patients in its clinical trials, its clinical development activities
could be delayed or otherwise adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen may not be able to initiate or continue clinical trials for its current
or potential future product candidates if it is unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or other regulatory authorities. In particular, Surrozen is preparing to
advance <FONT STYLE="white-space:nowrap">SZN-1326</FONT> into a Phase 1 clinical trial in patients with UC, a type of IBD, in 2022, and advance <FONT STYLE="white-space:nowrap">SZN-043</FONT> into a Phase 1 clinical trial in healthy volunteers and
in patients with impaired liver function in 2022. Surrozen cannot predict how difficult it will be to enroll patients for trials in these indications. Surrozen may experience difficulties in patient enrollment in its clinical trials for a variety of
reasons. The enrollment of patients depends on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patient eligibility criteria defined in the clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the patient population required for analysis of the trial&#146;s primary endpoints;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity and availability of clinical trial sites for prospective patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">willingness of physicians to refer their patients to its clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s ability to recruit clinical trial investigators with the appropriate competencies and
experience; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages of the product candidate being
studied in relation to other available therapies, including any new drugs that may be approved for the indications Surrozen is investigating; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s ability to obtain and maintain patient consents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">factors Surrozen may not be able to control, such as current or potential pandemics, including <FONT
STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic,</FONT> that may limit patients, principal investigators or staff or clinical site available. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, Surrozen&#146;s future clinical trials will compete with other clinical trials for product candidates that are in the same
therapeutic areas as Surrozen&#146;s product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in its trials may instead opt to enroll in a trial being
conducted by one of Surrozen&#146;s competitors. Since the number of qualified clinical investigators is limited, Surrozen expects to conduct some of its clinical trials at the same clinical trial sites that some of its competitors use, which will
reduce the number of patients who are available for their clinical trials at such clinical trial sites. Additionally, because some of Surrozen&#146;s clinical trials will be in patients with advanced disease who may experience disease progression or
adverse events independent from its product candidates, such patients may be unevaluable for purposes of the trial and, as a result, Surrozen may require additional enrollment. Delays in patient enrollment may result in increased costs or may affect
the timing or outcome of the planned </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
clinical trials, which could prevent completion of these trials and adversely affect Surrozen&#146;s ability to advance the development of its product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If clinical trials for Surrozen&#146;s product candidates are prolonged, delayed or stopped, Surrozen may be unable to seek or obtain
regulatory approval and commercialize Surrozen&#146;s product candidates on a timely basis, or at all, which would require us to incur additional costs and delay Surrozen&#146;s receipt of any product revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen may experience delays in Surrozen&#146;s ongoing or future preclinical studies or clinical trials, and Surrozen does not know whether
future preclinical studies or clinical trials will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. The commencement or completion of these clinical trials could be
substantially delayed or prevented by many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">further discussions with the FDA or comparable foreign regulatory authorities regarding the scope or design of
Surrozen&#146;s clinical trials, including the endpoint measures required for regulatory approval and Surrozen&#146;s statistical plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the limited number of, and competition for, suitable study sites and investigators to conduct Surrozen&#146;s
clinical trials, many of which may already be engaged in other clinical trial programs with similar patients, including some that may be for the same indication as its product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any delay or failure to obtain timely approval or agreement to commence a clinical trial in any of the
countries where enrollment is planned; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to obtain sufficient funds required for a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay or failure to manufacture sufficient quantities or inability to produce quantities of consistent
quality, purity and potency of the product candidate for Surrozen&#146;s clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay or failure to reach agreement on acceptable clinical trial agreement terms or clinical trial protocols
with prospective sites or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay or failure to obtain institutional review board, or IRB, approval to conduct a clinical trial at a
prospective site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other comparable foreign regulatory authorities may require Surrozen to submit additional data or
impose other requirements before permitting Surrozen to initiate a clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">slower than expected rates of patient recruitment and enrollment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of patients to complete the clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to enroll a sufficient number of patients in studies to ensure adequate statistical power to
detect statistically significant treatment effects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients,
including possible deaths; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of efficacy or failure to measure a statistically significant clinical benefit within the dose range with
an acceptable safety margin during clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination of its clinical trials by one or more clinical trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability or unwillingness of patients or clinical investigators to follow its clinical trial protocols;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to monitor patients adequately during or after treatment by Surrozen or its CROs;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our CROs or clinical study sites failing to comply with regulatory requirements or meet their contractual
obligations to us in a timely manner, or at all, deviating from the protocol or dropping out of a study; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to address any noncompliance with regulatory requirements or safety concerns that arise during the
course of a clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of, and delays related to, health epidemics such as the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the need to suspend, repeat or terminate clinical trials as a result
<FONT STYLE="white-space:nowrap">of&nbsp;non-compliance&nbsp;with</FONT> regulatory requirements, inconclusive or negative results or unforeseen complications in testing; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the suspension or termination of Surrozen&#146;s clinical trials upon a breach or pursuant to the terms of any
agreement with, or for any other reason by, any future strategic collaborator that have responsibility for the clinical development of any of its product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Changes in regulatory requirements, policies and guidelines may also occur and Surrozen may need to&nbsp;significantly modify Surrozen&#146;s
clinical development plans to reflect these changes with appropriate regulatory authorities. These changes may require Surrozen to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs
<FONT STYLE="white-space:nowrap">for&nbsp;re-examination,&nbsp;which</FONT> may impact the costs, timing or successful completion of a clinical trial. Surrozen&#146;s clinical trials may be suspended or terminated at any time by them, the FDA, other
regulatory authorities, the IRB overseeing the clinical trial at issue, any of Surrozen&#146;s clinical trial sites&nbsp;with respect to that site, or us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any failure or significant delay in commencing or completing clinical trials for Surrozen&#146;s product candidates, any failure to obtain
positive results from clinical trials, any safety concerns related to Surrozen&#146;s product candidates, or any requirement to conduct additional clinical trials or other testing of Surrozen&#146;s product candidates beyond those that it currently
contemplates would adversely affect Surrozen&#146;s ability to obtain regulatory approval and Surrozen&#146;s commercial prospects and ability to generate product revenue will be diminished. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If Surrozen decides to seek orphan drug designation for one or more of Surrozen&#146;s product candidates, Surrozen may be unsuccessful
or may be unable to maintain the benefits associated with orphan drug designation for Surrozen&#146;s current or future product candidates that it may develop. If Surrozen&#146;s competitors are able to obtain orphan product exclusivity for their
products in specific indications, Surrozen may not be able to have competing products approved in those indications by the applicable regulatory authority for a significant period of time. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is a drug or biologic product intended to treat a
rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. Surrozen may seek orphan drug designation for certain indications for Surrozen&#146;s product candidates
in the future. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Generally, if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has
such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug for the same indication for seven years. The FDA may reduce the seven-year
exclusivity if the same drug from a competitor demonstrates clinical superiority to the product with orphan exclusivity or if the FDA finds that the holder of the orphan exclusivity has not shown that it can assure the availability of sufficient
quantities of the orphan product to meet the needs of patients with the disease or condition for which the drug was designated. Even if one of Surrozen&#146;s product candidates receives orphan exclusivity, the FDA can still approve other drugs that
have a different active ingredient for use in treating the same indication or disease. Furthermore, the FDA can waive orphan exclusivity if Surrozen is unable to manufacture sufficient supply of its product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen may not be able to conduct, or contract with others to conduct, animal
testing in the future, which could harm its research and development activities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain laws and regulations relating to drug
development require Surrozen to test its product candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other
organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these
groups are successful, Surrozen&#146;s research and development activities may be interrupted or delayed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The manufacturing of
Surrozen&#146;s product candidates is complex. Surrozen and its third-party manufacturers may encounter difficulties in production. If Surrozen encounters any such difficulties, its ability to supply its product candidates for clinical trials or, if
approved, for commercial sale, could be delayed or halted entirely. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Historically engineered antibodies have been particularly
difficult to manufacture and CMOs have limited experience in the manufacturing of antibodies to selectively activate Wnt signaling. The process of manufacturing Surrozen&#146;s product candidates is extremely susceptible to product loss due to
contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, contamination and inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even
minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in Surrozen&#146;s product candidates or in the
manufacturing facilities in which its product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of Surrozen&#146;s engineered antibodies are manufactured by culturing cells from a master cell bank. Surrozen has one master cell bank
for each antibody manufactured in accordance with cGMP standards and regulations. It is possible that Surrozen could lose multiple cell bank sites and have its manufacturing severely impacted by the need to replace the cell bank sites, and it may
fail to have adequate backup should any particular cell bank site be lost in a catastrophic event. Any adverse developments affecting manufacturing operations for Surrozen&#146;s product candidates, if any are approved, may result in shipment
delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of its products. Surrozen may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet
specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Furthermore, it is too early to estimate Surrozen&#146;s cost of goods sold. The actual cost to manufacture Surrozen product candidates could be
greater than Surrozen expects because it is early in its development efforts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Because Surrozen may rely on third parties for
manufacturing and supply of its product candidates, some of which may be sole source vendors, for preclinical and clinical development materials and commercial supplies, its supply may become limited or interrupted or may not be of satisfactory
quantity or quality. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen relies on third-party contract manufacturers for Surrozen&#146;s preclinical and future clinical
trial product materials and supplies. Surrozen does not produce its product candidates in quantities sufficient for preclinical and clinical development, and Surrozen does not currently own manufacturing facilities for producing such supplies.
Furthermore, some of Surrozen&#146;s manufacturers represent its sole source of supplies of preclinical and future clinical development materials, including its source for the manufacture of <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT
STYLE="white-space:nowrap">SZN-043.</FONT> Surrozen cannot assure you that its preclinical or future clinical development product supplies and commercial supplies will not be limited or interrupted, especially with respect to its sole source
third-party manufacturing and supply collaborators, or will be of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of Surrozen&#146;s manufacturers could require significant effort and expertise
because there may be a limited number of qualified replacements. For Surrozen&#146;s current and future sole source third-party manufacturing and supply collaborators, Surrozen may be unable to negotiate binding agreements with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
them or find replacement manufacturers to support its preclinical and future clinical activities at commercially reasonable terms in the event that their services to Surrozen becomes interrupted
for any reason. Surrozen does not always have arrangements in place for a redundant or second-source supply for its sole source vendors in the event they cease to provide their products or services to Surrozen or do not timely provide sufficient
quantities to it. Establishing additional or replacement sole source vendors, if required, may not be accomplished quickly. Any delays resulting from manufacturing or supply interruptions associated with Surrozen&#146;s reliance on third-party
manufacturing and supply collaborators, including those that are sole source, could impede, delay, limit or prevent its drug development efforts, which could harm its business, result of operations, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The manufacturing process for a product candidate is subject to FDA and other regulatory authority review. Suppliers and manufacturers must
meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMP. In the event that any of Surrozen&#146;s
manufacturers fails to comply with such requirements or to perform its obligations to Surrozen in relation to quality, timing or otherwise, or if Surrozen&#146;s supply of components or other materials becomes limited or interrupted for other
reasons, Surrozen may be forced to manufacture the materials ourselves, for which it currently does not have the capabilities or resources, or enter into an agreement with another third party, which it may not be able to do on reasonable terms, or
at all. In some cases, the technical skills or technology required to manufacture Surrozen&#146;s current and future product candidates may be unique or proprietary to the original manufacturer and Surrozen may have difficulty transferring such
skills or technology to another third party and a feasible alternative may not exist. These factors would increase Surrozen&#146;s reliance on such manufacturer or require it to obtain a license from such manufacturer in order to have another
third-party manufacture Surrozen&#146;s product candidates. If Surrozen is required to change manufacturers for any reason, it will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality
standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect Surrozen&#146;s ability to develop product candidates in a timely manner or within budget. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen also expects to rely on third-party manufacturers if it receives regulatory approval for any product candidate. It has existing, and
may enter into future, manufacturing arrangements with third parties. Surrozen will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to
quality control and assurance. If Surrozen is unable to obtain or maintain third-party manufacturing for any product candidate, or to do so on commercially reasonable terms, it may not be able to develop and commercialize its product candidates
successfully. Surrozen or a third party&#146;s failure to execute on its manufacturing requirements and comply with cGMP could adversely affect Surrozen&#146;s business in a number of ways, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an inability to initiate or continue clinical trials of product candidates under development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of the cooperation of a potential future collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjecting third-party manufacturing facilities or Surrozen&#146;s potential future manufacturing facilities
to additional inspections by regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to cease distribution or to recall batches of product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event of approval to market and commercialize a product candidate, an inability to meet commercial
demands for Surrozen&#146;s products. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen&#146;s third-party manufacturers may be unable to successfully scale
manufacturing of <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT STYLE="white-space:nowrap">SZN-043</FONT> or potential future product candidates in sufficient quality and quantity, which would delay or prevent Surrozen from developing
Surrozen&#146;s current and future product candidates and commercializing approved products candidates, if ever approved, if any. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to conduct clinical trials for <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043</FONT> as
well as any potential future product candidates or commercialize, Surrozen will need to manufacture large quantities of these product candidates. Surrozen may continue to and currently expect to use third parties for its manufacturing needs.
Surrozen&#146;s manufacturing collaborators may be unable to successfully increase the manufacturing capacity for any current or potential future product candidate in a timely or cost-effective manner, or at all. In addition, quality issues may
arise during <FONT STYLE="white-space:nowrap">scale-up</FONT> activities. For example, Surrozen is currently working with one of its manufacturing collaborators to <FONT STYLE="white-space:nowrap">scale-up</FONT> production of Surrozen&#146;s <FONT
STYLE="white-space:nowrap">SZN-043</FONT> drug product and have experienced lower yields than initially expected. While Surrozen believes these yield issues can be addressed without significant changes to the production process, any significant
revisions to the manufacturing process may create delays, which could negatively impact Surrozen&#146;s overall development timelines. In addition, Surrozen has not yet initiated <FONT STYLE="white-space:nowrap">scale-up</FONT> production activities
for <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and it may run into similar or additional manufacturing issues in connection with such <FONT STYLE="white-space:nowrap">scale-up.</FONT> If Surrozen&#146;s manufacturing collaborators are unable
to successfully scale the manufacture of any current or potential future product candidate in sufficient quality and quantity, the development, testing, clinical trials and commercialization of that product candidate may be delayed or infeasible and
regulatory approval or commercial launch of any potential resulting product may be delayed or not obtained, which could significantly harm Surrozen&#146;s business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen or the third parties upon whom Surrozen depends may be adversely affected by natural disasters and its business continuity and
disaster recovery plans may not adequately protect us from a serious disaster. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s current operations are located in
the San Francisco Bay Area. Any unplanned event, such as earthquake, flood, fire, explosion, extreme weather condition, medical epidemics, including any potential effects from the current global spread of
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> power shortage, telecommunication failure or other natural or <FONT STYLE="white-space:nowrap">man-made</FONT> accidents or incidents that result in Surrozen being unable to fully utilize its
facilities, or the manufacturing facilities of its third-party contract manufacturers, may have a material and adverse effect on Surrozen&#146;s ability to operate Surrozen&#146;s business, particularly on a daily basis and have significant negative
consequences on Surrozen&#146;s financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of Surrozen&#146;s product candidates or interruption of its business operations. Natural
disasters or pandemics such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak could further disrupt Surrozen&#146;s operations and have a material and adverse effect on its business, financial condition, results of operations and
prospects. If a natural disaster, power outage or other event occurred that prevented Surrozen from using all or a significant portion of Surrozen&#146;s headquarters, that damaged critical infrastructure, such as its research facilities or the
manufacturing facilities of its third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for Surrozen to continue Surrozen&#146;s business for a substantial period of time. The
disaster recovery and business continuity plans Surrozen&#146;s have in place may prove inadequate in the event of a serious disaster or similar event. Surrozen may incur substantial expenses as a result of the limited nature of Surrozen&#146;s
disaster recovery and business continuity plans, which could have a material adverse effect on its business. As part of Surrozen&#146;s risk management policy, Surrozen maintains insurance coverage at levels that Surrozen believes are appropriate
for Surrozen&#146;s business. However, in the event of an accident or incident at these facilities, Surrozen cannot assure its investors that the amounts of insurance will be sufficient to satisfy any damages and losses. If Surrozen&#146;s
facilities or the manufacturing facilities of Surrozen&#146;s third-party contract manufacturers are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of Surrozen&#146;s
research and development programs may be harmed. Any business interruption may have a material and adverse effect on Surrozen&#146;s business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Changes in methods of product candidate manufacturing or formulation may result in the
need to perform new clinical trials, which would require additional costs and cause delay. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As product candidates are developed
through preclinical to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize
yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause Surrozen&#146;s product candidates to
perform differently and affect the results of ongoing, planned or future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one
or more clinical trials, increase clinical trial costs, delay approval of Surrozen&#146;s product candidates and jeopardize Surrozen&#146;s ability to commence product sales and generate revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If the market opportunities for Surrozen&#146;s current and potential future product candidates, including <FONT
STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043,</FONT> are smaller than Surrozen believes they are, Surrozen&#146;s future product revenues may be adversely affected and Surrozen&#146;s business may suffer.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s understanding of the number of people who suffer from certain types of moderate to severe IBD and severe AH that <FONT
STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043,</FONT> respectively, may be able to treat are based on estimates. These estimates may prove to be incorrect, and new studies may reduce the estimated incidence
or prevalence of these diseases. The number of patients in the United States or elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with Surrozen&#146;s current or potential future product candidates or
patients may become increasingly difficult to identify and access, all of which would adversely affect Surrozen&#146;s business prospects and financial condition. In particular, the treatable population for Surrozen&#146;s candidates may further be
reduced if its estimates of addressable populations are erroneous or <FONT STYLE="white-space:nowrap">sub-populations</FONT> of patients do not derive benefit from <FONT STYLE="white-space:nowrap">SZN-1326</FONT> or
<FONT STYLE="white-space:nowrap">SZN-043.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, there are several factors that could contribute to making the actual number of
patients who receive Surrozen&#146;s current or potential future product candidates less than the potentially addressable market. These include the lack of widespread availability of, and limited reimbursement for, new therapies in many
underdeveloped markets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen faces competition from entities that have developed or may develop product candidates for the
treatment of the diseases that Surrozen may target, including companies developing novel treatments and therapeutic platforms. If these companies develop therapeutics or product candidates more rapidly than Surrozen does, or if their therapeutics or
product candidates are more effective or have fewer side effects, Surrozen&#146;s ability to develop and successfully commercialize product candidates may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis
on intellectual property. Surrozen faces potential competition from many different sources, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other
academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for the research, development, manufacturing, and
commercialization of therapies aimed at treating autoimmune, inflammatory, metabolic, and other diseases, including indications that Surrozen is pursuing or may pursue in the future. Any product candidates that Surrozen successfully develop and
commercialize will compete with current therapies and new therapies that may become available in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The key competitive factors
affecting the success of Surrozen&#146;s product candidates, if approved, are likely to be their efficacy, safety, convenience and price, the level of competition and the availability of coverage and adequate reimbursement from third-party payors.
If any of Surrozen&#146;s product candidates are approved and commercialized, it is likely that Surrozen will face increased competition as a result of other companies pursuing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
development of products to address similar diseases. For <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT STYLE="white-space:nowrap">SZN-043</FONT> and Surrozen&#146;s earlier stage
research programs, Surrozen faces competition from approved therapies and potential competition from product candidates in development for the indications Surrozen is pursuing or may pursue. For additional information about Surrozen&#146;s
competitors and competing therapies and product candidates, please see the section titled &#147;<I>Business&#151;Competition</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of the companies against which Surrozen is competing or against which Surrozen may compete in the future have significantly greater
financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved drugs than Surrozen does. Mergers and acquisitions in the
pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of Surrozen&#146;s competitors. Smaller or early-stage companies may also prove to be significant competitors,
particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and enrolling
subjects for Surrozen&#146;s clinical trials, as well as in acquiring technologies complementary to, or necessary for, Surrozen&#146;s programs. Surrozen could see a reduction or elimination of its commercial opportunity if its competitors develop
and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that Surrozen or Surrozen&#146;s collaborators may develop, including if competitors
develop a safer and/or more effective Wnt modulation platform. Surrozen competitors also may obtain FDA or foreign regulatory approval for their products more rapidly than Surrozen, which could result in Surrozen&#146;s competitors establishing a
strong market position before Surrozen or its collaborators are able to enter the market and materially and adversely impact Surrozen&#146;s business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen has identified a material weakness in its internal control over financial reporting. If its remediation of the material
weakness is not effective, or if Surrozen experiences additional material weaknesses in the future or otherwise fails to maintain an effective system of internal controls in the future, Surrozen may not be able to accurately report its financial
condition or results of operations, which may adversely affect investor confidence in New Surrozen and, as a result, the value of New Surrozen&#146;s common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen has been a private company with limited accounting personnel and other resources with which to address its internal control over
financial reporting. In connection with Surrozen&#146;s preparation and the audit of Surrozen&#146;s financial statements as of and for the year ended December&nbsp;31, 2020, Surrozen and its independent registered public accounting firm identified
a material weakness as defined under the Exchange Act and by the Public Company Accounting Oversight Board (United States) in Surrozen&#146;s internal control over financial reporting. The material weakness related to a lack of sufficient accounting
and financial reporting personnel with requisite knowledge and experience in application of generally accepted accounting principles in the United States (&#147;U.S. GAAP&#148;) and Securities and Exchange Commission (&#147;SEC&#148;) rules. A
material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of Surrozen&#146;s financial statements will not be prevented
or detected on a timely basis. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen is in the process of implementing measures designed to improve its internal control over
financial reporting and remediate the control deficiencies that led to the material weakness, including hiring additional accounting personnel, obtaining advisory services from professional consultants with U.S. GAAP and SEC reporting experience in
their industry, and expanding the capabilities of the existing accounting and financial personnel through continuous training and education in the accounting and reporting requirements under U.S. GAAP and the SEC rules and regulations. The process
of designing and implementing effective internal controls is a continuous effort that requires Surrozen to anticipate and react to changes in its business and the economic and regulatory environments and to expend significant resources to maintain a
system of internal controls that is adequate to satisfy New Surrozen&#146;s reporting obligations as a public company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen cannot be
certain that the measures Surrozen has taken to date, and actions it may take in the future, will be sufficient to remediate the control deficiencies that led to Surrozen&#146;s material weakness in Surrozen&#146;s
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
internal control over financial reporting or that such measures will prevent or avoid potential future material weaknesses. In addition, neither Surrozen&#146;s management nor an independent
registered public accounting firm has performed an evaluation of Surrozen&#146;s internal control over financial reporting because no such evaluation has been previously required. The rules governing the standards that must be met for
Surrozen&#146;s management to assess its internal control over financial reporting are complex and require significant documentation, testing and remediation. Testing internal controls may divert management&#146;s attention from other matters that
are important to Surrozen&#146;s business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if Surrozen&#146;s management concludes that its internal control over financial
reporting is effective, Surrozen&#146;s independent registered public accounting firm may issue a report that is qualified if it is not satisfied with Surrozen&#146;s controls or the level at which its controls are documented, designed, operated or
reviewed. However, Surrozen&#146;s independent registered public accounting firm will not be required to attest formally to the effectiveness of Surrozen&#146;s internal control over financial reporting pursuant to Section&nbsp;404 of the
Sarbanes-Oxley Act (&#147;Section&nbsp;404&#148;) until the filing of New Surrozen&#146;s annual report following the date New Surrozen is no longer an &#147;emerging growth company,&#148; as defined in the JOBS Act. Accordingly, you may not be able
to depend on any attestation concerning Surrozen&#146;s internal control over financial reporting from its independent registered public accountants for the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s testing, or the subsequent testing by Surrozen&#146;s independent registered public accounting firm, may reveal deficiencies
in Surrozen&#146;s internal controls over financial reporting that are deemed to be material weaknesses. A material weakness in internal controls could result in Surrozen&#146;s failure to detect a material misstatement of Surrozen&#146;s annual or
quarterly consolidated financial statements or disclosures. New Surrozen may not be able to conclude on an ongoing basis that it has effective internal controls over financial reporting in accordance with Section&nbsp;404. If Surrozen is unable to
conclude that it has effective internal controls over financial reporting, investors could lose confidence in Surrozen&#146;s reported financial information, which could have a material adverse effect on the trading price of New Surrozen&#146;s
common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen cannot be certain as to the timing of completion of its evaluation, testing and any remediation actions or the
impact of the same on Surrozen&#146;s operations. If Surrozen is unable to successfully remediate its existing or any future material weaknesses in its internal control over financial reporting, or identify any additional material weaknesses, the
accuracy and timing of Surrozen&#146;s financial reporting may be negatively impacted, New Surrozen may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock
exchange listing requirements, investors may lose confidence in New Surrozen&#146;s financial reporting and New Surrozen&#146;s stock price may decline as a result. If New Surrozen is not able to implement the requirements of Section&nbsp;404 in a
timely manner or with adequate compliance, its independent registered public accounting firm may issue an adverse opinion due to ineffective internal controls over financial reporting, and New Surrozen may be subject to sanctions or investigation by
regulatory authorities, such as the SEC. As a result, there could be a negative reaction in the financial markets due to a loss of confidence in the reliability of Surrozen&#146;s financial statements. In addition, Surrozen may be required to incur
costs in improving its internal control system and the hiring of additional personnel. Any such action could negatively affect Surrozen&#146;s results of operations and cash flows. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Members of Surrozen&#146;s management team have limited experience in managing the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of a public company and, as a result, Surrozen may incur additional expenses associated with the management of Surrozen&#146;s company. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Members of Surrozen&#146;s management team have limited experience in managing the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of a public company. As a result, Surrozen may need to obtain outside assistance from legal, accounting, investor relations, or other professionals that could be more costly than
planned. Surrozen also plans to hire additional personnel to comply with additional SEC reporting requirements. These compliance costs will make some activities significantly more time-consuming and costly. If Surrozen lacks cash resources to cover
these costs in the future, its failure to comply with reporting requirements and other provisions of securities laws could </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
negatively affect its stock price and adversely affect its potential results of operations, cash flow and financial condition after closing the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen&#146;s history of recurring losses and anticipated expenditures raises substantial doubt about its ability to continue as a
going concern. Surrozen&#146;s ability to continue as a going concern requires that it obtain sufficient funding to finance its operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen has incurred significant operating losses to date and it is possible it may never generate a profit. Surrozen has concluded that its
recurring losses from operations and need for additional financing to fund future operations raise substantial doubt about its ability to continue as a going concern. Similarly, Surrozen&#146;s independent registered public accounting firm included
an explanatory paragraph in its report on Surrozen&#146;s financial statements as of and for the year ended December&nbsp;31, 2020 with respect to this uncertainty. Surrozen&#146;s future capital requirements will depend on many factors, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, rate of progress, results and costs of drug discovery, preclinical development, laboratory testing
and clinical trials for Surrozen&#146;s product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and development requirements of product candidates that Surrozen may pursue, and other indications
for its current product candidates that it may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of Surrozen&#146;s product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope and costs of manufacturing development and commercial manufacturing activities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost associated with commercializing any approved product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of developing its and the ability to establish sales and marketing capabilities, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications, maintaining, enforcing and protecting
Surrozen&#146;s intellectual property rights, defending intellectual property-related claims and obtaining licenses to third-party intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of milestone and royalty payments Surrozen is required to make under its license
agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s ability to establish and maintain collaborations on favorable terms, if at all; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which Surrozen acquires or <FONT STYLE="white-space:nowrap">in-licenses</FONT> other product
candidates and technologies and associated intellectual property. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen will require additional capital to complete
its planned clinical development programs for its current product candidates to obtain regulatory approval. Any additional capital raising efforts may divert Surrozen management from their <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect Surrozen&#146;s ability to develop and commercialize Surrozen&#146;s current and future product candidates, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, Surrozen cannot guarantee that future financing will be available on a timely basis, in sufficient amounts or on terms acceptable
to Surrozen, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of Surrozen stockholders and the issuance of additional securities by Surrozen, whether equity or debt, or the market perception that such
issuances are likely to occur, could cause the market price of New Surrozen&#146;s common stock to decline. If Surrozen is unable to raise sufficient capital when needed, Surrozen&#146;s business, financial condition and results of operations will
be harmed, and Surrozen will need to significantly modify Surrozen&#146;s operational plans to continue as a going concern. If Surrozen is unable to continue as a going concern, it might have to liquidate assets, and the value it receives for any
assets in liquidation or dissolution could be significantly lower than the values reflected in Surrozen&#146;s financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen&#146;s ability to use net operating loss carryforwards (&#147;NOLs&#148;) to
offset future taxable income may be subject to certain limitations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s NOLs could expire unused and be unavailable to
offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law.&nbsp;NOLs generated in taxable years beginning before January&nbsp;1, 2018 are permitted to be carried forward for only 20 taxable
years under applicable U.S. federal income tax law.&nbsp;Under the Tax Cuts and Jobs Act of 2017 (the &#147;Tax Act&#148;), as modified by the Coronavirus Aid, Relief and Economic Security Act (the &#147;CARES Act&#148;), NOLs arising in tax years
beginning after December&nbsp;31, 2020 may not be carried back.&nbsp;Moreover, under the Tax Act as modified by the CARES Act, NOLs generated in taxable years beginning after December&nbsp;31, 2017 may be carried forward indefinitely, but the
deductibility of such NOLs generally will be limited in taxable years beginning after December&nbsp;31, 2020 to 80% of current year taxable income.&nbsp;The extent to which state income tax law will conform to the Tax Act and CARES Act is uncertain.
For example, California recently enacted legislation limiting the ability to use state NOLs for taxable years 2020, 2021 and 2022. As of December&nbsp;31, 2020, Surrozen had NOLs of approximately $80.8&nbsp;million and $80.6&nbsp;million available
to reduce future taxable income, if any, for federal and California state income tax purposes, respectively. NOLs generated after 2018 for federal tax reporting purposes of $68.3&nbsp;million have an indefinite carryforward period. The remaining
federal and all state NOLs begin expiring in 2036. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended
(the &#147;Code&#148;), a corporation that undergoes an &#147;ownership change&#148; (as defined under Section&nbsp;382 of the Code and applicable Treasury Regulations) is subject to limitations on its ability to utilize its <FONT
STYLE="white-space:nowrap">pre-change</FONT> NOLs to offset future taxable income. Surrozen has not determined whether its NOLs are limited under Section&nbsp;382 of the Code.&nbsp;Surrozen may have experienced ownership changes in the past, and may
experience ownership changes in the future as a result of subsequent shifts in its stock ownership, and some of which are outside Surrozen&#146;s control. Furthermore, Surrozen&#146;s ability to utilize NOLs of companies that it may acquire in the
future may be subject to limitations. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs or other unforeseen reasons, Surrozen&#146;s existing NOLs could expire or otherwise be unavailable to reduce future
income tax liabilities, including for state tax purposes.&nbsp;For these reasons, Surrozen may not be able to utilize a material portion of the NOLs reflected on its balance sheet, even if it attains profitability, which could potentially result in
increased future tax liability to Surrozen and could adversely affect Surrozen&#146;s operating results and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The implementation of a new accounting system could interfere with Surrozen&#146;s business and operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen intends to implement a new accounting system. The implementation of new systems and enhancements may be disruptive to Surrozen&#146;s
business and can be time-consuming and divert management&#146;s attention. Any disruptions relating to Surrozen&#146;s systems or any problems with the implementation, particularly any disruptions impacting its operations or its ability to
accurately report its financial performance on a timely basis during the implementation period, could materially and adversely affect Surrozen&#146;s business and operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Any inability to attract and retain qualified key management, technical personnel and employees would impair Surrozen&#146;s ability to
implement its business plan. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s success largely depends on the continued service of key executive management,
advisors and other specialized personnel, including Craig Parker, its President and Chief Executive Officer, Trudy Vanhove, its Chief Medical Officer, <FONT STYLE="white-space:nowrap">Wen-Chen</FONT> Yeh, its Chief Scientific Officer, and Charles
Williams, its Chief Financial Officer. Surrozen senior management may terminate their employment with Surrozen at any time. Surrozen does not maintain &#147;key person&#148; insurance for any of its employees. The loss of one or more members of the
executive team, management team or other key employees or advisors could delay research and development programs and have a material and adverse effect on Surrozen&#146;s business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Recruiting and retaining qualified scientific and clinical personnel and, if Surrozen progresses the development of any of its product
candidates, commercialization, manufacturing and sales and marketing personnel, will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
critical to its success. The loss of the services of members of senior management or other key employees could impede the achievement of research, development and commercialization objectives and
seriously harm Surrozen&#146;s ability to successfully implement its business strategy. Furthermore, replacing members of senior management and key employees may be difficult and may take an extended period of time because of the limited number of
individuals in the industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize Surrozen&#146;s product candidates. Surrozen&#146;s success also depends on Surrozen&#146;s ability
to continue to attract, retain and motivate highly skilled <FONT STYLE="white-space:nowrap">junior,&nbsp;mid-level&nbsp;and</FONT> senior managers, as well as junior, <FONT STYLE="white-space:nowrap">mid-level&nbsp;and</FONT> senior scientific and
medical personnel. Competition to hire from this limited candidate pool is intense, and Surrozen may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and
biotechnology companies for similar personnel. Surrozen also experiences competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, Surrozen relies on consultants and advisors, including
scientific and clinical advisors, to assist in formulating research and development and commercialization strategies. Surrozen&#146;s consultants and advisors may have commitments under consulting or advisory contracts with other entities that may
limit their availability to Surrozen. If Surrozen is unable to continue to attract and retain high-quality personnel, its ability to pursue its growth strategy will be limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen may experience difficulties in managing growth and expanding operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen has limited experience in therapeutic development. As its current and potential future product candidates enter and advance through
preclinical studies and any clinical trials, Surrozen will need to expand its development, regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen may also experience difficulties in the discovery and development of potential future product candidates using its Wnt therapeutics
platform if Surrozen is unable to meet demand as it grows its operations. In the future, Surrozen also expects to have to manage additional relationships with collaborators, suppliers and other organizations. Surrozen&#146;s ability to manage
operations and future growth will require it to continue to improve its operational, financial and management controls, reporting systems and procedures and secure adequate facilities for operational needs. Surrozen may not be able to implement
improvements to management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If any of Surrozen&#146;s product candidates is approved for marketing and commercialization in the future and it is unable to develop
sales, marketing and distribution capabilities on its own or enter into agreements with third parties to perform these functions on acceptable terms, Surrozen will be unable to successfully commercialize any such future products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen currently has no sales, marketing or distribution capabilities or experience. Surrozen will need to develop internal sales, marketing
and distribution capabilities to commercialize each current and potential future product candidate that gains, if ever, FDA or other regulatory authority approval, which would be expensive and time-consuming, or enter into collaborations with third
parties to perform these services. If Surrozen decides to market any approved products directly, it will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and supporting
distribution, administration and compliance capabilities. If Surrozen relies on third parties with such capabilities to market any approved products or decide to <FONT STYLE="white-space:nowrap">co-promote</FONT> products with third parties,
Surrozen will need to establish and maintain marketing and distribution arrangements with third parties, and there can be no assurance that Surrozen will be able to enter into such arrangements on acceptable terms or at all. In entering into
third-party marketing or distribution arrangements, any revenue Surrozen receives will depend upon the efforts of the third parties and Surrozen can make no assurances that such third parties will establish adequate sales and distribution
capabilities or be successful in gaining market acceptance for any approved product. If Surrozen is not successful in commercializing any product approved in the future, either on its own or through third parties, its business and results of
operations could be materially and adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen&#146;s potential future international operations may expose it to business,
political, operational and financial risks associated with doing business outside of the United States. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s business
is subject to risks associated with conducting business internationally. Some of its suppliers are located outside of the United States and Surrozen anticipates that future clinical trials, including its planned Phase 1 trials for <FONT
STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043,</FONT> may also be located outside of the United States. Furthermore, if Surrozen or any future collaborator succeeds in developing any products, Surrozen
anticipates marketing them in the European Union (&#147;EU&#148;) and other jurisdictions in addition to the United States. If approved, Surrozen or any future collaborator may hire sales representatives and conduct physician and patient association
outreach activities outside of the United States. Doing business internationally involves a number of risks, including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">multiple, conflicting and changing laws and regulations such as those relating to privacy, data protection and
cybersecurity, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by Surrozen to obtain and maintain regulatory approvals for the use of its products in various
countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rejection or qualification of foreign clinical trial data by the competent authorities of other countries;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional potentially relevant third-party patent rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complexities and difficulties in obtaining, maintaining, protecting and enforcing its intellectual property;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in staffing and managing foreign operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complexities associated with managing multiple payor reimbursement regimes, government payors or patient <FONT
STYLE="white-space:nowrap">self-pay</FONT> systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limits in Surrozen&#146;s ability to penetrate international markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local
and regional financial crises on demand and payment for products and exposure to foreign currency exchange rate fluctuations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">natural disasters, political and economic instability, including wars, terrorism and political unrest,
outbreak of disease (including the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic), boycotts, curtailment of trade and other business restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain expenses including, among others, expenses for travel, translation and insurance; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory and compliance risks that relate to anti-corruption compliance and record-keeping that may fall
within the purview of the U.S. Foreign Corrupt Practices Act, its accounting provisions or its anti-bribery provisions or provisions of anti-corruption or anti-bribery laws in other countries. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any of these factors could harm Surrozen&#146;s ongoing international operations and supply chain, as well as any future international
expansion and operations and, consequently, its business, financial condition, prospects and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen&#146;s
future growth may depend, in part, on its ability to operate in foreign markets, where it would be subject to additional regulatory burdens and other risks and uncertainties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s future growth may depend, in part, on its ability to develop and commercialize product candidates in foreign markets for which
it may rely on collaborations with third parties. Surrozen will not be permitted to market or promote any product candidate before it receives regulatory approval from the applicable regulatory authority in a foreign market, and it may never receive
such regulatory approval for any product candidate. To </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
obtain separate regulatory approval in foreign countries, Surrozen generally must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and
governing, among other things, clinical trials and commercial sales, pricing and distribution of a product candidate, and Surrozen cannot predict success in these jurisdictions. If Surrozen obtains approval of any current or potential future product
candidates and ultimately commercialize any such product candidate in foreign markets, it would be subject to risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal
requirements and the reduced protection of intellectual property rights in some foreign countries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen&#146;s business entails
a significant risk of product liability, and its inability to obtain sufficient insurance coverage could have a material and adverse effect on its business, financial condition, results of operations and prospects. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As Surrozen conducts preclinical studies and future clinical trials of <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT
STYLE="white-space:nowrap">SZN-043</FONT> and other potential future product candidates, it will be exposed to significant product liability risks inherent in the development, testing, manufacturing and marketing of these product candidates. Product
liability claims could delay or prevent completion of development programs. If Surrozen succeeds in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of Surrozen&#146;s products, manufacturing
processes and facilities or marketing programs and potentially a recall of products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the
merits or eventual outcome, liability claims may also result in decreased demand for Surrozen&#146;s products, injury to its reputation, costs to defend the related litigation, a diversion of management&#146;s time and its resources, substantial
monetary awards to trial participants or patients and a decline in its stock price. Any insurance it has or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is
becoming increasingly expensive. As a result, Surrozen or any future collaborators may be unable to obtain sufficient insurance at a reasonable cost to protect Surrozen against losses caused by product liability claims that could have a material and
adverse effect on Surrozen&#146;s business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen&#146;s employees,
principal investigators, consultants and commercial collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen is exposed to the risk of fraud or other misconduct by employees, principal investigators, consultants and commercial collaborators.
Misconduct by employees could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards Surrozen may establish, comply with federal and state healthcare fraud and abuse
laws and regulations, report financial information or data accurately or disclose unauthorized activities to Surrozen. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations
intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and
other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to Surrozen&#146;s reputation. It is not always
possible to identify and deter misconduct, and the precautions Surrozen takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Surrozen from governmental investigations or
other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against Surrozen, and Surrozen is not successful in defending itself or asserting its rights, those actions could
have a material and adverse effect on Surrozen&#146;s business and financial condition, including the imposition of significant criminal, civil and administrative fines or other sanctions, such as monetary penalties, damages, fines, disgorgement,
imprisonment, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, integrity obligations, reputational harm and the curtailment or restructuring of Surrozen&#146;s operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Failure to comply with health and data protection laws and regulations could lead to
government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could negatively affect Surrozen&#146;s operating results and business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen may collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect and share personal information,
health information and other information to develop its products, to operate its business, for clinical trial purposes, for legal and marketing purposes, and for other business-related purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen and any potential future collaborators, partners or service providers may be subject to federal, state and foreign data protection
laws, regulations and regulatory guidance, the number and scope of which is changing, subject to differing applications and interpretations, and which may be inconsistent among jurisdictions, or in conflict with other rules, laws or contractual
obligations. In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, such as the Health Insurance Portability and Accountability Act (&#147;HIPAA&#148;), state data breach
notification laws, state health information privacy laws and federal and state consumer protection laws, that govern the collection, use, disclosure and protection of health-related and other personal information could apply to Surrozen&#146;s
operations or the operations of any future potential collaborators or service providers. In addition, Surrozen may obtain health information from third parties (including research institutions from which it obtains clinical trial data) that are
subject to privacy and security requirements under HIPAA, or other privacy and data security laws. Depending on the facts and circumstances, Surrozen could be subject to civil or criminal penalties if Surrozen knowingly obtains, uses, or discloses
individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA, or if Surrozen otherwise violates applicable privacy and data security laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">International data protection laws, including the EU&#146;s General Data Protection Regulation (&#147;GDPR&#148;), may also apply to
health-related and other personal information obtained outside of the United States. The GDPR went into effect on May&nbsp;25, 2018. The GDPR introduced new data protection requirements in the EU, as well as potential fines for noncompliant
companies of up to the greater of &#128;20&nbsp;million or 4% of annual global revenue. The regulation imposes numerous requirements for the collection, use and disclosure of personal information, including stringent requirements relating to consent
and the information that must be shared with data subjects about how their personal information is used, the obligation to notify regulators and affected individuals of personal data breaches, extensive internal privacy governance obligations and
obligations to honor expanded rights of individuals in relation to their personal information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the GDPR includes
restrictions on cross-border data transfers. A recent decision by the Court of Justice of the European Union (the &#147;Schrems II ruling&#148;), has invalidated the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield Framework, which was
one of the primary mechanisms used by U.S. companies to import personal information from Europe in compliance with the GDPR&#146;s cross-border data transfer restrictions, and raised questions about whether the European Commission&#146;s Standard
Contractual Clauses (&#147;SCCs&#148;), one of the primary alternatives to the Privacy Shield, can lawfully be used for personal information transfers from Europe to the United States or most other countries. Similarly, the Swiss Federal Data
Protection and Information Commissioner has opined that the <FONT STYLE="white-space:nowrap">Swiss-U.S.</FONT> Privacy Shield is inadequate for transfers of data from Switzerland to the U.S. The United Kingdom, or UK, whose data protection laws are
similar to those of the EU, may similarly determine that the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield is not a valid mechanism for lawfully transferring personal information from the UK to the U.S. The European Commission
recently proposed updates to the SCCs, and additional regulatory guidance has been released that seeks to impose additional obligations on companies seeking to rely on the SCCs. Given that, at present, there are few, if any, viable alternatives to
the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield and the SCCs, any transfers by Surrozen or its vendors of personal data from Europe may not comply with European data protection law, which may increase Surrozen&#146;s exposure to
the GDPR&#146;s heightened sanctions for violations of its cross-border data transfer restrictions and may prohibit the transfer of EU personal data outside of the EU (including clinical trial data), and may adversely impact Surrozen&#146;s
operations, product development, and ability to provide its products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The GDPR has increased the responsibilities and potential liability in relation to personal
data processed subject to the GDPR, and Surrozen may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Further, the exit of the UK from the EU, often referred to
as Brexit, has created uncertainty with regard to data protection regulation in the UK. The UK now is considered a &#147;third country&#148; under the GDPR and transfers of European personal data to the UK will, unless the UK is determined by the EU
to provide adequate protection for personal data, require an adequacy mechanism to render such transfers lawful under the GDPR following the expiration or termination of a grace period that presently is scheduled to last for four months from
January&nbsp;1, 2021, with a potential additional <FONT STYLE="white-space:nowrap">two-month</FONT> extension. Aspects of the relationship between the EU and the UK with respect to data protection, including with respect to cross-border data
transfers, remain uncertain. Compliance with the GDPR and applicable laws and regulations relating to privacy and data protection of EU Member States and the UK will be a rigorous and time-intensive process that may increase Surrozen&#146;s cost of
doing business or require Surrozen to change its business practices, and despite those efforts, there is a risk that Surrozen may be subject to fines and penalties, litigation, and reputational harm in connection with Surrozen&#146;s European
activities. In addition, failure to comply with GDPR and applicable laws and regulations relating to privacy and data protection of EU Member States and the UK may result in regulators prohibiting Surrozen&#146;s processing of the personal
information of EU data subjects, which could impact Surrozen&#146;s operations and ability to develop its products and provide its services, including interrupting or ending EU clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, states are constantly adopting new laws or amending existing laws, requiring attention to frequently changing regulatory
requirements. For example, California enacted the California Consumer Privacy Act (the &#147;CCPA&#148;), on June&nbsp;28, 2018, which took effect on January&nbsp;1, 2020 and has been dubbed the first &#147;GDPR-like&#148; law in the United States.
The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered
companies to provide new disclosures to California consumers (as that term is broadly defined and can include any of Surrozen&#146;s current or future employees who may be California residents) and provide such residents new ways to <FONT
STYLE="white-space:nowrap">opt-out</FONT> of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches and statutory damages ranging from $100 to $750 per
violation, which is expected to increase data breach class action litigation and result in significant exposure to costly legal judgments and settlements. As Surrozen expands its operations and trials (both preclinical and clinical), the CCPA may
increase compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States. In November 2020, California passed the California Privacy
Rights Act (the &#147;CPRA&#148;), which amends and expands the CCPA. The CPRA creates obligations relating to consumer data beginning on January&nbsp;1, 2022, with implementing regulations expected on or before July&nbsp;1, 2022, and enforcement
beginning July&nbsp;1, 2023. The CPRA has created additional uncertainty and may increase Surrozen&#146;s cost of compliance. Other states are beginning to pass similar laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Compliance with U.S. and international data protection laws and regulations could require Surrozen to take on more onerous obligations in its
contracts, restrict its ability to collect, use and disclose data, or in some cases, impact its ability to operate in certain jurisdictions. Laws and regulations worldwide relating to privacy, data protection and cybersecurity are, and are likely to
remain, uncertain for the foreseeable future. While Surrozen strives to comply with applicable laws and regulations relating to privacy, data protection and cybersecurity, external and internal privacy and security policies and contractual
obligations relating to privacy, data protection and cybersecurity to the extent possible, it may at times fail to do so, or may be perceived to have failed to do so. Moreover, despite its efforts, Surrozen may not be successful in achieving
compliance if its personnel, collaborators, partners or vendors do not comply with applicable laws and regulations relating to privacy, data protection and cybersecurity, external and internal privacy and security policies and contractual
obligations relating to privacy, data protection and cybersecurity. Actual or perceived failure to comply with any laws and regulations relating to privacy, data protection or cybersecurity in the U.S. or foreign jurisdictions could result in
government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could negatively affect Surrozen&#146;s operating results and business. Moreover, clinical trial subjects
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
about whom Surrozen or its potential collaborators or service providers obtain information, as well as the providers who share this information with Surrozen, may contractually limit
Surrozen&#146;s ability to use and disclose the information. Claims that Surrozen has violated individuals&#146; privacy rights, failed to comply with applicable laws or regulations, or breached its contractual obligations, even if Surrozen is not
found liable, could be expensive and time consuming to defend, result in regulatory actions and proceedings, in addition to private claims and litigation, and could result in adverse publicity that could harm Surrozen&#146;s business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen also is, or may be asserted to be, subject to the terms of its external and internal privacy and security policies, representations,
certifications, publications and frameworks and contractual obligations to third parties related to privacy, data protection, information security and processing. Failure to comply with any of these, or if any of these policies or any of
Surrozen&#146;s representations, certifications, publications or frameworks are, in whole or part, found or perceived to be inaccurate, incomplete, deceptive, unfair, or misrepresentative of its actual practices, could result in reputational harm;
result in litigation; cause a material adverse impact to business operations or financial results; and otherwise result in other material harm to Surrozen&#146;s business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen depends on sophisticated information technology systems and data processing to operate its business. If Surrozen experiences
security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of its proprietary or confidential data, employee data or personal data, Surrozen may face costs, significant liabilities, harm to its brand and
business disruption. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen relies on information technology systems and data processing that it or its service providers,
collaborators, consultants, contractors or partners operate to collect, process, transmit and store electronic information in Surrozen&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations,
including a variety of personal data, such as name, mailing address, email addresses, phone number and clinical trial information. Additionally, Surrozen, and its service providers, collaborators, consultants, contractors or partners, do or will
collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect and share personal information, health information and other information to host or otherwise process some data and that of users, develop its products, to
operate its business, for clinical trial purposes, for legal and marketing purposes, and for other business-related purposes. Surrozen&#146;s internal computer systems and data processing and those of its third-party vendors, consultants,
collaborators, contractors or partners, including existing and future CROs may be vulnerable to a cyber-attack, malicious intrusion, breakdown, destruction, loss of data privacy, theft or destruction of intellectual property or other confidential or
proprietary information, business interruption or other significant security incidents. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication and intensity, and are becoming increasingly difficult to detect.
In addition to traditional computer &#147;hackers,&#148; threat actors, software bugs, malicious code (such as viruses and worms), employee theft or misuse,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks (such as credential stuffing), phishing and ransomware attacks, sophisticated nation-state and nation-state supported actors now engage in
attacks (including advanced persistent threat intrusions). These risks may increase as a result of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> owing to an increase in personnel working remotely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There can be no assurance that Surrozen, its service providers, collaborators, consultants, contractors or partners will be successful in
efforts to detect, prevent, or fully recover systems or data from all breakdowns, service interruptions, attacks, or breaches of systems that could adversely affect Surrozen&#146;s business and operations and/or result in the loss of critical or
sensitive data. Any failure by Surrozen or its service providers, collaborators, consultants, contractors or partners to detect, prevent, respond to or mitigate security breaches or improper access to, use of, or inappropriate disclosure of any of
this information or other confidential or sensitive information, including patients&#146; personal data, or the perception that any such failure has occurred, could result in claims, litigation, regulatory investigations and other proceedings,
significant liability under state, federal and international law, and other financial, legal or reputational harm to Surrozen. Further, such failures or perceived failures could result in liability and a material disruption of Surrozen&#146;s
development programs and its business operations, which could lead to significant delays or setbacks in research, delays to commercialization of product candidates, lost revenues or other adverse consequences, any of which could have a material
adverse effect on its business, results of operations, financial condition, prospects and cashflow. For example, the loss of clinical trial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
data from completed, ongoing, or future clinical trials could result in delays in Surrozen&#146;s regulatory approval efforts and significantly increase costs to recover or reproduce the data.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, applicable laws and regulations relating to privacy, data protection or cybersecurity, external contractual commitments and
internal privacy and security policies may require Surrozen to notify relevant stakeholders if there has been a security breach, including affected individuals, business partners and regulators. Such disclosures are costly, and the disclosures or
any actual or alleged failure to comply with such requirements could lead to a materially adverse impact on the business, including negative publicity, a loss of confidences in Surrozen&#146;s services or security measures by its business partners
or breach of contract claims. There can be no assurance that the limitations of liability in Surrozen&#146;s contracts would be enforceable or adequate or would otherwise protect Surrozen from liabilities or damages if Surrozen fails to comply with
applicable data protection laws, privacy policies or other data protection obligations related to information security or security breaches. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If Surrozen does not comply with laws regulating the protection of the environment and health and human safety, its business could be
adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s research, development and manufacturing involves the use of hazardous materials and various
chemicals. Surrozen maintains quantities of various flammable and toxic chemicals in its facilities that are required for research, development and manufacturing activities. Surrozen is subject to federal, state and local laws and regulations
governing the use, manufacture, storage, handling and disposal of these hazardous materials. Surrozen believes its procedures for storing, handling and disposing of these materials in its facilities comply with the relevant guidelines of the state
of California and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although Surrozen believes that its safety procedures for handling and disposing of these materials comply with the standards mandated by applicable
regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, Surrozen could be held liable for resulting damages, which could be substantial. Surrozen is also subject to numerous
environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Although Surrozen maintains workers&#146;
compensation insurance to cover Surrozen for costs and expenses Surrozen may incur due to injuries to its employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. Although
Surrozen has some environmental liability insurance covering certain facilities, it may not maintain adequate insurance for all environmental liability or toxic tort claims that may be asserted against Surrozen in connection with the storage or
disposal of biological or hazardous materials. Additional federal, state and local laws and regulations affecting Surrozen&#146;s operations may be adopted in the future. Surrozen may incur substantial costs to comply with, and substantial fines or
penalties if it violates, any of these laws or regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen&#146;s business, operations and clinical development plans and
timelines could be adversely affected by the effects of health epidemics, including the ongoing <FONT STYLE="white-space:nowrap">COVID-19&nbsp;pandemic,</FONT> on the manufacturing, clinical trial and other business activities performed by Surrozen
or by third parties with whom it conducts business, including contract manufacturers, CROs, shippers and others. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Health epidemics
could cause significant disruption in Surrozen&#146;s operations and the operations of third-party manufacturers, CROs and other third parties upon whom Surrozen relies. For example, in December 2019, a novel strain of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">coronavirus,&nbsp;SARS-CoV-2,&nbsp;causing</FONT></FONT> a disease referred to <FONT STYLE="white-space:nowrap">as&nbsp;COVID-19,&nbsp;was</FONT> reported to have surfaced in Wuhan,
China. Since <FONT STYLE="white-space:nowrap">then,&nbsp;COVID-19&nbsp;has</FONT> spread to most countries and all 50 states within the United States. In March 2020, the World Health Organization declared
<FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;outbreak</FONT> a pandemic, and the U.S. government ordered the closure of <FONT STYLE="white-space:nowrap">all&nbsp;non-essential&nbsp;businesses,</FONT> imposed social distancing measures, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;shelter-in-place&#148;</FONT></FONT> orders and restrictions on travel between the United States, Europe and certain other countries. The global pandemic and government measures taken
in response have also had a significant impact on businesses and commerce worldwide, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended across a variety of industries; and demand for
certain goods and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. In connection
<FONT STYLE="white-space:nowrap">with&nbsp;COVID-19,&nbsp;Surrozen</FONT> implemented work-from-home policies for most employees. The effects of government orders and Surrozen&#146;s work-from-home policies may negatively impact productivity,
disrupt business and delay clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on Surrozen&#146;s ability to conduct its business in the ordinary course.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If relationships with suppliers or other vendors are terminated or scaled back as a result of
<FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> or other health epidemics, Surrozen may not be able to enter into arrangements with alternative suppliers or vendors or do so on commercially reasonable terms or in a timely
manner. Switching or adding additional suppliers or vendors involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new supplier or vendor commences work. As a result, delays may
occur, which could adversely impact Surrozen&#146;s ability to meet desired clinical development and any future commercialization timelines. Although Surrozen carefully manages relationships with suppliers and vendors, there can be no assurance that
Surrozen will not encounter challenges or delays in the future or that these delays or challenges will not harm Surrozen&#146;s business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, Surrozen&#146;s preclinical studies and future clinical trials may be affected by
<FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic.</FONT> Clinical site initiation, patient enrollment and activities that require visits to clinical sites, including data monitoring, may be delayed due to prioritization of hospital
resources toward <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> or concerns among patients about participating in clinical trials during a pandemic. Some patients may have difficulty following certain aspects of clinical
trial protocols if quarantines impede patient movement or interrupt healthcare services. These challenges may also increase the costs of completing Surrozen&#146;s clinical trials. Similarly, if Surrozen is unable to successfully recruit and retain
patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure <FONT STYLE="white-space:nowrap">to&nbsp;COVID-19&nbsp;or</FONT> experience additional restrictions by their institutions, city or state,
preclinical studies and future clinical trial operations could be adversely impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The spread
<FONT STYLE="white-space:nowrap">of&nbsp;COVID-19,&nbsp;which</FONT> has caused a broad impact globally, may materially affect Surrozen economically. While the potential economic impact brought by, and the duration
<FONT STYLE="white-space:nowrap">of,&nbsp;COVID-19&nbsp;may</FONT> be difficult to assess or predict, a widespread pandemic has resulted in significant volatility for global financial markets, resulting in economic uncertainty that could continue to
significantly impact Surrozen&#146;s business and operations and may reduce its ability to access capital, which could in the future negatively affect its liquidity. In addition, a recession or market correction resulting from the spread <FONT
STYLE="white-space:nowrap">of&nbsp;COVID-19&nbsp;could</FONT> materially affect Surrozen&#146;s business and the value of its common stock. In addition, a recurrence or &#147;second wave&#148; of <FONT STYLE="white-space:nowrap">COVID-19</FONT>
cases could cause other widespread or more severe impacts depending on where infection rates are highest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Surrozen may experience additional
disruptions that could severely impact its business and future clinical trials, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of
hospitals serving as clinical trial sites and hospital staff supporting the conduct of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review
and approval timelines; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on employee resources that would otherwise be focused on the conduct of preclinical studies and
clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risk that participants enrolled in clinical trials will acquire
<FONT STYLE="white-space:nowrap">COVID-19</FONT> while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA or other regulatory authorities to accept data from clinical trials in these affected
geographies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These and similar, and perhaps more severe, disruptions in Surrozen&#146;s operations could have a
material adverse effect on its business, results of operations, cash flows, financial condition and/or prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> public health emergency, Surrozen may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects from the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> virus. The ultimate impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on Surrozen&#146;s business operations is highly uncertain and subject to change and will depend on future
developments, including new regulatory requirements and changes to existing regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The global pandemic of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> continues to evolve rapidly. The ultimate impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or a similar health epidemic is highly uncertain and subject to change. Surrozen does not
yet know the full extent of potential delays or impacts on its business, future clinical trials, healthcare systems or the global economy as a whole. However, these effects could have a material impact on Surrozen&#146;s operations, and Surrozen
continues to monitor the <FONT STYLE="white-space:nowrap">COVID-19</FONT> situation closely. To the extent the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic adversely affects Surrozen&#146;s business, results of operations, cash flows,
financial condition and/or prospects, it may also have the effect of heightening many of the other risks described in this &#147;Risk Factors&#148; section. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_30"></A>Risks Related to Surrozen Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If Surrozen is unable to obtain or protect intellectual property rights related to its technology and current or future product
candidates, or if its intellectual property rights are inadequate, Surrozen may not be able to compete effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s success depends in part on its ability to obtain and maintain protection for its owned and
<FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property rights and proprietary technology. Surrozen relies on patents and other forms of intellectual property rights, including <FONT STYLE="white-space:nowrap">in-licenses</FONT> of
intellectual property rights and biologic materials of others, to protect current or future discovery platform, product candidates, methods used to manufacture current or future product candidates, and methods for treating patients using current or
future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen owns or <FONT STYLE="white-space:nowrap">in-license</FONT> patents and patent applications relating
to its discovery platform and product candidates. There is no guarantee that any patents covering its discovery platform or product candidates will issue from the patent applications Surrozen owns or
<FONT STYLE="white-space:nowrap">in-licenses,</FONT> or, if they do, that the issued claims will provide adequate protection for Surrozen&#146;s discovery platform or product candidates, or any meaningful competitive advantage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The patent prosecution process is expensive, complex and time-consuming. Patent license negotiations also can be complex and protracted, with
uncertain results. Surrozen may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patents and patent applications at a reasonable cost or in a timely manner. It is also possible that Surrozen will fail to
identify patentable aspects of its research and development output before it is too late to obtain patent protection. The patent applications that Surrozen owns or <FONT STYLE="white-space:nowrap">in-licenses</FONT> may fail to result in issued
patents, and, even if they do issue as patents, such patents may not cover Surrozen&#146;s current or future technologies or product candidates in the United States or in other countries or provide sufficient protection from competitors. In
addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Surrozen may not have the right to control the preparation, filing and prosecution of
patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of Surrozen&#146;s business. Even if
Surrozen&#146;s owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications issue as patents, they may not issue in a form that will provide Surrozen with any meaningful protection, prevent competitors from competing with
Surrozen or otherwise provide Surrozen with any competitive advantage. Surrozen&#146;s competitors may be able to circumvent Surrozen&#146;s patents by developing similar or alternative product candidates in a
<FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, although Surrozen makes reasonable efforts to ensure patentability of its
inventions, Surrozen cannot guarantee that all of the potentially relevant prior art relating to its owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications has been found. For example, publications of
discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, and in some cases not at all. Additionally,
pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover Surrozen&#146;s discovery platform, its product candidates, or the use of its technologies. Surrozen thus cannot
know with certainty whether it or its licensors were the first to make the inventions claimed in Surrozen&#146;s owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or patent applications, or that Surrozen or its licensors were the
first to file for patent protection of such inventions. There is no assurance that all potentially relevant prior art relating to Surrozen&#146;s owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications has been found. For
this reason, and because there is no guarantee that any prior art search is absolutely correct and comprehensive, Surrozen may be unaware of prior art that could be used to invalidate an issued patent or to prevent its owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patent applications from issuing as patents. Invalidation of any of Surrozen&#146;s patent rights, including <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights, could materially harm its
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, the patent positions of biopharmaceutical companies are generally uncertain because they may involve complex legal
and factual considerations that have, in recent years, been the subject of legal development and change. As a result, the issuance, scope, validity, enforceability and commercial value of Surrozen&#146;s pending patent rights is uncertain. The
standards applied by the United States Patent and Trademark Office (the &#147;USPTO&#148;), and foreign patent offices in granting patents are not always certain and moreover, are not always applied uniformly or predictably. For example, there is no
uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in patents. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of
Surrozen&#146;s owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications or narrow the scope of any patent protection it may obtain from its owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if patents do successfully issue from Surrozen&#146;s owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent
application, and even if such patents cover Surrozen&#146;s current or any future technologies or product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated,
or held unenforceable. Any successful challenge to these patents or any other patents owned by or licensed to Surrozen could deprive Surrozen of rights necessary for the successful commercialization of any current or future technologies or product
candidates that it may develop. Likewise, if patent applications Surrozen owns or has <FONT STYLE="white-space:nowrap">in-licensed</FONT> with respect to Surrozen&#146;s development programs and current or future technologies or product candidates
fail to issue, if their breadth or strength is threatened, or if they fail to provide meaningful exclusivity, other companies could be dissuaded from collaborating with Surrozen to develop current or future technologies or product candidates. Lack
of valid and enforceable patent protection could threaten Surrozen&#146;s ability to commercialize current or future products and could prevent Surrozen from maintaining exclusivity with respect to the invention or feature claimed in the patent
applications. Any failure to obtain or any loss of patent protection could have a material adverse impact on Surrozen&#146;s business and ability to achieve profitability. Surrozen may be unable to prevent competitors from entering the market with a
product that is similar or identical to <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT STYLE="white-space:nowrap">SZN-043</FONT> or any future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The filing of a patent application or the issuance of a patent is not conclusive as to its ownership, inventorship, scope, patentability,
validity or enforceability. Issued patents and patent applications may be challenged in the courts and in the patent office in the United States and abroad. For example, Surrozen&#146;s patent applications or patent applications filed by its
licensors, or any patents that grant therefrom, may be challenged through third-party submissions, opposition or derivation proceedings. By further example, any issued patents that may result from Surrozen&#146;s owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patent applications may be challenged through reexamination, inter partes review or post-grant review proceedings before the USPTO, or in declaratory judgment actions or counterclaims. An adverse
determination in any such submission, proceeding or litigation could prevent the issuance of, reduce the scope of, invalidate or render unenforceable Surrozen&#146;s owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights; result
in the loss of exclusivity; limit Surrozen&#146;s ability to stop others from using or commercializing similar or identical platforms </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and product candidates; allow third parties to compete directly with Surrozen without payment to Surrozen; or result in Surrozen&#146;s inability to manufacture or commercialize product
candidates without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by any patents that might result from Surrozen&#146;s owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent
applications is threatened, it could dissuade companies from collaborating with Surrozen to license, develop or commercialize current or future platforms or product candidates. Any of the foregoing could have a material adverse effect son
Surrozen&#146;s business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, future owned and <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications may be <FONT STYLE="white-space:nowrap">co-owned</FONT> with third parties. If Surrozen is unable to obtain an exclusive license to any such third-party <FONT
STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such patents or patent application, such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other third parties, including Surrozen&#146;s
competitors, and its competitors could market competing products and technology. Surrozen may need the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> to enforce such patents against third parties, and such cooperation may
not be provided to Surrozen. Any of the foregoing could have a material adverse effect on Surrozen&#146;s competitive position, business prospects and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights may be subject to a reservation of rights by one or more
third parties, such as the U.S. government. In addition, Surrozen&#146;s rights in such inventions may be subject to certain requirements to manufacture product candidates embodying such inventions in the United States. Any exercise by the U.S.
government of such rights could harm Surrozen&#146;s competitive position, business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The patent protection and patent prosecution for some of Surrozen&#146;s product candidates may be dependent on third parties.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While Surrozen normally seeks to obtain the right to control prosecution, maintenance and enforcement of the patents relating to
its product candidates, there may be times when the filing and prosecution activities for patents and patent applications relating to its product candidates are controlled by Surrozen&#146;s licensors or collaborators. If any of Surrozen&#146;s
licensors or collaborators fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of Surrozen&#146;s business, including by payment of all applicable fees for patents covering
Surrozen&#146;s product candidates, Surrozen could lose its rights to the intellectual property or exclusivity with respect to those rights, its ability to develop and commercialize those product candidates may be adversely affected and Surrozen may
not be able to prevent competitors from making, using and selling competing product candidates. In addition, even where Surrozen has the right to control patent prosecution of patents and patent applications Surrozen has licensed to and from third
parties, it may still be adversely affected or prejudiced by actions or inactions of Surrozen&#146;s licensees, future licensors and their counsel that took place prior to the date upon which Surrozen assumed control over patent prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>In the future, Surrozen may enter agreements involving licenses or collaborations that provide for access or sharing of intellectual
property. If Surrozen fails to comply with its obligations under any license, collaboration or other agreements, it may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting its
current and future product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen currently licenses, and in the future may continue to license, from third
parties&#146; certain patents and other intellectual property relating to Surrozen&#146;s current and future product candidates. Surrozen has certain obligations to its existing licensors, and may owe additional obligations in the future to any
additional licensors. If Surrozen breaches any material obligations, including diligence obligations with respect to development and commercialization of product candidates covered by the intellectual property licensed to Surrozen, or uses the
licensed intellectual property in an unauthorized manner, Surrozen may be required to pay damages and the licensor may have the right to terminate the license, which could result in Surrozen being unable to develop, manufacture, and sell products
that are covered by the licensed intellectual property or enable a competitor to gain access to the licensed intellectual property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Disputes may arise between Surrozen and its present and future licensors regarding
intellectual property subject to a license agreement, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which Surrozen&#146;s technology and processes infringe on intellectual property of
the licensor that is not subject to the license agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s right to sublicense patents and other rights to third parties, including the terms and
conditions therefor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s diligence obligations with respect to the development and commercialization of its product
candidates that are covered by the licensed intellectual property, and what activities satisfy those diligence obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s right to transfer or assign the license; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by any of Surrozen&#146;s licensors and Surrozen and its collaborators. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If
disputes over intellectual property that Surrozen licenses in the future prevent or impair Surrozen&#146;s ability to maintain its licensing arrangements on acceptable terms, Surrozen may not be able to successfully develop and commercialize the
affected product candidates, which would have a material adverse effect on its business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, certain of Surrozen&#146;s future
agreements with third parties may limit or delay its ability to consummate certain transactions, may impact the value of those transactions, or may limit its ability to pursue certain activities. For example, Surrozen may in the future enter into
license agreements that are not assignable or transferable, or that require the licensor&#146;s express consent in order for an assignment or transfer to take place. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, Surrozen or its licensors, if any, may fail to identify patentable aspects of inventions made in the course of development and
commercialization activities before it is too late to obtain patent protection on them. Therefore, Surrozen may miss potential opportunities to strengthen its patent position. It is possible that defects of form in the preparation or filing of
Surrozen&#146;s patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If Surrozen or its licensors fail to
establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If Surrozen&#146;s licensors are not fully cooperative or disagree with Surrozen as to the prosecution, maintenance or
enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of Surrozen&#146;s patents or patent applications, such patents may be invalid and/or
unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair Surrozen&#146;s ability to prevent competition from third parties, which may have an adverse impact on its business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, even where Surrozen has the right to control patent prosecution of patents and patent applications under license from third
parties, it may still be adversely affected or prejudiced by actions or inactions of its predecessors or licensors and their counsel that took place prior to it assuming control over patent prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s technology acquired or licensed currently or in the future from various third parties is or may be subject to retained rights.
Surrozen&#146;s predecessors or licensors do and may retain certain rights under their agreements with Surrozen, including the right to use the underlying technology for <FONT STYLE="white-space:nowrap">non-commercial</FONT> academic and research
use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether Surrozen&#146;s
predecessors or licensors limit their use of the technology to these uses, and Surrozen could incur substantial expenses to enforce its rights to licensed technology in the event of misuse. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If Surrozen is limited in its ability to utilize acquired or licensed technologies, or if Surrozen loses its rights to critical <FONT
STYLE="white-space:nowrap">in-licensed</FONT> technology, it may be unable to successfully develop, <FONT STYLE="white-space:nowrap">out-license,</FONT> market and sell its product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
candidates, which could prevent or delay new product introductions. Surrozen&#146;s business strategy depends on the successful development of acquired technologies and licensed technology into
commercial product candidates. Therefore, any limitations on its ability to utilize these technologies may impair Surrozen&#146;s ability to develop, <FONT STYLE="white-space:nowrap">out-license</FONT> or market and sell its product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If Surrozen fails to comply with its obligations under any license, collaboration or other intellectual property-related agreements, it
may be required to pay damages and could lose intellectual property rights that may be necessary for developing, commercializing and protecting its current or future technologies or product candidates or Surrozen could lose certain rights to grant
sublicenses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen is party to an exclusive license agreement with Stanford University covering patents relevant to one or more
product candidates and may need to obtain additional licenses from others to advance its research and development activities or allow the commercialization of its current and future product candidates it may identify and pursue. The license
agreements with Stanford impose, and any future license agreements Surrozen enters into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement
or other obligations on Surrozen. For a more detailed description of the license agreements with Stanford, see the section titled &#147;<I>Business&#151;Stanford License Agreements</I>.&#148; If Surrozen breaches any of these obligations, or uses
the intellectual property licensed to it in an unauthorized manner, it may be required to pay damages and the licensor may have the right to terminate the license. License termination could result in Surrozen&#146;s inability to develop, manufacture
and sell products that are covered by the licensed technology or could enable a competitor to gain access to the licensed technology. Furthermore, Surrozen may not have the right to control the preparation, filing, prosecution, maintenance,
enforcement and defense of patents and patent applications that it licenses from third parties. In certain circumstances, Surrozen&#146;s licensed patent rights are subject to reimbursing licensors for their patent prosecution and maintenance costs.
If Surrozen&#146;s licensors and future licensors fail to prosecute, maintain, enforce and defend patents Surrozen may license, or lose rights to licensed patents or patent applications, Surrozen&#146;s licensed rights may be reduced or eliminated.
In such circumstances, Surrozen&#146;s right to develop and commercialize any of its products or product candidates that is the subject of such licensed rights could be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, Surrozen&#146;s current or future licensors may own or control intellectual property that has not been licensed to Surrozen and, as
a result, Surrozen may be subject to claims, regardless of their merit, that it is infringing, misappropriating or otherwise violating the licensor&#146;s intellectual property rights. In addition, while Surrozen cannot currently determine the
amount of the royalty obligations Surrozen would be required to pay on sales of future products if infringement or misappropriation were found, those amounts could be significant. The amount of future royalty obligations will depend on the
technology and intellectual property Surrozen uses in products that it successfully develops and commercializes, if any. Therefore, even if Surrozen successfully develops and commercializes products, it may be unable to achieve or maintain
profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which product candidates, technology and processes infringe on intellectual property of the
licensor that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sublicensing of patent and other rights under Surrozen&#146;s collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s diligence obligations under the license agreement and what activities satisfy those diligence
obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting
from the joint creation or use of intellectual property by Surrozen&#146;s licensors and Surrozen and its collaborators; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the agreements under which Surrozen currently licenses intellectual property or
technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what Surrozen believes to be
the scope of its rights to the relevant intellectual property or technology, or increase what Surrozen believes to be its financial or other obligations under the relevant agreement, either of which could have a material adverse effect on
Surrozen&#146;s business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that Surrozen has licensed prevent or impair its ability to maintain its current licensing arrangements on
commercially acceptable terms, Surrozen may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on its business, financial conditions, results of operations, and prospects.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Patent terms may not be able to protect Surrozen&#146;s competitive position for an adequate period of time with respect to its
current or future technologies or product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patents have a limited lifespan. In the United States, if all maintenance
fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Various extensions may be available. Even so, the life of a patent and the
protection it affords are limited. As a result, Surrozen&#146;s owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent portfolio provides it with limited rights that may not last for a sufficient period of time to exclude others from
commercializing product candidates similar or identical to Surrozen&#146;s. Even if patents covering Surrozen&#146;s product candidates are obtained, once the patent life has expired, Surrozen may be open to competition from competitive products,
including generics or biosimilars. For example, given the large amount of time required for the research, development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after
such candidates are commercialized. As a result, Surrozen&#146;s owned and licensed patent portfolio may not provide it with sufficient rights to exclude others from commercializing products similar or identical to Surrozen&#146;s. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Extensions of patent term may be available, but there is no guarantee that Surrozen would have patents eligible for extension, or that
Surrozen would succeed in obtaining any particular extension&#151;and no guarantee any such extension would confer patent term for a sufficient period of time to exclude others from commercializing product candidates similar or identical to
Surrozen&#146;s. In the United States, depending upon the timing, duration and specifics of FDA marketing approval of product candidates, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to
five years beyond the normal expiration of the patent, which is limited to the approved product or approved indication. In the United States, patent term extension cannot extend the remaining term of a patent beyond 14 years from the date of product
approval; only one patent may be extended; and extension is available for only those claims covering the approved drug, a method for using it, or a method for manufacturing it. The applicable authorities, including the FDA and the USPTO in the
United States, and any equivalent regulatory authority in other countries, may not agree with Surrozen&#146;s assessment of whether such extensions are available, and may refuse to grant extensions to its patents, or may grant more limited
extensions than Surrozen requests. An extension may not be granted or may be limited where there is, for example, a failure to exercise due diligence during the testing phase or regulatory review process, failure to apply within applicable
deadlines, failure to apply before expiration of relevant patents, or some other failure to satisfy applicable requirements. If this occurs, Surrozen&#146;s competitors may be able to launch their products earlier by taking advantage of its
investment in development and clinical trials along with its clinical and preclinical data. This could have a material adverse effect on Surrozen&#146;s business and ability to achieve profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby
impairing Surrozen&#146;s ability to protect its current or any future technologies or product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Changes in either the
patent laws or interpretation of the patent laws in the United States or elsewhere could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
defense of issued patents. The United States has enacted and implemented wide-ranging patent reform legislation. On September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or the
Leahy-Smith Act, was signed into law, which could increase the uncertainties and costs surrounding the prosecution of Surrozen&#146;s owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications and the enforcement or defense of
any future owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted,
redefine prior art, may affect patent litigation and switch the U.S. patent system from a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-invent&#148;</FONT></FONT> system to a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system. Under a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-file</FONT></FONT> system, assuming the other requirements for patentability are met, the
first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the USPTO after
March&nbsp;16, 2013, but before Surrozen, could therefore be awarded a patent covering an invention of Surrozen&#146;s even if Surrozen had made the invention before it was made by such third party. This will require Surrozen to be cognizant of the
time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, Surrozen cannot be certain that it or its licensors
were the first to either (i)&nbsp;file any patent application related to its product candidates or (ii)&nbsp;invent any of the inventions claimed in its or its licensor&#146;s patents or patent applications. The Leahy-Smith Act also allows
third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to challenge the validity of a patent by the USPTO administered post grant proceedings, including derivation, reexamination, inter partes
review, post-grant review and interference proceedings. The USPTO developed additional regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act,
and, in particular, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-file</FONT></FONT> provisions, became effective on March&nbsp;16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will
have on the operation of Surrozen&#146;s business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of Surrozen&#146;s owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT>
patent applications and the enforcement or defense of Surrozen&#146;s issued, owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, all of which could have a material adverse impact on Surrozen&#146;s business prospects and financial
condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As referenced above, for example, courts in the U.S. continue to refine the heavily <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">fact-and-circumstance-dependent</FONT></FONT> jurisprudence defining the scope of patent protection available for therapeutics, narrowing the scope of patent protection available in certain circumstances or weakening the
rights of patent owners in certain situations. This creates uncertainty about Surrozen&#146;s ability to obtain patents in the future and the value of such patents. In addition, the patent positions of companies in the development and
commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This
combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents
could change in unpredictable ways that could have a material adverse effect on Surrozen&#146;s existing patent portfolio and its ability to protect and enforce its intellectual property in the future. Surrozen cannot provide assurance that future
developments in U.S. Congress, the federal courts and the USPTO will not adversely impact its owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or patent applications. The laws and regulations governing patents could change in
unpredictable ways that could weaken Surrozen&#146;s and its licensors&#146; ability to obtain new patents or to enforce its existing owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patents that it might obtain or <FONT
STYLE="white-space:nowrap">in-license</FONT> in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental
authority enforces patent laws or regulations may have a material adverse effect on Surrozen&#146;s and its licensors&#146; ability to obtain new patents or to protect and enforce Surrozen&#146;s owned or
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or patents that it may obtain or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Other companies or organizations may challenge Surrozen&#146;s or its licensors&#146; patent rights. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Third parties may attempt to invalidate Surrozen&#146;s or its licensors&#146; intellectual property rights via procedures including but not
limited to patent infringement lawsuits, interferences, oppositions and inter partes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
reexamination proceedings before the USPTO, U.S. courts, and foreign patent offices or foreign courts. Even if such rights are not directly challenged, disputes could lead to the weakening of
Surrozen&#146;s or its licensors&#146; intellectual property rights. Surrozen&#146;s defense against any attempt by third parties to circumvent or invalidate its intellectual property rights could be costly to it, could require significant time and
attention of its management, and could have a material and adverse impact on its profitability, financial condition and prospects or ability to successfully compete. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen or its licensors may find it necessary to pursue claims or to initiate lawsuits to protect or enforce Surrozen&#146;s owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patent or other intellectual property rights. The cost to Surrozen in defending or initiating any litigation or other proceeding relating to its owned or
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patent or other intellectual property rights, even if resolved in its favor, could be substantial, and any litigation or other proceeding would divert its management&#146;s attention. Such
litigation or proceedings could materially increase Surrozen&#146;s operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. Some of Surrozen&#146;s competitors may be
able to more effectively to sustain the costs of complex patent litigation because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay
Surrozen&#146;s research and development efforts and materially limit its ability to continue its operations. Furthermore, because of the substantial amount of discovery required in connection with certain such proceedings, there is a risk that some
of Surrozen&#146;s confidential information could be compromised by disclosure. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors
perceive these results to be negative, such announcements could have a material adverse effect on the price of New Surrozen&#146;s common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If Surrozen or its licensors were to initiate legal proceedings against a third party to enforce a patent covering one of Surrozen&#146;s
product candidates or its technology, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds
for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, claiming patent-ineligible subject matter, lack of novelty, indefiniteness, lack of written description,
<FONT STYLE="white-space:nowrap">non-enablement,</FONT> anticipation or obviousness. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO
or made a misleading statement during prosecution. The outcome of such invalidity and unenforceability claims is unpredictable. With respect to the validity question, for example, Surrozen cannot be certain that there is no invalidating prior art of
which Surrozen or its licensors and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, Surrozen could lose at least part, and perhaps all, of the patent
protection for one or more of its product candidates or certain aspects of its platform technology. Such a loss of patent protection could have a material adverse effect on Surrozen&#146;s business, financial condition, results of operations and
prospects. Patents and other intellectual property rights also will not protect Surrozen&#146;s product candidates and technologies if competitors or third parties design around such product candidates and technologies without legally infringing,
misappropriating or violating Surrozen&#146;s owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or other intellectual property rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen may not be able to protect its intellectual property rights throughout the world, which could negatively impact its business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Filing, prosecuting and defending patents on current or future technologies or product candidates in all countries throughout the
world would be prohibitively expensive. Competitors or other third parties may use Surrozen&#146;s technologies in jurisdictions where it has not obtained patent protection to develop its own products and, further, may export infringing product
candidates to territories where it has patent protection or licenses but enforcement is not as strong as that in the United States. These product candidates may compete with Surrozen&#146;s products, and its patents or other intellectual property
rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, the laws of some foreign jurisdictions do not
protect intellectual property rights to the same extent as the laws in the United States. Many companies have encountered significant difficulties in protecting and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
defending such rights in such jurisdictions. The legal systems of certain countries, including certain developing countries, do not favor the enforcement of patents and other intellectual
property protection, particularly those relating to biotechnology, which could make it difficult for Surrozen to stop the infringement of any owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents it may obtain in other countries, or
the marketing of competing products in violation of its intellectual property and proprietary rights generally. Proceedings to enforce its owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property and proprietary rights in
foreign jurisdictions could result in substantial costs and could divert its efforts and attention from other aspects of its business. Such proceedings could also put any owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents at risk
of being invalidated or interpreted narrowly, could put Surrozen&#146;s owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications at risk of not issuing, and could provoke third parties to assert claims against it or its
licensors. Surrozen or its licensors may not prevail in any lawsuits or other adversarial proceedings that it or its licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, Surrozen and
its licensors&#146; efforts to enforce such intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that it develops or <FONT
STYLE="white-space:nowrap">in-licenses.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, many countries have compulsory licensing laws under which a patent owner may be
compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could
materially diminish the value of its patents. If Surrozen or any of its licensors are forced to grant a license to third parties with respect to any patents relevant to its business, its competitive position in the relevant jurisdiction may be
impaired and its business prospects may be materially adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Third parties may initiate legal proceedings alleging
that Surrozen is infringing, misappropriating or violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse impact on the success of Surrozen&#146;s business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s commercial success depends, in part, upon its ability or the ability of its potential future collaborators to develop,
manufacture, market and sell its current or any future product candidates and to use its proprietary technologies without infringing, misappropriating or violating the proprietary and intellectual property rights of third parties. There is a
substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences,
oppositions and inter partes reexamination proceedings before the USPTO, U.S. courts, foreign patent offices or foreign courts. As the field of antibody-based therapeutics matures, patent applications are being processed by national patent offices
around the world. There is uncertainty about which patents will issue, and, if they do, there is uncertainty as to when, to whom, and with what claims. Any claims of patent infringement asserted by third parties would be time consuming and could:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">result in costly litigation that may cause negative publicity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">divert the time and attention of Surrozen&#146;s technical personnel and management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cause development delays; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prevent Surrozen from commercializing any of its product candidates until the asserted patent expires or is
held finally invalid or not infringed in a court of law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require Surrozen to develop <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology, which may not
be possible on a cost-effective basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject Surrozen to significant liability to third parties; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require Surrozen to enter into royalty or licensing agreements, which may not be available on commercially
reasonable terms, or at all, or which might be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which could result in its competitors gaining access to the same technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which
Surrozen is pursuing development candidates. As the biotechnology and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
pharmaceutical industries expand and more patents are issued, the risk increases that Surrozen may be subject to claims of infringement of the patent rights of third parties. Because patent
applications can take many years to issue, there may also be currently pending patent applications that may later result in issued patents that Surrozen&#146;s technology or product candidates may infringe. Further, Surrozen cannot guarantee that it
is aware of all of patents and patent applications potentially relevant to its technology or products. It may not be aware of potentially relevant third-party patents or applications for several reasons. For example, U.S. applications filed before
November&nbsp;29, 2000, and certain U.S. applications filed after that date that will not be filed outside the U.S. remain confidential until a patent issues. Patent applications in the United States and elsewhere are published approximately 18
months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering Surrozen&#146;s product candidates or platform technologies could
have been filed by others without its knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover its platform, its product candidates or the use of
its technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although no third party has asserted a claim of patent infringement against Surrozen as of the date hereof, others may
hold proprietary rights that could prevent its product candidates from being marketed. Surrozen or its licensors, or any future strategic collaborator, may be party to, or be threatened with, adversarial proceedings or litigation regarding
intellectual property rights with respect to its current or any potential future product candidates and technologies, including derivation, reexamination, inter partes review, post-grant review or interference proceedings before the USPTO and
similar proceedings in jurisdictions outside of the United States such as opposition proceedings. In some instances, Surrozen may be required to indemnify its licensors for the costs associated with any such adversarial proceedings or litigation.
Third parties may assert infringement claims against Surrozen, its licensors or its strategic collaborators based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may
choose to engage in litigation or other adversarial proceedings with Surrozen, its licensors or its strategic collaborators to enforce or otherwise assert their patent rights. Even if Surrozen believes such claims are without merit, a court of
competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could have a material adverse impact on Surrozen&#146;s ability to utilize its discovery platform or to commercialize its current or any
future product candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, Surrozen would need to overcome a presumption of validity by presenting clear and convincing evidence of invalidity. There is no
assurance that a court of competent jurisdiction, even if presented with evidence Surrozen believes to be clear and convincing, would invalidate the claims of any such U.S. patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, Surrozen cannot guarantee that it will be able to successfully settle or otherwise resolve such adversarial proceedings or
litigation. If Surrozen is unable to successfully settle future claims on terms acceptable to it, it may be required to engage in or to continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial
delays in marketing its product candidates. If Surrozen, or its licensors, or any future strategic collaborators are found to infringe, misappropriate or violate a third-party patent or other intellectual property rights, Surrozen could be required
to pay damages, including treble damages and attorney&#146;s fees, if it is found to have willfully infringed. In addition, Surrozen, or its licensors, or any future strategic collaborators may choose to seek, or be required to seek, a license from
a third party, which may not be available on commercially reasonable terms, if at all. Even if a license can be obtained on commercially reasonable terms, the rights may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which could give
Surrozen&#146;s competitors access to the same technology or intellectual property rights licensed to it, and it could be required to make substantial licensing and royalty payments. Parties making claims against Surrozen may obtain injunctive or
other equitable relief, which could effectively block its ability to further develop and commercialize its current or future product candidates. It could be forced, including by court order, to cease utilizing, developing, manufacturing and
commercializing its discovery platform or product candidates deemed to be infringing. It may be forced to redesign current or future technologies or products. Defense of these claims, regardless of their merit, would involve substantial litigation
expense and would be a substantial diversion of employee resources from Surrozen&#146;s business. Any of the foregoing could have a material adverse effect on Surrozen&#146;s ability to generate revenue or achieve profitability and possibly prevent
it from generating revenue sufficient to sustain its operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Thus, it is possible that one or more third parties will hold patent rights to which
Surrozen will need a license, which may not be available on reasonable terms or at all. If such third parties refuse to grant Surrozen a license to such patent rights on reasonable terms or at all, it may be required to expend significant time and
resources to redesign its technology, product candidates or the methods for manufacturing its product candidates, or to develop or license replacement technology, all of which may not be commercially or technically feasible. In such case, Surrozen
may not be able to market such technology or product candidates and may not be able to perform research and development or other activities covered by these patents. This could have a material adverse effect on Surrozen&#146;s ability to
commercialize its product candidates and its business and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Intellectual property litigation may lead to
unfavorable publicity that harms Surrozen&#146;s reputation and causes the market price of our common shares to decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During
the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings or developments in the litigation. If
securities analysts or investors regard these announcements as negative, the perceived value of Surrozen&#146;s existing product candidates, approved products, programs or intellectual property could be diminished. Accordingly, the market price of
shares of its common stock may decline. Such announcements could also harm its reputation or the market for its future products, which could have a material adverse effect on its business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Intellectual property rights of third parties could adversely affect Surrozen&#146;s ability to commercialize its current or future
technologies or product candidates, and it might be required to litigate or obtain licenses from third parties to develop or market its current or future technologies or product candidates, which may not be available on commercially reasonable terms
or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because the antibody landscape is still evolving, it is difficult to conclusively assess Surrozen&#146;s freedom to
operate without infringing, misappropriating or violating third-party rights. There are numerous companies that have pending patent applications and issued patents broadly covering antibodies generally or covering portions of antibodies that may be
relevant for product candidates that Surrozen wishes to develop. Surrozen is aware of third party patents and patent applications that claim aspects of its current or potential future product candidates and modifications that it may need to apply to
its current or potential future product candidates. In particular, it is aware of granted patents that cover certain aspects of the <FONT STYLE="white-space:nowrap">SZN-1326</FONT> product candidate and pending patent applications that could result
in patents that cover aspects of the <FONT STYLE="white-space:nowrap">SZN-043</FONT> product candidate. There are also many issued patents that claim antibodies or portions of antibodies that may be relevant to products Surrozen wishes to develop.
The holders of such patents and patent applications may be able to block or delay Surrozen&#146;s ability to develop and commercialize the applicable product candidates, including <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT
STYLE="white-space:nowrap">SZN-043,</FONT> unless it obtains a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all, or it may be
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which could result in Surrozen&#146;s competitors gaining access to the same intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s competitive position may materially suffer if patents issued to third parties or other third-party intellectual property
rights cover its current or future technologies product candidates or elements thereof or its manufacture or uses relevant to its development plans. In such cases, Surrozen may not be in a position to develop or commercialize current or future
technologies, product candidates unless it successfully pursues litigation to narrow or invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, if available on
commercially reasonable terms. There may be issued patents of which Surrozen is not aware, held by third parties that, if found to be valid and enforceable, could be alleged to be infringed by its current or future technologies or product
candidates. There also may be pending patent applications of which it is not aware that may result in issued patents, which could be alleged to be infringed by its current or future technologies or product candidates. If such an infringement claim
should successfully be brought, Surrozen may be required to pay substantial damages or be forced to abandon its current or future technologies or product candidates or to seek a license from any patent holders. No assurances can be given that a
license will be available on commercially reasonable terms, if at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Third-party intellectual property right holders may also actively bring infringement,
misappropriation, or other claims alleging violations of intellectual property rights against Surrozen. Surrozen cannot guarantee that it will be able to successfully settle or otherwise resolve such claims. If Surrozen is unable to successfully
settle future claims on terms acceptable to it, it may be required to engage in or to continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing its product candidates. If
Surrozen fails in any such dispute, in addition to being forced to pay damages, it may be temporarily or permanently prohibited from commercializing any of its current or future technologies or product candidates that are held to be infringing,
misappropriating or otherwise violating third-party intellectual property rights. Surrozen might, if possible, also be forced to redesign current or future technologies or product candidates so that it no longer infringes, misappropriate or violate
the third-party intellectual property rights. Any of these events, even if Surrozen were ultimately to prevail, could require Surrozen to divert substantial financial and management resources that it would otherwise be able to devote to its
business, which could have a material adverse effect on its financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If, in the future,
Surrozen develops trade secrets and is unable to protect the confidentiality of its trade secrets, its business and competitive position would be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to seeking patent protection for certain aspects of its current or future technologies and product candidates, Surrozen may in the
future consider trade secrets, including confidential and unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> to be important to the maintenance of its competitive position. However, trade secrets and
<FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. If Surrozen develops trade secrets, it plans to protect trade secrets and confidential and unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> in part, by
entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to such knowledge, such as its employees, corporate collaborators, outside scientific collaborators, contract research
organizations, contract manufacturers, consultants, advisors and other third parties. Surrozen also enters into confidentiality and invention or patent assignment agreements with its employees and consultants under which they are obligated to
maintain confidentiality and to assign their inventions to it. However, Surrozen cannot be certain that such agreements have been entered into with all relevant parties, and cannot be certain that its trade secrets and other confidential proprietary
information will not be disclosed or that competitors will not otherwise gain access to its trade secrets or independently develop substantially equivalent information and techniques. Moreover, individuals with whom Surrozen has such agreements may
not comply with their terms. Any of these parties may breach such agreements and disclose Surrozen&#146;s proprietary information, including its trade secrets, and it may not be able to obtain adequate remedies for any such breaches. Surrozen may
also become involved in inventorship disputes relating to inventions and patents developed by its employees or consultants under such agreements. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret, or securing title
to an employee- or consultant-developed invention if a dispute arises, is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the United States and certain foreign jurisdictions disfavor or are
unwilling to protect trade secrets. Further, if any of Surrozen&#146;s trade secrets were to be lawfully obtained or independently developed by a competitor, it would have no right to prevent that competitor from using the technology or information
to compete with it. If, in the future, any of Surrozen&#146;s trade secrets were to be disclosed to or independently developed by a competitor, its competitive position would be materially and adversely harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen may be subject to claims that it or its employees or consultants have wrongfully used or disclosed alleged trade secrets or
other proprietary information of its employees&#146; or consultants&#146; former employers or their clients. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of
Surrozen&#146;s employees or consultants and its licensors&#146; employees or consultants were previously employed at universities or biotechnology or biopharmaceutical companies, including its competitors or potential competitors. Surrozen may be
subject to claims that one or more of these employees or consultants or Surrozen has inadvertently or otherwise used or disclosed trade secrets or other proprietary information of former employers. Litigation or arbitration may be necessary to
defend against these claims. If Surrozen fails in defending such claims, in addition to paying monetary damages, it may lose valuable intellectual property rights </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
or personnel or may be enjoined from using such intellectual property. Any such proceedings and possible aftermath would likely divert significant resources from its core business, including
distracting its technical and management personnel from their normal responsibilities. A loss of key research personnel or their work product could limit Surrozen&#146;s ability to commercialize, or prevent it from commercializing, its current or
future technologies or product candidates, which could materially harm its business. Even if Surrozen is successful in defending against any such claims, litigation or arbitration could result in substantial costs and could be a distraction to
management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen may be subject to claims challenging the inventorship of its patents and other intellectual property.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen or its licensors may be subject to claims that former employees, collaborators or other third parties have an interest in
its owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets, or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> For example, Surrozen or its licensors may have
inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing its product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or
Surrozen&#146;s or its licensors&#146; ownership of its owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets or other intellectual property. If Surrozen or its licensors fail in defending any such claims, in addition
to paying monetary damages, it may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to its product candidates. Even if Surrozen is successful in defending against
such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on Surrozen&#146;s business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen may not be successful in obtaining or maintaining necessary rights to its product candidates through
acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because Surrozen&#146;s development programs may in the
future require the use of proprietary rights held by third parties, the growth of its business may depend in part on its ability to acquire, <FONT STYLE="white-space:nowrap">in-license,</FONT> or use these third-party proprietary rights. Surrozen
may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, processes or other third-party intellectual property rights from third parties that it identifies as necessary for its product
candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that
Surrozen may consider attractive or necessary. These established companies may have a competitive advantage over Surrozen due to their size, capital resources and greater clinical development and commercialization capabilities. In addition,
companies that perceive Surrozen to be a competitor may be unwilling to assign or license rights to it. Surrozen also may be unable to license or acquire third-party intellectual property rights on terms that would allow it to make an appropriate
return on its investment or at all. If Surrozen is unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights it has, it may have to abandon development of the
relevant program or product candidate, which could have a material adverse effect on its business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Obtaining and maintaining Surrozen&#146;s patent protection depends on compliance with various procedural, document submission, fee
payment and other requirements imposed by government patent agencies, and Surrozen&#146;s patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents or applications will be due to be paid to
the USPTO and various government patent agencies outside of the United States over the lifetime of Surrozen&#146;s owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or applications and any patent rights it may own or <FONT
STYLE="white-space:nowrap">in-license</FONT> in the future. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent offices require compliance with several procedural, documentary, fee payment and other similar provisions
during the patent application process. Surrozen employs reputable law firms and other professionals to help it comply with these requirements, and it is also dependent on its licensors to take the necessary action to comply with these requirements
with respect to its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
<FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the
applicable rules. There are situations, however, in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the
relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical product candidates or platforms, which could have a material adverse effect on Surrozen&#146;s business prospects and
financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Some intellectual property that Surrozen has <FONT STYLE="white-space:nowrap">in-licensed</FONT> may have been
discovered through government funded programs and thus may be subject to federal regulations such as <FONT STYLE="white-space:nowrap">&#147;march-in&#148;</FONT> rights, certain reporting requirements and a preference for U.S.-based companies.
Compliance with such regulations may limit Surrozen&#146;s exclusive rights, and limit its ability to contract with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> manufacturers. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Intellectual property rights Surrozen has licensed were generated through the use of U.S. government funding and are therefore subject to
certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in Surrozen&#146;s current or future product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act, and implementing
regulations. These U.S. government rights in certain inventions developed under a government-funded program include a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">non-transferable,</FONT> irrevocable
worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require Surrozen or its licensors to grant exclusive, partially exclusive, or <FONT STYLE="white-space:nowrap">non-exclusive</FONT>
licenses to any of these inventions to a third party if it determines that: (i)&nbsp;adequate steps have not been taken to commercialize the invention; (ii)&nbsp;government action is necessary to meet public health or safety needs; or
(iii)&nbsp;government action is necessary to meet requirements for public use under federal regulations (also referred to as <FONT STYLE="white-space:nowrap">&#147;march-in</FONT> rights&#148;). The U.S. government also has the right to take title
to these inventions if Surrozen, or the applicable licensor, fails to disclose the invention to the government and fails to file an application to register the intellectual property within specified time limits. These time limits have recently been
changed by regulation, and may change in the future. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require Surrozen or the applicable licensor to expend
substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference
requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the
United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit Surrozen&#146;s ability to contract with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> product
manufacturers for products covered by such intellectual property. To the extent any of Surrozen&#146;s current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly
apply. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If Surrozen&#146;s trademarks and trade names are not adequately protected, then it may not be able to build name
recognition in its markets of interest and its business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s trademarks or trade names may
be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. Surrozen may not be able to protect its rights to these trademarks and trade names or may be forced to stop using these names, which it uses for
name recognition by potential collaborators or customers in its markets of interest. If Surrozen is unable to establish name recognition based on its trademarks and trade names, it may not be able to compete effectively and its business may be
materially adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Intellectual property rights do not necessarily address all potential threats to
Surrozen&#146;s business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The degree of future protection afforded by Surrozen&#146;s intellectual property rights is uncertain
because intellectual property rights have limitations and may not adequately protect its business. The following examples are illustrative: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make antibodies or portions of antibodies or formulations that are similar to
Surrozen&#146;s product candidates, but that are not covered by the claims of any patents that it owns, licenses or controls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen or any strategic collaborators might not have been the first to make the inventions covered by the
issued patents or pending patent applications that it owns, licenses or controls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen or its licensors might not have been the first to file patent applications covering certain of its
owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop the same, similar, or alternative technologies without infringing,
misappropriating or violating Surrozen&#146;s owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that Surrozen&#146;s owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> pending
patent applications will not lead to issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that Surrozen owns, <FONT STYLE="white-space:nowrap">in-licenses,</FONT> or controls may not
provide it with any competitive advantages, or may be narrowed or held invalid or unenforceable, including as a result of legal challenges; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s competitors might conduct research and development activities in the United States and other
countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where it does not have patent rights, and may then use the information learned from such activities to
develop competitive products for sale in its major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen may choose not to file a patent application in order to maintain certain trade secrets or <FONT
STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent application covering such trade secrets or <FONT STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may have an adverse effect on Surrozen&#146;s business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Should any of these events occur, they could have a material adverse impact on Surrozen&#146;s business and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_31"></A>Risks Related to Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Clinical development includes a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may
not be predictive of future trial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s product candidates <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and
<FONT STYLE="white-space:nowrap">SZN-043</FONT> are in preclinical development and their risk of failure is high. It is impossible to predict when or if Surrozen&#146;s candidates or any potential future product candidates will prove effective in
humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, Surrozen must complete preclinical studies for <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT
STYLE="white-space:nowrap">SZN-043</FONT> and then conduct extensive clinical trials to demonstrate the safety, purity, and potency, or efficacy of that product candidate in humans. Clinical testing is expensive and can take many years to complete,
and its outcome is inherently uncertain. Failure can occur at any time during the development process. The results of preclinical studies and clinical trials of any of Surrozen&#146;s current or potential future product candidates may not be
predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical
trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or safety profiles, notwithstanding promising results in earlier trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen is currently conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT>
studies for <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and intends to initiate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trials of <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT
STYLE="white-space:nowrap">SZN-043</FONT> in 2022. Surrozen may experience delays in completing its preclinical studies and initiating or completing its clinical studies. It does not know whether planned preclinical studies and clinical trials will
be completed on schedule or at all, or whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Its development programs may be delayed for a variety of reasons,
including delays related to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other regulatory authorities requiring it to submit additional data or imposing other requirements
before permitting it to initiate a clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining regulatory approval to commence a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can
be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining institutional review board, or IRB, approval at each clinical trial site; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recruiting suitable patients to participate in a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">having patients complete a clinical trial or return for post-treatment
<FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trial sites deviating from trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding new clinical trial sites; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing sufficient quantities of its product candidates for use in clinical trials.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, Surrozen expects to rely on its CROs and clinical trial sites to ensure the proper and timely conduct of
its clinical trials and, while it expects to enter into agreements governing their committed activities, it has limited influence over their actual performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen could encounter delays if prescribing physicians encounter unresolved ethical issues associated with enrolling patients in clinical
trials of its current or potential future product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by Surrozen, its collaborators, the
IRBs of the institutions in which such trials are being conducted, the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in
accordance with regulatory requirements or Surrozen&#146;s clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety
issues or adverse side effects, failure to demonstrate a benefit from using a drug or therapeutic biologic, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If Surrozen
experiences delays in the completion of, or termination of, any clinical trial of any of its current or potential future product candidates, the commercial prospects of such product candidate will be harmed, and its ability to generate product
revenue from such product candidates will be delayed. In addition, any delays in completing Surrozen&#146;s clinical trials will increase its costs, slow its product development and approval process and jeopardize its ability to commence product
sales and generate revenue. Any of these occurrences may materially and adversely affect Surrozen&#146;s business, financial condition, results of operations and prospects. In addition, many of the factors that cause, or lead to, a delay in the
commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of Surrozen&#146;s current or potential future product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen may be unable to obtain U.S. or foreign regulatory approval and, as a result, be unable to commercialize <FONT
STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT STYLE="white-space:nowrap">SZN-043</FONT> or potential future product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT STYLE="white-space:nowrap">SZN-043,</FONT> and any potential future product candidates
are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of therapeutic biologics. Rigorous preclinical testing and
clinical trials and an extensive regulatory approval process are required to be successfully completed in the U.S. and in many foreign jurisdictions before a new drug or therapeutic biologic can be marketed. Satisfaction of these and other
regulatory requirements is costly, time-consuming, uncertain and subject to unanticipated delays. It is possible that none of the product candidates Surrozen may develop will obtain the regulatory approvals necessary for it or its potential future
collaborators to begin selling them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen has very limited experience in conducting and managing the clinical trials necessary to
obtain regulatory approvals, including approval by the FDA and other regulatory authorities. The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending
upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when regulating Surrozen require judgment and can change, which makes it difficult to predict with certainty how they will be
applied. Any analysis Surrozen performs of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. Surrozen may also encounter
unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in regulatory policy during the period of product development, clinical trials and FDA regulatory
review in the United States and other jurisdictions. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if
any, may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any delay or failure in obtaining required approvals could have a material and adverse effect on Surrozen&#146;s ability to
generate revenue from the particular product candidate for which it is seeking approval. Further, Surrozen and its potential future collaborators may never receive approval to market and commercialize any product candidate. Even if Surrozen or a
potential future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as it intended or desired or may require labeling that includes significant use or
distribution restrictions or safety warnings. Surrozen or a potential future collaborator may be subject to post-marketing testing requirements to maintain regulatory approval. If any of Surrozen&#146;s product candidates prove to be ineffective,
unsafe or commercially unviable, it may have to <FONT STYLE="white-space:nowrap">re-engineer</FONT> <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT STYLE="white-space:nowrap">SZN-043,</FONT> or its potential future product candidates, and
its entire pipeline could have little, if any, value, which could require it to change its focus and approach to drug discovery and therapeutic development, which would have a material and adverse effect on its business, financial condition, results
of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen will also be subject to numerous foreign regulatory requirements governing, among other things, the
conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described
above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Obtaining and maintaining regulatory approval of Surrozen&#146;s product candidates in one jurisdiction does not mean that it will be
successful in obtaining regulatory approval of its product candidates in other jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If Surrozen succeeds in developing
any products, it intends to market them in the United States as well as the European Union and other foreign jurisdictions. In order to market and sell its products in other jurisdictions, Surrozen must obtain separate marketing approvals and comply
with numerous and varying regulatory requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Obtaining and maintaining regulatory approval of Surrozen&#146;s product candidates in
one jurisdiction does not guarantee that it will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA or EMA grants marketing approval
of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing, and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can
involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory
authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that Surrozen intends to
charge for its products is also subject to approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Obtaining foreign regulatory approvals and compliance with foreign regulatory
requirements could result in significant delays, difficulties, and costs for Surrozen and could delay or prevent the introduction of its products in certain countries. If Surrozen or any partner it works with fails to comply with the regulatory
requirements in international markets or fail to receive applicable marketing approvals, its target market will be reduced, and its ability to realize the full market potential of its product candidates will be harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen may in the future conduct certain of its clinical trials for its product candidates outside of the United States. However, the
FDA and other foreign equivalents may not accept data from such trials, in which case its development plans will be delayed, which could materially harm its business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen may in the future choose to conduct one or more of its clinical trials for its product candidates outside the United States. For
example, for its anticipated Phase 1 trials of <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043,</FONT> it is evaluating conducting these trials outside the United States, including potentially in
Australia or Eastern Europe. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. In cases where data from foreign clinical trials are
intended to serve as the basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless (i)&nbsp;those data are applicable to the U.S. population and U.S. medical practice;
(ii)&nbsp;the studies were performed by clinical investigators of recognized competence; and (iii)&nbsp;the data are considered valid without the need for an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection by the FDA or, if the FDA
considers such an inspection to be necessary, the FDA is able to validate the data through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection or other appropriate means. Additionally, the FDA&#146;s clinical trial requirements, including
sufficient size of patient populations and statistical powering, must be met. For studies that are conducted only at sites outside of the United States and not subject to an IND, the FDA requires the clinical trial to have been conducted in
accordance with GCPs, and the FDA must be able to validate the data from the clinical trial through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection if it deems such inspection necessary. For such studies not subject to an IND, the FDA
generally does not provide advance comment on the clinical protocols for the studies, and therefore there is an additional potential risk that the FDA could determine that the study design or protocol for a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> clinical trial was inadequate, which could require us to conduct additional clinical trials. There can be no assurance the FDA will accept data from clinical trials conducted outside of the United
States. If the FDA does not accept data from Surrozen&#146;s clinical trials of its product candidates, it would likely result in the need for additional clinical trials, which would be costly and time consuming and delay or permanently halt
Surrozen&#146;s development of its product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many foreign regulatory bodies have similar approval requirements. In addition,
such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any similar foreign regulatory authority will accept data from trials conducted
outside of the United States or the applicable jurisdiction. If the FDA or any similar foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay
aspects of Surrozen&#146;s business plan, and which may result in its product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conducting clinical trials outside the United States also exposes Surrozen to additional risks, including
risks associated with: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional foreign regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign exchange fluctuations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with foreign manufacturing, customs, shipment and storage requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cultural differences in medical practice and clinical research; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diminished protection of intellectual property in some countries. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if Surrozen receives regulatory approval for any of its current or potential future product candidates, it will be subject to
ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, Surrozen&#146;s current or potential future product candidates, if approved, could be subject to labeling and other
restrictions and market withdrawal and it may be subject to penalties if it fails to comply with regulatory requirements or experience unanticipated problems with its products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any regulatory approvals that Surrozen or its potential future collaborators obtain for <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT
STYLE="white-space:nowrap">SZN-043,</FONT> or any potential future product candidate may also be subject to limitations on the approved indicated uses for which a product may be marketed or to the conditions of approval, or contain requirements for
potentially costly post-marketing testing, including &#147;Phase 4&#148; clinical trials, and surveillance to monitor the safety and efficacy of such product candidate. In addition, if the FDA or any other regulatory authority approves <FONT
STYLE="white-space:nowrap">SZN-1326,</FONT> <FONT STYLE="white-space:nowrap">SZN-043,</FONT> or any of Surrozen&#146;s future product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage,
import, export, advertising, promotion and recordkeeping for such product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports,
registration, as well as continued compliance with cGMP and good clinical practices for any clinical trials that Surrozen conducts post-approval. Later discovery of previously unknown problems with a product candidate, including adverse events of
unanticipated severity or frequency, or with Surrozen&#146;s third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product candidate, withdrawal of the product candidate
from the market or voluntary or mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or its
strategic collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension or revocation of product license approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention or refusal to permit the import or export of products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, the FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the
market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. While physicians may prescribe, in their independent professional medical judgment, products for <FONT
STYLE="white-space:nowrap">off-label</FONT> uses as the FDA does not regulate the behavior of physicians in their choice of drug treatments, the FDA does restrict manufacturer&#146;s communications on the subject of
<FONT STYLE="white-space:nowrap">off-label</FONT> use of their products. Companies may only share truthful and not misleading information that is otherwise consistent with a product&#146;s FDA approved labeling. The FDA and other authorities
actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be
subject to significant liability including, among other things, adverse publicity, warning letters, corrective advertising and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
potential civil and criminal penalties. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of
<FONT STYLE="white-space:nowrap">off-label</FONT> use and has enjoined companies from engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. The FDA and other regulatory authorities have also required that companies enter into
consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Occurrence of any of the
foregoing could have a material and adverse effect on Surrozen&#146;s business and results of operations. The FDA&#146;s and other regulatory authorities&#146; policies may change, and additional government regulations may be enacted that could
prevent, limit or delay regulatory approval of Surrozen&#146;s product candidates. Surrozen cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the
United States or abroad. If Surrozen is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if Surrozen is not able to maintain regulatory compliance, it may lose any marketing approval
that it may have obtained and it may not achieve or sustain profitability, which would adversely affect its business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Healthcare
legislative reform measures may have a material adverse effect on Surrozen&#146;s business and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the
United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, or the ACA, was enacted, which substantially changed the
way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. Among the provisions of the ACA, of greatest importance to the pharmaceutical and biotechnology industry are the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription
drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to
23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated
for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are
enrolled in Medicaid managed care organizations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer
Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (and 70%
as of January&nbsp;1, 2019) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a
condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of the entities eligible for discounts under the Public Health program; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery
models to lower Medicare and Medicaid spending; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implementation of the federal physician payment transparency requirements, sometimes referred to as the
&#147;Physician Payments Sunshine Act.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Some of the provisions of the ACA have yet to be fully implemented, and
there have been legal and political challenges to certain aspects of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. On August&nbsp;2, 2011,
the Budget Control Act of 2011 among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years
2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year. These
reductions went into effect on April&nbsp;1, 2013 and will remain in effect through 2030, with the exception of a temporary suspension implemented under various <FONT STYLE="white-space:nowrap">COVID-19</FONT> relief legislation from May&nbsp;1,
2020 through March&nbsp;31, 2021, unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012 among other things, reduced Medicare payments to several providers, including hospitals and increased the statute of
limitations period for the government to recover overpayments to providers from three to five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On January&nbsp;2, 2013, the
American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers. Additionally, there has been heightened governmental scrutiny recently over the manner in which
manufacturers set prices for their marketed products. For example, there have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug
pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control
pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage
importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in
their prescription drug and other health care programs. These measures could reduce the ultimate demand for Surrozen&#146;s products, once approved, or put pressure on its product pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen expects that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the
amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for Surrozen&#146;s current or future product candidates or additional pricing pressures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If Surrozen or its existing or potential future collaborators, manufacturers or service providers fail to comply with healthcare laws
and regulations, it or they could be subject to enforcement actions, which could affect Surrozen&#146;s ability to develop, market and sell its product candidates and may harm its reputation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Healthcare providers, physicians and third-party payors, among others, will play a primary role in the prescription and recommendation of any
product candidates for which Surrozen obtains marketing approval. Surrozen&#146;s current and future arrangements with third-party payors, providers and customers, among others, may expose it to broadly applicable fraud and abuse and other
healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which it markets, sells and distributes its product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
candidates for which it obtains marketing approval. Restrictions under applicable federal and state healthcare laws and regulations in the United States and other countries, include the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, a person or entity from knowingly and
willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease order, arranging for or recommendation of,
any good, facility, item or service, for which payment may be made, in whole or in part, by a federal healthcare program, such as Medicare or Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to
violate it in order to have committed a violation. In addition, a violation of the Anti-Kickback Statute can form the basis for a violation of the federal False Claims Act (discussed below); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal civil and criminal false claims laws and civil monetary penalties laws, including the federal False
Claims Act, which provides for civil whistleblower or qui tam actions, that impose penalties against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or
fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a referral made in violation
of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit
program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal
Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by HITECH, and its implementing regulations, including the Final Omnibus Rule published in
January 2013, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually
identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information, and require notification to affected individuals and
regulatory authorities of certain breaches of security of individually identifiable health information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or
covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal physician payment transparency requirements, sometimes referred to as the &#147;Sunshine Act&#148;
under the Affordable Care Act, require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#146;s Health Insurance Program to report to the Centers for
Medicare&nbsp;&amp; Medicaid Services, or CMS, information related to transfers of value made to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership
and investment interests of such physicians and their immediate family members. Effective January&nbsp;1, 2022, these reporting obligations will extend to include payments and transfers of value, including ownership interest, made during the
previous year to certain <FONT STYLE="white-space:nowrap">non-physician</FONT> providers such as physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified nurse midwives; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous local, state and foreign laws and regulations, such as state anti-kickback and false claims laws
that may apply to healthcare items or services reimbursed by third party payors, including private insurers; local, state and foreign transparency laws that require manufacturers to report information related to payments and transfers of value to
other healthcare providers and healthcare entities, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
marketing expenditures, or drug pricing; state laws that require pharmaceutical companies to register certain employees engaged in marketing activities in the location and comply with the
pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; and state and foreign laws governing the privacy and security of health information in certain circumstances,
many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ensuring that Surrozen&#146;s future business arrangements with third parties comply with applicable healthcare reporting, privacy, data
protection, cybersecurity and other laws and regulations could involve substantial costs. If Surrozen&#146;s operations are found to be in violation of any such requirements, it may be subject to penalties, including criminal and significant civil
monetary penalties, damages, fines, individual imprisonment, disgorgement, contractual damages, reputational harm, exclusion from participation in government healthcare programs, integrity obligations, injunctions, recall or seizure of products,
total or partial suspension of production, denial or withdrawal of <FONT STYLE="white-space:nowrap">pre-marketing</FONT> product approvals, private qui tam actions brought by individual whistleblowers in the name of the government, refusal to allow
Surrozen to enter into supply contracts, including government contracts, additional reporting requirements and oversight if subject to a corporate integrity agreement or similar agreement to resolve allegations of
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and the curtailment or restructuring of Surrozen&#146;s operations, any of which could adversely affect its ability to operate its business and its results of operations.
Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against Surrozen for an alleged or suspected violation could cause it
to incur significant legal expenses and could divert its management&#146;s attention from the operation of its business, even if its defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be
costly to Surrozen in terms of money, time and resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If Surrozen fails to comply with U.S. and foreign regulatory
requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals it may receive and subject it to other penalties that could materially harm its business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if Surrozen receives marketing and commercialization approval of a product candidate, it will be subject to continuing regulatory
requirements, including in relation to adverse patient experiences with the product and clinical results that are reported after a product is made commercially available, both in the United States and any foreign jurisdiction in which it seeks
regulatory approval. The FDA and other regulatory authorities have significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to
evaluate safety risks related to the use of a product or to require withdrawal of the product candidate from the market. The FDA and other regulatory authorities also have the authority to require a Risk Evaluation and Mitigation Strategy, or a
REMS, after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug or therapeutic biologic. The manufacturer and manufacturing facilities Surrozen uses to make a future product, if any, will
also be subject to periodic review and inspection by the FDA and other regulatory authorities, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with Surrozen&#146;s third-party
manufacturers, manufacturing processes or facilities may result in restrictions on the product candidate, manufacturer or facility, including withdrawal of the product candidate from the market. Surrozen intends to rely on third-party manufacturers
and will not have control over compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. If Surrozen or any of its
existing or future collaborators, manufacturers or service providers fails to comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which Surrozen seeks to market its products, it or they may be subject
to, among other things, fines, warning letters, holds on clinical trials, delay of approval or refusal by the FDA or other regulatory authorities to approve pending applications or supplements to approved applications, suspension or withdrawal of
regulatory approval, product recalls and seizures, administrative detention of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
products, refusal to permit the import or export of products, operating restrictions, injunction, civil penalties and criminal prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if Surrozen is able to commercialize any product candidate, such product candidate may become subject to unfavorable pricing
regulations or third-party coverage and reimbursement policies, which would harm Surrozen&#146;s business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s ability
to commercialize any products successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, such as government authorities, private
health insurers and health maintenance organizations. Patients who are prescribed medications for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs.
Coverage and adequate reimbursement from government healthcare programs, such as Medicare and Medicaid, and private health insurers are critical to new product acceptance. Patients are unlikely to use Surrozen&#146;s future products, if any, unless
coverage is provided and reimbursement is adequate to cover a significant portion of the cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cost-containment is a priority in the U.S.
healthcare industry and elsewhere. As a result, government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are
requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Third-party payors also may request additional clinical evidence beyond the data required to obtain
marketing approval, requiring a company to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of its product. Commercial third-party payors often rely upon Medicare coverage policy and
payment limitations in setting their reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. Therefore, coverage and reimbursement for pharmaceutical products in the U.S. can differ significantly
from payor to payor. Surrozen cannot be sure that coverage and adequate reimbursement will be available for any product that it commercializes and, if reimbursement is available, that the level of reimbursement will be adequate. Coverage and
reimbursement may impact the demand for, or the price of, any product candidate for which Surrozen obtains marketing approval. If coverage and reimbursement are not available or are available only at limited levels, Surrozen may not be able to
successfully commercialize any product candidate for which it obtains marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, the regulations that govern
regulatory approvals, pricing and reimbursement for new drugs and therapeutic biologics vary widely from country to country. Some countries require approval of the sale price of a drug or therapeutic biologic before it can be marketed. In many
countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result,
Surrozen might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay its commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues it is
able to generate from the sale of the product in that country. Adverse pricing limitations may hinder Surrozen&#146;s ability to recoup its investment in one or more product candidates, even if its product candidates obtain regulatory approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen is subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to its operations and <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with such laws can subject it to criminal or civil liability and harm its business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen is subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, the U.S. domestic bribery statute contained in
18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and possibly other state and national anti-bribery and anti-money laundering laws in countries in which Surrozen conducts activities. Anti-corruption laws are interpreted broadly and
prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. Surrozen interacts with officials and employees of government agencies and
government-affiliated hospitals, universities and other organizations. In addition, it may engage third-party intermediaries to promote its clinical research activities abroad or to obtain necessary permits, licenses and other regulatory approvals.
Surrozen can be held liable for the corrupt or other illegal activities of these third-party intermediaries, its employees, representatives, contractors, collaborators, and agents, even if it does not explicitly authorize or have actual knowledge of
such activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Noncompliance with anti-corruption and anti-money laundering laws could subject Surrozen to whistleblower complaints,
investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension or debarment from contracting with certain persons,
the loss of export privileges, reputational harm, adverse media coverage and other collateral consequences. If any subpoenas, investigations or other enforcement actions are launched, or governmental or other sanctions are imposed, or if Surrozen
does not prevail in any possible civil or criminal litigation, its business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of
management&#146;s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause Surrozen to appoint an independent compliance monitor which can result in
added costs and administrative burdens. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Inadequate funding for the FDA, the SEC and other government agencies could hinder their
ability to hire and retain key leadership and other personnel, prevent new product candidates and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on
which the operation of Surrozen&#146;s business may rely, which could negatively impact its business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ability of the FDA to
review and approve new product candidates can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy
changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which Surrozen&#146;s operations may rely, including those that fund research and
development activities, is subject to the political process, which is inherently fluid and unpredictable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Disruptions at the FDA and
other agencies may also slow the time necessary for product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect Surrozen&#146;s business. For example, over the last several years, the U.S.
government has shut down several times, and certain regulatory authorities, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, or if global health concerns
continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process Surrozen&#146;s
regulatory submissions, which could have a material adverse effect on its business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_32"></A>Risks Related to the
Business Combination and CHFW </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Unless the context otherwise requires, any reference in this section of this proxy
statement/prospectus to the &#147;CHFW,&#148; &#147;we,&#148; &#147;us&#148; or &#147;our&#148; refers to CHFW prior to the Business Combination and to New Surrozen following the Business Combination. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our Sponsor and certain other shareholders have entered into letter agreements with us to vote in favor of the Business Combination,
regardless of how our public shareholders vote. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unlike some other blank check companies in which the initial shareholders
agree to vote their shares in accordance with the majority of the votes cast by the public shareholders in connection with an initial business combination, our Sponsor and certain other of our shareholders, pursuant to the Sponsor Letter Agreement
and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the CHFW Shareholder Support Agreements, have agreed, among other things, to vote all of their Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares in favor of all the proposals being
presented at the extraordinary general meeting, including the Business Combination Proposal and the Transactions. As of the date of this proxy statement/prospectus, Sponsor and such shareholders own approximately 33.8% of the issued and outstanding
voting power of CHFW ordinary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Neither the CHFW Board nor any committee thereof obtained a third-party valuation in
determining whether or not to pursue the Business Combination. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither the CHFW Board nor any committee thereof is required to
obtain an opinion from an independent investment banking or accounting firm that the price that CHFW is paying for Surrozen is fair to CHFW from a financial point of view. Neither the CHFW Board nor any committee thereof obtained a third party
valuation in connection with the Business Combination. In analyzing the Business Combination, the CHFW Board and management conducted due diligence on Surrozen and researched the industry in which Surrozen operates. The CHFW Board reviewed, among
other things, an illustrative financial and valuation analysis prepared by management and the financial terms set forth in the Business Combination Agreement, and concluded that the Business Combination was in the best interest of its shareholders.
For more information, please see the section titled &#147;Business Combination Proposal&#151;Background to the Business Combination.&#148; Accordingly, investors will be relying solely on the judgment of the CHFW Board and management in valuing
Surrozen, and the CHFW Board and management may not have properly valued Surrozen&#146;s business. The lack of a third-party valuation may also lead an increased number of shareholders to vote against the Business Combination or demand redemption of
their shares, which could potentially impact our ability to consummate the Business Combination. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>CHFW&#146;s and
Surrozen&#146;s ability to consummate the Business Combination, and the operations of New Surrozen following the Business Combination, may be materially adversely affected by the recent coronavirus <FONT STYLE="white-space:nowrap">(COVID-19)</FONT>
pandemic. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2019, a novel strain of coronavirus was reported to have surfaced in Wuhan, China, which has and is
continuing to spread throughout the world, including the United States. On January&nbsp;30, 2020, the World Health Organization declared the outbreak of <FONT STYLE="white-space:nowrap">COVID-19</FONT> a &#147;Public Health Emergency of
International Concern.&#148; On January&nbsp;31, 2020, the U.S. Department of Health and Human Services declared a public health emergency for the U.S., and on March&nbsp;11, 2020, the World Health Organization characterized the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> outbreak as a &#147;pandemic.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic has resulted, and other infectious diseases could result, in a widespread health crisis that has adversely affected, and could continue to adversely affect the economies and financial markets worldwide, which may delay or prevent the
consummation of the Business Combination, and the business of CHFW, Surrozen or New Surrozen following the Business Combination could be materially and adversely affected. The extent of such impact will depend on future developments, which are
highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and the actions to contain <FONT STYLE="white-space:nowrap">COVID-19</FONT> or treat its
impact, among others. There is no guarantee that efforts by CHFW, Surrozen and New Surrozen to address the adverse impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> will be effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If CHFW or Surrozen are unable to recover from a business disruption on a timely basis, the Business Combination and New Surrozen&#146;s
business and financial conditions and results of operations following the completion of the Business Combination would be adversely affected. The Business Combination may also be delayed and adversely affected by the coronavirus pandemic, and become
more costly. Each of CHFW and Surrozen may also incur additional costs to remedy damages caused by such disruptions, which could adversely affect its financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The parties will be required to consummate the Business Combination even if Surrozen, its business, financial condition and results of
operations are materially affected by <FONT STYLE="white-space:nowrap">COVID-19.</FONT> The disruptions posed by <FONT STYLE="white-space:nowrap">COVID-19</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
have continued, and other matters of global concern may continue, for an extensive period of time. Each of Surrozen and New Surrozen may also incur additional costs due to delays caused by <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> which could adversely affect New Surrozen&#146;s financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Since the initial shareholders, including CHFW&#146;s directors and executive officers, have interests that are different, or in
addition to (and which may conflict with), the interests of our shareholders, a conflict of interest may have existed in determining whether the Business Combination with Surrozen is appropriate as our initial business combination. Such interests
include that Sponsor, as well as our executive officers and directors, will lose their entire investment in us if our business combination is not completed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">When you consider the recommendation of the CHFW Board in favor of approval of the Business Combination Proposal, you should keep in mind that
the initial shareholders, including CHFW&#146;s directors and executive officers, have interests in such proposal that are different from, or in addition to (which may conflict with), those of CHFW shareholders and warrant holders generally. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table details the number of ordinary shares and warrants held by Sponsor, its affiliates and the directors and officers of
CHFW, and quantifies the purchase price and the current value of such securities. The value of such securities could have significantly higher value at the time of, or following, the Business Combination. </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Entity<SUP STYLE="font-size:85%; vertical-align:top">1</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value<SUP STYLE="font-size:85%; vertical-align:top">2</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Promote<BR>shares<SUP STYLE="font-size:85%; vertical-align:top">3</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IPO units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IPO PIPE<BR>units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PIPE<BR>Financing<BR>units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="right">Consonance Capital Management</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of ordinary shares</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,497,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,497,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of warrants</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">832,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,165,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Aggregate Purchase Price</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,975,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,975,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Estimated Current Value</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,223,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,723,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="right">Consonance Life Sciences, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of ordinary shares</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,451,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">434,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,885,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of warrants</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Aggregate Purchase Price</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,340,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,365,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Estimated Current Value</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,510,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,557,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,067,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="right">Donald Santel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of ordinary shares</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of warrants</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Aggregate Purchase Price</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Estimated Current Value</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="right">Christopher Haqq</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of ordinary shares</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of warrants</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Aggregate Purchase Price</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Estimated Current Value</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="right">Jennifer Jarrett</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of ordinary shares</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of warrants</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Aggregate Purchase Price</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Estimated Current Value</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="right"><B>Total</B> <B></B><B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>No. of ordinary shares</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>1,541,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,000,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>434,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,497,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,472,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>No. of warrants</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>333,333</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>144,667</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>832,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,310,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>Aggregate&nbsp;Purchase&nbsp;Price</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>25,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,000,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,340,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>24,975,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>39,3400,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>Estimated Current Value</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>15,410,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,500,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,557,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>26,223,750</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>56,690,751</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="justify">Please see <I>Beneficial Ownership of Securities</I> for details regarding voting and dispositive power of
the securities held by the persons included in this table. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="justify">The Estimated Current Value assumes a $10.00 per share price and a $1.50 price per warrant. As of
June&nbsp;<U></U>22, 2021, the trading price was $<U>9.90</U> per CHFW Class A ordinary share and $1.58 per warrant. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="justify">Net of contributions for no consideration. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="justify">This number is net of (i) 90,000 shares transferred (in the aggregate) to the independent directors of the
CHFW Board, (ii) 759,000 founder shares which will be forfeited for no consideration at the closing of the Business Combination and (iii) 718,750 and 575,000 founder shares previously contributed back to CHFW for no consideration on October 8, 2020
and November 10, 2020. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These interests also include, among other things, the interests listed below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that our initial shareholders have agreed not to redeem any Class&nbsp;A ordinary shares held by them
in connection with a shareholder vote to approve a proposed initial business combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that Sponsor and its affiliates has made a sizable investment in CHFW securities, which securities
would be worthless if a business combination is not consummated by November&nbsp;23, 2022 (unless such date is extended in accordance with the Existing Governing Documents); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the initial shareholders and CHFW&#146;s other current officers and directors have agreed to
waive their rights to liquidating distributions from the trust account, which, as of June&nbsp;22, 2021, included an amount of approximately $92&nbsp;million, with respect to any ordinary shares (other than public shares) held by them if CHFW fails
to complete an initial business combination by November&nbsp;23, 2022; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Investor Rights Agreement will be entered into by the initial shareholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continued indemnification of CHFW&#146;s directors and officers and the continuation of CHFW&#146;s
directors&#146; and officers&#146; liability insurance after the Business Combination (<I>i.e.</I>, a &#147;tail policy&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor and CHFW&#146;s officers and directors will lose their entire investment in CHFW and
will not be reimbursed for any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses if an initial business combination is not consummated by November&nbsp;23, 2022; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that CHFW will reimburse Sponsor for office space, secretarial and administrative services provided
to members of the CHFW founding team, in the amount of $55,000 per month, which payments will cease upon completion of the Business Combination; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that if the trust account is liquidated, including in the event CHFW is unable to complete an initial
business combination by November&nbsp;23, 2022, the Sponsor has agreed to indemnify CHFW to ensure that the proceeds in the trust account are not reduced below $10.00 per public share, or such lesser per public share amount as is in the trust
account on the liquidation date, by the claims of prospective target businesses with which CHFW has entered into an acquisition agreement or claims of any third party for services rendered or products sold to CHFW, but only if such a vendor or
target business has not executed a waiver of any and all rights to seek access to the trust account; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that CHFW may be entitled to distribute or pay over funds held by CHFW outside the trust account to
the Sponsor or any of its Affiliates prior to the Closing. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June 22, 2021, Sponsor and its affiliates have
invested or committed to invest an aggregate of $39.3&nbsp;million, including its commitment with respect to the PIPE Financing and assuming consummation of the Business Combination (the &#147;Total Commitment&#148;). Assuming the issuance of all
securities underlying the Total Commitment and utilizing a per share price of $10.00 and a per warrant value of $1.50, the Total Commitment would have an approximate value of $56.7 million. If the Business Combination is not consummated, Sponsor and
its affiliates will lose approximately $4.3&nbsp;million of their amounts already invested. Although Sponsor and its affiliates have committed considerable capital to CHFW, including through its participation in the CHFW IPO and its contribution of
a portion of the Promote for no consideration, if the Business Combination is consummated, taking into account the investments described above, including the Promote, it is possible that Sponsor and its affiliates could realize a positive rate of
return on such investments even if other CHFW shareholders experience a negative rate of return following the Business Combination. Except as described above, there are no outstanding loans or material fee or reimbursement arrangements among CHFW,
Sponsor, its affiliates, or the CHFW directors or officers. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">See &#147;<I>Business Combination Proposal&#151;Interests of CHFW&#146;s
Directors and Executive Officers in the Business Combination</I>&#148; for additional information on interests of CHFW&#146;s directors and executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The personal and financial interests of the initial shareholders as well as CHFW&#146;s directors and executive officers may have influenced
their motivation in identifying and selecting Surrozen as business combination targets, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
completing an initial business combination with Surrozen and influencing the operation of the business following the initial business combination. In considering the recommendations of the CHFW
Board to vote for the proposals, its shareholders should consider these interests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The exercise of CHFW&#146;s directors&#146; and
executive officers&#146; discretion in agreeing to changes or waivers in the terms of the Business Combination may result in a conflict of interest when determining whether such changes to the terms of the Business Combination or waivers of
conditions are appropriate and in CHFW&#146;s shareholders&#146; best interest. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the period leading up to the closing of the
Business Combination, events may occur that, pursuant to the Business Combination Agreement, would require CHFW to agree to amend the Business Combination Agreement, to consent to certain actions taken by Surrozen or to waive rights that CHFW is
entitled to under the Business Combination Agreement. Such events could arise because of changes in the course of Surrozen&#146;s business, a request by Surrozen to undertake actions that would otherwise be prohibited by the terms of the Business
Combination Agreement or the occurrence of other events that would have a material adverse effect on Surrozen&#146;s business and would entitle CHFW to terminate the Business Combination Agreement. In any of such circumstances, it would be at
CHFW&#146;s discretion, acting through its board of directors, to grant its consent or waive those rights. The existence of financial and personal interests of one or more of the directors described in the preceding risk factors may result in a
conflict of interest on the part of such director(s) between what he, she or they may believe is best for CHFW and its shareholders and what he, she or they may believe is best for himself or themselves in determining whether or not to take the
requested action. As of the date of this proxy statement/prospectus, CHFW does not believe there will be any changes or waivers that CHFW&#146;s directors and executive officers would be likely to make after shareholder approval of the Business
Combination Proposal has been obtained. While certain changes could be made without further shareholder approval, CHFW will circulate a new or amended proxy statement/prospectus and resolicit CHFW&#146;s shareholders if changes to the terms of the
transaction that would have a material impact on its shareholders are required prior to the vote on the Business Combination Proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Subsequent to consummation of the Business Combination, we may be required to subsequently take write-downs or write-offs, restructuring
and impairment or other charges that could have a significant negative effect on our financial condition, results of operations and the share price of our securities, which could cause you to lose some or all of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot assure you that the due diligence conducted in relation to Surrozen has identified all material issues or risks associated with
Surrozen, its business or the industry in which it competes. As a result of these factors, we may incur additional costs and expenses and we may be forced to later write-down or <FONT STYLE="white-space:nowrap">write-off</FONT> assets, restructure
our operations, or incur impairment or other charges that could result in our reporting losses. Even if our due diligence has identified certain risks, unexpected risks may arise and previously known risks may materialize in a manner not consistent
with our preliminary risk analysis. If any of these risks materialize, this could have a material adverse effect on our financial condition and results of operations and could contribute to negative market perceptions about our securities or New
Surrozen. Accordingly, any shareholders of CHFW who choose to remain New Surrozen stockholders following the Business Combination could suffer a reduction in the value of their shares and warrants. Such shareholders are unlikely to have a remedy for
such reduction in value unless they are able to successfully claim that the reduction was due to the breach by our officers or directors of a duty of care or other fiduciary duty owed to them, or if they are able to successfully bring a private
claim under securities laws that the registration statement or proxy statement/prospectus relating to the Business Combination contained an actionable material misstatement or material omission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our warrant agreement designates the courts of the State of New York or the United
States District Court for the Southern District of New York as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by holders of our warrants, which could limit the ability of warrant holders to obtain a
favorable judicial forum for disputes with our company. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our warrant agreement provides that, subject to applicable law,
(i)&nbsp;any action, proceeding or claim against us arising out of or relating to the warrant agreement, including under the Securities Act, will be brought and enforced in the courts of the State of New York or the United States District Court for
the Southern District of New York, and (ii)&nbsp;that we irrevocably submit to such jurisdiction, which jurisdiction will be the exclusive forum for any such action, proceeding or claim. We will waive any objection to such exclusive jurisdiction and
that such courts represent an inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing, these provisions of the warrant agreement do not apply
to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal district courts of the United States of America are the sole and exclusive forum. Any person or entity purchasing or otherwise
acquiring any interest in any of our warrants will be deemed to have notice of and to have consented to the forum provisions in our warrant agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If any action, the subject matter of which is within the scope of the forum provisions of the warrant agreement, is filed in a court other
than a court of the State of New York or the United States District Court for the Southern District of New York (a &#147;foreign action&#148;) in the name of any holder of our warrants, such holder will be deemed to have consented to: (x)&nbsp;the
personal jurisdiction of the state and federal courts located in the State of New York in connection with any action brought in any such court to enforce the forum provisions (an &#147;enforcement action&#148;), and (y)&nbsp;having service of
process made upon such warrant holder in any such enforcement action by service upon such warrant holder&#146;s counsel in the foreign action as agent for such warrant holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">choice-of-forum</FONT></FONT> provision may limit a warrant
holder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with our company, which may discourage such lawsuits. Alternatively, if a court were to find this provision of our warrant agreement inapplicable or
unenforceable with respect to one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could materially and adversely affect our business,
financial condition and results of operations and result in a diversion of the time and resources of our management and board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our ability to successfully effect the Business Combination and to be successful thereafter will be dependent upon the efforts of key
personnel of New Surrozen, some of whom may be from CHFW and Surrozen, and some of whom may join New Surrozen following the Business Combination. The loss of key personnel or the hiring of ineffective personnel after the Business Combination could
negatively impact the operations and profitability of New Surrozen. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our ability to successfully effect the Business Combination
and be successful thereafter will be dependent upon the efforts of our and New Surrozen&#146;s key personnel. Although some of CHFW&#146;s key personnel may remain with the target business in senior management or advisory positions following our
business combination, we expect New Surrozen&#146;s current management to remain in place. We cannot assure you that we will be successful in integrating and retaining such key personnel, or in identifying and recruiting additional key individuals
we determine may be necessary following the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The unaudited pro forma financial information included elsewhere
in this proxy statement/prospectus may not be indicative of what New Surrozen&#146;s actual financial position or results of operations would have been. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The unaudited pro forma financial information in this proxy statement/prospectus is presented for illustrative purposes only and has been
prepared based on a number of assumptions including, but not limited to, Surrozen being considered the accounting acquirer in the Business Combination, the cash and cash equivalents of Surrozen </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
at the Closing and the number of public shares that are redeemed in connection with the Business Combination. Accordingly, such pro forma financial information may not be indicative of our future
operating or financial performance and our actual financial condition and results of operations may vary materially from our pro forma results of operations and balance sheet contained elsewhere in this proxy statement/prospectus, including as a
result of such assumptions not being accurate. Additionally, the final acquisition accounting adjustments could differ materially from the unaudited pro forma adjustments presented in this proxy statement/prospectus. See &#147;<I>Unaudited Pro Forma
Condensed Combined Financial Information</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>There is no assurance that the Aggregate Transaction Proceeds of our initial
public offering and the private placement will be sufficient to allow us to complete the Business Combination or, even if the condition is satisfied, that the funds will be sufficient to fund the operations of New Surrozen for at least the next 12
months. Further, if we are unable to complete our initial business combination, our public shareholders may receive only approximately $10.00 per public share, or less in certain circumstances, on the liquidation of our trust account and our
warrants will expire worthless. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we believe that the Aggregate Transaction Proceeds will be sufficient to satisfy the $100
million Aggregate Transaction Proceeds Condition to closing of the Business Combination, there is no assurance that the Aggregate Transaction Proceeds will be sufficient to allow us to complete the Business Combination or, even if the condition is
satisfied, that the funds will be sufficient to fund the operations of New Surrozen for at least the next 12 months. We may be required to seek additional financing or to abandon the proposed Business Combination if we are not able to satisfy the
Aggregate Transaction Proceeds Condition either because we have redemptions that exceed our expectations or one or more of our PIPE investors fails to purchase securities of New Surrozen notwithstanding their commitments in the Subscription
Agreements. To the extent that additional financing proves to be unavailable when needed to complete our the Business Combination, we would be compelled to either restructure the transaction or abandon the Business Combination and seek an
alternative partner business candidate. If we do not complete our initial business combination within the required time period, our public shareholders may receive only approximately $10.00 per public share, or less in certain circumstances, on the
liquidation of our trust account and our warrants will expire worthless. In addition, even if we do not need additional financing to complete our Business Combination, we may require such financing to fund the operations or growth of New Surrozen.
The failure to secure additional financing could have a material adverse effect on the continued development or growth of the New Surrozen&#146;s business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may amend the terms of the warrants in a manner that may be adverse to holders of public warrants with the approval by the holders of
at least 50% of the then outstanding public warrants. As a result, the exercise price of your warrants could be increased, the exercise period could be shortened and the number of our Class&nbsp;A ordinary shares purchasable upon exercise of a
warrant could be decreased, all without your approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The warrant agreement between Continental Stock Transfer&nbsp;&amp; Trust
Company, as warrant agent, and us provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision or correct any mistake, including to conform the provisions of the
warrant agreement to the description of the terms of the warrants and the warrant agreement set forth in our other filings with the SEC, but requires the approval by the holders of at least 50% of the then-outstanding public warrants to make any
change that adversely affects the interests of the registered holders of public warrants. Accordingly, we may amend the terms of the public warrants in a manner adverse to a holder if holders of at least 50% of the then-outstanding public warrants
approve of such amendment and, solely with respect to any amendment to the terms of the private placement warrants or any provision of the warrant agreement with respect to the private placement warrants, 50% of the number of the then outstanding
private placement warrants. Although our ability to amend the terms of the public warrants with the consent of at least 50% of the then-outstanding public warrants is unlimited, examples of such amendments could be amendments to, among other things,
increase the exercise price of the warrants, convert the warrants into cash, shorten the exercise period or decrease the number of Class&nbsp;A ordinary shares purchasable upon exercise of a warrant. We may redeem your unexpired warrants prior to
their exercise at a time that is disadvantageous to you, thereby making your warrants worthless. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>A provision of our warrant agreement may make it more difficult for us to consummate
an initial business combination. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If (x)&nbsp;we issue additional Class&nbsp;A ordinary shares or equity linked securities for
capital raising purposes in connection with the closing of the Business Combination at an issue price or effective issue price of less than $9.20 per Class&nbsp;A ordinary share (with such issue price or effective issue price to be determined in
good faith by our board of directors and, in the case of any such issuance to our initial shareholders or their affiliates, without taking into account any founder shares held by our initial shareholders or such affiliates, as applicable, prior to
such issuance including any transfer or reissuance of such shares), (y)&nbsp;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial
business combination, and (z)&nbsp;the volume-weighted average trading price of our Class&nbsp;A ordinary shares during the 10 trading day period starting on the trading day after the day on which we consummate our initial business combination (such
price, the &#147;Market Value&#148;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the Market Value, and the $10.00 and $18.00 per share redemption trigger prices of the
warrants will be adjusted (to the nearest cent) to be equal to 100% and 180% of the Market Value, respectively. This may make it more difficult for us to consummate the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our warrant agreement designates the courts of the State of New York or the U.S. District Court for the Southern District of New York as
the sole and exclusive forum for certain types of actions and proceedings that may be initiated by holders of our warrants, which could limit the ability of warrant holders to obtain a favorable judicial forum for disputes with our company.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our warrant agreement provides that, subject to applicable law, (i)&nbsp;any action, proceeding or claim against us arising out of
or relating in any way to the warrant agreement, including under the Securities Act, will be brought and enforced in the courts of the State of New York or the U.S. District Court for the Southern District of New&nbsp;York, and (ii)&nbsp;that we
irrevocably submit to such jurisdiction, which jurisdiction shall be the exclusive forum for any such action, proceeding or claim. We will waive any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing, these provisions of the warrant agreement do not apply to suits brought to enforce any liability or duty
created by the Exchange Act or any other claim for which the federal district courts of the U.S. of America are the sole and exclusive forum. Any person or entity purchasing or otherwise acquiring any interest in any of our warrants shall be deemed
to have notice of and to have consented to the forum provisions in our warrant agreement. If any action, the subject matter of which is within the scope of the forum provisions of the warrant agreement, is filed in a court other than a court of the
State of New York or the U.S. District Court for the Southern District of New York (a &#147;foreign action&#148;) in the name of any holder of our warrants, such holder shall be deemed to have consented to: (x)&nbsp;the personal jurisdiction of the
state and federal courts located in the State of New York in connection with any action brought in any such court to enforce the forum provisions (an &#147;enforcement action&#148;), and (y)&nbsp;having service of process made upon such warrant
holder in any such enforcement action by service upon such warrant holder&#146;s counsel in the foreign action as agent for such warrant holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">choice-of-forum</FONT></FONT> provision may limit a warrant
holder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with our company, which may discourage such lawsuits. Alternatively, if a court were to find this provision of our warrant agreement inapplicable or
unenforceable with respect to one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could materially and adversely affect our business,
financial condition and results of operations and result in a diversion of the time and resources of our founding team and board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may redeem your unexpired warrants prior to their exercise at a time that is
disadvantageous to you, thereby making your warrants worthless. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have the ability to redeem the outstanding warrants at any time
after they become exercisable and prior to their expiration, at a price of $0.01 per warrant, if, among other things, the Reference Value equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations,
recapitalizations and the like). If and when the warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws.
Redemption of the outstanding warrants as described above could force you to (i)&nbsp;exercise your warrants and pay the exercise price therefor at a time when it may be disadvantageous for you to do so, (ii)&nbsp;sell your warrants at the
then-current market price when you might otherwise wish to hold your warrants or (iii)&nbsp;accept the nominal redemption price which, at the time the outstanding warrants are called for redemption, we expect would be substantially less than the
Market Value of your warrants. None of the private placement warrants will be redeemable by us so long as they are held by our Sponsor or their permitted transferees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we have the ability to redeem the outstanding warrants at any time after they become exercisable and prior to their expiration,
at a price of $0.10 per warrant if, among other things, the Reference Value equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like). In such
a case, the holders will be able to exercise their warrants prior to redemption for a number of shares of our Class&nbsp;A ordinary shares determined based on the redemption date and the fair market value of our Class&nbsp;A ordinary shares. The
value received upon exercise of the warrants (1)&nbsp;may be less than the value the holders would have received if they had exercised their warrants at a later time where the underlying share price is higher and (2)&nbsp;may not compensate the
holders for the value of the warrants, including because the number of ordinary shares received is capped at 0.361 shares of our Class&nbsp;A ordinary shares per warrant (subject to adjustment) irrespective of the remaining life of the warrants.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The ability of our public shareholders to exercise redemption rights with respect to a large number of our public shares may not
allow us to complete the most desirable business combination or optimize the capital structure of New Surrozen. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At the time of
entering into the Business Combination Agreement, we did not know how many shareholders may exercise their redemption rights, and therefore, we needed to structure the transaction based on our expectations as to the number of shares that will be
submitted for redemption. The consummation of the Business Combination is conditioned upon, among other things, (i)&nbsp;the approval of the Condition Precedent Proposals being obtained; (ii)&nbsp;CHFW having at least $5,000,001 of net tangible
assets (as determined in accordance with Rule <FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange Act) after giving effect to the transactions contemplated by the Business Combination Agreement and the PIPE Financing, (iii)&nbsp;the
aggregate cash proceeds from CHFW&#146;s trust account, together with the proceeds from the PIPE Financing, equaling no less than $100,000,000 (after deducting any amounts paid to CHFW shareholders who exercise their redemption rights in connection
with the Business Combination, and net of certain CHFW unpaid transaction liabilities and expenses (iv)&nbsp;the approval by Nasdaq of our initial listing application in connection with the Business Combination; and (v)&nbsp;the consummation of the
Domestication . Therefore, unless these conditions are waived by the applicable parties to the Business Combination Agreement, the Business Combination Agreement could terminate and the Business Combination may not be consummated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Sponsor, as well as Surrozen, our directors, executive officers, advisors and their affiliates may elect to purchase public shares prior
to the consummation of the Business Combination, which may influence the vote on the Business Combination and reduce the public &#147;float&#148; of our Class&nbsp;A ordinary shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At any time at or prior to the Business Combination, during a period when they are not then aware of any material nonpublic information
regarding us or our securities, our initial shareholders, Surrozen and/or their directors, officers, advisors or respective affiliates may purchase public shares from institutional and other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
investors who vote, or indicate an intention to vote, against any of the Condition Precedent Proposals, or execute agreements to purchase such shares from such investors in the future, or they
may enter into transactions with such investors and others to provide them with incentives to acquire public shares or vote their public shares in favor of the Condition Precedent Proposals. Such a purchase may include a contractual acknowledgement
that such shareholder, although still the record or beneficial holder of our shares, is no longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights. In the event that our initial shareholders, Surrozen and/or
their directors, officers, advisors or respective affiliates purchase shares in privately negotiated transactions from public shareholders who have already elected to exercise their redemption rights, such selling shareholder would be required to
revoke their prior elections to redeem their shares. The purpose of such share purchases and other transactions would be to increase the likelihood of satisfaction of the requirements that (i)&nbsp;the Business Combination Proposal, the Governing
Documents Proposal A, the Share Issuance Proposal, the Incentive Award Plan Proposal, the Employee Stock Purchase Plan Proposal and the Adjournment Proposal are approved by the affirmative vote of at least a majority of the votes cast by the holders
of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter, (ii)&nbsp;the Domestication Proposal, the New Organizational Documents Proposal, the Governing
Documents Proposal B, the Governing Documents Proposal C and the Governing Documents Proposal D are approved by the affirmative vote of at least a <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) majority of the votes cast by the holders of
the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter, (iii)&nbsp;otherwise limit the number of public shares electing to redeem and (iv)&nbsp;New
Surrozen&#146;s net tangible assets (as determined in accordance with Rule <FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange Act) being at least $5,000,001 after giving effect to the transactions contemplated by the Business
Combination Agreement and the PIPE Financing. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Entering into any such arrangements may have a depressive effect on the ordinary
shares. For example, as a result of these arrangements, an investor or holder may have the ability to effectively purchase shares at a price lower than market and may therefore be more likely to sell the shares he or she owns, either at or prior to
the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If such transactions are effected, the consequence could be to cause the Business Combination to be consummated
in circumstances where such consummation could not otherwise occur. Purchases of shares by the persons described above would allow them to exert more influence over the approval of the proposals to be presented at the extraordinary general meeting
and would likely increase the chances that such proposals would be approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, if such purchases are made, the public
&#147;float&#148; of our public shares and the number of beneficial holders of our securities may be reduced, possibly making it difficult to maintain or obtain the quotation, listing or trading of our securities on a national securities exchange.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If third parties bring claims against us, the proceeds held in the trust account could be reduced and the per share redemption
amount received by shareholders may be less than $10.00 per share (which was the offering price in our initial public offering). </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our placing of funds in the trust account may not protect those funds from third-party claims against us. Although we will seek to have all
vendors, service providers (other than our independent registered public accounting firm), prospective target businesses or other entities with which we do business execute agreements with us waiving any right, title, interest or claim of any kind
in or to any monies held in the trust account, there is no guarantee that they will execute such agreements or even if they execute such agreements that they would be prevented from bringing claims against the trust account, including, but not
limited to, fraudulent inducement, breach of fiduciary responsibility or other similar claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain advantage with respect to a claim against our assets,
including the funds held in the trust account. If any third party refuses to execute an agreement waiving such claims to the monies held in the trust account, our management will perform an analysis of the alternatives available to it and will only
enter into an agreement with a third party that has not executed a waiver if management believes that such third party&#146;s engagement would be significantly more beneficial to us than any alternative. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Examples of possible instances where we may engage a third party that refuses to execute a
waiver include the engagement of a third party consultant whose particular expertise or skills are believed by management to be significantly superior to those of other consultants that would agree to execute a waiver or in cases where management is
unable to find a service provider willing to execute a waiver. In addition, there is no guarantee that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts or
agreements with us and will not seek recourse against the trust account for any reason. Upon redemption of our public shares, if we are unable to complete our business combination within the prescribed time frame, or upon the exercise of a
redemption right in connection with our business combination, we will be required to provide for payment of claims of creditors that were not waived that may be brought against us within the ten years following redemption. Accordingly, the per share
redemption amount received by public shareholders could be less than the $10.00 per share initially held in the trust account, due to claims of such creditors. In order to protect the amounts held in the trust account, Sponsor has agreed to be
liable to us if and to the extent any claims by a vendor for services rendered or products sold to us, or a prospective target business with which we have discussed entering into a transaction agreement, reduces the amount of funds in the trust
account. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the trust account or to any claims under our indemnity of the
underwriters of our initial public offering against certain liabilities, including liabilities under the Securities Act. Moreover, even in the event that an executed waiver is deemed to be unenforceable against a third party, Sponsor will not be
responsible to the extent of any liability for such third party claims. We have not independently verified whether Sponsor has sufficient funds to satisfy its indemnity obligations and we have not asked Sponsor to reserve for such indemnification
obligations. Therefore, we cannot assure you that Sponsor would be able to satisfy those obligations. None of our officers will indemnify us for claims by third parties including, without limitation, claims by vendors and prospective target
businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, if we are forced to file a bankruptcy case or an involuntary bankruptcy case is filed against us which is not
dismissed, or if we otherwise enter compulsory or court supervised liquidation, the proceeds held in the trust account could be subject to applicable bankruptcy law, and may be included in our bankruptcy estate and subject to the claims of third
parties with priority over the claims of our shareholders. To the extent any bankruptcy claims deplete the trust account, we may not be able to return to our public shareholders $10.00 per share (which was the offering price in our initial public
offering). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If, after we distribute the proceeds in the trust account to our public shareholders, we file a bankruptcy petition or
an involuntary bankruptcy petition is filed against us that is not dismissed, a bankruptcy court may seek to recover such proceeds, and we and our board of directors may be exposed to claims of punitive damages. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If, after we distribute the proceeds in the trust account to our public shareholders, we file a bankruptcy petition or an involuntary
bankruptcy petition is filed against us that is not dismissed, any distributions received by shareholders could be viewed under applicable debtor/creditor and/or bankruptcy laws as either a &#147;preferential transfer&#148; or a &#147;fraudulent
conveyance.&#148; As a result, a bankruptcy court could seek to recover all amounts received by our shareholders. In addition, our board of directors may be viewed as having breached its fiduciary duty to our creditors and/or having acted in bad
faith, thereby exposing it and us to claims of punitive damages, by paying public shareholders from the trust account prior to addressing the claims of creditors. We cannot assure you that claims will not be brought against us for these reasons.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If, before distributing the proceeds in the trust account to our public shareholders, we file a bankruptcy petition or an
involuntary bankruptcy petition is filed against us that is not dismissed, the claims of creditors in such proceeding may have priority over the claims of our shareholders and the per share amount that would otherwise be received by our shareholders
in connection with our liquidation may be reduced. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If, before distributing the proceeds in the trust account to our public
shareholders, we file a bankruptcy petition or an involuntary bankruptcy petition is filed against us that is not dismissed, the proceeds held in the trust account </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
could be subject to applicable bankruptcy law, and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our shareholders. To the
extent any bankruptcy claims deplete the trust account, the per share amount that would otherwise be received by our shareholders in connection with our liquidation may be reduced. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our shareholders may be held liable for claims by third parties against us to the extent of distributions received by them upon
redemption of their shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are forced to enter into an insolvent liquidation, any distributions received by shareholders
could be viewed as an unlawful payment if it was proved that immediately following the date on which the distribution was made, we were unable to pay our debts as they fall due in the ordinary course of business. As a result, a liquidator could seek
to recover all amounts received by our shareholders. Furthermore, our directors may be viewed as having breached their fiduciary duties to us or our creditors and/or may have acted in bad faith, and thereby exposing themselves and our company to
claims, by paying public shareholders from the trust account prior to addressing the claims of creditors. Claims may be brought against us for these reasons. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are an emerging growth company and a smaller reporting company within the meaning of the Securities Act, and if we take advantage of
certain exemptions from disclosure requirements available to &#147;emerging growth companies&#148; or &#147;smaller reporting companies,&#148; this could make our securities less attractive to investors and may make it more difficult to compare our
performance with other public companies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are an &#147;emerging growth company&#148; within the meaning of the Securities Act,
as modified by the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#147;emerging growth companies&#148; including, but not limited to, not
being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the
requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. As a result, our shareholders may not have access to certain information they may deem
important. We could be an emerging growth company for up to five years, although circumstances could cause us to lose that status earlier, including if the market value of our Class&nbsp;A ordinary shares held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of any June&nbsp;30 before that time, in which case we would no longer be an emerging growth company as of the following December 31. We cannot predict whether
investors will find our securities less attractive because we will rely on these exemptions. If some investors find our securities less attractive as a result of our reliance on these exemptions, the trading prices of our securities may be lower
than they otherwise would be, there may be a less active trading market for our securities and the trading prices of our securities may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial
accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or
revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies
but any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, we,
as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with another public company which is neither an emerging
growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, we are a &#147;smaller reporting company&#148; as defined in Item 10(f)(1) of Regulation
<FONT STYLE="white-space:nowrap">S-K.</FONT> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i)&nbsp;the market value of our
ordinary shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $250&nbsp;million as of the prior June&nbsp;30, or (ii)&nbsp;our annual revenues exceeded $100&nbsp;million during such completed fiscal year and the market value
of our ordinary shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June 30. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our
financial statements with other public companies difficult or impossible. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>You may not have the same benefits as an investor in
an underwritten public offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Like other business combination transactions and spin-offs, in connection with the Business
Combination, you will not receive the benefits of due diligence review that would be performed by the underwriters and their advisors in an underwritten public offering. Investors in an underwritten public offering may benefit from the role of the
underwriters in such an offering. In an underwritten public offering, an issuer initially sells its securities to the public market via one or more underwriters, who distribute or resell such securities to the public. Underwriters have liability
under the U.S. securities laws for material misstatements or omissions in a registration statement pursuant to which an issuer sells securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because the underwriters have a defense to any such liability by, among other things, conducting a reasonable investigation, the underwriters
and their counsel conduct a &#147;due diligence&#148; investigation of the issuer and the statements made or incorporated in the prospectus. Due diligence entails engaging legal, financial and/or other experts to perform an investigation as to the
accuracy of an issuer&#146;s disclosure regarding, among other things, its business and financial results. The independent registered public accounting firm of the issuer also will deliver a &#147;comfort&#148; letter with respect to the financial
information contained in the registration statement. Additionally, negative assurance letters from counsel with respect to the accuracy of the disclosure are customarily provided. In making their investment decision, investors in underwritten public
offerings have the benefit of such diligence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In contrast, CHFW and Surrozen each have engaged a financial advisor (rather than
underwriters) in connection with the Business Combination. The role of a financial advisor typically differs from that of an underwriter. For example, financial advisors do not act as intermediaries in the public sale of securities and therefore do
not face the same potential liability under the U.S. securities laws as underwriters. As a result, financial advisors typically do not undertake the same level of, or any, due diligence investigation of the issuer as is typically undertaken by
underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this proxy statement/prospectus, no parties other than CHFW and Surrozen have conducted an investigation
of the disclosure contained herein. In addition, as an unaffiliated investor, you will not be afforded the opportunity to perform your own due diligence investigation of, or otherwise obtain information on, CHFW or Surrozen beyond the information
that is contained in this proxy statement/prospectus (or is otherwise publicly available). You therefore may not have the benefit of the same level of review as an investor in an underwritten public offering, who has the benefit of the
underwriters&#146; evaluation and due diligence investigation of the issuer. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Compliance obligations under the Sarbanes-Oxley
Act may make it more difficult for us to effectuate the Business Combination, require substantial financial and management resources and increase the time and costs of completing a business combination. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fact that we are a blank check company makes compliance with the requirements of the Sarbanes-Oxley Act particularly burdensome on us as
compared to other public companies. Surrozen is not a publicly reporting company required to comply with Section&nbsp;404 of the Sarbanes-Oxley Act and New Surrozen management may not be able to effectively and timely implement controls and
procedures that adequately respond to the increased regulatory compliance and reporting requirements that will be applicable to New Surrozen after the Business Combination. If we are not able to implement the requirements of Section&nbsp;404,
including any additional requirements once we are no longer an emerging growth company, in a timely manner or with adequate compliance, we may not be able to assess whether its internal control over financial reporting are effective,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
which may subject us to adverse regulatory consequences and could harm investor confidence and the market price of New Surrozen Common Stock. Additionally, once we are no longer an emerging
growth company, we will be required to comply with the independent registered public accounting firm attestation requirement on our internal control over financial reporting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The price of New Surrozen Common Stock and New Surrozen&#146;s warrants may be volatile. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon consummation of the Business Combination, the price of New Surrozen Common Stock and New Surrozen&#146;s warrants may fluctuate due to a
variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the industries in which New Surrozen and its customers operate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in its operating performance and the performance of its competitors in general;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">material and adverse impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the markets
and the broader global economy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated fluctuations in New Surrozen&#146;s quarterly or annual operating results;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of research reports by securities analysts about New Surrozen or its competitors or its industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the public&#146;s reaction to New Surrozen&#146;s press releases, its other public announcements and its
filings with the SEC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New Surrozen&#146;s failure or the failure of its competitors to meet analysts&#146; projections or guidance
that New Surrozen or its competitors may give to the market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions and departures of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in laws and regulations affecting its business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commencement of, or involvement in, litigation involving New Surrozen; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in New Surrozen&#146;s capital structure, such as future issuances of securities or the incurrence of
additional debt; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the volume of shares of New Surrozen Common Stock available for public sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic and political conditions such as recessions, interest rates, fuel prices, foreign currency
fluctuations, international tariffs, social, political and economic risks and acts of war or terrorism. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These market
and industry factors may materially reduce the market price of New Surrozen Common Stock and New Surrozen&#146;s warrants regardless of the operating performance of New Surrozen. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>A significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the near
future. This could cause the market price of New Surrozen Common Stock to drop significantly, even if New Surrozen&#146;s business is doing well. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales of a substantial number of shares of New Surrozen Common Stock in the public market could occur at any time. These sales, or the
perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of New Surrozen Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is anticipated that, following the Business Combination (1)&nbsp;CHFW&#146;s public shareholders are expected to own approximately 21.3% of
the outstanding New Surrozen Common Stock (excluding the PIPE subscriptions by certain CHFW public shareholders), (2) Surrozen Stockholders (without taking into account any public shares held by Surrozen Stockholders prior to the consummation of the
Business Combination or shares of New </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Surrozen Common Stock issuable to holders of New Surrozen Awards, but taking into account the PIPE subscriptions by certain Surrozen Stockholders) are expected to own approximately 53.5% of the
outstanding New Surrozen Common Stock, (3)&nbsp;the Sponsor (taking into account Sponsor&#146;s PIPE subscription) is expected to own approximately 10.4% of the outstanding New Surrozen Common Stock and (4)&nbsp;the PIPE Investors (excluding
subscriptions from Surrozen Stockholders and from the Sponsor) are expected to own approximately 14.8% of the outstanding New Surrozen Common Stock. These&nbsp;percentages assume (i)&nbsp;that no public shareholders exercise their redemption rights
in connection with the Business Combination, (ii)&nbsp;no exercise of the public warrants or issuance of any shares of New Surrozen Common Stock, (iii)&nbsp;that (x)&nbsp;New Surrozen issues or reserves 20,000,000 shares of New Surrozen Common Stock
to Surrozen Stockholders and holders of vested and unvested Surrozen equity awards as part of the Merger consideration pursuant to the Business Combination Agreement and (y)&nbsp;New Surrozen issues 12,020,000 shares of New Surrozen Common Stock to
the PIPE Investors pursuant to the PIPE Investment. If the actual facts are different from these assumptions, the&nbsp;percentage ownership retained by current CHFW shareholders and Surrozen Stockholders will be different. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although certain holders of shares of New Surrozen Common Stock will be subject to certain restrictions regarding the transfer of New Surrozen
Common Stock, these shares may be sold after the expiration of the respective applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> under the Investor Rights Agreement. We intend to file one or more registration statements prior to or shortly
after the closing of the Business Combination to provide for the resale of such shares from time to time. As restrictions on resale end and the registration statements are available for use, the market price of New Surrozen Common Stock could
decline if the holders of currently restricted shares sell them or are perceived by the market as intending to sell them. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The
public stockholders will experience immediate dilution as a consequence of the issuance of New Surrozen Common Stock as consideration in the Business Combination and in the PIPE Financing. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with the terms and subject to the conditions of the Business Combination Agreement, at the Effective Time, each share and vested
equity award (whether vested or unvested) of Surrozen outstanding as of immediately prior to the Effective Time will be exchanged for shares of New Surrozen Common Stock or comparable vested or unvested equity awards that are settled or are
exercisable for shares of New Surrozen Common stock, as applicable, based on an implied Surrozen equity value of $200,000,000 and a $10.00 per share value for New Surrozen Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The issuance of additional common stock will significantly dilute the equity interests of existing holders of CHFW securities, and may
adversely affect prevailing market prices for the New Surrozen Common Stock and/or the New Surrozen warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the holders of
Surrozen capital stock who have not waived appraisal rights and who do not vote in the favor of the Merger under Delaware law will be entitled to exercise appraisal rights in connection with the Merger. The Surrozen Supporting Stockholders who own
more than 67% of the outstanding capital stock have waived their appraisal rights. If any Surrozen Stockholders elect to exercise appraisal rights they could reduce the cash resources of New Surrozen and cause New Surrozen to incur significant
additional expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Warrants will become exercisable for New Surrozen Common Stock, which would increase the number of shares
eligible for future resale in the public market and result in dilution to our stockholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the Business Combination, including
the PIPE Financing, is completed, outstanding warrants to purchase an aggregate of approximately 7.2 million shares of New Surrozen Common Stock will become exercisable in accordance with the terms of the warrant agreements governing those
securities. These warrants will become exercisable 30 days after the completion of the Business Combination. The exercise price of these warrants will be $11.50 per share. To the extent such warrants are exercised, additional shares of New Surrozen
Common Stock will be issued, which will result in dilution to the holders of New Surrozen Common Stock and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
public market or the fact that such warrants may be exercised could adversely affect the market price of New Surrozen Common Stock. However, there is no guarantee that the public warrants will
ever be in the money prior to their expiration, and as such, the warrants may expire worthless. See &#147;<I>&#151;Even if the Business Combination is consummated, the public warrants may never</I> <I>be in the money, and they may expire worthless
and the terms of the warrants may be amended in a manner adverse to a holder if holders of at least 50% of the then outstanding public warrants approve of such amendment</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if the Business Combination is consummated, the public warrants may never be in the money, and they may expire worthless and the
terms of the warrants may be amended in a manner adverse to a holder if holders of at least 50% of the then outstanding public warrants approve of such amendment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The warrants were issued in registered form under a warrant agreement between Continental Stock Transfer&nbsp;&amp; Trust Company, as warrant
agent, and CHFW. The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision or correct any mistake, but requires the approval by the holders
of at least 50% of the then-outstanding public warrants to make any change that adversely affects the interests of the registered holders of public warrants. Accordingly, we may amend the terms of the public warrants in a manner adverse to a holder
if holders of at least 50% of the then-outstanding public warrants approve of such amendment and, solely with respect to any amendment to the terms of the private placement warrants or any provision of the warrant agreement with respect to the
private placement warrants, 50% of the number of the then outstanding private placement warrants. Although our ability to amend the terms of the public warrants with the consent of at least 50% of the then-outstanding public warrants is unlimited,
examples of such amendments could be amendments to, among other things, increase the exercise price of the warrants, convert the warrants into cash, shorten the exercise period or decrease the number of shares of New Surrozen Common Stock
purchasable upon exercise of a warrant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may redeem your unexpired warrants prior to their exercise at a time that is
disadvantageous to you, thereby making your warrants worthless. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have the ability to redeem outstanding warrants at any time
after they become exercisable and prior to their expiration, at a price of $0.01 per warrant upon a minimum of 30 days&#146; prior written notice of redemption, provided that (i)&nbsp;the last reported sales price of the New Surrozen Common Stock
equals or exceeds $18.00 per share (as adjusted for share subdivisions, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20 trading days within a 30
<FONT STYLE="white-space:nowrap">trading-day</FONT> period ending on the third trading day prior to the date we send the notice of redemption to the warrant holders and (ii)&nbsp;there is an effective registration statement covering the issuance of
the underlying securities issuable upon exercise of the warrants, and a current prospectus relating thereto, available throughout the <FONT STYLE="white-space:nowrap">30-day</FONT> period prior to the date of redemption. Redemption of the
outstanding warrants could force you to: (x)&nbsp;exercise your warrants and pay the exercise price therefor at a time when it may be disadvantageous for you to do so; (y)&nbsp;sell your warrants at the then-current market price when you might
otherwise wish to hold your warrants; or (z)&nbsp;accept the nominal redemption price which, at the time the outstanding warrants are called for redemption, is likely to be substantially less than the market value of your warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we may redeem your warrants at any time after they become exercisable and prior to their expiration at a price of $0.10 per
warrant upon a minimum of 30 days&#146; prior written notice of redemption, provided that (i)&nbsp;the last reported sales price of the New Surrozen Common Stock equals or exceeds $10.00 per share (as adjusted for share subdivisions, share
dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20 trading days within a 30 <FONT STYLE="white-space:nowrap">trading-day</FONT> period ending on the third trading day prior to the date we send the
notice of redemption to the warrant holders, (ii)&nbsp;if the last reported sales price of the New Surrozen Common Stock is less than $18.00 per share (as adjusted for share subdivisions, share dividends, rights issuances, subdivisions,
reorganizations, recapitalizations and the like) for any 20 trading days within a 30 <FONT STYLE="white-space:nowrap">trading-day</FONT> period ending on the third trading day prior to the date we send the notice of redemption to the warrant
holders, the private placement warrants are also concurrently called for redemption on the same terms as the outstanding public warrants and (iii)&nbsp;holders will be able to exercise their warrants prior to redemption for a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
number of Class&nbsp;A ordinary shares determined based on the redemption date and the fair market value of our Class&nbsp;A ordinary shares and in accordance with the table reflected in
Section&nbsp;6.2 of the warrant agreement governing the terms of each public warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The value received upon exercise of the warrants
(1)&nbsp;may be less than the value the holders would have received if they had exercised their warrants at a later time where the underlying share price is higher and (2)&nbsp;may not compensate the holders for the value of the warrants, including
because the number of ordinary shares received is capped at 0.361 Class&nbsp;A ordinary shares per warrant (subject to adjustment) irrespective of the remaining life of the warrants. None of the private placement warrants will be redeemable by us,
subject to certain circumstances, so long as they are held by our Sponsor or its permitted transferees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Nasdaq may not list New
Surrozen&#146;s securities on its exchange, which could limit investors&#146; ability to make transactions in New Surrozen&#146;s securities and subject New Surrozen to additional trading restrictions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares of CHFW are currently listed for trading on the New York Stock Exchange Americas market but the Business Combination Agreement provides
that we will move the listing to Nasdaq in connection with the closing of the Business Combination. An active trading market for New Surrozen&#146;s securities following the Business Combination may never develop or, if developed, it may not be
sustained. In connection with the Business Combination, in order to continue to maintain the listing of our securities on Nasdaq, we will be required to demonstrate compliance with Nasdaq&#146;s listing requirements. We will apply to have New
Surrozen&#146;s securities listed on Nasdaq upon consummation of the Business Combination. We cannot assure you that we will be able to meet all listing requirements. Even if New Surrozen&#146;s securities are listed on Nasdaq, New Surrozen may be
unable to maintain the listing of its securities in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If New Surrozen fails to meet the listing requirements and Nasdaq does
not list its securities on its exchange, Surrozen would not be required to consummate the Business Combination. In the event that Surrozen elected to waive this condition, and the Business Combination was consummated without New Surrozen&#146;s
securities being listed on the Nasdaq or on another national securities exchange, New Surrozen could face significant material adverse consequences, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited availability of market quotations for New Surrozen&#146;s securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced liquidity for New Surrozen&#146;s securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination that New Surrozen Common Stock is a &#147;penny stock&#148; which will require brokers trading
in New Surrozen Common Stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for New Surrozen&#146;s securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited amount of news and analyst coverage; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a decreased ability to issue additional securities or obtain additional financing in the future.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states
from regulating the sale of certain securities, which are referred to as &#147;covered securities.&#148; If New Surrozen&#146;s securities were not listed on Nasdaq, such securities would not qualify as covered securities and we would be subject to
regulation in each state in which we offer our securities because states are not preempted from regulating the sale of securities that are not covered securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Reports published by analysts, including projections in those reports that differ from our actual results, could adversely affect the
price and trading volume of our common shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Securities research analysts may establish and publish their own periodic
projections for New Surrozen following consummation of the Business Combination. These projections may vary widely and may not accurately predict the results we actually achieve. Our share price may decline if our actual results do not match the
projections of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
these securities research analysts. Similarly, if one or more of the analysts who write reports on us downgrades our stock or publishes inaccurate or unfavorable research about our business, our
share price could decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, our share price or trading volume could decline. While we expect research analyst coverage following consummation of the
Business Combination, if no analysts commence coverage of us, the market price and volume for our common shares could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are subject to and New Surrozen will be subject to changing law and regulations regarding regulatory matters, corporate governance
and public disclosure that have increased both CHFW&#146;s costs and the risk of <FONT STYLE="white-space:nowrap">non-compliance</FONT> and will increase both New Surrozen&#146;s costs and the risk of
<FONT STYLE="white-space:nowrap">non-compliance.</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are and New Surrozen will be subject to rules and regulations by
various governing bodies, including, for example, the SEC, which are charged with the protection of investors and the oversight of companies whose securities are publicly traded, and to new and evolving regulatory measures under applicable law. Our
efforts to comply with new and changing laws and regulations have resulted in and New Surrozen&#146;s efforts to comply likely will result in, increased general and administrative expenses and a diversion of management time and attention from
seeking a business combination target. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, because these laws, regulations and standards are subject to varying interpretations,
their application in practice may evolve over time as new guidance becomes available. This evolution may result in continuing uncertainty regarding compliance matters and additional costs necessitated by ongoing revisions to New Surrozen&#146;s
disclosure and governance practices. If we fail to address and comply with these regulations and any subsequent changes, we may be subject to penalty and our business may be harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our warrants are accounted for as a liability and the change in value of our warrants or any other similar derivative liabilities could
have a material effect on our financial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April 12, 2021, the SEC&#146;s Acting Director of the Division of Corporation
Finance and Acting Chief Accountant together issued guidance regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies entitled &#147;Staff Statement on Accounting and Reporting Considerations
for Warrants Issued by Special Purpose Acquisition Companies (the &#147;SEC Guidance&#148;). Specifically, the SEC Guidance focused on certain settlement terms and provisions related to certain partial tender offers following a business combination,
which terms are similar to those contained in the warrant agreement governing our warrants. As a result of the SEC Guidance, we re-evaluated the accounting treatment of our 3,066,667 public warrants and 410,000 private placement warrants, and
concluded that the warrants should be classified as a liability measured at fair value, with changes in fair value each period reported in earnings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subsequent to the completion of the audit of our financial statements for the period from August 21, 2020 (inception) through December 31,
2020 and in light of the SEC Guidance, our management re-evaluated the warrants under Accounting Standards Codification (&#147;ASC&#148;) Subtopic 815-40, Contracts in Entity&#146;s Own Equity. ASC Section 815-40-15 addresses equity versus liability
treatment and classification of equity-linked financial instruments, including warrants, and states that a warrant may be classified as a component of equity only if, among other things, the warrant is indexed to the issuer&#146;s common stock.
Under ASC Section 815-40-15, a warrant is not indexed to the issuer&#146;s common stock if the terms of the warrant require an adjustment to the exercise price upon a specified event and that event is not an input to the fair value of the warrant.
Based on management&#146;s revaluation, our audit committee, in consultation with management and after discussion with our independent registered public accounting firm, concluded that our warrants are not indexed to our common shares in the manner
contemplated by ASC Section 815-40-15 because the holder of the instrument is not an input into the pricing of a fixed-for-fixed option on equity shares. In addition, based on such re-evaluation, our audit committee, in consultation with management
and after discussion with our independent registered public accounting firm, concluded the tender offer provision included in the warrant agreement fails the &#147;classified in shareholders&#146; equity&#148; criteria as contemplated by ASC Section
815-40-25. Based on the foregoing analysis, we should have classified the warrants as derivative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
liabilities in our previously issued financial statements. Under this accounting treatment, we are required to measure the fair value of the warrants at the end of each reporting period and
recognize changes in the fair value from the prior period in our operating results for the current period. As a result of the recurring fair value measurement of our warrants and any subsequent changes in fair value from a prior period, our results
of operations in our financial statements may fluctuate quarterly based on factors which are outside of our control. Due to this recurring fair value measurement, we expect that we will recognize non-cash gains or losses on our warrants each
reporting period and that the amount of such gains or losses could be material. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have identified a material weakness in our
internal control over financial reporting as of December 31, 2020. If we are unable to develop and maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results in a timely
manner, which may adversely affect investor confidence in us and materially and adversely affect our business and operating results. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in the Exchange
Act Rule 13a-15(f). Our internal control over financial reporting are designed to provide reasonable assurance to our management and board of directors regarding the preparation and fair presentation of published financial statements. A material
weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented, or
detected and corrected on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the issuance of the SEC Guidance, our audit committee, in consultation with our
management and after discussions with our independent registered public accounting firm, concluded that we should have classified our warrants as derivative liabilities in our previously issued financial statements, and, for the purposes of properly
reflecting such treatment in our financial statements, it was appropriate to restate our previously issued audited financial statements as of and for the period from August 21, 2020 (inception) through December 31, 2020 (the
&#147;Restatement&#148;). See &#147;&#151;Our warrants are accounted for as a liability and the change in value of our derivative liabilities could have a material effect on our financial results.&#148; As part of such process, our management,
including our principal executive officers and principal financial officer, have evaluated the effectiveness of our internal control over financial reporting and concluded that we did not maintain effective internal control over financial reporting
as of December 31, 2020 because of a material weakness in our internal control over financial reporting solely related to the accounting for the warrants we issued in connection with our initial public offering and concurrent private placement. To
respond to this material weakness, we have devoted, and plan to continue to devote, effort and resources to the remediation and improvement of our internal control over financial reporting. While we have processes to identify and apply applicable
accounting requirements, we plan to enhance these processes, including providing enhanced access to accounting literature and research materials and increased communication among our personnel and third-party professionals with whom we consult
regarding complex accounting applications. These elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the Business Combination is not consummated and we identify any new material weaknesses in the future, any such newly identified material
weakness could limit our ability to prevent or detect a misstatement of our accounts or disclosures that could result in a material misstatement of our annual or interim financial statements. In such case, we may be unable to maintain compliance
with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting and our stock price may decline as a result. If the
Business Combination is not consummated, we cannot assure you that the measures we have taken to date, or any measures we may take in the future, will be sufficient to avoid potential future material weaknesses. If the Business Combination is
consummated, Surrozen&#146;s internal controls and procedures over financial reporting will instead be established and maintained following Closing, and we can provide no assurance that Surrozen&#146;s internal controls and procedures over financial
reporting will be effective. See &#147;&#151;Risks Related to the Business Combination and CHFW&#151;Compliance obligations under the Sarbanes-Oxley Act may make it more difficult for us to effectuate
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the Business Combination, require substantial financial and management resources and increase the time and costs of completing a business combination.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may face litigation and other risks as a result of the material weakness in our internal control over financial reporting.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result of material weakness described above, the Restatement, the change in accounting for the warrants, and other matters
raised publicly by the SEC, we face potential for litigation or other disputes which may include, among others, claims under federal and state securities laws, contractual claims or other claims arising from the Restatement and material weaknesses
in our internal control over financial reporting and the preparation of our financial statements. As of the date of this proxy statement/prospectus, we have no knowledge of any such litigation or dispute. However, we can provide no assurance that
such litigation or dispute will not arise in the future. Any such litigation or dispute, whether successful or not, could have a material adverse effect on our business, results of operations and financial condition or our ability to complete our
proposed Business Combination. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_33"></A>Risks Related to the Consummation of the Domestication </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Unless the context otherwise requires, any reference in this section of this proxy statement/prospectus to &#147;we,&#148; &#147;us&#148; or
&#147;our&#148; refers to CHFW prior to the Business Combination and to New Surrozen and its subsidiaries following the Business Combination. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The Domestication may result in adverse tax consequences for holders of public shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">U.S. Holders (as defined in &#147;<I>Certain Material U.S. Federal Income Tax Considerations&#151;U.S. Holders</I>&#148;) may be subject to
U.S. federal income tax as a result of the Domestication. Because the Domestication will occur immediately prior to the redemption of New Surrozen Common Stock, U.S. Holders exercising redemption rights will be subject to the potential tax
consequences of the Domestication. Additionally, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holders (as defined in &#147;<I>U.S. Federal Income Tax <FONT STYLE="white-space:nowrap">Considerations&#151;Non-U.S.</FONT> Holders</I>&#148; below)
may become subject to withholding tax on any dividends paid or deemed paid on shares of New Surrozen Common Stock after the Domestication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As discussed more fully under &#147;<I>Certain Material U.S. Federal Income Tax Considerations,</I>&#148; the Domestication should constitute
a <FONT STYLE="white-space:nowrap">tax-deferred</FONT> reorganization within the meaning of Section&nbsp;368(a)(l)(F) of the U.S. Internal Revenue Code of 1986, as amended (the &#147;Code&#148;). However, due to the absence of direct guidance on the
application of Section&nbsp;368(a)(1)(F) to a statutory conversion of a corporation holding only investment-type assets such as CHFW, this result is not entirely clear. Accordingly, due to the absence of such guidance, it is not possible to predict
whether the IRS or a court considering the issue would take a contrary position. If the Domestication fails to qualify as a reorganization under Section&nbsp;368(a)(1)(F) of the Code, a U.S. Holder generally would recognize gain or loss with respect
to its public shares or public warrants in an amount equal to the difference, if any, between the fair market value of the corresponding shares of New Surrozen Common Stock or New Surrozen warrants received in the Domestication and the U.S.
Holder&#146;s adjusted tax basis in its public shares and public warrants surrendered in exchange therefor. If the PFIC rules apply and the U.S. Holder has not made certain elections with respect to its public shares, the character of the gain, and
the amount of tax required to be paid with respect to such gain, may differ. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the PFIC rules described in further detail
below, if the Domestication qualifies as a <FONT STYLE="white-space:nowrap">tax-deferred</FONT> reorganization within the meaning of Section&nbsp;368(a)(1)(F) of the Code, U.S. Holders will be subject to Section&nbsp;367(b) of the Code and, as a
result (i)&nbsp;a U.S. Holder who on the day of the Domestication beneficially owns (actually and constructively) public shares with a fair market value of less than $50,000 on the date of the Domestication generally will not recognize any gain or
loss and will not be required to include any part of CHFW&#146;s earnings in income in respect of the Domestication (ii)&nbsp;a U.S. Holder who on the day of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Domestication beneficially owns (actually and constructively) public shares with a fair market value of $50,000 or more, but less than 10% of the total combined voting power of all classes of our
stock entitled to vote and less than 10% or more of the total value of all classes of our stock, generally will recognize gain (but not loss) in respect of the Domestication as if such U.S. Holder exchanged its public shares for shares of New
Surrozen Common Stock in a taxable transaction, unless such U.S. Holder elects in accordance with applicable Treasury Regulations to include in income as a deemed dividend the &#147;all earnings and profits amount&#148; (as defined in the Treasury
Regulations under Section&nbsp;367(b) of the Code) attributable to the public shares held directly by such U.S. Holder; and (iii)&nbsp;a U.S. Holder who on the day of the Domestication beneficially owns (actually or constructively) 10% or more of
the total combined voting power of all classes of our stock entitled to vote or 10% or more of the total value of all classes of our stock, will generally be required to include in income as a deemed dividend the &#147;all earnings and profits
amount&#148; attributable to the public shares held directly by such U.S. Holder. A U.S. Holder that is a corporation may, under certain circumstances, effectively be exempt from taxation on a portion or all of the deemed dividend pursuant to
Section&nbsp;245A of the Code. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, CHFW believes it is likely that it qualified as a &#147;passive foreign investment
company (&#147;PFIC&#148;) for the 2020 taxable year and will qualify as a PFIC for the short taxable year that will end on the date of the Domestication. If CHFW is treated as a PFIC, proposed Treasury Regulations under Section&nbsp;1291(f) of the
Code that have a retroactive effective date, if finalized in their current form, would require U.S. Holders of public shares and public warrants to recognize gain on the Domestication in certain circumstances. The PFIC rules known as the <FONT
STYLE="white-space:nowrap">&#147;start-up</FONT> exception.&#148; The requirement to qualify for the <FONT STYLE="white-space:nowrap">start-up</FONT> exception and the potential application of the PFIC rules to the Domestication are discussed more
fully under &#147;<I>U.S. Federal Income Tax Considerations&#151;U.S. Holders&#151;PFIC Considerations.</I>&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>All holders are
urged to consult their tax advisors for the tax consequences of the Domestication to their particular situation. For a more detailed description of the U.S. federal income tax consequences associated with the Domestication, see
&#147;</B><B><I>Certain Material U.S. Federal Income Tax Considerations</I></B><B>.&#148; </B></P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Upon consummation of the
Business Combination, the rights of holders of New Surrozen Common Stock arising under the DGCL as well as Proposed Governing Documents will differ from and may be less favorable to the rights of holders of Class&nbsp;A ordinary shares arising under
Cayman Islands law as well as our current memorandum and articles of association. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon consummation of the Business Combination,
the rights of holders of New Surrozen Common Stock will arise under the Proposed Governing Documents as well as the DGCL. Those new organizational documents and the DGCL contain provisions that differ in some respects from those in the Existing
Governing Documents and Cayman Islands law and, therefore, some rights of holders of New Surrozen Common Stock could differ from the rights that holders of Class&nbsp;A ordinary shares currently possess. For instance, while class actions are
generally not available to shareholders under Cayman Islands law, such actions are generally available under the DGCL. This change could increase the likelihood that New Surrozen becomes involved in costly litigation, which could have a material
adverse effect on New Surrozen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, there are differences between the Proposed Governing Documents of New Surrozen and the
current constitutional documents of CHFW. For a more detailed description of the rights of holders of New Surrozen Common Stock and how they may differ from the rights of holders of Class&nbsp;A ordinary shares, please see &#147;<I>Comparison of
Corporate Governance and Shareholder Rights</I>.&#148; The forms of the Proposed Certificate of Incorporation and the Proposed Bylaws of New Surrozen are attached as Annex C and Annex D, respectively, to this proxy statement/prospectus, and we urge
you to read them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Delaware law and New Surrozen&#146;s Proposed Governing Documents contain certain
provisions, including anti-takeover provisions, that limit the ability of stockholders to take certain actions and could delay or discourage takeover attempts that stockholders may consider favorable. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Proposed Governing Documents that will be in effect upon consummation of the Business Combination, and the DGCL, contain provisions that
could have the effect of rendering more difficult, delaying, or preventing an acquisition deemed undesirable by the New Surrozen Board and therefore depress the trading price of New Surrozen Common Stock. These provisions could also make it
difficult for stockholders to take certain actions, including electing directors who are not nominated by the current members of the New Surrozen Board or taking other corporate actions, including effecting changes in our management. Among other
things, the Proposed Governing Documents include provisions regarding: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of the New Surrozen Board to issue shares of preferred stock, including &#147;blank check&#148;
preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the limitation of the liability of, and the indemnification of, New Surrozen&#146;s directors and officers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the New Surrozen Board is a classified board with generally only one-third of the directors
subject to election at each annual meeting of stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an
annual or special meeting of stockholders after such date and could delay the ability of stockholders to force consideration of a stockholder proposal or to take action, including the removal of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement that a special meeting of stockholders may be called only by a majority of the entire New
Surrozen Board, which could delay the ability of stockholders to force consideration of a proposal or to take action, including the removal of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">controlling the procedures for the conduct and scheduling of board of directors and stockholder meetings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of the New Surrozen Board to amend the bylaws, which may allow the New Surrozen Board to take
additional actions to prevent an unsolicited takeover and inhibit the ability of an acquirer to amend the bylaws to facilitate an unsolicited takeover attempt; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice procedures with which stockholders must comply to nominate candidates to the New Surrozen Board
or to propose matters to be acted upon at a stockholders&#146; meeting, which could preclude stockholders from bringing matters before annual or special meetings of stockholders and delay changes in the New Surrozen Board, and also may discourage or
deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of directors or otherwise attempting to obtain control of New Surrozen. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in the New Surrozen Board or
management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>New Surrozen&#146;s Proposed Certificate of Incorporation will designate a state or federal court located within the
State of Delaware as the sole and exclusive forum for substantially all disputes between New Surrozen and its stockholders, which could limit New Surrozen&#146;s stockholders&#146; ability to obtain a favorable judicial forum for disputes with New
Surrozen or its directors, officers, stockholders, employees or agents. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Proposed Certificate of Incorporation, which will be
in effect upon consummation of the Business Combination, provides that, unless New Surrozen consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the
State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) shall be
the sole and exclusive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
forum for state law claims for (i)&nbsp;any derivative action or proceeding brought on behalf of New Surrozen, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any
current or former director, officer or other employee of New Surrozen to New Surrozen or New Surrozen&#146;s stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, the
Proposed Certificate of Incorporation or Proposed Bylaws, (iv)&nbsp;any action to interpret, apply, enforce or determine the validity of the Proposed Certificate of Incorporation or Proposed Bylaws, (v)&nbsp;any claim or cause of action as to which
the Delaware General Corporation Law confers jurisdiction on the Court of Chancery of the State of Delaware and (vi)&nbsp;any claim or cause of action against New Surrozen or any current or former director, officer or other employee of New Surrozen,
governed by the internal-affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. The forgoing provisions will not apply to any
claims arising under the Exchange Act, the Securities Act or any other claim for which the federal courts have exclusive jurisdiction and, unless New Surrozen consents in writing to the selection of an alternative forum, any United States District
Court will be the sole and exclusive forum for resolving any action asserting a claim arising under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This choice of
forum provision in our Proposed Certificate of Incorporation may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with New Surrozen or any of New Surrozen&#146;s directors, officers, or
other employees, which may discourage lawsuits with respect to such claims. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies&#146; charter
documents has been challenged in legal proceedings. It is possible that a court could find these types of provisions to be inapplicable or unenforceable, and if a court were to find the choice of forum provision contained in the Proposed Certificate
of Incorporation to be inapplicable or unenforceable in an action, New Surrozen may incur additional costs associated with resolving such action in other jurisdictions, which could harm New Surrozen&#146;s business, results of operations and
financial condition. </P>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_34"></A>Risks Related to the Redemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Public Shareholders who wish to redeem their public shares for a pro rata portion of the trust account must comply with specific
requirements for redemption that may make it more difficult for them to exercise their redemption rights prior to the deadline. If shareholders fail to comply with the redemption requirements specified in this proxy statement/prospectus, they will
not be entitled to redeem their public shares for a pro rata portion of the funds held in the trust account. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A public shareholder
will be entitled to receive cash for any public shares to be redeemed only if such public shareholder: (i)(a) holds public shares, or (b)&nbsp;if the public shareholder holds public shares through units, the public shareholder elects to separate its
units into the underlying public shares and public warrants prior to exercising its redemption rights with respect to the public shares; (ii)&nbsp;submits a written request to Continental, CHFW&#146;s transfer agent, in which it (a)&nbsp;requests
that New Surrozen redeem all or a portion of its public shares for cash, and (b)&nbsp;identifies itself as a beneficial holder of the public shares and provides its legal name, phone number and address; and (iii)&nbsp;delivers its public shares to
Continental, CHFW&#146;s transfer agent, physically or electronically through DTC. Holders must complete the procedures for electing to redeem their public shares in the manner described above prior to 5:00 p.m., Eastern Time,
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 (two business days before the extraordinary general meeting) in order for their shares to be redeemed. In order to obtain a physical share
certificate, a shareholder&#146;s broker and/or clearing broker, DTC and Continental, CHFW&#146;s transfer agent, will need to act to facilitate this request. It is CHFW&#146;s understanding that shareholders should generally allot at least two
weeks to obtain physical certificates from the transfer agent. However, because CHFW does not have any control over this process or over DTC, it may take significantly longer than two weeks to obtain a physical stock certificate. If it takes longer
than anticipated to obtain a physical certificate, public shareholders who wish to redeem their public shares may be unable to obtain physical certificates by the deadline for exercising their redemption rights and thus will be unable to redeem
their shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the Business Combination is consummated, and if a public shareholder properly exercises its right to redeem all or a
portion of the public shares that it holds and timely delivers its shares to Continental, CHFW&#146;s transfer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
agent, New Surrozen will redeem such public shares for a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the pro rata portion of the trust account established
at the consummation of our initial public offering, calculated as of two business days prior to the consummation of the Business Combination. Please see the section entitled &#147;<I>Extraordinary General Meeting of CHFW&#151;Redemption
Rights</I>&#148; for additional information on how to exercise your redemption rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If a public shareholder fails to receive
notice of CHFW&#146;s offer to redeem public shares in connection with the Business Combination, or fails to comply with the procedures for tendering its shares, such shares may not be redeemed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If, despite CHFW&#146;s compliance with the proxy rules, a public shareholder fails to receive CHFW&#146;s proxy materials, such public
shareholder may not become aware of the opportunity to redeem his, her or its public shares. In addition, the proxy materials that CHFW is furnishing to holders of public shares in connection with the Business Combination describes the various
procedures that must be complied with in order to validly redeem the public shares. In the event that a public shareholder fails to comply with these procedures, its public shares may not be redeemed. Please see the section entitled
&#147;<I>Extraordinary General Meeting of CHFW&#151;Redemption Rights</I>&#148; for additional information on how to exercise your redemption rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>CHFW does not have a specified maximum redemption threshold. The absence of such a redemption threshold may make it possible for us to
complete the Business Combination with which a substantial majority of CHFW&#146;s shareholders do not agree. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Existing
Governing Documents do not provide a specified maximum redemption threshold, except that CHFW will not redeem public shares in an amount that would cause CHFW&#146;s net tangible assets to be less than $5,000,001 after giving effect to the
transactions contemplated by the Business Combination Agreement and the PIPE Financing (as determined in accordance with Rule <FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange Act). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result, CHFW may be able to complete the Business Combination even though a substantial portion of public shareholders do not agree with
the transaction and have redeemed their shares or have entered into privately negotiated agreements to sell their shares to Sponsor, directors or officers or their affiliates. As of the date of this proxy statement/prospectus, no agreements with
respect to the private purchase of public shares by CHFW or the persons described above have been entered into with any such investor or holder. CHFW will file or submit a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to
disclose any material arrangements entered into or significant purchases made by any of the aforementioned persons that would affect the vote on the proposals to be put to the extraordinary general meeting or the redemption threshold. Any such
report will include descriptions of any arrangements entered into or significant purchases by any of the aforementioned persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If
you or a &#147;group&#148; of shareholders of which you are a part are deemed to hold an aggregate of more than 15% of the public shares, you (or, if a member of such a group, all of the members of such group in the aggregate) will lose the ability
to redeem all such shares in excess of 15% of the public shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A public shareholder, together with any of his, her or its
affiliates or any other person with whom it is acting in concert or as a &#147;group&#148; (as defined under Section&nbsp;13 of the Exchange Act), will be restricted from redeeming in the aggregate his, her or its shares or, if part of such a group,
the group&#146;s shares, in excess of 15% of the public shares. In order to determine whether a shareholder is acting in concert or as a group with another shareholder, CHFW will require each public shareholder seeking to exercise redemption rights
to certify to CHFW whether such shareholder is acting in concert or as a group with any other shareholder. Such certifications, together with other public information relating to stock ownership available to CHFW at that time, such as
Section&nbsp;13D, Section&nbsp;13G and Section&nbsp;16 filings under the Exchange Act, will be the sole basis on which CHFW makes the above-referenced determination. Your inability to redeem any such excess shares will reduce your influence over
CHFW&#146;s ability to consummate the Business Combination and you could suffer a material loss on your investment in CHFW if you sell such excess shares in open market transactions. Additionally, you will not receive redemption distributions with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
respect to such excess shares if CHFW consummates the Business Combination. As a result, you will continue to hold that number of shares aggregating to more than 15% of the public shares and, in
order to dispose of such excess shares, would be required to sell your stock in open market transactions, potentially at a loss. CHFW cannot assure you that the value of such excess shares will appreciate over time following the Business Combination
or that the market price of the public shares will exceed the <FONT STYLE="white-space:nowrap">per-share</FONT> redemption price. Notwithstanding the foregoing, shareholders may challenge CHFW&#146;s determination as to whether a shareholder is
acting in concert or as a group with another shareholder in a court of competent jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">However, CHFW&#146;s shareholders&#146;
ability to vote all of their shares (including such excess shares) for or against the Business Combination is not restricted by this limitation on redemption. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>There is no guarantee that a shareholder&#146;s decision whether to redeem its shares for a pro rata portion of the trust account will
put the shareholder in a better future economic position. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW can give no assurance as to the price at which a shareholder may be
able to sell its public shares in the future following the completion of the Business Combination or any alternative business combination. Certain events following the consummation of any initial business combination, including the Business
Combination, may cause an increase in CHFW share price, and may result in a lower value realized now than a shareholder of CHFW might realize in the future had the shareholder not redeemed its shares. Similarly, if a shareholder does not redeem its
shares, the shareholder will bear the risk of ownership of the public shares after the consummation of any initial business combination, and there can be no assurance that a shareholder can sell its shares in the future for a greater amount than the
redemption price set forth in this proxy statement/prospectus. A shareholder should consult the shareholder&#146;s own financial advisor for assistance on how this may affect his, her or its individual situation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The securities in which we invest the funds held in the trust account could bear a negative rate of interest, which could reduce the
value of the assets held in trust such that the <FONT STYLE="white-space:nowrap">per-share</FONT> redemption amount received by public shareholders may be less than $10.00 per share. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The proceeds held in the trust account will be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in
money market funds meeting certain conditions under Rule <FONT STYLE="white-space:nowrap">2a-7</FONT> under the Investment Company Act, which invest only in direct U.S. government treasury obligations. While short-term U.S. government treasury
obligations currently yield a positive rate of interest, they have briefly yielded negative interest rates in recent years. Central banks in Europe and Japan pursued interest rates below zero in recent years, and the Open Market Committee of the
Federal Reserve has not ruled out the possibility that it may in the future adopt similar policies in the United States. In the event that we are unable to complete our initial business combination or make certain amendments to our amended and
restated memorandum and articles of association, our public shareholders are entitled to receive their <FONT STYLE="white-space:nowrap">pro-rata</FONT> share of the proceeds held in the trust account, plus any interest income, net of income taxes
paid or payable (less, in the case we are unable to complete our initial business combination, $100,000 of interest to pay dissolution expenses). Negative interest rates could reduce the value of the assets held in trust such that the <FONT
STYLE="white-space:nowrap">per-share</FONT> redemption amount received by public shareholders may be less than $10.00 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_35">
</A>Risks if the Adjournment Proposal is Not Approved </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If the Adjournment Proposal is not approved, and an insufficient number of
votes have been obtained to authorize the consummation of the Business Combination and the Domestication, the CHFW Board will not have the ability to adjourn the extraordinary general meeting to a later date in order to solicit further votes, and,
therefore, the Business Combination will not be approved, and, therefore, the Business Combination may not be consummated. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
CHFW Board is seeking approval to adjourn the extraordinary general meeting to a later date or dates if, at the extraordinary general meeting, based upon the tabulated votes, there are insufficient votes to approve each of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the Condition Precedent Proposals. If the Adjournment Proposal is not approved, the CHFW Board will not have the ability to adjourn the extraordinary general meeting to a later date and,
therefore, will not have more time to solicit votes to approve the Condition Precedent Proposals. In such events, the Business Combination would not be completed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_36"></A>Risks if the Domestication and the Business Combination are not Consummated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we are not able to complete the Business Combination with Surrozen nor able to complete another business combination by
November&nbsp;23, 2022, in each case, as such date may be extended pursuant to our Existing Governing Documents, we would cease all operations except for the purpose of winding up and we would redeem our Class&nbsp;A ordinary shares and liquidate
the trust account, in which case our public shareholders may only receive approximately $10.00 per share and our warrants will expire worthless. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are not able to complete the Business Combination with Surrozen nor able to complete another business combination by November&nbsp;23,
2022, in each case, as such date may be extended pursuant to our Existing Governing Documents we will (i)&nbsp;cease all operations except for the purpose of winding up, (ii)&nbsp;as promptly as reasonably possible but not more than ten business
days thereafter, redeem the public shares, at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest (which interest will be net of taxes
payable, and less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public shareholders&#146; rights as shareholders (including the right to
receive further liquidating distributions, if any), subject to applicable law; and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our board of directors, liquidate
and dissolve, subject in each case to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. In such case, our public shareholders may only receive approximately $10.00 per share and
our warrants will expire worthless. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>You will not have any rights or interests in funds from the trust account, except under certain
limited circumstances. To liquidate your investment, therefore, you may be forced to sell your public shares or public warrants, potentially at a loss. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our public shareholders will be entitled to receive funds from the trust account only upon the earlier to occur of: (i)&nbsp;the completion of
a business combination (including the closing of the Business Combination), and then only in connection with those Class&nbsp;A ordinary shares that such shareholder properly elected to redeem, subject to the limitations described herein,
(ii)&nbsp;the redemption of any public shares properly tendered in connection with a shareholder vote to amend the Existing Governing Documents (A)&nbsp;to modify the substance or timing of our obligation to provide holders of our Class&nbsp;A
ordinary shares the right to have their shares redeemed in connection with a business combination or to redeem 100% of our public shares if we do not complete our initial business combination by November&nbsp;23, 2022 or (B)&nbsp;with respect to any
other provision relating to the rights of holders of our Class&nbsp;A ordinary shares, and (iii)&nbsp;the redemption of our public shares if we have not consummated an initial business by November&nbsp;23, 2022, subject to applicable law and as
further described herein. Public shareholders who redeem their public shares in connection with a shareholder vote described in clause (ii)&nbsp;in the preceding sentence will not be entitled to funds from the trust account upon the subsequent
completion of an initial business combination or liquidation if we have not consummated an initial business combination by November&nbsp;23, 2022, with respect to such public shares so redeemed. In no other circumstances will a shareholder have any
right or interest of any kind to or in the trust account. Holders of warrants will not have any right to the proceeds held in the trust account with respect to the warrants. Accordingly, to liquidate your investment, you may be forced to sell your
public shares or warrants, potentially at a loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we do not consummate an initial business combination by November&nbsp;23,
2022, our public shareholders may be forced to wait until after November&nbsp;23, 2022 before redemption from the trust account. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are unable to consummate our initial business combination by November&nbsp;23, 2022 (as such date may be extended pursuant to our
Existing Governing Documents), we will distribute the aggregate amount then on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to us to pay our income taxes, if any (less up to $100,000 of the net
interest earned thereon to pay dissolution expenses), pro rata to our public shareholders by way of redemption and cease all operations except for the purposes of winding up of our affairs, as further described in this proxy statement/prospectus.
Any redemption of public shareholders from the trust account shall be affected automatically by function of the Existing Governing Documents prior to any voluntary winding up. If we are required to <FONT STYLE="white-space:nowrap">wind-up,</FONT>
liquidate the trust account and distribute such amount therein, pro rata, to our public shareholders, as part of any liquidation process, such winding up, liquidation and distribution must comply with Cayman Islands law. In that case, investors may
be forced to wait beyond November&nbsp;23, 2022 (as such date may be extended pursuant to our Existing Governing Documents), before the redemption proceeds of the trust account become available to them, and they receive the return of their pro rata
portion of the proceeds from the trust account. We have no obligation to return funds to investors prior to the date of our redemption or liquidation unless, prior thereto, we consummate our initial business combination or amend certain provisions
of our Existing Governing Documents, and only then in cases where investors have sought to redeem their public shares. Only upon our redemption or any liquidation will public shareholders be entitled to distributions if we do not complete our
initial business combination and do not amend our Existing Governing Documents. Our Existing Governing Documents provide that, if we wind up for any other reason prior to the consummation of our initial business combination, we will follow the
foregoing procedures with respect to the liquidation of the trust account as promptly as reasonably possible but not more than ten business days thereafter, subject to applicable Cayman Islands law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If the net proceeds of our initial public offering not being held in the trust account are insufficient to allow us to operate through
November&nbsp;23, 2022, and we are unable to obtain additional capital, we may be unable to complete our initial business combination, in which case our public shareholders may only receive $10.00 per share, and our warrants will expire worthless.
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2021, we had cash of approximately $774,931 held outside the trust account, which is available for use by
us to cover the costs associated with identifying a target business and negotiating a business combination and other general corporate uses. In addition, as of March&nbsp;31, 2021, we had total current liabilities of approximately $1&nbsp;million.
The funds available to us outside of the trust account may not be sufficient to allow us to operate until November&nbsp;23, 2022, assuming that our initial business combination is not completed during that time. Of the funds available to us, we
could use a portion of the funds available to us to pay fees to consultants to assist us with our search for a target business. We could also use a portion of the funds as a down payment or to fund a
<FONT STYLE="white-space:nowrap">&#147;no-shop&#148;</FONT> provision (a provision in letters of intent designed to keep target businesses from &#147;shopping&#148; around for transactions with other companies on terms more favorable to such target
businesses) with respect to a particular proposed business combination, although we do not have any current intention to do so. If we entered into a letter of intent where we paid for the right to receive exclusivity from a target business and were
subsequently required to forfeit such funds (whether as a result of our breach or otherwise), we might not have sufficient funds to continue searching for, or conduct due diligence with respect to, a target business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are required to seek additional capital, we would need to borrow funds from Sponsor, members of our management team or other third
parties to operate or may be forced to liquidate. Any such advances would be repaid only from funds held outside the trust account or from funds released to us upon completion of our initial business combination. If we are unable to obtain
additional financing, we may be unable to complete our initial business combination. If we are unable to complete our initial business combination because we do not have sufficient funds available to us, we will be forced to cease operations and
liquidate the trust account. Consequently, our public shareholders may only receive approximately $10.00 per share on our redemption of the public shares and the public warrants will expire worthless. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_37"></A>EXTRAORDINARY GENERAL MEETING OF CHFW </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_38"></A>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW is furnishing this proxy statement/prospectus to CHFW&#146;s shareholders as part of the solicitation of proxies by the CHFW Board for use
at the extraordinary general meeting of CHFW to be held on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, and at any adjournment thereof. This proxy statement/prospectus is first being
furnished to CHFW&#146;s shareholders on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 in connection with the vote on the proposals described in this proxy statement/prospectus. This
proxy statement/prospectus provides CHFW&#146;s shareholders with information they need to know to be able to vote or instruct their vote to be cast at the extraordinary general meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_39"></A>Date, Time and Place </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The extraordinary general meeting will be held at 10:30 a.m., Eastern Time,
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. The meeting will be held via live webcast at the following address: https://www.cstproxy.com/consonancehfw/sm2021. You will need the <FONT
STYLE="white-space:nowrap">12-digit</FONT> meeting control number that is printed on your proxy card to enter the extraordinary general meeting. CHFW recommends that you log in at least 15 minutes before the extraordinary general meeting to ensure
you are logged in when the extraordinary general meeting starts. Please note that you will not be able to attend the extraordinary general meeting in person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_40"></A>Purpose of the CHFW Extraordinary General Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At the extraordinary general meeting, CHFW is asking holders of its ordinary shares to consider and vote upon seven (7)&nbsp;separate
proposals: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a proposal to approve by ordinary resolution and adopt the Business Combination Agreement, including the
Merger, and the Transactions (the &#147;Business Combination Proposal&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a proposal to approve by special resolution the Domestication (the &#147;Domestication Proposal&#148;);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a proposal to approve the replacement of CHFW&#146;s existing amended and restated memorandum and articles of
association (the &#147;Existing Governing Documents&#148;) with a proposed new certificate of incorporation (the &#147;Proposed Certificate of Incorporation) and proposed new bylaws (the &#147;Proposed Bylaws&#148;) and, together with the Proposed
Certificate of Incorporation, the &#147;Proposed Governing Documents&#148;) of New Surrozen (the &#147;New Organizational Documents Proposal&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">four (4) separate proposals to approve material differences between the Existing Governing Documents and the
Proposed Governing Documents, including to approve the change in the authorized share capital of CHFW from (i) $50,100 divided into 350,000,000 Class A ordinary shares, par value $0.0001 per share, 150,000,000 Class B ordinary shares, par value
$0.0001 per share and 1,000,000 preference shares, par value $0.0001 per share, to (ii) 300,000,000 shares of common stock, par value $0.0001 per share and 10,000,000 shares of preferred stock, par value $0.0001 per share (collectively, the
&#147;Governing Documents Proposals&#148;); </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a proposal to approve by ordinary resolution shares of New Surrozen Common Stock in connection with the
Business Combination and the PIPE Financing in compliance with the Nasdaq Listing Rules (the &#147;Share Issuance Proposal&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a proposal to approve and adopt by ordinary resolution the Equity Incentive Plan (the &#147;Incentive Award
Plan Proposal&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a proposal to approve and adopt by ordinary resolution the ESPP (the &#147;Employee Stock Purchase Plan
Proposal&#148;); and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a proposal to approve by ordinary resolution the adjournment of the extraordinary general meeting to a later
date or dates, if necessary, to, among other things, permit further solicitation and vote of proxies in the event that there are insufficient votes for the approval of one or more proposals at the extraordinary general meeting (the &#147;Adjournment
Proposal&#148;). </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each of the Business Combination Proposal, the Domestication Proposal, the New Organizational
Documents Proposal, the Incentive Award Plan Proposal and the Share Issuance Proposal is conditioned on the approval and adoption of each of the other Condition Precedent Proposals. The Employee Stock Purchase Plan Proposal is conditioned on the
approval of the Condition Precedent Proposals. The Adjournment Proposal is not conditioned on any other proposal. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_41">
</A>Recommendation of the CHFW Board </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The CHFW Board believes that the Business Combination Proposal and the other proposals to be
presented at the extraordinary general meeting are in the best interest of CHFW and its shareholders and unanimously recommends that its shareholders vote &#147;FOR&#148; the Business Combination Proposal, &#147;FOR&#148; the Domestication Proposal,
&#147;FOR&#148; the New Organizational Documents Proposal, &#147;FOR&#148; each of the Governing Documents Proposals, &#147;FOR&#148; the Share Issuance Proposal, &#147;FOR&#148; the Incentive Award Plan Proposal, &#147;FOR&#148; the Employee Stock
Purchase Plan Proposal and &#147;FOR&#148; the Adjournment Proposal, in each case, if presented to the extraordinary general meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The existence of financial and personal interests of one or more of CHFW&#146;s directors may result in a conflict of interest on the part of
such director(s) between what he, she or they may believe is in the best interests of CHFW and its shareholders and what he, she or they may believe is best for himself or themselves in determining to recommend that shareholders vote for the
proposals. In addition, CHFW&#146;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#147;<I>Business Combination Proposal&#151;Interests of CHFW&#146;s Directors
and Executive Officers in the Business Combination</I>&#148; for a further discussion of these considerations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_42"></A>Record Date; Who is Entitled to Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW shareholders holding shares in &#147;street name&#148; will be entitled to vote or direct votes to be cast at the extraordinary general
meeting if they owned ordinary shares at the close of business on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, which is the &#147;record date&#148; for the extraordinary general meeting.
Shareholders will have one vote for each ordinary share owned at the close of business on the record date. If your shares are held in &#147;street name&#148; or are in a margin or similar account, you should contact your broker to ensure that votes
related to the shares you beneficially own are properly counted. Our warrants do not have voting rights. As of the close of business on the record date, there were 11,934,000 ordinary shares issued and outstanding, of which 9,200,000 were issued and
outstanding public shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_43"></A>Quorum </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A quorum of CHFW shareholders is necessary to hold a valid meeting. A quorum will be present at the extraordinary general meeting if one or
more shareholders who together hold not less than a majority of the issued and outstanding ordinary shares entitled to vote at the extraordinary general meeting are represented in person or by proxy at the extraordinary general meeting. As of the
record date for the extraordinary general meeting, 5,967,001 ordinary shares would be required to achieve a quorum. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_44">
</A>Abstentions and Broker <FONT STYLE="white-space:nowrap">Non-Votes</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Proxies that are marked &#147;abstain&#148; and proxies
relating to &#147;street name&#148; shares that are returned to CHFW but marked by brokers as &#147;not voted&#148; will be treated as shares present for purposes of determining the presence of a quorum on all matters. Abstentions and broker <FONT
STYLE="white-space:nowrap">non-votes,</FONT> while considered present for the purposes of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
establishing a quorum, will not count as votes cast at the extraordinary general meeting, and otherwise will have no effect on a particular proposal. If a shareholder does not give the broker
voting instructions, under applicable self-regulatory organization rules, its broker may not vote its shares on <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> proposals, such as the Business Combination Proposal or any of the other
Condition Precedent Proposals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_45"></A>Vote Required for Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The approval of the Business Combination Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of at
least a majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The approval of the Domestication Proposal requires a special resolution under Cayman Islands law, being the affirmative vote of at least a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> (2/3) majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The approval of the New Organizational Documents Proposal and each of the Governing Documents Proposal requires a special resolution under
Cayman Islands law, being the affirmative vote of at least a <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the
extraordinary general meeting and entitled to vote on such matter, save for Governing Documents Proposal A, which proposes to alter CHFW&#146;s authorized share capital and which will require an ordinary resolution, being the affirmative vote of
holders of a majority of the ordinary shares represented in person or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The approval of the Share Issuance Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of at least a
majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The approval of the Incentive Award Plan Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of at
least a majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The approval of the Employee Stock Purchase Plan Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote
of a majority of the ordinary shares represented in person or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The approval of the Adjournment Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of at least a
majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter. The Adjournment Proposal is not conditioned upon the approval
of any other proposal. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each of the Business Combination Proposal, the Domestication Proposal, the New Organizational Documents
Proposal, the Incentive Award Plan Proposal and the Share Issuance Proposal is conditioned on the approval and adoption of each of the other Condition Precedent Proposals. The Employee Stock Purchase Plan Proposal is conditioned on the approval of
the Condition Precedent Proposals. The Adjournment Proposal is not conditioned on any other proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_46"></A>Voting Your Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each ordinary share that you own in your name entitles you to one vote. Your proxy card shows the number of ordinary shares that you own. If
your shares are held in &#147;street name&#148; or are in a margin or similar account, you should contact your broker to ensure that votes related to the shares you beneficially own are properly counted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are two ways to vote your ordinary shares at the extraordinary general meeting: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You can vote by signing and returning the enclosed proxy card. If you vote by proxy card, your
&#147;proxy,&#148; whose name is listed on the proxy card, will vote your shares as you instruct on the proxy card. If you sign and return the proxy card but do not give instructions on how to vote your shares, your shares will be voted as
recommended by the CHFW Board &#147;FOR&#148; the Business Combination Proposal, &#147;FOR&#148; the Domestication Proposal, &#147;FOR&#148; the New Organizational Documents Proposal, &#147;FOR&#148; each of the separate Governing Documents
Proposals, &#147;FOR&#148; the Share Issuance Proposal, &#147;FOR&#148; the Incentive Award Plan Proposal, &#147;FOR&#148; the Employee Stock Purchase Plan Proposal and &#147;FOR&#148; the Adjournment Proposal, in each case, if presented to the
extraordinary general meeting. Votes received after a matter has been voted upon at the extraordinary general meeting will not be counted. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You can attend the extraordinary general meeting and vote in person. You will receive a ballot when you
arrive. However, if your shares are held in the name of your broker, bank or another nominee, you must get a valid legal proxy from the broker, bank or other nominee. That is the only way CHFW can be sure that the broker, bank or nominee has not
already voted your shares. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_48"></A>Revoking Your Proxy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you are an CHFW shareholder and you give a proxy, you may revoke it at any time before it is exercised by doing any one of the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">you may send another proxy card with a later date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">you may notify us in writing before the extraordinary general meeting that you have revoked your proxy; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">you may attend the extraordinary general meeting, revoke your proxy, and vote in person, as indicated above.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_49"></A>Who Can Answer Your Questions About Voting Your Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you are a shareholder and have any questions about how to vote or direct a vote in respect of your ordinary shares, you may call Okapi
Partners LLC, our proxy solicitor, by calling (844) <FONT STYLE="white-space:nowrap">203-3605,</FONT> or banks and brokers can call collect at (212) <FONT STYLE="white-space:nowrap">297-0720,</FONT> or by emailing info@okapipartners.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_50"></A>Redemption Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with the proposed Business Combination, pursuant to the Existing Governing Documents, a public shareholder may request of CHFW
that New Surrozen redeem all or a portion of its public shares for cash if the Business Combination is consummated. As a holder of public shares, you will be entitled to receive cash for any public shares to be redeemed only if you: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">(a) hold public shares, or (b)&nbsp;if you hold public shares through units, you elect to separate your
units into the underlying public shares and warrants prior to exercising your redemption rights with respect to the public shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">submit a written request to Continental, CHFW&#146;s transfer agent, in which you (i)&nbsp;request that New
Surrozen redeem all or a portion of your public shares for cash, and (ii)&nbsp;identify yourself as the beneficial holder of the public shares and provide your legal name, phone number and address; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">deliver your public shares to Continental, CHFW&#146;s transfer agent, physically or electronically through
DTC. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Holders must complete the procedures for electing to redeem their public shares in the manner described above
prior to 5:00 p.m., Eastern Time, on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 (two business days before the extraordinary general meeting) in order for their shares to be redeemed.
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Holders of units must elect to separate the units into the underlying public shares and
public warrants prior to exercising redemption rights with respect to the public shares. If holders hold their units in an account at a brokerage firm or bank, holders must notify their broker or bank that they elect to separate the units into the
underlying public shares and public warrants, or if a holder holds units registered in its own name, the holder must contact Continental, CHFW&#146;s transfer agent, directly and instruct them to do so. The redemption rights include the requirement
that a holder must identify itself in writing as a beneficial holder and provide its legal name, phone number and address to Continental in order to validly redeem its shares. Public shareholders (other than those who have agreed not to do so by
executing an CHFW Shareholder Support Agreement) may elect to redeem all or a portion of the public shares held by them regardless of if or how they vote in respect of the Business Combination Proposal. </B>If the Business Combination is not
consummated, the public shares will be returned to the respective holder, broker or bank. If the Business Combination is consummated, and if a public shareholder properly exercises its right to redeem all or a portion of the public shares that it
holds and timely delivers its shares to Continental, CHFW&#146;s transfer agent, New Surrozen will redeem such public shares for a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the pro rata portion of the trust
account, calculated as of two business days prior to the consummation of the Business Combination. For illustrative purposes, as of March&nbsp;31, 2021, this would have amounted to approximately $10.00 per issued and outstanding public share. If a
public shareholder exercises its redemption rights in full, then it will be electing to exchange its public shares for cash and will no longer own public shares. The redemption takes place following the Domestication and accordingly it is shares of
New Surrozen Common Stock that will be redeemed immediately after consummation of the Business Combination<B>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you hold the shares
in &#147;street name,&#148; you will have to coordinate with your broker to have your shares certificated or delivered electronically. Shares of New Surrozen Common Stock that have not been tendered (either physically or electronically) in
accordance with these procedures will not be redeemed for cash. There is a nominal cost associated with this tendering process and the act of certificating the shares or delivering them through DTC&#146;s DWAC system. The transfer agent will
typically charge the tendering broker $80 and it would be up to the broker whether or not to pass this cost on to the redeeming shareholder. In the event the proposed business combination is not consummated this may result in an additional cost to
shareholders for the return of their shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any request for redemption, once made by a holder of public shares, may be withdrawn at any
time up to the time the vote is taken with respect to the Business Combination Proposal at the extraordinary general meeting. If you deliver your shares for redemption to Continental, our transfer agent, and later decide prior to the extraordinary
general meeting not to elect redemption, you may request that our transfer agent return the shares (physically or electronically) to you. You may make such request by contacting Continental, our transfer agent, at the phone number or address listed
at the end of this section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any corrected or changed written exercise of redemption rights must be received by Continental, our transfer
agent, prior to the vote taken on the Business Combination Proposal at the extraordinary general meeting. No request for redemption will be honored unless the holder&#146;s public shares have been delivered (either physically or electronically) to
Continental, our agent, at least two business days prior to the vote at the extraordinary general meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing,
a public shareholder, together with any affiliate of such public shareholder or any other person with whom such public shareholder is acting in concert or as a &#147;group&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act), will be
restricted from redeeming its public shares with respect to more than an aggregate of 15% of the public shares. Accordingly, if a public shareholder, alone or acting in concert or as a group, seeks to redeem more than 15% of the public shares, then
any such shares in excess of that 15% limit would not be redeemed for cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The initial shareholders have, pursuant to the Sponsor Letter
Agreement, agreed to, among other things, vote all of their ordinary shares in favor of the proposals being presented at the extraordinary general meeting and waive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
their redemption rights with respect to such ordinary shares in connection with the consummation of the Business Combination. Such shares will be excluded from the pro rata calculation used to
determine the <FONT STYLE="white-space:nowrap">per-share</FONT> redemption price. As of the date of this proxy statement/prospectus, the initial shareholders own approximately 22.9% of the issued and outstanding ordinary shares. See
&#147;<I>Business Combination Proposal&#151;Related Agreements&#151;Sponsor Letter Agreement</I>&#148; in the accompanying proxy statement/prospectus for more information related to the Sponsor Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Holders of the warrants will not have redemption rights with respect to the warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The closing price of public shares on May 10, 2021 was $9.87 per Class&nbsp;A ordinary share. For illustrative purposes, as of March&nbsp;31,
2021, funds in the trust account plus accrued interest thereon totaled approximately $92.0&nbsp;million or $10.00 per issued and outstanding public share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to exercising redemption rights, public shareholders should verify the market price of the public shares as they may receive higher
proceeds from the sale of their public shares in the public market than from exercising their redemption rights if the market price per share is higher than the redemption price. CHFW cannot assure its shareholders that they will be able to sell
their public shares in the open market, even if the market price per share is higher than the redemption price stated above, as there may not be sufficient liquidity in its securities when its shareholders wish to sell their shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_51"></A>Appraisal Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither our shareholders nor our warrant holders have appraisal rights in connection with the Business Combination or the Domestication under
the Cayman Islands Companies Act or under the DGCL. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_52"></A>Proxy Solicitation Costs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW is soliciting proxies on behalf of its board of directors. This solicitation is being made by mail but also may be made by telephone or in
person. CHFW and its directors, officers and employees may also solicit proxies in person, by telephone or by other electronic means. CHFW will bear the cost of the solicitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW has hired Okapi Partners LLC to assist in the proxy solicitation process. CHFW will pay that firm a fee of $22,500 plus disbursements.
Such fee will be paid with <FONT STYLE="white-space:nowrap">non-trust</FONT> account funds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW will ask banks, brokers and other
institutions, nominees and fiduciaries to forward the proxy materials to their principals and to obtain their authority to execute proxies and voting instructions. CHFW will reimburse them for their reasonable expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_53"></A>CHFW Initial Shareholders&#146; Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of the date of this proxy statement/prospectus, there are 11,934,000 ordinary shares issued and outstanding, which includes an aggregate of
2,300,000 Class&nbsp;B ordinary shares held by the initial shareholders, including Sponsor. In addition, as of the date of this proxy statement/prospectus, there is outstanding an aggregate of 3,211,334 warrants, comprised of 144,667 private
placement warrants held by Sponsor and the 3,066,667 public warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At any time at or prior to the Business Combination, during a
period when they are not then aware of any material nonpublic information regarding us or our securities, our initial shareholders, Surrozen and/or their directors, officers, advisors or respective affiliates may purchase public shares from
institutional and other investors who vote, or indicate an intention to vote, against any of the Condition Precedent Proposals, or execute agreements to purchase such shares from such investors in the future, or they may enter into transactions with
such investors and others to provide them with incentives to acquire public shares or vote their public shares in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
favor of the Condition Precedent Proposals. Such a purchase may include a contractual acknowledgement that such shareholder, although still the record or beneficial holder of our shares, is no
longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights. In the event that our initial shareholders, Surrozen and/or their directors, officers, advisors or respective affiliates purchase shares in privately
negotiated transactions from public shareholders who have already elected to exercise their redemption rights, such selling shareholder would be required to revoke their prior elections to redeem their shares. The purpose of such share purchases and
other transactions would be to increase the likelihood of satisfaction of the requirements that (i)&nbsp;the Business Combination Proposal, the Governing Documents Proposal A, the Share Issuance Proposal, the Incentive Award Plan Proposal, the
Employee Stock Purchase Plan Proposal and the Adjournment Proposal are approved by the affirmative vote of at least a majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the
extraordinary general meeting and entitled to vote on such matter (ii)&nbsp;the Domestication Proposal, the New Organizational Documents Proposal, the Governing Documents Proposal B, the Governing Documents Proposal C and the Governing Documents
Proposal&nbsp;D are approved by the affirmative vote of at least a <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the
extraordinary general meeting and entitled to vote on such matter, (iii)&nbsp;otherwise limit the number of public shares electing to redeem and (iv)&nbsp;New Surrozen&#146;s net tangible assets (as determined in accordance with Rule <FONT
STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange Act) being at least $5,000,001 after giving effect to the transactions contemplated by the Business Combination Agreement and the PIPE Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Entering into any such arrangements may have a depressive effect on the ordinary shares. For example, as a result of these arrangements, an
investor or holder may have the ability to effectively purchase shares at a price lower than market and may therefore be more likely to sell the shares he or she owns, either at or prior to the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If such transactions are effected, the consequence could be to cause the Business Combination to be consummated in circumstances where such
consummation could not otherwise occur. Purchases of shares by the persons described above would allow them to exert more influence over the approval of the proposals to be presented at the extraordinary general meeting and would likely increase the
chances that such proposals would be approved. We will file or submit a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to disclose any material arrangements entered into or significant purchases made by any of the aforementioned
persons that would affect the vote on the proposals to be put to the extraordinary general meeting or the redemption threshold. Any such report will include descriptions of any arrangements entered into or significant purchases by any of the
aforementioned persons. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_54"></A>BUSINESS COMBINATION PROPOSAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_55"></A>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are asking our shareholders to adopt and approve the Business Combination Agreement, certain related agreements and the Transactions
(including the Domestication). CHFW shareholders should read carefully this proxy statement/prospectus in its entirety for more detailed information concerning the Business Combination Agreement, which is attached as Annex A to this proxy
statement/prospectus, and the Transactions. Please see &#147;<I>&#151;The Business Combination Agreement</I>&#148; below for additional information and a summary of certain terms of the Business Combination Agreement. You are urged to read carefully
the Business Combination Agreement in its entirety before voting on this proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because we are holding a shareholder vote on the
Business Combination, we may consummate the Business Combination only if it is approved by the affirmative vote of at least a majority of the votes cast by the holders of the issued of ordinary shares present in person or represented by proxy at the
extraordinary general meeting and entitled to vote on such matter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_56"></A>The Business Combination Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This subsection of the proxy statement/prospectus describes the material provisions of the Business Combination Agreement, but does not purport
to describe all of the terms of the Business Combination Agreement. The following summary is qualified in its entirety by reference to the complete text of the Business Combination Agreement, which is attached as Annex A to this proxy
statement/prospectus. You are urged to read the Business Combination Agreement in its entirety because it is the primary legal document that governs the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Business Combination Agreement contains representations, warranties and covenants that the respective parties made to each other as of the
date of the Business Combination Agreement or other specific dates. The assertions embodied in those representations, warranties and covenants were made for purposes of the contract among the respective parties and are subject to important
qualifications and limitations agreed to by the parties in connection with negotiating the Business Combination Agreement. The representations, warranties and covenants in the Business Combination Agreement are also modified in part by the
underlying disclosure schedules (the &#147;disclosure schedules&#148;), which are not filed publicly and which are subject to a contractual standard of materiality different from that generally applicable to shareholders and were used for the
purpose of allocating risk among the parties rather than establishing matters as facts. We do not believe that the disclosure schedules contain information that is material to an investment decision. Additionally, the representations and warranties
of the parties to the Business Combination Agreement may or may not have been accurate as of any specific date and do not purport to be accurate as of the date of this proxy statement/prospectus and<B> </B>the disclosure schedules contain
information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the attached Business Combination Agreement. Accordingly, no person should rely on the representations and warranties in the Business
Combination Agreement or the summaries thereof in this proxy statement/prospectus as characterizations of the actual state of facts about CHFW, Sponsor, Surrozen or any other matter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_57"></A>General; Structure of the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April&nbsp;15, 2021, CHFW, Merger Sub and Surrozen entered into the Business Combination Agreement, which provides for, among other things,
the following transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">On the Closing Date and immediately prior to the Effective Time, CHFW will change its jurisdiction of
incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware, upon which CHFW will change its name to &#147;Surrozen, Inc.&#148;; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the parties to the Business Combination Agreement will cause a certificate of merger to be executed and
filed with the Secretary of State of the State of Delaware, pursuant to which Merger Sub will merge with and into Surrozen, with Surrozen as the surviving company in the Merger and, after giving effect to such merger, Surrozen shall be a
wholly-owned subsidiary of CHFW. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW entered into Subscription Agreements with the PIPE Investors to consummate
the PIPE Financing, pursuant to which the PIPE Investors have agreed to subscribe for and purchase, and CHFW has agreed to issue and sell to the PIPE Investors, an aggregate of 12,020,000 units, each consisting of the PIPE Warrants, the PIPE Units,
for aggregate gross proceeds of $120,200,000. The PIPE Units were offered to facilitate the subscriptions, however, the shares of CHFW Common Stock and the PIPE Warrants which comprise the PIPE Units are not attached and will trade separately
without any instruction or detachment obligations on the part of the investors, CHFW or the warrant agent. Each whole PIPE Warrant entitles the holder thereof to purchase one share of CHFW Common Stock at a price of $11.50 per share, subject to
adjustment as described in the form of warrant agreement attached to the form of Subscription Agreement and only whole PIPE Warrants will be exercisable. The PIPE Warrants have substantially the same provisions as the public warrants issued in
connection with CHFW&#146;s initial public offering. The PIPE Financing is contingent upon, among other things, the substantially </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
concurrent closing of the Business Combination. For additional information, see &#147;<I>Business Combination Proposal&#151;Related Agreements&#151;PIPE Financing</I>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_58"></A>Effect of the Domestication on Existing CHFW Equity in the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Domestication will result in, among other things, the following, each of which will occur prior to the Effective Time on the Closing Date:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each issued and outstanding Class&nbsp;A ordinary share of CHFW will convert automatically by operation of
law, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, into shares of New Surrozen Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each issued and outstanding Class&nbsp;B ordinary share of CHFW will convert automatically by operation of
law, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, into shares of New Surrozen Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each issued and outstanding whole warrant to purchase Class&nbsp;A ordinary shares of CHFW will represent the
right to purchase one share of New Surrozen Common Stock at an exercise price of $11.50 per share on the terms and conditions set forth in the CHFW warrant agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the governing documents of CHFW will be replaced and become the certificate of incorporation and the bylaws as
described in this proxy statement/prospectus and CHFW&#146;s name will change to &#147;Surrozen, Inc.&#148;; and </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in connection with the first three bullets above, each issued and outstanding unit of CHFW that has not been
previously separated into the underlying Class&nbsp;A ordinary shares of CHFW and underlying CHFW warrants upon the request of the holder thereof prior to the Domestication will be cancelled and will entitle the holder thereof to one share of New
Surrozen Common Stock and <FONT STYLE="white-space:nowrap">one-third</FONT> of one warrant representing the right to purchase one share of New Surrozen Common Stock at an exercise price of $11.50 per share on the terms and subject to the conditions
set forth in the CHFW warrant agreement. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Business Combination Agreement also provides that the Proposed
Governing Documents shall be appropriately adjusted to give effect to any changes thereto that are not adopted and approved by the CHFW shareholders at the extraordinary general meeting (other than the changes to the Existing Governing Documents
described in the Business Combination Agreement). </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_59"></A>Consideration to Surrozen Equityholders in the
Business Combination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with the terms and subject to the conditions of the Business Combination Agreement, at the
Effective Time, share and equity award (whether vested or unvested) of Surrozen outstanding as of immediately prior to the Effective Time will be exchanged for shares of New Surrozen Common Stock or comparable vested or unvested equity awards that
are settled or are exercisable for shares of New Surrozen Common Stock, as applicable, based on an implied Surrozen equity value of $200,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At the Effective Time, by virtue of the Merger and without any action on the part of CHFW, Merger Sub, Surrozen or the holders of any of the
following securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">each outstanding preferred share (on an as converted to common stock basis) and each common share issued and
outstanding immediately prior to the Effective Time (excluding any shares that exercise appraisal rights) shall be canceled and converted into the right to receive the number of shares of New Surrozen Common Stock equal to the Exchange Ratio (the
&#147;Per Share Merger Consideration&#148;) with any fractional shares to be cashed out based on the CHFW Share Value of $10.00 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">each Surrozen option that is outstanding immediately prior to the Effective Time shall be assumed by CHFW
and converted into an option to purchase shares of New Surrozen Common Stock under the New Surrozen Equity Incentive Plan (each such option, a &#147;Converted Option&#148;) on the same terms and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
conditions (including applicable vesting and exercisability terms) as were applicable to the corresponding former Surrozen option immediately prior to the Effective Time, except (i)&nbsp;the
number of shares subject to the Converted Option shall be equal to the product (rounded down to the nearest whole number) of (x)&nbsp;the number of shares of common shares subject to such Surrozen option immediately prior to the Effective Time
multiplied by (y)&nbsp;the Exchange Ratio, and (ii)&nbsp;the exercise price per share of the Converted Option (rounded up to the nearest whole cent) shall be equal to the quotient of (x)&nbsp;the exercise price per share of such Surrozen option
immediately prior to the Effective Time divided by (y)&nbsp;the Exchange Ratio (the &#147;Company Option Treatment&#148;). The conversions and adjustments shall be done in a manner intended to comply with the requirements of Section&nbsp;409A of the
Code and for any rollover option that is an incentive stock option, Section&nbsp;424 of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">each unvested Surrozen restricted stock award shall be converted into a right to receive restricted shares
of CHFW Common Stock (each, a &#147;Rollover Restricted Award&#148;) with substantially the same terms and conditions that were applicable to such Surrozen restricted stock award prior to the Effective Time, except that such Rollover Restricted
Awards shall relate to such number of shares of CHFW Common Stock equal to the product of (i)&nbsp;the number of Company Common Shares subject to such Restricted Stock Award immediately prior to the Effective Time multiplied by (ii)&nbsp;the
Exchange Ratio, with any fractional shares rounded down to the nearest whole share (the &#147;Company RSU Treatment&#148; and together with the Company Option Treatment, the &#147;Company Equity Award Treatment&#148;); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The &#147;Exchange Ratio&#148; means the quotient of the Equity Value Per Share divided by (b) $10.00 per
share.&nbsp;&nbsp;&nbsp;&nbsp;The &#147;Equity Value Per Share&#148; means $200,000,000 divided by the &#147;Fully Diluted Company Capitalization.&#148; &#147;Fully Diluted Company Capitalization&#148; means the sum of the aggregate number of shares
of Surrozen common stock issued and outstanding immediately prior to the Effective Time determined with preferred treated on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common basis plus the aggregate number of shares of Surrozen
common stock subject to equity awards outstanding immediately prior to the Effective Time.&nbsp;&nbsp;&nbsp;&nbsp;The Fully Diluted Company Capitalization does not include any shares reserved and available for future awards under any Surrozen or New
Surrozen equity plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, as discussed above in connection with the PIPE Financing, the PIPE Investors have
agreed to subscribe for and purchase, and CHFW has agreed to issue and sell to the PIPE Investors, an aggregate of 12,020,000 units, each consisting of the PIPE Warrants, the PIPE Units, for aggregate gross proceeds of $120,200,000. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_60"></A>Aggregate New Surrozen Proceeds </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Aggregate Transaction Proceeds will be used for general corporate purposes after the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_61"></A>Closing and Effective Time of the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Closing of the Transactions is required to take place electronically by exchange of the closing deliverables as promptly as reasonably
practicable, but in no event later than the 3rd business day, following the satisfaction (or, to the extent permitted by applicable law, waiver) of the conditions described below under the section entitled <I>&#147;&#151;Conditions to Closing of the
Business Combination</I>,&#148; (other than those conditions that by their nature are to be satisfied at the Closing, but subject to satisfaction or waiver of such conditions) or at such other place, date and/or time as CHFW and Surrozen may agree
in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_62"></A>Conditions to Closing of the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Conditions to Each Party&#146;s Obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The respective obligations of each party to the Business Combination Agreement to consummate the transactions contemplated by the Business
Combination are subject to the satisfaction or, if permitted by applicable law, waiver by the party whose benefit such condition exists of the following conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no order or law issued by any court of competent jurisdiction or other governmental entity or other legal
restraint or prohibition preventing the consummation of the transactions contemplated by Business Combination being in effect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">this registration statement/proxy statement becoming effective in accordance with the provisions of the
Securities Act, no stop order being issued by the SEC and remaining in effect with respect to this registration statement/proxy statement, and no proceeding seeking such a stop order being threatened or initiated by the SEC and remaining pending;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval of the Business Combination Agreement, the ancillary documents to the Business Combination
Agreement to which Surrozen is or will be a party and Transactions (including the Merger) being obtained by the requisite number of stockholders of Surrozen in accordance with the DGCL, Surrozen&#146;s governing documents and Surrozen&#146;s
stockholder agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval of each Condition Precedent Proposal by the affirmative vote of the holders of the requisite
number of ordinary shares of CHFW being obtained in accordance with CHFW&#146;s Governing Documents and applicable law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Aggregate Transaction Proceeds (as defined in the Business Combination Agreement) shall be equal to or
greater than $100,000,000; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CHFW&#146;s initial listing application with Nasdaq in connection with the Business Combination Agreement
shall have been approved and all of the outstanding CHFW shares (after giving effect to the Domestication), including those issued in the Merger shall have been approved for listing on Nasdaq; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and composition of the CHFW Board shall be as contemplated under Section&nbsp;5.16 of the Business
Combination Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after giving effect to the transactions contemplated by the Business Combination Agreement (including the PIPE
Financing), CHFW having at least $5,000,001 of net tangible assets (as determined in accordance with Rule <FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange Act) immediately after the Effective Time of the Merger; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Domestication shall have been consummated on or prior to the Closing Date prior to the Effective Time.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Other Conditions to the Obligations of the CHFW Parties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The obligations of CHFW to consummate the transactions contemplated by the Business Combination Agreement are subject to the satisfaction or,
if permitted by applicable law, waiver by CHFW (on behalf of itself and the other CHFW Parties) of the following further conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the representations and warranties of Surrozen regarding organization and qualification of Surrozen and its
subsidiaries, certain representations and warranties regarding the capitalization, and amounts payable upon a change in control, of Surrozen and the representations and warranties of Surrozen regarding the authority of Surrozen to, among other
things, consummate the transactions contemplated by the Business Combination Agreement, the intended tax treatment of the Merger and brokers fees being true and correct (without giving effect to any limitation as to &#147;materiality&#148; or
&#147;Company Material Adverse Effect&#148; (as defined therein) or any similar limitation) (except for <I>de minimis</I> inaccuracies) in all material respects as of the Closing Date as if made at and as of such date (or, if given as of an earlier
date, as of such earlier date); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain other representations and warranties regarding the capitalization of Surrozen being true and correct
in all respects (except for <I>de minimis</I> inaccuracies) as of the Closing Date (or, if given as of an earlier date, as of such earlier date); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other representations and warranties of Surrozen being true and correct (without giving effect to any
limitation as to &#147;materiality&#148; or &#147;Company Material Adverse Effect&#148; or any similar limitation set forth in the Business Combination Agreement) in all respects as of the Closing Date (or, if given as of an earlier date, as of such
earlier date), except where the failure of such representations and warranties to be true and correct, taken as a whole, does not cause a Company Material Adverse Effect; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen having performed and complied in all material respects with the covenants and agreements required to
be performed or complied with by it under the Business Combination Agreement prior to the Closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">since the date of the Business Combination Agreement, no Company Material Adverse Effect has occurred that is
continuing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CHFW must have received a certificate duly executed by an authorized officer of Surrozen confirming the
conditions set forth above have been satisfied, dated as of the Closing Date; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CHFW must have received the Investors Rights Agreement duly executed by CHFW and certain Surrozen
Stockholders. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Other Conditions to the Obligations of Surrozen </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The obligations of Surrozen to consummate the transactions contemplated by the Business Combination Agreement are subject to the satisfaction
or, if permitted by applicable law, waiver by Surrozen of the following further conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the representations and warranties of CHFW regarding organization and qualification of the CHFW Parties,
certain representations and warranties regarding the capitalization, the representations and warranties of CHFW regarding the authority of CHFW to, among other things, consummate the transactions contemplated by the Business Combination Agreement,
and brokers fees being true and correct in all material respects as of the Closing Date as if made at and as of such date (or, if given as of an earlier date, as of such earlier date); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain other representations and warranties regarding the capitalization of CHFW being true and correct in
all respects (except for <I>de minimis</I> inaccuracies) as of the Closing Date (or, if given as of an earlier date, as of such earlier date); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other representations and warranties of CHFW being true and correct (without giving effect to any
limitation as to &#147;materiality&#148; or &#147;CHFW Material Adverse Effect&#148; or any similar limitation set forth in the Business Combination Agreement) in all respects as of the Closing Date (or, if given as of an earlier date, as of such
earlier date), except where the failure of such representations and warranties to be true and correct, taken as a whole, does not cause a CHFW Material Adverse Effect; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CHFW Parties having performed and complied in all material respects with the covenants and agreements required
to be performed or complied with by it under the Business Combination Agreement prior to the Closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen must have received a certificate duly executed by an authorized officer of CHFW confirming the
conditions set forth above have been satisfied, dated as of the Closing Date; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen must have received the Investors Rights Agreement duly executed by CHFW and certain Surrozen
Stockholders. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_63"></A>Representations and Warranties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Business Combination Agreement contains customary representations, warranties and covenants of (a)&nbsp;Surrozen and (b)&nbsp;the CHFW
Parties, in each case relating to, among other things, their ability to enter into the Business Combination Agreement and their respective outstanding capitalization. These representations and warranties are subject to materiality, knowledge and
other similar qualifications in many respects and expire at the Effective Time. These representations and warranties have been made solely for the benefit of the other parties to the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Business Combination Agreement, Surrozen made customary representations and warranties to CHFW relating to, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">organization and qualification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">capitalization; authorization; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial statements, absence of undisclosed liabilities, consents and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">material contracts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">absence of certain changes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">litigation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">environmental matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">labor matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real and personal property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transactions with affiliates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">data privacy and security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with international trade and anti-corruption laws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information supplied; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">and regulatory compliance and investigation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Business Combination Agreement, the CHFW Parties made customary representations and warranties to Surrozen relating to, among other
things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">organization and qualification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consent and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information supplier; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">capitalization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">SEC Filings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trust account; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transactions with affiliates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">litigation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">internal controls and financial statements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">absence of undisclosed liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investigation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with international trade and anti-corruption laws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information supplied; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory compliance and investigation. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_64"></A>Material Adverse Effect </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Business Combination Agreement, certain representations and warranties of Surrozen and CHFW are qualified in whole or in part by
materiality thresholds. In addition, certain representations and warranties of Surrozen and CHFW are qualified in whole or in part by a material adverse effect standard for purposes of determining whether a breach of such representations and
warranties has occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the Business Combination Agreement, a &#147;Company Material Adverse Effect&#148; means any change,
event, effect or occurrence that, individually or in the aggregate with any other change, event, effect or occurrence, has had or would reasonably be expected to have a material adverse effect on (a)&nbsp;the business, results of operations or
financial condition of the Group Companies, taken as a whole, or (b)&nbsp;the ability of the Company to consummate the Merger; provided, however, that, in the case of clause (a), none of the following shall be taken into account in determining
whether a Company Material Adverse Effect has occurred or is reasonably likely to occur: any adverse change, event, effect or occurrence arising after the date of this Agreement from or related to (i)&nbsp;general business or economic conditions in
or affecting the United States, or changes therein, or the global economy generally, (ii)&nbsp;any national or international political or social conditions in the United States or any other country, including the engagement by the United States or
any other country in hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence in any place of any military or terrorist attack, sabotage or cyberterrorism, (iii)&nbsp;changes in conditions of the
financial, banking, capital or securities markets generally in the United States or any other country or region in the world, or changes therein, including changes in interest rates in the United States or any other country and changes in exchange
rates for the currencies of any countries, (iv)&nbsp;changes in any applicable Laws, (v)&nbsp;any change, event, effect or occurrence that is generally applicable to the industries or markets in which any Group Company operates, (vi)&nbsp;the
execution or public announcement of this Agreement or the pendency or consummation of the Transactions, including the impact thereof on the relationships, contractual or otherwise, of any Group Company with employees, customers, investors,
contractors, lenders, suppliers, vendors, partners, licensors, licensees, payors or other third parties related thereto (provided that the exception in this clause (vi)&nbsp;shall not apply to the representations and warranties set forth in
Section&nbsp;3.5(b) of the Business Combination Agreement to the extent that its purpose is to address the consequences resulting from the public announcement or pendency or consummation of the Transactions or the condition set forth in
Section&nbsp;6.2(a) of the Business Combination Agreement to the extent it relates to such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
representations and warranties), (vii) any failure by any Group Company to meet, or changes to, any internal or published budgets, projections, forecasts, estimates or predictions (although the
underlying facts and circumstances resulting in such failure may be taken into account to the extent not otherwise excluded from this definition pursuant to clauses (i)&nbsp;through (vi) or (viii)), or (viii)&nbsp;any hurricane, tornado, flood,
earthquake, tsunami, natural disaster, mudslides, wild fires, epidemics, pandemics (including <FONT STYLE="white-space:nowrap">COVID-19)</FONT> or quarantines, acts of God or other natural disasters or comparable events in the United States or any
other country or region in the world, or any escalation of the foregoing; provided, however, that any change, event, effect or occurrence resulting from a matter described in any of the foregoing clauses (i)&nbsp;through (v) or (viii)&nbsp;may be
taken into account in determining whether a Company Material Adverse Effect has occurred or is reasonably likely to occur to the extent such change, event, effect or occurrence has a disproportionate adverse effect on the Group Companies, taken as a
whole, relative to other participants operating in the industries or markets in which the Group Companies operate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Business
Combination Agreement, certain representations and warranties of the CHFW Parties are qualified in whole or in part by a material adverse effect standard for purposes of determining whether a breach of such representations and warranties has
occurred. Pursuant to the Business Combination Agreement, an &#147;CHFW Material Adverse Effect&#148; means any change, event, effect or occurrence that, individually or in the aggregate with any other change, event, effect or occurrence, has had or
would reasonably be expected to have a material adverse effect on (a)&nbsp;the business, results of operations or financial condition of the CHFW Parties, taken as a whole, or (b)&nbsp;the ability of CHFW or Merger Sub, Inc. to consummate the
Merger; provided, however, that, in the case of clause (a), none of the following shall be taken into account in determining whether a CHFW Material Adverse Effect has occurred or is reasonably likely to occur: any adverse change, event, effect or
occurrence arising after the date of this Agreement from or related to (i)&nbsp;general business or economic conditions in or affecting the United States, or changes therein, or the global economy generally, (ii)&nbsp;any national or international
political or social conditions in the United States or any other country, including the engagement by the United States or any other country in hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence
in any place of any military or terrorist attack, sabotage or cyberterrorism, (iii)&nbsp;changes in conditions of the financial, banking, capital or securities markets generally in the United States or any other country or region in the world, or
changes therein, including changes in interest rates in the United States or any other country and changes in exchange rates for the currencies of any countries, (iv)&nbsp;changes in any applicable Laws, (v)&nbsp;any change, event, effect or
occurrence that is generally applicable to the industries or markets in which any CHFW Party operates, (vi)&nbsp;the execution or public announcement of this Agreement or the pendency or consummation of the Transactions, including the impact thereof
on the relationships, contractual or otherwise, of any CHFW Party with investors, contractors, lenders, suppliers, vendors, partners, licensors, licensees, payors or other third parties related thereto (provided that the exception in this clause
(vi)&nbsp;shall not apply to the representations and warranties set forth in Section&nbsp;4.3(b) to the extent that its purpose is to address the consequences resulting from the public announcement or pendency or consummation of the Transactions or
the condition set forth in Section&nbsp;6.3(a) to the extent it relates to such representations and warranties), (vii) any failure by any CHFW Party to meet, or changes to, any internal or published budgets, projections, forecasts, estimates or
predictions (although the underlying facts and circumstances resulting in such failure may be taken into account to the extent not otherwise excluded from this definition pursuant to clauses (i)&nbsp;through (vi) or (viii)), or (viii)&nbsp;any
hurricane, tornado, flood, earthquake, tsunami, natural disaster, mudslides, wild fires, epidemics, pandemics (including <FONT STYLE="white-space:nowrap">COVID-19)</FONT> or quarantines, acts of God or other natural disasters or comparable events in
the United States or any other country or region in the world, or any escalation of the foregoing; provided, however, that any change, event, effect or occurrence resulting from a matter described in any of the foregoing clauses (i)&nbsp;through (v)
or (viii)&nbsp;may be taken into account in determining whether a CHFW Material Adverse Effect has occurred or is reasonably likely to occur to the extent such change, event, effect or occurrence has a disproportionate adverse effect on the CHFW
Parties, taken as a whole, relative to other &#147;SPACs&#148; operating in the industries in which the CHFW Parties operate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_65"></A>Covenants of the Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Covenants of Surrozen </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to certain exceptions or as consented to in writing by CHFW (such consent not to be unreasonably withheld, conditioned or delayed),
prior to the Closing, Surrozen will and will cause its subsidiaries to, (i)&nbsp;operate the business of the Surrozen and its subsidiaries (the &#147;Group Company&#148;) in the ordinary course in all material respects and (ii)&nbsp;use commercially
reasonable efforts to maintain and preserve intact in all material respects the business organization, assets, properties and material business relations of the Surrozen and its subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to certain exceptions, prior to the Closing, Surrozen will and will cause its subsidiaries to, not do any of the following without
CHFW&#146;s consent (such consent not to be unreasonably withheld, conditioned or delayed): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">declare, set aside, make or pay a dividend on, or make any other distribution or payment in respect of, any
Equity Securities of any Group Company or repurchase any outstanding Equity Securities of any Group Company, other than dividends or distributions, declared, set aside or paid by any of the Company&#146;s Subsidiaries to the Company or any
Subsidiary that is, directly or indirectly, wholly owned by the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(A) merge, consolidate, combine or amalgamate any Group Company with any person or (B)&nbsp;purchase or
otherwise acquire (through acquisition, license, joint venture, collaboration or otherwise) any equity securities, assets or other rights of any corporation, partnership, association or other business entity or organization or division thereof;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adopt any amendments, supplements, restatements or modifications to any Group Company&#146;s governing
documents, the Surrozen stockholders agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(A) sell, assign, abandon, lease, license or otherwise dispose of any material assets or properties of the
Group Companies, including any intellectual property rights (whether through a sale, license, joint venture, collaboration or otherwise), other than inventory or obsolete equipment in the ordinary course of business or nonexclusive licenses in the
ordinary course of business, or (B)&nbsp;create, subject or incur any lien any material assets or properties of the Group Companies (other than permitted liens or nonexclusive licenses in the ordinary course of business); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfer, issue, sell, grant or otherwise directly or indirectly dispose of, or subject to a lien,
(A)&nbsp;any equity securities of any Group Company or (B)&nbsp;any options, warrants, rights of conversion or other rights, agreements, arrangements or commitments obligating any Group Company to issue, deliver or sell any equity securities of any
Group Company; other than the issuance of shares of the applicable class of capital stock of the Surrozen upon the exercise or conversion of any Surrozen option on the date of this Agreement in accordance with the terms of the Surrozen equity plan
and the underlying grant, award or similar agreement or the issuance of Surrozen options or restricted stock covering up to 600,000 Surrozen common shares under the Surrozen equity plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur, create or assume any Indebtedness, other than ordinary course trade payables; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(A) amend, modify or terminate any material contract (excluding, for the avoidance of doubt, any expiration or
automatic extension or renewal of any such material contract pursuant to its terms or entering into additional work orders pursuant to, and in accordance with the terms of, any material contract in the ordinary course of business and consistent with
past practice), (B) waive any material benefit or right under any material contract or (C)&nbsp;enter into any contract that would constitute a material contract; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any loans, advances or capital contributions to, or guarantees for the benefit of, or any investments in,
any person, other than (A)&nbsp;intercompany loans or capital contributions between Surrozen and any of its wholly owned subsidiaries and (B)&nbsp;the reimbursement of expenses of employees in the ordinary course of business; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except as required under the terms of any employee benefit plan of any Group Company that is set forth on the
Section&nbsp;3.11(a) of the disclosure schedules or required under applicable law, (A)&nbsp;amend, modify, adopt, enter into or terminate any material employee benefit plan of any Group Company or any material benefit or compensation plan, policy,
program or Contract that would be an employee benefit plan if in effect as of the date of the Business Combination Agreement, (B)&nbsp;increase the compensation or benefits payable to any current or former director, manager, officer, employee,
individual independent contractor or other service provider of any Group Company, (C)&nbsp;take any action to accelerate any payment, right to payment, or benefit, or the funding of any payment, right to payment or benefit, payable or to become
payable to any current or former director, manager, officer, employee, individual independent contractor or other service provider of any Group Company, (D)&nbsp;waive or release any noncompetition, nonsolicitation,
<FONT STYLE="white-space:nowrap">no-hire,</FONT> nondisclosure or other restrictive covenant obligation of any current or former director, manager, officer, employee, individual independent contractor or other service provider of any Group Company,
(E)&nbsp;terminate without cause the employment of any director, manager or officer (provided that the Company agrees to provide prompt written notice to CHFW of any termination of a director, manager or officer for cause) of any Group Company or
terminate the employment of any group of employees of any Group Company, (F)&nbsp;hire any director or officer, or hire any other individuals outside of the approved budget and hiring plan attached to Section&nbsp;5.1(b)(ix)(F) of the disclosure
schedules, (G)&nbsp;initiate any Proceeding with respect to any current or former director, manager, officer, employee, individual independent contractor, or other service provider of the Group Companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make, change or revoke any material election concerning taxes, enter into any material tax closing agreement,
settle any material tax claim or assessment, or consent to any extension or waiver of the limitation period applicable to or relating to any material tax claim or assessment, other than any such extension or waiver that is obtained in the ordinary
course of business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any settlement, conciliation or similar contract the performance of which would involve the payment
by the Group Companies in excess of $2,000,000, in the aggregate, or that imposes, or by its terms will impose at any point in the future, any material, <FONT STYLE="white-space:nowrap">non-monetary</FONT> obligations on any Group Company (or CHFW
or any of its Affiliates after the Closing); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize, recommend, propose or announce an intention to adopt, or otherwise effect, a plan of complete or
partial liquidation, dissolution, restructuring, recapitalization, reorganization or similar transaction involving any Group Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change any Group Company&#146;s methods of accounting in any material respect, other than changes that are
made in accordance with FASB standards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any Contract with any broker, finder, investment banker or other Person under which such Person is
or will be entitled to any brokerage fee, finders&#146; fee or other commission in connection with the Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change of control payment that is not set forth on Section&nbsp;3.11(d) of the disclosure schedules;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any contract to take, or cause to be taken, any of the actions set forth above.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Additional Agreements of Surrozen </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to certain exceptions, prior to the Closing or termination of the Business Combination Agreement in accordance with its terms, Surrozen
shall not, and shall cause its subsidiaries and its and their respective representatives not to: (i) solicit, initiate, knowingly encourage (including by means of furnishing or disclosing information), knowingly facilitate, discuss or negotiate,
directly or indirectly, any inquiry, proposal or offer (written or oral) with respect to a Surrozen Acquisition Proposal; (ii)&nbsp;furnish or disclose any <FONT STYLE="white-space:nowrap">non-public</FONT> information to any Person in connection
with, or that could reasonably be expected to lead to, a Surrozen </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Acquisition Proposal; (iii)&nbsp;enter into any Contract or other arrangement or understanding regarding a Surrozen Acquisition Proposal; (iv)&nbsp;prepare or take any steps in connection with a
public offering of any equity securities of any Group Company (or any affiliate or successor of any Group Company); or (v)&nbsp;otherwise cooperate in any way with, or assist or participate in, or knowingly facilitate or encourage any effort or
attempt by any person to do or seek to do any of the foregoing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Conduct of Business of CHFW </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW made certain covenants under the Business Combination Agreement, including, among others, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Subject to certain exceptions, from and after the date of this Agreement until the earlier of the Closing or
the termination of the Business Combination Agreement in accordance with its terms CHFW shall not, and shall cause its subsidiaries not to, as applicable, except as expressly contemplated by the Business Combination Agreement or any ancillary
document (including, for the avoidance of doubt, in connection with the Domestication or the PIPE Financing), as required by applicable Law, as set forth on Section&nbsp;5.10 of the CHFW disclosure schedules or as consented to in writing by Surrozen
(such consent not to be unreasonably withheld, conditioned or delayed), do any of the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adopt any amendments, supplements, restatements or modifications to the trust agreement, CHFW Warrant
Agreement, or the CHFW governing documents of any CHFW party or any of its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">declare, set aside, make or pay a dividend on, or make any other distribution or payment in respect of, any
equity securities of CHFW or any of its subsidiaries, or repurchase, redeem or otherwise acquire, or offer to repurchase, redeem or otherwise acquire, any outstanding equity securities of CHFW or any of its subsidiaries, as applicable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">split, combine or reclassify any of its capital stock or other equity securities or issue any other security
in respect of, in lieu of or in substitution for shares of its capital stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur, create or assume any indebtedness or other liabilities (other than in connection with the
Transactions); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any loans or advances to, or capital contributions in, any other person, other than to, or in, CHFW or
any of its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue any equity securities of CHFW or any of its subsidiaries or grant any additional options, warrants or
stock appreciation rights with respect to Equity Securities of the foregoing of CHFW or any of its wholly-owned subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into, renew, modify or revise any CHFW related party transaction (or any contract or agreement that if
entered into prior to the execution and delivery of the Business Combination Agreement would be a CHFW related party transaction); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make, change or revoke any material election concerning taxes, enter into any material tax closing agreement,
settle any material tax claim or assessment, or consent to any extension or waiver of the limitation period applicable to or relating to any material tax claim or assessment, other than any such extension or waiver that is obtained in the ordinary
course of business. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Proxy Statement; Registration Statement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As soon as reasonably practicable, CHFW and Surrozen agreed to prepare and file with the SEC this proxy statement/prospectus. CHFW agrees to
use its reasonable best efforts to cause this proxy statement/prospectus to be declared effective under the Securities Act as soon as reasonably practicable after filing. CHFW shall cause this proxy statement/prospectus to be mailed to its
shareholders of record, as of the record date to be established by the CHFW Board and in compliance with the Business Combination Agreement, as promptly as practicable, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
following this proxy statement/prospectus being declared effective under the Securities Act. CHFW will cause all documents that it is responsible for filing with the SEC or other regulatory
authorities in connection with the merger to (i)&nbsp;comply as to form with all applicable SEC requirements and (ii)&nbsp;otherwise comply in all material respects with all applicable law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>CHFW Shareholder Meeting and CHFW Board Recommendation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW has agreed, in accordance with applicable law, NYSE American and Nasdaq rules and its existing governance documents, to establish a record
date for call and hold a meeting of its shareholders as soon as reasonably practicable after the date on which this proxy statement/prospectus is declared effective, and in no event later than 40 days from the effective date and to solicit from its
shareholders the approval of the proposals contained in this proxy statement/prospectus. CHFW has further agreed (i)&nbsp;to include a statement to the effect that CHFW&#146;s board of directors has unanimously recommended that the shareholders vote
in favor of each of the proposals in this proxy statement/prospectus and (ii)&nbsp;that CHFW&#146;s board of directors will not withdraw, amend, qualify or modify the board&#146;s recommendation for each required proposal except to the extent
required by applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>No Solicitation; Change in Recommendation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to the Closing or termination of the Business Combination Agreement in accordance with its terms, each of CHFW, Merger Sub and Surrozen
have agreement that they shall not and shall cause its representatives not to, directly or indirectly: (i)&nbsp;solicit, initiate, knowingly encourage (including by means of furnishing or disclosing information), knowingly facilitate, discuss or
negotiate, directly or indirectly, any inquiry, proposal or offer (written or oral) with respect to a CHFW Acquisition Proposal<B> </B>or Surrozen Acquisition Proposal, as applicable; (ii)&nbsp;furnish or disclose any nonpublic information to any
Person in connection with, or that could reasonably be expected to lead to, a CHFW Acquisition Proposal<B> </B>or Surrozen Acquisition Proposal, as applicable; (iii)&nbsp;enter into any Contract or other arrangement or understanding regarding a CHFW
Acquisition Proposal<B> </B>or Surrozen Acquisition Proposal, as applicable; (iv)&nbsp;prepare or take any steps in connection with an offering of any securities of any CHFW<B> </B>party) or prepare or take any steps in connection with an offering
of any securities of any Surrozen party (or any Affiliate or successor of any Surrozen party (or any Affiliate or successor of any CHFW party); or (v)&nbsp;otherwise cooperate in any way with, or assist or participate in, or knowingly facilitate or
encourage any effort or attempt by any Person to do or seek to do any of the foregoing. CHFW agrees to (A)&nbsp;notify Surrozen promptly upon receipt of any CHFW Acquisition Proposal by any CHFW party, and to describe the material terms and
conditions of any such Acquisition Proposal in reasonable detail (including the identity of any person or entity making such CHFW Acquisition Proposal) and (B)&nbsp;keep Surrozen reasonably informed on a current basis of any modifications to such
offer or information and Surrozen agrees to (A)&nbsp;notify CHFW promptly upon receipt of any Surrozen Acquisition Proposal by any Surrozen party, and to describe the material terms and conditions of any such Acquisition Proposal in reasonable
detail (including the identity of any person or entity making such Surrozen acquisition Proposal) and (B)&nbsp;keep CHFW reasonably informed on a current basis of any modifications to such offer or information; except as required by law, each of
CHFW, Merger Sub and Surrozen shall not (vii)&nbsp;withhold, withdraw, qualify, amend or modify (or publicly propose or announce any intention or desire to withhold, withdraw, qualify, amend or modify), in a manner adverse to the other party, the
approval of such party&#146;s board of directors of the merger agreement and/or any of the transactions contemplated thereby, or, in the case of CHFW, the board of director recommendation, (viii)&nbsp;approve any transaction, or any third party
becoming an &#147;interested stockholder&#148;, under applicable laws or (ix)&nbsp;resolve, propose or agree to do any of the foregoing (any of the actions described in clauses&nbsp;(iii)-(ix), a &#147;change in recommendation&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Stock Exchange Listing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW has agreed to use reasonable best efforts to cause CHFW shares issuable under the Business Combination Agreement, including shares
issuable upon the exercise of Converted Options, and the outstanding CHFW shares to be approved for listing on Nasdaq, subject to official notice of issuance, and to satisfy any applicable initial and continual listing requirements of Nasdaq. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>PIPE Financing Covenants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless otherwise approved by Surrozen, CHFW has agreed not to permit any amendment or modification to be made, not to grant any waiver of, and
not to provide any consent to modify or terminate any provision or remedy under, or any replacements of, any of the Subscription Agreements for the PIPE Financing other than certain permitted assignments or transfers of the Subscription Agreements.
CHFW further agrees to use reasonable best efforts to take, or cause to be taken all actions required, necessary or that CHFW deems to be proper or advisable to consummate the PIPE Financing contemplated by the Subscription Agreements on the terms
of the Subscription Agreements and cause the PIPE Investors to pay the purchase price under the Subscription Agreement. CHFW also agrees to provide certain notices to Surrozen of any potential amendments or modifications to the Subscription
Agreements or if CHFW does not expect to receive all or any portion of the purchase price under the Subscription Agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Mutual
Covenants of the Parties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The parties made certain covenants under the Business Combination Agreement, including, among others, the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">using reasonable best efforts to consummate the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">notify the other party in writing promptly after learning of any shareholder demands or other shareholder
proceedings relating to the Business Combination Agreement, any ancillary document or any matters relating thereto and reasonably cooperate with one another in connection therewith; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">keeping certain information confidential in accordance with the existing
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making relevant public announcements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">confidentiality and publicity relating to the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">director and officer indemnification and insurance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CHFW making appropriate arrangements for certain disbursements from the trust account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CHFW taking steps to exempt the acquisition of CHFW Class&nbsp;A common stock and founder shares from
Section&nbsp;16(b) of the Exchange Act pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3&nbsp;thereunder;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">using reasonable best efforts to cause the each of the Domestication and the Merger to constitute a
transaction treated as a &#147;reorganization&#148; within the meaning of Section&nbsp;368 of the IRS Code or otherwise use commercially reasonable efforts to restructure the Merger to so qualify; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cooperate in connection with certain tax matters and filings. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_66"></A>Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Business Combination Agreement provides that following the Closing, the current management of Surrozen will become the management of New
Surrozen. CHFW will take all action within its power as may be necessary or appropriate such that, effective immediately after the closing of the Business Combination, the New Surrozen Board shall consist of nine directors, who shall be divided into
three classes, which directors shall include (i)&nbsp;eight individuals identified by Surrozen (and reasonably acceptable to CHFW) and (ii)&nbsp;one individual identified by CHFW (and reasonably acceptable to the Chief Executive Officer of
Surrozen), which shall be divided into three classes, designated Class&nbsp;I, II and III, with Class&nbsp;I consisting of three directors who shall initially <FONT STYLE="white-space:nowrap">be&nbsp;re-elected&nbsp;at</FONT> the 2022 annual
stockholders meeting, Class&nbsp;II consisting of three directors who shall initially <FONT STYLE="white-space:nowrap">be&nbsp;re-elected&nbsp;at</FONT> the 2023 annual stockholders meeting and Class&nbsp;III consisting of three directors who shall
initially <FONT STYLE="white-space:nowrap">be&nbsp;re-elected&nbsp;at</FONT> the 2024 annual stockholders meeting. The CHFW designee shall be appointed to Class&nbsp;III and the Surrozen designees shall be appointed to such Classes as Surrozen
reasonably determines. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_67"></A>Survival of Representations, Warranties and Covenants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The representations, warranties, agreements and covenants in the Business Combination Agreement terminate at the Effective Time, except for the
covenants and agreements that, by their terms, contemplate performance after the Effective Time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_68"></A>Termination
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Business Combination Agreement may be terminated under certain customary and limited circumstances at any time prior to the
Closing, including, among others, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by the mutual written consent of CHFW and Surrozen; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by CHFW, if any of the representations or warranties set forth in Article 3 of the Business Combination
Agreement shall not be true and correct or if Surrozen has failed to perform any covenant or agreement on the part of Surrozen set forth in the Business Combination Agreement (including an obligation to consummate the Closing) such that the
condition to Closing set forth in either Section&nbsp;6.2(a) or Section&nbsp;6.2(b) of the Business Combination Agreement could not be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the
failures to perform any covenant or agreement, as applicable, is (or are) not cured or cannot be cured within the earlier of (i)&nbsp;thirty (30) days after written notice thereof is delivered to Surrozen by CHFW, and (ii)&nbsp;the Termination Date;
provided, however, that none of the CHFW Parties is then in breach of the Business Combination Agreement so as to prevent the condition to Closing set forth in either Section&nbsp;6.3(a) or Section&nbsp;6.3(b) of the Business Combination Agreement
from being satisfied; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Surrozen, if any of the representations or warranties set forth in Article 4 of the Business Combination
Agreement shall not be true and correct or if any CHFW party has failed to perform any covenant or agreement on the part of such applicable CHFW party set forth in the Business Combination Agreement (including an obligation to consummate the
Closing) such that the condition to Closing set forth in either Section&nbsp;6.3(a) or Section&nbsp;6.3(b) of the Business Combination Agreement could not be satisfied and the breach or breaches causing such representations or warranties not to be
true and correct, or the failures to perform any covenant or agreement, as applicable, is (or are) not cured or cannot be cured within the earlier of (i)&nbsp;thirty (30) days after written notice thereof is delivered to CHFW by Surrozen and
(ii)&nbsp;the Termination Date; provided, however, Surrozen is not then in breach of this Agreement so as to prevent the condition to Closing set forth in Section&nbsp;6.2(a) or Section&nbsp;6.2(b) of the Business Combination Agreement from being
satisfied; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either CHFW or Surrozen, if the transactions contemplated by the Business Combination Agreement shall not
have been consummated on or prior to October&nbsp;12, 2021 (the &#147;Termination Date&#148;); provided that if the Registration Statement filed pursuant to Section&nbsp;5.7 of the Business Combination Agreement, is not declared effective by
August&nbsp;13, 2021 then the Termination will be automatically extended by 60 days; provided, that (i)&nbsp;the right to terminate this Agreement pursuant to Section&nbsp;7.1(d) of the Business Combination Agreement shall not be available to CHFW
if any CHFW party&#146;s breach of any of its covenants or obligations under this Agreement shall have proximately caused the failure to consummate the transactions contemplated by the Business Combination Agreement on or before the Termination
Date, and (ii)&nbsp;the right to terminate this Agreement pursuant to Section&nbsp;7.1(d) of the Business Combination Agreement shall not be available to Surrozen if the Surrozen&#146;s breach of its covenants or obligations under the Business
Combination Agreement shall have proximately caused the failure to consummate the transactions contemplated by the Business Combination Agreement on or before the Termination Date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either CHFW or Surrozen, if any governmental entity shall have issued an order or taken any other action
permanently enjoining, restraining or otherwise prohibiting the transactions contemplated by the Business Combination Agreement and such order or other action shall have become final and nonappealable; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by either CHFW or Surrozen if the CHFW shareholders meeting has been held (including any adjournment or
postponement thereof), has concluded, CHFW&#146;s shareholders have duly voted and the required CHFW shareholder approval<B> </B>of each of the Condition Precedent Approvals was not obtained; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by CHFW, if Surrozen does not deliver, or cause to be delivered to, to CHFW (i)&nbsp;a Company Support
Agreement duly executed by Surrozen Stockholders holding at least 67% of the preferred stock on or prior to one business day following the date of the Business Combination Agreement or (ii)&nbsp;Surrozen stockholder written consent approving the
Merger on or prior to five business days following the time at which the registration statement/proxy statement is declared effective under the Securities Act; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by Surrozen if there is a Modification of the Recommendation (as defined in the Business Combination
Agreement). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_69"></A>Effect of Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the Business Combination Agreement is validly terminated, none of the parties to the Business Combination Agreement will have any liability
or any further obligation under the Business Combination Agreement&nbsp;other than customary confidentiality obligations<B> </B>and certain provisions in Article 8 and Article 1 of the Business Combination Agreement (to the extent related to the
foregoing), except in the case of a Willful Breach (as defined in the Business Combination Agreement) of any covenant or agreement under the Business Combination Agreement, fraud or any person&#146;s liability under any Subscription Agreement, any
confidentiality agreement, any transaction support agreement to which he, she or it is a party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_70"></A>Expenses
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fees and expenses incurred in connection with the Business Combination Agreement and the ancillary documents thereto, and the
transactions contemplated thereby, including the fees and disbursements of counsel, financial advisors and accountants, shall be paid by the party incurring such fees or expenses; provided that, for the avoidance of doubt, (a)&nbsp;if this Agreement
is terminated in accordance with its terms, Surrozen shall pay, or cause to be paid, all unpaid Surrozen expenses and CHFW shall pay, or cause to be paid, all unpaid CHFW expenses and (b)&nbsp;if the Closing occurs, then CHFW shall pay, or cause to
be paid, all unpaid Surrozen expenses and all unpaid CHFW expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_71"></A>Governing Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Business Combination Agreement is governed by and construed in accordance with the laws of the State of Delaware, without giving effect to
any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the law of any jurisdiction other than the State of Delaware. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_72"></A>Amendments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Business Combination Agreement may be amended or modified only by a written agreement executed and delivered by (a)&nbsp;CHFW and Surrozen
prior to the Closing and (b)&nbsp;CHFW and the Sponsor after the Closing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_73"></A>Ownership of New Surrozen </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of the date of this proxy statement/prospectus, there are 11,934,000 ordinary shares issued and outstanding, which includes the 2,300,000
Class&nbsp;B shares held by the Sponsor and certain directors of CHFW (before giving effect to the contribution of 759,000 Class&nbsp;B shares by the Sponsor to CHFW, for no consideration, that will be effective as of the closing), 434,000
Class&nbsp;A private placement shares and the 9,200,000 Class&nbsp;A public shares. As of the date of this proxy statement/prospectus, there is outstanding an aggregate of 3,211,334 warrants, which includes the 144,667 private placement warrants
held by the Sponsor and the 3,066,667 public warrants. Each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
whole warrant entitles the holder thereof to purchase one Class&nbsp;A ordinary share and, following the Domestication, will entitle the holder thereof to purchase one share of New Surrozen
common stock. Therefore, as of the date of this proxy statement/prospectus (without giving effect to the Business Combination) the CHFW fully diluted share capital would be 15,145,334. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is anticipated that, following the Business Combination (1)&nbsp;CHFW&#146;s public shareholders are expected to own approximately 21.3% of
the outstanding New Surrozen Common Stock (excluding the PIPE subscriptions by certain CHFW public shareholders), (2) Surrozen Stockholders (without taking into account any public shares held by Surrozen Stockholders prior to the consummation of the
Business Combination or shares of New Surrozen Common Stock issuable to holders of New Surrozen Awards, but taking into account the PIPE subscriptions by certain Surrozen Stockholders) are expected to own approximately 53.5% of the outstanding New
Surrozen Common Stock, (3)&nbsp;the Sponsor (taking into account Sponsor&#146;s PIPE subscription) is expected to own approximately 10.4% of the outstanding New Surrozen Common Stock and (4)&nbsp;the PIPE Investors (excluding subscriptions from
Surrozen Stockholders and from the Sponsor) are expected to own approximately 14.8% of the outstanding New Surrozen Common Stock. These&nbsp;percentages assume (i)&nbsp;that no public shareholders exercise their redemption rights in connection with
the Business Combination, (ii)&nbsp;no exercise of the public warrants or issuance of any shares of New Surrozen Common Stock, (iii)&nbsp;that (x)&nbsp;New Surrozen issues or reserves 20,000,000 shares of New Surrozen Common Stock to Surrozen
Stockholders and holders of vested and unvested Surrozen equity awards as part of the Merger consideration pursuant to the Business Combination Agreement and (y)&nbsp;New Surrozen issues 12,020,000 shares of New Surrozen Common Stock to the PIPE
Investors pursuant to the PIPE Investment. If the actual facts are different from these assumptions, the&nbsp;percentage ownership retained by current CHFW shareholders and Surrozen Stockholders will be different. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table illustrates varying ownership levels in New Surrozen immediately following the consummation of the Business Combination
based on the assumptions above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share Ownership in New Surrozen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma Combined<BR>(Assuming No Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma Combined<BR>(Assuming Maximum<BR>Redemptions)<SUP STYLE="font-size:85%; vertical-align:top">5</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Ownership<SUP STYLE="font-size:85%; vertical-align:top">6</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Ownership<SUP STYLE="font-size:85%; vertical-align:top">6</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surrozen stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,122,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,122,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CHFW&#146;s public shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,200,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsor and certain directors of CHFW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,472,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,472,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Investors (excluding Surrozen stockholders and Sponsor)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,400,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,195,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,295,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Includes 20,000,000 shares issuable to Surrozen equityholders as merger consideration per the terms of the
Business Combination Agreement, and 3,122,500 PIPE shares subscribed for by Surrozen stockholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Includes 1,000,000 shares purchased by affiliates of Consonance Capital Management in the CHFW IPO. Does not
reflect impact of any PIPE shares subscribed for by CHFW public shareholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Calculated as the sum of the following: (1) 1,541,000 founder&#146;s shares (which number is net of the
forfeiture of 759,000 founder&#146;s shares); (2) 434,000 shares underlying the private placement units; and (3) 2,497,500 shares subscribed for by Sponsor in the PIPE. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">12,020,000 PIPE shares, less subscriptions from existing Surrozen stockholders (3,122,500 shares) and
Sponsor (2,497,500 shares) </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">This scenario assumes the redemption of 7,900,000 public shares, equal to the number of public shares not
covered by CHFW Shareholder Support Agreements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Columns may not sum to 100% due to rounding. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_74"></A>Related Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This section describes certain additional agreements entered into or to be entered into pursuant to the Business Combination Agreement, but
does not purport to describe all of the terms thereof. The following summary is qualified in its entirety by reference to the complete text of each of the agreements. The form of Investor Rights Agreement, the form of Company Support Agreement, the
form of CHFW Shareholder Support Agreement and the form of Sponsor Letter Agreement are attached hereto as Annex F, Annex G, Annex H and Annex I, respectively. You are urged to read such agreements in their entirety prior to voting on the proposals
presented at the extraordinary general meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>PIPE Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW entered into Subscription Agreements with the PIPE Investors to consummate the PIPE Financing, pursuant to which the PIPE Investors have
agreed to subscribe for and purchase, and CHFW has agreed to issue and sell to the PIPE Investors, an aggregate of 12,020,000 units, each consisting of one share of CHFW Common Stock <FONT STYLE="white-space:nowrap">and&nbsp;one-third&nbsp;of</FONT>
one redeemable warrant for one share of CHFW Common Stock (the &#147;<U>PIPE Warrants</U>&#148;), for a purchase price of $10.00 per unit (the &#147;<U>PIPE Units</U>&#148;), for aggregate gross proceeds of $120,200,000 (the &#147;<U>PIPE
Financing</U>&#148;). The PIPE Units were offered to facilitate the subscriptions, however, the shares of CHFW Common Stock and the PIPE Warrants which comprise the PIPE Units are not attached and will trade separately without any instruction or
detachment obligations on the part of the investors, CHFW or the warrant agent. Each whole PIPE Warrant entitles the holder thereof to purchase one share of CHFW Common Stock at a price of $11.50 per share, subject to adjustment as described in the
form of warrant agreement attached to the form of Subscription Agreement and only whole PIPE Warrants will be exercisable. The PIPE Warrants have substantially the same provisions as the public warrants issued in connection with CHFW&#146;s initial
public offering. The PIPE Financing is contingent upon, among other things, the substantially concurrent closing of the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Investor Rights Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At, and as a condition to, the closing of the Business Combination, CHFW, Sponsor, and Surrozen stockholders affiliated with the Column Group
and the Regents of the University of California will enter into the Investor Rights Agreement pursuant to which, among other things, certain stockholders will agree not to effect any sale or distribution of CHFW equity securities during the <FONT
STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period as described therein, and will be granted certain customary registration rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The foregoing description of the Investor Rights Agreement is subject to and qualified in its entirety by reference to the full text of the
form of Investor Rights Agreement (filed as Exhibit 10.4 to CHFW&#146;s Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on April&nbsp;15, 2021). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Surrozen Company Support Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the Business Combination Agreement, certain stockholders of Surrozen, together holding more than 67% of the outstanding preferred
stock and voting power of Surrozen (collectively, the &#147;Surrozen Supporting Stockholders&#148;), each entered into a Company Support Agreement (the &#147;Transaction Support Agreements&#148;) with CHFW and Surrozen, pursuant to which the
Surrozen Supporting Stockholders have agreed to, among other things, (i)&nbsp;vote in favor of the Business Combination Agreement and the Transactions, (ii)&nbsp;irrevocably appoint Surrozen, and any designee thereof, and each of them individually,
as such Surrozen Stockholder&#146;s proxy <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">and&nbsp;attorney-in-fact&nbsp;to</FONT></FONT> deliver any action by written consent of the stockholders of Surrozen or attend any meeting
of the stockholders of Surrozen concerning the Business Combination and related stockholder proposals, and to include the Surrozen equity securities owned by the Surrozen Supporting Stockholders in any computation for purposes of establishing a
quorum at any such meeting, and to vote against any competing proposal and (iii)&nbsp;not transfer subject shares during the period prior to closing under or termination of the Business Combination Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The foregoing description of the Support Agreements is subject to and qualified in its
entirety by reference to the full text of the form of Support Agreement (filed as Exhibit 10.3 to CHFW&#146;s Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on April&nbsp;15, 2021). For additional information, see
&#147;<I>Business Combination Proposal&#151;Related Agreements&#151;Support Agreements</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>CHFW Shareholder Transaction
Support Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Concurrently with the execution of the Subscription Agreements, CHFW, Surrozen and certain affiliates of
Sponsor holding 1,300,000 public shares entered into shareholder support agreements (the &#147;Shareholder Support Agreements&#148;) pursuant to which each such holder agreed (i)&nbsp;to vote at any meeting of the shareholders of CHFW all of its
ordinary shares held of record or thereafter acquired in favor of the Business Combination and the other Transaction Proposals and (ii)&nbsp;not to redeem any such securities in connection with the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Sponsor Letter Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the Business Combination Agreement, CHFW, Sponsor, Donald J. Santel, Christopher Haqq, Jennifer Jarrett, who collectively hold
2,300,000 CHFW Class&nbsp;B ordinary shares, and Surrozen entered into the Sponsor Letter Agreement (the &#147;Sponsor Letter Agreement&#148;), pursuant to which the Sponsor and each of Mr.&nbsp;Santel, Dr.&nbsp;Haqq and Ms.&nbsp;Jarrett, each as a
holder of CHFW Class&nbsp;B ordinary shares, has agreed to: (i)&nbsp;vote in favor of the Business Combination, including each of the Transaction Proposals (as defined in the Business Combination Agreement), (ii) waive any adjustment to the
conversion ratio set forth in the governing documents of CHFW or any other anti-dilution or similar protection with respect to the Class&nbsp;B ordinary shares (whether resulting from the transactions contemplated by the Subscription Agreements (as
defined below) or otherwise), (iii) be bound by certain other covenants and agreements related to the Business Combination, (iv)&nbsp;be bound by certain transfer restrictions with respect to his, her or its shares in CHFW prior to the closing of
the Business Combination, and (v)&nbsp;in the case of the Sponsor, effective as of the closing, contribute to CHFW 759,000 Class&nbsp;B ordinary shares, in each case, for no consideration on the terms and subject to the conditions set forth in the
Sponsor Letter Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The foregoing description of the Sponsor Letter Agreement is subject to and qualified in its entirety by
reference to the full text of the form of Transaction Support Agreement (filed as Exhibit 10.1 to CHFW&#146;s Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on April&nbsp;15, 2021).<B> </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Background to the Business Combination </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following chronology summarizes the key meetings and events that led to the signing of the Business Combination Agreement. This chronology
does not purport to catalogue every conversation or correspondence among representatives of CHFW, Surrozen and the other various parties. In compliance with social distancing, travel restrictions and other
<FONT STYLE="white-space:nowrap">COVID-19</FONT> protocols, all meetings were held virtually (including by telephone, teleconference and <FONT STYLE="white-space:nowrap">web-based</FONT> video and meeting systems) where all participants could hear
and be heard. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW is a blank check company incorporated on August&nbsp;21, 2020 as a Cayman Islands exempted company and formed for the
purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September 2020, CHFW issued 3,593,750 founder shares to Sponsor in exchange for a capital contribution of $25,000. In October and November
2020, 718,750 and 575,000 founder shares were contributed back to CHFW for no consideration. In November 2020, Sponsor transferred 30,000 founder shares to each of Dr.&nbsp;Haqq, Ms.&nbsp;Jarrett, and Mr.&nbsp;Santel who joined the board of
directors of CHFW. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On November&nbsp;23, 2020, CHFW completed its initial public offering or IPO generating gross proceeds of
$80.0&nbsp;million before underwriting discounts and expenses. Subsequently, the underwriters of the IPO exercised </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
their option to purchase additional units from CHFW, generating additional gross proceeds of $12.0&nbsp;million before underwriting discounts and expenses. Simultaneous with the closing of its
IPO, CHFW completed the private placement of 410,000 private placement units at a price of $10.00 per private placement unit to Sponsor, and subsequently, simultaneous with the exercise of the underwriters&#146; option to purchase additional units,
CHFW completed the private placement of an additional 24,000 private placement units at a price of $10.00 per private placement unit to Sponsor. Prior to the consummation of CHFW&#146;s IPO, neither CHFW, nor any authorized person on its behalf,
initiated any substantive discussions, formal or otherwise, with respect to a business combination involving CHFW. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After completing its
IPO, CHFW utilized its and Sponsor&#146;s operating and investment management experience and networks to identify and evaluate potential targets with a life sciences and biotechnology focus, as more fully described below. CHFW&#146;s management and
directors commenced an active, targeted search for an initial set of potential business combination targets leveraging Sponsor&#146;s network of investment bankers, private equity and venture firms and hedge fund investors (including Consonance
Capital and its affiliates), consulting firms, legal and accounting firms and numerous other business relationships, as well as the prior experience and network of CHFW&#146;s management and directors to identify potential targets. Specifically,
CHFW&#146;s management and directors identified potential business combination partners in the growing life sciences and medical technology sectors, which CHFW&#146;s management and directors believed, based on their experience, could satisfy some
or all the following key criteria for a business combination target: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Multiple clinical and or <FONT STYLE="white-space:nowrap">pre-clinical</FONT> product candidates in its
pipeline, diversifying risk away from a single asset and providing multiple potential catalysts for value creation, business development or financing activities once public. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Existing clinical or preclinical data, whether or not generated by the target company, suggesting a validated
biologic or mechanistic rationale for the most advanced product candidates in its pipeline. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Pre-clinical</FONT> or clinical development programs designed to address
significant challenges in areas of high unmet need where opportunities exist for accelerated clinical development and registration due to the paucity of existing treatments or the limited safety or efficacy of current treatments.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A valuation at acquisition suggesting an attractive risk/reward profile for investors. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Management team with significant scientific, clinical, and operational expertise, with a track record of drug
development giving CHFW confidence that they can execute against stated timelines. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Company would be funded well beyond significant value inflection points once the was business combination
completed, and would benefit from CHFW&#146;s experience and network to bring value to patients and shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since
its IPO, CHFW identified and evaluated approximately 100 potential business combination partners, and proceeded to conduct varying levels of preliminary due diligence on each, including their product candidate pipelines and related preclinical
and/or clinical trial data, their market potential and financial information, in each case based on publicly available information and other market research available to the management team and its advisors. CHFW&#146;s initial target exploration
focused on certain targets with whom CHFW&#146;s directors and management, or Sponsor, were already familiar through their networks and investment activities, who they felt were unique and attractive, and who could satisfy some or all the key
criteria for a business combination target described above, including, Surrozen. As the initial exploration progressed, the list of potential business combination partners was refined to exclude potential partners who did not meet all or most of the
key criteria, or who CHFW management believed were unlikely to consider a business combination with a SPAC. The list of potential business combination partners was also expanded to include potential partners introduced to CHFW by venture capital
investors, investment bankers and inbound inquiries, and through the ongoing search efforts of CHFW management. During the process, CHFW had preliminary discussions with 39 potential targets (the &#147;Potential Targets&#148;), including 21
Potential Targets that had entered into customary confidentiality agreements with CHFW, including Surrozen on December&nbsp;18, 2020. The confidentiality agreements entered into with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Potential Targets contain customary <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-use</FONT> provisions and a customary trust account waiver
provision pursuant to which the Potential Targets waived any right, title, interest or claim in CHFW&#146;s trust account and agreed not to seek recourse against CHFW&#146;s trust account for any reason. CHFW did not enter into confidentiality
agreements with 18 Potential Targets for a variety of reasons, including because CHFW determined after preliminary discussions that such target was unlikely to meet a sufficient number of the stated acquisition criteria, or the target company was
not interested in pursuing a business combination with CHFW for differing reasons, including a desire to pursue a traditional initial public offering or timing considerations or for no stated reason. Throughout its evaluation of a potential business
combination, until CHFW and Surrozen entered into the term sheet with binding mutual exclusivity provisions described below, CHFW continuously refined its list of potential business combination partners and considered viable partner opportunities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the initial screening of targets, CHFW determined to initially focus its resources and efforts on three Potential Targets,
which we refer to as Company A, Company B and Company C, which CHFW believed were suitable candidates for a business combination for a variety of reasons, including each target&#146;s novel technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As part of this process, representatives of CHFW had multiple discussions with Company A, Company B and Company C, and representatives of CHFW
participated in management presentations and engaged in due diligence and discussions directly with the potential target&#146;s senior executives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On December&nbsp;22, 2020, the CHFW Board held a meeting with members of management and CHFW&#146;s outside counsel, Goodwin Procter, present.
At this meeting, management reviewed its targeting and evaluation process and results and the results of its more <FONT STYLE="white-space:nowrap">in-depth</FONT> evaluation of Company A, Company B and Company C, including the pros and cons of each
opportunity. With respect to Company A, the CHFW Board focused on Company A&#146;s positive attributes, including its differentiated approach to its candidate&#146;s lead target programs, the fact that it is a platform company with programs in
various stages of development and its relationship with a reputable collaboration partner, but also noted as potential areas of concern, the competitive landscape of the company&#146;s lead programs, the limited public company experience of, and the
need to build out, its management team, and potential tax and structural complications that would have to be overcome in the business combination. With respect to Company B, the CHFW Board focused on Company B&#146;s strong pipeline, with a lead
asset in Phase 1 in immuno-oncology, reputable backing and opportunities where CHFW could provide value to Company B&#146;s management team, but also noted concerns relating to the lack of public company experience of, and the need to build out, the
senior management team, the competitive landscape of its pipeline, historical challenges with the target class of the lead program, and potential tax and structural complications that would have to be overcome in the business combination. With
respect to Company C, the CHFW Board focused on Company C management&#146;s history of successful drug development and management of a public company, Company C&#146;s relationship with investors and its strong crossover investor backing, but also
noted challenges in developing a compelling valuation and concerns with competitive dynamics in the evolving clinical and commercial landscape facing its lead program. After discussion, and based on the recommendation of management, the CHFW Board
authorized management to conduct further due diligence exercise with respect to both Company A and Company B, while continuing to assess other potential targets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Over the next several weeks, CHFW management and its advisors conducted additional due diligence on Company A and Company B, and engaged in
further discussions with two other Potential Targets, namely a target we refer to as Company D and Surrozen. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Given their varying
roles and networks as biopharmaceutical executives over the years, the Surrozen CFO, Charles Williams, and the CHFW CEO, Gad Soffer, would connect with one another from time to time, and on December 8, 2020, Mr. Williams reached out to Mr. Soffer to
inform Mr. Soffer that Mr. Williams had recently joined Surrozen as its CFO, and suggesting that the two reconnect. On December, 11, 2020 Mr. Williams and Mr. Soffer engaged in a telephone conversation and discussed one another&#146;s new roles at
Surrozen and CHFW, respectively, and discussed the possibility of exploring a business combination between Surrozen and CHFW. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On January 9, 2021, members of the Surrozen and CHFW management teams participated in a
video conference during which the Surrozen team gave and the CHFW reviewed an overview of the Surrozen business. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On January&nbsp;26,
2021, CHFW and its advisors were granted access to Surrozen&#146;s virtual data room. On January&nbsp;28, 2021, the CHFW Board held a meeting at which members of management and Goodwin Procter were present. At this meeting, management presented the
results of its additional due diligence on Company A and Company B, and reported on management&#146;s further discussions with Company D and Surrozen. The management team presented the CHFW Board with proposed terms of a <FONT
STYLE="white-space:nowrap">non-binding</FONT> term sheet for a potential transaction with Company A, including a proposed binding exclusivity provision on Company A. Management provided the CHFW Board with its preliminary approach to valuation of
Company A. The CHFW Board also discussed the pros and cons of Company D and Surrozen. With respect to Company D, the CHFW Board focused on Company D&#146;s pipeline of indications and reputation, but also noted that there could be challenges in
developing a compelling valuation. With respect to Surrozen, the CHFW Board focused on Surrozen&#146;s strong Wnt pathway capabilities, the Wnt pathway&#146;s broad therapeutic potential, Surrozen&#146;s experienced management team and board of
directors and differentiated <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data, but also noted Surrozen was preparing for and may continue to pursue an initial public offering. After discussion, the CHFW Board authorized management to
deliver a <FONT STYLE="white-space:nowrap">non-binding</FONT> term sheet to Company A on the terms discussed at the meeting, and also encouraged management to continue due diligence efforts and discussion with Company B, Company D and Surrozen, and
to continue to assess other potential targets. Also at this meeting, the CHFW Board and management discussed engaging J.P. Morgan to act as placement agent for the PIPE Financing and as an M&amp;A advisor for the business combination, and that J.P.
Morgan was well-suited for the role given its experience in the life sciences industry and with transactions of this nature, and also given its role as lead underwriter for CHFW&#146;s IPO and the benefits of having familiarity with CHFW and its
team. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On February&nbsp;2, 2021, Surrozen held a board meeting in which members of management and Cooley were present. At this meeting
the Surrozen board considered Surrozen&#146;s planned cross-over financing and initial public offering, and alternative means to capitalize Surrozen if it appeared Surrozen would be unable to complete the planned cross-over financing and initial
public offering on terms and a timeline that would permit Surrozen to maintain its desired timelines for and investments in a development programs, including a SPAC merger, and the potential advantages, disadvantages and risks of each. The Surrozen
board approved formation of an informal Finance Committee of the board to meet regularly with management and review the progress of the proposed financings. Thereafter, weekly calls were held between the Finance Committee and Surrozen management.
The Finance Committee shifted to reviewing progress on the proposed business combination with CHFW after the Surrozen board approved entering into a <FONT STYLE="white-space:nowrap">non-binding</FONT> term sheet with CHFW later in February. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On February&nbsp;2, 2021, CHFW delivered the <FONT STYLE="white-space:nowrap">non-binding</FONT> term sheet to Company A. For the next
two weeks, representatives of CHFW participated in management presentations and engaged in due diligence and discussions with the respective senior executives of Company B, Company D and Surrozen, and discussed with Company A the terms of the <FONT
STYLE="white-space:nowrap">non-binding</FONT> term sheet and continued to conduct due diligence on Company A. During these discussions, management evaluated the risks associated with pursuing a business combination with Company A, including a
potential restructuring to change the jurisdiction of incorporation, and the associated complexities and delays that could arise and the work that Company A would need to undertake to be able to operate as a public company, and concluded that
continuing further term sheet negotiations with Company A could result in a protracted and risky process. Contemporaneously, Company A received term sheets for a private financing, and, given the potentially lengthy overall timeline for the
transactions contemplated by the CHFW term sheet, the parties agreed to pause negotiations of the <FONT STYLE="white-space:nowrap">non-binding</FONT> term sheet. Also during this time, CHFW management engaged in further discussions with two of the
Potential Targets, both of which had entered into confidentiality agreements which are referred to as Company E and Company F. Between January&nbsp;26, 2021 and CHFW&#146;s submission of the initial
<FONT STYLE="white-space:nowrap">non-binding</FONT> term sheet to Surrozen on February&nbsp;18, 2021, CHFW personnel conducted an extensive review of the documents in the Surrozen dataroom, held numerous diligence calls with Surrozen management,
engaged consultants in the areas of antibody engineering and manufacturing and preclinical toxicology, and discussed the Surrozen technology and pipeline with external experts in the fields of Wnt </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
biology, hepatology, gastroenterology and ophthalmology. During this time, management of CHFW became increasingly enthusiastic about the Surrozen technology, pipeline opportunities and
competitive positioning, and, given the level of engagement by Surrozen, the rapid progress of discussions with the Surrozen management team and Surrozen&#146;s preparedness to operate as a public company, management of CHFW believed Surrozen was
emerging as the most attractive potential business combination target that met CHFW&#146;s key criteria. On February&nbsp;18, 2021, the CHFW Board held a meeting at which members of management, J.P. Morgan and Goodwin Procter were present (with J.P.
Morgan present only for a portion). At this meeting, representatives of J.P. Morgan provided a market update, and management reported to the CHFW Board on the status of discussions with Company A, Company B, Company D and Surrozen, including the
progress that had been made with Surrozen, and the challenges with the Company A opportunity. Management also reported on the preliminary discussions with Company E and Company F, and noted that these discussions were not as advanced as with other
Potential Targets. Management presented to the CHFW Board its rationale for concluding that Surrozen was the most attractive potential target that met CHFW&#146;s key investment criteria, including the fact that Surrozen has two lead programs with
differentiated <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data, strong Wnt pathway capabilities to generate additional programs, an experienced management team and board with public company experience and the fact that the proceeds from
the business combination and the expected PIPE Financing as well as Surrozen&#146;s existing cash resources have the potential to enable Surrozen to fund development of its two lead programs through Phase 1b proof of concept studies and further
invest in additional pipeline opportunities. At this meeting, management also presented its preliminary approach to valuation of Surrozen, which included: (1)&nbsp;a review of <FONT STYLE="white-space:nowrap">pre-money</FONT> IPO valuations attained
by preclinical therapeutics life sciences companies conducting an IPO in 2020 and 2021 (which analysis excluded certain outliers) which showed an interquartile range of approximately $360.0&nbsp;million to $600.0&nbsp;million, (2)&nbsp;a review of <FONT
STYLE="white-space:nowrap">pre-money</FONT> IPO valuations of a select group of preclinical life sciences companies (the &#147;Comparable Companies&#148;), listed below, which were believed by CHFW to be the most comparable to Surrozen, which showed
a <FONT STYLE="white-space:nowrap">pre-money</FONT> equity value range of approximately $200.0&nbsp;million to $380.0&nbsp;million and (3)&nbsp;a review of the implied <FONT STYLE="white-space:nowrap">step-up</FONT> in valuation from the most recent
private financing to the <FONT STYLE="white-space:nowrap">pre-money</FONT> IPO valuation achieved by these Comparable Companies (which were in the range of 1.2x to 2.0x), described in more detail as follows (the &#147;February 18
Valuation&#148;).</P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Company Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IPO Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Pre-Money&nbsp;Equity</FONT><BR>Value at IPO<BR>(million)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Implied&nbsp;Step-up&nbsp;from&nbsp;Last</FONT><BR>Private Financing</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decibel Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/11/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Codiak Biosciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/13/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.3x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inozyme Pharma, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/23/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nkarta, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/9/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.7x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Akouos, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/25/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avidity Biosciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/11/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IgM Biosciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9/17/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morphic Holding, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/26/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.9x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Atreca, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/19/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2x</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW management used the following as the bases for identifying the Comparable Companies: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Is the company at a preclinical stage of development? </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Did the company complete an initial public offering within the prior 18 months or so? </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Does the company have multiple preclinical assets advancing towards IND? </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW management also excluded several companies who satisfied the criteria above, but were otherwise considered in the judgment of CHFW
management to be outliers and not comparable to Surrozen, including because of their business models or given the valuation on their last private financings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Management did not perform a discounted cash flow analysis of Surrozen given the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> status
of its programs. After extensive discussion, the CHFW Board authorized management to focus its efforts on pursuing a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
transaction with Surrozen, including to prepare and submit a <FONT STYLE="white-space:nowrap">non-binding</FONT> term sheet for a <FONT STYLE="white-space:nowrap">pre-money</FONT> valuation of
between $225.0&nbsp;million to $250.0&nbsp;million. The valuation range implied <FONT STYLE="white-space:nowrap">step-up</FONT> valuation multiple of between 1.15x and 1.28x, to the approximately $195 million fully-diluted post-money valuation of
Surrozen in its Series C preferred stock financing, its most recent round of financing, and was informed by the status of Surrozen&#146;s ongoing third-party financing discussions, and considerations regarding the post-money equity value of Surrozen
and the range of valuation multiples CHFW management believed would be attractive to Surrozen based on a business combination of this sort. After the representatives of J.P. Morgan left the meeting, the CHFW Board and management also discussed the
possibility of engaging BofA Securities, Inc. (&#147;BofAS&#148;) to act as joint placement agent, to support the efforts of J.P. Morgan, including to leverage its existing relationships in the industry and given its familiarity with Surrozen and
its investors. The CHFW Board and management discussed the roles and proposed terms of J.P. Morgan and BofAS as placement agents for the PIPE Financing and, in the case of J.P. Morgan, as an M&amp;A advisor for the business combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Later on February&nbsp;18, 2021, CHFW delivered a <FONT STYLE="white-space:nowrap">non-binding</FONT> term sheet to Surrozen, which proposed
an implied Surrozen equity value of $230.0&nbsp;million, which represented an implied <FONT STYLE="white-space:nowrap">step-up</FONT> valuation multiple of approximately 1.18x, a PIPE Financing, the size of which would be further discussed and
mutually agreed to by the parties, the ability of CHFW to appoint one director to the New Surrozen board of directors, a minimum cash closing condition, the amount of which would be mutually agreed between the parties, that the parties would discuss
a post-closing equity incentive plan, and a <FONT STYLE="white-space:nowrap">30-day</FONT> binding exclusivity provision providing that Surrozen would not engage in discussions with other third parties regarding a potential business combination. On
February&nbsp;21, 2021, following discussions between the Surrozen CEO and CFO and CHFW&#146;s CEO and VP of Business Development, Surrozen delivered a revised <FONT STYLE="white-space:nowrap">non-binding</FONT> term sheet to CHFW, which proposed an
implied Surrozen equity value of $250.0&nbsp;million, a $100.0&nbsp;million PIPE Financing (including $25.0&nbsp;million committed by CHFW), a nine person New Surrozen board of directors, with the ability of CHFW to appoint one director, subject to
such individual being acceptable to the Surrozen CEO, a minimum cash closing condition of $150.0&nbsp;million (net of CHFW transaction expenses), that the New Surrozen equity incentive plan would have an award pool equal to 10% of New
Surrozen&#146;s outstanding stock immediately after the closing, with an additional automatic 5% annual &#147;evergreen&#148; provision, and a <FONT STYLE="white-space:nowrap">21-day</FONT> binding and mutual exclusivity provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On February&nbsp;22, 2021, the CEO and CFO of Surrozen met with the CEO and VP of Business Development of CHFW during which the CEO and CFO of
Surrozen indicated Surrozen was willing to proceed with discussions and negotiations but indicated the importance of mutual exclusivity given Surrozen&#146;s IPO process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On February&nbsp;23, 2021, CHFW delivered a further revised <FONT STYLE="white-space:nowrap">non-binding</FONT> term sheet to Surrozen, which
proposed an implied Surrozen equity value of $250.0&nbsp;million, a $100.0&nbsp;million PIPE Financing (including $25.0&nbsp;million committed by CHFW and Surrozen&#146;s obligation to obtain $25.0&nbsp;million in commitments from current Surrozen
investors), the nine person New Surrozen board of directors, with the ability of CHFW to appoint one director, subject to such individual being acceptable to the Surrozen CEO, proposing a minimum cash closing condition of $100.0&nbsp;million (net of
certain CHFW transaction expenses), agreeing that the New Surrozen equity incentive plan would have an award pool equal to 10% of New Surrozen&#146;s outstanding stock immediately after the closing, with an additional automatic 5% annual
&#147;evergreen&#148; provision and proposing a <FONT STYLE="white-space:nowrap">30-day</FONT> binding and mutual exclusivity provision. On February&nbsp;24, 2021, the CEO and CFO of Surrozen and the CEO and VP of Business Development of CHFW
engaged in a conference call to further discuss the term sheet. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On February&nbsp;25, 2021, the CHFW Board held a meeting at which
members of management, J.P. Morgan and Goodwin Procter were present. At this meeting, representatives of J.P. Morgan provided a market update, and representatives from J.P. Morgan and the members of CHFW management provided the Board with an update
on recent discussions and negotiations with Surrozen. CHFW management also presented the currently proposed term sheet with Surrozen, including perspectives on the February 18 Valuation and Surrozen&#146;s alternative of pursuing its pending IPO
process. Management also provided an overview of the status and results of ongoing diligence of Surrozen. Management and the CHFW Board also discussed the fact that although the discussions with Company B, Company D, Company E or Company F were
ongoing, none had progressed to a term sheet </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
stage or progressed in such a way that management or the CHFW Board was willing to risk foregoing the opportunity with Surrozen. After discussing CHFW strategic alternatives, including continuing
to pursue discussions with other Potential Targets, CHFW Board determined that entering in the <FONT STYLE="white-space:nowrap">non-binding</FONT> term sheet with a 30-day mutual exclusivity provision would be in the best interest of the CHFW
shareholders. After discussion, the CHFW Board authorized management to finalize negotiations of and enter into the term sheet with Surrozen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On February&nbsp;25, 2021, Surrozen held a board meeting with representatives of management and Guggenheim, one of Surrozen&#146;s underwriter
for its IPO, present. Management presented the details of the <FONT STYLE="white-space:nowrap">non-binding</FONT> term sheet received from CHFW, which had previously been reviewed with the Finance Committee. The Surrozen board discussed the proposed
terms of the business combination, including the valuation of Surrozen and the required PIPE Financing, and the relatively short timeline before a definitive business combination agreement could potentially be entered into, in comparison to the IPO
alternative with the anticipated need, based on feedback from its advisors, to identify a lead investor for and to complete a cross-over financing to facilitate a successful IPO and the associated challenges in doing so, the relatively longer
timeline until an IPO could be completed and the increased exposure to market risk during this time, as well as additional risks of each alternative. The board also discussed the 30-day mutual exclusivity provision in the term sheet and the fact
that there is a <FONT STYLE="white-space:nowrap">carve-out</FONT> that enables Surrozen to continue its confidential review process with the SEC for its pending IPO as a fall-back if Surrozen were unable to reach definitive agreement with CHFW.
Following a discussion of the terms, and with the recommendation of the Finance Committee, the Surrozen board approved the signing of the <FONT STYLE="white-space:nowrap">non-binding</FONT> term sheet (with binding exclusivity) with CHFW, by no
later than March&nbsp;1, 2021. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Between February&nbsp;25, 2021 and March&nbsp;1, 2021, CHFW continued its due diligence of Surrozen,
and CHFW and Surrozen finalized the term sheet, which was executed on March&nbsp;1, 2021. The executed term sheet provided for an implied Surrozen equity value of $250.0&nbsp;million, a $100.0&nbsp;million PIPE Financing (including
$25.0&nbsp;million committed by Sponsor and Surrozen&#146;s obligation to obtain $5&nbsp;million from the Column Group and to use commercially reasonable efforts to obtain $20&nbsp;million in commitments from other current Surrozen investors), a
nine person New Surrozen board of directors, with the ability of CHFW to appoint one director, subject to such individual being acceptable to the Surrozen CEO, a minimum cash closing condition of $100.0&nbsp;million (net of CHFW transaction
expenses), that the New Surrozen equity incentive plan would have an award pool equal to 10% of New Surrozen&#146;s outstanding stock immediately after the closing, with an additional automatic 5% annual &#147;evergreen&#148; provision and a <FONT
STYLE="white-space:nowrap">30-day</FONT> binding and mutual exclusivity provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Between March&nbsp;1, 2021 and April&nbsp;14, 2021,
representatives of CHFW, including its directors and officers, and Sponsor, conducted further business, financial and other due diligence with respect to Surrozen and, over the same period of time, CHFW&#146;s third party advisors, including legal
counsel, conducted due diligence with respect to Surrozen and the proposed business combination transaction. Before reaching the determination that it was in the best interests of CHFW and its shareholders to approve the proposed transaction, during
various CHFW Board meetings during which the CHFW Board considered the proposed transaction, the CHFW Board was provided with high-level summaries of the due diligence process and key due diligence findings of CHFW&#146;s directors&#146; and
officers&#146;, Sponsor&#146;s and their respective representatives&#146; and advisors&#146; due diligence. The due diligence process included the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a comprehensive review of the materials provided in the online data room; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requests for <FONT STYLE="white-space:nowrap">follow-up</FONT> data and information from Surrozen, including
Surrozen management responses to due diligence questions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">meetings with Surrozen&#146;s management team, including Surrozen&#146;s CEO, CFO, Chief Medical Officer,
Chief Scientific Officer, Senior Vice President of Biology, Vice President of Legal, Vice President of Human Resources, Head of Technical Operations, and Head of Preclinical Development, regarding Surrozen&#146;s business and pipeline, operations,
intellectual property and technical diligence matters, as well as tax and legal matters, including those related to regulatory matters and clinical operations, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
corporate matters (including material contracts, capitalization and other customary corporate matters) and labor and employment matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review of publicly available key competitor data; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">due diligence calls and discussions with third party industry experts (including various researchers and
professors in the fields of Wnt biology, liver disease, gastroenterology, and ophthalmology), and including CHFW consultants in the fields of antibody engineering, process development and manufacturing, and preclinical toxicology;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an illustrative financial and valuation analysis (the Feb. 18 Valuation), comprising review of information
relating to Surrozen&#146;s valuation in its last financing, a review of IPO valuations attained by all preclinical companies conducting an IPO in 2020 and 2021 (which analysis excluded certain outliers), a review of pre-IPO valuations of Comparable
Companies that had recently conducted a public offering, and a review of the implied <FONT STYLE="white-space:nowrap">step-ups</FONT> in valuation from the most recent financings to the IPO valuations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a summary by CHFW management to the CHFW Board with respect to their key findings with respect to their
business, operational and financial due diligence; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a report by Goodwin Procter on legal due diligence which was provided to CHFW management on or around
March&nbsp;20, 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;3, 2021, representatives of Surrozen and its financial and legal advisors,
Guggenheim Securities, LLC and Cooley LLP, respectively, and CHFW, J.P. Morgan, BofAS and Goodwin Procter held a meeting to discuss the PIPE Financing, including timeline, next steps, roles and responsibilities, potential investors and a proposed
investor presentation. As part of these discussions, the parties agreed that, given the Sponsor&#146;s commitment, indications of interest from existing Surrozen stockholders and expected interest from potential investors, it would be advisable to
increase the marketed PIPE from the $100&nbsp;million agreed between CHFW and Surrozen and, after discussion, the parties agreed to target a PIPE Financing of $125&nbsp;million in aggregate proceeds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;7, 2021, CHFW formalized J.P. Morgan and BofAS&#146;s roles to act as joint placement agents in connection with the PIPE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Beginning on March&nbsp;8, 2021, representatives of J.P. Morgan and BofAS held conversations with potential investors with respect to the PIPE
Financing. Goodwin, Cooley and Wilson, Sonsini, Goodrich&nbsp;&amp; Rosati LLP (&#147;WSGR&#148;), counsel to J.P. Morgan and BofAS, exchanged drafts of the form of Subscription Agreement to be used in the PIPE Financing, the proposed form of which
was finalized and distributed to potential PIPE investors with respect to the PIPE Financing on March&nbsp;15, 2021. During this time, on March&nbsp;9, 2021, Goodwin Procter delivered an initial draft of the Business Combination Agreement to
Surrozen and Cooley. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Also on March&nbsp;15, 2021, the CHFW Board held a meeting at which representatives of management, J.P. Morgan and
Goodwin Procter were present (with J.P. Morgan present only for a portion). At this meeting, management provided the CHFW Board with an update on continued due diligence, the PIPE Financing efforts and discussions with Surrozen. Also at this
meeting, Goodwin Procter gave a detailed overview of directors&#146; fiduciary duties in the context of a business combination of this sort. The CHFW Board also formally approved and ratified the engagement of J.P. Morgan and BofAS as placement
agents for the PIPE Financing and, in the case of J.P. Morgan, as an M&amp;A advisor for the business combination. Representatives of J.P. Morgan then joined the meeting and reported to the CHFW Board regarding the status of the PIPE Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;17, 2021, Surrozen&#146;s CEO and CFO, CHFW&#146;s CEO and VP of Business Development and representatives of Cooley and Goodwin
participated in a meeting to discuss certain business and legal issues in the Business Combination Agreement, matters related to Cayman law and the fiduciary duties of directors as they relate to the change of recommendation provision of the
Business Combination Agreement, certain business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
development efforts that Surrozen proposed to have the ability to pursue during the pendency of the transaction, which transaction expenses and liabilities would be deducted from the minimum cash
closing condition and the timing for certain deliverables. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;18, 2021, Baker Bros. Advisors LP (the &#147;Lead
Investor&#148;), which proposed to invest $20.0 to $25.0&nbsp;million in the PIPE, indicated to J.P. Morgan that it would require the restructuring of certain terms of the business combination and PIPE Financing as a condition to its investment. The
Lead Investor then <FONT STYLE="white-space:nowrap">e-mailed</FONT> proposed terms for a commitment to invest $20.0 to $25.0&nbsp;million in the PIPE if the Surrozen <FONT STYLE="white-space:nowrap">pre-money</FONT> equity value in the business
combination were reduced to $200.0&nbsp;million, the PIPE investors would receive units on the same terms as the investors received in the initial public offering, including 1/3 warrant coverage on substantially the same terms as the warrants issued
in CHFW&#146;s initial public offering, and the Sponsor would forfeit 33% of the founder shares. On March&nbsp;19, 2021, the Lead Investor sent CHFW a term sheet memorializing the <FONT STYLE="white-space:nowrap">e-mailed</FONT> terms, including an
investment size of $25.0&nbsp;million. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen management discussed the Lead Investor&#146;s term sheet, including the proposed
change in Surrozen&#146;s valuation, with its Finance Committee and ultimately agreed with CHFW to accept the valuation change in order to secure the PIPE Financing commitment from the Lead Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After CHFW had discussions with Surrozen and the Sponsor and both agreed to the revised terms, management presented the Lead Investor term
sheet to the CHFW Board on an update call and the Board approved the revised terms of the business combination and the term sheet with the Lead Investor. Later that day, CHFW and the Lead Investor executed the term sheet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;22, 2021, Cooley provided Goodwin with a revised draft of the Business Combination Agreement that, in addition to proposed
revisions to the overall suite of representations, warranties and covenants to be provided by each party under the Business Combination Agreement and revisions to the timing of certain deliverables, eliminated the CHFW Board&#146;s ability to change
its recommendation under any circumstances, including in connection with a defined intervening event relating to Surrozen and proposing that approval of the equity incentive plan by the CHFW shareholders be conditions to closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;23, 2021, CHFW formalized J.P. Morgan&#146;s role to act as M&amp;A advisor in connection with the proposed transaction with
Surrozen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;24, 2021, a revised Subscription Agreement reflecting the revised PIPE Financing terms, including the warrant
coverage, was distributed to potential PIPE investors with respect to the PIPE Financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">March&nbsp;26, 2021, the CHFW Board held a
meeting with representatives of management and Goodwin Procter present. At this meeting, management provided the CHFW Board with an update on the PIPE Financing, including investor outreach, indications of interest to date and expected timing,
noting that the exclusivity period in the executed term sheet between Surrozen and CHFW was due to expire on March&nbsp;31, 2021. The CHFW Board authorized management to continue its efforts with the PIPE Financing and to extend exclusivity with
Surrozen, if needed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;28, 2021, a form of warrant agreement was distributed to potential PIPE investors with respect to the
PIPE Financing (which form was substantially the same as the warrant agreement entered into in connection with the CHFW initial public offering). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;30, 2021, Surrozen and CHFW entered into an agreement to extend exclusivity until April&nbsp;9, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From March&nbsp;24, 2021 to April&nbsp;15, 2021, the terms of the proposed form of Subscription Agreement were further negotiated between the
representatives of Goodwin Procter and Cooley, on behalf of their respective clients, and on behalf of the PIPE Investors by their respective advisors, and multiple drafts of the Subscription Agreements were shared prior to the execution of the
agreed form of Subscription Agreement by the investors and CHFW as of April&nbsp;15, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;31, 2021, Goodwin Procter sent a revised draft of the Business Combination
Agreement to Cooley, proposing revisions to the overall suite of representations, warranties and covenants to be provided by each party under the Business Combination Agreement and revisions to the timing of certain deliverables. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Between April&nbsp;1 and April&nbsp;14, 2021, Cooley and Goodwin Procter held numerous meetings to discuss and negotiate the outstanding
issues and other matters in the Business Combination Agreement. During this same time period, Cooley and Goodwin Procter exchanged revised drafts of the Business Combination Agreement and the parties came to agreement on the outstanding issues and
other matters in the Business Combination Agreement, including that the CHFW Board would be able to change its recommendation if required by law, but that, if the CHFW Board did make a change in its recommendation, Surrozen could then terminate the
Business Combination Agreement, and that the CHFW transaction liabilities and expenses that would be deducted from aggregate transaction proceeds for purposes of calculating the minimum cash condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Between March&nbsp;29, 2021 and April&nbsp;14, 2021, Cooley and Goodwin Procter drafted and negotiated the disclosure schedules to the
Business Combination Agreement and drafted and negotiated certain other ancillary documents, including the Sponsor Letter Agreement, the Investor Rights Agreement, the form of Surrozen Transaction Support Agreement, the form of CHFW Shareholder
Transaction Support Agreement and the certificate of incorporation and bylaws of New Surrozen to be attached to the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During this time, representatives of CHFW, Surrozen, J.P. Morgan and BofAS continued discussions with potential PIPE investors, including
discussions and updates regarding the restructured terms for the PIPE Financing that had been agreed to with the Lead Investor. As part of this process, CHFW and Surrozen agreed that New Surrozen would not redeem the warrants issued in the PIPE
Financing for 12 months following the closing of the business combination, which concept was not included in the warrants issued in connection with the CHFW initial public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April&nbsp;9, 2021, the Surrozen board held a meeting with representatives of management and Cooley present. The Surrozen management team
updated the Surrozen board on recent business developments. Cooley then reviewed the board&#146;s fiduciary duties in the context of the proposed business combination, the terms of the Business Combination Agreement and the fact that Surrozen
stockholders holding the requisite voting power to approve the business combination were entering into support agreements agreeing to vote in favor of the transactions. Cooley also reviewed in detail the terms of the Business Combination Agreement
and proposed PIPE Financing. The Surrozen board discussed the <FONT STYLE="white-space:nowrap">pre-money</FONT> valuation of the Surrozen, the potential net proceeds from the combination and PIPE Financing, and the potential cash runway for the
combined company. The Surrozen board also considered the proposed governance of the combined company, including the independent director expected to be designated by CHFW, and considered Surrozen&#146;s strategic alternatives, including completing
its pending IPO and the need to complete a cross over financing in order to market the IPO. Following an extensive discussion, the Surrozen board unanimously determined that the business combination, including the Merger and related transactions are
in the best interest of Surrozen and its stockholders, approved the adoption of the Business Combination Agreement and the execution and delivery of the Business Combination Agreement and other documents contemplated by the Business Combination
Agreement and resolved to recommend that the Surrozen stockholders approve the business combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Given that certain potential
investors in the PIPE Financing required additional time to conduct due diligence and review the investment opportunity, on April&nbsp;9, 2021, CHFW and Surrozen entered into an agreement to extend exclusivity until April&nbsp;14, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April&nbsp;13, 2021, the CHFW Board held a meeting with representatives of management and Goodwin Procter present. At this meeting,
management provided an update regarding the status of the PIPE Financing and the potential business combination transaction involving CHFW and Surrozen, including with respect to the status of negotiations of the Business Combination Agreement, the
finalization of due diligence review by CHFW advisors and related matters. Representatives from Goodwin Procter reviewed with the CHFW Board the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
material terms of the Business Combination Agreement and recent negotiations, which had been distributed to the CHFW Board members in advance of the meeting. The CHFW Board, management and
Goodwin Procter discussed next steps and anticipated timeline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April&nbsp;14, 2021, the parties finalized all remaining open items and
received the final Subscription Agreements. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Later on April&nbsp;14, 2021, a meeting of the CHFW Board was held with representatives
of CHFW management and Goodwin Procter present. At this meeting, the CHFW Board was provided with a further overview of the proposed business combination transaction involving CHFW and Surrozen and the key terms of the Business Combination Agreement
and the related ancillary documents, final drafts of which had been circulated the CHFW Board in advance of the meeting. Based on the factors cited in &#147;<I>&#151;The CHFW Board&#146;s Reasons for the Business Combination</I>&#148; and in light
of the fact that the implied fair market value of the vested equity of Surrozen to be acquired in the business combination was significantly in excess of 80% of the assets held in the Trust Account (excluding the deferred underwriting commissions
and taxes payable on the income earned on the Trust Account), the CHFW Board then unanimously adopted and approved resolutions (a)&nbsp;determining that it is in the best interests of CHFW and its shareholders to adopt and approve the execution and
delivery of the Business Combination Agreement and the ancillary documents thereto and to approve the transactions contemplated by each of the Business Combination Agreement and the ancillary documents thereto (including the Domestication, the
Merger and the PIPE Financing); (b) adopting and approving the Business Combination Agreement and ancillary documents thereto and approving CHFW&#146;s execution, delivery and performance of the same and the consummation of the transactions
contemplated by the Business Combination Agreement and the ancillary documents thereto, including the Domestication, the Merger and the PIPE Financing; (c)&nbsp;recommending that the CHFW shareholders vote in favor of the Business Combination
Proposal, the Domestication Proposal, the New Organizational Documents Proposal, each of the Governing Documents Proposals, the Share Issuance Proposal, the Incentive Award Plan Proposal, the Equity Stock Purchase Plan Proposal and the Adjournment
Proposal; and (d)&nbsp;adopting and approving, conditioned upon the Closing and the receipt of the required CHFW shareholders vote in favor of the Incentive Award Plan Proposal and the Employee Stock Purchase Plan Proposal, as applicable, the
Incentive Equity Plan and the Employee Stock Purchase Plan and that the applicable number of shares of New Surrozen Common Stock as set forth in the Business Combination Agreement be reserved for issuance under each of the Incentive Equity Plan and
the Employee Stock Purchase Plan. The CHFW Board did not obtain a third-party valuation or fairness opinion in connection with its resolution to approve the Business Combination but determined that CHFW&#146;s directors and officers and the other
representatives of CHFW had substantial experience in evaluating the operating and financial merits of companies similar to Surrozen and reviewed Surrozen&#146;s valuation in its most recent financing and compared it to certain publicly traded
companies, selected based on the experience and the professional judgement of CHFW&#146;s directors and officers and considered the valuation of Surrozen by the Lead Investor, and concluded that the experience and background of CHFW&#146;s directors
and officers members, the members of the CHFW Board and the other representatives of CHFW enabled the CHFW Board to make the necessary analyses and determinations regarding the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By April&nbsp;15, 2021, final versions of such ancillary documents were distributed to the CHFW Parties, Surrozen, the Lead Investor, certain
other PIPE investors and the other parties thereto which reflected the outcome of the negotiations between the parties and their respective representatives and advisors and the parties to such ancillary documents to be executed and delivered at
signing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April&nbsp;15, 2021, the parties entered into the Business Combination Agreement and the related ancillary documents and the
PIPE investors released their respective signatures to the Subscription Agreements, which provided for binding subscriptions to purchase an aggregate of 12.02&nbsp;million units of New Surrozen Common Stock at $10.00 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April&nbsp;15, 2021, CHFW and Surrozen issued a joint press release announcing the execution and delivery of the Business Combination
Agreement, and CHFW filed a Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> which filed or furnished as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
exhibits (a)&nbsp;the Business Combination Agreement, (b)&nbsp;an investor presentation providing information on Surrozen and a summary of certain key terms of the Business Combination,
(c)&nbsp;the form of Investor Rights Agreement, (d)&nbsp;the Sponsor Letter Agreement, (e)&nbsp;the form of Subscription Agreement, (f)&nbsp;the form of Surrozen Shareholder Transaction Support Agreement, (g)&nbsp;the form of CHFW Shareholder
Transaction Support Agreement, (h)&nbsp;the joint press release, dated April&nbsp;15, 2021 and (i)&nbsp;certain risk factors and a business description that had been prepared by Surrozen and provided to prospective PIPE Financing investors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_75"></A>The CHFW Board&#146;s Reasons for the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The CHFW Board considered a number of factors pertaining to the Business Combination as generally supporting its decision to enter into the
Business Combination Agreement and the transactions contemplated thereby, including but not limited to, the following material factors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Pioneering, industry leading platform and technologies to harness a fundamental pathway in tissue
regeneration</I></B>. Surrozen is harnessing Wnt biology, one of the body&#146;s innate tissue repair mechanisms, to treat a broad array of diseases. The company&#146;s scientific <FONT STYLE="white-space:nowrap">co-founders</FONT> are among the
world&#146;s preeminent Wnt biologists and discovered the first mammalian Wnt gene. Surrozen possesses a deep, industry-leading understanding of the Wnt pathway as well as the internal antibody discovery capabilities to rapidly design and develop
precisely-targeted <FONT STYLE="white-space:nowrap">Wnt-directed</FONT> antibody therapeutics in tissue specific applications. Its two proprietary antibody technologies are designed to selectively activate Wnt signaling in specific tissues by
activation of physiologic Wnt signal with <FONT STYLE="white-space:nowrap">Wnt-mimetic</FONT> antibodies, or by amplification of endogenous Wnt with <FONT STYLE="white-space:nowrap">R-spondin</FONT> mimetic antibodies. In light of such factors, and
after conducting due diligence, including reviewing the competitive landscape, speaking with a number of experts in Wnt biology who were familiar with the Surrozen platform and speaking with a number of key opinion leaders in the therapeutic areas
relevant to the Surrozen programs who confirmed the novelty of the Surrozen approach and the promise of the preclinical data generated by them, CHFW management concluded that Surrozen&#146;s Wnt platform was pioneering and industry-leading, and
reported such considerations and conclusions to the CHFW Board. Surrozen&#146;s two proprietary antibody technologies are designed to selectively activate Wnt signaling in specific tissues by activation of physiologic Wnt signal with Wnt-mimetic
antibodies, or by amplification of endogenous Wnt with R-spondin mimetic antibodies. The CHFW Board believes Surrozen is well positioned to unlock the therapeutic potential of the Wnt pathway. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Broad therapeutic potential across a wide range of diseases.</I></B> The Wnt pathway holds broad
therapeutic potential in view of its ability to regulate stem cell renewal, proliferation and differentiation, and its central role in tissue repair and regeneration. Surrozen has worked to identify and characterize tissues where Wnt biology is
central to structure and function and has prioritized a number of potential applications for its technologies, including diseases of the eye <FONT STYLE="white-space:nowrap">(age-related</FONT> macular degeneration (&#147;AMD&#148;) and diabetic
retinopathy), liver (alcoholic hepatitis and cirrhosis), lung (idiopathic pulmonary fibrosis (&#147;IPF&#148;) and COPD), gastrointestinal tract IBD and short bowel syndrome), cochlea (sensorineural hearing loss), pancreas <FONT
STYLE="white-space:nowrap">(type-1</FONT> diabetes), kidney (polycystic kidney disease), and others. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Multiple, wholly-owned, pipeline programs in development in areas of high unmet medical need.</I></B>
Surrozen has established a diverse pipeline of wholly owned product candidates led by <FONT STYLE="white-space:nowrap">SZN-1326</FONT> for moderate to severe IBD and <FONT STYLE="white-space:nowrap">SZN-043</FONT> for severe alcoholic hepatitis. In
IBD, many patients fail to respond to available approved therapies which reduce inflammation but do not directly drive mucosal healing, whereas <FONT STYLE="white-space:nowrap">SZN-1326</FONT> may promote restoration of intestinal tissue
architecture and function. In severe alcoholic hepatitis, there are an estimated 100,000 hospitalizations annually in the United States, the overall <FONT STYLE="white-space:nowrap">90-day</FONT> mortality rate in hospitalized patients is
approximately 30%, and there are few treatment options available. If clinical trials with <FONT STYLE="white-space:nowrap">SZN-043</FONT> demonstrate the ability to stimulate proliferation of hepatocytes and improve liver function in these patients,
the data could support the potential for a rapid path to approval. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Differentiated <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data for lead programs demonstrating
potential for disease modifying effects.</I></B> In preclinical models used to evaluate treatments for IBD, <FONT STYLE="white-space:nowrap">SZN-1326</FONT> led to proliferation and differentiation of intestinal stem cells, restoration of intestinal
barrier function and tissue architecture, reduction in inflammation and reduced disease activity. Similarly, in animal models of alcoholic hepatitis, treatment with <FONT STYLE="white-space:nowrap">SZN-043</FONT> led to hepatocyte proliferation and
improved liver function. These effects, if demonstrated in human clinical trials, could signal the potential for disease modifying efficacy and support use as monotherapy or in combination with other approved agents. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Emerging ophthalmology programs bolster pipeline and may provide breakthrough potential. </I></B>The
Surrozen pipeline is supplemented by numerous ongoing research efforts in a diverse set of tissues, including ophthalmic applications such as wet AMD, dry AMD, diabetic retinopathy, Fuch&#146;s dystrophy and Sj&ouml;gren&#146;s dry eye. In
preclinical experiments, Surrozen has shown that activation of the Wnt pathway can potentially reverse vascular damage through a mechanism that is different from that of currently approved agents that target angiogenesis. Surrozen is developing an
agonist of a specific Fzd receptor found in retinal vasculature, which the company has shown in animal models can inhibit retinal pathology in the eye. We believe that the ability to deliver this agonist locally to the eye has the potential to treat
multiple ocular disorders with high unmet need by inducing repair of damaged tissue. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Multiple upcoming catalysts funded by proceeds from this transaction.</I></B> Surrozen expects to
initiate Phase 1a trials for <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043</FONT> in 2022, with Phase 1b trials in ulcerative colitis and severe alcoholic hepatitis patients expected to start in 2023.
Each of these programs is expected to yield clinical proof of concept data in patients from the Phase 1b trials in 2024. The company also expects to nominate additional lead candidates and advance them into the clinic in 2023 to explore the
potential breadth and utility of its product candidates in other clinical settings, including ophthalmology. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Opportunities for strategic alliances to support and fuel growth.</I></B> Given the breadth of
therapeutic applications enabled by targeting the Wnt pathway and Surrozen&#146;s ability to modulate Wnt biology in a tissue specific manner, we believe there may be opportunities for strategic alliances that further support the company&#146;s
capital needs and growth. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Experienced management team and board of directors.</I></B> The CHFW Board believes that Surrozen has a
proven and experienced team that will continue to lead the company after the Business Combination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Strong commitment from top tier U.S. healthcare investors and existing Surrozen stockholders</I></B>.
Leading healthcare-focused and life sciences-dedicated investors, as well as current existing Surrozen stockholders, including The Column Group, committed to investment of a total of $120,200,000 in the PIPE Financing. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Other alternatives</I></B>. The CHFW Board believed, after a thorough review of other business combination opportunities
reasonably available to CHFW, that the proposed Business Combination represents the best potential business combination for CHFW and its shareholders based upon the process utilized to evaluate and assess other potential acquisition targets and the
CHFW Board and CHFW management&#146;s belief that such processes had not presented a better alternative. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Terms of the Business Combination Agreement</I></B>. The CHFW Board reviewed and considered the terms of
the Business Combination Agreement and the related agreements, including the parties&#146; conditions to their respective obligations to complete the transactions contemplated therein and their ability to terminate such agreements under the
circumstances described therein. See the section titled &#147;<I>Proposal</I> <I>No. 1&#151;The Business Combination Proposal</I>&#148; for detailed discussions of the terms and conditions of these agreements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The CHFW Board also considered a variety of uncertainties and risks and other potentially negative factors concerning the Business
Combination, including, but not limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Benefits may not be achieved.</I></B> The risk that some or all of the potential benefits of the
Business Combination may not be fully achieved, or may not be achieved within the expected timeframe. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Liquidation of CHFW.</I></B> The risks and costs to CHFW if the Business Combination is not completed,
including the risk of diverting management focus and resources from other businesses combination opportunities, which could result in CHFW being unable to effect a business combination by November&nbsp;22, 2022 (the &#147;Liquidation Date&#148;) and
force CHFW to liquidate and CHFW warrants to expire for no value. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Exclusivity.</I></B> The fact that the Business Combination Agreement includes an exclusivity provision,
which prohibits CHFW from soliciting other business combination proposals so long as the Business Combination Agreement is in effect, which restricts and would delay CHFW&#146;s ability to consider other potential business combinations to complete
prior to the Liquidation Date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Shareholder vote.</I></B> The risk that CHFW&#146;s shareholders may fail to provide the respective
votes necessary to effect the Business Combination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Closing conditions.</I></B> The fact that completion of the Business Combination is conditioned on the
satisfaction of certain closing conditions that are not within CHFW&#146;s control. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>No survival of remedies for breach of representations, warranties or covenants of Surrozen</I></B>. The
risk that CHFW will not have any surviving remedies against Surrozen&#146;s existing stockholders after the closing of the Business Combination to recover any losses that may result from any inaccuracies or breaches of Surrozen&#146;s
representations, warranties or covenants set forth in the Business Combination Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Litigation.</I></B> The possibility of litigation challenging the Business Combination or that an
adverse judgment granting permanent injunctive relief could indefinitely enjoin consummation of the Business Combination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Fees and Expenses.</I></B> The fees and expenses associated with completing the Business Combination.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Redemptions</I></B>. The risk that CHFW&#146;s current public shareholders may redeem their public
shares for cash in connection with consummation of the Business Combination, thereby reducing the amount of cash available to CHFW and potentially resulting in an inability to consummate the Business Combination if our total cash proceeds, after
giving effect to the PIPE Financing and deducting certain CHFW expenses and liabilities, does not equal or exceed $100.0&nbsp;million. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Limitations of review</I></B>. The CHFW Board considered that they were not obtaining an opinion from
any independent investment banking or accounting firm that the consideration to be received by the existing Surrozen stockholders is fair to CHFW or its shareholders from a financial point of view. Accordingly, the CHFW Board considered that CHFW
may not have properly valued Surrozen. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Closing Conditions</I></B>. The fact that completion of the Business Combination is conditioned on the
satisfaction of certain closing conditions that are not within CHFW&#146;s control, including approval by Surrozen&#146;s stockholders and approval by Nasdaq of the initial listing application in connection with the Business Combination.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Other Risks.</I></B> Various other risks associated with the Business Combination, the business of CHFW
and the business of Surrozen described under the section entitled &#147;Risk Factors.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to considering the factors
described above, the CHFW Board also considered: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Interests of certain persons</I></B>. Some officers and directors of CHFW may have interests in the
Business Combination as individuals that are in addition to, and that may be different from, the interests of CHFW&#146;s shareholders (see &#147;<I>&#151;Interests of Certain Persons in the Business Combination</I>&#148; below). Our independent
directors reviewed and considered these interests during the negotiation of the Business Combination and in evaluating and unanimously approving, as members of the CHFW Board, the Business Combination Agreement and the transactions contemplated
therein, including the Business Combination. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The CHFW Board concluded that the potential benefits that it expected CHFW
and its shareholders to achieve as a result of the Business Combination outweighed the potentially negative factors associated with the Business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Combination. Accordingly, the CHFW Board unanimously determined that the Business Combination Agreement and the transactions contemplated thereby, including the Business Combination, were
advisable, fair to, and in the best interests of, CHFW and its shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_76"></A>Satisfaction of 80% Test
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is a requirement under the Existing Governing Documents that any business acquired by CHFW have a fair market value equal to at
least 80% of the balance of the funds in the trust account at the time of the execution of a definitive agreement for an initial business combination. Based on the financial analysis of Surrozen generally used to approve the transaction, the
Surrozen board of directors determined that this requirement was met. The board determined that the consideration being paid in the Business Combination, which amount was negotiated at arms-length, was fair to and in the best interests of CHFW and
its shareholders and appropriately reflected Surrozen&#146;s value. In reaching this determination, the board concluded that it was appropriate to base such valuation in part on qualitative factors such as management strength and depth, competitive
positioning, customer relationships, and technical skills, as well as quantitative factors such as Surrozen&#146;s historical growth rate and its potential for future growth in revenue and profits. The CHFW Board believes that the financial skills
and background of its members qualify it to conclude that the acquisition of Surrozen met this requirement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_77"></A>Interests of CHFW&#146;s Directors and Executive Officers in the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">When you consider the recommendation of the CHFW Board in favor of approval of the Business Combination Proposal, you should keep in mind that
the initial shareholders, including CHFW&#146;s directors and executive officers, have interests in such proposal that are different from, or in addition to, those of CHFW shareholders and warrant holders generally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table details the number of ordinary shares and warrants held by Sponsor, its affiliates and the directors and officers of CHFW,
and quantifies the purchase price and the current value of such securities. The value of such securities could have significantly higher value at the time of, or following, the Business Combination. </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Entity<SUP STYLE="font-size:85%; vertical-align:top">1</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value<SUP STYLE="font-size:85%; vertical-align:top">2</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Promote<BR>shares<SUP STYLE="font-size:85%; vertical-align:top">3</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IPO units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IPO PIPE<BR>units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PIPE<BR>Financing<BR>units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="right">Consonance Capital Management</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of ordinary shares</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,497,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,497,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of warrants</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">832,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,165,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Aggregate Purchase Price</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,975,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,975,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Estimated Current Value</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,223,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,723,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="right">Consonance Life Sciences, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of ordinary shares</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,451,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">434,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,885,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of warrants</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Aggregate Purchase Price</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,340,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,365,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Estimated Current Value</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,510,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,557,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,067,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="right">Donald Santel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of ordinary shares</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of warrants</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Aggregate Purchase Price</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Estimated Current Value</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="right">Christopher Haqq</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of ordinary shares</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of warrants</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Aggregate Purchase Price</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Estimated Current Value</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="right">Jennifer Jarrett</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of ordinary shares</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">No. of warrants</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Aggregate Purchase Price</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Estimated Current Value</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="right"><B>Total</B> <B></B><B></B><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>No. of ordinary shares</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>1,541,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,000,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>434,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,497,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,472,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>No. of warrants</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>333,333</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>144,667</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>832,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,310,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>Aggregate&nbsp;Purchase&nbsp;Price</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>25,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,000,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,340,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>24,975,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>39,340,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>Estimated Current Value</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>15,410,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,500,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,557,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>26,223,750</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>56,690,751</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="justify">Please see <I>Beneficial Ownership of Securities</I> for details regarding voting and dispositive power of
the securities held by the persons included in this table. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="justify">The Estimated Current Value assumes a $10.00 per share price and a $1.50 price per warrant. As of
June&nbsp;22, 2021, the trading price was $9.90 per CHFW Class A ordinary share and $1.58 per warrant. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="justify">Net of contributions for no consideration. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="justify">This number is net of (i)&nbsp;90,000 shares transferred (in the aggregate) to the independent directors of
the CHFW Board, (ii)&nbsp;759,000 founder shares which will be forfeited for no consideration at the closing of the Business Combination and (iii)&nbsp;718,750 and 575,000 founder shares previously contributed back to CHFW for no consideration on
October&nbsp;8, 2020 and November&nbsp;10, 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These interests also include, among other things, the interests listed
below: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that our initial shareholders have agreed not to redeem any Class&nbsp;A ordinary shares held by them
in connection with a shareholder vote to approve a proposed initial business combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that Sponsor and its affiliates has made a sizable investment in CHFW securities, which securities
would be worthless if a business combination is not consummated by November&nbsp;23, 2022 (unless such date is extended in accordance with the Existing Governing Documents); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the initial shareholders and CHFW&#146;s other current officers and directors have agreed to
waive their rights to liquidating distributions from the trust account, which, as of June&nbsp;22, 2021, included an amount of approximately $92&nbsp;million, with respect to any ordinary shares (other than public shares) held by them if CHFW fails
to complete an initial business combination by November&nbsp;23, 2022; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Investor Rights Agreement will be entered into by the initial shareholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that, at the option of the Sponsor, any amounts outstanding under any loan made by the Sponsor or any
of its affiliates to CHFW in an aggregate amount of up to $1,500,000 may be converted into warrants to purchase Class&nbsp;A ordinary shares in connection with the consummation of the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continued indemnification of CHFW&#146;s directors and officers and the continuation of CHFW&#146;s
directors&#146; and officers&#146; liability insurance after the Business Combination through the purchase of a six year tail policy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor and CHFW&#146;s officers and directors will lose their entire investment in CHFW and
will not be reimbursed for any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses if an initial business combination is not consummated by November&nbsp;23, 2022; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that CHFW will reimburse Sponsor for office space, secretarial and administrative services provided
to members of the CHFW founding team, in the amount of $55,000 per month, which payments will cease upon completion of the Business Combination; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that if the trust account is liquidated, including in the event CHFW is unable to complete an initial
business combination by November&nbsp;23, 2022, the Sponsor has agreed to indemnify CHFW to ensure that the proceeds in the trust account are not reduced below $10.00 per public share, or such lesser per public share amount as is in the trust
account on the liquidation date, by the claims of prospective target businesses with which CHFW has entered into an acquisition agreement or claims of any third party for services rendered or products sold to CHFW, but only if such a vendor or
target business has not executed a waiver of any and all rights to seek access to the trust account; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that CHFW may be entitled to distribute or pay over funds held by CHFW outside the Trust Account to
the Sponsor or any of its Affiliates prior to the Closing. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June 22, 2021, Sponsor and its affiliates have
invested or committed to invest an aggregate of $39.3 million, including its commitment with respect to the PIPE Financing and assuming consummation of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Business Combination (the &#147;Total Commitment&#148;). Assuming the issuance of all securities underlying the Total Commitment and utilizing a per share price of $10.00 and a per warrant value
of $1.50, the Total Commitment would have an approximate value of $56.7&nbsp;million. If the Business Combination is not consummated, Sponsor and its affiliates will lose approximately $4.3&nbsp;million of their amounts already invested. Although
Sponsor and its affiliates have committed considerable capital to CHFW, including through its participation in the CHFW IPO and its contribution of a portion of the Promote for no consideration, if the Business Combination is consummated, taking
into account the investments described above, including the Promote, it is possible that Sponsor and its affiliates could realize a positive rate of return on such investments even if other CHFW shareholders experience a negative rate of return
following the Business Combination. Except as described above, there are no outstanding loans or material fee or reimbursement arrangements among CHFW, Sponsor, its affiliates, or the CHFW directors or officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The initial shareholders have, pursuant to the Sponsor Letter Agreement, agreed to, among other things, vote all of their ordinary shares in
favor of the proposals being presented at the extraordinary general meeting and waive their anti-dilution rights with respect to their Class&nbsp;B ordinary shares in connection with the consummation of the Business Combination. Such shares will be
excluded from the pro rata calculation used to determine <FONT STYLE="white-space:nowrap">the&nbsp;per-share&nbsp;redemption</FONT> price. As of the date of this proxy statement/prospectus, the initial shareholders own approximately 22.9% of the
issued and outstanding ordinary shares. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At any time at or prior to the Business Combination, during a period when they are not then
aware of any material nonpublic information regarding us or our securities, our initial shareholders, Surrozen and/or their directors, officers, advisors or respective affiliates may purchase public shares from institutional and other investors who
vote, or indicate an intention to vote, against any of the Condition Precedent Proposals, or execute agreements to purchase such shares from such investors in the future, or they may enter into transactions with such investors and others to provide
them with incentives to acquire public shares or vote their public shares in favor of the Condition Precedent Proposals. Such a purchase may include a contractual acknowledgement that such shareholder, although still the record or beneficial holder
of our shares, is no longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights. In the event that our initial shareholders, Surrozen and/or their directors, officers, advisors or respective affiliates purchase
shares in privately negotiated transactions from public shareholders who have already elected to exercise their redemption rights, such selling shareholder would be required to revoke their prior elections to redeem their shares. The purpose of such
share purchases and other transactions would be to increase the likelihood of satisfaction of the requirements that (i)&nbsp;the Business Combination Proposal, the Governing Documents Proposal A, the Share Issuance Proposal, the Incentive Award Plan
Proposal, the Employee Stock Purchase Plan Proposal and the Adjournment Proposal are approved by the affirmative vote of at least a majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at
the extraordinary general meeting and entitled to vote on such matter (ii)&nbsp;the Domestication Proposal, the New Organizational Documents Proposal, the Governing Documents Proposal B, the Governing Documents Proposal C and the Governing Documents
Proposal D are approved by the affirmative vote of at least <FONT STYLE="white-space:nowrap">a&nbsp;two-thirds&nbsp;(2/3)</FONT> majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the
extraordinary general meeting and entitled to vote on such matter, (iii)&nbsp;otherwise limit the number of public shares electing to redeem and (iv)&nbsp;New Surrozen&#146;s net tangible assets (as determined in accordance with <FONT
STYLE="white-space:nowrap">Rule&nbsp;3a51-1(g)(1)&nbsp;of</FONT> the Exchange Act) being at least $5,000,001 after giving effect to the transactions contemplated by the Business Combination Agreement and the PIPE Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Entering into any such arrangements may have a depressive effect on the ordinary shares. For example, as a result of these arrangements, an
investor or holder may have the ability to effectively purchase shares at a price lower than market and may therefore be more likely to sell the shares he or she owns, either at or prior to the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If such transactions are effected, the consequence could be to cause the Business Combination to be consummated in circumstances where such
consummation could not otherwise occur. Purchases of shares by the persons described above would allow them to exert more influence over the approval of the proposals to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
presented at the extraordinary general meeting and would likely increase the chances that such proposals would be approved. We will file or submit a Current Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;to</FONT> disclose any material arrangements entered into or significant purchases made by any of the aforementioned persons that would affect the vote on the proposals to be put to the extraordinary
general meeting or the redemption threshold. Any such report will include descriptions of any arrangements entered into or significant purchases by any of the aforementioned persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The existence of financial and personal interests of one or more of CHFW&#146;s directors may result in a conflict of interest on the part of
such director(s) between what he, she or they may believe is in the best interests of CHFW and its shareholders and what he, she or they may believe is best for himself, herself or themselves in determining to recommend that shareholders vote for
the proposals. In addition, CHFW&#146;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_78"></A>Expected Accounting Treatment of the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen has been determined to be the accounting acquirer in the Business Combination based on the following predominate factors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s existing stockholders will have the greatest voting interest in the combined entity under the
no redemption and maximum redemption scenarios with over 50% of the voting interest in each scenario; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen will have the ability to nominate a majority of the members of the Board of Directors of the combined
entity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s senior management will be the senior management of the combined entity; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen is the larger entity based on historical operating activity and has the larger employee base.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Business Combination is expected to be accounted for as a reverse recapitalization in accordance with GAAP. Under
this method of accounting, CHFW is treated as the acquired company and Surrozen is treated as the acquirer. Accordingly, for accounting purposes, the Business Combination will be treated as the equivalent of Surrozen issuing stock for the net assets
of CHFW, accompanied by a recapitalization. The net assets of CHFW will be stated at historical cost, with no goodwill or other intangible assets recorded. Operations presented for the period prior to the Business Combination will be those of
Surrozen. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_79"></A>Regulatory Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Business Combination and the transactions contemplated by the Business Combination Agreement are not subject to any additional federal or
state regulatory requirement or approval, (i)&nbsp;except for filings with the Cayman Islands and Delaware necessary to effectuate the Domestication and (ii)&nbsp;the Business Combination and filings required of solicitation materials pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14a-12&nbsp;of</FONT> the Exchange Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_80"></A>Vote Required for Approval
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The approval of the Business Combination Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote
of a majority of the ordinary shares represented in person or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_81"></A>Resolution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
full text of the resolution to be passed is as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>&#147;RESOLVED</B>, as an ordinary resolution, that CHFW&#146;s entry into the
Business Combination Agreement, a copy of which is attached to the proxy statement/prospectus as Annex A, pursuant to which, among other things, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
following <FONT STYLE="white-space:nowrap">the&nbsp;de-registration&nbsp;of</FONT> CHFW as an exempted company in the Cayman Islands and the continuation and domestication of CHFW as a
corporation in the State of Delaware with the name &#147;Surrozen, Inc.,&#148; (a) Merger Sub will merge with and into Surrozen, with Surrozen as the surviving company in the Merger and, after giving effect to such Merger, Surrozen shall be a
wholly-owned subsidiary of CHFW and (b)&nbsp;at the Effective Time, each share and equity award of Surrozen (whether vested or unvested) outstanding as of immediately prior to the Effective Time will be exchanged for shares of New Surrozen Common
Stock or comparable equity awards that are settled or are exercisable for shares of New Surrozen Common Stock, as applicable, based on an implied Surrozen equity value of $200,000,000, on the terms and subject to the conditions set forth in the
Business Combination Agreement.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_82"></A>DOMESTICATION PROPOSAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_83"></A>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As discussed in this proxy statement/prospectus, CHFW is asking its shareholders to approve the Domestication Proposal. Under the Business
Combination Agreement, the approval of the Domestication Proposal is also a condition to the consummation of the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As
a condition to closing the Business Combination, the board of directors of CHFW has unanimously approved, and CHFW shareholders are being asked to consider and vote upon a proposal to approve (the &#147;<U>Domestication Proposal</U>&#148;), a change
of CHFW&#146;s jurisdiction of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware. To effect the Domestication, CHFW will file an
application to deregister with the Cayman Islands Registrar of Companies, together with the necessary accompanying documents, and file a certificate of incorporation and a certificate of corporate domestication with the Secretary of State of the
State of Delaware, under which CHFW will be domesticated and continue as a Delaware corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with the Domestication, on
the Closing Date prior to the Effective Time, (i)&nbsp;each issued and outstanding Class&nbsp;A ordinary share and each issued and outstanding Class&nbsp;B ordinary share of CHFW will convert automatically by operation of law, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, into shares of New Surrozen Common Stock; (ii)&nbsp;each issued and outstanding warrant to purchase Class&nbsp;A ordinary shares of CHFW will automatically
represent the right to purchase one share of New Surrozen Common Stock at an exercise price of $11.50 per shares of New Surrozen Common Stock on the terms and conditions set forth in the warrant agreement; and (iii)&nbsp;each issued and outstanding
unit of CHFW that has not been previously separated into the underlying Class&nbsp;A ordinary share and underlying warrant upon the request of the holder thereof, will be cancelled and will entitle the holder thereof to one share of New Surrozen
Common Stock and <FONT STYLE="white-space:nowrap">one-third</FONT> of one warrant to acquire one share of New Surrozen Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Domestication Proposal, if approved, will approve a change of CHFW&#146;s jurisdiction of incorporation from the Cayman Islands to the
State of Delaware. Accordingly, while CHFW is currently incorporated as an exempted company under the Cayman Islands Companies Act, upon the Domestication, New Surrozen will be governed by the DGCL. We encourage shareholders to carefully consult the
information set out below under &#147;Comparison of Corporate Governance and Shareholder Rights.&#148; Additionally, we note that if the Domestication Proposal is approved, then CHFW will also ask its shareholders to approve each of the Governing
Documents Proposal (discussed below), which, if approved, will replace the Existing Governing Documents with a new certificate of incorporation and bylaws of New Surrozen under the DGCL. The Proposed Governing Documents differ in certain material
respects from the Existing Governing Documents and we encourage shareholders to carefully consult the information set out below under &#147;Governing Documents Proposal,&#148; the Existing Governing Documents of CHFW, attached hereto as Annex B and
the Proposed Governing Documents of New Surrozen, attached hereto as Annex C and Annex D. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_84"></A>Reasons for
the Domestication </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors believes that there are significant advantages to us that will arise as a result of a change
of our domicile to Delaware. Further, our board of directors believes that any direct benefit that the DGCL provides to a corporation also indirectly benefits its stockholders, who are the owners of the corporation. The board of directors believes
that there are several reasons why a reincorporation in Delaware is in the best interests of CHFW and its shareholders. As explained in more detail below, these reasons can be summarized as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Prominence, Predictability, and Flexibility of Delaware Law</I>. For many years Delaware has followed a
policy of encouraging incorporation in its state and, in furtherance of that policy, has been a leader in adopting, construing, and implementing comprehensive, flexible corporate laws responsive to the legal and business needs of corporations
organized under its laws. Many corporations have chosen Delaware </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
initially as a state of incorporation or have subsequently changed corporate domicile to Delaware. Because of Delaware&#146;s prominence as the state of incorporation for many major corporations,
both the legislature and courts in Delaware have demonstrated the ability and a willingness to act quickly and effectively to meet changing business needs. The DGCL is frequently revised and updated to accommodate changing legal and business needs
and is more comprehensive, widely used and interpreted than other state corporate laws. This favorable corporate and regulatory environment is attractive to businesses such as ours. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Well-Established Principles of Corporate Governance</I>. There is substantial judicial precedent in the
Delaware courts as to the legal principles applicable to measures that may be taken by a corporation and to the conduct of a company&#146;s board of directors, such as under the business judgment rule and other standards. Because the judicial system
is based largely on legal precedents, the abundance of Delaware case law provides clarity and predictability to many areas of corporate law. We believe, such clarity would be advantageous to New Surrozen, its board of directors and management to
make corporate decisions and take corporate actions with greater assurance as to the validity and consequences of those decisions and actions. Further, investors and securities professionals are generally more familiar with Delaware corporations,
and the laws governing such corporations, increasing their level of comfort with Delaware corporations relative to other jurisdictions. The Delaware courts have developed considerable expertise in dealing with corporate issues, and a substantial
body of case law has developed construing Delaware law and establishing public policies with respect to corporate legal affairs. Moreover, Delaware&#146;s vast body of law on the fiduciary duties of directors provides appropriate protection for New
Surrozen&#146;s stockholders from possible abuses by directors and officers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Increased Ability to Attract and Retain Qualified Officers and Directors</I>. Reincorporation from the
Cayman Islands to Delaware is attractive to directors, officers, and stockholders alike. New Surrozen&#146;s incorporation in Delaware may make New Surrozen more attractive to future candidates for our board of directors and officer positions,
because many such candidates are already familiar with Delaware corporate law from their past business experience. To date, we have not experienced difficulty in retaining directors or officers, but directors and officers of public companies are
exposed to significant potential liability. Thus, candidates&#146; familiarity and comfort with Delaware laws&#151;especially those relating to director indemnification (as discussed below)&#151;draw such qualified candidates to Delaware
corporations. Our board of directors therefore believes that providing the benefits afforded directors by Delaware law will enable New Surrozen to compete more effectively with other public companies in the recruitment of talented and experienced
directors and officers. Moreover, Delaware&#146;s vast body of law on the fiduciary duties of directors and officers provides appropriate protection for our stockholders from possible abuses by directors and officers. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The frequency of claims and litigation pursued against directors and officers has greatly expanded the risks facing directors and officers of
corporations in carrying out their respective duties. The amount of time and money required to respond to such claims and to defend such litigation can be substantial. While both Cayman and Delaware law permit a corporation to include a provision in
its governing documents to reduce or eliminate the monetary liability of directors for breaches of fiduciary duty in certain circumstances, we believe that, in general, Delaware law is more developed and provides more guidance than Cayman law on
matters regarding a company&#146;s ability to limit director liability. As a result, we believe that the corporate environment afforded by Delaware will enable the surviving corporation to compete more effectively with other public companies in
attracting and retaining new directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_85"></A>Expected Accounting Treatment of the Domestication </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There will be no accounting effect or change in the carrying amount of the consolidated assets and liabilities of CHFW as a result of the
Domestication. The business, capitalization, assets and liabilities and financial statements of New Surrozen immediately following the Domestication will be the same as those of CHFW immediately prior to the Domestication. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_86"></A>Vote Required for Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The approval of the Domestication Proposal requires a special resolution under Cayman Islands law, being the affirmative vote of at least a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> (2/3) majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter.
Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes,</FONT> while considered present for the purposes of establishing a quorum, will not count as votes cast at the extraordinary general meeting, and otherwise will have no effect on the
proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Domestication Proposal is conditioned on the approval and adoption of each of the other Condition Precedent Proposals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_87"></A>Resolution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The full text of the resolution to be passed is as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>RESOLVED</B>, as a special resolution, that CHFW be transferred by way of continuation to Delaware pursuant to Part
XII of the Companies Act (as revised) of the Cayman Islands and Section&nbsp;388 of the General Corporation Law of the State of Delaware and, immediately upon being <FONT STYLE="white-space:nowrap">de-registered</FONT> in the Cayman Islands, CHFW be
continued and domesticated as a corporation under the laws of the state of Delaware and, conditional upon, and with effect from, the registration of CHFW as a corporation in the State of Delaware, the name of CHFW be changed from <FONT
STYLE="white-space:nowrap">&#147;Consonance-HFW</FONT> Acquisition Corp.&#148; to &#147;Surrozen, Inc.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_88"></A>Recommendation of the CHFW Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THE CHFW BOARD UNANIMOUSLY RECOMMENDS THAT CHFW SHAREHOLDERS VOTE &#147;FOR&#148; THE APPROVAL OF THE DOMESTICATION PROPOSAL. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The existence of financial and personal interests of one or more of CHFW&#146;s directors may result in a conflict of interest on the part of
such director(s) between what he, she or they may believe is in the best interests of CHFW and its shareholders and what he, she or they may believe is best for himself or themselves in determining to recommend that shareholders vote for the
proposals. In addition, CHFW&#146;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#147;<I>Business Combination Proposal&#151;Interests of CHFW&#146;s Directors
and Executive Officers in the Business Combination</I>&#148; for a further discussion of these considerations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEW ORGANIZATIONAL DOCUMENTS PROPOSAL </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the Condition
Precedent Proposals are approved and the Business Combination is to be consummated, CHFW will replace the Existing Governing Documents with a proposed new certificate of incorporation (the &#147;<U>Proposed Certificate of Incorporation</U>&#148;)
and proposed new bylaws (the &#147;<U>Proposed Bylaws</U>&#148; and, together with the Proposed Certificate of Incorporation, the &#147;<U>Proposed Governing Documents</U>&#148;) of New Surrozen, in each case, under the DGCL. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Reasons for the New Organizational Documents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Proposed Certificate of Incorporation and the Proposed Bylaws were negotiated as part of the Business Combination. CHFW&#146;s Board&#146;s
specific reasons for each of the Governing Documents Proposals (each of which are included in the Proposed Governing Documents) are set forth below in the section &#147;Governing Documents Proposals.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Vote Required for Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The approval of New Organizational Documents Proposal requires a special resolution under Cayman Islands law, being the affirmative vote of at
least a <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such
matters. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes,</FONT> while considered present for the purpose of establishing a quorum, will not count as votes cast at the extraordinary general meeting, and other will have no effect on
the proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The New Organizational Documents Proposal is conditioned on the approval and adoption of each of the other Condition
Precedent Proposals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Resolution to be Voted Upon </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The full text of the resolution to be passed is as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>RESOLVED</B>, as a special resolution, that the Proposed Certificate of Incorporation and the Proposed Bylaws, copies of which are
attached to the proxy statement/prospectus as Annex C and Annex D, respectively, be approved as the certificate of incorporation and bylaws, respectively, of New Surrozen, effective upon the effectiveness of the Domestication.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Recommendation of the CHFW Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THE CHFW BOARD UNANIMOUSLY RECOMMENDS THAT CHFW SHAREHOLDERS VOTE &#147;FOR&#148; THE APPROVAL OF THE NEW ORGANIZATIONAL DOCUMENTS PROPOSAL.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The existence of financial and personal interests of one or more of CHFW&#146;s directors may result in a conflict of interest on the
part of such director(s) between what he, she or they may believe is in the best interests of CHFW and its shareholders and what he, she or they may believe is best for himself or themselves in determining to recommend that shareholders vote for the
proposals. In addition, CHFW&#146;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#147;<I>Business Combination Proposal&#151;Interests of CHFW&#146;s Directors
and Executive Officers in the Business Combination</I>&#148; for a further discussion of these considerations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_89"></A>GOVERNING DOCUMENTS PROPOSALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the New Organizational Documents Proposal and the other Condition Precedent Proposals are approved and the Business Combination is to be
consummated, CHFW will replace the Existing Governing Documents, with a proposed new certificate of incorporation and proposed new bylaws of New Surrozen, in each case, under the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW&#146;s shareholders are asked to consider and vote upon and to approve, on an advisory, non-binding basis, by special resolution the
Governing Documents Proposal, save for Governing Documents Proposal A, which proposes to alter CHFW&#146;s authorized share capital and which will require an ordinary resolution, to replace the Existing Governing Documents with the Proposed
Governing Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Proposed Governing Documents differ in certain respects from the Existing Governing Documents. The following
table sets forth a summary of the principal changes proposed to be made between the Existing Governing Documents and the Proposed Certificate of Incorporation and Proposed Bylaws for New Surrozen. This summary is qualified by reference to the
complete text of the Existing Governing Documents of CHFW, attached to this proxy statement/prospectus as Annex B, the complete text of the Proposed Certificate of Incorporation, a copy of which is attached to this proxy statement/prospectus as
Annex C and the complete text of the Proposed Bylaws, a copy of which is attached to this proxy statement/prospectus as Annex D. All shareholders are encouraged to read each of the Proposed Governing Documents in its entirety for a more complete
description of its terms. Additionally, as the Existing Governing Documents governed by Cayman Islands law and the Proposed Governing Documents will be governed by the DGCL, we encourage shareholders to carefully consult the information set out
under the &#147;<I>Comparison of Corporate Governance and Shareholder Rights</I>&#148; section of this proxy statement/prospectus. While certain material changes between the Existing Governing Documents and the Proposed Governing Documents have been
unbundled into distinct Governing Documents Proposals or otherwise identified, there are other differences between the Existing Governing Documents and the Proposed Governing Documents (arising from, among other things, differences between the
Cayman Islands Companies Act and the DGCL and the typical form of organizational documents under each such body of law) that will be approved (subject to the approval aforementioned related proposals and consummation of the Business Combination) if
CHFW shareholders approve the New Organizational Documents Proposal and each of the Governing Document Proposals. Accordingly, CHFW encourages shareholders to carefully review the terms of the Proposed Governing Documents of New Surrozen, as well as
the information set forth in the table below. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="39%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Existing Governing Documents</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Proposed Governing Documents</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Authorized&nbsp;Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The share capital under the Existing Governing Documents is US$50,100 divided into 350,000,000 Class&nbsp;A ordinary shares
of par value US$0.0001 per share, 150,000,000 Class&nbsp;B ordinary shares of par value US$0.0001 per share and 1,000,000 preference shares of par value US$0.0001 per share.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents authorize 300,000,000 shares of New Surrozen Common Stock and 10,000,000 shares of New
Surrozen Preferred Stock.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See paragraph 8 of the Existing Governing Documents.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See Article IV subsection A of the Proposed Certificate of Incorporation.</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Authorize the Board of Directors to Issue Preferred Stock Without Stockholder Consent</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Existing Governing Documents authorize the issuance of 1,000,000 preference shares with such designation, rights and
preferences as may be determined from time to time by our board of directors. Accordingly, the CHFW Board is empowered under the Existing Governing Documents, without shareholder approval, to issue preference shares with dividend, liquidation,
redemption, voting or other rights which could adversely affect the voting power or</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents authorize the board of directors to issue all or any shares of preferred stock in one or
more series to fix the number of shares and to determine or alter for each such series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such
qualifications, limitations, or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="39%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Existing Governing Documents</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Proposed Governing Documents</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other rights of the holders of ordinary shares.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Board of Directors providing for the issuance of such shares and as may be permitted by the DGCL.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See paragraph 8 of the Existing Governing Documents and Article 3 of the Articles of Association.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See Article IV subsection B of the Proposed Certificate of Incorporation.</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Corporate Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Existing Governing Documents provide the name of the company is
<FONT STYLE="white-space:nowrap">&#147;Consonance-HFW</FONT> Acquisition Corp.&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents will provide that the name of the corporation will be &#147;Surrozen,
Inc.&#148;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See paragraph 1 of our Existing Governing Documents.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See Article I of the Proposed Certificate of Incorporation.</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Perpetual Existence</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Existing Governing Documents provide that if we do not consummate a business combination (as defined in the Existing
Governing Documents) by November&nbsp;23, 2022 (24 months after the closing of CHFW&#146;s initial public offering), CHFW will cease all operations except for the purposes of winding up and will redeem the shares issued in CHFW&#146;s initial public
offering and liquidate its trust account.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents do not include any provisions relating to New Surrozen&#146;s ongoing existence; the
default under the DGCL will make New Surrozen&#146;s existence perpetual.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See Article 38 of our Articles of Association.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>This is the default rule under the DGCL.</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Shareholder/Stockholder Written Consent In Lieu of a Meeting</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Existing Governing Documents provide that resolutions may be passed by a vote in person, by proxy at a general meeting,
or by unanimous written resolution.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>See Articles 14
and 15 of our Articles of Association.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Certificate of Incorporation allows stockholders to vote in person or by proxy at a meeting of stockholders,
but prohibits the ability of stockholders to act by written consent in lieu of a meeting.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Exclusive Forum</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Existing Governing Documents do not contain a provision adopting an exclusive forum for certain shareholder
litigation.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents adopt Delaware as the exclusive forum for certain stockholder litigation and the federal
district courts of the United Stated of America shall be the exclusive forum for litigation arising out of the Securities Act.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See Article VII subsections A and B of the Proposed Certificate of Incorporation</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Provisions related to the Corporate Opportunity Doctrine</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Existing Governing Documents do not address corporate opportunities under Cayman Law.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents provide a waiver of the obligation of nonemployee directors of New Surrozen to offer
certain corporate opportunities to New Surrozen unless the opportunity is acquired or become in the possession of the direct expressly and solely in connection with such individual&#146;s service on the board of New
Surrozen.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="39%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Existing Governing Documents</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Proposed Governing Documents</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See Article V of the Proposed Certificate of Incorporation.</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Provisions Related to Status as a Blank Check Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Existing Governing Documents set forth various provisions related to our status as a blank check company prior to the
consummation of a business combination.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents do not include such provisions related to our status as a blank check company, which no
longer will apply upon consummation of the Business Combination, as we will cease to be a blank check company at such time.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>See Article 38 of our Articles of Association.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_90"></A>Overview of Change in Authorized Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Governing Documents Proposal</B>s&#151;as a special resolution, to approve the Proposed Governance Documents, including the change in the
authorized share capital of CHFW from US$50,100 divided into (i) 350,000,000 Class&nbsp;A ordinary shares, par value $0.0001 per share, 150,000,000 Class&nbsp;B ordinary shares, par value $0.0001 per share, and 1,000,000 preference shares, par value
$0.0001 per share, to (ii) 300,000,000 shares of New Surrozen Common Stock and 10,000,000 shares of New Surrozen Preferred Stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As
of the date of this proxy statement/prospectus, there are 11,934,000 ordinary shares issued and outstanding, which includes an aggregate of 2,300,000 Class&nbsp;B ordinary shares held by the initial shareholders, including Sponsor. In addition, as
of the date of this proxy statement/prospectus, there is outstanding an aggregate of 3,211,334 warrants to acquire ordinary shares, comprised of 144,667 private placement warrants held by Sponsor and 3,066,667 public warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with the Domestication, on the Closing Date prior to the Effective Time, (i)&nbsp;each issued and outstanding Class&nbsp;A
ordinary share and each issued and outstanding Class&nbsp;B ordinary share of CHFW will convert automatically by operation of law, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, into shares of
New Surrozen Common Stock; (ii)&nbsp;each issued and outstanding warrant to purchase Class&nbsp;A ordinary shares of CHFW will automatically represent the right to purchase one share of New Surrozen Common Stock at an exercise price of $11.50 per
shares of New Surrozen Common Stock on the terms and conditions set forth in the warrant agreement; and (iii)&nbsp;each issued and outstanding unit of CHFW that has not been previously separated into the underlying Class&nbsp;A ordinary share and
underlying warrant upon the request of the holder thereof, will be cancelled and will entitle the holder thereof to one share of New Surrozen Common Stock and <FONT STYLE="white-space:nowrap">one-third</FONT> of one warrant to acquire one share of
New Surrozen Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with the terms and subject to the conditions of the Business Combination Agreement, at the
Effective Time, each share and equity award of Surrozen (whether vested or unvested) outstanding as of immediately prior to the Effective Time will be exchanged for shares of New Surrozen Common Stock or comparable equity awards that are settled or
are exercisable for shares of New Surrozen Common Stock, as applicable, based on an implied Surrozen <FONT STYLE="white-space:nowrap">pre-combination</FONT> equity value of $200,000,000 and a $10.00 per share value for New Surrozen Common Stock. For
further details, including the calculation of the exchange ratio see &#147;<I>Consideration to Surrozen Equityholders in the Business Combination</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to ensure that New Surrozen has sufficient authorized capital for future issuances, the CHFW Board has approved, subject to
shareholder approval, that the Proposed Governing Documents of New Surrozen change in the authorized share capital of CHFW from US$50,100 divided into (i) 350,000,000 Class&nbsp;A ordinary shares, 150,000,000 Class&nbsp;B ordinary shares and
1,000,000 preference shares of CHFW to (ii) 300,000,000 shares of New Surrozen Common Stock and 10,000,000 shares of New Surrozen Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_91"></A>Reasons for the Change in Authorized Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The principal purpose of this proposal is to provide for an authorized capital structure of New Surrozen that will enable it to continue as an
operating company governed by the DGCL. The CHFW Board believes that it is important for New Surrozen to have available for issuance a number of authorized shares of common stock and preferred stock sufficient to support its capital needs and its
growth and to provide flexibility for future corporate needs (including, if needed, as part of financing for future growth acquisitions). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_92"></A>Overview of Issuance of Preferred Stock by the Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Approval of the Governing Documents Proposals will also<B> </B>authorize the New Surrozen Board to issue any or all shares of New Surrozen
Preferred Stock in one or more classes or series, with such terms and conditions as may be expressly determined by the New Surrozen Board and as may be permitted by the DGCL, which will allow for issuance of any or all of the shares of preferred
stock from time to time at the discretion of the board of directors, as may be permitted by the DGCL, and without further stockholder action. The shares of preferred stock would be issuable for any proper corporate purpose, including, among other
things, future acquisitions, capital raising transactions consisting of equity or convertible debt, stock dividends or issuances under current and any future stock incentive plans, pursuant to which we may provide equity incentives to employees,
officers and directors, and in certain instances may be used as an anti-takeover defense. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_93"></A>Reasons for
the Issuance of Preferred Stock by the Board </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The CHFW Board believes that these additional shares will provide us with needed
flexibility to issue shares in the future in a timely manner and under circumstances we consider favorable without incurring the risk, delay and potential expense incident to obtaining stockholder approval for a particular issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Authorized but unissued preferred stock may enable the board of directors to render it more difficult or to discourage an attempt to obtain
control of New Surrozen and thereby protect continuity of or entrench its management, which may adversely affect the market price of New Surrozen. If, in the due exercise of its fiduciary obligations, for example, the board of directors was to
determine that a takeover proposal was not in the best interests of New Surrozen, such preferred stock could be issued by the board without stockholder approval in one or more private placements or other transactions that might prevent or render
more difficult or make more costly the completion of any attempted takeover transaction by diluting voting or other rights of the proposed acquirer or insurgent stockholder group, by creating a substantial voting bloc in institutional or other hands
that might support the position of the board of directors, by effecting an acquisition that might complicate or preclude the takeover, or otherwise. Allowing the New Surrozen Board to issue the authorized preferred stock on its own volition will
enable New Surrozen to have the flexibility to issue such preferred stock in the future for financing its business, for acquiring other businesses, for forming strategic partnerships and alliances and for stock dividends and stock splits. New
Surrozen currently has no such plans, proposals, or arrangements, written or otherwise, to issue any of the additional authorized stock for such purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_94"></A>Reasons for the Removal of Stockholder Action by Written Consent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Proposed Governing Documents, New Surrozen&#146;s stockholders will have the ability to propose items of business (subject to the
restrictions set forth therein) at duly convened stockholder meetings. Eliminating the right of stockholders to act by written consent limits the circumstances under which stockholders can act on their own initiative to remove directors, or alter or
amend New Surrozen&#146;s organizational documents outside of a duly called special or annual meeting of the stockholders of New Surrozen. Permitting stockholder action by written consent would circumvent the usual process of allowing deliberation
at a meeting of stockholders, would be contrary to principles of openness and good governance, and would have the potential to inappropriately disenfranchise stockholders, potentially permitting a small group of short-term, special interest or
self-interested stockholders, who together hold a threshold amount of shares, and who do not owe any fiduciary responsibilities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
to other stockholders, to take important actions without the involvement of, and with little or no advance notice to, New Surrozen or other stockholders. Allowing stockholder action by written
consent would also deny all stockholders the right to receive accurate and complete information on a proposal in advance and to present their opinions and consider presentation of the opinions of New Surrozen&#146;s board of directors and other
stockholders on a proposal before voting on a proposed action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the elimination of the stockholders&#146; ability to act by
written consent may have certain anti-takeover effects by forcing a potential acquirer to take control of the board of directors only at a duly called special or annual meeting. However, this proposal is not in response to any effort of which CHFW
is aware to obtain control of New Surrozen, and CHFW and its management do not presently intend to propose other anti-takeover measures in future proxy solicitations. Further, the board of directors does not believe that the effects of the
elimination of stockholder action by written consent will create a significant impediment to a tender offer or other effort to take control of New Surrozen. Inclusion of these provisions in the Proposed Governing Documents might also increase the
likelihood that a potential acquirer would negotiate the terms of any proposed transaction with the board of directors and thereby help protect stockholders from the use of abusive and coercive takeover tactics. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_95"></A>Overview of Other Provisions of the Proposed Governance Documents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Approval of each of the Governing Documents Proposals, assuming approval of each of the Condition Precedent Proposals, will result, upon the
consummation of the Domestication, in the wholesale replacement of the Existing Governing Documents with New Surrozen&#146;s Proposed Governing Documents, which the CHFW Board believes is necessary to adequately address the needs of New Surrozen
after the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Proposed Governing Documents will be replaced in connection with the Business Combination to provide
that the name of the corporation will be &#147;Surrozen, Inc.&#148; In addition, the Proposed Governing Documents will make New Surrozen&#146;s corporate existence perpetual. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Proposed Certificate of Incorporation, which will be in effect upon consummation of the Domestication, provides that, unless New Surrozen
consents in writing to the selection of an alternative forum (an &#147;Alternative Forum Consent&#148;), the Court of Chancery of the State of Delaware will, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&nbsp;any
derivative action or proceeding brought on behalf of New Surrozen, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty (including any fiduciary duty) owed by any current or former director, officer, stockholder or employee of New
Surrozen to New Surrozen or New Surrozen&#146;s stockholders, (iii)&nbsp;any action asserting a claim against New Surrozen or any current or former director, officer, stockholder or employee of New Surrozen arising out of or relating to any
provision of the General Corporation Law of Delaware, the Proposed Certificate of Incorporation or Proposed Bylaws (each, as in effect from time to time), or (iv)&nbsp;any action asserting a claim against New Surrozen or any current or former
director, officer, stockholder or employee of New Surrozen governed by the internal affairs doctrine of the State of Delaware. The forgoing shall not apply to any claims under the Exchange Act or the Securities Act of 1933, as amended. In addition,
unless New Surrozen gives an Alternate Forum Consent, the federal district courts of the United States of America shall be the sole and exclusive forum for resolving any action asserting a claim arising under the Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Proposed Certificate of Incorporation of New Surrozen will provide a waiver of the obligation of nonemployee directors of New Surrozen to
offer certain corporate opportunities to New Surrozen unless the opportunity is acquired or become in the possession of the direct expressly and solely in connection with such individual&#146;s service on the board of New Surrozen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Proposed Certificate of Incorporation will not contain provisions related to a blank check company (including those related to operation
of the trust account, winding up of our operations should we not complete a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
business combination by a specified date, and other such blank check-specific provisions as are present in the Existing Governing Documents) because following the consummation of the Business
Combination, New Surrozen will not be a blank check company. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Approval of the Governing Documents Proposals, assuming approval of each
of the other Condition Precedent Proposals, will result, upon the consummation of the Domestication, in the wholesale replacement of CHFW&#146;s Existing Governing Documents with New Surrozen&#146;s Proposed Governing Documents. While certain
changes between the Existing Governing Documents and the Proposed Governing Documents have been summarized above, there are other differences between the Existing Governing Documents and the Proposed Governing Documents (arising from, among other
things, differences between Cayman Islands law and the DGCL and the typical form of organizational documents under each such body of law) that will be approved (subject to the approval aforementioned proposals and consummation of the Business
Combination) if our shareholders approve each of the Governing Documents Proposals. Accordingly, we encourage shareholders to carefully review the terms of the Proposed Governing Documents of New Surrozen, attached hereto as Annex C and Annex D, as
well as the information set under the &#147;<I>Comparison of Corporate Governance and Shareholder Rights</I>&#148; section of this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_96"></A>Reasons for the Other Provisions of the Proposed Governance Documents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The CHFW Board believes that changing the post-business combination corporate name from
<FONT STYLE="white-space:nowrap">&#147;Consonance-HFW</FONT> Acquisition Corp.&#148; to &#147;Surrozen, Inc.&#148; is desirable to reflect the Business Combination with Surrozen and to clearly identify New Surrozen as the publicly traded entity.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The CHFW Board believes that making New Surrozen&#146;s corporate existence perpetual is desirable to reflect the Business Combination.
Additionally, perpetual existence is the usual period of existence for public corporations, and the CHFW Board believes that it is the most appropriate period for New Surrozen following the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Adopting Delaware as the exclusive forum for certain stockholder litigation is intended to assist New Surrozen in avoiding multiple lawsuits
in multiple jurisdictions regarding the same matter. The ability to require such claims to be brought in a single forum will help to assure consistent consideration of the issues, the application of a relatively known body of case law and level of
expertise and should promote efficiency and cost-savings in the resolutions of such claims. The CHFW Board believes that the Delaware courts are best suited to address disputes involving such matters given that the after the Domestication, New
Surrozen will be incorporated in Delaware. Delaware law generally applies to such matters and the Delaware courts have a reputation for expertise in corporate law matters. Delaware offers a specialized Court of Chancery to address corporate law
matters, with streamlined procedures and processes which help provide relatively quick decisions. This accelerated schedule can minimize the time, cost and uncertainty of litigation for all parties. The Court of Chancery has developed considerable
expertise with respect to corporate law issues, as well as a substantial and influential body of case law construing Delaware&#146;s corporate law and long-standing precedent regarding corporate governance. This provides stockholders and the
post-combination company with more predictability regarding the outcome of intra-corporate disputes. In the event the Court of Chancery does not have jurisdiction, the other state courts located in Delaware would be the most appropriate forums
because these courts have more expertise on matters of Delaware law compared to other jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, this provision would
promote judicial fairness and avoid conflicting results, as well as make the post-combination company&#146;s defense of applicable claims less disruptive and more economically feasible, principally by avoiding duplicative discovery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Adopting the federal district courts of the United States of America as the exclusive forum for resolving any complaint asserting a cause of
action arising under the Securities Act, unless New Surrozen consents in writing to an alternative forum, is intended to allow for the consolidation of multi-jurisdiction litigation, avoid state court
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
forum shopping, provide efficiencies in managing the procedural aspects of securities litigation and reduce the risk that the outcome of cases in multiple jurisdictions could be inconsistent.
CHFW&#146;s Board has chosen the federal courts of the United States of America as the exclusive forum for such Securities Act causes of action because Surrozen&#146;s principal executive offices are located in the United States of America and
because potential plaintiffs should not be inconvenienced in bringing claims in the federal courts located in the states where they reside. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The &#147;corporate opportunity&#148; doctrine provides that directors and officers of a corporation, as part of their duty of loyalty to the
corporation and its stockholders, generally have a fiduciary duty to disclose opportunities to the corporation that are related to its business and are prohibited from pursuing those opportunities unless the corporation determines that it is not
going to pursue them. Section&nbsp;122(17) of the DGCL expressly permits Delaware corporations, such as New Surrozen to renounce any interest or expectancy of the corporation in certain business opportunities. The Existing Governing Documents does
not address the &#147;corporate opportunity&#148; doctrine<B>.</B> In order to attract and retain independent directors who work in the life sciences field and may acquire opportunities while serving as employees or outside directors of other
unrelated companies, the Proposed Certificate of Incorporation waives this obligation for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for corporate opportunities that arise or become in possession of the director not expressly and
solely in connection with such individual&#146;s service on the board of New Surrozen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Proposed Governance Documents require the
approval by affirmative vote of holders of at least 66<SUP STYLE="vertical-align:top">2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of the voting power of New Surrozen&#146;s then-outstanding shares of capital stock entitled to vote in
an election of directors to make any amendment to New Surrozen&#146;s bylaws not approved by the Board. The Proposed Governance Documents require the approval by affirmative vote of holders of at least
66<SUP STYLE="vertical-align:top">2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of the voting power of New Surrozen&#146;s then-outstanding shares of capital stock entitled to vote in an election of directors to make any amendment to
certain provisions of New Surrozen&#146;s Proposed Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These provisions are intended to protect key provisions
of the Proposed Bylaws and Proposed Certificate of Incorporation from arbitrary amendment and to prevent a simple majority of stockholders from taking actions that may be harmful to other stockholders or making changes to provisions that are
intended to protect all stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The elimination of certain provisions related to our status as a blank check company is desirable
because these provisions will serve no purpose following the Business Combination. For example, the Proposed Certificate of Incorporation does not include the requirement to dissolve New Surrozen and allows it to continue as a corporate entity with
perpetual existence following consummation of the Business Combination. Perpetual existence is the usual period of existence for public corporations, and the CHFW Board believes it is the most appropriate period for New Surrozen following the
Business Combination. In addition, certain other provisions in our current certificate require that proceeds from the CHFW&#146;s initial public offering be held in the trust account until a business combination or liquidation of CHFW has occurred.
These provisions cease to apply once the Business Combination is consummated and are therefore not included in the Proposed Certificate of Incorporation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_97"></A>Vote Required for Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The non-binding, advisory approval of the Governing Documents Proposals requires a special resolution under Cayman Islands law, being the
affirmative vote of at least a <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and
entitled to vote on such matters, save for Governing Documents Proposal A, which proposes to alter CHFW&#146;s authorized share capital and which will require an ordinary resolution, being the affirmative vote of holders of a majority of the
ordinary shares represented in person or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes,</FONT> while considered present for the purposes of
establishing a quorum, will not count as votes cast at the extraordinary general meeting, and otherwise will have no effect on the proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because the vote on each Governing Documents Proposal is advisory only, it will not be
binding on the CHFW Board or New Surrozen. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_98"></A>Resolution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The full text of each Governing Document Proposal to be passed is as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Governing Document Proposal A </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>RESOLVED</B>, as a special resolution, that each of the Governing Documents Proposals, including the change in the authorized share
capital of CHFW from US$50,100 divided into (i) 350,000,000 Class&nbsp;A ordinary shares, par value $0.0001 per share, 150,000,000 Class&nbsp;B ordinary shares, par value $0.0001 per share and 1,000,000 preference shares, par value $0.0001 per
share, to (ii) 300,000,000 shares of common stock, par value $0.0001 per share, of New Surrozen and 10,000,000 shares of preferred stock, par value $0.0001 per share, of New Surrozen be approved.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Governing Document Proposal&nbsp;B </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>RESOLVED</B>, as a special resolution, that the authorization to the New Surrozen Board to issue any or all shares of New Surrozen
Preferred Stock in one or more classes or series, with such terms and conditions as may be expressly determined by the New Surrozen Board and as may be permitted by the Delaware General Corporation Law be approved.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Governing Document Proposal&nbsp;C </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>RESOLVED</B>, as a special resolution, that the removal of the ability of New Surrozen stockholders to take action by written consent
in lieu of a meeting be approved.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Governing Document Proposal&nbsp;D </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>RESOLVED</B>, as a special resolution, that the amendment and restatement of the Existing Governing Documents be approved and that all
other immaterial changes necessary or, as mutually agreed in good faith by CHFW and Surrozen, desirable in connection with the replacement of Existing Governing Documents with the Proposed Certificate of Incorporation and Proposed Bylaws as part of
the Domestication (copies of which are attached to the proxy statement/prospectus as Annex&nbsp;C and Annex&nbsp;D, respectively), including (i)&nbsp;changing the post-Business Combination corporate name from Consonance-HFW Acquisition Corp. to
Surrozen, Inc. (which is expected to occur upon the consummation of the Domestication), (ii)&nbsp;making New Surrozen&#146;s corporate existence perpetual, (iii)&nbsp;adopting Delaware as the exclusive forum for certain stockholder litigation and
federal district courts of the United States of America as the exclusive forum for litigation arising out of the Securities Act of 1933, as amended and (iv)&nbsp;removing certain provisions related to our status as a blank check company that will no
longer be applicable upon consummation of the Business Combination be approved.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_99"></A>Recommendation of
the CHFW Board </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THE CHFW BOARD UNANIMOUSLY RECOMMENDS THAT CHFW SHAREHOLDERS VOTE &#147;FOR&#148; THE APPROVAL, ON AN ADVISORY,
NON-BINDING BASIS, OF EACH OF THE SEPARATE GOVERNING DOCUMENTS PROPOSAL. </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The existence of financial and personal interests of
one or more of CHFW&#146;s directors may result in a conflict of interest on the part of such director(s) between what he or they may believe is in the best interests of CHFW and its shareholders and what he or they may believe is best for himself
or themselves in determining to recommend that shareholders vote for the proposals. In addition, CHFW&#146;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled
&#147;<I>Business Combination Proposal&#151;Interests of CHFW&#146;s Directors and Executive Officers in the Business Combination</I>&#148; for a further discussion of these considerations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_100"></A>SHARE ISSUANCE PROPOSAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_101"></A>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Share Issuance Proposal&#151;to consider and vote upon a proposal to approve by ordinary resolution, for the purposes of complying with the
applicable provisions of the Nasdaq Stock Exchange Listing Rules (each, a &#147;Nasdaq Listing Rule&#148;) 5635(a), (b) and (d), the issuance of shares of New Surrozen Common Stock in connection with the Business Combination and the PIPE Financing,
to the extent such issuance would require a shareholder vote under Nasdaq Listing Rule 5635(a), (b), or (d) (such proposal, the &#147;Share Issuance Proposal&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_102"></A>Reasons for the Approval for Purposes of Nasdaq Listing Rule 5635 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under Nasdaq Listing Rule 5635(a)(1), shareholder approval is required prior to the issuance of common stock, or of securities convertible into
or exercisable for common stock, in connection with the acquisition of another company if such securities are not issued in a public offering for cash and (i)&nbsp;the common stock has, or will have upon issuance, voting power equal to or in excess
of 20% of the voting power outstanding before the issuance of such securities (or securities convertible into or exercisable for common stock; or (ii)&nbsp;the number of shares of common stock to be issued is or will be equal to or in excess of 20%
of the number of shares of common stock outstanding before the issuance of the stock or securities. Additionally, under Nasdaq Listing Rule 5635(b), shareholder approval is required prior to the issuance of securities when the issuance or potential
issuance will result in a change of control of the registrant. Under Nasdaq Listing Rule 5635(d), shareholder approval is required for a transaction other than a public offering, involving the sale, issuance or potential issuance by an issuer of
common stock (or securities convertible into or exercisable for common stock) at a price that is less than the lesser of the official Nasdaq closing price immediately before signing of the binding agreement and the average official Nasdaq closing
price for the five trading days immediately preceding the signing of the binding agreement of the stock if the number of shares of common stock to be issued is or may be equal to 20% or more of the common stock, or 20% or more of the voting power,
outstanding before the issuance. If the Business Combination is completed pursuant to the Business Combination Agreement, CHFW currently expects to issue an
estimated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of New Surrozen Common Stock and equity awards
representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of New Surrozen Common Stock in connection with the Business Combination and the PIPE Financing. For further details, see
&#147;<I>Business Combination Proposal&#151;Consideration to Surrozen Equityholders in the Business Combination</I>&#148; and &#147;<I>Incentive Award Plan Proposal</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, pursuant to Nasdaq Listing Rule 5635(a)(2), when a Nasdaq-listed company proposes to issue securities in connection with the
acquisition of the stock or assets of another company, shareholder approval is required if any director, officer or substantial shareholder of such company has a 5% or greater interest, directly or indirectly, in such company or the assets to be
acquired or in the consideration to be paid in the transaction or series of related transactions and the present or potential issuance of common stock (or securities convertible into or exercisable for common stock) could result in an increase in
outstanding shares of common stock or voting power of 5% or more. Nasdaq Listing Rule 5635(e)(3) defines a substantial stockholder as the holder of an interest of 5% or more of either the number of shares of common stock or the voting power
outstanding of a Nasdaq-listed company. Because Sponsor currently owns greater than 5% of CHFW&#146;s ordinary shares, Sponsor and the Consonance PIPE Investor are considered substantial shareholders of CHFW under Nasdaq Listing Rule 5635(e)(3). In
connection with the PIPE Financing, the Consonance PIPE Investor is expected to be issued 2,497,500 shares of New Surrozen Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that this proposal is not approved by CHFW shareholders, the Business Combination cannot be consummated. In the event that this
proposal is approved by CHFW shareholders, but the Business Combination Agreement is terminated (without the Business Combination being consummated) prior to the issuance of shares of New Surrozen Common Stock pursuant to the Business Combination
Agreement, New Surrozen will not issue such shares of New Surrozen Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_103"></A>Vote Required for Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The approval of the Share Issuance Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of at least a
majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter. Abstentions and broker
<FONT STYLE="white-space:nowrap">non-votes,</FONT> while considered present for the purposes of establishing a quorum, will not count as votes cast at the extraordinary general meeting, and otherwise will have no effect on the proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Share Issuance Proposal is conditioned on the approval and adoption of each of the other Condition Precedent Proposals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_104"></A>Resolution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The full text of the resolution to be passed is as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>RESOLVED</B>, as an ordinary resolution, that for the purposes of complying with the applicable provisions of Nasdaq
Stock Exchange Listing Rule 5635, the issuance of shares of New Surrozen Common Stock be approved.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_105"></A>Recommendation of the CHFW Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THE CHFW BOARD UNANIMOUSLY RECOMMENDS THAT CHFW SHAREHOLDERS VOTE &#147;FOR&#148; THE APPROVAL OF THE SHARE ISSUANCE PROPOSAL</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The existence of financial and personal interests of one or more of CHFW&#146;s directors may result in a conflict of interest on the part of
such director(s) between what he, she or they may believe is in the best interests of CHFW and its shareholders and what he, she or they may believe is best for himself or themselves in determining to recommend that shareholders vote for the
proposals. In addition, CHFW&#146;s directors and officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#147;<I>Business Combination Proposal&#151;Interests of
CHFW&#146;s Directors and Executive Officers in the Business Combination</I>&#148; for a further discussion of these considerations. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_106">
</A>INCENTIVE AWARD PLAN PROPOSAL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_107"></A>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In this proposal, we are asking our shareholders to approve the 2021 Plan. CHFW&#146;s board of directors has approved the 2021 Plan, subject
to shareholder approval. If shareholders approve this proposal, the 2021 Plan will become effective on the consummation of the Business Combination. However, this proposal is cross-conditioned on the other Condition Precedent Proposals. If the 2021
Plan is not approved by the shareholders, it will not become effective and no awards will be granted thereunder and the Board will be able to grant awards under the Surrozen, Inc. 2015 Equity Incentive Plan, which we refer to herein as the
&#147;2015 Plan.&#148; If the 2021 Plan is adopted, no awards will be granted under the 2015 Plan following the Closing. The 2021 Plan is described in more detail below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_108"></A>General Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The purpose of the 2021 Plan is to provide a means whereby New Surrozen can secure and retain the services of employees, directors and
consultants, to provide incentives for such persons to exert maximum efforts for the success of New Surrozen and its affiliates and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the common
stock through the granting of awards under the 2021 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Approval of the 2021 Plan by our shareholders is required, among other things, in order to
comply with stock exchange rules requiring stockholder approval of equity compensation plans and allow the grant of incentive stock options and restricted stock&nbsp;units under the 2021 Plan. If this proposal is approved by our shareholders, the
2021 Plan will become effective as of the date of the closing of the Business Combination. In the event that our shareholders do not approve this proposal, the 2021 Plan will not become effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New Surrozen&#146;s equity compensation program, as implemented under the 2021 Plan, will allow New Surrozen to be competitive with comparable
companies in its industry by giving it the resources to attract and retain talented individuals to achieve its business objectives and build stockholder value. It is critical to New Surrozen&#146;s long-term success that the interests of employees
and other service providers be tied to their success as &#147;owners&#148; of the business. Approval of the 2021 Plan will allow New Surrozen to grant stock options and other equity awards at levels it determines to be appropriate in order to
attract new employees and other service providers, retain existing employees and service providers and to provide incentives for such persons to exert maximum efforts for New Surrozen&#146;s success and ultimately increase stockholder value. The
2021 Plan allows New Surrozen to utilize a broad array of equity incentives with flexibility in designing equity incentives, including traditional stock option grants, stock appreciation rights, restricted stock awards, restricted stock unit awards,
other stock awards and performance awards to offer competitive equity compensation packages in order to retain and motivate the talent necessary for New Surrozen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the request to approve the 2021 Plan is approved by our shareholders, there will be that number of shares of New Surrozen common stock that
is equal to 10% of the fully diluted common stock as of immediately following the closing of the Business Combination, subject to adjustment for specified changes in New Surrozen&#146;s capitalization, available for grant under the 2021 Plan as of
the effective time of the Business Combination. In addition, as further described below under the section titled &#147;&#151;<I>Description of the Surrozen, Inc. 2021 Equity Incentive Plan</I><I></I><I>&#151;</I><I></I><I>Authorized
Shares</I>,&#148; the share reserve is subject to annual increases each January&nbsp;1 of up to 5% of shares of New Surrozen fully diluted common stock outstanding (or a lesser number determined by the Board). CHFW&#146;s board of directors believes
this pool size is necessary to provide sufficient reserved shares for a level of grants that will attract, retain, and motivate employees and other participants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_109"></A>Description of the 2021 Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A summary description of the material features of the 2021 Plan is set forth below. The following summary does not purport to be a complete
description of all the provisions of the 2021 Plan and is qualified by reference to the 2021 Plan, the form of which is attached to this proxy statement/prospectus as Annex J and incorporated by reference in its entirety. CHFW&#146;s shareholders
should refer to the 2021 Plan for more complete and detailed information about the terms and conditions of the 2021 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Eligibility</I>. Any individual who is an employee of New Surrozen or any of its affiliates, or any person who provides services to New
Surrozen or its affiliates, including consultants and members of the Board, is eligible to receive awards under the 2021 Plan at the discretion of the plan administrator. If this proposal is approved by the shareholders, all of New Surrozen&#146;s
employees, directors and consultants will be eligible to receive awards following the closing of the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Awards</I>.
The 2021 Plan provides for the grant of incentive stock options (&#147;ISOs&#148;), within the meaning of Section&nbsp;422 of the Code to employees, including employees of any parent or subsidiary, and for the grant of nonstatutory stock options
(&#147;NSOs&#148;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of New Surrozen&#146;s
affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Authorized Shares</I>. Initially, the maximum number of shares of New Surrozen common stock that may be issued under the
2021 Plan after it becomes effective will be that number of shares that is equal to 10% of the fully diluted common stock as of immediately following the closing of the Business Combination. In addition, the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
number of shares of New Surrozen common stock reserved for issuance under the 2021 Plan will automatically increase on January&nbsp;1 of each year, starting on January&nbsp;1, 2022 and ending on
(and including) January&nbsp;1, 2031, in an amount equal to the lesser of (1)&nbsp;5% of the total number of shares of New Surrozen fully diluted common stock outstanding on December&nbsp;31 of the preceding year, or (2)&nbsp;a lesser number of
shares of New Surrozen common stock determined by the Board prior to the date of the increase. The maximum number of shares of New Surrozen common stock that may be issued on the exercise of ISOs under the 2021 Plan is a number of shares equal to
three hundred percent (300%) of the number of shares initially reserved for issuance under the 2021 Plan. As of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, the record date for the
extraordinary general meeting, the closing price of CHFW&#146;s common stock as reported on NYSE American LLC was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The unused shares subject to stock awards granted under the 2021 Plan that expire or are terminated, exchanged for or settled in cash,
reacquired to satisfy the purchase or exercise price, reacquired to satisfy any applicable tax withholding, forfeited or repurchased because of a failure to satisfy any applicable vesting condition, canceled without having been fully exercised or
forfeited, will, as applicable, become or again be available for stock award grants under the 2021 Plan.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit</I>. The aggregate value of all compensation granted or
paid to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director with respect to any calendar year, including awards granted and cash fees paid to such <FONT STYLE="white-space:nowrap">non-employee</FONT> director, will not exceed
(1)&nbsp;$750,000 in total value or (2)&nbsp;if such <FONT STYLE="white-space:nowrap">non-employee</FONT> director is first appointed or elected to the Board during such calendar year, $1,000,000 in total value, in each case, calculating the value
of any equity awards based on the grant date fair value of such equity awards for financial reporting purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Plan</I><I></I><I>&nbsp;Administration</I>. The Board, or a duly authorized committee thereof, will administer the 2021 Plan and is
referred to as the &#147;plan administrator&#148; herein. The Board may also delegate to one or more of New Surrozen&#146;s officers the authority to (1)&nbsp;designate employees (other than officers) to receive specified stock awards and
(2)&nbsp;determine the number of shares subject to such stock awards. Under the 2021 Plan, the Board has the authority to determine award recipients, grant dates, the numbers and types of stock awards to be granted, the applicable fair market value,
and the provisions of each stock award, including the period of exercisability and the vesting schedule applicable to a stock award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Stock Options</I>. ISOs and NSOs are granted under stock option agreements adopted by the plan administrator. The plan administrator
determines the exercise price for stock options, within the terms and conditions of the 2021 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of a share of New Surrozen common stock
on the date of grant. Options granted under the 2021 Plan vest at the rate specified in the stock option agreement as determined by the plan administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The plan administrator determines the term of stock options granted under the 2021 Plan, up to a maximum of 10&nbsp;years. Unless the terms of
an optionholder&#146;s stock option agreement provide otherwise or as otherwise provided by the plan administrator, if an optionholder&#146;s service relationship with New Surrozen or any of New Surrozen&#146;s affiliates ceases for any reason other
than disability, death, or cause, the optionholder may generally exercise any vested options for a period of three&nbsp;months following the cessation of service. This period may be extended in the event that exercise of the option is prohibited by
applicable securities laws. Unless the terms of an optionholder&#146;s stock option agreement provide otherwise or as otherwise provided by the plan administrator, if an optionholder&#146;s service relationship with New Surrozen or any of New
Surrozen&#146;s affiliates ceases due to death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 18&nbsp;months following the
date of death. Unless the terms of an optionholder&#146;s stock option agreement provide otherwise or as otherwise provided by the plan administrator, if an optionholder&#146;s service relationship with New Surrozen or any of New Surrozen&#146;s
affiliates ceases due to disability, the optionholder may generally exercise any vested options for a period of 12&nbsp;months following the date of disability. In the event of a termination for cause, options generally terminate upon the
termination date. In no event may an option be exercised beyond the expiration of its term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Acceptable consideration for the purchase of New Surrozen common stock issued upon the
exercise of a stock option will be determined by the plan administrator and may include (1)&nbsp;cash, check, bank draft or money order, (2)&nbsp;a broker-assisted cashless exercise, (3)&nbsp;the tender of shares of New Surrozen common stock
previously owned by the optionholder, (4)&nbsp;a net exercise of the option if it is an NSO or (5)&nbsp;other legal consideration approved by the plan administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless the plan administrator provides otherwise, options and stock appreciation rights generally are not transferable except by will or the
laws of descent and distribution. Subject to approval of the plan administrator or a duly authorized officer, an option may be transferred pursuant to a domestic relations order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Tax Limitations on ISOs</I>. The aggregate fair market value, determined at the time of grant, of New Surrozen common stock with respect to
ISOs that are exercisable for the first time by an award holder during any calendar year under all of New Surrozen&#146;s stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No
ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of New Surrozen&#146;s total combined voting power or that of any of New Surrozen&#146;s parent or subsidiary corporations unless
(1)&nbsp;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant and (2)&nbsp;the term of the ISO does not exceed five&nbsp;years from the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Restricted Stock Unit Awards</I>. Restricted stock unit awards are granted under restricted stock unit award agreements adopted by the plan
administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to the plan administrator and permissible under applicable law. A restricted stock unit award may be settled by
cash, delivery of shares of New Surrozen common stock, a combination of cash and shares of New Surrozen common stock as determined by the plan administrator, or in any other form of consideration set forth in the restricted stock unit award
agreement. Additionally, dividend equivalents may be paid or credited in respect of shares covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement or by the plan administrator, restricted stock unit
awards that have not vested will be forfeited once the participant&#146;s continuous service ends for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Restricted Stock
Awards</I>. Restricted stock awards are granted under restricted stock award agreements adopted by the plan administrator. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, services to us, or any
other form of legal consideration that may be acceptable to the plan administrator and permissible under applicable law. The plan administrator determines the terms and conditions of restricted stock awards, including vesting and forfeiture terms.
If a participant&#146;s service relationship with New Surrozen ends for any reason, New Surrozen may receive any or all of the shares of New Surrozen common stock held by the participant that have not vested as of the date the participant terminates
service with New Surrozen through a forfeiture condition or a repurchase right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Stock Appreciation Rights</I>. Stock appreciation
rights are granted under stock appreciation right agreements adopted by the plan administrator. The plan administrator determines the strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of
New Surrozen common stock on the date of grant. A stock appreciation right granted under the 2021 Plan vests at the rate specified in the stock appreciation right agreement as determined by the plan administrator. Stock appreciation rights may be
settled in cash or shares of New Surrozen common stock or in any other form of payment, as determined by the plan administrator and specified in the stock appreciation right agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The plan administrator determines the term of stock appreciation rights granted under the 2021 Plan, up to a maximum of 10&nbsp;years. Unless
the terms of a participant&#146;s stock appreciation rights agreement provide otherwise or as otherwise provided by the plan administrator, if a participant&#146;s service relationship with New Surrozen or any of its affiliates ceases for any reason
other than cause, disability, or death, the participant may generally exercise any vested stock appreciation right for a period of three&nbsp;months following the cessation of service. This period may be further extended in the event that exercise
of the stock appreciation right following such a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
termination of service is prohibited by applicable securities laws. Unless the terms of a participant&#146;s stock appreciation rights agreement provide otherwise or as otherwise provided by the
plan administrator, if a participant&#146;s service relationship with New Surrozen or any of its affiliates, ceases due to disability or death, or a participant dies within a certain period following cessation of service, the participant or a
beneficiary may generally exercise any vested stock appreciation right for a period of 12&nbsp;months in the event of disability and 18&nbsp;months in the event of death. In the event of a termination for cause, stock appreciation rights generally
terminate immediately upon the occurrence of the event giving rise to the termination of the individual for cause. In no event may a stock appreciation right be exercised beyond the expiration of its term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Performance Awards</I>. The 2021 Plan permits the grant of performance awards that may be settled in stock, cash or other property.
Performance awards may be structured so that the stock or cash will be issued or paid only following the achievement of certain <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals during a designated performance period.
Performance awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, New Surrozen common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Other Stock Awards</I>. The plan administrator may grant other awards based in whole or in part by reference to New Surrozen common stock.
The plan administrator will set the number of shares under the stock award (or cash equivalent) and all other terms and conditions of such awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Changes to Capital Structure</I>. In the event there is a specified type of change in the capital structure of New Surrozen, such as a
stock split, reverse stock split, or recapitalization, appropriate adjustments will be made to (1)&nbsp;the class and maximum number of shares reserved for issuance under the 2021 Plan, (2)&nbsp;the class of shares by which the share reserve may
increase automatically each year, (3)&nbsp;the class and maximum number of shares that may be issued on the exercise of ISOs and (4)&nbsp;the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all
outstanding stock awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Corporate Transactions</I>. The following applies to stock awards under the 2021 Plan in the event of a
corporate transaction (as defined in the 2021 Plan), unless otherwise provided in a participant&#146;s stock award agreement or other written agreement with New Surrozen or one of its affiliates or unless otherwise expressly provided by the plan
administrator at the time of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of a corporate transaction, any stock awards outstanding under the 2021 Plan may be
assumed, continued or substituted for by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by New Surrozen with respect to the stock award may be assigned to New Surrozen&#146;s successor
(or its parent company). If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then (i)&nbsp;with respect to any such stock awards that are held by participants whose
continuous service has not terminated prior to the effective time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards will be accelerated in full (or, in the case of performance
awards with multiple vesting levels depending on the level of performance, vesting will accelerate at 100% of the target level) to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate
transaction), and such stock awards will terminate if not exercised (if applicable) at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by New Surrozen with respect to such stock awards
will lapse (contingent upon the effectiveness of the corporate transaction), and (ii)&nbsp;any such stock awards that are held by persons other than current participants will terminate if not exercised (if applicable) prior to the effective time of
the corporate transaction, except that any reacquisition or repurchase rights held by New Surrozen with respect to such stock awards will not terminate and may continue to be exercised notwithstanding the corporate transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event a stock award will terminate if not exercised prior to the effective time of a corporate transaction, the plan administrator may
provide, in its sole discretion, that the holder of such stock award may not exercise such stock award but instead will receive a payment equal in value to the excess (if any) of (i)&nbsp;the per share amount payable to holders of New Surrozen
common stock in connection with the corporate transaction, over (ii)&nbsp;any per share exercise price payable by such holder, if applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Plan</I><I></I><I>&nbsp;Amendment or Termination</I>. The Board has the authority to
amend, suspend, or terminate the 2021 Plan at any time, provided that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. Certain material amendments also require approval of
New Surrozen&#146;s stockholders. No ISOs may be granted after the tenth anniversary of the date CHFW&#146;s board of directors adopts the 2021 Plan. No stock awards may be granted under the 2021 Plan while it is suspended or after it is terminated.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_110"></A>U.S. Federal Income Tax Consequences </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following is a summary of the principal U.S. federal income tax consequences to participants and New Surrozen with respect to participation
in the 2021 Plan, which will not become effective until the date of the closing of the Business Combination. No awards will be issued under the 2021 Plan prior to the date of the closing of the Business Combination. This summary is not intended to
be exhaustive and does not discuss the income tax laws of any local, state or foreign jurisdiction in which a participant may reside. The information is based upon current U.S. federal income tax rules and therefore is subject to change when those
rules change. Because the tax consequences to any participant may depend on his or her particular situation, each participant should consult the participant&#146;s tax adviser regarding the federal, state, local and other tax consequences of the
grant or exercise of an award or the disposition of stock acquired under the 2021 Plan. The 2021 Plan is not qualified under the provisions of Section&nbsp;401(a) of the Code and is not subject to any of the provisions of the Employee Retirement
Income Security Act of 1974, as amended. New Surrozen&#146;s ability to realize the benefit of any tax deductions described below depends on New Surrozen&#146;s generation of taxable income as well as the requirement of reasonableness and the
satisfaction of New Surrozen&#146;s tax reporting obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Nonstatutory Stock Options.</I> Generally, there is no taxation upon
the grant of a NSO. Upon exercise, a participant will recognize ordinary income equal to the excess, if any, of the fair market value of the underlying stock on the date of exercise of the stock option over the exercise price. If the participant is
employed by New Surrozen or one of its affiliates, that income will be subject to withholding taxes. The participant&#146;s tax basis in those shares will be equal to their fair market value on the date of exercise of the stock option, and the
participant&#146;s capital gain holding period for those shares will begin on the day after they are transferred to the participant. Subject to the requirement of reasonableness, the deduction limits under Section&nbsp;162(m) of the Code and the
satisfaction of a tax reporting obligation, New Surrozen will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Incentive Stock Options.</I> The 2021 Plan provides for the grant of stock options that are intended to qualify as &#147;incentive stock
options,&#148; as defined in Section&nbsp;422 of the Code. Under the Code, a participant generally is not subject to ordinary income tax upon the grant or exercise of an ISO. If the participant holds a share received upon exercise of an ISO for more
than two&nbsp;years from the date the stock option was granted and more than one year from the date the stock option was exercised, which is referred to as the required holding period, the difference, if any, between the amount realized on a sale or
other taxable disposition of that share and the participant&#146;s tax basis in that share will be long-term capital gain or loss. If, however, a participant disposes of a share acquired upon exercise of an ISO before the end of the required holding
period, which is referred to as a disqualifying disposition, the participant generally will recognize ordinary income in the year of the disqualifying disposition equal to the excess, if any, of the fair market value of the share on the date of
exercise of the stock option over the exercise price. However, if the sales proceeds are less than the fair market value of the share on the date of exercise of the stock option, the amount of ordinary income recognized by the participant will not
exceed the gain, if any, realized on the sale. If the amount realized on a disqualifying disposition exceeds the fair market value of the share on the date of exercise of the stock option, that excess will be short-term or long-term capital gain,
depending on whether the holding period for the share exceeds one year. For purposes of the alternative minimum tax, the amount by which the fair market value of a share of stock acquired upon exercise of an ISO exceeds the exercise price of the
stock option generally will be an adjustment included in the participant&#146;s alternative minimum taxable income for the year in which the stock option is exercised. If, however, there is a disqualifying disposition of the share in the year in
which the stock option is exercised, there will be no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
adjustment for alternative minimum tax purposes with respect to that share. In computing alternative minimum taxable income, the tax basis of a share acquired upon exercise of an ISO is increased
by the amount of the adjustment taken into account with respect to that share for alternative minimum tax purposes in the year the stock option is exercised. New Surrozen is not allowed a tax deduction with respect to the grant or exercise of an ISO
or the disposition of a share acquired upon exercise of an ISO after the required holding period. If there is a disqualifying disposition of a share, however, New Surrozen will generally be entitled to a tax deduction equal to the taxable ordinary
income realized by the participant, subject to the requirement of reasonableness, the deduction limits under Section&nbsp;162(m) of the Code and provided that either the employee includes that amount in income or New Surrozen timely satisfies its
reporting requirements with respect to that amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Restricted Stock Awards.</I> Generally, the recipient of a restricted stock award
will recognize ordinary income at the time the stock is received equal to the excess, if any, of the fair market value of the stock received over any amount paid by the recipient in exchange for the stock. If, however, the stock is subject to
restrictions constituting a substantial risk of forfeiture when it is received (for example, if the employee is required to work for a period of time in order to have the right to transfer or sell the stock), the recipient generally will not
recognize income until the restrictions constituting a substantial risk of forfeiture lapse, at which time the recipient will recognize ordinary income equal to the excess, if any, of the fair market value of the stock on the date it becomes vested
over any amount paid by the recipient in exchange for the stock. A recipient may, however, file an election with the Internal Revenue Service, within 30&nbsp;days following the date of grant, to recognize ordinary income, as of the date of grant,
equal to the excess, if any, of the fair market value of the stock on the date the award is granted over any amount paid by the recipient for the stock. The recipient&#146;s basis for the determination of gain or loss upon the subsequent disposition
of shares acquired from a restricted stock award will be the amount paid for such shares plus any ordinary income recognized either when the stock is received or when the restrictions constituting a substantial risk of forfeiture lapse. Subject to
the requirement of reasonableness, the deduction limits under Section&nbsp;162(m) of the Code and the satisfaction of a tax reporting obligation, New Surrozen will generally be entitled to a tax deduction equal to the taxable ordinary income
realized by the recipient of the restricted stock award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Restricted Stock Unit Awards.</I> Generally, the recipient of a restricted
stock unit award will generally recognize ordinary income at the time the stock is delivered equal to the excess, if any, of (i)&nbsp;the fair market value of the stock received over any amount paid by the recipient in exchange for the stock or
(ii)&nbsp;the amount of cash paid to the participant. The recipient&#146;s basis for the determination of gain or loss upon the subsequent disposition of shares acquired from a restricted stock unit award will be the amount paid for such shares plus
any ordinary income recognized when the stock is delivered, and the participant&#146;s capital gain holding period for those shares will begin on the day after they are transferred to the participant. Subject to the requirement of reasonableness,
the deduction limits under Section&nbsp;162(m) of the Code and the satisfaction of a tax reporting obligation, New Surrozen will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the
restricted stock unit award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Stock Appreciation Rights.</I> Generally, the recipient of a stock appreciation right will recognize
ordinary income equal to the fair market value of the stock or cash received upon such exercise. Subject to the requirement of reasonableness, the deduction limits under Section&nbsp;162(m) of the Code and the satisfaction of a tax reporting
obligation, New Surrozen will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the stock appreciation right. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_111"></A>Tax Consequences to New Surrozen </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Compensation of Covered Employees.</I> The ability of New Surrozen to obtain a deduction for amounts paid under the 2021 Plan could be
limited by Section&nbsp;162(m) of the Code. Section&nbsp;162(m) of the Code limits New Surrozen&#146;s ability to deduct compensation, for U.S. federal income tax purposes, paid during any year to a &#147;covered employee&#148; (within the meaning
of Section&nbsp;162(m) of the Code) in excess of $1&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Golden Parachute Payments</I>. The ability of New Surrozen (or the ability of one of its
subsidiaries) to obtain a deduction for future payments under the 2021 Plan could also be limited by the golden parachute rules of Section&nbsp;280G of the Code, which prevent the deductibility of certain &#147;excess parachute payments&#148; made
in connection with a change in control of an employer-corporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_112"></A>New Plan&nbsp;Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The awards, if any, that will be made to eligible persons under the 2021 Plan are subject to the discretion of the compensation committee of
the Board. Therefore, CHFW cannot currently determine the benefits or number of shares subject to awards that may be granted in the future and a new plan benefits table is thus not provided. In addition, because CHFW has not maintained a comparable
compensatory equity plan prior to the Business Combination, CHFW cannot determine the benefits or number of shares subject to awards that would have been received by any service provider of CHFW if the 2021 Plan had been in effect. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_113"></A>Interests of CHFW&#146;s Directors and Officers in the Equity Incentive Plan&nbsp;Proposal </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">When you consider the recommendation of CHFW&#146;s board of directors in favor of approval of the 2021 Plan, you should keep in mind that
certain of CHFW&#146;s board of directors and officers have interests in the 2021 Plan that are different from, or in addition to, your interests as a stockholder or warrantholder, including, among other things, the potential future issuance of
awards to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as a director of New Surrozen. See the section titled &#147;<I>Proposal No.</I><I></I><I>&nbsp;1</I><I></I><I>&#151;</I><I></I><I>The Business
Combination</I><I></I><I>&#151;</I><I></I><I>Interests of CHFW&#146;s Directors and Officers in the Business Combination</I>&#148; for a further discussion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_114"></A>Vote Required for Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Equity Incentive Plan&nbsp;Proposal may be approved by an ordinary resolution under Cayman Islands law, being the affirmative vote of a
majority of the ordinary shares represented in person or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes,</FONT> while considered present for
the purposes of establishing a quorum, will not count as votes cast at the extraordinary general meeting, and otherwise will have no effect on a particular proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_115"></A>Resolution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The full text of the resolution to be passed is as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>RESOLVED</B>, as an ordinary resolution, that the Company&#146;s adoption of New Surrozen 2021 Equity Incentive Plan and any form
award agreements thereunder, be approved, ratified and confirmed in all respects.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_116"></A>Recommendation of
CHFW&#146;s Board </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THE CHFW BOARD UNANIMOUSLY RECOMMENDS THAT THE CHFW SHAREHOLDERS VOTE &#147;FOR&#148; THE
APPROVAL OF THE EQUITY INCENTIVE PLAN PROPOSAL. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The existence of financial and personal interests of one or more of CHFW&#146;s
directors may result in a conflict of interest on the part of such director(s) between what he, she or they may believe is in the best interests of CHFW and its shareholders and what he, she or they may believe is best for himself or themselves in
determining to recommend that shareholders vote for the proposals. In addition, CHFW&#146;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section titled &#147;<I>Proposal
No.</I><I></I><I>&nbsp;1</I><I></I><I>&#151;</I><I></I><I>The Business Combination</I><I></I><I>&#151;</I><I></I><I>Interests of CHFW</I><I>&#146;</I><I>s Directors and Officers in the Business Combination</I>&#148; for a further discussion of these
considerations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_117"></A>EMPLOYEE STOCK PURCHASE PLAN PROPOSAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_118"></A>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In this proposal, CHFW is asking its shareholders to approve the ESPP. CHFW&#146;s board of directors approved the ESPP on April&nbsp;15, 2021,
subject to stockholder approval at the special meeting of shareholders. If shareholders approve this proposal, the ESPP will become effective on the consummation of the Business Combination. However, this proposal is cross-conditioned on the other
Condition Precedent Proposals. If the ESPP is not approved by the shareholders, it will not become effective. The ESPP is described in more detail below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The purpose of the ESPP is to provide a means whereby New Surrozen can align the long-term financial interests of its employees with the
financial interests of its shareholders. In addition, the board of directors believes that the ability to allow its employees to purchase shares of New Surrozen common stock will help New Surrozen to attract, retain, and motivate employees and
encourage them to devote their best efforts to New Surrozen&#146;s business and financial success. Approval of the ESPP by CHFW&#146;s shareholders will allow New Surrozen to provide its employees with the opportunity to acquire an ownership
interest in New Surrozen through their participation in the ESPP, thereby encouraging them to remain in service and more closely aligning their interests with those of New Surrozen&#146;s stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_119"></A>Description of the ESPP </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The material features of the ESPP are described below. The following description of the ESPP is a summary only. This summary is not a complete
statement of the ESPP and is qualified in its entirety by reference to the complete text of the ESPP, a copy of which is attached hereto as Annex K. CHFW&#146;s shareholders should refer to the ESPP for more complete and detailed information about
the terms and conditions of the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Purpose</I>. The purpose of the ESPP is to provide a means by which eligible employees of New
Surrozen and certain designated companies may be given an opportunity to purchase shares of New Surrozen common stock following the closing of the Business Combination, to assist New Surrozen in retaining the services of eligible employees, to
secure and retain the services of new employees and to provide incentives for such persons to exert maximum efforts for New Surrozen&#146;s success. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Plan includes two components: a 423 Component and a <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. New Surrozen intends that
the 423 Component will qualify as options issued under an &#147;employee stock purchase plan&#148; as that term is defined in Section&nbsp;423(b) of the Code. Except as otherwise provided in the ESPP or determined by the Board, the <FONT
STYLE="white-space:nowrap">Non-423</FONT> Component will operate and be administered in the same manner as the 423 Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Share
Reserve</I>. The maximum number of shares of New Surrozen common stock that may be issued under the ESPP is equal to 1% of the fully diluted common stock immediately following the consummation of the Business Combination. Additionally, the number of
shares of New Surrozen common stock reserved for issuance under the ESPP will automatically increase on January&nbsp;1st of each year, beginning on January&nbsp;1, 2022 and continuing through and including January&nbsp;1, 2031, by the lesser of
(1)&nbsp;1% of the fully diluted number of shares of New Surrozen common stock outstanding on December&nbsp;31st of the preceding calendar year, (2)&nbsp;a number of shares of New Surrozen common stock equal to 200% of the initial share reserve, or
(3)&nbsp;such lesser number of shares of New Surrozen as determined by the Board. Shares subject to purchase rights granted under the ESPP that terminate without having been exercised in full will not reduce the number of shares available for
issuance under the ESPP. As of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, the record date for the extraordinary general meeting, the closing price of CHFW&#146;s common stock as reported on
NYSE American LLC was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Administration</I>. The Board, or a duly authorized committee thereof, will administer the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Limitations</I>. New Surrozen employees and the employees of any of its designated affiliates, as designated by the Board, will be eligible
to participate in the ESPP, provided they may have to satisfy one or more of the following </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
service requirements before participating in the ESPP, as determined by the administrator: (1)&nbsp;customary employment with New Surrozen or one of its affiliates for more than 20 hours per week
and five or more&nbsp;months per calendar year or (2)&nbsp;continuous employment with New Surrozen or one of its affiliates for a minimum period of time, not to exceed two&nbsp;years, prior to the first date of an offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the Board may also exclude from participation in the ESPP or any offering, employees who are &#147;highly compensated
employees&#148; (within the meaning of Section&nbsp;423(b)(4)(D) of the Code) or a subset of such highly compensated employees. If this proposal is approved by the shareholders, all the employees of New Surrozen and its related corporations will be
eligible to participate in the ESPP following the closing of the Business Combination. An employee may not be granted rights to purchase stock under the ESPP (a)&nbsp;if such employee immediately after the grant would own stock possessing 5% or more
of the total combined voting power or value of all classes of New Surrozen stock or (b)&nbsp;to the extent that such rights would accrue at a rate that exceeds $25,000 worth of New Surrozen stock for each calendar year that the rights remain
outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ESPP is intended to qualify as an employee stock purchase plan under Section&nbsp;423 of the Code. The administrator may
specify offerings with a duration of not more than 27&nbsp;months, and may specify one or more shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of New Surrozen common stock will be
purchased for the employees who are participating in the offering. The administrator, in its discretion, will determine the terms of offerings under the ESPP. The administrator has the discretion to structure an offering so that if the fair market
value of a share of New Surrozen stock on the first trading date of a new purchase period within an existing offering period is less than or equal to the fair market value of a share of New Surrozen stock on the first day of the offering period,
then that offering will terminate immediately, and the participants in such terminated offering will be automatically enrolled in a new offering that begins immediately after such trading date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A participant may not transfer purchase rights under the ESPP other than by will, the laws of descent and distribution, or as otherwise
provided under the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Payroll Deductions</I>. The ESPP permits participants to purchase shares of New Surrozen common stock through
payroll deductions. Unless otherwise determined by the administrator, the purchase price of the shares will be 85% of the lower of the fair market value of New Surrozen common stock on the first day of an offering or on the date of purchase.
Participants may end their participation at any time during an offering and will be paid their accrued contributions that have not yet been used to purchase shares, without interest. Participation ends automatically upon termination of employment
with New Surrozen and its related corporations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Withdrawal.</I> Participants may withdraw from an offering by delivering a withdrawal
form to New Surrozen and terminating their contributions. Such withdrawal may be elected at any time prior to the end of an offering, except as otherwise provided by the Plan&nbsp;Administrator. Upon such withdrawal, New Surrozen will distribute to
the employee his or her accumulated but unused contributions without interest, and such employee&#146;s right to participate in that offering will terminate. However, an employee&#146;s withdrawal from an offering does not affect such
employee&#146;s eligibility to participate in any other offerings under the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Termination of Employment.</I> A participant&#146;s
rights under any offering under the ESPP will terminate immediately if the participant either (i)&nbsp;is no longer employed by New Surrozen or any of its parent or subsidiary companies (subject to any post-employment participation period required
by law) or (ii)&nbsp;is otherwise no longer eligible to participate. In such event, New Surrozen will distribute to the participant his or her accumulated but unused contributions, without interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Corporate Transactions</I>. In the event of certain specified significant corporate transactions, such as a merger or change in control, a
successor corporation may assume, continue, or substitute each outstanding purchase right. If the successor corporation does not assume, continue, or substitute for the outstanding purchase rights, the offering in progress will be shortened and a
new purchase date will be set. The participants&#146; purchase rights will be exercised on the new purchase date and such purchase rights will terminate immediately thereafter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Amendment and Termination</I>. The Board has the authority to amend, suspend, or
terminate the ESPP, at any time and for any reason, provided certain types of amendments will require the approval of New Surrozen stockholders. Any benefits, privileges, entitlements and obligations under any outstanding purchase rights granted
before an amendment, suspension or termination of the ESPP will not be materially impaired by any such amendment, suspension or termination except (i)&nbsp;with the consent of the person to whom such purchase rights were granted, (ii)&nbsp;as
necessary to facilitate compliance with any laws, listing requirements, or governmental regulations, or (iii)&nbsp;as necessary to obtain or maintain favorable tax, listing, or regulatory treatment. The ESPP will remain in effect until terminated by
the Board in accordance with the terms of the ESPP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_120"></A>U.S. Federal Income Tax Consequences </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following is a summary of the principal U.S. federal income tax consequences to participants and New Surrozen with respect to participation
in the ESPP. This summary is not intended to be exhaustive and does not discuss the income tax laws of any local, state or foreign jurisdiction in which a participant may reside. The information is based upon current U.S. federal income tax rules
and therefore is subject to change when those rules change. Because the tax consequences to any participant may depend on his or her particular situation, each participant should consult the participant&#146;s tax adviser regarding the federal,
state, local, and other tax consequences of the grant or exercise of a purchase right or the sale or other disposition of New Surrozen common stock acquired under the ESPP. The ESPP is not qualified under the provisions of Section&nbsp;401(a) of the
Code and is not subject to any of the provisions of the Employee Retirement Income Security Act of 1974, as amended. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>423 Component of the ESPP
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Rights granted under the 423 Component of the ESPP are intended to qualify for favorable U.S. federal income tax treatment associated
with rights granted under an employee stock purchase plan which qualifies under the provisions of Section&nbsp;423 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A
participant will be taxed on amounts withheld for the purchase of shares of New Surrozen common stock as if such amounts were actually received. Otherwise, no income will be taxable to a participant as a result of the granting or exercise of a
purchase right until a sale or other disposition of the acquired shares. The taxation upon such sale or other disposition will depend upon the holding period of the acquired shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the shares are sold or otherwise disposed of more than two&nbsp;years after the beginning of the offering period and more than one year
after the shares are transferred to the participant, then the lesser of the following will be treated as ordinary income: (i)&nbsp;the excess of the fair market value of the shares at the time of such sale or other disposition over the purchase
price; or (ii)&nbsp;the excess of the fair market value of the shares as of the beginning of the offering period over the purchase price (determined as of the beginning of the offering period). Any further gain or any loss will be taxed as a
long-term capital gain or loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the shares are sold or otherwise disposed of before the expiration of either of the holding periods
described above, then the excess of the fair market value of the shares on the purchase date over the purchase price will be treated as ordinary income at the time of such sale or other disposition. The balance of any gain will be treated as capital
gain. Even if the shares are later sold or otherwise disposed of for less than their fair market value on the purchase date, the same amount of ordinary income is attributed to the participant, and a capital loss is recognized equal to the
difference between the sales price and the fair market value of the shares on such purchase date. Any capital gain or loss will be short-term or long-term, depending on how long the shares have been held. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-423</FONT> Component </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A participant will be taxed on amounts withheld for the purchase of shares of New Surrozen common stock as if such amounts were actually
received. Under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, a participant will recognize ordinary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
income equal to the excess, if any, of the fair market value of the underlying stock on the date of exercise of the purchase right over the purchase price. If the participant is employed by New
Surrozen or one of its affiliates, that income will be subject to withholding taxes. The participant&#146;s tax basis in those shares will be equal to their fair market value on the date of exercise of the purchase right, and the participant&#146;s
capital gain holding period for those shares will begin on the day after they are transferred to the participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are no U.S.
federal income tax consequences to New Surrozen by reason of the grant or exercise of rights under the ESPP. New Surrozen is entitled to a deduction to the extent amounts are taxed as ordinary income to a participant for shares sold or otherwise
disposed of before the expiration of the holding periods described above (subject to the requirement of reasonableness, the deduction limits under Section&nbsp;162(m) of the Code and the satisfaction of tax reporting obligations). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_121"></A>New Plan&nbsp;Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Participation in the ESPP is voluntary and each eligible employee will make his or her own decision regarding whether and to what extent to
participate in the ESPP. Therefore, CHFW cannot currently determine the benefits or number of shares subject to purchase rights and a new plan benefits table is thus not provided. In addition, because CHFW has not maintained a comparable plan prior
to the Business Combination, CHFW cannot determine the benefits or number of shares subject to awards that would have been received by any service provider of CHFW if the ESPP had been in effect. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_122"></A>Interests of CHFW&#146;s Directors and Officers in the Employee Stock Purchase Plan&nbsp;Proposal </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">When you consider the recommendation of CHFW&#146;s board of directors in favor of approval of the ESPP, you should keep in mind that certain
of CHFW&#146;s directors and officers have interests in the ESPP that are different from, in addition to, or in conflict with your interests as a stockholder or warrantholder, including,&nbsp;among other things, the existence of financial and
personal interests. See the section titled &#147;<I>Proposal No.</I><I></I><I>&nbsp;1</I><I></I><I>&#151;</I><I></I><I>The Business Combination</I><I></I><I>&#151;</I><I></I><I>Interests of CHFW&#146;s Directors and Officers in the Business
Combination</I>&#148; for a further discussion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_123"></A>Vote Required for Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ESPP Proposal may be approved by an ordinary resolution under Cayman law, being the affirmative vote of a majority of the ordinary shares
represented in person or by proxy and entitled to vote thereon and who vote at the extraordinary general meeting. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes,</FONT> while considered present for the purposes of establishing a
quorum, will not count as votes cast at the extraordinary general meeting, and otherwise will have no effect on a particular proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_124"></A>Resolution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The full text of the resolution to be passed is as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>RESOLVED</B>, as an ordinary resolution, that the Company&#146;s adoption of the New Surrozen 2021 Employee Stock Purchase Plan and
any form award agreements thereunder, be approved, ratified and confirmed in all respects.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_125"></A>Recommendation of CHFW&#146;s Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THE CHFW BOARD UNANIMOUSLY RECOMMENDS THAT THE CHFW SHAREHOLDERS VOTE &#147;FOR&#148; THE APPROVAL OF THE ESPP PROPOSAL.
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_126"></A>ADJOURNMENT PROPOSAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Adjournment Proposal allows the CHFW Board to submit a proposal to approve, by ordinary resolution, the adjournment of the extraordinary
general meeting to a later date or dates (i)&nbsp;to the extent necessary to ensure that any required supplement or amendment to the accompanying proxy statement/prospectus is provided to CHFW shareholders or, if as of the time for which the
extraordinary general meeting is scheduled, there are insufficient CHFW ordinary shares represented (either in person or by proxy) to constitute a quorum necessary to conduct business at the extraordinary general meeting, (ii)&nbsp;in order to
solicit additional proxies from CHFW shareholders in favor of one or more of the proposals at the extraordinary general meeting or (iii)&nbsp;if CHFW shareholders redeem an amount of public shares such that the condition to consummation of the
Business Combination that the aggregate cash proceeds to be received by CHFW from the trust account in connection with the Business Combination, together with aggregate gross proceeds from the PIPE Financing, equal no less than $100,000,000 after
deducting CHFW&#146;s unpaid expenses, liabilities, and any amounts paid to CHFW shareholders that exercise their redemption rights in connection with the Business Combination would not be satisfied.<B> </B>CHFW is not allowed to adjourn the meeting
for more than 15 business days or adjourn the meeting more than twice without the consent of Surrozen. See &#147;<I>Business Combination Proposal&#151;Interests of CHFW&#146;s Directors and Executive Officers in the Business Combination</I>.&#148;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_127"></A>Consequences if the Adjournment Proposal is Not Approved </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the Adjournment Proposal is presented to the extraordinary general meeting and is not approved by the shareholders, the CHFW Board may not
be able to adjourn the extraordinary general meeting to a later date in the event that, based on the tabulated votes, there are not sufficient votes at the time of the extraordinary general meeting to approve the Condition Precedent Proposals. In
such events, the Business Combination would not be completed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_128"></A>Vote Required for Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The approval of the Adjournment Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of at least a
majority of the votes cast by the holders of the issued ordinary shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter. Abstentions and broker
<FONT STYLE="white-space:nowrap">non-votes,</FONT> while considered present for the purposes of establishing a quorum, will not count as votes cast at the extraordinary general meeting, and otherwise will have no effect on the proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Adjournment Proposal is not conditioned on any other proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_129"></A>Resolution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The full text of the resolution to be passed is as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;<B>RESOLVED</B>, as an ordinary resolution, that the adjournment of the extraordinary general meeting to a later date or
dates (A)&nbsp;to the extent necessary to ensure that any required supplement or amendment to the proxy statement/prospectus is provided to CHFW shareholders or, if as of the time for which the extraordinary general meeting is scheduled, there are
insufficient CHFW ordinary shares represented (either in person or by proxy) to constitute a quorum necessary to conduct business at the extraordinary general meeting, (B)&nbsp;in order to solicit additional proxies from CHFW shareholders in favor
of one or more of the proposals at the extraordinary general meeting or (C)&nbsp;if CHFW shareholders redeem an amount of the public shares such that the condition to consummation of the Business Combination that the aggregate cash proceeds to be
received by CHFW from the trust account in connection with the Business Combination, together with aggregate gross proceeds from the PIPE Financing, equal no less than $100,000,000 after deducting CHFW&#146;s unpaid expenses, liabilities, and any
amounts paid to CHFW shareholders that exercise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
their redemption rights in connection with the Business Combination would not be satisfied, at the extraordinary general meeting be approved.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_130"></A>Recommendation of the CHFW Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THE CHFW BOARD UNANIMOUSLY RECOMMENDS THAT CHFW SHAREHOLDERS VOTE &#147;FOR&#148; THE APPROVAL OF THE ADJOURNMENT PROPOSAL. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The existence of financial and personal interests of one or more of CHFW&#146;s directors may result in a conflict of interest on the part of
such director (s)&nbsp;between what he, she or they may believe is in the best interests of CHFW and its shareholders and what he, she or they may believe is best for himself or themselves in determining to recommend that shareholders vote for the
proposals. In addition, CHFW&#146;s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled &#147;<I>Business Combination Proposal&#151;Interests of CHFW&#146;s Directors
and Executive Officers in the Business Combination</I>&#148; for a further discussion of these considerations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_131"></A>CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS
</B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following discussion is a summary of certain material U.S. federal income tax considerations generally applicable to holders
of our public shares or public warrants (other than our Sponsor or any of its affiliates) as a consequence of the (i)&nbsp;Domestication, (ii) exercise of redemption rights and (iii)&nbsp;ownership and disposition of shares of New Surrozen Common
Stock and public warrants following the Domestication. The discussions below under the headings &#147;&#151;Effects of the Domestication on U.S. Holders and &#147;Effects on U.S. Holders Exercising Redemption Rights&#148; constitute the opinion of
Goodwin Procter, United States tax counsel to CHFW, insofar as it discusses the material U.S. federal income tax considerations applicable to U.S. Holders of CHFW securities as a result of the Domestication and the exercise of redemption rights,
based on, and subject to, customary assumptions, qualifications and limitations, and the assumptions, qualifications and limitations herein and in the opinion included as Exhibit&nbsp;8.1 hereto. This section applies only to holders that hold their
public shares, public warrants or New Surrozen Common Stock as capital assets for U.S. federal income tax purposes (generally, as property held for investment). This discussion is a summary only and does not discuss all aspects of U.S. federal
income taxation that may be relevant to particular holders in light of their particular circumstances or status including: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions or financial services entities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">S corporations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">taxpayers that are subject to the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> accounting rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">governments or agencies or instrumentalities thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies or real estate investment trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expatriates or former long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that actually or constructively own five percent or more of our voting shares or five percent or more
of the total value of all classes of our shares (except as specifically addressed below); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that acquired our securities pursuant to an exercise of employee share options, in connection with
employee share incentive plans or otherwise as compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold our securities as part of a straddle, constructive sale, hedging, conversion or other
integrated or similar transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. Holders (as defined below) whose functional currency is not the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">controlled foreign corporations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who purchase stock in New Surrozen as part of the PIPE Financing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">accrual method taxpayers that file applicable financial statements as described in Section&nbsp;451(b) of the
Code; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">passive foreign investment companies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This discussion is based on current U.S. federal income tax law, which is subject to change, possibly on a retroactive basis, which may affect
the U.S. federal income tax consequences described herein. Furthermore, this discussion does not address any aspect of U.S. federal <FONT STYLE="white-space:nowrap">non-income</FONT> tax laws, such as gift, estate or Medicare contribution tax laws,
the alternative minimum tax, or state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws. In addition, this summary does not address any tax consequences to investors that directly or indirectly hold equity interests in Surrozen
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
prior to the Business Combination, including holders of our public shares or public warrants that also hold, directly or indirectly, equity interests in Surrozen. With respect to the consequences
of holding shares of New Surrozen Common Stock, this discussion is limited to holders who acquire such shares of New Surrozen Common Stock in connection with the Domestication or as a result of the exercise of a public warrant. We have not sought,
and will not seek, a ruling from the U.S. Internal Revenue Service (&#147;IRS&#148;) as to any U.S. federal income tax consideration described herein. The IRS may disagree with the discussion herein, and its determination may be upheld by a court.
Moreover, there can be no assurance that future legislation, regulations, administrative rulings or court decisions will not adversely affect the accuracy of the statements in this discussion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This discussion does not consider the U.S. federal income tax treatment of partnerships or other pass-through entities or persons who hold our
securities through such entities. If a partnership (or other entity or arrangement classified as a partnership for U.S. federal income tax purposes) is the beneficial owner of our public shares or public warrants, the U.S. federal income tax
treatment of a partner in the partnership generally will depend on the status of the partner and the activities of the partner and the partnership. If you are a partner of a partnership holding our public shares or public warrants, we urge you to
consult your tax advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THE FOLLOWING IS FOR INFORMATIONAL PURPOSES ONLY. EACH HOLDER SHOULD CONSULT ITS TAX ADVISOR WITH RESPECT TO
THE PARTICULAR TAX CONSEQUENCES, INCLUDING THE EFFECTS OF U.S. FEDERAL, STATE AND LOCAL AND <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX LAWS, TO SUCH HOLDER OF THE DOMESTICATION, THE EXERCISE OF REDEMPTION RIGHTS AND OWNERSHIP AND
DISPOSITION OF SHARES OF NEW SURROZEN COMMON STOCK AND PUBLIC WARRANTS. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of this discussion, because any unit consisting
of one Class&nbsp;A ordinary share and <FONT STYLE="white-space:nowrap">one-third</FONT> of one warrant to acquire one Class&nbsp;A ordinary share is separable at the option of the holder, CHFW is treating any Class&nbsp;A ordinary share and <FONT
STYLE="white-space:nowrap">one-third</FONT> of one warrant to acquire one Class&nbsp;ordinary share held by a holder in the form of a single unit as separate instruments and is assuming that the unit itself will not be treated as an integrated
instrument. Accordingly, the cancellation or separation of the units in connection with the consummation of the Domestication or the exercise of redemption rights generally should not be a taxable event for U.S. federal income tax purposes. This
position is not free from doubt, and no assurance can be given that the IRS would not assert, or that a court would not sustain, a contrary position. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_132"></A>U.S. Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As used herein, a &#147;U.S. Holder&#148; is a beneficial owner of our public shares, public warrants or New Surrozen Common Stock, as
applicable, and is, for U.S. federal income tax purposes: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">an individual citizen or resident of the United States; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a corporation (or other entity that is treated as a corporation for U.S. federal income tax purposes) that is created or organized (or treated
as created or organized) in or under the laws of the United States or any state thereof or the District of Columbia; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">an estate whose
income is subject to U.S. federal income tax regardless of its source; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a trust if (i)&nbsp;a U.S. court can exercise primary
supervision over the administration of such trust and one or more U.S. persons have the authority to control all substantial decisions of the trust or (ii)&nbsp;it has a valid election in place to be treated as a U.S. person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Effects of the Domestication on U.S. Holders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The U.S. federal income tax consequences of the Domestication will depend primarily upon whether the Domestication qualifies as a
&#147;reorganization&#148; within the meaning of Section&nbsp;368 of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under Section&nbsp;368(a)(1)(F) of the Code, a reorganization is a &#147;mere change in
identity, form, or place of organization of one corporation, however effected&#148; (an &#147;F Reorganization&#148;). Pursuant to the Domestication, we will change our jurisdiction of incorporation by deregistering as an exempted company in the
Cayman Islands and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware, changing our name to &#147;Surrozen, Inc.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Domestication should qualify as an F Reorganization. However, due to the absence of direct guidance on the application of
Section&nbsp;368(a)(1)(F) to a statutory conversion of a corporation holding only investment-type assets such as CHFW, this result is not entirely clear. Accordingly, due to the absence of such guidance, it is not possible to predict whether the IRS
or a court considering the issue would take a contrary position. The Domestication should be treated for U.S. federal income tax purposes as if CHFW (i)&nbsp;transferred all of its assets and liabilities to New Surrozen in exchange for all of the
outstanding common stock and warrants of New Surrozen and then (ii)&nbsp;distributed the common stock and warrants of New Surrozen to the shareholders and warrant holders of CHFW, respectively, in liquidation of CHFW. The taxable year of CHFW should
be deemed to end on the date of the Domestication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although the Domestication should qualify as an F reorganization, the Domestication
could be a taxable event to U.S. Holders under the PFIC provisions of the Code. As discussed in greater detail below under &#147;&#151;<I>PFIC Considerations,</I>&#148; CHFW believes it is likely that it qualified as a PFIC for the 2020 taxable year
and that it will qualify as a PFIC for the short taxable year that should be deemed to end on the date of the Domestication. If CHFW is treated as a PFIC, proposed Treasury Regulations under Section&nbsp;1291(f) of the Code that have a retroactive
effective date, if finalized in their current form, would require U.S. Holders of public shares and public warrants to recognize gain on the Domestication if the U.S. Holder did not timely make (a)&nbsp;a QEF Election (as described below) for the
first taxable year in which the U.S. Holder owned the public shares or in which CHFW was a PFIC, whichever is later, or (b)&nbsp;a mark-to-market election (as described below, with respect to such public shares. The tax on any such recognized gain
would be imposed based on a complex set of computational rules, which are discussed more fully below. It is not possible to predict whether, in what form and with what effective date, final Treasury Regulations under Section&nbsp;1291(f) of the Code
will be adopted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the rules discussed in the preceding paragraph do not apply to cause a U.S. Holder to recognize gain on the
Domestication, except as provided under &#147;&#151;<I>Effects of Section&nbsp;367(b) to U.S.&nbsp;Holders,</I>&#148; (i)&nbsp;a U.S. Holder of public shares or public warrants generally should not recognize gain or loss for U.S. federal income tax
purposes on the Domestication, (ii)&nbsp;a U.S. Holder&#146;s tax basis in a share of New Surrozen Common Stock or a New Surrozen warrant received in the Domestication should generally be the same as its tax basis in the public share or public
warrant surrendered in exchange therefor, increased by any amount included in the income of such U.S.&nbsp;Holder under Section&nbsp;367(b) of the Code (as discussed below) and (iii)&nbsp;the holding period for a share of New Surrozen Common Stock
or New Surrozen warrant should generally include such U.S. Holder&#146;s holding period for the public share or public warrant surrendered in exchange therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the Domestication fails to qualify as an F Reorganization, a U.S. Holder generally would recognize gain or loss with respect to a public
share or public warrant in an amount equal to the difference, if any, between the fair market value of the corresponding share of New Surrozen Common Stock or New Surrozen warrant received in the Domestication and the U.S. Holder&#146;s adjusted tax
basis in its public share or public warrant surrendered in exchange therefor. In such event, such U.S. Holder&#146;s basis in the share of New Surrozen Common Stock or New Surrozen warrant would be equal to the fair market value of that share of New
Surrozen Common Stock or New Surrozen warrant on the date of the Domestication and such U.S. Holder&#146;s holding period for the share of New Surrozen Common Stock or New Surrozen warrant would begin on the day following the date of the
Domestication. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because the Domestication will occur immediately prior to the redemption of U.S. Holders that exercise redemption
rights with respect to our public shares, U.S. Holders exercising such redemption rights will be subject to the potential tax consequences of the Domestication. All U.S. Holders considering exercising
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
redemption rights with respect to their public shares are urged to consult with their tax advisors with respect to the potential tax consequences to them of the Domestication and exercise of
redemption rights. The remainder of this discussion assumes that the Domestication will qualify as a &#147;reorganization.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Effects of Section&nbsp;367(b) on U.S. Holders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;367(b) of the Code applies to certain transactions involving foreign corporations, including an inbound domestication of a foreign
corporation in an F Reorganization. Section&nbsp;367(b) of the Code imposes U.S. federal income tax on certain U.S. persons in connection with transactions that would otherwise qualify as a &#147;reorganization&#148; within the meaning of
Section&nbsp;368 of the Code. Section&nbsp;367(b) of the Code will generally apply to U.S. Holders on the date of the Domestication. Because the Domestication will occur immediately prior to the redemption of U.S. Holders that exercise redemption
rights with respect to our public shares, U.S. Holders exercising such redemption rights will be subject to the potential tax consequences of Section&nbsp;367(b) of the Code as a result of the Domestication. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>A.&nbsp;&nbsp;&nbsp;&nbsp;U.S. Holders That Hold 10 Percent or More of CHFW </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A U.S. Holder that, on the date of the Domestication, beneficially owns (actually or constructively) 10% or more of the total combined voting
power of all classes of our stock entitled to vote or 10% or more of the total value of all classes of our stock (a &#147;U.S. Shareholder&#148;) must include in income as a dividend the &#147;all earnings and profits amount&#148; attributable to
the public shares it directly owns, within the meaning of Treasury Regulations under Section&nbsp;367(b) of the Code. A U.S. Holder&#146;s ownership of public warrants will be taken into account in determining whether such U.S. Holder is a U.S.
Shareholder. Complex attribution rules apply in determining whether a U.S. Holder is a U.S. Shareholder and all U.S. Holders are urged to consult their tax advisors with respect to these attribution rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A U.S. Shareholder&#146;s &#147;all earnings and profits amount&#148; with respect to its public shares is the net positive earnings and
profits of CHFW (as determined under Treasury Regulations under Section&nbsp;367 of the Code) attributable to such public shares (as determined under Treasury Regulations under Section&nbsp;367 of the Code) but without regard to any gain that would
be realized on a sale or exchange of such public shares. Treasury Regulations under Section&nbsp;367 provide that the all earnings and profits amount attributable to a shareholder&#146;s stock is determined according to the principles of
Section&nbsp;1248 of the Code and the Treasury Regulations thereunder. In general, Section&nbsp;1248 of the Code and the Treasury Regulations thereunder provide that the amount of earnings and profits attributable to a block of stock (as defined in
Treasury Regulations promulgated under Section&nbsp;1248 of the Code) in a foreign corporation is the ratably allocated portion of the foreign corporation&#146;s earnings and profits generated during the period the shareholder held the block of
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW does not expect to have significant, cumulative earnings and profits through the date of the Domestication. If CHFW&#146;s
cumulative net earnings and profits through the date of the Domestication is less than or equal to zero, then a U.S. Holder should not be required to include in gross income an &#147;all earnings and profits amount&#148; with respect to its public
shares. If CHFW&#146;s cumulative net earnings and profits are greater than zero through the date of the Domestication, a U.S. Shareholder would be required to include its &#147;all earnings and profits amount&#148; in income as a deemed dividend
under Treasury Regulations under Section&nbsp;367(b) of the Code as a result of the Domestication. Any such U.S. Holder that is a corporation may, under certain circumstances, be exempt from taxation on a portion or all of the deemed dividend
pursuant to Section&nbsp;245A of the Code. Such U.S. Holders that are corporate shareholders should consult their tax advisors as to the applicability of Section&nbsp;245A of the Code in their particular circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>B.&nbsp;&nbsp;&nbsp;&nbsp;U.S. Holders That Own Less Than 10 Percent of CHFW </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A U.S. Holder that, on the date of the Domestication, beneficially owns (actually or constructively) public shares with a fair market value of
$50,000 or more, but is not a U.S. Shareholder, will recognize gain (but not loss) with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
respect to the Domestication or, in the alternative, may elect to recognize the &#147;all earnings and profits&#148; amount attributable to such U.S. Holder as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless a U.S. Holder makes the &#147;all earnings and profits&#148; election as described below, such U.S. Holder generally must recognize
gain (but not loss) with respect to shares of New Surrozen Common Stock received in the Domestication in an amount equal to the excess of the fair market value of such shares of New Surrozen Common Stock over the U.S. Holder&#146;s adjusted tax
basis in the public shares deemed surrendered in exchange therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In lieu of recognizing any gain as described in the preceding
paragraph, a U.S. Holder may elect to include in income the &#147;all earnings and profits amount,&#148;<B> </B>which is described more fully under &#147;<I>&#151;U.S. Holders That Hold 10 Percent or More of CHFW</I>,&#148; above, attributable to
its public shares under Section&nbsp;367(b) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are, however, strict conditions for making this election. This election
must comply with applicable Treasury Regulations and generally must include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a statement that the Domestication is a Section&nbsp;367(b) exchange (within the meaning of the applicable
Treasury Regulations); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a complete description of the Domestication; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a description of any stock, securities or other consideration transferred or received in the Domestication;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a statement describing the amounts required to be taken into account for U.S. federal income tax purposes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a statement that the U.S. Holder is making the election including (A)&nbsp;a copy of the information that
the U.S. Holder received from CHFW establishing and substantiating the U.S. Holder&#146;s &#147;all earnings and profits amount&#148; with respect to the U.S. Holder&#146;s public shares and (B)&nbsp;a representation that the U.S. Holder has
notified CHFW (or New Surrozen) that the U.S. Holder is making the election; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">certain other information required to be furnished with the U.S. Holder&#146;s tax return or otherwise
furnished pursuant to the Code or the Treasury Regulations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the election must be attached by an electing
U.S. Holder to such U.S. Holder&#146;s timely filed U.S. federal income tax return for the year of the Domestication, and the U.S. Holder must send notice of making the election to New Surrozen no later than the date such tax return is filed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW does not expect to have significant cumulative earnings and profits through the date of the Domestication. However, as noted above, if it
were determined that CHFW had positive earnings and profits through the date of the Domestication, a U.S. Holder that makes the election described herein could have an &#147;all earnings and profits amount&#148; with respect to its public shares,
and thus could be required to include that amount in income as a deemed dividend under applicable Treasury Regulations as a result of the Domestication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>EACH U.S. HOLDER IS URGED TO CONSULT ITS TAX ADVISOR REGARDING THE CONSEQUENCES TO IT OF MAKING THE ELECTION DESCRIBED HEREIN AND THE
APPROPRIATE FILING REQUIREMENTS WITH RESPECT TO SUCH ELECTION. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>C.&nbsp;&nbsp;&nbsp;&nbsp;U.S. Holders that Own Public Shares with a Fair Market
Value of Less Than $50,000 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A U.S. Holder that, on the date of the Domestication, beneficially owns (actually or constructively) public
shares with a fair market value less than $50,000 generally should not be required to recognize any gain or loss under Section&nbsp;367(b) of the Code in connection with the Domestication, and generally should not be required to include any part of
the &#147;all earnings and profits amount&#148; in income. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>ALL U.S. HOLDERS ARE URGED TO CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE EFFECT OF
SECTION 367(b) OF THE CODE TO THEIR PARTICULAR CIRCUMSTANCES. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tax Consequences for U.S. Holders of Public Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the considerations described above relating to a U.S. Holder&#146;s ownership of public warrants being taken into account in
determining whether such U.S. Holder is a U.S. Shareholder for purposes of Section&nbsp;367(b) of the Code, and the considerations relating to PFICs, a U.S. Holder of public warrants should not be subject to U.S. federal income tax with respect to
the exchange of warrants for newly issued public warrants in the Domestication. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>PFIC Considerations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the discussion under &#147;<I>&#151;Effects of Section</I><I></I><I>&nbsp;367(b) to U.S. Holders</I>,&#148; the Domestication
could be a taxable event to U.S. Holders under the PFIC provisions of the Code. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>A.&nbsp;&nbsp;&nbsp;&nbsp;Definition of a PFIC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A foreign (i.e., <FONT STYLE="white-space:nowrap">non-U.S.)</FONT> corporation will be classified as a PFIC for U.S. federal income tax
purposes if either (i)&nbsp;at least 75% of its gross income in a taxable year, including its pro rata share of the gross income of any corporation in which it is considered to own at least 25% of the shares by value, is passive income or
(ii)&nbsp;at least 50% of its assets in a taxable year (ordinarily determined based on fair market value and averaged quarterly over the year), including its pro rata share of the assets of any corporation in which it is considered to own at least
25% of the shares by value, are held for the production of, or produce, passive income. Passive income generally includes dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade or business)
and gains from the disposition of passive assets. For purposes of these rules, which may apply to CHFW prior to the Domestication, interest income earned by CHFW would be considered passive income and cash held by CHFW would be considered a passive
asset. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>B.&nbsp;&nbsp;&nbsp;&nbsp;PFIC Status of CHFW </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because CHFW is a blank check company with no current active business, based upon the composition of its income and assets, and upon a review
of its financial statements, CHFW believes that, but for application of the <FONT STYLE="white-space:nowrap">start-up</FONT> exception described below, it likely would be treated a PFIC. Under the <FONT STYLE="white-space:nowrap">start-up</FONT>
exception, a foreign corporation that would otherwise be treated as a PFIC will not be a PFIC for the first taxable year the corporation has gross income (the <FONT STYLE="white-space:nowrap">&#147;start-up</FONT> year&#148;), if (1)&nbsp;no
predecessor of the corporation was a PFIC; (2)&nbsp;the corporation satisfies the IRS that it will not be a PFIC for either of the first two taxable years following the <FONT STYLE="white-space:nowrap">start-up</FONT> year; and (3)&nbsp;the
corporation is not in fact a PFIC for either of those years. Because CHFW&#146;s <FONT STYLE="white-space:nowrap">&#147;start-up</FONT> year&#148; and its year of formation are both 2020, and the Domestication (which will close CHFW&#146;s taxable
year for U.S. federal income tax purposes) is expected to be completed in 2021, CHFW believes it will not satisfy these requirements, and therefore, it is likely to be treated as a PFIC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>C.&nbsp;&nbsp;&nbsp;&nbsp;Effects of PFIC Rules on the Domestication </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If CHFW is treated as a PFIC for U.S. federal income tax purposes, U.S. Holders could be subject to adverse PFIC rules as a result of the
Domestication. These rules are discussed in the immediately following paragraphs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;1291(f) of the Code requires that, to the
extent provided in Treasury Regulations, a United States person who disposes of stock of a PFIC recognizes gain notwithstanding any other provision of the Code. No final Treasury Regulations are currently in effect under Section&nbsp;1291(f) of the
Code. However, proposed Treasury Regulations under Section&nbsp;1291(f) of the Code have been promulgated with a retroactive effective date. If finalized in their current form, those proposed Treasury Regulations may require gain recognition to U.S.
Holders of public shares and public warrants upon the Domestication if (i)&nbsp;CHFW was treated as a PFIC at any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
time during such U.S. Holder&#146;s holding period for such public shares or public warrants and (ii)&nbsp;the U.S. Holder did not timely make (a)&nbsp;a QEF Election (as described below) for the
first taxable year in which the U.S. Holder owned such public shares or in which CHFW was a PFIC, whichever is later, or (b)&nbsp;a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election (as described
below) with respect to such public shares. Generally, neither election is available with respect to the public warrants. The tax on any such recognized gain would be imposed based on a complex set of computational rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under these rules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Holder&#146;s gain will be allocated ratably over the U.S. Holder&#146;s holding period for such U.S.
Holder&#146;s public shares or public warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of gain allocated to the U.S. Holder&#146;s taxable year in which the U.S. Holder recognized the
gain, or to the period in the U.S. Holder&#146;s holding period before the first day of the first taxable year in which CHFW was a PFIC, will be taxed as ordinary income; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of gain allocated to other taxable years (or portions thereof) of the U.S. Holder and included in
such U.S. Holder&#146;s holding period would be taxed at the highest tax rate in effect for that year and applicable to the U.S. Holder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an additional tax equal to the interest charge generally applicable to underpayments of tax will be imposed on
the U.S. Holder in respect of the tax attributable to each such other taxable year of such U.S. Holder. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition,
the proposed Treasury Regulations provide coordinating rules with Section&nbsp;367(b) of the Code, whereby, if the gain recognition rule of the proposed Treasury Regulations under Section&nbsp;1291(f) of the Code applies to a disposition of PFIC
stock that results from a transfer with respect to which Section&nbsp;367(b) of the Code requires the shareholder to recognize gain or include an amount in income as discussed under the &#147;<I>&#151;Effects of Section</I><I></I><I>&nbsp;367(b) to
U.S. Holders</I>,&#148; the gain realized on the transfer is taxable under the PFIC rules discussed above, and the excess, if any, of the amount to be included in income under Section&nbsp;367(b) of the Code over the gain realized under
Section&nbsp;1291 of the Code is taxable as provided under Section&nbsp;367(b) of the Code. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is not possible to predict whether, in
what form and with what effective date, final Treasury Regulations under Section&nbsp;1291(f) of the Code will be adopted. Therefore, if CHFW is determined to be a PFIC, U.S. Holders of public shares that have not made a timely QEF Election or a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election (both as defined and described below) and U.S. Holders of public warrants may, pursuant to the proposed Treasury Regulations, be subject to taxation on
the Domestication to the extent their public shares or public warrants have a fair market value in excess of their tax basis therein. An Electing Shareholder (as defined below) generally would not be subject to the adverse PFIC rules discussed above
with respect to its public shares but rather would include annually in gross income its pro rata share of the ordinary earnings and net capital gain of CHFW, whether or not such amounts are actually distributed to such shareholders in any taxable
year. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>D.&nbsp;&nbsp;&nbsp;&nbsp;QEF Election and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Mark-to-Market</FONT></FONT>
Election </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The impact of the PFIC rules on a U.S. Holder of public shares would depend on whether the U.S. Holder makes a timely and
effective election to treat CHFW as a &#147;qualified electing fund&#148; under Section&nbsp;1295 of the Code for the taxable year that is the first year in the U.S. Holder&#146;s holding period of public shares during which CHFW qualified as a PFIC
(a &#147;QEF Election&#148;). The QEF Election is made on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shareholder-by-shareholder</FONT></FONT> basis and, once made, can be revoked only with the consent of the IRS. A U.S.
Holder generally makes a QEF election by attaching a completed IRS Form 8621 (Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund), including the information provided in a &#147;PFIC Annual Information
Statement,&#148; to a timely filed U.S. federal income tax return for the tax year to which the election relates. Retroactive QEF Elections generally may be made only by filing a protective statement with such return and if certain other conditions
are met or with the consent of the IRS. If applicable, U.S. Holders should consult their tax advisors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
regarding the availability and tax consequences of a retroactive QEF Election under their particular circumstances. A U.S. Holder&#146;s ability to make a QEF Election with respect to CHFW is
contingent upon, among other things, the provision by CHFW of a &#147;PFIC Annual Information Statement&#148; to such U.S. Holder. If we determine we are a PFIC for any taxable year, upon written request, we will endeavor to provide to a U.S. Holder
such information as the IRS may require, including a PFIC Annual Information Statement, in order to enable the U.S. Holder to make and maintain a QEF Election. There is no assurance, however, that we would timely provide such required information. A
U.S. Holder that makes a QEF Election may be referred to as an &#147;Electing Shareholder&#148; and a U.S. Holder that does not make a QEF Election may be referred to as a <FONT STYLE="white-space:nowrap">&#147;Non-Electing</FONT> Shareholder.&#148;
A QEF Election is not available with respect to public warrants. An Electing Shareholder generally would not be subject to the adverse PFIC rules discussed above with respect to their public shares. As a result, if we are determined to be a PFIC,
such an Electing Shareholder should not recognize gain or loss as a result of the Domestication except to the extent described under &#147;&#151;<I>Effects of Section</I><I></I><I>&nbsp;367(b) to U.S. Holders</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The impact of the PFIC rules on a U.S. Holder of public shares may also depend on whether the U.S. Holder has made an election under
Section&nbsp;1296 of the Code. U.S. Holders that hold (actually or constructively) stock of a foreign corporation that is classified as a PFIC may annually elect to mark such stock to its market value if such stock is regularly traded on an
established exchange (a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market</FONT></FONT> election&#148;). No assurance can be given that the public shares are considered to be regularly traded for purposes of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election or whether the other requirements of this election are satisfied. If such an election is available and has been made, such U.S. Holders will generally
not be subject to the special taxation rules of Section&nbsp;1291 of the Code discussed herein. However, if the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election is made by a <FONT
STYLE="white-space:nowrap">Non-Electing</FONT> Shareholder after the beginning of the holding period for the PFIC stock, then the Section&nbsp;1291 of the Code rules will apply to certain dispositions of, distributions on and other amounts taxable
with respect to public shares. A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election is not currently available with respect to public warrants under applicable Treasury Regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>ALL U.S. HOLDERS ARE URGED TO CONSULT THEIR TAX ADVISORS CONCERNING THE CONSEQUENCES TO THEM OF THE PFIC RULES. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Effects on U.S. Holders of Exercising Redemption Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The U.S. federal income tax consequences to a U.S. Holder of public shares (which will be exchanged for shares of New Surrozen Common Stock in
the Domestication) that exercises its redemption rights to receive cash from the trust account in exchange for all or a portion of its shares of New Surrozen Common Stock will depend on whether the redemption qualifies as a sale of the shares of New
Surrozen Common Stock redeemed under Section&nbsp;302 of the Code or is treated as a distribution under Section&nbsp;301 of the Code. If the redemption qualifies as a sale of such U.S. Holder&#146;s shares of New Surrozen Common Stock redeemed, such
U.S. Holder will generally be treated in the same manner as described under &#147;&#151;<I>Sale, Exchange or Other Disposition of Shares of New Surrozen Common Stock and New Surrozen Public Warrants</I>&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The redemption of shares of New Surrozen Common Stock generally will qualify as a sale of the shares of New Surrozen Common Stock redeemed if
such redemption either (i)&nbsp;is &#147;substantially disproportionate&#148; with respect to the redeeming U.S. Holder, (ii)&nbsp;results in a &#147;complete termination&#148; of such U.S. Holder&#146;s interest in New Surrozen or (iii)&nbsp;is
&#147;not essentially equivalent to a dividend&#148; with respect to such U.S. Holder. These tests are explained more fully below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For
purposes of such tests, a U.S. Holder takes into account not only shares of New Surrozen Common Stock actually owned by such U.S. Holder, but also shares of New Surrozen Common Stock that are constructively owned by such U.S. Holder. A redeeming
U.S. Holder may constructively own, in addition to shares of New Surrozen Common Stock owned directly, shares of New Surrozen Common Stock owned by certain related individuals and entities in which such U.S. Holder has an interest or that have an
interest in such U.S. Holder, as well as any shares of New Surrozen Common Stock such U.S. Holder has a right to acquire by exercise of an option, which would generally include shares of New Surrozen Common Stock which could be acquired pursuant to
the exercise of the public warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The redemption of shares of New Surrozen Common Stock generally will be &#147;substantially
disproportionate&#148; with respect to a redeeming U.S. Holder if the percentage of New Surrozen&#146;s outstanding voting shares that such U.S. Holder actually or constructively owns immediately after the redemption is less than 80&nbsp;percent of
the percentage of New Surrozen&#146;s outstanding voting shares that such U.S. Holder actually or constructively owned immediately before the redemption, and such U.S. Holder immediately after the redemption actually and constructively owned less
than 50&nbsp;percent of the total combined voting power of New Surrozen Common Stock. There will be a complete termination of such U.S. Holder&#146;s interest if either (i)&nbsp;all of the shares of New Surrozen Common Stock actually or
constructively owned by such U.S. Holder are redeemed or (ii)&nbsp;all of the shares of New Surrozen Common Stock actually owned by such U.S. Holder are redeemed and such U.S. Holder is eligible to waive, and effectively waives in accordance with
specific rules, the attribution of the shares of New Surrozen Common Stock owned by certain family members and such U.S. Holder does not constructively own any other shares of New Surrozen Common Stock. The redemption of shares of New Surrozen
Common Stock will not be essentially equivalent to a dividend if it results in a &#147;meaningful reduction&#148; of such U.S. Holder&#146;s proportionate interest in New Surrozen. Whether the redemption will result in a &#147;meaningful
reduction&#148; in such U.S. Holder&#146;s proportionate interest will depend on the particular facts and circumstances applicable to it. The IRS has indicated in a published ruling that even a small reduction in the proportionate interest of a
small minority shareholder in a publicly held corporation who exercises no control over corporate affairs may constitute such a &#147;meaningful reduction.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If none of the above tests is satisfied, a redemption will be treated as a distribution with respect to the shares of New Surrozen Common
Stock, the U.S. federal income tax consequences of which are described under &#147;<I>&#151;Distributions on Shares of New Surrozen Common Stock</I>&#148; below. After the application of those rules, any remaining tax basis of the U.S. Holder in the
redeemed New Surrozen Common Stock will be added to the U.S. Holder&#146;s adjusted tax basis in its remaining shares, or, if it has none, to the U.S. Holder&#146;s adjusted tax basis in its public warrants or possibly in other shares constructively
owned by it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because the Domestication will occur prior to the redemption of U.S. Holders that exercise redemption rights, U.S. Holders
exercising redemption rights will take into account the potential tax consequences of Section&nbsp;367(b) of the Code as a result of the Domestication (discussed further above). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>ALL U.S. HOLDERS ARE URGED TO CONSULT THEIR TAX ADVISORS AS TO THE TAX CONSEQUENCES TO THEM OF A REDEMPTION OF ALL OR A PORTION OF THEIR
SHARES OF NEW SURROZEN COMMON STOCK PURSUANT TO AN EXERCISE OF REDEMPTION RIGHTS. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Distributions on Shares of New Surrozen
Common Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A U.S. Holder generally will be required to include in gross income as dividends the amount of any distribution paid
with respect to shares of New Surrozen Common Stock, to the extent the distribution is paid out of New Surrozen&#146;s current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Distributions in excess of
current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#146;s adjusted tax basis in its shares of New Surrozen Common Stock. Any remaining excess
will be treated as gain realized on the sale or other disposition of the shares of New Surrozen Common Stock and will be treated as described under &#147;<I>&#151;Sale, Exchange or Other Disposition of Shares of New Surrozen Common Stock and New
Surrozen Public Warrants</I>&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dividends that New Surrozen pays to a U.S. Holder that is a corporation generally will qualify
for the dividends received deduction if the requisite holding period requirement is satisfied. With certain exceptions (including, but not limited to, dividends treated as investment income for purposes of investment interest deduction limitations),
and provided certain holding period requirements are met, dividends that New Surrozen pays to a <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder may be taxed as &#147;qualified dividend income&#148; at the preferential tax rate
accorded to long-term capital gains. It is unclear whether the redemption rights described herein with respect to the shares of New Surrozen Common Stock may have suspended the running of the applicable holding period for these purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Sale, Exchange or Other Disposition of Shares of New Surrozen Common Stock and New
Surrozen Public Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon a sale or other taxable disposition of shares of New Surrozen Common Stock or public warrants which,
in general, would include a redemption of shares of New Surrozen Common Stock or public warrants that is treated as a sale of such securities as described above and below, a U.S. Holder generally will recognize capital gain or loss. Any such capital
gain or loss generally will be long-term capital gain or loss if the U.S. Holder&#146;s holding period for the shares of New Surrozen Common Stock or public warrants so disposed of exceeds one year. Long-term capital gains recognized by <FONT
STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders will be eligible to be taxed at reduced rates. The deductibility of capital losses is subject to limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Generally, the amount of gain or loss recognized by a U.S. Holder is an amount equal to the difference between (i)&nbsp;the sum of the amount
of cash and the fair market value of any property received in such disposition and (ii)&nbsp;the U.S. Holder&#146;s adjusted tax basis in its shares of New Surrozen Common Stock or public warrants so disposed of. See &#147;<I>&#151;Effects of the
Domestication on U.S. Holders</I>&#148; above for discussion of a U.S. Holder&#146;s adjusted tax basis in its shares of New Surrozen Common Stock and/or public warrants following the Domestication. See &#147;<I>&#151;Exercise, Lapse or Redemption
of New Surrozen Public Warrants</I>&#148; below for a discussion regarding a U.S. Holder&#146;s tax basis in New Surrozen Common Shares acquired pursuant to the exercise of a New Surrozen Public Warrant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Exercise, Lapse or Redemption of New Surrozen Public Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except as discussed below with respect to the cashless exercise of a New Surrozen Public Warrant, a U.S. Holder generally will not recognize
taxable gain or loss as a result of the acquisition of shares of New Surrozen Common Stock upon exercise of a New Surrozen Public Warrant for cash. The U.S. Holder&#146;s tax basis in the share of New Surrozen Common Stock received upon exercise of
the New Surrozen Public Warrant generally will be an amount equal to the sum of the U.S. Holder&#146;s tax basis in the New Surrozen Public Warrant, and the exercise price of such New Surrozen Public Warrant. It is unclear whether a U.S.
Holder&#146;s holding period for the shares of New Surrozen Common Stock received upon exercise of the New Surrozen Public Warrant will commence on the date of exercise of the New Surrozen Public Warrant or the day following the date of exercise of
the New Surrozen Public Warrant; in either case, the holding period will not include the period during which the U.S. Holder held the New Surrozen Public Warrant. If a New Surrozen Public Warrant is allowed to lapse unexercised, a U.S. Holder
generally will recognize a capital loss equal to such U.S. Holder&#146;s tax basis in the New Surrozen Public Warrant. See &#147;<I>&#151;Effects of the Domestication on U.S. Holders</I>&#148; above for a discussion of a U.S. Holder&#146;s adjusted
tax basis in its public warrants following the Domestication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The tax consequences of a cashless exercise of a New Surrozen Public
Warrant are not clear under current tax law. A cashless exercise may not be taxable, either because the exercise is not a realization event or because the exercise is treated as a recapitalization for U.S. federal income tax purposes. In either
situation, a U.S. Holder&#146;s tax basis in the shares of New Surrozen Common Stock received generally should equal the U.S. Holder&#146;s tax basis in the public warrants. If the cashless exercise was not a realization event, it is unclear whether
a U.S. Holder&#146;s holding period for the shares of New Surrozen Common Stock would be treated as commencing on the date of exercise of the New Surrozen Public Warrant or the day following the date of exercise of the New Surrozen Public Warrant.
If the cashless exercise is treated as a recapitalization, the holding period of the shares of New Surrozen Common Stock received would include the holding period of the public warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is also possible that a cashless exercise may be treated in part as a taxable exchange in which gain or loss would be recognized. In such
event, a U.S. Holder may be deemed to have surrendered a number of public warrants having a value equal to the exercise price for the total number of public warrants to be exercised. The U.S. Holder would recognize capital gain or loss in an amount
equal to the difference between the fair market value of the public warrants deemed surrendered and the U.S. Holder&#146;s tax basis in the public warrants deemed surrendered. In this case, a U.S. Holder&#146;s tax basis in the shares of New
Surrozen Common Stock received would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
equal the sum of the U.S. Holder&#146;s tax basis in the public warrants exercised, and the exercise price of such public warrants. It is unclear whether a U.S. Holder&#146;s holding period for
the shares of New Surrozen Common Stock would commence on the date of exercise of the New Surrozen Public Warrant or the day following the date of exercise of the New Surrozen Public Warrant; in either case, the holding period will not include the
period during which the U.S. Holder held the New Surrozen Public Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Due to the absence of authority on the U.S. federal income tax
treatment of a cashless exercise, including when a U.S. Holder&#146;s holding period would commence with respect to the shares of New Surrozen Common Stock received, there can be no assurance as to which, if any, of the alternative tax consequences
and holding periods described above would be adopted by the IRS or a court of law. Accordingly, U.S. Holders should consult their tax advisors regarding the tax consequences of a cashless exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The U.S. federal income tax consequences of an exercise of a public warrant occurring after New Surrozen&#146;s giving notice of an intention
to redeem the public warrants described in the section entitled &#147;<I>Description of New Surrozen Securities&#151;Warrants&#151;New Surrozen Public Warrants</I>&#148; are unclear under current law. In the case of a cashless exercise, the exercise
may be treated either as if New Surrozen redeemed such New Surrozen Public Warrant for shares of New Surrozen Common Stock or as an exercise of the New Surrozen Public Warrant. If the cashless exercise of public warrants for shares of New Surrozen
Common Stock is treated as a redemption, then such redemption generally should be treated as a <FONT STYLE="white-space:nowrap">tax-deferred</FONT> recapitalization for U.S. federal income tax purposes, in which case a U.S. Holder should not
recognize any gain or loss on such redemption, and accordingly, a U.S. Holder&#146;s tax basis in the shares of New Surrozen Common Stock received should equal the U.S. Holder&#146;s tax basis in the public warrants and the holding period of the
shares of New Surrozen Common Stock should include the holding period of the public warrants. Alternatively, if the cashless exercise of a New Surrozen public warrant is treated as such, the U.S. federal income tax consequences generally should be
as described above in the second and third paragraphs under the heading &#147;<I>&#151; Exercise, Lapse or Redemption of New Surrozen Public Warrants</I>.&#148; In the case of an exercise of a New Surrozen public warrant for cash, the U.S. federal
income tax treatment generally should be as described above in the first paragraph under the heading &#147;<I>&#151;Exercise, Lapse or Redemption of New Surrozen Public Warrants</I>.&#148; Due to the lack of clarity under current law regarding the
treatment described in this paragraph, there can be no assurance as to which, if any, of the alternative tax consequences described above would be adopted by the IRS or a court of law. Accordingly, U.S. Holders should consult their tax advisors
regarding the tax consequences of the exercise of a New Surrozen public warrant occurring after Surrozen&#146;s giving notice of an intention to redeem the New Surrozen Public Warrant as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If New Surrozen redeems public warrants for cash or if New Surrozen purchases public warrants in an open market transaction, such redemption
or purchase generally will be treated as a taxable disposition to the U.S. Holder, taxed as described above under &#147;&#151;<I>Sale, Exchange or Other Disposition of Shares of New Surrozen Common Stock and New Surrozen Public Warrants</I>.&#148;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Possible Constructive Distributions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The terms of each New Surrozen public warrant provide for an adjustment to the exercise price of the New Surrozen public warrant or an increase
in the shares of New Surrozen Common Stock issuable on exercise in certain circumstances discussed in &#147;<I>Description of New Surrozen Securities&#151;Warrants&#151;New Surrozen Public Warrants.</I>&#148; An adjustment which has the effect of
preventing dilution generally is not taxable. The U.S. Holders of the public warrants would, however, be treated as receiving a constructive distribution from New Surrozen if, for example, the adjustment increases the U.S. Holder&#146;s
proportionate interest in New Surrozen&#146;s assets or earnings and profits (e.g., through a decrease to the exercise price or an increase in the number of shares of New Surrozen Common Stock that would be obtained upon exercise) as a result of a
distribution of cash or other property to the U.S. Holders of shares of New Surrozen Common Stock which is taxable to them as described under &#147;<I>&#151;Distributions on Shares of New Surrozen Common Stock</I>&#148; above. For example, U.S.
Holders of public warrants would generally be treated as receiving a constructive distribution from New Surrozen where the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
exercise price of the public warrants is reduced in connection with the payment of certain dividends as described in &#147;<I>Description of New Surrozen Securities&#151;Warrants&#151;New
Surrozen Public Warrants.</I>&#148; Such constructive distribution received by a U.S. Holder would be subject to U.S. federal income tax in the same manner as if the U.S. Holders of the New Surrozen Public Warrant received a cash distribution from
New Surrozen equal to the fair market value of such increased interest. The rules governing constructive distributions as a result of certain adjustments with respect to a public warrants are complex, and U.S. Holders are urged to consult their tax
advisors on the tax consequences any such constructive distribution with respect to a New Surrozen public warrant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_133">
</A><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As used herein, a <FONT STYLE="white-space:nowrap">&#147;non-U.S.</FONT>
Holder&#148; is a beneficial owner (other than a partnership or entity or arrangement treated as a partnership for U.S. federal income tax purposes) of public shares, public warrants or New Surrozen Common Stock, as applicable, that is not a U.S.
Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following describes U.S. federal income tax considerations relating to the (i)&nbsp;Domestication, (ii) exercise of
redemption rights and (iii)&nbsp;ownership and disposition of shares of New Surrozen Common Stock and public warrants by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder after the Domestication. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Effects of the Domestication on <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW does not expect the Domestication to result in any U.S. federal income tax consequences to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holders of public shares or public warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Effects to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of Exercising Redemption Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because the Domestication will occur
immediately prior to the redemption of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holders that exercise redemption rights with respect to our public shares, the U.S. federal income tax consequences to a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder of shares of New Surrozen Common Stock that exercises its redemption rights to receive cash from the trust account in exchange for all or a portion of its shares of New Surrozen Common Stock
will depend on whether the redemption qualifies as a sale of the shares of New Surrozen Common Stock redeemed, as described above under &#147;<I>&#151;U.S. Holders&#151;Effects to U.S. Holders of Exercising Redemption Rights</I>.&#148; If such a
redemption qualifies as a sale of shares of New Surrozen Common Stock, the U.S. federal income tax consequences to the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder will be as described below under
&#147;<I><FONT STYLE="white-space:nowrap">&#151;Non-U.S.</FONT> Holders&#151;Sale, Exchange or Other Disposition of Shares of New Surrozen Common Stock and New Surrozen</I> <I>Public Warrants</I>.&#148; If such a redemption does not qualify as a
sale of shares of New Surrozen Common Stock, the <FONT STYLE="white-space:nowrap">non-</FONT> U.S. Holder will be treated as receiving a distribution, the U.S. federal income tax consequences of which are described below under &#147;<I><FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders&#151;Distributions on Shares of New Surrozen Common Stock</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_134">
</A>Distributions on Shares of New Surrozen Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, any distributions made to a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder with respect to shares of New Surrozen Common Stock, to the extent paid out of New Surrozen&#146;s current or accumulated earnings and profits (as determined under U.S. federal income tax
principles), will constitute dividends for U.S. federal income tax purposes and, provided such dividends are not effectively connected with such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the
United States, will be subject to withholding tax from the gross amount of the dividend at a rate of 30%, unless such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder is eligible for a reduced rate of withholding tax under an applicable
income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on an applicable IRS Form <FONT STYLE="white-space:nowrap">W-8).</FONT> Any distribution not constituting a dividend will be treated first as
reducing (but not below zero) the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder&#146;s adjusted tax basis in its shares of New Surrozen Common Stock and then, to the extent such distribution exceeds the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder&#146;s adjusted tax basis, as gain realized from the sale or other disposition of such shares of New Surrozen Common Stock, which will be treated as described below under &#147;<I>&#151;Sale,
Exchange or Other Disposition of Shares</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
<I>of New Surrozen Common Stock and New Surrozen</I> <I>Public Warrants</I>.&#148; Dividends paid by New Surrozen to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder that are effectively
connected with such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and if an income tax treaty applies, are attributable to a U.S. permanent establishment or fixed base
maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder) will generally not be subject to U.S. withholding tax, provided such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder complies with certain certification and
disclosure requirements (usually by providing an IRS Form <FONT STYLE="white-space:nowrap">W-8ECI).</FONT> Instead, such dividends will generally be subject to U.S. federal income tax, net of certain deductions, at the same graduated individual or
corporate rates applicable to U.S. Holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_135"></A>Sale, Exchange or Other Disposition of Shares of New Surrozen
Common Stock and New Surrozen Public Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder will generally not be subject
to U.S. federal income tax on gain realized on a sale or other disposition of shares of New Surrozen Common Stock or public warrants unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder is an individual who was present in the United
States for a period or periods aggregating 183 days or more in the taxable year of such disposition (subject to certain exceptions as a result of the COVID pandemic) and certain other requirements are met, in which case any gain realized will
generally be subject to a flat 30% U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the gain is effectively connected with a trade or business of such
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder in the United States (and if an income tax treaty applies, is attributable to a U.S. permanent establishment or fixed base maintained by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
Holder), in which case such gain will be subject to U.S. federal income tax, net of certain deductions, at the same graduated individual or corporate rates applicable to U.S. Holders, and, if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
Holder is a corporation, an additional &#147;branch profits tax&#148; may also apply; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">New Surrozen is or has been a &#147;U.S. real property holding corporation&#148; at any time during the
shorter of the five-year period preceding such disposition and such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder&#146;s holding period and either (A)&nbsp;the shares of New Surrozen Common Stock has ceased to be regularly traded on an
established securities market or (B)&nbsp;such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder has owned or is deemed to have owned, at any time, during the shorter of the five-year period preceding such disposition and such <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Holder&#146;s holding period, more than 5% of outstanding shares of New Surrozen Common Stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If paragraph (iii)&nbsp;above applies to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder, gain recognized by such <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Holder on the sale, exchange or other disposition of shares of New Surrozen Common Stock or public warrants will be subject to tax at generally applicable U.S. federal income tax rates. In addition, a buyer
of such shares of New Surrozen Common Stock or public warrants from a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder may be required to withhold U.S. income tax at a rate of 15% of the amount realized upon such disposition. New Surrozen
will be classified as a &#147;U.S. real property holding corporation&#148; if the fair market value of its &#147;United States real property interests&#148; equals or exceeds 50% of the sum of the fair market value of its worldwide real property
interests and its other assets used or held for use in a trade or business, as determined for U.S. federal income tax purposes. We do not expect New Surrozen to be classified as a &#147;U.S. real property holding corporation&#148; following the
Business Combination. However, such determination is factual and in nature and subject to change and no assurance can be provided as to whether New Surrozen will be a U.S. real property holding corporation with respect to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Holder following the Business Combination or at any future time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Exercise, Lapse or
Redemption of New Surrozen Public Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The U.S. federal income tax treatment of a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder&#146;s exercise of a New Surrozen public warrant, or the lapse of a New Surrozen public warrant held by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder, generally will correspond to
the U.S. federal income tax treatment of the exercise or lapse of a warrant held by a U.S. Holder, as described above under &#147;<I>&#151;U.S. Holders&#151;Exercise, Lapse or Redemption of New Surrozen Public Warrants,</I>&#148; although to the
extent a cashless exercise results in a taxable exchange, the consequences would be similar to those described above under &#147;<I><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders&#151;Sale, Exchange or Other Disposition of Shares of New
Surrozen Common Stock and</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
<I>New Surrozen Public Warrants</I>.&#148; If New Surrozen redeems public warrants for cash or if it purchases public warrants in an open market transaction, such redemption or purchase generally
will be treated as a disposition to the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder, the consequences of which would be similar to those described above under &#147;<I><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders&#151;Sale,
Exchange or Other Disposition of Shares of New Surrozen Common Stock and New Surrozen Public Warrants</I>.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Possible
Constructive Distributions </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The terms of each New Surrozen public warrant provide for an adjustment to the exercise price of
the New Surrozen public warrant or an increase in the shares of New Surrozen Common Stock issuable on exercise in certain circumstances discussed in &#147;<I>Description of New Surrozen Securities&#151;Warrants&#151;New Surrozen Public
Warrants</I>.&#148; As described above under &#147;<I>&#151;U.S. Holders &#151;Possible Constructive Distributions</I>,&#148; certain adjustments with respect to the public warrants can give rise to a constructive distribution. Any constructive
distribution received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder would be subject to U.S. federal income tax (including any applicable withholding) in the same manner as if such <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder received a cash distribution from New Surrozen equal to the fair market value of such increased interest,<B> </B>the consequences of which would be similar to those described above under
&#147;<I><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders&#151;Distributions on Shares of New Surrozen Common Stock</I>.&#148; If withholding applies to any constructive distribution received by a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder, it is possible that the tax would be withheld from any amount paid to or held on behalf of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder by the applicable withholding agent. The
rules governing constructive distributions as a result of certain adjustments with respect to a public warrants are complex, and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holders are urged to consult their tax advisors on the tax consequences
any such constructive distribution with respect to a New Surrozen public warrant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Information Reporting Requirements and Backup
Withholding </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Information returns will be filed with the IRS in connection with payments of dividends on and the proceeds from a
sale or other disposition of shares of New Surrozen Common Stock. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder may have to comply with certification procedures to establish that it is not a United States person for U.S. federal income
tax purposes or otherwise establish an exemption in order to avoid information reporting and backup withholding requirements or to claim a reduced rate of withholding under an applicable income tax treaty. The amount of any backup withholding from a
payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder will be allowed as a credit against such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability and may entitle such <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Holder to a refund, provided that the required information is furnished by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder to the IRS in a timely manner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_136"></A>Foreign Account Tax Compliance Act </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sections 1471 through 1474 of the Code and the Treasury Regulations and administrative guidance promulgated thereunder (commonly referred as
the &#147;Foreign Account Tax Compliance Act&#148; or &#147;FATCA&#148;) generally impose withholding at a rate of 30% in certain circumstances on dividends in respect of, and (subject to the proposed Treasury Regulations discussed below) gross
proceeds from the sale or other disposition of, securities (including public shares, public warrants and shares of New Surrozen Common Stock) which are held by or through certain foreign financial institutions (including investment funds), unless
any such institution (i)&nbsp;enters into, and complies with, an agreement with the IRS to report, on an annual basis, information with respect to interests in, and accounts maintained by, the institution that are owned by certain U.S. persons and
by certain <FONT STYLE="white-space:nowrap">non-</FONT> U.S. entities that are wholly or partially owned by U.S. persons and to withhold on certain payments, or (ii)&nbsp;if required under an intergovernmental agreement between the United States and
an applicable foreign country, reports such information to its local tax authority, which will exchange such information with the U.S. authorities. An intergovernmental agreement between the United States and an applicable foreign country may modify
these requirements. Accordingly, the entity through which public shares or public warrants and shares of New Surrozen Common Stock or New Surrozen warrants are held will affect the determination of whether such withholding is required. Similarly,
dividends in respect of, and (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, public shares or public warrants and shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of New Surrozen Common Stock or New Surrozen warrants held by an investor that is a <FONT STYLE="white-space:nowrap">non-financial</FONT> <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entity
that does not qualify under certain exceptions will generally be subject to withholding at a rate of 30%, unless such entity either (i)&nbsp;certifies to the applicable withholding agent that such entity does not have any &#147;substantial United
States owners&#148; or (ii)&nbsp;provides certain information regarding the entity&#146;s &#147;substantial United States owners,&#148; which will in turn be provided to the U.S. Department of Treasury. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends in
respect of our securities. While withholding under FATCA generally would also apply to payments of gross proceeds from the sale or other disposition of securities (including shares of New Surrozen Common Stock or New Surrozen warrants), proposed
Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. All holders should consult their tax advisors
regarding the possible implications of FATCA on their investment in public shares, public warrants, shares of New Surrozen Common Stock or New Surrozen warrants. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_137"></A>UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following unaudited pro forma condensed combined financial information presents the combination of the financial information of Surrozen
and CHFW adjusted to give effect to the Business Combination. The following unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation <FONT STYLE="white-space:nowrap">S-X,</FONT> as
amended by the final rule, Release <FONT STYLE="white-space:nowrap">33-10786</FONT> &#147;Amendments to Financial Disclosures about Acquired and Disposed Businesses.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW is a blank check company incorporated on August&nbsp;21, 2020, as a Cayman Islands exempted company and incorporated for the purpose of
effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. CHFW has neither engaged in any operations nor generated any revenue to date. Based on CHFW&#146;s
business activities, it is a &#147;shell company&#148; as defined under the Exchange Act because it has no operations and nominal assets consisting almost entirely of cash. On November&nbsp;23, 2020, CHFW consummated an initial public offering of
8,000,000 units at an offering price of $10.00 per unit, and a private placement with the Sponsor of 410,000 private placement units at an offering price of $10.00 per unit. Each unit sold in the initial public offering and private placement
consists of one Class&nbsp;A ordinary share and <FONT STYLE="white-space:nowrap">one-third</FONT> of one redeemable warrant. On December&nbsp;1, 2020, the underwriters fully exercised their over-allotment option, resulting in an additional 1,200,000
units issued at $10.00 per unit, generating gross proceeds of $12.0&nbsp;million. In connection with the underwriters&#146; full exercise of their over-allotment option, the Company also consummated the sale of an additional 24,000 private placement
units at $10.00 per private placement unit, generating additional gross proceeds of approximately $0.2&nbsp;million. Following the closing of CHFW&#146;s initial public offering, an amount equal to $92.0 million of the net proceeds from its initial
public offering and the sale of the private placement units was placed in the trust account. The trust account may be invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in
United States Treasuries and meeting certain conditions under Rule <FONT STYLE="white-space:nowrap">2a-7</FONT> under the Investment Company Act of 1940, as amended, which invest only in direct U.S. government obligations. As of March 31, 2021,
funds in the trust account totaled approximately $92.0&nbsp;million. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen is a
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and
tissues. Surrozen is located in South San Francisco, California and was incorporated in the state of Delaware on August&nbsp;12, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The unaudited pro forma condensed combined balance sheet as of March&nbsp;31, 2021 combines the historical balance sheets of Surrozen and CHFW
on a pro forma basis as if the Business Combination had been consummated on March&nbsp;31, 2021. The unaudited pro forma condensed combined statements of operations for the three months ended </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
March&nbsp;31, 2021 and year ended December&nbsp;31, 2020 combine the historical statements of operations of Surrozen and CHFW for such periods on a pro forma basis as if the Business Combination
had been consummated on January&nbsp;1, 2020, the beginning of the earliest period presented. The Business Combination contemplated in the Business Combination Agreement are as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Domestication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Merger; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the PIPE Financing. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The pro forma condensed combined financial information may not be useful in predicting the future financial condition and results of operations
of the post-combination company. The actual financial position and results of operations of the post-combination company may differ significantly from the pro forma amounts reflected herein due to a variety of factors. The pro forma financial
information is presented for illustrative purposes only and does not reflect the cost of any integration activities or cost savings or synergies that may be achieved as a result of the Business Combination. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The information should be read together with the accompanying notes to the unaudited pro forma condensed combined financial information, the
audited and unaudited financial statements of Surrozen and CHFW, the sections titled &#147;<I>Surrozen&#146;s</I> <I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;</I> <I></I>and<I> &#147;CHFW&#146;s
Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;, </I>and other information relating to Surrozen and CHFW contained in this proxy statement/prospectus, including the Business Combination Agreement and
the description of certain terms thereof set forth in the section entitled<I> &#147;The Business Combination Proposal&#148;. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen has been determined to be the accounting acquirer in the Business Combination based on the following predominate factors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s existing stockholders will have the greatest voting interest in the combined entity under the
no redemption and maximum redemption scenarios with over 50% of the voting interest in each scenario; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen will have the ability to nominate a majority of the members of the Board of Directors of the combined
entity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s senior management will be the senior management of the combined entity; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen is the larger entity based on historical operating activity and has the larger employee base.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Business Combination is expected to be accounted for as a reverse recapitalization in accordance with GAAP, whereby
CHFW is treated as the acquired company and Surrozen is treated as the acquirer. Accordingly, for accounting purposes, the Business Combination will be treated as the equivalent of Surrozen issuing stock for the net assets of CHFW, accompanied by a
recapitalization. The net assets of CHFW will be stated at historical cost, with no goodwill or other intangible assets recorded. Subsequently, results of operations presented for the period prior to the Business Combination will be those of
Surrozen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the closing of the Business Combination, public shareholders are being offered the opportunity to redeem shares of CHFW
Class&nbsp;A ordinary shares held by them for cash equal to their pro rata share of the aggregate amount on deposit (as of two business days prior to the Closing) in the trust account pursuant to the Existing Governing Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The unaudited pro forma condensed combined financial information presents two redemption scenarios as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Assuming No Redemptions</I>: This presentation assumes that no CHFW shareholders exercise redemption rights
with respect to their public shares; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Assuming Maximum Redemptions:</I> This presentation assumes the redemption of 7,900,000 public shares,
equal to the number of public shares not covered by CHFW Shareholder Support Agreements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen has been determined
to be the accounting acquirer under both scenarios based on the factors analyzed above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Description of the Business Combination
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April&nbsp;15, 2021, CHFW, Merger Sub and Surrozen entered into the Business Combination Agreement, which provides for, among
other things, the following transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">On the Closing Date and immediately prior to the Effective Time, CHFW will change its jurisdiction of
incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware, upon which CHFW will change its name to &#147;Surrozen, Inc.&#148;; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the parties to the Business Combination Agreement will cause a certificate of merger to be executed and
filed with the Secretary of State of the State of Delaware, pursuant to which Merger Sub will merge with and into Surrozen, with Surrozen as the surviving company in the Merger and, after giving effect to such merger, Surrozen shall be a
wholly-owned subsidiary of CHFW. </P></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Concurrently with the execution of the Business Combination Agreement, CHFW entered
into Subscription Agreements with the PIPE Investors to consummate the PIPE Financing, pursuant to which the PIPE Investors have agreed to subscribe for and purchase, and CHFW has agreed to issue and sell to the PIPE Investors, an aggregate of
12,020,000 units, each consisting of one share of New Surrozen Common Stock <FONT STYLE="white-space:nowrap">and&nbsp;one-third&nbsp;of</FONT> one redeemable warrant for one share of New Surrozen Common Stock for a purchase price of $10.00 per unit,
for aggregate gross proceeds of $120.2 million to be consummated in connection with Closing. For more information about the Business Combination, please see the section entitled &#147;The Business Combination Proposal.&#148; A copy of the Business
Combination Agreement is attached to this proxy statement/prospectus as Annex A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the consideration
issuable in the Business Combination in both the no redemption and maximum redemption scenarios: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>(in thousands, except for share and per share amounts)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares transferred at Closing<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Value per share<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Share Consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Shares transferred at Closing includes approximately 1,787,841 shares underlying Surrozen options and
restricted stock awards, which are subject to future exercise, service conditions, or a combination thereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Share consideration is calculated using a $10.00 reference price. Actual total share consideration will be
dependent on the value of the common stock at Closing. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the pro forma capitalization expected at the Closing
under the no redemption and maximum redemption scenarios: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming<BR>No<BR>Redemptions<BR>(Shares)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming<BR>Max<BR>Redemptions<BR>(Shares)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surrozen stockholders<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,212,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,212,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surrozen options and restricted stock
awards<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,787,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,787,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Surrozen Business Combination shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>20,000,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>46.3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>20,000,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>56.7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%</B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surrozen stockholders - PIPE<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,122,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,122,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CHFW&#146;s public shareholders<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsor<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,472,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,472,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Investors (excluding Surrozen stockholders and Sponsor)<SUP
STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pro Forma Common Stock</B><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>43,195,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>35,295,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>100.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%</B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents shares issued as consideration for Surrozen outstanding common stock not subject to future
service conditions and Surrozen redeemable convertible preferred stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents shares issued as consideration for Surrozen options and restricted stock awards, which are
subject to future exercise, service conditions, or a combination thereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents 3,122,500 PIPE shares subscribed for by Surrozen stockholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Includes 1,000,000 shares purchased by affiliates of Consonance Capital Management in the CHFW IPO. Does not
reflect impact of any PIPE shares subscribed for by CHFW public shareholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Calculated as the sum of the following: (i) 1,541,000 founder&#146;s shares, which is net of the forfeiture
of 759,000 founder&#146;s shares; (ii) 434,000 shares underlying the private placement units; and (iii) 2,497,500 shares subscribed for by Sponsor in the PIPE. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">12,020,000 PIPE shares, less subscriptions from existing Surrozen stockholders (3,122,500 shares) and
Sponsor (2,497,500 shares). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Total pro forma common stock outstanding excludes 3,066,667 shares issuable upon exercise of the Public
Warrants and 144,667 shares issuable upon exercise of the private placement warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Assumptions and estimates
underlying the unaudited pro forma adjustments included in the unaudited pro forma condensed combined financial information are described in the accompanying notes. The unaudited pro forma condensed combined financial information has been presented
for illustrative purposes only and is not necessarily indicative of the operating results and financial position that would have been achieved had the Business Combination occurred on the date indicated. Further, the unaudited pro forma condensed
combined financial information does not purport to project the future operating results or financial position of CHFW following the completion of the Business Combination. The unaudited pro forma adjustments represent management&#146;s estimates
based on information available as of the date of the unaudited pro forma condensed combined financial information and are subject to change as additional information becomes available and analyses are performed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_138"></A>UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS OF MARCH&nbsp;31, 2021 (in thousands) </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of March&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction</B><br><B>Accounting</B><br><B>Adjustments</B><br><B>(Assuming&nbsp;No</B><br><B>Redemptions)</B><br><B>(Note 3)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>March&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B>Transaction</B><br><B>Accounting</B><br><B>Adjustments</B><br><B>(Assuming</B><br><B>Maximum</B><br><B>Redemptions)</B><br><B>(Note
 3)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>March&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Surrozen</B><br><B>(Historical)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CHFW</B><br><B>(Historical)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B><br><B>Combined</B><br><B>(Assuming No</B><br><B>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B><br><B>Combined</B><br><B>(Assuming</B><br><B>Maximum</B><br><B>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;23,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 92,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(a</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;214,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;(79,023</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(j</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;135,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,220</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(b</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(c</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(d</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>40,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,409</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>190,227</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>231,708</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(79,023</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>152,685</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(92,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(a</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(c</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>51,469</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>93,436</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>97,933</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>242,838</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(79,023</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>163,815</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(c</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,597 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Lease liability, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,585</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>987</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(940</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,632</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,632</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Lease liability, noncurrent portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,484</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(h</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred underwriting fee payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,220</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(b</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>16,617</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>6,808</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,644</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>16,781</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>16,781</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Commitments and contingencies</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Class&nbsp;A ordinary shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(81,628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(e</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of March&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction</B><br><B>Accounting</B><br><B>Adjustments</B><br><B>(Assuming&nbsp;No</B><br><B>Redemptions)</B><br><B>(Note 3)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>March&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B>Transaction</B><br><B>Accounting</B><br><B>Adjustments</B><br><B>(Assuming</B><br><B>Maximum</B><br><B>Redemptions)</B><br><B>(Note
 3)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>March&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Surrozen</B><br><B>(Historical)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CHFW</B><br><B>(Historical)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B><br><B>Combined</B><br><B>(Assuming No</B><br><B>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B><br><B>Combined</B><br><B>(Assuming</B><br><B>Maximum</B><br><B>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(133,097</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(g</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Stockholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Preference shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Class&nbsp;A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(e</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(f</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Class&nbsp;B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(f</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Common Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(d</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(j</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(f</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(g</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(g</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,094</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(c</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">327,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(79,022</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(j</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">248,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(d</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(e</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(g</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(h</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(i</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(101,023</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(i</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(101,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(101,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(c</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total stockholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(98,245</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>319,302</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>226,057</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(79,023</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>147,034</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total liabilities, redeemable stock and stockholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> 51,469</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;93,436</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> 97,933</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> 242,838</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;(79,023</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> 163,815</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE THREE MONTHS ENDED MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B><br><B>March&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction</B><br><B>Accounting</B><br><B>Adjustments</B><br><B>(Assuming&nbsp;No</B><br><B>Redemptions)</B><br><B>(Note 3)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months</B><br><B>Ended</B><br><B>March&nbsp;31,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction</B><br><B>Accounting</B><br><B>Adjustments</B><br><B>(Assuming</B><br><B>Maximum</B><br><B>Redemptions)</B><br><B>(Note 3)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months</B><br><B>Ended</B><br><B>March&nbsp;31,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Surrozen</B><br><B>(Historical)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CHFW</B><br><B>(Historical)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B><br><B>Combined</B><br><B>(Assuming</B><br><B>No</B><br><B>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B><br><B>Combined</B><br><B>(Assuming</B><br><B>Maximum</B><br><B>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 8,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(aa</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(673</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(ee</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>13,031</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,065</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(838</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>13,258</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>13,258</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(13,031</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,065</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>838</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(13,258</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(13,258</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other income (expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(bb</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(bb</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(767</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(cc</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other income (expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>832</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(796</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>45</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>45</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> (13,022</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> (233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> 42</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> (13,213</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> &#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> (13,213</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted weighted average shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,062,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,407,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,507,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (1.62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_139"></A>UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEAR ENDED DECEMBER&nbsp;31, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B><U>December&nbsp;31,&nbsp;2020</U></B><br><B>Surrozen</B><br><B>(Historical)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;period</B><br><B>from</B><br><B>August&nbsp;21,&nbsp;2020</B><br><B>(inception)</B><br><B>through</B><br><B><U>December&nbsp;31,&nbsp;
2020</U></B><br><B>CHFW</B><br><B>(Historical)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction</B><br><B>Accounting</B><br><B>Adjustments</B><br><B>(Assuming&nbsp;No</B><br><B>Redemptions)</B><br><B>(Note 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B><br><B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B><br><B>Pro
Forma</B><br><B>Combined</B><br><B>(Assuming</B><br><B>No</B><br><B>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction</B><br><B>Accounting</B><br><B>Adjustments</B><br><B>(Assuming</B><br><B>Maximum</B><br><B>Redemptions)</B><br><B>(Note 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B><br><B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B><br><B>Pro
Forma</B><br><B>Combined</B><br><B>(Assuming</B><br><B>Maximum</B><br><B>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 25,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 25,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 25,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(aa</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32,807</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>439</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(55</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>33,191</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>33,191</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,807</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(439</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>55</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(33,191</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(33,191</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Other income (expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Interest earned on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(bb</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Unrealized loss on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(bb</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,574</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(cc</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(108</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(dd</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total other income (expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>91</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,684</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,492</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(101</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(101</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> (32,716</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;(2,123</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;1,547</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> (33,292</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> &#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> (33,292</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Basic and diluted weighted average shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,394,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,407,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,507,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (4.42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_140"></A>NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
INFORMATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>1. Basis of Presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Business Combination is expected to be accounted for as a reverse recapitalization in accordance with GAAP, whereby CHFW is treated as the
acquired company and Surrozen is treated as the accounting acquirer. Accordingly, for accounting purposes, the Business Combination is expected to be treated as the equivalent of Surrozen issuing stock for the net assets of CHFW, accompanied by a
recapitalization. The net assets of CHFW will be stated at historical cost, with no goodwill or other intangible assets recorded. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
unaudited pro forma condensed combined balance sheet as of March&nbsp;31, 2021 gives pro forma effect to the Business Combination as if it had been consummated on March&nbsp;31, 2021. The unaudited pro forma condensed combined statements of
operations for the three months ended March&nbsp;31, 2021 and year ended December&nbsp;31, 2020 give the pro forma effect to the Business Combination as if it had been consummated on January&nbsp;1, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The unaudited pro forma condensed combined balance sheet as of March&nbsp;31, 2021 has been prepared using, and should be read in conjunction
with, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s unaudited balance sheet as of March&nbsp;31, 2021 and the related notes included elsewhere in
this proxy statement/prospectus; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CHFW&#146;s unaudited balance sheet as of March&nbsp;31, 2021 and the related notes included elsewhere in this
proxy statement/prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The unaudited pro forma condensed combined statement of operations for the three months
ended March&nbsp;31, 2021 has been prepared using, and should be read in conjunction with, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s unaudited statement of operations for the three months ended March&nbsp;31, 2021 and the
related notes included elsewhere in this proxy statement/prospectus; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CHFW&#146;s unaudited statement of operations for the three months ended March&nbsp;31, 2021 and the related
notes included elsewhere in this proxy statement/prospectus. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The unaudited pro forma condensed combined statement
of operations for the year ended December&nbsp;31, 2020 has been prepared using, and should be read in conjunction with, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen&#146;s audited statement of operations for the year ended December&nbsp;31, 2020 and the related
notes included elsewhere in this proxy statement/prospectus; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CHFW&#146;s audited statement of operations for the period August&nbsp;21, 2020 (inception) through
December&nbsp;31, 2020 and the related notes included elsewhere in this proxy statement/prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Management has made
significant estimates and assumptions in its determination of the pro forma adjustments. As the unaudited pro forma condensed combined financial information has been prepared based on these preliminary estimates, the final amounts recorded may
differ materially from the information presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The unaudited pro forma condensed combined financial information does not give effect
to any anticipated synergies, operating efficiencies, tax savings or cost savings that may be associated with the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The pro forma adjustments reflecting the completion of the Business Combination are based on currently available information and assumptions
and methodologies that CHFW believes are reasonable under the circumstances. The unaudited condensed pro forma adjustments, which are described in the accompanying notes, may be revised as additional information becomes available and is evaluated.
Therefore, it is likely that the actual adjustments will differ from the pro forma adjustments and it is possible the difference may be material. CHFW believes that its assumptions and methodologies provide a reasonable basis for presenting all of
the significant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
effects of the Business Combination based on information available to management at the current time and that the pro forma adjustments give appropriate effect to those assumptions and are
properly applied in the unaudited pro forma condensed combined financial information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The unaudited pro forma condensed combined
financial information is not necessarily indicative of what the actual results of operations and financial position would have been had the Business Combination taken place on the date indicated, nor is it indicative of the future consolidated
results of operations or financial position of the post-combination company. They should be read in conjunction with the historical financial statements and notes thereto of Surrozen and CHFW. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2. Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon consummation of the Business Combination, management will perform a comprehensive review of Surrozen&#146;s and CHFW&#146;s accounting
policies. As a result of the review, management may identify differences between the accounting policies of the two entities which, when conformed, could have a material impact on the financial statements of the post-combination company. Based on
its initial analysis, management did not identify any differences that would have a material impact on the unaudited pro forma condensed combined financial information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3. Adjustments to Unaudited Pro Forma Condensed Combined Financial Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The unaudited pro forma condensed combined financial information has been prepared to illustrate the effect of the Business Combination and has
been prepared for informational purposes only. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following unaudited pro forma condensed combined financial information has been
prepared in accordance with Article 11 of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> as amended by the final rule, Release <FONT STYLE="white-space:nowrap">No.&nbsp;33-10786</FONT> &#147;Amendments to Financial Disclosures about Acquired
and Disposed Businesses.&#148; Release <FONT STYLE="white-space:nowrap">No.&nbsp;33-10786</FONT> replaces the existing pro forma adjustment criteria with simplified requirements to depict the accounting for the transaction (&#147;Transaction
Accounting Adjustments&#148;) and the option to present the reasonably estimable synergies and other transaction effects that have occurred or are reasonably expected to occur (&#147;Management&#146;s Adjustments&#148;). CHFW has elected not to
present Management&#146;s Adjustments and has only presented Transaction Accounting Adjustments in the following unaudited pro forma condensed combined financial information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The pro forma combined provision for income taxes does not necessarily reflect the amounts that would have resulted had the post-combination
company filed consolidated income tax returns during the periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The pro forma basic and diluted net loss per share amounts
presented in the unaudited pro forma condensed combined statement of operations are based upon the number of CHFW&#146;s shares outstanding, assuming the Business Combination occurred on January&nbsp;1, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Transaction Accounting Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The pro forma adjustments included in the unaudited pro forma condensed combined balance sheet as of March&nbsp;31, 2021 are as follows: </P>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Reflects the reclassification of cash and marketable securities held in the trust account that becomes
available following the Business Combination, assuming no redemption. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Reflects the settlement of $3.2&nbsp;million in deferred underwriting fee payable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents total preliminary estimated transaction costs incurred by Surrozen and CHFW of approximately
$18.8&nbsp;million for legal, financial advisory and other professional fees. Of these costs: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.3 million was deferred in other assets and accrued in accrued liabilities by Surrozen as of March&nbsp;31,
2021; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.7 million was accrued by CHFW in accrued liabilities and recognized as expense as of March&nbsp;31, 2021;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.01 million was not capitalized as part of the Business Combination and reflected as a decrease in
accumulated deficit. The costs expensed through accumulated deficit are included in the unaudited pro forma condensed combined statement of operations for the year ended December&nbsp;31, 2020 as discussed in Note 3(dd) below; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$18.1 were capitalized and offset against the proceeds from the Business Combination and reflected as a
decrease in additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. This amount represents total preliminary estimated transaction costs less: $0.7 million recognized in expense by CHFW and reclassified to additional paid-in capital in
Note 3(i) below; and $0.01 million that was not capitalized as part of the Business Combination and reflected as a decrease in accumulated deficit. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Reflects proceeds of $120.2&nbsp;million from the issuance and sale of 12,020,000 units, each consisting of
one share of New Surrozen Common Stock and <FONT STYLE="white-space:nowrap">one-third</FONT> of one redeemable warrant for one share of New Surrozen Common Stock, for a purchase price of $10.00 per unit in the PIPE Financing. The PIPE Warrants are
expected to be equity classified under Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) Topic 815-40, Derivatives and Hedging - Contracts in Entity&#146;s Own Equity (&#147;ASC 815-40&#148;)
after considering, amongst other factors, the post-combination company will have a single class equity structure. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Reflects the reclassification of $81.6&nbsp;million of CHFW Class&nbsp;A ordinary shares subject to possible
redemption to permanent equity. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Reflects the conversion of Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, into shares of New Surrozen Common Stock upon the Domestication. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Reflects the recapitalization of Surrozen equity comprised of 95,289,932 shares of Surrozen redeemable
convertible preferred stock and 10,061,166 shares of Surrozen Common Stock into 18,498,529 shares of New Surrozen Common Stock. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Reflects adjustment to reclassify CHFW&#146;s public warrants from liabilities to additional paid-in
capital. Upon consummation of the Business Combination, CHFW&#146;s public warrants are expected to be equity classified under ASC 815-40 after considering, amongst other factors, the post-combination company will have a single class equity
structure. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Reflects the elimination of CHFW&#146;s historical accumulated deficit. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents the redemption of the maximum number of shares of 7,900,000 shares of CHFW Class&nbsp;A ordinary
shares for $79.0&nbsp;million allocated to New Surrozen Common Stock and additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital using par value of $0.0001 per share and at a redemption price of $10.00 per share (based on the cash and
marketable securities held in the trust account as of March&nbsp;31, 2021 of $92.0 million). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Transaction
Accounting Adjustments to Unaudited Pro Forma Condensed Combined Statements of Operations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The pro forma adjustments included in
the unaudited pro forma condensed combined statements of operations for the three months ended March&nbsp;31, 2021 and year ended December&nbsp;31, 2020 are as follows: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(aa)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents pro forma adjustment to eliminate historical expenses related to CHFW&#146;s office space and
administrative support services paid to the Sponsor, which will terminate upon consummation of the Business Combination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(bb)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents pro forma adjustment to eliminate interest and unrealized losses on marketable securities held in
the trust account. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(cc)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Reflects the elimination of the change in fair value of warrant liability associated with CHFW&#146;s public
warrants. Upon consummation of the Business Combination, CHFW&#146;s public warrants are expected to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
be equity classified under ASC 815-40 after considering, amongst other factors, the post-combination company will have a single class equity structure. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(dd)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Reflects preliminary estimated transaction costs allocated to the private placement warrant liabilities that
were assumed as part of the Business Combination. These costs are reflected as if incurred on January&nbsp;1, 2020, the date the Business Combination occurred for the purposes of the unaudited pro forma condensed combined statement of operations.
This is a <FONT STYLE="white-space:nowrap">non-recurring</FONT> item. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ee)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents adjustment to eliminate transaction costs expensed by CHFW during the three months ended
March&nbsp;31, 2021. These costs will be considered equity issuance costs of the post-combination company and will be either capitalized as a reduction of additional paid-in capital or recognized in expense at the Closing. Transaction costs
recognized in expense at Closing are reflected as if incurred on January&nbsp;1, 2020, the date the Business Combination occurred for the purposes of the unaudited pro forma condensed combined statements of operations, and accordingly, have been
eliminated from the unaudited pro forma condensed combined statement of operations for the three months ended March&nbsp;31, 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>4. Net Loss per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Represents the net loss per share calculated using the historical weighted average shares outstanding, and the issuance of additional shares in
connection with the Business Combination, assuming the shares were outstanding since January&nbsp;1, 2020. As the Business Combination is being reflected as if it had occurred at the beginning of the periods presented, the calculation of weighted
average shares outstanding for basic and diluted net loss per share assumes that the shares issuable relating to the Business Combination have been outstanding for the entire periods presented. When assuming maximum redemption, this calculation is
adjusted to eliminate such shares for the entire period. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The unaudited pro forma condensed combined financial information has been
prepared assuming two alternative levels of redemption for the three months ended March&nbsp;31, 2021 and year ended December&nbsp;31, 2020: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>March&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming No<BR>Redemptions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming<BR>Maximum<BR>Redemptions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming No<BR>Redemptions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming<BR>Maximum<BR>Redemptions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss (in thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (13,213</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (13,213</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (33,292</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (33,292</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,407,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,507,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,407,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,507,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares calculation, basis and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CHFW&#146;s public shareholders (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsor (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,472,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,472,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,472,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,472,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Investors (excluding Surrozen stockholders and Sponsor) (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surrozen stockholders (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,334,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,334,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,334,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,334,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,407,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,507,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,407,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,507,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Includes 1,000,000 shares purchased by affiliates of Consonance Capital Management in the CHFW IPO. Does not
reflect impact of any PIPE shares subscribed for by CHFW public shareholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Calculated as the sum of the following: (i) 1,541,000 founder&#146;s shares, which is net of the forfeiture
of 759,000 founder&#146;s shares; (ii) 434,000 shares underlying the private placement units; and (iii) 2,497,500 shares subscribed for by Sponsor in the PIPE. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Calculated as the sum of the following: (i) 18,212,159 shares issued as consideration for Surrozen
outstanding common stock not subject to future service conditions and Surrozen redeemable convertible preferred stock; and (ii) 3,122,500 shares subscribed for by Surrozen stockholders in the PIPE. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Calculated as 12,020,000 PIPE shares, less subscriptions from existing Surrozen stockholders (3,122,500
shares) and Sponsor (2,497,500 shares). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">For the purpose of calculating diluted net loss per share, it was assumed that all outstanding public and
private placement warrants are exchanged for shares of New Surrozen Common Stock. However, since this results in anti-dilution, the effect of such exchange was not included in the calculation of diluted net loss per share. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_141"></A>INFORMATION ABOUT CHFW </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a blank check company incorporated in the Cayman Islands on August&nbsp;21, 2020 as a Cayman Islands exempted company and formed for
the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. We reviewed a number of opportunities to enter into a business combination with an
operating business, and entered into the Business Combination Agreement on April&nbsp;15, 2021. We intend to finance the Business Combination through the issuance of New Surrozen Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Sponsor, Consonance Life Sciences, combines life sciences and biotechnology investing expertise and market knowledge with industry-based
business development, transactional and operational experience. Consonance Life Sciences was formed by the founders of Consonance Capital Management, a leading healthcare-dedicated hedge fund manager, and then partnered with a dedicated team of
biotechnology industry professionals with extensive experience identifying attractive and unique acquisition opportunities. Our management team and Board of Directors have significant, meaningful experience as executives, clinicians, project
leaders, corporate strategists and business development heads within public and private biotechnology companies. Our Chairman, Mitchell Blutt, is the Founder and Chief Executive Officer, or CEO, of Consonance Capital and Founder, CEO and Chairman of
the Investment Committee of Consonance Capital Management, the hedge fund business of Consonance Capital, and a <FONT STYLE="white-space:nowrap">Co-Managing</FONT> Partner and <FONT STYLE="white-space:nowrap">Co-Founder</FONT> of Consonance Capital
Partners, the private equity business of Consonance Capital, collectively referred to as Consonance Capital. Our CEO, Gad Soffer, is a life sciences and biotechnology industry-experienced business development and operating professional who has held
a number of leadership positions at both early-clinical stage and commercial biopharmaceutical companies. Our Chief Financial Officer, or CFO, Kevin Livingston, is a <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> Partner, and Member of the
Investment Committee of Consonance Capital Management. Benny Soffer, a member of our sponsor and Board of Directors, is a <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> Partner, Chief Investment Officer, or CIO, Portfolio Manager, and Member of
the Investment Committee of Consonance Capital Management. We believe the combination of our investment, business development and operational backgrounds enable us to identify promising acquisition opportunities and also add substantial value to a
target business beyond the initial business combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Consonance Capital Management was founded in 2007 with approximately
$50&nbsp;million of assets under management by Mitchell Blutt, Benny Soffer and Kevin Livingston. As of March&nbsp;31, 2021, the fund has grown to over $1&nbsp;billion in assets under management and focuses on equity investments in publicly-traded
life sciences companies, with an emphasis on small and <FONT STYLE="white-space:nowrap">mid-cap</FONT> life sciences companies. The founding team of Consonance Capital Management brings significant investment and transactional experience with
clinical medical expertise, which will provide a significant advantage as we seek to identify, evaluate and acquire a private company in the life sciences and biotechnology industry. Our team of operating professionals and Board of Directors combine
wide therapeutic area experience covering hematology, oncology, autoimmunity, inflammatory diseases, and rare diseases; a strong drug development track record with numerous regulatory filings in the United States and the European Union including
Investigational New Drug, or IND, applications, Breakthrough Therapy applications, New Drug Applications, or NDA, and Marketing Authorization Applications, or MAAs; extensive operating experience spanning different therapeutic modalities including
small molecules, biologics, as well as cell </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
therapy; and leadership in the areas of strategic prioritization of external opportunities, diversification and growth through business development, product life cycle management, public and
private financings, mergers and acquisitions, scientific, translational, clinical, and regulatory strategy, and manufacturing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On
November&nbsp;23, 2020, we consummated an initial public offering of 8,000,000 units at an offering price of $10.00 per unit, and a private placement with the Sponsor of 410,000 private placement units at an offering price of $10.00 per unit. On
December&nbsp;1, 2020, the underwriters fully exercised their over-allotment option, resulting in the sale of an additional 1,200,000 units issued at $10.00 per unit and an additional 24,000 private placement units at $10.00 per private placement
unit. Each unit sold in the initial public offering and private placement consists of one Class&nbsp;A ordinary share and <FONT STYLE="white-space:nowrap">one-third</FONT> of one redeemable warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the closing of our initial public offering, an amount equal to $92,0000,000 of the net proceeds from our initial public offering and
the sale of the private placement units was placed in the trust account. The trust account may be invested only in U.S. &#147;government securities&#148; within the meaning set forth in Section&nbsp;2(a)(16) of the Investment Company Act, as amended
(the &#147;Investment Company Act&#148;), with a maturity of 185 days or less, or in money market funds meeting the conditions of paragraphs (d)(1), (d)(2), (d)(3) and (d)(4) of Rule <FONT STYLE="white-space:nowrap">2a-7</FONT> of the Investment
Company Act. As of March&nbsp;31, 2021, funds in the trust account totaled approximately $92.0&nbsp;million and were held in U.S. treasury securities. These funds will remain in the trust account, except for the withdrawal of interest to pay taxes,
if any, until the earliest of (i)&nbsp;the completion of our initial business combination, (ii)&nbsp;the redemption of any public shares properly tendered in connection with a shareholder vote to amend the Existing Governing Documents to modify the
substance and timing of our obligation to redeem 100% of the public shares if CHFW does not complete a business combination by November&nbsp;23, 2022, or (iii)&nbsp;the redemption of all of the public shares if CHFW is unable to complete a business
combination by November&nbsp;23, 2022 (unless such date is extended in accordance with the Existing Governing Documents), subject to applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW&#146;s units, public shares and public warrants are currently listed on NYSE American under the symbols &#147;CHFW.U,&#148;
&#147;CHFW&#148; and &#147;CHFW.W,&#148; respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_142"></A>Financial Position </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2021, we had approximately $774,931.42 in cash held outside of the trust account, approximately $92&nbsp;million in
marketable securities held in the trust account and deferred offering costs of approximately $3.2&nbsp;million. With the funds available, we offer a target business a variety of options such as creating a liquidity event for its owners, providing
capital for the potential growth and expansion of its operations or strengthening its balance sheet by reducing its debt ratio. Because we are able to complete our initial business combination using CHFW&#146;s cash, debt or equity securities, or a
combination of the foregoing, we have the flexibility to use the most efficient combination that will allow us to tailor the consideration to be paid to the target business to fit its needs and desires. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_143"></A>Effecting Our Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Fair Market Value of Target Business </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NYSE American rules and the Existing Governing Documents require that our business combination must be with one or more target businesses that
together have a fair market value equal to at least 80% of the balance in the trust account (less any deferred underwriting commissions and taxes payable on interest earned) at the time of our signing a definitive agreement in connection with our
initial business combination. Our board of directors determined that this test was met in connection with the proposed Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Lack of Business Diversification </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For an indefinite period of time after the completion of our initial business combination, the prospects for our success may depend entirely on
the future performance of a single business. Unlike other entities that have the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
resources to complete business combinations with multiple entities in one or several industries, it is probable that we will not have the resources to diversify our operations and mitigate the
risks of being in a single line of business. By completing our initial business combination with only a single entity, our lack of diversification may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject us to negative economic, competitive and regulatory developments, any or all of which may have a
substantial adverse impact on the particular industry in which we operate after our initial business combination; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cause us to depend on the marketing and sale of a single product or limited number of products or services.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Redemption Rights for Public Shareholders upon Completion of the Business Combination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are providing our public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of our
initial business combination at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation of the
initial business combination, including interest earned on the funds held in the trust account and not previously released to us to pay our income taxes, if any, divided by the number of the then-outstanding public shares, subject to the limitations
described herein. The amount in the trust account was approximately $10.00 per public share as of March&nbsp;31, 2021. The per share amount we will distribute to shareholders who properly redeem their shares will not be reduced by the deferred
underwriting commissions that we will pay to the underwriters of our initial public offering. The redemption rights include the requirement that a beneficial holder must identify itself in writing as a beneficial holder and provide its legal name,
phone number and address to the transfer agent in order to validly redeem its shares. There will be no redemption rights upon the completion of our initial business combination with respect to our warrants. Further, we will not proceed with
redeeming our public shares, even if a public shareholder has properly elected to redeem its shares, if the Business Combination does not close. The Redemptions referred to herein shall take effect as repurchases under the Existing Governing
Documents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Limitations on Redemption Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing, the Existing Governing Documents provide that in no event will we redeem our public shares in an amount that
would cause our net tangible assets to be less than $5,000,001 (so that we do not then become subject to the SEC&#146;s &#147;penny stock&#148; rules). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Redemption of Public Shares and Liquidation if No Business Combination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have until November&nbsp;23, 2022 (unless such date is extended in accordance with the Existing Governing Documents) to complete a business
combination. If we are unable to consummate an initial business combination by November&nbsp;23, 2022, we will: (i)&nbsp;cease all operations except for the purpose of winding up; (ii)&nbsp;as promptly as reasonably possible but not more than ten
business days thereafter, redeem the public shares, at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the
trust account and not previously released to us to pay our income taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then-outstanding public shares, which redemption will completely extinguish
public shareholders&#146; rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of our remaining
shareholders and our board of directors, liquidate and dissolve, subject in the case of clauses (ii)&nbsp;and (iii) to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There
will be no redemption rights or liquidating distributions with respect to our warrants, which will expire worthless if we fail to consummate an initial business combination by November&nbsp;23, 2022. The Existing Governing Documents provide that, if
we wind up for any other reason prior to the consummation of our initial business combination, we will follow the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
foregoing procedures with respect to the liquidation of the trust account as promptly as reasonably possible but not more than ten business days thereafter, subject to applicable Cayman Islands
law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Sponsor and each member of our management team have entered into an agreement with us, pursuant to which they have agreed to
waive their rights to liquidating distributions from the trust account with respect to any founder shares or private placement shares they hold if we fail to consummate an initial business combination by November&nbsp;23, 2022 (although they will be
entitled to liquidating distributions from the trust account with respect to any public shares they hold if we fail to complete our initial business combination by November&nbsp;23, 2022). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Sponsor, executive officers and directors have agreed, pursuant to a written agreement with us, that they will not propose any amendment
to the Existing Governing Documents (A)&nbsp;that would modify the substance or timing of our obligation to provide holders of our Class&nbsp;A ordinary shares the right to have their shares redeemed in connection with our initial business
combination or to redeem 100% of our public shares if we do not complete our initial business combination by November&nbsp;23, 2022 or (B)&nbsp;with respect to any other provision relating to the rights of holders of our Class&nbsp;A ordinary
shares, unless we provide our public shareholders with the opportunity to redeem their public shares upon approval of any such amendment at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount
then on deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to us to pay our income taxes, if any, divided by the number of the then-outstanding public shares. However, we may
not redeem our public shares in an amount that would cause our net tangible assets to be less than $5,000,001 (so that we do not then become subject to the SEC&#146;s &#147;penny stock&#148; rules). If this optional redemption right is exercised
with respect to an excessive number of public shares such that we cannot satisfy the net tangible asset requirement, we would not proceed with the amendment or the related redemption of our public shares at such time. This redemption right shall
apply in the event of the approval of any such amendment, whether proposed by our Sponsor, any executive officer, director or director nominee, or any other person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect that all costs and expenses associated with implementing our plan of dissolution, as well as payments to any creditors, will be
funded from amounts remaining out of the proceeds of our initial public offering held outside the trust account plus up to $100,000 of funds from the trust account available to us to pay dissolution expenses, although we cannot assure you that there
will be sufficient funds for such purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we were to expend all of the net proceeds of our initial public offering and the sale of
the private placement units, other than the proceeds deposited in the trust account, and without taking into account interest, if any, earned on the trust account, the <FONT STYLE="white-space:nowrap">per-share</FONT> redemption amount received by
shareholders upon our dissolution would be $10.00. The proceeds deposited in the trust account could, however, become subject to the claims of our creditors which would have higher priority than the claims of our public shareholders. We cannot
assure you that the actual <FONT STYLE="white-space:nowrap">per-share</FONT> redemption amount received by shareholders will not be less than $10.00. While we intend to pay such amounts, if any, we cannot assure you that we will have funds
sufficient to pay or provide for all creditors&#146; claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we will seek to have all vendors, service providers (excluding our
independent registered public accounting firm), prospective target businesses and other entities with which we do business execute agreements with us waiving any right, title, interest or claim of any kind in or to any monies held in the trust
account for the benefit of our public shareholders, there is no guarantee that they will execute such agreements or even if they execute such agreements that they would be prevented from bringing claims against the trust account including but not
limited to fraudulent inducement, breach of fiduciary responsibility or other similar claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain an advantage with respect to a claim against our assets,
including the funds held in the trust account. If any third party refuses to execute an agreement waiving such claims to the monies held in the trust account, our management will perform an analysis of the alternatives available to it and will only
enter into an agreement with a third party that has not executed a waiver if management believes that such third party&#146;s engagement would be significantly more beneficial to us than any alternative. Examples of possible instances where we may
engage a third party that refuses to execute a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
waiver include the engagement of a third party consultant whose particular expertise or skills are believed by management to be significantly superior to those of other consultants that would
agree to execute a waiver or in cases where management is unable to find a service provider willing to execute a waiver. The underwriters of our initial public offering will not execute agreements with us waiving such claims to the monies held in
the trust account. In addition, there is no guarantee that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with us and will not seek recourse
against the trust account for any reason. In order to protect the amounts held in the trust account, our Sponsor has agreed that it will be liable to us if and to the extent any claims by a vendor for services rendered or products sold to us, or a
prospective target business with which we have discussed entering into a transaction agreement, reduce the amounts in the trust account to below the lesser of (i) $10.00 per public share and (ii)&nbsp;the actual amount per public share held in the
trust account as of the date of the liquidation of the trust account if less than $10.00 per public share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay our tax obligations, provided
that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to seek access to the trust account nor will it apply to any claims under our indemnity of the underwriters
of our initial public offering against certain liabilities, including liabilities under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third party, our Sponsor will not be responsible to the extent
of any liability for such third party claims. However, we have not asked our Sponsor to reserve for such indemnification obligations, nor have we independently verified whether our Sponsor has sufficient funds to satisfy its indemnity obligations
and we believe that our Sponsor&#146;s only assets are securities of our company. Our Sponsor may not be able to satisfy those obligations. None of our officers or directors will indemnify us for claims by third parties including, without
limitation, claims by vendors and prospective target businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that the proceeds in the trust account are reduced below
the lesser of (i) $10.00 per public share and (ii)&nbsp;the actual amount per public share held in the trust account as of the date of the liquidation of the trust account if less than $10.00 per public share due to reductions in the value of the
trust assets, in each case net of the interest that may be withdrawn to pay our tax obligations, and our Sponsor asserts that it is unable to satisfy its indemnification obligations or that it has no indemnification obligations related to a
particular claim, our independent directors would determine whether to take legal action against our Sponsor to enforce its indemnification obligations. While we currently expect that our independent directors would take legal action on our behalf
against our Sponsor to enforce its indemnification obligations to us, it is possible that our independent directors in exercising their business judgment may choose not to do so in any particular instance. Accordingly, we cannot assure you that due
to claims of creditors the actual value of the <FONT STYLE="white-space:nowrap">per-share</FONT> redemption price will not be less than $10.00 per public share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will seek to reduce the possibility that our Sponsor will have to indemnify the trust account due to claims of creditors by endeavoring to
have all vendors, service providers (excluding our independent registered public accounting firm), prospective target businesses or other entities with which we do business execute agreements with us waiving any right, title, interest or claim of
any kind in or to monies held in the trust account. Our Sponsor will also not be liable as to any claims under our indemnity of the underwriters of our initial public offering against certain liabilities, including liabilities under the Securities
Act. At March&nbsp;31, 2021, we had access to up to $774,931.42 from the proceeds of the initial public offering and the sale of the private placement units with which to pay any such potential claims (including costs and expenses incurred in
connection with our liquidation, currently estimated to be no more than approximately $100,000). In the event that we liquidate and it is subsequently determined that the reserve for claims and liabilities is insufficient, shareholders who received
funds from our trust account could be liable for claims made by creditors; however, such liability will not be greater than the amount of funds from our trust account received by any such shareholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we file a bankruptcy petition or an involuntary bankruptcy petition is filed against us that is not dismissed, the proceeds held in the
trust account could be subject to applicable bankruptcy law, and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our shareholders. To the extent any bankruptcy claims deplete the
trust account, we cannot assure you we will be able to return $10.00 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
per public share to our public shareholders. Additionally, if we file a bankruptcy petition or an involuntary bankruptcy petition is filed against us that is not dismissed, any distributions
received by shareholders could be viewed under applicable debtor/creditor and/or bankruptcy laws as either a &#147;preferential transfer&#148; or a &#147;fraudulent conveyance.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result, a bankruptcy court could seek to recover some or all amounts received by our shareholders. Furthermore, our board of directors
may be viewed as having breached its fiduciary duty to our creditors and/or may have acted in bad faith, and thereby exposing itself and our company to claims of punitive damages, by paying public shareholders from the trust account prior to
addressing the claims of creditors. We cannot assure you that claims will not be brought against us for these reasons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">See &#147;<I>Risk
Factors&#151;Risks Related to the Business Combination and CHFW&#151;If, after we distribute the proceeds in the trust account to our public shareholders, we file a bankruptcy petition or an involuntary bankruptcy petition is filed against us that
is not dismissed, a bankruptcy court may seek to recover such proceeds, and we and our board of directors may be exposed to claims of punitive damages</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_144"></A>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently have three executive officers. These individuals are not obligated to devote any specific number of hours to our matters but they
intend to devote as much of their time as they deem necessary to our affairs until we have completed our initial business combination. The amount of time they will devote in any time period will vary based on whether a target business has been
selected for our initial business combination and the stage of the business combination process we are in. We do not intend to have any full-time employees prior to the completion of our initial business combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_145"></A>Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2021, our officers and directors are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Mitchell Blutt, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chairman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gad Soffer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin Livingston</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Benny Soffer, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joshua House</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>VP Business Development</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Donald J. Santel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Christopher Haqq, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Jarrett</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Dr.</B><B></B><B>&nbsp;Mitchell Blutt, M.D.</B>, our Chairman, is the founder and CEO of Consonance
Capital, founder, CEO and Chairman of the Investment Committee of Consonance Capital Management, and a <FONT STYLE="white-space:nowrap">Co-Managing</FONT> Partner and <FONT STYLE="white-space:nowrap">co-founder</FONT> of Consonance Capital Partners.
Prior to founding Consonance Capital Management in 2007, he was Executive Partner at JP Morgan Partners, or JPMP, from 1992 until 2004. In addition to his general management responsibilities across JPMP, Dr.&nbsp;Blutt founded and led JPMP&#146;s
healthcare group for nearly 18&nbsp;years, including its private equity and venture capital platforms. He was one of the earliest employees at Chemical Venture Partners, the predecessor to JPMP, joining in 1987. Dr.&nbsp;Blutt currently sits on the
board of directors of the Commonwealth Fund, a health policy research foundation. He is also on the Board of Overseers of the University of Pennsylvania School of Arts and Sciences as well as the Wharton School. Dr.&nbsp;Blutt currently serves or
formerly served on 38&nbsp;healthcare corporate boards of directors including numerous public and venture stage company boards of directors. He also formerly served on the board of directors of the Michael J. Fox Foundation for Parkinson&#146;s
Research, the board of trustees of Penn Medicine (the University of Pennsylvania Health System), the board of trustees of the University of Pennsylvania, and the board of directors of The Brearley </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
School. Dr.&nbsp;Blutt is a Clinical Assistant Professor of Medicine, in the Department of Medicine at Weill Cornell Medical College. He is on the New York Weill Cornell Council and the
Dean&#146;s Council of the Weil Cornell Medical College as well as the board of overseers of Weill from Cornell Medical College. Dr.&nbsp;Blutt holds BA and MD degrees from the University of Pennsylvania. He received his MBA from the Wharton School
of the University of Pennsylvania through the Clinical Scholars Fellowship sponsored by the Robert Wood Johnson Foundation. He completed his medical residency at the New York Presbyterian Hospital/Weill Cornell Medical College. We believe that
Dr.&nbsp;Blutt&#146;s experience in the medical and healthcare industries, combined with his extensive investment and management skills, qualifies Dr.&nbsp;Blutt to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Gad Soffer</B>, our CEO, was previously Chief Operating Officer, or COO, at Rheos Medicines, Inc., a Third Rock Ventures-funded startup
launched in 2018. Prior to joining Rheos, Mr.&nbsp;Soffer was part of the founding team at Atara Biotherapeutics, a Kleiner, Perkins, Caufield&nbsp;&amp; Byers, Domain Associates-funded startup where he served initially as COO and then Chief
Strategy Officer, or CSO. At Atara, Mr.&nbsp;Soffer led the strategic evaluation and <FONT STYLE="white-space:nowrap">in-licensing</FONT> of the company&#146;s allogeneic T cell therapy platform as well as the subsequent identification and licensing
of technologies leading to the development of its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> <FONT STYLE="white-space:nowrap">CAR-T</FONT> programs. Prior to joining Atara, Mr.&nbsp;Soffer worked at
Celgene Corporation as Executive Director and Global Project Leader where he led the team responsible for product development and lifecycle management for Abraxane, a breast, lung, and pancreatic cancer treatment also in development for a variety of
solid tumors. He also served as Director of Business Development at Celgene where he drove and supported numerous business development transactions including its strategic collaboration with Agios Pharmaceuticals and the acquisition of Abraxis
Biosciences while advising on venture investment and strategic partnerships. Earlier, Mr.&nbsp;Soffer was a healthcare consultant with Easton Associates. He earned an MBA. from Harvard Business School, an MS from Columbia University and an AB from
Harvard University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Kevin Livingston</B>, our CFO, is a <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> Partner, and Member of the
Investment Committee of Consonance Capital Management. Prior to joining Consonance Capital Management, Mr.&nbsp;Livingston was a Managing Director in the Investment Management Division at U.S. Trust Company of New York. At U.S. Trust,
Mr.&nbsp;Livingston managed client capital in discretionary multi-manager portfolios, and was a Member of the Open Architecture Investment Committee. Mr.&nbsp;Livingston currently serves on the board of directors of DC Safety. He is a trustee of
Alfred University and serves as the Chair of the Investment Committee. Kevin is a Certified Public Accountant and a graduate of Alfred University, where he received his BS. He also received his Executive MBA from Columbia Business School. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Dr.</B><B></B><B>&nbsp;Benny Soffer, M.D.</B>, serves on our Board of Directors. Dr.&nbsp;Soffer is a
<FONT STYLE="white-space:nowrap">Co-Founder,</FONT> Partner, CIO, Portfolio Manager, and Member of the Investment Committee of Consonance Capital Management. Prior to joining Consonance Capital Management, Dr.&nbsp;Soffer completed a residency in
internal medicine at Yale School of Medicine and served in a variety of managerial roles at Yale New Haven Hospital, including as Medical Director of Clinical Process Improvement and as Interim Medical Director of Medical Information Systems.
Dr.&nbsp;Soffer is a Clinical Assistant Professor of Medicine, in the Department of Medicine at Weill Cornell Medical College. He is also a member of the Scientific Advisory Committee of Daedalus Fund for Innovation. Dr.&nbsp;Soffer is a graduate of
Williams College, where he received his BA, of Emory University, where he received his MD, and of Yale University, where he received his MBA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Joshua House</B> serves as our VP Business Development. Mr.&nbsp;House joined Consonance Life Sciences Management in September&nbsp;2020
where he currently serves as Vice President. Between November 2018 and September&nbsp;2020, Mr.&nbsp;House held the role of Senior Director, Business Development and Corporate Strategy at Atara Biotherapeutics, where he was responsible for business
development, <FONT STYLE="white-space:nowrap">in-licensing</FONT> and corporate strategic activities. Between April 2017 and November 2018 he held the role of Director of Corporate Strategy at Atara Biotherapeutics. Prior to joining Atara,
Mr.&nbsp;House was an Investment Banking Vice President at Citigroup in San Francisco, where he executed capital markets and M&amp;A transactions for clients in the biotechnology sector. Mr.&nbsp;House earned a JD and MBA from Columbia University,
and a BA in Public Policy from Stanford University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Donald J. Santel</B> serves on our Board of Directors. Mr.&nbsp;Santel served as
Executive Chairman of Adicet Bio, Inc., a private allogeneic cell therapy oncology company, from October&nbsp;2017 through its reverse merger with resTORbio, Inc. in September&nbsp;2020. From March&nbsp;2018 through April&nbsp;2019, Mr.&nbsp;Santel
also served as Adicet Bio&#146;s interim Chief Executive Officer. He previously served as Chief Executive Officer of Hyperion Therapeutics (Nasdaq GM: HPTX) from June&nbsp;2008 until the sale of the company to Horizon Pharma (Nasdaq GM: HZNP) for
$1.1B in May&nbsp;2015. He led Hyperion from a development stage private company through the approval and commercial launch of Ravicti<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for the treatment of urea cycle disorders.
Mr.&nbsp;Santel was a member of Hyperion&#146;s board of directors from March&nbsp;2007 through the company&#146;s sale. Previously, Mr.&nbsp;Santel was a <FONT STYLE="white-space:nowrap">co-founder,</FONT> member of the board of directors and the
Chief Executive Officer of CoTherix, Inc., (Nasdaq GM: CTRX) from January&nbsp;2000 through its sale to Actelion for $419M in January&nbsp;2007. He led CoTherix from a development stage private company, through the approval and commercial launch of
Ventavis<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for the treatment of pulmonary arterial hypertension. Prior to joining CoTherix, Mr.&nbsp;Santel was employed by several medical device companies, including Cardiac Pathways
Corporation (acquired by Boston Scientific) and Medtronic, Inc. Mr.&nbsp;Santel previously served on the board of directors and the audit and compensation committees of Anthera Pharmaceuticals, Inc. and as a director of ChemGenex Pharmaceuticals,
Inc. Mr.&nbsp;Santel holds an MS in electrical engineering from the University of Minnesota and a BSE in biomedical engineering from Purdue University. We believe that Mr.&nbsp;Santel is qualified to serve on our board of directors given his
managerial and consultant roles in the biopharmaceutical industry and his experience with bringing companies public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Dr.</B><B></B><B>&nbsp;Christopher Haqq, M.D., Ph.D.</B>, serves on our Board of Directors. Dr.&nbsp;Haqq brings over 20&nbsp;years of drug
development leadership across large and small biotechnology companies and across cell therapy, small molecule and biologics in large and small biotech settings. Dr.&nbsp;Haqq joined Elicio Therapeutics as Executive Vice President, Head of Research
and Development and Chief Medical Officer, or CMO, in October&nbsp;2019. He was the first employee and CMO of Atara Biotherapeutics, and later CSO, where he was the architect of an innovative allogeneic T cell product candidate pipeline for oncology
and autoimmune disease, and led the design of next-generation <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> CAR T cells for solid tumors. Earlier at Cougar Biotechnology and Janssen, he was the lead
clinician for a pivotal prostate cancer study leading to market approval for Zytiga<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (abiraterone acetate). At Amgen, he led early development studies of the anti-insulin like growth factor
type 1 receptor AMG 479 (ganitumab) antibody. Dr.&nbsp;Haqq has worked closely with the US Food and Drug Administration, or the FDA, and other global regulatory agencies. He has filed successful applications for INDs, breakthrough therapies,
priority medicines, special protocol assessments and their international equivalents, and marketing approvals. Dr.&nbsp;Haqq initially practiced as a medical oncologist and led a translational science laboratory as an Assistant Professor in the
Division of Hematology/Oncology at the University of California, San Francisco following his post-graduate training as an Intern and Resident in Internal Medicine, Fellow in Medical Oncology and Fellow in Molecular Medicine. Dr.&nbsp;Haqq completed
his MD and PhD in Genetics at Harvard Medical School and his undergraduate training at Stanford University and the University of British Columbia. We believe that Dr.&nbsp;Haqq&#146;s leadership roles in drug development across a broad spectrum of
biotechnology companies over the last two decades qualifies Dr.&nbsp;Haqq to serve on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Jennifer Jarrett</B>
serves on our Board of Directors. Ms.&nbsp;Jarrett currently serves as Chief Operating Officer at Arcus Biosciences, Inc. (NYSE: RCUS) where she is responsible for Arcus&#146;s commercial and general and administrative organizations, including
finance and human resources. Ms.&nbsp;Jarrett previously served as the Vice President of Corporate Development and Capital Markets at Uber Technologies, Inc. (NYSE: UBER) from January&nbsp;2019 to September&nbsp;2020. Prior to Uber, Ms.&nbsp;Jarrett
served as the Chief Financial Officer and Chief Operating Officer of Arcus Biosciences, Inc. from March&nbsp;2017 to January&nbsp;2019. From March&nbsp;2016 to October&nbsp;2016, Ms.&nbsp;Jarrett served as the Chief Financial Officer of Medivation,
Inc. until it was acquired by Pfizer Inc. (NYSE: PFE). Ms.&nbsp;Jarrett brings over 20&nbsp;years of experience in biotechnology investment banking, including her experience as managing director and head of West Coast Life Sciences Investment
Banking at Citigroup and managing director and head of U.S. Biotechnology Investment Banking at Credit Suisse. Ms.&nbsp;Jarrett currently serves on the board of directors of Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), Syndax Pharmaceuticals, Inc.
(Nasdaq: SNDX) and Arcus Biosciences. Ms.&nbsp;Jarrett is a graduate of Dartmouth College, where she received her BA in economics, and Stanford University, where she received her MBA. We believe that Ms.&nbsp;Jarrett is qualified
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
to serve on our board of directors given her experience in the biotechnology sector and her investment and management skills. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_146"></A>Number and Terms of Office of Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors is divided into three classes (Class I, II and III) with Class&nbsp;I consisting of four directors and Class&nbsp;II and
III consisting of three director. Only one class of directors will be elected in each year, and each class (except for those directors appointed prior to our first annual general meeting of shareholders) will serve a three-year term. The term of
office of the first class of directors, consisting of Christopher Haqq, will expire at our first general annual meeting of shareholders. The term of office of the second class of directors, consisting of Jennifer Jarrett and Donald J. Santel, will
expire at our second annual general meeting of shareholders. The term of office of the third class of directors, consisting of Benny Soffer and Mitchell Blutt, will expire at our third annual general meeting of shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to the completion of an initial business combination, any vacancy on the board of directors may be filled by a nominee chosen by holders
of a majority of our Class&nbsp;B ordinary shares. In addition, prior to the completion of an initial business combination, holders of a majority of our Class&nbsp;B ordinary shares may remove a member of the board of directors for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Sponsor is entitled to nominate three individuals for election to our board of directors, as long as the Sponsor holds any securities
covered by the registration and shareholder rights agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our officers are appointed by the board of directors and serve at the
discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in the Existing Governing Documents as it deems appropriate. The Existing Governing
Documents provide that our officers may consist of one or more chairman of the board, chief executive officer, chief financial officer, chief business officer, president, vice presidents, secretary, treasurer and such other offices as may be
determined by the board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_147"></A>Committees of the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors has three standing committees: an audit committee, a nominating and corporate governance committee and a compensation
committee. Each committee operates under a charter that has been approved by our board and has the composition and responsibilities described below. The charter of each committee is available on our website. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have established an audit committee of the board of directors. Christopher Haqq, Jennifer Jarrett and Donald J. Santel serve as members of
our audit committee. Our board of directors has determined that each of Christopher Haqq, Jennifer Jarrett and Donald J. Santel serve are independent. Jennifer Jarrett serves as the Chairperson of the audit committee. Each member of the audit
committee meets the financial literacy requirements of NYSE American and our board of directors has determined that qualifies as an &#147;audit committee financial expert&#148; as defined in applicable SEC rules and has accounting or related
financial management expertise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The audit committee is responsible for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">meeting with our independent registered public accounting firm regarding, among other issues, audits, and
adequacy of our accounting and control systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring the independence of the independent registered public accounting firm; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit
and the audit partner responsible for reviewing the audit as required by law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inquiring and discussing with management our compliance with applicable laws and regulations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> all audit services and permitted <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by our independent registered public accounting firm, including the fees and terms of the services to be performed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing or replacing the independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining the compensation and oversight of the work of the independent registered public accounting firm
(including resolution of disagreements between management and the independent auditor regarding financial reporting) for the purpose of preparing or issuing an audit report or related work; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for the receipt, retention and treatment of complaints received by us regarding
accounting, internal accounting controls or reports which raise material issues regarding our financial statements or accounting policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring compliance on a quarterly basis with the terms of our initial public offering and, if any
noncompliance is identified, immediately taking all action necessary to rectify such noncompliance or otherwise causing compliance with the terms of our initial public offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving all payments made to our existing shareholders, executive officers or directors and
their respective affiliates. Any payments made to members of our audit committee will be reviewed and approved by our board of directors, with the interested director or directors abstaining from such review and approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We established a nominating and corporate governance committee of our board of directors. he members of our nominating and corporate governance
committee are Christopher Haqq, Jennifer Jarrett and Donald J. Santel. Donald J. Santel serves as chairperson of the nominating and corporate governance committee. Our board of directors has determined that each of Christopher Haqq, Jennifer Jarrett
and Donald J. Santel are independent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The nominating committee is responsible for overseeing the selection of persons to be nominated to
serve on our board of directors. The nominating committee considers persons identified by its members, management, shareholders, investment bankers and others. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Guidelines for Selecting Director Nominees </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The guidelines for selecting nominees, which are specified in a charter adopted by us, generally provide that persons to be nominated: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">should have demonstrated notable or significant achievements in business, education or public service;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">should possess the requisite intelligence, education and experience to make a significant contribution to the
board of directors and bring a range of skills, diverse perspectives and backgrounds to its deliberations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">should have the highest ethical standards, a strong sense of professionalism and intense dedication to serving
the interests of the shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The nominating and corporate governance committee considers a number of
qualifications relating to management and leadership experience, background and integrity and professionalism in evaluating a person&#146;s candidacy for membership on the board of directors. The nominating committee may require certain skills or
attributes, such as financial or accounting experience, to meet specific board needs that arise from time to time </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and will also consider the overall experience and makeup of its members to obtain a broad and diverse mix of board members. The nominating and corporate governance committee does not distinguish
among nominees recommended by shareholders and other persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We established a compensation committee of our board of directors. The members of our compensation committee are Christopher Haqq, Jennifer
Jarrett and Donald J. Santel, and Christopher Haqq serves as chairperson of the compensation committee. Our board of directors has determined that each of Christopher Haqq, Jennifer Jarrett and Donald J. Santel are independent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have adopted a compensation committee charter, which details the principal functions of the compensation committee, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive
Officer&#146;s compensation, evaluating our Chief Executive Officer&#146;s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the compensation of all of our other Section&nbsp;16 executive officers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our executive compensation policies and plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implementing and administering our incentive compensation equity-based remuneration plans;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assisting management in complying with our proxy statement and annual report disclosure requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving all special perquisites, special cash payments and other special compensation and benefit
arrangements for our executive officers and employees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">producing a report on executive compensation to be included in our annual proxy statement; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors. The charter
also provides that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of
the work of any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider the independence of each such adviser, including the
factors required by Nasdaq and the SEC. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Compensation Committee Interlocks and Insider Participation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None of our executive officers currently serves, and in the past year has not served, as a member of the compensation committee of any entity
that has one or more executive officers serving on our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_148"></A>Code of Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have adopted a Code of Ethics applicable to our directors, officers and employees. A copy of the Code of Ethics will be provided without
charge upon request from us. We intend to disclose any amendments to or waivers of certain provisions of our Code of Ethics in a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_149"></A>Section&nbsp;16(a) Beneficial Ownership Reporting Compliance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;16(a) of the Exchange Act requires our officers, directors and persons who beneficially own more than ten percent of our ordinary
shares to file reports of ownership and changes in ownership with the SEC. These reporting persons are also required to furnish us with copies of all Section&nbsp;16(a) forms they file. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_150"></A>Conflicts of Interest </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under Cayman Islands law, directors and officers owe the following fiduciary duties: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">duty to act in good faith in what the director or officer believes to be in the best interests of the company
as a whole; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">duty to exercise powers for the purposes for which those powers were conferred and not for a collateral
purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directors should not improperly fetter the exercise of future discretion; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">duty to exercise powers fairly as between different sections of shareholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">duty not to put themselves in a position in which there is a conflict between their duty to the company and
their personal interests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">duty to exercise independent judgment. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the above, directors also owe a duty of care which is not fiduciary in nature. This duty has been defined as a requirement to
act as a reasonably diligent person having both the general knowledge, skill and experience that may reasonably be expected of a person carrying out the same functions as are carried out by that director in relation to the company and the general
knowledge skill and experience of that director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As set out above, directors have a duty not to put themselves in a position of conflict
and this includes a duty not to engage in self-dealing, or to otherwise benefit as a result of their position. However, in some instances what would otherwise be a breach of this duty can be forgiven and/or authorized in advance by the shareholders
provided that there is full disclosure by the directors. This can be done by way of permission granted in the amended and restated memorandum and articles of association or alternatively by shareholder approval at general meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each of our officers and directors presently has, and any of them in the future may have additional, fiduciary or contractual obligations to
another entity, including private funds under the management of Consonance Capital and their respective portfolio companies, pursuant to which such officer or director is or will be required to present a business combination opportunity to such
entity. In addition, existing and future funds managed by Consonance Capital and their respective portfolio companies may compete with us for business combination opportunities and, if such opportunities are pursued by such entities, we may be
precluded from pursuing such opportunities. Accordingly, if any of our officers or directors becomes aware of a business combination opportunity which is suitable for an entity to which he or she has then-current fiduciary or contractual
obligations, he or she will honor his or her fiduciary or contractual obligations to present such business combination opportunity to such entity, and may only decide to present it to us if such entity rejects the opportunity and consummating the
same would not violate any restrictive covenants to which such officers and directors are subject. Notwithstanding the foregoing, we may pursue a business combination opportunity jointly with our Sponsor, Consonance Life Sciences, or one or more
affiliates of and/or investors in Consonance Capital with an entity to which an officer or director has a fiduciary or contractual obligation. Any such entity may <FONT STYLE="white-space:nowrap">co-invest</FONT> with us in the target business at
the time of our initial business combination, or we could raise additional proceeds to complete the acquisition by issuing to such entity a class of equity or equity-linked securities. The Existing Governing Documents provide that we renounce our
interest in any corporate opportunity offered to any director or officer unless such opportunity is expressly offered to such person solely in his or her capacity as a director or officer of the company and such opportunity is one we are legally and
contractually permitted to undertake and would otherwise be reasonable for us to pursue, and to the extent the director or officer is permitted to refer that opportunity to us without violating another legal obligation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">242 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Below is a table summarizing the entities to which our executive officers and directors
currently have fiduciary duties, contractual obligations or other material management relationships: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>INDIVIDUAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>ENTITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>ENTITY&#146;S BUSINESS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>AFFILIATION</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mitchell Blutt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consonance Capital Management LP and Consonance Capital Partners, L.P.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Investment manager to hedge funds and managed accounts and investment manager to private equity funds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer, Chairman of the Investment Committee and Partner of Consonance Capital Management LP and Managing Partner and <FONT STYLE="white-space:nowrap">Co-Founder</FONT> of Consonance Capital Partners</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benny Soffer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consonance Capital Management LP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Investment manager to hedge funds and managed accounts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Investment Officer, Portfolio Manager, Member of the Investment Committee and Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin Livingston</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consonance Capital Management LP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Investment manager to hedge funds and managed accounts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Member of the Investment Committee and Partner</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Potential investors should also be aware of the following other potential conflicts of interest: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our executive officers and directors are not required to, and will not, commit their full time to our affairs,
which may result in a conflict of interest in allocating their time between our operations and our search for a business combination and their other businesses. We do not intend to have any fulltime employees prior to the completion of our initial
business combination. Each of our executive officers is engaged in several other business endeavors for which he may be entitled to substantial compensation, and our executive officers are not obligated to contribute any specific number of hours per
week to our affairs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Sponsor subscribed for founder shares prior to the date of our initial public offering and purchased
private placement warrants in a transaction that closed simultaneously with the closing of the initial public offering. Our Sponsor and our founding team have entered into an agreement with us, pursuant to which they have agreed to waive their
redemption rights with respect to their founder shares and any public shares purchased during or after our initial public offering in connection with (i)&nbsp;the completion of our initial business combination and (ii)&nbsp;a shareholder vote to
approve an amendment to our amended and restated memorandum and articles of association (A)&nbsp;that would modify the substance or timing of our obligation to provide holders of our Class&nbsp;A ordinary shares the right to have their shares
redeemed in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within 24&nbsp;months from the closing of our initial public offering or (B)&nbsp;with respect
to any other provision relating to the rights of holders of our Class&nbsp;A ordinary shares or <FONT STYLE="white-space:nowrap">pre-initial</FONT> business combination activity. Additionally, our Sponsor agreed to waive its rights to liquidating
distributions from the trust account with respect to its founder shares if we fail to complete our initial business combination within the required time period. If we do not complete our initial business combination within the required time period,
the private placement warrants and the underlying securities will expire worthless. Except as described herein, our Sponsor and our founding team have agreed not to transfer, assign or sell any of their founder shares until the earliest of
(A)&nbsp;one year after the completion of our initial business combination and (B)&nbsp;subsequent to our initial business combination, (x)&nbsp;if the closing price of our Class&nbsp;A ordinary shares equals or exceeds $12.00 per share
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">243 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
(as adjusted for share <FONT STYLE="white-space:nowrap">sub-divisions,</FONT> share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any <FONT
STYLE="white-space:nowrap">30-trading</FONT> day period commencing at least 150&nbsp;days after our initial business combination, or (y)&nbsp;the date on which we complete a liquidation, merger, share exchange, reorganization or other similar
transaction that results in all of our public shareholders having the right to exchange their ordinary shares for cash, securities or other property. With certain limited exceptions, private placement warrants and the Class&nbsp;A ordinary shares
underlying such warrants, are not transferable until 30&nbsp;days following the completion of our initial business combination. Because each of our executive officers and certain of our directors will own ordinary shares or warrants directly or
indirectly, they may have a conflict of interest in determining whether a particular partner business is an appropriate business with which to effectuate our initial business combination. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our officers and directors may have a conflict of interest with respect to evaluating a particular business
combination if the retention or resignation of any such officers and directors was included by a partner business as a condition to any agreement with respect to our initial business combination. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are not prohibited from pursuing an initial business combination or subsequent transaction with a company that is affiliated with our
Sponsor, founders, officers or directors. In the event we seek to complete our initial business combination with a company that is affiliated with our Sponsor or any of our founders, officers or directors, we, or a committee of independent
directors, will obtain an opinion from an independent investment banking firm which is a member of FINRA or an independent valuation or accounting firm that such initial business combination or transaction is fair to our company from a financial
point of view. We are not required to obtain such an opinion in any other context. Furthermore, in no event will our Sponsor or any of our existing officers or directors, or any of their respective affiliates, be paid by us any finder&#146;s fee,
consulting fee or other compensation prior to, or for any services they render in order to effectuate, the completion of our initial business combination. We also reimburse our Sponsor for office space, secretarial and administrative services
provided to us in the amount of $55,000 per month. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot assure you that any of the above mentioned conflicts will be resolved in our
favor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_151"></A>Limitation on Liability and Indemnification of Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cayman Islands law does not limit the extent to which a company&#146;s memorandum and articles of association may provide for indemnification
of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against willful default, willful neglect, civil fraud or the consequences
of committing a crime. The Existing Governing Documents provide for indemnification of our officers and directors to the maximum extent permitted by law, including for any liability incurred in their capacities as such, except through their own
actual fraud, willful default or willful neglect. We will enter into agreements with our directors and officers to provide contractual indemnification in addition to the indemnification provided for in the Existing Governing Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We purchased a policy of directors&#146; and officers&#146; liability insurance that insures our officers and directors against the cost of
defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our officers and directors have agreed to waive any right, title, interest or claim of any kind in or to any monies in the trust account, and
have agreed to waive any right, title, interest or claim of any kind they may have in the future as a result of, or arising out of, any services provided to us and will not seek recourse against the trust account for any reason whatsoever (except to
the extent they are entitled to funds from the trust account due to their ownership of public shares). Accordingly, any indemnification provided will only be able to be satisfied by us if (i)&nbsp;we have sufficient funds outside of the trust
account or (ii)&nbsp;we consummate an initial business combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">244 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our indemnification obligations may discourage shareholders from bringing a lawsuit against
our officers or directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against our officers and directors, even though such an action, if successful, might
otherwise benefit us and our shareholders. Furthermore, a shareholder&#146;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against our officers and directors pursuant to these indemnification
provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that these provisions, the insurance and the indemnity agreements are necessary to attract and retain talented and
experienced officers and directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_152"></A>Executive Compensation and Director Compensation and Other Interests
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On November&nbsp;18, 2020, our Sponsor transferred an aggregate of 90,000 founder shares to our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors. None of our executive officers or directors have received any cash compensation for services rendered to us. Since the consummation of our initial public offering and until the earlier
consummation of our initial business combination and our liquidation, we will reimburse our Sponsor for office space, secretarial and administrative services provided to us in the amount of $55,000 per month. In addition, our Sponsor, executive
officers and directors, or any of their respective affiliates are reimbursed for any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with activities on our behalf such as
identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee reviews on a quarterly basis all payments that were made by us to our Sponsor, executive officers or directors, or our or
their affiliates. Any such payments prior to an initial business combination will be made using funds held outside the trust account. Other than quarterly audit committee review of such reimbursements, we do not have any additional controls in place
governing our reimbursement payments to our directors and executive officers for their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with our activities on our behalf in
connection with identifying and consummating an initial business combination. Other than these payments and reimbursements, no compensation of any kind, including finder&#146;s and consulting fees, will be paid by the company to Sponsor, executive
officers and directors, or any of their respective affiliates, prior to completion of our initial business combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After the
completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting or management fees from New Surrozen. All of these fees will be fully disclosed to shareholders, to the extent then
known, in the proxy solicitation materials or tender offer materials furnished to our shareholders in connection with a proposed business combination. We have not established any limit on the amount of such fees that may be paid by New Surrozen to
our directors or members of management. It is unlikely the amount of such compensation will be known at the time of the proposed business combination, because the directors of the post-combination business will be responsible for determining
executive officer and director compensation. Any compensation to be paid to our executive officers will be determined, or recommended to the board of directors for determination, either by a compensation committee constituted solely by independent
directors or by a majority of the independent directors on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not intend to take any action to ensure that
members of our management team maintain their positions with us after the consummation of our initial business combination, although it is possible that some or all of our executive officers and directors may negotiate employment or consulting
arrangements to remain with us after our initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our management&#146;s motivation in identifying or
selecting a target business but we do not believe that the ability of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision to proceed with any potential business
combination. We are not party to any agreements with our executive officers and directors that provide for benefits upon termination of employment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">245 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_153"></A>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NYSE American rules require that a majority of our board of directors be independent. An &#147;independent director&#148; is defined generally
as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship with the company which in the opinion of the company&#146;s board of directors, could interfere with the director&#146;s
exercise of independent judgment in carrying out the responsibilities of a director. Our board of directors has determined that each of Christopher Haqq, Jennifer Jarrett and Donald J. Santel are &#147;independent directors&#148; as defined in NYSE
American listing standards and applicable SEC rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_154"></A>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On May 21, 2021, a purported CHFW shareholder filed a complaint in the Superior Court of New Jersey, Chancery Division, Mercer County, entitled
Rai v. Consonance-HFW Acquisition Corp., et al., MER-L-001095-21 (the &#147;Complaint&#148;). The Complaint names CHFW and members of the CHFW Board as defendants. The Complaint alleges breaches of fiduciary duties against members of the CHFW Board
and aiding and abetting the board of directors&#146; alleged breaches of fiduciary duties against CHFW. The Complaint also alleges that the registration statement of which this proxy statement/prospectus forms a part is materially deficient and
omits and/or misrepresents material information including, among other things, certain financial information, certain details regarding the engagement of J.P. Morgan and BofAS, and other information relating to the background of the Business
Combination. The Complaint generally seeks to enjoin the Business Combination or in the event that it is consummated, recover damages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Another purported CHFW shareholder sent a demand letter on June 2, 2021 (the &#147;Demand&#148;), making similar allegations as those made in
the Complaint and demanding additional disclosure regarding the Business Combination. CHFW believes that the claims asserted in the Complaint and Demand are without merit and intends to defend these against these claims; however, additional lawsuits
may be filed against CHFW, or the CHFW Board, and CHFW cannot predict with certainty the ultimate resolution of any proceedings that may be brought in connection with these allegations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_155"></A>Properties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently maintain our executive offices at 1 Palmer Square, Suite 305, Princeton, NJ 08540. The cost for our use of this space is included
in the $55,000 per month fee we will pay to our Sponsor for office space, administrative and support services. Upon consummation of the Business Combination, the principal executive offices of New Surrozen will be located at 171 Oyster Point Blvd.,
Suite 400, South San Francisco, CA 94080. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_156"></A>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we succeed in effecting the Business Combination with Surrozen, there will be, in all likelihood, significant competition from their
competitors. We cannot assure you that, subsequent to the Business Combination, we will have the resources or ability to compete effectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_157"></A>Periodic Reporting and Audited Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW has registered its securities under the Exchange Act and has reporting obligations, including the requirement to file annual and quarterly
reports with the SEC. In accordance with the requirements of the Exchange Act, CHFW&#146;s annual reports contain financial statements audited and reported on by CHFW&#146;s independent registered public accounting firm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are required to evaluate our internal control procedures as required by the Sarbanes-Oxley Act. Only in the event we are deemed to be a
large accelerated filer or an accelerated filer and no longer qualify as an emerging </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">246 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
growth company, will we be required to comply with the independent registered public accounting firm attestation requirement on our internal control over financial reporting. The fact that we are
a blank check company makes compliance with the requirements of the Sarbanes-Oxley Act particularly burdensome on us as compared to other public companies because a target business with which we seek to complete our initial business combination may
not be in compliance with the provisions of the Sarbanes-Oxley Act regarding adequacy of its internal controls. The development of the internal controls of any such entity to achieve compliance with the Sarbanes-Oxley Act may increase the time and
costs necessary to complete any such acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a Cayman Islands exempted company. Exempted companies are Cayman Islands
companies conducting business mainly outside the Cayman Islands and, as such, are exempted from complying with certain provisions of the Cayman Islands Companies Act. As an exempted company, we applied for and received a tax exemption undertaking
from the Cayman Islands government that, in accordance with Section&nbsp;6 of the Tax Concessions Act (2018 Revision) of the Cayman Islands, for a period of 20 years from the date of the undertaking, no law which is enacted in the Cayman Islands
imposing any tax to be levied on profits, income, gains or appreciations will apply to us or our operations and, in addition, that no tax to be levied on profits, income, gains or appreciations or which is in the nature of estate duty or inheritance
tax will be payable (i)&nbsp;on or in respect of our shares, debentures or other obligations or (ii)&nbsp;by way of the withholding in whole or in part of a payment of dividend or other distribution of income or capital by us to our shareholders or
a payment of principal or interest or other sums due under a debenture or other obligation of us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are an &#147;emerging growth
company,&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the JOBS Act. As such, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies
that are not &#147;emerging growth companies&#148; including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act reduced disclosure obligations regarding executive
compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation and shareholder approval of any golden parachute
payments not previously approved. If some investors find our securities less attractive as a result, there may be a less active trading market for our securities and the prices of our securities may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, Section&nbsp;107 of the JOBS Act also provides that an &#147;emerging growth company&#148; can take advantage of the extended
transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an &#147;emerging growth company&#148; can delay the adoption of certain accounting standards until
those standards would otherwise apply to private companies. We intend to take advantage of the benefits of this extended transition period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will remain an emerging growth company until the earlier of (i)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth
anniversary of the completion of our initial public offering, (b)&nbsp;in which we have total annual gross revenue of at least $1.0&nbsp;billion, or (c)&nbsp;in which we are deemed to be a large accelerated filer, which means the market value of our
Class&nbsp;A ordinary shares that are held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June 30th, and (ii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, we are a &#147;smaller reporting
company&#148; as defined in Item 10(f)(1) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of
audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i)&nbsp;the market value of our ordinary shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds
$250&nbsp;million as of the prior June&nbsp;30, or (ii)&nbsp;our annual revenues exceeded $100&nbsp;million during such completed fiscal year and the market value of our ordinary shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT>
exceeds $700&nbsp;million as of the prior June 30. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">247 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_158"></A>CHFW&#146;S MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Unless the context otherwise requires, all references in this section to the
&#147;Company,&#148; &#147;CHFW,&#148; &#147;we,&#148; &#147;us&#148; or &#147;our&#148; refer to CHFW prior to the consummation of the Business Combination. The following discussion and analysis of CHFW&#146;s financial condition and results of
operations should be read in conjunction with CHFW&#146;s consolidated financial statements and notes to those statements included in this proxy statement/prospectus. Certain information contained in the discussion and analysis set forth below
includes forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors. Please see &#147;Cautionary Note Regarding
Forward-Looking Statements&#148; and &#147;Risk Factors&#148; in this proxy statement/prospectus. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_159"></A>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a blank check company incorporated in the Cayman Islands on August&nbsp;21, 2020 as a Cayman Islands exempted company and formed for the
purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. We are an emerging growth company and, as such, we are subject to all of the risks
associated with emerging growth companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW&#146;s Sponsor is Consonance Life Sciences, a Cayman Islands limited liability company.
The registration statement for the initial public offering was declared effective on November&nbsp;18, 2020. On November&nbsp;23, 2020, CHFW consummated its initial public offering of 8,000,000 units at $10.00 per unit, generating gross proceeds of
$80&nbsp;million. Simultaneously with the closing of the initial public offering, CHFW consummated the private placement of 410,000 units at a price of $10.00 per private placement unit in a private placement to the Sponsor, generating gross
proceeds of approximately $4.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On December&nbsp;1, 2020, the underwriters fully exercised their over-allotment option,
resulting in an additional 1,200,000 units issued at $10.00 per unit, generating gross proceeds of $12.0&nbsp;million. In connection with the underwriters&#146; full exercise of their over-allotment option, the Company also consummated the sale of
an additional 24,000 private placement units at $10.00 per private placement unit, generating additional gross proceeds of approximately $0.2&nbsp;million. The total transaction costs of the initial public offering and the private placements
amounted to approximately $5.7&nbsp;million, inclusive of approximately $3.2&nbsp;million in deferred underwriting commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the
closing of initial public offering and the private placement, $92&nbsp;million (or $10.00 per unit) of the net proceeds of the initial public offering and certain of the proceeds of the private placement were placed in the trust account and was
invested only in U.S. &#147;government securities&#148; within the meaning set forth in Section&nbsp;2(a)(16) of the Investment Company Act, as amended (the &#147;<U>Investment Company Act</U>&#148;), with a maturity of 185 days or less, or in money
market funds meeting the conditions of paragraphs (d)(1), (d)(2), (d)(3) and (d)(4) of Rule <FONT STYLE="white-space:nowrap">2a-7</FONT> of the Investment Company Act, as determined by us, until the earlier of: (i)&nbsp;the completion of a business
combination and (ii)&nbsp;the distribution of the trust account as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW&#146;s management has broad discretion with
respect to the specific application of the net proceeds of the initial public offering and the sale of private placement units, although substantially all of the net proceeds are intended to be applied generally toward consummating a business
combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If CHFW is unable to complete an initial business combination within 24 months from the closing of the initial public
offering, or November&nbsp;23, 2022 (the &#147;Combination Period&#148;), CHFW will (i)&nbsp;cease all operations except for the purpose of winding up; (ii)&nbsp;as promptly as reasonably possible but not more than ten business days thereafter,
redeem the public shares, at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account and not
previously released to CHFW to pay for CHFW&#146;s income taxes, if any (less up to $100,000 of interest to pay dissolution </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">248 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
expenses), divided by the number of the then-outstanding public shares, which redemption will completely extinguish public shareholders&#146; rights as shareholders (including the right to
receive further liquidation distributions, if any); and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of CHFW&#146;s remaining shareholders and CHFW&#146;s board of directors, liquidate and
dissolve, subject in the case of clauses (ii)&nbsp;and (iii) to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions
with respect to CHFW&#146;s warrants, which will expire worthless if CHFW fails to consummate an initial business combination within the Combination Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2021, we had approximately $774,931.42 in cash held outside of the trust account, approximately $92&nbsp;million in
marketable securities held in the trust account and deferred offering costs of approximately $3.2&nbsp;
million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_160"></A>Proposed Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April&nbsp;15, 2021, CHFW entered into the Business Combination Agreement. In connection with the Business Combination, CHFW also entered
into the Subscription Agreements and the CHFW Shareholder Support Agreements and Shareholder Support Agreements, as further described in &#147;<I>Business Combination Proposal&#151;Related Agreements.</I>&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At the closing of the Business Combination, The Column Group III, L.P., The Column Group <FONT STYLE="white-space:nowrap">III-A,</FONT> L.P.,
The Regents of the University of California and Consonance Capital Management, LP,<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>and certain other individuals will enter into the Investor Rights Agreement with CHFW. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_161"></A>Results of Operations and Known Trends or Future Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW&#146;s entire activity since inception up to December&nbsp;31, 2020 was in preparation for its formation and the initial public offering.
CHFW will not be generating any operating revenues until the closing and completion of an initial business combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the period
from August&nbsp;21, 2020 (inception) through December&nbsp;31, 2020, we had a net loss of approximately $2,122,328, which consisted of operating costs of approximately $438,756 and an unrealized loss on marketable securities held in the trust
account of approximately $92&nbsp;
million, offset by interest earned on marketable securities held in the trust </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_162"></A>Liquidity and Capital
Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2020, CHFW had approximately $987,187 in its operating bank account, and working capital of
approximately $1,487,380&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW&#146;s liquidity needs to date have been satisfied through a contribution of $25,000 from the
Sponsor to cover for certain offering costs in exchange for the issuance of the founder shares, the loan proceeds of $300,000 from the Sponsor pursuant to a promissory note, and the proceeds from the consummation of the private placement not held in
the trust account. On November&nbsp;23, 2020, CHFW repaid the outstanding balance on the note of $147,753 in full to the Sponsor. In addition, in order to finance transaction costs in connection with a business combination, the Sponsor or an
affiliate of the Sponsor, or certain of CHFW&#146;s officers and directors may, but are not obligated to, provide us the working capital loans. As of December&nbsp;31, 2020, there were no amounts outstanding under any working capital loan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on the foregoing, CHFW&#146;s management believes that CHFW will have sufficient working capital and borrowing capacity from the Sponsor
or an affiliate of the Sponsor, or certain of CHFW&#146;s officers and directors to meet its needs through the earlier of the consummation of a business combination or one year from this filing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">249 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Over this time period, CHFW will be using these funds for paying existing accounts payable, identifying and evaluating prospective initial business combination candidates, performing due
diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the business combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW&#146;s management continues to evaluate the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the industry and
has concluded that while it is reasonably possible that the virus could have a negative effect on CHFW&#146;s financial position, results of CHFW&#146;s operations and/or search for a target company, the specific impact is not readily determinable
as of the date of the financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_163"></A>Contractual Obligations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Administrative Support Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Commencing on the effective date of the registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> related to the initial
public offering through the earlier of consummation of the initial business combination and CHFW&#146;s liquidation, CHFW will reimburse the Sponsor for office space, secretarial and administrative services provided to us in the amount of $55,000
per month. CHFW incurred approximately $433,795 and $438,756 in general and administrative expenses in the accompanying unaudited condensed statements of operations for the three months ended December&nbsp;31, 2020 and for the period from
August&nbsp;21, 2020 (inception) through December&nbsp;31, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holders of Class&nbsp;B ordinary shares, private placement units, private placement shares, private placement warrants, Class&nbsp;A
ordinary shares underlying the private placement warrants and warrants that may be issued upon conversion of working capital loans (and any Class&nbsp;A ordinary shares issuable upon the exercise of the private placement warrants and warrants that
may be issued upon conversion of working capital loans), will be entitled to registration rights pursuant to a registration and shareholder rights agreement. The holders of these securities are entitled to make up to three demands, excluding short
form demands, that CHFW register such securities. In addition, the holders have certain &#147;piggy-back&#148; registration rights with respect to registration statements filed subsequent to CHFW&#146;s completion of its business combination.
However, the registration and shareholder rights agreement provides that CHFW will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable
<FONT STYLE="white-space:nowrap">lock-up</FONT> period, which occurs (i)&nbsp;in the case of the Class&nbsp;B ordinary shares, in accordance with the letter agreement CHFW&#146;s initial shareholders entered into and (ii)&nbsp;in the case of the
private placement warrants and the respective Class&nbsp;A ordinary shares underlying such warrants, 30 days after the completion of its business combination. CHFW will bear the expenses incurred in connection with the filing of any such
registration statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Underwriting Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW granted the underwriters in the initial public offering a <FONT STYLE="white-space:nowrap">45-day</FONT> option from the final prospectus
relating to the initial public offering to purchase up to 1,200,000 additional units to cover over-allotments, if any, at the initial public offering price less the underwriting discounts and commissions. On December&nbsp;1, 2020, the underwriters
in the initial public offering fully exercised their over-allotment option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters in the initial public offering were entitled
to an underwriting discount of $0.20 per unit, or approximately $1.8&nbsp;million in the aggregate, paid upon the closing of the initial public offering. In addition, $0.35 per unit, or approximately $3.2&nbsp;million in the aggregate will be
payable to the underwriters in the initial public offering for deferred underwriting commissions. The deferred fee will become payable to the underwriters in the initial public offering from the amounts held in the trust account solely in the event
that CHFW completes an initial business combination, subject to the terms of the underwriting agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">250 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_164"></A>Critical Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United
States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses
during the periods reported. Actual results could materially differ from those estimates. CHFW has identified the following critical accounting policies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Class&nbsp;A ordinary shares subject to possible redemption </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW accounts for its Class&nbsp;A ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards
Codification (&#147;ASC&#148;) Topic 480 &#147;<I>Distinguishing Liabilities from Equity</I>.&#148; Class&nbsp;A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value.
Conditionally redeemable Class&nbsp;A ordinary shares (including Class&nbsp;A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely
within CHFW&#146;s control) are classified as temporary equity. At all other times, Class&nbsp;A ordinary shares are classified as shareholders&#146; equity. CHFW&#146;s Class&nbsp;A ordinary shares feature certain redemption rights that are
considered to be outside of CHFW&#146;s control and subject to the occurrence of uncertain future events. Accordingly, at December&nbsp;31, 2020, 8,186,086 Class&nbsp;A ordinary shares subject to possible redemption are presented as temporary
equity, outside of the shareholders&#146; equity section of CHFW&#146;s balance sheet. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net income (loss) per ordinary share </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW applies the <FONT STYLE="white-space:nowrap">two-class</FONT> method in calculating earnings per share. Net income (loss) per ordinary
share, basic and diluted for Class&nbsp;A ordinary shares subject to possible redemption is calculated by dividing the interest income earned on the trust account, net of applicable taxes, if any, by the weighted average number of shares of
Class&nbsp;A ordinary shares subject to possible redemption outstanding for the period. Net income (loss) per ordinary share, basic and diluted for and <FONT STYLE="white-space:nowrap">non-redeemable</FONT> ordinary shares is calculated by dividing
net loss less income attributable to Class&nbsp;A ordinary shares subject to possible redemption, by the weighted average number of shares of <FONT STYLE="white-space:nowrap">non-redeemable</FONT> ordinary shares outstanding for the period
presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW has not considered the effect of the warrants underlying the units sold in the initial public offering (including the
consummation of the over-allotment) and the private placement warrants underlying the private placement units to purchase an aggregate of 3,619,334 Class&nbsp;A ordinary shares in the calculation of diluted income per share, because their inclusion
would be anti-dilutive under the treasury stock method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net loss per share, basic and diluted for Class&nbsp;A ordinary shares for three
months ended December&nbsp;31, 2020 and for the period from August&nbsp;21, 2020 (inception) through December&nbsp;31, 2020 are calculated by dividing the loss on marketable securities, dividends and interest held in trust account of approximately
$0 for each period by the weighted average number of Class&nbsp;A ordinary shares outstanding for the periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net loss per share, basic
and diluted for Class&nbsp;B ordinary shares for the three months ended December&nbsp;31, 2020 and for the period from August&nbsp;21, 2020 (inception) through June&nbsp;30, 2020 are calculated by dividing the net loss of approximately $($0.86),
less net loss attributable to Class&nbsp;A ordinary shares of approximately $2,223, resulted to a net loss of approximately $2,120,104, respectively, by the weighted average number of Class&nbsp;B ordinary shares outstanding for the periods. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recent Accounting Pronouncements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material
effect on the accompanying unaudited condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">251 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a blank check company incorporated in the Cayman Islands on August 21, 2020 formed for the purpose of effecting a merger, amalgamation,
share exchange, asset acquisition, share purchase, reorganization or other similar Business Combination with one or more businesses. We intend to effectuate our Business Combination using cash derived from the proceeds of the Initial Public Offering
and the sale of the Private Placement Units, our shares, debt or a combination of cash, shares and debt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect to continue to incur
significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete a Business Combination will be successful. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Recent Development </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Business
Combination Agreement and PIPE Financing </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April 15, 2021, the Company entered into a business combination agreement with Surrozen,
Inc. (&#147;Surrozen&#148;), pursuant to which a wholly-owned subsidiary of the Company will merge with and into Surrozen, with Surrozen surviving as a wholly-owned subsidiary of the Company and the Company will redomicile as a Delaware corporation.
In accordance with the terms and subject to the conditions of the Business Combination Agreement, each share and equity award (whether vested or unvested) of Surrozen outstanding as of closing will be exchanged for shares of the Company&#146;s
common stock or comparable equity awards that are settled or are exercisable for shares of the Company&#146;s common stock, as applicable, based on an implied Surrozen equity value of $200,000,000 and a $10.00 per share value of the Company&#146;s
Common Stock. In connection with the foregoing and concurrently with the execution of the Business Combination Agreement, the Company entered into Subscription Agreements with certain investors (the &#147;Subscription Agreements&#148; and such
investors, the &#147;PIPE Investors&#148;), pursuant to which the PIPE Investors have agreed to subscribe for and purchase, and the Company has agreed to issue and sell to the PIPE Investors, an aggregate of 12,020,000 units, each consisting of one
share of the Company&#146;s common stock and one-third of one redeemable warrant for one share of the Company&#146;s common stock (the &#147;PIPE Warrants&#148;), for a purchase price of $10.00 per unit (the &#147;PIPE Units&#148;), for aggregate
gross proceeds of $120,200,000 (the &#147;PIPE Financing&#148;). Each whole PIPE Warrant entitles the holder thereof to purchase one share of the Company&#146;s common stock at a price of $11.50 per share, subject to adjustment as described in the
form of warrant agreement attached to the form of Subscription Agreement, and only whole PIPE Warrants will be exercisable. The PIPE Warrants have substantially the same provisions as the public warrants issued in connection with the Company&#146;s
initial public offering. The securities to be issued pursuant to the Subscription Agreements have not been registered under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) in reliance upon the exemption provided in Section
4(a)(2) of the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have neither engaged in any operations nor generated any operating revenues to date. Our only activities from inception through March 31,
2021 were organizational activities and those necessary to prepare for the Initial Public Offering, described below. We do not expect to generate any operating revenues until after the completion of our initial Business Combination. We expect to
generate non-operating income in the form of interest income on marketable securities held after the Initial Public Offering. We expect that we will incur increased expenses as a result of being a public company (for legal, financial reporting,
accounting and auditing compliance), as well as for due diligence expenses in connection with searching for, and completing, a Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the three months ended March 31, 2021, we had a net loss of $232,964, which consists of operating and formation costs of $1,065,209,
offset by the change in fair value of warrant liability of $802,834, interest income of $23,112, and an unrealized gain on marketable securities held in our Trust Account of $6,299. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">252 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On November 23, 2020, we consummated the Initial Public Offering of 8,000,000 units, at a price of $10.00 per unit, generating gross proceeds
of $80,000,000. Simultaneously with the closing of the Initial Public Offering, we consummated the sale of 410,000 Private Placement units to the Sponsor at a price of $10.00 per private placement unit generating gross proceeds of $4,100,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, on December 1, 2020, the underwriters fully exercised their over-allotment option, resulting in an additional 1,200,000 units
issued for an aggregate amount of $12,000,000. In connection with the underwriters&#146; full exercise of their over-allotment option, the company also consummated the sale of an additional 24,000 private placement units at $10.00 per private
placement unit, generating total proceeds of $12,240,000. A total of $12,000,000 was deposited into the trust account, bringing the aggregate proceeds held in the trust account to $92,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the three months ended March 31, 2021, cash used in operating activities was $212,256. Net loss of $232,964 was affected by interest
earned on marketable securities held in the Trust Account of $23,112, the change in fair value of warrant liability of $802,834 and an unrealized gain on marketable securities held in our Trust Account of $6,299. Changes in operating assets and
liabilities provided $852,953 of cash for operating activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the Initial Public Offering, the sale of the Private Placement
Units, and the full exercise of the underwriter&#146;s over-allotment option, a total of $92,000,000 was placed in the Trust Account. We incurred $5,658,864 in transaction costs, including $1,840,000 of underwriting fees, $3,220,000 of deferred
underwriting fees and $598,864 of other costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At March 31, 2021, we had marketable securities held in the trust account of $92,026,912.
We intend to use substantially all of the funds held in the trust account, including any amounts representing interest earned on the trust account, which interest shall be net of taxes payable and excluding deferred underwriting commissions, to
complete our business combination. We may withdraw interest from the trust account to pay taxes, if any. To the extent that our share capital or debt is used, in whole or in part, as consideration to complete a business combination, the remaining
proceeds held in the trust account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At March 31, 2021, we had cash of $774,931. We intend to use the funds held outside the trust account primarily to identify and evaluate
target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and
material agreements of prospective target businesses, structure, negotiate and complete a business combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to fund working
capital deficiencies or finance transaction costs in connection with a Business Combination, our Sponsor or an affiliate of our Sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. If we
complete a Business Combination, we may repay such loaned amounts out of the proceeds of the Trust Account released to us. In the event that a Business Combination does not close, we may use a portion of the working capital held outside the Trust
Account to repay such loaned amounts, but no proceeds from our Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into Private Placement Units of the Post-Business Combination entity, at a price of
$10.00 per unit, at the option of the lender. The units would be identical to the Private Placement Units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not believe we will need
to raise additional funds in order to meet the expenditures required for operating our business. However, if our estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are
less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to our initial Business Combination. Moreover, we may need to obtain additional financing either to complete our Business
Combination or because we become obligated to redeem a significant number of our public shares upon completion of our Business Combination, in which case we may issue additional securities or incur debt in connection with such Business Combination.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">253 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_166"></A>Off-Balance Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of March 31, 2021. We do not
participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet
arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Contractual obligations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than an agreement to
pay the Sponsor a monthly fee of $55,000 for office space and administrative support services provided to the Company. We began incurring these fees on November 18, 2020 and will continue to incur these fees monthly until the earlier of the
completion of a Business Combination and the Company&#146;s liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters are entitled to a deferred fee of $0.35 per
Unit or $3,220,000. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that we complete a Business Combination, subject to the terms of the underwriting agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Critical Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preparation of condensed financial statements and related disclosures in conformity with accounting principles generally accepted in the
United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and
expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following critical accounting policies: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Warrant Liability </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We account for
warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#146;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#147;FASB&#148;) Accounting
Standards Codification (&#147;ASC&#148;) 480, Distinguishing Liabilities from Equity (&#147;ASC 480&#148;) and ASC 815, Derivatives and Hedging (&#147;ASC 815&#148;). The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own ordinary
shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are
outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be
recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the
date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Class A Ordinary Shares Subject to Redemption </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We apply the two-class method in calculating earnings per share. Net income (loss) per common share, basic and diluted for Class A ordinary
shares subject to possible redemption is calculated by dividing the interest income earned on the Trust Account, net of applicable taxes, if any, by the weighted average number of shares of Class A </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">254 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
ordinary shares subject to possible redemption outstanding for the period. Net income (loss) per ordinary share, basic and diluted for and non-redeemable common stock is calculated by dividing
net loss less income attributable to Class A ordinary shares subject to possible redemption, by the weighted average number of shares of non-redeemable ordinary shares outstanding for the period presented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net Loss Per Ordinary Share </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We apply the
two-class method in calculating earnings per share. Net loss per ordinary share, basic and diluted for Class A ordinary shares subject to possible redemption is calculated by dividing the interest income earned on the Trust Account, net of
applicable taxes, if any, by the weighted average number of shares of Class A ordinary shares subject to possible redemption outstanding for the period. Net loss per ordinary share, basic and diluted for and non-redeemable common stock is calculated
by dividing net loss less income attributable to Class A ordinary shares subject to possible redemption, by the weighted average number of shares of non-redeemable ordinary shares outstanding for the period presented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recent Accounting Standards </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Management
does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our condensed financial statements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2020, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) 2020-06, Debt
&#151; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#151; Contracts in Entity&#146;s Own Equity (Subtopic 815-40) (&#147;ASU 2020-06&#148;) to simplify accounting for certain financial instruments. ASU
2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts
in an entity&#146;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#146;s own equity. ASU 2020-06 amends the diluted earnings per
share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted
beginning on January 1, 2021. We are currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_168"></A>INFORMATION ABOUT SURROZEN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Unless the context otherwise requires, all references in this section to &#147;Surrozen,&#148; the &#147;Company,&#148; &#147;we,&#148;
&#147;us,&#148; &#147;our&#148; and other similar terms refer to the business of Surrozen, Inc. and its subsidiaries prior to the consummation of the Business Combination, which will be the business of New Surrozen and its subsidiaries following the
consummation of the Business Combination. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_169"></A>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen&#146;s mission is to transform the treatment of serious disease by fully exploiting the Wnt pathway. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen is discovering and developing biologic drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair,
in a broad range of organs and tissues. Building upon the seminal work of our founders and scientific advisors who discovered the Wnt gene and key regulators of the Wnt pathway, we have made breakthrough discoveries that we believe will overcome
previous limitations in harnessing the potential of Wnt biology. These breakthroughs enable us to rapidly and flexibly design tissue-targeted therapeutics that modulate Wnt signaling. As a result of our discoveries, we are pioneering the selective
activation of Wnt signaling, designing and engineering Wnt pathway mimetics, and advancing tissue-specific Wnt candidates. Our lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">255 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
occurring Wnt or <FONT STYLE="white-space:nowrap">R-spondin</FONT> proteins, both of which are involved in activation of the Wnt pathway. Given Wnt signaling is essential in tissue maintenance
and regeneration throughout the body, we have the potential to target a wide variety of severe diseases, including certain diseases that afflict the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas and central nervous system.
In each of these areas, we believe our approach has the potential to change the treatment paradigm for the disease and substantially impact patient outcomes. Our strategy is to exploit the full potential of Wnt signaling by identifying disease
states responsive to Wnt modulation, design tissue-specific therapeutics, and advance candidates into clinical development in targeted indications with high unmet need. Our unique approach and platform technologies have led to the discovery and
advancement of two lead product candidates. We are currently conducting preclinical studies and plan to initiate a Phase 1 clinical trial in 2022 for <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> our candidate in development for moderate to
severe inflammatory bowel disease, or IBD, with ulcerative colitis, or UC, as our first proposed indication. Furthermore, we plan to initiate a Phase 1 clinical trial in 2022 for <FONT STYLE="white-space:nowrap">SZN-043,</FONT> our candidate in
development for severe alcoholic hepatitis, or AH. We expect to nominate additional lead candidates and advance them into the clinic in 2023 and beyond. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_170"></A>Fundamental Importance of the Wnt Pathway and Our Founders&#146; Roles in Its Discovery </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Wnt pathway holds significant therapeutic promise in view of its ability to regulate stem cell renewal, proliferation and differentiation,
and its central role in tissue regeneration. Over the past 30 years our founders and advisors have helped establish the fundamental importance of the Wnt pathway in tissue regeneration. Each has been on the forefront of the Wnt signaling pathway
research, and their discoveries are the foundation of our approach to therapeutic development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Wnt proteins exert a wide variety of
effects on target cells during development. Fundamentally, Wnts are growth stimulatory factors that promote cell proliferation. Compared to other growth factors, two distinctive aspects of Wnt proteins are their lack of specificity and their ability
to give shape to growing tissues while inducing cells to proliferate, acting in the process as directional growth factors. Wnt signals can instruct new cells in such a way that organized body plans are generated. Moreover, Wnt proteins employ a
number of receptor isoforms and <FONT STYLE="white-space:nowrap">sub-families,</FONT> generating an array of combinatorial Wnt signaling critical for correctly shaping tissues during development, maintaining tissue architecture in adult life and
repairing tissue injury. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Roel Nusse and Dr.&nbsp;Harold Varmus discovered the first Wnt gene in 1982. Wnt signaling has now been
shown to be critical to many essential normal functions. Dr.&nbsp;Nusse is a founder of our company and Scientific Advisory Board member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_171"></A>Past Limitations in Targeting the Wnt Pathway for Drug Discovery </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although modulation of Wnt signaling has held significant promise for decades, a number of characteristics of Wnt signaling have created
obstacles to conventional protein therapeutic approaches. The key obstacles to drug development targeting the Wnt signaling pathway are described below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Potent Pathway Activation:</B> While the activity of naturally occurring Wnt pathway agonists is well established, previous
attempts to engineer synthetic Wnt and <FONT STYLE="white-space:nowrap">R-spondin</FONT> ligands have not resulted in selective, potent activation of Wnt signaling. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Selectivity:</B> Naturally occurring Wnt ligands are not selective in their interactions. The same lack of selectivity is
observed with naturally occurring <FONT STYLE="white-space:nowrap">R-spondin</FONT> ligands and their interactions with the cell surface receptors. Moreover, components of the Wnt signaling pathway, which can be targeted with small molecules, are
widely expressed and therefore cannot be selectively targeted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Manufacturing:</B> Wnt ligands are highly hydrophobic,
making them difficult to express, solubilize and purify and therefore difficult to manufacture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">256 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_172"></A>Our Wnt Therapeutics Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our Scientific Capabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that our breakthrough discoveries and technologies will enable us to overcome the challenges facing drug developers targeting the
Wnt pathway. We believe we are potentially the first developer to manufacture synthetic, soluble Wnt mimetics. To date, we have developed potent, selective and manufacturable Wnt and <FONT STYLE="white-space:nowrap">R-spondin</FONT> mimetics that
are designed to replicate the role of naturally occurring Wnt and <FONT STYLE="white-space:nowrap">R-spondin</FONT> proteins. In pursuit of our goal to develop a portfolio of Wnt product candidates that can repair tissue damage and regenerate
functional tissues for patients, we are continuing to expand our platform through the development of novel technologies and capabilities required to research, develop, manufacture and ultimately commercialize therapeutic products that address unmet
medical needs. Our core capabilities are described below: </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Wnt Biology Expertise:</B> We have established a deep
understanding of the Wnt pathway and its role in disease biology and have invested significantly in our people and technologies that enable us to selectively modulate Wnt signaling. Our research and development organization is led by world class
scientists. We have partnered with key thought leaders in the field, including those on our Scientific Advisory Board, and have developed significant expertise in various areas of biology relevant to the Wnt signaling pathway. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Proprietary Antibody Discovery and Research Technologies:</B> We have developed proprietary antibody discovery capabilities
that have led to the discovery of two initial antibody technologies that enable us to potently and selectively modulate the Wnt pathway. Our SWAP (Surrozen Wnt signal Activating Protein) technology enables the design and development of <FONT
STYLE="white-space:nowrap">Wnt-mimetics,</FONT> and our SWEETS (Surrozen Wnt signal Enhancers Engineered for Tissue Specificity) technology enables the design and development of <FONT STYLE="white-space:nowrap">R-spondin</FONT> mimetics.
Importantly, our approach provides a flexible and robust platform that has generated multiple antibodies that possess either tissue or cell selectivity based on preclinical studies. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Additional Novel Wnt Modulating Technologies:</B> We have developed and filed patent applications for additional Wnt
modulating antibody technologies, and are committed to continuously integrating new insights, tools, technologies and capabilities to apply to additional diseases and areas. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Genetic Mapping of Wnt Signaling:</B> The role of Wnt signaling in disease and the differential expression of genes involved
in Wnt signaling have not been well characterized across many disease states. We isolate RNA for gene expression to identify potential deficiencies in Wnt signaling in specific diseases. Through our genetic mapping, we have increased our
understanding of Wnt biology in numerous diseases and Wnts&#146; involvement in diseases that had previously not been well-characterized. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Protein Science Capabilities:</B> We have invested in building capabilities in key areas of antibody discovery which
include: <I>in vitro</I> and <I>in vivo</I> binder discovery, antibody optimization including humanization, structural biology, cell line construction, upstream and downstream process development and purification, bioanalytical characterization,
developability assessments including stability and formulatability. These capabilities enable discovery of novel structures and sequences and optimization for pharmacokinetics, potency, selectivity, manufacturability and other drug-like properties.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our Scientific Approach </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By combining our Wnt biology expertise with our proprietary technologies and capabilities, we have been able to establish a broad array of
therapeutic opportunities. Our approach includes: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Identifying and characterizing areas where Wnt biology is critical to
tissue structure and function. To date, we have investigated the importance of Wnt signaling in over 20 different tissue types and have prioritized over 10 tissue types for further exploration, with a plan to continue to expand our efforts. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prioritizing disease opportunities where there is significant evidence based on our proprietary model systems and tool
compounds that Wnt activation could play a role in tissue repair in severe disease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Focusing efforts and investments in
diseases where the strength of our capabilities can potentially address key limitations of existing therapeutic approaches. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">257 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Seeking to limit or eliminate the potential oncogenic risk from Wnt
pathway activation through our selective activation in the target disease tissue, our focus on severe disease and limited treatment exposure, and mimicking a physiologic repair process that is self-limiting. In preclinical studies, we have observed
diseased tissue responses to Wnt signaling while we have observed little or no activity in healthy and non-targeted tissue, and there has been no significant evidence of hyperplasia or dysplasia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our Technologies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our two initial proprietary technologies, SWAP and SWEETS, enable us to potently and selectively modulate Wnt signaling through the generation
of Wnt and <FONT STYLE="white-space:nowrap">R-spondin</FONT> mimetics. Using these technologies, we design and develop antibodies that modulate Wnt signaling. Product candidates generated by these technologies have demonstrated the ability to repair
tissue damage in multiple preclinical models including colitis and liver injury. We have developed specific candidate molecules for each disease area that have been developed based on the associated tissue biology, the role of Wnt signaling in
disease versus normal tissue, and a functional assessment of our candidate molecules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our SWAP and SWEETS technologies focus on key
regulators of Wnt signaling, Wnt proteins and <FONT STYLE="white-space:nowrap">R-spondins.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Wnt Activation: SWAP
(Surrozen Wnt signal Activating Protein)</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our SWAP molecules are designed to mimic the activity of naturally occurring Wnt proteins.
They are bispecific full-length human (IgG) antibodies that, like Wnt proteins, directly activate the <FONT STYLE="white-space:nowrap">Wnt-signaling</FONT> pathway in target tissue by binding to two of its natural
<FONT STYLE="white-space:nowrap">co-receptors,</FONT> Fzd and Lrp. With our SWAP technology, we combine Fzd and Lrp antibody-binding domains into bispecific antibodies to selectively activate Wnt signaling. We have generated and validated a broad
library of SWAPs that have successfully activated <FONT STYLE="white-space:nowrap">Wnt-signaling</FONT> <I>in vivo</I>.&nbsp;Our initial product candidate, <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> utilizes our SWAP technology and is
designed to activate the Wnt pathway in injured tissue where certain Fzd receptors are expressed and the natural Wnt ligand is disturbed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Key characteristics of our SWAP technology include: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Potency:</B> Our Wnt mimetics are multivalent, designed to bind one or more Fzd receptors and one or more Lrp receptors. We
demonstrated that the ability to bind to one or more receptors leads to highly potent Wnt signal activation as compared to a protein that can only bind to one Lrp receptor and one Fzd receptor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Selectivity:</B> Our antibody-based proteins are capable of selective binding to individual Fzd and Lrp receptor isoforms
and selective isoform binding has the potential to confer tissue selectivity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Manufacturability:</B> Our antibody
platform is designed to produce molecules with properties suitable for manufacturing and to overcome the challenges of Wnt protein derivates. Unlike our antibodies, Wnt proteins are highly hydrophobic, making them difficult to express, solubilize
and purify. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Christopher Garcia, a Howard Hughes Medical Institute Investigator and one of our founders, enabled our SWAP
approach through the discovery of surrogate Wnt agonists. His surrogate ligands were water soluble, consisted of two domains and provided the building blocks for our SWAP technology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">258 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subsequent discoveries made at Surrozen improved on the potency and selectivity of the
surrogate ligands discovered by Dr.&nbsp;Garcia. Our technology allows for targeting of Fzd and Lrp receptors, and we believe we can identify an optimized ratio of Fzds and Lrps required to activate Wnt signaling. We have also discovered that
binding two different Fzds together with Lrp leads to efficient Wnt signal activation. Figure 1 below compares natural Wnt signaling to how our SWAP product candidates engage receptors on the cell surface to trigger Wnt signal activation. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g21m31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 1. Like endogenous Wnt (left side), our SWAP technology activates Wnt signaling
by binding specific Fzd and Lrp receptors (right side) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Wnt Amplification: SWEETS (Surrozen Wnt signal Enhancer Engineered for
Tissue Specificity) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our SWEETS molecules are designed to amplify the body&#146;s response to naturally occurring Wnt proteins. They
are antibody-based molecules that, like <FONT STYLE="white-space:nowrap">R-spondin,</FONT> enhance Wnt signaling by stabilizing Fzd receptors. Our SWEETS molecules are designed to modify the specificity of
<FONT STYLE="white-space:nowrap">R-spondin</FONT> activity such that it can be directed to a cell surface antigen of our choosing. Our SWEETS molecules consist of a full-length antibody fusion protein in which an antibody-binding domain of one of
these antigens is combined with an <FONT STYLE="white-space:nowrap">R-spondin</FONT> derivative. <FONT STYLE="white-space:nowrap">SZN-043</FONT> is our initial product candidate to utilize our SWEETS technology and is designed to selectively amplify
the Wnt pathway in hepatocytes, the most abundant type of liver cell. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">R-spondin</FONT> may be
beneficial in adult tissue repair, particularly in situations where naturally occurring Wnt ligands are present but signaling is insufficient to repair tissue damage. One major challenge facing drug developers targeting the Wnt pathway in harnessing
<FONT STYLE="white-space:nowrap">R-spondin-based</FONT> Wnt amplification has been limiting <FONT STYLE="white-space:nowrap">R-spondin&#146;s</FONT> effects to a specific tissue of interest, which we believe we have overcome through: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Reducing <FONT STYLE="white-space:nowrap">non-specific</FONT> binding.</B> Naturally occurring <FONT
STYLE="white-space:nowrap">R-spondins</FONT> are dependent on E3 ligases and leucine-rich repeat-containing <FONT STYLE="white-space:nowrap">G-protein</FONT> coupled receptors, or LGRs, for activity. LGRs are widely expressed and result in <FONT
STYLE="white-space:nowrap">R-spondins</FONT> activating Wnt signaling in a broad variety of tissues. Based on preclinical studies, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">259 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
have been able to eliminate the requirement for LGR binding through substitution of binding to different cell surface receptors; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Targeting specific cell types.</B> We have designed multiple antibodies targeted to several cell surface receptors. Based on
preclinical studies, these antibodies have demonstrated specificity to multiple tissues and cell lineages. The engineered antibodies specifically upregulated <FONT STYLE="white-space:nowrap">Wnt-signaling</FONT> with greater tissue specificity than <FONT
STYLE="white-space:nowrap">non-targeted</FONT> controls and stimulated proliferation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Figure 2 below illustrates the effect of Fzd (and
Lrp) stabilization on promoting Wnt signaling. On the left side of the image, unbound E3 ligases induce internalization and ubiquitination of Fzd receptors, leading to disruption of Wnt signaling. With our SWEETS technology, we have demonstrated
tissue-targeted binding and sequestration of E3 ligases leading to the stabilization of Fzd and Lrp and promotion of Wnt signaling. With our SWEETS technology, we have been able to affect tissue-targeted binding and inhibition of E3 ligase promoted
degradation of Fzd, leading to the promotion of Wnt signaling. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g03t65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 2. Our SWEETS technology leads to amplification of the Wnt signaling pathway by inhibition of Fzd
degradation by the E3 ligase/proteasome pathway. Specificity of SWEETS binding is driven by an antigen-binding domain that can be targeted to specific cell surface protein </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_173"></A>Our Product Candidates and Research Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that both our SWAP and SWEETS technologies have the potential to generate a portfolio of product candidates that can harness the
tissue repair activity of the Wnt pathway for a broad spectrum of severe diseases. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The chart below represents a summary of our wholly-owned product candidates: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g66m96.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 3. Lead programs <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> a SWAP in development for the
treatment of moderate to severe IBD, and <FONT STYLE="white-space:nowrap">SZN-043,</FONT> a SWEETS in development for the treatment of severe AH. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">260 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our first product candidate, <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> is being
developed as a novel treatment for moderate to severe IBD, with UC as our first proposed indication, and utilizes our proprietary SWAP technology to activate Wnt signaling. Wnt signaling plays a critical role in intestinal epithelial turnover and
normal function. Abnormal signaling has been observed in patients with IBD and restoration of normal signaling is believed to play a role in the repair of damaged intestinal epithelial cells in IBD. <FONT STYLE="white-space:nowrap">SZN-1326</FONT>
targets Fzd 5, Fzd 8 and Lrp 6 to activate Wnt signaling. We have observed that Fzd 5, Fzd 8 and Lrp 6 are expressed in the large bowel epithelium of UC tissue samples and that Fzd 5 is the most abundant, representing an attractive target for our
therapeutic approach. IBD affects an estimated two million patients in the United States and is caused by damage to the intestinal barrier and an enhanced inflammatory response, which further exacerbates tissue damage.
<FONT STYLE="white-space:nowrap">SZN-1326</FONT> is designed to activate <FONT STYLE="white-space:nowrap">Wnt-pathway</FONT> signaling in intestinal epithelial cells. In multiple mouse models of IBD<I>,</I>
<FONT STYLE="white-space:nowrap">SZN-1326</FONT> stimulated intestinal epithelial regeneration, characterized by restoration of the intestinal barrier and reduced histology severity score, lower levels of inflammatory cytokines and reduced disease
activity. We anticipate initiating a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">SZN-1326</FONT> in healthy volunteers in 2022, followed by a Phase 1b trial of <FONT STYLE="white-space:nowrap">SZN-1326</FONT> in patients with UC, a
type of IBD, in 2023. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our second product candidate, <FONT STYLE="white-space:nowrap">SZN-043,</FONT> is being developed as a novel
treatment for severe liver diseases, including severe AH, and utilizes our proprietary SWEETS technology. Severe AH is a disease with a <FONT STYLE="white-space:nowrap">90-day</FONT> mortality rate of 30% and has an estimated incidence of 100,000
patients in the United States annually. In severe AH, damage to hepatocytes due to excessive alcohol use leads to jaundice, inflammation, impaired blood coagulation and increased risk of infections that may impact other organs such as the kidneys,
brain and gastrointestinal system. We have designed <FONT STYLE="white-space:nowrap">SZN-043</FONT> to modulate naturally occurring Wnt signaling that is specifically targeted to hepatocytes. We have shown in preclinical models of liver injury that <FONT
STYLE="white-space:nowrap">SZN-043</FONT> selectively and transiently stimulates hepatocyte proliferation and maturation, and restores liver function as measured by plasma ammonia and liver enzyme tests. The selectivity of <FONT
STYLE="white-space:nowrap">SZN-043</FONT> is achieved through the inclusion of an antibody binding to ASGR1 that is solely expressed on hepatocytes. We anticipate initiating a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">SZN-043</FONT>
in healthy volunteers and in patients with impaired liver function in 2022, followed by a Phase 1b trial of SZN-043 in patients with severe AH in 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">261 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our Research Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By leveraging our scientific capabilities and approach, we have identified more than 20 potential tissue types to explore. In our most advanced
research programs, we are developing potential therapeutics for ocular diseases such as <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, or AMD, and diabetic retinopathy. Genetic studies in the literature have identified
that the Wnt signaling pathway is critical for maintenance of healthy retinal blood vessels. We have shown that activation of <FONT STYLE="white-space:nowrap">Wnt-pathway</FONT> signaling can potentially reverse vascular damage through a mechanism
that is distinct from the mechanisms of currently approved therapeutics that target angiogenesis. We also have identified the potential for regeneration of retinal pigment epithelium, or RPE, an important cell type in the retina. RPE cells are
required for maintenance and viability of photoreceptors and as such are a potential target for the treatment of dry AMD. We are also assessing the potential to drive tissue repair in conditions such as hearing loss and diseases resulting in tissue
injury to organs including the cornea, lacrimal gland, lung and kidney. The chart below represents a summary of our research programs: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g40h04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 4. Our current Research Programs </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_174"></A>Our People </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our people are the most important strength of our company. We have assembled a diverse group of experienced executives, scientists, engineers
and operators that consist of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Experienced Company Builders.</B> Craig Parker, our President and Chief Executive Officer, has extensive
experience in the science and business of building companies in the biotechnology industry. He was previously Senior Vice President of Corporate Development at Jazz Pharmaceuticals and held similar executive positions at Geron Corporation, Human
Genome Sciences (acquired by GSK), Proteolix (acquired by Onyx) and Immunex (acquired by Amgen). He is a member of the Scientific Advisory Board of the Life Sciences Institute at the University of Michigan and previously served as a director of
Xcyte Therapies and vTv Therapeutics. Our Chief Financial Officer, Charles Williams, has extensive experience at multiple public companies across various leadership positions in strategy, operations, finance and corporate development, and was
previously at Jazz Pharmaceuticals and CV Therapeutics (acquired by Gilead). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Accomplished Scientific Leadership.</B> Our team consists of discovery scientists along with a team of drug
developers experienced in advancing drug product candidates through the drug development process. Our Chief Medical Officer, Trudy Vanhove, MD, PhD, was Vice President of Medical Affairs and, subsequently, Vice President Search and Evaluation at
Jazz Pharmaceuticals before joining Surrozen. Before joining Jazz, she led clinical development in different therapeutic areas at NeurogesX, XOMA and Abbott, resulting in several successful US and European Union, or EU,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">262 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
regulatory approval filings. Our Chief Scientific Officer, <FONT STYLE="white-space:nowrap">Wen-Chen</FONT> Yeh, MD, PhD, was previously at Amgen, where he led research teams in a variety of
disease indications including inflammation, diabetes, dyslipidemia and cardiovascular disease. At Amgen, Dr.&nbsp;Yeh helped advance multiple programs towards clinical trials. Our Senior Vice President of Biology, Yang Li, Ph.D., was previously at
Amgen, where he advanced multiple programs into the clinic in a variety of disease indications. Collectively, our scientific team are authors or <FONT STYLE="white-space:nowrap">co-authors</FONT> on over 200 scientific publications.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Founders and Scientific Advisory Board</B><B><I>.</I></B><B> </B>We are supported by our founders and
Scientific Advisory Board which includes world class researchers who have made seminal discoveries in Wnt biology and have successfully collaborated prior to their involvement with our company. Dr.&nbsp;Varmus, a member of our Scientific Advisory
Board, is a <FONT STYLE="white-space:nowrap">co-recipient</FONT> of the 1989 Nobel Prize in Physiology or Medicine for studies on the genetic basis of cancer. Dr.&nbsp;Nusse was recently awarded the 2017 Breakthrough Prize in Life Sciences and the
2020 Canada Gairdner International Award for Biomedical Research for his continued pioneering work on the Wnt signaling pathway. Our <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> Dr.&nbsp;Hans Clever, was awarded the 2013 Breakthrough Prize in
Life Sciences for his work describing the role of Wnt signaling in tissue stem cells and cancer. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Board of Directors and Investors with Shared Long-Term Vision</B><B><I>.</I></B> Our board of directors is
composed of renowned company builders, operators, leaders, scientists, drug developers and investors with experience across a diverse array of companies. This team is supported by investors who share our long-term vision around building the leading
company in Wnt biology, including The Column Group, a recognized leader in early-stage biotechnology venture investing. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_175"></A>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our strategy is to develop a portfolio of product candidates that can repair tissue damage and regenerate functional tissues for a variety of
diseases. Consistent throughout our strategy is our goal to activate Wnt signaling only within targeted diseased tissue, focusing on severe diseases, and mimicking the self-limiting physiologic repair process. We plan to achieve this goal by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Continuing to build on our pioneering research, insights and intellectual property in Wnt pathway
modulation.</I></B> Our scientific capabilities and approaches are built upon the groundbreaking work of our academic <FONT STYLE="white-space:nowrap">co-founders</FONT> and have been developed further by our experienced team. We consider ourselves
to be pioneers in the selective modulation of the Wnt signaling pathway and intend to utilize our proprietary insights into Wnt biology and our proprietary technologies to further advance our research and exploration of its therapeutic potential.
</P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Developing <FONT STYLE="white-space:nowrap">SZN-1326</FONT> for the treatment of moderate to severe
IBD</I></B>. We have shown that <FONT STYLE="white-space:nowrap">SZN-1326</FONT> leads to rapid repair of tissue damage and functional improvements in mouse models of IBD. We intend to initially develop
<FONT STYLE="white-space:nowrap">SZN-1326</FONT> in patients with UC and then expand into the treatment of other intestinal diseases including CD. We anticipate initiating a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">SZN-1326</FONT>
in 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Developing <FONT STYLE="white-space:nowrap">SZN-043</FONT> for the treatment of liver disease.</I></B>
We have shown that <FONT STYLE="white-space:nowrap">SZN-043</FONT> selectively stimulates hepatocyte proliferation and leads to improvement of liver function in multiple animal models of liver injury. We intend to develop <FONT
STYLE="white-space:nowrap">SZN-043</FONT> in patients with severe AH. We believe that the mechanism of <FONT STYLE="white-space:nowrap">SZN-043</FONT> has the potential to bring therapeutic benefit to patients with liver disease beyond our initial
indication of severe AH. We anticipate initiating a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">SZN-043</FONT> in healthy volunteers and in patients with severe impaired liver function in 2022. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Developing novel product candidates and expanding our platform technologies to further our leading
position in developing the Wnt signaling pathway modulators</I></B><B>. </B>Wnt signaling is critical in tissue regeneration throughout the body, including in intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas and central
nervous system. Our research suggests that SWAP and SWEETS will provide us with the opportunity to generate tissue-specific modulators of Wnt signaling. We have generated libraries of Wnt and <FONT STYLE="white-space:nowrap">R-spondin</FONT>
receptor binders that have helped us create a broad portfolio </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">263 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
of product candidates. We have developed and filed patent applications for additional Wnt modulating antibody technologies and are committed to continuously applying new insights, tools,
technologies and capabilities to additional diseases and areas and adding to our platform technologies and pipeline. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Pursuing strategic alliances to maximize the full potential of our pipeline.</I></B><B> </B>The
importance of the Wnt signaling pathway and the potential therapeutic applications of Wnt pathway mimetics are expected to provide us with an abundance of product candidates. We believe this generates an exciting opportunity to enter into strategic
alliances to accelerate product development and maximize commercial potential. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Wnt Signaling Pathway &#150; A
Central Regulator of Tissue Regeneration </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As gatekeepers for the maintenance of stem cells and functions, prior attempts at modulating
Wnt signaling in a tissue-specific manner were hampered by an absence of drug-like properties. Through our technologies, we can modulate Wnt signaling with antibodies, which could open the door for the development of a new classes of drugs with the
ability to repair and regenerate damaged tissues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Signaling through the Wnt pathway can stimulate cell proliferation as well as control
cell differentiation and movement. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Cell-to-cell</FONT></FONT> communication is needed during embryonic development and Wnt signaling is essential for development to proceed properly.
In both embryonic stem cells and pluripotent stem cells, the Wnt pathway has a dual role in both promoting the self-renewal properties of stem cells and driving the differentiation of stem cells that have been primed to differentiate. In adults, Wnt
has a critical role in promoting proliferation and stem cell renewal in multiple tissues. Maintenance of the intestinal surface or epithelium homeostasis, for example, is dependent on Wnt signaling. Wnt signaling is also important for bone
formation, retina development and function, liver regeneration and renewal of cells in the lung and pancreas among other tissues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
believe that several characteristics of the Wnt signaling pathway make this pathway attractive for drug development: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Broad potential for therapeutic intervention</I></B><I>. </I>Signaling through the Wnt pathway is
critical in cell fate determination in tissues throughout the body. Aberrant Wnt signaling underlies a broad range of pathologies in humans. In some cases, such as in certain rare bone diseases, mutations in the Wnt signaling pathway are the cause
of the disease. Mutations in Wnt signal pathway components are also associated with retina vessel disorders such as Norrie disease and familial exudative vitreoretinopathy, or FEVR, tooth development disorders, and metabolic diseases including
diabetes. Preclinical model studies have shown that Wnt signaling is instrumental for liver regeneration, intestine epithelium turnover and injury repair, and plays a role in maintaining residential stem cells in many more adult tissues including
lung, kidney, cochlea, skin and the central nervous system. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Common activation mechanism across Wnt proteins. </I></B>There are 19 Wnt protein genes in the human
genome and the genomes of other mammals. Most Wnt proteins bind interchangeably to the 10 different Fzd receptors with little discrimination. Genetic knockouts in mice have shown that individual Wnt protein genes have distinct functions. The
differences in biological functions likely arise from discrete localized expression and the relative insolubility of Wnt proteins which limits migration from the site of synthesis. On the other hand, when it comes to biochemical signaling, the
different Wnt proteins have very similar activities upon target cells. This, in turn, implies that the same therapeutic approach could be used to address multiple diseases. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Multiple modulators of activity. </I></B>Multiple modulators of the Wnt signaling pathway have been
identified that activate, amplify, dampen or inhibit the pathway&#146;s activity and limit the potential consequences of either over-activation or inhibition of Wnt signaling. These modulators can serve both as direct targets for therapeutic
intervention and as examples of how novel therapeutics could be developed that mimic their action. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The low solubility
of Wnt proteins due to the required fatty acid modification limits the ability of natural Wnt proteins themselves to be developed as therapeutic agents. The lack of solubility of Wnt proteins makes them
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
difficult to purify; difficult to formulate into an easily administered drug; and difficult to deliver to various tissues in the body. In contrast, we have developed technologies enabling us to
develop activators and amplifiers of Wnt signaling and which avoid the low solubility of natural Wnt proteins. These technologies trigger the Wnt pathway to act in a transient manner by mimicking the binding of Wnt proteins and other regulators of
the pathway. Our goal is to use our technologies to develop therapeutics that can modulate the naturally occurring Wnt response and promote healing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Our Wnt Therapeutics Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have discovered two proprietary technologies of modulators of Wnt signaling: SWAP and SWEETS. We have designed and continue to design
antibodies that modulate the Wnt signaling pathway by acting as mimetics of either Wnt protein or one of its regulators, <FONT STYLE="white-space:nowrap">R-spondin.</FONT> Product candidates generated by our technologies have demonstrated the
ability to repair tissue damage in multiple preclinical models including IBD and acute liver injury. We were able to select a specific candidate molecule and technology for each disease area based on tissue biology, profile of Wnt signaling in
disease versus normal, and functional test of molecules. We are advancing two of these candidates, <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043,</FONT> into clinical development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Wnt Activation: SWAP </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Wnt pathway is equipped with binding sites for two receptors found on the surface of cells that can be triggered by Wnt protein. Binding to
just one of these two receptors does not cause activation of the Wnt pathway. But when Wnt protein simultaneously binds to both receptors, this pair of interactions activates several intracellular signaling pathways, as can be seen in Figure 5
below. The two Wnt receptors are called frizzled, or Fzd, and <FONT STYLE="white-space:nowrap">low-density</FONT> lipoprotein receptor-related protein 5 or 6, or Lrp 5/6. Fzd is an integral membrane protein that binds to Wnt protein, in part,
through the fatty acid posttranslational modification on the Wnt protein. The second receptor, Lrp 5/6, contains an intracellular domain that is chemically modified by <FONT STYLE="white-space:nowrap">Wnt-protein-induced</FONT> receptor dimerization
to initiate the Wnt signaling pathway cascade in cells. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g17m48.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 5. Like endogenous Wnt (left side), our SWAP technology activates Wnt signaling
by binding specific Fzd and Lrp receptors (right side) </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">265 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Published work by Dr.&nbsp;Christopher Garcia, one of our founders and Scientific Advisory
Board members, showed that Wnt signaling could be induced by identifying <FONT STYLE="white-space:nowrap">non-Wnt</FONT> proteins capable of selectively binding to Fzd and Lrp and linking these binding domains together. These <FONT
STYLE="white-space:nowrap">non-Wnt</FONT> proteins led to an activation of Wnt signaling that in many ways was indistinguishable from that induced by Wnt itself. Furthermore, these <FONT STYLE="white-space:nowrap">non-Wnt</FONT> proteins were
soluble and did not require posttranslational modification with fatty acid for activity. These observations revealed the opportunity to develop <FONT STYLE="white-space:nowrap">Wnt-mimetic</FONT> therapeutics freed from the burden of containing a
fatty acid, which decreases their solubility. There was no apparent restriction on the type of interacting domains that could be used to create these molecules. Several categories of molecules, including domains from natural proteins, artificial
protein binding domains, and antibodies were all found to be able to function as binding domains for Fzd or Lrp. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have focused our
efforts developing antibody-binding domains that independently bind to Fzd and to Lrp. Antibody-binding domains provide a potential advantage over other binding domains due to the ability to identify domains with high potency and with high
specificity, in addition to the maturing manufacturing process. We have identified antibody-binding domains capable of distinguishing individual Fzd family members, providing an opportunity to selectively activate Wnt signaling in cells expressing
specific Fzd receptors &#150; a property that naturally occurring Wnt proteins do not have. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In our SWAP technology, we created
multivalent bispecific antibodies that bring together two different sets of antibody-binding domains &#150; one set that binds to Fzd and another set that binds to Lrp. We found that certain recombinant proteins containing these two antibody-binding
domains were able to simultaneously bind both Fzd and Lrp, however, inducing the simple bimolecular interaction of one Fzd and one Lrp was, in most cases, insufficient to induce Wnt signaling, as can be observed in Figure 6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In Figure 6 below, in an assay measuring protein concentration <FONT STYLE="white-space:nowrap">(x-axis)</FONT> against Wnt pathway activation
(as measured by relative light units, or RLU, <FONT STYLE="white-space:nowrap">y-axis),</FONT> we have demonstrated that a simple bivalent antibody containing a single Fzd binding domain (F1) (the blue line) and a single Lrp binding domain (L2) (the
red line) did not significantly induce the Wnt signaling pathway. At similar concentrations, naturally-occurring Wnt (Wnt3a) (the green line) demonstrated pathway activation. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g85t45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 6. A simple bivalent antibody containing a single Fzd binding domain (F1) and a single Lrp
binding domain (L2) did not significantly induce the Wnt signaling pathway. At similar concentrations, naturally-occurring Wnt (Wnt3a) demonstrated pathway activation. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">However, multivalent antibodies that contained multiple binding domains, either two <FONT STYLE="white-space:nowrap">Fzd-binding</FONT>
domains with one Lrp binding domain (the blue line in Figure 7 below) or two of each binding domain (the light green line), </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">266 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
led to activation of the Wnt signaling pathway at concentrations that were 100 times or lower than required for activation by Wnt3a (the dark green line), as can be observed in Figure 7. For
comparison, an antibody with a single Fzd binding domain (the red line) did not demonstrate significant activity. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g45l12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 7. Multivalent antibodies with two Fzd binding domains (F3) and at least one Lrp binding domain
(L2) led to more potent activation of the Wnt signaling pathway. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are developing a series of product candidates based on the SWAP
technology, which combines binding domains for specific Fzd receptors and binding domains for specific Lrp receptors. Our current SWAP lead product candidate, <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> is being evaluated for its ability to
treat moderate to severe IBD. In addition, we are developing other product candidates, including for the potential treatment of ocular diseases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Wnt Amplification: SWEETS </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have designed our SWEETS technology for those diseases that are characterized by the presence of naturally occurring Wnt, yet with
insufficient Wnt signaling for specific cells. This technology allows us to target Wnt pathway activation to specific cells in the body. For this, our SWEETS technology couples the regulation of the Wnt pathway to the binding of cell-specific
surface antigens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">R-spondins</FONT> are a family of four proteins that amplify Wnt pathway signals by
reducing the destruction of Fzd by internalization and degradation.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>Proteins that are destined for degradation, such as Fzd, are normally tagged by E3 ligases.
<FONT STYLE="white-space:nowrap">R-spondin</FONT> prevents E3 ligase from tagging Fzd, thereby increasing the amount of time that Fzd remains on the cell surface. This results in an increased activation of the Wnt signaling pathway. Importantly, <FONT
STYLE="white-space:nowrap">R-spondin</FONT> does not directly cause signaling through the Wnt pathway, but rather it extends or amplifies the signaling that arises from already-present naturally occurring Wnt protein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">267 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Wild type <FONT STYLE="white-space:nowrap">R-spondin</FONT> activity requires binding to two
cell surface proteins: the E3 ligases and a member of a family of membrane proteins, referred to as LGR <FONT STYLE="white-space:nowrap">4-6.</FONT> We have shown that derivatives of <FONT STYLE="white-space:nowrap">R-spondin</FONT> can be generated
that couple its E3 binding domain to an antigen-binding domain that recognizes a specific cell surface protein of our choosing resulting in <FONT STYLE="white-space:nowrap">R-spondin</FONT> like activity. This technology creates <FONT
STYLE="white-space:nowrap">R-spondin</FONT> mimetics that can be targeted to specific cells in the body that express the chosen cell surface protein, which is illustrated in the Figure 8 below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g67p62.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 8. Our SWEETS technology leads to amplification of the Wnt signaling pathway by inhibition of Fzd
degradation by the E3 ligase/proteasome pathway. Specificity of SWEETS binding is driven by an antigen-binding domain that can be targeted to specific cell surface proteins. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> experiment conducted internally, an
antibody-binding domain recognizing a cell surface protein was fused to a <FONT STYLE="white-space:nowrap">R-spondin</FONT> protein in which the binding site for LGR <FONT STYLE="white-space:nowrap">4-6</FONT> had been inactivated. This recombinant
antibody <FONT STYLE="white-space:nowrap">R-spondin</FONT> construct (the red line in &#147;Target Cell&#148; in Figure 9 below) stimulated the Wnt signaling pathway in cells that expressed the cell surface protein and was inactive in cells lacking
the cell surface protein (the red line in <FONT STYLE="white-space:nowrap">&#147;Non-Target</FONT> Cell&#148;). Wild-type <FONT STYLE="white-space:nowrap">R-spondin</FONT> did not exhibit this selectivity and led to the Wnt signaling pathway
amplification in both types of cells (the black lines in the figure below). A <FONT STYLE="white-space:nowrap">non-cell</FONT> surface targeted molecule serving as a negative control (the blue lines in the figure below) did not demonstrate any
activity. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g17g74.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 9. Cell specificity of <FONT STYLE="white-space:nowrap">R-spondin</FONT> was altered by
inactivating the LGR <FONT STYLE="white-space:nowrap">4-6</FONT> binding site and adding an antigen-binding domain for a specific cell surface protein. SWEETS shown in red. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">268 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">SZN-1326:</FONT> a SWAP Product Candidate for the
Treatment of moderate to severe IBD </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our first product candidate, <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> is being developed
as a novel treatment for moderate to severe IBD, with UC as our first proposed indication, and utilizes our proprietary SWAP technology to activate Wnt signaling. Wnt signaling plays a critical role in intestinal epithelial turnover and normal
function. Abnormal signaling has been observed in patients with IBD and restoration of normal signaling is expected to play a role in the repair of intestinal epithelial cells in IBD. <FONT STYLE="white-space:nowrap">SZN-1326</FONT> targets Fzd 5,
Fzd 8, and Lrp 6 to activate Wnt signaling. We have observed that Fzd 5, Fzd 8, and Lrp 6 are expressed in the large bowel epithelium UC tissue samples and that Fzd 5 is the most abundant Fzd, representing an attractive target for our therapeutic
approach. We have shown that <FONT STYLE="white-space:nowrap">SZN-1326</FONT> has several simultaneous beneficial effects in that it: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">activates the Wnt signaling pathway in intestinal stem cells resulting in proliferation and differentiation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restores intestinal barrier function and tissue architecture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreases inflammation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduces disease activity in mouse models of moderate to severe IBD. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We anticipate initiating a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial of <FONT
STYLE="white-space:nowrap">SZN-1326</FONT> in 2022 and will pursue initial development for the treatment of UC, a type of IBD limited to the large intestine. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Ulcerative Colitis Disease Background </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">UC is a form of IBD characterized by inflammation and ulcers in the large intestine. The hallmark clinical symptoms of UC are diarrhea, bloody
stool, and urgency to defecate, and its clinical course is marked by exacerbations and remissions, which may occur spontaneously or in response to dietary changes, alterations in treatment regimens, other illnesses or stress. In UC, inflammation is
continuous throughout the large bowel and lacks healthy patches distributed adjacent to the inflamed tissue. The extent of disease is variable but starts at the left side (the rectum) and can involve the whole, large intestine. UC is limited to the
inner most layer of the intestinal wall. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">UC can be debilitating with frequent diarrhea, bloody stools, weight loss, dehydration, and
anemia. Intestinal complications from severe and chronic inflammation can become life-threatening. Patients with active disease are more likely to suffer psychological conditions such as anxiety and depression and are more likely to have impaired
social interactions. Persistent UC is associated with an increased risk of developing colon cancer. It is estimated that there are two million individuals in the United States with IBD, of which roughly half have UC. An even higher number of
individuals in Europe are estimated to have UC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">UC is typically treated with anti-inflammatory drugs. The typical treatment regimen
begins with fairly mild and locally-delivered drugs and progresses to stronger systemic immunosuppressive drugs that are only prescribed for patients with moderate to severe disease. First-line therapy for patients with mild disease consists of
locally delivered or oral <FONT STYLE="white-space:nowrap">5-aminosalicylates</FONT> such as mesalamine and sulfasalazine, or corticosteroids. This is done with the intent of inducing remission and transitioning patients to drugs such as <FONT
STYLE="white-space:nowrap">5-aminosalicylates</FONT> for maintenance. Patients with moderate to severe disease will usually be treated first-line with anti-inflammatory biologics such as infliximab, adalimumab, and golimumab. Infliximab, adalimumab,
and golimumab are antibodies directed against tumor necrosis factor alpha, or TNF&#945;, an inflammatory cytokine secreted during acute inflammation. However, over time, many patients lose responsiveness to these
<FONT STYLE="white-space:nowrap">anti-TNF</FONT> antibodies and approximately 20% do not initially respond to this treatment. Patients <FONT STYLE="white-space:nowrap">non-responsive</FONT> to <FONT STYLE="white-space:nowrap">anti-TNF&#945;</FONT>
antibody therapy are instead treated with other approved biologics such as ustekinumab, an inhibitor of interleukin 12 and interleukin 23, and vedolizumab, an integrin inhibitor or with a JAK inhibitor, tofacitinib, an oral anti-inflammatory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Despite the availability of a number of approved drugs and validated drug targets, many patients with UC have an inadequate response to
therapy, lose responsiveness, or cannot tolerate existing treatments. For example, up to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">269 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
20% of patients do not respond to <FONT STYLE="white-space:nowrap">anti-TNF</FONT> antibodies and 10% to 15% lose responsiveness every year despite initial benefit. Overall, it is estimated that
only 48% of UC patients are in clinical remission. 70% of patients with active disease in a given year will have another episode in the following year. Once a patient has successfully been treated and is in remission, the longer the patient is in
remission, the less likely he or she is to experience a <FONT STYLE="white-space:nowrap">flare-up</FONT> in the following year. A potential factor driving longer-term remissions is the repair of the intestinal barrier and absence of any inflammatory
activity in the large intestine gut wall. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Crohn&#146;s Disease Background </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Crohn&#146;s disease, or CD, is a chronic inflammatory disease that most commonly affects the end of the small intestine and the beginning of
the large intestine, although it may involve any part of the gastrointestinal tract. Like UC, CD is a type of IBD and many of the symptoms and demographics overlap. In addition to the potential of CD developing in other segments of the intestine, CD
differs from UC in that there can be normal healthy tissue between patches of diseased tissue. CD can also occur in all layers of the intestinal wall unlike UC which is limited to the inner most layer. It is estimated that there are approximately
1&nbsp;million individuals in the United States and approximately 1.1&nbsp;million individuals in Europe with CD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The treatment paradigm
for CD is very similar to that of UC. Currently approved therapies are mostly anti-inflammatory agents. It is estimated that 60% of patients have moderate to severe disease and will eventually require surgery to treat complications such as fistulas,
or abnormal connections between body parts; life-threatening bleeding; and intestinal obstructions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The Wnt Signaling Pathway and
its Role in IBD </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although the two most common forms of IBD, UC and CD, are treated with anti-inflammatory agents, the root cause of
these diseases has been proposed to be an impaired intestinal barrier that occurs due to initial damages by genetic, environmental, inflammatory or other factors. This impairment is thought to allow bacteria to penetrate through the intestinal
epithelium, leading both to immune cell activation and to an inflammatory reaction that exacerbates the damage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">270 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The intestinal epithelium is one of the fastest proliferating tissues in adults, being
largely made anew every four to five days. The wall of the small intestine is made up of villi, finger-like projections that extend into the lumen of the intestine, which greatly increase the surface area available for nutrient absorption. The cells
at the tips of these villi are continuously shed and are replenished by cells that originate from stem cells located at the base of the villus, called the intestinal crypts. The colon (large intestine) wall is made up of a lining of columnar
epithelial cells with pouches called colonic crypts. Similar to the small intestine villi, the stem cells are located at the base of colonic crypts, as shown in Figure 10, below. The Wnt signaling pathway is critical for the renewal and
proliferation of these stem cells. Inactivation of the Wnt signaling pathway blocks stem cell proliferation and differentiation causing a rapid loss of intestinal epithelial cells in mice. Figure 10 below illustrates how the Wnt signaling pathway
potentially stimulates stem cell renewal and proliferation in colonic crypts leading to increased turnover of epithelial cells. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g26z45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 10. Wnt signaling pathway stimulates stem cell renewal and proliferation leading to increased
synthesis and turnover of epithelial cells </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There is direct evidence linking dysregulation in the Wnt signaling pathway to the
development of moderate to severe IBD in patients<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>and deficiency in the Wnt signaling pathway has been associated not only with the reduced turnover of stem cells in the intestinal crypt but also
with a reduced production of cells that secrete anti-bacterial proteins. It has been proposed that transient elevations in the Wnt signaling pathway may be beneficial in wound healing and evidence from mouse IBD models provide further support for
treatment with a Wnt signal activator. The Wnt protein inhibitor Dkk1 is induced by inflammatory cytokines in colitis and, in mice, blocking Dkk1 function resulted in elevated Wnt signaling and the promotion of wound repair. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">271 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our Solution: <FONT STYLE="white-space:nowrap">SZN-1326</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our product candidate, <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> is a Wnt protein mimetic based on our SWAP technology, for the
treatment of moderate to severe IBD. Our goal for <FONT STYLE="white-space:nowrap">SZN-1326</FONT> was to create a Wnt protein mimetic that could specifically support the proliferation and differentiation of stem cells in the damaged intestinal or
colonic crypts of patients with moderate to severe IBD. We believe that treatment with <FONT STYLE="white-space:nowrap">SZN-1326</FONT> has the potential to accelerate the repair of the intestinal barrier, which can result in a reduction of bacteria
penetrating through the intestinal epithelium and a reduction of immune cell activation and inflammation, thereby treating IBD. Figure 11 below demonstrates how <FONT STYLE="white-space:nowrap">SZN-1326</FONT> potentially binds to Fzd5/8 and Lrp6 on
intestinal stem cells to activate Wnt signaling. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g57k72.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 11: <FONT STYLE="white-space:nowrap">SZN-1326</FONT> binds to Fzd5/8 and Lrp6 on intestinal stem
cells to activate Wnt signaling </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">272 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Selective Wnt Pathway Activation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">SZN-1326</FONT> is a bispecific antibody targeting Fzd5/8 and Lrp6. Fzd5 was reported to be highly expressed
in intestinal mucosal cells from IBD patients. Our research found that Fzd5, was also highly expressed in a mouse model of colitis induced by dextran sodium sulfate, or DSS, as shown in Figure 12. In this model, DSS exposure leads to disruption of
the intestinal barrier resulting in an inflammatory response similar to that seen in IBD patients. We identified <FONT STYLE="white-space:nowrap">SZN-1326</FONT> through testing of multiple SWAP antibodies both in na&iuml;ve and injured intestinal
tissue and in DSS models. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g96k44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 12. Fzd5 is highly expressed in intestinal tissue from a DSS mouse model </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have shown that <FONT STYLE="white-space:nowrap">SZN-1326</FONT> can stimulate Wnt signal activation in
<FONT STYLE="white-space:nowrap">DSS-injured</FONT> intestine epithelial cells as measured by the expression of <I>Axin2</I>, a downstream target gene in the Wnt pathway. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">273 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Restoration of Epithelial Tight Junctions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mice exposed to DSS for seven days led to the breakdown of the intestinal barrier, which can be readily visualized in stained cross sections of
the colon, as shown in Figure 13. In the absence of DSS, there is an intact intestinal wall and the crypts are tightly packed to form a continuous structure. Exposure to DSS followed by treatment with a negative control antibody, <FONT
STYLE="white-space:nowrap">anti-GFP,</FONT> resulted in several effects: a breakdown of the intestinal wall; shrinkage of the crypts; and the creation of multiple discontinuous segments by day ten. However,
<FONT STYLE="white-space:nowrap">DSS-exposed</FONT> mice treated with <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> administered on days four and seven, led to a dose-dependent repair of this damage, with a dose of 1 mg/kg or higher restoring
most of the damage visible by histology. Similar results were observed in a chronic model of DSS, as can be seen in Figure 13. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g53a53.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 13. <FONT STYLE="white-space:nowrap">SZN-1326</FONT> administration led to the restoration of the
intestinal epithelium in a DSS model </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">274 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The degree of epithelial repair as measured by histology with
<FONT STYLE="white-space:nowrap">SZN-1326</FONT> was greater than what we obtained in additional experiments with cyclosporine, an <FONT STYLE="white-space:nowrap">anti-TNF</FONT> antibody or an anti-IL12/23 antibody. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Histologic staining showed that treatment with <FONT STYLE="white-space:nowrap">SZN-1326</FONT> led to the restoration of tight junctions, the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cell-to-cell</FONT></FONT> structures that create the intestinal barrier that prevents the free flow of material. In healthy intestinal tissue, the zonula occludens 1 protein, or <FONT
STYLE="white-space:nowrap">ZO-1,</FONT> a component of tight junctions, was found as a continuous layer along the intestinal wall. In <FONT STYLE="white-space:nowrap">DSS-damaged</FONT> intestinal tissue, no such barrier was observed. Treatment with
<FONT STYLE="white-space:nowrap">SZN-1326</FONT> restored <FONT STYLE="white-space:nowrap">ZO-1</FONT> localization as a continuous layer along the intestinal wall, as can be observed in Figure 14. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g54a54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 14. <FONT STYLE="white-space:nowrap">SZN-1326</FONT> restored
<FONT STYLE="white-space:nowrap">ZO-1</FONT> localization (green) and reestablishment of the intestinal barrier in a DSS mouse model. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">275 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Inflammation Reduction </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The breakdown of the intestinal barrier triggers an inflammatory response that leads to further tissue damage. Disease modification in IBD can
be measured by the levels of inflammatory cytokines present in the injured tissue and in serum. In the mouse DSS model, treatment with <FONT STYLE="white-space:nowrap">SZN-1326</FONT> administration led to a significant dose-dependent decrease in a
number of inflammatory cytokines such as TNF&#945;, <FONT STYLE="white-space:nowrap">interleukin-6,</FONT> or <FONT STYLE="white-space:nowrap">IL-6,</FONT> and <FONT STYLE="white-space:nowrap">interleukin-8,</FONT> or
<FONT STYLE="white-space:nowrap">IL-8.</FONT> Reductions in cytokine levels were observed both in colon tissue and in serum, as can be seen in Figure 15 below. We believe that these results suggest that
<FONT STYLE="white-space:nowrap">SZN-1326</FONT> not only has the potential of directly repairing the epithelium but also, as a result, of reducing inflammation. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g55a55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 15. <FONT STYLE="white-space:nowrap">SZN-1326</FONT> administration led to significant reductions
in cytokine levels in a DSS mouse model. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>* p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001, **** p &lt; 0.0001 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the description of the preclinical studies above and throughout, a p-value represents the probability that random chance caused the result.
For example, a p-value of 0.001 means that there is a 0.1% probability that the difference between the control group and the treatment group is purely due to random chance. A p-value of less than or equal to 0.05 is a commonly used threshold for
identifying statistically significant outcomes. The FDA&#146;s evidentiary standard of efficacy when evaluating the results of a clinical trial generally relies on a p-value of less than or equal to 0.05. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">276 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Functional Improvement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Most importantly, <FONT STYLE="white-space:nowrap">SZN-1326</FONT> administration led to an improvement in the disease activity index, or DAI,
in the DSS model. The DAI is a composite score composed of body weight change, diarrhea, and bloody stools that is frequently used to quantify disease severity. <FONT STYLE="white-space:nowrap">SZN-1326</FONT> treatments led to a dose dependent
decrease in DAI which was superior to that which we observed with cyclosporine, an <FONT STYLE="white-space:nowrap">anti-TNF</FONT> antibody, or an anti-IL12/23 antibody in acute and chronic DS models, respectively. Figure 16 below demonstrates that
<FONT STYLE="white-space:nowrap">SZN-1326</FONT> administration led to improvements in DAI in an acute DSS model. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g56a56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 16. <FONT STYLE="white-space:nowrap">SZN-1326</FONT> administration led to
improvement in the disease activity index in an acute DSS model. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>* p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001, **** p &lt;
0.0001 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Planned Clinical Development of <FONT STYLE="white-space:nowrap">SZN-1326</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to initiate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trials of <FONT
STYLE="white-space:nowrap">SZN-1326</FONT> in 2022. Our initial trial will focus on assessing safety and tolerability as well as on obtaining human pharmacokinetic data in healthy volunteers. We intend to conduct a multiple ascending dose trial in
patients with UC with the goal of assessing safety, tolerability, pharmacokinetics and initial signs of clinical activity through the effects on symptoms, cytokines, biomarkers and histological changes in the colon. This trial will also investigate
whether the activity of <FONT STYLE="white-space:nowrap">SZN-1326</FONT> can be enhanced by combining it with an approved anti-inflammatory biologic. We anticipate that later stage trials would include the induction of clinical and histological
remission, either alone or in combination with anti-inflammatory drugs. Based both on the mechanism of action of <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and our preclinical results, we believe that dosing of
<FONT STYLE="white-space:nowrap">SZN-1326</FONT> for several weeks has the potential to demonstrate durable remissions. If we obtain initial signs of efficacy in UC, we anticipate also initiating clinical development in CD. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">SZN-043,</FONT> a SWEETS product candidate for the treatment of severe liver diseases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">SZN-043</FONT> is a product candidate based on our SWEETS technology that we are developing to treat severe AH
and other severe liver diseases, including acute liver failure. We have shown that <FONT STYLE="white-space:nowrap">SZN-043</FONT> activates Wnt signaling in hepatocytes and contributes both to increasing hepatocyte proliferation and to restoring
liver function. We anticipate initiating a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial of <FONT STYLE="white-space:nowrap">SZN-043</FONT> in 2022 and pursuing initial development of <FONT
STYLE="white-space:nowrap">SZN-043</FONT> for the treatment of severe AH. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Severe Alcoholic Hepatitis Background </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">AH is inflammation of the liver caused by excessive alcohol ingestion. AH is most likely to occur in people who drink heavily over many years;
however, the relationship between drinking and alcoholic hepatitis is complex. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">277 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Not all heavy drinkers develop alcoholic hepatitis, and the disease can occur in people who drink only moderately. AH is characterized by the rapid onset of jaundice, malaise, anorexia, liver
enlargement and a systemic inflammatory response syndrome, or SIRS. AH is characterized by impaired hepatocyte proliferation. In these patients, higher Wnt signaling and hepatocyte proliferation has been associated with better outcomes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many patients with severe AH require inpatient hospitalization due to the high risk of developing renal failure, liver failure, infections and
the effects of alcohol withdrawal. AH is treated with anti-inflammatory drugs such as glucocorticoids, typically prednisolone. Glucocorticoid treatment requires close monitoring because of the increased risk of infections, glucose intolerance and
gastrointestinal bleeding. For patients who respond to glucocorticoids, the duration of treatment is typically 28 days. Mortality rates after one to six months among patients treated with glucocorticoids in clinical trials ranged from approximately
20% to 40%. The effectiveness of glucocorticoid treatment is controversial. A 2017 meta-analysis of 15 randomized trials found that glucocorticoid treatment did not significantly lower mortality rates compared to placebo. In addition, only 25% to
45% of patients are eligible for glucocorticoid therapy due to other comorbidities. Those not qualifying include patients with infections, poorly controlled diabetes mellitus, renal failure, and active gastrointestinal bleeding. Although levels of
TNF&#945; are highly elevated in AH, treatment with <FONT STYLE="white-space:nowrap">anti-TNF&#945;</FONT> antibodies has not been determined to be effective. The overall <FONT STYLE="white-space:nowrap">30-day</FONT> mortality rate in patients
hospitalized with AH is approximately 15% and the <FONT STYLE="white-space:nowrap">90-day</FONT> rate is approximately 30%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are an
estimated 100,000 unique severe <FONT STYLE="white-space:nowrap">AH-related</FONT> hospitalizations annually in the United States. Alcoholism affects an estimated 8% of the U.S. population and between 10% and 35% of alcoholics have characteristics
consistent with the development of AH. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">278 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our Solution: <FONT STYLE="white-space:nowrap">SZN-043</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are developing <FONT STYLE="white-space:nowrap">SZN-043,</FONT> a tissue-specific <FONT STYLE="white-space:nowrap">R-spondin</FONT> mimetic
based on our SWEETS technology, for the treatment of severe liver disease. Our goal was to create a molecule that could stimulate liver regeneration by amplifying the effect of naturally occurring Wnt proteins.
<FONT STYLE="white-space:nowrap">SZN-043</FONT> is a bispecific antibody that mimics the stimulatory effect of <FONT STYLE="white-space:nowrap">R-spondin</FONT> specifically on hepatocytes through targeting of asialoglycoprotein receptor 1, or
ASGR1. Liver regeneration has been shown to be an important predictor and biomarker for disease severity, response to corticosteroids and patient survival in those with severe AH. We believe that the regenerative capacity that <FONT
STYLE="white-space:nowrap">SZN-043</FONT> has shown in preclinical models will potentially improve the outcome of patients with severe AH. We anticipate initiating clinical testing of <FONT STYLE="white-space:nowrap">SZN-043</FONT> in 2022. Figure
17 below describes the proposed mechanism of action of <FONT STYLE="white-space:nowrap">SZN-043.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g57a57.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 17. In liver injury, <FONT STYLE="white-space:nowrap">SZN-043</FONT> amplifies
the regenerative activity of endogenous Wnts by stabilizing their Fzd receptors on hepatocytes </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">279 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Selective Wnt Pathway Activation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Similar to <FONT STYLE="white-space:nowrap">R-spondin,</FONT> <FONT STYLE="white-space:nowrap">SZN-043</FONT> leads to an amplification of Wnt
signaling by inhibiting internalization and degradation of Fzd. However, an important difference from <FONT STYLE="white-space:nowrap">R-spondin</FONT> is that <FONT STYLE="white-space:nowrap">SZN-043</FONT> requires binding to ASGR1, a protein that
is exclusively expressed on hepatocytes, for activity. A single dose of <FONT STYLE="white-space:nowrap">SZN-043</FONT> at 10 mg/kg led to the amplification of the Wnt signaling pathway, as measured by <I>Axin2 </I>expression, a common indicator of
Wnt signaling activity, in mouse liver, but not in any of the other tissues analyzed. In a similar experiment, <FONT STYLE="white-space:nowrap">R-spondin</FONT> at 10 mg/kg led to Wnt pathway activation in multiple tissues including liver, lung,
stomach, intestines, and pancreas, as can be seen in Figure 18 below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g58a58.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 18. <FONT STYLE="white-space:nowrap">R-spondin</FONT>
<FONT STYLE="white-space:nowrap">(R-spo2)</FONT> significantly increased </B><B><I>Axin2 </I></B><B>expression in many tissues, whereas <FONT STYLE="white-space:nowrap">SZN-043</FONT> only increases </B><B><I>Axin2 </I></B><B>expression in the
liver. (* p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001, **** p &lt; 0.0001) </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">280 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Hepatocyte Proliferation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mice treated with a single dose of <FONT STYLE="white-space:nowrap">SZN-043</FONT> had significantly increased proliferation of hepatocytes at
48 hours as measured by <FONT STYLE="white-space:nowrap">Ki-67</FONT> expression (green signal in Figure 19 below), a nuclear protein that is associated with, and used as, a cellular marker of proliferation. Treatment with <FONT
STYLE="white-space:nowrap">SZN-043</FONT> led to an increased number of hepatocytes that express hepatocyte nuclear factor 4&#945;, or HNF4&#945; (red signal in Figure 19, below), a master regulator of hepatic differentiation that is critical to the
regulation of liver differentiation and development. In Figure 19, a yellow signal results from the merging of a green and red signal, indicating that the proliferating cells are hepatocytes. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g59a59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 19. <FONT STYLE="white-space:nowrap">SZN-043</FONT> led to increased proliferation and
differentiation of hepatocytes in mice </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>* p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001, **** p &lt; 0.0001 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Functional Improvement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">High levels of ammonia in the blood, a condition known as hyperammonemia, is believed to contribute to the pathogenesis of hepatic
encephalopathy and a sign of severe liver disease. Ammonia levels have been shown to predict mortality in patients with acute hepatitis. Acute liver failure patients who have decreased ammonia levels have improved survival. Measurement of ammonia
levels is a standard clinical test used to screen for liver function and follow progression of liver disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">281 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Elevated ammonia levels are also observed in a mouse model of AH. In this model, AH is
induced by seven weeks of a binge ethanol diet. After seven weeks, the ethanol diet is suspended, and liver injury is assessed. Treatment with <FONT STYLE="white-space:nowrap">SNZ-043</FONT> significantly lowered ammonia levels in this model by day
three, as shown in Figure&nbsp;20. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g60a60.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 20. <FONT STYLE="white-space:nowrap">SZN-043</FONT> treatment significantly reduced ammonia levels in an
alcoholic hepatitis mouse model. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>* p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001, **** p &lt; 0.0001 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Aspartate transaminase, or AST, and alanine aminotransferase, or ALT, are liver enzymes that are clinically measured to assess the degree of
liver damage. A high ratio of AST to ALT is interpreted as a measure of the severity of AH. In this mouse AH model, the AST:ALT ratio is found to also be elevated. <FONT STYLE="white-space:nowrap">SZN-043</FONT> treatment led to the significant
reduction in the AST:ALT ratio compared to an inactive control antibody, as can be seen in Figure 21. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40894g60b60.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 21. <FONT STYLE="white-space:nowrap">SZN-043</FONT> led to significant reduction in the AST:ALT
ratio in an alcoholic hepatitis mouse model </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>* p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001, **** p &lt; 0.0001 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">282 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT STYLE="white-space:nowrap">SZN-043</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to initiate clinical testing of <FONT STYLE="white-space:nowrap">SZN-043</FONT> with a first in human trial in 2022 in patients with
mild liver cirrhosis classified as Child-Turcotte-Pugh, or CTP, a disease. The initial single ascending dose trial will assess pharmacokinetics, safety and tolerability, and will enable us to collect pharmacodynamic markers. We anticipate conducting
a multiple dose escalation trial in patients with severe AH with the primary endpoints of safety and pharmacokinetics and exploratory efficacy endpoints consisting of the Lille and MELD scores. The Lille model is a highly predictive measure of
likelihood of death at three and six months calculated by taking into account patient age, renal insufficiency, albumin, prothrombin time, bilirubin, and evolution of bilirubin at day seven. The MELD score is a separate prognostic scoring system
that is used to predict the three-month mortality due to liver disease based on laboratory parameters such as creatinine, bilirubin, and INR measurements. Based on our estimates of the prevalence of severe AH, we are exploring whether <FONT
STYLE="white-space:nowrap">SZN-043</FONT> may qualify for orphan drug designation or fast track designation or both, which may accelerate its path towards potential regulatory approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Research Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that both our SWAP and SWEETS technologies have the potential to generate a portfolio of product candidates that can harness the
tissue regenerative activity of the Wnt pathway and potentially bring therapeutic benefit to patients suffering from a broad spectrum of diseases. Our goal in each of these programs is to activate the natural ability of tissues in the body to heal
themselves by increasing the Wnt signaling pathway in a localized, transient, and, we believe, safe manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Among our research programs,
we are developing potential therapeutics for ocular diseases such as <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, or AMD, and diabetic retinopathy. We have shown that activation of the Wnt signaling pathway can
potentially reverse vascular damage through a mechanism that is different from the mechanisms of currently approved therapeutics that target angiogenesis. We are also assessing the potential of our Wnt therapeutics platform to drive tissue repair in
conditions such as hearing loss and diseases caused by tissue injury to organs including the lungs, pancreas and kidney. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">One of our more
advanced preclinical programs is designed to specifically activate the Wnt signaling pathway in the retina. Genetic studies have identified that the Wnt signaling pathway is critical for maintenance of healthy retinal blood vessels. We are
developing an agonist of a specific Fzd receptor found in the retinal vasculature, which we have shown in animal models can inhibit retinal pathology in the eye. We believe that the ability to deliver this agonist locally to the eye has the
potential to treat multiple ocular disorders by inducing repair of damaged tissue, such as diabetic retinopathy and macular degeneration by inducing repair of damaged tissue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_176"></A>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We strive to protect and enhance the proprietary technologies, inventions and improvements that we believe are important to our business,
including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. We also rely on <FONT STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation and <FONT
STYLE="white-space:nowrap">in-licensing</FONT> opportunities to develop, strengthen and maintain our proprietary position in our field and other fields that are or may be important for the development of our business. Our policy is to seek to
protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, platforms and
our product candidates that are important to the development and implementation of our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Licensing Arrangements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stanford License Agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2016, we entered into a license agreement with Stanford, or the 2016 Stanford Agreement, which was amended in July 2016, October 2016
and January 2021, pursuant to which we obtained from Stanford, a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">283 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
worldwide, exclusive, sublicensable license under certain patent rights or licensed patents, and technology related to our engineered Wnt surrogate molecules to make, use, import, offer to sell
and sell products that are claimed by the licensed patents or that use or incorporate that technology, or licensed products, for the treatment, diagnosis and prevention of human and veterinary diseases. The 2016 Stanford Agreement covers two patent
families and any patents that grant from these families are predicted to expire in 2035 and 2037, absent any patent term adjustments or extensions. In consideration for that license, we paid Stanford a nominal upfront fee and issued an aggregate of
241,688 shares of our common stock to Stanford, the University of Washington and two <FONT STYLE="white-space:nowrap">co-inventors</FONT> of the licensed patents. We agreed to pay Stanford nominal annual license maintenance fees which are creditable
against earned royalties owed to Stanford for the same year, an aggregate of up to $1.4&nbsp;million for the achievement of specified development and regulatory milestones, and an aggregate of up to $5.0&nbsp;million for the achievement of specified
sales milestones. Stanford is also entitled to receive royalties from us equal to a very low single digit percentage of our and our sublicensees&#146; net sales of licensed products that are covered by a valid claim of a licensed patent. Our
obligation to pay royalties will continue, on a country-by-country basis, until the last-to-expire valid claim of a licensed patent covering a licensed product in the country of manufacture or sale. Additionally, we agreed to pay Stanford a <FONT
STYLE="white-space:nowrap">sub-teen</FONT> double digit percentage of certain consideration we receive as a result of granting sublicenses to the licensed patents and, if we are acquired, a <FONT STYLE="white-space:nowrap">one-time</FONT> change of
control fee in the low six figures. Stanford retains the right under the 2016 Stanford Agreement, on behalf of itself, Stanford Hospital and Clinics, the University of Washington, and all other <FONT STYLE="white-space:nowrap">non-profit</FONT>
research institutions, to practice the licensed patents and technology for <FONT STYLE="white-space:nowrap">any&nbsp;non-profit</FONT> purpose. The licensed patents and technology are additionally subject to a
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> irrevocable, worldwide license held by the Howard Hughes Medical Institute to practice the licensed patents and technology for its research purposes, but with no right to assign or sublicense.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2018, we entered into another license agreement with Stanford, or the 2018 Stanford Agreement, pursuant to which we obtained from
Stanford, a worldwide, exclusive, sublicensable license under certain patents related to our surrogate <FONT STYLE="white-space:nowrap">R-spondin</FONT> proteins, or licensed patents, to make, use, import, offer to sell and sell products that are
claimed by the licensed patents, or licensed products, for the treatment, diagnosis and prevention of human and veterinary diseases, or the exclusive field. The 2018 Stanford Agreement covers one patent family, and any patents that grant from this
family are predicted to expire in 2038, absent any patent term adjustment or extension. Additionally, Stanford granted us a worldwide, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable license under the licensed patents to make
and use licensed products for research and development purposes in furtherance of the exclusive field and a worldwide, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to make, use and import, but not to offer to sell or sell, licensed
products for any other use. In consideration for those licenses, we paid Stanford a nominal upfront fee. We agreed to pay Stanford nominal annual license maintenance fees which are creditable against earned royalties owed to Stanford for the same
year, and an aggregate of up to $0.425&nbsp;million for the achievement of specified development and regulatory milestones. Stanford is also entitled to receive royalties from us equal to a <FONT STYLE="white-space:nowrap">sub-single</FONT> digit
percentage of our and our sublicensees&#146; net sales of licensed products that are covered by a valid claim of a licensed patent. Our obligation to pay royalties will continue, on a country-by-country basis, until the last-to-expire valid claim of
a licensed patent covering a licensed product in the country of manufacture or sale. Additionally, we agreed to pay Stanford a <FONT STYLE="white-space:nowrap">one-time</FONT> payment in the low six figures for each sublicense of the licensed
patents that we grant to a third party and, if we are acquired, a <FONT STYLE="white-space:nowrap">one-time</FONT> nominal change of control fee. Stanford retains the right under the 2018 Stanford Agreement, on behalf of itself, Stanford Health
Care, Lucile Packard Children&#146;s Hospital at Stanford, and all other <FONT STYLE="white-space:nowrap">non-profit&nbsp;research</FONT> institutions, to practice the licensed patents for <FONT STYLE="white-space:nowrap">any&nbsp;non-profit</FONT>
purpose. The licensed patents are additionally subject to a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> irrevocable, worldwide license held by the Howard Hughes Medical Institute to exercise any intellectual property rights with respect
to the licensed patents for research purposes, including the right to sublicense <FONT STYLE="white-space:nowrap">to&nbsp;non-profit</FONT> and governmental entities but with no other rights to assign or sublicense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under each of the 2016 Stanford Agreement and the 2018 Stanford Agreement, or Stanford Agreement, we agreed to use commercially reasonable
efforts to develop and commercialize licensed products and we agreed to achieve certain funding and development milestones by certain dates. Unless earlier terminated, each Stanford Agreement will continue until the expiration of the patents
licensed under that Stanford Agreement. We may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">284 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
terminate either Stanford Agreement at any time for any reason by providing at least 30 days&#146; written notice to Stanford. Stanford may terminate either Stanford Agreement if we breach
certain provisions of such Stanford Agreement and fail to remedy such breach within 90 days after written notice of such breach by Stanford. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>UCSF
License and Option Agreements </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September and October 2016, we entered into two separate license and option agreements with The
Regents of the University of California, or the UCSF Agreements, pursuant to which we obtained from The Regents of the University of California, or UCSF, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses to make and use a certain human
Fab na&iuml;ve phage display library and to make and use a certain phage display llama VHH single domain antibody library for internal research and antibody discovery purposes and an option to negotiate with UCSF to obtain a <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> license under UCSF&#146;s rights in the applicable library to make, use, sell, offer for sale and import products incorporating antibodies identified or resulting from our use of such library, or
licensed products. We are using these libraries in connection with our development of SZN-1326. In consideration for the license and option rights under each UCSF Agreement, we paid UCSF a nominal option issue fee and agreed to pay UCSF a nominal
annual option maintenance fee. If we exercise the option under either UCSF Agreement, we and UCSF will negotiate in good faith the terms of a commercial license agreement in addition to the <FONT STYLE="white-space:nowrap">pre-agreed</FONT> terms
which include payment to UCSF of a nominal license issue fee, nominal annual license maintenance fees, nominal to low six figure milestone payments for the achievement of a specified regulatory milestone event for each licensed product (with the
maximum potential aggregate amount of such payments in the six figures, depending on the number of licensed products), nominal annual minimum royalties, which are creditable against earned royalties for the same year, and earned royalties equal to a
<FONT STYLE="white-space:nowrap">sub-single</FONT> digit percentage of our and our sublicensees&#146; net sales of licensed products (which extend for the duration of the applicable UCSF Agreement). Both agreements were amended and restated in
January 2020. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless earlier terminated, each UCSF Agreement will continue until four years from its execution date and we may
exercise the option to negotiate a commercial license at any time during that term. Additionally, we may extend each UCSF Agreement for any additional four years by paying UCSF a nominal term extension fee. We may terminate either UCSF Agreement at
any time for any reason by providing at least 60 days&#146; written notice to UCSF. UCSF may terminate either UCSF Agreement if UCSF reasonably believes we are in material breach of that UCSF Agreement and we fail to remedy such breach within 60
days after written notice of such breach by UCSF. Additionally, the UCSF Agreements will automatically terminate in the event of our bankruptcy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Distributed Bio Subscription Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September 2016, we entered into, and in January 2019 we amended, an antibody library subscription agreement with Distributed Bio, or the
Distributed Bio Agreement, in which we obtained from Distributed Bio a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to use Distributed Bio&#146;s antibody library to identify antibodies directed to an unlimited number of our
proprietary targets and to make, use, sell, offer for sale, import and exploit products incorporating the antibodies that we identify, or licensed products. We are using Distributed Bio&#146;s antibody library in connection with our development of
SZN-1326. In consideration for the rights granted to us under the Distributed Bio Agreement, we paid Distributed Bio a nominal upfront fee and an additional nominal fee upon entering into the amendment. We agreed to pay Distributed Bio an annual fee
of $200,000 on the third and fourth year anniversaries of the original agreement date and $250,000 on each annual anniversary thereafter. Additionally, we agreed to pay Distributed Bio an aggregate of $5.9&nbsp;million for each licensed product that
achieves specified development, regulatory and commercial milestones and royalties equal to a very low single digit percentage of our and our sublicensees&#146; net sales of licensed products. Our obligation to pay royalties will end for each
licensed product ten years after its first commercial sale. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless earlier terminated, the Distributed Bio Agreement will continue
for an initial four year term and will thereafter automatically renew for additional <FONT STYLE="white-space:nowrap">one-year</FONT> terms. We may terminate the Distributed Bio Agreement for convenience at any time by providing written notice to
Distributed Bio. We and Distributed Bio may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">285 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
terminate the Distributed Bio Agreement for the other party&#146;s material breach and failure to cure such breach within 60 days after notice of such breach. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Patents and Other Proprietary Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of January&nbsp;31, 2021, our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent portfolio consisted of 16 pending patent
application families, including nine families that have entered national phase in the United States and other countries, five families with pending Patent Cooperation Treaty, or PCT, applications, and two families with pending U.S. provisional
applications. These patent applications are directed to, for example, the SWAP and SWEETS platforms, the parental constructs of our two lead product candidate molecules, the lead product candidate molecule,
<FONT STYLE="white-space:nowrap">SZN-043,</FONT> as well as methods of treating disorders of the liver, intestine, retina, and inner ear. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>SWAP
Platform Technology </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;16, 2021, we solely own or exclusively license 12 patent families related to our SWAP
platform. These patent families are directed to compositions of matter and methods of use, and relate to Wnt mimetics that bind to both a FZD receptor and an LRP receptor, and binding domains and uses thereof. Any patents that issue from these
patent families are predicted to expire between 2035 and 2042 absent any patent term adjustment or extension. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have exclusively
licensed two patent families from The Board of Trustees of the Leland Stanford Junior University, or Stanford, related to our SWAP platform. One patent family related to the SWAP platform and <FONT STYLE="white-space:nowrap">SZN-1326,</FONT> has
been allowed or granted in Australia and Japan and is pending in the United States, Australia, Canada, Europe and Japan, and any patents that grant from this patent family are predicted to expire in 2035 absent any patent term adjustment or
extension. The other patent family is pending in the United States, and any patents that grant from this patent family are predicted to expire in 2037 absent any patent term adjustment or extension. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our exclusively owned patent families related to our SWAP platform include five patent families related to compositions of matter and/or
methods of use relevant to <FONT STYLE="white-space:nowrap">SZN-1326.</FONT> Two of these patent families are filed in the United States, Australia, Canada, China, Europe, Hong Kong and Japan, and any patents that grant from these patent families
are predicted to expire in 2038 absent any patent term adjustment or extension. One is filed in the United States, Australia, Canada, China, Europe, Hong Kong, India, and Japan, and any patents that grant from these patent families are predicted to
expire in 2038 absent any patent term adjustment or extension. Another is a pending PCT application, and any patents that grant from national stage applications resulting from this PCT application are predicted to expire in 2040 absent any patent
term adjustment or extension. Another is a provisional application, and any patents that grant from applications claiming priority to this provisional application are predicted to expire in 2042. Other exclusively owned patent families related to
the SWAP program are directed to compositions of matter and/or methods of use relevant to potential future product candidates. They include a patent family filed in the United States, Australia, Canada, China, Europe, India, and Japan, and four
pending PCT applications, and any patents that grant from these patent families are predicted to expire between 2039 and 2041 absent any patent term adjustment or extension. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>SWEETS Platform Technology </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of
January&nbsp;31, 2021, we solely own or exclusively license four patent families related to our SWEETS platform. These patent families are directed to compositions of matter and methods of use of SWEETS molecules, and relate to tissue-specific <FONT
STYLE="white-space:nowrap">R-spondin</FONT> mimetics and binding domains and uses thereof. Any patents that grant from these patent families are predicted to expire between 2038 and 2041 absent any patent term adjustment or extension. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have exclusively licensed one patent family from Stanford related to our SWEETS platform. This patent family is filed in the United States,
Australia, Canada, China, Europe, Hong Kong, India, and Japan, and any patents that grant from this patent family are predicted to expire in 2038 absent any patent term adjustment or extension. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">286 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our solely owned patent families related to our SWEETS platform include two patent
families related to compositions of matter and/or methods of use relevant to <FONT STYLE="white-space:nowrap">SZN-043.</FONT> One of these patent families has been filed in the United States, Australia, Canada, China, Europe, Hong, Kong, India, and
Japan, and any patents that grant from these patent families are predicted to expire in 2038 absent any patent term adjustment or extension. The other patent family directed to <FONT STYLE="white-space:nowrap">SZN-043</FONT> composition of matter
and methods of use is a U.S. provisional patent application that is expected to be filed as a PCT application in November 2021, and any patents that grant from national stage applications resulting from this PCT application are predicted to expire
in 2041 absent any patent term adjustment or extension. We plan on filing additional applications on any improvements or modifications of <FONT STYLE="white-space:nowrap">SZN-043</FONT> and methods of use thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The actual term of any patent that may issue from the above-described patent applications claiming one of our product candidates could be
longer than described above due to patent term adjustment or patent term extension, if available, or shorter if we are required to file terminal disclaimers. The term of individual patents depends upon the legal term for patents in the countries in
which they are granted. In most countries, including the United States, the patent term is 20 years from the earliest claimed filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application in the applicable country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the
legal term of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United States are granted a term of 20&nbsp;years from the earliest effective
<FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the U.S. Patent and Trademark Office, or the USPTO, delay in issuing the patent as well
as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the total patent term including the restoration period must not
exceed 14&nbsp;years following FDA approval. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. However, the actual protection
afforded by a patent varies on a product by product basis, from country to country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal
remedies in a particular country and the validity and enforceability of the patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, we may rely upon trade secrets and <FONT
STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our collaborators,
employees and consultants and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with selected consultants. These agreements are designed to protect our proprietary
information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any
breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes
may arise as to the rights in related or resulting <FONT STYLE="white-space:nowrap">know-how</FONT> and inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial
success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, or our product
candidates or processes, obtain licenses, or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future product candidates may have
an adverse impact on us. If third parties have prepared and filed patent applications prior to March&nbsp;16, 2013 in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the
USPTO, to determine priority of invention. For more information, please see &#147;Risk Factors&#151;Risks Related to Intellectual Property&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">287 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_177"></A>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis
on intellectual property. We face potential competition from many different sources, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other academic
institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for the research, development, manufacturing, and commercialization of
therapies aimed at treating autoimmune, inflammatory, metabolic, and other diseases. Any product candidates that we successfully develop and commercialize will compete with current therapies and new therapies that may become available in the future.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The key competitive factors affecting the success of our product candidates, if approved, are likely to be their efficacy, safety,
convenience and price, the level of competition and the availability of coverage and adequate reimbursement from third-party payors. If any of our product candidates are approved and successfully commercialized, it is likely that we will face
increased competition as a result of other companies pursuing development of products to address similar diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With respect to <FONT
STYLE="white-space:nowrap">SZN-1326,</FONT> there are no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapeutics targeted towards the Wnt signaling pathway for the treatment of IBD. There are currently oral and biologic therapeutics
approved for the treatment of IBD marketed by Johnson&nbsp;&amp; Johnson, Amgen Inc., Abbvie Inc., Takeda and Pfizer Inc. in addition to other major pharmaceutical companies, against which our product candidate may compete, if approved. In addition,
we are aware of product candidates under development targeting epithelial barrier repair for the treatment of IBD, including an <FONT STYLE="white-space:nowrap">IL-22</FONT> agonist program from Roche Holding AG (RG7880) in phase 2 trials. Immunic
is investigating <FONT STYLE="white-space:nowrap">IMU-856,</FONT> a small molecule inhibitor of a transcription regulatory factor involved in epithelial barrier repair, in phase 1 trials. In addition, Thetis Pharmaceuticals is investigating <FONT
STYLE="white-space:nowrap">TP-317,</FONT> an oral therapeutic designed to deliver Resolvin E1 to the gastrointestinal tract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If approved,
<FONT STYLE="white-space:nowrap">SZN-043</FONT> would compete with already approved, low cost anti-inflammatory drugs such as glucocorticoids (typically prednisolone) for the treatment of severe AH. In addition, we are aware of product candidates
under development for AH and liver failure. Durect Corp is investigating <FONT STYLE="white-space:nowrap">DUR-928</FONT> in a phase 2 clinical and Akaza Bioscience is investigating resatorvid in a phase 2 clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With respect to our earlier stage research programs, we are aware of one <FONT STYLE="white-space:nowrap">FDA-approved</FONT> treatment
targeting the Wnt pathway. Evenity (romosozumab) is a humanized monoclonal antibody targeting sclerostin and currently marketed by Amgen Inc. and UCB for postmenopausal osteoporosis. Several companies are also developing product candidates targeting
the Wnt signaling pathway including Samumed and AntlerA Therapeutics. Samumed is developing a portfolio of small molecule product candidates for a variety of degenerative diseases including candidates in clinical development for osteoarthritis and
degenerative disk disease (lorecivivint), Alzheimer&#146;s disease (SM07883) and idiopathic pulmonary fibrosis (SMO4646). AntlerA Therapeutics is a preclinical stage company developing antibody like molecules (ANTs) that activate specific Fzd
receptor complexes and are designed to control tissue stem cells and promote tissue repair and rejuvenation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For additional information
on the competitive risks we face, please see the section of this prospectus titled &#147;Risk Factors&#151;We face competition from entities that have developed or may develop product candidates for the treatment of the diseases that we may target,
including companies developing novel treatments and therapeutic platforms. If these companies develop therapeutics or product candidates more rapidly than we do, or if their therapeutics or product candidates are more effective or have fewer side
effects, our ability to develop and successfully commercialize product candidates may be adversely affected.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_178">
</A>Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Government authorities in the United States at the federal, state and local level and in other countries and
jurisdictions including the European Union, extensively regulate, among other things, the research, development, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">288 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export
and import of biological products, such as our product candidates and any future product candidates. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the
governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state,
local and foreign statutes and regulations require the expenditure of substantial time and financial resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Regulatory Approval
in the United States </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, biological products are subject to regulation under the Federal Food, Drug, and
Cosmetic Act (FDCA) the Public Health Service Act (PHSA), and other federal, state, local and foreign statutes and regulations. The process required by the FDA before biologic product candidates may be marketed in the United States generally
involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of extensive preclinical laboratory and animal studies in accordance with applicable regulations,
including studies conducted in accordance with the FDA&#146;s Good Laboratory Practice (GLP), requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an institutional review board (IRB) or independent ethics committee at each clinical trial site
before each clinical trial may be commenced; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with applicable IND
regulations, Good Clinical Practice (GCP) requirements and other clinical trial-related regulations to establish the safety, purity and potency of the product candidate for each proposed indication; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation and submission to the FDA of a biologics license application (BLA), after completion of all
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment of any user fees for FDA review of the BLA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination by the FDA within 60 days of its receipt of a BLA to accept the application for review;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA Advisory Committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of one or more FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections of
the manufacturing facility or facilities where the biologic, or components thereof, will be produced to assess compliance with current cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the biologic&#146;s
identity, strength, quality and purity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of any potential FDA audits of the clinical trial sites that generated the data in
support of the BLA to assure compliance with GCPs and integrity of the clinical data; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications
for use in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Preclinical Studies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Before testing any biological product candidates in humans, the product candidate must undergo rigorous preclinical testing. Preclinical
studies include laboratory evaluation of product chemistry and formulation, as well as in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical
studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">289 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an
IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. Some long-term preclinical testing may continue after the IND is submitted.
An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND
sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Clinical Trials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the
supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#146;s control. Clinical trials must be conducted: (i)&nbsp;in compliance with federal regulations; (ii)&nbsp;in compliance with GCPs, an
international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors; as well as (iii)&nbsp;under protocols detailing, among other things, the objectives of the
trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated in the trial. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.
Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable
in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.
Information about certain clinical trials, including clinical trial results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. Information related to the product, patient population, phase of
investigation, clinical trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Disclosure of the results of these clinical trials can be delayed in certain circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the
clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. The FDA will accept a well- designed and well-conducted foreign clinical
trial not conducted under an IND if the clinical trial was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of BLA submission and approval, clinical trials are generally conducted in three sequential phases, known as Phase 1, Phase 2 and
Phase 3, which may overlap or be combined: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients
who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the safety, dosage tolerance, absorption, metabolism and distribution of the product candidate in
humans, the side effects associated with increasing doses, and, if possible, early evidence of effectiveness.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2 clinical trials generally involve studies conducted in a limited patient population with a specified
disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning
larger and more expensive Phase 3 clinical trials. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">290 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to
provide statistically significant evidence of clinical efficacy of the product for its intended use, further evaluate its safety and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product
approval. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the biologic. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Phase 1, Phase 2, Phase 3 and other types of clinical trials may not be completed successfully within any specified period, if at all. The
FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements or a finding that the patients are being exposed to
an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the biologic has been
associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This
group provides authorization for whether a trial may move forward at designated checkpoints based on access to certain data from the trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the
chemistry and physical characteristics of the biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing
quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality, potency and purity of the final product. Additionally, appropriate packaging must be selected and tested, and
stability studies must be conducted to demonstrate that the biologic does not undergo unacceptable deterioration over their shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>FDA Review Processes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product
development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from preclinical and clinical
studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#146;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from
company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by independent investigators. To support marketing approval, the data
submitted must be sufficient in quality and quantity to establish the safety, purity and potency of the investigational product to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a biologic may be marketed in the United
States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The cost of preparing and submitting a BLA is substantial. Under the PDUFA, each BLA must be accompanied by a substantial user
fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees
are assessed on BLAs for products designated as orphan drugs, unless the product also includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication. The applicant under an approved BLA is also subject to an annual program fee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA reviews a submitted BLA to determine if it is substantially complete before the FDA accepts it for filing and may request additional
information from the sponsor. The FDA must make a decision on accepting a BLA for filing within 60 days of receipt, and may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission. In this event, the BLA
must be resubmitted with any additional information requested. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> review of the BLA. The FDA reviews a BLA to determine, among other things,
whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#146;s continued safety, purity and potency. Under the goals agreed to by the FDA under
the Prescription Drug User Fee Act </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">291 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
(PDUFA), the FDA has ten months, from the filing date, in which to complete its initial review of an original BLA and respond to the applicant, and six months from the filing date of an original
BLA designated for priority review. The review process for both standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information
already provided in the submission. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs, and the review process can be extended by FDA requests for additional information or clarification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Before approving a BLA, the FDA will typically conduct a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing
facilities for the new product to determine whether such facilities comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and
adequate to assure consistent production of the product within required specifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA also may audit data from clinical trials
to ensure compliance with GCP requirements and the integrity of the data supporting safety, purity, and potency of the product candidate. Additionally, the FDA may refer applications for novel products or products that present difficult questions of
safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not
bound by recommendations of an advisory committee, but it generally considers such recommendations carefully when making decisions on approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product is produced, it will
issue either an approval letter or a Complete Response Letter (CRL). An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A CRL indicates that the review cycle of the
application is complete and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the BLA and may require additional clinical data, additional pivotal clinical trial(s) and/or other significant and
time-consuming requirements related to clinical trials, preclinical studies or manufacturing in order for FDA to reconsider the application. If a CRL is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified
in the letter, or withdraw the application or request an opportunity for a hearing. The FDA has committed to reviewing such resubmissions in two or six months from receipt, depending on the type of information included. Even if such data and
information are submitted, the FDA may decide that the BLA does not satisfy the criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If regulatory approval of a
product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may require a REMS to help ensure that the benefits of the
biologic outweigh the potential risks to patients. A REMS is a safety strategy implemented to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe
use. A REMS can include medication guides, communication plans for healthcare professionals and elements to assure a product&#146;s safe use (&#147;ETASU&#148;). An ETASU can include, but is not limited to, special training or certification for
prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring and the use of patient-specific registries. The requirement for a REMS can materially affect the potential market and profitability of
the product. FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with <FONT
STYLE="white-space:nowrap">pre-</FONT> and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess
and monitor the product&#146;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">292 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Orphan Drug Designation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition,
which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States but for which there is no reasonable expectation that the cost of developing and making
the product for this type of disease or condition will be recovered from sales of the product in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Orphan drug
designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation on its own does not
convey any advantage in or shorten the duration of the regulatory review and approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Among the benefits of orphan drug
designation are tax credits for certain research and a waiver of the BLA application user fee. In addition, if a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years from the date of such approval, except in limited
circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care, or in instances of drug supply issues. Competitors,
however, may receive approval of either a different product for the same indication or the same product for a different indication. In the latter case, because healthcare professionals are free to prescribe products for <FONT
STYLE="white-space:nowrap">off-label</FONT> uses, the competitor&#146;s product could be used for the orphan indication despite another product&#146;s orphan exclusivity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A designated orphan drug many not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it
received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if a second applicant
demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare
disease or condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Expedited Development and Review Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA offers a number of expedited development and review programs for qualifying product candidates intended to address an unmet medical
need in the treatment of a serious or life-threatening disease or condition. For example, fast track designation may be granted for products that are intended to treat a serious or life-threatening disease or condition for which there is no
effective treatment and where preclinical or clinical data demonstrate the potential to address unmet medical needs for the disease condition. Fast track designation applies to combination of the product and the specific indication for which it is
being studied. The sponsor of a biological product candidate can request the FDA to designate the candidate for a specific indication for fast track status concurrent with, or after, the submission of the IND for the candidate. The FDA must
determine if the biologic candidate qualifies for fast track designation within 60 days of receipt of the sponsor&#146;s request. The sponsor of a fast track product has opportunities for more frequent interactions with the applicable FDA review
team during product development and, once a BLA is submitted, the product candidate may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a
rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the
sponsor pays any required user fees upon submission of the first section of the BLA. Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite
development and review, such as priority review and accelerated approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">293 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Breakthrough therapy designation may be granted for products that are intended, alone or in
combination with one or more other products, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more
clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new biologic candidate may request that the FDA designate the candidate for a specific indication as a breakthrough therapy concurrent with, or after, the
submission of the IND for the biologic candidate. The FDA must determine if the biological product qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor&#146;s request. The FDA may take certain actions with respect
to breakthrough therapies, including holding meetings with the sponsor throughout the development process, providing timely advice to the product sponsor regarding development and approval, involving more senior staff in the review process,
assigning a cross-disciplinary project lead for the review team and taking other steps to design the clinical studies in an efficient manner. The designation also includes all of the fast track program features, including eligibility for rolling
review of BLA submissions if the relevant criteria are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Priority review may be granted for products that are intended to treat a
serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application
designated for priority review in an effort to facilitate the review. For original BLAs, priority review designation means the FDA&#146;s goal is to take action on the marketing application within six months of the
<FONT STYLE="white-space:nowrap">60-day</FONT> filing date (as compared to ten months under standard review). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accelerated approval may be
granted for products that are intended to treat a serious or life-threatening condition and that generally provide a meaningful therapeutic advantage to patients over existing treatments. A product eligible for accelerated approval may be approved
on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on
irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. In clinical trials, a surrogate endpoint is a measurement
of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions or survives. The accelerated approval pathway is most often used in settings in which the course of a disease is
long, and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the
development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large
studies to demonstrate a clinical or survival benefit. The accelerated approval pathway is contingent on a sponsor&#146;s agreement to conduct additional post-approval confirmatory studies to verify and describe the product&#146;s clinical benefit.
These confirmatory trials must be completed with due diligence and, in some cases, the FDA may require that the trial be designed, initiated and/or fully enrolled prior to approval. Failure to conduct required post-approval studies, or to confirm a
clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by
the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the
conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, breakthrough therapy designation, priority review and accelerated approval do not change the standards for
approval, but may expedite the development or approval process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Additional Controls for Biologics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for
products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">294 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or
spread of communicable diseases in the United States and between states. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After a BLA is approved, the product may also be subject to
official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official
release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on
the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the
regulatory standards on the safety, purity, potency and effectiveness of biological products. As with drugs, after approval of biologics, manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and
are subject to periodic inspection after approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Pediatric Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Pediatric Research Equity Act (PREA), BLAs or supplements to BLAs must contain data to assess the safety and effectiveness of the
biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. The FDA may grant full or
partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA generally does not apply to any biological product for an indication for which orphan designation has been granted. PREA applies to BLAs for
orphan-designated biologics if the biologic is a molecularly targeted cancer product intended for the treatment of an adult cancer and is directed at a molecular target that FDA has determined is substantially relevant to the growth or progression
of a pediatric cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Best Pharmaceuticals for Children Act (BPCA) provides a <FONT STYLE="white-space:nowrap">six-month</FONT>
extension of any exclusivity&#151;patent or <FONT STYLE="white-space:nowrap">non-patent&#151;for</FONT> a biologic if certain conditions are met. Conditions for exclusivity include the FDA&#146;s determination that information relating to the use of
a new biologic in the pediatric population may produce health benefits in that population, FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory
timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including,
among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product,
such as adding new indications or other labeling claims, are subject to prior FDA review and approval. Once a BLA is approved, a product will be subject to certain additional post-approval requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA also may require post-marketing testing, known as Phase 4 testing, may impose a REMS and/or post-market surveillance to monitor the
effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, biological product manufacture, packaging and labeling procedures must continue
to conform to cGMPs after approval. Biologic manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Manufacturers are subject to periodic unannounced inspections by
the FDA, including those focused on manufacturing facilities to assess compliance with cGMPs. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being
implemented. FDA regulations also require investigation and correction of any deviations from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">295 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
cGMP. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or
if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes or failure to comply with
regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks or imposition of distribution or other restrictions under a
REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal
of the product from the market or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning or other enforcement-related letters or holds on post-approval clinical studies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of
product license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandated modification of promotional materials and labeling and the issuance of corrective information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications
containing warnings or other safety information about the product; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to
safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT
STYLE="white-space:nowrap">off-label</FONT> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may
prescribe legally available products for uses that are not described in the product&#146;s labeling and that differ from those tested by us and approved by the FDA. Such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are common across
medical specialties. Physicians may believe that such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of
treatments. The FDA does, however, restrict manufacturer&#146;s communications on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Biosimilars and Reference Product Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Affordable Care Act, signed into law in 2010, includes a subtitle called The Biologics Price Competition and Innovation Act of 2009
(BPCIA), which created an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. Biosimilarity, which requires
that the biological product be highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the biological product and the reference
product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product
can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has
been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">296 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
without such alternation or switch. However, complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products
are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the BPCIA an application for a biosimilar or interchangeable product may not be submitted to the FDA until four years following the date
that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date of first licensure of the reference product. &#147;First licensure&#148;
typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the
licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest or other related entity) for a change (not including a
modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological
product that does not result in a change in safety, purity or potency. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of the reference product if the FDA
approves a full BLA for the competing product containing that applicant&#146;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>International Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to regulations in the United States and Europe, a variety of foreign regulations govern clinical trials, commercial sales and
distribution of product candidates. The approval process varies from country to country and the time to approval may be longer or shorter than that required for FDA or European Commission approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_179"></A>Other Healthcare Laws and Regulations and Legislative Reform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Healthcare Laws and Regulations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product
candidates for which we obtain marketing approval. Our operations, including any arrangements with healthcare providers, physicians, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws that
may affect the business or financial arrangements and relationships through which we would market, sell and distribute our products. Our current and future operations are subject to regulation by various federal, state, and local authorities in
addition to the FDA, including but not limited to CMS, HHS (including the Office of Inspector General, Office for Civil Rights and the Health Resources and Services Administration), the U.S. Department of Justice, or DOJ, and individual U.S.
Attorney offices within the DOJ, and state and local governments. The healthcare laws that may affect our ability to operate include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Anti-Kickback Statute, which prohibits any person or entity from, among other things, knowingly
and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an
item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value. The federal Anti-Kickback
Statute has also been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand. There are a number of statutory exceptions and regulatory safe
harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Additionally, a person or entity does not need to have actual knowledge of
the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">297 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Federal civil and criminal false claims laws, such as the False Claims Act, which can be enforced by private
citizens through civil qui tam actions, and civil monetary penalty laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment of federal funds,
and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. As a result of a modification made by
the Fraud Enforcement and Recovery Act of 2009, a claim includes &#147;any request or demand&#148; for money or property presented to the U.S. government. Drug manufacturers can be held liable under the False Claims Act even when they do not submit
claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims. For example, pharmaceutical companies have been prosecuted under the False Claims Act in connection with their alleged <FONT
STYLE="white-space:nowrap">off-label</FONT> promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to
customers with the expectation that the customers would bill federal healthcare programs for the product. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or
fraudulent claim for purposes of the False Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, among other things, imposes criminal liability for executing or attempting to execute a scheme to
defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and creates
federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document
knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity
does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by Health Information Technology for Economic and Clinical Health Act of 2009
(&#147;HITECH&#148;), and their implementing regulations, which impose privacy, security and breach reporting obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare
clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates that perform services for them that involve individually identifiable health information. HITECH also created new tiers of civil
monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce
HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Federal and state consumer protection and unfair competition laws, which broadly regulate marketplace
activities and activities that potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal transparency requirements under the Physician Payments Sunshine Act, created under the Affordable
Care Act, which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually
to CMS information related to payments and other transfers of value provided to physicians, as defined by such law, and teaching hospitals and physician ownership and investment interests, including such ownership and investment interests held by a
physician&#146;s immediate family members. Effective January&nbsp;1, 2022, these reporting obligations will extend to include payments and transfers of value made to certain <FONT STYLE="white-space:nowrap">non-physician</FONT> providers such as
physician assistants and nurse practitioners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Federal government price reporting laws, which require us to calculate and report complex pricing metrics in
an accurate and timely manner to government programs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">298 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">State and foreign laws that are analogous to each of the above federal laws, such as anti-kickback and false
claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, and state laws that
require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">State and foreign laws that require pharmaceutical companies to implement compliance programs, comply with the
pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other healthcare
providers; state laws that require the reporting of marketing expenditures or drug pricing, including information pertaining to and justifying price increases; state and local laws that require the registration of pharmaceutical sales
representatives; state laws that prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals; state laws that require the posting of information relating to clinical trials and their outcomes; and other
federal, state and foreign laws that govern the privacy and security of health information or personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the
collection, use, disclosure and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not <FONT STYLE="white-space:nowrap">pre-empted</FONT> by HIPAA, thus requiring
additional compliance efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If our operations are found to be in violation of any of these laws or any other current
or future healthcare laws that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and
Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations. Although effective compliance programs can mitigate the risk of
investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our
management&#146;s attention from the operation of our business, even if our defense is successful. In addition, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance
with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Legislative Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We operate in a highly regulated industry, and new laws, regulations and judicial decisions, or new interpretations of existing laws,
regulations and decisions, related to healthcare availability, the method of delivery and payment for healthcare products and services could negatively affect our business, financial condition and prospects. There is significant interest in
promoting healthcare reforms, and it is likely that federal and state legislatures within the United States and the governments of other countries will continue to consider changes to existing healthcare legislation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In
2010, the U.S. Congress enacted the Affordable Care Act, which included changes to the coverage and reimbursement of drug products under government healthcare programs such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established a branded prescription drug fee that pharmaceutical manufacturers of certain branded prescription
drugs must pay to the federal government; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">299 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanded the list of covered entities eligible to participate in the 340B drug pricing program by adding new
entities to the program; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer
50% (increased to 70%, effective as of 2019) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap
period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extended manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are
enrolled in Medicaid managed care organizations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid
coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are
calculated for certain drugs and biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct
comparative clinical effectiveness research, along with funding for such research; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established a Center for Medicare and Medicaid Innovation at the CMS to test innovative payment and service
delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">created a licensure framework for <FONT STYLE="white-space:nowrap">follow-on</FONT> biologic products.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There remain judicial and congressional challenges to certain aspects of the Affordable Care Act. It is unclear how
efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act. It is difficult to predict the future legislative landscape in healthcare and the effect on our business, results of operations, financial condition and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, there have been and continue to be a number of initiatives at the United States federal and state levels that
seek to reduce healthcare costs. If government spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA, to continue to function at current levels, which may impact the ability
of relevant agencies to timely review and approve research and development, manufacturing and marketing activities, which may delay our ability to develop, market and sell any product candidates we may develop. Moreover, any significant spending
reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented, or any significant taxes or fees that may be imposed on us, as part of any broader deficit reduction effort or legislative
replacement to the Budget Control Act, could have an adverse impact on our anticipated product revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, there has been
heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several congressional inquiries and proposed legislation designed to, among other things, bring more transparency
to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. Individual states in the United States have also become increasingly active in
passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and
transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what
pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Further, it is possible that additional governmental action is taken in response to the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. We expect that additional state and federal healthcare reform measures will be adopted in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">300 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_180"></A>Employees and Human Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2020, we had 67 full-time employees, with 53 in research and development and 14 in general and administrative
functions. As of December&nbsp;31, 2020, 37 of our full-time employees had completed a Ph.D. or other advanced science or medical degree. None of our employees is represented by a labor union or covered by collective bargaining agreements, and we
have not experienced any work stoppages.&nbsp;We consider our relationship with our employees to be good. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our human capital objectives
include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants
and directors through the granting of stock-based compensation awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_181"></A>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our principal executive offices are located in South San Francisco, California, pursuant to a lease that expires in 2025. We believe that our
current facilities are adequate to meet our ongoing needs, and that, if we require additional space, we will be able to obtain additional facilities on commercially reasonable terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_182"></A>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will
have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of
management resources, and other factors. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_183"></A>SURROZEN&#146;S MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The following discussion and analysis of Surrozen&#146;s financial condition and
results of operations should be read together with Surrozen&#146;s financial statements and related notes included elsewhere in this proxy statement/prospectus. The discussion and analysis should also be read together with Surrozen&#146;s pro forma
financial information as of and for the three months ended March 31, 2021 and the year ended December 31, 2020. This discussion includes both historical information and forward-looking statements that involve risks, uncertainties and assumptions.
Surrozen&#146;s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, those discussed in the section titled &#147;Risk Factors&#148; and
&#147;Cautionary Note Regarding Forward-Looking Statements&#148; included elsewhere in this proxy statement/prospectus. For the purposes of this Surrozen&#146;s Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations section, &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;Surrozen,&#148; and other similar terms refer to Surrozen, Inc., a Delaware corporation. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_184"></A>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are discovering and developing biologic drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a
broad range of organs and tissues. Building upon the seminal work of our founders and scientific advisors who discovered the Wnt gene and key regulators of the Wnt pathway, we have made breakthrough discoveries that we believe will overcome previous
limitations in harnessing the potential of Wnt biology. These breakthroughs enable us to rapidly and flexibly design tissue-targeted therapeutics that modulate Wnt signaling. As a result of our discoveries, we are pioneering the selective activation
of Wnt signaling, designing and engineering Wnt pathway mimetics, and advancing tissue-specific Wnt candidates. Our lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">301 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Wnt or <FONT STYLE="white-space:nowrap">R-spondin</FONT> proteins, both of which are involved in activation of the Wnt pathway. Given Wnt signaling is essential in tissue maintenance and
regeneration throughout the body, we have the potential to target a wide variety of severe diseases, including certain diseases that afflict the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas and central nervous system. Our
strategy is to exploit the full potential of Wnt signaling by identifying disease states responsive to Wnt modulation, design tissue-specific therapeutics, and advance candidates into clinical development in targeted indications with high unmet
need. Our unique approach and platform technologies have led to the discovery and advancement of two lead product candidates. We are currently conducting preclinical studies and plan to initiate a Phase 1 clinical trial in 2022 for <FONT
STYLE="white-space:nowrap">SZN-1326,</FONT> our candidate in development for moderate to severe inflammatory bowel disease, or IBD, with ulcerative colitis, or UC, as our first proposed indication. Furthermore, we plan to initiate a Phase 1 clinical
trial in 2022 for <FONT STYLE="white-space:nowrap">SZN-043,</FONT> our candidate in development for severe alcoholic hepatitis, or AH. We expect to nominate additional lead candidates and advance them into the clinic in 2023 and beyond. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception in 2015, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company,
business planning, raising capital, developing and optimizing our Wnt therapeutics platform, identifying potential product candidates, undertaking research and development activities, engaging in strategic transactions, establishing and enhancing
our intellectual property portfolio, and providing general and administrative support for these operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have no products approved
for commercial sale and have not generated any revenue to date, and we continue to incur significant research and development and other expenses related to our ongoing operations. Our ability to generate product revenue sufficient to achieve
profitability, if ever, will depend on the successful development of any future product candidates, which we expect will take a number of years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_185"></A>The Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April&nbsp;15, 2021, we entered into the Business Combination Agreement with CHFW and Merger Sub, a subsidiary of CHFW . Upon closing of the
Business Combination, CHFW will become a Delaware corporation and will be renamed to Surrozen, Inc., or New Surrozen, and Merger Sub will merge with and into the Company, with the Company as the surviving company and, after giving effect to such
merger, continuing as a wholly-owned subsidiary of New Surrozen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Business Combination is expected to be accounted for as a reverse
recapitalization. Surrozen will be deemed the accounting predecessor and the combined entity will be the successor SEC registrant, meaning that Surrozen&#146;s financial statements for previous periods will be disclosed in the registrant&#146;s
future periodic reports filed with the SEC. Under this method of accounting, CHFW will be treated as the acquired company for financial statement reporting purposes. The most significant change in the successor&#146;s future reported financial
position and results are expected to be an estimated net increase in cash and cash equivalents (as compared to Surrozen&#146;s balance sheet at March 31, 2021) of between approximately $112.0&nbsp;million, assuming maximum shareholder redemptions
permitted under the Business Combination Agreement, and $191.0&nbsp;million, assuming no shareholder redemptions, and in each case including $120.0&nbsp;million in gross proceeds from the private investment in public equity of New Surrozen, or PIPE
Financing, which is contingent upon the substantially concurrent closing of the Business Combination. Total transaction costs are estimated at approximately $18.8&nbsp;million. See &#147;<I>Unaudited Pro Forma Condensed Combined Financial
Information</I>.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result of the Business Combination, Surrozen will become the successor
<FONT STYLE="white-space:nowrap">to&nbsp;an&nbsp;SEC-registered&nbsp;and&nbsp;Nasdaq-listed</FONT> company, which will require Surrozen to hire additional personnel and implement procedures and processes to address public company regulatory
requirements and customary practices. Surrozen expects to incur additional annual expenses as a public company for, among other things, directors&#146; and officers&#146; liability insurance, director fees, and additional internal and external
accounting, legal, and administrative resources, including increased personnel costs, audit and other professional service fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">302 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_186"></A>Key Trends, Opportunities and Uncertainties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From our inception through March 31, 2021, we financed our operations primarily with $133.1&nbsp;million in net cash proceeds from private
placements of our redeemable convertible preferred stock. We have incurred net losses in each year since inception. During the years ended December 31, 2020 and 2019, we incurred net losses of $32.7&nbsp;million and $24.4&nbsp;million, respectively,
and used $29.1&nbsp;million and $21.1&nbsp;million of cash in operations, respectively. During the three months ended March 31, 2021 and 2020, we incurred net losses of $13.0&nbsp;million and $6.3 million, respectively, and used $10.3 million and
$6.1 million of cash in operations, respectively. As of March 31, 2021, we had an accumulated deficit of $101.0&nbsp;million, and we do not expect positive cash flows from operations for the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March 31, 2021, we had cash, cash equivalents and short-term investments of $38.7&nbsp;million. We estimate, based on our current
operating plan, that our existing cash, cash equivalents and short-term investments, together with the estimated net proceeds from the Business Combination and the PIPE Financing described above, will be sufficient to fund our operating expenses and
capital expenditure requirements for at least the next 12 months from the date of this proxy statement/prospectus. We have based this projection on assumptions that may be inaccurate and as a result, we may utilize our capital resources sooner than
we expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect to continue to incur losses for the foreseeable future and expect to incur increased expenses as we expand our
pipeline and advance our product candidates through clinical development and regulatory submissions. Specifically, in the near term we expect to incur substantial expenses relating to our planned Phase 1 clinical trials, the development and
validation of our manufacturing processes, and other research and development activities. Furthermore, upon the completion of the Business Combination and PIPE Financing, we expect to incur additional costs associated with operating as a public
company, increased expenses related to legal, accounting, insurance, regulatory and <FONT STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with exchange listing and Securities and Exchange Commission
requirements, directors and officers liability insurance premiums, and investor relations activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will need substantial additional
funding to support our continuing operations and pursue our development strategy. Until such time as we can generate sufficient revenue from sales of our product candidates, if ever, we expect to finance our operations through public or private
equity offerings, debt financings or other capital sources, including government grants, potential collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or to enter into such agreements or
arrangements on favorable terms, or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the disruptions to, and volatility in, the credit and financial markets in the United
States, or U.S. and worldwide resulting from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and actions taken to slow its spread, including severely diminished liquidity and credit availability, declines in consumer confidence,
declines in economic growth, increases in unemployment rates, and uncertainty about economic stability. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive.
If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back, or discontinue the development of our product pipeline or other research and development initiatives. We
also could be required to seek collaborators for our product pipeline and any future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or
license on unfavorable terms our rights to our product pipeline and any future product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The amount and timing of our future funding requirements will depend on many factors including the pace and results of our development
efforts. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We rely, and
expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical studies and clinical trials, as well as for commercial manufacture if any of our product candidates
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">303 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
obtains marketing approval. We also rely, and expect to continue to rely, on third parties to manufacture, package, label, store, and distribute our product candidates and, if marketing approval
is obtained, our products. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment, and personnel while also enabling us to focus our
expertise and resources on the development of our products. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic
continues to rapidly evolve, and we will continue to monitor the <FONT STYLE="white-space:nowrap">COVID-19</FONT> situation closely. The extent of the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> on our business, operations and
clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on our preclinical development activities, planning for regulatory submissions and
clinical trials, clinical research organizations, or CROs, third-party manufacturers, other third parties with whom we do business, and, if we obtain regulatory approval to commence dosing in humans, trial enrollment, trial sites. In addition, the
pandemic has impacted and may continue to impact regulatory authorities and our key scientific and management personnel. The ultimate impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or a similar health epidemic is highly
uncertain and subject to change. To the extent possible, we are conducting business as usual, with necessary or advisable modifications to employee travel and most of our employees working remotely. We will continue to actively monitor the rapidly
evolving situation related to <FONT STYLE="white-space:nowrap">COVID-19</FONT> and may take further actions that alter our operations, including those that may be required by federal, state or local authorities, or that we determine are in the best
interests of our employees and other third parties with whom we do business. At this point, the extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may affect our business, operations and clinical development timelines and
plans, including the resulting impact on our expenditures and capital needs, remains uncertain. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_187"></A>Stanford License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Below is a summary of the key terms for our agreements with The Board of Trustees of the Leland Stanford Junior University, or Stanford. For a
more detailed description, see the section titled &#147;Business&#151;Stanford License Agreements&#148; and Note 6 to our audited financial statements and unaudited condensed interim financial statements included elsewhere in this proxy
statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2016, we entered into a license agreement with Stanford, or the 2016 Stanford Agreement, which was amended
in July 2016, October 2016 and January 2021, pursuant to which we obtained from Stanford, a worldwide, exclusive, sublicensable license under certain patents, rights, or licensed patents and technology related to our engineered Wnt surrogate
molecules to make, use, import, offer to sell and sell products that are claimed by the licensed patents or that use or incorporate such technology, or licensed products, for the treatment, diagnosis and prevention of human and veterinary diseases.
The 2016 Stanford Agreement covers two patent families and any patents that grant from these families are predicted to expire in 2035 and 2037, absent any patent term adjustments or extensions. In consideration for this license, we paid Stanford a
nominal upfront fee and issued an aggregate of 241,688 shares of our common stock to Stanford, the University of Washington and two <FONT STYLE="white-space:nowrap">co-inventors</FONT> of the licensed patents. In addition, we agreed to pay Stanford
nominal annual license maintenance fees which are creditable against earned royalties owed to Stanford for the same year, an aggregate of up to $1.4&nbsp;million for the achievement of specified development and regulatory milestones, and an
aggregate of up to $5.0&nbsp;million for achievement of specified sales milestones. Stanford is also entitled to receive royalties from us equal to a very low single digit percentage of our and our sublicensees&#146; net sales of licensed products
that are covered by a valid claim of a licensed patent. Additionally, we agreed to pay Stanford a <FONT STYLE="white-space:nowrap">sub-teen</FONT> double digit percentage of certain consideration we receive as a result of granting sublicenses to the
licensed patents and, if we are acquired, a <FONT STYLE="white-space:nowrap">one-time</FONT> change of control fee in the low six figures. Stanford retains the right under the 2016 Stanford Agreement, on behalf of itself, Stanford Hospital and
Clinics, the University of Washington and all other <FONT STYLE="white-space:nowrap">non-profit</FONT> research institutions, to practice the licensed patents and technology for any <FONT STYLE="white-space:nowrap">non-profit</FONT> purpose. The
licensed patents and technology are additionally subject to a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> irrevocable, worldwide license held by the Howard Hughes Medical Institute to practice the licensed patents and technology for its
research purposes, but with no right to assign or sublicense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">304 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2018, we entered into another license agreement with Stanford, or the 2018
Stanford Agreement, pursuant to which we obtained from Stanford, a worldwide, exclusive, sublicensable license under certain patent rights related to our surrogate <FONT STYLE="white-space:nowrap">R-spondin</FONT> proteins, or the licensed patents,
to make, use, import, offer to sell and sell products that are claimed by the licensed patents, or licensed products, for the treatment, diagnosis and prevention of human and veterinary diseases, or the exclusive field. The 2018 Stanford Agreement
covers one patent family, and any patents that grant from this family are predicted to expire in 2038, absent any patent term adjustment or extension. Additionally, Stanford granted us a worldwide, non- exclusive, sublicensable license under the
licensed patents to make and use licensed products for research and development purposes in furtherance of the exclusive field and a worldwide, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to make, use and import, but not to offer
to sell or sell, licensed products in any other field of use. In consideration for these licenses, we paid Stanford a nominal upfront fee. We also agreed to pay Stanford nominal annual license maintenance fees which are creditable against earned
royalties owed to Stanford for the same year, and an aggregate of up to $0.425&nbsp;million for the achievement of specified development and regulatory milestones. Stanford is also entitled to receive royalties from us equal to a <FONT
STYLE="white-space:nowrap">sub-single</FONT> digit percentage of our and our sublicensees&#146; net sales of licensed products. Additionally, we agreed to pay Stanford a <FONT STYLE="white-space:nowrap">one-time</FONT> payment in the low six figures
for each sublicense of the licensed patents that we grant to a third party and, if we are acquired, a <FONT STYLE="white-space:nowrap">one-time</FONT> nominal change of control fee. Stanford retains the right under the 2018 Stanford Agreement, on
behalf of itself, Stanford Health Care, Lucile Packard Children&#146;s Hospital at Stanford and all other <FONT STYLE="white-space:nowrap">non-profit</FONT> research institutions, to practice the licensed patents for any <FONT
STYLE="white-space:nowrap">non-profit</FONT> purpose. The licensed patents are additionally subject to a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> irrevocable, worldwide license held by the Howard Hughes Medical Institute to exercise
any intellectual property rights with respect to the licensed patents for research purposes, including the right to sublicense to <FONT STYLE="white-space:nowrap">non-profit</FONT> and governmental entities but with no other rights to assign or
sublicense. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under each of the 2016 Stanford Agreement and the 2018 Stanford Agreement, or Stanford Agreements, we agreed to use
commercially reasonable efforts to develop and commercialize licensed products and we agreed to achieve certain funding and development milestones by certain dates. Unless earlier terminated, each Stanford Agreement will continue until the
expiration of the patents licensed under such Stanford Agreement. We may terminate either Stanford Agreement at any time for any reason by providing at least 30 days&#146; written notice to Stanford. Stanford may terminate either Stanford Agreement
if we breach certain provisions of that Stanford Agreement and fail to remedy such breach within 90 days after written notice of the breach given by Stanford. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_188"></A>UCSF License and Option Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Below is a summary of the key terms for our agreements with The Regents of the University of California, or UCSF. For a more detailed
description, see the section titled &#147;Business&#151;UCSF License and Option Agreements&#148; and Note 6 to our audited financial statements and unaudited condensed interim financial statements included elsewhere in this proxy
statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September and October 2016, we entered into two license and option agreements with UCSF pursuant to which we
obtained <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses from UCSF for internal research and antibody discovery purposes and an option to negotiate with UCSF to obtain a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license
under UCSF&#146;s rights in the applicable library to make, use, sell, offer for sale and import products incorporating antibodies identified or resulting from our use of such library, or licensed products. Our SZN-1326 candidate comprises a VHH
domain isolated from the phage display llama VHH single domain antibody library. In consideration for the license and option rights under each UCSF Agreement, we paid UCSF a nominal option issue fee and agreed to pay UCSF a nominal annual option
maintenance fee. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2020, we amended and restated our license and option agreements with UCSF, to provide <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> licenses to make and use a certain human Fab na&iuml;ve phage display library and to make and use a certain phage display llama VHH single domain antibody library for internal research and antibody
discovery purposes and an option to negotiate with UCSF to obtain a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under UCSF&#146;s rights in the applicable library to make, use, sell, offer for sale and import products incorporating
antibodies identified or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">305 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
resulting from our use of such library, or licensed products. If we exercise the option under the UCSF Agreement, we and UCSF will negotiate in good faith the terms of a commercial license
agreement in addition to the <FONT STYLE="white-space:nowrap">pre-agreed</FONT> terms which include payment to UCSF of a nominal license issue fee, nominal annual license maintenance fees, nominal to low six figure milestone payments for the
achievement of a specified regulatory milestone event for each licensed product, nominal annual minimum royalties, which are creditable against earned royalties for the same year, and earned royalties equal to a
<FONT STYLE="white-space:nowrap">sub-single</FONT> digit percentage of our and our sublicensees&#146; net sales of licensed products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless earlier terminated, each UCSF Agreement will continue until four years from its execution date and we may exercise the option to
negotiate a commercial license at any time during that term. Additionally, we may extend each UCSF Agreement for any additional four years by paying UCSF a nominal term extension fee. We may terminate either UCSF Agreement at any time for any reason
by providing at least 60 days&#146; written notice to UCSF. UCSF may terminate either UCSF Agreement if UCSF reasonably believes we are in material breach of such UCSF Agreement and we fail to remedy such breach within 60 days after written notice
of such breach given by UCSF. Additionally, the UCSF Agreements will automatically terminate in the event of our bankruptcy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_189">
</A>Distributed Bio Subscription Agreement </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Below is a summary of the key terms for our agreement with Distributed Bio. For a more
detailed description, see the section titled &#147;Business&#151;Distributed Bio Subscription Agreement&#148; and Note 6 to our audited financial statements and unaudited condensed interim financial statements included elsewhere in this proxy
statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September 2016, we entered into, and in January 2019 we amended, an antibody library subscription agreement with
Distributed Bio, or the Distributed Bio Agreement, in which we obtained from Distributed Bio a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to use Distributed Bio&#146;s antibody library to identify antibodies directed to an
unlimited number of our proprietary targets and to make, use, sell, offer for sale, import and exploit products incorporating the antibodies that we identify, or licensed products. Our SZN-1326 candidate incorporates a binding component isolated
from the Distributed Bio antibody library. In consideration for the rights granted to us under the Distributed Bio Agreement, we paid Distributed Bio a nominal upfront fee and an additional nominal fee upon entering into the amendment. We agreed to
pay Distributed Bio an annual fee in the low six figures after the first three years. Additionally, we agreed to pay Distributed Bio an aggregate of $5.9&nbsp;million for each licensed product that achieves specified development, regulatory and
commercial milestones and royalties equal to a very low single digit percentage of our and our sublicensees&#146; net sales of licensed products. Our obligation to pay royalties will end for each licensed product ten years after its first commercial
sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless earlier terminated, the Distributed Bio Agreement will continue for an initial four-year term and will thereafter
automatically renew for additional <FONT STYLE="white-space:nowrap">one-year</FONT> terms. We may terminate the Distributed Bio Agreement for convenience at any time by providing written notice to Distributed Bio. We and Distributed Bio may
terminate the Distributed Bio Agreement for the other party&#146;s material breach and failure to cure such breach within 60 days after notice of such breach. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_190"></A>Components of Our Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have not generated any revenue
from the sale of our products, and we do not expect to generate any revenue unless and until we obtain regulatory clearance or approval of, and commercialize, our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We classify operating
expenses into two main categories: (i)&nbsp;research and development expenses and (ii)&nbsp;general and administrative expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">306 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception, we have focused significant resources on our research and development activities. Our research and development expenses
consist of external and internal expenses incurred in connection with our research activities and development programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">External expenses
include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs incurred under agreements with third parties, including CROs and other third parties conducting research
and development activities on our behalf; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs of outside consultants, including their fees, stock-based compensation and related travel expenses;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs of laboratory supplies and acquiring, developing and manufacturing drug candidate materials; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">license payments under our license agreements made for intellectual property used in research and development
activities. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Internal expenses include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel-related costs, including salaries, bonuses, benefits and stock-based compensation for individuals
involved in our research and product development activities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilities, depreciation, and other allocated costs, which include rent and insurance. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect our research and development expenses will increase significantly for the foreseeable future as we identify and develop product
candidates, in particular as we seek to initiate clinical trials and pursue regulatory approval and commercialization for <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expenses are recognized as they are incurred. <FONT STYLE="white-space:nowrap">Non-refundable</FONT> advance payments
for services that will be used or rendered for future research and development activities are recorded as prepaid expenses and recognized as an expense as the related services are performed. We track external expenses by stage of program, clinical
or preclinical. However, we do not track internal expenses on a program specific or stage of program basis because these costs are deployed across multiple programs and, as such, are not separately classified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered, and may continue to enter, into license agreements to access and utilize certain molecules. We evaluate if the license
agreement is an acquisition of an asset or a business. To date, none of our license agreements have been considered to be an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future
milestone payments made before product approval, are immediately recognized as research and development expenses when due, provided there is no alternative future use of the rights in other research and development projects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or
costs required to complete the remaining development of <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043</FONT> or any future product candidates. This is due to the numerous risks and uncertainties
associated with the development of product candidates, many of which are outside of our control, including those associated with: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and progress of preclinical and clinical development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and scope of preclinical and clinical programs we decide to pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain our current research and development programs and to establish new ones;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing an appropriate safety profile with <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of sites and patients included in the clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">307 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the countries in which the clinical trials are conducted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">per patient trial costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful patient enrollment in, and the initiation of, clinical trials, as well as drop out or
discontinuation rates, particularly in light of the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic environment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the successful completion of clinical trials with safety, tolerability and efficacy profiles that are
satisfactory to the FDA or any comparable foreign regulatory authority; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of trials required for regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, receipt and terms of any regulatory approvals from applicable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish new licensing or collaboration arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the performance of our future collaborators, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant and changing government regulation and regulatory guidance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of any business interruptions to our operations or to those of the third parties with whom we work,
particularly in light of the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic environment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launching commercial sales of our drug candidates, if approved, whether alone or in collaboration with others;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining a continued acceptable safety profile of the drug candidates following approval.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any changes in the outcome of any of these variables could mean a significant change in the costs and timing associated
with the development of our drug candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses consist primarily of personnel-related costs, including salaries, bonuses, benefits and stock-based
compensation expense for personnel in executive, finance, human resources, business and corporate development, legal, and other administrative functions. General and administrative expenses also include legal fees, professional fees paid for
accounting, auditing, consulting, tax, investor relations services, insurance costs, and facility costs not otherwise included in research and development expenses, and following the Business Combination, will include public company expenses such as
costs associated with compliance with the rules and regulations of the SEC and those of the Nasdaq listing rules. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect that our
general and administrative expenses will increase significantly for the foreseeable future as we expand our operating activities and prepare for clinical trials of our product candidates, increase our headcount and support our operations as a public
company and our growth, including increased expenses related to legal, accounting, insurance, regulatory and <FONT STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with exchange listing and SEC
requirements, directors and officers liability insurance premiums and investor relations activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other income consists primarily of interest earned on our cash equivalents and short-term investments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">308 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_191"></A>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Comparison of the Three Months Ended March 31, 2021 and 2020</I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our results of operations for the periods presented (dollars in thousands): </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended</B><br><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Dollar</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,031</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,361</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,670</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(65</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-88</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,022</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,735</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our research and development expenses for the three months ended March 31, 2021 and 2020 (in thousands): </P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended</B><br><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Internal costs:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel expenses (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities and other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In future periods when clinical trial expenses are incurred, external expenses will be broken out between
our clinical programs and preclinical programs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The increase of $3.9 million in research and development expenses for
the three months ended March 31, 2021, compared to the three months ended March 31, 2020, is due in part to the $2.9 million increase in external expenses as we continue to invest in research and development activities related to SZN-1326 and
SZN-043 and the $1.0 million increase in personnel-related expenses and facility costs as a result of a higher headcount. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative
Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The increase of $2.7 million in general and administrative expenses for the three months ended March 31, 2021, compared to
the three months ended March 31, 2020, is primarily attributable to the $1.9 million increase in professional service fees and consulting services to support the growth of our operations and the $0.6 million increase in personnel-related expenses
due to an increase in headcount and options granted to the employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The decrease of $65,000 in other income for the three months ended March 31, 2021, compared to the three months ended March 31, 2020, is due to
the decrease in interest income on our money market funds and marketable securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">309 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Comparison of the Years Ended December 31, 2020 and 2019 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our results of operations for the periods presented (dollars in thousands): </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,807</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,701</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(653</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-88</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,362</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,354</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our research and development expenses for the years ended December 31, 2020 and 2019 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Internal costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel expenses (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities and other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In future periods when clinical trial expenses are incurred, external expenses will be broken out between
our clinical programs and preclinical programs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The increase of $6.1&nbsp;million in research and development expenses
for the year ended December&nbsp;31, 2020, compared to the year ended December&nbsp;31, 2019 is due in part to the $4.0&nbsp;million increase in external expenses as we continue to invest in research and development activities related to <FONT
STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043</FONT> and the $1.9&nbsp;million increase in personnel-related expenses as a result of a higher headcount. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
increase of $1.6&nbsp;million in general and administrative expenses for the year ended December&nbsp;31, 2020, compared to the year ended December&nbsp;31, 2019 is primarily attributable to the $0.8&nbsp;million increase in personnel-related
expenses due to an increase in headcount and the $0.6&nbsp;million increase in professional service fees and consulting services to support the growth of our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Income </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The decrease of
$0.7&nbsp;million in other income for the year ended December&nbsp;31, 2020, compared to the year ended December&nbsp;31, 2019 is due to the decrease of $0.4&nbsp;million in interest income on our money market funds and marketable securities and the
decrease of $0.3&nbsp;million in sublease income as the sublease ended in April 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">310 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_192"></A>Liquidity, Capital Resources and Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since inception, we have not generated any revenue from product sales and have incurred significant net operating losses and negative cash
flows from operations. As of March 31, 2021, we had an accumulated deficit of $101.0&nbsp;million. During the years ended December&nbsp;31, 2020 and 2019, we used $29.1&nbsp;million and $21.1&nbsp;million in cash flows from operations, respectively.
During the three months ended March 31, 2021 and 2020, we used $10.3 million and $6.1 million in cash flows from operations, respectively. We anticipate that we will continue to incur net losses for the foreseeable future because of additional costs
and expenses related to our research and development activities, including increased expenses from pipeline advancement and advancement of our product candidates into and through clinical development and associated regulatory submissions, and
increased general and administrative expenses as we scale our organization. We have historically financed our operations primarily through private placements of redeemable convertible preferred stock. Through March&nbsp;31, 2021, we raised aggregate
net financing proceeds of approximately $133.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We had cash, cash equivalents, and short-term investments of
$38.7&nbsp;million as of March 31, 2021. On a pro forma basis, assuming shareholder approval and consummation of the Business Combination, our cash, cash equivalents and short-term investments would have been between approximately
$150.7&nbsp;million and $229.7&nbsp;million as of March&nbsp;31, 2021, depending on the extent of redemptions by CHFW stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
believe, based on our current operating plan, that our existing cash, cash equivalents, and short-term investments, together with the estimated net proceeds from the Business Combination and PIPE Financing described above, will be sufficient to fund
our operations for at least the next 12 months from the date of this proxy statement/prospectus. However, we estimate, based on our current operating plan, that our existing cash, cash equivalents, and short-term investments will not be sufficient
to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the date of this proxy statement/prospectus. Our ability to continue as a going concern is dependent upon our ability to successfully secure
sources of financing and ultimately achieve profitable operations. Insufficient liquidity may require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_193"></A>Funding Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To date, we have not generated any revenue. We do not expect to generate any meaningful revenue unless and until we obtain regulatory approval
and commercialize <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043</FONT> or any future product candidates, and we do not know when, or if, that will occur. We will continue to require additional capital
to develop <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043</FONT> and fund operations for the foreseeable future. Since our inception in 2015, we have devoted substantially all of our efforts and
financial resources to organizing and staffing our company, business planning, raising capital, developing and optimizing our Wnt therapeutics platform, identifying potential product candidates, undertaking research and development activities,
engaging in strategic transactions, establishing and enhancing our intellectual property portfolio, and providing general and administrative support for these operations. We expect our expenses to continue to increase in connection with our ongoing
activities as we continue to advance <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043</FONT> into clinical development and regulatory approval. In addition, upon the completion of the Business
Combination, we expect to incur additional costs associated with operating as a public company. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will need to raise substantial
additional capital through public or private equity offerings, debt financings or other capital sources, including government grants, potential collaborations with other companies or other strategic transactions. There can be no assurance that
sufficient funds will be available to us at all or on attractive terms when needed from these sources. If we are unable to obtain additional funding from these or other sources when needed, it may be necessary to significantly reduce expenses
through reductions in staff and delaying, scaling back operations, or stopping certain research and development programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have based
our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. Because of the numerous risks and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">311 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future
funding requirements will depend on many factors, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, rate of progress, results and costs of researching and developing our lead product candidates or
any future product candidates, conducting preclinical studies, in particular our current ongoing preclinical studies of <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome, costs, and timing of involved in, obtaining regulatory approvals for our lead product candidate
or our other product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and scope of clinical programs we decide to pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of acquiring, licensing, or investing in product candidates and technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with securing and establishing commercialization; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the
amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense, and enforcement of any patents or other intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need and ability to retain key management and hire scientific, technical, business, and medical personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing products and product candidates and other market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, receipt, and amount of sales from <FONT STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT
STYLE="white-space:nowrap">SZN-043</FONT> and any future product candidates, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to implement additional internal systems and infrastructure, including financial and reporting
systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the economic and other terms, timing of, and success of any collaboration, licensing, or other arrangements
which we may enter in the future; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of the disruptions to and volatility in the credit and financial markets in the U.S. and worldwide
from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we raise additional funds by issuing equity
securities, our stockholders will experience dilution. If we raise additional capital through debt financing, we may be subject to covenants that restrict our operations including limitations on our ability to incur liens or additional debt, pay
dividends, repurchase our common stock, make certain investments, and engage in certain merger, consolidation, or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our
stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to others our rights to <FONT
STYLE="white-space:nowrap">SZN-1326</FONT> and <FONT STYLE="white-space:nowrap">SZN-043</FONT> and any future product candidates or discovery programs in certain territories or indications that we would prefer to develop and commercialize ourselves.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">312 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary of Statements of Cash Flows </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth the primary sources and uses of cash, cash equivalents and restricted cash for the periods presented below (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended</B><br><B>March 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,074</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,056</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,578</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,997</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Used in Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash used in operating activities of $10.3 million for the three months ended March 31, 2021 was primarily due to the use of funds in our
operations and the resulting net loss of $13.0&nbsp;million, partially offset by $1.3 million in non-cash charges and a net change of $1.4&nbsp;million in our net operating assets and liabilities. The net change in our operating assets and
liabilities was primarily due to a net increase in prepaid expenses, accounts payable and accrued liabilities. Cash used in operating activities of $6.1 million for the three months ended March&nbsp;31, 2020 was primarily due to the use of funds in
our operations and the resulting net loss of $6.3 million and a net change of $0.7 million in our net operating assets and liabilities, partially offset by $0.9 million in non-cash charges. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash used in operating activities of $29.1&nbsp;million in 2020 was primarily due to the use of funds in our operations and the resulting net
loss of $32.7&nbsp;million and a net change of $0.05&nbsp;million in our net operating assets and liabilities, partially offset by $3.6&nbsp;million in <FONT STYLE="white-space:nowrap">non-cash</FONT> charges. The net change in our operating assets
and liabilities was primarily due to a net increase in prepaid expenses, accounts payable and accrued liabilities. Cash used in operating activities of $21.1&nbsp;million in 2019 was primarily due to the use of funds in our operations and the
resulting net loss of $24.4&nbsp;million and a net change of $0.4&nbsp;million in our net operating assets and liabilities, partially offset by $3.7&nbsp;million in <FONT STYLE="white-space:nowrap">non-cash</FONT> charges. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Used in Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash used in investing activities of $1.4 million for the three months ended March 31, 2021 consisted primarily of $1.1 million of cash used
for the purchase of marketable securities and $0.3 million of cash used for the purchase of property and equipment. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash used in
investing activities of $15.1&nbsp;million in 2020 consisted primarily of $14.2&nbsp;million of cash used for the purchase of marketable securities and $0.9&nbsp;million of cash used for the purchase of property and equipment. Cash used in investing
activities of $1.6&nbsp;million in 2019 consisted of purchases of property and equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Provided by Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash provided by financing activities of $0.2 million and $0.1 million for the three months ended March 31, 2021 and 2020, respectively,
consisted primarily of the proceeds from the exercise of options. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash provided by financing activities of $50.1&nbsp;million in
2020 consisted primarily of net proceeds of $49.9&nbsp;million from the issuance and sale of shares of our Series C redeemable convertible preferred stock. Cash used in financing activities of $28.9&nbsp;million in 2019 consisted primarily of net
proceeds from the issuance and sale of shares of our Series B redeemable convertible preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">313 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_194"></A>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March 31, 2021, we have lease obligations consisting of two operating leases for our operating facilities. The leases expire in November
2021 and in April 2025. Under the terms of the leases, we had lease obligations consisting of $10.7&nbsp;million in payments through 2025 as of March 31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are party to license or subscription agreements pursuant to which we have <FONT STYLE="white-space:nowrap">in-licensed</FONT> various
intellectual property rights. The license agreements obligate us to make certain milestone payments related to achievement of specified events, as well as royalties in the low single-digit percentages based on sales of licensed products. The payment
obligations under the license agreements are contingent upon future events, such as our achievement of specified milestones or generating product sales. As of March 31, 2021, we were unable to estimate the timing or likelihood of achieving these
milestones or generating future product sales. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We enter into contracts in the normal course of business with third-party vendors for
preclinical research studies, research supplies, and other services and products for operating purposes. These contracts generally provide for termination on notice, and therefore we believe that our
<FONT STYLE="white-space:nowrap">non-cancelable</FONT> obligations under these agreements are not material. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_195"></A>Critical Accounting Policies, Significant Judgments and Use of Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these
financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported
expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about
the carrying value of assets and liabilities that are not readily apparent from other sources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Actual results may differ from these
estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving
management&#146;s judgments and estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While our significant accounting policies are described in the notes to our financial
statements included elsewhere in this proxy statement/prospectus, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development costs are expensed as incurred. Research and development costs consist of external and internal expenses directly
attributable to the conduct of research and development programs. The external expenses include the costs of services provided by outside contractors, clinical research organizations and contract manufacturing organizations. The internal expenses
include the costs of salaries, payroll taxes, stock-based compensation, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, and the facility costs for laboratory space used for research and development
activities, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into
and may continue to enter into, license agreements to access and utilize certain technology. In each case, we evaluate if the license agreement results in the acquisition of an asset or a business. To date, none of our license agreements have been
considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately
recognized as research and development expense when they are paid or become payable, provided there is no alternative future use of the rights in other research and development projects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">314 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Accrued Research and Development Expense </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We record accruals for estimated costs of research, preclinical, and manufacturing development, within accrued expenses which are significant
components of research and development expenses. A substantial portion of our ongoing research and development activities is conducted by third-party service providers. We accrue the costs incurred under agreements with these third parties based on
estimates of actual work completed in accordance with the respective agreements. We determine the estimated costs through discussions with internal personnel and external service providers as to the progress, or stage of completion or actual
timeline (start-date and <FONT STYLE="white-space:nowrap">end-date)</FONT> of the services and the agreed-upon fees to be paid for such services. Payments made to third parties under these arrangements in advance of the performance of the related
services are recorded as prepaid expenses until the services are rendered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the actual timing of the performance of services or the
level of effort varies from the estimate, we adjust accrued expenses or prepaid expenses accordingly, which impact research and development expenses. Although we do not expect our estimates to be materially different from amounts actually incurred,
our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock-Based Compensation Expense </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
recognize stock-based compensation expense for all stock-based awards. Stock-based compensation costs are estimated at the grant date based on the fair value of the equity for financial reporting purposes and recognized as expense, net of actual
forfeitures when occur, on a straight-line basis over the requisite service period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We calculate the fair value of options using the
Black-Scholes option-pricing model, which requires the use of various highly subjective assumptions as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Fair Value of Common Stock</I>&#151;See the subsection titled &#147;Common Stock Valuations&#148; below.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected Term</I>&#151;We have opted to use the &#147;simplified method&#148; for estimating the expected
term of options, whereby the expected term equals the arithmetic average of the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the end of contractual term of the option (generally ten years). The expected term for
nonemployee awards is calculated based on the remaining contractual life to measure the remaining life of an award. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected Volatility</I>&#151;Due to our limited operating history and a lack of company-specific historical
and implied volatility data, we have based our estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The comparable companies were chosen based on their similar size, stage in the life
cycle or area of specialty. The historical volatility data was computed using the daily closing prices for the selected companies&#146; shares during the equivalent period of the calculated expected term of the stock-based awards. We will continue
to apply this process until a sufficient amount of historical information regarding the volatility of our own stock becomes available. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Risk-Free Interest Rate</I>&#151;The risk-free rate assumption is based on the U.S. Treasury zero coupon
issued in effect at the time of grant with maturities similar to the expected term of our options. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected Dividend Yield</I>&#151;We have not issued any dividends in our history and do not expect to pay
dividends on our common stock over the life of the options and therefore have estimated the dividend yield to be zero. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to the adoption of Accounting Standard Updated (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2018-07</FONT><I>, Compensation- Stock
Compensation (Topic 718) </I>(&#147;ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07&#148;),</FONT> on January&nbsp;1, 2020, the fair value of <FONT STYLE="white-space:nowrap">non-employee</FONT> awards were subject to periodic <FONT
STYLE="white-space:nowrap">re-measurement</FONT> over the period during which services were rendered. The fair value of these <FONT STYLE="white-space:nowrap">non-employee</FONT> awards were remeasured at each reporting period prior to vesting and
finally at the vesting date of the award. Subsequent to the adoption of ASU&nbsp;No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2018-07,&nbsp;non-employee</FONT></FONT> compensation costs are recognized over the requisite
service period based on a measurement of fair value on the date of grant of each stock award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">315 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will continue to use judgment in evaluating the expected volatility, expected terms and
interest rates utilized for our stock-based compensation expense calculations on a prospective basis. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We recorded stock-based
compensation expense of $0.6&nbsp;million and $0.8&nbsp;million for the years ended December&nbsp;31, 2020 and 2019, respectively. For the three months ended March 31, 2021 and 2020, stock-based compensation expense was $0.5 million and $0.2
million, respectively. As of March 31, 2021, we had $6.2&nbsp;million of total unrecognized stock-based compensation costs, which we expect to recognize over an estimated weighted-average period of 3.50 years. We expect to continue to grant options
and other stock-based awards in the future, and to the extent that we do, our stock-based compensation expense recognized in future periods will likely increase. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Common Stock Valuations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Given the
absence of a public trading market of our common stock, and in accordance with the American Institute of Certified Public Accountants Practice Guide, <I>Valuation of Privately Held Company Equity Securities Issued as Compensation</I>, or the
Practice Aid, our board of directors exercised reasonable judgment and considered numerous and subjective factors to determine the best estimate of fair value of our common stock, including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">relevant precedent transactions involving our capital stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">contemporaneous valuations performed by third-party specialists; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rights, preferences, and privileges of our redeemable convertible preferred stock relative to those of our
common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual operating and financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">current business conditions and financial projections; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">likelihood of achieving a liquidity event, such as an initial public offering or a sale of our business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of marketability of our common stock, and the illiquidity of stock-based awards involving securities
in a private company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market multiples of comparable publicly-traded companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stage of development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">industry information such as market size and growth; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. and global capital and macroeconomic conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Practice Aid identifies various available methods for allocating enterprise value across classes and series of capital stock to determine
the estimated fair value of common stock at each valuation date. In accordance with the Practice Aid, we considered the following methods: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Option Pricing Method, or OPM. </I>Under the OPM, shares are valued by creating a series of call options
with exercise prices based on the liquidation preferences and conversion terms of each equity class. The estimated fair values of the preferred and common stock are inferred by analyzing these options. This method is appropriate to use when the
range of possible future outcomes is so difficult to predict that estimates would be highly speculative, and dissolution or liquidation is not imminent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Probability-Weighted Expected Return Method, or PWERM. </I>The PWERM is a scenario-based analysis that
estimates value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">316 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For valuations performed in 2019 and 2020, based on our early stage of development, the
difficulty in predicting the range of possible outcomes at the time of the valuations, and other relevant factors, in accordance with the Practice Aid, we determined that a Hybrid OPM and OPM, respectively, were the most appropriate method for
allocating our enterprise value to determine the estimated fair value of our common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For valuations performed beginning in
2021, in accordance with the Practice Aid, we used a hybrid approach of the OPM and the PWERM methods to determine the estimated fair value of our common stock as a result of the increasing likelihood of the occurrence of certain discrete events,
such as a potential initial public offering, improving market conditions and receptivity of the market to initial public offerings. The enterprise value determined under the OPM and PWERM methods was weighted according to our board of
directors&#146; estimate of the probability of the occurrence of a certain discrete event as of the valuation date. The resulting equity value for the common stock was then divided by the number of shares of common stock outstanding at the date of
the valuation to derive a per share value on a <FONT STYLE="white-space:nowrap">non-marketable</FONT> basis. In order to determine the fair value of our common stock on a marketable basis, we then applied a discount for lack of marketability which
we derived based on inputs including a company-specific volatility rate, a term equal to the expected time to a future liquidity event and a risk-free rate equal to the yield on treasuries of similar duration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Application of these approaches involves the use of estimates, judgment and assumptions that are highly complex and subjective, such as those
regarding our expected future revenue, expenses, cash flows, discount rates, market multiples, the selection of comparable companies and the probability of future events. Changes in any or all of these estimates and assumptions, or the relationships
between those assumptions, impact our valuations as of each valuation date and may have a material impact on the valuation of common stock. The assumptions underlying these valuations represent our management&#146;s best estimate, which involve
inherent uncertainties and the application of management judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation expense could be materially different.
Following the closing of the Business Combination, the fair value of our common stock will be determined based on the quoted market price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We reassessed the determination of the fair value of the common shares for financial reporting purposes underlying the grants made in 2019 and
2020. This analysis revised our implied equity value and stock compensation expense for equity awards for the year ended December&nbsp;31, 2020 and 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Income Taxes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We account for income taxes
under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates
expected to be in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized. Realization of the future
tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our recent history of operating losses, management believes that recognition of the deferred tax assets arising from the
above-mentioned future tax benefits is not likely to be realized and, accordingly, has provided a full valuation allowance. During the year ended December&nbsp;31, 2020, the Company&#146;s valuation allowance increased $9.6&nbsp;million. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still
subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#146;s sustainability and is measured at the largest amount of benefit that is more likely
than not of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether (i)&nbsp;the factors underlying the sustainability assertion have changed and
(ii)&nbsp;the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new
information becomes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">317 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
available. Our unrecognized tax benefits, if recognized, would not have an impact on our effective tax rate assuming we continue to maintain a full valuation allowance position. We do not expect
our unrecognized tax benefits to change significantly over the next 12 months. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our policy is to recognize interest and penalties related
to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to unrecognized tax benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_196"></A>Emerging Growth Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;102(b)(1) of the Jumpstart Our Business Startups Act of 2012, or JOBS Act, exempts emerging growth companies from being required
to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can choose not to take advantage of the extended
transition period and comply with the requirements that <FONT STYLE="white-space:nowrap">apply&nbsp;to&nbsp;non-emerging&nbsp;growth&nbsp;companies,</FONT> and any such election to not take advantage of the extended transition period is irrevocable.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW is an &#147;emerging growth company&#148; as defined in Section&nbsp;2(a) of the Securities Act of 1933, as amended, and has elected
to take advantage of the benefits of the extended transition period for new or revised financial accounting standards. Following the consummation of the Business Combination, we expect to remain an emerging growth company at least through the end of
the 2021 fiscal year and we expect to continue to take advantage of the benefits of the extended transition period, although we may decide to early adopt such new or revised accounting standards to the extent permitted by such standards. This may
make it difficult or impossible to compare our financial results with the financial results of another public company that is either not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the
extended transition period exemptions because of the potential differences in accounting standards used. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_197"></A>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">See Note 2 to our audited financial statements and unaudited condensed interim financial statements included elsewhere in this proxy
statement/prospectus for more information about recent accounting pronouncements, the timing of their adoption and our assessment, to the extent they have been made, of their potential impact on our financial condition and results of operations and
cash flows. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_198"></A>Quantitative and Qualitative Disclosures About Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have not, to date, been exposed to material market risks given our early stage of operations. Upon commencing commercial operations, we
expect to be exposed to foreign currency translation and transaction risks and potentially other market risks, including those related to our valuation of financial instruments, among others. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Rate Risk </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The market
interest risk in our financial positions represents the potential loss arising from adverse changes in interest rates. As of March 31, 2021, we had cash, cash equivalents and short-term investments of $38.7&nbsp;million, consisting of
interest-bearing money market funds and marketable securities, for which the fair value would be affected by change in U.S. interest rates. However, due to the short-term maturities and
<FONT STYLE="white-space:nowrap">the&nbsp;low-risk&nbsp;profile</FONT> of our investments, an immediate 10% change in the interest rate would not have a material effect on the fair value of our cash equivalents and short-term investments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Inflation Risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not believe that
inflation has had a material effect on our business, financial condition or results of operations. Given our early stage of operations, if our costs become subject to significant inflationary pressures,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">318 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
we will not be able to fully offset such higher costs. Our inability or failure to do so could harm our business, financial condition, and operating results. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_199"></A>SURROZEN&#146;S EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Unless the context otherwise requires, all references in this section to the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; or
&#147;our&#148; refer to the business of Surrozen, Inc. and its subsidiaries prior to the consummation of the Business Combination and to New Surrozen and its subsidiaries after the Business Combination. This discussion may contain forward-looking
statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt following the completion of the Business Combination may differ
materially from the currently planned programs summarized in this discussion. All share counts in this section are shown on a <FONT STYLE="white-space:nowrap">pre-Business</FONT> Combination basis. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our named executive officers for the fiscal year ended December&nbsp;31, 2020, consisting of our principal executive officer and the next two
most highly compensated executive officers, were: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Craig Parker, our President and Chief Executive Officer; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Charles Williams, our Chief Financial Officer; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Wen-Chen</FONT> Yeh, M.D., Ph.D., our Chief Scientific Officer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_200"></A>Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table presents all of the compensation awarded to our named executive officers during the fiscal year ended December&nbsp;31,
2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Craig Parker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">441,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">553,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles Williams</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">510,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">581,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Wen-Chen</FONT> Yeh, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">358,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">497,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The amounts disclosed represent the aggregate grant date fair value of the stock options granted to our
named executive officers during the fiscal year ended December&nbsp;31, 2020 under our 2015 Plan, computed in accordance with ASC Topic 718. The assumptions used in calculating the grant date fair value of the stock options are set forth in the
notes to our audited financial statements included elsewhere in this prospectus. This amount does not reflect the actual economic value that may be realized by the named executive officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The amounts disclosed represent the applicable named executive officer&#146;s total performance bonus earned
for the fiscal year ended December&nbsp;31, 2020, as described below under <FONT STYLE="white-space:nowrap">&#147;&#151;Non-Equity</FONT> Incentive Plan Compensation.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Amounts comprised of 401(k) plan matching contributions. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents Mr.&nbsp;Williams&#146; signing bonus in November 2020. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_201"></A>Employment Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to the consummation of the Business Combination, we will enter into employment agreements or offer letters with each of our named
executive officers setting forth the terms and conditions of such executive&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">319 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
employment with us. The employment agreements or offer letters generally will provide for <FONT STYLE="white-space:nowrap">at-will</FONT> employment and set forth the executive officer&#146;s
initial base salary. Each of our named executive officers has executed our standard confidential information and invention assignment agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_202"></A><FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to base salaries, our named executive officers are eligible to receive annual performance-based cash bonuses under our Annual Cash
Bonus Plan, which is designed to provide appropriate incentives to our employees to achieve defined performance goals, subject to the terms of such plan. The performance-based cash bonus each named executive officer is eligible to receive is
generally based on the extent to which we achieve the corporate goals that the Surrozen board of directors establishes at the beginning of each year, but can be modified based on individual performance. For the fiscal year ended December&nbsp;31,
2020, Mr.&nbsp;Parker and Dr.&nbsp;Yeh were eligible to receive a bonus at an annual target of 30% of their respective base salaries based on our achievement of our 2020 corporate goals. Mr.&nbsp;Williams joined in November 2020 and was not eligible
for a performance bonus for the fiscal year ended December&nbsp;31, 2020. All bonuses for the fiscal year ended December&nbsp;31, 2020, were paid in cash in 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_203"></A>Outstanding Equity Awards as of December&nbsp;31, 2020 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table presents the outstanding equity incentive plan awards held by each named executive officer as of December&nbsp;31, 2020.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting<BR>Commencement<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Exercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Unexercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price&nbsp;Per<BR>Share<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of Shares<BR>that<BR>Have Not<BR>Vested(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>Value&nbsp;of<BR>Shares<BR>that&nbsp;Have<BR>Not<BR>Vested<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Craig&nbsp;Parker</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">04/11/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">03/19/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">04/10/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">02/07/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">01/01/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">02/06/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles&nbsp;Williams</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/14/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/30/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/13/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Wen-Chen&nbsp;Yeh,&nbsp;M.D.,</FONT> Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">02/7/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">01/01/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/31/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">02/13/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">01/01/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">02/12/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Each of the equity awards was granted under the 2015 Plan, the terms of which is described below under
&#147;&#151;Employee Benefit and Stock Plans.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The shares subject to the option award vest over a four-year period, with 25% of the total number of shares
subject to the option vesting on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the vesting commencement date, and the balance of the shares vesting in 36 equal monthly installments thereafter, subject to continued service
through each such vesting date. The option award is subject to an early exercise provision and is immediately exercisable as of the grant date. 100% of the unvested shares subject to the option will immediately become fully vested in the event that,
upon or following a change in control, the holder&#146;s employment is terminated without cause or the holder resigns for good reason. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The shares subject to the option award vest over a four-year period, with 25% of the total number of shares
subject to the option vesting on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the vesting commencement date, and the balance of the shares vesting in 36 equal monthly installments thereafter, subject to continued service
through each such vesting date. The option award is subject to an early exercise provision and is immediately exercisable as of the grant date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The shares subject to the option award vest over a four-year period in 48 equal monthly installments
measured from the vesting commencement date, subject to continued service through each such vesting date. The option award is subject to an early exercise provision and is immediately exercisable as of the grant date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">320 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_204"></A>Other Compensation and Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our named executive officers are eligible to participate in our employee benefit plans, including our medical, dental, vision, life, disability
and accidental death and dismemberment insurance plans, in each case on the same basis as generally all of our other full-time exempt employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our named executive officers did not participate in, or earn any benefits under, any nonqualified deferred compensation plan sponsored by us
during the fiscal year ended December&nbsp;31, 2020. The New Surrozen Board may elect to provide our officers and other employees with nonqualified deferred compensation benefits in the future if it determines that doing so is in our best interests.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_205"></A>Employee Benefit and Stock Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The principal features of our equity incentive plans and 401(k) plan are summarized below. These summaries are qualified in their entirety by
reference to the actual text of the plans, which, other than the 401(k) plan, are filed as exhibits to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>2021 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to consummation of the Business Combination, the CHFW Board is expected to approve and adopt, subject to CHFW stockholder approval, the
Surrozen Inc. 2021 Equity Incentive Plan (the &#147;2021 Plan&#148;), effective as of and contingent on the Closing. If the 2021 Plan is approved by stockholders, New Surrozen will be authorized to grant equity and cash incentive awards to eligible
service providers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Stock Awards.</I> The 2021 Plan provides for the grant of incentive stock options, or ISOs, within the meaning of
Section&nbsp;422 of the Code, nonstatutory stock options, or NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based stock awards, and other forms of equity compensation, which are collectively
referred to as stock awards. Additionally, the 2021 Plan provides for the grant of performance cash awards. ISOs may be granted only to our employees and to any of our parent or subsidiary corporation&#146;s employees. All other awards may be
granted to employees, including officers, and to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants of ours and any of our affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Share Reserve.</I> Initially, the aggregate number of shares of our common stock that may be issued pursuant to stock awards under the 2021
Plan is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares. The number of shares of our common stock reserved for issuance under our 2021 Plan will automatically increase on January&nbsp;1 of each
year, beginning on January&nbsp;1, 2022, and continuing through and including January&nbsp;1, 2031, by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our capital
stock outstanding on December&nbsp;31 of the preceding calendar year, or a lesser number of shares determined by the New Surrozen Board. The maximum number of shares that may be issued upon the exercise of ISOs under our 2021 Plan is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a stock award granted under
the 2021 Plan expires or otherwise terminates without being exercised in full, or is settled in cash, the shares of our common stock not acquired pursuant to the stock award again will become available for subsequent issuance under the 2021 Plan. In
addition, the following types of shares under the 2021 Plan may become available for the grant of new stock awards under the 2021 Plan: (i)&nbsp;shares that are forfeited to or repurchased by us prior to becoming fully vested; (ii)&nbsp;shares
withheld to satisfy income or employment withholding taxes; or (iii)&nbsp;shares used to pay the exercise or purchase price of a stock award. Shares issued under the 2021 Plan may be previously unissued shares or reacquired shares bought by us on
the open market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The maximum number of shares of common stock subject to stock awards granted under the 2021 Plan or otherwise during any
one calendar year to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director, taken together with any cash fees paid by us to such <FONT STYLE="white-space:nowrap">non-employee</FONT> director during such calendar year for service on the
board of directors, will not exceed $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in total value (calculating the value of any such stock awards based on the grant date fair value of such stock awards for financial reporting purposes), or, with
respect to the calendar year in which a <FONT STYLE="white-space:nowrap">non-employee</FONT> director is first appointed or elected to the New Surrozen Board,
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">321 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Administration.</I> The New Surrozen Board, or a duly authorized committee thereof, will
have the authority to administer the 2021 Plan. The New Surrozen Board may also delegate to one or more of our officers the authority to (i)&nbsp;designate employees (other than other officers) to be recipients of certain stock awards,
(ii)&nbsp;determine the number of shares of common stock to be subject to such stock awards and (iii)&nbsp;specify the other terms and conditions, including the strike price or purchase price and vesting schedule, applicable to such awards. Subject
to the terms of the 2021 Plan, the New Surrozen Board or the authorized committee, referred to as the plan administrator, determines recipients, dates of grant, the numbers and types of stock awards to be granted and the terms and conditions of the
stock awards, including the period of their exercisability and the vesting schedule applicable to a stock award. Subject to the limitations set forth below, the plan administrator will also determine the exercise price, strike price or purchase
price of stock awards granted and the types of consideration to be paid for the stock award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The plan administrator has the authority to
modify outstanding stock awards under our 2021 Plan. Subject to the terms of our 2021 Plan, the plan administrator has the authority, without stockholder approval, to reduce the exercise, purchase or strike price of any outstanding stock award,
cancel any outstanding stock award in exchange for new stock awards, cash or other consideration, or take any other action that is treated as a repricing under generally accepted accounting principles, with the consent of any adversely affected
participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Stock Options.</I> ISOs and NSOs are evidenced by stock option agreements adopted by the plan administrator. The plan
administrator determines the exercise price for a stock option, within the terms and conditions of the 2021 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock on
the date of grant. Options granted under the 2021 Plan vest at the rate specified by the plan administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The plan administrator
determines the term of stock options granted under the 2021 Plan, up to a maximum of ten years. Unless the terms of an option holder&#146;s stock option agreement provide otherwise, if an option holder&#146;s service relationship with us, or any of
our affiliates, ceases for any reason other than disability, death or cause, the option holder may generally exercise any vested options for a period of three months following the cessation of service. The option term will automatically be extended
in the event that exercise of the option following such a termination of service is prohibited by applicable securities laws or our insider trading policy. If an option holder&#146;s service relationship with us or any of our affiliates ceases due
to disability or death, or an option holder dies within a certain period following cessation of service, the option holder or a beneficiary may generally exercise any vested options for a period of 12 months in the event of disability and 18 months
in the event of death. In the event of a termination for cause, options generally terminate immediately. In no event may an option be exercised beyond the expiration of its term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the plan
administrator and may include (i)&nbsp;cash, check, bank draft or money order, (ii)&nbsp;a broker-assisted cashless exercise, (iii)&nbsp;the tender of shares of our common stock previously owned by the option holder, (iv)&nbsp;a net exercise of the
option if it is an NSO and (v)&nbsp;other legal consideration approved by the plan administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless the plan administrator provides
otherwise, options generally are not transferable except by will, the laws of descent and distribution, or pursuant to a domestic relations order. An option holder may designate a beneficiary, however, who may exercise the option following the
option holder&#146;s death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Tax Limitations on ISOs.</I> The aggregate fair market value, determined at the time of grant, of our
common stock with respect to ISOs that are exercisable for the first time by an option holder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will be treated as NSOs.
No ISOs may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our parent or subsidiary corporations unless (i)&nbsp;the option
exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant and (ii)&nbsp;the term of the ISO does not exceed five years from the date of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">322 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Restricted Stock Awards.</I> Restricted stock awards are evidenced by restricted stock
award agreements adopted by the plan administrator. Restricted stock awards may be granted in consideration for (i)&nbsp;cash, check, bank draft or money order, (ii)&nbsp;services rendered to us or our affiliates or (iii)&nbsp;any other form of
legal consideration. Common stock acquired under a restricted stock award may, but need not, be subject to a share repurchase option in our favor in accordance with a vesting schedule as determined by the plan administrator. Rights to acquire shares
under a restricted stock award may be transferred only upon such terms and conditions as set by the plan administrator. Except as otherwise provided in the applicable award agreement, restricted stock awards that have not vested will be forfeited
upon the participant&#146;s cessation of continuous service for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Restricted Stock Unit Awards.</I> Restricted stock unit
awards are evidenced by restricted stock unit award agreements adopted by the plan administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration or for no consideration. A restricted stock unit award
may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend
equivalents may be credited in respect of shares covered by a restricted stock unit award. Rights under a restricted stock unit award may be transferred only upon such terms and conditions as set by the plan administrator. Restricted stock unit
awards may be subject to vesting as determined by the plan administrator. Except as otherwise provided in the applicable award agreement, restricted stock units that have not vested will be forfeited upon the participant&#146;s cessation of
continuous service for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Stock Appreciation Rights.</I> Stock appreciation rights are evidenced by stock appreciation right
agreements adopted by the plan administrator. The plan administrator determines the strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Upon the
exercise of a stock appreciation right, we will pay the participant an amount in cash or stock equal to (i)&nbsp;the excess of the per share fair market value of our common stock on the date of exercise over the strike price, multiplied by
(ii)&nbsp;the number of shares of common stock with respect to which the stock appreciation right is exercised. A stock appreciation right granted under the 2021 Plan vests at the rate specified in the stock appreciation right agreement as
determined by the plan administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The plan administrator determines the term of stock appreciation rights granted under the 2021
Plan, up to a maximum of ten years. Unless the terms of a participant&#146;s stock appreciation right agreement provide otherwise, if a participant&#146;s service relationship with us or any of our affiliates ceases for any reason other than cause,
disability or death, the participant may generally exercise any vested stock appreciation right for a period of three months following the cessation of service. The stock appreciation right term will be further extended in the event that exercise of
the stock appreciation right following such a termination of service is prohibited by applicable securities laws. If a participant&#146;s service relationship with us, or any of our affiliates, ceases due to disability or death, or a participant
dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation right for a period of 12 months in the event of disability and 18 months in the event of death. In the
event of a termination for cause, stock appreciation rights generally terminate immediately upon the occurrence of the event giving rise to the termination of the individual for cause. In no event may a stock appreciation right be exercised beyond
the expiration of its term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless the plan administrator provides otherwise, stock appreciation rights generally are not transferable
except by will, the laws of descent and distribution, or pursuant to a domestic relations order. A stock appreciation right holder may designate a beneficiary, however, who may exercise the stock appreciation right following the holder&#146;s death.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Performance Awards.</I> Our 2021 Plan permits the grant of performance-based stock and cash awards. The performance goals that may be
selected include one or more of the following: (i)&nbsp;earnings (including earnings per share and net earnings); (ii) earnings before interest, taxes and depreciation; (iii)&nbsp;earnings before interest, taxes, depreciation and amortization;
(iv)&nbsp;earnings before interest, taxes, depreciation, amortization and legal settlements; (v)&nbsp;earnings before interest, taxes, depreciation, amortization, legal settlements and other income </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">323 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
(expense); (vi) earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense) and stock-based compensation; (vii)&nbsp;earnings before interest, taxes,
depreciation, amortization, legal settlements, other income (expense), stock-based compensation and changes in deferred revenue; (viii)&nbsp;total stockholder return; (ix)&nbsp;return on equity or average stockholder&#146;s equity; (x)&nbsp;return
on assets, investment, or capital employed; (xi)&nbsp;stock price; (xii)&nbsp;margin (including gross margin); (xiii) income (before or after taxes); (xiv) operating income; (xv)&nbsp;operating income after taxes;
<FONT STYLE="white-space:nowrap">(xvi)&nbsp;pre-tax</FONT> profit; (xvii)&nbsp;operating cash flow; (xviii)&nbsp;sales or revenue targets; (xix)&nbsp;increases in revenue or product revenue; (xx)&nbsp;expenses and cost reduction goals;
(xxi)&nbsp;improvement in or attainment of working capital levels; (xxii)&nbsp;economic value added (or an equivalent metric); (xxiii) market share; (xxiv)&nbsp;cash flow; (xv)&nbsp;cash flow per share; (xxvi)&nbsp;share price performance;
(xxvii)&nbsp;debt reduction; (xxviii)&nbsp;implementation or completion of projects or processes; (xxix)&nbsp;stockholders&#146; equity; (xxx)&nbsp;capital expenditures; (xxxi)&nbsp;debt levels; (xxxii)&nbsp;operating profit or net operating profit;
(xxxiii)&nbsp;workforce diversity; (xxiv)&nbsp;growth of net income or operating income; xxxv)&nbsp;billings; (xxxvi)&nbsp;bookings; (xxxvii)&nbsp;employee retention; (xxxviii)&nbsp;user satisfaction; (xxxix)&nbsp;the number of users, including
unique users; (xl)&nbsp;budget management; (xli)&nbsp;partner satisfaction; (xlii)&nbsp;entry into or completion of strategic partnerships or transactions (including <FONT STYLE="white-space:nowrap">in-licensing</FONT> and <FONT
STYLE="white-space:nowrap">out-licensing</FONT> of intellectual property); and (xliii)&nbsp;other measures of performance selected by the New Surrozen Board or a committee thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The performance goals may be based on company-wide performance or performance of one or more business units, divisions, affiliates, or
business segments, and may be either absolute or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise in the award agreement at the time the award is granted
or in such other document setting forth the performance goals at the time the goals are established, we will appropriately make adjustments in the method of calculating the attainment of performance goals as follows: (i)&nbsp;to exclude
restructuring and/or other nonrecurring charges; (ii)&nbsp;to exclude exchange rate effects; (iii)&nbsp;to exclude the effects of changes to generally accepted accounting principles; (iv)&nbsp;to exclude the effects of any statutory adjustments to
corporate tax rates; (v)&nbsp;to exclude the effects of any items that are unusual in nature or occur infrequently as determined under generally accepted accounting principles; (vi)&nbsp;to exclude the dilutive effects of acquisitions or joint
ventures; (vii)&nbsp;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (viii)&nbsp;to exclude the effect of any change in the
outstanding shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other
similar corporate change, or any distributions to common stockholders other than regular cash dividends; (ix)&nbsp;to exclude the effects of stock-based compensation and the award of bonuses under our bonus plans; (x)&nbsp;to exclude costs incurred
in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; (xi)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded
under generally accepted accounting principles; and (xii)&nbsp;to exclude the effects of any other unusual, nonrecurring gain or loss or other extraordinary item. In addition, we retain the discretion to adjust or eliminate the compensation or
economic benefit due upon attainment of the goals. The performance goals may differ from participant to participant and from award to award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Other Stock Awards.</I> The plan administrator may grant other awards based in whole or in part by reference to our common stock. The plan
administrator will set the number of shares under the stock award and all other terms and conditions of such awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Changes to
Capital Structure.</I> If there is a specified type of change in our capital structure, such as a stock split or recapitalization, appropriate adjustments will be made to (i)&nbsp;the class and maximum number of shares reserved for issuance under
the 2021 Plan, (ii)&nbsp;the class and maximum number of shares by which the share reserve may increase automatically each year, (iii)&nbsp;the class and number of shares that may be issued upon the exercise of ISOs and (iv)&nbsp;the class and
number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding stock awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">324 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions.</I> In the event of certain specified significant corporate transactions, the
plan administrator has the discretion to take any of the following actions with respect to stock awards: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">arrange for the assumption, continuation or substitution of a stock award by a surviving or acquiring entity
or parent company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">arrange for the assignment of any reacquisition or repurchase rights held by us to the surviving or acquiring
entity or parent company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">accelerate the vesting of the stock award and provide for its termination prior to the effective time of the
corporate transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">arrange for the lapse of any reacquisition or repurchase right held by us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cancel or arrange for the cancellation of the stock award in exchange for such cash consideration, if any, as
the New Surrozen Board may deem appropriate; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make a payment equal to the excess of (i)&nbsp;the value of the property the participant would have received
upon exercise of the stock award over (ii)&nbsp;the exercise price or strike price otherwise payable in connection with the stock award. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our plan administrator is not obligated to treat all stock awards, even those that are of the same type, in the same manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the 2021 Plan, a significant corporate transaction is generally the consummation of (i)&nbsp;a sale or other disposition of all or
substantially all of our assets, (ii)&nbsp;a sale or other disposition of at least 50% of our outstanding securities, (iii)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation or (iv)&nbsp;a
merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the
transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Change in Control.</I> The plan administrator may provide, in an individual award agreement or in any other written
agreement between a participant and us that the stock award will be subject to additional acceleration of vesting and exercisability or settlement in the event of a change in control. Under the 2021 Plan, a change in control is generally
(i)&nbsp;the acquisition by a person or entity of more than 50% of our combined voting power other than by merger, consolidation or similar transaction, (ii )&nbsp;a consummated merger, consolidation or similar transaction immediately after which
our stockholders do not own more than 50% of the combined voting power of the surviving entity (or its parent company), (iii) a consummated sale, lease or exclusive license or other disposition of all or substantially all of our assets and
(iv)&nbsp;certain dissolutions, liquidations and changes in the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Transferability. </I>A participant may not
transfer stock awards under our 2021 Plan other than by will, the laws of descent and distribution, or as otherwise provided under our 2021 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Amendment and Termination.</I> The New Surrozen Board will have the authority to amend, suspend or terminate our 2021 Plan, provided that
such action does not materially impair the existing rights of any participant without such participant&#146;s written consent and provided further that certain types of amendments will require the approval of our stockholders. No ISOs may be granted
after the tenth anniversary of the date the New Surrozen Board adopts the 2021 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>2021 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to consummation of the Business Combination, the CHFW Board is expected to approve and adopt, subject to CHFW stockholder
approval, the Surrozen, Inc. 2021 Employee Stock Purchase Plan (the &#147;ESPP&#148;), effective as of and contingent on the Closing. If the ESPP is approved by stockholders, CHFW will be authorized to provide eligible employees with an opportunity
to request payroll deductions to purchase a number of shares of New Surrozen Common Stock at a discount and in an amount determined in accordance with the ESPP&#146;s terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">325 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Share Reserve</I>. The ESPP will authorize the issuance of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock pursuant to purchase rights granted to our employees or to employees of any of our designated affiliates. The number of
shares of our common stock reserved for issuance will automatically increase on January&nbsp;1 of each calendar year, from January&nbsp;1, 2022 through and including January&nbsp;1, 2031, by the lesser of (i)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding on December&nbsp;31 of the preceding calendar year, and (ii)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares; provided, that prior to the date of any such increase, our board of directors may determine that such increase will be less than the amount set
forth in clauses (i)&nbsp;and (ii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Administration</I>. The New Surrozen Board will have the authority to delegate concurrent
authority to administer the ESPP to a compensation committee thereof. The ESPP is implemented through a series of offerings under which eligible employees are granted purchase rights to purchase shares of our common stock on specified dates during
such offerings. Under the ESPP, we may specify offerings with durations of not more than 27 months and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of our common stock
will be purchased for employees participating in the offering. An offering under the ESPP may be terminated under certain circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Payroll Deductions</I>. Generally, all regular employees, including executive officers, employed by us or by any of our designated
affiliates, may participate in the ESPP and may contribute, normally through payroll deductions, up to 15% of their earnings (as defined in the ESPP) for the purchase of our common stock under the ESPP. Unless otherwise determined by our board of
directors, common stock will be purchased for the accounts of employees participating in the ESPP at a price per share equal to the lower of (i)&nbsp;85% of the fair market value of a share of our common stock on the first trading date of an
offering or (ii)&nbsp;85% of the fair market value of a share of our common stock on the date of purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Limitations.</I> Employees
may have to satisfy one or more of the following service requirements before participating in the ESPP, as determined by our board of directors, including: (i)&nbsp;being customarily employed for more than 20 hours per week; (ii)&nbsp;being
customarily employed for more than five months per calendar year; or (iii)&nbsp;continuous employment with us or one of our affiliates for a period of time (not to exceed two years). No employee may purchase shares under the ESPP at a rate in excess
of $25,000 worth of our common stock based on the fair market value per share of our common stock at the beginning of an offering for each year such a purchase right is outstanding. Finally, no employee will be eligible for the grant of any purchase
rights under the ESPP if immediately after such rights are granted, such employee has voting power over 5% or more of our outstanding capital stock measured by vote or value pursuant to Section&nbsp;424(d) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Changes to Capital Structure</I>. If there occurs a change in our capital structure through such actions as a stock split, merger,
consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, liquidating dividend, combination of shares, exchange of shares, change in corporate structure
or similar transaction, the board of directors will make appropriate adjustments to (i)&nbsp;the number of shares reserved under the ESPP, (ii)&nbsp;the maximum number of shares by which the share reserve may increase automatically each year,
(iii)&nbsp;the number of shares and purchase price of all outstanding purchase rights and (iv)&nbsp;the number of shares that are subject to purchase limits under ongoing offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Corporate Transactions</I>. In the event of certain significant corporate transactions, including (i)&nbsp;a sale of all or substantially
all of our assets, (ii)&nbsp;the sale or disposition of 50% of our outstanding securities, (iii)&nbsp;the consummation of a merger or consolidation where we do not survive the transactions and (iv)&nbsp;the consummation of a merger or consolidation
where we do survive the transaction but the shares of our common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction, any then-outstanding rights to purchase our stock
under the ESPP may be assumed, continued or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to assume, continue or substitute for such purchase
rights, then the participants&#146; accumulated payroll contributions will be used to purchase shares of our common stock within ten business days prior to such corporate transaction, and such purchase rights will terminate immediately. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">326 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>ESPP Amendments, Termination</I>. Our board of directors has the authority to amend or
terminate our ESPP, provided that except in certain circumstances such amendment or termination may not materially impair any outstanding purchase rights without the holder&#146;s consent. We will obtain stockholder approval of any amendment to our
ESPP, as required by applicable law or listing requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>2015 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Surrozen board of directors adopted the 2015 Plan and our stockholders approved the 2015 Plan in August 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2015 Plan allows us to provide ISOs, within the meaning of Section&nbsp;422 of the Code, NSOs, stock appreciation rights, restricted stock
awards and restricted stock units, which are collectively referred to as stock awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the effective date of the 2021 Plan, no
additional awards will be granted under the 2015 Plan, and the 2015 Plan will be terminated on such date. However, our 2015 Plan will continue to govern the terms and conditions of the outstanding awards previously granted under our 2015 Plan until
such outstanding awards are exercised, terminate or expire by their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2021, stock options
covering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares subject to
restricted stock awards were outstanding under our 2015 Plan and there were no stock appreciation rights or restricted stock units outstanding under our 2015 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Administration</I>.&nbsp;Our compensation committee has the authority, concurrent with our board of directors to administer our 2015 Plan
(referred to herein as the plan administrator). Different committees may administer our 2015 Plan with respect to different service providers. Under our 2015 Plan, the plan administrator has the authority (i)&nbsp;to determine the fair market value
of our common stock; (ii)&nbsp;to select the persons to receive awards; (iii)&nbsp;to determine the number of shares subject to awards; (vi)&nbsp;to approve the forms of award agreements; (v)&nbsp;to determine the terms and conditions of awards,
such as the exercise price and vesting terms; (vi)&nbsp;to institute and determine the terms of an exchange program (as described below); (vii) to construe and interpret the terms of the 2015 Plan and awards granted thereunder; (viii)&nbsp;to
prescribe, amend and rescind rules relating to the 2015 Plan; (ix)&nbsp;to modify or amend each award; (x)&nbsp;to allow for participants to enter into certain tax withholding arrangements; (xi)&nbsp;to allow a participant to defer the receipt of
the payment of cash or delivery of shares that would be due to a participant under a stock award; and (xii)&nbsp;to make all other determinations necessary or advisable for the administration of the 2015 Plan. The plan administrator&#146;s decisions
are final and binding on all participants and any other persons holding awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The administrator&#146;s powers include the power to
institute an exchange program (without stockholder approval) under which (i)&nbsp;outstanding awards are surrendered or cancelled in exchange for awards of the same type (which may have higher or lower exercise prices and different terms), awards of
a different type and/or cash, (ii)&nbsp;participants would have the opportunity to transfer any outstanding awards to a financial institution or other person or entity selected by the administrator and/or (iii)&nbsp;the exercise price of an
outstanding award is increased or reduced. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Eligibility</I>.&nbsp;Employees, directors and consultants, including employees and
consultants of any of our parent or subsidiary companies, are eligible to receive awards, provided such consultants render bona fide services not in connection with the offer or sale of securities in a capital-raising transaction and do not directly
promote or maintain a market for our securities. Only our employees or employees of our parent or subsidiary companies are eligible to receive incentive stock options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Stock Options</I>.&nbsp;Stock options have been granted under our 2015 Plan. Subject to the provisions of our 2015 Plan, the administrator
determines the term of a stock option, the number of shares subject to a stock option, and the time period in which a stock option may be exercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">327 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The term of an option is stated in the applicable award agreement, but the term of an option
may not exceed ten years from the grant date. The administrator determines the exercise price of stock options, which generally may not be less than 100% of the fair market value of our common stock on the grant date, except as provided for in the
2015 Plan. However, an incentive stock option granted to an individual who directly or by attribution owns more than 10% of the total combined voting power of all of our classes of stock or of any our parent or subsidiary companies will have a term
of no longer than five years from the grant date and will have an exercise price of at least 110% of the fair market value of our common stock on the grant date. In addition, to the extent that the aggregate fair market value of the shares with
respect to which incentive stock options are exercisable for the first time by an employee during any calendar year (under all plans of ours and any of our parent or subsidiary companies) exceeds $100,000, such options will be treated as
nonstatutory stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock options granted under the 2015 Plan vest at the rate specified by the plan administrator. Payment for
the purchase of common stock issued upon the exercise of a stock option may be made in a form of consideration as determined by the plan administrator, including: (i)&nbsp;cash; (ii) check; (iii)&nbsp;promissory note; (iv)&nbsp;surrendering shares
of common stock already owned by a participant; (v)&nbsp;under a cashless exercise program; (vi)&nbsp;by net exercise; (vii)&nbsp;other consideration to the extent permitted by applicable laws; or (viii)&nbsp;any combination of the above. The plan
administrator determines the term of options granted under the 2015 Plan, up to a maximum of ten years (or five years in the case of incentive stock options granted to certain stockholders). The plan administrator shall determine the effect on a
stock option of the disability, death, leave of absence or any other change or purported change in a participant&#146;s status. Stock options generally are not transferable except by will, the laws of descent and distribution, or as otherwise
provided by the plan administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The administrator determines how a participant may pay the exercise price of an option, and the
permissible methods are generally set forth in the applicable award agreement. If a participant&#146;s status as a &#147;service provider&#148; (as defined in our 2015 Plan) terminates, that participant may exercise the vested portion of his or her
option for the period of time stated in the applicable award agreement. Vested options generally will remain exercisable for 30 days or such longer period of time as set forth in the applicable award agreement if a participant&#146;s status as a
service provider terminates for a reason other than death or disability. If a participant&#146;s status as a service provider terminates due to death or disability, vested options generally will remain exercisable for six months from the date of
termination (or such other longer period as set forth in the applicable award agreement). In no event will an option remain exercisable beyond its original term. If a participant does not exercise his or her option within the time specified in the
award agreement, the option will terminate. Except as described above, the administrator has the discretion to determine the post-termination exercisability periods for an option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Restricted Stock Awards. </I>Restricted stock awards have been granted under our 2015 Plan. Restricted stock awards granted under the 2015
Plan vest at the rate specified by the plan administrator. Restricted stock awards are evidenced by restricted stock award agreements adopted by the plan administrator. Common stock acquired under a restricted stock award may, but need not, be
subject to a share repurchase option in our favor in accordance with a vesting schedule as determined by the plan administrator. Except as otherwise provided in the applicable award agreement, restricted stock awards that have not vested will be
forfeited upon the participant&#146;s cessation of continuous service for any reason. Unless determined otherwise by the plan administrator, a participant holding a restricted stock award will have full voting rights with respect to the shares
subject to the award and will be entitled to receive all dividends and other distributions paid with respect to such shares. If any dividends or distributions are paid in shares, those shares will be subject to the same restrictions on
transferability and forfeitability as the shares of restricted stock on which they were paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I><FONT STYLE="white-space:nowrap">Non-transferability</FONT></I><I></I><I>&nbsp;of Awards</I>. Unless determined otherwise by the
administrator, awards may not be sold, transferred, pledged, assigned or otherwise alienated or hypothecated in any manner other than by will or by the laws of descent and distribution. In addition, during an applicable participant&#146;s lifetime,
only that participant may exercise their award. If the administrator makes an award transferable, such award may only be transferred (i)&nbsp;by will, (ii)&nbsp;by the laws of descent and distribution or (3)&nbsp;as permitted by Rule&nbsp;701 of the
Securities Act of 1933, as amended (the Securities Act). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">328 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Changes to Capital Structure</I>. If there is a dividend or other distribution (whether
in the form of cash, shares, other securities or other property), recapitalization, stock split, reverse stock split, reorganization,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">merger,&nbsp;consolidation,&nbsp;split-up,&nbsp;spin-off,&nbsp;combination,&nbsp;repurchase,</FONT></FONT> exchange of shares or our other securities or other change in our corporate
structure affecting the shares, the plan administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the 2015&nbsp;Plan, will make adjustments to the number and class of
shares that may be delivered under our 2015 Plan and/or the number, class and price of shares covered by each outstanding award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Dissolution or Liquidation</I>.&nbsp;In the event of our proposed dissolution or liquidation a stock award will terminate immediately prior
to the consummation of such proposed action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Merger and Change in Control</I>. In the event of our merger with or into another corporation or entity
or a &#147;change in control&#148; (as defined in our 2015 Plan), the plan administrator may take any of the following actions with regards to each outstanding award: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that the awards will be assumed, or substantially equivalent awards will be substituted, by the
acquiring or succeeding corporation (or an affiliate thereof); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon written notice to a participant, provide for the termination of the participant&#146;s awards upon or
immediately prior to the consummation of such merger or change in control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that outstanding awards will vest and become exercisable, realizable or payable, or restrictions
applicable to an award will lapse, in whole or in part, prior to or upon consummation of such merger or change in control, and, to the extent the plan administrator determines, terminate upon or immediately prior to the effectiveness of such merger
or change in control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for the termination of an award in exchange for an amount of cash or property, if any, equal to the
amount that would have been attained upon the exercise of such award or realization of the participant&#146;s rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for the replacement of such award with other rights or property selected by the plan administrator in
its sole discretion; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any combination of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The plan administrator is not obligated to treat all awards (or portions thereof) similarly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that the successor corporation does not assume or substitute an award, the award will fully vest and become exercisable. If a
stock option or stock appreciation right is not assumed or substituted in the event of a merger or change in control, the plan administrator will notify the participant in writing or electronically that the option or stock appreciation right will be
exercisable for a period of time determined by the plan administrator in its sole discretion, and the option or stock appreciation right will terminate upon the expiration of such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Amendment and Termination</I>.&nbsp;Our board of directors may, at any time, amend, alter, suspend or terminate our 2015 Plan in any
respect, including, without limitation, amendment of any form of award agreement or instrument to be executed pursuant to our 2015 Plan. To the extent necessary and desirable to comply with applicable laws, we will obtain stockholder approval of any
amendment to our 2015 Plan. No amendment, alteration, suspension or termination of our 2015 Plan will impair the rights of a participant, unless mutually agreed otherwise between the participant and the administrator in writing. As noted above, upon
the effective date of our 2021&nbsp;Plan, our 2015 Plan will terminate, and we will not grant any additional awards under our 2015 Plan thereafter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>401(k) Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
currently maintain a 401(k) retirement savings plan for our employees, including our named executive officers, who satisfy certain eligibility requirements. The 401(k) plan is intended to qualify as a
<FONT STYLE="white-space:nowrap">tax-qualified</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">329 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
retirement plan under the Code. Our named executive officers are eligible to participate in the 401(k) plan on the same basis as our other employees and defer a portion of their compensation,
within prescribed limits, through payroll contributions to the 401(k) plan. The 401(k) plan provides for an annual matching contribution of $500. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_206"></A>Limitations of Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Proposed Certificate of Incorporation, which will be effective upon consummation of the Business Combination, will limit the liability of
our current and former directors for monetary damages to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for any breach of fiduciary duties as
directors, except liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to the corporation or its stockholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Such limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of
equitable remedies such as injunctive relief or rescission. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Proposed Certificate of Incorporation, which will be effective upon
consummation of the Business Combination, will authorize us to indemnify our directors, officers, employees and other agents to the fullest extent permitted by Delaware law. The Proposed Bylaws, which will be effective upon consummation of the
Business Combination, will provide that we are required to indemnify our directors and officers to the fullest extent permitted by Delaware law and may indemnify our other employees and agents. The Proposed Bylaws, which will be effective upon
consummation of the Business Combination, will also provide that, on satisfaction of certain conditions, we will advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to
secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under the provisions of
Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors and executive officers. With certain exceptions, these agreements provide for indemnification for related expenses including attorneys&#146;
fees, judgments, fines and settlement amounts incurred by any of these individuals in connection with any action, proceeding or investigation. We believe that the Proposed Certificate of Incorporation and Proposed Bylaws provisions and
indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain customary directors&#146; and officers&#146; liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The limitation of liability and indemnification provisions in our Proposed Certificate of Incorporation and Proposed Bylaws may discourage
stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us
and other stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Insofar as indemnification for liabilities arising under the Securities Act may be permitted for directors, executive officers or persons
controlling us, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_207"></A>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Sales Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our directors and executive officers may adopt written plans, known as Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans, in which they
will contract with a broker to buy or sell shares of common stock on a periodic basis. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">330 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
broker executes trades pursuant to parameters established by the director or executive officer when entering into the plan, without further direction from them. The director or executive officer
may amend a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan in some circumstances and may terminate a plan at any time. Our directors and executive officers also may buy or sell additional shares outside of a Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> plan when they are not in possession of material nonpublic information, subject to compliance with the terms of our insider trading policy. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_208"></A>MANAGEMENT OF NEW SURROZEN FOLLOWING THE BUSINESS COMBINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_209"></A>Executive Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following sets forth certain information, as of May&nbsp;1, 2021, concerning the persons who are expected to serve as directors and
executive officers of New Surrozen following the consummation of the Business Combination as well as certain key employees of Surrozen. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Craig Parker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President, Chief Executive Officer and Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Geertrui (Trudy) Vanhove, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Wen-Chen</FONT> Yeh, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Scientific Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles Williams</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anna Berkenblit, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tim Kutzkey, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Shao-Lee</FONT> Lin, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David J. Woodhouse, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Haak-Frendscho, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mace Rothenberg, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Y. Chai</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_210"></A>Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Craig Parker</I> has served as our President and Chief Executive Officer since March 2018 and as a member of our board of directors since
April 2018. From August 2014 to March 2018, Mr.&nbsp;Parker served as Senior Vice President of Corporate Development at Jazz Pharmaceuticals plc, a biopharmaceutical company. From 2012 to 2014, Mr.&nbsp;Parker served as Executive Vice President of
Corporate Development and Scientific Affairs at Geron Corporation and from 2011 to 2012 as Senior Vice President of Strategy and Corporate Development at Human Genome Sciences, or HGS, until its acquisition by GlaxoSmithKline plc. Prior to HGS,
Mr.&nbsp;Parker worked in various positions at J.P. Morgan and other Wall Street financial institutions. Mr.&nbsp;Parker chairs the Leadership Council of the Scientific Advisory Board of Life Sciences Institute, University of Michigan and has been a
member since 2005. Mr.&nbsp;Parker received a A.B. in biological sciences from the University of Chicago, an M.B.A. from the University of Michigan and attended the Georgetown University School of Medicine. We believe that Mr.&nbsp;Parker&#146;s
extensive scientific, business and leadership experience in both public and privately-held companies in the life sciences industry provide him with the qualifications and skills to serve on our board of directors and as our President and Chief
Executive Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Geertrui (Trudy) Vanhove, M.D., Ph.D.</I> has served as our Chief Medical Officer since April 2019.
From June 2012 to October 2015, she served as Vice President, Medical Affairs and, from October 2015 to April 2019, she served as Vice President, Head of Research and Development Search and Evaluation at Jazz Pharmaceuticals plc.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">331 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
From 2011 to 2012, she served as Vice President, Medical Affairs at Depomed, Inc., a pharmaceutical company. Prior to this, Dr.&nbsp;Vanhove held positions of increasing responsibility from 2006
to 2011 in Clinical Development at NeurogesX, Inc., a biopharmaceutical company. Prior to NeurogesX, Dr.&nbsp;Vanhove served as Medical Director at XOMA (US) LLC and Abbot Laboratories. Dr.&nbsp;Vanhove also served on the board of Insys Therapeutics
from April 2018 to February 2020. Dr.&nbsp;Vanhove received an M.D. and a Ph.D. in pharmacology from the Catholic University in Leuven, Belgium and completed a fellowship in clinical pharmacology at Stanford University. Dr.&nbsp;Vanhove also
received an M.B.A. from St. Mary&#146;s College. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I><FONT STYLE="white-space:nowrap">Wen-Chen</FONT> Yeh, M.D., Ph.D.</I> has served as
our Chief Scientific Officer since May 2016. From December 2006 to April 2016, he held various positions of increasing responsibility at Amgen Inc., or Amgen, a biopharmaceutical company, as an Associate Director, Director of Research and Scientific
Executive Director. Prior to Amgen, Dr.&nbsp;Yeh served as a professor and led a research laboratory at the University of Toronto. Dr.&nbsp;Yeh received an M.D. from the National Taiwan University and a Ph.D. from The Johns Hopkins University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Charles Williams</I> has served as our Chief Financial Officer since November 2020. From 2013 to November 2020, he served as Head of
Corporate Development at Jazz Pharmaceuticals plc. From 2008 to 2013, he served as Director of Corporate and Business Development at MAP Pharmaceuticals, Inc., a biopharmaceutical company acquired by Allergan, Inc. Prior to MAP, Mr.&nbsp;Williams
held various roles related to business development, finance and strategic planning at CV Therapeutics, Inc., a biopharmaceutical company acquired by Gilead Sciences, Inc. Mr.&nbsp;Williams received a B.A. in economics from Cornell University. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_211"></A><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Anna Berkenblit, M.D.</I> has served on our board of directors since March 2019. Dr.&nbsp;Berkenblit has served as the Senior Vice President
and Chief Medical Officer at ImunnoGen, Inc., a biotechnology company, since April 2015. Prior to ImmunoGen, Dr.&nbsp;Berkenblit served as Senior Vice President Head of Clinical Development at H3, Biomedicine Inc., a developer of targeted
anti-cancer compounders, from 2013 to 2015. From 2011 to 2013, she served as Head of Clinical Research at AVEO Pharmaceuticals, Inc., a biopharmaceutical company, where she led the clinical development of oncology product candidates spanning early
testing to registration trials. From January 2007 to September 2011, Dr.&nbsp;Berkenblit held various positions of increasing responsibility at Pfizer Inc., a biopharmaceutical company. Dr.&nbsp;Berkenblit received an M.D. from Harvard Medical
School and an M.M.S. degree in the Clinical Investigator Training Program of Harvard/MIT Health Sciences and Technology. We believe that Dr.&nbsp;Berkenblit&#146;s extensive leadership and scientific experience, especially in the clinical
development of biopharmaceuticals, provide her with the qualifications and skills to serve as a director of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Tim Kutzkey,
Ph.D.</I> has served on our board of directors since April 2016 and served as our interim Chief Executive Officer from inception to April 2018. Dr.&nbsp;Kutzkey serves as Managing Partner of The Column Group, LLC, a venture capital partnership,
where he has served in various roles since 2007. Prior to The Column Group, Dr.&nbsp;Kutzkey served as a scientist at Kai Pharmaceuticals, Inc. Dr.&nbsp;Kutzkey also serves on the board of directors of Kallyope Inc., Nura Bio Inc., Neurona
Therapeutics Inc., Synthekine Inc., Plexium, Inc. and Cajal Neuroscience Inc., all biotechnology companies. Dr.&nbsp;Kutzkey obtained a Ph.D. in molecular and cell biology from the University of California, Berkeley and completed his undergraduate
degree in biological sciences from Stanford. We believe that Dr.&nbsp;Kutzkey&#146;s scientific training and experience as a director of other publicly traded and privately held biopharmaceutical companies provide him with the qualifications and
skills to serve as a director of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I><FONT STYLE="white-space:nowrap">Shao-Lee</FONT> Lin, M.D., Ph.D.</I> has served on our
board of directors since January 2021. Dr.&nbsp;Lin <FONT STYLE="white-space:nowrap">co-founded</FONT> and serves as the Chief Executive Officer of ACELYRIN, INC. formed in July 2020. From January 2018 to January 2020, she served as Executive Vice
President, Research and Development and Chief Scientific Officer at Horizon Pharma plc, a biopharmaceutical company. From April 2015 to December 2017, she served as a corporate officer and Vice President, Therapeutic Areas, Development Excellence
and International Development at Abbvie Inc., a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">332 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
biopharmaceutical company. Prior to Abbvie, Dr.&nbsp;Lin served as Vice President, Inflammation and Respiratory Development at Gilead from August 2012 to February 2015 and served in various roles
of increasing responsibility at Amgen from April 2004 to August 2012, Dr.&nbsp;Lin served on the board of directors of Principia Biopharma Inc., a biopharmaceutical company, from April 2019 until it was acquired in September 2020 Dr.&nbsp;Lin has
also been faculty as a Clinical Scholar at The Rockefeller University and adjunct faculty at the medical schools of Cornell University, The University of California, Los Angeles, or UCLA, Stanford University and Northwestern University. Dr.&nbsp;Lin
received her bachelor&#146;s degree in chemical engineering and biochemistry from Rice University and holds an M.D. and Ph.D. from The Johns Hopkins University School of Medicine. We believe that Dr.&nbsp;Lin&#146;s scientific training, work
experience, and experience as a director of other publicly traded biopharmaceutical companies provide her with the qualifications and skills to serve as a director of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>David J. Woodhouse, Ph.D.</I> has served on our board of directors since September 2020. Dr.&nbsp;Woodhouse has served as the Chief
Executive Officer and director of NGM Biopharmaceuticals, Inc., or NGM, since September 2018 Dr.&nbsp;Woodhouse also served as Chief Financial Officer from March 2015 until September 2018 and acting Chief Financial Officer from September 2018 until
June 2020 at NGM. From 2002 to 2015, he was an investment banker at Goldman Sachs&nbsp;&amp; Co. LLC, most recently as a managing director in the healthcare investment banking group and <FONT STYLE="white-space:nowrap">co-head</FONT> of
biotechnology investment banking. Earlier in his career, Dr.&nbsp;Woodhouse worked at Dynavax Technologies and also as a research assistant at Amgen, Inc. Dr.&nbsp;Woodhouse received a B.A. in pharmacology from the University of California, Santa
Barbara, an M.B.A. from the Tuck School of Business at Dartmouth and a Ph.D. in molecular pharmacology from Stanford University School of Medicine. We believe that Dr.&nbsp;Woodhouse&#146;s extensive financial and executive experience provide him
with the qualifications and skills to serve as a director of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Mary Haak-Frendscho, Ph.D.</I> has served on our board of
directors since March 2021. Dr.&nbsp;Haak-Frendscho has served as the president and chief executive officer of Spotlight Therapeutics, Inc., a privately held biotechnology company, since January 2019. Prior to Spotlight, from January 2017 to January
2019, she was a venture partner with Versant Ventures and, from January 2016 to January 2019, she served as the chief executive officer of Blueline Bioscience, Versant&#146;s vehicle for new company creation in Canada. Earlier,
Dr.&nbsp;Haak-Frendscho established and served as the chair of Compugen USA, Inc. from 2012 to 2016, was the chief executive officer of Igenica Biotherapeutics from 2012 to 2014, and was the founding president and chief scientific officer of Takeda
San Francisco from 2008 to 2012. She received her B.S. from the University of Michigan, M.L.A. from Washington University, M.S. from SUNY-Stony Brook, C.S.E.P. from Columbia University Graduate School of Business, and Ph.D. from the University of
Wisconsin. We believe that Dr.&nbsp;Haak-Frendscho&#146;s scientific training, work experience, and experience as a director of other biopharmaceutical companies provide her with the qualifications and skills to serve as a director of our company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Mace Rothenberg, M.D.</I> has served on our board of directors since April 2021. Dr.&nbsp;Rothenberg served as chief medical officer
of Pfizer Inc., a biopharmaceutical company from January 2019 to January 2021, where he led Pfizer&#146;s Worldwide Medical&nbsp;&amp; Safety organization that is responsible for ensuring that patients, physicians, and regulatory agencies are
provided with information on the safe and appropriate use of Pfizer medications. From January 2021 to March 2021, Dr.&nbsp;Rothenberg also served as a member of Pfizer&#146;s Portfolio Strategy and Investment Committee, Worldwide Research,
Development, and Medical Leadership Team, and Blueprint Leaders Forum. Prior to becoming Pfizer&#146;s chief medical officer, Dr.&nbsp;Rothenberg led Pfizer&#146;s oncology clinical drug development efforts. He received his B.A. from the University
of Pennsylvania and his M.D. from the New York University School of Medicine. Dr.&nbsp;Rothenberg received his post-graduate training in Internal Medicine at Vanderbilt University and in Medical Oncology at the National Cancer Institute. We believe
that Dr.&nbsp;Rothenberg&#146;s scientific training, work experience, and experience as a director of other biopharmaceutical companies provide him with the qualifications and skills to serve as a director of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Christopher Y. Chai.</I> has served on our board of directors since April 2021. Mr.&nbsp;Chai has served as a venture partner at SR One.
since January 2021, where he works with portfolio companies on their engagement with Wall Street and their overall financing strategy and execution. Prior to joining SR One, Mr.&nbsp;Chai served as Chief
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">333 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Financial Officer of Principia Biopharma Inc. from 2013 to 2020, where he led the company from an early-stage private venture-backed company to its acquisition by Sanofi S.A.. Mr.&nbsp;Chai
previously served as Chief Financial Officer at MAP Pharmaceuticals, Inc. (acquired by Allergan, Inc.) and Vice President, Treasury and Investor Relations at CV Therapeutics, Inc. (acquired by Gilead Sciences, Inc.). Mr.&nbsp;Chai received his B.S.
in Operations Research and Industrial Engineering from Cornell University. We believe that Mr.&nbsp;Chai&#146;s extensive financial and executive experience provide him with the qualifications and skills to serve as a director of our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_212"></A>Family Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are no family relationships among any of our executive officers or directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_213"></A>Composition of Our Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business and affairs are managed under the direction of our board of directors. The Business Combination Agreement provides that the New
Surrozen board of directors will consist of nine directors. After the consummation of the Business Combination, the number of directors will be fixed by our board of directors, subject to the terms of our amended and restated certificate of
incorporation and amended and restated bylaws that will become effective immediately prior to the consummation of the Business Combination. Each director will continue to serve until the election and qualification of his or her successor, or until
his or her earlier death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors may establish the authorized number of directors from time to
time by resolution. In accordance with our amended and restated certificate of incorporation that will be in effect upon the consummation of the Business Combination, immediately after the consummation of the Business Combination our board of
directors will be divided into three classes with staggered three-year terms. At each annual general meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification
until the third annual meeting following election. Our directors will be divided among the three classes as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;I directors will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our first annual meeting of stockholders following the consummation of the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;II directors will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our second annual meeting of stockholders following the consummation of the Business Combination; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;III directors will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at our third annual meeting of stockholders following the consummation of the Business Combination. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect that any additional directorships resulting from an increase in the number of directors will be distributed among the three classes
so that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of
our management or a change in control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_214"></A>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning
his or her background, employment and affiliations, our board of directors has determined that Mr.&nbsp;Chai and Drs. Berkenblit, Lin, Woodhouse, Haak-Frendscho, Kutzkey and Rothenberg do not have relationships that would interfere with the exercise
of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#147;independent&#148; as that term is defined under the applicable listing standards. In making these determinations, our board of
directors considered the current and prior relationships that each <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their
independence, including the beneficial ownership of our shares held by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director and the transactions described in the section titled &#147;Certain Relationships and Related Party
Transactions&#151;Surrozen&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">334 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_215"></A>Committees of Our Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the consummation of the Business Combination, our board of directors will have an audit committee, a compensation committee, and a
nominating and corporate governance committee. The composition and responsibilities of each of the committees of our board of directors following the consummation of the Business Combination are described below. Members will serve on these
committees until their resignation or until otherwise determined by our board of directors. Our board of directors may establish other committees as it deems necessary or appropriate from time to time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Audit Committee </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The New Surrozen board
of directors will continue to have an audit committee, which will be reconstituted upon the consummation of the Business Combination to consist of the following members:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our board of directors has determined that each member of the audit committee satisfies the independence requirements under the Nasdaq listing
standards and Rule <FONT STYLE="white-space:nowrap">10A-3(b)(1)</FONT> of the Exchange Act. The chair of our audit committee will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our board of
directors has determined that &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is an &#147;audit committee financial expert&#148; within the meaning of SEC regulations. Each member of our audit
committee can read and understand fundamental financial statements in accordance with applicable listing standards. In arriving at these determinations, our board of directors has examined each audit committee member&#146;s scope of experience and
the nature of his or her employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The primary purpose of the audit committee is to discharge the responsibilities of our board of
directors with respect to our corporate accounting and financial reporting processes, systems of internal control and financial statement audits, and to oversee our independent registered public accounting firm. Specific responsibilities of our
audit committee include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">helping our board of directors oversee our corporate accounting and financial reporting processes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing and/or assessing the selection, engagement, qualifications, independence and performance of a
qualified firm to serve as the independent registered public accounting firm to audit our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the scope and results of the audit with the independent registered public accounting firm, and
reviewing, with management and the independent accountants, our interim and <FONT STYLE="white-space:nowrap">year-end</FONT> operating results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing procedures for employees to submit concerns anonymously about questionable accounting or audit
matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing related party transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our policies on risk assessment and risk management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, with our independent registered public accounting firm, our internal quality control procedures,
any material issues with such procedures and any steps taken to deal with such issues; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> audit and permissible
<FONT STYLE="white-space:nowrap">non-audit</FONT> services to be performed by the independent registered public accounting firm. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The New Surrozen&#146;s audit committee will operate under a written charter that satisfies the applicable listing standards of Nasdaq. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compensation Committee </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The New Surrozen
board of directors will continue to have a compensation committee, which will be reconstituted upon the consummation of the Business Combination to consist of the following members: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">335 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The chair of our compensation committee will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our
board of directors has determined that each member of the compensation committee satisfies the independence requirements under the listing standards of Nasdaq, and is a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; as
defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The primary purpose of our compensation
committee is to discharge the responsibilities of our board of directors in overseeing our compensation policies, plans and programs and to review and determine the compensation to be paid to our executive officers, directors and other senior
management, as appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Specific responsibilities of our compensation committee include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our board of directors the compensation of our chief executive officer and other
executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our board of directors the compensation of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering our equity incentive plans and other benefit programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, adopting, amending and terminating incentive compensation and equity plans, severance agreements,
profit sharing plans, bonus plans, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> protections and any other compensatory arrangements for our executive officers and other senior management; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and establishing general policies relating to compensation and benefits of our employees, including
our overall compensation philosophy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New Surrozen&#146;s compensation committee will operate under a written charter
that satisfies the applicable listing standards of Nasdaq. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Nominating and Corporate Governance Committee </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The New Surrozen board of directors will continue to have a nominating and corporate governance committee, which will be reconstituted upon the
consummation of the Business Combination to consist of the following members: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The chair of our nominating and corporate governance committee will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our board of directors has determined that each member of the nominating and corporate governance committee satisfies the independence requirements
under the listing standards of Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Specific responsibilities of our nominating and corporate governance committee include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying and evaluating candidates, including the nomination of incumbent directors for reelection and
nominees recommended by stockholders, to serve on our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering and making recommendations to our board of directors regarding the composition and chairpersonship
of the board of directors and committees of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing developments in corporate governance practices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and making recommendations to our board of directors regarding corporate governance guidelines and
matters; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing periodic evaluations of the board of directors&#146; performance, including committees of the board
of directors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The New Surrozen&#146;s nominating and corporate governance committee will operate under a written
charter that satisfies the applicable listing standards of Nasdaq. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_217"></A>Compensation Committee Interlocks and
Insider Participation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None of the members of the compensation committee is currently or has been at any time one of our officers or
employees. None of our executive officers currently serves, or has served during the last year, as a member of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">336 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_218"></A>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen previously provided cash and equity-based compensation to certain of its <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors. In addition, all <FONT STYLE="white-space:nowrap">non-employee</FONT> directors are entitled to reimbursement of direct expenses incurred in connection with attending meetings of the board of directors or committees thereof. In connection
with the consummation of the Business Combination, our board of directors expects to approve a policy providing for annual <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation, which will become effective following the
consummation of the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information regarding the compensation earned by or paid to
Surrozen&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors during fiscal year ended December&nbsp;31, 2020. Craig Parker, Surrozen&#146;s President and Chief Executive Officer, is also a member of its board of directors, but did
not receive any additional compensation for service as a director. The compensation earned by or paid to Mr.&nbsp;Parker as a named executive officer of Surrozen for the fiscal year ended December&nbsp;31, 2020 is set forth below under
&#147;Executive Compensation&#151;Summary Compensation Table.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or&nbsp;Paid&nbsp;in&nbsp;Cash<BR>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anna Berkenblit, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David V. Goeddel, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tim Kutzkey, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Shao-Lee</FONT> Lin, M.D., Ph.D.<SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Harold Varmus, M.D<SUP STYLE="font-size:85%; vertical-align:top">(4).</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David J. Woodhouse, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Haak-Frendscho, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mace Rothenberg, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Y. Chai<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The amounts reported represent the aggregate grant date fair value of the restricted stock awards granted
during the fiscal year ended December&nbsp;31, 2020 under Surrozen&#146;s 2015 Plan, computed in accordance with Financial Accounting Standard Board Accounting Standards Codification, Topic&nbsp;718, or ASC Topic&nbsp;718. The assumptions used in
calculating the grant-date fair value of the stock options reported in this column are set forth in the notes to Surrozen&#146;s financial statements included elsewhere in this prospectus. This amount does not reflect the actual economic value that
may be realized by the <FONT STYLE="white-space:nowrap">non-employee</FONT> director. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">As of December&nbsp;31, 2020, Drs. Berkenblit, Varmus and Woodhouse held restricted stock awards covering
100,000, 125,000 and 100,000 shares of Surrozen common stock, respectively. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Dr.&nbsp;Lin joined Surrozen&#146;s board of directors in January 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Dr.&nbsp;Varmus resigned from Surrozen&#146;s board of directors in April 2021. Pursuant to a letter
agreement entered into with Dr.&nbsp;Varmus in connection with his service on Surrozen&#146;s board of directors and Scientific Advisory Board, Surrozen paid Dr.&nbsp;Varmus $6,000 in cash compensation per quarter of service on its board of
directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Pursuant to a letter agreement that Surrozen entered into with Dr.&nbsp;Woodhouse in connection with his
service on board of directors, Surrozen granted Dr.&nbsp;Woodhouse a restricted stock award of 100,000 shares in September 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Dr.&nbsp;Haak-Frendscho joined Surrozen&#146;s board of directors in March 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Dr.&nbsp;Rothenberg joined Surrozen&#146;s board of directors in April 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Mr.&nbsp;Chai joined Surrozen&#146;s board of directors in April 2021. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">337 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_219"></A>BENEFICIAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the beneficial ownership of CHFW Class&nbsp;A and Class&nbsp;B shares as of May&nbsp;1, 2021 and of New
Surrozen Common Stock immediately following consummation of the Business Combination by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person known by CHFW to be the beneficial owner of more than 5% of CHFW&#146;s outstanding Class&nbsp;A
and Class&nbsp;B shares as of May&nbsp;1, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person known by CHFW who may become beneficial owner of more than 5% of New Surrozen&#146;s outstanding
Common Stock immediately following the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of CHFW&#146;s current executive officers and directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person who will become an executive officer or a director of New Surrozen upon consummation of the
Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of CHFW&#146;s current executive officers and directors as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of New Surrozen&#146;s executive officers and directors as a group after the consummation of the Business
Combination. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a
person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security. Under those rules, beneficial ownership includes securities that the individual or entity has the right to
acquire, such as through the exercise of warrants or stock options or the vesting of restricted stock units, within 60 days of May&nbsp;1, 2021. Shares subject to warrants or options that are currently exercisable or exercisable within 60 days of
May&nbsp;1, 2021 or subject to restricted stock units that vest within 60 days of May&nbsp;1, 2021 are considered outstanding and beneficially owned by the person holding such warrants, options or restricted stock units for the purpose of computing
the percentage ownership of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Except as noted by footnote, and subject to community property laws where applicable, based on the
information provided to CHFW, CHFW believes that the persons and entities named in the table below have sole voting and investment power with respect to all shares shown as beneficially owned by them. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before the Business Combination <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After the Business Combination</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming&nbsp;No&nbsp;Redemption<BR>of Public&nbsp;Shares <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming&nbsp;Maximum<BR>Redemption<BR>of&nbsp;Public&nbsp;Shares <SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name and Address of<BR>Beneficial&nbsp;Owners <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Shares<BR>Beneficially<BR>Owned</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Percentage<BR>of Class</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Shares<BR>Beneficially<BR>Owned</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Percentage<BR>of Class</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Shares<BR>Beneficially<BR>Owned</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Percentage<BR>of Class</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Shares<BR>Beneficially<BR>Owned</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Percentage<BR>of Class</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5%+ Holders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consonance Life Sciences&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">578,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.92</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,210,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96.09</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,359,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,359,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.78</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Consonance Capital Management, LP <SUP
STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.38</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.06</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.74</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baker Bros. Advisors LP&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.57</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.23</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with the Column Group
<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,409,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,409,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26.54</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Regents of the University of
California&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,080,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.81</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,080,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.88</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Hartford
HealthCare&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,950,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,950,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">338 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before the Business Combination <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After the Business Combination</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming&nbsp;No&nbsp;Redemption<BR>of Public&nbsp;Shares <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming&nbsp;Maximum<BR>Redemption<BR>of&nbsp;Public&nbsp;Shares <SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name and Address of<BR>Beneficial&nbsp;Owners <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Shares<BR>Beneficially<BR>Owned</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Percentage<BR>of Class</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Shares<BR>Beneficially<BR>Owned</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Percentage<BR>of Class</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Shares<BR>Beneficially<BR>Owned</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Percentage<BR>of Class</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Shares<BR>Beneficially<BR>Owned</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Percentage<BR>of Class</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Directors and Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benny Soffer <SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mitchell Blutt <SUP STYLE="font-size:85%; vertical-align:top">(6)(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.38</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.06</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.74</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Donald Santel</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Jarrett</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Haqq</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gad Soffer <SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin Livingston&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>All CHFW directors and executive officers prior to the Business Combination&nbsp;</I><SUP
STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.38</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.91</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,423,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.27</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,423,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Craig Parker <SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">702,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.60</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">702,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.95</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Wen-Chen</FONT> Yeh
<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">298,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">298,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles Williams&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trudy Vanhove&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anna Berkenblit&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(17)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tim Kutzkey <SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,409,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,409,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26.54</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Shao-Lee</FONT> Lin
<SUP STYLE="font-size:85%; vertical-align:top">(18)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Woodhouse&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(19)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Haak-Frendscho&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(20)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mace Rothenberg</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Y. Chai</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>All New Surrozen directors and executive officers after the Business Combination&nbsp;</I><SUP
STYLE="font-size:85%; vertical-align:top">(21)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,884,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28.15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,884,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30.67</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Unless otherwise noted, the business address of each of the directors and officers prior to the Business
Combination is 1&nbsp;Palmer Square, Suite 305, Princeton, New Jersey 08540 and the business address of each of the directors and officers after the Business Combination is 171&nbsp;Oyster Point Boulevard, Suite&nbsp;400, South San Francisco,
California 94080. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Prior to the Business Combination, the percentage of beneficial ownership of CHFW is calculated based on
(i)&nbsp;9,634,000 Class&nbsp;A ordinary shares and (ii) 2,300,000 Class&nbsp;B ordinary shares, in each case, outstanding as of May&nbsp;1, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The expected beneficial ownership of New Surrozen immediately upon closing of the Business Combination,
assuming no holders of public shares exercise their redemption rights in connection therewith, is based on 43,195,000 shares of New Surrozen Common Stock outstanding following the closing, and consists of (i)&nbsp;9,634,000 Class&nbsp;A ordinary
shares that will convert into a like number of shares of New Surrozen Common Stock, (ii)&nbsp;1,541,000 Class&nbsp;B ordinary shares that will convert into a like number of shares of New Surrozen Common Stock, (iii)&nbsp;20,000,000 shares of New
Surrozen Common Stock that will be issued to the Surrozen equityholders at Closing (representing the maximum number of shares that could be issued to Surrozen equityholders at Closing), and (iv)&nbsp;12,020,000 shares of New Surrozen Common Stock
that will be issued in the PIPE Financing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The expected beneficial ownership of New Surrozen immediately upon consummation of the Business Combination,
assuming all holders of CHFW&#146;s public shares exercise their redemption rights in connection </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">339 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
therewith (taking into account the CHFW Shareholder Transaction Support Agreements entered into by certain public shareholders), is based on 43,195,000 shares of New Surrozen Common Stock
outstanding as of such date minus 7,900,000 shares that may be redeemed (reflecting the impact of the CHFW Shareholder Transaction Support Agreements), and assumes of (i)&nbsp;1,734,000 Class&nbsp;A ordinary shares that will convert into a like
number of shares of New Surrozen Common Stock, (ii)&nbsp;1,541,000 Class&nbsp;B ordinary shares that will convert into a like number of shares of New Surrozen Common Stock, (iii)&nbsp;20,000,000 shares of New Surrozen Common Stock, which represents
the maximum number of shares that will be issued to the Surrozen equityholders at Closing, and (iv)&nbsp;12,020,000 of New Surrozen Common Stock that will be issued in the PIPE Financing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Prior to the Business Combination, includes (a) 434,000 Class&nbsp;A ordinary shares underlying private
placement units acquired by Sponsor in the private placement that closed simultaneously with the IPO, (b) 144,667 Class&nbsp;A ordinary shares underlying the warrants included in the private placement units and (c) 2,210,000 Class&nbsp;B ordinary
shares. Following the Business Combination, includes (a)&nbsp;1,451,000 shares of New Surrozen Common Stock, which gives effect to the contribution by the Sponsor, effective as of the closing of the Business Combination, to CHFW of 759,000
Class&nbsp;B ordinary shares for no consideration on the terms and subject to the conditions set forth in the Sponsor Letter Agreement, (b)&nbsp;434,000 Class&nbsp;A ordinary shares underlying private placement units acquired by Sponsor in the
private placement that closed simultaneously with the IPO, (c)&nbsp;144,667 shares of New Surrozen common stock underlying New Surrozen warrants and (d)&nbsp;(i)&nbsp;2,497,500 shares of New Surrozen Common Stock underlying PIPE Units and
(ii)&nbsp;832,500 shares of New Surrozen Common Stock underlying PIPE Warrants. Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer
and Kevin Livingston have voting and investment discretion of the shares held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of the shares held by Consonance Life Sciences. Each of Mitchell J. Blutt, Benny Soffer
and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Prior to the Business Combination, includes (a)&nbsp;(i)&nbsp;500,000 Class&nbsp;A ordinary shares
underlying 500,000 units held by Consonance Capital Master Account LP (the &#147;Master Account&#148;), 371,100 Class&nbsp;A ordinary shares underlying 371,100 units held by Consonance Capital Opportunity Master Fund, LP (the &#147;Opportunity
Master&#148;) and 128,900 Class&nbsp;A ordinary shares underlying 128,900 units held by a certain managed account for which Consonance Management (as defined below) serves as investment advisor (the &#147;Managed Fund&#148;) and
(b)&nbsp;(i)&nbsp;166,667 Class&nbsp;A ordinary shares underlying the public warrants included in the units held by the Master Account, (ii)&nbsp;123,700 Class&nbsp;A ordinary shares underlying the public warrants included in the units held by the
Opportunity Master and (iii)&nbsp;42,966 Class&nbsp;A ordinary shares underlying the public warrants included in the units held by the Managed Fund. Following closing of the Business Combination, includes: (a)&nbsp;(i)&nbsp;500,000 shares of New
Surrozen Common Stock held by the Master Account, (ii)&nbsp;371,100 shares of New Surrozen Common Stock held by the Opportunity Master and (iii)&nbsp;128,900 shares of New Surrozen Common Stock held by the Managed Fund, in each case pursuant to the
conversion of Class&nbsp;A ordinary shares held prior to the Business Combination; and (b)&nbsp;(i)&nbsp;166,667 shares of New Surrozen common stock underlying the New Surrozen warrants held by the Master Account, (ii)&nbsp;123,700 shares of New
Surrozen common stock underlying the New Surrozen warrants held by the Opportunity Master and (iii) 42,966 shares of New Surrozen common stock underlying the New Surrozen warrants held by the Managed Fund. Consonance Capital Management LP
(&#147;Consonance Management&#148;) is the investment adviser of the Managed Fund, the Master Account and Opportunity Master, and pursuant to investment advisory agreements, Consonance Management exercises voting and investment power over the
securities of the issuer held by the Master Account and Opportunity Master and thus may be deemed to beneficially own the securities of the issuer held by the Master Account and Opportunity Master. Consonance Capman GP LLC (&#147;Capman&#148;), as
the general partner of Consonance Management, and Mitchell J. Blutt, as the manager and member of Capman, may be deemed to beneficially own the securities of the Issuer held by the Master Account, Opportunity Master and the Managed Fund. The address
of the principal business office of each of these entities is 1370 Avenue of the Americas, Suite 3301, New York, NY 10019. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">340 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Following the Business Combination, includes (a) (i) 2,315,223 shares of New Surrozen Common Stock
underlying PIPE Units and (ii) 771,741 shares of New Surrozen Common Stock underlying PIPE Warrants, in each case held by Baker Brothers Life Sciences, L.P. (&#147;BBLS&#148;) and (b) (i) 184,777 shares of New Surrozen Common Stock underlying PIPE
Units and (ii) 61,592 shares of New Surrozen Common Stock underlying PIPE Warrants, in each case held by 667, L.P. (&#147;667&#148;, and together with BBLS, the &#147;BBA Funds&#148;). Baker Bros. Advisors LP (&#147;BBA&#148;), is the investment
adviser to the BBA Funds and has sole voting and investment power with respect to the securities held by the BBA Funds and thus may be deemed to beneficially own such securities. Baker Bros. Advisors (GP) LLC
<FONT STYLE="white-space:nowrap">(&#147;BBA-GP&#148;),</FONT> is the sole general partner of BBA and thus may be deemed to beneficially own the securities held by the BBA Funds. The principals of <FONT STYLE="white-space:nowrap">BBA-GP</FONT> are
Julian C. Baker and Felix J. Baker, who may be deemed to beneficially own the securities held by the BBA Funds. The address for BBA, <FONT STYLE="white-space:nowrap">BBA-GP,</FONT> Julian C. Baker and Felix J. Baker and the BBA Funds is 860
Washington Street, 3rd Floor, New York, NY 10014. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Following the Business Combination, includes: (a) (i) 4,106,072 shares of New Surrozen Common Stock received
by The Column Group III, LP (&#147;TCG III&#148;) as an equityholder of Surrozen and (ii) 4,637,041 shares of New Surrozen Common Stock received by The Column Group <FONT STYLE="white-space:nowrap">III-A,</FONT> LP (&#147;TCG <FONT
STYLE="white-space:nowrap">III-A&#148;;</FONT> (b) (i) 234,818 shares of New Surrozen Common Stock underlying PIPE Units held by TCG III and (ii) 265,182 shares of New Surrozen Common Stock underlying PIPE Units acquired in the PIPE Financing by TCG
<FONT STYLE="white-space:nowrap">III-A;</FONT> and (c) (i)&nbsp;78,272 shares of New Surrozen Common Stock underlying PIPE Warrants held by TCG III and (ii)&nbsp;88,394 shares of New Surrozen Common Stock underlying PIPE Warrants held by TCG <FONT
STYLE="white-space:nowrap">III-A,</FONT> LP. The Column Group III GP, LP (&#147;TCG III GP&#148;), is the general partner of each of TCG III and TCG <FONT STYLE="white-space:nowrap">III-A.</FONT> Dr.&nbsp;Kutzkey, David Goeddel and Peter Svennilson
are the Managing Partners of TCG III GP and as such may each be deemed to share voting and investment power with respect to the securities held by each of TCG III and TCG <FONT STYLE="white-space:nowrap">III-A</FONT> and disclaims beneficial
ownership of the securities except to the extent of his pecuniary interests therein. The address for the entities listed herein is 1&nbsp;Letterman Drive, Building D, Suite <FONT STYLE="white-space:nowrap">DM-900,</FONT> San Francisco, CA 94129.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Following the Business Combination, includes: (a) 1,747,118 shares of New Surrozen Common Stock received by
The Regents of the University of California (&#147;UC&#148;) as an equityholder of Surrozen and (b) (i) 250,000 shares of New Surrozen Common Stock underlying PIPE Units held by UC and (ii)&nbsp;83,333 shares of New Surrozen Common Stock underlying
PIPE Units acquired in the PIPE Financing by UC. The address for UC is 1111 Franklin Street, 6<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Oakland, CA 94607. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Following the Business Combination, includes: (a) (i) 535,002 shares of New Surrozen Common Stock received
by Hartford HealthCare Endowment, LLC (&#147;HHC Endowment&#148;) as an equityholder of Surrozen and (ii) 535,002 shares of New Surrozen Common Stock received by Hartford HealthCare Corporation Defined Benefit Master Trust (&#147;HHC Pension&#148;);
(b) (i) 330,000 shares of New Surrozen Common Stock underlying PIPE Units held by HHC Endowment and (ii) 330,000 shares of New Surrozen Common Stock underlying PIPE Units acquired in the PIPE Financing by HHC Pension; and (c) (i) 110,000 shares of
New Surrozen Common Stock underlying PIPE Warrants held by HHC Endowment and (ii) 110,000 shares of New Surrozen Common Stock underlying PIPE Warrants held by HHC Pension. David Holmgren serves as Chief Investment Officer of Hartford HealthCare and
may be deemed to hold voting and/or dispositive control over the shares held by HHC Endowment and HHC Pension. The address for Hartford HealthCare is 80 Seymour Street &#150; Cheney Bldg, Hartford, CT 06102. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of Benny Soffer, Mitchell Blutt, Donald Santel, Jennifer Jarrett, Christopher Haqq, Gad Soffer and
Kevin Livingston. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Does not include any shares indirectly owned by this individual because of his ownership interest in
CHFW&#146;s Sponsor. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Following the Business Combination, consists of 702,190 shares of New Surrozen common stock issuable
pursuant to stock options exercisable within 60 days of May&nbsp;1, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Following the Business Combination, consists of (a) 219,434 shares of New Surrozen common stock and 78,996
shares of New Surrozen common stock issuable pursuant to stock options exercisable within 60 days of May&nbsp;1, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Following the Business Combination, consists of 175,547 shares of New Surrozen common stock subject to
restricted stock awards. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">341 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Following the Business Combination, consists of 157,992 shares of New Surrozen common stock subject to
restricted stock awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Following the Business Combination, consists of 35,109 shares of New Surrozen common stock subject to
restricted stock awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Following the Business Combination, consists of 35,109 shares of New Surrozen common stock subject to
restricted stock awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(19)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Following the Business Combination, consists of 35,109 shares of New Surrozen common stock subject to
restricted stock awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(20)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Following the Business Combination, consists of 35,109 shares of New Surrozen common stock subject to
restricted stock awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(21)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of Craig Parker, Trudy Vanhove, Wen-Chen Yeh, Charles Williams, Anna Berkenblit, Christopher Chai,
Tim Kutzkey, Shao-Lee Lin, David Woodhouse, Mary Haak-Frendscho and Mace Rothenberg. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">342 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_220"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_221"></A>Certain Relationships and Related Person Transactions&#151;CHFW </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Class&nbsp;B Ordinary Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On
September&nbsp;4, 2020, Sponsor paid $25,000, or approximately $0.007 per share, to cover for certain offering costs in consideration for 3,593,750 founder shares. On October&nbsp;8, 2020 and November&nbsp;10, 2020, 718,750 and 575,000 founder
shares were contributed back to CHFW for no consideration, respectively, resulting in there being 2,300,000 founder shares issued and outstanding (at approximately $0.011 per share). On November&nbsp;18, 2020, Sponsor transferred an aggregate of
90,000 founder shares to each of CHFW&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. The founder shares (including the Class&nbsp;A ordinary shares issuable upon exercise thereof) may not, subject to certain limited
exceptions, be transferred, assigned or sold by the holder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Class&nbsp;A Ordinary Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sponsor entered into a Subscription Agreement to purchase 2,497,500 PIPE Units in the PIPE Financing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Private Placement Warrants </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sponsor has
purchased 410,000 private placement warrants for a purchase price of $4,100,000 in a private placement that occurred simultaneously with the closing of CHFW&#146;s initial public offering. As such, Sponsor&#146;s interest in the initial public
offering is valued at $4,100,000. Additionally, Sponsor purchased an additional 24,000 private placement&nbsp;units on December&nbsp;1, 2020 as a result of the underwriter&#146;s full exercise of the over-allotment option for a total of $240,000.
The private placement warrants and Class&nbsp;A ordinary shares issued upon the exercise or conversion thereof may not, subject to certain limited exceptions, be transferred, assigned or sold by the holder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administrative Services Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW
currently maintains executive offices at 1 Palmer Square, Suite 305, Princeton, NJ 08540. The cost for CHFW&#146;s use of this space is included in the $55,000 per month fee we will pay to Sponsor for office space, administrative and support
services, commencing on the date that CHFW securities are first listed on NYSE American. Upon completion of CHFW&#146;s initial business combination or our liquidation, CHFW will cease paying these monthly fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No compensation of any kind, including finder&#146;s and consulting fees, will be paid to Sponsor, officers and directors, or any of their
respective affiliates, for services rendered prior to or in connection with the completion of an initial business combination. However, these individuals will be reimbursed for any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with activities on our behalf such as identifying potential partner businesses and performing due diligence on suitable
business combinations. Our audit committee will review on a quarterly basis all payments that were made by us to our Sponsor, officers, directors or our or their affiliates and will determine which expenses and the amount of expenses that will be
reimbursed. There is no cap or ceiling on the reimbursement of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by such persons in connection with activities on our behalf. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Related Party Loans </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sponsor and its
affiliate had loaned CHFW an aggregate of $300,000 to cover expenses related to initial public offering pursuant to a promissory note. This loan was <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and became payable upon the completion
of CHFW initial public offering. On November&nbsp;23, 2020, CHFW repaid the outstanding balance on the note of $147,753 in full to Sponsor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, in order to finance transaction costs in connection with an intended initial business combination, Sponsor or an affiliate of
Sponsor or certain of CHFW&#146;s officers and directors may, but are not obligated to, loan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">343 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
CHFW funds as may be required. If CHFW complete an initial business combination, CHFW may repay such loaned amounts out of the proceeds of the trust account released to CHFW. In the event that
the initial business combination does not close, CHFW may use a portion of the working capital held outside the trust account to repay such loaned amounts but no proceeds from CHFW trust account would be used for such repayment. Up to $1,500,000 of
such loans may be convertible into warrants at a price of $1.50 per warrant at the option of the lender. The warrants would be identical to the private placement warrants, including as to exercise price, exercisability and exercise period. The terms
of such loans by CHFW&#146;s officers and directors, if any, have not been determined and no written agreements exist with respect to such loans. CHFW does not expect to seek loans from parties other than Sponsor, members of CHFW&#146;s founding
team or any of their affiliates as CHFW does not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in CHFW&#146;s trust account. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>CHFW Registration and Shareholder Rights Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW has entered into a registration and shareholder rights agreement pursuant to which CHFW&#146;s initial shareholders, and their permitted
transferees, if any, are entitled to certain registration rights with respect to the private placement warrants, the securities issuable upon conversion of working capital loans (if any) and the Class&nbsp;A ordinary shares issuable upon exercise of
the foregoing and upon conversion of the founder shares. Further, Sponsor, upon and following consummation of an initial business combination, will be entitled to nominate three individuals for appointment to CHFW&#146;s board of directors, as long
as Sponsor holds any securities covered by the registration and shareholder rights agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_222"></A>Certain
Relationships and Related Person Transactions&#151;Surrozen </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other than compensation arrangements for Surrozen&#146;s directors and
executive officers, which are described elsewhere in this proxy statement/prospectus, described below are transactions since January&nbsp;1, 2018 and each currently proposed transaction in which: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Surrozen have been or are to be a participant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amounts involved exceeded or will exceed $120,000; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any of Surrozen directors, executive officers or holders of more than 5% of Surrozen outstanding capital
stock, or any immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Equity and other compensation, termination, change in control and other arrangements are described in the section titled &#147;Executive
Compensation.&#148; Surrozen also describe below certain other transactions with Surrozen directors, executive officers and stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_223"></A>Preferred Stock Financings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Series A Preferred Stock Financing </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
January 2018, Surrozen issued and sold to investors in a private placement an aggregate of 14,540,740 shares of Surrozen&#146;s Series A preferred stock in a subsequent closing of Surrozen&#146;s Series A preferred stock financing at a purchase
price of $1.00 per share for aggregate cash proceeds of approximately $14.5&nbsp;million. Each share of Series A preferred stock will automatically convert into one share of Surrozen&#146;s common stock upon the consummation of the Business
Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">344 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the Series A preferred stock purchased by holders of more
than 5% of Surrozen&#146;s capital stock and entities affiliated with the Surrozen directors in January 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Participants</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Column Group III, LP<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,105,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,105,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Column Group <FONT STYLE="white-space:nowrap">III-A,</FONT> LP<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,894,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,894,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Each of David Goeddel and Tim Kutzkey is a member of the Surrozen board of directors and is a Managing
Partner of The Column Group, LLC, which is the general partner of The Column Group III GP, LP, which is the general partner of The Column Group III, LP and The Column Group <FONT STYLE="white-space:nowrap">III-A,</FONT> LP. Drs. Goeddel and Kutzkey
are also managing members of The Column Group III Management, LP. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Series B Preferred Stock Financing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Between October 2018 and September 2019, Surrozen issued and sold to investors in a private placement an aggregate of 33,162,954 shares of
Surrozen&#146;s Series B preferred stock in Surrozen&#146;s Series B preferred stock financing at a purchase price of $1.50 per share for aggregate cash proceeds of approximately $49.7&nbsp;million. Each share of Series B preferred stock will
automatically convert into one share of Surrozen&#146;s common stock upon the consummation of the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following
table summarizes the Series B preferred stock purchased by holders of more than 5% of Surrozen&#146;s capital stock and entities affiliated with Surrozen&#146;s directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Participants</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Column Group III, LP<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,261,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 9,392,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Column Group <FONT STYLE="white-space:nowrap">III-A,</FONT> LP<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,071,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,607,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Regents of the University of California</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,666,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 8,499,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Hartford
Healthcare<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,666,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3,999,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Each of David Goeddel and Tim Kutzkey is a member of Surrozen&#146;s board of directors and is a Managing
Partner of The Column Group, LLC, which is the general partner of The Column Group III GP, LP, which is the general partner of The Column Group III, LP and The Column Group <FONT STYLE="white-space:nowrap">III-A,</FONT> LP. Drs. Goeddel and Kutzkey
are also managing members of The Column Group III Management, LP. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 1,333,332 shares of Series B Preferred Stock purchased by Hartford HealthCare Corporation
Defined Benefit Master Trust and 1,333,332 shares of Series B Preferred Stock purchased by Hartford HealthCare Endowment, LLC. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Series C Preferred Stock Financing </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
May 2020 and June 2020, Surrozen issued and sold to investors in a private placement an aggregate of 28,571,423 shares of Surrozen&#146;s Series C preferred stock in Surrozen&#146;s Series C preferred stock financing at a purchase price of $1.75 per
share for aggregate cash proceeds of approximately $50.0&nbsp;million. Each share of such Series C preferred stock will automatically convert into one share of Surrozen common stock upon the consummation of the Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">345 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the Series C preferred stock purchased by holders of more
than 5% of Surrozen&#146;s capital stock and entities affiliated with Surrozen&#146;s directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Participants</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Column Group III, LP<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,898,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,072,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Column Group <FONT STYLE="white-space:nowrap">III-A,</FONT> LP<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,273,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,727,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Regents of the University of California</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,285,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Hartford
Healthcare<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,428,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Each of David Goeddel and Tim Kutzkey is a member of Surrozen&#146;s board of directors and is a Managing
Partner of The Column Group, LLC, which is the general partner of The Column Group III GP, LP, which is the general partner of The Column Group III, LP and The Column Group <FONT STYLE="white-space:nowrap">III-A,</FONT> LP. Drs. Goeddel and Kutzkey
are also managing members of The Column Group III Management, LP. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 1,714,285 shares of Series C Preferred Stock purchased by Hartford HealthCare Corporation
Defined Benefit Master Trust and 1,714,285 shares of Series C Preferred Stock purchased by Hartford HealthCare Endowment, LLC. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_224"></A>UCSF License and Option Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2020, Surrozen entered into the UCSF Agreements with The Regents of the University of California, a holder of more than 5% of
Surrozen&#146;s capital stock, pursuant to which Surrozen obtained from The Regents of the University of California, or UCSF, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses to make and use a certain human Fab na&iuml;ve phage display
library and to make and use a certain phage display llama VHH single domain antibody library for internal research and antibody discovery purposes and an option to negotiate with UCSF to obtain a <FONT STYLE="white-space:nowrap">non-exclusive</FONT>
license under UCSF&#146;s rights in the applicable library to make, use, sell, offer for sale and import products incorporating antibodies identified or resulting from Surrozen&#146;s use of such library, or licensed products. In consideration for
the license and option rights under each UCSF Agreement, Surrozen paid UCSF a nominal option issue fee and agreed to pay UCSF a nominal annual option maintenance fee. If Surrozen exercise the option under either UCSF Agreement, Surrozen and UCSF
will negotiate in good faith the terms of a commercial license agreement in addition to the <FONT STYLE="white-space:nowrap">pre-agreed</FONT> terms which include payment to UCSF of a nominal license issue fee, nominal annual license maintenance
fees, nominal to low six figure milestone payments for the achievement of a specified regulatory milestone event for each licensed product, nominal annual minimum royalties, which are creditable against earned royalties for the same year, and earned
royalties equal to a <FONT STYLE="white-space:nowrap">sub-single</FONT> digit percentage of Surrozen&#146;s and Surrozen&#146;s sublicensees&#146; net sales of licensed products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For a more detailed description of the UCSF Agreements, see the section titled &#147;<I>Information About Surrozen&#151;UCSF License and
Option Agreements.</I>&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_225"></A>Investors&#146; Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with the Closing, that certain investors&#146; rights agreement, dated November&nbsp;18, 2020, will be terminated, and New
Surrozen, the Sponsor and certain stockholders of Surrozen (the &#147;Target Holders&#148;) (the Sponsor, the Target Holders and the Investor Stockholders, collectively, the &#147;Holders&#148;) will enter into the Investors&#146; Rights Agreement,
the form of which is attached to this proxy statement/prospectus as <I>Annex G</I>, at the Closing, pursuant to which the Holders (as defined in the Investors&#146; Rights Agreement), subject to certain conditions, will be entitled to registration
rights. Pursuant to the Investors&#146; Rights Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_226"></A>Voting Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen is party to an amended and restated voting agreement under which certain holders of Surrozen&#146;s capital stock, including the
holders of more than 5% of Surrozen&#146;s outstanding capital stock, such as entities affiliated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">346 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
with The Column Group III, LP, The Regents of the University of California and entities affiliated with Hartford Healthcare, have agreed as to the manner in which they will vote their shares of
Surrozen&#146;s capital stock on certain matters, including with respect to the election of directors. Upon the consummation of the Business Combination, the amended and restated voting agreement will terminate, and none of Surrozen&#146;s
stockholders will have any special rights regarding the election or designation of members of Surrozen&#146;s board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_227">
</A>Indemnification Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Proposed Certificate of Incorporation, which will be effective upon consummation of the Business
Combination, will contain provisions limiting the liability of directors, and the Proposed Certificate of Incorporation, which will be effective upon consummation of the Business Combination will provide that Surrozen will indemnify each of
Surrozen&#146;s directors and officers to the fullest extent permitted under Delaware law. The Proposed Certificate of Incorporation, which will be effective upon consummation of the Business Combination, will also provide Surrozen&#146;s board of
directors with discretion to indemnify Surrozen&#146;s employees and other agents when determined appropriate by the board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition,
Surrozen have entered into an indemnification agreement with each of Surrozen&#146;s directors and executive officers, which requires Surrozen to indemnify them. For more information regarding these agreements, see the section titled
&#147;<I>Surrozen&#146;s Executive Compensation&#151;Limitations of Liability and Indemnification Matters</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_228">
</A>Policies and Procedures for Related Person Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the consummation of the Business Combination, the Surrozen board of
directors will adopt a related person transaction policy setting forth the policies and procedures for the identification, review, and approval or ratification of related person transactions. This policy covers, with certain exceptions set forth in
Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which Surrozen and a related person
were or will be participants and the amount involved exceeds $120,000, including purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness and guarantees of
indebtedness. In reviewing and approving any such transactions, the Surrozen audit committee will consider all relevant facts and circumstances as appropriate, such as the purpose of the transaction, the availability of other sources of comparable
products or services, whether the transaction is on terms comparable to those that could be obtained in an arm&#146;s length transaction, management&#146;s recommendation with respect to the proposed related person transaction, and the extent of the
related person&#146;s interest in the transaction. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_229"></A>COMPARISON OF CORPORATE GOVERNANCE AND SHAREHOLDER RIGHTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW is an exempted company incorporated under the Cayman Islands Companies Act. The Cayman Islands Companies Act, Cayman Islands law
generally and the Existing Governing Documents govern the rights of its shareholders. The Cayman Islands Companies Act and Cayman Islands law generally differs in some material respects from laws generally applicable to United States corporations
and their stockholders. In addition, the Existing Governing Documents differ in certain material respects from the Proposed Governing Documents. As a result, when you become a stockholder of New Surrozen, your rights will differ in some regards as
compared to when you were a shareholder of CHFW. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Below is a summary chart outlining important similarities and differences in the
corporate governance and stockholder/shareholder rights associated with each of CHFW and New Surrozen according to applicable law and/or the organizational documents of CHFW and New Surrozen. You also should review the Proposed Certificate of
Incorporation and the Proposed Bylaws of New Surrozen attached hereto as Annex C and Annex D to this proxy statement/prospectus, as well as the Delaware corporate law and corporate laws of the Cayman Islands, including the Cayman Islands Companies
Act, to understand how these laws apply to CHFW and New Surrozen. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">347 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Existing Governing Documents</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Proposed Governing Documents</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Authorized Shares<BR></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The share capital under the Existing Governing Documents is US$50,100 divided into 350,000,000 Class&nbsp;A ordinary shares
of par value US$0.0001 per share, 150,000,000 Class&nbsp;B ordinary shares of par value US$0.0001 per share and 1,000,000 preference shares of par value US$0.0001 per share.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents authorize 300,000,000 shares of New Surrozen Common Stock and 10,000,000 shares of New
Surrozen Preferred Stock.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>See paragraph 8 of the Existing Governing Documents.</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>See Article IV subsection A of the Proposed Certificate of Incorporation.</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Authorize the Board of Directors to Issue Preferred Stock Without Stockholder
Consent<BR></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Existing Governing Documents authorize the issuance of 1,000,000 preference shares with such designation, rights and
preferences as may be determined from time to time by our board of directors. Accordingly, the CHFW Board is empowered under the Existing Governing Documents, without shareholder approval, to issue preference shares with dividend, liquidation,
redemption, voting or other rights which could adversely affect the voting power or other rights of the holders of ordinary shares.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents authorize the board of directors to issue all or any shares of preferred stock in one or
more series to fix the number of shares and to determine or alter for each such series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such
qualifications, limitations, or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by the Board of Directors providing for the issuance of such shares and as may be permitted by the DGCL.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>See paragraph 8 of the Existing Governing Documents and Article 3 of the Articles of Association.</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>See Article IV subsection B of the Proposed Certificate of Incorporation.</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Corporate Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Existing Governing Documents provide the name of the company is
<FONT STYLE="white-space:nowrap">&#147;Consonance-HFW</FONT> Acquisition Corp.&#148;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents will provide that the name of the corporation will be &#147;Surrozen,
Inc.&#148;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>See paragraph 1 of our Existing Governing Documents.</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>See Article I of the Proposed Certificate of Incorporation.</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Perpetual Existence</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Existing Governing Documents provide that if we do not consummate a business combination (as defined in the Existing
Governing Documents) by November&nbsp;23, 2022 (twenty-four months after the closing of CHFW&#146;s initial public offering), CHFW will cease all operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents do not include any provisions relating to New Surrozen&#146;s ongoing existence; the
default under the DGCL will make New Surrozen&#146;s existence perpetual.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">348 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Existing Governing Documents</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Proposed Governing Documents</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except for the purposes of winding up and will redeem the shares issued in CHFW&#146;s initial public offering and
liquidate its trust account.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>See Article 38 of our Articles of Association.</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>This is the default rule under the DGCL.</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Shareholder/Stockholder Written Consent In Lieu of a Meeting</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Existing Governing Documents provide that resolutions may be passed by a vote in person, by proxy at a general meeting,
or by unanimous written resolution.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>See Articles 14
and 15 of our Articles of Association.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Certificate of Incorporation allows stockholders to vote in person or by proxy at a meeting of stockholders,
but prohibits the ability of stockholders to act by written consent in lieu of a meeting.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Exclusive Forum</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Existing Governing Documents do not contain a provision adopting an exclusive forum for certain shareholder
litigation.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents adopt Delaware as the exclusive forum for certain stockholder litigation and the federal
district courts of the United Stated of America shall be the exclusive forum for litigation arising out of the Securities Act.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>See Article VII subsections A and B of the Proposed Certificate of Incorporation</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Provisions related to the Corporate Opportunity Doctrine</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Existing Governing Documents do not address corporate opportunities under Cayman Law.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents provide a waiver of the obligation of nonemployee directors of New Surrozen to offer
certain corporate opportunities to New Surrozen unless the opportunity is acquired or become in the possession of the direct expressly and solely in connection with such individual&#146;s service on the board of New Surrozen.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>See Article V of the Proposed Certificate of Incorporation.</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Provisions Related to Status as a Blank Check Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Existing Governing Documents set forth various provisions related to our status as a blank check company prior to the
consummation of a business combination.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Governing Documents do not include such provisions related to our status as a blank check company, which no
longer will apply upon consummation of the Business Combination, as we will cease to be a blank check company at such time.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>See Article 38 of our Articles of Association.</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">349 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_230"></A>DESCRIPTION OF NEW SURROZEN SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following summary of certain provisions of New Surrozen securities does not purport to be complete and is subject to the Proposed
Certificate of Incorporation, the Proposed Bylaws and the provisions of applicable law. Copies of the Proposed Certificate of Incorporation and the Proposed Bylaws are attached to this proxy statement/prospectus as Annex C and Annex D, respectively.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_231"></A>Authorized Capitalization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>General </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The total
amount of New Surrozen&#146;s authorized capital stock consists of 300,000,000 shares of New Surrozen common stock, par value $0.0001 per share, and 10,000,000 shares of New Surrozen preferred stock, par value $0.0001 per share. New Surrozen expects
to have&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million shares of New Surrozen common stock outstanding immediately after the consummation of the Business Combination, excluding contingent
shares and assuming no public shareholders exercise their redemption rights in connection with the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following
summary describes all material provisions of New Surrozen&#146;s capital stock. New Surrozen urges you to read the Proposed Certificate of Incorporation and the Proposed Bylaws (copies of which are attached to this proxy statement/prospectus as
Annex C and Annex D, respectively). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Board of New Surrozen has authority to issue shares of New Surrozen&#146;s preferred stock in one or more series, to fix for each such
series such voting powers, designations, preferences, qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, redemption privileges and liquidation preferences for the issue of such series all to the
fullest extent permitted by the DGCL. The issuance of New Surrozen&#146;s preferred stock could have the effect of decreasing the trading price of New Surrozen&#146;s common stock, restricting dividends on New Surrozen&#146;s capital stock, diluting
the voting power of New Surrozen&#146;s common stock, impairing the liquidation rights of New Surrozen&#146;s capital stock, or delaying or preventing a change in control of New Surrozen. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Common Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New
Surrozen common stock is not entitled to preemptive or other similar subscription rights to purchase any of New Surrozen&#146;s securities. New Surrozen common stock is neither convertible nor redeemable. Unless New Surrozen&#146;s board of
directors determines otherwise, New Surrozen will issue all of New Surrozen&#146;s capital stock in uncertificated form. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Voting
Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each holder of New Surrozen common stock is entitled to one vote for each share on all matters submitted to a vote of the
stockholders, including the election of directors. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Dividend Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each holder of shares of New Surrozen&#146;s common stock is entitled to the payment of dividends and other distributions as may be declared by
the Board from time to time out of New Surrozen&#146;s assets or funds legally available for dividends or other distributions. These rights are subject to the preferential rights of the holders of New Surrozen&#146;s Preferred Stock, if any, and any
contractual limitations on New Surrozen&#146;s ability to declare and pay dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">350 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Other Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each holder of New Surrozen common stock is subject to, and may be adversely affected by, the rights of the holders of any series of New
Surrozen preferred stock that New Surrozen may designate and issue in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Liquidation Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If New Surrozen is involved in voluntary or involuntary liquidation, dissolution or winding up of New Surrozen&#146;s affairs, or a similar
event, each holder of New Surrozen common stock will participate pro rata in all assets remaining after payment of liabilities, subject to prior distribution rights of New Surrozen preferred stock, if any, then outstanding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_232"></A>Action by Written Consent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Proposed Certificate of Incorporation provides that any action required or permitted to be taken by the stockholders must be effected at an
annual or special meeting of the stockholders, and may not be taken by written consent in lieu of a meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_233"></A>Anti-Takeover Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Section&nbsp;203 of the Delaware General Corporation Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New Surrozen is subject to Section&nbsp;203 of the Delaware General Corporation Law, which generally prohibits a publicly held Delaware
corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before such date, the board of directors of the corporation approved either the business combination or the
transaction that resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the
interested stockholder, those shares owned (1)&nbsp;by persons who are directors and also officers and (2)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the
plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or after such date, the business combination is approved by the board of directors and authorized at an
annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>/<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>% of the outstanding
voting stock that is not owned by the interested stockholder. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, Section&nbsp;203 defines a &#147;business
combination&#148; to include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the
interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of
any stock of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the
stock or any class or series of the corporation beneficially owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits by or through the corporation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">351 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, Section&nbsp;203 defines an &#147;interested stockholder&#148; as an entity or
person who, together with the person&#146;s affiliates and associates, beneficially owns or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the
corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A Delaware corporation may &#147;opt out&#148; of these provisions with an express provision in its original certificate of
incorporation or an express provision in its amended and restated certificate of incorporation or amended and restated bylaws resulting from a stockholders&#146; amendment approved by at least a majority of the outstanding voting shares. New
Surrozen has not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of New Surrozen may be discouraged or prevented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Proposed Certificate of Incorporation and Proposed Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among other things, the Proposed Certificate of Incorporation and Proposed Bylaws: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permit New Surrozen&#146;s board of directors to issue up to 10,000,000 shares of preferred stock, with any
rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change of control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that the authorized number of directors may be changed only by resolution of the Board;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that New Surrozen&#146;s board of directors will be classified into three classes of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, subject to the rights of any series of preferred stock to elect directors, directors may only be
removed for cause, which removal may be effected, subject to any limitation imposed by law, by the holders of at least 66<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>/<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>% of the voting
power of all of our then-outstanding shares of the capital stock entitled to vote generally at an election of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law,
be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that any action to be taken by New Surrozen stockholders must be effected at a duly called annual or
special meeting of stockholders and not be taken by written consent or electronic transmission; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate
candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#146;s notice; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that special meetings of our stockholders may be called only by the chairman of the Board, its chief
executive officer or by its board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The amendment of any of these provisions would require approval by the holders of at least
66<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>/<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>% of the voting power of all of the New Surrozen then-outstanding capital stock entitled to vote generally in the election of
directors, voting together as a single class. The Board may also act without stockholder action to amend, adopt or repeal the Proposed Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The combination of these provisions will make it more difficult for New Surrozen&#146;s existing stockholders to replace New Surrozen&#146;s
board of directors as well as for another party to obtain control of New Surrozen by replacing its board of directors. Since New Surrozen&#146;s board of directors has the power to retain and discharge its officers, these provisions could also make
it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for New Surrozen&#146;s board of directors to issue preferred stock with
voting or other rights or preferences that could impede the success of any attempt to change our control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">352 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These provisions are intended to enhance the likelihood of continued stability in the
composition of New Surrozen&#146;s board of directors and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce New Surrozen&#146;s vulnerability to hostile takeovers
and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for New Surrozen&#146;s capital stock and may have the effect of delaying changes in
New Surrozen&#146;s control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of New Surrozen&#146;s common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_234"></A>Limitations on Liability and Indemnification of Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Proposed Certificate of Incorporation contains provisions that limit the liability of New Surrozen&#146;s directors for monetary damages to the fullest
extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for any breach of fiduciary duties as directors, except liability for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to the corporation or its stockholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Such limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of
equitable remedies such as injunctive relief or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Proposed Certificate of Incorporation authorizes New Surrozen to
indemnify its directors, officers, employees and other agents to the fullest extent permitted by Delaware law. The Proposed Bylaws provides that New Surrozen is required to indemnify its directors and officers to the fullest extent permitted by
Delaware law and may indemnify its other employees and agents. The Proposed bylaws also provide that, on satisfaction of certain conditions, New Surrozen will advance expenses incurred by a director or officer in advance of the final disposition of
any action or proceeding, and permit New Surrozen to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether New Surrozen would otherwise
be permitted to indemnify him or her under the provisions of Delaware law. New Surrozen expects to enter into agreements to indemnify its directors and executive officers in connection with the Business Combination. With certain exceptions, these
agreements provide for indemnification for related expenses, including attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in connection with any action, proceeding or investigation. New Surrozen
believes that Proposed Certificate of Incorporation and Proposed Bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. New Surrozen will also maintain customary
directors&#146; and officers&#146; liability insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The limitation of liability and indemnification provisions in the Proposed
Certificate of Incorporation and Proposed Bylaws may discourage stockholders from bringing a lawsuit against New Surrozen&#146;s directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against New
Surrozen&#146;s directors and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that New Surrozen pays the costs of settlement
and damage awards against directors and officers as required by these indemnification provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_235"></A>Exclusive
Jurisdiction of Certain Actions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Proposed Certificate of Incorporation provides that the Court of Chancery of the State of Delaware
(or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">353 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) is the sole and exclusive
forum for the following types of actions or proceedings under Delaware statutory or common law: (i)&nbsp;any derivative action or proceeding brought on New Surrozen&#146;s behalf; (ii)&nbsp;any action or proceeding asserting a claim of breach of a
fiduciary duty owed by any of New Surrozen&#146;s directors, officers, or other employees to us or our stockholders; (iii)&nbsp;any action or proceeding asserting a claim against New Surrozen or any of New Surrozen&#146;s directors, officers or
other employees arising out of or pursuant to any provision of the Delaware General Corporation Law, the Proposed Certificate of Incorporation or the Proposed Bylaws; (iv)&nbsp;any action or proceeding to interpret, apply, enforce or determine the
validity of the Proposed Certificate of Incorporation or the Proposed Bylaws (including any right, obligation, or remedy thereunder); (v) any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of
Chancery of the State of Delaware; and (vi)&nbsp;any action or proceeding asserting a claim against New Surrozen or any of New Surrozen&#146;s directors, officers, or other employees that is governed by the internal affairs doctrine, in all cases to
the fullest extent permitted by law and subject to the court&#146;s having personal jurisdiction over the indispensable parties named as defendants. This choice of forum provision would not apply to suits brought to enforce a duty or liability
created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction, or the Securities Act. The Proposed Certificate of Incorporation further provides that, unless New Surrozen consents in writing to the selection
of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act,
including all causes of action asserted against any defendant named in such complaint. Additionally, the Proposed Certificate of Incorporation provides that any person or entity holding, owning or otherwise acquiring any interest in any of New
Surrozen&#146;s securities shall be deemed to have notice of and consented to these provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">354 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_237"></A>SECURITIES ACT RESTRICTIONS ON RESALE OF NEW SURROZEN COMMON
STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to Rule 144 under the Securities Act (&#147;Rule 144&#148;), a person who has beneficially owned restricted New
Surrozen Common Stock for at least six months would be entitled to sell their securities provided that (i)&nbsp;such person is not deemed to have been an affiliate of New Surrozen at the time of, or at any time during the three months preceding, a
sale and (ii)&nbsp;New Surrozen is subject to the Exchange Act periodic reporting requirements for at least three months before the sale and have filed all required reports under Section&nbsp;13 or 15(d) of the Exchange Act during the twelve months
(or such shorter period as New Surrozen was required to file reports) preceding the sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Persons who have beneficially owned restricted
New Surrozen Common Stock shares for at least six months but who are affiliates of New Surrozen at the time of, or at any time during the three months preceding, a sale, would be subject to additional restrictions, by which such person would be
entitled to sell within any three-month period only a number of securities that does not exceed the greater of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the total number of New Surrozen Common Stock then outstanding; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly reported trading volume of the New Surrozen Common Stock during the four calendar weeks
preceding the filing of a notice on Form 144 with respect to the sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales by affiliates of New Surrozen under Rule
144 are also limited by manner of sale provisions and notice requirements and to the availability of current public information about New Surrozen. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_238"></A>Restrictions on the Use of Rule 144 by Shell Companies or Former Shell Companies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Rule 144 is not available for the resale of securities initially issued by shell companies (other than business combination related shell
companies) or issuers that have been at any time previously a shell company. However, Rule 144 also includes an important exception to this prohibition if the following conditions are met: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuer of the securities that was formerly a shell company has ceased to be a shell company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuer of the securities is subject to the reporting requirements of Section&nbsp;13 or 15(d) of the
Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuer of the securities has filed all Exchange Act reports and material required to be filed, as
applicable, during the preceding twelve months (or such shorter period that the issuer was required to file such reports and materials), other than <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;reports;</FONT> and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at least one year has elapsed from the time that the issuer filed current Form 10 type information with the
SEC reflecting its status as an entity that is not a shell company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result, our initial shareholders will be able
to sell their Class&nbsp;B ordinary shares and private placement warrants, as applicable, pursuant to Rule 144 without registration one year after we have completed our initial business combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We anticipate that following the consummation of the Business Combination, New Surrozen will no longer be a shell company, and so, once the
conditions set forth in the exceptions listed above are satisfied, Rule 144 will become available for the resale of the above noted restricted securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">355 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_239"></A>STOCKHOLDER PROPOSALS AND NOMINATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_240"></A>Stockholder Proposals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New Surrozen&#146;s Proposed Bylaws establish an advance notice procedure for stockholders who wish to present a proposal before an annual
meeting of stockholders. New Surrozen&#146;s Proposed Bylaws provide that the only business that may be conducted at an annual meeting of stockholders is business that is (i)&nbsp;specified in the notice of such meeting (or any supplement or
amendment thereto) given by or at the direction of New Surrozen&#146;s board of directors, (ii)&nbsp;otherwise properly brought before such meeting by or at the direction of New Surrozen&#146;s board of directors or the chairperson of the board, or
(iii)&nbsp;otherwise properly brought before such meeting by a stockholder present in person who (A)&nbsp;(1) was a record owner of shares of New Surrozen both at the time of giving the notice and at the time of such meeting, (2)&nbsp;is entitled to
vote at such meeting, and (3)&nbsp;has complied with notice procedures specified in New Surrozen&#146;s Proposed Bylaws in all applicable respects or (B)&nbsp;properly made such proposal in accordance with Rule
<FONT STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act. To be timely for New Surrozen&#146;s annual meeting of stockholders, New Surrozen&#146;s secretary must receive the written notice at New Surrozen&#146;s principal executive
offices not earlier than the 90th day, and not later than the 120th day, before the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the preceding year&#146;s annual meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that no annual meeting was held in the previous year or New Surrozen holds its annual meeting of stockholders more than more than
30 days before or more than 60 days after the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of a preceding year&#146;s annual meeting, notice of a stockholder proposal must be not later than the 90th day prior to such annual meeting
or, if later, the 10th day following the day on which public disclosure of the date of such annual meeting was first made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accordingly,
for New Surrozen&#146;s &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; annual meeting, assuming the meeting is held on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , notice of a nomination or proposal must be
delivered to New Surrozen no later than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and no
earlier than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Nominations and proposals also must satisfy other requirements set forth in the bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> of the Exchange Act, a stockholder proposal to be included in the proxy statement and
proxy card for the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; annual general meeting pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8,</FONT> assuming the meeting is held on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , must be received at CHFW&#146;s principal office on or before
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and must comply with Rule <FONT
STYLE="white-space:nowrap">14a-8.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_241"></A>Stockholder Director Nominees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New Surrozen&#146;s Proposed Bylaws permit stockholders to nominate directors for election at an annual meeting or at a special meeting (but
only if the election of directors is a matter specified in the notice of meeting given by or at the direction of the person calling such special meeting) of stockholders, subject to the provisions of New Surrozen&#146;s Proposed Certificate of
Incorporation. To nominate a director, the stockholder must provide the information required by New Surrozen&#146;s Proposed Bylaws. In addition, the stockholder must give timely notice to New Surrozen&#146;s secretary in accordance with New
Surrozen&#146;s Proposed Bylaws, which, in general, require that the notice be received by New Surrozen&#146;s secretary within the time periods described above under &#147;&#151;Stockholder Proposals&#148; for stockholder proposals. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_242"></A>SHAREHOLDER COMMUNICATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shareholders and interested parties may communicate with the CHFW Board, any committee chairperson or the
<FONT STYLE="white-space:nowrap">non-management</FONT> directors as a group by writing to the board or committee chairperson in care of <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., 1 Palmer Square, Suite 350, Princeton,
NJ 08540. Following the Business Combination, such communications should be sent in care of Surrozen, Inc., 171 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080. Each communication will be forwarded, depending on the subject matter, to
the board of directors, the appropriate committee chairperson or all <FONT STYLE="white-space:nowrap">non-management</FONT> directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">356 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_243"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Goodwin Procter LLP, Boston, MA, has passed upon the validity of the securities of New Surrozen offered by this proxy statement/prospectus and
certain other legal matters related to this proxy statement/prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_244"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The financial statements of <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. for the period from inception through
December&nbsp;31, 2020 appearing in this proxy statement/prospectus have been audited by Marcum LLP, independent registered public accounting firm, as set forth in their report thereon, appearing elsewhere herein, and are included in reliance upon
such report given on the authority of such firm as experts in accounting and auditing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The financial statements of Surrozen, Inc. at
December&nbsp;31, 2020 and 2019 and for the years then ended, included in the Proxy Statement of <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., which is referred to and made a part of this Prospectus and Registration
Statement, have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as
experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_245"></A>DELIVERY OF DOCUMENTS TO SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the rules of the SEC, CHFW and services that it employs to deliver communications to its shareholders are permitted to deliver to
two or more shareholders sharing the same address a single copy of each of CHFW&#146;s annual report to shareholders and CHFW&#146;s proxy statement. Upon written or oral request, CHFW will deliver a separate copy of the annual report to
shareholders and/or proxy statement to any shareholder at a shared address to which a single copy of each document was delivered and who wishes to receive separate copies of such documents. Shareholders receiving multiple copies of such documents
may likewise request that CHFW delivers single copies of such documents in the future. Shareholders receiving multiple copies of such documents may request that CHFW delivers single copies of such documents in the future. Shareholders may notify
CHFW of their requests by calling or writing CHFW at its principal executive offices at 1 Palmer Square, Suite 350, Princeton, NJ 08540 or (609) <FONT STYLE="white-space:nowrap">921-2333.</FONT> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_246"></A>ENFORCEABILITY OF CIVIL LIABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW is a Cayman Islands exempted company. If CHFW does not change its jurisdiction of incorporation from the Cayman Islands to Delaware by
effecting the Domestication, you may have difficulty serving legal process within the United States upon CHFW. You may also have difficulty enforcing, both in and outside the United States, judgments you may obtain in U.S. courts against CHFW in any
action, including actions based upon the civil liability provisions of U.S. federal or state securities laws. Furthermore, there is doubt that the courts of the Cayman Islands would enter judgments in original actions brought in those courts
predicated on U.S. federal or state securities laws. However, CHFW may be served with process in the United States with respect to actions against CHFW arising out of or in connection with violation of U.S. federal securities laws relating to offers
and sales of CHFW&#146;s securities by serving CHFW&#146;s U.S. agent irrevocably appointed for that purpose. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_247"></A>TRANSFER AGENT AND REGISTRAR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The transfer agent for CHFW&#146;s securities is Continental Stock Transfer&nbsp;&amp; Trust Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">357 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom40894_248"></A>WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW has filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> to register the issuance of securities
described elsewhere in this proxy statement/prospectus. This proxy statement/prospectus is a part of that registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CHFW
files reports, proxy statements and other information with the SEC as required by the Exchange Act. You may access information on CHFW at the SEC website containing reports, proxy statements and other information at: http://www.sec.gov. Those
filings are also available free of charge to the public on, or accessible through, CHFW&#146;s corporate website at www.consonancehfw.com. CHFW&#146;s website and the information contained on, or that can be accessed through, the website is not
deemed to be incorporated by reference in, and is not considered part of, this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Information and statements
contained in this proxy statement/prospectus or any Annex to this proxy statement/prospectus are qualified in all respects by reference to the copy of the relevant contract or other annex filed as an exhibit to the registration statement of which
this proxy statement/prospectus forms a part, which includes exhibits incorporated by reference from other filings made with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All
information contained in this proxy statement/prospectus relating to CHFW has been supplied by CHFW, and all such information relating to Surrozen has been supplied by Surrozen. Information provided by one another does not constitute any
representation, estimate or projection of the other. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you would like additional copies of this proxy statement/prospectus or if you
have questions about the Business Combination, you should contact via phone or in writing: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Okapi Partners LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Banks and Brokers Call Collect: (212) <FONT STYLE="white-space:nowrap">297-0720</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">All Others Call Toll Free: (844) <FONT STYLE="white-space:nowrap">203-3605</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: <U>info@okapipartners.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To obtain timely delivery of the documents, you must request them no later than five business days before the date of the meeting, or no later
than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All information contained in
this document relating to CHFW has been supplied by CHFW and all such information relating to Surrozen has been supplied by Surrozen. Information provided by CHFW or Surrozen does not constitute any representation, estimate or projection of the
other. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">358 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A><A NAME="rom40894_249"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Financial Statements of Consonance-HFW Acquisition Corp.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Unaudited Condensed Financial Statements of Consonance-HFW Acquisition
Corp.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_13">Condensed Balance Sheet as of March 31, 2021 (unaudited) and
December 31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_14">Unaudited Condensed Statements of Operations for the three
 months ended March 31, 2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_15">Unaudited Condensed Statements of Changes in Stockholders&#146;
 Equity for the three months ended March&nbsp;31, 2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_16">Unaudited Condensed Statement of Cash Flows for three months
 ended March 31, 2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_17">Notes to Unaudited Condensed Financial
Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Audited Financial Statements of Consonance-HFW Acquisition Corp.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_1">Report of Independent Registered Public Accounting
Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-21</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_2">Balance Sheet as of December&nbsp;31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-22</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_3">Statement of Operations for the period from August&nbsp;
21, 2020 (inception) through December&nbsp;31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-23</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_4">Statement of Changes in Shareholders&#146; Equity for the period
from August&nbsp;21, 2020 (inception) through December&nbsp;31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-24</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_5">Statement of Cash Flows for the period from August&nbsp;
21, 2020 (inception) through December&nbsp;31, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-25</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-26</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Financial Statements of Surrozen, Inc. </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Unaudited Condensed Interim Financial Statements for the Three Months Ended
March 31, 2021 and 2020</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_18">Condensed Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_19">Condensed Statements of Operations and Comprehensive Loss
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_20">Condensed Statements of Redeemable Convertible Preferred Stock
and Stockholders&#146; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_21">Condensed Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_22">Notes to the Unaudited Condensed Interim Financial Statements
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Audited Financial Statements of Surrozen, Inc. for the Years Ended December 31,
2020 and 2019</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_7">Report of Independent Registered Public Accounting
Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-59</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_8">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-60</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_9">Statements of Operations and Comprehensive
Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-61</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_10">Statements of Redeemable Convertible Preferred Stock and Stockholders&#146;
Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-62</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_11">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-63</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#fin40894_12">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-64</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART I - FINANCIAL INFORMATION </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Item&nbsp;1.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Interim Financial Statements. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_13"></A><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED BALANCE SHEETS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(unaudited)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">774,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">987,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">633,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">790,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total Current Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,408,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,777,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash and marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,026,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,997,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>TOTAL ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>93,435,668</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>93,775,029</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">986,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">290,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total Current Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">986,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">290,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,601,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,404,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Deferred underwriting fee payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,220,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,220,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Total Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>6,807,765</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>6,914,162</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Commitments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Class&nbsp;A ordinary shares subject to possible redemption 8,162,790 and
8,186,086 shares at redemption value at March&nbsp;31, 2021 and December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,627,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,860,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Shareholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Class&nbsp;A ordinary shares, $0.0001 par value; 350,000,000 shares authorized;
1,471,210 and 1,447,914 shares issued and outstanding (excluding 8,162,790 and 8,186,086 shares subject to possible redemption) at March&nbsp;31, 2021 and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Class&nbsp;B ordinary shares, $0.0001 par value; 150,000,000 shares authorized;
2,300,000 shares issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,354,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,121,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,355,292</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,122,328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Total Shareholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,000,003</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,000,007</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>TOTAL LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>93,435,668</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>93,775,029</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of the unaudited condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_14"></A><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT>
ACQUISITION CORP. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED STATEMENT OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THREE MONTHS ENDED MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating and formation costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,065,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(<B></B>1,065,209</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interest earned on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Changes in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">802,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unrealized gain on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">832,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(232,964</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted weighted average shares outstanding, Class&nbsp;A ordinary
shares subject to redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,186,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Basic and diluted net income per share, Class&nbsp;A ordinary shares subject to
redemption</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted weighted average shares outstanding, <FONT
STYLE="white-space:nowrap">Non-redeemable</FONT> ordinary shares<SUP STYLE="font-size:85%; vertical-align:top"> </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,747,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Basic and diluted net loss per share,
<FONT STYLE="white-space:nowrap">Non-redeemable</FONT> ordinary shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.07</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of the unaudited condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_15"></A><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT>
ACQUISITION CORP. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED STATEMENT OF CHANGES IN SHAREHOLDERS&#146; EQUITY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THREE MONTHS ENDED MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B><br><B>Ordinary Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B><br><B>Ordinary Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Additional</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Accumulated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shareholders&#146;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Balance &#151; January&nbsp;1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,447,914</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>145</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,300,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>230</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>7,121,960</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,122,328</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,000,007</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Change in value of Class&nbsp;A ordinary shares subject to redemption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">232,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">232,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(232,964</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(232,964</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Balance &#150; March&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,471,210</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>147</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,300,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>230</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>7,354,918</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,355,292</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,000,003</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of the unaudited condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_16"></A><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT>
ACQUISITION CORP. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED STATEMENT OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THREE MONTHS ENDED MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Cash Flows from Operating Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(232,964</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Adjustments to reconcile net loss to net cash used in operating
activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interest earned on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,112</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Changes in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(802,834</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unrealized gain on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">696,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(212,256</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Net Change in Cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(212,256</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash &#150; Beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">987,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Cash &#150; End of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>774,931</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">Non-Cash</FONT> investing and financing
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Change in value of Class&nbsp;A ordinary shares subject to possible
redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(232,960</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of the unaudited condensed financial statements.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_17"></A><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT>
ACQUISITION CORP. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 1.
DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. (the
&#147;Company&#148;) is a blank check company incorporated as a Cayman Islands exempted company on August&nbsp;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more businesses (&#147;Business Combination&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is not limited to a
particular industry or geographic region for purposes of completing a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging
growth companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2021, the Company had not commenced any operations. All activity through March&nbsp;31, 2021
relates to the Company&#146;s formation, the initial public offering (&#147;Initial Public Offering&#148;), which is described below, and subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company
will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate <FONT STYLE="white-space:nowrap">non-operating</FONT> income in the form of interest income from the proceeds
derived from the Initial Public Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The registration statement for the Company&#146;s Initial Public Offering became effective on
November&nbsp;18, 2020. On November&nbsp;23, 2020, the Company consummated the Initial Public Offering of 8,000,000 units (the &#147;Units&#148; and, with respect to the Class&nbsp;A ordinary shares included in the Units sold, the &#147;Public
Shares&#148;), at $10.00 per Unit, generating gross proceeds of $80,000,000 which is described in Note 3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Simultaneously with the
consummation of the Initial Public Offering, the Company consummated the sale of 410,000 units (the &#147;Private Placement Units&#148;) at a price of $10.00 per Private Placement Unit in a private placement to Consonance Life Sciences (the
&#147;Sponsor&#148;), generating gross proceeds of $4,100,000, which is described in Note 4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the consummation of the Initial
Public Offering on November&nbsp;23, 2020, an amount of $80,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Units was placed in a trust account (the
&#147;Trust Account&#148;) and invested in U.S. government securities, within the meaning set forth in Section&nbsp;2(a)(16) of the Investment Company Act of 1940, as amended (the &#147;Investment Company Act&#148;), with a maturity of 185&nbsp;days
or less, or in any open-ended investment company that holds itself out as a money market fund meeting certain conditions of <FONT STYLE="white-space:nowrap">Rule&nbsp;2a-7</FONT> of the Investment Company Act, as determined by the Company, until the
earlier of: (i)&nbsp;the completion of a Business Combination and (ii)&nbsp;the distribution of the funds in the Trust Account to the Company&#146;s shareholders, as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On December&nbsp;1, 2020, the underwriters fully exercised their over-allotment option, resulting in an additional 1,200,000 Units issued for
an aggregate amount of $12,000,000. In connection with the underwriters&#146; full exercise of their over-allotment option, the Company also consummated the sale of an additional 24,000 Private Placement Units at $10.00 per Private Placement Unit,
generating total proceeds of $12,240,000. A total of $12,000,000 was deposited into the Trust Account, bringing the aggregate proceeds held in the Trust Account to $92,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Transaction costs amounted to $5,658,864, consisting of $1,840,000 of underwriting fees, $2,800,000 of deferred underwriting fees and $598,864
of other offering costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s management has broad discretion with respect to the specific application of the net proceeds
of the Initial Public Offering and the sale of the Private Placement Units, although substantially all of the net </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
proceeds are intended to be applied generally toward completing a Business Combination. The Company must complete its initial Business Combination with one or more target businesses that together
have a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding any deferred underwriting commissions held in the Trust Account and taxes payable on the interest earned on the Trust Account) at the time of the
agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise
acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act. On April&nbsp;15, 2021, the Company has entered into a Business Combination Agreement
with Surrozen, Inc., see Note 10. Subsequent Events &#151; Business Combination Agreement and PIPE Financing, however, There is no assurance that the Company will be able to successfully effect a Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company will provide its shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a
Business Combination either (i)&nbsp;in connection with a shareholder meeting called to approve the Business Combination or (ii)&nbsp;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business
Combination or conduct a tender offer will be made by the Company. The shareholders will be entitled to redeem their shares for a pro&nbsp;rata portion of the amount held in the Trust Account (initially $10.00 per share), calculated as of two
business days prior to the completion of a Business Combination, including any pro&nbsp;rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. There will be no redemption
rights upon the completion of a Business Combination with respect to the Company&#146;s warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Risks and Uncertainties
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Management continues to evaluate the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and has concluded
that while it is reasonably possible that the virus could have a negative effect on the Company&#146;s financial position and/or effecting our Business Combination, the specific impact is not readily determinable as of the date of the financial
statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#147;GAAP&#148;) for interim financial information and in accordance with the instructions to Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Article 8 of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> of the
SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting.
Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial
statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accompanying unaudited condensed financial statements should be read in conjunction with the Company&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K/A</FONT> for the year ended December&nbsp;31, 2020 as filed with the SEC on May&nbsp;14, 2021. The interim results for the three months ended March&nbsp;31, 2021 are not necessarily indicative of the results to be
expected for the year ending December&nbsp;31, 2021 or for any future periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Emerging Growth Company </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the Jumpstart Our
Business Startups Act of 2012 (the &#147;JOBS Act&#148;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not
limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and
exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial
accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or
revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies
but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#146;s financial statement with another public company which
is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preparation of the condensed financial statements in conformity with GAAP requires the Company&#146;s management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a
condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the
actual results could differ significantly from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The
Company did not have any cash equivalents as of March&nbsp;31, 2021 and December&nbsp;31, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Marketable Securities Held in Trust
Account </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At March&nbsp;31, 2021 and December&nbsp;31, 2020, substantially all of the assets held in the Trust Account were held in
U.S. Treasury Bills.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Warrant Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#146;s
specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) 480, Distinguishing Liabilities from Equity (&#147;ASC 480&#148;) and ASC 815,
Derivatives and Hedging (&#147;ASC 815&#148;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the
requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#146;s own ordinary shares, among other conditions for equity classification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent
quarterly period end date while the warrants are outstanding. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For issued or modified warrants that meet all of the criteria for
equity classification, the warrants are required to be recorded as a component of additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital at the time of issuance or modification. For issued or modified warrants that do not meet all the
criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a <FONT
STYLE="white-space:nowrap">non-cash</FONT> gain or loss on the statements of operations. The fair value of the warrants was determined by using the publicly traded price on March&nbsp;31, 2021 (see Note 9). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Class&nbsp;A Ordinary Shares Subject to Possible Redemption </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for its Class&nbsp;A ordinary shares subject to possible redemption in accordance with the guidance in Accounting
Standards Codification (&#147;ASC&#148;) Topic 480 &#147;Distinguishing Liabilities from Equity.&#148; Class&nbsp;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value.
Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#146;s
control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#146; equity. The Company&#146;s Class&nbsp;A ordinary shares feature certain redemption rights that are considered to be outside of the
Company&#146;s control and subject to occurrence of uncertain future events. Accordingly, Class&nbsp;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders&#146; equity
section of the Company&#146;s balance sheet. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for income taxes under ASC 740, &#147;Income Taxes&#148; (&#147;ASC 740&#148;). ASC 740 requires the recognition of
deferred tax assets and liabilities for both the expected impact of differences between the condensed financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit
carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#146;s condensed financial statements and
prescribes a recognition threshold and measurement process for condensed financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <FONT
STYLE="white-space:nowrap">more-likely-than-not</FONT> to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March&nbsp;31, 2021 and December&nbsp;31, 2020. The Company is currently not
aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is considered an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in
the Cayman Islands or the United&nbsp;States. As such, the Company&#146;s tax provision was zero for the period presented. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Net
Loss Per Ordinary Share </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net loss per share is computed by dividing net loss by the weighted-average number of ordinary shares
outstanding during the period, excluding ordinary shares subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 3,211,334 shares in the
calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s statement of operations includes a presentation of loss per share for ordinary shares subject to possible redemption in a
manner similar to the <FONT STYLE="white-space:nowrap">two-class</FONT> method of loss per share. Net loss per ordinary share, basic and diluted, for Class&nbsp;A ordinary shares subject to possible redemption is calculated by dividing the
proportionate share of income or loss on marketable securities held by the Trust Account by the weighted average number of Class&nbsp;A ordinary shares subject to possible redemption outstanding since original issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net loss per share, basic and diluted, for <FONT STYLE="white-space:nowrap">non-redeemable</FONT> ordinary shares is calculated by dividing
the net income (loss), adjusted for income or loss on marketable securities attributable to Class&nbsp;A ordinary shares subject to possible redemption, by the weighted average number of <FONT STYLE="white-space:nowrap">non-redeemable</FONT>
ordinary shares outstanding for the period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-redeemable</FONT> common stock includes Founder Shares
and <FONT STYLE="white-space:nowrap">non-redeemable</FONT> ordinary shares as these shares do not have any redemption features. <FONT STYLE="white-space:nowrap">Non-redeemable</FONT> ordinary shares participate in the income or loss on marketable
securities based on <FONT STYLE="white-space:nowrap">non-redeemable</FONT> shares&#146; proportionate interest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table reflects the calculation of basic and diluted net loss per ordinary share
(in dollars, except per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months</B><br><B>Ended</B><br><B>March&nbsp;31,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Class&nbsp;A ordinary Shares subject to possible redemption</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Numerator: Earnings allocable to Class&nbsp;A ordinary shares subject to possible
redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interest earned on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>20,507</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unrealized gain on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,589</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net income attributable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>26,096</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Denominator: Weighted Average Class&nbsp;A ordinary shares subject to possible
redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted weighted average shares outstanding, Class&nbsp;A ordinary
shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,186,086</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted net income per share, Class&nbsp;A ordinary shares subject to
possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I><FONT STYLE="white-space:nowrap">Non-Redeemable</FONT> Ordinary
Shares</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Numerator: Net Loss minus Net Earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(232,964</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Less: Net income allocable to Class&nbsp;A ordinary shares subject to possible
redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(26,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-Redeemable</FONT> Net Loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(259,060</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Denominator: Weighted Average
<FONT STYLE="white-space:nowrap">Non-redeemable</FONT> ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted weighted average shares outstanding, <FONT
STYLE="white-space:nowrap">Non-redeemable</FONT> ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,747,914</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted net loss per share,
<FONT STYLE="white-space:nowrap">Non-redeemable</FONT> ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.07</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial
institution, which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of the Company&#146;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#147;Fair Value
Measurement,&#148; approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Fair Value Measurements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction
between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active
markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in
active markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2, defined as inputs other than quoted prices in active markets that are either directly or
indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an
entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value
hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Derivative Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, &#147;Derivatives and Hedging&#148;. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is
then <FONT STYLE="white-space:nowrap">re-valued</FONT> at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be
recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or <FONT STYLE="white-space:nowrap">non-current</FONT> based on whether or not <FONT
STYLE="white-space:nowrap">net-cash</FONT> settlement or conversion of the instrument could be required within 12 months of the balance sheet date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Recent Accounting Standards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material
effect on the Company&#146;s condensed financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2020, the Financial Accounting Standards Board (&#147;FASB&#148;)
issued Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2020-06,</FONT> Debt &#151; Debt with Conversion and Other Options (Subtopic <FONT STYLE="white-space:nowrap">470-20)</FONT> and Derivatives and Hedging &#151;
Contracts in Entity&#146;s Own Equity (Subtopic <FONT STYLE="white-space:nowrap">815-40)</FONT> (&#147;ASU <FONT STYLE="white-space:nowrap">2020-06&#148;)</FONT> to simplify accounting for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
certain financial instruments. ASU <FONT STYLE="white-space:nowrap">2020-06</FONT> eliminates the current models that require separation of beneficial conversion and cash conversion features from
convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#146;s own equity. The new standard also introduces additional disclosures for convertible debt and
freestanding instruments that are indexed to and settled in an entity&#146;s own equity. ASU <FONT STYLE="white-space:nowrap">2020-06</FONT> amends the diluted earnings per share guidance, including the requirement to use the <FONT
STYLE="white-space:nowrap">if-converted</FONT> method for all instruments. ASU <FONT STYLE="white-space:nowrap">2020-06</FONT> is effective January&nbsp;1, 2022 and should be applied on a full or modified retrospective basis, with early adoption
permitted beginning on January&nbsp;1, 2021. The Company is currently assessing the impact, if any, that ASU <FONT STYLE="white-space:nowrap">2020-06</FONT> would have on its financial position, results of operations or cash flows. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 3. INITIAL PUBLIC OFFERING </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the Initial Public Offering, the Company sold 9,200,000&nbsp;Units, inclusive of 1,200,000 Units sold to the underwriters on
December&nbsp;1, 2020 upon the underwriters&#146; election to fully exercise their over-allotment option, at a purchase price of $10.00 per Unit. Each Unit consists of one Class&nbsp;A ordinary share and
<FONT STYLE="white-space:nowrap">one-third</FONT> of one redeemable warrant (&#147;Public Warrant&#148;). Each whole Public Warrant entitles the holder to purchase one Class&nbsp;A ordinary share at an exercise price of $11.50 per share, subject to
adjustment (see Note 8). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On December&nbsp;1, 2020, the underwriters fully exercised their over-allotment option, resulting in an
additional 1,200,000 Units issued for an aggregate amount of $12,000,000. In connection with the underwriters&#146; full exercise of their over-allotment option, the Company also consummated the sale of an additional 24,000 Private Placement Units
at $10.00 per Private Placement Unit, generating total proceeds of $12,240,000. A total of $12,000,000 was deposited into the Trust Account, bringing the aggregate proceeds held in the Trust Account to $92,000,000. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 4. PRIVATE PLACEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Simultaneously with the consummation of the Initial Public Offering, the Sponsor purchased an aggregate of 410,000 Private Placement Units at a
price of $10.00 per Private Placement Unit, for an aggregate purchase price of $4,100,000. On December&nbsp;1, 2020, as a result of the underwriters&#146; election to fully exercise their over-allotment option, the Sponsor purchased an additional
24,000 Private Placement Units, at a price of $10.00 per Private Placement Unit, or $240,000 in the aggregate (see Note 8). Each Private Placement Unit consists of one Class&nbsp;A ordinary share (&#147;Private Placement Share&#148; or,
collectively, &#147;Private Placement Shares&#148;) and <FONT STYLE="white-space:nowrap">one-third</FONT> of one redeemable warrant (each, a &#147;Private Placement Warrant&#148;). Each whole Private Placement Warrant is exercisable for one
Class&nbsp;A ordinary share at a price of $11.50 per share, subject to adjustment (see Note 8). The proceeds from the sale of the Private Placement Units were added to the net proceeds from the Initial Public Offering held in the Trust Account. If
the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the
requirements of applicable law) and the Private Placement Units and all underlying securities will expire worthless. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 5. RELATED
PARTY TRANSACTIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Founder Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On September&nbsp;4, 2020, the Sponsor paid $25,000 to cover certain offering and formation costs of the Company in consideration for 3,593,750
Class&nbsp;B ordinary shares. On October&nbsp;8, 2020 and November&nbsp;10, 2020, 718,750 and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
575,000 Class&nbsp;B ordinary shares were contributed back to the Company for no consideration, respectively, resulting in there being 2,300,000 Class&nbsp;B ordinary shares (the &#147;Founder
Shares&#148;) being issued and outstanding. The Founder Shares include an aggregate of up to 300,000 shares subject to forfeiture by the Sponsor to the extent that the underwriters&#146; over-allotment is not exercised in full or in part, so that
the number of Founder Shares will collectively represent 20% of the Company&#146;s issued and outstanding shares upon the completion of the Initial Public Offering (not including the Private Placement Shares).&nbsp;On December&nbsp;1, 2020, the
underwriters fully exercised their over-allotment option, therefore there are no Founder Shares subject to forfeiture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Sponsor has
agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of: (A)&nbsp;one year after the completion of a Business Combination; and (B)&nbsp;subsequent to a Business Combination,
(x)&nbsp;if the closing price of the Class&nbsp;A ordinary shares equals or exceeds $12.00 per share (as adjusted for <FONT STYLE="white-space:nowrap">share&nbsp;sub-divisions,&nbsp;share</FONT> capitalizations, reorganizations, recapitalizations
and the like) for any 20 trading days within <FONT STYLE="white-space:nowrap">any&nbsp;30-trading&nbsp;day</FONT> period commencing at least 150&nbsp;days after a Business Combination, or (y)&nbsp;the date on which the Company completes a
liquidation, merger, amalgamation, share exchange, reorganization or other similar transaction that results in all of the Company&#146;s shareholders having the right to exchange their Class&nbsp;A ordinary shares for cash, securities or other
property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Administrative Services Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company entered into an agreement, commencing on November&nbsp;18, 2020 through the earlier of the Company&#146;s consummation of a
Business Combination and its liquidation, to pay the Sponsor a total of up to $55,000 per month for office space and administrative support services. For the period three months ended March&nbsp;31, 2021, the Company incurred and paid $165,000 of
such fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Related Party Loans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the
Company&#146;s directors and officers may, but are not obligated to, loan the Company funds as may be required (&#147;Working Capital Loans&#148;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans
out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a
portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if
any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender&#146;s discretion, up to
$1,500,000 of such Working Capital Loans may be convertible into Private Placement Units of the post-Business Combination entity at a price of $10.00 per Private Placement Unit. The Private Placement Units would be identical to the Units. As of
March&nbsp;31, 2021 and December&nbsp;31, 2020, the Company had no outstanding borrowings under the Working Capital Loans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 6.
COMMITMENTS</B><B><I>&nbsp;</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Registration and Shareholder Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to a registration rights agreement entered into on November&nbsp;18, 2020, the holders of the Founder Shares, Private Placement Units
(including securities contained therein) and warrants that may be issued upon </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
conversion of the Working Capital Loans (and any Class&nbsp;A ordinary shares issuable upon the exercise of the Private Placement Units and warrants that may be issued upon conversion of Working
Capital Loans and upon conversion of the Founder Shares) will be entitled to registration rights. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In
addition, the holders have certain &#147;piggy-back&#148; registration rights with respect to registration statements filed subsequent to the completion of a Business Combination. However, the registration and shareholder rights agreement provides
that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> period. The registration rights agreement does not
contain liquidating damages or other cash settlement provisions resulting from delays in registering the Company&#146;s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.&nbsp;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Underwriting Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters are entitled to a deferred fee of $0.35 per Unit, or $3,220,000 in the aggregate (see Note 8). The deferred fee will become
payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 7. STOCKHOLDERS&#146; EQUITY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Preference Shares</I></B> <B>&#151;</B> The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per
share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#146;s board of directors. At March&nbsp;31, 2021 and December&nbsp;31, 2020, there were no preference shares issued or
outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Class</I></B><B><I></I></B><B><I>&nbsp;A ordinary shares</I></B><I>&#151;</I>The Company is authorized to issue
350,000,000 Class&nbsp;A ordinary shares, with a par value of $0.0001 per share. Holders of Class&nbsp;A ordinary shares are entitled to one vote for each share. At March&nbsp;31, 2021 and December&nbsp;31, 2020, there were 1,471,210 and 1,447,914
(excluding 8,162,790 and 8,186,086 shares subject to possible redemption) Class&nbsp;A ordinary shares issued and outstanding, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Class</I></B><B><I></I></B><B><I>&nbsp;B ordinary shares</I></B><I>&#151;</I> The Company is authorized to issue 150,000,000
Class&nbsp;B ordinary shares, with a par value of $0.0001 per share. Holders of the Class&nbsp;B ordinary shares are entitled to one vote for each share. At March&nbsp;31, 2021 and December&nbsp;31, 2020, there were 2,300,000 Class&nbsp;B ordinary
shares issued and outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Only holders of the Class&nbsp;B ordinary shares will have the right to vote on the election of directors
prior to the Business Combination. Holders of Class&nbsp;A ordinary shares and holders of Class&nbsp;B ordinary shares will vote together as a single class on all other matters submitted to a vote of the Company&#146;s shareholders except as
otherwise required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Class&nbsp;B ordinary shares will automatically convert into Class&nbsp;A ordinary shares on the first
business day following the consummation of a Business Combination at a ratio such that the number of Class&nbsp;A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> basis, 20% of the sum of (i)&nbsp;the total number of ordinary shares issued and outstanding (excluding the Private Placement Shares underlying the Private Placement Units) upon completion of the
Initial Public Offering, plus (ii)&nbsp;the sum of the total number of Class&nbsp;A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in
connection with or in relation to the consummation of a Business Combination, excluding any Class&nbsp;A ordinary shares or equity-linked </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
securities exercisable for or convertible into Class&nbsp;A ordinary shares issued, deemed issued, or to be issued, to any seller in a Business Combination and any Private Placement Warrants
issued to the Sponsor, members of the Company&#146;s founding team or any of their affiliates upon conversion of Working Capital Loans. In no event will the Class&nbsp;B ordinary shares convert into Class&nbsp;A ordinary shares at a rate of less
than one to one. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 8. WARRANT LIABILITY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants.
The Public Warrants will become exercisable on the later of (a)&nbsp;30&nbsp;days after the completion of a Business Combination and (b)&nbsp;one year from the closing of the Initial Public Offering. The Public Warrants will expire five&nbsp;years
from the completion of a Business Combination or earlier upon redemption or liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company will not be obligated to deliver any
Class&nbsp;A ordinary shares pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the issuance of the Class&nbsp;A ordinary
shares issuable upon exercise of the warrants is then effective and a current prospectus relating thereto is available, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is
available. No warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or
qualified under the securities laws of the state of the exercising holder, or an exemption is available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has agreed that as
soon as practicable, but in no event later than 20 business days, after the closing of a Business Combination, it will use its commercially reasonable efforts to file with the SEC a registration statement covering the Class&nbsp;A ordinary shares
issuable upon exercise of the warrants, and the Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of a Business Combination, and to maintain the effectiveness of such
registration statement and a current prospectus relating to those Class&nbsp;A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; if the Class&nbsp;A ordinary shares are, at the time of any exercise of
a warrant, not listed on a national securities exchange such that they satisfy the definition of a &#147;covered security&#148; under Section&nbsp;18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who
exercise their warrants to do so on a &#147;cashless basis&#148; in accordance with Section&nbsp;3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration
statement. If a registration statement covering the Class&nbsp;A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of a Business Combination, warrant holders may, until such time as there is an
effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &#147;cashless basis&#148; in accordance with Section&nbsp;3(a)(9) of the Securities Act
or another exemption, but will use its best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Redemption of warrants when the price per Class</I><I></I><I>&nbsp;A ordinary share equals or exceeds $18.00</I>&#151;Once the warrants
become exercisable, the Company may redeem the outstanding Public Warrants (except with respect to the Private Placement Warrants): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a price of $0.01 per Public Warrant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon not less than 30&nbsp;days&#146; prior written notice of redemption to each warrant holder; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the closing price of the Class&nbsp;A ordinary shares equals or exceeds $18.00 per share (as
adjusted for share <FONT STYLE="white-space:nowrap">sub-divisions,</FONT> share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a <FONT STYLE="white-space:nowrap">30-trading</FONT> day period ending
on the third trading day prior to the date on which notice of the redemption is given to the warrant holders (the &#147;Reference Value&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if the Company is unable to
register or qualify the underlying securities for sale under all applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Redemption of Warrants When the
Price per Class</I><I></I><I>&nbsp;A Ordinary Share Equals or Exceeds $10.00</I>&#151;Once the warrants become exercisable, the Company may redeem the outstanding warrants:&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at $0.10 per warrant upon a minimum of 30&nbsp;days&#146; prior written notice of redemption; provided that
during such 30 day period holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares, based on the redemption date and the fair market value of the Class&nbsp;A ordinary shares, that if
the warrants are not exercised on a cashless basis or otherwise during such 30&nbsp;day period, the Company shall redeem such warrants for $0.10 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted for share subdivisions,
share dividends, reorganizations, recapitalizations and the like) on the trading day before the Company sends the notice of redemption to the warrant holders; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the Reference Value is less than $18.00 per share (as adjusted for share splits, share dividends,
reorganizations, recapitalizations and the like), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The exercise price and number of ordinary shares issuable upon exercise of the Public Warrants may be adjusted in certain circumstances
including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of ordinary shares at a price
below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds
held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company&#146;s assets held outside of the Trust Account with respect to
such Public Warrants. Accordingly, the Public Warrants may expire worthless. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, if (x)&nbsp;the Company issues additional
Class&nbsp;A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per Class&nbsp;A ordinary share (with such
issue price or effective issue price to be determined in good faith by the Company&#146;s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor
or such affiliates, as applicable, prior to such issuance) (the &#147;Newly Issued Price&#148;), (y)&nbsp;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the
funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&nbsp;the volume weighted average trading price of its Class&nbsp;A ordinary shares during the 20 trading day period starting on
the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#147;Market Value&#148;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to
115% of the higher of the Market Value and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Newly Issued Price, and the $10.00 and $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 100% and 180% of the higher of the Market Value and the
Newly Issued Price, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the
Initial Public Offering, except that the Private Placement Warrants and the Class&nbsp;A ordinary shares issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30&nbsp;days after the
completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and be <FONT STYLE="white-space:nowrap">non-redeemable,</FONT> except as described
above, so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be
redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 9. FAIR VALUE
MEASUREMENTS</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company follows the guidance in ASC 820 for its financial assets and liabilities that are <FONT
STYLE="white-space:nowrap">re-measured</FONT> and reported at fair value at each reporting period, and <FONT STYLE="white-space:nowrap">non-financial</FONT> assets and liabilities that are <FONT STYLE="white-space:nowrap">re-measured</FONT> and
reported at fair value at least annually.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of the Company&#146;s financial assets and liabilities reflects management&#146;s
estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In
connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions
about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and
liabilities: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market
in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Observable inputs other than Level&nbsp;1 inputs. Examples of Level&nbsp;2 inputs include quoted prices in active markets
for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or
liability.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table presents information about the Company&#146;s assets and liabilities that are measured at
fair value on a recurring basis at March&nbsp;31, 2021 and December&nbsp;31, 2020, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="justify"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,026,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,997,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Warrant liability &#150; Public Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,484,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,250,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Warrant liability &#150; Private Placement Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Warrants were accounted for as liabilities in accordance with ASC <FONT
STYLE="white-space:nowrap">815-40</FONT> and are presented within warrant liabilities on our balance sheet. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change
in fair value of warrant liabilities in the consolidated statement of operations. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Both the Private Placement Warrants and the Public
Warrants were initially valued using a binomial lattice model, which is considered to be a Level&nbsp;3 fair value measurement. As of March&nbsp;31, 2021, the Public Warrants were valued using the instrument&#146;s publicly listed trading notice as
of the balance sheet date, which is considered to be a Level&nbsp;1 measurement due to the use of an observable market quote in an active market. The Private Warrants were valued using a binomial lattice model, which is considered to be a
Level&nbsp;3 fair value measurement. The binomial lattice model&#146;s primary unobservable input utilized in determining the fair value of the Private Placement Warrants is the expected volatility of the common stock. The expected volatility as of
the IPO date was derived from observable public warrant pricing on comparable &#145;blank-check&#146; companies without an identified target. The expected volatility as of subsequent valuation dates will be implied from the Company&#146;s own public
warrant pricing. A binomial lattice model methodology was also used in estimating the fair value of the Public Warrants for periods where no observable traded price was available, using the same expected volatility as was used in measuring the fair
value of the Private Placement Warrants. For periods subsequent to the detachment of the Warrants from the Units, the close price of the Public Warrant price will be used as the fair value as of each relevant date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table presents the changes in the fair value of warrant liabilities: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Private&nbsp;Placement</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Public</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrant&nbsp;Liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Fair value as of January&nbsp;1, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153,347</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,250,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,404,014</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Change in valuation inputs or other assumptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(766,667</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(802,834</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Fair value as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,180</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,484,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,601,180</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There were no transfers in or out of Level&nbsp;3 from other levels in the fair value hierarchy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 10. SUBSEQUENT EVENTS</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed financial
statements were issued. Based upon this review, except as set forth below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Business Combination Agreement and PIPE Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April&nbsp;15, 2021, the Company entered into a business combination agreement with Surrozen, Inc. (&#147;Surrozen&#148;), pursuant to which
a wholly-owned subsidiary of the Company will merge with and into Surrozen, with Surrozen surviving as a wholly-owned subsidiary of the Company and the Company will redomicile as a Delaware corporation. In accordance with the terms and subject to
the conditions of the Business Combination Agreement, each share and equity award (whether vested or unvested) of Surrozen outstanding as of closing will be exchanged for shares of the Company&#146;s common stock or comparable equity awards that are
settled or are exercisable for shares of the Company&#146;s common stock, as applicable, based on an implied Surrozen equity value </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARCH&nbsp;31, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of $200,000,000 and a $10.00 per share value of the Company&#146;s Common Stock. In connection with the foregoing and concurrently with the execution of the Business Combination Agreement, the
Company entered into Subscription Agreements with certain investors (the &#147;Subscription Agreements&#148; and such investors, the &#147;PIPE Investors&#148;), pursuant to which the PIPE Investors have agreed to subscribe for and purchase, and the
Company has agreed to issue and sell to the PIPE Investors, an aggregate of 12,020,000 units, each consisting of one share of the Company&#146;s common stock and <FONT STYLE="white-space:nowrap">one-third</FONT> of one redeemable warrant for one
share of the Company&#146;s common stock (the &#147;PIPE Warrants&#148;), for a purchase price of $10.00 per unit (the &#147;PIPE Units&#148;), for aggregate gross proceeds of $120,200,000 (the &#147;PIPE Financing&#148;). Each whole PIPE Warrant
entitles the holder thereof to purchase one share of the Company&#146;s common stock at a price of $11.50 per share, subject to adjustment as described in the form of warrant agreement attached to the form of Subscription Agreement, and only whole
PIPE Warrants will be exercisable. The PIPE Warrants have substantially the same provisions as the public warrants issued in connection with the Company&#146;s initial public offering. The securities to be issued pursuant to the Subscription
Agreements have not been registered under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) in reliance upon the exemption provided in Section&nbsp;4(a)(2) of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the Shareholders and Board of Directors of </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Opinion on the Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have audited the accompanying balance sheet of <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. (the
&#147;Company&#148;) as of December&nbsp;31, 2020, the related statements of operations, changes in shareholders&#146; equity and cash flows for the period from August&nbsp;21, 2020 (inception) through December&nbsp;31, 2020, and the related notes
(collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2020, and the results of its
operations and its cash flows for the period from August&nbsp;21, 2020 (inception) through December&nbsp;31, 2020, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Restatement of 2020 Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As discussed in Note&nbsp;2 to the financial statements, the accompanying financial statements as of December&nbsp;31, 2020 and for the period
from August&nbsp;21, 2020 (inception) through December&nbsp;31, 2020 have been restated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the
Company&#146;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (the &#147;PCAOB&#148;) and are required to be independent with respect to the
Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial
reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our audit included performing procedures to assess the risks of material misstatement
of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our
audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our
opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/S/ Marcum LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Marcum LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have served as
the Company&#146;s auditor since 2020<B>.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Los Angeles, CA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">March&nbsp;31, 2021, except for the restatement discussed in Notes&nbsp;2, 3, 9 and Note&nbsp;10, as to which date is May&nbsp;14, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_2"></A>BALANCE SHEET </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2020 (As Restated) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Current Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">987,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">790,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total Current Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,777,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash and marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,997,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Total Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>93,775,029</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Current liabilities&nbsp;&#150;&nbsp;accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">290,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Warrant Liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,404,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Deferred underwriting fee payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,220,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Total Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>6,914,162</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Commitments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Class&nbsp;A ordinary shares subject to possible redemption, 8,186,086 shares at
redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,860,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Shareholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Class&nbsp;A ordinary shares, $0.0001 par value; 350,000,000 shares authorized;
1,447,914 shares issued and outstanding (excluding 8,186,086 shares subject to possible redemption)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Class&nbsp;B ordinary shares, $0.0001 par value; 150,000,000 shares authorized;
2,300,000 shares issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,121,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,122,328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Total Shareholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,000,007</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Total Liabilities and Shareholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>93,775,029</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:260pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_3"></A>STATEMENT OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE PERIOD FROM AUGUST&nbsp;21, 2020 (INCEPTION) THROUGH </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2020 (As Restated) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Formation and operational costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">438,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(438,756</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Other income:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interest earned on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Transaction costs associated with initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(107,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,573,554</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unrealized loss on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other loss, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,683,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,122,328</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted weighted average shares outstanding, Class&nbsp;A ordinary
shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,181,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Basic and diluted net loss per share, Class&nbsp;A ordinary shares subject to
possible redemption</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted weighted average shares outstanding, <FONT
STYLE="white-space:nowrap">Non-redeemable</FONT> ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,461,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Basic and diluted net loss per share,
<FONT STYLE="white-space:nowrap">Non-redeemable</FONT> ordinary shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.86</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:360pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_4"></A>STATEMENT OF CHANGES IN SHAREHOLDERS&#146; EQUITY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE PERIOD FROM AUGUST&nbsp;21, 2020 (INCEPTION) THROUGH </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2020 (As Restated) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Class&nbsp;A<BR>Ordinary Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Class&nbsp;B<BR>Ordinary Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"><B>Total<BR>Shareholders&#146;<BR>Equity</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Balance&nbsp;&#150;&nbsp;August&nbsp;21, 2020 (inception)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Issuance of Class&nbsp;B ordinary shares to Sponsor<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sale of 9,200,000&nbsp;Units, net of underwriting discounts, offering costs and
warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,112,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,113,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sale of 434,000 Private Placement Units, net of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">434,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,844,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,844,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Class&nbsp;A ordinary shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,186,086</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(818</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(81,860,042</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(81,860,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,122,328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,122,328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Balance&nbsp;&#150;&nbsp;December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,447,914</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>145</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,300,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>230</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>7,121,960</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,122,328</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,000,007</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:300pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_5"></A>STATEMENT OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE PERIOD FROM AUGUST&nbsp;21, 2020 (INCEPTION) THROUGH </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2020 (As Restated) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Cash Flows from Operating Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,122,328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Adjustments to reconcile net loss to net cash used in operating
activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Payment of formation costs through issuance of Class&nbsp;B ordinary
shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interest earned on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,892</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,573,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Transaction costs in connection with the initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unrealized loss on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(790,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">290,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(933,988</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Cash Flows from Investing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Investment of cash in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(92,000,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(92,000,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Cash Flows from Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Proceeds from sale of Units, net of underwriting discounts paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,160,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Proceeds from sale of Private Placement Units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,340,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Proceeds from promissory note&nbsp;&#150;&nbsp;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Repayment of promissory note&nbsp;&#150;&nbsp;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(147,753</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Payment of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(578,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>93,921,175</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Net Change in Cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>987,187</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash&nbsp;&#150;&nbsp;Beginning</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Cash&nbsp;&#150;&nbsp;Ending</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>987,187</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">Non-Cash</FONT> Investing and Financing
Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Initial classification of Class&nbsp;A ordinary shares subject to possible
redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,522,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Change in value of Class&nbsp;A ordinary shares subject to possible
redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,429,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Initial classification of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,830,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Offering costs paid directly by Sponsor from proceeds from issuance of
Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Deferred underwriting fee payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,220,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:150pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_6"></A>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE&nbsp;1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. (the &#147;Company&#148;) is a blank check company incorporated as a
Cayman Islands exempted company on August&nbsp;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses
(&#147;Business Combination&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is not limited to a particular industry or geographic region for purposes of completing a
Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2020, the Company had not commenced any operations. All activity for the period from August&nbsp;21, 2020 (inception)
through December&nbsp;31, 2020 relates to the Company&#146;s formation and the initial public offering (&#147;Initial Public Offering&#148;), which is described below. The Company will not generate any operating revenues until after the completion
of a Business Combination, at the earliest. The Company will generate <FONT STYLE="white-space:nowrap">non-operating</FONT> income in the form of interest income from the proceeds derived from the Initial Public Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The registration statement for the Company&#146;s Initial Public Offering became effective on November&nbsp;18, 2020. On November&nbsp;23,
2020, the Company consummated the Initial Public Offering of 8,000,000&nbsp;units (the &#147;Units&#148; and, with respect to the Class&nbsp;A ordinary shares included in the Units sold, the &#147;Public Shares&#148;), at $10.00 per Unit, generating
gross proceeds of $80,000,000 which is described in Note&nbsp;4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Simultaneously with the consummation of the Initial Public Offering, the
Company consummated the sale of 410,000&nbsp;units (the &#147;Private Placement Units&#148;) at a price of $10.00 per Private Placement Unit in a private placement to Consonance Life Sciences (the &#147;Sponsor&#148;), generating gross proceeds of
$4,100,000, which is described in Note&nbsp;5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the consummation of the Initial Public Offering on November&nbsp;23, 2020, an
amount of $80,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Units was placed in a trust account (the &#147;Trust Account&#148;) and invested in U.S.
government securities, within the meaning set forth in Section&nbsp;2(a)(16) of the Investment Company Act of 1940, as amended (the &#147;Investment Company Act&#148;), with a maturity of 185&nbsp;days or less, or in any open-ended investment
company that holds itself out as a money market fund meeting certain conditions of <FONT STYLE="white-space:nowrap">Rule&nbsp;2a-7</FONT> of the Investment Company Act, as determined by the Company, until the earlier of: (i)&nbsp;the completion of a
Business Combination and (ii)&nbsp;the distribution of the funds in the Trust Account to the Company&#146;s shareholders, as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On December&nbsp;1, 2020, the underwriters fully exercised their over-allotment option, resulting in an additional 1,200,000&nbsp;Units issued
for an aggregate amount of $12,000,000. In connection with the underwriters&#146; full exercise of their over-allotment option, the Company also consummated the sale of an additional 24,000 Private Placement Units at $10.00 per Private Placement
Unit, generating total proceeds of $12,240,000. A total of $12,000,000 was deposited into the Trust Account, bringing the aggregate proceeds held in the Trust Account to $92,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Transaction costs amounted to $5,658,864, consisting of $1,840,000 of underwriting fees, $3,220,000 of deferred underwriting fees and $598,864
of other offering costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s management has broad discretion with respect to the specific application
of the net proceeds of the Initial Public Offering and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward completing a Business Combination. The Company must complete
its initial Business Combination with one or more target businesses that together have a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding any deferred underwriting commissions held in the Trust Account
and taxes payable on the interest earned on the Trust Account) at the time of the agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or
more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act. There
is no assurance that the Company will be able to successfully effect a Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company will provide its shareholders
with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&nbsp;in connection with a shareholder meeting called to approve the Business Combination or (ii)&nbsp;by means of a
tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The shareholders will be entitled to redeem their shares for a pro&nbsp;rata portion
of the amount held in the Trust Account (initially $10.00 per share), calculated as of two business days prior to the completion of a Business Combination, including any pro&nbsp;rata interest earned on the funds held in the Trust Account and not
previously released to the Company to pay its tax obligations. There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#146;s warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Risks and Uncertainties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Management continues to evaluate the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and has concluded that while it is
reasonably possible that the virus could have a negative effect on the Company&#146;s financial position and/or search for a target company, the specific impact is not readily determinable as of the date of the financial statements. The financial
statements do not include any adjustments that might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 2&nbsp;&#151;&nbsp;RESTATEMENT
OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company previously accounted for its outstanding Public Warrants (as defined in Note 4)
and Private Placement Warrants issued in connection with its Initial Public Offering as components of equity instead of as derivative liabilities.&nbsp;The warrant agreement governing the warrants includes a provision that provides for potential
changes to the settlement amounts dependent upon the characteristics of the holder of the warrant. In addition, the warrant agreement includes a provision that in the event of a tender or exchange offer made to and accepted by holders of more than
50% of the outstanding shares of a single class of ordinary shares, all holders of the warrants would be entitled to receive cash for their warrants (the &#147;tender offer provision&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with the audit of the Company&#146;s financial statements for the period ended December&nbsp;31, 2020, the Company&#146;s
management further evaluated the warrants under Accounting Standards Codification (&#147;ASC&#148;) Subtopic <FONT STYLE="white-space:nowrap">815-40,</FONT> Contracts in Entity&#146;s Own Equity. ASC <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Section&nbsp;815-40-15</FONT></FONT> addresses equity versus liability treatment and classification of equity-linked financial instruments, including warrants, and states that a warrant may be classified as a component of
equity only if, among other things, the warrant is indexed to the issuer&#146;s common stock. Under ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Section&nbsp;815-40-15,</FONT></FONT> a warrant is not indexed to the
issuer&#146;s common stock if the terms of the warrant require an adjustment to the exercise price upon a specified event and that event is not an input to the fair value of the warrant. Based on management&#146;s evaluation, the Company&#146;s
audit committee, in consultation with management and after discussion with the Company&#146;s independent registered public accounting firm, concluded that the Company&#146;s Private Placement Warrants are not indexed to the Company&#146;s ordinary
shares in the manner contemplated by ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Section&nbsp;815-40-15</FONT></FONT> because the holder of the instrument is not an input into the pricing of a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fixed-for-fixed</FONT></FONT> option on equity shares. In addition, based on management&#146;s evaluation, the Company&#146;s audit committee, in consultation with management and
after discussion with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Company&#146;s independent registered public accounting firm, concluded the tender offer provision included in the warrant agreement fails the &#147;classified in shareholders&#146; equity&#148;
criteria as contemplated by ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Section&nbsp;815-40-25.</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result of the above, the Company should have classified the warrants as derivative liabilities in its previously issued financial
statements. Under this accounting treatment, the Company is required to measure the fair value of the warrants at the end of each reporting period and recognize changes in the fair value from the prior period in the Company&#146;s operating results
for the current period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s accounting for the warrants as components of equity instead of as derivative liabilities did
not have any effect on the Company&#146;s previously reported operating expenses, cash or investments held in the trust account. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As<BR>Previously<BR>Reported</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Balance sheet as of November 23, 2020 (audited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Warrant Liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,598,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,598,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,167,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,598,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,765,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ordinary Shares Subject to Possible Redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,121,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,598,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,522,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Class&nbsp;A Ordinary Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additional <FONT STYLE="white-space:nowrap">Paid-in</FONT> Capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,004,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,112,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accumulated Deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(107,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(112,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Balance sheet as of December&nbsp;31, 2020 (audited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Warrant Liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,404,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,404,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,510,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,404,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,914,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ordinary Shares Subject to Possible Redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,264,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,404,020</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,860,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Class&nbsp;A Ordinary Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additional <FONT STYLE="white-space:nowrap">Paid-in</FONT> Capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,440,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,681,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,121,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accumulated Deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(441,255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,681,073</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,122,328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shareholders&#146; Equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Period from August&nbsp;20, 2020 (inception) to December&nbsp;31, 2020
(audited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,573,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,573,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Allocation of initial public offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(441,255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,681,073</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,122,328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Weighted average shares outstanding of Class&nbsp;A redeemable ordinary
shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,326,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(144,993</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,181,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Weighted average shares outstanding of Class&nbsp;B
<FONT STYLE="white-space:nowrap">non-redeemable</FONT> ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,414,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,461,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted net loss per share, Class&nbsp;B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.86</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Cash Flow Statement for the Period from August&nbsp;20, 2020 (inception) to
December&nbsp;31, 2020 (audited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(441,255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,681,073</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,122,328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Allocation of initial public offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,573,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,573,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Initial classification of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,830,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,830,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Initial classification of common stock subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,121,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,598,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,522,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Change in value of common stock subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(436,290</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,993,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,429,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America
(&#147;GAAP&#148;) and pursuant to the rules and regulations of the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Emerging Growth Company </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act of 1933, as amended (the
&#147;Securities Act&#148;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies
that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, reduced
disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden
parachute payments not previously approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being
required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the
Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <FONT
STYLE="white-space:nowrap">non-emerging</FONT> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it
has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the
Company&#146;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a
condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the
actual results could differ significantly from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company considers all short-term investments with an original maturity of three&nbsp;months or less when purchased to be cash equivalents.
The Company did not have any cash equivalents as of December&nbsp;31, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Marketable Securities Held in Trust Account
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At December&nbsp;31, 2020, substantially all of the assets held in the Trust Account were held in U.S. Treasury Bills. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Warrant Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#146;s
specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) 480, Distinguishing Liabilities from Equity (&#147;ASC 480&#148;) and ASC
815,&nbsp;Derivatives and Hedging&nbsp;(&#147;ASC 815&#148;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants
meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#146;s own ordinary shares and whether the warrant holders could potentially require &#147;net cash settlement&#148; in a
circumstance outside of the Company&#146;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly
period end date while the warrants are outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For issued or modified warrants that meet all of the criteria for equity
classification, the warrants are required to be recorded as a component of additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity
classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a <FONT
STYLE="white-space:nowrap">non-cash</FONT> gain or loss on the statements of operations. The fair value of the warrants was estimated using a binomial lattice simulation methodology (see Note 9). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Class&nbsp;A Ordinary Shares Subject to Possible Redemption </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for its Class&nbsp;A ordinary shares subject to possible redemption in accordance with the guidance in Accounting
Standards Codification (&#147;ASC&#148;) Topic 480 &#147;Distinguishing Liabilities from Equity.&#148; Class&nbsp;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value.
Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#146;s
control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#146; equity. The Company&#146;s Class&nbsp;A ordinary shares feature certain redemption rights that are considered to be outside of the
Company&#146;s control and subject to occurrence of uncertain future events. Accordingly, Class&nbsp;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders&#146; equity
section of the Company&#146;s balance sheet. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for income taxes under ASC 740, &#147;Income Taxes&#148; (&#147;ASC 740&#148;). ASC 740 requires the recognition of
deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry
forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#146;s financial statements and prescribes a
recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <FONT
STYLE="white-space:nowrap">more-likely-than-not</FONT> to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no
unrecognized tax benefits and no amounts accrued for interest and penalties as of December&nbsp;31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from
its position. The Company is subject to income tax examinations by major taxing authorities since inception. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is considered an exempted Cayman Islands company and is presently not subject to
income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#146;s tax provision was zero for the period presented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Net Income (Loss) Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net income (loss) per share is computed by dividing net income by the weighted-average number of ordinary shares outstanding during the period,
excluding ordinary shares subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 3,211,334 shares in the calculation of diluted loss per
share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s statement of operations includes a presentation of income (loss) per share for ordinary shares subject to possible
redemption in a manner similar to the <FONT STYLE="white-space:nowrap">two-class</FONT> method of income (loss) per share. Net income (loss) per ordinary share, basic and diluted, for ordinary shares subject to possible redemption is calculated by
dividing the proportionate share of income or loss on marketable securities held by the Trust Account by the weighted average number of ordinary shares subject to possible redemption outstanding since original issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net income (loss) per share, basic and diluted, for <FONT STYLE="white-space:nowrap">non-redeemable</FONT> ordinary shares is calculated by
dividing the net income (loss), adjusted for income or loss on marketable securities attributable to ordinary shares subject to possible redemption, by the weighted average number of <FONT STYLE="white-space:nowrap">non-redeemable</FONT> ordinary
shares outstanding for the period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-redeemable</FONT> ordinary shares include Founder Shares and <FONT
STYLE="white-space:nowrap">non-redeemable</FONT> ordinary shares as these shares do not have any redemption features. <FONT STYLE="white-space:nowrap">Non-redeemable</FONT> ordinary shares participate in the income or loss on marketable securities
based on <FONT STYLE="white-space:nowrap">non-redeemable</FONT> shares&#146; proportionate interest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table reflects the calculation of basic and diluted net income (loss) per
ordinary share (in dollars, except per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Period<BR>from<BR>August&nbsp;21,&nbsp;2020<BR>(Inception)<BR>Through<BR>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Ordinary shares subject to possible redemption</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Numerator: Earnings allocable to ordinary shares subject to possible
redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interest earned on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unrealized gain (loss) on marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,466</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net income attributable to Class&nbsp;A ordinary shares subject to possible
redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,223</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Denominator: Weighted Average Class&nbsp;A ordinary shares subject to possible
redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted weighted average shares outstanding, Class&nbsp;A ordinary
shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,181,335</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted net loss per share, Class&nbsp;A ordinary shares subject to
possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I><FONT STYLE="white-space:nowrap">Non-Redeemable</FONT> Common
Stock</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Numerator: Net Loss minus Net Earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,122,328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Add: Net loss allocable to Class&nbsp;A ordinary shares subject to possible
redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-Redeemable</FONT> Net Loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,120,105</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Denominator: Weighted Average
<FONT STYLE="white-space:nowrap">Non-redeemable</FONT> ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted weighted average shares outstanding, <FONT
STYLE="white-space:nowrap">Non-redeemable</FONT> ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,461,095</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted net loss per share,
<FONT STYLE="white-space:nowrap">Non-redeemable</FONT> ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.86</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial
institution which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of the Company&#146;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#147;Fair Value
Measurement,&#148; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Recent Accounting Standards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material
effect on the accompanying financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 4. INITIAL PUBLIC OFFERING </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the Initial Public Offering, the Company sold 8,000,000&nbsp;Units at a purchase price of $10.00 per Unit. Each Unit consists of
one Class&nbsp;A ordinary share and <FONT STYLE="white-space:nowrap">one-third</FONT> of one redeemable warrant (&#147;Public Warrant&#148;). Each whole Public Warrant entitles the holder to purchase one Class&nbsp;A ordinary share at an exercise
price of $11.50 per share, subject to adjustment (see Note 8). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On December&nbsp;1, 2020, the underwriters fully exercised their
over-allotment option, resulting in an additional 1,200,000&nbsp;Units issued for an aggregate amount of $12,000,000. In connection with the underwriters&#146; full exercise of their over-allotment option, the Company also consummated the sale of an
additional 24,000 Private Placement Units at $10.00 per Private Placement Unit, generating total proceeds of $12,240,000. A total of $12,000,000 was deposited into the Trust Account, bringing the aggregate proceeds held in the Trust Account to
$92,000,000 (see Note 9). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 5. PRIVATE PLACEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Simultaneously with the consummation of the Initial Public Offering, the Sponsor purchased an aggregate of 410,000 Private Placement Units at a
price of $10.00 per Private Placement Unit, for an aggregate purchase price of $4,100,000. On December&nbsp;1, 2020, as a result of the underwriters&#146; election to fully exercise their over-allotment option, the Sponsor purchased an additional
24,000 Private Placement Units, at a price of $10.00 per Private Placement Unit, or $240,000 in the aggregate. Each Private Placement Unit consists of one Class&nbsp;A ordinary share (&#147;Private Placement Share&#148; or, collectively,
&#147;Private Placement Shares&#148;) and <FONT STYLE="white-space:nowrap">one-third</FONT> of one redeemable warrant (each, a &#147;Private Placement Warrant&#148;). Each whole Private Placement Warrant is exercisable for one Class&nbsp;A ordinary
share at a price of $11.50 per share, subject to adjustment (see Note 8). The proceeds from the sale of the Private Placement Units were added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not
complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable
law) and the Private Placement Units and all underlying securities will expire worthless. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 6. RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Founder Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On September&nbsp;4, 2020, the Sponsor paid $25,000 to cover certain offering and formation costs of the Company in
consideration for 3,593,750 Class&nbsp;B ordinary shares. On October&nbsp;8, 2020 and November&nbsp;10, 2020, 718,750 and 575,000 Class&nbsp;B ordinary shares were contributed back to the Company for no consideration, respectively, resulting in
there being 2,300,000 Class&nbsp;B ordinary shares (the &#147;Founder Shares&#148;) being issued and outstanding. The Founder Shares include an aggregate of up to 300,000 shares subject to forfeiture by the Sponsor to the extent that the
underwriters&#146; over-allotment is not exercised in full or in part, so that the number of Founder Shares will collectively represent 20% of the Company&#146;s issued and outstanding shares upon the completion of the Initial Public Offering (not
including the Private Placement Shares).&nbsp;On December&nbsp;1, 2020, the underwriters fully exercised their over-allotment option, therefore there are no Founder Shares subject to forfeiture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur
of: (A)&nbsp;one year after the completion of a Business Combination; and (B)&nbsp;subsequent to a Business Combination, (x)&nbsp;if the closing price of the Class&nbsp;A ordinary shares equals or exceeds $12.00 per share (as adjusted for share <FONT
STYLE="white-space:nowrap">sub-divisions,</FONT> share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any <FONT STYLE="white-space:nowrap">30-trading</FONT> day period commencing at least
150&nbsp;days after a Business Combination, or (y)&nbsp;the date on which the Company completes a liquidation, merger, amalgamation, share exchange, reorganization or other similar transaction that results in all of the Company&#146;s shareholders
having the right to exchange their Class&nbsp;A ordinary shares for cash, securities or other property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Administrative Services Agreement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company entered into an agreement, commencing on November&nbsp;18, 2020 through the earlier of the Company&#146;s consummation of a
Business Combination and its liquidation, to pay the Sponsor a total of up to $55,000 per month for office space and administrative support services. For the period from August&nbsp;21, 2020 (inception) through December&nbsp;31, 2020, the Company
incurred and paid $55,000 of such fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Promissory Note&nbsp;&#151;&nbsp;Related Party </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On September&nbsp;4, 2020, the Company issued an unsecured promissory note to the Sponsor (the &#147;Promissory Note&#148;), pursuant to which
the Company could borrow up to an aggregate principal amount of $300,000. The Promissory Note was <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and payable on the earlier of (i)&nbsp;December&nbsp;31, 2021 or (i)&nbsp;the consummation
of the Initial Public Offering. The outstanding balance under the Promissory Note of $147,753 was repaid at the closing of the Initial Public Offering on November&nbsp;23, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Related Party Loans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the
Company&#146;s directors and officers may, but are not obligated to, loan the Company funds as may be required (&#147;Working Capital Loans&#148;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans
out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a
portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if
any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender&#146;s discretion, up to
$1,500,000 of such Working Capital Loans may be convertible into Private Placement Units of the post-Business Combination entity at a price of $10.00 per Private Placement Unit. The Private Placement Units would be identical to the Units. As of
December&nbsp;31, 2020, the Company had no outstanding borrowings under the Working Capital Loans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 7. COMMITMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Registration and Shareholder Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to a registration rights agreement entered into on November&nbsp;18, 2020, the holders of the Founder Shares, Private Placement Units
(including securities contained therein) and warrants that may be issued upon conversion of the Working Capital Loans (and any Class&nbsp;A ordinary shares issuable upon the exercise of the Private Placement Units and warrants that may be issued
upon conversion of Working Capital Loans and upon conversion of the Founder Shares) will be entitled to registration rights. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company
register such securities. In addition, the holders have certain &#147;piggy-back&#148; registration rights with respect to registration statements filed subsequent to the completion of a Business Combination. However, the registration and
shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> period. The
registration rights agreement does not contain liquidating damages or other cash settlement provisions resulting from delays in registering the Company&#146;s securities. The Company will bear the expenses incurred in connection with the filing of
any such registration statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Underwriting Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters are entitled to a deferred fee of $0.35 per Unit, or $3,220,000 in the aggregate. The deferred fee will become payable to the
underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 8. SHAREHOLDERS&#146; EQUITY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Preference shares &#151;</I></B> The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share,
with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#146;s board of directors. At December&nbsp;31, 2020, there were no preference shares issued or outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Class</I></B><B><I></I></B><B><I>&nbsp;A ordinary shares &#151;</I></B> The Company is authorized to issue 350,000,000 Class&nbsp;A
ordinary shares, with a par value of $0.0001 per share. Holders of Class&nbsp;A ordinary shares are entitled to one vote for each share. At December&nbsp;31, 2020, there were 1,447,914 Class&nbsp;A ordinary shares issued and outstanding, excluding
8,186,086 Class&nbsp;A ordinary shares subject to possible redemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Class</I></B><B><I></I></B><B><I>&nbsp;B ordinary shares
&#151;</I></B> The Company is authorized to issue 150,000,000 Class&nbsp;B ordinary shares, with a par value of $0.0001 per share. Holders of the Class&nbsp;B ordinary shares are entitled to one vote for each share. At December&nbsp;31, 2020, there
were 2,300,000 Class&nbsp;B ordinary shares issued and outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Only holders of the Class&nbsp;B ordinary shares will have the right
to vote on the election of directors prior to the Business Combination. Holders of Class&nbsp;A ordinary shares and holders of Class&nbsp;B ordinary shares will vote together as a single class on all other matters submitted to a vote of the
Company&#146;s shareholders except as otherwise required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Class&nbsp;B ordinary shares will automatically convert into
Class&nbsp;A ordinary shares on the first business day following the consummation of a Business Combination at a ratio such that the number of Class&nbsp;A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate,
on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, 20% of the sum of (i)&nbsp;the total number of ordinary shares issued and outstanding (excluding the Private Placement Shares underlying the Private Placement Units) upon completion
of the Initial Public Offering, plus (ii)&nbsp;the sum of the total number of Class&nbsp;A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the
Company in connection with or in relation to the consummation of a Business Combination, excluding any Class&nbsp;A ordinary shares or equity-linked securities exercisable for or convertible into Class&nbsp;A ordinary shares issued, deemed issued,
or to be issued, to any seller in a Business Combination and any Private Placement Warrants issued to the Sponsor, members of the Company&#146;s founding team or any of their affiliates upon conversion of Working Capital Loans. In no event will the
Class&nbsp;B ordinary shares convert into Class&nbsp;A ordinary shares at a rate of less than one to one.&nbsp; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 9. Warrants
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Warrants &#151;</I></B> Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued
upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a)&nbsp;30&nbsp;days after the completion of a Business Combination and (b)&nbsp;one year from the closing of the Initial Public Offering. The Public
Warrants will expire five&nbsp;years from the completion of a Business Combination or earlier upon redemption or liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company
will not be obligated to deliver any Class&nbsp;A ordinary shares pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the
issuance of the Class&nbsp;A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating thereto is available, subject to the Company satisfying its obligations with respect to registration, or a valid
exemption from registration is available. No warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon
such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption is available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has agreed that as soon as practicable, but in no event later than 20 business days, after the closing of a Business Combination,
it will use its commercially reasonable efforts to file with the SEC a registration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
statement covering the Class&nbsp;A ordinary shares issuable upon exercise of the warrants, and the Company will use its commercially reasonable efforts to cause the same to become effective
within 60 business days after the closing of a Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class&nbsp;A ordinary shares until the warrants expire or are redeemed,
as specified in the warrant agreement; if the Class&nbsp;A ordinary shares are, at the time of any exercise of a warrant, not listed on a national securities exchange such that they satisfy the definition of a &#147;covered security&#148; under
Section&nbsp;18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a &#147;cashless basis&#148; in accordance with Section&nbsp;3(a)(9) of the Securities Act and,
in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement. If a registration statement covering the Class&nbsp;A ordinary shares issuable upon exercise of the warrants is not
effective by the 60th day after the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration
statement, exercise warrants on a &#147;cashless basis&#148; in accordance with Section&nbsp;3(a)(9) of the Securities Act or another exemption, but will use its best efforts to register or qualify the shares under applicable blue sky laws to the
extent an exemption is not available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Redemption of Warrants When the Price per Class</I></B><B><I></I></B><B><I>&nbsp;A Ordinary
Share Equals or Exceeds $18.00</I></B>&nbsp;&#151;&nbsp;Once the warrants become exercisable, the Company may redeem the outstanding Public Warrants: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a price of $0.01 per Public Warrant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon not less than 30&nbsp;days&#146; prior written notice of redemption to each warrant holder; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the closing price of the Class&nbsp;A ordinary shares equals or exceeds $18.00 per share (as
adjusted for share <FONT STYLE="white-space:nowrap">sub-divisions,</FONT> share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a <FONT STYLE="white-space:nowrap">30-trading</FONT> day period ending
on the third trading day prior to the date on which notice of the redemption is given to the warrant holders (the &#147;Reference Value&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if the Company are unable to
register or qualify the underlying securities for sale under all applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Redemption of Warrants When the
Price per Class</I></B><B><I></I></B><B><I>&nbsp;A Ordinary Share Equals or Exceeds $10.00</I></B>&nbsp;&#151;&nbsp;Once the warrants become exercisable, the Company may redeem the outstanding warrants: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at $0.10 per warrant upon a minimum of 30&nbsp;days&#146; prior written notice of redemption; provided that
during such 30 day period holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares, based on the redemption date and the fair market value of the Class&nbsp;A ordinary shares, that if
the warrants are not exercised on a cashless basis or otherwise during such 30 day period, the Company shall redeem such warrants for $0.10 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted for share subdivisions,
share dividends, reorganizations, recapitalizations and the like) on the trading day before the Company sends the notice of redemption to the warrant holders; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the Reference Value is less than $18.00 per share (as adjusted for share splits, share dividends,
reorganizations, recapitalizations and the like), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The exercise price and number of ordinary shares issuable upon exercise of the Public Warrants may be adjusted in certain circumstances
including in the event of a share dividend, extraordinary dividend or recapitalization, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of ordinary shares at a price below its exercise price.
Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account,
holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company&#146;s assets held outside of the Trust Account with respect to such Public Warrants.
Accordingly, the Public Warrants may expire worthless. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, if (x)&nbsp;the Company issues additional Class&nbsp;A ordinary
shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per Class&nbsp;A ordinary share (with such issue price or
effective issue price to be determined in good faith by the Company&#146;s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such
affiliates, as applicable, prior to such issuance) (the &#147;Newly Issued Price&#148;), (y)&nbsp;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding
of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&nbsp;the volume weighted average trading price of its Class&nbsp;A ordinary shares during the 20 trading day period starting on the
trading day prior to the day on which the Company consummates its Business Combination (such price, the &#147;Market Value&#148;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115%
of the higher of the Market Value and the Newly Issued Price, and the $10.00 and $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 100% and 180% of the higher of the Market Value and the Newly Issued
Price, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public
Offering, except that the Private Placement Warrants and the Class&nbsp;A ordinary shares issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30&nbsp;days after the completion of a
Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and be <FONT STYLE="white-space:nowrap">non-redeemable,</FONT> except as described above, so long as
they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the
Company and exercisable by such holders on the same basis as the Public Warrants.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 10. FAIR VALUE MEASUREMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company follows the guidance in ASC Topic 820 for its financial assets and liabilities that are
<FONT STYLE="white-space:nowrap">re-measured</FONT> and reported at fair value at each reporting period, and <FONT STYLE="white-space:nowrap">non-financial</FONT> assets and liabilities that are <FONT STYLE="white-space:nowrap">re-measured</FONT>
and reported at fair value at least annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of the Company&#146;s financial assets and liabilities reflects
management&#146;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement
date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal
assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and
liabilities: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Level&nbsp;1: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in
which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Level&nbsp;2: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Observable inputs other than Level&nbsp;1 inputs. Examples of Level&nbsp;2 inputs include quoted prices in active markets for
similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Level&nbsp;3: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or
liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table presents information about the Company&#146;s assets that are measured at fair value on a recurring basis
at December&nbsp;31, 2020, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="justify"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,997,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Warrant Liability &#150; Public Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,250,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Warrant Liability &#150; Private Placement Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Warrants were accounted for as liabilities in accordance with ASC
<FONT STYLE="white-space:nowrap">815-40</FONT> and are presented within warrant liabilities on our consolidated balance sheet. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value
presented within change in fair value of warrant liabilities in the consolidated statement of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Initial Measurement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Both the Private Placement Warrants and the Public Warrants were initially valued using a binomial lattice model, which is considered to be a
Level&nbsp;3 fair value measurement. The binomial lattice model&#146;s primary unobservable input utilized in determining the fair value of the Private Placement Warrants is the expected volatility of the common stock. The expected volatility as of
the IPO date was derived from observable public warrant pricing on comparable &#145;blank-check&#146; companies without an identified target. The expected volatility as of subsequent valuation dates will be implied from the Company&#146;s own public
warrant pricing. A binomial lattice model methodology was also used in estimating the fair value of the Public Warrants for periods where no observable traded price was available, using the same expected volatility as was used in measuring the fair
value of the Private Placement Warrants. For periods subsequent to the detachment of the Warrants from the Units, the close price of the Public Warrant price will be used as the fair value as of each relevant date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The key inputs into the binomial lattice simulation model for the Private Placement Warrants and Public Warrants were as follows at initial
measurement: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">Input</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">November&nbsp;23,<BR>2020 (Initial<BR>Measurement</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">December&nbsp;31,<BR>2020</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.50</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.50</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Fair value of Units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.81</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.12</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On November&nbsp;23, 2020, the Private Placement Warrants and Public Warrants were determined to be $.57 per
warrant for aggregate values of $82,460 and $1,748,000, respectively (these values include the underwriters exercise of their overallotment option on December&nbsp;1, 2020). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Subsequent Measurement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Warrants are measured at fair value on a recurring basis. The subsequent measurement of the Public Warrants as of December&nbsp;31, 2020 is
classified as Level&nbsp;1 due to the use of an observable market quote in an active market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2020, the aggregate
values of the Private Placement Warrants and Public Warrants were $153,347 and $3,250,667&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table
presents the changes in the fair value of warrant liabilities: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Private<BR>Placement</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Public</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Warrant<BR>Liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Initial measurement on November&nbsp;23, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,900</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,520,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,597,900</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Change in valuation inputs or other assumptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,447</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,730,667</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,806,114</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Fair value as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153,347</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,250,667</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,404,014</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Due to the use of quoted prices in an active market (Level 1) to measure the fair value of the Public
Warrants, subsequent to initial measurement, the Company had transfers out of Level&nbsp;3 totaling $1,597,900 during the period from November&nbsp;23, 2020 through December&nbsp;31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOTE 11. SUBSEQUENT EVENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial
statements were issued. Based upon this review, except as noted in footnote 2 and as set forth below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Business Combination Agreement and PIPE Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April 15, 2021, the Company entered into a business combination agreement with Surrozen, Inc. (&#147;Surrozen&#148;), pursuant to which a
wholly-owned subsidiary of the Company will merge with and into Surrozen, with Surrozen surviving as a wholly-owned subsidiary of the Company and the Company will redomicile as a Delaware corporation. In accordance with the terms and subject to the
conditions of the Business Combination Agreement, each share and equity award (whether vested or unvested) of Surrozen outstanding as of closing will be exchanged for shares of the Company&#146;s common stock or comparable equity awards that are
settled or are exercisable for shares of the Company&#146;s common stock, as applicable, based on an implied Surrozen equity value of $200,000,000 and a $10.00 per share value of the Company&#146;s Common Stock. In connection with the foregoing and
concurrently with the execution of the Business Combination Agreement, the Company entered into Subscription Agreements with certain investors (the &#147;Subscription Agreements&#148; and such investors, the &#147;PIPE Investors&#148;), pursuant to
which the PIPE Investors have agreed to subscribe for and purchase, and the Company has agreed to issue and sell to the PIPE Investors, an aggregate of 12,020,000 units, each consisting of one share of the Company&#146;s common stock and one-third
of one redeemable warrant for one share of the Company&#146;s common stock (the &#147;PIPE Warrants&#148;), for a purchase price of $10.00 per unit (the &#147;PIPE Units&#148;), for aggregate gross proceeds of $120,200,000 (the &#147;PIPE
Financing&#148;). Each whole PIPE Warrant entitles the holder thereof to purchase one share of the Company&#146;s common stock at a price of $11.50 per share, subject to adjustment as described in the form of warrant agreement attached to the form
of Subscription Agreement, and only whole PIPE Warrants will be exercisable. The PIPE Warrants have substantially the same provisions as the public warrants issued in connection with the Company&#146;s initial public offering. The securities to be
issued pursuant to the Subscription Agreements have not been registered under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) in reliance upon the exemption provided in Section 4(a)(2) of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(As of May 14, 2021) </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_18"></A>Condensed Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Liabilities, redeemable convertible preferred stock and stockholders&#146;
deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lease liabilities, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lease liabilities, noncurrent portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Commitments and contingencies (Note 5 and Note 10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Redeemable convertible preferred stock, $0.0001 par value; 95,289,938 shares
authorized as of March&nbsp;31, 2021 and December&nbsp;31, 2020; 95,289,932 shares issued and outstanding as of March&nbsp;31, 2021 and December&nbsp;31, 2020; liquidation preference of $133,300 as of March&nbsp;31, 2021 and December&nbsp;31,
2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Common stock, $0.0001 par value, 120,000,000 shares authorized as of
March&nbsp;31, 2021 and December&nbsp;31, 2020; 9,583,529 and 8,648,718 shares issued and outstanding as of March&nbsp;31, 2021 and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additional
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(101,023</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,001</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(98,245</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(85,804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total liabilities, redeemable convertible preferred stock and stockholders&#146;
deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the unaudited condensed interim financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_19"></A>Condensed Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In
thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,031</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,361</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,022</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net loss per share attributable to common stockholders, basic and diluted</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Weighted-average shares used in computing net loss per share attributable to
common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;8,062,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;7,042,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the unaudited condensed interim financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_20"></A>Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In
thousands, except share amounts) </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable&nbsp;convertible<BR>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>stockholders&#146;<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,289,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">133,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,648,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(88,001</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(85,804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Exercises of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">434,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Restricted stock granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Reclassification to liability for early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Vesting of early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,022</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,022</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Balance at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,289,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">133,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,583,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(101,023</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(98,245</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable&nbsp;convertible<BR>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>stockholders&#146;<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,718,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,178,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(55,285</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Issuance costs of Series C redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Exercises of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Reclassification to liability for early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Vesting of early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Restricted stock forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Balance at March&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,718,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,373,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(61,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(59,901</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the unaudited condensed interim financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_21"></A>Condensed Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In
thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,022</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Adjustments to reconcile net loss to net cash used in operating
activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(507</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(351</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,074</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(343</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Purchases of investment securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Issuance cost of Series C redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net decrease in cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,578</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,997</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash and cash equivalents and restricted cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash and cash equivalents and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Supplemental disclosure of noncash investing and financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Capital expenditures in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Vesting of early exercises of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Reclassification to liability for early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Deferred transaction costs included in accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table presents a reconciliation of the Company&#146;s cash, cash
equivalents and restricted cash in the Company&#146;s condensed balance sheets: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the unaudited condensed interim financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_22"></A>Notes to the Unaudited Condensed Interim Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 1. Organization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Description of Business </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen, Inc. (the &#147;Company&#148;) is a preclinical stage biotechnology company committed to discovering and developing drug candidates
to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The Company is located in South San Francisco, California and was incorporated in the state of Delaware on August&nbsp;12, 2015.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Liquidity, Capital Resources and Going Concern </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has incurred net operating losses each period since inception. During the three months ended March&nbsp;31, 2021, the Company
incurred a net loss of $13.0&nbsp;million and used $10.3&nbsp;million of cash in operations. As of March&nbsp;31, 2021, the Company had an accumulated deficit of approximately $101.0&nbsp;million. The Company expects operating losses to continue in
the foreseeable future because of additional costs and expenses related to the research and development activities. To date, the Company has been able to fund its operations through private placements of redeemable convertible preferred stock. As of
March&nbsp;31, 2021, the Company had cash and cash equivalents of $23.4&nbsp;million and short-term investments of $15.3&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Management does not believe that the existing financial resources are sufficient for the Company to continue operating activities and
therefore has concluded that substantial doubt exists about the Company&#146;s ability to continue as a going concern within 12 months from the date of issuance of its condensed interim financial statements. The accompanying condensed interim
financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The accompanying
condensed interim financial statements do not reflect any adjustments relating to the recoverability and reclassifications of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. Insufficient
liquidity may require the Company to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than the Company would otherwise choose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company plans to continue to fund its operations through public or private equity financings, debt financings or other capital sources,
including government grants, potential collaborations with other companies or other strategic transactions. The Company&#146;s ultimate success depends on the outcome of its research and development activities. Failure to generate sufficient cash
flows from operations, raise additional capital and reduce discretionary spending could have a material adverse effect on the Company&#146;s ability to achieve its intended business objectives. These factors would have a material adverse effect on
the Company&#146;s future financial results, financial position and cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s business has been and could continue
to be adversely affected by the evolving Coronavirus Disease 2019 <FONT STYLE="white-space:nowrap">(COVID-19)</FONT> pandemic. For example, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has resulted in and could result in delays to
the Company&#146;s preclinical studies of its product pipeline. At this time, the extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacts the Company&#146;s business will depend on future developments, which are highly
uncertain and cannot be predicted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s condensed interim financial statements and accompanying notes have been prepared in accordance with generally accepted
accounting principles in the United States of America (&#147;U.S. GAAP&#148;) as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Interim Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
determined by the Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) and pursuant to the regulations of the U.S. Securities and Exchange
Commission (&#147;SEC&#148;). The Company has no subsidiaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Use of Estimates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preparation of condensed interim financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and
assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed interim financial statements and the reported amounts of expenses during the reporting period.
Significant estimates and assumptions made in the accompanying condensed interim financial statements include, but are not limited to, certain accruals for research and development activities, the fair value of common stock, stock-based compensation
expense, uncertain tax positions and lease liabilities. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that are believed to be reasonable under the circumstances, the results of
which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could materially differ from those estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Unaudited Condensed Interim Financial Statements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accompanying condensed balance sheet as of March&nbsp;31, 2021, the condensed statements of redeemable convertible preferred stock and
stockholders&#146; deficit, the condensed statements of operations and comprehensive loss, and the condensed statements of cash flows for the three months ended March&nbsp;31, 2021 and 2020 are unaudited. The unaudited condensed interim financial
statements have been prepared on the same basis as the audited annual financial statements and, in management&#146;s opinion, include all adjustments consisting of only normal recurring adjustments necessary for the fair statement of the
Company&#146;s financial position as of March&nbsp;31, 2021 and its results of operations and cash flows for the three months ended March&nbsp;31, 2021 and 2020. The financial data and the other financial information disclosed in the notes to these
condensed interim financial statements related to the three-month&nbsp;periods are also unaudited. The condensed balance sheet as of December&nbsp;31, 2020 was derived from the audited financial statements as of that date. The results of operations
for the three months ended March&nbsp;31, 2021 are not necessarily indicative of the results to be expected for the full fiscal year or any other period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These unaudited condensed interim financial statements should be read in conjunction with the Company&#146;s financial statements for the year
ended December&nbsp;31, 2020 included elsewhere in this proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Deferred Transaction Costs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company capitalizes transaction costs consisting of direct, incremental legal, accounting and other fees in connection with the anticipated
business combination with <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp (see Note 11). The deferred transaction costs will be offset against the proceeds from the transaction upon the consummation of the business
combination. Should the business combination be abandoned, the deferred transaction costs will be expensed immediately as a charge to operating expenses in the condensed statements of operations and comprehensive loss. As of March&nbsp;31, 2021, the
Company incurred $0.3&nbsp;million of deferred transaction costs, which were included in other assets on the condensed balance sheets. As of December&nbsp;31, 2020, the Company had not incurred any such costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Interim Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Restricted Cash </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of both March&nbsp;31, 2021 and December&nbsp;31, 2020, the Company had $0.4&nbsp;million of restricted cash. The restricted cash serves as
collateral for facility leases entered into in 2016 (Note 5). Restricted cash is classified as current if the collateral will be returned in less than 12 months. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Concentration of Credit Risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist of cash and cash equivalents,
short-term investments and restricted cash. The Company is exposed to credit risk in the event of default to the extent recorded in the condensed balance sheets. The Company has not experienced any losses in such accounts. Management believes that
the Company is not exposed to significant credit risk due to the financial position of the depository institution in which its bank deposits are held. To manage credit risks related to short-term investments, the Company invests in various highly
rated corporate debt and commercial paper securities. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development costs are expensed as incurred. Research and development costs consist of external and internal expenses directly
attributable to the conduct of research and development programs. The external expenses include the cost of services provided by outside contractors, clinical research organizations and contract manufacturing organizations. The internal expenses
include the cost of salaries, payroll taxes, stock-based compensation, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, and the facility costs for laboratory space used for research and development
activities, such as rent, utilities, insurance, repairs and maintenance, and general support services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has entered into and
may continue to enter into licensing or subscription arrangements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the
Company&#146;s license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the
definition of a derivative, are immediately recognized as research and development expense when they are paid or become payable, provided there is no alternative future use of the rights in other research and development projects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Interim Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Net Loss Per Share </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic net loss per share is calculated by dividing the net loss attributable to common shares by the weighted-average number of shares of
common stock outstanding for the period, without consideration for potential dilutive securities. Since the Company was in a loss position for the periods presented, basic net loss per share is the same as diluted net loss per share since the
effects of potentially dilutive securities are antidilutive. The following table presents the potential common shares outstanding that were excluded from the computation of diluted net loss per share of common stock as of the periods presented
because including them would have been antidilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,289,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,718,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Options Outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,749,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,641,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unvested RSAs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">702,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">338,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unvested common stock subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">655,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">968,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,396,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,666,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Emerging Growth Company Status </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act,
emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended
transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&nbsp;no longer an emerging growth company or
(ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these condensed interim financial statements may not be comparable to companies that comply with the new or revised accounting
pronouncements as of public company effective dates. </P>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Recently Adopted Accounting Pronouncements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-12,</FONT> <I>Income Taxes (Topic 740): Simplifying the
Accounting for Income Taxes</I>, which amends the existing guidance relating to the accounting for income taxes. This standard is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of
accounting for income taxes and to improve the consistent application of U.S. GAAP for other areas of accounting for income taxes by clarifying and amending existing guidance. The standard is effective for public business entities for fiscal years
beginning after December 15, 2020 and interim periods within those fiscal years. The standard is effective for entities other than public business entities for fiscal years beginning after December 15, 2021. The Company early adopted this guidance
as of January&nbsp;1, 2021, with no material impact upon adoption. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Interim Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 3. Fair Value Measurement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables summarize the Company&#146;s financial assets and liabilities that are measured at fair value on a recurring basis (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of March&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Money market funds <SUP STYLE="font-size:85%; vertical-align:top">(1)
</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;21,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Corporate bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total financial assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 21,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Money market funds <SUP STYLE="font-size:85%; vertical-align:top">(1)
</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 31,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Corporate bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Commercial paper <SUP STYLE="font-size:85%; vertical-align:top">(2)
</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total financial assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 31,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(1)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Money market funds are included in cash and cash equivalents on the condensed balance sheets as of
March&nbsp;31, 2021 and December&nbsp;31, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(2)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">As of December&nbsp;31, 2020, marketable securities with original maturities of three months or less, in the
amount of $2.2&nbsp;million, are included in cash and cash equivalents on the condensed balance sheet. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There have
been no changes to the valuation methods utilized during the three months ended March&nbsp;31, 2021. The Company&#146;s financial instruments include cash and cash equivalents, short-term investments, restricted cash, accounts payable and accrued
liabilities. The carrying amount of cash and cash equivalents, restricted cash, accounts payable, and accrued liabilities approximate their fair values due to their short-term maturities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Investments in corporate bonds and commercial paper are classified as Level&nbsp;2 as they were valued based upon quoted market prices for
similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by
observable market data for substantially the full term of the assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Interim Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table provides the Company&#146;s marketable securities by security type (in
thousands): </P>   <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of March&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross</B><br><B>Unrealized</B><br><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross</B><br><B>Unrealized</B><br><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated</B><br><B>Fair<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Corporate bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross</B><br><B>Unrealized</B><br><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross</B><br><B>Unrealized</B><br><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated</B><br><B>Fair<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Corporate bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2021 and December&nbsp;31, 2020, $15.3&nbsp;million and $14.2&nbsp;million,
respectively, of marketable securities are included in short-term investments. As of March&nbsp;31, 2021, all marketable securities had maturities of one year or less. Gains and losses on marketable security transactions are reported on the
specific-identification method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2021, one investment of $1.1&nbsp;million was in an unrealized loss position, with
an unrealized loss of less than $1,000. This investment has not been in a continuous unrealized loss position for more than 12 months. The Company determined that the unrealized loss was not attributed to credit risk but was primarily associated
with changes in interest rates. The Company does not intend to sell the investment that is in an unrealized loss position, nor is it more likely than not that the Company will be required to sell the investment before the recovery of the amortized
cost basis, which may be its maturity. Accordingly, the Company did not record an allowance for credit losses associated with this investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 4. Balance Sheet Components </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Accrued Liabilities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued liabilities consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Payroll and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued professional service fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Liability for early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 5. Leases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2016, the Company entered into a lease agreement for office space, which consists of approximately 32,813 square feet of rental space
in South San Francisco, California. The office space lease is classified as an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Interim Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
operating lease. The initial lease term commenced in May 2017 and ends in April 2025, with rent payments escalating each year. The Company has options to extend the lease for additional years,
but the exercise of the option was not reasonably certain. The landlord provided the Company with a tenant improvement allowance of up to $4.6&nbsp;million. In connection with the lease, the Company maintains a letter of credit for the benefit of
the landlord in the amount of $0.4&nbsp;million, which is recorded as restricted cash on the condensed balance sheets. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
January 2020, the Company entered into a new lease agreement for a term of 18 months for approximately 6,478 square feet of space. The new office space lease is classified as an operating lease. The new lease commenced in June 2020 and rent payments
escalate after 14 months. The Company has the option to terminate the lease after six months, but the exercise of the option was not reasonably certain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with its operating leases, as of March&nbsp;31, 2021 and December 31, 2020, the Company has operating lease <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets of $5.2&nbsp;million and $5.6&nbsp;million, respectively, and aggregate lease liabilities of $9.1&nbsp;million and $9.6&nbsp;million, respectively, on its
condensed balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating lease expense during the three months ended March&nbsp;31, 2021 and 2020 was $0.5&nbsp;million and
$0.4&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Aggregate future minimum rental payments under operating leases as of March&nbsp;31, 2021, were as
follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Nine months ending December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Year ending December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Year ending December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Year ending December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Year ending December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Less: Imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,615</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 6. License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Stanford License Agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2016, the Company entered into a license agreement with Stanford, or the 2016 Stanford Agreement, which was amended in July 2016,
October 2016 and January 2021, pursuant to which the Company obtained from Stanford, a worldwide, exclusive, sublicensable license under certain patents, rights, or licensed patents and technology related to its engineered Wnt surrogate molecules to
make, use, import, offer to sell and sell products that are claimed by the licensed patents or that use or incorporate such technology, or licensed products, for the treatment, diagnosis and prevention of human and veterinary diseases. In
consideration for this license, the Company paid Stanford a nominal upfront fee and issued an aggregate of 241,688 shares of our common stock to Stanford, the University of Washington and two <FONT STYLE="white-space:nowrap">co-inventors</FONT> of
the licensed patents. In addition, the Company agreed to pay Stanford nominal annual license maintenance fees which are creditable against earned royalties owed to Stanford for the same year, an aggregate of up to $1.4&nbsp;million for the
achievement of specified development and regulatory milestones, and an aggregate of up to $5.0&nbsp;million for achievement of specified sales milestones. Stanford is also entitled to receive royalties from the Company equal to a very low single
digit percentage of the Company&#146;s and its sublicensees&#146; net sales of licensed products that are covered by a valid claim of a licensed patent. Additionally, the Company agreed to pay Stanford a
<FONT STYLE="white-space:nowrap">sub-teen</FONT> double digit percentage of certain consideration the Company receives as a result of granting sublicenses to the licensed patents and, if the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Interim Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Company acquired, a <FONT STYLE="white-space:nowrap">one-time</FONT> change of control fee in the low six figures. Stanford retains the right under the 2016 Stanford Agreement, on behalf of
itself, Stanford Hospital and Clinics, the University of Washington and all other <FONT STYLE="white-space:nowrap">non-profit</FONT> research institutions, to practice the licensed patents and technology for any
<FONT STYLE="white-space:nowrap">non-profit</FONT> purpose. The licensed patents and technology are additionally subject to a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> irrevocable, worldwide license held by the Howard Hughes Medical
Institute to practice the licensed patents and technology for its research purposes, but with no right to assign or sublicense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2018, the Company entered into another license agreement with Stanford, or the 2018 Stanford Agreement, pursuant to which the Company
obtained from Stanford, a worldwide, exclusive, sublicensable license under certain patent rights related to its surrogate R-spondin proteins, or the licensed patents, to make, use, import, offer to sell and sell products that are claimed by the
licensed patents, or licensed products, for the treatment, diagnosis and prevention of human and veterinary diseases, or the exclusive field. Additionally, Stanford granted the Company a worldwide,
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable license under the licensed patents to make and use licensed products for research and development purposes in furtherance of the exclusive field and a worldwide, <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> license to make, use and import, but not to offer to sell or sell, licensed products in any other field of use. In consideration of these licenses, the Company paid Stanford a nominal upfront fee. The
Company also agreed to pay Stanford nominal annual license maintenance fees which are creditable against earned royalties owed to Stanford for the same year, and an aggregate of up to $0.425&nbsp;million for the achievement of specified development
and regulatory milestones. Stanford is also entitled to receive royalties from the Company equal to a <FONT STYLE="white-space:nowrap">sub-single</FONT> digit percentage of the Company&#146;s and its sublicensees&#146; net sales of licensed
products. Additionally, the Company agreed to pay Stanford a <FONT STYLE="white-space:nowrap">one-time</FONT> payment in the low six figures for each sublicense of the licensed patents that the Company grants to a third party and, if the Company is
acquired, a <FONT STYLE="white-space:nowrap">one-time</FONT> nominal change of control fee. Stanford retains the right under the 2018 Stanford Agreement, on behalf of itself, Stanford Health Care, Lucile Packard Children&#146;s Hospital at Stanford
and all other <FONT STYLE="white-space:nowrap">non-profit</FONT> research institutions, to practice the licensed patents for any <FONT STYLE="white-space:nowrap">non-profit</FONT> purpose. The licensed patents are additionally subject to a <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> irrevocable, worldwide license held by the Howard Hughes Medical Institute to exercise any intellectual property rights with respect to the licensed patents for research purposes, including the right
to sublicense to <FONT STYLE="white-space:nowrap">non-profit</FONT> and governmental entities but with no other rights to assign or sublicense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under each of the 2016 Stanford Agreement and the 2018 Stanford Agreement, or Stanford Agreements, the Company agreed to use commercially
reasonable efforts to develop and commercialize licensed products and the Company agreed to achieve certain funding and development milestones by certain dates. Unless earlier terminated, each Stanford Agreement will continue until the expiration of
the patents licensed under such Stanford Agreement. The Company may terminate either Stanford Agreement at any time for any reason by providing at least 30 days&#146; written notice to Stanford. Stanford may terminate either Stanford Agreement if
the Company breaches certain provisions of that Stanford Agreement and fail to remedy such breach within 90 days after written notice of the breach by Stanford. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the three months ended March&nbsp;31, 2021, the Company paid de minimis research and development expenses related to the Stanford
Agreements. For the three months ended March&nbsp;31, 2020, the Company paid approximately $30,000 research and development expenses related to the Stanford Agreements. No milestone payments or earned royalties were paid by the Company to Stanford
as of March&nbsp;31, 2021 pursuant to the Stanford Agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>UCSF License and Option Agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September and October 2016, the Company entered into two separate license and option agreements with The Regents of the University of
California, or UCSF, pursuant to which the Company obtained <FONT STYLE="white-space:nowrap">non-exclusive</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Interim Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
licenses from UCSF for internal research and antibody discovery purposes and an option to negotiate with UCSF to obtain a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under
UCSF&#146;s rights in the applicable library to make, use, sell, offer for sale and import products incorporating antibodies identified or resulting from the Company&#146;s use of such library, or licensed products. In consideration of the license
and option rights under the UCSF Agreement, the Company paid UCSF a nominal option issue fee and agreed to pay UCSF a nominal annual option maintenance fee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2020, the Company amended and restated its license and option agreements with UCSF, or UCSF Agreement, to provide <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> licenses to make and use a certain human Fab na&iuml;ve phage display library and to make and use a certain phage display llama VHH single domain antibody library for internal research and antibody
discovery purposes and an option to negotiate with UCSF to obtain a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under UCSF&#146;s rights in the applicable library to make, use, sell, offer for sale and import products incorporating
antibodies identified or resulting from the Company&#146;s use of such library, or licensed products. If the Company exercises the option under the UCSF Agreement, the Company and UCSF will negotiate in good faith the terms of a commercial license
agreement in addition to the <FONT STYLE="white-space:nowrap">pre-agreed</FONT> terms which include payment to UCSF of a nominal license issue fee, nominal annual license maintenance fees, nominal to low six figure milestone payments for the
achievement of a specified regulatory milestone event for each licensed product, nominal annual minimum royalties, which are creditable against earned royalties for the same year, and earned royalties equal to a
<FONT STYLE="white-space:nowrap">sub-single</FONT> digit percentage of the Company&#146;s and the Company&#146;s sublicensees&#146; net sales of licensed products. As of December&nbsp;31, 2020, the Company has not exercised the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the three months ended March&nbsp;31, 2021 and 2020, the Company paid $25,000 and zero for the annual license maintenance fee. For both
the three months ended March&nbsp;31, 2021 and 2020, the Company paid no research and development expenses related to the UCSF agreements. No milestone payments or earned royalties were paid by the Company to UCSF as of March&nbsp;31, 2021 pursuant
to the UCSF agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless earlier terminated, the UCSF Agreement will continue until four years from its effective date, and the
Company may exercise the option to negotiate a commercial license at any time during that term. Additionally, the Company may extend the UCSF Agreement for any additional four years by paying UCSF a nominal term extension fee. The Company may
terminate the UCSF Agreement at any time for any reason by providing at least 60 days&#146; written notice to UCSF. UCSF may terminate the UCSF Agreement if UCSF reasonably believes the Company is in material breach of the UCSF Agreement and the
Company fails to remedy such breach within 60 days after written notice of such breach by UCSF. Additionally, the UCSF Agreement will automatically terminate in the event of the Company&#146;s bankruptcy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Distributed Bio Subscription Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September 2016, the Company entered into, and in January 2019 the Company amended, an antibody library subscription agreement with
Distributed Bio, or the Distributed Bio Agreement, in which the Company obtained from Distributed Bio a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to use Distributed Bio&#146;s antibody library to identify antibodies directed to
an unlimited number of the Company&#146;s proprietary targets and to make, use, sell, offer for sale, import and exploit products incorporating the antibodies that the Company identifies, or licensed products. In consideration for the rights granted
to the Company under the Distributed Bio Agreement, the Company paid Distributed Bio a nominal upfront fee and an additional nominal fee upon entering into the amendment. The Company agreed to pay Distributed Bio an annual fee in the low six figures
after the first three years. Additionally, the Company agreed to pay Distributed Bio an aggregate of $5.9&nbsp;million for each licensed product that achieves specified development, regulatory and commercial milestones and royalties equal to a very
low single digit percentage of the Company&#146;s and its sublicensees&#146; net sales of licensed products. The Company&#146;s obligation to pay royalties will end for each licensed product ten years after its first commercial sale. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Interim Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For both the three months ended March&nbsp;31, 2021 and 2020, the Company did not make any
payments related to the Distributed Bio Agreement. No milestone payments or earned royalties were paid by the Company to Distributed Bio as of March&nbsp;31, 2021 pursuant to the Subscription Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless earlier terminated, the Distributed Bio Agreement will continue for an initial four-year term and will thereafter automatically renew
for additional <FONT STYLE="white-space:nowrap">one-year</FONT> terms. The Company may terminate the Distributed Bio Agreement for convenience at any time by providing written notice to Distributed Bio. The Company and Distributed Bio may terminate
the Distributed Bio Agreement for the other party&#146;s material breach and failure to cure such breach within 60 days after notice of such breach. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 7. Redeemable Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the redeemable convertible preferred stock as of March&nbsp;31, 2021 and December&nbsp;31, 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Liquidation&nbsp;Preference</B><br><B>(In thousands)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issued</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Original&nbsp;Issue&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,555,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,555,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,162,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,162,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,571,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,571,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,289,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,289,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The rights, preferences and privileges of the Series A, Series B and Series C redeemable convertible
preferred stock (together, the &#147;Redeemable Convertible Preferred Stock&#148;) are as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(a)</I></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>Dividend Rights </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Through March&nbsp;31, 2021, no dividends have been declared, authorized, or paid. From and after the date of issuance of the shares of
Redeemable Convertible Preferred Stock, the holders of the outstanding shares of Series A, Series B and Series C redeemable convertible preferred stock are entitled to receive, when and if declared by the Board of Directors, and prior and in
preference to dividends on the Company&#146;s common stock, a noncumulative cash dividend at the rate of $0.12, $0.08, and $0.14, respectively, per share per annum. The preferred stockholders also participate in any additional dividends on an <FONT
STYLE="white-space:nowrap">as-if</FONT> converted basis with common stockholders. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(b)</I></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>Redemption Rights </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Redeemable Convertible Preferred Stock is not redeemable as of March&nbsp;31, 2021. Upon certain change in control events that are outside
of the Company&#146;s control, including liquidation, sale or transfer of control of the Company, the Redeemable Convertible Preferred Stock is contingently redeemable. As such, the Redeemable Convertible Preferred Stock is classified as temporary
equity. The redemption price of the Redeemable Convertible Preferred Stock is equal to their respective original issue price per share plus any declared but unpaid dividends. Any discount to liquidation preference of the Redeemable Convertible
Preferred Stock is not being accreted as a deemed dividend, as it not currently probable that the Redeemable Convertible Preferred Stock will become redeemable. Subsequent adjustments to increase the carrying values to the ultimate redemption values
will be made only when it becomes probable that such a liquidation event will occur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Interim Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(c)</I></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>Conversion Rights </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each share of Redeemable Convertible Preferred Stock is, at the option of the holder, convertible into the number of fully paid and
nonassessable shares of common stock as determined by dividing the original issue price applicable to such series of redeemable convertible preferred stock by the conversion price in effect at that time with respect to such series. The conversion
price for the Redeemable Convertible Preferred Stock is the original issue price of such series of Redeemable Convertible Preferred Stock and shall be adjusted in accordance with conversion provisions contained in the Company&#146;s Amended and
Restated Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each share of Redeemable Convertible Preferred Stock shall automatically be converted into fully
paid, nonassessable shares of common stock at the then effective conversion rate for such share (i)&nbsp;immediately prior to the closing of a firm commitment underwritten initial public offering pursuant to an effective registration statement filed
under the Securities Act of 1933, as amended (the Securities Act), covering the offer and sale of the Company&#146;s common stock, provided that the public offering price represents a <FONT STYLE="white-space:nowrap">pre-money</FONT> valuation of at
least $250.0&nbsp;million and the aggregate gross proceeds to the Company are not less than $40.0&nbsp;million, or (ii)&nbsp;upon the receipt by the Company of a written request for such conversion from the holders of a majority of the redeemable
convertible preferred stock then outstanding (voting as a single class and on an <FONT STYLE="white-space:nowrap">as-if</FONT> converted basis), or, if later, the effective date for conversion specified in such requests. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(d)</I></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>Voting Rights </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each holder of a share of Redeemable Convertible Preferred Stock is entitled to the number of votes, with respect to such share, equal to the
number of shares of common stock into which such share of Redeemable Convertible Preferred Stock could be converted on the record date for the vote or consent of stockholders, except as otherwise required by law, and has voting rights and powers
equal to the voting rights and powers of the holders of common stock voting as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2021, the Board of
Directors was comprised of six members, three of whom are elected by the holders of Redeemable Convertible Preferred Stock, voting exclusively and as a separate class, and one of whom is the then current Chief Executive Officer of the Company and is
elected by the holders of common stock, voting exclusively and as a separate class. The holders of common stock and Redeemable Convertible Preferred Stock, voting as a single class on an <FONT STYLE="white-space:nowrap">as-if</FONT> converted basis,
were entitled to elect the balance of the total number of directors. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(e)</I></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>Liquidation Rights </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, the holders of the Redeemable
Convertible Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the Company to the holders of the common stock by reason of their ownership of such stock, an amount per share for each
share of Redeemable Convertible Preferred Stock held by them equal to the sum of (i)&nbsp;the liquidation preference of $1.00, $1.50, and $1.75 per share of Series A, Series B, and Series C redeemable convertible preferred stock, respectively, and
(ii)&nbsp;all declared but unpaid dividends (if any) on such share of Redeemable Convertible Preferred Stock, or such lesser amount as may be approved by the holders of the majority of the then-outstanding shares of redeemable convertible preferred
stock, voting as a single class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis. If upon the liquidation, dissolution or winding up of the Company, the assets of the Company legally available for distribution to the holders of
the Redeemable Convertible Preferred Stock are insufficient to permit the payment to such holders of the full amounts, then the entire assets of the Company legally available for distribution shall be distributed with equal priority and pro rata
among the holders of the Redeemable Convertible Preferred Stock in proportion to the full amounts they would otherwise be entitled to receive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Interim Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After the payment or setting aside for payment to the holders of the Redeemable Convertible
Preferred Stock of the full amounts specified above, the remaining assets of the Company legally available for distribution shall be distributed with equal priority and ratably to the holders of the common stock in proportion to the number of shares
of common stock held by them. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 8. Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holder of each share of common stock is entitled to one vote in respect of each share of stock held. The holders of common stock are also
entitled to receive dividends whenever funds and assets are legally available and when declared by the Board of Directors, subject to the prior rights of holders of redeemable convertible preferred stock outstanding. No dividends have been declared
as of March&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company had reserved the following shares of common stock for future issuance as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Redeemable convertible preferred stock, as converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,289,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unissued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Options issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,749,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares available for future stock option grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">908,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104,948,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 9. Stock-Based Compensation Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company maintains the 2015 Stock Plan (the &#147;Plan&#148;) with the authorized shares of 17,450,000 as of March&nbsp;31, 2021. The Plan
provides for the issuance of options to purchase shares of common stock to officers, employees, directors, consultants and key persons who provide services to the Company. Stock options granted under the Plan may be either incentive stock options
(&#147;ISOs&#148;) or nonqualified stock options (&#147;NSOs&#148;). According to the Plan, stock options are exercisable in whole or in part and common stock is issued upon the option exercise. The Plan also allows for the grant of restricted stock
awards (&#147;RSAs&#148;). As of March&nbsp;31, 2021, the Company had 908,734 shares of common stock available for issuance under the Plan. Such issuances are subject to vesting, forfeiture and other restrictions as deemed appropriate by the Board
of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Options under the Plan may be granted for periods of up to 10 years. All options issued to date have a <FONT
STYLE="white-space:nowrap">10-year</FONT> contractual life. To date, options granted generally vest over four years and vest at a rate of 25% upon the first anniversary of the issuance date and
1/48<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> per month thereafter. The exercise price of an ISO and NSO shall not be less than 100% of the estimated fair value of the shares on the date of grant, respectively, as determined by the
Board of Directors. The exercise price of an ISO and NSO granted to a 10% shareholder shall not be less than 110% of the estimated fair value of the shares on the date of grant, respectively, as determined by the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Interim Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A summary of stock option activity is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Exercise</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Remaining</B><br><B>Contractual&nbsp;Life</B><br><B>(In years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B><br><B>(In<BR>thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Outstanding &#150; December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,093,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,094,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(434,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Outstanding &#150; March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,749,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Options outstanding and exercisable as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,749,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Options vested and expect to vest as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,749,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest is the
difference between the exercise price of the options and the estimated fair value of the Company&#146;s common stock for financial reporting purposes as of March&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The intrinsic value of options exercised during the three months ended March&nbsp;31, 2021 was $0.6&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the three months ended March&nbsp;31, 2021, the Company granted options with a weighted average grant date fair value of $1.08 per
share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s Board of Directors granted equity awards in the form of RSAs for certain of the Company&#146;s employees under
the Plan. In April 2016, the Company&#146;s Board of Directors approved equity awards in the form of RSAs outside of the Plan. The Company&#146;s outstanding RSAs began vesting one month after the grant date and vest 1/48<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> per month over four years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the Company&#146;s RSA
activity: </P>   <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Grant&nbsp;Date</B><br><B>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">RSAs, unvested at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">263,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(60,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">RSAs, unvested at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">702,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of RSAs vested during the three months ended March&nbsp;31, 2021 was $0.1&nbsp;million.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Interim Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(a)</I></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>Fair Value of Employee Stock Options </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of employee options is estimated at the grant date using the Black-Scholes option-pricing model with the following
weighted-average assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63.43</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58.89</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.78</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(b)</I></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>Stock-Based Compensation </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total stock-based compensation recorded in the condensed statements of operations and comprehensive loss
related to options and RSAs was as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of March&nbsp;31, 2021, there was approximately $6.2&nbsp;million of stock-based compensation expense
to be recognized over a weighted-average period of approximately 3.50 years. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(c)</I></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>Early Exercise of Stock Options </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Plan allows for the granting of options that may be exercised before the options have vested. Shares issued as a result of early exercise
that have not vested are subject to repurchase by the Company upon termination of the purchaser&#146;s employment or services, at the price paid by the purchaser. The Company&#146;s right to repurchase these shares generally lapses 1/48 of the
original grant date amount per month over four years. The proceeds initially are recorded in a liability for early exercised stock options and are reclassified to common stock and additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital as
the Company&#146;s repurchase right lapses. At March&nbsp;31, 2021, there were 655,054 shares of common stock outstanding, subject to the Company&#146;s right of repurchase at a weighted average exercise price of $0.42 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 10. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Indemnification </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time
to time, the Company enters into certain types of contracts that contingently require the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i)&nbsp;the Company&#146;s bylaws, under which the
Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship with the Company, (ii)&nbsp;contracts under which the Company must indemnify directors and
certain officers for liabilities arising out of their relationship with the Company, (iii)&nbsp;contracts under which the Company may be required to indemnify customers or partners against certain claims, including claims from third parties
asserting, among other things, infringement of their intellectual property rights and (iv)&nbsp;procurement, consulting, or license agreements under which the Company may be required to indemnify vendors, consultants or licensors for certain claims,
including claims that may be brought against them arising from acts or omissions with respect to the supplied products, technology or services. From time to time, the Company may receive indemnification claims under these contracts in the normal
course </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Interim Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of business. In addition, under these contracts the Company may have to modify the accused infringing intellectual property and/or refund amounts received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or
settlement, may cause a material adverse effect on the Company&#146;s future business, operating results or financial condition. It is not possible to determine the maximum potential amount under these contracts due to the limited history of prior
indemnification claims and the unique facts and circumstances involved in each particular agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company maintains director and
officer insurance, which may cover certain liabilities arising from the Company&#146;s obligation to indemnify its directors and certain officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the date the condensed interim financial statements were issued, the Company has not incurred any material costs or accrued any liabilities
in the condensed interim financial statements as a result of these provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Litigation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s industry is characterized by frequent claims and litigation, including claims regarding intellectual property. As a result,
the Company may be subject to various legal proceedings from time to time. The results of any future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of
defense and settlement costs, diversion of management resources and other factors. Management is not aware of any pending or threatened litigation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 11. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has completed an evaluation of all subsequent events through June&nbsp;24, 2021, the date the condensed interim financial
statements were issued, to ensure that these condensed interim financial statements include appropriate disclosure of events both recognized in the condensed interim financial statements and events that occurred but were not recognized in the
condensed interim financial statements. The Company is unaware of any specific event or circumstance that would require it to update its estimates, judgments or revise the carrying value of its assets or liabilities. These estimates may change, as
new events occur and as additional information related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and other information is obtained, the impact of which would be recognized in the condensed interim financial statements as soon
as such information becomes known. Actual results could differ from those estimates and any such differences may be material to the Company&#146;s condensed interim financial statements. Except as described below, the Company has concluded that no
subsequent event has occurred that requires disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April&nbsp;15, 2021, the Company entered into a business combination agreement
with <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp, a Cayman Islands exempted company (&#147;CHFW&#148;) and Perseverance Merger Sub Inc., a subsidiary of CHFW (&#147;Merger Sub&#148;). Upon closing of the business
combination, CHFW will become a Delaware corporation and will be renamed to Surrozen, Inc. (&#147;New Surrozen&#148;), and Merger Sub will merge with and into the Company, with the Company as the surviving company and, after giving effect to such
merger, continuing as a wholly-owned subsidiary of New Surrozen. Pursuant to the business combination agreement, the Company&#146;s outstanding equity shares and equity award (whether vested or unvested) as of closing will be exchanged for shares of
New Surrozen&#146;s common stock or comparable equity awards that are settled or are exercisable for shares of New Surrozen&#146;s common stock. Additionally, immediately after the consummation of the business combination, certain investors,
including certain of the Company&#146;s existing stockholders, committed to subscribe for and purchase an aggregate of 12,020,000 units, each consisting of one share of New Surrozen&#146;s common stock and
<FONT STYLE="white-space:nowrap">one-third</FONT> of one redeemable warrant for one share of New Surrozen&#146;s common stock, for a purchase price of $10.00 per unit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_7"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the Stockholders and the Board of Directors of Surrozen, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Opinion on the Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have audited the accompanying balance sheets of Surrozen, Inc. (the Company) as of December&nbsp;31, 2020 and 2019, the related statements
of operations, redeemable convertible preferred stock and stockholders&#146; deficit and cash flows for the years then ended, and the related notes (collectively referred to as &#147;the financial statements&#148;). In our opinion, the financial
statements present fairly, in all material respects, the financial position of the Company at December&nbsp;31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted
accounting principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>The Company&#146;s Ability to Continue as a Going Concern </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to
the financial statements, the Company has suffered recurring losses from operations and has stated that substantial doubt exists about the Company&#146;s ability to continue as a going concern. Management&#146;s evaluation of the events and
conditions and management&#146;s plans regarding these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These
financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange
Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards
generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test
basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
financial statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Ernst &amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have served as the Company&#146;s auditor since 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Redwood City, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">April
30, 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_8"></A>Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Liabilities, redeemable convertible preferred stock and stockholders&#146;
deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lease liabilities, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lease liabilities, noncurrent portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Commitments and contingencies (Note 6 and Note 11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Redeemable convertible preferred stock, $0.0001 par value; 95,289,938 and
68,555,555&nbsp;shares authorized as of December&nbsp;31, 2020 and 2019, respectively; 95,289,932 and 66,718,509 shares issued and outstanding as of December&nbsp;31, 2020 and 2019, respectively; liquidation preference of $133,300 and $83,300 as of
December&nbsp;31, 2020 and 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Common stock, $0.0001 par value, 120,000,000 and 85,888,000 shares authorized as
of December&nbsp;31, 2020 and 2019, respectively; 8,648,718 and 8,178,290 shares issued and outstanding as of December&nbsp;31, 2020 and 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additional
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,001</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,285</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(85,804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total liabilities, redeemable convertible preferred stock and stockholders&#146;
deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_9"></A>Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,807</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,362</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net loss per share attributable to common stockholders, basic and diluted</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4.42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Weighted-average shares used in computing net loss per share attributable to
common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,394,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,899,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_10"></A>Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable&nbsp;convertible<BR>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>stockholders&#146;<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Balance at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,470,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,938,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,923</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Issuance of Series B redeemable convertible preferred stock, net of issuance
costs of $16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,248,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Exercises of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">337,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Reclassification to liability for early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Vesting of early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Repurchase of early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(98,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,362</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,362</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,718,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,178,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,285</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Issuance of Series C redeemable convertible preferred stock, net of issuance
costs of&nbsp;$114</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,571,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Exercises of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">407,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Reclassification to liability for early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Vesting of early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Repurchase of early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,938</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Restricted stock granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Restricted stock forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman" ALIGN="justify">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,289,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,648,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,001</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(85,804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_11"></A>Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,362</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Adjustments to reconcile net loss to net cash used in operating
activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Amortization of premium on investment securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,311</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,056</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Purchases of investment securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,201</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Proceeds from issuance of redeemable convertible preferred stock, net of issuance
costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Repurchases of early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net increase in cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash and cash equivalents and restricted cash at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash and cash equivalents and restricted cash at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Supplemental disclosure of noncash investing and financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Capital expenditures in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Vesting of early exercises of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Reclassification to liability for early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> asset
obtained in exchange for operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table presents a reconciliation of the Company&#146;s cash, cash equivalents and restricted cash
by category in the Company&#146;s balance sheets: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin40894_12"></A>Notes to the Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 1. Organization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Description of Business </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen, Inc. (the &#147;Company&#148;) is a preclinical stage biotechnology company committed to discovering and developing drug candidates
to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The Company is located in South San Francisco, California and was incorporated in the state of Delaware on August&nbsp;12, 2015.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Liquidity, Capital Resources and Going Concern </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has incurred net operating losses each year since inception. During the year ended December&nbsp;31, 2020, the Company incurred a
net loss of $32.7&nbsp;million and used $29.1&nbsp;million of cash in operations. As of December&nbsp;31, 2020, the Company had an accumulated deficit of approximately $88.0&nbsp;million. The Company expects operating losses to continue in the
foreseeable future because of additional costs and expenses related to the research and development activities. To date, the Company has been able to fund its operations through private placements of redeemable convertible preferred stock. As of
December&nbsp;31, 2020, the Company had cash and cash equivalents of $35.0&nbsp;million and short-term investments of $14.2&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Management does not believe that the existing financial resources are sufficient for the Company to continue operating activities and
therefore has concluded that substantial doubt exists about the Company&#146;s ability to continue as a going concern within 12 months from the date of issuance of its financial statements. The accompanying financial statements have been prepared
assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The accompanying financial statements do not reflect any
adjustments relating to the recoverability and reclassifications of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. Insufficient liquidity may require the Company to relinquish rights to
product candidates at an earlier stage of development or on less favorable terms than the Company would otherwise choose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company
plans to continue to fund its operations through public or private equity financings, debt financings or other capital sources, including government grants, potential collaborations with other companies or other strategic transactions. The
Company&#146;s ultimate success depends on the outcome of its research and development activities. Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending could have a material adverse
effect on the Company&#146;s ability to achieve its intended business objectives. These factors would have a material adverse effect on the Company&#146;s future financial results, financial position and cash flows. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Risks and Uncertainties </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#146;s
future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#146;s
potential drug candidates, uncertainty of market acceptance of the Company&#146;s products, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key
individuals and sole source suppliers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Products developed by the Company require clearances from the U.S. Food and Drug Administration or
other international regulatory agencies prior to commercial sales. There can be no assurance that the products will receive the necessary clearances. If the Company was denied clearance, clearance was delayed or the Company was unable to maintain
clearance, it could have a materially adverse impact on the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s business has been and could continue to be adversely affected by the
evolving Coronavirus Disease 2019 <FONT STYLE="white-space:nowrap">(COVID-19)</FONT> pandemic. For example, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has resulted in and could result in delays to the Company&#146;s preclinical
studies of its product pipeline. At this time, the extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacts the Company&#146;s business will depend on future developments, which are highly uncertain and cannot be
predicted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The financial statements and accompanying notes have been prepared in accordance with generally accepted accounting principles in the United
States of America (&#147;U.S. GAAP&#148;) as determined by the Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) and pursuant to the regulations of the U.S. Securities and Exchange Commission
(&#147;SEC&#148;). The financial statements and accompanying notes include all adjustments necessary for the fair presentation of the Company&#146;s financial position, results of operations and cash flows for the periods presented. The Company has
no subsidiaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Use of Estimates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and
assumptions made in the accompanying financial statements include, but are not limited to, certain accruals for research and development activities, the fair value of common stock, redeemable convertible preferred stock tranche rights liabilities,
stock-based compensation expense, uncertain tax positions and lease liabilities. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that are believed to be reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could materially differ from those estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Segment Reporting </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed
by the Chief Operating Decision Maker (&#147;CODM&#148;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#146;s CODM is its Chief Executive Officer. The Company has determined that it operates
in one segment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Fair Value Measurement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ASC 820, <I>Fair Value Measurement</I>, or Topic 820, establishes a fair value hierarchy for instruments measured at fair value that
distinguishes between assumptions based on market data (observable inputs) and the Company&#146;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on
market data obtained from independent sources. Unobservable inputs are inputs that reflect the Company&#146;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best
information available in the circumstances. Topic 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. As a
basis for considering market participant assumptions in fair value measurements, Topic 820 establishes a three-tiered value hierarchy that distinguishes between the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Level 1&#151;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Level 2&#151;Inputs (other than quoted prices included in Level&nbsp;1) are either directly
or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Level 3&#151;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or
liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the
determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&nbsp;3. A financial instrument&#146;s level within the fair
value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Cash and Cash Equivalents
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash equivalents relate to securities having an original maturity of three months or less at the time of purchase. The Company limits
its credit risk associated with cash and cash equivalents by placing its investments with a bank it believes is highly creditworthy, with highly rated money market funds and commercial paper. As of December&nbsp;31, 2020 and 2019, cash and cash
equivalents consisted of bank deposits, investments in money market funds and commercial paper. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Restricted Cash </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of both December&nbsp;31, 2020 and 2019, the Company had $0.4&nbsp;million of restricted cash. The restricted cash serves as collateral for
facility leases entered into in 2016 (Note 5). Restricted cash is classified as current if the collateral will be returned in less than 12 months. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Concentration of Credit Risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist of cash and cash equivalents
and short-term investments. The Company is exposed to credit risk in the event of default to the extent recorded in the balance sheets. The Company has not experienced any losses in such accounts. Management believes that the Company is not exposed
to significant credit risk due to the financial position of the depository institution in which its bank deposits are held. To manage credit risks related to short-term investments, the Company invests in various highly rated corporate debt and
commercial paper securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Short-term Investments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has investments in marketable securities. The Company&#146;s investment policy is consistent with the definition of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities. The Company does not buy or hold securities principally for the purpose of selling them in the near future. The Company&#146;s policy is focused
on the preservation of capital, liquidity, and return. From time to time, the Company may sell certain securities, but the objectives are generally not to generate profits on short-term differences in price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These marketable securities are carried at estimated fair value with unrealized holding gains and losses included in other comprehensive
income (loss) in stockholders&#146; deficit until realized. Gains and losses on marketable security transactions are reported on the specific-identification method. Dividend and interest income are recognized in other income on the statements of
operations when earned. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company early adopted Accounting Standards Update (ASU)
<FONT STYLE="white-space:nowrap">No.&nbsp;2016-13,</FONT> <I>Financial Instruments&#151;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</I>, on January&nbsp;1, 2020 and applied the new modified credit impairment
guidance related to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities prospectively. Under the new guidance, at each reporting date, entities must evaluate their individual <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities that are in an unrealized loss position and determine whether the decline in fair value below the amortized cost basis is from a credit loss
or other factors. The amount of the decline related to credit losses is recorded as a credit loss expense in earnings with a corresponding allowance for credit losses and the amount of decline not related to credit losses is recorded through other
comprehensive income (loss), net of tax. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Property and Equipment </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Property and equipment, including leasehold improvements, are recorded at cost net of accumulated depreciation. Property and equipment are
depreciated using the straight-line method over the estimated useful lives of the assets as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Shorter&nbsp;of&nbsp;useful&nbsp;life&nbsp;of&nbsp;asset&nbsp;or&nbsp;lease&nbsp;term</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3 years</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furniture, fixtures and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">3-8</FONT> years</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3 years</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed
from the balance sheet and the resulting gain or loss is reflected in operations in the period realized. Maintenance and repairs are charged to operations as incurred. The leasehold improvements are any additions, alterations, or remodeling on the
Company&#146;s leased premise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Leases </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for its leases under ASC 842, <I>Leases</I>. Under this guidance, the Company determines if an arrangement is or contains
a lease at inception. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets, or ROU assets, represent the Company&#146;s right to use an underlying asset for the lease term and lease liabilities
represent the Company&#146;s obligation to make lease payments arising from the lease. The classification of the Company&#146;s leases as operating or finance leases along with the initial measurement and recognition of the associated ROU assets and
lease liabilities is performed at the lease commencement date. The measurement of lease liabilities is based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate, based on the information
available at the commencement date, to determine the present value of lease payments when its leases do not provide an implicit rate. The Company uses the implicit rate when readily determinable. The ROU asset is based on the measurement of the
lease liability and is adjusted for lease incentives provided by the landlord. Lease expense for the Company&#146;s operating leases is recognized on a straight-line basis over the lease term. The Company considers a lease term to be the <FONT
STYLE="white-space:nowrap">non-cancelable</FONT> period that it has the right to use the underlying asset, including any periods where it is reasonably certain the Company will exercise the option to extend or not terminate the contract. Periods
covered by an option to extend or not terminate the contract are included in the lease term if the lessor controls the exercise of that option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s lease agreement includes lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components, and the Company has
elected to separate lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components. Further, the Company elected the short-term lease exception policy, permitting it to not apply the recognition requirements of this standard to leases with
terms of 12 months or less (short-term leases) for all classes of assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Impairment of Long-Lived Assets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset
may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is
measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. The Company has not identified any such impairment losses to date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development costs are expensed as incurred. Research and development costs consist of external and internal expenses directly
attributable to the conduct of research and development programs. The external expenses include the cost of services provided by outside contractors, clinical research organizations and contract manufacturing organizations. The internal expenses
include the cost of salaries, payroll taxes, stock-based compensation, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, and the facility costs for laboratory space used for research and development
activities, such as rent, utilities, insurance, repairs and maintenance, and general support services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has entered into and
may continue to enter into licensing or subscription arrangements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the
Company&#146;s license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the
definition of a derivative, are immediately recognized as research and development expense when they are paid or become payable, provided there is no alternative future use of the rights in other research and development projects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Accrued Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company records accruals for estimated costs of research, preclinical, and manufacturing development, which are significant components of
research and development expenses, within accrued expenses in the accompanying balance sheets. A substantial portion of the Company&#146;s ongoing research and development activities is conducted by third-party service providers. The Company accrues
the costs incurred under agreements with these third parties based on estimates of actual work completed in accordance with the respective agreements. The Company determines the estimated costs through discussions with internal personnel and
external service providers as to the progress, or stage of completion or actual timeline (start-date and <FONT STYLE="white-space:nowrap">end-date)</FONT> of the services and the agreed-upon fees to be paid for such services. Payments made to third
parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered. For the years ended December&nbsp;31, 2020 and 2019, the Company has not
experienced any material differences between accrued costs and actual costs incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the actual timing of the performance of services
or the level of effort varies from the estimate, the Company adjusts accrued expenses or prepaid expenses accordingly, which impact research and development expenses. Although the Company does not expect its estimates to be materially different from
amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular
period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Redeemable Convertible Preferred Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has classified redeemable convertible preferred stock as temporary equity on the accompanying balance sheets because it may become
redeemable due to certain change in control clauses that are outside of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Company&#146;s control. The carrying value of the redeemable convertible preferred stock has not been accreted to their redemption value as these events are not considered probable of occurrence.
Subsequent adjustments of the carrying values to redemption values will be made only if and when it becomes probable redemption will occur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Stock-Based Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has an equity incentive plan under which various types of equity-based awards including, but not limited to, incentive stock
options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, and restricted stock awards, may be granted to employees, directors, and consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company recognizes stock-based compensation expense for all stock-based payments. Employee stock-based compensation cost is estimated at
the grant date based on the fair value of the equity for financial reporting purposes and is recognized as expense over the requisite service period. Fair value of common stock for financial reporting purposes is determined considering numerous
objective and subjective factors and requires judgment. These objective and subjective factors include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">relevant precedent transactions involving the Company&#146;s capital stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">contemporaneous valuations performed by third-party specialists; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rights, preferences, and privileges of the Company&#146;s redeemable convertible preferred stock relative to
those of the Company&#146;s common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual operating and financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">current business conditions and financial projections; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">likelihood of achieving a liquidity event, such as an initial public offering or a sale of the Company&#146;s
business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of marketability of the Company&#146;s common stock, and the illiquidity of stock-based awards
involving securities in a private company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market multiples of comparable publicly traded companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stage of development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">industry information such as market size and growth; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. and global capital and macroeconomic conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has elected to calculate the fair value of options based on the Black Scholes option pricing model. The Black Scholes model
requires the use of various assumptions including common stock valuation, expected option life and expected stock price volatility. The Company estimates the expected term for stock options using the simplified method due to the lack of historical
exercise activity. The simplified method calculates the expected term as the midpoint between the vesting date and the contractual expiration date of the award. The Company estimates the options&#146; volatility using volatilities of a group of
public companies in a comparable industry, stage of life cycle, and size. The interest rate is derived from the U.S. Treasury instruments with maturities similar to the expected term of the Company&#146;s stock options. The Company has not declared
nor expects to declare dividends. Therefore, there is no dividend impact on the valuation of options. The Company is using the straight-line method for employee expense attribution for stock options. The Company accounts for forfeitures as they
occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to the adoption of ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07</FONT> on January&nbsp;1, 2020, options and other
equity awards granted to <FONT STYLE="white-space:nowrap">non-employees</FONT> were subject to periodic remeasurement over the period during which services were rendered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
The Company remeasured the fair value of these <FONT STYLE="white-space:nowrap">non-employee</FONT> awards at each reporting period prior to vesting and finally at the vesting date of the award.
Subsequent to the adoption of ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> the Company recognizes <FONT STYLE="white-space:nowrap">non-employee</FONT> compensation costs over the requisite service period based on a measurement of
fair value on the date of grant of each stock award. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Comprehensive Income (Loss) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s comprehensive income or loss consists of net income or loss and other comprehensive income (loss). Unrealized gains or
losses on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities are included in the Company&#146;s other comprehensive income or loss. As of December&nbsp;31, 2020, the Company&#146;s
unrealized gain (loss) on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-</FONT></FONT> sale securities was de minimis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Net Loss Per Share </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic
net loss per share is calculated using the <FONT STYLE="white-space:nowrap">two-class</FONT> method under which earnings are allocated to both common shares and participating securities. Undistributed net losses are allocated entirely to common
shareholders since the participating security has no contractual obligation to share in the losses. Basic net loss per share is calculated by dividing the net loss attributable to common shares by the weighted-average number of shares of common
stock outstanding for the period, without consideration for potential dilutive securities. Shares of common stock subject to repurchase are excluded from the weighted-average shares. Diluted net loss per share is computed by dividing the net loss by
the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Since the Company was in a loss position for the periods presented, basic net loss per share is the same as diluted net
loss per share since the effects of potentially dilutive securities are antidilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table presents the potential common
shares outstanding that were excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been antidilutive: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,289,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,718,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Options outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,093,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,091,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unvested RSAs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">263,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">460,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unvested common stock subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">590,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">839,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,237,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,109,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Income Taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are
determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates expected to be in effect for the year in which the differences are expected to reverse. Valuation
allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company
assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position
begins with the initial determination of the position&#146;s sustainability and is measured at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the largest amount of benefit that is more likely than not of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and
the Company will determine whether (i)&nbsp;the factors underlying the sustainability assertion have changed and (ii)&nbsp;the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits require
significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax
expense or benefit. To date, there have been no interest or penalties charged in relation to unrecognized tax benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Emerging
Growth Company Status </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the
JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected
to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&nbsp;no longer an emerging growth
company or (ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting
pronouncements as of public company effective dates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Recently Adopted Accounting Pronouncements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-13,</FONT> <I>Financial Instruments&#151;Credit Losses (Topic
326): Measurement of Credit Losses on Financial Instruments</I>. This update will require the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and
reasonable and supportable forecasts. Financial institutions and other organizations will now include forward-looking information in the determination of their credit loss estimates. Many of the loss estimation techniques applied today will still be
permitted, although the inputs to those techniques will change to reflect the full amount of expected credit losses. In addition, this update amends the accounting for credit losses on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities and purchased financial assets with credit deterioration. The Company early adopted this standard as of January&nbsp;1, 2020, with no
impact upon adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Compensation-Stock
Compensation (Topic 718)</I>: <I>Improvements to <FONT STYLE="white-space:nowrap">Non-employee</FONT> Share-Based Payment Accounting</I>. ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07</FONT> simplifies the accounting for stock-based payments
to <FONT STYLE="white-space:nowrap">non-employees</FONT> by aligning it with the accounting for stock-based payments to employees, with certain exceptions. The Company adopted this guidance as of January&nbsp;1, 2020, with an immaterial impact upon
adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13,</FONT> <I>Fair Value Measurement (Topic
820): Disclosure Framework&#151;Changes to the Disclosure Requirements for Fair Value Measurement</I>, which removes, modifies and adds various disclosure requirements on fair value measurements in Topic 820. The Company adopted this guidance as of
January&nbsp;1, 2020, with no impact upon adoption. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Recently Issued Accounting Pronouncements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-12,</FONT> <I>Income Taxes (Topic 740): Simplifying the
Accounting for Income Taxes</I>, which amends the existing guidance relating to the accounting for income taxes. This standard </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
is intended to simplify the accounting for income taxes by removing certain exceptions to the general principles of accounting for income taxes and to improve the consistent application of U.S.
GAAP for other areas of accounting for income taxes by clarifying and amending existing guidance. The standard is effective for public business entities for fiscal years beginning after December&nbsp;15, 2020 and interim periods within those fiscal
years. The standard is effective for entities other than public business entities for fiscal years beginning after December&nbsp;15, 2021. Early adoption is permitted. The Company does not expect a material impact on its financial statements from
adopting this update. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 3. Fair Value </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables summarize the Company&#146;s financial assets and liabilities that are measured at fair value on a recurring basis (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Money market
funds<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Corporate bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Commercial paper<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total financial assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Money market
funds<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total financial assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(1)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Money market funds are included in cash and cash equivalents on the balance sheets as of December&nbsp;31,
2020 and 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(2)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Marketable securities with original maturities of three months or less, in the amount of $2.2&nbsp;million,
are included in cash and cash equivalents on the balance sheet as of December&nbsp;31, 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There have been no changes
to the valuation methods utilized during the year ended December&nbsp;31, 2020. The Company&#146;s financial instruments include cash and cash equivalents, short-term investments, accounts payable, accrued liabilities, and redeemable convertible
preferred stock tranche rights liabilities. The carrying amount of cash and cash equivalents, accounts payable, and accrued liabilities approximate their fair values due to their short-term maturities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Investments in corporate bonds and commercial paper are classified as Level&nbsp;2 as they were valued based upon quoted market prices for
similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by
observable market data for substantially the full term of the assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The redeemable convertible preferred stock tranche rights
liabilities were initially recorded at fair value and remeasured at each reporting period and upon the exercise or expiration of the right. The redeemable convertible preferred stock tranche rights were exercised during 2019 and remeasured and
reclassified to redeemable convertible preferred stock. The initial valuation of the redeemable convertible preferred stock tranche rights was determined using Level&nbsp;3 unobservable inputs, and its subsequent remeasurement was not significant.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table provides the Company&#146;s marketable securities by security type (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Corporate bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2020, $2.2&nbsp;million of marketable securities are included in cash and cash
equivalents and $14.2&nbsp;million are included in short-term investments. As of December&nbsp;31, 2020, all marketable securities had maturities of one year or less. As of December&nbsp;31, 2020, one investment of $1.1&nbsp;million was in an
unrealized loss position, with an unrealized loss of less than $1,000. This investment has not been in a continuous unrealized loss position for more than twelve months. The Company determined that the unrealized loss was not attributed to credit
risk but was primarily associated with changes in interest rates. The Company does not intend to sell the investment that is in an unrealized loss position, nor is it more likely than not that the Company will be required to sell the investment
before the recovery of the amortized cost basis, which may be its maturity. Accordingly, the Company did not record an allowance for credit losses associated with this investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company did not hold marketable securities as of December&nbsp;31, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 4. Balance Sheet Components </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Property and Equipment, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Property and equipment, net, consists of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furniture and office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Less accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,747</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,810</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Depreciation expense for the years ended December&nbsp;31, 2020 and 2019 was $1.9&nbsp;million and
$2.3&nbsp;million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Accrued Liabilities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued liabilities consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Payroll and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Liability for early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 5. Leases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2016, the Company entered into a lease agreement for office space, which consists of approximately 32,813 square feet of rental space
in South San Francisco, California. The office space lease is classified as an operating lease. The initial lease term commenced in May 2017 and ends in April 2025, with rent payments escalating each year. The Company has options to extend the lease
for additional years, but the exercise of the option was not reasonably certain. The landlord provided the Company with a tenant improvement allowance of up to $4.6&nbsp;million. In connection with the lease, the Company maintains a letter of credit
for the benefit of the landlord in the amount of $0.4&nbsp;million, which is recorded as restricted cash on the balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
January 2020, the Company entered into a new lease agreement for a term of 18 months for approximately 6,478 square feet of space. The new office space lease is classified as an operating lease. The new lease commenced in June 2020 and rent payments
escalate after 14 months. The Company has the option to terminate the lease after six months, but the exercise of the option was not reasonably certain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with its operating leases, the Company has operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets of $5.6&nbsp;million and $6.0&nbsp;million as of December&nbsp;31, 2020 and 2019, respectively, and aggregate lease liabilities of $9.6&nbsp;million
and $10.7&nbsp;million, respectively, on its balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating lease expense during the years ended December&nbsp;31, 2020 and
2019 was $1.8&nbsp;million and $1.6&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Aggregate future minimum rental payments under operating leases as of
December&nbsp;31, 2020, were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Year ending December 31:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Less: Imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,808</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following represents supplemental information related to the Company&#146;s operating
leases: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash paid for amounts included in the measurement of lease <BR>liabilities (in
thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Weighted-average remaining lease term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Weighted-average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company subleased a small portion of the office space leased above. The sublease ended in 2019. Sublease
income for the year ended December&nbsp;31, 2019 was $0.3&nbsp;million, recorded under other income in the statement of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 6. License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Stanford License Agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2016, the Company entered into a license agreement with Stanford, or the 2016 Stanford Agreement, which was amended in July 2016,
October 2016 and January 2021, pursuant to which the Company obtained from Stanford, a worldwide, exclusive, sublicensable license under certain patents, rights, or licensed patents and technology related to its engineered Wnt surrogate molecules to
make, use, import, offer to sell and sell products that are claimed by the licensed patents or that use or incorporate such technology, or licensed products, for the treatment, diagnosis and prevention of human and veterinary diseases. In
consideration for this license, the Company paid Stanford a nominal upfront fee and issued an aggregate of 241,688 shares of common stock to Stanford, the University of Washington and two <FONT STYLE="white-space:nowrap">co-inventors</FONT> of the
licensed patents. In addition, the Company agreed to pay Stanford nominal annual license maintenance fees which are creditable against earned royalties owed to Stanford for the same year, an aggregate of up to $1.4&nbsp;million for the achievement
of specified development and regulatory milestones, and an aggregate of up to $5.0&nbsp;million for achievement of specified sales milestones. Stanford is also entitled to receive royalties from us equal to a very low single digit percentage of the
Company&#146;s and its sublicensees&#146; net sales of licensed products that are covered by a valid claim of a licensed patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, the Company agreed to pay Stanford a <FONT STYLE="white-space:nowrap">sub-teen</FONT> double digit percentage of certain
consideration the Company receives as a result of granting sublicenses to the licensed patents and, if the Company acquired, a onetime change of control fee in the low six figures. Stanford retains the right under the 2016 Stanford Agreement, on
behalf of itself, Stanford Hospital and Clinics, the University of Washington and all other <FONT STYLE="white-space:nowrap">non-profit</FONT> research institutions, to practice the licensed patents and technology for any <FONT
STYLE="white-space:nowrap">non-profit</FONT> purpose. The licensed patents and technology are additionally subject to a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> irrevocable, worldwide license held by the Howard Hughes Medical Institute
to practice the licensed patents and technology for its research purposes, but with no right to assign or sublicense. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2018,
the Company entered into another license agreement with Stanford, or the 2018 Stanford Agreement, pursuant to which the Company obtained from Stanford, a worldwide, exclusive, sublicensable license under certain patent rights related to its
surrogate R-spondin proteins, or the licensed patents, to make, use, import, offer to sell and sell products that are claimed by the licensed patents, or licensed products, for the treatment, diagnosis and prevention of human and veterinary
diseases, or the exclusive field. Additionally, Stanford granted the Company a worldwide, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> sublicensable license under the licensed patents to make and use licensed products for research and
development purposes in furtherance of the exclusive field and a worldwide, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to make, use and import, but not to offer to sell or sell, licensed products in any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
other field of use. In consideration of these licenses, the Company paid Stanford a nominal upfront fee. The Company also agreed to pay Stanford nominal annual license maintenance fees which are
creditable against earned royalties owed to Stanford for the same year, and an aggregate of up to $0.425&nbsp;million for the achievement of specified development and regulatory milestones. Stanford is also entitled to receive royalties from the
Company equal to a <FONT STYLE="white-space:nowrap">sub-single</FONT> digit percentage of the Company&#146;s and its sublicensees&#146; net sales of licensed products. Additionally, the Company agreed to pay Stanford a
<FONT STYLE="white-space:nowrap">one-time</FONT> payment in the low six figures for each sublicense of the licensed patents that the Company grants to a third party and, if the Company is acquired, a onetime nominal change of control fee. Stanford
retains the right under the 2018 Stanford Agreement, on behalf of itself, Stanford Health Care, Lucile Packard Children&#146;s Hospital at Stanford and all other <FONT STYLE="white-space:nowrap">non-profit</FONT> research institutions, to practice
the licensed patents for any <FONT STYLE="white-space:nowrap">non-profit</FONT> purpose. The licensed patents are additionally subject to a nonexclusive, irrevocable, worldwide license held by the Howard Hughes Medical Institute to exercise any
intellectual property rights with respect to the licensed patents for research purposes, including the right to sublicense to <FONT STYLE="white-space:nowrap">non-profit</FONT> and governmental entities but with no other rights to assign or
sublicense. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under each of the 2016 Stanford Agreement and the 2018 Stanford Agreement, or Stanford Agreements, the Company agreed to
use commercially reasonable efforts to develop and commercialize licensed products and the Company agreed to achieve certain funding and development milestones by certain dates. Unless earlier terminated, each Stanford Agreement will continue until
the expiration of the patents licensed under such Stanford Agreement. The Company may terminate either Stanford Agreement at any time for any reason by providing at least 30 days&#146; written notice to Stanford. Stanford may terminate either
Stanford Agreement if the Company breaches certain provisions of that Stanford Agreement and fail to remedy such breach within 90 days after written notice of the breach by Stanford. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the years ended December&nbsp;31, 2020 and 2019, the Company paid de minimis research and development expenses related to the Stanford
Agreements. No milestone payments or earned royalties were paid by the Company to Stanford during the fiscal years ended December&nbsp;31, 2020 and 2019 or were due as of such date pursuant to the Stanford Agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>UCSF License and Option Agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September and October 2016, the Company entered into two separate license and option agreements with The Regents of the University of
California, or UCSF, pursuant to which the Company obtained <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses from UCSF for internal research and antibody discovery purposes and an option to negotiate with UCSF to obtain a <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> license under UCSF&#146;s rights in the applicable library to make, use, sell, offer for sale and import products incorporating antibodies identified or resulting from the Company&#146;s use of such
library, or licensed products. In consideration of the license and option rights under the UCSF Agreement, the Company paid UCSF a nominal option issue fee and agreed to pay UCSF a nominal annual option maintenance fee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2020, the Company amended and restated its license and option agreements with UCSF, or UCSF Agreement, to provide <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> licenses to make and use a certain human Fab naive phage display library and to make and use a certain phage display llama VHH single domain antibody library for internal research and antibody
discovery purposes and an option to negotiate with UCSF to obtain a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under UCSF&#146;s rights in the applicable library to make, use, sell, offer for sale and import products incorporating
antibodies identified or resulting from the Company&#146;s use of such library, or licensed products. If the Company exercises the option under the UCSF Agreement, the Company and UCSF will negotiate in good faith the terms of a commercial license
agreement in addition to the <FONT STYLE="white-space:nowrap">pre-agreed</FONT> terms which include payment to UCSF of a nominal license issue fee, nominal annual license maintenance fees, nominal to low six figure milestone payments for the
achievement of a specified regulatory milestone event for each licensed product, nominal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
annual minimum royalties, which are creditable against earned royalties for the same year, and earned royalties equal to a <FONT STYLE="white-space:nowrap">sub-single</FONT> digit percentage of
the Company&#146;s and the Company&#146;s sublicensees&#146; net sales of licensed products. As of December&nbsp;31, 2020, the Company has not exercised the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For both the years ended December&nbsp;31, 2020 and 2019, the Company paid $0.1&nbsp;million for research and development expenses related to
the UCSF agreements. No milestone payments or earned royalties were paid by the Company to UCSF during the fiscal years ended December&nbsp;31, 2020 and 2019 or were due as of such date pursuant to the UCSF agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless earlier terminated, the UCSF Agreement will continue until four years from its effective date, and the Company may exercise the option
to negotiate a commercial license at any time during that term. Additionally, the Company may extend the UCSF Agreement for any additional four years by paying UCSF a nominal term extension fee. The Company may terminate the UCSF Agreement at any
time for any reason by providing at least 60 days&#146; written notice to UCSF. UCSF may terminate the UCSF Agreement if UCSF reasonably believes the Company is in material breach of the UCSF Agreement and the Company fails to remedy such breach
within 60 days after written notice of such breach by UCSF. Additionally, the UCSF Agreement will automatically terminate in the event of the Company&#146;s bankruptcy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Distributed Bio Subscription Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September 2016, the Company entered into, and in January 2019 the Company amended, an antibody library subscription agreement with
Distributed Bio, or the Distributed Bio Agreement, in which the Company obtained from Distributed Bio a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to use Distributed Bio&#146;s antibody library to identify antibodies directed to
an unlimited number of the Company&#146;s proprietary targets and to make, use, sell, offer for sale, import and exploit products incorporating the antibodies that the Company identifies, or licensed products. In consideration for the rights granted
to the Company under the Distributed Bio Agreement, the Company paid Distributed Bio a nominal upfront fee and an additional nominal fee upon entering into the amendment. The Company agreed to pay Distributed Bio an annual fee in the low six figures
after the first three years. Additionally, the Company agreed to pay Distributed Bio an aggregate of $5.9&nbsp;million for each licensed product that achieves specified development, regulatory and commercial milestones and royalties equal to a very
low single digit percentage of the Company&#146;s and its sublicensees&#146; net sales of licensed products. The Company&#146;s obligation to pay royalties will end for each licensed product ten years after its first commercial sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the years ended December&nbsp;31, 2020 and 2019, the Company incurred $0.2&nbsp;million and $0.3&nbsp;million, respectively, related to
the Distributed Bio Agreement. No milestone payments or earned royalties were paid by the Company to Distributed Bio during the fiscal years ended December&nbsp;31, 2020 and 2019 or were due as of such date pursuant to the Subscription Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless earlier terminated, the Distributed Bio Agreement will continue for an initial four-year term and will thereafter automatically
renew for additional <FONT STYLE="white-space:nowrap">one-year</FONT> terms. The Company may terminate the Distributed Bio Agreement for convenience at any time by providing written notice to Distributed Bio. The Company and Distributed Bio may
terminate the Distributed Bio Agreement for the other party&#146;s material breach and failure to cure such breach within 60 days after notice of such breach. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 7. Redeemable Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the redeemable convertible preferred stock: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Original&nbsp;Issue&nbsp;Price</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Liquidation&nbsp;Preference<BR>(in thousands)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issued</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,555,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,555,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,162,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,162,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,571,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,571,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">95,289,938</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">95,289,932</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">$133,300</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Original Issue Price</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Liquidation&nbsp;Preference<BR>(in thousands)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issued</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,555,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,555,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,162,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">68,555,555</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">66,718,509</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">$83,300</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From April 2016 to January 2018, the Company issued and sold an aggregate of 33,555,555 shares of
Series&nbsp;A redeemable convertible preferred stock at a purchase price of $1.00 per share for aggregate proceeds of approximately $33.5&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From October 2018 to September 2019, the Company issued and sold an aggregate of 33,162,954 shares of Series B redeemable convertible
preferred stock at a purchase price of $1.50 per share for aggregate proceeds of approximately $49.7&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2020, the
Company issued 28,571,429 shares of Series C redeemable convertible preferred stock at a purchase price of $1.75 per share for aggregate proceeds of approximately $50.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with the Series B redeemable convertible preferred stock purchase agreements, the holders of Series B redeemable convertible
preferred stock had the right to participate in the future purchases of Series B redeemable convertible preferred stock, but did not have an obligation to invest in the second tranche. The Company&#146;s Amended and Restated Certificate of
Incorporation also included a special mandatory conversion feature whereby if an investor decided not to participate in the second tranche closing, each share of Series B preferred stock then held by such investor would have automatically converted
into 1/10th of a fully-paid, nonassessable share of common stock. The underlying shares of the future tranche rights were not puttable by the holder or mandatorily redeemable. In addition, the tranche rights to participate in the future tranche
closing involved the issuance of a fixed number of shares at a fixed price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determined that the future rights to participate
in the second tranche closing of Series B redeemable convertible preferred stock was a freestanding financial instrument as it met the criteria for being legally detachable and separately exercisable. In 2019, the Series B redeemable convertible
preferred stock tranche right was exercised, remeasured and classified to redeemable convertible preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The rights, preferences and privileges of the Series A, Series B and Series C redeemable
convertible preferred stock (together, the &#147;Redeemable Convertible Preferred Stock&#148;) are as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(a)</I></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>Dividend Rights </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Through December&nbsp;31, 2020, no dividends have been declared, authorized, or paid. From and after the date of issuance of the shares of
Redeemable Convertible Preferred Stock, the holders of the outstanding shares of Series A, Series B and Series C redeemable convertible preferred stock are entitled to receive, when and if declared by the Board of Directors, and prior and in
preference to dividends on the Company&#146;s common stock, a noncumulative cash dividend at the rate of $0.12, $0.08, and $0.14, respectively, per share per annum. The preferred stockholders also participate in any additional dividends on an <FONT
STYLE="white-space:nowrap">as-if</FONT> converted basis with common stockholders. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(b)</I></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>Redemption Rights </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Redeemable Convertible Preferred Stock is not redeemable as of December&nbsp;31, 2020. Upon certain change in control events that are
outside of the Company&#146;s control, including liquidation, sale or transfer of control of the Company, the Redeemable Convertible Preferred Stock is contingently redeemable. As such, the Redeemable Convertible Preferred Stock is classified as
temporary equity. The redemption price of the Redeemable Convertible Preferred Stock is equal to their respective original issue price per share plus any declared but unpaid dividends. Any discount to liquidation preference of the Redeemable
Convertible Preferred Stock is not being accreted as a deemed dividend, as it not currently probable that the Redeemable Convertible Preferred Stock will become redeemable. Subsequent adjustments to increase the carrying values to the ultimate
redemption values will be made only when it becomes probable that such a liquidation event will occur. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(c)</I></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>Conversion Rights </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each share of Redeemable Convertible Preferred Stock is, at the option of the holder, convertible into the number of fully paid and
nonassessable shares of common stock as determined by dividing the original issue price applicable to such series of redeemable convertible preferred stock by the conversion price in effect at that time with respect to such series. At
December&nbsp;31, 2020, the conversion price for the Redeemable Convertible Preferred Stock is the original issue price of such series of Redeemable Convertible Preferred Stock and shall be adjusted in accordance with conversion provisions contained
in the Company&#146;s Amended and Restated Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each share of Redeemable Convertible Preferred Stock shall
automatically be converted into fully paid, nonassessable shares of common stock at the then effective conversion rate for such share (i)&nbsp;immediately prior to the closing of a firm commitment underwritten initial public offering pursuant to an
effective registration statement filed under the Securities Act of 1933, as amended (the Securities Act), covering the offer and sale of the Company&#146;s common stock, provided that the public offering price represents a <FONT
STYLE="white-space:nowrap">pre-money</FONT> valuation of at least $250.0&nbsp;million and the aggregate gross proceeds to the Company are not less than $40.0&nbsp;million, or (ii)&nbsp;upon the receipt by the Company of a written request for such
conversion from the holders of a majority of the redeemable convertible preferred stock then outstanding (voting as a single class and on an <FONT STYLE="white-space:nowrap">as-if</FONT> converted basis), or, if later, the effective date for
conversion specified in such requests. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(d)</I></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>Voting Rights </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each holder of a share of Redeemable Convertible Preferred Stock is entitled to the number of votes, with respect to such share, equal to the
number of shares of common stock into which such share of Redeemable Convertible </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Preferred Stock could be converted on the record date for the vote or consent of stockholders, except as otherwise required by law, and has voting rights and powers equal to the voting rights and
powers of the holders of common stock voting as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2020, the Board of Directors was comprised of six
members, three of whom are elected by the holders of Redeemable Convertible Preferred Stock, voting exclusively and as a separate class, and one of whom is the then current Chief Executive Officer of the Company and is elected by the holders of
common stock, voting exclusively and as a separate class. The holders of common stock and Redeemable Convertible </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Preferred Stock, voting
as a single class on an <FONT STYLE="white-space:nowrap">as-if</FONT> converted basis, were entitled to elect the balance of the total number of directors. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(e)</I></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>Liquidation Rights </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, the holders of the Redeemable
Convertible Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the Company to the holders of the common stock by reason of their ownership of such stock, an amount per share for each
share of Redeemable Convertible Preferred Stock held by them equal to the sum of (i)&nbsp;the liquidation preference of $1.00, $1.50, and $1.75 per share of Series A, Series B, and Series C redeemable convertible preferred stock, respectively, and
(ii)&nbsp;all declared but unpaid dividends (if any) on such share of Redeemable Convertible Preferred Stock, or such lesser amount as may be approved by the holders of the majority of the then-outstanding shares of redeemable convertible preferred
stock, voting as a single class and on an as-converted basis. If upon the liquidation, dissolution or winding up of the Company, the assets of the Company legally available for distribution to the holders of the Redeemable Convertible Preferred
Stock are insufficient to permit the payment to such holders of the full amounts, then the entire assets of the Company legally available for distribution shall be distributed with equal priority and pro rata among the holders of the Redeemable
Convertible Preferred Stock in proportion to the full amounts they would otherwise be entitled to receive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After the payment or setting
aside for payment to the holders of the Redeemable Convertible Preferred Stock of the full amounts specified above, the remaining assets of the Company legally available for distribution shall be distributed with equal priority and ratably to the
holders of the common stock in proportion to the number of shares of common stock held by them. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 8. Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The holder of each share of common stock is entitled to one vote in respect of each share of stock held. The holders of common stock are also
entitled to receive dividends whenever funds and assets are legally available and when declared by the Board of Directors, subject to the prior rights of holders of redeemable convertible preferred stock outstanding. No dividends have been declared
as of December&nbsp;31, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company had reserved the following shares of common stock for future issuance as follows:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Redeemable convertible preferred stock, as converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,289,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unissued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Options issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,093,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares available for future stock option grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,499,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,882,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 9. Stock-Based Compensation Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2015, the Board of Directors approved the 2015 Stock Plan (the &#147;Plan&#148;) with the authorized shares of 14,450,000 as of
December&nbsp;31, 2020. The Plan provides for the issuance of options to purchase shares of common stock to officers, employees, directors, consultants and key persons who provide services to the Company. Stock options granted under the 2015 Plan
may be either incentive stock options (&#147;ISOs&#148;) or nonqualified stock options (&#147;NSOs&#148;). According to the 2015 Plan, stock options are exercisable in whole or in part and common stock is issued option exercise. The Plan also allows
for the grant of restricted stock awards (&#147;RSAs&#148;). As of December&nbsp;31, 2020, the Company had 1,499,359 shares of common stock available for issuance under the Plan. Such issuances are subject to vesting, forfeiture and other
restrictions as deemed appropriate by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Options under the Plan may be granted for periods of up to 10 years. All
options issued to date have a <FONT STYLE="white-space:nowrap">10-</FONT> year contractual life. To date, options granted generally vest over four years and vest at a rate of 25% upon the first anniversary of the issuance date and 1/48th per month
thereafter. The exercise price of an ISO and NSO shall not be less than 100% of the estimated fair value of the shares on the date of grant, respectively, as determined by the Board of Directors. The exercise price of an ISO and NSO granted to a 10%
shareholder shall not be less than 110% of the estimated fair value of the shares on the date of grant, respectively, as determined by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A summary of stock option activity is as follows (in thousands except per share amounts): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Life&nbsp;(In&nbsp;Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Outstanding&#151;January 1, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(407</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Outstanding&#151;December 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Options outstanding and exercisable <BR>as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Options vested and expect to vest <BR>as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to
vest is the difference between the exercise price of the options and the estimated fair value of the Company&#146;s common stock for financial reporting purposes as of December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The intrinsic value of options exercised during the years ended December&nbsp;31, 2020 and 2019 was $0.2&nbsp;million and $0.1&nbsp;million,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the years ended December&nbsp;31, 2020 and 2019, the Company granted options with a weighted average grant date fair
value of $0.74 and $0.31 per share, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s Board of Directors granted equity awards in the form of RSAs for
certain of the Company&#146;s employees under the 2015 Equity Incentive Plan. In April 2016, the Company&#146;s Board of Directors approved equity awards in the form of RSAs outside of the 2015 Equity Incentive Plan. The Company&#146;s outstanding
RSAs began vesting one month after the grant date and vest 1/48th per month over four years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes the
Company&#146;s RSA activity (in thousands except per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average&nbsp;Grant<BR>Date&nbsp;Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">RSAs, unvested at January&nbsp;1, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">RSAs, unvested at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of RSAs vested during the years ended December&nbsp;31, 2020 and 2019 was $0.3&nbsp;million and
$0.8&nbsp;million, respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(a)</I></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>Fair Value of Employee Stock Options </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The fair value of employee options is estimated at the grant date using the Black-Scholes option-pricing model with the following
weighted-average assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5.96&#151;6.07</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5.92&#151;6.08</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">58.71%&#151;62.88%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">59.76%&#151;64.12%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0.31%&#151;1.48%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1.42%&#151;2.48%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;%</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(b)</I></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>Stock-Based Compensation </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total stock-based compensation recorded in the statements of operations related to options and RSAs was as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2020, there was approximately $2.5&nbsp;million of unrecognized
stock-based compensation expense to be recognized over a weighted-average period of approximately 3.28 years. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(c)</I></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>Early Exercise of Stock Options </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2015 Plan allows for the granting of options that may be exercised before the options have vested. Shares issued as a result of early
exercise that have not vested are subject to repurchase by the Company upon termination of the purchaser&#146;s employment or services, at the price paid by the purchaser. The Company&#146;s right to repurchase these shares generally lapses 1/48 of
the original grant date amount per month over four years. The proceeds initially are recorded in a liability for early exercised stock options and are reclassified to common stock and additional <FONT STYLE="white-space:nowrap">paid-in</FONT>
capital as the Company&#146;s repurchase right lapses. At December&nbsp;31, 2020, there were 0.6&nbsp;million shares of common stock outstanding, subject to the Company&#146;s right of repurchase at a weighted average exercise price of $0.32 per
share. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(d)</I></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>Stock-Based Compensation Associated with Awards to <FONT STYLE="white-space:nowrap">Non-employees</FONT>
</I></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company did not grant any new options to purchase shares to consultants during the years ended December&nbsp;31,
2020 and 2019. The Company recorded $0.01&nbsp;million and $0.4&nbsp;million in stock-based compensation for prior grants to <FONT STYLE="white-space:nowrap">non-employees</FONT> for the year ended December&nbsp;31, 2020 and 2019, respectively. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>(e)</I></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><I>Founders Shares </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2015, the Company issued 3,400,000 common shares for cash of $0.0001 per share to the original founding members of the Company. The
shares were issued under the terms of the respective restricted stock purchase agreements and unvested shares are subject to be repurchased by the Company at the original purchase price per share upon the holder&#146;s termination of their
relationship with the Company. The restricted shares are not deemed to be issued for accounting purposes until they vest and are therefore excluded from shares outstanding and from basic and diluted net loss per share until the repurchase right
lapses and the shares are no longer subject to the repurchase feature. Under the founders&#146; agreements, 1/48th of the shares subject to the RSA shall vest on the date one month after the vesting commencement date, and 1/48th of the shares
subject to the RSA shall vest each month thereafter on the same day of the month as the vesting commencement date (and if there is no corresponding day, on the last day of the month), subject to the founders continuing to be a service provider
through each such date. As of December&nbsp;31, 2019, all 3,400,000 common shares were vested. The Company recorded $0.4&nbsp;million in stock-based compensation of founders&#146; RSAs for the year ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 10. Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No
provision for income taxes was recorded for the years ended December&nbsp;31, 2020 and 2019. The Company has incurred net operating losses for all the periods presented. The Company accounts for income taxes in accordance with the asset and
liability method, which requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#147;more likely than not.&#148;
Realization of the future tax benefits is dependent on the Company&#146;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#146;s recent history of operating losses, management believes that
recognition of the deferred tax assets arising from the above-mentioned future tax benefits is not likely to be realized and, accordingly, has provided a full valuation allowance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Significant components of the Company&#146;s net deferred tax assets consist of the following
(in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accrual and reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Capitalized intangible costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Less valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,339</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Deferred tax assets, net of valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,675</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(340</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(552</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gross deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,917</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The net valuation allowance increased by $9.6&nbsp;million and $7.0&nbsp;million for the years ended
December&nbsp;31, 2020 and 2019, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2020, the Company had net operating loss (&#147;NOL&#148;)
carryforwards of approximately $80.8&nbsp;million and $80.6&nbsp;million available to reduce future taxable income, if any, for federal and California state income tax purposes, respectively. NOL carryforwards generated after 2018 for federal tax
reporting purposes of $68.3&nbsp;million have an indefinite carryforward period. The remaining federal and state net operating loss carryforwards begin expiring in 2036. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2020, the Company had research and development credit carryforwards of approximately $1.5&nbsp;million and
$1.9&nbsp;million available to reduce future taxable income, if any, for federal and California state income tax purposes, respectively. The federal credit carryforwards begin expiring in 2036 and the state credits carry forward indefinitely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of
an ownership change for tax purposes, as defined in Section&nbsp;382 of the Internal Revenue Code. As a result of such ownership changes, the Company&#146;s ability to realize the potential future benefit of tax losses and tax credits that existed
at the time of the ownership change may be limited and may expire unutilized. Such impairment of tax losses and tax credits would reduce the deferred tax asset and corresponding valuation allowance, as a result of the limitation. The Company has not
conducted a study to assess whether a limitation would apply under Section&nbsp;382. The Company plans to conduct a Section&nbsp;382 study when it begins generating taxable income and starts utilizing the above-mentioned tax loss and tax credit
carryforwards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company recognizes uncertain income tax positions at the largest amount that is more
likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. The unrecognized tax benefits, if recognized, would not
have an impact on the Company&#146;s effective tax rate assuming the Company continues to maintain a full valuation allowance position. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A reconciliation of the Company&#146;s unrecognized tax benefits is as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Balance at beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additions based on tax positions related to current year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additions based on tax positions of prior year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Balance at end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company files income tax returns in the U.S. federal jurisdiction and California. As of the date these
financial statements were issued, the Company is not under examination by any income tax authority. The statute of limitations remains effectively open for all tax years from inception in 2015 through 2020. Tax years outside the normal statute of
limitations remain open to examination by tax authorities due to tax attributes generated in earlier years, which have been carried forward and may be examined and adjusted in subsequent years when utilized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A reconciliation of the statutory U.S. federal tax rate to the Company&#146;s effective tax rate is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">State tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29.43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;27, 2020, the Coronavirus Aid, Relief and Economic Securities Act (&#147;CARES Act&#148;) was
enacted and signed into law in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before
2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. Other provisions include increased limits on the
deduction of interest expense from 30% to 50% of adjusted taxable income for tax years beginning in 2019 and 2020, increased limits on 2020 charitable contribution deductions from 10% to 25% of taxable income and accelerated refunds of alternative
minimum tax credits. The provisions of the CARES Act did not have a material impact for the year ended December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On
December&nbsp;21, 2020, the Consolidated Appropriations Act, 2021 (the &#147;Appropriations Act&#148;) was signed into law which expanded and extended some of CARES Act provisions, including the expansion of the employee retention credits. The
Company will claim employee retention credits of $0.3&nbsp;million for the 2020 tax year and will file amended payroll tax returns to claim the employee retention credits. The Company will recognize the benefit of those credits as the refunds are
received. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 11. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Indemnification </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time
to time, the Company enters into certain types of contracts that contingently require the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i)&nbsp;the Company&#146;s bylaws, under which the
Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship with the Company, (ii)&nbsp;contracts under which the Company must indemnify directors and
certain officers for liabilities arising out of their relationship with the Company, (iii)&nbsp;contracts under which the Company may be required to indemnify customers or partners against certain claims, including claims from third parties
asserting, among other things, infringement of their intellectual property rights and (iv)&nbsp;procurement, consulting, or license agreements under which the Company may be required to indemnify vendors, consultants or licensors for certain claims,
including claims that may be brought against them arising from acts or omissions with respect to the supplied products, technology or services. From time to time, the Company may receive indemnification claims under these contracts in the normal
course of business. In addition, under these contracts the Company may have to modify the accused infringing intellectual property and/or refund amounts received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or
settlement, may cause a material adverse effect on the Company&#146;s future business, operating results or financial condition. It is not possible to determine the maximum potential amount under these contracts due to the limited history of prior
indemnification claims and the unique facts and circumstances involved in each particular agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company maintains director and
officer insurance, which may cover certain liabilities arising from the Company&#146;s obligation to indemnify its directors and certain officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the date the financial statements were issued, the Company has not incurred any material costs or accrued any liabilities in the financial
statements as a result of these provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Litigation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s industry is characterized by frequent claims and litigation, including claims regarding intellectual property. As a result,
the Company may be subject to various legal proceedings from time to time. The results of any future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of
defense and settlement costs, diversion of management resources and other factors. Management is not aware of any pending or threatened litigation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 12. 401(k) Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective January&nbsp;1, 2016, the Company established the Surrozen 401(k) Plan&nbsp;&amp; Trust for the exclusive benefit of all eligible
employees and their beneficiaries with the intention to provide a measure of retirement security. The 401(k) Plan is intended to qualify as a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> plan under Section&nbsp;401 of the Internal Revenue
Code so that contributions to the 401(k) Plan and income earned on such contributions are not taxable to participants until withdrawn or distributed from the 401(k) Plan. The 401(k) Plan provides that each participant may contribute up to 100% of
his or her <FONT STYLE="white-space:nowrap">pre-tax</FONT> compensation, up to annual statutory limits. Under the 401(k) Plan, each employee is fully vested in his or her deferred salary contributions. Employee contributions are held and invested by
the plan&#146;s trustee. The 401(k) Plan also permits the Company to make discretionary and matching contributions, subject to established limits and a vesting schedule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each year, at the discretion of the Company, employer&#146;s match may be a discretionary
percentage allocated proportionate to salary deferral, as the Company elects each year. The employer matching contributions in 2020 and 2019 were nominal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 13. Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has entered into license agreements with Stanford and license and option agreements with UCSF, as described in Note 6. Starting in
2018, Stanford and UCSF each invested in the Company by participating in the Company&#146;s redeemable convertible preferred stock financings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In June 2020, UCSF purchased 4,285,714 shares of Series C redeemable convertible preferred stock for aggregate proceeds of approximately
$7.5&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2020, Stanford and UCSF own approximately 4.4% and 9.6%, respectively, of the Company&#146;s
outstanding capital stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Note 14. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has completed an evaluation of all subsequent events through April&nbsp;30, 2021, the date the financial statements were issued, to
ensure that these financial statements include appropriate disclosure of events both recognized in the financial statements and events that occurred but were not recognized in the financial statements. The Company is unaware of any specific event or
circumstance that would require it to update its estimates, judgments or revise the carrying value of its assets or liabilities. These estimates may change, as new events occur and as additional information related to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic and other information is obtained, the impact of which would be recognized in the financial statements as soon as such information becomes known. Actual results could differ from those estimates
and any such differences may be material to the Company&#146;s financial statements. Except as described below, the Company has concluded that no subsequent event has occurred that requires disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April&nbsp;15, 2021, the Company entered into a business combination agreement with <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT>
Acquisition Corp, a Cayman Islands exempted company (&#147;CHFW&#148;) and Perseverance Merger Sub Inc., a subsidiary of CHFW (&#147;Merger Sub&#148;). Upon closing of the business combination, CHFW will become a Delaware corporation and will be
renamed to Surrozen, Inc., and Merger Sub will merge with and into the Company, with the Company as the surviving company and, after giving effect to such merger, continuing as a wholly-owned subsidiary of CHFW. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="annex_a"></A><A NAME="rom40894_250"></A>ANNEX A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BUSINESS COMBINATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BY AND AMONG </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP., </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PERSEVERANCE MERGER SUB INC., </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND, </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DATED AS OF APRIL&nbsp;15, 2021 </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="tocanxa"></A>TABLE OF CONTENTS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#anxa40894_1">ARTICLE 1 CERTAIN DEFINITIONS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;1.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_2">Definitions </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#anxa40894_3">ARTICLE 2 MERGERS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-18</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;2.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_4"></A></B>Closing Transactions<B> </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;2.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_5">Closing of the Transactions Contemplated by this
Agreement</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;2.3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_6">Allocation Schedule</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;2.4</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_7">Treatment of Company Equity Awards</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;2.5</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_8">Company Stockholder Deliverables</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;2.6</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_9">Withholding</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;2.7</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_10">Appraisal Rights</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#anxa40894_11">ARTICLE 3 REPRESENTATIONS AND WARRANTIES RELATING
 TO THE GROUP COMPANIES </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_12">Organization and Qualification</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_13">Capitalization of the Group Companies</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_14">Authority</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.4</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_15">Financial Statements; Undisclosed Liabilities</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.5</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_16">Consents and Requisite Governmental Approvals;
No&nbsp;Violations</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.6</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_17">Permits</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.7</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_18">Material Contracts</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.8</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_19">Absence of Changes</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.9</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_20">Litigation</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.10</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_21">Compliance with Applicable Law</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.11</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_22">Employee Plans</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.12</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_23">Environmental Matters</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.13</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_24">Intellectual Property</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.14</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_25">Labor Matters</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.15</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_26">Insurance</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.16</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_27">Tax Matters</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.17</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_28">Brokers</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.18</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_29">Real and Personal Property</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.19</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_30">Transactions with Affiliates</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-37</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.20</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_31">Data Privacy and Security</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.21</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_32">Compliance with International Trade&nbsp;
&amp; Anti-Corruption Laws</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.22</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_33">Information Supplied</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.23</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_34">Regulatory Compliance</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.24</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_35">Investigation; No Other Representations</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;3.25</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_36">EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">ARTICLE 4 REPRESENTATIONS AND WARRANTIES RELATING TO THE CHFW
PARTIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;4.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_38">Organization and Qualification</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;4.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_39">Authority</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;4.3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_40">Consents and Requisite Governmental Approvals; No
Violations</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;4.4</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_41">Brokers</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;4.5</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_42">Information Supplied</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;4.6</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_43">Capitalization of the CHFW Parties</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;4.7</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_44">SEC Filings</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;4.8</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_45">Trust Account</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;4.9</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_46">Transactions with Affiliates</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;4.10</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_47">Litigation</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;4.11</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_48">Compliance with Applicable Law</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;4.12</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_49">Merger Sub Activities</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;4.13</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_50">Internal Controls; Listing; Financial Statements</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;4.14</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_51">No Undisclosed Liabilities</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;4.15</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_52">Tax Matters</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;4.16</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_53">Investigation; No Other Representations</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;4.17</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_54">PIPE Financing</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;4.18</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_55">Compliance with International Trade&nbsp;
&amp; Anti-Corruption Laws</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;4.19</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_56">EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#anxa40894_57">ARTICLE 5 COVENANTS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_58">Conduct of Business of the Company</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_59">Efforts to Consummate</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-51</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_60">Confidentiality and Access to Information</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.4</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_61">Public Announcements</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.5</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_62">Tax Matters</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.6</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_63">Exclusive Dealing</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.7</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_64">Preparation of Registration Statement/Proxy
Statement</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.8</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_65">CHFW Shareholder Approval</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.9</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_66">Merger Subs Shareholder Approvals</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.10</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_67">Conduct of Business of CHFW</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.11</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_68">Nasdaq Listing</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.12</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_69">Trust Account</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.13</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_70">Transaction Support Agreements; Company Stockholder
Approval</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.14</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_71">CHFW Indemnification; Directors&#146; and Officers&#146;
Insurance</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.15</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_72">Company Indemnification; Directors&#146; and Officers&#146; Insurance
</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.16</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_73">Post-Closing Directors and Officers</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.17</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_74">PCAOB Financials</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.18</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_75">CHFW Incentive Equity Plan</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.19</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_76">CHFW Employee Stock Purchase Plan</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.20</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_77">FIRPTA Certificates</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.21</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_78">PIPE Subscriptions</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;5.22</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_79">Section&nbsp;16 Matters</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#anxa40894_80">ARTICLE 6 CONDITIONS TO CONSUMMATION OF THE TRANSACTIONS
 CONTEMPLATED BY THIS AGREEMENT </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;6.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_81">Conditions to the Obligations of the Parties</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;6.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_82">Other Conditions to the Obligations of the CHFW
Parties</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;6.3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_83">Other Conditions to the Obligations of the
Company</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;6.4</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_84">Frustration of Closing Conditions</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#anxa40894_85">ARTICLE 7 TERMINATION </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;7.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_86">Termination</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;7.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_87">Effect of Termination</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_88"></A>ARTICLE 8 MISCELLANEOUS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;8.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_89"><FONT STYLE="white-space:nowrap">Non-Survival</FONT></A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;8.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_90">Entire Agreement; Assignment</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;8.3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_91">Amendment</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-68</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;8.4</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_92">Notices</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;8.5</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_93">Governing Law</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;8.6</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_94">Fees and Expenses</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;8.7</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_95">Construction; Interpretation</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;8.8</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_96">Exhibits and Schedules</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;8.9</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_97">Parties in Interest</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;8.10</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_98">Severability</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;8.11</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_99">Counterparts; Electronic Signatures</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;8.12</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_100">Knowledge of Company; Knowledge of CHFW</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;8.13</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_101">No Recourse</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;8.14</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_102">Extension; Waiver</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;8.15</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_103">Waiver of Jury Trial</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;8.16</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_104">Submission to Jurisdiction</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;8.17</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_105">Remedies</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;8.18</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxa40894_106">Trust Account Waiver</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>ANNEXES AND EXHIBITS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annex&nbsp;A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PIPE Investors</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annex&nbsp;B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Supporting Company Stockholders</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annex C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Unpaid CHFW Expenses and Unpaid CHFW Liabilities</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annex D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Required Governing Documents Proposals</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exhibit A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Form of Subscription Agreement</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exhibit B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Form of Investor Rights Agreement</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exhibit C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Form of Transaction Support Agreement</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exhibit D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Form of Letter of Transmittal</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exhibit E</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Form of CHFW Certificate of Incorporation</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exhibit F</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Form of CHFW Bylaws</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exhibit G</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Form of CHFW Equity Incentive Plan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exhibit H</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Form of Employee Stock Purchase Plan</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BUSINESS COMBINATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This BUSINESS COMBINATION AGREEMENT (this &#147;Agreement&#148;), dated as of April&nbsp;15, 2021, is made by and among <FONT
STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp, a Cayman Islands exempted company (&#147;CHFW&#148;), Perseverance Merger Sub Inc., a Delaware corporation (&#147;Merger Sub&#148;) and Surrozen, Inc., a Delaware corporation (the
&#147;Company&#148;). CHFW, Merger Sub and the Company shall be referred to herein from time to time collectively as the &#147;Parties&#148;. Capitalized terms used but not otherwise defined herein have the meanings set forth in
<U>Section</U><U></U><U>&nbsp;1.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, (a)&nbsp;CHFW is a blank check company incorporated as a Cayman Islands exempted company
on August&nbsp;21, 2020 and incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, and (b)&nbsp;Merger Sub is, as of the date
of this Agreement, a wholly-owned Subsidiary of CHFW that was formed for purposes of consummating the transactions contemplated by this Agreement and the Ancillary Documents; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, pursuant to the Governing Documents of CHFW, CHFW is required to provide an opportunity for its shareholders to have their
outstanding CHFW Class&nbsp;A Shares redeemed on the terms and subject to the conditions set forth therein in connection with obtaining the CHFW Shareholder Approval; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, as of the date of this Agreement, Consonance Life Sciences, a Cayman Islands limited liability company (the &#147;Sponsor&#148;), and
the Other Class&nbsp;B Shareholders collectively own 2,300,000 CHFW Class&nbsp;B Shares; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, concurrently with the execution of this
Agreement, the Sponsor, the Other Class&nbsp;B Shareholders, CHFW and the Company are entering into the sponsor letter agreement (the &#147;Sponsor Letter Agreement&#148;), pursuant to which the Sponsor and each Other Class&nbsp;B Shareholder has
agreed to (a)&nbsp;vote in favor of the adoption of this Agreement and the transactions contemplated hereby (including the Merger) and each of the Transaction Proposals, (b)&nbsp;waive any adjustment to the conversion ratio set forth in the
Governing Documents of CHFW or any other anti-dilution or similar protection with respect to the CHFW Class&nbsp;B Shares (whether resulting from the transactions contemplated by the Subscription Agreements or otherwise), in each case, on the terms
and subject to the conditions set forth in the Sponsor Letter Agreement and (c)&nbsp;contribute to CHFW 759,000 Class&nbsp;B Shares; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, prior to the Closing, CHFW shall domesticate as a Delaware corporation in accordance with Section&nbsp;388 of the General Corporation
Law of the State of Delaware (the &#147;DGCL&#148;) and Part XII of the Cayman Islands Companies Act (2021 Revision) (the &#147;Domestication&#148;), on the terms and subject to the conditions set forth in this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, on the Closing Date, Merger Sub will merge with and into the Company, with the Company as the surviving company in the merger and,
after giving effect to such merger, becoming a wholly-owned Subsidiary of CHFW (the &#147;Merger&#148;), and each Company Share will be converted into the right to receive a portion of the Transaction Share Consideration, on the terms and subject to
the conditions set forth in this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, concurrently with the execution of this Agreement, Consonance Capital and each of
the investors set forth on <U>Annex A</U> (collectively, the &#147;PIPE Investors&#148;) is entering into a subscription agreement, substantially in the form attached hereto as <U>Exhibit A</U> (the &#147;Subscription Agreement&#148;) with CHFW and
the Company, pursuant to which, among other things, the PIPE Investors have agreed to subscribe for and purchase, and CHFW has agreed to issue and sell to the PIPE Investors, a number of units comprised of one share of Class&nbsp;A Common Stock and <FONT
STYLE="white-space:nowrap">one-third</FONT> of one redeemable PIPE Warrant, each whole PIPE Warrant exercisable for one Class&nbsp;A Common Stock as set forth in each applicable Subscription Agreement in exchange for an aggregate purchase price of
$120,200,000, on the terms and subject to the conditions set forth therein (such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
aggregate purchase price under all Subscription Agreements, the &#147;PIPE Financing Amount&#148;, and such equity financing hereinafter referred to as the &#147;PIPE Financing&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, at the Closing, CHFW, Sponsor, the Company Stockholders listed on <U>Annex</U><U> <FONT STYLE="white-space:nowrap">B-1</FONT></U>
attached hereto, and the directors and officers of the Company (collectively, the &#147;IRA Shareholders&#148;) shall enter into an investor rights agreement, substantially in the form attached hereto as <U>Exhibit B</U> (the &#147;Investor Rights
Agreement&#148;), pursuant to which, among other things, the IRA Shareholders (a)&nbsp;will agree not to effect any sale or distribution of any Equity Securities of CHFW held by any of them during the <FONT STYLE="white-space:nowrap">lock-up</FONT>
period described therein, and (b)&nbsp;will be granted certain registration rights with respect to their respective CHFW Shares, in each case, on the terms and subject to the conditions therein; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, concurrently with the execution of this Agreement, each of the PIPE Investors who are not IRA Shareholders but who are the record and
beneficial owners on the date hereof of Equity Securities of CHFW and marked with an asterisk on <U>Annex A</U>, are entering into shareholder support letter agreements (collectively, the &#147;CHFW Shareholder Support Agreements&#148;), with the
Company pursuant to which, among other things, each such PIPE Investor is agreeing to (a)&nbsp;vote in favor of this Agreement and the transactions contemplated hereby (including the Merger) and (b)&nbsp;not to redeem any of the Equity Securities of
CHFW it owns, in each case, on the terms and subject to the conditions set forth in the applicable CHFW Shareholder Support Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, promptly after the execution of this Agreement, each Company Stockholder listed on <U>Annex
<FONT STYLE="white-space:nowrap">B-2</FONT></U> attached hereto (collectively, the &#147;Supporting Company Stockholders&#148;) will duly execute and deliver to CHFW a transaction support agreement, substantially in the form attached hereto as
<U>Exhibit C</U> (collectively, the &#147;Transaction Support Agreements&#148;), pursuant to which each such Supporting Company Stockholder will agree to, among other things, (a)&nbsp;support and vote in favor of this Agreement, the Ancillary
Documents to which the Company is or will be a party and the transactions contemplated hereby and thereby (including the Merger), and (b)&nbsp;take, or cause to be taken, any actions necessary or advisable to cause certain agreements to be
terminated effective as of the Closing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, the board of directors of CHFW (the &#147;CHFW Board&#148;) has unanimously (a)
determined that this Agreement and the Transactions are advisable and fair to, and in the best interest of, CHFW and Merger Sub, (b)&nbsp;approved the execution, delivery and performance by CHFW of this Agreement and the consummation of the
Transactions, and approved each of the Transaction Proposals and (b)&nbsp;resolved to recommend, among other things, approval of the Agreement and the Transactions and each of the Transaction Proposals by the holders of CHFW Shares entitled to vote
thereon; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, the board of directors of Merger Sub has approved this Agreement, the Ancillary Documents to which such Merger Sub is
or will be a party and the transactions contemplated hereby and thereby (including the Merger); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, CHFW, as the sole shareholder of
Merger Sub, will as promptly as reasonably practicable (and in any event within one Business Day) following the date of this Agreement, approve this Agreement, the Ancillary Documents to which Merger Sub is or will be a party and the transactions
contemplated hereby and thereby (including the Merger); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, the board of directors of the Company has unanimously
(a)&nbsp;determined that this Agreement and the Transactions are advisable and fair to, and in the best interest of, the Company and the Company Stockholders, (b)&nbsp;approved the execution, delivery and performance by the Company of this Agreement
and the consummation of the Transactions and (c)&nbsp;resolved to recommend, among other things, the approval of this Agreement and the Transactions by the holders of Company Shares entitled to vote thereon; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, each of the Parties intends for U.S. federal income tax purposes that (a)&nbsp;this Agreement constitute a &#147;plan of
reorganization&#148; within the meaning of Section&nbsp;368 of the Code and Treasury Regulations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
promulgated thereunder, (b)&nbsp;the Domestication constitute a transaction treated as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a)(1)(F) of the Code and (c)&nbsp;the
Merger constitutes a transaction treated as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code (clauses (a)-(c), the &#147;Intended Tax Treatment&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NOW, THEREFORE, in consideration of the premises and the mutual promises set forth herein and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxa40894_1">
</A>ARTICLE 1 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN DEFINITIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_2"></A><B>Section</B><B></B><B>&nbsp;1.1</B> <B>Definitions</B>. As used in this Agreement, the following terms have the
respective meanings set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Additional CHFW SEC Reports&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.7.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Affiliate&#148; means, with respect to any Person, any other Person who directly or
indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. The term &#147;control&#148; means the possession, directly or indirectly, of the power to direct or cause the direction of the
management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise, and the terms &#147;controlled&#148; and &#147;controlling&#148; have meanings correlative thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Affordable Care Act&#148; means the Patient Protection and Affordable Care Act (Pub. L.
<FONT STYLE="white-space:nowrap">111-148),</FONT> as amended by the Health Care and Education Reconciliation Act of 2010 (Pub. L. <FONT STYLE="white-space:nowrap">111-152),</FONT> and the regulations promulgated pursuant to each of the foregoing
laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Aggregate Closing PIPE Proceeds&#148; means the aggregate cash proceeds to be actually received (or deemed received) by CHFW
or any of its Affiliates in respect of the PIPE Financing (whether prior to or on the Closing Date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Aggregate Transaction
Proceeds&#148; means an amount equal to (a)&nbsp;the sum of (i)&nbsp;the cash proceeds to be received by CHFW or any of its Affiliates from the Trust Account in connection with the transactions contemplated hereby (after, for the avoidance of doubt,
giving effect to the CHFW Shareholder Redemption) and (ii)&nbsp;the Aggregate Closing PIPE Proceeds, <U>minus</U> (b)&nbsp;those Unpaid CHFW Expenses and Unpaid CHFW Liabilities identified on <U>Annex C</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Agreement&#148; has the meaning set forth in the introductory paragraph to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Allocation Schedule&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Alternative Transaction Structure&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.5(a)(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Ancillary Documents&#148; means the Investor Rights Agreement, Sponsor Letter Agreement, the CHFW Shareholder Support Agreements, the
Subscription Agreements, the Transaction Support Agreements, and each other agreement, document, instrument and/or certificate contemplated by this Agreement to be executed by the Parties in connection with the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Anti-Corruption Laws&#148; means, collectively, (a)&nbsp;the U.S. Foreign Corrupt Practices Act (FCPA); (b) the UK Bribery Act 2010; and
(c)&nbsp;any other anti-bribery or anti-corruption Laws related to combatting bribery, corruption and money laundering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Business&#148; means the business of the Company as conducted as of the date hereof,
including, directly or indirectly, researching, developing, testing (whether <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical) or manufacturing, products, substances or therapies to selectively modulate the Wnt pathway, or any
activities, services or products incidental or attendant thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Business Combination Proposal&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;5.8</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Business Day&#148; means a day, other than a Saturday or Sunday, on which commercial banks
in New York, New York and San Francisco, California are open for the general transaction of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CARES Act&#148; means
(i)&nbsp;the Coronavirus Aid, Relief, and Economic Security Act (Pub. L. <FONT STYLE="white-space:nowrap">116-136)</FONT> and any administrative or other guidance published with respect thereto by any Governmental Authority (including IRS Notices <FONT
STYLE="white-space:nowrap">2020-22</FONT> and <FONT STYLE="white-space:nowrap">2020-65),</FONT> or any other Law or executive order or executive memorandum (including the Memorandum on Deferring Payroll Tax Obligations in Light of the Ongoing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> Disaster, dated August&nbsp;8, 2020) intended to address the consequences of <FONT STYLE="white-space:nowrap">COVID-19</FONT> (in each case, including any comparable provisions of state, local or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Law and including any related or similar orders or declarations from any Governmental Authority) and (ii)&nbsp;any extension of, amendment, supplement, correction, revision or similar treatment to any
provision of the CARES Act contained in the Consolidated Appropriations Act, 2021, H.R. 133. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Certificate of Merger&#148; has the
meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1(b)(ii)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Certificates&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.1(b)(vii).</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Change of Control Payments&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.11(d)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW&#148; has the meaning set forth in the introductory paragraph to this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Acquisition Proposal&#148; means (a)&nbsp;any transaction or series of related transactions under which CHFW or any of its
controlled Affiliates, directly or indirectly, (i)&nbsp;acquires or otherwise purchases any other Person(s), (ii) engages in a business combination with any other Person(s) or (iii)&nbsp;acquires or otherwise purchases all or a material portion of
the assets or businesses of any other Persons(s) (in the case of each of clause (i), (ii) and (iii), whether by merger, consolidation, recapitalization, purchase or issuance of equity securities, tender offer or otherwise) or (b)&nbsp;any equity,
debt or similar investment in CHFW or any of its controlled Affiliates. Notwithstanding the foregoing or anything to the contrary herein, none of this Agreement, the Ancillary Documents or the Transactions shall constitute a CHFW Acquisition
Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Board&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Bylaws&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Certificate of Incorporation&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Class<U></U> A Shares&#148; means CHFW&#146;s Class&nbsp;A ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Class<U></U>&nbsp;B Shares&#148; means CHFW&#146;s Class&nbsp;B ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Common Stock&#148; means shares of common stock, par value $0.0001 per share, of CHFW. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW D&amp;O Persons&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.14(a).</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW D&amp;O Tail Policy&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.14(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Designee&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.16(b)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Disclosure Schedules&#148; means the disclosure schedules to this Agreement
delivered to the Company by CHFW on the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Equity Incentive Plan&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;5.18</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Expenses&#148; means, as of any determination time, the aggregate amount of fees,
expense, commissions or other amounts incurred by or on behalf of a CHFW Party that are due and payable and not otherwise expressly allocated to the Company pursuant to the terms of this Agreement or any Ancillary Document in connection with the
negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance of its covenants or agreements in this Agreement or any Ancillary Document or the consummation of the Transactions, including (a)&nbsp;the fees and
expenses of outside legal counsel, accountants, advisors, brokers, investment bankers, consultants, or other agents or service providers of any CHFW Party and (b)&nbsp;any other fees, expenses, commissions or other amounts that are expressly
allocated to any CHFW Party pursuant to this Agreement or any Ancillary Document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Financial Statements&#148; means all of the
financial statements of CHFW included in the CHFW SEC Reports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Fundamental Representations&#148; means the representations and
warranties set forth in Section&nbsp;4.1 (Organization and Qualification), Section&nbsp;4.2(a) (Authority), Section&nbsp;4.4 (Brokers) and Section&nbsp;4.6(a) &#150; (c) (Capitalization of the CHFW Parties). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Liabilities&#148; means, as of any determination time, without duplication of any CHFW Expenses, the aggregate amount of
Liabilities that would be accrued on a balance sheet, whether such Liabilities then due and payable by the CHFW Parties as of such time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Material Adverse Effect&#148; means any change, event, effect or occurrence that, individually or in the aggregate with any other
change, event, effect or occurrence, has had or would reasonably be expected to have a material adverse effect on (a)&nbsp;the business, results of operations or financial condition of the CHFW Parties, taken as a whole, or (b)&nbsp;the ability of
CHFW or Merger Sub to consummate the Merger; <U>provided</U>, <U>however</U>, that, in the case of <U>clause (a)</U>, none of the following shall be taken into account in determining whether a CHFW Material Adverse Effect has occurred or is
reasonably likely to occur: any adverse change, event, effect or occurrence arising after the date of this Agreement from or related to (i)&nbsp;general business or economic conditions in or affecting the United States, or changes therein, or the
global economy generally, (ii)&nbsp;any national or international political or social conditions in the United States or any other country, including the engagement by the United States or any other country in hostilities, whether or not pursuant to
the declaration of a national emergency or war, or the occurrence in any place of any military or terrorist attack, sabotage or cyberterrorism, (iii)&nbsp;changes in conditions of the financial, banking, capital or securities markets generally in
the United States or any other country or region in the world, or changes therein, including changes in interest rates in the United States or any other country and changes in exchange rates for the currencies of any countries, (iv)&nbsp;changes in
any applicable Laws, (v)&nbsp;any change, event, effect or occurrence that is generally applicable to the industries or markets in which any CHFW Party operates, (vi)&nbsp;the execution or public announcement of this Agreement or the pendency or
consummation of the Transactions, including the impact thereof on the relationships, contractual or otherwise, of any CHFW Party with investors, contractors, lenders, suppliers, vendors, partners, licensors, licensees, payors or other third parties
related thereto (<U>provided</U> that the exception in this <U>clause</U><U></U><U>&nbsp;(vi)</U> shall not apply to the representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;4.3(b)</U> to the extent that its purpose is to
address the consequences resulting from the public announcement or pendency or consummation of the Transactions or the condition set forth in <U>Section</U><U></U><U>&nbsp;6.3(a)</U> to the extent it relates to such representations and warranties),
(vii) any failure by any CHFW Party to meet, or changes to, any internal or published budgets, projections, forecasts, estimates or predictions (although the underlying facts and circumstances resulting in such failure may be taken into account to
the extent not otherwise excluded from this definition pursuant to <U>clauses (i)</U>&nbsp;through <U>(vi)</U> or <U>(viii)</U>), or (viii)&nbsp;any hurricane, tornado, flood, earthquake, tsunami, natural disaster, mudslides, wild fires,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
epidemics, pandemics (including <FONT STYLE="white-space:nowrap">COVID-19)</FONT> or quarantines, acts of God or other natural disasters or comparable events in the United States or any other
country or region in the world, or any escalation of the foregoing; <U>provided</U>, <U>however</U>, that any change, event, effect or occurrence resulting from a matter described in any of the foregoing <U>clauses</U><U></U><U>&nbsp;(i)</U> through
<U>(v)</U>&nbsp;or <U>(viii)</U> may be taken into account in determining whether a CHFW Material Adverse Effect has occurred or is reasonably likely to occur to the extent such change, event, effect or occurrence has a disproportionate adverse
effect on the CHFW Parties, taken as a whole, relative to other &#147;<U>SPACs</U>&#148; operating in the industries in which the CHFW Parties operate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Parties&#148; means, together, CHFW and Merger Sub. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Related Parties&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.9.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Related Party Transactions&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.9</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW SEC Reports&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.7.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Share Value&#148; means $10.00. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Shareholder Approval&#148; means, collectively, the Required CHFW Shareholder Approval and the Other CHFW Shareholder Approval.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Shareholder Redemption&#148; means the right of the holders of CHFW Class&nbsp;A Shares to redeem all or a portion of their
CHFW Class&nbsp;A Shares (in connection with the Transactions or otherwise) as set forth in Governing Documents of CHFW. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW
Shareholder Support Agreements&#148; has the meaning set forth in the recitals to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Shareholders Meeting&#148;
has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.8.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;CHFW Shares&#148; means (a)&nbsp;prior to the occurrence of the
Domestication, collectively, the CHFW Class&nbsp;A Shares and the CHFW Class&nbsp;B Shares and (b)&nbsp;from and after the occurrence of the Domestication, shares of Common Stock. Any reference to the CHFW Shares in this Agreement or any Ancillary
Document shall be deemed to refer to clause (a)&nbsp;and/or clause (b)&nbsp;of this definition, as the context so requires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Closing&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Closing Company Unaudited Financial Statements&#148; means the unaudited consolidated balance sheets of the Group Companies as of
March&nbsp;31, 2020 and March&nbsp;31, 2021 and the related unaudited consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#146; deficit and cash flows of the Group Companies for each of the
three month periods then ended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Closing Date&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Closing Filing&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.4(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Closing Press Release&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.4(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;COBRA&#148; means Part 6 of Subtitle B of Title I of ERISA, Section&nbsp;4980B of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Code&#148; means the U.S. Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company&#148; has the meaning set forth in the introductory paragraph to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Acquisition Proposal&#148; means (a)&nbsp;any transaction or series of related
transactions under which any Person(s), directly or indirectly, (i)&nbsp;acquires or otherwise purchases the Company or any of its controlled Affiliates or (ii)&nbsp;or all or a more than 15% in value of assets or businesses of the Company or any of
its controlled Affiliates (in the case of each of clause (i)&nbsp;and (ii), whether by merger, consolidation, recapitalization, purchase or issuance of equity securities, tender offer or otherwise), or (b) 15% or more of any equity, debt or similar
investment in the Company or any of its controlled Affiliates (other than any Company Equity Awards). Notwithstanding the foregoing or anything to the contrary herein, none of this Agreement, the Ancillary Documents or the transactions contemplated
hereby or thereby shall constitute a Company Acquisition Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Common Shares&#148; means shares of common stock, par
value $0.0001 per share, of the Company authorized under the Amended and Restated Certificate of Incorporation of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement&#148; means the Amended and Restated Right of First Refusal and <FONT
STYLE="white-space:nowrap">Co-Sale</FONT> Agreement, dated as of May&nbsp;29, 2020, by and among the Company and the Company Stockholders party thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company D&amp;O Persons&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.15(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company D&amp;O Tail Policy&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.15(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Designees&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.16(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Disclosure Schedules&#148; means the disclosure schedules to this Agreement delivered to CHFW by the Company on the date of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Equity Award&#148; means, as of any determination time, each Company Option, each Company Restricted Stock Award
and each other award to any current or former director, manager, officer, employee, individual independent contractor or other service provider of any Group Company of rights of any kind to receive any Equity Security of any Group Company under the
Company Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Equity Plan&#148; means the Surrozen, Inc. 2015 Equity Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Expenses&#148; means, as of any determination time, the aggregate amount of fees, expense, commissions or other amounts incurred
by or on behalf of any Group Company that are due and payable and not otherwise expressly allocated to a CHFW Party pursuant to the terms this Agreement or any Ancillary Document, in connection with the negotiation, preparation or execution of this
Agreement or any Ancillary Documents, the performance of its covenants or agreements in this Agreement or any Ancillary Document or the consummation of the transactions contemplated hereby or thereby, including (a)&nbsp;the fees and expenses of
outside legal counsel, accountants, advisors, brokers, investment bankers, consultants, or other agents or service providers of any Group Company (b)&nbsp;any other fees, expenses, commissions or other amounts that are expressly allocated to any
Group Company pursuant to this Agreement or any Ancillary Document and (c)&nbsp;Change of Control Payments paid or payable by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Fundamental Representations&#148; means the representations and warranties set forth in Section&nbsp;3.1 (Organization and
Qualification), Section&nbsp;3.2(a) and Section&nbsp;3.2(b) (Capitalization of the Group Companies), Section&nbsp;3.3&nbsp;(Authority), Section&nbsp;3.8(a) (No Company Material Adverse Effect) and Section&nbsp;3.17 (Brokers). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company IT Systems&#148; means all computer systems, computer software and hardware, communication systems, servers, network equipment
and related documentation, in each case, owned, licensed or leased by a Group Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Licensed Intellectual Property&#148;
means Intellectual Property Rights owned by any Person (other than a Group Company) that is licensed to any Group Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Material Adverse Effect&#148; means any change, event, effect or occurrence
that, individually or in the aggregate with any other change, event, effect or occurrence, has had or would reasonably be expected to have a material adverse effect on (a)&nbsp;the business, results of operations or financial condition of the Group
Companies, taken as a whole, or (b)&nbsp;the ability of the Company to consummate the Merger; <U>provided</U>, <U>however</U>, that, in the case of <U>clause (a)</U>, none of the following shall be taken into account in determining whether a Company
Material Adverse Effect has occurred or is reasonably likely to occur: any adverse change, event, effect or occurrence arising after the date of this Agreement from or related to (i)&nbsp;general business or economic conditions in or affecting the
United States, or changes therein, or the global economy generally, (ii)&nbsp;any national or international political or social conditions in the United States or any other country, including the engagement by the United States or any other country
in hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence in any place of any military or terrorist attack, sabotage or cyberterrorism, (iii)&nbsp;changes in conditions of the financial, banking,
capital or securities markets generally in the United States or any other country or region in the world, or changes therein, including changes in interest rates in the United States or any other country and changes in exchange rates for the
currencies of any countries, (iv)&nbsp;changes in any applicable Laws, (v)&nbsp;any change, event, effect or occurrence that is generally applicable to the industries or markets in which any Group Company operates, (vi)&nbsp;the execution or public
announcement of this Agreement or the pendency or consummation of the Transactions, including the impact thereof on the relationships, contractual or otherwise, of any Group Company with employees, customers, investors, contractors, lenders,
suppliers, vendors, partners, licensors, licensees, payors or other third parties related thereto (<U>provided</U> that the exception in this <U>clause</U><U></U><U>&nbsp;(vi)</U> shall not apply to the representations and warranties set forth in
<U>Section</U><U></U><U>&nbsp;3.5(b)</U> to the extent that its purpose is to address the consequences resulting from the public announcement or pendency or consummation of the Transactions or the condition set forth in
<U>Section</U><U></U><U>&nbsp;6.2(a)</U> to the extent it relates to such representations and warranties), (vii) any failure by any Group Company to meet, or changes to, any internal or published budgets, projections, forecasts, estimates or
predictions (although the underlying facts and circumstances resulting in such failure may be taken into account to the extent not otherwise excluded from this definition pursuant to <U>clauses (i)</U>&nbsp;through <U>(vi)</U> or <U>(viii)</U>), or
(viii)&nbsp;any hurricane, tornado, flood, earthquake, tsunami, natural disaster, mudslides, wild fires, epidemics, pandemics (including <FONT STYLE="white-space:nowrap">COVID-19)</FONT> or quarantines, acts of God or other natural disasters or
comparable events in the United States or any other country or region in the world, or any escalation of the foregoing; <U>provided</U>, <U>however</U>, that any change, event, effect or occurrence resulting from a matter described in any of the
foregoing <U>clauses</U><U></U><U>&nbsp;(i)</U> through <U>(v)</U>&nbsp;or <U>(viii)</U> may be taken into account in determining whether a Company Material Adverse Effect has occurred or is reasonably likely to occur to the extent such change,
event, effect or occurrence has a disproportionate adverse effect on the Group Companies, taken as a whole, relative to other participants operating in the industries or markets in which the Group Companies operate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Option&#148; means, as of any determination time, each option to purchase Company Common Shares that is outstanding and
unexercised and granted under the Company Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Owned Intellectual Property&#148; means all Intellectual Property
Rights that are owned and used, held for use or practiced by any Group Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Preferred Shares&#148; means the Company
Series A Preferred Shares, the Company Series B Preferred Shares and the Company Series C Preferred Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Product&#148;
means each product candidate that as of the date of this Agreement is being researched, tested, developed or manufactured by or on behalf of the Group Companies (excluding any compounds that are being screened or researched that have not be selected
by the Group Companies for clinical development). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Registered Intellectual Property&#148; means all Registered Intellectual
Property owned or purported to be owned by, or filed by or in the name of any Group Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Registration Rights
Agreement&#148; means the Amended and Restated Investors&#146; Rights Agreement, dated as of May&nbsp;29, 2020, by and among the Company and the Company Stockholders party thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Related Party&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.19</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Related Party Transactions&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.19</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Restricted Stock Award&#148; means, as of any determination time, each restricted
stock award that is outstanding with respect to Company Common Shares that is granted under the Company Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Series
A Preferred Shares&#148; means shares of preferred stock, par value $0.0001 per share, of the Company designated as &#147;Series A Preferred Stock&#148; pursuant to the Amended and Restated Certificate of Incorporation of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Series B Preferred Shares&#148; means shares of preferred stock, par value $0.0001 per share, of the Company designated as
&#147;Series A Preferred Stock&#148; pursuant to the Amended and Restated Certificate of Incorporation of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company
Series C Preferred Shares&#148; means shares of preferred stock, par value $0.0001 per share, of the Company designated as &#147;Series C Preferred Stock&#148; pursuant to the Amended and Restated Certificate of Incorporation of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Shares&#148; means, collectively, the Company Series A Preferred Shares, the Company Series B Preferred Shares, the Company
Series C Preferred Shares and the Company Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Share Consideration&#148; means (a)&nbsp;with respect to each
Company Common Share, a number of CHFW Shares equal to the Exchange Ratio, and (b)&nbsp;with respect to each Company Preferred Share, a number of CHFW Shares equal to (i)&nbsp;the aggregate number of Company Common Shares that would be issued upon
conversion of such Company Preferred Share based on the applicable conversion ratio immediately prior to the Effective Time, <U>multiplied by</U> (ii)&nbsp;the Exchange Ratio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Stockholders&#148; means, collectively, the holders of Company Shares as of any determination time prior to the Effective Time.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Stockholders Agreements&#148; means the agreements governing the terms of the Company Preferred Shares, including the
Amended and Restated Investors&#146; Rights Agreement, dated as of May&nbsp;29, 2020, by and among the Company and the Company Stockholder parties thereto, the Company <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement, the Company
Registration Rights Agreement and the Company Voting Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Stockholder Approval&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;5.13(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Stockholder Written Consent Deadline&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;5.13(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Company Voting Agreement&#148; means the Amended and Restated Voting Agreement, dated as
of May&nbsp;29, 2020, by and among the Company and the Company Stockholders parties thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Confidentiality Agreement&#148; means
that certain confidentiality agreement entered into between the Company and CHFW, dated December&nbsp;17, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Consent&#148; means
any notice, authorization, qualification, registration, filing, notification, waiver, order, consent or approval to be obtained from, filed with or delivered to, a Governmental Entity or other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Continental&#148; means Continental Stock Transfer&nbsp;&amp; Trust Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Contract&#148; or &#147;Contracts&#148; means any written or oral agreement, contract, license, lease, obligation, undertaking or other
commitment or arrangement that is legally binding upon a Person or any of his, her or its properties or assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Copyrights&#148; has the meaning set forth in the definition of Intellectual Property
Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">&#147;COVID-19&#148;</FONT> means <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> or <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and any evolutions thereof or related or associated epidemics, pandemic or disease outbreaks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Creator&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.13(d)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;DGCL&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Domestication&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Domestication Proposal&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Effective Time&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1(b)(ii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Employee Benefit Plan&#148; means each &#147;employee benefit plan&#148; (as such term is defined in
<U>Section</U><U></U><U>&nbsp;3(3)</U> of ERISA, whether or not subject to ERISA) and each other benefit or compensatory plan, program, policy or Contract that any Group Company maintains, sponsors or contributes to, or under or with respect to
which any Group Company has any Liability, other than any plan sponsored or maintained by a Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Environmental
Laws&#148; means all Laws and Orders concerning pollution, protection of the environment, or human health or safety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Equity
Securities&#148; means any share, share capital, capital stock, partnership, membership, joint venture or similar interest in any Person (including any stock appreciation, phantom stock, profit participation or similar rights), and any option,
warrant, right or security (including debt securities) convertible, exchangeable or exercisable therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Equity Value&#148; means
$200,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Equity Value Per Share&#148; means (a)&nbsp;the Equity Value, <U>divided by</U> (b)&nbsp;the Fully Diluted Company
Capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;ERISA&#148; means the Employee Retirement Income Security Act of 1974. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;ESPP&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.19</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Exchange Act&#148; means the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Exchange Agent&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.5(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Exchange Fund&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.5(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Exchange Ratio&#148; means (a)&nbsp;the Equity Value Per Share, <U>divided by</U> (b)&nbsp;the CHFW Share Value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;FDA&#148; means the U.S. Food and Drug Administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Federal Securities Laws&#148; means the Exchange Act, the Securities Act and the other U.S. federal securities laws and the rules and
regulations of the SEC promulgated thereunder or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Financial Statements&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.4(a)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Fully Diluted Company Capitalization&#148; means, without duplication, the sum of
(a)&nbsp;the aggregate number of Company Common Shares issued and outstanding as of immediately prior to the Effective Time, determined on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Company Common Share basis (including, for the
avoidance of doubt, the number of shares of Company Common Shares issuable upon conversion of the Company Series A Preferred Shares, the Company Series B Preferred Shares and the Company Series C Preferred Shares based on the then applicable
conversion ratio), and (b)&nbsp;the aggregate number of Company Common Shares subject to Company Equity Awards outstanding as of immediately prior to the Effective Time. For the avoidance of doubt, Fully Diluted Company Capitalization shall not
include Company Common Shares reserved and available for issuance of future awards of Company Equity Awards under the Company Equity Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;GAAP&#148; means United States generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;GLP&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.23(d)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Governing Document Proposals&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Governing Documents&#148; means the legal document(s) by which any Person (other than an individual) establishes its legal existence or
which govern its internal affairs. For example, the &#147;Governing Documents&#148; of a U.S. corporation are its certificate or articles of incorporation and <FONT STYLE="white-space:nowrap">by-laws,</FONT> the &#147;Governing Documents&#148; of a
U.S. limited partnership are its limited partnership agreement and certificate of limited partnership, the &#147;Governing Documents&#148; of a U.S. limited liability company are its operating or limited liability company agreement and certificate
of formation and the &#147;Governing Documents&#148; of a Cayman Islands exempted company are its memorandum and articles of association. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Governmental Entity&#148; means any United States or <FONT STYLE="white-space:nowrap">non-United</FONT> States (a)&nbsp;federal, state,
local, municipal or other government, (b)&nbsp;governmental or quasi-governmental entity of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal) or (c)&nbsp;body exercising or
entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature, including any arbitral tribunal (public or private). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Group Company&#148; and &#147;Group Companies&#148; means, collectively, the Company and its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Hazardous Substance&#148; means any hazardous, toxic, explosive or radioactive material, substance, waste or other pollutant that is
regulated by, or may give rise to Liability pursuant to, any Environmental Law, including any petroleum products or byproducts, asbestos, lead, polychlorinated biphenyls, <FONT STYLE="white-space:nowrap">per-</FONT> and poly-fluoroakyl substances,
or radon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Incentive Stock Option&#148; means a Company Option intended to be an &#147;incentive stock option&#148; (as defined in
Section&nbsp;422 of the Code). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Indebtedness&#148; means, as of any time, without duplication, with respect to any Person, the
outstanding principal amount of, accrued and unpaid interest on, fees and expenses arising under or in respect of (a)&nbsp;indebtedness for borrowed money, (b)&nbsp;other obligations evidenced by any note, bond, debenture or other debt security,
(c)&nbsp;obligations for the deferred purchase price of property or assets, including &#147;earn-outs&#148; and &#147;seller notes&#148; (but excluding any trade payables arising in the ordinary course of business), (d)&nbsp;reimbursement and other
obligations with respect to letters of credit, bank guarantees, bankers&#146; acceptances or other similar instruments, in each case, solely to the extent drawn, (e)&nbsp;leases required to be capitalized under GAAP, (f)&nbsp;derivative, hedging,
swap, foreign exchange or similar arrangements, including swaps, caps, collars, hedges or similar arrangements, (g)&nbsp;all &#147;applicable employment taxes&#148; (as defined in Section&nbsp;2302(d)(1) of the CARES Act) that the Group Companies
have elected to defer pursuant to Section&nbsp;2302 of the CARES Act, (h)&nbsp;all Taxes (including withholding Taxes) deferred pursuant to Internal Revenue Service Notice <FONT STYLE="white-space:nowrap">2020-65</FONT> or any related or similar
order or declaration from any Governmental Entity (including, without limitation, the Presidential Memorandum, dated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
August&nbsp;8, 2020, issued by the President of the United States), and (i)&nbsp;any of the obligations of any other Person of the type referred to in clauses (a)&nbsp;through (h) above directly
or indirectly guaranteed by such Person or secured by any assets of such Person, whether or not such Indebtedness has been assumed by such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Intellectual Property Rights&#148; means all intellectual property rights and related priority rights protected, created or arising
under the Laws of the United States or any other jurisdiction or under any international convention, including all (a)&nbsp;patents and patent applications, industrial designs and design patent rights, including any continuations, divisionals, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part</FONT></FONT> and provisional applications and statutory invention registrations, and any patents issuing on any of the foregoing and any reissues, reexaminations,
substitutes, supplementary protection certificates, extensions of any of the foregoing (collectively, &#147;Patents&#148;); (b)&nbsp;trademarks, service marks, trade names, service names, brand names, trade dress rights, logos, Internet domain
names, corporate names and other source or business identifiers, together with the goodwill associated with any of the foregoing, and all applications, registrations, extensions and renewals of any of the foregoing (collectively, &#147;Marks&#148;);
(c) copyrights and works of authorship, database and design rights, mask work rights and moral rights, whether or not registered or published, and all registrations, applications, renewals, extensions and reversions of any of any of the foregoing
(collectively, &#147;Copyrights&#148;); (d) trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and confidential and proprietary information, including invention disclosures, inventions and formulae, whether patentable or not;
(e)&nbsp;rights in or to Software or other technology; and (f)&nbsp;any other intellectual or proprietary rights protectable, arising under or associated with any of the foregoing, including those protected by any Law anywhere in the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Intended Tax Treatment&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Investment Company Act&#148; means the Investment Company Act of 1940. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Investor Rights Agreement&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Investors&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;IPO&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.18</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;IPO Warrant Agreement&#148; means the Warrant Agreement, dated as of November&nbsp;18, 2020, by and between CHFW and the Trustee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;IPO Warrants&#148; means the warrants to purchase one CHFW Share at an exercise price of $11.50 per share, subject to adjustment in
accordance with the IPO Warrant Agreement (including, for the avoidance of doubt, each such warrant held by the Sponsor or any Other Class&nbsp;B Shareholder). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;JOBS Act&#148; means the Jumpstart Our Business Startups Act of 2012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Latest Balance Sheet&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.4(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Law&#148; means any federal, state, local, foreign, national or supranational statute, law (including common law), act, statute,
ordinance, treaty, rule, code, regulation or other binding directive or guidance issued, promulgated or enforced by a Governmental Entity having jurisdiction over a given matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Leased Real Property&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.18(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Letter of Transmittal&#148; means the letter of transmittal, substantially in the form attached as <U>Exhibit D</U> hereto and with such
modifications, amendments or supplements as may be requested by the Exchange Agent and mutually agreed to by each of CHFW and the Company (such agreement not to be unreasonably withheld, conditioned or delayed). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Liability&#148; or &#147;liability&#148; means any and all debts, liabilities and
obligations, whether accrued or fixed, absolute or contingent, known or unknown, matured or unmatured or determined or determinable, including those arising under any Law (including any Environmental Law), Proceeding or Order and those arising under
any Contract, agreement, arrangement, commitment or undertaking. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Lien&#148; means any mortgage, pledge, security interest,
encumbrance, lien, license or <FONT STYLE="white-space:nowrap">sub-license,</FONT> charge, or other similar encumbrance or interest (including, in the case of any Equity Securities, any voting, transfer or similar restrictions). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Marks&#148; has the meaning set forth in the definition of Intellectual Property Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Material Contracts&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.7(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Material Permits&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.6</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Merger&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Merger Sub&#148; has the meaning set forth in the introductory paragraph to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Modification in Recommendation&#148; means any withdrawal, amendment, qualification or modification of the CHFW Board Recommendation for
each of the Required Transaction Proposals in a manner adverse to the Company and Merger Sub. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Multiemployer Plan&#148; has the
meaning set forth in Section (3)37 or Section&nbsp;4001(a)(3) of ERISA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Nasdaq&#148; means the Nasdaq Global Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Nasdaq Proposal&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Newco&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.5(a)(i).</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;NYSE American&#148; means the NYSE American LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Off-the-Shelf</FONT></FONT> Software&#148; means any Software that is
made generally and widely available to the public on a commercial basis and is licensed to any of the Group Companies on a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis under standard terms and conditions for a <FONT
STYLE="white-space:nowrap">one-time</FONT> license fee of less than $100,000 per license or an ongoing licensee fee of less than $50,000 per year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Officers&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.16(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Order&#148; means any outstanding writ, order, judgment, injunction, decision, determination, award, ruling, subpoena, verdict or decree
entered, issued or rendered by any Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Other CHFW Shareholder Approval&#148; means the approval of each Other
Transaction Proposal by the affirmative vote of the holders of the requisite number of CHFW Shares entitled to vote thereon, whether in person or by proxy at the CHFW Shareholders Meeting (or any adjournment or postponement thereof), in accordance
with the Governing Documents of CHFW and applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Other Class<U></U> B Shareholders&#148; means, collectively,
Dr.&nbsp;Mitchell Blutt, M.D., Dr.&nbsp;Benny Soffer, M.D., Donald J. Santel, Dr.&nbsp;Christopher Haqq, M.D., Ph.D. and Jennifer Jarrett. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Other Transaction Proposal&#148; means each Transaction Proposal, other than the Required Transaction Proposals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Parties&#148; has the meaning set forth in the introductory paragraph to this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Patents&#148; has the meaning set forth in the definition of Intellectual Property Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;PCAOB&#148; means the Public Company Accounting Oversight Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Permits&#148; means any approvals, authorizations, clearances, licenses, registrations, permits or certificates of a Governmental
Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Permitted Liens&#148; means (a)&nbsp;mechanic&#146;s, materialmen&#146;s, carriers&#146;, repairers&#146; and other similar
statutory Liens arising or incurred in the ordinary course of business for amounts that are not yet delinquent or are being contested in good faith by appropriate proceedings and for which sufficient reserves have been established in accordance with
GAAP, (b)&nbsp;Liens for Taxes, assessments or other governmental charges not yet due and payable as of the Closing Date or which are being contested in good faith by appropriate proceedings and for which sufficient reserves have been established on
the in accordance with GAAP, (c)&nbsp;encumbrances and restrictions on real property (including easements, covenants, conditions, rights of way and similar restrictions) that do not prohibit or materially interfere with any of the Group
Companies&#146; use or occupancy of such real property, (d)&nbsp;zoning, building codes and other land use Laws regulating the use or occupancy of real property or the activities conducted thereon which are imposed by any Governmental Entity having
jurisdiction over such real property and which are not violated by the use or occupancy of such real property or the operation of the businesses of the Group Company and do not prohibit or materially interfere with any of the Group Companies&#146;
use or occupancy of such real property, (e)&nbsp;cash deposits or cash pledges to secure the payment of workers&#146; compensation, unemployment insurance, social security benefits or obligations arising under similar Laws or to secure the
performance of public or statutory obligations, surety or appeal bonds, and other obligations of a like nature, in each case in the ordinary course of business and which are not yet due and payable, (f)&nbsp;grants by any Group Company of <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> rights in Intellectual Property in the ordinary course of business consistent with past practice and (g)&nbsp;other Liens that do not materially and adversely affect the value, use or operation of the
asset subject thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Person&#148; means an individual, partnership, corporation, limited liability company, joint stock company,
unincorporated organization or association, trust, joint venture or other similar entity, whether or not a legal entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Personal
Data&#148; means any data or information maintained by or on behalf of a Group Company that identifies or is reasonably capable of being used to identify a natural person, which data or information is regulated by the Privacy Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;PIPE Financing&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;PIPE Financing Amount&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;PIPE Investors&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;PIPE Warrant Agreement&#148; means the Warrant Agreement, dated as of the date hereof, by and between CHFW and the Trustee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;PIPE Warrants&#148; means each warrant to purchase one CHFW Share at an exercise price of $11.50 per share, subject to adjustment in
accordance with the PIPE Warrant Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">&#147;Pre-Closing</FONT> CHFW Holders&#148; means the
holders of CHFW Shares at any time prior to the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Privacy and Data Security Policies&#148; has the meaning set forth
in <U>Section</U><U></U><U>&nbsp;3.20(a)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Privacy Laws&#148; means Laws in any jurisdiction relating to the Processing or
protection of Personal Data that apply to the Group Companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Proceeding&#148; means any lawsuit, litigation, action, audit,
examination, claim, complaint, charge, proceeding, suit or arbitration (in each case, whether civil, criminal or administrative and whether public or private) pending by or before or otherwise involving any Governmental Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Process&#148; (or &#147;Processing&#148; or &#147;Processes&#148;) means the collection, use, storage, processing, recording,
distribution, transfer, import, export, protection (including security measures), disposal or disclosure or other activity regarding data (whether electronically or in any other form or medium). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Prospectus&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.18</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Public Health Laws&#148; means all applicable Laws relating to the development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
testing, clinical testing, manufacture, production, analysis, distribution, importation, exportation, use, handling, quality, sale or promotion of any drug or biologic (including any ingredient or component of the foregoing products) subject to
regulation under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167; 301 <I>et seq</I>.), the Public Health Service Act (42 U.S.C. &#167; 201 <I>et </I>seq.) or similar federal, state or foreign, pharmaceutical Laws, advanced therapy
medicinal product Laws, Laws on the collection and processing of blood, blood components, tissues and/or cells, genetically engineered products Laws, infection protocol Laws and clinical investigation Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Public Shareholders&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.18.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Public Software&#148; means any Software that contains, includes, incorporates, or has instantiated therein, or is derived in any manner
(in whole or in part) from, any Software that is distributed as free software, open source software (e.g., Linux) or similar licensing or distribution models, including under any terms or conditions that impose any requirement that any Software
using, linked with, incorporating, distributed with or derived from such Public Software (a)&nbsp;be made available or distributed in source code form; (b)&nbsp;be licensed for purposes of making derivative works; or (c)&nbsp;be redistributable at
no, or a nominal, charge. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Real Property Leases&#148; means all leases, <FONT STYLE="white-space:nowrap">sub-leases,</FONT> licenses
or other agreements, in each case, pursuant to which any Group Company leases or <FONT STYLE="white-space:nowrap">sub-leases</FONT> any real property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Registered Intellectual Property&#148; means all issued Patents, pending Patent applications, registered Marks, pending applications for
registration of Marks, registered Copyrights, pending applications for registration of Copyrights and Internet domain name registrations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Registration Statement/Proxy Statement&#148; means a registration statement on Form S-4 relating to the Transactions and containing a
prospectus and proxy statement of CHFW. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Regulatory Permits&#148; means all Permits granted by FDA or any comparable Governmental
Entity to any Group Company, including investigational new drug applications, new drug applications, biologics license applications, manufacturing approvals and authorizations, EC certificates, EC declarations of conformity, authorization of tissue
establishment and tissue and cell preparation processes, clinical trial authorizations and ethical reviews, scientific opinions for advanced therapy medicinal product, genetic engineering authorizations, infection protection authorizations or their
national or foreign equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Representatives&#148; means with respect to any Person, such Person&#146;s Affiliates and its and
such Affiliates&#146; respective directors, officers, managers, employees, members, owners, accountants, consultants, advisors, attorneys, agents and other representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Required CHFW Shareholder Approval&#148; means the approval of each Required Transaction Proposal by the affirmative vote of the holders
of the requisite number of CHFW Shares entitled to vote thereon, whether in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
person or by proxy at the CHFW Shareholders Meeting (or any adjournment or postponement thereof), in accordance with the Governing Documents of CHFW and applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Required Governing Document Proposals&#148; means the Governing Document Proposals solely to the extent related to the amendments to the
Governing Documents of CHFW set forth on <U>Annex D</U> attached hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Required Transaction Proposals&#148; means, collectively,
the Business Combination Proposal, the Domestication Proposal, the Nasdaq Proposal, the Equity Incentive Plan Proposal and the Required Governing Document Proposals </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Rollover Option&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.4(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Rollover Restricted Stock Award&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.4(b)</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Sanctions and Export Control Laws&#148; means any Law in any part of the world related to (a)&nbsp;import and export controls, including
the U.S. Export Administration Regulations, (b)&nbsp;economic sanctions, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury, the U.S. Department of State, the European Union, any European
Union Member State, the United Nations, and Her Majesty&#146;s Treasury of the United Kingdom or (c)&nbsp;anti-boycott measures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Sarbanes-Oxley Act&#148; means the Sarbanes-Oxley Act of 2002. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Schedules&#148; means, collectively, the Company Disclosure Schedules and the CHFW Disclosure Schedules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;SEC&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Securities Act&#148; means the U.S. Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Securities Laws&#148; means Federal Securities Laws and other applicable foreign and domestic securities or similar Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Signing Filing&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.4(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Signing Press Release&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.4(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Software&#148; shall mean any and all (a)&nbsp;computer programs, including any and all software implementations of algorithms, models
and methodologies, whether in source code or object code; (b)&nbsp;databases and compilations, including any and all data and collections of data, whether machine readable or otherwise; (c)&nbsp;descriptions, flowcharts and other work product used
to design, plan, organize and develop any of the foregoing, screens, user interfaces, report formats, firmware, development tools, templates, menus, buttons and icons; and (d)&nbsp;all documentation, including user manuals and other training
documentation, related to any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Sponsor&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Sponsor Letter Agreement&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Subscription Agreement&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Subsidiary&#148; means, with respect to any Person, any corporation, limited liability company, partnership or other legal entity of
which (a)&nbsp;if a corporation, a majority of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or
controlled, directly or indirectly, by such Person or one or more of the other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Subsidiaries of such Person or a combination thereof, or (b)&nbsp;if a limited liability company, partnership, association or other business entity (other than a corporation), a majority of the
partnership or other similar ownership interests thereof is at the time owned or controlled, directly or indirectly, by such Person or one or more Subsidiaries of such Person or a combination thereof and for this purpose, a Person or Persons own a
majority ownership interest in such a business entity (other than a corporation) if such Person or Persons shall be allocated a majority of such business entity&#146;s gains or losses or shall be a, or control any, managing director or general
partner of such business entity (other than a corporation). The term &#147;Subsidiary&#148; shall include all Subsidiaries of such Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Supporting Company Stockholders&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Surviving Company&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1(b)(i).</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Tax&#148; means any federal, state, local or <FONT STYLE="white-space:nowrap">non-United</FONT> States income, gross receipts,
franchise, estimated, alternative minimum, imputed underpayment, sales, use, transfer, value added, excise, stamp, customs, duties, ad valorem, real property, personal property (tangible and intangible), capital stock, social security, unemployment,
payroll, wage, employment, severance, occupation, registration, environmental, communication, mortgage, profits, license, lease, service, goods and services, withholding, premium, unclaimed property, escheat, turnover, windfall profits or other
taxes of any kind whatever, whether computed on a separate or combined, unitary or consolidated basis or in any other manner, together with any interest, deficiencies, penalties, additions to tax, or additional amounts imposed by any Governmental
Entity with respect thereto, whether disputed or not, and including any secondary Liability for any of the aforementioned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Tax
Authority&#148; means any Governmental Entity responsible for the collection or administration of Taxes or Tax Returns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Tax
Return&#148; means returns, information returns, statements, declarations, claims for refund, schedules, attachments and reports relating to Taxes required to be filed with any Governmental Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Termination Date&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;7.1(d).</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Transactions&#148; means the transactions contemplated by this Agreement, including, the Domestication and the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Transaction Litigation&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.2(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Transaction Proposals&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Transaction Share Consideration&#148; means an aggregate number of CHFW Shares equal to (a)&nbsp;the Equity Value, <U>divided by</U>
(b)&nbsp;the CHFW Share Value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Transaction Support Agreement Deadline&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;5.13(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Transaction Support Agreements&#148; has the meaning set forth in the recitals to this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Trust Account&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.18.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Trust Account <U>Released Claims</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.18</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Trust Agreement&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Trustee&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.8</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Unpaid CHFW Expenses&#148; means the CHFW Expenses that are unpaid as of immediately
prior to the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Unpaid CHFW Liabilities&#148; means the CHFW Liabilities as of immediately prior to the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Unpaid Company Expenses&#148; means the Company Expenses that are unpaid as of immediately prior to the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Unvested Company Equity Awards&#148; means, collectively, the Unvested Company Options and the Unvested Company Restricted Stock Awards.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Unvested Company Option&#148; means each Company Option outstanding as of immediately prior to the Effective Time that is not a
Vested Company Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Unvested Company Restricted Stock Award&#148; means each Company Restricted Stock Award outstanding as of
immediately prior to the Effective Time that has not satisfied its vesting conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Vested Company Option&#148; means each
Company Option outstanding as of immediately prior to the Effective Time that is vested or will vest solely as a result of the consummation of the Merger (whether at the Effective Time or otherwise). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;WARN&#148; means the Worker Adjustment Retraining and Notification Act of 1988, as well as analogous applicable foreign, state or local
Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Willful Breach&#148; means a material breach that is the consequence of an act undertaken or a failure to act by the
breaching party with the knowledge that the taking of such act or failure to act would, or would reasonably be expected to, constitute or result in a breach of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#147;Written Consent&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.13(b)</U>.<U> </U> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxa40894_3"></A>ARTICLE 2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MERGERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_4">
</A><B>Section</B><B></B><B>&nbsp;2.1</B> Closing Transactions. On the terms and subject to the conditions set forth in this Agreement,<B> </B>the following transactions shall occur in the order set forth in this
<U>Section</U><U></U><U>&nbsp;2.1</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Domestication</U>. Prior to the Closing, CHFW shall cause
the Domestication to occur in accordance with Section&nbsp;388 of the DGCL and Part XII of the Cayman Islands Companies Act (2021 Revision). In connection with the Domestication, (i)&nbsp;each CHFW Class&nbsp;A Share and each CHFW Class&nbsp;B Share
that is issued and outstanding immediately prior to the Domestication shall become one share of CHFW Common Stock, (ii)&nbsp;each IPO Warrant that is outstanding immediately prior to the Domestication shall, from and after the Domestication,
represent the right to purchase one share of CHFW Common Stock at an exercise price of $11.50 per share on the terms and subject to the conditions set forth in the IPO Warrant Agreement, (iii)&nbsp;the Governing Documents of CHFW shall be replaced
by and become the certificate of incorporation, substantially in the form attached hereto as <U>Exhibit</U><U></U><U>&nbsp;E</U> (the &#147;CHFW Certificate of Incorporation&#148;), and the bylaws, substantially in the form attached hereto as
<U>Exhibit </U><U>F</U> (the &#147;CHFW Bylaws&#148;) and (iv)&nbsp;CHFW&#146;s name shall be changed to &#147;Surrozen, Inc.&#148;; <U>provided</U>, <U>however</U>, that, in the case of clause (iii), each of the Parties hereby acknowledges and
agrees that each of the CHFW Certificate of Incorporation and the CHFW Bylaws shall be appropriately adjusted to give effect to any amendments to the Governing Documents of CHFW contemplated by the CHFW Certificate of Incorporation and the CHFW
Bylaws that are not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
adopted and approved by the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> CHFW Holders at the CHFW Shareholders Meeting (other than, for the avoidance of doubt, the amendments to the
Governing Documents of CHFW that are contemplated by the Required Governing Document Proposals). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b)
<U>Merger</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) On the terms and subject to the conditions set forth in this Agreement and in accordance with the
DGCL, on the Closing Date but following the consummation of the Domestication, Merger Sub shall merge with and into the Company (the &#147;Merger&#148;) at the Effective Time. Following the Effective Time, the separate existence of Merger Sub shall
cease and the Company shall continue as the surviving company of the Merger (the &#147;Surviving Company&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) At
the Closing, the parties hereto shall cause a certificate of merger, in a form reasonably satisfactory to the Company and CHFW (the &#147;Certificate of Merger&#148;), to be executed and filed with the Secretary of State of the State of Delaware.
The Merger shall become effective on the date and time at which the Certificate of Merger is accepted for filing by the Secretary of State of the State of Delaware or at such later date and/or time as is agreed by CHFW and the Company and specified
in the Certificate of Merger (the time the Merger becomes effective being referred to herein as the &#147;Effective Time&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) The Merger shall have the effects set forth in Section&nbsp;251 of the DGCL. Without limiting the generality of the
foregoing, and subject thereto, at the Effective Time, all of the assets, properties, rights, privileges, powers and franchises of the Company and Merger Sub shall vest in the Surviving Company and all debts, liabilities, obligations, restrictions,
disabilities and duties of each of the Company and Merger Sub shall become the debts, liabilities, obligations and duties of the Surviving Company, in each case, in accordance with the DGCL. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv) At the Effective Time, the Governing Documents of Merger Sub shall be the Governing Documents of the Surviving Company,
in each case, until thereafter changed or amended as provided therein or by applicable Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v) At the Effective Time,
the directors and officers of the Company immediately prior to the Effective Time shall be the initial directors and officers of the Surviving Company, each to hold office in accordance with the Governing Documents of the Surviving Company until
such director&#146;s or officer&#146;s successor is duly elected or appointed and qualified, or until the earlier of their death, resignation or removal. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vi) At the Effective Time, by virtue of the Merger and without any action on the part of any Party or any other Person, each
share of capital stock of Merger Sub issued and outstanding immediately prior to the Effective Time shall be automatically cancelled and extinguished and converted into one share of common stock, par value $0.0001, of the Surviving Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vii) At the Effective Time, by virtue of the Merger and without any action on the part of any Party or any other Person, each
Company Share (other than the Company Shares cancelled and extinguished pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)(viii)</U>) issued and outstanding as of immediately prior to the Effective Time shall be automatically cancelled and
extinguished and converted into the right to receive a number of CHFW Shares equal to the Company Share Consideration. From and after the Effective Time, the holder(s) of certificates (the &#147;Certificates&#148;), if any, evidencing ownership of
the Company Shares and the Company Shares held in book-entry form issued and outstanding immediately prior to the Effective Time shall each cease to have any rights with respect to such Company Shares except as otherwise expressly provided for
herein or under applicable Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(viii) At the Effective Time, by virtue of the Merger and without any action on the part
of any Party or any other Person, each Company Share held immediately prior to the Effective Time by the Company as treasury stock shall be automatically cancelled and extinguished, and no consideration shall be paid with respect thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ix) No fraction of a CHFW Share shall be issued in connection with the Merger, and no certificates or scrip for any such
fractional shares shall be issued. Any holder of a Company Share who would otherwise be entitled to receive a fraction of a share of a CHFW Share (after aggregating all fractional shares of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
CHFW Shares issuable to such holder) shall, in lieu of such fraction of a share and upon surrender by such holder of a Letter of Transmittal in accordance with
<U>Section</U><U></U><U>&nbsp;2.5</U> and any accompanying documents as required therein, be paid in cash the dollar amount (rounded to the nearest whole cent), without interest, determined by multiplying such fraction by the CHFW Share Value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_5"></A><B>Section</B><B></B><B>&nbsp;2.2</B> <B>Closing of the Transactions Contemplated by this Agreement</B>. The closing
of the Transactions (the &#147;Closing&#148;) shall take place electronically by exchange of the closing deliverables by the means provided in <U>Section</U><U></U><U>&nbsp;8.11</U> as promptly as reasonably practicable, but in no event later than
the third (3rd) Business Day, following the satisfaction (or, to the extent permitted by applicable Law, waiver) of the conditions set forth in <U>Article 6</U> (other than those conditions that by their nature are to be satisfied at the Closing,
but subject to satisfaction or waiver of such conditions) (the &#147;Closing Date&#148;) or at such other place, date and/or time as CHFW and the Company may agree in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_6"></A><B>Section</B><B></B><B>&nbsp;2.3</B> <B>Allocation Schedule</B>. No later than three (3)&nbsp;Business Days prior
to the scheduled Closing Date, the Company shall deliver to CHFW an allocation schedule (the &#147;Allocation Schedule&#148;) setting forth (a)&nbsp;the number of each class and series of Company Shares held by each Company Stockholder, the number
of Company Shares subject to each Company Equity Award held by each holder thereof, as well as to what extent each such Company Equity Award will be vested or unvested as of immediately prior to the Effective Time, and, in the case of the Company
Options, the exercise price of thereof, as well as reasonably detailed calculations and vesting schedule with respect to the components and subcomponents thereof, (b)&nbsp;the portion of the Transaction Share Consideration allocated to each Company
Stockholder pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)(vii)</U>, as well as reasonably detailed calculations with respect to the component and subcomponents thereof, and (c)&nbsp;a certification, duly executed by an authorized officer of the
Company, that the information and calculations delivered pursuant to clauses (a), and (b)&nbsp;are, and will be as of immediately prior to the Effective Time, (i)&nbsp;true and correct in all respects and (ii)&nbsp;in accordance with the applicable
provisions of this Agreement, the Governing Documents of the Company, the Company Stockholders Agreements and applicable Laws and, in the case of the Company Equity Awards, the Company Equity Plan and any applicable grant or similar agreement with
respect to any such Company Equity Award. The Company will review any comments to the Allocation Schedule provided by CHFW or any of its Representatives and consider in good faith and incorporate any reasonable comments proposed by CHFW or any of
its Representatives. Notwithstanding the foregoing or anything to the contrary herein, the aggregate number of CHFW Shares that each Company Stockholder will have a right to receive pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)(vii)</U> will be
rounded down to the nearest whole share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_7"></A><B>Section</B><B></B><B>&nbsp;2.4</B> <B>Treatment of Company Equity
Awards</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) At the Effective Time, by virtue of the Merger and without any action of any Party or any
other Person (but subject to, in the case of the Company, <U>Section</U><U></U><U>&nbsp;2.4(c)</U>), each Company Option (whether a Vested Company Option or an Unvested Company Option) shall cease to represent the right to purchase Company Common
Shares and shall be assumed by CHFW and converted into an option to purchase CHFW Shares under the CHFW Equity Incentive Plan (each, a &#147;Rollover Option&#148;). Each Rollover Option shall be subject to the same terms and conditions (including
applicable vesting, expiration and forfeiture provisions) that applied to the corresponding Company Option immediately prior to the Effective Time, except each Rollover Option shall (x)&nbsp;be exercisable for that number of CHFW Shares equal to the
product (rounded down to the nearest whole share) of (i)&nbsp;the number of shares of Company Common Shares subject to the Company Option immediately prior to the Effective Time multiplied by (ii)&nbsp;the Exchange Ratio, and (y)&nbsp;have a per
share exercise price for each CHFW share issuable upon exercise of such Rollover Option equal to the quotient (rounded up to the nearest whole cent) of (i)&nbsp;the exercise price per Company Common Share of such Company Option immediately prior to
the Effective Time divided by (ii)&nbsp;the Exchange Ratio. Such conversion and adjustments shall occur in a manner intended to comply with the requirements of Section&nbsp;409A of the Code and, for any Rollover Option that is an Incentive Stock
Option, Section&nbsp;424 of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) At the Effective Time, by virtue of the Merger and
without any action of any Party or any other Person (but subject to, in the case of the Company, <U>Section</U><U></U><U>&nbsp;2.4(c)</U>), each Unvested Company Restricted Stock Award shall be converted into a right to receive restricted CHFW
Shares (each, a &#147;Rollover Restricted Award&#148;) with substantially the same terms and conditions that were applicable to such Company Restricted Stock Award immediately prior to the Effective Time (including with respect to vesting and
termination related provisions), except that such Rollover Restricted Stock Award shall relate to such number of CHFW Shares equal to the product of (i)&nbsp;the number of Company Common Shares subject to such Restricted Stock Award immediately
prior to the Effective Time multiplied by (ii)&nbsp;the Exchange Ratio, with any fractional shares rounded down to the nearest whole share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) Prior to the Closing, the Company shall take, or cause to be taken, all necessary or appropriate actions
under the Company Equity Plan (and the underlying grant, award or similar agreements) or otherwise to give effect to the provisions of this <U>Section&nbsp;2.4(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_8"></A><B>Section</B><B></B><B>&nbsp;2.5</B> <B>Company Stockholder Deliverables</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) As promptly as reasonably practicable following the date of this Agreement, but in no event later than five
(5) Business Days prior to the Closing Date, CHFW shall appoint Continental (or its applicable Affiliate) as an exchange agent (the &#147;Exchange Agent&#148;) and enter into an exchange agent agreement with the Exchange Agent for the purpose of
exchanging Certificates, if any, representing the Company Common Shares and each Company Share held in book-entry form on the stock transfer books of the Company immediately prior to the Effective Time, in either case, for the portion of the
Transaction Share Consideration issuable in respect of such Company Shares pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)(vii)</U> and on the terms and subject to the other conditions set forth in this Agreement. Notwithstanding the foregoing or
anything to the contrary herein, in the event that Continental is unable or unwilling to serve as the Exchange Agent, then CHFW and the Company shall, as promptly as reasonably practicable thereafter, but in no event later than the Closing Date,
mutually agree upon an exchange agent (in either case, such agreement not to be unreasonably withheld, conditioned or delayed), CHFW shall appoint and enter into an exchange agent agreement with such exchange agent, who shall for all purposes under
this Agreement constitute the Exchange Agent and each of CHFW and the Company shall mutually agree to any changes to the Letter of Transmittal in order to satisfy any requirements of such exchange agent (in either case, such agreement not to be
unreasonably withheld, conditioned or delayed). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) At least three (3)&nbsp;Business Days prior to the
Closing Date, the Company shall mail or otherwise deliver, or shall cause to be mailed or otherwise delivered, to the Company Stockholders a Letter of Transmittal. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) At the Effective Time, CHFW shall deposit, or cause to be deposited, with the Exchange Agent, for the
benefit of the Company Stockholders and for exchange in accordance with this <U>Section</U><U></U><U>&nbsp;2.5</U> through the Exchange Agent, evidence of CHFW Shares in book-entry form representing the portion of the Transaction Share Consideration
issuable pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)(vii)</U> in exchange for the Company Shares outstanding immediately prior to the Effective Time. All shares in book-entry form representing the portion of the Transaction Share Consideration
issuable pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)(vii)</U> deposited with the Exchange Agent shall be referred to in this Agreement as the &#147;Exchange Fund&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) Each Company Stockholder whose Company Shares have been converted into the right to receive a portion of
the Transaction Share Consideration pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)(vii)</U> shall be entitled to receive the portion of the Transaction Share Consideration to which he, she or it is entitled on the date provided in
<U>Section</U><U></U><U>&nbsp;2.5(e)</U> upon (i)&nbsp;surrender of a Certificate (or affidavit of loss in lieu thereof in the form required by the Letter of Transmittal), together with the delivery of a properly completed and duly executed Letter
of Transmittal (including, for the avoidance of doubt, any documents or agreements required by the Letter of Transmittal), to the Exchange Agent or (ii)&nbsp;delivery </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of an &#147;agent&#146;s message&#148; in the case of Company Common Shares held in book-entry form, together with the delivery of a properly completed and duly executed Letter of Transmittal
(including, for the avoidance of doubt, any documents or agreements required by the Letter of Transmittal), to the Exchange Agent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) If a properly completed and duly executed Letter of Transmittal, together with any Certificates (or
affidavit of loss in lieu thereof in the form required by the Letter of Transmittal) or an &#147;agent&#146;s message&#148;, as applicable, is delivered to the Exchange Agent in accordance with <U>Section</U><U></U><U>&nbsp;2.5(d)</U>&nbsp;(i) at
least one (1)&nbsp;Business Day prior to the Closing Date, then CHFW and the Company shall take all necessary actions to cause the applicable portion of the Transaction Share Consideration to be issued to the applicable Company Stockholder in
book-entry form on the Closing Date, or (ii)&nbsp;less than one (1)&nbsp;Business Day prior to the Closing Date, then CHFW and the Company (or the Surviving Company) shall take all necessary actions to cause the applicable portion of the Transaction
Share Consideration to be issued to the Company Stockholder in book-entry form within two (2)&nbsp;Business Days after such delivery. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) If any portion of the Transaction Share Consideration is to be issued to a Person other than the Company
Stockholder in whose name the surrendered Certificate or the transferred Company Share in book-entry form is registered, it shall be a condition to the issuance of the applicable portion of the Transaction Share Consideration that (i)&nbsp;either
such Certificate shall be properly endorsed or shall otherwise be in proper form for transfer or such Company Share in book-entry form shall be properly transferred and (ii)&nbsp;the Person requesting such consideration pay to the Exchange Agent any
transfer or similar Taxes required as a result of such consideration being issued to a Person other than the registered holder of such Certificate or Company Share in book-entry form or establish to the satisfaction of the Exchange Agent that such
transfer or similar Taxes have been paid or are not payable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) No interest will be paid or accrued on
the Transaction Share Consideration (or any portion thereof). From and after the Effective Time, until surrendered or transferred, as applicable, in accordance with this <U>Section</U><U></U><U>&nbsp;2.5</U>, each Company Share (other than, for the
avoidance of doubt, the Company Shares cancelled and extinguished pursuant to <U>Section</U><U></U><U>&nbsp;2.1(b)(viii)</U>) shall solely represent the right to receive a portion of the Transaction Share Consideration and payment for any fractional
shares to which such Company Share is entitled to receive pursuant to <U>Section&nbsp;2.1(b)(vii)</U> and <U>Section&nbsp;2.1(b)(ix)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) At the Effective Time, the stock transfer books of the Company shall be closed and there shall be no
transfers of Company Shares that were outstanding immediately prior to the Effective Time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) Any portion
of the Exchange Fund that remains unclaimed by the Company Stockholders twelve (12)&nbsp;months following the Closing Date shall be delivered to CHFW or as otherwise instructed by CHFW, and any Company Stockholder who has not exchanged his, her or
its Company Shares for the applicable portion of the Transaction Share Consideration in accordance with this <U>Section</U><U></U><U>&nbsp;2.5</U> prior to that time shall thereafter look only to CHFW for the issuance of the applicable portion of
the Transaction Share Consideration, without any interest thereon. Neither of CHFW nor the Surviving Company or any of their respective Affiliates shall be liable to any Person in respect of any consideration delivered to a public official pursuant
to any applicable abandoned property, unclaimed property, escheat, or similar Law. Any portion of the Transaction Share Consideration remaining unclaimed by the Company Stockholders immediately prior to such time when the amounts would otherwise
escheat to or become property of any Governmental Entity shall become, to the extent permitted by applicable Law, the property of CHFW free and clear of any claims or interest of any Person previously entitled thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_9"></A><B>Section</B><B></B><B>&nbsp;2.6</B> <B>Withholding</B>. CHFW and the Exchange Agent (and, in each case, any
Affiliate thereof) shall be entitled to deduct and withhold (or cause to be deducted and withheld) from any consideration payable pursuant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
to this Agreement such amounts as are required to be deducted and withheld under applicable Tax Law. To the extent that amounts are so withheld and timely remitted to the applicable Governmental
Entity, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of which such deduction and withholding was made. The Parties shall cooperate in good faith to eliminate or reduce any
such deduction or withholding (including through the request and provision of any statements, forms or other documents to reduce or eliminate any such deduction or withholding). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_10"></A><B>Section</B><B></B><B>&nbsp;2.7</B> <B>Appraisal Rights</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Notwithstanding any provision of this Agreement to the contrary and to the extent available under the DGCL,
Company Shares that are outstanding immediately prior to the Effective Time and that are held by Company Stockholders who shall have neither voted in favor of the Merger nor consented thereto in writing and who shall have demanded properly in
writing appraisal for such Company Shares in accordance with Section&nbsp;262 of the DGCL and otherwise complied with all of the provisions of the DGCL relevant to the exercise and perfection of dissenters&#146; rights shall not be converted into,
and such stockholders shall have no right to receive, the Company Share Consideration unless and until such stockholder fails to perfect or withdraws or otherwise loses his, her or its right to appraisal and payment under the DGCL. Any Company
Stockholder who fails to perfect or who effectively withdraws or otherwise loses his, her or its dissenters&#146; rights to appraisal of such Company Shares under Section&nbsp;262 of the DGCL, shall thereupon be deemed to have been converted into,
and to have become exchangeable for, as of the Effective Time, the right to receive the applicable Company Share Consideration, without any interest thereon. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Prior to the Closing, the Company shall give CHFW (i)&nbsp;prompt notice of any demands for appraisal
rights received by the Company in writing and any withdrawals of such demands made in writing, and (ii)&nbsp;the opportunity to participate in all negotiations and proceedings with respect to demands for appraisal under the DGCL. The Company shall
not, except with the prior written consent of CHFW (which consent shall not be unreasonably conditioned, withheld or delayed), make any payment with respect to any demands for appraisal rights or offer to settle or settle any such demands. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxa40894_11"></A>ARTICLE 3 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES RELATING </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO THE GROUP COMPANIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to <U>Section</U><U></U><U>&nbsp;8.8</U>, except as set forth in the Company Disclosure Schedules, the Company hereby represents and
warrants to the CHFW Parties, in each case, as of the date of this Agreement and as of the Closing, as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_12"></A><B>Section</B><B></B><B>&nbsp;3.1</B> <B>Organization and Qualification</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Each Group Company is a corporation, limited liability company or other applicable business entity duly
organized or formed, as applicable, validly existing and in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the
Laws of its jurisdiction of formation or organization (as applicable). <U>Section</U><U></U><U>&nbsp;3.1(a)</U> of the Company Disclosure Schedules sets forth the jurisdiction of formation or organization (as applicable) for each Group Company. Each
Group Company has the requisite corporate, limited liability company or other applicable business entity power and authority to own, lease and operate its properties and to carry on its businesses as presently conducted in all material respects.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) True and complete copies of the Governing Documents of the Company and the Company Stockholders
Agreements have been made available to CHFW, in each case, as amended and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
in effect as of the date of this Agreement. The Governing Documents of the Company and the Company Stockholders Agreements are in full force and effect, and the Company is not in breach or
violation of any provision set forth in its Governing Documents or in material breach of the Company Stockholders Agreements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) Each Group Company is duly qualified or licensed to transact business and is in good standing (or the
equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) in each jurisdiction in which the property and assets owned, leased or operated by it, or the
nature of the business conducted by it, makes such qualification or licensing necessary, except where the failure to be so duly qualified or licensed and in good standing would not result in a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_13"></A><B>Section</B><B></B><B>&nbsp;3.2</B> <B>Capitalization of the Group Companies</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Schedule 3.2(a)</U> of the Company Disclosure Schedules sets forth a true and complete statement as of
the date of this Agreement of (i)&nbsp;the number and class or series (as applicable) of all of the Equity Securities of the Company issued and outstanding, (ii)&nbsp;the identity of the Persons that are the record owners thereof, (iii)&nbsp;with
respect to each Company Equity Award, (A)&nbsp;the date of grant, (B)&nbsp;any applicable exercise (or similar) price, (C)&nbsp;the expiration date, and (D)&nbsp;any applicable vesting schedule (including acceleration provisions) and (iv)&nbsp;with
respect to any Company Option, whether such Company Option is an Incentive Stock Option. All of the Equity Securities of the Company have been duly authorized and validly issued and all of the outstanding Company Shares are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> The Equity Securities of the Company (1)&nbsp;were not issued in violation of the Governing Documents of the Company or the Company Stockholders Agreements or any other Contract to which the Company
is party or bound, (2)&nbsp;were not issued in violation of any preemptive rights, call option, right of first refusal or first offer, subscription rights, transfer restrictions or similar rights of any Person under the Governing Documents of the
Company or any other Contract to which the Company is a party or bound or applicable Laws and (3)&nbsp;have been offered, sold and issued in compliance with applicable Law, including Securities Laws. Except for the Company Equity Awards set forth on
<U>Section</U><U></U><U>&nbsp;3.2(a)</U> of the Company Disclosure Schedules, the Company has no outstanding (x)&nbsp;equity appreciation, phantom equity or profit participation rights or (y)&nbsp;options, restricted stock, phantom stock, warrants,
purchase rights, subscription rights, conversion rights, exchange rights, calls, puts, rights of first refusal or first offer or other Contracts that could require the Company to issue, sell or otherwise cause to become outstanding or to acquire,
repurchase or redeem any Equity Securities or securities convertible into or exchangeable for Equity Securities of the Company. The Company Equity Plan is the only equity incentive plan maintained by the Company and all outstanding option,
restricted stock and similar awards have been granted under the Company Equity Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) The Equity
Securities of the Company are free and clear of all Liens (other than transfer restrictions under applicable Securities Law or under the Company Stockholders Agreements). Except for the Company Stockholders Agreements, there are no voting trusts,
proxies or other Contracts with respect to the voting or transfer of the Company&#146;s Equity Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <U>Section 3.2(c)</U> of the Company Disclosure Schedules sets forth a true and complete statement of
(i)&nbsp;the number and class or series (as applicable) of all of the Equity Securities of each Subsidiary of the Company issued and outstanding and (ii)&nbsp;the identity of the Persons that are the record and beneficial owners thereof. There are
no outstanding (A)&nbsp;equity appreciation, phantom equity, or profit participation rights or (B)&nbsp;options, restricted stock, phantom stock, warrants, purchase rights, subscription rights, conversion rights, exchange rights, calls, puts, rights
of first refusal or first offer or other Contracts that could require any Subsidiary of the Company to issue, sell or otherwise cause to become outstanding or to acquire, repurchase or redeem any Equity Securities or securities convertible into or
exchangeable for Equity Securities of the Subsidiaries of the Company. There are no voting trusts, proxies or other Contracts with respect to the voting or transfer of any Equity Securities of any Subsidiary of the Company to which the Company or
any Subsidiary is a party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) None of the Group Companies owns or holds (of record,
beneficially, legally or otherwise), directly or indirectly, any Equity Securities in any other Person or the right to acquire any such Equity Security, and none of the Group Companies are a partner or member of any partnership, limited liability
company or joint venture. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) <U>Section 3.2(e)</U> of the Company Disclosure Schedules sets forth a list
of all Indebtedness of the Group Companies as of the date of this Agreement, including the principal amount of such Indebtedness, the outstanding balance as of the date of this Agreement, and the debtor and the creditor thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_14"></A><B>Section</B><B></B><B>&nbsp;3.3</B> <B>Authority</B>. The Company has the requisite corporate, limited liability
company or other similar power and authority to execute and deliver this Agreement and each Ancillary Document to which it is or will be a party, to perform its obligations hereunder and thereunder, and to consummate the transactions contemplated
hereby and thereby. Subject to the receipt of the Company Stockholder Approval, the execution and delivery of this Agreement, the Ancillary Documents to which the Company is or will be a party and the consummation of the transactions contemplated
hereby and thereby have been (or, in the case of any Ancillary Document entered into after the date of this Agreement, will be upon execution thereof) duly authorized by all necessary corporate (or other similar) action on the part of the Company.
This Agreement and each Ancillary Document to which the Company is or will be a party has been or will be, upon execution thereof, as applicable, duly and validly executed and delivered by the Company and constitutes or will constitute, upon
execution and delivery thereof, as applicable, a valid, legal and binding agreement of the Company (assuming that this Agreement and the Ancillary Documents to which the Company is or will be a party are or will be upon execution thereof, as
applicable, duly authorized, executed and delivered by the other Persons party thereto), enforceable against the Company in accordance with its terms (subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting
generally the enforcement of creditors&#146; rights and subject to general principles of equity). On or prior to the date of this Agreement, the board of directors of the Company has duly and unanimously adopted resolutions (i)&nbsp;determining that
this Agreement and the Transactions are advisable and fair to, and in the best interest of, the Company and the Company Stockholders, (ii)&nbsp;approving the execution, delivery and performance by the Company of this Agreement and the consummation
of the Transactions and (iii)&nbsp;resolving to recommend the approval of this Agreement and the Transactions by the holders of Company Shares entitled to vote thereon. No other corporate action or vote is required under applicable Law, the
Governing Documents of the Company or the Company Stockholders Agreements, on the part of the Company or any Company Stockholders, to enter into this Agreement and each Ancillary Document to which it is or will be a party, to perform its obligations
hereunder and thereunder, and to consummate the transactions contemplated hereby and thereby, or to approve the Merger, other than the Company Stockholder Approval by the Written Consent of 65% of the then outstanding Company Preferred Shares,
voting as a separate class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis and a majority of the then outstanding Company Common Shares and Company Preferred Shares (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to
common basis) voting together as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_15"></A><B>Section</B><B></B><B>&nbsp;3.4</B> <B>Financial
</B><B>Statements</B><B>; Undisclosed Liabilities</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) The Company has made available to CHFW a true
and complete copy of draft audited consolidated balance sheets of the Group Companies as of December&nbsp;31, 2019 and December&nbsp;31, 2020 (the &#147;Latest Balance Sheet&#148;) and the related audited consolidated statements of operations and
comprehensive loss, convertible preferred stock and stockholders&#146; deficit and cash flows of the Group Companies for each of the years then ended (collectively, the &#147;Financial Statements&#148;), each of which are attached as
<U>Section</U><U></U><U>&nbsp;3.4(a)</U> of the Company Disclosure Schedules. Each of the Financial Statements (including the notes thereto)&nbsp;(A) was prepared in accordance with GAAP applied on a consistent basis throughout the periods indicated
(except as may be indicated in the notes thereto), and (B)&nbsp;fairly presents, in all material respects, the financial position, results of operations and cash flows of the Group Companies as at the date thereof and for the period indicated
therein, except as otherwise specifically noted therein. When the final, audited Financial Statements (including the notes thereto) are delivered following the date of this Agreement in accordance with <U>Section</U><U></U><U>&nbsp;5.17</U>, each
Financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Statement shall (A)&nbsp;be prepared in accordance with GAAP applied on a consistent basis throughout the periods indicated (except as may be indicated in the notes thereto), (B) fairly present,
in all material respects, the financial position, results of operations and cash flows of the Group Companies as at the date thereof and for the period indicated therein, except as otherwise specifically noted therein, (C)&nbsp;have been audited in
accordance with the standards of the PCAOB and contain an unqualified report of the Company&#146;s auditors and (D)&nbsp;comply in all material respects with the applicable accounting requirements and with the rules and regulations of the SEC, the
Exchange Act and the Securities Act in effect as of the respective dates thereof (including Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> or Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> as applicable). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Except (i)&nbsp;as set forth on the face of the Latest Balance Sheet, (ii)&nbsp;for Liabilities incurred in
the ordinary course of business since the date of the Latest Balance Sheet (none of which is a Liability for breach of contract, breach of warranty, tort, infringement or violation of Law), (iii) for Liabilities incurred in connection with the
negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance of their respective covenants or agreements in this Agreement or any Ancillary Document or the consummation of the transactions contemplated hereby
or thereby and (iv)&nbsp;for Liabilities that are not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole, no Group Company has any Liabilities of the type required to be
set forth on a balance sheet in accordance with GAAP. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) The Group Companies have established and
maintain systems of internal accounting controls that are designed to provide, in all material respects, reasonable assurance that (i)&nbsp;all transactions are executed in accordance with management&#146;s authorization and (ii)&nbsp;all
transactions are recorded as necessary to permit preparation of proper and accurate financial statements in accordance with GAAP and to maintain accountability for the Group Companies&#146; assets. The Group Companies maintain and, for all periods
covered by the Financial Statements, have maintained books and records of the Group Companies in the ordinary course of business that are accurate and complete and reflect the revenues, expenses, assets and liabilities of the Group Companies in all
material respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) Except as set forth in Section&nbsp;3.4(d) of the Company&#146;s Disclosure
Schedule since January&nbsp;1, 2019, neither any Group Company nor the independent auditors of the Group Companies has identified any &#147;material weakness&#148; or &#147;significant deficiency&#148; in the internal controls over financial
reporting of the Group Companies. Since January&nbsp;1, 2019, no Group Company has received any written complaint, allegation, assertion or claim that there is fraud, whether or not material, that involves management or other employees of the Group
Companies who have a significant role in the internal controls over financial reporting of the Group Companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_16"></A><B>Section</B><B></B><B>&nbsp;3.5</B> <B>Consents and Requisite Governmental Approvals;
No</B><B></B><B>&nbsp;Violations</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) No consent, approval or authorization of, or designation,
declaration or filing with, any Governmental Entity is required on the part of the Company with respect to the Company&#146;s execution, delivery or performance of its obligations under this Agreement or the Ancillary Documents to which the Company
is or will be party or the consummation of the transactions contemplated hereby or by the Ancillary Documents, except for (i)&nbsp;the filing by CHFW with the SEC of (A)&nbsp;the Registration Statement/Proxy Statement and the declaration of the
effectiveness thereof by the SEC and (B)&nbsp;such reports under Section&nbsp;13(a) or 15(d) of the Exchange Act as may be required to be filed by CHFW in connection with this Agreement, the Ancillary Documents or the transactions contemplated
hereby or thereby or (ii)&nbsp;filing of the Certificate of Merger </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Neither the execution, delivery or
performance by the Company of this Agreement nor the Ancillary Documents to which the Company is or will be a party nor the consummation of the transactions contemplated hereby or thereby will, directly or indirectly (with or without due notice or
lapse of time or both)&nbsp;(i) result in any breach of any provision of the Company&#146;s Governing Documents, (ii)&nbsp;result in a violation or breach of, or constitute a default or give rise to any right of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
termination, Consent, cancellation, amendment, modification, suspension, revocation or acceleration under, any of the terms, conditions or provisions of (A)&nbsp;any Contract to which any Group
Company is a party or (B)&nbsp;any Material Permits, (iii)&nbsp;violate, or constitute a breach under, any Order or applicable Law to which any Group Company or any of its properties or assets are bound or (iv)&nbsp;result in the creation of any
Lien upon any of the assets or properties (other than any Permitted Liens) or Equity Securities of any Group Company, except, in the case of any of <U>clauses</U><U></U><U>&nbsp;(ii)</U> through <U>(iv)</U>&nbsp;above, as would not have a Company
Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_17"></A><B>Section</B><B></B><B>&nbsp;3.6</B> <B>Permits</B>. Each of the Group Companies has
all Permits (the &#147;Material Permits&#148;) that are required to own, lease or operate its properties and assets and to conduct its business as currently conducted, except where the failure to obtain or hold the same would not result in a Company
Material Adverse Effect. Except as is not and would not reasonably be expected to be material to the Group Companies, taken as a whole, (i)&nbsp;each Material Permit is in full force and effect in accordance with its terms and (ii)&nbsp;no written
notice of revocation, cancellation or termination of any Material Permit has been received by the Group Companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_18">
</A><B>Section</B><B></B><B>&nbsp;3.7</B> <B>Material Contracts</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Section 3.7(a)</U> of the Company Disclosure
Schedules sets forth a list of the following Contracts to which a Group Company is, as of the date of this Agreement, a party (each Contract required to be set forth on <U>Section</U><U></U><U>&nbsp;3.7(a)</U> of the Company Disclosure Schedules,
collectively, the &#147;Material Contracts&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) any Contract relating to Indebtedness of any Group Company or to
the placing of a Lien (other than any Permitted Lien) on any material assets or properties of any Group Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii)
any Contract under which any Group Company is lessee of or holds or operates, in each case, any tangible property (other than real property), owned by any other Person, except for any lease or agreement under which the aggregate annual rental
payments do not exceed $1,000,000; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) any Contract under which any Group Company is lessor of or permits any third
party to hold or operate, in each case, any tangible property (other than real property), owned or controlled by such Group Company, except for any lease or agreement under which the aggregate annual rental payments do not exceed $1,000,000; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv) any material joint venture, profit-sharing, partnership, collaboration,
<FONT STYLE="white-space:nowrap">co-promotion,</FONT> commercialization, research and development or other similar Contract; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v) any Contract that (A)&nbsp;limits or purports to limit, in any material respect, the freedom of any Group Company to
engage or compete in any line of business or with any Person or in any area or that would so limit or purport to limit, in any material respect, the operations of CHFW or any of its Affiliates after the Closing, (B)&nbsp;contains any exclusivity,
&#147;most favored nation&#148; or similar provisions, obligations or restrictions or (C)&nbsp;contains any other provisions restricting or purporting to restrict the ability of any Group Company to sell, manufacture, develop, commercialize, test or
research its Products, directly or indirectly through third parties, in any material respect or that would so limit or purports to limit, in any material respect, CHFW or any of its Affiliates after the Closing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vi) any Contract requiring any future capital commitment or capital expenditure (or series of capital expenditures) by any
Group Company in an amount in excess of (A) $1,000,000 annually or (B) $2,500,000<B> </B>over the life of the agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vii) any Contract requiring any Group Company to guarantee the Liabilities of any Person (other than the Company or a
Subsidiary) or pursuant to which any Person (other than the Company or a Subsidiary) has guaranteed the Liabilities of a Group Company, in each case in excess of $1,000,000; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(viii) any Contract under which any Group Company has, directly or
indirectly, made or agreed to make any loan, advance, or assignment of payment to any Person or made any capital contribution to, or other investment in, any Person; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ix) any Contract required to be disclosed on <U>Section</U><U></U><U>&nbsp;3.19</U> of the Company Disclosure Schedules;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(x) any Contract with any Person (A)&nbsp;pursuant to which any Group Company (or CHFW or any of its Affiliates after
the Closing) may be required to pay milestones, royalties or other contingent payments based on any research, testing, development, regulatory filings or approval, sale, distribution, commercial manufacture or other similar occurrences,
developments, activities or events or (B)&nbsp;under which any Group Company grants to any Person any right of first refusal, right of first negotiation, option to purchase, option to license or any other similar rights with respect to any Company
Product or any Intellectual Property; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(xi) any Contract governing the terms of, or otherwise related to, the employment,
engagement or services of any current director, manager, officer, employee, individual independent contractor or other service provider of a Group Company whose annual base salary (or, in the case of an independent contractor, annual base
compensation) is in excess of $200,000; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(xii) any Contract for the disposition of any portion of the assets or business
of any Group Company or for the acquisition by any Group Company of the assets or business of any other Person (other than acquisitions or dispositions made in the ordinary course of business), or under which any Group Company has any continuing
obligation with respect to an <FONT STYLE="white-space:nowrap">&#147;earn-out&#148;,</FONT> contingent purchase price or other contingent or deferred payment obligation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(xiii) any settlement, conciliation or similar Contract (A)&nbsp;the performance of which would be reasonably likely to
involve any payments after the date of this Agreement, (B)&nbsp;with a Governmental Entity or (C)&nbsp;that imposes or is reasonably likely to impose, at any time in the future, any material, <FONT STYLE="white-space:nowrap">non-monetary</FONT>
obligations on any Group Company (or CHFW or any of its Affiliates after the Closing); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(xiv) any other Contract the
performance of which requires either (A)&nbsp;annual payments to or from any Group Company in excess of $1,000,000 or (B)&nbsp;aggregate payments to or from any Group Company in excess of $2,500,000 over the life of the agreement and, in each case,
that is not terminable by the applicable Group Company without penalty upon less than thirty (30)&nbsp;days&#146; prior written notice; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(xv) all settlement or separation Contracts that any Group Company has entered into with any employee or contingent worker at
any time during the past four (4)&nbsp;years. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) (i) Each Material Contract is valid and binding on the
applicable Group Company and, to the knowledge of the Company, the counterparty thereto, and is in full force and effect and (ii)&nbsp;the applicable Group Company and, to the knowledge of the Company, the counterparties thereto are not in material
breach of, or default under, any Material Contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_19"></A><B>Section</B><B></B><B>&nbsp;3.8</B> <B>Absence of
Changes</B>. During the period beginning on January&nbsp;1, 2021 and ending on the date of this Agreement, (a)&nbsp;no Company Material Adverse Effect has occurred and (b)&nbsp;except as expressly contemplated by this Agreement, any Ancillary
Document or in connection with the transactions contemplated hereby and thereby, (i)&nbsp;the Company has conducted its business in the ordinary course in all material respects and (ii)&nbsp;no Group Company has taken any action that would require
the consent of CHFW if taken during the period from the date of this Agreement until the Closing pursuant to <U>Section</U><U></U><U>&nbsp;5.1(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_20"></A><B>Section</B><B></B><B>&nbsp;3.9</B> <B>Litigation</B>. As of the date of this Agreement, there is (and since
December&nbsp;31, 2018 there has been) no Proceeding pending or, to the Company&#146;s knowledge, threatened against or involving any Group Company that, if adversely decided or resolved, has been or would reasonably be expected to be, individually
or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
in the aggregate, material to the Group Companies, taken as a whole. Neither the Group Companies nor any of their respective properties or assets is subject to any material Order. As of the date
of this Agreement, there are no material Proceedings by a Group Company pending against any other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_21"></A><B>Section</B><B></B><B>&nbsp;3.10</B> <B>Compliance with Applicable Law</B>. Each Group Company (a)&nbsp;conducts
(and since December&nbsp;31, 2018 has conducted) its business in accordance with all Laws and Orders applicable to such Group Company and is not in violation of any such Law or Order and (b)&nbsp;has not received any written communications from a
Governmental Entity that alleges that such Group Company is not in compliance with any such Law or Order, except in each case of <U>clauses (a)</U>&nbsp;and <U>(b)</U>, as is not and would not reasonably be expected to be, individually or in the
aggregate, material to the Group Companies, taken as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_22"></A><B>Section</B><B></B><B>&nbsp;3.11</B>
<B>Employee Plans</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Section 3.11(a)</U> of the Company Disclosure Schedules sets forth a true
and complete list of all material Employee Benefit Plans. With respect to each material Employee Benefit Plan, the Group Companies have provided CHFW with true and complete copies of the material documents pursuant to which the plan is maintained,
funded and administered. The Company does not maintain any Employee Benefit Plans for its current or former employees, officers, directors or other individual service providers located outside of the United States and no Employee Benefit Plan is
subject to the laws of any jurisdiction outside the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) True, complete and correct copies
of the following documents, with respect to each Employee Benefit Plan, where applicable, have been made available to CHFW: (i)&nbsp;all documents embodying or governing such Employee Benefit Plan (or for unwritten Employee Benefit Plans a written
description of the material terms of such Employee Benefit Plan) and any funding medium for the Employee Benefit Plan; (ii)&nbsp;the most recent IRS determination, advisory or opinion letter; (iii)&nbsp;the most recently filed Form 5500; (iv) the
most recent actuarial valuation report; (v)&nbsp;the most recent summary plan description (or other descriptions provided to employees) and all modifications thereto; (vi)&nbsp;the last three years of
<FONT STYLE="white-space:nowrap">non-discrimination</FONT> testing results; and (vii)&nbsp;all <FONT STYLE="white-space:nowrap">non-routine</FONT> correspondence to and from any governmental agency. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) No Group Company has ever maintained, contributed to, been required to contribute to or has any Liability
with respect to or under: (i)&nbsp;a Multiemployer Plan; (ii)&nbsp;a &#147;defined benefit plan&#148; (as defined in Section&nbsp;3(35) of ERISA, whether or not subject to ERISA) or a plan that is or was subject to Title IV of ERISA Section&nbsp;412
of the Code or Section&nbsp;312 of ERISA; (iii)&nbsp;a &#147;multiple employer plan&#148; within the meaning of Section of 413(c) of the Code or Section&nbsp;210 of ERISA; (iv)&nbsp;a &#147;multiple employer welfare arrangement&#148; as defined in
Section&nbsp;3(40) of ERISA; or (v)&nbsp;any funded welfare benefit plan within the meaning of Section&nbsp;419 of the Code. No Group Company has any material Liabilities to provide any retiree or post-termination or power-ownership health or life
insurance or other welfare-type benefits to any Person other than health continuation coverage pursuant to COBRA or similar Law and for which the recipient pays the full cost of coverage and no Group Company has ever promised to provide such
benefits. No Group Company has any material Liabilities by reason of at any time being considered a single employer under Section&nbsp;414 of the Code with any other Person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) Each Employee Benefit Plan that is intended to be qualified under Section&nbsp;401(a) of the Code is so
qualified and has timely received a favorable determination or opinion or advisory letter issued by the IRS with respect to a volume submitter or prototype plan adopted in accordance with the requirements for such reliance, or has time remaining for
application to the IRS for a determination of the qualified status of such Employee Benefit Plan for any period for which such Employee Benefit Plan would not otherwise be covered by an IRS determination and, to the knowledge of the Company, no
event or omission has occurred that would cause any Employee Benefit Plan to lose such qualification or require corrective action to the IRS or Employee Plan Compliance Resolution System to maintain such qualification. None of the Group Companies
has incurred (whether or not assessed) any material penalty or Tax under Section&nbsp;4980H, 4980B, 4980D, 6721 or 6722 of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) Each Employee Benefit Plan is and has been established,
operated, and administered in all material respects in accordance with applicable laws and regulations and with its terms, including without limitation ERISA, the Code, and the Affordable Care Act. As of the date hereof, there are no pending or, to
the Company&#146;s knowledge, threatened, material claims or Proceedings with respect to any Employee Benefit Plan (other than routine claims for benefits). There have been no <FONT STYLE="white-space:nowrap">non-exempt</FONT> &#147;prohibited
transactions&#148; within the meaning of Section&nbsp;4975 of the Code or Sections 406 or 407 of ERISA and no breaches of fiduciary duty (as determined under ERISA) with respect to any Employee Benefit Plan. With respect to each Employee Benefit
Plan, all contributions, distributions, reimbursements and premium payments that are due have been timely made, except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as
a whole. No Employee Benefit Plan is, or within the past six (6)&nbsp;years has been, the subject of an application or filing under a government sponsored amnesty, voluntary compliance, or similar program, or been the subject of any self-correction
under any such program. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) The execution and delivery of this Agreement and the consummation of the
transactions contemplated by this Agreement will not materially (alone or in combination with any other event)&nbsp;(i) result in any payment or benefit becoming due to or result in the forgiveness of any indebtedness of any current or former
director, manager, officer, employee, individual independent contractor or other service providers of any of the Group Companies, (ii)&nbsp;increase the amount or value of any compensation or benefits payable to any current or former director,
manager, officer, employee, individual independent contractor or other service providers of any of the Group Companies or (iii)&nbsp;result in the acceleration of the time of payment or vesting, or trigger any payment or funding of any compensation
or benefits to any current or former director, manager, officer, employee, individual independent contractor or other service providers of any of the Group Companies. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) No amount that could be received (whether in cash or property or the vesting of property) by any
&#147;disqualified individual&#148; of any of the Group Companies under any Employee Benefit Plan or otherwise as a result of the consummation of the Transactions could, separately or in the aggregate, be nondeductible under Section&nbsp;280G of the
Code or subjected to an excise tax under Section&nbsp;4999 of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) The Group Companies have no
obligation to make a <FONT STYLE="white-space:nowrap">&#147;gross-up&#148;</FONT> or similar payment in respect of any taxes that may become payable under Section&nbsp;4999 or 409A of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) Any transfer of property which was subject to a substantial risk of forfeiture and which would otherwise
have been subject to taxation under Section&nbsp;83(a) of the Code is covered by a valid and timely filed election under Section&nbsp;83(b) of the Code, and a copy of such election has been provided to the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(j) Each Employee Benefit Plan that constitutes in any part a nonqualified deferred compensation plan within
the meaning of Section&nbsp;409A of the Code has been operated and maintained in all material respects in operational and documentary compliance with Section&nbsp;409A of the Code and applicable guidance thereunder. No payment to be made under any
Employee Benefit Plan is, or to the knowledge of the Company, will be, subject to the penalties of Section&nbsp;
409A(a)(1) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_23"></A><B>Section</B><B></B><B>&nbsp;3.12</B> <B>Environmental Matters</B>. Except as would
not have a Company Material Adverse Effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) None of the Group Companies have received any written
notice or communication from any Governmental Entity or any other Person regarding any actual, alleged, or potential violation in any respect of, or a failure to comply in any respect with, any Environmental Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) There is (and since January&nbsp;1, 2018 there has been) no Proceeding pending or, to the Company&#146;s
knowledge, threatened in writing against any Group Company pursuant to Environmental Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) There has been no manufacture, release, treatment,
storage, disposal, arrangement for disposal, transport or handling of, contamination by, or exposure of any Person to, any Hazardous Substances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Group Companies have made available to CHFW copies of all material environmental, health and safety reports and documents that are in any
Group Company&#146;s possession or control relating to the current or former operations, properties or facilities of the Group Companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_24"></A><B>Section</B><B></B><B>&nbsp;3.13</B> <B>Intellectual Property</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Section 3.13(a)</U> of the Company Disclosure Schedules sets forth a true and complete list of
(i)&nbsp;all currently issued or pending Company Registered Intellectual Property, (ii)&nbsp;Company Licensed Intellectual Property and (iii)&nbsp;material unregistered Marks and Copyrights owned by any Group Company, in each case, as of the date of
this Agreement. <U>Section</U><U></U><U>&nbsp;3.13(a)</U> of the Company Disclosure Schedules lists, for each item of Company Registered Intellectual Property as of the date of this Agreement (A)&nbsp;the record owner of such item, (B)&nbsp;the
jurisdictions in which such item has been issued or registered or filed, (C)&nbsp;the issuance, registration or application date, as applicable, for such item and (D)&nbsp;the issuance, registration or application number, as applicable, for such
item. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) As of the date of this Agreement, all necessary fees and filings with respect to any material
Company Registered Intellectual Property have been timely submitted to the relevant intellectual property office or Governmental Entity and Internet domain name registrars to maintain such material Company Registered Intellectual Property in full
force and effect. As of the date of this Agreement, no issuance or registration obtained and no application filed by the Group Companies for any Intellectual Property has been cancelled, abandoned, allowed to lapse or not renewed, except where such
Group Company has, in its reasonable business judgment, decided to cancel, abandon, allow to lapse or not renew such issuance, registration or application. As of the date of this Agreement, there are no material Proceedings, including litigations,
interference, <FONT STYLE="white-space:nowrap">re-examination,</FONT> <I>inter parties</I> review, reissue, opposition, nullity, or cancellation proceedings pending that relate to any of the Company Registered Intellectual Property and no such
material Proceedings are threatened by any Governmental Entity or any other Person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) A Group Company
exclusively owns all right, title and interest in and to all material Company Owned Intellectual Property, free and clear of all Liens or obligations to others (other than Permitted Liens). For all Patents owned by the Group Companies, each inventor
on the Patent has assigned their rights to a Group Company. No Group Company has (i)&nbsp;transferred ownership of, or granted any exclusive license with respect to, any material Company Owned Intellectual Property to any other Person or
(ii)&nbsp;granted any customer the right to use any material Company Product or service on anything other than a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis. <U>Section</U><U></U><U>&nbsp;3.13(c)</U> of the Company Disclosure
Schedules sets forth a list of all current Contracts for Company Licensed Intellectual Property as of the date of this Agreement to which any Person has been granted any license or covenant not to sue under, or otherwise has received or acquired any
right (whether or not exercisable) or interest in, any Company Owned Intellectual Property, other than (A)&nbsp;licenses to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Off-the-Shelf</FONT></FONT> Software, (B)&nbsp;licenses to
Public Software and <FONT STYLE="white-space:nowrap">(C)&nbsp;non-disclosure</FONT> agreements and nonexclusive licenses granted in the ordinary course of business to vendors or suppliers of any Group Company. The applicable Group Company has valid
rights under all Contracts for Company Licensed Intellectual Property to use, sell, license and otherwise exploit, as the case may be, all Company Owned Intellectual Property licensed pursuant to such Contracts as the same is currently used, sold,
licensed and otherwise exploited by such Group Company, except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole. The Company Owned Intellectual Property and the
Company Licensed Intellectual Property, to the knowledge of the Company, constitutes all of the Intellectual Property used or held for use by the Group Companies in the operation of their respective businesses, and all Intellectual Property
necessary and sufficient to enable the Group </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Companies to conduct their respective businesses as currently conducted in all material respects. The Company Registered Intellectual Property and the Company Licensed Intellectual Property, to
the knowledge of the Company, is valid, subsisting and enforceable, and, to the Company&#146;s knowledge, all of the Group Companies&#146; rights in and to the Company Registered Intellectual Property, all other Company Owned Intellectual Property
and the Company Licensed Intellectual Property, are valid and enforceable (in each case, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors&#146; rights and subject
to general principles of equity). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) Each Group Company&#146;s employees, consultants, advisors and
independent contractors who independently or jointly contributed to or otherwise participated in the authorship, invention, creation, improvement, modification or development of any material Company Owned Intellectual Property since
December&nbsp;31, 2018 (each such person, a &#147;Creator&#148;) have agreed to maintain and protect the trade secrets and confidential information of all Group Companies. Each Creator has assigned or has agreed to a present assignment to such Group
Company all Intellectual Property Rights authored, invented, created, improved, modified or developed by such person in the course of such Creator&#146;s employment or other engagement with such Group Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) Each Group Company has taken reasonable steps to safeguard and maintain the secrecy of any trade secrets, <FONT
STYLE="white-space:nowrap">know-how</FONT> and other confidential information owned by Each Group Company. Without limiting the foregoing, each Group Company has not disclosed any trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> or
confidential information to any other Person unless such disclosure was under an appropriate written <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement containing appropriate limitations on use, reproduction and disclosure. To the
Company&#146;s knowledge, there has been no violation or unauthorized access to or disclosure of any trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> or confidential information of or in the possession each Group Company, or of any
written obligations with respect to such. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) None of the Company Owned Intellectual Property and, to the
Company&#146;s knowledge, none of the Company Licensed Intellectual Property is subject to any outstanding Order that restricts in any manner the use, sale, transfer, licensing or exploitation thereof by the Group Companies or affects the validity,
use or enforceability of any such Company Owned Intellectual Property, except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) To the Company&#146;s knowledge, neither the conduct of the business of the Group Companies as currently
conducted nor any of the Company Products as currently offered, marketed, licensed, provided, sold, distributed or otherwise exploited by the Group Companies nor the current design, development, manufacturing, reproduction, use, marketing, offer for
sale, sale, importation, exportation, distribution, maintenance or other exploitation of any Company Product infringes, constitutes or results from an unauthorized use or misappropriation of or otherwise violates any Intellectual Property Rights of
any other Person, except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) Since December&nbsp;31, 2018, there is no material Proceeding pending nor has any Group Company received
any written communications (i)&nbsp;alleging that a Group Company has infringed, misappropriated or otherwise violated any Intellectual Property Rights of any other Person, (ii)&nbsp;challenging the validity, enforceability, use or exclusive
ownership of any Company Owned Intellectual Property or (iii)&nbsp;inviting any Group Company to take a license under any Patent or consider the applicability of any Patents to any products or services of the Group Companies or to the conduct of the
business of the Group Companies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) To the Company&#146;s knowledge, no Person is infringing,
misappropriating, misusing, diluting or violating any Company Owned Intellectual Property in any material respect. Since December&nbsp;31, 2018, no Group Company has made any written claim against any Person alleging any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
infringement, misappropriation or other violation of any Company Owned Intellectual Property in any material respect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_25"></A><B>Section</B><B></B><B>&nbsp;3.14</B> <B>Labor Matters</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) The Group Companies as of the date of this Agreement are, and since December&nbsp;31, 2018 have been, in
compliance with all applicable Law respecting labor and employment matters, including fair employment practices, immigration, harassment, discrimination, pay equity, restrictive covenants, the classification of independent contractors and employees,
workplace safety and health, work authorization and immigration, unemployment compensation, workers&#146; compensation, affirmative action, terms and conditions of employment, employee leave and wages and hours, including payment of minimum wages
and overtime except in each case, as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) As of the date of this Agreement and since December&nbsp;31, 2018, no Group Company has been a party to or
received written notice of any material litigation, governmental audit, governmental investigation, administrative agency proceeding, private dispute resolution procedure, or internal or external investigation of alleged employee misconduct, in each
case with respect to employment or labor matters (including allegations of employment discrimination, retaliation, noncompliance with wage and hour laws, the misclassification of independent contractors, violation of restrictive covenants, sexual
harassment, other unlawful harassment or unfair labor practices). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) As of the date of this Agreement,
and since December&nbsp;31, 2018, all Group Companies have maintained policies (i)&nbsp;prohibiting employment discrimination on all grounds constituting unlawful discrimination, (ii)&nbsp;prohibiting sexual harassment and all other forms of
discriminatory harassment, and (iii)&nbsp;providing complaint and investigation procedures with respect to (i)&nbsp;and (ii). As of the date of this Agreement, and since December&nbsp;31, 2018, any and all such policies have conformed, in all
material respects, with applicable Law, including, as applicable, with respect to independent contractors. As of the date of this Agreement, and since December&nbsp;31, 2018, all Group Companies have complied with any applicable Law with respect to
training concerning prevention of sexual harassment prevention and/or abusive conduct. To the knowledge of the Group Companies, as of the date of this Agreement, and since December&nbsp;31, 2018, no allegations or investigations of any violation of
the policies referenced in (i)&nbsp;and/or (ii)&nbsp;has been made through the reporting channels identified in such policies or otherwise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) Except as set forth on <U>Section</U><U></U><U>&nbsp;3.14(d)</U> of the Company Disclosure Schedule, the
consummation of the Transactions will not (i)&nbsp;entitle any employee of any Group Company to severance pay, unemployment compensation, bonus payment or any other payment, (ii)&nbsp;accelerate the time of payment for vesting of, or increase the
amount of compensation due to, any such employee, or (iii)&nbsp;entitle any such employee to terminate, shorten or otherwise change the terms of his employment (collectively, the &#147;Change of Control Payments&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) Except as set forth on <U>Section</U><U></U><U>&nbsp;3.14(e)</U> of the Company Disclosure Schedules, all
employees of the Group Companies are employed <FONT STYLE="white-space:nowrap">at-will</FONT> and no employee is subject to any employment contract with any Group Company, whether oral or written. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) Except as set forth on <U>Section</U><U></U><U>&nbsp;3.14(f)</U> of the Company Disclosure Schedules, in
the twelve (12)&nbsp;months preceding the date of this Agreement, (i)&nbsp;no officer or executive&#146;s employment with any Group Company has been terminated for any reason; and (ii)&nbsp;to the knowledge of the Group Companies, as of the date of
this Agreement, no officer, executive or group of employees has expressed any plans to terminate his, her, their or its employment or service arrangement with any Group Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) Except as set forth on <U>Section&nbsp;3.14(g)</U> of the Company Disclosure Schedules, all employees of
the Group Companies have signed the Company&#146;s <FONT STYLE="white-space:nowrap">At-Will</FONT> Employment, Confidential </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Information, Invention Assignment and Arbitration Agreement, a true and correct copy of which has been made available to CHFW. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) Since January&nbsp;1, 2019, there has been no &#147;mass layoff&#148; or &#147;plant closing&#148; as
defined by WARN or any similar state, local, or foreign law or regulation affecting any site of employments of any Group Company or one or more facilities or operating units within any site of employment or facility of any Group Company. During the
ninety (90)&nbsp;day period preceding the date of this Agreement, no employee has suffered any &#147;employment loss&#148; as defined by the WARN Act with respect to any Group Company, The Group Companies will not incur any Liability under WARN as a
result of the Transactions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) No Group Company is a party to or bound by any collective bargaining
agreements or other agreements with any labor organization, labor union, works council or other employee representative or any other Contract with a labor union, labor organization, works council, employee delegate, representative or other employee
collective group nor is there any duty on the part of any Group Company to bargain with any labor union, labor organization, works council, employee delegate, representative or other employee collective group. Since January&nbsp;1, 2018, there has
been no actual or to the knowledge of the Company, threatened unfair labor practice charges, grievances, arbitrations, strikes, lockouts, work stoppages, slowdowns, picketing, hand billing or other labor disputes against or affecting any Group
Company. Since January&nbsp;1, 2018, to the knowledge of the Company, there have been no labor organizing activities with respect to any employees of any Group Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(j) No employee layoff, facility closure or shutdown (whether voluntary or by Order), <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">reduction-in-force,</FONT></FONT> furlough, temporary layoff, material work schedule change or reduction in hours, or reduction in salary or wages, or other workforce changes affecting
employees of the Group Companies has occurred within the six (6)&nbsp;months preceding the date of this Agreement or, as of the date of this Agreement, is currently contemplated, planned or announced, including as a result of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> or any Law, Order, directive, guidelines or recommendations by any Governmental Entity in connection with or in response to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> The Group Companies have not
otherwise experienced any employment-related liability with respect to or arising out of <FONT STYLE="white-space:nowrap">COVID-19</FONT> or any Law, Order, directive, guidelines or recommendations by any Governmental Entity in connection with or in
response to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> The Group Companies are and at all relevant times have been in compliance in material respects with <FONT STYLE="white-space:nowrap">(i)&nbsp;COVID-19</FONT> related Laws, Orders,
directives, guidelines and recommendations (including without limitation relating to business reopening), including those issued and enforced by the Occupational Safety and Health Administration, the Centers for Disease Control, the Equal Employment
Opportunity Commission, and any other Governmental Entity; (ii)&nbsp;the Families First Coronavirus Response Act (including with respect to eligibility for tax credits under such Act) and (iii)&nbsp;any other applicable <FONT
STYLE="white-space:nowrap">COVID-19</FONT> related leave Law, whether state, local, or otherwise, except in each case of clauses (i), (ii) or (iii)&nbsp;as is not and would not reasonably be expected to be individually or in the aggregate, material
to the Group Companies, taken as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_26"></A><B>Section</B><B></B><B>&nbsp;3.15</B> <B>Insurance</B>.
<U>Section</U><U></U><U>&nbsp;3.15</U> of the Company Disclosure Schedules sets forth a list of all material policies of fire, liability, workers&#146; compensation, property, casualty and other forms of insurance owned or held by any Group Company
as of the date of this Agreement. All such policies are in full force and effect, all premiums due and payable thereon as of the date of this Agreement have been paid in full as of the date of this Agreement, and true and complete copies of all such
policies have been made available to CHFW. As of the date of this Agreement, no claim by any Group Company is pending under any such policies as to which coverage has been denied or disputed, or rights reserved to do so, by the underwriters thereof,
except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_27"></A><B>Section</B><B></B><B>&nbsp;3.16</B> <B>Tax Matters</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Each Group Company has prepared and filed all material Tax Returns required to have been filed by it, all
such Tax Returns are true and complete in all material respects and prepared in compliance in all material respects with all applicable Law, and each Group Company has paid all material Taxes required to have been paid by it regardless of whether
shown on a Tax Return. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Each Group Company has (i)&nbsp;timely withheld and paid to the appropriate Tax
Authority all material amounts required to have been withheld and paid in connection with amounts paid or owing to any employee, individual independent contractor, other service providers, equity interest holder or other <FONT
STYLE="white-space:nowrap">third-party</FONT> (ii)&nbsp;remitted, or will remit on a timely basis, such amounts to the appropriate Governmental Entity; and (iii)&nbsp;complied in all material respects with applicable Law with respect to Tax
withholding, including all reporting and record keeping requirements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) No Group Company is currently
the subject of a Tax audit or examination, or has been informed in writing of the commencement or anticipated commencement of any Tax audit or examination that has not been resolved or completed in each case with respect to material Taxes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) No Group Company has consented to extend or waive the time in which any material Tax may be assessed or
collected by any Tax Authority, other than any such extensions or waivers that are no longer in effect or that were extensions of time to file Tax Returns obtained in the ordinary course of business. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) No &#147;closing agreement&#148; as described in Section&nbsp;7121 of the Code (or any corresponding or
similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income Tax Law), private letter rulings, technical advice memoranda or similar agreements or rulings have been entered into or issued by any Tax Authority with
respect to a Group Company which agreement or ruling would be effective after the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) No
Group Company is or has been a party to any &#147;listed transaction&#148; as defined in Section&nbsp;6707A of the Code and Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4</FONT> (or any corresponding or similar provision
of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income Tax Law). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) No Group Company
will be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any: (i)&nbsp;change in method of accounting for a
taxable period (or portion thereof) ending on or prior to the Closing Date and made prior to the Closing; (ii)&nbsp;written agreement with a Governmental Entity executed on or prior to the Closing; (iii)&nbsp;installment sale or open transaction
disposition made on or prior to the Closing; (iv)&nbsp;deferred revenue or prepaid amount received outside the ordinary course of business on or prior to the Closing; (v)&nbsp;gain recognition agreement or (vi)&nbsp;any intercompany transaction or
excess loss account. No Group Company will be required to make any payment after the Closing Date as a result of an election under Section&nbsp;965 of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) There are no Liens for material Taxes on any assets of the Group Companies other than Permitted Liens. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) During the two (2)-year period ending on the date of this Agreement, no Group Company was a distributing
corporation or a controlled corporation in a transaction purported or intended to be governed by Section&nbsp;355 of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(j) No Group Company (i)&nbsp;has been a member of an affiliated group filing a consolidated federal income Tax
Return (other than a group the common parent of which was a Group Company or any of its current Affiliates) or (ii)&nbsp;has any material Liability for the Taxes of any Person (other than a Group Company or any of its current Affiliates) under <FONT
STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> of the Treasury Regulations (or any similar provision of state, local or <FONT STYLE="white-space:nowrap">non-United</FONT> States Law), as a transferee or successor or by Contract (other than
any Contract the principal purpose of which does not relate to Taxes). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(k) No written claims have ever been made by any Tax
Authority in a jurisdiction where a Group Company does not file Tax Returns that such Group Company is or may be subject to taxation by that jurisdiction, which claims have not been resolved or withdrawn. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(l) No Group Company is a party to any Tax allocation, Tax sharing or Tax indemnity or similar agreements
(other than one that is included in a Contract entered into in the ordinary course of business that is not primarily related to Taxes) and no Group Company is a party to any joint venture, partnership or other arrangement that is treated as a
partnership for U.S. federal income Tax purposes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(m) Each Group Company is tax resident only in its
country of formation, and is not managed or controlled outside such country for Income Tax purposes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(n)
No Group Company has a permanent establishment (within the meaning of an applicable Tax treaty) or otherwise has an office or fixed place of business in a country other than the country in which it is organized. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(o) No Group Company has been, is, or immediately prior to the Closing will be, treated as an &#147;investment
company&#148; within the meaning of Code Section&nbsp;368(a)(2)(F). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(p) Notwithstanding anything to the
contrary in this Agreement, no Group Company makes any representations as to the amount of, or the limitations on the use after the Closing, of any net operating losses, capital losses, deductions, Tax credits and similar items of the Company Group.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(q) No Group Company has taken or agreed to take any action not contemplated by this Agreement and/or any
Ancillary Document that could reasonably be expected to prevent the Merger from qualifying for the Intended Tax Treatment. To the knowledge of the Company, no facts or circumstances exist that could reasonably be expected to prevent the Merger from
qualifying the Intended Tax Treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_28"></A><B>Section</B><B></B><B>&nbsp;3.17</B> <B>Brokers</B>. Except for fees
(including the amounts due and payable assuming the Closing occurs) set forth on <U>Section</U><U></U><U>&nbsp;3.17</U> of the Company Disclosure Schedules (which fees shall be the sole responsibility of the Company, except as otherwise provided in
<U>Section</U><U></U><U>&nbsp;8.6</U>), no broker, finder, investment banker or other Person is entitled to any brokerage fee, finders&#146; fee or other commission in connection with the Transactions based upon arrangements made by or on behalf of
the Company or any of its Affiliates for which any of the Group Companies has any obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_29"></A><B>Section</B><B></B><B>&nbsp;3.18</B> <B>Real and Personal Property</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Owned Real Property</U>. No Group Company owns any real property. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Leased Real Property</U>. <U>Section</U><U></U><U>&nbsp;3.18(b)</U> of the Company Disclosure Schedules
sets forth a true and complete list (including street addresses) of all real property leased by any of the Group Companies (the &#147;Leased Real Property&#148;) and all Real Property Leases pursuant to which any Group Company is a tenant or
landlord as of the date of this Agreement. True and complete copies of all such Real Property Leases have been made available to CHFW. Each Real Property Lease is in full force and effect and is a valid, legal and binding obligation of the
applicable Group Company party thereto, enforceable in accordance with its terms against such Group Company and, to the Company&#146;s knowledge, each other party thereto (subject to applicable bankruptcy, insolvency, reorganization, moratorium or
other Laws affecting generally the enforcement of creditors&#146; rights and subject to general principles of equity). There is no material breach or default by any Group Company or, to the Company&#146;s knowledge, any third party under any Real
Property Lease, and, to the Company&#146;s knowledge, no event has occurred which (with or without notice or lapse of time or both) would constitute a material breach or default or would permit termination of, or a material modification or
acceleration thereof by any party to such Real Property Leases. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) <U>Personal Property</U>. Each Group
Company has good, marketable and indefeasible title to, or a valid leasehold interest in or license or right to use, all of the material assets and properties of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Group Companies reflected in the Financial Statements or thereafter acquired by the Group Companies, except for assets disposed of in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_30"></A><B>Section</B><B></B><B>&nbsp;3.19</B> <B>Transactions with Affiliates</B>. <U>Section</U><U></U><U>&nbsp;3.19</U>
of the Company Disclosure Schedules sets forth all Contracts between (a)&nbsp;any Group Company, on the one hand, and (b)&nbsp;any officer, director, employee, partner, member, manager, direct or indirect equityholder or Affiliate of any Group
Company (other than, for the avoidance of doubt, any other Group Company) or any family member of the foregoing Persons, on the other hand (each Person identified in this <U>clause</U><U></U><U>&nbsp;(b)</U>, a &#147;Company Related Party&#148;),
other than (i)&nbsp;Contracts with respect to a Company Related Party&#146;s employment with (including benefit plans and other ordinary course compensation from) any of the Group Companies entered into in the ordinary course of business,
(ii)&nbsp;Contracts related solely to a Company Stockholder&#146;s or a holder of Company Equity Awards&#146; status as a holder of Equity Securities of the Company entered into in the ordinary course of business and (iii)&nbsp;Contracts entered
into after the date of this Agreement that are either permitted pursuant to <U>Section</U><U></U><U>&nbsp;5.1(b)</U> or entered into in accordance with <U>Section</U><U></U><U>&nbsp;5.1(b)</U>. No Company Related Party (A)&nbsp;owns any interest in
any material asset used in any Group Company&#146;s business, (B)&nbsp;possesses, directly or indirectly, any material financial interest in, or is a director or executive officer of, any Person which is a supplier, lender, partner, lessor, lessee
or other material business relation of any Group Company or (C)&nbsp;owes any material amount to, or is owed any material amount by, any Group Company (other than ordinary course accrued compensation, employee benefits, employee or director expense
reimbursement or other transactions entered into after the date of this Agreement that are either permitted pursuant to <U>Section</U><U></U><U>&nbsp;5.1(b)</U> or entered into in accordance with <U>Section</U><U></U><U>&nbsp;5.1(b)</U>). All
Contracts, arrangements, understandings, interests and other matters that are required to be disclosed pursuant to this <U>Section</U><U></U><U>&nbsp;3.19</U> are referred to herein as &#147;<U>Company </U>Related Party Transactions&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_31"></A><B>Section</B><B></B><B>&nbsp;3.20</B> <B>Data Privacy and Security</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Each Group Company has implemented commercially reasonable practices, procedures and policies designed to
address the security and privacy of Personal Data Processed by each such Group Company to the extent required by applicable Law (&#147;Privacy and Data Security Policies&#148;) and such Privacy and Data Security Policies comply with all applicable
Privacy Laws in all material respects. Each Group Company complies in all material respects with all applicable Privacy Laws and with all Privacy and Data Security Policies. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) The Company has not received notice of any pending Proceedings, nor to the Company&#146;s knowledge has
there been any material Proceedings against any Group Company initiated by (i)&nbsp;any Person; (ii)&nbsp;the United States Federal Trade Commission, any state attorney general or similar state official; (iii)&nbsp;any other Governmental Entity
foreign or domestic; or (iv)&nbsp;any regulatory or self-regulatory entity that, in each case of (i)&nbsp;to (iv), allege that any Processing of Personal Data by or on behalf of a Group Company (A)&nbsp;is in violation of any applicable Privacy Laws
or (B)&nbsp;is in violation of any Privacy and Data Security Policies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) Since January&nbsp;1, 2018, (i)
there has been no material instance of unauthorized access, use or disclosure of Personal Data in the possession or control of any Group Company and, to the knowledge of the Company, any of its contractors with regard to any Personal Data obtained
from or on behalf of a Group Company and (ii) there have been no material unauthorized intrusions or breaches of security into any Company IT Systems. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) Each of the Group Companies has established and complied in all material respects with its information
security practices, procedures, and policies, which include commercially reasonable measures such as <FONT STYLE="white-space:nowrap">back-ups,</FONT> disaster recovery and administrative, technical, and physical safeguards designed to safeguard the
security, confidentiality, integrity and availability of Company IT Systems and Personal Data in its possession, custody, or under its control, including against loss, theft, misuse or unauthorized Processing, access, use, modification or
disclosure. Each Group Company owns or has a license or right to use the Company IT Systems as necessary to operate the business of each Group Company as currently conducted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_32"></A><B>Section</B><B></B><B>&nbsp;3.21</B> <B>Compliance with
</B><B>International Trade</B><B></B><B>&nbsp;&amp; Anti-Corruption Laws</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Neither the Group
Companies nor, to the Company&#146;s knowledge, any of their Representatives, or any other Persons acting for or on behalf of any of the foregoing,&nbsp;is or has been, since January&nbsp;1, 2019, (i) a Person named on any Sanctions and Export
Control Laws-related list of designated Persons maintained by a Governmental Entity; (ii)&nbsp;located, organized or resident in a country or territory which is itself the subject of or target of any Sanctions and Export Control Laws; (iii)&nbsp;an
entity owned, directly or indirectly, by one or more Persons described in clause (i)&nbsp;or (ii); or (iv)&nbsp;otherwise engaging in dealings with or for the benefit of any Person described in clauses (i) - (iii) or any country or territory which
is or has, since January&nbsp;1, 2019, been the subject of or target of any Sanctions and Export Control Laws (at the time of this Agreement, the Crimea region of Ukraine, Cuba, Iran, North Korea, Venezuela, Sudan and Syria). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Neither the Group Companies nor, to the Company&#146;s knowledge, any of their Representatives, or any
other Persons acting for or on behalf of any of the foregoing has (i)&nbsp;made, offered, promised, paid or received any unlawful bribes, kickbacks or other similar payments to or from any Person, (ii)&nbsp;made or paid any contributions, directly
or indirectly, to a domestic or foreign political party or candidate or (iii)&nbsp;otherwise made, offered, received, authorized, promised or paid any improper payment under any Anti-Corruption Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_33"></A><B>Section</B><B></B><B>&nbsp;3.22</B> <B>Information Supplied</B>. None of the information supplied or to be
supplied by or on behalf of the Group Companies expressly for inclusion or incorporation by reference prior to the Closing in the Registration Statement/Proxy Statement will, when the Registration Statement/Proxy Statement is declared effective or
when the Registration Statement/Proxy Statement is mailed to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> CHFW Holders or at the time of the CHFW Shareholders Meeting, and in the case of any amendment thereto, at the time of such
amendment, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not
misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_34"></A><B>Section</B><B></B><B>&nbsp;3.23</B> <B>Regulatory Compliance</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Section 3.23(a)</U> of the Company Disclosure Schedules sets forth, as of the date of this Agreement, a
complete and correct list of all material Regulatory Permits held by the Group Companies, which are the only Regulatory Permits that are necessary for the Group Companies to conduct their Business. The Group Companies and the Company Products are in
compliance in all material respects with all Regulatory Permits, and to the knowledge of the Company, no event, circumstance or state of facts has occurred which (with or without due notice or lapse of time or both) would reasonably be expected to
result in the failure of a Group Company to be in compliance in all material respects with the terms of any such Regulatory Permit. To the knowledge of the Company, (i)&nbsp;no Governmental Entity is considering limiting, suspending or revoking any
Regulatory Permit and (ii)&nbsp;each third party that is a manufacturer, contractor or agent for the Group Companies is in compliance in all material respects with all Regulatory Permits required by all Public Health Laws insofar as they reasonably
pertain to the Company Products. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) There is no act, omission, event or circumstance of which the Company
has knowledge that would reasonably be expected to give rise to or lead to any material Proceeding against any Group Company related to compliance with Public Health Laws. To the Company&#146;s knowledge, the Group Companies do not have any
Liability for failure to comply with any Public Health Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) All Company Products are being and have,
since January&nbsp;1, 2019, been developed, tested, investigated, manufactured, prepared, packaged, labeled and distributed in compliance in all material respects with the Public Health Laws or any comparable Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) To the knowledge of the Company, the preclinical studies conducted by or on behalf of the Group Companies
are being and have been conducted in all material respects in accordance with all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
applicable requirements and Laws of the FDA and any comparable Governmental Entity, including to the extent required, Good Laboratory Practices (&#147;GLP&#148;). The Company has not received any
notice that the FDA or any other Governmental Entity has recommended, initiated, or threatened to initiate any action to suspend, terminate, or otherwise restrict any preclinical studies conducted by or on behalf of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) Since January&nbsp;1, 2019, the Group Companies have not distributed any Company Products that were upon
their shipment by any Group Company adulterated or misbranded in violation of 21 U.S.C. &#167; 331 or any other Governmental Entity&#146;s jurisdiction. No Company Products have been seized, withdrawn, recalled, detained or subject to a suspension
(other than in the ordinary course of business) of research, manufacturing or distribution, and to the Company&#146;s knowledge, there are no facts or circumstances reasonably likely to cause (i)&nbsp;the seizure, denial, withdrawal, recall, or
detention of, or public health notification or safety alert relating to any Company Product or (ii)&nbsp;a termination or suspension of research, manufacturing, distributing or other activity of any Company Product, in either case, except as would
not have a Company Material Adverse Effect. As of the date of this Agreement, no proceedings in the United States or any other jurisdiction seeking the withdrawal, recall, revocation, suspension, import detention or seizure of any Company Product
are pending or threatened against the Group Companies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) Neither the Group Companies nor any of its
directors, managers, officers, employees, or to the knowledge of the Company, individual independent contractors or other service providers, including clinical trial investigators, coordinators, or monitors, (i)&nbsp;have been excluded or debarred
from any federal healthcare program (including Medicare or Medicaid) or any other federal program and/or any other healthcare program or reimbursement regulation or agreement or (ii)&nbsp;have received notice from the FDA, any other Governmental
Entity and/or any health insurance institution with respect to debarment, disqualification or restriction. None of the Group Companies nor to the knowledge of the Company any of their officers, directors, employees, agents or contractors have been
convicted of any crime or engaged in any conduct for which (A)&nbsp;debarment is mandated or permitted by 21 U.S.C. &#167; 335a or (B)&nbsp;such Person could be excluded from participating in the federal healthcare programs under Section&nbsp;1128
of the Social Security Act or any similar law. No officer and, to the knowledge of the Company, no other employee or agent of any Group Company has (x)&nbsp;made any untrue statement of material fact or fraudulent statement to the FDA or any other
Governmental Entity; (y)&nbsp;failed to disclose a material fact required to be disclosed to the FDA or any other Governmental Entity; or (z)&nbsp;committed an act, made a statement or failed to make a statement that would reasonably be expected to
provide the basis for the FDA or any other Governmental Entity to refuse to grant a Regulatory Permit for any Company Product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) No event has occurred or condition or state of facts exists which would form a reasonable basis for product
liability related, in whole or in part, to any of the Company Products, nor is there any complaint, claim, litigation or other suit pending against any Group Company related to product liability for the Company Products or the Group Company&#146;s
services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_35"></A><B>Section</B><B></B><B>&nbsp;3.24</B> <B>Investigation; No Other Representations</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) The Company, on its own behalf and on behalf of its Representatives, acknowledges, represents, warrants and
agrees that (i)&nbsp;it has conducted its own independent review and analysis of, and, based thereon, has formed an independent judgment concerning, the business, assets, condition, operations and prospects of, the CHFW Parties and (ii)&nbsp;it has
been furnished with or given access to such documents and information about the CHFW Parties and their respective businesses and operations as it and its Representatives have deemed necessary to enable it to make an informed decision with respect to
the execution, delivery and performance of this Agreement, the Ancillary Documents and the transactions contemplated hereby and thereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) In entering into this Agreement and the Ancillary Documents to which it is or will be a party, the Company
has relied solely on its own investigation and analysis and the representations and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
warranties expressly set forth in <U>Article 4</U> and in the Ancillary Documents to which it is or will be a party and no other representations or warranties of any CHFW Party or any other
Person, either express or implied, and the Company, on its own behalf and on behalf of its Representatives, acknowledges, represents, warrants and agrees that, except for the representations and warranties expressly set forth in <U>Article 4</U> and
in the Ancillary Documents to which it is or will be a party, none of the CHFW Parties or any other Person makes or has made any representation or warranty, either express or implied, in connection with or related to this Agreement, the Ancillary
Documents or the transactions contemplated hereby or thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_36"></A><B>Section</B><B></B><B>&nbsp;3.25</B>
<B>EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES</B>. NOTWITHSTANDING THE DELIVERY OR DISCLOSURE TO ANY CHFW PARTY OR ANY OF THEIR RESPECTIVE REPRESENTATIVES OF ANY DOCUMENTATION OR OTHER INFORMATION (INCLUDING ANY FINANCIAL PROJECTIONS OR OTHER
SUPPLEMENTAL DATA), EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS <U>ARTICLE 3</U> OR THE ANCILLARY DOCUMENTS, NEITHER THE COMPANY NOR OR ANY OTHER PERSON MAKES, AND THE COMPANY EXPRESSLY DISCLAIMS, ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND OR
NATURE, EXPRESS OR IMPLIED, IN CONNECTION WITH THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY, INCLUDING, AS TO THE MATERIALS RELATING TO THE BUSINESS AND AFFAIRS OR HOLDINGS OF THE GROUP COMPANIES
THAT HAVE BEEN MADE AVAILABLE TO ANY CHFW PARTY OR ANY OF THEIR REPRESENTATIVES OR IN ANY PRESENTATION OF THE BUSINESS AND AFFAIRS OF THE GROUP COMPANIES BY THE MANAGEMENT OF THE COMPANY OR OTHERS IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED
HEREBY OR BY THE ANCILLARY DOCUMENTS, AND NO STATEMENT CONTAINED IN ANY OF SUCH MATERIALS OR MADE IN ANY SUCH PRESENTATION SHALL BE DEEMED A REPRESENTATION OR WARRANTY HEREUNDER OR OTHERWISE OR DEEMED TO BE RELIED UPON BY ANY CHFW PARTY IN
EXECUTING, DELIVERING AND PERFORMING THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN <U>ARTICLE 3</U> OR THE ANCILLARY DOCUMENTS, IT IS
UNDERSTOOD THAT ANY COST ESTIMATES, PROJECTIONS OR OTHER PREDICTIONS, ANY DATA, ANY FINANCIAL INFORMATION OR ANY MEMORANDA OR OFFERING MATERIALS OR PRESENTATIONS, INCLUDING, BUT NOT LIMITED TO, ANY OFFERING MEMORANDUM OR SIMILAR MATERIALS MADE
AVAILABLE BY ANY GROUP COMPANY ARE NOT AND SHALL NOT BE DEEMED TO BE OR TO INCLUDE REPRESENTATIONS OR WARRANTIES OF THE COMPANY, AND ARE NOT AND SHALL NOT BE DEEMED TO BE RELIED UPON BY ANY CHFW PARTY IN EXECUTING, DELIVERING OR PERFORMING THIS
AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxa40894_37"></A>ARTICLE 4 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES RELATING TO THE CHFW PARTIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to <U>Section</U><U></U><U>&nbsp;8.8</U>, (a) except as set forth on the CHFW Disclosure Schedules, or (b)&nbsp;except as set forth in
any CHFW SEC Reports filed or furnished before the date of this Agreement (excluding any disclosures in any &#147;risk factors&#148; section, disclosures in any forward-looking statements disclaimers and other disclosures that are generally
cautionary, predictive or forward-looking in nature), each CHFW Party hereby represents and warrants to the Company, in each case, as of the date of this Agreement and as of the Closing, as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_38"></A><B>Section</B><B></B><B>&nbsp;4.1</B> <B>Organization and Qualification</B>. Each CHFW Party is an exempted
company, corporation, limited liability company or other applicable business entity duly organized, incorporated or formed, as applicable, validly existing and in good standing (or the equivalent thereof, if applicable, in each case, with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the Laws of its jurisdiction of organization, incorporation or formation (as applicable).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_39"></A><B>Section</B><B></B><B>&nbsp;4.2</B> <B>Authority</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Each CHFW Party has the requisite exempted company, corporate, limited liability company or other similar
power and authority to execute and deliver this Agreement and each of the Ancillary Documents to which it is or will be a party and to consummate the transactions contemplated hereby and thereby. Subject to the receipt of the CHFW Required
Shareholder Approval and the approvals and consents to be obtained by Merger Sub pursuant to <U>Section</U><U></U><U>&nbsp;5.9</U>, the execution and delivery of this Agreement, the Ancillary Documents to which a CHFW Party is or will be a party and
the consummation of the transactions contemplated hereby and thereby have been (or, in the case of any Ancillary Document entered into after the date of this Agreement, will be upon execution thereof) duly authorized by all necessary exempted
company, corporate, limited liability company or other similar action on the part of such CHFW Party. This Agreement has been and each Ancillary Document to which a CHFW Party is or will be a party will be, upon execution thereof, duly and validly
executed and delivered by such CHFW Party and constitutes or will constitute, upon execution thereof, as applicable, a valid, legal and binding agreement of such CHFW Party (assuming this Agreement has been and the Ancillary Documents to which such
CHFW Party is or will be a party are or will be, upon execution thereof, as applicable, duly authorized, executed and delivered by the other Persons party hereto or thereto, as applicable), enforceable against such CHFW Party in accordance with
their terms (subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors&#146; rights and subject to general principles of equity). On or prior to the date of this
Agreement, the board of directors of the CHFW has duly and unanimously adopted resolutions (i)&nbsp;determining that this Agreement and the Transactions are advisable and fair to, and in the best interest of, CHFW and the CHFW Shareholders,
(ii)&nbsp;approving the execution, delivery and performance by CHFW of this Agreement and the consummation of the Transactions and (iii)&nbsp;resolving to recommend the approval of this Agreement and the Transactions by the holders of CHFW Shares
entitled to vote thereon. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) The affirmative vote of a majority of the votes cast by the holders of
outstanding CHFW Shares present in person or represented by proxy at the extraordinary general meeting of CHFW Shareholders and entitled to vote is the only vote required under applicable Law and the Governing Documents of CHFW to approve by
ordinary resolutions the Business Combination Proposal, the Incentive Award Plan Proposal, the Employee Stock Purchase Plan Proposal, the Nasdaq Proposal and the Adjournment Proposal. The affirmative vote of a
<FONT STYLE="white-space:nowrap">sixty-six</FONT> and <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast by the holders of outstanding CHFW Shares present in person or represented by proxy at the extraordinary general meeting of
CHFW Shareholders and entitled to vote is the only vote required under applicable Law and the Governing Documents of CHFW to approve by extraordinary resolutions the Domestication Proposal and the Governing Document Proposal. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) The CHFW Board has taken all actions necessary to ensure that no &#147;moratorium,&#148; &#147;fair
price,&#148; &#147;business combination,&#148; &#147;control share acquisition&#148; or similar provision of any anti-takeover Law is, or at the Closing will be, applicable to this Agreement or the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_40"></A><B>Section</B><B></B><B>&nbsp;4.3</B> <B>Consents and Requisite Governmental Approvals; No Violations</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) No consent, approval or authorization of, or designation, declaration or filing with, any Governmental
Entity is required on the part of a CHFW Party with respect to such CHFW Party&#146;s execution, delivery or performance of its obligations under this Agreement or the Ancillary Documents to which it is or will be party or the consummation of the
Transactions, except for (i)&nbsp;the filing with the SEC of (A)&nbsp;the Registration Statement/Proxy Statement and the declaration of the effectiveness thereof by the SEC and (B)&nbsp;such reports under Section&nbsp;13(a) or 15(d) of the Exchange
Act as may be required in connection with this Agreement, the Ancillary Documents or the Transactions, (ii)&nbsp;such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
filings with and approvals of Nasdaq to permit the CHFW Shares to be issued in connection with the Transactions to be listed on Nasdaq, (iii)&nbsp;such filings and approvals required in
connection with the Domestication, (iv)&nbsp;filing of the Certificate of Merger, (v)&nbsp;the approvals and consents to be obtained by Merger Sub pursuant to <U>Section</U><U></U><U>&nbsp;5.9</U>, (vi) the CHFW Shareholder Approval or
(vii)&nbsp;where the failure to obtain such consents, approvals, authorizations, designations, declarations, waivers or filings, the absence of which would not individually or in the aggregate, prevent or materially delay consummation of any of the
Transactions or otherwise prevent the CHFW Parties from performing its material obligations under the Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Neither the execution, delivery or performance by a CHFW Party of this Agreement nor the Ancillary
Documents to which a CHFW Party is or will be a party nor the consummation by a CHFW Party of the transactions contemplated hereby or thereby will, directly or indirectly (with or without due notice or lapse of time or both) (i)&nbsp;result in any
breach of any provision of the Governing Documents of a CHFW Party, (ii)&nbsp;result in a violation or breach of, or constitute a default or give rise to any right of termination, cancellation, amendment, modification, suspension, revocation or
acceleration under, any of the terms, conditions or provisions of any Contract to which a CHFW Party is a party, (iii)&nbsp;violate, or constitute a breach under, any Order or applicable Law to which any such CHFW Party or any of its properties or
assets are bound or (iv)&nbsp;result in the creation of any Lien upon any of the assets or properties (other than any Permitted Liens) of a CHFW Party, except in the case of <U>clauses</U><U></U><U>&nbsp;(ii)</U> through <U>(iv)</U>&nbsp;above, as
would not have a CHFW Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_41"></A><B>Section</B><B></B><B>&nbsp;4.4</B> <B>Brokers</B>. Except
for fees (including the amounts due and payable assuming the Closing occurs) set forth on <U>Section</U><U></U><U>&nbsp;4.4</U> of the CHFW Disclosure Schedules (which fees shall be the sole responsibility of the CHFW, except as otherwise provided
in <U>Section</U><U></U><U>&nbsp;8.6</U>), no broker, finder, investment banker or other Person is entitled to any brokerage fee, finders&#146; fee or other commission in connection with the Transactions based upon arrangements made by or on behalf
of CHFW for which CHFW has any obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_42"></A><B>Section</B><B></B><B>&nbsp;4.5</B> <B>Information Supplied</B>.
None of the information supplied or to be supplied by or on behalf of either CHFW Party expressly for inclusion or incorporation by reference&nbsp;prior to the Closing in the Registration Statement/Proxy Statement will, when the Registration
Statement/Proxy Statement is declared effective or when the Registration Statement/Proxy Statement is mailed to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> CHFW Holders or at the time of the CHFW Shareholders Meeting, and in the case of
any amendment thereto, at the time of such amendment, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they are made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_43"></A><B>Section</B><B></B><B>&nbsp;4.6</B>
<B>Capitalization of </B><B>the CHFW Parties</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Section 4.6(a)</U> of the CHFW Disclosure
Schedules sets forth a true and complete statement of the number and class or series (as applicable) of the issued and outstanding CHFW Shares and the IPO Warrants prior to consummation of the Domestication and after giving pro forma effect to the
Domestication. All outstanding Equity Securities of CHFW (except to the extent such concepts are not applicable under the applicable Law of CHFW&#146;s jurisdiction of organization, incorporation or formation, as applicable, or other applicable Law)
prior to the consummation of the Domestication have been duly authorized and validly issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and will be deemed to be duly authorized and validly issued and fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> after consummation of the Domestication. Such Equity Securities (i)&nbsp;were not issued in violation of the Governing Documents of CHFW and (ii)&nbsp;are not subject to any preemptive rights, call
option, right of first refusal, subscription rights, transfer restrictions or similar rights of any Person (other than transfer restrictions under applicable Securities Laws or under the Governing Documents of CHFW) and were not issued in violation
of any preemptive rights, call option, right of first refusal, subscription rights, transfer restrictions or similar rights of any Person. Except for the CHFW Shares and IPO Warrants set forth on <U>Section</U><U></U><U>&nbsp;4.6(a)</U> of the CHFW
Disclosure Schedules (taking into account, for the avoidance of doubt, any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
changes or adjustments to such CHFW Shares and the IPO Warrants as a result of, or to give effect to, the Domestication and assuming that no CHFW Shareholder Redemptions are effected),
immediately prior to Closing, there shall be no outstanding Equity Securities of CHFW. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) As of the
Closing, (i)&nbsp;the authorized share capital of CHFW will consist of 300,000,000 shares of CHFW Common Stock and 10,000,000 shares of preferred stock, par value $0.0001 per share and (ii)&nbsp;all of the issued and outstanding CHFW Shares when
issued in accordance with the terms hereof (A)&nbsp;will be duly authorized, validly issued, fully paid and nonassessable, (B)&nbsp;will have been issued in compliance in all material respects with applicable Law and (C)&nbsp;will not have been
issued in breach or violation of any preemptive rights or Contract to which CHFW is a party or bound. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c)
Except for the IPO Warrants and the Subscription Agreements (including the PIPE Warrant Agreement), there are no outstanding (A)&nbsp;equity appreciation, phantom equity or profit participation rights or (B)&nbsp;options, restricted stock, phantom
stock, warrants, purchase rights, subscription rights, conversion rights, exchange rights, calls, puts, rights of first refusal or first offer or other Contracts that could require CHFW, and, except as expressly contemplated by this Agreement or the
Ancillary Documents, there is no obligation of CHFW, to issue, sell or otherwise cause to become outstanding or to acquire, repurchase or redeem any Equity Securities or securities convertible into or exchangeable for Equity Securities of CHFW. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) The Equity Securities of Merger Sub outstanding as of the date of this Agreement (i)&nbsp;have been duly
authorized and validly issued and are fully paid and nonassessable, (ii)&nbsp;were issued in compliance in all material respects with applicable Law, and (iii)&nbsp;were not issued in breach or violation of any preemptive rights or Contract to which
Merger Sub is a party or bound. All of the outstanding Equity Securities of Merger Sub are owned directly by CHFW free and clear of all Liens (other than transfer restrictions under applicable Securities Law). As of the date of this Agreement, CHFW
has no Subsidiaries other than Merger Sub and does not own, directly or indirectly, any Equity Securities in any Person other than Merger Sub. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) Except as set forth on <U>Section</U><U></U><U>&nbsp;4.6(e)</U> of the CHFW Disclosure Schedules neither
CHFW nor Merger Sub has any Indebtedness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_44"></A><B>Section</B><B></B><B>&nbsp;4.7</B> <B>SEC Filings</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) CHFW has timely filed or furnished all statements, forms, reports and documents required to be filed or
furnished by it prior to the date of this Agreement with the SEC pursuant to Federal Securities Laws since its initial public offering (collectively, and together with any exhibits and schedules thereto and other information incorporated therein,
and as they have been supplemented, modified or amended since the time of filing, the &#147;CHFW SEC Reports&#148;), and, as of the Closing, will have filed or furnished all other statements, forms, reports and other documents required to be filed
or furnished by it subsequent to the date of this Agreement with the SEC pursuant to Federal Securities Laws through the Closing (collectively, and together with any exhibits and schedules thereto and other information incorporated therein, and as
they have been supplemented, modified or amended since the time of filing, but excluding the Registration Statement/Proxy Statement, the &#147;Additional CHFW SEC Reports&#148;). Each of the CHFW SEC Reports, as of their respective dates of filing,
and as of the date of any amendment or filing that superseded the initial filing, complied with, and each of the Additional CHFW SEC Reports, as of their respective dates of filing, and as of the date of any amendment or filing that superseded the
initial filing, will comply, in all material respects with the applicable requirements of the Federal Securities Laws (including, as applicable, the Sarbanes-Oxley Act and any rules and regulations promulgated thereunder) applicable to the CHFW SEC
Reports or the Additional CHFW SEC Reports (for purposes of the Additional CHFW SEC Reports, assuming that the representation and warranty set forth in <U>Section</U><U></U><U>&nbsp;3.22</U> is true and correct in all respects with respect to all
information supplied by or on behalf of Group Companies expressly for inclusion or incorporation by reference therein). As of their respective dates of filing, the CHFW SEC Reports did not contain any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were
made or will be made, as applicable, not misleading (for purposes of the Additional SEC Reports, assuming that the representation and warranty set forth in <U>Section</U><U></U><U>&nbsp;3.22</U> is true and correct in all respects with respect to
all information supplied by or on behalf of Group Companies expressly for inclusion or incorporation by reference therein). As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC
with respect to the CHFW SEC Reports. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) CHFW is not an &#147;investment company&#148; or a Person
directly or indirectly &#147;controlled&#148; by or acting on behalf of an &#147;investment company,&#148; in each case within the meaning of the Investment Company Act. As of the date hereof, CHFW constitutes an &#147;emerging growth company&#148;
within the meaning of the JOBS Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_45"></A><B>Section</B><B></B><B>&nbsp;4.8</B> <B>Trust Account</B><B>. </B>As of
the date of this Agreement, CHFW has an amount in cash in the Trust Account equal to at least $92,000,000. The funds held in the Trust Account are (a)&nbsp;invested in United States &#147;government securities&#148; within the meaning of
Section&nbsp;2(a)(16) of the Investment Company Act, having a maturity of 180 days or less or in money market funds meeting certain conditions under Rule <FONT STYLE="white-space:nowrap">2a-7</FONT> promulgated under the Investment Company Act which
invest only in direct U.S. government treasury obligations and (b)&nbsp;held in trust pursuant to that certain Investment Management Trust Agreement (the &#147;Trust Agreement&#148;)., dated November&nbsp;18, 2020, between CHFW and Continental Stock
Transfer&nbsp;&amp; Trust Company, as trustee (the &#147;Trustee&#148;) There are no separate agreements, side letters or other agreements or understandings (whether written or unwritten, express or implied) that would cause the description of the
Trust Agreement in the CHFW SEC Reports to be inaccurate in any material respect or, to CHFW&#146;s knowledge, that would entitle any Person to any portion of the funds in the Trust Account (other than (i)&nbsp;in respect of deferred underwriting
commissions or Taxes, (ii)&nbsp;the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> CHFW Holders who shall have elected to redeem their CHFW Class&nbsp;A Shares pursuant to the Governing Documents of CHFW or (iii)&nbsp;if CHFW fails to complete
a business combination within the allotted time period set forth in the Governing Documents of CHFW and liquidates the Trust Account, subject to the terms of the Trust Agreement, CHFW (in limited amounts to permit CHFW to pay the expenses of the
Trust Account&#146;s liquidation, dissolution and winding up of CHFW) and then the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> CHFW Holders). Prior to the Closing, none of the funds held in the Trust Account are permitted to be released,
except in the circumstances described in the Governing Documents of CHFW and the Trust Agreement. CHFW has performed all material obligations required to be performed by it to date under, and is not in material default or delinquent in performance
or any other respect (claimed or actual) in connection with the Trust Agreement, and, to the knowledge of CHFW, no event has occurred which, with due notice or lapse of time or both, would constitute such a material default thereunder. As of the
date of this Agreement, there are no claims or proceedings pending with respect to the Trust Account. Since November&nbsp;18, 2020, CHFW has not released any money from the Trust Account (other than interest income earned on the funds held in the
Trust Account as permitted by the Trust Agreement). Upon the consummation of the transactions contemplated hereby, including the distribution of assets from the Trust Account (A)&nbsp;in respect of deferred underwriting commissions or Taxes or
(B)&nbsp;to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> CHFW Holders who have elected to redeem their CHFW Class&nbsp;A Shares pursuant to the Governing Documents of CHFW, each in accordance with the terms of and as set forth in the
Trust Agreement, CHFW shall have no further obligation under either the Trust Agreement or the Governing Documents of CHFW to liquidate or distribute any assets held in the Trust Account, and the Trust Agreement shall terminate in accordance with
its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_46"></A><B>Section</B><B></B><B>&nbsp;4.9</B> <B>Transactions with Affiliates</B>.
<U>Section</U><U></U><U>&nbsp;4.9</U> of the CHFW Disclosure Schedules sets forth all Contracts between (a)&nbsp;CHFW, on the one hand, and (b)&nbsp;any officer, director, employee, partner, member, manager, direct or indirect equityholder
(including the Sponsor) or Affiliate of either CHFW or the Sponsor, on the other hand (each Person identified in this <U>clause</U><U></U><U>&nbsp;(b)</U>, a &#147;CHFW Related Party&#148;), other than (i)&nbsp;Contracts solely related to a CHFW
Related Party&#146;s or a holder of IPO Warrants&#146; status as a holder of CHFW Shares or IPO Warrants, as applicable, in the ordinary course of business, (ii)&nbsp;employment with, or the provision of services to,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
CHFW entered into in the ordinary course of business (including benefit plans, indemnification arrangements and other ordinary course compensation), (iii) Contracts with respect to <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> CHFW Holders and (iv)&nbsp;Contracts entered into after the date of this Agreement that are either permitted pursuant to <U>Section</U><U></U><U>&nbsp;5.7</U> or entered into in accordance with
<U>Section</U><U></U><U>&nbsp;5.7</U>. No CHFW Related Party (A)&nbsp;owns any interest in any material asset used in the business of CHFW, (B)&nbsp;possesses, directly or indirectly, any material financial interest in, or is a director or executive
officer of, any Person which is a material client, supplier, customer, lessor or lessee of CHFW or (C)&nbsp;owes any material amount to, or is owed material any amount by, CHFW. All Contracts, arrangements, understandings, interests and other
matters that are required to be disclosed pursuant to this <U>Section</U><U></U><U>&nbsp;4.9</U> are referred to herein as &#147;CHFW Related Party Transactions&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_47"></A><B>Section</B><B></B><B>&nbsp;4.10</B> <B>Litigation</B>. As of the date of this Agreement, there is (and since its
organization, incorporation or formation, as applicable, there has been) no Proceeding pending or, to CHFW&#146;s knowledge, threatened against or involving any CHFW Party that, if adversely decided or resolved, would be material to the CHFW
Parties, taken as a whole. None of the CHFW Parties nor any of their respective properties or assets is subject to any material Order. As of the date of this Agreement, there are no material Proceedings by any CHFW Party pending against any other
Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_48"></A><B>Section</B><B></B><B>&nbsp;4.11</B> <B>Compliance with Applicable Law</B>. Each CHFW Party is (and
since its organization, incorporation or formation, as applicable, has been) in compliance with all applicable Laws, except as would not have a CHFW Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_49"></A><B>Section</B><B></B><B>&nbsp;4.12</B> <B>Merger Sub Activities</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Since its incorporation, CHFW has not conducted any business activities other than activities (i)&nbsp;in
connection with or incident or related to its incorporation or continuing corporate (or similar) existence, (ii)&nbsp;its initial public offering, (iii)&nbsp;directed toward the accomplishment of a business combination, including those incident or
related to or incurred in connection with the negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance of its covenants or agreements in this Agreement or any Ancillary Document or the consummation of the
transactions contemplated hereby or thereby or (iv)&nbsp;those that are administrative, ministerial or otherwise immaterial in nature. Except as set forth in CHFW&#146;s Governing Documents, there is no Contract binding upon any CHFW Party or to
which any CHFW Party is a party which has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of it or its Subsidiaries, any acquisition of property by it or its Subsidiaries or the conduct
of business by it or its Subsidiaries (including, in each case, following the Closing). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Merger Sub was
organized solely for the purpose of entering into this Agreement, the Ancillary Documents and consummating the transactions contemplated hereby and thereby and has not engaged in any activities or business, other than those incident or related to or
incurred in connection with its organization, incorporation or formation, as applicable, or the negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance of its covenants or agreements in this Agreement or
any Ancillary Document or the consummation of the transactions contemplated hereby or thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_50"></A><B>Section</B><B></B><B>&nbsp;4.13</B> <B>Internal Controls; Listing; Financial Statements</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Except as not required in reliance on exemptions from various reporting requirements by virtue of
CHFW&#146;s status as an &#147;emerging growth company&#148; within the meaning of the Securities Act, as modified by the JOBS Act, or &#147;smaller reporting company&#148; within the meaning of the Exchange Act,&nbsp;since its initial public
offering, (i)&nbsp;CHFW has established and maintained a system of internal controls over financial reporting (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> and Rule <FONT STYLE="white-space:nowrap">15d-15</FONT> under the
Exchange Act) sufficient to provide reasonable assurance regarding the reliability of CHFW&#146;s financial reporting and the preparation of CHFW&#146;s financial statements for external purposes in accordance with GAAP and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
(ii)&nbsp;CHFW has established and maintained disclosure controls and procedures (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> and Rule
<FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act) designed to ensure that material information relating to CHFW is made known to CHFW&#146;s principal executive officer and principal financial officer by others within CHFW. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) CHFW has not taken any action prohibited by Section&nbsp;402 of the Sarbanes-Oxley Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) Since its initial public offering, CHFW has complied in all material respects with all applicable listing
and corporate governance rules and regulations of NYSE American. The classes of securities representing issued and outstanding CHFW Class&nbsp;A Shares are registered pursuant to Section&nbsp;12(b) of the Exchange Act and are listed for trading on
NYSE American. As of the date of this Agreement, there is no material Proceeding pending or, to the knowledge of CHFW, threatened against CHFW by NYSE American or the SEC with respect to any intention by such entity to deregister CHFW Class&nbsp;A
Shares or prohibit or terminate the listing of CHFW Class&nbsp;A Shares on NYSE American or prohibit the transfer of the listing to Nasdaq. CHFW has not taken any action that is designed to terminate the registration of CHFW Class&nbsp;A Shares
under the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) The CHFW SEC Reports contain true and complete copies of the applicable CHFW
Financial Statements. The CHFW Financial Statements (i)&nbsp;fairly present in all material respects the financial position of CHFW as at the respective dates thereof, and the results of its operations, shareholders&#146; equity and cash flows for
the respective periods then ended (subject, in the case of any unaudited interim financial statements, to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments (none of which is material) and the absence of footnotes),
(ii)&nbsp;were prepared in conformity with GAAP applied on a consistent basis during the periods involved (subject, in the case of any unaudited financial statements, to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments (none
of which is material) and the absence of footnotes), (iii) in the case of the audited CHFW Financial Statements, were audited in accordance with the standards of the PCAOB and (iv)&nbsp;comply in all material respects with the applicable accounting
requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities Act in effect as of the respective dates thereof (including Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> or Regulation <FONT
STYLE="white-space:nowrap">S-K,</FONT> as applicable). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) CHFW has established and maintains systems of
internal accounting controls that are designed to provide, in all material respects, reasonable assurance that (i)&nbsp;all transactions are executed in accordance with management&#146;s authorization and (ii)&nbsp;all transactions are recorded as
necessary to permit preparation of proper and accurate financial statements in accordance with GAAP and to maintain accountability for CHFW&#146;s and its Subsidiaries&#146; assets. CHFW maintains and, for all periods covered by the CHFW Financial
Statements, has maintained books and records of CHFW in the ordinary course of business that are accurate and complete and reflect the revenues, expenses, assets and liabilities of CHFW in all material respects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) Since its incorporation, CHFW has not received any written complaint, allegation, assertion or claim that
there is (i)&nbsp;a &#147;significant deficiency&#148; in the internal controls over financial reporting of CHFW to CHFW&#146;s knowledge, (ii)&nbsp;a &#147;material weakness&#148; in the internal controls over financial reporting of CHFW to
CHFW&#146;s knowledge or (iii)&nbsp;fraud, whether or not material, that involves management or other employees of CHFW who have a significant role in the internal controls over financial reporting of CHFW. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_51"></A><B>Section</B><B></B><B>&nbsp;4.14</B> <B>No Undisclosed Liabilities</B>. Except for the Liabilities (a)&nbsp;set
forth in <U>Section</U><U></U><U>&nbsp;4.14</U> of the CHFW Disclosure Schedules, (b)&nbsp;incurred in connection with the negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance of its covenants or
agreements in this Agreement or any Ancillary Document or the consummation of the Transactions or transactions contemplated by the Ancillary Documents, (c)&nbsp;set forth or disclosed in the CHFW Financial Statements included in the CHFW SEC
Reports, (d)&nbsp;that have arisen since the date of the most recent balance sheet included in the CHFW SEC Reports in the ordinary course of business, or (e)&nbsp;either permitted to be incurred pursuant to <U>Section</U><U></U><U>&nbsp;5.10</U> or
incurred in accordance with <U>Section</U><U></U><U>&nbsp;5.10</U>, CHFW does not have any Liabilities of the type required to be set forth on a balance sheet in accordance with GAAP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_52"></A><B>Section</B><B></B><B>&nbsp;4.15</B> <B>Tax Matters</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) CHFW has prepared and filed all material Tax Returns required to have been filed by it, all such Tax
Returns are true and complete in all material respects and prepared in compliance in all material respects with all applicable Laws and Orders, and CHFW has paid all material Taxes required to have been paid or deposited by it regardless of whether
shown on a Tax Return. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) CHFW has timely withheld and paid to the appropriate Tax Authority all material
amounts required to have been withheld and paid in connection with amounts paid or owing to any employee, individual independent contractor, other service providers, equity interest holder or other
<FONT STYLE="white-space:nowrap">third-party.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) CHFW is not currently the subject of a Tax audit
or examination, or has been informed in writing of the commencement or anticipated commencement of any Tax audit or examination that has not been resolved or completed, in each case with respect to material Taxes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) CHFW has not consented to extend or waive the time in which any material Tax may be assessed or collected
by any Tax Authority, other than any such extensions or waivers that are no longer in effect or that were extensions of time to file Tax Returns obtained in the ordinary course of business, in each case with respect to material Taxes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) No &#147;closing agreement&#148; as described in Section&nbsp;7121 of the Code (or any corresponding or
similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income Tax Law), private letter rulings, technical advice memoranda or similar agreements or rulings have been entered into or issued by any Tax Authority with
respect to any CHFW Party which agreement or ruling would be effective after the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) None of
the CHFW Parties is and none of the CHFW Parties has been a party to any &#147;listed transaction&#148; as defined in Section&nbsp;6707A of the Code and Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4</FONT> (or any
corresponding or similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income Tax Law). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) Each CHFW Party is tax resident only in its country of organization, incorporation or formation, as
applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) None of the CHFW Parties has taken or agreed to take any action not contemplated by this
Agreement and/or any Ancillary Documents that could reasonably be expected to prevent the Merger or the Domestication from qualifying for the Intended Tax Treatment. To the knowledge of CHFW, no facts or circumstances exist that could reasonably be
expected to prevent the Merger or the Domestication from qualifying for the Intended Tax Treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_53"></A><B>Section</B><B></B><B>&nbsp;4.16</B> <B>Investigation; No Other Representations</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Each CHFW Party, on its own behalf and on behalf of its Representatives, acknowledges, represents, warrants
and agrees that (i)&nbsp;it has conducted its own independent review and analysis of, and, based thereon, has formed an independent judgment concerning, the business, assets, condition, operations and prospects, of the Group Companies and
(ii)&nbsp;it has been furnished with or given access to such documents and information about the Group Companies and their respective businesses and operations as it and its Representatives have deemed necessary to enable it to make an informed
decision with respect to the execution, delivery and performance of this Agreement, the Ancillary Documents and the transactions contemplated hereby and thereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) In entering into this Agreement and the Ancillary Documents to which it is or will be a party, each CHFW
Party has relied solely on its own investigation and analysis and the representations and warranties expressly set forth in <U>Article 3</U> and in the Ancillary Documents to which it is or will be a party and no other representations or warranties
of the Company or any other Person, either express or implied, and each CHFW Party, on its own behalf and on behalf of its Representatives, acknowledges, represents, warrants and agrees that, except for the representations and warranties expressly
set forth in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
<U>Article 3</U> and in the Ancillary Documents to which it is or will be a party, neither the Company nor any other Person makes or has made any representation or warranty, either express or
implied, in connection with or related to this Agreement, the Ancillary Documents or the transactions contemplated hereby or thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_54">
</A><B>Section</B><B></B><B>&nbsp;4.17</B> <B>PIPE Financing</B>. On or prior to the date of this Agreement, CHFW has entered into Subscription Agreements with PIPE Investors, true and correct copies of which have been provided to the Company on or
prior to the date of this Agreement, pursuant to which, and on the terms and subject to the conditions of which, such PIPE Investors have agreed, in connection with the transactions contemplated hereby, to purchase from CHFW shares of CHFW Common
Stock for an aggregate purchase price of $120,200,000. Such Subscription Agreements are in full force and effect with respect to, and binding on, CHFW and, to the knowledge of CHFW, on each PIPE Investor party thereto, in accordance with their
terms. There are no other agreements, side letters or arrangements between CHFW and any PIPE Investor relating to any such Subscription Agreement that would reasonably be expected to materially and adversely affect the obligation of such PIPE
Investor to purchase from CHFW the applicable portion of the PIPE Financing Amount set forth in such Subscription Agreement of such PIPE Investors and, as of the date hereof, CHFW does not have knowledge of any facts or circumstances that would
reasonably be expected to result in any of the conditions set forth in any such Subscription Agreement not being satisfied, or the PIPE Financing Amount not being available to CHFW on the Closing Date. No event has occurred that, with or without
notice, lapse of time or both, would constitute a material default or breach on the part of CHFW under such Subscription Agreement and, as of the date hereof, CHFW has no reason to believe that CHFW will be unable to satisfy in all material respects
on a timely basis the terms and conditions of closing to be satisfied by CHFW contained in any such Subscription Agreement. Such Subscription Agreements contain all of the conditions precedent (other than the conditions contained in this Agreement
and the Ancillary Documents, as applicable) to the obligations of the PIPE Investors to contribute to CHFW the applicable portion of the PIPE Financing Amount set forth in such Subscription Agreements on the terms therein. No fees, cash
consideration or other discounts are payable or have been agreed to be paid by CHFW or any of its Subsidiaries (including, from and after the Closing, the Company and its Subsidiaries) to any PIPE Investor in respect of its PIPE investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_55"></A><B>Section</B><B></B><B>&nbsp;4.18</B> <B>Compliance with International Trade</B><B></B><B>&nbsp;&amp;
Anti-Corruption Laws</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Since CHFW&#146;s incorporation, neither CHFW nor, to CHFW&#146;s knowledge,
any of their Representatives, or any other Persons acting for or on behalf of any of the foregoing,&nbsp;is or has been, (i)&nbsp;a Person named on any Sanctions and Export Control Laws-related list of designated Persons maintained by a Governmental
Entity; (ii)&nbsp;located, organized or resident in a country or territory which is itself the subject of or target of any Sanctions and Export Control Laws; (iii)&nbsp;an entity owned, directly or indirectly, by one or more Persons described in
clause (i)&nbsp;or (ii); or (iv)&nbsp;otherwise engaging in dealings with or for the benefit of any Person described in clauses (i) - (iii) or any country or territory which is or has, since CHFW&#146;s incorporation, been the subject of or target
of any Sanctions and Export Control Laws (at the time of this Agreement, the Crimea region of Ukraine, Cuba, Iran, North Korea, Venezuela, Sudan and Syria). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Since CHFW&#146;s incorporation, neither CHFW nor, to CHFW&#146;s knowledge, any of their Representatives,
or any other Persons acting for or on behalf of any of the foregoing has (i)&nbsp;made, offered, promised, paid or received any unlawful bribes, kickbacks or other similar payments to or from any Person, (ii)&nbsp;made or paid any contributions,
directly or indirectly, to a domestic or foreign political party or candidate or (iii)&nbsp;otherwise made, offered, received, authorized, promised or paid any improper payment under any Anti-Corruption Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_56"></A><B>Section</B><B></B><B>&nbsp;4.19</B> <B>EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES</B>. NOTWITHSTANDING THE
DELIVERY OR DISCLOSURE TO THE COMPANY OR ANY OF ITS REPRESENTATIVES OF ANY DOCUMENTATION OR OTHER INFORMATION (INCLUDING ANY FINANCIAL PROJECTIONS OR OTHER SUPPLEMENTAL DATA), EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS <U>Article 4</U>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
AND THE ANCILLARY DOCUMENTS, NONE OF THE CHFW PARTIES NOR ANY OTHER PERSON MAKES, AND EACH CHFW PARTY EXPRESSLY DISCLAIMS, ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND OR NATURE, EXPRESS OR
IMPLIED IN CONNECTION WITH THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY, INCLUDING AS TO THE MATERIALS RELATING TO THE BUSINESS AND AFFAIRS OR HOLDINGS OF ANY CHFW PARTY THAT HAVE BEEN MADE
AVAILABLE TO THE COMPANY OR ANY OF ITS REPRESENTATIVES OR IN ANY PRESENTATION OF THE BUSINESS AND AFFAIRS OF ANY CHFW PARTY BY OR ON BEHALF OF THE MANAGEMENT OF SUCH CHFW PARTY OR OTHERS IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREBY OR BY
THE ANCILLARY DOCUMENTS, AND NO STATEMENT CONTAINED IN ANY OF SUCH MATERIALS OR MADE IN ANY SUCH PRESENTATION SHALL BE DEEMED A REPRESENTATION OR WARRANTY HEREUNDER OR OTHERWISE OR DEEMED TO BE RELIED UPON BY THE COMPANY OR ANY OF ITS
REPRESENTATIVES IN EXECUTING, DELIVERING AND PERFORMING THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN <U>Article 4</U> OR THE
ANCILLARY DOCUMENTS, IT IS UNDERSTOOD THAT ANY COST ESTIMATES, PROJECTIONS OR OTHER PREDICTIONS, ANY DATA, ANY FINANCIAL INFORMATION OR ANY MEMORANDA OR OFFERING MATERIALS OR PRESENTATIONS, INCLUDING, BUT NOT LIMITED TO, ANY OFFERING MEMORANDUM OR
SIMILAR MATERIALS MADE AVAILABLE BY OR ON BEHALF OF ANY CHFW PARTY ARE NOT AND SHALL NOT BE DEEMED TO BE OR TO INCLUDE REPRESENTATIONS OR WARRANTIES OF ANY CHFW PARTY, AND ARE NOT AND SHALL NOT BE DEEMED TO BE RELIED UPON BY THE COMPANY OR ANY OF
ITS REPRESENTATIVES IN EXECUTING, DELIVERING OR PERFORMING THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxa40894_57"></A>ARTICLE 5 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COVENANTS<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_58"></A><B>Section</B><B></B><B>&nbsp;5.1</B> <B>Conduct of Business of the Company</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) From and after the date of this Agreement until the earlier of the Closing or the termination of this
Agreement in accordance with its terms, the Company shall, and the Company shall cause its Subsidiaries to, except as expressly contemplated by this Agreement or any Ancillary Document, as required by applicable Law, as set forth on
<U>Section</U><U></U><U>&nbsp;5.1(a)</U> of the Company Disclosure Schedules, or as consented to in writing by CHFW (it being agreed that any request for a consent shall not be unreasonably withheld, conditioned or delayed), (i) operate the business
of the Group Companies in the ordinary course in all material respects and (ii)&nbsp;use commercially reasonable efforts to maintain and preserve intact in all material respects the business organization, assets, properties and material business
relations of the Group Companies, taken as a whole. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Without limiting the generality of the foregoing,
from and after the date of this Agreement until the earlier of the Closing or the termination of this Agreement in accordance with its terms, the Company shall, and the Company shall cause its Subsidiaries to, except as expressly contemplated by
this Agreement or any Ancillary Document, as required by applicable Law, as set forth on <U>Section</U><U></U><U>&nbsp;5.1(b)</U> of the Company Disclosure Schedules or as consented to in writing by CHFW (such consent not to be unreasonably
withheld, conditioned or delayed) not do any of the following:<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i)
declare, set aside, make or pay a dividend on, or make any other distribution or payment in respect of, any Equity Securities of any Group Company or repurchase any outstanding Equity Securities of any Group Company, other than dividends or
distributions, declared, set aside or paid by any of the Company&#146;s Subsidiaries to the Company or any Subsidiary that is, directly or indirectly, wholly owned by the Company; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) (A) merge, consolidate, combine or amalgamate any Group Company with
any Person or (B)&nbsp;purchase or otherwise acquire (through acquisition, license, joint venture, collaboration or otherwise) any Equity Securities, assets or other rights of any corporation, partnership, association or other business entity or
organization or division thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) adopt any amendments, supplements, restatements or modifications to any Group
Company&#146;s Governing Documents, the Company Stockholders Agreements; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv) (A) sell, assign, abandon, lease, license
or otherwise dispose of any material assets or properties of the Group Companies, including any Intellectual Property Rights (whether through a sale, license, joint venture, collaboration or otherwise), other than inventory or obsolete equipment in
the ordinary course of business or nonexclusive licenses in the ordinary course of business, or (B)&nbsp;create, subject or incur any Lien any material assets or properties of the Group Companies (other than Permitted Liens or nonexclusive licenses
in the ordinary course of business); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v) transfer, issue, sell, grant or otherwise directly or indirectly dispose of, or
subject to a Lien, (A)&nbsp;any Equity Securities of any Group Company or (B)&nbsp;any options, warrants, rights of conversion or other rights, agreements, arrangements or commitments obligating any Group Company to issue, deliver or sell any Equity
Securities of any Group Company; other than the issuance of shares of the applicable class of capital stock of the Company upon the exercise or conversion of any Company Options on the date of this Agreement in accordance with the terms of the
Company Equity Plan and the underlying grant, award or similar agreement or the issuance of Company Options or Restricted Stock covering up to 600,000 Company Common Shares under the Company Equity Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vi) incur, create or assume any Indebtedness, other than ordinary course trade payables; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vii) (A) amend, modify or terminate any Material Contract (excluding, for the avoidance of doubt, any expiration or
automatic extension or renewal of any such Material Contract pursuant to its terms or entering into additional work orders pursuant to, and in accordance with the terms of, any Material Contract in the ordinary course of business and consistent with
past practice), (B) waive any material benefit or right under any Material Contract or (C)&nbsp;enter into any Contract that would constitute a Material Contract; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(viii) make any loans, advances or capital contributions to, or guarantees for the benefit of, or any investments in, any
Person, other than (A)&nbsp;intercompany loans or capital contributions between the Company and any of its wholly owned Subsidiaries and (B)&nbsp;the reimbursement of expenses of employees in the ordinary course of business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ix) except as required under the terms of any Employee Benefit Plan of any Group Company that is set forth on the
<U>Section</U><U></U><U>&nbsp;3.11(a)</U> of the Company Disclosure Schedules or required under applicable Law, (A)&nbsp;amend, modify, adopt, enter into or terminate any material Employee Benefit Plan of any Group Company or any material benefit or
compensation plan, policy, program or Contract that would be an Employee Benefit Plan if in effect as of the date of this Agreement, (B)&nbsp;increase the compensation or benefits payable to any current or former director, manager, officer,
employee, individual independent contractor or other service provider of any Group Company, (C)&nbsp;take any action to accelerate any payment, right to payment, or benefit, or the funding of any payment, right to payment or benefit, payable or to
become payable to any current or former director, manager, officer, employee, individual independent contractor or other service provider of any Group Company, (D)&nbsp;waive or release any noncompetition,
<FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT STYLE="white-space:nowrap">no-hire,</FONT> nondisclosure or other restrictive covenant obligation of any current or former director, manager, officer, employee, individual independent
contractor or other service provider of any Group Company, (E)&nbsp;terminate without cause the employment of any director, manager or officer (provided that the Company agrees to provide prompt written notice to CHFW of any termination of a
director, manager or officer for cause) of any Group Company or terminate the employment of any group of employees of any Group Company, (F)&nbsp;hire any director or officer, or hire any other individuals
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
outside of the approved budget and hiring plan attached to <U>Section&nbsp;5.1(b)(ix)(F)</U> of the Company Disclosure Schedules, (G)&nbsp;initiate any Proceeding with respect to any current or
former director, manager, officer, employee, individual independent contractor, or other service provider of the Group Companies; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(x) make, change or revoke any material election concerning Taxes, enter into any material Tax closing agreement, settle any
material Tax claim or assessment, or consent to any extension or waiver of the limitation period applicable to or relating to any material Tax claim or assessment, other than any such extension or waiver that is obtained in the ordinary course of
business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(xi) enter into any settlement, conciliation or similar Contract the performance of which would involve the
payment by the Group Companies in excess of $2,000,000, in the aggregate, or that imposes, or by its terms will impose at any point in the future, any material, <FONT STYLE="white-space:nowrap">non-monetary</FONT> obligations on any Group Company
(or CHFW or any of its Affiliates after the Closing); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(xii) authorize, recommend, propose or announce an intention to
adopt, or otherwise effect, a plan of complete or partial liquidation, dissolution, restructuring, recapitalization, reorganization or similar transaction involving any Group Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(xiii) change any Group Company&#146;s methods of accounting in any material respect, other than changes that are made in
accordance with PCAOB standards; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(xiv) enter into any Contract with any broker, finder, investment banker or other
Person under which such Person is or will be entitled to any brokerage fee, finders&#146; fee or other commission in connection with the transactions contemplated by this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(xv) make any Change of Control Payment that is not set forth on <U>Section</U><U></U><U>&nbsp;3.11(d)</U> of the Company
Disclosure Schedules; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(xvi) enter into any Contract to take, or cause to be taken, any of the actions set forth in
this <U>Section</U><U></U><U>&nbsp;5.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding anything in this <U>Section</U><U></U><U>&nbsp;5.1</U> or this Agreement to
the contrary, nothing set forth in this Agreement shall give CHFW, directly or indirectly, the right to control or direct the operations of the Group Companies prior to the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxa40894_59"></A>Section&nbsp;5.2 Efforts to Consummate. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Subject to the terms and conditions herein provided, each of the Parties shall use reasonable best efforts
to take, or cause to be taken, all actions and to do, or cause to be done, all things reasonably necessary or advisable to consummate and make effective as promptly as reasonably practicable the transactions contemplated by this Agreement (including
(i)&nbsp;the satisfaction, but not waiver, of the closing conditions set forth in <U>Article 6</U> and, in the case of any Ancillary Document to which such Party will be a party after the date of this Agreement, to execute and delivery such
Ancillary Document when required pursuant to this Agreement, (ii)&nbsp;using reasonable best efforts to obtain the PIPE Financing on the terms and subject to the conditions set forth in the Subscription Agreements and (iii)&nbsp;the Company taking,
or causing to be taken, all actions necessary or advisable to cause the agreements set forth on <U>Schedule 5.2(a)</U> to be terminated effective as of the Closing without any further obligations or liabilities to the Company or any of its
Affiliates (including the other Group Companies and, from and after the Effective Time, CHFW)). Without limiting the generality of the foregoing, each of the Parties shall use reasonable best efforts to obtain, file with or deliver to, as
applicable, any Consents of any Governmental Entities or other Persons necessary, proper or advisable to consummate the transactions contemplated by this Agreement or the Ancillary Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) From and after the date of this Agreement until the
earlier of the Closing or termination of this Agreement in accordance with its terms, CHFW, on the one hand, and the Company, on the other hand, shall each notify the other in writing promptly after learning of any shareholder demands or other
shareholder Proceedings (including derivative claims) relating to this Agreement, any Ancillary Document or any matters relating thereto (collectively, the &#147;Transaction Litigation&#148;) commenced against, in the case of CHFW, any of the CHFW
Parties or any of their respective Representatives (in their capacity as a representative of a CHFW Party) or, in the case of the Company, any Group Company or any of their respective Representatives (in their capacity as a representative of a CHFW
Party). CHFW and the Company shall each (i)&nbsp;keep the other reasonably informed regarding any Transaction Litigation, (ii)&nbsp;give the other the opportunity to, at its own cost and expense, participate in the defense, settlement and compromise
of any such Transaction Litigation and reasonably cooperate with the other in connection with the defense, settlement and compromise of any such Transaction Litigation, (iii)&nbsp;consider in good faith the other&#146;s advice with respect to any
such Transaction Litigation and (iv)&nbsp;reasonably cooperate with each other. Notwithstanding the foregoing, the Company shall, subject to and without limiting the covenants and agreements, and the rights of CHFW, set forth in the immediately
preceding sentence, control the negotiation, defense and settlement of any such Transaction Litigation; provided, however, that in no event shall the Company, any other Group Company or any of their respective Representatives settle or compromise
any Transaction Litigation without the prior written consent of CHFW (not to be unreasonably withheld, conditioned or delayed, provided that it shall be deemed to be reasonable for CHFW to withhold, condition or delay its consent if any such
settlement or compromise (A)&nbsp;does not provide for a legally binding, full, unconditional and irrevocable release of each CHFW Party and Representative that is the subject of such Transaction Litigation, (B)&nbsp;provides for (x)&nbsp;the
payment of cash any portion of which is payable by any CHFW Party or Representative thereof or would otherwise constitute a CHFW Liability or (y)&nbsp;any <FONT STYLE="white-space:nowrap">non-monetary,</FONT> injunctive, equitable or similar relief
against any CHFW Party or (C)&nbsp;contains an admission of wrongdoing or Liability by a CHFW Party or any of its Representatives). Without limiting the generality of the foregoing, in no event shall CHFW, any of the CHFW Parties or any of their
respective Representatives settle or compromise any Transaction Litigation without the Company&#146;s prior written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_60">
</A><B>Section</B><B></B><B>&nbsp;5.3</B> <B>Confidentiality and Access to Information</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) The
Parties hereby acknowledge and agree that the information being provided in connection with this Agreement and the consummation of the Transactions is subject to the terms of the Confidentiality Agreements, the terms of which are incorporated herein
by reference. Notwithstanding the foregoing or anything to the contrary in this Agreement, in the event that this <U>Section</U><U></U><U>&nbsp;5.3(a)</U> or either Confidentiality Agreement conflicts with any other covenant or agreement contained
herein or in the Ancillary Documents that contemplates the disclosure, use or provision of information or otherwise, then such other covenant or agreement contained herein shall govern and control to the extent of such conflict. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) From and after the date of this Agreement until the earlier of the Closing Date or the termination of this
Agreement in accordance with its terms, upon reasonable advance written notice, the Company shall provide, or cause to be provided, to CHFW and its Representatives during normal business hours reasonable access, under the supervision of the Group
Companies, to the books and records and personnel of the Group Companies (in a manner so as to not interfere with the normal business operations of the Group Companies). Notwithstanding the foregoing, none of the Group Companies shall be required to
provide to CHFW or any of its Representatives any information (i)&nbsp;if and to the extent doing so would (A)&nbsp;violate any Law to which any Group Company is subject, (B)&nbsp;result in the disclosure of any trade secrets of third parties in
breach of any Contract with such third party, (C)&nbsp;violate any legally-binding obligation of any Group Company with respect to confidentiality, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> or privacy or (D)&nbsp;jeopardize protections
afforded to any Group Company under the attorney-client privilege or the attorney work product doctrine (<U>provided</U> that, in case of each of <U>clauses</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
<U>(A)</U>&nbsp;through <U>(D)</U>, the Company shall, and shall cause the other Group Companies to, use commercially reasonable efforts to (x)&nbsp;provide such access as can be provided (or
otherwise convey such information regarding the applicable matter as can be conveyed) without violating such privilege, doctrine, Contract, obligation or Law and (y)&nbsp;provide such information in a manner without violating such privilege,
doctrine, Contract, obligation or Law), or (ii)&nbsp;if any Group Company, on the one hand, and any CHFW Party or any of its Representatives, on the other hand, are adverse parties in a litigation and such information is reasonably pertinent
thereto; <U>provided</U> that the Company shall, in the case of <U>clause (i)</U>&nbsp;or <U>(ii)</U>, provide prompt written notice of the withholding of access or information on any such basis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) From and after the date of this Agreement until the earlier of the Closing Date or the termination of this
Agreement in accordance with its terms, upon reasonable advance written notice, CHFW shall provide, or cause to be provided, to the Company and its Representatives during normal business hours reasonable access to the directors, officers, books and
records of the CHFW Parties (in a manner so as to not interfere with the normal business operations of the CHFW Parties). Notwithstanding the foregoing, CHFW shall not be required to provide, or cause to be provided to, the Company or any of its
Representatives any information (i)&nbsp;if and to the extent doing so would (A)&nbsp;violate any Law to which any CHFW Party is subject, (B)&nbsp;result in the disclosure of any trade secrets of third parties in breach of any Contract with such
third party, (C)&nbsp;violate any legally-binding obligation of any CHFW Party with respect to confidentiality, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> or privacy or (D)&nbsp;jeopardize protections afforded to any CHFW Party under the
attorney-client privilege or the attorney work product doctrine (<U>provided</U> that, in case of each of <U>clauses (A)</U>&nbsp;through <U>(D)</U>, CHFW shall use, and shall cause the other CHFW Parties to use, commercially reasonable efforts to
(x)&nbsp;provide such access as can be provided (or otherwise convey such information regarding the applicable matter as can be conveyed) without violating such privilege, doctrine, Contract, obligation or Law and (y)&nbsp;provide such information
in a manner without violating such privilege, doctrine, Contract, obligation or Law), or (ii)&nbsp;if a CHFW Party, on the one hand, and any Group Company, or any of their respective Representatives, on the other hand, are adverse parties in a
litigation and such information is reasonably pertinent thereto; <U>provided</U> that CHFW shall, in the case of <U>clause (i)</U>&nbsp;or <U>(ii)</U>, provide prompt written notice of the withholding of access or information on any such basis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) The Parties hereby acknowledge and agree that each Confidentiality Agreement shall be automatically
terminated effective as of the Closing without any further action by any Party or any other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_61"></A><B>Section</B><B></B><B>&nbsp;5.4</B> <B>Public Announcements</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Subject to <U>Section</U><U></U><U>&nbsp;5.4(a)</U>, <U>Section</U><U></U><U>&nbsp;5.7</U> and
<U>Section</U><U></U><U>&nbsp;5.8</U>, none of the Parties or any of their respective Representatives shall issue any press releases or make any public announcements with respect to this Agreement or the Transactions without the prior written
consent of the Company and CHFW; <U>provided</U>, <U>however</U>, that each Party may make any such announcement or other communication (i)&nbsp;if such announcement or other communication is required by applicable Law, in which case prior to the
Closing, the disclosing Party and its Representatives shall use reasonable best efforts to consult with the Company, if the disclosing party is any CHFW Party, or CHFW, if the disclosing party is the Company, to review such announcement or
communication and the opportunity to comment thereon and the disclosing Party shall consider such comments in good faith, (ii)&nbsp;to the extent such announcements or other communications contain only information previously disclosed in a public
statement, press release or other communication previously approved in accordance with this&nbsp;<U>Section 5.4</U> and (iii)&nbsp;to Governmental Entities in connection with any Consents required to be made under this Agreement, the Ancillary
Documents or in connection with the Transactions. Notwithstanding anything to the contrary in this <U>Section</U><U></U><U>&nbsp;5.4</U> or otherwise in this Agreement, the Company agrees that CHFW and its Representatives may provide general
information about the subject matter of this Agreement and the transactions contemplated hereby to any CHFW investor; provided the recipients of such information are subject to customary confidentiality obligations prior to the receipt of such
information and such information is provided consistent with the Securities Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) The initial press release concerning this Agreement and
the Transactions shall be a joint press release in the form agreed by the Company and CHFW prior to the execution of this Agreement and such initial press release (the &#147;Signing Press Release&#148;) shall be released as promptly as reasonably
practicable after the execution of this Agreement on the day thereof. Promptly after the execution of this Agreement, CHFW shall file a current report on Form 8-K (the &#147;Signing Filing&#148;) with the Signing Press Release and a description of
this Agreement as required by, and in compliance with, the Securities Laws, which the Company shall have the opportunity to review and comment upon prior to filing and CHFW shall consider such comments in good faith. The Company, on the one hand,
and CHFW, on the other hand, shall mutually agree upon (such agreement not to be unreasonably withheld, conditioned or delayed by either the Company or CHFW, as applicable) a press release announcing the consummation of the Transactions (the
&#147;Closing Press Release&#148;) prior to the Closing, and, on the Closing Date, the Parties shall cause the Closing Press Release to be released. Promptly after the Closing (but in any event within four (4)&nbsp;Business Days after the Closing),
CHFW shall file a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (the &#147;Closing Filing&#148;) with the Closing Press Release and a description of the Closing as required by Securities Laws, which Closing Filing shall be
mutually agreed upon by the Company and CHFW prior to the Closing (such agreement not to be unreasonably withheld, conditioned or delayed by either the Company or CHFW, as applicable). In connection with the preparation of each of the Signing Press
Release, the Signing Filing, the Closing Press Release and the Closing Filing, each Party shall, upon written request by any other Party, furnish such other Party with all information concerning itself, its directors, officers and equityholders, and
such other matters as may be reasonably necessary for such press release or filing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_62"></A><B>Section</B><B></B><B>&nbsp;5.5</B> <B>Tax Matters</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <U>Tax Treatment</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) The Parties intend that the Domestication shall constitute a transaction treated as a &#147;reorganization&#148; within
the meaning of Section&nbsp;368(a)(1)(F) of the Code. The Parties intend that the Merger shall be treated as a transaction that qualifies as a &#147;reorganization&#148; within the meaning of Section&nbsp;368 of the Code, and each Party shall, and
shall cause its respective Affiliates to, use commercially reasonable efforts to so qualify. The Parties shall file all Tax Returns consistent with, and take no position inconsistent with (whether in audits, Tax Returns or otherwise), the treatment
described in this <U>Section</U><U></U><U>&nbsp;5.5 (a)(i)</U> unless required to do so pursuant to a &#147;determination&#148; that is final within the meaning of Section&nbsp;1313(a) of the Code. Notwithstanding anything to the contrary herein,
if, after the date hereof but prior to the time at which the Required CHFW Shareholder Approval has been obtained, CHFW and the Company determine in good faith that the Merger is not reasonably expected to qualify as a &#147;reorganization&#148;
within the meaning of Section&nbsp;368(a) of the Code, the Parties shall use commercially reasonable efforts to restructure the transactions contemplated hereby (such restructured transactions, the &#147;Alternative Transaction Structure&#148;) in a
manner that is reasonably expected to cause the Alternative Transaction Structure to so qualify, including by adding a second merger to take place immediately after the Merger whereby the surviving company in the Merger would merge with and into a
new limited liability company that is a wholly-owned Subsidiary of CHFW (&#147;Newco&#148;), with Newco being the surviving company in such merger; provided that the parties will discuss in good faith any disagreement as to whether the Alternative
Transaction Structure is necessary for the transactions contemplated hereby to qualify as a &#147;reorganization&#148; and neither party will unreasonably withhold consent to such Alternative Transaction Structure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) CHFW and the Company hereby adopt this Agreement as a &#147;plan of reorganization&#148; within the meaning of Treasury
Regulations Sections <FONT STYLE="white-space:nowrap">1.368-2(g)</FONT> and <FONT STYLE="white-space:nowrap">1.368-3(a).</FONT> The Parties shall not take any action, or knowingly fail to take any action, which action or failure to act prevents or
impedes, or would reasonably be expected to prevent or impede, the Intended Tax Treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) If, in connection with
the preparation and filing of the Registration Statement/Proxy Statement, the SEC requests or requires that tax opinions be prepared and submitted in such connection, CHFW and the Company shall deliver to Goodwin Procter LLP and Cooley LLP, (or, in
each case, other nationally </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
recognized tax counsel described in this <U>Section</U><U></U><U>&nbsp;5.6(a)(iii)</U>), respectively, customary Tax representation letters satisfactory to its tax counsel, dated and executed as
of the date the Registration Statement/Proxy Statement shall have been declared effective by the SEC and such other date(s) as determined reasonably necessary by such tax counsel in connection with the preparation and filing of the Registration
Statement/Proxy Statement, and, if required, CHFW shall cause Goodwin Procter LLP (or such other nationally recognized tax counsel to CHFW reasonably satisfactory to the Company) to furnish an opinion, subject to customary assumptions and
limitations, to the effect that the Intended Tax Treatment should apply to the Domestication and, if required, the Company shall cause Cooley LLP (or such other nationally recognized tax counsel to the Company reasonably satisfactory to CHFW) to
furnish an opinion, subject to customary assumptions and limitations, to the effect that the Intended Tax Treatment should apply to the Merger. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) <U>Tax Matters Cooperation</U>.<B> </B>Each of the Parties shall (and shall cause their respective
Affiliates to) cooperate fully, as and to the extent reasonably requested by another Party, in connection with the filing of relevant Tax Returns, and any audit or tax proceeding. Such cooperation shall include the retention and (upon the other
Party&#146;s request) the provision (with the right to make copies) of records and information reasonably relevant to any tax proceeding or audit, making employees available on a mutually convenient basis to provide additional information and
explanation of any material provided hereunder and making available to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> CHFW Holders information reasonably necessary to compute any income of any such holder (or its direct or indirect owners)
arising (i)&nbsp;if applicable, as a result of CHFW&#146;s status as a &#147;passive foreign investment company&#148; within the meaning of Section&nbsp;1297(a) of the Code or a &#147;controlled foreign corporation&#148; within the meaning of
Section&nbsp;957(a) of the Code for any taxable period ending on or prior to the Closing, including timely providing (A)&nbsp;a PFIC Annual Information Statement to enable such holders to make a &#147;Qualifying Electing Fund&#148; election under
Section&nbsp;1295 of the Code for such taxable period, and (B)&nbsp;information to enable applicable holders to report their allocable share of &#147;subpart F&#148; income under Section&nbsp;951 of the Code and &#147;GILTI&#148; income under
Section&nbsp;951A of the Code for such taxable period and (ii)&nbsp;under Section&nbsp;367(b) of the Code and the Treasury Regulations promulgated thereunder as a result of the Domestication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_63"></A><B>Section</B><B></B><B>&nbsp;5.6</B> <B>Exclusive Dealing</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) From the date of this Agreement until the earlier of the Closing or the termination of this Agreement in
accordance with its terms, the Company shall not, and shall cause the other Group Companies and instruct and use reasonable best efforts to cause its and their respective Representatives not to, directly or indirectly: (i)&nbsp;solicit, initiate,
knowingly encourage (including by means of furnishing or disclosing information), knowingly facilitate, discuss or negotiate, directly or indirectly, any inquiry, proposal or offer (written or oral) with respect to a Company Acquisition Proposal;
(ii)&nbsp;furnish or disclose any <FONT STYLE="white-space:nowrap">non-public</FONT> information to any Person in connection with, or that could reasonably be expected to lead to, a Company Acquisition Proposal; (iii)&nbsp;enter into any Contract or
other arrangement or understanding regarding a Company Acquisition Proposal; (iv)&nbsp;prepare or take any steps in connection with a public offering of any Equity Securities of any Group Company (or any Affiliate or successor of any Group Company);
or (v)&nbsp;otherwise cooperate in any way with, or assist or participate in, or knowingly facilitate or encourage any effort or attempt by any Person to do or seek to do any of the foregoing. The Company agrees to (A)&nbsp;notify CHFW promptly upon
receipt of any Company Acquisition Proposal by any Group Company, and to describe the material terms and conditions of any such Company Acquisition Proposal in reasonable detail (including the identity of the Persons making such Company Acquisition
Proposal) and (B)&nbsp;keep CHFW reasonably informed on a current basis of any modifications to such offer or information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) From the date of this Agreement until the earlier of the Closing or the termination of this Agreement in
accordance with its terms, the CHFW Parties shall not, and each of them shall instruct and use reasonable best efforts to cause their Representatives not to, directly or indirectly: (i)&nbsp;solicit, initiate, knowingly encourage (including by means
of furnishing or disclosing information), knowingly facilitate, discuss or negotiate, directly or indirectly, any inquiry, proposal or offer (written or oral) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
with respect to a CHFW Acquisition Proposal; (ii)&nbsp;furnish or disclose any <FONT STYLE="white-space:nowrap">non-public</FONT> information to any Person in connection with, or that could
reasonably be expected to lead to, a CHFW Acquisition Proposal; (iii)&nbsp;enter into any Contract or other arrangement or understanding regarding a CHFW Acquisition Proposal; (iv)&nbsp;prepare or take any steps in connection with an offering of any
securities of any CHFW Party (or any Affiliate or successor of any CHFW Party); or (v)&nbsp;otherwise cooperate in any way with, or assist or participate in, or knowingly facilitate or encourage any effort or attempt by any Person to do or seek to
do any of the foregoing. CHFW agrees to (A)&nbsp;notify the Company promptly upon receipt of any CHFW Acquisition Proposal by any CHFW Party, and to describe the material terms and conditions of any such Acquisition Proposal in reasonable detail
(including the identity of any person or entity making such CHFW Acquisition Proposal) and (B)&nbsp;keep the Company reasonably informed on a current basis of any modifications to such offer or information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_64"></A><B>Section</B><B></B><B>&nbsp;5.7</B> <B>Preparation of Registration Statement/Proxy Statement</B>. As promptly as
reasonably practicable following the date of this Agreement,<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>CHFW and the Company shall prepare and mutually agree upon (such agreement not to be unreasonably withheld, conditioned or delayed by
either CHFW or the Company) the Registration Statement/Proxy Statement, and CHFW shall file with the SEC the Registration Statement/Proxy Statement (it being understood that the Registration Statement/Proxy Statement shall include a proxy
statement/prospectus of CHFW which will be included therein as a prospectus and which will be used for the CHFW Shareholders Meeting to adopt and approve the Transaction Proposals and other matters reasonably related to the Transaction Proposals,
all in accordance with and as required by CHFW&#146;s Governing Documents, applicable Law, and any applicable rules and regulations of the SEC, NYSE American and Nasdaq). CHFW shall use its reasonable best efforts to (a)&nbsp;cause the Registration
Statement/Proxy Statement to comply in all material respects with the applicable rules and regulations promulgated by the SEC (including, with respect to the Group Companies, the provision of financial statements of, and any other information with
respect to, the Group Companies for all periods, and in the form, required to be included in the Registration Statement/Proxy Statement under Securities Laws (after giving effect to any waivers received) or in response to any comments from the SEC);
(b)&nbsp;promptly notify the Company of the receipt of any comments of the SEC or its staff (with the Parties reasonably cooperating with each other with respect to a prompt response to any such comments); (c) have the Registration Statement/Proxy
Statement declared effective under the Securities Act as promptly as reasonably practicable after it is filed with the SEC; and (d)&nbsp;keep the Registration Statement/Proxy Statement effective through the Closing in order to permit the
consummation of the transactions contemplated by this Agreement. CHFW, on the one hand, and the Company, on the other hand, shall promptly furnish, or cause to be furnished, to the other all information concerning such Party and its Representatives
that may be required or reasonably requested in connection with any action contemplated by this <U>Section</U><U></U><U>&nbsp;5.7</U> or for including in any other statement, filing, notice or application made by or on behalf of CHFW to the SEC,
NYSE American or Nasdaq in connection with the Transactions and the Ancillary Documents, including delivering customary tax representation letters to counsel to enable counsel to deliver any tax opinions requested or required by the SEC to be
submitted in connection therewith as described in <U>Section</U><U></U><U>&nbsp;5.5(a)(iii)</U>. If any Party becomes aware of any information that should be disclosed in an amendment or supplement to the Registration Statement/Proxy Statement, then
(i)&nbsp;such Party shall promptly inform, in the case of any CHFW Party, the Company, or, in the case of the Company, CHFW thereof; (ii)&nbsp;such Party shall prepare and mutually agree upon with, in the case of CHFW, the Company, or, in the case
of the Company, CHFW (in either case, such agreement not to be unreasonably withheld, conditioned or delayed), an amendment or supplement to the Registration Statement/Proxy Statement; (iii)&nbsp;CHFW shall file such mutually agreed upon amendment
or supplement with the SEC; and (iv)&nbsp;the Parties shall reasonably cooperate, if appropriate, in mailing such amendment or supplement to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> CHFW Holders. CHFW shall as promptly as reasonably
practicable advise the Company of the time of effectiveness of the Registration Statement/Proxy Statement, the issuance of any stop order relating thereto or the suspension of the qualification of CHFW Shares for offering or sale in any
jurisdiction, and CHFW and the Company shall each use its reasonable best efforts to have any such stop order or suspension lifted, reversed or otherwise terminated. Each of the Parties hereto shall use reasonable best efforts to ensure that none of
the information related to it or any of its Representatives, supplied by such Party or on its behalf for inclusion or incorporation by reference in the Registration Statement/Proxy Statement will, at the time the Registration
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Statement/Proxy Statement is initially filed with the SEC, at each time at which it is amended, or at the time it becomes effective under the Securities Act contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they are made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_65"></A><B>Section</B><B></B><B>&nbsp;5.8</B> <B>CHFW Shareholder Approval</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) As promptly as reasonably practicable following the time at which the Registration Statement/Proxy
Statement is declared effective under the Securities Act, CHFW shall (a)&nbsp;cause the Proxy Statement to be disseminated to the CHFW Shareholders in compliance with applicable Law, and (b)&nbsp;duly give notice of the meeting of its shareholders
in accordance with CHFW Governing Documents and Nasdaq Listing Rules solely for the purpose of voting upon the Transaction Proposals and matters incidental thereto (the &#147;CHFW Shareholders Meeting&#148;) (with CHFW to convene and hold the CHFW
Shareholders Meeting as promptly as practicable (and in any event within forty (40)&nbsp;days after the effective date of the Registration Statement/Proxy Statement)), and (c)&nbsp;solicit proxies from the CHFW Shareholders to vote in favor of each
of the Transaction Proposals, and provide its shareholders with the opportunity to elect to effect a CHFW Shareholder Redemption. CHFW shall, through the approval of the CHFW Board, unanimously recommend to its shareholders (the &#147;CHFW Board
Recommendation&#148;), (i) the adoption and approval of this Agreement and the Transactions (including the Merger) (the &#147;Business Combination Proposal&#148;); (ii) the adoption and the approval of the Domestication (the &#147;Domestication
Proposal&#148;); (iii) the adoption and approval of the issuance of the CHFW Shares in connection with the transactions contemplated by this Agreement as required by NYSE- American and Nasdaq listing requirements, as appliable (the &#147;Nasdaq
Proposal&#148;); (iv) the adoption and approval of the amendments to the Governing Documents of CHFW contemplated by the CHFW Certificate of Incorporation and the CHFW Bylaws (the &#147;Governing Document Proposals&#148;); (v) the adoption and
approval of the CHFW Equity Incentive Plan (the &#147;Equity Incentive Plan Proposal&#148;) and the CHFW Employee Stock Purchase Plan; (vi)&nbsp;the adoption and approval of each other proposal that either the SEC, NYSE American or Nasdaq (or the
respective staff members thereof) indicates is necessary in its comments to the Registration Statement/Proxy Statement or in correspondence related thereto, (vii)&nbsp;the adoption and approval of each other proposal reasonably agreed by CHFW and
the Company as necessary or appropriate in connection with the consummation of the Transactions; and (viii)&nbsp;the adoption and approval of a proposal for the adjournment of the CHFW Shareholders Meeting, if necessary, to permit further
solicitation of proxies because there are not sufficient votes to approve and adopt any of the foregoing (such proposals in (i)&nbsp;through (viii) together, the &#147;Transaction Proposals&#148;); <U>provided</U>, that CHFW may postpone or adjourn
the CHFW Shareholders Meeting (A)&nbsp;to solicit additional proxies for the purpose of obtaining the CHFW Shareholder Approval, (B)&nbsp;for the absence of a quorum, (C)&nbsp;to allow reasonable additional time for the filing or mailing of any
supplemental or amended disclosures that CHFW has determined, based on the advice of outside legal counsel, is reasonably likely to be required under applicable Law and for such supplemental or amended disclosure to be disseminated and reviewed by
the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> CHFW Holders prior to the CHFW Shareholders Meeting or (D)&nbsp;if the holders of CHFW Class&nbsp;A Shares have elected to redeem a number of Class&nbsp;A Shares as of such time that would
reasonably be expected to result in the condition set forth in <U>Section</U><U></U><U>&nbsp;6.3(c)</U> not being satisfied; provided that, without the consent of the Company, in no event shall CHFW adjourn the CHFW Shareholders Meeting for more
than fifteen (15)&nbsp;Business Days later than the most recently adjourned meeting or to a date that is beyond the Termination Date or adjourn the CHFW Shareholders Meeting more than twice without the Company&#146;s consent. The CHFW Board
Recommendation shall be included in the Registration Statement/Proxy Statement. Except as otherwise required by applicable Law, the CHFW Board shall not make a Modification in Recommendation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_66"></A><B>Section</B><B></B><B>&nbsp;5.9</B> <B>Merger Sub</B><B>s Shareholder Approvals</B>. As promptly as reasonably
practicable (and in any event within one (1)&nbsp;Business Day) following the date of this Agreement, CHFW, as the sole shareholder of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Merger Sub, will approve and adopt this Agreement, the Ancillary Documents to which such Merger Sub is or will be a party and the transactions contemplated hereby and thereby (including the
Merger). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_67"></A><B>Section</B><B></B><B>&nbsp;5.10</B> <B>Conduct of Business</B><B> of</B><B> CHFW</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) From and after the date of this Agreement until the earlier of the Closing or the termination of this
Agreement in accordance with its terms, CHFW and its Subsidiaries shall conduct themselves in the ordinary course of business and comply with, and continue performing under, their Governing Documents and the Trust Agreement and use commercially
reasonable efforts to maintain and preserve intact in all material respects the business organization, assets, properties and material business relations of CHFW, taken as a whole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Without limiting the generality of the foregoing, from and after the date of this Agreement until the
earlier of the Closing or the termination of this Agreement in accordance with its terms CHFW shall not, and shall cause its Subsidiaries not to, as applicable, except as expressly contemplated by this Agreement or any Ancillary Document (including,
for the avoidance of doubt, in connection with the Domestication or the PIPE Financing), as required by applicable Law, as set forth on <U>Section</U><U></U><U>&nbsp;5.10</U> of the CHFW Disclosure Schedules or as consented to in writing by the
Company (such consent not to be unreasonably withheld, conditioned or delayed), do any of the following:<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) adopt any amendments, supplements, restatements or modifications to the Trust Agreement, Warrant Agreement,
or the Governing Documents of any CHFW Party or any of its Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) declare, set aside, make or
pay a dividend on, or make any other distribution or payment in respect of, any Equity Securities of CHFW or any of its Subsidiaries, or repurchase, redeem or otherwise acquire, or offer to repurchase, redeem or otherwise acquire, any outstanding
Equity Securities of CHFW or any of its Subsidiaries, as applicable; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) split, combine or reclassify any
of its capital stock or other Equity Securities or issue any other security in respect of, in lieu of or in substitution for shares of its capital stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) incur, create or assume any Indebtedness or other Liabilities (other than in connection with the
Transactions or the transactions contemplated by the Ancillary Documents); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) make any loans or advances
to, or capital contributions in, any other Person, other than to, or in, CHFW or any of its Subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) issue any Equity Securities of CHFW or any of its Subsidiaries or&nbsp;grant any additional options,
warrants or stock appreciation rights with respect to Equity Securities of the foregoing of CHFW or any of its wholly-owned Subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) enter into, renew, modify or revise any CHFW Related Party Transaction (or any Contract or agreement that
if entered into prior to the execution and delivery of this Agreement would be a CHFW Related Party Transaction); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(j) make, change or revoke any material election concerning Taxes, enter into any material Tax closing
agreement, settle any material Tax claim or assessment, or consent to any extension or waiver of the limitation period applicable to or relating to any material Tax claim or assessment, other than any such extension or waiver that is obtained in the
ordinary course of business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(k) engage in any activities or business or incur any material CHFW
Liabilities, other than any activities, businesses or CHFW Liabilities that are otherwise permitted under this <U>Section</U><U></U><U>&nbsp;5.10</U>; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(l) authorize, recommend, propose or announce an intention to adopt a plan of complete or partial liquidation
or dissolution; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(m) enter into any Contract with any broker, finder, investment banker or other Person
under which such Person is or will be entitled to any brokerage fee, finders&#146; fee or other commission in connection with the transactions contemplated by this Agreement; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(n) enter into any Contract to take, or cause to be taken,
any of the actions set forth in this <U>Section</U><U></U><U>&nbsp;5.10</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding anything in this
<U>Section</U><U></U><U>&nbsp;5.10</U> or this Agreement to the contrary, (i)&nbsp;nothing set forth in this Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of any CHFW Party and
(ii)&nbsp;nothing set forth in this Agreement other than the restrictions on incurring CHFW Liabilities or Indebtedness shall prohibit, or otherwise restrict the ability of, any CHFW Party from using the funds held by CHFW outside the Trust Account
to pay any CHFW Expenses or CHFW Liabilities or from otherwise distributing or paying over any funds held by CHFW outside the Trust Account to the Sponsor or any of its Affiliates, in each case, prior to the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_68"></A><B>Section</B><B></B><B>&nbsp;5.11</B> <B>Nasdaq Listing</B>. CHFW shall use its reasonable best efforts to cause
the CHFW Shares issuable in accordance with this Agreement, including shares issuable upon the exercise of Rollover Options and shares issuable under the Equity Plans and the outstanding CHFW Shares to be approved for listing on Nasdaq (and the
Company shall reasonably cooperate in connection therewith), subject to official notice of issuance, as promptly as reasonably practicable after the date of this Agreement, and in any event prior to the Effective Time, and to satisfy any applicable
initial and continuing listing requirements of Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_69"></A><B>Section</B><B></B><B>&nbsp;5.12</B> <B>Trust
Account</B>. Upon satisfaction or, to the extent permitted by applicable Law, waiver of the conditions set forth in <U>Article 6</U> and provision of notice thereof to the Trustee, (a)&nbsp;at the Closing, CHFW shall (i)&nbsp;cause the documents,
certificates and notices required to be delivered to the Trustee pursuant to the Trust Agreement to be so delivered, and (ii)&nbsp;make all appropriate arrangements to cause the Trustee to (A)&nbsp;pay as and when due all amounts, if any, payable to
the Public Shareholders of CHFW pursuant to the CHFW Shareholder Redemption, (B)&nbsp;pay the amounts due to the underwriters of CHFW&#146;s initial public offering for their deferred underwriting commissions as set forth in the Trust Agreement and
(C)&nbsp;immediately thereafter, pay all remaining amounts then available in the Trust Account to CHFW in accordance with the Trust Agreement, and (b)&nbsp;thereafter, the Trust Account shall terminate, except as otherwise provided therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_70"></A><B>Section</B><B></B><B>&nbsp;5.13</B> <B>Transaction Support Agreements; Company Stockholder Approval</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) As promptly as reasonably practicable (and in any event within one Business Day) following the date of this
Agreement (the &#147;Transaction Support Agreement Deadline&#148;), the Company shall deliver, or cause to be delivered, to CHFW Transaction Support Agreements duly executed by each Supporting Company Stockholder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) As promptly as reasonably practicable (and in any event within five (5)&nbsp;Business Days) following the
time at which the Registration Statement/Proxy Statement is declared effective under the Securities Act (the &#147;Company Stockholder Written Consent Deadline&#148;), the Company shall have delivered to the Company Stockholders an information
statement containing a pro forma calculation of the Exchange Ratio and the prospectus contained in the Registration Statement/Proxy Statement and obtain and deliver to CHFW, by the Company Stockholder Written Consent Deadline, a true and correct
copy of a written consent (in form and substance reasonably satisfactory to CHFW) adopting and approving this Agreement, the Ancillary Documents to which the Company is or will be a party and the transactions contemplated hereby and thereby
including the Merger (the &#147;Written Consent&#148;), duly executed by the Company Stockholders who hold at least the requisite number of issued and outstanding Company Shares required to approve and adopt such matters in accordance with the DGCL,
the Company&#146;s Governing Documents and the Company Stockholders Agreements (the &#147;Company Stockholder Approval&#148;). The Company, through its board of directors, shall unanimously recommend to the holders of Company Shares the approval and
adoption of this Agreement and the Transactions including the Merger. After the Company obtains the Company Stockholder Approval, the Company shall prepare and mail to each Company Stockholder who has not previously executed the Written Consent a
notice contemplated by Section&nbsp;228(e) of the DGCL of the taking of a corporate action without a meeting by less than a unanimous written consent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) The Company may not amend, modify or waive any
provisions of a CHFW Shareholder Support Agreement without the prior written consent of CHFW. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_71"></A><B>Section</B><B></B><B>&nbsp;5.14</B> <B>CHFW Indemnification; Directors</B><B>&#146;</B><B> and
Officers</B><B>&#146;</B><B> Insurance</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Each Party agrees that (i)&nbsp;all rights to
indemnification or exculpation now existing in favor of the directors and officers of each CHFW Party, as provided in the Governing Documents of the applicable CHFW Party&#146;s Governing Documents or otherwise in effect as of immediately prior the
Effective Time, in either case, solely with respect to any matters occurring on or prior to the Effective Time, shall survive the transactions contemplated by this Agreement and shall continue in full force and effect from and after the Effective
Time for a period of six (6)&nbsp;years and (ii)&nbsp;CHFW will perform and discharge, or cause to be performed and discharged, all obligations to provide such indemnity and exculpation during such six (6)-year period. To the maximum extent
permitted by applicable Law, during such six (6)-year period, CHFW shall advance, or caused to be advanced, expenses in connection with such indemnification as provided in the applicable CHFW Party&#146;s Governing Documents or other applicable
agreements as in effect immediately prior the Effective Time. The indemnification and liability limitation or exculpation provisions of the CHFW Parties&#146; Governing Documents shall not, during such six (6)-year period, be amended, repealed or
otherwise modified after the Effective Time, in any manner that would materially and adversely affect the rights thereunder of individuals who, as of immediately prior to the Effective Time, or at any time prior to such time, were directors or
officers of any CHFW Party (the &#147;CHFW D&amp;O Persons&#148;) entitled to be so indemnified, have their liability limited or be exculpated with respect to any matters occurring on or prior to the Effective Time and relating to the fact that such
CHFW D&amp;O Person was a director or officer of any CHFW Party immediately prior the Effective Time, unless such amendment, repeal or other modification is required by applicable Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) CHFW shall not have any obligation under this <U>Section</U><U></U><U>&nbsp;5.14</U> to any CHFW D&amp;O
Person when and if a court of competent jurisdiction shall ultimately determine (and such determination shall have become final and <FONT STYLE="white-space:nowrap">non-appealable)</FONT> that the indemnification of such CHFW D&amp;O Person in the
manner contemplated hereby is prohibited by applicable Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) CHFW shall purchase prior the Effective
Time, and will cause the Group Companies to maintain, for a period of six (6)&nbsp;years after the Effective Time, without lapses in coverage, a &#147;tail&#148; policy providing directors&#146; and officers&#146; liability insurance coverage for
the benefit of those Persons who are currently covered by any comparable insurance policies of the CHFW Parties as of the date of this Agreement with respect to matters occurring on or prior to the Effective Time (the &#147;CHFW D&amp;O Tail
Policy&#148;). Such &#147;tail&#148; policy shall provide coverage on terms (with respect to coverage and amount) that are substantially the same as (and no less favorable in the aggregate to the insured than) the coverage provided under CHFW&#146;s
directors&#146; and officers&#146; liability insurance policies as of the date of this Agreement; <U>provided</U> that CHFW shall not be obligated to pay a premium for such &#147;tail&#148; policy in excess of 250% of the most recent premium paid by
CHFW prior to the date of this Agreement. In the event that the premium for the CHFW D&amp;O Tail Policy exceeds 250% of the most recent premium paid by CHFW prior to the date of this Agreement, CHFW shall purchase the maximum coverage available for
250% of the most recent premium paid by CHFW prior to the date of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) If CHFW or any of
its successors or assigns (i)&nbsp;shall merge or consolidate with or merge into any other corporation or entity and shall not be the surviving or continuing corporation or entity of such consolidation or merger or (ii)&nbsp;shall transfer all or
substantially all of their respective properties and assets as an entity in one or a series of related transactions to any Person, then in each such case, proper provisions shall be made so that the successors or assigns of CHFW shall assume all of
the obligations set forth in this <U>Section</U><U></U><U>&nbsp;5.14</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) The CHFW D&amp;O Persons
entitled to the indemnification, liability limitation, exculpation and insurance set forth in this <U>Section</U><U></U><U>&nbsp;5.14</U> are intended to be third-party beneficiaries of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
<U>Section</U><U></U><U>&nbsp;5.14</U>. This <U>Section</U><U></U><U>&nbsp;5.14</U> shall survive the consummation of the transactions contemplated by this Agreement and shall be binding on all
successors and assigns of CHFW. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_72"></A><B>Section</B><B></B><B>&nbsp;5.15</B> <B>Company Indemnification;
Directors</B><B>&#146;</B><B> and Officers</B><B>&#146;</B><B> Insurance</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) Each Party agrees that
(i)&nbsp;all rights to indemnification or exculpation now existing in favor of the directors and officers of the Group Companies, as provided in the Group Companies&#146; Governing Documents or otherwise in effect as of immediately prior to the
Effective Time, in either case, solely with respect to any matters occurring on or prior to the Effective Time, shall survive the transactions contemplated by this Agreement and shall continue in full force and effect from and after the Effective
Time for a period of six (6)&nbsp;years and (ii)&nbsp;CHFW will cause the applicable Group Companies to perform and discharge all obligations to provide such indemnity and exculpation during such six (6)-year period. To the maximum extent permitted
by applicable Law, during such six (6)-year period, CHFW shall cause the applicable Group Companies to advance expenses in connection with such indemnification as provided in the Group Companies&#146; Governing Documents or other applicable
agreements in effect as of immediately prior to the Effective Time. The indemnification and liability limitation or exculpation provisions of the Group Companies&#146; Governing Documents shall not, during such six (6)-year period, be amended,
repealed or otherwise modified after the Effective Time in any manner that would materially and adversely affect the rights thereunder of individuals who, as of the Effective Time or at any time prior to the Effective Time, were directors or
officers of the Group Companies (the &#147;Company D&amp;O Persons&#148;) entitled to be so indemnified, have their liability limited or be exculpated with respect to any matters occurring prior to Closing and relating to the fact that such Company
D&amp;O Person was a director or officer of any Group Company prior to the Effective Time, unless such amendment, repeal or other modification is required by applicable Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) None of CHFW or the Group Companies shall have any obligation under this
<U>Section</U><U></U><U>&nbsp;5.15</U> to any Company D&amp;O Person when and if a court of competent jurisdiction shall ultimately determine (and such determination shall have become final and <FONT STYLE="white-space:nowrap">non-appealable)</FONT>
that the indemnification of such Company D&amp;O Person in the manner contemplated hereby is prohibited by applicable Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) The Company shall purchase, at or prior to the Closing, and CHFW shall maintain, or cause to be maintained,
in effect for a period of six (6)&nbsp;years after the Effective Time, without lapses in coverage, a &#147;tail&#148; policy providing directors&#146; and officers&#146; liability insurance coverage for the benefit of those Persons who are currently
covered by any comparable insurance policies of the Group Companies as of the date of this Agreement with respect to matters occurring on or prior to the Effective Time (the &#147;Company D&amp;O Tail Policy&#148;). Such &#147;tail&#148; policy
shall provide coverage on terms (with respect to coverage and amount) that are substantially the same as (and no less favorable in the aggregate to the insured than) the coverage provided under the Group Companies&#146; directors&#146; and
officers&#146; liability insurance policies as of the date of this Agreement; <U>provided</U> that none of the Company, CHFW or any of their respective Affiliates shall be obligated to pay a premium for such &#147;tail&#148; policy in excess of 250%
of the most recent annual premium paid by the Group Companies prior to the date of this Agreement. and, in such event, the Company, CHFW or one of their respective Affiliates shall purchase the maximum coverage available for 250% of the most recent
annual premium paid by the Group Companies prior to the date of this Agreement. In the event that the premium for the Company D&amp;O Tail Policy exceeds 250% of the most recent annual premium paid by the Company prior to the date of this Agreement,
the Company shall purchase the maximum coverage available for 250% of the most recent annual premium paid by the Company prior to the date of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) If CHFW or any of its successors or assigns (i)&nbsp;shall merge or consolidate with or merge into any
other corporation or entity and shall not be the surviving or continuing corporation or entity of such consolidation or merger or (ii)&nbsp;shall transfer all or substantially all of their respective properties and assets as an entity in one or a
series of related transactions to any Person, then in each such case, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
proper provisions shall be made so that the successors or assigns of CHFW shall assume the appropriate obligations set forth in this <U>Section</U><U></U><U>&nbsp;5.15</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) The Company D&amp;O Persons entitled to the indemnification, liability limitation, exculpation and
insurance set forth in this <U>Section</U><U></U><U>&nbsp;5.15</U> are intended to be third-party beneficiaries of this <U>Section</U><U></U><U>&nbsp;5.15</U>. This <U>Section</U><U></U><U>&nbsp;5.15</U> shall survive the consummation of the
transactions contemplated by this Agreement and shall be binding on all successors and assigns of CHFW. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_73"></A><B>Section</B><B></B><B>&nbsp;5.16</B> <B>Post-Closing Directors and Officers</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) CHFW shall take all actions within its power as may be necessary or appropriate such that (assuming the
Company satisfies its obligations under <U>Section</U><U></U><U>&nbsp;5.16(b)</U> and <U>(c)</U>) effective immediately after the Effective Time (i)&nbsp;the CHFW Board shall consist of nine (9)&nbsp;directors, which shall be divided into three
(3)&nbsp;classes, designated Class&nbsp;I, II and III, with Class&nbsp;I consisting of three (3)&nbsp;directors who shall initially be <FONT STYLE="white-space:nowrap">re-elected</FONT> at the 2022 annual stockholders meeting, Class&nbsp;II
consisting of three (3)&nbsp;directors who shall initially be <FONT STYLE="white-space:nowrap">re-elected</FONT> at the 2023 annual stockholders meeting and Class&nbsp;III consisting of three (3)&nbsp;directors who shall initially be <FONT
STYLE="white-space:nowrap">re-elected</FONT> at the 2024 annual stockholders meeting; (ii)&nbsp;the members of the CHFW Board are the individuals determined in accordance with <U>Section</U><U></U><U>&nbsp;5.16(b)</U> and (iii)&nbsp;the officers of
CHFW (the &#147;Officers&#148;) are the individuals determined in accordance with <U>Section</U><U></U><U>&nbsp;5.16(c)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) Promptly following the date hereof, and in any event within sufficient time to allow for customary due
diligence and background checks and on the designated individuals prior to the mailing of the Registration Statement/Proxy Statement to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> CHFW Holders, (i)&nbsp;CHFW shall identify one
(1)&nbsp;individual (reasonably acceptable to the chief executive officer of the Company) to be a director on the CHFW Board immediately after the Effective Time (the &#147;CHFW Designee&#148;) and (ii)&nbsp;the Company shall identify eight
(8)&nbsp;individuals (reasonably acceptable to CHFW) to be directors on the CHFW Board immediately after the Effective Time (the &#147;Company Designees&#148;) in all cases subject to applicable listing rules of Nasdaq and applicable Law and subject
to customary due diligence and review of background checks. The CHFW Designee shall be appointed to Class&nbsp;III and the Company Designees shall be appointed to such Classes as the Company reasonably determines. Prior to the Effective Time, the
Company may in its sole discretion replace any Company Designee with any individual (reasonably acceptable to CHFW) by written notice and subject to applicable listing rules of Nasdaq and applicable Law and subject to customary due diligence and
review of background checks. Sponsor may in its sole discretion (x)&nbsp;appoint an individual to fill any vacancies created by the resignation, removal, death or incapacity of the CHFW Designee should any such resignation, removal, death or
incapacity of the CHFW Designee occur prior to the date that is two (2)&nbsp;years from the date of the CHFW Shareholders Meeting and (ii)&nbsp;replace the CHFW Designee prior to the Effective Time; in each of clauses (x)&nbsp;and (y) with any
individual (reasonably acceptable to the chief executive officer of the Company) by written notice and subject to applicable listing rules of Nasdaq and applicable Law and subject to customary due diligence and review of background checks. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) The individuals identified on <U>Section</U><U></U><U>&nbsp;5.16(c)</U> of the Company Disclosure Schedules
shall be the Officers immediately after the Effective Time, with each such individual holding the title set forth opposite his or her name. In the event that any individual identified on <U>Section</U><U></U><U>&nbsp;5.16(c)</U> of the Company
Disclosure Schedules is unwilling or unable (whether due to death, disability, termination of service or otherwise) to serve as an Officer, then, prior to the mailing of the Registration Statement / Proxy Statement to the <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> CHFW Holders, the Company may, with the prior written consent of CHFW (such consent not to be unreasonably withheld, conditioned or delayed), replace such individual with another individual to serve as
such Officer by amending <U>Section</U><U></U><U>&nbsp;5.16(c)</U> of the Company Disclosure Schedules to include such replacement individual as such Officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_74"></A><B>Section</B><B></B><B>&nbsp;5.17</B> <B>PCAOB Financials</B>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) As promptly as reasonably practicable (and, in the case of clause (i), in any event by April&nbsp;30,
2021), the Company shall deliver to CHFW (i)&nbsp;the final audited Financial Statements,<B> </B>and (ii)<B></B>&nbsp;any other audited or unaudited consolidated balance sheets and the related audited or unaudited consolidated statements of
operations and comprehensive loss, convertible preferred stock and stockholders&#146; deficit and cash flows of the Group Companies as of and for a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> period
ended as of the end of any other different fiscal quarter (and as of and for the same period from the previous fiscal year) or fiscal year (and as of and for the prior fiscal year), as applicable that is required to be included in the Registration
Statement/Proxy Statement and any other filings to be made by CHFW with the SEC in connection with the Transactions. All such financial statements, together with any audited or unaudited consolidated balance sheet and the related audited or
unaudited consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#146; deficit and cash flows of the Group Companies as of and for a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> period ended as of the end of a different fiscal quarter (and as of and for the same period from the previous fiscal year) or fiscal year (and as of and for
the prior fiscal year) that is required to be included in the Registration Statement/Proxy Statement and any other filings to be made by CHFW with the SEC in connection with the Transactions (A)&nbsp;will fairly present in all material respects the
financial position of the Group Companies as at the date thereof, and the results of its operations, stockholders&#146; equity and cash flows for the respective periods then ended (subject, in the case of any unaudited interim financial statements,
to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments (none of which is expected to be material) and the absence of footnotes), (B)&nbsp;will be prepared in conformity with GAAP applied on a consistent basis during the periods
involved (except, in the case of any audited financial statements, as may be indicated in the notes thereto and subject, in the case of any unaudited financial statements, to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments
(none of which is expected to be material) and the absence of footnotes), (C) in the case of any audited financial statements, will be audited in accordance with the standards of the PCAOB and contain an unqualified report of the Company&#146;s
auditor and (D)&nbsp;will comply in all material respects with the applicable accounting requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities Act in effect as of the respective dates thereof (including
Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> or Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> as applicable). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) The Company shall use its reasonable best efforts (i)&nbsp;to assist, upon advance written notice, during
normal business hours and in a manner such as to not unreasonably interfere with the normal operation of any member of such Group Company, CHFW in causing to be prepared in a timely manner any other financial information or statements (including
customary pro forma financial statements) that are required to be included in the Registration Statement/Proxy Statement and any other filings to be made by CHFW with the SEC in connection with the transactions contemplated by this Agreement or any
Ancillary Document and (ii)&nbsp;to obtain the consents of its auditors with respect thereto as may be required by applicable Law or requested by the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_75"></A><B>Section</B><B></B><B>&nbsp;5.18</B> <B>CHFW Incentive Equity Plan</B>. Prior to the effectiveness of the
Registration Statement/Proxy Statement, the CHFW Board shall approve and adopt an equity incentive plan, in substantially the form attached hereto as <U>Exhibit G</U> and with any changes or modifications thereto as the Company and CHFW may mutually
agree (such agreement not to be unreasonably withheld, conditioned or delayed by either the Company or CHFW, as applicable) (the &#147;CHFW Equity Incentive Plan&#148;), in the manner prescribed under Section&nbsp;422 of the Code and other
applicable Laws, effective as the Closing Date. The CHFW Equity Incentive Plan will provide that ten percent (10%) of the total number of CHFW Shares on a fully diluted basis following the Effective Time be initially available for issuance under
awards granted pursuant to the CHFW Equity Incentive Plan (inclusive of the shares available for issuance under the CHFW Equity Incentive Plan) and the number of CHFW Shares reserved for issuance thereunder will automatically increase annual on the
first date of each fiscal year beginning with the 2022 fiscal year in an amount equal to five percent (5%) of CHFW Shares as determined in the CHFW Equity Incentive Plan. The Rollover Options corresponding to the Unvested Company Options and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the Rollover RSU Awards shall not be deemed to have been granted pursuant to the CHFW Equity Incentive Plan and shall not reduce the number of CHFW Shares reserved for grant thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_76"></A><B>Section</B><B></B><B>&nbsp;5.19</B> <B>CHFW Employee Stock Purchase Plan</B>. Prior to the effectiveness of the
Registration Statement/Proxy Statement, the CHFW Board shall approve and adopt an employee stock purchase plan, in substantially the form attached hereto as Exhibit H and with any changes or modifications thereto as the Company and CHFW may mutually
agree (such agreement not to be unreasonably withheld, conditioned or delayed by either the Company or CHFW, as applicable) (the &#147;ESPP&#148;), in the manner prescribed under Section&nbsp;423 of the Code and other applicable Laws, effective as
of prior to the Closing Date. The ESPP will provide that one percent (1%) of the total number of CHFW Shares on a fully diluted basis following the Effective Time be initially available for issuance under awards granted pursuant to the ESPP
(inclusive of the shares available for issuance under the ESPP) and the number of CHFW Shares reserved for issuance thereunder will automatically increase annual on the first date of each fiscal year beginning with the 2022 fiscal year in an amount
equal to one percent (1%) of CHFW Shares as determined in the ESPP CHFW Equity (or such lesser amount as determined by the administrator of the ESPP). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_77"></A><B>Section</B><B></B><B>&nbsp;5.20</B> <B>FIRPTA Certificates</B>. At or prior to the Closing, the Company shall
deliver, or cause to be delivered, to CHFW (a)&nbsp;a certificate, duly executed by the Company, complying with Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1445-2(c)(3),</FONT> together with evidence that the Company has
provided notice to the Internal Revenue Service in accordance with the provisions of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.897-2(h)(2),</FONT> in each case, in a form and substance reasonably acceptable to CHFW,
(b)&nbsp;a statement in accordance with the requirements of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1445-2(b)(2)</FONT> from the Company certifying that it is not a &#147;foreign person&#148; as defined in
Section&nbsp;1445(f)(3) of the Code and (c)&nbsp;
an IRS Form <FONT STYLE="white-space:nowrap">W-9</FONT> duly executed by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_78"></A><B>Section</B><B></B><B>&nbsp;5.21
</B> <B>PIPE Subscriptions</B>. Unless otherwise approved in writing by the Company, CHFW shall not (other than changes that are solely ministerial and other <FONT STYLE="white-space:nowrap">non-economic</FONT> de minimis changes) permit any
amendment or modification to be made to, any waiver (in whole or in part) of, or provide consent to modify (including consent to terminate), any provision or remedy under, or any replacements of, any of the Subscription Agreements, in each case,
other than any assignment or transfer contemplated therein or expressly permitted thereby (without any further amendment, modification or waiver to such assignment or transfer provision); provided, that in the case of any such permitted assignment
or transfer, the initial party to such Subscription Agreement remains bound by its obligations with respect thereto in the event that the transferee or assignee, as applicable, does not comply with its obligations to consummate the purchase of
shares of CHFW Common Stock contemplated thereby. Subject to the immediately preceding sentence and in the event that all conditions in the Subscription Agreements have been satisfied, CHFW shall use its reasonable best efforts to take, or to cause
to be taken, all actions required, necessary or that it otherwise deems to be proper or advisable to consummate the transactions contemplated by the Subscription Agreements on the terms described therein, including using its reasonable best efforts
to enforce its rights under the Subscription Agreements to cause the PIPE Investors to pay to (or as directed by) CHFW the applicable purchase price under each PIPE Investor&#146;s applicable Subscription Agreement in accordance with its terms.
Without limiting the generality of the foregoing, CHFW shall give the Company prompt written notice: (i)&nbsp;of the receipt of any request from a PIPE Investor for an amendment to any Subscription Agreement; (ii)&nbsp;of any material breach or
material default to the knowledge of CHFW (or any event or circumstance that, to the knowledge of CHFW, with or without notice, lapse of time or both, would be reasonably likely to give rise to any such breach or default) by any party to any
Subscription Agreement; (iii)&nbsp;of the receipt by the CHFW of any written notice or other written communication from any PIPE Investor with respect to any actual or threatened or claimed expiration, lapse, withdrawal, breach, default, termination
or repudiation of the Subscription Agreement by such PIPE Investor; and (iv)&nbsp;if CHFW does not expect to receive all or any portion of the applicable purchase price under any PIPE Investor&#146;s Subscription Agreement in accordance with its
terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_79"></A><B>Section</B><B></B><B>&nbsp;5.22</B> <B>Section</B><B></B><B>&nbsp;16 Matters</B>. CHFW shall, prior
to the Effective Time, cause the CHFW Board to approve the issuance of CHFW Shares in connection with the Transactions with respect to any employees of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Company who, as a result of their relationship with CHFW as of or following the Effective Time, are subject or will become subject to the reporting requirements of Section&nbsp;16 of the Exchange
Act to the extent necessary for such issuance to be an exempt acquisition pursuant to Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. . </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxa40894_80"></A>ARTICLE 6 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDITIONS TO CONSUMMATION OF THE TRANSACTIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTEMPLATED BY THIS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_81"></A><B>Section</B><B></B><B>&nbsp;6.1</B> <B>Conditions to the Obligations of the Parties</B>. The obligations of the
Parties to consummate the transactions contemplated by this Agreement are subject to the satisfaction or, if permitted by applicable Law, waiver by the Party for whose benefit such condition exists of the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) no Order or Law issued by any court of competent jurisdiction or other Governmental Entity or other legal
restraint or prohibition preventing the consummation of the transactions contemplated by this Agreement shall be in effect; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) the Registration Statement/Proxy Statement shall have become effective in accordance with the provisions of
the Securities Act, no stop order shall have been issued by the SEC and shall remain in effect with respect to the Registration Statement/Proxy Statement, and no proceeding seeking such a stop order shall have been threatened or initiated by the SEC
and remain pending; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) the Company Stockholder Approval shall have been obtained; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) the Required CHFW Shareholder Approval shall have been obtained; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) the Aggregate Transaction Proceeds shall be equal to or greater than $100,000,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) CHFW&#146;s initial listing application with Nasdaq in connection with the Transactions shall have been
approved and all of the outstanding CHFW Shares (after giving effect to the Domestication), including those issued in the Merger shall have been approved for listing on Nasdaq; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) the size and composition of CHFW Board shall be as contemplated under
<U>Section</U><U></U><U>&nbsp;5.16</U>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) after giving effect to the transactions contemplated hereby
(including the PIPE Financing), CHFW shall have at least $5,000,001 of net tangible assets (as determined in accordance with Rule <FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange Act) immediately after the Effective Time; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) the Domestication shall have been consummated on or prior to the Closing Date prior to the Effective
Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_82"></A><B>Section</B><B></B><B>&nbsp;6.2</B> <B>Other Conditions to the Obligations of </B><B>the CHFW
Parties</B>. The obligations of the CHFW Parties to consummate the transactions contemplated by this Agreement are subject to the satisfaction or, if permitted by applicable Law, waiver by CHFW (on behalf of itself and the other CHFW Parties) of the
following further conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) (i) the Company Fundamental Representations (other than the
representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;3.2(a)</U>) shall be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or &#147;Company Material Adverse Effect&#148; or any similar
limitation set forth herein) in all material respects as of the date of this Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made of an earlier
date, in which case such representation and warranty shall be true and correct in all material respects as of such earlier date), (ii) the representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;3.2(a)</U> shall be true and correct
in all respects (except for <I>de minimis </I>inaccuracies) as of the date of this Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made of an
earlier date, in which case such representation and warranty shall be true and correct in all respects (except for <I>de minimis </I>inaccuracies) as of such earlier date), and (iii)&nbsp;the representations and warranties of the of the Company set
forth in <U>Article 3</U> (other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
than the Company Fundamental Representations) shall be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or &#147;Company Material Adverse Effect&#148; or
any similar limitation set forth herein) in all respects as of the date of this Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made of an earlier
date, in which case such representation and warranty shall be true and correct in all respects as of such earlier date), except where the failure of such representations and warranties to be true and correct, taken as a whole, does not cause a
Company Material Adverse Effect; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) the Company shall have performed and complied in all material
respects with the covenants and agreements required to be performed or complied with by the Company under this Agreement at or prior to the Closing; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) since the date of this Agreement, no Company Material Adverse Effect has occurred that is continuing; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) at or prior to the Closing, the Company shall have delivered, or caused to be delivered, to CHFW the
following documents: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) a certificate duly executed by an authorized officer of the Company, dated as of the Closing
Date, to the effect that the conditions specified in <U>Section</U><U></U><U>&nbsp;6.2(a)</U>, <U>Section</U><U></U><U>&nbsp;6.2(b)</U> and <U>Section</U><U></U><U>&nbsp;6.2(c)</U> are satisfied, in a form and substance reasonably satisfactory to
CHFW; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) the Investor Rights Agreement duly executed by the Company Stockholders listed on <U>Annex</U>&nbsp;<U><FONT
STYLE="white-space:nowrap">B-1</FONT></U> attached hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_83"></A><B>Section</B><B></B><B>&nbsp;6.3</B> <B>Other
Conditions to the Obligations of </B><B>the Company</B>. The obligations of the Company to consummate the transactions contemplated by this Agreement are subject to the satisfaction or, if permitted by applicable Law, waiver by the Company of the
following further conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) (i) the CHFW Fundamental Representations (other than the representations
and warranties set forth in <U>Section</U><U></U><U>&nbsp;4.6(a)</U>) shall be true and correct in all material respects as of the date of this Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the extent
that any such representation and warranty is made of an earlier date, in which case such representation and warranty shall be true and correct in all material respects as of such earlier date), (ii) the representations and warranties set forth in
<U>Section</U><U></U><U>&nbsp;4.6(a)</U> shall be true and correct in all respects (except for <I>de minimis </I>inaccuracies) as of the date of this Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the
extent that any such representation and warranty is made of an earlier date, in which case such representation and warranty shall be true and correct in all respects (except for <I>de minimis </I>inaccuracies) as of such earlier date) and
(iii)&nbsp;the representations and warranties of the CHFW Parties (other than the CHFW Fundamental Representations) contained in <U>Article 4</U> of this Agreement shall be true and correct (without giving effect to any limitation as to
&#147;materiality&#148; or &#147;CHFW Material Adverse Effect&#148; or any similar limitation set forth herein) in all respects as of the date of this Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the
extent that any such representation and warranty is made of an earlier date, in which case such representation and warranty shall be true and correct in all material respects as of such earlier date), except where the failure of such representations
and warranties to be true and correct, taken as a whole, does not cause a CHFW Material Adverse Effect; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) the CHFW Parties shall have performed and complied in all material respects with the covenants and
agreements required to be performed or complied with by them under this Agreement at or prior to the Closing; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) at or prior to the Closing, CHFW shall have delivered, or caused to be delivered, the following documents
to the Company: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) a certificate duly executed by an authorized officer of CHFW, dated as
of the Closing Date, to the effect that the conditions specified in <U>Section</U><U></U><U>&nbsp;6.3(a)</U> and <U>Section</U><U></U><U>&nbsp;6.3(b)</U> are satisfied, in a form and substance reasonably satisfactory to the Company; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) the Investors Rights Agreement duly executed by CHFW and the Company Stockholders listed on Annex <FONT
STYLE="white-space:nowrap">B-1.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_84"></A><B>Section</B><B></B><B>&nbsp;6.4</B> <B>Frustration of Closing
Conditions</B>. The Company may not rely on the failure of any condition set forth in this <U>Article 6</U> to be satisfied if such failure was proximately caused by the Company&#146;s failure to use reasonable best efforts to cause the Closing to
occur, as required by <U>Section</U><U></U><U>&nbsp;5.3</U>, or a breach of this Agreement. None of the CHFW Parties may rely on the failure of any condition set forth in this <U>Article 6</U> to be satisfied if such failure was proximately caused
by a CHFW Party&#146;s failure to use reasonable best efforts to cause the Closing to occur, as required by <U>Section</U><U></U><U>&nbsp;5.3</U>, or a breach of this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxa40894_85"></A>ARTICLE 7 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMINATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_86">
</A><B>Section</B><B></B><B>&nbsp;7.1</B> <B>Termination</B>. This Agreement may be terminated and the transactions contemplated by this Agreement may be abandoned at any time prior to the Closing: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) by mutual written consent of CHFW and the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) by CHFW, if any of the representations or warranties set forth in <U>Article 3</U> shall not be true and
correct or if the Company has failed to perform any covenant or agreement on the part of the Company set forth in this Agreement (including an obligation to consummate the Closing) such that the condition to Closing set forth in either
<U>Section</U><U></U><U>&nbsp;6.2(a)</U> or <U>Section</U><U></U><U>&nbsp;6.2(b)</U> could not be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failures to perform any covenant or
agreement, as applicable, is (or are) not cured or cannot be cured within the earlier of (i)&nbsp;thirty (30)&nbsp;days after written notice thereof is delivered to the Company by CHFW, and (ii)&nbsp;the Termination Date; <U>provided</U>,
<U>however</U>, that none of the CHFW Parties is then in breach of this Agreement so as to prevent the condition to Closing set forth in either <U>Section</U><U></U><U>&nbsp;6.3(a)</U> or <U>Section</U><U></U><U>&nbsp;6.3(b)</U> from being
satisfied; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(c) by the Company, if any of the representations or warranties set forth in <U>Article 4</U>
shall not be true and correct or if any CHFW Party has failed to perform any covenant or agreement on the part of such applicable CHFW Party set forth in this Agreement (including an obligation to consummate the Closing) such that the condition to
Closing set forth in either <U>Section</U><U></U><U>&nbsp;6.3(a)</U> or <U>Section</U><U></U><U>&nbsp;6.3(b)</U> could not be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failures
to perform any covenant or agreement, as applicable, is (or are) not cured or cannot be cured within the earlier of (i)&nbsp;thirty (30) days after written notice thereof is delivered to CHFW by the Company and (ii)&nbsp;the Termination Date;
<U>provided</U>, <U>however</U>, the Company is not then in breach of this Agreement so as to prevent the condition to Closing set forth in <U>Section</U><U></U><U>&nbsp;6.2(a)</U> or <U>Section</U><U></U><U>&nbsp;6.2(b)</U> from being satisfied;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(d) by either CHFW or the Company, if the transactions contemplated by this Agreement shall not have been
consummated on or prior to October&nbsp;12, 2021 (the &#147;Termination Date&#148;); provided that if the Registration Statement filed pursuant <U>to Section</U><U></U><U>&nbsp;5.7,</U> is not declared effective by August&nbsp;13, 2021 then the
Termination will be automatically extended by 60 days; <U>provided</U>, that (i)&nbsp;the right to terminate this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(d)</U> shall not be available to CHFW if any CHFW Party&#146;s breach of
any of its covenants or obligations under this Agreement shall have proximately caused the failure to consummate the transactions contemplated by this Agreement on or before the Termination Date, and (ii)&nbsp;the right to terminate this Agreement
pursuant to this <U>Section</U><U></U><U>&nbsp;7.1(d)</U> shall not be available to the Company if the Company&#146;s breach of its covenants or obligations under this Agreement shall have proximately caused the failure to consummate the
transactions contemplated by this Agreement on or before the Termination Date; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(e) by either CHFW or the Company, if any Governmental
Entity shall have issued an Order or taken any other action permanently enjoining, restraining or otherwise prohibiting the transactions contemplated by this Agreement and such Order or other action shall have become final and nonappealable; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(f) by either CHFW or the Company if the CHFW Shareholders Meeting has been held (including any adjournment or
postponement thereof), has concluded, CHFW&#146;s shareholders have duly voted and the Required CHFW Shareholder Approval was not obtained; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(g) by CHFW, if the Company does not deliver, or cause to be delivered to, to CHFW (i)&nbsp;a Transaction
Support Agreement duly executed by each Supporting Company Stockholder in accordance with <U>Section</U><U></U><U>&nbsp;5.13(a)</U> on or prior to the Transaction Support Agreement Deadline or (ii)&nbsp;the Company Stockholder Written Consent in
accordance with <U>Section</U><U></U><U>&nbsp;5.13(b)</U> on or prior to the Company Stockholder Written Consent Deadline; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(h) by the Company if there is a Modification of the Recommendation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_87"></A><B>Section</B><B></B><B>&nbsp;7.2</B> <B>Effect of Termination</B>. In the event of the termination of this
Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U>, this entire Agreement shall forthwith become void (and there shall be no Liability or obligation on the part of the Parties and their respective Representatives) with the exception of
<U>Section</U><U></U><U>&nbsp;5.3</U>, this <U>Section</U><U></U><U>&nbsp;7.2</U>, <U>Article 8</U> and <U>Article 1</U> (to the extent related to the foregoing), each of which shall survive such termination and remain valid and binding obligations
of the Parties and (b)&nbsp;the Confidentiality Agreements, which shall survive such termination and remain valid and binding obligations of the parties thereto in accordance with their respective terms. Notwithstanding the foregoing, the
termination of this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U> shall not affect (i)&nbsp;any Liability on the part of any Party for a Willful Breach of any covenant or agreement set forth in this Agreement prior to such termination
or common law fraud or (ii)&nbsp;any Person&#146;s Liability under any Subscription Agreement, any Confidentiality Agreement, any Transaction Support Agreement to which he, she or it is a party. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxa40894_88"></A>ARTICLE 8 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_89">
</A><B>Section</B><B></B><B>&nbsp;8.1</B> <B><FONT STYLE="white-space:nowrap">Non-Survival</FONT></B>. The representations, warranties, agreements and covenants in this Agreement shall terminate at the Effective Time, except for those covenants and
agreements that, by their terms, contemplate performance after the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_90"></A><B>Section</B><B></B><B>&nbsp;8.2</B> <B>Entire Agreement; Assignment</B>. This Agreement (together with the
Ancillary Documents) constitutes the entire agreement among the Parties with respect to the subject matter hereof and supersedes all other prior agreements and understandings, both written and oral, among the Parties with respect to the subject
matter hereof. This Agreement&nbsp;may not be assigned by any Party (whether by operation of law or otherwise) without the prior written consent of (a)&nbsp;CHFW and the Company prior to Closing and (b)&nbsp;CHFW and the Sponsor after the Closing.
Any attempted assignment of this Agreement not in accordance with the terms of this <U>Section</U><U></U><U>&nbsp;
8.2</U> shall be void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_91"></A><B>Section</B><B></B><B>&nbsp;8.3</B> <B>Amendment</B>. This Agreement may be amended or
modified only by a written agreement executed and delivered by (a)&nbsp;CHFW and the Company prior to the Closing and (b)&nbsp;CHFW and the Sponsor after the Closing. This Agreement may not be modified or amended except as provided in the
immediately preceding sentence and any purported amendment by any Party or Parties effected in a manner which does not comply with this <U>Section</U><U></U><U>&nbsp;8.3</U> shall be void, <I>ab initio</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_92"></A><B>Section</B><B></B><B>&nbsp;8.4</B> <B>Notices</B>. All notices, requests, claims, demands and other
communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly given ) by delivery in person, by <FONT STYLE="white-space:nowrap">e-mail</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
(having obtained electronic delivery confirmation thereof), or by registered or certified mail (postage prepaid, return receipt requested) (upon receipt thereof) to the other Parties as follows:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) If to any CHFW Party, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1 Palmer Square </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Suite 305 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Princeton, New Jersey 08540 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Attention:&nbsp;&nbsp;&nbsp;&nbsp;Gad Soffer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Josh
House </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>with a copy (which shall not constitute notice) to</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Goodwin Procter LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">100 Norther Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Boston, Massachusetts 02210 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Attention:&nbsp;&nbsp;&nbsp;&nbsp;Mitchell S. Bloom </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Jocelyn M. Arel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Jacqueline Mercier </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(b) If to the Company, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Surrozen, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">171 Oyster Point Blvd, Suite 400 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">South San Francisco, California 94080 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Attention: Craig Parker </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>with a copy (which shall not constitute notice) to</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">440 Eastgate Mall </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">San Diego, California 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Attention: Barbara Borden </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Michael Tenta </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;&nbsp;&nbsp;</FONT> [***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">or to such other address as the Party to whom notice is given may have previously furnished to the others in writing in the manner set forth
above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_93"></A><B>Section</B><B></B><B>&nbsp;8.5</B> <B>Governing Law</B>. This Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the law
of any jurisdiction other than the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_94"></A><B>Section</B><B></B><B>&nbsp;8.6</B> <B>Fees and
Expenses</B>. Except as otherwise set forth in this Agreement, all fees and expenses incurred in connection with this Agreement, the Ancillary Documents and the transactions contemplated hereby and thereby, including the fees and disbursements of
counsel, financial advisors and accountants, shall be paid by the Party incurring such fees or expenses; <U>provided</U> that, for the avoidance of doubt, (a)&nbsp;if this Agreement is terminated in accordance with its terms, the Company shall pay,
or cause to be paid, all Unpaid Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Expenses and CHFW shall pay, or cause to be paid, all Unpaid CHFW Expenses and (b)&nbsp;if the Closing occurs, then CHFW shall pay, or cause to be paid, all Unpaid Company Expenses and all Unpaid
CHFW Expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_95"></A><B>Section</B><B></B><B>&nbsp;8.7</B> <B>Construction; Interpretation</B>. The term &#147;this
Agreement&#148; means this Business Combination Agreement together with the Schedules and Exhibits hereto, as the same may from time to time be amended, modified, supplemented or restated in accordance with the terms hereof. The headings set forth
in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement. No Party, nor its respective counsel, shall be deemed the drafter of this Agreement for purposes of construing the
provisions hereof, and all provisions of this Agreement shall be construed according to their fair meaning and not strictly for or against any Party. Unless otherwise indicated to the contrary herein by the context or use thereof: (a)&nbsp;the
words, &#147;herein,&#148; &#147;hereto,&#148; &#147;hereof&#148; and words of similar import refer to this Agreement as a whole, including the Schedules and Exhibits, and not to any particular section, subsection, paragraph, subparagraph or clause
set forth in this Agreement; (b)&nbsp;masculine gender shall also include the feminine and neutral genders, and vice versa; (c)&nbsp;words importing the singular shall also include the plural, and vice versa; (d)&nbsp;the words &#147;include,&#148;
&#147;includes&#148; or &#147;including&#148; shall be deemed to be followed by the words &#147;without limitation&#148;; (e) references to &#147;$&#148; or &#147;dollar&#148; or &#147;US$&#148; shall be references to United States dollars;
(f)&nbsp;the word &#147;or&#148; is disjunctive but not necessarily exclusive; (g)&nbsp;the words &#147;writing&#148;, &#147;written&#148; and comparable terms refer to printing, typing and other means of reproducing words (including electronic
media) in a visible form; (h)&nbsp;the word &#147;day&#148; means calendar day unless Business Day is expressly specified; (i)&nbsp;the word &#147;extent&#148; in the phrase &#147;to the extent&#148; means the degree to which a subject or other
thing extends, and such phrase shall not mean simply &#147;if&#148;; (j) all references to Articles, Sections, Exhibits or Schedules are to Articles, Sections, Exhibits and Schedules of this Agreement; (k)&nbsp;the words &#147;provided&#148; or
&#147;made available&#148; or words of similar import (regardless of whether capitalized or not) shall mean, when used with reference to documents or other materials required to be provided or made available to CHFW, any documents or other materials
posted to the electronic data room located www.dfsvenue.com under the project name &#147;Project Big Sur&#148; as of 5:00 p.m., Eastern Time, at least one (1)&nbsp;day prior to the date of this Agreement; (l)&nbsp;all references to any Law will be
to such Law as amended, supplemented or otherwise modified or <FONT STYLE="white-space:nowrap">re-enacted</FONT> from time to time; and (m)&nbsp;all references to any Contract are to that Contract as amended or modified from time to time in
accordance with the terms thereof (subject to any restrictions on amendments or modifications set forth in this Agreement). If any action under this Agreement is required to be done or taken on a day that is not a Business Day, then such action
shall be required to be done or taken not on such day but on the first succeeding Business Day thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_96"></A><B>Section</B><B></B><B>&nbsp;8.8</B> <B>Exhibits and Schedules</B>. All Exhibits and Schedules, or documents
expressly incorporated into this Agreement, are hereby incorporated into this Agreement and are hereby made a part hereof as if set out in full in this Agreement. The Schedules shall be arranged in sections and subsections corresponding to the
numbered and lettered Sections and subsections set forth in this Agreement. Any item disclosed in the Company Disclosure Schedules or in the CHFW Disclosure Schedules corresponding to any Section or subsection of <U>Article 3</U> (in the case of the
Company Disclosure Schedules) or <U>Article 4</U> (in the case of the CHFW Disclosure Schedules) shall be deemed to have been disclosed with respect to every other section and subsection of <U>Article 3</U> (in the case of the Company Disclosure
Schedules) or <U>Article 4</U> (in the case of the CHFW Disclosure Schedules), as applicable, where the relevance of such disclosure to such other Section or subsection is reasonably apparent on the face of the disclosure. The information and
disclosures set forth in the Schedules that correspond to the section or subsections of <U>Article 3</U> or <U>5</U> may not be limited to matters required to be disclosed in the Schedules, and any such additional information or disclosure is for
informational purposes only and does not necessarily include other matters of a similar nature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_97"></A><B>Section</B><B></B><B>&nbsp;8.9</B> <B>Parties in Interest</B>. This Agreement shall be binding upon and inure
solely to the benefit of each Party and its successors and permitted assigns and, except as provided in <U>Section</U><U></U><U>&nbsp;5.14</U>, <U>Section&nbsp;5.15</U>, the last sentence of this <U>Section</U><U></U><U>&nbsp;8.9</U> and
<U>Section</U><U></U><U>&nbsp;8.14</U>, nothing in this Agreement, express or implied, is intended to or shall confer upon any other Person any rights, benefits or remedies of any nature whatsoever under or by reason of this Agreement. The Sponsor
shall be an express third-party beneficiary of <U>Section</U><U></U><U>&nbsp;5.16(b)</U>, <U>Section</U><U></U><U>&nbsp;8.2</U>, <U>Section</U><U></U><U>&nbsp;8.3</U>, this <U>Section</U><U></U><U>&nbsp;8.8</U> and
<U>Section</U><U></U><U>&nbsp;8.13</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_98"></A><B>Section</B><B></B><B>&nbsp;8.10</B> <B>Severability</B>.
Whenever possible, each provision of this Agreement will be interpreted in such a manner as to be effective and valid under applicable Law, but if any term or other provision of this Agreement is held to be invalid, illegal or unenforceable under
applicable Law, all other provisions of this Agreement shall remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any Party. Upon such
determination that any term or other provision of this Agreement is invalid, illegal or unenforceable under applicable Law, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as
closely as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_99"></A><B>Section</B><B></B><B>&nbsp;8.11</B> <B>Counterparts; Electronic Signatures</B>. This Agreement and each
Ancillary Document (including any of the closing deliverables contemplated hereby) may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which shall constitute one and the same agreement. Delivery
of an executed counterpart of a signature page to this Agreement or any Ancillary Document (including any of the closing deliverables contemplated hereby) by facsimile, <FONT STYLE="white-space:nowrap">e-mail,</FONT> or scanned pages shall be
effective as delivery of a manually executed counterpart to this Agreement or any such Ancillary Document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_100"></A><B>Section</B><B></B><B>&nbsp;8.12</B> <B>Knowledge of </B><B>Company; Knowledge of </B><B>CHFW</B>. For all
purposes of this Agreement, the phrase &#147;to the Company&#146;s knowledge&#148; and &#147;known by the Company&#148; and any derivations thereof shall mean as of the applicable date, the actual knowledge of the individuals set forth on
<U>Section</U><U></U><U>&nbsp;8.12(a)</U> of the Company Disclosure Schedules, assuming reasonable due inquiry and investigation of his or her direct reports. For all purposes of this Agreement, the phrase &#147;to CHFW&#146;s knowledge&#148; and
&#147;to the knowledge of CHFW&#148; and any derivations thereof shall mean as of the applicable date, the actual knowledge of the individuals set forth on <U>Section</U><U></U><U>&nbsp;8.12(b)</U> of the CHFW Disclosure Schedules, assuming
reasonable due inquiry and investigation of his or her direct reports. For the avoidance of doubt, none of the individuals set forth on <U>Section</U><U></U><U>&nbsp;8.12(a)</U> of the Company Disclosure Schedules or
<U>Section</U><U></U><U>&nbsp;8.12(b)</U> of the CHFW Disclosure Schedules shall have any personal Liability or obligations regarding such knowledge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_101"></A><B>Section</B><B></B><B>&nbsp;8.13</B> <B>No Recourse</B>. This Agreement may only be enforced against, and any
action for breach of this Agreement may only be made against, the Parties, and none of the Representatives of CHFW (including the Sponsor) or the Company (including directors, officers, employees and shareholders) shall have any Liability arising
out of or relating to this Agreement or the transactions contemplated hereby, including with respect to any claim (whether in tort, contract or otherwise) for breach of this Agreement or in respect of any written or oral representations made or
alleged to be made in connection herewith, as expressly provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_102"></A><B>Section</B><B></B><B>&nbsp;8.14</B> <B>Extension; Waiver</B>. The Company prior to the Closing and the
Surviving Company and the Sponsor after the Closing may (a)&nbsp;extend the time for the performance of any of the obligations or other acts of the CHFW Parties set forth herein, (b)&nbsp;waive any inaccuracies in the representations and warranties
of the CHFW Parties set forth herein or (c)&nbsp;waive compliance by the CHFW Parties with any of the agreements or conditions set forth herein. CHFW may (i)&nbsp;extend the time for the performance of any of the obligations or other acts of the
Company, set forth herein, (ii)&nbsp;waive any inaccuracies in the representations and warranties of the Company set forth herein or (iii)&nbsp;waive compliance by the Company with any of the agreements or conditions set forth herein. Any agreement
on the part of any such Party to any such extension or waiver shall be valid only if set forth in a written instrument signed on behalf of such Party. Any waiver of any term or condition shall not be construed as a waiver of any subsequent breach or
a subsequent waiver of the same term or condition, or a waiver of any other term or condition of this Agreement. The failure of any Party to assert any of its rights hereunder shall not constitute a waiver of such rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_103"></A><B>Section</B><B></B><B>&nbsp;8.15</B> <B>Waiver of Jury Trial</B>. THE PARTIES EACH HEREBY WAIVES, TO THE FULLEST
EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY PROCEEDING, CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (I)&nbsp;ARISING UNDER THIS AGREEMENT OR UNDER ANY ANCILLARY DOCUMENT OR (II)&nbsp;IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
TO THE DEALINGS OF THE PARTIES IN RESPECT OF THIS AGREEMENT OR ANY ANCILLARY DOCUMENT OR ANY OF THE TRANSACTIONS RELATED HERETO OR THERETO OR ANY FINANCING IN CONNECTION WITH THE TRANSACTIONS
CONTEMPLATED HEREBY OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREBY, IN EACH CASE, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE. THE PARTIES EACH HEREBY AGREES AND CONSENTS THAT ANY SUCH PROCEEDING,
CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE
WAIVER OF THEIR RIGHT TO TRIAL BY JURY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A)&nbsp;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION,
SEEK TO ENFORCE THE FOREGOING WAIVER, (B)&nbsp;EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C)&nbsp;EACH SUCH PARTY MAKES THIS WAIVER VOLUNTARILY AND (D)&nbsp;EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS
AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <U>SECTION</U><U></U><U>&nbsp;
8.15</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_104"></A><B>Section</B><B></B><B>&nbsp;8.16</B> <B>Submission to Jurisdiction</B>. Each of the Parties
irrevocably and unconditionally submits to the exclusive jurisdiction of the Chancery Court of the State of Delaware (or, if the Chancery Court of the State of Delaware declines to accept jurisdiction, any state or federal court within State of New
York, New York County), for the purposes of any Proceeding, claim, demand, action or cause of action (a)&nbsp;arising under this Agreement or under any Ancillary Document or (b)&nbsp;in any way connected with or related or incidental to the dealings
of the Parties in respect of this Agreement or any Ancillary Document or any of the transactions contemplated hereby or any of the transactions contemplated thereby, and irrevocably and unconditionally waives any objection to the laying of venue of
any such Proceeding in any such court, and further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such Proceeding has been brought in an inconvenient forum. Each Party hereby irrevocably and
unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any Proceeding claim, demand, action or cause of action (i)&nbsp;arising under this Agreement or under any Ancillary Document or
(ii)&nbsp;in any way connected with or related or incidental to the dealings of the Parties in respect of this Agreement or any Ancillary Document or any of the transactions contemplated hereby or any of the transactions contemplated thereby,
(A)&nbsp;any claim that it is not personally subject to the jurisdiction of the courts as described in this <U>Section</U><U></U><U>&nbsp;8.16</U> for any reason, (B)&nbsp;that it or its property is exempt or immune from the jurisdiction of any such
court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (C)&nbsp;that (x)&nbsp;the Proceeding,
claim, demand, action or cause of action in any such court is brought in an inconvenient forum, (y)&nbsp;the venue of such Proceeding, claim, demand, action or cause of action is improper or (z)&nbsp;this Agreement, or the subject matter hereof, may
not be enforced in or by such courts. Each Party agrees that service of any process, summons, notice or document by registered mail to such party&#146;s respective address set forth in <U>Section</U><U></U><U>&nbsp;8.4</U> shall be effective service
of process for any such Proceeding, claim, demand, action or cause of action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_105"></A><B>Section</B><B></B><B>&nbsp;8.17</B> <B>Remedies</B>. Except as otherwise expressly provided herein, any and all
remedies provided herein will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy.
The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that the Parties do not perform their respective obligations under the provisions of this Agreement
(including failing to take such actions as are required of them hereunder to consummate the transactions contemplated by this Agreement) in accordance with their specific terms or otherwise breach such provisions. It is accordingly agreed that the
Parties shall be entitled to an injunction or injunctions, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, in each case, without posting a
bond or undertaking and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
without proof of damages and this being in addition to any other remedy to which they are entitled at law or in equity. Each of the Parties agrees that it will not oppose the granting of an
injunction, specific performance and other equitable relief when expressly available pursuant to the terms of this Agreement on the basis that the other parties have an adequate remedy at law or an award of specific performance is not an appropriate
remedy for any reason at law or equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxa40894_106"></A><B>Section</B><B></B><B>&nbsp;8.18</B> <B>Trust Account Waiver</B>.
Reference is made to the final prospectus of CHFW, filed with the SEC (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-249394)</FONT> on November&nbsp;19, 2020 (the &#147;Prospectus&#148;). The Company acknowledges and agrees and understands that
CHFW has established a trust account (the &#147;Trust Account&#148;) containing the proceeds of its initial public offering (the &#147;IPO&#148;) and from certain private placements occurring simultaneously with the IPO (including interest accrued
from time to time thereon) for the benefit of CHFW&#146;s public shareholders (including overallotment shares acquired by CHFW&#146;s underwriters, the &#147;Public Shareholders&#148;), and CHFW may disburse monies from the Trust Account only in the
express circumstances described in the Prospectus. For and in consideration of CHFW entering into this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company hereby agrees
on behalf of itself and its Representatives that, notwithstanding anything to the contrary in this Agreement, none of the Company or its Representatives does now or shall at any time hereafter have any right, title, interest or claim of any kind in
or to any monies in the Trust Account or distributions therefrom, or make any claim against the Trust Account (including any distributions therefrom), regardless of whether such claim arises as a result of, in connection with or relating in any way
to, this Agreement or any proposed or actual business relationship between CHFW or any of its Representatives, on the one hand, and, the Company or any of its Representatives, on the other hand, or any other matter, and regardless of whether such
claim arises based on contract, tort, equity or any other theory of legal liability (any and all such claims are collectively referred to hereafter as the &#147;Trust Account Released Claims&#148;). The Company, on its own behalf and on behalf of
its Representatives, hereby irrevocably waives any Trust Account Released Claims that it or any of its Representatives may have against the Trust Account (including any distributions therefrom) now or in the future as a result of, or arising out of,
any negotiations, or Contracts with CHFW or its Representatives and will not seek recourse against the Trust Account (including any distributions therefrom) for any reason whatsoever (including for an alleged breach of any agreement with CHFW or its
Affiliates). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp; *&nbsp;&nbsp;&nbsp;&nbsp; *&nbsp;&nbsp;&nbsp;&nbsp; *&nbsp;&nbsp;&nbsp;&nbsp; * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, each of the Parties has caused this Business Combination
Agreement to be duly executed on its behalf as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP.</B></P></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Gad Soffer</P></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name: Gad Soffer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:<B> </B>Chief Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>PERSEVERANCE MERGER SUB INC.</B></P></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Gad Soffer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name: Gad Soffer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:<B> </B>President</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>SURROZEN, INC.</B></P></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Craig Parker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name: Craig Parker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:<B> </B>Chief Executive Officer <B></B></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Business Combination Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annex A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PIPE Investors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annex B </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Supporting Company Stockholders </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annex C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unpaid CHFW Expenses and Unpaid CHFW Liabilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annex D </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Required Governing Documents Proposals </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following Governing Document Proposals are Required Governing Document Proposals: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve the change in the authorized share capital of CHFW from (i)&nbsp;US$50,000 divided into 350,000,000
Class&nbsp;A ordinary shares, par value $0.0001 per share, 150,000,000 Class&nbsp;B ordinary shares, par value $0.0001 per share and 1,000,000 preference shares, par value $0.0001 per share, to (ii) 300,000,000 shares of common stock, par value
$0.0001 per share and 10,000,000 shares of preferred stock, par value $0.0001 per share; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to authorize all other changes necessary or, as mutually agreed in good faith by CHFW and the Company,
desirable in connection with the replacement of CHFW&#146;s Governing Documents existing prior to the Domestication with the proposed CHFW Certificate of Incorporation and the proposed CHFW Bylaws as part of the Domestication. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPONSOR LETTER AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This SPONSOR LETTER AGREEMENT (this &#147;<B>Agreement</B>&#148;), dated as of April [&#149;], 2021, is made by and among <FONT
STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., a Cayman Islands exempted company (&#147;<B>CHFW</B>&#148;), Consonance Life Sciences, a Cayman Islands exempted company (the &#147;<B>Sponsor</B>&#148;), the other holders of CHFW
Class&nbsp;B ordinary shares set forth on&nbsp;the signature page hereto (the &#147;<B>Founders</B>&#148;, and together with the Sponsor, collectively, the &#147;<B>CHFW Shareholders</B>&#148;), and Surrozen, Inc., a Delaware corporation (the
&#147;<B>Company</B>&#148;). CHFW, the CHFW Shareholders and the Company shall be referred to herein from time to time collectively as the &#147;<B>Parties</B>&#148;. Capitalized terms used herein and not otherwise defined will have the meaning
given such terms in the Business Combination Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, CHFW, the Company and certain other persons party
thereto entered into that certain Business Combination Agreement, dated as of the date hereof (as it may be amended, restated or otherwise modified from time to time in accordance with its terms, the &#147;<B>Business Combination
Agreement</B>&#148;) providing for the merger of a subsidiary of CHFW with and into the Company, with the Company surviving as the surviving corporation in such merger (the &#147;<B>Merger</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, as of the date hereof and in any event prior to the Merger and the Closing, the Sponsor has agreed to forfeit 759,000 CHFW
Class&nbsp;B Shares (the &#147;Forfeited Shares&#148;) so that immediately prior to the Effective Time and the Closing, the Sponsor shall be the holder of record and the &#147;beneficial owner&#148; (within the meaning of Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of 1,451,000 CHFW Class&nbsp;B Shares, 434,000 CHFW Class&nbsp;A Shares and 144,667 IPO Warrants in the aggregate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, (i)&nbsp;the Sponsor is the record and beneficial owner of the number of CHFW Class&nbsp;A Shares and CHFW Class&nbsp;B Shares as set
forth on Schedule I hereto and (ii)&nbsp;each Founder is the record and beneficial owner of the number of CHFW Class&nbsp;B Shares, as set forth on Schedule I hereto (in each case, together with any other Equity Securities of CHFW that such CHFW
Shareholder holds of record or beneficially, as of the date of this Agreement, or acquires record or beneficial ownership after the date hereof, collectively, the &#147;<B>Subject CHFW Equity Securities</B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, the Business Combination Agreement contemplates that the Parties will enter into this Agreement concurrently with the entry into the
Business Combination Agreement by the parties thereto, pursuant to which, among other things, (a)&nbsp;the CHFW Shareholders will vote in favor of approval of the Business Combination Agreement and the transactions contemplated thereby (including
the Domestication and the Merger) and (b)&nbsp;the CHFW Shareholders will agree to waive any adjustment to the conversion ratio set forth in the Governing Documents of CHFW or any other anti-dilution or similar protection with respect to all of the
CHFW Class&nbsp;B Shares related to the transactions contemplated by the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NOW, THEREFORE, in consideration
of the premises and the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. <U>Agreement to Vote</U>.&nbsp;Each CHFW Shareholder hereby agrees to (i)&nbsp;appear (in person or by proxy) at any meeting of the
shareholders of CHFW and (ii)&nbsp;vote (in person or by proxy) at any such meeting, and in any action by written resolution of the shareholders of CHFW, all of such CHFW Shareholder&#146;s Subject CHFW Equity Securities in favor of (A)&nbsp;each of
the Transaction Proposals to be submitted to the holders of CHFW ordinary shares in connection with the Merger and the other transactions contemplated by the Business Combination Agreement and (B)&nbsp;such other resolutions upon which a consent or
other approval is required under CHFW&#146;s amended and restated memorandum and articles of association, law, securities exchange or otherwise is sought with respect to effecting the Business Combination Agreement and the Merger, and (ii)&nbsp;vote
(in person or by proxy) against any merger, purchase of all or substantially all of a third party (other than the Merger) or all of the assets of a third party or other business combination transaction with a third party (other than the Business
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Combination Agreement and the Merger) (a &#147;<B>Competing Transaction</B>&#148;) or any proposal relating to a Competing Transaction and against any proposal, action or agreement that would
(A)&nbsp;impede, frustrate, prevent or nullify any provision of this Agreement, the Business Combination Agreement or any Merger, (B)&nbsp;result in a breach in any respect of any covenant, representation, warranty or any other obligation or
agreement of CHFW or Perseverance Merger Sub Inc. under the Business Combination Agreement, (C)&nbsp;result in any of the conditions set forth in Article VI of the Business Combination Agreement not being fulfilled or (D)&nbsp;change in any manner
the dividend policy or capitalization of, including the voting rights of any class of capital stock of, CHFW (other than the Transaction Proposals). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each CHFW Shareholder hereby agrees that it shall not commit or agree to take any action inconsistent with the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. <U>Waiver of Anti-dilution Protection</U>. Each CHFW Shareholder hereby (a)&nbsp;waives, subject to, and conditioned upon, the occurrence
of the Closing (for himself, herself or itself and for his, her or its, successors, heirs and assigns), to the fullest extent permitted by law and the Amended and Restated Memorandum and Articles of Association of CHFW, and (b)&nbsp;agrees not to
assert or perfect, any rights to adjustment or other anti-dilution protections with respect to the rate that the CHFW Class&nbsp;B Shares held by him, her or it convert into CHFW Class&nbsp;A Shares in connection with the transactions contemplated
by the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. <U>Forfeiture</U>. The Sponsor agrees that, in connection with the Business Combination
Agreement and the transactions contemplated thereby, the Forfeited Shares are hereby forfeited as of immediately prior to the Effective Time, such shares shall no longer be outstanding, and the Sponsor shall have no further rights with respect to
the Forfeited Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. <U>Transfer of Shares</U>. Each CHFW Shareholder hereby agrees that he, she or it shall not, directly or
indirectly, (i)&nbsp;sell, assign, transfer (including by operation of law), place a lien on, pledge, dispose of or otherwise encumber any of its Subject CHFW Equity Securities or otherwise agree to do any of the foregoing (each, a
&#147;<B>Transfer</B>&#148;), (ii) deposit any of her, his or its Subject CHFW Equity Securities into a voting trust or enter into a voting agreement or arrangement or grant any proxy or power of attorney with respect to any of its Subject CHFW
Equity Securities that conflicts with any of the covenants or agreements set forth in this Agreement, (iii)&nbsp;enter into any contract, option or other arrangement or undertaking with respect to the direct or indirect acquisition or sale,
assignment, transfer (including by operation of law) or other disposition of any of his, her or its Subject CHFW Equity Securities, (iv)&nbsp;engage in any hedging or other transaction which is designed to, or which would (either alone or in
connection with one or more events, developments or events (including the satisfaction or waiver of any conditions precedent)), lead to or result in a sale or disposition of his, her or its Subject CHFW Equity Securities even if such Subject CHFW
Equity Securities would be disposed of by a person other than the CHFW Shareholder or (v)&nbsp;take any action that would have the effect of preventing or materially delaying the performance of its obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. <U>Further Assurances</U>. Each CHFW Shareholder shall take, or cause to be taken, all actions and do, or cause to be done, all things
reasonably necessary under applicable Laws to consummate the Merger and the other transactions contemplated by the Business Combination Agreement on the terms and subject to the conditions set forth therein and herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6. <U>No Inconsistent Agreement</U>. Each CHFW Shareholder hereby represents and covenants that such CHFW Shareholder has not entered into,
and shall not enter into, any agreement that would restrict, limit or interfere with the performance of such CHFW Shareholder&#146;s obligations hereunder </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7. <U>CHFW Shareholder Representations and Warranties</U>. The CHFW Shareholder represents and warrants to CHFW and the Company as follows:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. The CHFW Shareholder is a corporation, limited liability company or other applicable business entity duly organized or formed, as
applicable, validly existing and in good standing (or the equivalent thereof, if </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the Laws of its jurisdiction of formation or organization
(as applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b. The CHFW Shareholder has the requisite corporate, limited liability company or other similar power and authority to
execute and deliver this Agreement, to perform its covenants, agreements and obligations hereunder. The execution and delivery of this Agreement has been duly authorized by all necessary corporate (or other similar) action on the part of the CHFW
Shareholder. This Agreement has been duly and validly executed and delivered by the CHFW Shareholder and constitutes a valid, legal and binding agreement of the CHFW Shareholder (assuming that this Agreement is duly authorized, executed and
delivered by CHFW and the Company), enforceable against the CHFW Shareholder in accordance with its terms (subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors&#146;
rights and subject to general principles of equity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c. The execution and delivery of this Agreement by such CHFW Shareholder, does not,
and the performance by such CHFW Shareholder of his, her or its obligations hereunder will not, (i)&nbsp;if such CHFW Shareholder is not an individual, conflict with or result in a violation of the organizational documents of such CHFW Shareholder
or (ii)&nbsp;require any consent or approval that has not been given or other action that has not been taken by any Person (including under any Contract binding upon such CHFW Shareholder or such CHFW Shareholder&#146;s Subject CHFW Equity
Securities), in each case, to the extent such consent, approval or other action would prevent, enjoin or materially delay the performance by such CHFW Shareholder of its, his or her obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">d. There are no proceedings pending against such CHFW Shareholder, or to the knowledge of such CHFW Shareholder threatened against such CHFW
Shareholder, before (or, in the case of threatened proceedings, that would be before) any arbitrator or any Governmental Entity, which in any manner challenges or seeks to prevent, enjoin or materially delay the performance by such CHFW Shareholder
of its, his or her obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">e. Except as described on Section&nbsp;4.4 of the CHFW Disclosure Schedules, no
broker, finder, investment banker or other Person is entitled to any brokerage fee, finders&#146; fee or other commission in connection with the transactions contemplated by the Business Combination Agreement based upon arrangements made by such
CHFW Shareholder, for which CHFW or any of its Affiliates may become liable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Such CHFW Shareholder understands and acknowledges that each
of CHFW and the Company is entering into the Business Combination Agreement in reliance upon such CHFW Shareholder&#146;s execution and delivery of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8. <U>Other Covenants</U>. Each CHFW Shareholder hereby agrees to be bound by and subject to (i)&nbsp;Sections 5.3(a) (Confidentiality) and
5.4(a) (Public Announcements) of the Business Combination Agreement to the same extent as such provisions apply to the parties to the Business Combination Agreement, as if such CHFW Shareholder is directly a party thereto, and
(ii)&nbsp;Section&nbsp;5.6(b) (Exclusive Dealing) of the Business Combination Agreement to the same extent as such provisions apply to CHFW as if such CHFW Shareholder is directly party thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9. <U>Termination</U>.&nbsp;This Agreement shall automatically terminate, without any notice or other action by any Party, and be void <I>ab
initio</I> upon the earlier of (a)&nbsp;the effective time of the Merger; and (b)&nbsp;the termination of the Business Combination Agreement in accordance with its terms. Upon termination of this Agreement as provided in the immediately preceding
sentence, none of the Parties shall have any further obligations or liabilities under, or with respect to, this Agreement. Notwithstanding the foregoing or anything to the contrary in this Agreement, the termination of this Agreement pursuant to
this <U>Section</U><U></U><U>&nbsp;9</U> shall not affect any liability on the part of any Party for a willful breach of any covenant or agreement set forth in this Agreement prior to such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10. <U>No Recourse</U>.&nbsp;Except for claims pursuant to the Business Combination Agreement or any other Ancillary Document by any
party(ies) thereto against any other party(ies) thereto, each Party agrees that (a)&nbsp;this Agreement </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
may only be enforced against, and any action for breach of this Agreement may only be made against, the Parties, and no claims of any nature whatsoever (whether in tort, contract or otherwise)
arising under or relating to this Agreement, the negotiation hereof or its subject matter, or the transactions contemplated hereby shall be asserted against any Company <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate or any CHFW <FONT
STYLE="white-space:nowrap">Non-Party</FONT> Affiliate (other than the CHFW Shareholders named as parties hereto, on the terms and subject to the conditions set forth herein), and (b)&nbsp;none of the Company
<FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates or the CHFW <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates (other than the CHFW Shareholders named as parties hereto, on the terms and subject to the conditions set forth
herein) shall have any Liability arising out of or relating to this Agreement, the negotiation hereof or its subject matter, or the transactions contemplated hereby, including with respect to any claim (whether in tort, contract or otherwise) for
breach of this Agreement or in respect of any written or oral representations made or alleged to be made in connection herewith, as expressly provided herein, or for any actual or alleged inaccuracies, misstatements or omissions with respect to any
information or materials of any kind furnished in connection with this Agreement, the negotiation hereof or the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11. <U>Fiduciary Duties</U>.&nbsp;Notwithstanding anything in this Agreement to the contrary, (a)&nbsp;each CHFW Shareholder makes no
agreement or understanding herein in any capacity other than in such CHFW Shareholder&#146;s capacity as a record holder and beneficial owner of the Subject CHFW Equity Securities, and not, in the case of each Other CHFW Shareholder in such Other
CHFW Shareholder&#146;s capacity as a director, officer or employee of any CHFW Party, and (b)&nbsp;nothing herein will be construed to limit or affect any action or inaction by each Other CHFW Shareholder or any representative of the Sponsor
serving&nbsp;as a member of the board of directors (or other similar governing body) of any CHFW Party or as an officer, employee or fiduciary of any CHFW Party, in each case, acting in such person&#146;s capacity as a director, officer, employee or
fiduciary of such CHFW Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12. <U>No Third Party Beneficiaries</U>.&nbsp;This Agreement shall be for the sole benefit of the Parties
and their respective successors and permitted assigns and is not intended, nor shall be construed, to give any Person, other than the Parties and their respective successors and assigns, any legal or equitable right, benefit or remedy of any nature
whatsoever by reason this Agreement. Nothing in this Agreement, expressed or implied, is intended to or shall constitute the Parties, partners or participants in a joint venture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">13. <U>Incorporation by Reference</U>. Sections 8.1 <FONT STYLE="white-space:nowrap">(Non-Survival),</FONT> 8.2 (Entire Agreement;
Assignment), 8.3 (Amendment), 8.5 (Governing Law), 8.7 (Constructions; Interpretation), 8.10 (Severability), 8.11 (Counterparts; Electronic Signatures), 8.15 (Waiver of Jury Trial), 8.16 (Submission to Jurisdiction) and 8.17 (Remedies) of the
Business Combination Agreement are incorporated herein and shall apply to this Agreement <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">14. <U>Effect of
Headings</U>. The section headings herein are for convenience only and shall not affect the construction of interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[signature page follows] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, each of the Parties has caused this Agreement to be duly executed
on its behalf as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION
CORP.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>SURROZEN, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>CONSONANCE LIFE SCIENCES</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Title:</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Christopher Haqq</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jennifer Jarrett</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Donald Santel</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE I </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ownership </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF
INVESTORS&#146; RIGHTS AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>T<SMALL>HIS</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (this &#147;<B><I>Agreement</I></B>&#148;) is dated as of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]<SUP
STYLE="font-size:85%; vertical-align:top">1</SUP>, 2021, and is by and among Surrozen, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;) (formerly named <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp.),
Consonance Life Sciences, a Cayman Islands limited liability company (the &#147;<B><I>Sponsor</I></B>&#148;), the persons and entities listed on <B>E<SMALL>XHIBIT</SMALL> A</B> (together with their Permitted Transferees that become party hereto,
each, a &#147;<B><I>Named</I></B> <B><I>Investor</I></B>&#148;) and the persons and entities listed on <B>E<SMALL>XHIBIT</SMALL> B</B> (together with their Permitted Transferees that become party hereto, each, an &#147;<B><I>Individual
Investor</I></B>&#148;, and collectively with the Named Investors, the &#147;<B><I>Investors</I></B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company, Perseverance Merger Sub, Inc., a Delaware corporation (the &#147;<B><I>Merger Sub</I></B>&#148;), and Surrozen Holdings,
Inc. (formerly named Surrozen, Inc. (&#147;<B><I>Surrozen</I></B>&#148;) have entered into that certain Business Combination Agreement, dated as of April [&nbsp;&nbsp;&nbsp;&nbsp;], 2021 (as amended, modified and/or supplemented from time to time,
the &#147;<B><I>BCA</I></B>&#148;), pursuant to which, among other things, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, became a wholly-owned subsidiary of
the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the BCA, the Company, the Sponsor and the Investors have agreed to enter into this Agreement concurrently with
the Closing (as defined in the BCA), pursuant to which, among other things, the Investors (a)&nbsp;will agree not to effect any sale or distribution of any Equity Securities (as defined in the BCA) of the Company held by any of them during the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period described therein, and (b)&nbsp;will be granted certain registration rights with respect to their respective CHFW Shares (as defined in the BCA), in each case, on the terms and subject to the
conditions of this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company, the Sponsor, the Consonance Investors and certain other Investors are party to that certain
Registration and Shareholder Rights Agreement, dated as of November&nbsp;18, 2020 (the &#147;<B><I>Original Agreement</I></B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to Section&nbsp;6.8 of the Original Agreement, the provisions, covenants and conditions set forth therein may be amended or modified
upon the written consent of the Company and the Holders (as defined in the Original Agreement) of at least a majority in interest of the Registrable Securities (as defined in the Original Agreement) at the time in question, and the Sponsor, the
Consonance Investors and such other Investors are Holders in the aggregate of all of the Registrable Securities as of the date hereof; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company, the Sponsor and certain of the Named Investors desire to amend and restate the Original Agreement in its entirety and enter into
this Agreement, pursuant to which the Company shall grant the Holders certain registration rights with respect to certain securities of the Company, as set forth in this Agreement, and terminate the Original Agreement. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">NTD: Closing date of BCA. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company and the other parties to this Agreement therefore agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>1.1</B> <B>Certain Definitions</B>. As used in this Agreement, the following terms shall have the meanings set forth below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> &#147;<B><I>Affiliate</I></B>&#148; means, (i)&nbsp;with respect to any specified Person that is not a natural person, (a)&nbsp;any
other Person which directly or indirectly through one or more intermediaries controls, or is controlled by, or is under common control with, such specified Person, and (b)&nbsp;any corporation, trust, limited liability company, general or limited
partnership or other entity advised or managed by, or under common control or management with, such Person (for the purposes of this definition, &#147;control&#148; (including, with correlative meanings, the terms &#147;controlling,&#148;
&#147;controlled by&#148; and &#147;under common control with&#148;), as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such Person,
whether through the ownership of voting securities, by agreement or otherwise) and (ii)&nbsp;with respect to any natural person, any Member of the Immediate Family of such natural person, or any Person that is, directly or indirectly, controlled by
such specified natural person; <I>provided</I> that the Company and each of its subsidiaries shall be deemed not to be Affiliates of any Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> &#147;<B><I>Commission</I></B>&#148; shall mean the Securities and Exchange Commission or any other federal agency at the time
administering the Securities Act (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> &#147;<B><I>Common Stock</I></B>&#148; shall mean the Common Stock of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> &#147;<B><I>Consonance Investors</I></B>&#148; shall mean those Named Investors on Exhibit A under the heading
&#147;Consonance Investors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> &#147;<B><I>Consonance Holders</I></B>&#148; means, as of any determination time, Consonance
Investors who hold Registrable Securities under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B> &#147;<B><I>Exchange Act</I></B>&#148; shall mean the
Securities Exchange Act of 1934, as amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g)</B> &#147;<B><I>Holder</I></B>&#148; shall mean any Investor who holds Registrable Securities and any holder of Registrable Securities
to whom the registration rights conferred by this Agreement have been duly and validly transferred in accordance with Section&nbsp;3.2 of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(h)</B> <B><I>&#147;Form <FONT STYLE="white-space:nowrap">S-1</FONT> Shelf&#148; </I></B>shall have the meaning given in
<U>Section</U><U></U><U>&nbsp;2.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> <B><I>&#147;Form <FONT STYLE="white-space:nowrap">S-3</FONT> Shelf&#148; </I></B>shall
have the meaning given in <U>Section</U><U></U><U>&nbsp;2.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(j)</B> &#147;<B><I>Indemnified Party</I></B>&#148; shall have the
meaning set forth in Section&nbsp;2.6(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(k)</B> &#147;<B><I>Indemnifying Party</I></B>&#148; shall have the meaning set forth in
Section&nbsp;2.6(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(l)</B> &#147;<B><I>Individual Investor</I></B>&#148; shall have the meaning set forth in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(m)</B> &#147;<B><I>Individual Investor Shares</I></B>&#148; means all shares of Common Stock originally issued to, or issued with respect
to shares originally issued to, or held by, an Individual Investor, whenever issued, including all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
shares of Common Stock issued upon the exercise, conversion or exchange of any options, warrants or convertible securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(n)</B> &#147;<B><I>Individual Holders</I></B>&#148; means, as of any determination time, Individual Investors who hold Registrable
Securities under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(o)</B> &#147;<B><I>Permitted Transferee</I></B>&#148; shall mean with respect to each Holder and its
Permitted Transferees, (a)&nbsp;prior to the expiration of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, any person or entity to whom such Holder is permitted to transfer such Registrable Securities prior to the expiration of the <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Period pursuant to <U>Section</U><U></U><U>&nbsp;2.11</U> and (b)&nbsp;after the expiration of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, any person or entity to whom such Holder is
permitted to transfer such Registrable Securities, subject to and in accordance with any applicable agreement between such Holder and/or its Permitted Transferees and the Company and any transferee thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(p)</B> &#147;<B><I>PIPE Securities</I></B>&#148; shall mean the shares of Common Stock and warrants (including shares of Common Stock
issued or issuable upon exercise or conversion of such warrants) issued in the PIPE Financing (as defined in the BCA). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(q)</B>
&#147;<B><I>Qualified Holders</I></B>&#148; shall mean the Sponsor or any Consonance Holder or Consonance Holders who in the aggregate hold not less than [_]% of the outstanding Registrable Securities or any Surrozen Holder or Surrozen Holders who
in the aggregate hold not less than [_]% of the outstanding Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(r)</B> &#147;<B>Other Selling
Stockholders</B>&#148; shall mean persons other than Holders who, by virtue of agreements with the Company, are entitled to include their Other Shares in certain registrations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(s)</B> &#147;<B>Other Shares</B>&#148; shall mean shares of Common Stock, other than Registrable Securities (as defined below), with
respect to which registration rights have been granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(t)</B> &#147;<B><I>Registrable Securities</I></B>&#148; shall mean
(i)&nbsp;any outstanding shares of Common Stock and any other equity security (including shares of Common Stock issued or issuable upon the exercise or conversion of any other equity security and including, for the avoidance of doubt, the PIPE
Securities), (ii) any outstanding shares of Common Stock or any other equity security (including warrants to purchase shares of Common Stock and shares of Common Stock issued or issuable upon the exercise or conversion of any other equity security)
of the Company acquired by an Investor following the date hereof to the extent that such securities are &#147;restricted securities&#148; (as defined in Rule 144) or are otherwise held by an &#147;affiliate&#148; (as defined in Rule 144) of the
Company and (iii)&nbsp;any other equity security of the Company or any of its subsidiaries issued or issuable with respect to any securities referenced in clause (i)&nbsp;or (ii) above as a dividend or other distribution with respect thereto or in
exchange therefor or in replacement thereof; <I>provided, however</I>, that Registrable Securities shall not include any shares of Common Stock described in clause (i), (ii) or (iii)&nbsp;above for which (a)&nbsp;a registration statement with
respect to the sale of such shares of Common Stock has become effective under the Securities Act and such shares have been sold, transferred, disposed of or exchanged in accordance with such registration statement by the applicable Investor,
(b)&nbsp;such shares have been sold to the public pursuant to Rule 144 (but with no volume or manner of sale or current public information requirement) or (c)&nbsp;such shares have been sold to, or through, a broker, dealer or underwriter in a
public distribution or other public securities transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(u)</B> The terms &#147;register,&#148; &#147;registered&#148; and
&#147;registration&#148; shall refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act (as defined below) and applicable rules and regulations thereunder, and the declaration or
ordering of the effectiveness of such registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v)</B> &#147;<B><I>Registration Expenses</I></B>&#148; shall mean all
expenses incurred in effecting any registration pursuant to this Agreement, including, without limitation, all registration, qualification, and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company,
reasonable documented fees and disbursements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of one special counsel for the Named Holders not to exceed $75,000 without the consent of the Company, blue sky fees and expenses, and expenses of any regular or special audits incident to or
required by any such registration, but shall not include Selling Expenses, and the compensation of regular employees of the Company, which shall be paid in any event by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(w)</B> <B>&#147;</B><B><I>Registration Statement</I></B>&#148; means any registration statement of the Company filed with, or to be filed
with, the SEC under the Securities Act, including the related prospectus, amendments and supplements to such registration statement, including <FONT STYLE="white-space:nowrap">pre-</FONT> and post-effective amendments, and all exhibits and all
material incorporated by reference in such registration statement other than a registration statement (and related Prospectus) filed on Form <FONT STYLE="white-space:nowrap">S-4</FONT> or Form <FONT STYLE="white-space:nowrap">S-8</FONT> or any
successor form thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(x)</B> &#147;<B><I>Restated Certificate</I></B>&#148; shall mean the Company&#146;s Amended and Restated
Certificate of Incorporation, as the same may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(y)</B> &#147;<B><I>Restricted Securities</I></B>&#148;
shall mean any Registrable Securities that were not issued to an Investor pursuant to an effective registration statement in accordance with the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(z)</B> &#147;<B><I>Rule 144</I></B>&#148; shall mean Rule 144 as promulgated by the Commission under the Securities Act, as such Rule may
be amended from time to time, or any similar successor rule that may be promulgated by the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(aa)</B> &#147;<B><I>Rule
145</I></B>&#148; shall mean Rule 145 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(bb)</B> &#147;<B><I>Rule 415</I></B>&#148; shall mean Rule 415 as promulgated by the Commission under the Securities Act, as such Rule may
be amended from time to time, or any similar successor rule that may be promulgated by the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(cc)</B> &#147;<B><I>Securities
Act</I></B>&#148; shall mean the Securities Act of 1933, as amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(dd)</B> &#147;<B><I>Selling Expenses</I></B>&#148; shall mean all underwriting discounts, selling commissions and stock transfer taxes
applicable to the sale of Registrable Securities and fees and disbursements of counsel for any Holder (other than the fees and disbursements of one special counsel to the Holders included in Registration Expenses). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ee)</B> <B><I>&#147;Shelf Registration&#148; </I></B>shall mean a registration of securities pursuant to a registration statement filed
with the Commission in accordance with and pursuant to Rule 415 promulgated under the Securities Act (or any successor rule then in effect). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ff)</B> <B><I>&#147;Shelf Takedown&#148; </I></B>shall mean an Underwritten Shelf Takedown or any proposed transfer or sale using a
Registration Statement, including a Piggyback Registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(gg)</B> &#147;<B><I>Surrozen Holders</I></B>&#148; means, as of any
determination time, Surrozen Investors who hold Registrable Securities under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(hh)</B> &#147;<B><I>Surrozen
Investors</I></B>&#148; shall mean those Named Investors on Exhibit A under the heading &#147;Surrozen Investors.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.1</B> <B>Requested Registration</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B><I>Filing</I></B>. Within thirty (30)&nbsp;days following the Closing Date, the Company shall file with the Commission a
Registration Statement for a Shelf Registration on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (the <B><I>&#147;Form <FONT STYLE="white-space:nowrap">S-1</FONT> Shelf&#148;</I></B>)<B><I> </I></B>or a Registration Statement for a Shelf
Registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (the <B><I>&#147;Form <FONT STYLE="white-space:nowrap">S-3</FONT> Shelf&#148;</I></B>),<B><I> </I></B>if the Company is then eligible to use a Form
<FONT STYLE="white-space:nowrap">S-3</FONT> Shelf, in each case, covering the resale of all the Registrable Securities (determined as of two (2)&nbsp;business days prior to such submission or filing) on a delayed or continuous basis and shall use
its commercially reasonable efforts to have such Shelf declared effective as soon as practicable after the filing thereof, but no later than the earlier of (a)&nbsp;sixty (60) calendar days (or ninety (90)&nbsp;calendar days if the Commission
notifies the Company that it will &#147;review&#148; such Shelf Registration) following the initial filing date thereof and (b)&nbsp;ten (10) business days after the Company is notified (orally or in writing, whichever is earlier) by the SEC that
such Shelf Registration will not be &#147;reviewed&#148; or will not be subject to further review. Such Shelf shall provide for the resale of the Registrable Securities included therein pursuant to any method or combination of methods legally
available (the <B><I>&#147;Plan of Distribution&#148;) </I></B>to, and requested by, any Holder named therein. The Company shall engage an underwriter or underwriters reasonably acceptable to the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the Registerable Securities to participate in the preparation of the Shelf to enable the Holders to resell Registrable Securities pursuant to the Plan of Distribution. The Company
shall maintain a Shelf in accordance with the terms hereof, and shall prepare and file with the Commission such amendments, including post-effective amendments, and supplements as may be necessary to keep a Shelf continuously effective, available
for use to permit the Holders named therein to sell their Registrable Securities included therein and in compliance with the provisions of the Securities Act until such time as there are no longer any Registrable Securities. In the event the Company
files a Form <FONT STYLE="white-space:nowrap">S-1</FONT> Shelf, the Company shall use its commercially reasonable efforts to convert the Form <FONT STYLE="white-space:nowrap">S-1</FONT> Shelf (and any Subsequent Shelf Registration Statement) to a
Form <FONT STYLE="white-space:nowrap">S-3</FONT> Shelf as soon as practicable after the Company is eligible to use a Form <FONT STYLE="white-space:nowrap">S-3</FONT> Shelf. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B><I>Reserved</I></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B><I>Subsequent Shelf Registration</I></B><B>.</B> If any Shelf ceases to be effective under the Securities Act for any reason at
any time while Registrable Securities are still outstanding, upon the written request from a Qualified Holder, the Company shall, subject to <U>Section</U><U></U><U>&nbsp;2.1(e)</U>, use its commercially reasonable efforts to as promptly as
practicable cause such Shelf to again become effective under the Securities Act (including using its commercially reasonable efforts to obtain the prompt withdrawal of any order suspending the effectiveness of such Shelf), and shall use its
commercially reasonable efforts to as promptly as is reasonably practicable amend such Shelf in a manner reasonably expected to result in the withdrawal of any order suspending the effectiveness of such Shelf or file an additional registration
statement as a Shelf Registration (a <B><I>&#147;Subsequent Shelf Registration Statement&#148;) </I></B>registering the resale of all Registrable Securities (determined as of two (2)&nbsp;business days prior to such filing), and pursuant to the Plan
of Distribution. The Company shall engage an underwriter or underwriters reasonably acceptable to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the Registerable Securities to participate
in the preparation of the Subsequent Shelf Registration Statement to enable the Holders to resell Registrable Securities pursuant to the Plan of Distribution. If a Subsequent Shelf Registration Statement is filed, the Company shall use its
commercially reasonable efforts to (i)&nbsp;cause such Subsequent Shelf Registration Statement to become effective under the Securities Act as promptly as is reasonably practicable after the filing thereof and (ii)&nbsp;keep such Subsequent Shelf
Registration Statement continuously effective, available for use to permit the Holders named therein to sell their Registrable Securities included therein and in compliance with the provisions of the Securities Act until such time as there are no
longer any Registrable Securities. Any such Subsequent Shelf Registration Statement shall be on Form <FONT STYLE="white-space:nowrap">S-3</FONT> to the extent that the Company is eligible to use such form. Otherwise, such Subsequent Shelf
Registration Statement shall be on another appropriate form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> <B><I>Additional Registrable Securities</I></B>. Subject to
<U>Section</U><U></U><U>&nbsp;2.1(e),</U> in the event that any Holder holds Registrable Securities that are not registered for resale on a delayed or continuous basis, the Company, upon </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
written request of such Holder, shall promptly use its commercially reasonable efforts to cause the resale of such Registrable Securities to be covered by either, at the Company&#146;s option,
any then available Shelf (including by means of a post-effective amendment) or by filing a Subsequent Shelf Registration Statement and cause the same to become effective as soon as practicable after such filing and such Shelf or Subsequent Shelf
Registration Statement shall be subject to the terms hereof; <U>provided</U>, <U>however</U>, that the Company shall only be required to cause such additional Registrable Securities to be so covered two per calendar year for each Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> <B><I>Deferral</I></B>. If (i)&nbsp;in the good faith judgment of the Board of Directors of the Company, the filing of a
registration statement covering the Registrable Securities would be materially detrimental to the Company and the Board of Directors of the Company concludes, as a result, that it is in the best interests of the Company to defer the filing of such
registration statement at such time, and (ii)&nbsp;the Company shall furnish to such Holders a certificate signed by the President of the Company stating that in the good faith judgment of the Board of Directors of the Company, it would be
materially detrimental to the Company for such registration statement to be filed in the near future and that it is, therefore, in the best interests of the Company to defer the filing of such registration statement (which notice shall not specify
the nature of the event giving rise to such delay or suspension), then (in addition to the limitations set forth in Section&nbsp;2.1(b)(v) above) the Company shall have the right to defer such filing for the shortest period of time determined in
good faith by the Company to be necessary for such purpose, but in no event for a period of more than ninety (90)&nbsp;days following such good faith determination by the Board of Directors of the Company, and, provided further, that the Company
shall not defer its obligation in this manner more than two (2)&nbsp;times in any twelve-month period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B>
<B><I>Underwriting</I></B>. At any time and from time to time when an effective Shelf is on file with the Commission, a Qualified Holder or Qualified Holders (an &#147;<B><I>Initiating Holder</I></B>&#148; or &#147;<B><I>Initiating
Holders</I></B><I>&#148;</I>) may request to sell all or any portion of its Registrable Securities by means of an underwriting that is registered pursuant to the Shelf (each, an &#147;<B><I>Underwritten Shelf Takedown</I></B>&#148;);<B><I>
</I></B><U>provided</U> that the Company shall only be obligated to effect an Underwritten Shelf Takedown if such offering shall include Registrable Securities proposed to be sold by the Initiating Holder, either individually or together with other
Initiating Holders, with a total offering price reasonably expected to exceed, in the aggregate, at least $[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] million (the <B><I>&#147;Minimum Takedown Threshold&#148;)</I></B>.
The Company shall not be required to effect more than [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] Underwritten Shelf Takedowns for the Consonance Holders or more than
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] for the Surrozen Holders. All requests for Underwritten Shelf Takedowns shall be made by giving written notice to the Company, which shall specify the approximate number of
Registrable Securities proposed to be sold in the Underwritten Shelf Takedown. If the Company shall request inclusion in any underwriting pursuant to this Section&nbsp;2.1(f) of securities being sold for its own account, or if other persons shall
request inclusion in such underwriting, the Initiating Holders shall, on behalf of all Holders, offer to include such securities in the underwriting and such offer shall be conditioned upon the participation of the Company or such other persons in
such underwriting and the inclusion of the Company&#146;s and such person&#146;s other securities of the Company and their acceptance of the further applicable provisions of this Section&nbsp;2 (including Section&nbsp;2.10). The Initiating Holders
shall (together with all Holders and other persons proposing to distribute their securities through such underwriting) enter into an underwriting agreement in customary form with the representative of the underwriter or underwriters selected for
such underwriting by the Initiating Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding any other provision of this Section&nbsp;2.1, if the Initiating Holders are
(A)&nbsp;Consonance Holders and the underwriters advise such Initiating Holders in good faith in writing that marketing factors require a limitation on the number of shares to be underwritten, the number of Registrable Securities that may be so
included shall be allocated as follows: (i)&nbsp;first, among all Consonance Holders requesting to include Registrable Securities in such registration statement based on the <I>pro rata</I> percentage of Registrable Securities held by such
Consonance Holders; (ii)&nbsp;second, to Surrozen Holders based on the <I>pro rata</I> percentage of Registrable Securities held by such Surrozen Holders; (iii)&nbsp;third, to the other Holders based on the <I>pro rata</I> percentage of Registrable
Securities held by such Holders; and (iii)&nbsp;fourth, to the Company, which the Company may allocate, at its discretion, for its own account, or for the account of other holders or employees of the Company or (B)&nbsp;Surrozen Holders and the
underwriters advise such Initiating Holders in good faith in writing that marketing factors require </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
a limitation on the number of shares to be underwritten, the number of Registrable Securities that may be so included shall be allocated as follows: (i)&nbsp;first, among all Surrozen Holders
requesting to include Registrable Securities in such registration statement based on the <I>pro rata</I> percentage of Registrable Securities held by such Surrozen Holders; (ii)&nbsp;second, to Consonance Holders based on the <I>pro rata</I>
percentage of Registrable Securities held by such Consonance Holders; (iii)&nbsp;third, to the other Holders based on the <I>pro rata</I> percentage of Registrable Securities held by such Holders; and (iii)&nbsp;fourth, to the Company, which the
Company may allocate, at its discretion, for its own account, or for the account of other holders or employees of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a
person who has requested inclusion in such registration as provided above does not agree to the terms of any such underwriting, such person shall be excluded therefrom by written notice from the Company, the underwriter or the Initiating Holders.
The securities so excluded shall also be withdrawn from registration. Any Registrable Securities or other securities excluded or withdrawn from such underwriting shall also be withdrawn from such registration. If shares are so withdrawn from the
registration and if the number of shares to be included in such registration was previously reduced as a result of marketing factors pursuant to this Section&nbsp;2.1(d), then the Company shall then offer to all Holders and Other Selling
Stockholders who have retained rights to include securities in the registration the right to include additional Registrable Securities or Other Shares in the registration in an aggregate amount equal to the number of shares so withdrawn, with such
shares to be allocated among such Holders and Other Selling Stockholders requesting additional inclusion, as set forth above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.2</B>
<B>Company Registration</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B><I>Company Registration</I></B>. If the Company or any Holder proposes to conduct a registered
offering, or if the Company proposes to register any of its securities either for its own account or the account of a security holder or holders (or by the Company and by the stockholders of the Company including, without limitation, an Underwritten
Shelf Takedown pursuant to <U>Section</U><U></U><U>&nbsp;2.1(f)</U>), other than a Registration Statement (or any registered offering with respect thereto)&nbsp;(i) filed in connection with any employee stock option or other benefit plan,
(ii)&nbsp;pursuant to a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> (or similar form that relates to a transaction subject to Rule 145 under the Securities Act or any successor rule thereto), (iii) for an offering of
debt that is convertible into equity securities of the Company, (iv)&nbsp;for a dividend reinvestment plan, (v)&nbsp;a Block Trade or (vi)&nbsp;an Other Coordinated Offering, the Company will: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> give written notice of the proposed registration to all Holders of Registrable Securities as soon as practicable
but not less than ten (10)&nbsp;days before the anticipated filing date of such Registration Statement or, in the case of an Underwritten Offering pursuant to a Shelf Registration, the applicable &#147;red herring&#148; prospectus or prospectus
supplement used for marketing such offering, which notice shall (A)&nbsp;describe the amount and type of securities to be included in such offering, the intended method(s) of distribution, and the name of the proposed managing Underwriter or
Underwriters, if any, in such offering, and (B)&nbsp;offer to all of the Holders of Registrable Securities the opportunity to include in such registered offering such number of Registrable Securities as such Holders may request in writing within
five (5)&nbsp;days after receipt of such written notice (such registered offering, a <B><I>&#147;Piggyback Registration&#148;)</I></B>; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> include, or, if applicable, use its commercially reasonable efforts to cause the managing Underwriter or
Underwriters of such Piggyback Registration to include, in such registration (and any related qualification under blue sky laws or other compliance), except as set forth in Section&nbsp;2.2(b) below, in any underwriting involved therein, and to
permit the sale or other disposition of such Registrable Securities in accordance with the intended method(s) of distribution thereof, all of such Registrable Securities as are specified in a written request or requests made by any Holder or Holders
received by the Company within ten (10)&nbsp;days after such written notice from the Company is mailed or delivered. Such written request may specify all or a part of a Holder&#146;s Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B><I>Underwriting</I></B>. If the registration of which the Company gives notice is for a registered public offering involving an
underwriting, the Company shall so advise the Holders as a part of the written notice given </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
pursuant to Section&nbsp;2.2(a)(i). In such event, the right of any Holder to registration pursuant to this Section&nbsp;2.2 shall be conditioned upon such Holder&#146;s participation in such
underwriting and the inclusion of such Holder&#146;s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company and the
other holders of securities of the Company with registration rights to participate therein distributing their securities through such underwriting) enter into an underwriting agreement in customary form with the representative of the underwriter or
underwriters selected by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding any other provision of this Section&nbsp;2.2, if the underwriters advise the
Company in writing that marketing factors require a limitation on the number of shares to be underwritten, the underwriters may (subject to the limitations set forth below) exclude all Registrable Securities from, or limit the number of Registrable
Securities to be included in, the registration and underwriting. The Company shall so advise all holders of securities requesting registration, and the number of shares of securities that are entitled to be included in the registration and
underwriting shall be allocated, as follows: (i)&nbsp;first, to the Company for securities being sold for its own account, (ii)&nbsp;second, to the Holders requesting to include Registrable Securities in such registration statement based on the
<I>pro rata</I> percentage of Registrable Securities held by such Holders, assuming conversion and (iii)&nbsp;third, to the other Other Selling Stockholders requesting to include Other Shares in such registration statement based on the <I>pro
rata</I> percentage of Other Shares held by such Other Selling Stockholders, assuming conversion. Notwithstanding the foregoing, no such reduction shall reduce the value of the Registrable Securities of the Holders included in such registration
below twenty five percent (25%) of the total value of securities included in such registration, unless such registration does not include shares of any Other Selling Stockholders (excluding shares registered for the account of the Company), in which
event any or all of the Registrable Securities of the Holders may be excluded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a person who has requested inclusion in such
registration as provided above does not agree to the terms of any such underwriting, such person shall also be excluded therefrom by written notice from the Company or the underwriter. The Registrable Securities or other securities so excluded shall
also be withdrawn from such registration. Any Registrable Securities or other securities excluded or withdrawn from such underwriting shall be withdrawn from such registration. If shares are so withdrawn from the registration and if the number of
shares of Registrable Securities to be included in such registration was previously reduced as a result of marketing factors pursuant to Section&nbsp;2.2(b), the Company shall then offer to all persons who have retained the right to include
securities in the registration the right to include additional securities in the registration in an aggregate amount equal to the number of shares so withdrawn, with such shares to be allocated among the persons requesting additional inclusion, in
the manner set forth above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B><I>Right to Terminate Registration</I></B>. The Company shall have the right to terminate or
withdraw any registration initiated by it under this Section&nbsp;2.2 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. The Registration Expenses of any such terminated
or withdrawn registration shall be borne by the Company, any Piggyback Registration effected pursuant to this Section&nbsp;2.2 shall not be counted as an Underwritten Shelf Takedown under Section&nbsp;2.1(f). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.3</B> <B><I>Block Trades; Other Coordinated Offerings</I></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> Notwithstanding any other provision of this <U>Article II,</U> at any time and from time to time when an effective Shelf is on file
with the Commission, if an Initiating Holder notifies the Company that such Initiating Holder wishes to engage in (a)&nbsp;an underwritten registered offering not involving a &#147;roadshow,&#148; an offer commonly known as a &#147;block trade&#148;
(a <B><I>&#147;Block Trade&#148;), </I></B>or (b)&nbsp;an &#147;at the market&#148; or similar registered offering through a broker, sales agent or distribution agent, whether as agent or principal (an <B><I>&#147;Other Coordinated Offering&#148;),
</I></B>in each case, (x)&nbsp;with a total offering price reasonably expected to exceed $[__] million in the aggregate or (y)&nbsp;with respect to all remaining Registrable Securities held by the Initiating Holder, then such Initiating Holder only
needs to notify the Company of the Block Trade or Other Coordinated Offering at least five (5)&nbsp;business days prior to the day such offering is to commence and the Company shall, use its reasonable
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
best efforts to facilitate as expeditiously as possible, such Block Trade or Other Coordinated Offering of the Registrable Securities for which such Initiating Holder has requested such offering,
without giving any effect to any required notice periods or delivery of notices to any other Holders; <U>provided,</U> that the Initiating Holders representing a majority of the Registrable Securities wishing to engage in the Block Trade or Other
Coordinated Offering shall use reasonable best efforts to work with the Company and any Underwriters, brokers, sales agents or placement agents prior to making such request in order to facilitate preparation of the registration statement, prospectus
and other offering documentation related to the Block Trade or Other Coordinated Offering. Any offering conducted as a Block Trade or Other Coordinated Offering will not count as an Underwritten Shelf Takedown for the purposes of
Section&nbsp;2.1(f). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> Prior to the filing of the applicable &#147;red herring&#148; prospectus or prospectus supplement used in
connection with a Block Trade or Other Coordinated Offering, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the Initiating Holders initiating such Block Trade or Other Coordinated Offering
shall have the right to submit a Withdrawal Notice to the Company, the Underwriter or Underwriters (if any) and any brokers, sales agents or placement agents (if any) of their intention to withdraw from such Block Trade or Other Coordinated
Offering. Notwithstanding anything to the contrary in this Agreement, the Company shall be responsible for the Registration Expenses incurred in connection with a Block Trade or Other Coordinated Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> Notwithstanding anything to the contrary in this Agreement, <U>Section</U><U></U><U>&nbsp;2.2 </U>shall not apply to a Block Trade
or Other Coordinated Offering initiated by an Initiating Holder pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> The Initiating Holder in a Block
Trade or Other Coordinated Offering shall have the right to select the Underwriters and any brokers, sales agents or placement agents (if any) for such Block Trade or Other Coordinated Offering (in each case, which shall consist of one or more
reputable nationally recognized investment banks). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.4</B> <B>Expenses of Registration</B>. All Registration Expenses incurred in
connection with registrations pursuant to Sections 2.1, 2.2 and 2.3 shall be borne by the Company; <I>provided, however</I>, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Sections 2.1
and 2.3 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered or because a sufficient number of Holders shall have withdrawn so that the minimum offering
conditions set forth in Sections 2.1 and 2.3 are no longer satisfied (in which case all participating Holders shall bear such expenses <I>pro rata</I> among each other based on the number of Registrable Securities requested to be so registered),
unless the Holders of a majority of the Registrable Securities agree to forfeit their right to a demand registration pursuant to Section&nbsp;2.1; <I>provided, however</I>, in the event that a withdrawal by the Holders is based upon material adverse
information relating to the Company that is different from the information known or available (upon request from the Company or otherwise) to the Holders requesting registration at the time of their request for registration under Section&nbsp;2.1,
such registration shall not be treated as a counted registration for purposes of Section&nbsp;2.1, even though the Holders do not bear the Registration Expenses for such registration. All Selling Expenses relating to securities registered on behalf
of the Holders shall be borne by the holders of securities included in such registration <I>pro rata</I> among each other on the basis of the number of Registrable Securities so registered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.5</B> <B>Registration Procedures</B>. In the case of each registration effected by the Company pursuant to Section&nbsp;2, the Company
will keep each Holder advised in writing as to the initiation of each registration and as to the completion thereof. Without limiting anything else in this Agreement, at its expense, the Company will use its commercially reasonable efforts to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> Keep such registration continuously effective available for use to permit the Holders named therein to sell their Registrable
Securities included therein and in compliance with the provisions of the Securities Act until such time as there are no longer any Registrable Securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> Prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus used in
connection with such registration statement as may be necessary to comply </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement for the period set forth in subsection (a)&nbsp;above; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> Furnish such number of prospectuses, including any preliminary prospectuses, and other documents incident thereto, including any
amendment of or supplement to the prospectus, as a Holder from time to time may reasonably request; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> Use its reasonable best
efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdiction as shall be reasonably requested by the Holders; <I>provided</I>, that the Company shall not be
required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> At least five (5)&nbsp;days prior to the filing of any registration or any amendment or supplement to such registration (or such
shorter period of time as may be (a)&nbsp;necessary in order to comply with the Securities Act, the Exchange Act, and the rules and regulations promulgated under the Securities Act or Exchange Act, as applicable or (b)&nbsp;advisable in order to
reduce the number of days that sales are suspended pursuant to Section&nbsp;2.11), furnish a copy thereof to each seller of such Registrable Securities or its counsel (excluding any exhibits thereto and any filing made under the Exchange Act that is
to be incorporated by reference therein); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B> Notify each seller of Registrable Securities covered by such registration statement
at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue
statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing, and following such notification
promptly prepare and furnish to such seller a reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such shares, such prospectus shall not include
an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g)</B> In the event of an Underwritten Offering, a Block Trade, an Other Coordinated Offering, or sale by a broker, placement agent or
sales agent pursuant to such Registration, in each of the following cases to the extent customary for a transaction of its type, permit a representative of the Holders, the Underwriters or other financial institutions facilitating such Underwritten
Offering, Block Trade, Other Coordinated Offering or other sale pursuant to such registration, if any, and any attorney, consultant or accountant retained by such Holders or Underwriter to participate, at each such person&#146;s or entity&#146;s own
expense, in the preparation of the registration statement, and cause the Company&#146;s officers, directors and employees to supply all information reasonably requested by any such representative, Underwriter, financial institution, attorney,
consultant or accountant in connection with the registration; provided, however, that such representatives, Underwriters or financial institutions agree to confidentiality arrangements in form and substance reasonably satisfactory to the Company,
prior to the release or disclosure of any such information; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(h)</B> Obtain a &#147;comfort&#148; letter from the Company&#146;s
independent registered public accountants in the event of an Underwritten Offering, a Block Trade, an Other Coordinated Offering or sale by a broker, placement agent or sales agent pursuant to such registration (subject to such broker, placement
agent or sales agent providing such certification or representation reasonably requested by the Company&#146;s independent registered public accountants and the Company&#146;s counsel) in customary form and covering such matters of the type
customarily covered by &#147;comfort&#148; letters for a transaction of its type as the managing Underwriter may reasonably request, and as reasonably satisfactory to a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the participating Holders; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> In the event of an Underwritten Offering, a Block Trade, an Other Coordinated Offering or sale by a broker, placement agent or
sales agent pursuant to such registration, on the date the Registrable Securities are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
delivered for sale pursuant to such registration, to the extent customary for a transaction of its type, obtain an opinion, dated such date, of counsel representing the Company for the purposes
of such registration, addressed to the participating Holders, the broker, placement agents or sales agent, if any, and the Underwriters, if any, covering such legal matters with respect to the registration in respect of which such opinion is being
given as the participating Holders, broker, placement agent, sales agent or Underwriter may reasonably request and as are customarily included in such opinions and negative assurance letters; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(j)</B> In the event of any Underwritten Offering, a Block Trade, an Other Coordinated Offering or sale by a broker, placement agent or
sales agent pursuant to such registration, enter into and perform its obligations under an underwriting or other purchase or sales agreement, in usual and customary form, with the managing Underwriter or the broker, placement agent or sales agent of
such offering or sale; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(k)</B> Make available to its security holders, as soon as reasonably practicable, an earnings statement
covering the period of at least twelve (12)&nbsp;months beginning with the first day of the Company&#146;s first full calendar quarter after the effective date of the registration statement which satisfies the provisions of Section&nbsp;11(a) of the
Securities Act and Rule 158 thereunder (or any successor rule then in effect); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(l)</B> With respect to an Underwritten Offering
pursuant to Section&nbsp;2.1(f), use its commercially reasonable efforts to make available senior executives of the Company to participate in customary &#147;road show&#148; presentations that may be reasonably requested by the Underwriter in such
Underwritten Offering; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(m)</B> Provide a transfer agent and registrar for all Registrable Securities registered pursuant to such
registration statement and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(n)</B> Advise each seller of Registrable Securities, promptly after it shall receive notice or obtain knowledge thereof, of the issuance
of any stop order by the Commission suspending the effectiveness of any registration or the initiation or threatening of any proceeding for such purpose and promptly use its commercially reasonable efforts to prevent the issuance of any stop order
or to obtain its withdrawal if such stop order should be issued; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(o)</B> Cause all such Registrable Securities registered pursuant
hereunder to be listed on each securities exchange on which similar securities issued by the Company are then listed; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(p)</B> In
connection with any underwritten offering pursuant to a registration statement filed pursuant to Section&nbsp;2.1, enter into an underwriting agreement in form reasonably necessary to effect the offer and sale of Common Stock, <I>provided</I> such
underwriting agreement contains reasonable and customary provisions, and <I>provided further</I>, that each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(q)</B> Otherwise, in good faith, cooperate reasonably with, and take such customary actions as may reasonably be requested by the
participating Holders, consistent with the terms of this Agreement, in connection with such Registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing,
the Company shall not be required to provide any documents or information to an Underwriter, broker, sales agent or placement agent if such Underwriter, broker, sales agent or placement agent has not then been named with respect to the applicable
Underwritten Offering or other offering involving a registration as an Underwriter, broker, sales agent or placement agent, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.6</B> <B>Removal of Restrictive Legends</B>. The Company shall, if requested by the Holder, use its commercially reasonable best efforts
to (i)&nbsp;cause the removal of any restrictive legend related to compliance with the federal securities laws set forth on the Registrable Securities, (ii)&nbsp;cause its legal counsel to deliver an opinion, if
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
necessary, to the transfer agent in connection with the instruction under subclause (i)&nbsp;to the effect that removal of such legends in such circumstances may be effected in compliance under
the Securities Act, and (iii)&nbsp;issue Registrable Securities without any such legend in certificated or book-entry form or by electronic delivery through The Depository Trust Company, at the Holder&#146;s option, within two (2)&nbsp;trading days
of such request, if (A)&nbsp;the Registrable Securities are registered for resale under the Securities Act, (B)&nbsp;the Registrable Securities may be sold by the Holder without restriction under Rule 144, including without limitation, any volume
and manner of sale restrictions, or (C)&nbsp;the Holder has sold or transferred, or proposes to sell or transfer within five (5)&nbsp;Business Days of such request, Registrable Securities pursuant to the Registration Statement or in compliance with
Rule 144. The Company&#146;s obligation to remove legends under this Section&nbsp;2.6 may be conditioned upon the Holder timely providing such representations and documentation as are reasonably necessary and customarily required in connection with
the removal of restrictive legends related to compliance with the federal securities laws. If restrictive legends are no longer required for Registrable Securities pursuant to the foregoing, the Company shall, in accordance with the provisions of
this section and within two (2)&nbsp;trading days of any request therefor from the Investor accompanied by such customary and reasonably acceptable representations and other documentation referred to above establishing that restrictive legends are
no longer required, deliver to the transfer agent irrevocable instructions that the transfer agent shall make a new, <FONT STYLE="white-space:nowrap">non-legended</FONT> entry for such book entry Registrable Securities. The Company shall be
responsible for the fees of its transfer agent and any DTC fees associated with such issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.7</B> <B>Indemnification</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> To the extent permitted by law, the Company will indemnify and hold harmless each Holder, each of its officers, directors, members
and partners, legal counsel and accountants and each person controlling such Holder within the meaning of Section&nbsp;15 of the Securities Act, with respect to which registration, qualification or compliance has been effected pursuant to this
Section&nbsp;2, and each underwriter, if any, and each person who controls within the meaning of Section&nbsp;15 of the Securities Act any underwriter, against all expenses, claims, losses, damages and liabilities (or actions, proceedings or
settlements in respect thereof) arising out of or based on: (i)&nbsp;any untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any prospectus, offering circular, or other document (including any
related registration statement, notification or the like) incident to any such registration, qualification or compliance, (ii)&nbsp;any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to
make the statements therein not misleading, or (iii)&nbsp;any violation (or alleged violation) by the Company of the Securities Act, any state securities laws or any rule or regulation thereunder applicable to the Company and relating to action or
inaction required of the Company in connection with any offering covered by such registration, qualification or compliance, and the Company will reimburse each such Holder, each of its officers, directors, members, partners, legal counsel and
accountants and each person controlling such Holder, each such underwriter and each person who controls any such underwriter, for any legal and any other expenses reasonably incurred in connection with investigating and defending or settling any
such claim, loss, damage, liability or action; <I>provided</I> that the Company will not be liable in any such case to the extent that any such claim, loss, damage, liability, or action arises out of or is based on any untrue statement or omission
based upon written information furnished to the Company by such Holder, any of such Holder&#146;s officers, directors, members, partners, legal counsel or accountants, any person controlling such Holder, such underwriter or any person who controls
any such underwriter, and stated to be specifically for use therein; and <I>provided, further</I> that, the indemnity agreement contained in this Section&nbsp;2.6(a) shall not apply to amounts paid in settlement of any such loss, claim, damage,
liability or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> To the extent permitted by law, each Holder will, if Registrable Securities held by such Holder are included in the securities as
to which such registration, qualification or compliance is being effected, indemnify and hold harmless the Company, each of its directors, officers, partners, legal counsel and accountants and each underwriter, if any, of the Company&#146;s
securities covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of Section&nbsp;15 of the Securities Act, each other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
such Holder, and each of their officers, directors, members and partners, and each person controlling each other such Holder, against all claims, losses, damages and liabilities (or actions in
respect thereof) arising out of or based on: (i)&nbsp;any untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any prospectus, offering circular or other document (including any related
registration statement, notification, or the like) incident to any such registration, qualification or compliance, or (ii)&nbsp;any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make
the statements therein not misleading, and will reimburse the Company and such Holders, officers, directors, members, partners, legal counsel and accountants, persons, underwriters, or control persons for any legal or any other expenses reasonably
incurred in connection with investigating or defending any such claim, loss, damage, liability or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission)
is made in such registration statement, prospectus, offering circular or other document in reliance upon and in conformity with written information furnished to the Company by such Holder and stated to be specifically for use therein; <I>provided,
however</I>, that the obligations of such Holder hereunder shall not apply to amounts paid in settlement of any such claims, losses, damages or liabilities (or actions in respect thereof) if such settlement is effected without the consent of such
Holder (which consent shall not be unreasonably withheld); and <I>provided</I> that in no event shall any indemnity under this Section&nbsp;2.6 exceed the net proceeds from the offering received by such Holder, except in the case of fraud or willful
misconduct by such Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> Each party entitled to indemnification under this Section&nbsp;2.6 (the &#147;<B><I>Indemnified
Party</I></B>&#148;) shall give notice to the party required to provide indemnification (the &#147;<B><I>Indemnifying Party</I></B>&#148;) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought,
and shall permit the Indemnifying Party to assume the defense of such claim or any litigation resulting therefrom; <I>provided</I> that counsel for the Indemnifying Party, who shall conduct the defense of such claim or any litigation resulting
therefrom, shall be approved by the Indemnified Party (whose approval shall not be unreasonably withheld), and the Indemnified Party may participate in such defense at such party&#146;s expense; and <I>provided further</I> that the failure of any
Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Section&nbsp;2.6, to the extent such failure is not prejudicial. No Indemnifying Party, in the defense of any such claim or
litigation, shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified
Party of a release from all liability in respect to such claim or litigation. Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably request in writing and as shall be
reasonably required in connection with defense of such claim and litigation resulting therefrom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> If the indemnification
provided for in this Section&nbsp;2.6 is held by a court of competent jurisdiction to be unavailable to an Indemnified Party with respect to any loss, liability, claim, damage, or expense referred to herein, then the Indemnifying Party, in lieu of
indemnifying such Indemnified Party hereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault
of the Indemnifying Party on the one hand and of the Indemnified Party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable
considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material
fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and the parties&#146; relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. No person or entity
will be required under this Section&nbsp;2.6(d) to contribute any amount in excess of the net proceeds from the offering received by such person or entity, except in the case of fraud or willful misconduct by such person or entity. No person or
entity guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) will be entitled to contribution from any person or entity who was not guilty of such fraudulent misrepresentation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> Notwithstanding the foregoing, to the extent that the provisions on
indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.8</B> <B>Information by Holder</B>. Each Holder of Registrable Securities shall furnish to the Company such information regarding such
Holder and the distribution proposed by such Holder as the Company may reasonably request in writing and as shall be reasonably required in connection with any registration, qualification, or compliance referred to in this Section&nbsp;2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.9</B> <B>Restrictions on Transfer</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> The holder of each certificate representing Registrable Securities by acceptance thereof agrees to comply in all respects with the
provisions of this Section&nbsp;2.8. Each Holder agrees not to make any sale, assignment, transfer, pledge or other disposition of all or any portion of the Restricted Securities, or any beneficial interest therein, unless and until the transferee
thereof has agreed in writing for the benefit of the Company to take and hold such Restricted Securities subject to, and to be bound by, the terms and conditions set forth in this Agreement, including, without limitation, this Section&nbsp;2.8 and
Section&nbsp;2.11, and: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> there is then in effect a registration statement under the Securities Act covering such proposed
disposition and such disposition is made in accordance with such registration statement; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> such Holder shall have given
prior written notice to the Company of the Holder&#146;s intention to make such disposition and shall have furnished the Company with a detailed description of the manner and circumstances of the proposed disposition, and, if requested by the
Company, such Holder shall have furnished the Company, at the Holder&#146;s expense, with (A)&nbsp;an opinion of counsel, reasonably satisfactory to the Company, to the effect that such disposition will not require registration of such Restricted
Securities under the Securities Act or (B)&nbsp;a &#147;no action&#148; letter from the Commission to the effect that the transfer of such securities without registration will not result in a recommendation by the staff of the Commission that action
be taken with respect thereto, whereupon the holder of such Restricted Securities shall be entitled to transfer such Restricted Securities in accordance with the terms of the notice delivered by the Holder to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> Notwithstanding the provisions of Section&nbsp;2.8(a), no such registration statement, opinion of counsel or &#147;no action&#148;
letter shall be necessary for (i)&nbsp;a transfer not involving a change in beneficial ownership, or (ii)&nbsp;transactions involving the distribution without consideration of Restricted Securities by any Holder to (x)&nbsp;a parent, subsidiary or
other affiliate of the Holder, if the Holder is a corporation, (y)&nbsp;any of the Holder&#146;s partners, members or other equity owners, or retired partners, retired members or other equity owners, or to the estate of any of the Holder&#146;s
partners, members or other equity owners or retired partners, retired members or other equity owners, or (z)&nbsp;a venture capital fund that is controlled by or under common control with one or more general partners or managing members of, or
shares the same management company with, the Holder; provided, in each case, that the Holder thereof shall give written notice to the Company of such Holder&#146;s intention to effect such disposition and shall have furnished the Company with a
detailed description of the manner and circumstances of the proposed disposition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> Each certificate representing Restricted
Securities shall (unless otherwise permitted by the provisions of this Agreement) be stamped or otherwise imprinted with a legend substantially similar to the following (in addition to any legend required under applicable state securities laws):
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
&#147;<B><I>ACT</I></B>&#148;), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO
REGISTRATION OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Holders consent to the Company making a notation on its records and giving instructions to any transfer agent of the Restricted Securities
in order to implement the restrictions on transfer established in this Section&nbsp;2.8. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> Each certificate representing
Registrable Securities shall (unless otherwise permitted by the provisions of this Agreement) be stamped or otherwise imprinted with a legend substantially similar to the following (in addition to any legend required under applicable state
securities laws): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE,
INCLUDING A <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> PERIOD IN THE EVENT OF A PUBLIC OFFERING, AS SET FORTH IN AN INVESTORS&#146; RIGHTS AGREEMENT BY AND AMONG THE COMPANY AND THE ORIGINAL HOLDERS OF THESE SHARES, A COPY OF WHICH MAY BE
OBTAINED AT THE PRINCIPAL OFFICE OF THE COMPANY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Holders consent to the Company making a notation on its records and giving
instructions to any transfer agent of the Registrable Securities in order to implement the restrictions on transfer established in this Section&nbsp;2.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> The legend referring to federal and state securities laws identified in Section&nbsp;2.8(c) stamped on a certificate evidencing the
Restricted Securities and the stock transfer instructions and record notations with respect to such Restricted Securities shall be removed and the Company shall issue a certificate without such legend to the holder of such Restricted Securities if
(i)&nbsp;such securities are registered under the Securities Act, or (ii)&nbsp;such holder provides the Company with an opinion of counsel reasonably acceptable to the Company to the effect that a sale or transfer of such securities may be made
without registration or qualification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.10</B> <B>Rule 144 Reporting</B>. With a view to making available the benefits of certain
rules and regulations of the Commission that may permit the sale of the Restricted Securities to the public without registration, the Company agrees to use its commercially reasonable efforts to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> Make and keep adequate current public information with respect to the Company available in accordance with Rule 144 under the
Securities Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> File with the Commission in a timely manner all reports and other documents required of the Company under the
Securities Act and the Exchange Act at any time after it has become subject to such reporting requirements; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> So long as a
Holder owns any Restricted Securities, furnish to the Holder forthwith upon written request a written statement by the Company as to its compliance with the reporting requirements of Rule 144 (at any time from and after ninety (90)&nbsp;days
following the effective date of the first registration statement filed by the Company for an offering of its securities to the general public), and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting
requirements), a copy of the most recent annual or quarterly report of the Company, and such other reports and documents so filed as a Holder may reasonably request in availing itself of any rule or regulation of the Commission allowing a Holder to
sell any such securities without registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.11</B> <B>Market <FONT STYLE="white-space:nowrap">Stand-Off</FONT> Agreement</B>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> Investor agrees that such Investor shall not transfer any shares of Common Stock or any securities convertible into or
exercisable or exchangeable (directly or indirectly) for the shares of Common Stock (excluding the PIPE Securities) until the earlier of one hundred eighty (180)-days following the Closing Date (as defined in the BCA) and the consummation of a
change of control of the Company (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#148;). The foregoing restriction is expressly agreed to preclude each Investor during such one hundred eighty
<FONT STYLE="white-space:nowrap">(180)-day</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
period from engaging in any hedging or other transaction which is designed to or which reasonably could be expected to lead to or result in a sale or disposition of such Investor&#146;s shares of
Common Stock even if such shares of Common Stock would be disposed of by someone other than the undersigned. Such prohibited hedging or other transactions during such one hundred eighty <FONT STYLE="white-space:nowrap">(180)-day</FONT> period would
include without limitation any short sale or any purchase, sale or grant of any right (including, without limitation, any put or call option) with respect to any of the Investor&#146;s shares of Common Stock or with respect to any security that
includes, relates to, or derives any significant part of its value from such shares of Common Stock. The foregoing notwithstanding, (x)&nbsp;each executive officer and director of the Company shall be permitted to establish a plan to acquire and
sell shares of Common Stock pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act, provided that such plan does not provide for the transfer of shares of Common Stock during the
<FONT STYLE="white-space:nowrap">Lock-up</FONT> Period and (y)&nbsp;to the extent any Named Investor is granted a release or waiver from the restrictions contained in this Section&nbsp;2.11 prior to the expiration of the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period, then all Named Investors shall be automatically granted a release or waiver from the restrictions contained in this Section&nbsp;2.11 to the same extent, on substantially the same terms as and on a
<I>pro rata</I> basis with, the Named Investor to which such release or waiver is granted. [The foregoing restrictions shall not apply to transfers made: (i)&nbsp;pursuant to a <I>bona fide</I> gift or charitable contribution; (ii)&nbsp;by will or
intestate succession upon the death of an Investor; (iii)&nbsp;to any Affiliate (including, for the avoidance of doubt, pursuant to distributions of shares of Common Stock to partners, limited liability company members or stockholders of an
Investor, including, for the avoidance of doubt, where an Investor is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership); (iv) pursuant to a court order or settlement agreement
related to the distribution of assets in connection with the dissolution of marriage or civil union; (v)<I>&nbsp;pro rata</I> to the partners, members or shareholders of a Named Investor upon its liquidation or dissolution; or (vi)&nbsp;in the event
of the Company&#146;s completion of a liquidation, merger, share exchange or other similar transaction which results in all of its shareholders having the right to exchange their Common Stock for cash, securities or other property; <I>provided</I>
that in the case of (i), (iii) or (v), the recipient of such transfer must enter into a written agreement agreeing to be bound by the terms of this Agreement, including the transfer restrictions set forth in this Section&nbsp;2.11].<SUP
STYLE="font-size:85%; vertical-align:top">2</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> Each Named Investor who is participating in the applicable underwritten
public offering also agrees, and the Company agrees and shall cause each director and officer of the Company to agree, that, in connection with each Registration or sale of Registrable Securities conducted as an underwritten public offering, if
requested, to become bound by and to execute and deliver a <FONT STYLE="white-space:nowrap">customary&nbsp;lock-up&nbsp;agreement</FONT> with the underwriter(s) of such underwritten public offering restricting such applicable person or entity&#146;s
right to (a)&nbsp;transfer, directly or indirectly, any equity securities of the Company held by such person or entity or (b)&nbsp;enter into any swap or other arrangement that transfers to another any of the economic consequences of ownership of
such securities during the period commencing on the date of the final Prospectus relating to the underwritten public offering and ending on the date specified by the underwriters (such period not to exceed ninety (90)&nbsp;days). The terms of <FONT
STYLE="white-space:nowrap">such&nbsp;lock-up&nbsp;agreements</FONT> shall be negotiated among the applicable Named Investors requested to enter <FONT STYLE="white-space:nowrap">into&nbsp;lock-up&nbsp;agreements</FONT> and participating in the
underwritten public offering in accordance with the immediately preceding sentence, the Company and the underwriters, and the terms of such <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements shall include customary exclusions from the
restrictions on transfer set forth therein, including that such restrictions on the applicable Named Investors shall be conditioned upon all officers and directors of the Company, as well as all Named Investors participating in the offering, being
subject to the same restrictions;&nbsp;provided, that, to the extent any Named Investor is granted a release or waiver from the restrictions contained in this&nbsp;Section&nbsp;2.11 and in such Named
<FONT STYLE="white-space:nowrap">Investor&#146;s&nbsp;lock-up&nbsp;agreement</FONT> prior to the expiration of the period set forth in such Named <FONT STYLE="white-space:nowrap">Investor&#146;s&nbsp;lock-up&nbsp;agreement,</FONT> then all Named
Investors shall be automatically granted a release or waiver from the restrictions contained in this&nbsp;Section 2.11 and the <FONT STYLE="white-space:nowrap">applicable&nbsp;lock-up&nbsp;agreements</FONT> to which they are party to the same
extent, on substantially the same terms as and on a pro rata basis with, the Named Investor to which such release or waiver is granted. The provisions of this&nbsp;Section 2.11 shall not apply to any Named Investor that holds less than one percent
(1%) of then total issued and outstanding Common Stock. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Additional carve-outs to be included as needed and as appropriate. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.1</B>
<B>Termination and Effect of Termination</B>. This Agreement may be terminated only by an agreement in writing signed by the holders of a majority of the total Registrable Securities; provided, that the consent of any Holder will be required for any
termination of this Agreement which has an adverse effect on the rights, limitations or obligations of such Holder. Notwithstanding any provision hereof to the contrary, the right of any Holder to request a registration or inclusion of Registrable
Securities in any registration pursuant to Section&nbsp;2.2 shall terminate upon the third anniversary of the date hereof. Notwithstanding any termination of this Agreement in accordance with the foregoing sentence, the provisions of Sections 2.4,
2.6 and 2.9 shall survive any such termination. No termination under this Agreement shall relieve any Person of liability for breach or Registration Expenses incurred prior to termination. In the event this Agreement is terminated, each Person
entitled to indemnification rights pursuant to Section&nbsp;2.6 hereof shall retain such indemnification rights with respect to any matter that (i)&nbsp;may be an indemnified liability thereunder and (ii)&nbsp;occurred prior to such termination.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.2</B> <B>Permitted Transferees</B>. The rights of a Holder hereunder may be assigned (but only with all related obligations as set
forth below) in connection with a transfer of Registrable Securities to a Permitted Transferee of that Holder. Without prejudice to any other or similar conditions imposed hereunder with respect to any such transfer, no assignment permitted under
the terms of this Section&nbsp;3.2 will be effective unless the Permitted Transferee to which the assignment is being made, if not a Holder, has delivered to the Company a written acknowledgment and agreement in form and substance reasonably
satisfactory to the Company that the Permitted Transferee will be bound by, and will be a party to, this Agreement. A Permitted Transferee to whom rights are transferred pursuant to this Section&nbsp;3.2 may not again transfer those rights to any
other Permitted Transferee, other than as provided in this Section&nbsp;3.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.3</B> <B>Amendment</B>. This Agreement may not be
orally amended, modified or extended, nor shall any oral waiver of any of its terms be effective. This Agreement may be amended, modified or extended, and the provisions hereof may be waived, only by an agreement in writing signed by the Company and
the Holders of a majority of the total Registrable Securities. Each such amendment, modification, extension or waiver shall be binding upon each party hereto; provided that (a)&nbsp;the consent of any Holder shall be required for any amendment,
modification, extension or waiver which has an adverse effect on the rights, limitations or obligations of such Holder and (b)&nbsp;any such amendment, modification, extension or waiver that by its terms would adversely affect a Holder or group of
Holders in a disproportionate manner relative to the Holders generally shall require the written consent of the Holder (or a majority in interest based on Registrable Securities of such group of Holders) so affected. In addition, each party hereto
may waive any right hereunder (solely as applicable to such party) by an instrument in writing signed by such party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.4</B>
<B>Notices</B>. All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered or certified mail, postage prepaid, sent by facsimile or electronic mail (if to an Investor or Holder) or
otherwise delivered by hand, messenger or courier service addressed: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> if to an Investor, to the Investor&#146;s address,
facsimile number or electronic mail address as shown in the Company&#146;s records, as may be updated in accordance with the provisions hereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> if to any Holder, to such address, facsimile number or electronic mail address or facsimile number as shown in the Company&#146;s
records, or, until any such Holder so furnishes an address, facsimile number or electronic mail address to the Company, then to the address, facsimile number or electronic mail address of the last holder of such shares for which the Company has
contact information in its records; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> if to the Company, to the attention of the President and Chief Executive Officer of the
Company at 171 Oyster Point Blvd, Suite 400, South San Francisco, CA 94080 or at such other current address as the Company shall have furnished to the Investors or Holders, with a copy (which shall not constitute notice) to Michael Tenta, Cooley
LLP, 3175 Hanover Street, Palo Alto, CA 94304. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each such notice or other communication shall for all purposes of this Agreement be treated
as effective or having been given (i)&nbsp;if delivered by hand, messenger or courier service, when delivered (or if sent via a nationally-recognized overnight courier service, freight prepaid, specifying
<FONT STYLE="white-space:nowrap">next-business-day</FONT> delivery, one business day after deposit with the courier), or (ii)&nbsp;if sent via mail, at the earlier of its receipt or five days after the same has been deposited in a
regularly-maintained receptacle for the deposit of the United States mail, addressed and mailed as aforesaid, or (iii)&nbsp;if sent via facsimile, upon confirmation of facsimile transfer or, if sent via electronic mail, upon confirmation of delivery
when directed to the relevant electronic mail address, if sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient&#146;s next business day. In the event of any conflict
between the Company&#146;s books and records and this Agreement or any notice delivered hereunder, the Company&#146;s books and records will control absent fraud or error. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the limitations set forth in Delaware General Corporation Law &#167;232(e), each Investor and Holder consents to the delivery of
any notice to stockholders given by the Company under the Delaware General Corporation Law or the Company&#146;s certificate of incorporation or bylaws by (i)&nbsp;facsimile telecommunication to the facsimile number set forth on Exhibit A (or to any
other facsimile number for the Investor or Holder in the Company&#146;s records), (ii) electronic mail to the electronic mail address set forth on Exhibit A (or to any other electronic mail address for the Investor or Holder in the Company&#146;s
records), (iii) posting on an electronic network together with separate notice to the Investor or Holder of such specific posting or (iv)&nbsp;any other form of electronic transmission (as defined in the Delaware General Corporation Law) directed to
the Investor or Holder. This consent may be revoked by an Investor or Holder by written notice to the Company and may be deemed revoked in the circumstances specified in Delaware General Corporation Law &#167;232. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.5</B> <B>Governing Law</B>. This Agreement shall be governed in all respects by the internal laws of the State of Delaware as applied to
agreements entered into among Delaware residents to be performed entirely within Delaware, without regard to principles of conflicts of law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.6</B> <B>Successors and Assigns</B>. This Agreement, and any and all rights, duties and obligations hereunder, shall not be assigned,
transferred, delegated or sublicensed by any Investor without the prior written consent of the Company. Any attempt by an Investor without such permission to assign, transfer, delegate or sublicense any rights, duties or obligations that arise under
this Agreement shall be void. Subject to the foregoing and except as otherwise provided herein, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the
parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.7</B> <B>Entire Agreement</B>. This Agreement and the exhibits hereto constitute the full and entire understanding
and agreement between the parties with regard to the subjects hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. No party hereto shall be liable or bound to any
other party in any manner with regard to the subjects hereof or thereof by any warranties, representations or covenants except as specifically set forth herein. The Sponsor and the other Investors who are party to the Original Agreement hereby agree
that the Original Agreement is hereby terminated and superseded by this Agreement, effective upon the execution of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.8</B> <B>Delays or Omissions</B>. Except as expressly provided herein, no delay or omission to exercise any right, power or remedy
accruing to any party to this Agreement upon any breach or default of any other party under this Agreement shall impair any such right, power or remedy of such <FONT STYLE="white-space:nowrap">non-defaulting</FONT> party, nor shall it be construed
to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default
theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of
this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party to this Agreement, shall be cumulative and
not alternative. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.9</B> <B>Severability</B>. If any provision of this Agreement becomes or is declared by
a court of competent jurisdiction to be illegal, unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Agreement, and such court will replace such illegal, void or
unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the same economic, business and other purposes of the illegal, void or unenforceable provision. The balance of this Agreement
shall be enforceable in accordance with its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.10</B> <B>Titles and Subtitles</B>. The titles and subtitles used in this
Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. All references in this Agreement to sections, paragraphs and exhibits shall, unless otherwise provided, refer to sections and
paragraphs hereof and exhibits attached hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.11</B> <B>Counterparts</B>. This Agreement may be executed in any number of
counterparts, each of which shall be enforceable against the parties that execute such counterparts, and all of which together shall constitute one instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.12</B> <B>Telecopy Execution and Delivery</B>. A facsimile, telecopy or other reproduction of this Agreement may be executed by one or
more parties hereto and delivered by such party by facsimile or any similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen. Such execution and delivery shall be considered valid, binding and
effective for all purposes. At the request of any party hereto, all parties hereto agree to execute and deliver an original of this Agreement as well as any facsimile, telecopy or other reproduction hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.13</B> <B>Jurisdiction; Venue</B>. With respect to any disputes arising out of or related to this Agreement, each of the parties hereto
irrevocably consents to the exclusive jurisdiction of, and venue in, the courts of the State of Delaware and, other than with regard to [***], the United States District Court for the District of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.14</B> <B>Further Assurances</B>. Each party hereto agrees to execute and deliver, by the proper exercise of its corporate, limited
liability company, partnership or other powers, all such other and additional instruments and documents and do all such other acts and things as may be necessary to more fully effectuate this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.15</B> <B>Conflict</B>. In the event of any conflict between the terms of this Agreement and the Company&#146;s Restated Certificate or
its bylaws, the terms of the Company&#146;s Restated Certificate or its bylaws, as the case may be, will control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.16</B>
<B>Attorney</B><B>&#146;</B><B>s Fees</B>. In the event that any suit or action is instituted to enforce any provisions in this Agreement, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and
expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including without limitation, such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs
and expenses of appeals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.17</B> <B>Aggregation of Stock</B>. All securities held or acquired by affiliated entities (including
affiliated venture capital funds) or persons shall be aggregated together for purposes of determining the availability of any rights under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(signature page follows) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The parties are signing this Investors&#146; Rights Agreement as of the date stated in the
introductory clause. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>COMPANY</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gad Soffer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> <SMALL>PAGE</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The parties are signing this Investors&#146; Rights Agreement as of the date stated in the
introductory clause. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>SPONSOR</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>CONSONANCE LIFE SCIENCES</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gad Soffer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Member</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> <SMALL>PAGE</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The parties are signing this Investors&#146; Rights Agreement as of the date stated in the
introductory clause. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>NAMED INVESTORS</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[***]</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> <SMALL>PAGE</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The parties are signing this Investors&#146; Rights Agreement as of the date stated in the
introductory clause. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>NAMED INVESTOR</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[***]</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> <SMALL>PAGE</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The parties are signing this Investors&#146; Rights Agreement as of the date stated in the
introductory clause. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>NAMED INVESTOR</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>CONSONANCE CAPITAL MANAGEMENT, LP</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kevin Livingston</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Partner</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> <SMALL>PAGE</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL>
I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NAMED INVESTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDIVIDUAL INVESTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPANY STOCKHOLDER SUPPORT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This COMPANY STOCKHOLDER SUPPORT AGREEMENT (this &#147;<B>Agreement</B>&#148;), dated as of April [&#9679;], 2021, is made by and among <FONT
STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., a Cayman Islands exempted company (&#147;<B>CHFW</B>&#148;), [&#9679;], a [&#9679;], a holder of capital stock of Surrozen, Inc. (the &#147;<B>Company Stockholder</B>&#148;), and
Surrozen, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;). CHFW, the Company Stockholder and the Company shall be referred to herein from time to time collectively as the &#147;<B>Parties</B>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, CHFW, the Company and certain other persons party thereto entered into that certain Business Combination Agreement, dated as of the
date hereof (as it may be amended, restated or otherwise modified from time to time in accordance with its terms, the &#147;<B>Business Combination Agreement</B>&#148;) providing for the merger of a subsidiary of CHFW with and into the Company, with
the Company surviving as the surviving wholly owned corporation of CHFW in such merger (the &#147;<B>Merger</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, the
Company Stockholder is the record and beneficial owner of the number of shares of common stock and number and series of preferred stock of Company as set forth on the signature page hereto (together with any other equity securities of Company that
the Company Stockholder holds of record or beneficially, as of the date of this Agreement, or acquires record or beneficial ownership after the date hereof, collectively, the &#147;<B>Subject Company Equity Securities</B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, the Company Stockholder acknowledges and agrees that CHFW and the Company would not have entered into and agreed to consummate the
transactions contemplated by the Business Combination Agreement without the Company Stockholder entering into this Agreement and agreeing to be bound by the agreements, covenants and obligations contained in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NOW, THEREFORE, in consideration of the premises and the mutual promises contained herein and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1.
<U>Agreement to Vote</U>. The Company Stockholder hereby agrees to (i)&nbsp;execute and deliver to the Company a written consent of the stockholders of the Company in lieu of a meeting of the stockholders (which written consent shall be delivered
promptly, and in any event within five (5)&nbsp;Business Days following the time at which the Registration Statement/Proxy Statement (as defined in the Business Combination Agreement) is declared effective under the U.S. Securities Act of 1933) or
appear (in person or by proxy) at any meeting of the stockholders of Company, and vote all of such Company Stockholder&#146;s Subject Company Equity Securities in favor of (A)&nbsp;the Business Combination Agreement to be submitted to the
stockholders of the Company in connection with the Merger and the other transactions contemplated by the Business Combination Agreement and (B)&nbsp;such other resolutions upon which a consent or other approval is required under the Company&#146;s
amended and restated certificate of incorporation or applicable law or otherwise is sought with respect to effecting the Business Combination Agreement and the Merger, and (C)&nbsp;against (i) any merger, purchase of all or substantially all of a
third party (other than the Merger) or all of the assets of a third party or other business combination transaction with a third party (other than the Business Combination Agreement and the Merger) (a &#147;<B>Competing Transaction</B>&#148;) or
(ii)&nbsp;any proposal relating to a Competing Transaction and against any proposal, action or agreement that would (A)&nbsp;impede, frustrate, prevent or nullify any provision of this Agreement, the Business Combination Agreement or any Merger,
(B)&nbsp;result in a breach in any respect of any covenant, representation, warranty or any other obligation or agreement of the Company under the Business Combination Agreement, or (C)&nbsp;result in any of the conditions set forth in Article VI of
the Business Combination Agreement not being fulfilled The Company Stockholder hereby agrees that it shall not commit or agree to take any action inconsistent with the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the failure of a Company Stockholder to timely provide its consent or vote its Subject Company Equity Securities in accordance with this
Section&nbsp;1 pursuant to any action by written consent of the stockholders </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of the Company or at any applicable meeting of the stockholders of the Company such Company Stockholder shall be deemed to have irrevocably granted to, and appointed, the Company, and any
designee thereof, and each of them individually, as such Company Stockholder&#146;s proxy and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> (with full power of substitution), for and in such Company
Stockholder&#146;s name, place and stead, to deliver any action by written consent of the Company Stockholder&#146;s concerning any of the matters specified in this Section&nbsp;1 or attend any meeting of the Company Stockholders concerning any of
the matters specified in this Section&nbsp;1, to include such Company Subject Equity Securities in any computation for purposes of establishing a quorum at any such meeting of the Company Stockholders and to provide consent or vote such Company
Stockholder&#146;s Subject Equity Securities in any action by written consent of the Company Stockholders or at any meeting of the Company Stockholders called with respect to any of the matters specified in, and in accordance and consistent with,
this Section&nbsp;1. Each Company Stockholder hereby affirms that the irrevocable proxy is coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable. Notwithstanding
any other provision of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate upon the termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. <U>Transfer of Shares</U>. The Company Stockholder hereby agrees that it shall not, directly or indirectly, (i)&nbsp;sell, assign, transfer
(including by operation of law), place a lien on, pledge, dispose of or otherwise encumber any of its Subject Company Equity Securities or otherwise agree to do any of the foregoing (each, a &#147;<B>Transfer</B>&#148;), (ii) deposit any of its
Subject Company Equity Securities into a voting trust or enter into a voting agreement or arrangement or grant any proxy or power of attorney with respect to any of its Subject Company Equity Securities that conflicts with any of the covenants or
agreements set forth in this Agreement, (iii)&nbsp;enter into any contract, option or other arrangement or undertaking with respect to the direct or indirect acquisition or sale, assignment, transfer (including by operation of law) or other
disposition of any of its Subject Company Equity Securities, (iv)&nbsp;engage in any hedging or other transaction which is designed to, or which would (either alone or in connection with one or more events, developments or events (including the
satisfaction or waiver of any conditions precedent)), lead to or result in a sale or disposition of its Subject Company Equity Securities even if such Subject Company Equity Securities would be disposed of by a person other than the Company
Stockholder or (v)&nbsp;take any action that would have the effect of preventing or materially delaying the performance of its obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. <U>Further Assurances</U>. Each Company Stockholder shall take, or cause to be taken, all actions and do, or cause to be done, all things
reasonably necessary under applicable Laws and within the control of such Company Stockholder to consummate the Merger and the other transactions contemplated by the Business Combination Agreement on the terms and subject to the conditions set forth
therein and herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. <U>No Inconsistent Agreement</U>. Each Company Stockholder hereby represents and covenants that such Company
Stockholder has not entered into, and shall not enter into, any agreement that would restrict, limit or interfere with the performance of such Company Stockholder&#146;s obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. <U>Company Stockholder Representations and Warranties</U>. The Company Stockholder represents and warrants to CHFW and the Company as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. The Company Stockholder is either an individual (or a revocable trust of which the individual is a trustee) or a corporation,
limited liability company or other applicable business entity duly organized or formed, as applicable, validly existing and in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize
the concept of good standing or any equivalent thereof) under the Laws of its jurisdiction of formation or organization (as applicable). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b. For Company Stockholders that are business entities, the Company Stockholder has the requisite corporate, limited liability company or
other similar power and authority to execute and deliver this Agreement and to perform its covenants, agreements and obligations hereunder. Each individual Company Stockholder has the personal capacity to execute and deliver this Agreement, to
perform their covenants, agreement and obligations hereunder. For Company Stockholders that are business entities, the execution and delivery of this Agreement has been duly authorized by all necessary corporate (or other similar) action on the part
of the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Company Stockholder. This Agreement has been duly and validly executed and delivered by the Company Stockholder and constitutes a valid, legal and binding agreement of the Company Stockholder
(assuming that this Agreement is duly authorized, executed and delivered by CHFW and the Company), enforceable against the Company Stockholder in accordance with its terms (subject to applicable bankruptcy, insolvency, reorganization, moratorium or
other Laws affecting generally the enforcement of creditors&#146; rights and subject to general principles of equity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c. The execution
and delivery of this Agreement by such Company Stockholder, does not, and the performance by such Company Stockholder of his, her or its obligations hereunder will not, (i)&nbsp;if such Company Stockholder is not an individual, conflict with or
result in a violation of the organizational documents of such Company Stockholder or (ii)&nbsp;require any consent or approval that has not been given or other action that has not been taken by any Person (including under any Contract binding upon
such Company Stockholder or such Company Stockholder&#146;s Subject Company Equity Securities), in each case, to the extent such consent, approval or other action would prevent, enjoin or materially delay the performance by such Company Stockholder
of its, his or her obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">d. There are no proceedings pending against such Company Stockholder, or to the
knowledge of such Company Stockholder threatened against such Company Stockholder, before (or, in the case of threatened proceedings, that would be before) any arbitrator or any Governmental Entity, which in any manner challenges or seeks to
prevent, enjoin or materially delay the performance by such Company Stockholder of its, his or her obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">e.
Except as described on Section&nbsp;3.17 of the Company Disclosure Schedules, no broker, finder, investment banker or other Person is entitled to any brokerage fee, finders&#146; fee or other commission in connection with the transactions
contemplated by the Business Combination Agreement based upon arrangements made by such Company Stockholder, for which the Company or any of its Affiliates may become liable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">f. Such Company Stockholder understands and acknowledges that each of CHFW and the Company is entering into the Business Combination Agreement
in reliance upon such Company Stockholder&#146;s execution and delivery of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6. <U>Waiver of Appraisal Rights</U>. Such
Company Stockholder hereby irrevocably and unconditionally waives, and agrees not to assert, exercise or perfect (or attempt to exercise, assert or perfect), any rights of appraisal or rights to dissent from the Merger or appraisal or
dissenters&#146; rights that it may at any time have under applicable Laws, including Section&nbsp;262 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7. <U>Termination of
Investor Agreements and Certain Other Agreements</U>. Such Company Stockholder, by this Agreement hereby agrees that, subject to and effective immediately prior to the Closing, that Amended and Restated Investors&#146; Rights Agreement, dated as of
May&nbsp;29, 2020, by and among the Company and the Company Stockholder parties thereto, the Amended and Restated Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement, dated as of May&nbsp;29, 2020, by and among the
Company and the Company Stockholders party thereto and the Amended and Restated Voting Agreement, dated as of May&nbsp;29, 2020, by and among the Company and the Company Stockholders parties thereto and any management letter or other agreement
between such Company Stockholder and the Company (excluding any employment agreement or offer letter, equity award or employment benefit agreement) shall terminate without any further liability to the Company or its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8. <U>Termination</U>. This Agreement shall automatically terminate, without any notice or other action by any Party, and be void <I>ab
initio</I> upon the earlier of (a)&nbsp;the effective time of the Merger; and (b)&nbsp;the termination of the Business Combination Agreement in accordance with its terms. Upon termination of this Agreement as provided in the immediately preceding
sentence, none of the Parties shall have any further obligations or liabilities under, or with respect to, this Agreement. Notwithstanding the foregoing or anything to the contrary in this Agreement, the termination of this Agreement pursuant to
<U>Section</U><U></U><U>&nbsp;5(b)</U> shall not affect any liability on the part of any Party for a willful breach of any covenant or agreement set forth in this Agreement prior to such termination. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9. <U>No Third Party Beneficiaries</U>. This Agreement shall be for the sole benefit of the
Parties and their respective successors and permitted assigns and is not intended, nor shall be construed, to give any Person, other than the Parties and their respective successors and assigns, any legal or equitable right, benefit or remedy of any
nature whatsoever by reason this Agreement. Nothing in this Agreement, expressed or implied, is intended to or shall constitute the Parties, partners or participants in a joint venture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10. <U>Severability</U>. If any term or other provision of this Agreement is determined to be invalid, illegal or incapable of being enforced
by any rule of law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any
manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original
intent of the Parties as closely as possible to the fullest extent permitted by applicable law in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11. <U>Binding Effect and Assignment</U>. All of the covenants and agreements contained in this Agreement shall be binding upon, and inure to
the benefit of, the respective Parties and their permitted successors, assigns, heirs, executors, administrators and other legal representatives, as the case may be. This Agreement may not be assigned by any Party hereto without the prior written
consent of the other Party hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12. <U>No Waivers</U>. No waivers of any breach of this Agreement extended by CHFW to the Company
Stockholder shall be construed as a waiver of any rights or remedies of CHFW with respect to any other stockholder of the Company that has executed an agreement substantially in the form of this Agreement with respect to equity held or subsequently
held by such stockholder or with respect to any subsequent breach of the Company Stockholder or any other such stockholder of Company. No waiver of any provisions hereof by either Party shall be deemed a waiver of any other provisions hereof by any
such Party, nor shall any such waiver be deemed a continuing waiver of any provision hereof by such Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">13. <U>Governing Law;
Jurisdiction and Venue</U>. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware without regard to its rules of conflict of laws. The parties hereto hereby irrevocably and unconditionally consent
to and submit to the exclusive jurisdiction of the courts of the State of Delaware and of the United States of America located in such state (the &#147;<B>Delaware Courts</B>&#148;) for any litigation arising out of or relating to this Agreement and
the transactions contemplated hereby (and agree not to commence any litigation relating thereto except in such courts), waive any objection to the laying of venue of any such litigation in the Delaware Courts and agree not to plead or claim in any
Delaware Court that such litigation brought therein has been brought in any inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">14. <U>Waiver of Jury Trial</U>. The
parties hereto hereby waive any right to trial by jury with respect to any action or proceeding related to or arising out of this Agreement, any document executed in connection herewith and the matters contemplated hereby and thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15. <U>No Agreement Until Executed</U>. Irrespective of negotiations among the parties or the exchanging of drafts of this Agreement, this
Agreement shall not constitute or be deemed to evidence a contract, agreement, arrangement or understanding between the parties hereto unless and until (a)&nbsp;each of the Board of Directors of CHFW and the Board of Directors of the Company has
approved the transactions contemplated by the Business Combination Agreement, (b)&nbsp;the Business Combination Agreement is executed by all parties thereto, and (c)&nbsp;this Agreement is executed by all parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">16. <U>Entire Agreement; Amendment</U>. This Agreement supersedes all prior agreements, written or oral, among the parties hereto with respect
to the subject matter hereof and contains the entire agreement among the parties with respect to the subject matter hereof. This Agreement may not be amended, supplemented or modified, and no provisions hereof may be modified or waived, except by an
instrument in writing signed by each party hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">17. <U>Specific Performance</U>. The parties hereto agree that irreparable damage may
occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
breached. It is accordingly agreed that the parties hereto shall be entitled to seek an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and
provisions of this Agreement in the Delaware Courts, this being in addition to any other remedy to which such party is entitled at law or in equity. Each of the parties hereby further waives (a)&nbsp;any defense in any action for specific
performance that a remedy at law would be adequate and (b)&nbsp;any requirement under any Law to post security or a bond as a prerequisite to obtaining equitable relief. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">18. <U>Severability</U>. If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other
provisions of this Agreement will remain in full force and effect. Any provision of this Agreement held invalid or unenforceable only in part or degree will remain in full force and effect to the extent not held invalid or unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">19. <U>Effect of Headings</U>. The section headings herein are for convenience only and shall not affect the construction of interpretation of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">20. <U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which will be deemed an
original but all of which together shall constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[signature page follows] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, each of the Parties has caused this Agreement to be duly executed
on its behalf as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION
CORP.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>SURROZEN, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>COMPANY STOCKHOLDER</B>:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Shares of Common Stock:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Shares of Series A Preferred Stock:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares of Series B Preferred Stock:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares of Series C Preferred Stock:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit D </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LETTER OF TRANSMITTAL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">To
Surrender Shares of [Common Stock/Series&nbsp;A Preferred Stock/Series&nbsp;B Preferred Stock/Series&nbsp;C Preferred&nbsp;Stock] of </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Surrozen, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DESCRIPTION OF SURRENDERED SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B></B>&#9744;<B></B><B> Physical Certificates. </B>Although you are not required to surrender any physical certificate(s) to receive the
merger consideration, in the event you currently hold any such certificate(s) in your possession, please include such certificate(s) with the above documents that you deliver to the Company.<B> </B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="justify"><B>Names(s) and Address(es) of Registered
Owner(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Share(s) Surrendered</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Attach additional list if necessary)</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Share</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total Number of Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>and Series of Shares</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">[&nbsp;&nbsp;&nbsp;&nbsp;] If any certificate(s) representing shares of stock that you own have been lost or
destroyed, check this box and see Instruction 8. Please fill out the remainder of this Letter of Transmittal and indicate here the number of shares of stock represented by the lost or destroyed certificates.
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> (Number of Shares) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>SPECIAL PAYMENT INSTRUCTIONS</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(See Instructions 1, 4, and 5)</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To be completed ONLY if the shares are to be issued in the name of someone other than the undersigned.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Issue check to:</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Please Print)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Include Zip Code)</B></TD></TR></TABLE>
</DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Tax Identification or Social Security No.)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPECIAL DELIVERY INSTRUCTIONS</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(See Instructions 1, 4 and 5)</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To be completed ONLY if the shares are to be sent to someone other than the undersigned or to the undersigned at an address other than that
shown above.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Deliver check to:</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Please Print)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Include Zip Code)</B></TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; margin-right:8%; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMPORTANT &#151; STOCKHOLDERS SIGN HERE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(U.S. Holders Also Please Complete Substitute Form <FONT STYLE="white-space:nowrap">W-9</FONT> Below) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">(Non-U.S.</FONT> Holders Please Obtain and Complete Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or
Other Form <FONT STYLE="white-space:nowrap">W-8)</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(Must be signed by former registered holder(s) exactly as name(s) appear(s)
on stock certificate(s) or on a security position listing or by person(s) authorized to become registered holder(s) as evidenced by certificates or documents transmitted herewith. If signature is by trustees, executors, administrators, guardians, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact,</FONT></FONT> officers of corporations or others acting in a fiduciary or representative capacity, please set forth full title and see Instruction 4.) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name(s):&nbsp;<B>X</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Area&nbsp;Code&nbsp;and&nbsp;Telephone&nbsp;Number:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Dated:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U>,&nbsp;2021</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GUARANTEE OF SIGNATURE(S) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(See Instructions 1 and 4) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Complete ONLY if required by Instruction 1. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>FOR USE BY FINANCIAL INSTITUTION ONLY. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>PLACE MEDALLION GUARANTEE IN SPACE BELOW. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Firm:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Title:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Address:
<U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE COMPLETED BY ALL SURRENDERING U.S. HOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(See Instruction 6) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="37%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>PAYER: CONTINENTAL STOCK TRANSFER&nbsp;&amp;
TRUST COMPANY</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="5"> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>SUBSTITUTE</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Form <FONT
STYLE="white-space:nowrap">W-9</FONT></B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Department of the Treasury Internal Revenue Service</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Request for Taxpayer Identification Number (TIN) And
Certification</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Name:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Address:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Check appropriate box:</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Individual/Sole
Proprietor&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp; Corporation&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Partnership
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp; Other (specify)&nbsp;&nbsp;&#9744; Exempt
from</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Backup Withholding&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Part I</B>. Please provide your taxpayer identification number in the space at right. If awaiting TIN, write &#147;Applied
For&#148; in space at right and complete the Certificate of Awaiting Taxpayer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Identification Number below.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>SSN:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>OR</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>EIN:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Part II</B>. For Payees exempt from
backup withholding, see the enclosed &#147;Guidelines for Certification of Taxpayer Identification Number on Substitute Form <FONT STYLE="white-space:nowrap">W-9&#148;</FONT> and complete as instructed therein.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Part III. Certification</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under penalties of perjury, I certify that:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(1)&#8194;&#8201;&#8202;The number shown on this form is my correct Taxpayer Identification Number
(or, as indicated, I am waiting for a number to be issued to me):</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(2)&#8194;&#8201;&#8202;I am not subject to backup withholding because: (a)&nbsp;I am exempt from
backup withholding, or (b)&nbsp;I have not been notified by the IRS that I am subject to backup withholding as a result of a failure to report all interests or dividends, or (c)&nbsp;the IRS has notified me that I am no longer subject to backup
withholding; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(3)&#8194;&#8201;&#8202;I am a U.S. person (including a U.S. resident alien).</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Certification Instructions&#151;</B>You must cross out
item (2)&nbsp;above if you have been notified by the IRS that you are subject to backup withholding because you have failed to report all interest or dividends on your tax return. However, if after being notified by the IRS that you were subject to
backup withholding you received another notification from the IRS that you are no longer subject to backup withholding, do not cross out item (2).</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Signature:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Date:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2021</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>You must complete the following certificate if you wrote &#147;applied for&#148; in part I of this substitute
Form <FONT STYLE="white-space:nowrap">W-9</FONT> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AWAITING TAXPAYER IDENTIFICATION NUMBER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I certify under penalties of perjury that a taxpayer identification number has not been issued to me, and either (a)&nbsp;I have mailed or
delivered an application to receive a taxpayer identification number to the appropriate Internal Revenue Service Center or Social Security Administration Office or (b)&nbsp;I intend to mail or deliver an application in the near future. I understand
that, notwithstanding the information I provided in Part III of the Substitute Form <FONT STYLE="white-space:nowrap">W-9</FONT> (and the fact that I have completed this Certificate of Awaiting Taxpayer Identification Number), all reportable payments
made to me hereafter will be subject to backup withholding tax until I provide a properly certified taxpayer identification number within 60 days of the date of this Substitute Form <FONT STYLE="white-space:nowrap">W-9.</FONT> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Signature:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Date:&nbsp;<U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INSTRUCTIONS FOR LETTER OF TRANSMITTAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. <B><I>Guarantee of Signature. </I></B>Signatures on all Letters of Transmittal must be guaranteed by a financial institution that is a
member of a Securities Transfer Association approved medallion program such as STAMP, SEMP or MSP (an &#147;Eligible Institution&#148;), except in cases where securities are surrendered (i)&nbsp;by a registered holder of the securities who has
<B><I>not </I></B>completed either the box entitled &#147;Special Payment/Issuance Instructions&#148; or the box entitled &#147;Special Delivery Instructions&#148; on the Letter of Transmittal or (ii)&nbsp;for the account of an Eligible Institution.
<B>See Instruction 4.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. <B><I>Delivery of Letter of Transmittal. </I></B>The Letter of Transmittal, properly completed and duly
executed for the securities described should be delivered to Continental Stock Transfer&nbsp;&amp; Trust Company in the envelope enclosed for your convenience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THE METHOD OF DELIVERY OF ALL REQUIRED DOCUMENTS IS AT THE ELECTION AND RISK OF THE OWNER, BUT IF SENT BY MAIL, IT IS RECOMMENDED THAT THEY
BE SENT BY REGISTERED MAIL WITH RETURN RECEIPT REQUESTED. DELIVERY OF THE DOCUMENTS WILL BE EFFECTIVE, AND RISK OF LOSS AND TITLE WITH RESPECT THERETO SHALL PASS, ONLY WHEN THE MATERIALS ARE ACTUALLY RECEIVED BY THE PAYING AGENT. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. <B><I>Inadequate Space. </I></B>If the space provided on the Letter of Transmittal is inadequate, the share numbers and the number of
shares should be listed on a separate schedule to be attached thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. <B><I>Signatures of Letter of Transmittal, Stock Powers and
Endorsements. </I></B>When the Letter of Transmittal is signed by the registered owner(s) of the share(s) listed and surrendered thereby, no endorsements of shares or separate stock powers are required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the share(s) surrendered is (are) owned of record by two or more joint owners, all such owners must sign the Letter of Transmittal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If any surrendered shares are registered in different names, it will be necessary to complete, sign and submit as many separate Letters of
Transmittal as there are different registrations of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the Letter of Transmittal is signed by a person other than the registered
owner of the share(s) listed, such share(s) must be endorsed or accompanied by appropriate stock powers, in either case signed exactly as the name or names of the registered owner or owners appear on the share(s). Signatures on such shares or stock
powers must be guaranteed by an Eligible Institution. <B>See Instruction 1</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the Letter of Transmittal or any certificate or stock
power is signed by trustees, executors, administrators, guardians, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact,</FONT></FONT> officers of corporations or others, acting in a fiduciary or representative
capacity, such persons should so indicate when signing and proper evidence, satisfactory to Continental Stock Transfer&nbsp;&amp; Trust Company, the Company&#146;s transfer agent, of their authority to do so must be submitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. <B><I>Special Payment and Delivery Instructions. </I></B>Indicate the name and address to which payment for the securities is to be issued
and/or sent if different from the name and address of the person(s) signing the Letter of Transmittal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6. <B><I>Substitute Form <FONT
STYLE="white-space:nowrap">W-9.</FONT> </I></B>Enter your social security or employer identification number, and complete, sign and date the Substitute <FONT STYLE="white-space:nowrap">W-9</FONT> certification. If you are a foreign person, you must
provide a properly completed and executed Internal Revenue Service Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> which you can obtain from Continental Stock Transfer&nbsp;&amp; Trust Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7. <B><I>Additional Copies. </I></B>Additional copies of the Letter of Transmittal may be obtained from the Reorganization Department of
Continental Stock Transfer&nbsp;&amp; Trust Company at the address listed below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8. <B><I>Lost, Stolen or Destroyed Certificates.
</I></B>If any stock certificates have been lost, stolen or destroyed, please so indicate on the front of the Letter of Transmittal, and additional paperwork will be sent to you to replace the lost, stolen or destroyed certificates. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All questions as to the validity, form and eligibility of any surrender of shares will be
determined by Continental Stock Transfer&nbsp;&amp; Trust Company and Surrozen, Inc. (the &#147;Company&#148;), and such determination shall be final and binding. Continental Stock Transfer&nbsp;&amp; Trust Company and the Company reserve the right
to waive any irregularities or defects in the surrender of any shares. A surrender will not be deemed to have been made until all irregularities have been cured or waived. Neither Continental Stock Transfer&nbsp;&amp; Trust Company nor the Company
is under any obligation to waive or to provide any notification of any irregularities or defects in the surrender of any shares, nor shall Continental Stock Transfer&nbsp;&amp; Trust Company or the Company be liable for any failure to give such
notification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>For Information</U>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Continental Stock Transfer&nbsp;&amp; Trust Company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 State Street &#150; 30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, New York 10004 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">917-262-2378</FONT></FONT> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit E </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The name of
this corporation is Surrozen, Inc. (the &#147;<B><I>Company</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>II. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The address of the registered office of the Company in the State of Delaware is The Corporation Trust Company, 1209 Orange Street in the City
of Wilmington, County of New Castle, Delaware 19801 and the name of the registered agent of the Company at such address is The Corporation Trust Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>III. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The purpose of the
Company is to engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law of the State of Delaware (the &#147;<B><I>DGCL</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IV. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>A.</B> This
Company is authorized to issue two classes of stock to be designated, respectively, &#147;<B><I>Common Stock</I></B>&#148; and &#147;<B><I>Preferred Stock</I></B>.&#148; The total number of shares which the Company is authorized to issue is
310,000,000 shares. 300,000,000 shares of which shall be Common Stock, having a par value per share of $0.0001. 10,000,000 shares of which shall be Preferred Stock, having a par value per share of $0.0001. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>B.</B> The Preferred Stock may be issued from time to time in one or more series. The Board of Directors of the Company (the
&#147;<B><I>Board of Directors</I></B>&#148;) is hereby expressly authorized to provide for the issue of all or any of the shares of the Preferred Stock in one or more series, and to fix the number of shares and to determine or alter for each such
series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and
expressed in the resolution or resolutions adopted by the Board of Directors providing for the issuance of such shares and as may be permitted by the DGCL. The Board of Directors is also expressly authorized to increase or decrease the number of
shares of any series subsequent to the issuance of shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of any series shall be decreased in accordance with the foregoing sentence,
the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series. The number of authorized shares of Preferred Stock may be increased or
decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of the stock of the Company entitled to vote thereon, without a separate vote of the holders of the
Preferred Stock, or of any series thereof, unless a vote of any such holders is required pursuant to the terms of any certificate of designation filed with respect to any series of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>C.</B> Each outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the
stockholders of the Company for their vote; <I>provided, however</I>, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (including any certificate
of designation filed with respect to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class
with the holders of one or more other such series, to vote thereon by law or pursuant to this Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>V. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the management of the business and for the conduct of the affairs of the Company, and in further definition, limitation and regulation of
the powers of the Company, of its directors and of its stockholders or any class thereof, as the case may be, it is further provided that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>A.</B> <B>M<SMALL>ANAGEMENT</SMALL> <SMALL>OF</SMALL> B<SMALL>USINESS</SMALL>. </B>The management of the business and the conduct of the
affairs of the Company shall be vested in its Board of Directors. The number of directors which shall constitute the Board of Directors shall be fixed exclusively by resolutions adopted by a majority of the authorized number of directors
constituting the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>B.</B> <B>B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>. </B>Subject to the
rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, upon the filing of this Certificate of Incorporation, the directors shall be divided into three classes designated as Class&nbsp;I,
Class&nbsp;II and Class&nbsp;III, respectively. The Board of Directors is authorized to assign members of the Board of Directors already in office to such classes at the time the classification becomes effective. At the first annual meeting of
stockholders following the initial classification of the Board of Directors, the term of office of the Class&nbsp;I directors shall expire and Class&nbsp;I directors shall be elected for a full term of three years. At the second annual meeting of
stockholders following such initial classification, the term of office of the Class&nbsp;II directors shall expire and Class&nbsp;II directors shall be elected for a full term of three years. At the third annual meeting of stockholders following
such initial classification, the term of office of the Class&nbsp;III directors shall expire and Class&nbsp;III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected
for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the
foregoing provisions of this section, each director shall serve until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. No decrease in the number of directors constituting the Board of
Directors shall shorten the term of any incumbent director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>C. R<SMALL>EMOVAL</SMALL> <SMALL>OF</SMALL>
D<SMALL>IRECTORS</SMALL>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>1.</B> Subject to the rights of any series of Preferred Stock to elect additional directors under
specified circumstances,<B> </B>neither the Board of Directors nor any individual director may be removed without cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.</B>
Subject to any limitation imposed by applicable law, any individual director or directors may be removed with cause by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">sixty-six</FONT> and <FONT
STYLE="white-space:nowrap">two-thirds</FONT> percent (66 2/3%) of the voting power of all then-outstanding shares of capital stock of the Company entitled to vote generally at an election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>D.</B> <B>V<SMALL>ACANCIES</SMALL>. </B>Subject to any limitations imposed by applicable law and subject to the rights of the holders of
any series of Preferred Stock, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors, shall,
unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders and except as otherwise provided by applicable law, be filled only by the affirmative vote of a
majority of the directors then in office, even though less than a quorum of the Board of Directors, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of
the director for which the vacancy was created or occurred and until such director&#146;s successor shall have been elected and qualified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>E. B<SMALL>YLAW</SMALL> A<SMALL>MENDMENTS</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>1.</B> The Board of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the Company.<B> </B>Any adoption, amendment or
repeal of the Bylaws of the Company by the Board of Directors shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
require the approval of a majority of the directors then in office. The stockholders shall also have power to adopt, amend or repeal the Bylaws of the Company; <I>provided, however, </I>that, in
addition to any vote of the holders of any class or series of stock of the Company required by law or by this Certificate of Incorporation, such action by stockholders shall require the affirmative vote of the holders of at least <FONT
STYLE="white-space:nowrap">sixty-six</FONT> and <FONT STYLE="white-space:nowrap">two-thirds</FONT> percent (66 2/3%) of the voting power of all of the then-outstanding shares of the capital stock of the Company entitled to vote generally in the
election of directors, voting together as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.</B> The directors of the Company need not be elected by written ballot
unless the Bylaws so provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.</B> No action shall be taken by the stockholders of the Company except at an annual or special
meeting of stockholders called in accordance with the Bylaws, and no action shall be taken by the stockholders by written consent or electronic transmission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>4.</B> Advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any
meeting of the stockholders of the Company shall be given in the manner provided in the Bylaws of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>5.</B> In the event
that a member of the Board of Directors of the Company who is not an employee of the Company, or any partner, member, director, stockholder, employee or agent of such member, other than someone who is an employee of the Company (collectively, the
&#147;<B><I>Covered Persons</I></B>&#148;), acquires knowledge of any business opportunity matter, potential transaction, interest or other matter, unless such matter, transaction or interest is presented to, or acquired, created or developed by, or
otherwise comes into the possession of, a Covered Person expressly and solely in connection with such individual&#146;s service as a member of the Board of Directors of the Company (a &#147;<B><I>Corporate Opportunity</I></B>&#148;), then the
Company, pursuant to Section&nbsp;122(17) of the DGCL and to the maximum extent permitted from time to time under Delaware law, (i)&nbsp;renounces any expectancy that such Covered Person offer an opportunity to participate in such Corporate
Opportunity to the Company and (ii)&nbsp;to the fullest extent permitted by law, waives any claim that such opportunity constituted a Corporate Opportunity that should have been presented by such Covered Person to the Company or any of its
affiliates. No amendment or repeal of this paragraph shall apply to or have any effect on the liability or alleged liability of any officer, director or stockholder of the Company for or with respect to any opportunities of which such officer,
director or stockholder becomes aware prior to such amendment or repeal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VI. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>A.</B> The liability of the directors for monetary damages shall be eliminated to the fullest extent under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>B.</B> To the fullest extent permitted by applicable law, the Company is authorized to provide indemnification of (and advancement of
expenses to) directors, officers and agents of the Company (and any other persons to which applicable law permits the Company to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or
disinterested directors or otherwise in excess of the indemnification and advancement otherwise permitted by such applicable law. If applicable law is amended after approval by the stockholders of this Article VI to authorize corporate action
further eliminating or limiting the personal liability of directors, then the liability of a director to the Company shall be eliminated or limited to the fullest extent permitted by applicable law as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>C.</B> Any repeal or modification of this Article VI shall only be prospective and shall not affect the rights or protections or increase
the liability of any director under this Article VI in effect at the time of the alleged occurrence of any act or omission to act giving rise to liability or indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VII. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>A.</B> Unless
the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of
Delaware) and any appellate court therefrom shall be the sole and exclusive forum for the following claims or causes of action under the Delaware statutory or common law: (A)&nbsp;any derivative claim or cause of action brought on behalf of the
Company; (B)&nbsp;any claim or cause of action for breach of a fiduciary duty owed by any current or former director, officer or other employee of the Company, to the Company or the Company&#146;s stockholders; (C)&nbsp;any claim or cause of action
against the Company or any current or former director, officer or other employee of the Company , arising out of or pursuant to any provision of the DGCL, this Certificate of Incorporation or the Bylaws of the Company (as each may be amended from
time to time); (D) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of this Certificate of Incorporation or the Bylaws of the Company (as each may be amended from time to time, including any right,
obligation, or remedy thereunder); (E) any claim or cause of action as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; and (F)&nbsp;any claim or cause of action against the Company or any current or former
director, officer or other employee of the Company , governed by the internal-affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as
defendants. This Section A of Article VII shall not apply to claims or causes of action brought to enforce a duty or liability created by the Securities Act of 1933, as amended (the &#147;<B><I>1933 Act</I></B>&#148;), or the Securities Exchange Act
of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>B.</B> Unless the Company consents
in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action
arising under the 1933 Act, including all causes of action asserted against any defendant named in such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the
underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>C.</B> Any person or entity holding, owning or otherwise acquiring any interest in any security of the Company shall be
deemed to have notice of and consented to the provisions of this Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VIII. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>A.</B> The Company reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in
the manner now or hereafter prescribed by statute, except as provided in paragraph B. of this Article&nbsp;VIII, and all rights conferred upon the stockholders herein are granted subject to this reservation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>B.</B> Notwithstanding any other provisions of this Certificate of Incorporation or any provision of applicable law which might otherwise
permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class or series of the capital stock of the Company required by law or by this Certificate of Incorporation or any certificate of designation
filed with respect to a series of Preferred Stock, the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">sixty-six</FONT> and <FONT STYLE="white-space:nowrap">two-thirds</FONT> percent (66 2/3%) of the voting power of all
of the then outstanding shares of capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class, shall be required to alter, amend or repeal Articles V, VI, VII and VIII. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>,
Surrozen, Inc. has caused this Certificate of Incorporation to be executed this [&#9679;] day of [&#9679;], 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>S<SMALL>URROZEN</SMALL>, I<SMALL>NC</SMALL>.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit F </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BYLAWS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(A
DELAWARE CORPORATION) </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>T<SMALL>ABLE</SMALL> O<SMALL>F</SMALL> C<SMALL>ONTENTS</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>P<SMALL>AGE</SMALL></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_1">ARTICLE I OFFICES</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_2">Section&nbsp;1.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_2">Registered Office</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_3">Section&nbsp;2.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_3">Other Offices</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="#anxaex40894_4"><B>ARTICLE II CORPORATE SEAL</B></A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_5">Section&nbsp;3.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_5">Corporate Seal</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_6">ARTICLE III STOCKHOLDERS&#146;
MEETINGS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_7">Section&nbsp;4.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_7">Place of Meetings</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_8">Section&nbsp;5.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_8">Annual Meetings</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_9">Section&nbsp;6.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_9">Special Meetings</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_10">Section&nbsp;7.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_10">Notice of Meetings</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_11">Section&nbsp;8.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_11">Quorum</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_12">Section&nbsp;9.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_12">Adjournment And Notice Of Adjourned Meetings</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_13">Section&nbsp;10.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_13">Voting Rights</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_14">Section&nbsp;11.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_14">Joint Owners of Stock</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_15">Section&nbsp;12.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_15">List of Stockholders</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_16">Section&nbsp;13.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_16">Action Without Meeting</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_17">Section&nbsp;14.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_17">Organization</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_18">ARTICLE IV DIRECTORS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_19">Section&nbsp;15.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_19">Number And Term Of Office</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_20">Section&nbsp;16.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_20">Powers</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_21">Section&nbsp;17.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_21">Classes of Directors</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_22">Section&nbsp;18.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_22">Vacancies</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_23">Section&nbsp;19.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_23">Resignation</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_24">Section&nbsp;20.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_24">Removal</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_25">Section&nbsp;21.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_25">Meetings</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_26">Section&nbsp;22.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_26">Quorum and Voting</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_27">Section&nbsp;23.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_27">Action Without Meeting</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_28">Section&nbsp;24.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_28">Fees and Compensation</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_29">Section&nbsp;25.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_29">Committees</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_30">Section&nbsp;26.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_30">Lead Independent Director</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_31">Section&nbsp;27.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_31">Organization</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_32">ARTICLE V OFFICERS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_33">Section&nbsp;28.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_33">Officers Designated</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_34">Section&nbsp;29.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_34">Tenure And Duties Of Officers</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>ABLE</SMALL> O<SMALL>F</SMALL> C<SMALL>ONTENTS</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>P<SMALL>AGE</SMALL></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_35">Section&nbsp;30.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_35">Delegation Of Authority</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_36">Section&nbsp;31.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_36">Resignations</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_37">Section&nbsp;32.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_37">Removal</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_38">ARTICLE VI EXECUTION OF CORPORATE INSTRUMENTS
 AND VOTING OF SECURITIES OWNED BY THE CORPORATION</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_39">Section&nbsp;33.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_39">Execution Of Corporate Instruments</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_40">Section&nbsp;34.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_40">Voting Of Securities Owned By The Corporation</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_41">ARTICLE VII SHARES OF
STOCK</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_42">Section&nbsp;35.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_42">Form And Execution Of Certificates</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_43">Section&nbsp;36.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_43">Lost Certificates</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_44">Section&nbsp;37.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_44">Transfers</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_45">Section&nbsp;38.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_45">Fixing Record Dates</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_46">Section&nbsp;39.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_46">Registered Stockholders</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_47">ARTICLE VIII OTHER SECURITIES OF THE CORPORATION
</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_48">Section&nbsp;40.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_48">Execution Of Other Securities</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_49">ARTICLE IX DIVIDENDS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_50">Section&nbsp;41.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_50">Declaration Of Dividends</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_51">Section&nbsp;42.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_51">Dividend Reserve</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_52">ARTICLE X FISCAL YEAR</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_53">Section&nbsp;43.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_53">Fiscal Year</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_54">ARTICLE XI
INDEMNIFICATION</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_55">Section&nbsp;44.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_55">Indemnification of Directors, Executive Officers, Other Officers, Employees and Other Agents
</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_56">ARTICLE XII NOTICES</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_57">Section&nbsp;45.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_57">Notices</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_58">ARTICLE XIII AMENDMENTS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_59">Section&nbsp;46.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_59">Amendments</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_60">ARTICLE XIV LOANS TO
OFFICERS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxaex40894_61">Section&nbsp;47.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><A HREF="#anxaex40894_61">Loans To Officers</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BYLAWS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(A DELAWARE CORPORATION) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxaex40894_1"></A>ARTICLE I </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_2"></A><B>Section</B><B></B><B>&nbsp;1. Registered Office</B><B>.</B> The registered
office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_3"></A><B>Section</B><B></B><B>&nbsp;2. Other Offices</B><B>.</B> The corporation may also
have and maintain an office or principal place of business at such place as may be fixed by the Board of Directors, and may also have offices at such other places, both within and without the State of Delaware as the Board of Directors may from time
to time determine or the business of the corporation may require. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxaex40894_4"></A>ARTICLE II </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CORPORATE SEAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_5"></A><B>Section</B><B></B><B>&nbsp;3. Corporate Seal</B><B>.</B> The Board of Directors
may adopt a corporate seal. If adopted, the corporate seal shall consist of a die bearing the name of the corporation and the inscription, &#147;Corporate Seal-Delaware.&#148; Said seal may be used by causing it or a facsimile thereof to be
impressed or affixed or reproduced or otherwise. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxaex40894_6"></A>ARTICLE III </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDERS&#146; MEETINGS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_7"></A><B>Section</B><B></B><B>&nbsp;4. Place of Meetings</B><B>.</B> Meetings of the
stockholders of the corporation may be held at such place, either within or without the State of Delaware, as may be determined from time to time by the Board of Directors. The Board of Directors may, in its sole discretion, determine that the
meeting shall not be held at any place, but may instead be held solely by means of remote communication as provided under the Delaware General Corporation Law (&#147;DGCL&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxaex40894_8"></A>Section&nbsp;5. Annual Meetings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>The annual meeting of the stockholders of the corporation, for the purpose of election of directors and for such other business as
may properly come before it, shall be held on such date and at such time as may be designated from time to time by the Board of Directors. Nominations of persons for election to the Board of Directors of the corporation and the proposal of business
to be considered by the stockholders may be made at an annual meeting of stockholders: (i)&nbsp;pursuant to the corporation&#146;s notice of meeting of stockholders (with respect to business other than nominations); (ii) brought specifically by or
at the direction of the Board of Directors; or (iii)&nbsp;by any stockholder of the corporation who was a stockholder of record at the time of giving the stockholder&#146;s notice provided for in Section&nbsp;5(b) below, who is entitled to vote at
the meeting and who complied with the notice procedures set forth in Section&nbsp;5. For the avoidance of doubt, clause (iii)&nbsp;above shall be the exclusive means for a stockholder to make nominations and submit other business (other than matters
properly included in the corporation&#146;s notice of meeting of stockholders and proxy statement under Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Securities Exchange Act of 1934, as amended, and the rules and regulations
thereunder (the &#147;1934 Act&#148;)) before an annual meeting of stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>At an annual meeting of the stockholders, only such business shall be conducted
as is a proper matter for stockholder action under Delaware law and as shall have been properly brought before the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)
</B>For nominations for the election to the Board of Directors to be properly brought before an annual meeting by a stockholder pursuant to clause (iii)&nbsp;of Section&nbsp;5(a) of these Bylaws, the stockholder must deliver written notice to the
Secretary at the principal executive offices of the corporation on a timely basis as set forth in Section&nbsp;5(b)(iii) and must update and supplement such written notice on a timely basis as set forth in Section&nbsp;5(c). Such stockholder&#146;s
notice shall set forth: (A)&nbsp;as to each nominee such stockholder proposes to nominate at the meeting: (1)&nbsp;the name, age, business address and residence address of such nominee, (2)&nbsp;the principal occupation or employment of such
nominee, (3)&nbsp;the class and number of shares of each class of capital stock of the corporation which are owned of record and beneficially by such nominee, (4)&nbsp;the date or dates on which such shares were acquired and the investment intent of
such acquisition, (5)&nbsp;such other information concerning such nominee as would be required to be disclosed in a proxy statement soliciting proxies for the election of such nominee as a director in an election contest (even if an election contest
is not involved), or that is otherwise required to be disclosed pursuant to Section&nbsp;14 of the 1934 Act and the rules and regulations promulgated thereunder (including such person&#146;s written consent to being named as a nominee and to serving
as a director if elected); and (B)&nbsp;the information required by Section&nbsp;5(b)(iv). The corporation may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility of such proposed
nominee to serve as an independent director of the corporation or that could be material to a reasonable stockholder&#146;s understanding of the independence, or lack thereof, of such proposed nominee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>Other than proposals sought to be included in the corporation&#146;s proxy materials pursuant to Rule <FONT
STYLE="white-space:nowrap">14a-8</FONT> under the 1934 Act, for business other than nominations for the election to the Board of Directors to be properly brought before an annual meeting by a stockholder pursuant to clause (iii)&nbsp;of
Section&nbsp;5(a), the stockholder must deliver written notice to the Secretary at the principal executive offices of the corporation on a timely basis as set forth in Section&nbsp;5(b)(iii), and must update and supplement such written notice on a
timely basis as set forth in Section&nbsp;5(c). Such stockholder&#146;s notice shall set forth: (A)&nbsp;as to each matter such stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the
meeting, the reasons for conducting such business at the meeting, and any material interest (including any anticipated benefit of such business to any Proponent (as defined below) other than solely as a result of its ownership of the
corporation&#146;s capital stock, that is material to any Proponent individually, or to the Proponents in the aggregate) in such business of any Proponent; and (B)&nbsp;the information required by Section&nbsp;5(b)(iv). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii) </B>To be timely, the written notice required by Section&nbsp;5(b)(i) or 5(b)(ii) must be received by the Secretary at the principal
executive offices of the corporation not later than the close of business on the ninetieth (90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day nor earlier than the close of business on the one hundred twentieth (120<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) day prior to the first anniversary of the preceding year&#146;s annual meeting; <I>provided, however,</I> that, subject to the last sentence of this Section&nbsp;5(b)(iii), in the event that the
date of the annual meeting is advanced more than thirty (30)&nbsp;days prior to or delayed by more than thirty (30)&nbsp;days after the anniversary of the preceding year&#146;s annual meeting, notice by the stockholder to be timely must be so
received not earlier than the close of business on the one hundred twentieth (120<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day prior to such annual meeting and not later than the close of business on the later of the ninetieth (90<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>)<B> </B>day prior to such annual meeting or the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day following the day on which public announcement of the date of such meeting is
first made. In no event shall an adjournment or a postponement of an annual meeting for which notice has been given, or the public announcement thereof has been made, commence a new time period for the giving of a stockholder&#146;s notice as
described above. Notwithstanding anything to the contrary provided herein, for the first annual meeting following the initial public offering of common stock of the corporation, a stockholder&#146;s notice shall be timely if received by the
Secretary at the principal executive offices of the corporation not later than the close of business on the later of the ninetieth (90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day prior to the scheduled date of such annual meeting or
the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day following the day on which public announcement of the date of such annual meeting is first made or sent by the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv) </B>The written notice required by Section&nbsp;5(b)(i) or 5(b)(ii) shall also set forth, as of the date of the notice and as to the
stockholder giving the notice and the beneficial owner, if any, on whose behalf the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
nomination or proposal is made (each, a &#147;Proponent&#148; and collectively, the &#147;Proponents&#148;): (A) the name and address of each Proponent, as they appear on the corporation&#146;s
books; (B)&nbsp;the class, series and number of shares of the corporation that are owned beneficially and of record by each Proponent; (C)&nbsp;a description of any agreement, arrangement or understanding (whether oral or in writing) with respect to
such nomination or proposal between or among any Proponent and any of its affiliates or associates, and any others (including their names) acting in concert, or otherwise under the agreement, arrangement or understanding, with any of the foregoing;
(D)&nbsp;a representation that the Proponents are holders of record or beneficial owners, as the case may be, of shares of the corporation entitled to vote at the meeting and intend to appear in person or by proxy at the meeting to nominate the
person or persons specified in the notice (with respect to a notice under Section&nbsp;5(b)(i)) or to propose the business that is specified in the notice (with respect to a notice under Section&nbsp;5(b)(ii)); (E) a representation as to whether the
Proponents intend to deliver a proxy statement and form of proxy to holders of a sufficient number of holders of the corporation&#146;s voting shares to elect such nominee or nominees (with respect to a notice under Section&nbsp;5(b)(i)) or to carry
such proposal (with respect to a notice under Section&nbsp;5(b)(ii)); (F) to the extent known by any Proponent, the name and address of any other stockholder supporting the proposal on the date of such stockholder&#146;s notice; and (G)&nbsp;a
description of all Derivative Transactions (as defined below) by each Proponent during the previous twelve (12)&nbsp;month period, including the date of the transactions and the class, series and number of securities involved in, and the material
economic terms of, such Derivative Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of Sections 5 and 6, a &#147;Derivative Transaction&#148; means any
agreement, arrangement, interest or understanding entered into by, or on behalf or for the benefit of, any Proponent or any of its affiliates or associates, whether record or beneficial: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(w) the value of which is derived in whole or in part from the value of any class or series of shares or other securities of
the corporation, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(x) which otherwise provides any direct or indirect opportunity to gain or share in any gain derived from
a change in the value of securities of the corporation, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(y) the effect or intent of which is to mitigate loss, manage risk
or benefit of security value or price changes, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(z) which provides the right to vote or increase or decrease the voting
power of, such Proponent, or any of its affiliates or associates, with respect to any securities of the corporation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">which agreement,
arrangement, interest or understanding may include, without limitation, any option, warrant, debt position, note, bond, convertible security, swap, stock appreciation right, short position, profit interest, hedge, right to dividends, voting
agreement, performance-related fee or arrangement to borrow or lend shares (whether or not subject to payment, settlement, exercise or conversion in any such class or series), and any proportionate interest of such Proponent in the securities of the
corporation held by any general or limited partnership, or any limited liability company, of which such Proponent is, directly or indirectly, a general partner or managing member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> A stockholder providing written notice required by Section&nbsp;5(b)(i) or (ii)&nbsp;shall update and supplement such notice in
writing, if necessary, so that the information provided or required to be provided in such notice is true and correct in all material respects as of (i)&nbsp;the record date for the meeting and (ii)&nbsp;the date that is five (5)&nbsp;business days
prior to the meeting and, in the event of any adjournment or postponement thereof, five (5)&nbsp;business days prior to such adjourned or postponed meeting. In the case of an update and supplement pursuant to clause (i)&nbsp;of this
Section&nbsp;5(c), such update and supplement shall be received by the Secretary at the principal executive offices of the corporation not later than five (5)&nbsp;business days after the record date for the meeting. In the case of an update and
supplement pursuant to clause (ii)&nbsp;of this Section&nbsp;5(c), such update and supplement shall be received by the Secretary at the principal executive offices of the corporation not later than two (2)&nbsp;business days prior to the date for
the meeting, and, in the event of any adjournment or postponement thereof, two (2)&nbsp;business days prior to such adjourned or postponed meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d) </B>Notwithstanding anything in Section&nbsp;5(b)(iii) to the contrary, in the event
that the number of directors in an Expiring Class (as defined below) is increased and there is no public announcement of the appointment of a director to such class, or, if no appointment was made, of the vacancy in such class, made by the
corporation at least ten (10)&nbsp;days before the last day a stockholder may deliver a notice of nomination in accordance with Section&nbsp;5(b)(iii), a stockholder&#146;s notice required by this Section&nbsp;5 and which complies with the
requirements in Section&nbsp;5(b)(i), other than the timing requirements in Section&nbsp;5(b)(iii), shall also be considered timely, but only with respect to nominees for any new positions in such Expiring Class&nbsp;created by such increase, if it
shall be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the tenth (10th) day following the day on which such public announcement is first made by the corporation. For purposes
of this section, an &#147;Expiring Class&#148; shall mean a class of directors whose term shall expire at the next annual meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e) </B>A person shall not be eligible for election or <FONT STYLE="white-space:nowrap">re-election</FONT> as a director, unless the person
is nominated in accordance with either clause (ii)&nbsp;or (iii) of Section&nbsp;5(a). Except as otherwise required by law, the chairperson of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be
brought before the meeting was made, or proposed, as the case may be, in accordance with the procedures set forth in these Bylaws and, if any proposed nomination or business is not in compliance with these Bylaws, or the Proponent does not act in
accordance with the representations in Sections 5(b)(iv)(D) and 5(b)(iv)(E), to declare that such proposal or nomination shall not be presented for stockholder action at the meeting and shall be disregarded, notwithstanding that proxies in respect
of such nominations or such business may have been solicited or received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f) </B>Notwithstanding the foregoing provisions of this
Section&nbsp;5, in order to include information with respect to a stockholder proposal in the proxy statement and form of proxy for a stockholders&#146; meeting, a stockholder must also comply with all applicable requirements of the 1934 Act and the
rules and regulations thereunder. Nothing in these Bylaws shall be deemed to affect any rights of stockholders to request inclusion of proposals in the corporation&#146;s proxy statement pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT>
under the 1934 Act; <I>provided, however, </I>that any references in these Bylaws to the 1934 Act or the rules and regulations thereunder are not intended to and shall not limit the requirements applicable to proposals and/or nominations to be
considered pursuant to Section&nbsp;5(a)(iii) of these Bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g) </B>For purposes of Sections&nbsp;5 and 6, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) </B>&#147;public announcement&#148; shall mean disclosure in a press release reported by the Dow Jones News Service,
Associated Press or comparable national news service or in a document publicly filed by the corporation with the Securities and Exchange Commission pursuant to Section&nbsp;13, 14 or 15(d) of the 1934 Act; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>&#147;affiliates&#148; and &#147;associates&#148; shall have the meanings set forth in Rule 405 under the
Securities Act of 1933, as amended (the &#147;1933 Act&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxaex40894_9"></A>Section&nbsp;6. Special Meetings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>Special meetings of the stockholders of the corporation may be called, for any purpose as is a proper matter for stockholder action
under Delaware law, by (i)&nbsp;the Chairperson of the Board of Directors, (ii)&nbsp;the Chief Executive Officer, or (iii)&nbsp;the Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors
(whether or not there exist any vacancies in previously authorized directorships at the time any such resolution is presented to the Board of Directors for adoption). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>The Board of Directors shall determine the time and place, if any, of such special meeting. Upon determination of the time and
place, if any, of the meeting, the Secretary shall cause a notice of meeting to be given to the stockholders entitled to vote, in accordance with the provisions of Section&nbsp;7. No business may be transacted at such special meeting otherwise than
specified in the notice of meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) </B>Nominations of persons for election to the Board of Directors may be made at a
special meeting of stockholders at which directors are to be elected (i)&nbsp;by or at the direction of the Board of Directors or (ii)&nbsp;by any stockholder of the corporation who is a stockholder of record at the time of giving notice provided
for in this paragraph, who shall be entitled to vote at the meeting and who delivers written notice to the Secretary of the corporation setting forth the information required by Section&nbsp;5(b)(i). In the event the corporation calls a special
meeting of stockholders for the purpose of electing one or more directors to the Board of Directors, any such stockholder of record may nominate a person or persons (as the case may be), for election to such position(s) as specified in the
corporation&#146;s notice of meeting, if written notice setting forth the information required by Section&nbsp;5(b)(i) of these Bylaws shall be received by the Secretary at the principal executive offices of the corporation not later than the close
of business on the later of the ninetieth (90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day prior to such meeting or the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day following the day on which public
announcement is first made of the date of the special meeting and of the nominees proposed by the Board of Directors to be elected at such meeting. The stockholder shall also update and supplement such information as required under
Section&nbsp;5(c). In no event shall an adjournment or a postponement of a special meeting for which notice has been given, or the public announcement thereof has been made, commence a new time period for the giving of a stockholder&#146;s notice as
described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d) </B>Notwithstanding the foregoing provisions of this Section&nbsp;6, a stockholder must also comply with all
applicable requirements of the 1934 Act and the rules and regulations thereunder with respect to matters set forth in this Section&nbsp;6. Nothing in these Bylaws shall be deemed to affect any rights of stockholders to request inclusion of proposals
in the corporation&#146;s proxy statement pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the 1934 Act; <I>provided, however, </I>that any references in these Bylaws to the 1934 Act or the rules and regulations thereunder are
not intended to and shall not limit the requirements applicable to nominations for the election to the Board of Directors to be considered pursuant to <B></B>Section&nbsp;6(c) of these Bylaws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_10"></A><B>Section</B><B></B><B>&nbsp;7. Notice of Meetings</B><B>.</B> Except as
otherwise provided by law, notice, given in writing or by electronic transmission, of each meeting of stockholders shall be given not less than ten (10)&nbsp;nor more than sixty (60)&nbsp;days before the date of the meeting to each stockholder
entitled to vote at such meeting, such notice to specify the place, if any, date and hour, in the case of special meetings, the purpose or purposes of the meeting, and the means of remote communications, if any, by which stockholders and proxy
holders may be deemed to be present in person and vote at any such meeting. If mailed, notice is given when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder&#146;s address as it appears on the
records of the corporation. Notice of the time, place, if any, and purpose of any meeting of stockholders may be waived in writing, signed by the person entitled to notice thereof, or by electronic transmission by such person, either before or after
such meeting, and will be waived by any stockholder by his or her attendance thereat in person, by remote communication, if applicable, or by proxy, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning
of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if due notice
thereof had been given. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_11"></A><B>Section</B><B></B><B>&nbsp;8. Quorum</B><B>.</B>
At all meetings of stockholders, except where otherwise provided by statute or by the Certificate of Incorporation, or by these Bylaws, the presence, in person, by remote communication, if applicable, or by proxy duly authorized, of the holders of a
majority of the outstanding shares of stock entitled to vote shall constitute a quorum for the transaction of business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, either by the chairperson of the
meeting or by vote of the holders of a majority of the shares represented thereat, but no other business shall be transacted at such meeting. The stockholders present at a duly called or convened meeting, at which a quorum is present, may continue
to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Except as otherwise provided by statute or by applicable stock exchange rules, or by the Certificate of Incorporation or these
Bylaws, in all matters other than the election of directors, the affirmative vote of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the majority of shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the subject matter shall be the act of
the stockholders. Except as otherwise provided by statute, the Certificate of Incorporation or these Bylaws, directors shall be elected by a plurality of the votes of the shares present in person, by remote communication, if applicable, or
represented by proxy at the meeting and entitled to vote generally on the election of directors. Where a separate vote by a class or classes or series is required, except where otherwise provided by the statute or by the Certificate of Incorporation
or these Bylaws, a majority of the outstanding shares of such class or classes or series, present in person, by remote communication, if applicable, or represented by proxy duly authorized, shall constitute a quorum entitled to take action with
respect to that vote on that matter. Except where otherwise provided by statute or by the Certificate of Incorporation or these Bylaws, the affirmative vote of the majority (plurality, in the case of the election of directors) of shares of such
class or classes or series present in person, by remote communication, if applicable, or represented by proxy at the meeting shall be the act of such class or classes or series. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_12"></A><B>Section</B><B></B><B>&nbsp;9. Adjournment And Notice Of Adjourned
Meetings</B><B>.</B> Any meeting of stockholders, whether annual or special, may be adjourned from time to time either by the chairperson of the meeting or by the vote of a majority of the shares present in person, by remote communication, if
applicable, or represented by proxy at the meeting. When a meeting is adjourned to another time or place, if any, notice need not be given of the adjourned meeting if the time and place, if any, thereof are announced at the meeting at which the
adjournment is taken. At the adjourned meeting, the corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty (30)&nbsp;days or if after the adjournment a new record
date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_13"></A><B>Section</B><B></B><B>&nbsp;10. Voting Rights</B><B>.</B> For the purpose of
determining those stockholders entitled to vote at any meeting of the stockholders, except as otherwise provided by law, only persons in whose names shares stand on the stock records of the corporation on the record date, as provided in
Section&nbsp;12 of these Bylaws, shall be entitled to vote at any meeting of stockholders. Every person entitled to vote shall have the right to do so either in person, by remote communication, if applicable, or by an agent or agents authorized by a
proxy granted in accordance with Delaware law. An agent so appointed need not be a stockholder. No proxy shall be voted after three (3)&nbsp;years from its date of creation unless the proxy provides for a longer period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_14"></A><B>Section</B><B></B><B>&nbsp;11. Joint Owners of Stock</B><B>.</B> If shares or
other securities having voting power stand of record in the names of two (2)&nbsp;or more persons, whether fiduciaries, members of a partnership, joint tenants, tenants in common, tenants by the entirety, or otherwise, or if two (2)&nbsp;or more
persons have the same fiduciary relationship respecting the same shares, unless the Secretary is given written notice to the contrary and is furnished with a copy of the instrument or order appointing them or creating the relationship wherein it is
so provided, their acts with respect to voting shall have the following effect: (a)&nbsp;if only one (1)&nbsp;votes, his or her act binds all; (b)&nbsp;if more than one (1)&nbsp;votes, the act of the majority so voting binds all; (c)&nbsp;if more
than one (1)&nbsp;votes, but the vote is evenly split on any particular matter, each faction may vote the securities in question proportionally, or may apply to the Delaware Court of Chancery for relief as provided in the DGCL, Section&nbsp;217(b).
If the instrument filed with the Secretary shows that any such tenancy is held in unequal interests, a majority or even-split for the purpose of subsection&nbsp;(c) shall be a majority or even-split in interest. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_15"></A><B>Section</B><B></B><B>&nbsp;12. List of Stockholders</B><B>.</B> The Secretary
(or the corporation&#146;s transfer agent or other person authorized by these Bylaws or by law) shall prepare and make, at least ten (10)&nbsp;days before every meeting of stockholders, a complete list of the stockholders entitled to vote at said
meeting, arranged in alphabetical order, showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the
meeting, (a)&nbsp;on a reasonably accessible electronic network, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
provided that the information required to gain access to such list is provided with the notice of the meeting, or (b)&nbsp;during ordinary business hours, at the principal place of business of
the corporation. In the event that the corporation determines to make the list available on an electronic network, the corporation may take reasonable steps to ensure that such information is available only to stockholders of the corporation. The
list shall be open to examination of any stockholder during the time of the meeting as provided by law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_16">
</A><B>Section&nbsp;13. Action Without Meeting.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No action shall be taken by the stockholders except at an annual or special meeting of
stockholders called in accordance with these Bylaws, and no action shall be taken by the stockholders by written consent or by electronic transmission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxaex40894_17"></A>Section&nbsp;14. Organization. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>At every meeting of stockholders, the Chairperson of the Board of Directors, or, if a Chairperson has not been appointed or is
absent, the President, or, if the President is absent, a chairperson of the meeting chosen by a majority in interest of the stockholders entitled to vote, present in person or by proxy, shall act as chairperson. The Secretary, or, in his or her
absence, an Assistant Secretary directed to do so by the President, shall act as secretary of the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>The Board of
Directors of the corporation shall be entitled to make such rules or regulations for the conduct of meetings of stockholders as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations of the Board of Directors, if
any, the chairperson of the meeting shall have the right and authority to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chairperson, are necessary, appropriate or convenient for the proper
conduct of the meeting, including, without limitation, establishing an agenda or order of business for the meeting, with consultation by the Lead Independent Director (as defined below), rules and procedures for maintaining order at the meeting and
the safety of those present, limitations on participation in such meeting to stockholders of record of the corporation and their duly authorized and constituted proxies and such other persons as the chairperson shall permit, restrictions on entry to
the meeting after the time fixed for the commencement thereof, limitations on the time allotted to questions or comments by participants and regulation of the opening and closing of the polls for balloting on matters which are to be voted on by
ballot. The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at the meeting shall be announced at the meeting. Unless and to the extent determined by the Board of Directors or the
chairperson of the meeting, meetings of stockholders shall not be required to be held in accordance with rules of parliamentary procedure. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxaex40894_18"></A>ARTICLE IV </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_19"></A><B>Section</B><B></B><B>&nbsp;15. Number And Term Of Office</B><B>.</B> The
authorized number of directors of the corporation shall be fixed in accordance with the Certificate of Incorporation. Directors need not be stockholders unless so required by the Certificate of Incorporation. If for any cause, the directors shall
not have been elected at an annual meeting, they may be elected as soon thereafter as convenient at a special meeting of the stockholders called for that purpose in the manner provided in these Bylaws. Each director shall serve until his or her
successor is duly elected and qualified or until his or her earlier death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_20"></A><B>Section</B><B></B><B>&nbsp;16. Powers</B><B>.</B> The business and affairs of
the corporation shall be managed by or under the direction of the Board of Directors, except as may be otherwise provided by statute or by the Certificate of Incorporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_21"></A><B>Section</B><B></B><B>&nbsp;17. Classes of Directors</B><B>. </B>Subject to the
rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the directors shall be divided into three classes designated as Class&nbsp;I, Class&nbsp;II and Class&nbsp;III, respectively. The
Board of Directors is authorized to assign members of the Board of Directors already in office to such classes at the time the classification becomes effective. At the first annual meeting of stockholders following the initial classification of the
Board of Directors, the term of office of the Class&nbsp;I directors shall expire and Class&nbsp;I directors shall be elected for a full term of three years. At the second annual meeting of stockholders following such initial classification, the
term of office of the Class&nbsp;II directors shall expire and Class&nbsp;II directors shall be elected for a full term of three years. At the third annual meeting of stockholders following such initial classification, the term of office of the
Class&nbsp;III directors shall expire and Class&nbsp;III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors
of the class whose terms expire at such annual meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing provisions of this Section&nbsp;17, each director
shall serve until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent
director. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_22"></A><B>Section</B><B></B><B>&nbsp;18. Vacancies</B><B>. </B>Unless
otherwise provided in the Certificate of Incorporation, and subject to the rights of the holders of any series of Preferred Stock, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes
and any newly created directorships resulting from any increase in the number of directors shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be
filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors, or by a sole remaining director, and not by the stockholders, <I>provided, however</I>, that whenever the
holders of any class or classes of stock or series thereof are entitled to elect one or more directors by the provisions of the Certificate of Incorporation, vacancies and newly created directorships of such class or classes or series shall, unless
the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be filled by a majority of the directors elected by such class or classes or series thereof then in office, or by
a sole remaining director so elected, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and
until such director&#146;s successor shall have been elected and qualified. A vacancy in the Board of Directors shall be deemed to exist under this Bylaw in the case of the death, removal or resignation of any director. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_23"></A><B>Section</B><B></B><B>&nbsp;19. Resignation</B><B>.</B> Any director may resign
at any time by delivering his or her notice in writing or by electronic transmission to the Secretary, such resignation to specify whether it will be effective at a particular time. If no such specification is made, it shall be deemed effective at
the time of delivery to the Secretary. When one or more directors shall resign from the Board of Directors, effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such
vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each Director so chosen shall hold office for the unexpired portion of the term of the Director whose place shall be vacated and
until his or her successor shall have been duly elected and qualified. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxaex40894_24"></A>Section&nbsp;20. Removal. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>Subject to the rights of holders of any series of Preferred Stock to elect additional directors under specified circumstances<B>
</B>neither the Board of Directors nor any individual director may be removed without cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> Subject to any limitation imposed
by applicable law, any individual director or directors may be removed with cause by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">sixty-six</FONT> and <FONT STYLE="white-space:nowrap">two-thirds</FONT> percent (66
2/3%) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of the voting power of all then-outstanding shares of capital stock of the Company entitled to vote generally at an election of directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxaex40894_25"></A>Section&nbsp;21. Meetings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) Regular Meetings.</B> Unless otherwise restricted by the Certificate of Incorporation, regular meetings of the Board of Directors may be
held at any time or date and at any place within or without the State of Delaware which has been designated by the Board of Directors and publicized among all directors, either orally or in writing, by telephone, including a voice-messaging system
or other system designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means. No further notice shall be required for regular meetings of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) Special Meetings. </B>Unless otherwise restricted by the Certificate of Incorporation, special meetings of the Board of Directors may
be held at any time and place within or without the State of Delaware whenever called by the Chairperson of the Board, the Chief Executive Officer or a majority of the authorized number of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) Meetings by Electronic Communications Equipment. </B>Any member of the Board of Directors, or of any committee thereof, may participate
in a meeting by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting by such means shall constitute presence in person at such
meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d) Notice of Special Meetings. </B>Notice of the time and place of all special meetings of the Board of Directors shall be
orally or in writing, by telephone, including a voice messaging system or other system or technology designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means, during normal business
hours, at least twenty-four (24)&nbsp;hours before the date and time of the meeting. If notice is sent by US mail, it shall be sent by first class mail, charges prepaid, at least three (3)&nbsp;days before the date of the meeting. Notice of any
meeting may be waived in writing, or by electronic transmission, at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends the meeting for the express purpose of objecting, at
the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e) Waiver of
Notice. </B>The transaction of all business at any meeting of the Board of Directors, or any committee thereof, however called or noticed, or wherever held, shall be as valid as though it had been transacted at a meeting duly held after regular call
and notice, if a quorum be present and if, either before or after the meeting, each of the directors not present who did not receive notice shall sign a written waiver of notice or shall waive notice by electronic transmission. All such waivers
shall be filed with the corporate records or made a part of the minutes of the meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxaex40894_26">
</A>Section&nbsp;22. Quorum and Voting. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>Unless the Certificate of Incorporation requires a greater number, and except with
respect to questions related to indemnification arising under<B> </B>Section&nbsp;44 for which a quorum shall be <FONT STYLE="white-space:nowrap">one-third</FONT> (1/3) of the exact number of directors fixed from time to time, a quorum of the Board
of Directors shall consist of a majority of the exact number of directors fixed from time to time by the Board of Directors in accordance with the Certificate of Incorporation; <I>provided, however,</I> at any meeting whether a quorum be present or
otherwise, a majority of the directors present may adjourn from time to time until the time fixed for the next regular meeting of the Board of Directors, without notice other than by announcement at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>At each meeting of the Board of Directors at which a quorum is present, all questions and business shall be
determined by the affirmative vote of a majority of the directors present, unless a different vote be required by law, the Certificate of Incorporation or these Bylaws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_27"></A><B>Section</B><B></B><B>&nbsp;23. Action Without Meeting</B><B>.</B> Unless
otherwise restricted by the Certificate of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of Directors or of any committee thereof may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent thereto in writing or by electronic
transmission, and such writing or writings or transmission or transmissions are filed with the minutes of proceedings of the Board of Directors or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be
in electronic form if the minutes are maintained in electronic form. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_28"></A><B>Section</B><B></B><B>&nbsp;24. Fees and Compensation</B><B>.</B> Directors
shall be entitled to such compensation for their services as may be approved by the Board of Directors, including, if so approved, by resolution of the Board of Directors, a fixed sum and expenses of attendance, if any, for attendance at each
regular or special meeting of the Board of Directors and at any meeting of a committee of the Board of Directors. Nothing herein contained shall be construed to preclude any director from serving the corporation in any other capacity as an officer,
agent, employee, or otherwise and receiving compensation therefor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxaex40894_29"></A>Section&nbsp;25. Committees. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) Executive Committee.</B> The Board of Directors may appoint an Executive Committee to consist of one (1)&nbsp;or more members of the
Board of Directors. The Executive Committee, to the extent permitted by law and provided in the resolution of the Board of Directors shall have and may exercise all the powers and authority of the Board of Directors in the management of the business
and affairs of the corporation, and may authorize the seal of the corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority in reference to (i)&nbsp;approving or adopting, or recommending
to the stockholders, any action or matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval, or (ii)&nbsp;adopting, amending or repealing any Bylaw of the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) Other Committees.</B> The Board of Directors may, from time to time, appoint such other committees as may be permitted by law. Such
other committees appointed by the Board of Directors shall consist of one (1)&nbsp;or more members of the Board of Directors and shall have such powers and perform such duties as may be prescribed by the resolution or resolutions creating such
committees, but in no event shall any such committee have the powers denied to the Executive Committee in these Bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) Term.</B>
The Board of Directors, subject to any requirements of any outstanding series of Preferred Stock and the provisions of subsections&nbsp;(a) or (b)&nbsp;of this Section&nbsp;25, may at any time increase or decrease the number of members of a
committee or terminate the existence of a committee. The membership of a committee member shall terminate on the date of his or her death or voluntary resignation from the committee or from the Board of Directors. The Board of Directors may at any
time for any reason remove any individual committee member and the Board of Directors may fill any committee vacancy created by death, resignation, removal or increase in the number of members of the committee. The Board of Directors may designate
one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee, and, in addition, in the absence or disqualification of any member of a committee, the member or members
thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified
member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d) Meetings.</B> Unless the Board of Directors shall otherwise provide, regular meetings of the Executive Committee or any
other committee appointed pursuant to this Section&nbsp;25 shall be held at such times and places as are determined by the Board of Directors, or by any such committee, and when notice thereof has been given to each member of such committee, no
further notice of such regular meetings need be given thereafter. Special meetings of any such committee may be held at any place which has been determined from time to time by such committee, and may be called by any Director<B> </B>who is a member
of such committee, upon notice to the members of such committee of the time and place of such special meeting given in the manner provided for the giving of notice to members of the Board of Directors of the time and place of special meetings of the
Board of Directors. Notice of any special meeting of any committee may be waived in writing or by electronic transmission at any time before or after the meeting and will be waived by any director by attendance thereat, except when the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
director attends such special meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or
convened. Unless otherwise provided by the Board of Directors in the resolutions authorizing the creation of the committee, a majority of the authorized number of members of any such committee shall constitute a quorum for the transaction of
business, and the act of a majority of those present at any meeting at which a quorum is present shall be the act of such committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_30"></A><B>Section&nbsp;26. Lead Independent Director.</B> The Chairperson of the Board
of Directors, or if the Chairperson is not an independent director, one of the independent directors, may be designated by the Board of Directors as lead independent director to serve until replaced by the Board of Directors (&#147;Lead Independent
Director&#148;). The Lead Independent Director will: serve as chairperson of Board of Directors meetings in the absence of the Chairperson of the Board of Directors; establish the agenda for meetings of the independent directors; coordinate with the
committee chairs regarding meeting agendas and informational requirements; preside over meetings of the independent directors; preside over any portions of meetings of the Board of Directors at which the evaluation or compensation of the Chief
Executive Officer is presented or discussed; preside over any portions of meetings of the Board of Directors at which the performance of the Board of Directors is presented or discussed; and coordinate the activities of the other independent
directors and perform such other duties as may be established or delegated by the Chairperson of the Board of Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_31"></A><B>Section</B><B></B><B>&nbsp;27. Organization</B><B>.</B> At every meeting of the
directors, the Chairperson of the Board of Directors, or, if a Chairperson has not been appointed or is absent, the Lead Independent Director, or if the Lead Independent Director is absent<B>,</B> the Chief Executive Officer (if a director), or, if
a Chief Executive Officer is absent, the President (if a director), or if the President is absent, the most senior Vice President (if a director), or, in the absence of any such person, a chairperson of the meeting chosen by a majority of the
directors present, shall preside over the meeting. The Secretary, or in his or her absence, any Assistant Secretary or other officer or director or other person directed to do so by the Chairperson of the Board, the Lead Independent Director or the
President, shall act as secretary of the meeting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxaex40894_32"></A>ARTICLE V </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_33"></A><B>Section</B><B></B><B>&nbsp;28. Officers Designated</B><B>.</B> The officers of
the corporation shall include, if and when designated by the Board of Directors, the Chief Executive Officer, the President, one or more Vice Presidents, the Secretary, the Chief Financial Officer and the Treasurer. The Board of Directors may also
appoint one or more Assistant Secretaries and Assistant Treasurers and such other officers and agents with such powers and duties as it shall deem necessary. The Board of Directors may assign such additional titles to one or more of the officers as
it shall deem appropriate. Any one person may hold any number of offices of the corporation at any one time unless specifically prohibited therefrom by law. The salaries and other compensation of the officers of the corporation shall be fixed by or
in the manner designated by the Board of Directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxaex40894_34"></A>Section&nbsp;29.
Tenure And Duties Of Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) General.</B> All officers shall hold office at the pleasure of the Board of Directors and until
their successors shall have been duly elected and qualified, unless sooner removed. Any officer elected or appointed by the Board of Directors may be removed at any time by the Board of Directors. If the office of any officer becomes vacant for any
reason, the vacancy may be filled by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B><B>Duties of Chief Executive Officer.</B> The Chief Executive
Officer shall preside at all meetings of the stockholders (subject to Section&nbsp;14) and at all meetings of the Board of Directors, unless the Chairperson of the Board of Directors or the Lead Independent Director has been appointed and is
present. Unless an officer has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
been appointed Chief Executive Officer of the corporation, the President shall be the chief executive officer of the corporation and shall, subject to the control of the Board of Directors, have
general supervision, direction and control of the business and officers of the corporation. To the extent that a Chief Executive Officer has been appointed and no President has been appointed, all references in these Bylaws to the President shall be
deemed references to the Chief Executive Officer. <B></B>The Chief Executive Officer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall
designate from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) Duties of President.</B> The President shall preside at all meetings of the stockholders (subject to
Section&nbsp;14) and at all meeting of the Board of Directors<B>, </B>unless the Chairperson of the Board of Directors, the Lead Independent Director, or the Chief Executive Officer has been appointed and is present. Unless another officer has been
appointed Chief Executive Officer of the corporation, the President shall be the chief executive officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business
and officers of the corporation.<B> </B>The President shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d) Duties of Vice Presidents.</B> The Vice Presidents may assume and perform the duties of the President in the absence or disability of
the President or whenever the office of President is vacant. The Vice Presidents shall perform other duties commonly incident to their office and shall also perform such other duties and have such other powers as the Board of Directors or the Chief
Executive Officer, or, if the Chief Executive Officer has not been appointed or is absent, the President shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e) Duties of Secretary.</B> The Secretary shall attend all meetings of the stockholders and of the Board of Directors and shall record all
acts and proceedings thereof in the minute book of the corporation. The Secretary shall give notice in conformity with these Bylaws of all meetings of the stockholders and of all meetings of the Board of Directors and any committee thereof requiring
notice. The Secretary shall perform all other duties provided for in these Bylaws and other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from
time to time. The President may direct any Assistant Secretary or other officer to assume and perform the duties of the Secretary in the absence or disability of the Secretary, and each Assistant Secretary shall perform other duties commonly
incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f) Duties of Chief Financial Officer.</B> The Chief Financial Officer shall keep or cause to be kept the books of account of the
corporation in a thorough and proper manner and shall render statements of the financial affairs of the corporation in such form and as often as required by the Board of Directors or the President. The Chief Financial Officer, subject to the order
of the Board of Directors, shall have the custody of all funds and securities of the corporation. The Chief Financial Officer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other
powers as the Board of Directors or the President shall designate from time to time. To the extent that a Chief Financial Officer has been appointed and no Treasurer has been appointed, all references in these Bylaws to the Treasurer shall be deemed
references to the Chief Financial Officer. <B></B>The President may direct the Treasurer, if any, or any Assistant Treasurer, or the Controller or any Assistant Controller to assume and perform the duties of the Chief Financial Officer in the
absence or disability of the Chief Financial Officer, and each Treasurer and Assistant Treasurer and each Controller and Assistant Controller shall perform other duties commonly incident to the office and shall also perform such other duties and
have such other powers as the Board of Directors or the President shall designate from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g) Duties of Treasurer.</B>
Unless another officer has been appointed Chief Financial Officer of the corporation, the Treasurer shall be the chief financial officer of the corporation and shall keep or cause to be kept the books of account of the corporation in a thorough and
proper manner and shall render statements of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
financial affairs of the corporation in such form and as often as required by the Board of Directors or the President, and, subject to the order of the Board of Directors, shall have the custody
of all funds and securities of the corporation.<B> </B>The Treasurer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall
designate from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_35"></A><B>Section</B><B></B><B>&nbsp;30. Delegation Of
Authority</B><B>.</B> The Board of Directors may from time to time delegate the powers or duties of any officer to any other officer or agent, notwithstanding any provision hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_36"></A><B>Section</B><B></B><B>&nbsp;31. Resignations</B><B>.</B> Any officer may resign
at any time by giving notice in writing or by electronic transmission to the Board of Directors or to the President or to the Secretary. Any such resignation shall be effective when received by the person or persons to whom such notice is given,
unless a later time is specified therein, in which event the resignation shall become effective at such later time. Unless otherwise specified in such notice, the acceptance of any such resignation shall not be necessary to make it effective. Any
resignation shall be without prejudice to the rights, if any, of the corporation under any contract with the resigning officer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_37"></A><B>Section</B><B></B><B>&nbsp;32. Removal</B><B>.</B> Any officer may be removed
from office at any time, either with or without cause, by the affirmative vote of a majority of the directors in office at the time, or by the unanimous written consent of the directors in office at the time, or by any committee or by the Chief
Executive Officer or by other superior officers upon whom such power of removal may have been conferred by the Board of Directors. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxaex40894_38">
</A>ARTICLE VI </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTION OF CORPORATE INSTRUMENTS AND VOTING OF SECURITIES OWNED BY THE CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_39"></A><B>Section</B><B></B><B>&nbsp;33. Execution Of Corporate Instruments</B><B>.</B>
The Board of Directors may, in its discretion, determine the method and designate the signatory officer or officers, or other person or persons, to execute on behalf of the corporation any corporate instrument or document, or to sign on behalf of
the corporation the corporate name without limitation, or to enter into contracts on behalf of the corporation, except where otherwise provided by law or these Bylaws, and such execution or signature shall be binding upon the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All checks and drafts drawn on banks or other depositaries on funds to the credit of the corporation or in special accounts of the corporation
shall be signed by such person or persons as the Board of Directors shall authorize so to do. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless authorized or ratified by the Board
of Directors or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any
amount. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_40"></A><B>Section</B><B></B><B>&nbsp;34. Voting Of Securities Owned By The
Corporation</B><B>.</B> All stock and other securities of other corporations owned or held by the corporation for itself, or for other parties in any capacity, shall be voted, and all proxies with respect thereto shall be executed, by the person
authorized so to do by resolution of the Board of Directors, or, in the absence of such authorization, by the Chairperson of the Board of Directors, the Chief Executive Officer, the President, or any Vice President. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxaex40894_41"></A>ARTICLE VII </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARES OF STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_42"></A><B>Section</B><B></B><B>&nbsp;35. Form And Execution Of Certificates</B><B>.</B>
The shares of the corporation shall be represented by certificates, or shall be uncertificated. Certificates for the shares of stock, if any, of the corporation shall be in such form<B> </B>as is consistent with the Certificate of Incorporation and
applicable law. Every holder of stock represented by certificate<B> </B>in the corporation shall be entitled to have a certificate signed by or in the name of the corporation by the Chairperson of the Board of Directors, or the President or any Vice
President and by the Treasurer or Assistant Treasurer or the Secretary or Assistant Secretary, certifying the number of shares owned by him in the corporation. Any or all of the signatures on the certificate may be facsimiles. In case any officer,
transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may be issued with the same effect
as if he were such officer, transfer agent, or registrar at the date of issue. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_43"></A><B>Section</B><B></B><B>&nbsp;36. Lost Certificates</B><B>.</B> A new certificate
or certificates shall be issued in place of any certificate or certificates theretofore issued by the corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of
stock to be lost, stolen, or destroyed. The corporation may require, as a condition precedent to the issuance of a new certificate or certificates, the owner of such lost, stolen, or destroyed certificate or certificates, or the owner&#146;s legal
representative, to agree to indemnify the corporation in such manner as it shall require or to give the corporation a surety bond in such form and amount as it may direct as indemnity against any claim that may be made against the corporation with
respect to the certificate alleged to have been lost, stolen, or destroyed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxaex40894_44"></A>Section&nbsp;37. Transfers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>Transfers of record of shares of stock of the corporation shall be made only upon its books by the holders thereof, in person or by
attorney duly authorized, and, in the case of stock represented by certificate, upon the surrender of a properly endorsed certificate or certificates for a like number of shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>The corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes
of stock of the corporation to restrict the transfer of shares of stock of the corporation of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxaex40894_45"></A>Section&nbsp;38. Fixing Record Dates. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any
adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall, subject to applicable
law, not be more than sixty (60)&nbsp;nor less than ten (10)&nbsp;days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting
of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of
stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <I>provided, however,</I> that the Board of Directors may fix a new record date for the adjourned meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>In order that the corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or
allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which
record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than sixty (60)&nbsp;days prior to such action. If no record date is fixed, the record date for determining
stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_46"></A><B>Section</B><B></B><B>&nbsp;39. Registered Stockholders</B><B>.</B> The
corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or
interest in such share or shares on the part of any other person whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxaex40894_47"></A>ARTICLE VIII </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER SECURITIES OF THE CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_48"></A><B>Section</B><B></B><B>&nbsp;40. Execution Of Other Securities</B><B>.</B> All
bonds, debentures and other corporate securities of the corporation, other than stock certificates (covered in Section&nbsp;35), may be signed by the Chairperson of the Board of Directors, the President or any Vice President, or such other person as
may be authorized by the Board of Directors, and the corporate seal impressed thereon or a facsimile of such seal imprinted thereon and attested by the signature of the Secretary or an Assistant Secretary, or the Chief Financial Officer or Treasurer
or an Assistant Treasurer; <I>provided, however,</I> that where any such bond, debenture or other corporate security shall be authenticated by the manual signature, or where permissible facsimile signature, of a trustee under an indenture pursuant
to which such bond, debenture or other corporate security shall be issued, the signatures of the persons signing and attesting the corporate seal on such bond, debenture or other corporate security may be the imprinted facsimile of the signatures of
such persons. Interest coupons appertaining to any such bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be signed by the Treasurer or an Assistant Treasurer of the corporation or such other person as may
be authorized by the Board of Directors, or bear imprinted thereon the facsimile signature of such person. In case any officer who shall have signed or attested any bond, debenture or other corporate security, or whose facsimile signature shall
appear thereon or on any such interest coupon, shall have ceased to be such officer before the bond, debenture or other corporate security so signed or attested shall have been delivered, such bond, debenture or other corporate security nevertheless
may be adopted by the corporation and issued and delivered as though the person who signed the same or whose facsimile signature shall have been used thereon had not ceased to be such officer of the corporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxaex40894_49"></A>ARTICLE IX </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIVIDENDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_50"></A><B>Section</B><B></B><B>&nbsp;41. Declaration Of Dividends</B><B>.</B> Dividends
upon the capital stock of the corporation, subject to the provisions of the Certificate of Incorporation and applicable law, if any, may be declared by the Board of Directors pursuant to law at any regular or special meeting. Dividends may be paid
in cash, in property, or in shares of the capital stock, subject to the provisions of the Certificate of Incorporation and applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_51"></A><B>Section</B><B></B><B>&nbsp;42. Dividend Reserve</B><B>.</B> Before payment of
any dividend, there may be set aside out of any funds of the corporation available for dividends such sum or sums as the Board of Directors from time to time, in their absolute discretion, think proper as a reserve or reserves to meet contingencies,
or for equalizing dividends, or for repairing or maintaining any property of the corporation, or for such other purpose as the Board of Directors shall think conducive to the interests of the corporation, and the Board of Directors may modify or
abolish any such reserve in the manner in which it was created. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxaex40894_52"></A>ARTICLE X </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FISCAL YEAR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_53"></A><B>Section</B><B></B><B>&nbsp;43. Fiscal Year</B><B>.</B> The fiscal year of the
corporation shall be fixed by resolution of the Board of Directors. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxaex40894_54"></A>ARTICLE XI </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxaex40894_55"></A>Section&nbsp;44. Indemnification of Directors, Executive Officers, Other
Officers, Employees and Other Agents. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) Directors</B><B> </B><B>and Executive Officers</B><B>. </B>The corporation shall
indemnify its directors and executive officers (for the purposes of this Article&nbsp;XI, &#147;executive officers&#148; shall have the meaning defined in Rule <FONT STYLE="white-space:nowrap">3b-7</FONT> promulgated under the 1934 Act)<B> </B>to
the extent not prohibited by the DGCL or any other applicable law; <I>provided, however,</I> that the corporation may modify the extent of such indemnification by individual contracts with its directors and executive officers; and, <I>provided,
further,</I> that the corporation shall not be required to indemnify any director or executive officer in connection with any proceeding (or part thereof) initiated by such person unless (i)&nbsp;such indemnification is expressly required to be made
by law, (ii)&nbsp;the proceeding was authorized by the Board of Directors of the corporation, (iii)&nbsp;such indemnification is provided by the corporation, in its sole discretion, pursuant to the powers vested in the corporation under the DGCL or
any other applicable law or (iv)&nbsp;such indemnification is required to be made under subsection (d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) Other Officers,</B><B>
</B><B>Employees and Other Agents.</B> The corporation shall have power to indemnify its other officers, employees and other agents as set forth in the DGCL or any other applicable law. The Board of Directors shall have the power to delegate the
determination of whether indemnification shall be given to any such person to such officers or other persons as the Board of Directors shall determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) Expenses.</B> The corporation shall advance to any person who was or is a party or is threatened to be made a party to any threatened,
pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was a director or executive officer, of the corporation, or is or was serving at the request of the
corporation as a director or executive officer of another corporation, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request therefor, all expenses incurred by any
director or executive officer<B> </B>in connection with such proceeding provided, however, that if the DGCL requires, an advancement of expenses incurred by a director or executive officer<B> </B>in his or her capacity as a director or executive
officer<B> </B>(and not in any other capacity in which service was or is rendered by such indemnitee, including, without limitation, service to an employee benefit plan) shall be made only upon delivery to the corporation of an undertaking
(hereinafter an &#147;undertaking&#148;), by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal (hereinafter a &#147;final
adjudication&#148;) that such indemnitee is not entitled to be indemnified for such expenses under this section or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing, unless otherwise determined pursuant to paragraph&nbsp;(e) of this section, no advance shall be made by the
corporation to an executive officer of the corporation (except by reason of the fact that such executive officer is or was a director of the corporation in which event this paragraph shall not apply) in any action, suit or proceeding, whether civil,
criminal, administrative or investigative, if a determination is reasonably and promptly made (i)&nbsp;by a majority vote of directors who were not parties to the proceeding, even if not a quorum, or (ii)&nbsp;by a committee of such directors
designated by a majority vote of such directors, even though less than a quorum, or (iii)&nbsp;if there are no such directors, or such directors so direct, by independent legal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
counsel in a written opinion, that the facts known to the decision-making party at the time such determination is made demonstrate clearly and convincingly that such person acted in bad faith or
in a manner that such person did not believe to be in or not opposed to the best interests of the corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d) Enforcement.
</B>Without the necessity of entering into an express contract, all rights to indemnification and advances to directors and executive officers under this Bylaw shall be deemed to be contractual rights and be effective to the same extent and as if
provided for in a contract between the corporation and the director or executive officer. Any right to indemnification or advances granted by this section to a director or executive officer shall be enforceable by or on behalf of the person holding
such right in any court of competent jurisdiction if (i)&nbsp;the claim for indemnification or advances is denied, in whole or in part, or (ii)&nbsp;no disposition of such claim is made within ninety (90)&nbsp;days of request therefor. To the extent
permitted by law, the claimant in such enforcement action, if successful in whole or in part, shall be entitled to be paid also the expense of prosecuting the claim. In connection with any claim for indemnification, the corporation shall be entitled
to raise as a defense to any such action that the claimant has not met the standards of conduct that make it permissible under the DGCL or any other applicable law for the corporation to indemnify the claimant for the amount claimed. Neither the
failure of the corporation (including its Board of Directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances
because he has met the applicable standard of conduct set forth in the DGCL or any other applicable law, nor an actual determination by the corporation (including its Board of Directors, independent legal counsel or its stockholders) that the
claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that claimant has not met the applicable standard of conduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e) <FONT STYLE="white-space:nowrap">Non-Exclusivity</FONT> of Rights. </B>The rights conferred on any person by this Bylaw shall not be
exclusive of any other right which such person may have or hereafter acquire under any applicable statute, provision of the Certificate of Incorporation, Bylaws, agreement, vote of stockholders or disinterested directors or otherwise, both as to
action in his or her official capacity and as to action in another capacity while holding office. The corporation is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents
respecting indemnification and advances, to the fullest extent not prohibited by the DGCL, or by any other applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)
Survival of Rights. </B>The rights conferred on any person by this Bylaw shall continue as to a person who has ceased to be a director<B> </B>or executive officer<B> </B>and shall inure to the benefit of the heirs, executors and administrators of
such a person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g) Insurance. </B>To the fullest extent permitted by the DGCL or any other applicable law, the corporation, upon
approval by the Board of Directors, may purchase insurance on behalf of any person required or permitted to be indemnified pursuant to this section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(h) Amendments. </B>Any repeal or modification of this section shall only be prospective and shall not affect the rights under this Bylaw
in effect at the time of the alleged occurrence of any action or omission to act that is the cause of any proceeding against any agent of the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) Saving Clause. </B>If this Bylaw or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then
the corporation shall nevertheless indemnify each director and executive officer to the full extent not prohibited by any applicable portion of this section that shall not have been invalidated, or by any other applicable law. If this section shall
be invalid due to the application of the indemnification provisions of another jurisdiction, then the corporation shall indemnify each director and executive officer<B> </B>to the full extent under any other applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(j) Certain Definitions. </B>For the purposes of this Bylaw, the following definitions
shall apply: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) </B>The term &#147;proceeding&#148; shall be broadly construed and shall include, without limitation,
the investigation, preparation, prosecution, defense, settlement, arbitration and appeal of, and the giving of testimony in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>The term &#147;expenses&#148; shall be broadly construed and shall include, without limitation, court costs,
attorneys&#146; fees, witness fees, fines, amounts paid in settlement or judgment and any other costs and expenses of any nature or kind incurred in connection with any proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii) </B>The term the &#147;corporation&#148; shall include, in addition to the resulting corporation, any constituent
corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that
any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise, shall stand in the same position under the provisions of this section with respect to the resulting or surviving corporation as he would have with respect to such constituent corporation if its separate existence
had continued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv) </B>References to a &#147;director,&#148; &#147;executive officer,&#148; &#147;officer,&#148;
&#147;employee,&#148; or &#147;agent&#148; of the corporation shall include, without limitation, situations where such person is serving at the request of the corporation as, respectively, a director, executive officer, officer, employee, trustee or
agent of another corporation, partnership, joint venture, trust or other enterprise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v) </B>References to &#147;other
enterprises&#148; shall include employee benefit plans; references to &#147;fines&#148; shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to &#147;serving at the request of the
corporation&#148; shall include any service as a director, officer, employee or agent of the corporation which imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit plan, its
participants, or beneficiaries; and a person who acted in good faith and in a manner he reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &#147;not
opposed to the best interests of the corporation&#148; as referred to in this section. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxaex40894_56"></A>ARTICLE XII
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxaex40894_57"></A>Section&nbsp;45. Notices. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) Notice To Stockholders. </B>Written notice to stockholders of stockholder meetings shall be given as provided in Section&nbsp;7 herein.
Without limiting the manner by which notice may otherwise be given effectively to stockholders under any agreement or contract with such stockholder, and except as otherwise required by law, written notice to stockholders for purposes other than
stockholder meetings may be sent by US mail or nationally recognized overnight courier, or by facsimile, telegraph or telex or by electronic mail or other electronic means. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) Notice To Directors. </B>Any notice required to be given to any director may be given by the method stated in subsection&nbsp;(a), as
otherwise provided in these Bylaws, or by overnight delivery service, facsimile, telex or telegram, except that such notice other than one which is delivered personally shall be sent to such address as such director shall have filed in writing with
the Secretary, or, in the absence of such filing, to the last known post office address of such director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) Affidavit Of Mailing.
</B>An affidavit of mailing, executed by a duly authorized and competent employee of the corporation or its transfer agent appointed with respect to the class of stock affected, or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
agent, specifying the name and address or the names and addresses of the stockholder or stockholders, or director or directors, to whom any such notice or notices was or were given, and the time
and method of giving the same, shall in the absence of fraud, be prima facie evidence of the facts therein contained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d) Methods of
Notice. </B>It shall not be necessary that the same method of giving notice be employed in respect of all recipients of notice, but one permissible method may be employed in respect of any one or more, and any other permissible method or methods may
be employed in respect of any other or others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e) Notice To Person With Whom Communication Is Unlawful. </B>Whenever notice is
required to be given, under any provision of law or of the Certificate of Incorporation or Bylaws of the corporation, to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and there shall
be no duty to apply to any governmental authority or agency for a license or permit to give such notice to such person. Any action or meeting which shall be taken or held without notice to any such person with whom communication is unlawful shall
have the same force and effect as if such notice had been duly given. In the event that the action taken by the corporation is such as to require the filing of a certificate under any provision of the DGCL, the certificate shall state, if such is
the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f) Notice to Stockholders Sharing an Address. </B>Except as otherwise prohibited under DGCL, any notice given under the provisions of
DGCL, the Certificate of Incorporation or the Bylaws shall be effective if given by a single written notice to stockholders who share an address if consented to by the stockholders at that address to whom such notice is given. Such consent shall
have been deemed to have been given if such stockholder fails to object in writing to the corporation within sixty (60)&nbsp;days of having been given notice by the corporation of its intention to send the single notice. Any consent shall be
revocable by the stockholder by written notice to the corporation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxaex40894_58"></A>ARTICLE XIII </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxaex40894_59"></A><B>Section</B><B></B><B>&nbsp;46. </B><B>Amendments. </B>Subject to the
limitations set forth in Section&nbsp;44(h) of these Bylaws or the provisions of the Certificate of Incorporation, the Board of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the corporation. The stockholders also shall
have power to adopt, amend or repeal the Bylaws of the corporation; <I>provided, however, </I>that, in addition to any vote of the holders of any class or series of stock of the corporation required by law or by the Certificate of Incorporation,
such action by stockholders shall require the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">sixty-six</FONT> and <FONT STYLE="white-space:nowrap">two-thirds</FONT> percent (66 2/3%) of the voting power of all of the
then-outstanding shares of the capital stock of the corporation entitled to vote generally in the election of directors, voting together as a single class. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxaex40894_60"></A>ARTICLE XIV </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LOANS TO OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxaex40894_61"></A>Section&nbsp;47. Loans To Officers. EXCEPT AS OTHERWISE PROHIBITED BY
APPLICABLE LAW, THE CORPORATION MAY LEND MONEY TO, OR GUARANTEE ANY OBLIGATION OF, OR OTHERWISE ASSIST ANY OFFICER OR OTHER EMPLOYEE OF THE CORPORATION OR OF ITS SUBSIDIARIES, INCLUDING ANY OFFICER OR EMPLOYEE WHO IS A DIRECTOR OF THE CORPORATION OR
ITS SUBSIDIARIES, WHENEVER, IN THE JUDGMENT OF THE BOARD OF DIRECTORS, SUCH LOAN, GUARANTEE OR ASSISTANCE MAY REASONABLY BE EXPECTED TO BENEFIT THE </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>
CORPORATION. THE LOAN, GUARANTEE OR OTHER ASSISTANCE MAY BE WITH OR WITHOUT INTEREST AND MAY BE UNSECURED, OR SECURED IN SUCH MANNER AS THE BOARD OF DIRECTORS SHALL APPROVE, INCLUDING, WITHOUT
LIMITATION, A PLEDGE OF SHARES OF STOCK OF THE CORPORATION. NOTHING IN THESE BYLAWS SHALL BE DEEMED TO DENY, LIMIT OR RESTRICT THE POWERS OF GUARANTY OR WARRANTY OF THE CORPORATION AT COMMON LAW OR UNDER ANY STATUTE. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF SECRETARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>I hereby certify that: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I am the duly elected and acting Secretary of <B>Surrozen, Inc.</B>, a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Attached hereto is a complete and accurate copy of the Bylaws of the Company as duly adopted by the Board of Directors of the Company by
Unanimous Written Consent dated<B> </B>[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021 and said Bylaws are presently in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This Certificate of Secretary may be executed via facsimile, electronic mail (including pdf or any electronic signature complying with the
U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and will be deemed to have been duly and validly delivered and be valid and effective for all purposes. Signed on
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Secretary</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit G </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>URROZEN</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>:
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>:
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>1. G<SMALL>ENERAL</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B><B>Plan Purpose.</B> The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and
Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Common
Stock through the granting of Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B><B>Available Awards.</B> The Plan provides for the grant of the following Awards:
(i)&nbsp;Incentive Stock Options; (ii)&nbsp;Nonstatutory Stock Options; (iii)&nbsp;SARs; (iv) Restricted Stock Awards; (v)&nbsp;RSU Awards; (vi)&nbsp;Performance Awards; and (vii)&nbsp;Other Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) Adoption Date; Effective Date. </B>The Plan will come into existence on the Adoption Date, but no Award may be granted prior to the
Effective Date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2. S<SMALL>HARES</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B><B>Share Reserve. </B>Subject to adjustment in accordance with Section&nbsp;2(c) and any adjustments as necessary to implement any
Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed [&#9679;] shares (equal to 10% of the shares of Fully-Diluted Common Stock as of immediately following closing of the
transactions contemplated by the Business Combination Agreement). In addition, subject to any adjustments as necessary to implement any Capitalization Adjustments, such aggregate number of shares of Common Stock will automatically increase on
January&nbsp;1 of each year for a period of ten years commencing on January&nbsp;1, 2022 and ending on (and including) January&nbsp;1, 2031, in an amount equal to five percent (5%) of the Fully-Diluted Common Stock on December&nbsp;31 of the
preceding year; provided, however, that the Board may act prior to January 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of a given year to provide that the increase for such year will be a lesser number of shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) Aggregate Incentive Stock Option Limit.</B> Notwithstanding anything to the contrary in Section&nbsp;2(a) and subject to any
adjustments as necessary to implement any Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is [&#9679;] shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) Share Reserve Operation. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) Limit Applies to Common Stock Issued Pursuant to Awards. </B>For clarity, the Share Reserve is a limit on the number of shares of
Common Stock that may be issued pursuant to Awards and does not limit the granting of Awards, except that the Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy its obligations to issue
shares pursuant to such Awards. Shares may be issued in connection with a merger or acquisition as permitted by, as applicable, Nasdaq Listing Rule 5635(c), NYSE Listed Company Manual Section&nbsp;303A.08, NYSE American Company Guide
Section&nbsp;711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) Actions that Do Not Constitute Issuance of Common Stock and Do Not Reduce Share Reserve.</B> The following actions do not result in an
issuance of shares under the Plan and accordingly do not reduce the number of shares subject to the Share Reserve and available for issuance under the Plan: (1)&nbsp;the expiration or termination of any portion of an Award without the shares covered
by such portion of the Award having been issued, (2)&nbsp;the settlement of any portion of an Award in cash (i.e., the Participant receives cash </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
rather than Common Stock), (3) the withholding of shares that would otherwise be issued by the Company to satisfy the exercise, strike or purchase price of an Award; or (4)&nbsp;the withholding
of shares that would otherwise be issued by the Company to satisfy a tax withholding obligation in connection with an Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)
</B><B>Reversion of Previously Issued Shares of Common Stock to Share Reserve.</B> The following shares of Common Stock previously issued pursuant to an Award and accordingly initially deducted from the Share Reserve will be added back to the Share
Reserve and again become available for issuance under the Plan: (1)&nbsp;any shares that are forfeited back to or repurchased by the Company because of a failure to meet a contingency or condition required for the vesting of such shares;
(2)&nbsp;any shares that are reacquired by the Company to satisfy the exercise, strike or purchase price of an Award; and (3)&nbsp;any shares that are reacquired by the Company to satisfy a tax withholding obligation in connection with an Award.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3. E<SMALL>LIGIBILITY</SMALL> <SMALL>AND</SMALL> L<SMALL>IMITATIONS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) Eligible Award Recipients.</B> Subject to the terms of the Plan, Employees, Directors and Consultants are eligible to receive Awards.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) Specific Award Limitations. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) Limitations on Incentive Stock Option Recipients.</B> Incentive Stock Options may be granted only to Employees of the Company or a
&#147;parent corporation&#148; or &#147;subsidiary corporation&#148; thereof (as such terms are defined in Sections 424(e) and (f)&nbsp;of the Code). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) Incentive Stock Option $100,000 Limitation.</B> To the extent that the aggregate Fair Market Value (determined at the time of grant)
of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in
the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be
treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii) Limitations
on Incentive Stock Options Granted to Ten Percent Stockholders.</B> A Ten Percent Stockholder may not be granted an Incentive Stock Option unless (i)&nbsp;the exercise price of such Option is at least 110% of the Fair Market Value on the date of
grant of such Option and (ii)&nbsp;the Option is not exercisable after the expiration of five years from the date of grant of such Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv) Limitations on Nonstatutory Stock Options and SARs.</B> Nonstatutory Stock Options and SARs may not be granted to Employees, Directors
and Consultants unless the stock underlying such Awards is treated as &#147;service recipient stock&#148; under Section&nbsp;409A or unless such Awards otherwise comply with the requirements of Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) Aggregate Incentive Stock Option Limit.</B> The aggregate maximum number of shares of Common Stock that may be issued pursuant to the
exercise of Incentive Stock Options is the number of shares specified in Section&nbsp;2(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit. </B>The aggregate value of all compensation granted or paid, as applicable, to any individual for service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director with respect to any calendar year, including Awards granted and cash fees paid by the Company to such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, will not exceed (i) [$750,000] in total value or (ii)&nbsp;in the event
such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director is first appointed or elected to the Board during such calendar year, [$1,000,000] in total value, in each case, calculating the value of any equity awards based on the grant date
fair value of such equity awards for financial reporting purposes. The limitations in this Section&nbsp;3(d) shall apply commencing with the first calendar year that begins following the Effective Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>4. O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL> S<SMALL>TOCK</SMALL>
A<SMALL>PPRECIATION</SMALL> R<SMALL>IGHTS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each Option and SAR will have such terms and conditions as determined by the Board.
Each Option will be designated in writing as an Incentive Stock Option or Nonstatutory Stock Option at the time of grant; provided, however, that if an Option is not so designated or if an Option designated as an Incentive Stock Option fails to
qualify as an Incentive Stock Option, then such Option will be a Nonstatutory Stock Option, and the shares purchased upon exercise of each type of Option will be separately accounted for. Each SAR will be denominated in shares of Common Stock
equivalents. The terms and conditions of separate Options and SARs need not be identical; provided, however, that each Option Agreement and SAR Agreement will conform (through incorporation of provisions hereof by reference in the Award Agreement or
otherwise) to the substance of each of the following provisions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) Term.</B> Subject to Section&nbsp;3(b) regarding Ten Percent
Stockholders, no Option or SAR will be exercisable after the expiration of ten years from the date of grant of such Award or such shorter period specified in the Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) Exercise or Strike Price.</B> Subject to Section&nbsp;3(b) regarding Ten Percent Stockholders, the exercise or strike price of each
Option or SAR will not be less than 100% of the Fair Market Value on the date of grant of such Award. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value on the
date of grant of such Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Sections 409A and,
if applicable, 424(a) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) </B><B>Exercise Procedure and Payment of Exercise Price for Options.</B> In order to exercise
an Option, the Participant must provide notice of exercise to the Plan Administrator in accordance with the procedures specified in the Option Agreement or otherwise provided by the Company. The Board has the authority to grant Options that do not
permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment. The exercise price of an Option may be
paid, to the extent permitted by Applicable Law and as determined by the Board, by one or more of the following methods of payment to the extent set forth in the Option Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) </B>by cash or check, bank draft or money order payable to the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>pursuant to a &#147;cashless exercise&#148; program developed under Regulation T as promulgated by the Federal Reserve Board that,
prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the exercise price to the Company from the sales proceeds; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii) </B>by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are already owned by the
Participant free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1)&nbsp;at the time of exercise the Common Stock is
publicly traded, (2)&nbsp;any remaining balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (3)&nbsp;such delivery would not violate any Applicable Law or agreement
restricting the redemption of the Common Stock, (4)&nbsp;any certificated shares are endorsed or accompanied by an executed assignment separate from certificate, and (5)&nbsp;such shares have been held by the Participant for any minimum period
necessary to avoid adverse accounting treatment as a result of such delivery; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv) </B>if the Option is a Nonstatutory Stock Option,
by a &#147;net exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value on the date of exercise that does not
exceed the exercise price, provided that (1)&nbsp;such shares used to pay the exercise price will not be exercisable thereafter and (2)&nbsp;any remaining balance of the exercise price not satisfied by such net exercise is paid by the Participant in
cash or other permitted form of payment; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v) </B>in any other form of consideration that may be acceptable to the Board and
permissible under Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d) </B><B>Exercise Procedure and Payment of Appreciation Distribution for SARs</B><B>.</B> In order
to exercise any SAR, the Participant must provide notice of exercise to the Plan Administrator in accordance with the SAR Agreement. The appreciation distribution payable to a Participant upon the exercise of a SAR will not be greater than an amount
equal to the excess of (i)&nbsp;the aggregate Fair Market Value on the date of exercise of a number of shares of Common Stock equal to the number of Common Stock equivalents that are vested and being exercised under such SAR, over (ii)&nbsp;the
strike price of such SAR. Such appreciation distribution may be paid to the Participant in the form of Common Stock or cash (or any combination of Common Stock and cash) or in any other form of payment, as determined by the Board and specified in
the SAR Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e) Transferability.</B> Options and SARs may not be transferred to third party financial institutions for value.
The Board may impose such additional limitations on the transferability of an Option or SAR as it determines. In the absence of any such determination by the Board, the following restrictions on the transferability of Options and SARs will apply,
provided that except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration and provided, further, that if an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option
as a result of such transfer: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) Restrictions on Transfer.</B> An Option or SAR will not be transferable, except by will or by the
laws of descent and distribution, and will be exercisable during the lifetime of the Participant only by the Participant; provided, however, that the Board may permit transfer of an Option or SAR in a manner that is not prohibited by applicable tax
and securities laws upon the Participant&#146;s request, including to a trust if the Participant is considered to be the sole beneficial owner of such trust (as determined under Section&nbsp;671 of the Code and applicable state law) while such
Option or SAR is held in such trust, provided that the Participant and the trustee enter into a transfer and other agreements required by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) Domestic Relations Orders.</B> Notwithstanding the foregoing, subject to the execution of transfer documentation in a format
acceptable to the Company and subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to a domestic relations order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f) </B><B>Vesting.</B> The Board may impose such restrictions on or conditions to the vesting and/or exercisability of an Option or SAR as
determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Options and SARs will cease upon termination of the Participant&#146;s
Continuous Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g) Termination of Continuous Service for Cause.</B> Except as explicitly otherwise provided in the Award
Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#146;s Continuous Service is terminated for Cause, the Participant&#146;s Options and SARs will terminate and be forfeited immediately upon
such termination of Continuous Service, and the Participant will be prohibited from exercising any portion (including any vested portion) of such Awards on and after the date of such termination of Continuous Service and the Participant will have no
further right, title or interest in such forfeited Award, the shares of Common Stock subject to the forfeited Award, or any consideration in respect of the forfeited Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(h) Post-Termination Exercise Period Following Termination of Continuous Service for Reasons Other than Cause.</B> Subject to
Section&nbsp;4(i), if a Participant&#146;s Continuous Service terminates for any reason other than for Cause, the Participant may exercise his or her Option or SAR to the extent vested, but only within the following period of time or, if applicable,
such other period of time provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate; provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as
set forth in Section&nbsp;4(a)): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) </B>three months following the date of such termination if such termination is a termination
without Cause (other than any termination due to the Participant&#146;s Disability or death); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>12 months following the date of such termination if such termination is due to
the Participant&#146;s Disability; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii) </B>18 months following the date of such termination if such termination is due to the
Participant&#146;s death; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv) </B>18 months following the date of the Participant&#146;s death if such death occurs following the
date of such termination but during the period such Award is otherwise exercisable (as provided in (i)&nbsp;or (ii) above). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the
date of such termination, to the extent the Participant does not exercise such Award within the applicable Post-Termination Exercise Period (or, if earlier, prior to the expiration of the maximum term of such Award), such unexercised portion of the
Award will terminate, and the Participant will have no further right, title or interest in the terminated Award, the shares of Common Stock subject to the terminated Award, or any consideration in respect of the terminated Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) </B><B>Restrictions on Exercise; Extension of Exercisability. </B>A Participant may not exercise an Option or SAR at any time that the
issuance of shares of Common Stock upon such exercise would violate Applicable Law. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#146;s
Continuous Service terminates for any reason other than for Cause and, at any time during the last thirty days of the applicable Post-Termination Exercise Period: (i)&nbsp;the exercise of the Participant&#146;s Option or SAR would be prohibited
solely because the issuance of shares of Common Stock upon such exercise would violate Applicable Law, or (ii)&nbsp;the immediate sale of any shares of Common Stock issued upon such exercise would violate the Company&#146;s Trading Policy, then the
applicable Post-Termination Exercise Period will be extended to the last day of the calendar month that commences following the date the Award would otherwise expire, with an additional extension of the exercise period to the last day of the next
calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period, generally without limitation as to the maximum permitted number of extensions); provided, however, that in no event may such Award
be exercised after the expiration of its maximum term (as set forth in Section&nbsp;4(a)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(j)
</B><B><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employees</B>. No Option or SAR, whether or not vested, granted to an Employee who is a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee for purposes of the Fair Labor Standards
Act of 1938, as amended, will be first exercisable for any shares of Common Stock until at least six months following the date of grant of such Award. Notwithstanding the foregoing, in accordance with the provisions of the Worker Economic
Opportunity Act, any vested portion of such Award may be exercised earlier than six months following the date of grant of such Award in the event of (i)&nbsp;such Participant&#146;s death or Disability, (ii)&nbsp;a Corporate Transaction in which
such Award is not assumed, continued or substituted, (iii)&nbsp;a Change in Control, or (iv)&nbsp;such Participant&#146;s retirement (as such term may be defined in the Award Agreement or another applicable agreement or, in the absence of any such
definition, in accordance with the Company&#146;s then current employment policies and guidelines). This Section&nbsp;4(j) is intended to operate so that any income derived by a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee in
connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(k) Whole Shares</B>.
Options and SARs may be exercised only with respect to whole shares of Common Stock or their equivalents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>5. A<SMALL>WARDS</SMALL>
O<SMALL>THER</SMALL> T<SMALL>HAN</SMALL> O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>PPRECIATION</SMALL> R<SMALL>IGHTS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B><B>Restricted Stock Awards and RSU Awards.</B> Each Restricted Stock Award and RSU Award will have such terms and conditions as
determined by the Board; provided, however, that each Restricted Stock Award Agreement and RSU Award Agreement will conform (through incorporation of the provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of
the following provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) Form of Award.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(1) </B>Restricted Stock Awards: To the extent consistent with the Company&#146;s Bylaws, at the Board&#146;s election,
shares of Common Stock subject to a Restricted Stock Award may be (i)&nbsp;held in book entry form </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
subject to the Company&#146;s instructions until such shares become vested or any other restrictions lapse, or (ii)&nbsp;evidenced by a certificate, which certificate will be held in such form
and manner as determined by the Board. Unless otherwise determined by the Board, a Participant will have voting and other rights as a stockholder of the Company with respect to any shares subject to a Restricted Stock Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(2) </B>RSU Awards: An RSU Award represents a Participant&#146;s right to be issued on a future date the number of shares
of Common Stock that is equal to the number of restricted stock units subject to the RSU Award. As a holder of an RSU Award, a Participant is an unsecured creditor of the Company with respect to the Company&#146;s unfunded obligation, if any, to
issue shares of Common Stock in settlement of such Award and nothing contained in the Plan or any RSU Agreement, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship
between a Participant and the Company or an Affiliate or any other person. A Participant will not have voting or any other rights as a stockholder of the Company with respect to any RSU Award (unless and until shares are actually issued in
settlement of a vested RSU Award). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) Consideration.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(1) </B>Restricted Stock Awards: A Restricted Stock Award may be granted in consideration for (A)&nbsp;cash or check, bank
draft or money order payable to the Company, (B)&nbsp;services to the Company or an Affiliate, or (C)&nbsp;any other form of consideration as the Board may determine and permissible under Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(2) </B>RSU Awards: Unless otherwise determined by the Board at the time of grant, an RSU Award will be granted in
consideration for the Participant&#146;s services to the Company or an Affiliate, such that the Participant will not be required to make any payment to the Company (other than such services) with respect to the grant or vesting of the RSU Award, or
the issuance of any shares of Common Stock pursuant to the RSU Award. If, at the time of grant, the Board determines that any consideration must be paid by the Participant (in a form other than the Participant&#146;s services to the Company or an
Affiliate) upon the issuance of any shares of Common Stock in settlement of the RSU Award, such consideration may be paid in any form of consideration as the Board may determine and permissible under Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii) Vesting. </B>The Board may impose such restrictions on or conditions to the vesting of a Restricted Stock Award or RSU Award as
determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Restricted Stock Awards and RSU Awards will cease upon termination of the
Participant&#146;s Continuous Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv) Termination of Continuous Service.</B> Except as otherwise provided in the Award Agreement
or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#146;s Continuous Service terminates for any reason, (i)&nbsp;the Company may receive through a forfeiture condition or a repurchase right any or all
of the shares of Common Stock held by the Participant under his or her Restricted Stock Award that have not vested as of the date of such termination as set forth in the Restricted Stock Award Agreement and the Participant will have no further
right, title or interest in the Restricted Stock Award, the shares of Common Stock subject to the Restricted Stock Award, or any consideration in respect of the Restricted Stock Award and (ii)&nbsp;any portion of his or her RSU Award that has not
vested will be forfeited upon such termination and the Participant will have no further right, title or interest in the RSU Award, the shares of Common Stock issuable pursuant to the RSU Award, or any consideration in respect of the RSU Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v) Dividends and Dividend Equivalents. </B>Dividends or dividend equivalents may be paid or credited, as applicable, with respect to any
shares of Common Stock subject to a Restricted Stock Award or RSU Award, as determined by the Board and specified in the Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(vi) </B><B>Settlement of RSU Awards</B>. An RSU Award may be settled by the issuance of shares of Common Stock or cash (or any combination
thereof) or in any other form of payment, as determined by the Board and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
specified in the RSU Award Agreement. At the time of grant, the Board may determine to impose such restrictions or conditions that delay such delivery to a date following the vesting of the RSU
Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B><B>Performance Awards</B>. With respect to any Performance Award, the length of any Performance Period, the Performance
Goals to be achieved during the Performance Period, the other terms and conditions of such Award, and the measure of whether and to what degree such Performance Goals have been attained will be determined by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) </B><B>Other Awards</B>. Other forms of Awards valued in whole or in part by reference to, or otherwise based on, Common Stock,
including the appreciation in value thereof, may be granted either alone or in addition to Awards provided for under Section&nbsp;4 and the preceding provisions of this Section&nbsp;5. Subject to the provisions of the Plan, the Board will have sole
and complete discretion to determine the persons to whom and the time or times at which such Other Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Awards and all
other terms and conditions of such Other Awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>6. A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL>
<SMALL>IN</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; O<SMALL>THER</SMALL> C<SMALL>ORPORATE</SMALL> E<SMALL>VENTS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B><B>Capitalization Adjustments</B>. In the event of a Capitalization Adjustment, the Board shall appropriately and proportionately
adjust: (i)&nbsp;the class(es) and maximum number of shares of Common Stock subject to the Plan and the maximum number of shares by which the Share Reserve may annually increase pursuant to Section&nbsp;2(a), (ii) the class(es) and maximum number of
shares that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section&nbsp;2(b), and (iii)&nbsp;the class(es) and number of securities and exercise price, strike price or purchase price of Common Stock subject to
outstanding Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive. Notwithstanding the foregoing, no fractional shares or rights for fractional shares of Common Stock shall be created in order to
implement any Capitalization Adjustment. The Board shall determine an appropriate equivalent benefit, if any, for any fractional shares or rights to fractional shares that might be created by the adjustments referred to in the preceding provisions
of this Section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) Dissolution or Liquidation</B>. Except as otherwise provided in the Award Agreement, in the event of a
dissolution or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#146;s right of repurchase) will terminate
immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#146;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company
notwithstanding the fact that the holder of such Award is providing Continuous Service; provided, however, that the Board may determine to cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or
forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) Corporate Transaction. </B>The following provisions will apply to Awards in the event of a Corporate Transaction unless otherwise
provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of an Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) Awards May Be Assumed.</B> In the event of a Corporate Transaction, any surviving corporation or acquiring corporation (or the
surviving or acquiring corporation&#146;s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar awards for Awards outstanding under the Plan (including but not limited to, awards to acquire the
same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Awards may be assigned by the Company to
the successor of the Company (or the successor&#146;s parent company, if any), in connection with such Corporate Transaction. A </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of an Award or substitute a similar award for only a portion of an Award, or may
choose to assume or continue the Awards held by some, but not all Participants. The terms of any assumption, continuation or substitution will be set by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) Awards Held by Current Participants.</B> In the event of a Corporate Transaction in which the surviving corporation or acquiring
corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by
Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the &#147;<B>Current Participants</B>&#148;), the vesting of such Awards (and, with respect to Options and Stock
Appreciation Rights, the time when such Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board determines
(or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Corporate Transaction), and such Awards will terminate if not exercised (if applicable) at or prior to the effective time of the
Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Corporate Transaction). With respect to the vesting of Performance Awards that
will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii)&nbsp;and that have multiple vesting levels depending on the level of performance, unless otherwise provided in the Award Agreement, the vesting of such
Performance Awards will accelerate at 100% of the target level upon the occurrence of the Corporate Transaction in which the Awards are not assumed in accordance with Section&nbsp;6(c)(i). With respect to the vesting of Awards that will accelerate
upon the occurrence of a Corporate Transaction pursuant to this subsection (ii)&nbsp;and are settled in the form of a cash payment, such cash payment will be made no later than 30 days following the occurrence of the Corporate Transaction or such
later date as required to comply with Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii) Awards Held by Persons other than Current Participants.</B>
In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with
respect to Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Awards will terminate if not exercised (if applicable) prior to the occurrence of the Corporate Transaction;
provided, however, that any reacquisition or repurchase rights held by the Company with respect to such Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv) Payment for Awards in Lieu of Exercise.</B> Notwithstanding the foregoing, in the event an Award will terminate if not exercised prior
to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Award may not exercise such Award but will receive a payment, in such form as may be determined by the Board, equal in value, at
the effective time, to the excess, if any, of (1)&nbsp;the value of the property the Participant would have received upon the exercise of the Award (including, at the discretion of the Board, any unvested portion of such Award), over (2)&nbsp;any
exercise price payable by such holder in connection with such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d) Appointment of Stockholder Representative.</B> As a
condition to the receipt of an Award under this Plan, a Participant will be deemed to have agreed that the Award will be subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a
provision for the appointment of a stockholder representative that is authorized to act on the Participant&#146;s behalf with respect to any escrow, indemnities and any contingent consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e) No Restriction on Right to Undertake Transactions</B>. The grant of any Award under the Plan and the issuance of shares pursuant to any
Award does not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the Company&#146;s capital structure or its
business, any merger or consolidation of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the Company, any issue of stock or of options, rights or options to purchase stock or of bonds, debentures, preferred or prior preference stocks whose rights are superior to or affect the Common
Stock or the rights thereof or which are convertible into or exchangeable for Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or
proceeding, whether of a similar character or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>7. A<SMALL>DMINISTRATION</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) Administration by Board.</B> The Board will administer the Plan unless and until the Board delegates administration of the Plan to a
Committee or Committees, as provided in subsection (c)&nbsp;below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) Powers of Board.</B> The Board will have the power, subject to,
and within the limitations of, the express provisions of the Plan: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) </B>To determine from time to time: (1)&nbsp;which of the
persons eligible under the Plan will be granted Awards; (2)&nbsp;when and how each Award will be granted; (3)&nbsp;what type or combination of types of Award will be granted; (4)&nbsp;the provisions of each Award granted (which need not be
identical), including the time or times when a person will be permitted to receive an issuance of Common Stock or other payment pursuant to an Award; (5)&nbsp;the number of shares of Common Stock or cash equivalent with respect to which an Award
will be granted to each such person; (6)&nbsp;the Fair Market Value applicable to an Award; and (7)&nbsp;the terms of any Performance Award that is not valued in whole or in part by reference to, or otherwise based on, the Common Stock, including
the amount of cash payment or other property that may be earned and the timing of payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>To construe and interpret the Plan
and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a
manner and to the extent it deems necessary or expedient to make the Plan or Award fully effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii) </B>To settle all
controversies regarding the Plan and Awards granted under it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv) </B>To accelerate the time at which an Award may first be exercised
or the time during which an Award or any part thereof will vest, notwithstanding the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v) </B>To prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to 30 days prior to the consummation
of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock
or the share price of the Common Stock including any Corporate Transaction, for reasons of administrative convenience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(vi) </B>To
suspend or terminate the Plan at any time. Suspension or termination of the Plan will not Materially Impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(vii) </B>To amend the Plan in any respect the Board deems necessary or advisable; provided, however, that stockholder approval will be
required for any amendment to the extent required by Applicable Law. Except as provided above, rights under any Award granted before amendment of the Plan will not be Materially Impaired by any amendment of the Plan unless (1)&nbsp;the Company
requests the consent of the affected Participant, and (2)&nbsp;such Participant consents in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(viii) </B>To submit any
amendment to the Plan for stockholder approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ix) </B>To approve forms of Award Agreements for use under the Plan and to amend the
terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board
discretion; provided however, that, a Participant&#146;s rights under any Award will not be Materially Impaired by any such amendment unless (1)&nbsp;the Company requests the consent of the affected Participant, and (2)&nbsp;such Participant
consents in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(x) </B>Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to
promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(xi) </B>To adopt
such procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit and facilitate participation in the Plan by, or take advantage of specific tax treatment for Awards granted to, Employees, Directors or
Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement to ensure or facilitate compliance with the laws of the
relevant foreign jurisdiction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(xii) </B>To effect, at any time and from time to time, subject to the consent of any Participant
whose Award is Materially Impaired by such action, (1)&nbsp;the reduction of the exercise price (or strike price) of any outstanding Option or SAR; (2)&nbsp;the cancellation of any outstanding Option or SAR and the grant in substitution therefor of
(A)&nbsp;a new Option, SAR, Restricted Stock Award, RSU Award or Other Award, under the Plan or another equity plan of the Company, covering the same or a different number of shares of Common Stock, (B)&nbsp;cash and/or (C)&nbsp;other valuable
consideration (as determined by the Board); or (3)&nbsp;any other action that is treated as a repricing under generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) Delegation to Committee.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) </B><B>General.</B> The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If
administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to
delegate to another Committee or a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject,
however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Each Committee may retain the authority to concurrently administer the Plan with Committee or subcommittee to which it
has delegated its authority hereunder and may, at any time, revest in such Committee some or all of the powers previously delegated. The Board may retain the authority to concurrently administer the Plan with any Committee and may, at any time,
revest in the Board some or all of the powers previously delegated. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B><B>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT>
Compliance.</B> To the extent an Award is intended to qualify for the exemption from Section&nbsp;16(b) of the Exchange Act that is available under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> of the Exchange Act, the Award will be granted by
the Board or a Committee that consists solely of two or more Non-Employee Directors, as determined under Rule <FONT STYLE="white-space:nowrap">16b-3(b)(3)</FONT> of the Exchange Act and thereafter any action establishing or modifying the terms of
the Award will be approved by the Board or a Committee meeting such requirements to the extent necessary for such exemption to remain available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d) </B><B>Effect of Board</B><B>&#146;</B><B>s Decision.</B> All determinations, interpretations and constructions made by the Board or
any Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)
</B><B>Delegation to an Officer.</B> The Board or any Committee may delegate to one or more Officers the authority to do one or both of the following (i)&nbsp;designate Employees who are not Officers to be recipients of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Options and SARs (and, to the extent permitted by Applicable Law, other types of Awards) and, to the extent permitted by Applicable Law, the terms thereof, and (ii)&nbsp;determine the number of
shares of Common Stock to be subject to such Awards granted to such Employees; provided, however, that the resolutions or charter adopted by the Board or any Committee evidencing such delegation will specify the total number of shares of Common
Stock that may be subject to the Awards granted by such Officer and that such Officer may not grant an Award to himself or herself. Any such Awards will be granted on the applicable form of Award Agreement most recently approved for use by the Board
or the Committee, unless otherwise provided in the resolutions approving the delegation authority. Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to an Officer who is acting solely in the capacity
of an Officer (and not also as a Director) the authority to determine the Fair Market Value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>8. T<SMALL>AX</SMALL>
W<SMALL>ITHHOLDING</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B><B>Withholding Authorization.</B> As a condition to acceptance of any Award under the Plan, a
Participant authorizes withholding from payroll and any other amounts payable to such Participant, and otherwise agrees to make adequate provision for (including), any sums required to satisfy any U.S. federal, state, local and/or foreign tax or
social insurance contribution withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise, vesting or settlement of such Award, as applicable. Accordingly, a Participant may not be able to exercise an
Award even though the Award is vested, and the Company shall have no obligation to issue shares of Common Stock subject to an Award, unless and until such obligations are satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) Satisfaction of Withholding Obligation.</B> To the extent permitted by the terms of an Award Agreement, the Company may, in its sole
discretion, satisfy any U.S. federal, state, local and/or foreign tax or social insurance withholding obligation relating to an Award by any of the following means or by a combination of such means: (i)&nbsp;causing the Participant to tender a cash
payment; (ii)&nbsp;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; (iii)&nbsp;withholding cash from an Award settled in cash; (iv)&nbsp;withholding
payment from any amounts otherwise payable to the Participant; (v)&nbsp;by allowing a Participant to effectuate a &#147;cashless exercise&#148; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board, or
(vi)&nbsp;by such other method as may be set forth in the Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) No Obligation to Notify or Minimize Taxes; No Liability
to Claims. </B>Except as required by Applicable Law the Company has no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Award. Furthermore, the Company has no duty or obligation to warn or
otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such
Award and will not be liable to any holder of an Award for any adverse tax consequences to such holder in connection with an Award. As a condition to accepting an Award under the Plan, each Participant (i)&nbsp;agrees to not make any claim against
the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or other Company compensation and (ii)&nbsp;acknowledges that such Participant was advised to consult with his or her own
personal tax, financial and other legal advisors regarding the tax consequences of the Award and has either done so or knowingly and voluntarily declined to do so. Additionally, each Participant acknowledges any Option or SAR granted under the Plan
is exempt from Section&nbsp;409A only if the exercise or strike price is at least equal to the &#147;fair market value&#148; of the Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other impermissible
deferral of compensation associated with the Award. Additionally, as a condition to accepting an Option or SAR granted under the Plan, each Participant agrees not make any claim against the Company, or any of its Officers, Directors, Employees or
Affiliates in the event that the Internal Revenue Service asserts that such exercise price or strike price is less than the &#147;fair market value&#148; of the Common Stock on the date of grant as subsequently determined by the Internal Revenue
Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d) Withholding Indemnification. </B>As a condition to accepting an Award under the Plan, in the event that the amount of the
Company&#146;s and/or its Affiliate&#146;s withholding obligation in connection with such Award was </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
greater than the amount actually withheld by the Company and/or its Affiliates, each Participant agrees to indemnify and hold the Company and/or its Affiliates harmless from any failure by the
Company and/or its Affiliates to withhold the proper amount. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>9. M<SMALL>ISCELLANEOUS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) Source of Shares.</B> The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including
shares repurchased by the Company on the open market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) Use of Proceeds from Sales of Common Stock. </B>Proceeds from
the sale of shares of Common Stock pursuant to Awards will constitute general funds of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) Corporate Action Constituting
Grant of Awards.</B> Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument,
certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action approving
the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the Award Agreement or related grant
documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d) Stockholder Rights.</B> No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to,
any shares of Common Stock subject to such Award unless and until (i)&nbsp;such Participant has satisfied all requirements for exercise of the Award pursuant to its terms, if applicable, and (ii)&nbsp;the issuance of the Common Stock subject to such
Award is reflected in the records of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e) No Employment or Other Service Rights.</B> Nothing in the Plan, any Award
Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the
Award was granted or affect the right of the Company or an Affiliate to terminate at will and without regard to any future vesting opportunity that a Participant may have with respect to any Award (i)&nbsp;the employment of an Employee with or
without notice and with or without cause, (ii)&nbsp;the service of a Consultant pursuant to the terms of such Consultant&#146;s agreement with the Company or an Affiliate, or (iii)&nbsp;the service of a Director pursuant to the Bylaws of the Company
or an Affiliate, and any applicable provisions of the corporate law of the state or foreign jurisdiction in which the Company or the Affiliate is incorporated, as the case may be. Further, nothing in the Plan, any Award Agreement or any other
instrument executed thereunder or in connection with any Award will constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term
or condition of employment or service or confer any right or benefit under the Award or the Plan unless such right or benefit has specifically accrued under the terms of the Award Agreement and/or Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f) Change in Time Commitment</B>. In the event a Participant&#146;s regular level of time commitment in the performance of his or her
services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an
extended leave of absence) after the date of grant of any Award to the Participant, the Board may determine, to the extent permitted by Applicable Law, to (i)&nbsp;make a corresponding reduction in the number of shares or cash amount subject to any
portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii)&nbsp;in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In
the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g) Execution of Additional Documents.</B> As a condition to accepting an Award under the
Plan, the Participant agrees to execute any additional documents or instruments necessary or desirable, as determined in the Plan Administrator&#146;s sole discretion, to carry out the purposes or intent of the Award, or facilitate compliance with
securities and/or other regulatory requirements, in each case at the Plan Administrator&#146;s request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(h) Electronic Delivery and
Participation</B>. Any reference herein or in an Award Agreement to a &#147;written&#148; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or
posted on the Company&#146;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). By accepting any Award the Participant consents to receive documents by electronic delivery and to participate
in the Plan through any <FONT STYLE="white-space:nowrap">on-line</FONT> electronic system established and maintained by the Plan Administrator or another third party selected by the Plan Administrator. The form of delivery of any Common Stock (e.g.,
a stock certificate or electronic entry evidencing such shares) shall be determined by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) Clawback/Recovery</B>. All
Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#146;s
securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law and any clawback policy that the Company otherwise adopts, to the extent applicable and permissible under
Applicable Law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of
previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a Participant&#146;s right to voluntary terminate employment
upon a &#147;resignation for good reason,&#148; or for a &#147;constructive termination&#148; or any similar term under any plan of or agreement with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(j) Securities Law Compliance. </B>A Participant will not be issued any shares in respect of an Award unless either (i)&nbsp;the shares are
registered under the Securities Act; or (ii)&nbsp;the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act. Each Award also must comply with other Applicable Law governing the Award, and
a Participant will not receive such shares if the Company determines that such receipt would not be in material compliance with Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(k) Transfer or Assignment of Awards; Issued Shares.</B> Except as expressly provided in the Plan or the form of Award Agreement, Awards
granted under the Plan may not be transferred or assigned by the Participant. After the vested shares subject to an Award have been issued, or in the case of Restricted Stock and similar awards, after the issued shares have vested, the holder of
such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of the Trading Policy and Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(l) Effect on Other Employee Benefit Plans. </B>The value of any Award granted under the Plan, as determined upon grant, vesting or
settlement, shall not be included as compensation, earnings, salaries, or other similar terms used when calculating any Participant&#146;s benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan
otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#146;s or any Affiliate&#146;s employee benefit plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(m) Deferrals.</B> To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine that the delivery of Common
Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may also establish programs and procedures for deferral elections to be made by Participants. Deferrals will be made in
accordance with the requirements of Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(n) Section</B><B></B><B>&nbsp;409A. </B>Unless otherwise expressly provided
for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
granted hereunder exempt from Section&nbsp;409A, and, to the extent not so exempt, in compliance with the requirements of Section&nbsp;409A. If the Board determines that any Award granted
hereunder is not exempt from and is therefore subject to Section&nbsp;409A, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section&nbsp;409A(a)(1) of the Code, and
to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement
specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes &#147;deferred compensation&#148; under Section&nbsp;409A is a &#147;specified employee&#148; for purposes of
Section&nbsp;409A, no distribution or payment of any amount that is due because of a &#147;separation from service&#148; (as defined in Section&nbsp;409A without regard to alternative definitions thereunder) will be issued or paid before the date
that is six months and one day following the date of such Participant&#146;s &#147;separation from service&#148; or, if earlier, the date of the Participant&#146;s death, unless such distribution or payment can be made in a manner that complies with
Section&nbsp;409A, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(o) Choice of Law.</B> This Plan and any controversy arising out of or relating to this Plan shall be governed by, and construed in
accordance with, the internal laws of the State of Delaware, without regard to conflict of law principles that would result in any application of any law other than the law of the State of Delaware. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>10. C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B><B>Compliance with Law.</B> The Company will seek to obtain from each regulatory commission or agency, as may be deemed to be
necessary, having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise or vesting of the Awards; provided, however, that this undertaking will not require the Company
to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or
agency the authority that counsel for the Company deems necessary or advisable for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise
or vesting of such Awards unless and until such authority is obtained. A Participant is not eligible for the grant of an Award or the subsequent issuance of Common Stock pursuant to the Award if such grant or issuance would be in violation of any
Applicable Law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>11. A<SMALL>DDITIONAL</SMALL> R<SMALL>ULES</SMALL> <SMALL>FOR</SMALL> A<SMALL>WARDS</SMALL> S<SMALL>UBJECT</SMALL>
<SMALL>TO</SMALL> S<SMALL>ECTION</SMALL>&nbsp;409A. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) Application. </B>Unless the provisions of this Section of the Plan are
expressly superseded by the provisions in the form of Award Agreement, the provisions of this Section shall apply and shall supersede anything to the contrary set forth in the Award Agreement for a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT>
Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Subject to <FONT STYLE="white-space:nowrap">Non-Exempt</FONT>
Severance Arrangements.</B> To the extent a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award is subject to Section&nbsp;409A due to application of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, the following
provisions of this subsection (b)&nbsp;apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) </B>If the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award vests in the
ordinary course during the Participant&#146;s Continuous Service in accordance with the vesting schedule set forth in the Award Agreement, and does not accelerate vesting under the terms of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT>
Severance Arrangement, in no event will the shares be issued in respect of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award any later than the later of: (i)&nbsp;December 31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of the
calendar year that includes the applicable vesting date, or (ii)&nbsp;the 60<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day that follows the applicable vesting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>If vesting of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award accelerates under the terms of a <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement in connection with the Participant&#146;s Separation from Service, and such vesting acceleration provisions were in effect as of the date of grant of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award and, therefore, are part of the terms of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award as of the date of grant, then the shares will be earlier issued in settlement of such
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award upon the Participant&#146;s Separation from Service in accordance with the terms of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, but in no event later than the
60<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day that follows the date of the Participant&#146;s Separation from Service. However, if at the time the shares would otherwise be issued the Participant is subject to the distribution
limitations contained in Section&nbsp;409A applicable to &#147;specified employees,&#148; as defined in Section&nbsp;409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of such
Participant&#146;s Separation from Service, or, if earlier, the date of the Participant&#146;s death that occurs within such six month period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii) </B>If vesting of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award accelerates under the terms of a <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement in connection with a Participant&#146;s Separation from Service, and such vesting acceleration provisions were not in effect as of the date of grant of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award and, therefore, are not a part of the terms of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award on the date of grant, then such acceleration of vesting of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall not accelerate the issuance date of the shares, but the shares shall instead be issued on the same schedule as set forth in the Grant Notice as if they had vested in the ordinary course during
the Participant&#146;s Continuous Service, notwithstanding the vesting acceleration of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Such issuance schedule is intended to satisfy the requirements of payment on a specified date or
pursuant to a fixed schedule, as provided under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(a)(4).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) Treatment of <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Upon a Corporate Transaction for Employees and Consultants.</B>
The provisions of this subsection (c)&nbsp;shall apply and shall supersede anything to the contrary set forth in the Plan with respect to the permitted treatment of any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award in connection with a
Corporate Transaction if the Participant was either an Employee or Consultant upon the applicable date of grant of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards.</B> The following provisions shall apply to any Vested <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award in connection with a Corporate Transaction: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(1) </B>If the
Corporate Transaction is also a Section&nbsp;409A Change in Control then the Acquiring Entity may not assume, continue or substitute the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Upon the Section&nbsp;409A Change in Control
the settlement of the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will automatically be accelerated and the shares will be immediately issued in respect of the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award.
Alternatively, the Company may instead provide that the Participant will receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section&nbsp;409A Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(2) </B>If the Corporate Transaction is not also a Section&nbsp;409A Change in Control, then the Acquiring Entity must
either assume, continue or substitute each Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. The shares to be issued in respect of the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be issued to the Participant
by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#146;s discretion, in lieu of an issuance of shares, the Acquiring Entity
may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of the Fair Market Value of the
shares made on the date of the Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards.</B> The
following provisions shall apply to any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award unless otherwise determined by the Board pursuant to subsection (e)&nbsp;of this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(1) </B>In the event of a Corporate Transaction, the Acquiring Entity shall assume, continue or substitute any Unvested <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Unless otherwise determined by the Board, any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will remain subject to the same vesting and forfeiture restrictions that were
applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be issued to the Participant by the Acquiring Entity on the same schedule
that the shares would have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#146;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead
substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value of the shares made on the
date of the Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(2) </B>If the Acquiring Entity will not assume, substitute or continue any
Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award in connection with a Corporate Transaction, then such Award shall automatically terminate and be forfeited upon the Corporate Transaction with no consideration payable to any
Participant in respect of such forfeited Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Notwithstanding the foregoing, to the extent permitted and in compliance with the requirements of Section&nbsp;409A, the Board may in its
discretion determine to elect to accelerate the vesting and settlement of the Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award upon the Corporate Transaction, or instead substitute a cash payment equal to the Fair Market Value of
such shares that would otherwise be issued to the Participant, as further provided in subsection (e)(ii) below. In the absence of such discretionary election by the Board, any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall
be forfeited without payment of any consideration to the affected Participants if the Acquiring Entity will not assume, substitute or continue the Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards in connection with the Corporate
Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(3) </B>The foregoing treatment shall apply with respect to all Unvested
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards upon any Corporate Transaction, and regardless of whether or not such Corporate Transaction is also a Section&nbsp;409A Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d) Treatment of <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Upon a Corporate Transaction for
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors.</B> The following provisions of this subsection (d)&nbsp;shall apply and shall supersede anything to the contrary that may be set forth in the Plan with respect to the permitted
treatment of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award in connection with a Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)
</B>If the Corporate Transaction is also a Section&nbsp;409A Change in Control then the Acquiring Entity may not assume, continue or substitute the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Upon the Section&nbsp;409A Change
in Control the vesting and settlement of any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award will automatically be accelerated and the shares will be immediately issued to the Participant in respect of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Alternatively, the Company may provide that the Participant will instead receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the
Participant upon the Section&nbsp;409A Change in Control pursuant to the preceding provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>If the Corporate Transaction is
not also a Section&nbsp;409A Change in Control, then the Acquiring Entity must either assume, continue or substitute the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Unless otherwise determined by the Board, the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In
the Acquiring Entity&#146;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the
Participant on such issuance dates, with the determination of Fair Market Value made on the date of the Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)
</B>If the RSU Award is a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award, then the provisions in this Section&nbsp;11(e) shall apply and supersede anything to the contrary that may be set forth in the Plan or the Award Agreement with
respect to the permitted treatment of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) </B>Any exercise by the Board
of discretion to accelerate the vesting of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall not result in any acceleration of the scheduled issuance dates for the shares in respect of the
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
unless earlier issuance of the shares upon the applicable vesting dates would be in compliance with the requirements of Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>The Company explicitly reserves the right to earlier settle any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award to the
extent permitted and in compliance with the requirements of Section&nbsp;409A, including pursuant to any of the exemptions available in Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(j)(4)(ix).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii) </B>To the extent the terms of any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award provide that it will be settled upon a
Change in Control or Corporate Transaction, to the extent it is required for compliance with the requirements of Section&nbsp;409A, the Change in Control or Corporate Transaction event triggering settlement must also constitute a Section&nbsp;409A
Change in Control. To the extent the terms of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award provides that it will be settled upon a termination of employment or termination of Continuous Service, to the extent it is required for
compliance with the requirements of Section&nbsp;409A, the termination event triggering settlement must also constitute a Separation From Service. However, if at the time the shares would otherwise be issued to a Participant in connection with a
&#147;separation from service&#148; such Participant is subject to the distribution limitations contained in Section&nbsp;409A applicable to &#147;specified employees,&#148; as defined in Section&nbsp;409A(a)(2)(B)(i) of the Code, such shares shall
not be issued before the date that is six months following the date of the Participant&#146;s Separation From Service, or, if earlier, the date of the Participant&#146;s death that occurs within such six month period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv) </B>The provisions in this subsection (e)&nbsp;for delivery of the shares in respect of the settlement of an RSU Award that is a <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award are intended to comply with the requirements of Section&nbsp;409A so that the delivery of the shares to the Participant in respect of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award
will not trigger the additional tax imposed under Section&nbsp;409A, and any ambiguities herein will be so interpreted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>12.
S<SMALL>EVERABILITY</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If all or any part of the Plan or any Award Agreement is declared by any court or governmental authority
to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award Agreement not declared to be unlawful or invalid. Any Section of the Plan or any Award Agreement (or part of such a Section) so
declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>13. T<SMALL>ERMINATION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Board may suspend or terminate the Plan at any time. No Incentive Stock Options may be granted after the tenth anniversary of the earlier
of: (i)&nbsp;the Adoption Date, or (ii)&nbsp;the date the Plan is approved by the Company&#146;s stockholders. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>14. D<SMALL>EFINITIONS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As used in the Plan, the following definitions apply to the capitalized terms indicated below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>&#147;<B><I>Acquiring Entity</I></B>&#148; means the surviving or acquiring corporation (or its parent company) in connection with a
Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>&#147;<B><I>Adoption Date</I></B>&#148; means the date the Plan is first approved by the Board or
Compensation Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) </B>&#147;<B><I>Affiliate</I></B>&#148; means, at the time of determination, any &#147;parent&#148; or
&#147;subsidiary&#148; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board may determine the time or times at which &#147;parent&#148; or &#147;subsidiary&#148; status is determined within the
foregoing definition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d) </B>&#147;<B><I>Applicable Law</I></B>&#148; means any applicable securities,
federal, state, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing rule, regulation, judicial decision, ruling or requirement issued, enacted,
adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of any applicable self-regulating organization such as the Nasdaq Stock Market, New York Stock Exchange,
or the Financial Industry Regulatory Authority). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e) </B>&#147;<B><I>Award</I></B>&#148; means any right to receive Common Stock, cash
or other property granted under the Plan (including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, an RSU Award, a SAR, a Performance Award or any Other Award). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f) </B>&#147;<B><I>Award Agreement</I></B>&#148; means a written or electronic agreement between the Company and a Participant evidencing
the terms and conditions of an Award. The Award Agreement generally consists of the Grant Notice and the agreement containing the written summary of the general terms and conditions applicable to the Award and which is provided, including through
electronic means, to a Participant along with the Grant Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g) </B>&#147;<B><I>Board</I></B>&#148; means the Board of Directors
of the Company (or its designee). Any decision or determination made by the Board shall be a decision or determination that is made in the sole discretion of the Board (or its designee), and such decision or determination shall be final and binding
on all Participants </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(h) </B>&#147;<B><I>Business Combination Agreement</I></B>&#148; means that certain Business Combination Agreement
by and among <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., Perseverance Merger Sub Inc., and Surrozen, Inc., dated as of April 15, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) </B><I>&#147;</I><B><I>Capitalization Adjustment</I></B>&#148; means any change that is made in, or other events that occur with
respect to, the Common Stock subject to the Plan or subject to any Award after the date the Plan is adopted by the Board without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization,
reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar
equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible
securities of the Company will not be treated as a Capitalization Adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(j) </B>&#147;<B><I>Cause</I></B>&#148; has the meaning
ascribed to such term in any written agreement between a Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events:&nbsp;(i)
the Participant&#146;s dishonest statements or acts with respect to the Company or any Affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business; (ii)&nbsp;the
Participant&#146;s commission of (A)&nbsp;a felony or (B)&nbsp;any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&nbsp;the Participant&#146;s failure to perform the Participant&#146;s assigned duties and responsibilities
to the reasonable satisfaction of the Company which failure continues, in the reasonable judgment of the Company, after written notice given to the Participant by the Company; (iv)&nbsp;the Participant&#146;s gross negligence, willful misconduct or
insubordination with respect to the Company or any Affiliate of the Company; or (v)&nbsp;the Participant&#146;s material violation of any provision of any agreement(s) between the Participant and the Company relating to noncompetition,
nonsolicitation, nondisclosure and/or assignment of inventions. The determination that a termination of the Participant&#146;s Continuous Service is either for Cause or without Cause will be made by the Board with respect to Participants who are
executive officers of the Company and by the Company&#146;s Chief Executive Officer with respect to Participants who are not executive officers of the Company. Any determination by the Company that the Continuous Service of a Participant was
terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(k) </B>&#147;<B><I>Change in Control</I></B>&#148; or &#147;<B><I>Change of</I></B>
<B><I>Control</I></B>&#148; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) </B>any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the
combined voting power of the Company&#146;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A)&nbsp;on account of
the acquisition of securities of the Company directly from the Company, (B)&nbsp;on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#146;s
securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, or (C)&nbsp;solely because the level of Ownership held by any Exchange Act
Person (the &#147;<B><I>Subject Person</I></B>&#148;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares
outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any
additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change
in Control shall be deemed to occur; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>there is consummated a merger, consolidation or similar transaction involving (directly
or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A)&nbsp;outstanding voting
securities representing more than 50% of the combined outstanding voting power of the Acquiring Entity in such merger, consolidation or similar transaction or (B)&nbsp;more than 50% of the combined outstanding voting power of the parent of the
Acquiring Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii) </B>there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets
of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the
voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; or
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv) </B>individuals who, on the date the Plan is adopted by the Board, are members of the Board (the &#147;<B><I>Incumbent
Board</I></B>&#148;) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a
majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing or any other provision of this Plan, (A)&nbsp;the term Change in Control shall not include a sale of assets,
merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B)&nbsp;the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate
and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement,
the foregoing definition shall apply, and (C)&nbsp;with respect to any nonqualified deferred compensation that becomes payable on account of the Change in Control, the transaction or event described in clause (i), (ii), (iii), or (iv)&nbsp;also
constitutes a Section&nbsp;409A Change in Control if required in order for the payment not to violate Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(l) </B>&#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and
guidance thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(m) </B>&#147;<B><I>Committee</I></B>&#148; means the Compensation Committee and any
other committee of one or more Directors to whom authority has been delegated by the Board or Compensation Committee in accordance with the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(n) </B>&#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(o) </B>&#147;<B><I>Company</I></B>&#148; means Surrozen, Inc., a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(p) </B>&#147;<B><I>Compensation Committee</I></B>&#148; means the Compensation Committee of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(q) </B>&#147;<B><I>Consultant</I></B>&#148; means any person, including an advisor, who is (i)&nbsp;engaged by the Company or an Affiliate
to render consulting or advisory services and is compensated for such services, or (ii)&nbsp;serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a
fee for such service, will not cause a Director to be considered a &#147;Consultant&#148; for purposes of the Plan.<B><I> </I></B>Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form <FONT
STYLE="white-space:nowrap">S-8</FONT> Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#146;s securities to such person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(r) </B>&#147;<B><I>Continuous Service</I></B>&#148; means that the Participant&#146;s service with the Company or an Affiliate, whether as
an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the
Participant renders such service, provided that there is no interruption or termination of the Participant&#146;s service with the Company or an Affiliate, will not terminate a Participant&#146;s Continuous Service; provided, however, that if the
Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, such Participant&#146;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an
Affiliate. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive
officer of the Company, in that party&#146;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i)&nbsp;any leave of absence approved by the Board or chief executive officer, including sick
leave, military leave or any other personal leave, or (ii)&nbsp;transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an
Award only to such extent as may be provided in the Company&#146;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. In addition, to the extent
required for exemption from or compliance with Section&nbsp;409A, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of
&#147;separation from service&#148; as defined under Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)</FONT> (without regard to any alternative definition thereunder). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(s) </B>&#147;<B><I>Corporate Transaction</I></B>&#148; means the consummation, in a single transaction or in a series of related
transactions, of any one or more of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) </B>a sale<B> </B>or other disposition of all or substantially all, as
determined by the Board, of the consolidated assets of the Company and its Subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>a sale or other disposition of at
least 50% of the outstanding securities of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii) </B>a merger, consolidation or similar transaction following which the
Company is not the surviving corporation; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv) </B>a merger, consolidation or similar transaction following which the Company is
the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property,
whether in the form of securities, cash or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing or any other provision of this Plan, (A)&nbsp;the term
Corporate Transaction shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B)&nbsp;the definition of Corporate Transaction (or any analogous term) in an
individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Corporate Transaction or any
analogous term is set forth in such an individual written agreement, the foregoing definition shall apply, and (C)&nbsp;with respect to any nonqualified deferred compensation that becomes payable on account of the Corporate Transaction, the
transaction or event described in clause (i), (ii), (iii), or (iv)&nbsp;also constitutes a Section&nbsp;409A Change in Control if required in order for the payment not to violate Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(t) </B>&#147;<B><I>Director</I></B>&#148; means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(u) </B>&#147;<B><I>determine</I></B>&#148;<B><I> or </I></B>&#147;<B><I>determined</I></B>&#148;<B><I> </I></B>means as determined by the
Board or the Committee (or its designee) in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v) </B>&#147;<B><I>Disability</I></B>&#148; means, with respect to a
Participant, such Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a
continuous period of not less than 12 months, as provided in Section&nbsp;22(e)(3) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(w) </B>&#147;<B><I>Effective Date</I></B>&#148; means the effective date of this Plan, which is the date of the closing of the
transactions contemplated by the Business Combination Agreement, provided that this Plan is approved by the Company&#146;s stockholders prior to such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(x) </B>&#147;<B><I>Employee</I></B>&#148; means any person employed by the Company or an Affiliate. However, service solely as a Director,
or payment of a fee for such services, will not cause a Director to be considered an &#147;Employee&#148; for purposes of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(y) </B>&#147;<B><I>Employer</I></B>&#148; means the Company or the Affiliate of the Company that employs the Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(z) </B>&#147;<B><I>Entity</I></B>&#148; means a corporation, partnership, limited liability company or other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(aa) </B>&#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(bb) </B>&#147;<B><I>Exchange Act Person</I></B>&#148;<B><I> </I></B>means any natural person, Entity or
&#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act), except that &#147;Exchange Act Person&#148; will not include (i)&nbsp;the Company or any Subsidiary of the Company, (ii)&nbsp;any employee benefit plan of the
Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii)&nbsp;an underwriter temporarily holding securities pursuant to a
registered public offering of such securities, (iv)&nbsp;an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company, or (v)&nbsp;any natural person,
Entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting
power of the Company&#146;s then outstanding securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(cc) </B>&#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date,
unless otherwise determined by the Board, the value of the Common Stock (as determined on a per share or aggregate basis, as applicable) determined as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) </B>If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value will be
the closing sales price for such stock as quoted on such exchange or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>If there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the
closing selling price on the last preceding date for which such quotation exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii) </B>In the absence of such markets for the
Common Stock, or if otherwise determined by the Board, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(dd) </B>&#147;<B><I>Fully-Diluted Common Stock</I></B>&#148; means, as of any date, the aggregate number of (i)&nbsp;shares of Common
Stock issued and outstanding and (ii)&nbsp;securities convertible into or exercisable for shares of Common Stock (whether vested or unvested). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ee) </B>&#147;<B><I>Governmental</I></B><B> </B><B><I>Body</I></B>&#148; means any: (a)&nbsp;nation, state, commonwealth, province,
territory, county, municipality, district or other jurisdiction of any nature; (b)&nbsp;federal, state, local, municipal, foreign or other government; (c)&nbsp;governmental or regulatory body, or quasi-governmental body of any nature (including any
governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of
doubt, any Tax authority) or other body exercising similar powers or authority; or (d)&nbsp;self-regulatory organization (including the Nasdaq Stock Market, New York Stock Exchange, and the Financial Industry Regulatory Authority). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ff) </B>&#147;<B><I>Grant Notice</I></B>&#148; means the notice provided to a Participant that he or she has been granted an Award under
the Plan and which includes the name of the Participant, the type of Award, the date of grant of the Award, number of shares of Common Stock subject to the Award or potential cash payment right, (if any), the vesting schedule for the Award (if any)
and other key terms applicable to the Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(gg) </B>&#147;<B><I>Incentive Stock Option</I></B>&#148; means an option granted
pursuant to Section&nbsp;4 of the Plan that is intended to be, and qualifies as, an &#147;incentive stock option&#148; within the meaning of Section&nbsp;422 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(hh) </B>&#147;<B><I>Materially Impair</I></B>&#148;<B><I> </I></B>means any amendment to the terms of the Award that materially adversely
affects the Participant&#146;s rights under the Award. A Participant&#146;s rights under an Award will not be deemed to have been Materially Impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as
a whole, does not materially impair the Participant&#146;s rights. For example, the following types of amendments to the terms of an Award do not Materially Impair the Participant&#146;s rights under the Award: (i)&nbsp;imposition of reasonable
restrictions on the minimum number of shares subject to an Option or SAR that may be exercised, (ii)&nbsp;to maintain the qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the Code, (iii)&nbsp;to change the terms
of an Incentive Stock Option in a manner that disqualifies, impairs or otherwise affects the qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the Code, (iv)&nbsp;to clarify the manner of exemption from, or to
bring the Award into compliance with or qualify it for an exemption from, Section&nbsp;409A, or (v)&nbsp;to comply with other Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>&#147;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</I></B>&#148;<B> </B>means a Director who either
(i)&nbsp;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a
Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated pursuant to the Securities Act (&#147;<B><I>Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT></I></B>&#148;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> and is not engaged
in a business relationship for which disclosure would be required pursuant to Item&nbsp;404(b) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> or (ii)&nbsp;is otherwise considered a
<FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; for purposes of Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(jj) </B>&#147;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT>
Award</I></B>&#148;<B><I> </I></B>means any Award that is subject to, and not exempt from, Section&nbsp;409A, including as the result of (i)&nbsp;a deferral of the issuance of the shares subject to the Award which is elected by the Participant or
imposed by the Company, or (ii)&nbsp;the terms of any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(kk)
</B>&#147;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award</I></B>&#148; means a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award granted to a Participant who was a Director but not an Employee on the applicable grant
date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ll) </B>&#147;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement</I></B>&#148; means a severance
arrangement or other agreement between the Participant and the Company that provides for acceleration of vesting of an Award and issuance of the shares in respect of such Award upon the Participant&#146;s termination of employment or separation from
service (as such term is defined in Section&nbsp;409A(a)(2)(A)(i) of the Code (and without regard to any alternative definition thereunder) (&#147;<B><I>Separation from Service</I></B>&#148;) and such severance benefit does not satisfy the
requirements for an exemption from application of Section&nbsp;409A provided under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4),</FONT> <FONT STYLE="white-space:nowrap">1.409A-1(b)(9)</FONT> or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(mm) </B>&#147;<B><I>Nonstatutory Stock Option</I></B>&#148; means any option granted pursuant to Section&nbsp;4 of the Plan that does not
qualify as an Incentive Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(nn) </B>&#147;<B><I>Officer</I></B>&#148; means a person who is an officer of the Company
within the meaning of Section&nbsp;16 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(oo) </B>&#147;<B><I>Option</I></B>&#148; means an Incentive Stock Option
or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(pp) </B>&#147;<B><I>Option
Agreement</I></B>&#148; means a written or electronic agreement between the Company and the Optionholder evidencing the terms and conditions of the Option grant. The Option Agreement includes the Grant Notice for the Option and the agreement
containing the written summary of the general terms and conditions applicable to the Option and which is provided, including through electronic means, to a Participant along with the Grant Notice. Each Option Agreement will be subject to the terms
and conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(qq) </B>&#147;<B><I>Optionholder</I></B>&#148; means a person to whom an Option is granted pursuant to
the Plan or, if applicable, such other person who holds an outstanding Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(rr) </B>&#147;<B><I>Other Award</I></B>&#148; means an
award valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value at the
time of grant) that is not an Incentive Stock Option, Nonstatutory Stock Option, SAR, Restricted Stock Award, RSU Award or Performance Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ss) </B>&#147;<B><I>Other Award Agreement</I></B>&#148;<B><I> </I></B>means a written or electronic agreement between the Company and a
holder of an Other Award evidencing the terms and conditions of an Other Award grant. Each Other Award Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(tt) </B>&#147;<B><I>Own,</I></B>&#148;<B><I> </I></B>&#147;<B><I>Owned,</I></B>&#148;<B><I> </I></B>&#147;<B><I>Owner,</I></B>&#148;<B><I>
</I></B>&#147;<B><I>Ownership</I></B>&#148;<B> </B>means that a person or Entity will be deemed to &#147;Own,&#148; to have &#147;Owned,&#148; to be the &#147;Owner&#148; of, or to have acquired &#147;Ownership&#148; of securities if such person or
Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(uu) </B>&#147;<B><I>Participant</I></B>&#148; means an Employee, Director or Consultant to whom an Award is granted pursuant to the Plan
or, if applicable, such other person who holds an outstanding Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(vv) </B>&#147;<B><I>Performance Award</I></B>&#148; means an
Award that may vest or may be exercised or a cash award that may vest or become earned and paid contingent upon the attainment during a Performance Period of certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Performance Goals and which is granted under the terms and conditions of Section&nbsp;5(b) pursuant to such terms as are approved by the Board. In addition, to the extent permitted by Applicable
Law and set forth in the applicable Award Agreement, the Board may determine that cash or other property may be used in payment of Performance Awards. Performance Awards that are settled in cash or other property are not required to be valued in
whole or in part by reference to, or otherwise based on, the Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ww) </B>&#147;<B><I>Performance Criteria</I></B>&#148;
means the one or more criteria that the Board will select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or
combination of, the following as determined by the Board: earnings (including earnings per share and net earnings); earnings before interest, taxes and depreciation; earnings before interest, taxes, depreciation and amortization; total stockholder
return; return on equity or average stockholder&#146;s equity; return on assets, investment, or capital employed; stock price; margin (including gross margin); income (before or after taxes); operating income; operating income after taxes; <FONT
STYLE="white-space:nowrap">pre-tax</FONT> profit; operating cash flow; sales or revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of working capital levels; economic value added
(or an equivalent metric); market share; cash flow; cash flow per share; share price performance; debt reduction; customer satisfaction; stockholders&#146; equity; capital expenditures; debt levels; operating profit or net operating profit;
workforce diversity; growth of net income or operating income; billings; financing; regulatory milestones; stockholder liquidity; corporate governance and compliance; intellectual property; personnel matters; progress of internal research; progress
of partnered programs; partner satisfaction; budget management; partner or collaborator achievements; internal controls, including those related to the Sarbanes-Oxley Act of 2002; investor relations, analysts and communication; implementation or
completion of projects or processes; employee retention; number of users, including unique users; strategic partnerships or transactions (including <FONT STYLE="white-space:nowrap">in-licensing</FONT> and
<FONT STYLE="white-space:nowrap">out-licensing</FONT> of intellectual property); establishing relationships with respect to the marketing, distribution and sale of the Company&#146;s products; supply chain achievements; <FONT
STYLE="white-space:nowrap">co-development,</FONT> <FONT STYLE="white-space:nowrap">co-marketing,</FONT> profit sharing, joint venture or other similar arrangements; individual performance goals; corporate development and planning goals; and other
measures of performance selected by the Board or Committee whether or not listed herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(xx) </B>&#147;<B><I>Performance
Goals</I></B>&#148; means, for a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more
business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Board
(i)&nbsp;in the Award Agreement at the time the Award is granted or (ii)&nbsp;in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Board will appropriately make adjustments in the method
of calculating the attainment of Performance Goals for a Performance Period as follows: (1)&nbsp;to exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects; (3)&nbsp;to exclude the effects of changes to
generally accepted accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as
determined under generally accepted accounting principles; (6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (7)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted levels
during the balance of a Performance Period following such divestiture; (8)&nbsp;to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization,
recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends;
(9)&nbsp;to exclude the effects of stock based compensation and the award of bonuses under the Company&#146;s bonus plans; (10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed
under generally accepted accounting principles; and (11)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. In addition, the Board may establish or
provide for other adjustment items in the Award Agreement at the time the Award is granted or in such other document setting forth the Performance Goals at the time the Performance Goals are established. In addition, the Board retains the discretion
to reduce or eliminate the compensation or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for such Performance Period. Partial achievement of
the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the Award Agreement or the written terms of a Performance Cash Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(yy) </B>&#147;<B><I>Performance Period</I></B>&#148; means the period of time selected by the Board over which the attainment of one or
more Performance Goals will be measured for the purpose of determining a Participant&#146;s right to vesting or exercise of an Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(zz) </B>&#147;<B><I>Plan</I></B>&#148; means this Surrozen, Inc. 2021 Equity Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(aaa) </B>&#147;<B><I>Plan Administrator</I></B>&#148; means the person, persons, and/or third-party administrator designated by the
Company to administer the day to day operations of the Plan and the Company&#146;s other equity incentive programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(bbb)
</B>&#147;<B><I>Post-Termination Exercise Period</I></B>&#148; means the period following termination of a Participant&#146;s Continuous Service within which an Option or SAR is exercisable, as specified in Section&nbsp;4(h). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ccc) </B>&#147;<B><I>Restricted Stock Award</I></B>&#148; or &#147;<B><I>RSA</I></B>&#148; means an Award of shares of Common Stock which
is granted pursuant to the terms and conditions of Section&nbsp;5(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ddd) </B>&#147;<B><I>Restricted Stock Award
Agreement</I></B>&#148; means a written or electronic agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. The Restricted Stock Award Agreement includes the
Grant Notice for the Restricted Stock Award and the agreement containing the written summary of the general terms and conditions applicable to the Restricted Stock Award and which is provided, including by electronic means, to a Participant along
with the Grant Notice. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(eee)
</B>&#147;<B><I>RSU Award</I></B>&#148; or &#147;<B><I>RSU</I></B>&#148;<B><I> </I></B>means an Award of restricted stock units representing the right to receive an issuance of shares of Common Stock which is granted pursuant to the terms and
conditions of Section&nbsp;5(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(fff) </B>&#147;<B><I>RSU Award Agreement</I></B>&#148;<B><I> </I></B>means a written or electronic
agreement between the Company and a holder of an RSU Award evidencing the terms and conditions of an RSU Award. The RSU Award Agreement includes the Grant Notice for the RSU Award and the agreement containing the written summary of the general terms
and conditions applicable to the RSU Award and which is provided, including by electronic means, to a Participant along with the Grant Notice. Each RSU Award Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ggg) </B>&#147;<B><I>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></I></B>&#148; means Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act or any successor to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(hhh) </B>&#147;<B><I>Rule 405</I></B>&#148; means Rule 405 promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii) </B>&#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148; means Section&nbsp;409A of the Code and the regulations
and other guidance thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(jjj) </B>&#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A Change in Control</I></B>&#148;
means a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company&#146;s assets, as provided in Section&nbsp;409A(a)(2)(A)(v) of the Code and Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT> (without regard to any alternative definition thereunder). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(kkk)
</B>&#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(lll) </B>&#147;<B><I>Share Reserve</I></B>&#148; means the number of shares available
for issuance under the Plan as set forth in Section&nbsp;2(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(mmm) </B>&#147;<B><I>Stock Appreciation Right</I></B>&#148; or
&#147;<B><I>SAR</I></B>&#148;<B><I> </I></B>means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section&nbsp;4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(nnn) </B>&#147;<B><I>SAR Agreement</I></B>&#148; means a written or electronic agreement between the Company and a holder of a SAR
evidencing the terms and conditions of a SAR grant. The SAR Agreement includes the Grant Notice for the SAR and the agreement containing the written summary of the general terms and conditions applicable to the SAR and which is provided, including
by electronic means, to a Participant along with the Grant Notice. Each SAR Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ooo) </B>&#147;<B><I>Subsidiary</I></B>&#148; means, with respect to the Company, (i)&nbsp;any corporation of which more than 50% of the
outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting
power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&nbsp;any partnership, limited liability company or other entity in which the Company has a direct or indirect interest
(whether in the form of voting or participation in profits or capital contribution) of more than 50%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ppp) </B>&#147;<B><I>Ten
Percent Stockholder</I></B>&#148; means a person who Owns (or is deemed to Own pursuant to Section&nbsp;424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(qqq) </B>&#147;<B><I>Trading Policy</I></B>&#148; means the Company&#146;s policy permitting certain individuals to sell Company
shares only during certain &#147;window&#148; periods and/or otherwise restricts the ability of certain individuals to transfer or encumber Company shares, as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(rrr) </B>&#147;<B><I>Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#148; means the portion of any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award that had not vested in accordance with its terms upon or prior to the date of any Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(sss) </B>&#147;<B><I>Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#148; means the portion of any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award that had vested in accordance with its terms upon or prior to the date of a Corporate Transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit H </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>URROZEN</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 E<SMALL>MPLOYEE</SMALL> S<SMALL>TOCK</SMALL> P<SMALL>URCHASE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>:
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>:
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>1. G<SMALL>ENERAL</SMALL>; P<SMALL>URPOSE</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to
purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to
Eligible Employees that do not meet the requirements of an Employee Stock Purchase Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>The Plan includes two components: a
423 Component and a <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. The Company intends (but makes no undertaking or representation to maintain) the 423 Component to qualify as an Employee Stock Purchase Plan. The provisions of the 423
Component, accordingly, will be construed in a manner that is consistent with the requirements of Section&nbsp;423 of the Code. Except as otherwise provided in the Plan or determined by the Board, the <FONT STYLE="white-space:nowrap">Non-423</FONT>
Component will operate and be administered in the same manner as the 423 Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) </B>The Company, by means of the Plan, seeks
to retain the services of Eligible Employees, to secure and retain the services of new Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2. A<SMALL>DMINISTRATION</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>The Board or the Committee will administer the Plan. References herein to the Board shall be deemed to refer to the Committee except
where context dictates otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>The Board will have the power, subject to, and within the limitations of, the express
provisions of the Plan: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) </B>To determine how and when Purchase Rights will be granted and the provisions of each Offering (which
need not be identical). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>To designate from time to time (A)&nbsp;which Related Corporations will be eligible to participate in
the Plan as Designated 423 Corporations, (B)&nbsp;which Related Corporations or Affiliates will be eligible to participate in the Plan as Designated <FONT STYLE="white-space:nowrap">Non-423</FONT> Corporations, and (C)&nbsp;which Designated
Companies will participate in each separate Offering (to the extent that the Company makes separate Offerings). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii) </B>To construe
and interpret the Plan and Purchase Rights, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to
the extent it deems necessary or expedient to make the Plan fully effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv) </B>To settle all controversies regarding the Plan
and Purchase Rights granted under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v) </B>To suspend or terminate the Plan at any time as provided in Section&nbsp;12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(vi) </B>To amend the Plan at any time as provided in Section&nbsp;12. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(vii) </B>Generally, to exercise such powers and to perform such acts as it deems
necessary or expedient to promote the best interests of the Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan with respect to the 423 Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(viii) </B>To adopt such rules, procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit
or facilitate participation in the Plan by Employees who are foreign nationals or employed or located outside the United States. Without limiting the generality of, and consistent with, the foregoing, the Board specifically is authorized to adopt
rules, procedures, and <FONT STYLE="white-space:nowrap">sub-plans</FONT> regarding, without limitation, eligibility to participate in the Plan, the definition of eligible &#147;earnings,&#148; handling and making of Contributions, establishment of
bank or trust accounts to hold Contributions, payment of interest, conversion of local currency, obligations to pay payroll tax, determination of beneficiary designation requirements, withholding procedures and handling of share issuances, any of
which may vary according to applicable requirements, and which, if applicable to a Designated <FONT STYLE="white-space:nowrap">Non-423</FONT> Corporation, do not have to comply with the requirements of Section&nbsp;423 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) </B>The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration is delegated
to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee any of the
administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as
may be adopted from time to time by the Board. Further, to the extent not prohibited by Applicable Law, the Board or Committee may, from time to time, delegate some or all of its authority under the Plan to one or more officers of the Company or
other persons or groups of persons as it deems necessary, appropriate or advisable under conditions or limitations that it may set at or after the time of the delegation. The Board may retain the authority to concurrently administer the Plan with
the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. Whether or not the Board has delegated administration of the Plan to a Committee, the Board will have the final power to determine all questions
of policy and expediency that may arise in the administration of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d) </B>All determinations, interpretations and
constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3. S<SMALL>HARES</SMALL> <SMALL>OF</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL>
<SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>Subject to the provisions of Section&nbsp;11(a) relating to Capitalization
Adjustments, the maximum number of shares of Common Stock that may be issued under the Plan will not exceed [&#9679;] shares (equal to 1% of the shares of Fully-Diluted Common Stock as of immediately following completion of the transactions
contemplated by the Business Combination Agreement), plus the number of shares of Common Stock that are automatically added on January&nbsp;1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of each year for a period of ten years commencing on
January&nbsp;1, 2022 and ending on (and including) January&nbsp;1, 2031, in an amount equal to the lesser of (i)&nbsp;1% of the Fully-Diluted Common Stock on December 31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of the preceding
calendar year, and (ii)&nbsp;[&#9679;] shares of Common Stock. Notwithstanding the foregoing, the Board may act prior to the first day of any calendar year to provide that there will be no January
1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year will be a lesser number of shares of Common Stock than would otherwise
occur pursuant to the preceding sentence. For the avoidance of doubt, up to the maximum number of shares of Common Stock reserved under this Section 3(a) may be used to satisfy purchases of Common Stock under the 423 Component and any remaining
portion of such maximum number of shares may be used to satisfy purchases of Common Stock under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>If any Purchase Right granted under the Plan terminates without having been exercised in full, the shares of Common Stock not
purchased under such Purchase Right will again become available for issuance under the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) </B>The stock purchasable under the Plan will be shares of authorized but unissued or
reacquired Common Stock, including shares repurchased by the Company on the open market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>4. G<SMALL>RANT</SMALL> <SMALL>OF</SMALL>
P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>; O<SMALL>FFERING</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>The Board may from time to time grant or provide
for the grant of Purchase Rights to Eligible Employees under an Offering (consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such form and will contain such terms and
conditions as the Board will deem appropriate, and, with respect to the 423 Component, will comply with the requirement of Section&nbsp;423(b)(5) of the Code that all Employees granted Purchase Rights will have the same rights and privileges. The
terms and conditions of an Offering shall be incorporated by reference into the Plan and treated as part of the Plan. The provisions of separate Offerings need not be identical, but each Offering will include (through incorporation of the provisions
of this Plan by reference in the document comprising the Offering or otherwise) the period during which the Offering will be effective, which period will not exceed 27 months beginning with the Offering Date, and the substance of the provisions
contained in Sections 5 through 8, inclusive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>If a Participant has more than one Purchase Right outstanding under the Plan,
unless he or she otherwise indicates in forms delivered to the Company or a third party designated by the Company (each, a &#147;<B><I>Company Designee</I></B>&#148;): (i) each form will apply to all of his or her Purchase Rights under the Plan, and
(ii)&nbsp;a Purchase Right with a lower exercise price (or an earlier-granted Purchase Right, if different Purchase Rights have identical exercise prices) will be exercised to the fullest possible extent before a Purchase Right with a higher
exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise prices) will be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)
</B>The Board will have the discretion to structure an Offering so that if the Fair Market Value of a share of Common Stock on the first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a
share of Common Stock on the Offering Date for that Offering, then (i)&nbsp;that Offering will terminate immediately as of that first Trading Day, and (ii)&nbsp;the Participants in such terminated Offering will be automatically enrolled in a new
Offering beginning on the first Trading Day of such new Purchase Period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>5. E<SMALL>LIGIBILITY</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>Purchase Rights may be granted only to Employees of the Company or, as the Board may designate in accordance with Section&nbsp;2(b),
to Employees of a Related Corporation or an Affiliate. Except as provided in Section&nbsp;5(b) or as required by Applicable Law, an Employee will not be eligible to be granted Purchase Rights unless, on the Offering Date, the Employee has been in
the employ of the Company, a Related Corporation or an Affiliate, as the case may be, for such continuous period preceding such Offering Date as the Board may require, but in no event will the required period of continuous employment be equal to or
greater than two years. In addition, the Board may (unless prohibited by Applicable Law) provide that no Employee will be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date, such Employee&#146;s customary employment
with the Company, the Related Corporation, or the Affiliate is more than 20 hours per week and more than five months per calendar year or such other criteria as the Board may determine consistent with Section&nbsp;423 of the Code with respect to the
423 Component. The Board may also exclude from participation in the Plan or any Offering Employees who are &#147;highly compensated employees&#148; (within the meaning of Section&nbsp;423(b)(4)(D) of the Code) of the Company or a Related Corporation
or a subset of such highly compensated employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>The Board may provide that each person who, during the course of an
Offering, first becomes an Eligible Employee will, on a date or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs thereafter, receive a Purchase Right under that Offering,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
which Purchase Right will thereafter be deemed to be a part of that Offering. Such Purchase Right will have the same characteristics as any Purchase Rights originally granted under that Offering,
as described herein, except that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) </B>the date on which such Purchase Right is granted will be the &#147;Offering Date&#148; of
such Purchase Right for all purposes, including determination of the exercise price of such Purchase Right; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>the period of the
Offering with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of such Offering; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii) </B>the Board may provide that if such person first becomes an Eligible Employee within a specified period of time before the end of
the Offering, he or she will not receive any Purchase Right under that Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) </B>No Employee will be eligible for the grant of
any Purchase Rights under the 423 Component if, immediately after any such Purchase Rights are granted, such Employee owns stock possessing five percent or more of the total combined voting power or value of all classes of stock of the Company or of
any Related Corporation. For purposes of this Section&nbsp;5(c), the rules of Section&nbsp;424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase
Rights and options will be treated as stock owned by such Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d) </B>As specified by Section&nbsp;423(b)(8) of the Code, an
Eligible Employee may be granted Purchase Rights under the 423 Component only if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such
Eligible Employee&#146;s rights to purchase stock of the Company or any Related Corporation to accrue at a rate which, when aggregated, exceeds US $25,000 of Fair Market Value of such stock (determined at the time such rights are granted, and which,
with respect to the Plan, will be determined as of their respective Offering Dates) for each calendar year in which such rights are outstanding at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e) </B>Officers of the Company and any Designated Company, if they are otherwise Eligible Employees, will be eligible to participate in
Offerings under the Plan. Notwithstanding the foregoing, the Board may (unless prohibited by Applicable Law) provide in an Offering that Employees who are highly compensated Employees within the meaning of Section&nbsp;423(b)(4)(D) of the Code will
not be eligible to participate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f) </B>Notwithstanding anything in this Section&nbsp;5 to the contrary, in the case of an Offering
under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, an Eligible Employee (or group of Eligible Employees) may be excluded from participation in the Plan or an Offering if the Board has determined, in its sole discretion, that
participation of such Eligible Employee(s) is not advisable or practical for any reason. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>6. P<SMALL>URCHASE</SMALL>
R<SMALL>IGHTS</SMALL>; P<SMALL>URCHASE</SMALL> P<SMALL>RICE</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>On each Offering Date, each Eligible Employee,
pursuant to an Offering made under the Plan, will be granted a Purchase Right to purchase up to that number of shares of Common Stock purchasable either with a percentage of earnings or with a maximum dollar amount, as designated by the Board,
during the period that begins on the Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date stated in the Offering, which date will be no later than the end of the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>The Board will establish one or more Purchase Dates during an Offering on which Purchase Rights granted for that Offering will be
exercised and shares of Common Stock will be purchased in accordance with such Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) </B>In connection with each Offering made
under the Plan, the Board may specify (i)&nbsp;a maximum number of shares of Common Stock that may be purchased by any Participant on any Purchase Date during such Offering,<SUP STYLE="font-size:85%; vertical-align:top">
</SUP></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
(ii)&nbsp;a maximum aggregate number of shares of Common Stock that may be purchased by all Participants pursuant to such Offering and/or (iii)&nbsp;a maximum aggregate number of shares of Common
Stock that may be purchased by all Participants on any Purchase Date under the Offering. If the aggregate purchase of shares of Common Stock issuable upon exercise of Purchase Rights granted under the Offering would exceed any such maximum aggregate
number, then, in the absence of any Board action otherwise, a pro rata (based on each Participant&#146;s accumulated Contributions) allocation of the shares of Common Stock (rounded down to the nearest whole share) available will be made in as
nearly a uniform manner as will be practicable and equitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d) </B>The purchase price of shares of Common Stock acquired pursuant
to Purchase Rights will be specified by Board prior to the commencement of an Offering and will not be less than the lesser of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)
</B>an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the Offering Date; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>an amount equal to
85% of the Fair Market Value of the shares of Common Stock on the applicable Purchase Date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>7. P<SMALL>ARTICIPATION</SMALL>;
W<SMALL>ITHDRAWAL</SMALL>; T<SMALL>ERMINATION</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>An Eligible Employee may elect to participate in an Offering and
authorize payroll deductions as the means of making Contributions by completing and delivering to the Company or a Company Designee, within the time specified for the Offering, an enrollment form provided by the Company or Company Designee. The
enrollment form will specify the amount of Contributions not to exceed the maximum amount specified by the Board. Each Participant&#146;s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be
deposited with the general funds of the Company except where Applicable Law requires that Contributions be deposited with a third party. If permitted in the Offering, a Participant may begin such Contributions with the first payroll occurring on or
after the Offering Date (or, in the case of a payroll date that occurs after the end of the prior Offering but before the Offering Date of the next new Offering, Contributions from such payroll will be included in the new Offering). If permitted in
the Offering, a Participant may thereafter reduce (including to zero) or increase his or her Contributions. If required under Applicable Law or if specifically provided in the Offering and to extent permitted by Section&nbsp;423 of the Code with
respect to the 423 Component, in addition to or instead of making Contributions by payroll deductions, a Participant may make Contributions through payment by cash, check or wire transfer prior to a Purchase Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>During an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to the Company or a
Company Designee a withdrawal form provided by the Company. The Company may impose a deadline before a Purchase Date for withdrawing. Upon such withdrawal, such Participant&#146;s Purchase Right in that Offering will immediately terminate and the
Company will distribute as soon as practicable to such Participant all of his or her accumulated but unused Contributions and such Participant&#146;s Purchase Right in that Offering shall thereupon terminate. A Participant&#146;s withdrawal from
that Offering will have no effect upon his or her eligibility to participate in any other Offerings under the Plan, but such Participant will be required to deliver a new enrollment form to participate in subsequent Offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) </B>Unless otherwise required by Applicable Law, Purchase Rights granted pursuant to any Offering under the Plan will terminate
immediately if the Participant either (i)&nbsp;is no longer an Employee for any reason or for no reason (subject to any post-employment participation period required by Applicable Law) or (ii)&nbsp;is otherwise no longer eligible to participate. The
Company will distribute as soon as practicable to such individual all of his or her accumulated but unused Contributions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)
</B>Unless otherwise determined by the Board, a Participant whose employment transfers or whose employment terminates with an immediate rehire (with no break in service) by or between the Company and a Designated Company or between Designated
Companies will not be treated as having terminated employment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
for purposes of participating in the Plan or an Offering; however, if a Participant transfers from an Offering under the 423 Component to an Offering under the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component, the exercise of the Participant&#146;s Purchase Right will be qualified under the 423 Component only to the extent such exercise complies with Section&nbsp;423 of the Code. If a Participant
transfers from an Offering under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component to an Offering under the 423 Component, the exercise of the Purchase Right will remain <FONT STYLE="white-space:nowrap">non-qualified</FONT> under the <FONT
STYLE="white-space:nowrap">Non-423</FONT> Component. The Board may establish different and additional rules governing transfers between separate Offerings within the 423 Component and between Offerings under the 423 Component and Offerings under the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e) </B>During a Participant&#146;s lifetime, Purchase Rights will be
exercisable only by such Participant. Purchase Rights are not transferable by a Participant, except by will, by the laws of descent and distribution, or, if permitted by the Company, by a beneficiary designation as described in Section&nbsp;10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f) </B>Unless otherwise specified in the Offering or as required by Applicable Law, the Company will have no obligation to pay interest on
Contributions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>8. E<SMALL>XERCISE</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>On each Purchase Date, each Participant&#146;s accumulated Contributions will be applied to the purchase of shares of Common Stock,
up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional shares will be issued unless specifically provided for in the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>Unless otherwise provided in the Offering, if any amount of accumulated Contributions remains in a Participant&#146;s account after
the purchase of shares of Common Stock on the final Purchase Date of an Offering, then such remaining amount will not roll over to the next Offering and will instead be distributed in full to such Participant after the final Purchase Date of such
Offering without interest (unless otherwise required by Applicable Law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) </B>No Purchase Rights may be exercised to any extent
unless the shares of Common Stock to be issued upon such exercise under the Plan are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable U.S. federal and state,
foreign and other securities, exchange control and other laws applicable to the Plan. If on a Purchase Date the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights will be exercised on such Purchase
Date, and, subject to Section&nbsp;423 of the Code with respect to the 423 Component, the Purchase Date will be delayed until the shares of Common Stock are subject to such an effective registration statement and the Plan is in material compliance,
except that the Purchase Date will in no event be more than 27 months from the Offering Date. If, on the Purchase Date, as delayed to the maximum extent permissible, the shares of Common Stock are not registered and the Plan is not in material
compliance with all Applicable Laws, as determined by the Company in its sole discretion, no Purchase Rights will be exercised and all accumulated but unused Contributions will be distributed to the Participants without interest (unless the payment
of interest is otherwise required by Applicable Law). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>9. C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL>
C<SMALL>OMPANY</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company will seek to obtain from each U.S. federal or state, foreign or other regulatory commission,
agency or other Governmental Body having jurisdiction over the Plan such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder unless the Company determines, in its sole discretion, that doing so
is not practical or would cause the Company to incur costs that are unreasonable. If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company deems necessary for the grant of Purchase Rights
or the lawful issuance and sale of Common Stock under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and/or to issue and sell Common Stock upon exercise of such
Purchase Rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>10. D<SMALL>ESIGNATION</SMALL> <SMALL>OF</SMALL> B<SMALL>ENEFICIARY</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>The Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who will receive any
shares of Common Stock and/or Contributions from the Participant&#146;s account under the Plan if the Participant dies before such shares and/or Contributions are delivered to the Participant. The Company may, but is not obligated to, permit the
Participant to change such designation of beneficiary. Any such designation and/or change must be on a form approved by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>If a Participant dies, and in the absence of a valid beneficiary designation, the Company will deliver any shares of Common Stock
and/or Contributions to the executor or administrator of the estate of the Participant. If no executor or administrator has been appointed (to the knowledge of the Company), the Company, in its sole discretion, may deliver such shares of Common
Stock and/or Contributions, without interest (unless the payment of interest is otherwise required by Applicable Law), to the Participant&#146;s spouse, dependents or relatives, or if no spouse, dependent or relative is known to the Company, then to
such other person as the Company may designate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>11. A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL>
<SMALL>IN</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; C<SMALL>ORPORATE</SMALL> T<SMALL>RANSACTIONS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>In the
event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the Plan pursuant to Section&nbsp;3(a), (ii) the class(es) and maximum number of
securities by which the share reserve is to increase automatically each year pursuant to Section&nbsp;3(a), (iii) the class(es) and number of securities subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights, and
(iv)&nbsp;the class(es) and number of securities that are the subject of the purchase limits under each ongoing Offering. The Board will make these adjustments, and its determination will be final, binding and conclusive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>In the event of a Corporate Transaction, then: (i)&nbsp;any surviving corporation or acquiring corporation (or the surviving or
acquiring corporation&#146;s parent company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including a right to acquire the same consideration paid to the stockholders in the Corporate Transaction) for
outstanding Purchase Rights, or (ii)&nbsp;if any surviving or acquiring corporation (or its parent company)<B> </B>does not assume or continue such Purchase Rights or does not substitute similar rights for such Purchase Rights, then the
Participants&#146; accumulated Contributions will be used to purchase shares of Common Stock (rounded down to the nearest whole share) within ten business days (or such other period specified by the Board) prior to the Corporate Transaction under
the outstanding Purchase Rights, and the Purchase Rights will terminate immediately after such purchase. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>12. A<SMALL>MENDMENT</SMALL>,
T<SMALL>ERMINATION</SMALL> <SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>The Board may amend the Plan at any time in any respect the Board deems necessary or advisable. However, except as provided in
Section&nbsp;11(a) relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is required by Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>The Board may suspend or terminate the Plan at any time. No Purchase Rights may be granted under the Plan while the Plan is
suspended or after it is terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any benefits, privileges, entitlements and obligations under any outstanding Purchase Rights granted
before an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i)&nbsp;with the consent of the person to whom such Purchase Rights were granted, (ii)&nbsp;as
necessary to facilitate compliance with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section&nbsp;423 of the Code and the regulations and other interpretive guidance issued thereunder
relating to Employee Stock Purchase Plans) including without limitation any such regulations or other guidance that may be issued or amended after the date the Plan is adopted by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Board, or (iii)&nbsp;as necessary to obtain or maintain favorable tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant&#146;s
consent if such amendment is necessary to ensure that the Purchase Right and/or the Plan complies with the requirements of Section&nbsp;423 of the Code with respect to the 423 Component or with respect to other Applicable Laws. Notwithstanding
anything in the Plan or any Offering Document to the contrary, the Board will be entitled to: (i)&nbsp;establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars; (ii)&nbsp;permit Contributions in excess of the
amount designated by a Participant in order to adjust for mistakes in the Company&#146;s processing of properly completed Contribution elections; (iii)&nbsp;establish reasonable waiting and adjustment periods and/or accounting and crediting
procedures to ensure that amounts applied toward the purchase of Common Stock for each Participant properly correspond with amounts withheld from the Participant&#146;s Contributions; (iv)&nbsp;amend any outstanding Purchase Rights or clarify any
ambiguities regarding the terms of any Offering to enable the Purchase Rights to qualify under and/or comply with Section&nbsp;423 of the Code with respect to the 423 Component; and (v)&nbsp;establish other limitations or procedures as the Board
determines in its sole discretion advisable that are consistent with the Plan. The actions of the Board pursuant to this paragraph will not be considered to alter or impair any Purchase Rights granted under an Offering as they are part of the
initial terms of each Offering and the Purchase Rights granted under each Offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>13. T<SMALL>AX</SMALL>
Q<SMALL>UALIFICATION</SMALL>; T<SMALL>AX</SMALL> W<SMALL>ITHHOLDING</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>Although the Company may endeavor to
(i)&nbsp;qualify a Purchase Right for special tax treatment under the laws of the United States or jurisdictions outside of the United States or (ii)&nbsp;avoid adverse tax treatment, the Company makes no representation to that effect and expressly
disavows any covenant to maintain special or to avoid unfavorable tax treatment, notwithstanding anything to the contrary in this Plan.&nbsp;The Company will be unconstrained in its corporate activities without regard to the potential negative tax
impact on Participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>Each Participant will make arrangements, satisfactory to the Company and any applicable Related
Corporation, to enable the Company or the Related Corporation to fulfill any withholding obligation for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items. Without limitation to the foregoing, in the Company&#146;s sole discretion and subject
to Applicable Law, such withholding obligation may be satisfied in whole or in part by (i)&nbsp;withholding from the Participant&#146;s salary or any other cash payment due to the Participant from the Company or a Related Corporation;
(ii)&nbsp;withholding from the proceeds of the sale of shares of Common Stock acquired under the Plan, either through a voluntary sale or a mandatory sale arranged by the Company; or (iii)&nbsp;any other method deemed acceptable by the Board. The
Company shall not be required to issue any shares of Common Stock under the Plan until such obligations are satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) </B>The 423
Component is exempt from the application of Section&nbsp;409A of the Code, and any ambiguities herein shall be interpreted to so be exempt from Section&nbsp;409A of the Code. The <FONT STYLE="white-space:nowrap">Non-423</FONT> Component is intended
to be exempt from the application of Section&nbsp;409A of the Code under the short-term deferral exception and any ambiguities shall be construed and interpreted in accordance with such intent. In furtherance of the foregoing and notwithstanding any
provision in the Plan to the contrary, if the Committee determines that an option granted under the Plan may be subject to Section&nbsp;409A of the Code or that any provision in the Plan would cause an option under the Plan to be subject to
Section&nbsp;409A, the Committee may amend the terms of the Plan and/or of an outstanding option granted under the Plan, or take such other action the Committee determines is necessary or appropriate, in each case, without the participant&#146;s
consent, to exempt any outstanding option or future option that may be granted under the Plan from or to allow any such options to comply with Section&nbsp;409A of the Code, but only to the extent any such amendments or action by the Committee would
not violate Section&nbsp;409A of the Code. Notwithstanding the foregoing, the Company shall have no liability to a participant or any other party if the option under the Plan that is intended to be exempt from or compliant with Section&nbsp;409A of
the Code is not so exempt or compliant or for any action taken by the Committee with respect thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>14. E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Plan will become effective immediately prior to and contingent upon the Effective Date. No Purchase Rights will be exercised
unless and until the Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date the Plan is adopted (or if required under Section&nbsp;12(a) above, materially amended) by the Board.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>15. M<SMALL>ISCELLANEOUS</SMALL> P<SMALL>ROVISIONS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) </B>A Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of Common
Stock subject to Purchase Rights unless and until the Participant&#146;s shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) </B>The Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering will in any way alter the at
will nature of a Participant&#146;s employment or amend a Participant&#146;s employment contract, if applicable, or be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a
Related Corporation or an Affiliate, or on the part of the Company, a Related Corporation or an Affiliate to continue the employment of a Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d) </B>The provisions of the Plan will be governed by the laws of the State of Delaware without resort to that state&#146;s conflicts of
laws rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e) </B>If any particular provision of the Plan is found to be invalid or otherwise unenforceable, such provision will not
affect the other provisions of the Plan, but the Plan will be construed in all respects as if such invalid provision were omitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)
</B>If any provision of the Plan does not comply with Applicable Law, such provision shall be construed in such a manner as to comply with Applicable Law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>16. D<SMALL>EFINITIONS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As used in the Plan, the following definitions will apply to the capitalized terms indicated below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a) </B>&#147;<B><I>423 Component</I></B>&#148; means the part of the Plan, which excludes the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component, pursuant to which Purchase Rights that satisfy the requirements for an Employee Stock Purchase Plan may be granted to Eligible Employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) &#147;</B><B><I>Affiliate</I></B><B>&#148;</B> means any entity, other than a Related Corporation, whether now or subsequently
established, which is at the time of determination, a &#147;parent&#148; or &#147;subsidiary&#148; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board may determine the time or times at which
&#147;parent&#148; or &#147;subsidiary&#148; status is determined within the foregoing definition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) </B>&#147;<B><I>Applicable
Law</I></B>&#148; means shall mean the Code and any applicable securities, federal, state, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing
rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (or under the authority of the NASDAQ Stock Market, the New
York Stock Exchange or the Financial Industry Regulatory Authority). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d) </B>&#147;<B><I>Board</I></B>&#148;<I> </I>means the board of directors of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e) </B>&#147;<B><I>Business Combination Agreement</I></B>&#148; means that certain Business Combination Agreement by and
among <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., Perseverance Merger Sub Inc., and Surrozen, Inc., dated as of April 15, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f) </B>&#147;<B><I>Capitalization Adjustment</I></B>&#148; means any change that is made in, or other events that occur with respect to,
the Common Stock subject to the Plan or subject to any Purchase Right after the date the Plan is adopted by the Board without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization,
reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other similar equity
restructuring transaction, as that term is used in Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the
Company will not be treated as a Capitalization Adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g) </B>&#147;<B><I>Code</I></B>&#148;<I> </I>means the U.S. Internal
Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder<I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(h)
</B>&#147;<B><I>Committee</I></B>&#148;<I> </I>means a committee of one or more members of the Board to whom authority has been delegated by the Board in accordance with Section&nbsp;2(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) </B>&#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(j) </B>&#147;<B><I>Company</I></B>&#148; means Surrozen, Inc., a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(k) </B><B><I>&#147;Contributions</I></B>&#148; means the payroll deductions and other additional payments specifically provided for in the
Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make additional payments into his or her account if specifically provided for in the Offering, and then only if the Participant has not already had
the maximum permitted amount withheld during the Offering through payroll deductions and, with respect to the 423 Component, to the extent permitted by Section&nbsp;423 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(l) </B>&#147;<B><I>Corporate Transaction</I></B>&#148; means the consummation, in a single transaction or in a series of related
transactions, of any one or more of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) </B>a sale<B> </B>or other disposition of all or substantially all, as
determined by the Board in its sole discretion, of the consolidated assets of the Company and its subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>a sale or
other disposition of more than 50% of the outstanding securities of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii) </B>a merger, consolidation or similar
transaction following which the Company is not the surviving corporation; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv) </B>a merger, consolidation or similar transaction
following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar
transaction into other property, whether in the form of securities, cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(m) &#147;</B><B><I>Designated 423
Corporation</I></B><B>&#148;</B> means any Related Corporation selected by the Board to participate in the 423 Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(n)
&#147;</B><B><I>Designated Company</I></B><B>&#148; </B>means any Designated <FONT STYLE="white-space:nowrap">Non-423</FONT> Corporation or Designated 423 Corporation, provided, however, that at any given time, a Related Corporation participating in
the 423 Component shall not be a Related Corporation participating in the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(o) &#147;</B><B><I>Designated <FONT STYLE="white-space:nowrap">Non-423</FONT>
Corporation</I></B><B>&#148;</B> means any Related Corporation or Affiliate selected by the Board to participate in the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(p) </B>&#147;<B><I>Director</I></B>&#148;<I> </I>means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(q) </B>&#147;<B><I>Effective Date</I></B>&#148; means the effective date of this Plan, which is the date of the closing of the
transactions contemplated by the Business Combination Agreement, provided that this Plan is approved by the Company&#146;s stockholders prior to such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(r) </B>&#147;<B><I>Eligible Employee</I></B>&#148;<I> </I>means an Employee who meets the requirements set forth in the document(s)
governing the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(s) </B>&#147;<B><I>Employee</I></B>&#148;<I> </I>means any person, including an Officer or Director, who is &#147;employed&#148; for
purposes of Section&nbsp;423(b)(4) of the Code by the Company or a Related Corporation, or solely with respect to the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, an Affiliate. However, service solely as a Director, or payment of a fee
for such services, will not cause a Director to be considered an &#147;Employee&#148; for purposes of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(t)
</B>&#147;<B><I>Employee Stock Purchase Plan</I></B>&#148;<I> </I>means a plan that grants Purchase Rights intended to be options issued under an &#147;employee stock purchase plan,&#148; as that term is defined in Section&nbsp;423(b) of the Code.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(u) </B>&#147;<B><I>Exchange Act</I></B>&#148;<I> </I>means the U.S. Securities Exchange Act of 1934, as amended and the rules and
regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v) </B>&#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of the Common
Stock determined as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) </B>If the Common Stock is listed on any established stock exchange or traded on any established
market, the Fair Market Value of a share of Common Stock will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of
determination, as reported in such source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing sales
price on the last preceding date for which such quotation exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>In the absence of such markets for the Common Stock, the
Fair Market Value will be determined by the Board in good faith in compliance with Applicable Laws and regulations and, to the extent applicable as determined in the sole discretion of the Board, in a manner that complies with Sections 409A of the
Code </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(w) </B>&#147;<B><I>Fully-Diluted Common Stock</I></B>&#148; means, as of any date, the aggregate number of (i)&nbsp;shares of
Common Stock issued and outstanding and (ii)&nbsp;securities convertible into or exercisable for shares of Common Stock (whether vested or unvested). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(x) </B>&#147;<B><I>Governmental</I></B><B> </B><B><I>Body</I></B>&#148; means any: (a)&nbsp;nation, state, commonwealth, province,
territory, county, municipality, district or other jurisdiction of any nature; (b)&nbsp;federal, state, local, municipal, foreign or other government; (c)&nbsp;governmental or regulatory body, or quasi-governmental body of any nature (including any
governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or entity and any court or other tribunal, and for the avoidance of
doubt, any tax authority) or other body exercising similar powers or authority; or (d)&nbsp;self-regulatory organization (including the NASDAQ Stock Market, the New York Stock Exchange and the Financial Industry Regulatory Authority). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(y)</B> &#147;<B><I><FONT STYLE="white-space:nowrap">Non-423</FONT>
Component</I></B>&#148; means the part of the Plan, which excludes the 423 Component, pursuant to which Purchase Rights that are not intended to satisfy the requirements for an Employee Stock Purchase Plan may be granted to Eligible Employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(z) </B>&#147;<B><I>Offering</I></B>&#148;<I> </I>means the grant to Eligible Employees of Purchase Rights, with the exercise of those
Purchase Rights automatically occurring at the end of one or more Purchase Periods. The terms and conditions of an Offering will generally be set forth in the &#147;<B><I>Offering Document</I></B>&#148; approved by the Board for that Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(aa) </B>&#147;<B><I>Offering Date</I></B>&#148; means a date selected by the Board for an Offering to commence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(bb) </B>&#147;<B><I>Officer</I></B>&#148;<B> </B>means<B> </B>a person who is an officer of the Company or a Related Corporation within
the meaning of Section&nbsp;16 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(cc) </B>&#147;<B><I>Participant</I></B>&#148;<I> </I>means an Eligible Employee
who holds an outstanding Purchase Right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(dd) </B>&#147;<B><I>Plan</I></B>&#148;<I> </I>means this Surrozen, Inc. 2021 Employee Stock
Purchase Plan, as amended from time to time, including both the 423 Component and the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ee) </B>&#147;<B><I>Purchase Date</I></B>&#148;<I> </I>means one or more dates during an Offering selected by the Board on which Purchase
Rights will be exercised and on which purchases of shares of Common Stock will be carried out in accordance with such Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ff)
</B>&#147;<B><I>Purchase Period</I></B>&#148; means a period of time specified within an Offering, generally beginning on the Offering Date or on the first Trading Day following a Purchase Date, and ending on a Purchase Date. An Offering may consist
of one or more Purchase Periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(gg) </B>&#147;<B><I>Purchase Right</I></B>&#148;<I> </I>means an option to purchase shares of Common
Stock granted pursuant to the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(hh) </B>&#147;<B><I>Related Corporation</I></B>&#148;<I> </I>means any &#147;parent
corporation&#148; or &#147;subsidiary corporation&#148; of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) </B>&#147;<B><I>Securities Act</I></B>&#148;<I> </I>means the U.S. Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(jj) </B>&#147;<B><I><FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items</I></B>&#148; means any income tax, social insurance,
payroll tax, fringe benefit tax, payment on account or other <FONT STYLE="white-space:nowrap">tax-related</FONT> items arising out of or in relation to a Participant&#146;s participation in the Plan, including, but not limited to, the exercise of a
Purchase Right and the receipt of shares of Common Stock or the sale or other disposition of shares of Common Stock acquired under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(kk) </B>&#147;<B><I>Trading Day</I></B>&#148;<B> </B>means any day on which the exchange(s) or market(s) on which shares of Common Stock
are listed, including but not limited to the New York Stock Exchange, Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto, is open for trading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="annex_b"></A><A NAME="rom40894_251"></A>ANNEX B </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPANIES LAW (AS REVISED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPANY LIMITED BY SHARES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLES OF ASSOCIATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADOPTED BY SPECIAL RESOLUTION
EFFECTIVE ON [</B>&#9679;<B></B><B>], 2020 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPANIES LAW (AS REVISED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPANY LIMITED BY SHARES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEMORANDUM OF ASSOCIATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADOPTED BY SPECIAL RESOLUTION ON [</B>&#9679;<B></B><B>], 2020
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The name of the Company is <B><FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp.</B>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company&#146;s registered office will be situated at the office of Campbells Corporate Services Limited,
Floor 4, Willow House, Cricket Square, Grand Cayman <FONT STYLE="white-space:nowrap">KY1-9010,</FONT> Cayman Islands, , or at such other place in the Cayman Islands as the directors may at any time decide. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company&#146;s objects are unrestricted. As provided by section 7(4)&nbsp;of the Companies Law (as
revised), the Company has full power and authority to carry out any object not prohibited by any law of the Cayman Islands. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company has unrestricted corporate capacity. Without limitation to the foregoing, as provided by section
27 (2)&nbsp;of the Companies Law (as revised), the Company has and is capable of exercising all the functions of a natural person of full capacity irrespective of any question of corporate benefit. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Nothing in any of the preceding paragraphs permits the Company to carry on any of the following businesses
without being duly licensed, namely: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the business of a bank or trust company without being licensed in that behalf under the Banks and Trust
Companies Law (as revised); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">insurance business from within the Cayman Islands or the business of an insurance manager, agent, <FONT
STYLE="white-space:nowrap">sub-agent</FONT> or broker without being licensed in that behalf under the Insurance Law (as revised);or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the business of company management without being licensed in that behalf under the Companies Management Law
(as revised). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company will not trade in the Cayman Islands with any person, firm or corporation except in furtherance
of its business carried on outside the Cayman Islands. Despite this, the Company may effect and conclude contracts in the Cayman Islands and exercise in the Cayman Islands any of its powers necessary for the carrying on of its business outside the
Cayman Islands. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company is a company limited by shares and accordingly the liability of each member is limited to the
amount (if any) unpaid on that member&#146;s shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">8</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The authorised share capital of the Company is US$50,100.00 divided into 350,000,000 Class&nbsp;A Ordinary
Shares of US$0.0001 each, 150,000,000 Class&nbsp;B Ordinary Shares of US$0.0001 and 1,000,000 Preference Shares of US$0.0001 each. There is no limit on the number of shares of any class which the Company is authorised to issue. However, subject to
the Companies Law (as revised) and the Company&#146;s articles of association, the Company has power to do any one or more of the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to redeem or repurchase any of its shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to increase or reduce its capital; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to issue any part of its capital (whether original, redeemed, increased or reduced): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">with or without any preferential, deferred, qualified or special rights, privileges or conditions; or
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(ii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">subject to any limitations or restrictions </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">and unless the condition of issue expressly declares otherwise, every issue of shares (whether declared to be ordinary,
preference or otherwise) is subject to this power; or </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(d)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to alter any of those rights, privileges, conditions, limitations or restrictions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">9</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company has power to register by way of continuation as a body corporate limited by shares under the
laws of any jurisdiction outside the Cayman Islands and to be deregistered in the Cayman Islands. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPANIES LAW (AS REVISED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPANY LIMITED BY SHARES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLES OF ASSOCIATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADOPTED BY SPECIAL RESOLUTION ON [</B>&#9679;<B></B><B>], 2020
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CONTENTS </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1.&#8195;&#8194;&#8201;Definitions, interpretation and exclusion of Table
A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Definitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interpretation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Exclusionof Table A Articles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.&#8195;&#8194;&#8201;Commencement of Business</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.&#8195;&#8194;&#8201;Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Powerto issue Shares and options, with or without special rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Powerto issue fractions of a Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Powerto pay commissions and brokerage fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Trustsnot recognised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Powerto vary class rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effectof new Share issue on existing class rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No bearer Shares or warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">TreasuryShares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Rightsattaching to Treasury Shares and related matters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.&#8195;&#8194;&#8201;Register of Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.&#8195;&#8194;&#8201;Share certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Issue&#8201;&#8201;of share certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Renewalof lost or damaged share certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.&#8195;&#8194;&#8201;Lien on Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Natureand scope of lien</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Company may sell Shares to satisfy lien</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Authority to execute instrument of transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Consequences of sale of Shares to satisfy lien</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Application of proceeds of sale</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.&#8195;&#8194;&#8201;Calls on Shares and forfeiture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Power to make calls and effect of calls</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Time when call made</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Liability of joint holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interest on unpaid calls</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Deemed calls</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Power to accept early payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Power to make different arrangements at time of issue of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notice of default</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Forfeiture or surrender of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Disposal of forfeited or surrendered Share and power to cancel forfeiture or
surrender</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effect of forfeiture or surrender on former Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Evidence of forfeiture or surrender</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sale of forfeited or surrendered Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.&#8195;&#8194;&#8201;Transfer of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Form&nbsp;of transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Power to refuse registration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Power to suspend registration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Company may retain instrument of transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9.&#8195;&#8194;&#8201;Transmission of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Persons entitled on death of a Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Registration of transfer of a Share following death or bankruptcy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indemnity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Rights of person entitled to a Share following death or bankruptcy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.&#8195;&#8201;Alteration of capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Increasing, consolidating, converting, dividing and cancelling share
capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dealing with fractions resulting from consolidation of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Reducing share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.&#8195;&#8201;Redemption and purchase of own Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Power to issue redeemable Shares and to purchase own Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Power to pay for redemption or purchase in cash or in specie</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effect of redemption or purchase of a Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12.&#8195;&#8201;Class&nbsp;B Share Conversion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">13&#8195;&#8201;&#8201;Meetings of Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Power to call meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Content of notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Period of notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Persons entitled to receive notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Publication of notice on a website</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Time a website notice is deemed to be given</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Required duration of publication on a website</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accidental omission to give notice or
<FONT STYLE="white-space:nowrap">non-receipt</FONT> of notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">14.&#8195;&#8201;Proceedings at meetings of Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Quorum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lack of quorum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Use of technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Chairman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Right of a director to attend and speak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Adjournment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Method of voting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Taking of a poll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.30em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Chairman&#146;s casting vote</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Amendmentsto resolutions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Writtenresolutions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sole-membercompany</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15.&#8195;&#8201;Voting rights of Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Right&#8201;to vote</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Rightsof joint holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Representationof corporate Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Memberwith mental disorder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Objectionsto admissibility of votes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Form&#8201;&#8202;of proxy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">How&#8194;and when proxy is to be delivered</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Votingby proxy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">16.&#8195;&#8201;Number of directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">17.&#8195;&#8201;Appointment, disqualification and removal of
directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:1.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No age limit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Corporatedirectors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:1.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No shareholding qualification</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Appointmentand removal of directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Resignationof directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Terminationof the office of director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">18.&#8195;&#8201;Alternate directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Appointmentand removal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Rightsof alternate director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Appointmentceases when the appointor ceases to be a director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Statusof alternate director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Statusof the director making the appointment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">19.&#8195;&#8201;Powers of directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Powersof directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Appointmentsto office</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Remuneration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Disclosureof information</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">20.&#8195;&#8201;Delegation of powers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Powerto delegate any of the directors&#146; powers to a committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Powerto appoint an agent of the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Powerto appoint an attorney or authorised signatory of the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Powerto appoint a proxy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">21.&#8195;&#8201;Meetings of directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Regulationof directors&#146; meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Callingmeetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Noticeof meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Periodof notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Use of technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Place&#8201;&#8202;of meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Quorum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Voting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Validity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Recordingof dissent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Writtenresolutions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sole&#8194;&#8201;director&#146;s minute</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">22.&#8195;&#8201;Permissible directors&#146; interests and disclosure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Permissibleinterests subject to disclosure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notificationof interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Votingwhere a director is interested in a matter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">23.&#8195;&#8201;Minutes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">24.&#8195;&#8201;Accounts and audit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No automatic right of inspection</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sendingof accounts and reports</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Validitydespite accidental error in publication on website</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Audit&#8201;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">25.&#8195;&#8201;Financial year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">26.&#8195;&#8201;Record dates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">27.&#8195;&#8201;Dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Declarationof dividends by Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Paymentof interim dividends and declaration of final dividends by
directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Apportionmentof dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Right&#8201;of set off</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Powerto pay other than in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">How&#8194;payments may be made</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dividendsor other moneys not to bear interest in absence of special
rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dividendsunable to be paid or unclaimed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">28.&#8195;&#8201;Capitalisation of profits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Capitalisationof profits or of any share premium account or capital redemption
reserve</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Applyingan amount for the benefit of members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">29.&#8195;&#8201;Share premium account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">directorsto maintain share premium account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Debitsto share premium account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">30.&#8195;&#8201;Seal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Companyseal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Duplicateseal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">When&#8202;and how seal is to be used</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If no seal is adopted or used</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Powerto allow <FONT STYLE="white-space:nowrap">non-manual</FONT> signatures and
facsimile printing of seal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Validityof execution</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-vi </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">31.&#8195;&#8201;Indemnity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indemnity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Release</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">32.&#8195;&#8201;Notices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Form&#8201;&#8202;of notices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Electroniccommunications</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Personsauthorised to give notices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Deliveryof written notices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Joint&#8194;holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Signatures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Evidenceof transmission</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Givingnotice to a deceased or bankrupt Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Date&#8194;&#8202;of giving notices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Savingprovision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">33.&#8195;&#8201;Authentication of Electronic Records</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Applicationof Articles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Authenticationof documents sent by Members by Electronic means</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Authenticationof document sent by the Secretary or Officers of the Company by
Electronic means</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mannerof signing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Savingprovision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">34.&#8195;&#8201;Transfer by way of continuation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">35.&#8195;&#8201;Winding up</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Distributionof assets in specie</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No obligation to accept liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The directors are authorised to present a winding up petition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">36.&#8195;&#8201;Amendment of Memorandum and Articles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Power to change name or amend Memorandum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-vii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.50em; text-indent:1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Power to amend these Articles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">37.&#8195;&#8201;Mergers and Consolidations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">38.&#8195;&#8201;Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">39.&#8195;&#8201;Certain Tax Filings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">40.&#8195;&#8201;Business Opportunities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">B-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-viii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPANIES LAW (AS REVISED) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPANY LIMITED BY SHARES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLES OF ASSOCIATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADOPTED BY SPECIAL RESOLUTION ON [</B>&#9679;<B></B><B>], 2020
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>1.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Definitions, interpretation and exclusion of Table A </B></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Definitions </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In these Articles, the following definitions apply: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Affiliate </B>in respect of a person, means any other person that, directly or indirectly, through one or more
intermediaries, controls, is controlled by, or is under common control with, such person, and (a)&nbsp;in the case of a natural person, shall include, without limitation, such person&#146;s spouse, parents, children, siblings, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law</FONT></FONT> and brothers and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">sisters-in-law,</FONT></FONT> whether by blood, marriage or adoption or anyone residing in such person&#146;s home, a trust for the benefit of any of the foregoing, a company, partnership or any natural person or entity
wholly or jointly owned by any of the foregoing and (b)&nbsp;in the case of an entity, shall include a partnership, a corporation or any natural person or entity which directly, or indirectly through one or more intermediaries, controls, is
controlled by, or is under common control with, such entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Applicable Law </B>means, with respect to any person, all
provisions of laws, statutes, ordinances, rules, regulations, permits, certificates, judgments, decisions, decrees or orders of any governmental authority applicable to such person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Articles </B>means, as appropriate: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">these Amended and Restated Articles of Association as amended, restated, supplemented and/or otherwise
modified from time to time: or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">two or more particular Articles of these Articles; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">and <B>Article</B><B></B>&nbsp;refers to a particular Article&nbsp;of these Articles. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Audit Committee </B>means the audit committee of the board of directors of the Company established pursuant to
Article&nbsp;24.8 hereof, or any successor audit committee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Auditor </B>means the person for the time being performing
the duties of auditor of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Business Combination </B>means a merger, share exchange, asset acquisition, share
purchase, reorganisation or similar business combination involving the Company, with one or more businesses or entities (each a <B>partner business</B>), which Business Combination: (a)&nbsp;must be with one or more partner businesses that together
have an aggregate fair market value of at least 80% of the net assets held in the trust account (excluding the amount of deferred underwriting discounts held in trust and taxes payable on the interest earned on the trust account) at the time of
signing the agreement to enter into the Business Combination; and (b)&nbsp;must not be effectuated solely with another blank cheque company or a similar company with nominal operations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Business Day </B>means a day other than a day on which banking institutions or trust companies are authorised or obligated
by law to close in New York City, a Saturday or a Sunday. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Class</B><B></B><B>&nbsp;A Ordinary Share </B>means a Class&nbsp;A
ordinary share of a par value of US$0.0001 in the share capital of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Class</B><B></B><B>&nbsp;B Ordinary
Share </B>means a Class&nbsp;B ordinary share of a par value of US$0.0001 in the share capital of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Clear
Days</B>, in relation to a period of notice, means that period excluding: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the day when the notice is given or deemed to be given; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the day for which it is given or on which it is to take effect. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Clearing House </B>means a clearing house recognised by the laws of the jurisdiction in which the Shares (or depositary
receipts therefor) are listed or quoted on a stock exchange or interdealer quotation system in such jurisdiction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Company </B>means the above-named company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Compensation Committee </B>means the compensation committee of the board of directors of the Company established pursuant to
the Articles, or any successor committee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Default Rate </B>means 10% (ten per cent) per annum. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Designated Stock Exchange </B>means any United States national securities exchange, including the Nasdaq Stock Market LLC,
the NYSE American LLC or The New York Stock Exchange LLC or any OTC market on which the Shares are listed for trading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Electronic </B>has the meaning given to that term in the Electronic Transactions Law (as revised). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Electronic Record </B>has the meaning given to that term in the Electronic Transactions Law (as revised). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Electronic Signature </B>has the meaning given to that term in the Electronic Transactions Law (as revised). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Exchange Act </B>means the United States Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Founders </B>means all Members immediately prior to the consummation of the IPO. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Fully Paid </B>and <B>Paid Up</B>: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in relation to a Share with par value, means that the par value for that Share and any premium payable in
respect of the issue of that Share, has been fully paid or credited as paid in money or money&#146;s worth; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in relation to a Share without par value, means that the agreed issue price for that Share has been fully
paid or credited as paid in money or money&#146;s worth. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Independent Director </B>means a director
who is an independent director as defined in the rules&nbsp;and regulations of the Designated Stock Exchange as determined by the directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Investor Group </B>means the Sponsor and its Affiliates, successors and assigns. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>IPO </B>means the Company&#146;s initial public offering of securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>IPO Redemption </B>has the meaning given to it in Article&nbsp;38.6. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Islands </B>means the British Overseas Territory of the Cayman Islands. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Law </B>means the Companies Law (as revised). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Member </B>means any person or persons entered on the Register of Members from time to time as the holder of a Share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Memorandum </B>means the Amended and Restated Memorandum of Association of the Company as amended, restated, supplemented
and/or otherwise modified from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Nominating Committee </B>means the nominating committee of the board of
directors of the Company established pursuant to the Articles, or any successor committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Officer </B>means a person then appointed to hold an office in the
Company; and the expression includes a director, alternate director or liquidator. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Ordinary Resolution </B>means a
resolution of a duly constituted general meeting of the Company passed by a simple majority of the votes cast by, or on behalf of, the Members entitled to vote thereon. The expression also includes a unanimous written resolution. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Over-Allotment Option </B>means the option of the Underwriters to purchase up to an additional 15% of the firm units (as
described at Article&nbsp;3.4) issued in the IPO at a price equal to US$10.00 per unit, less underwriting discount and commissions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Preference Share</B> means a preference share of a par value of US$0.0001 in the share capital of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Public Share</B> means a Class&nbsp;A Ordinary Share issued as part of the units (as described in Article 3.4) issued in the
IPO. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Redemption Price </B>has the meaning given to it in Article&nbsp;38.6. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Register of Members </B>means the register of Members maintained in accordance with the Law and includes (except where
otherwise stated) any branch or duplicate register of Members. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Representative </B>means a representative of the
Underwriters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>SEC </B>means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Secretary </B>means a person appointed to perform the duties of the secretary of the Company, including a joint, assistant
or deputy secretary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Share </B>means a Class&nbsp;A Ordinary Share, a Class&nbsp;B Ordinary Share or a Preference Share
in the share capital of the Company; and the expression: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">includes stock (except where a distinction between shares and stock is expressed or implied); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">where the context permits, also includes a fraction of a share. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Special Resolution </B>has the meaning given to that term in the Law; and the expression includes a unanimous written
resolution. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Sponsor </B>means Consonance Life Sciences, a Cayman Islands limited liability company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Tax Filing Authorised Person </B>means such person as any director shall designate from time to time, acting severally. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Treasury Shares </B>means Shares of the Company held in treasury pursuant to the Law and Article&nbsp;3.14. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Trust Account </B>means the trust account established by the Company upon the consummation of its IPO and into which a
certain amount of the net proceeds of the IPO, together with a certain amount of the proceeds of a private placement of units simultaneously with the closing date of the IPO, will be deposited. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Underwriter </B>means an underwriter of the IPO from time to time, and any successor underwriter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Interpretation </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In the interpretation of these Articles, the following provisions apply unless the context otherwise
requires: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A reference in these Articles to a statute is a reference to a statute of the Islands as known by its short
title, and includes: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">any statutory modification, amendment or <FONT STYLE="white-space:nowrap">re-enactment;</FONT> and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(ii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">any subordinate legislation or regulations issued under that statute. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Without limitation to the preceding sentence, a reference to a revised Law
of the Cayman Islands is taken to be a reference to the revision of that Law in force from time to time as amended from time to time. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Headings are inserted for convenience only and do not affect the interpretation of these Articles, unless
there is ambiguity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If a day on which any act, matter or thing is to be done under these Articles is not a Business Day, the
act, matter or thing must be done on the next Business Day. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(d)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A word which denotes the singular also denotes the plural, a word which denotes the plural also denotes the
singular, and a reference to any gender also denotes the other genders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(e)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A reference to a person includes, as appropriate, a company, trust, partnership, joint venture, association,
body corporate or government agency. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(f)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Where a word or phrase is given a defined meaning another part of speech or grammatical form in respect to
that word or phrase has a corresponding meaning. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(g)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">All references to time are to be calculated by reference to time in the place where the Company&#146;s
registered office is located. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(h)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The words written and in writing include all modes of representing or reproducing words in a visible form,
but do not include an Electronic Record where the distinction between a document in writing and an Electronic Record is expressed or implied. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The words including, include and in particular or any similar expression are to be construed without
limitation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(j)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Any requirements as to execution or signature under the Articles including the execution of the Articles
themselves can be satisfied in the form of an Electronic Signature. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(k)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Sections 8 and 19(3)&nbsp;of the Electronic Transactions Law shall not apply. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(l)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The term &#147;holder&#148; in relation to a Share means a person whose name is entered in the Register of
Members as the holder of such Share. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Exclusion of Table A Articles </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The regulations contained in Table A in the First Schedule of the Law and any other regulations contained in
any statute or subordinate legislation are expressly excluded and do not apply to the Company. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>2.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Commencement of Business </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The business of the Company may be commenced as soon after incorporation of the Company as the directors see
fit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may pay, out of the capital or any other monies of the Company, all expenses incurred in or
about the formation and establishment of the Company, including the expenses of registration. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>3.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to issue Shares and options, with or without special rights </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Subject to the provisions, if any, in the Memorandum (and to any direction that may be given by the Company
in general meeting), these Articles and, where applicable, the rules&nbsp;and regulations of the Designated Stock Exchange, the SEC and/or any other competent regulatory authority or otherwise under Applicable Law, and without prejudice to any
rights attached to any existing Shares, the directors have general and unconditional authority to allot (with or without confirming rights of renunciation), issue, grant </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
options over or otherwise deal with any unissued Shares of the Company to such persons, at such times and on such terms and conditions as they may decide, save that the directors may not allot,
issue, grant options over or otherwise deal with any unissued Shares to the extent that it may affect the ability of the Company to carry out a Class&nbsp;B Share Conversion described at Article&nbsp;12. No Share may be issued at a discount except
in accordance with the provisions of the Law. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Without limitation to the preceding Article, the directors may so deal with the unissued Shares of the
Company: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">either at a premium or at par; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">with or without preferred, deferred or other special rights or restrictions whether in regard to dividend,
voting, return of capital or otherwise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company may issue rights, options, warrants or convertible securities or securities of similar nature
conferring the right upon the holders thereof to subscribe for, purchase or receive any class of Shares or other securities in the Company at such times and on such terms and conditions as the directors may decide. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company may issue units of securities in the Company, which may be comprised of Shares, rights, options,
warrants or convertible securities or securities of similar nature conferring the right upon the holders thereof to subscribe for, purchase or receive any class of Shares or other securities in the Company, on such terms and conditions as the
directors may decide. The securities comprising any such units which are issued pursuant to the IPO can only be traded separately from one another on the 52nd day following the date of the prospectus relating to the IPO unless the
Representative(s)&nbsp;determines that an earlier date is acceptable, subject to the Company having filed a current report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> containing an audited balance sheet reflecting the Company&#146;s
receipt of the gross proceeds of the IPO with the SEC and a press release announcing when such separate trading will begin. Prior to such date, the units can be traded, but the securities comprising such units cannot be traded separately from one
another. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to issue fractions of a Share </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Subject to the Law, the Company may issue fractions of a Share of any class. A fraction of a Share shall be
subject to and carry the corresponding fraction of liabilities (whether with respect to calls or otherwise), limitations, preferences, privileges, qualifications, restrictions, rights and other attributes of a Share of that class of Shares.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to pay commissions and brokerage fees </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company may, in so far as the Law permits, pay a commission to any person in consideration of that
person: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">subscribing or agreeing to subscribe, whether absolutely or conditionally; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">procuring or agreeing to procure subscriptions, whether absolute or conditional for any Shares in the
Company. That commission may be satisfied by the payment of cash or the allotment of Fully Paid or partly-paid Shares or partly in one way and partly in another. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.7</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company may employ a broker in the issue of its capital and pay him any proper commission or brokerage.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Trusts not recognised </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.8</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Except as required by Applicable Law: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the Company shall not be bound by or compelled to recognise in any way (even when notified) any equitable,
contingent, future or partial interest in any Share, or (except only as is otherwise provided by </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
these Articles or the Law) any other rights in respect of any Share other than an absolute right to the entirety thereof in the holder; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">no person other than the Member shall be recognised by the Company as having any right in a Share.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to vary class rights </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.9</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If the share capital is divided into different classes of Shares then, unless the terms on which a class of
Shares was issued state otherwise, the rights attaching to a class of Shares may only be varied if one of the following applies: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the Members holding two thirds of the issued Shares of that class consent in writing to the variation; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the variation is made with the sanction of a Special Resolution passed at a separate general meeting of the
Members holding the issued Shares of that class. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.10</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">For the purpose of paragraph (b) of the preceding Article, all the provisions of these Articles relating to
general meetings apply, mutatis mutandis, to every such separate meeting except that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the necessary quorum shall be one or more persons holding, or representing by proxy, not less than one third
of the issued Shares of the class; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">any Member holding issued Shares of the class, present in person or by proxy or, in the case of a corporate
Member, by its duly authorised representative, may demand a poll. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Effect of new Share issue on existing class rights
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.11</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Unless the terms on which a class of Shares was issued state otherwise, the rights conferred on the Member
holding Shares of any class shall not be deemed to be varied by the creation or issue of further Shares ranking pari passu with the existing Shares of that class. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Capital contributions without issue of further Shares </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.12</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">With the consent of a Member, the directors may accept a voluntary contribution to the capital of the
Company from that Member without issuing Shares in consideration for that contribution. In that event, the contribution shall be dealt with in the following manner: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">It shall be treated as if it were a share premium. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Unless the Member agrees otherwise: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if the Member holds Shares in a single class of Shares, it shall be credited to the share premium account
for that class of Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(ii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if the Member holds Shares of more than one class, it shall be credited rateably to the share premium
accounts for those classes of Shares (in the proportion that the sum of the issue prices for each class of Shares that the Member holds bears to the total issue prices for all classes of Shares that the Member holds). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">It shall be subject to the provisions of the Law and these Articles applicable to share premiums.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>No bearer Shares or warrants </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.13</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company shall not issue Shares or warrants to bearers. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Treasury Shares </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.14</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Shares that the Company purchases, redeems or acquires by way of surrender in accordance with the Law shall
be held as Treasury Shares and not treated as cancelled if: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the directors so determine prior to the purchase, redemption or surrender of those shares; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the relevant provisions of the Memorandum and Articles and the Law are otherwise complied with.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Rights attaching to Treasury Shares and related matters </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.15</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">No dividend may be declared or paid, and no other distribution (whether in cash or otherwise) of the
Company&#146;s assets (including any distribution of assets to members on a winding up) may be made to the Company in respect of a Treasury Share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.16</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company shall be entered in the Register as the holder of the Treasury Shares. However:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the Company shall not be treated as a member for any purpose and shall not exercise any right in respect of
the Treasury Shares, and any purported exercise of such a right shall be void; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a Treasury Share shall not be voted, directly or indirectly, at any meeting of the Company and shall not be
counted in determining the total number of issued shares at any given time, whether for the purposes of these Articles or the Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.17</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Nothing in the preceding Article&nbsp;prevents an allotment of Shares as fully paid bonus shares in respect
of a Treasury Share and Shares allotted as fully paid bonus shares in respect of a Treasury Share shall be treated as Treasury Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.18</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Treasury Shares may be disposed of by the Company in accordance with the Law and otherwise on such terms and
conditions as the directors determine. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>4.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Register of Members </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company shall maintain or cause to be maintained the Register of Members in accordance with the Law.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may determine that the Company shall maintain one or more branch registers of Members in
accordance with the Law. The directors may also determine which Register of Members shall constitute the principal register and which shall constitute the branch register or registers, and to vary such determination from time to time.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>5.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Share certificates </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Issue of share certificates </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Upon being entered in the Register of Members as the holder of a Share, a Member shall be entitled:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">without payment, to one certificate for all the Shares of each class held by that Member (and, upon
transferring a part of the Member&#146;s holding of Shares of any class, to a certificate for the balance of that holding); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">upon payment of such reasonable sum as the directors may determine for every certificate after the first, to
several certificates each for one or more of that Member&#146;s Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Every certificate shall specify the number, class and distinguishing numbers (if any) of the Shares to which
it relates and whether they are Fully Paid or partly paid up. A certificate may be executed under seal or executed in such other manner as the directors determine. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company shall not be bound to issue more than one certificate for Shares held jointly by several persons
and delivery of a certificate for a Share to one joint holder shall be a sufficient delivery to all of them. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Renewal
of lost or damaged share certificates </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If a share certificate is defaced, worn-out, lost or destroyed, it may be renewed on such terms (if any) as
to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">evidence; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">indemnity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">payment of the expenses reasonably incurred by the Company in investigating the evidence; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(d)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">payment of a reasonable fee, if any, for issuing a replacement share certificate </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">as the directors may determine, and (in the case of defacement or wearing-out) on delivery to the Company of the old
certificate. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>6.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Lien on Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Nature and scope of lien </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company has a first and paramount lien on all Shares (whether Fully Paid or not) registered in the name
of a Member (whether solely or jointly with others). The lien is for all moneys payable to the Company by the Member or the Member&#146;s estate: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">either alone or jointly with any other person, whether or not that other person is a Member; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">whether or not those moneys are presently payable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">At any time the directors may declare any Share to be wholly or partly exempt from the provisions of this
Article. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Company may sell Shares to satisfy lien </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company may sell any Shares over which it has a lien if all of the following conditions are met:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the sum in respect of which the lien exists is presently payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the Company gives notice to the Member holding the Share (or to the person entitled to it in consequence of
the death or bankruptcy of that Member) demanding payment and stating that if the notice is not complied with the Shares may be sold; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">that sum is not paid within 14 Clear Days after that notice is deemed to be given under these Articles.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Shares may be sold in such manner as the directors determine. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To the maximum extent permitted by Applicable Law, the directors shall incur no personal liability to the
Member concerned in respect of the sale. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Authority to execute instrument of transfer</B> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6.6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To give effect to a sale, the directors may authorise any person to execute an instrument of transfer of the
Shares sold to, or in accordance with the directions of, the purchaser. The title of the transferee of the Shares shall not be affected by any irregularity or invalidity in the proceedings in respect of the sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Consequences of sale of Shares to satisfy lien</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6.7</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">On sale pursuant to the preceding Articles: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the name of the Member concerned shall be removed from the Register of Members as the holder of those
Shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">that person shall deliver to the Company for cancellation the certificate for those Shares.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Despite this, that person shall remain liable to the Company for all monies which, at the date of sale,
were presently payable by him to the Company in respect of those Shares. That person shall also be liable to pay interest on those monies from the date of sale until payment at the rate at which interest was payable before that sale or, failing
that, at the Default Rate. The directors may waive payment wholly or in part or enforce payment without any allowance for the value of the Shares at the time of sale or for any consideration received on their disposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Application of proceeds of sale </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6.8</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The net proceeds of the sale, after payment of the costs, shall be applied in payment of so much of the sum
for which the lien exists as is presently payable. Any residue shall be paid to the person whose Shares have been sold: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if no certificate for the Shares was issued, at the date of the sale; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if a certificate for the Shares was issued, upon surrender to the Company of that certificate for
cancellation </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">but, in either case, subject to the Company retaining a like lien for all sums not
presently payable as existed on the Shares before the sale. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>7.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Calls on Shares and forfeiture </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to make calls and effect of calls </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Subject to the terms of allotment, the directors may make calls on the Members in respect of any moneys
unpaid on their Shares including any premium. The call may provide for payment to be by instalments. Subject to receiving at least 14 Clear Days&#146; notice specifying when and where payment is to be made, each Member shall pay to the Company the
amount called on his Shares as required by the notice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Before receipt by the Company of any sum due under a call, that call may be revoked in whole or in part and
payment of a call may be postponed in whole or in part. Where a call is to be paid in instalments, the Company may revoke the call in respect of all or any remaining instalments in whole or in part and may postpone payment of all or any of the
remaining instalments in whole or in part. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A Member on whom a call is made shall remain liable for that call notwithstanding the subsequent transfer of
the Shares in respect of which the call was made. A person shall not be liable for calls made after such person is no longer registered as Member in respect of those Shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Time when call made </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A call shall be deemed to have been made at the time when the resolution of the directors authorising the
call was passed. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Liability of joint holders </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Members registered as the joint holders of a Share shall be jointly and severally liable to pay all calls in
respect of the Share. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Interest on unpaid calls </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7.6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If a call remains unpaid after it has become due and payable the person from whom it is due and payable
shall pay interest on the amount unpaid from the day it became due and payable until it is paid: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">at the rate fixed by the terms of allotment of the Share or in the notice of the call; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if no rate is fixed, at the Default Rate. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The directors may waive payment of the interest wholly or in part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Deemed calls </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7.7</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Any amount payable in respect of a Share, whether on allotment or on a fixed date or otherwise, shall be
deemed to be payable as a call. If the amount is not paid when due the provisions of these Articles shall apply as if the amount had become due and payable by virtue of a call. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to accept early payment </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7.8</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company may accept from a Member the whole or a part of the amount remaining unpaid on Shares held by
him although no part of that amount has been called up. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to make different arrangements at time of issue of
Shares </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7.9</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Subject to the terms of allotment, the directors may make arrangements on the issue of Shares to distinguish
between Members in the amounts and times of payment of calls on their Shares. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Notice of default </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7.10</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If a call remains unpaid after it has become due and payable the directors may give to the person from whom
it is due not less than 14 Clear Days&#146; notice requiring payment of: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the amount unpaid; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">any interest which may have accrued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">any expenses which have been incurred by the Company due to that person&#146;s default.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7.11</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The notice shall state the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the place where payment is to be made; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a warning that if the notice is not complied with the Shares in respect of which the call is made will be
liable to be forfeited. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Forfeiture or surrender of Shares </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7.12</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If the notice under the preceding Article&nbsp;is not complied with, the directors may, before the payment
required by the notice has been received, resolve that any Share the subject of that notice be forfeited. The forfeiture shall include all dividends or other moneys payable in respect of the forfeited Share and not paid before the forfeiture.
Despite the foregoing, the directors may determine that any Share the subject of that notice be accepted by the Company as surrendered by the Member holding that Share in lieu of forfeiture. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7.13</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may accept the surrender for no consideration of any Fully Paid Share. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Disposal of forfeited or surrendered Share and power to cancel forfeiture or surrender </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7.14</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A forfeited or surrendered Share may be sold, <FONT STYLE="white-space:nowrap">re-allotted</FONT> or
otherwise disposed of on such terms and in such manner as the directors determine either to the former Member who held that Share or to any other person. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
The forfeiture or surrender may be cancelled on such terms as the directors think fit at any time before a sale, <FONT STYLE="white-space:nowrap">re-allotment</FONT> or other disposition. Where,
for the purposes of its disposal, a forfeited or surrendered Share is to be transferred to any person, the directors may authorise some person to execute an instrument of transfer of the Share to the transferee. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Effect of forfeiture or surrender on former Member </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7.15</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">On forfeiture or surrender: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the name of the Member concerned shall be removed from the Register of Members as the holder of those Shares
and that person shall cease to be a Member in respect of those Shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">that person shall surrender to the Company for cancellation the certificate (if any) for the forfeited or
surrendered Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7.16</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Despite the forfeiture or surrender of his Shares, that person shall remain liable to the Company for all
moneys which at the date of forfeiture or surrender were presently payable by him to the Company in respect of those Shares together with: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">all expenses; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">interest from the date of forfeiture or surrender until payment: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">at the rate of which interest was payable on those moneys before forfeiture; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(ii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if no interest was so payable, at the Default Rate. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The directors, however, may waive payment wholly or in part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Evidence of forfeiture or surrender </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7.17</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A declaration, whether statutory or under oath, made by a director or the Secretary shall be conclusive
evidence of the following matters stated in it as against all persons claiming to be entitled to forfeited Shares: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">that the person making the declaration is a director or Secretary of the Company, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">that the particular Shares have been forfeited or surrendered on a particular date. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the execution of an instrument of transfer, if necessary, the declaration shall constitute good title to the Shares.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Sale of forfeited or surrendered Shares </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7.18</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Any person to whom the forfeited or surrendered Shares are disposed of shall not be bound to see to the
application of the consideration, if any, of those Shares nor shall his title to the Shares be affected by any irregularity in, or invalidity of the proceedings in respect of, the forfeiture, surrender or disposal of those Shares.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>8.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Transfer of Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Form&nbsp;of transfer </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">8.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Subject to the following Articles about the transfer of Shares, and provided that such transfer complies
with the rules&nbsp;and regulations of the Designated Stock Exchange, the SEC and/or any other competent regulatory authority or otherwise under Applicable Law, a Member may transfer Shares to another person by completing an instrument of transfer
in a common form or in a form prescribed by the rules&nbsp;and regulations </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of the Designated Stock Exchange, the SEC and/or any other competent regulatory authority or otherwise under Applicable Law or in any other form approved by the directors, executed:
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">where the Shares are Fully Paid, by or on behalf of that Member; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">where the Shares are partly paid, by or on behalf of that Member and the transferee. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">8.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The transferor shall be deemed to remain the holder of a Share until the name of the transferee is entered
into the Register of Members. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to refuse registration </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">8.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If the Shares in question were issued in conjunction with rights, options or warrants issued pursuant to
Article 3.4 on terms that one cannot be transferred without the other, the directors shall refuse to register the transfer of any such Share without evidence satisfactory to them of the like transfer of such option or warrant. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to suspend registration </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">8.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may suspend registration of the transfer of Shares at such times and for such periods, not
exceeding 30 days in any calendar year, as they determine. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Company may retain instrument of transfer </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">8.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company shall be entitled to retain any instrument of transfer which is registered; but an instrument of
transfer which the directors refuse to register shall be returned to the person lodging it when notice of the refusal is given. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>9.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Transmission of Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Persons entitled on death of a Member </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">9.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If a Member dies, the only persons recognised by the Company as having any title to the deceased
Members&#146; interest are the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">where the deceased Member was a joint holder, the survivor or survivors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">where the deceased Member was a sole holder, that Member&#146;s personal representative or representatives.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">9.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Nothing in these Articles shall release the deceased Member&#146;s estate from any liability in respect of
any Share, whether the deceased was a sole holder or a joint holder. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Registration of transfer of a Share following
death or bankruptcy </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">9.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A person becoming entitled to a Share in consequence of the death or bankruptcy of a Member may elect to do
either of the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to become the holder of the Share; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to transfer the Share to another person. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">9.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">That person must produce such evidence of his entitlement as the directors may properly require.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">9.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If the person elects to become the holder of the Share, he must give notice to the Company to that effect.
For the purposes of these Articles, that notice shall be treated as though it were an executed instrument of transfer. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">9.6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If the person elects to transfer the Share to another person then: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if the Share is Fully Paid, the transferor must execute an instrument of transfer; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if the Share is partly paid, the transferor and the transferee must execute an instrument of transfer.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">9.7</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">All these Articles relating to the transfer of Shares shall apply to the notice or, as appropriate, the
instrument of transfer. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Indemnity </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">9.8</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A person registered as a Member by reason of the death or bankruptcy of another Member shall indemnify the
Company and the directors against any loss or damage suffered by the Company or the directors as a result of that registration. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Rights of person entitled to a Share following death or bankruptcy </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">9.9</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A person becoming entitled to a Share by reason of the death or bankruptcy of a Member shall have the rights
to which he would be entitled if he were registered as the holder of the Share. However, until he is registered as Member in respect of the Share, he shall not be entitled to attend or vote at any meeting of the Company or at any separate meeting of
the holders of that class of Shares in the Company. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>10.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Alteration of capital </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Increasing, consolidating, converting, dividing and cancelling share capital </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">10.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To the fullest extent permitted by the Law, the Company may by Ordinary Resolution do any of the following
and amend its Memorandum for that purpose: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">increase its share capital by new Shares of the amount fixed by that Ordinary Resolution and with the
attached rights, priorities and privileges set out in that Ordinary Resolution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">consolidate and divide all or any of its share capital into Shares of larger amount than its existing
Shares; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">convert all or any of its Paid Up Shares into stock, and reconvert that stock into Paid Up Shares of any
denomination; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(d)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><FONT STYLE="white-space:nowrap">sub-divide</FONT> its Shares or any of them into Shares of an amount
smaller than that fixed by the Memorandum, so, however, that in the <FONT STYLE="white-space:nowrap">sub-division,</FONT> the proportion between the amount paid and the amount, if any, unpaid on each reduced Share shall be the same as it was in case
of the Share from which the reduced Share is derived; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(e)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">cancel Shares which, at the date of the passing of that Ordinary Resolution, have not been taken or agreed
to be taken by any person, and diminish the amount of its share capital by the amount of the Shares so cancelled or, in the case of Shares without nominal par value, diminish the number of Shares into which its capital is divided.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Dealing with fractions resulting from consolidation of Shares </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">10.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Whenever, as a result of a consolidation of Shares, any Members would become entitled to fractions of a
Share the directors may on behalf of those Members: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">sell the Shares representing the fractions for the best price reasonably obtainable to any person
(including, subject to the provisions of the Law, the Company); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">distribute the net proceeds in due proportion among those Members. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For that purpose, the directors may authorise some person to execute an
instrument of transfer of the Shares to, or in accordance with the directions of, the purchaser. The transferee shall not be bound to see to the application of the purchase money nor shall the transferee&#146;s title to the Shares be affected by any
irregularity in, or invalidity of, the proceedings in respect of the sale. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Reducing share capital </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">10.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Subject to the Law and to any rights for the time being conferred on the Members holding a particular class
of Shares, the Company may, by Special Resolution, reduce its share capital in any way. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>11.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Redemption and purchase of own Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to issue redeemable Shares and to purchase own Shares </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">11.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Subject to the Law and Article&nbsp;38, and to any rights for the time being conferred on the Members
holding a particular class of Shares, and, where applicable, the rules&nbsp;and regulations of the Designated Stock Exchange, the SEC and/or any other competent regulatory authority or otherwise under Applicable Law, the Company may by its
directors: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">issue Shares that are to be redeemed or liable to be redeemed, at the option of the Company or the Member
holding those redeemable Shares, on the terms and in the manner its directors determine before the issue of those Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">with the consent by Special Resolution of the Members holding Shares of a particular class, vary the rights
attaching to that class of Shares so as to provide that those Shares are to be redeemed or are liable to be redeemed at the option of the Company on the terms and in the manner which the directors determine at the time of such variation; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">purchase all or any of its own Shares of any class including any redeemable Shares on the terms and in the
manner which the directors determine at the time of such purchase. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company may make a payment in
respect of the redemption or purchase of its own Shares in any manner authorised by the Law, including out of any combination of the following: capital, its profits and the proceeds of a fresh issue of Shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">11.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">With respect to redeeming, repurchasing or surrendering of Shares: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Members who hold Public Shares are entitled to request the redemption of such Shares in the circumstances
described in Article&nbsp;38.3; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Class&nbsp;B Ordinary Shares held by the Sponsor shall be surrendered by the Sponsor for no consideration to
the extent that the Over-Allotment Option is not exercised in full so that the Class&nbsp;B Ordinary Shares will represent 20% of the Company&#146;s issued Shares after the IPO (exclusive of any securities purchased in a private placement
simultaneously with the IPO); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Public Shares shall be repurchased by way of Tender Offer in the circumstances set out in
Article&nbsp;38.2(b). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to pay for redemption or purchase in cash or in specie </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">11.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">When making a payment in respect of the redemption or purchase of Shares, the directors may make the payment
in cash or in specie (or partly in one and partly in the other) if so authorised by the terms of the allotment of those Shares, or by the terms applying to those Shares in accordance with Article&nbsp;11.1, or otherwise by agreement with the Member
holding those Shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Effect of redemption or purchase of a Share </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">11.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Upon the date of redemption or purchase of a Share: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the Member holding that Share shall cease to be entitled to any rights in respect of the Share other than
the right to receive: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) the price for the Share; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) any dividend declared in respect of the Share prior to the date of redemption or purchase; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the Member&#146;s name shall be removed from the Register of Members with respect to the Share; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the Share shall be cancelled or held as a Treasury Shares, as the directors may determine.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the purpose of this Article, the date of redemption or purchase is the date when the redemption or
purchase falls due. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">11.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">For the avoidance of doubt, redemptions and repurchases of Shares in the circumstances described in Articles
11.2(a), 11.2(b)&nbsp;and 11.2(c)&nbsp;above shall not require further approval of the Members. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>12.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Class&nbsp;B Share Conversion</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">12.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Save and except for the conversion rights referred to in this Article&nbsp;12 and as otherwise set out in
these Articles, subject to Article&nbsp;3.9, the rights attaching to the Class&nbsp;A Ordinary Shares and the Class&nbsp;B Ordinary Shares shall rank <I>pari passu</I> in all respects, and the Class&nbsp;A Ordinary Shares and Class&nbsp;B Ordinary
Shares shall vote together as a single class on all matters. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">12.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">On the first business day following the consummation of the Company&#146;s initial Business Combination, the
issued Class&nbsp;B Ordinary Shares shall automatically be converted into such number of Class&nbsp;A Ordinary Shares as is equal, in the aggregate, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, to 20% of the sum of:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the total number of Class&nbsp;A Ordinary Shares issued (excluding the private placement shares underlying
the private placement warrants) upon completion of the IPO (including pursuant to the Over-Allotment Option, if applicable), plus </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the sum of (i)&nbsp;the total number of Class&nbsp;A Ordinary Shares issued or deemed issued, or issuable
upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class&nbsp;A Ordinary Shares or
equity-linked securities exercisable for or convertible into Class&nbsp;A Ordinary Shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination, any Class&nbsp;A Ordinary Shares and private placement warrants
issued to the Sponsor, members of the Company&#146;s management team or their Affiliates and any warrants issued upon conversion of working capital loans, if any, minus (ii)&nbsp;the total number of Public Shares repurchased pursuant to the IPO
Redemption. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">12.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">References in this Article&nbsp;to <B>converted</B>, <B>conversion </B>or <B>exchange </B>shall mean the
compulsory redemption without notice of Class&nbsp;B Ordinary Shares of any Member and, on behalf of such Members, automatic application of such redemption proceeds in paying for such new Class&nbsp;A Ordinary Shares into which the Class&nbsp;B
Ordinary Shares have been converted or exchanged at a price per Class&nbsp;B Share necessary to give effect to a conversion or exchange calculated on the basis that the Class&nbsp;A Ordinary Shares to be issued as part of the conversion or exchange
will be issued at par. The Class&nbsp;A Ordinary Shares to be issued on an exchange or conversion shall be registered in the name of such Member or in such name as the Member may direct. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">12.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Notwithstanding anything to the contrary in this Article&nbsp;12, in no event may any Class&nbsp;B Share
convert into Class&nbsp;A Ordinary Shares at a ratio that is less than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one.</FONT></FONT> Each Class&nbsp;B Share shall convert into its pro rata number of Class&nbsp;A
Ordinary Shares as set forth in this Article&nbsp;12. The pro rata share for each holder of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Class&nbsp;B Ordinary Shares will be determined as follows: Each Class&nbsp;B Share shall convert into such number of Class&nbsp;A Ordinary Shares as is equal to the product of 1 multiplied by a
fraction, the numerator of which shall be the total number of Class&nbsp;A Ordinary Shares into which all of the issued Class&nbsp;B Ordinary Shares shall be converted pursuant to this Article&nbsp;and the denominator of which shall be the total
number of issued Class&nbsp;B Ordinary Shares at the time of conversion. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">12.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors shall not allot or issue Class&nbsp;A Ordinary Shares such that the number of authorised but
unissued Class&nbsp;A Ordinary Shares would at any time be insufficient to permit the conversion of all Class&nbsp;B Ordinary Shares from time to time issued into Class&nbsp;A Ordinary Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>13.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Meetings of Members </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to call meetings </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To the extent required by the rules&nbsp;and regulations of the Designated Stock Exchange, the SEC and/or
any other competent regulatory authority or otherwise under Applicable Law, an annual general meeting of the Company shall be held no later than one year after the first financial year end occurring after the IPO, and shall be held in each year
thereafter at such time as determined by the directors and the Company may, but shall not (unless required by the Law or the rules&nbsp;and regulations of the Designated Stock Exchange, the SEC and/or any other competent regulatory authority or
otherwise under Applicable Law) be obliged to, in each year hold any other general meeting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The agenda of the annual general meeting shall be set by the directors and shall include the presentation of
the Company&#146;s annual accounts and the report of the directors (if any). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Annual general meetings shall be held in New York, USA or in such other places as the directors may
determine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">All general meetings other than annual general meetings shall be called extraordinary general meetings and
the Company shall specify the meeting as such in the notices calling it. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may call a general meeting at any time. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If there are insufficient directors to constitute a quorum and the remaining directors are unable to agree
on the appointment of additional directors, the directors must call a general meeting for the purpose of appointing additional directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.7</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors must also call a general meeting if requisitioned in the manner set out in the next two
Articles. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.8</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The requisition must be in writing and given by one or more Members who together hold at least 40% of the
rights to vote at such general meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.9</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The requisition must also: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">specify the purpose of the meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">be signed by or on behalf of each requisitioner (and for this purpose each joint holder shall be obliged to
sign). The requisition may consist of several documents in like form signed by one or more of the requisitioners. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">be delivered in accordance with the notice provisions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.10</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Should the directors fail to call a general meeting within 21 Clear Days from the date of receipt of a
requisition, the requisitioners or any of them may call a general meeting within three months after the end of that period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.11</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Without limitation to the foregoing, if there are insufficient directors to constitute a quorum and the
remaining directors are unable to agree on the appointment of additional directors, any one or more Members who together hold at least 40% of the rights to vote at a general meeting may call a general meeting for the purpose of considering the
business specified in the notice of meeting which shall include as an item of business the appointment of additional directors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.12</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Members seeking to bring business before the annual general meeting or to nominate candidates for election
as directors at the annual general meeting must deliver notice to the principal executive offices of the Company not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the scheduled date
of the annual general meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Content of notice </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.13</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Notice of a general meeting shall specify each of the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the place, the date and the hour of the meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if the meeting is to be held in two or more places, the technology that will be used to facilitate the
meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">subject to paragraph (d), the general nature of the business to be transacted; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(d)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if a resolution is proposed as a Special Resolution, the text of that resolution. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.14</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In each notice there shall appear with reasonable prominence the following statements:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">that a Member who is entitled to attend and vote is entitled to appoint one or more proxies to attend and
vote instead of that Member; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">that a proxyholder need not be a Member. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Period of notice </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.15</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">At least five Clear Days&#146; notice of a general meeting must be given to Members, provided that a general
meeting of the Company shall, whether or not the notice specified in this Article&nbsp;has been given and whether or not the provisions of these Articles regarding general meetings have been complied with, be deemed to have been duly convened if it
is so agreed: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in the case of an annual general meeting, by all of the Members entitled to attend and vote thereat; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in the case of an extraordinary general meeting, by a majority in number of the Members having a right to
attend and vote at the meeting, together holding not less than 95% in par value of the Shares giving that right. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Persons entitled to receive notice </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.16</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Subject to the provisions of these Articles and to any restrictions imposed on any Shares, the notice shall
be given to the following people: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the Members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">persons entitled to a Share in consequence of the death or bankruptcy of a Member; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Publication of notice on a website </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.17</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Subject to the Law or the rules&nbsp;and regulations of the Designated Stock Exchange, the SEC and/or any
other competent regulatory authority or otherwise under Applicable Law, a notice of a general meeting may be published on a website providing the recipient is given separate notice of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the publication of the notice on the website; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the place on the website where the notice may be accessed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">how it may be accessed; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(d)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the place, date and time of the general meeting. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.18</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If a Member notifies the Company that he is unable for any reason to access the website, the Company must as
soon as practicable give notice of the meeting to that Member by any other means permitted by these Articles. This will not affect when that Member is deemed to have received notice of the meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Time a website notice is deemed to be given </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.19</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A website notice is deemed to be given when the Member is given notice of its publication.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Required duration of publication on a website </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.20</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Where the notice of meeting is published on a website, it shall continue to be published in the same place
on that website from the date of the notification until at least the conclusion of the meeting to which the notice relates. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Accidental omission to give notice or <FONT STYLE="white-space:nowrap">non-receipt</FONT> of notice </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.21</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Proceedings at a meeting shall not be invalidated by the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">an accidental failure to give notice of the meeting to any person entitled to notice; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><FONT STYLE="white-space:nowrap">non-receipt</FONT> of notice of the meeting by any person entitled to
notice. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.22</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In addition, where a notice of meeting is published on a website, proceedings at the meeting shall not be
invalidated merely because it is accidentally published: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in a different place on the website; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">for part only of the period from the date of the notification until the conclusion of the meeting to which
the notice relates. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>14.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Proceedings at meetings of Members </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Quorum </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Save as provided in the following Article, no business shall be transacted at any meeting unless a quorum is
present in person or by proxy. One or more Members who together hold not less than <FONT STYLE="white-space:nowrap">one-third</FONT> of the Shares entitled to vote at such meeting being individuals present in person or by proxy or if a corporation
or other <FONT STYLE="white-space:nowrap">non-natural</FONT> person by its duly authorised representative or proxy shall be a quorum; provided that a quorum in connection with any meeting that is convened to vote on a Business Combination or any
meeting convened with regards to an amendment described in Article&nbsp;38.9 shall be a majority of the Shares entitled to vote at such meeting being individuals present in person or by proxy or if a corporation or other <FONT
STYLE="white-space:nowrap">non-natural</FONT> person by its duly authorised representative or proxy. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Lack of quorum
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If a quorum is not present within 15 minutes of the time appointed for the meeting, or if at any time during
the meeting it becomes inquorate, then the following provisions apply: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If the meeting was requisitioned by Members, it shall be cancelled. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In any other case, the meeting shall stand adjourned to the same time and place seven days hence, or to such
other time or place as is determined by the directors. If a quorum is not present within 15 minutes of the time appointed for the adjourned meeting, then the meeting shall be dissolved. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Use of technology </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A person may participate in a general meeting through the medium of conference telephone, video or any other
form of communications equipment providing all persons participating in the meeting are able to hear </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and speak to each other throughout the meeting. A person participating in this way is deemed to be present in person at the meeting. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Chairman </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The chairman of a general meeting shall be the chairman of the board or such other director as the directors
have nominated to chair board meetings in the absence of the chairman of the board. Absent any such person being present within 15 minutes of the time appointed for the meeting, the directors present shall elect one of their number to chair the
meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If no director is present within 15 minutes of the time appointed for the meeting, or if no director is
willing to act as chairman, the Members present in person or by proxy and entitled to vote shall choose one of their number to chair the meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Right of a director to attend and speak </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Even if a director is not a Member, he shall be entitled to attend and speak at any general meeting and at
any separate meeting of Members holding a particular class of Shares in the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Adjournment and Postponement
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.7</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The chairman may at any time adjourn a meeting. The chairman must adjourn the meeting if so directed by the
meeting. No business, however, can be transacted at an adjourned meeting other than business which might properly have been transacted at the original meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.8</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Should a meeting be adjourned for more than twenty Clear Days, whether because of a lack of quorum or
otherwise, Members shall be given at least five Clear Days&#146; notice of the date, time and place of the adjourned meeting and the general nature of the business to be transacted. Otherwise it shall not be necessary to give any notice of the
adjournment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.9</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If, prior to a Business Combination, a notice is issued in respect of a general meeting and the directors,
in their absolute discretion, consider that it is impractical or undesirable for any reason to hold that general meeting at the place, the day and the hour specified in the notice calling such general meeting, the directors may postpone the general
meeting to another place, day and/or hour provided that notice of the place, the day and the hour of the rearranged general meeting is promptly given to all Members. No business shall be transacted at any postponed meeting other than the business
specified in the notice of the original meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.10</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">When a general meeting is postponed for thirty days or more, notice of the postponed meeting shall be given
as in the case of an original meeting. Otherwise it shall not be necessary to give any such notice of a postponed meeting. All proxy forms submitted for the original general meeting shall remain valid for the postponed meeting. The directors may
postpone a general meeting which has already been postponed. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Method of voting </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.11</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A resolution put to the vote of the meeting shall be decided on a poll. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Taking of a poll </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.12</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A poll demanded on the question of adjournment shall be taken immediately. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.13</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A poll demanded on any other question shall be taken either immediately or at an adjourned meeting at such
time and place as the chairman directs, not being more than 30 Clear Days after the poll was demanded. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.14</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The demand for a poll shall not prevent the meeting continuing to transact any business other than the
question on which the poll was demanded. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.15</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A poll shall be taken in such manner as the chairman directs. He may appoint scrutineers (who need not be
Members) and fix a place and time for declaring the result of the poll. If, through the aid of technology, the meeting is held in more than place, the chairman may appoint scrutineers in more than place; but if he considers that the poll cannot be
effectively monitored at that meeting, the chairman shall adjourn the holding of the poll to a date, place and time when that can occur. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Chairman&#146;s casting vote </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.16</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If the votes on a resolution are equal, the chairman may if he wishes exercise a casting vote.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Amendments to resolutions </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.17</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">An Ordinary Resolution to be proposed at a general meeting may be amended by Ordinary Resolution if:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">not less than 48 hours before the meeting is to take place (or such later time as the chairman of the
meeting may determine), notice of the proposed amendment is given to the Company in writing by a Member entitled to vote at that meeting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the proposed amendment does not, in the reasonable opinion of the chairman of the meeting, materially alter
the scope of the resolution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.18</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A Special Resolution to be proposed at a general meeting may be amended by Ordinary Resolution, if:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the chairman of the meeting proposes the amendment at the general meeting at which the resolution is to be
proposed, and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the amendment does not go beyond what the chairman considers is necessary to correct a grammatical or other <FONT
STYLE="white-space:nowrap">non-substantive</FONT> error in the resolution. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.19</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If the chairman of the meeting, acting in good faith, wrongly decides that an amendment to a resolution is
out of order, the chairman&#146;s error does not invalidate the vote on that resolution. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Written resolutions
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.20</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Members may pass a resolution in writing without holding a meeting if the following conditions are met:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">all Members entitled so to vote are given notice of the resolution as if the same were being proposed at a
meeting of Members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">all Members entitled so to vote : </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">sign a document; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(ii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">sign several documents in the like form each signed by one or more of those Members; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the signed document or documents is or are delivered to the Company, including, if the Company so nominates,
by delivery of an Electronic Record by Electronic means to the address specified for that purpose. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Such
written resolution shall be as effective as if it had been passed at a meeting of the Members entitled to vote duly convened and held. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.21</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If a written resolution is described as a Special Resolution or as an Ordinary Resolution, it has effect
accordingly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.22</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may determine the manner in which written resolutions shall be put to Members. In particular,
they may provide, in the form of any written resolution, for each Member to indicate, out of the number of votes the Member would have been entitled to cast at a meeting to consider the resolution, how
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
many votes he wishes to cast in favour of the resolution and how many against the resolution or to be treated as abstentions. The result of any such written resolution shall be determined on the
same basis as on a poll. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Sole-member company </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.23</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If the Company has only one Member, and the Member records in writing his decision on a question, that
record shall constitute both the passing of a resolution and the minute of it. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>15.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Voting rights of Members </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Right to vote </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Unless their Shares carry no right to vote, or unless a call or other amount presently payable has not been
paid, all Members are entitled to vote at a general meeting, and all Members holding Shares of a particular class of Shares are entitled to vote at a meeting of the holders of that class of Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Members may vote in person or by proxy. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Every Member shall have one vote for each Share he holds, unless any Share carries special voting rights.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A fraction of a Share shall entitle its holder to an equivalent fraction of one vote. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">No Member is bound to vote on his Shares or any of them; nor is he bound to vote each of his Shares in the
same way. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Rights of joint holders </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If Shares are held jointly, only one of the joint holders may vote. If more than one of the joint holders
tenders a vote, the vote of the holder whose name in respect of those Shares appears first in the Register of Members shall be accepted to the exclusion of the votes of the other joint holder. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Representation of corporate Members </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.7</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Save where otherwise provided, a corporate Member must act by a duly authorised representative.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.8</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A corporate Member wishing to act by a duly authorised representative must identify that person to the
Company by notice in writing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.9</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The authorisation may be for any period of time, and must be delivered to the Company not less than two
hours before the commencement of the meeting at which it is first used. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.10</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors of the Company may require the production of any evidence which they consider necessary to
determine the validity of the notice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.11</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Where a duly authorised representative is present at a meeting that Member is deemed to be present in
person; and the acts of the duly authorised representative are personal acts of that Member. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.12</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A corporate Member may revoke the appointment of a duly authorised representative at any time by notice to
the Company; but such revocation will not affect the validity of any acts carried out by the duly authorised representative before the directors of the Company had actual notice of the revocation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.13</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If a clearing house (or its nominee(s)), being a corporation, is a Member, it may authorise such persons as
it sees fit to act as its representative at any meeting of the Company or at any meeting of any class of Members provided that the authorisation shall specify the number and class of Shares in respect of which each such representative is so
authorised. Each person so authorised under the provisions of this Article&nbsp;shall be deemed to have been duly authorised without further evidence of the facts and be entitled to exercise the same rights and powers on behalf of the clearing house
(or its nominee(s)) as if such person was the registered holder of such Shares held by the clearing house (or its nominee(s)). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Member with mental disorder </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.14</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A Member in respect of whom an order has been made by any court having jurisdiction (whether in the Islands
or elsewhere) in matters concerning mental disorder may vote, by that Member&#146;s receiver, curator bonis or other person authorised in that behalf appointed by that court. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.15</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">For the purpose of the preceding Article, evidence to the satisfaction of the directors of the authority of
the person claiming to exercise the right to vote must be received not less than 24 hours before holding the relevant meeting or the adjourned meeting in any manner specified for the delivery of forms of appointment of a proxy, whether in writing or
by Electronic means. In default, the right to vote shall not be exercisable. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Objections to admissibility of votes
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.16</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">An objection to the validity of a person&#146;s vote may only be raised at the meeting or at the adjourned
meeting at which the vote is sought to be tendered. Any objection duly made shall be referred to the chairman whose decision shall be final and conclusive. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Form&nbsp;of proxy </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.17</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">An instrument appointing a proxy shall be in any common form or in any other form approved by the directors.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.18</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The instrument must be in writing and signed in one of the following ways: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">by the Member; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">by the Member&#146;s authorised attorney; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if the Member is a corporation or other body corporate, under seal or signed by an authorised officer,
secretary or attorney. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the directors so resolve, the Company may accept an Electronic Record of that
instrument delivered in the manner specified below and otherwise satisfying these Articles about authentication of Electronic Records. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.19</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may require the production of any evidence which they consider necessary to determine the
validity of any appointment of a proxy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.20</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A Member may revoke the appointment of a proxy at any time by notice to the Company duly signed in
accordance with the Article&nbsp;above about signing proxies; but such revocation will not affect the validity of any acts carried out by the proxy before the directors of the Company had actual notice of the revocation. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>How and when proxy is to be delivered </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.21</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Subject to the following Articles, the form of appointment of a proxy and any authority under which it is
signed (or a copy of the authority certified notarially or in any other way approved by the directors) must be delivered so that it is received by the Company not less than 48 hours before the time for holding the meeting or adjourned meeting at
which the person named in the form of appointment of proxy proposes to vote. They must be delivered in either of the following ways: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In the case of an instrument in writing, it must be left at or sent by post: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to the registered office of the Company; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(ii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to such other place specified in the notice convening the meeting or in any form of appointment of proxy
sent out by the Company in relation to the meeting. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If, pursuant to the notice provisions, a notice may be given to the Company in an Electronic Record, an
Electronic Record of an appointment of a proxy must be sent to the address specified pursuant to those provisions unless another address for that purpose is specified: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in the notice convening the meeting; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(ii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in any form of appointment of a proxy sent out by the Company in relation to the meeting; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(iii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in any invitation to appoint a proxy issued by the Company in relation to the meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.22</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Where a poll is taken: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if it is taken more than seven Clear Days after it is demanded, the form of appointment of a proxy and any
accompanying authority (or an Electronic Record of the same) must be delivered as required under the preceding Article&nbsp;not less than 24 hours before the time appointed for the taking of the poll; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">but if it to be taken within seven Clear Days after it was demanded, the form of appointment of a proxy and
any accompanying authority (or an Electronic Record of the same) must be e delivered as required under the preceding Article&nbsp;not less than two hours before the time appointed for the taking of the poll. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.23</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If the form of appointment of proxy is not delivered on time, it is invalid. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Voting by proxy </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.24</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A proxy shall have the same voting rights at a meeting or adjourned meeting as the Member would have had
except to the extent that the instrument appointing him limits those rights. Notwithstanding the appointment of a proxy, a Member may attend and vote at a meeting or adjourned meeting. If a Member votes on any resolution a vote by his proxy on the
same resolution, unless in respect of different Shares, shall be invalid. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>16.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Number of directors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless otherwise determined by Ordinary Resolution, the minimum number of directors shall be one and the maximum shall be ten.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>17.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Appointment, disqualification and removal of directors No age limit </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">17.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">There is no age limit for directors save that they must be aged at least 18 years. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Corporate directors </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">17.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Unless prohibited by law, a body corporate may be a director. If a body corporate is a director, these
Articles about representation of corporate Members at general meetings apply, mutatis mutandis, to these Articles about directors&#146; meetings. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>No shareholding qualification </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">17.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Unless a shareholding qualification for directors is fixed by Ordinary Resolution, no director shall be
required to own Shares as a condition of his appointment. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Appointment and removal of directors </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">17.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors shall be divided into three classes: Class&nbsp;I, Class&nbsp;II and Class&nbsp;III. The
number of directors in each class shall be as nearly equal as possible. Upon the adoption of the Articles, the existing directors </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
shall by resolution classify themselves as Class&nbsp;I, Class&nbsp;II or Class&nbsp;III directors. The Class&nbsp;I directors shall stand elected for a term expiring at the Company&#146;s first
annual general meeting, the Class&nbsp;II directors shall stand elected for a term expiring at the Company&#146;s second annual general meeting and the Class&nbsp;III directors shall stand elected for a term expiring at the Company&#146;s third
annual general meeting. Commencing at the Company&#146;s first annual general meeting, and at each annual general meeting thereafter, directors elected to succeed those directors whose terms expire shall be elected for a term of office to expire at
the third succeeding annual general meeting after their election. All directors shall hold office until the expiration of their respective terms of office and until their successors shall have been elected and qualified. A director elected to fill a
vacancy resulting from the death, resignation or removal of a director shall serve for the remainder of the full term of the director whose death, resignation or removal shall have created such vacancy and until his successor shall have been elected
and qualified. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">17.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Prior to the closing of a Business Combination, the Company may by Ordinary Resolution of the holders of the
Class&nbsp;B Ordinary Shares appoint any person to be a director or may by Ordinary Resolution of the holders of the Class&nbsp;B Ordinary Shares remove any director. For the avoidance of doubt, prior to the closing of a Business Combination holders
of Class&nbsp;A Ordinary Shares shall have no right to vote on the appointment or removal of any director. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">17.6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">After the closing of a Business Combination, the Company may by Ordinary Resolution appoint any person to be
a director or may by Ordinary Resolution remove any director. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">17.7</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Article&nbsp;17.5 may only be amended by a Special Resolution passed by holders representing at least <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of the Class&nbsp;B Ordinary Shares in issue. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">17.8</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Without prejudice to the Company&#146;s power to appoint a person to be a director pursuant to these
Articles, the directors shall have power at any time to appoint any person who is willing to act as a director, either to fill a vacancy or as an additional director. A director elected to fill a vacancy resulting from the death, resignation or
removal of a director shall serve for the remainder of the full term of the director whose death, resignation or removal shall have created such vacancy and until his successor shall have been elected and qualified. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">17.9</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Notwithstanding the other provisions of these Articles, in any case where, as a result of death, the Company
has no directors and no shareholders, the personal representatives of the last shareholder to have died have the power, by notice in writing to the Company, to appoint a person to be a director. For the purpose of this Article:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">where two or more shareholders die in circumstances rendering it uncertain who was the last to die, a
younger shareholder is deemed to have survived an older shareholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if the last shareholder died leaving a will which disposes of that shareholder&#146;s shares in the Company
(whether by way of specific gift, as part of the residuary estate, or otherwise): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the expression personal representatives of the last shareholder means: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(A)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">until a grant of probate in respect of that will has been obtained from the Grand Court of the Cayman
Islands, all of the executors named in that will who are living at the time the power of appointment under this Article&nbsp;is exercised; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(B)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">after such grant of probate has been obtained, only such of those executors who have proved that will;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(ii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">without derogating from section 3(1)&nbsp;of the Succession Law (as revised), the executors named in that
will may exercise the power of appointment under this Article&nbsp;without first obtaining a grant of probate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">17.10</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A remaining director may appoint a director even though there is not a quorum of directors.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">17.11</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">No appointment can cause the number of directors to exceed the maximum; and any such appointment shall be
invalid. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">17.12</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">For so long as Shares are listed on a Designated Stock Exchange, the directors shall include at least such
number of Independent Directors as Applicable Law or the rules&nbsp;and regulations of the Designated Stock Exchange require, subject to applicable <FONT STYLE="white-space:nowrap">phase-in</FONT> rules&nbsp;of the Designated Stock Exchange.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Resignation of directors </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">17.13</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A director may at any time resign office by giving to the Company notice in writing or, if permitted
pursuant to the notice provisions, in an Electronic Record delivered in either case in accordance with those provisions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">17.14</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Unless the notice specifies a different date, the director shall be deemed to have resigned on the date that
the notice is delivered to the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Termination of the office of director </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">17.15</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A director&#146;s office shall be terminated forthwith if: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">he is prohibited by the law of the Islands from acting as a director; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">he is made bankrupt or makes an arrangement or composition with his creditors generally; or
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in the opinion of a registered medical practitioner by whom he is being treated he becomes physically or
mentally incapable of acting as a director; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(d)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">he is made subject to any law relating to mental health or incompetence, whether by court order or
otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(e)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">without the consent of the other directors, he is absent from meetings of directors for a continuous period
of six months; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(f)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">all of the other directors (being not less than two in number) determine that he should be removed as a
director, either by a resolution passed by all of the other directors at a meeting of the directors duly convened and held in accordance with these Articles or by a resolution in writing signed by all of the other directors. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>18.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Alternate directors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Appointment and removal </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">18.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Any director may appoint any other person, including another director, to act in his place as an alternate
director. No appointment shall take effect until the director has given notice of the appointment to the other directors. Such notice must be given to each other director by either of the following methods: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">by notice in writing in accordance with the notice provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if the other director has an email address, by emailing to that address a scanned copy of the notice as a
PDF attachment (the PDF version being deemed to be the notice unless Article&nbsp;33.7 applies), in which event notice shall be taken to be given on the date of receipt by the recipient in readable form. For the avoidance of doubt, the same email
may be sent to the email address of more than one director (and to the email address of the Company pursuant to Article&nbsp;18.4(c)). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">18.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Without limitation to the preceding Article, a director may appoint an alternate for a particular meeting by
sending an email to his fellow directors informing them that they are to take such email as notice of such appointment for such meeting. Such appointment shall be effective without the need for a signed notice of appointment or the giving of notice
to the Company in accordance with Article&nbsp;18.4. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">18.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A director may revoke his appointment of an alternate at any time. No revocation shall take effect until the
director has given notice of the revocation to the other directors. Such notice must be given by either of the methods specified in Article&nbsp;18.1. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">18.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A notice of appointment or removal of an alternate director must also be given to the Company by any of the
following methods: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">by notice in writing in accordance with the notice provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if the Company has a facsimile address for the time being, by sending by facsimile transmission to that
facsimile address a facsimile copy or, otherwise, by sending by facsimile transmission to the facsimile address of the Company&#146;s registered office a facsimile copy (in either case, the facsimile copy being deemed to be the notice unless
Article&nbsp;33.7 applies), in which event notice shall be taken to be given on the date of an error-free transmission report from the sender&#146;s fax machine; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if the Company has an email address for the time being, by emailing to that email address a scanned copy of
the notice as a PDF attachment or, otherwise, by emailing to the email address provided by the Company&#146;s registered office a scanned copy of the notice as a PDF attachment (in either case, the PDF version being deemed to be the notice unless
Article&nbsp;33.7 applies), in which event notice shall be taken to be given on the date of receipt by the Company or the Company&#146;s registered office (as appropriate) in readable form; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(d)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if permitted pursuant to the notice provisions, in some other form of approved Electronic Record delivered
in accordance with those provisions in writing. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Notices </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">18.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">All notices of meetings of directors shall continue to be given to the appointing director and not to the
alternate. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Rights of alternate director </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">18.6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">An alternate director shall be entitled to attend and vote at any board meeting or meeting of a committee of
the directors at which the appointing director is not personally present, and generally to perform all the functions of the appointing director in his absence. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">18.7</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">For the avoidance of doubt: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if another director has been appointed an alternate director for one or more directors, he shall be entitled
to a separate vote in his own right as a director and in right of each other director for whom he has been appointed an alternate; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if a person other than a director has been appointed an alternate director for more than one director, he
shall be entitled to a separate vote in right of each director for whom he has been appointed an alternate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">18.8</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">An alternate director, however, is not entitled to receive any remuneration from the Company for services
rendered as an alternate director. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Appointment ceases when the appointor ceases to be a director </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">18.9</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">An alternate director shall cease to be an alternate director if the director who appointed him ceases to be
a director. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Status of alternate director </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">18.10</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">An alternate director shall carry out all functions of the director who made the appointment.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">18.11</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Save where otherwise expressed, an alternate director shall be treated as a director under these Articles.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">18.12</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">An alternate director is not the agent of the director appointing him. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">18.13</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">An alternate director is not entitled to any remuneration for acting as alternate director.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Status of the director making the appointment </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">18.14</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A director who has appointed an alternate is not thereby relieved from the duties which he owes the Company.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>19.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Powers of directors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Powers of directors </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Subject to the provisions of the Law, the Memorandum and these Articles, the business of the Company shall
be managed by the directors who may for that purpose exercise all the powers of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">No prior act of the directors shall be invalidated by any subsequent alteration of the Memorandum or these
Articles. However, to the extent allowed by the Law, following the consummation of the IPO Members may by Special Resolution validate any prior or future act of the directors which would otherwise be in breach of their duties. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Appointments to office </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may appoint a director: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">as chairman of the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">as vice-chairman of the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">as managing director; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(d)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to any other executive office </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">for such period and on such terms, including as to remuneration, as they think fit. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The appointee must consent in writing to holding that office. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Where a chairman is appointed he shall, unless unable to do so, preside at every meeting of directors.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19.6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If there is no chairman, or if the chairman is unable to preside at a meeting, that meeting may select its
own chairman; or the directors may nominate one of their number to act in place of the chairman should he ever not be available. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19.7</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Subject to the provisions of the Law, the directors may also appoint any person, who need not be a director:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">as Secretary; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to any office that may be required (including, for the avoidance of doubt, one or more chief executive
officers, presidents, a chief financial officer, a treasurer, vice-presidents, one or more assistant vice-presidents, one or more assistant treasurers and one or more assistant secretaries), </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">for such period and on such terms, including as to remuneration, as they think fit. In the case of an Officer, that Officer may
be given any title the directors decide. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19.8</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Secretary or Officer must consent in writing to holding that office. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19.9</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A director, Secretary or other Officer of the Company may not hold the office, or perform the services, of
Auditor. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Remuneration </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19.10</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The remuneration to be paid to the directors, if any, shall be such remuneration as the directors shall
determine, provided that no cash remuneration shall be paid to any director prior to the consummation of a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Business Combination. The directors shall also, whether prior to or after the consummation of a Business Combination, be entitled to be paid all out of pocket expenses properly incurred by them
in connection with activities on behalf of the Company, including identifying and consummating a Business Combination. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19.11</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Remuneration may take any form and may include arrangements to pay pensions, health insurance, death or
sickness benefits, whether to the director or to any other person connected to or related to him. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19.12</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Unless his fellow directors determine otherwise, a director is not accountable to the Company for
remuneration or other benefits received from any other company which is in the same group as the Company or which has common shareholdings. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Disclosure of information </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">19.13</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may release or disclose to a third party any information regarding the affairs of the Company,
including any information contained in the Register of Members relating to a Member, (and they may authorise any director, Officer or other authorised agent of the Company to release or disclose to a third party any such information in his
possession) if: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the Company or that person, as the case may be, is lawfully required to do so under the laws of any
jurisdiction to which the Company is subject; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">such disclosure is in compliance with the rules&nbsp;of any stock exchange upon which the Company&#146;s
shares are listed; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">such disclosure is in accordance with any contract entered into by the Company; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(d)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the directors are of the opinion such disclosure would assist or facilitate the Company&#146;s operations.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>20.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Delegation of powers </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to delegate any of the directors&#146; powers to a committee </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">20.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may delegate any of their powers to any committee consisting of one or more persons who need
not be Members (including, without limitation, the Audit Committee, the Compensation Committee and the Nominating Committee). Persons on the committee may include <FONT STYLE="white-space:nowrap">non-directors</FONT> so long as the majority of those
persons are directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">20.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The delegation may be collateral with, or to the exclusion of, the directors&#146; own powers.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">20.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The delegation may be on such terms as the directors think fit, including provision for the committee itself
to delegate to a <FONT STYLE="white-space:nowrap">sub-committee;</FONT> save that any delegation must be capable of being revoked or altered by the directors at will. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">20.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Unless otherwise permitted by the directors, a committee must follow the procedures prescribed for the
taking of decisions by directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">20.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may adopt formal written charters for committees and, if so adopted, shall review and assess
the adequacy of such formal written charters on an annual basis. Each of these committees shall be empowered to do all things necessary to exercise the rights of such committee set forth in the Articles and shall have such powers as the directors
may delegate pursuant to the Articles and as required by the rules&nbsp;and regulations of the Designated Stock Exchange, the SEC and/or any other competent regulatory authority or otherwise under Applicable Law. Each of the Audit Committee, the
Compensation Committee and the Nominating Committee, if established, shall consist of such number of directors as the directors shall from time to time determine (or such minimum number as may be required from time to time by the rules&nbsp;and
regulations of the Designated Stock Exchange, the SEC and/or any other competent regulatory authority or otherwise under Applicable Law). For so long as any class of Shares is listed on the
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Designated Stock Exchange, the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee shall be made up of such number of Independent Directors as is
required from time to time by the rules&nbsp;and regulations of the rules&nbsp;and regulations of the Designated Stock Exchange, the SEC and/or any other competent regulatory authority or otherwise under Applicable Law. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to appoint an agent of the Company </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">20.6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may appoint any person, either generally or in respect of any specific matter, to be the agent
of the Company with or without authority for that person to delegate all or any of that person&#146;s powers. The directors may make that appointment: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">by causing the Company to enter into a power of attorney or agreement; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in any other manner they determine. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to appoint an attorney or authorised signatory of the Company </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">20.7</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may appoint any person, whether nominated directly or indirectly by the directors, to be the
attorney or the authorised signatory of the Company. The appointment may be: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">for any purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">with the powers, authorities and discretions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">for the period; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(d)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">subject to such conditions </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">as they think fit. The powers, authorities and discretions, however, must not exceed those vested in, or exercisable, by the
directors under these Articles. The directors may do so by power of attorney or any other manner they think fit. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">20.8</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Any power of attorney or other appointment may contain such provision for the protection and convenience for
persons dealing with the attorney or authorised signatory as the directors think fit. Any power of attorney or other appointment may also authorise the attorney or authorised signatory to delegate all or any of the powers, authorities and
discretions vested in that person. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to appoint a proxy </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">20.9</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Any director may appoint any other person, including another director, to represent him at any meeting of
the directors. If a director appoints a proxy, then for all purposes the presence or vote of the proxy shall be deemed to be that of the appointing director. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">20.10</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Articles 18.1 to 18.4 inclusive (relating to the appointment by directors of alternate directors) apply,
mutatis mutandis, to the appointment of proxies by directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">20.11</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A proxy is an agent of the director appointing him and is not an Officer. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>21.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Meetings of directors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Regulation of directors&#146; meetings </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">21.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Subject to the provisions of these Articles, the directors may regulate their proceedings as they think fit.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Calling meetings </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">21.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Any director may call a meeting of directors at any time. The Secretary, if any, must call a meeting of the
directors if requested to do so by a director. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Notice of meetings </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">21.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Every director shall be given notice of a meeting, although a director may waive retrospectively the
requirement to be given notice. Notice may be oral. Attendance at a meeting without written objection shall be deemed to be a waiver of such notice requirement. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Period of notice </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">21.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">At least five Clear Days&#146; notice of a meeting of directors must be given to directors. A meeting may be
convened on shorter notice with the consent of all directors. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Use of technology </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">21.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A director may participate in a meeting of directors through the medium of conference telephone, video or
any other form of communications equipment providing all persons participating in the meeting are able to hear and speak to each other throughout the meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">21.6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A director participating in this way is deemed to be present in person at the meeting.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Place of meetings </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">21.7</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If all the directors participating in a meeting are not in the same place, they may decide that the meeting
is to be treated as taking place wherever any of them is. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Quorum </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">21.8</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The quorum for the transaction of business at a meeting of directors shall be two unless the directors fix
some other number or unless the Company has only one director. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Voting </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">21.9</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A question which arises at a board meeting shall be decided by a majority of votes. If votes are equal the
chairman may, if he wishes, exercise a casting vote. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Validity </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">21.10</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Anything done at a meeting of directors is unaffected by the fact that it is later discovered that any
person was not properly appointed, or had ceased to be a director, or was otherwise not entitled to vote. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Recording
of dissent </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">21.11</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A director present at a meeting of directors shall be presumed to have assented to any action taken at that
meeting unless: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">his dissent is entered in the minutes of the meeting; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">he has filed with the meeting before it is concluded signed dissent from that action; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">he has forwarded to the Company as soon as practical following the conclusion of that meeting signed
dissent. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A director who votes in favour of an action is not entitled to record his dissent to it. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Written resolutions </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">21.12</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may pass a resolution in writing without holding a meeting if all directors sign a document or
sign several documents in the like form each signed by one or more of those directors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">21.13</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Despite the foregoing, a resolution in writing signed by a validly appointed alternate director or by a
validly appointed proxy need not also be signed by the appointing director. If a written resolution is signed personally by the appointing director, it need not also be signed by his alternate or proxy. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">21.14</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Such written resolution shall be as effective as if it had been passed at a meeting of the directors duly
convened and held; and it shall be treated as having been passed on the day and at the time that the last director signs. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Sole director&#146;s minute </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">21.15</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Where a sole director signs a minute recording his decision on a question, that record shall constitute the
passing of a resolution in those terms. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>22.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Permissible directors&#146; interests and disclosure </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Permissible interests subject to disclosure </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">22.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Save as expressly permitted by these Articles or as set out below, a director may not have a direct or
indirect interest or duty which conflicts or may possibly conflict with the interests of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">22.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If, notwithstanding the prohibition in the preceding Article, a director discloses to his fellow directors
the nature and extent of any material interest or duty in accordance with the next Article, he may: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">be a party to, or otherwise interested in, any transaction or arrangement with the Company or in which the
Company is or may otherwise be interested; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">be interested in another body corporate promoted by the Company or in which the Company is otherwise
interested. In particular, the director may be a director, secretary or officer of, or employed by, or be a party to any transaction or arrangement with, or otherwise interested in, that other body corporate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">22.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Such disclosure may be made at a meeting of the board or otherwise (and, if otherwise, it must be made in
writing). The director must disclose the nature and extent of his direct or indirect interest in or duty in relation to a transaction or arrangement or series of transactions or arrangements with the Company or in which the Company has any material
interest. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">22.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If a director has made disclosure in accordance with the preceding Article, then he shall not, by reason
only of his office, be accountable to the Company for any benefit that he derives from any such transaction or arrangement or from any such office or employment or from any interest in any such body corporate, and no such transaction or arrangement
shall be liable to be avoided on the ground of any such interest or benefit. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Notification of interests </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">22.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">For the purposes of the preceding Articles: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a general notice that a director gives to the other directors that he is to be regarded as having an
interest of the nature and extent specified in the notice in any transaction or arrangement in which a specified person or class of persons is interested shall be deemed to be a disclosure that he has an interest in or duty in relation to any such
transaction of the nature and extent so specified; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">an interest of which a director has no knowledge and of which it is unreasonable to expect him to have
knowledge shall not be treated as an interest of his. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Voting where a director is interested in a matter </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">22.6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A director may vote at a meeting of directors on any resolution concerning a matter in which that director
has an interest or duty, whether directly or indirectly, so long as that director discloses any material interest pursuant to these Articles. The director shall be counted towards a quorum of those present at the meeting. If the director votes on
the resolution, his vote shall be counted. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">22.7</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Where proposals are under consideration concerning the appointment of two or more directors to offices or
employment with the Company or any body corporate in which the Company is interested, the proposals may be divided and considered in relation to each director separately and each of the directors concerned shall be entitled to vote and be counted in
the quorum in respect of each resolution except that concerning his or her own appointment. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>23.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Minutes </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company shall cause minutes to be made in books kept for the purpose in accordance with the Law. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>24.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Accounts and audit </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Accounting and other records </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors must ensure that proper accounting and other records are kept, and that accounts and
associated reports are distributed in accordance with the requirements of the Law. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>No automatic right of inspection
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Members are only entitled to inspect the Company&#146;s records if they are expressly entitled to do so by
law, or by resolution made by the directors or passed by Ordinary Resolution. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Sending of accounts and reports
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company&#146;s accounts and associated directors&#146; report or auditor&#146;s report that are required
or permitted to be sent to any person pursuant to any law shall be treated as properly sent to that person if: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">they are sent to that person in accordance with the notice provisions: or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">they are published on a website providing that person is given separate notice of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the fact that publication of the documents has been published on the website; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(ii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the address of the website; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(iii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the place on the website where the documents may be accessed; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(iv)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">how they may be accessed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If, for any reason, a person notifies the Company that he is unable to access the website, the Company must,
as soon as practicable, send the documents to that person by any other means permitted by these Articles. This, however, will not affect when that person is taken to have received the documents under the next Article. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Time of receipt if documents are published on a website </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Documents sent by being published on a website in accordance with the preceding two Articles are only
treated as sent at least five Clear Days before the date of the meeting at which they are to be laid if: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the documents are published on the website throughout a period beginning at least five Clear Days before the
date of the meeting and ending with the conclusion of the meeting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the person is given at least five Clear Days&#146; notice of the hearing. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Validity despite accidental error in publication on website </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24.6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If, for the purpose of a meeting, documents are sent by being published on a website in accordance with the
preceding Articles, the proceedings at that meeting are not invalidated merely because: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">those documents are, by accident, published in a different place on the website to the place notified; or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">they are published for part only of the period from the date of notification until the conclusion of that
meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Audit </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24.7</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may appoint an Auditor of the Company who shall hold office on such terms as the directors
determine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24.8</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Without prejudice to the freedom of the directors to establish any other committee, if the Shares (or
depositary receipts therefor) are listed or quoted on the Designated Stock Exchange, and if required by the Designated Stock Exchange, the directors shall establish and maintain an Audit Committee as a committee of the directors and shall adopt a
formal written Audit Committee charter and review and assess the adequacy of the formal written charter on an annual basis. The composition and responsibilities of the Audit Committee shall comply with the rules&nbsp;and regulations of the SEC and
the Designated Stock Exchange. The Audit Committee shall meet at least once every financial quarter, or more frequently as circumstances dictate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24.9</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If the Shares are listed or quoted on the Designated Stock Exchange, the Company shall conduct an
appropriate review of all related party transactions on an ongoing basis and shall utilise the Audit Committee for the review and approval of potential conflicts of interest. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24.10</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The remuneration of the Auditor shall be fixed by the Audit Committee (if one exists).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24.11</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If the office of Auditor becomes vacant by resignation or death of the Auditor, or by his becoming incapable
of acting by reason of illness or other disability at a time when his services are required, the directors shall fill the vacancy and determine the remuneration of such Auditor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24.12</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Every Auditor of the Company shall have a right of access at all times to the books and accounts and
vouchers of the Company and shall be entitled to require from the directors and officers of the Company such information and explanation as may be necessary for the performance of the duties of the Auditor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24.13</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Auditors shall, if so required by the directors, make a report on the accounts of the Company during their
tenure of office at the next annual general meeting following their appointment in the case of a company which is registered with the Registrar of Companies as an ordinary company, and at the next extraordinary general meeting following their
appointment in the case of a company which is registered with the Registrar of Companies as an exempted company, and at any other time during their term of office, upon request of the directors or any general meeting of the Members.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24.14</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Any payment made to members of the Audit Committee (if one exists) shall require the review and approval of
the directors, with any director interested in such payment abstaining from such review and approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24.15</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Audit Committee shall monitor compliance with the terms of the IPO and, if any <FONT
STYLE="white-space:nowrap">non-compliance</FONT> is identified, the Audit Committee shall be charged with the responsibility to take all action necessary to rectify such <FONT STYLE="white-space:nowrap">non-compliance</FONT> or otherwise cause
compliance with the terms of the IPO. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>25.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Financial year </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless the directors otherwise specify, the financial year of the Company: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">shall end on 31st December&nbsp;in the year of its incorporation and each following year; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">shall begin when it was incorporated and on 1st January&nbsp;each following year. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>26.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Record dates </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Except to the extent of any conflicting rights attached to Shares, the directors may fix any time and date as the record date
for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">calling a general meeting; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">declaring or paying a dividend; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">making or issuing an allotment of Shares; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(d)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">conducting any other business required pursuant to these Articles. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The record date may be before or after the date on which a dividend, allotment or issue is declared, paid or made. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>27.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Dividends </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Declaration of dividends by Members </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Subject to the provisions of the Law, the Company may by Ordinary Resolution declare dividends in accordance
with the respective rights of the Members but no dividend shall exceed the amount recommended by the directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Payment of interim dividends and declaration of final dividends by directors </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may pay interim dividends or declare final dividends in accordance with the respective rights
of the Members if it appears to them that they are justified by the financial position of the Company and that such dividends may lawfully be paid. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Subject to the provisions of the Law, in relation to the distinction between interim dividends and final
dividends, the following applies: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Upon determination to pay a dividend or dividends described as interim by the directors in the dividend
resolution, no debt shall be created by the declaration until such time as payment is made. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Upon declaration of a dividend or dividends described as final by the directors in the dividend resolution,
a debt shall be created immediately following the declaration, the due date to be the date the dividend is stated to be payable in the resolution. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the resolution fails to specify whether a dividend is final or interim, it shall be assumed to be interim. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In relation to Shares carrying differing rights to dividends or rights to dividends at a fixed rate, the
following applies: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If the share capital is divided into different classes, the directors may pay dividends on Shares which
confer deferred or <FONT STYLE="white-space:nowrap">non-</FONT> preferred rights with regard to dividends as well as on Shares which confer preferential rights with regard to dividends but no dividend shall be paid on Shares carrying deferred or <FONT
STYLE="white-space:nowrap">non-preferred</FONT> rights if, at the time of payment, any preferential dividend is in arrears. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may also pay, at intervals settled by them, any dividend payable at a fixed rate if it appears
to them that there are sufficient funds of the Company lawfully available for distribution to justify the payment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If the directors act in good faith, they shall not incur any liability to the Members holding Shares
conferring preferred rights for any loss those Members may suffer by the lawful payment of the dividend on any Shares having deferred or <FONT STYLE="white-space:nowrap">non-preferred</FONT> rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Apportionment of dividends </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Except as otherwise provided by the rights attached to Shares, all dividends shall be declared and paid
according to the amounts paid up on the Shares on which the dividend is paid. All dividends shall be apportioned and paid proportionately to the amount paid up on the Shares during the time or part of the time in respect of which the dividend is
paid. If a Share is issued on terms providing that it shall rank for dividend as from a particular date, that Share shall rank for dividend accordingly. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Right of set off </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27.6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may deduct from a dividend or any other amount payable to a person in respect of a Share any
amount due by that person to the Company on a call or otherwise in relation to a Share. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to pay other than in
cash </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27.7</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If the directors so determine, any resolution declaring a dividend may direct that it shall be satisfied
wholly or partly by the distribution of assets. If a difficulty arises in relation to the distribution, the directors may settle that difficulty in any way they consider appropriate. For example, they may do any one or more of the following:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">issue fractional Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">fix the value of assets for distribution and make cash payments to some Members on the footing of the value
so fixed in order to adjust the rights of Members; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">vest some assets in trustees. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>How payments may be made </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27.8</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A dividend or other monies payable on or in respect of a Share may be paid in any of the following ways:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">if the Member holding that Share or other person entitled to that Share nominates a bank account for that
purpose - by wire transfer to that bank account; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">by cheque or warrant sent by post to the registered address of the Member holding that Share or other person
entitled to that Share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27.9</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">For the purpose of paragraph (a)&nbsp;of the preceding Article, the nomination may be in writing or in an
Electronic Record and the bank account nominated may be the bank account of another person. For the purpose of paragraph (b)&nbsp;of the preceding Article, subject to any Applicable Law or regulation, the cheque or warrant shall be made to the order
of the Member holding that Share or other person entitled to the Share or to his nominee, whether nominated in writing or in an Electronic Record, and payment of the cheque or warrant shall be a good discharge to the Company. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27.10</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If two or more persons are registered as the holders of the Share or are jointly entitled to it by reason of
the death or bankruptcy of the registered holder (Joint Holders), a dividend (or other amount) payable on or in respect of that Share may be paid as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to the registered address of the Joint Holder of the Share who is named first on the Register of Members or
to the registered address of the deceased or bankrupt holder, as the case may be; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to the address or bank account of another person nominated by the Joint Holders, whether that nomination is
in writing or in an Electronic Record. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27.11</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Any Joint Holder of a Share may give a valid receipt for a dividend (or other amount) payable in respect of
that Share. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Dividends or other moneys not to bear interest in absence of special rights </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27.12</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Unless provided for by the rights attached to a Share, no dividend or other monies payable by the Company in
respect of a Share shall bear interest. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Dividends unable to be paid or unclaimed </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27.13</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If a dividend cannot be paid to a Member or remains unclaimed within six weeks after it was declared or
both, the directors may pay it into a separate account in the Company&#146;s name. If a dividend is paid into a separate account, the Company shall not be constituted trustee in respect of that account and the dividend shall remain a debt due to the
Member. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27.14</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A dividend that remains unclaimed for a period of six years after it became due for payment shall be
forfeited to, and shall cease to remain owing by, the Company. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>28.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Capitalisation of profits </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Capitalisation of profits or of any share premium account or capital redemption reserve </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">28.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may resolve to capitalise: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">any part of the Company&#146;s profits not required for paying any preferential dividend (whether or not
those profits are available for distribution); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">any sum standing to the credit of the Company&#146;s share premium account or capital redemption reserve, if
any. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The amount resolved to be capitalised must be appropriated to the Members who would have been
entitled to it had it been distributed by way of dividend and in the same proportions. The benefit to each Member so entitled must be given in either or both of the following ways: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">by paying up the amounts unpaid on that Member&#146;s Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">by issuing Fully Paid Shares, debentures or other securities of the Company to that Member or as that Member
directs. The directors may resolve that any Shares issued to the Member in respect of partly paid Shares (Original Shares) rank for dividend only to the extent that the Original Shares rank for dividend while those Original Shares remain partly
paid. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Applying an amount for the benefit of members </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">28.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The amount capitalised must be applied to the benefit of Members in the proportions to which the Members
would have been entitled to dividends if the amount capitalised had been distributed as a dividend. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">28.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Subject to the Law, if a fraction of a Share, a debenture, or other security is allocated to a Member, the
directors may issue a fractional certificate to that Member or pay him the cash equivalent of the fraction. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>29.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Share premium account directors to maintain share premium account </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">29.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors shall establish a share premium account in accordance with the Law. They shall carry to the
credit of that account from time to time an amount equal to the amount or value of the premium paid on the issue of any Share or capital contributed or such other amounts required by the Law. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Debits to share premium account </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">29.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The following amounts shall be debited to any share premium account: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">on the redemption or purchase of a Share, the difference between the nominal value of that Share and the
redemption or purchase price; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">any other amount paid out of a share premium account as permitted by the Law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">29.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Notwithstanding the preceding Article, on the redemption or purchase of a Share, the directors may pay the
difference between the nominal value of that Share and the redemption purchase price out of the profits of the Company or, as permitted by the Law, out of capital. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>30.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Seal </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Company seal </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">30.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company may have a seal if the directors so determine. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Duplicate seal </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">30.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Subject to the provisions of the Law, the Company may also have a duplicate seal or seals for use in any
place or places outside the Islands. Each duplicate seal shall be a facsimile of the original seal of the Company. However, if the directors so determine, a duplicate seal shall have added on its face the name of the place where it is to be used.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>When and how seal is to be used </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">30.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A seal may only be used by the authority of the directors. Unless the directors otherwise determine, a
document to which a seal is affixed must be signed in one of the following ways: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">by a director (or his alternate) and the Secretary; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">by a single director (or his alternate). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>If no seal is adopted or used </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">30.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If the directors do not adopt a seal, or a seal is not used, a document may be executed in the following
manner: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">by a director (or his alternate) or any Officer to which authority has been delegated by resolution duly
adopted by the directors; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">by a single director (or his alternate); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in any other manner permitted by the Law. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to allow <FONT STYLE="white-space:nowrap">non-manual</FONT> signatures and facsimile printing of seal </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">30.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors may determine that either or both of the following applies: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">that the seal or a duplicate seal need not be affixed manually but may be affixed by some other method or
system of reproduction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">that a signature required by these Articles need not be manual but may be a mechanical or Electronic
Signature. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Validity of execution </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">30.6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If a document is duly executed and delivered by or on behalf of the Company, it shall not be regarded as
invalid merely because, at the date of the delivery, the Secretary, or the director, or other Officer or person who signed the document or affixed the seal for and on behalf of the Company ceased to be the Secretary or hold that office and authority
on behalf of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>31.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Indemnity </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Indemnity </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">31.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To the extent permitted by Applicable Law, the Company shall indemnify each existing or former Secretary,
director (including alternate director), and other Officer of the Company (including an investment adviser or an administrator or liquidator) and their personal representatives against: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by
the existing or former Secretary or Officer in or about the conduct of the Company&#146;s business or affairs or in the execution or discharge of the existing or former Secretary&#146;s or Officer&#146;s duties, powers, authorities or discretions;
and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">without limitation to paragraph (a), all costs, expenses, losses or liabilities incurred by the existing or
former Secretary or Officer in defending (whether successfully or otherwise) any civil, criminal, administrative or investigative proceedings (whether threatened, pending or completed) concerning the Company or its affairs in any court or tribunal,
whether in the Islands or elsewhere. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No such existing or former Secretary or Officer, however, shall be
indemnified in respect of any matter arising out of his own actual fraud, wilful default or wilful neglect. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">31.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To the extent permitted by Applicable Law, the Company may make a payment, or agree to make a payment,
whether by way of advance, loan or otherwise, for any legal costs incurred by an existing or former Secretary or Officer of the Company in respect of any matter identified in paragraph (a)&nbsp;or paragraph (b)&nbsp;of the preceding Article&nbsp;on
condition that the Secretary or Officer must repay the amount paid by the Company to the extent that it is ultimately found not liable to indemnify the Secretary or that Officer for those legal costs. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Release </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">31.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To the extent permitted by Applicable Law, the Company may by Special Resolution release any existing or
former director (including alternate director), Secretary or other Officer of the Company from liability for any loss or damage or right to compensation which may arise out of or in connection with the execution or discharge of the duties, powers,
authorities or discretions of his office; but there may be no release from liability arising out of or in connection with that person&#146;s own actual fraud, wilful default or wilful neglect. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Insurance </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">31.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To the extent permitted by Applicable Law, the Company may pay, or agree to pay, a premium in respect of a
contract insuring each of the following persons against risks determined by the directors, other than liability arising out of that person&#146;s own dishonesty: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">an existing or former director (including alternate director), Secretary or Officer or auditor of:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(ii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a company which is or was a subsidiary of the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(iii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a company in which the Company has or had an interest (whether direct or indirect); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a trustee of an employee or retirement benefits scheme or other trust in which any of the persons referred
to in paragraph (a)&nbsp;is or was interested. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>32.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Notices </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Form&nbsp;of notices </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">32.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Save where these Articles provide otherwise, any notice to be given to or by any person pursuant to these
Articles shall be: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in writing signed by or on behalf of the giver in the manner set out below for written notices; or
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">subject to the next Article, in an Electronic Record signed by or on behalf of the giver by Electronic
Signature and authenticated in accordance with Articles about authentication of Electronic Records; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">where these Articles expressly permit, by the Company by means of a website. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Electronic communications </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">32.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Without limitation to Articles 18.1 to 18.4 inclusive (relating to the appointment and removal by directors
of alternate directors) and to Articles 20.8 to 20.10 inclusive (relating to the appointment by directors of proxies), a notice may only be given to the Company in an Electronic Record if: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the directors so resolve; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the resolution states how an Electronic Record may be given and, if applicable, specifies an email address
for the Company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the terms of that resolution are notified to the Members for the time being and, if applicable, to those
directors who were absent from the meeting at which the resolution was passed. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the resolution is
revoked or varied, the revocation or variation shall only become effective when its terms have been similarly notified. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">32.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A notice may not be given by Electronic Record to a person other than the Company unless the recipient has
notified the giver of an Electronic address to which notice may be sent. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Persons authorised to give notices </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">32.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A notice by either the Company or a Member pursuant to these Articles may be given on behalf of the Company
or a Member by a director or company secretary of the Company or a Member. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Delivery of written notices </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">32.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Save where these Articles provide otherwise, a notice in writing may be given personally to the recipient,
or left at (as appropriate) the Member&#146;s or director&#146;s registered address or the Company&#146;s registered office, or posted to that registered address or registered office. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Joint holders </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">32.6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Where Members are joint holders of a Share, all notices shall be given to the Member whose name first
appears in the Register of Members. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Signatures </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">32.7</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A written notice shall be signed when it is autographed by or on behalf of the giver, or is marked in such a
way as to indicate its execution or adoption by the giver. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">32.8</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">An Electronic Record may be signed by an Electronic Signature. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Evidence of transmission </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">32.9</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A notice given by Electronic Record shall be deemed sent if an Electronic Record is kept demonstrating the
time, date and content of the transmission, and if no notification of failure to transmit is received by the giver. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">32.10</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A notice given in writing shall be deemed sent if the giver can provide proof that the envelope containing
the notice was properly addressed, <FONT STYLE="white-space:nowrap">pre-paid</FONT> and posted, or that the written notice was otherwise properly transmitted to the recipient. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Giving notice to a deceased or bankrupt Member </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">32.11</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A notice may be given by the Company to the persons entitled to a Share in consequence of the death or
bankruptcy of a Member by sending or delivering it, in any manner authorised by these Articles for the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
giving of notice to a Member, addressed to them by name, or by the title of representatives of the deceased, or trustee of the bankrupt or by any like description, at the address, if any,
supplied for that purpose by the persons claiming to be so entitled. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">32.12</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Until such an address has been supplied, a notice may be given in any manner in which it might have been
given if the death or bankruptcy had not occurred. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Date of giving notices </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">32.13</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A notice is given on the date identified in the following table. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="justify"><B>Method for giving notices</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><B>When taken to be given</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Personally</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">At the time and date of delivery</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By leaving it at the member&#146;s registered address</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">At the time and date it was left</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the recipient has an address within the Islands, by posting it by prepaid post to the street or postal address of that
recipient</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">48 hours after it was posted</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the recipient has an address outside the Islands, by posting it by prepaid airmail to the street or postal address of
that recipient</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3 Clear Days after posting</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By Electronic Record (other than publication on a website), to recipient&#146;s Electronic address</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Within 24 hours after it was sent</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By publication on a website</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">See these Articles about the time when notice of a meeting of Members or accounts and reports, as the case may be, are
published on a website</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Saving provision </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">32.14</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">None of the preceding notice provisions shall derogate from these Articles about the delivery of written
resolutions of directors and written resolutions of Members. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>33.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Authentication of Electronic Records </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Application of Articles </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">33.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Without limitation to any other provision of these Articles, any notice, written resolution or other
document under these Articles that is sent by Electronic means by a Member, or by the Secretary, or by a director or other Officer of the Company, shall be deemed to be authentic if either Article&nbsp;33.2 or Article&nbsp;33.4 applies.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Authentication of documents sent by Members by Electronic means </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">33.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">An Electronic Record of a notice, written resolution or other document sent by Electronic means by or on
behalf of one or more Members shall be deemed to be authentic if the following conditions are satisfied: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the Member or each Member, as the case may be, signed the original document, and for this purpose Original
Document includes several documents in like form signed by one or more of those Members; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the Electronic Record of the Original Document was sent by Electronic means by, or at the direction of, that
Member to an address specified in accordance with these Articles for the purpose for which it was sent; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Article&nbsp;33.7 does not apply. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">33.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">For example, where a sole Member signs a resolution and sends the Electronic Record of the original
resolution, or causes it to be sent, by facsimile transmission to the address in these Articles specified for that purpose, the facsimile copy shall be deemed to be the written resolution of that Member unless Article&nbsp;33.7 applies.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Authentication of document sent by the Secretary or Officers of the Company by Electronic means </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">33.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">An Electronic Record of a notice, written resolution or other document sent by or on behalf of the Secretary
or an Officer or Officers of the Company shall be deemed to be authentic if the following conditions are satisfied: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the Secretary or the Officer or each Officer, as the case may be, signed the original document, and for this
purpose Original Document includes several documents in like form signed by the Secretary or one or more of those Officers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the Electronic Record of the Original Document was sent by Electronic means by, or at the direction of, the
Secretary or that Officer to an address specified in accordance with these Articles for the purpose for which it was sent; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Article&nbsp;33.7 does not apply. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This Article&nbsp;applies whether the document is sent by or on behalf of the Secretary or Officer in his own right or as a
representative of the Company. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">33.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">For example, where a sole director signs a resolution and scans the resolution, or causes it to be scanned,
as a PDF version which is attached to an email sent to the address in these Articles specified for that purpose, the PDF version shall be deemed to be the written resolution of that director unless Article&nbsp;33.7 applies. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Manner of signing </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">33.6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">For the purposes of these Articles about the authentication of Electronic Records, a document will be taken
to be signed if it is signed manually or in any other manner permitted by these Articles. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Saving provision </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">33.7</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A notice, written resolution or other document under these Articles will not be deemed to be authentic if
the recipient, acting reasonably: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">believes that the signature of the signatory has been altered after the signatory had signed the original
document; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">believes that the original document, or the Electronic Record of it, was altered, without the approval of
the signatory, after the signatory signed the original document; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">otherwise doubts the authenticity of the Electronic Record of the document and the recipient promptly gives
notice to the sender setting the grounds of its objection. If the recipient invokes this Article, the sender may seek to establish the authenticity of the Electronic Record in any way the sender thinks fit. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>34.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Transfer by way of continuation </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">34.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company may, by Special Resolution, resolve to be registered by way of continuation in a jurisdiction
outside: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">the Islands; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">such other jurisdiction in which it is, for the time being, incorporated, registered or existing.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">34.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To give effect to any resolution made pursuant to the preceding Article, the directors may cause the
following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">an application be made to the Registrar of Companies to deregister the Company in the Islands or in the
other jurisdiction in which it is for the time being incorporated, registered or existing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">all such further steps as they consider appropriate to be taken to effect the transfer by way of
continuation of the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>35. Winding up </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Distribution of assets in specie </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">35.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If the Company is wound up, the Members may, subject to these Articles and any other sanction required by
the Law, pass a Special Resolution allowing the liquidator to do either or both of the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to divide in specie among the Members the whole or any part of the assets of the Company and, for that
purpose, to value any assets and to determine how the division shall be carried out as between the Members or different classes of Members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to vest the whole or any part of the assets in trustees for the benefit of Members and those liable to
contribute to the winding up. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>No obligation to accept liability </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">35.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">No Member shall be compelled to accept any assets if an obligation attaches to them. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>The directors are authorised to present a winding up petition </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">35.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The directors have the authority to present a petition for the winding up of the Company to the Grand Court
of the Cayman Islands on behalf of the Company without the sanction of a resolution passed at a general meeting. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>36.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Amendment of Memorandum and Articles </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to change name or amend Memorandum </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">36.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Subject to the Law, the Company may, by Special Resolution: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">change its name; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">change the provisions of its Memorandum with respect to its objects, powers or any other matter specified in
the Memorandum. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Power to amend these Articles </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">36.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Subject to the Law and as provided in these Articles, the Company may, by Special Resolution, amend these
Articles in whole or in part. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>37.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Mergers and Consolidations </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company shall have the power to merge or consolidate with one or more constituent companies (as defined in the Law) upon
such terms as the directors may determine and (to the extent required by the Law) with the approval of a Special Resolution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>38.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Business Combination </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Notwithstanding any other provision of these Articles, this Article&nbsp;38 shall apply during the period
commencing upon the adoption of these Articles and terminating upon the first to occur of the consummation of any Business Combination and the distribution of the Trust Account pursuant to Article&nbsp;38.10. In the event of a conflict between this
Article&nbsp;38 and any other Articles, the provisions of this Article&nbsp;38 shall prevail and this Article&nbsp;may not be amended prior to the consummation of a Business Combination without a Special Resolution. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Prior to the consummation of any Business Combination, the Company shall either: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">submit such Business Combination to its Members for approval; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">provide Members with the opportunity to have their Shares repurchased by means of a tender offer (a
<B>Tender Offer</B>) for a <FONT STYLE="white-space:nowrap">per-Share</FONT> repurchase price payable in cash, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of such
Business Combination, including interest earned on the funds held in the Trust Account not previously released to the Company to pay its income taxes, if any, divided by the number of Public Shares then in issue, provided that the Company shall not
repurchase Public Shares in an amount that would cause the Company&#146;s net tangible assets to be less than US$5,000,001. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If the Company initiates any Tender Offer in accordance with
<FONT STYLE="white-space:nowrap">Rule&nbsp;13e-4</FONT> and Regulation 14E of the Exchange Act in connection with a proposed Business Combination, it shall file Tender Offer documents with the SEC prior to completing such Business Combination which
contain substantially the same financial and other information about such Business Combination and the redemption rights as is required under Regulation 14A of the Exchange Act. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If, alternatively, the Company holds a general meeting to approve a proposed Business Combination, the
Company will conduct any redemptions in conjunction with a proxy solicitation pursuant to Regulation 14A of the Exchange Act, and not pursuant to the Tender Offer rules, and file proxy materials with the SEC. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38.5</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">At a general meeting called for the purposes of approving a Business Combination pursuant to this Article,
in the event that such Business Combination is approved by Ordinary Resolution, the Company shall be authorised to consummate such Business Combination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38.6</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Any Member holding Public Shares who is not a Founder, Officer or director may, contemporaneously with any
vote on a Business Combination, elect to have their Public Shares redeemed for cash (the <B>IPO Redemption</B>), provided that no such Member acting together with any Affiliate of his or any other person with whom he is acting in concert or as a
partnership, syndicate, or other group for the purposes of acquiring, holding, or disposing of Shares may exercise this redemption right with respect to more than 15% of the Public Shares without the Company&#146;s prior consent, and provided
further that any holder that holds Public Shares beneficially through a nominee must identify itself to the Company in connection with any redemption election in order to validly redeem such Public Shares. In connection with any vote held to approve
a proposed Business Combination, holders of Public Shares seeking to exercise their redemption rights will be required to either tender their certificates (if any) to the Company&#146;s transfer agent or to deliver their shares to the transfer agent
electronically using The Depository Trust Company&#146;s DWAC (Deposit/Withdrawal At Custodian) System, at the holder&#146;s option, in each case up to two business days prior to the initially scheduled vote on the proposal to approve a Business
Combination. If so demanded, the Company shall pay any such redeeming Member, regardless of whether he is voting for or against such proposed Business Combination or abstains from voting, a <FONT STYLE="white-space:nowrap">per-Share</FONT>
redemption price payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of a Business Combination, including interest earned on the Trust Account not
previously released to the Company to pay its income taxes, if any, divided by the number of Public Shares then in issue (such redemption price being referred to herein as the <B>Redemption Price</B>), provided that the Company shall not repurchase
Public Shares in an amount that would cause the Company&#146;s net tangible assets to be less than US$5,000,001. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38.7</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Redemption Price shall be paid promptly following the consummation of the relevant Business Combination.
If the proposed Business Combination is not approved or completed for any reason then such redemptions shall be cancelled and share certificates (if any) returned to the relevant Members as appropriate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38.8</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In the event that the Company does not consummate a Business Combination by twenty-four months after the
closing of the IPO, or such later time as the Members of the Company may approve in accordance with these Articles, the Company shall: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">cease all operations except for the purpose of winding up; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares,
at a <FONT STYLE="white-space:nowrap">per-Share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the
Company to pay income taxes, if any (less up to US$100,000 of interest to pay dissolution expenses), divided by the number of the Public Shares then in issue, which redemption will completely extinguish public Members&#146; rights as Members
(including the right to receive further liquidation distributions, if any); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">as promptly as reasonably possible following such redemption, subject to the approval of the Company&#146;s
remaining Members and the directors, liquidate and dissolve, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">subject in each case, to its obligations
under Cayman Islands law to provide for claims of creditors and in all cases subject to the other requirements of Applicable Law. If the Company shall wind up for any other reason prior to the consummation of a Business Combination, the Company
shall, as promptly as reasonably possible but not more than ten business days thereafter, follow the foregoing procedures set out in this Article&nbsp;38.8 with respect to the liquidation of the Trust Account, subject to its obligations under Cayman
Islands law to provide for claims of creditors and in all cases subject to the other requirements of Applicable Law. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38.9</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In the event that any amendment is made to these Articles: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">that would modify the substance or timing of the Company&#146;s obligation to provide holders of Public
Shares the right to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">have their shares redeemed or repurchased in connection with a Business Combination pursuant to Articles
38.2(b)&nbsp;or 38.6; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(ii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">redeem 100% of the Public Shares if the Company has not consummated an initial Business Combination within
twenty-four months after the closing of the IPO pursuant to Article&nbsp;38.8; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">with respect to any other provision relating to the rights of holders of Public Shares,
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">each holder of Public Shares who is not a Founder, Officer or director shall be provided with the
opportunity to redeem their Public Shares upon the approval of any such amendment (an <B>Amendment Redemption</B>) at a <FONT STYLE="white-space:nowrap">per-Share</FONT> price, payable in cash, equal to the aggregate amount then on deposit in the
Trust Account, including interest earned on the funds held in the Trust Account not previously released to the Company to pay income taxes, if any, divided by the number of Public Shares then in issue. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38.10</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Except for the withdrawal of interest to pay income taxes, if any, none of the funds held in the Trust
Account shall be released from the Trust Account: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to the Company, until completion of any Business Combination; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to the Members holding Public Shares, until the earliest of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a repurchase of Shares by means of a Tender Offer pursuant to Article&nbsp;38.2(b); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(ii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">an IPO Redemption pursuant to Article&nbsp;38.6; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(iii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a distribution of the Trust Account pursuant to Article&nbsp;38.8; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(iv)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">an Amendment Redemption pursuant to Article&nbsp;38.9. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In no other circumstance shall a holder of Public Shares have any right or interest of any kind in the Trust Account. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38.11</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">After the issue of Public Shares (including pursuant to the Over-Allotment Option), and prior to the
consummation of a Business Combination, the directors shall not issue additional Shares or any other securities that would entitle the holders thereof to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">receive funds from the Trust Account; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">vote as a class with the Public Shares: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">on a Business Combination or on any other proposal presented to Members prior to or in connection with the
completion of a Business Combination; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(ii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to approve an amendment to these Articles to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(A)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">extend the time the Company has to consummate a Business Combination beyond twenty-four months after the
closing of the IPO or twenty-seven months after the closing of the IPO if the Company has executed a letter of intent, agreement in principle or definitive agreement for an initial Business Combination within twenty-four months from the closing of
IPO; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(B)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">amend the foregoing provisions of these Articles. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38.12</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company must complete one or more Business Combinations having an aggregate fair market value of at
least 80% of the net assets held in the Trust Account (excluding the amount of deferred underwriting discounts held in the Trust Account and taxes payable on the interest earned on the Trust Account) at the time of the Company&#146;s signing the
agreement to enter into a Business Combination. An initial Business Combination must not be effectuated solely with another blank cheque company or a similar company with nominal operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38.13</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The uninterested Independent Directors shall approve any transaction or transactions between the Company and
any of the following parties: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">any Member owning an interest in the voting power of the Company that gives such Member a significant
influence over the Company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">any director or Officer of the Company and any Affiliate or relative of such director or Officer.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38.14</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">A director may vote in respect of any Business Combination in which such director has a conflict of interest
with respect to the evaluation of such Business Combination. Such director must disclose such interest or conflict to the other directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38.15</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The Company may enter into a Business Combination with a target business that is Affiliated with the
Sponsor, a Founder, the directors of the Company or Officers. In the event the Company seeks to complete the Business Combination with a target that is Affiliated with the Sponsor, a Founder, Officers or directors, the Company, or a committee of
Independent Directors, will obtain an opinion from an independent investment banking firm, which is a member of United States Financial Industry Regulatory Authority, or another independent valuation or accounting firm that such a Business
Combination or transaction is fair to the Company from a financial point of view. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38.16</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Any Business Combination must be approved by the a majority of the Independent Directors.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>39.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Certain Tax Filings </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">39.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Each Tax Filing Authorised Person and any such other person, acting alone, as any director shall designate
from time to time, are authorised to file tax forms <FONT STYLE="white-space:nowrap">SS-4,</FONT> <FONT STYLE="white-space:nowrap">W-8</FONT> BEN, <FONT STYLE="white-space:nowrap">W-8</FONT> IMY, <FONT STYLE="white-space:nowrap">W-9,</FONT> 8832 and
2553 and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
such other similar tax forms as are customary to file with any US state or federal governmental authorities or foreign governmental authorities in connection with the formation, activities and/or
elections of the Company and such other tax forms as may be approved from time to time by any director of the Company or an Officer. The Company further ratifies and approves any such filing made by any Tax Filing Authorised Person or such other
person prior to the date of these Articles. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>40.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Business Opportunities </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">40.1</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In recognition and anticipation of the facts that: (a)&nbsp;directors, managers, officers, members,
partners, managing members, employees and/or agents of one or more members of the Investor Group (each of the foregoing, an &#147;<B>Investor Group Related Person</B>&#148;) may serve as directors of the Company and/or Officers; and (b)&nbsp;the
Investor Group engages, and may continue to engage in the same or similar activities or related lines of business as those in which the Company, directly or indirectly, may engage and/or other business activities that overlap with or compete with
those in which the Company, directly or indirectly, may engage, the provisions under this heading &#147;Business Opportunities&#148; are set forth to regulate and define the conduct of certain affairs of the Company as they may involve the Members
and the Investor Group Related Persons, and the powers, rights, duties and liabilities of the Company and its Officers, directors and Members in connection therewith. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">40.2</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To the fullest extent permitted by Applicable Law, the Investor Group and the Investor Group Related Persons
shall have no duty, except and to the extent expressly assumed by contract, to refrain from engaging directly or indirectly in the same or similar business activities or lines of business as the Company. To the fullest extent permitted by Applicable
Law, the Company renounces any interest or expectancy of the Company in, or in being offered an opportunity to participate in, any potential transaction or matter which may be a corporate opportunity for either the Investor Group or the Investor
Group Related Persons, on the one hand, and the Company, on the other. Except to the extent expressly assumed by contract, to the fullest extent permitted by Applicable Law, the Investor Group and the Investor Group Related Persons shall have no
duty to communicate or offer any such corporate opportunity to the Company and shall not be liable to the Company or its Members for breach of any fiduciary duty as a Member, director of the Company and/or Officer solely by reason of the fact that
such party pursues or acquires such corporate opportunity for itself, himself or herself, directs such corporate opportunity to another person, or does not communicate information regarding such corporate opportunity to the Company, unless such
opportunity is expressly offered to such Investor Group Related Person solely in their capacity as an Officer or director of the Company and the opportunity is one the Company is permitted to complete on a reasonable basis. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">40.3</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Except as provided elsewhere in these Articles, the Company hereby renounces any interest or expectancy of
the Company in, or in being offered an opportunity to participate in, any potential transaction or matter which may be a corporate opportunity for both the Company and the Investor Group, about which a director of the Company and/or Officer who is
also an Investor Group Related Person acquires knowledge. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">40.4</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To the extent a court might hold that the conduct of any activity related to a corporate opportunity that is
renounced in this Article&nbsp;to be a breach of duty to the Company or its Members, the Company hereby waives, to the fullest extent permitted by Applicable Law, any and all claims and causes of action that the Company may have for such activities.
To the fullest extent permitted by Applicable Law, the provisions of this Article&nbsp;apply equally to activities conducted in the future and that have been conducted in the past. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="annex_c"></A><A NAME="rom40894_252"></A>ANNEX C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The name of
this corporation is Surrozen, Inc. (the &#147;<B><I>Company</I></B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>II. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The address of the registered office of the Company in the State of Delaware is The Corporation Trust Company, 1209 Orange Street in the City
of Wilmington, County of New Castle, Delaware 19801 and the name of the registered agent of the Company at such address is The Corporation Trust Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>III. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The purpose of the
Company is to engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law of the State of Delaware (the &#147;<B><I>DGCL</I></B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IV. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>A.</B> This
Company is authorized to issue two classes of stock to be designated, respectively, &#147;<B><I>Common Stock</I></B>&#148; and &#147;<B><I>Preferred Stock</I></B>.&#148; The total number of shares which the Company is authorized to issue is
510,000,000 shares. 500,000,000 shares of which shall be Common Stock, having a par value per share of $0.0001. 10,000,000 shares of which shall be Preferred Stock, having a par value per share of $0.0001. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>B.</B> The Preferred Stock may be issued from time to time in one or more series. The Board of Directors of the Company (the
&#147;<B><I>Board of Directors</I></B>&#148;) is hereby expressly authorized to provide for the issue of all or any of the shares of the Preferred Stock in one or more series, and to fix the number of shares and to determine or alter for each such
series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and
expressed in the resolution or resolutions adopted by the Board of Directors providing for the issuance of such shares and as may be permitted by the DGCL. The Board of Directors is also expressly authorized to increase or decrease the number of
shares of any series subsequent to the issuance of shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of any series shall be decreased in accordance with the foregoing sentence,
the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series. The number of authorized shares of Preferred Stock may be increased or
decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of the stock of the Company entitled to vote thereon, without a separate vote of the holders of the
Preferred Stock, or of any series thereof, unless a vote of any such holders is required pursuant to the terms of any certificate of designation filed with respect to any series of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>C.</B> Each outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the
stockholders of the Company for their vote; <I>provided, however</I>, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (including any certificate
of designation filed with respect to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon by law or pursuant to this Certificate of Incorporation
(including any certificate of designation filed with respect to any series of Preferred Stock). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>V. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the management of the business and for the conduct of the affairs of the Company, and in further definition, limitation and regulation of
the powers of the Company, of its directors and of its stockholders or any class thereof, as the case may be, it is further provided that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>A.</B> <B>M<SMALL>ANAGEMENT</SMALL> <SMALL>OF</SMALL> B<SMALL>USINESS</SMALL>. </B>The management of the business and the conduct of the
affairs of the Company shall be vested in its Board of Directors. The number of directors which shall constitute the Board of Directors shall be fixed exclusively by resolutions adopted by a majority of the authorized number of directors
constituting the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>B.</B> <B>B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>. </B>Subject to the
rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, upon the filing of this Certificate of Incorporation, the directors shall be divided into three classes designated as Class&nbsp;I,
Class&nbsp;II and Class&nbsp;III, respectively. The Board of Directors is authorized to assign members of the Board of Directors already in office to such classes at the time the classification becomes effective. At the first annual meeting of
stockholders following the initial classification of the Board of Directors, the term of office of the Class&nbsp;I directors shall expire and Class&nbsp;I directors shall be elected for a full term of three years. At the second annual meeting of
stockholders following such initial classification, the term of office of the Class&nbsp;II directors shall expire and Class&nbsp;II directors shall be elected for a full term of three years. At the third annual meeting of stockholders following
such initial classification, the term of office of the Class&nbsp;III directors shall expire and Class&nbsp;III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected
for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the
foregoing provisions of this section, each director shall serve until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. No decrease in the number of directors constituting the Board of
Directors shall shorten the term of any incumbent director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>C. R<SMALL>EMOVAL</SMALL> <SMALL>OF</SMALL>
D<SMALL>IRECTORS</SMALL>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>1.</B> Subject to the rights of any series of Preferred Stock to elect additional
directors under specified circumstances,<B> </B>neither the Board of Directors nor any individual director may be removed without cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.</B> Subject to any limitation imposed by applicable law, any individual director or directors may be removed with cause
by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">sixty-six</FONT> and <FONT STYLE="white-space:nowrap">two-thirds</FONT> percent (66 2/3%) of the voting power of all then-outstanding shares of capital stock of the
Company entitled to vote generally at an election of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>D.</B> <B>V<SMALL>ACANCIES</SMALL>. </B>Subject to any limitations
imposed by applicable law and subject to the rights of the holders of any series of Preferred Stock, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created
directorships resulting from any increase in the number of directors, shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders and except as otherwise
provided by applicable law, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors, and not by the stockholders. Any director elected in accordance with the
preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#146;s successor shall have been elected and qualified. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>E. B<SMALL>YLAW</SMALL> A<SMALL>MENDMENTS</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>1.</B> The Board of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the Company.<B> </B>Any adoption, amendment or
repeal of the Bylaws of the Company by the Board of Directors shall require the approval of a majority of the directors then in office. The stockholders shall also have power to adopt, amend or repeal the Bylaws of the Company; <I>provided, however,
</I>that, in addition to any vote of the holders of any class or series of stock of the Company required by law or by this Certificate of Incorporation, such action by stockholders shall require the affirmative vote of the holders of at least <FONT
STYLE="white-space:nowrap">sixty-six</FONT> and <FONT STYLE="white-space:nowrap">two-thirds</FONT> percent (66 2/3%) of the voting power of all of the then-outstanding shares of the capital stock of the Company entitled to vote generally in the
election of directors, voting together as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.</B> The directors of the Company need not be elected by written ballot
unless the Bylaws so provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.</B> No action shall be taken by the stockholders of the Company except at an annual or special
meeting of stockholders called in accordance with the Bylaws, and no action shall be taken by the stockholders by written consent or electronic transmission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>4.</B> Advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any
meeting of the stockholders of the Company shall be given in the manner provided in the Bylaws of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>5.</B> In the event
that a member of the Board of Directors of the Company who is not an employee of the Company, or any partner, member, director, stockholder, employee or agent of such member, other than someone who is an employee of the Company (collectively, the
&#147;<B><I>Covered Persons</I></B>&#148;), acquires knowledge of any business opportunity matter, potential transaction, interest or other matter, unless such matter, transaction or interest is presented to, or acquired, created or developed by, or
otherwise comes into the possession of, a Covered Person expressly and solely in connection with such individual&#146;s service as a member of the Board of Directors of the Company (a &#147;<B><I>Corporate Opportunity</I></B>&#148;), then the
Company, pursuant to Section&nbsp;122(17) of the DGCL and to the maximum extent permitted from time to time under Delaware law, (i)&nbsp;renounces any expectancy that such Covered Person offer an opportunity to participate in such Corporate
Opportunity to the Company and (ii)&nbsp;to the fullest extent permitted by law, waives any claim that such opportunity constituted a Corporate Opportunity that should have been presented by such Covered Person to the Company or any of its
affiliates. No amendment or repeal of this paragraph shall apply to or have any effect on the liability or alleged liability of any officer, director or stockholder of the Company for or with respect to any opportunities of which such officer,
director or stockholder becomes aware prior to such amendment or repeal. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VI. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>A.</B> The liability of the directors for monetary damages shall be eliminated to the fullest extent under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>B.</B> To the fullest extent permitted by applicable law, the Company is authorized to provide indemnification of (and advancement of
expenses to) directors, officers and agents of the Company (and any other persons to which applicable law permits the Company to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or
disinterested directors or otherwise in excess of the indemnification and advancement otherwise permitted by such applicable law. If applicable law is amended after approval by the stockholders of this Article VI to authorize corporate action
further eliminating or limiting the personal liability of directors, then the liability of a director to the Company shall be eliminated or limited to the fullest extent permitted by applicable law as so amended. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>C.</B> Any repeal or modification of this Article VI shall only be prospective and shall
not affect the rights or protections or increase the liability of any director under this Article VI in effect at the time of the alleged occurrence of any act or omission to act giving rise to liability or indemnification. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VII. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>A.</B> Unless
the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located
within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall be the sole and exclusive forum for the
following claims or causes of action under the Delaware statutory or common law: (A)&nbsp;any derivative claim or cause of action brought on behalf of the Company; (B)&nbsp;any claim or cause of action for breach of a fiduciary duty owed by any
current or former director, officer or other employee of the Company, to the Company or the Company&#146;s stockholders; (C)&nbsp;any claim or cause of action against the Company or any current or former director, officer or other employee of the
Company , arising out of or pursuant to any provision of the DGCL, this Certificate of Incorporation or the Bylaws of the Company (as each may be amended from time to time); (D) any claim or cause of action seeking to interpret, apply, enforce or
determine the validity of this Certificate of Incorporation or the Bylaws of the Company (as each may be amended from time to time, including any right, obligation, or remedy thereunder); (E) any claim or cause of action as to which the DGCL confers
jurisdiction on the Court of Chancery of the State of Delaware; and (F)&nbsp;any claim or cause of action against the Company or any current or former director, officer or other employee of the Company , governed by the internal-affairs doctrine, in
all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. This Section A of Article VII shall not apply to claims or causes of action brought to enforce
a duty or liability created by the Securities Act of 1933, as amended (the &#147;<B><I>1933 Act</I></B>&#148;), or the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>B.</B> Unless the Company consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal
district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the 1933 Act, including all causes of action asserted against any defendant named in such
complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession
gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>C.</B> Any person or entity holding, owning or otherwise acquiring any interest in any security of the Company shall be deemed to have
notice of and consented to the provisions of this Certificate of Incorporation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VIII. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>A.</B> The Company reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in
the manner now or hereafter prescribed by statute, except as provided in paragraph B. of this Article&nbsp;VIII, and all rights conferred upon the stockholders herein are granted subject to this reservation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>B.</B> Notwithstanding any other provisions of this Certificate of Incorporation or any provision of applicable law which might otherwise
permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class or series of the capital stock of the Company required by law or by this Certificate of Incorporation or any certificate of designation
filed with respect to a series of Preferred Stock, the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">sixty-six</FONT> and <FONT STYLE="white-space:nowrap">two-thirds</FONT> percent (66 2/3%) of the voting power of all
of the then </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
outstanding shares of capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class, shall be required to alter, amend or repeal Articles
V, VI, VII and VIII. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, Surrozen, Inc. has caused this Certificate of
Incorporation to be executed this [&#9679;] day of [&#9679;], 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>S<SMALL>URROZEN</SMALL>, I<SMALL>NC</SMALL>.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="annex_d"></A><A NAME="rom40894_253"></A>ANNEX D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BYLAWS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(A
DELAWARE CORPORATION) </B></P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>T<SMALL>ABLE</SMALL> O<SMALL>F</SMALL> C<SMALL>ONTENTS</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>P<SMALL>AGE</SMALL></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_1">ARTICLE I OFFICES</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_2">Section&nbsp;1.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_2">Registered Office</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_3">Section&nbsp;2.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_3">Other Offices</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_4">ARTICLE II CORPORATE SEAL</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_5">Section&nbsp;3.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_5">Corporate Seal</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_6">ARTICLE III STOCKHOLDERS&#146;
MEETINGS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_7">Section&nbsp;4.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_7">Place of Meetings</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_8">Section&nbsp;5.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_8">Annual Meetings</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_9">Section&nbsp;6.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_9">Special Meetings</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_10">Section&nbsp;7.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_10">Notice of Meetings</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_11">Section&nbsp;8.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_11">Quorum</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_12">Section&nbsp;9.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_12">Adjournment And Notice Of Adjourned
Meetings</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_13">Section&nbsp;10.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_13">Voting Rights</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_14">Section&nbsp;11.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_14">Joint Owners of Stock</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_15">Section&nbsp;12.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_15">List of Stockholders</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_16">Section&nbsp;13.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_16">Action Without Meeting</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_17">Section&nbsp;14.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_17">Organization</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_18">ARTICLE IV DIRECTORS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_19">Section&nbsp;15.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_19">Number And Term Of Office</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_20">Section&nbsp;16.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_20">Powers</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_21">Section&nbsp;17.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_21">Classes of Directors</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_22">Section&nbsp;18.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_22">Vacancies</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_23">Section&nbsp;19.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_23">Resignation</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_24">Section&nbsp;20.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_24">Removal</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_25">Section&nbsp;21.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_25">Meetings</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_26">Section&nbsp;22.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_26">Quorum and Voting</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_27">Section&nbsp;23.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_27">Action Without Meeting</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_28">Section&nbsp;24.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_28">Fees and Compensation</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_29">Section&nbsp;25.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_29">Committees</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_30">Section&nbsp;26.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_30">Lead Independent Director</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_31">Section&nbsp;27.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_31">Organization</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_32">ARTICLE V OFFICERS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_33">Section&nbsp;28.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_33">Officers Designated</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_34">Section&nbsp;29.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_34">Tenure And Duties Of
Officers</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_35">Section&nbsp;30.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_35">Delegation Of Authority</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_36">Section&nbsp;31.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_36">Resignations</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_37">Section&nbsp;32.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_37">Removal</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_38">ARTICLE VI EXECUTION OF CORPORATE INSTRUMENTS AND
VOTING OF SECURITIES OWNED BY THE CORPORATION</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_39">Section&nbsp;33.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_39">Execution Of Corporate
Instruments</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_40">Section&nbsp;34.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_40">Voting Of Securities Owned By The
Corporation</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>ABLE</SMALL> O<SMALL>F</SMALL> C<SMALL>ONTENTS</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>



<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>P<SMALL>AGE</SMALL></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_41">ARTICLE VII SHARES OF STOCK</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_42">Section&nbsp;35.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_42">Form And Execution Of
Certificates</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_43">Section&nbsp;36.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_43">Lost Certificates</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_44">Section&nbsp;37.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_44">Transfers</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_45">Section&nbsp;38.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_45">Fixing Record Dates</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_46">Section&nbsp;39.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_46">Registered Stockholders</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_47">ARTICLE VIII OTHER SECURITIES OF THE CORPORATION
</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_48">Section&nbsp;40.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_48">Execution Of Other
Securities</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_49">ARTICLE IX DIVIDENDS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_50">Section&nbsp;41.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_50">Declaration Of Dividends</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_51">Section&nbsp;42.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_51">Dividend Reserve</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_52">ARTICLE X FISCAL YEAR</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_53">Section&nbsp;43.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_53">Fiscal Year</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_54">ARTICLE XI INDEMNIFICATION</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_55">Section&nbsp;44.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_55">Indemnification of Directors, Executive Officers,
 Other Officers, Employees and Other Agents</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_56">ARTICLE XII NOTICES</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_57">Section&nbsp;45.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_57">Notices</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_58">ARTICLE XIII AMENDMENTS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><B><A HREF="#anxd40894_59">Section&nbsp;46.</A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_59">Amendments </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_60">ARTICLE XIV LOANS TO
OFFICERS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A HREF="#anxd40894_61">Section&nbsp;47.</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A HREF="#anxd40894_61">Loans To Officers</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BYLAWS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(A DELAWARE CORPORATION) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxd40894_1"></A>ARTICLE I </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_2"></A><B>Section</B><B></B><B>&nbsp;1.</B> <B>Registered Office</B><B>.</B> The registered
office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_3"></A><B>Section</B><B></B><B>&nbsp;2.</B> <B>Other Offices</B><B>.</B> The corporation may
also have and maintain an office or principal place of business at such place as may be fixed by the Board of Directors, and may also have offices at such other places, both within and without the State of Delaware as the Board of Directors may from
time to time determine or the business of the corporation may require. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxd40894_4"></A>ARTICLE II </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CORPORATE SEAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_5"></A><B>Section</B><B></B><B>&nbsp;3.</B> <B>Corporate Seal</B><B>.</B> The Board of
Directors may adopt a corporate seal. If adopted, the corporate seal shall consist of a die bearing the name of the corporation and the inscription, &#147;Corporate Seal-Delaware.&#148; Said seal may be used by causing it or a facsimile thereof to
be impressed or affixed or reproduced or otherwise. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxd40894_6"></A>ARTICLE III </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDERS&#146; MEETINGS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_7"></A><B>Section</B><B></B><B>&nbsp;4.</B> <B>Place of Meetings</B><B>.</B> Meetings of
the stockholders of the corporation may be held at such place, either within or without the State of Delaware, as may be determined from time to time by the Board of Directors. The Board of Directors may, in its sole discretion, determine that the
meeting shall not be held at any place, but may instead be held solely by means of remote communication as provided under the Delaware General Corporation Law (&#147;DGCL&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_8"></A><B>Section&nbsp;5. Annual Meetings.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> The annual meeting of the stockholders of the corporation, for the purpose of election of directors and for such other business as
may properly come before it, shall be held on such date and at such time as may be designated from time to time by the Board of Directors. Nominations of persons for election to the Board of Directors of the corporation and the proposal of business
to be considered by the stockholders may be made at an annual meeting of stockholders: (i)&nbsp;pursuant to the corporation&#146;s notice of meeting of stockholders (with respect to business other than nominations); (ii) brought specifically by or
at the direction of the Board of Directors; or (iii)&nbsp;by any stockholder of the corporation who was a stockholder of record at the time of giving the stockholder&#146;s notice provided for in Section&nbsp;5(b) below, who is entitled to vote at
the meeting and who complied with the notice procedures set forth in Section&nbsp;5. For the avoidance of doubt, clause (iii)&nbsp;above shall be the exclusive means for a stockholder to make nominations and submit other business (other than matters
properly included in the corporation&#146;s notice of meeting of stockholders and proxy statement under Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Securities Exchange Act of 1934, as amended, and the rules and regulations
thereunder (the &#147;1934 Act&#148;)) before an annual meeting of stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> At an annual meeting of the stockholders, only such business shall be conducted
as is a proper matter for stockholder action under Delaware law and as shall have been properly brought before the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(</B><B>i</B><B>)</B> For nominations for the election to the Board of Directors to be properly brought before an annual meeting by a
stockholder pursuant to clause (iii)&nbsp;of Section&nbsp;5(a) of these Bylaws, the stockholder must deliver written notice to the Secretary at the principal executive offices of the corporation on a timely basis as set forth in
Section&nbsp;5(b)(iii) and must update and supplement such written notice on a timely basis as set forth in Section&nbsp;5(c). Such stockholder&#146;s notice shall set forth: (A)&nbsp;as to each nominee such stockholder proposes to nominate at the
meeting: (1)&nbsp;the name, age, business address and residence address of such nominee, (2)&nbsp;the principal occupation or employment of such nominee, (3)&nbsp;the class and number of shares of each class of capital stock of the corporation which
are owned of record and beneficially by such nominee, (4)&nbsp;the date or dates on which such shares were acquired and the investment intent of such acquisition, (5)&nbsp;such other information concerning such nominee as would be required to be
disclosed in a proxy statement soliciting proxies for the election of such nominee as a director in an election contest (even if an election contest is not involved), or that is otherwise required to be disclosed pursuant to Section&nbsp;14 of the
1934 Act and the rules and regulations promulgated thereunder (including such person&#146;s written consent to being named as a nominee and to serving as a director if elected); and (B)&nbsp;the information required by Section&nbsp;5(b)(iv). The
corporation may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility of such proposed nominee to serve as an independent director of the corporation or that could be material to a
reasonable stockholder&#146;s understanding of the independence, or lack thereof, of such proposed nominee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> Other than
proposals sought to be included in the corporation&#146;s proxy materials pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the 1934 Act, for business other than nominations for the election to the Board of Directors to be
properly brought before an annual meeting by a stockholder pursuant to clause (iii)&nbsp;of Section&nbsp;5(a), the stockholder must deliver written notice to the Secretary at the principal executive offices of the corporation on a timely basis as
set forth in Section&nbsp;5(b)(iii), and must update and supplement such written notice on a timely basis as set forth in Section&nbsp;5(c). Such stockholder&#146;s notice shall set forth: (A)&nbsp;as to each matter such stockholder proposes to
bring before the meeting, a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting, and any material interest (including any anticipated benefit of such business to any
Proponent (as defined below) other than solely as a result of its ownership of the corporation&#146;s capital stock, that is material to any Proponent individually, or to the Proponents in the aggregate) in such business of any Proponent; and
(B)&nbsp;the information required by Section&nbsp;5(b)(iv). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> To be timely, the written notice required by
Section&nbsp;5(b)(i) or 5(b)(ii) must be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the ninetieth (90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day nor
earlier than the close of business on the one hundred twentieth (120<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day prior to the first anniversary of the preceding year&#146;s annual meeting; <I>provided, however,</I> that, subject to
the last sentence of this Section&nbsp;5(b)(iii), in the event that the date of the annual meeting is advanced more than thirty (30)&nbsp;days prior to or delayed by more than thirty (30)&nbsp;days after the anniversary of the preceding year&#146;s
annual meeting, notice by the stockholder to be timely must be so received not earlier than the close of business on the one hundred twentieth (120<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day prior to such annual meeting and not
later than the close of business on the later of the ninetieth (90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)<B> </B>day prior to such annual meeting or the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day following
the day on which public announcement of the date of such meeting is first made. In no event shall an adjournment or a postponement of an annual meeting for which notice has been given, or the public announcement thereof has been made, commence a new
time period for the giving of a stockholder&#146;s notice as described above. Notwithstanding anything to the contrary provided herein, for the first annual meeting following the initial public offering of common stock of the corporation, a
stockholder&#146;s notice shall be timely if received by the Secretary at the principal executive offices of the corporation not later than the close of business on the later of the ninetieth
(90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day prior to the scheduled date of such annual meeting or the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day following the day on which public announcement of the
date of such annual meeting is first made or sent by the corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B> The written notice required by Section&nbsp;5(b)(i) or 5(b)(ii) shall also set
forth, as of the date of the notice and as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made (each, a &#147;Proponent&#148; and collectively, the &#147;Proponents&#148;): (A)
the name and address of each Proponent, as they appear on the corporation&#146;s books; (B)&nbsp;the class, series and number of shares of the corporation that are owned beneficially and of record by each Proponent; (C)&nbsp;a description of any
agreement, arrangement or understanding (whether oral or in writing) with respect to such nomination or proposal between or among any Proponent and any of its affiliates or associates, and any others (including their names) acting in concert, or
otherwise under the agreement, arrangement or understanding, with any of the foregoing; (D)&nbsp;a representation that the Proponents are holders of record or beneficial owners, as the case may be, of shares of the corporation entitled to vote at
the meeting and intend to appear in person or by proxy at the meeting to nominate the person or persons specified in the notice (with respect to a notice under Section&nbsp;5(b)(i)) or to propose the business that is specified in the notice (with
respect to a notice under Section&nbsp;5(b)(ii)); (E) a representation as to whether the Proponents intend to deliver a proxy statement and form of proxy to holders of a sufficient number of holders of the corporation&#146;s voting shares to elect
such nominee or nominees (with respect to a notice under Section&nbsp;5(b)(i)) or to carry such proposal (with respect to a notice under Section&nbsp;5(b)(ii)); (F) to the extent known by any Proponent, the name and address of any other stockholder
supporting the proposal on the date of such stockholder&#146;s notice; and (G)&nbsp;a description of all Derivative Transactions (as defined below) by each Proponent during the previous twelve (12)&nbsp;month period, including the date of the
transactions and the class, series and number of securities involved in, and the material economic terms of, such Derivative Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of Sections 5 and 6, a &#147;Derivative Transaction&#148; means any agreement, arrangement, interest or understanding entered
into by, or on behalf or for the benefit of, any Proponent or any of its affiliates or associates, whether record or beneficial: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(w) the value of which is derived in whole or in part from the value of any class or series of shares or other securities of
the corporation, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(x) which otherwise provides any direct or indirect opportunity to gain or share in any gain derived from
a change in the value of securities of the corporation, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(y) the effect or intent of which is to mitigate loss, manage risk
or benefit of security value or price changes, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(z) which provides the right to vote or increase or decrease the voting
power of, such Proponent, or any of its affiliates or associates, with respect to any securities of the corporation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">which agreement,
arrangement, interest or understanding may include, without limitation, any option, warrant, debt position, note, bond, convertible security, swap, stock appreciation right, short position, profit interest, hedge, right to dividends, voting
agreement, performance-related fee or arrangement to borrow or lend shares (whether or not subject to payment, settlement, exercise or conversion in any such class or series), and any proportionate interest of such Proponent in the securities of the
corporation held by any general or limited partnership, or any limited liability company, of which such Proponent is, directly or indirectly, a general partner or managing member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> A stockholder providing written notice required by Section&nbsp;5(b)(i) or (ii)&nbsp;shall update and supplement such notice in
writing, if necessary, so that the information provided or required to be provided in such notice is true and correct in all material respects as of (i)&nbsp;the record date for the meeting and (ii)&nbsp;the date that is five (5)&nbsp;business days
prior to the meeting and, in the event of any adjournment or postponement thereof, five (5)&nbsp;business days prior to such adjourned or postponed meeting. In the case of an update and supplement pursuant to clause (i)&nbsp;of this
Section&nbsp;5(c), such update and supplement shall be received by the Secretary at the principal executive offices of the corporation not later than five (5)&nbsp;business days after the record date for the meeting. In the case of an update and
supplement pursuant to clause (ii)&nbsp;of this Section&nbsp;5(c), such update and supplement shall be received by the Secretary at the principal executive offices of the corporation not later than two (2)&nbsp;business days prior to the date for
the meeting, and, in the event of any adjournment or postponement thereof, two (2)&nbsp;business days prior to such adjourned or postponed meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> Notwithstanding anything in Section&nbsp;5(b)(iii) to the contrary, in the event
that the number of directors in an Expiring Class (as defined below) is increased and there is no public announcement of the appointment of a director to such class, or, if no appointment was made, of the vacancy in such class, made by the
corporation at least ten (10)&nbsp;days before the last day a stockholder may deliver a notice of nomination in accordance with Section&nbsp;5(b)(iii), a stockholder&#146;s notice required by this Section&nbsp;5 and which complies with the
requirements in Section&nbsp;5(b)(i), other than the timing requirements in Section&nbsp;5(b)(iii), shall also be considered timely, but only with respect to nominees for any new positions in such Expiring Class&nbsp;created by such increase, if it
shall be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the tenth (10th) day following the day on which such public announcement is first made by the corporation. For purposes
of this section, an &#147;Expiring Class&#148; shall mean a class of directors whose term shall expire at the next annual meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> A person shall not be eligible for election or <FONT STYLE="white-space:nowrap">re-election</FONT> as a director, unless the person
is nominated in accordance with either clause (ii)&nbsp;or (iii) of Section&nbsp;5(a). Except as otherwise required by law, the chairperson of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be
brought before the meeting was made, or proposed, as the case may be, in accordance with the procedures set forth in these Bylaws and, if any proposed nomination or business is not in compliance with these Bylaws, or the Proponent does not act in
accordance with the representations in Sections 5(b)(iv)(D) and 5(b)(iv)(E), to declare that such proposal or nomination shall not be presented for stockholder action at the meeting and shall be disregarded, notwithstanding that proxies in respect
of such nominations or such business may have been solicited or received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B> Notwithstanding the foregoing provisions of this
Section&nbsp;5, in order to include information with respect to a stockholder proposal in the proxy statement and form of proxy for a stockholders&#146; meeting, a stockholder must also comply with all applicable requirements of the 1934 Act and the
rules and regulations thereunder. Nothing in these Bylaws shall be deemed to affect any rights of stockholders to request inclusion of proposals in the corporation&#146;s proxy statement pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT>
under the 1934 Act; <I>provided, however, </I>that any references in these Bylaws to the 1934 Act or the rules and regulations thereunder are not intended to and shall not limit the requirements applicable to proposals and/or nominations to be
considered pursuant to Section&nbsp;5(a)(iii) of these Bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g)</B> For purposes of Sections&nbsp;5 and 6, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> &#147;public announcement&#148; shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press
or comparable national news service or in a document publicly filed by the corporation with the Securities and Exchange Commission pursuant to Section&nbsp;13, 14 or 15(d) of the 1934 Act; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> &#147;affiliates&#148; and &#147;associates&#148; shall have the meanings set forth in Rule 405 under the Securities Act of 1933,
as amended (the &#147;1933 Act&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxd40894_9"></A>Section&nbsp;6. Special Meetings. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> Special meetings of the stockholders of the corporation may be called, for any purpose as is a proper matter for stockholder action
under Delaware law, by (i)&nbsp;the Chairperson of the Board of Directors, (ii)&nbsp;the Chief Executive Officer, or (iii)&nbsp;the Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors
(whether or not there exist any vacancies in previously authorized directorships at the time any such resolution is presented to the Board of Directors for adoption). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> The Board of Directors shall determine the time and place, if any, of such special meeting. Upon determination of the time and
place, if any, of the meeting, the Secretary shall cause a notice of meeting to be given to the stockholders entitled to vote, in accordance with the provisions of Section&nbsp;7. No business may be transacted at such special meeting otherwise than
specified in the notice of meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B></B>Nominations of persons for election to the Board of Directors may be made
at a special meeting of stockholders at which directors are to be elected (i)&nbsp;by or at the direction of the Board of Directors or (ii)&nbsp;by any stockholder of the corporation who is a stockholder of record at the time of giving notice
provided for in this paragraph, who shall be entitled to vote at the meeting and who delivers written notice to the Secretary of the corporation setting forth the information required by Section&nbsp;5(b)(i). In the event the corporation calls a
special meeting of stockholders for the purpose of electing one or more directors to the Board of Directors, any such stockholder of record may nominate a person or persons (as the case may be), for election to such position(s) as specified in the
corporation&#146;s notice of meeting, if written notice setting forth the information required by Section&nbsp;5(b)(i) of these Bylaws shall be received by the Secretary at the principal executive offices of the corporation not later than the close
of business on the later of the ninetieth (90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day prior to such meeting or the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day following the day on which public
announcement is first made of the date of the special meeting and of the nominees proposed by the Board of Directors to be elected at such meeting. The stockholder shall also update and supplement such information as required under
Section&nbsp;5(c). In no event shall an adjournment or a postponement of a special meeting for which notice has been given, or the public announcement thereof has been made, commence a new time period for the giving of a stockholder&#146;s notice as
described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> Notwithstanding the foregoing provisions of this Section&nbsp;6, a stockholder must also comply with all
applicable requirements of the 1934 Act and the rules and regulations thereunder with respect to matters set forth in this Section&nbsp;6. Nothing in these Bylaws shall be deemed to affect any rights of stockholders to request inclusion of proposals
in the corporation&#146;s proxy statement pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the 1934 Act; <I>provided, however, </I>that any references in these Bylaws to the 1934 Act or the rules and regulations thereunder are
not intended to and shall not limit the requirements applicable to nominations for the election to the Board of Directors to be considered pursuant to <B></B>Section&nbsp;6(c) of these Bylaws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_10"></A><B>Section</B><B></B><B>&nbsp;7.</B> <B>Notice of Meetings</B><B>.</B> Except as
otherwise provided by law, notice, given in writing or by electronic transmission, of each meeting of stockholders shall be given not less than ten (10)&nbsp;nor more than sixty (60)&nbsp;days before the date of the meeting to each stockholder
entitled to vote at such meeting, such notice to specify the place, if any, date and hour, in the case of special meetings, the purpose or purposes of the meeting, and the means of remote communications, if any, by which stockholders and proxy
holders may be deemed to be present in person and vote at any such meeting. If mailed, notice is given when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder&#146;s address as it appears on the
records of the corporation. Notice of the time, place, if any, and purpose of any meeting of stockholders may be waived in writing, signed by the person entitled to notice thereof, or by electronic transmission by such person, either before or after
such meeting, and will be waived by any stockholder by his or her attendance thereat in person, by remote communication, if applicable, or by proxy, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning
of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if due notice
thereof had been given. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_11"></A><B>Section</B><B></B><B>&nbsp;8.</B>
<B>Quorum</B><B>.</B> At all meetings of stockholders, except where otherwise provided by statute or by the Certificate of Incorporation, or by these Bylaws, the presence, in person, by remote communication, if applicable, or by proxy duly
authorized, of the holders of a majority of the outstanding shares of stock entitled to vote shall constitute a quorum for the transaction of business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time,
either by the chairperson of the meeting or by vote of the holders of a majority of the shares represented thereat, but no other business shall be transacted at such meeting. The stockholders present at a duly called or convened meeting, at which a
quorum is present, may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Except as otherwise provided by statute or by applicable stock exchange rules, or by the
Certificate of Incorporation or these Bylaws, in all matters other than the election of directors, the affirmative vote of the majority of shares present in person, by remote communication, if applicable, or represented by
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
proxy at the meeting and entitled to vote generally on the subject matter shall be the act of the stockholders. Except as otherwise provided by statute, the Certificate of Incorporation or these
Bylaws, directors shall be elected by a plurality of the votes of the shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the election of directors. Where a
separate vote by a class or classes or series is required, except where otherwise provided by the statute or by the Certificate of Incorporation or these Bylaws, a majority of the outstanding shares of such class or classes or series, present in
person, by remote communication, if applicable, or represented by proxy duly authorized, shall constitute a quorum entitled to take action with respect to that vote on that matter. Except where otherwise provided by statute or by the Certificate of
Incorporation or these Bylaws, the affirmative vote of the majority (plurality, in the case of the election of directors) of shares of such class or classes or series present in person, by remote communication, if applicable, or represented by proxy
at the meeting shall be the act of such class or classes or series. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_12"></A><B>Section</B><B></B><B>&nbsp;9.</B> <B>Adjournment </B><B>And</B><B> Notice Of
Adjourned Meetings</B><B>.</B> Any meeting of stockholders, whether annual or special, may be adjourned from time to time either by the chairperson of the meeting or by the vote of a majority of the shares present in person, by remote communication,
if applicable, or represented by proxy at the meeting. When a meeting is adjourned to another time or place, if any, notice need not be given of the adjourned meeting if the time and place, if any, thereof are announced at the meeting at which the
adjournment is taken. At the adjourned meeting, the corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty (30)&nbsp;days or if after the adjournment a new record
date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_13"></A><B>Section</B><B></B><B>&nbsp;10.</B> <B>Voting Rights</B><B>.</B> For the purpose
of determining those stockholders entitled to vote at any meeting of the stockholders, except as otherwise provided by law, only persons in whose names shares stand on the stock records of the corporation on the record date, as provided in
Section&nbsp;12 of these Bylaws, shall be entitled to vote at any meeting of stockholders. Every person entitled to vote shall have the right to do so either in person, by remote communication, if applicable, or by an agent or agents authorized by a
proxy granted in accordance with Delaware law. An agent so appointed need not be a stockholder. No proxy shall be voted after three (3)&nbsp;years from its date of creation unless the proxy provides for a longer period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_14"></A><B>Section</B><B></B><B>&nbsp;11.</B> <B>Joint Owners of Stock</B><B>.</B> If shares
or other securities having voting power stand of record in the names of two (2)&nbsp;or more persons, whether fiduciaries, members of a partnership, joint tenants, tenants in common, tenants by the entirety, or otherwise, or if two (2)&nbsp;or more
persons have the same fiduciary relationship respecting the same shares, unless the Secretary is given written notice to the contrary and is furnished with a copy of the instrument or order appointing them or creating the relationship wherein it is
so provided, their acts with respect to voting shall have the following effect: (a)&nbsp;if only one (1)&nbsp;votes, his or her act binds all; (b)&nbsp;if more than one (1)&nbsp;votes, the act of the majority so voting binds all; (c)&nbsp;if more
than one (1)&nbsp;votes, but the vote is evenly split on any particular matter, each faction may vote the securities in question proportionally, or may apply to the Delaware Court of Chancery for relief as provided in the DGCL, Section&nbsp;217(b).
If the instrument filed with the Secretary shows that any such tenancy is held in unequal interests, a majority or even-split for the purpose of subsection&nbsp;(c) shall be a majority or even-split in interest. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_15"></A><B>Section</B><B></B><B>&nbsp;12.</B> <B>List of Stockholders</B><B>.</B> The
Secretary (or the corporation&#146;s transfer agent or other person authorized by these Bylaws or by law) shall prepare and make, at least ten (10)&nbsp;days before every meeting of stockholders, a complete list of the stockholders entitled to vote
at said meeting, arranged in alphabetical order, showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to
the meeting, (a)&nbsp;on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
meeting, or (b)&nbsp;during ordinary business hours, at the principal place of business of the corporation. In the event that the corporation determines to make the list available on an
electronic network, the corporation may take reasonable steps to ensure that such information is available only to stockholders of the corporation. The list shall be open to examination of any stockholder during the time of the meeting as provided
by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxd40894_16"></A>Section&nbsp;13. Action Without Meeting. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No action shall be taken by the stockholders except at an annual or special meeting of stockholders called in accordance with these Bylaws,
and no action shall be taken by the stockholders by written consent or by electronic transmission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxd40894_17">
</A>Section&nbsp;14. Organization. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> At every meeting of stockholders, the Chairperson of the Board of Directors, or, if a
Chairperson has not been appointed or is absent, the President, or, if the President is absent, a chairperson of the meeting chosen by a majority in interest of the stockholders entitled to vote, present in person or by proxy, shall act as
chairperson. The Secretary, or, in his or her absence, an Assistant Secretary directed to do so by the President, shall act as secretary of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> The Board of Directors of the corporation shall be entitled to make such rules or regulations for the conduct of meetings of
stockholders as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations of the Board of Directors, if any, the chairperson of the meeting shall have the right and authority to prescribe such rules, regulations and
procedures and to do all such acts as, in the judgment of such chairperson, are necessary, appropriate or convenient for the proper conduct of the meeting, including, without limitation, establishing an agenda or order of business for the meeting,
with consultation by the Lead Independent Director (as defined below), rules and procedures for maintaining order at the meeting and the safety of those present, limitations on participation in such meeting to stockholders of record of the
corporation and their duly authorized and constituted proxies and such other persons as the chairperson shall permit, restrictions on entry to the meeting after the time fixed for the commencement thereof, limitations on the time allotted to
questions or comments by participants and regulation of the opening and closing of the polls for balloting on matters which are to be voted on by ballot. The date and time of the opening and closing of the polls for each matter upon which the
stockholders will vote at the meeting shall be announced at the meeting. Unless and to the extent determined by the Board of Directors or the chairperson of the meeting, meetings of stockholders shall not be required to be held in accordance with
rules of parliamentary procedure. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxd40894_18"></A>ARTICLE IV </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_19"></A><B>Section</B><B></B><B>&nbsp;15.</B> <B>Number </B><B>And</B><B> Term Of
Office</B><B>.</B> The authorized number of directors of the corporation shall be fixed in accordance with the Certificate of Incorporation. Directors need not be stockholders unless so required by the Certificate of Incorporation. If for any cause,
the directors shall not have been elected at an annual meeting, they may be elected as soon thereafter as convenient at a special meeting of the stockholders called for that purpose in the manner provided in these Bylaws. Each director shall serve
until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_20"></A><B>Section</B><B></B><B>&nbsp;16.</B> <B>Powers</B><B>.</B> The business and affairs
of the corporation shall be managed by or under the direction of the Board of Directors, except as may be otherwise provided by statute or by the Certificate of Incorporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_21"></A><B>Section</B><B></B><B>&nbsp;17.</B> <B>Classes of Directors</B><B>. </B>Subject to
the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the directors shall be divided into three classes designated as Class&nbsp;I, Class&nbsp;II and Class&nbsp;III, respectively. The
Board of Directors is authorized to assign members of the Board of Directors already in office to such classes at the time the classification becomes effective. At the first annual meeting of stockholders following the initial classification of the
Board of Directors, the term of office of the Class&nbsp;I directors shall expire and Class&nbsp;I directors shall be elected for a full term of three years. At the second annual meeting of stockholders following such initial classification, the
term of office of the Class&nbsp;II directors shall expire and Class&nbsp;II directors shall be elected for a full term of three years. At the third annual meeting of stockholders following such initial classification, the term of office of the
Class&nbsp;III directors shall expire and Class&nbsp;III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors
of the class whose terms expire at such annual meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing provisions of this Section&nbsp;17, each director
shall serve until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent
director. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_22"></A><B>Section</B><B></B><B>&nbsp;18.</B> <B>Vacancies</B><B>. </B>Unless
otherwise provided in the Certificate of Incorporation, and subject to the rights of the holders of any series of Preferred Stock, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes
and any newly created directorships resulting from any increase in the number of directors shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be
filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors, or by a sole remaining director, and not by the stockholders, <I>provided, however</I>, that whenever the
holders of any class or classes of stock or series thereof are entitled to elect one or more directors by the provisions of the Certificate of Incorporation, vacancies and newly created directorships of such class or classes or series shall, unless
the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be filled by a majority of the directors elected by such class or classes or series thereof then in office, or by
a sole remaining director so elected, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and
until such director&#146;s successor shall have been elected and qualified. A vacancy in the Board of Directors shall be deemed to exist under this Bylaw in the case of the death, removal or resignation of any director. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_23"></A><B>Section</B><B></B><B>&nbsp;19.</B> <B>Resignation</B><B>.</B> Any director may
resign at any time by delivering his or her notice in writing or by electronic transmission to the Secretary, such resignation to specify whether it will be effective at a particular time. If no such specification is made, it shall be deemed
effective at the time of delivery to the Secretary. When one or more directors shall resign from the Board of Directors, effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power
to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each Director so chosen shall hold office for the unexpired portion of the term of the Director whose place shall be
vacated and until his or her successor shall have been duly elected and qualified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxd40894_24">
</A>Section&nbsp;20. Removal. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> Subject to the rights of holders of any series of Preferred Stock to elect additional
directors under specified circumstances<B> </B>neither the Board of Directors nor any individual director may be removed without cause. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> Subject to any limitation imposed by applicable law, any individual director or
directors may be removed with cause by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">sixty-six</FONT> and <FONT STYLE="white-space:nowrap">two-thirds</FONT> percent (66 2/3%) of the voting power of all
then-outstanding shares of capital stock of the Company entitled to vote generally at an election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxd40894_25"></A>Section&nbsp;21. Meetings. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Regular Meetings.</B> Unless otherwise restricted by the Certificate of Incorporation, regular meetings of the Board of
Directors may be held at any time or date and at any place within or without the State of Delaware which has been designated by the Board of Directors and publicized among all directors, either orally or in writing, by telephone, including a
voice-messaging system or other system designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means. No further notice shall be required for regular meetings of the Board of Directors.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Special Meetings. </B>Unless otherwise restricted by the Certificate of Incorporation, special meetings of the Board of
Directors may be held at any time and place within or without the State of Delaware whenever called by the Chairperson of the Board, the Chief Executive Officer or a majority of the authorized number of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Meetings by Electronic Communications Equipment. </B>Any member of the Board of Directors, or of any committee thereof, may
participate in a meeting by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting by such means shall constitute presence in
person at such meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> <B>Notice of Special Meetings. </B>Notice of the time and place of all special meetings of the Board
of Directors shall be orally or in writing, by telephone, including a voice messaging system or other system or technology designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means,
during normal business hours, at least twenty-four (24)&nbsp;hours before the date and time of the meeting. If notice is sent by US mail, it shall be sent by first class mail, charges prepaid, at least three (3)&nbsp;days before the date of the
meeting. Notice of any meeting may be waived in writing, or by electronic transmission, at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends the meeting for the express
purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> <B>Waiver of Notice. </B>The transaction of all business at any meeting of the Board of Directors, or any committee thereof,
however called or noticed, or wherever held, shall be as valid as though it had been transacted at a meeting duly held after regular call and notice, if a quorum be present and if, either before or after the meeting, each of the directors not
present who did not receive notice shall sign a written waiver of notice or shall waive notice by electronic transmission. All such waivers shall be filed with the corporate records or made a part of the minutes of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxd40894_26"></A>Section&nbsp;22. Quorum and Voting. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> Unless the Certificate of Incorporation requires a greater number, and except with respect to questions related to indemnification
arising under<B> </B>Section&nbsp;44 for which a quorum shall be <FONT STYLE="white-space:nowrap">one-third</FONT> (1/3) of the exact number of directors fixed from time to time, a quorum of the Board of Directors shall consist of a majority of the
exact number of directors fixed from time to time by the Board of Directors in accordance with the Certificate of Incorporation; <I>provided, however,</I> at any meeting whether a quorum be present or otherwise, a majority of the directors present
may adjourn from time to time until the time fixed for the next regular meeting of the Board of Directors, without notice other than by announcement at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> At each meeting of the Board of Directors at which a quorum is present, all questions and business shall be determined by the
affirmative vote of a majority of the directors present, unless a different vote be required by law, the Certificate of Incorporation or these Bylaws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_27"></A><B>Section</B><B></B><B>&nbsp;23.</B> <B>Action </B><B>Without</B><B>
Meeting</B><B>.</B> Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if
all members of the Board of Directors or committee, as the case may be, consent thereto in writing or by electronic transmission, and such writing or writings or transmission or transmissions are filed with the minutes of proceedings of the Board of
Directors or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_28"></A><B>Section</B><B></B><B>&nbsp;24.</B> <B>Fees and Compensation</B><B>.</B> Directors
shall be entitled to such compensation for their services as may be approved by the Board of Directors, including, if so approved, by resolution of the Board of Directors, a fixed sum and expenses of attendance, if any, for attendance at each
regular or special meeting of the Board of Directors and at any meeting of a committee of the Board of Directors. Nothing herein contained shall be construed to preclude any director from serving the corporation in any other capacity as an officer,
agent, employee, or otherwise and receiving compensation therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxd40894_29"></A>Section&nbsp;25. Committees. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Executive Committee.</B> The Board of Directors may appoint an Executive Committee to consist of one (1)&nbsp;or more members of
the Board of Directors. The Executive Committee, to the extent permitted by law and provided in the resolution of the Board of Directors shall have and may exercise all the powers and authority of the Board of Directors in the management of the
business and affairs of the corporation, and may authorize the seal of the corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority in reference to (i)&nbsp;approving or adopting, or
recommending to the stockholders, any action or matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval, or (ii)&nbsp;adopting, amending or repealing any Bylaw of the
corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Other Committees.</B> The Board of Directors may, from time to time, appoint such other committees as may be
permitted by law. Such other committees appointed by the Board of Directors shall consist of one (1)&nbsp;or more members of the Board of Directors and shall have such powers and perform such duties as may be prescribed by the resolution or
resolutions creating such committees, but in no event shall any such committee have the powers denied to the Executive Committee in these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Term.</B> The Board of Directors, subject to any requirements of any outstanding series of Preferred Stock and the provisions of
subsections&nbsp;(a) or (b)&nbsp;of this Section&nbsp;25, may at any time increase or decrease the number of members of a committee or terminate the existence of a committee. The membership of a committee member shall terminate on the date of his or
her death or voluntary resignation from the committee or from the Board of Directors. The Board of Directors may at any time for any reason remove any individual committee member and the Board of Directors may fill any committee vacancy created by
death, resignation, removal or increase in the number of members of the committee. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of
the committee, and, in addition, in the absence or disqualification of any member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously
appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B>
<B>Meetings.</B> Unless the Board of Directors shall otherwise provide, regular meetings of the Executive Committee or any other committee appointed pursuant to this Section&nbsp;25 shall be held at such times and places as are determined by the
Board of Directors, or by any such committee, and when notice thereof has been given to each member of such committee, no further notice of such regular meetings need be given thereafter. Special meetings of any such committee may be held at any
place which has been determined from time to time by such committee, and may be called by any Director<B> </B>who is a member of such committee, upon notice to the members of such committee of the time and place of such special meeting given in the
manner provided for the giving of notice to members of the Board of Directors of the time and place of special meetings of the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Notice of any special meeting of any committee may be waived in writing or by electronic transmission at any time before or after the meeting and will be waived by any director by attendance
thereat, except when the director attends such special meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Unless otherwise
provided by the Board of Directors in the resolutions authorizing the creation of the committee, a majority of the authorized number of members of any such committee shall constitute a quorum for the transaction of business, and the act of a
majority of those present at any meeting at which a quorum is present shall be the act of such committee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_30">
</A><B>Section&nbsp;26. Lead Independent Director.</B> The Chairperson of the Board of Directors, or if the Chairperson is not an independent director, one of the independent directors, may be designated by the Board of Directors as lead independent
director to serve until replaced by the Board of Directors (&#147;Lead Independent Director&#148;). The Lead Independent Director will: serve as chairperson of Board of Directors meetings in the absence of the Chairperson of the Board of Directors;
establish the agenda for meetings of the independent directors; coordinate with the committee chairs regarding meeting agendas and informational requirements; preside over meetings of the independent directors; preside over any portions of meetings
of the Board of Directors at which the evaluation or compensation of the Chief Executive Officer is presented or discussed; preside over any portions of meetings of the Board of Directors at which the performance of the Board of Directors is
presented or discussed; and coordinate the activities of the other independent directors and perform such other duties as may be established or delegated by the Chairperson of the Board of Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_31"></A><B>Section</B><B></B><B>&nbsp;27.</B> <B>Organization</B><B>.</B> At every meeting
of the directors, the Chairperson of the Board of Directors, or, if a Chairperson has not been appointed or is absent, the Lead Independent Director, or if the Lead Independent Director is absent<B>,</B> the Chief Executive Officer (if a director),
or, if a Chief Executive Officer is absent, the President (if a director), or if the President is absent, the most senior Vice President (if a director), or, in the absence of any such person, a chairperson of the meeting chosen by a majority of the
directors present, shall preside over the meeting. The Secretary, or in his or her absence, any Assistant Secretary or other officer or director or other person directed to do so by the Chairperson of the Board, the Lead Independent Director or the
President, shall act as secretary of the meeting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxd40894_32"></A>ARTICLE V </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_33"></A><B>Section</B><B></B><B>&nbsp;28.</B> <B>Officers Designated</B><B>.</B> The
officers of the corporation shall include, if and when designated by the Board of Directors, the Chief Executive Officer, the President, one or more Vice Presidents, the Secretary, the Chief Financial Officer and the Treasurer. The Board of
Directors may also appoint one or more Assistant Secretaries and Assistant Treasurers and such other officers and agents with such powers and duties as it shall deem necessary. The Board of Directors may assign such additional titles to one or more
of the officers as it shall deem appropriate. Any one person may hold any number of offices of the corporation at any one time unless specifically prohibited therefrom by law. The salaries and other compensation of the officers of the corporation
shall be fixed by or in the manner designated by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="anxd40894_34"></A>Section&nbsp;29. Tenure And Duties Of Officers. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>General.</B> All officers shall hold office at the pleasure of the Board of Directors and until their successors shall have been
duly elected and qualified, unless sooner removed. Any officer elected or appointed by the Board of Directors may be removed at any time by the Board of Directors. If the office of any officer becomes vacant for any reason, the vacancy may be filled
by the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Duties of Chief Executive Officer.</B> The Chief Executive Officer shall
preside at all meetings of the stockholders (subject to Section&nbsp;14) and at all meetings of the Board of Directors, unless the Chairperson of the Board of Directors or the Lead Independent Director has been appointed and is present. Unless an
officer has been appointed Chief Executive Officer of the corporation, the President shall be the chief executive officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control
of the business and officers of the corporation. To the extent that a Chief Executive Officer has been appointed and no President has been appointed, all references in these Bylaws to the President shall be deemed references to the Chief Executive
Officer. <B></B>The Chief Executive Officer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Duties of President.</B> The President shall preside at all meetings of the stockholders (subject to Section&nbsp;14) and at all
meeting of the Board of Directors<B>, </B>unless the Chairperson of the Board of Directors, the Lead Independent Director, or the Chief Executive Officer has been appointed and is present. Unless another officer has been appointed Chief Executive
Officer of the corporation, the President shall be the chief executive officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business and officers of the
corporation.<B> </B>The President shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> <B>Duties of Vice Presidents.</B> The Vice Presidents may assume and perform the duties of the President in the absence or
disability of the President or whenever the office of President is vacant. The Vice Presidents shall perform other duties commonly incident to their office and shall also perform such other duties and have such other powers as the Board of Directors
or the Chief Executive Officer, or, if the Chief Executive Officer has not been appointed or is absent, the President shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> <B>Duties of Secretary.</B> The Secretary shall attend all meetings of the stockholders and of the Board of Directors and shall
record all acts and proceedings thereof in the minute book of the corporation. The Secretary shall give notice in conformity with these Bylaws of all meetings of the stockholders and of all meetings of the Board of Directors and any committee
thereof requiring notice. The Secretary shall perform all other duties provided for in these Bylaws and other duties commonly incident to the office and shall also perform such other duties and have such other powers, as the Board of Directors shall
designate from time to time. The President may direct any Assistant Secretary or other officer to assume and perform the duties of the Secretary in the absence or disability of the Secretary, and each Assistant Secretary shall perform other duties
commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B> <B>Duties of Chief Financial Officer.</B> The Chief Financial Officer shall keep or cause to be kept the books of account of the
corporation in a thorough and proper manner and shall render statements of the financial affairs of the corporation in such form and as often as required by the Board of Directors or the President. The Chief Financial Officer, subject to the order
of the Board of Directors, shall have the custody of all funds and securities of the corporation. The Chief Financial Officer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other
powers as the Board of Directors or the President shall designate from time to time. To the extent that a Chief Financial Officer has been appointed and no Treasurer has been appointed, all references in these Bylaws to the Treasurer shall be deemed
references to the Chief Financial Officer. <B></B>The President may direct the Treasurer, if any, or any Assistant Treasurer, or the Controller or any Assistant Controller to assume and perform the duties of the Chief Financial Officer in the
absence or disability of the Chief Financial Officer, and each Treasurer and Assistant Treasurer and each Controller and Assistant Controller shall perform other duties commonly incident to the office and shall also perform such other duties and
have such other powers as the Board of Directors or the President shall designate from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g)</B> <B>Duties of Treasurer.</B> Unless another officer has been appointed Chief
Financial Officer of the corporation, the Treasurer shall be the chief financial officer of the corporation and shall keep or cause to be kept the books of account of the corporation in a thorough and proper manner and shall render statements of the
financial affairs of the corporation in such form and as often as required by the Board of Directors or the President, and, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the corporation.<B>
</B>The Treasurer shall perform other duties commonly incident to the office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_35"></A><B>Section</B><B></B><B>&nbsp;30.</B> <B>Delegation </B><B>Of</B><B>
Authority</B><B>.</B> The Board of Directors may from time to time delegate the powers or duties of any officer to any other officer or agent, notwithstanding any provision hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_36"></A><B>Section</B><B></B><B>&nbsp;31.</B> <B>Resignations</B><B>.</B> Any officer may
resign at any time by giving notice in writing or by electronic transmission to the Board of Directors or to the President or to the Secretary. Any such resignation shall be effective when received by the person or persons to whom such notice is
given, unless a later time is specified therein, in which event the resignation shall become effective at such later time. Unless otherwise specified in such notice, the acceptance of any such resignation shall not be necessary to make it effective.
Any resignation shall be without prejudice to the rights, if any, of the corporation under any contract with the resigning officer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_37"></A><B>Section</B><B></B><B>&nbsp;32.</B> <B>Removal</B><B>.</B> Any officer may be
removed from office at any time, either with or without cause, by the affirmative vote of a majority of the directors in office at the time, or by the unanimous written consent of the directors in office at the time, or by any committee or by the
Chief Executive Officer or by other superior officers upon whom such power of removal may have been conferred by the Board of Directors. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxd40894_38"></A>ARTICLE VI </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTION OF CORPORATE INSTRUMENTS AND VOTING OF SECURITIES OWNED BY THE CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_39"></A><B>Section</B><B></B><B>&nbsp;33.</B> <B>Execution </B><B>Of</B><B> Corporate
Instruments</B><B>.</B> The Board of Directors may, in its discretion, determine the method and designate the signatory officer or officers, or other person or persons, to execute on behalf of the corporation any corporate instrument or document, or
to sign on behalf of the corporation the corporate name without limitation, or to enter into contracts on behalf of the corporation, except where otherwise provided by law or these Bylaws, and such execution or signature shall be binding upon the
corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All checks and drafts drawn on banks or other depositaries on funds to the credit of the corporation or in special accounts
of the corporation shall be signed by such person or persons as the Board of Directors shall authorize so to do. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless authorized or
ratified by the Board of Directors or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the corporation by any contract or engagement or to pledge its credit or to render it liable for any
purpose or for any amount. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_40"></A><B>Section</B><B></B><B>&nbsp;34.</B> <B>Voting Of
Securities Owned By </B><B>The</B><B> Corporation</B><B>.</B> All stock and other securities of other corporations owned or held by the corporation for itself, or for other parties in any capacity, shall be voted, and all proxies with respect
thereto shall be executed, by the person authorized so to do by resolution of the Board of Directors, or, in the absence of such authorization, by the Chairperson of the Board of Directors, the Chief Executive Officer, the President, or any Vice
President. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxd40894_41"></A>ARTICLE VII </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARES OF STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_42"></A><B>Section</B><B></B><B>&nbsp;35.</B> <B>Form </B><B>And</B><B> Execution Of
Certificates</B><B>.</B> The shares of the corporation shall be represented by certificates, or shall be uncertificated. Certificates for the shares of stock, if any, of the corporation shall be in such form<B> </B>as is consistent with the
Certificate of Incorporation and applicable law. Every holder of stock represented by certificate<B> </B>in the corporation shall be entitled to have a certificate signed by or in the name of the corporation by the Chairperson of the Board of
Directors, or the President or any Vice President and by the Treasurer or Assistant Treasurer or the Secretary or Assistant Secretary, certifying the number of shares owned by him in the corporation. Any or all of the signatures on the certificate
may be facsimiles. In case any officer, transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued,
it may be issued with the same effect as if he were such officer, transfer agent, or registrar at the date of issue. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_43"></A><B>Section</B><B></B><B>&nbsp;36.</B> <B>Lost Certificates</B><B>.</B> A new
certificate or certificates shall be issued in place of any certificate or certificates theretofore issued by the corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the
certificate of stock to be lost, stolen, or destroyed. The corporation may require, as a condition precedent to the issuance of a new certificate or certificates, the owner of such lost, stolen, or destroyed certificate or certificates, or the
owner&#146;s legal representative, to agree to indemnify the corporation in such manner as it shall require or to give the corporation a surety bond in such form and amount as it may direct as indemnity against any claim that may be made against the
corporation with respect to the certificate alleged to have been lost, stolen, or destroyed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_44">
</A><B>Section&nbsp;37. Transfers.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> Transfers of record of shares of stock of the corporation shall be made only upon its
books by the holders thereof, in person or by attorney duly authorized, and, in the case of stock represented by certificate, upon the surrender of a properly endorsed certificate or certificates for a like number of shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> The corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes
of stock of the corporation to restrict the transfer of shares of stock of the corporation of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_45"></A><B>Section&nbsp;38. Fixing Record Dates.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of
stockholders or any adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall,
subject to applicable law, not be more than sixty (60)&nbsp;nor less than ten (10)&nbsp;days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or
to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A
determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <I>provided, however,</I> that the Board of Directors may fix a new record date for the adjourned
meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> In order that the corporation may determine the stockholders entitled to receive payment of any
dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix,
in advance, a record date, which record date shall not precede the date upon which the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
resolution fixing the record date is adopted, and which record date shall be not more than sixty (60)&nbsp;days prior to such action. If no record date is fixed, the record date for determining
stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_46"></A><B>Section</B><B></B><B>&nbsp;39.</B> <B>Registered Stockholders</B><B>.</B> The
corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or
interest in such share or shares on the part of any other person whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxd40894_47"></A>ARTICLE VIII </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER SECURITIES OF THE CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_48"></A><B>Section</B><B></B><B>&nbsp;40.</B> <B>Execution </B><B>Of</B><B> Other
Securities</B><B>.</B> All bonds, debentures and other corporate securities of the corporation, other than stock certificates (covered in Section&nbsp;35), may be signed by the Chairperson of the Board of Directors, the President or any Vice
President, or such other person as may be authorized by the Board of Directors, and the corporate seal impressed thereon or a facsimile of such seal imprinted thereon and attested by the signature of the Secretary or an Assistant Secretary, or the
Chief Financial Officer or Treasurer or an Assistant Treasurer; <I>provided, however,</I> that where any such bond, debenture or other corporate security shall be authenticated by the manual signature, or where permissible facsimile signature, of a
trustee under an indenture pursuant to which such bond, debenture or other corporate security shall be issued, the signatures of the persons signing and attesting the corporate seal on such bond, debenture or other corporate security may be the
imprinted facsimile of the signatures of such persons. Interest coupons appertaining to any such bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be signed by the Treasurer or an Assistant Treasurer of the
corporation or such other person as may be authorized by the Board of Directors, or bear imprinted thereon the facsimile signature of such person. In case any officer who shall have signed or attested any bond, debenture or other corporate security,
or whose facsimile signature shall appear thereon or on any such interest coupon, shall have ceased to be such officer before the bond, debenture or other corporate security so signed or attested shall have been delivered, such bond, debenture or
other corporate security nevertheless may be adopted by the corporation and issued and delivered as though the person who signed the same or whose facsimile signature shall have been used thereon had not ceased to be such officer of the corporation.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxd40894_49"></A>ARTICLE IX </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIVIDENDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_50"></A><B>Section</B><B></B><B>&nbsp;41.</B> <B>Declaration </B><B>Of</B><B>
Dividends</B><B>.</B> Dividends upon the capital stock of the corporation, subject to the provisions of the Certificate of Incorporation and applicable law, if any, may be declared by the Board of Directors pursuant to law at any regular or special
meeting. Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of the Certificate of Incorporation and applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_51"></A><B>Section</B><B></B><B>&nbsp;42.</B> <B>Dividend Reserve</B><B>.</B> Before payment
of any dividend, there may be set aside out of any funds of the corporation available for dividends such sum or sums as the Board of Directors from time to time, in their absolute discretion, think proper as a reserve or reserves to meet
contingencies, or for equalizing dividends, or for repairing or maintaining any property of the corporation, or for such other purpose as the Board of Directors shall think conducive to the interests of the corporation, and the Board of Directors
may modify or abolish any such reserve in the manner in which it was created. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxd40894_52"></A>ARTICLE X </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FISCAL YEAR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_53"></A><B>Section</B><B></B><B>&nbsp;43.</B> <B>Fiscal Year</B><B>.</B> The fiscal year of
the corporation shall be fixed by resolution of the Board of Directors. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxd40894_54"></A>ARTICLE XI </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_55"></A><B>Section&nbsp;44. Indemnification of Directors, Executive Officers, Other
Officers, Employees and Other Agents.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Directors</B><B> </B><B>and Executive Officers</B><B>. </B>The corporation shall
indemnify its directors and executive officers (for the purposes of this Article&nbsp;XI, &#147;executive officers&#148; shall have the meaning defined in Rule <FONT STYLE="white-space:nowrap">3b-7</FONT> promulgated under the 1934 Act)<B> </B>to
the extent not prohibited by the DGCL or any other applicable law; <I>provided, however,</I> that the corporation may modify the extent of such indemnification by individual contracts with its directors and executive officers; and, <I>provided,
further,</I> that the corporation shall not be required to indemnify any director or executive officer in connection with any proceeding (or part thereof) initiated by such person unless (i)&nbsp;such indemnification is expressly required to be made
by law, (ii)&nbsp;the proceeding was authorized by the Board of Directors of the corporation, (iii)&nbsp;such indemnification is provided by the corporation, in its sole discretion, pursuant to the powers vested in the corporation under the DGCL or
any other applicable law or (iv)&nbsp;such indemnification is required to be made under subsection (d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Other
Officers,</B><B> </B><B>Employees and Other Agents.</B> The corporation shall have power to indemnify its other officers, employees and other agents as set forth in the DGCL or any other applicable law. The Board of Directors shall have the power to
delegate the determination of whether indemnification shall be given to any such person to such officers or other persons as the Board of Directors shall determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Expenses.</B> The corporation shall advance to any person who was or is a party or is threatened to be made a party to any
threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was a director or executive officer, of the corporation, or is or was serving at the request
of the corporation as a director or executive officer of another corporation, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request therefor, all expenses incurred by any
director or executive officer<B> </B>in connection with such proceeding provided, however, that if the DGCL requires, an advancement of expenses incurred by a director or executive officer<B> </B>in his or her capacity as a director or executive
officer<B> </B>(and not in any other capacity in which service was or is rendered by such indemnitee, including, without limitation, service to an employee benefit plan) shall be made only upon delivery to the corporation of an undertaking
(hereinafter an &#147;undertaking&#148;), by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal (hereinafter a &#147;final
adjudication&#148;) that such indemnitee is not entitled to be indemnified for such expenses under this section or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing, unless otherwise determined pursuant to paragraph&nbsp;(e) of this section, no advance shall be made by the
corporation to an executive officer of the corporation (except by reason of the fact that such executive officer is or was a director of the corporation in which event this paragraph shall not apply) in any action, suit or proceeding, whether civil,
criminal, administrative or investigative, if a determination is reasonably and promptly made (i)&nbsp;by a majority vote of directors who were not parties to the proceeding, even if not a quorum, or (ii)&nbsp;by a committee of such directors
designated by a majority vote of such directors, even though less than a quorum, or (iii)&nbsp;if there are no such directors, or such directors so direct, by independent legal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
counsel in a written opinion, that the facts known to the decision-making party at the time such determination is made demonstrate clearly and convincingly that such person acted in bad faith or
in a manner that such person did not believe to be in or not opposed to the best interests of the corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> <B>Enforcement.
</B>Without the necessity of entering into an express contract, all rights to indemnification and advances to directors and executive officers under this Bylaw shall be deemed to be contractual rights and be effective to the same extent and as if
provided for in a contract between the corporation and the director or executive officer. Any right to indemnification or advances granted by this section to a director or executive officer shall be enforceable by or on behalf of the person holding
such right in any court of competent jurisdiction if (i)&nbsp;the claim for indemnification or advances is denied, in whole or in part, or (ii)&nbsp;no disposition of such claim is made within ninety (90)&nbsp;days of request therefor. To the extent
permitted by law, the claimant in such enforcement action, if successful in whole or in part, shall be entitled to be paid also the expense of prosecuting the claim. In connection with any claim for indemnification, the corporation shall be entitled
to raise as a defense to any such action that the claimant has not met the standards of conduct that make it permissible under the DGCL or any other applicable law for the corporation to indemnify the claimant for the amount claimed. Neither the
failure of the corporation (including its Board of Directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances
because he has met the applicable standard of conduct set forth in the DGCL or any other applicable law, nor an actual determination by the corporation (including its Board of Directors, independent legal counsel or its stockholders) that the
claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that claimant has not met the applicable standard of conduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> <B><FONT STYLE="white-space:nowrap">Non-Exclusivity</FONT> of Rights. </B>The rights conferred on any person by this Bylaw shall
not be exclusive of any other right which such person may have or hereafter acquire under any applicable statute, provision of the Certificate of Incorporation, Bylaws, agreement, vote of stockholders or disinterested directors or otherwise, both as
to action in his or her official capacity and as to action in another capacity while holding office. The corporation is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents
respecting indemnification and advances, to the fullest extent not prohibited by the DGCL, or by any other applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B>
<B>Survival of Rights. </B>The rights conferred on any person by this Bylaw shall continue as to a person who has ceased to be a director<B> </B>or executive officer<B> </B>and shall inure to the benefit of the heirs, executors and administrators of
such a person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g)</B> <B>Insurance. </B>To the fullest extent permitted by the DGCL or any other applicable law, the corporation,
upon approval by the Board of Directors, may purchase insurance on behalf of any person required or permitted to be indemnified pursuant to this section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(h)</B> <B>Amendments. </B>Any repeal or modification of this section shall only be prospective and shall not affect the rights under this
Bylaw in effect at the time of the alleged occurrence of any action or omission to act that is the cause of any proceeding against any agent of the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> <B>Saving Clause. </B>If this Bylaw or any portion hereof shall be invalidated on any ground by any court of competent
jurisdiction, then the corporation shall nevertheless indemnify each director and executive officer to the full extent not prohibited by any applicable portion of this section that shall not have been invalidated, or by any other applicable law. If
this section shall be invalid due to the application of the indemnification provisions of another jurisdiction, then the corporation shall indemnify each director and executive officer<B> </B>to the full extent under any other applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(j)</B> <B>Certain Definitions. </B>For the purposes of this Bylaw, the following definitions shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> The term &#147;proceeding&#148; shall be broadly construed and shall include, without limitation, the investigation, preparation,
prosecution, defense, settlement, arbitration and appeal of, and the giving of testimony </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> The term &#147;expenses&#148; shall be broadly construed and shall include, without limitation, court costs, attorneys&#146; fees,
witness fees, fines, amounts paid in settlement or judgment and any other costs and expenses of any nature or kind incurred in connection with any proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> The term the &#147;corporation&#148; shall include, in addition to the resulting corporation, any constituent corporation
(including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person
who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture,
trust or other enterprise, shall stand in the same position under the provisions of this section with respect to the resulting or surviving corporation as he would have with respect to such constituent corporation if its separate existence had
continued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B> References to a &#147;director,&#148; &#147;executive officer,&#148; &#147;officer,&#148; &#147;employee,&#148; or
&#147;agent&#148; of the corporation shall include, without limitation, situations where such person is serving at the request of the corporation as, respectively, a director, executive officer, officer, employee, trustee or agent of another
corporation, partnership, joint venture, trust or other enterprise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v)</B> References to &#147;other enterprises&#148; shall include
employee benefit plans; references to &#147;fines&#148; shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to &#147;serving at the request of the corporation&#148; shall include any service
as a director, officer, employee or agent of the corporation which imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit plan, its participants, or beneficiaries; and a person who
acted in good faith and in a manner he reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner &#147;not opposed to the best interests of the
corporation&#148; as referred to in this section. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxd40894_56"></A>ARTICLE XII </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_57"></A><B>Section&nbsp;45. Notices.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Notice To Stockholders. </B>Written notice to stockholders of stockholder meetings shall be given as provided in Section&nbsp;7
herein. Without limiting the manner by which notice may otherwise be given effectively to stockholders under any agreement or contract with such stockholder, and except as otherwise required by law, written notice to stockholders for purposes other
than stockholder meetings may be sent by US mail or nationally recognized overnight courier, or by facsimile, telegraph or telex or by electronic mail or other electronic means. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Notice To Directors. </B>Any notice required to be given to any director may be given by the method stated in
subsection&nbsp;(a), as otherwise provided in these Bylaws, or by overnight delivery service, facsimile, telex or telegram, except that such notice other than one which is delivered personally shall be sent to such address as such director shall
have filed in writing with the Secretary, or, in the absence of such filing, to the last known post office address of such director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Affidavit Of Mailing. </B>An affidavit of mailing, executed by a duly authorized and competent employee of the corporation or
its transfer agent appointed with respect to the class of stock affected, or other agent, specifying the name and address or the names and addresses of the stockholder or stockholders, or director or directors, to whom any such notice or notices was
or were given, and the time and method of giving the same, shall in the absence of fraud, be prima facie evidence of the facts therein contained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> <B>Methods of Notice. </B>It shall not be necessary that the same method of
giving notice be employed in respect of all recipients of notice, but one permissible method may be employed in respect of any one or more, and any other permissible method or methods may be employed in respect of any other or others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> <B>Notice To Person With Whom Communication Is Unlawful. </B>Whenever notice is required to be given, under any provision of law or
of the Certificate of Incorporation or Bylaws of the corporation, to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to any governmental authority or
agency for a license or permit to give such notice to such person. Any action or meeting which shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had
been duly given. In the event that the action taken by the corporation is such as to require the filing of a certificate under any provision of the DGCL, the certificate shall state, if such is the fact and if notice is required, that notice was
given to all persons entitled to receive notice except such persons with whom communication is unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B> <B>Notice to
Stockholders Sharing an Address. </B>Except as otherwise prohibited under DGCL, any notice given under the provisions of DGCL, the Certificate of Incorporation or the Bylaws shall be effective if given by a single written notice to stockholders who
share an address if consented to by the stockholders at that address to whom such notice is given. Such consent shall have been deemed to have been given if such stockholder fails to object in writing to the corporation within sixty (60)&nbsp;days
of having been given notice by the corporation of its intention to send the single notice. Any consent shall be revocable by the stockholder by written notice to the corporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxd40894_58"></A>ARTICLE XIII </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_59"></A><B>Section</B><B></B><B>&nbsp;46.</B> <B>Amendments. </B>Subject to the limitations
set forth in Section&nbsp;44(h) of these Bylaws or the provisions of the Certificate of Incorporation, the Board of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the corporation. The stockholders also shall have power to
adopt, amend or repeal the Bylaws of the corporation; <I>provided, however, </I>that, in addition to any vote of the holders of any class or series of stock of the corporation required by law or by the Certificate of Incorporation, such action by
stockholders shall require the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">sixty-six</FONT> and <FONT STYLE="white-space:nowrap">two-thirds</FONT> percent (66 2/3%) of the voting power of all of the then-outstanding
shares of the capital stock of the corporation entitled to vote generally in the election of directors, voting together as a single class. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="anxd40894_60"></A>ARTICLE XIV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LOANS TO OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A NAME="anxd40894_61"></A><B>Section&nbsp;47. Loans To Officers. EXCEPT AS OTHERWISE PROHIBITED BY APPLICABLE
LAW, THE CORPORATION MAY LEND MONEY TO, OR GUARANTEE </B><B>ANY OBLIGATION OF, OR OTHERWISE ASSIST ANY OFFICER OR OTHER EMPLOYEE OF THE CORPORATION OR OF ITS SUBSIDIARIES, INCLUDING ANY OFFICER OR EMPLOYEE WHO IS A DIRECTOR OF THE CORPORATION OR ITS
SUBSIDIARIES, WHENEVER, IN THE JUDGMENT OF THE BOARD OF DIRECTORS, SUCH LOAN, GUARANTEE OR ASSISTANCE MAY REASONABLY BE EXPECTED TO BENEFIT THE CORPORATION. THE LOAN, GUARANTEE OR OTHER ASSISTANCE MAY BE WITH OR WITHOUT INTEREST AND MAY BE
UNSECURED, OR SECURED IN SUCH MANNER AS THE BOARD OF DIRECTORS SHALL APPROVE, INCLUDING, WITHOUT LIMITATION,</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
<B>A PLEDGE OF SHARES OF STOCK OF THE CORPORATION. NOTHING IN THESE BYLAWS SHALL BE DEEMED TO DENY, LIMIT OR RESTRICT THE POWERS OF GUARANTY OR WARRANTY OF THE CORPORATION AT COMMON LAW OR UNDER
ANY STATUTE.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF SECRETARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>I hereby certify that: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">I am the duly elected and acting Secretary of <B>Surrozen, Inc.</B>, a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Attached hereto is a complete and accurate copy of the Bylaws of the Company as duly adopted by the Board of Directors of the Company by
Unanimous Written Consent dated<B> </B>[____________], 2021 and said Bylaws are presently in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This Certificate of Secretary may be
executed via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and will be deemed to
have been duly and validly delivered and be valid and effective for all purposes. Signed on [____________], 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Secretary</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="annex_e"></A><A NAME="rom40894_254"></A>ANNEX E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPONSOR LETTER AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This SPONSOR LETTER AGREEMENT (this &#147;<B>Agreement</B>&#148;), dated as of April [&#9679;], 2021, is made by and among <FONT
STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., a Cayman Islands exempted company (&#147;<B>CHFW</B>&#148;), Consonance Life Sciences, a Cayman Islands exempted company (the &#147;<B>Sponsor</B>&#148;), the other holders of CHFW
Class&nbsp;B ordinary shares set forth on&nbsp;the signature page hereto (the &#147;<B>Founders</B>&#148;, and together with the Sponsor, collectively, the &#147;<B>CHFW Shareholders</B>&#148;), and Surrozen, Inc., a Delaware corporation (the
&#147;<B>Company</B>&#148;). CHFW, the CHFW Shareholders and the Company shall be referred to herein from time to time collectively as the &#147;<B>Parties</B>&#148;. Capitalized terms used herein and not otherwise defined will have the meaning
given such terms in the Business Combination Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, CHFW, the Company and certain other persons party
thereto entered into that certain Business Combination Agreement, dated as of the date hereof (as it may be amended, restated or otherwise modified from time to time in accordance with its terms, the &#147;<B>Business Combination
Agreement</B>&#148;) providing for the merger of a subsidiary of CHFW with and into the Company, with the Company surviving as the surviving corporation in such merger (the &#147;<B>Merger</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, as of the date hereof and in any event prior to the Merger and the Closing, the Sponsor has agreed to forfeit 759,000 CHFW
Class&nbsp;B Shares (the &#147;Forfeited Shares&#148;) so that immediately prior to the Effective Time and the Closing, the Sponsor shall be the holder of record and the &#147;beneficial owner&#148; (within the meaning of Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of 1,451,000 CHFW Class&nbsp;B Shares, 434,000 CHFW Class&nbsp;A Shares and 144,667 IPO Warrants in the aggregate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, (i)&nbsp;the Sponsor is the record and beneficial owner of the number of CHFW Class&nbsp;A Shares and CHFW Class&nbsp;B Shares as set
forth on Schedule I hereto and (ii)&nbsp;each Founder is the record and beneficial owner of the number of CHFW Class&nbsp;B Shares, as set forth on Schedule I hereto (in each case, together with any other Equity Securities of CHFW that such CHFW
Shareholder holds of record or beneficially, as of the date of this Agreement, or acquires record or beneficial ownership after the date hereof, collectively, the &#147;<B>Subject CHFW Equity Securities</B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, the Business Combination Agreement contemplates that the Parties will enter into this Agreement concurrently with the entry into the
Business Combination Agreement by the parties thereto, pursuant to which, among other things, (a)&nbsp;the CHFW Shareholders will vote in favor of approval of the Business Combination Agreement and the transactions contemplated thereby (including
the Domestication and the Merger) and (b)&nbsp;the CHFW Shareholders will agree to waive any adjustment to the conversion ratio set forth in the Governing Documents of CHFW or any other anti-dilution or similar protection with respect to all of the
CHFW Class&nbsp;B Shares related to the transactions contemplated by the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NOW, THEREFORE, in consideration
of the premises and the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. <U>Agreement to Vote</U>.&nbsp;Each CHFW Shareholder hereby agrees to (i)&nbsp;appear (in person or by proxy) at any meeting of the
shareholders of CHFW and (ii)&nbsp;vote (in person or by proxy) at any such meeting, and in any action by written resolution of the shareholders of CHFW, all of such CHFW Shareholder&#146;s Subject CHFW Equity Securities in favor of (A)&nbsp;each of
the Transaction Proposals to be submitted to the holders of CHFW ordinary shares in connection with the Merger and the other transactions contemplated by the Business Combination Agreement and (B)&nbsp;such other resolutions upon which a consent or
other approval is required under CHFW&#146;s amended and restated memorandum and articles of association, law, securities exchange or otherwise is sought with respect to effecting the Business Combination Agreement and the Merger, and (ii)&nbsp;vote
(in person or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
by proxy) against any merger, purchase of all or substantially all of a third party (other than the Merger) or all of the assets of a third party or other business combination transaction with a
third party (other than the Business Combination Agreement and the Merger) (a &#147;<B>Competing Transaction</B>&#148;) or any proposal relating to a Competing Transaction and against any proposal, action or agreement that would (A)&nbsp;impede,
frustrate, prevent or nullify any provision of this Agreement, the Business Combination Agreement or any Merger, (B)&nbsp;result in a breach in any respect of any covenant, representation, warranty or any other obligation or agreement of CHFW or
Perseverance Merger Sub Inc. under the Business Combination Agreement, (C)&nbsp;result in any of the conditions set forth in Article VI of the Business Combination Agreement not being fulfilled or (D)&nbsp;change in any manner the dividend policy or
capitalization of, including the voting rights of any class of capital stock of, CHFW (other than the Transaction Proposals). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each CHFW
Shareholder hereby agrees that it shall not commit or agree to take any action inconsistent with the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. <U>Waiver of
Anti-dilution Protection</U>. Each CHFW Shareholder hereby (a)&nbsp;waives, subject to, and conditioned upon, the occurrence of the Closing (for himself, herself or itself and for his, her or its, successors, heirs and assigns), to the fullest
extent permitted by law and the Amended and Restated Memorandum and Articles of Association of CHFW, and (b)&nbsp;agrees not to assert or perfect, any rights to adjustment or other anti-dilution protections with respect to the rate that the CHFW
Class&nbsp;B Shares held by him, her or it convert into CHFW Class&nbsp;A Shares in connection with the transactions contemplated by the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. <U>Forfeiture</U>. The Sponsor agrees that, in connection with the Business Combination Agreement and the transactions contemplated
thereby, the Forfeited Shares are hereby forfeited as of immediately prior to the Effective Time, such shares shall no longer be outstanding, and the Sponsor shall have no further rights with respect to the Forfeited Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. <U>Transfer of Shares</U>. Each CHFW Shareholder hereby agrees that he, she or it shall not, directly or indirectly, (i)&nbsp;sell, assign,
transfer (including by operation of law), place a lien on, pledge, dispose of or otherwise encumber any of its Subject CHFW Equity Securities or otherwise agree to do any of the foregoing (each, a &#147;<B>Transfer</B>&#148;), (ii) deposit any of
her, his or its Subject CHFW Equity Securities into a voting trust or enter into a voting agreement or arrangement or grant any proxy or power of attorney with respect to any of its Subject CHFW Equity Securities that conflicts with any of the
covenants or agreements set forth in this Agreement, (iii)&nbsp;enter into any contract, option or other arrangement or undertaking with respect to the direct or indirect acquisition or sale, assignment, transfer (including by operation of law) or
other disposition of any of his, her or its Subject CHFW Equity Securities, (iv)&nbsp;engage in any hedging or other transaction which is designed to, or which would (either alone or in connection with one or more events, developments or events
(including the satisfaction or waiver of any conditions precedent)), lead to or result in a sale or disposition of his, her or its Subject CHFW Equity Securities even if such Subject CHFW Equity Securities would be disposed of by a person other than
the CHFW Shareholder or (v)&nbsp;take any action that would have the effect of preventing or materially delaying the performance of its obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. <U>Further Assurances</U>. Each CHFW Shareholder shall take, or cause to be taken, all actions and do, or cause to be done, all things
reasonably necessary under applicable Laws to consummate the Merger and the other transactions contemplated by the Business Combination Agreement on the terms and subject to the conditions set forth therein and herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6. <U>No Inconsistent Agreement</U>. Each CHFW Shareholder hereby represents and covenants that such CHFW Shareholder has not entered into,
and shall not enter into, any agreement that would restrict, limit or interfere with the performance of such CHFW Shareholder&#146;s obligations hereunder </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7. <U>CHFW Shareholder Representations and Warranties</U>. The CHFW Shareholder represents
and warrants to CHFW and the Company as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. The CHFW Shareholder is a corporation, limited liability company or
other applicable business entity duly organized or formed, as applicable, validly existing and in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or
any equivalent thereof) under the Laws of its jurisdiction of formation or organization (as applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b. The CHFW
Shareholder has the requisite corporate, limited liability company or other similar power and authority to execute and deliver this Agreement, to perform its covenants, agreements and obligations hereunder. The execution and delivery of this
Agreement has been duly authorized by all necessary corporate (or other similar) action on the part of the CHFW Shareholder. This Agreement has been duly and validly executed and delivered by the CHFW Shareholder and constitutes a valid, legal and
binding agreement of the CHFW Shareholder (assuming that this Agreement is duly authorized, executed and delivered by CHFW and the Company), enforceable against the CHFW Shareholder in accordance with its terms (subject to applicable bankruptcy,
insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors&#146; rights and subject to general principles of equity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c. The execution and delivery of this Agreement by such CHFW Shareholder, does not, and the performance by such CHFW
Shareholder of his, her or its obligations hereunder will not, (i)&nbsp;if such CHFW Shareholder is not an individual, conflict with or result in a violation of the organizational documents of such CHFW Shareholder or (ii)&nbsp;require any consent
or approval that has not been given or other action that has not been taken by any Person (including under any Contract binding upon such CHFW Shareholder or such CHFW Shareholder&#146;s Subject CHFW Equity Securities), in each case, to the extent
such consent, approval or other action would prevent, enjoin or materially delay the performance by such CHFW Shareholder of its, his or her obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">d. There are no proceedings pending against such CHFW Shareholder, or to the knowledge of such CHFW Shareholder threatened
against such CHFW Shareholder, before (or, in the case of threatened proceedings, that would be before) any arbitrator or any Governmental Entity, which in any manner challenges or seeks to prevent, enjoin or materially delay the performance by such
CHFW Shareholder of its, his or her obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">e. Except as described on Section&nbsp;4.4 of the
CHFW Disclosure Schedules, no broker, finder, investment banker or other Person is entitled to any brokerage fee, finders&#146; fee or other commission in connection with the transactions contemplated by the Business Combination Agreement based upon
arrangements made by such CHFW Shareholder, for which CHFW or any of its Affiliates may become liable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Such CHFW Shareholder understands
and acknowledges that each of CHFW and the Company is entering into the Business Combination Agreement in reliance upon such CHFW Shareholder&#146;s execution and delivery of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8. <U>Other Covenants</U>. Each CHFW Shareholder hereby agrees to be bound by and subject to (i)&nbsp;Sections 5.3(a) (Confidentiality) and
5.4(a) (Public Announcements) of the Business Combination Agreement to the same extent as such provisions apply to the parties to the Business Combination Agreement, as if such CHFW Shareholder is directly a party thereto, and
(ii)&nbsp;Section&nbsp;5.6(b) (Exclusive Dealing) of the Business Combination Agreement to the same extent as such provisions apply to CHFW as if such CHFW Shareholder is directly party thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9. <U>Termination</U>.&nbsp;This Agreement shall automatically terminate, without any notice or other action by any Party, and be void <I>ab
initio</I> upon the earlier of (a)&nbsp;the effective time of the Merger; and (b)&nbsp;the termination of the Business Combination Agreement in accordance with its terms. Upon termination of this Agreement as provided
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
in the immediately preceding sentence, none of the Parties shall have any further obligations or liabilities under, or with respect to, this Agreement. Notwithstanding the foregoing or anything
to the contrary in this Agreement, the termination of this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;9</U> shall not affect any liability on the part of any Party for a willful breach of any covenant or agreement set forth in this
Agreement prior to such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10. <U>No Recourse</U>.&nbsp;Except for claims pursuant to the Business Combination Agreement or any
other Ancillary Document by any party(ies) thereto against any other party(ies) thereto, each Party agrees that (a)&nbsp;this Agreement may only be enforced against, and any action for breach of this Agreement may only be made against, the Parties,
and no claims of any nature whatsoever (whether in tort, contract or otherwise) arising under or relating to this Agreement, the negotiation hereof or its subject matter, or the transactions contemplated hereby shall be asserted against any Company <FONT
STYLE="white-space:nowrap">Non-Party</FONT> Affiliate or any CHFW <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate (other than the CHFW Shareholders named as parties hereto, on the terms and subject to the conditions set forth herein),
and (b)&nbsp;none of the Company <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates or the CHFW <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates (other than the CHFW Shareholders named as parties hereto, on the terms and
subject to the conditions set forth herein) shall have any Liability arising out of or relating to this Agreement, the negotiation hereof or its subject matter, or the transactions contemplated hereby, including with respect to any claim (whether in
tort, contract or otherwise) for breach of this Agreement or in respect of any written or oral representations made or alleged to be made in connection herewith, as expressly provided herein, or for any actual or alleged inaccuracies, misstatements
or omissions with respect to any information or materials of any kind furnished in connection with this Agreement, the negotiation hereof or the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11. <U>Fiduciary Duties</U>.&nbsp;Notwithstanding anything in this Agreement to the contrary, (a)&nbsp;each CHFW Shareholder makes no
agreement or understanding herein in any capacity other than in such CHFW Shareholder&#146;s capacity as a record holder and beneficial owner of the Subject CHFW Equity Securities, and not, in the case of each Other CHFW Shareholder in such Other
CHFW Shareholder&#146;s capacity as a director, officer or employee of any CHFW Party, and (b)&nbsp;nothing herein will be construed to limit or affect any action or inaction by each Other CHFW Shareholder or any representative of the Sponsor
serving&nbsp;as a member of the board of directors (or other similar governing body) of any CHFW Party or as an officer, employee or fiduciary of any CHFW Party, in each case, acting in such person&#146;s capacity as a director, officer, employee or
fiduciary of such CHFW Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12. <U>No Third Party Beneficiaries</U>.&nbsp;This Agreement shall be for the sole benefit of the Parties
and their respective successors and permitted assigns and is not intended, nor shall be construed, to give any Person, other than the Parties and their respective successors and assigns, any legal or equitable right, benefit or remedy of any nature
whatsoever by reason this Agreement. Nothing in this Agreement, expressed or implied, is intended to or shall constitute the Parties, partners or participants in a joint venture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">13. <U>Incorporation by Reference</U>. Sections 8.1 <FONT STYLE="white-space:nowrap">(Non-Survival),</FONT> 8.2 (Entire Agreement;
Assignment), 8.3 (Amendment), 8.5 (Governing Law), 8.7 (Constructions; Interpretation), 8.10 (Severability), 8.11 (Counterparts; Electronic Signatures), 8.15 (Waiver of Jury Trial), 8.16 (Submission to Jurisdiction) and 8.17 (Remedies) of the
Business Combination Agreement are incorporated herein and shall apply to this Agreement <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">14. <U>Effect of
Headings</U>. The section headings herein are for convenience only and shall not affect the construction of interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[signature page follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, each of the Parties has caused this Agreement to
be duly executed on its behalf as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION
CORP.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">/s/ Gad Soffer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Name: Gad Soffer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Title: &nbsp;&nbsp;Chief Executive Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>SURROZEN, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">/s/ Craig Parker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Name: Craig Parker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Title: &nbsp;&nbsp;Chief Executive Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>CONSONANCE LIFE SCIENCES</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">/s/ Mitchell Blutt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Name: Mitchell Blutt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Title: &nbsp;&nbsp;Manager</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">/s/ Christopher Haqq</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Christopher Haqq</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">/s/ Jennifer Jarrett</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jennifer Jarrett</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">/s/ Donald Santel</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Donald Santel</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE I </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ownership </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="annex_f"></A><A NAME="rom40894_255"></A>ANNEX F </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNIT SUBSCRIPTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1 Palmer Square, Suite 305 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Princeton, New Jersey 08540 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This
Subscription Agreement (this &#147;Subscription Agreement&#148;) is being entered into as of the date set forth on the signature page hereto, by and among <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., a Cayman Islands
exempted company (&#147;CHFW&#148;), and the undersigned Investor (the &#147;Investor&#148;), in connection with the Business Combination Agreement, dated as of the date hereof (as may be amended, supplemented or otherwise modified from time to
time, the &#147;Merger Agreement&#148;), by and among CHFW, Surrozen, Inc., a Delaware corporation (the &#147;Company&#148;), and Perseverance Merger Sub, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of CHFW (&#147;Merger
Sub&#148;), pursuant to which, among other things, (a) Merger Sub will merge with and into the Company, with the Company as the surviving corporation of such merger (the &#147;Surviving Corporation&#148;) (such merger, the &#147;Transaction&#148;).
Prior to the closing of the Transaction (and as more fully described in the Merger Agreement), CHFW will domesticate as a Delaware corporation in accordance with Section&nbsp;388 of the General Corporation Law of the State of Delaware and Part XII
of the Cayman Islands Companies Act (2021 Revision) (the &#147;Domestication&#148;). In connection with the Transaction, CHFW is seeking commitments from interested investors to purchase, following the Domestication and prior to the closing of the
Transaction, units (&#147;Units&#148;) consisting of (a)&nbsp;one share of CHFW common stock, par value $0.0001 per share (the &#147;Common Stock&#148; and such shares to be purchased, the &#147;Shares&#148;) and
<FONT STYLE="white-space:nowrap">(b)&nbsp;one-third</FONT> of one redeemable warrant (a &#147;Warrant&#148;). The Units will be purchased in a private placement for a purchase price of $10.00 per unit (the &#147;Price Per Unit&#148;). Each whole
Warrant will entitle the holder thereof to purchase one share of Common Stock at a price of $11.50 per share, subject to adjustment and on the terms and subject to the limitations described in the warrant agreement attached as <U>Exhibit A</U>
hereto (the &#147;Warrant Agreement&#148;). The aggregate purchase price to be paid by the Investor for the subscribed Units (as set forth on the signature page hereto) is referred to herein as the &#147;Subscription Amount&#148; and the Units,
Shares, Warrants and the shares of Common Stock underlying the Warrants are referred to herein as the &#147;PIPE Securities&#148; and the Shares, Warrants and the shares of Common Stock underlying the Warrants are referred to herein as the
&#147;Listed Securities&#148;. The Units are being offered to facilitate the subscriptions, however, the Shares and the Warrants which comprise the Units are not attached and will trade separately without any instruction or detachment obligations on
the part of the Investor, CHFW or the Warrant Agent (as defined in the Warrant Agreement). Substantially concurrently with the execution of this Subscription Agreement, CHFW is entering into separate subscription agreements with certain investors
(the &#147;Other Investors,&#148; and such other subscription agreements, the &#147;Other Subscription Agreements&#148;) acquiring Units at the same Price Per Unit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection therewith, and in consideration of the foregoing and the mutual representations, warranties and covenants, and subject to the
conditions, set forth herein, and intending to be legally bound hereby, each of the Investor and CHFW acknowledges and agrees as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. <U>Subscription</U>. The Investor hereby subscribes for and agrees to purchase from CHFW, and CHFW agrees to issue and sell to the Investor,
the number of Units set forth on the signature page of this Subscription Agreement on the terms and subject to the conditions provided for herein. The Investor acknowledges and agrees that, as a result of the Domestication, the Shares that will be
issued pursuant hereto, and any shares issued upon the exercise of Warrants, shall be shares of Common Stock in a Delaware corporation (and not, for the avoidance of doubt, ordinary shares in a Cayman Islands exempted company). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. <U>Closing</U>. The closing of the sale of the Units contemplated hereby (the &#147;Closing&#148;) shall occur on the date of and
substantially concurrently with and conditioned upon the closing of the Transaction and satisfaction of the other conditions set forth in <U>Section</U><U></U><U>&nbsp;3</U> hereof (such date, the &#147;Closing Date&#148;). At least five
(5)&nbsp;business days prior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
to the anticipated Closing Date, CHFW shall deliver a written notice (the &#147;Closing Notice&#148;) to the Investor, specifying (a)&nbsp;the anticipated Closing Date and (b)&nbsp;wire
instructions for the account(s) into which the Investor shall fund the Subscription Amount. [On the Closing Date, the Investor shall deliver (i)&nbsp;the Subscription Amount by wire transfer of United States dollars in immediately available funds to
the account(s) specified by CHFW in the Closing Notice (which account shall not be an escrow account) and (ii)&nbsp;any other customary information that is reasonably requested in the Closing Notice in order for CHFW to issue the subscribed Units,
including, without limitation, the legal name of the person in whose name such Units are to be issued and a duly executed Internal Revenue Service Form <FONT STYLE="white-space:nowrap">W-9</FONT> or <FONT STYLE="white-space:nowrap">W-8,</FONT> as
applicable. On the Closing Date, CHFW shall deliver to the Investor the number of Units set forth on the signature page to this Subscription Agreement in book-entry form, free and clear of any liens or other restrictions whatsoever (other than those
set forth in this Subscription Agreement, arising under any written agreement to which the Investor is a party or arising under applicable securities laws), in the name of the Investor (or its nominee in accordance with its delivery instructions) by
causing such Units to be registered on CHFW&#146;s share register, and the Subscription Amount shall be released from escrow automatically and without further action by CHFW or the Investor.]<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> [No
later than two (2)&nbsp;business days prior to the Closing Date, the Investor shall provide CHFW information that is reasonably requested in the Closing Notice in order for CHFW to issue the Units, including, without limitation, the name of the
person in whose name such Units are to be issued (or a nominee as indicated by the Investor) and a duly executed Internal Revenue Service Form <FONT STYLE="white-space:nowrap">W-9</FONT> or <FONT STYLE="white-space:nowrap">W-8,</FONT> as applicable.
On the Closing Date, (a)&nbsp;promptly following receipt of evidence of issuance of the Units as set forth in clause (b). the Investor shall deliver the Subscription Amount by wire transfer of United States dollars in immediately available funds to
the account(s) specified by CHFW in the Closing Notice (which shall not be escrow accounts) and (b)&nbsp;CHFW shall deliver to the Investor the Units in book-entry form, free and clear of any liens or other restrictions whatsoever (other than those
set forth in this Subscription Agreement, arising under any written agreement to which the Investor is a party or arising under applicable securities laws), in the name of the Investor (or its nominee in accordance with its delivery instructions) by
causing such Units to be registered on CHFW&#146;s share register and will provide the Investor evidence of such issuance from CHFW&#146;s transfer agent.]<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> In the event the closing of the
Transaction does not occur within one (1)&nbsp;business day of the Closing Date specified in the Closing Notice, unless otherwise instructed by the Investor, CHFW shall promptly (but not later than one (1)&nbsp;business day thereafter) return the
Subscription Amount to the Investor by wire transfer of U.S. dollars in immediately available funds to the account specified by the Investor without any deduction for or on account of any tax, withholding, charges, or
<FONT STYLE="white-space:nowrap">set-off,</FONT> and any book entries shall be deemed cancelled. For purposes of this Subscription Agreement, &#147;business day&#148; shall mean a day, other than a Saturday or Sunday, on which commercial banks in
New York, New York and San Francisco, California are open for the general transaction of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. <U>Closing Conditions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. The obligations of the parties hereto to consummate the purchase and sale of the Units pursuant to this Subscription Agreement is subject
to the following conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) no suspension of the qualification of the Units for offering or sale or
trading in any jurisdiction, or initiation or threatening of any proceedings for any of such purposes, shall have occurred; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) no applicable governmental authority shall have enacted, issued, promulgated, enforced or entered any
judgment, order, law, rule or regulation (whether temporary, preliminary or permanent) which is then in effect and has the effect of making the consummation of the transactions contemplated hereby illegal or otherwise restraining or prohibiting
consummation of the transactions contemplated hereby; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) all conditions precedent to the closing of
the Transaction under the Merger Agreement shall have been satisfied or waived (as determined by the parties to the Merger Agreement and other than </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">For <FONT STYLE="white-space:nowrap">non-mutual</FONT> fund investors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">For mutual fund investors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
those conditions under the Merger Agreement which, by their nature, are to be fulfilled at the closing of the Transaction, including to the extent that any such condition is dependent upon the
consummation of the purchase and sale of the Units pursuant to this Subscription Agreement, but subject to the satisfaction or waiver of such conditions at the closing of the Transaction) and the closing of the Transaction shall occur, in accordance
with the terms of the Merger Agreement, on the Closing Date, substantially concurrently with the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b. The obligation of CHFW to
consummate the issuance and sale of the Units pursuant to this Subscription Agreement shall be subject to the conditions that (i)&nbsp;all representations and warranties of the Investor contained in this Subscription Agreement be true and correct in
all material respects when made, and be true and correct in all material respects on and as of the Closing Date (unless they specifically speak as of an earlier date in which case they shall be true and correct in all material respects as of such
date), and the Investor hereby acknowledges that the consummation of the Closing shall constitute a reaffirmation by the Investor of each of the representations and warranties of the Investor contained in this Subscription Agreement as of the
Closing Date; and (ii)&nbsp;all obligations, covenants and agreements of the Investor required to be performed by it at or prior to the Closing Date shall have been performed in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c. The obligation of the Investor to consummate the purchase of the Units pursuant to this Subscription Agreement shall be subject to the
conditions that: (i)&nbsp;all representations and warranties of CHFW contained in this Subscription Agreement shall (x)&nbsp;be true and correct in all material respects (other than representations and warranties that are qualified as to materiality
or CHFW Material Adverse Effect (as defined herein), which representations and warranties shall be true and correct in all respects) when made, and (y)&nbsp;be true and correct in all material respects on and as of the Closing Date (other than
(1)&nbsp;representations and warranties that are qualified as to materiality or CHFW Material Adverse Effect, which representations and warranties shall be true and correct in all respects on and as of the Closing Date, and (2)&nbsp;those
representations that expressly speak as of an earlier date, which shall be true and correct in all material respects (or, if qualified by materiality or CHFW Material Adverse Effect, in all respects) as of such earlier date), and CHFW hereby
acknowledges that the consummation of the Closing shall constitute a reaffirmation by CHFW of each of the representations and warranties of CHFW contained in this Subscription Agreement as of the Closing Date; (ii)&nbsp;all obligations, covenants
and agreements of CHFW required to be performed by it at or prior to the Closing Date shall have been performed in all material respects; <I><U>provided</U></I>, that, the obligations of any Investor whose Subscription Amount (together with the
subscription amounts under Other Subscription Agreements with Other Investors who are affiliates of Investor) is for an amount of at least $25&nbsp;million to consummate the purchase of the Units pursuant to this Subscription Agreement shall also be
subject to the condition that CHFW has complied in all respects with its obligations, covenants and agreements set forth in the Section&nbsp;10.p; (iii)&nbsp;no amendment, waiver or modification of the Merger Agreement (as the same exists on the
date hereof as provided to the Investor) shall have occurred that materially and adversely affects the Investor&#146;s economic benefits under this Subscription Agreement; (iv)&nbsp;assuming funding by Investor of the full Subscription Amount
hereunder, CHFW shall have received aggregate gross proceeds of not less than $120.2&nbsp;million from the issuance of Units under this Subscription Agreement and the Other Subscription Agreements; and (v)&nbsp;there shall have been no amendment,
waiver or modification to the Other Subscription Agreements that materially economically benefits the investors thereunder unless the Investor has been offered substantially the same benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. <U>Further Assurances</U>. At or prior to the Closing, the parties hereto shall execute and deliver such additional documents and take such
additional actions as the parties reasonably may deem to be practical and necessary in order to consummate the subscription as contemplated by this Subscription Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. <U>CHFW Representations and Warranties</U><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>. CHFW represents and warrants to the
Investor that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. CHFW is as of the date of this Agreement duly incorporated, validly existing and in good standing in the Cayman Islands
(to the extent such concept exists in such jurisdiction) and will be duly incorporated, validly existing and in good standing under the laws of the State of Delaware as of the Closing Date. CHFW has all </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">power (corporate or otherwise) and authority to own, lease and operate its properties and
conduct its business as presently conducted and to enter into, deliver and perform its obligations under this Subscription Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b.
As of the Closing Date, the Units will be duly authorized and, when issued and delivered to the Investor in exchange for the Subscription Amount in accordance with the terms of this Subscription Agreement and the Warrant Agreement, as applicable,
the Shares and the shares of Common Stock underlying the Warrants will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and, when issued, will be free and clear of all liens or other restrictions (other than
those arising under applicable securities laws) and will not have been issued in violation of any preemptive or similar rights created under CHFW&#146;s organizational documents (as amended as of the Closing Date) or under the General Corporation
Law of the State of Delaware pursuant to any agreement or other instrument to which CHFW is a party or by which it is otherwise bound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c.
This Subscription Agreement and the Merger Agreement (collectively, the &#147;Transaction Documents&#148;) have been duly authorized, executed and delivered by CHFW and, assuming that the Transaction Documents constitute the valid and binding
agreement of the other parties thereto, the Transaction Documents are valid and binding obligations of CHFW, enforceable against CHFW in accordance with their respective terms, except as may be limited or otherwise affected by (i)&nbsp;bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally, or (ii)&nbsp;principles of equity, whether considered at law or equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">d. The execution and delivery of, and the performance of the transactions contemplated by this Subscription Agreement and the other
Transaction Documents, including the issuance and sale of the Units and the compliance by CHFW with all of the provisions of this Subscription Agreement and the consummation of the transactions contemplated herein, will not (i)&nbsp;conflict with or
result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the property or assets of CHFW or any of its subsidiaries
pursuant to the terms of any indenture, mortgage, deed of trust, loan agreement, lease, license or other agreement or instrument to which CHFW or any of its subsidiaries is a party or by which CHFW or any of its subsidiaries is bound or to which any
of the property or assets of CHFW is subject that would reasonably be expected to have, individually or in the aggregate, a material adverse effect on the business, properties, financial condition, stockholders&#146; equity or results of operations
of CHFW and its subsidiaries, individually or taken as a whole or prevents, materially impairs the validity of the Units or the legal authority of CHFW to comply in all material respects with the terms of this Subscription Agreement (a &#147;CHFW
Material Adverse Effect&#148;); (ii) result in any violation of the provisions of the organizational documents of CHFW or any of its subsidiaries; or (iii)&nbsp;result in any violation of any statute or any judgment, order, rule or regulation of any
court or governmental agency or body, domestic or foreign, having jurisdiction over CHFW or any of its subsidiaries or any of their respective properties that would reasonably be expected to have, individually or in the aggregate, a CHFW Material
Adverse Effect or materially affect the validity of the Shares or the legal authority of CHFW to timely comply in all material respects with this Subscription Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">e. As of their respective dates, all reports (the &#147;SEC Reports&#148;) required to be filed by CHFW with the U.S. Securities and Exchange
Commission (the &#147;SEC&#148;) complied in all material respects with the applicable requirements of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), and/or the Securities Exchange Act of 1934, as amended (the
&#147;Exchange Act&#148;), and the rules and regulations of the SEC promulgated thereunder, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein
or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements of CHFW included in the SEC Reports comply in all material respects with applicable
accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing and fairly present in all material respects the financial position of CHFW as of and for the dates thereof and the results of
operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments. CHFW has timely filed with the SEC each SEC Report that CHFW was
required to file with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
SEC. There are no outstanding or unresolved comments in comment letters received by CHFW from the staff of the Division of Corporation Finance of the SEC with respect to any of the SEC Reports.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">f. Except for such matters as have not had and would not be reasonably expected to have, individually or in the aggregate, a CHFW
Material Adverse Effect, as of the date hereof, there is no (i)&nbsp;action, suit, claim or other proceeding, in each case by or before any governmental authority pending, or, to the knowledge of CHFW, threatened against CHFW or (ii)&nbsp;judgment,
decree, injunction, ruling or order of any governmental authority or arbitrator outstanding against CHFW. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">g. As of the date of this
Subscription Agreement, the authorized capital stock of CHFW consists of (i)&nbsp;1,000,000 preference shares of CHFW, par value $0.0001 per share (the &#147;Preference Shares&#148;), of which no Preference Shares are issued and outstanding; (ii)
350,000,000 Class&nbsp;A ordinary shares, par value $0.0001 per share (the &#147;Class A Ordinary Shares&#148;), of which 9,634,000 Class&nbsp;A Ordinary Shares are issued and outstanding; (iii) 150,000,000 Class&nbsp;B ordinary shares of CHFW, par
value $0.0001 per share (the &#147;Class&nbsp;B Ordinary Shares&#148;), of which 2,300,000 Class&nbsp;B Ordinary Shares are issued and outstanding; (iv)&nbsp;shares underlying 144,667 warrants to purchase one Class&nbsp;A Ordinary Share (the
&#147;Cayman Private Placement Warrants&#148;), all of which are outstanding; and (v) 3,066,667 shares underlying warrants to purchase one Class&nbsp;A Ordinary Share (the &#147;Cayman Public Warrants,&#148; collectively with the Private Placement
Warrants, the &#147;Cayman Warrants&#148;), all of which are outstanding.&nbsp;All outstanding Class&nbsp;A Ordinary Shares and Class&nbsp;B Ordinary Shares have been duly authorized, validly issued, fully paid and are not subject to preemptive or
similar rights. All Class&nbsp;A Ordinary Shares issuable upon exercise of the Cayman Warrants have been duly authorized and reserved for issuance and, upon issuance in accordance with the terms of the Cayman Warrants, will be validly issued, fully
paid and not subject to preemptive or similar rights. Immediately following the Domestication and prior to the consummation of the Transaction, the authorized capital stock of CHFW will consist of (i) 10,000,000 preferred shares, par value $0.0001
(&#147;Preferred Shares&#148;), of which no Preferred Shares will be issued or outstanding; (ii) 300,000,000 shares of Common Stock of CHFW, of which 11,934,000 shares of Common Stock will be issued and outstanding; (iii) 144,667 shares underlying
warrants to purchase one share of Common Stock (the &#147;US Private Placement Warrants&#148;), all of which will be outstanding; and (iv) 3,066,667 shares underlying warrants to purchase one share of Common Stock (the &#147;US Public
Warrants,&#148; collectively with the US Private Placement Warrants, the &#147;US Warrants,&#148; and collectively with the Cayman Warrants, the &#147;Legacy Warrants&#148;), all of which will be outstanding. All outstanding shares of Common Stock
will have been duly authorized, validly issued, fully paid, and will not be subject to preemptive or similar rights. All shares of Common Stock issuable upon exercise of the Legacy Warrants will have been duly authorized and reserved for issuance
and, upon issuance in accordance with the terms of the Legacy Warrants, will be validly issued, fully paid and not subject to preemptive or similar rights. Except as set forth above and pursuant to the Domestication, the Other Subscription
Agreements, the Merger Agreement and the other agreements and arrangements referred to in the Merger Agreement, as of the date hereof, there are no outstanding, and between the date hereof and the Closing, CHFW will not issue, sell or cause to be
outstanding any (A)&nbsp;shares, equity interests or voting securities of CHFW, (B)&nbsp;securities of CHFW convertible into or exchangeable for shares or other equity interests or voting securities of CHFW, (C)&nbsp;options, warrants or other
rights (including preemptive rights) or agreements, arrangements or commitments of any character, whether or not contingent, of CHFW to subscribe for, purchase or acquire from any individual, entity or other person, and no obligation of CHFW to
issue, any shares or other equity interests or voting securities of CHFW, or any securities convertible into or exchangeable or exercisable for such shares or other equity interests or voting securities, (D)&nbsp;equity equivalents or other similar
rights of or with respect to CHFW, or (E)&nbsp;obligations of CHFW to repurchase, redeem or otherwise acquire any of the foregoing securities, shares, options, equity equivalents, interests or rights (other than as provided in CHFW&#146;s
organizational documents). As of the date hereof, CHFW has no subsidiaries other than Merger Sub and does not own, directly or indirectly, interests or investments (whether equity or debt) in any person, whether incorporated or unincorporated. There
are no shareholder agreements, voting trusts or other agreements or understandings to which CHFW is a party or by which it is bound relating to the voting of any securities of CHFW, other than (1)&nbsp;as set forth in the SEC Reports and (2)&nbsp;as
contemplated by the Merger Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">h. As of the date hereof, the issued and outstanding Class&nbsp;A Ordinary Shares, the
Cayman Public Warrants and units comprised of one Class&nbsp;A Ordinary Share and <FONT STYLE="white-space:nowrap">one-third</FONT> of a Cayman Public Warrant (collectively, the &#147;IPO Listed Securities&#148;) are registered pursuant to
Section&nbsp;12(b) of the Exchange Act, and the Class&nbsp;A Ordinary Shares and the Cayman Public Warrants are listed for trading on NYSE American LLC (&#147;NYSE&#148;). As of the Closing Date, the issued and outstanding Listed Securities will be
listed for trading on the Nasdaq Stock Market (the &#147;Nasdaq&#148; and, together with NYSE, the &#147;Exchanges&#148;). There is no suit, action, proceeding or investigation pending or, to the knowledge of CHFW, threatened against CHFW by either
Exchange or the SEC with respect to any intention by such entity to deregister such Listed Securities or prohibit or terminate the listing of the IPO Listed Securities or the Listed Securities on either Exchange. CHFW has taken no action that is
designed to terminate the registration of such equity under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">i. CHFW is not, and immediately after receipt of payment
for the Units will not be, an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">j.
CHFW has not entered into any side letter or similar agreement with any Other Investor or any other person in connection with such Other Investor&#146;s direct or indirect investment in CHFW other than the Other Subscription Agreements, the Merger
Agreement and any other agreement expressly contemplated by the Merger Agreement. The Other Subscription Agreements reflect the same Price Per Unit and other terms and conditions (economic or otherwise) that are no more favorable to such Other
Investor thereunder than the terms of this Subscription Agreement (other than terms particular to the regulatory requirements of such Other Investor or its affiliates or related funds), and they shall not be amended after the date hereof to provide
for terms with respect to the purchase of the Units that are more favorable to such Other Investor thereunder than the terms of this Subscription Agreement, unless such terms are also offered to the Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">k. Neither CHFW nor any officer, director, affiliate or other party acting on the behalf of any such person has paid any amount or transferred
any securities of CHFW or other value to any Other Investor, or agreed to do so, in connection with such Investor&#146;s entering into an Other Subscription Agreement or otherwise in connection with the Transaction. CHFW is not required to obtain
any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority, self-regulatory organization or other person in connection with
the issuance of the Units, other than (i)&nbsp;filings with the SEC, (ii)&nbsp;filings required by applicable state securities laws, (iii)&nbsp;the filings required in accordance with <U>Section</U><U></U><U>&nbsp;7</U>; (iv) those required by the
Exchanges, including with respect to obtaining approval of CHFW&#146;s stockholders, and (v)&nbsp;consents, waivers, authorizations, orders, notices, filings, or registrations the failure of which to obtain or make would not be reasonably be
expected to have, individually or in the aggregate, a CHFW Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">l. As of the date hereof, CHFW has not received any
written communication from a governmental authority that alleges that CHFW is not in compliance with or is in default or violation of any applicable law, except where such <FONT STYLE="white-space:nowrap">non-compliance,</FONT> default or violation
would not reasonably be expected to have, individually or in the aggregate, a CHFW Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">m. Assuming the accuracy of
the Investor&#146;s representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;6</U>, no registration under the Securities Act is required for the offer and sale of the Units by CHFW to the Investor and the Units are not being offered
in a manner involving a public offering under, or in a distribution in violation of, the Securities Act or any state securities laws. Neither CHFW nor any person acting on its behalf has offered or sold the Units by any form of general solicitation
or general advertising in violation of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">n. Other than the Placement Agents (as defined below), CHFW has not engaged
any broker, finder, commission agent, placement agent or arranger in connection with the sale of the Units, and CHFW is not under any obligation to pay any broker&#146;s fee or commission in connection with the sale of the Units, other than to the
Placement Agents (as defined below). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6. <U>Investor Representations and Warranties</U>. The Investor represents and warrants to
CHFW that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. The Investor is (i)&nbsp;a &#147;qualified institutional buyer&#148; (as defined in Rule 144A under the Securities Act) or
an institutional &#147;accredited investor&#148; (within the meaning of Rule 501(a) under the Securities Act), in each case, satisfying the applicable requirements set forth on <U>Schedule A</U>, (ii)&nbsp;an Institutional Account as defined in
FINRA Rule 4512(c), (iii) a sophisticated institutional investor, experienced in investing in private equity transactions and capable of evaluating investment risks independently, both in general and with regard to all transactions and investment
strategies involving a security or securities, including the Investor&#146;s purchase of the Units, (iv)&nbsp;acquiring the Units only for the Investor&#146;s own account and not for the account of others, or if the Investor is subscribing for the
Units as a fiduciary or agent for one or more investor accounts, the Investor has full investment discretion with respect to each such account, and the full power and authority to make the acknowledgements, representations and agreements herein on
behalf of each owner of each such account, and (v)&nbsp;not acquiring the Units with a view to, or for offer or sale in connection with, any distribution thereof in violation of the Securities Act (and shall provide the requested information set
forth on <U>Schedule A</U>). The Investor is not an entity formed for the specific purpose of acquiring the Units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b. The Investor
acknowledges and agrees that the Units are being offered in a transaction not involving any public offering within the meaning of the Securities Act and that the Units have not been registered under the Securities Act. The Investor acknowledges and
agrees that the PIPE Securities may not be offered, resold, transferred, pledged (other than in connection with ordinary course prime brokerage relationships) or otherwise disposed of by the Investor absent an effective registration statement under
the Securities Act except (i)&nbsp;to CHFW or a subsidiary thereof, (ii)&nbsp;to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> persons pursuant to offers and sales that occur outside the United States within the meaning of Regulation S under the
Securities Act or (iii)&nbsp;pursuant to another applicable exemption from the registration requirements of the Securities Act (including, without limitation, a private resale pursuant to the <FONT STYLE="white-space:nowrap">so-called</FONT>
Section&nbsp;4(a)(1 <SUP STYLE="vertical-align:top">1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">2</SUB>) exemption or pursuant to Section&nbsp;4(a)(7) of the Securities Act), and, in each of clauses (i)&nbsp;and (iii) in accordance with any
applicable securities laws of the states and other jurisdictions of the United States, and that the applicable records of CHFW and its transfer agent wherein the book entries recording ownership of the PIPE Securities (and, if applicable, any
certificates representing PIPE Securities) shall contain a restrictive legend to such effect. The Investor acknowledges and agrees that the PIPE Securities will be subject to transfer restrictions and, as a result of these transfer restrictions, the
Investor may not be able to readily offer, resell, transfer, pledge or otherwise dispose of the PIPE Securities and may be required to bear the financial risk of an investment in the Units for an indefinite period of time. The Investor acknowledges
and agrees that the Investor has been advised to consult with its legal counsel and tax and accounting advisors prior to making any offer, resale, transfer, pledge or disposition of any of the PIPE Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c. The Investor acknowledges and agrees that the Investor is purchasing the Units from CHFW and that CHFW will become a Delaware corporation
on or before the Closing Date. The Investor further acknowledges that there have been no representations, warranties, covenants and agreements made to the Investor by or on behalf of CHFW, the Company, any of their respective affiliates or any
control persons, direct or indirect equityholders, officers, managers, directors, employees, consultants, partners, agents or representatives of any of the foregoing or any other person or entity, expressly or by implication, other than those
representations, warranties, covenants and agreements of CHFW expressly set forth in this Subscription Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">d. The Investor
acknowledges and agrees that the Investor has received such information as the Investor deems necessary in order to make an investment decision with respect to the Units, including, with respect to CHFW, the Transaction and the business of the
Company and its subsidiaries. Without limiting the generality of the foregoing, the Investor acknowledges that he, she or it has had the opportunity to review CHFW&#146;s filings with the SEC. The Investor acknowledges and agrees that the Investor
and the Investor&#146;s professional advisor(s), if any, have had the full opportunity to ask such questions, receive such answers and obtain such information as the Investor and such Investor&#146;s professional advisor(s), if any, have deemed
necessary to make an investment decision with respect to the Units. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">e. The Investor became aware of this offering of the Units solely by means of direct contact
between the Investor and CHFW, the Company or a representative of CHFW or the Company, and the Units were offered to the Investor solely by direct contact between the Investor and CHFW, the Company or a representative of CHFW or the Company. The
Investor did not become aware of this offering of the Units, nor were the Units offered to the Investor, by any other means. The Investor acknowledges that the Units (i)&nbsp;were not offered by any form of general solicitation or general
advertising and (ii)&nbsp;are not being offered in a manner involving a public offering under, or in a distribution in violation of, the Securities Act or any state securities laws. The Investor acknowledges that it is not relying upon, and has not
relied upon, any statement, representation or warranty made by any person, firm or corporation (including, without limitation, CHFW, the Company, the Placement Agents, any of their respective affiliates or any control persons, direct or indirect
equityholders, officers, managers, directors, employees, consultants, partners, agents or representatives of any of the foregoing), other than the representations and warranties of CHFW contained in this Subscription Agreement, in making its
investment or decision to invest in CHFW. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">f. The Investor acknowledges that it is aware that there are substantial risks incident to the
purchase and ownership of the Units, including those set forth in CHFW&#146;s filings with the SEC. The Investor has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of an investment
in the Units, and the Investor has sought such accounting, legal and tax advice as the Investor has considered necessary to make an informed investment decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">g. Alone, or together with any professional advisor(s), the Investor has adequately analyzed and fully considered the risks of an investment
in the Units and determined that the Units are a suitable investment for the Investor and that the Investor is able at this time and in the foreseeable future to bear the economic risk of a total loss of the Investor&#146;s investment in CHFW. The
Investor acknowledges specifically that a possibility of total loss exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">h. In making its decision to purchase the Units, the Investor
has relied solely upon independent investigation made by the Investor. Without limiting the generality of the foregoing, the Investor has not relied on any statements or other information provided by or on behalf of either Placement Agent or any of
their respective affiliates or any control persons, officers, directors, employees, partners, agents or representatives of any of the foregoing concerning CHFW, the Company, the Transaction, the Merger Agreement, this Subscription Agreement or the
transactions contemplated hereby or thereby, the Units or the offer and sale of the Units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">i. The Investor acknowledges and agrees that
no federal or state agency has passed upon or endorsed the merits of the offering of the Units or made any findings or determination as to the fairness of this investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">j. The Investor has been duly formed or incorporated and is validly existing and is in good standing under the laws of its jurisdiction of
formation or incorporation, with power and authority to enter into, deliver and perform its obligations under this Subscription Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">k. The execution, delivery and performance by the Investor of this Subscription Agreement are within the powers of the Investor, have been
duly authorized and will not constitute or result in a breach or default under or conflict with any order, ruling or regulation of any court or other tribunal or of any governmental commission or agency, or any agreement or other undertaking, to
which the Investor is a party or by which the Investor is bound, and, if the Investor is not an individual, will not violate any provisions of the Investor&#146;s organizational documents, including, without limitation, its incorporation or
formation papers, bylaws, indenture of trust or partnership or operating agreement, as may be applicable. The signature on this Subscription Agreement is genuine, and the signatory has been duly authorized to execute the same and, assuming that this
Subscription Agreement constitutes the valid and binding agreement of CHFW, this Subscription Agreement constitutes a legal, valid and binding obligation of the Investor, enforceable against the Investor in accordance with its terms except as may be
limited or otherwise affected by (i)&nbsp;bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally, and (ii)&nbsp;principles of equity, whether considered at
law or equity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">l. The Investor is not (i)&nbsp;a person or entity named on the List of Specially Designated
Nationals and Blocked Persons administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Control (&#147;OFAC&#148;) or in any Executive Order issued by the President of the United States and administered by OFAC (&#147;OFAC
List&#148;), or a person or entity prohibited by any OFAC sanctions program, (ii)&nbsp;owned, directly or indirectly, or controlled by, or acting on behalf of, one or more persons that are named on the OFAC List, (iii)&nbsp;organized, incorporated,
established, located, resident or born in, or a citizen, national or the government, including any political subdivision, agency or instrumentality thereof, of, Cuba, Iran, North Korea, Syria, the Crimea region of Ukraine or any other country or
territory embargoed or subject to substantial trade restrictions by the United States, (iv)&nbsp;a Designated National as defined in the Cuban Assets Control Regulations, 31 C.F.R. Part 515, or (v)&nbsp;a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> shell bank or providing banking services indirectly to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> shell bank. If the Investor is a financial institution subject to the Bank Secrecy Act (31
U.S.C. Section&nbsp;5311 et seq.), as amended by the USA PATRIOT Act of 2001 and its implementing regulations (collectively, the &#147;BSA/PATRIOT Act&#148;), the Investor, directly or indirectly through a third-party administrator, maintains
policies and procedures reasonably designed to comply with applicable obligations under the BSA/PATRIOT Act. The Investor also represents and warrants that, to the extent required by applicable law, it maintains policies and procedures reasonably
designed to ensure compliance with OFAC-administered sanctions programs, including for the screening of its investors against the OFAC sanctions programs, including the OFAC List. Investor further, directly or indirectly through a third-party
administrator, represents and warrants that, to the extent required by applicable law, the Investor, directly or indirectly through a third-party administrator, maintains policies and procedures reasonably designed to ensure that the funds held by
the Investor and used to purchase the Units were legally derived. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">m. The Investor&#146;s acquisition and holding of the Units will not
constitute or result in a <FONT STYLE="white-space:nowrap">non-exempt</FONT> prohibited transaction under Section&nbsp;406 of the Employee Retirement Income Security Act of 1974, as amended (&#147;ERISA&#148;), Section&nbsp;4975 of the Internal
Revenue Code of 1986, as amended (the &#147;Code&#148;), or any other federal, state, local, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> or other laws or regulations that are similar to such provisions of ERISA or the Code (collectively,
&#147;Similar Laws&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">n. If Investor is, or is acting (directly or indirectly) on behalf of, an employee benefit plan that is
subject to Title I of ERISA, a plan, individual retirement account or other arrangement that is subject to Section&nbsp;4975 of the Code or an employee benefit plan that is a governmental plan (as defined in Section&nbsp;3(32) of ERISA), a church
plan (as defined in Section&nbsp;3(33) of ERISA), a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> plan (as described in Section&nbsp;4(b)(4) of ERISA) or other plan that is not subject to the foregoing but may be subject to provisions under any
Similar Law, or an entity whose underlying assets are considered to include &#147;plan assets&#148; of any such plan, account or arrangement (each, a &#147;Plan&#148;) subject to the fiduciary or prohibited transaction provisions of ERISA or
Section&nbsp;4975 of the Code, then the Investor represents and warrants that (i)&nbsp;it has notified CHFW in writing of its status as a Plan and will provide such additional information as may be requested by the Company prior to Closing in
connection therewith, (ii)&nbsp;it has not relied on CHFW, the Company or any of their respective employees, representatives or affiliates (the &#147;Transaction Parties&#148;) as the Plan&#146;s fiduciary with respect to its decision to acquire and
hold the Units, and (iii)&nbsp;it has not relied on any investment advice or recommendation from the Transaction Parties, including, without limitation, in a fiduciary capacity, with respect to its decision to acquire and hold the Units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">o. No foreign person (as defined in 31 C.F.R. Part 800.224) in which the national or subnational governments of a single foreign state have a
substantial interest (as defined in 31 C.F.R. Part 800.244) will acquire a substantial interest in CHFW as a result of the purchase and sale of Units hereunder such that a declaration to the Committee on Foreign Investment in the United States would
be mandatory under 31 C.F.R. Part 800.401, and no foreign person will have control (as defined in 31 C.F.R. Part 800.208) over CHFW from and after the Closing as a result of the purchase and sale of Units hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">p. The Investor acknowledges that no disclosure or offering document has been prepared by J. P. Morgan Securities LLC, BofA Securities, Inc.
or any of their respective affiliates (collectively, the &#147;Placement Agents&#148;) in connection with the offer and sale of the Units. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">q. The Investor acknowledges that neither Placement Agent, nor any of its respective
affiliates nor any control persons, officers, directors, employees, partners, agents or representatives of any of the foregoing have made any independent investigation with respect to CHFW, the Company or its subsidiaries or any of their respective
businesses, or the Units or the accuracy, completeness or adequacy of any information supplied to the Investor by CHFW. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">r. In connection
with the issue and purchase of the Units, neither Placement Agent has acted as the Investor&#146;s financial advisor or fiduciary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">s. The
Investor has or has commitments to have and, when required to deliver payment to CHFW pursuant to <U>Section</U><U></U><U>&nbsp;2</U> above, will have, sufficient funds to pay the Subscription Amount and consummate the purchase and sale of the Units
pursuant to this Subscription Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">t. The Investor agrees that, from the date of this Subscription Agreement, none of the Investor
nor any person or entity acting on behalf of the Investor or pursuant to any understanding with the Investor will engage in any Short Sales with respect to securities of CHFW prior to the Closing (or such earlier termination of this Subscription
Agreement). For the purposes hereof, &#147;Short Sales&#148; shall mean all &#147;short sales&#148; as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act, and all short positions effected through any direct or indirect stock
pledges (other than pledges in the ordinary course of business as part of prime brokerage arrangements), forward sale contracts, options, puts, calls, swaps and similar arrangements (including on a total return basis), or other short transactions
through <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker dealers or foreign regulated brokers. Notwithstanding the foregoing, nothing herein shall prohibit other entities under common management with the Investor that have no knowledge of
this Subscription Agreement or of Investor&#146;s participation in this transaction (including the Investor&#146;s controlled affiliates and/or affiliates) from entering into any Short Sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">u. The Investor is aware, and acknowledges, that J.P. Morgan Securities LLC (i)&nbsp;is acting as financial advisor to CHFW in connection with
the Transaction, and (ii)&nbsp;will receive deferred underwriting commissions upon the closing of the Transaction for having acted as underwriter in CHFW&#146;s initial public offering, as disclosed in the Prospectus (as defined herein). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7. <U>Registration Rights</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. CHFW agrees that, within thirty (30)&nbsp;calendar days after the consummation of the Transaction (the &#147;Filing Date&#148;), CHFW will
file with the SEC (at CHFW&#146;s sole cost and expense) a registration statement (the &#147;Registration Statement&#148;), registering the resale of the Listed Securities, which Registration Statement may register the issuance or resale of other
shares of the Common Stock, including, without limitation, shares of the Common Stock issuable upon exercise of the Legacy Warrants, and CHFW shall use its reasonable best efforts to have the Registration Statement declared effective as soon as
practicable after the filing thereof, but no later than the earlier of (i)&nbsp;the 60th calendar day (or 90th calendar day if the SEC notifies CHFW that it will &#147;review&#148; the Registration Statement) following the Filing Date and
(ii)&nbsp;the 10th business day after the date CHFW is notified (orally or in writing, whichever is earlier) by the SEC that the Registration Statement will not be &#147;reviewed&#148; or will not be subject to further review (or, in either case of
(i)&nbsp;or (ii) above, if such date falls on a Saturday, Sunday or other day that the SEC is closed for business, the next business day on which the SEC is open for business) (such earlier date, the &#147;Effectiveness Date&#148;); <I>provided</I>,
<I>however</I>, that CHFW&#146;s obligations to include the Listed Securities in the Registration Statement are contingent upon the Investor furnishing in writing to CHFW such information regarding the Investor, the securities of CHFW held by the
Investor and the intended method of disposition of the Listed Securities as shall be reasonably requested by CHFW to effect the registration of the Listed Securities, and the Investor shall execute such documents in connection with such registration
as CHFW may reasonably request that are customary of a selling stockholder in similar situations, including providing that CHFW shall be entitled to postpone and suspend the effectiveness or use of the Registration Statement during any customary
blackout or similar period or as permitted hereunder; <I>provided</I>, that Investor shall not in connection with the foregoing be required to execute any <FONT STYLE="white-space:nowrap">lock-up</FONT> or similar agreement or otherwise be subject
to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
any contractual restrictions on the ability to transfer the Listed Securities. Notwithstanding the foregoing, if the SEC prevents CHFW from including any or all of the Listed Securities proposed
to be registered under the Registration Statement due to limitations on the use of Rule 415 of the Securities Act for the resale of the Listed Securities by the applicable stockholders or otherwise, such Registration Statement shall register for
resale such number of Listed Securities which is equal to the maximum number of Listed Securities as is permitted by the SEC. In such event, the number of Listed Securities to be registered for each selling stockholder named in the Registration
Statement shall be reduced pro rata among all such selling stockholders. Upon notification by the SEC that the Registration Statement has been declared effective by the SEC, within two (2)&nbsp;business days thereafter, CHFW shall file the final
prospectus under Rule 424 of the Securities Act. CHFW will provide a draft of the Registration Statement to the Investor for review at least two (2)&nbsp;business days in advance of filing the Registration Statement. In no event shall the Investor
be identified as a statutory underwriter in the Registration Statement without the Investor&#146;s prior written consent. For purposes of clarification, any failure by CHFW to file the Registration Statement by the Filing Date or to effect such
Registration Statement by the Effectiveness Date shall not otherwise relieve CHFW of its obligations to file or effect the Registration Statement as set forth above in this <U>Section</U><U></U><U>&nbsp;7</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b. In the case of the registration effected by CHFW pursuant to this Subscription Agreement, CHFW shall, upon reasonable request, inform the
Investor as to the status of such registration. At its expense, CHFW shall: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(i) except for such times as
CHFW is permitted hereunder to suspend the use of the prospectus forming part of the Registration Statement, use its commercially reasonable efforts to keep such registration continuously effective with respect to the Investor, and to keep the
Registration Statement (or any subsequent shelf registration statement registers the resale of the Listed Securities by the Investor, which shall constitute the Registration Statement following its effectiveness) free of any material misstatements
or omissions, until the earlier of the following: (i)&nbsp;the Investor ceases to hold any of the Listed Securities or (ii)&nbsp;the date all of the Listed Securities held by the Investor may be sold without restriction under Rule 144, including
without limitation, any volume and manner of sale restrictions which may be applicable to affiliates under Rule 144 and without the requirement for CHFW to be in compliance with the current public information required under Rule 144(c)(1) or Rule
144(i)(2), as applicable, and (iii)&nbsp;three years from the Effectiveness Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(ii) advise the Investor
within two (2)&nbsp;business days: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(1) when the Registration Statement or any amendment thereto has been
filed with the SEC and when the Registration Statement or any post-effective amendment thereto has become effective; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(2) of any request by the SEC for amendments or supplements to the Registration Statement or the prospectus
included therein or for additional information with respect to the Investor; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(3) of the issuance by the
SEC of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for such purpose; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(4) of the receipt by CHFW of any notification with respect to the suspension of the qualification of the
Listed Securities included in the Registration Statement for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(5) subject to the provisions in this Subscription Agreement, of the occurrence of any event that requires the
making of any changes in the Registration Statement or prospectus included therein so that, as of such date, the Registration Statement does not contain an untrue statement of a material fact or does not omit to state a material fact required to be
stated therein or necessary to make the statements therein not misleading, or any prospectus included therein does not include an untrue statement of a material fact or does not omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding anything to the contrary set forth herein, CHFW shall not,
when so advising the Investor of such events, provide the Investor with any material, nonpublic information regarding CHFW other than to the extent that providing notice to the Investor of the occurrence of the events listed in (1)&nbsp;through (5)
above constitutes material, nonpublic information regarding CHFW; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iii) use its commercially reasonable
efforts to obtain the withdrawal of any order suspending the effectiveness of the Registration Statement as soon as reasonably practicable; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(iv) upon the occurrence of any event contemplated above, except for a Suspension (as defined below), CHFW
shall use its commercially reasonable efforts to as soon as reasonably practicable prepare a post-effective amendment to the Registration Statement or a supplement to the related prospectus, or file any other required document so that, as thereafter
delivered to purchasers of the Listed Securities included therein, such prospectus will not include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(v) use its commercially reasonable efforts to
cause all of the Listed Securities to be listed on each securities exchange or market, if any, on which the Common Stock issued by CHFW have been listed; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(vi) use its commercially reasonable efforts to take all other steps necessary to effect the registration of
the Listed Securities contemplated hereby and to enable the Investor to sell the Listed Securities under Rule 144. In addition, in connection with any sale, assignment, transfer or other disposition of the PIPE Securities by the Investor pursuant to
Rule 144 or pursuant to any other exemption under the Securities Act such that the PIPE Securities held by the Investor become freely tradable and upon compliance by the Investor with the requirements of this Subscription Agreement, if requested by
the Investor, CHFW shall cause the transfer agent for the PIPE Securities to remove any restrictive legends related to the book entry account holding such PIPE Securities and make a new, unlegended entry for such book entry PIPE Securities sold or
disposed of, or expected to be disposed of, without restrictive legends within two (2)&nbsp;trading days of any such request therefor from the Investor, provided that CHFW and the transfer agent have timely received from the Investor customary
representations and other documentation reasonably acceptable to CHFW and the transfer agent in connection therewith. Subject to receipt from the Investor by CHFW and the transfer agent of customary representations and other documentation reasonably
acceptable to CHFW and the transfer agent in connection therewith, including, if required by the transfer agent, an opinion of CHFW&#146;s counsel, in a form reasonably acceptable to the transfer agent, to the effect that the removal of such
restrictive legends in such circumstances may be effected under the Securities Act, the Investor may request that CHFW remove any legend from the book entry position evidencing its PIPE Securities following the earliest of such time as such PIPE
Securities (i)&nbsp;(x) are subject to or (y)&nbsp;have been or are expected to be sold or transferred pursuant to an effective registration statement, (ii)&nbsp;have been or are expected to be sold or otherwise transferred pursuant to Rule 144, or
(iii)&nbsp;are eligible for resale under Rule 144(b)(1) or any successor provision without the requirement for CHFW to be in compliance with the current public information requirement under Rule 144 and without volume or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions applicable to the sale or transfer of such PIPE Securities. If restrictive legends are no longer required for such PIPE Securities pursuant to the
foregoing, CHFW shall, in accordance with the provisions of this section and within two (2)&nbsp;trading days of any request therefor from the Investor accompanied by such customary and reasonably acceptable representations and other documentation
referred to above establishing that restrictive legends are no longer required, deliver to the transfer agent irrevocable instructions that the transfer agent shall make a new, unlegended entry for such book entry PIPE Securities. CHFW shall be
responsible for the fees of its transfer agent and any DTC fees associated with such issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c. Notwithstanding anything to the
contrary in this Subscription Agreement, CHFW shall be entitled to delay or postpone the effectiveness of the Registration Statement, and from time to time to require the Investor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
not to sell under the Registration Statement or to suspend the effectiveness thereof (such event being referred to as a &#147;Suspension&#148;), if (x)&nbsp;the use of the Registration Statement
would require the inclusion of financial statements that are unavailable for reasons beyond CHFW&#146;s control or (y)&nbsp;the negotiation or consummation of a transaction by CHFW or its subsidiaries is pending or an event has occurred, which
negotiation, consummation or event CHFW&#146;s board of directors reasonably believes, upon the advice of external legal counsel, would require additional disclosure by CHFW in the Registration Statement of information that CHFW has a bona fide
business purpose for keeping confidential and the <FONT STYLE="white-space:nowrap">non-disclosure</FONT> of which in the Registration Statement would be expected, in the reasonable determination of CHFW&#146;s board of directors, upon the advice of
external legal counsel, to cause the Registration Statement to fail to comply with applicable disclosure requirements (each such circumstance, a &#147;Suspension Event&#148;); provided, however, that CHFW shall not be entitled to cause a Suspension
on more than two occasions or for more than thirty (30)&nbsp;consecutive calendar days, or more than sixty (60)&nbsp;total calendar days, in each case during any twelve-month period. Upon receipt of any written notice from CHFW of the happening of a
Suspension during the period that the Registration Statement is effective or if as a result of a Suspension Event the Registration Statement contains any untrue statement of a material fact or omits to state any material fact required to be stated
therein or necessary to make the statements therein not misleading, or any related prospectus includes any untrue statement of a material fact or omits to state any material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading, the Investor agrees that (i)&nbsp;it will immediately discontinue offers and sales of the Listed Securities under the Registration Statement until the Investor receives copies of a
supplemental or amended prospectus that corrects the misstatement(s) or omission(s) referred to above and receives notice that any post-effective amendment has become effective or unless otherwise notified by CHFW that it may resume such offers and
sales and (ii)&nbsp;it will maintain the confidentiality of any information included in such written notice delivered by CHFW unless otherwise required by law or subpoena. If so directed by CHFW, the Investor will deliver to CHFW or, in the
Investor&#146;s sole discretion destroy, all copies of the prospectus covering the Listed Securities in the Investor&#146;s possession; provided, however, that this obligation to deliver or destroy all copies of the prospectus covering the Listed
Securities shall not apply (A)&nbsp;to the extent the Investor is required to retain a copy of such prospectus (x)&nbsp;in order to comply with applicable legal, regulatory, self-regulatory or professional requirements or (y)&nbsp;in accordance with
a bona fide <FONT STYLE="white-space:nowrap">pre-existing</FONT> document retention policy or (B)&nbsp;to copies stored electronically on archival servers as a result of automatic data <FONT STYLE="white-space:nowrap">back-up.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">d. The Investor may deliver written notice (an <FONT STYLE="white-space:nowrap">&#147;Opt-Out</FONT> Notice&#148;) to CHFW requesting that the
Investor not receive notices from CHFW otherwise required by this <U>Section</U><U></U><U>&nbsp;7</U>; provided, however, that the Investor may later revoke any such <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Notice in writing. Following
receipt of an <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Notice from the Investor (unless subsequently revoked), (i) CHFW shall not deliver any such notices to the Investor and the Investor shall no longer be entitled to the rights associated
with any such notice and (ii)&nbsp;each time prior to the Investor&#146;s intended use of the Registration Statement, the Investor will notify CHFW in writing at least two (2)&nbsp;business days in advance of such intended use, and if a notice of a
Suspension or Suspension Event that still applies was previously delivered (or would have been delivered but for the provisions of this <U>Section</U><U></U><U>&nbsp;7(d)</U>), CHFW will so notify the Investor, within one (1)&nbsp;business day of
the Investor&#146;s notification to CHFW, by delivering to the Investor a copy of such previous notice of the Suspension or Suspension Event, and thereafter will provide the Investor with the related notice of the conclusion the Suspension or that
such Suspension Event no longer applies immediately upon its availability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">e. CHFW shall, notwithstanding any termination of this
Subscription Agreement, indemnify, defend and hold harmless the Investor (to the extent a seller under the Registration Statement), its directors, officers, agents, advisors and employees and each person who controls the Investor (within the meaning
of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act) and each affiliate of the Investor (within the meaning of Rule 405 under the Securities Act) to the fullest extent permitted by applicable law, from and against any and
all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> losses, claims, damages, liabilities, costs (including reasonable attorneys&#146; fees) and expenses (collectively, &#147;Losses&#148;), as incurred,
that arise out of or are based upon (i)&nbsp;any untrue or alleged untrue statement of a material fact contained in the Registration Statement or in any amendment or supplement thereto or arise out of or relate to any omission or alleged omission of
a material fact required to be stated therein or necessary to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
make the statements therein not misleading or (ii)&nbsp;any untrue or alleged untrue statement of a material fact included in any prospectus included in the Registration Statement or any form of
prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading or (iii)&nbsp;any violation of or alleged violation by CHFW of the federal or state securities laws or any rule or regulation thereunder, except to the extent, but only to the extent, that
such untrue statements, alleged untrue statements, omissions or alleged omissions are based upon information regarding the Investor furnished in writing to CHFW by the Investor expressly for use therein or the Investor has omitted a material fact
from such information or otherwise violated the Securities Act, Exchange Act or any state securities law or any rule or regulation thereunder; provided, however, that the indemnification contained in this <U>Section</U><U></U><U>&nbsp;7</U> shall
not apply to amounts paid in settlement of any Losses if such settlement is effected without the consent of CHFW, which shall not be unreasonably withheld, conditioned or delayed, nor shall CHFW be liable for any Losses to the extent they arise out
of or are based upon a violation which occurs (A)&nbsp;in reliance upon and in conformity with written information furnished by the Investor, (B)&nbsp;in connection with any failure of such person to deliver or cause to be delivered a prospectus
made available by CHFW in a timely manner or (C)&nbsp;in connection with any offers or sales effected by or on behalf of the Investor in violation of <U>Section</U><U></U><U>&nbsp;7(c)</U> hereof. CHFW shall notify the Investor reasonably promptly
of the institution, threat or assertion of any proceeding arising from or in connection with the transactions contemplated by this <U>Section</U><U></U><U>&nbsp;7</U> of which CHFW receives notice in writing. Such indemnity shall remain in full
force and effect regardless of any investigation made by or on behalf of an indemnified party and shall survive the transfer of the PIPE Securities by the Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">f. The Investor shall, severally and not jointly with any Other Investor or person named as a selling stockholder in the Registration
Statement, indemnify and hold harmless CHFW, its directors, officers, agents and employees, and each person who controls CHFW (within the meaning of Section&nbsp;15 of the Securities Act and Section&nbsp;20 of the Exchange Act), to the fullest
extent permitted by applicable law, from and against all Losses, as incurred, (i)&nbsp;arising out of or based upon any untrue or alleged untrue statement of a material fact contained in any Registration Statement or in any amendment or supplement
thereto or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii)&nbsp;arising out of or based upon any untrue or alleged
untrue statement of a material fact included in any prospectus included in the Registration Statement or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus or arising out of or relating to any omission
or alleged omission of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, with respect to (i)&nbsp;and/or (ii), to the extent, but only to the extent, that
such untrue or alleged untrue statements or omissions or alleged omissions are based upon information regarding the Investor furnished in writing to CHFW by the Investor expressly for use therein; <I>provided</I>, <I>however</I>, that the
indemnification contained in this <U>Section</U><U></U><U>&nbsp;7(f)</U> shall not apply to amounts paid in settlement of any Losses if such settlement is effected without the consent of the Investor. In no event shall the liability of the Investor
be greater in amount than the dollar amount of the net proceeds received by the Investor upon the sale of the PIPE Securities giving rise to such indemnification obligation. The Investor shall notify CHFW reasonably promptly of the institution,
threat or assertion of any proceeding arising from or in connection with the transactions contemplated by this <U>Section</U><U></U><U>&nbsp;7(f)</U> of which the Investor is aware. Such indemnity shall remain in full force and effect regardless of
any investigation made by or on behalf of an indemnified party and shall survive the transfer of the PIPE Securities by the Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">g.
If the indemnification provided under this <U>Section</U><U></U><U>&nbsp;7</U> from the indemnifying party is unavailable or insufficient to hold harmless an indemnified party in respect of any Losses, then the indemnifying party, in lieu of
indemnifying the indemnified party, shall contribute to the amount paid or payable by the indemnified party as a result of such Losses in such proportion as is appropriate to reflect the relative fault of the indemnifying party and the indemnified
party, as well as any other relevant equitable considerations. The relative fault of the indemnifying party and indemnified party shall be determined by reference to, among other things, whether any action in question, including any untrue or
alleged untrue statement of a material fact or omission or alleged </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
omission to state a material fact, was made by, or relates to information supplied by, such indemnifying party or indemnified party, and the indemnifying party&#146;s and indemnified party&#146;s
relative intent, knowledge, access to information and opportunity to correct or prevent such action. The amount paid or payable by a party as a result of the Losses shall be deemed to include, subject to the limitations set forth above, any legal or
other fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled
to contribution pursuant to this <U>Section</U><U></U><U>&nbsp;7(g)</U> from any person who was not guilty of such fraudulent misrepresentation. In no event shall the liability of the Investor be greater in amount than the dollar amount of the net
proceeds received by the Investor upon the sale of the PIPE Securities purchased pursuant to this Subscription Agreement giving rise to such contribution obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8. <U>Termination</U>. This Subscription Agreement shall terminate and be void and of no further force and effect, and all rights and
obligations of the parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the earlier to occur of (a)&nbsp;such date and time as the Merger Agreement is terminated in accordance with its
terms without being consummated, (b)&nbsp;upon the mutual written agreement of each of the parties hereto and the Company to terminate this Subscription Agreement, (c)&nbsp;thirty (30) days after the Outside Date (as defined in the Merger Agreement
as of the date hereof), if the Closing has not occurred by such date, (d)&nbsp;by written notice of the Investor to CHFW in the event the Merger Agreement is amended, supplemented or otherwise modified after the date hereof in a manner that
materially adversely affects the Investor, or (e)&nbsp;if any of the conditions to Closing set forth in Section&nbsp;3 of this Subscription Agreement are not satisfied or waived prior to the Closing (other than those conditions that by their nature
can only be satisfied at and not prior to the Closing, unless such conditions are not capable of being satisfied at the Closing), and, in each case, as a result thereof, the transactions contemplated by this Subscription Agreement cannot be and are
not consummated at the Closing (the termination events described in clauses (a)&#150;(e) above, collectively, the &#147;Termination Events&#148;); <I>provided</I> that nothing herein will relieve any party from liability for any willful breach
hereof prior to the time of termination, and each party will be entitled to any remedies at law or in equity to recover losses, liabilities or damages arising from any such willful breach. CHFW shall notify the Investor in writing of the termination
of the Merger Agreement promptly after the termination of such agreement. Upon the occurrence of any Termination Event, this Subscription Agreement shall be void and of no further effect and any monies paid by the Investor to CHFW in connection
herewith shall promptly (and in any event within one (1)&nbsp;business day) following a Termination Event be returned to the Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9.
<U>Trust Account Waiver</U>. The Investor acknowledges that CHFW is a blank check company with the powers and privileges to effect a merger, asset acquisition, reorganization or similar business combination involving CHFW and one or more businesses
or assets. The Investor further acknowledges that, as described in CHFW&#146;s prospectus relating to its initial public offering dated November&nbsp;18, 2020 (the &#147;Prospectus&#148;) available at www.sec.gov, substantially all of CHFW&#146;s
assets consist of the cash proceeds of CHFW&#146;s initial public offering and private placement of its securities, and substantially all of those proceeds have been deposited in a trust account (the &#147;Trust Account&#148;) for the benefit of
CHFW, its public shareholders and the underwriters of CHFW&#146;s initial public offering. Except with respect to interest earned on the funds held in the Trust Account that may be released to CHFW to pay its tax obligations, if any, the cash in the
Trust Account may be disbursed only for the purposes set forth in the Prospectus. For and in consideration of CHFW entering into this Subscription Agreement, the receipt and sufficiency of which are hereby acknowledged, the Investor hereby
irrevocably waives any and all right, title and interest, or any claim of any kind it has or may have in the future, in or to any monies held in the Trust Account, and agrees not to seek recourse against the Trust Account, regardless of whether such
claim arises as a result of, in connection with or relating in any way to, this Subscription Agreement or any other matter, and regardless of whether such claim arises based on contract, tort, equity or any other theory of liability (the
&#147;Released Claims&#148;); <I>provided</I>, that the Released Claims shall not include any claims that the Investor may have solely in the Investor&#146;s capacity as a record or beneficial holder of any Class&nbsp;A Ordinary Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. Neither this Subscription Agreement nor any rights that may accrue to the parties hereunder (other than the PIPE Securities acquired
hereunder, if any) may be transferred or assigned without the prior written consent of each of the other parties hereto; <I>provided</I> that this Subscription Agreement and any of the Investor&#146;s rights and obligations hereunder may be assigned
to one or more of its affiliates or to any investment fund or account managed or advised by the same investment manager as the Investor or by an affiliate of such investment manager, without the prior consent of CHFW; <I>provided</I> <I>further</I>
that (x)&nbsp;prior to such assignment any such assignee shall agree in writing to be bound by the terms hereof and (y)&nbsp;no such assignment shall relieve the Investor of its obligations hereunder if any such assignee fails to fully perform such
obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b. CHFW may request from the Investor such additional information as CHFW may reasonably deem necessary to register the
resale of the Listed Securities and evaluate the eligibility of the Investor to acquire the Units, and the Investor shall provide such information as may reasonably be requested to the extent readily available; <I>provided</I> that CHFW expressly
agrees to keep any such information provided by the Investor confidential except (i)&nbsp;as required by the applicable securities laws or pursuant to proceedings of regulatory authorities or (ii)&nbsp;to the extent such disclosure is required by
law, at the request of the staff of the SEC or other regulatory agency or under the regulations of any national securities exchange on which CHFW&#146;s securities are listed for trading, in which case, CHFW shall (to the extent legally permissible
and reasonably practical) provide Investor with prior written notice. The Investor acknowledges that CHFW may file a copy of this Subscription Agreement with the SEC as an exhibit to a periodic report or a registration statement of CHFW. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c. The Investor acknowledges that CHFW and the Placement Agents will rely on the acknowledgments, understandings, agreements, representations
and warranties of the Investor contained in this Subscription Agreement and that the Company (following the Closing) will rely on the representations and warranties of the Investor contained in this Subscription Agreement. Prior to the Closing, each
party hereto agrees to promptly notify the other party hereto and the Placement Agents if any of the acknowledgments, understandings, agreements, representations and warranties set forth herein with respect to it are no longer accurate. The Investor
agrees that each purchase by the Investor of Units from the Company will constitute a reaffirmation of the acknowledgments, understandings, agreements, representations and warranties herein (as modified by any such notice) by the Investor as of the
time of such purchase. The Investor further acknowledges and agrees that the Placement Agents are third-party beneficiaries of the representations and warranties of the Investor contained in <U>Section</U><U></U><U>&nbsp;6</U> (except
<U>Section</U><U></U><U>&nbsp;6(t)</U>) and <U>Section</U><U></U><U>&nbsp;11</U> of this Subscription Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">d. CHFW and the Investor
each is irrevocably authorized to produce this Subscription Agreement or a copy hereof to any interested party in any administrative or legal proceeding or official inquiry with respect to the matters covered hereby to the extent required by law or
regulatory bodies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">e. All of the agreements, representations and warranties made by each party hereto in this Subscription Agreement
shall survive the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">f. This Subscription Agreement may not be modified, waived or terminated (other than pursuant to the terms of
<U>Section</U><U></U><U>&nbsp;8</U> above) except by an instrument in writing, signed by each of the parties hereto. No failure or delay of either party in exercising any right or remedy hereunder shall operate as a waiver thereof, nor shall any
single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such right or power, or any course of conduct, preclude any other or further exercise thereof or the exercise of any other right or
power. The rights and remedies of the parties hereunder are cumulative and are not exclusive of any rights or remedies that they would otherwise have hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">g. This Subscription Agreement (including the schedule hereto) constitutes the entire agreement, and supersedes all other prior agreements,
understandings, representations and warranties, both written and oral, among the parties, with respect to the subject matter hereof. Except as set forth in <U>Section</U><U></U><U>&nbsp;7</U>, <U>Section</U><U></U><U>&nbsp;10(c)</U>, this
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
<U>Section</U><U></U><U>&nbsp;10(g)</U> and <U>Section</U><U></U><U>&nbsp;11</U> with respect to the persons specifically referenced therein, this Subscription Agreement shall not confer any
rights or remedies upon any person other than the parties hereto, and their respective successor and assigns, and the parties hereto acknowledge that such persons so referenced are third party beneficiaries of this Subscription Agreement solely for
the purposes of, and to the extent of, the rights granted to them, if any, pursuant to the applicable provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">h. Except as otherwise
provided herein, this Subscription Agreement shall be binding upon, and inure to the benefit of the parties hereto and their heirs, executors, administrators, successors, legal representatives, and permitted assigns, and the agreements,
representations, warranties, covenants and acknowledgments contained herein shall be deemed to be made by, and be binding upon, such heirs, executors, administrators, successors, legal representatives and permitted assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">i. If any provision of this Subscription Agreement shall be adjudicated by a court of competent jurisdiction to be invalid, illegal or
unenforceable, the validity, legality or enforceability of the remaining provisions of this Subscription Agreement shall not in any way be affected or impaired thereby and shall continue in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">j. This Subscription Agreement may be executed in one or more counterparts (including by facsimile or electronic mail or in .pdf or by
www.docusign.com or similar service) and by different parties in separate counterparts, with the same effect as if all parties hereto had signed the same document. All counterparts so executed and delivered shall be construed together and shall
constitute one and the same agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">k. The parties hereto acknowledge and agree that irreparable damage would occur in the event that
any of the provisions of this Subscription Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to seek an injunction or injunctions to prevent
breaches or threatened breaches of this Subscription Agreement, without posting a bond or undertaking and without proof of damages, to enforce specifically the terms and provisions of this Subscription Agreement, this being in addition to any other
remedy to which such party is entitled at law, in equity, in contract, in tort or otherwise. The right to specific enforcement shall include the right of each party hereto to cause the other party hereto to cause the transactions contemplated hereby
to be consummated on the terms and subject to the conditions and limitations set forth in this Subscription Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">l. This
Subscription Agreement shall be governed by and construed in accordance with the laws of the State of Delaware<B> </B>(regardless of the laws that might otherwise govern under applicable principles of conflicts of laws thereof) as to all matters
(including any action, suit, litigation, arbitration, mediation, claim, charge, complaint, inquiry, proceeding, hearing, audit, investigation or reviews by or before any governmental entity related hereto), including matters of validity,
construction, effect, performance and remedies; <I>provided</I>, <I>however</I>, that notwithstanding the foregoing, the obligations of the Investor under the California Public Records Act shall be construed and enforced in accordance with the
internal law of the State of California, without referenced to principles of conflicts of laws that would result in the application of any law other than the law of the State of California. Notwithstanding anything to the contrary in this
Section&nbsp;10(l) or in Section&nbsp;10(m) below, the Investor reserves all of its rights arising under the Eleventh Amendment to the United States Constitution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">m. Each party hereto and any person asserting rights as a third party beneficiary may do so only if he, she or it irrevocably agrees that any
action, suit or proceeding between or among the parties hereto, whether arising in contract, tort or otherwise, arising in connection with any disagreement, dispute, controversy or claim arising out of or relating to this Subscription Agreement or
any related document or any of the transactions contemplated hereby or thereby (&#147;Legal Dispute&#148;) shall be brought only to the exclusive jurisdiction of the state courts of the State of Delaware (or the federal courts located in the State
of Delaware if the state courts decline to hear the case), and each party hereto hereby consents to the jurisdiction of such courts (and of the appropriate appellate courts therefrom) in any such suit, action or proceeding and irrevocably waives, to
the fullest extent permitted by law, any objection that it may now or hereafter have to the laying of the venue of any such suit, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
action or proceeding in any such court or that any such suit, action or proceeding that is brought in any such court has been brought in an inconvenient forum. During the period a Legal Dispute
that is filed in accordance with this <U>Section</U><U></U><U>&nbsp;10(m)</U> is pending before a court, all actions, suits or proceedings with respect to such Legal Dispute or any other Legal Dispute, including any counterclaim, cross-claim or
interpleader, shall be subject to the exclusive jurisdiction of such court. Each party hereto and any person asserting rights as a third party beneficiary may do so only if he, she or it hereby waives, and shall not assert as a defense in any Legal
Dispute, that (i)&nbsp;such party is not personally subject to the jurisdiction of the above named courts for any reason, (ii)&nbsp;such action, suit or proceeding may not be brought or is not maintainable in such court, (iii)&nbsp;such party&#146;s
property is exempt or immune from execution, (iv)&nbsp;such action, suit or proceeding is brought in an inconvenient forum, or (v)&nbsp;the venue of such action, suit or proceeding is improper. A final judgment in any action, suit or proceeding
described in this <U>Section</U><U></U><U>&nbsp;10(m)</U> following the expiration of any period permitted for appeal and subject to any stay during appeal shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in
any other manner provided by applicable Laws. EACH OF THE PARTIES HERETO AND ANY PERSON ASSERTING RIGHTS AS A THIRD PARTY BENEFICIARY MAY DO SO ONLY IF HE, SHE OR IT IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT TO TRIAL BY JURY ON ANY CLAIMS OR
COUNTERCLAIMS ASSERTED IN ANY LEGAL DISPUTE RELATING TO THIS SUBSCRIPTION AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY AND FOR ANY COUNTERCLAIM RELATING THERETO. IF THE SUBJECT MATTER OF ANY SUCH LEGAL DISPUTE IS ONE IN WHICH THE WAIVER OF JURY
TRIAL IS PROHIBITED, NO PARTY HERETO NOR ANY PERSON ASSERTING RIGHTS AS A THIRD PARTY BENEFICIARY SHALL ASSERT IN SUCH LEGAL DISPUTE A NONCOMPULSORY COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS SUBSCRIPTION AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY. FURTHERMORE, NO PARTY HERETO NOR ANY PERSON ASSERTING RIGHTS AS A THIRD PARTY BENEFICIARY SHALL SEEK TO CONSOLIDATE ANY SUCH LEGAL DISPUTE WITH A SEPARATE ACTION OR OTHER LEGAL PROCEEDING IN WHICH A JURY TRIAL CANNOT BE WAIVED.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">n. Unless required by applicable law or any regulation or stock exchange listing requirement, CHFW will not disclose (i)&nbsp;the
Investor&#146;s identity in the form of this Subscription Agreement publicly filed, (ii)&nbsp;the Investor&#146;s identity or beneficial ownership of the subscribed Units or (iii)&nbsp;the nature of the Investor&#146;s commitments, arrangements and
understandings under and relating to this Subscription Agreement. If such disclosure is required by applicable law or any regulation or stock exchange listing requirement, CHFW shall provide the Investor with prior written notice (including by <FONT
STYLE="white-space:nowrap">e-mail)</FONT> of such required disclosure and provide the Investor with a reasonable opportunity to review and comment on the disclosure (and CHFW shall consider all of Investor&#146;s comments in good faith). The
Investor will promptly provide any information reasonably requested by CHFW or the Company for any regulatory application or filing made or approval sought in connection with the Transaction (including filings with the SEC). Notwithstanding anything
in this Subscription Agreement to the contrary, CHFW shall not (and shall cause the Company and the Placement Agents not to), without the prior written consent of the Investor, publicly disclose the name of the Investor or any of its affiliates or
advisors, or include the name of the Investor or any of its affiliates or advisors, in any press release or marketing materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">o. CHFW
shall, by 9:30 a.m., New York City time, on the first (1st) business day immediately following the date of this Subscription Agreement, issue one or more press releases or file with the SEC a Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> (collectively, the &#147;Disclosure Document&#148;), each in a form agreed between CHFW and the Investor so long as the Investor&#146;s Subscription Amount is for an amount of at least $10.0&nbsp;million,
disclosing, to the extent not previously publicly disclosed, all material terms of the transactions contemplated hereby (and of the other subscription agreements related to the private placement of the Units entered into prior to the release or
filing of such Disclosure Document), the Transaction and any other material, <FONT STYLE="white-space:nowrap">non-public</FONT> information that CHFW or the Company has provided to the Investor at any time prior to the filing of the Disclosure
Document. As of immediately following the filing of the Disclosure Document with the SEC, the Investor shall not be in possession of any material, <FONT STYLE="white-space:nowrap">non-public</FONT> information received from CHFW, the Company, any of
their respective subsidiaries or any of their respective officers, directors, employees, affiliates or agents or the Placement Agents that is not disclosed in the Disclosure Document or in prior filings with the SEC. In
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
addition, effective upon the filing of the Disclosure Document, CHFW acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral,
between CHFW, on the one hand, and the Investor or any of its affiliates, on the other hand, relating to the transactions contemplated by this Subscription Agreement shall terminate and be of no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">p. If any change in the number, type or classes of authorized shares of CHFW (including the Shares) shall occur between the date hereof and
immediately prior to the Closing by reason of reclassification, recapitalization, stock split (including reverse stock split) or combination, exchange or readjustment of shares, redomicilation or any stock dividend, or otherwise, the number of Units
issued to the Investor shall be appropriately adjusted to reflect such change. Further, CHFW agrees that without the consent of the Investor, so long as the Investor&#146;s Subscription Amount (together with the subscription amounts under Other
Subscription Agreements with Other Investors who are affiliates of Investor) is for an amount of at least $25.0&nbsp;million, (i)&nbsp;CHFW will not consent to, waive, amend or otherwise modify (or seek a consent, waiver, amendment or other
modification from the Company regarding) any provision of the Merger Agreement to permit the Company or CHFW to issue or accelerate the vesting of any securities not expressly contemplated by Section&nbsp;2.1 and Section&nbsp;2.4 of the Merger
Agreement, including any consents or waivers pursuant to Section&nbsp;5.1 or Section&nbsp;5.10 of the Merger Agreement, (ii)&nbsp;CHFW will not issue more than 12,020,000 Units, in the aggregate, pursuant to this Subscription Agreement and the Other
Subscription Agreements (or any other agreement contemplating the issuance of securities at or prior to the Closing, other than pursuant to the Merger Agreement) and (iii)&nbsp;CHFW will not consent to, waive, amend or otherwise modify (or seek a
consent, waiver, amendment or other modification from the Company regarding) the Sponsor Letter Agreement, dated as of the date hereof, by and among CHFW, Consonance Life Sciences, the other holders of CHFW Class&nbsp;B ordinary shares set forth on
the signature page thereto and the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">q. The obligations of Investor under this Subscription Agreement are several and not joint
with the obligations of any Other Investor or investor under the Other Subscription Agreements, and Investor shall not be responsible in any way for the performance of the obligations of any Other Investor or investor under this Subscription
Agreement or the Other Subscription Agreements. The decision of Investor to purchase Units has been made by Investor independently of any Other Investor or investor. Nothing contained herein or in any Other Subscription Agreement, and no action
taken by the Investor or any Other Investor or investor, shall be deemed to constitute Investor and any Other Investor or investor as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that Investor
and any Other Investors or investors are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this Subscription Agreement and the Other Subscription Agreements. Investor shall be entitled to
independently protect and enforce its rights, including without limitation the rights arising out of this Subscription Agreement, and it shall not be necessary for any Other Investor or investor to be joined as an additional party in any proceeding
for such purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11. <U><FONT STYLE="white-space:nowrap">Non-Reliance</FONT> and Exculpation</U>. The Investor acknowledges that it is
not relying upon, and has not relied upon, any statement, representation or warranty made by any person, firm or corporation (including, without limitation, the Company, <U>the Placement Agents</U>, any of their respective affiliates or any control
persons, officers, directors, employees, partners, agents or representatives of any of the foregoing), other than the statements, representations and warranties of CHFW expressly contained in this Subscription Agreement, in making its investment or
decision to invest in CHFW. The Investor further acknowledges and agrees that none of the Placement Agents, their respective affiliates or any control persons, officers, directors, employees, partners, agents or representatives, or any <FONT
STYLE="white-space:nowrap">Non-Party</FONT> Affiliate of the Placement Agents, shall have any liability to the Investor, or to any other investor, pursuant to, arising out of or relating to this Subscription Agreement or any other subscription
agreement related to the private placement of the Units, the negotiation hereof or thereof or its subject matter, or the transactions contemplated hereby or thereby, including, without limitation, with respect to any action heretofore or hereafter
taken or omitted to be taken by any of them in connection with the purchase of the Units. For purposes of this Subscription Agreement, <FONT STYLE="white-space:nowrap">&#147;Non-Party</FONT> Affiliates&#148; means each former, current or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
future officer, director, employee, partner, member, manager, direct or indirect equityholder or affiliate of any Placement Agent and any Placement Agent&#146;s controlled affiliates or any
family member of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>SIGNATURE PAGES FOLLOW</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, the Investor has executed or caused this Subscription Agreement
to be executed by its duly authorized representative as of the date set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name of Investor:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">State/Country of Formation or Domicile:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name in which Units are to be registered (if different):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Investor&#146;s EIN:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Business Address-Street:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mailing Address-Street (if different):</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">City, State, Zip:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">City, State, Zip:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attn:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attn:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Telephone No.:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Telephone No.:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Facsimile No.:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Facsimile No.:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Number of Units subscribed for:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Aggregate Subscription Amount: $</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Price Per Unit: $10.00</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You must pay the Subscription Amount by wire transfer of United States dollars in immediately available funds
to the account specified by CHFW in the Closing Notice. To the extent the offering is oversubscribed, the number of Units received may be less than the number of Units subscribed for. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">IN WITNESS WHEREOF, <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp.
has accepted this Subscription Agreement as of the date set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION
CORP.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&nbsp;</P></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Title:</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ,
2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE A </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELIGIBILITY REPRESENTATIONS OF THE INVESTOR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A.</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">QUALIFIED INSTITUTIONAL BUYER STATUS </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(Please check the applicable subparagraphs): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#9744;&nbsp;We are a &#147;qualified institutional buyer&#148; (as defined in Rule 144A under the Securities Act (a
&#147;QIB&#148;)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">**OR** </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">B.</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">INSTITUTIONAL ACCREDITED INVESTOR STATUS </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(Please check the applicable subparagraphs): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1.</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">&#9744; We are an &#147;accredited investor&#148; (within the meaning of Rule 501(a) under the Securities
Act or an entity in which all of the equity holders are accredited investors within the meaning of Rule 501(a) under the Securities Act), and have marked and initialed the appropriate box below indicating the provision under which we qualify as an
&#147;accredited investor.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2.</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">&#9744; We are not a natural person. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Rule 501(a), in relevant part, states that an &#147;accredited investor&#148; shall mean any person who comes within any of the below listed
categories, or who CHFW reasonably believes comes within any of the below listed categories, at the time of the sale of the securities to that person. The Investor has indicated, by marking and initialing the appropriate box below, the provision(s)
below which apply to the Investor and under which the Investor accordingly qualifies as an &#147;accredited investor.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#9744;&nbsp;Any bank, registered broker or dealer, insurance company, registered investment company, business development
company, or small business investment company, as described in Rule 501(a)(1) or (2); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#9744;&nbsp;Any plan established
and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions for the benefit of its employees, if such plan has total assets in excess of $5,000,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#9744;&nbsp;Any employee benefit plan, within the meaning of the Employee Retirement Income Security Act of 1974, if a bank,
insurance company, or registered investment adviser makes the investment decisions, or if the plan has total assets in excess of $5,000,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#9744;&nbsp;Any organization described in Section&nbsp;501(c)(3) of the Internal Revenue Code, corporation, Massachusetts or
similar business trust, partnership, or limited liability company, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#9744;&nbsp;Any trust with assets in excess of $5,000,000, not formed to acquire the securities offered, whose purchase is
directed by a sophisticated person as described in Rule 506(b)(2)(ii); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">&#9744;&nbsp;Any entity in which all of the
equity owners are accredited investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>This page should be completed by the Investor </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>and constitutes a part of the Subscription Agreement. </I></B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Warrant Agreement </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="annex_g"></A><A NAME="rom40894_256"></A>ANNEX G </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN, INC. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF
INVESTORS&#146; RIGHTS AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>T<SMALL>HIS</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (this &#147;<B><I>Agreement</I></B>&#148;) is dated as of April&nbsp;15, 2021, and is by and among Surrozen, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;) (formerly named <FONT
STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp.), Consonance Life Sciences, a Cayman Islands limited liability company (the &#147;<B><I>Sponsor</I></B>&#148;), the persons and entities listed on <B>E<SMALL>XHIBIT</SMALL> A</B>
(together with their Permitted Transferees that become party hereto, each, a &#147;<B><I>Named</I></B> <B><I>Investor</I></B>&#148;) and the persons and entities listed on <B>E<SMALL>XHIBIT</SMALL> B</B> (together with their Permitted Transferees
that become party hereto, each, an &#147;<B><I>Individual Investor</I></B>&#148;, and collectively with the Named Investors, the &#147;<B><I>Investors</I></B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company, Perseverance Merger Sub, Inc., a Delaware corporation (the &#147;<B><I>Merger Sub</I></B>&#148;), and Surrozen Holdings, Inc.
(formerly named Surrozen, Inc. (&#147;<B><I>Surrozen</I></B>&#148;) have entered into that certain Business Combination Agreement, dated as of April&nbsp;15, 2021 (as amended, modified and/or supplemented from time to time, the
&#147;<B><I>BCA</I></B>&#148;), pursuant to which, among other things, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, became a wholly-owned subsidiary of the
Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the BCA, the Company, the Sponsor and the Investors have agreed to enter into this Agreement concurrently with the
Closing (as defined in the BCA), pursuant to which, among other things, the Investors (a)&nbsp;will agree not to effect any sale or distribution of any Equity Securities (as defined in the BCA) of the Company held by any of them during the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period described therein, and (b)&nbsp;will be granted certain registration rights with respect to their respective CHFW Shares (as defined in the BCA), in each case, on the terms and subject to the
conditions of this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company, the Sponsor, the Consonance Investors and certain other Investors are party to that certain
Registration and Shareholder Rights Agreement, dated as of November&nbsp;18, 2020 (the &#147;<B><I>Original Agreement</I></B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to Section&nbsp;6.8 of the Original Agreement, the provisions, covenants and conditions set forth therein may be amended or modified
upon the written consent of the Company and the Holders (as defined in the Original Agreement) of at least a majority in interest of the Registrable Securities (as defined in the Original Agreement) at the time in question, and the Sponsor, the
Consonance Investors and such other Investors are Holders in the aggregate of all of the Registrable Securities as of the date hereof; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company, the Sponsor and certain of the Named Investors desire to amend and restate the Original Agreement in its entirety and enter into
this Agreement, pursuant to which the Company shall grant the Holders certain registration rights with respect to certain securities of the Company, as set forth in this Agreement, and terminate the Original Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company and the other parties to this Agreement therefore agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>1.1</B> <B>Certain Definitions</B>. As used in this Agreement, the following terms shall have the meanings set forth below:
<B></B>&#147;<B><I>Affiliate</I></B>&#148; means, (i)&nbsp;with respect to any specified Person that is not a natural person, (a)&nbsp;any other Person which directly or indirectly through one or more intermediaries controls, or is controlled by, or
is under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
common control with, such specified Person, and (b)&nbsp;any corporation, trust, limited liability company, general or limited partnership or other entity advised or managed by, or under common
control or management with, such Person (for the purposes of this definition, &#147;control&#148; (including, with correlative meanings, the terms &#147;controlling,&#148; &#147;controlled by&#148; and &#147;under common control with&#148;), as used
with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such Person, whether through the ownership of voting securities, by agreement or otherwise) and
(ii)&nbsp;with respect to any natural person, any Member of the Immediate Family of such natural person, or any Person that is, directly or indirectly, controlled by such specified natural person; <I>provided</I> that the Company and each of its
subsidiaries shall be deemed not to be Affiliates of any Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> &#147;<B><I>Commission</I></B>&#148; shall
mean the Securities and Exchange Commission or any other federal agency at the time administering the Securities Act (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> &#147;<B><I>Common Stock</I></B>&#148; shall mean the Common Stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> &#147;<B><I>Consonance Investors</I></B>&#148; shall mean those Named Investors on Exhibit A under the heading
&#147;Consonance Investors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> &#147;<B><I>Consonance Holders</I></B>&#148; means, as of any determination
time, Consonance Investors who hold Registrable Securities under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B> &#147;<B><I>Exchange
Act</I></B>&#148; shall mean the Securities Exchange Act of 1934, as amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g)</B> &#147;<B><I>Holder</I></B>&#148; shall mean any Investor who holds Registrable Securities and any holder of
Registrable Securities to whom the registration rights conferred by this Agreement have been duly and validly transferred in accordance with Section&nbsp;3.2 of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(h)</B> <B><I>&#147;Form <FONT STYLE="white-space:nowrap">S-1</FONT> Shelf&#148; </I></B>shall have the meaning given in
<U>Section</U><U></U><U>&nbsp;2.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> <B><I>&#147;Form <FONT STYLE="white-space:nowrap">S-3</FONT>
Shelf&#148; </I></B>shall have the meaning given in <U>Section</U><U></U><U>&nbsp;2.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(j)</B>
&#147;<B><I>Indemnified Party</I></B>&#148; shall have the meaning set forth in Section&nbsp;2.6(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(k)</B>
&#147;<B><I>Indemnifying Party</I></B>&#148; shall have the meaning set forth in Section&nbsp;2.6(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(l)</B>
&#147;<B><I>Individual Investor</I></B>&#148; shall have the meaning set forth in the preamble. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(m)</B>
&#147;<B><I>Individual Investor Shares</I></B>&#148; means all shares of Common Stock originally issued to, or issued with respect to shares originally issued to, or held by, an Individual Investor, whenever issued, including all shares of Common
Stock issued upon the exercise, conversion or exchange of any options, warrants or convertible securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(n)</B>
&#147;<B><I>Individual Holders</I></B>&#148; means, as of any determination time, Individual Investors who hold Registrable Securities under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(o)</B> &#147;<B><I>Permitted Transferee</I></B>&#148; shall mean with respect to each Holder and its Permitted
Transferees, (a)&nbsp;prior to the expiration of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, any person or entity to whom such Holder is permitted to transfer such Registrable Securities prior to the expiration of the <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Period pursuant to <U>Section</U><U></U><U>&nbsp;2.11</U> and (b)&nbsp;after the expiration of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, any person or entity to whom such Holder is
permitted to transfer such Registrable Securities, subject to and in accordance with any applicable agreement between such Holder and/or its Permitted Transferees and the Company and any transferee thereafter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(p)</B> &#147;<B><I>PIPE Securities</I></B>&#148; shall mean the shares
of Common Stock and warrants (including shares of Common Stock issued or issuable upon exercise or conversion of such warrants) issued in the PIPE Financing (as defined in the BCA). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(q)</B> &#147;<B><I>Qualified Holders</I></B>&#148; shall mean the Sponsor or any Consonance Holder or Consonance Holders
who in the aggregate hold not less than [_]% of the outstanding Registrable Securities or any Surrozen Holder or Surrozen Holders who in the aggregate hold not less than [_]% of the outstanding Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(r)</B> &#147;<B>Other Selling Stockholders</B>&#148; shall mean persons other than Holders who, by virtue of agreements
with the Company, are entitled to include their Other Shares in certain registrations hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(s)</B>
&#147;<B>Other Shares</B>&#148; shall mean shares of Common Stock, other than Registrable Securities (as defined below), with respect to which registration rights have been granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(t)</B> &#147;<B><I>Registrable Securities</I></B>&#148; shall mean (i)&nbsp;any outstanding shares of Common Stock and any
other equity security (including shares of Common Stock issued or issuable upon the exercise or conversion of any other equity security and including, for the avoidance of doubt, the PIPE Securities), (ii) any outstanding shares of Common Stock or
any other equity security (including warrants to purchase shares of Common Stock and shares of Common Stock issued or issuable upon the exercise or conversion of any other equity security) of the Company acquired by an Investor following the date
hereof to the extent that such securities are &#147;restricted securities&#148; (as defined in Rule 144) or are otherwise held by an &#147;affiliate&#148; (as defined in Rule 144) of the Company and (iii)&nbsp;any other equity security of the
Company or any of its subsidiaries issued or issuable with respect to any securities referenced in clause (i)&nbsp;or (ii) above as a dividend or other distribution with respect thereto or in exchange therefor or in replacement thereof; <I>provided,
however</I>, that Registrable Securities shall not include any shares of Common Stock described in clause (i), (ii) or (iii)&nbsp;above for which (a)&nbsp;a registration statement with respect to the sale of such shares of Common Stock has become
effective under the Securities Act and such shares have been sold, transferred, disposed of or exchanged in accordance with such registration statement by the applicable Investor, (b)&nbsp;such shares have been sold to the public pursuant to Rule
144 (but with no volume or manner of sale or current public information requirement) or (c)&nbsp;such shares have been sold to, or through, a broker, dealer or underwriter in a public distribution or other public securities transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(u)</B> The terms &#147;register,&#148; &#147;registered&#148; and &#147;registration&#148; shall refer to a registration
effected by preparing and filing a registration statement in compliance with the Securities Act (as defined below) and applicable rules and regulations thereunder, and the declaration or ordering of the effectiveness of such registration statement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v)</B> &#147;<B><I>Registration Expenses</I></B>&#148; shall mean all expenses incurred in effecting any registration
pursuant to this Agreement, including, without limitation, all registration, qualification, and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company, reasonable documented fees and disbursements of one
special counsel for the Named Holders not to exceed $75,000 without the consent of the Company, blue sky fees and expenses, and expenses of any regular or special audits incident to or required by any such registration, but shall not include Selling
Expenses, and the compensation of regular employees of the Company, which shall be paid in any event by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(w)</B> <B>&#147;</B><B><I>Registration Statement</I></B>&#148; means any registration statement of the Company filed with,
or to be filed with, the SEC under the Securities Act, including the related prospectus, amendments and supplements to such registration statement, including <FONT STYLE="white-space:nowrap">pre-</FONT> and post-effective amendments, and all
exhibits and all material incorporated by reference in such registration statement other than a registration statement (and related Prospectus) filed on Form <FONT STYLE="white-space:nowrap">S-4</FONT> or Form
<FONT STYLE="white-space:nowrap">S-8</FONT> or any successor form thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(x)</B> &#147;<B><I>Restated
Certificate</I></B>&#148; shall mean the Company&#146;s Amended and Restated Certificate of Incorporation, as the same may be amended from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(y)</B> &#147;<B><I>Restricted Securities</I></B>&#148; shall mean any
Registrable Securities that were not issued to an Investor pursuant to an effective registration statement in accordance with the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(z)</B> &#147;<B><I>Rule 144</I></B>&#148; shall mean Rule 144 as promulgated by the Commission under the Securities Act,
as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(aa)</B> &#147;<B><I>Rule 145</I></B>&#148; shall mean Rule 145 as promulgated by the Commission under the Securities Act,
as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(bb)</B> &#147;<B><I>Rule 415</I></B>&#148; shall mean Rule 415 as promulgated by the Commission under the Securities Act,
as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(cc)</B> &#147;<B><I>Securities Act</I></B>&#148; shall mean the Securities Act of 1933, as amended, or any similar
successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(dd)</B> &#147;<B><I>Selling Expenses</I></B>&#148; shall mean all underwriting discounts, selling commissions and stock
transfer taxes applicable to the sale of Registrable Securities and fees and disbursements of counsel for any Holder (other than the fees and disbursements of one special counsel to the Holders included in Registration Expenses). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ee)</B> <B><I>&#147;Shelf Registration&#148; </I></B>shall mean a registration of securities pursuant to a registration
statement filed with the Commission in accordance with and pursuant to Rule 415 promulgated under the Securities Act (or any successor rule then in effect). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ff)</B> <B><I>&#147;Shelf Takedown&#148; </I></B>shall mean an Underwritten Shelf Takedown or any proposed transfer or
sale using a Registration Statement, including a Piggyback Registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(gg)</B> &#147;<B><I>Surrozen
Holders</I></B>&#148; means, as of any determination time, Surrozen Investors who hold Registrable Securities under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(hh)</B> &#147;<B><I>Surrozen Investors</I></B>&#148; shall mean those Named Investors on Exhibit A under the heading
&#147;Surrozen Investors.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.1</B> <B>Requested Registration</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(a) <B><I>Filing</I></B>. Within thirty (30)&nbsp;calendar days following the Closing Date, the Company shall file with the
Commission a Registration Statement for a Shelf Registration on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (the <B><I>&#147;Form <FONT STYLE="white-space:nowrap">S-1</FONT> Shelf&#148;</I></B>)<B><I> </I></B>or a Registration Statement for a
Shelf Registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (the <B><I>&#147;Form <FONT STYLE="white-space:nowrap">S-3</FONT> Shelf&#148;</I></B>),<B><I> </I></B>if the Company is then eligible to use a Form
<FONT STYLE="white-space:nowrap">S-3</FONT> Shelf, in each case, covering the resale of all the Registrable Securities (determined as of two (2)&nbsp;business days prior to such submission or filing) on a delayed or continuous basis and shall use
its commercially reasonable efforts to have such Shelf declared effective as soon as practicable after the filing thereof, but no later than the earlier of (a)&nbsp;sixty (60) calendar days (or ninety (90)&nbsp;calendar days if the Commission
notifies the Company that it will &#147;review&#148; such Shelf Registration) following the initial filing date thereof and (b)&nbsp;ten (10) business days after the Company is notified (orally or in writing, whichever is earlier) by the SEC that
such Shelf Registration will not be &#147;reviewed&#148; or will not be subject to further review. Such Shelf </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
shall provide for the resale of the Registrable Securities included therein pursuant to any method or combination of methods legally available (the <B><I>&#147;Plan </I></B><B><I>of
Distribution&#148;) </I></B>to, and requested by, any Holder named therein. The Company shall engage an underwriter or underwriters reasonably acceptable to the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the Registerable Securities to participate in the preparation of the Shelf to enable the Holders to resell Registrable Securities pursuant to the
Plan of Distribution. The Company shall maintain a Shelf in accordance with the terms hereof, and shall prepare and file with the Commission such amendments, including post-effective amendments, and supplements as may be necessary to keep a Shelf
continuously effective, available for use to permit the Holders named therein to sell their Registrable Securities included therein and in compliance with the provisions of the Securities Act until such time as there are no longer any Registrable
Securities. In the event the Company files a Form <FONT STYLE="white-space:nowrap">S-1</FONT> Shelf, the Company shall use its commercially reasonable efforts to convert the Form <FONT STYLE="white-space:nowrap">S-1</FONT> Shelf (and any Subsequent
Shelf Registration Statement) to a Form <FONT STYLE="white-space:nowrap">S-3</FONT> Shelf as soon as practicable after the Company is eligible to use a Form <FONT STYLE="white-space:nowrap">S-3</FONT> Shelf. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B><I>Reserved</I></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B><I>Subsequent Shelf Registration</I></B><B>.</B> If any Shelf ceases to be effective under the Securities Act
for any reason at any time while Registrable Securities are still outstanding, upon the written request from a Qualified Holder, the Company shall, subject to <U>Section</U><U></U><U>&nbsp;2.1(e)</U>, use its commercially reasonable efforts to as
promptly as practicable cause such Shelf to again become effective under the Securities Act (including using its commercially reasonable efforts to obtain the prompt withdrawal of any order suspending the effectiveness of such Shelf), and shall use
its commercially reasonable efforts to as promptly as is reasonably practicable amend such Shelf in a manner reasonably expected to result in the withdrawal of any order suspending the effectiveness of such Shelf or file an additional registration
statement as a Shelf Registration (a <B><I>&#147;Subsequent Shelf Registration Statement&#148;) </I></B>registering the resale of all Registrable Securities (determined as of two (2)&nbsp;business days prior to such filing), and pursuant to the Plan
of Distribution. The Company shall engage an underwriter or underwriters reasonably acceptable to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the Registerable Securities to participate
in the preparation of the Subsequent Shelf Registration Statement to enable the Holders to resell Registrable Securities pursuant to the Plan of Distribution. If a Subsequent Shelf Registration Statement is filed, the Company shall use its
commercially reasonable efforts to (i)&nbsp;cause such Subsequent Shelf Registration Statement to become effective under the Securities Act as promptly as is reasonably practicable after the filing thereof and (ii)&nbsp;keep such Subsequent Shelf
Registration Statement continuously effective, available for use to permit the Holders named therein to sell their Registrable Securities included therein and in compliance with the provisions of the Securities Act until such time as there are no
longer any Registrable Securities. Any such Subsequent Shelf Registration Statement shall be on Form <FONT STYLE="white-space:nowrap">S-3</FONT> to the extent that the Company is eligible to use such form. Otherwise, such Subsequent Shelf
Registration Statement shall be on another appropriate form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> <B><I>Additional Registrable Securities</I></B>.
Subject to <U>Section</U><U></U><U>&nbsp;2.1(e),</U> in the event that any Holder holds Registrable Securities that are not registered for resale on a delayed or continuous basis, the Company, upon written request of such Holder, shall promptly use
its commercially reasonable efforts to cause the resale of such Registrable Securities to be covered by either, at the Company&#146;s option, any then available Shelf (including by means of a post-effective amendment) or by filing a Subsequent Shelf
Registration Statement and cause the same to become effective as soon as practicable after such filing and such Shelf or Subsequent Shelf Registration Statement shall be subject to the terms hereof; <U>provided</U>, <U>however</U>, that the Company
shall only be required to cause such additional Registrable Securities to be so covered two per calendar year for each Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> <B><I>Deferral</I></B>. If (i)&nbsp;in the good faith judgment of the Board of Directors of the Company, the filing
of a registration statement covering the Registrable Securities would be materially detrimental to the Company and the Board of Directors of the Company concludes, as a result, that it is in the best interests of the Company to defer the filing of
such registration statement at such time, and (ii)&nbsp;the Company shall furnish to such Holders a certificate signed by the President of the Company stating that in the good faith judgment of the Board of Directors of the Company, it would be
materially detrimental to the Company for such registration statement to be filed in the near future and that it is, therefore, in the best interests of the Company to defer the filing of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
registration statement (which notice shall not specify the nature of the event giving rise to such delay or suspension), then (in addition to the limitations set forth in Section&nbsp;2.1(b)(v)
above) the Company shall have the right to defer such filing for the shortest period of time determined in good faith by the Company to be necessary for such purpose, but in no event for a period of more than ninety (90)&nbsp;days following such
good faith determination by the Board of Directors of the Company, and, provided further, that the Company shall not defer its obligation in this manner more than two (2)&nbsp;times in any twelve-month period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B> <B><I>Underwriting</I></B>. At any time and from time to time when an effective Shelf is on file with the
Commission, a Qualified Holder or Qualified Holders (an &#147;<B><I>Initiating Holder</I></B>&#148; or &#147;<B><I>Initiating Holders</I></B><I>&#148;</I>) may request to sell all or any portion of its Registrable Securities by means of an
underwriting that is registered pursuant to the Shelf (each, an &#147;<B><I>Underwritten Shelf Takedown</I></B>&#148;);<B><I> </I></B><U>provided</U> that the Company shall only be obligated to effect an Underwritten Shelf Takedown if such offering
shall include Registrable Securities proposed to be sold by the Initiating Holder, either individually or together with other Initiating Holders, with a total offering price reasonably expected to exceed, in the aggregate, at least $[__] million
(the <B><I>&#147;Minimum Takedown Threshold&#148;)</I></B>. The Company shall not be required to effect more than [__] Underwritten Shelf Takedowns for the Consonance Holders or more than [__] for the Surrozen Holders. All requests for Underwritten
Shelf Takedowns shall be made by giving written notice to the Company, which shall specify the approximate number of Registrable Securities proposed to be sold in the Underwritten Shelf Takedown. If the Company shall request inclusion in any
underwriting pursuant to this Section&nbsp;2.1(f) of securities being sold for its own account, or if other persons shall request inclusion in such underwriting, the Initiating Holders shall, on behalf of all Holders, offer to include such
securities in the underwriting and such offer shall be conditioned upon the participation of the Company or such other persons in such underwriting and the inclusion of the Company&#146;s and such person&#146;s other securities of the Company and
their acceptance of the further applicable provisions of this Section&nbsp;2 (including Section&nbsp;2.10). The Initiating Holders shall (together with all Holders and other persons proposing to distribute their securities through such underwriting)
enter into an underwriting agreement in customary form with the representative of the underwriter or underwriters selected for such underwriting by the Initiating Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding any other provision of this Section&nbsp;2.1, if the Initiating Holders are (A)&nbsp;Consonance Holders and the underwriters
advise such Initiating Holders in good faith in writing that marketing factors require a limitation on the number of shares to be underwritten, the number of Registrable Securities that may be so included shall be allocated as follows:
(i)&nbsp;first, among all Consonance Holders requesting to include Registrable Securities in such registration statement based on the <I>pro rata</I> percentage of Registrable Securities held by such Consonance Holders; (ii)&nbsp;second, to Surrozen
Holders based on the <I>pro rata</I> percentage of Registrable Securities held by such Surrozen Holders; (iii)&nbsp;third, to the other Holders based on the <I>pro rata</I> percentage of Registrable Securities held by such Holders; and
(iii)&nbsp;fourth, to the Company, which the Company may allocate, at its discretion, for its own account, or for the account of other holders or employees of the Company or (B)&nbsp;Surrozen Holders and the underwriters advise such Initiating
Holders in good faith in writing that marketing factors require a limitation on the number of shares to be underwritten, the number of Registrable Securities that may be so included shall be allocated as follows: (i)&nbsp;first, among all Surrozen
Holders requesting to include Registrable Securities in such registration statement based on the <I>pro rata</I> percentage of Registrable Securities held by such Surrozen Holders; (ii)&nbsp;second, to Consonance Holders based on the <I>pro rata</I>
percentage of Registrable Securities held by such Consonance Holders; (iii)&nbsp;third, to the other Holders based on the <I>pro rata</I> percentage of Registrable Securities held by such Holders; and (iii)&nbsp;fourth, to the Company, which the
Company may allocate, at its discretion, for its own account, or for the account of other holders or employees of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a
person who has requested inclusion in such registration as provided above does not agree to the terms of any such underwriting, such person shall be excluded therefrom by written notice from the Company, the underwriter or the Initiating Holders.
The securities so excluded shall also be withdrawn from registration. Any Registrable Securities or other securities excluded or withdrawn from such underwriting shall also be withdrawn from such registration. If shares are so withdrawn from the
registration and if the number of shares to be included in such registration was previously reduced as a result of marketing factors pursuant to this Section&nbsp;2.1(d), then </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the Company shall then offer to all Holders and Other Selling Stockholders who have retained rights to include securities in the registration the right to include additional Registrable
Securities or Other Shares in the registration in an aggregate amount equal to the number of shares so withdrawn, with such shares to be allocated among such Holders and Other Selling Stockholders requesting additional inclusion, as set forth above.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.2</B> <B>Company Registration</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B><I>Company Registration</I></B>. If the Company or any Holder proposes to conduct a registered offering, or if
the Company proposes to register any of its securities either for its own account or the account of a security holder or holders (or by the Company and by the stockholders of the Company including, without limitation, an Underwritten Shelf Takedown
pursuant to <U>Section</U><U></U><U>&nbsp;2.1(f)</U>), other than a Registration Statement (or any registered offering with respect thereto)&nbsp;(i) filed in connection with any employee stock option or other benefit plan, (ii)&nbsp;pursuant to a
Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> (or similar form that relates to a transaction subject to Rule 145 under the Securities Act or any successor rule thereto), (iii) for an offering of debt that is convertible
into equity securities of the Company, (iv)&nbsp;for a dividend reinvestment plan, (v)&nbsp;a Block Trade or (vi)&nbsp;an Other Coordinated Offering, the Company will: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> give written notice of the proposed registration to all Holders of Registrable Securities as soon as practicable
but not less than ten (10)&nbsp;days before the anticipated filing date of such Registration Statement or, in the case of an Underwritten Offering pursuant to a Shelf Registration, the applicable &#147;red herring&#148; prospectus or prospectus
supplement used for marketing such offering, which notice shall (A)&nbsp;describe the amount and type of securities to be included in such offering, the intended method(s) of distribution, and the name of the proposed managing Underwriter or
Underwriters, if any, in such offering, and (B)&nbsp;offer to all of the Holders of Registrable Securities the opportunity to include in such registered offering such number of Registrable Securities as such Holders may request in writing within
five (5)&nbsp;days after receipt of such written notice (such registered offering, a <B><I>&#147;Piggyback Registration&#148;)</I></B>; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> include, or, if applicable, use its commercially reasonable efforts to cause the managing Underwriter or
Underwriters of such Piggyback Registration to include, in such registration (and any related qualification under blue sky laws or other compliance), except as set forth in Section&nbsp;2.2(b) below, in any underwriting involved therein, and to
permit the sale or other disposition of such Registrable Securities in accordance with the intended method(s) of distribution thereof, all of such Registrable Securities as are specified in a written request or requests made by any Holder or Holders
received by the Company within ten (10)&nbsp;days after such written notice from the Company is mailed or delivered. Such written request may specify all or a part of a Holder&#146;s Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B><I>Underwriting</I></B>. If the registration of which the Company gives notice is for a registered public
offering involving an underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to Section&nbsp;2.2(a)(i). In such event, the right of any Holder to registration pursuant to this Section&nbsp;2.2 shall be
conditioned upon such Holder&#146;s participation in such underwriting and the inclusion of such Holder&#146;s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through
such underwriting shall (together with the Company and the other holders of securities of the Company with registration rights to participate therein distributing their securities through such underwriting) enter into an underwriting agreement in
customary form with the representative of the underwriter or underwriters selected by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding any other provision of
this Section&nbsp;2.2, if the underwriters advise the Company in writing that marketing factors require a limitation on the number of shares to be underwritten, the underwriters may (subject to the limitations set forth below) exclude all
Registrable Securities from, or limit the number of Registrable Securities to be included in, the registration and underwriting. The Company shall so advise all holders of securities requesting registration, and the number of shares of securities
that are entitled to be included in the registration and underwriting shall be allocated, as follows: (i)&nbsp;first, to the Company for securities being </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
sold for its own account, (ii)&nbsp;second, to the Holders requesting to include Registrable Securities in such registration statement based on the <I>pro rata</I> percentage of Registrable
Securities held by such Holders, assuming conversion and (iii)&nbsp;third, to the other Other Selling Stockholders requesting to include Other Shares in such registration statement based on the <I>pro rata</I> percentage of Other Shares held by such
Other Selling Stockholders, assuming conversion. Notwithstanding the foregoing, no such reduction shall reduce the value of the Registrable Securities of the Holders included in such registration below twenty five percent (25%) of the total value of
securities included in such registration, unless such registration does not include shares of any Other Selling Stockholders (excluding shares registered for the account of the Company), in which event any or all of the Registrable Securities of the
Holders may be excluded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a person who has requested inclusion in such registration as provided above does not agree to the terms of
any such underwriting, such person shall also be excluded therefrom by written notice from the Company or the underwriter. The Registrable Securities or other securities so excluded shall also be withdrawn from such registration. Any Registrable
Securities or other securities excluded or withdrawn from such underwriting shall be withdrawn from such registration. If shares are so withdrawn from the registration and if the number of shares of Registrable Securities to be included in such
registration was previously reduced as a result of marketing factors pursuant to Section&nbsp;2.2(b), the Company shall then offer to all persons who have retained the right to include securities in the registration the right to include additional
securities in the registration in an aggregate amount equal to the number of shares so withdrawn, with such shares to be allocated among the persons requesting additional inclusion, in the manner set forth above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B><I>Right to Terminate Registration</I></B>. The Company shall have the right to terminate or withdraw any
registration initiated by it under this Section&nbsp;2.2 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. The Registration Expenses of any such terminated or withdrawn
registration shall be borne by the Company, any Piggyback Registration effected pursuant to this Section&nbsp;2.2 shall not be counted as an Underwritten Shelf Takedown under Section&nbsp;2.1(f). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.3</B> <B><I>Block Trades; Other Coordinated Offerings</I></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> Notwithstanding any other provision of this <U>Article II,</U> at any time and from time to time when an effective
Shelf is on file with the Commission, if an Initiating Holder notifies the Company that such Initiating Holder wishes to engage in (a)&nbsp;an underwritten registered offering not involving a &#147;roadshow,&#148; an offer commonly known as a
&#147;block trade&#148; (a <B><I>&#147;Block Trade&#148;), </I></B>or (b)&nbsp;an &#147;at the market&#148; or similar registered offering through a broker, sales agent or distribution agent, whether as agent or principal (an <B><I>&#147;Other
Coordinated Offering&#148;), </I></B>in each case, (x)&nbsp;with a total offering price reasonably expected to exceed $[__] million in the aggregate or (y)&nbsp;with respect to all remaining Registrable Securities held by the Initiating Holder, then
such Initiating Holder only needs to notify the Company of the Block Trade or Other Coordinated Offering at least five (5)&nbsp;business days prior to the day such offering is to commence and the Company shall, use its reasonable best efforts to
facilitate as expeditiously as possible, such Block Trade or Other Coordinated Offering of the Registrable Securities for which such Initiating Holder has requested such offering, without giving any effect to any required notice periods or delivery
of notices to any other Holders; <U>provided,</U> that the Initiating Holders representing a majority of the Registrable Securities wishing to engage in the Block Trade or Other Coordinated Offering shall use reasonable best efforts to work with the
Company and any Underwriters, brokers, sales agents or placement agents prior to making such request in order to facilitate preparation of the registration statement, prospectus and other offering documentation related to the Block Trade or Other
Coordinated Offering. Any offering conducted as a Block Trade or Other Coordinated Offering will not count as an Underwritten Shelf Takedown for the purposes of Section&nbsp;2.1(f). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> Prior to the filing of the applicable &#147;red herring&#148; prospectus or prospectus supplement used in
connection with a Block Trade or Other Coordinated Offering, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the Initiating Holders initiating such Block Trade or Other Coordinated Offering
shall have the right to submit a Withdrawal Notice to the Company, the Underwriter or Underwriters (if any) and any brokers, sales agents or placement agents (if any) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of their intention to withdraw from such Block Trade or Other Coordinated Offering. Notwithstanding anything to the contrary in this Agreement, the Company shall be responsible for the
Registration Expenses incurred in connection with a Block Trade or Other Coordinated Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> Notwithstanding
anything to the contrary in this Agreement, <U>Section</U><U></U><U>&nbsp;2.2 </U>shall not apply to a Block Trade or Other Coordinated Offering initiated by an Initiating Holder pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> The Initiating Holder in a Block Trade or Other Coordinated Offering shall have the right to select the
Underwriters and any brokers, sales agents or placement agents (if any) for such Block Trade or Other Coordinated Offering (in each case, which shall consist of one or more reputable nationally recognized investment banks). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.4</B> <B>Expenses of Registration</B>. All Registration Expenses incurred in connection with registrations pursuant to Sections 2.1, 2.2
and 2.3 shall be borne by the Company; <I>provided, however</I>, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Sections 2.1 and 2.3 if the registration request is subsequently
withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered or because a sufficient number of Holders shall have withdrawn so that the minimum offering conditions set forth in Sections 2.1 and 2.3 are no
longer satisfied (in which case all participating Holders shall bear such expenses <I>pro rata</I> among each other based on the number of Registrable Securities requested to be so registered), unless the Holders of a majority of the Registrable
Securities agree to forfeit their right to a demand registration pursuant to Section&nbsp;2.1; <I>provided, however</I>, in the event that a withdrawal by the Holders is based upon material adverse information relating to the Company that is
different from the information known or available (upon request from the Company or otherwise) to the Holders requesting registration at the time of their request for registration under Section&nbsp;2.1, such registration shall not be treated as a
counted registration for purposes of Section&nbsp;2.1, even though the Holders do not bear the Registration Expenses for such registration. All Selling Expenses relating to securities registered on behalf of the Holders shall be borne by the holders
of securities included in such registration <I>pro rata</I> among each other on the basis of the number of Registrable Securities so registered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.5</B> <B>Registration Procedures</B>. In the case of each registration effected by the Company pursuant to Section&nbsp;2, the Company
will keep each Holder advised in writing as to the initiation of each registration and as to the completion thereof. Without limiting anything else in this Agreement, at its expense, the Company will use its commercially reasonable efforts to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> Keep such registration continuously effective available for use to permit the Holders named therein to sell their
Registrable Securities included therein and in compliance with the provisions of the Securities Act until such time as there are no longer any Registrable Securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> Prepare and file with the Commission such amendments and supplements to such registration statement and the
prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement for the period set forth
in subsection (a)&nbsp;above; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> Furnish such number of prospectuses, including any preliminary prospectuses, and
other documents incident thereto, including any amendment of or supplement to the prospectus, as a Holder from time to time may reasonably request; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> Use its reasonable best efforts to register and qualify the securities covered by such registration statement under
such other securities or Blue Sky laws of such jurisdiction as shall be reasonably requested by the Holders; <I>provided</I>, that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to
file a general consent to service of process in any such states or jurisdictions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> At least five (5)&nbsp;days
prior to the filing of any registration or any amendment or supplement to such registration (or such shorter period of time as may be (a)&nbsp;necessary in order to comply with the Securities Act, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the Exchange Act, and the rules and regulations promulgated under the Securities Act or Exchange Act, as applicable or (b)&nbsp;advisable in order to reduce the number of days that sales are
suspended pursuant to Section&nbsp;2.11), furnish a copy thereof to each seller of such Registrable Securities or its counsel (excluding any exhibits thereto and any filing made under the Exchange Act that is to be incorporated by reference
therein); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B> Notify each seller of Registrable Securities covered by such registration statement at any time when
a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a
material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing, and following such notification promptly prepare and
furnish to such seller a reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such shares, such prospectus shall not include an untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g)</B> In the event of an Underwritten Offering, a Block Trade, an Other Coordinated Offering, or sale by a broker,
placement agent or sales agent pursuant to such Registration, in each of the following cases to the extent customary for a transaction of its type, permit a representative of the Holders, the Underwriters or other financial institutions facilitating
such Underwritten Offering, Block Trade, Other Coordinated Offering or other sale pursuant to such registration, if any, and any attorney, consultant or accountant retained by such Holders or Underwriter to participate, at each such person&#146;s or
entity&#146;s own expense, in the preparation of the registration statement, and cause the Company&#146;s officers, directors and employees to supply all information reasonably requested by any such representative, Underwriter, financial
institution, attorney, consultant or accountant in connection with the registration; provided, however, that such representatives, Underwriters or financial institutions agree to confidentiality arrangements in form and substance reasonably
satisfactory to the Company, prior to the release or disclosure of any such information; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(h)</B> Obtain a
&#147;comfort&#148; letter from the Company&#146;s independent registered public accountants in the event of an Underwritten Offering, a Block Trade, an Other Coordinated Offering or sale by a broker, placement agent or sales agent pursuant to such
registration (subject to such broker, placement agent or sales agent providing such certification or representation reasonably requested by the Company&#146;s independent registered public accountants and the Company&#146;s counsel) in customary
form and covering such matters of the type customarily covered by &#147;comfort&#148; letters for a transaction of its type as the managing Underwriter may reasonably request, and as reasonably satisfactory to a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the participating Holders; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> In the event of an
Underwritten Offering, a Block Trade, an Other Coordinated Offering or sale by a broker, placement agent or sales agent pursuant to such registration, on the date the Registrable Securities are delivered for sale pursuant to such registration, to
the extent customary for a transaction of its type, obtain an opinion, dated such date, of counsel representing the Company for the purposes of such registration, addressed to the participating Holders, the broker, placement agents or sales agent,
if any, and the Underwriters, if any, covering such legal matters with respect to the registration in respect of which such opinion is being given as the participating Holders, broker, placement agent, sales agent or Underwriter may reasonably
request and as are customarily included in such opinions and negative assurance letters; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(j)</B> In the event of any
Underwritten Offering, a Block Trade, an Other Coordinated Offering or sale by a broker, placement agent or sales agent pursuant to such registration, enter into and perform its obligations under an underwriting or other purchase or sales agreement,
in usual and customary form, with the managing Underwriter or the broker, placement agent or sales agent of such offering or sale; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(k)</B> Make available to its security holders, as soon as reasonably practicable, an earnings statement covering the
period of at least twelve (12)&nbsp;months beginning with the first day of the Company&#146;s first full </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
calendar quarter after the effective date of the registration statement which satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 thereunder (or any successor rule
then in effect); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(l)</B> With respect to an Underwritten Offering pursuant to Section&nbsp;2.1(f), use its
commercially reasonable efforts to make available senior executives of the Company to participate in customary &#147;road show&#148; presentations that may be reasonably requested by the Underwriter in such Underwritten Offering; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(m)</B> Provide a transfer agent and registrar for all Registrable Securities registered pursuant to such registration
statement and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(n)</B> Advise each seller of Registrable Securities, promptly after it shall receive notice or obtain knowledge thereof,
of the issuance of any stop order by the Commission suspending the effectiveness of any registration or the initiation or threatening of any proceeding for such purpose and promptly use its commercially reasonable efforts to prevent the issuance of
any stop order or to obtain its withdrawal if such stop order should be issued; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(o)</B> Cause all such Registrable
Securities registered pursuant hereunder to be listed on each securities exchange on which similar securities issued by the Company are then listed; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(p)</B> In connection with any underwritten offering pursuant to a registration statement filed pursuant to
Section&nbsp;2.1, enter into an underwriting agreement in form reasonably necessary to effect the offer and sale of Common Stock, <I>provided</I> such underwriting agreement contains reasonable and customary provisions, and <I>provided further</I>,
that each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(q)</B> Otherwise, in good faith, cooperate reasonably with, and take such customary actions as may reasonably be requested
by the participating Holders, consistent with the terms of this Agreement, in connection with such Registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the
foregoing, the Company shall not be required to provide any documents or information to an Underwriter, broker, sales agent or placement agent if such Underwriter, broker, sales agent or placement agent has not then been named with respect to the
applicable Underwritten Offering or other offering involving a registration as an Underwriter, broker, sales agent or placement agent, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.6</B> <B>Removal of Restrictive Legends</B>. The Company shall, if requested by the Holder, use its commercially reasonable best efforts
to (i)&nbsp;cause the removal of any restrictive legend related to compliance with the federal securities laws set forth on the Registrable Securities, (ii)&nbsp;cause its legal counsel to deliver an opinion, if necessary, to the transfer agent in
connection with the instruction under subclause (i)&nbsp;to the effect that removal of such legends in such circumstances may be effected in compliance under the Securities Act, and (iii)&nbsp;issue Registrable Securities without any such legend in
certificated or book-entry form or by electronic delivery through The Depository Trust Company, at the Holder&#146;s option, within two (2)&nbsp;trading days of such request, if (A)&nbsp;the Registrable Securities are registered for resale under the
Securities Act, (B)&nbsp;the Registrable Securities may be sold by the Holder without restriction under Rule 144, including without limitation, any volume and manner of sale restrictions, or (C)&nbsp;the Holder has sold or transferred, or proposes
to sell or transfer within five (5)&nbsp;Business Days of such request, Registrable Securities pursuant to the Registration Statement or in compliance with Rule 144. The Company&#146;s obligation to remove legends under this Section&nbsp;2.6 may be
conditioned upon the Holder timely providing such representations and documentation as are reasonably necessary and customarily required in connection with the removal of restrictive legends related to compliance with the federal securities laws. If
restrictive legends are no longer required for Registrable Securities pursuant to the foregoing, the Company shall, in accordance with the provisions of this section and within two (2)&nbsp;trading days of any request therefor from the Investor
accompanied by such customary and reasonably acceptable representations and other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
documentation referred to above establishing that restrictive legends are no longer required, deliver to the transfer agent irrevocable instructions that the transfer agent shall make a new, <FONT
STYLE="white-space:nowrap">non-legended</FONT> entry for such book entry Registrable Securities. The Company shall be responsible for the fees of its transfer agent and any DTC fees associated with such issuance. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.7</B> <B>Indemnification</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> To the extent permitted by law, the Company will indemnify and hold harmless each Holder, each of its officers,
directors, members and partners, legal counsel and accountants and each person controlling such Holder within the meaning of Section&nbsp;15 of the Securities Act, with respect to which registration, qualification or compliance has been effected
pursuant to this Section&nbsp;2, and each underwriter, if any, and each person who controls within the meaning of Section&nbsp;15 of the Securities Act any underwriter, against all expenses, claims, losses, damages and liabilities (or actions,
proceedings or settlements in respect thereof) arising out of or based on: (i)&nbsp;any untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any prospectus, offering circular, or other document
(including any related registration statement, notification or the like) incident to any such registration, qualification or compliance, (ii)&nbsp;any omission (or alleged omission) to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, or (iii)&nbsp;any violation (or alleged violation) by the Company of the Securities Act, any state securities laws or any rule or regulation thereunder applicable to the Company and relating
to action or inaction required of the Company in connection with any offering covered by such registration, qualification or compliance, and the Company will reimburse each such Holder, each of its officers, directors, members, partners, legal
counsel and accountants and each person controlling such Holder, each such underwriter and each person who controls any such underwriter, for any legal and any other expenses reasonably incurred in connection with investigating and defending or
settling any such claim, loss, damage, liability or action; <I>provided</I> that the Company will not be liable in any such case to the extent that any such claim, loss, damage, liability, or action arises out of or is based on any untrue statement
or omission based upon written information furnished to the Company by such Holder, any of such Holder&#146;s officers, directors, members, partners, legal counsel or accountants, any person controlling such Holder, such underwriter or any person
who controls any such underwriter, and stated to be specifically for use therein; and <I>provided, further</I> that, the indemnity agreement contained in this Section&nbsp;2.6(a) shall not apply to amounts paid in settlement of any such loss, claim,
damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> To the extent permitted by law, each Holder will, if Registrable Securities held by such Holder are included in the
securities as to which such registration, qualification or compliance is being effected, indemnify and hold harmless the Company, each of its directors, officers, partners, legal counsel and accountants and each underwriter, if any, of the
Company&#146;s securities covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of Section&nbsp;15 of the Securities Act, each other such Holder, and each of their officers, directors,
members and partners, and each person controlling each other such Holder, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based on: (i)&nbsp;any untrue statement (or alleged untrue statement) of
a material fact contained or incorporated by reference in any prospectus, offering circular or other document (including any related registration statement, notification, or the like) incident to any such registration, qualification or compliance,
or (ii)&nbsp;any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the Company and such Holders, officers, directors, members,
partners, legal counsel and accountants, persons, underwriters, or control persons for any legal or any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action, in each case
to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular or other document in reliance upon and in
conformity with written information furnished to the Company by such Holder and stated to be specifically for use therein; <I>provided, however</I>, that the obligations of such Holder hereunder shall not apply to amounts paid in settlement of any
such claims, losses, damages or liabilities (or actions in respect thereof) if such settlement is effected without the consent of such Holder (which consent shall not be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
unreasonably withheld); and <I>provided</I> that in no event shall any indemnity under this Section&nbsp;2.6 exceed the net proceeds from the offering received by such Holder, except in the case
of fraud or willful misconduct by such Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> Each party entitled to indemnification under this
Section&nbsp;2.6 (the &#147;<B><I>Indemnified Party</I></B>&#148;) shall give notice to the party required to provide indemnification (the &#147;<B><I>Indemnifying Party</I></B>&#148;) promptly after such Indemnified Party has actual knowledge of
any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of such claim or any litigation resulting therefrom; <I>provided</I> that counsel for the Indemnifying Party, who shall conduct the defense
of such claim or any litigation resulting therefrom, shall be approved by the Indemnified Party (whose approval shall not be unreasonably withheld), and the Indemnified Party may participate in such defense at such party&#146;s expense; and
<I>provided further</I> that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Section&nbsp;2.6, to the extent such failure is not prejudicial. No
Indemnifying Party, in the defense of any such claim or litigation, shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the
giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation. Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnifying
Party may reasonably request in writing and as shall be reasonably required in connection with defense of such claim and litigation resulting therefrom. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> If the indemnification provided for in this Section&nbsp;2.6 is held by a court of competent jurisdiction to be
unavailable to an Indemnified Party with respect to any loss, liability, claim, damage, or expense referred to herein, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder, shall contribute to the amount paid or
payable by such Indemnified Party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party on the one hand and of the Indemnified Party on the other
in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall
be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and
the parties&#146; relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. No person or entity will be required under this Section&nbsp;2.6(d) to contribute any amount in excess of the net
proceeds from the offering received by such person or entity, except in the case of fraud or willful misconduct by such person or entity. No person or entity guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the
Securities Act) will be entitled to contribution from any person or entity who was not guilty of such fraudulent misrepresentation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in
the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.8</B> <B>Information by Holder</B>. Each Holder of Registrable Securities shall furnish to the Company such information regarding such
Holder and the distribution proposed by such Holder as the Company may reasonably request in writing and as shall be reasonably required in connection with any registration, qualification, or compliance referred to in this Section&nbsp;2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.9</B> <B>Restrictions on Transfer</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> The holder of each certificate representing Registrable Securities by acceptance thereof agrees to comply in all
respects with the provisions of this Section&nbsp;2.8. Each Holder agrees not to make any sale, assignment, transfer, pledge or other disposition of all or any portion of the Restricted Securities, or any beneficial interest therein, unless and
until the transferee thereof has agreed in writing for the benefit of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Company to take and hold such Restricted Securities subject to, and to be bound by, the terms and conditions set forth in this Agreement, including, without limitation, this Section&nbsp;2.8 and
Section&nbsp;2.11, and: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> there is then in effect a registration statement under the Securities Act covering
such proposed disposition and such disposition is made in accordance with such registration statement; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B>
such Holder shall have given prior written notice to the Company of the Holder&#146;s intention to make such disposition and shall have furnished the Company with a detailed description of the manner and circumstances of the proposed disposition,
and, if requested by the Company, such Holder shall have furnished the Company, at the Holder&#146;s expense, with (A)&nbsp;an opinion of counsel, reasonably satisfactory to the Company, to the effect that such disposition will not require
registration of such Restricted Securities under the Securities Act or (B)&nbsp;a &#147;no action&#148; letter from the Commission to the effect that the transfer of such securities without registration will not result in a recommendation by the
staff of the Commission that action be taken with respect thereto, whereupon the holder of such Restricted Securities shall be entitled to transfer such Restricted Securities in accordance with the terms of the notice delivered by the Holder to the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> Notwithstanding the provisions of Section&nbsp;2.8(a), no such registration statement, opinion of
counsel or &#147;no action&#148; letter shall be necessary for (i)&nbsp;a transfer not involving a change in beneficial ownership, or (ii)&nbsp;transactions involving the distribution without consideration of Restricted Securities by any Holder to
(x)&nbsp;a parent, subsidiary or other affiliate of the Holder, if the Holder is a corporation, (y)&nbsp;any of the Holder&#146;s partners, members or other equity owners, or retired partners, retired members or other equity owners, or to the estate
of any of the Holder&#146;s partners, members or other equity owners or retired partners, retired members or other equity owners, or (z)&nbsp;a venture capital fund that is controlled by or under common control with one or more general partners or
managing members of, or shares the same management company with, the Holder; provided, in each case, that the Holder thereof shall give written notice to the Company of such Holder&#146;s intention to effect such disposition and shall have furnished
the Company with a detailed description of the manner and circumstances of the proposed disposition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> Each
certificate representing Restricted Securities shall (unless otherwise permitted by the provisions of this Agreement) be stamped or otherwise imprinted with a legend substantially similar to the following (in addition to any legend required under
applicable state securities laws): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE &#147;<B><I>ACT</I></B>&#148;), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND
APPLICABLE STATE SECURITIES LAWS PURSUANT TO REGISTRATION OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION
OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Holders consent to the Company making a notation on its
records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer established in this Section&nbsp;2.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> Each certificate representing Registrable Securities shall (unless otherwise permitted by the provisions of this
Agreement) be stamped or otherwise imprinted with a legend substantially similar to the following (in addition to any legend required under applicable state securities laws): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, INCLUDING A <FONT
STYLE="white-space:nowrap">LOCK-UP</FONT> PERIOD IN THE EVENT OF A PUBLIC OFFERING, AS SET FORTH IN AN INVESTORS&#146; RIGHTS AGREEMENT BY AND AMONG THE COMPANY AND THE ORIGINAL HOLDERS OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE
PRINCIPAL OFFICE OF THE COMPANY. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Holders consent to the Company making a notation on its records and giving instructions
to any transfer agent of the Registrable Securities in order to implement the restrictions on transfer established in this Section&nbsp;2.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> The legend referring to federal and state securities laws identified in Section&nbsp;2.8(c) stamped on a
certificate evidencing the Restricted Securities and the stock transfer instructions and record notations with respect to such Restricted Securities shall be removed and the Company shall issue a certificate without such legend to the holder of such
Restricted Securities if (i)&nbsp;such securities are registered under the Securities Act, or (ii)&nbsp;such holder provides the Company with an opinion of counsel reasonably acceptable to the Company to the effect that a sale or transfer of such
securities may be made without registration or qualification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.10</B> <B>Rule 144 Reporting</B>. With a view to making available the
benefits of certain rules and regulations of the Commission that may permit the sale of the Restricted Securities to the public without registration, the Company agrees to use its commercially reasonable efforts to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> Make and keep adequate current public information with respect to the Company available in accordance with Rule 144
under the Securities Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> File with the Commission in a timely manner all reports and other documents required
of the Company under the Securities Act and the Exchange Act at any time after it has become subject to such reporting requirements; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> So long as a Holder owns any Restricted Securities, furnish to the Holder forthwith upon written request a written
statement by the Company as to its compliance with the reporting requirements of Rule 144 (at any time from and after ninety (90)&nbsp;days following the effective date of the first registration statement filed by the Company for an offering of its
securities to the general public), and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), a copy of the most recent annual or quarterly report of the Company, and such other reports
and documents so filed as a Holder may reasonably request in availing itself of any rule or regulation of the Commission allowing a Holder to sell any such securities without registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2.11</B> <B>Market <FONT STYLE="white-space:nowrap">Stand-Off</FONT> Agreement</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> Investor agrees that such Investor shall not transfer any shares of Common Stock or any securities convertible into
or exercisable or exchangeable (directly or indirectly) for the shares of Common Stock (excluding the PIPE Securities) until the earlier of one hundred eighty (180)-days following the Closing Date (as defined in the BCA) and the consummation of a
change of control of the Company (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#148;). The foregoing restriction is expressly agreed to preclude each Investor during such one hundred eighty
<FONT STYLE="white-space:nowrap">(180)-day</FONT> period from engaging in any hedging or other transaction which is designed to or which reasonably could be expected to lead to or result in a sale or disposition of such Investor&#146;s shares of
Common Stock even if such shares of Common Stock would be disposed of by someone other than the undersigned. Such prohibited hedging or other transactions during such one hundred eighty <FONT STYLE="white-space:nowrap">(180)-day</FONT> period would
include without limitation any short sale or any purchase, sale or grant of any right (including, without limitation, any put or call option) with respect to any of the Investor&#146;s shares of Common Stock or with respect to any security that
includes, relates to, or derives any significant part of its value from such shares of Common Stock. The foregoing notwithstanding, (x)&nbsp;each executive officer and director of the Company shall be permitted to establish a plan to acquire and
sell shares of Common Stock pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act, provided that such plan does not provide for the transfer of shares of Common Stock during the
<FONT STYLE="white-space:nowrap">Lock-up</FONT> Period and (y)&nbsp;to the extent any Named Investor is granted a release or waiver from the restrictions contained in this Section&nbsp;2.11 prior to the expiration of the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period, then all Named Investors shall be automatically granted a release or waiver from the restrictions contained in this Section&nbsp;2.11 to the same extent, on substantially the same terms as and on a
<I>pro rata</I> basis with, the Named Investor to which such release or waiver is granted. [The foregoing restrictions shall not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
apply to transfers made: (i)&nbsp;pursuant to a <I>bona fide</I> gift or charitable contribution; (ii)&nbsp;by will or intestate succession upon the death of an Investor; (iii)&nbsp;to any
Affiliate (including, for the avoidance of doubt, pursuant to distributions of shares of Common Stock to partners, limited liability company members or stockholders of an Investor, including, for the avoidance of doubt, where an Investor is a
partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership); (iv) pursuant to a court order or settlement agreement related to the distribution of assets in connection with the dissolution
of marriage or civil union; (v)<I>&nbsp;pro rata</I> to the partners, members or shareholders of a Named Investor upon its liquidation or dissolution; or (vi)&nbsp;in the event of the Company&#146;s completion of a liquidation, merger, share
exchange or other similar transaction which results in all of its shareholders having the right to exchange their Common Stock for cash, securities or other property; <I>provided</I> that in the case of (i), (iii) or (v), the recipient of such
transfer must enter into a written agreement agreeing to be bound by the terms of this Agreement, including the transfer restrictions set forth in this Section&nbsp;2.11].<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> Each Named Investor who is participating in the applicable underwritten public offering also agrees, and the
Company agrees and shall cause each director and officer of the Company to agree, that, in connection with each Registration or sale of Registrable Securities conducted as an underwritten public offering, if requested, to become bound by and to
execute and deliver a <FONT STYLE="white-space:nowrap">customary&nbsp;lock-up&nbsp;agreement</FONT> with the underwriter(s) of such underwritten public offering restricting such applicable person or entity&#146;s right to (a)&nbsp;transfer, directly
or indirectly, any equity securities of the Company held by such person or entity or (b)&nbsp;enter into any swap or other arrangement that transfers to another any of the economic consequences of ownership of such securities during the period
commencing on the date of the final Prospectus relating to the underwritten public offering and ending on the date specified by the underwriters (such period not to exceed ninety (90)&nbsp;days). The terms of
<FONT STYLE="white-space:nowrap">such&nbsp;lock-up&nbsp;agreements</FONT> shall be negotiated among the applicable Named Investors requested to enter <FONT STYLE="white-space:nowrap">into&nbsp;lock-up&nbsp;agreements</FONT> and participating in the
underwritten public offering in accordance with the immediately preceding sentence, the Company and the underwriters, and the terms of such <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements shall include customary exclusions from the
restrictions on transfer set forth therein, including that such restrictions on the applicable Named Investors shall be conditioned upon all officers and directors of the Company, as well as all Named Investors participating in the offering, being
subject to the same restrictions;&nbsp;provided, that, to the extent any Named Investor is granted a release or waiver from the restrictions contained in this&nbsp;Section&nbsp;2.11 and in such Named
<FONT STYLE="white-space:nowrap">Investor&#146;s&nbsp;lock-up&nbsp;agreement</FONT> prior to the expiration of the period set forth in such Named <FONT STYLE="white-space:nowrap">Investor&#146;s&nbsp;lock-up&nbsp;agreement,</FONT> then all Named
Investors shall be automatically granted a release or waiver from the restrictions contained in this&nbsp;Section 2.11 and the <FONT STYLE="white-space:nowrap">applicable&nbsp;lock-up&nbsp;agreements</FONT> to which they are party to the same
extent, on substantially the same terms as and on a pro rata basis with, the Named Investor to which such release or waiver is granted. The provisions of this&nbsp;Section 2.11 shall not apply to any Named Investor that holds less than one percent
(1%) of then total issued and outstanding Common Stock. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.1</B>
<B>Termination and Effect of Termination</B>. This Agreement may be terminated only by an agreement in writing signed by the holders of a majority of the total Registrable Securities; provided, that the consent of any Holder will be required for any
termination of this Agreement which has an adverse effect on the rights, limitations or obligations of such Holder. Notwithstanding any provision hereof to the contrary, the right of any Holder to request a registration or inclusion of Registrable
Securities in any registration pursuant to Section&nbsp;2.2 shall terminate upon the third anniversary of the date hereof. Notwithstanding any termination of this Agreement in accordance with the foregoing sentence, the provisions of Sections 2.4,
2.6 and 2.9 shall survive any such termination. No termination under this Agreement shall relieve any Person of liability for breach or Registration Expenses incurred prior to termination. In the event this Agreement is terminated, each Person
entitled to </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Additional carve-outs to be included as needed and as appropriate. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
indemnification rights pursuant to Section&nbsp;2.6 hereof shall retain such indemnification rights with respect to any matter that (i)&nbsp;may be an indemnified liability thereunder and
(ii)&nbsp;occurred prior to such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.2</B> <B>Permitted Transferees</B>. The rights of a Holder hereunder may be assigned
(but only with all related obligations as set forth below) in connection with a transfer of Registrable Securities to a Permitted Transferee of that Holder. Without prejudice to any other or similar conditions imposed hereunder with respect to any
such transfer, no assignment permitted under the terms of this Section&nbsp;3.2 will be effective unless the Permitted Transferee to which the assignment is being made, if not a Holder, has delivered to the Company a written acknowledgment and
agreement in form and substance reasonably satisfactory to the Company that the Permitted Transferee will be bound by, and will be a party to, this Agreement. A Permitted Transferee to whom rights are transferred pursuant to this Section&nbsp;3.2
may not again transfer those rights to any other Permitted Transferee, other than as provided in this Section&nbsp;3.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.3</B>
<B>Amendment</B>. This Agreement may not be orally amended, modified or extended, nor shall any oral waiver of any of its terms be effective. This Agreement may be amended, modified or extended, and the provisions hereof may be waived, only by an
agreement in writing signed by the Company and the Holders of a majority of the total Registrable Securities. Each such amendment, modification, extension or waiver shall be binding upon each party hereto; provided that (a)&nbsp;the consent of any
Holder shall be required for any amendment, modification, extension or waiver which has an adverse effect on the rights, limitations or obligations of such Holder and (b)&nbsp;any such amendment, modification, extension or waiver that by its terms
would adversely affect a Holder or group of Holders in a disproportionate manner relative to the Holders generally shall require the written consent of the Holder (or a majority in interest based on Registrable Securities of such group of Holders)
so affected. In addition, each party hereto may waive any right hereunder (solely as applicable to such party) by an instrument in writing signed by such party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.4</B> <B>Notices</B>. All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by
registered or certified mail, postage prepaid, sent by facsimile or electronic mail (if to an Investor or Holder) or otherwise delivered by hand, messenger or courier service addressed: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> if to an Investor, to the Investor&#146;s address, facsimile number or electronic mail address as shown in the
Company&#146;s records, as may be updated in accordance with the provisions hereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> if to any Holder, to such
address, facsimile number or electronic mail address or facsimile number as shown in the Company&#146;s records, or, until any such Holder so furnishes an address, facsimile number or electronic mail address to the Company, then to the address,
facsimile number or electronic mail address of the last holder of such shares for which the Company has contact information in its records; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> if to the Company, to the attention of the President and Chief Executive Officer of the Company at 171 Oyster Point
Blvd, Suite 400, South San Francisco, CA 94080 or at such other current address as the Company shall have furnished to the Investors or Holders, with a copy (which shall not constitute notice) to Michael Tenta, Cooley LLP, 3175 Hanover Street, Palo
Alto, CA 94304. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each such notice or other communication shall for all purposes of this Agreement be treated as effective or having been
given (i)&nbsp;if delivered by hand, messenger or courier service, when delivered (or if sent via a nationally-recognized overnight courier service, freight prepaid, specifying <FONT STYLE="white-space:nowrap">next-business-day</FONT> delivery, one
business day after deposit with the courier), or (ii)&nbsp;if sent via mail, at the earlier of its receipt or five days after the same has been deposited in a regularly-maintained receptacle for the deposit of the United States mail, addressed and
mailed as aforesaid, or (iii)&nbsp;if sent via facsimile, upon confirmation of facsimile transfer or, if sent via electronic mail, upon confirmation of delivery when directed to the relevant electronic mail address, if sent during normal business
hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient&#146;s next business day. In the event of any conflict between the Company&#146;s books and records and this Agreement or any notice
delivered hereunder, the Company&#146;s books and records will control absent fraud or error. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the limitations set forth in Delaware General Corporation Law &#167;232(e), each
Investor and Holder consents to the delivery of any notice to stockholders given by the Company under the Delaware General Corporation Law or the Company&#146;s certificate of incorporation or bylaws by (i)&nbsp;facsimile telecommunication to the
facsimile number set forth on Exhibit A (or to any other facsimile number for the Investor or Holder in the Company&#146;s records), (ii) electronic mail to the electronic mail address set forth on Exhibit A (or to any other electronic mail address
for the Investor or Holder in the Company&#146;s records), (iii) posting on an electronic network together with separate notice to the Investor or Holder of such specific posting or (iv)&nbsp;any other form of electronic transmission (as defined in
the Delaware General Corporation Law) directed to the Investor or Holder. This consent may be revoked by an Investor or Holder by written notice to the Company and may be deemed revoked in the circumstances specified in Delaware General Corporation
Law &#167;232. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.5</B> <B>Governing Law</B>. This Agreement shall be governed in all respects by the internal laws of the State of
Delaware as applied to agreements entered into among Delaware residents to be performed entirely within Delaware, without regard to principles of conflicts of law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.6</B> <B>Successors and Assigns</B>. This Agreement, and any and all rights, duties and obligations hereunder, shall not be assigned,
transferred, delegated or sublicensed by any Investor without the prior written consent of the Company. Any attempt by an Investor without such permission to assign, transfer, delegate or sublicense any rights, duties or obligations that arise under
this Agreement shall be void. Subject to the foregoing and except as otherwise provided herein, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the
parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.7</B> <B>Entire Agreement</B>. This Agreement and the exhibits hereto constitute the full and entire understanding
and agreement between the parties with regard to the subjects hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. No party hereto shall be liable or bound to any
other party in any manner with regard to the subjects hereof or thereof by any warranties, representations or covenants except as specifically set forth herein. The Sponsor and the other Investors who are party to the Original Agreement hereby agree
that the Original Agreement is hereby terminated and superseded by this Agreement, effective upon the execution of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.8</B> <B>Delays or Omissions</B>. Except as expressly provided herein, no delay or omission to exercise any right, power or remedy
accruing to any party to this Agreement upon any breach or default of any other party under this Agreement shall impair any such right, power or remedy of such <FONT STYLE="white-space:nowrap">non-defaulting</FONT> party, nor shall it be construed
to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default
theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of
this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party to this Agreement, shall be cumulative and
not alternative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.9</B> <B>Severability</B>. If any provision of this Agreement becomes or is declared by a court of competent
jurisdiction to be illegal, unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Agreement, and such court will replace such illegal, void or unenforceable
provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the same economic, business and other purposes of the illegal, void or unenforceable provision. The balance of this Agreement shall be
enforceable in accordance with its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.10</B> <B>Titles and Subtitles</B>. The titles and subtitles used in this Agreement are
used for convenience only and are not to be considered in construing or interpreting this Agreement. All references in this Agreement to sections, paragraphs and exhibits shall, unless otherwise provided, refer to sections and paragraphs hereof and
exhibits attached hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.11</B> <B>Counterparts</B>. This Agreement may be executed in any number of
counterparts, each of which shall be enforceable against the parties that execute such counterparts, and all of which together shall constitute one instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.12</B> <B>Telecopy Execution and Delivery</B>. A facsimile, telecopy or other reproduction of this Agreement may be executed by one or
more parties hereto and delivered by such party by facsimile or any similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen. Such execution and delivery shall be considered valid, binding and
effective for all purposes. At the request of any party hereto, all parties hereto agree to execute and deliver an original of this Agreement as well as any facsimile, telecopy or other reproduction hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.13</B> <B>Jurisdiction; Venue</B>. With respect to any disputes arising out of or related to this Agreement, each of the parties hereto
irrevocably consents to the exclusive jurisdiction of, and venue in, the courts of the State of Delaware and, other than with regard to The Regents of the University of California, the United States District Court for the District of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.14</B> <B>Further Assurances</B>. Each party hereto agrees to execute and deliver, by the proper exercise of its corporate, limited
liability company, partnership or other powers, all such other and additional instruments and documents and do all such other acts and things as may be necessary to more fully effectuate this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.15</B> <B>Conflict</B>. In the event of any conflict between the terms of this Agreement and the Company&#146;s Restated Certificate or
its bylaws, the terms of the Company&#146;s Restated Certificate or its bylaws, as the case may be, will control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.16</B>
<B>Attorney</B><B>&#146;</B><B>s Fees</B>. In the event that any suit or action is instituted to enforce any provisions in this Agreement, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and
expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including without limitation, such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs
and expenses of appeals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>3.17</B> <B>Aggregation of Stock</B>. All securities held or acquired by affiliated entities (including
affiliated venture capital funds) or persons shall be aggregated together for purposes of determining the availability of any rights under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(signature page follows) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The parties are signing this Investors&#146; Rights Agreement as of the date stated in the
introductory clause. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>COMPANY</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name: Gad Soffer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title: &nbsp;&nbsp;Chief Executive Officer</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> <SMALL>PAGE</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL></B><SMALL><B></B></SMALL><B>]</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The parties are signing this Investors&#146; Rights Agreement as of the date stated in the
introductory clause. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>SPONSOR</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>CONSONANCE LIFE SCIENCES</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name: Gad Soffer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title: &nbsp;&nbsp;Member</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> <SMALL>PAGE</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL></B><SMALL><B></B></SMALL><B>]</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The parties are signing this Investors&#146; Rights Agreement as of the date stated in the
introductory clause. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NAMED INVESTORS</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THE COLUMN GROUP III, LP</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By: The Column Group III GP, LP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Its: General Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By: The Column Group, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Its: General Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Name:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Title:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THE COLUMN GROUP <FONT STYLE="white-space:nowrap">III-A,</FONT>
LP</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By: The Column Group III GP, LP</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Its: General Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By: The Column Group, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Its: General Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Name:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Title:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> <SMALL>PAGE</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL></B><SMALL><B></B></SMALL><B>]</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The parties are signing this Investors&#146; Rights Agreement as of the date stated in the
introductory clause. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>NAMED INVESTOR</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jagdeep Bachher</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Investment Officer</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> <SMALL>PAGE</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL></B><SMALL><B></B></SMALL><B>]</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The parties are signing this Investors&#146; Rights Agreement as of the date stated in the
introductory clause. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>NAMED INVESTOR</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>CONSONANCE CAPITAL MANAGEMENT, LP</B></P></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Kevin Livingston</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Partner</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> <SMALL>PAGE</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL></B><SMALL><B></B></SMALL><B>]</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NAMED INVESTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><U>Surrozen Investors: </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>The Column Group III, L.P. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>The Column Group <FONT STYLE="white-space:nowrap">III-A,</FONT> L.P. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>The Regents of the University of California </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><U>Consonance Investors: </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Consonance Capital Management, LP </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDIVIDUAL INVESTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="annex_h"></A><A NAME="rom40894_257"></A>ANNEX H </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPANY STOCKHOLDER SUPPORT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This COMPANY STOCKHOLDER SUPPORT AGREEMENT (this &#147;<B>Agreement</B>&#148;), dated as of April [&#9679;], 2021, is made by and among <FONT
STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., a Cayman Islands exempted company (&#147;<B>CHFW</B>&#148;), [&#9679;], a [&#9679;], a holder of capital stock of Surrozen, Inc. (the &#147;<B>Company Stockholder</B>&#148;), and
Surrozen, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;). CHFW, the Company Stockholder and the Company shall be referred to herein from time to time collectively as the &#147;<B>Parties</B>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, CHFW, the Company and certain other persons party thereto entered into that certain Business Combination Agreement, dated as of the
date hereof (as it may be amended, restated or otherwise modified from time to time in accordance with its terms, the &#147;<B>Business Combination Agreement</B>&#148;) providing for the merger of a subsidiary of CHFW with and into the Company, with
the Company surviving as the surviving wholly owned corporation of CHFW in such merger (the &#147;<B>Merger</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, the
Company Stockholder is the record and beneficial owner of the number of shares of common stock and number and series of preferred stock of Company as set forth on the signature page hereto (together with any other equity securities of Company that
the Company Stockholder holds of record or beneficially, as of the date of this Agreement, or acquires record or beneficial ownership after the date hereof, collectively, the &#147;<B>Subject Company Equity Securities</B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, the Company Stockholder acknowledges and agrees that CHFW and the Company would not have entered into and agreed to consummate the
transactions contemplated by the Business Combination Agreement without the Company Stockholder entering into this Agreement and agreeing to be bound by the agreements, covenants and obligations contained in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NOW, THEREFORE, in consideration of the premises and the mutual promises contained herein and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1.
<U>Agreement to Vote</U>. The Company Stockholder hereby agrees to (i)&nbsp;execute and deliver to the Company a written consent of the stockholders of the Company in lieu of a meeting of the stockholders (which written consent shall be delivered
promptly, and in any event within five (5)&nbsp;Business Days following the time at which the Registration Statement/Proxy Statement (as defined in the Business Combination Agreement) is declared effective under the U.S. Securities Act of 1933) or
appear (in person or by proxy) at any meeting of the stockholders of Company, and vote all of such Company Stockholder&#146;s Subject Company Equity Securities in favor of (A)&nbsp;the Business Combination Agreement to be submitted to the
stockholders of the Company in connection with the Merger and the other transactions contemplated by the Business Combination Agreement and (B)&nbsp;such other resolutions upon which a consent or other approval is required under the Company&#146;s
amended and restated certificate of incorporation or applicable law or otherwise is sought with respect to effecting the Business Combination Agreement and the Merger, and (C)&nbsp;against (i) any merger, purchase of all or substantially all of a
third party (other than the Merger) or all of the assets of a third party or other business combination transaction with a third party (other than the Business Combination Agreement and the Merger) (a &#147;<B>Competing Transaction</B>&#148;) or
(ii)&nbsp;any proposal relating to a Competing Transaction and against any proposal, action or agreement that would (A)&nbsp;impede, frustrate, prevent or nullify any provision of this Agreement, the Business Combination Agreement or any Merger,
(B)&nbsp;result in a breach in any respect of any covenant, representation, warranty or any other obligation or agreement of the Company under the Business Combination Agreement, or (C)&nbsp;result in any of the conditions set forth in Article VI of
the Business Combination Agreement not being fulfilled The Company Stockholder hereby agrees that it shall not commit or agree to take any action inconsistent with the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the failure of a Company Stockholder to timely provide its consent or vote its Subject
Company Equity Securities in accordance with this Section&nbsp;1 pursuant to any action by written consent of the stockholders of the Company or at any applicable meeting of the stockholders of the Company such Company Stockholder shall be deemed to
have irrevocably granted to, and appointed, the Company, and any designee thereof, and each of them individually, as such Company Stockholder&#146;s proxy and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> (with full power of substitution), for and in such Company Stockholder&#146;s name, place and stead, to deliver any action by written consent of the
Company Stockholder&#146;s concerning any of the matters specified in this Section&nbsp;1 or attend any meeting of the Company Stockholders concerning any of the matters specified in this Section&nbsp;1, to include such Company Subject Equity
Securities in any computation for purposes of establishing a quorum at any such meeting of the Company Stockholders and to provide consent or vote such Company Stockholder&#146;s Subject Equity Securities in any action by written consent of the
Company Stockholders or at any meeting of the Company Stockholders called with respect to any of the matters specified in, and in accordance and consistent with, this Section&nbsp;1. Each Company Stockholder hereby affirms that the irrevocable proxy
is coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable. Notwithstanding any other provision of this Agreement, the irrevocable proxy granted hereunder shall
automatically terminate upon the termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. <U>Transfer of Shares</U>. The Company Stockholder hereby agrees that
it shall not, directly or indirectly, (i)&nbsp;sell, assign, transfer (including by operation of law), place a lien on, pledge, dispose of or otherwise encumber any of its Subject Company Equity Securities or otherwise agree to do any of the
foregoing (each, a &#147;<B>Transfer</B>&#148;), (ii) deposit any of its Subject Company Equity Securities into a voting trust or enter into a voting agreement or arrangement or grant any proxy or power of attorney with respect to any of its Subject
Company Equity Securities that conflicts with any of the covenants or agreements set forth in this Agreement, (iii)&nbsp;enter into any contract, option or other arrangement or undertaking with respect to the direct or indirect acquisition or sale,
assignment, transfer (including by operation of law) or other disposition of any of its Subject Company Equity Securities, (iv)&nbsp;engage in any hedging or other transaction which is designed to, or which would (either alone or in connection with
one or more events, developments or events (including the satisfaction or waiver of any conditions precedent)), lead to or result in a sale or disposition of its Subject Company Equity Securities even if such Subject Company Equity Securities would
be disposed of by a person other than the Company Stockholder or (v)&nbsp;take any action that would have the effect of preventing or materially delaying the performance of its obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. <U>Further Assurances</U>. Each Company Stockholder shall take, or cause to be taken, all actions and do, or cause to be done, all things
reasonably necessary under applicable Laws and within the control of such Company Stockholder to consummate the Merger and the other transactions contemplated by the Business Combination Agreement on the terms and subject to the conditions set forth
therein and herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. <U>No Inconsistent Agreement</U>. Each Company Stockholder hereby represents and covenants that such Company
Stockholder has not entered into, and shall not enter into, any agreement that would restrict, limit or interfere with the performance of such Company Stockholder&#146;s obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. <U>Company Stockholder Representations and Warranties</U>. The Company Stockholder represents and warrants to CHFW and the Company as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. The Company Stockholder is either an individual (or a revocable trust of which the individual is a trustee) or a corporation,
limited liability company or other applicable business entity duly organized or formed, as applicable, validly existing and in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize
the concept of good standing or any equivalent thereof) under the Laws of its jurisdiction of formation or organization (as applicable). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b. For Company Stockholders that are business entities, the Company Stockholder has the requisite corporate, limited liability company or
other similar power and authority to execute and deliver this Agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and to perform its covenants, agreements and obligations hereunder. Each individual Company Stockholder has the personal capacity to execute and deliver this Agreement, to perform their
covenants, agreement and obligations hereunder. For Company Stockholders that are business entities, the execution and delivery of this Agreement has been duly authorized by all necessary corporate (or other similar) action on the part of the
Company Stockholder. This Agreement has been duly and validly executed and delivered by the Company Stockholder and constitutes a valid, legal and binding agreement of the Company Stockholder (assuming that this Agreement is duly authorized,
executed and delivered by CHFW and the Company), enforceable against the Company Stockholder in accordance with its terms (subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of
creditors&#146; rights and subject to general principles of equity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c. The execution and delivery of this Agreement by such Company
Stockholder, does not, and the performance by such Company Stockholder of his, her or its obligations hereunder will not, (i)&nbsp;if such Company Stockholder is not an individual, conflict with or result in a violation of the organizational
documents of such Company Stockholder or (ii)&nbsp;require any consent or approval that has not been given or other action that has not been taken by any Person (including under any Contract binding upon such Company Stockholder or such Company
Stockholder&#146;s Subject Company Equity Securities), in each case, to the extent such consent, approval or other action would prevent, enjoin or materially delay the performance by such Company Stockholder of its, his or her obligations under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">d. There are no proceedings pending against such Company Stockholder, or to the knowledge of such Company Stockholder
threatened against such Company Stockholder, before (or, in the case of threatened proceedings, that would be before) any arbitrator or any Governmental Entity, which in any manner challenges or seeks to prevent, enjoin or materially delay the
performance by such Company Stockholder of its, his or her obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">e. Except as described on Section&nbsp;3.17
of the Company Disclosure Schedules, no broker, finder, investment banker or other Person is entitled to any brokerage fee, finders&#146; fee or other commission in connection with the transactions contemplated by the Business Combination Agreement
based upon arrangements made by such Company Stockholder, for which the Company or any of its Affiliates may become liable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">f. Such
Company Stockholder understands and acknowledges that each of CHFW and the Company is entering into the Business Combination Agreement in reliance upon such Company Stockholder&#146;s execution and delivery of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6. <U>Waiver of Appraisal Rights</U>. Such Company Stockholder hereby irrevocably and unconditionally waives, and agrees not to assert,
exercise or perfect (or attempt to exercise, assert or perfect), any rights of appraisal or rights to dissent from the Merger or appraisal or dissenters&#146; rights that it may at any time have under applicable Laws, including Section&nbsp;262 of
the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7. <U>Termination of Investor Agreements and Certain Other Agreements</U>. Such Company Stockholder, by this Agreement hereby
agrees that, subject to and effective immediately prior to the Closing, that Amended and Restated Investors&#146; Rights Agreement, dated as of May&nbsp;29, 2020, by and among the Company and the Company Stockholder parties thereto, the Amended and
Restated Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement, dated as of May&nbsp;29, 2020, by and among the Company and the Company Stockholders party thereto and the Amended and Restated Voting Agreement, dated as
of May&nbsp;29, 2020, by and among the Company and the Company Stockholders parties thereto and any management letter or other agreement between such Company Stockholder and the Company (excluding any employment agreement or offer letter, equity
award or employment benefit agreement) shall terminate without any further liability to the Company or its Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.
<U>Termination</U>. This Agreement shall automatically terminate, without any notice or other action by any Party, and be void <I>ab initio</I> upon the earlier of (a)&nbsp;the effective time of the Merger; and (b)&nbsp;the termination of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Business Combination Agreement in accordance with its terms. Upon termination of this Agreement as provided in the immediately preceding sentence, none of the Parties shall have any further
obligations or liabilities under, or with respect to, this Agreement. Notwithstanding the foregoing or anything to the contrary in this Agreement, the termination of this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;5(b)</U> shall not affect
any liability on the part of any Party for a willful breach of any covenant or agreement set forth in this Agreement prior to such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9. <U>No Third Party Beneficiaries</U>. This Agreement shall be for the sole benefit of the Parties and their respective successors and
permitted assigns and is not intended, nor shall be construed, to give any Person, other than the Parties and their respective successors and assigns, any legal or equitable right, benefit or remedy of any nature whatsoever by reason this Agreement.
Nothing in this Agreement, expressed or implied, is intended to or shall constitute the Parties, partners or participants in a joint venture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10. <U>Severability</U>. If any term or other provision of this Agreement is determined to be invalid, illegal or incapable of being enforced
by any rule of law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any
manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original
intent of the Parties as closely as possible to the fullest extent permitted by applicable law in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11. <U>Binding Effect and Assignment</U>. All of the covenants and agreements contained in this Agreement shall be binding upon, and inure to
the benefit of, the respective Parties and their permitted successors, assigns, heirs, executors, administrators and other legal representatives, as the case may be. This Agreement may not be assigned by any Party hereto without the prior written
consent of the other Party hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12. <U>No Waivers</U>. No waivers of any breach of this Agreement extended by CHFW to the Company
Stockholder shall be construed as a waiver of any rights or remedies of CHFW with respect to any other stockholder of the Company that has executed an agreement substantially in the form of this Agreement with respect to equity held or subsequently
held by such stockholder or with respect to any subsequent breach of the Company Stockholder or any other such stockholder of Company. No waiver of any provisions hereof by either Party shall be deemed a waiver of any other provisions hereof by any
such Party, nor shall any such waiver be deemed a continuing waiver of any provision hereof by such Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">13. <U>Governing Law;
Jurisdiction and Venue</U>. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware without regard to its rules of conflict of laws. The parties hereto hereby irrevocably and unconditionally consent
to and submit to the exclusive jurisdiction of the courts of the State of Delaware and of the United States of America located in such state (the &#147;<B>Delaware Courts</B>&#148;) for any litigation arising out of or relating to this Agreement and
the transactions contemplated hereby (and agree not to commence any litigation relating thereto except in such courts), waive any objection to the laying of venue of any such litigation in the Delaware Courts and agree not to plead or claim in any
Delaware Court that such litigation brought therein has been brought in any inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">14. <U>Waiver of Jury Trial</U>. The
parties hereto hereby waive any right to trial by jury with respect to any action or proceeding related to or arising out of this Agreement, any document executed in connection herewith and the matters contemplated hereby and thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15. <U>No Agreement Until Executed</U>. Irrespective of negotiations among the parties or the exchanging of drafts of this Agreement, this
Agreement shall not constitute or be deemed to evidence a contract, agreement, arrangement or understanding between the parties hereto unless and until (a)&nbsp;each of the Board of Directors of CHFW and the Board of Directors of the Company has
approved the transactions contemplated by the Business Combination Agreement, (b)&nbsp;the Business Combination Agreement is executed by all parties thereto, and (c)&nbsp;this Agreement is executed by all parties hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">16. <U>Entire Agreement; Amendment</U>. This Agreement supersedes all prior agreements,
written or oral, among the parties hereto with respect to the subject matter hereof and contains the entire agreement among the parties with respect to the subject matter hereof. This Agreement may not be amended, supplemented or modified, and no
provisions hereof may be modified or waived, except by an instrument in writing signed by each party hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">17. <U>Specific
Performance</U>. The parties hereto agree that irreparable damage may occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed
that the parties hereto shall be entitled to seek an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in the Delaware Courts, this being in addition to any other
remedy to which such party is entitled at law or in equity. Each of the parties hereby further waives (a)&nbsp;any defense in any action for specific performance that a remedy at law would be adequate and (b)&nbsp;any requirement under any Law to
post security or a bond as a prerequisite to obtaining equitable relief. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">18. <U>Severability</U>. If any provision of this Agreement is
held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Agreement will remain in full force and effect. Any provision of this Agreement held invalid or unenforceable only in part or degree will remain in
full force and effect to the extent not held invalid or unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">19. <U>Effect of Headings</U>. The section headings herein are for
convenience only and shall not affect the construction of interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">20. <U>Counterparts</U>. This Agreement may
be executed in one or more counterparts, each of which will be deemed an original but all of which together shall constitute one and the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[signature page follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, each of the Parties has caused this Agreement to
be duly executed on its behalf as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION
CORP.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>SURROZEN, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>COMPANY STOCKHOLDER</B>:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Shares of Common Stock:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Shares of Series A Preferred Stock:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares of Series B Preferred Stock:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares of Series C Preferred Stock:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="annex_i"></A><A NAME="rom40894_258"></A>ANNEX I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHFW SHAREHOLDER SUPPORT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This CHFW SHAREHOLDER SUPPORT AGREEMENT (this &#147;<B>Agreement</B>&#148;), dated as of April [&#9679;], 2021, is made by and among <FONT
STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., a Cayman Islands exempted company (&#147;<B>CHFW</B>&#148;), [&#9679;], a [&#9679;], a holder of CHFW Class&nbsp;A ordinary shares (the &#147;<B>CHFW Shareholder</B>&#148;), and
Surrozen, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;). CHFW, the CHFW Shareholder and the Company shall be referred to herein from time to time collectively as the &#147;<B>Parties</B>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, CHFW, the Company and certain other persons party thereto entered into that certain Business Combination Agreement, dated as of the
date hereof (as it may be amended, restated or otherwise modified from time to time in accordance with its terms, the &#147;<B>Business Combination Agreement</B>&#148;) providing for the merger of a subsidiary of CHFW with and into the Company, with
the Company surviving as the surviving corporation in such merger (the &#147;<B>Merger</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, the CHFW Shareholder is the
record and beneficial owner of the number of Class&nbsp;A ordinary shares of CHFW and warrants exercisable for the number of Class&nbsp;A ordinary shares of CHFW, each as set forth on the signature page hereto (together with any other Equity
Securities of CHFW that the CHFW Shareholder holds of record or beneficially, as of the date of this Agreement, or acquires record or beneficial ownership after the date hereof, collectively, the &#147;<B>Subject CHFW Equity Securities</B>&#148;);
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">WHEREAS, the CHFW Shareholder acknowledges and agrees that CHFW and the Company would not have entered into and agreed to consummate
the transactions contemplated by the Business Combination Agreement without the CHFW Shareholder entering into this Agreement and agreeing to be bound by the agreements, covenants and obligations contained in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NOW, THEREFORE, in consideration of the premises and the mutual promises contained herein and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1.
<U>Agreement to Vote</U>. The CHFW Shareholder hereby agrees to (i)&nbsp;appear (in person or by proxy) at any meeting of the shareholders of CHFW and (ii)&nbsp;vote (in person or by proxy) at any such meeting, and in any action by written
resolution of the shareholders of CHFW, all of such CHFW Shareholder&#146;s Subject CHFW Equity Securities in favor of (A)&nbsp;each of the Transaction Proposals to be submitted to the holders of CHFW Class&nbsp;A ordinary shares in connection with
the Merger and the other transactions contemplated by the Business Combination Agreement and (B)&nbsp;such other resolutions upon which a consent or other approval is required under CHFW&#146;s amended and restated memorandum and articles of
association, law, securities exchange or otherwise is sought with respect to effecting the Business Combination Agreement and the Merger, and (ii)&nbsp;vote (in person or by proxy) against any merger, purchase of all or substantially all of a third
party (other than the Merger) or all of the assets of a third party or other business combination transaction with a third party (other than the Business Combination Agreement and the Merger) (a &#147;<B>Competing Transaction</B>&#148;) or any
proposal relating to a Competing Transaction and against any proposal, action or agreement that would (A)&nbsp;impede, frustrate, prevent or nullify any provision of this Agreement, the Business Combination Agreement or any Merger, (B)&nbsp;result
in a breach in any respect of any covenant, representation, warranty or any other obligation or agreement of CHFW or Perseverance Merger Sub Inc. under the Business Combination Agreement, (C)&nbsp;result in any of the conditions set forth in Article
VI of the Business Combination Agreement not being fulfilled or (D)&nbsp;change in any manner the dividend policy or capitalization of, including the voting rights of any class of capital stock of, CHFW (other than the Transaction Proposals). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The CHFW Shareholder hereby agrees that it shall not commit or agree to take any action inconsistent with the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the failure of a CHFW Shareholder to timely provide its consent or vote its Subject
CHFW Equity Securities in accordance with this Section&nbsp;1 pursuant to any action by written consent of the shareholders of the CHFW or at any applicable meeting of the shareholders of the CHFW, such CHFW Shareholder shall be deemed to have
irrevocably granted to, and appointed, CHFW, and any designee thereof, and each of them individually, as such CHFW Shareholder&#146;s proxy and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> (with
full power of substitution), for and in such CHFW Shareholder&#146;s name, place and stead, to deliver any action by written consent of the CHFW Shareholder&#146;s concerning any of the matters specified in this Section&nbsp;1 or attend any meeting
of the CHFW Shareholders concerning any of the matters specified in this Section&nbsp;1, to include such Subject Equity Securities in any computation for purposes of establishing a quorum at any such meeting of the CHFW Shareholders and to provide
consent or vote such CHFW Shareholder&#146;s Subject Equity Securities in any action by written consent of the CHFW Shareholders or at any meeting of the CHFW Shareholders called with respect to any of the matters specified in, and in accordance and
consistent with, this Section&nbsp;1. Each CHFW Shareholder hereby affirms that the irrevocable proxy is coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable.
Notwithstanding any other provision of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate upon the termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. <U>No Redemption</U>. The CHFW Shareholder hereby agrees that it shall not redeem, or submit a request to CHFW&#146;s transfer agent or
otherwise exercise any right to redeem, any Subject CHFW Equity Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. <U>Transfer of Shares</U>. The CHFW Shareholder hereby
agrees that it shall not, directly or indirectly, (i)&nbsp;sell, assign, transfer (including by operation of law), place a lien on, pledge, dispose of or otherwise encumber any of its Subject CHFW Equity Securities or otherwise agree to do any of
the foregoing (each, a &#147;<B>Transfer</B>&#148;), (ii) deposit any of its Subject CHFW Equity Securities into a voting trust or enter into a voting agreement or arrangement or grant any proxy or power of attorney with respect to any of its
Subject CHFW Equity Securities that conflicts with any of the covenants or agreements set forth in this Agreement, (iii)&nbsp;enter into any contract, option or other arrangement or undertaking with respect to the direct or indirect acquisition or
sale, assignment, transfer (including by operation of law) or other disposition of any of its Subject CHFW Equity Securities, (iv)&nbsp;engage in any hedging or other transaction which is designed to, or which would (either alone or in connection
with one or more events, developments or events (including the satisfaction or waiver of any conditions precedent)), lead to or result in a sale or disposition of its Subject CHFW Equity Securities even if such Subject CHFW Equity Securities would
be disposed of by a person other than the CHFW Shareholder or (v)&nbsp;take any action that would have the effect of preventing or materially delaying the performance of its obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. <U>Further Assurances</U>. Each CHFW Shareholder shall take, or cause to be taken, all actions and do, or cause to be done, all things
reasonably necessary under applicable Laws to consummate the Merger and the other transactions contemplated by the Business Combination Agreement on the terms and subject to the conditions set forth therein and herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. <U>No Inconsistent Agreement</U>. Each CHFW Shareholder hereby represents and covenants that such CHFW Shareholder has not entered into,
and shall not enter into, any agreement that would restrict, limit or interfere with the performance of such CHFW Shareholder&#146;s obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6. <U>CHFW Shareholder Representations and Warranties</U>. The CHFW Shareholder represents and warrants to CHFW and the Company as follows:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">a. The CHFW Shareholder is a corporation, limited liability company or other applicable business entity duly organized or formed, as
applicable, validly existing and in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the Laws of its jurisdiction of
formation or organization (as applicable). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">b. The CHFW Shareholder has the requisite corporate, limited liability company or other
similar power and authority to execute and deliver this Agreement, to perform its covenants, agreements and obligations hereunder. The execution and delivery of this Agreement has been duly authorized by all necessary corporate (or other similar)
action on the part of the CHFW Shareholder. This Agreement has been duly and validly executed and delivered by the CHFW Shareholder and constitutes a valid, legal and binding agreement of the CHFW Shareholder (assuming that this Agreement is duly
authorized, executed and delivered by CHFW and the Company), enforceable against the CHFW Shareholder in accordance with its terms (subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the
enforcement of creditors&#146; rights and subject to general principles of equity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">c. The execution and delivery of this Agreement by
such CHFW Shareholder, does not, and the performance by such CHFW Shareholder of his, her or its obligations hereunder will not, (i)&nbsp;if such CHFW Shareholder is not an individual, conflict with or result in a violation of the organizational
documents of such CHFW Shareholder or (ii)&nbsp;require any consent or approval that has not been given or other action that has not been taken by any Person (including under any Contract binding upon such CHFW Shareholder or such CHFW
Shareholder&#146;s Subject CHFW Equity Securities), in each case, to the extent such consent, approval or other action would prevent, enjoin or materially delay the performance by such CHFW Shareholder of its, his or her obligations under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">d. There are no proceedings pending against such CHFW Shareholder, or to the knowledge of such CHFW Shareholder threatened
against such CHFW Shareholder, before (or, in the case of threatened proceedings, that would be before) any arbitrator or any Governmental Entity, which in any manner challenges or seeks to prevent, enjoin or materially delay the performance by such
CHFW Shareholder of its, his or her obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">e. Except as described on Section&nbsp;4.4 of the CHFW Disclosure
Schedules, no broker, finder, investment banker or other Person is entitled to any brokerage fee, finders&#146; fee or other commission in connection with the transactions contemplated by the Business Combination Agreement based upon arrangements
made by such CHFW Shareholder, for which CHFW or any of its Affiliates may become liable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">f. Such CHFW Shareholder understands and
acknowledges that each of CHFW and the Company is entering into the Business Combination Agreement in reliance upon such CHFW Shareholder&#146;s execution and delivery of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7. <U>Termination</U>. This Agreement shall automatically terminate, without any notice or other action by any Party, and be void <I>ab
initio</I> upon the earlier of (a)&nbsp;the effective time of the Merger; and (b)&nbsp;the termination of the Business Combination Agreement in accordance with its terms. Upon termination of this Agreement as provided in the immediately preceding
sentence, none of the Parties shall have any further obligations or liabilities under, or with respect to, this Agreement. Notwithstanding the foregoing or anything to the contrary in this Agreement, the termination of this Agreement pursuant to
<U>Section</U><U></U><U>&nbsp;5(b)</U> shall not affect any liability on the part of any Party for a willful breach of any covenant or agreement set forth in this Agreement prior to such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8. <U>No Third Party Beneficiaries</U>. This Agreement shall be for the sole benefit of the Parties and their respective successors and
permitted assigns and is not intended, nor shall be construed, to give any Person, other than the Parties and their respective successors and assigns, any legal or equitable right, benefit or remedy of any nature whatsoever by reason this Agreement.
Nothing in this Agreement, expressed or implied, is intended to or shall constitute the Parties, partners or participants in a joint venture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9. <U>Severability</U>. If any term or other provision of this Agreement is determined to be invalid, illegal or incapable of being enforced
by any rule of law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any
manner materially adverse to any party. Upon such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original
intent of the Parties as closely as possible to the fullest extent permitted by applicable law in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10. <U>Binding Effect and Assignment</U>. All of the covenants and agreements contained in this Agreement shall be binding upon, and inure to
the benefit of, the respective Parties and their permitted successors, assigns, heirs, executors, administrators and other legal representatives, as the case may be. This Agreement may not be assigned by any Party hereto without the prior written
consent of the other Party hereto; <U>provided</U>, <U>however</U>, that, notwithstanding the foregoing, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11. <U>No Waivers</U>. No
waivers of any breach of this Agreement extended by CHFW to the CHFW Shareholder shall be construed as a waiver of any rights or remedies of CHFW with respect to any other shareholder of CHFW who has executed an agreement substantially in the form
of this Agreement with respect to equity held or subsequently held by such shareholder or with respect to any subsequent breach of the CHFW Shareholder or any other such shareholder or CHFW. No waiver of any provisions hereof by either Party shall
be deemed a waiver of any other provisions hereof by any such Party, nor shall any such waiver be deemed a continuing waiver of any provision hereof by such Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12. <U>Governing Law; Jurisdiction and Venue</U>. This Agreement shall be governed by, and construed in accordance with, the laws of the State
of Delaware without regard to its rules of conflict of laws (except to the extent that the laws of the Cayman Islands govern the giving or voting of any proxies given under this Agreement). The parties hereto hereby irrevocably and unconditionally
consent to and submit to the exclusive jurisdiction of the courts of the State of Delaware and of the United States of America located in such state (the &#147;<B>Delaware Courts</B>&#148;) for any litigation arising out of or relating to this
Agreement and the transactions contemplated hereby (and agree not to commence any litigation relating thereto except in such courts), waive any objection to the laying of venue of any such litigation in the Delaware Courts and agree not to plead or
claim in any Delaware Court that such litigation brought therein has been brought in any inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">13. <U>Waiver of Jury
Trial</U>. The parties hereto hereby waive any right to trial by jury with respect to any action or proceeding related to or arising out of this Agreement, any document executed in connection herewith and the matters contemplated hereby and thereby.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">14. <U>No Agreement Until Executed</U>. Irrespective of negotiations among the parties or the exchanging of drafts of this Agreement,
this Agreement shall not constitute or be deemed to evidence a contract, agreement, arrangement or understanding between the parties hereto unless and until (a)&nbsp;the Board of Directors of CHFW has approved the transactions contemplated by the
Business Combination Agreement, (b)&nbsp;the Business Combination Agreement is executed by all parties thereto, and (c)&nbsp;this Agreement is executed by all parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15. <U>Entire Agreement; Amendment</U>. This Agreement supersedes all prior agreements, written or oral, among the parties hereto with respect
to the subject matter hereof and contains the entire agreement among the parties with respect to the subject matter hereof. This Agreement may not be amended, supplemented or modified, and no provisions hereof may be modified or waived, except by an
instrument in writing signed by each party hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">16. <U>Specific Performance</U>. The parties hereto agree that irreparable damage may
occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties hereto shall be entitled to seek an injunction or
injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in the Delaware Courts, this being in addition to any other remedy to which such party is entitled at law or in equity. Each of
the parties hereby further waives (a)&nbsp;any defense in any action for specific performance that a remedy at law would be adequate and (b)&nbsp;any requirement under any Law to post security or a bond as a prerequisite to obtaining equitable
relief. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">17. <U>Severability</U>. If any provision of this Agreement is held invalid or unenforceable
by any court of competent jurisdiction, the other provisions of this Agreement will remain in full force and effect. Any provision of this Agreement held invalid or unenforceable only in part or degree will remain in full force and effect to the
extent not held invalid or unenforceable </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">18. <U>Effect of Headings</U>. The section headings herein are for convenience only and shall
not affect the construction of interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">19. <U>Counterparts</U>. This Agreement may be executed in one or more
counterparts, each of which will be deemed an original but all of which together shall constitute one and the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[signature page follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>IN WITNESS WHEREOF</B>, each of the Parties has caused this Agreement to
be duly executed on its behalf as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION
CORP.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Name:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>SURROZEN, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Name:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>CHFW SHAREHOLDER</B>:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Name:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Title:</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;A&nbsp;Ordinary&nbsp;Shares:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="annex_j"></A><A NAME="rom40894_259"></A>ANNEX J </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>URROZEN</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>: [_______], 2021
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: [_______], 2021 </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>1.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>G<SMALL>ENERAL</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Plan Purpose.</B> The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and
Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Common
Stock through the granting of Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Available Awards.</B> The Plan provides for the grant of the following Awards:
(i)&nbsp;Incentive Stock Options; (ii)&nbsp;Nonstatutory Stock Options; (iii)&nbsp;SARs; (iv) Restricted Stock Awards; (v)&nbsp;RSU Awards; (vi)&nbsp;Performance Awards; and (vii)&nbsp;Other Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Adoption Date; Effective Date. </B>The Plan will come into existence on the Adoption Date, but no Award may be granted prior to
the Effective Date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>2.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>S<SMALL>HARES</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Share Reserve. </B>Subject to adjustment in accordance with Section&nbsp;2(c) and any adjustments as
necessary to implement any Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed [&#149;] shares (equal to 10% of the shares of Fully-Diluted Common Stock as of immediately
following closing of the transactions contemplated by the Business Combination Agreement). In addition, subject to any adjustments as necessary to implement any Capitalization Adjustments, such aggregate number of shares of Common Stock will
automatically increase on January&nbsp;1 of each year for a period of ten years commencing on January&nbsp;1, 2022 and ending on (and including) January&nbsp;1, 2031, in an amount equal to five percent (5%) of the Fully-Diluted Common Stock on
December&nbsp;31 of the preceding year; provided, however, that the Board may act prior to January 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of a given year to provide that the increase for such year will be a lesser number of shares
of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Aggregate Incentive Stock Option Limit.</B> Notwithstanding anything to the contrary in Section&nbsp;2(a)
and subject to any adjustments as necessary to implement any Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is [&#149;] shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) Share Reserve Operation.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> <B>Limit Applies to Common Stock Issued Pursuant to Awards. </B>For clarity, the Share Reserve is a limit on the
number of shares of Common Stock that may be issued pursuant to Awards and does not limit the granting of Awards, except that the Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy its
obligations to issue shares pursuant to such Awards. Shares may be issued in connection with a merger or acquisition as permitted by, as applicable, Nasdaq Listing Rule 5635(c), NYSE Listed Company Manual Section&nbsp;303A.08, NYSE American Company
Guide Section&nbsp;711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> <B>Actions that Do Not Constitute Issuance of Common Stock and Do Not Reduce Share Reserve.</B> The following
actions do not result in an issuance of shares under the Plan and accordingly do not reduce the number of shares subject to the Share Reserve and available for issuance under the Plan: (1)&nbsp;the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
expiration or termination of any portion of an Award without the shares covered by such portion of the Award having been issued, (2)&nbsp;the settlement of any portion of an Award in cash (i.e.,
the Participant receives cash rather than Common Stock), (3) the withholding of shares that would otherwise be issued by the Company to satisfy the exercise, strike or purchase price of an Award; or (4)&nbsp;the withholding of shares that would
otherwise be issued by the Company to satisfy a tax withholding obligation in connection with an Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B>
<B>Reversion of Previously Issued Shares of Common Stock to Share Reserve.</B> The following shares of Common Stock previously issued pursuant to an Award and accordingly initially deducted from the Share Reserve will be added back to the Share
Reserve and again become available for issuance under the Plan: (1)&nbsp;any shares that are forfeited back to or repurchased by the Company because of a failure to meet a contingency or condition required for the vesting of such shares;
(2)&nbsp;any shares that are reacquired by the Company to satisfy the exercise, strike or purchase price of an Award; and (3)&nbsp;any shares that are reacquired by the Company to satisfy a tax withholding obligation in connection with an Award.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>3.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>E<SMALL>LIGIBILITY</SMALL> <SMALL>AND</SMALL> L<SMALL>IMITATIONS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Eligible Award Recipients.</B> Subject to the terms of the Plan, Employees, Directors and Consultants are eligible to receive
Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b) Specific Award Limitations. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> <B>Limitations on Incentive Stock Option Recipients.</B> Incentive Stock Options may be granted only to Employees
of the Company or a &#147;parent corporation&#148; or &#147;subsidiary corporation&#148; thereof (as such terms are defined in Sections 424(e) and (f)&nbsp;of the Code). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> <B>Incentive Stock Option $100,000 Limitation.</B> To the extent that the aggregate Fair Market Value (determined
at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other
limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with
such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> <B>Limitations on Incentive Stock Options Granted to Ten Percent Stockholders.</B> A Ten Percent Stockholder may
not be granted an Incentive Stock Option unless (i)&nbsp;the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant of such Option and (ii)&nbsp;the Option is not exercisable after the expiration of five years
from the date of grant of such Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B> <B>Limitations on Nonstatutory Stock Options and SARs.</B>
Nonstatutory Stock Options and SARs may not be granted to Employees, Directors and Consultants unless the stock underlying such Awards is treated as &#147;service recipient stock&#148; under Section&nbsp;409A or unless such Awards otherwise comply
with the requirements of Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Aggregate Incentive Stock Option Limit.</B> The aggregate maximum number of
shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is the number of shares specified in Section&nbsp;2(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> <B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit. </B>The aggregate value of all compensation
granted or paid, as applicable, to any individual for service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director with respect to any calendar year, including Awards granted and cash fees paid by the Company to such <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director, will not exceed (i) [$750,000] in total value or (ii)&nbsp;in the event such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director is first appointed or elected to the Board during
such calendar year, [$1,000,000] in total value, in each case, calculating the value of any equity awards based on the grant date fair value of such equity awards for financial reporting purposes. The limitations in this Section&nbsp;3(d) shall
apply commencing with the first calendar year that begins following the Effective Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>4.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>PPRECIATION</SMALL>
R<SMALL>IGHTS</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each Option and SAR will have such terms and conditions as determined by the Board. Each
Option will be designated in writing as an Incentive Stock Option or Nonstatutory Stock Option at the time of grant; provided, however, that if an Option is not so designated or if an Option designated as an Incentive Stock Option fails to qualify
as an Incentive Stock Option, then such Option will be a Nonstatutory Stock Option, and the shares purchased upon exercise of each type of Option will be separately accounted for. Each SAR will be denominated in shares of Common Stock equivalents.
The terms and conditions of separate Options and SARs need not be identical; provided, however, that each Option Agreement and SAR Agreement will conform (through incorporation of provisions hereof by reference in the Award Agreement or otherwise)
to the substance of each of the following provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Term.</B> Subject to Section&nbsp;3(b) regarding Ten Percent
Stockholders, no Option or SAR will be exercisable after the expiration of ten years from the date of grant of such Award or such shorter period specified in the Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Exercise or Strike Price.</B> Subject to Section&nbsp;3(b) regarding Ten Percent Stockholders, the exercise or strike price of
each Option or SAR will not be less than 100% of the Fair Market Value on the date of grant of such Award. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value on
the date of grant of such Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Sections 409A
and, if applicable, 424(a) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Exercise Procedure and Payment of Exercise Price for Options.</B> In order to
exercise an Option, the Participant must provide notice of exercise to the Plan Administrator in accordance with the procedures specified in the Option Agreement or otherwise provided by the Company. The Board has the authority to grant Options that
do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment. The exercise price of an Option
may be paid, to the extent permitted by Applicable Law and as determined by the Board, by one or more of the following methods of payment to the extent set forth in the Option Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> by cash or check, bank draft or money order payable to the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> pursuant to a &#147;cashless exercise&#148; program developed under Regulation T as promulgated by the Federal Reserve Board that,
prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the exercise price to the Company from the sales proceeds; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are already owned by the
Participant free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1)&nbsp;at the time of exercise the Common Stock is
publicly traded, (2)&nbsp;any remaining balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (3)&nbsp;such delivery would not violate any Applicable Law or agreement
restricting the redemption of the Common Stock, (4)&nbsp;any certificated shares are endorsed or accompanied by an executed assignment separate from certificate, and (5)&nbsp;such shares have been held by the Participant for any minimum period
necessary to avoid adverse accounting treatment as a result of such delivery; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B> if the Option is a Nonstatutory Stock Option,
by a &#147;net exercise&#148; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value on the date of exercise that does not
exceed the exercise price, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
provided that (1)&nbsp;such shares used to pay the exercise price will not be exercisable thereafter and (2)&nbsp;any remaining balance of the exercise price not satisfied by such net exercise is
paid by the Participant in cash or other permitted form of payment; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v)</B> in any other form of consideration that may be
acceptable to the Board and permissible under Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> <B>Exercise Procedure and Payment of Appreciation Distribution
for SARs</B><B>.</B> In order to exercise any SAR, the Participant must provide notice of exercise to the Plan Administrator in accordance with the SAR Agreement. The appreciation distribution payable to a Participant upon the exercise of a SAR will
not be greater than an amount equal to the excess of (i)&nbsp;the aggregate Fair Market Value on the date of exercise of a number of shares of Common Stock equal to the number of Common Stock equivalents that are vested and being exercised under
such SAR, over (ii)&nbsp;the strike price of such SAR. Such appreciation distribution may be paid to the Participant in the form of Common Stock or cash (or any combination of Common Stock and cash) or in any other form of payment, as determined by
the Board and specified in the SAR Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> <B>Transferability.</B> Options and SARs may not be transferred to third party
financial institutions for value. The Board may impose such additional limitations on the transferability of an Option or SAR as it determines. In the absence of any such determination by the Board, the following restrictions on the transferability
of Options and SARs will apply, provided that except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration and provided, further, that if an Option is an Incentive Stock Option, such Option may be deemed to
be a Nonstatutory Stock Option as a result of such transfer: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> <B>Restrictions on Transfer.</B> An Option or SAR will not be
transferable, except by will or by the laws of descent and distribution, and will be exercisable during the lifetime of the Participant only by the Participant; provided, however, that the Board may permit transfer of an Option or SAR in a manner
that is not prohibited by applicable tax and securities laws upon the Participant&#146;s request, including to a trust if the Participant is considered to be the sole beneficial owner of such trust (as determined under Section&nbsp;671 of the Code
and applicable state law) while such Option or SAR is held in such trust, provided that the Participant and the trustee enter into a transfer and other agreements required by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> <B>Domestic Relations Orders.</B> Notwithstanding the foregoing, subject to the execution of transfer documentation in a format
acceptable to the Company and subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to a domestic relations order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B> <B>Vesting.</B> The Board may impose such restrictions on or conditions to the vesting and/or exercisability of an Option or SAR as
determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Options and SARs will cease upon termination of the Participant&#146;s
Continuous Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g)</B> <B>Termination of Continuous Service for Cause.</B> Except as explicitly otherwise provided in the Award
Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#146;s Continuous Service is terminated for Cause, the Participant&#146;s Options and SARs will terminate and be forfeited immediately upon
such termination of Continuous Service, and the Participant will be prohibited from exercising any portion (including any vested portion) of such Awards on and after the date of such termination of Continuous Service and the Participant will have no
further right, title or interest in such forfeited Award, the shares of Common Stock subject to the forfeited Award, or any consideration in respect of the forfeited Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(h)</B> <B>Post-Termination Exercise Period Following Termination of Continuous Service for Reasons Other than Cause.</B> Subject to
Section&nbsp;4(i), if a Participant&#146;s Continuous Service terminates for any reason other than for Cause, the Participant may exercise his or her Option or SAR to the extent vested, but only within the following period of time or, if applicable,
such other period of time provided in the Award Agreement or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
written agreement between a Participant and the Company or an Affiliate; provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in
Section&nbsp;4(a)): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> three months following the date of such termination if such termination is a termination without Cause
(other than any termination due to the Participant&#146;s Disability or death); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> 12 months following the date of such
termination if such termination is due to the Participant&#146;s Disability; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> 18 months following the date of such
termination if such termination is due to the Participant&#146;s death; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B> 18 months following the date of the
Participant&#146;s death if such death occurs following the date of such termination but during the period such Award is otherwise exercisable (as provided in (i)&nbsp;or (ii) above). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the date of such termination, to the extent the Participant does not exercise such Award within the applicable Post-Termination
Exercise Period (or, if earlier, prior to the expiration of the maximum term of such Award), such unexercised portion of the Award will terminate, and the Participant will have no further right, title or interest in the terminated Award, the shares
of Common Stock subject to the terminated Award, or any consideration in respect of the terminated Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> <B>Restrictions on
Exercise; Extension of Exercisability. </B>A Participant may not exercise an Option or SAR at any time that the issuance of shares of Common Stock upon such exercise would violate Applicable Law. Except as otherwise provided in the Award Agreement
or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#146;s Continuous Service terminates for any reason other than for Cause and, at any time during the last thirty days of the applicable
Post-Termination Exercise Period: (i)&nbsp;the exercise of the Participant&#146;s Option or SAR would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate Applicable Law, or (ii)&nbsp;the immediate
sale of any shares of Common Stock issued upon such exercise would violate the Company&#146;s Trading Policy, then the applicable Post-Termination Exercise Period will be extended to the last day of the calendar month that commences following the
date the Award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period, generally
without limitation as to the maximum permitted number of extensions); provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section&nbsp;4(a)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(j)</B> <B><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employees</B>. No Option or SAR, whether or not vested, granted to an
Employee who is a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee for purposes of the Fair Labor Standards Act of 1938, as amended, will be first exercisable for any shares of Common Stock until at least six months following the date of
grant of such Award. Notwithstanding the foregoing, in accordance with the provisions of the Worker Economic Opportunity Act, any vested portion of such Award may be exercised earlier than six months following the date of grant of such Award in the
event of (i)&nbsp;such Participant&#146;s death or Disability, (ii)&nbsp;a Corporate Transaction in which such Award is not assumed, continued or substituted, (iii)&nbsp;a Change in Control, or (iv)&nbsp;such Participant&#146;s retirement (as such
term may be defined in the Award Agreement or another applicable agreement or, in the absence of any such definition, in accordance with the Company&#146;s then current employment policies and guidelines). This Section&nbsp;4(j) is intended to
operate so that any income derived by a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(k)</B> <B>Whole Shares</B>. Options and SARs may be exercised only with respect to whole shares of Common Stock or their equivalents. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>5.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>A<SMALL>WARDS</SMALL> O<SMALL>THER</SMALL> T<SMALL>HAN</SMALL> O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL>
S<SMALL>TOCK</SMALL> A<SMALL>PPRECIATION</SMALL> R<SMALL>IGHTS</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Restricted Stock Awards and
RSU Awards.</B> Each Restricted Stock Award and RSU Award will have such terms and conditions as determined by the Board; provided, however, that each Restricted Stock Award Agreement and RSU Award Agreement will conform (through incorporation of
the provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i) Form
of Award.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(1)</B> Restricted Stock Awards: To the extent consistent with the Company&#146;s Bylaws, at the Board&#146;s election,
shares of Common Stock subject to a Restricted Stock Award may be (i)&nbsp;held in book entry form subject to the Company&#146;s instructions until such shares become vested or any other restrictions lapse, or (ii)&nbsp;evidenced by a certificate,
which certificate will be held in such form and manner as determined by the Board. Unless otherwise determined by the Board, a Participant will have voting and other rights as a stockholder of the Company with respect to any shares subject to a
Restricted Stock Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(2)</B> RSU Awards: An RSU Award represents a Participant&#146;s right to be issued on a future date the
number of shares of Common Stock that is equal to the number of restricted stock units subject to the RSU Award. As a holder of an RSU Award, a Participant is an unsecured creditor of the Company with respect to the Company&#146;s unfunded
obligation, if any, to issue shares of Common Stock in settlement of such Award and nothing contained in the Plan or any RSU Agreement, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a
fiduciary relationship between a Participant and the Company or an Affiliate or any other person. A Participant will not have voting or any other rights as a stockholder of the Company with respect to any RSU Award (unless and until shares are
actually issued in settlement of a vested RSU Award). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii) Consideration.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(1)</B> Restricted Stock Awards: A Restricted Stock Award may be granted in consideration for (A)&nbsp;cash or check, bank draft or money
order payable to the Company, (B)&nbsp;services to the Company or an Affiliate, or (C)&nbsp;any other form of consideration as the Board may determine and permissible under Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(2)</B> RSU Awards: Unless otherwise determined by the Board at the time of grant, an RSU Award will be granted in consideration for the
Participant&#146;s services to the Company or an Affiliate, such that the Participant will not be required to make any payment to the Company (other than such services) with respect to the grant or vesting of the RSU Award, or the issuance of any
shares of Common Stock pursuant to the RSU Award. If, at the time of grant, the Board determines that any consideration must be paid by the Participant (in a form other than the Participant&#146;s services to the Company or an Affiliate) upon the
issuance of any shares of Common Stock in settlement of the RSU Award, such consideration may be paid in any form of consideration as the Board may determine and permissible under Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> <B>Vesting. </B>The Board may impose such restrictions on or conditions to the vesting of a Restricted Stock Award or RSU Award
as determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Restricted Stock Awards and RSU Awards will cease upon termination of the
Participant&#146;s Continuous Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B> <B>Termination of Continuous Service.</B> Except as otherwise provided in the Award
Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#146;s Continuous Service terminates for any reason, (i)&nbsp;the Company may receive through a forfeiture condition or a repurchase right
any or all of the shares of Common Stock held by the Participant under his or her Restricted Stock Award that have not vested as of the date of such termination as set forth in the Restricted Stock Award Agreement and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the Participant will have no further right, title or interest in the Restricted Stock Award, the shares of Common Stock subject to the Restricted Stock Award, or any consideration in respect of
the Restricted Stock Award and (ii)&nbsp;any portion of his or her RSU Award that has not vested will be forfeited upon such termination and the Participant will have no further right, title or interest in the RSU Award, the shares of Common Stock
issuable pursuant to the RSU Award, or any consideration in respect of the RSU Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v)</B> <B>Dividends and Dividend Equivalents.
</B>Dividends or dividend equivalents may be paid or credited, as applicable, with respect to any shares of Common Stock subject to a Restricted Stock Award or RSU Award, as determined by the Board and specified in the Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(vi)</B> <B>Settlement of RSU Awards</B>. An RSU Award may be settled by the issuance of shares of Common Stock or cash (or any combination
thereof) or in any other form of payment, as determined by the Board and specified in the RSU Award Agreement. At the time of grant, the Board may determine to impose such restrictions or conditions that delay such delivery to a date following the
vesting of the RSU Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Performance Awards</B>. With respect to any Performance Award, the length of any Performance
Period, the Performance Goals to be achieved during the Performance Period, the other terms and conditions of such Award, and the measure of whether and to what degree such Performance Goals have been attained will be determined by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Other Awards</B>. Other forms of Awards valued in whole or in part by reference to, or otherwise based on, Common Stock,
including the appreciation in value thereof, may be granted either alone or in addition to Awards provided for under Section&nbsp;4 and the preceding provisions of this Section&nbsp;5. Subject to the provisions of the Plan, the Board will have sole
and complete discretion to determine the persons to whom and the time or times at which such Other Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Awards and all
other terms and conditions of such Other Awards. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>6.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL>
C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; O<SMALL>THER</SMALL> C<SMALL>ORPORATE</SMALL> E<SMALL>VENTS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Capitalization Adjustments</B>. In the event of a Capitalization Adjustment, the Board shall appropriately and proportionately
adjust: (i)&nbsp;the class(es) and maximum number of shares of Common Stock subject to the Plan and the maximum number of shares by which the Share Reserve may annually increase pursuant to Section&nbsp;2(a), (ii) the class(es) and maximum number of
shares that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section&nbsp;2(b), and (iii)&nbsp;the class(es) and number of securities and exercise price, strike price or purchase price of Common Stock subject to
outstanding Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive. Notwithstanding the foregoing, no fractional shares or rights for fractional shares of Common Stock shall be created in order to
implement any Capitalization Adjustment. The Board shall determine an appropriate equivalent benefit, if any, for any fractional shares or rights to fractional shares that might be created by the adjustments referred to in the preceding provisions
of this Section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Dissolution or Liquidation</B>. Except as otherwise provided in the Award Agreement, in the event of a
dissolution or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#146;s right of repurchase) will terminate
immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#146;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company
notwithstanding the fact that the holder of such Award is providing Continuous Service; provided, however, that the Board may determine to cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or
forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Corporate Transaction. </B>The following provisions will apply to Awards in
the event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the
time of grant of an Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> <B>Awards May Be Assumed.</B> In the event of a Corporate Transaction, any surviving corporation or
acquiring corporation (or the surviving or acquiring corporation&#146;s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar awards for Awards outstanding under the Plan (including but not
limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Awards
may be assigned by the Company to the successor of the Company (or the successor&#146;s parent company, if any), in connection with such Corporate Transaction. A surviving corporation or acquiring corporation (or its parent) may choose to assume or
continue only a portion of an Award or substitute a similar award for only a portion of an Award, or may choose to assume or continue the Awards held by some, but not all Participants. The terms of any assumption, continuation or substitution will
be set by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> <B>Awards Held by Current Participants.</B> In the event of a Corporate Transaction in which the
surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or
substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the &#147;<B>Current Participants</B>&#148;), the vesting of such Awards (and, with
respect to Options and Stock Appreciation Rights, the time when such Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate
Transaction) as the Board determines (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Corporate Transaction), and such Awards will terminate if not exercised (if applicable) at or
prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Corporate Transaction). With respect to the
vesting of Performance Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii)&nbsp;and that have multiple vesting levels depending on the level of performance, unless otherwise provided in the
Award Agreement, the vesting of such Performance Awards will accelerate at 100% of the target level upon the occurrence of the Corporate Transaction in which the Awards are not assumed in accordance with Section&nbsp;6(c)(i). With respect to the
vesting of Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii)&nbsp;and are settled in the form of a cash payment, such cash payment will be made no later than 30 days following the occurrence
of the Corporate Transaction or such later date as required to comply with Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> <B>Awards Held by
Persons other than Current Participants.</B> In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards
for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Awards will terminate if not exercised (if applicable) prior to the
occurrence of the Corporate Transaction; provided, however, that any reacquisition or repurchase rights held by the Company with respect to such Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B> <B>Payment for Awards in Lieu of Exercise.</B> Notwithstanding the foregoing, in the event an Award will terminate if not
exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Award may not exercise such Award but will receive a payment, in such form as may be determined by the Board,
equal in value, at the effective time, to the excess, if any, of (1)&nbsp;the value of the property the Participant would have received upon the exercise of the Award (including, at the discretion of the Board, any unvested portion of such Award),
over (2)&nbsp;any exercise price payable by such holder in connection with such exercise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> <B>Appointment of Stockholder Representative.</B> As a condition to the receipt
of an Award under this Plan, a Participant will be deemed to have agreed that the Award will be subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the
appointment of a stockholder representative that is authorized to act on the Participant&#146;s behalf with respect to any escrow, indemnities and any contingent consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> <B>No Restriction on Right to Undertake Transactions</B>. The grant of any Award under the Plan and the issuance of shares pursuant
to any Award does not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the Company&#146;s capital structure or
its business, any merger or consolidation of the Company, any issue of stock or of options, rights or options to purchase stock or of bonds, debentures, preferred or prior preference stocks whose rights are superior to or affect the Common Stock or
the rights thereof or which are convertible into or exchangeable for Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding,
whether of a similar character or otherwise. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>7.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>A<SMALL>DMINISTRATION</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Administration by Board.</B> The Board will administer the Plan unless and until the Board delegates administration of the Plan
to a Committee or Committees, as provided in subsection (c)&nbsp;below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Powers of Board.</B> The Board will have the power,
subject to, and within the limitations of, the express provisions of the Plan: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> To determine from time to time: (1)&nbsp;which
of the persons eligible under the Plan will be granted Awards; (2)&nbsp;when and how each Award will be granted; (3)&nbsp;what type or combination of types of Award will be granted; (4)&nbsp;the provisions of each Award granted (which need not be
identical), including the time or times when a person will be permitted to receive an issuance of Common Stock or other payment pursuant to an Award; (5)&nbsp;the number of shares of Common Stock or cash equivalent with respect to which an Award
will be granted to each such person; (6)&nbsp;the Fair Market Value applicable to an Award; and (7)&nbsp;the terms of any Performance Award that is not valued in whole or in part by reference to, or otherwise based on, the Common Stock, including
the amount of cash payment or other property that may be earned and the timing of payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> To construe and interpret the Plan
and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a
manner and to the extent it deems necessary or expedient to make the Plan or Award fully effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> To settle all
controversies regarding the Plan and Awards granted under it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B> To accelerate the time at which an Award may first be exercised
or the time during which an Award or any part thereof will vest, notwithstanding the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v)</B> To prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to 30 days prior to the consummation
of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock
or the share price of the Common Stock including any Corporate Transaction, for reasons of administrative convenience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(vi)</B> To
suspend or terminate the Plan at any time. Suspension or termination of the Plan will not Materially Impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(vii)</B> To amend the Plan in any respect the Board deems necessary or advisable;
provided, however, that stockholder approval will be required for any amendment to the extent required by Applicable Law. Except as provided above, rights under any Award granted before amendment of the Plan will not be Materially Impaired by any
amendment of the Plan unless (1)&nbsp;the Company requests the consent of the affected Participant, and (2)&nbsp;such Participant consents in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(viii)</B> To submit any amendment to the Plan for stockholder approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ix)</B> To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not
limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; provided however, that, a
Participant&#146;s rights under any Award will not be Materially Impaired by any such amendment unless (1)&nbsp;the Company requests the consent of the affected Participant, and (2)&nbsp;such Participant consents in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(x)</B> Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests
of the Company and that are not in conflict with the provisions of the Plan or Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(xi)</B> To adopt such procedures and <FONT
STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit and facilitate participation in the Plan by, or take advantage of specific tax treatment for Awards granted to, Employees, Directors or Consultants who are foreign
nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement to ensure or facilitate compliance with the laws of the relevant foreign
jurisdiction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(xii)</B> <B></B>To effect, at any time and from time to time, subject to the consent of any Participant whose Award is
Materially Impaired by such action, (1)&nbsp;the reduction of the exercise price (or strike price) of any outstanding Option or SAR; (2)&nbsp;the cancellation of any outstanding Option or SAR and the grant in substitution therefor of (A)&nbsp;a new
Option, SAR, Restricted Stock Award, RSU Award or Other Award, under the Plan or another equity plan of the Company, covering the same or a different number of shares of Common Stock, (B)&nbsp;cash and/or (C)&nbsp;other valuable consideration (as
determined by the Board); or (3)&nbsp;any other action that is treated as a repricing under generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c) Delegation to Committee. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> <B>General.</B> The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If
administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to
delegate to another Committee or a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject,
however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Each Committee may retain the authority to concurrently administer the Plan with Committee or subcommittee to which it
has delegated its authority hereunder and may, at any time, revest in such Committee some or all of the powers previously delegated. The Board may retain the authority to concurrently administer the Plan with any Committee and may, at any time,
revest in the Board some or all of the powers previously delegated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> <B>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT>
Compliance.</B> To the extent an Award is intended to qualify for the exemption from Section&nbsp;16(b) of the Exchange Act that is available under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> of the Exchange Act, the Award will be granted by
the Board or a Committee that consists solely of two or more Non- Employee Directors, as determined under Rule <FONT STYLE="white-space:nowrap">16b-3(b)(3)</FONT> of the Exchange Act and thereafter any action establishing or modifying the terms of
the Award will be approved by the Board or a Committee meeting such requirements to the extent necessary for such exemption to remain available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> <B>Effect of Board</B><B>&#146;</B><B>s Decision.</B> All determinations,
interpretations and constructions made by the Board or any Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> <B>Delegation to an Officer.</B> The Board or any Committee may delegate to one or more Officers the authority to do one or both of
the following (i)&nbsp;designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by Applicable Law, other types of Awards) and, to the extent permitted by Applicable Law, the terms thereof, and
(ii)&nbsp;determine the number of shares of Common Stock to be subject to such Awards granted to such Employees; provided, however, that the resolutions or charter adopted by the Board or any Committee evidencing such delegation will specify the
total number of shares of Common Stock that may be subject to the Awards granted by such Officer and that such Officer may not grant an Award to himself or herself. Any such Awards will be granted on the applicable form of Award Agreement most
recently approved for use by the Board or the Committee, unless otherwise provided in the resolutions approving the delegation authority. Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to an Officer
who is acting solely in the capacity of an Officer (and not also as a Director) the authority to determine the Fair Market Value. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>8.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>T<SMALL>AX</SMALL> W<SMALL>ITHHOLDING</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Withholding Authorization.</B> As a condition to acceptance of any Award under the Plan, a Participant authorizes withholding
from payroll and any other amounts payable to such Participant, and otherwise agrees to make adequate provision for (including), any sums required to satisfy any U.S. federal, state, local and/or foreign tax or social insurance contribution
withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise, vesting or settlement of such Award, as applicable. Accordingly, a Participant may not be able to exercise an Award even though the Award is
vested, and the Company shall have no obligation to issue shares of Common Stock subject to an Award, unless and until such obligations are satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Satisfaction of Withholding Obligation.</B> To the extent permitted by the terms of an Award Agreement, the Company may, in its
sole discretion, satisfy any U.S. federal, state, local and/or foreign tax or social insurance withholding obligation relating to an Award by any of the following means or by a combination of such means: (i)&nbsp;causing the Participant to tender a
cash payment; (ii)&nbsp;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; (iii)&nbsp;withholding cash from an Award settled in cash; (iv)&nbsp;withholding
payment from any amounts otherwise payable to the Participant; (v)&nbsp;by allowing a Participant to effectuate a &#147;cashless exercise&#148; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board, or
(vi)&nbsp;by such other method as may be set forth in the Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>No Obligation to Notify or Minimize Taxes; No
Liability to Claims. </B>Except as required by Applicable Law the Company has no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Award. Furthermore, the Company has no duty or obligation to
warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of
such Award and will not be liable to any holder of an Award for any adverse tax consequences to such holder in connection with an Award. As a condition to accepting an Award under the Plan, each Participant (i)&nbsp;agrees to not make any claim
against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or other Company compensation and (ii)&nbsp;acknowledges that such Participant was advised to consult with his or her
own personal tax, financial and other legal advisors regarding the tax consequences of the Award and has either done so or knowingly and voluntarily declined to do so. Additionally, each Participant acknowledges any Option or SAR granted under the
Plan is exempt from Section&nbsp;409A only if the exercise or strike price is at least equal to the &#147;fair market value&#148; of the Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other
impermissible deferral of compensation associated with the Award. Additionally, as a condition to accepting an Option or SAR granted under the Plan, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
each Participant agrees not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that such
exercise price or strike price is less than the &#147;fair market value&#148; of the Common Stock on the date of grant as subsequently determined by the Internal Revenue Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> <B>Withholding Indemnification. </B>As a condition to accepting an Award under the Plan, in the event that the amount of the
Company&#146;s and/or its Affiliate&#146;s withholding obligation in connection with such Award was greater than the amount actually withheld by the Company and/or its Affiliates, each Participant agrees to indemnify and hold the Company and/or its
Affiliates harmless from any failure by the Company and/or its Affiliates to withhold the proper amount. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>9.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>M<SMALL>ISCELLANEOUS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Source of Shares.</B> The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock,
including shares repurchased by the Company on the open market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>Use of Proceeds from Sales of Common Stock.
</B>Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute general funds of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B>
<B>Corporate Action Constituting Grant of Awards.</B> Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board,
regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes)
documenting the corporate action approving the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the
Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> <B>Stockholder Rights.</B> No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect
to, any shares of Common Stock subject to such Award unless and until (i)&nbsp;such Participant has satisfied all requirements for exercise of the Award pursuant to its terms, if applicable, and (ii)&nbsp;the issuance of the Common Stock subject to
such Award is reflected in the records of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> <B>No Employment or Other Service Rights.</B> Nothing in the Plan, any
Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time
the Award was granted or affect the right of the Company or an Affiliate to terminate at will and without regard to any future vesting opportunity that a Participant may have with respect to any Award (i)&nbsp;the employment of an Employee with or
without notice and with or without cause, (ii)&nbsp;the service of a Consultant pursuant to the terms of such Consultant&#146;s agreement with the Company or an Affiliate, or (iii)&nbsp;the service of a Director pursuant to the Bylaws of the Company
or an Affiliate, and any applicable provisions of the corporate law of the state or foreign jurisdiction in which the Company or the Affiliate is incorporated, as the case may be. Further, nothing in the Plan, any Award Agreement or any other
instrument executed thereunder or in connection with any Award will constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term
or condition of employment or service or confer any right or benefit under the Award or the Plan unless such right or benefit has specifically accrued under the terms of the Award Agreement and/or Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B> <B>Change in Time Commitment</B>. In the event a Participant&#146;s regular level of time commitment in the performance of his or
her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full -time Employee to a part-time Employee or takes an
extended leave of absence) after the date of grant of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Award to the Participant, the Board may determine, to the extent permitted by Applicable Law, to (i)&nbsp;make a corresponding reduction in the number of shares or cash amount subject to any
portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii)&nbsp;in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In
the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g)</B> <B>Execution of Additional Documents.</B> As a condition to accepting an Award under the Plan, the Participant agrees to execute
any additional documents or instruments necessary or desirable, as determined in the Plan Administrator&#146;s sole discretion, to carry out the purposes or intent of the Award, or facilitate compliance with securities and/or other regulatory
requirements, in each case at the Plan Administrator&#146;s request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(h)</B> <B>Electronic Delivery and Participation</B>. Any
reference herein or in an Award Agreement to a &#147;written&#148; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the
Company&#146;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). By accepting any Award the Participant consents to receive documents by electronic delivery and to participate in the Plan
through any <FONT STYLE="white-space:nowrap">on-line</FONT> electronic system established and maintained by the Plan Administrator or another third party selected by the Plan Administrator. The form of delivery of any Common Stock (e.g., a stock
certificate or electronic entry evidencing such shares) shall be determined by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> <B>Clawback/Recovery</B>. All
Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#146;s
securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law and any clawback policy that the Company otherwise adopts, to the extent applicable and permissible under
Applicable Law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of
previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a Participant&#146;s right to voluntary terminate employment
upon a &#147;resignation for good reason,&#148; or for a &#147;constructive termination&#148; or any similar term under any plan of or agreement with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(j)</B> <B>Securities Law Compliance. </B>A Participant will not be issued any shares in respect of an Award unless either (i)&nbsp;the
shares are registered under the Securities Act; or (ii)&nbsp;the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act. Each Award also must comply with other Applicable Law governing the
Award, and a Participant will not receive such shares if the Company determines that such receipt would not be in material compliance with Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(k)</B> <B>Transfer or Assignment of Awards; Issued Shares.</B> Except as expressly provided in the Plan or the form of Award Agreement,
Awards granted under the Plan may not be transferred or assigned by the Participant. After the vested shares subject to an Award have been issued, or in the case of Restricted Stock and similar awards, after the issued shares have vested, the holder
of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of the Trading Policy and Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(l)</B> <B>Effect on Other Employee Benefit Plans. </B>The value of any Award granted under the Plan, as determined upon grant, vesting or
settlement, shall not be included as compensation, earnings, salaries, or other similar terms used when calculating any Participant&#146;s benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan
otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#146;s or any Affiliate&#146;s employee benefit plans. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(m)</B> <B>Deferrals.</B> To the extent permitted by Applicable Law, the Board, in its
sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may also establish programs and procedures for deferral elections
to be made by Participants. Deferrals will be made in accordance with the requirements of Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(n)</B> <B>Section 409A.
</B>Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section&nbsp;409A, and,
to the extent not so exempt, in compliance with the requirements of Section&nbsp;409A. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section&nbsp;409A, the Award Agreement evidencing such
Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section&nbsp;409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby
incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant
holding an Award that constitutes &#147;deferred compensation&#148; under Section&nbsp;409A is a &#147;specified employee&#148; for purposes of Section&nbsp;409A, no distribution or payment of any amount that is due because of a &#147;separation
from service&#148; (as defined in Section&nbsp;409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participant&#146;s &#147;separation from
service&#148; or, if earlier, the date of the Participant&#146;s death, unless such distribution or payment can be made in a manner that complies with Section&nbsp;409A, and any amounts so deferred will be paid in a lump sum on the day after such
six month period elapses, with the balance paid thereafter on the original schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(o)</B> <B>Choice of Law.</B> This Plan and any
controversy arising out of or relating to this Plan shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to conflict of law principles that would result in any application of any law
other than the law of the State of Delaware. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>10.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Compliance with Law.</B> The Company will seek to obtain from each regulatory commission or agency, as
may be deemed to be necessary, having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise or vesting of the Awards; provided, however, that this undertaking will not
require the Company to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such
regulatory commission or agency the authority that counsel for the Company deems necessary or advisable for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell
Common Stock upon exercise or vesting of such Awards unless and until such authority is obtained. A Participant is not eligible for the grant of an Award or the subsequent issuance of Common Stock pursuant to the Award if such grant or issuance
would be in violation of any Applicable Law. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>11.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>A<SMALL>DDITIONAL</SMALL> R<SMALL>ULES</SMALL> <SMALL>FOR</SMALL> A<SMALL>WARDS</SMALL>
S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> S<SMALL>ECTION</SMALL>&nbsp;409A. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> <B>Application. </B>Unless the
provisions of this Section of the Plan are expressly superseded by the provisions in the form of Award Agreement, the provisions of this Section shall apply and shall supersede anything to the contrary set forth in the Award Agreement for a <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Subject to <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangements.</B> To the extent a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award is subject to Section&nbsp;409A due to application of a
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, the following provisions of this subsection (b)&nbsp;apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> If the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award vests in the ordinary course during the Participant&#146;s
Continuous Service in accordance with the vesting schedule set forth in the Award Agreement, and does not accelerate vesting under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the terms of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, in no event will the shares be issued in respect of such
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award any later than the later of: (i)&nbsp;December 31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of the calendar year that includes the applicable vesting date, or (ii)&nbsp;the 60<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day that follows the applicable vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> If vesting of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award accelerates under the terms of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement in connection with the Participant&#146;s Separation from Service, and such vesting
acceleration provisions were in effect as of the date of grant of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award and, therefore, are part of the terms of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award as of the date of
grant, then the shares will be earlier issued in settlement of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award upon the Participant&#146;s Separation from Service in accordance with the terms of the
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, but in no event later than the 60<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day that follows the date of the Participant&#146;s Separation from Service. However,
if at the time the shares would otherwise be issued the Participant is subject to the distribution limitations contained in Section&nbsp;409A applicable to &#147;specified employees,&#148; as defined in Section&nbsp;409A(a)(2)(B)(i) of the Code,
such shares shall not be issued before the date that is six months following the date of such Participant&#146;s Separation from Service, or, if earlier, the date of the Participant&#146;s death that occurs within such six month period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> If vesting of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award accelerates under the terms of a <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement in connection with a Participant&#146;s Separation from Service, and such vesting acceleration provisions were not in effect as of the date of grant of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award and, therefore, are not a part of the terms of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award on the date of grant, then such acceleration of vesting of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall not accelerate the issuance date of the shares, but the shares shall instead be issued on the same schedule as set forth in the Grant Notice as if they had vested in the ordinary course during
the Participant&#146;s Continuous Service, notwithstanding the vesting acceleration of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Such issuance schedule is intended to satisfy the requirements of payment on a specified date or
pursuant to a fixed schedule, as provided under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(a)(4).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> <B>Treatment of <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Upon a Corporate Transaction for Employees and
Consultants.</B> The provisions of this subsection (c)&nbsp;shall apply and shall supersede anything to the contrary set forth in the Plan with respect to the permitted treatment of any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award in
connection with a Corporate Transaction if the Participant was either an Employee or Consultant upon the applicable date of grant of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> <B>Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards.</B> The following provisions shall apply to any Vested <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award in connection with a Corporate Transaction: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(1)</B> If the Corporate Transaction is
also a Section&nbsp;409A Change in Control then the Acquiring Entity may not assume, continue or substitute the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Upon the Section&nbsp;409A Change in Control the settlement of the
Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will automatically be accelerated and the shares will be immediately issued in respect of the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Alternatively, the Company
may instead provide that the Participant will receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section&nbsp;409A Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(2)</B> If the Corporate Transaction is not also a Section&nbsp;409A Change in Control, then the Acquiring Entity must either assume,
continue or substitute each Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. The shares to be issued in respect of the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be issued to the Participant by the
Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#146;s discretion, in lieu of an issuance of shares, the Acquiring Entity may
instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of the Fair Market Value of the shares
made on the date of the Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> <B>Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards.</B> The
following provisions shall apply to any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award unless otherwise determined by the Board pursuant to subsection (e)&nbsp;of this Section. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(1)</B> In the event of a Corporate Transaction, the Acquiring Entity shall assume,
continue or substitute any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Unless otherwise determined by the Board, any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will remain subject to the same vesting and
forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be issued to the Participant by the
Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#146;s discretion, in lieu of an issuance of shares, the Acquiring Entity may
instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value of the shares made
on the date of the Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(2)</B> If the Acquiring Entity will not assume, substitute or continue any Unvested <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award in connection with a Corporate Transaction, then such Award shall automatically terminate and be forfeited upon the Corporate Transaction with no consideration payable to any Participant in respect
of such forfeited Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Notwithstanding the foregoing, to the extent permitted and in compliance with the requirements of Section&nbsp;409A, the Board may in its discretion determine to
elect to accelerate the vesting and settlement of the Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award upon the Corporate Transaction, or instead substitute a cash payment equal to the Fair Market Value of such shares that would
otherwise be issued to the Participant, as further provided in subsection (e)(ii) below. In the absence of such discretionary election by the Board, any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be forfeited without
payment of any consideration to the affected Participants if the Acquiring Entity will not assume, substitute or continue the Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards in connection with the Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(3)</B> The foregoing treatment shall apply with respect to all Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards upon any
Corporate Transaction, and regardless of whether or not such Corporate Transaction is also a Section&nbsp;409A Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> <B>Treatment of <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Upon a Corporate Transaction for <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Directors.</B> The following provisions of this subsection (d)&nbsp;shall apply and shall supersede anything to the contrary that may be set forth in the Plan with respect to the permitted treatment of
a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award in connection with a Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> If the
Corporate Transaction is also a Section&nbsp;409A Change in Control then the Acquiring Entity may not assume, continue or substitute the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Upon the Section&nbsp;409A Change in Control
the vesting and settlement of any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award will automatically be accelerated and the shares will be immediately issued to the Participant in respect of the
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Alternatively, the Company may provide that the Participant will instead receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the
Participant upon the Section&nbsp;409A Change in Control pursuant to the preceding provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> If the Corporate Transaction is
not also a Section&nbsp;409A Change in Control, then the Acquiring Entity must either assume, continue or substitute the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Unless otherwise determined by the Board, the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In
the Acquiring Entity&#146;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the
Participant on such issuance dates, with the determination of Fair Market Value made on the date of the Corporate Transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> If the RSU Award is a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award,
then the provisions in this Section&nbsp;11(e) shall apply and supersede anything to the contrary that may be set forth in the Plan or the Award Agreement with respect to the permitted treatment of such
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> Any exercise by the Board of discretion to accelerate the vesting of
a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall not result in any acceleration of the scheduled issuance dates for the shares in respect of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award unless earlier issuance of the
shares upon the applicable vesting dates would be in compliance with the requirements of Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> The Company
explicitly reserves the right to earlier settle any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award to the extent permitted and in compliance with the requirements of Section&nbsp;409A, including pursuant to any of the exemptions available
in Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(j)(4)(ix).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> To the extent the terms of
any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award provide that it will be settled upon a Change in Control or Corporate Transaction, to the extent it is required for compliance with the requirements of Section&nbsp;409A, the Change in
Control or Corporate Transaction event triggering settlement must also constitute a Section&nbsp;409A Change in Control. To the extent the terms of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award provides that it will be settled upon a
termination of employment or termination of Continuous Service, to the extent it is required for compliance with the requirements of Section&nbsp;409A, the termination event triggering settlement must also constitute a Separation From Service.
However, if at the time the shares would otherwise be issued to a Participant in connection with a &#147;separation from service&#148; such Participant is subject to the distribution limitations contained in Section&nbsp;409A applicable to
&#147;specified employees,&#148; as defined in Section&nbsp;409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of the Participant&#146;s Separation From Service, or, if earlier, the
date of the Participant&#146;s death that occurs within such six month period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B> The provisions in this subsection (e)&nbsp;for
delivery of the shares in respect of the settlement of an RSU Award that is a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award are intended to comply with the requirements of Section&nbsp;409A so that the delivery of the shares to the
Participant in respect of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will not trigger the additional tax imposed under Section&nbsp;409A, and any ambiguities herein will be so interpreted. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>12.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>S<SMALL>EVERABILITY</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If all or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such
unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award Agreement not declared to be unlawful or invalid. Any Section of the Plan or any Award Agreement (or part of such a Section) so declared to be unlawful or invalid
shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>13.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>T<SMALL>ERMINATION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Board may suspend or terminate the Plan at any time. No Incentive Stock Options may be granted after the tenth
anniversary of the earlier of: (i)&nbsp;the Adoption Date, or (ii)&nbsp;the date the Plan is approved by the Company&#146;s stockholders. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>14. D<SMALL>EFINITIONS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As used in the Plan, the following definitions apply to the capitalized terms indicated below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> &#147;<B><I>Acquiring Entity</I></B>&#148; means the surviving or acquiring corporation (or its parent company) in connection with a
Corporate Transaction. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> &#147;<B><I>Adoption Date</I></B>&#148; means the date the Plan is first approved
by the Board or Compensation Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> &#147;<B><I>Affiliate</I></B>&#148; means, at the time of determination, any
&#147;parent&#148; or &#147;subsidiary&#148; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board may determine the time or times at which &#147;parent&#148; or &#147;subsidiary&#148; status is
determined within the foregoing definition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> &#147;<B><I>Applicable Law</I></B>&#148; means any applicable securities, federal,
state, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted,
promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of any applicable self-regulating organization such as the Nasdaq Stock Market, New York Stock Exchange, or the
Financial Industry Regulatory Authority). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> &#147;<B><I>Award</I></B>&#148; means any right to receive Common Stock, cash or
other property granted under the Plan (including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, an RSU Award, a SAR, a Performance Award or any Other Award). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B> &#147;<B><I>Award Agreement</I></B>&#148; means a written or electronic agreement between the Company and a Participant evidencing
the terms and conditions of an Award. The Award Agreement generally consists of the Grant Notice and the agreement containing the written summary of the general terms and conditions applicable to the Award and which is provided, including through
electronic means, to a Participant along with the Grant Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g)</B> &#147;<B><I>Board</I></B>&#148; means the Board of Directors
of the Company (or its designee). Any decision or determination made by the Board shall be a decision or determination that is made in the sole discretion of the Board (or its designee), and such decision or determination shall be final and binding
on all Participants </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(h)</B> &#147;<B><I>Business Combination Agreement</I></B>&#148; means that certain Business Combination Agreement
by and among <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., Perseverance Merger Sub Inc., and Surrozen, Inc., dated as of [&#9679;], 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> <I>&#147;</I><B><I>Capitalization Adjustment</I></B>&#148; means any change that is made in, or other events that occur with
respect to, the Common Stock subject to the Plan or subject to any Award after the date the Plan is adopted by the Board without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization,
reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar
equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible
securities of the Company will not be treated as a Capitalization Adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(j)</B> &#147;<B><I>Cause</I></B>&#148; has the meaning
ascribed to such term in any written agreement between a Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events:&nbsp;(i)
the Participant&#146;s dishonest statements or acts with respect to the Company or any Affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business; (ii)&nbsp;the
Participant&#146;s commission of (A)&nbsp;a felony or (B)&nbsp;any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&nbsp;the Participant&#146;s failure to perform the Participant&#146;s assigned duties and responsibilities
to the reasonable satisfaction of the Company which failure continues, in the reasonable judgment of the Company, after written notice given to the Participant by the Company; (iv)&nbsp;the Participant&#146;s gross negligence, willful misconduct or
insubordination with respect to the Company or any Affiliate of the Company; or (v)&nbsp;the Participant&#146;s material violation of any provision of any agreement(s) between the Participant and the Company relating to noncompetition,
nonsolicitation, nondisclosure and/or assignment of inventions. The determination that a termination of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Participant&#146;s Continuous Service is either for Cause or without Cause will be made by the Board with respect to Participants who are executive officers of the Company and by the
Company&#146;s Chief Executive Officer with respect to Participants who are not executive officers of the Company. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of
outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(k)</B> &#147;<B><I>Change in Control</I></B>&#148; or &#147;<B><I>Change of</I></B> <B><I>Control</I></B>&#148; means the occurrence, in a
single transaction or in a series of related transactions, of any one or more of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> any Exchange Act Person
becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#146;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction.
Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A)&nbsp;on account of the acquisition of securities of the Company directly from the Company, (B)&nbsp;on account of the acquisition of securities of the Company by an
investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#146;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance
of equity securities, or (C)&nbsp;solely because the level of Ownership held by any Exchange Act Person (the &#147;<B><I>Subject Person</I></B>&#148;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a
repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting
securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then
outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and,
immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A)&nbsp;outstanding voting securities representing more
than 50% of the combined outstanding voting power of the Acquiring Entity in such merger, consolidation or similar transaction or (B)&nbsp;more than 50% of the combined outstanding voting power of the parent of the Acquiring Entity in such merger,
consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets
of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the
voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; or
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B> individuals who, on the date the Plan is adopted by the Board, are members of the Board (the &#147;<B><I>Incumbent
Board</I></B>&#148;) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a
majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing or any other provision of this Plan, (A)&nbsp;the term Change in Control shall not include a sale of assets,
merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B)&nbsp;the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate
and the Participant shall supersede the foregoing definition </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the
foregoing definition shall apply, and (C)&nbsp;with respect to any nonqualified deferred compensation that becomes payable on account of the Change in Control, the transaction or event described in clause (i), (ii), (iii), or (iv)&nbsp;also
constitutes a Section&nbsp;409A Change in Control if required in order for the payment not to violate Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(l)</B> &#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and
guidance thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(m)</B> &#147;<B><I>Committee</I></B>&#148; means the Compensation Committee and any other committee of one or
more Directors to whom authority has been delegated by the Board or Compensation Committee in accordance with the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(n)</B>
&#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(o)</B> &#147;<B><I>Company</I></B>&#148; means
Surrozen, Inc., a Delaware corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(p)</B> &#147;<B><I>Compensation Committee</I></B>&#148; means the Compensation Committee of
the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(q)</B> &#147;<B><I>Consultant</I></B>&#148; means any person, including an advisor, who is (i)&nbsp;engaged by the Company
or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii)&nbsp;serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director,
or payment of a fee for such service, will not cause a Director to be considered a &#147;Consultant&#148; for purposes of the Plan.<B><I> </I></B>Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form <FONT
STYLE="white-space:nowrap">S-8</FONT> Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#146;s securities to such person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(r)</B> &#147;<B><I>Continuous Service</I></B>&#148; means that the Participant&#146;s service with the Company or an Affiliate, whether as
an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the
Participant renders such service, provided that there is no interruption or termination of the Participant&#146;s service with the Company or an Affiliate, will not terminate a Participant&#146;s Continuous Service; provided, however, that if the
Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, such Participant&#146;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an
Affiliate. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive
officer of the Company, in that party&#146;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i)&nbsp;any leave of absence approved by the Board or chief executive officer, including sick
leave, military leave or any other personal leave, or (ii)&nbsp;transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an
Award only to such extent as may be provided in the Company&#146;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. In addition, to the extent
required for exemption from or compliance with Section&nbsp;409A, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of
&#147;separation from service&#148; as defined under Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)</FONT> (without regard to any alternative definition thereunder). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(s)</B> &#147;<B><I>Corporate Transaction</I></B>&#148; means the consummation, in a single transaction or in a series of related
transactions, of any one or more of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> a sale<B> </B>or other disposition of all or substantially all, as
determined by the Board, of the consolidated assets of the Company and its Subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> a sale or other disposition of at
least 50% of the outstanding securities of the Company; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> a merger, consolidation or similar transaction following which the Company is
not the surviving corporation; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B> a merger, consolidation or similar transaction following which the Company is the surviving
corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in
the form of securities, cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Notwithstanding the foregoing or any other provision of this Plan, (A)&nbsp;the term Corporate
Transaction shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B)&nbsp;the definition of Corporate Transaction (or any analogous term) in an individual
written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Corporate Transaction or any analogous
term is set forth in such an individual written agreement, the foregoing definition shall apply, and (C)&nbsp;with respect to any nonqualified deferred compensation that becomes payable on account of the Corporate Transaction, the transaction or
event described in clause (i), (ii), (iii), or (iv)&nbsp;also constitutes a Section&nbsp;409A Change in Control if required in order for the payment not to violate Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(t)</B> &#147;<B><I>Director</I></B>&#148; means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(u)</B> &#147;<B><I>determine</I></B>&#148;<B><I> or </I></B>&#147;<B><I>determined</I></B>&#148;<B><I> </I></B>means as determined by the
Board or the Committee (or its designee) in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v)</B> &#147;<B><I>Disability</I></B>&#148; means, with respect to a
Participant, such Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a
continuous period of not less than 12 months, as provided in Section&nbsp;22(e)(3) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(w)</B> &#147;<B><I>Effective Date</I></B>&#148; means the effective date of this Plan, which is the date of the closing of the
transactions contemplated by the Business Combination Agreement, provided that this Plan is approved by the Company&#146;s stockholders prior to such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(x)</B> &#147;<B><I>Employee</I></B>&#148; means any person employed by the Company or an Affiliate. However, service solely as a Director,
or payment of a fee for such services, will not cause a Director to be considered an &#147;Employee&#148; for purposes of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(y)</B> &#147;<B><I>Employer</I></B>&#148; means the Company or the Affiliate of the Company that employs the Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(z)</B> &#147;<B><I>Entity</I></B>&#148; means a corporation, partnership, limited liability company or other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(aa)</B> &#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(bb)</B> &#147;<B><I>Exchange Act Person</I></B>&#148;<B><I> </I></B>means any natural person, Entity or
&#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act), except that &#147;Exchange Act Person&#148; will not include (i)&nbsp;the Company or any Subsidiary of the Company, (ii)&nbsp;any employee benefit plan of the
Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii)&nbsp;an underwriter temporarily holding securities pursuant to a
registered public offering of such securities, (iv)&nbsp;an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company, or (v)&nbsp;any natural
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
person, Entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of
the Company representing more than 50% of the combined voting power of the Company&#146;s then outstanding securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(cc)</B>
&#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, unless otherwise determined by the Board, the value of the Common Stock (as determined on a per share or aggregate basis, as applicable) determined as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value will be
the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> If there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the
closing selling price on the last preceding date for which such quotation exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> In the absence of such markets for the
Common Stock, or if otherwise determined by the Board, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(dd)</B> &#147;<B><I>Fully-Diluted Common Stock</I></B>&#148; means, as of any date, the aggregate number of (i)&nbsp;shares of Common
Stock issued and outstanding and (ii)&nbsp;securities convertible into or exercisable for shares of Common Stock (whether vested or unvested). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ee)</B> &#147;<B><I>Governmental</I></B><B> </B><B><I>Body</I></B>&#148; means any: (a)&nbsp;nation, state, commonwealth, province,
territory, county, municipality, district or other jurisdiction of any nature; (b)&nbsp;federal, state, local, municipal, foreign or other government; (c)&nbsp;governmental or regulatory body, or quasi-governmental body of any nature (including any
governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of
doubt, any Tax authority) or other body exercising similar powers or authority; or (d)&nbsp;self-regulatory organization (including the Nasdaq Stock Market, New York Stock Exchange, and the Financial Industry Regulatory Authority). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ff)</B> &#147;<B><I>Grant Notice</I></B>&#148; means the notice provided to a Participant that he or she has been granted an Award under
the Plan and which includes the name of the Participant, the type of Award, the date of grant of the Award, number of shares of Common Stock subject to the Award or potential cash payment right, (if any), the vesting schedule for the Award (if any)
and other key terms applicable to the Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(gg)</B> &#147;<B><I>Incentive Stock Option</I></B>&#148; means an option granted
pursuant to Section&nbsp;4 of the Plan that is intended to be, and qualifies as, an &#147;incentive stock option&#148; within the meaning of Section&nbsp;422 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(hh)</B> &#147;<B><I>Materially Impair</I></B>&#148;<B><I> </I></B>means any amendment to the terms of the Award that materially adversely
affects the Participant&#146;s rights under the Award. A Participant&#146;s rights under an Award will not be deemed to have been Materially Impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as
a whole, does not materially impair the Participant&#146;s rights. For example, the following types of amendments to the terms of an Award do not Materially Impair the Participant&#146;s rights under the Award: (i)&nbsp;imposition of reasonable
restrictions on the minimum number of shares subject to an Option or SAR that may be exercised, (ii)&nbsp;to maintain the qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the Code, (iii)&nbsp;to change the terms
of an Incentive Stock Option in a manner that disqualifies, impairs or otherwise affects the qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the Code, (iv)&nbsp;to clarify the manner of exemption from, or to
bring the Award into compliance with or qualify it for an exemption from, Section&nbsp;409A, or (v)&nbsp;to comply with other Applicable Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> &#147;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director</I></B>&#148;<B> </B>means a Director who either (i)&nbsp;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services
rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated pursuant to the
Securities Act (&#147;<B><I>Regulation <FONT STYLE="white-space:nowrap">S-K</FONT></I></B>&#148;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation <FONT
STYLE="white-space:nowrap">S-K,</FONT> and is not engaged in a business relationship for which disclosure would be required pursuant to Item&nbsp;404(b) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> or (ii)&nbsp;is otherwise considered
a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; for purposes of Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(jj)</B> &#147;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#148;<B><I> </I></B>means any Award that is subject
to, and not exempt from, Section&nbsp;409A, including as the result of (i)&nbsp;a deferral of the issuance of the shares subject to the Award which is elected by the Participant or imposed by the Company, or (ii)&nbsp;the terms of any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(kk)</B>
&#147;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award</I></B>&#148; means a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award granted to a Participant who was a Director but not an Employee on the applicable grant
date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ll)</B> &#147;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement</I></B>&#148; means a severance
arrangement or other agreement between the Participant and the Company that provides for acceleration of vesting of an Award and issuance of the shares in respect of such Award upon the Participant&#146;s termination of employment or separation from
service (as such term is defined in Section&nbsp;409A(a)(2)(A)(i) of the Code (and without regard to any alternative definition thereunder) (&#147;<B><I>Separation from Service</I></B>&#148;) and such severance benefit does not satisfy the
requirements for an exemption from application of Section&nbsp;409A provided under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4),</FONT> <FONT STYLE="white-space:nowrap">1.409A-1(b)(9)</FONT> or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(mm)</B> &#147;<B><I>Nonstatutory Stock Option</I></B>&#148; means any option granted pursuant to Section&nbsp;4 of the Plan that does not
qualify as an Incentive Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(nn)</B> &#147;<B><I>Officer</I></B>&#148; means a person who is an officer of the Company
within the meaning of Section&nbsp;16 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(oo)</B> &#147;<B><I>Option</I></B>&#148; means an Incentive Stock Option
or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(pp)</B> &#147;<B><I>Option
Agreement</I></B>&#148; means a written or electronic agreement between the Company and the Optionholder evidencing the terms and conditions of the Option grant. The Option Agreement includes the Grant Notice for the Option and the agreement
containing the written summary of the general terms and conditions applicable to the Option and which is provided, including through electronic means, to a Participant along with the Grant Notice. Each Option Agreement will be subject to the terms
and conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(qq)</B> &#147;<B><I>Optionholder</I></B>&#148; means a person to whom an Option is granted pursuant to
the Plan or, if applicable, such other person who holds an outstanding Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(rr)</B> &#147;<B><I>Other Award</I></B>&#148; means an
award valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value at the
time of grant) that is not an Incentive Stock Option, Nonstatutory Stock Option, SAR, Restricted Stock Award, RSU Award or Performance Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ss)</B> &#147;<B><I>Other Award Agreement</I></B>&#148;<B><I> </I></B>means a written or electronic agreement between the Company and a
holder of an Other Award evidencing the terms and conditions of an Other Award grant. Each Other Award Agreement will be subject to the terms and conditions of the Plan. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(tt)</B> &#147;<B><I>Own,</I></B>&#148;<B><I>
</I></B>&#147;<B><I>Owned,</I></B>&#148;<B><I> </I></B>&#147;<B><I>Owner,</I></B>&#148;<B><I> </I></B>&#147;<B><I>Ownership</I></B>&#148;<B> </B>means that a person or Entity will be deemed to &#147;Own,&#148; to have &#147;Owned,&#148; to be the
&#147;Owner&#148; of, or to have acquired &#147;Ownership&#148; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes
the power to vote or to direct the voting, with respect to such securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(uu)</B> &#147;<B><I>Participant</I></B>&#148; means an
Employee, Director or Consultant to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(vv)</B> &#147;<B><I>Performance Award</I></B>&#148; means an Award that may vest or may be exercised or a cash award that may vest or
become earned and paid contingent upon the attainment during a Performance Period of certain Performance Goals and which is granted under the terms and conditions of Section&nbsp;5(b) pursuant to such terms as are approved by the Board. In addition,
to the extent permitted by Applicable Law and set forth in the applicable Award Agreement, the Board may determine that cash or other property may be used in payment of Performance Awards. Performance Awards that are settled in cash or other
property are not required to be valued in whole or in part by reference to, or otherwise based on, the Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ww)</B>
&#147;<B><I>Performance Criteria</I></B>&#148; means the one or more criteria that the Board will select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to establish such
Performance Goals may be based on any one of, or combination of, the following as determined by the Board: earnings (including earnings per share and net earnings); earnings before interest, taxes and depreciation; earnings before interest, taxes,
depreciation and amortization; total stockholder return; return on equity or average stockholder&#146;s equity; return on assets, investment, or capital employed; stock price; margin (including gross margin); income (before or after taxes);
operating income; operating income after taxes; <FONT STYLE="white-space:nowrap">pre-tax</FONT> profit; operating cash flow; sales or revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or
attainment of working capital levels; economic value added (or an equivalent metric); market share; cash flow; cash flow per share; share price performance; debt reduction; customer satisfaction; stockholders&#146; equity; capital expenditures; debt
levels; operating profit or net operating profit; workforce diversity; growth of net income or operating income; billings; financing; regulatory milestones; stockholder liquidity; corporate governance and compliance; intellectual property; personnel
matters; progress of internal research; progress of partnered programs; partner satisfaction; budget management; partner or collaborator achievements; internal controls, including those related to the Sarbanes-Oxley Act of 2002; investor relations,
analysts and communication; implementation or completion of projects or processes; employee retention; number of users, including unique users; strategic partnerships or transactions (including <FONT STYLE="white-space:nowrap">in-licensing</FONT>
and <FONT STYLE="white-space:nowrap">out-licensing</FONT> of intellectual property); establishing relationships with respect to the marketing, distribution and sale of the Company&#146;s products; supply chain achievements; <FONT
STYLE="white-space:nowrap">co-development,</FONT> <FONT STYLE="white-space:nowrap">co-marketing,</FONT> profit sharing, joint venture or other similar arrangements; individual performance goals; corporate development and planning goals; and other
measures of performance selected by the Board or Committee whether or not listed herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(xx)</B> &#147;<B><I>Performance
Goals</I></B>&#148; means, for a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more
business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Board
(i)&nbsp;in the Award Agreement at the time the Award is granted or (ii)&nbsp;in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Board will appropriately make adjustments in the method
of calculating the attainment of Performance Goals for a Performance Period as follows: (1)&nbsp;to exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects; (3)&nbsp;to exclude the effects of changes to
generally accepted accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as
determined under generally accepted accounting principles; (6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (7)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted levels
during the balance of a Performance Period following such divestiture; (8)&nbsp;to exclude the effect of any change in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <FONT
STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9)&nbsp;to exclude the effects of stock based
compensation and the award of bonuses under the Company&#146;s bonus plans; (10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting
principles; and (11)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. In addition, the Board may establish or provide for other adjustment items in
the Award Agreement at the time the Award is granted or in such other document setting forth the Performance Goals at the time the Performance Goals are established. In addition, the Board retains the discretion to reduce or eliminate the
compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for such Performance Period. Partial achievement of the specified criteria may result in the
payment or vesting corresponding to the degree of achievement as specified in the Award Agreement or the written terms of a Performance Cash Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(yy)</B> &#147;<B><I>Performance Period</I></B>&#148; means the period of time selected by the Board over which the attainment of one or
more Performance Goals will be measured for the purpose of determining a Participant&#146;s right to vesting or exercise of an Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(zz)</B> &#147;<B><I>Plan</I></B>&#148; means this Surrozen, Inc. 2021 Equity Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(aaa)</B> &#147;<B><I>Plan Administrator</I></B>&#148; means the person, persons, and/or third-party administrator designated by the
Company to administer the day to day operations of the Plan and the Company&#146;s other equity incentive programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(bbb)</B>
&#147;<B><I>Post-Termination Exercise Period</I></B>&#148; means the period following termination of a Participant&#146;s Continuous Service within which an Option or SAR is exercisable, as specified in Section&nbsp;4(h). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ccc)</B> &#147;<B><I>Restricted Stock Award</I></B>&#148; or &#147;<B><I>RSA</I></B>&#148; means an Award of shares of Common Stock which
is granted pursuant to the terms and conditions of Section&nbsp;5(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ddd)</B> &#147;<B><I>Restricted Stock Award
Agreement</I></B>&#148; means a written or electronic agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. The Restricted Stock Award Agreement includes the
Grant Notice for the Restricted Stock Award and the agreement containing the written summary of the general terms and conditions applicable to the Restricted Stock Award and which is provided, including by electronic means, to a Participant along
with the Grant Notice. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(eee)</B>
&#147;<B><I>RSU Award</I></B>&#148; or &#147;<B><I>RSU</I></B>&#148;<B><I> </I></B>means an Award of restricted stock units representing the right to receive an issuance of shares of Common Stock which is granted pursuant to the terms and conditions
of Section&nbsp;5(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(fff)</B> &#147;<B><I>RSU Award Agreement</I></B>&#148;<B><I> </I></B>means a written or electronic agreement
between the Company and a holder of an RSU Award evidencing the terms and conditions of an RSU Award. The RSU Award Agreement includes the Grant Notice for the RSU Award and the agreement containing the written summary of the general terms and
conditions applicable to the RSU Award and which is provided, including by electronic means, to a Participant along with the Grant Notice. Each RSU Award Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ggg)</B> &#147;<B><I>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></I></B>&#148; means Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act or any successor to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(hhh)</B> &#147;<B><I>Rule 405</I></B>&#148; means Rule 405 promulgated under the Securities Act. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> &#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148; means
Section&nbsp;409A of the Code and the regulations and other guidance thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(jjj)</B>
&#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A Change in Control</I></B>&#148; means a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company&#146;s assets, as provided in
Section&nbsp;409A(a)(2)(A)(v) of the Code and Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT> (without regard to any alternative definition thereunder). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(kkk)</B> &#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(lll)</B> &#147;<B><I>Share Reserve</I></B>&#148; means the number of shares available for issuance under the Plan as set forth in
Section&nbsp;2(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(mmm)</B> &#147;<B><I>Stock Appreciation Right</I></B>&#148; or &#147;<B><I>SAR</I></B>&#148;<B><I> </I></B>means a
right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section&nbsp;4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(nnn)</B>
&#147;<B><I>SAR Agreement</I></B>&#148; means a written or electronic agreement between the Company and a holder of a SAR evidencing the terms and conditions of a SAR grant. The SAR Agreement includes the Grant Notice for the SAR and the agreement
containing the written summary of the general terms and conditions applicable to the SAR and which is provided, including by electronic means, to a Participant along with the Grant Notice. Each SAR Agreement will be subject to the terms and
conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ooo)</B> &#147;<B><I>Subsidiary</I></B>&#148; means, with respect to the Company, (i)&nbsp;any corporation of
which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will
have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&nbsp;any partnership, limited liability company or other entity in which the Company has a direct
or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ppp)</B>
&#147;<B><I>Ten Percent Stockholder</I></B>&#148; means a person who Owns (or is deemed to Own pursuant to Section&nbsp;424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or
any Affiliate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(qqq)</B> &#147;<B><I>Trading Policy</I></B>&#148; means the Company&#146;s policy permitting certain individuals to
sell Company shares only during certain &#147;window&#148; periods and/or otherwise restricts the ability of certain individuals to transfer or encumber Company shares, as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(rrr)</B> &#147;<B><I>Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#148; means the portion of any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award that had not vested in accordance with its terms upon or prior to the date of any Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(sss)</B> &#147;<B><I>Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#148; means the portion of any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award that had vested in accordance with its terms upon or prior to the date of a Corporate Transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">J-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="annex_k"></A><A NAME="rom40894_260"></A>ANNEX K </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>URROZEN</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 E<SMALL>MPLOYEE</SMALL> S<SMALL>TOCK</SMALL> P<SMALL>URCHASE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>: [ _______], 2021
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: [ _______], 2021 </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>1.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>G<SMALL>ENERAL</SMALL>; P<SMALL>URPOSE</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to
purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to
Eligible Employees that do not meet the requirements of an Employee Stock Purchase Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> The Plan includes two components: a
423 Component and a <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. The Company intends (but makes no undertaking or representation to maintain) the 423 Component to qualify as an Employee Stock Purchase Plan. The provisions of the 423
Component, accordingly, will be construed in a manner that is consistent with the requirements of Section&nbsp;423 of the Code. Except as otherwise provided in the Plan or determined by the Board, the <FONT STYLE="white-space:nowrap">Non-423</FONT>
Component will operate and be administered in the same manner as the 423 Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> The Company, by means of the Plan, seeks
to retain the services of Eligible Employees, to secure and retain the services of new Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>2.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>A<SMALL>DMINISTRATION</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> The Board or the Committee will administer the Plan. References herein to the Board shall be deemed to refer to the Committee except
where context dictates otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> The Board will have the power, subject to, and within the limitations of, the express
provisions of the Plan: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> To determine how and when Purchase Rights will be granted and the provisions of each Offering (which
need not be identical). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> To designate from time to time (A)&nbsp;which Related Corporations will be eligible to participate in
the Plan as Designated 423 Corporations, (B)&nbsp;which Related Corporations or Affiliates will be eligible to participate in the Plan as Designated <FONT STYLE="white-space:nowrap">Non-423</FONT> Corporations, and (C)&nbsp;which Designated
Companies will participate in each separate Offering (to the extent that the Company makes separate Offerings). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> To construe
and interpret the Plan and Purchase Rights, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to
the extent it deems necessary or expedient to make the Plan fully effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B> To settle all controversies regarding the Plan
and Purchase Rights granted under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v)</B> To suspend or terminate the Plan at any time as provided in Section&nbsp;12. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">K-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(vi)</B> To amend the Plan at any time as provided in Section&nbsp;12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(vii)</B> Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of
the Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan with respect to the 423 Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(viii)</B> To adopt such rules, procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit
or facilitate participation in the Plan by Employees who are foreign nationals or employed or located outside the United States. Without limiting the generality of, and consistent with, the foregoing, the Board specifically is authorized to adopt
rules, procedures, and <FONT STYLE="white-space:nowrap">sub-plans</FONT> regarding, without limitation, eligibility to participate in the Plan, the definition of eligible &#147;earnings,&#148; handling and making of Contributions, establishment of
bank or trust accounts to hold Contributions, payment of interest, conversion of local currency, obligations to pay payroll tax, determination of beneficiary designation requirements, withholding procedures and handling of share issuances, any of
which may vary according to applicable requirements, and which, if applicable to a Designated <FONT STYLE="white-space:nowrap">Non-423</FONT> Corporation, do not have to comply with the requirements of Section&nbsp;423 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration is delegated
to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee any of the
administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as
may be adopted from time to time by the Board. Further, to the extent not prohibited by Applicable Law, the Board or Committee may, from time to time, delegate some or all of its authority under the Plan to one or more officers of the Company or
other persons or groups of persons as it deems necessary, appropriate or advisable under conditions or limitations that it may set at or after the time of the delegation. The Board may retain the authority to concurrently administer the Plan with
the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. Whether or not the Board has delegated administration of the Plan to a Committee, the Board will have the final power to determine all questions
of policy and expediency that may arise in the administration of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> All determinations, interpretations and
constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>3.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>S<SMALL>HARES</SMALL> <SMALL>OF</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL> S<SMALL>UBJECT</SMALL>
<SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> Subject to the provisions of Section&nbsp;11(a)
relating to Capitalization Adjustments, the maximum number of shares of Common Stock that may be issued under the Plan will not exceed [&#9679;] shares (equal to 1% of the shares of Fully-Diluted Common Stock as of immediately following completion
of the transactions contemplated by the Business Combination Agreement), plus the number of shares of Common Stock that are automatically added on January&nbsp;1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of each year for a period of ten
years commencing on January&nbsp;1, 2022 and ending on (and including) January&nbsp;1, 2031, in an amount equal to the lesser of (i)&nbsp;1% of the Fully-Diluted Common Stock on December 31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of
the preceding calendar year, and (ii)&nbsp;[&#9679;] shares of Common Stock. Notwithstanding the foregoing, the Board may act prior to the first day of any calendar year to provide that there will be no January 1<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP> increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year will be a lesser number of shares of Common Stock than would otherwise occur
pursuant to the preceding sentence. For the avoidance of doubt, up to the maximum number of shares of Common Stock reserved under this Section 3(a) may be used to satisfy purchases of Common Stock under the 423 Component and any remaining portion of
such maximum number of shares may be used to satisfy purchases of Common Stock under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> If any Purchase Right granted under the Plan terminates without having been exercised in full, the shares of Common Stock not
purchased under such Purchase Right will again become available for issuance under the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">K-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> The stock purchasable under the Plan will be shares of authorized but unissued or
reacquired Common Stock, including shares repurchased by the Company on the open market. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>4.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>G<SMALL>RANT</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>;
O<SMALL>FFERING</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> The Board may from time to time grant or provide for the grant of Purchase
Rights to Eligible Employees under an Offering (consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such form and will contain such terms and conditions as the Board will
deem appropriate, and, with respect to the 423 Component, will comply with the requirement of Section&nbsp;423(b)(5) of the Code that all Employees granted Purchase Rights will have the same rights and privileges. The terms and conditions of an
Offering shall be incorporated by reference into the Plan and treated as part of the Plan. The provisions of separate Offerings need not be identical, but each Offering will include (through incorporation of the provisions of this Plan by reference
in the document comprising the Offering or otherwise) the period during which the Offering will be effective, which period will not exceed 27 months beginning with the Offering Date, and the substance of the provisions contained in Sections 5
through 8, inclusive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> If a Participant has more than one Purchase Right outstanding under the Plan, unless he or she otherwise
indicates in forms delivered to the Company or a third party designated by the Company (each, a &#147;<B><I>Company Designee</I></B>&#148;): (i) each form will apply to all of his or her Purchase Rights under the Plan, and (ii)&nbsp;a Purchase Right
with a lower exercise price (or an earlier-granted Purchase Right, if different Purchase Rights have identical exercise prices) will be exercised to the fullest possible extent before a Purchase Right with a higher exercise price (or a later-granted
Purchase Right if different Purchase Rights have identical exercise prices) will be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> The Board will have the
discretion to structure an Offering so that if the Fair Market Value of a share of Common Stock on the first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a share of Common Stock on the
Offering Date for that Offering, then (i)&nbsp;that Offering will terminate immediately as of that first Trading Day, and (ii)&nbsp;the Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first
Trading Day of such new Purchase Period. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>5.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>E<SMALL>LIGIBILITY</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> Purchase Rights may be granted only to Employees of the Company or, as the Board may designate in accordance with Section&nbsp;2(b),
to Employees of a Related Corporation or an Affiliate. Except as provided in Section&nbsp;5(b) or as required by Applicable Law, an Employee will not be eligible to be granted Purchase Rights unless, on the Offering Date, the Employee has been in
the employ of the Company, a Related Corporation or an Affiliate, as the case may be, for such continuous period preceding such Offering Date as the Board may require, but in no event will the required period of continuous employment be equal to or
greater than two years. In addition, the Board may (unless prohibited by Applicable Law) provide that no Employee will be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date, such Employee&#146;s customary employment
with the Company, the Related Corporation, or the Affiliate is more than 20 hours per week and more than five months per calendar year or such other criteria as the Board may determine consistent with Section&nbsp;423 of the Code with respect to the
423 Component. The Board may also exclude from participation in the Plan or any Offering Employees who are &#147;highly compensated employees&#148; (within the meaning of Section&nbsp;423(b)(4)(D) of the Code) of the Company or a Related Corporation
or a subset of such highly compensated employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> The Board may provide that each person who, during the course of an
Offering, first becomes an Eligible Employee will, on a date or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs thereafter, receive a Purchase Right under that Offering,
which Purchase Right will thereafter be deemed to be a part of that Offering. Such Purchase Right will have the same characteristics as any Purchase Rights originally granted under that Offering, as described herein, except that: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">K-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> the date on which such Purchase Right is granted will be the &#147;Offering
Date&#148; of such Purchase Right for all purposes, including determination of the exercise price of such Purchase Right; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> the
period of the Offering with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of such Offering; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> the Board may provide that if such person first becomes an Eligible Employee within a specified period of time before the end of
the Offering, he or she will not receive any Purchase Right under that Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> No Employee will be eligible for the grant of
any Purchase Rights under the 423 Component if, immediately after any such Purchase Rights are granted, such Employee owns stock possessing five percent or more of the total combined voting power or value of all classes of stock of the Company or of
any Related Corporation. For purposes of this Section&nbsp;5(c), the rules of Section&nbsp;424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase
Rights and options will be treated as stock owned by such Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> As specified by Section&nbsp;423(b)(8) of the Code, an
Eligible Employee may be granted Purchase Rights under the 423 Component only if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such
Eligible Employee&#146;s rights to purchase stock of the Company or any Related Corporation to accrue at a rate which, when aggregated, exceeds US $25,000 of Fair Market Value of such stock (determined at the time such rights are granted, and which,
with respect to the Plan, will be determined as of their respective Offering Dates) for each calendar year in which such rights are outstanding at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> Officers of the Company and any Designated Company, if they are otherwise Eligible Employees, will be eligible to participate in
Offerings under the Plan. Notwithstanding the foregoing, the Board may (unless prohibited by Applicable Law) provide in an Offering that Employees who are highly compensated Employees within the meaning of Section&nbsp;423(b)(4)(D) of the Code will
not be eligible to participate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B> Notwithstanding anything in this Section&nbsp;5 to the contrary, in the case of an Offering
under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, an Eligible Employee (or group of Eligible Employees) may be excluded from participation in the Plan or an Offering if the Board has determined, in its sole discretion, that
participation of such Eligible Employee(s) is not advisable or practical for any reason. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>6.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>; P<SMALL>URCHASE</SMALL> P<SMALL>RICE</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> On each Offering Date, each Eligible Employee, pursuant to an Offering made under the Plan, will be
granted a Purchase Right to purchase up to that number of shares of Common Stock purchasable either with a percentage of earnings or with a maximum dollar amount, as designated by the Board, during the period that begins on the Offering Date (or
such later date as the Board determines for a particular Offering) and ends on the date stated in the Offering, which date will be no later than the end of the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> The Board will establish one or more Purchase Dates during an Offering on which Purchase Rights granted for that Offering will be
exercised and shares of Common Stock will be purchased in accordance with such Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> In connection with each Offering made
under the Plan, the Board may specify (i)&nbsp;a maximum number of shares of Common Stock that may be purchased by any Participant on any Purchase Date during such Offering,<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>(ii)&nbsp;a maximum
aggregate number of shares of Common Stock that may be purchased by all Participants pursuant to such Offering and/or (iii)&nbsp;a maximum aggregate number of shares of Common Stock that may be purchased by all Participants on any Purchase Date
under the Offering. If the aggregate purchase of shares of Common Stock issuable upon exercise of Purchase Rights granted under the Offering would exceed any such maximum </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">K-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
aggregate number, then, in the absence of any Board action otherwise, a pro rata (based on each Participant&#146;s accumulated Contributions) allocation of the shares of Common Stock (rounded
down to the nearest whole share) available will be made in as nearly a uniform manner as will be practicable and equitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B>
The purchase price of shares of Common Stock acquired pursuant to Purchase Rights will be specified by Board prior to the commencement of an Offering and will not be less than the lesser of: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the Offering Date; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the applicable Purchase Date. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>7.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>P<SMALL>ARTICIPATION</SMALL>; W<SMALL>ITHDRAWAL</SMALL>; T<SMALL>ERMINATION</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> An Eligible Employee may elect to participate in an Offering and authorize payroll deductions as the
means of making Contributions by completing and delivering to the Company or a Company Designee, within the time specified for the Offering, an enrollment form provided by the Company or Company Designee. The enrollment form will specify the amount
of Contributions not to exceed the maximum amount specified by the Board. Each Participant&#146;s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general funds of the Company
except where Applicable Law requires that Contributions be deposited with a third party. If permitted in the Offering, a Participant may begin such Contributions with the first payroll occurring on or after the Offering Date (or, in the case of a
payroll date that occurs after the end of the prior Offering but before the Offering Date of the next new Offering, Contributions from such payroll will be included in the new Offering). If permitted in the Offering, a Participant may thereafter
reduce (including to zero) or increase his or her Contributions. If required under Applicable Law or if specifically provided in the Offering and to extent permitted by Section&nbsp;423 of the Code with respect to the 423 Component, in addition to
or instead of making Contributions by payroll deductions, a Participant may make Contributions through payment by cash, check or wire transfer prior to a Purchase Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> During an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to the Company or a
Company Designee a withdrawal form provided by the Company. The Company may impose a deadline before a Purchase Date for withdrawing. Upon such withdrawal, such Participant&#146;s Purchase Right in that Offering will immediately terminate and the
Company will distribute as soon as practicable to such Participant all of his or her accumulated but unused Contributions and such Participant&#146;s Purchase Right in that Offering shall thereupon terminate. A Participant&#146;s withdrawal from
that Offering will have no effect upon his or her eligibility to participate in any other Offerings under the Plan, but such Participant will be required to deliver a new enrollment form to participate in subsequent Offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> Unless otherwise required by Applicable Law, Purchase Rights granted pursuant to any Offering under the Plan will terminate
immediately if the Participant either (i)&nbsp;is no longer an Employee for any reason or for no reason (subject to any post-employment participation period required by Applicable Law) or (ii)&nbsp;is otherwise no longer eligible to participate. The
Company will distribute as soon as practicable to such individual all of his or her accumulated but unused Contributions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B>
Unless otherwise determined by the Board, a Participant whose employment transfers or whose employment terminates with an immediate rehire (with no break in service) by or between the Company and a Designated Company or between Designated Companies
will not be treated as having terminated employment for purposes of participating in the Plan or an Offering; however, if a Participant transfers from an Offering under the 423 Component to an Offering under the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component, the exercise of the Participant&#146;s Purchase Right will be qualified under the 423 Component only to the extent such exercise complies with Section&nbsp;423 of the Code. If a Participant
transfers from an Offering under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component to an Offering under the 423 Component, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">K-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the exercise of the Purchase Right will remain <FONT STYLE="white-space:nowrap">non-qualified</FONT> under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. The Board may establish
different and additional rules governing transfers between separate Offerings within the 423 Component and between Offerings under the 423 Component and Offerings under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> During a Participant&#146;s lifetime, Purchase Rights will be exercisable only by such Participant. Purchase Rights are not
transferable by a Participant, except by will, by the laws of descent and distribution, or, if permitted by the Company, by a beneficiary designation as described in Section&nbsp;10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B> Unless otherwise specified in the Offering or as required by Applicable Law, the Company will have no obligation to pay interest on
Contributions. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>8.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>E<SMALL>XERCISE</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> On each Purchase Date, each Participant&#146;s accumulated Contributions will be applied to the purchase
of shares of Common Stock, up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional shares will be issued unless specifically provided for in
the Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> Unless otherwise provided in the Offering, if any amount of accumulated Contributions remains in a
Participant&#146;s account after the purchase of shares of Common Stock on the final Purchase Date of an Offering, then such remaining amount will not roll over to the next Offering and will instead be distributed in full to such Participant after
the final Purchase Date of such Offering without interest (unless otherwise required by Applicable Law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> No Purchase Rights
may be exercised to any extent unless the shares of Common Stock to be issued upon such exercise under the Plan are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all
applicable U.S. federal and state, foreign and other securities, exchange control and other laws applicable to the Plan. If on a Purchase Date the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights
will be exercised on such Purchase Date, and, subject to Section&nbsp;423 of the Code with respect to the 423 Component, the Purchase Date will be delayed until the shares of Common Stock are subject to such an effective registration statement and
the Plan is in material compliance, except that the Purchase Date will in no event be more than 27 months from the Offering Date. If, on the Purchase Date, as delayed to the maximum extent permissible, the shares of Common Stock are not registered
and the Plan is not in material compliance with all Applicable Laws, as determined by the Company in its sole discretion, no Purchase Rights will be exercised and all accumulated but unused Contributions will be distributed to the Participants
without interest (unless the payment of interest is otherwise required by Applicable Law). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>9.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company will seek to obtain from each U.S. federal or state, foreign or other regulatory commission, agency or
other Governmental Body having jurisdiction over the Plan such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder unless the Company determines, in its sole discretion, that doing so is not
practical or would cause the Company to incur costs that are unreasonable. If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company deems necessary for the grant of Purchase Rights or the
lawful issuance and sale of Common Stock under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and/or to issue and sell Common Stock upon exercise of such Purchase
Rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">K-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>10.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>D<SMALL>ESIGNATION</SMALL> <SMALL>OF</SMALL> B<SMALL>ENEFICIARY</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> The Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who will receive any
shares of Common Stock and/or Contributions from the Participant&#146;s account under the Plan if the Participant dies before such shares and/or Contributions are delivered to the Participant. The Company may, but is not obligated to, permit the
Participant to change such designation of beneficiary. Any such designation and/or change must be on a form approved by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> If a Participant dies, and in the absence of a valid beneficiary designation, the Company will deliver any shares of Common Stock
and/or Contributions to the executor or administrator of the estate of the Participant. If no executor or administrator has been appointed (to the knowledge of the Company), the Company, in its sole discretion, may deliver such shares of Common
Stock and/or Contributions, without interest (unless the payment of interest is otherwise required by Applicable Law), to the Participant&#146;s spouse, dependents or relatives, or if no spouse, dependent or relative is known to the Company, then to
such other person as the Company may designate. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>11.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL>
C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; C<SMALL>ORPORATE</SMALL> T<SMALL>RANSACTIONS</SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> In the
event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the Plan pursuant to Section&nbsp;3(a), (ii) the class(es) and maximum number of
securities by which the share reserve is to increase automatically each year pursuant to Section&nbsp;3(a), (iii) the class(es) and number of securities subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights, and
(iv)&nbsp;the class(es) and number of securities that are the subject of the purchase limits under each ongoing Offering. The Board will make these adjustments, and its determination will be final, binding and conclusive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> In the event of a Corporate Transaction, then: (i)&nbsp;any surviving corporation or acquiring corporation (or the surviving or
acquiring corporation&#146;s parent company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including a right to acquire the same consideration paid to the stockholders in the Corporate Transaction) for
outstanding Purchase Rights, or (ii)&nbsp;if any surviving or acquiring corporation (or its parent company)<B> </B>does not assume or continue such Purchase Rights or does not substitute similar rights for such Purchase Rights, then the
Participants&#146; accumulated Contributions will be used to purchase shares of Common Stock (rounded down to the nearest whole share) within ten business days (or such other period specified by the Board) prior to the Corporate Transaction under
the outstanding Purchase Rights, and the Purchase Rights will terminate immediately after such purchase. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>12. A<SMALL>MENDMENT</SMALL>,
T<SMALL>ERMINATION</SMALL> <SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> The Board may amend the Plan at any time in any respect the Board deems necessary or advisable. However, except as provided in
Section&nbsp;11(a) relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is required by Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> The Board may suspend or terminate the Plan at any time. No Purchase Rights may be granted under the Plan while the Plan is
suspended or after it is terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any benefits, privileges, entitlements and obligations under any outstanding Purchase Rights granted
before an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i)&nbsp;with the consent of the person to whom such Purchase Rights were granted, (ii)&nbsp;as
necessary to facilitate compliance with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section&nbsp;423 of the Code and the regulations and other interpretive guidance issued thereunder
relating to Employee Stock Purchase Plans) including without limitation any such regulations or other guidance that may be issued or amended after the date the Plan is adopted by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">K-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Board, or (iii)&nbsp;as necessary to obtain or maintain favorable tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant&#146;s
consent if such amendment is necessary to ensure that the Purchase Right and/or the Plan complies with the requirements of Section&nbsp;423 of the Code with respect to the 423 Component or with respect to other Applicable Laws. Notwithstanding
anything in the Plan or any Offering Document to the contrary, the Board will be entitled to: (i)&nbsp;establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars; (ii)&nbsp;permit Contributions in excess of the
amount designated by a Participant in order to adjust for mistakes in the Company&#146;s processing of properly completed Contribution elections; (iii)&nbsp;establish reasonable waiting and adjustment periods and/or accounting and crediting
procedures to ensure that amounts applied toward the purchase of Common Stock for each Participant properly correspond with amounts withheld from the Participant&#146;s Contributions; (iv)&nbsp;amend any outstanding Purchase Rights or clarify any
ambiguities regarding the terms of any Offering to enable the Purchase Rights to qualify under and/or comply with Section&nbsp;423 of the Code with respect to the 423 Component; and (v)&nbsp;establish other limitations or procedures as the Board
determines in its sole discretion advisable that are consistent with the Plan. The actions of the Board pursuant to this paragraph will not be considered to alter or impair any Purchase Rights granted under an Offering as they are part of the
initial terms of each Offering and the Purchase Rights granted under each Offering. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>13.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>T<SMALL>AX</SMALL> Q<SMALL>UALIFICATION</SMALL>; T<SMALL>AX</SMALL> W<SMALL>ITHHOLDING</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> Although the Company may endeavor to (i)&nbsp;qualify a Purchase Right for special tax treatment under
the laws of the United States or jurisdictions outside of the United States or (ii)&nbsp;avoid adverse tax treatment, the Company makes no representation to that effect and expressly disavows any covenant to maintain special or to avoid unfavorable
tax treatment, notwithstanding anything to the contrary in this Plan.&nbsp;The Company will be unconstrained in its corporate activities without regard to the potential negative tax impact on Participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> Each Participant will make arrangements, satisfactory to the Company and any applicable Related Corporation, to enable the Company
or the Related Corporation to fulfill any withholding obligation for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items. Without limitation to the foregoing, in the Company&#146;s sole discretion and subject to Applicable Law, such
withholding obligation may be satisfied in whole or in part by (i)&nbsp;withholding from the Participant&#146;s salary or any other cash payment due to the Participant from the Company or a Related Corporation; (ii)&nbsp;withholding from the
proceeds of the sale of shares of Common Stock acquired under the Plan, either through a voluntary sale or a mandatory sale arranged by the Company; or (iii)&nbsp;any other method deemed acceptable by the Board. The Company shall not be required to
issue any shares of Common Stock under the Plan until such obligations are satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> The 423 Component is exempt from the
application of Section&nbsp;409A of the Code, and any ambiguities herein shall be interpreted to so be exempt from Section&nbsp;409A of the Code. The <FONT STYLE="white-space:nowrap">Non-423</FONT> Component is intended to be exempt from the
application of Section&nbsp;409A of the Code under the short-term deferral exception and any ambiguities shall be construed and interpreted in accordance with such intent. In furtherance of the foregoing and notwithstanding any provision in the Plan
to the contrary, if the Committee determines that an option granted under the Plan may be subject to Section&nbsp;409A of the Code or that any provision in the Plan would cause an option under the Plan to be subject to Section&nbsp;409A, the
Committee may amend the terms of the Plan and/or of an outstanding option granted under the Plan, or take such other action the Committee determines is necessary or appropriate, in each case, without the participant&#146;s consent, to exempt any
outstanding option or future option that may be granted under the Plan from or to allow any such options to comply with Section&nbsp;409A of the Code, but only to the extent any such amendments or action by the Committee would not violate
Section&nbsp;409A of the Code. Notwithstanding the foregoing, the Company shall have no liability to a participant or any other party if the option under the Plan that is intended to be exempt from or compliant with Section&nbsp;409A of the Code is
not so exempt or compliant or for any action taken by the Committee with respect thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">K-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>14.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Plan will become effective immediately prior to and contingent upon the Effective Date. No Purchase Rights will
be exercised unless and until the Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date the Plan is adopted (or if required under Section&nbsp;12(a) above, materially amended) by
the Board. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>15.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>M<SMALL>ISCELLANEOUS</SMALL> P<SMALL>ROVISIONS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> A Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of Common
Stock subject to Purchase Rights unless and until the Participant&#146;s shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> The Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering will in any way alter the at
will nature of a Participant&#146;s employment or amend a Participant&#146;s employment contract, if applicable, or be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a
Related Corporation or an Affiliate, or on the part of the Company, a Related Corporation or an Affiliate to continue the employment of a Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> The provisions of the Plan will be governed by the laws of the State of Delaware without resort to that state&#146;s conflicts of
laws rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> If any particular provision of the Plan is found to be invalid or otherwise unenforceable, such provision will not
affect the other provisions of the Plan, but the Plan will be construed in all respects as if such invalid provision were omitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B> If any provision of the Plan does not comply with Applicable Law, such provision shall be construed in such a manner as to comply
with Applicable Law. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>16.</B></P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>D<SMALL>EFINITIONS</SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As used in the Plan, the following definitions will apply to the capitalized terms indicated below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(a)</B> &#147;<B><I>423 Component</I></B>&#148; means the part of the Plan, which excludes the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component, pursuant to which Purchase Rights that satisfy the requirements for an Employee Stock Purchase Plan may be granted to Eligible Employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(b)</B> <B>&#147;</B><B><I>Affiliate</I></B><B>&#148;</B> means any entity, other than a Related Corporation, whether now or subsequently
established, which is at the time of determination, a &#147;parent&#148; or &#147;subsidiary&#148; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board may determine the time or times at which
&#147;parent&#148; or &#147;subsidiary&#148; status is determined within the foregoing definition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(c)</B> &#147;<B><I>Applicable
Law</I></B>&#148; means shall mean the Code and any applicable securities, federal, state, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing
rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (or under the authority of the NASDAQ Stock Market, the New
York Stock Exchange or the Financial Industry Regulatory Authority). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">K-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(d)</B> &#147;<B><I>Board</I></B>&#148;<I> </I>means the board of directors of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(e)</B> &#147;<B><I>Business Combination Agreement</I></B>&#148; means that certain Business Combination Agreement by and
among <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., Perseverance Merger Sub Inc., and Surrozen, Inc., dated as of [&#9679;], 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(f)</B> &#147;<B><I>Capitalization Adjustment</I></B>&#148; means any change that is made in, or other events that occur with respect to,
the Common Stock subject to the Plan or subject to any Purchase Right after the date the Plan is adopted by the Board without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization,
reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other similar equity
restructuring transaction, as that term is used in Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the
Company will not be treated as a Capitalization Adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(g)</B> &#147;<B><I>Code</I></B>&#148;<I> </I>means the U.S. Internal
Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder<I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(h)</B>
&#147;<B><I>Committee</I></B>&#148;<I> </I>means a committee of one or more members of the Board to whom authority has been delegated by the Board in accordance with Section&nbsp;2(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> &#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(j)</B> &#147;<B><I>Company</I></B>&#148; means Surrozen, Inc., a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(k)</B> <B><I>&#147;Contributions</I></B>&#148; means the payroll deductions and other additional payments specifically provided for in the
Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make additional payments into his or her account if specifically provided for in the Offering, and then only if the Participant has not already had
the maximum permitted amount withheld during the Offering through payroll deductions and, with respect to the 423 Component, to the extent permitted by Section&nbsp;423 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(l)</B> &#147;<B><I>Corporate Transaction</I></B>&#148; means the consummation, in a single transaction or in a series of related
transactions, of any one or more of the following events: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> a sale<B> </B>or other disposition of all or substantially all, as
determined by the Board in its sole discretion, of the consolidated assets of the Company and its subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> a sale or
other disposition of more than 50% of the outstanding securities of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iii)</B> a merger, consolidation or similar
transaction following which the Company is not the surviving corporation; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(iv)</B> a merger, consolidation or similar transaction
following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar
transaction into other property, whether in the form of securities, cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(m)</B> <B>&#147;</B><B><I>Designated 423
Corporation</I></B><B>&#148;</B> means any Related Corporation selected by the Board to participate in the 423 Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(n)</B>
<B>&#147;</B><B><I>Designated Company</I></B><B>&#148; </B>means any Designated <FONT STYLE="white-space:nowrap">Non-423</FONT> Corporation or Designated 423 Corporation, provided, however, that at any given time, a Related Corporation participating
in the 423 Component shall not be a Related Corporation participating in the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">K-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(o)</B> <B>&#147;</B><B><I>Designated <FONT STYLE="white-space:nowrap">Non-423</FONT>
Corporation</I></B><B>&#148;</B> means any Related Corporation or Affiliate selected by the Board to participate in the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(p)</B> &#147;<B><I>Director</I></B>&#148;<I> </I>means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(q)</B> &#147;<B><I>Effective Date</I></B>&#148; means the effective date of this Plan, which is the date of the closing of the
transactions contemplated by the Business Combination Agreement, provided that this Plan is approved by the Company&#146;s stockholders prior to such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(r)</B> &#147;<B><I>Eligible Employee</I></B>&#148;<I> </I>means an Employee who meets the requirements set forth in the document(s)
governing the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(s)</B> &#147;<B><I>Employee</I></B>&#148;<I> </I>means any person, including an Officer or Director, who is &#147;employed&#148; for
purposes of Section&nbsp;423(b)(4) of the Code by the Company or a Related Corporation, or solely with respect to the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, an Affiliate. However, service solely as a Director, or payment of a fee
for such services, will not cause a Director to be considered an &#147;Employee&#148; for purposes of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(t)</B>
&#147;<B><I>Employee Stock Purchase Plan</I></B>&#148;<I> </I>means a plan that grants Purchase Rights intended to be options issued under an &#147;employee stock purchase plan,&#148; as that term is defined in Section&nbsp;423(b) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(u)</B> &#147;<B><I>Exchange Act</I></B>&#148;<I> </I>means the U.S. Securities Exchange Act of 1934, as amended and the rules and
regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(v)</B> &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of the Common
Stock determined as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(i)</B> If the Common Stock is listed on any established stock exchange or traded on any established
market, the Fair Market Value of a share of Common Stock will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of
determination, as reported in such source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing sales
price on the last preceding date for which such quotation exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> In the absence of such markets for the Common Stock, the
Fair Market Value will be determined by the Board in good faith in compliance with Applicable Laws and regulations and, to the extent applicable as determined in the sole discretion of the Board, in a manner that complies with Sections 409A of the
Code </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(w)</B> &#147;<B><I>Fully-Diluted Common Stock</I></B>&#148; means, as of any date, the aggregate number of (i)&nbsp;shares of
Common Stock issued and outstanding and (ii)&nbsp;securities convertible into or exercisable for shares of Common Stock (whether vested or unvested). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(x)</B> &#147;<B><I>Governmental</I></B><B> </B><B><I>Body</I></B>&#148; means any: (a)&nbsp;nation, state, commonwealth, province,
territory, county, municipality, district or other jurisdiction of any nature; (b)&nbsp;federal, state, local, municipal, foreign or other government; (c)&nbsp;governmental or regulatory body, or quasi-governmental body of any nature (including any
governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or entity and any court or other tribunal, and for the avoidance of
doubt, any tax authority) or other body exercising similar powers or authority; or (d)&nbsp;self-regulatory organization (including the NASDAQ Stock Market, the New York Stock Exchange and the Financial Industry Regulatory Authority). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">K-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(y)</B> &#147;<B><I><FONT STYLE="white-space:nowrap">Non-423</FONT>
Component</I></B>&#148; means the part of the Plan, which excludes the 423 Component, pursuant to which Purchase Rights that are not intended to satisfy the requirements for an Employee Stock Purchase Plan may be granted to Eligible Employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(z)</B> &#147;<B><I>Offering</I></B>&#148;<I> </I>means the grant to Eligible Employees of Purchase Rights, with the exercise of those
Purchase Rights automatically occurring at the end of one or more Purchase Periods. The terms and conditions of an Offering will generally be set forth in the &#147;<B><I>Offering Document</I></B>&#148; approved by the Board for that Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(aa)</B> &#147;<B><I>Offering Date</I></B>&#148; means a date selected by the Board for an Offering to commence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(bb)</B> &#147;<B><I>Officer</I></B>&#148;<B> </B>means<B> </B>a person who is an officer of the Company or a Related Corporation within
the meaning of Section&nbsp;16 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(cc)</B> &#147;<B><I>Participant</I></B>&#148;<I> </I>means an Eligible Employee
who holds an outstanding Purchase Right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(dd)</B> &#147;<B><I>Plan</I></B>&#148;<I> </I>means this Surrozen, Inc. 2021 Employee Stock
Purchase Plan, as amended from time to time, including both the 423 Component and the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ee)</B> &#147;<B><I>Purchase Date</I></B>&#148;<I> </I>means one or more dates during an Offering selected by the Board on which Purchase
Rights will be exercised and on which purchases of shares of Common Stock will be carried out in accordance with such Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ff)</B> &#147;<B><I>Purchase Period</I></B>&#148; means a period of time specified within an Offering, generally beginning on the Offering
Date or on the first Trading Day following a Purchase Date, and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(gg)</B> &#147;<B><I>Purchase Right</I></B>&#148;<I> </I>means an option to purchase shares of Common Stock granted pursuant to the Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(hh)</B> &#147;<B><I>Related Corporation</I></B>&#148;<I> </I>means any &#147;parent corporation&#148; or &#147;subsidiary
corporation&#148; of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(ii)</B> &#147;<B><I>Securities Act</I></B>&#148;<I> </I>means the U.S. Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(jj)</B> &#147;<B><I><FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items</I></B>&#148; means any income tax, social insurance,
payroll tax, fringe benefit tax, payment on account or other <FONT STYLE="white-space:nowrap">tax-related</FONT> items arising out of or in relation to a Participant&#146;s participation in the Plan, including, but not limited to, the exercise of a
Purchase Right and the receipt of shares of Common Stock or the sale or other disposition of shares of Common Stock acquired under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>(kk)</B> &#147;<B><I>Trading Day</I></B>&#148;<B> </B>means any day on which the exchange(s) or market(s) on which shares of Common Stock
are listed, including but not limited to the New York Stock Exchange, Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto, is open for trading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">K-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Item&nbsp;20. Indemnification of directors and officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cayman Islands law does not limit the extent to which a company&#146;s memorandum and articles of association may provide for indemnification
of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against willful default, willful neglect, civil fraud or the consequences
of committing a crime. The Existing Organizational Documents provided for indemnification of our officers and directors to the maximum extent permitted by law, including for any liability incurred in their capacities as such, except through their
own actual fraud, willful default or willful neglect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into agreements with our officers and directors to provide
contractual indemnification in addition to the indemnification provided for in the Existing Organizational Documents. We have purchased a policy of directors&#146; and officers&#146; liability insurance that insures our officers and directors
against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us
pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><A NAME="rom40894_261"></A>Item&nbsp;21. Exhibits and Financial Statements Schedules </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2.1&#134;&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="#annex_a">Business Combination Agreement, dated as of April&nbsp;
15, 2021, by and among CHFW, Perseverance Merger Sub Inc., and Surrozen, Inc. (included as <U>Annex A-1</U> to the proxy statement/prospectus). </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="#annex_b">Amended and Restated Memorandum and Articles of Association of CHFW (included as <U>Annex B</U> to the proxy
 statement/prospectus). </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="#annex_c">Form of Certificate of Incorporation of Surrozen, Inc., to become effective upon Domestication (included as
<U>Annex C</U> to the proxy statement/prospectus). </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="#annex_d">Form of Bylaws of Surrozen, Inc., to become effective upon Domestication (included as <U>Annex&nbsp;
D</U> to the proxy statement/prospectus). </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1824893/000110465920113567/tm2030948d3_ex4-1.htm">Specimen Unit Certificate (incorporated
by reference to Exhibit 4.1 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> filed by the Registrant on October&nbsp;13, 2020). </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1824893/000110465920114246/tm2030948d4_ex4-2.htm">Specimen Ordinary Share Certificate
 (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> filed by the Registrant on October&nbsp;13, 2020). </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1824893/000110465920114246/tm2030948d4_ex4-3.htm">Specimen Warrant Certificate
 (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> filed by the Registrant on October&nbsp;13, 2020). </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4.4**</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Form of Certificate of Corporate Domestication of CHFW, to be filed with the Secretary of the State of
Delaware.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1824893/000110465920129281/tm2037076d1_ex4-1.htm">Warrant Agreement between Continental
Stock Transfer&nbsp;&amp; Trust Company and <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., dated November&nbsp;18, 2020 (incorporated by reference to Exhibit 4.1 to the Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> filed by the Registrant on November&nbsp;25, 2020). </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4.6**</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Form of Warrant Agreement between Continental Stock Transfer &amp; Trust Company and Consonance-HFW Acquisition
Corp.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5.1**</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Opinion of Goodwin Procter LLP.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex81.htm">Opinion of Goodwin Procter LLP regarding certain tax
matters.</A></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;10.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="#annex_e">Sponsor Letter Agreement, dated as of November&nbsp;18, 2020 by and among Consonance Life Sciences and <FONT
STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. (included as <U>Annex E</U> to the proxy statement/prospectus). </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;10.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="#annex_f">Form of Subscription Agreement (and related form of warrant agreement) (included as <U>Annex F</U> to the proxy
 statement/prospectus). </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;10.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="#annex_g">Form of Investor Rights Agreement (included as <U>Annex G</U> to the proxy statement/prospectus).
</A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;10.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="#annex_h">Form of Surrozen Company Support Agreement (included as <U>Annex H</U> to the proxy statement/prospectus).
 </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;10.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="#annex_i">Form of CHFW Shareholder Support Agreement (included as <U>Annex I</U> to the proxy statement/prospectus).
 </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;10.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="#annex_j">Form of Surrozen, Inc. 2021 Equity Incentive Plan (included as <U>Annex J</U> to the proxy statement/prospectus).
 </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;10.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="#annex_k">Form of Surrozen, Inc. 2021 Employee Stock Purchase Plan (included as <U>Annex K</U> to the proxy statement/prospectus).
 </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;10.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1824893/000110465920113567/tm2030948d3_ex10-4.htm">Form of Indemnity Agreement
 (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> filed by the Registrant on October&nbsp;9, 2020). </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;10.9#</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex109.htm">Amended and Restated License and Option Agreement for Llama Single Domain Antibody Phage Library, dated
 as of January&nbsp;17, 2020, by and between Regents of the University of California and Surrozen, Inc. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;10.10#</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex1010.htm">Amended and Restated License and Option Agreement for Human Na&iuml;ve Fab Library, dated as of January&nbsp;17,
2020, by and between Regents of the University of California and Surrozen, Inc. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;10.11#</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex1011.htm">Antibody Library Subscription Agreement, dated as of September&nbsp;
30, 2016, by and between Distributed Bio, Inc. and Surrozen, Inc. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;10.12#</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex1012.htm">First Amendment to the Antibody Library Subscription Agreement, dated as of January&nbsp;
15, 2019, by and between Distributed Bio, Inc. and Surrozen, Inc.</A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;10.13#</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex1013.htm">Exclusive (Equity) Agreement, dated as of March&nbsp;
23, 2016, by and between The Board of Trustees of the Leland Stanford Junior University and Surrozen, Inc. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;10.14#</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex1014.htm">Amendment No.&nbsp;1 to the Exclusive (Equity) Agreement, dated as of July&nbsp;
5, 2016, by and between The Board of Trustees of the Leland Stanford Junior University and Surrozen, Inc. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;10.15#</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex1015.htm">Amendment No.&nbsp;2 to the Exclusive (Equity) Agreement, dated as of October&nbsp;
7, 2016, by and between The Board of Trustees of the Leland Stanford Junior University and Surrozen, Inc.</A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;10.16#</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex1016.htm">Amendment No.&nbsp;3 to the Exclusive (Equity) Agreement, dated as of January&nbsp;
19, 2021, by and between The Board of Trustees of the Leland Stanford Junior University and Surrozen, Inc.</A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;10.17#</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex1017.htm">Exclusive License Agreement, dated as of June&nbsp;
6, 2018, by and between The Board of Trustees of the Leland Stanford Junior University and Surrozen, Inc. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;21.1*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1824893/000119312521162051/d40894dex211.htm">List of Subsidiaries of the Company.
 </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;23.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex231.htm">Consent of Marcum LLP, independent registered accounting firm for CHFW. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;23.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex232.htm">Consent of Ernst &amp; Young, LLP, independent registered public accounting firm for Surrozen.
</A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;23.3**</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Consent of Goodwin Procter LLP (included as part of Exhibit&nbsp;5.1).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;23.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex81.htm">Consent of Goodwin Procter LLP (included as part of Exhibit&nbsp;8.1). </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;24.1*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="#sig">Power of Attorney (included on signature page to this Registration Statement).
</A></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;99.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex991.htm">Consent of Craig Parker to be named as a director. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;99.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex992.htm">Consent of Anna Berkenblit to be named as a director. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;99.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex993.htm">Consent of Tim Kutzkey to be named as a director. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;99.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex994.htm">Consent of Shao-Lee Lin to be named as a director. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;99.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex995.htm">Consent of David J. Woodhouse to be named as a director. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;99.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex996.htm">Consent of Mary Haak-Frendscho to be named as a director. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;99.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex997.htm">Consent of Mace Rothenberg to be named as a director. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;99.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex998.htm">Consent of Christopher Chai to be named as a director. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;99.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d40894dex999.htm">Form of Proxy for Extraordinary General Meeting. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">101.INS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">XBRL Instance Document</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">101.SCH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">XBRL Taxonomy Extension Schema Document</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">101.CAL</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">XBRL Taxonomy Extension Calculation Linkbase Document</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">101.DEF</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">XBRL Taxonomy Extension Definition Linkbase Document</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">101.LAB</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">XBRL Taxonomy Extension Label Linkbase Document</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">101.PRE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">XBRL Taxonomy Extension Presentation Linkbase Document</P></TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">*</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Previously filed. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">**</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To be filed by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">#</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Pursuant to Item&nbsp;601(b)(10) of Regulation&nbsp;S-K, portions of this exhibit (indicated by asterisks)
have been omitted as the registrant has determined that the omitted information is both not material and is the type that the registrant treats as private or confidential. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#134;&#134;</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Schedules and exhibits to this Exhibit omitted pursuant to
<FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> Item&nbsp;601(b)(2). The Registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Item&nbsp;22. Undertakings </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">11.</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The undersigned Registrant hereby undertakes: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To file, during any period in which offers or sales are being made, a post-effective amendment to this
Registration Statement: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To include any prospectus required by section 10(a)(3) of the Securities Act of 1933; </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(ii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To reflect in the prospectus any facts or events arising after the effective date of this Registration
Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of
prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148;
table in the effective registration statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(iii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To include any material information with respect to the plan of distribution not previously disclosed in
this Registration Statement or any material change to such information in this Registration Statement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(b)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">That, for the purpose of determining any liability under the Securities Act of 1933, each such
post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(c)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">To remove from registration by means of a post-effective amendment any of the securities being registered
which remain unsold at the termination of the offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(d)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each
prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of
and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any
statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(e)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any
purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used
to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to
be filed pursuant to Rule 424; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(ii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant
or used or referred to by the undersigned registrant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(iii)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The portion of any other free writing prospectus relating to the offering containing material information
about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(iv)</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Any other communication that is an offer in the offering made by the undersigned registrant to the
purchaser. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">12.</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to
directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the
Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of
the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the
matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by them is against public policy as expressed in the Securities Act of 1933 and will be governed by the final
adjudication of such issue. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13.</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The undersigned registrant hereby undertakes as follows: that prior to any public reoffering of the
securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule 145(c), the issuer undertakes that such reoffering
prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14.</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The registrant undertakes that every prospectus: (1)&nbsp;that is filed pursuant to the immediately
preceding paragraph, or (2)&nbsp;that purports to meet the requirements of Section&nbsp;10(a)(3) of the Act and is used in connection with an offering of securities subject to Rule 415, will be filed as a part of an amendment to the registration
statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to
the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15.</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The undersigned Registrant hereby undertakes to respond to requests for information that is incorporated by
reference into the prospectus pursuant to Items 4, 10(b), 11, or 13 of this Form <FONT STYLE="white-space:nowrap">S-4,</FONT> within one business day of receipt of such request, and to send the incorporated documents by first class mail or other
equally prompt means. This includes information contained in documents filed subsequent to the effective date of the Registration Statement through the date of responding to the request. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="justify"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">16.</P></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The undersigned Registrant hereby undertakes to supply by means of a post-effective amendment all
information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the Registration Statement when it became effective. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by
the undersigned, thereunto duly authorized, in the City of Princeton, New Jersey on the 24th&nbsp;day of June, 2021. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">/s/ Gad Soffer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gad Soffer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned constitutes and appoints each of Gad Soffer and Kevin Livingston, each acting
alone, his true and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">lawful&nbsp;attorneys-in-fact&nbsp;and</FONT></FONT> agents, with full power of substitution and resubstitution, for such person and in his name, place and stead,
in any and all capacities, to sign this Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4&nbsp;(including</FONT> <FONT STYLE="white-space:nowrap">all&nbsp;pre-effective&nbsp;and</FONT> post-effective amendments and
registration statements filed pursuant to Rule 462 under the Securities Act of 1933, as amended), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission,
granting unto <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">said&nbsp;attorneys-in-fact&nbsp;and</FONT></FONT> agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and
necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">such&nbsp;attorney-in-fact&nbsp;and</FONT></FONT> agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following
persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>POSITION</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>DATE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gad Soffer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Chief Executive Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(<I>Principal Executive Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">June 24,&nbsp;2021.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Kevin Livingston</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(<I>Principal Financial and Accounting Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">June 24, 2021.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Mitchell Blutt, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">June 24, 2021.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Benny Soffer, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">June 24, 2021.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Donald J. Santel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">June 24, 2021.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Christopher Haqq, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">June 24, 2021.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Jennifer Jarrett</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">June 24, 2021.</TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">*By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Gad Soffer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">June 24, 2021.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gad Soffer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Attorney-in-Fact</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>2
<FILENAME>d40894dex81.htm
<DESCRIPTION>EX-8.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-8.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 8.1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g40894g28q92.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwin Procter <SMALL>LLP</SMALL></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 Northern
Avenue</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02210</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">goodwinlaw.com</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+1 617 570 1000</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">June&nbsp;24, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 Palmer Square, Suite 305 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Princeton, NJ 08540 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are United States tax
counsel to <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp., a Cayman Islands exempted company (&#147;<U>CHFW</U>&#148;), in connection with the preparation of the registration statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> (as amended or supplemented as of June&nbsp;24, 2021, and together with the Proxy Statement/Prospectus filed therewith, the &#147;<U>Registration Statement</U>&#148;) (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-256146),</FONT> under the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), by CHFW. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registration Statement is being filed in connection with the transactions (the &#147;<U>Business Combination</U>&#148;) contemplated by
the Business Combination Agreement, dated as of April&nbsp;15, 2021 (the &#147;<U>BCA</U>&#148;), by and among CHFW Perseverance Merger Sub Inc., Inc., a Delaware corporation, and Surrozen, Inc., a Delaware corporation. Capitalized terms not
otherwise defined herein shall have the same meanings attributed to such terms in the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You have requested our
opinion concerning the discussions set forth in the sections entitled &#147;Certain Material U.S. Federal Income Tax Considerations&#151;Effect of the Domestication on U.S. Holders&#148; and &#147;Certain Material U.S. Federal Income Tax
Considerations&#151;Effects on U.S. Holders Exercising Redemption Rights&#148; in the Registration Statement as they relate to the Domestication and the exercise of redemption rights (the &#147;<U>Tax Disclosure</U>&#148;). In providing this
opinion, we have assumed (without any independent investigation or review thereof) that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. All original documents submitted to us
(including signatures thereto) are authentic, all documents submitted to us as copies conform to the original documents, all such documents have been duly and validly executed and delivered where due execution and delivery are a prerequisite to the
effectiveness thereof, and all parties to such documents had or will have, as applicable, the requisite corporate powers and authority to enter into such documents and to undertake and consummate the Business Combination; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. All factual representations, warranties and statements made or agreed to by the parties to the BCA, the Sponsor Letter Agreement, the
Subscription Agreements, and the other agreements referred to therein or otherwise relating to the Business Combination (collectively, the &#147;<U>Agreements</U>&#148; and, together with the Registration Statement, the
&#147;<U>Documents</U>&#148;), and in the representation letter provided to us by CHFW are true, correct and complete as of the date hereof without regard to any qualification as to knowledge, belief, or otherwise; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 24, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c. The description of the Business Combination (and other statements set forth) in the
Registration Statement are accurate, the Business Combination will be consummated in accordance with such description and with the BCA and the other Agreements, without any waiver or breach of any material provision thereof, and the Business
Combination will be effective under applicable corporate law as described in the BCA and the other Agreements; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d. The Documents
represent the entire understanding of the parties with respect to the Business Combination, there are no other written or oral agreements regarding the Business Combination other than the Agreements and none of the material terms and conditions
thereof have been or will be waived or modified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is based on current provisions of the U.S. Internal Revenue Code of 1986,
as amended (the &#147;<U>Code</U>&#148;), the U.S. Treasury Regulations promulgated thereunder, and the interpretation of the Code and such regulations by the courts and the U.S. Internal Revenue Service, in each case, as they are in effect and
exist at the date of this opinion. It should be noted that statutes, regulations, judicial decisions and administrative interpretations are subject to change at any time and, in some circumstances, with retroactive effect. Any change that is made
after the date hereof in any of the foregoing bases for our opinion, or any inaccuracy in the facts or assumptions on which we have relied in issuing our opinion, could adversely affect our conclusion. We assume no responsibility to inform you of
any such change or inaccuracy that may occur or come to our attention. No opinion is expressed as to any transactions other than the Business Combination, or any matter other than those specifically covered by this opinion. In particular, this
opinion is limited to the matters discussed in the Tax Disclosure, and does not address (i)&nbsp;the U.S. federal income tax treatment of any shareholder subject to special rules under the Code or the Treasury Regulations, as further described in
the Tax Disclosure or (ii)&nbsp;the status of any entity under the &#147;passive foreign investment company&#148; rules of Sections 1291-1297 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. federal income tax consequences of the transactions described in the Registration Statement are complex and are subject to varying
interpretations. Our opinion is not binding on the U.S. Internal Revenue Service or any court, and there is no assurance or guarantee that either will agree with our conclusions. Indeed, the U.S. Internal Revenue Service may challenge one or more of
the conclusions contained herein and the U.S. Internal Revenue Service may take a position that is inconsistent with the views expressed herein. There is no assurance or guarantee that a court would, if presented with the issues addressed herein,
reach the same or similar conclusions as we have reached. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 24, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, we confirm that the statements set forth in the
Registration Statement under the headings &#147;Material U.S. Federal Income Tax Considerations to U.S. Holders&#151;Effects of the Domestication on U.S. Holders&#148; and &#147;Material U.S. Federal Income Tax Considerations&#151;Effects on U.S.
Holders Exercising Redemption Rights,&#148; insofar as they address certain material U.S. federal income tax considerations for beneficial owners of CHFW securities in connection with the Domestication and the exercise of redemption rights and
matters of U.S. federal income tax law and regulations or legal conclusions with respect thereto, and except to the extent stated otherwise therein, are our opinion, subject to the assumptions, qualifications and limitations stated herein and
therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is furnished to you solely for use in connection with the Registration Statement. This opinion is based on facts
and circumstances existing on the date hereof. We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby concede that we are within the category of persons whose consent is
required under Section&nbsp;7 of the Securities Act or the rules and regulations of the Commission thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Goodwin Procter LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Goodwin Procter LLP</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>3
<FILENAME>d40894dex109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.9 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I)&nbsp;NOT MATERIAL AND
(II)&nbsp;THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDED AND RESTATED </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">LICENSE AND OPTION AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">between </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SURROZEN </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">for </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Llama Single Domain Antibody Phage Library </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">UC Case No. [****] </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Article&nbsp;No.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Title</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">BACKGROUND</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DEFINITIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">GRANT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">OPTION FEES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EXERCISE OF THE OPTION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TERMS OF THE PROPOSED COMMERCIAL LICENSE AGREEMENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PROGRESS REPORTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">LIFE OF THE AGREEMENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TERMINATION BY THE REGENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TERMINATION BY OPTIONEE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DISPOSITION OF BIOLOGICAL MATERIALS ON HAND UPON TERMINATION OR EXPIRATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">USE OF NAMES AND TRADEMARKS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CONFIDENTIALITY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">LIMITED WARRANTY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">LIMITATION OF LIABILITY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">INDEMNIFICATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">16.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">NOTICES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">17.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ASSIGNABILITY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">18.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">WAIVER</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">19.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FORCE MAJEURE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">20.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">GOVERNING LAWS; VENUE; ATTORNEYS FEES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">21.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">GOVERNMENT APPROVAL OR REGISTRATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">22.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">COMPLIANCE WITH LAWS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">23.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">MISCELLANEOUS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">EXHIBIT A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">EXHIBIT B: CONSENT TO SUBSTITUTION OF PARTY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDED AND RESTATED LICENSE AND OPTION AGREEMENT FOR </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">UC Case No [****] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#147;Llama
Single Domain Antibody Phage Library&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This amended and restated license and option agreement (&#147;<B>Agreement</B>&#148;) is
effective this 17th day of January, 2020 (&#147;<B>Amended and Restated Effective Date</B>&#148;), between <B>The Regents of the University of California</B> (&#147;<B>The Regents</B>&#148;), a California corporation, having its statewide
administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, and acting through its Office of Technology Management, University of California San Francisco, 600 16th Street, Suite
<FONT STYLE="white-space:nowrap">S-272,</FONT> San Francisco, CA 94143 and <B>Surrozen, Inc.</B>, a Delaware corporation, having a principal place of business at171 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080
(&#147;<B>Surrozen</B>&#148;). The Regents and Surrozen are sometimes referred to herein individually as a &#147;Party&#148; and collectively as the &#147;Parties.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BACKGROUND </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;Certain inventions, generally characterized as the Llama Single Domain Antibody Phage Library and disclosed in UC Case No. [****]
(&#147;<B>Invention</B>&#148;), are covered by the Technology Rights (as defined in Paragraph 1.12 below) and were made in the course of research at the University of California, San Francisco by [****]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B.&nbsp;&nbsp;&nbsp;&nbsp;Development of the Invention was sponsored by The National Institutes of Health (&#147;<B>NIH</B>&#148;) and as a consequence, this
Agreement, any Commercial License Agreement, and the Invention are subject to overriding obligations to the United States Federal Government under 35 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">200-212</FONT> and applicable regulations
including a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">non-transferable,</FONT> irrevocable, <FONT STYLE="white-space:nowrap">paid-up</FONT> license to practice or have practiced the Invention for or on
behalf of the United States Government throughout the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C.&nbsp;&nbsp;&nbsp;&nbsp;The Regents elected on [****] to retain title and granted the
aforementioned licenses to the United States Government. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">D.&nbsp;&nbsp;&nbsp;&nbsp;Surrozen wishes to use the Biological Material under the Agreement to
discover Identified Antibodies and to determine its interest in exercising its option to obtain a commercial license to develop and commercialize the Identified Antibody(ies) or Derivative Antibody(ies). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E.&nbsp;&nbsp;&nbsp;&nbsp;The Regents wishes to grant Surrozen the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license and the option so that the
Invention is used to discover and develop Identified Antibodies or Derivative Antibody(ies), if any, for the benefit of the general public by treating serious disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">F.&nbsp;&nbsp;&nbsp;&nbsp;The Regents and Surrozen entered into a License and Option Agreement dated October&nbsp;5, 2016 (the &#147;<B>Effective
Date</B>&#148;) with UC Agreement Control No. [****] (&#147;<B>Original Agreement</B>&#148;). Surrozen and The Regents now desire to amend and restate the Original Agreement in its entirety with this Agreement for the purpose of updating the option
and terms of the proposed Commercial License Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 1
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;DEFINITIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Antibody(ies)</B>&#148; means a protein or immunoglobulin that binds to an antigen or target of interest
through a complementarity determining region (&#147;<B>CDR</B>&#148;), or any fragment of such protein, including, but not limited to, an antibody, antibody fragment, [****]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Biological Materials</B>&#148; means: (a)&nbsp;the Original Materials and their Progeny;
(b)&nbsp;Unmodified Derivatives; (c)&nbsp;Identified Antibody(ies); or (d)&nbsp;Derivative Antibody(ies). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Commercial License Agreement</B>&#148; means the license agreement as more fully described in Article 5
and Exhibit A (Terms of the Proposed Commercial License Agreement) by and between The Regents and Surrozen that may result if Surrozen exercises its option under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>CRO</B>&#148; means a contract research organization under contract with Surrozen to perform research for
or on behalf of Surrozen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Derivative Antibody</B>&#148; means an Antibody that is the result of
Surrozen&#146;s (i)&nbsp;research, development or optimization efforts using an Identified Antibody as a starting compound, [****], or (ii)&nbsp;combining an Identified Antibody with a third-party Antibody, [****]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Field of Use</B>&#148; means the use of the Biological Materials for internal research, drug discovery and
screening by Surrozen on Surrozen&#146;s own premises or by a CRO on behalf of Surrozen, to identify Antibodies against targets of interest and to test such Antibodies in vitro and in vivo (in animal models) as candidates for further development.
The Field of Use specifically excludes (i)&nbsp;the Sale, transfer, lease, exchange or other disposition or provision of Biological Materials, including but not limited to the Original Materials, or Product(s); (ii) any use in humans of the
Biological Materials or Product(s); (iii) the use or testing of the Products in any clinical trials; and (iv)&nbsp;the modification, in any way, of the Original Materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.7&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Identified Antibody(ies)</B>&#148; means a) an Antibody identified, produced or derived from the
Biological Materials by Surrozen, b) a polynucleotide encoding the Antibody described in a) above, or c) the amino acid or nucleotide sequence of the CDR of the Antibody described in a) above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 2
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.8&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Original Materials</B>&#148; means the Phage Display
Llama VHH Single Domain Antibody Library developed by [****] as described UC Case No. [****]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.9&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Product</B>&#148; means any article of manufacture, composition of matter, material, compound, component
or product that consists of, contains or incorporates Identified Antibody(ies) or Derivative Antibody(ies). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.10&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Progeny</B>&#148; means descendants from the Original Materials, Progeny and/or Unmodified Derivatives,
including those with mutations such as: virus from virus; cell from cell; or organism from organism. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.11&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Sale</B>&#148; means the act of selling, leasing or otherwise transferring, providing, or furnishing for
use for any financial consideration. Correspondingly, &#147;<B>Sell</B>&#148; means to make or cause to be made a Sale, and &#147;<B>Sold</B>&#148; means to have made or caused to be made a Sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.12&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Technology Rights</B>&#148; means (i)&nbsp;The Regents&#146; personal property rights in the Biological
Materials; and (ii)&nbsp;The Regents&#146; personal proprietary rights in the existing <FONT STYLE="white-space:nowrap">know-how</FONT> associated with the Biological Materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.13&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Unmodified Derivative(s)</B>&#148; means a substance(s) derived from the Original Materials, Progeny or
Unmodified Derivatives that constitutes an unmodified functional subunit or derivative of the Original Materials, Progeny or Unmodified Derivatives, [****]. For the avoidance of doubt, Unmodified Derivatives shall not include any Antibody (ies)
identified by Licensee through screening the Original Materials, Progeny or Unmodified Derivatives. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;GRANT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Supply</B>. The Regents, and Surrozen acknowledge that a viable sample of the existing Original
Materials (or an equivalent thereof), has been provided to Surrozen. Surrozen is responsible for any handling and shipping costs associated with the provision of any additional samples of Original Materials to Surrozen. Surrozen may use such
Original Materials solely as necessary to exercise the rights granted to Surrozen hereunder; provided, however, in no event may Surrozen Sell, transfer, lease, exchange or otherwise dispose of or provide such Original Materials and/or any Biological
Materials to any third party except solely as provided for in Paragraph 2.11. Surrozen shall notify The Regents if Surrozen receives any biological material from [****] or any representative of The Regents that is not Original Materials. Surrozen
may not use such biological material without the written permission of The Regents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 3
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2&nbsp;&nbsp;&nbsp;&nbsp;<B><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT>
License</B>. Subject to the limitations and other terms and conditions set forth in this Agreement, including the license granted to the United States Government as set forth in the recitals and in Paragraph 2.4, The Regents grants Surrozen, under
the Technology Rights, the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right to make (propagate) and use the Biological Materials only in the Field of Use, in the United States and in other countries where The Regents may lawfully grant
such licenses, solely to provide Surrozen the opportunity to discover Identified Antibodies and determine its interest in a Commercial License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Option</B>. Subject to the limitations and other terms and conditions set forth in this Agreement, including the
license granted to the United States Government as set forth in the recitals and in Paragraph 2.4, The Regents grants Surrozen a time-limited right to negotiate in good faith the terms of the Commercial License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4&nbsp;&nbsp;&nbsp;&nbsp;<B>U.S. Government Rights</B>. The rights and licenses granted hereunder are subject to the overriding obligations
to the United States Government under 35 USC&#167;&#167; <FONT STYLE="white-space:nowrap">200-212</FONT> and all applicable governmental implementing regulations, as amended from time to time, including the obligation to report on the utilization of
the Invention as set forth in 37 CFR.&#167; 401.14(h), and all applicable provisions of any license to the United States Government executed by The Regents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5&nbsp;&nbsp;&nbsp;&nbsp;<B>Limitations</B>. The rights and licenses granted in Paragraphs 2.1, 2.2 and 2.3 do not constitute a license to
make or use Identified Antibodies or Derivative Antibodies except for the sole purpose of conducting an evaluation to determine the interest by Surrozen in exercising the rights granted in Paragraph 2.3 above. The right to test in clinical trials,
import, offer for Sale, and Sell Biological Materials or Product(s) is expressly excluded from this Agreement. Unless there is an executed and active Commercial License Agreement between the parties covering the subject Identified Antibody,
Derivative Antibody or Product, Surrozen is prohibited from filing an Investigational New Drug (IND) application with the FDA (or a similar application with a foreign regulatory authority) on any Identified Antibody, Derivative Antibody, or Product.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6&nbsp;&nbsp;&nbsp;&nbsp;<B>Patent Filings</B>. Inventorship of inventions conceived or reduced to practice in the course of activities
performed under or contemplated by this Agreement shall be determined under U.S. patent laws pertaining to inventorship. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7&nbsp;&nbsp;&nbsp;&nbsp;<B>Title</B>. Title in and to the Original Materials, Progeny and Unmodified Derivatives and any rights, including
any and all intellectual property rights, relating thereto is owned by The Regents and is not transferred to Surrozen under this Agreement. Surrozen will own any Derivative Antibody(ies), except that The Regents retains ownership of any Original
Materials, Progeny, and Unmodified Derivatives, as well as portions of Unmodified Derivatives contained or incorporated in any such Derivative Antibody. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 4
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.8&nbsp;&nbsp;&nbsp;&nbsp;<B>The Regents&#146; Retention of Rights</B>. The Regents
reserves and retains the right (and the rights granted to Surrozen in this Agreement shall be limited accordingly) to make, use and practice the Invention, the Technology Rights, and the Original Materials, Progeny and Unmodified Derivatives and any
technology relating to any of the foregoing created by The Regents for educational and research purposes, including without limitation, any sponsored research performed for or on behalf of commercial entities and including publication and other
communication of any research results. Surrozen understands that the right of The Regents to transfer the Original Materials, Progeny and Unmodified Derivatives to other educational and <FONT STYLE="white-space:nowrap">non-profit</FONT> institutions
as provided for in this Paragraph 2.8 could lead to the inadvertent loss or diminution of the proprietary and commercial value of the Original Material, Progeny and Unmodified Derivatives and that such loss or diminution does not affect the
consideration Surrozen is to convey to The Regents hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9&nbsp;&nbsp;&nbsp;&nbsp;<B>Additional Licenses</B>. Subject to
Section&nbsp;4.2, The Regents is free to issue additional licenses under the Technology Rights and to the Original Materials and any biological materials made from the Original Materials for commercial or
<FONT STYLE="white-space:nowrap">non-commercial</FONT> purposes and is free to transfer the Original Materials and any biological materials made from the Original Materials to third parties, except The Regents shall not transfer the Derivative
Antibodies to a Third Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.10&nbsp;&nbsp;&nbsp;&nbsp;<B>No Right to Sublicense</B>. This Agreement specifically excludes the right to
sublicense, except as permitted under Paragraph 2.11 (CROs) below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.11&nbsp;&nbsp;&nbsp;&nbsp;<B>CROs</B>. Surrozen&#146;s right to
transfer possession of the Biological Materials and Identified Antibody(ies) and/or Derivative Antibody(ies) to third parties is expressly limited under the terms of this Agreement. Surrozen shall have the right to transfer the Biological Materials,
Identified Antibody(ies) and/or Derivative Antibody(ies) solely to CROs for the express purpose of performing research in the Field of Use on behalf of Surrozen. If Surrozen transfers any Biological Materials, Identified Antibody(ies) and/or
Derivative Antibody(ies) to CROs, it hereby agrees that such CROs shall be required to comply with the terms and conditions of this Agreement. For the purpose of this Agreement, Surrozen shall remain responsible for the performance of its rights and
obligations set out in this Agreement by such recipient CROs, including the confidentiality and material handling protections set forth in this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;OPTION FEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Option Issue Fee</B>. As partial consideration for the rights granted to Surrozen herein, Surrozen will pay The
Regents an option issue fee of [****]. The option issue fee is due The Regents within [****] of the Effective Date. The option issue fee was paid in full on [****]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 5
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Option Maintenance Fee</B>. Surrozen will also pay The Regents
an option maintenance fee of [****] beginning on the first anniversary of the Effective Date and continuing annually on each anniversary of the Effective Date until, the earlier of, either the Parties executing a Commercial License Agreement or
termination of this Agreement. The option maintenance fee is due The Regents within [****] of each anniversary of the Effective Date beginning with the first anniversary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Term Extension</B>. Upon receipt of Surrozen&#146;s notice of a request to extend the Term, the Parties may
extend the Term of this Agreement for an additional four (4)&nbsp;years by written agreement. If the Parties agree to an additional Term, Surrozen will pay an option extension fee of [****], which is due within [****] of the Parties written
agreement to extend the Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4&nbsp;&nbsp;&nbsp;&nbsp;The option issue fee, option maintenance fee and option extension fee are <FONT
STYLE="white-space:nowrap">non-refundable,</FONT> non&nbsp;-cancelable, <FONT STYLE="white-space:nowrap">non-creditable</FONT> and not an advance against royalties or other payments required to be paid under the terms of this Agreement or the
Commercial License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5&nbsp;&nbsp;&nbsp;&nbsp;In the event that fees or other monies owed to The Regents are not received by
The Regents when due, then Surrozen will pay The Regents interest at a rate of [****]. Such interest will be calculated from the date payment was due until actually received by The Regents. Such accrual of interest will be in addition to and not in
lieu of, enforcement of any other rights of The Regents due to such late payment. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;EXERCISE OF THE OPTION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1&nbsp;&nbsp;&nbsp;&nbsp;If Surrozen elects to exercise its right to negotiate the terms of the Commercial License Agreement, then
Surrozen will notify The Regents in writing not later than [****] prior to the expiration of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2&nbsp;&nbsp;&nbsp;&nbsp;Within the [****] following Surrozen&#146;s election to exercise its option pursuant to Paragraph 4.1, Surrozen and
The Regents will begin, in good faith, to negotiate the outstanding terms and conditions of the Commercial License Agreement. The Parties shall have a maximum of [****] from the date of election to conclude a Commercial License Agreement
(&#147;<B>Negotiation Period</B>&#148;). Such Negotiation Period may be extended by written mutual agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3&nbsp;&nbsp;&nbsp;&nbsp;The Parties mutually acknowledge that good-faith negotiations may or may not result in the execution of the
Commercial License Agreement. Neither Party will be liable to the other in the event of any termination of negotiations or failure to execute the Commercial License Agreement unless and to the extent the other Party proves, by clear and convincing
evidence, that the terms sought by such Party are so unreasonable as to clearly constitute bad faith. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 6
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;TERMS OF THE PROPOSED COMMERCIAL LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1&nbsp;&nbsp;&nbsp;&nbsp;If Surrozen exercises its rights under Paragraph 2.3, Article 3 (Option Fees), Article 4 (Exercise of the Option)
and this Article 5, then The Regents and Surrozen will thereafter negotiate, in good faith, the terms of the Commercial License Agreement. The terms of the Commercial License Agreement will include, but not be limited to, the agreed upon terms set
forth in Exhibit A and the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>5.1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">confidentiality terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>5.1.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">indemnification by Surrozen of The Regents, the sponsors of the research that led to the Invention and the
development of the Original Materials to the extent of their sponsorship of the research, and the inventors of the Original Materials and their employers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>5.1.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a warranty that is limited to The Regents&#146; right to grant a license under Technology Rights as set forth
in Article 13 (Limited Warranty) hereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>5.1.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">limitation of liability of The Regents; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>5.1.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">other standard terms normally found in exclusive license agreements executed by The Regents.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2&nbsp;&nbsp;&nbsp;&nbsp;Surrozen and The Regents have agreed upon a term sheet (&#147;<B>Term Sheet</B>&#148;) which
sets forth the basic terms under which the Parties have agreed to negotiate a Commercial License Agreement, a copy of which is attached to this Agreement as Exhibit A. The Term Sheet shall not create any binding obligations on the part of either
Surrozen or The Regents to execute a Commercial License Agreement. Any rights and obligations of the Parties pursuant to the Commercial License Agreement will be subject to the negotiation and execution of the Commercial License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3&nbsp;&nbsp;&nbsp;&nbsp;The Commercial License Agreement will be subject to the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>5.3.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The obligations to the U.S. Government under 35 U.S.C. &#167;&#167;
<FONT STYLE="white-space:nowrap">200-212</FONT> and applicable governmental implementing regulations, as amended from time to time, including the obligation to report on the utilization of the Invention as set forth in 37 CFR. &#167; 401.14(h), and
all applicable provisions of any license to the United States Government executed by The Regents; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>5.3.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The National Institutes of Health &#147;Principles and Guidelines for Recipients of NIH Research Grants and
Contracts on Obtaining and Disseminating Biomedical Research Resources,&#148; 64 F.R. 72090 (Dec. 23, 1999), as amended from time to time. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 7
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;PROGRESS REPORTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1&nbsp;&nbsp;&nbsp;&nbsp;Beginning on the [****], and [****] thereafter (&#147;<B>Progress Report Due Date</B>&#148;), Surrozen will provide
to The Regents a written progress report as described in Paragraph 6.2 below covering Surrozen&#146;s activities related to the use of the Biological Material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2&nbsp;&nbsp;&nbsp;&nbsp;The progress reports will include, but are not limited to, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>6.2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A summary of work completed and in progress as of the submission date, related to the use of the Biological
Material. The summary of work should provide The Regents with enough information so that The Regents may understand the usefulness and effectiveness of The Regents&#146; libraries, the success of Surrozen&#146;s screenings, and the development
status of any Identified Antibodies and Derivative Antibodies. [****] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>6.2.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>6.2.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3&nbsp;&nbsp;&nbsp;&nbsp;A progress report will be considered timely if provided to The Regents within [****] of the Progress Report Due
Date. If Surrozen fails to submit a timely progress report to The Regents, then The Regents will provide Surrozen written notice that it has failed to submit a timely progress report and Surrozen will have an additional [****] after receiving The
Regents&#146; written notice to submit the progress report. If Surrozen fails to submit a progress report during this additional [****] window, then The Regents will be entitled to terminate this Agreement in accordance with Section&nbsp;8. If
either Party terminates this Agreement before expiration, then Surrozen shall submit within [****] following termination a final progress report to cover the period up to the time of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4&nbsp;&nbsp;&nbsp;&nbsp;In the event that Surrozen elects to extend the term of this Agreement as provided for in Paragraph 3.3, Surrozen
must continue to submit progress reports in accordance with the provisions of Paragraphs 6.1, 6.2 and 6.3 above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 8
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;LIFE OF THE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise terminated by operation of law or by acts of the Parties in accordance with the terms of this
Agreement, this Agreement will be in force from the Effective Date and will remain in effect for four (4)&nbsp;years thereafter (the &#147;<B>Term</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2&nbsp;&nbsp;&nbsp;&nbsp;Surrozen may extend this Agreement for an additional Term in accordance with the provisions of Paragraph 3.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3&nbsp;&nbsp;&nbsp;&nbsp;This Agreement will automatically terminate without the obligation to provide sixty (60)&nbsp;days notice as set
forth in Article 8 upon the filing of a petition for relief under the United States Bankruptcy Code by or against Surrozen as a debtor or alleged debtor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4&nbsp;&nbsp;&nbsp;&nbsp;Any termination of this Agreement will not affect the rights and obligations set forth in the following Paragraph
and Articles: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Article 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitions Option Fees </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Article 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Option Fees </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Article 7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Life of the Agreement </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Article</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disposition of Biological Materials on Hand Upon Termination
or Expiration </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Article 11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use of Names and Trademarks </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Article 12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidentiality </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Article 13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limited Warranty </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Article 14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitation of Liability </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Article 15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Article 16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Article 20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing Laws; Venue; Attorneys Fees </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.5&nbsp;&nbsp;&nbsp;&nbsp;Any termination or expiration of this Agreement will not relieve the Surrozen of its obligation to pay any fees or
monies, including the option fee and extension fee (if any), due or owing at the time of termination or expiration and will not impair any accrued right of The Regents. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;TERMINATION BY THE REGENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1&nbsp;&nbsp;&nbsp;&nbsp;If The Regents believes that Surrozen is in material breach of this Agreement, then The Regents shall give written
notice of the breach (&#147;<B>Notice of Breach</B>&#148;) to Surrozen such Notice of Breach describing the alleged material breach in sufficient detail to put Surrozen on notice. If Surrozen fails to repair the material breach within sixty
(60)&nbsp;days of receipt of the Notice of Breach, then The Regents will have the right to immediately terminate this Agreement and its licenses by providing a written notice of termination (&#147;<B>Notice of Termination</B>&#148;) to Surrozen.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;TERMINATION BY OPTIONEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1&nbsp;&nbsp;&nbsp;&nbsp;Surrozen has the right to terminate this Agreement at any time by providing a Notice of Termination to The Regents.
Termination of this Agreement will be effective sixty (60)&nbsp;days from the effective date of such notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 9
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;DISPOSITION OF BIOLOGICAL MATERIALS ON HAND UPON TERMINATION OR
EXPIRATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1&nbsp;&nbsp;&nbsp;&nbsp;Surrozen must destroy any Biological Materials in its possession within [****] after any of
the following events have occurred: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>10.1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date the termination of this Agreement takes effect, prior to expiration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>10.1.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Agreement has not been terminated earlier, the date of expiration of this Agreement takes effect, if
Surrozen has not exercised the Option according to the provisions of Article 4 (Exercise of the Option); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>10.1.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the termination of negotiations where Surrozen exercised the Option in accordance with Article 4 (Exercise of
the Option), but negotiations between The Regents and Surrozen were terminated without an agreement on the terms of the Commercial License Agreement being reached. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2&nbsp;&nbsp;&nbsp;&nbsp;Surrozen will provide The Regents within [****] following the destruction of the Biological Materials with written
notice that they have been destroyed. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11.&nbsp;&nbsp;&nbsp;&nbsp;USE OF NAMES AND TRADEMARKS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1&nbsp;&nbsp;&nbsp;&nbsp;Nothing contained in this Agreement confers any right to use in advertising, publicity or other promotional
activities any name, trade name, trademark or other designation of either Party hereto (including contraction, abbreviation or simulation of any of the foregoing). Without Surrozen&#146;s consent <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case,</FONT></FONT> The Regents may list Surrozen&#146;s name as a licensee of technology from The Regents without further identifying the technology. Unless required by law or unless consented to in writing by
Executive Director, Office of Technology Transfer of The Regents, the use by Surrozen of the name &#147;<B>The Regents of the University of California</B>&#148; or the name of any campus of the University of California in advertising, publicity or
other promotional activities is expressly prohibited. Notwithstanding the foregoing, Surrozen shall be permitted to acknowledge in a scientific publication, consistent with standard practice for such publications, the source of the Biological
Materials. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>12.&nbsp;&nbsp;&nbsp;&nbsp;CONFIDENTIALITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.1&nbsp;&nbsp;&nbsp;&nbsp;Each Party agrees that, during the Term and for a period of [****] thereafter, a Party (the &#147;<B>Receiving
Party</B>&#148;) receiving proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> inventions, Biological Materials, business, patent prosecution, software, engineering drawings, process and technical information, and other proprietary
information, including the negotiated terms of this Agreement and any progress reports (&#147;<B>Proprietary Information</B>&#148;) of the other Party (the &#147;<B>Disclosing Party</B>&#148;) shall (a)&nbsp;maintain in confidence such Proprietary
Information using reasonable efforts, but not less than the efforts such Receiving Party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 10
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">uses to maintain in confidence its own proprietary information of similar kind and value, (b)&nbsp;not
disclose such Proprietary Information to any third party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted in this Article 12 (Confidentiality), and (c)&nbsp;not use such Proprietary Information
for any purpose except those permitted by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.2&nbsp;&nbsp;&nbsp;&nbsp;Surrozen and The Regents may use and disclose
Proprietary Information to their employees, agents, consultants, contractors, lawyers, investment bankers and potential investors provided that such parties are bound by a like duty of confidentiality as that found in this Article 12
(Confidentiality). Notwithstanding anything to the contrary contained in this Agreement, The Regents may disclose this Agreement as required pursuant to the California Public Records Act or other applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.3&nbsp;&nbsp;&nbsp;&nbsp;All written Proprietary Information will be labeled or marked confidential or proprietary. If the Proprietary
Information is orally disclosed, it will be reduced to writing or some other physically tangible form, marked, and labeled as confidential or proprietary by the disclosing party, and delivered to the receiving party within [****] after the oral
disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.4&nbsp;&nbsp;&nbsp;&nbsp;Nothing contained herein will in any way restrict or impair the right of Surrozen or The Regents
to use or disclose any Proprietary Information that the Receiving Party can show by written documentation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>12.4.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">was previously known to it prior to its disclosure by the Disclosing Party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>12.4.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is now, or becomes in the future, public knowledge other than through acts or omissions of Receiving Party;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>12.4.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">was lawfu1ly obtained without restrictions on the Receiving Party from sources independent of the Disclosing
Party; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>12.4.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that The Regents is required to disclose pursuant to the California Public Records Act or other applicable law
(subject to Section&nbsp;12.5(ii)). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.5&nbsp;&nbsp;&nbsp;&nbsp;Surrozen or The Regents may also use or disclose
Proprietary Information that is required to be disclosed (i)&nbsp;to a governmental entity or agency in connection with seeking any governmental or regulatory approval, governmental audit, or other governmental contractual requirement or
(ii)&nbsp;by law, provided that the Receiving Party uses reasonable efforts to give the c sufficient notice of such required disclosure to allow the Disclosing Party reasonable opportunity to object to, and to take legal action to prevent, such
disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.6&nbsp;&nbsp;&nbsp;&nbsp;Upon any termination of this Agreement, Surrozen and The Regents will destroy or return any of
the Disclosing Party&#146;s Proprietary Information in its possession within [****] following the termination of this Agreement. Surrozen and The Regents will provide each other, within [****] following termination, with written notice that such
Proprietary Information has been returned or destroyed. Each Party may, however, retain one copy of such Proprietary Information for archival purposes in <FONT STYLE="white-space:nowrap">non-working</FONT> files. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page <B>11</B> of
<B>21</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.7&nbsp;&nbsp;&nbsp;&nbsp;With regard to the Biological Materials, Surrozen agrees: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>12.7.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not to use the Biological Materials except for the sole purpose of performing under the terms of this
Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>12.7.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not to transfer the Biological Materials to others (except to its employees, agents, CROs or consultants who
are bound to Surrozen by like obligations conditioning and restricting access, use and continued use of Biological Material) without the express written permission of The Regents, except that Surrozen is not prevented from transferring any
Biological Material that is lawfully obtained by the Surrozen from sources independent of The Regents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>12.7.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to safeguard the Biological Materials against disclosure and transmission to others with the same degree of
care as it exercises with its own biological materials of similar nature; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>12.7.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to destroy all copies of the Biological Materials at the termination or expiration of this Agreement within
[****] following the effective date of such termination or expiration. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>13.&nbsp;&nbsp;&nbsp;&nbsp;LIMITED WARRANTY
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.1&nbsp;&nbsp;&nbsp;&nbsp;The Regents warrants to Surrozen that it has the lawful right to grant this option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.2&nbsp;&nbsp;&nbsp;&nbsp;Except as expressly set forth in this Agreement, the licenses and the associated Invention and any Biological
Materials are provided by The Regents WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. THE REGENTS MAKES NO EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY THAT THE
INVENTION, PRODUCTS OR BIOLOGICAL MATERIALS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR OTHER RIGHTS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.3&nbsp;&nbsp;&nbsp;&nbsp;This Agreement does not: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>13.3.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">express or imply a warranty or representation as to the validity, enforceability, or scope of any Technology
Rights; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>13.3.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">express or imply a warranty or representation that anything made, used, Sold, offered for Sale or imported or
otherwise disposed of under any license from The Regents is or will be free from infringement of patents, copyrights, or other rights of third parties; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page <B>12</B> of
<B>21</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>13.3.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">obligate The Regents to bring or prosecute actions or suits against third parties for patent infringement; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>13.3.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">confer by implication, estoppel or otherwise any license or rights under any patents or other rights of The
Regents; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>13.3.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">obligate The Regents to furnish any <FONT STYLE="white-space:nowrap">know-how,</FONT> technology or information
not provided in Biological Materials or Technology Rights; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>13.3.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">obligate The Regents to update the technology in Technology Rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>14.&nbsp;&nbsp;&nbsp;&nbsp;LIMITATION OF LIABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.1 &nbsp;&nbsp;&nbsp;&nbsp;THE REGENTS WILL NOT BE LIABLE FOR ANY LOST PROFITS, COSTS Of PROCURING SUBSTITUTE GOODS OR SERVICES, LOST
BUSINESS, ENHANCED DAMAGES FOR INTELLECTUAL PROPERTY INFRINGEMENT OR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR OTHER SPECIAL DAMAGES SUFFERED BY SURROZEN ARISING OUT OF OR RELATED TO THIS AGREEMENT FOR ALL CAUSES OF ACTION OF ANY KIND
(INCLUDING TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF THE REGENTS HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>15.&nbsp;&nbsp;&nbsp;&nbsp;INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.1&nbsp;&nbsp;&nbsp;&nbsp;Surrozen will indemnify, hold harmless and defend The Regents and its officers, employees and agents, the sponsors
of the research that led to the Invention and the development of the Original Materials (to the extent of their sponsorship of the research), and the inventors of the Original Materials and their employers against any and all claims, suits, losses,
damage, costs, fees and expenses resulting from, or arising out of, this Agreement, including, but not be limited to, product liability (&#147;<B>Claims</B>&#148;), provided such Claims do not arise due to The Regents&#146; gross negligence or
willful misconduct. Surrozen will not use or test the Biological Materials, including the Identified Antibody(ies) or Derivative Antibody(ies), or the Products on or in human subjects. If there is a conflict of interest or The Regents&#146; believes
it will not otherwise be adequately represented by counsel chosen by the Surrozen to defend The Regents in accordance with this Paragraph 15.1, then The Regents may retain counsel of its choice to represent it, and Surrozen will pay all expenses for
such representation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page <B>13</B> of
<B>21</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.2&nbsp;&nbsp;&nbsp;&nbsp;During the term of this Agreement and for [****] following its
termination or expiration, the Surrozen, at its sole cost and expense, will insure its activities in connection with any work performed hereunder and will obtain and maintain the following insurance (or an equivalent program of self insurance): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>15.2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Comprehensive or commercial form general liability insurance (contractual liability included) with limits as
follows: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="60%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Each Occurrence</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[****]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Personal and Advertising Injury</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[****]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">General Aggregate (commercial form only)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[****]</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>15.2.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The coverage referred to in Paragraph 15.2. above will not in any way limit the liability of Surrozen. Surrozen
will furnish The Regents with certificates of insurance evidencing compliance with all requirements. Such certificates will: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Provide for [****] advance written notice to The Regents of any material modification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Indicate that The Regents are included as an additional insured under the coverage described above; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Include a provision that the coverage will be primary and will not participate with, nor will be excess over, any
valid and collectable insurance or program of self-insurance maintained by The Regents. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.3&nbsp;&nbsp;&nbsp;&nbsp;The
Regents will promptly notify Surrozen in writing of any claim or suit brought against The Regents for which The Regents intends to invoke the provisions of this Article 15 (Indemnification). The Surrozen will keep The Regents informed on a current
basis of its defense of any claims pursuant to this Article 15 (Indemnification). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16.&nbsp;&nbsp;&nbsp;&nbsp;NOTICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.1&nbsp;&nbsp;&nbsp;&nbsp;Any notice or payment required to be given to either Party shall be deemed to have been properly given and to be
effective as of the date specified below if delivered to the respective address given below or to another address as designated by written notice given to the other party: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>16.1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the date of delivery if delivered in person; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>16.1.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the date of mailing if mailed by first-class certified mail, postage paid; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>16.1.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the date of mailing if mailed by any global express carrier service that requires recipient to sign the
documents demonstrating the delivery of such notice or payment. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman"><B>In the case of Surrozen: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">[****] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page <B>14</B> of
<B>21</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman"><B>In the case of The Regents: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman"><B><I>For notices: </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman"><B><I>For remittance of
payments: </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>17.&nbsp;&nbsp;&nbsp;&nbsp;ASSIGNABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement is personal to Surrozen. Surrozen may not assign or transfer this Agreement without The Regents&#146; prior written consent
except that such consent will not be required in the case of assignment or transfer to a party that succeeds to all or substantially all of Surrozen&#146;s business or assets relating to this Agreement, whether by sale, merger, operation of law or
otherwise, provided that such assignee or transferee promptly agrees to be bound by the terms and conditions of this Agreement and signs The Regents&#146; standard substitution of party letter (the form of which is attached hereto as Exhibit B). Any
attempted assignment by Surrozen in violation of this Article 17 (Assignability) will be null and void. This Agreement is binding upon and will inure to the benefit of The Regents, its successors and assigns. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>18.&nbsp;&nbsp;&nbsp;&nbsp;WAIVER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No waiver by either party of any breach or default of any of the covenants or agreements contained herein will be deemed a waiver as to any
subsequent and/or similar breach or default. No waiver will be valid or binding upon the parties unless made in writing and signed by a duly authorized officer of each party. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>19.&nbsp;&nbsp;&nbsp;&nbsp;FORCE MAJEURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.1&nbsp;&nbsp;&nbsp;&nbsp;Except for Surrozen&#146;s obligation to make any payments to The Regents hereunder, the Parties shall not be
responsible for any failure to perform due to the occurrence of any events beyond their reasonable control which render their performance impossible or onerous, including, but not limited to: accidents (environmental, toxic spill, etc.); acts of
God; biological or nuclear incidents; casualties; earthquakes; fires; floods; governmental acts; orders or restrictions; inability to obtain suitable and sufficient labor, transportation, fuel and materials; local, national or state emergency; power
failure and power outages; acts of terrorism; strike; and war. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page <B>15</B> of
<B>21</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.2&nbsp;&nbsp;&nbsp;&nbsp;Either Party to this Agreement however, will have the right to
terminate this Agreement upon [****] prior written notice if either party is unable to fulfill its obligations under this Agreement due to any of the causes mentioned in Paragraph 19.1 for a period of [****]. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>20.&nbsp;&nbsp;&nbsp;&nbsp;GOVERNING LAWS; VENUE; ATTORNEYS FEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.1&nbsp;&nbsp;&nbsp;&nbsp;THIS AGREEMENT WILL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, excluding
any choice of law rules that would direct the application of the laws of another jurisdiction and without regard to which party drafted particular provisions of this Agreement, but the scope and validity of any patent or patent application will be
governed by the applicable laws of the country of such patent or patent application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.2&nbsp;&nbsp;&nbsp;&nbsp;Any legal action brought
by the parties hereto relating to this Agreement will be conducted in San Francisco, California. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.3&nbsp;&nbsp;&nbsp;&nbsp;[****] </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>21.&nbsp;&nbsp;&nbsp;&nbsp;GOVERNMENT APPROVAL OR REGISTRATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this Agreement or any associated transaction is required by the law of any nation to be either approved or registered with any governmental
agency, Surrozen will assume all legal obligations to do so. Surrozen will notify The Regents if it becomes aware that this Agreement is subject to a United States or foreign government reporting or approval requirement. The Surrozen will make all
necessary filings and pay all costs including fees, penalties and all other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs associated with such reporting or approval process. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>22.&nbsp;&nbsp;&nbsp;&nbsp;COMPLIANCE WITH LAWS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Surrozen shall comply with all applicable international, national, state, regional and local laws and regulations in performing its
obligations hereunder and in its use, manufacture, or import of the Biological Materials. Surrozen will observe all applicable United States and foreign laws with respect to the transfer of Biological Materials and related technical data to foreign
countries, including, without limitation, the International Traffic in Arms Regulations (ITAR) and the Export Administration Regulations. Surrozen shall manufacture Biological Materials in compliance with applicable government importation laws and
regulations of a particular country for Biological Materials made outside the particular country in which such Biological Materials are made or used. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 16
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>23.&nbsp;&nbsp;&nbsp;&nbsp;MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.1&nbsp;&nbsp;&nbsp;&nbsp;The headings of the several sections are inserted for convenience of reference only and are not intended to be a
part of or to affect the meaning or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.2&nbsp;&nbsp;&nbsp;&nbsp;This Agreement is not binding upon the
Parties until it has been signed below by each Party. It is then effective as of the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.3&nbsp;&nbsp;&nbsp;&nbsp;No
amendment or modification hereof is valid or binding upon the patties unless made in writing and signed on behalf of each Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.4&nbsp;&nbsp;&nbsp;&nbsp;This Agreement embodies the entire understanding of the Patties and supersedes all previous communications,
representations and understandings, either oral or written, between the Patties relating to the subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.5&nbsp;&nbsp;&nbsp;&nbsp;In case any of the provisions contained in this Agreement is held to be invalid, illegal or unenforceable in any
respect, then such invalidity, illegality or unenforceability will not affect any other provisions of this agreement and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained in it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.6&nbsp;&nbsp;&nbsp;&nbsp;No provisions of this Agreement are intended or shall be construed to confer upon or give to any person or entity
other than The Regents and the Surrozen any rights, remedies or other benefits under, or by reason of, this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.7&nbsp;&nbsp;&nbsp;&nbsp;In performing their respective duties under this Agreement, each of the parties will be operating as an
independent contractor. Nothing contained herein will in any way constitute any association, partnership, or joint venture between the parties hereto, or be construed to evidence the intention of the patties to establish any such relationship.
Neither party will have the power to bind the other party or incur obligations on the other party&#146;s behalf without the other party&#146;s prior written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Remainder of page intentionally left blank. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signatures follow on next page </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 17
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Regents and Surrozen have executed this Agreement by their duly authorized
representatives, on the day and year written below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SURROZEN, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ <FONT STYLE="white-space:nowrap">Wen-Chen</FONT> Yeh</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gonzalo Bariera Hernandez</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Signature)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Signature)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Wen-Chen</FONT> Yeh</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Gonzalo Bariera Hernandez, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Please print)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Please print)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CSO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Associate Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Innovation Ventures, UCSF</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1/17/2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1/23/2020</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 18
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREED-UPON TERM SHEET FOR THE COMMERCIAL LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR PRODUCTS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UC CASE NO.
[****] </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This exhibit represents only a summary of certain agreed upon terms and is intended solely as a basis for completing a
Commercial License Agreement. While the terms set forth herein have been agreed to by Surrozen and The Regents, the Parties acknowledge and agree additional terms remain to be negotiated. For purpose of clarification, the Parties agree the terms set
forth herein shall be included in the Commercial License Agreement. This term sheet is not binding. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Scope of the Commercial License Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent permitted by law, a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> worldwide license under The Regents&#146; property
rights in the Biological Materials to make, use, sell, offer for sale and import Products used in the treatment, palliation, diagnosis or prevention of any human or animal disease.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The right to sublicense to third parties the rights granted to licensee under the
Commercial License Agreement through multiple tiers.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Commercial License Agreement Issue Fee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****], <FONT STYLE="white-space:nowrap">non-refundable</FONT> and <FONT STYLE="white-space:nowrap">non-</FONT> creditable, due within [****] of the effective date of the license agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Commercial License Agreement Annual Maintenance Fee (AMF)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****], non -refundable and <FONT STYLE="white-space:nowrap">non-creditable,</FONT> due on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the effective date of the Commercial License and due annually on each
subsequent anniversary and ending upon the first commercial sale of a Product.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Commercial License Agreement Earned Royalties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">An earned royalty of [****] of net sales of any Product, whether sold by Surrozen or any of its <FONT STYLE="white-space:nowrap">Sub-licensees.</FONT> [****]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commercial License</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Agreement Annual Minimum
Royalties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****] per year beginning with the year of first commercial sale of a Product. Creditable against earned royalties in the same calendar year and <FONT STYLE="white-space:nowrap">pro-rated</FONT> in the first year</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Commercial License Agreement Milestone Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Diligence Terms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">To be discussed and mutually agreed.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Miscellaneous</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Standard UC language for Use of Names, Limited Warranties, Indemnification and Insurance.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 19
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B: CONSENT TO SUBSTITUTION OF PARTY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This substitution of parties (&#147;<B>Agreement</B>&#148;) is effective this&nbsp;&nbsp;&nbsp;&nbsp;day of , 20_, among The Regents of the University of
California (&#147;The Regents), a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, CA 94607-5200, and acting through its Office of Innovation, Technology, and Alliances, University of
California San Francisco, 3333 California Street, Suite <FONT STYLE="white-space:nowrap">S-</FONT> 11, San Francisco, CA 94143-1209; Surrozen (&#147;Surrozen&#148;), a Delaware corporation, having a principal place of business at
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; and [new licensee name][(&#147;YYY&#148;)] a
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;corporation, having a principal place of business at
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BACKGROUND </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Regents and Surrozen entered into a license agreement effective
<U></U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (UC Control No._-_-_), entitled Option Agreement between The Regents of the University of California and Surrozen for Llama Single Domain
Antibody Phage Library under UC Case No. [****] (&#147;Option Agreement&#148;), wherein Surrozen was granted certain rights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Surrozen desires that [YYY] be substituted as &#147;Surrozen&#148; (defined in the Option Agreement) in place
of Surrozen, and The Regents is agreeable to such substitution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[YYY] has read the Option Agreement and agrees to abide by its terms and conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The parties agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[YYY] assumes all liability and obligations under the Option Agreement and is bound by all its terms in all
respects as if it were the original &#147;<B>Surrozen</B>&#148; of the Option Agreement in place of Surrozen. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[YYY] is substituted for Surrozen, provided that [YYY] assumes all liability and obligations under the Option
Agreement as if [YYY] were the original party named as &#147;<B>Surrozen</B>&#148; as of the effective date of the Option Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Regents releases Surrozen from all liability and obligations under the Option Agreement arising before or
after the effective date of this Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties have executed this Agreement in triplicate originals by their respective
authorized officers on the following day and year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 20
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SURROZEN, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(Signature)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(Signature)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(Please print)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(Please print)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>[YYY] COMPANY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Signature)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Please print)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 21</B>
of<B> 21 </B></P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>4
<FILENAME>d40894dex1010.htm
<DESCRIPTION>EX-10.10
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.10 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I)&nbsp;NOT MATERIAL AND (II)&nbsp;THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDED AND RESTATED </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">LICENSE AND OPTION AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">between </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SURROZEN </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">for </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Human Na&iuml;ve Fab Library </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">UC
Case No. [****] </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS</B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Article&nbsp;No.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BACKGROUND</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>DEFINITIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>GRANT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>OPTION FEES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>EXERCISE OF THE OPTION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>TERMS OF THE PROPOSED COMMERCIAL LICENSE AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PROGRESS REPORTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>LIFE OF THE AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>TERMINATION BY THE REGENTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>TERMINATION BY OPTIONEE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>DISPOSITION OF BIOLOGICAL MATERIALS ON HAND UPON TERMINATION OR EXPIRATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>USE OF NAMES AND TRADEMARKS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CONFIDENTIALITY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>LIMITED WARRANTY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>LIMITATION OF LIABILITY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>INDEMNIFICATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>NOTICES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ASSIGNABILITY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>WAIVER</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>FORCE MAJEURE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">20.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>GOVERNING LAWS; VENUE; ATTORNEYS FEES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>GOVERNMENT APPROVAL OR REGISTRATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">22.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>COMPLIANCE WITH LAWS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>MISCELLANEOUS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EXHIBIT A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EXHIBIT B: CONSENT TO SUBSTITUTION OF PARTY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDED AND RESTATED LICENSE AND OPTION AGREEMENT FOR </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">UC Case No [****] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#147;Human
Na&iuml;ve Fab Library&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This amended and restated license and option agreement (&#147;<B>Agreement</B>&#148;) is effective this 17th
day of January, 2020 (&#147;<B>Amended and Restated Effective Date</B>&#148;), between <B>The Regents of the University of California</B> (&#147;<B>The Regents</B>&#148;), a California corporation, having its statewide administrative offices at 1111
Franklin Street, 12th Floor, Oakland, California 94607-5200, and acting through its Office of Technology Management, University of California San Francisco, 600 16th Street, Suite <FONT STYLE="white-space:nowrap">S-272,</FONT> San Francisco, CA
94143 and <B>Surrozen, Inc.</B>, a Delaware corporation, having a principal place of business at 171 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080 (&#147;<B>Surrozen</B>&#148;). The Regents and Surrozen are sometimes referred to
herein individually as a &#147;Party&#148; and collectively as the &#147;Parties.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BACKGROUND </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;Certain inventions, generally characterized as the Human Na&iuml;ve Fab Library and disclosed in UC Case No. [****]
(&#147;<B>Invention</B>&#148;), are covered by the Technology Rights (as defined in Paragraph 1.12 below) and were made in the course of research at the University of California, San Francisco by [****]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B.&nbsp;&nbsp;&nbsp;&nbsp;Development of the Invention was sponsored by The National Institutes of Health (&#147;<B>NIH</B>&#148;) and as a consequence, this
Agreement, any Commercial License Agreement, and the Invention are subject to overriding obligations to the United States Federal Government under 35 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">200-212</FONT> and applicable regulations
including a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">non-transferable,</FONT> irrevocable, <FONT STYLE="white-space:nowrap">paid-up</FONT> license to practice or have practiced the Invention for or on
behalf of the United States Government throughout the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C.&nbsp;&nbsp;&nbsp;&nbsp;The Regents elected on [****] to retain title and granted the
aforementioned licenses to the United States Government. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">D.&nbsp;&nbsp;&nbsp;&nbsp;Surrozen wishes to use the Biological Material under the Agreement to
discover Identified Antibodies and to determine its interest in exercising its option to obtain a commercial license to develop and commercialize the Identified Antibody(ies) or Derivative Antibody(ies). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E.&nbsp;&nbsp;&nbsp;&nbsp;The Regents wishes to grant Surrozen the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license and the option so that the
Invention is used to discover and develop Identified Antibodies or Derivative Antibody(ies), if any, for the benefit of the general public by treating serious disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">F.&nbsp;&nbsp;&nbsp;&nbsp;The Regents and Surrozen entered into a License and Option Agreement dated September&nbsp;30, 2016 (the &#147;<B>Effective
Date</B>&#148;) with UC Agreement Control No. [****] (&#147;<B>Original Agreement</B>&#148;). The Regents and Surrozen also entered into a first amendment effective October&nbsp;17, 2018 (UC Agreement Control No. [****]) (&#147;<B>First
Amendment</B>&#148;) to allow for an additional transfer of Original </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 1
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Materials and an associated scientific protocol to Surrozen. Surrozen and The Regents now desire to amend and restate the Original Agreement in its entirety with this Agreement for the purpose of
updating the option and terms of the proposed Commercial License Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;DEFINITIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Antibody(ies)</B>&#148; means a protein or immunoglobulin that binds to an antigen or target of interest
through a complementarity determining region (&#147;<B>CDR</B>&#148;), or any fragment of such protein, including, but not limited to, an antibody, antibody fragment, [****]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Biological Materials</B>&#148; means: (a)&nbsp;the Original Materials and their Progeny;
(b)&nbsp;Unmodified Derivatives; (c)&nbsp;Identified Antibody(ies); or (d)&nbsp;Derivative Antibody(ies). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Commercial License Agreement</B>&#148; means the license agreement as more fully described in Article 5
and Exhibit A (Terms of the Proposed Commercial License Agreement) by and between The Regents and Surrozen that may result if Surrozen exercises its option under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>CRO</B>&#148; means a contract research organization under contract with Surrozen to perform research for
or on behalf of Surrozen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Derivative Antibody</B>&#148; means an Antibody that is the result of
Surrozen&#146;s (i)&nbsp;research, development or optimization efforts using an Identified Antibody as a starting compound, [****], or (ii)&nbsp;combining an Identified Antibody with a third-party Antibody, [****]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Field of Use</B>&#148; means the use of the Biological Materials for internal research, drug discovery and
screening by Surrozen on Surrozen&#146;s own premises or by a CRO on behalf of Surrozen, to identify Antibodies against targets of interest and to test such Antibodies in vitro and in vivo (in animal models) as candidates for further development.
The Field of Use specifically excludes (i)&nbsp;the Sale, transfer, lease, exchange or other disposition or provision of Biological Materials, including but not limited to the Original Materials, or Product(s); (ii) any use in humans of the
Biological Materials or Product(s); (iii) the use or testing of the Products in any clinical trials; and (iv)&nbsp;the modification, in any way, of the Original Materials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 2
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.7&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Identified Antibody(ies)</B>&#148; means a) an Antibody
identified, produced or derived from the Biological Materials by Surrozen, b) a polynucleotide encoding the Antibody described in a) above, or c) the amino acid or nucleotide sequence of the CDR of the Antibody described in a) above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.8&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Original Materials</B>&#148; means the Human Fab Na&iuml;ve Phage Display Library developed by [****] and
described in the following publication: [****]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.9&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Product</B>&#148; means any article of manufacture,
composition of matter, material, compound, component or product that consists of, contains or incorporates Identified Antibody(ies) or Derivative Antibody(ies). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.10&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Progeny</B>&#148; means descendants from the Original Materials, Progeny and/or Unmodified Derivatives,
including those with mutations such as: virus from virus; cell from cell; or organism from organism. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.11&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Sale</B>&#148; means the act of selling, leasing or otherwise transferring, providing, or furnishing for
use for any financial consideration. Correspondingly, &#147;<B>Sell</B>&#148; means to make or cause to be made a Sale, and &#147;<B>Sold</B>&#148; means to have made or caused to be made a Sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.12&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Technology Rights</B>&#148; means (i)&nbsp;The Regents&#146; personal property rights in the Biological
Materials; and (ii)&nbsp;The Regents&#146; personal proprietary rights in the existing <FONT STYLE="white-space:nowrap">know-how</FONT> associated with the Biological Materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.13&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Unmodified Derivative(s)</B>&#148; means a substance(s) derived from the Original Materials, Progeny or
Unmodified Derivatives that constitutes an unmodified functional subunit or derivative of the Original Materials, Progeny or Unmodified Derivatives, [****]. For the avoidance of doubt, Unmodified Derivatives shall not include any Antibody (ies)
identified by Licensee through screening the Original Materials, Progeny or Unmodified Derivatives. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;GRANT
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Supply</B>. The Regents, and Surrozen acknowledge that a viable sample of the existing Original
Materials (or an equivalent thereof), has been provided to Surrozen. Surrozen is responsible for any handling and shipping costs associated with the provision of any additional samples of Original Materials to Surrozen. Surrozen may use such
Original Materials solely as necessary to exercise the rights granted to Surrozen hereunder; provided, however, in no event may Surrozen Sell, transfer, lease, exchange or otherwise dispose of or provide such Original Materials and/or any Biological
Materials to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 3
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any third party except solely as provided for in Paragraph 2.11. Surrozen shall notify The Regents if Surrozen receives any biological material from [****] or any representative of The Regents
that is not Original Materials. Surrozen may not use such biological material without the written permission of The Regents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2&nbsp;&nbsp;&nbsp;&nbsp;<B><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> License</B>. Subject to the limitations and other terms
and conditions set forth in this Agreement, including the license granted to the United States Government as set forth in the recitals and in Paragraph 2.4, The Regents grants Surrozen, under the Technology Rights, the
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> right to make (propagate) and use the Biological Materials only in the Field of Use, in the United States and in other countries where The Regents may lawfully grant such licenses, solely to
provide Surrozen the opportunity to discover Identified Antibodies and determine its interest in a Commercial License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Option</B>. Subject to the limitations and other terms and conditions set forth in this Agreement, including the
license granted to the United States Government as set forth in the recitals and in Paragraph 2.4, The Regents grants Surrozen a time-limited right to negotiate in good faith the terms of the Commercial License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4&nbsp;&nbsp;&nbsp;&nbsp;<B>U.S. Government Rights</B>. The rights and licenses granted hereunder are subject to the overriding obligations
to the United States Government under 35 USC&#167;&#167; <FONT STYLE="white-space:nowrap">200-212</FONT> and all applicable governmental implementing regulations, as amended from time to time, including the obligation to report on the utilization of
the Invention as set forth in 37 CFR.&#167; 401.14(h), and all applicable provisions of any license to the United States Government executed by The Regents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5&nbsp;&nbsp;&nbsp;&nbsp;<B>Limitations</B>. The rights and licenses granted in Paragraphs 2.1, 2.2 and 2.3 do not constitute a license to
make or use Identified Antibodies or Derivative Antibodies except for the sole purpose of conducting an evaluation to determine the interest by Surrozen in exercising the rights granted in Paragraph 2.3 above. The right to test in clinical trials,
import, offer for Sale, and Sell Biological Materials or Product(s) is expressly excluded from this Agreement. Unless there is an executed and active Commercial License Agreement between the parties covering the subject Identified Antibody,
Derivative Antibody or Product, Surrozen is prohibited from filing an Investigational New Drug (IND) application with the FDA (or a similar application with a foreign regulatory authority) on any Identified Antibody, Derivative Antibody, or Product.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6&nbsp;&nbsp;&nbsp;&nbsp;<B>Patent Filings</B>. Inventorship of inventions conceived or reduced to practice in the course of activities
performed under or contemplated by this Agreement shall be determined under U.S. patent laws pertaining to inventorship. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7&nbsp;&nbsp;&nbsp;&nbsp;<B>Title</B>. Title in and to the Original Materials, Progeny and Unmodified Derivatives and any rights, including
any and all intellectual property rights, relating thereto is owned by The Regents and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 4
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is not transferred to Surrozen under this Agreement. Surrozen will own any Derivative Antibody(ies), except that The Regents retains ownership of any Original Materials, Progeny, and Unmodified
Derivatives, as well as portions of Unmodified Derivatives contained or incorporated in any such Derivative Antibody. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.8&nbsp;&nbsp;&nbsp;&nbsp;<B>The Regents&#146; Retention of Rights</B>. The Regents reserves and retains the right (and the rights granted to
Surrozen in this Agreement shall be limited accordingly) to make, use and practice the Invention, the Technology Rights, and the Original Materials, Progeny and Unmodified Derivatives and any technology relating to any of the foregoing created by
The Regents for educational and research purposes, including without limitation, any sponsored research performed for or on behalf of commercial entities and including publication and other communication of any research results. Surrozen understands
that the right of The Regents to transfer the Original Materials, Progeny and Unmodified Derivatives to other educational and <FONT STYLE="white-space:nowrap">non-profit</FONT> institutions as provided for in this Paragraph 2.8 could lead to the
inadvertent loss or diminution of the proprietary and commercial value of the Original Material, Progeny and Unmodified Derivatives and that such loss or diminution does not affect the consideration Surrozen is to convey to The Regents hereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9&nbsp;&nbsp;&nbsp;&nbsp;<B>Additional Licenses</B>. Subject to Section&nbsp;4.2, The Regents is free to issue additional licenses
under the Technology Rights and to the Original Materials and any biological materials made from the Original Materials for commercial or <FONT STYLE="white-space:nowrap">non-commercial</FONT> purposes and is free to transfer the Original Materials
and any biological materials made from the Original Materials to third parties, except The Regents shall not transfer the Derivative Antibodies to a Third Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.10&nbsp;&nbsp;&nbsp;&nbsp;<B>No Right to Sublicense</B>. This Agreement specifically excludes the right to sublicense, except as permitted
under Paragraph 2.11 (CROs) below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.11&nbsp;&nbsp;&nbsp;&nbsp;<B>CROs</B>. Surrozen&#146;s right to transfer possession of the
Biological Materials and Identified Antibody(ies) and/or Derivative Antibody(ies) to third parties is expressly limited under the terms of this Agreement. Surrozen shall have the right to transfer the Biological Materials, Identified Antibody(ies)
and/or Derivative Antibody(ies) solely to CROs for the express purpose of performing research in the Field of Use on behalf of Surrozen. If Surrozen transfers any Biological Materials, Identified Antibody(ies) and/or Derivative Antibody(ies) to
CROs, it hereby agrees that such CROs shall be required to comply with the terms and conditions of this Agreement. For the purpose of this Agreement, Surrozen shall remain responsible for the performance of its rights and obligations set out in this
Agreement by such recipient CROs, including the confidentiality and material handling protections set forth in this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 5
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;OPTION FEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Option Issue Fee</B>. As partial consideration for the rights granted to Surrozen herein, Surrozen will pay The
Regents an option issue fee of [****]. The option issue fee is due The Regents within [****] of the Effective Date. The option issue fee was paid in full on [****]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Option Maintenance Fee</B>. Surrozen will also pay The Regents an option maintenance fee of [****] beginning on
the first anniversary of the Effective Date and continuing annually on each anniversary of the Effective Date until, the earlier of, either the Parties executing a Commercial License Agreement or termination of this Agreement. The option maintenance
fee is due The Regents within [****] of each anniversary of the Effective Date beginning with the first anniversary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Term Extension</B>. Upon receipt of Surrozen&#146;s notice of a request to extend the Term, the Parties may
extend the Term of this Agreement for an additional four (4)&nbsp;years by written agreement. If the Parties agree to an additional Term, Surrozen will pay an option extension fee of [****], which is due within [****] of the Parties written
agreement to extend the Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4&nbsp;&nbsp;&nbsp;&nbsp;The option issue fee, option maintenance fee and option extension fee are <FONT
STYLE="white-space:nowrap">non-refundable,</FONT> non-cancelable, <FONT STYLE="white-space:nowrap">non-creditable</FONT> and not an advance against royalties or other payments required to be paid under the terms of this Agreement or the Commercial
License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5&nbsp;&nbsp;&nbsp;&nbsp;In the event that fees or other monies owed to The Regents are not received by The Regents
when due, then Surrozen will pay The Regents interest at a rate of [****]. Such interest will be calculated from the date payment was due until actually received by The Regents. Such accrual of interest will be in addition to and not in lieu of,
enforcement of any other rights of The Regents due to such late payment. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;EXERCISE OF THE OPTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1&nbsp;&nbsp;&nbsp;&nbsp;If Surrozen elects to exercise its right to negotiate the terms of the Commercial License Agreement, then Surrozen
will notify The Regents in writing not later than [****] prior to the expiration of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2&nbsp;&nbsp;&nbsp;&nbsp;Within the
[****] following Surrozen&#146;s election to exercise its option pursuant to Paragraph 4.1, Surrozen and The Regents will begin, in good faith, to negotiate the outstanding terms and conditions of the Commercial License Agreement. The Parties shall
have a maximum of [****] from the date of election to conclude a Commercial License Agreement (&#147;<B>Negotiation Period</B>&#148;). Such Negotiation Period may be extended by written mutual agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 6 </B>of
<B>21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3&nbsp;&nbsp;&nbsp;&nbsp;The Parties mutually acknowledge that good-faith negotiations may
or may not result in the execution of the Commercial License Agreement. Neither Party will be liable to the other in the event of any termination of negotiations or failure to execute the Commercial License Agreement unless and to the extent the
other Party proves, by clear and convincing evidence, that the terms sought by such Party are so unreasonable as to clearly constitute bad faith. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;TERMS OF THE PROPOSED COMMERCIAL LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1&nbsp;&nbsp;&nbsp;&nbsp;If Surrozen exercises its rights under Paragraph 2.3, Article 3 (Option Fees), Article 4 (Exercise of the Option)
and this Article 5, then The Regents and Surrozen will thereafter negotiate, in good faith, the terms of the Commercial License Agreement. The terms of the Commercial License Agreement will include, but not be limited to, the agreed upon terms set
forth in Exhibit A and the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">5.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">confidentiality terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">5.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">indemnification by Surrozen of The Regents, the sponsors of the research that led to the Invention and the
development of the Original Materials to the extent of their sponsorship of the research, and the inventors of the Original Materials and their employers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">5.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a warranty that is limited to The Regents&#146; right to grant a license under Technology Rights as set forth
in Article 13 (Limited Warranty) hereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">5.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">limitation of liability of The Regents; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">5.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">other standard terms normally found in exclusive license agreements executed by The Regents.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2&nbsp;&nbsp;&nbsp;&nbsp;Surrozen and The Regents have agreed upon a term sheet (&#147;<B>Term Sheet</B>&#148;) which
sets forth the basic terms under which the Parties have agreed to negotiate a Commercial License Agreement, a copy of which is attached to this Agreement as Exhibit A. The Term Sheet shall not create any binding obligations on the part of either
Surrozen or The Regents to execute a Commercial License Agreement. Any rights and obligations of the Parties pursuant to the Commercial License Agreement will be subject to the negotiation and execution of the Commercial License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3&nbsp;&nbsp;&nbsp;&nbsp;The Commercial License Agreement will be subject to the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">5.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The obligations to the U.S. Government under 35 U.S.C. &#167;&#167;
<FONT STYLE="white-space:nowrap">200-212</FONT> and applicable governmental implementing regulations, as amended from time to time, including the obligation to report on the utilization of the Invention as set forth in 37 CFR. &#167; 401.14(h), and
all applicable provisions of any license to the United States Government executed by The Regents; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 7
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">5.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The National Institutes of Health &#147;Principles and Guidelines for Recipients of NIH Research Grants and
Contracts on Obtaining and Disseminating Biomedical Research Resources,&#148; 64 F.R. 72090 (Dec. 23, 1999), as amended from time to time. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;PROGRESS REPORTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1&nbsp;&nbsp;&nbsp;&nbsp;Beginning on the [****], and [****] thereafter (&#147;<B>Progress Report Due Date</B>&#148;), Surrozen will provide
to The Regents a written progress report as described in Paragraph 6.2 below covering Surrozen&#146;s activities related to the use of the Biological Material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2&nbsp;&nbsp;&nbsp;&nbsp;The progress reports will include, but are not limited to, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">6.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A summary of work completed and in progress as of the submission date, related to the use of the Biological
Material. The summary of work should provide The Regents with enough information so that The Regents may understand the usefulness and effectiveness of The Regents&#146; libraries, the success of Surrozen&#146;s screenings, and the development
status of any Identified Antibodies and Derivative Antibodies. [****] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">6.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">6.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3&nbsp;&nbsp;&nbsp;&nbsp;A progress report will be considered timely if provided to The Regents within [****] of the Progress Report Due
Date. If Surrozen fails to submit a timely progress report to The Regents, then The Regents will provide Surrozen written notice that it has failed to submit a timely progress report and Surrozen will have an additional [****] after receiving The
Regents&#146; written notice to submit the progress report. If Surrozen fails to submit a progress report during this additional [****] window, then The Regents will be entitled to terminate this Agreement in accordance with Section&nbsp;8. If
either Party terminates this Agreement before expiration, then Surrozen shall submit within [****] following termination a final progress report to cover the period up to the time of termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 8
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4&nbsp;&nbsp;&nbsp;&nbsp;In the event that Surrozen elects to extend the term of this
Agreement as provided for in Paragraph 3.3, Surrozen must continue to submit progress reports in accordance with the provisions of Paragraphs 6.1, 6.2 and 6.3 above. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;LIFE OF THE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise terminated by operation of law or by acts of the Parties in accordance with the terms of this
Agreement, this Agreement will be in force from the Effective Date and will remain in effect for four (4)&nbsp;years thereafter (the &#147;<B>Term</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2&nbsp;&nbsp;&nbsp;&nbsp;Surrozen may extend this Agreement for an additional Term in accordance with the provisions of Paragraph 3.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3&nbsp;&nbsp;&nbsp;&nbsp;This Agreement will automatically terminate without the obligation to provide sixty (60)&nbsp;days notice as set
forth in Article 8 upon the filing of a petition for relief under the United States Bankruptcy Code by or against Surrozen as a debtor or alleged debtor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4&nbsp;&nbsp;&nbsp;&nbsp;Any termination of this Agreement will not affect the rights and obligations set forth in the following Paragraph
and Articles: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Article 1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Definitions Option Fees</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Article 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Option Fees</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Article 7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Life of the Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Article 10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Disposition of Biological Materials on Hand Upon Termination or Expiration</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Article 11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Use of Names and Trademarks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Article 12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Confidentiality</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Article 13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Limited Warranty</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Article 14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Limitation of Liability</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Article 15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Indemnification</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Article 16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Notices</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Article 20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Governing Laws; Venue; Attorneys Fees</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.5&nbsp;&nbsp;&nbsp;&nbsp;Any termination or expiration of this Agreement will not relieve the Surrozen of
its obligation to pay any fees or monies, including the option fee and extension fee (if any), due or owing at the time of termination or expiration and will not impair any accrued right of The Regents. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;TERMINATION BY THE REGENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1&nbsp;&nbsp;&nbsp;&nbsp;If The Regents believes that Surrozen is in material breach of this Agreement, then The Regents shall give written
notice of the breach (&#147;<B>Notice of Breach</B>&#148;) to Surrozen such Notice of Breach describing the alleged material breach in sufficient detail to put Surrozen on notice. If Surrozen fails to repair the material breach within sixty
(60)&nbsp;days of receipt of the Notice of Breach, then The Regents will have the right to immediately terminate this Agreement and its licenses by providing a written notice of termination (&#147;<B>Notice of Termination</B>&#148;) to Surrozen.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 9
</B>of<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;TERMINATION BY OPTIONEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1&nbsp;&nbsp;&nbsp;&nbsp;Surrozen has the right to terminate this Agreement at any time by providing a Notice of Termination to The Regents.
Termination of this Agreement will be effective sixty (60)&nbsp;days from the effective date of such notice. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;DISPOSITION OF BIOLOGICAL MATERIALS ON HAND UPON TERMINATION OR EXPIRATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1&nbsp;&nbsp;&nbsp;&nbsp;Surrozen must destroy any Biological Materials in its possession within [****] after any of the following events
have occurred: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date the termination of this Agreement takes effect, prior to expiration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Agreement has not been terminated earlier, the date of expiration of this Agreement takes effect, if
Surrozen has not exercised the Option according to the provisions of Article 4 (Exercise of the Option); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the termination of negotiations where Surrozen exercised the Option in accordance with Article 4 (Exercise of
the Option), but negotiations between The Regents and Surrozen were terminated without an agreement on the terms of the Commercial License Agreement being reached. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2&nbsp;&nbsp;&nbsp;&nbsp;Surrozen will provide The Regents within [****] following the destruction of the Biological Materials with written
notice that they have been destroyed. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11.&nbsp;&nbsp;&nbsp;&nbsp;USE OF NAMES AND TRADEMARKS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1&nbsp;&nbsp;&nbsp;&nbsp;Nothing contained in this Agreement confers any right to use in advertising, publicity or other promotional
activities any name, trade name, trademark or other designation of either Party hereto (including contraction, abbreviation or simulation of any of the foregoing). Without Surrozen&#146;s consent <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case,</FONT></FONT> The Regents may list Surrozen&#146;s name as a licensee of technology from The Regents without further identifying the technology. Unless required by law or unless consented to in writing by
Executive Director, Office of Technology Transfer of The Regents, the use by Surrozen of the name &#147;The Regents of the University of California&#148; or the name of any campus of the University of California in advertising, publicity or other
promotional activities is expressly prohibited. Notwithstanding the foregoing, Surrozen shall be permitted to acknowledge in a scientific publication, consistent with standard practice for such publications, the source of the Biological Materials.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>12.&nbsp;&nbsp;&nbsp;&nbsp;CONFIDENTIALITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.1&nbsp;&nbsp;&nbsp;&nbsp;Each Party agrees that, during the Term and for a period of [****] thereafter, a Party (the &#147;<B>Receiving
Party</B>&#148;) receiving proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> inventions, Biological Materials, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 10 </B>of
<B>21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business, patent prosecution, software, engineering drawings, process and technical information, and other proprietary information, including the negotiated terms of this Agreement and any
progress reports (&#147;<B>Proprietary Information</B>&#148;) of the other Party (the &#147;<B>Disclosing Party</B>&#148;) shall (a)&nbsp;maintain in confidence such Proprietary Information using reasonable efforts, but not less than the efforts
such Receiving Party uses to maintain in confidence its own proprietary information of similar kind and value, (b)&nbsp;not disclose such Proprietary Information to any third party without the prior written consent of the Disclosing Party, except
for disclosures expressly permitted in this Article 12 (Confidentiality), and (c)&nbsp;not use such Proprietary Information for any purpose except those permitted by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.2&nbsp;&nbsp;&nbsp;&nbsp;Surrozen and The Regents may use and disclose Proprietary Information to their employees, agents, consultants,
contractors, lawyers, investment bankers and potential investors provided that such parties are bound by a like duty of confidentiality as that found in this Article 12 (Confidentiality). Notwithstanding anything to the contrary contained in this
Agreement, The Regents may disclose this Agreement as required pursuant to the California Public Records Act or other applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.3&nbsp;&nbsp;&nbsp;&nbsp;All written Proprietary Information will be labeled or marked confidential or proprietary. If the Proprietary
Information is orally disclosed, it will be reduced to writing or some other physically tangible form, marked, and labeled as confidential or proprietary by the disclosing party, and delivered to the receiving party within [****] after the oral
disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.4&nbsp;&nbsp;&nbsp;&nbsp;Nothing contained herein will in any way restrict or impair the right of Surrozen or The Regents
to use or disclose any Proprietary Information that the Receiving Party can show by written documentation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">12.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">was previously known to it prior to its disclosure by the Disclosing Party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">12.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is now, or becomes in the future, public knowledge other than through acts or omissions of Receiving Party;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">12.4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">was lawfully obtained without restrictions on the Receiving Party from sources independent of the Disclosing
Party; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">12.4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that The Regents is required to disclose pursuant to the California Public Records Act or other applicable law
(subject to Section&nbsp;12.5(ii)). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.5&nbsp;&nbsp;&nbsp;&nbsp;Surrozen or The Regents may also use or disclose
Proprietary Information that is required to be disclosed (i)&nbsp;to a governmental entity or agency in connection with seeking any governmental or regulatory approval, governmental audit, or other governmental contractual requirement or
(ii)&nbsp;by law, provided that the Receiving Party uses reasonable efforts to give the c sufficient notice of such required disclosure to allow the Disclosing Party reasonable opportunity to object to, and to take legal action to prevent, such
disclosure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page <B>11</B> of
<B>21</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.6&nbsp;&nbsp;&nbsp;&nbsp;Upon any termination of this Agreement, Surrozen and The Regents
will destroy or return any of the Disclosing Party&#146;s Proprietary Information in its possession within [****] following the termination of this Agreement. Surrozen and The Regents will provide each other, within [****] following termination,
with written notice that such Proprietary Information has been returned or destroyed. Each Party may, however, retain one copy of such Proprietary Information for archival purposes in <FONT STYLE="white-space:nowrap">non-working</FONT> files. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.7&nbsp;&nbsp;&nbsp;&nbsp;With regard to the Biological Materials, Surrozen agrees: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">12.7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not to use the Biological Materials except for the sole purpose of performing under the terms of this
Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">12.7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not to transfer the Biological Materials to others (except to its employees, agents, CROs or consultants who
are bound to Surrozen by like obligations conditioning and restricting access, use and continued use of Biological Material) without the express written permission of The Regents, except that Surrozen is not prevented from transferring any
Biological Material that is lawfully obtained by the Surrozen from sources independent of The Regents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">12.7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to safeguard the Biological Materials against disclosure and transmission to others with the same degree of
care as it exercises with its own biological materials of a similar nature; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">12.7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to destroy all copies of the Biological Materials at the termination or expiration of this Agreement within
[****] following the effective date of such termination or expiration. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>13.&nbsp;&nbsp;&nbsp;&nbsp;LIMITED WARRANTY
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.1&nbsp;&nbsp;&nbsp;&nbsp;The Regents warrants to Surrozen that it has the lawful right to grant this option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.2&nbsp;&nbsp;&nbsp;&nbsp;Except as expressly set forth in this Agreement, the licenses and the associated Invention and any Biological
Materials are provided by The Regents WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. THE REGENTS MAKES NO EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY THAT THE
INVENTION, PRODUCTS OR BIOLOGICAL MATERIALS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR OTHER RIGHTS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.3&nbsp;&nbsp;&nbsp;&nbsp;This Agreement does not: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">express or imply a warranty or representation as to the validity, enforceability, or scope of any Technology
Rights; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page <B>12</B> of
<B>2</B><B>1</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">express or imply a warranty or representation that anything made, used, Sold, offered for Sale or imported or
otherwise disposed of under any license from The Regents is or will be free from infringement of patents, copyrights, or other rights of third parties; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">obligate The Regents to bring or prosecute actions or suits against third parties for patent infringement; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">confer by implication, estoppel or otherwise any license or rights under any patents or other rights of The
Regents; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">obligate The Regents to furnish any <FONT STYLE="white-space:nowrap">know-how,</FONT> technology or information
not provided in Biological Materials or Technology Rights; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">obligate The Regents to update the technology in Technology Rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>14.&nbsp;&nbsp;&nbsp;&nbsp;LIMITATION OF LIABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.1&nbsp;&nbsp;&nbsp;&nbsp;THE REGENTS WILL NOT BE LIABLE FOR ANY LOST PROFITS, COSTS Of PROCURING SUBSTITUTE GOODS OR SERVICES, LOST
BUSINESS, ENHANCED DAMAGES FOR INTELLECTUAL PROPERTY INFRINGEMENT OR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR OTHER SPECIAL DAMAGES SUFFERED BY SURROZEN ARISING OUT OF OR RELATED TO THIS AGREEMENT FOR ALL CAUSES OF ACTION OF ANY KIND
(INCLUDING TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF THE REGENTS HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>15.&nbsp;&nbsp;&nbsp;&nbsp;INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.1&nbsp;&nbsp;&nbsp;&nbsp;Surrozen will indemnify, hold harmless and defend The Regents and its officers, employees and agents, the sponsors
of the research that led to the Invention and the development of the Original Materials (to the extent of their sponsorship of the research), and the inventors of the Original Materials and their employers against any and all claims, suits, losses,
damage, costs, fees and expenses resulting from, or arising out of, this Agreement, including, but not be limited to, product liability (&#147;Claims&#148;), provided such Claims do not arise due to The Regents&#146; gross negligence or willful
misconduct. Surrozen will not use or test the Biological Materials, including the Identified Antibody(ies) or Derivative Antibody(ies), or the Products on or in human subjects. If there is a conflict of interest or The Regents&#146; believes it will
not otherwise be adequately represented by counsel chosen by the Surrozen to defend The Regents in accordance with this Paragraph 15.1, then The Regents may retain counsel of its choice to represent it, and Surrozen will pay all expenses for such
representation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page <B>13</B> of
<B>21</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.2&nbsp;&nbsp;&nbsp;&nbsp;During the term of this Agreement and for [****] following its
termination or expiration, the Surrozen, at its sole cost and expense, will insure its activities in connection with any work performed hereunder and will obtain and maintain the following insurance (or an equivalent program of self insurance): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Comprehensive or commercial form general liability insurance (contractual liability included) with limits as
follows: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="60%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Each Occurrence</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[****]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personal and Advertising Injury</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[****]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Aggregate (commercial form only)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[****]</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The coverage referred to in Paragraph 15.2.1 above will not in any way limit the liability of Surrozen.
Surrozen will furnish The Regents with certificates of insurance evidencing compliance with all requirements. Such certificates will: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Provide for [****] advance written notice to The Regents of any material modification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Indicate that The Regents are included as an additional insured under the coverage described above; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="19%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Include a provision that the coverage will be primary and will not participate with, nor will be excess over, any
valid and collectable insurance or program of self-insurance maintained by The Regents. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.3&nbsp;&nbsp;&nbsp;&nbsp;The
Regents will promptly notify Surrozen in writing of any claim or suit brought against The Regents for which The Regents intends to invoke the provisions of this Article 15 (Indemnification). The Surrozen will keep The Regents informed on a current
basis of its defense of any claims pursuant to this Article 15 (Indemnification). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16.&nbsp;&nbsp;&nbsp;&nbsp;NOTICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.1&nbsp;&nbsp;&nbsp;&nbsp;Any notice or payment required to be given to either Party shall be deemed to have been properly given and to be
effective as of the date specified below if delivered to the respective address given below or to another address as designated by written notice given to the other party: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the date of delivery if delivered in person; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the date of mailing if mailed by first-class certified mail, postage paid; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the date of mailing if mailed by any global express carrier service that requires recipient to sign the
documents demonstrating the delivery of such notice or payment. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page <B>14</B> of
<B>21</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><B>In the case of Surrozen:</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><B>In the case of The
Regents:</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><B><I>For notices: </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><B><I>For remittance of
payments: </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>17.&nbsp;&nbsp;&nbsp;&nbsp;ASSIGNABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement is personal to Surrozen. Surrozen may not assign or transfer this Agreement without The Regents&#146; prior written consent
except that such consent will not be required in the case of assignment or transfer to a party that succeeds to all or substantially all of Surrozen&#146;s business or assets relating to this Agreement, whether by sale, merger, operation of law or
otherwise, provided that such assignee or transferee promptly agrees to be bound by the terms and conditions of this Agreement and signs The Regents&#146; standard substitution of party letter (the form of which is attached hereto as Exhibit B). Any
attempted assignment by Surrozen in violation of this Article 17 (Assignability) will be null and void. This Agreement is binding upon and will inure to the benefit of The Regents, its successors and assigns. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>18.&nbsp;&nbsp;&nbsp;&nbsp;WAIVER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No waiver by either party of any breach or default of any of the covenants or agreements contained herein will be deemed a waiver as to any
subsequent and/or similar breach or default. No waiver will be valid or binding upon the parties unless made in writing and signed by a duly authorized officer of each party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page <B>15</B> of
<B>21</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>19.&nbsp;&nbsp;&nbsp;&nbsp;FORCE MAJEURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.1&nbsp;&nbsp;&nbsp;&nbsp;Except for Surrozen&#146;s obligation to make any payments to The Regents hereunder, the Parties shall not be
responsible for any failure to perform due to the occurrence of any events beyond their reasonable control which render their performance impossible or onerous, including, but not limited to: accidents (environmental, toxic spill, etc.); acts of
God; biological or nuclear incidents; casualties; earthquakes; fires; floods; governmental acts; orders or restrictions; inability to obtain suitable and sufficient labor, transportation, fuel and materials; local, national or state emergency; power
failure and power outages; acts of terrorism; strike; and war. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.2&nbsp;&nbsp;&nbsp;&nbsp;Either Party to this Agreement however, will
have the right to terminate this Agreement upon [****] prior written notice if either party is unable to fulfill its obligations under this Agreement due to any of the causes mentioned in Paragraph 19.1 for a period of [****]. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>20.&nbsp;&nbsp;&nbsp;&nbsp;GOVERNING LAWS; VENUE; ATTORNEYS FEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.1&nbsp;&nbsp;&nbsp;&nbsp;THIS AGREEMENT WILL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, excluding
any choice of law rules that would direct the application of the laws of another jurisdiction and without regard to which party drafted particular provisions of this Agreement, but the scope and validity of any patent or patent application will be
governed by the applicable laws of the country of such patent or patent application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.2&nbsp;&nbsp;&nbsp;&nbsp;Any legal action brought
by the parties hereto relating to this Agreement will be conducted in San Francisco, California. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.3&nbsp;&nbsp;&nbsp;&nbsp;[****] </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>21.&nbsp;&nbsp;&nbsp;&nbsp;GOVERNMENT APPROVAL OR REGISTRATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this Agreement or any associated transaction is required by the law of any nation to be either approved or registered with any governmental
agency, Surrozen will assume all legal obligations to do so. Surrozen will notify The Regents if it becomes aware that this Agreement is subject to a United States or foreign government reporting or approval requirement. The Surrozen will make all
necessary filings and pay all costs including fees, penalties and all other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs associated with such reporting or approval process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page <B>16 </B>of
<B>21</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>22.&nbsp;&nbsp;&nbsp;&nbsp;COMPLIANCE WITH LAWS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Surrozen shall comply with all applicable international, national, state, regional and local laws and regulations in performing its
obligations hereunder and in its use, manufacture, or import of the Biological Materials. Surrozen will observe all applicable United States and foreign laws with respect to the transfer of Biological Materials and related technical data to foreign
countries, including, without limitation, the International Traffic in Arms Regulations (ITAR) and the Export Administration Regulations. Surrozen shall manufacture Biological Materials in compliance with applicable government importation laws and
regulations of a particular country for Biological Materials made outside the particular country in which such Biological Materials are made or used. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>23.&nbsp;&nbsp;&nbsp;&nbsp;MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.1&nbsp;&nbsp;&nbsp;&nbsp;The headings of the several sections are inserted for convenience of reference only and are not intended to be a
part of or to affect the meaning or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.2&nbsp;&nbsp;&nbsp;&nbsp;This Agreement is not binding upon the
Parties until it has been signed below by each Party. It is then effective as of the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.3&nbsp;&nbsp;&nbsp;&nbsp;No
amendment or modification hereof is valid or binding upon the parties unless made in writing and signed on behalf of each Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.4&nbsp;&nbsp;&nbsp;&nbsp;This Agreement embodies the entire understanding of the Parties and supersedes all previous communications,
representations and understandings, either oral or written, between the Parties relating to the subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.5&nbsp;&nbsp;&nbsp;&nbsp;In case any of the provisions contained in this Agreement is held to be invalid, illegal or unenforceable in any
respect, then such invalidity, illegality or unenforceability will not affect any other provisions of this agreement and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained in it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.6&nbsp;&nbsp;&nbsp;&nbsp;No provisions of this Agreement are intended or shall be construed to confer upon or give to any person or entity
other than The Regents and the Surrozen any rights, remedies or other benefits under, or by reason of, this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.7&nbsp;&nbsp;&nbsp;&nbsp;In performing their respective duties under this Agreement, each of the parties will be operating as an
independent contractor. Nothing contained herein will in any way constitute any association, partnership, or joint venture between the parties hereto, or be construed to evidence the intention of the parties to establish any such relationship.
Neither party will have the power to bind the other party or incur obligations on the other party&#146;s behalf without the other party&#146;s prior written consent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page <B>17</B> of
<B>21</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Regents and Surrozen have executed this Agreement by their duly authorized
representatives, on the day and year written below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SURROZEN, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ <FONT STYLE="white-space:nowrap">Wen-Chen</FONT> Yeh</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gonzalo Barrera Hernandez</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Signature)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Signature)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Wen-Chen</FONT> Yeh</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Gonzalo Barrera Hernandez, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Please print)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Please print)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CSO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Associate Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Innovation Ventures, UCSF</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1/17/2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1/23/2020</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page <B>18</B> of
<B>21</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREED-UPON TERM SHEET FOR THE COMMERCIAL LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR PRODUCTS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UC CASE NO.
[****] </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This exhibit represents only a summary of certain agreed upon terms and is intended solely as a basis for completing a Commercial License
Agreement. While the terms set forth herein have been agreed to by Surrozen and The Regents, the Parties acknowledge and agree additional terms remain to be negotiated. For purpose of clarification, the Parties agree the terms set forth herein shall
be included in the Commercial License Agreement. This term sheet is not binding. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="78%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Scope of the Commercial</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>License
Agreement</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent permitted by law, a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> worldwide license under The Regents&#146; property
rights in the Biological Materials to make, use, sell, offer for sale and import Products used in the treatment, palliation, diagnosis or prevention of any human or animal disease.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The right to sublicense to third parties the rights granted to licensee under the
Commercial License Agreement through multiple tiers.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercial License</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Agreement Issue
Fee</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****], <FONT STYLE="white-space:nowrap">non-refundable</FONT> and <FONT STYLE="white-space:nowrap">non-creditable,</FONT> due within [****] of the effective date of the license agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercial License</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreement
Annual</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Maintenance Fee (AMF)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****], non -refundable and <FONT STYLE="white-space:nowrap">non-creditable,</FONT> due on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the effective date of the Commercial License and due annually on each
subsequent anniversary and ending upon the first commercial sale of a Product.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercial License</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreement
Earned</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Royalties</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">An earned royalty of [****] of net sales of any Product, whether sold by Surrozen or any of its <FONT STYLE="white-space:nowrap">Sub-licensees.</FONT> [****]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercial License</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreement
Annual</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Minimum Royalties</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****] per year beginning with the year of first commercial sale of a Product. Creditable against earned royalties in the same calendar year and <FONT STYLE="white-space:nowrap">pro-rated</FONT> in the first year</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercial License</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreement
Milestone</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Payments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Diligence Terms</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">To be discussed and mutually agreed.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Miscellaneous</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Standard UC language for Use of Names, Limited Warranties, Indemnification and Insurance.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Page<B> 19
</B>o<B></B>f<B> 21 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B: CONSENT TO SUBSTITUTION OF PARTY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This substitution of parties (&#147;<B>Agreement</B>&#148;) is effective
this&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20_, among The Regents of the University of
California (&#147;The Regents&#148;), a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, CA 94607-5200, and acting through its Office of Innovation, Technology, and Alliances,
University of California San Francisco, 3333 California Street, Suite <FONT STYLE="white-space:nowrap">S-11,</FONT> San Francisco, CA 94143-1209; Surrozen (&#147;Surrozen&#148;), a Delaware corporation, having a principal place of business
at&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; and
[new licensee name] [(&#147;YYY&#148;)] a
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
corporation, having a principal place of business at&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BACKGROUND </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Regents and Surrozen entered into a license agreement
effective&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (UC Control
No&nbsp;&nbsp;&nbsp;&nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;), entitled Option Agreement between The Regents of the University of California and Surrozen for Human Na&iuml;ve Fab
Library under UC Case No. [****] (&#147;Option Agreement&#148;), wherein Surrozen was granted certain rights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Surrozen desires that [YYY] be substituted as &#147;Surrozen&#148; (defined in the Option Agreement) in place
of Surrozen, and The Regents is agreeable to such substitution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[YYY] has read the Option Agreement and agrees to abide by its terms and conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The parties agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[YYY] assumes all liability and obligations under the Option Agreement and is bound by all its terms in all
respects as if it were the original &#147;<B>Surrozen</B>&#148; of the Option Agreement in place of Surrozen. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[YYY] is substituted for Surrozen, provided that [YYY] assumes all liability and obligations under the Option
Agreement as if [YYY] were the original party named as &#147;<B>Surrozen</B>&#148; as of the effective date of the Option Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Regents releases Surrozen from all liability and obligations under the Option Agreement arising before or
after the effective date of this Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties have executed this Agreement in triplicate originals by their respective
authorized officers on the following day and year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page <B>20</B> of
<B>21</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SURROZEN, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman"><B>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(Signature)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(Signature)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(Please print)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(Please print)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>[YYY] COMPANY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Signature)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Please print)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page <B>21</B> of
<B>21</B> </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>5
<FILENAME>d40894dex1011.htm
<DESCRIPTION>EX-10.11
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.11 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE
REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Distributed Bio, Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANTIBODY LIBRARY SUBSCRIPTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Antibody Library Subscription Agreement <B>(</B><B>&#147;</B><B>Agreement</B><B>&#148;</B><B>), </B>effective as of September 30<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>, 2016 (the <B>&#147;</B><B></B><B>Effective Date</B><B>&#148;</B><B> ), </B>is made by and between Distributed Bio, Inc, a California corporation, having offices at 329 Oyster Point Blvd, 3<SUP
STYLE="font-size:85%; vertical-align:top">rd</SUP> Floor, South San Francisco, CA US 94080 <B>(</B><B>&#147;</B><B>Distributed </B><B>B</B><B>io</B><B>&#148;</B><B>) </B>and Surrozen Inc., a Delaware corporation having a principal place of business
at 1700 Owens Street, Suite 500, San Francisco, CA 94158 <B>(</B><B>&#147;</B><B></B><B>Surrozen</B><B>&#148;</B><B> ), </B>and sets forth the terms and conditions on which Distributed Bio will transfer certain materials to Surrozen and
Surrozen&#146;s use thereof. Distributed Bio and Surrozen are each referred to herein as a <B>&#147;</B><B>Party</B><B>&#148;</B><B> </B>or collectively as the<B>&#148;</B><B> </B><B>Parties</B><B>.</B><B>&#148;</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Background</U>. Distributed Bio is willing to transfer the Antibody Library for use as set forth herein. Surrozen
desires to obtain the Antibody Library for the purpose of conducting certain research related to the discovery of antibodies against biological target(s) of interest to Surrozen (the &#147;<U>Purpose</U>&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Antibody</U>&#148; means a molecule obtained by Surrozen using the Antibody Library which comprises or contains: (a)&nbsp;one or more
immunoglobulin variable domains; (b)&nbsp;fragments, variants, modifications or derivatives of such immunoglobulin variable domains, including but not limited to antigen binding portions including [****] (&#147;Derivatives&#148;) wherein said
Derivatives [****]; or (c)&nbsp;the nucleic acid consisting of a sequence of nucleotides encoding (or complementary to a nucleic acid encoding) the foregoing molecules in (a)&nbsp;or (b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Antibody Library</U>&#148; means Distributed Bio&#146;s antibody library identified on Exhibit A, and all updates and new versions of
that library provided to Surrozen by Distributed Bio during the Term of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Antibody Product</U>&#148; means any
Antibody that includes a complementarity determining region derived by Surrozen from an Antibody in the Antibody Library, including fragments, variants, modifications and derivatives thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Development</U>&#148; means <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical drug development activities reasonably
relating to the discovery and development of pharmaceutical compounds and submission of information to a Regulatory Authority, including without limitation toxicology, pharmacology, and other discovery and
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> efforts, stability testing, manufacturing process development, formulation development, delivery system development, quality assurance and quality control development, statistical analysis,
clinical studies. When used as a verb, &#147;Develop&#148; means to engage in Development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Indication</U>&#148; means an
application for a label indicating the applicable drug for a patient population, or indicating the drug for use in combination with another treatment or drug, in each case that [****]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Licensed IP</U>&#148; means any patent rights and/or property rights of Distributed Bio that cover the composition of matter of any
Antibody Product as of the Effective Date. For clarity, Licensed IP does not include any methods of generating antibody libraries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Materials</U>&#148; means the Antibody Library and any associated materials transferred to Surrozen, as well as any progeny,
derivatives or improvements developed or derived by Surrozen therefrom, and any combination of the foregoing with other substances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Phase I Clinical Trial</U>&#148; means a study of an Antibody Product in human subjects or patients with the endpoint of determining
initial tolerance, safety, metabolism or pharmacokinetic information and clinical pharmacology of such product as and to the extent defined for the United States in 21 C.F.R. &#167; 312.21(a), or its successor regulation, or the equivalent
regulation in any other country. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Phase II Clinical Trial</U>&#148; means a study of an Antibody Product in human
patients to determine the safe and effective dose range in a proposed therapeutic indication as and to the extent defined for the United States in 21 C.F.R. &#167; 312.21(b), or its successor regulation, or the equivalent regulation in any other
country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Phase Ill Clinical Trial</U>&#148; means a study of an Antibody Product in human patients with a defined dose or a set
of defined doses of a Antibody Product designed to (a)&nbsp;ascertain efficacy and safety of such Antibody Product for its intended use; (b)&nbsp;define warnings, precautions and adverse reactions that are associated with the Antibody Product in the
dosage range to be prescribed; and (c)&nbsp;support preparing and submitting applications for Regulatory Approval to the competent Regulatory Authorities in a country of the world, as and to the extent defined for the United States in 21
C.F.R.&#167; 312.21(c), or its successor regulation, or the equivalent regulation in any other country. Phase Ill Clinical Study shall also include any other human clinical trial serving as a pivotal study from which the data are actually submitted
to the applicable Regulatory Authority in connection with a Regulatory Marketing Approval Application, whether or not such trial is called a &#147;Phase Il l&#148; study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Research</U>&#148; means the research undertaken by Surrozen using the Antibody Library to identify Antibody(ies) directed to up to
[****] of Surrozen&#146;s proprietary targets per year in each of the first [****] calendar years and [****] of targets in each year thereafter that the annual maintenance fee is paid. Surrozen shall not be obligated to disclose the identity of its
proprietary targets to Distributed Bio. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Subscription Payments and Milestones</U>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Surrozen shall pay to Distributed Bio an upfront fee of [****], due within [****] after the Effective Date of
this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Surrozen shall make an annual fee payment due within [****] of the Effective Date (&#147;Annual Fee&#148;) as
follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Annual Fee shall be due on the first and second anniversaries of the Effective Date; and,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On the third anniversary and each anniversary thereafter of the Effective Date, Surrozen will pay to
Distributed Bio an Annual Fee of [****] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Milestones. Surrozen also shall pay to Distributed Bio, the following milestone payments:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Milestone&nbsp;Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Milestone</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(i)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[****]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(ii)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[****]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(iii)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[****]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(iv)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[****]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(v)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[****]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(vi)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[****]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(vii)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[****]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within [****] after achievement of any of the Milestone Events, Surrozen shall provide
Distributed Bio with written notice of such achievement, and shall pay the corresponding Milestone payment within [****] after such achievement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Milestones (i) - (vi) set forth in this Section&nbsp;3(c) shall be paid once for an Antibody Product. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Surrozen obtains [****] of an Antibody Product without having paid Milestones 3(c)(ii)-(v) then those
Milestones 3(c)(ii)-(v) which had not been paid, shall be due and payable within [****] of [****] of the Antibody Product. Royalties. Surrozen agrees to pay to Distributed Bio a royalty on Net Sales of Antibody Products of [****] of Net Sales of
such Antibody Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The royalties to be paid under this Section&nbsp;3(d) shall continue, on an Antibody <FONT
STYLE="white-space:nowrap">Product-by-Antibody</FONT> Product basis for ten (10)&nbsp;years after the first commercial sale of such Antibody Product (&#147;Royalty Term&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Net Sales&#148; means payments actually received by Surrozen, its Affiliates or Sublicensees, from sales
of Antibody Products to third party customers, less reasonable and customary deductions for any: [****]. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Royalty Reports; Records. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Commencing on the first commercial sale of an Antibody Product, Surrozen shall furnish to Distributed Bio a
written report for each calendar quarter during the term of this Agreement showing: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the gross sales of all Antibody Products sold by Surrozen, its affiliates and sublicensees during such calendar
quarter and the calculation of Net Sales of the Antibody Products from such gross sales; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the royalties, payable in United States Dollars, which shall have accrued under this Agreement based upon such
Net Sales of the Antibody Products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date of the launch of each Antibody Product; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the exchange rates used in determining the amount of royalties payable in United States Dollars.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reports to be provided by Surrozen to Distributed Bio under this section shall be due [****] following the end
of each calendar quarter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Records. Surrozen shall keep, and shall require that its affiliates and sublicensees keep, complete and
accurate books of account and records in sufficient detail to enable the amounts payable under this Agreement to be determined. Such books and records shall be kept at the principal place of business of Surrozen, its affiliate or sublicensee, as the
case may be, for at least [****] following the end of the calendar year to which such books and records pertain. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All payments are non-refundable. All payments shall be made in U.S. dollars by wire transfer to Distributed Bio
in accordance with wiring instructions provided by Distributed Bio. All sales, use, gross receipts, compensating, value-added or other taxes, duties, licenses or fees (excluding Distributed Bio&#146;s net income and franchise taxes) assessed by any
tax jurisdiction arising from payments under this Agreement are the responsibility of Surrozen, whether paid by Distributed Bio or Surrozen. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Overdue Payments. In the event any milestone payment or any royalty payment payable by Surrozen to Distributed
Bio under this Agreement is not made when due, such outstanding payment shall accrue interest (from the date such payment is due through and including the date upon which full payment is made) at the lesser of: (i) [****] or (ii)&nbsp;the maximum
rate per annum permitted by applicable law. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Audits. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Audit Rights</U>. Upon at least [****] prior written notice from Distributed Bio and [****], Surrozen shall
permit, and shall require its Affiliates and shall use reasonable efforts to require its sublicensees, to permit, an independent certified public accounting firm of nationally recognized standing, selected by Distributed Bio and reasonably
acceptable to Surrozen, to have access during normal business hours to such books of account and records of Surrozen, and its Affiliates and sublicensees, at such party&#146;s principal place of business, as may be reasonably necessary to verify the
accuracy of the royalty reports hereunder for any calendar year ending not more than [****] prior to the date of such request for the sole purpose of verifying the calculation and reporting of Net Sales in the previous [****] and the correctness of
any royalty payment made under this Agreement for the previous [****]. Results of any such examination shall be made available to both Distributed Bio and Surrozen. The independent, certified public accountant shall disclose to the Distributed Bio
only the amount of royalties or milestone payments, if any, that the independent auditor believes to be due and payable hereunder to the Distributed Bio, details concerning any discrepancy from the amount paid and the amount due, and shall disclose
no other information revealed in such audit. Any and all records examined by such independent accountant shall be </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">deemed Surrozen&#146;s Confidential Information which may not be disclosed by said independent, certified public accountant to any third party. If Surrozen is unable to obtain from any sublicensee a right for
Distributed Bio to audit the books of account and records of such sublicensee, Surrozen shall obtain the right to inspect and audit such Sublicensee&#146;s books and records for itself and shall exercise such audit rights on behalf of Distributed
Bio upon Distributed Bio&#146;s written request and disclose the results of any such audit to Distributed Bio. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Audit Results</U>. If such audit establishes that additional royalties were owed to Distributed Bio during
the period covered by any audit pursuant to Section&nbsp;3(g), Surrozen shall remit to Distributed Bio within [****] of the date on which Distributed Bio delivers to Surrozen such accounting firm&#146;s written report so concluding: (i)&nbsp;the
amount of such additional royalties; and (ii)&nbsp;interest on such amount which shall be calculated pursuant to Section&nbsp;3(f). In the event amounts were overpaid by Surrozen during such period, the amount of such overpayment shall promptly be
refunded by Distributed Bio to Surrozen. The fees charged by such accounting firm in connection with any audit pursuant to this Section&nbsp;3(g) shall be paid by Distributed Bio; provided, however, that if a discrepancy in favor of Distributed Bio
of more than [****] of the royalties due hereunder for the period being audited is identified, then Surrozen shall pay the reasonable fees and expenses charged by such accounting firm in connection with such audit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery of Materials</U>. Distributed Bio agrees to provide the Materials to Surrozen within [****] after the
Effective Date of this Agreement and Distributed Bio will provide updated versions of the Materials as they become available from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> during the term of this
Agreement. Materials will be delivered to Surrozen by a carrier selected by Distributed Bio at Distributed Bio&#146;s expense. Distributed Bio will bear the risk of loss of the Materials until the Materials are delivered to Surrozen. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidentiality</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidential Information</U>. Each Party shall treat all information received from the other Party including the
terms of this Agreement (collectively, the &#147;Confidential Information&#148;) and shall not disclose any of such Confidential Information to any third party, without the disclosing Party&#146;s prior written consent. The Materials shall be deemed
the Confidential Information of Distributed Bio, and Surrozen shall only use Distributed Bio&#146;s Confidential Information or Materials for the Purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Exceptions</U>. Notwithstanding the foregoing, neither Party shall have any obligation with respect to
information (other than the Materials that can be shown by documentary evidence: (a)&nbsp;is or becomes publicly known and made generally available from sources who have not obtained such information, directly or indirectly, from the disclosing
Party; or (b)&nbsp;was in the receiving Party&#146;s possession at the time of disclosure by the disclosing Party and was not acquired directly or indirectly from the disclosing Party or from any other party under an obligation of confidentiality to
the disclosing Party. Surrozen further agrees that any and all of Surrozen&#146;s employees who require access to the Materials to conduct the Research shall be subject to contractual obligations of <FONT STYLE="white-space:nowrap">non-use</FONT>
and <FONT STYLE="white-space:nowrap">non-disclosure</FONT> at least as restrictive as those set forth in this Agreement. Surrozen also may disclose Confidential Information derived from the Antibody Library in its patent filings for any Antibody
identified by Surrozen as binding to a biological target of interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.3&nbsp;&nbsp;&nbsp;&nbsp;The obligations of non-disclosure and <FONT
STYLE="white-space:nowrap">non-use</FONT> with respect to Confidential Information shall survive termination or expiration of this Agreement for a period of [****]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Protection of Information and Material</U>. Without limiting Section&nbsp;5 above, Surrozen shall not transfer
any of the Materials to any third party without Distributed Bio&#146;s prior written consent. Upon the expiration or termination of this Agreement, and in the absence of further written agreement of the Parties, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Surrozen shall cease all use and make no further use of the Confidential Information and the Materials.
Surrozen shall take all reasonable steps, including, but not limited to, those steps taken to protect information and other property of its own of a confidential nature, to ensure that the Confidential Information and Materials are not disclosed or
duplicated or in any manner delivered or disseminated to others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-exclusive</FONT> Agreement.</U> Surrozen acknowledges that the Materials may
be provided by Distributed Bio to third parties, including Distributed Bio&#146;s other customers, collaborators and subscribers, and Distributed Bio reserves the right to use the Materials for its own purposes, whatever they may be. Such third
parties may be competitors of Surrozen and may use the Antibody Library for similar research as being performed by Surrozen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Title to Materials and Antibody(ies)</U>. All right, title and interest in and to Materials shall remain vested
in Distributed Bio. For purpose of clarification, all right, title and interest in and to any Antibody(ies) identified by Surrozen shall be vested in Surrozen. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual Property</U>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ownership of all data, discoveries, inventions and other subject matter (whether patentable or not) conceived,
reduced to practice or otherwise discovered by Surrozen in the course of performing the Research or otherwise in connection with its use of the Materials, including but not limited to the Antibody Library, as permitted under this Agreement and all
intellectual property rights therein, will be owned by Surrozen (&#147;Surrozen Inventions&#148;). For clarity, Surrozen shall be free to patent individual Antibody (or complementarity determining region (CDR)) sequences for any Antibody(ies) that
were identified or derived by Surrozen in carrying out the Research. Because the Antibody Library is provided to Surrozen nonexclusively, Surrozen acknowledges that a third party may have filed patent applications on an Antibody or CDR sequence
identified by Surrozen in the Research. Distributed Bio makes no warranties that any antibody in the Antibody Library or the Materials will not infringe any patent rights of any third party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of Patent Filings. If Surrozen files any patent application on [****], then Surrozen agrees to provide
written notice to Distributed Bio within [****] after filing any such patent application. Surrozen may provide Distributed Bio [****] at a time of its own choosing. The notice and [****] are Surrozen&#146;s Confidential Information and shall not be
disclosed to any third party in accordance with the provisions of Section&nbsp;5. Within [****] after receipt of Surrozen&#146;s notice of a patent filing, Distributed Bio will provide Surrozen with notice identifying: [****]. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>License</U>. Distributed Bio hereby grants to Surrozen a nonexclusive license under Distributed Bio&#146;s
Licensed IP to make, have made, use, sell, offer for sale, import or otherwise to undertake the Research and to exploit any Antibody Product identified by Surrozen using the Antibody Library.. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Publication</U>. Surrozen shall not disclose any Confidential Information specifically relating to the Antibody
Library or other Materials, orally or in writing, (e.g., by submission of a manuscript, abstract, or otherwise) to any third party, without prior written approval of Distributed Bio. Notwithstanding the foregoing, Surrozen has the right to publish
on an Antibody(ies), including but not limited to patent filings in accordance with Section&nbsp;9. Distributed Bio shall not disclose Surrozen Confidential Information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Care in Use of Materials</U>. Surrozen acknowledges that the
Materials are experimental in nature and may have unknown characteristics and therefore agrees to use prudence and reasonable care in the use, handling, storage, transportation and disposition and containment of the Materials. Surrozen shall at all
times use the Materials in compliance with all state, federal and other applicable laws, rules and regulations pertaining to use of the Materials. Surrozen agrees to use the Antibody Library solely for the Research. For clarity, such restriction
does not apply to Antibody(ies) identified by Surrozen in carrying out the Research. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver of
Warranties</U>. DISTRIBUTED BIO SUPPLIES ALL INFORMATION AND MATERIALS WITHOUT ANY WARRANTY, REPRESENTATION OR UNDERTAKING WHATSOEVER, EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTY RESPECTING THE EFFICIENCY, PERFORMANCE,
WORKMANSHIP, CONDITION, MERCHANTABILITY, FITNESS FOR PARTICULAR PURPOSE, OR NON-INFRINGEMENT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation of
Liability</U>. DISTRIBUTED BIO SHALL NOT BE RESPONSIBLE OR LIABLE WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT OR TERMS AND CONDITIONS RELATED THERETO UNDER ANY THEORY OF LIABILITY INCLUDING BUT NOT LIMITED TO CONTRACT, TORT (INCLUDING
NEGLIGENCE AND STRICT LIABILITY) OR OTHERWISE FOR ANY DIRECT, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES INCLUDING, BUT NOT LIMITED TO, LOSS OF REVENUES AND LOSS OF PROFITS. THIS LIMITATION WILL APPLY EVEN IF DISTRIBUTED BIO HAS BEEN ADVISED OF
THE POSSIBILITY OF SUCH DAMAGES. THE PARTIES AGREE THAT THE FOREGOING LIMITATIONS REPRESENT A REASONABLE ALLOCATION OF RISK UNDER THIS AGREEMENT. DISTRIBUTED BIO&#146;S LIABILITY UNDER THIS AGREEMENT SHALL NOT EXCEED THE AMOUNTS PAID BY SUBSCRIBER
TO DISTRIBUTED BIO IN THE TWELVE MONTHS PRIOR TO ANY CLAIM BEING MADE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;<U>Term and Termination.</U> This
Agreement shall have an initial term of [****] from the Effective Date (the &#147;Initial Term&#148;) and shall automatically renew for additional one year terms, unless terminated by Surrozen. Surrozen may terminate this Agreement effective upon
written notice to Distributed Bio. Either Party (the &#147;Non-breaching Party&#148;) may, without prejudice to any other remedies available to it, terminate this Agreement in the event the other Party (the &#147;Breaching Party&#148;) has
materially breached this Agreement, and such breach has continued for sixty (60)&nbsp;days (the &#147;Cure Period&#148;) after written notice thereof is provided to the Breaching Party by the Non-breaching Party, such notice describing the alleged
material breach in sufficient detail to put the Breaching Party on notice. Within [****] after termination or expiration of this Agreement, Surrozen shall return or destroy, at Distributed Bio&#146;s discretion, the Materials, and if destroyed,
provide written certification of such destruction; provided that Surrozen may retain any Materials to the extent such Materials encompass an Antibody for which Surrozen has filed for patent protection pursuant to Section&nbsp;9. The provisions of
Sections 2, 3 (with respect to payments due prior to such termination), 5, 6, 7, 8, 9, 14, 15, and <FONT STYLE="white-space:nowrap">17-21</FONT> shall survive any termination or expiration of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;<U>No Conflict</U>. Surrozen shall not use any of the Materials in any research that is subject to consulting,
licensing or similar obligations (including the provision of research services whether paid or <FONT STYLE="white-space:nowrap">un-paid)</FONT> to any third party, unless written permission is first obtained from Distributed Bio. Surrozen hereby
warrants that the rights and obligations set forth herein do not, and during the term of the Agreement will not, conflict with any other right or obligation provided under any other agreement that Surrozen has with any third party, including any
company or government entity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnity</U>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Surrozen shall defend, indemnify and hold harmless Distributed Bio and its directors, officers and employees
from and against any loss, claims or liability of any kind brought by a third party (collectively, &#147;Claims&#148;) to the extent that such Claims arise out of, in connection with, or as a result of: (a)&nbsp;the use, handling, storage
transportation, containment or disposition of the Materials by Surrozen, (b)&nbsp;the research, development, manufacture, use, commercialization and other exploitation of a Surrozen Antibody Product(s), and (c)&nbsp;any breach of this Agreement by
Surrozen; except in each case, to the extent such liability arises from Distributed Bio&#146;s gross negligence, willful misconduct or breach of this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Distributed Bio will defend, indemnify and hold Surrozen, its directors, officers, employees and agents
harmless from and against any and all loss or expense by reason of Claims to the extent such Claims arise out of, are based on, or result from Distributed Bio&#146;s gross negligence, willful misconduct or breach of this Agreement.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.&nbsp;&nbsp;&nbsp;&nbsp;<U>No Implied License</U>. No license or other right is or shall be created or granted
hereunder by implication, estoppel, or otherwise. All licenses and rights are or shall be granted only as expressly provided in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.&nbsp;&nbsp;&nbsp;&nbsp;<U>Cost of Research</U>. Surrozen shall be responsible for its own expenses in conducting the Research, and
Distributed Bio shall have no obligation to pay Surrozen therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>. Except as otherwise
provided herein, each Party hereto represents that it has the full right, power and authority to enter into this Agreement. This Agreement shall be construed and enforced in accordance with the laws of the United States of America and the State of
California without reference to conflicts of law principles. This Agreement sets forth the entire agreement between the Parties with respect to the subject matter contained herein and supersedes any previous understandings, commitments or
agreements, whether oral or written. This Agreement may only be amended by a written document signed by authorized representatives of both Parties hereto that specifically and expressly refers to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Remainder of page intentionally left blank. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Paragraph 21 and signatures follow immediately. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment</U>. This Agreement <I>may not be assigned </I>or
otherwise transferred by either Party without the consent of the other Party which consent shall not be unreasonably withheld; <I>provided , however, </I>that Distributed Bio or Surrozen may, without such consent, assign this Agreement together with
all of its rights and obligations hereunder to its Affiliates, or to a successor in interest in connection with the transfer or sale of all or substantially all of its business to which this Agreement relates, or in the event of its merger,
consolidation, change of control, or similar transaction, subject in each such case to the assignee agreeing to be bound by the terms of this Agreement. Any purported assignment in violation of the preceding sentences shall be void. Any permitted
assignee or successor shall assume and be bound by all applicable obligations of its assignor or predecessor under this Agreement. [****] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Distributed Bio, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Surrozen, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(&#147;Distributed Bio&#148;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">(&#147;Surrozen&#148;)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Giles Day</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Wen-Chen Yeh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Giles Day</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Wen-Chen Yeh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President &amp; CEO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">CSO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9/30/2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Oct. 3, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Phone:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[****]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Phone:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[****]</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANTIBODY LIBRARY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">[****] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[****]</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[****] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>6
<FILENAME>d40894dex1012.htm
<DESCRIPTION>EX-10.12
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.12</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.12 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE REGISTRANT
TREATS AS PRIVATE OR CONFIDENTIAL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIRST AMENDMENT TO THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANTIBODY LIBRARY SUBSCRIPTON AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BETWEEN </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISTRIBUTED BIO
INC. AND SURROZEN, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS FIRST AMENDMENT TO THE AGREEMENT</B> (&#147;<B><I>First Amendment</I></B><I>&#148;</I>) is made
effective as of January 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>, 2019 (the &#147;<B><I>Amendment Date</I></B>&#148;) and is entered into by and between <B>Distributed Bio, Inc.</B> a California corporation, having offices at 329
Oyster Point Blvd, 3rd Floor, South San Francisco, CA US 94080 (&#147;<B><I>Distributed Bio</I></B>&#148;) and <B>Surrozen, Inc.</B> having its principal offices at 171 Oyster Point Blvd, Suite 400, So San Francisco, CA 94080
(&#147;<B><I>Surrozen</I></B>&#148;) to amend their Antibody Library Subscription Agreement dated September&nbsp;30, 2016 (the &#147;<B><I>Agreement</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms used in this First Amendment that are not otherwise defined herein shall have the meanings set forth in the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Distributed Bio and Surrozen entered into the Agreement for Surrozen&#146;s use of Distributed
Bio&#146;s Antibody Library; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Surrozen and Distributed Bio agree to amend the Agreement as
set forth below; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL>, T<SMALL>HEREFORE</SMALL></B><SMALL></SMALL>, in consideration of the foregoing and the mutual
promises set forth below, Distributed Bio and Surrozen agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Research </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Distributed Bio and Surrozen agree to replace the definition of &#147;Research&#148; in the Agreement with the following definition: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Research</U>&#148; means the research undertaken by Surrozen using the Antibody Library to identify Antibody(ies) directed to an
unlimited number of Surrozen&#146;s proprietary targets per year beginning the second year (i.e., after the first anniversary of the Effective Date) and each year thereafter that the annual maintenance fee is paid. Surrozen shall not be obligated to
disclose the identity of its proprietary targets to Distributed Bio. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Subscription Payments and Milestones </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Distributed Bio and Surrozen agree to amend Paragraph 3(b) as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(1) &nbsp;&nbsp;&nbsp;&nbsp;Within [****] of the Amendment Date, Surrozen shall pay Distributed Bio [****];
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Surrozen shall make an annual fee payment (&#147;Annual Fee&#148;) due within [****] of the Effective Date as
follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Annual Fee shall be due on the first and second anniversaries of the Effective Date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On the third and fourth anniversaries of the Effective Date, Surrozen will pay to Distributed Bio an Annual Fee
of Two Hundred Thousand Dollars ($200,000); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On the fifth anniversary and each anniversary thereafter of the Effective Date, Surrozen will pay to
Distributed Bio an Annual Fee of Two Hundred Fifty Thousand Dollars ($250,000). </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Distributed Bio and Surrozen agree to amend Paragraph 15 as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Term and Termination</U>. This Agreement shall have an initial term of four (4)&nbsp;years from the Effective Date (the &#147;Initial
Term&#148;) and shall automatically renew for additional <FONT STYLE="white-space:nowrap">one-year</FONT> terms, unless terminated by Surrozen. Surrozen may terminate this Agreement at any time after the fourth anniversary of the Effective Date, but
not before, and such termination shall be effective upon written notice to Distributed Bio. Either Party (the &#147;<U><FONT STYLE="white-space:nowrap">Non-breaching</FONT> Party</U>&#148;) may, without prejudice to any other remedies available to
it, terminate this Agreement in the event the other Party (the &#147;<U>Breaching Party</U>&#148;) has materially breached this Agreement, and such breach has continued for sixty (60)&nbsp;days (the &#147;<U>Cure Period</U>&#148;) after written
notice thereof is provided to the Breaching Party by the <FONT STYLE="white-space:nowrap">Non-breaching</FONT> Party, such notice describing the alleged material breach in sufficient detail to put the Breaching Party on notice. Within [****] after
termination or expiration of this Agreement, Surrozen shall return or destroy, at Distributed Bio&#146;s discretion, the Materials, and if destroyed, provide written certification of such destruction; provided that Surrozen may retain any Materials
to the extent such Materials encompass an Antibody for which Surrozen has filed for patent protection pursuant to Section&nbsp;9. The provisions of Sections 2, 3 (with respect to payments due prior to such termination), 5, 6, 7, 8, 9, 13, 14, and <FONT
STYLE="white-space:nowrap">16-20</FONT> shall survive any termination or expiration of this Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Other Changes. </B>Except as expressly provided in this First Amendment, all terms of the Agreement shall
remain in full force and effect.<B> </B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
Parties have executed this First Amendment by its duly authorized officer as of the day and year written below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DISTRIBUTED BIO INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B></B>(&#147;Distributed Bio&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SURROZEN INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(&#147;Surrozen&#148;)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Giles Day</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Craig Parker</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Giles Day</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Craig Parker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President&nbsp;&amp; CEO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January 10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January&nbsp;15, 2019</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>7
<FILENAME>d40894dex1013.htm
<DESCRIPTION>EX-10.13
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.13</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.13 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I)&nbsp;NOT MATERIAL AND (II)&nbsp;THE
REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCLUSIVE (EQUITY) AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (&#147;Stanford&#148;), an institution of higher education having powers
under the laws of the State of California, and Surrozen (&#147;Surrozen&#148;), a corporation having a principal place of business at 1700 Owens St., Ste 500, San Francisco, CA, 94158, is effective on the 23rd day of March, 2016 (&#147;Effective
Date&#148;). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>BACKGROUND </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stanford and University of Washington (&#147;UW&#148;) have an assignment of an invention consisting of surrogate Wnt proteins that target specific Frizzled
subtypes to activate and antagonize Wnt pathway signaling. It is entitled &#147;Surrogate WNT Proteins&#148; and was invented in the laboratory of [****], a Howard Hughes Medical Institute (&#147;HHMI&#148;) investigator at Stanford and in the
laboratory of [****], a Howard Hughes Medical Institute (&#147;HHMI&#148;) investigator at UW and is described in Stanford Docket [****]. The invention was made in the course of research supported by HHMI and NIH. Stanford and UW want to have the
invention perfected and marketed as soon as possible so that resulting products may be available for public use and benefit. UW has exclusively granted Stanford the right to license UW&#146;s rights in the invention to third parties. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Change of Control</B>&#148; means the following, as applied only to the entirety of that part of
Surrozen&#146;s business that exercises all of the rights granted under this Agreement: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">acquisition of ownership&#151;directly or indirectly, beneficially or of record&#151;by any person or group
(within the meaning of the Exchange Act and the rules of the SEC or equivalent body under a different jurisdiction) of the capital stock of Surrozen representing more than [****] of either the aggregate ordinary voting power or the aggregate equity
value represented by the issued and outstanding capital stock of Surrozen; and/or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the sale of all or substantially all Surrozen&#146;s assets and/or business in one transaction or in a series
of related transactions. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">provided, however, that in no event shall the sale of equity or other securities for the sole
purpose of financing Surrozen be a Change of Control. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Exclusive</B>&#148; means that, subject to Articles 3 and 5, Stanford will not grant further licenses
under the Licensed Patents in the Licensed Field of Use in the Licensed Territory. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 1 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Fully Diluted Basis</B>&#148; means the total number of shares of Surrozen&#146;s issued and
outstanding common stock, assuming: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the conversion of all issued and outstanding securities convertible into common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the exercise of all issued and outstanding warrants or options, regardless of whether then exercisable; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the issuance, grant, and exercise of all securities reserved for issuance pursuant to any Surrozen stock or
stock option plan then in effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>HHMI Indemnitees</B>&#148; means HHMI and its trustees, officers, employees and agents.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Licensed Field of Use</B>&#148; means all fields. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">2.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Licensed Patent</B>&#148; means U.S. Patent Application, [****], any foreign patent application
corresponding thereto, and any divisional, continuation, or reexamination application, extension, and each patent that issues or reissues from any of these patent applications. Any claim of an unexpired Licensed Patent is presumed to be valid unless
it has been held to be invalid by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken. &#147;Licensed Patent&#148; excludes any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuation-in-part</FONT></FONT> (CIP) patent application or patent. Neither party shall file or authorize another party to file a CIP of any Licensed Patent without the written
approval of the other Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">2.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Licensed Product</B>&#148; means a product or part of a product in the Licensed Field of Use:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the making, using, importing or selling of which, absent this license, infringes, induces infringement, or
contributes to infringement of a Licensed Patent; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">which is made with, uses or incorporates any Technology. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">2.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Licensed Territory</B>&#148; means worldwide. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">2.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Net Sales</B>&#148; means all gross revenue received by Surrozen or sublicensees from the sale,
transfer or other disposition of Licensed Product to a third party customer. Net Sales excludes the following items (but only as they pertain to the making, using, importing or selling of Licensed Products, are included in gross revenue, and are
separately billed): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">import, export, excise, value-added and sales taxes, and custom duties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">trade, quantity or cash discounts and customary rebates and chargebacks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">costs of insurance, packing, and transportation from the place of manufacture to the customer&#146;s premises
or point of installation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 2 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">costs of installation at the place of use; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">credit for returns, allowances, or trades. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">For clarity, in the event there is any sale of Licensed Products between Surrozen and its sublicensee for resale, Net Sales shall be calculated
based on such resale to third parties, but not the sale between Surrozen and its sublicensee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In the event that a Licensed Product is sold
in combination with another product which is not a Licensed Product, the amount paid to Stanford [****] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;<B>Nonroyalty Sublicensing
Consideration</B>&#148; means any consideration received by Surrozen from a sublicensee hereunder but excluding any consideration for: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">2.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><FONT STYLE="white-space:nowrap">Non-Valid</FONT> Claim Period</B>&#148; means any uninterrupted
period of time when the manufacture, use, sale or importation of Licensed Product would not infringe, induce infringement, or contribute to infringement of a Valid Claim. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">2.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Patent Matters</B>&#148; means preparing, filing, and prosecuting broad and extensive patent claims
(including any interference or reexamination actions) for Stanford&#146;s benefit in the Licensed Territory and for maintaining all Licensed Patents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">2.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Stanford and UW Indemnitees</B>&#148; means Stanford and Stanford Hospitals and Clinics, and their
respective trustees, officers, employees, students, agents, faculty, representatives, and volunteers and UW and their respective regents, trustees, officers, employees, students, agents, faculty, representatives, and volunteers.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 3 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">2.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Sublicense</B>&#148; means any agreement between Surrozen and a third party that contains a grant to
Stanford&#146;s Licensed Patents regardless of the name given to the agreement by the parties; however, an agreement to make, have made, use or sell Licensed Products on behalf of Surrozen is not considered a Sublicense. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">2.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Technology</B>&#148; means information or materials listed in Appendix C that will be provided by
Stanford to Surrozen, including certain reagents and research materials. Technology may or may not be confidential in nature. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">2.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Valid Claim</B>&#148; means (a)&nbsp;any claim of an issued and unexpired Licensed Patent which has
not been held unenforceable or invalid by a court or other governmental agency of competent jurisdiction from which no appeal can be taken and which has not been disclaimed or admitted to be invalid or unenforceable through abandonment, reissue,
disclaimer or otherwise, or (b)&nbsp;a pending claim in a pending Licensed Patent application, provided that if such pending claim does not issue as a valid and enforceable claim within [****] from its earliest priority date, such pending claim will
cease to be a Valid Claim unless and until actually issued. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GRANT </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Grant.</B> Subject to the terms and conditions of this Agreement, Stanford grants Surrozen: (a)&nbsp;a
license under the Licensed Patent in the Licensed Field of Use to make, have made, use, import, offer to sell and sell Licensed Product in the Licensed Territory and (b)&nbsp;a nonexclusive license under the Technology to make, have made, use,
import, offer to sell and sell Licensed Product in the Licensed Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exclusivity.</B> The license under 3.1(a) is Exclusive, including the right to sublicense under Article
3.4(C), in the Licensed Field of Use beginning on the Effective Date and ending when the last of the Licensed Patent expires. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Retained Rights.</B> Stanford retains the right, on behalf of itself, Stanford Hospital and Clinics, UW, and
all other <FONT STYLE="white-space:nowrap">non-profit</FONT> research institutions, to practice the Licensed Patent and use Technology for any <FONT STYLE="white-space:nowrap">non-profit</FONT> purpose, including sponsored research and
collaborations. Surrozen agrees that, notwithstanding any other provision of this Agreement, it has no right to enforce the Licensed Patent against any such institution. Stanford and any such other institution have the right to publish any
information included in the Technology or a Licensed Patent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Specific Exclusion.</B> Stanford does not: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">grant to Surrozen any other licenses, implied or otherwise, to any patents or other rights of Stanford other
than those rights granted under Licensed Patent, regardless of whether the patents or other rights are dominant or subordinate to any Licensed Patent, or are required to exploit any Licensed Patent or Technology; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 4 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">commit to Surrozen to bring suit against third parties for infringement, except as described in Article 14; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">agree to furnish to Surrozen any technology or technological information other than the Technology or to
provide Surrozen with any assistance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>HHMI Research License.</B> Surrozen acknowledges that it has been informed that the Licensed Patent and
Technology was developed, at least in part, by employees of HHMI and that HHMI has a <FONT STYLE="white-space:nowrap">paid-up,</FONT> <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> irrevocable license to use the Licensed Patent and
Technology for HHMI&#146;s research purposes, but with no right to assign or sublicense (the &#147;HHMI License&#148;). This Agreement is explicitly made subject to the HHMI License. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SUBLICENSING </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Permitted Sublicensing.</B> Surrozen may grant Sublicenses in the Licensed Field of Use only during the
Exclusive term [****]. Sublicenses with any exclusivity must include diligence requirements commensurate with the diligence requirements of Appendix A. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">To the extent that <FONT STYLE="white-space:nowrap">Non-Royalty</FONT> Sublicense Income represents an unallocated combined payment for both a
sublicense of the Licensed Patents as well as other intellectual property or the like, such <FONT STYLE="white-space:nowrap">Non-Royalty</FONT> Sublicense Income from such sublicensing arrangement shall, for the purpose of calculating payments due
to Stanford pursuant, be [****]. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Required Sublicensing.</B> Stanford would like licensees to address unmet needs, such as those of neglected
patient populations or geographic areas, giving particular attention to improved therapeutics, diagnostics and agricultural technologies for the developing world. If Surrozen, directly or through its sublicensee(s), is unable or unwilling to serve
or develop a potential market or market territory for which there is a reputable Surrozen willing to be a sublicensee which has adequate resources and (a)&nbsp;such potential sublicensee has provided Stanford and Surrozen with a bona fide, detailed
proposal to develop a Licensed Product for such potential market or market territory, and (b)&nbsp;such proposed development is not within or competitive with Surrozen&#146;s current or planned Licensed Products, as reasonably demonstrated by
Surrozen in a written document to Stanford, then Surrozen will, at Stanford&#146;s request, negotiate in good faith a Sublicense with any such potential sublicensee. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sublicense Requirements.</B> Any Sublicense: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is subject to this Agreement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 5 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">will reflect that any sublicensee will not further sublicense; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">will prohibit sublicensee from paying royalties to an escrow or other similar account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">will expressly include the provisions of Articles 8, 9, 10, 13 and Section&nbsp;19.5 for the benefit of
Stanford, UW and/or HHMI, as the case may be; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">will include the provisions of Section&nbsp;4.4 and require the transfer of all the sublicensee&#146;s
obligations to Surrozen with respect to the grant of rights under the Licensed Patents and Technology to the Surrozen, including the payment of royalties specified in the Sublicense, to Stanford or its designee, if this Agreement is terminated ,
provided that such sublicensee&#146;s payment obligation to Stanford shall be limited to the amount that Stanford would have otherwise received as a result of such sublicensee&#146;s activities if this Agreement had remained in effect. If the
sublicensee is a <FONT STYLE="white-space:nowrap">spin-out</FONT> from Surrozen, Surrozen must guarantee the sublicensee&#146;s performance with respect to the payment of Stanford&#146;s share of Sublicense royalties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Litigation by Sublicensee.</B> Any Sublicense must include the following clauses: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event sublicensee brings an action seeking to invalidate any Licensed Patent: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sublicensee will [****] the payment paid to Surrozen during the pendency of such action. Moreover, should the
outcome of such action determine that any claim of a patent challenged by the sublicensee is both valid and infringed by a Licensed Product, sublicensee will pay [****] the payment paid under the original Sublicense; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sublicensee will have no right to recoup any royalties paid before or during the period challenge;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any dispute regarding the validity of any Licensed Patent shall be litigated in the courts located in Santa
Clara County, and the parties agree not to challenge personal jurisdiction in that forum; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sublicensee shall not pay royalties into any escrow or other similar account. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sublicensee will provide written notice to Stanford at least [****] prior to bringing an action seeking to
invalidate a Licensed Patent. Sublicensee will include with such written notice [****]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Copy of Sublicenses and Sublicensee Royalty Reports.</B> Surrozen will submit to Stanford a copy of each
Sublicense, any subsequent amendments and all copies of sublicensees&#146; royalty reports, each may be redacted for information not necessary to determine compliance with this Agreement. Beginning with the first Sublicense, [****] [****].
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 6 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sharing of Sublicensing Income.</B> Surrozen will pay to Stanford a portion of all Nonroyalty Sublicensing
Consideration for the Sublicense of Licensed Patents, as provided below: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] of <FONT STYLE="white-space:nowrap">Non-Royalty</FONT> Sublicense Income for Sublicenses granted within
[****] of the Effective Date in a transaction in which Surrozen will [****]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] of <FONT STYLE="white-space:nowrap">Non-Royalty</FONT> Sublicense Income for all other Sublicenses.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">4.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Royalty-Free Sublicenses.</B> If Surrozen pays all royalties due Stanford from a sublicensee&#146;s Net
Sales, Surrozen may grant that sublicensee a royalty-free or <FONT STYLE="white-space:nowrap">non-cash:</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sublicense or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cross-license. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GOVERNMENT RIGHTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement is subject to Title 35 Sections <FONT STYLE="white-space:nowrap">200-204</FONT> of the United States Code. Among other things, these provisions
provide the United States Government with nonexclusive rights in the Licensed Patent. They also impose the obligation that Licensed Product sold or produced in the United States be &#147;manufactured substantially in the United States,&#148; subject
to such waivers as may be obtained under applicable laws. Surrozen will ensure all obligations of these provisions are met. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DILIGENCE </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Milestones.</B> Because the invention is not yet commercially viable as of the Effective Date, Surrozen,
directly or through its affiliates, sublicensees or partners and/or its or their contractors, will use commercially reasonable efforts to develop, manufacture and sell a Licensed Product. In addition, Surrozen, directly or through its affiliates,
sublicensees or partners and/or its or their contractors, will meet the milestones shown on the attached Exhibit A. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Stanford agrees to grant reasonable extensions to the target dates of any applicable milestone and the subsequent milestones (without payment)
if Surrozen&#146;s failure to meet the applicable milestones is due to [****]. If any diligence milestone is extended, all subsequent milestones also shall be extended. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Progress Report.</B> By [****] of each year, Surrozen will submit a written annual report to Stanford
covering the preceding calendar year. The report will include </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 7 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">information sufficient to enable Stanford to satisfy reporting requirements of the U.S. Government and for Stanford to ascertain progress by Surrozen toward meeting this Agreement&#146;s diligence requirements. Each
report will describe, where relevant: Surrozen&#146;s progress toward commercialization of Licensed Product, [****]. Surrozen will specifically describe how each Licensed Product is related to each Licensed Patent. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Clinical Trial Notice.</B> Surrozen will notify the Stanford University Office of Technology Licensing prior
to commencing any clinical trials at Stanford. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ROYALTIES </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Issue Royalty.</B> Surrozen will pay to Stanford a noncreditable, nonrefundable license issue royalty of
[****] as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] upon signing this Agreement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] upon Initial Funding close or [****] from Effective Date, whichever comes first. &#147;Initial
Funding&#148; means an equity financing of Surrozen with at least [****]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Equity Interest.</B> As further consideration, Surrozen will grant to Stanford 241,688 shares of common
stock in Surrozen upon the Effective Date. When issued, those shares will represent [****] of the common stock in Surrozen on a Fully Diluted Basis. Surrozen agrees the shares are valued as of the Effective Date as set forth in the letter from
Surrozen to Stanford attached as Appendix E. Surrozen agrees to provide Stanford with the capitalization table upon which the above calculation is made. Surrozen will issue [****] of all shares granted to Stanford pursuant to this Section&nbsp;7.2
and Section&nbsp;7.3 directly to and in the name of the inventors listed below allocated as stated below: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">In addition, Surrozen
will issue [****] of all the shares granted to Stanford pursuant to this Section&nbsp;7.2 and Section&nbsp;7.3 directly to and in the name of [****] and will use the stock issuance agreement shown in Appendix D for such shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">In connection with the grant of shares of common stock pursuant to this Section&nbsp;7.2 and Section&nbsp;7.3, Stanford and each of the
inventors listed above will enter into a stock issuance agreement with Surrozen that includes customary provisions, including, without limitation, securities law representations and warranties, <FONT STYLE="white-space:nowrap">lock-up</FONT>
provisions and a right of first refusal on behalf of Surrozen. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 8 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Anti-Dilution Protection.</B> Surrozen will issue Stanford, without further consideration, any additional
shares of stock of the class issued pursuant to Section&nbsp;7.2 necessary to ensure that the number of shares issued Stanford pursuant to Section&nbsp;7.2 and this Section&nbsp;7.3 represents [****] of the shares issued and outstanding (prior to
the issuance of shares to Stanford pursuant to this Section&nbsp;7.3) on a Fully-Diluted Basis upon the final closing of the First Round of bona fide equity investment in Surrozen from a single or group of investors which is both (i)&nbsp;at least
[****] in size (including the principal amount and interest of all outstanding indebtedness converted into shares of Surrozen in connection therewith) and (ii)&nbsp;at a price per share which, when applied to stock actually outstanding immediately
after such round, implies a post-financing equity valuation of Surrozen of at least [****] (the &#147;First Round Financing&#148;). Notwithstanding the foregoing, in the event the amount invested in the First Round Financing is greater than [****],
the number of shares to be issued to Stanford shall be calculated as if the total amount invested in the First Round Financing is [****] (the &#147;Maximum Investment&#148;). A &#147;First Round&#148; is a bona fide round of equity, warrant, option
or convertible equity investment for capital raising purposes which includes all the tranches prior to the completion of the financing. This right will expire upon the earlier of (i)&nbsp;the issuance of all shares to be issued in connection with
such First Round Financing and (ii)&nbsp;the investment of the Maximum Investment in the First Round Financing, but will apply to all shares to be issued in or in connection with such First Round Financing, subject to the Maximum Investment
limitation described above. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Purchase Right.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stanford shall have the right, but not the obligation, to purchase for cash up to its Share of the securities
issued in any Qualifying Offering on the terms, and subject to the conditions, set forth in this Section&nbsp;7.4 and Section&nbsp;7.5 (the &#147;Purchase Right&#148;). For purposes of this Section&nbsp;7.4 and Section&nbsp;7.5:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Adjustment Event&#148; means the final closing of the first Threshold Qualifying Offering occurring after
the date of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Board of Directors&#148; means (i)&nbsp;if Surrozen is organized as a corporation, its board of
directors, and (ii)&nbsp;if Surrozen is organized as a limited liability company, Surrozen manager(s) or member(s) or both that have the power to direct the principal management and activities of Surrozen, whether through ownership of voting
securities, by agreement, or otherwise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Qualifying Offering&#148; means a private offering of Surrozen&#146;s equity securities (or securities
convertible into or exercisable for Surrozen&#146;s equity securities) for cash (or in satisfaction of debt issued for cash) having its final closing on or after the date of this Agreement and which includes investment by one or more venture
capital, professional angel, corporate or other similar </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 9 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
institutional investors other than Stanford. For the avoidance of doubt, if Surrozen is a limited liability company, then &#147;equity securities&#148; means limited liability company interests
in Surrozen. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Share&#148; means: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] with respect to any Qualifying Offering having a closing on or before the date of an Adjustment Event;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with respect to any Qualifying Offering having a closing after an Adjustment Event, but before a Termination
Event, the percentage necessary for Stanford to maintain its pro rata ownership interest in Surrozen on a Fully-Diluted Basis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Threshold Qualifying Offering&#148; means any Qualifying Offering which either (i)&nbsp;is at least
[****] in size or (ii)&nbsp;involves the sale to outside investors of at least [****] of the equity securities outstanding after such round on a Fully-Diluted Basis. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties shall construe the term &#147;Fully-Diluted Basis&#148; mutatis mutandis in the case where Surrozen
is organized as a limited liability company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Purchase Right shall terminate upon the earliest to occur of the following (each a &#147;Termination
Event&#148;): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stanford&#146;s execution of an investor rights agreement or similar agreement (each a &#147;Rights
Agreement&#148;) in connection with a Threshold Qualifying Offering so long the Rights Agreement satisfies the terms of this Section&nbsp;7.4 and Section&nbsp;7.5 below; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stanford purchases less than its entire Share of a Qualifying Offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stanford fails to give an election notice within the Notice Period for a Qualifying Offering which has its
final closing within [****] of the date such notice is received by Stanford and which is closed on terms that are the same or less favorable to the investors as the terms stated in Surrozen&#146;s notice to Stanford; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The closing of a firm commitment underwritten public offering of Surrozen&#146;s common stock; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The closing of the sale of all or substantially all of Surrozen&#146;s assets to a company publicly traded on
one of the major recognized exchanges. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Purchase Right shall not apply to the issuance of securities: (i)&nbsp;to employees, individuals who are
members of Surrozen&#146;s Board of Directors as of the time of issuance, and service providers to Surrozen pursuant to a plan approved by Surrozen&#146;s Board of Directors; or (ii)&nbsp;as additional consideration in lending or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 10 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
leasing transactions; or (iii)&nbsp;to an entity pursuant to an arrangement that Surrozen&#146;s Board of Directors determines in good faith is a strategic partnership or similar arrangement of
Surrozen (i.e., an arrangement in which the entity&#146;s purchase of securities is not primarily for the purpose of financing Surrozen); or (iv)&nbsp;(iv) to owners of another entity in connection with the acquisition of that entity by Surrozen.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt: (i)&nbsp;any securities Stanford may acquire or have the right to acquire under
Section&nbsp;7.2 or 7.3 shall not reduce the number of securities Stanford may purchase under this Section&nbsp;7.4 or under any applicable Rights Agreement; and (ii)&nbsp;Stanford shall not be obligated to purchase under this Section&nbsp;7.4 any
Surrozen securities it has the right to acquire under Section&nbsp;7.2 or 7.3 above. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Rights Agreements; Information Rights; Notice; Elections.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Surrozen shall ensure that each Rights Agreement executed by Stanford in connection with a Qualifying Offering
will grant to Stanford the same rights as all other investors who are parties to that Rights Agreement. In particular, Surrozen shall ensure that each such Rights Agreement will grant to Stanford the same right to purchase additional securities in
future offerings, the same information rights, and the same registration rights as are granted to other parties thereto, including all such rights granted to any investor designated as a &#147;Major Investor&#148; or other similar designation, even
if Stanford is not so designated. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any terms to the contrary contained in any applicable Rights Agreement: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stanford shall not have any representation on the Board of Directors or rights to attend meetings of the Board
of Directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In connection with all Qualifying Offerings, Surrozen shall give Stanford notice of the terms of the offering,
including: [****]; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stanford may elect to exercise its Purchase Right, in whole or in part, by notice given to Surrozen within
[****] after receipt of Surrozen&#146;s notice (&#147;Notice Period&#148;). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 11 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Stanford has no information rights under a Rights Agreement and to the extent that such information has been
prepared by Surrozen for other purposes, so long as Stanford holds Surrozen securities, Surrozen shall furnish to Stanford, upon request [****]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any notice provision in this Agreement to the contrary, any notice given under this Agreement
that refers or relates to any of Section&nbsp;7.4 above or this Section&nbsp;7.5 shall be copied concurrently to [****]; provided, however, that delivery of the copy will not by itself constitute notice for any purpose under this Agreement.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><B>License Maintenance Fee.</B> Surrozen will pay Stanford a yearly license maintenance fee on the anniversary of the
Effective Date as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Yearly maintenance payments are nonrefundable, but they are creditable each year as described in Section&nbsp;7.10. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Milestone Payments.</B> Surrozen will pay Stanford the following milestone payments: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[[****]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 12 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Earned Royalty.</B> Surrozen will pay Stanford earned royalties of [****] on Net Sales of a Licensed Product
that is covered by a Valid Claim. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Earned Royalty if Surrozen Challenges the Patent.</B> Notwithstanding the above, should Surrozen bring an
action seeking to invalidate any Licensed Patent, Surrozen will pay royalties to Stanford at the rate of [****] during the pendency of such action. Moreover, should the outcome of such action determine that any claim of a patent challenged by
Surrozen is both valid and infringed by a Licensed Product, Surrozen will pay royalties at the rate of [****]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Creditable Payments.</B> The license maintenance fee for a year may be offset against earned royalty
payments due on Net Sales occurring in that year. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">For example: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if Surrozen pays Stanford a $10 maintenance payment for year Y, and according to Section&nbsp;7.8 $15 in earned
royalties are due Stanford for Net Sales in year Y, Surrozen will only need to pay Stanford an additional $5 for that year&#146;s earned royalties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if Surrozen pays Stanford a $10 maintenance payment for year Y, and according to Section&nbsp;7.8 $3 in earned
royalties are due Stanford for Net Sales in year Y, Surrozen will not need to pay Stanford any earned royalty payment for that year. Surrozen will not be able to offset the remaining $7 against a future year&#146;s earned royalties.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Obligation to Pay Royalties.</B> A royalty is due Stanford under this Agreement for any activity conducted
under the licenses granted. For convenience&#146;s sake, the amount of that royalty is calculated using Net Sales. Nonetheless, if certain Licensed Products are made, used, imported, or offered for sale before the date this Agreement terminates, and
those Licensed Products are sold after the termination date, Surrozen will pay Stanford an earned royalty for its exercise of rights based on the Net Sales of those Licensed Products. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Earned Royalties will be payable on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis
on Net Sales of Licensed Products until the last to expire Valid Claim covering Licensed Product in the Licensed Field of Use in the country of manufacture or sale. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Surrozen&#146;s payment of Earned Royalties due Stanford for Net Sales that occur during a <FONT STYLE="white-space:nowrap">Non-Valid</FONT>
Claim Period will be deferred until the end of such <FONT STYLE="white-space:nowrap">Non-Valid</FONT> Claim Period. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Escrow.</B> Surrozen shall not pay royalties into any escrow or other similar account.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 13 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Currency.</B> Surrozen will calculate the royalty on sales in currencies other than U.S. Dollars using the
appropriate foreign exchange rate for the currency quoted by the Wall Street Journal on the close of business on the last banking day of each calendar quarter. Surrozen will make royalty payments to Stanford in U.S. Dollars. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Taxes.</B> Surrozen will pay all <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> taxes related to royalty payments. These payments are not deductible from any payments due to Stanford. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interest.</B> Any payments not made when due will bear interest at the lower of (a) [****] or (b)&nbsp;the
maximum rate permitted by law. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ROYALTY REPORTS, PAYMENTS, AND ACCOUNTING </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Quarterly Earned Royalty Payment and Report.</B> Beginning with the first sale of a Licensed Product by
Surrozen or a sublicensee, Surrozen will submit to Stanford a written report (even if there are no sales) and an earned royalty payment within [****] after the end of each calendar quarter. This report will be in the form of Appendix B and will
state the number, description, and aggregate Net Sales of Licensed Product during the completed calendar quarter. The report will include an overview of the process and documents relied upon to permit Stanford to understand how the earned royalties
are calculated. With each report Surrozen will include any earned royalty payment due Stanford for the completed calendar quarter (as calculated under Section&nbsp;7.8). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Refund.</B> In the event that a validity or <FONT STYLE="white-space:nowrap">non-infringement</FONT>
challenge of a Licensed Patent brought by Surrozen is successful, Surrozen will have no right to recoup any royalties paid before or during the period challenge. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination Report.</B> Surrozen will pay to Stanford all applicable royalties and submit to Stanford a
written report within [****] after the license terminates. Surrozen will continue to submit earned royalty payments and reports to Stanford after the license terminates, until all Licensed Products made or imported under the license have been sold.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Accounting.</B> Surrozen will maintain records showing manufacture, importation, sale, and use of a Licensed
Product for [****]. Records will include general-ledger records showing cash receipts and expenses, and records that include: production records, customers, invoices, serial numbers, and related information in sufficient detail to enable Stanford to
determine the royalties payable under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">8.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Audit by Stanford.</B> Subject to reasonable advanced notice and during normal business hours, and no more
than once per each [****] period, Surrozen will allow Stanford or its designee to examine Surrozen&#146;s records for a period not to exceed the [****] prior to the audit request to verify payments made by Surrozen under this Agreement.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 14 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">8.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Paying for Audit.</B> Stanford will pay for any audit done under Section&nbsp;8.5. But if the audit reveals
an underreporting of earned royalties due Stanford of [****] or more for the period being audited, Surrozen will pay the audit costs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">8.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>[****]</B> </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXCLUSIONS AND NEGATION OF WARRANTIES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Representations of Stanford&#146;s Office of Technology Licensing.</B> To the extent it has knowledge as of
the Effective Date, Stanford&#146;s Office of Technology Licensing represents: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stanford has not granted or transferred any rights to any third party in a manner that would prevent Stanford
from granting the licenses to Surrozen under this Agreement, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">UW has exclusively granted Stanford the right to license UW&#146;s rights in the Licensed Patents to third
parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Negation of Warranties.</B> Stanford and UW provide Surrozen the rights granted in this Agreement AS IS and
WITH ALL FAULTS. Except as provided in Section&nbsp;9. 1, Stanford and UW make no representations and extend no warranties of any kind, either express or implied. Among other things, Stanford and UW disclaim any express or implied warranty:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">of merchantability, of fitness for a particular purpose; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">of <FONT STYLE="white-space:nowrap">non-infringement;</FONT> or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">arising out of any course of dealing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Representation of Licensed Patent.</B> Surrozen also acknowledges that Stanford and UW do not represent
or warrant: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the validity or scope of any Licensed Patent; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the exploitation of Licensed Patent or Technology will be successful. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 15 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEMNITY </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Surrozen will indemnify, hold harmless, and defend all Stanford and UW Indemnitees against any claim of any
kind arising out of or related to the exercise of any rights granted Surrozen under this Agreement or the breach of this Agreement by Surrozen. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">HHMI Indemnitees will be indemnified, defended by counsel acceptable to HHMI, and held harmless by Surrozen
from and against any claim, liability, cost, expense, damage, deficiency, loss, or obligation, of any kind or nature (including, without limitation, reasonable attorneys&#146; fees and other costs and expenses of defense) (collectively,
&#147;Claims&#148;), based upon, arising out of, or otherwise relating to this Agreement, including without limitation any cause of action relating to product liability or the use, handling, storage, or disposition of the Technology by Surrozen or
others who possess the Technology through a chain of possession leading back, directly or indirectly, to Surrozen. The previous sentence will not apply to any Claim that is determined with finality by a court of competent jurisdiction to result
solely from the gross negligence or willful misconduct of an HHMI Indemnitee. Notwithstanding any other provision of this Agreement, Surrozen&#146;s obligation to defend, indemnify and hold harmless the HHMI Indemnitees under this paragraph will not
be subject to any limitation or exclusion of liability or damages or otherwise limited in any way. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Indirect Liability.</B> Neither party shall be liable to the other party for any special, consequential,
lost profit, expectation, punitive or other indirect damages in connection with any claim arising out of or related to this Agreement, whether grounded in tort (including negligence), strict liability, contract, or otherwise. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Workers&#146; Compensation.</B> Surrozen will comply with all statutory workers&#146; compensation and
employers&#146; liability requirements for activities performed under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Insurance.</B> During the term of this Agreement, Surrozen will maintain Comprehensive General Liability
Insurance, including Product Liability Insurance, with a reputable and financially secure insurance carrier to cover the activities of Surrozen and its sublicensees; provided that Product Liability Insurance shall not be required to be maintained
until Surrozen&#146;s first use of Licensed Products in humans. The insurance will include all Stanford and UW Indemnitees and HHMI Indemnitees as additional insureds. The Comprehensive General Liability Insurance will provide minimum limits of
liability of [****], and will be increased prior to any first use of the Licensed Product in a human to a minimum limit of [****]. Insurance must cover claims incurred, discovered, manifested, or made during or after the expiration of this Agreement
and must be placed with carriers with ratings of at least [[****]]. Within [****] of the Effective Date of this Agreement, Surrozen will furnish a Certificate of Insurance evidencing primary coverage and additional insured requirements. Surrozen
will provide to Stanford [****] prior written notice of cancellation or material change to this insurance coverage. Surrozen will advise Stanford in writing that it maintains excess liability coverage (following form) over primary insurance for at
least the minimum limits set forth above. All insurance of Surrozen will be primary coverage; insurance of Stanford Indemnitees and HHMI Indemnitees will be excess and noncontributory. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 16 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXPORT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Surrozen and its affiliates and sublicensees shall comply with all United States laws and regulations controlling the export of licensed commodities and
technical data. (For the purpose of this paragraph, &#147;licensed commodities&#148; means any article, material or supply but does not include information; and &#147;technical data&#148; means tangible or intangible technical information that is
subject to U.S. export regulations, including blueprints, plans, diagrams, models, formulae, tables, engineering designs and specifications, manuals and instructions.) These laws and regulations may include, but are not limited to, the Export
Administration Regulations (15 CFR <FONT STYLE="white-space:nowrap">730-774),</FONT> the International Traffic in Arms Regulations (22 CFR <FONT STYLE="white-space:nowrap">120-130)</FONT> and the various economic sanctions regulations administered
by the U.S. Department of the Treasury (31 CFR <FONT STYLE="white-space:nowrap">500-600).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among other things, these laws and regulations prohibit
or require a license for the export or retransfer of certain commodities and technical data to specified countries, entities and persons. Surrozen hereby gives written assurance that it will comply with, and will cause its affiliates and
sublicensees to comply with all United States export control laws and regulations, that it bears sole responsibility for any violation of such laws and regulations by itself or its affiliates or sublicensees, and that it will indemnify, defend and
hold Stanford and UW and HHMI Indemnitiees harmless for the consequences of any such violation. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MARKING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before any Licensed Patent issues, Surrozen will mark Licensed Product with the words &#147;Patent Pending.&#148; Otherwise, Surrozen will mark Licensed
Product with the number of any issued Licensed Patent. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>STANFORD NAMES AND MARKS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Surrozen will not use (i)&nbsp;Stanford&#146;s, UW&#146;s or HHMI&#146;s name or other trademarks, (ii)&nbsp;the name or trademarks of any organization related
to Stanford, UW or HHMI, or (iii)&nbsp;the name of any Stanford, UW or HHMI faculty member, employee, student or volunteer without the prior written consent of the party (Stanford, UW or HHMI, as the case may be) whose name or trademark is being
used. Permission may be withheld at Stanford&#146;s, UW&#146;s or HHMI&#146;s sole discretion. This prohibition includes, but is not limited to, use in press releases, advertising, marketing materials, other promotional materials, presentations,
case studies, reports, websites, application or software interfaces, and other electronic media. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PROSECUTION AND PROTECTION OF PATENTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Patent Prosecution.</B> Stanford will be responsible for and will keep Surrozen reasonably informed as to
the preparing, filing, and prosecuting and maintaining the Licensed Patents using patent counsel selected by Stanford and reasonably acceptable to Surrozen. Surrozen will receive copies of all documentation and substantive
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 17 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
actions pertaining to the filing, prosecution, and maintenance of Licensed Patents. Surrozen will have reasonable opportunities to participate in decision making and Stanford will give Surrozen a
reasonable opportunity to comment on material documents filed with any patent office with respect to the License Patents and will consider in good faith and use reasonable efforts to incorporate Surrozen&#146;s comments. Stanford will, at
Surrozen&#146;s request, file, prosecute and maintain Licensed Patents in foreign countries. In the event Surrozen decides that it no longer intends to pay for prosecution or maintenance of one or more Licensed Patents, Surrozen shall give Stanford
a [****] notice. Stanford may in its discretion continue to prosecute and maintain such Licensed Patent(s) at its expense, in which case such Licensed Patent(s) shall no longer be covered by the licenses granted under this Agreement.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Patent Costs.</B> Within [****] after receiving a statement from Stanford, Surrozen will reimburse Stanford:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] to offset Licensed Patent&#146;s patenting expenses, including any interference or reexamination
matters, incurred by Stanford before the Effective Date. Surrozen is responsible for paying [****] of these past patenting expenses upon the Effective Date with the remaining amount of [****] due [[****]]; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for all Licensed Patent&#146;s patenting expenses, including any interference or reexamination matters,
incurred by Stanford after the Effective Date. In all instances, Stanford will pay the fees prescribed for large entities to the United States Patent and Trademark Office. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">14.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Infringement Procedure.</B> Surrozen will promptly notify Stanford if it believes a third party infringes a
Licensed Patent or if a third party files a declaratory judgment action with respect to any Licensed Patent. During the Exclusive term of this Agreement and if Surrozen is developing Licensed Product, Surrozen may have the right to institute a suit
against or defend any declaratory judgment action initiated by this third party as provided in Section <B>Error! Reference source not found.</B> through and including Section&nbsp;14.8. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><B>Surrozen Suit.</B> Subject to Section&nbsp;14.3, Surrozen has the first right to institute and prosecute a suit or defend any declaratory
judgment action so long as it conforms with the requirements of this Section&nbsp;14.4 [****]. If Surrozen decides to institute suit, it will notify Stanford in writing and give Stanford the opportunity to institute suit jointly as provided in
Section&nbsp;14.5. Surrozen will diligently pursue the suit and Surrozen will bear the entire cost of the litigation, including expenses and counsel fees incurred by Stanford if Stanford is named as a party pursuant to this Section&nbsp;14.4.
Surrozen will keep Stanford reasonably apprised of all developments in the suit, and will seek Stanford&#146;s input and approval on any substantive submissions or positions taken in the litigation regarding the scope, validity and enforceability of
the Licensed Patent. Surrozen will not prosecute, settle or otherwise compromise any such suit in a manner that adversely affects Stanford&#146;s interests without Stanford&#146;s prior written consent. Stanford may be named as a party [****] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 18 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">14.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Joint Suit.</B> If Stanford and Surrozen so agree, they may institute suit or defend the declaratory
judgment action jointly. If so, they will: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">prosecute the suit in both their names; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">bear the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs
[****]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">share any recovery or settlement [****]; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">agree how they will exercise control over the action. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">14.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Stanford Suit.</B> If neither Section&nbsp;14.4 nor 14.5 apply, Stanford may institute and prosecute a suit
or defend any declaratory judgment action so long as it conforms with the requirements of this Section&nbsp;14.6. Stanford may name Surrozen as a party for standing purposes. If Stanford decides to institute suit, it will notify Surrozen in writing
and give Surrozen the opportunity to institute suit jointly as provided in Section&nbsp;14.5. If Surrozen does not notify Stanford in writing that it desires to jointly prosecute the suit within [****] after the date of Stanford&#146;s notice to
Surrozen, [****]. Stanford will bear the entire cost of the litigation and will [****] of any recovery or settlement. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><B>Recovery.</B> If Surrozen sues under Section&nbsp;14.4, then any recovery in excess of any unrecovered litigation costs and fees will be
shared with Stanford as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">14.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Abandonment of Suit.</B> If either Stanford or Surrozen commences a suit and then wants to abandon the suit,
it will give [****] notice to the other party. The other party may continue prosecution of the suit after Stanford and Surrozen agree on the sharing of expenses and any recovery in the suit. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 19 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERMINATION </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination by Surrozen.</B> Surrozen may terminate this Agreement by giving Stanford written notice at
least 30 days in advance of the effective date of termination selected by Surrozen. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination by Stanford.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stanford may also terminate this Agreement if Surrozen: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is in material breach of any provision; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Termination under this Section&nbsp;15.2 will take effect 90 days after written notice by Stanford unless
Surrozen remedies the problem in that <FONT STYLE="white-space:nowrap">90-day</FONT> period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Surviving Provisions.</B> Surviving any termination or expiration are: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Surrozen&#146;s obligation to pay royalties accrued or accruable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any claim of Surrozen or Stanford, accrued or to accrue, because of any breach or default by the other party;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the provisions of Articles 8, 9, 10 and 19.5 and any other provision that by its nature is intended to survive;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Sublicenses hereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CHANGE OF CONTROL AND <FONT STYLE="white-space:nowrap">NON-ASSIGNABILITY</FONT> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Change of Control.</B> If there is a Change of Control, Surrozen will pay Stanford a <FONT
STYLE="white-space:nowrap">one-time</FONT> payment of [****] (&#147;Change of Control Fee&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Conditions of Assignment under Change of Control.</B> Surrozen may assign this Agreement as part of a Change
of Control upon prior and complete performance of the following conditions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Surrozen must give Stanford written notice of the assignment no later than [****] after such assignment,
including the new assignee&#146;s contact information; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 20 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the new assignee must agree in writing to Stanford to be bound by this Agreement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stanford must have received the full Change of Control Fee; provided that the Change of Control Fee shall only
be due <FONT STYLE="white-space:nowrap">one-time</FONT> on the first assignment of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>After the Assignment.</B> Upon a permitted assignment of this Agreement pursuant to Article 16, Surrozen
will be released of liability under this Agreement and the term &#147;Surrozen&#148; in this Agreement will mean the assignee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Bankruptcy.</B> In the event of a bankruptcy or insolvency, assignment is permitted only to a party that can
provide adequate assurance of future performance, including diligent development and sales of Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Nonassignability of Agreement.</B> Except in conformity with Sections 16.2 and 16.4, this Agreement is not
assignable by Surrozen under any other circumstances and any attempt to assign this Agreement by Surrozen is null and void. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DISPUTE RESOLUTION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">17.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Dispute Resolution by Arbitration.</B> Any dispute between the parties regarding any payments made or due
under this Agreement (including without limitation, any disputes arising under apportionment of Nonroyalty Sublicense Income pursuant to Section&nbsp;4.1) will be settled by arbitration in accordance with the [****], provided that in the case of a
good faith dispute as to the amount owed, Surrozen shall not be in breach of this Agreement and the cure period under Section&nbsp;15.2 shall be tolled until the amount owed has been finally determined in such an arbitration. The parties are not
obligated to settle any other dispute that may arise under this Agreement by arbitration. Notwithstanding the foregoing, no dispute affecting the rights or property of HHMI shall be subject to the arbitration provisions set forth in this Article 17.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">17.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Request for Arbitration.</B> Either party may request such arbitration. Stanford and Surrozen will mutually
agree in writing on a third party arbitrator within [****] of the arbitration request. The arbitrator&#146;s decision will be final and nonappealable and may be entered in any court having jurisdiction. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">17.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Discovery.</B> The parties will be entitled to discovery as if the arbitration were a civil suit in the
California Superior Court. The arbitrator may limit the scope, time, and issues involved in discovery. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 21 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">17.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Place of Arbitration.</B> The arbitration will be held in [****] unless the parties mutually agree in
writing to another place. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">17.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Patent Validity.</B> Any dispute regarding the validity of any Licensed Patent shall be litigated in the
courts located in Santa Clara County, California, and the parties agree not to challenge personal jurisdiction in that forum. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NOTICES </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">18.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Legal Action.</B> Surrozen will provide written notice to Stanford at least [****] prior to bringing an
action seeking to invalidate any Licensed Patent or a declaration of <FONT STYLE="white-space:nowrap">non-infringement.</FONT> [****] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">18.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>All Notices.</B> All notices under this Agreement are deemed fully given when written, addressed, and sent
as follows: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">All general notices to Surrozen are mailed or emailed to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">All financial invoices
to Surrozen (i.e., accounting contact) are <FONT STYLE="white-space:nowrap">e-mailed</FONT> to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">All progress report invoices to Surrozen (i.e., technical contact) are <FONT STYLE="white-space:nowrap">e-mailed</FONT> to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">All general notices to
Stanford are <FONT STYLE="white-space:nowrap">e-mailed</FONT> or mailed to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 22 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">All payments to Stanford are mailed to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">All progress reports to
Stanford are <FONT STYLE="white-space:nowrap">e-mailed</FONT> or mailed to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Any notice related to Section&nbsp;0 or Section&nbsp;0 (Stanford Purchase Rights) shall be copied concurrently to [****] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Either party may change its address with written notice to the other party. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">19.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Waiver.</B> No term of this Agreement can be waived except by the written consent of the party waiving
compliance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">19.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Choice of Law.</B> This Agreement and any dispute arising under it is governed by the laws of the State of
California, United States of America, applicable to agreements negotiated, executed, and performed within California. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">19.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entire Agreement.</B> The parties have read this Agreement and agree to be bound by its terms, and further
agree that it constitutes the complete and entire agreement of the parties and supersedes all previous communications, oral or written, and all other communications between them relating to the license and to the subject hereof. This Agreement may
not be amended except by writing executed by authorized representatives of both parties. No representations or statements of any kind made by either party, which are not expressly stated herein, will be binding on such party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">19.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exclusive Forum.</B> The state and federal courts having jurisdiction over Stanford, California, United
States of America, provide the exclusive forum for any court action between the parties relating to this Agreement. Surrozen submits to the jurisdiction of such courts, and waives any claim that such a court lacks jurisdiction over Surrozen or
constitutes an inconvenient or improper forum. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">19.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Beneficiary.</B> HHMI is not a party to this Agreement and has no liability to any licensee,
sublicensee, or user of anything covered by this Agreement, but HHMI is an intended third-party beneficiary of this Agreement and certain of its provisions are for the benefit of HHMI and are enforceable by HHMI in its own name.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 23 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">19.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Headings.</B> No headings in this Agreement affect its interpretation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">19.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Electronic Copy.</B> The parties to this document agree that a copy of the original signature (including an
electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the
absence of an original signature. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">19.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidentiality.</B> Stanford shall maintain the financial terms of this Agreement as well as the reports
and any information provided by Surrozen to Stanford pursuant to Sections 4.5, 6.2, 7.6, 8.1, 8.3, 8.5 and 8.7 of this Agreement, in confidence and not disclose such information or reports to any third party, except as required by law.
Stanford&#146;s obligation to Surrozen hereunder shall be fulfilled by using at least the same degree of care with Surrozen&#146;s confidential information as Stanford uses to protect its own confidential information. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 24 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties execute this Agreement in duplicate originals by their duly authorized officers or
representatives. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>THE&nbsp;BOARD&nbsp;OF&nbsp;TRUSTEES&nbsp;OF&nbsp;THE LELAND STANFORD JUNIOR UNIVERSITY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Katharine Ku</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Katharine Ku</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Executive&nbsp;Director,&nbsp;Technology&nbsp;Licensing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mar 23, 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>SURROZEN, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tim Kutzkey</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tim Kutzkey</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President and CEO</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mar 23, 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 25 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appendix A &#150; Milestones </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>[****]</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 26 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appendix B &#151; Sample Reporting Form </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[****] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 27 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appendix C &#150; Technology </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[****]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[****]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[****]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>[****]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[****]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[****] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 28 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appendix D &#151; UW Stock Issuance Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>[****] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 29 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[****] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 30 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[****] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 31 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL> (E<SMALL>QUITY</SMALL>) A<SMALL>GREEMENT</SMALL></B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[****] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 32 <SMALL>OF</SMALL> 32 <SMALL>FILED</SMALL> <SMALL>LAST</SMALL> <SMALL>SAVED</SMALL> 3/22/2016 </B></P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>8
<FILENAME>d40894dex1014.htm
<DESCRIPTION>EX-10.14
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.14</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.14 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE REGISTRANT
TREATS AS PRIVATE OR CONFIDENTIAL. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>A<SMALL>MENDMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>7/5/2016</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT No. 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO THE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE
AGREEMENT EFFECTIVE THE 23RD DAY OF MARCH 2016 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BETWEEN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STANFORD UNIVERSITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective the 5th day of July 2016, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (&#147;Stanford&#148;), an institution of higher education
having powers under the laws of the State of California, and Surrozen (&#147;Surrozen&#148;), a corporation having a principal place of business at 1700 Owens St., Suite 500, San Francisco, CA 94158 agree as follows: </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>BACKGROUND </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stanford and Surrozen are parties to a license agreement effective the 23rd day of March 2016 (&#147;Original Agreement&#148;) covering &#147;Surrogate WNT
Proteins&#148; disclosed in Stanford docket [****]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stanford and Surrozen wish to amend the Original Agreement to add additional past patent expenses.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>AMENDMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paragraph 14.2(A) of Original Agreement is hereby replaced by the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] to offset Licensed Patent&#146;s patenting expenses, including any interference or reexamination
matters, incurred by Stanford before the Effective Date. Surrozen is responsible for paying [****] of these past patenting expenses upon the Effective Date with the remaining amount of [****] due [****] of the Effective Date or [****], whichever
date occurs first; and </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OTHER TERMS </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All other terms of the Original Agreement remain in full force and effect. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties to this document agree that a copy of the original signature (including an electronic copy) may be
used for any and all purposes for which the original signature may have been used. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>AGE</SMALL> </B><B>1</B><B> <SMALL>OF</SMALL> </B><B>2</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>A<SMALL>MENDMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>7/5/2016</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The parties further waive any right to challenge the admissibility or authenticity of this
document in a court of law based solely on the absence of an original signature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Amendment No 1
in duplicate originals by their duly authorized officers or representatives. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Luis R. Mejia</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Luis R. Mejia</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Associate Director, OTL</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">July 14, 2016</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SURROZEN</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tim Kutzkey</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Tim Kutzkey</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President and CEO</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">July 14, 2016</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>AGE</SMALL> </B><B>2</B><B> <SMALL>OF</SMALL> </B><B>2</B> </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>9
<FILENAME>d40894dex1015.htm
<DESCRIPTION>EX-10.15
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.15</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.15 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE REGISTRANT
TREATS AS PRIVATE OR CONFIDENTIAL. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>A<SMALL>MENDMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>10/7/2016</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO THE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE
AGREEMENT EFFECTIVE THE 23RD DAY OF MARCH 2016 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BETWEEN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STANFORD UNIVERSITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SURROZEN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective the 7th day of October 2016, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (&#147;Stanford&#148;), an institution of higher
education having powers under the laws of the State of California, and Surrozen (&#147;Surrozen&#148;), a corporation having a principal place of business at 240 E. Grand Ave., 2nd Floor, South San Francisco, CA 94080 agree as follows: </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>BACKGROUND </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stanford and Surrozen are parties to a license agreement effective the 23rd day of March 2016 (&#147;Original Agreement&#148;) covering &#147;Surrogate WNT
Proteins&#148; disclosed in Stanford docket [****]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stanford and Surrozen wish to further amend the Original Agreement to add a new provisional patent
application to the license. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>AMENDMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paragraph 2.6 of Original Agreement is hereby deleted in its entirety and replaced with the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.6&nbsp;&nbsp;&nbsp;&nbsp;&#147;Licensed Patent&#148; means U.S. Patent Applications, [****], any foreign patent application corresponding thereto, and any
divisional, continuation, or reexamination application, extension, and each patent that issues or reissues from any of these patent applications. Any claim of an unexpired Licensed Patent is presumed to be valid unless it has been held to be invalid
by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken. &#147;Licensed Patent&#148; excludes any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuation-in-part</FONT></FONT> (CIP)
patent application or patent. Neither party shall file or authorize another party to file a CIP of any Licensed Patent without the written approval of the other Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>AGE</SMALL> </B><B>1</B><B> <SMALL>OF</SMALL> </B><B>2</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S13-348:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>A<SMALL>MENDMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>10/7/2016</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OTHER TERMS </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Within [****] following execution of this Amendment, Surrozen will pay Stanford [****] to cover past patent
costs for the added patent application. All other terms of the Original Agreement remain in full force and effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties to this document agree that a copy of the original signature (including an electronic copy) may be
used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original
signature. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Amendment No 2 in duplicate originals by their duly authorized
officers or representatives. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Katharine Ku</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executor Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Technology Licensing</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Oct 25, 2016</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SURROZEN</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tim Kutzkey</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Tim Kutzkey</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">10/24/16</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>AGE</SMALL> </B><B>2</B><B> <SMALL>OF</SMALL> </B><B>2</B> </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>10
<FILENAME>d40894dex1016.htm
<DESCRIPTION>EX-10.16
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.16</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.16 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE REGISTRANT
TREATS AS PRIVATE OR CONFIDENTIAL. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDMENT NO. 3 TO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXCLUSIVE (EQUITY) AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS AMENDMENT NO. 3 TO THE EXCLUSIVE (EQUITY) AGREEMENT (this &#147;Amendment&#148;) dated as of January&nbsp;19, 2021 (the &#147;Amendment
Date&#148;), is entered into between Surrozen, Inc., a Delaware corporation (hereinafter, &#147;Surrozen&#148;), having offices at 171 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080 and Board of Trustees of the Leland Stanford Junior
University (hereinafter, &#147;Stanford&#148;), an institution of higher education, having powers under the laws of the State of California, and having offices at 3000 El Camino Real, Building 5, Suite 300, Palo Alto, CA 94306-2100, with respect to
the following facts: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;The Parties entered into the EXCLUSIVE (EQUITY) AGREEMENT on March&nbsp;23, 2016, and
subsequently amended on July&nbsp;5, 2016 (Amendment No.&nbsp;1) and again on October&nbsp;7, 2016 (Amendment No.&nbsp;2; collectively the &#147;Agreement&#148;). All terms used, but not defined, herein shall have the respective meanings set forth
in the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B.&nbsp;&nbsp;&nbsp;&nbsp;The Parties now desire to amend the Agreement in certain respects on the terms and conditions
set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties hereby
amend the Agreement and otherwise agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Amendments</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Preamble is amended as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (&#147;Stanford&#148;), an
institution of higher education having powers under the laws of the State of California, and Surrozen, Inc. (&#147;Surrozen&#148;), a Delaware corporation having a principal place of business at 171 Oyster Point Blvd., Suite 400, South San
Francisco, CA 94080, is effective on the 23<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP> day of March, 2016 (&#147;Effective Date&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section 2.5 is amended as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Licensed Field of Use&#148; means treatment, palliation, diagnosis, assessment or prevention of any human
or veterinary disease, disorder or condition. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section 7.7 is amended as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Milestone Payments.</B> Surrozen will pay Stanford the following milestone payments: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[****] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section 7.8 is amended as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Earned Royalty.</B> Surrozen will pay Stanford earned royalties of [****] on Net Sales booked by Surrozen of a
Licensed Product that is covered by a Valid Claim. Surrozen will pay Stanford earned royalties of [****] on Net Sales booked by a <FONT STYLE="white-space:nowrap">sub-licensee</FONT> of a Licensed Product that is covered by a Valid Claim.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section 18.2 is amended as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>All Notices.</B> All notices under this Agreement are deemed fully given when written, addressed and sent as
follows: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">All general notices to Surrozen are mailed or emailed to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">All financial invoices to Surrozen (i.e., accounting contact) are emailed to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">All progress reports to Surrozen (i.e., technical contact) are emailed to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[****]Appendix A is amended as follows:[****] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Miscellaneous. </U></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1&nbsp;&nbsp;&nbsp;&nbsp;This Amendment shall be effective for all purposes as of January&nbsp;19, 2021. Except as otherwise expressly
modified by this Amendment, the Agreement shall remain in full force and effect in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2&nbsp;&nbsp;&nbsp;&nbsp;Upon execution of this Amendment, Surrozen will pay to Stanford a [****] amendment fee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3&nbsp;&nbsp;&nbsp;&nbsp;This Amendment may be executed in counterparts, each of which shall be deemed to be an original and together shall
be deemed to be one and the same agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4&nbsp;&nbsp;&nbsp;&nbsp;This Agreement has been executed in the State of California and
its validity, construction, and all rights under it shall be governed by the laws of the State of California without reference to conflicts of law principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have duly executed and delivered this Amendment as of the Amendment Date. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SURROZEN, INC.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Craig Parker</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sunita Rajdev</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Craig Parker</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Sunita Rajdev</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">CEO</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Senior Associate Director</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>11
<FILENAME>d40894dex1017.htm
<DESCRIPTION>EX-10.17
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.17</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.17 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I)&nbsp;NOT MATERIAL AND (II)&nbsp;THE
REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCLUSIVE LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (&#147;Stanford&#148;), an institution of higher education having powers
under the laws of the State of California, and Surrozen, Inc. (&#147;Surrozen&#148;), a corporation having a principal place of business at 171 Oyster Point Blvd, Suite 400, South San Francisco, CA, 94080, is effective on June&nbsp;6, 2018
(&#147;Effective Date&#148;). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>BACKGROUND </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Stanford has an assignment of an invention encompassing <FONT STYLE="white-space:nowrap">bi-specific</FONT> proteins that mimic <FONT
STYLE="white-space:nowrap">R-spo,</FONT> resulting in increased surface expression of Frizzled proteins and enhancement of Wnt signaling. It is entitled &#147;Surrogate RSPO Proteins&#148; and was invented in the laboratory of [****], a Howard
Hughes Medical Institute (&#147;HHMI&#148;) investigator at Stanford and is described in Stanford Docket [****]. The invention was made in the course of research supported by HHMI. Stanford wants to have the invention perfected and marketed as soon
as possible so that resulting products may be available for public use and benefit. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Affiliate</B>&#148; means, with respect to a specified entity, any person, corporation, or other
business entity which controls, is controlled by, or is under common control with such specified entity; and for this purpose, &#147;control&#148; of a corporation means the direct or indirect ownership of more than fifty percent (50%) of its voting
stock, and &#147;control&#148; of any other business entity means the direct or indirect ownership of greater than a fifty percent (50%) interest in the income of such business entity. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Change of Control</B>&#148; means the following, as applied only to the entirety of that part of
Surrozen&#146;s business that exercises all of the rights granted under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">acquisition of ownership directly or indirectly, beneficially or of record by any person or group (within the
meaning of the Exchange Act and the rules of the SEC or equivalent body under a different jurisdiction) of the capital stock of Surrozen representing more than [****] of either the aggregate ordinary voting power or the aggregate equity value
represented by the issued and outstanding capital stock of Surrozen; and/or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The sale of all or substantially all Surrozen&#146;s assets and/or business in one transaction or in a series
of related transactions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 1 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">provided, however, that in no event shall the sale of equity or other securities for the sole
purpose of financing Surrozen be a Change of Control. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Exclusive</B>&#148; means that, subject to Sections 3 and 5, Stanford will not grant further licenses
under the Licensed Patents in the Licensed Field of Use in the Licensed Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Further Sublicense</B>&#148; means any agreement between a Sublicensee and an entity that is not an
Affiliate of such Sublilcensee that contains a grant to Stanford&#146;s Licensed Patents regardless of the name given to the agreement by the parties; excluding any agreement to make, have made, use or sell Licensed Products on behalf of such
Sublicensee or any agreement with a third party performing activities on behalf of such Sublicensee, such as a contract research organization, clinical trial site, manufacturing organization, or distributor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>HHMI Indemnities</B>&#148; means HHMI and its trustees, officers, employees and agents.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Licensed Field of Use</B>&#148; means the treatment, palliation, or prevention of any human or animal
disease, disorder or condition, including the conduct of commercialization activities in furtherance thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Licensed Patent</B>&#148; means Stanford&#146;s US Provisional Patent Application, [****], any foreign
patent application corresponding thereto, and any divisional, continuation, or reexamination application, extension and each patent that issues or reissues from any of these patent applications. Any claim of an unexpired Licensed Patent is presumed
to be valid unless it has been held to be invalid by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken. &#147;Licensed Patent&#148; excludes any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">continuation-in-part</FONT></FONT> (CIP) patent application or patent. Neither party shall file or authorize another party to file a CIP of any Licensed Patent without the written approval of the other party.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Licensed Product</B>&#148; means any product or part of a product in the Licensed Field of Use, the
making, using, importing or selling of which, absent this license, infringes, induces infringement, or contributes to infringement of a Valid Claim. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Licensed R&amp;D Field of Use</B>&#148; means the conduct of research and development activities in
furtherance of applications within the Licensed Field of Use. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Licensed Territory</B>&#148; means worldwide. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Net Sales</B>&#148; means all gross revenue received by Surrozen or sublicensees (under both
Sublicenses as well as Further Sublicenses) from the sale, transfer or other disposition of Licensed Product to a third-party customer. Net Sales excludes the following items (but only as they pertain to the making, using, importing or selling of
Licensed Products, are included in gross revenue, and are separately billed): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">import, export, excise, value-added and sales taxes, and custom duties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">trade, quantity or cash discounts and customary rebates and chargebacks; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 2 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">costs of insurance, packing, and transportation from the place of manufacture to the customer&#146;s premises
or point of installation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">costs of installation at the place of use; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">credit for returns, allowances, or trades. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">For clarity, in the event there is any sale of Licensed Products between Surrozen and its sublicensee for resale, Net Sales shall be calculated
based on such resale to third parties, but not the sale between Surrozen and its sublicensee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In the event that a Licensed Product is sold
in combination with another product or active pharmaceutical ingredient which is not a Licensed Product, the amount paid to Stanford [****] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Other Field of Use</B>&#148; means all fields other than the Licensed Field of Use and the Licensed
R&amp;D Field of Use. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Patent Matters</B>&#148; means preparing, filing, and prosecuting broad and extensive patent claims
(including any opposition, interference or reexamination actions or other proceedings established by the America Invents Act or any foreign counterpart) for Standord&#146;s benefit in the Licensed Territory and for maintaining all Licensed Patents.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Stanford Indemnities</B>&#148; means Stanford, Stanford Health Care and Lucile Packard Children&#146;s
Hospital at Stanford and their respective trustees, officers, employees, students, agents, faculty, representatives, and volunteers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Sublicense</B>&#148; means any agreement between Surrozen and a
<FONT STYLE="white-space:nowrap">non-Affiliate</FONT> third party that contains a grant to Stanford&#146;s Licensed Patents regardless of the name given to the agreement by the parties; excluding any agreement to make, have made, use or sell
Licensed Products on behalf of Surrozen or any agreement with a third party performing activities on behalf of Surrozen, such as a contract research organization, clinical trial site, manufacturing organization, or distributor.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Valid Claim</B>&#148; means (a)&nbsp;any claim of an issued and unexpired Licensed Patent which has
not been held unenforceable or invalid by a court or other governmental agency of competent jurisdiction from which no appeal can be taken and which has not been disclaimed or admitted to be invalid or unenforceable through abandonment, reissue,
disclaimer or otherwise, or (b)&nbsp;a pending claim in a pending Licensed Patent application, provided that if such pending claim does not issue as a valid and enforceable claim within [****] from its earliest priority date, such pending claim will
cease to be a Valid Claim unless and until actually issued. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 3 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GRANT </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Grant.</B> Subject to the terms and conditions of this Agreement, Stanford grants Surrozen: (a)&nbsp;an
Exclusive license under the Licensed Patent in the Licensed Field of Use to make, have made, use, import, offer to sell and sell Licensed Product in the Licensed Territory, (b)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license
under the Licensed Patent in the Licensed R&amp;D Field of Use to make, have made and use Licensed Product in the Licensed Territory and (c)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under the Licensed Patents in the Other
Field of Use to make, have made, use, and import, but not offer to sell or sell, Licensed Product in the Licensed Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exclusivity.</B> The license to the Licensed Patents under Section&nbsp;3.1(a) is Exclusive, including the
right to sublicense under Section&nbsp;3.5, in the Licensed Field of Use beginning on the Effective Date and ending when the last of the Licensed Patent expires. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Retained Rights.</B> Stanford retains the right, on behalf of itself, Stanford Health Care, Lucile Packard
Children&#146;s Hospital at Stanford and all other <FONT STYLE="white-space:nowrap">non-profit</FONT> research institutions, to practice the Licensed Patent for any <FONT STYLE="white-space:nowrap">non-profit</FONT> purpose, including sponsored
research and collaborations. Surrozen agrees that, notwithstanding any other provision of this Agreement, it has no right to enforce the Licensed Patent against any such institution. Stanford and any such other institution have the right to publish
any information included in a Licensed Patent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Specific Exclusion.</B> Stanford does not: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">grant to Surrozen any other licenses, implied or otherwise, to any patents or other rights of Stanford other
than those rights granted under Licensed Patent, regardless of whether the patents or other rights are dominant or subordinate to any Licensed Patent, or are required to exploit any Licensed Patent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">commit to Surrozen to bring suit against third parties for infringement, except as described in
Section&nbsp;14; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">agree to furnish to Surrozen any technology or technological information or to provide Surrozen with any
assistance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>HHMI Research License.</B> Surrozen acknowledges that it has been informed that the Licensed Patent was
developed, at least in part, by employees of HHMI and that HHMI has a fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> irrevocable, worldwide license to exercise any intellectual property
rights with respect to the Licensed Patent for research purposes, with the right to sublicense to <FONT STYLE="white-space:nowrap">non-profit</FONT> and governmental entities for research purposes, but with no other rights to assign or sublicense
(the &#147;HHMI License&#148;). This Agreement is explicitly made subject to the HHMI License. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SUBLICENSING </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Permitted Sublicensing.</B> Surrozen may grant sublicenses under any or all of the rights granted in
Section&nbsp;3.1(a) and Section&nbsp;3.1(b) during the Exclusive term [****], directly or through its Affiliates, sublicensees and/or their contractors, provided that any sublicense under the rights granted
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 4 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
in Section&nbsp;3.1(b) shall be granted only along with a sublicense under the rights granted in Section&nbsp;3.1(a). Surrozen&#146;s sublicensees under any Sublicense shall have the right to
extend its sublicense to the Licensed Patents to any of such sublicensee&#146;s Affiliates (each of such sublicensees and such Affiliates, a &#147;Sublicensee&#148;). Such Sublicensee may further sublicense their sublicense to the Licensed Patents
(through only one additional tier) to third parties, (i)&nbsp;so long as such third party is also granted rights under other intellectual property controlled by Surrozen or such Sublicensee, (ii)&nbsp;any sublicense under Section&nbsp;3.1(b) is
granted along with a sublicense under Section&nbsp;3.1(a), and (iii)&nbsp;Surrozen notifies Stanford of any such Further Sublicense with any such third party (&#147;Further Sublicensee&#148;) within [****] of the grant of such Further Sublicense and
provides a copy of the Further Sublicense to Stanford within such [****] period. If Surrozen does not notify and provide a copy of the Further Sublicense to Stanford University Office of Technology Licensing of a Further Sublicense within at least
[****] after the grant of such Further Sublicense, Surrozen agrees that it will pay [****] to Stanford. Sublicenses and Further Sublicenses with any exclusivity under the Licensed Patents must include diligence requirements sufficient to enable to
comply with its diligence requirements of Appendix A. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Required Sublicensing.</B> Stanford would like licensees to address unmet needs, such as those of neglected
patient populations or geographic areas, giving particular attention to improved therapeutics, diagnostics and agricultural technologies for the developing world. If Surrozen, directly or through its sublicensee(s), is unable or unwilling to serve
or develop a potential market or market territory for which there is a reputable company willing to be a sublicensee which has adequate resources and (a)&nbsp;such potential sublicensee has provided Stanford and Surrozen with a bona fide, detailed
proposal to develop a Licensed Product for such potential market or market territory, and (b)&nbsp;such proposed development is not within or competitive with Surrozen s current or planned Licensed Products, as reasonably demonstrated by Surrozen in
a written document to Stanford, then Surrozen will, at Stanford&#146;s request, negotiate in good faith a Sublicense with any such potential sublicensee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sublicense Requirements.</B> Any Sublicense or Further Sublicense: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is subject to this Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">will reflect that any sublicensee will not further sublicense, except as permitted under Section&nbsp;4.1, and
for avoidance of doubt, Further Sublicensees may not further sublicense; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">will prohibit sublicensee from paying royalties to an escrow or other similar account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">will expressly include the provisions of Sections 8, 9, 10 and Section&nbsp;19.5 for the benefit of Stanford
and/or HHMI as the case may be; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">will include the provisions of Section&nbsp;4.4 and require the sublicensee to assume all obligations of
Surrozen hereunder to the extent applicable to the sublicensee&#146;s activities under the sublicense, including the payment of royalties and milestones specified in Article 7 below, to Stanford or its designee, if this Agreement is
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 5 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
terminated, unless the sublicensee elects for its sublicense to terminate upon the termination of this Agreement. If the sublicensee is a <FONT STYLE="white-space:nowrap">spin-out</FONT> from
Surrozen, Surrozen must guarantee the sublicensee&#146;s performance with respect to the payment of Stanford&#146;s share of Sublicense royalties. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Litigation by Sublicensee.</B> Any Sublicense and Further Sublicense must include the following clauses:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event sublicensee brings an action seeking to invalidate any Licensed Patent: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sublicensee will [****] the payment paid to Surrozen during the pendency of such action. Moreover, should the
outcome of such action determine that any claim of a patent challenged by the sublicensee is both valid and infringed by a Licensed Product, sublicensee will pay [****] the payment paid under the original Sublicense; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sublicensee will have no right to recoup any royalties paid before or during the period challenge;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any dispute regarding the validity of any Licensed Patent shall be litigated in the courts located in Santa
Clara County, and the parties agree not to challenge personal jurisdiction in that forum; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sublicensee shall not pay royalties into any escrow or other similar account. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sublicensee will provide written notice to Stanford at least [****] prior to bringing an action seeking to
invalidate a Licensed Patent. Sublicensee will include with such written notice [****]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding the foregoing, in the event a sublicensee files a counterclaim or defense asserting the
invalidity of one or more Licensed Patents in response to an actual infringement suit in the Other Field of Use directed to the Licensed Patents initiated by Stanford, such sublicensee shall not be deemed to have brought an action seeking to
invalidate a Licensed Patent and Sections 4.4(A) and (B)&nbsp;above shall not apply. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Copy of Sublicenses and Sublicensee Royalty Reports.</B> Surrozen will submit to Stanford (A)&nbsp;a copy of
each Sublicense and each Further Sublicense, any subsequent amendments within [****] of execution; and (B)&nbsp;all copies of Sublicensees&#146; and Further Sublicensee&#146;s royalty reports for Licensed Products within [****] from the date of
receipt, as applicable. Each Sublicense and Further Sublicense may be redacted for information not necessary to determine compliance with this Agreement. Beginning with the first Sublicense, [****]. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sublicensing Fee.</B> For each third party that has entered into a Sublicense with Surrozen, Surrozen will
pay [****] to Stanford (each, a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 6 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
&#147;Sublicense Fee&#148;). For avoidance of doubt, no such payment shall be made on the basis of Surrozen entering into an agreement with a third party performing activities on behalf Surrozen,
such as a contract research organization, clinical trial site, or distributor. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Royalty-Free Sublicenses.</B> If Surrozen pays all royalties due Stanford from a sublicensee&#146;s Net
Sales, Surrozen may grant that sublicensee a royalty-free or <FONT STYLE="white-space:nowrap">non-cash:</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sublicense or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cross-license. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GOVERNMENT RIGHTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This Agreement is subject to Title 35 Sections <FONT STYLE="white-space:nowrap">200-204</FONT> of the United States Code. Among other things,
these provisions provide the United States Government with nonexclusive rights in the Licensed Patent. They also impose the obligation that Licensed Product sold or produced in the Untied States be &#147;manufactured substantially in the United
States,&#148; subject to such waivers as may be obtained under applicable laws. Surrozen will ensure all obligations of these provisions are met. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DILIGENCE </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Milestones.</B> Because the invention is not yet commercially viable as of the Effective Date, Surrozen,
directly or through its Affiliates, sublicensees or partners and/or its or their contractors, will use commercially reasonable efforts to develop, manufacture and sell a Licensed Product. In addition, Surrozen, directly or through its Affiliates,
sublicensees or partners and/or its or their contractors, will meet the milestones shown on the attached Exhibit A. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Stanford agrees to grant reasonable extensions to the target dates of any applicable milestone and the subsequent milestones (without payment)
if Surrozen&#146;s failure to meet the applicable milestones is due to [****]. If any diligence milestone is extended, all subsequent milestones also shall be extended. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Progress Report.</B> By [****] of each year, Surrozen will submit a written annual report to Stanford
covering the preceding calendar year. The report will include information sufficient to enable Stanford to satisfy reporting requirements of the U.S. Government and for Stanford to ascertain progress by Surrozen toward meeting this Agreement&#146;s
diligence requirements. Each report will describe, where relevant: Surrozen&#146;s progress toward commercialization of Licensed Product, [****]. For the purpose of facilitating Stanford&#146;s accounting practices, including with respect to
payments made to its inventors of the Licensed Patents, Surrozen will specifically identify each claim of a Licensed Patent that covers each Licensed Product. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 7 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Clinical Trial Notice.</B> Surrozen will notify the Stanford University Office of Technology Licensing at
least [****] prior to enrolling the first patient in any human clinical trials at Stanford. If Surrozen does not notify Stanford University Office of Technology Licensing at least [****] prior to enrolling the first patient in a clinical trial at
Stanford, Surrozen agrees that it will pay [****] to Stanford. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ROYALTIES </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Issue Royalty.</B> Surrozen will pay to Stanford a noncreditable, nonrefundable license issue royalty of
[****] upon signing this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Purchase Right.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stanford shall have the right, but not the obligation, to purchase for cash up to its Share of the securities
issued in any Qualifying Offering on the terms, and subject to the conditions, set forth in this Section&nbsp;7.2 and Section&nbsp;7.3 (the &#147;Purchase Right&#148;). For purposes of this Section&nbsp;7.2 and Section&nbsp;7.3:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Adjustment Event&#148; means the final closing of the first Threshold Qualifying Offering.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Board of Directors&#148; means (i)&nbsp;if Surrozen is organized as a corporation, its board of
directors, and (ii)&nbsp;if Surrozen is organized as a limited liability company, Surrozen manager(s) or member(s) or both that have the power to direct the principal management and activities of Surrozen, whether through ownership of voting
securities, by agreement, or otherwise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Qualifying Offering&#148; means a private offering of Surrozen&#146;s equity securities (or securities
convertible into or exercisable for Surrozen&#146;s equity securities) for cash (or in satisfaction of debt issued for cash) and which includes investment by one or more venture capital, professional angel, corporate or other similar institutional
investors other than Stanford. For the avoidance of doubt, if Surrozen is a limited liability company, then &#147;equity securities&#148; means limited liability company interests in Surrozen. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Share&#148; means: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] with respect to any Qualifying Offering having a closing on or before the date of an Adjustment Event;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with respect to any Qualifying Offering having a closing after an Adjustment Event, but before a Termination
Event, the percentage necessary for Stanford to maintain its pro rata ownership interest in Surrozen on a Fully-Diluted Basis. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 8 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Threshold Qualifying Offering&#148; means anyt Qualifying Offering which either (i)&nbsp;is at least
[****] in size or (ii)&nbsp;involves the sale to outside investors of at least [****] of the equity securities outstanding after such round on a Fully-Diluted Basis. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties shall construe the term &#147;Fully-Diluted Basis&#148; <U>mutatis</U> <U>mutandis</U> in the case
where Surrozen is organized as a limited liability company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Purchase Right shall terminate upon the earliest to occur of the following (each a &#147;Termination
Event&#148;): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stanford&#146;s execution of an investor rights agreement or similar agreement (each a &#147;Rights
Agreement&#148;) in connection with a Threshold Qualifying Offering so long the Rights Agreement satisfies the terms of this Section&nbsp;7.2 and Section&nbsp;7.3 below; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stanford purchases less than its entire Share of a Qualifying Offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stanford fails to give an election notice within the Notice Period for a Qualifying Offering which has its
final closing within [****] of the date such notice is received by Stanford and which is closed on terms that are the same or less favorable to the investors as the terms stated in Surrozen&#146;s notice to Stanford; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The closing of a firm commitment underwritten public offering of Surrozen&#146;s common stock; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The closing of the sale of all or substantially all of Surrozen&#146;s assets to a company publicly traded on
one of the major recognized exchanges. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Purchase Right shall not apply to the issuance of securities: (i)&nbsp;to employees, individuals who are
members of Surrozen&#146;s Board of Directors as of the time of issuance, and service providers to Surrozen pursuant to a plan approved by Surrozen&#146;s Boazrd of Directors; or (ii)&nbsp;as additional consideration in lending or leasing
transactions; or (iii)&nbsp;to an entity pursuant to an arrangement that Surrozen&#146;s Board of Directors determines in good faith is a strategic partnership or similar arrangement of Surrozen (i.e., an arrangement in which the entity&#146;s
purchase of securities is not primarily for the purpose of financing Surrozen); or (iv)&nbsp;to owners of another entity in connection with the acquisition of that entity by Surrozen. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Surrozen has entered into more than one Exclusive (Equity) Agreement or other agreement to license
intellectual property from Stanford, and Stanford has fully exercised its right to purchase its Share in connection with a Qualifying Offering under any such agreement, Stanford will waive its right to purchase its Share in connection with a
Qualifying Offering under all other applicable agreements. In the event that Stanford has not fully exercised its right to purchase its Share in connection with a Qualifying Offering under any agreement, then Stanford may only exercise its right to
purchase under a single agreement, and will waive its right to purchase under all others. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 9 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Rights Agreements; Information Rights; Notice; Elections.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Surrozen shall ensure that each Rights Agreement executed by Stanford in connection with a Qualifying Offering
will grant to Stanford the same rights as all other investors who are parties to that Rights Agreement. In particular, Surrozen shall ensure that each such Rights Agreement will grant to Stanford the same right to purchase additional securities in
future offerings, the same information rights, and the same registration rights as are granted to other parties thereto, including all such rights granted to any investor designated as a &#147;Major Investor&#148; or other similar designation, even
if Stanford is not so designated. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any terms to the contrary contained in any applicable Rights Agreement: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stanford shall not have any representation on the Board of Directors or rights to attend meetings of the Board
of Directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In connection with all Qualifying Offerings, Surrozen shall give Stanford notice of the terms of the offering,
including: [****]; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stanford may elect to exercise its Purchase Right, in whole or in part, by notice given to Surrozen within
[****] after receipt of Surrozen&#146;s notice (&#147;Notice Period&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Stanford has no information rights under a Rights Agreement and to the extent that such information has been
prepared by Surrozen for other purposes, so long as Stanford holds Surrozen securities, Surrozen shall furnish to Stanford, upon request [****]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any notice provision in this Agreement to the contrary, any notice given under this Agreement
that refers or relates to any of Section&nbsp;7.2 above or this Section&nbsp;7.3 shall be copied concurrently to [****]; <U>provided</U>, <U>however</U>, that delivery of the copy will not by itself constitute notice for any purpose under this
Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 10 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties acknowledge that Stanford participated in Surrozen&#146;s Series A preferred stock financing prior
to the date of this Agreement, and in connection therewith, Stanford became a party to that certain Investors&#146; Rights Agreement, dated [****], among Surrozen, Stanford and certain other stockholders of Surrozen (as it may be amended from time
to time, the &#147;Rights Agreement&#148;), pursuant to which Stanford has the right to participate in future financings of Surrozen on the terms set forth in the Rights Agreement. Therefore, notwithstanding anything to the contrary in this
Agreement, the parties acknowledge and agree that a Termination Event has occurred resulting in the termination of Stanford&#146;s Participation Right hereunder as described in Section&nbsp;7.2(B). For the avoidance of doubt, Section&nbsp;7.2 of
this Agreement is not applicable <U>(other than, in each case, the definitions set forth in Section</U><U></U><U>&nbsp;7.2(A)(1)-(6))</U> and Stanford shall have no rights with respect to, and Surrozen shall have no obligations to Stanford under,
Section&nbsp;7.2 of this Agreement <STRIKE>(other than, in each case, the definitions set forth in Section</STRIKE><STRIKE></STRIKE><STRIKE>&nbsp;7.2(A)(1) (6)</STRIKE>. Moreover, so long as Stanford is a party to the Rights Agreement and
notwithstanding anything to the contrary in this Agreement, (i)&nbsp;Sections 7.3 (A), (C) and (D)&nbsp;of this Agreement (together, the &#147;Participation Provisions&#148;) shall not be applicable and Stanford shall have no rights with respect to,
and Surrozen shall have no obligations to Stanford under, such Participation Provisions and (ii)&nbsp;Stanford shall at all times be deemed a &#147;Major Investor&#148; under the Rights Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>License Maintenance Fee.</B> Beginning on the first anniversary of the Effective Date and each anniversary
thereafter, Surrozen will pay Stanford a yearly license maintenance fee as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****]. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Yearly license maintenance payments are nonrefundable, but they are creditable each year as described in Section&nbsp;7.8. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Milestone Payments.</B> Surrozen will pay Stanford the following milestone payments: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Due <FONT STYLE="white-space:nowrap">one-time</FONT> on the 1st Licensed Product to achieve the below milestones: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****]. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 11 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Earned Royalty.</B> Surrozen will pay Stanford earned royalties [****] on Net Sales of a Licensed Product
that is covered by a Valid Claim </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Earned Royalty if Surrozen Challenges the Patent.</B> Notwithstanding the above, should Surrozen bring an
action seeking to invalidate any Licensed Patent, Surrozen will pay royalties to Stanford at the rate of [****] during the pendency of such action. Moreover, should the outcome of such action determine that any claim of a patent challenged by
Surrozen is both valid and infringed by a Licensed Product, Surrozen will pay royalties at the rate of [****]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Creditable Payments.</B> The license maintenance fee for a year may be offset against earned royalty
payments due on Net Sales occurring in that year. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">For example: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if Surrozen pays Stanford a $10 maintenance payment for year Y, and according to Section&nbsp;7.6 $15 in earned
royalties are due Stanford for Net Sales in year Y, Surrozen will only need to pay Stanford an additional $5 for that year&#146;s earned royalties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if Surrozen pays Stanford a $10 maintenance payment for year Y, and according to Section&nbsp;7.6 $3 in earned
royalties are due Stanford for Net Sales in year Y, Surrozen will not need to pay Stanford any earned royalty payment for that year. Surrozen will not be able to offset the remaining $7 against a future year&#146;s earned royalites.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Obligation to Pay Royalties.</B> A royalty is due Stanford under this Agreement for any activity conducted
under the licenses granted. For convenience&#146;s sake, the amount of that royalty is calculated using Net Sales. Nonetheless, if certain Licensed Products are made, used, imported, or offered for sale before the date this Agreement terminates, and
those Licensed Products are sold after the termination date, Surrozen will pay Stanford an earned royalty for its exercise of rights based on the Net Sales of those Licensed Products. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Earned Royalties will be payable on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis
on Net Sales of Licensed Products until the last to expire Valid Claim covering Licensed Product in the Licensed Field of Use in the country of manufacture or sale. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Escrow.</B> Surrozen shall not pay royalties into any escrow or other similar account.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Currency.</B> Surrozen will calculate the royalty on sales in currencies other than U.S. Dollars using the
appropriate foreign exchange rate for the currency quoted by the Wall Street Journal on the close of business on the last banking day of each calendar quarter. Surrozen will make royalty payments to Stanford in U.S. Dollars. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Taxes.</B> Surrozen will pay all <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> taxes related to royalty payments. These payments are not deductible from any payments due to Stanford. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 12 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interest.</B> Any payments not made when due will bear interest at the lower of (a) [****] or (b)&nbsp;the
maximum rate permitted by law. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ROYALTY REPORTS, PAYMENTS, AND ACCOUNTING </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Quarterly Earned Royalty Payment and Report.</B> Beginning with the first sale of a Licensed Product by
Surrozen or a sublicensee or a first Sublicense, whichever is first, Surrozen will submit to Stanford a written report (even if there are no sales or Sublicenses) and an earned royalty payment and a Sublicense Fee payment within [****] after the end
of each calendar quarter. This report will be in the form of Appendix B and will state the number, description, and aggregate Net Sales of Licensed Product during the completed calendar quarter and details about any Sublicenses. The report will
include an overview of the process and documents relied upon to permit Stanford to understand how the earned royalties are calculated. With each report Surrozen will include any earned royalty payment and Sublicense Fee payment due Stanford for the
completed calendar quarter (as calculated under Section&nbsp;7.6 and Section&nbsp;4.6). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Refund.</B> In the event that a validity or <FONT STYLE="white-space:nowrap">non-infringement</FONT>
challenge of a Licensed Patent brought by Surrozen is successful, Surrozen will have no right to recoup any royalties paid before or during the period challenge. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination Report.</B> Surrozen will pay to Stanford all applicable royalties and submit to Stanford a
written report within [****] after the license terminates. Surrozen will continue to submit earned royalty payments and reports to Stanford after the license terminates, until all Licensed Products made or imported under the license have been sold.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Accounting.</B> Surrozen will maintain records showing manufacture, importation, sale, and use of a Licensed
Product for [****]. Records will include general-ledger records showing cash receipts and expenses, and records that include: production records, customers, invoices, serial numbers, and related information in sufficient detail to enable Stanford to
determine the royalties payable under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Audit by Stanford.</B> Subject to reasonable advanced notice and during normal business hours, and no more
than once per each [****] period, Surrozen will allow Stanford or its designee to examine Surrozen&#146;s records for a period not to exceed the [****] prior to the audit request to verify payments made by Surrozen under this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Paying for Audit.</B> Stanford will pay for any audit done under Section&nbsp;8.5. But if the audit reveals
an underreporting of earned royalties due Stanford of [****] or more for the period being audited, Surrozen will pay the audit costs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[****] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 13 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXCLUSIONS AND NEGATION OF WARRANTIES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Representations of Stanford&#146;s Office of Technology Licensing.</B> To the extent it has knowledge as of
the Effective Date, Stanford&#146;s Office of Technology Licensing represents that Stanford has not granted or transferred any rights to any third party in a manner that would prevent Stanford from granting the licenses to Surrozen under this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Negation of Warranties.</B> Stanford provides Surrozen the rights granted in this Agreement AS IS and WITH
ALL FAULTS. Except as provided in Section&nbsp;9. 1, Stanford makes no representations and extends no warranties of any kind, either express or implied. Among other things, Stanford disclaims any express or implied warranty: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">of merchantability, of fitness for a particular purpose; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">of <FONT STYLE="white-space:nowrap">non-infringement;</FONT> or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">arising out of any course of dealing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Representation of Licensed Patent.</B> Surrozen also acknowledges that Stanford does not represent or
warrant: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the validity or scope of any Licensed Patent; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the exploitation of Licensed Patent will be successful. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEMNITY </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Surrozen will indemnify, hold harmless, and defend all Stanford Indemnitees against any claim of any kind
arising out of or related to the exercise of any rights granted Surrozen under this Agreement or the breach of this Agreement by Surrozen. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">HHMI and its trustees, officers, employees, and agents (collectively, &#147;HHMI Indemnities&#148;), will be
indemnified, defended by counsel acceptable to HHMI, and held harmless by Surrozen from and against any claim, liability, cost, expense, damage, deficiency, loss, or obligation, of any kind or nature (including, without limitation, reasonable
attorneys&#146; fees and other costs and expenses of defense) (collectively, &#147;Claims&#148;), based upon, arising out of, or otherwise relating to this Agreement or any Sublicense, including without limitation any cause of action relating to
product liability. The previous sentence will not apply to any Claim that is determined with finality by a court of competent jurisdiction to result solely from the gross negligence or willful misconduct of an HHMI Indemnitee. Notwithstanding any
other provision of this Agreement, Surrozen&#146;s obligation to defend, indemnify and hold harmless the HHMI Indemnitees under this paragraph will not be subject to any limitation or exclusion of liability or damages or otherwise limited in any
way. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 14 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Indirect Liability. EXCEPT FOR EITHER PARTY&#146;S INFRINGEMENT OF THE OTHER PARTY&#146;S INTELLECTUAL
PROPERTY RIGHTS AND INDEMNIFICATION OBLIGATIONS HEREUNDER</B>, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, LOST PROFIT, EXPECTATION, PUNITIVE OR OTHER INDIRECT DAMAGES IN CONNECTION WITH ANY CLAIM ARISING OUT OF
OR RELATED TO THIS AGREEMENT OR THE BREACH HEREOF, WHETHER GROUNDED IN TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, CONTRACT, OR OTHERWISE, AND REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. Except with respect to Stanford&#146;s
responsibilities and liabilities as expressly agreed by the parties in this Agreement, Stanford shall not have any responsibilities or liabilities whatsoever with respect to Licensed Products. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Workers&#146; Compensation.</B> Surrozen will comply with all statutory workers&#146; compensation and
employers&#146; liability requirements for activities performed under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Insurance.</B> During the term of this Agreement, Surrozen will maintain Comprehensive General Liability
Insurance, including Product Liability Insurance, with a reputable and financially secure insurance carrier to cover the activities of Surrozen and its sublicensees; provided that Product Liability Insurance shall not be required to be maintained
until Surrozen&#146;s first use of Licensed Products in humans. The insurance will include all Stanford and HHMI Indemnitees as additional insureds. The Comprehensive General Liability Insurance will provide minimum limits of liability of [****] and
will be increased prior to any first use of the Licensed Product in a human to a minimum limit of [****]. Insurance must cover claims incurred, discovered, manifested, or made during or after the expiration of this Agreement and must be placed with
carriers with ratings of at least [****]. Within [****] of the Effective Date of this Agreement, Surrozen will furnish a Certificate of Insurance evidencing primary coverage and additional insured requirements. Surrozen will provide to Stanford
[****] prior written notice of cancellation or material change to this insurance coverage. Surrozen will advise Stanford in writing that it maintains excess liability coverage (following form) over primary insurance for at least the minimum limits
set forth above. All insurance of Surrozen will be primary coverage; insurance of Stanford Indemnitees and HHMI Indemnitees will be excess and noncontributory. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXPORT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Surrozen shall and shall require its Affiliates and sublicensees to comply with all applicable United States laws and regulations controlling
the export of licensed commodities and technical data relating to this Agreement. (For the purpose of this paragraph, &#147;licensed commodities&#148; means any article, material or supply but does not include information; and &#147;technical
data&#148; means tangible or intangible technical information that is subject to U.S. export regulations, including blueprints, plans, diagrams, models, formulae, tables, engineering designs and specifications, manuals and instructions.) These laws
and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 15 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">regulations may include, but are not limited to, the Export Administration Regulations (15
CFR <FONT STYLE="white-space:nowrap">730-774),</FONT> the International Traffic in Arms Regulations (22 CFR <FONT STYLE="white-space:nowrap">120-130)</FONT> and the various economic sanctions regulations administered by the U.S. Department of the
Treasury (31 CFR <FONT STYLE="white-space:nowrap">500-600).</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Among other things, these laws and regulations may prohibit or require
a license for the export or retransfer of certain commodities and technical data to specified countries, entities and persons. Surrozen hereby gives written assurance that it will comply with, and will require its Affiliates and sublicensees to
comply with all applicable United States export control laws and regulations, that it understands it may be held responsible for any violation of such laws and regulations by itself or its Affiliates or sublicensees, and that it will indemnify,
defend and hold Stanford and HHMI Indemnitees harmless for the consequences of any such violation. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MARKING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Before any Licensed Patent issues, Surrozen will mark Licensed Product with the words &#147;Patent pending.&#148; Otherwise, Surrozen will mark
Licensed Product with the number of any issues Licensed Patent. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>STANFORD NAMES AND MARKS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Surrozen will not use (i)&nbsp;Stanford&#146;s or HHMI&#146;s name or other trademarks, (ii)&nbsp;the name of trademarks of any organization
related to Stanford or HHMI, or (iii)&nbsp;the name of any Stanford or HHMI faculty member, employee, student or volunteer without the prior written consent of the party (Stanford or HHMI, as the case may be), whose name or trademark is being used.
Permission may be withheld at Stanford&#146;s or HHMI&#146;s sole discretion. This prohibition includes, but is not limited to, use in press releases, advertising, marketing materials, other promotional materials, presentations, case studies,
reports, websites, application or software interfaces, and other electronic media. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PROSECUTION AND PROTECTION OF PATENTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Patent Prosecution.</B> Stanford will be responsible for and will keep Surrozen reasonably informed as to
the preparing, filing, and prosecuting and maintaining the Licensed Patents using patent counsel selected by Stanford and reasonably acceptable to Surrozen. Surrozen will receive copies of all documentation and substantive actions pertaining to the
filing, prosecution, and maintenance of Licensed Patents. Surrozen will have reasonable opportunities to participate in decision making and Stanford will give Surrozen a reasonable opportunity to comment on material documents filed with any patent
office with respect to the License Patents and will consider in good faith and use reasonable efforts to incorporate Surrozen&#146;s comments. Stanford will, at Surrozen&#146;s request, file, prosecute and maintain Licensed Patents in foreign
countries. In the event Surrozen decides that it no longer intends to pay for prosecution or maintenance of one or more Licensed Patents, Surrozen shall give Stanford a [****] notice. Stanford may in its discretion continue to prosecute and maintain
such Licensed Patent(s) at its expense, in which case such Licensed Patent(s) shall no longer be covered by the licenses granted under this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 16 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Patent Costs.</B> Within [****] after receiving a statement from Stanford, Surrozen will reimburse Stanford:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] to offset Licensed Patent&#146;s patenting expenses, including any interference or reexamination
matters, incurred by Stanford before the Effective Date; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for all Licensed Patent&#146;s patenting expenses, including any interference or reexamination matters,
incurred by Stanford after the Effective Date. In all instances, Stanford will pay the fees prescribed for large entities to the United States Patent and Trademark Office. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Infringement Procedure.</B> Each party will promptly notify the other party if it believes a third party
infringes a Licensed Patent or if a third party files a declaratory judgment action with respect to any Licensed Patent. During the Exclusive term of this Agreement and if Surrozen is developing Licensed Product, Surrozen may have the right to
institute a suit against or defend any declaratory judgment action initiated by this third party as provided in Section&nbsp;14.4 through and including Section&nbsp;14.8. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Surrozen Suit.</B> Surrozen has the first right to institute suit, and prosecute a suit or defend any
declaratory judgment action so long as it conforms with the requirements of this Section&nbsp;14.4 [****]. If Surrozen decides to institute suit or defend any action, it will notify Stanford in writing and give Stanford the opportunity to jointly
initiate suit or defend the action as provided in Section&nbsp;14.5. If Stanford declines to jointly initiate suit or defend the action, Surrozen will diligently pursue the suit and Surrozen will bear the entire cost of the litigation, including
expenses and counsel fees incurred by Stanford in the course of activities required of Stanford for Surrozen to pursue such suit. Surrozen will keep Stanford reasonably apprised of all developments in the suit, and will seek Stanford&#146;s input
and approval on any substantive submissions or positions taken in the litigation regarding the scope, validity and enforceability of the Licensed Patent. Surrozen will not prosecute, settle or otherwise compromise any such suit in a manner that
adversely affects Stanford&#146;s interests without Stanford&#146;s interests without Stanford&#146;s prior written consent. Stanford may be named as a party [****] </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 17 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Joint Suit.</B> If Stanford and Surrozen so agree, they may institute suit, and prosecute a suit or defend
the declaratory judgment action jointly. If so, they will: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">prosecute the suit in both their names; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">bear the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs
[****]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">share any recovery or settlement [****]; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">agree how they will exercise control over the action. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Stanford Suit.</B> If neither Section&nbsp;14.4 nor 14.5 apply, Stanford may institute suit, and prosecute a
suit or defend any declaratory judgment action so long it conforms with the requirements of this Section&nbsp;14.6. Stanford may name Surrozen as a party for standing purposes. If Stanford decides to institute suit and give Surrozen the opportunity
to institute suit jointly as provided in Section&nbsp;14.5, it will notify Surrozen in writing. If Surrozen does not notify Stanford in writing that it desires to jointly prosecute the suit within [****] after the date of Stanford&#146;s notice to
Surrozen with respect to an alleged infringement, [****]. Stanford will bear the entire cost of the litigation and [****] of any recovery or settlement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Recovery.</B> If Surrozen sues under Section&nbsp;14.4, then any recovery in excess of any unrecovered
litigation costs and fees will be shared with Stanford as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****] </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Abandonment of Suit.</B> If either Stanford or Surrozen commences a suit and then wants to abandon the suit
without entering into a settlement with the counterparty to the suit, it will give [****] notice to the other party. The other party may continue prosecution of the suit after Stanford and Surrozen agree on the sharing of expenses and any recovery
in the suit. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERMINATION </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination by Surrozen.</B> Surrozen may terminate this Agreement by giving Stanford written notice at
least 30 days in advance of the effective date of termination selected by Surrozen. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination by Stanford.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stanford may also terminate this Agreement if Surrozen: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****]; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 18 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is in material breach of any provision; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[****]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Termination under this Section&nbsp;15.2 will take effect 90 days after written notice by Stanford unless
Surrozen remedies the problem in that <FONT STYLE="white-space:nowrap">90-day</FONT> period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Surviving Provisions.</B> Surviving any termination or expiration are: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Surrozen&#146;s obligation to pay royalties accrued or accruable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any claim of Surrozen or Stanford, accrued or to accrue, because of any breach or default by the other party;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the provisions of Articles 8, 9, 10 and Section&nbsp;19.5 and any other provision that by its nature is
intended to survive; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Sublicenses hereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CHANGE OF CONTROL AND <FONT STYLE="white-space:nowrap">NON-ASSIGNABILITY</FONT> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Change of Control.</B> If there is a Change of Control, Surrozen will pay Stanford a [****] (&#147;Change of
Control Fee&#148;) upon the first assignment of this Agreement per Section&nbsp;16.2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Conditions of Assignment under Change of Control.</B> Surrozen may assign this Agreement to an Affiliate or
as part of a Change of Control upon prior and complete performance of the following conditions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Surrozen must give Stanford written notice of the assignment no later than [****] after such assignment,
including the new assignee&#146;s contact information; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the new assignee must agree in writing to Stanford to be bound by this Agreement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If assigned as part of a Change of Control, Stanford must have received the full Change of Control Fee,
provided that the Change of Control Fee shall only be due once time on the first assignment of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>After the Assignment.</B> Upon a permitted assignment of this Agreement pursuant to Section&nbsp;16,
Surrozen will be released of liability under this Agreement and the term &#147;Surrozen&#148; in this Agreement will mean the assignee. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 19 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Bankruptcy.</B> In the event of a bankruptcy or insolvency, assignment is permitted only to a party that can
provide adequate assurance of future performance, including diligent development and sales of Licensed Product. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Nonassignability of Agreement.</B> Except in conformity with Section&nbsp;16.2 and Section&nbsp;16.4, this
Agreement is not assignable by Surrozen under any other circumstances and any attempt to assign this Agreement by Surrozen is null and void. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DISPUTE RESOLUTION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Dispute Resolution by Arbitration.</B> Any dispute between the parties regarding any payments made or due
under this Agreement will be settled by arbitration in accordance with [****], provided that in the case of a good faith dispute as to the amount owed, Surrozen shall not be in breach of this Agreement and the cure period under Section&nbsp;15.2
shall be tolled until the amount owed has been finally determined in such an arbitration. The parties are not obligated to settle any other dispute that may arise under this Agreement by arbitration. Notwithstanding the foregoing, no dispute
affecting the rights or property of HHMI shall be subject to the arbitration provisions set forth in this Article 17. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Request for Arbitration.</B> Either party may request such arbitration. Stanford and Surrozen will mutually
agree in writing on a third-party arbitrator within [****] of the arbitration request. The arbitrator&#146;s decision will be final and nonappealable and may be entered in any court having jurisdiction. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Discovery.</B> The parties will be entitled to discovery as if the arbitration were a civil suit in the
California Superior Court. The arbitrator may limit the scope, time, and issues involved in discovery. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Place of Arbitration.</B> The arbitration will be held in [****] unless the parties mutually agree in
writing to another place. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Patent Validity.</B> Any dispute regarding the validity of any Licensed Patent shall be litigated in the
courts located in Santa Clara County, California, and the parties agree not to challenge personal jurisdiction in that forum. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NOTICES </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Legal Action.</B> Surrozen will provide written notice to Stanford at least [****] prior to bringing an
action seeking to invalidate any Licensed Patent or a declaration of <FONT STYLE="white-space:nowrap">non-infringement.</FONT> [****] </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 20 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>All Notices.</B> All notices under this Agreement are deemed fully given when written, addressed, and sent
as follows: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">All general notices to Surrozen are mailed or emailed to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">All financial invoices to
Surrozen (i.e., accounting contact) are <FONT STYLE="white-space:nowrap">e-mailed</FONT> to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">All progress report invoices to Surrozen (i.e., technical contact) are <FONT STYLE="white-space:nowrap">e-mailed</FONT> to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">All general notices to
Stanford are <FONT STYLE="white-space:nowrap">e-mailed</FONT> or mailed to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">All payments to Stanford are mailed to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">All progress reports to
Stanford are <FONT STYLE="white-space:nowrap">e-mailed</FONT> or mailed to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[****] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 21 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Any notice related to Section&nbsp;7.2 or Section&nbsp;7.3 (Stanford Purchase Rights) shall
be copied concurrently to [****]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Either party may change its address with written notice to the other party. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Waiver.</B> No term of this Agreement can be waived except by the written consent of the party waiving
compliance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Choice of Law.</B> This Agreement and any dispute arising under it is governed by the laws of the State of
California, United States of America, applicable to agreements negotiated, executed, and performed within California. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entire Agreement.</B> The parties have read this Agreement and agree to be bound by its terms, and further
agree that it constitutes the complete and entire agreement of the parties and supersedes all previous communications, oral or written, and all other communications between them relating to the license and to the subject hereof. The parties agree
that this Agreement supersedes all previous and future purchase orders. This Agreement may not be amended except by writing executed by authorized representatives of both parties. No representations or statements of any kind made by either party,
which are not expressly stated herein, will be binding on such party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exclusive Forum.</B> The state and federal courts having jurisdiction over Stanford, California, United
States of America, provide the exclusive forum for any court action between the parties relating to this Agreement. Surrozen submits to the jurisdiction of such courts, and waives any claim that such a court lacks jurisdiction over Surrozen or
constitutes an inconvenient or improper forum. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Third Party Beneficiary.</B> HHMI is not a party to this Agreement and has no liability to any licensee,
sublicensee, or user of anything covered by this Agreement, but HHMI is an intended third-party beneficiary of this Agreement and certain of its provisions are for the benefit of HHMI and are enforceable by HHMI in its own name.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Headings.</B> No headings in this Agreement affect its interpretation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Electronic Copy.</B> The parties to this document agree that a copy of the original signature (including an
electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the
absence of an original signature. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidentiality.</B> Stanford shall maintain the financial terms of this Agreement as well as the reports
and any information provided by Surrozen to Stanford pursuant to Sections 4.5, 6, 7, 8, 14, and 16 of this Agreement, in confidence and not disclose such information or reports to any third party, except as required by law. Stanford&#146;s
obligation to Surrozen hereunder shall be fulfilled by using at least the same degree of care with Surrozen&#146;s </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 22 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
confidential information as Stanford uses to protect its own confidential information. Stanford may acknowledge the existence of this Agreement and the extent of the grant in Article 3 to third
parties and provide aggregated financial information in standard reports, provided that such financial information is aggregated in a manner that would not allow discovery of any financial information specific to Surrozen. Surrozen hereby grants
permission for Stanford to include Surrozen&#146;s name and a link to Surrozen&#146;s website in Stanford&#146;s annual reports and on Stanford&#146;s websites that showcase technology transfer related stories. The parties acknowledge and agree that
Stanford may share the terms of this Agreement with HHMI in confidence. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 23 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties execute this Agreement in duplicate originals by their duly authorized officers or
representatives. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Elrod</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Scott Elrod</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Associate Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Jun 12, 2018</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>SURROZEN, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Craig C Parker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Craig C Parker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">CEO</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Jun 12, 2018</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 24 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appendix A &#150; Milestones </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[****] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 25 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><B>S16-362:MW</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>E<SMALL>XCLUSIVE</SMALL>&nbsp;L<SMALL>ICENSE</SMALL>&nbsp;A<SMALL>GREEMENT</SMALL></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>6/6/2018</B></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appendix B Sample Reporting Form </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[****] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>AGE</SMALL> 26 <SMALL>OF</SMALL> 26 </B></P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>12
<FILENAME>d40894dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&#146;S CONSENT </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We consent to the inclusion in this Registration Statement of <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. (the
&#147;Company&#148;) on Amendment No.&nbsp;1 to Form <FONT STYLE="white-space:nowrap">S-4</FONT> of our report dated March&nbsp;31, 2021 and May&nbsp;14, 2021, with respect to our audit of the financial statements of
<FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. as of December&nbsp;31, 2020 and for the period August&nbsp;21, 2020 (inception) through December&nbsp;31, 2020, which report appears in the Prospectus, which is part of this
Registration Statement. We also consent to the reference to our Firm under the heading &#147;Experts&#148; in such Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Marcum
LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Marcum LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Los
Angeles, CA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">June&nbsp;24, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>13
<FILENAME>d40894dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report dated April 30, 2021, with respect to the financial
statements of Surrozen, Inc. included in the Proxy Statement of Consonance-HFW Acquisition Corporation that is made a part of Amendment No. 1 to the Registration Statement (Form S-4 No. 333-256146) and related Prospectus of Consonance-HFW
Acquisition Corporation for the registration of 37,597,668 shares of its common stock. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst &amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redwood City, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 24, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>14
<FILENAME>d40894dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Consent of Person to be Named as Director </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. (the &#147;Company&#148;) is filing a Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act,
to the reference to me in the proxy statement/prospectus included in such Registration Statement as a future member of the board of directors of the Company, such appointment to commence upon the effective time of the merger described in the proxy
statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ C<SMALL>RAIG</SMALL> P<SMALL>ARKER</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Craig Parker</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">June&nbsp;24, 2021</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>15
<FILENAME>d40894dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Consent of Person to be Named as Director </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. (the &#147;Company&#148;) is filing a Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act,
to the reference to me in the proxy statement/prospectus included in such Registration Statement as a future member of the board of directors of the Company, such appointment to commence upon the effective time of the merger described in the proxy
statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ Anna Berkenblit</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Anna Berkenblit</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">June&nbsp;24, 2021</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>16
<FILENAME>d40894dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.3 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Consent of Person to be Named as Director </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. (the &#147;Company&#148;) is filing a Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act,
to the reference to me in the proxy statement/prospectus included in such Registration Statement as a future member of the board of directors of the Company, such appointment to commence upon the effective time of the merger described in the proxy
statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ T<SMALL>IM</SMALL> K<SMALL>UTZKEY</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Tim Kutzkey</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">June&nbsp;24, 2021</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>17
<FILENAME>d40894dex994.htm
<DESCRIPTION>EX-99.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.4 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Consent of Person to be Named as Director </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. (the &#147;Company&#148;) is filing a Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act,
to the reference to me in the proxy statement/prospectus included in such Registration Statement as a future member of the board of directors of the Company, such appointment to commence upon the effective time of the merger described in the proxy
statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ S<SMALL>HAO</SMALL><FONT STYLE="white-space:nowrap">-L</FONT><SMALL>EE</SMALL>
L<SMALL>IN</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Shao-Lee</FONT> Lin</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">June&nbsp;24, 2021</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>18
<FILENAME>d40894dex995.htm
<DESCRIPTION>EX-99.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.5 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Consent of Person to be Named as Director </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. (the &#147;Company&#148;) is filing a Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act,
to the reference to me in the proxy statement/prospectus included in such Registration Statement as a future member of the board of directors of the Company, such appointment to commence upon the effective time of the merger described in the proxy
statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ D<SMALL>AVID</SMALL> J. W<SMALL>OODHOUSE</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David J. Woodhouse</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">June&nbsp;24, 2021</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.6
<SEQUENCE>19
<FILENAME>d40894dex996.htm
<DESCRIPTION>EX-99.6
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.6 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Consent of Person to be Named as Director </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. (the &#147;Company&#148;) is filing a Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act,
to the reference to me in the proxy statement/prospectus included in such Registration Statement as a future member of the board of directors of the Company, such appointment to commence upon the effective time of the merger described in the proxy
statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ M<SMALL>ARY</SMALL> H<SMALL>AAK</SMALL>-F<SMALL>RENDSCHO</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mary Haak-Frendscho</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">June&nbsp;24, 2021</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.7
<SEQUENCE>20
<FILENAME>d40894dex997.htm
<DESCRIPTION>EX-99.7
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Consent of Person to be Named as Director </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. (the &#147;Company&#148;) is filing a Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act,
to the reference to me in the proxy statement/prospectus included in such Registration Statement as a future member of the board of directors of the Company, such appointment to commence upon the effective time of the merger described in the proxy
statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ M<SMALL>ACE</SMALL> R<SMALL>OTHENBERG</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mace Rothenberg</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">June&nbsp;24, 2021</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.8
<SEQUENCE>21
<FILENAME>d40894dex998.htm
<DESCRIPTION>EX-99.8
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Consent of Person to be Named as Director </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. (the &#147;Company&#148;) is filing a Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act,
to the reference to me in the proxy statement/prospectus included in such Registration Statement as a future member of the board of directors of the Company, such appointment to commence upon the effective time of the merger described in the proxy
statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ C<SMALL>HRISTOPHER</SMALL> C<SMALL>HAI</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Christopher Chai</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">June&nbsp;24, 2021</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.9
<SEQUENCE>22
<FILENAME>d40894dex999.htm
<DESCRIPTION>EX-99.9
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.9 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRELIMINARY PROXY CARD </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUBJECT TO COMPLETION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. Extraordinary General Meeting </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1 Palmer Square, Suite 305 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Princeton, NJ 08540 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXTRAORDINARY GENERAL MEETING </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF SHAREHOLDERS OF <FONT STYLE="white-space:nowrap">CONSONANCE-HFW</FONT> ACQUISITION CORP. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>YOUR VOTE IS IMPORTANT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned, revoking any previous proxies relating to these shares, hereby acknowledges receipt of the Notice and Proxy Statement, dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, in connection with the Extraordinary General Meeting of Shareholders (the &#147;Extraordinary General Meeting&#148;) to be held at
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.m., Eastern Time, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, via live webcast at the
following address: https://www.cstproxy.com/consonancehfw/sm2021, and hereby appoints Gad Soffer and Kevin Livingston, and each of them (with full power to act alone), the attorneys and proxies of the undersigned, with power of substitution to each,
to vote all ordinary shares of <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. (&#147;CHFW&#148;) registered in the name provided, which the undersigned is entitled to vote at the Extraordinary General Meeting, and at any
adjournments thereof, with all the powers the undersigned would have if personally present. Without limiting the general authorization hereby given, said proxies are, and each of them is, instructed to vote or act as follows on the proposals set
forth in the accompanying proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS PROXY, WHEN EXECUTED, WILL BE VOTED IN THE MANNER DIRECTED HEREIN. IF NO DIRECTION IS MADE,
THIS PROXY WILL BE VOTED &#147;FOR&#148; PROPOSALS 1 THROUGH 7. </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Continued and to be marked, dated and signed on reverse side)
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Please</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">mark vote</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">as</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">indicated</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">in this</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">example</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;FOR&#148; PROPOSALS 1, 2, 3, 4-A, <FONT
STYLE="white-space:nowrap">4-B,</FONT> <FONT STYLE="white-space:nowrap">4-C,</FONT> <FONT STYLE="white-space:nowrap">4-D,</FONT> 5, 6, 7&nbsp;and 8</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Proposal No. 1&#151;The Business Combination Proposal</B>&#151;<B>RESOLVED</B>, as an ordinary resolution, that CHFW&#146;s entry into the Business Combination Agreement, dated as of April&nbsp;15, 2021 (as may be amended,
supplemented or otherwise modified from time to time, the &#147;Business Combination Agreement&#148;), by and among CHFW, Perseverance Merger Sub, Inc., a Delaware corporation (&#147;Merger Sub&#148;), and Surrozen, Inc., a Delaware corporation,
which will change its name to Surrozen Operating, Inc. (&#147;Surrozen&#148;), a copy of which is attached to the proxy statement/prospectus as Annex A, pursuant to which, among other things, following the
<FONT STYLE="white-space:nowrap">de-registration</FONT> of CHFW as an exempted company in the Cayman Islands and the continuation and domestication of CHFW as a corporation in the State of Delaware with the name &#147;Surrozen, Inc.,&#148; (a)
Merger Sub will merge with and into Surrozen (the &#147;Merger&#148;), with Surrozen as the surviving company in the Merger and, after giving effect to such Merger, Surrozen shall be a wholly-owned subsidiary of CHFW and (b)&nbsp;at the Effective
Time, (i)&nbsp;each share and equity award (whether vested or unvested) of Surrozen outstanding as of immediately prior to the Effective Time will be exchanged for shares of common stock, par value $0.0001 per share, of New Surrozen (&#147;New
Surrozen Common Stock&#148;) or comparable vested or unvested equity awards that are settled or are exercisable for shares of New Surrozen Common Stock, as applicable, based on an implied Surrozen equity value of $200,000,000, on the terms and
subject to the conditions set forth in the Business Combination Agreement, certain related agreements (including the Subscription Agreements, the Company Stockholder Support Agreements, the CHFW Shareholder Transaction Support Agreements, the
Sponsor Letter Agreement and the Investor Rights Agreement, each in the form attached to the proxy statement/prospectus as Annex F, Annex H, Annex I, Annex E and Annex G, respectively), and the Transactions, be approved, ratified and confirmed in
all respects.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGAINST</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABSTAIN</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Proposal No.</B><B></B><B>&nbsp;2&#151; The Domestication Proposal</B>&#151;<B>RESOLVED</B>, as a special resolution, that CHFW be transferred by way of continuation to Delaware pursuant to Part XII of the Companies Act (as
revised) of the Cayman Islands and Section&nbsp;388 of the General Corporation Law of the State of Delaware and, immediately upon being <FONT STYLE="white-space:nowrap">de-registered</FONT> in the Cayman Islands, CHFW be continued and domesticated
as a corporation under the laws of the state of Delaware and, conditional upon, and with effect from, the registration of CHFW as a corporation in the State of Delaware, the name of CHFW be changed from
<FONT STYLE="white-space:nowrap">&#147;Consonance-HFW</FONT> Acquisition Corp.&#148; to &#147;Surrozen, Inc.<B>&nbsp;</B>(the &#147;Domestication&#148;)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGAINST</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABSTAIN</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Proposal No.&nbsp;3&#151;New Organizational Documents Proposal&#151;RESOLVED</B>, as a special resolution, that the Proposed Certificate of Incorporation and the Proposed Bylaws, copies of which are attached to the proxy
statement/prospectus as Annex&nbsp;C and Annex&nbsp;D, respectively, be approved as the certificate of incorporation and bylaws, respectively, of New Surrozen, effective upon the effectiveness of the Domestication;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGAINST</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABSTAIN</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Proposal No.</B><B></B><B>&nbsp;4&#151;Governing Documents Proposals</B>&#151;to consider and vote, on an advisory, non-binding basis, upon the following four (4)&nbsp;separate resolutions to approve that, upon the Domestication,
CHFW&#146;s existing amended and restated memorandum and articles of association (the &#147;Existing Governing Documents&#148;) be replaced in their entirety and the substitution in their place of the proposed new certificate of incorporation, a
copy of which is attached to the proxy statement/prospectus as Annex C (the &#147;Proposed Certificate of Incorporation&#148;) and the proposed new bylaws, a copy of which is attached to the proxy statement/prospectus as Annex&nbsp;D (the
&#147;Proposed Bylaws&#148;) of &#147;Surrozen, Inc.&#148; upon the Domestication (such proposals, collectively, the &#147;Governing Documents Proposals&#148;):</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGAINST</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABSTAIN</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>(A) Proposal No. 4&#151;Governing Documents Proposal A&#151;RESOLVED,</B>&nbsp;as an ordinary resolution, that the change in the authorized share capital of CHFW from (i) 350,000,000 Class&nbsp;A ordinary shares, par value
$0.0001 per share, (ii) 150,000,000 Class&nbsp;B ordinary shares, par value $0.0001 per share and (iii) 1,000,000 preference shares, par value $0.0001 per share, to (a) 500,000,000 shares of common stock, par value $0.0001 per share, of Surrozen,
Inc. (f/k/a Consonance-HFW Acquisition Corp.) upon and after the Domestication (&#147;New Surrozen&#148;) and (b) 10,000,000 shares of preferred stock, par value $0.0001 per share, of New Surrozen be approved.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGAINST</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABSTAIN</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>(B) Proposal No.&nbsp;4&#151;Governing Documents Proposal B&#151;RESOLVED,</B>&nbsp;as a special resolution, that the authorization to the board of directors of New Surrozen to issue any or all shares of preferred stock of New
Surrozen in one or more classes or series, with such terms and conditions as may be expressly determined by the board of directors of New Surrozen and as may be permitted by the Delaware General Corporation Law be approved.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGAINST</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABSTAIN</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>(C) Proposal No.&nbsp;4&#151;Governing Documents Proposal C&#151;RESOLVED,</B>&nbsp;as a special resolution, that the removal of the ability of New Surrozen stockholders to take action by written consent in lieu of a meeting
be approved.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGAINST</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABSTAIN</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>(D) Proposal No.&nbsp;4&#151;Governing Documents Proposal D&#151;RESOLVED,</B>&nbsp;as a special resolution, that the replacement of the Existing Governing Documents be approved and that all other immaterial changes necessary
or, as mutually agreed in good faith by CHFW and Surrozen, desirable in connection with the replacement of Existing Governing Documents with the Proposed Certificate of Incorporation and Proposed Bylaws as part of the Domestication (copies of which
are attached to the proxy statement/prospectus as Annex C and Annex D, respectively), including (i)&nbsp;changing the post-Business Combination corporate name from <FONT STYLE="white-space:nowrap">&#147;Consonance-HFW</FONT> Acquisition Corp.&#148;
to &#147;Surrozen, Inc.&#148; (which is expected to occur upon the consummation of the Domestication), (ii) making New Surrozen&#146;s corporate existence perpetual, (iii)&nbsp;adopting Delaware as the exclusive forum for certain stockholder
litigation and federal district courts of the United States of America as the exclusive forum for litigation arising out of the Securities Act of 1933, as amended and (iv)&nbsp;removing certain provisions related to CHFW&#146;s status as a blank
check company that will no longer be applicable upon consummation of the Business Combination be approved.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGAINST</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABSTAIN</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Proposal No.&nbsp;5&#151;The Share Issuance Proposal</B>&#151;<B>RESOLVED</B>, as an ordinary resolution, that for the purposes of complying with the applicable provisions of Nasdaq Stock Exchange Listing Rule 5635, the
issuance of shares of New Surrozen Common Stock in the Merger and in the transactions contemplated by those certain subscription agreements entered into by CHFW and certain investors party thereto (the &#147;PIPE Financing&#148;) be approved.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGAINST</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABSTAIN</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Proposal No.&nbsp;6&#151;The Incentive Award Plan Proposal</B>&#151;<B>RESOLVED</B>, as an ordinary resolution, that the Surrozen, Inc. 2021 Equity Incentive Plan, a copy of which is attached to the proxy statement/prospectus
as Annex J, be adopted and approved.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGAINST</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABSTAIN</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Proposal No.&nbsp;7&#151;The Equity Stock Purchase Plan Proposal</B>&#151;<B>RESOLVED</B>, as an ordinary resolution, that the Surrozen, Inc. 2021 Employee Stock Purchase Plan, a copy of which is attached to the proxy
statement/prospectus as Annex K, be adopted and approved.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGAINST</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABSTAIN</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Proposal No.&nbsp;8&#151;The Adjournment Proposal</B>&#151;<B>RESOLVED</B>, as an ordinary resolution, that the adjournment of the extraordinary general meeting to a later date or dates (A)&nbsp;to the extent necessary to ensure
that any required supplement or amendment to the proxy statement/prospectus is provided to CHFW shareholders or, if as of the time for which the extraordinary general meeting is scheduled, there are insufficient CHFW ordinary shares represented
(either in person or by proxy) to constitute a quorum necessary to conduct business at the extraordinary general meeting, (B)&nbsp;in order to solicit additional proxies from CHFW shareholders in favor of one or more of the proposals at the
extraordinary general meeting or (C)&nbsp;if CHFW shareholders redeem an amount of the public shares such that the condition to consummation of the Business Combination that the aggregate cash proceeds to be received by CHFW from the trust account
in connection with the Business Combination, together with aggregate gross proceeds from the PIPE Financing, equal no less than $100,000,000 after deducting certain of CHFW&#146;s unpaid expenses and liabilities would not be satisfied, at the
extraordinary general meeting be approved.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGAINST</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABSTAIN</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>&#9744;<B></B><B></B></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Shareholder Certification</B>&nbsp;I hereby certify that I am not acting in concert or as a &#147;group&#148; as defined in Section&nbsp;13(d)(3) of the Securities Exchange Act of 1934, as amended, with any other shareholder with
respect to the Shares in connection with the proposed business combination.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>SHAREHOLDER CERTIFICATION </B>&#9744;<B></B><B></B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Dated:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">,&nbsp;2021</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="5" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Signature)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Signature if held Jointly)</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signature should agree with name printed hereon. If stock is held in the name of more than one person, EACH joint owner should
sign. Executors, administrators, trustees, guardians, and attorneys should indicate the capacity in which they sign. Attorneys should submit powers of attorney. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PLEASE SIGN, DATE AND RETURN THE PROXY IN THE ENVELOPE ENCLOSED TO CONTINENTAL STOCK TRANSFER&nbsp;&amp; TRUST COMPANY. THIS PROXY WILL BE VOTED IN THE
MANNER DIRECTED HEREIN BY THE UNDERSIGNED SHAREHOLDER. IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED &#147;FOR&#148; THE PROPOSAL SET FORTH IN PROPOSALS 1, 2, 3, <FONT STYLE="white-space:nowrap">4-A,</FONT>
<FONT STYLE="white-space:nowrap">4-B,</FONT> <FONT STYLE="white-space:nowrap">4-C,</FONT> <FONT STYLE="white-space:nowrap">4-D,</FONT> 5, 6, 7 AND 8 AND WILL GRANT DISCRETIONARY AUTHORITY TO VOTE UPON SUCH OTHER MATTERS AS MAY PROPERLY COME BEFORE
THE MEETING OR ANY ADJOURNMENTS THEREOF. THIS PROXY WILL REVOKE ALL PRIOR PROXIES SIGNED BY YOU. </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>23
<FILENAME>chfw-20210331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 67.4 -->
<!-- Creation date: 6/23/2021 12:10:17 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrli:xbrl xmlns:chfw="http://Consonance.com/20210331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31">
	<link:schemaRef xlink:type="simple" xlink:href="chfw-20210331.xsd"/>
	<dei:AmendmentDescription contextRef="P01_01_2021To03_31_2021">AMENDMENT NO. 1</dei:AmendmentDescription>
	<xbrli:context id="PAsOn03_31_2021">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P01_01_2021To03_31_2021">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2021-01-01</xbrli:startDate>
			<xbrli:endDate>2021-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P08_21_2020To12_31_2020">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-21</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P12_01_2020To12_01_2020">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-12-01</xbrli:startDate>
			<xbrli:endDate>2020-12-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn12_01_2020">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn03_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PublicWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn03_31_2021_InitialPublicOfferingAndPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chfw:InitialPublicOfferingAndPrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn03_31_2021_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis_WorkingCapitalLoansWarrantMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chfw:RelatedPartyLoansMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn03_31_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chfw:FounderSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chfw:SponsorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PublicWarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P01_01_2021To03_31_2021_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonredeemablePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2021-01-01</xbrli:startDate>
			<xbrli:endDate>2021-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PublicWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2021-01-01</xbrli:startDate>
			<xbrli:endDate>2021-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P01_01_2021To03_31_2021_ClassAOrdinarySharesSubjectForRedemptionMemberusgaapStatementClassOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">chfw:ClassAOrdinarySharesSubjectForRedemptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2021-01-01</xbrli:startDate>
			<xbrli:endDate>2021-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P01_01_2021To03_31_2021_WarrantMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2021-01-01</xbrli:startDate>
			<xbrli:endDate>2021-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P01_01_2021To03_31_2021_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chfw:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2021-01-01</xbrli:startDate>
			<xbrli:endDate>2021-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PublicWarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">chfw:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2021-01-01</xbrli:startDate>
			<xbrli:endDate>2021-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PublicWarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">chfw:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2021-01-01</xbrli:startDate>
			<xbrli:endDate>2021-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P01_01_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chfw:FounderSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2021-01-01</xbrli:startDate>
			<xbrli:endDate>2021-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P01_01_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2021-01-01</xbrli:startDate>
			<xbrli:endDate>2021-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2021-01-01</xbrli:startDate>
			<xbrli:endDate>2021-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2021-01-01</xbrli:startDate>
			<xbrli:endDate>2021-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P01_01_2021To03_31_2021_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2021-01-01</xbrli:startDate>
			<xbrli:endDate>2021-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P01_01_2021To03_31_2021_WarrantsLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">chfw:WarrantsLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2021-01-01</xbrli:startDate>
			<xbrli:endDate>2021-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P11_23_2020To11_23_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-11-23</xbrli:startDate>
			<xbrli:endDate>2020-11-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P11_23_2020To11_23_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-11-23</xbrli:startDate>
			<xbrli:endDate>2020-11-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P11_23_2020To11_23_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PublicWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-11-23</xbrli:startDate>
			<xbrli:endDate>2020-11-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn11_23_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn11_23_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn11_23_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PublicWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn12_01_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P12_01_2020To12_01_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-12-01</xbrli:startDate>
			<xbrli:endDate>2020-12-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P12_01_2020To12_01_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-12-01</xbrli:startDate>
			<xbrli:endDate>2020-12-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P12_01_2020To12_01_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-12-01</xbrli:startDate>
			<xbrli:endDate>2020-12-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P12_01_2020To12_01_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-12-01</xbrli:startDate>
			<xbrli:endDate>2020-12-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn12_31_2020_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis_WorkingCapitalLoansWarrantMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chfw:RelatedPartyLoansMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:WorkingCapitalLoansWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn12_31_2020_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PublicWarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P09_04_2020To09_04_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chfw:FounderSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chfw:SponsorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-09-04</xbrli:startDate>
			<xbrli:endDate>2020-09-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P09_04_2020To09_04_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chfw:FounderSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chfw:SponsorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-09-04</xbrli:startDate>
			<xbrli:endDate>2020-09-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn09_04_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chfw:FounderSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-09-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P10_08_2020To10_08_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chfw:FounderSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-10-08</xbrli:startDate>
			<xbrli:endDate>2020-10-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P11_10_2020To11_10_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chfw:FounderSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-11-10</xbrli:startDate>
			<xbrli:endDate>2020-11-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P11_18_2020To11_18_2020_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chfw:AdministrativeSupportAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-11-18</xbrli:startDate>
			<xbrli:endDate>2020-11-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P04_15_2021To04_15_2021_PipeInvestorsMemberCHFWInvestorAxis_SubscriptionAgreementMemberusgaapTypeOfArrangementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chfw:SubscriptionAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="chfw:InvestorAxis">chfw:PipeInvestorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2021-04-15</xbrli:startDate>
			<xbrli:endDate>2021-04-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="P04_15_2021To04_15_2021_PipeInvestorsMemberCHFWInvestorAxis_PipeWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubscriptionAgreementMemberusgaapTypeOfArrangementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chfw:SubscriptionAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="chfw:InvestorAxis">chfw:PipeInvestorsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PipeWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2021-04-15</xbrli:startDate>
			<xbrli:endDate>2021-04-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn04_15_2021_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chfw:BusinessCombinationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-04-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn04_15_2021_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chfw:BusinessCombinationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-04-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn04_15_2021_PipeInvestorsMemberCHFWInvestorAxis_SubscriptionAgreementMemberusgaapTypeOfArrangementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chfw:SubscriptionAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="chfw:InvestorAxis">chfw:PipeInvestorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-04-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn04_15_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_PipeInvestorsMemberCHFWInvestorAxis_SubscriptionAgreementMemberusgaapTypeOfArrangementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">chfw:SubscriptionAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="chfw:InvestorAxis">chfw:PipeInvestorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-04-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PublicWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn12_31_2020_WarrantsLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">chfw:WarrantsLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn03_31_2021_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn03_31_2021_WarrantsLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">chfw:WarrantsLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2021-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">774931</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:PrepaidExpenseCurrent contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">633825</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:AssetsCurrent contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">1408756</us-gaap:AssetsCurrent>
	<us-gaap:AssetsHeldInTrustNoncurrent contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">92026912</us-gaap:AssetsHeldInTrustNoncurrent>
	<us-gaap:Assets contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">93435668</us-gaap:Assets>
	<chfw:WarrantLiability contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">2601180</chfw:WarrantLiability>
	<us-gaap:Liabilities contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">6807765</us-gaap:Liabilities>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">81627900</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:PreferredStockValue contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" xsi:nil="true"/>
	<us-gaap:CommonStockValue contextRef="PAsOn03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD" decimals="0">147</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="PAsOn03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD" decimals="0">230</us-gaap:CommonStockValue>
	<us-gaap:AdditionalPaidInCapital contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">7354918</us-gaap:AdditionalPaidInCapital>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">-2355292</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:StockholdersEquity contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">5000003</us-gaap:StockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">93435668</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:OperatingCostsAndExpenses contextRef="P01_01_2021To03_31_2021" unitRef="iso4217_USD" decimals="0">1065209</us-gaap:OperatingCostsAndExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="P01_01_2021To03_31_2021" unitRef="iso4217_USD" decimals="0">-1065209</us-gaap:OperatingIncomeLoss>
	<us-gaap:InvestmentIncomeInterest contextRef="P01_01_2021To03_31_2021" unitRef="iso4217_USD" decimals="0">23112</us-gaap:InvestmentIncomeInterest>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="P01_01_2021To03_31_2021" unitRef="iso4217_USD" decimals="0">-802834</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="P01_01_2021To03_31_2021" unitRef="iso4217_USD" decimals="0">6299</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:NetIncomeLoss contextRef="P01_01_2021To03_31_2021" unitRef="iso4217_USD" decimals="0">-232964</us-gaap:NetIncomeLoss>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2021To03_31_2021_ClassAOrdinarySharesSubjectForRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="0">8186086</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2021To03_31_2021_ClassAOrdinarySharesSubjectForRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">0.00</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2021To03_31_2021_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="0">3747914</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2021To03_31_2021_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:ProfitLoss contextRef="P01_01_2021To03_31_2021" unitRef="iso4217_USD" decimals="0">-232964</us-gaap:ProfitLoss>
	<us-gaap:InvestmentIncomeInterest contextRef="P01_01_2021To03_31_2021" unitRef="iso4217_USD" decimals="0">23112</us-gaap:InvestmentIncomeInterest>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="P01_01_2021To03_31_2021" unitRef="iso4217_USD" decimals="0">-802834</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="P01_01_2021To03_31_2021" unitRef="iso4217_USD" decimals="0">-156516</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="P01_01_2021To03_31_2021" unitRef="iso4217_USD" decimals="0">696437</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P01_01_2021To03_31_2021" unitRef="iso4217_USD" decimals="0">-212256</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="P01_01_2021To03_31_2021" unitRef="iso4217_USD" decimals="0">-212256</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">774931</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<chfw:ChangeInValueOfCommonStockSubjectToPossibleRedemption contextRef="P01_01_2021To03_31_2021" unitRef="iso4217_USD" decimals="0">-232960</chfw:ChangeInValueOfCommonStockSubjectToPossibleRedemption>
	<chfw:UnitsIssuedDuringPeriodSharesNewIssues contextRef="P11_23_2020To11_23_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="xbrli_shares" decimals="INF">8000000</chfw:UnitsIssuedDuringPeriodSharesNewIssues>
	<chfw:UnitsIssuedDuringPeriodValueNewIssues contextRef="P11_23_2020To11_23_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="iso4217_USD" decimals="0">80000000</chfw:UnitsIssuedDuringPeriodValueNewIssues>
	<chfw:UnitsIssuedDuringPeriodValueNewIssues contextRef="P12_01_2020To12_01_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="iso4217_USD" decimals="0">12000000</chfw:UnitsIssuedDuringPeriodValueNewIssues>
	<chfw:UnitsIssuedDuringPeriodValueNewIssues contextRef="P12_01_2020To12_01_2020" unitRef="iso4217_USD" decimals="0">12240000</chfw:UnitsIssuedDuringPeriodValueNewIssues>
	<chfw:AdditionsToAssetsHeldInTrust contextRef="P12_01_2020To12_01_2020" unitRef="iso4217_USD" decimals="0">12000000</chfw:AdditionsToAssetsHeldInTrust>
	<us-gaap:AssetsHeldInTrust contextRef="PAsOn12_01_2020" unitRef="iso4217_USD" decimals="0">92000000</us-gaap:AssetsHeldInTrust>
	<chfw:SaleOfStockUnderwritingFees contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">1840000</chfw:SaleOfStockUnderwritingFees>
	<chfw:SaleOfStockOtherOfferingCosts contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">598864</chfw:SaleOfStockOtherOfferingCosts>
	<chfw:ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount contextRef="P01_01_2021To03_31_2021" unitRef="xbrli_pure" decimals="2">0.80</chfw:ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount>
	<chfw:ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination contextRef="P01_01_2021To03_31_2021" unitRef="xbrli_pure" decimals="2">0.50</chfw:ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn03_31_2021_InitialPublicOfferingAndPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="xbrli_shares" decimals="INF">3211334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:InvestmentIncomeInterest contextRef="P01_01_2021To03_31_2021_ClassAOrdinarySharesSubjectForRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD" decimals="0">20507</us-gaap:InvestmentIncomeInterest>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="P01_01_2021To03_31_2021_ClassAOrdinarySharesSubjectForRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD" decimals="0">5589</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="P01_01_2021To03_31_2021_ClassAOrdinarySharesSubjectForRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD" decimals="0">26096</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLoss contextRef="P01_01_2021To03_31_2021_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD" decimals="0">-232964</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="P01_01_2021To03_31_2021_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD" decimals="0">-259060</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:CashFDICInsuredAmount contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">250000</us-gaap:CashFDICInsuredAmount>
	<chfw:UnitsIssuedDuringPeriodSharesNewIssues contextRef="P12_01_2020To12_01_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="xbrli_shares" decimals="0">9200000</chfw:UnitsIssuedDuringPeriodSharesNewIssues>
	<us-gaap:SharePrice contextRef="PAsOn11_23_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">10.00</us-gaap:SharePrice>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn11_23_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<chfw:UnitsIssuedDuringPeriodSharesNewIssues contextRef="P12_01_2020To12_01_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="xbrli_shares" decimals="0">1200000</chfw:UnitsIssuedDuringPeriodSharesNewIssues>
	<chfw:UnitsIssuedDuringPeriodSharesNewIssues contextRef="P12_01_2020To12_01_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="xbrli_shares" decimals="0">24000</chfw:UnitsIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P09_04_2020To09_04_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="iso4217_USD" decimals="0">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P09_04_2020To09_04_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="xbrli_shares" decimals="INF">3593750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockRepurchasedDuringPeriodShares contextRef="P10_08_2020To10_08_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis" unitRef="xbrli_shares" decimals="INF">718750</us-gaap:StockRepurchasedDuringPeriodShares>
	<us-gaap:StockRepurchasedDuringPeriodShares contextRef="P11_10_2020To11_10_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis" unitRef="xbrli_shares" decimals="INF">575000</us-gaap:StockRepurchasedDuringPeriodShares>
	<us-gaap:CommonStockSharesIssued contextRef="PAsOn09_04_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis" unitRef="xbrli_shares" decimals="INF">2300000</us-gaap:CommonStockSharesIssued>
	<chfw:NumberOfSharesSubjectToForfeiture contextRef="PAsOn03_31_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="xbrli_shares" decimals="INF">300000</chfw:NumberOfSharesSubjectToForfeiture>
	<chfw:PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders contextRef="P01_01_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis" unitRef="xbrli_pure" decimals="2">0.20</chfw:PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders>
	<chfw:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger contextRef="P09_04_2020To09_04_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">12.00</chfw:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger>
	<chfw:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays contextRef="P09_04_2020To09_04_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="chfw_item" decimals="INF">20</chfw:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays>
	<chfw:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays contextRef="P09_04_2020To09_04_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="chfw_item" decimals="INF">30</chfw:TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays>
	<chfw:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences contextRef="P09_04_2020To09_04_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">P150D</chfw:ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences>
	<chfw:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth contextRef="P11_18_2020To11_18_2020_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="iso4217_USD" decimals="0">55000</chfw:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="P01_01_2021To03_31_2021_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="iso4217_USD" decimals="0">165000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<chfw:MaximumLoansConvertibleIntoWarrants contextRef="PAsOn03_31_2021_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis_WorkingCapitalLoansWarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">1500000</chfw:MaximumLoansConvertibleIntoWarrants>
	<chfw:ClassOfWarrantOrRightPriceOfWarrantsOrRights contextRef="PAsOn03_31_2021_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis_WorkingCapitalLoansWarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">10.00</chfw:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
	<chfw:DeferredFeePerUnit contextRef="PAsOn03_31_2021" unitRef="iso4217_USD_xbrli_shares" decimals="2">0.35</chfw:DeferredFeePerUnit>
	<chfw:DeferredOfferingCostsNoncurrent contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">3220000</chfw:DeferredOfferingCostsNoncurrent>
	<us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn03_31_2021" unitRef="xbrli_shares" decimals="0">1000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn03_31_2021" unitRef="iso4217_USD_xbrli_shares" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="PAsOn03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="INF">350000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD_xbrli_shares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="PAsOn03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD_xbrli_shares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<chfw:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion contextRef="P01_01_2021To03_31_2021_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">P30D</chfw:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion>
	<chfw:MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement contextRef="P01_01_2021To03_31_2021_WarrantMemberusgaapClassOfWarrantOrRightAxis">P20D</chfw:MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement>
	<chfw:PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective contextRef="P01_01_2021To03_31_2021_WarrantMemberusgaapClassOfWarrantOrRightAxis">P60D</chfw:PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective>
	<chfw:WarrantRedemptionConditionMinimumSharePrice contextRef="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">10.00</chfw:WarrantRedemptionConditionMinimumSharePrice>
	<chfw:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant contextRef="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="xbrli_pure" decimals="0">60</chfw:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant>
	<chfw:SharePricetriggerUsedToMeasureDilutionOfWarrant contextRef="PAsOn03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">9.20</chfw:SharePricetriggerUsedToMeasureDilutionOfWarrant>
	<chfw:WarrantExercisePriceAdjustmentMultiple contextRef="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="xbrli_pure" decimals="0">115</chfw:WarrantExercisePriceAdjustmentMultiple>
	<chfw:WarrantRedemptionConditionMinimumSharePrice contextRef="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">10.00</chfw:WarrantRedemptionConditionMinimumSharePrice>
	<chfw:WarrantRedemptionConditionMinimumSharePriceScenarioTwo contextRef="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">18.00</chfw:WarrantRedemptionConditionMinimumSharePriceScenarioTwo>
	<chfw:WarrantRedemptionPriceAdjustmentMultiple contextRef="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="xbrli_pure" decimals="0">100</chfw:WarrantRedemptionPriceAdjustmentMultiple>
	<chfw:WarrantRedemptionPriceAdjustmentMultiple contextRef="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" unitRef="xbrli_pure" decimals="INF">180</chfw:WarrantRedemptionPriceAdjustmentMultiple>
	<us-gaap:AssetsHeldInTrustNoncurrent contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="iso4217_USD" decimals="0">92026912</us-gaap:AssetsHeldInTrustNoncurrent>
	<chfw:WarrantLiability contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">2484000</chfw:WarrantLiability>
	<chfw:WarrantLiability contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">117180</chfw:WarrantLiability>
	<dei:DocumentType contextRef="P01_01_2021To03_31_2021">S-4/A</dei:DocumentType>
	<dei:EntityFilerCategory contextRef="P01_01_2021To03_31_2021">Non-accelerated Filer</dei:EntityFilerCategory>
	<dei:EntitySmallBusiness contextRef="P01_01_2021To03_31_2021">true</dei:EntitySmallBusiness>
	<dei:EntityEmergingGrowthCompany contextRef="P01_01_2021To03_31_2021">true</dei:EntityEmergingGrowthCompany>
	<dei:EntityExTransitionPeriod contextRef="P01_01_2021To03_31_2021">false</dei:EntityExTransitionPeriod>
	<dei:EntityCentralIndexKey contextRef="P01_01_2021To03_31_2021">0001824893</dei:EntityCentralIndexKey>
	<dei:AmendmentFlag contextRef="P01_01_2021To03_31_2021">true</dei:AmendmentFlag>
	<dei:EntityAddressStateOrProvince contextRef="P01_01_2021To03_31_2021">NJ</dei:EntityAddressStateOrProvince>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">987187</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:PrepaidExpenseCurrent contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">790341</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:AssetsCurrent contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">1777528</us-gaap:AssetsCurrent>
	<us-gaap:AssetsHeldInTrustNoncurrent contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">91997501</us-gaap:AssetsHeldInTrustNoncurrent>
	<us-gaap:Assets contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">93775029</us-gaap:Assets>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">986585</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">290148</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">986585</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">290148</us-gaap:LiabilitiesCurrent>
	<chfw:WarrantLiability contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">3404014</chfw:WarrantLiability>
	<chfw:DeferredOfferingCostsNoncurrent contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">3220000</chfw:DeferredOfferingCostsNoncurrent>
	<us-gaap:Liabilities contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">6914162</us-gaap:Liabilities>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">81860860</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:PreferredStockValue contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" xsi:nil="true"/>
	<us-gaap:CommonStockValue contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD" decimals="0">145</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD" decimals="0">230</us-gaap:CommonStockValue>
	<us-gaap:AdditionalPaidInCapital contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">7121960</us-gaap:AdditionalPaidInCapital>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">-2122328</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">93775029</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="PAsOn03_31_2021" unitRef="xbrli_shares" decimals="INF">8162790</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="PAsOn12_31_2020" unitRef="xbrli_shares" decimals="INF">8186086</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2021To03_31_2021" unitRef="iso4217_USD" decimals="0">832245</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="P01_01_2021To03_31_2021" unitRef="iso4217_USD" decimals="0">6299</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consonance-HFW&lt;/div&gt; Acquisition Corp. (the &amp;#8220;Company&amp;#8221;) is a blank check company incorporated as a Cayman Islands exempted company on August&amp;#160;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (&amp;#8220;Business Combination&amp;#8221;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is not limited to a particular industry or geographic region for purposes of completing a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&amp;#160;31, 2021, the Company had not commenced any operations. All activity through March&amp;#160;31, 2021 relates to the Company&amp;#8217;s formation, the initial public offering (&amp;#8220;Initial Public Offering&amp;#8221;), which is described below, and subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-operating&lt;/div&gt; income in the form of interest income from the proceeds derived from the Initial Public Offering. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The registration statement for the Company&amp;#8217;s Initial Public Offering became effective on November&amp;#160;18, 2020. On November&amp;#160;23, 2020, the Company consummated the Initial Public Offering of 8,000,000 units (the &amp;#8220;Units&amp;#8221; and, with respect to the Class&amp;#160;A ordinary shares included in the Units sold, the &amp;#8220;Public Shares&amp;#8221;), at $10.00 per Unit, generating gross proceeds of $80,000,000 which is described in Note 3. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Simultaneously with the consummation of the Initial Public Offering, the Company consummated the sale of 410,000 units (the &amp;#8220;Private Placement Units&amp;#8221;) at a price of $10.00 per Private Placement Unit in a private placement to Consonance Life Sciences (the &amp;#8220;Sponsor&amp;#8221;), generating gross proceeds of $4,100,000, which is described in Note 4. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;Following the consummation of the Initial Public Offering on November&amp;#160;23, 2020, an amount of $80,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Units was placed in a trust account (the &amp;#8220;Trust Account&amp;#8221;) and invested in U.S. government securities, within the meaning set forth in Section&amp;#160;2(a)(16) of the Investment Company Act of 1940, as amended (the &amp;#8220;Investment Company Act&amp;#8221;), with a maturity of 185&amp;#160;days or less, or in any open-ended investment company that holds itself out as a money market fund meeting certain conditions of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rule&amp;#160;2a-7&lt;/div&gt; of the Investment Company Act, as determined by the Company, until the earlier of: (i)&amp;#160;the completion of a Business Combination and (ii)&amp;#160;the distribution of the funds in the Trust Account to the Company&amp;#8217;s shareholders, as described below. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&amp;#160;1, 2020, the underwriters fully exercised their over-allotment option, resulting in an additional 1,200,000 Units issued for an aggregate amount of $12,000,000. In connection with the underwriters&amp;#8217; full exercise of their over-allotment option, the Company also consummated the sale of an additional 24,000 Private Placement Units at $10.00 per Private Placement Unit, generating total proceeds of $12,240,000. A total of $12,000,000 was deposited into the Trust Account, bringing the aggregate proceeds held in the Trust Account to $92,000,000. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transaction costs amounted to $5,658,864, consisting of $1,840,000 of underwriting fees, $2,800,000 of deferred underwriting fees and $598,864 of other offering costs. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward completing a Business Combination. The Company must complete its initial Business Combination with one or more target businesses that together have a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding any deferred underwriting commissions held in the Trust Account and taxes payable on the interest earned on the Trust Account) at the time of the agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act. On April&amp;#160;15, 2021, the Company has entered into a Business Combination Agreement with Surrozen, Inc., see Note 10. Subsequent Events &amp;#8212; Business Combination Agreement and PIPE Financing, however, There is no assurance that the Company will be able to successfully effect a Business Combination. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will provide its shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&amp;#160;in connection with a shareholder meeting called to approve the Business Combination or (ii)&amp;#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The shareholders will be entitled to redeem their shares for a pro&amp;#160;rata portion of the amount held in the Trust Account (initially $10.00 per share), calculated as of two business days prior to the completion of a Business Combination, including any pro&amp;#160;rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. There will be no redemption rights upon the completion of a Business Combination with respect to the Company&amp;#8217;s warrants. &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; page-break-before: always;"&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Management continues to evaluate the impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&amp;#8217;s financial position and/or effecting our Business Combination, the specific impact is not readily determinable as of the date of the financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. &lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) for interim financial information and in accordance with the instructions to Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; and Article 8 of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X&lt;/div&gt; of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying unaudited condensed financial statements should be read in conjunction with the Company&amp;#8217;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K/A&lt;/div&gt; for the year ended December&amp;#160;31, 2020 as filed with the SEC on May&amp;#160;14, 2021. The interim results for the three months ended March&amp;#160;31, 2021 are not necessarily indicative of the results to be expected for the year ending December&amp;#160;31, 2021 or for any future periods. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &amp;#8220;emerging growth company,&amp;#8221; as defined in Section&amp;#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &amp;#8220;JOBS Act&amp;#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&amp;#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Further, Section&amp;#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&amp;#8217;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the condensed financial statements in conformity with GAAP requires the Company&amp;#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of March&amp;#160;31, 2021 and December&amp;#160;31, 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Marketable Securities Held in Trust Account &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At March&amp;#160;31, 2021 and December&amp;#160;31, 2020, substantially all of the assets held in the Trust Account were held in U.S. Treasury Bills.&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Warrant Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&amp;#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 480, Distinguishing Liabilities from Equity (&amp;#8220;ASC 480&amp;#8221;) and ASC 815, Derivatives and Hedging (&amp;#8220;ASC 815&amp;#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&amp;#8217;s own ordinary shares, among other conditions for equity classification.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital at the time of issuance or modification. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; gain or loss on the statements of operations. The fair value of the warrants was determined by using the publicly traded price on March&amp;#160;31, 2021 (see Note 9). &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Class&amp;#160;A Ordinary Shares Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for its Class&amp;#160;A ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) Topic 480 &amp;#8220;Distinguishing Liabilities from Equity.&amp;#8221; Class&amp;#160;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&amp;#8217;s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders&amp;#8217; equity. The Company&amp;#8217;s Class&amp;#160;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&amp;#8217;s control and subject to occurrence of uncertain future events. Accordingly, Class&amp;#160;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders&amp;#8217; equity section of the Company&amp;#8217;s balance sheet. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes under ASC 740, &amp;#8220;Income Taxes&amp;#8221; (&amp;#8220;ASC 740&amp;#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the condensed financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASC &lt;/div&gt;740&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&amp;#8217;s condensed financial statements and prescribes a recognition threshold and measurement process for condensed financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were &lt;/div&gt;no&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; unrecognized tax benefits and &lt;/div&gt;no&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; amounts accrued for interest and penalties as of March&amp;#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and December&amp;#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is considered an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United&amp;#160;States. As such, the Company&amp;#8217;s tax provision was zero for the period presented. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Net Loss Per Ordinary Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period, excluding ordinary shares subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; 3,211,334 shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company&amp;#8217;s statement of operations includes a presentation of loss per share for ordinary shares subject to possible redemption in a manner similar to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method of loss per share. Net loss per ordinary share, basic and diluted, for Class&amp;#160;A ordinary shares subject to possible redemption is calculated by dividing the proportionate share of income or loss on marketable securities held by the Trust Account by the weighted average number of Class&amp;#160;A ordinary shares subject to possible redemption outstanding since original issuance. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Net loss per share, basic and diluted, for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable&lt;/div&gt; ordinary shares is calculated by dividing the net income (loss), adjusted for income or loss on marketable securities attributable to Class&amp;#160;A ordinary shares subject to possible redemption, by the weighted average number of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable&lt;/div&gt; ordinary shares outstanding for the period. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; common stock includes Founder Shares and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable&lt;/div&gt; ordinary shares as these shares do not have any redemption features. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares participate in the income or loss on marketable securities based on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable&lt;/div&gt; shares&amp;#8217; proportionate interest.&lt;/div&gt; &lt;div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:84%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight:bold;display:inline;"&gt;Ended&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight:bold;display:inline;"&gt;March&amp;#160;31,&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Class&amp;#160;A ordinary Shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator: Earnings allocable to Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Interest earned on marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20,507&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unrealized gain on marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,589&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net income attributable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;26,096&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator: Weighted Average Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1pt;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Basic and diluted weighted average shares outstanding, Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,186,086&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net income per share, Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;0.00&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Non-Redeemable&lt;/div&gt; Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator: Net Loss minus Net Earnings&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(232,964&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1pt;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Net income allocable to Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(26,096&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Non-Redeemable&lt;/div&gt; Net Loss&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(259,060&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Denominator: Weighted Average &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Basic and diluted weighted average shares outstanding, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,747,914&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Basic and diluted net loss per share, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(0.07&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;   &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&amp;#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &amp;#8220;Fair Value Measurement,&amp;#8221; approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&amp;#160;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&amp;#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&amp;#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Derivative Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &amp;#8220;Derivatives and Hedging&amp;#8221;. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-valued&lt;/div&gt; at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; based on whether or not &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;net-cash&lt;/div&gt; settlement or conversion of the instrument could be required within 12 months of the balance sheet date.&lt;/div&gt;  &lt;div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&amp;#8217;s condensed financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In August 2020, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06,&lt;/div&gt; Debt &amp;#8212; Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging &amp;#8212; Contracts in Entity&amp;#8217;s Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40)&lt;/div&gt; (&amp;#8220;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&amp;#8221;)&lt;/div&gt; to simplify accounting for certain financial instruments. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&amp;#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&amp;#8217;s own equity. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; amends the diluted earnings per share guidance, including the requirement to use the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;if-converted&lt;/div&gt; method for all instruments. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; is effective January&amp;#160;1, 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January&amp;#160;1, 2021. The Company is currently assessing the impact, if any, that ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; would have on its financial position, results of operations or cash flows. &lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) for interim financial information and in accordance with the instructions to Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; and Article 8 of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X&lt;/div&gt; of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying unaudited condensed financial statements should be read in conjunction with the Company&amp;#8217;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K/A&lt;/div&gt; for the year ended December&amp;#160;31, 2020 as filed with the SEC on May&amp;#160;14, 2021. The interim results for the three months ended March&amp;#160;31, 2021 are not necessarily indicative of the results to be expected for the year ending December&amp;#160;31, 2021 or for any future periods. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<chfw:EmergingGrowthCompanyPolicyTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &amp;#8220;emerging growth company,&amp;#8221; as defined in Section&amp;#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &amp;#8220;JOBS Act&amp;#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&amp;#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Further, Section&amp;#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&amp;#8217;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chfw:EmergingGrowthCompanyPolicyTextBlock>
	<us-gaap:UseOfEstimates contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the condensed financial statements in conformity with GAAP requires the Company&amp;#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UseOfEstimates>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of March&amp;#160;31, 2021 and December&amp;#160;31, 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<chfw:AssetsHeldInTrustAccountPolicyPolicyTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Marketable Securities Held in Trust Account &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At March&amp;#160;31, 2021 and December&amp;#160;31, 2020, substantially all of the assets held in the Trust Account were held in U.S. Treasury Bills.&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chfw:AssetsHeldInTrustAccountPolicyPolicyTextBlock>
	<chfw:WarrantLiabilityPolicyTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Warrant Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&amp;#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 480, Distinguishing Liabilities from Equity (&amp;#8220;ASC 480&amp;#8221;) and ASC 815, Derivatives and Hedging (&amp;#8220;ASC 815&amp;#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&amp;#8217;s own ordinary shares, among other conditions for equity classification.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital at the time of issuance or modification. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; gain or loss on the statements of operations. The fair value of the warrants was determined by using the publicly traded price on March&amp;#160;31, 2021 (see Note 9). &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chfw:WarrantLiabilityPolicyTextBlock>
	<chfw:TemporaryEquityPolicyPolicyTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Class&amp;#160;A Ordinary Shares Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for its Class&amp;#160;A ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) Topic 480 &amp;#8220;Distinguishing Liabilities from Equity.&amp;#8221; Class&amp;#160;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&amp;#8217;s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders&amp;#8217; equity. The Company&amp;#8217;s Class&amp;#160;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&amp;#8217;s control and subject to occurrence of uncertain future events. Accordingly, Class&amp;#160;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders&amp;#8217; equity section of the Company&amp;#8217;s balance sheet. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chfw:TemporaryEquityPolicyPolicyTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes under ASC 740, &amp;#8220;Income Taxes&amp;#8221; (&amp;#8220;ASC 740&amp;#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the condensed financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASC &lt;/div&gt;740&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&amp;#8217;s condensed financial statements and prescribes a recognition threshold and measurement process for condensed financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were &lt;/div&gt;no&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; unrecognized tax benefits and &lt;/div&gt;no&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; amounts accrued for interest and penalties as of March&amp;#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and December&amp;#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is considered an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United&amp;#160;States. As such, the Company&amp;#8217;s tax provision was zero for the period presented. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Net Loss Per Ordinary Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period, excluding ordinary shares subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; 3,211,334 shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company&amp;#8217;s statement of operations includes a presentation of loss per share for ordinary shares subject to possible redemption in a manner similar to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method of loss per share. Net loss per ordinary share, basic and diluted, for Class&amp;#160;A ordinary shares subject to possible redemption is calculated by dividing the proportionate share of income or loss on marketable securities held by the Trust Account by the weighted average number of Class&amp;#160;A ordinary shares subject to possible redemption outstanding since original issuance. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Net loss per share, basic and diluted, for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable&lt;/div&gt; ordinary shares is calculated by dividing the net income (loss), adjusted for income or loss on marketable securities attributable to Class&amp;#160;A ordinary shares subject to possible redemption, by the weighted average number of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable&lt;/div&gt; ordinary shares outstanding for the period. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; common stock includes Founder Shares and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable&lt;/div&gt; ordinary shares as these shares do not have any redemption features. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares participate in the income or loss on marketable securities based on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable&lt;/div&gt; shares&amp;#8217; proportionate interest.&lt;/div&gt; &lt;div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:84%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight:bold;display:inline;"&gt;Ended&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight:bold;display:inline;"&gt;March&amp;#160;31,&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Class&amp;#160;A ordinary Shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator: Earnings allocable to Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Interest earned on marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20,507&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unrealized gain on marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,589&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net income attributable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;26,096&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator: Weighted Average Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1pt;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Basic and diluted weighted average shares outstanding, Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,186,086&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net income per share, Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;0.00&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Non-Redeemable&lt;/div&gt; Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator: Net Loss minus Net Earnings&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(232,964&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1pt;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Net income allocable to Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(26,096&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Non-Redeemable&lt;/div&gt; Net Loss&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(259,060&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Denominator: Weighted Average &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Basic and diluted weighted average shares outstanding, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,747,914&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Basic and diluted net loss per share, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(0.07&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&amp;#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &amp;#8220;Fair Value Measurement,&amp;#8221; approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&amp;#160;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&amp;#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:9%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&amp;#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
	<us-gaap:DerivativesReportingOfDerivativeActivity contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Derivative Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &amp;#8220;Derivatives and Hedging&amp;#8221;. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-valued&lt;/div&gt; at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; based on whether or not &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;net-cash&lt;/div&gt; settlement or conversion of the instrument could be required within 12 months of the balance sheet date.&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DerivativesReportingOfDerivativeActivity>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&amp;#8217;s condensed financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In August 2020, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06,&lt;/div&gt; Debt &amp;#8212; Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging &amp;#8212; Contracts in Entity&amp;#8217;s Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40)&lt;/div&gt; (&amp;#8220;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&amp;#8221;)&lt;/div&gt; to simplify accounting for certain financial instruments. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&amp;#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&amp;#8217;s own equity. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; amends the diluted earnings per share guidance, including the requirement to use the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;if-converted&lt;/div&gt; method for all instruments. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; is effective January&amp;#160;1, 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January&amp;#160;1, 2021. The Company is currently assessing the impact, if any, that ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; would have on its financial position, results of operations or cash flows. &lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:84%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight:bold;display:inline;"&gt;Ended&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight:bold;display:inline;"&gt;March&amp;#160;31,&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Class&amp;#160;A ordinary Shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator: Earnings allocable to Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Interest earned on marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20,507&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unrealized gain on marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,589&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net income attributable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;26,096&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator: Weighted Average Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1pt;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Basic and diluted weighted average shares outstanding, Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,186,086&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net income per share, Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;0.00&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Non-Redeemable&lt;/div&gt; Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator: Net Loss minus Net Earnings&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(232,964&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1pt;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Net income allocable to Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(26,096&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Non-Redeemable&lt;/div&gt; Net Loss&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(259,060&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Denominator: Weighted Average &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Basic and diluted weighted average shares outstanding, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,747,914&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Basic and diluted net loss per share, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(0.07&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="P01_01_2021To03_31_2021_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD" decimals="0">26096</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
	<us-gaap:UnrecognizedTaxBenefits contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">0</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
	<us-gaap:UnrecognizedTaxBenefits contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">0</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
	<chfw:InitialPublicOfferingTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 3. INITIAL PUBLIC OFFERING &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"&gt;Pursuant to the Initial Public Offering, the Company sold 9,200,000&amp;#160;Units, inclusive of 1,200,000 Units sold to the underwriters on December&amp;#160;1, 2020 upon the underwriters&amp;#8217; election to fully exercise their over-allotment option, at a purchase price of $10.00 per Unit. Each Unit consists of one Class&amp;#160;A ordinary share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-third&lt;/div&gt; of one redeemable warrant (&amp;#8220;Public Warrant&amp;#8221;). Each whole Public Warrant entitles the holder to purchase one Class&amp;#160;A ordinary share at an exercise price of $11.50 per share, subject to adjustment (see Note 8). &lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&amp;#160;1, 2020, the underwriters fully exercised their over-allotment option, resulting in an additional 1,200,000 Units issued for an aggregate amount of $12,000,000. In connection with the underwriters&amp;#8217; full exercise of their over-allotment option, the Company also consummated the sale of an additional 24,000 Private Placement Units at $10.00 per Private Placement Unit, generating total proceeds of $12,240,000. A total of $12,000,000 was deposited into the Trust Account, bringing the aggregate proceeds held in the Trust Account to $92,000,000. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chfw:InitialPublicOfferingTextBlock>
	<chfw:NumberOfSharesIssuedPerUnit contextRef="P11_23_2020To11_23_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="xbrli_shares" decimals="INF">1</chfw:NumberOfSharesIssuedPerUnit>
	<chfw:NumberOfSharesIssuedPerUnit contextRef="P12_01_2020To12_01_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="xbrli_shares" decimals="INF">1</chfw:NumberOfSharesIssuedPerUnit>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="PAsOn11_23_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="xbrli_shares" decimals="INF">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
	<chfw:PrivatePlacementTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 4. PRIVATE PLACEMENT &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;Simultaneously with the consummation of the Initial Public Offering, the Sponsor purchased an aggregate of 410,000 Private Placement Units at a price of $10.00 per Private Placement Unit, for an aggregate purchase price of $4,100,000. On December&amp;#160;1, 2020, as a result of the underwriters&amp;#8217; election to fully exercise their over-allotment option, the Sponsor purchased an additional 24,000 Private Placement Units, at a price of $10.00 per Private Placement Unit, or $240,000 in the aggregate (see Note 8). Each Private Placement Unit consists of one Class&amp;#160;A ordinary share (&amp;#8220;Private Placement Share&amp;#8221; or, collectively, &amp;#8220;Private Placement Shares&amp;#8221;) and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-third&lt;/div&gt; of one redeemable warrant (each, a &amp;#8220;Private Placement Warrant&amp;#8221;). Each whole Private Placement Warrant is exercisable for one Class&amp;#160;A ordinary share at a price of $11.50 per share, subject to adjustment (see Note 8). The proceeds from the sale of the Private Placement Units were added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Units and all underlying securities will expire worthless. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chfw:PrivatePlacementTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 10. SUBSEQUENT EVENTS&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed financial statements were issued. Based upon this review, except as set forth below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Business Combination Agreement and PIPE Financing &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;On April&amp;#160;15, 2021, the Company entered into a business combination agreement with Surrozen, Inc. (&amp;#8220;Surrozen&amp;#8221;), pursuant to which a wholly-owned subsidiary of the Company will merge with and into Surrozen, with Surrozen surviving as a wholly-owned subsidiary of the Company and the Company will redomicile as a Delaware corporation. In accordance with the terms and subject to the conditions of the Business Combination Agreement, each share and equity award (whether vested or unvested) of Surrozen outstanding as of closing will be exchanged for shares of the Company&amp;#8217;s common stock or comparable equity awards that are settled or are exercisable for shares of the Company&amp;#8217;s common stock, as applicable, based on an implied Surrozen equity value of $200,000,000 and a $10.00 per share value of the Company&amp;#8217;s Common Stock. In connection with the foregoing and concurrently with the execution of the Business Combination Agreement, the Company entered into Subscription Agreements with certain investors (the &amp;#8220;Subscription Agreements&amp;#8221; and such investors, the &amp;#8220;PIPE Investors&amp;#8221;), pursuant to which the PIPE Investors have agreed to subscribe for and purchase, and the Company has agreed to issue and sell to the PIPE Investors, an aggregate of 12,020,000 units, each consisting of one share of the Company&amp;#8217;s common stock and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-third&lt;/div&gt; of one redeemable warrant for one share of the Company&amp;#8217;s common stock (the &amp;#8220;PIPE Warrants&amp;#8221;), for a purchase price of $10.00 per unit (the &amp;#8220;PIPE Units&amp;#8221;), for aggregate gross proceeds of $120,200,000 (the &amp;#8220;PIPE Financing&amp;#8221;). Each whole PIPE Warrant entitles the holder thereof to purchase one share of the Company&amp;#8217;s common stock at a price of $11.50 per share, subject to adjustment as described in the form of warrant agreement attached to the form of Subscription Agreement, and only whole PIPE Warrants will be exercisable. The PIPE Warrants have substantially the same provisions as the public warrants issued in connection with the Company&amp;#8217;s initial public offering. The securities to be issued pursuant to the Subscription Agreements have not been registered under the Securities Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;) in reliance upon the exemption provided in Section&amp;#160;4(a)(2) of the Securities Act. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 9. FAIR VALUE MEASUREMENTS&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company follows the guidance in ASC 820 for its financial assets and liabilities that are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measured&lt;/div&gt; and reported at fair value at each reporting period, and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; assets and liabilities that are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measured&lt;/div&gt; and reported at fair value at least annually.&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&amp;#8217;s financial assets and liabilities reflects management&amp;#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:3%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:1%;"&gt;&lt;/td&gt;&lt;td style="width:6%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:1%;"&gt;&lt;/td&gt;&lt;td style="width:89%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Level&amp;#160;1:&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1pt;"&gt;&lt;td style="height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Level&amp;#160;2:&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Observable inputs other than Level&amp;#160;1 inputs. Examples of Level&amp;#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1pt;"&gt;&lt;td style="height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Level&amp;#160;3:&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&amp;#8217;s assets and liabilities that are measured at fair value on a recurring basis at March&amp;#160;31, 2021 and December&amp;#160;31, 2020, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:67%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&amp;#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;"&gt;1&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;92,026,912&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;91,997,501&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1pt;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrant liability &amp;#8211; Public Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;"&gt;1&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;2,484,000&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3,250,667&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Warrant liability &amp;#8211; Private Placement Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;"&gt;3&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;117,180&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;153,347&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The Warrants were accounted for as liabilities in accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40&lt;/div&gt; and are presented within warrant liabilities on our balance sheet. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the consolidated statement of operations. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Both the Private Placement Warrants and the Public Warrants were initially valued using a binomial lattice model, which is considered to be a Level&amp;#160;3 fair value measurement. As of March&amp;#160;31, 2021, the Public Warrants were valued using the instrument&amp;#8217;s publicly listed trading notice as of the balance sheet date, which is considered to be a Level&amp;#160;1 measurement due to the use of an observable market quote in an active market. The Private Warrants were valued using a binomial lattice model, which is considered to be a Level&amp;#160;3 fair value measurement. The binomial lattice model&amp;#8217;s primary unobservable input utilized in determining the fair value of the Private Placement Warrants is the expected volatility of the common stock. The expected volatility as of the IPO date was derived from observable public warrant pricing on comparable &amp;#8216;blank-check&amp;#8217; companies without an identified target. The expected volatility as of subsequent valuation dates will be implied from the Company&amp;#8217;s own public warrant pricing. A binomial lattice model methodology was also used in estimating the fair value of the Public Warrants for periods where no observable traded price was available, using the same expected volatility as was used in measuring the fair value of the Private Placement Warrants. For periods subsequent to the detachment of the Warrants from the Units, the close price of the Public Warrant price will be used as the fair value as of each relevant date. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the changes in the fair value of warrant liabilities: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:56%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&amp;#160;Placement&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Public&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Warrant&amp;#160;Liabilities&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Fair value as of January&amp;#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;153,347&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3,250,667&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3,404,014&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(36,167&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(766,667&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(802,834&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Fair value as of March&amp;#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;117,180&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,484,000&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,601,180&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no transfers in or out of Level&amp;#160;3 from other levels in the fair value hierarchy. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<chfw:NumberOfWarrantsIssuedPerUnit contextRef="P12_01_2020To12_01_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="xbrli_shares" decimals="INF">0.33</chfw:NumberOfWarrantsIssuedPerUnit>
	<us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2021To03_31_2021">The following table presents information about the Company&amp;#8217;s assets and liabilities that are measured at fair value on a recurring basis at March&amp;#160;31, 2021 and December&amp;#160;31, 2020, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:67%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&amp;#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;"&gt;1&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;92,026,912&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;91,997,501&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1pt;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4" style="font-family: &amp;quot;times new roman&amp;quot;;;height:8;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrant liability &amp;#8211; Public Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;"&gt;1&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;2,484,000&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3,250,667&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Warrant liability &amp;#8211; Private Placement Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;"&gt;3&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;117,180&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;153,347&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
	<us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the changes in the fair value of warrant liabilities: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:56%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&amp;#160;Placement&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Public&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Warrant&amp;#160;Liabilities&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Fair value as of January&amp;#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;153,347&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3,250,667&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3,404,014&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(36,167&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(766,667&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(802,834&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Fair value as of March&amp;#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;117,180&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,484,000&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,601,180&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 5. RELATED PARTY TRANSACTIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Founder Shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&amp;#160;4, 2020, the Sponsor&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"&gt;paid $&lt;/div&gt;25,000&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"&gt; to cover certain offering and formation costs of the Company in consideration for &lt;/div&gt;3,593,750&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"&gt; Class&amp;#160;B ordinary shares. On October&amp;#160;&lt;/div&gt;8&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"&gt; and November&amp;#160;&lt;/div&gt;10&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"&gt;, &lt;/div&gt;718,750&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"&gt; and &lt;/div&gt;575,000&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"&gt; Class&amp;#160;B ordinary shares were contributed back to the Company for &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"&gt; consideration, respectively, resulting in there being &lt;/div&gt;2,300,000&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"&gt; Class&amp;#160;B ordinary shares (the &amp;#8220;Founder Shares&amp;#8221;) being issued and outstanding. The Founder Shares include an aggregate of up to &lt;/div&gt;300,000&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"&gt; shares subject to forfeiture by the Sponsor to the extent that the underwriters&amp;#8217; over-allotment is not exercised in full or in part, so that the number of Founder Shares will collectively represent &lt;/div&gt;20&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"&gt;% of the Company&amp;#8217;s issued and outstanding shares upon the completion of the Initial Public Offering (not including the Private Placement Shares).&amp;#160;On December&amp;#160;&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"&gt;, the underwriters fully exercised their over-allotment option, therefore there are no Founder Shares subject to forfeiture.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of: (A)&amp;#160;one year after the completion of a Business Combination; and (B)&amp;#160;subsequent to a Business Combination, (x)&amp;#160;if the closing price of the Class&amp;#160;A ordinary shares equals or exceeds $12.00 per share (as adjusted for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;share&amp;#160;sub-divisions,&amp;#160;share&lt;/div&gt; capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;any&amp;#160;30-trading&amp;#160;day&lt;/div&gt; period commencing at least 150&amp;#160;days after a Business Combination, or (y)&amp;#160;the date on which the Company completes a liquidation, merger, amalgamation, share exchange, reorganization or other similar transaction that results in all of the Company&amp;#8217;s shareholders having the right to exchange their Class&amp;#160;A ordinary shares for cash, securities or other property.&lt;/div&gt; &lt;div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Administrative Services Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company entered into an agreement, commencing on November&amp;#160;18, 2020 through the earlier of the Company&amp;#8217;s consummation of a Business Combination and its liquidation, to pay the Sponsor a total of up to $55,000 per month for office space and administrative support services. For the period three months ended March&amp;#160;31, 2021, the Company incurred and paid $165,000 of such fees. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Related Party Loans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company&amp;#8217;s directors and officers may, but are not obligated to, loan the Company funds as may be required (&amp;#8220;Working Capital Loans&amp;#8221;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender&amp;#8217;s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into Private Placement Units of the post-Business Combination entity at a price of $10.00 per Private Placement Unit. The Private Placement Units would be identical to the Units. As of March&amp;#160;31, 2021 and December&amp;#160;31, 2020, the Company had no outstanding borrowings under the Working Capital Loans. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:AssetsHeldInTrustNoncurrent contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="iso4217_USD" decimals="0">91997501</us-gaap:AssetsHeldInTrustNoncurrent>
	<chfw:WarrantLiability contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">3250667</chfw:WarrantLiability>
	<chfw:WarrantLiability contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">153347</chfw:WarrantLiability>
	<us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="PAsOn12_31_2020_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">153347</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
	<us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="PAsOn12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">3250667</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
	<us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="PAsOn12_31_2020_WarrantsLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" unitRef="iso4217_USD" decimals="0">3404014</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
	<us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss contextRef="P01_01_2021To03_31_2021_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">-36167</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
	<us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss contextRef="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">-766667</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
	<us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss contextRef="P01_01_2021To03_31_2021_WarrantsLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" unitRef="iso4217_USD" decimals="0">-802834</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
	<us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="PAsOn03_31_2021_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">117180</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
	<us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="PAsOn03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">2484000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
	<us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="PAsOn03_31_2021_WarrantsLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" unitRef="iso4217_USD" decimals="0">2601180</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
	<us-gaap:StockRepurchasedDuringPeriodValue contextRef="P10_08_2020To10_08_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis" unitRef="iso4217_USD" decimals="0">0</us-gaap:StockRepurchasedDuringPeriodValue>
	<us-gaap:StockRepurchasedDuringPeriodValue contextRef="P11_10_2020To11_10_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis" unitRef="iso4217_USD" decimals="0">0</us-gaap:StockRepurchasedDuringPeriodValue>
	<us-gaap:CommonStockSharesOutstanding contextRef="PAsOn09_04_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis" unitRef="xbrli_shares" decimals="INF">2300000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet contextRef="P01_01_2021To03_31_2021_WarrantsLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" unitRef="iso4217_USD" decimals="0">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
	<chfw:WarrantsTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 8. WARRANT LIABILITY &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a)&amp;#160;30&amp;#160;days after the completion of a Business Combination and (b)&amp;#160;one year from the closing of the Initial Public Offering. The Public Warrants will expire five&amp;#160;years from the completion of a Business Combination or earlier upon redemption or liquidation. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will not be obligated to deliver any Class&amp;#160;A ordinary shares pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the issuance of the Class&amp;#160;A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating thereto is available, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption is available. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has agreed that as soon as practicable, but in no event later than 20 business days, after the closing of a Business Combination, it will use its commercially reasonable efforts to file with the SEC a registration statement covering the Class&amp;#160;A ordinary shares issuable upon exercise of the warrants, and the Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of a Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class&amp;#160;A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; if the Class&amp;#160;A ordinary shares are, at the time of any exercise of a warrant, not listed on a national securities exchange such that they satisfy the definition of a &amp;#8220;covered security&amp;#8221; under Section&amp;#160;18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a &amp;#8220;cashless basis&amp;#8221; in accordance with Section&amp;#160;3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement. If a registration statement covering the Class&amp;#160;A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &amp;#8220;cashless basis&amp;#8221; in accordance with Section&amp;#160;3(a)(9) of the Securities Act or another exemption, but will use its best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Redemption of warrants when the price per Class&amp;#160;A ordinary share equals or exceeds $18.00&lt;/div&gt;&amp;#8212;Once the warrants become exercisable, the Company may redeem the outstanding Public Warrants (except with respect to the Private Placement Warrants): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in whole and not in part; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at a price of $0.01 per Public Warrant; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;upon not less than 30&amp;#160;days&amp;#8217; prior written notice of redemption to each warrant holder; and &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;if, and only if, the closing price of the Class&amp;#160;A ordinary shares equals or exceeds $18.00 per share (as adjusted for share &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-divisions,&lt;/div&gt; share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-trading&lt;/div&gt; day period ending on the third trading day prior to the date on which notice of the redemption is given to the warrant holders (the &amp;#8220;Reference Value&amp;#8221;). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws. &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Redemption of Warrants When the Price per Class&lt;/div&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&amp;#160;A Ordinary Share Equals or Exceeds $10.00&lt;/div&gt;&amp;#8212;Once the warrants become exercisable, the Company may redeem the outstanding warrants:&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in whole and not in part; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at $0.10 per warrant upon a minimum of 30&amp;#160;days&amp;#8217; prior written notice of redemption; provided that during such 30 day period holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares, based on the redemption date and the fair market value of the Class&amp;#160;A ordinary shares, that if the warrants are not exercised on a cashless basis or otherwise during such 30&amp;#160;day period, the Company shall redeem such warrants for $0.10 per share; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted for share subdivisions, share dividends, reorganizations, recapitalizations and the like) on the trading day before the Company sends the notice of redemption to the warrant holders; and&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-size: 1px; margin-top: 6px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;if the Reference Value is less than $18.00 per share (as adjusted for share splits, share dividends, reorganizations, recapitalizations and the like), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The exercise price and number of ordinary shares issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company&amp;#8217;s assets held outside of the Trust Account with respect to such Public Warrants. Accordingly, the Public Warrants may expire worthless. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt;In addition, if (x)&amp;#160;the Company issues additional Class&amp;#160;A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per Class&amp;#160;A ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&amp;#8217;s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the &amp;#8220;Newly Issued Price&amp;#8221;), (y)&amp;#160;the aggregate gross proceeds from such issuances represent more than &lt;/div&gt;60&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt;% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&amp;#160;the volume weighted average trading price of its Class&amp;#160;A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &amp;#8220;Market Value&amp;#8221;) is below $&lt;/div&gt;9.20&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt; per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to &lt;/div&gt;115&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt;% of the higher of the Market Value and the Newly Issued Price, and the $&lt;/div&gt;10.00&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt; and $&lt;/div&gt;18.00&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt; per share redemption trigger price will be adjusted (to the nearest cent) to be equal to &lt;/div&gt;100&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt;% and &lt;/div&gt;180&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt;% of the higher of the Market Value and the Newly Issued Price, respectively.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the Class&amp;#160;A ordinary shares issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30&amp;#160;days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable,&lt;/div&gt; except as described above, so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. &lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chfw:WarrantsTextBlock>
	<chfw:MaximumLoansConvertibleIntoWarrants contextRef="PAsOn12_31_2020_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis_WorkingCapitalLoansWarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">1500000</chfw:MaximumLoansConvertibleIntoWarrants>
	<chfw:ClassOfWarrantOrRightPriceOfWarrantsOrRights contextRef="PAsOn12_31_2020_RelatedPartyLoansMemberusgaapRelatedPartyTransactionAxis_WorkingCapitalLoansWarrantMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">10.00</chfw:ClassOfWarrantOrRightPriceOfWarrantsOrRights>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 6. COMMITMENTS&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Registration and Shareholder Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Pursuant to a registration rights agreement entered into on November&amp;#160;18, 2020, the holders of the Founder Shares, Private Placement Units (including securities contained therein) and warrants that may be issued upon conversion of the Working Capital Loans (and any Class&amp;#160;A ordinary shares issuable upon the exercise of the Private Placement Units and warrants that may be issued upon conversion of Working Capital Loans and upon conversion of the Founder Shares) will be entitled to registration rights. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &amp;#8220;piggy-back&amp;#8221; registration rights with respect to registration statements filed subsequent to the completion of a Business Combination. However, the registration and shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lock-up&lt;/div&gt; period. The registration rights agreement does not contain liquidating damages or other cash settlement provisions resulting from delays in registering the Company&amp;#8217;s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.&amp;#160; &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Underwriting Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The underwriters are entitled to a deferred fee of $0.35 per Unit, or $3,220,000 in the aggregate (see Note 8). The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<chfw:WarrantExercisePeriodConditionOne contextRef="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">P30D</chfw:WarrantExercisePeriodConditionOne>
	<chfw:NumberOfWarrantsIssuedPerUnit contextRef="P11_23_2020To11_23_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="xbrli_shares" decimals="INF">0.33</chfw:NumberOfWarrantsIssuedPerUnit>
	<chfw:WarrantExercisePeriodConditionTwo contextRef="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">P1Y</chfw:WarrantExercisePeriodConditionTwo>
	<us-gaap:WarrantsAndRightsOutstandingTerm contextRef="PAsOn03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
	<chfw:WarrantRedemptionConditionMinimumSharePriceScenarioTwo contextRef="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">18.00</chfw:WarrantRedemptionConditionMinimumSharePriceScenarioTwo>
	<chfw:WarrantRedemptionConditionMinimumSharePriceScenarioTwo contextRef="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">18.00</chfw:WarrantRedemptionConditionMinimumSharePriceScenarioTwo>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 7. STOCKHOLDERS&amp;#8217; EQUITY &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Preference Shares&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt;&amp;#8212;&lt;/div&gt; The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company&amp;#8217;s board of directors. At March&amp;#160;31, 2021 and December&amp;#160;31, 2020, there were no preference shares issued or outstanding. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Class&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&amp;#160;A ordinary shares&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&amp;#8212;&lt;/div&gt;The Company is authorized to issue 350,000,000 Class&amp;#160;A ordinary shares, with a par value of $0.0001 per share. Holders of Class&amp;#160;A ordinary shares are entitled to one vote for each share. At March&amp;#160;31, 2021 and December&amp;#160;31, 2020, there were 1,471,210 and 1,447,914 (excluding 8,162,790 and 8,186,086 shares subject to possible redemption) Class&amp;#160;A ordinary shares issued and outstanding, respectively. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Class&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&amp;#160;B ordinary shares&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&amp;#8212;&lt;/div&gt; The Company is authorized to issue 150,000,000 Class&amp;#160;B ordinary shares, with a par value of $0.0001 per share. Holders of the Class&amp;#160;B ordinary shares are entitled to one vote for each share. At March&amp;#160;31, 2021 and December&amp;#160;31, 2020, there were 2,300,000 Class&amp;#160;B ordinary shares issued and outstanding. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Only holders of the Class&amp;#160;B ordinary shares will have the right to vote on the election of directors prior to the Business Combination. Holders of Class&amp;#160;A ordinary shares and holders of Class&amp;#160;B ordinary shares will vote together as a single class on all other matters submitted to a vote of the Company&amp;#8217;s shareholders except as otherwise required by law. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;The Class&amp;#160;B ordinary shares will automatically convert into Class&amp;#160;A ordinary shares on the first business day following the consummation of a Business Combination at a ratio such that the number of Class&amp;#160;A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis, 20% of the sum of (i)&amp;#160;the total number of ordinary shares issued and outstanding (excluding the Private Placement Shares underlying the Private Placement Units) upon completion of the Initial Public Offering, plus (ii)&amp;#160;the sum of the total number of Class&amp;#160;A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of a Business Combination, excluding any Class&amp;#160;A ordinary shares or equity-linked securities exercisable for or convertible into Class&amp;#160;A ordinary shares issued, deemed issued, or to be issued, to any seller in a Business Combination and any Private Placement Warrants issued to the Sponsor, members of the Company&amp;#8217;s founding team or any of their affiliates upon conversion of Working Capital Loans. In no event will the Class&amp;#160;B ordinary shares convert into Class&amp;#160;A ordinary shares at a rate of less than one to one.&amp;#160; &lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<chfw:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights contextRef="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" unitRef="iso4217_USD_xbrli_shares" decimals="INF">0.10</chfw:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
	<chfw:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights contextRef="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" unitRef="iso4217_USD_xbrli_shares" decimals="INF">0.01</chfw:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
	<chfw:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays contextRef="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" unitRef="chfw_item" decimals="INF">20</chfw:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays>
	<chfw:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays contextRef="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" unitRef="chfw_item" decimals="INF">30</chfw:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays>
	<chfw:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays contextRef="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" unitRef="chfw_item" decimals="INF">30</chfw:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays>
	<us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn12_31_2020" unitRef="xbrli_shares" decimals="0">1000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn12_31_2020" unitRef="iso4217_USD_xbrli_shares" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<chfw:RedemptionPeriod contextRef="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis">P30D</chfw:RedemptionPeriod>
	<chfw:RedemptionPeriod contextRef="P01_01_2021To03_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis">P30D</chfw:RedemptionPeriod>
	<us-gaap:PreferredStockSharesIssued contextRef="PAsOn03_31_2021" unitRef="xbrli_shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2020" unitRef="xbrli_shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn03_31_2021" unitRef="xbrli_shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2020" unitRef="xbrli_shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
	<chfw:CommonStockNumberOfVotesPerShare contextRef="PAsOn03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="chfw_item" decimals="INF">1</chfw:CommonStockNumberOfVotesPerShare>
	<chfw:CommonStockNumberOfVotesPerShare contextRef="PAsOn03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="chfw_item" decimals="INF">1</chfw:CommonStockNumberOfVotesPerShare>
	<chfw:ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders contextRef="P01_01_2021To03_31_2021" unitRef="chfw_item" decimals="INF">3</chfw:ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders>
	<chfw:TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant contextRef="P01_01_2021To03_31_2021" unitRef="utr_D" decimals="INF">20</chfw:TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant>
	<chfw:CommonStockNumberOfVotesPerShare contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="chfw_item" decimals="INF">1</chfw:CommonStockNumberOfVotesPerShare>
	<chfw:CommonStockNumberOfVotesPerShare contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="chfw_item" decimals="INF">1</chfw:CommonStockNumberOfVotesPerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="INF">350000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD_xbrli_shares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesIssued contextRef="PAsOn03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="INF">1471210</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="INF">1447914</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="PAsOn03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="INF">1471210</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="INF">1447914</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:TemporaryEquitySharesIssued contextRef="PAsOn03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="INF">8162790</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="INF">8186086</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:CommonStockSharesAuthorized contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD_xbrli_shares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesIssued contextRef="PAsOn03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="INF">2300000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="INF">2300000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="PAsOn03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="INF">2300000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="INF">2300000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:TemporaryEquitySharesIssued contextRef="PAsOn03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="INF">2300000</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:CommitmentsAndContingencies contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" xsi:nil="true"/>
	<us-gaap:CommitmentsAndContingencies contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" xsi:nil="true"/>
	<us-gaap:SharesIssued contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="xbrli_shares" decimals="INF">1447914</us-gaap:SharesIssued>
	<us-gaap:StockholdersEquity contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">145</us-gaap:StockholdersEquity>
	<us-gaap:SharesIssued contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="xbrli_shares" decimals="INF">2300000</us-gaap:SharesIssued>
	<us-gaap:StockholdersEquity contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">230</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">7121960</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">-2122328</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">5000007</us-gaap:StockholdersEquity>
	<chfw:StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption contextRef="P01_01_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">2</chfw:StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption>
	<chfw:StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">232958</chfw:StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption>
	<chfw:StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption contextRef="P01_01_2021To03_31_2021" unitRef="iso4217_USD" decimals="0">232960</chfw:StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption>
	<us-gaap:NetIncomeLoss contextRef="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">-232964</us-gaap:NetIncomeLoss>
	<us-gaap:SharesIssued contextRef="PAsOn03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="xbrli_shares" decimals="INF">1471210</us-gaap:SharesIssued>
	<us-gaap:StockholdersEquity contextRef="PAsOn03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">147</us-gaap:StockholdersEquity>
	<us-gaap:SharesIssued contextRef="PAsOn03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="xbrli_shares" decimals="INF">2300000</us-gaap:SharesIssued>
	<us-gaap:StockholdersEquity contextRef="PAsOn03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">230</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">7354918</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">-2355292</us-gaap:StockholdersEquity>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">987187</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<chfw:StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption contextRef="P01_01_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="xbrli_shares" decimals="INF">23296</chfw:StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption>
	<chfw:TransactionCosts contextRef="PAsOn03_31_2021" unitRef="iso4217_USD" decimals="0">5658864</chfw:TransactionCosts>
	<us-gaap:SharePrice contextRef="PAsOn03_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">10.00</us-gaap:SharePrice>
	<chfw:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum contextRef="P08_21_2020To12_31_2020" unitRef="xbrli_pure" decimals="0">1</chfw:ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum>
	<chfw:UnitsIssuedDuringPeriodSharesNewIssues contextRef="P11_23_2020To11_23_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="xbrli_shares" decimals="0">410000</chfw:UnitsIssuedDuringPeriodSharesNewIssues>
	<us-gaap:SharePrice contextRef="PAsOn12_01_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">10.00</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="PAsOn11_23_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">10.00</us-gaap:SharePrice>
	<chfw:UnitsIssuedDuringPeriodValueNewIssues contextRef="P11_23_2020To11_23_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="iso4217_USD" decimals="0">4100000</chfw:UnitsIssuedDuringPeriodValueNewIssues>
	<chfw:UnitsIssuedDuringPeriodValueNewIssues contextRef="P12_01_2020To12_01_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="iso4217_USD" decimals="0">240000</chfw:UnitsIssuedDuringPeriodValueNewIssues>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn12_31_2020_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="PAsOn04_15_2021_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="iso4217_USD" decimals="0">200000000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
	<us-gaap:BusinessAcquisitionSharePrice contextRef="PAsOn04_15_2021_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">10.00</us-gaap:BusinessAcquisitionSharePrice>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P04_15_2021To04_15_2021_PipeInvestorsMemberCHFWInvestorAxis_SubscriptionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="xbrli_shares" decimals="0">12020000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:SaleOfStockPricePerShare contextRef="PAsOn04_15_2021_PipeInvestorsMemberCHFWInvestorAxis_SubscriptionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">10.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="P04_15_2021To04_15_2021_PipeInvestorsMemberCHFWInvestorAxis_PipeWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubscriptionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="iso4217_USD" decimals="0">120200000</us-gaap:ProceedsFromIssuanceOfWarrants>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="PAsOn04_15_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_PipeInvestorsMemberCHFWInvestorAxis_SubscriptionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="xbrli_shares" decimals="0">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn04_15_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_PipeInvestorsMemberCHFWInvestorAxis_SubscriptionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<dei:EntityRegistrantName contextRef="P01_01_2021To03_31_2021">Consonance-HFW Acquisition Corp.</dei:EntityRegistrantName>
	<xbrli:unit id="iso4217_USD">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="xbrli_shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="xbrli_pure">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="iso4217_USD_xbrli_shares">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="chfw_item">
		<xbrli:measure>chfw:item</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="utr_D">
		<xbrli:measure>utr:D</xbrli:measure>
	</xbrli:unit>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended"/>

<xbrli:context id="PAsOn12_31_2020">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>




<xbrli:context id="PAsOn08_20_2020">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-08-20</xbrli:instant>
		</xbrli:period>
	</xbrli:context>



<xbrli:context id="P08_21_2020To12_31_2020_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonredeemablePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-21</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PublicWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-21</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_21_2020To12_31_2020_ClassOrdinarySharesSubjectForRedemptionMemberusgaapStatementClassOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">chfw:ClassOrdinarySharesSubjectForRedemptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-21</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_21_2020To12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-21</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-21</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_21_2020To12_31_2020_WarrantMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-21</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_21_2020To12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-21</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PublicWarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">chfw:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-21</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PublicWarrantsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">chfw:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-21</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_21_2020To12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chfw:FounderSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-21</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-21</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_21_2020To12_31_2020_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-21</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>




<xbrli:context id="PAsOn12_31_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>


<xbrli:context id="PAsOn12_31_2020_InitialPublicOfferingAndPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chfw:InitialPublicOfferingAndPrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>


<xbrli:context id="PAsOn12_31_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chfw:FounderSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chfw:SponsorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>



<xbrli:context id="PAsOn12_31_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn12_31_2020_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn12_31_2020_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn12_31_2020_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn12_31_2020_MeasurementInputFairValueOfUnitsMemberusgaapMeasurementInputTypeAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">chfw:MeasurementInputFairValueOfUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>


<xbrli:context id="PAsOn12_31_2020_RestatementAdjustmentMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn12_31_2020_RestatedMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">chfw:RestatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_RestatementAdjustmentMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_RestatedMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">chfw:RestatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>


<xbrli:context id="PAsOn12_01_2020_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-12-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn11_23_2020_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chfw:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>




<xbrli:context id="PAsOn11_23_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn11_23_2020_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn11_23_2020_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn11_23_2020_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn11_23_2020_MeasurementInputFairValueOfUnitsMemberusgaapMeasurementInputTypeAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">chfw:MeasurementInputFairValueOfUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn11_23_2020_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn11_23_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PublicWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn11_23_2020_RestatementAdjustmentMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn11_23_2020_RestatedMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">chfw:RestatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn11_23_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn11_23_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn11_23_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_RestatementAdjustmentMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn11_23_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_RestatedMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">chfw:RestatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn09_04_2020_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chfw:PromissoryNoteWithRelatedPartyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-09-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>




<xbrli:context id="P12_01_2020To12_01_2020_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-12-01</xbrli:startDate>
			<xbrli:endDate>2020-12-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>








<xbrli:context id="P11_23_2020To12_31_2020_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-11-23</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P11_23_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PublicWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-11-23</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P11_23_2020To12_31_2020_WarrantsLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">chfw:WarrantsLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-11-23</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_20_2020To12_31_2020_RestatementAdjustmentMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-20</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_20_2020To12_31_2020_RestatedMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">chfw:RestatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-20</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_20_2020To12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-20</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_20_2020To12_31_2020_ClassOrdinarySharesSubjectForRedemptionMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">chfw:ClassOrdinarySharesSubjectForRedemptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-20</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_20_2020To12_31_2020_ClassOrdinarySharesSubjectForRedemptionMemberusgaapStatementClassOfStockAxis_RestatementAdjustmentMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">chfw:ClassOrdinarySharesSubjectForRedemptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-20</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_20_2020To12_31_2020_ClassOrdinarySharesSubjectForRedemptionMemberusgaapStatementClassOfStockAxis_RestatedMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">chfw:RestatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">chfw:ClassOrdinarySharesSubjectForRedemptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-20</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_20_2020To12_31_2020_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonredeemablePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-20</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_20_2020To12_31_2020_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis_RestatementAdjustmentMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonredeemablePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-20</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="P08_20_2020To12_31_2020_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis_RestatedMembersrtRestatementAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">chfw:RestatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonredeemablePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-08-20</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>







<xbrli:context id="PAsOn08_20_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-08-20</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn08_20_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-08-20</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn08_20_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-08-20</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn08_20_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-08-20</xbrli:instant>
		</xbrli:period>
	</xbrli:context>





<xbrli:context id="PAsOn11_22_2020_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn11_22_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chfw:PublicWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

<xbrli:context id="PAsOn11_22_2020_WarrantsLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">chfw:WarrantsLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-11-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context>

	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">987187</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:PrepaidExpenseCurrent contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">790341</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:AssetsCurrent contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">1777528</us-gaap:AssetsCurrent>
	<us-gaap:AssetsHeldInTrustNoncurrent contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">91997501</us-gaap:AssetsHeldInTrustNoncurrent>
	<us-gaap:Assets contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">93775029</us-gaap:Assets>
	<chfw:AccruedLiabilitiesExcludingOfferingCostsCurrent contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">290148</chfw:AccruedLiabilitiesExcludingOfferingCostsCurrent>
	<us-gaap:Liabilities contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">6914162</us-gaap:Liabilities>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">81860860</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:PreferredStockValue contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" xsi:nil="true"/>
	<us-gaap:AdditionalPaidInCapital contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">7121960</us-gaap:AdditionalPaidInCapital>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">-2122328</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:StockholdersEquity contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">5000007</us-gaap:StockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">93775029</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:CommitmentsAndContingencies contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" xsi:nil="true"/>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="PAsOn12_31_2020" unitRef="xbrli_shares" decimals="0">8186086</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:OperatingCostsAndExpenses contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">438756</us-gaap:OperatingCostsAndExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">-438756</us-gaap:OperatingIncomeLoss>
	<us-gaap:InvestmentIncomeInterest contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">5892</us-gaap:InvestmentIncomeInterest>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">-8391</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:NonoperatingIncomeExpense contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">-1683572</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NetIncomeLoss contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">-2122328</us-gaap:NetIncomeLoss>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P08_21_2020To12_31_2020_ClassOrdinarySharesSubjectForRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="0">8181335</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="P08_21_2020To12_31_2020_ClassOrdinarySharesSubjectForRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">0.00</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P08_21_2020To12_31_2020_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="0">2461095</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="P08_21_2020To12_31_2020_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">-0.86</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:SharesIssued contextRef="PAsOn08_20_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="xbrli_shares" decimals="0">0</us-gaap:SharesIssued>
	<us-gaap:StockholdersEquity contextRef="PAsOn08_20_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">0</us-gaap:StockholdersEquity>
	<us-gaap:SharesIssued contextRef="PAsOn08_20_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="xbrli_shares" decimals="0">0</us-gaap:SharesIssued>
	<us-gaap:StockholdersEquity contextRef="PAsOn08_20_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="PAsOn08_20_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="PAsOn08_20_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="PAsOn08_20_2020" unitRef="iso4217_USD" decimals="0">0</us-gaap:StockholdersEquity>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P08_21_2020To12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="xbrli_shares" decimals="0">2300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P08_21_2020To12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">230</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P08_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">24770</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<chfw:UnitsIssuedDuringPeriodSharesNewIssues contextRef="P08_21_2020To12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="xbrli_shares" decimals="0">9200000</chfw:UnitsIssuedDuringPeriodSharesNewIssues>
	<chfw:UnitsIssuedDuringPeriodValueNewIssues contextRef="P08_21_2020To12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">920</chfw:UnitsIssuedDuringPeriodValueNewIssues>
	<chfw:UnitsIssuedDuringPeriodValueNewIssues contextRef="P08_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">86112771</chfw:UnitsIssuedDuringPeriodValueNewIssues>
	<chfw:UnitsIssuedDuringPeriodValueNewIssues contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">86113691</chfw:UnitsIssuedDuringPeriodValueNewIssues>
	<chfw:SaleOfPrivatePlacementUnitsShares contextRef="P08_21_2020To12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="xbrli_shares" decimals="0">434000</chfw:SaleOfPrivatePlacementUnitsShares>
	<chfw:SaleOfPrivatePlacementUnitsValue contextRef="P08_21_2020To12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">43</chfw:SaleOfPrivatePlacementUnitsValue>
	<chfw:SaleOfPrivatePlacementUnitsValue contextRef="P08_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">2844461</chfw:SaleOfPrivatePlacementUnitsValue>
	<chfw:SaleOfPrivatePlacementUnitsValue contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">2844504</chfw:SaleOfPrivatePlacementUnitsValue>
	<chfw:CommonStockSubjectToPossibleRedemptionShares contextRef="P08_21_2020To12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="xbrli_shares" decimals="0">8186086</chfw:CommonStockSubjectToPossibleRedemptionShares>
	<chfw:CommonStockSubjectToPossibleRedemptionValue contextRef="P08_21_2020To12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">818</chfw:CommonStockSubjectToPossibleRedemptionValue>
	<chfw:CommonStockSubjectToPossibleRedemptionValue contextRef="P08_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">81860042</chfw:CommonStockSubjectToPossibleRedemptionValue>
	<chfw:CommonStockSubjectToPossibleRedemptionValue contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">81860860</chfw:CommonStockSubjectToPossibleRedemptionValue>
	<us-gaap:NetIncomeLoss contextRef="P08_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="iso4217_USD" decimals="0">-2122328</us-gaap:NetIncomeLoss>
	<chfw:UnitsIssuedDuringPeriodSharesNewIssues contextRef="P08_21_2020To12_31_2020" unitRef="xbrli_shares" decimals="0">9200000</chfw:UnitsIssuedDuringPeriodSharesNewIssues>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn12_31_2020" unitRef="xbrli_shares" decimals="0">434000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ProfitLoss contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">-2122328</us-gaap:ProfitLoss>
	<chfw:FormationCosts contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">4961</chfw:FormationCosts>
	<us-gaap:InvestmentIncomeInterest contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">5892</us-gaap:InvestmentIncomeInterest>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">-8391</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">790341</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">290148</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">-933988</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<chfw:CashDepositedInTrustAccount contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">92000000</chfw:CashDepositedInTrustAccount>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">-92000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<chfw:NetProceedsFromInitialPublicOffering contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">90160000</chfw:NetProceedsFromInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">4340000</us-gaap:ProceedsFromIssuanceOfWarrants>
	<us-gaap:ProceedsFromRelatedPartyDebt contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">147753</us-gaap:ProceedsFromRelatedPartyDebt>
	<us-gaap:RepaymentsOfRelatedPartyDebt contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">147753</us-gaap:RepaymentsOfRelatedPartyDebt>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">578825</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">93921175</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">987187</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">987187</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<chfw:InitialClassificationOfCommonStockSubjectToPossibleRedemption contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">72522937</chfw:InitialClassificationOfCommonStockSubjectToPossibleRedemption>
	<chfw:ChangeInValueOfCommonStockSubjectToPossibleRedemption contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">-2429850</chfw:ChangeInValueOfCommonStockSubjectToPossibleRedemption>
	<chfw:OfferingCostsPaidBySponsorFromProceedsFromIssuanceOfCommonStockOrdinaryShares contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">20039</chfw:OfferingCostsPaidBySponsorFromProceedsFromIssuanceOfCommonStockOrdinaryShares>
	<chfw:DeferredUnderwritingFeePayable contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">3220000</chfw:DeferredUnderwritingFeePayable>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consonance-HFW&lt;/div&gt; Acquisition Corp. (the &amp;#8220;Company&amp;#8221;) is a blank check company incorporated as a Cayman Islands exempted company on August&amp;#160;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (&amp;#8220;Business Combination&amp;#8221;). &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is not limited to a particular industry or geographic region for purposes of completing a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As of December&amp;#160;31, 2020, the Company had not commenced any operations. All activity for the period from August&amp;#160;21, 2020 (inception) through December&amp;#160;31, 2020 relates to the Company&amp;#8217;s formation and the initial public offering (&amp;#8220;Initial Public Offering&amp;#8221;), which is described below. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-operating&lt;/div&gt; income in the form of interest income from the proceeds derived from the Initial Public Offering. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The registration statement for the Company&amp;#8217;s Initial Public Offering became effective on November&amp;#160;18, 2020. On November&amp;#160;23, 2020, the Company consummated the Initial Public Offering of 8,000,000&amp;#160;units (the &amp;#8220;Units&amp;#8221; and, with respect to the Class&amp;#160;A ordinary shares included in the Units sold, the &amp;#8220;Public Shares&amp;#8221;), at $10.00 per Unit, generating gross proceeds of $80,000,000 which is described in &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 4 &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Simultaneously with the consummation of the Initial Public Offering, the Company consummated the sale of 410,000&amp;#160;units (the &amp;#8220;Private Placement Units&amp;#8221;) at a price of $10.00 per Private Placement Unit in a private placement to Consonance Life Sciences (the &amp;#8220;Sponsor&amp;#8221;), generating gross proceeds of $4,100,000, which is described in &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 5. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Following the consummation of the Initial Public Offering on November&amp;#160;23, 2020, an amount of $80,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Units was placed in a trust account (the &amp;#8220;Trust Account&amp;#8221;) and invested in U.S. government securities, within the meaning set forth in Section&amp;#160;2(a)(16) of the Investment Company Act of 1940, as amended (the &amp;#8220;Investment Company Act&amp;#8221;), with a maturity of 185&amp;#160;days or less, or in any open-ended investment company that holds itself out as a money market fund meeting certain conditions of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rule&amp;#160;2a-7&lt;/div&gt; of the Investment Company Act, as determined by the Company, until the earlier of: (i)&amp;#160;the completion of a Business Combination and (ii)&amp;#160;the distribution of the funds in the Trust Account to the Company&amp;#8217;s shareholders, as described below. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&amp;#160;1, 2020, the underwriters fully exercised their over-allotment option, resulting in an additional 1,200,000&amp;#160;Units issued for an aggregate amount of $12,000,000. In connection with the underwriters&amp;#8217; full exercise of their over-allotment option, the Company also consummated the sale of an additional 24,000 Private Placement Units at $10.00 per Private Placement Unit, generating total proceeds of $12,240,000. A total of $12,000,000 was deposited into the Trust Account, bringing the aggregate proceeds held in the Trust Account to $92,000,000. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transaction costs amounted to $5,658,864, consisting of $1,840,000 of underwriting fees, $3,220,000 of deferred underwriting fees and $598,864 of other offering costs. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward completing a Business Combination. The Company must complete its initial Business Combination with one or more target businesses that together have a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding any deferred underwriting commissions held in the Trust Account and taxes payable on the interest earned on the Trust Account) at the time of the agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will provide its shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&amp;#160;in connection with a shareholder meeting called to approve the Business Combination or (ii)&amp;#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The shareholders will be entitled to redeem their shares for a pro&amp;#160;rata portion of the amount held in the Trust Account (initially $10.00 per share), calculated as of two business days prior to the completion of a Business Combination, including any pro&amp;#160;rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. There will be no redemption rights upon the completion of a Business Combination with respect to the Company&amp;#8217;s warrants. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Management continues to evaluate the impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&amp;#8217;s financial position and/or search for a target company, the specific impact is not readily determinable as of the date of the financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<chfw:TransactionCosts contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">5658864</chfw:TransactionCosts>
	<chfw:SaleOfStockUnderwritingFees contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">1840000</chfw:SaleOfStockUnderwritingFees>
	<chfw:SaleOfStockOtherOfferingCosts contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">598864</chfw:SaleOfStockOtherOfferingCosts>
	<chfw:ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount contextRef="P08_21_2020To12_31_2020" unitRef="xbrli_pure" decimals="2">0.80</chfw:ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount>
	<chfw:ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination contextRef="P08_21_2020To12_31_2020" unitRef="xbrli_pure" decimals="2">0.50</chfw:ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination>
	<us-gaap:AssetsHeldInTrust contextRef="PAsOn11_23_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="iso4217_USD" decimals="0">80000000</us-gaap:AssetsHeldInTrust>
	<us-gaap:SharePrice contextRef="PAsOn12_31_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">10.00</us-gaap:SharePrice>
	<us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) and pursuant to the rules and regulations of the SEC. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &amp;#8220;emerging growth company,&amp;#8221; as defined in Section&amp;#160;2(a) of the Securities Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &amp;#8220;JOBS Act&amp;#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&amp;#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Further, Section&amp;#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&amp;#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all short-term investments with an original maturity of three&amp;#160;months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December&amp;#160;31, 2020. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Marketable Securities Held in Trust Account &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&amp;#160;31, 2020, substantially all of the assets held in the Trust Account were held in U.S. Treasury Bills. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Warrant Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&amp;#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 480, Distinguishing Liabilities from Equity (&amp;#8220;ASC 480&amp;#8221;) and ASC 815,&amp;#160;Derivatives and Hedging&amp;#160;(&amp;#8220;ASC 815&amp;#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&amp;#8217;s own ordinary shares and whether the warrant holders could potentially require &amp;#8220;net cash settlement&amp;#8221; in a circumstance outside of the Company&amp;#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; gain or loss on the statements of operations. The fair value of the warrants was estimated using a binomial lattice simulation methodology (see Note 9). &lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Class&amp;#160;A Ordinary Shares Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for its Class&amp;#160;A ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) Topic 480 &amp;#8220;Distinguishing Liabilities from Equity.&amp;#8221; Class&amp;#160;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&amp;#8217;s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders&amp;#8217; equity. The Company&amp;#8217;s Class&amp;#160;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&amp;#8217;s control and subject to occurrence of uncertain future events. Accordingly, Class&amp;#160;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders&amp;#8217; equity section of the Company&amp;#8217;s balance sheet. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes under ASC 740, &amp;#8220;Income Taxes&amp;#8221; (&amp;#8220;ASC 740&amp;#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&amp;#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December&amp;#160;31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is considered an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&amp;#8217;s tax provision was zero for the period presented. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Net Income (Loss) Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) per share is computed by dividing net income by the weighted-average number of ordinary shares outstanding during the period, excluding ordinary shares subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 3,211,334 shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The Company&amp;#8217;s statement of operations includes a presentation of income (loss) per share for ordinary shares subject to possible redemption in a manner similar to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method of income (loss) per share. Net income (loss) per ordinary share, basic and diluted, for ordinary shares subject to possible redemption is calculated by dividing the proportionate share of income or loss on marketable securities held by the Trust Account by the weighted average number of ordinary shares subject to possible redemption outstanding since original issuance. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Net income (loss) per share, basic and diluted, for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable&lt;/div&gt; ordinary shares is calculated by dividing the net income (loss), adjusted for income or loss on marketable securities attributable to ordinary shares subject to possible redemption, by the weighted average number of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable&lt;/div&gt; ordinary shares outstanding for the period. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares include Founder Shares and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable&lt;/div&gt; ordinary shares as these shares do not have any redemption features. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares participate in the income or loss on marketable securities based on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable&lt;/div&gt; shares&amp;#8217; proportionate interest. &lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:85%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the&amp;#160; Period&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;from&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;August&amp;#160;21,&amp;#160; 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Inception)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Through&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator: Earnings allocable to Ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Interest earned on marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,243&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unrealized gain (loss) on marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(7,466&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net income attributable to Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(2,223&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator: Weighted Average Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Basic and diluted weighted average shares outstanding, Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8,181,335&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per share, Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;0.00&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:84%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Non-Redeemable&lt;/div&gt; Common Stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator: Net Loss minus Net Earnings&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(2,122,328&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Add: Net loss allocable to Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;2,223&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Non-Redeemable&lt;/div&gt; Net Loss&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(2,120,105&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Denominator: Weighted Average &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Basic and diluted weighted average shares outstanding, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,461,095&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Basic and diluted net loss per share, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(0.86&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;#160;&lt;/div&gt;  &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&amp;#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &amp;#8220;Fair Value Measurement,&amp;#8221; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying financial statements. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) and pursuant to the rules and regulations of the SEC. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<chfw:EmergingGrowthCompanyPolicyTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &amp;#8220;emerging growth company,&amp;#8221; as defined in Section&amp;#160;2(a) of the Securities Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &amp;#8220;JOBS Act&amp;#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&amp;#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Further, Section&amp;#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&amp;#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chfw:EmergingGrowthCompanyPolicyTextBlock>
	<us-gaap:UseOfEstimates contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UseOfEstimates>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all short-term investments with an original maturity of three&amp;#160;months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December&amp;#160;31, 2020. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<chfw:AssetsHeldInTrustAccountPolicyPolicyTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Marketable Securities Held in Trust Account &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&amp;#160;31, 2020, substantially all of the assets held in the Trust Account were held in U.S. Treasury Bills. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chfw:AssetsHeldInTrustAccountPolicyPolicyTextBlock>
	<chfw:TemporaryEquityPolicyPolicyTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Class&amp;#160;A Ordinary Shares Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for its Class&amp;#160;A ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) Topic 480 &amp;#8220;Distinguishing Liabilities from Equity.&amp;#8221; Class&amp;#160;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&amp;#8217;s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders&amp;#8217; equity. The Company&amp;#8217;s Class&amp;#160;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&amp;#8217;s control and subject to occurrence of uncertain future events. Accordingly, Class&amp;#160;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders&amp;#8217; equity section of the Company&amp;#8217;s balance sheet. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chfw:TemporaryEquityPolicyPolicyTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes under ASC 740, &amp;#8220;Income Taxes&amp;#8221; (&amp;#8220;ASC 740&amp;#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&amp;#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December&amp;#160;31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is considered an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&amp;#8217;s tax provision was zero for the period presented. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Net Income (Loss) Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income (loss) per share is computed by dividing net income by the weighted-average number of ordinary shares outstanding during the period, excluding ordinary shares subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 3,211,334 shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The Company&amp;#8217;s statement of operations includes a presentation of income (loss) per share for ordinary shares subject to possible redemption in a manner similar to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-class&lt;/div&gt; method of income (loss) per share. Net income (loss) per ordinary share, basic and diluted, for ordinary shares subject to possible redemption is calculated by dividing the proportionate share of income or loss on marketable securities held by the Trust Account by the weighted average number of ordinary shares subject to possible redemption outstanding since original issuance. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Net income (loss) per share, basic and diluted, for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable&lt;/div&gt; ordinary shares is calculated by dividing the net income (loss), adjusted for income or loss on marketable securities attributable to ordinary shares subject to possible redemption, by the weighted average number of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable&lt;/div&gt; ordinary shares outstanding for the period. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares include Founder Shares and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable&lt;/div&gt; ordinary shares as these shares do not have any redemption features. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares participate in the income or loss on marketable securities based on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable&lt;/div&gt; shares&amp;#8217; proportionate interest. &lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:85%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the&amp;#160; Period&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;from&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;August&amp;#160;21,&amp;#160; 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Inception)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Through&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator: Earnings allocable to Ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Interest earned on marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,243&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unrealized gain (loss) on marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(7,466&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net income attributable to Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(2,223&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator: Weighted Average Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Basic and diluted weighted average shares outstanding, Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8,181,335&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per share, Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;0.00&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:84%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Non-Redeemable&lt;/div&gt; Common Stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator: Net Loss minus Net Earnings&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(2,122,328&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Add: Net loss allocable to Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;2,223&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Non-Redeemable&lt;/div&gt; Net Loss&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(2,120,105&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Denominator: Weighted Average &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Basic and diluted weighted average shares outstanding, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,461,095&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Basic and diluted net loss per share, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(0.86&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;#160;&lt;/div&gt;  &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&amp;#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &amp;#8220;Fair Value Measurement,&amp;#8221; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying financial statements. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:85%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the&amp;#160; Period&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;from&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;August&amp;#160;21,&amp;#160; 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Inception)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Through&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;;text-align:center;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator: Earnings allocable to Ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Interest earned on marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,243&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unrealized gain (loss) on marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(7,466&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net income attributable to Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(2,223&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator: Weighted Average Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Basic and diluted weighted average shares outstanding, Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;8,181,335&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per share, Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;0.00&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:84%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Non-Redeemable&lt;/div&gt; Common Stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator: Net Loss minus Net Earnings&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(2,122,328&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Add: Net loss allocable to Class&amp;#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;2,223&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Non-Redeemable&lt;/div&gt; Net Loss&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(2,120,105&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Denominator: Weighted Average &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Basic and diluted weighted average shares outstanding, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2,461,095&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Basic and diluted net loss per share, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;(0.86&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;#160;&lt;/div&gt;  &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:InvestmentIncomeInterest contextRef="P08_21_2020To12_31_2020_ClassOrdinarySharesSubjectForRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD" decimals="0">5243</us-gaap:InvestmentIncomeInterest>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="P08_21_2020To12_31_2020_ClassOrdinarySharesSubjectForRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD" decimals="0">-7466</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="P08_21_2020To12_31_2020_ClassOrdinarySharesSubjectForRedemptionMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD" decimals="0">-2223</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLoss contextRef="P08_21_2020To12_31_2020_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD" decimals="0">-2122328</us-gaap:NetIncomeLoss>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="P08_21_2020To12_31_2020_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD" decimals="0">-2223</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="P08_21_2020To12_31_2020_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="iso4217_USD" decimals="0">-2120105</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn12_31_2020_InitialPublicOfferingAndPrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="xbrli_shares" decimals="INF">3211334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:CashFDICInsuredAmount contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">250000</us-gaap:CashFDICInsuredAmount>
	<us-gaap:UnrecognizedTaxBenefits contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">0</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
	<chfw:InitialPublicOfferingTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 4. INITIAL PUBLIC OFFERING &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Pursuant to the Initial Public Offering, the Company sold 8,000,000&amp;#160;Units at a purchase price of $10.00 per Unit. Each Unit consists of one Class&amp;#160;A ordinary share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-third&lt;/div&gt; of one redeemable warrant (&amp;#8220;Public Warrant&amp;#8221;). Each whole Public Warrant entitles the holder to purchase one Class&amp;#160;A ordinary share at an exercise price of $11.50 per share, subject to adjustment (see Note 8). &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&amp;#160;1, 2020, the underwriters fully exercised their over-allotment option, resulting in an additional 1,200,000&amp;#160;Units issued for an aggregate amount of $12,000,000. In connection with the underwriters&amp;#8217; full exercise of their over-allotment option, the Company also consummated the sale of an additional 24,000 Private Placement Units at $10.00 per Private Placement Unit, generating total proceeds of $12,240,000. A total of $12,000,000 was deposited into the Trust Account, bringing the aggregate proceeds held in the Trust Account to $92,000,000 (see Note 9). &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chfw:InitialPublicOfferingTextBlock>
	<chfw:PrivatePlacementTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 5. PRIVATE PLACEMENT &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Simultaneously with the consummation of the Initial Public Offering, the Sponsor purchased an aggregate of 410,000 Private Placement Units at a price of $10.00 per Private Placement Unit, for an aggregate purchase price of $4,100,000. On December&amp;#160;1, 2020, as a result of the underwriters&amp;#8217; election to fully exercise their over-allotment option, the Sponsor purchased an additional 24,000 Private Placement Units, at a price of $10.00 per Private Placement Unit, or $240,000 in the aggregate. Each Private Placement Unit consists of one Class&amp;#160;A ordinary share (&amp;#8220;Private Placement Share&amp;#8221; or, collectively, &amp;#8220;Private Placement Shares&amp;#8221;) and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-third&lt;/div&gt; of one redeemable warrant (each, a &amp;#8220;Private Placement Warrant&amp;#8221;). Each whole Private Placement Warrant is exercisable for one Class&amp;#160;A ordinary share at a price of $11.50 per share, subject to adjustment (see Note 8). The proceeds from the sale of the Private Placement Units were added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Units and all underlying securities will expire worthless. &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chfw:PrivatePlacementTextBlock>
	<chfw:NumberOfWarrantsIssuedPerUnit contextRef="P12_01_2020To12_01_2020_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="xbrli_shares" decimals="INF">1</chfw:NumberOfWarrantsIssuedPerUnit>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn12_01_2020_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 6. RELATED PARTY TRANSACTIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Founder Shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&amp;#160;4, 2020, the Sponsor paid $25,000 to cover certain offering and formation costs of the Company in consideration for 3,593,750 Class&amp;#160;B ordinary shares. On October&amp;#160;8, 2020 and November&amp;#160;10, 2020, 718,750 and 575,000 Class&amp;#160;B ordinary shares were contributed back to the Company for no consideration, respectively, resulting in there being 2,300,000 Class&amp;#160;B ordinary shares (the &amp;#8220;Founder Shares&amp;#8221;) being issued and outstanding. The Founder Shares include an aggregate of up to 300,000 shares subject to forfeiture by the Sponsor to the extent that the underwriters&amp;#8217; over-allotment is not exercised in full or in part, so that the number of Founder Shares will collectively represent 20% of the Company&amp;#8217;s issued and outstanding shares upon the completion of the Initial Public Offering (not including the Private Placement Shares).&amp;#160;On December&amp;#160;1, 2020, the underwriters fully exercised their over-allotment option, therefore there are no Founder Shares subject to forfeiture. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of: (A)&amp;#160;one year after the completion of a Business Combination; and (B)&amp;#160;subsequent to a Business Combination, (x)&amp;#160;if the closing price of the Class&amp;#160;A ordinary shares equals or exceeds $12.00 per share (as adjusted for share &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-divisions,&lt;/div&gt; share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-trading&lt;/div&gt; day period commencing at least 150&amp;#160;days after a Business Combination, or (y)&amp;#160;the date on which the Company completes a liquidation, merger, amalgamation, share exchange, reorganization or other similar transaction that results in all of the Company&amp;#8217;s shareholders having the right to exchange their Class&amp;#160;A ordinary shares for cash, securities or other property. &lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Administrative Services Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company entered into an agreement, commencing on November&amp;#160;18, 2020 through the earlier of the Company&amp;#8217;s consummation of a Business Combination and its liquidation, to pay the Sponsor a total of up to $55,000 per month for office space and administrative support services. For the period from August&amp;#160;21, 2020 (inception) through December&amp;#160;31, 2020, the Company incurred and paid $55,000 of such fees. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Promissory Note&amp;#160;&amp;#8212;&amp;#160;Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On September&amp;#160;4, 2020, the Company issued an unsecured promissory note to the Sponsor (the &amp;#8220;Promissory Note&amp;#8221;), pursuant to which the Company could borrow up to an aggregate principal amount of $300,000. The Promissory Note was &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and payable on the earlier of (i)&amp;#160;December&amp;#160;31, 2021 or (i)&amp;#160;the consummation of the Initial Public Offering. The outstanding balance under the Promissory Note of $147,753 was repaid at the closing of the Initial Public Offering on November&amp;#160;23, 2020. &lt;/div&gt;&lt;div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Related Party Loans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company&amp;#8217;s directors and officers may, but are not obligated to, loan the Company funds as may be required (&amp;#8220;Working Capital Loans&amp;#8221;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender&amp;#8217;s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into Private Placement Units of the post-Business Combination entity at a price of $10.00 per Private Placement Unit. The Private Placement Units would be identical to the Units. As of December&amp;#160;31, 2020, the Company had no outstanding borrowings under the Working Capital Loans. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<chfw:PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders contextRef="P08_21_2020To12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderSharesMemberusgaapRelatedPartyTransactionAxis" unitRef="xbrli_pure" decimals="2">0.20</chfw:PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders>
	<chfw:NumberOfSharesSubjectToForfeiture contextRef="PAsOn12_31_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="xbrli_shares" decimals="INF">300000</chfw:NumberOfSharesSubjectToForfeiture>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="P11_18_2020To11_18_2020_AdministrativeSupportAgreementMemberusgaapRelatedPartyTransactionAxis" unitRef="iso4217_USD" decimals="0">55000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<chfw:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote contextRef="PAsOn09_04_2020_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis" unitRef="iso4217_USD" decimals="0">300000</chfw:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote>
	<us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent contextRef="PAsOn11_23_2020_PromissoryNoteWithRelatedPartyMemberusgaapRelatedPartyTransactionAxis" unitRef="iso4217_USD" decimals="0">147753</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 7. COMMITMENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Registration and Shareholder Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Pursuant to a registration rights agreement entered into on November&amp;#160;18, 2020, the holders of the Founder Shares, Private Placement Units (including securities contained therein) and warrants that may be issued upon conversion of the Working Capital Loans (and any Class&amp;#160;A ordinary shares issuable upon the exercise of the Private Placement Units and warrants that may be issued upon conversion of Working Capital Loans and upon conversion of the Founder Shares) will be entitled to registration rights. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &amp;#8220;piggy-back&amp;#8221; registration rights with respect to registration statements filed subsequent to the completion of a Business Combination. However, the registration and shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lock-up&lt;/div&gt; period. The registration rights agreement does not contain liquidating damages or other cash settlement provisions resulting from delays in registering the Company&amp;#8217;s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.&amp;#160; &lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Underwriting Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The underwriters are entitled to a deferred fee of $0.35 per Unit, or $3,220,000 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<chfw:DeferredFeePerUnit contextRef="PAsOn12_31_2020" unitRef="iso4217_USD_xbrli_shares" decimals="2">0.35</chfw:DeferredFeePerUnit>
	<chfw:DeferredOfferingCostsNoncurrent contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">3220000</chfw:DeferredOfferingCostsNoncurrent>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 8. SHAREHOLDERS&amp;#8217; EQUITY &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Preference shares &amp;#8212;&lt;/div&gt;&lt;/div&gt; The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company&amp;#8217;s board of directors. At December&amp;#160;31, 2020, there were no preference shares issued or outstanding. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Class&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&amp;#160;A ordinary shares &amp;#8212;&lt;/div&gt;&lt;/div&gt; The Company is authorized to issue 350,000,000 Class&amp;#160;A ordinary shares, with a par value of $0.0001 per share. Holders of Class&amp;#160;A ordinary shares are entitled to one vote for each share. At December&amp;#160;31, 2020, there were 1,447,914 Class&amp;#160;A ordinary shares issued and outstanding, excluding 8,186,086 Class&amp;#160;A ordinary shares subject to possible redemption. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Class&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&amp;#160;B ordinary shares &amp;#8212;&lt;/div&gt;&lt;/div&gt; The Company is authorized to issue 150,000,000 Class&amp;#160;B ordinary shares, with a par value of $0.0001 per share. Holders of the Class&amp;#160;B ordinary shares are entitled to one vote for each share. At December&amp;#160;31, 2020, there were 2,300,000 Class&amp;#160;B ordinary shares issued and outstanding. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Only holders of the Class&amp;#160;B ordinary shares will have the right to vote on the election of directors prior to the Business Combination. Holders of Class&amp;#160;A ordinary shares and holders of Class&amp;#160;B ordinary shares will vote together as a single class on all other matters submitted to a vote of the Company&amp;#8217;s shareholders except as otherwise required by law. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Class&amp;#160;B ordinary shares will automatically convert into Class&amp;#160;A ordinary shares on the first business day following the consummation of a Business Combination at a ratio such that the number of Class&amp;#160;A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis, 20% of the sum of (i)&amp;#160;the total number of ordinary shares issued and outstanding (excluding the Private Placement Shares underlying the Private Placement Units) upon completion of the Initial Public Offering, plus (ii)&amp;#160;the sum of the total number of Class&amp;#160;A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of a Business Combination, excluding any Class&amp;#160;A ordinary shares or equity-linked securities exercisable for or convertible into Class&amp;#160;A ordinary shares issued, deemed issued, or to be issued, to any seller in a Business Combination and any Private Placement Warrants issued to the Sponsor, members of the Company&amp;#8217;s founding team or any of their affiliates upon conversion of Working Capital Loans. In no event will the Class&amp;#160;B ordinary shares convert into Class&amp;#160;A ordinary shares at a rate of less than one to one.&amp;#160; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn12_31_2020" unitRef="xbrli_shares" decimals="0">1000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn12_31_2020" unitRef="iso4217_USD_xbrli_shares" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2020" unitRef="xbrli_shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2020" unitRef="xbrli_shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:TemporaryEquitySharesIssued contextRef="PAsOn12_31_2020_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="xbrli_shares" decimals="INF">2300000</us-gaap:TemporaryEquitySharesIssued>
	<chfw:MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement contextRef="P08_21_2020To12_31_2020_WarrantMemberusgaapClassOfWarrantOrRightAxis">P20D</chfw:MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement>
	<chfw:PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective contextRef="P08_21_2020To12_31_2020_WarrantMemberusgaapClassOfWarrantOrRightAxis">P60D</chfw:PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective>
	<chfw:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion contextRef="P08_21_2020To12_31_2020_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">P30D</chfw:RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion>
	<chfw:WarrantRedemptionConditionMinimumSharePrice contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">10.00</chfw:WarrantRedemptionConditionMinimumSharePrice>
	<chfw:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" unitRef="iso4217_USD_xbrli_shares" decimals="INF">0.10</chfw:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
	<chfw:WarrantRedemptionConditionMinimumSharePriceScenarioTwo contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">18.00</chfw:WarrantRedemptionConditionMinimumSharePriceScenarioTwo>
	<chfw:RedemptionPeriod contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis">P30D</chfw:RedemptionPeriod>
	<chfw:WarrantRedemptionConditionMinimumSharePrice contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">10.00</chfw:WarrantRedemptionConditionMinimumSharePrice>
	<chfw:WarrantRedemptionConditionMinimumSharePriceScenarioTwo contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">18.00</chfw:WarrantRedemptionConditionMinimumSharePriceScenarioTwo>
	<chfw:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">0.01</chfw:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
	<chfw:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" unitRef="chfw_item" decimals="INF">30</chfw:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays>
	<chfw:WarrantRedemptionPriceAdjustmentMultiple contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" unitRef="xbrli_pure" decimals="INF">180</chfw:WarrantRedemptionPriceAdjustmentMultiple>
	<chfw:RedemptionPeriod contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis">P30D</chfw:RedemptionPeriod>
	<chfw:SharePricetriggerUsedToMeasureDilutionOfWarrant contextRef="PAsOn12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">9.20</chfw:SharePricetriggerUsedToMeasureDilutionOfWarrant>
	<chfw:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="xbrli_pure" decimals="0">60</chfw:PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant>
	<chfw:WarrantExercisePriceAdjustmentMultiple contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="xbrli_pure" decimals="0">115</chfw:WarrantExercisePriceAdjustmentMultiple>
	<chfw:WarrantRedemptionPriceAdjustmentMultiple contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="xbrli_pure" decimals="0">100</chfw:WarrantRedemptionPriceAdjustmentMultiple>
	<chfw:WarrantExercisePeriodConditionOne contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">P30D</chfw:WarrantExercisePeriodConditionOne>
	<chfw:WarrantExercisePeriodConditionTwo contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">P1Y</chfw:WarrantExercisePeriodConditionTwo>
	<us-gaap:WarrantsAndRightsOutstandingTerm contextRef="PAsOn12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
	<chfw:WarrantRedemptionConditionMinimumSharePriceScenarioTwo contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">18.00</chfw:WarrantRedemptionConditionMinimumSharePriceScenarioTwo>
	<us-gaap:SubsequentEventsTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="display:inline;"&gt;NOTE 11. SUBSEQUENT EVENTS&amp;#160;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, except as noted in footnote 2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;and as set forth below&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: 'times new roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Business Combination Agreement and PIPE Financing&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: 'times new roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 12pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On April 15, 2021, the Company entered into a business combination agreement with Surrozen, Inc. (&amp;#8220;Surrozen&amp;#8221;), pursuant to which a wholly-owned subsidiary of the Company will merge with and into Surrozen, with Surrozen surviving as a wholly-owned subsidiary of the Company and the Company will redomicile as a Delaware corporation. In accordance with the terms and subject to the conditions of the Business Combination Agreement, each share and equity award (whether vested or unvested) of Surrozen outstanding as of closing will be exchanged for shares of the Company&amp;#8217;s common stock or comparable equity awards that are settled or are exercisable for shares of the Company&amp;#8217;s common stock, as applicable, based on an implied Surrozen equity value of $200,000,000 and a $10.00 per share value of the Company&amp;#8217;s Common Stock. In connection with the foregoing and concurrently with the execution of the Business Combination Agreement, the Company entered into Subscription Agreements with certain investors (the &amp;#8220;Subscription Agreements&amp;#8221; and such investors, the &amp;#8220;PIPE Investors&amp;#8221;), pursuant to which the PIPE Investors have agreed to subscribe for and purchase, and the Company has agreed to issue and sell to the PIPE Investors, an aggregate of 12,020,000 units, each consisting of one share of the Company&amp;#8217;s common stock and one-third of one redeemable warrant for one share of the Company&amp;#8217;s common stock (the &amp;#8220;PIPE Warrants&amp;#8221;), for a purchase price of $10.00 per unit (the &amp;#8220;PIPE Units&amp;#8221;), for aggregate gross proceeds of $120,200,000 (the &amp;#8220;PIPE Financing&amp;#8221;). Each whole PIPE Warrant entitles the holder thereof to purchase one share of the Company&amp;#8217;s common stock at a price of $11.50 per share, subject to adjustment as described in the form of warrant agreement attached to the form of Subscription Agreement, and only whole PIPE Warrants will be exercisable. The PIPE Warrants have substantially the same provisions as the public warrants issued in connection with the Company&amp;#8217;s initial public offering. The securities to be issued pursuant to the Subscription Agreements have not been registered under the Securities Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;) in reliance upon the exemption provided in Section 4(a)(2) of the Securities Act.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(As of May 14, 2021)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;. FAIR VALUE MEASUREMENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company follows the guidance in ASC Topic 820 for its financial assets and liabilities that are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measured&lt;/div&gt; and reported at fair value at each reporting period, and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; assets and liabilities that are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measured&lt;/div&gt; and reported at fair value at least annually. &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&amp;#8217;s financial assets and liabilities reflects management&amp;#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 2%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&amp;#160;1: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 13%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 2%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&amp;#160;2: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 13%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Observable inputs other than Level&amp;#160;1 inputs. Examples of Level&amp;#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 2%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&amp;#160;3: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 13%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&amp;#8217;s assets that are measured at fair value on a recurring basis at December&amp;#160;31, 2020, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:80%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.7pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.7pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.7pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.7pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31,&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.7pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;91,997,501&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrant Liability &amp;#8211; Public Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3,250,667&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Warrant Liability &amp;#8211; Private Placement Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;153,347&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Warrants were accounted for as liabilities in accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40&lt;/div&gt; and are presented within warrant liabilities on our consolidated balance sheet. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the consolidated statement of operations. &lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Initial Measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Both the Private Placement Warrants and the Public Warrants were initially valued using a binomial lattice model, which is considered to be a Level&amp;#160;3 fair value measurement. The binomial lattice model&amp;#8217;s primary unobservable input utilized in determining the fair value of the Private Placement Warrants is the expected volatility of the common stock. The expected volatility as of the IPO date was derived from observable public warrant pricing on comparable &amp;#8216;blank-check&amp;#8217; companies without an identified target. The expected volatility as of subsequent valuation dates will be implied from the Company&amp;#8217;s own public warrant pricing. A binomial lattice model methodology was also used in estimating the fair value of the Public Warrants for periods where no observable traded price was available, using the same expected volatility as was used in measuring the fair value of the Private Placement Warrants. For periods subsequent to the detachment of the Warrants from the Units, the close price of the Public Warrant price will be used as the fair value as of each relevant date. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The key inputs into the binomial lattice simulation model for the Private Placement Warrants and Public Warrants were as follows at initial measurement: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:77%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;Input&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;November&amp;#160;23,&lt;br/&gt; 2020 (Initial&lt;br/&gt; Measurement)&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;December&amp;#160;3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;, &lt;br/&gt;2020&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.4&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.4&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Expected term (years)5&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;5&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;5&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;12.0&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;11.50&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;11.50&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Fair value of Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9.81&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;10.12&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On November&amp;#160;23, 2020, the Private Placement Warrants and Public Warrants were determined to be $.57 per warrant for aggregate values of $82,460 and $1,748,000, respectively (these values include the underwriters exercise of their overallotment option on December&amp;#160;1, 2020). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Subsequent Measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Warrants are measured at fair value on a recurring basis. The subsequent measurement of the Public Warrants as of December&amp;#160;31, 2020 is classified as Level&amp;#160;1 due to the use of an observable market quote in an active market. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&amp;#160;31, 2020, the aggregate values of the Private Placement Warrants and Public Warrants were $153,347 and $3,250,667&amp;#160;million, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the changes in the fair value of warrant liabilities: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:57%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&lt;br/&gt;Placement&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Public&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Warrant&lt;br/&gt;Liabilities&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on November&amp;#160;23, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;77,900&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,520,000&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,597,900&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;75,447&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,730,667&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,806,114&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of December&amp;#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;153,347&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3,250,667&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3,404,014&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;  &lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Due to the use of quoted prices in an active market (Level 1) to measure the fair value of the Public Warrants, subsequent to initial measurement, the Company had transfers out of Level&amp;#160;3 totaling $1,597,900 during the period from November&amp;#160;23, 2020 through December&amp;#160;31, 2020. &lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P08_21_2020To12_31_2020">The following table presents information about the Company&amp;#8217;s assets that are measured at fair value on a recurring basis at December&amp;#160;31, 2020, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:80%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.7pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.7pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.7pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.7pt;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31,&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.7pt;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;91,997,501&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrant Liability &amp;#8211; Public Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3,250,667&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Warrant Liability &amp;#8211; Private Placement Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;3&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;153,347&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
	<chfw:WarrantLiability contextRef="PAsOn12_31_2020" unitRef="iso4217_USD" decimals="0">3404014</chfw:WarrantLiability>
	<chfw:TransactionCostsAssociatedWithInitialPublicOffering contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">107519</chfw:TransactionCostsAssociatedWithInitialPublicOffering>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">1573554</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">1573554</us-gaap:FairValueAdjustmentOfWarrants>
	<chfw:TransactionCostsAssociatedWithInitialPublicOffering contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">107519</chfw:TransactionCostsAssociatedWithInitialPublicOffering>
	<chfw:InitialClassificationOfWarrantLiability contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">1830460</chfw:InitialClassificationOfWarrantLiability>
	<chfw:WarrantLiabilityPolicyTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Warrant Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&amp;#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 480, Distinguishing Liabilities from Equity (&amp;#8220;ASC 480&amp;#8221;) and ASC 815,&amp;#160;Derivatives and Hedging&amp;#160;(&amp;#8220;ASC 815&amp;#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&amp;#8217;s own ordinary shares and whether the warrant holders could potentially require &amp;#8220;net cash settlement&amp;#8221; in a circumstance outside of the Company&amp;#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; gain or loss on the statements of operations. The fair value of the warrants was estimated using a binomial lattice simulation methodology (see Note 9). &lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chfw:WarrantLiabilityPolicyTextBlock>
	<chfw:WarrantsTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 9. Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Warrants &amp;#8212;&lt;/div&gt;&lt;/div&gt; Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a)&amp;#160;30&amp;#160;days after the completion of a Business Combination and (b)&amp;#160;&lt;div style="display:inline;"&gt;one&lt;/div&gt; year from the closing of the Initial Public Offering. The Public Warrants will expire &lt;div style="display:inline;"&gt;five&lt;/div&gt;&amp;#160;years from the completion of a Business Combination or earlier upon redemption or liquidation. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will not be obligated to deliver any Class&amp;#160;A ordinary shares pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the issuance of the Class&amp;#160;A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating thereto is available, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption is available. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has agreed that as soon as practicable, but in no event later than 20 business days, after the closing of a Business Combination, it will use its commercially reasonable efforts to file with the SEC a registration statement covering the Class&amp;#160;A ordinary shares issuable upon exercise of the warrants, and the Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of a Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class&amp;#160;A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; if the Class&amp;#160;A ordinary shares are, at the time of any exercise of a warrant, not listed on a national securities exchange such that they satisfy the definition of a &amp;#8220;covered security&amp;#8221; under Section&amp;#160;18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a &amp;#8220;cashless basis&amp;#8221; in accordance with Section&amp;#160;3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement. If a registration statement covering the Class&amp;#160;A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &amp;#8220;cashless basis&amp;#8221; in accordance with Section&amp;#160;3(a)(9) of the Securities Act or another exemption, but will use its best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Redemption of Warrants When the Price per Class&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&amp;#160;A Ordinary Share Equals or Exceeds $18.00&lt;/div&gt;&lt;/div&gt;&amp;#160;&amp;#8212;&amp;#160;Once the warrants become exercisable, the Company may redeem the outstanding Public Warrants: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in whole and not in part; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at a price of $0.01 per Public Warrant; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;upon not less than 30&amp;#160;days&amp;#8217; prior written notice of redemption to each warrant holder; and &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;if, and only if, the closing price of the Class&amp;#160;A ordinary shares equals or exceeds $18.00 per share (as adjusted for share &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-divisions,&lt;/div&gt; share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-trading&lt;/div&gt; day period ending on the third trading day prior to the date on which notice of the redemption is given to the warrant holders (the &amp;#8220;Reference Value&amp;#8221;). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if the Company are unable to register or qualify the underlying securities for sale under all applicable state securities laws. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Redemption of Warrants When the Price per Class&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;&amp;#160;A Ordinary Share Equals or Exceeds $10.00&lt;/div&gt;&lt;/div&gt;&amp;#160;&amp;#8212;&amp;#160;Once the warrants become exercisable, the Company may redeem the outstanding warrants: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in whole and not in part; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at $0.10 per warrant upon a minimum of 30&amp;#160;days&amp;#8217; prior written notice of redemption; provided that during such 30 day period holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares, based on the redemption date and the fair market value of the Class&amp;#160;A ordinary shares, that if the warrants are not exercised on a cashless basis or otherwise during such 30 day period, the Company shall redeem such warrants for $0.10 per share; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 1px; margin-top: 6px; margin-bottom: 0px;"&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted for share subdivisions, share dividends, reorganizations, recapitalizations and the like) on the trading day before the Company sends the notice of redemption to the warrant holders; and &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:5%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:3%;"&gt;&amp;#8226;&lt;/td&gt;&lt;td style="vertical-align:top;;width:1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;if the Reference Value is less than $18.00 per share (as adjusted for share splits, share dividends, reorganizations, recapitalizations and the like), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The exercise price and number of ordinary shares issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company&amp;#8217;s assets held outside of the Trust Account with respect to such Public Warrants. Accordingly, the Public Warrants may expire worthless. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, if (x)&amp;#160;the Company issues additional Class&amp;#160;A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per Class&amp;#160;A ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&amp;#8217;s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the &amp;#8220;Newly Issued Price&amp;#8221;), (y)&amp;#160;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&amp;#160;the volume weighted average trading price of its Class&amp;#160;A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &amp;#8220;Market Value&amp;#8221;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $10.00 and $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 100% and 180% of the higher of the Market Value and the Newly Issued Price, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the Class&amp;#160;A ordinary shares issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30&amp;#160;days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable,&lt;/div&gt; except as described above, so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chfw:WarrantsTextBlock>
	<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The key inputs into the binomial lattice simulation model for the Private Placement Warrants and Public Warrants were as follows at initial measurement: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:77%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;Input&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;November&amp;#160;23,&lt;br/&gt; 2020 (Initial&lt;br/&gt; Measurement)&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;December&amp;#160;3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;, &lt;br/&gt;2020&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.4&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;0.4&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Expected term (years)5&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;5&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;5&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;12.0&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;16&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;11.50&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;11.50&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Fair value of Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9.81&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;10.12&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
	<us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the changes in the fair value of warrant liabilities: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:57%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&lt;br/&gt;Placement&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Public&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Warrant&lt;br/&gt;Liabilities&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on November&amp;#160;23, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;77,900&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,520,000&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;1,597,900&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;75,447&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,730,667&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,806,114&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of December&amp;#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;153,347&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3,250,667&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;3,404,014&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="PAsOn11_23_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" unitRef="xbrli_pure" decimals="1">0.4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="PAsOn12_31_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" unitRef="xbrli_pure" decimals="1">0.4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="PAsOn11_23_2020_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" unitRef="utr_Y" decimals="0">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="PAsOn12_31_2020_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" unitRef="utr_Y" decimals="0">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="PAsOn11_23_2020_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis" unitRef="xbrli_pure" decimals="1">12.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="PAsOn12_31_2020_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis" unitRef="xbrli_pure" decimals="0">16</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="PAsOn11_23_2020_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis" unitRef="xbrli_pure" decimals="2">11.50</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="PAsOn12_31_2020_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis" unitRef="xbrli_pure" decimals="2">11.50</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="PAsOn11_23_2020_MeasurementInputFairValueOfUnitsMemberusgaapMeasurementInputTypeAxis" unitRef="xbrli_pure" decimals="2">9.81</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="PAsOn12_31_2020_MeasurementInputFairValueOfUnitsMemberusgaapMeasurementInputTypeAxis" unitRef="xbrli_pure" decimals="2">10.12</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
	<us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="PAsOn11_22_2020_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">77900</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
	<us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="PAsOn11_22_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">1520000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
	<us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs contextRef="PAsOn11_22_2020_WarrantsLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" unitRef="iso4217_USD" decimals="0">1597900</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
	<us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss contextRef="P11_23_2020To12_31_2020_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">75447</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
	<us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss contextRef="P11_23_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">1730667</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
	<us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss contextRef="P11_23_2020To12_31_2020_WarrantsLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" unitRef="iso4217_USD" decimals="0">1806114</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
	<chfw:WarrantsPerShare contextRef="PAsOn11_23_2020_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD_xbrli_shares" decimals="0">57</chfw:WarrantsPerShare>
	<chfw:WarrantLiabilityFairValueDisclosure contextRef="PAsOn11_23_2020_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">82460</chfw:WarrantLiabilityFairValueDisclosure>
	<chfw:WarrantLiabilityFairValueDisclosure contextRef="PAsOn11_23_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">1748000</chfw:WarrantLiabilityFairValueDisclosure>
	<chfw:WarrantLiabilityFairValueDisclosure contextRef="PAsOn12_31_2020_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">153347</chfw:WarrantLiabilityFairValueDisclosure>
	<chfw:WarrantLiabilityFairValueDisclosure contextRef="PAsOn12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD" decimals="0">3250667</chfw:WarrantLiabilityFairValueDisclosure>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 contextRef="P11_23_2020To12_31_2020_WarrantsLiabilitiesMemberusgaapDerivativeInstrumentRiskAxis" unitRef="iso4217_USD" decimals="0">1597900</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
	<us-gaap:RepaymentsOfRelatedPartyDebt contextRef="P08_21_2020To12_31_2020" unitRef="iso4217_USD" decimals="0">147753</us-gaap:RepaymentsOfRelatedPartyDebt>
	<chfw:ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" unitRef="chfw_item" decimals="INF">3</chfw:ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders>
	<chfw:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00MembersrtStatementScenarioAxis" unitRef="chfw_item" decimals="INF">20</chfw:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays>
	<chfw:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00MembersrtStatementScenarioAxis" unitRef="chfw_item" decimals="INF">30</chfw:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays>
	<chfw:WarrantsPerShare contextRef="PAsOn11_23_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="iso4217_USD_xbrli_shares" decimals="0">57</chfw:WarrantsPerShare>
	<chfw:TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant contextRef="P08_21_2020To12_31_2020_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="utr_D" decimals="INF">20</chfw:TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant>
	<chfw:WarrantLiability contextRef="PAsOn11_23_2020_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">1598233</chfw:WarrantLiability>
	<chfw:WarrantLiability contextRef="PAsOn11_23_2020_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">1598233</chfw:WarrantLiability>
	<us-gaap:Liabilities contextRef="PAsOn11_23_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">3167722</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="PAsOn11_23_2020_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">1598233</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="PAsOn11_23_2020_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">4765955</us-gaap:Liabilities>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="PAsOn11_23_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">74121170</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="PAsOn11_23_2020_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">-1598233</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="PAsOn11_23_2020_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">72522937</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:CommonStockValue contextRef="PAsOn11_23_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">100</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="PAsOn11_23_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">18</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="PAsOn11_23_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">118</us-gaap:CommonStockValue>
	<us-gaap:AdditionalPaidInCapital contextRef="PAsOn11_23_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">5004636</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="PAsOn11_23_2020_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">107501</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="PAsOn11_23_2020_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">5112137</us-gaap:AdditionalPaidInCapital>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn11_23_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">-4961</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn11_23_2020_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">-107519</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn11_23_2020_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">-112480</us-gaap:RetainedEarningsAccumulatedDeficit>
	<chfw:WarrantLiability contextRef="PAsOn12_31_2020_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">3404014</chfw:WarrantLiability>
	<chfw:WarrantLiability contextRef="PAsOn12_31_2020_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">3404014</chfw:WarrantLiability>
	<us-gaap:Liabilities contextRef="PAsOn12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">3510148</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="PAsOn12_31_2020_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">3404014</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="PAsOn12_31_2020_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">6914162</us-gaap:Liabilities>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="PAsOn12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">85264880</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="PAsOn12_31_2020_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">-3404020</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="PAsOn12_31_2020_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">81860860</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:CommonStockValue contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">111</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">34</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">145</us-gaap:CommonStockValue>
	<us-gaap:AdditionalPaidInCapital contextRef="PAsOn12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">5440915</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="PAsOn12_31_2020_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">1681045</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="PAsOn12_31_2020_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">7121960</us-gaap:AdditionalPaidInCapital>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">-441255</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2020_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">-1681073</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2020_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">-2122328</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:StockholdersEquity contextRef="PAsOn12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">5000001</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="PAsOn12_31_2020_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">6</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="PAsOn12_31_2020_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">5000007</us-gaap:StockholdersEquity>
	<chfw:PercentageOfMinimumAcceptanceOfShareholdersOfTenderOfferProvision contextRef="P08_21_2020To12_31_2020" unitRef="xbrli_pure" decimals="2">0.50</chfw:PercentageOfMinimumAcceptanceOfShareholdersOfTenderOfferProvision>
	<chfw:RestatementOfPreviouslyIssuedFinancialStatementsTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 2&amp;#160;&amp;#8212;&amp;#160;RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company previously accounted for its outstanding Public Warrants (as defined in Note 4) and Private Placement Warrants issued in connection with its Initial Public Offering as components of equity instead of as derivative liabilities.&amp;#160;The warrant agreement governing the warrants includes a provision that provides for potential changes to the settlement amounts dependent upon the characteristics of the holder of the warrant. In addition, the warrant agreement includes a provision that in the event of a tender or exchange offer made to and accepted by holders of more than 50% of the outstanding shares of a single class of ordinary shares, all holders of the warrants would be entitled to receive cash for their warrants (the &amp;#8220;tender offer provision&amp;#8221;). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with the audit of the Company&amp;#8217;s financial statements for the period ended December&amp;#160;31, 2020, the Company&amp;#8217;s management further evaluated the warrants under Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40,&lt;/div&gt; Contracts in Entity&amp;#8217;s Own Equity. ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Section&amp;#160;815-40-15&lt;/div&gt;&lt;/div&gt; addresses equity versus liability treatment and classification of equity-linked financial instruments, including warrants, and states that a warrant may be classified as a component of equity only if, among other things, the warrant is indexed to the issuer&amp;#8217;s common stock. Under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Section&amp;#160;815-40-15,&lt;/div&gt;&lt;/div&gt; a warrant is not indexed to the issuer&amp;#8217;s common stock if the terms of the warrant require an adjustment to the exercise price upon a specified event and that event is not an input to the fair value of the warrant. Based on management&amp;#8217;s evaluation, the Company&amp;#8217;s audit committee, in consultation with management and after discussion with the Company&amp;#8217;s independent registered public accounting firm, concluded that the Company&amp;#8217;s Private Placement Warrants are not indexed to the Company&amp;#8217;s ordinary shares in the manner contemplated by ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Section&amp;#160;815-40-15&lt;/div&gt;&lt;/div&gt; because the holder of the instrument is not an input into the pricing of a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;fixed-for-fixed&lt;/div&gt;&lt;/div&gt; option on equity shares. In addition, based on management&amp;#8217;s evaluation, the Company&amp;#8217;s audit committee, in consultation with management and after discussion with the Company&amp;#8217;s independent registered public accounting firm, concluded the tender offer provision included in the warrant agreement fails the &amp;#8220;classified in shareholders&amp;#8217; equity&amp;#8221; criteria as contemplated by ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Section&amp;#160;815-40-25.&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As a result of the above, the Company should have classified the warrants as derivative liabilities in its previously issued financial statements. Under this accounting treatment, the Company is required to measure the fair value of the warrants at the end of each reporting period and recognize changes in the fair value from the prior period in the Company&amp;#8217;s operating results for the current period.&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s accounting for the warrants as components of equity instead of as derivative liabilities did not have any effect on the Company&amp;#8217;s previously reported operating expenses, cash or investments held in the trust account. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width: 63%;"&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Previously&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance sheet as of November&amp;#160;23, 2020 (audited)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrant Liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;1,598,233&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;1,598,233&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;3,167,722&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;1,598,233&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;4,765,955&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary Shares Subject to Possible Redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;74,121,170&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(1,598,233&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;72,522,937&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Class&amp;#160;A Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;100&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;18&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;118&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;Additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Paid-in&lt;/div&gt; Capital&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;5,004,636&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;107,501&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;5,112,137&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Accumulated Deficit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(4,961&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(107,519&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(112,480&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance sheet as of December&amp;#160;31, 2020 (audited)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Warrant Liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;3,404,014&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;3,404,014&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;3,510,148&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;3,404,014&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;6,914,162&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Ordinary Shares Subject to Possible Redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;85,264,880&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(3,404,020&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;81,860,860&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&amp;#160;A Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;111&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;34&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;145&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;Additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Paid-in&lt;/div&gt; Capital&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;5,440,915&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;1,681,045&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;7,121,960&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated Deficit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(441,255&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(1,681,073&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(2,122,328&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Shareholders&amp;#8217; Equity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;5,000,001&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;6&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;5,000,007&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Period from August&amp;#160;20, 2020 (inception) to December&amp;#160;31, 2020 (audited)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value of warrant liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;1,573,554&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;1,573,554&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Allocation of initial public offering costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;107,519&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;107,519&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(441,255&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(1,681,073&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(2,122,328&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Weighted average shares outstanding of Class&amp;#160;A redeemable ordinary shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;8,326,328&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(144,993&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;8,181,335&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;Weighted average shares outstanding of Class&amp;#160;B &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;2,414,403&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;46,692&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;2,461,095&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Basic and diluted net loss per share, Class&amp;#160;B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(0.18&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(0.68&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(0.86&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash Flow Statement for the Period from August&amp;#160;20, 2020 (inception) to December&amp;#160;31, 2020 (audited)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(441,255&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(1,681,073&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(2,122,328&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of initial public offering costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;107,519&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;107,519&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Change in fair value of warrant liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;1,573,554&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;1,573,554&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial classification of warrant liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;1,830,460&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;1,830,460&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Initial classification of common stock subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;74,121,170&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(1,598,233&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;72,522,937&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in value of common stock subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(436,290&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(1,993,560&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(2,429,850&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;"&gt;&amp;#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</chfw:RestatementOfPreviouslyIssuedFinancialStatementsTextBlock>
	<us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="P08_21_2020To12_31_2020">&lt;div style="text-indent: 4%; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s accounting for the warrants as components of equity instead of as derivative liabilities did not have any effect on the Company&amp;#8217;s previously reported operating expenses, cash or investments held in the trust account. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width: 63%;"&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Previously&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance sheet as of November&amp;#160;23, 2020 (audited)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrant Liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;1,598,233&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;1,598,233&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;3,167,722&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;1,598,233&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;4,765,955&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary Shares Subject to Possible Redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;74,121,170&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(1,598,233&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;72,522,937&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Class&amp;#160;A Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;100&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;18&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;118&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;Additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Paid-in&lt;/div&gt; Capital&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;5,004,636&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;107,501&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;5,112,137&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Accumulated Deficit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(4,961&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(107,519&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(112,480&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance sheet as of December&amp;#160;31, 2020 (audited)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Warrant Liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;3,404,014&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;3,404,014&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;3,510,148&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;3,404,014&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;6,914,162&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Ordinary Shares Subject to Possible Redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;85,264,880&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(3,404,020&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;81,860,860&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&amp;#160;A Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;111&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;34&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;145&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;Additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Paid-in&lt;/div&gt; Capital&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;5,440,915&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;1,681,045&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;7,121,960&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated Deficit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(441,255&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(1,681,073&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(2,122,328&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Shareholders&amp;#8217; Equity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;5,000,001&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;6&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;5,000,007&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Period from August&amp;#160;20, 2020 (inception) to December&amp;#160;31, 2020 (audited)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value of warrant liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;1,573,554&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;1,573,554&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Allocation of initial public offering costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;107,519&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;107,519&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(441,255&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(1,681,073&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(2,122,328&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Weighted average shares outstanding of Class&amp;#160;A redeemable ordinary shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;8,326,328&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(144,993&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;8,181,335&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;Weighted average shares outstanding of Class&amp;#160;B &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable&lt;/div&gt; ordinary shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;2,414,403&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;46,692&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;2,461,095&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Basic and diluted net loss per share, Class&amp;#160;B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(0.18&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(0.68&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(0.86&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash Flow Statement for the Period from August&amp;#160;20, 2020 (inception) to December&amp;#160;31, 2020 (audited)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(441,255&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(1,681,073&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(2,122,328&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of initial public offering costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;107,519&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;107,519&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Change in fair value of warrant liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;1,573,554&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;1,573,554&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial classification of warrant liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;1,830,460&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;1,830,460&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Initial classification of common stock subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;74,121,170&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;(1,598,233&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;72,522,937&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;div style="background-color: rgb(204, 238, 255);;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="font-size: 10pt; width: 63%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in value of common stock subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 6%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(436,290&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(1,993,560&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 5%;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;(2,429,850&lt;/div&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="display:inline;"&gt;)&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;"&gt;&amp;#160;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="P08_20_2020To12_31_2020_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">1573554</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="P08_20_2020To12_31_2020_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">1573554</us-gaap:FairValueAdjustmentOfWarrants>
	<chfw:AllocationOfInitialPublicOfferingCosts contextRef="P08_20_2020To12_31_2020_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">107519</chfw:AllocationOfInitialPublicOfferingCosts>
	<chfw:AllocationOfInitialPublicOfferingCosts contextRef="P08_20_2020To12_31_2020_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">107519</chfw:AllocationOfInitialPublicOfferingCosts>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P08_20_2020To12_31_2020_ClassOrdinarySharesSubjectForRedemptionMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="xbrli_shares" decimals="0">8326328</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P08_20_2020To12_31_2020_ClassOrdinarySharesSubjectForRedemptionMemberusgaapStatementClassOfStockAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="xbrli_shares" decimals="0">-144993</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P08_20_2020To12_31_2020_ClassOrdinarySharesSubjectForRedemptionMemberusgaapStatementClassOfStockAxis_RestatedMembersrtRestatementAxis" unitRef="xbrli_shares" decimals="0">8181335</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P08_20_2020To12_31_2020_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="xbrli_shares" decimals="0">2414403</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P08_20_2020To12_31_2020_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="xbrli_shares" decimals="0">46692</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P08_20_2020To12_31_2020_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis_RestatedMembersrtRestatementAxis" unitRef="xbrli_shares" decimals="0">2461095</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="P08_20_2020To12_31_2020_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="P08_20_2020To12_31_2020_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">-0.68</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="P08_20_2020To12_31_2020_NonredeemablePreferredStockMemberusgaapStatementClassOfStockAxis_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD_xbrli_shares" decimals="2">-0.86</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:NetIncomeLoss contextRef="P08_20_2020To12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">-441255</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="P08_20_2020To12_31_2020_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">-1681073</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="P08_20_2020To12_31_2020_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">-2122328</us-gaap:NetIncomeLoss>
	<chfw:InitialClassificationOfWarrantLiability contextRef="P08_20_2020To12_31_2020_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">1830460</chfw:InitialClassificationOfWarrantLiability>
	<chfw:InitialClassificationOfWarrantLiability contextRef="P08_20_2020To12_31_2020_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">1830460</chfw:InitialClassificationOfWarrantLiability>
	<chfw:InitialClassificationOfCommonStockSubjectToPossibleRedemption contextRef="P08_20_2020To12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">74121170</chfw:InitialClassificationOfCommonStockSubjectToPossibleRedemption>
	<chfw:InitialClassificationOfCommonStockSubjectToPossibleRedemption contextRef="P08_20_2020To12_31_2020_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">-1598233</chfw:InitialClassificationOfCommonStockSubjectToPossibleRedemption>
	<chfw:InitialClassificationOfCommonStockSubjectToPossibleRedemption contextRef="P08_20_2020To12_31_2020_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">72522937</chfw:InitialClassificationOfCommonStockSubjectToPossibleRedemption>
	<chfw:ChangeInValueOfCommonStockSubjectToPossibleRedemption contextRef="P08_20_2020To12_31_2020_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">-436290</chfw:ChangeInValueOfCommonStockSubjectToPossibleRedemption>
	<chfw:ChangeInValueOfCommonStockSubjectToPossibleRedemption contextRef="P08_20_2020To12_31_2020_RestatementAdjustmentMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">-1993560</chfw:ChangeInValueOfCommonStockSubjectToPossibleRedemption>
	<chfw:ChangeInValueOfCommonStockSubjectToPossibleRedemption contextRef="P08_20_2020To12_31_2020_RestatedMembersrtRestatementAxis" unitRef="iso4217_USD" decimals="0">-2429850</chfw:ChangeInValueOfCommonStockSubjectToPossibleRedemption>







<xbrli:unit id="utr_Y">
		<xbrli:measure>utr:Y</xbrli:measure>
	</xbrli:unit>
</xbrli:xbrl>



</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>24
<FILENAME>chfw-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 67.4 -->
<!-- Creation date: 6/23/2021 12:10:17 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://Consonance.com/20210331" elementFormDefault="qualified" xmlns:chfw="http://Consonance.com/20210331" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2020-01-31">
<xsd:annotation>
<xsd:appinfo>
<link:roleType roleURI="http://Consonance.com/role/BalanceSheets" id="CondensedBalanceSheets">
<link:definition>001002 - Statement - BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/BalanceSheetsParenthetical" id="CondensedBalanceSheetsParenthetical">
<link:definition>001003 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/DescriptionOfOrganizationAndBusinessOperations" id="DescriptionOfOrganizationAndBusinessOperations">
<link:definition>100007 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>100008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/InitialPublicOffering" id="InitialPublicOffering">
<link:definition>100009 - Disclosure - INITIAL PUBLIC OFFERING</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/PrivatePlacement" id="PrivatePlacement">
<link:definition>100010 - Disclosure - PRIVATE PLACEMENT</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>100011 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/Commitments" id="Commitments">
<link:definition>100012 - Disclosure - COMMITMENTS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>100013 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/WarrantLiability" id="WarrantLiability">
<link:definition>100014 - Disclosure - WARRANT LIABILITY</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>100015 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>100016 - Disclosure - SUBSEQUENT EVENTS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>20000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>300018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails" id="DescriptionOfOrganizationAndBusinessOperationsDetails">
<link:definition>400000 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatementsAdditionalInformationDetails" id="RestatementOfPreviouslyIssuedFinancialStatementsAdditionalInformationDetails">
<link:definition>400001 - Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatementsSummaryOfRestatementOfPreviouslyIssuedFinancialStatementsDetails" id="RestatementOfPreviouslyIssuedFinancialStatementsSummaryOfRestatementOfPreviouslyIssuedFinancialStatementsDetails">
<link:definition>400002 - Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Summary of restatement of previously issued financial statements (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
<link:definition>400003 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails" id="SummaryOfSignificantAccountingPoliciesBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails">
<link:definition>400004 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basic and diluted net income (loss) per ordinary share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/InitialPublicOfferingDetails" id="InitialPublicOfferingDetails">
<link:definition>400013 - Disclosure - INITIAL PUBLIC OFFERING (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/PrivatePlacementDetails" id="PrivatePlacementDetails">
<link:definition>400014 - Disclosure - PRIVATE PLACEMENT (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/RelatedPartyTransactionsFounderSharesDetails" id="RelatedPartyTransactionsFounderSharesDetails">
<link:definition>400015 - Disclosure - RELATED PARTY TRANSACTIONS - Founder Shares (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails" id="RelatedPartyTransactionsAdditionalInformationDetails">
<link:definition>400016 - Disclosure - RELATED PARTY TRANSACTIONS - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/CommitmentsDetails" id="CommitmentsDetails">
<link:definition>400017 - Disclosure - COMMITMENTS (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/StockholdersEquityPreferredStockSharesDetails" id="StockholdersEquityPreferredStockSharesDetails">
<link:definition>400018 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock Shares (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/StockholdersEquityCommonStockSharesDetails" id="StockholdersEquityCommonStockSharesDetails">
<link:definition>400019 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock Shares (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/WarrantsDetails" id="WarrantsDetails">
<link:definition>400020 - Disclosure - WARRANTS (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/WarrantLiabilityDetails" id="WarrantLiabilityDetails">
<link:definition>400030 - Disclosure - WARRANT LIABILITY (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="chfw-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="chfw-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="chfw-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="chfw-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:roleType roleURI="http://Consonance.com/role/CoverPage" id="CoverPage">
<link:definition>000001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/StatementOfOperations" id="StatementOfOperations">
<link:definition>001004 - Statement - STATEMENT OF OPERATIONS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/StatementOfChangesInStockholdersEquity" id="StatementOfChangesInStockholdersEquity">
<link:definition>001005 - Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/StatementOfChangesInStockholdersEquityParenthetical" id="StatementOfChangesInStockholdersEquityParenthetical">
<link:definition>001006 - Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/StatementOfCashFlows" id="StatementOfCashFlows">
<link:definition>001007 - Statement - STATEMENT OF CASH FLOWS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatements" id="RestatementOfPreviouslyIssuedFinancialStatements">
<link:definition>102009 - Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables" id="RestatementOfPreviouslyIssuedFinancialStatementsTables">
<link:definition>302020 - Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>302022 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
<link:definition>402036 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/FairValueMeasurementsSummaryOfKeyInputsIntoTheBinomialLatticeSimulationModelForThePrivatePlacementWarrantsAndPublicWarrantsDetails" id="FairValueMeasurementsSummaryOfKeyInputsIntoTheBinomialLatticeSimulationModelForThePrivatePlacementWarrantsAndPublicWarrantsDetails">
<link:definition>402037 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of key Inputs into the Binomial Lattice Simulation Model for the Private Placement Warrants and Public Warrants (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/FairValueMeasurementsSummaryOfFairValueOfTheWarrantLiabilitiesDetails" id="FairValueMeasurementsSummaryOfFairValueOfTheWarrantLiabilitiesDetails">
<link:definition>402038 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of fair value of the  warrant liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/FairValueMeasurementsAdditionalInformationDetails" id="FairValueMeasurementsAdditionalInformationDetails">
<link:definition>402039 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
<link:definition>402040 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<xsd:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
<xsd:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
<xsd:import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
<xsd:import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
<xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<xsd:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
<xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<xsd:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
<xsd:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
<xsd:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
<xsd:element name="AccruedLiabilitiesExcludingOfferingCostsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<xsd:element name="ClassOrdinarySharesSubjectForRedemptionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_ClassOrdinarySharesSubjectForRedemptionMember" substitutionGroup="xbrli:item" />
<xsd:element name="TransactionCostsAssociatedWithInitialPublicOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_TransactionCostsAssociatedWithInitialPublicOffering" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<xsd:element name="SaleOfPrivatePlacementUnitsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_SaleOfPrivatePlacementUnitsValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<xsd:element name="SaleOfPrivatePlacementUnitsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_SaleOfPrivatePlacementUnitsShares" substitutionGroup="xbrli:item" />
<xsd:element name="CommonStockSubjectToPossibleRedemptionValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_CommonStockSubjectToPossibleRedemptionValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<xsd:element name="CommonStockSubjectToPossibleRedemptionShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_CommonStockSubjectToPossibleRedemptionShares" substitutionGroup="xbrli:item" />
<xsd:element name="FormationCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_FormationCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<xsd:element name="CashDepositedInTrustAccount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_CashDepositedInTrustAccount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<xsd:element name="InitialClassificationOfCommonStockSubjectToPossibleRedemption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<xsd:element name="OfferingCostsPaidBySponsorFromProceedsFromIssuanceOfCommonStockOrdinaryShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_OfferingCostsPaidBySponsorFromProceedsFromIssuanceOfCommonStockOrdinaryShares" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<xsd:element name="DeferredUnderwritingFeePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_DeferredUnderwritingFeePayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<xsd:element name="InitialClassificationOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_InitialClassificationOfWarrantLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<xsd:element name="NetProceedsFromInitialPublicOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_NetProceedsFromInitialPublicOffering" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<xsd:element name="RestatementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_RestatementAbstract" substitutionGroup="xbrli:item" />
<xsd:element name="RestatementOfPreviouslyIssuedFinancialStatementsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock" substitutionGroup="xbrli:item" />
<xsd:element name="PercentageOfMinimumAcceptanceOfShareholdersOfTenderOfferProvision" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_PercentageOfMinimumAcceptanceOfShareholdersOfTenderOfferProvision" substitutionGroup="xbrli:item" />
<xsd:element name="RestatementTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_RestatementTable" substitutionGroup="xbrldt:hypercubeItem" />
<xsd:element name="RestatedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_RestatedMember" substitutionGroup="xbrli:item" />
<xsd:element name="RestatementLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_RestatementLineItems" substitutionGroup="xbrli:item" />
<xsd:element name="PriorPeriodRestatementOfBalanceSheetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_PriorPeriodRestatementOfBalanceSheetAbstract" substitutionGroup="xbrli:item" />
<xsd:element name="PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract" substitutionGroup="xbrli:item" />
<xsd:element name="AllocationOfInitialPublicOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_AllocationOfInitialPublicOfferingCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<xsd:element name="PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract" substitutionGroup="xbrli:item" />
<xsd:element name="MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="chfw_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<xsd:element name="PromissoryNoteWithRelatedPartyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_PromissoryNoteWithRelatedPartyMember" substitutionGroup="xbrli:item" />
<xsd:element name="MeasurementInputFairValueOfUnitsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_MeasurementInputFairValueOfUnitsMember" substitutionGroup="xbrli:item" />
<xsd:element name="WarrantLiabilityFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="chfw_WarrantLiabilityFairValueDisclosure" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<xsd:element name="WarrantsPerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="chfw_WarrantsPerShare" substitutionGroup="xbrli:item" />
<xsd:element name="UnitsEachConsistingOfOneShareOfClassOrdinarySharesAndOneThirdOfRedeemableWarrantToAcquireOneClassOrdinaryShareMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_UnitsEachConsistingOfOneShareOfClassOrdinarySharesAndOneThirdOfRedeemableWarrantToAcquireOneClassOrdinaryShareMember" substitutionGroup="xbrli:item" />
<xsd:element name="WarrantsEachWholeWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf1150Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_WarrantsEachWholeWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf1150Member" substitutionGroup="xbrli:item" />
<xsd:element name="DeferredOfferingCostsNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="chfw_DeferredOfferingCostsNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<xsd:element name="WarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="chfw_WarrantLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<xsd:element name="ClassAOrdinarySharesSubjectForRedemptionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_ClassAOrdinarySharesSubjectForRedemptionMember" substitutionGroup="xbrli:item" />
<xsd:element name="StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<xsd:element name="StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption" substitutionGroup="xbrli:item" />
<xsd:element name="ChangeInValueOfCommonStockSubjectToPossibleRedemption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<xsd:element name="InitialPublicOfferingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_InitialPublicOfferingAbstract" substitutionGroup="xbrli:item" />
<xsd:element name="InitialPublicOfferingTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_InitialPublicOfferingTextBlock" substitutionGroup="xbrli:item" />
<xsd:element name="PrivatePlacementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_PrivatePlacementAbstract" substitutionGroup="xbrli:item" />
<xsd:element name="PrivatePlacementTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_PrivatePlacementTextBlock" substitutionGroup="xbrli:item" />
<xsd:element name="WarrantsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_WarrantsTextBlock" substitutionGroup="xbrli:item" />
<xsd:element name="WarrantLiabilityPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_WarrantLiabilityPolicyTextBlock" substitutionGroup="xbrli:item" />
<xsd:element name="AssetsHeldInTrustAccountPolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_AssetsHeldInTrustAccountPolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<xsd:element name="TemporaryEquityPolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_TemporaryEquityPolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
<xsd:element name="EmergingGrowthCompanyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_EmergingGrowthCompanyPolicyTextBlock" substitutionGroup="xbrli:item" />
<xsd:element name="ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount" substitutionGroup="xbrli:item" />
<xsd:element name="TransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="chfw_TransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<xsd:element name="SaleOfStockOtherOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="chfw_SaleOfStockOtherOfferingCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<xsd:element name="SaleOfStockUnderwritingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="chfw_SaleOfStockUnderwritingFees" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<xsd:element name="AdditionsToAssetsHeldInTrust" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_AdditionsToAssetsHeldInTrust" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<xsd:element name="UnitsIssuedDuringPeriodValueNewIssues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_UnitsIssuedDuringPeriodValueNewIssues" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<xsd:element name="UnitsIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_UnitsIssuedDuringPeriodSharesNewIssues" substitutionGroup="xbrli:item" />
<xsd:element name="ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" substitutionGroup="xbrli:item" />
<xsd:element name="ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination" substitutionGroup="xbrli:item" />
<xsd:element name="InitialPublicOfferingAndPrivatePlacementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_InitialPublicOfferingAndPrivatePlacementMember" substitutionGroup="xbrli:item" />
<xsd:element name="PublicWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_PublicWarrantsMember" substitutionGroup="xbrli:item" />
<xsd:element name="NumberOfSharesIssuedPerUnit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_NumberOfSharesIssuedPerUnit" substitutionGroup="xbrli:item" />
<xsd:element name="NumberOfWarrantsIssuedPerUnit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_NumberOfWarrantsIssuedPerUnit" substitutionGroup="xbrli:item" />
<xsd:element name="PrivatePlacementWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_PrivatePlacementWarrantsMember" substitutionGroup="xbrli:item" />
<xsd:element name="SponsorMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_SponsorMember" substitutionGroup="xbrli:item" />
<xsd:element name="FounderSharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_FounderSharesMember" substitutionGroup="xbrli:item" />
<xsd:element name="NumberOfSharesSubjectToForfeiture" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="chfw_NumberOfSharesSubjectToForfeiture" substitutionGroup="xbrli:item" />
<xsd:element name="PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" substitutionGroup="xbrli:item" />
<xsd:element name="TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" substitutionGroup="xbrli:item" />
<xsd:element name="TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" substitutionGroup="xbrli:item" />
<xsd:element name="TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" substitutionGroup="xbrli:item" />
<xsd:element name="ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" substitutionGroup="xbrli:item" />
<xsd:element name="AdministrativeSupportAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_AdministrativeSupportAgreementMember" substitutionGroup="xbrli:item" />
<xsd:element name="RelatedPartyLoansMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_RelatedPartyLoansMember" substitutionGroup="xbrli:item" />
<xsd:element name="WorkingCapitalLoansWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_WorkingCapitalLoansWarrantMember" substitutionGroup="xbrli:item" />
<xsd:element name="RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<xsd:element name="MaximumLoansConvertibleIntoWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="chfw_MaximumLoansConvertibleIntoWarrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<xsd:element name="ClassOfWarrantOrRightPriceOfWarrantsOrRights" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="chfw_ClassOfWarrantOrRightPriceOfWarrantsOrRights" substitutionGroup="xbrli:item" />
<xsd:element name="DeferredFeePerUnit" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="chfw_DeferredFeePerUnit" substitutionGroup="xbrli:item" />
<xsd:element name="CommonStockNumberOfVotesPerShare" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="chfw_CommonStockNumberOfVotesPerShare" substitutionGroup="xbrli:item" />
<xsd:element name="RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" substitutionGroup="xbrli:item" />
<xsd:element name="RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" substitutionGroup="xbrli:item" />
<xsd:element name="ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" substitutionGroup="xbrli:item" />
<xsd:element name="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" substitutionGroup="xbrli:item" />
<xsd:element name="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" substitutionGroup="xbrli:item" />
<xsd:element name="ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" substitutionGroup="xbrli:item" />
<xsd:element name="RedemptionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_RedemptionPeriod" substitutionGroup="xbrli:item" />
<xsd:element name="SharePricetriggerUsedToMeasureDilutionOfWarrant" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant" substitutionGroup="xbrli:item" />
<xsd:element name="PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" substitutionGroup="xbrli:item" />
<xsd:element name="TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" substitutionGroup="xbrli:item" />
<xsd:element name="WarrantExercisePriceAdjustmentMultiple" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_WarrantExercisePriceAdjustmentMultiple" substitutionGroup="xbrli:item" />
<xsd:element name="WarrantRedemptionPriceAdjustmentMultiple" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_WarrantRedemptionPriceAdjustmentMultiple" substitutionGroup="xbrli:item" />
<xsd:element name="RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" substitutionGroup="xbrli:item" />
<xsd:element name="WarrantExercisePeriodConditionOne" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_WarrantExercisePeriodConditionOne" substitutionGroup="xbrli:item" />
<xsd:element name="WarrantRedemptionConditionMinimumSharePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_WarrantRedemptionConditionMinimumSharePrice" substitutionGroup="xbrli:item" />
<xsd:element name="WarrantRedemptionConditionMinimumSharePriceScenarioTwo" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo" substitutionGroup="xbrli:item" />
<xsd:element name="WarrantExercisePeriodConditionTwo" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_WarrantExercisePeriodConditionTwo" substitutionGroup="xbrli:item" />
<xsd:element name="MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" substitutionGroup="xbrli:item" />
<xsd:element name="PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" substitutionGroup="xbrli:item" />
<xsd:element name="WarrantsLiabilitiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_WarrantsLiabilitiesMember" substitutionGroup="xbrli:item" />
<xsd:element name="BusinessCombinationAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_BusinessCombinationAgreementMember" substitutionGroup="xbrli:item" />
<xsd:element name="SubscriptionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_SubscriptionAgreementMember" substitutionGroup="xbrli:item" />
<xsd:element name="InvestorAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_InvestorAxis" substitutionGroup="xbrldt:dimensionItem" />
<xsd:element name="InvestorDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_InvestorDomain" substitutionGroup="xbrli:item" />
<xsd:element name="PipeInvestorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_PipeInvestorsMember" substitutionGroup="xbrli:item" />
<xsd:element name="PipeWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="chfw_PipeWarrantsMember" substitutionGroup="xbrli:item" />
</xsd:schema>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>25
<FILENAME>chfw-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 67.4 -->
<!-- Creation date: 6/23/2021 12:10:17 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#CondensedBalanceSheets" roleURI="http://Consonance.com/role/BalanceSheets" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#DescriptionOfOrganizationAndBusinessOperationsDetails" roleURI="http://Consonance.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#SummaryOfSignificantAccountingPoliciesBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails" />
<link:calculationLink xlink:type="extended" xlink:role="http://Consonance.com/role/BalanceSheets">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="3" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent" use="optional" order="4" weight="1" />
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://Consonance.com/role/BalanceSheets">
    <link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent" xlink:label="chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent" order="15.01" weight="1" priority="2" use="optional"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="5" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="6" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="7" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="8" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="9" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="10" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="11" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="12" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="13" weight="1" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantLiability" xlink:label="loc_CHFW_WarrantLiability" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_CHFW_WarrantLiability" use="optional" order="14" weight="1" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_DeferredOfferingCostsNoncurrent" xlink:label="loc_CHFW_DeferredOfferingCostsNoncurrent" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_CHFW_DeferredOfferingCostsNoncurrent" use="optional" order="15" weight="1" />
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://Consonance.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails">
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_TransactionCosts" xlink:label="loc_CHFW_TransactionCosts" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_SaleOfStockUnderwritingFees" xlink:label="loc_CHFW_SaleOfStockUnderwritingFees" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CHFW_TransactionCosts" xlink:to="loc_CHFW_SaleOfStockUnderwritingFees" use="optional" order="1" weight="1" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_DeferredOfferingCostsNoncurrent" xlink:label="loc_CHFW_DeferredOfferingCostsNoncurrent" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CHFW_TransactionCosts" xlink:to="loc_CHFW_DeferredOfferingCostsNoncurrent" use="optional" order="2" weight="1" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_SaleOfStockOtherOfferingCosts" xlink:label="loc_CHFW_SaleOfStockOtherOfferingCosts" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CHFW_TransactionCosts" xlink:to="loc_CHFW_SaleOfStockOtherOfferingCosts" use="optional" order="3" weight="1" />
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="1" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="2" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments" use="optional" order="3" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" use="optional" order="4" weight="-1" />
</link:calculationLink>
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#StatementOfOperations" roleURI="http://Consonance.com/role/StatementOfOperations" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#StatementOfCashFlows" roleURI="http://Consonance.com/role/StatementOfCashFlows" />
<link:calculationLink xlink:type="extended" xlink:role="http://Consonance.com/role/StatementOfOperations">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="1" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingCostsAndExpenses" use="optional" order="2" weight="-1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="3" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="4" weight="1" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_TransactionCostsAssociatedWithInitialPublicOffering" xlink:label="loc_CHFW_TransactionCostsAssociatedWithInitialPublicOffering" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_CHFW_TransactionCostsAssociatedWithInitialPublicOffering" use="optional" order="5" weight="-1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="6" weight="-1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments" use="optional" order="7" weight="1" />
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://Consonance.com/role/StatementOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="17.01" weight="-1" priority="2" use="optional"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_CashDepositedInTrustAccount" xlink:label="loc_chfw_CashDepositedInTrustAccount" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_chfw_CashDepositedInTrustAccount" use="optional" order="2" weight="-1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="3" weight="1" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_NetProceedsFromInitialPublicOffering" xlink:label="loc_chfw_NetProceedsFromInitialPublicOffering" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_chfw_NetProceedsFromInitialPublicOffering" use="optional" order="4" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants" use="optional" order="5" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt" use="optional" order="6" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt" use="optional" order="7" weight="-1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="8" weight="-1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="9" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="10" weight="1" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_FormationCosts" xlink:label="loc_chfw_FormationCosts" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_chfw_FormationCosts" use="optional" order="11" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="12" weight="-1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments" use="optional" order="13" weight="-1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" use="optional" order="14" weight="-1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" use="optional" order="15" weight="1" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_TransactionCostsAssociatedWithInitialPublicOffering" xlink:label="loc_CHFW_TransactionCostsAssociatedWithInitialPublicOffering" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CHFW_TransactionCostsAssociatedWithInitialPublicOffering" use="optional" order="16" weight="1" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="17" weight="1" />
</link:calculationLink>
</link:linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>26
<FILENAME>chfw-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 67.4 -->
<!-- Creation date: 6/23/2021 12:10:17 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#CoverPage" roleURI="http://Consonance.com/role/CoverPage" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#CondensedBalanceSheets" roleURI="http://Consonance.com/role/BalanceSheets" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#CondensedBalanceSheetsParenthetical" roleURI="http://Consonance.com/role/BalanceSheetsParenthetical" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#DescriptionOfOrganizationAndBusinessOperations" roleURI="http://Consonance.com/role/DescriptionOfOrganizationAndBusinessOperations" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPolicies" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#InitialPublicOffering" roleURI="http://Consonance.com/role/InitialPublicOffering" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#PrivatePlacement" roleURI="http://Consonance.com/role/PrivatePlacement" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#RelatedPartyTransactions" roleURI="http://Consonance.com/role/RelatedPartyTransactions" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#Commitments" roleURI="http://Consonance.com/role/Commitments" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#StockholdersEquity" roleURI="http://Consonance.com/role/StockholdersEquity" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#WarrantLiability" roleURI="http://Consonance.com/role/WarrantLiability" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#FairValueMeasurements" roleURI="http://Consonance.com/role/FairValueMeasurements" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#SubsequentEvents" roleURI="http://Consonance.com/role/SubsequentEvents" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#DescriptionOfOrganizationAndBusinessOperationsDetails" roleURI="http://Consonance.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#SummaryOfSignificantAccountingPoliciesBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#InitialPublicOfferingDetails" roleURI="http://Consonance.com/role/InitialPublicOfferingDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#PrivatePlacementDetails" roleURI="http://Consonance.com/role/PrivatePlacementDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#RelatedPartyTransactionsFounderSharesDetails" roleURI="http://Consonance.com/role/RelatedPartyTransactionsFounderSharesDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#CommitmentsDetails" roleURI="http://Consonance.com/role/CommitmentsDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#StockholdersEquityPreferredStockSharesDetails" roleURI="http://Consonance.com/role/StockholdersEquityPreferredStockSharesDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#StockholdersEquityCommonStockSharesDetails" roleURI="http://Consonance.com/role/StockholdersEquityCommonStockSharesDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#WarrantLiabilityDetails" roleURI="http://Consonance.com/role/WarrantLiabilityDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#FairValueMeasurementsDetails" roleURI="http://Consonance.com/role/FairValueMeasurementsDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#FairValueMeasurementsSummaryOfFairValueOfTheWarrantLiabilitiesDetails" roleURI="http://Consonance.com/role/FairValueMeasurementsSummaryOfFairValueOfTheWarrantLiabilitiesDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#SubsequentEventsDetails" roleURI="http://Consonance.com/role/SubsequentEventsDetails" />
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/CoverPage">
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_939141" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_939142" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_939143" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_939143_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_939149" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_939151" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_UnitsEachConsistingOfOneShareOfClassOrdinarySharesAndOneThirdOfRedeemableWarrantToAcquireOneClassOrdinaryShareMember" xlink:label="loc_chfw_UnitsEachConsistingOfOneShareOfClassOrdinarySharesAndOneThirdOfRedeemableWarrantToAcquireOneClassOrdinaryShareMember_939164" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantsEachWholeWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf1150Member" xlink:label="loc_chfw_WarrantsEachWholeWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf1150Member_939172" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_939144" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_939177" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_939178" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_939179" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_939179" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_939182" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_939186" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_939187" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_939188" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_939189" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_939191" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_939192" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_939194" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_939195" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_939209" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_939211" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_939212" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_939215" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_939234" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_939258" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_939197" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_939203" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_941954" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_968680" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_939141" xlink:to="loc_us-gaap_StatementClassOfStockAxis_939142" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_939142" xlink:to="loc_us-gaap_ClassOfStockDomain_939143" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_939142" xlink:to="loc_us-gaap_ClassOfStockDomain_939143_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_939143" xlink:to="loc_us-gaap_CommonClassAMember_939149" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_939143" xlink:to="loc_us-gaap_CommonClassBMember_939151" order="5" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_939143" xlink:to="loc_chfw_UnitsEachConsistingOfOneShareOfClassOrdinarySharesAndOneThirdOfRedeemableWarrantToAcquireOneClassOrdinaryShareMember_939164" order="6" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_939143" xlink:to="loc_chfw_WarrantsEachWholeWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf1150Member_939172" order="7" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_DocumentInformationTable_939141" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_DocumentType_939177" order="9" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_DocumentPeriodEndDate_939178" order="10" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_AmendmentDescription_939179" order="11.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityRegistrantName_939179" order="11" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityCurrentReportingStatus_939182" order="12" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityInteractiveDataCurrent_939186" order="13" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityFilerCategory_939187" order="14" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntitySmallBusiness_939188" order="15" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityEmergingGrowthCompany_939189" order="16" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityExTransitionPeriod_939191" order="17" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityShellCompany_939192" order="18" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityCentralIndexKey_939194" order="19" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_CurrentFiscalYearEndDate_939195" order="20" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_Security12bTitle_939209" order="21" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_TradingSymbol_939211" order="22" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_SecurityExchangeName_939212" order="23" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_939215" order="24" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_DocumentFiscalYearFocus_939234" order="25" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_DocumentFiscalPeriodFocus_939258" order="26" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_AmendmentFlag_939197" order="27" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_DocumentTransitionReport_939203" order="28" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityAddressStateOrProvince_941954" order="29" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_DocumentQuarterlyReport_968680" order="30" priority="2" use="optional" />
</link:definitionLink>
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/BalanceSheets">
    <link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent" xlink:label="chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_36" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_37" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_38" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_38_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_44" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_45" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_39" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_40" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_41" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_46" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_47" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_48" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_49" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_50" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_968690" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_968693" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_968694" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantLiability" xlink:label="loc_chfw_WarrantLiability_939533" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_DeferredOfferingCostsNoncurrent" xlink:label="loc_chfw_DeferredOfferingCostsNoncurrent_52" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_53" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_54" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_55" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_43" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_56" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_57" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_58" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_59" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_60" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_61" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" xlink:to="chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent" order="29.01" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_36" xlink:to="loc_us-gaap_StatementClassOfStockAxis_37" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_37" xlink:to="loc_us-gaap_ClassOfStockDomain_38" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_37" xlink:to="loc_us-gaap_ClassOfStockDomain_38_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_38" xlink:to="loc_us-gaap_CommonClassAMember_44" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_38" xlink:to="loc_us-gaap_CommonClassBMember_45" order="5" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_39" xlink:to="loc_us-gaap_StatementTable_36" order="2" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39" xlink:to="loc_us-gaap_AssetsAbstract_40" order="7" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_40" xlink:to="loc_us-gaap_AssetsCurrentAbstract_41" order="8" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_41" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_46" order="9" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_41" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_47" order="10" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_41" xlink:to="loc_us-gaap_AssetsCurrent_48" order="11" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_40" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_49" order="12" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_40" xlink:to="loc_us-gaap_Assets_50" order="13" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" order="14" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_968690" order="15" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_968690" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_968693" order="16" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_968690" xlink:to="loc_us-gaap_LiabilitiesCurrent_968694" order="17" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" xlink:to="loc_chfw_WarrantLiability_939533" order="18" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" xlink:to="loc_chfw_DeferredOfferingCostsNoncurrent_52" order="19" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" xlink:to="loc_us-gaap_Liabilities_53" order="20" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" xlink:to="loc_us-gaap_CommitmentsAndContingencies_54" order="21" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_55" order="22" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" xlink:to="loc_us-gaap_StockholdersEquityAbstract_43" order="23" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43" xlink:to="loc_us-gaap_PreferredStockValue_56" order="24" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43" xlink:to="loc_us-gaap_CommonStockValue_57" order="25" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43" xlink:to="loc_us-gaap_AdditionalPaidInCapital_58" order="26" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_59" order="27" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43" xlink:to="loc_us-gaap_StockholdersEquity_60" order="28" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_61" order="29" priority="2" use="optional" />
</link:definitionLink>
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/BalanceSheetsParenthetical">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_64" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_65" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_66" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_66_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_68" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_69" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_67" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_70" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_71" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_72" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_73" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_74" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_75" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_76" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_77" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_78" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_64" xlink:to="loc_us-gaap_StatementClassOfStockAxis_65" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_65" xlink:to="loc_us-gaap_ClassOfStockDomain_66" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_65" xlink:to="loc_us-gaap_ClassOfStockDomain_66_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_66" xlink:to="loc_us-gaap_CommonClassAMember_68" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_66" xlink:to="loc_us-gaap_CommonClassBMember_69" order="5" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_67" xlink:to="loc_us-gaap_StatementTable_64" order="3" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_67" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_70" order="7" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_67" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_71" order="8" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_67" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_72" order="9" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_67" xlink:to="loc_us-gaap_PreferredStockSharesIssued_73" order="10" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_67" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_74" order="11" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_67" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_75" order="12" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_67" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_76" order="13" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_67" xlink:to="loc_us-gaap_CommonStockSharesIssued_77" order="14" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_67" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_78" order="15" priority="2" use="optional" />
</link:definitionLink>
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_208" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_209" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_210" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_210_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_213" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_214" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_215" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:label="loc_chfw_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_216" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_chfw_UnitsIssuedDuringPeriodSharesNewIssues_217" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_218" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_UnitsIssuedDuringPeriodValueNewIssues" xlink:label="loc_chfw_UnitsIssuedDuringPeriodValueNewIssues_219" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_220" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_AdditionsToAssetsHeldInTrust" xlink:label="loc_chfw_AdditionsToAssetsHeldInTrust_221" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_TransactionCosts" xlink:label="loc_chfw_TransactionCosts_212" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_SaleOfStockUnderwritingFees" xlink:label="loc_chfw_SaleOfStockUnderwritingFees_222" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_DeferredOfferingCostsNoncurrent" xlink:label="loc_chfw_DeferredOfferingCostsNoncurrent_223" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_SaleOfStockOtherOfferingCosts" xlink:label="loc_chfw_SaleOfStockOtherOfferingCosts_224" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount" xlink:label="loc_chfw_ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount_225" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination" xlink:label="loc_chfw_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination_226" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_208" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_209" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_209" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_210" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_209" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_210_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_210" xlink:to="loc_us-gaap_IPOMember_213" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_210" xlink:to="loc_us-gaap_PrivatePlacementMember_214" order="5" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_210" xlink:to="loc_us-gaap_OverAllotmentOptionMember_215" order="6" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_208" order="4" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" xlink:to="loc_chfw_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_216" order="8" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" xlink:to="loc_chfw_UnitsIssuedDuringPeriodSharesNewIssues_217" order="9" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" xlink:to="loc_us-gaap_SharePrice_218" order="10" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" xlink:to="loc_chfw_UnitsIssuedDuringPeriodValueNewIssues_219" order="11" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" xlink:to="loc_us-gaap_AssetsHeldInTrust_220" order="12" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" xlink:to="loc_chfw_AdditionsToAssetsHeldInTrust_221" order="13" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" xlink:to="loc_chfw_TransactionCosts_212" order="14" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_TransactionCosts_212" xlink:to="loc_chfw_SaleOfStockUnderwritingFees_222" order="15" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_TransactionCosts_212" xlink:to="loc_chfw_DeferredOfferingCostsNoncurrent_223" order="16" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_TransactionCosts_212" xlink:to="loc_chfw_SaleOfStockOtherOfferingCosts_224" order="17" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" xlink:to="loc_chfw_ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount_225" order="18" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" xlink:to="loc_chfw_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination_226" order="19" priority="2" use="optional" />
</link:definitionLink>
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_229" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_230" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_231" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_231_2" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_InitialPublicOfferingAndPrivatePlacementMember" xlink:label="loc_chfw_InitialPublicOfferingAndPrivatePlacementMember_233" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_232" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_234" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_235" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_236" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_237" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_229" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_230" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_230" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_231" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_230" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_231_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_231" xlink:to="loc_chfw_InitialPublicOfferingAndPrivatePlacementMember_233" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_232" xlink:to="loc_us-gaap_StatementTable_229" order="5" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_232" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_234" order="6" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_232" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_235" order="7" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_232" xlink:to="loc_us-gaap_CashFDICInsuredAmount_236" order="8" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_232" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_237" order="9" priority="2" use="optional" />
</link:definitionLink>
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails">
    <link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOrdinarySharesSubjectForRedemptionMember" xlink:label="chfw_ClassOrdinarySharesSubjectForRedemptionMember"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_240" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_241" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_242" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_242_2" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassAOrdinarySharesSubjectForRedemptionMember" xlink:label="loc_chfw_ClassAOrdinarySharesSubjectForRedemptionMember_244" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonredeemablePreferredStockMember" xlink:label="loc_us-gaap_NonredeemablePreferredStockMember_245" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_243" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_246" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_247" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_248" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_249" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_250" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_251" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_252" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_242" xlink:to="chfw_ClassOrdinarySharesSubjectForRedemptionMember" order="13.01" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_240" xlink:to="loc_us-gaap_StatementClassOfStockAxis_241" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_241" xlink:to="loc_us-gaap_ClassOfStockDomain_242" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_241" xlink:to="loc_us-gaap_ClassOfStockDomain_242_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_242" xlink:to="loc_chfw_ClassAOrdinarySharesSubjectForRedemptionMember_244" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_242" xlink:to="loc_us-gaap_NonredeemablePreferredStockMember_245" order="5" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_243" xlink:to="loc_us-gaap_StatementTable_240" order="6" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_243" xlink:to="loc_us-gaap_NetIncomeLoss_246" order="7" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_243" xlink:to="loc_us-gaap_InvestmentIncomeInterest_247" order="8" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_243" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_248" order="9" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_243" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_249" order="10" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_243" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_250" order="11" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_243" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_251" order="12" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_243" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_252" order="13" priority="2" use="optional" />
</link:definitionLink>
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/InitialPublicOfferingDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_255" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_256" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_257" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_257_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_261" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_262" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_263" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_258" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_259" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_259_2" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PublicWarrantsMember" xlink:label="loc_chfw_PublicWarrantsMember_264" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_chfw_UnitsIssuedDuringPeriodSharesNewIssues_265" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_266" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_NumberOfSharesIssuedPerUnit" xlink:label="loc_chfw_NumberOfSharesIssuedPerUnit_267" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_chfw_NumberOfWarrantsIssuedPerUnit_268" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_269" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_270" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_UnitsIssuedDuringPeriodValueNewIssues" xlink:label="loc_chfw_UnitsIssuedDuringPeriodValueNewIssues_271" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_AdditionsToAssetsHeldInTrust" xlink:label="loc_chfw_AdditionsToAssetsHeldInTrust_272" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_273" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_255" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_256" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_256" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_257" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_256" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_257_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_257" xlink:to="loc_us-gaap_IPOMember_261" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_257" xlink:to="loc_us-gaap_OverAllotmentOptionMember_262" order="5" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_257" xlink:to="loc_us-gaap_PrivatePlacementMember_263" order="6" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_255" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_258" order="2" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_258" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_259" order="8" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_258" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_259_2" order="8.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_259" xlink:to="loc_chfw_PublicWarrantsMember_264" order="9" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_255" order="7" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" xlink:to="loc_chfw_UnitsIssuedDuringPeriodSharesNewIssues_265" order="11" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" xlink:to="loc_us-gaap_SharePrice_266" order="12" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" xlink:to="loc_chfw_NumberOfSharesIssuedPerUnit_267" order="13" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" xlink:to="loc_chfw_NumberOfWarrantsIssuedPerUnit_268" order="14" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_269" order="15" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_270" order="16" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" xlink:to="loc_chfw_UnitsIssuedDuringPeriodValueNewIssues_271" order="17" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" xlink:to="loc_chfw_AdditionsToAssetsHeldInTrust_272" order="18" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" xlink:to="loc_us-gaap_AssetsHeldInTrust_273" order="19" priority="2" use="optional" />
</link:definitionLink>
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/PrivatePlacementDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_276" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_277" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_278" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_278_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_282" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_279" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_280" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_280_2" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PrivatePlacementWarrantsMember" xlink:label="loc_chfw_PrivatePlacementWarrantsMember_283" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_281" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_chfw_UnitsIssuedDuringPeriodSharesNewIssues_284" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_285" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_UnitsIssuedDuringPeriodValueNewIssues" xlink:label="loc_chfw_UnitsIssuedDuringPeriodValueNewIssues_286" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_NumberOfSharesIssuedPerUnit" xlink:label="loc_chfw_NumberOfSharesIssuedPerUnit_287" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_chfw_NumberOfWarrantsIssuedPerUnit_288" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_289" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_276" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_277" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_277" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_278" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_277" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_278_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_278" xlink:to="loc_us-gaap_PrivatePlacementMember_282" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_276" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_279" order="2" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_279" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_280" order="6" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_279" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_280_2" order="6.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_280" xlink:to="loc_chfw_PrivatePlacementWarrantsMember_283" order="7" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_281" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_276" order="8" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_281" xlink:to="loc_chfw_UnitsIssuedDuringPeriodSharesNewIssues_284" order="9" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_281" xlink:to="loc_us-gaap_SharePrice_285" order="10" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_281" xlink:to="loc_chfw_UnitsIssuedDuringPeriodValueNewIssues_286" order="11" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_281" xlink:to="loc_chfw_NumberOfSharesIssuedPerUnit_287" order="12" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_281" xlink:to="loc_chfw_NumberOfWarrantsIssuedPerUnit_288" order="13" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_281" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_289" order="14" priority="2" use="optional" />
</link:definitionLink>
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/RelatedPartyTransactionsFounderSharesDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_292" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_293" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_294" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_294_2" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_FounderSharesMember" xlink:label="loc_chfw_FounderSharesMember_300" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_295" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_296" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_296_2" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_SponsorMember" xlink:label="loc_chfw_SponsorMember_301" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_297" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_298" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_298_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_302" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_303" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_299" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_304" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_305" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_306" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_307" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_308" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_309" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_NumberOfSharesSubjectToForfeiture" xlink:label="loc_chfw_NumberOfSharesSubjectToForfeiture_310" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" xlink:label="loc_chfw_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders_311" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:label="loc_chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_312" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:label="loc_chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_313" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="loc_chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_314" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="loc_chfw_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_315" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_292" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_293" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_293" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_294" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_293" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_294_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_294" xlink:to="loc_chfw_FounderSharesMember_300" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_292" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_295" order="2" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_295" xlink:to="loc_us-gaap_RelatedPartyDomain_296" order="6" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_295" xlink:to="loc_us-gaap_RelatedPartyDomain_296_2" order="6.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_296" xlink:to="loc_chfw_SponsorMember_301" order="7" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_292" xlink:to="loc_us-gaap_StatementClassOfStockAxis_297" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_297" xlink:to="loc_us-gaap_ClassOfStockDomain_298" order="9" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_297" xlink:to="loc_us-gaap_ClassOfStockDomain_298_2" order="9.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_298" xlink:to="loc_us-gaap_CommonClassBMember_302" order="10" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_298" xlink:to="loc_us-gaap_CommonClassAMember_303" order="11" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_292" order="9" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_304" order="13" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_305" order="14" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_306" order="15" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_307" order="16" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_us-gaap_CommonStockSharesIssued_308" order="17" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_309" order="18" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_chfw_NumberOfSharesSubjectToForfeiture_310" order="19" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_chfw_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders_311" order="20" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_312" order="21" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_313" order="22" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_314" order="23" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_chfw_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_315" order="24" priority="2" use="optional" />
</link:definitionLink>
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/StockholdersEquityCommonStockSharesDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_347" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_348" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_349" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_349_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_351" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_352" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_350" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_353" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_354" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_CommonStockNumberOfVotesPerShare" xlink:label="loc_chfw_CommonStockNumberOfVotesPerShare_355" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_356" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_357" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_358" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_347" xlink:to="loc_us-gaap_StatementClassOfStockAxis_348" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_348" xlink:to="loc_us-gaap_ClassOfStockDomain_349" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_348" xlink:to="loc_us-gaap_ClassOfStockDomain_349_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_349" xlink:to="loc_us-gaap_CommonClassAMember_351" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_349" xlink:to="loc_us-gaap_CommonClassBMember_352" order="5" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_350" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_347" order="10" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_350" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_353" order="7" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_350" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_354" order="8" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_350" xlink:to="loc_chfw_CommonStockNumberOfVotesPerShare_355" order="9" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_350" xlink:to="loc_us-gaap_CommonStockSharesIssued_356" order="10" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_350" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_357" order="11" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_350" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_358" order="12" priority="2" use="optional" />
</link:definitionLink>
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/WarrantLiabilityDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_362" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_363" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_364" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_364_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_365" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_366" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_366_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_367" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PrivatePlacementWarrantsMember" xlink:label="loc_chfw_PrivatePlacementWarrantsMember_374" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PublicWarrantsMember" xlink:label="loc_chfw_PublicWarrantsMember_375" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_368" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_369" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_369_2" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xlink:label="loc_chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_376" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" xlink:label="loc_chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_377" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_370" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_371" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_371_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantExercisePeriodConditionOne" xlink:label="loc_chfw_WarrantExercisePeriodConditionOne_379" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantExercisePeriodConditionTwo" xlink:label="loc_chfw_WarrantExercisePeriodConditionTwo_380" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_381" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xlink:label="loc_chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_382" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xlink:label="loc_chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_383" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantRedemptionConditionMinimumSharePrice" xlink:label="loc_chfw_WarrantRedemptionConditionMinimumSharePrice_384" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo" xlink:label="loc_chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo_385" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="loc_chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_386" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="loc_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_387" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="loc_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_388" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:label="loc_chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_389" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RedemptionPeriod" xlink:label="loc_chfw_RedemptionPeriod_390" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant" xlink:label="loc_chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant_392" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:label="loc_chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_393" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:label="loc_chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_394" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantExercisePriceAdjustmentMultiple" xlink:label="loc_chfw_WarrantExercisePriceAdjustmentMultiple_395" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantRedemptionPriceAdjustmentMultiple" xlink:label="loc_chfw_WarrantRedemptionPriceAdjustmentMultiple_396" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:label="loc_chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_397" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_362" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_363" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_363" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_364" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_363" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_364_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_362" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_365" order="2" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_365" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_366" order="5" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_365" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_366_2" order="5.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_366" xlink:to="loc_us-gaap_WarrantMember_367" order="6" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_366" xlink:to="loc_chfw_PrivatePlacementWarrantsMember_374" order="7" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_366" xlink:to="loc_chfw_PublicWarrantsMember_375" order="8" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_362" xlink:to="loc_srt_StatementScenarioAxis_368" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_368" xlink:to="loc_srt_ScenarioUnspecifiedDomain_369" order="10" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_368" xlink:to="loc_srt_ScenarioUnspecifiedDomain_369_2" order="10.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_369" xlink:to="loc_chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_376" order="11" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_369" xlink:to="loc_chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_377" order="12" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_362" xlink:to="loc_us-gaap_StatementClassOfStockAxis_370" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_370" xlink:to="loc_us-gaap_ClassOfStockDomain_371" order="14" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_370" xlink:to="loc_us-gaap_ClassOfStockDomain_371_2" order="14.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_362" order="11" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantExercisePeriodConditionOne_379" order="16" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantExercisePeriodConditionTwo_380" order="17" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_381" order="18" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_382" order="19" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_383" order="20" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantRedemptionConditionMinimumSharePrice_384" order="21" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo_385" order="22" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_386" order="23" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_387" order="24" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_388" order="25" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_389" order="26" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_RedemptionPeriod_390" order="27" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant_392" order="28" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_393" order="29" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_394" order="30" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantExercisePriceAdjustmentMultiple_395" order="31" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantRedemptionPriceAdjustmentMultiple_396" order="32" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_397" order="33" priority="2" use="optional" />
</link:definitionLink>
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementsDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_400" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_401" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_402" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_402_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_407" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_940082" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_403" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_404" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_404_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_408" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_940093" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_940095" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_940095_2" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PublicWarrantsMember" xlink:label="loc_chfw_PublicWarrantsMember_940098" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PrivatePlacementWarrantsMember" xlink:label="loc_chfw_PrivatePlacementWarrantsMember_940111" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_405" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_406" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_409" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_940068" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantLiability" xlink:label="loc_chfw_WarrantLiability_940072" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_400" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_401" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_401" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_402" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_401" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_402_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_402" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_407" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_402" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_940082" order="5" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_400" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_403" order="2" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_403" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_404" order="7" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_403" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_404_2" order="7.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_404" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_408" order="8" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_400" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_940093" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_940093" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_940095" order="10" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_940093" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_940095_2" order="10.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_940095" xlink:to="loc_chfw_PublicWarrantsMember_940098" order="11" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_940095" xlink:to="loc_chfw_PrivatePlacementWarrantsMember_940111" order="12" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_405" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_400" order="12" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_405" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_406" order="14" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_406" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_409" order="15" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_405" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_940068" order="16" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_940068" xlink:to="loc_chfw_WarrantLiability_940072" order="17" priority="2" use="optional" />
</link:definitionLink>
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementsSummaryOfFairValueOfTheWarrantLiabilitiesDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_940408" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_940409" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_940412" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_940412_2" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PrivatePlacementWarrantsMember" xlink:label="loc_chfw_PrivatePlacementWarrantsMember_940414" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PublicWarrantsMember" xlink:label="loc_chfw_PublicWarrantsMember_940416" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_940417" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_941691" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_941691_2" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantsLiabilitiesMember" xlink:label="loc_chfw_WarrantsLiabilitiesMember_940418" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940419" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_940420" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_940421" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_941849" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_940408" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_940409" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_940409" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_940412" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_940409" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_940412_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_940412" xlink:to="loc_chfw_PrivatePlacementWarrantsMember_940414" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_940412" xlink:to="loc_chfw_PublicWarrantsMember_940416" order="5" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_940408" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_940417" order="2" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_940417" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_941691" order="7" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_940417" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_941691_2" order="7.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_941691" xlink:to="loc_chfw_WarrantsLiabilitiesMember_940418" order="8" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940419" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_940408" order="13" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940419" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_940420" order="10" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940419" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_940421" order="11" priority="2" use="optional" />
</link:definitionLink>
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/SubsequentEventsDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_948209" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_948210" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_948211" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_948211_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_948242" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_948244" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_948244_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_948245" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_948249" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_948250" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_948250_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_948252" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_948253" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_948254" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_948254_2" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_BusinessCombinationAgreementMember" xlink:label="loc_chfw_BusinessCombinationAgreementMember_948255" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_SubscriptionAgreementMember" xlink:label="loc_chfw_SubscriptionAgreementMember_948257" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_InvestorAxis" xlink:label="loc_chfw_InvestorAxis_948259" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_InvestorDomain" xlink:label="loc_chfw_InvestorDomain_948260" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_InvestorDomain" xlink:label="loc_chfw_InvestorDomain_948260_2" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PipeInvestorsMember" xlink:label="loc_chfw_PipeInvestorsMember_948262" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_948264" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_948265" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_948265_2" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PipeWarrantsMember" xlink:label="loc_chfw_PipeWarrantsMember_948268" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_948212" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_948217" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_948218" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_948221" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_948222" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_948224" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_948226" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_948227" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_948209" xlink:to="loc_us-gaap_StatementClassOfStockAxis_948210" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_948210" xlink:to="loc_us-gaap_ClassOfStockDomain_948211" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_948210" xlink:to="loc_us-gaap_ClassOfStockDomain_948211_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_948209" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_948242" order="2" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_948242" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_948244" order="5" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_948242" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_948244_2" order="5.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_948244" xlink:to="loc_us-gaap_SubsequentEventMember_948245" order="6" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_948209" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_948249" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_948249" xlink:to="loc_us-gaap_EquityComponentDomain_948250" order="8" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_948249" xlink:to="loc_us-gaap_EquityComponentDomain_948250_2" order="8.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_948250" xlink:to="loc_us-gaap_CommonStockMember_948252" order="9" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_948209" xlink:to="loc_us-gaap_TypeOfArrangementAxis_948253" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_948253" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_948254" order="11" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_948253" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_948254_2" order="11.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_948254" xlink:to="loc_chfw_BusinessCombinationAgreementMember_948255" order="12" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_948254" xlink:to="loc_chfw_SubscriptionAgreementMember_948257" order="13" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_948209" xlink:to="loc_chfw_InvestorAxis_948259" order="5" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_chfw_InvestorAxis_948259" xlink:to="loc_chfw_InvestorDomain_948260" order="15" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_chfw_InvestorAxis_948259" xlink:to="loc_chfw_InvestorDomain_948260_2" order="15.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_InvestorDomain_948260" xlink:to="loc_chfw_PipeInvestorsMember_948262" order="16" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_948209" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_948264" order="6" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_948264" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_948265" order="18" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_948264" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_948265_2" order="18.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_948265" xlink:to="loc_chfw_PipeWarrantsMember_948268" order="19" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_948212" xlink:to="loc_us-gaap_StatementTable_948209" order="14" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_948212" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_948217" order="21" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_948212" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_948218" order="22" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_948212" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_948221" order="23" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_948212" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_948222" order="24" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_948212" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_948224" order="25" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_948212" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_948226" order="26" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_948212" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_948227" order="27" priority="2" use="optional" />
</link:definitionLink>
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#StatementOfOperations" roleURI="http://Consonance.com/role/StatementOfOperations" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#StatementOfChangesInStockholdersEquity" roleURI="http://Consonance.com/role/StatementOfChangesInStockholdersEquity" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#StatementOfChangesInStockholdersEquityParenthetical" roleURI="http://Consonance.com/role/StatementOfChangesInStockholdersEquityParenthetical" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#StatementOfCashFlows" roleURI="http://Consonance.com/role/StatementOfCashFlows" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#RestatementOfPreviouslyIssuedFinancialStatements" roleURI="http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatements" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#RestatementOfPreviouslyIssuedFinancialStatementsTables" roleURI="http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#FairValueMeasurementsTables" roleURI="http://Consonance.com/role/FairValueMeasurementsTables" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#RestatementOfPreviouslyIssuedFinancialStatementsAdditionalInformationDetails" roleURI="http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatementsAdditionalInformationDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#RestatementOfPreviouslyIssuedFinancialStatementsSummaryOfRestatementOfPreviouslyIssuedFinancialStatementsDetails" roleURI="http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatementsSummaryOfRestatementOfPreviouslyIssuedFinancialStatementsDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#WarrantsDetails" roleURI="http://Consonance.com/role/WarrantsDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#FairValueMeasurementsSummaryOfKeyInputsIntoTheBinomialLatticeSimulationModelForThePrivatePlacementWarrantsAndPublicWarrantsDetails" roleURI="http://Consonance.com/role/FairValueMeasurementsSummaryOfKeyInputsIntoTheBinomialLatticeSimulationModelForThePrivatePlacementWarrantsAndPublicWarrantsDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#FairValueMeasurementsAdditionalInformationDetails" roleURI="http://Consonance.com/role/FairValueMeasurementsAdditionalInformationDetails" />
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/StatementOfOperations">
    <link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassAOrdinarySharesSubjectForRedemptionMember" xlink:label="chfw_ClassAOrdinarySharesSubjectForRedemptionMember"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_81" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_82" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_83" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_83_2" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOrdinarySharesSubjectForRedemptionMember" xlink:label="loc_chfw_ClassOrdinarySharesSubjectForRedemptionMember_86" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonredeemablePreferredStockMember" xlink:label="loc_us-gaap_NonredeemablePreferredStockMember_87" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_84" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_88" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_89" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_90" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_TransactionCostsAssociatedWithInitialPublicOffering" xlink:label="loc_chfw_TransactionCostsAssociatedWithInitialPublicOffering_939555" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_939559" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_91" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_92" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_93" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_94" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_95" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_83" xlink:to="chfw_ClassAOrdinarySharesSubjectForRedemptionMember" order="17.01" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_81" xlink:to="loc_us-gaap_StatementClassOfStockAxis_82" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_82" xlink:to="loc_us-gaap_ClassOfStockDomain_83" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_82" xlink:to="loc_us-gaap_ClassOfStockDomain_83_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_83" xlink:to="loc_chfw_ClassOrdinarySharesSubjectForRedemptionMember_86" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_83" xlink:to="loc_us-gaap_NonredeemablePreferredStockMember_87" order="5" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_84" xlink:to="loc_us-gaap_StatementTable_81" order="15" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_84" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_88" order="7" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_84" xlink:to="loc_us-gaap_OperatingIncomeLoss_89" order="8" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_84" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85" order="9" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85" xlink:to="loc_us-gaap_InvestmentIncomeInterest_90" order="10" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85" xlink:to="loc_chfw_TransactionCostsAssociatedWithInitialPublicOffering_939555" order="11" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_939559" order="12" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_91" order="13" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_92" order="14" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_84" xlink:to="loc_us-gaap_NetIncomeLoss_93" order="15" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_84" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_94" order="16" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_84" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_95" order="17" priority="2" use="optional" />
</link:definitionLink>
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/StatementOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption" xlink:label="chfw_StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption"/>
    <link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption" xlink:label="chfw_StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_101" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_102" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_108" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_108_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_106" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_107" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_103" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_112" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_112_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_109" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_110" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_111" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_104" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_113" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_114" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_115" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_116" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_UnitsIssuedDuringPeriodValueNewIssues" xlink:label="loc_chfw_UnitsIssuedDuringPeriodValueNewIssues_117" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_chfw_UnitsIssuedDuringPeriodSharesNewIssues_118" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_SaleOfPrivatePlacementUnitsValue" xlink:label="loc_chfw_SaleOfPrivatePlacementUnitsValue_119" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_SaleOfPrivatePlacementUnitsShares" xlink:label="loc_chfw_SaleOfPrivatePlacementUnitsShares_120" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_CommonStockSubjectToPossibleRedemptionValue" xlink:label="loc_chfw_CommonStockSubjectToPossibleRedemptionValue_121" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_CommonStockSubjectToPossibleRedemptionShares" xlink:label="loc_chfw_CommonStockSubjectToPossibleRedemptionShares_122" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_123" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_124" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_125" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="chfw_StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption" order="25.01" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="chfw_StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption" order="25.02" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_101" xlink:to="loc_us-gaap_StatementClassOfStockAxis_102" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_102" xlink:to="loc_us-gaap_ClassOfStockDomain_108" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_102" xlink:to="loc_us-gaap_ClassOfStockDomain_108_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_108" xlink:to="loc_us-gaap_CommonClassAMember_106" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_108" xlink:to="loc_us-gaap_CommonClassBMember_107" order="5" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_101" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_103" order="2" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_103" xlink:to="loc_us-gaap_EquityComponentDomain_112" order="7" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_103" xlink:to="loc_us-gaap_EquityComponentDomain_112_2" order="7.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_112" xlink:to="loc_us-gaap_CommonStockMember_109" order="8" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_112" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_110" order="9" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_112" xlink:to="loc_us-gaap_RetainedEarningsMember_111" order="10" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_104" xlink:to="loc_us-gaap_StatementTable_101" order="16" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_104" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" order="12" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_us-gaap_StockholdersEquity_113" order="13" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_us-gaap_SharesIssued_114" order="14" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_115" order="15" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_116" order="16" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_chfw_UnitsIssuedDuringPeriodValueNewIssues_117" order="17" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_chfw_UnitsIssuedDuringPeriodSharesNewIssues_118" order="18" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_chfw_SaleOfPrivatePlacementUnitsValue_119" order="19" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_chfw_SaleOfPrivatePlacementUnitsShares_120" order="20" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_chfw_CommonStockSubjectToPossibleRedemptionValue_121" order="21" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_chfw_CommonStockSubjectToPossibleRedemptionShares_122" order="22" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_us-gaap_NetIncomeLoss_123" order="23" priority="2" use="optional" />
</link:definitionLink>
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatementsSummaryOfRestatementOfPreviouslyIssuedFinancialStatementsDetails">
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RestatementTable" xlink:label="loc_chfw_RestatementTable_942033" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_942034" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_942035" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_942035_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_942036" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_942037" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RestatedMember" xlink:label="loc_chfw_RestatedMember_942886" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_942164" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_942165" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_942165_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_942166" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOrdinarySharesSubjectForRedemptionMember" xlink:label="loc_chfw_ClassOrdinarySharesSubjectForRedemptionMember_942839" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonredeemablePreferredStockMember" xlink:label="loc_us-gaap_NonredeemablePreferredStockMember_942841" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RestatementLineItems" xlink:label="loc_chfw_RestatementLineItems_942038" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PriorPeriodRestatementOfBalanceSheetAbstract" xlink:label="loc_chfw_PriorPeriodRestatementOfBalanceSheetAbstract_942818" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantLiability" xlink:label="loc_chfw_WarrantLiability_942062" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_942064" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_942156" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_942158" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_942160" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_942161" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_942162" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract" xlink:label="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract_942824" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_942827" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_AllocationOfInitialPublicOfferingCosts" xlink:label="loc_chfw_AllocationOfInitialPublicOfferingCosts_942828" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_942831" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_942832" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_942833" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract" xlink:label="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract_942826" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_942830" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_AllocationOfInitialPublicOfferingCosts" xlink:label="loc_chfw_AllocationOfInitialPublicOfferingCosts_942829" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_942834" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_InitialClassificationOfWarrantLiability" xlink:label="loc_chfw_InitialClassificationOfWarrantLiability_942835" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption" xlink:label="loc_chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption_942837" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption" xlink:label="loc_chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption_942838" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_chfw_RestatementTable_942033" xlink:to="loc_srt_RestatementAxis_942034" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_942034" xlink:to="loc_srt_RestatementDomain_942035" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_942034" xlink:to="loc_srt_RestatementDomain_942035_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_942035" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_942036" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_942035" xlink:to="loc_srt_RestatementAdjustmentMember_942037" order="5" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_942035" xlink:to="loc_chfw_RestatedMember_942886" order="6" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_chfw_RestatementTable_942033" xlink:to="loc_us-gaap_StatementClassOfStockAxis_942164" order="2" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_942164" xlink:to="loc_us-gaap_ClassOfStockDomain_942165" order="8" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_942164" xlink:to="loc_us-gaap_ClassOfStockDomain_942165_2" order="8.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_942165" xlink:to="loc_us-gaap_CommonClassAMember_942166" order="9" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_942165" xlink:to="loc_chfw_ClassOrdinarySharesSubjectForRedemptionMember_942839" order="10" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_942165" xlink:to="loc_us-gaap_NonredeemablePreferredStockMember_942841" order="11" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_chfw_RestatementLineItems_942038" xlink:to="loc_chfw_RestatementTable_942033" order="17" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_RestatementLineItems_942038" xlink:to="loc_chfw_PriorPeriodRestatementOfBalanceSheetAbstract_942818" order="13" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_PriorPeriodRestatementOfBalanceSheetAbstract_942818" xlink:to="loc_chfw_WarrantLiability_942062" order="14" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_PriorPeriodRestatementOfBalanceSheetAbstract_942818" xlink:to="loc_us-gaap_Liabilities_942064" order="15" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_PriorPeriodRestatementOfBalanceSheetAbstract_942818" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_942156" order="16" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_PriorPeriodRestatementOfBalanceSheetAbstract_942818" xlink:to="loc_us-gaap_CommonStockValue_942158" order="17" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_PriorPeriodRestatementOfBalanceSheetAbstract_942818" xlink:to="loc_us-gaap_AdditionalPaidInCapital_942160" order="18" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_PriorPeriodRestatementOfBalanceSheetAbstract_942818" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_942161" order="19" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_PriorPeriodRestatementOfBalanceSheetAbstract_942818" xlink:to="loc_us-gaap_StockholdersEquity_942162" order="20" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_RestatementLineItems_942038" xlink:to="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract_942824" order="21" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract_942824" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_942827" order="22" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract_942824" xlink:to="loc_chfw_AllocationOfInitialPublicOfferingCosts_942828" order="23" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract_942824" xlink:to="loc_us-gaap_NetIncomeLoss_942831" order="24" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract_942824" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_942832" order="25" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract_942824" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_942833" order="26" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_RestatementLineItems_942038" xlink:to="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract_942826" order="27" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract_942826" xlink:to="loc_chfw_InitialClassificationOfWarrantLiability_942835" order="31" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract_942826" xlink:to="loc_chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption_942837" order="32" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract_942826" xlink:to="loc_chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption_942838" order="33" priority="2" use="optional" />
</link:definitionLink>
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_318" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_319" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_320" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_320_2" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PromissoryNoteWithRelatedPartyMember" xlink:label="loc_chfw_PromissoryNoteWithRelatedPartyMember_324" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_AdministrativeSupportAgreementMember" xlink:label="loc_chfw_AdministrativeSupportAgreementMember_325" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RelatedPartyLoansMember" xlink:label="loc_chfw_RelatedPartyLoansMember_326" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_321" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_322" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_322_2" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WorkingCapitalLoansWarrantMember" xlink:label="loc_chfw_WorkingCapitalLoansWarrantMember_327" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_323" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:label="loc_chfw_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_328" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_329" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_330" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:label="loc_chfw_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_331" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_332" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_MaximumLoansConvertibleIntoWarrants" xlink:label="loc_chfw_MaximumLoansConvertibleIntoWarrants_333" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="loc_chfw_ClassOfWarrantOrRightPriceOfWarrantsOrRights_334" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_318" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_319" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_319" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_320" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_319" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_320_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_320" xlink:to="loc_chfw_PromissoryNoteWithRelatedPartyMember_324" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_320" xlink:to="loc_chfw_AdministrativeSupportAgreementMember_325" order="5" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_320" xlink:to="loc_chfw_RelatedPartyLoansMember_326" order="6" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_318" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_321" order="2" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_321" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_322" order="8" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_321" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_322_2" order="8.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_322" xlink:to="loc_chfw_WorkingCapitalLoansWarrantMember_327" order="9" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_323" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_318" order="18" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_323" xlink:to="loc_chfw_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_328" order="11" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_323" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_329" order="12" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_323" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_330" order="13" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_323" xlink:to="loc_chfw_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_331" order="14" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_323" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_332" order="15" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_323" xlink:to="loc_chfw_MaximumLoansConvertibleIntoWarrants_333" order="16" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_323" xlink:to="loc_chfw_ClassOfWarrantOrRightPriceOfWarrantsOrRights_334" order="17" priority="2" use="optional" />
</link:definitionLink>
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/WarrantsDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_362" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_363" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_364" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_364_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_365" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_366" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_366_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_367" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PrivatePlacementWarrantsMember" xlink:label="loc_chfw_PrivatePlacementWarrantsMember_374" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PublicWarrantsMember" xlink:label="loc_chfw_PublicWarrantsMember_375" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_368" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_369" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_369_2" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xlink:label="loc_chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_376" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" xlink:label="loc_chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_377" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_370" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_371" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_371_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantExercisePeriodConditionOne" xlink:label="loc_chfw_WarrantExercisePeriodConditionOne_379" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantExercisePeriodConditionTwo" xlink:label="loc_chfw_WarrantExercisePeriodConditionTwo_380" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_381" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xlink:label="loc_chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_382" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xlink:label="loc_chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_383" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantRedemptionConditionMinimumSharePrice" xlink:label="loc_chfw_WarrantRedemptionConditionMinimumSharePrice_384" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo" xlink:label="loc_chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo_385" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="loc_chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_386" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="loc_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_387" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="loc_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_388" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:label="loc_chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_389" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RedemptionPeriod" xlink:label="loc_chfw_RedemptionPeriod_390" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant" xlink:label="loc_chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant_392" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:label="loc_chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_393" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:label="loc_chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_394" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantExercisePriceAdjustmentMultiple" xlink:label="loc_chfw_WarrantExercisePriceAdjustmentMultiple_395" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantRedemptionPriceAdjustmentMultiple" xlink:label="loc_chfw_WarrantRedemptionPriceAdjustmentMultiple_396" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:label="loc_chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_397" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_362" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_363" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_363" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_364" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_363" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_364_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_362" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_365" order="2" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_365" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_366" order="5" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_365" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_366_2" order="5.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_366" xlink:to="loc_us-gaap_WarrantMember_367" order="6" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_366" xlink:to="loc_chfw_PrivatePlacementWarrantsMember_374" order="7" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_366" xlink:to="loc_chfw_PublicWarrantsMember_375" order="8" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_362" xlink:to="loc_srt_StatementScenarioAxis_368" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_368" xlink:to="loc_srt_ScenarioUnspecifiedDomain_369" order="10" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_368" xlink:to="loc_srt_ScenarioUnspecifiedDomain_369_2" order="10.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_369" xlink:to="loc_chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_376" order="11" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_369" xlink:to="loc_chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_377" order="12" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_362" xlink:to="loc_us-gaap_StatementClassOfStockAxis_370" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_370" xlink:to="loc_us-gaap_ClassOfStockDomain_371" order="14" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_370" xlink:to="loc_us-gaap_ClassOfStockDomain_371_2" order="14.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_362" order="19" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantExercisePeriodConditionOne_379" order="16" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantExercisePeriodConditionTwo_380" order="17" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_381" order="18" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_382" order="19" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_383" order="20" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantRedemptionConditionMinimumSharePrice_384" order="21" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo_385" order="22" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_386" order="23" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_387" order="24" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_388" order="25" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_389" order="26" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_RedemptionPeriod_390" order="27" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant_392" order="28" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_393" order="29" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_394" order="30" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantExercisePriceAdjustmentMultiple_395" order="31" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantRedemptionPriceAdjustmentMultiple_396" order="32" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_397" order="33" priority="2" use="optional" />
</link:definitionLink>
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementsSummaryOfKeyInputsIntoTheBinomialLatticeSimulationModelForThePrivatePlacementWarrantsAndPublicWarrantsDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_940147" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_940149" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_940151" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_940151_2" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_940157" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_940160" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_940162" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_940169" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_MeasurementInputFairValueOfUnitsMember" xlink:label="loc_chfw_MeasurementInputFairValueOfUnitsMember_940171" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_940178" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_940179" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_940147" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_940149" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_940149" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_940151" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_940149" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_940151_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_940151" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_940157" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_940151" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_940160" order="5" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_940151" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_940162" order="6" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_940151" xlink:to="loc_us-gaap_MeasurementInputExercisePriceMember_940169" order="7" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_940151" xlink:to="loc_chfw_MeasurementInputFairValueOfUnitsMember_940171" order="8" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_940178" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_940147" order="20" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_940178" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_940179" order="10" priority="2" use="optional" />
</link:definitionLink>
<link:definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_940458" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_940460" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_940462" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_940462_2" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PrivatePlacementWarrantsMember" xlink:label="loc_chfw_PrivatePlacementWarrantsMember_940463" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PublicWarrantsMember" xlink:label="loc_chfw_PublicWarrantsMember_940464" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_940468" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_940469" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_940469_2" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantsLiabilitiesMember" xlink:label="loc_chfw_WarrantsLiabilitiesMember_940474" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940479" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantLiabilityFairValueDisclosure" xlink:label="loc_chfw_WarrantLiabilityFairValueDisclosure_940492" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_940503" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantsPerShare" xlink:label="loc_chfw_WarrantsPerShare_941899" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940479" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" order="12.01" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_940458" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_940460" order="1" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_940460" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_940462" order="3" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_940460" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_940462_2" order="3.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_940462" xlink:to="loc_chfw_PrivatePlacementWarrantsMember_940463" order="4" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_940462" xlink:to="loc_chfw_PublicWarrantsMember_940464" order="5" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_940458" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_940468" order="2" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_940468" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_940469" order="7" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_940468" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_940469_2" order="7.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_940469" xlink:to="loc_chfw_WarrantsLiabilitiesMember_940474" order="8" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940479" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_940458" order="21" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940479" xlink:to="loc_chfw_WarrantLiabilityFairValueDisclosure_940492" order="10" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940479" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_940503" order="11" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940479" xlink:to="loc_chfw_WarrantsPerShare_941899" order="12" priority="2" use="optional" />
</link:definitionLink>
</link:linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>27
<FILENAME>chfw-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="yes" ?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 67.4 -->
<!-- Creation date: 6/23/2021 12:10:17 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_AdditionsToAssetsHeldInTrust" xlink:label="chfw_AdditionsToAssetsHeldInTrust" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_AdditionsToAssetsHeldInTrust" xlink:to="chfw_AdditionsToAssetsHeldInTrust_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_AdditionsToAssetsHeldInTrust_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of significant additions in the period in assets held in trust (current, noncurrent, or unclassified).</link:label>
    <link:label xlink:label="chfw_AdditionsToAssetsHeldInTrust_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions To Assets Held In Trust</link:label>
    <link:label xlink:label="chfw_AdditionsToAssetsHeldInTrust_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions to assets held in trust</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_AdministrativeSupportAgreementMember" xlink:label="chfw_AdministrativeSupportAgreementMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_AdministrativeSupportAgreementMember" xlink:to="chfw_AdministrativeSupportAgreementMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_AdministrativeSupportAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for Administrative Support Agreement.</link:label>
    <link:label xlink:label="chfw_AdministrativeSupportAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Administrative Support Agreement [Member]</link:label>
    <link:label xlink:label="chfw_AdministrativeSupportAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Administrative Services Agreement</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_AmendmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Description</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Current Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsHeldInTrust" xlink:label="us-gaap_AssetsHeldInTrust" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldInTrust" xlink:to="us-gaap_AssetsHeldInTrust_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_AssetsHeldInTrust_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Held-in-trust</link:label>
    <link:label xlink:label="us-gaap_AssetsHeldInTrust_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Held-in-trust</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xlink:label="chfw_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xlink:to="chfw_AssetsHeldInTrustAccountPolicyPolicyTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_AssetsHeldInTrustAccountPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of accounting policy for assets held in trust.</link:label>
    <link:label xlink:label="chfw_AssetsHeldInTrustAccountPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Held In Trust Account, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="chfw_AssetsHeldInTrustAccountPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities Held in Trust Account</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="us-gaap_AssetsHeldInTrustNoncurrent" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldInTrustNoncurrent" xlink:to="us-gaap_AssetsHeldInTrustNoncurrent_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Held-in-trust, Noncurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and marketable securities held in Trust Account</link:label>
    <link:label xlink:label="us-gaap_AssetsHeldInTrustNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities held in Trust Account</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:label xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</link:label>
    <link:label xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition equity interest issued or issuable value assigned</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:label xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition share price</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_BusinessCombinationAgreementMember" xlink:label="chfw_BusinessCombinationAgreementMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_BusinessCombinationAgreementMember" xlink:to="chfw_BusinessCombinationAgreementMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_BusinessCombinationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination Agreement [Member]</link:label>
    <link:label xlink:label="chfw_BusinessCombinationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash &#x2013; End of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash &#x2013; Beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Change in Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, FDIC Insured Amount</link:label>
    <link:label xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal Depository Insurance Coverage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Cash investing and financing activities:</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption" xlink:label="chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption" xlink:to="chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of change in value of common stock subject to possible redemption, classified as non-cash investing and financing activity.</link:label>
    <link:label xlink:label="chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Value Of Common Stock Subject To Possible Redemption</link:label>
    <link:label xlink:label="chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in value of Class A ordinary shares subject to possible redemption</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_ClassAOrdinarySharesSubjectForRedemptionMember" xlink:label="chfw_ClassAOrdinarySharesSubjectForRedemptionMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_ClassAOrdinarySharesSubjectForRedemptionMember" xlink:to="chfw_ClassAOrdinarySharesSubjectForRedemptionMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_ClassAOrdinarySharesSubjectForRedemptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:type="resource" xml:lang="en-US">Class A ordinary Shares subject to possible redemption</link:label>
    <link:label xlink:label="chfw_ClassAOrdinarySharesSubjectForRedemptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents about Class A ordinary shares subject for redemption.</link:label>
    <link:label xlink:label="chfw_ClassAOrdinarySharesSubjectForRedemptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class A Ordinary Shares Subject For Redemption [Member]</link:label>
    <link:label xlink:label="chfw_ClassAOrdinarySharesSubjectForRedemptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Class A ordinary shares subject to redemption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:type="resource" xml:lang="en-US">Class of warrant or right exercise price of warrants or rights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of warrants</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of warrant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares per warrant</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrant voting right per share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants to purchase shares issued</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="chfw_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:to="chfw_ClassOfWarrantOrRightPriceOfWarrantsOrRights_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_ClassOfWarrantOrRightPriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Price per share or per unit of warrants or rights outstanding.</link:label>
    <link:label xlink:label="chfw_ClassOfWarrantOrRightPriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Price of Warrants or Rights</link:label>
    <link:label xlink:label="chfw_ClassOfWarrantOrRightPriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price of warrant</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:to="chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.</link:label>
    <link:label xlink:label="chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Consecutive Trading Days</link:label>
    <link:label xlink:label="chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold consecutive trading days for redemption of public warrants</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:to="chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold number of specified trading days for stock price trigger considered for redemption of warrants.</link:label>
    <link:label xlink:label="chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Trading Days</link:label>
    <link:label xlink:label="chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold trading days for redemption of public warrants</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:to="chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redemption price per share or per unit of warrants or rights outstanding.</link:label>
    <link:label xlink:label="chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Redemption Price Of Warrants Or Rights</link:label>
    <link:label xlink:label="chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption price per public warrant (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COMMITMENTS</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:label xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class A ordinary</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:label xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class B ordinary</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_CommonStockNumberOfVotesPerShare" xlink:label="chfw_CommonStockNumberOfVotesPerShare" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_CommonStockNumberOfVotesPerShare" xlink:to="chfw_CommonStockNumberOfVotesPerShare_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_CommonStockNumberOfVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of votes that each common share is entitled.</link:label>
    <link:label xlink:label="chfw_CommonStockNumberOfVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number Of Votes Per Share</link:label>
    <link:label xlink:label="chfw_CommonStockNumberOfVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares, votes per share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares, par value, (per share)</link:label>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common shares, par value (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares, shares authorized</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common shares, shares authorized (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares, shares issued</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common shares, shares issued (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares, shares outstanding</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common shares, shares outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:label="chfw_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:to="chfw_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum number of businesses which the reporting entity must acquire with the net proceeds of the offering.</link:label>
    <link:label xlink:label="chfw_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condition for future business combination number of businesses minimum</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_DeferredFeePerUnit" xlink:label="chfw_DeferredFeePerUnit" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_DeferredFeePerUnit" xlink:to="chfw_DeferredFeePerUnit_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_DeferredFeePerUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the deferred fee per unit.</link:label>
    <link:label xlink:label="chfw_DeferredFeePerUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Fee Per Unit</link:label>
    <link:label xlink:label="chfw_DeferredFeePerUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred fee per unit</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_DeferredOfferingCostsNoncurrent" xlink:label="chfw_DeferredOfferingCostsNoncurrent" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_DeferredOfferingCostsNoncurrent" xlink:to="chfw_DeferredOfferingCostsNoncurrent_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_DeferredOfferingCostsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</link:label>
    <link:label xlink:label="chfw_DeferredOfferingCostsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred underwriting fee payable</link:label>
    <link:label xlink:label="chfw_DeferredOfferingCostsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred underwriting fee payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="us-gaap_DerivativesReportingOfDerivativeActivity" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesReportingOfDerivativeActivity" xlink:to="us-gaap_DerivativesReportingOfDerivativeActivity_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_DerivativesReportingOfDerivativeActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Reporting of Derivative Activity [Policy Text Block]</link:label>
    <link:label xlink:label="us-gaap_DerivativesReportingOfDerivativeActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document and Entity Information</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:type="resource" xml:lang="en-US">Basic and diluted net income (Loss) per share</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Ordinary Share</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_EmergingGrowthCompanyPolicyTextBlock" xlink:label="chfw_EmergingGrowthCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_EmergingGrowthCompanyPolicyTextBlock" xlink:to="chfw_EmergingGrowthCompanyPolicyTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_EmergingGrowthCompanyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the accounting policy on Emerging Growth Company.</link:label>
    <link:label xlink:label="chfw_EmergingGrowthCompanyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Emerging Growth Company [Policy Text Block]</link:label>
    <link:label xlink:label="chfw_EmergingGrowthCompanyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value of warrant liability</link:label>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value of warrant liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of company's assets that are measured at fair value on a recurring basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:label xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:to="us-gaap_FairValueInputsQuantitativeInformationAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueInputsQuantitativeInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers in or out of level 3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)</link:label>
    <link:label xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation inputs or other assumptions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair value of the warrant liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs</link:label>
    <link:label xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value as of December&#xA0;31, 2020</link:label>
    <link:label xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Initial measurement on November&#xA0;23, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_FounderSharesMember" xlink:label="chfw_FounderSharesMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_FounderSharesMember" xlink:to="chfw_FounderSharesMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_FounderSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">It represents the information pertaining to founder shares.</link:label>
    <link:label xlink:label="chfw_FounderSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Founder Shares [Member]</link:label>
    <link:label xlink:label="chfw_FounderSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Founder Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:label xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_InitialPublicOfferingAbstract" xlink:label="chfw_InitialPublicOfferingAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_InitialPublicOfferingAbstract" xlink:to="chfw_InitialPublicOfferingAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_InitialPublicOfferingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No definition available.</link:label>
    <link:label xlink:label="chfw_InitialPublicOfferingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">INITIAL PUBLIC OFFERING</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_InitialPublicOfferingAndPrivatePlacementMember" xlink:label="chfw_InitialPublicOfferingAndPrivatePlacementMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_InitialPublicOfferingAndPrivatePlacementMember" xlink:to="chfw_InitialPublicOfferingAndPrivatePlacementMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_InitialPublicOfferingAndPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information about Initial Public Offering and private placement.</link:label>
    <link:label xlink:label="chfw_InitialPublicOfferingAndPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Public Offering And Private Placement [Member]</link:label>
    <link:label xlink:label="chfw_InitialPublicOfferingAndPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Public Offering and private placement</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_InitialPublicOfferingTextBlock" xlink:label="chfw_InitialPublicOfferingTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_InitialPublicOfferingTextBlock" xlink:to="chfw_InitialPublicOfferingTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_InitialPublicOfferingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure on information about initial public offering.</link:label>
    <link:label xlink:label="chfw_InitialPublicOfferingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Public Offering [Text Block]</link:label>
    <link:label xlink:label="chfw_InitialPublicOfferingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INITIAL PUBLIC OFFERING</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest earned on marketable securities held in Trust Account</link:label>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest earned on marketable securities held in Trust Account</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_InvestorAxis" xlink:label="chfw_InvestorAxis" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_InvestorAxis" xlink:to="chfw_InvestorAxis_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_InvestorAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investor [Axis]</link:label>
    <link:label xlink:label="chfw_InvestorAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investor [Axis]</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_InvestorDomain" xlink:label="chfw_InvestorDomain" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_InvestorDomain" xlink:to="chfw_InvestorDomain_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_InvestorDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investor [Domain]</link:label>
    <link:label xlink:label="chfw_InvestorDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investor [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Current Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_MaximumLoansConvertibleIntoWarrants" xlink:label="chfw_MaximumLoansConvertibleIntoWarrants" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_MaximumLoansConvertibleIntoWarrants" xlink:to="chfw_MaximumLoansConvertibleIntoWarrants_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_MaximumLoansConvertibleIntoWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum amount which a potential loan could have repaid through issuance of warrants.</link:label>
    <link:label xlink:label="chfw_MaximumLoansConvertibleIntoWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">maximum Loans Convertible Into Warrants</link:label>
    <link:label xlink:label="chfw_MaximumLoansConvertibleIntoWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan conversion agreement warrant</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xlink:label="chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xlink:to="chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The period of time after completion of a business combination in which the reporting entity is required to file a registration statement with the SEC.</link:label>
    <link:label xlink:label="chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Period After Business Combination In Which To File Registration Statement</link:label>
    <link:label xlink:label="chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum period after business combination in which to file registration statement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to holder</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Standards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonredeemablePreferredStockMember" xlink:label="us-gaap_NonredeemablePreferredStockMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonredeemablePreferredStockMember" xlink:to="us-gaap_NonredeemablePreferredStockMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_NonredeemablePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonredeemable Preferred Stock [Member]</link:label>
    <link:label xlink:label="us-gaap_NonredeemablePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-redeemable ordinary shares</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_NumberOfSharesIssuedPerUnit" xlink:label="chfw_NumberOfSharesIssuedPerUnit" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_NumberOfSharesIssuedPerUnit" xlink:to="chfw_NumberOfSharesIssuedPerUnit_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_NumberOfSharesIssuedPerUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of shares in a unit.</link:label>
    <link:label xlink:label="chfw_NumberOfSharesIssuedPerUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Shares Issued Per Unit</link:label>
    <link:label xlink:label="chfw_NumberOfSharesIssuedPerUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares per unit</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_NumberOfSharesSubjectToForfeiture" xlink:label="chfw_NumberOfSharesSubjectToForfeiture" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_NumberOfSharesSubjectToForfeiture" xlink:to="chfw_NumberOfSharesSubjectToForfeiture_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_NumberOfSharesSubjectToForfeiture_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares owned by the founders subject to forfeiture if the underwriter overallotment option is not exercised in the proposed public offering.</link:label>
    <link:label xlink:label="chfw_NumberOfSharesSubjectToForfeiture_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Subject To Forfeiture</link:label>
    <link:label xlink:label="chfw_NumberOfSharesSubjectToForfeiture_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares subject to forfeiture</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_NumberOfWarrantsIssuedPerUnit" xlink:label="chfw_NumberOfWarrantsIssuedPerUnit" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_NumberOfWarrantsIssuedPerUnit" xlink:to="chfw_NumberOfWarrantsIssuedPerUnit_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_NumberOfWarrantsIssuedPerUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of warrants in a unit.</link:label>
    <link:label xlink:label="chfw_NumberOfWarrantsIssuedPerUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Warrants Issued Per Unit</link:label>
    <link:label xlink:label="chfw_NumberOfWarrantsIssuedPerUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants per unit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Costs and Expenses</link:label>
    <link:label xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating and formation costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:label xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-allotment option</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:label="chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:to="chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The ratio of gross proceeds from a future offering to total equity proceeds which is used to measure whether dilution of the warrant has occurred. If aggregate gross proceeds from a new offering exceeds a specified percentage of total equity proceeds, the warrant exercise price will be adjusted.</link:label>
    <link:label xlink:label="chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Gross New Proceeds To Total Equity Proceeds Used To Measure Dilution Of Warrant</link:label>
    <link:label xlink:label="chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" xlink:label="chfw_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" xlink:to="chfw_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The expected ownership percentage by the founders after completion of the proposed public offering.</link:label>
    <link:label xlink:label="chfw_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Issued And Outstanding Shares After The Initial Public Offering Collectively Held By Initial Stockholders</link:label>
    <link:label xlink:label="chfw_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xlink:label="chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xlink:to="chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The period of time after filing within which the registration statement filed with the SEC is expected to become effective.</link:label>
    <link:label xlink:label="chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Time Within Which Registration Statement Is Expected To Become Effective</link:label>
    <link:label xlink:label="chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of time within which registration statement is expected to become effective</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_PipeInvestorsMember" xlink:label="chfw_PipeInvestorsMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_PipeInvestorsMember" xlink:to="chfw_PipeInvestorsMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_PipeInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PIPE Investors [Member]</link:label>
    <link:label xlink:label="chfw_PipeInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PIPE Investors [Member]</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_PipeWarrantsMember" xlink:label="chfw_PipeWarrantsMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_PipeWarrantsMember" xlink:to="chfw_PipeWarrantsMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_PipeWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PIPE Warrants [Member]</link:label>
    <link:label xlink:label="chfw_PipeWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PIPE Warrants [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value, (per share)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value, (per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred shares, shares authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred shares, shares issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred shares, shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:label xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:label xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_PrivatePlacementAbstract" xlink:label="chfw_PrivatePlacementAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_PrivatePlacementAbstract" xlink:to="chfw_PrivatePlacementAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_PrivatePlacementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No definition available.</link:label>
    <link:label xlink:label="chfw_PrivatePlacementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PRIVATE PLACEMENT</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:label xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_PrivatePlacementTextBlock" xlink:label="chfw_PrivatePlacementTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_PrivatePlacementTextBlock" xlink:to="chfw_PrivatePlacementTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_PrivatePlacementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure on information about private placement.</link:label>
    <link:label xlink:label="chfw_PrivatePlacementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Text Block]</link:label>
    <link:label xlink:label="chfw_PrivatePlacementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PRIVATE PLACEMENT</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_PrivatePlacementWarrantsMember" xlink:label="chfw_PrivatePlacementWarrantsMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_PrivatePlacementWarrantsMember" xlink:to="chfw_PrivatePlacementWarrantsMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_PrivatePlacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a redeemable warrant (Private Placement Warrant) that entitles the holder to purchase shares of common stock if the underwriter's option is exercised in full.</link:label>
    <link:label xlink:label="chfw_PrivatePlacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement Warrants [Member]</link:label>
    <link:label xlink:label="chfw_PrivatePlacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_PublicWarrantsMember" xlink:label="chfw_PublicWarrantsMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_PublicWarrantsMember" xlink:to="chfw_PublicWarrantsMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_PublicWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a redeemable warrant (Public Warrant) that entitles the holder to purchase shares of common stock subject to adjustment.</link:label>
    <link:label xlink:label="chfw_PublicWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Warrants [Member]</link:label>
    <link:label xlink:label="chfw_PublicWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Warrants</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" xlink:label="chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" xlink:to="chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for the scenario, where redemption of warrants when the price per share of class a common stock equals or exceeds $10.00.</link:label>
    <link:label xlink:label="chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redemption Of Warrants When Price Per Share Of Class Common Stock Equals Or Exceeds10.00 [Member]</link:label>
    <link:label xlink:label="chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $10.00</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xlink:label="chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xlink:to="chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for the scenario, where redemption of warrants when the price per share of class a common stock equals or exceeds $18.00.</link:label>
    <link:label xlink:label="chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redemption Of Warrants When Price Per Share Of Class Common Stock Equals Or Exceeds18.00 [Member]</link:label>
    <link:label xlink:label="chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_RedemptionPeriod" xlink:label="chfw_RedemptionPeriod" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_RedemptionPeriod" xlink:to="chfw_RedemptionPeriod_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_RedemptionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redemption period.</link:label>
    <link:label xlink:label="chfw_RedemptionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redemption Period</link:label>
    <link:label xlink:label="chfw_RedemptionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_RelatedPartyLoansMember" xlink:label="chfw_RelatedPartyLoansMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_RelatedPartyLoansMember" xlink:to="chfw_RelatedPartyLoansMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_RelatedPartyLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for related party loans.</link:label>
    <link:label xlink:label="chfw_RelatedPartyLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Loans [Member]</link:label>
    <link:label xlink:label="chfw_RelatedPartyLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Loans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expenses incurred and paid</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:label="chfw_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:to="chfw_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The contractual monthly amount to be paid for support services.</link:label>
    <link:label xlink:label="chfw_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party Per Month</link:label>
    <link:label xlink:label="chfw_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses per month</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:label="chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:to="chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The period of time after completion of a business combination during which the shares or warrant may not be transferred.</link:label>
    <link:label xlink:label="chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions On Transfer Period Of Time After Business Combination Completion</link:label>
    <link:label xlink:label="chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restrictions on transfer period of time after business combination completion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_SaleOfStockOtherOfferingCosts" xlink:label="chfw_SaleOfStockOtherOfferingCosts" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_SaleOfStockOtherOfferingCosts" xlink:to="chfw_SaleOfStockOtherOfferingCosts_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_SaleOfStockOtherOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of other offering costs incurred.</link:label>
    <link:label xlink:label="chfw_SaleOfStockOtherOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Other Offering Costs</link:label>
    <link:label xlink:label="chfw_SaleOfStockOtherOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other offering costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:label xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock price per share</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_SaleOfStockUnderwritingFees" xlink:label="chfw_SaleOfStockUnderwritingFees" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_SaleOfStockUnderwritingFees" xlink:to="chfw_SaleOfStockUnderwritingFees_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_SaleOfStockUnderwritingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of offering fees incurred and paid for underwriters.</link:label>
    <link:label xlink:label="chfw_SaleOfStockUnderwritingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Underwriting fees</link:label>
    <link:label xlink:label="chfw_SaleOfStockUnderwritingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriting fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="arc"/>
    <link:label xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of basic and diluted net income (loss) per ordinary share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:label xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant" xlink:label="chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant" xlink:to="chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cutoff price used to measure whether dilution of the warrant has occurred. Shares issued below this price will cause the exercise price of the warrant to be adjusted.</link:label>
    <link:label xlink:label="chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share PriceTrigger Used To Measure Dilution Of Warrant</link:label>
    <link:label xlink:label="chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price trigger used to measure dilution of warrant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:label xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the end (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning (in shares)</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_SponsorMember" xlink:label="chfw_SponsorMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_SponsorMember" xlink:to="chfw_SponsorMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_SponsorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for sponsor.</link:label>
    <link:label xlink:label="chfw_SponsorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sponsor [Member]</link:label>
    <link:label xlink:label="chfw_SponsorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sponsor</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc"/>
    <link:label xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption" xlink:label="chfw_StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption" xlink:to="chfw_StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock issued during period value change in value of class a ordinary shares subject to redemption.</link:label>
    <link:label xlink:label="chfw_StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Change In Value Of Class A Ordinary Shares Subject To Redemption</link:label>
    <link:label xlink:label="chfw_StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in value of Class A ordinary shares subject to redemption (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:type="resource" xml:lang="en-US">Stock issued during period shares new shares</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption" xlink:label="chfw_StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption" xlink:to="chfw_StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock issued during period value change in value of class a ordinary shares subject to redemption.</link:label>
    <link:label xlink:label="chfw_StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Value Change In Value Of Class A Ordinary Shares Subject To Redemption</link:label>
    <link:label xlink:label="chfw_StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in value of Class A ordinary shares subject to redemption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate purchase price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:label xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchased during the period ( in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:label xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchased during the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the end</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Stockholder's Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholder's Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_SubscriptionAgreementMember" xlink:label="chfw_SubscriptionAgreementMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_SubscriptionAgreementMember" xlink:to="chfw_SubscriptionAgreementMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_SubscriptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subscription Agreement [Member]</link:label>
    <link:label xlink:label="chfw_SubscriptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subscription Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:label xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Class A ordinary shares subject to possible redemption, 8,186,086 shares at redemption value</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_TemporaryEquityPolicyPolicyTextBlock" xlink:label="chfw_TemporaryEquityPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_TemporaryEquityPolicyPolicyTextBlock" xlink:to="chfw_TemporaryEquityPolicyPolicyTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_TemporaryEquityPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of accounting policy for temporary equity.</link:label>
    <link:label xlink:label="chfw_TemporaryEquityPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="chfw_TemporaryEquityPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class A Ordinary Shares Subject to Possible Redemption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:label xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock subject to possible redemption, issued (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:label xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Temporary equity, shares outstanding</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount" xlink:label="chfw_ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount" xlink:to="chfw_ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the threshold minimum aggregate fair market value as a percentage of the assets held in the Trust Account.</link:label>
    <link:label xlink:label="chfw_ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Minimum Aggregate Fair Market Value As Percentage Of Assets Held In Trust Account</link:label>
    <link:label xlink:label="chfw_ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold minimum aggregate fair market value as a percentage of the assets held in the Trust Account</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:label="chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:to="chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold number of business days before sending notice of redemption to warrant holders.</link:label>
    <link:label xlink:label="chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Number of Business Days Before Sending Notice of Redemption to Warrant Holders</link:label>
    <link:label xlink:label="chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold number of business days before sending notice of redemption to warrant holders</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination" xlink:label="chfw_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination" xlink:to="chfw_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the threshold percentage of outstanding voting securities of the target to be acquired by post-transaction company to complete business combination.</link:label>
    <link:label xlink:label="chfw_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Percentage Of Outstanding Voting Securities Of Target To Be Acquired By Post Transaction Company To Complete Business Combination</link:label>
    <link:label xlink:label="chfw_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold percentage of outstanding voting securities of the target to be acquired by post-transaction company to complete business combination</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="chfw_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:to="chfw_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares.</link:label>
    <link:label xlink:label="chfw_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Period After Business Combination In Which Specified Trading Days Within Any Specified Trading Day Period Commences</link:label>
    <link:label xlink:label="chfw_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:label="chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:to="chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of trading days after a business combination during which the share price is compared to the specified dilution trigger share price in order to determine whether the warrant exercise price should be adjusted.</link:label>
    <link:label xlink:label="chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Period After Business Combination Used To Measure Dilution of Warrant</link:label>
    <link:label xlink:label="chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading period after business combination used to measure dilution of warrant</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_TransactionCosts" xlink:label="chfw_TransactionCosts" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_TransactionCosts" xlink:to="chfw_TransactionCosts_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_TransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of transaction costs incurred.</link:label>
    <link:label xlink:label="chfw_TransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction Costs</link:label>
    <link:label xlink:label="chfw_TransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Transaction Costs</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:label="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:to="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The share price threshold that must be achieved in order to waive the restriction on transfer of shares during a restricted period after a business combination.</link:label>
    <link:label xlink:label="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Stock Price Trigger</link:label>
    <link:label xlink:label="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:to="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">When determining the condition for transfer of shares without restriction after a business combination, the number of consecutive trading days used to observe the share price.</link:label>
    <link:label xlink:label="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Consecutive Trading Days</link:label>
    <link:label xlink:label="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:label="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:to="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">When determining the condition for transfer of shares without restriction after a business combination, the number of days in which the share price must exceed the specified amount.</link:label>
    <link:label xlink:label="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Trading Days</link:label>
    <link:label xlink:label="chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:label xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Net income allocable to Class A ordinary shares subject to possible redemption</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_UnitsEachConsistingOfOneShareOfClassOrdinarySharesAndOneThirdOfRedeemableWarrantToAcquireOneClassOrdinaryShareMember" xlink:label="chfw_UnitsEachConsistingOfOneShareOfClassOrdinarySharesAndOneThirdOfRedeemableWarrantToAcquireOneClassOrdinaryShareMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_UnitsEachConsistingOfOneShareOfClassOrdinarySharesAndOneThirdOfRedeemableWarrantToAcquireOneClassOrdinaryShareMember" xlink:to="chfw_UnitsEachConsistingOfOneShareOfClassOrdinarySharesAndOneThirdOfRedeemableWarrantToAcquireOneClassOrdinaryShareMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_UnitsEachConsistingOfOneShareOfClassOrdinarySharesAndOneThirdOfRedeemableWarrantToAcquireOneClassOrdinaryShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Unit each consisting of one class common stock.</link:label>
    <link:label xlink:label="chfw_UnitsEachConsistingOfOneShareOfClassOrdinarySharesAndOneThirdOfRedeemableWarrantToAcquireOneClassOrdinaryShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Units Each Consisting Of One Share Of Class Ordinary Shares And One Third Of Redeemable Warrant To Acquire One Class Ordinary Share [Member]</link:label>
    <link:label xlink:label="chfw_UnitsEachConsistingOfOneShareOfClassOrdinarySharesAndOneThirdOfRedeemableWarrantToAcquireOneClassOrdinaryShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Units, each consisting of one share of Class A ordinary shares, and one-third of a redeemable Warrant to acquire one Class A ordinary share</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="chfw_UnitsIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_UnitsIssuedDuringPeriodSharesNewIssues" xlink:to="chfw_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of new units issued during the period.</link:label>
    <link:label xlink:label="chfw_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Units Issued During Period, Shares, New Issues</link:label>
    <link:label xlink:label="chfw_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Units, net of underwriting discounts</link:label>
    <link:label xlink:label="chfw_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of Units (in shares)</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_UnitsIssuedDuringPeriodValueNewIssues" xlink:label="chfw_UnitsIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_UnitsIssuedDuringPeriodValueNewIssues" xlink:to="chfw_UnitsIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_UnitsIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity impact of the value of new unit issued during the period.</link:label>
    <link:label xlink:label="chfw_UnitsIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Units Issued During Period, Value, New Issues</link:label>
    <link:label xlink:label="chfw_UnitsIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:type="resource" xml:lang="en-US">Unrealized gain on marketable securities held in Trust Account</link:label>
    <link:label xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:label xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on marketable securities held in Trust Account</link:label>
    <link:label xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on marketable securities held in Trust Account</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amounts accrued for the payment of interest and penalties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_WarrantExercisePeriodConditionOne" xlink:label="chfw_WarrantExercisePeriodConditionOne" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_WarrantExercisePeriodConditionOne" xlink:to="chfw_WarrantExercisePeriodConditionOne_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_WarrantExercisePeriodConditionOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The period of time after completion of a business combination before a warrant may be exercised.</link:label>
    <link:label xlink:label="chfw_WarrantExercisePeriodConditionOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Exercise Period Condition One</link:label>
    <link:label xlink:label="chfw_WarrantExercisePeriodConditionOne_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise period condition one</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_WarrantExercisePeriodConditionTwo" xlink:label="chfw_WarrantExercisePeriodConditionTwo" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_WarrantExercisePeriodConditionTwo" xlink:to="chfw_WarrantExercisePeriodConditionTwo_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_WarrantExercisePeriodConditionTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The alternate period of time after completion of an initial public offering before a warrant may be exercised.</link:label>
    <link:label xlink:label="chfw_WarrantExercisePeriodConditionTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Exercise Period Condition Two</link:label>
    <link:label xlink:label="chfw_WarrantExercisePeriodConditionTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise period condition two</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_WarrantExercisePriceAdjustmentMultiple" xlink:label="chfw_WarrantExercisePriceAdjustmentMultiple" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_WarrantExercisePriceAdjustmentMultiple" xlink:to="chfw_WarrantExercisePriceAdjustmentMultiple_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_WarrantExercisePriceAdjustmentMultiple_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted exercise price.</link:label>
    <link:label xlink:label="chfw_WarrantExercisePriceAdjustmentMultiple_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Exercise Price Adjustment Multiple</link:label>
    <link:label xlink:label="chfw_WarrantExercisePriceAdjustmentMultiple_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise price adjustment multiple</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_WarrantLiability" xlink:label="chfw_WarrantLiability" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_WarrantLiability" xlink:to="chfw_WarrantLiability_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_WarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant liability.</link:label>
    <link:label xlink:label="chfw_WarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant liability</link:label>
    <link:label xlink:label="chfw_WarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Liability</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_WarrantLiabilityPolicyTextBlock" xlink:label="chfw_WarrantLiabilityPolicyTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_WarrantLiabilityPolicyTextBlock" xlink:to="chfw_WarrantLiabilityPolicyTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_WarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">warrant liability[Policy text block].</link:label>
    <link:label xlink:label="chfw_WarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability [Policy Text Block]</link:label>
    <link:label xlink:label="chfw_WarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:label xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_WarrantRedemptionConditionMinimumSharePrice" xlink:label="chfw_WarrantRedemptionConditionMinimumSharePrice" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_WarrantRedemptionConditionMinimumSharePrice" xlink:to="chfw_WarrantRedemptionConditionMinimumSharePrice_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_WarrantRedemptionConditionMinimumSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum trading price for the reporting entity's stock which must be achieved as a condition for redemption of the warrant.</link:label>
    <link:label xlink:label="chfw_WarrantRedemptionConditionMinimumSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Redemption Condition Minimum Share Price</link:label>
    <link:label xlink:label="chfw_WarrantRedemptionConditionMinimumSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant redemption condition minimum share price</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo" xlink:label="chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo" xlink:to="chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum trading price for the reporting entity's stock which must be achieved as a condition for redemption of the warrant under another scenario.</link:label>
    <link:label xlink:label="chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Redemption Condition Minimum Share Price Scenario Two</link:label>
    <link:label xlink:label="chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant redemption condition minimum share price scenario two</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_WarrantRedemptionPriceAdjustmentMultiple" xlink:label="chfw_WarrantRedemptionPriceAdjustmentMultiple" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_WarrantRedemptionPriceAdjustmentMultiple" xlink:to="chfw_WarrantRedemptionPriceAdjustmentMultiple_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_WarrantRedemptionPriceAdjustmentMultiple_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted redemption price.</link:label>
    <link:label xlink:label="chfw_WarrantRedemptionPriceAdjustmentMultiple_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Redemption Price Adjustment Multiple</link:label>
    <link:label xlink:label="chfw_WarrantRedemptionPriceAdjustmentMultiple_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant redemption price adjustment multiple</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Warrants expiration term</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_WarrantsEachWholeWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf1150Member" xlink:label="chfw_WarrantsEachWholeWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf1150Member" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_WarrantsEachWholeWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf1150Member" xlink:to="chfw_WarrantsEachWholeWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf1150Member_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_WarrantsEachWholeWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf1150Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price.</link:label>
    <link:label xlink:label="chfw_WarrantsEachWholeWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf1150Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Each Whole Warrant Exercisable For One Class Ordinary Share At Exercise Price Of 1150 [Member]</link:label>
    <link:label xlink:label="chfw_WarrantsEachWholeWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf1150Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_WarrantsLiabilitiesMember" xlink:label="chfw_WarrantsLiabilitiesMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_WarrantsLiabilitiesMember" xlink:to="chfw_WarrantsLiabilitiesMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_WarrantsLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Liabilities Member.</link:label>
    <link:label xlink:label="chfw_WarrantsLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Liabilities [Member]</link:label>
    <link:label xlink:label="chfw_WarrantsLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Liabilities</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_WarrantsTextBlock" xlink:label="chfw_WarrantsTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_WarrantsTextBlock" xlink:to="chfw_WarrantsTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_WarrantsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants [Text Block].</link:label>
    <link:label xlink:label="chfw_WarrantsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants [Text Block]</link:label>
    <link:label xlink:label="chfw_WarrantsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">WARRANT LIABILITY</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted weighted average shares outstanding</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_WorkingCapitalLoansWarrantMember" xlink:label="chfw_WorkingCapitalLoansWarrantMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_WorkingCapitalLoansWarrantMember" xlink:to="chfw_WorkingCapitalLoansWarrantMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_WorkingCapitalLoansWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Working capital loans warrant.</link:label>
    <link:label xlink:label="chfw_WorkingCapitalLoansWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Working Capital Loans Warrant [Member]</link:label>
    <link:label xlink:label="chfw_WorkingCapitalLoansWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Working capital loans warrant</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent" xlink:label="chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent" xlink:to="chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered, excluding offering costs (due within one year or within the normal operating cycle if longer).</link:label>
    <link:label xlink:label="chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities Excluding Offering Costs Current</link:label>
    <link:label xlink:label="chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities - accrued expenses</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_AllocationOfInitialPublicOfferingCosts" xlink:label="chfw_AllocationOfInitialPublicOfferingCosts" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_AllocationOfInitialPublicOfferingCosts" xlink:to="chfw_AllocationOfInitialPublicOfferingCosts_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_AllocationOfInitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allocation of initial public offering costs.</link:label>
    <link:label xlink:label="chfw_AllocationOfInitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocation of Initial Public Offering Costs</link:label>
    <link:label xlink:label="chfw_AllocationOfInitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocation of initial public offering costs</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_CashDepositedInTrustAccount" xlink:label="chfw_CashDepositedInTrustAccount" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_CashDepositedInTrustAccount" xlink:to="chfw_CashDepositedInTrustAccount_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_CashDepositedInTrustAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash outflow from cash deposited in trust account.</link:label>
    <link:label xlink:label="chfw_CashDepositedInTrustAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Deposited In Trust Account</link:label>
    <link:label xlink:label="chfw_CashDepositedInTrustAccount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Investment of cash in Trust Account</link:label>
    <link:label xlink:label="chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in value of common stock subject to possible redemption</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Private Placement Units, net of warrant liability</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_ClassOrdinarySharesSubjectForRedemptionMember" xlink:label="chfw_ClassOrdinarySharesSubjectForRedemptionMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_ClassOrdinarySharesSubjectForRedemptionMember" xlink:to="chfw_ClassOrdinarySharesSubjectForRedemptionMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_ClassOrdinarySharesSubjectForRedemptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents about Class A ordinary shares subject for redemption.</link:label>
    <link:label xlink:label="chfw_ClassOrdinarySharesSubjectForRedemptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Ordinary Shares Subject For Redemption [Member]</link:label>
    <link:label xlink:label="chfw_ClassOrdinarySharesSubjectForRedemptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class A ordinary shares subject to possible</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_CommonStockSubjectToPossibleRedemptionShares" xlink:label="chfw_CommonStockSubjectToPossibleRedemptionShares" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_CommonStockSubjectToPossibleRedemptionShares" xlink:to="chfw_CommonStockSubjectToPossibleRedemptionShares_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_CommonStockSubjectToPossibleRedemptionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of the shares of common stock subject to possible redemption.</link:label>
    <link:label xlink:label="chfw_CommonStockSubjectToPossibleRedemptionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Subject To Possible Redemption, Shares</link:label>
    <link:label xlink:label="chfw_CommonStockSubjectToPossibleRedemptionShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Class A ordinary shares subject to possible redemption (in shares)</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_CommonStockSubjectToPossibleRedemptionValue" xlink:label="chfw_CommonStockSubjectToPossibleRedemptionValue" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_CommonStockSubjectToPossibleRedemptionValue" xlink:to="chfw_CommonStockSubjectToPossibleRedemptionValue_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_CommonStockSubjectToPossibleRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity impact of the value of common stock subject to possible redemption.</link:label>
    <link:label xlink:label="chfw_CommonStockSubjectToPossibleRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Subject To Possible Redemption, Value</link:label>
    <link:label xlink:label="chfw_CommonStockSubjectToPossibleRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Class A ordinary shares subject to possible redemption</link:label>
    <link:label xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Class A Ordinary Shares</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_DeferredUnderwritingFeePayable" xlink:label="chfw_DeferredUnderwritingFeePayable" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_DeferredUnderwritingFeePayable" xlink:to="chfw_DeferredUnderwritingFeePayable_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_DeferredUnderwritingFeePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of underwriting fee payable deferred during the period, classified as non-cash investing and financing activity.</link:label>
    <link:label xlink:label="chfw_DeferredUnderwritingFeePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Underwriting Fee Payable</link:label>
    <link:label xlink:label="chfw_DeferredUnderwritingFeePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred underwriting fee payable</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:label xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of key Inputs into the Binomial Lattice Simulation Model for the Private Placement Warrants and Public Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers out of level 3</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_FormationCosts" xlink:label="chfw_FormationCosts" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_FormationCosts" xlink:to="chfw_FormationCosts_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_FormationCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to formation costs.</link:label>
    <link:label xlink:label="chfw_FormationCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Formation Costs</link:label>
    <link:label xlink:label="chfw_FormationCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment of formation costs through issuance of Class B ordinary shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption" xlink:label="chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption" xlink:to="chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of initial classification of common stock subject to possible redemption, classified as non-cash investing and financing activity.</link:label>
    <link:label xlink:label="chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Classification Of Common Stock Subject To Possible Redemption</link:label>
    <link:label xlink:label="chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial classification of Class A ordinary shares subject to possible redemption</link:label>
    <link:label xlink:label="chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Initial classification of common stock subject to possible redemption</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_InitialClassificationOfWarrantLiability" xlink:label="chfw_InitialClassificationOfWarrantLiability" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_InitialClassificationOfWarrantLiability" xlink:to="chfw_InitialClassificationOfWarrantLiability_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_InitialClassificationOfWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial classification of warrant liability.</link:label>
    <link:label xlink:label="chfw_InitialClassificationOfWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Classification of Warrant Liability</link:label>
    <link:label xlink:label="chfw_InitialClassificationOfWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial classification of warrant liability</link:label>
    <link:label xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:label="chfw_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:to="chfw_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of maximum borrowing capacity of related party promissory note.</link:label>
    <link:label xlink:label="chfw_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Borrowing Capacity of Related Party Promissory Note</link:label>
    <link:label xlink:label="chfw_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity of related party promissory note</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
    <link:label xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (years)</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_MeasurementInputFairValueOfUnitsMember" xlink:label="chfw_MeasurementInputFairValueOfUnitsMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_MeasurementInputFairValueOfUnitsMember" xlink:to="chfw_MeasurementInputFairValueOfUnitsMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_MeasurementInputFairValueOfUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Fair Value of Units [Member]</link:label>
    <link:label xlink:label="chfw_MeasurementInputFairValueOfUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of Units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:label xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:label xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_NetProceedsFromInitialPublicOffering" xlink:label="chfw_NetProceedsFromInitialPublicOffering" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_NetProceedsFromInitialPublicOffering" xlink:to="chfw_NetProceedsFromInitialPublicOffering_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_NetProceedsFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow associated with the amount received from entity's first offering of stock to the public, net of underwriting discounts paid.</link:label>
    <link:label xlink:label="chfw_NetProceedsFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Proceeds From Initial Public Offering</link:label>
    <link:label xlink:label="chfw_NetProceedsFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of Units, net of underwriting discounts paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Related Parties</link:label>
    <link:label xlink:label="us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding balance of related party note</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_OfferingCostsPaidBySponsorFromProceedsFromIssuanceOfCommonStockOrdinaryShares" xlink:label="chfw_OfferingCostsPaidBySponsorFromProceedsFromIssuanceOfCommonStockOrdinaryShares" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_OfferingCostsPaidBySponsorFromProceedsFromIssuanceOfCommonStockOrdinaryShares" xlink:to="chfw_OfferingCostsPaidBySponsorFromProceedsFromIssuanceOfCommonStockOrdinaryShares_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_OfferingCostsPaidBySponsorFromProceedsFromIssuanceOfCommonStockOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of offering costs paid directly by Sponsor from proceeds from issuance of common stock during the period, classified as non-cash investing and financing activity.</link:label>
    <link:label xlink:label="chfw_OfferingCostsPaidBySponsorFromProceedsFromIssuanceOfCommonStockOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offering Costs Paid by Sponsor From Proceeds From Issuance of Common Stock Ordinary Shares</link:label>
    <link:label xlink:label="chfw_OfferingCostsPaidBySponsorFromProceedsFromIssuanceOfCommonStockOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering costs paid directly by Sponsor from proceeds from issuance of Class B ordinary shares</link:label>
    <link:label xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Formation and operational costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of offering costs</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_PercentageOfMinimumAcceptanceOfShareholdersOfTenderOfferProvision" xlink:label="chfw_PercentageOfMinimumAcceptanceOfShareholdersOfTenderOfferProvision" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_PercentageOfMinimumAcceptanceOfShareholdersOfTenderOfferProvision" xlink:to="chfw_PercentageOfMinimumAcceptanceOfShareholdersOfTenderOfferProvision_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_PercentageOfMinimumAcceptanceOfShareholdersOfTenderOfferProvision_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of minimum acceptance of shareholders of tender offer provision.</link:label>
    <link:label xlink:label="chfw_PercentageOfMinimumAcceptanceOfShareholdersOfTenderOfferProvision_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Minimum Acceptance of Shareholders of Tender Offer Provision</link:label>
    <link:label xlink:label="chfw_PercentageOfMinimumAcceptanceOfShareholdersOfTenderOfferProvision_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of minimum acceptance of shareholders of tender offer provision</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract" xlink:label="chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract" xlink:to="chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prior period adjustment restatement of statement of cash flows.</link:label>
    <link:label xlink:label="chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Period Adjustment Restatement Of Statement Of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract" xlink:label="chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract" xlink:to="chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prior period adjustment restatement of statement of operations.</link:label>
    <link:label xlink:label="chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Period Adjustment Restatement of Statement Of Operations [Abstract]</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_PriorPeriodRestatementOfBalanceSheetAbstract" xlink:label="chfw_PriorPeriodRestatementOfBalanceSheetAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_PriorPeriodRestatementOfBalanceSheetAbstract" xlink:to="chfw_PriorPeriodRestatementOfBalanceSheetAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_PriorPeriodRestatementOfBalanceSheetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prior period restatement of balance sheet [Abstract].</link:label>
    <link:label xlink:label="chfw_PriorPeriodRestatementOfBalanceSheetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Period Restatement Of Balance Sheet [Abstract]</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of Private Placement Units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Related Party Debt</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from promissory note - related party</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_PromissoryNoteWithRelatedPartyMember" xlink:label="chfw_PromissoryNoteWithRelatedPartyMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_PromissoryNoteWithRelatedPartyMember" xlink:to="chfw_PromissoryNoteWithRelatedPartyMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_PromissoryNoteWithRelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for promissory note with related party.</link:label>
    <link:label xlink:label="chfw_PromissoryNoteWithRelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Promissory Note With Related Party [Member]</link:label>
    <link:label xlink:label="chfw_PromissoryNoteWithRelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Promissory Note with Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Related Party Debt</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of promissory note - related party</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of promissory note - related party</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_RestatedMember" xlink:label="chfw_RestatedMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_RestatedMember" xlink:to="chfw_RestatedMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_RestatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restated.</link:label>
    <link:label xlink:label="chfw_RestatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restated [Member]</link:label>
    <link:label xlink:label="chfw_RestatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">As Restated</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_RestatementAbstract" xlink:label="chfw_RestatementAbstract" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_RestatementAbstract" xlink:to="chfw_RestatementAbstract_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_RestatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="srt_RestatementAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</link:label>
    <link:label xlink:label="srt_RestatementAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xlink:type="arc"/>
    <link:label xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl" xlink:type="arc"/>
    <link:label xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_RestatementLineItems" xlink:label="chfw_RestatementLineItems" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_RestatementLineItems" xlink:to="chfw_RestatementLineItems_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_RestatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restatement [Line Items]</link:label>
    <link:label xlink:label="chfw_RestatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement [Line Items]</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock" xlink:label="chfw_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock" xlink:to="chfw_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restatement of previously issued financial statements [Text block].</link:label>
    <link:label xlink:label="chfw_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Of Previously Issued Financial Statements [Text Block]</link:label>
    <link:label xlink:label="chfw_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Of Previously Issued Financial Statements</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_RestatementTable" xlink:label="chfw_RestatementTable" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_RestatementTable" xlink:to="chfw_RestatementTable_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_RestatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restatement [Table]</link:label>
    <link:label xlink:label="chfw_RestatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement [Table]</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_SaleOfPrivatePlacementUnitsShares" xlink:label="chfw_SaleOfPrivatePlacementUnitsShares" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_SaleOfPrivatePlacementUnitsShares" xlink:to="chfw_SaleOfPrivatePlacementUnitsShares_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_SaleOfPrivatePlacementUnitsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares sale of private placement units during the period.</link:label>
    <link:label xlink:label="chfw_SaleOfPrivatePlacementUnitsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Private Placement Units, Shares</link:label>
    <link:label xlink:label="chfw_SaleOfPrivatePlacementUnitsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Private Placement Units, net of warrant liability (in shares)</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_SaleOfPrivatePlacementUnitsValue" xlink:label="chfw_SaleOfPrivatePlacementUnitsValue" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_SaleOfPrivatePlacementUnitsValue" xlink:to="chfw_SaleOfPrivatePlacementUnitsValue_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_SaleOfPrivatePlacementUnitsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity impact of the value of sale of private placement units during the period.</link:label>
    <link:label xlink:label="chfw_SaleOfPrivatePlacementUnitsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Private Placement Units, Value</link:label>
    <link:label xlink:label="chfw_SaleOfPrivatePlacementUnitsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Private Placement Units, net of warrant liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl" xlink:type="arc"/>
    <link:label xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:label xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">As Previously Reported</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</link:label>
    <link:label xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of restatement of previously issued financial statements</link:label>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Class B ordinary shares to Sponsor(1) (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary Shares Subject to Possible Redemption</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_TransactionCostsAssociatedWithInitialPublicOffering" xlink:label="chfw_TransactionCostsAssociatedWithInitialPublicOffering" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_TransactionCostsAssociatedWithInitialPublicOffering" xlink:to="chfw_TransactionCostsAssociatedWithInitialPublicOffering_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_TransactionCostsAssociatedWithInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transaction costs associated with initial public offering.</link:label>
    <link:label xlink:label="chfw_TransactionCostsAssociatedWithInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction Costs Associated with Initial Public Offering</link:label>
    <link:label xlink:label="chfw_TransactionCostsAssociatedWithInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Transaction costs associated with initial public offering</link:label>
    <link:label xlink:label="chfw_TransactionCostsAssociatedWithInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs in connection with the initial public offering</link:label>
    <link:label xlink:label="chfw_UnitsIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:type="resource" xml:lang="en-US">Sale of Units, net of underwriting discounts, offering costs and warrant liability (in shares)</link:label>
    <link:label xlink:label="chfw_UnitsIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Units, net of underwriting discounts, offering costs and warrant liability</link:label>
    <link:label xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on marketable securities held in Trust Account</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_WarrantLiabilityFairValueDisclosure" xlink:label="chfw_WarrantLiabilityFairValueDisclosure" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_WarrantLiabilityFairValueDisclosure" xlink:to="chfw_WarrantLiabilityFairValueDisclosure_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_WarrantLiabilityFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant liability fair value disclosure</link:label>
    <link:label xlink:label="chfw_WarrantLiabilityFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability Fair Value Disclosure</link:label>
    <link:label xlink:label="chfw_WarrantLiabilityFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate value of warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Measurement Input</link:label>
    <link:loc xlink:href="chfw-20210331.xsd#chfw_WarrantsPerShare" xlink:label="chfw_WarrantsPerShare" xlink:type="locator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chfw_WarrantsPerShare" xlink:to="chfw_WarrantsPerShare_lbl" xlink:type="arc"/>
    <link:label xlink:label="chfw_WarrantsPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants per share.</link:label>
    <link:label xlink:label="chfw_WarrantsPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants per share</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">weighted average shares outstanding</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>28
<FILENAME>chfw-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 67.4 -->
<!-- Creation date: 6/23/2021 12:10:17 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#CoverPage" roleURI="http://Consonance.com/role/CoverPage" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#CondensedBalanceSheets" roleURI="http://Consonance.com/role/BalanceSheets" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#CondensedBalanceSheetsParenthetical" roleURI="http://Consonance.com/role/BalanceSheetsParenthetical" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#DescriptionOfOrganizationAndBusinessOperations" roleURI="http://Consonance.com/role/DescriptionOfOrganizationAndBusinessOperations" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPolicies" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#InitialPublicOffering" roleURI="http://Consonance.com/role/InitialPublicOffering" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#PrivatePlacement" roleURI="http://Consonance.com/role/PrivatePlacement" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#RelatedPartyTransactions" roleURI="http://Consonance.com/role/RelatedPartyTransactions" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#Commitments" roleURI="http://Consonance.com/role/Commitments" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#StockholdersEquity" roleURI="http://Consonance.com/role/StockholdersEquity" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#WarrantLiability" roleURI="http://Consonance.com/role/WarrantLiability" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#FairValueMeasurements" roleURI="http://Consonance.com/role/FairValueMeasurements" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#SubsequentEvents" roleURI="http://Consonance.com/role/SubsequentEvents" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#DescriptionOfOrganizationAndBusinessOperationsDetails" roleURI="http://Consonance.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#SummaryOfSignificantAccountingPoliciesBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#InitialPublicOfferingDetails" roleURI="http://Consonance.com/role/InitialPublicOfferingDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#PrivatePlacementDetails" roleURI="http://Consonance.com/role/PrivatePlacementDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#RelatedPartyTransactionsFounderSharesDetails" roleURI="http://Consonance.com/role/RelatedPartyTransactionsFounderSharesDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#CommitmentsDetails" roleURI="http://Consonance.com/role/CommitmentsDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#StockholdersEquityPreferredStockSharesDetails" roleURI="http://Consonance.com/role/StockholdersEquityPreferredStockSharesDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#StockholdersEquityCommonStockSharesDetails" roleURI="http://Consonance.com/role/StockholdersEquityCommonStockSharesDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#WarrantLiabilityDetails" roleURI="http://Consonance.com/role/WarrantLiabilityDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#FairValueMeasurementsDetails" roleURI="http://Consonance.com/role/FairValueMeasurementsDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#FairValueMeasurementsSummaryOfFairValueOfTheWarrantLiabilitiesDetails" roleURI="http://Consonance.com/role/FairValueMeasurementsSummaryOfFairValueOfTheWarrantLiabilitiesDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#SubsequentEventsDetails" roleURI="http://Consonance.com/role/SubsequentEventsDetails" />
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/CoverPage">
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_939139" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_939141" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_939139" xlink:to="loc_dei_DocumentInformationTable_939141" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_939142" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_939141" xlink:to="loc_us-gaap_StatementClassOfStockAxis_939142" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_939143" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_939142" xlink:to="loc_us-gaap_ClassOfStockDomain_939143" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_939149" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_939143" xlink:to="loc_us-gaap_CommonClassAMember_939149" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_939151" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_939143" xlink:to="loc_us-gaap_CommonClassBMember_939151" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_UnitsEachConsistingOfOneShareOfClassOrdinarySharesAndOneThirdOfRedeemableWarrantToAcquireOneClassOrdinaryShareMember" xlink:label="loc_chfw_UnitsEachConsistingOfOneShareOfClassOrdinarySharesAndOneThirdOfRedeemableWarrantToAcquireOneClassOrdinaryShareMember_939164" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_939143" xlink:to="loc_chfw_UnitsEachConsistingOfOneShareOfClassOrdinarySharesAndOneThirdOfRedeemableWarrantToAcquireOneClassOrdinaryShareMember_939164" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantsEachWholeWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf1150Member" xlink:label="loc_chfw_WarrantsEachWholeWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf1150Member_939172" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_939143" xlink:to="loc_chfw_WarrantsEachWholeWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf1150Member_939172" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_939144" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_939141" xlink:to="loc_dei_DocumentInformationLineItems_939144" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_939177" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_DocumentType_939177" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_939178" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_DocumentPeriodEndDate_939178" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_939179" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_939179" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_AmendmentDescription_939179" use="optional" order="11.001" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityRegistrantName_939179" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_939182" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityCurrentReportingStatus_939182" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_939186" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityInteractiveDataCurrent_939186" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_939187" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityFilerCategory_939187" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_939188" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntitySmallBusiness_939188" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_939189" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityEmergingGrowthCompany_939189" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_939191" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityExTransitionPeriod_939191" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_939192" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityShellCompany_939192" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_939194" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityCentralIndexKey_939194" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_939195" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_CurrentFiscalYearEndDate_939195" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_939209" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_Security12bTitle_939209" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_939211" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_TradingSymbol_939211" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_939212" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_SecurityExchangeName_939212" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_939215" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_939215" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_939234" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_DocumentFiscalYearFocus_939234" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_939258" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_DocumentFiscalPeriodFocus_939258" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_939197" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_AmendmentFlag_939197" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_939203" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_DocumentTransitionReport_939203" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_941954" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_EntityAddressStateOrProvince_941954" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_968680" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_939144" xlink:to="loc_dei_DocumentQuarterlyReport_968680" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/BalanceSheets">
    <link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent" xlink:label="chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" xlink:to="chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent" order="29.01" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_35" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_36" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35" xlink:to="loc_us-gaap_StatementTable_36" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_37" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_36" xlink:to="loc_us-gaap_StatementClassOfStockAxis_37" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_38" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_37" xlink:to="loc_us-gaap_ClassOfStockDomain_38" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_44" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_38" xlink:to="loc_us-gaap_CommonClassAMember_44" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_45" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_38" xlink:to="loc_us-gaap_CommonClassBMember_45" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_39" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_36" xlink:to="loc_us-gaap_StatementLineItems_39" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_40" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39" xlink:to="loc_us-gaap_AssetsAbstract_40" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_41" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_40" xlink:to="loc_us-gaap_AssetsCurrentAbstract_41" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_46" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_41" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_46" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_47" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_41" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_47" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_48" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_41" xlink:to="loc_us-gaap_AssetsCurrent_48" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_49" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_40" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_49" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_50" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_40" xlink:to="loc_us-gaap_Assets_50" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_968690" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_968690" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_968693" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_968690" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_968693" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_968694" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_968690" xlink:to="loc_us-gaap_LiabilitiesCurrent_968694" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantLiability" xlink:label="loc_chfw_WarrantLiability_939533" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" xlink:to="loc_chfw_WarrantLiability_939533" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_DeferredOfferingCostsNoncurrent" xlink:label="loc_chfw_DeferredOfferingCostsNoncurrent_52" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" xlink:to="loc_chfw_DeferredOfferingCostsNoncurrent_52" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_53" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" xlink:to="loc_us-gaap_Liabilities_53" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_54" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" xlink:to="loc_us-gaap_CommitmentsAndContingencies_54" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_55" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_55" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_43" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" xlink:to="loc_us-gaap_StockholdersEquityAbstract_43" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_56" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43" xlink:to="loc_us-gaap_PreferredStockValue_56" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_57" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43" xlink:to="loc_us-gaap_CommonStockValue_57" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_58" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43" xlink:to="loc_us-gaap_AdditionalPaidInCapital_58" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_59" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_59" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_60" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43" xlink:to="loc_us-gaap_StockholdersEquity_60" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_61" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_61" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/BalanceSheetsParenthetical">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_63" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_64" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_63" xlink:to="loc_us-gaap_StatementTable_64" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_65" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_64" xlink:to="loc_us-gaap_StatementClassOfStockAxis_65" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_66" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_65" xlink:to="loc_us-gaap_ClassOfStockDomain_66" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_68" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_66" xlink:to="loc_us-gaap_CommonClassAMember_68" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_69" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_66" xlink:to="loc_us-gaap_CommonClassBMember_69" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_67" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_64" xlink:to="loc_us-gaap_StatementLineItems_67" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_70" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_67" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_70" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_71" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_67" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_71" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_72" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_67" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_72" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_73" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_67" xlink:to="loc_us-gaap_PreferredStockSharesIssued_73" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_74" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_67" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_74" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_75" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_67" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_75" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_76" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_67" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_76" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_77" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_67" xlink:to="loc_us-gaap_CommonStockSharesIssued_77" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_78" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_67" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_78" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/DescriptionOfOrganizationAndBusinessOperations">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_161" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_162" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_161" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_162" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/SummaryOfSignificantAccountingPolicies">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_164" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_165" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_164" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_165" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/InitialPublicOffering">
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_InitialPublicOfferingAbstract" xlink:label="loc_chfw_InitialPublicOfferingAbstract_167" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_InitialPublicOfferingTextBlock" xlink:label="loc_chfw_InitialPublicOfferingTextBlock_168" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_InitialPublicOfferingAbstract_167" xlink:to="loc_chfw_InitialPublicOfferingTextBlock_168" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/PrivatePlacement">
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PrivatePlacementAbstract" xlink:label="loc_chfw_PrivatePlacementAbstract_170" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PrivatePlacementTextBlock" xlink:label="loc_chfw_PrivatePlacementTextBlock_171" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PrivatePlacementAbstract_170" xlink:to="loc_chfw_PrivatePlacementTextBlock_171" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/RelatedPartyTransactions">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_173" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_174" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_173" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_174" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/Commitments">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_176" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_177" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_176" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_177" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/StockholdersEquity">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_179" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_180" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_179" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_180" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/WarrantLiability">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_939867" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantsTextBlock" xlink:label="loc_chfw_WarrantsTextBlock_939870" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_939867" xlink:to="loc_chfw_WarrantsTextBlock_939870" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurements">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_182" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_183" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_182" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_183" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/SubsequentEvents">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_185" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_186" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_185" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_186" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_188" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_189" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_188" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_189" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_EmergingGrowthCompanyPolicyTextBlock" xlink:label="loc_chfw_EmergingGrowthCompanyPolicyTextBlock_190" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_188" xlink:to="loc_chfw_EmergingGrowthCompanyPolicyTextBlock_190" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_191" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_188" xlink:to="loc_us-gaap_UseOfEstimates_191" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_192" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_188" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_192" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_AssetsHeldInTrustAccountPolicyPolicyTextBlock" xlink:label="loc_chfw_AssetsHeldInTrustAccountPolicyPolicyTextBlock_193" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_188" xlink:to="loc_chfw_AssetsHeldInTrustAccountPolicyPolicyTextBlock_193" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantLiabilityPolicyTextBlock" xlink:label="loc_chfw_WarrantLiabilityPolicyTextBlock_939683" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_188" xlink:to="loc_chfw_WarrantLiabilityPolicyTextBlock_939683" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_TemporaryEquityPolicyPolicyTextBlock" xlink:label="loc_chfw_TemporaryEquityPolicyPolicyTextBlock_194" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_188" xlink:to="loc_chfw_TemporaryEquityPolicyPolicyTextBlock_194" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_195" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_188" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_195" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_196" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_188" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_196" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_197" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_188" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_197" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_198" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_188" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_198" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_969038" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_188" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_969038" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="loc_us-gaap_DerivativesReportingOfDerivativeActivity_969039" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_188" xlink:to="loc_us-gaap_DerivativesReportingOfDerivativeActivity_969039" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_199" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_188" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_199" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesTables">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_201" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_202" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_201" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_202" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_207" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_208" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_207" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_208" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_209" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_208" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_209" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_210" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_209" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_210" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_213" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_210" xlink:to="loc_us-gaap_IPOMember_213" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_214" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_210" xlink:to="loc_us-gaap_PrivatePlacementMember_214" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_215" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_210" xlink:to="loc_us-gaap_OverAllotmentOptionMember_215" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_208" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum" xlink:label="loc_chfw_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_216" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" xlink:to="loc_chfw_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum_216" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_chfw_UnitsIssuedDuringPeriodSharesNewIssues_217" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" xlink:to="loc_chfw_UnitsIssuedDuringPeriodSharesNewIssues_217" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_218" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" xlink:to="loc_us-gaap_SharePrice_218" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_UnitsIssuedDuringPeriodValueNewIssues" xlink:label="loc_chfw_UnitsIssuedDuringPeriodValueNewIssues_219" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" xlink:to="loc_chfw_UnitsIssuedDuringPeriodValueNewIssues_219" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_220" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" xlink:to="loc_us-gaap_AssetsHeldInTrust_220" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_AdditionsToAssetsHeldInTrust" xlink:label="loc_chfw_AdditionsToAssetsHeldInTrust_221" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" xlink:to="loc_chfw_AdditionsToAssetsHeldInTrust_221" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_TransactionCosts" xlink:label="loc_chfw_TransactionCosts_212" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" xlink:to="loc_chfw_TransactionCosts_212" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_SaleOfStockUnderwritingFees" xlink:label="loc_chfw_SaleOfStockUnderwritingFees_222" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_TransactionCosts_212" xlink:to="loc_chfw_SaleOfStockUnderwritingFees_222" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_DeferredOfferingCostsNoncurrent" xlink:label="loc_chfw_DeferredOfferingCostsNoncurrent_223" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_TransactionCosts_212" xlink:to="loc_chfw_DeferredOfferingCostsNoncurrent_223" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_SaleOfStockOtherOfferingCosts" xlink:label="loc_chfw_SaleOfStockOtherOfferingCosts_224" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_TransactionCosts_212" xlink:to="loc_chfw_SaleOfStockOtherOfferingCosts_224" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount" xlink:label="loc_chfw_ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount_225" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" xlink:to="loc_chfw_ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount_225" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination" xlink:label="loc_chfw_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination_226" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_211" xlink:to="loc_chfw_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination_226" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_228" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_229" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_228" xlink:to="loc_us-gaap_StatementTable_229" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_230" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_229" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_230" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_231" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_230" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_231" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_InitialPublicOfferingAndPrivatePlacementMember" xlink:label="loc_chfw_InitialPublicOfferingAndPrivatePlacementMember_233" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_231" xlink:to="loc_chfw_InitialPublicOfferingAndPrivatePlacementMember_233" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_232" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_229" xlink:to="loc_us-gaap_StatementLineItems_232" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_234" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_232" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_234" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_235" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_232" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_235" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_236" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_232" xlink:to="loc_us-gaap_CashFDICInsuredAmount_236" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_237" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_232" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_237" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails">
    <link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOrdinarySharesSubjectForRedemptionMember" xlink:label="chfw_ClassOrdinarySharesSubjectForRedemptionMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_242" xlink:to="chfw_ClassOrdinarySharesSubjectForRedemptionMember" order="13.01" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_239" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_240" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_239" xlink:to="loc_us-gaap_StatementTable_240" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_241" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_240" xlink:to="loc_us-gaap_StatementClassOfStockAxis_241" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_242" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_241" xlink:to="loc_us-gaap_ClassOfStockDomain_242" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassAOrdinarySharesSubjectForRedemptionMember" xlink:label="loc_chfw_ClassAOrdinarySharesSubjectForRedemptionMember_244" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_242" xlink:to="loc_chfw_ClassAOrdinarySharesSubjectForRedemptionMember_244" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonredeemablePreferredStockMember" xlink:label="loc_us-gaap_NonredeemablePreferredStockMember_245" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_242" xlink:to="loc_us-gaap_NonredeemablePreferredStockMember_245" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_243" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_240" xlink:to="loc_us-gaap_StatementLineItems_243" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_246" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_243" xlink:to="loc_us-gaap_NetIncomeLoss_246" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_247" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_243" xlink:to="loc_us-gaap_InvestmentIncomeInterest_247" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_248" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_243" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_248" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_249" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_243" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_249" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_250" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_243" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_250" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_251" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_243" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_251" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_252" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_243" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_252" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/InitialPublicOfferingDetails">
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_InitialPublicOfferingAbstract" xlink:label="loc_chfw_InitialPublicOfferingAbstract_254" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_255" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_InitialPublicOfferingAbstract_254" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_255" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_256" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_255" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_256" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_257" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_256" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_257" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_261" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_257" xlink:to="loc_us-gaap_IPOMember_261" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_262" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_257" xlink:to="loc_us-gaap_OverAllotmentOptionMember_262" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_263" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_257" xlink:to="loc_us-gaap_PrivatePlacementMember_263" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_258" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_255" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_258" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_259" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_258" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_259" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PublicWarrantsMember" xlink:label="loc_chfw_PublicWarrantsMember_264" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_259" xlink:to="loc_chfw_PublicWarrantsMember_264" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_255" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_chfw_UnitsIssuedDuringPeriodSharesNewIssues_265" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" xlink:to="loc_chfw_UnitsIssuedDuringPeriodSharesNewIssues_265" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_266" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" xlink:to="loc_us-gaap_SharePrice_266" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_NumberOfSharesIssuedPerUnit" xlink:label="loc_chfw_NumberOfSharesIssuedPerUnit_267" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" xlink:to="loc_chfw_NumberOfSharesIssuedPerUnit_267" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_chfw_NumberOfWarrantsIssuedPerUnit_268" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" xlink:to="loc_chfw_NumberOfWarrantsIssuedPerUnit_268" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_269" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_269" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_270" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_270" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_UnitsIssuedDuringPeriodValueNewIssues" xlink:label="loc_chfw_UnitsIssuedDuringPeriodValueNewIssues_271" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" xlink:to="loc_chfw_UnitsIssuedDuringPeriodValueNewIssues_271" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_AdditionsToAssetsHeldInTrust" xlink:label="loc_chfw_AdditionsToAssetsHeldInTrust_272" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" xlink:to="loc_chfw_AdditionsToAssetsHeldInTrust_272" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_273" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_260" xlink:to="loc_us-gaap_AssetsHeldInTrust_273" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/PrivatePlacementDetails">
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PrivatePlacementAbstract" xlink:label="loc_chfw_PrivatePlacementAbstract_275" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_276" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PrivatePlacementAbstract_275" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_276" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_277" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_276" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_277" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_278" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_277" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_278" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_282" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_278" xlink:to="loc_us-gaap_PrivatePlacementMember_282" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_279" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_276" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_279" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_280" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_279" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_280" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PrivatePlacementWarrantsMember" xlink:label="loc_chfw_PrivatePlacementWarrantsMember_283" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_280" xlink:to="loc_chfw_PrivatePlacementWarrantsMember_283" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_281" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_276" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_281" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_chfw_UnitsIssuedDuringPeriodSharesNewIssues_284" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_281" xlink:to="loc_chfw_UnitsIssuedDuringPeriodSharesNewIssues_284" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_285" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_281" xlink:to="loc_us-gaap_SharePrice_285" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_UnitsIssuedDuringPeriodValueNewIssues" xlink:label="loc_chfw_UnitsIssuedDuringPeriodValueNewIssues_286" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_281" xlink:to="loc_chfw_UnitsIssuedDuringPeriodValueNewIssues_286" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_NumberOfSharesIssuedPerUnit" xlink:label="loc_chfw_NumberOfSharesIssuedPerUnit_287" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_281" xlink:to="loc_chfw_NumberOfSharesIssuedPerUnit_287" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_NumberOfWarrantsIssuedPerUnit" xlink:label="loc_chfw_NumberOfWarrantsIssuedPerUnit_288" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_281" xlink:to="loc_chfw_NumberOfWarrantsIssuedPerUnit_288" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_289" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_281" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_289" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/RelatedPartyTransactionsFounderSharesDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_291" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_292" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_291" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_292" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_293" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_292" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_293" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_294" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_293" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_294" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_FounderSharesMember" xlink:label="loc_chfw_FounderSharesMember_300" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_294" xlink:to="loc_chfw_FounderSharesMember_300" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_295" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_292" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_295" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_296" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_295" xlink:to="loc_us-gaap_RelatedPartyDomain_296" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_SponsorMember" xlink:label="loc_chfw_SponsorMember_301" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_296" xlink:to="loc_chfw_SponsorMember_301" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_297" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_292" xlink:to="loc_us-gaap_StatementClassOfStockAxis_297" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_298" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_297" xlink:to="loc_us-gaap_ClassOfStockDomain_298" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_302" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_298" xlink:to="loc_us-gaap_CommonClassBMember_302" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_303" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_298" xlink:to="loc_us-gaap_CommonClassAMember_303" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_299" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_292" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_299" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_304" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_304" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_305" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_305" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_306" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_306" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_307" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_307" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_308" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_us-gaap_CommonStockSharesIssued_308" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_309" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_309" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_NumberOfSharesSubjectToForfeiture" xlink:label="loc_chfw_NumberOfSharesSubjectToForfeiture_310" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_chfw_NumberOfSharesSubjectToForfeiture_310" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders" xlink:label="loc_chfw_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders_311" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_chfw_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders_311" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger" xlink:label="loc_chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_312" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger_312" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays" xlink:label="loc_chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_313" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays_313" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays" xlink:label="loc_chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_314" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays_314" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences" xlink:label="loc_chfw_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_315" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_299" xlink:to="loc_chfw_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences_315" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/CommitmentsDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_336" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_DeferredFeePerUnit" xlink:label="loc_chfw_DeferredFeePerUnit_337" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_336" xlink:to="loc_chfw_DeferredFeePerUnit_337" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_DeferredOfferingCostsNoncurrent" xlink:label="loc_chfw_DeferredOfferingCostsNoncurrent_338" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_336" xlink:to="loc_chfw_DeferredOfferingCostsNoncurrent_338" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/StockholdersEquityPreferredStockSharesDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_340" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_341" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_340" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_341" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_342" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_340" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_342" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_343" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_340" xlink:to="loc_us-gaap_PreferredStockSharesIssued_343" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_344" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_340" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_344" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/StockholdersEquityCommonStockSharesDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_346" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_347" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_346" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_347" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_348" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_347" xlink:to="loc_us-gaap_StatementClassOfStockAxis_348" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_349" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_348" xlink:to="loc_us-gaap_ClassOfStockDomain_349" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_351" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_349" xlink:to="loc_us-gaap_CommonClassAMember_351" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_352" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_349" xlink:to="loc_us-gaap_CommonClassBMember_352" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_350" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_347" xlink:to="loc_us-gaap_ClassOfStockLineItems_350" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_353" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_350" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_353" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_354" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_350" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_354" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_CommonStockNumberOfVotesPerShare" xlink:label="loc_chfw_CommonStockNumberOfVotesPerShare_355" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_350" xlink:to="loc_chfw_CommonStockNumberOfVotesPerShare_355" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_356" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_350" xlink:to="loc_us-gaap_CommonStockSharesIssued_356" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_357" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_350" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_357" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_358" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_350" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_358" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/WarrantLiabilityDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_361" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_362" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_361" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_362" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_363" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_362" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_363" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_364" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_363" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_364" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_365" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_362" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_365" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_366" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_365" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_366" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_367" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_366" xlink:to="loc_us-gaap_WarrantMember_367" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PrivatePlacementWarrantsMember" xlink:label="loc_chfw_PrivatePlacementWarrantsMember_374" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_366" xlink:to="loc_chfw_PrivatePlacementWarrantsMember_374" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PublicWarrantsMember" xlink:label="loc_chfw_PublicWarrantsMember_375" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_366" xlink:to="loc_chfw_PublicWarrantsMember_375" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_368" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_362" xlink:to="loc_srt_StatementScenarioAxis_368" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_369" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_368" xlink:to="loc_srt_ScenarioUnspecifiedDomain_369" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xlink:label="loc_chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_376" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_369" xlink:to="loc_chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_376" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" xlink:label="loc_chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_377" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_369" xlink:to="loc_chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_377" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_370" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_362" xlink:to="loc_us-gaap_StatementClassOfStockAxis_370" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_371" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_370" xlink:to="loc_us-gaap_ClassOfStockDomain_371" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_362" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantExercisePeriodConditionOne" xlink:label="loc_chfw_WarrantExercisePeriodConditionOne_379" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantExercisePeriodConditionOne_379" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantExercisePeriodConditionTwo" xlink:label="loc_chfw_WarrantExercisePeriodConditionTwo_380" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantExercisePeriodConditionTwo_380" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_381" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_381" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xlink:label="loc_chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_382" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_382" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xlink:label="loc_chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_383" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_383" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantRedemptionConditionMinimumSharePrice" xlink:label="loc_chfw_WarrantRedemptionConditionMinimumSharePrice_384" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantRedemptionConditionMinimumSharePrice_384" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo" xlink:label="loc_chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo_385" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo_385" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="loc_chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_386" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_386" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="loc_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_387" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_387" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="loc_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_388" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_388" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:label="loc_chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_389" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_389" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RedemptionPeriod" xlink:label="loc_chfw_RedemptionPeriod_390" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_RedemptionPeriod_390" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant" xlink:label="loc_chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant_392" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant_392" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:label="loc_chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_393" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_393" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:label="loc_chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_394" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_394" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantExercisePriceAdjustmentMultiple" xlink:label="loc_chfw_WarrantExercisePriceAdjustmentMultiple_395" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantExercisePriceAdjustmentMultiple_395" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantRedemptionPriceAdjustmentMultiple" xlink:label="loc_chfw_WarrantRedemptionPriceAdjustmentMultiple_396" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantRedemptionPriceAdjustmentMultiple_396" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:label="loc_chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_397" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_397" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementsDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_399" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_400" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_399" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_400" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_401" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_400" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_401" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_402" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_401" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_402" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_407" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_402" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_407" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_940082" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_402" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_940082" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_403" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_400" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_403" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_404" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_403" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_404" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_408" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_404" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_408" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_940093" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_400" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_940093" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_940095" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_940093" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_940095" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PublicWarrantsMember" xlink:label="loc_chfw_PublicWarrantsMember_940098" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_940095" xlink:to="loc_chfw_PublicWarrantsMember_940098" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PrivatePlacementWarrantsMember" xlink:label="loc_chfw_PrivatePlacementWarrantsMember_940111" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_940095" xlink:to="loc_chfw_PrivatePlacementWarrantsMember_940111" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_405" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_400" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_405" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_406" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_405" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_406" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_409" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_406" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_409" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_940068" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_405" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_940068" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantLiability" xlink:label="loc_chfw_WarrantLiability_940072" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_940068" xlink:to="loc_chfw_WarrantLiability_940072" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementsSummaryOfFairValueOfTheWarrantLiabilitiesDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_940403" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_940408" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_940403" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_940408" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_940409" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_940408" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_940409" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_940412" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_940409" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_940412" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PrivatePlacementWarrantsMember" xlink:label="loc_chfw_PrivatePlacementWarrantsMember_940414" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_940412" xlink:to="loc_chfw_PrivatePlacementWarrantsMember_940414" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PublicWarrantsMember" xlink:label="loc_chfw_PublicWarrantsMember_940416" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_940412" xlink:to="loc_chfw_PublicWarrantsMember_940416" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_940417" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_940408" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_940417" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_941691" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_940417" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_941691" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantsLiabilitiesMember" xlink:label="loc_chfw_WarrantsLiabilitiesMember_940418" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_941691" xlink:to="loc_chfw_WarrantsLiabilitiesMember_940418" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940419" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_940408" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940419" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_940420" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940419" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_940420" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_940421" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940419" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_940421" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_941849" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940419" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_941849" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/SubsequentEventsDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_948207" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_948209" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_948207" xlink:to="loc_us-gaap_StatementTable_948209" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_948210" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_948209" xlink:to="loc_us-gaap_StatementClassOfStockAxis_948210" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_948211" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_948210" xlink:to="loc_us-gaap_ClassOfStockDomain_948211" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_948242" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_948209" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_948242" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_948244" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_948242" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_948244" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_948245" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_948244" xlink:to="loc_us-gaap_SubsequentEventMember_948245" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_948249" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_948209" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_948249" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_948250" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_948249" xlink:to="loc_us-gaap_EquityComponentDomain_948250" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_948252" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_948250" xlink:to="loc_us-gaap_CommonStockMember_948252" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_948253" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_948209" xlink:to="loc_us-gaap_TypeOfArrangementAxis_948253" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_948254" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_948253" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_948254" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_BusinessCombinationAgreementMember" xlink:label="loc_chfw_BusinessCombinationAgreementMember_948255" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_948254" xlink:to="loc_chfw_BusinessCombinationAgreementMember_948255" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_SubscriptionAgreementMember" xlink:label="loc_chfw_SubscriptionAgreementMember_948257" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_948254" xlink:to="loc_chfw_SubscriptionAgreementMember_948257" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_InvestorAxis" xlink:label="loc_chfw_InvestorAxis_948259" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_948209" xlink:to="loc_chfw_InvestorAxis_948259" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_InvestorDomain" xlink:label="loc_chfw_InvestorDomain_948260" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_InvestorAxis_948259" xlink:to="loc_chfw_InvestorDomain_948260" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PipeInvestorsMember" xlink:label="loc_chfw_PipeInvestorsMember_948262" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_InvestorDomain_948260" xlink:to="loc_chfw_PipeInvestorsMember_948262" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_948264" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_948209" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_948264" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_948265" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_948264" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_948265" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PipeWarrantsMember" xlink:label="loc_chfw_PipeWarrantsMember_948268" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_948265" xlink:to="loc_chfw_PipeWarrantsMember_948268" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_948212" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_948209" xlink:to="loc_us-gaap_StatementLineItems_948212" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_948217" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_948212" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_948217" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_948218" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_948212" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_948218" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_948221" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_948212" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_948221" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_948222" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_948212" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_948222" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_948224" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_948212" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_948224" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_948226" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_948212" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_948226" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_948227" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_948212" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_948227" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</link:presentationLink>
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#StatementOfOperations" roleURI="http://Consonance.com/role/StatementOfOperations" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#StatementOfChangesInStockholdersEquity" roleURI="http://Consonance.com/role/StatementOfChangesInStockholdersEquity" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#StatementOfChangesInStockholdersEquityParenthetical" roleURI="http://Consonance.com/role/StatementOfChangesInStockholdersEquityParenthetical" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#StatementOfCashFlows" roleURI="http://Consonance.com/role/StatementOfCashFlows" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#RestatementOfPreviouslyIssuedFinancialStatements" roleURI="http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatements" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#RestatementOfPreviouslyIssuedFinancialStatementsTables" roleURI="http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#FairValueMeasurementsTables" roleURI="http://Consonance.com/role/FairValueMeasurementsTables" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#RestatementOfPreviouslyIssuedFinancialStatementsAdditionalInformationDetails" roleURI="http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatementsAdditionalInformationDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#RestatementOfPreviouslyIssuedFinancialStatementsSummaryOfRestatementOfPreviouslyIssuedFinancialStatementsDetails" roleURI="http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatementsSummaryOfRestatementOfPreviouslyIssuedFinancialStatementsDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#WarrantsDetails" roleURI="http://Consonance.com/role/WarrantsDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#FairValueMeasurementsSummaryOfKeyInputsIntoTheBinomialLatticeSimulationModelForThePrivatePlacementWarrantsAndPublicWarrantsDetails" roleURI="http://Consonance.com/role/FairValueMeasurementsSummaryOfKeyInputsIntoTheBinomialLatticeSimulationModelForThePrivatePlacementWarrantsAndPublicWarrantsDetails" />
<link:roleRef xlink:type="simple" xlink:href="chfw-20210331.xsd#FairValueMeasurementsAdditionalInformationDetails" roleURI="http://Consonance.com/role/FairValueMeasurementsAdditionalInformationDetails" />
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/StatementOfOperations">
    <link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassAOrdinarySharesSubjectForRedemptionMember" xlink:label="chfw_ClassAOrdinarySharesSubjectForRedemptionMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_83" xlink:to="chfw_ClassAOrdinarySharesSubjectForRedemptionMember" order="17.01" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_80" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_81" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_80" xlink:to="loc_us-gaap_StatementTable_81" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_82" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_81" xlink:to="loc_us-gaap_StatementClassOfStockAxis_82" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_83" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_82" xlink:to="loc_us-gaap_ClassOfStockDomain_83" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOrdinarySharesSubjectForRedemptionMember" xlink:label="loc_chfw_ClassOrdinarySharesSubjectForRedemptionMember_86" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_83" xlink:to="loc_chfw_ClassOrdinarySharesSubjectForRedemptionMember_86" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonredeemablePreferredStockMember" xlink:label="loc_us-gaap_NonredeemablePreferredStockMember_87" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_83" xlink:to="loc_us-gaap_NonredeemablePreferredStockMember_87" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_84" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_81" xlink:to="loc_us-gaap_StatementLineItems_84" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_88" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_84" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_88" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_89" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_84" xlink:to="loc_us-gaap_OperatingIncomeLoss_89" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_84" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_90" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85" xlink:to="loc_us-gaap_InvestmentIncomeInterest_90" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_TransactionCostsAssociatedWithInitialPublicOffering" xlink:label="loc_chfw_TransactionCostsAssociatedWithInitialPublicOffering_939555" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85" xlink:to="loc_chfw_TransactionCostsAssociatedWithInitialPublicOffering_939555" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_939559" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_939559" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_91" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_91" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_92" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_85" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_92" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_93" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_84" xlink:to="loc_us-gaap_NetIncomeLoss_93" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_94" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_84" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_94" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_95" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_84" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_95" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/StatementOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption" xlink:label="chfw_StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="chfw_StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption" order="25.01" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption" xlink:label="chfw_StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="chfw_StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption" order="25.02" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_100" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_101" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_100" xlink:to="loc_us-gaap_StatementTable_101" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_102" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_101" xlink:to="loc_us-gaap_StatementClassOfStockAxis_102" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_108" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_102" xlink:to="loc_us-gaap_ClassOfStockDomain_108" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_106" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_108" xlink:to="loc_us-gaap_CommonClassAMember_106" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_107" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_108" xlink:to="loc_us-gaap_CommonClassBMember_107" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_103" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_101" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_103" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_112" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_103" xlink:to="loc_us-gaap_EquityComponentDomain_112" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_109" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_112" xlink:to="loc_us-gaap_CommonStockMember_109" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_110" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_112" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_110" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_111" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_112" xlink:to="loc_us-gaap_RetainedEarningsMember_111" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_104" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_101" xlink:to="loc_us-gaap_StatementLineItems_104" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_104" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_113" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_us-gaap_StockholdersEquity_113" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_114" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_us-gaap_SharesIssued_114" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_115" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_115" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_116" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_116" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_UnitsIssuedDuringPeriodValueNewIssues" xlink:label="loc_chfw_UnitsIssuedDuringPeriodValueNewIssues_117" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_chfw_UnitsIssuedDuringPeriodValueNewIssues_117" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_chfw_UnitsIssuedDuringPeriodSharesNewIssues_118" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_chfw_UnitsIssuedDuringPeriodSharesNewIssues_118" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_SaleOfPrivatePlacementUnitsValue" xlink:label="loc_chfw_SaleOfPrivatePlacementUnitsValue_119" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_chfw_SaleOfPrivatePlacementUnitsValue_119" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_SaleOfPrivatePlacementUnitsShares" xlink:label="loc_chfw_SaleOfPrivatePlacementUnitsShares_120" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_chfw_SaleOfPrivatePlacementUnitsShares_120" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_CommonStockSubjectToPossibleRedemptionValue" xlink:label="loc_chfw_CommonStockSubjectToPossibleRedemptionValue_121" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_chfw_CommonStockSubjectToPossibleRedemptionValue_121" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_CommonStockSubjectToPossibleRedemptionShares" xlink:label="loc_chfw_CommonStockSubjectToPossibleRedemptionShares_122" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_chfw_CommonStockSubjectToPossibleRedemptionShares_122" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_123" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_us-gaap_NetIncomeLoss_123" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_124" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_us-gaap_StockholdersEquity_124" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_125" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_105" xlink:to="loc_us-gaap_SharesIssued_125" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/StatementOfChangesInStockholdersEquityParenthetical">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_127" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="loc_chfw_UnitsIssuedDuringPeriodSharesNewIssues_128" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_127" xlink:to="loc_chfw_UnitsIssuedDuringPeriodSharesNewIssues_128" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_129" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_127" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_129" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/StatementOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_134" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="30.01" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_131" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_132" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_131" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_132" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_138" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_132" xlink:to="loc_us-gaap_ProfitLoss_138" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_133" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_132" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_133" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_FormationCosts" xlink:label="loc_chfw_FormationCosts_139" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_133" xlink:to="loc_chfw_FormationCosts_139" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_140" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_133" xlink:to="loc_us-gaap_InvestmentIncomeInterest_140" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_939654" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_133" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_939654" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_TransactionCostsAssociatedWithInitialPublicOffering" xlink:label="loc_chfw_TransactionCostsAssociatedWithInitialPublicOffering_939650" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_133" xlink:to="loc_chfw_TransactionCostsAssociatedWithInitialPublicOffering_939650" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_141" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_133" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_141" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_134" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_133" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_134" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_142" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_134" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_142" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_143" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_134" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_143" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_144" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_132" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_144" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_135" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_131" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_135" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_CashDepositedInTrustAccount" xlink:label="loc_chfw_CashDepositedInTrustAccount_145" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_135" xlink:to="loc_chfw_CashDepositedInTrustAccount_145" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_146" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_135" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_146" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_136" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_131" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_136" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_NetProceedsFromInitialPublicOffering" xlink:label="loc_chfw_NetProceedsFromInitialPublicOffering_147" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_136" xlink:to="loc_chfw_NetProceedsFromInitialPublicOffering_147" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_148" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_136" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_148" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_149" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_136" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_149" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_150" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_136" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_150" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_151" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_136" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_151" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_152" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_136" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_152" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_153" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_131" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_153" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_155" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_131" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_155" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_137" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_131" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_137" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption" xlink:label="loc_chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption_156" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_137" xlink:to="loc_chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption_156" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption" xlink:label="loc_chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption_157" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_137" xlink:to="loc_chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption_157" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_InitialClassificationOfWarrantLiability" xlink:label="loc_chfw_InitialClassificationOfWarrantLiability_939661" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_137" xlink:to="loc_chfw_InitialClassificationOfWarrantLiability_939661" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_OfferingCostsPaidBySponsorFromProceedsFromIssuanceOfCommonStockOrdinaryShares" xlink:label="loc_chfw_OfferingCostsPaidBySponsorFromProceedsFromIssuanceOfCommonStockOrdinaryShares_158" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_137" xlink:to="loc_chfw_OfferingCostsPaidBySponsorFromProceedsFromIssuanceOfCommonStockOrdinaryShares_158" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_DeferredUnderwritingFeePayable" xlink:label="loc_chfw_DeferredUnderwritingFeePayable_159" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_137" xlink:to="loc_chfw_DeferredUnderwritingFeePayable_159" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatements">
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RestatementAbstract" xlink:label="loc_chfw_RestatementAbstract_939729" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock" xlink:label="loc_chfw_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock_939730" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_RestatementAbstract_939729" xlink:to="loc_chfw_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock_939730" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables">
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RestatementAbstract" xlink:label="loc_chfw_RestatementAbstract_939755" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_942780" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_RestatementAbstract_939755" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_942780" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementsTables">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_204" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_205" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_204" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_205" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_939891" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_204" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_939891" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_939894" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_204" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_939894" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatementsAdditionalInformationDetails">
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RestatementAbstract" xlink:label="loc_chfw_RestatementAbstract_942215" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PercentageOfMinimumAcceptanceOfShareholdersOfTenderOfferProvision" xlink:label="loc_chfw_PercentageOfMinimumAcceptanceOfShareholdersOfTenderOfferProvision_942216" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_RestatementAbstract_942215" xlink:to="loc_chfw_PercentageOfMinimumAcceptanceOfShareholdersOfTenderOfferProvision_942216" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatementsSummaryOfRestatementOfPreviouslyIssuedFinancialStatementsDetails">
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RestatementAbstract" xlink:label="loc_chfw_RestatementAbstract_942032" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RestatementTable" xlink:label="loc_chfw_RestatementTable_942033" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_RestatementAbstract_942032" xlink:to="loc_chfw_RestatementTable_942033" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_942034" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_RestatementTable_942033" xlink:to="loc_srt_RestatementAxis_942034" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_942035" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_942034" xlink:to="loc_srt_RestatementDomain_942035" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_942036" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_942035" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_942036" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_942037" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_942035" xlink:to="loc_srt_RestatementAdjustmentMember_942037" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RestatedMember" xlink:label="loc_chfw_RestatedMember_942886" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_942035" xlink:to="loc_chfw_RestatedMember_942886" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_942164" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_RestatementTable_942033" xlink:to="loc_us-gaap_StatementClassOfStockAxis_942164" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_942165" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_942164" xlink:to="loc_us-gaap_ClassOfStockDomain_942165" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_942166" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_942165" xlink:to="loc_us-gaap_CommonClassAMember_942166" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOrdinarySharesSubjectForRedemptionMember" xlink:label="loc_chfw_ClassOrdinarySharesSubjectForRedemptionMember_942839" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_942165" xlink:to="loc_chfw_ClassOrdinarySharesSubjectForRedemptionMember_942839" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonredeemablePreferredStockMember" xlink:label="loc_us-gaap_NonredeemablePreferredStockMember_942841" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_942165" xlink:to="loc_us-gaap_NonredeemablePreferredStockMember_942841" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RestatementLineItems" xlink:label="loc_chfw_RestatementLineItems_942038" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_RestatementTable_942033" xlink:to="loc_chfw_RestatementLineItems_942038" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PriorPeriodRestatementOfBalanceSheetAbstract" xlink:label="loc_chfw_PriorPeriodRestatementOfBalanceSheetAbstract_942818" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_RestatementLineItems_942038" xlink:to="loc_chfw_PriorPeriodRestatementOfBalanceSheetAbstract_942818" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantLiability" xlink:label="loc_chfw_WarrantLiability_942062" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PriorPeriodRestatementOfBalanceSheetAbstract_942818" xlink:to="loc_chfw_WarrantLiability_942062" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_942064" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PriorPeriodRestatementOfBalanceSheetAbstract_942818" xlink:to="loc_us-gaap_Liabilities_942064" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_942156" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PriorPeriodRestatementOfBalanceSheetAbstract_942818" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_942156" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_942158" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PriorPeriodRestatementOfBalanceSheetAbstract_942818" xlink:to="loc_us-gaap_CommonStockValue_942158" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_942160" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PriorPeriodRestatementOfBalanceSheetAbstract_942818" xlink:to="loc_us-gaap_AdditionalPaidInCapital_942160" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_942161" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PriorPeriodRestatementOfBalanceSheetAbstract_942818" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_942161" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_942162" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PriorPeriodRestatementOfBalanceSheetAbstract_942818" xlink:to="loc_us-gaap_StockholdersEquity_942162" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract" xlink:label="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract_942824" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_RestatementLineItems_942038" xlink:to="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract_942824" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_942827" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract_942824" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_942827" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_AllocationOfInitialPublicOfferingCosts" xlink:label="loc_chfw_AllocationOfInitialPublicOfferingCosts_942828" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract_942824" xlink:to="loc_chfw_AllocationOfInitialPublicOfferingCosts_942828" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_942831" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract_942824" xlink:to="loc_us-gaap_NetIncomeLoss_942831" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_942832" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract_942824" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_942832" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_942833" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract_942824" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_942833" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract" xlink:label="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract_942826" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_RestatementLineItems_942038" xlink:to="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract_942826" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_942830" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract_942826" xlink:to="loc_us-gaap_NetIncomeLoss_942830" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_AllocationOfInitialPublicOfferingCosts" xlink:label="loc_chfw_AllocationOfInitialPublicOfferingCosts_942829" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract_942826" xlink:to="loc_chfw_AllocationOfInitialPublicOfferingCosts_942829" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_942834" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract_942826" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_942834" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_InitialClassificationOfWarrantLiability" xlink:label="loc_chfw_InitialClassificationOfWarrantLiability_942835" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract_942826" xlink:to="loc_chfw_InitialClassificationOfWarrantLiability_942835" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption" xlink:label="loc_chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption_942837" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract_942826" xlink:to="loc_chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption_942837" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption" xlink:label="loc_chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption_942838" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract_942826" xlink:to="loc_chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption_942838" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_317" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_318" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_317" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_318" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_319" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_318" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_319" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_320" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_319" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_320" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PromissoryNoteWithRelatedPartyMember" xlink:label="loc_chfw_PromissoryNoteWithRelatedPartyMember_324" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_320" xlink:to="loc_chfw_PromissoryNoteWithRelatedPartyMember_324" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_AdministrativeSupportAgreementMember" xlink:label="loc_chfw_AdministrativeSupportAgreementMember_325" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_320" xlink:to="loc_chfw_AdministrativeSupportAgreementMember_325" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RelatedPartyLoansMember" xlink:label="loc_chfw_RelatedPartyLoansMember_326" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_320" xlink:to="loc_chfw_RelatedPartyLoansMember_326" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_321" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_318" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_321" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_322" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_321" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_322" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WorkingCapitalLoansWarrantMember" xlink:label="loc_chfw_WorkingCapitalLoansWarrantMember_327" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_322" xlink:to="loc_chfw_WorkingCapitalLoansWarrantMember_327" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_323" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_318" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_323" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" xlink:label="loc_chfw_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_328" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_323" xlink:to="loc_chfw_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote_328" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_329" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_323" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_329" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_330" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_323" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_330" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth" xlink:label="loc_chfw_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_331" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_323" xlink:to="loc_chfw_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth_331" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_332" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_323" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_332" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_MaximumLoansConvertibleIntoWarrants" xlink:label="loc_chfw_MaximumLoansConvertibleIntoWarrants_333" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_323" xlink:to="loc_chfw_MaximumLoansConvertibleIntoWarrants_333" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOfWarrantOrRightPriceOfWarrantsOrRights" xlink:label="loc_chfw_ClassOfWarrantOrRightPriceOfWarrantsOrRights_334" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_323" xlink:to="loc_chfw_ClassOfWarrantOrRightPriceOfWarrantsOrRights_334" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/WarrantsDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_361" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_362" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_361" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_362" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_363" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_362" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_363" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_364" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_363" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_364" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_365" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_362" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_365" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_366" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_365" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_366" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_367" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_366" xlink:to="loc_us-gaap_WarrantMember_367" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PrivatePlacementWarrantsMember" xlink:label="loc_chfw_PrivatePlacementWarrantsMember_374" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_366" xlink:to="loc_chfw_PrivatePlacementWarrantsMember_374" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PublicWarrantsMember" xlink:label="loc_chfw_PublicWarrantsMember_375" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_366" xlink:to="loc_chfw_PublicWarrantsMember_375" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_368" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_362" xlink:to="loc_srt_StatementScenarioAxis_368" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_369" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_368" xlink:to="loc_srt_ScenarioUnspecifiedDomain_369" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member" xlink:label="loc_chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_376" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_369" xlink:to="loc_chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member_376" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member" xlink:label="loc_chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_377" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_369" xlink:to="loc_chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member_377" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_370" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_362" xlink:to="loc_us-gaap_StatementClassOfStockAxis_370" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_371" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_370" xlink:to="loc_us-gaap_ClassOfStockDomain_371" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_362" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantExercisePeriodConditionOne" xlink:label="loc_chfw_WarrantExercisePeriodConditionOne_379" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantExercisePeriodConditionOne_379" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantExercisePeriodConditionTwo" xlink:label="loc_chfw_WarrantExercisePeriodConditionTwo_380" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantExercisePeriodConditionTwo_380" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_381" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_381" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement" xlink:label="loc_chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_382" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement_382" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective" xlink:label="loc_chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_383" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective_383" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantRedemptionConditionMinimumSharePrice" xlink:label="loc_chfw_WarrantRedemptionConditionMinimumSharePrice_384" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantRedemptionConditionMinimumSharePrice_384" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo" xlink:label="loc_chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo_385" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo_385" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="loc_chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_386" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_386" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays" xlink:label="loc_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_387" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays_387" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays" xlink:label="loc_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_388" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays_388" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders" xlink:label="loc_chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_389" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders_389" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RedemptionPeriod" xlink:label="loc_chfw_RedemptionPeriod_390" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_RedemptionPeriod_390" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant" xlink:label="loc_chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant_392" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant_392" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant" xlink:label="loc_chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_393" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant_393" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant" xlink:label="loc_chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_394" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant_394" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantExercisePriceAdjustmentMultiple" xlink:label="loc_chfw_WarrantExercisePriceAdjustmentMultiple_395" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantExercisePriceAdjustmentMultiple_395" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantRedemptionPriceAdjustmentMultiple" xlink:label="loc_chfw_WarrantRedemptionPriceAdjustmentMultiple_396" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_WarrantRedemptionPriceAdjustmentMultiple_396" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion" xlink:label="loc_chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_397" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_372" xlink:to="loc_chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion_397" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementsSummaryOfKeyInputsIntoTheBinomialLatticeSimulationModelForThePrivatePlacementWarrantsAndPublicWarrantsDetails">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_940143" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_940147" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_940143" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_940147" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_940149" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_940147" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_940149" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_940151" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_940149" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_940151" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_940157" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_940151" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_940157" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_940160" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_940151" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_940160" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_940162" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_940151" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_940162" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_940169" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_940151" xlink:to="loc_us-gaap_MeasurementInputExercisePriceMember_940169" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_MeasurementInputFairValueOfUnitsMember" xlink:label="loc_chfw_MeasurementInputFairValueOfUnitsMember_940171" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_940151" xlink:to="loc_chfw_MeasurementInputFairValueOfUnitsMember_940171" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_940178" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_940147" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_940178" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_940179" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_940178" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_940179" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</link:presentationLink>
<link:presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940479" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" order="12.01" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_940457" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_940458" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_940457" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_940458" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_940460" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_940458" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_940460" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_940462" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_940460" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_940462" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PrivatePlacementWarrantsMember" xlink:label="loc_chfw_PrivatePlacementWarrantsMember_940463" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_940462" xlink:to="loc_chfw_PrivatePlacementWarrantsMember_940463" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_PublicWarrantsMember" xlink:label="loc_chfw_PublicWarrantsMember_940464" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_940462" xlink:to="loc_chfw_PublicWarrantsMember_940464" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_940468" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_940458" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_940468" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_940469" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_940468" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_940469" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantsLiabilitiesMember" xlink:label="loc_chfw_WarrantsLiabilitiesMember_940474" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_940469" xlink:to="loc_chfw_WarrantsLiabilitiesMember_940474" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940479" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_940458" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940479" use="optional" order="1000000" preferredLabel="http://www.xbrl.org/2003/role/label" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantLiabilityFairValueDisclosure" xlink:label="loc_chfw_WarrantLiabilityFairValueDisclosure_940492" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940479" xlink:to="loc_chfw_WarrantLiabilityFairValueDisclosure_940492" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_940503" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940479" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_940503" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<link:loc xlink:type="locator" xlink:href="chfw-20210331.xsd#chfw_WarrantsPerShare" xlink:label="loc_chfw_WarrantsPerShare_941899" />
<link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_940479" xlink:to="loc_chfw_WarrantsPerShare_941899" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
</link:presentationLink>
</link:linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g40894g03t65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g03t65.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[19F4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q :X            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      T$    &
M  )F   %<0    8 1 !3 %  ,@ T #@    !
M  $             !7$   )F                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   )F     %)G:'1L;VYG   %<0    9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "9@    !29VAT;&]N9P  !7$    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     0X0DE-! P     "^\    !    H    $<
M  '@  "%(   "], &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( $< H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
M 00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B
M,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8G
ME*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"
M! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"
MDD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25
MQ-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _
M /54DDDE*22224I))))2DDDDE*22224I0M<YE3W,&YS6DM;XD#0*:%DE[<>T
MUSZ@8XL@2=T>V DISNGY^7=?0RPA[;:G/?#8@A]C0[_HM8M9<UT3,NNS,1@>
MYXLQGOOU)U]2W:ZV?S]RUSE=2VS]DUX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MD(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A&)_MKI)ZU6 I!4?Y!03@
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MFZA,6:QV^X/7F4ZS%6[?;W$F2@I<=U#JFVV.];*FRY'WK2590-^*RDK;GJZ
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MP[)[.R*RA%1+RE0"E+2YRV([+ D<+D"^L:/MUM-BM%M+*PJ65R\*6N5+7U:
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MX4MW)N<K#G>QL(3']164\5E]O-NZ6JV.$F2E-3,F2\N=0S*)7UJ4J25$,>T
M^YM!& Z(NC3%:'I'734DE7\(HIH4*F8@&84R^IF$9@4$JS%:0!+:SAPQ'U7V
MYX$\;DX:0 @K2HXSDJ"AR?SD@9&, 5Y&EU$V:N8F;(,K*HLKLG,' 8A*C?\
MJ-AOUCZ!JD"4H2DS<[2Q9R#8E)(M:X9K:7$>F5IW)27#G)QDDY\#C(X'NS5P
M%!5PPY:-[;QBD#D[) OI:X]-1'8:4%!1!)]<YR<X.$\#V#&,#RI$V4IUW]H=
MQ]F.2D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"
MD(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(VJ&4G'_.
M:0CSYX) X41M.=J2HCDYP #GWC!XJ28F:M)3)4$3#^%1RL.+YG3<.+\8B%B6
M<Y!(3N )WMH+[]WTC'?VF.RWJ36]\>UOH%$=ZZOLI^=[.]OCJN"FT*[F2TY@
MI4^A(" TK8%=YE2QL%>1>GC[/F,=)BE5>$U,BEK1VE**I2>L4E,_>J;+0',Q
M(=MWC'H'HTZ6*?9^F1AE<G)("BE$]>4!"'0 %/*6H  *[3D'0N\0$NG2+J]9
M'O1;ETZU<PZG=ZS=ME/,DY()CKCO/,.?!) QGBO#^)] 72;@M3*PQ6&UU4:.
M;-_G2:-4Z4H$94Y9DM,Q"AV7[*F9CHS^C\,V]V1Q:6FH.,X8@I2"TVJE2E D
M,04S#+.IOV=1>*@TKV>NM6KY[#$31%X@L.JV+N-]83;(,=*@"'7N]4XMT(.#
ML2SN4. 0,UN6S?V?=O\ :"OII%9155'(*T!<VHIA)0$F8D%2C,$H%@22'N!N
M<QCMI>E;9?!Z9::3$:.JGY242Z:>F:HJ3F# H2L!RW .=^ARX=GKHZSTAT6B
MS/K,J^3YGIM\G(2Z&7Y:V$(0B,E:SMBLI04MA(0D$J.P9.?HET3=&W_9ULNC
M YD],^:JLGU\V8DL N?+D2R@?S)@.7J=Q8OH+OX[V]VQF[6XW,Q%:<LM-/+I
MI*0$D]7*5,5F44I2 5%:OZ7  !.AB0[)6&DA:<+2D;N, JQDX'LS75U=@,+@
M%K?6[^C\8T$**B7[W]^Q'*#D#/%1%P'X1-&M1A"D(4A"D(4A"D(Z;R"7=V"?
M5 QM\P2<Y'/NY^RHVRFU^+L /?*(!)SYLS  6)W]WOYQ /MW=FFW=;>EMUN%
MAM#">HNDV5W;3L]M@"1+0T@N3[<M8PE27XP4$Y2H[\ >L,5F<$Q1=%4)!61)
M6<JDJL$J<@$.'9[$BS&[-&^;#;55F"8O(E]>44RU@$K*!+!((':4@@"Y=RSZ
MLT?+?-G2(DE^'+97%EQ7W8TB*YPY&D,%27V%ISPMHC*@1Q[, 5U.AF_>D%3=
MA0SI-\I! RLH .#J[L;79X]F4U4A<G#\1IE)J?ODF343#)6F:G^8')=!4D:"
M[)8$ @.QG=\G@W/U1V@FM-15.>@W[06L[9>E-'U#$DV">S##A'.TRW&BD^!4
M0E.":UO:1(D24K89D3$+2]VRS):B1=CO.MAKN,<ZZ:*JD^X4$\*EIG2YLF8I
M)4G."F?1*NEWL$DD$ @:V+F*75#2>I>DFO-0Z"U-!?@W6QS9<5 ?!*Y,/T@F
M'.864[51)<,A+#0)6RHD*.0:S&'K36R4343Y<P*2" %(S@VLI(<@@Z@Z!F8L
M8VS9#:.7B<A"S42I@6E*D@+ENQR$!20 7N020X(;?% B\Y&[. 4Y*@E*E!&T
M%:VP>"ZE&2UCQ<V'W5?=4I"AF4"@/F#][:<['6VHWG:IZYBJA+(*91)S3% A
M #%B5$!+&S.6>VIC(U\GGTOU7JW5VLNJ3,!U&G-$:.U%%BW8;4M3=33K>%1X
M#&TC>J$TV'9#J2I"G'@C)*"*UG:.ND)1)IDJ2HS)B H!0)"0MU/OTL'(UW1Q
M'I/QF5U])0RZF1,F3)LM/5RURUD K904!F9@H"[.6(+/&.^\7>2N\WAZ>M2I
MZ[I<ES5.+!/I8G/B6H_1_+''(&.!@'BMEH2])).4OU2"S$$J* >&X.;:MX1T
MK9^DG2-F\.G)5VI@1G_"2 :>4H.+M<D.V@%[7N)TNMAU'?GKE.,=O3&CHW\J
M-5R)QQ#%KMCB5M05;<ER1=)IC6]F/D!U+[G' !DP^0JLKI=,)<V9-G3420B6
MDK6"O59"2DI2B6%+426L_.-)Z9]K96Q>P.)8G/Q.DI)LNDJ9B$SZFFD*6I$F
M:0E F@YCF8,$W)2!<B+CN]6NL6O]16RQV?5MZ1<+W.19=-:?LDH6QF"N0Z&(
MELC,L)V,L)84XXXI:E=WM[Y:LA8'8)FRN#4& U"YM/*ESI:EJ7/6)@4&E))Z
MQ16ZE @EU.HNUK1\&L5Z8>D+I.VJF4&%8KU=-*Q>=** JA>;(2N8E.0*HDK,
MM2IR&*5D$ ER \9/K/:6KMH[IKT4U/=X=UT78I5HC:JN[0<9D7B_)7ONESA2
M4)#PCMW%;\=@K*@EIL$*/C7 :S#ZV5/FUE.%H2L*4CLDA,M(="25%24DN,S?
MU%SR]=5&+X1B-#@FSE>C^;+2A%=D*@9RB9*R2$=6;LIE)4-7#,(R+]-.S#TE
MZ=W1G46G+"Z+NRV/1IUQ?DSW66G-J@67%N;<8/D@':KV<'4J_:W$Z^0,.GK5
MU<@"4&EY0R04L%Y;CM'11>^L;YA/1_L]@]4JMPV0)2%K4N3+7,61+3V2D!,R
M:I0(RABO,0SN[1)]"2VSC;GC P,> QX  #/. ,>RM;NDN7+Z][Z_/YL^^-Q4
MQ "0S  >'GW7>/$O-GAWVVSK7<8K<V!<8DB)+BO(W-/QWT*9=9<22!M6VM23
MR.%9S561-73U:9TM654LI(4&L4J2H$ N";.!RB6HE2ZRDF4T\ IF)4E226<%
M*D\0=^KOSM?'EUG[(O1?2VC]1:FC1YUHDQ@)$"*B=*,!<]R4T8\1I@.*0#(=
M4F.@E)#1<#AP$&MW3M?C&,?=]FW5,EX@TC^7(+A,E'7OG2EPW4A^TG0WN7Y/
MB71YLMA(J=IJ^7-5)H2:B?*3-F*4L39O5 )1*F(FE6><D@"]GND&(/=I/4O4
M:?H[3/472-T?TE?NGUL:MVMV=-N%+DRT.I[B-?4N.)W*C1'0['E)PI:71WV
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MYQ.QOR+C95ZPQN\N!42P+&QX&Q?N@4J&J2.\$?6+@;D^&Y.?9D?OI$L:Y!.
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MX!X&>"H)!^S)'V4A'5C7&%,0IR,^V\A*UMJ4VH*"5MDA:%$$X4DC!!\Z*!2
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MJQ_I58W +$$&[:\8S,M06A"AH4@W]_2+F%0"0/'(\O#P\?W5CU*+D!FTB>.
MMD-)V_G!*L9'&XDGGQ/B?#W5$60!R8<;^_V@FQ?<X-N0'I&,+Y2#MM2>RGHV
MU6;1*H#G5'6ZWVK*J>V),:R6QHH;DWAR.'$AQU!4?1VU H6O;OS_ %9WG8C9
M88U5=9.D39]-+4ZY,H$+G*(S%.GX4L"H.-27M%C5U(0.K,]%/F<&?,5E3+%V
M)4Q9RP%C?OO\Q>M>U)UDZ@37)6M>JVK+\N0ZJ4F/(NSS,%3JWE9D,P8A8C10
MXH*0PVVEE+(0<!S.:[O3X!LS(0)$S!3)F$$'-(EI4[%GN23=]'TT=XP<R7B
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M>\7/JSH\7-*K@]MBVFTS8*")#Z&U(4XXE3V.[QR1R!S6*PK9U"JZ8%J9(F*
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M,4X_;^T6Y$,F/Z5#N41F6AEE<RVNL.N/&W)7)4VEUELHP97H[3B3W*@3N5N
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MRJ"\@0LJ*DI"2HJ0HH78$V4D$@G1QN)T#F 2I92A"4J4I24I2M(6DDJ [25
M@@:LW=>/F_[07:RZC]4M0WFT,7I5GT7"NTEBV6>WI2R9+5NDO1VY[\C:72\^
MXUWC2$K0 #RD[J^<FWOVA-M)>U>*TU)54DFAHU+D4R13$KRJD2E',O.E145.
M78 90+V?Z0[!=!FQ^'X9A<RKPTU5;5T4R;639AEE/6$I.5$M4M24I#L-2S.V
MD22[$':RU[+Z@63I%K2[)O%CNL7T"PSI3#*)EN=@I#C$-:VDH*F%,-EI)6E2
MBH))5P#6]] O33M+M%M')V>QBID3Z2MJ"L/)(F)SY 1+5F44Z%MR7(U$<ZZ<
M.AO9;!=EJS:C9VC71XC2550*A"5),F9) "GR94)!2M0(2E@UV>,D74W3.J+]
MK+3%WAZ:<U';;'9[T'&$38L5CYRF+B)C)6'I+:DN-I846W$)6/77OVD"O<,K
M(B;5H2&"$H4AR27*%*NX&\VX/H\>(Q,6)=*I3$K6OK V@"PD,'MV2;C?O,55
MT&TG>]+:>N[-]M+UD?NU^FW)-L=F,S?1F7XT%M*$/L.NH4DK861ZVX$J]4 B
MH2P,B57S+2%+?\QU &@#-HXOK%6<)8F*$JZ 2Q/!SR&YHOTV%)0$J\4\#[!X
M?J_\JGBE'GK=7Z<EC.&UME2@!SG>!X_9_P Q4Q ZI2FNE8 \4J/U ^?&*>8B
M<$[C*S-SSE/T$8.?EE2AB#TC+9Y<N%X2K.%%6R+E(.X'@9.,8X\.!BMPV05G
M6N6IBD#,S"Q2Y!!W!Q<-QY1XI^V5,,O!MG2D(S3JBJ0HE(+A(I5  M93W)!W
MWWQCQ[!"PYVAXS*G%%M&A]5!L()2I(,:.\?7&%G+BE$[B00<'(P1L6.+_P"Z
MY->.S43IB1-(/\L]J8D$(T20E" .Y][1YX^SJD3=OIA4M3)P7%,H0TL!D4ZM
M$)2&S*)8Z[K"(I:IEK3J[4Z@4D-:DOSR$E.4A;URDMK!23@IV^"<<*]8DBLC
M*EH1AE*H%3UB):9ZBHNPDIF_RRS([;[C:S[XY#M74SAM?M.DE,Q,G&L6R=8D
M3%!\3J$$E2W))2@.IA=R=6B9':*(1V7>R6ZEUSO'[/J!*B5D8"7Y#(" G"49
M;'.T#)];WG#2$)->I:BHE)"@RR0X*&!%[N+AN&IO'?.E52YG19T<3UK4J;.I
ML2F+45%B9=7,EL 7#% NDDO?2.M\GX6QVF--,I4K:BQW]U"MZE+;4(1X2M6Y
M00HC)2?5*LDU<[03E3J>2%Y09<U!2 &9@IGU#@$AF#Z&,?\ 9B0)O2%,F$J&
M7"IB1D"4!6:II@0I*0,WXG+A\P?4!H::FD+3>;TP%GN6K[?%I1G@*=G.DGRX
M)!.T< D\>S)450:C#YZYB96<I"73+ M+"P@OQ#,^_P HX7CM5.J-H*^;,4"3
MBE1V0G*D%53U;I #))2D9F8DNH]HDQ./MIOJ1T^['!00DH[/UK4"D$*!-TN
MR#XC@9R.<^?AC%;,SLLRL0 AE5RBZD@G\$KC9K,.'A'?.GR8L[(=$\L?A.Q>
M&S,P_P 1*TS\30G*NR@EBIP;6!UU[?R>SZW=;=7RX0LJZ#ZR0HJ&"4AV,2%*
M&TJ'K$G<5?G'.35#&UC[T0R0.ND'\(']2=Y=K@=[=\93[*\Q::_;'M$OL\H
MG7\%?XNZE.]X@--D+5.N16M2LJEI+86H-CO92U*VMI("0".$IP,>1/)S=.LG
M"42B61D*G#)462H74+DD%BYCR_55"_OE7+.5EUDR821V@OK",J""&E@K*L@[
M)5E)#AXG=VU7%)T5V6UA1)7T6L2@3RI)<9:<64G@@$I&00H8X(YK!X20C$9@
M#G+/F %1)[(0MB7+$\3OX</2W3\>JV9Z*I"65*7LA@U00OM*$R?AM,J84J-P
MDDG*+Y1OTBO_ )*IQ,KM":E2ZE!W=.;LHA"0A*4IE((2D)P G 'JCCP_32VG
MG*%%3J2LDKF)0<Q*B<Q4!KH[/9@+6C8_L< SMO<1IUG^7)PN?4RT) 2$S9:Y
M&4  90DN00 "=Y:,<G4TASJ7U*&$ISU UN=R$@*.[4EU6 5$$X0MQ2T 8PK!
M.<8K=\,3U&'X8N7<SY5.N;F)4"9E.%J8.,HS <6%H^Y^S\XC!\-2)<I)FX=2
MK,Q,M*9J5*D(*BB8!F2_+B3J[S^^2: /:L;'*2OI]J N%)([S^EVHC>,X."-
MPQCDD\YXUG;EA1!3!RI#V8,2@L -&T_35]$Z0T=70KF!<PJ+ YUE0N4C0\D]
MSW81]2$<^L1]3=GSR3S^CW5R9 L%.7(!/!RQ,<)?, 6 MNM';J>$*0A2$*0A
M2$*0A2$4]?K]"T]$5.N#SC48*(44M%Q8P?%*4@G'LX.0?.D(H\=6-)''],F\
MX_\ Y>[CG]%0<<1YPCE_G4TE_?YG^6O?NHXXCS$(?SJ:2_O\S_+7OW4<<1YB
M$/YU-)?W^9_EKW[J..(\Q"'\ZFDO[_,_RU[]U''$>8A#^=327]_F?Y:]^ZCC
MB/,0A_.II+^_S/\ +7OW4<<1YB$/YU-)?W^9_EKW[J..(\Q"/)G=4-**0LB7
M))RO!,%[S!]@\_LXYJPQ%*I.%5TV^7*3O=S,18#>PTOXF)I)3-J*.6&S*J5R
MP"6[24*)[APXMS$?*_U F(>UQK)YM3@0YJF[+QDI!)GN < @)&Q"1@83D9QG
M)KY(=(Z2O:NN6>T.NF7:X'426(+:%@"V@UL\?9S9.G2,!P-&4%1PQ8U)=3LH
MWYJ+/<;A81779[NC,;KCTKEON*0S'UE:77E!!6H!3X2L[<;E$Y'ADG!QS67Z
M(:69/Z1]E^K!S?>*/3=_-):WD2&U!C5^E],NDZ,-MQ,;_P"7*MW+.P  =]Q<
MG?R:T?36WU(T>AQ*'94G<UZI @O.#GO=H(P0H#!())P>?$U]94CJE3):RRA+
MD:ZL49M>YGTX1\C)X*IV8.R0"2]NTD;P!=^6OR[9ZI:1:!+<N8HD\CYO?W'/
MM)"B0/(>0X&!4V8<1YQ)&YOJOI1>=TN:C&,9MSQSG_X1X4S#B/.$<G\ZFDO[
M_,_RU[]U''$>8A#^=327]_F?Y:]^ZCCB/,0A_.II+^_S/\M>_=1QQ'F(1#7M
M5ZKME_BZ<-LD/.E+\I?K,EKU0HYSO'&,)]XQP<YK(T9<@<"?,LU_#?ZQROI-
M.29ADLEBI")@W@)6B9KO<D/;0VTBP?1JZ1;=U!M<R4H(9#5P;Y25K4MRTK2G
M.W  W$#.!P3@>V^G#M)'%22WB-U@=[ZV\8T+8HMCRR=!)F]X_P!UF:WMN/ZQ
M;^[R$+NUT4"G\I-F.)W9*0@25GR\<>SQ\!]M29O#:B]];>P_[OAZ\G^)8Z00
M3UM20=+A:7?Y>+AM(O+K:YQY723IQ$:65/0G9BGMR2GAU' 1R!RH \>S -6P
M+3";#YZ9OKQ.I/&T;9C2\NRN&_Y>NY"ZY1(\VNX-[;Q%$],)[,36EHDO*4&T
M*?!(&<E4=P $#P'O]N.*K/8\O#1GU;ZD=^D8+9>H J0M3A(47'PA^&^S;^=X
MH5V2EUQXI(6%R'EHQZ@3ND9&[=[,\8\<<YJHC1?,:OO).OCQWD1B<37GJ9P=
MR"GS*[.V@L;<;O>]YM<W:)(Z2],82%*+\%J>9(VD(RXM[U<D<@\'<#QCRJR3
M_BGP_2-SVE4!LGAH+VF7T O,FC=WA]+6X1XG2NX-0[GJ!4E82AW1UW: 0"O*
MW$,*&XCPY43Q[<\#PO)@N&(LE/S?<+!GW:LUHM-E%!,Z:^IPR4'W.3[Y1:I3
M@2I\<'"E<C@>HE)'!Y! /@#C.?=B3CQMKWEOU[HU*B(ZZNXLN[$_TK(&F_BS
MW&^T7YZN76++TWTN::7N7 TLU&>3M*0'$)(QN. 2"L\^_P #Q5O)_P 9=G_F
M&VO'Y?(#5HW#:M0-!LJ'N,-I"Q&F:3,"7N+N%!N5^?N=FF_P+#KZ1.N3BFHH
MM<I.&T*=<"@D('JH&3X^ Q^RH5MT'5[$NU@#I:SZ_M=LAT<7Q^:EQ>0IMY?J
MEDNVEDV=OG$_T]5='Y&)<P'(Y^;G>/?6(S#B/..ZQS*ZJZ2 SZ=,./+YN>'^
ME''$>8A''_.SI+^^3?\ +G:..(\Q"-JNJVD%@A4N:0000;<[@@C!'Z11T\1Y
MB$:#JIH].[$J9ZR@LYM[IRH  'G.#@#PQ^LT<<1YB$;1U2T:D83)F)&5G";>
M\.5G*O CQ//N/ABCCB/,0C4]4]&D@F3+) (!-N<R <YQ[/$\^/-'3Q'F(1$;
MMPZ\T[?.SAK^!;Y,I;[J;%L2J$XA(VWJ*%;BH >) )SD>.>#62P7M5R""&"U
M OW  B[%W8.=^D;KT=@G;'!RENQ/E*43N!F!(W:@E+AF8.\?/PE"=F<#@D>?
M@ "/#[3[ZZ*K_ TT^C.?,Q[*GWQ:3Q%,ECP_D-XL-T7XU-+C.]GWI?#0HE]G
M4NK5. A>W"W&P-N2<>/'V9\:QTI)$^<HZ*1)2/ K!Y[^'B\:+@X4-M<0/%"K
MM_YLAQONVO+RBPY0I "B0,>MDYP #GRY\/T_ZW<P (TN6N[\'[M?ESMO%->?
MB-Q9*QP8%4S7N;W>+]]HN?'N>O;"N(HEM'3;0<<I*5;MS-NDI(258)3@CG)X
MQSYU:TB"A"W.L^<0=S*F.+>C[WO:-"V##;.8@-_W\D^*)C'A?7R>*>Z"R6;=
MUOZ7RY!6AIC5]L4I2$%:TG<ZDX2/$@$^1\? FJM8EZ.I3QEJ'!W #^/]HS.V
M3_[*8F W_P#62;: CK46]]^Z/I=;ZGZ3;;0!,E @+!_H+QVDC//'(RL\\#Q_
M3S.7VITT#^E3GP#GU[O(>)0'HUS19*%L2]W*E[M')%KLPW.T=EOJOI)* /39
MGOQ;W2 <#(J 4,R[C\9Y&]]_)H)NB6?S(!\_V:.3^=G27]\F_P"7.U%QQ'F(
MC#^=G27]\F_Y<[1QQ'F(0_G9TE_?)O\ ESM''$>8A#^=G27]\F_Y<[1QQ'F(
M1YEWZIZ2<MEP"9<SO%0Y(23!=1ZQ:7CUO ?I&#X'BK>JF(13SEK4 A,M147&
MC6WC>W]XO,/&:NI19NOEN^C!0)'B 1'RB768';K=W@O>TJY2U-G:$#875D>K
MQZP/F.4DDYSDGY!;4R*.=M9C)*@0\Y3@N21)0W]7?ISW:?:+")<M5!A60,31
M ABX8$/>SNPXZ%]PB_\ V2+M'@]HGII*D%0;:NCZG%AH.K ,5P9 R3X#(_.P
M/LK=>@26E'2+@?5%U??@FP!/5I%F;-J3OMWDF.6]-=,#T:;4@C^FI*7)%\TL
MJ/ '7G;>(^CT]3M))6[LE20DN#<DP'L!39R<#&.3DC \>3[*^J,FGF";6EG*
M)4LJ>P8R5'5KVW%GT+O'R>JIR$"D2]ES)B4D7N)H!!WAB>]QN>_?1U6TB$@>
MER\9SQ;G""?;X#GC'Z*I2EI5+000Q2-3RY^QI%PL%*U ZA1!WW>]][&SQO\
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M33C6[;F?SM:*VK70K5.I5MJPA_45V4R5CD(5<I) < Y&><G@@XY&#623-/\
M"L+UL)>E[?=D<=UG&H9R^D<?VM &V&U XX]BX8-=L4JVN-7!.C<@!$P^T)<8
M\GLQ=D^*TLEZ-:[[WZ=I#8*I3Y3W2C^<,>.23D?#&4TT"M46.N@/^EQ\B+6
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M_8R!_P"T;%$BREX'6J#D,!+$I2@_)@P8OI&.OJ+<&G.I745Q!);>UYK)QHJ
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MRY4<W&5G.4%)$ASU5)\/:#G R/?Q\@,6DE6)XU-4AU_>%)*R 595(4_:+EB
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MDD8/K"/DIX\<8YQXX\Z=C_+\H,>7F/6+L]+7UOW2X*7 F1@F.WAV2UW07GQ
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M L@B6L$*_*1H0;C>(][LH_EM?31XDVI0SXCU4+!)\? D#/EGQ%1J[LUP_?\
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MN@';'!SJ3,DW:S=:DMO?0&PYC6/FJ%X(/EX#S\.#_H.?_/'4"DF0P#7-V_S
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MS%7"4%(F A9_"DNSN002!P?D7V@9*CT2[3)0A2E*PI*$)2DE2EH7*44!(U4
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M0^H[D-%1QZRP,C 5CV C-2B8Z2-2"1K\_I8Z[XGZ,Z2H5-FKF)4D#,RF+?\
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MZ.7E^T(XG%,-@O8;0Z@$API2E7=I!4L[E)X0@9W$D)2"<XR:IS<F0E1.1C8
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M(C_SZ=*TM-1T?^FUFY2RA) ,I.=IRHC].=O!XP:V7HBF(1M_LPE6&S$+,ZC
M/\07.S#K#VB,@ 4=<KV9M#&K=,2)\KHOVW755J K_9RJ["Y:"HDY7#*6<P=]
M!J7!M'T4:UZI=,]!W$0-7:^TAH^XO-K?BLZCOEOA/.Q%.KW.M19LE@+0L@A*
MCC;DXY%?4<8E02#/E594G++I>R$++NAP<Z$DL 1Q;2PCY9IPK:;$T-A\N8:5
MTO4R*5,U2%!LC)E@+)4I)22% "ZB"QBW^@>TCT#USKS4>@]&=2M'3=<0/05W
M"' E6]V3=.^A1W([D1U$A29NUI:4D1U.;#D'D$"G*KL)G3&D+.8D.Z)@)9@&
M*P-=PYO>,IB^RFVM%ALB?5KG*I@D@";3)EB4#G)S(6HE(.5R2+:/:)*("0$D
MI; 4A.5)2 HJ!5GO "0%^>/$>=9M)1E# A.YW(Y6-Q;S^NEJEY4I25RUS05=
M8$2T(R_AU4D]ISI8;S=XY,H]WP_VJ+HY>7[13R*X?,>L,H]WP_VHZ.7E^T,B
MN'S'K#*/=\/]J.CEY?M#(KA\QZQ2VM(<6?IR[(EQ&I328A*FG&^\"@!A&Q !
M]8CDDCW^)JF=2VA]^'U;OB2;0TM>@R:X RB D@HSV&C %.[@7?>=(\CIU8[)
M;;!&-H@0(2UJ4F4N'%9:<6O!)2X6LY(!QA6/: 3F@42-7.KOKN87YGC%&5A5
M#0$)H4HR$C,TLH+.27<J/'ESCH:SZ<6R^2X=ZB6ZWNWF X%!]Z*SWLI&XJ 4
ML\!Q!(VJ.?/%-UB?TTOP\N&^*4_!Z"JK$U,^3+[))"\KG5PX%[:/W[BT>9*E
M:EOT)>GG[%&6A8[N6J;$!CN)0, -!8#:0-HR0!N ('B )22V_5@-=3WV?FT9
M.=)IIX%&M(%$I/\ -4SMD2%( 0R5WF!G!MJ;._!.=TGT)T+<=2W&UR5PH2F7
MKDQIFSNSID@RGVHZ$(APFGI3H:<<25]VT0A"2HX2":A-F)D)S32 EV=B=Q9Q
M?0"Q^FD0PC9ZD$R8FF2@((<G*4DCLW+K!-V# M>._J?0EIU0+=J>!;(2KN&6
M);(EPFDO.,/M)=91(2YA0>;R00KU@<I(!!Q,%9TI6G\*@&U%B'T-[ZL>>IBP
MJ]G\.77&95H2#*4KJR$E3N5)/X5<&!)=V&Z.K<GM1WNWC3LBPQW24!E]3T)/
MHI2!MRWN(;3M3P",@>_%1<_4OOO['D^L38A22*DB2E(5(L%%20;/<L2^A(+$
MD^%ZQT3HVW:/M:XD./&9=ENB3*5'82W^4 3M94$#UDIP><_VCSX5$. X)%V\
M/U-]SMK;?-24%%AZ.KII:?N[9U'*QZU0&>Q*E;A?\.\!R8IS4W3V!<+O'U':
M;3;1>8:E/*6[#94ETD[]ZBO;N=!'!/) R,<"I2;V)W/KO%[M[L#%BG"Z6HK4
M3E24"Y*B4@;]X)=V?<7 N"T>5=?Y0:MAFQ2K#'6"@-O.RHBDMG!V*4P%C8GG
M^TGA((YP*C<\>'AHWS_3?&7JL+P^>GJ:[*F22R  9@*1^&R5)4'&;LOP>\5[
MH_2EKT9:68$&,PRM65RG&6&TJ6\3RD[!X)!QNY&/B(LJQ-KC4MXWX>?!XMD4
M.&X8"FB#)420TM0<$M=U%@<QT-G\!6I<P"<>'O\ ]JF=/YE>9](N'/Y!\)CC
M+R5<$$>_QQ0* WJ/>0T2DON [@T<#R4+(*><#'(_V]O_ #SJ=*T?U/\ .WD?
M6)% EF;Q ]"?>D=?N<^0_6/V"HE:+,XXN#^\4RE7 'N8?5H=R/=\34N=/'Y'
MTB&57Y3YI_\ =&O=8\D_K/[14P7+:[D^/[1,$J;0#D6)^3_6'=>Y/P_VJ.>5
MP/S]8CE5_E\A_P"V(P=LGIS?NI_9OZH:.TLE"K]=+()4%M: YWQM4F-)>BH2
M-NY<IIE26N=P40 ,\5D<)J)5-6T\V8II?6D$AK9TD!P]KD DDGOTC=.C^ME4
M&U.&UE2HRZ:1.1UBP"<J4S$DE@DO</8 < 8^/J59]36^\JT],L5X9OK,D0?F
MA=MFIG+E!3C09:C%GOG"5M+ V)5ZH"OS2#79)-;2+ICEFI+)))+@  <PVXD^
M0CW-1XYA5;4)KI%7+53RZ8J4M1R+&20K,R%$*404L -;,]HRL=9>RGU7T_V%
M^DMS^8I4N[Z4NLW4>I+)%8D/72%;;\''8ZUQ6]SQ5#0K>^C82GG<!S6F4V(T
MT[&%%*QU9$H(4I@E90IUIN000""1R/ D<3V=V[P56W^.S353!*Q+K9=&M4F8
MD+6N;2(2%!2'EAT7*@  -0QC&1TZT5K#J7K*PZ.TM9[E<;S<[I'CH9CQ)!,-
M34ALN/32&P(S<<C<XITH2 E041BMIQ"HD"G-1UB1*0E.968/< 62"Y.;2SLY
MT<QV7'=HL-P3"$UM=52Y4F6E4Q101-7EGA$N60B6ZR25I< =D%R6!C('\I-T
M)UWT[UGH'5JK=,N6G)O3K2^EYER@1WY4:W7G3L5YJ2W+<92M$=+Z7AW2W2E!
M#:MJN":UO9RNIIDZ>HKR_P V8640"4K6%)5K=Q>W AK1R;HQVHPZGH*VEJ:@
MRYLVL"Y:%(40I#*!4X2 +K  -^5HM1\GQTNUMU+[1^@[G9K7,3I[1=P.H]07
M=Z&^F W#MZ%!33,Q24LK?<<4E(:0M3CG(2DA-7VU%;34]$K-,2HU(5*DI0<Q
M)RNY <I2P_$;'34-&U])VU6#4NS,^7-JSGQ&F31T:4H4LKJ$)3-*%90>K2$
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MN)V+M'WK6O:.Z:-6B(ZZS8+_  KU=I(25,0X,)[>ZMU2DD(6I6$-I<2 O/'
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MUDDW_P!6HU+MQCTOTWXA/P;8O838WKRJ:JAE5533A0S%<Q<]))2%!8"%S$*
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MC&>2$W74MQ;$FUVI3C8&$6R.H)DLE2PM7HZE%!>(3CL _P!]KC]]5G1)6@H
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M3 2QD_EJ'9&6X*A_2!KW".)='^%3,<VTV<I$2A,?%*"9,01F"T"LDYRL$$*
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M:5.-MCN]Q2!BSD2L\[K)_P#,$Q95+$PY\H420D!3L D[N)8M'7NG#'Z?"Z'
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M?=3W67=KE)<'+;[[A6W$;V[D[(<?NV&&TG*]HV@YK8J):*&4NI04YYJ4RY:
MKM(0@DI.5R;A6](TU.L<)VOQNLVPVCQ?'*E4V;.Q'$ZRIE(*7F2Z>;/FKIJ4
M%"4.FFIE(EH=.91224@FWT&_)D]G ]-^F*^IFHH:&]3Z_;BRH3KS*^^@Z8;5
MWT>*A)(4E4M24O+)0%!7G@X&H8QB4RI4)3N23F_"Y+ !RP-[D-8Z#E]'?LP=
M&\O8_9R9M+C%*L8GBTL%"9B%(FR93*$M(2YRN4)4H%(-@#I?*5&9+(="CDN/
MNO?8'"%)2,YR$IP/$^&/+%:\H!)8!K7UUWZQZ7EH,L+*B/YLQ<Y#D.$3"X!&
MXAB&+&UQ'8J6*CCB/,0]OO\ 'W_;\!2#CB/,0P/92($AC<:'>(Z](HPI"%(0
MI"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(1JG&>20 "?5)23@$XR.><
M8./$$CSI#WY>[Q8S7_:(T-T\OUTT]>8U^E2M/VR'>-0O6:TKEQK3;I:L,/R5
MMH4K(SN5G!*=Q' )I$U[6(8O;EX'3B26TB[=GU+8KW;K/=H%RBN1]00(]RM9
M<?;8D3H4IL.QWA#6L.!1;4#ZJ3D$>T4]]WO]3$Z!J6OOOK<AR-Q#,^_G':?F
M6.2]Z%*E6IZ0PZTX(S\B,M]E\\L*#2G-Z%JR2@E()XP:1/'!(5IN4BYB2FPR
M&E!+%Y[U45X)"<!#4TE9#*4D)"0\4@*R!R*0CA7#TE*B,J<CZ>>M]H4$QU*1
M#<B0%MX4$M+"BW'<22%$D@[LGSS2$;G4Z7,EF\/BP*F/,CT:X2!"+BV$;4I4
MS(6K\J$A0"5MJ.-R0#R,H1M=DZ4M#EVNRW+'!?;8[VZS6U0TR5-1T %,LA?>
M-I0VE)/>8. ,Y %0T%W^6_NW]WS,/+GY=^_QCP+3U*TGJ!W3#5BFFYL:IB7*
MY6B;&:0_$+5M>,>0XZO(5']5.4E>!GD 9&9M/$;OUB@SW8?B#6!^5K\-SNS:
M16/SC;E,*D)NEO7'2H(4\B7'4T%J)2$%Q+A0%%25 )*LDI4,<&I 2]TMS<&)
MU.WXGT#,Q]1&Z-)CS&DOQ'V93"RH(>CN(>:64DI4$N-J4E1200K!.""#4T4X
MY\$>((_12$:4A"D(4A"D(XI\.'<H,NVS6$OPI\1R'+9/'I#;PPI)(Y0,<$\>
M !-(CN9QNY.;MNW/=[;GTBA(/2O0-L:=:AZ<CI2\U%86E3LR3O3&MR+>R@]Y
M(1P(C7=JRI(42"I6Y62X&_Z;]SW\OI%8%W8CZ[GW'O\ +6.],Z=:1GVF)IYV
M!(^9(9=7&@-W2ZMMDO**GVW2)ZBZVLDE<10+2DY3GG-/?OW^D 06;>/[CO'#
MZQ1%NZ#Z3M^M7=7,%]IIVW(B&R@#N6]I6YN;D]ZW,1'2Y(D%N$F1W;:R7%;P
MK94&?W^OO=PAR>[>RT58WTGZ?,7@Z@;L2OG=!0IN0JY3W.Z"%I<"FV7Y3[+9
MR@#*$A>,IS@D5'WO'OZ'F(D6Q&MQN<?,;^%N,5^H@J4H#E2L_G*5@8  Y ]G
MC2)#QXZZZM?7CRC;2(0I"%(0I"-4^(^T?MI$4ZCO'UCVK+_6N?9_H:1%.[_4
MG]8]2Z?]55]H_:*16BEU>!^P_LI$%:'N/TC@I%"%(0I"%(0I"%(0I"%(0I"%
M(1YUYEK@6:[SFV^]<AVR;);;P25K:86I*0!XDD8VX.[P\\TB9'5N>L_ 4J!\
M0WG>W.(9=FWI'T[O+5]Z@W72>F;GJ9_4DE2+@]:89EPUQT,A3A4XRI:%O.)*
MFG4D%2D$9S4<P&J0HGBY8@&[..3N]^9>,'2;"X1*K9N(KDR5KFJZP+6A)*;I
M)"3U;6(!.N@+L\6Y^4$[)6G.MNFM/ZVB29]EU-HX)MCMP@169?I.GYBR\^S-
MC LN!MAQ VNM2F2QWF25!0VWE+-2DK"]%!+.''9).\ZWX'=WQS_I2Z(L.Z1*
M:DE**>MPLSC+(R=M%1U*5:T\TN!)2 P2Z>8CJ=D;L8],=#=,KZ;1JN[WN\:Y
M8MS6H+^R(D6XVPPG42V;8TT8[SS#(>!3(#LA]3K7*EE)XIU*D%.5(;463I?=
M=]#=[G@8J]$O1AA6P%-,$LF9.FY53C,3+24E+'*EI:206!<F["PO$MM-]F_I
MW8KD;I,8E:IDM*#3(U J/+CL)_.4ZU'5&+7>)65>MLW%.T9QMQ9H3E4#WD.3
M9^=MVZU]UHZQ54.&5_;6B69B5$)*@@NE)#!LK\3JQ8VB*'RE70B5U6Z-V5&F
MY$>W7#2=^1,M\%48,Q)"-@0&AW"&VXN2"E!6G:<@^"B:RE-/2 4JU(T'<1Q#
MVX L['GQ_IKV!J]J=EET6')SS E65*1HZ5M^%"OZK:$&YM&.[LW]B#7'3UB]
M=H_JY!@,V'IM9I^J+#I1E\39UXGQ4)D,27U*3W"8Z65I<;"MP3D<C:0;K[YF
M"91W#(@\4I 8"]T]P L[:/YQZ-.@ZOV4H\0VQQNF_F8-UT^1)!"ES3),HR\S
MR@4A2EK*@I84$V*;E\:74'7]\ZF:\U)K_4#BW+IJ*Y+G);+Q?;BQ\=U!@- _
M^S16D]WM ("U>!\:O)"I9!=K.;N7-^%VTUT#7CRYMMM*O:_'JBLG))JU5(1+
M8-_,)ER4 .N8R1U8 96Y@-PG!:EN=E_LP/:A+JD=7NT1;Q8[*EXH:N&E>GY6
M[(F3MA =CO7!U)9"QC<AQL#(2,R'*[BRE**B P*IB@+GCS)X>$=YI3+Z*>C"
M:N?.4-I-N:15/)!6TZEIZJE"U(9I,U(744YRC,MCF4,UX@KI?3MRUGJ2TZ6T
M\P]<;QJFZQK9 C=VMYU<F6^A)>?*026VWU*D/ G!;0=V 2:N$U*T2E)59264
M.04ISE<@N$D BPX6L/-F%89BFTN,T6"4\N;/JJBK/425*49@34*$V<M7XAD"
M4*F)"0>PAUNQ::O:RU#8] 6K3?9:T/,](L?3:%'=UM>(TA+;6I=>RVBY/+Y;
MR'F(1DF.C>2I!:" , 5!$U4Q2%!/XE J3_4E 8$LYNU^#VXQW;IJQ'#-E:7"
M^C/9J=UE'@E,I6.S)"D)368DN;.1,1-,M,O/+,B8ES-EI4;N4N&HSL8] ;AV
M@NK]KL03(;TMII;-^U5*#3BV'$,+2ZS&;7M*%.2E-( 2H!7=;S@9YO:Z?+I9
M$J85#/,LDEB0D)20E]>R"Q&CV%G?6N@OHXG;=[33)DWK?X?A*:6LGD!1EJ3.
M,Z6)8["@5)$M*0ET9007TCZQ;5#C6NVPK=$8:C1HK#4>/'82&V&8[02VRVTV
MD!*&TMI&Q(  .[CP)T.;/*IY6[W<L_*[OIH3P87>X^K$E(IJ*FHT)"4RTA.5
M(8)&:S :,&+D.>,=UW&1@Y]4?OY]^21[L>-52LK[1W^^)[O"*L](2I %_P"6
ME^^X^@$<=0BC"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(4A"D(
M4A"D(WM\K QG.4X\/S@1P?(\\>^D3(NH#WH8QL]7^CO4G6&L>LVMH2]80HSE
MYT5I^+I>V*CM-:QTM'B6_P"=W6I3@WMH;+TQK> X ME: VLJ!$.[GY^^8^<5
M?JWM[>6GUBFKKHC7L#JM>D3[3JZ%IW3MXL=VTI?+9:"NQ6706F]+VU+%O8N;
MM]C.1IA=;E1[A$.G7/2)@+R7%I]537B+>_$0W_WW'R^=XMSTS3JK6VIY$>1
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M(9DC?]?D_P"T%+"D[-WJGQSGQS[@/^>VD L;W$:%9R<%)PE+:2<Y"$G(4,#
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M:_B/PTA#8?IK^(_#2$-A^FOXC\-(0V'Z:_B/PTA#9]=?Q'[J0C7;]90_2/\
M4&D(TV'Z:_B/PTA#8?IK^(_#2$-A^FOXC\-(0V'Z:_B/PTA#8?IK^(_#2$-A
M^FOXC\-(0V'Z:_B/PTA#9]=?Q'[J0C7;]90_2/\ 4&D(TV'Z:_B/PTA#8?IK
M^(_#2$-A^FOXC\-(0V'Z:_B/PTA#8?IK^(_#2$-A^FOXC\-(0V'Z:_B/PTA#
M8?IK^(_#2$-A^FOXC\-(0V'Z:_B/PTA#8?IK^(_#2$-A^FOXC\-(0V'Z:_B/
MPTA#8?IK^(_#2$-A^FOXC\-(0V'Z:_B/PTA#8?IK^(_#2$-A^FOXC\-(0V'Z
M:_B/PTA#8?IK^(_#2$-A^FOXC\-(0V'Z:_B/PTA#8?IK^(_#2$-A^FOXC\-(
M0V'Z:_B/PTA#8?IK^(_#2$-A^FOXC\-(0V'Z:_B/PTA#8?IK^(_#2$-A^FOX
MC\-(0V'Z:_B/PTA#8?IK^(_#2$-A^FOXC\-(0V'Z:_B/PTA#8?IK^(_#2$-A
M^FOXC\-(0V'Z:_B/PTA#8?IK^(_#2$-A^FOXC\-(0V'Z:_B/PTA#8?IK^(_#
?2$-A^FOXC\-(0V'Z:_B/PTA&H3C^TH_:1_H!2$?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g40894g17g74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g17g74.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1;^4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q :X            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      T$    &
M  %Y   %-P    8 1 !3 %  ,@ T #D    !
M  $             !3<   %Y                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   %Y     %)G:'1L;VYG   %-P    9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !>0    !29VAT;&]N9P  !3<    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M 0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E
M9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '
M9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y
M<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T
M;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S
M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     0X0DE-! P     #(@    !    GP   "T
M  '@  !48   #&P &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( "T GP,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
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M4M+[;6N?NML]
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( *4"1P,!$0 "$0$#$0'_Q  >  $  @,  P$!
M        " D"!@<!! 4* __$ $L0  $$ @( !0(#!04$!P,-  4" P0& 0<
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MG7R%TFVHA5B=*A6ZOM_2#58BRAZ\PSXO&)4E:\-K8;<2I&/-;I2M8+7P-RU
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MA9X>TW#<EJC(2WC*ZNI4Z^NOG7J5D&'6%RN!)0I1#7'6H,4"0 ,BD3F3%43
M04R4#S,SEC06;#K=,76'-$NF=>\H8UAP3CM6!-Q013$M(8@29/)E$1$S,1&7
MS\YMDQQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC(<]\NTQ/IMU
MNLV^ ]$1LD@ L5&!1Z>HM("K**N%M$UG/QYT887>^5'P2]^+&1!=^6^AN/E3
M6'/<3ONF],&^VJM:RS\(+566S8[(9 >!!N^L,FN.V>S@I[H[8YGWXXS4[K9%
MJ=>R\%>;1 RNN$0<@1R]ZTQ S ,GNCOY$8&>Z8@?;GF.2Z_\234-\O1-:9H
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MA[K3VV;#3<][#:YK)[C8PYDB(IGYS,S,_='RCB,V"E+0I:4@*E* 5K6$0(@
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M,8NX5RSL4G0!\H*FAH_N3#E*?6'@CBL?!!C/A,]QNX>FJ)6Q5MKAJ;&C4O5
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M'FDP31TS%DV*B#+%;I).-IT="1%GUF;939HS(H(XU69?RLKH[4L.H1E[_?\
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MWK8(F/(S!1W#'(S$Q[3&5$A,8("$AGY$,P0S]GM,<Q/O]V?<QY_GY^6?+/\
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MTDHV0)"4Q.<T]3NAF^HG3:.GAW#]2M.VJ;,I 9:EXI!J'):GO&.XTO(U,^M
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MTZ-1=ZXWQHM[6QLHH^9* ,YI:R\2?0M_L$:NF6+%KMZ<OVH9>V(%IKV7L_\
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MES%=U:J;*.3"-FO#L:?2K'P6W;>J:VCHMSL]A=7:<BG1I2;B33A4V6SYC0$
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M+3!1Q')K,PABP@QF9EI/4#3[O8+UD5=IK+=BM\92#:T_A8O5>"*'5BAC(,)
M#,2G@3$2D"*1*(L4YS7)SCC&.,8XQCC&<]NNTM?Z]-Z[KUTL,,$8VO;ET2@1
M9;$MS\16Q $Q9OHS,B/&>C1)"PH K*9<(/1([[D9,-EY<V1&CO,<?/\ #YY7
MMV!H_5;M7&U=V!=WH%!T]TV&UY))MSVH"+7'*7)JMBP,%HLTW."GUV<XQ#B2
MY(MV.[#)QYDEE(]44CCI_0_J?L>B=7M-97IU[87"*U2-LE'PE\E@F6-$9&;%
M<P6ON5WK(2#N$^"(9XUZE>C.J]1MQIMM:V%N@[7@%.^%> *;VK%S'^))L%@U
M;2F-=XWRIP%#)!BID0(>5%>G?4"KW&O7EGL-58&L:M",G[0'-7VJ&2QV32E2
M2QIF%+@KA8CBQ(^ ^JPM1XA$@PW&D-I;BK\W42F?7C>.TFRIV]?1+:6X-%6Y
M6 T5:M=JO&PS0QU@WV!*3E<=ZUC[2<' R,PE7]&3IRKU)J=A3VNR^A:'CLW-
M?<)5BY=NI?+4K"RFO476ID,+AT2MSCX(0)?=!C#NG],;-IWLEO.97[_7HC][
M-4>=K*_.1[#/KA36/8,ML(>S43)L=0[C7*X?OYV&"HHLT4>'.BY2T6FNNF,^
MP&(Q'U9Z]V?5O1'1>GZ0V+M'L]=8%N^6#G4QB-=1&M54ABD/$TV3-C*S1X9K
MVPJW"S=46IGTCZ!]/]$=#>H'6V\]4.G5]6Z'::R:_3R)U];9DC87MO7MMOV%
M6-GK""=8A!S9I>0J^^K&[36&5ZNP;:K2(\/_ *I"NH79;LUL6_[#U_0JH@J>
MUOK>F&+_ %M!YRHG+E@]6#]D8?)LNB43@U?@QZS&)ML%#;:R9#X<9AAK,J3>
MI?J-0ZJZ8Z8T]<IL[%2:.RW=GL(%(V$:^4MJ*DX$F%+GN-IQ$+#L6 D9$?CY
M?T#T+<Z;W_4>S=$)HO?<HZBOR,M;0B]Y56G"!&"N5*4*U]Q']8YF 'M[[P1-
MFK9^27A@K $-3*].R+/Q!): 2D@R>$8<R.+L0Y#SHV=AO.',Q)J&)&$9PKV_
M3GSYP_.M9]OC&.,8XQCC&8J_A_5C^O&,RXQCC&.,8XQCC&4YQNQO=0-WG[#5
M 5KW9FZM<U"F;(GU310ZHT+7-8;B 6.HB=,V2D;WO(>H B]EV=,V-V<<LXJT
M;5+"H\?534$0"K9 +)R=8R'OA(=F>WE2Z":8 4CPV]O[6K,(]NYP?>P?8;J7
M6!AER;OO9T\@Q'"77< *RQ%!2<J8"DKGBX[<R4->FCUR1LB)*>\CQ[\3S]:?
MV3]V,LC_ +7O>C_=+[U_XI.D'_/;GK&4;;%Z&]L"VZB^V];^'!M(=!M63Y*V
MTO=>S^EFYA,^T6,U-+S# I8;N!JE J+&Q(8CCQSL8B['4T_(=(R/D):8L$6X
M=4T^ML=2[UVIZ?F[.EUJW4]<JA\?)2^ NZFCK]M8&8,A$+>QL!$<<C,C$QUT
MO6+;*5MV:KI?HS2;KJ!&FK;WJ.GK-E>VFU3HE*53&Q6Z@W&ZT*2*$*)S*6FJ
M&1C,K)<%(S_5'1KN//\ -)OPXC8Y"L?GF@0_#P!/H\\8QGT.WGMKL]CS3^>6
M\KB+QA7EEQ#B,9;SZ['_ /6F_P#_ 'CW_P#\2S3?Z5>M_P#K#5_^ZO27_P #
MSG<CJ\ HN[-3:7V_X=7=B[;BW2.OMAUS5_[2GAYT,%8*_JZ&**7F(E6F#=.K
M@"(+@G(.<.ES4"S$<37/IA:;-CY<C>(#9!4VVN3U#U G6[TZ3-O1^DBL!>.A
M*YK$RU=7:V2O'XE\16NHB.R)&!GF9WM7UJZD26FMV]%T;M-WTXK;IZ?ZBN:'
MP;33ANEM7<BHK4W-9IV3'F8:BN:FT4&7]I+1B!BQL;H2 )@Q1T7_ */Q;76(
MC*&&G279[IR9GN(1CR2J65+]C9Q.>]G^*1.F2)"\_FMU6>7.U\?_ &EN_?\
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M&,Q-SM9QC/\ EC\N19NRV+_]=?NN_P#S;3V?_P!V3F?"UC^BL(^WV 8]_O\
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M"8II<R#$M 2";C0Y2V%*95)C,SD,OJ94II3J%9;5E&<9RQFX\8S%7W1^K/\
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28Y_QB?\ "><\\97'&,<8S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g40894g17m48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g17m48.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1G84&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q :X            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      T$    &
M  -&   $N0    8 1 !3 %  ,@ T #8    !
M  $             !+D   -&                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   -&     %)G:'1L;VYG   $N0    9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   #1@    !29VAT;&]N9P  !+D    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     0X0DE-! P     #V$    !    H    &\
M  '@  #0(   #T4 &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( &\ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
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M.#A>XMJ<!!WP;-IV>WX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1" %N A # 1$  A$! Q$!_\0 '@ !  $#!0$
M      D&!P@! P0%"@+_Q !K$  !! $# @,$! <*!0T+!PT! @,$!08 !Q$2
M(0@3,0D405$5(F%Q,E*!D9*ATQ87(S1"8G.QT>$D);+!\!@9)B<H,S4W159R
ME=4V.$938V9W@I.4HD-$=)>VPM(I1U155V5GEJ6UM^+Q_\0 '0$!   ' 0$
M              $" P4&!P@$"?_$ &01  $# @0#!04%! 0(" @*"P$  A$#
M(00%$C$&05$'$R)A<0B!D:'P%#*QP=$5(T+A)#-2\187-#5B<G.R&"4F-D-C
M=((G*$9459*BM#=35F1E9G6SPM(X1$5V@X24I*6U\O_:  P# 0 "$0,1 #\
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M%D.+""L'1%K'NZN4J<F-/A/FK><C60:EQG3 D-,HD+8FAMU1BNICN-OJ;?\
M+6EI:5D=)!)%P59?C:(M7.5>TR8-W(9B5$PVT 1K25()3'BUKWG^5/DR%I4V
MRQ%6ZXXH$(2K@\$7)MLCI*"&+"]M:VF@>8VT9EK/BUT5+KI/EM&1,=8:#BTI
M6I""L*4$$!.B+2ER;'LC9<D8_>5%XPTKH<>J+.%9LH7QR$+=A//MH5QW(4H$
M CGU&B+L7.5<I/QY^8X!7V^WD?'G[?NU3<#HU6M4!CT.UI') 07%MY#20;;Q
M^7+S7G'\0M@IGQ$;YH<<*W4[A26UJ4KGZK5%1,M)!4>0AIAMMMM/HD)X'  X
MWSP\7-R7+S1AFJA+IYG6Z]IWY[=((VU/G;IS6OK\3:;BS3SWFW+^*.1WZK;V
M&GI>WUV;05 <[BX[Q]8<<^<X!SP3\?B?C\=3YZTNR;,"Z"YN%JNF3?2PDC;F
M+#^:DRONW9IA'4VEL56S,&?$(V^M^JSJ]I/*$=.S:N>/\+S,<\CX5].OX_<0
M?E^76$\ #]YFAY4Z5.J1OJ!>60//QC?H>JRGB]X:W" @D$/GT+6@_7FHO_I,
MD<=1'4"GU'/)''ISP>1RD\\>OH.-;))<VB0P@ <H\S;SF/HP5@M,,;7;I$7!
MW-N4VY\B/5>A3PDJ*_#3LHI7J< HN!U%72D1@$)"B3]5"0$I'HE("1V UHG/
M/\[9A_VE_P"7UUZK;F5&<OPIZTR=Y_B=]?-9$ZM2N":(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(MB2>&5DGCMZ^G'VDG
MT '<]T]@1U#G1%#?E>-#;B?O7:>)_P .5KNIC.793DMNQX@,912Y=,QW"9[7
ME4\9%?.=3;XC'Q2&"67*Y(9;?074H6[TATG\OKW*Z>6W^,;%;G^'C<.+<VV1
MXNGPV;HX[!O;J4)5QDL2BA8SEN.(DR_(CIEVEFEOR6066GGY#Z4);4H'1%9;
M$;;/\#I]]]G9ED\=X?$%F6V4N L<MR*FQWNQMQS*W8Z4.!:HF%4U3=I]X21Y
M;E:R3TE207U]?HBI_P 1&3[6K?OL4I\WQ>BJ?"#2X5!VJQ1RYC1++)-S*2VH
M<@O[.#!#H7*73X_6*H&G$-K*K6RM$]0>;4 196^-'*,6NZ3PS5>05LG(L6S/
M=O'<GN**JHI>5R[?&J'%K6YE-1\?KV)<BS84[+@>>$LNI+*G%+' T^OKZY&4
M^OKJN7L5AU9:^(F9N5M+M;>;1;15^V\C&;IJPQ23M_&S[+9]S&G09D7#GT17
MR,=KF9#+EV_!9]X=F*BLJ6$+Z2*0I74"3ZD  ^OX74.QX[CG^KG[=2NCNR-S
MWFW/[V_NC\N:E:/WAD6TGWV&R\R'B?G&-XF=^FDK! W"<5Z@GJ<QZ@=5SV^)
M62#\0>=;_P"%F3D> +M0_<B+;C4[J?J9YK3_ ! \MS7%AI_Z0S<D[#S^"X7A
MWL2[OULVV7 .K<;&..X')^D&^0/M*>?R<Z]'$+ ,DS0MU$_8J_(6&@W._IRW
MW5+)*A.9X0.,?O!%SO-MYW-H\U(A[45WW:NV;D]7!^E\N8XY_#+E/7K(';X>
M7U=O3CX#6 =GK2^KG+6@N/V*F2!>(KL_&1ZWYK,.-7:68,DZ0=0FP_LQ<QSY
M;G91'?2Q[CS /3OR 024]^>QY/I^7CTUM84=5)]-@U5&CQ-%W- ZM&W6^\7,
MRM=.K]W787N#&.,-+C =.US8\K3U,\UZ4?!LI2_"YL:I1*B=OZ4\GN2/+7T_
M_#QQ]FN?.(!ISK,1M&)<(B-@WER6YLB+CE6#+MS3),^;W$?)9+ZLRNR:(FB)
MHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(N)/A
M,V,.5 D!1CS&'HSX2I2%*9?;4TZE*T*2MM2FUJ"7$*2M!(4D@@'1%A.WX/LH
M_<S)VM?\0N>2-E):I49_!GJ:@>OW:":\X])QE>?26G[Q50Z'51U=39F^Z*6Q
M[WP4J217.W3\,.$[IN[,-6+[U93;+Y'%O*BEAQF'(MI$A0&XD6DF+>)6U ;=
MC0I*PWU*<,1#*OX-:M$7S<^&FAMM]5[_ "+R5%RV/MT]@M)%]QCOU]/.<>G^
M3E2$K<#DFSC0IQ@,L/*#"6 [P4^>L:(MG'?"IMO1[13=JY4&!>/V]%D-;>9M
M:TE5)RBTMLH3/<N,C>F/L/.)L7IEC(EM .EN.2EMOA"4\$7W3^&^- N/#_<3
M\SM+9S8+%KC':MEZ!%:;R"3:TD2@%Q8%+BC&DQ:^,4--,!25+=4I;A X)%DN
MA'3SR02>!V'  '/'S)/<\\D_9Q\2+CO*"$K!/'\KGTXZE#@\CY<_D'IJ2H=+
M-1B-8!]YVB_Q1IFI'^B0?AR]WU8+RU>,M$VD\5F^L>:RY%5,RJON8:7"0)5;
M88M0&),8/ "V7BR\WU#GI?8>9/UD'70_!1&(R#"&?ZL&GR_AO&W(GW7W*TOQ
M2#1S?$"\/(?: +P+1Y"=AR70>&2:7_$1LHWU]05N-C:N.>_U9@5W!^[C[-7#
MB:D69!FKKQ]BKCXTSY#HO'D;]6:X(7_KV&]Q]X>?Y>Y2:>UC>]VQW99?/KDV
M4)Y]#WHXHY^WT]._W:UQV9&,9G1_^8TH]>_8LVX^/]&P?*"\$_\ =!Z'X>2A
M6<M0A*EK</0E/6H\CE*1]<D\D< =(Y(Y/IPDD\:W%2I!K<;7C:F\F.=OG\>A
MF5JVJYU<X.9GO& 7G8\^I!($>H"]4WA"KIM5X8MC8-BPY%F-;<8XX['=24NM
M"3"1*:2X@@*0LLO-J4A0"DD]*AR#KF3.ZHK9MF%0?Q8FH?>#!]T@QY+?^4L-
M/+L(P\J+/P^MED=JUJXIHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+Y6>$*/?T^!X/Y#\-$B;3$\^GU]2
MN(MY*5A)4L%0Y2"2$D=OC]G(Y/H/4]M2EWB@ N.\"^WN/O\ [U"1]TG2/[1_
M([V\_7S5KLJWEVGPJ8BNS+<W!\9GN$)1"R#*:>KEJ^MPG_!YDQM[I!X 6I('
M(]>VO93R?'XMFNEEN95J9.H/HTZSJ3KR2"TZ0)&PB(B  K57S[*,#5=1Q&;9
M90JL<6N96Q%%E5OD\/.H$@B3SG>X6*OB9\)VV7B\I:[+\4RBJJ<UK8*HE#GM
M"J+=U-I7^8IT4]ZU"D!FUKT/...1'V92)U8\\Z[%="7'67LBR+B/-^%ZIPKL
M/B&89[^\J8?%SJ:Z-.IC:A+FM+6W%FNB;1*MF8Y1E?$E$XG#XC"5G@=VW$84
MLJ D'5I=4IFY!/6TD*(BH\+N[6T6_P#B6.7MWB-,_2931ROW<P,LB0*FL1Y+
MENB6LVBZJR8D)JXJY*X377(;,N*RAQY2T*.=YIQOE6;Y/6H4PYN+J- ?A],:
MZ<.%1KF-)!!D"X((,FUQC&7\(8G+<PIUW5"YK"2WQ.($EL.DR01<@@>EX5^O
M&AMYG.74^!*J=X<7WB,"_L&#4Q<TBO3*]RT@L,1)2&+2\E+=2\XW[JLQ62\V
MI:75CRR1K$N",WH93C\55JM:*=5A#FNC2YK72UCKZ2 1(:;$W%P5?N+LKQ.:
MX7#TJ#G:VN%VD@@$7-C-X/E!ZP%7?A@]FNU,7B^Y6]^14UQ0O1:_(JS \>,F
M363TOM,3J\Y->2$1O?(:.I#KU5"B(C2'0E#D^3&3Y;MTSWC_ !.+;4PF7-?A
M>\!:]U$FE(VB*< @^=QM!W5ORO@BE0J,JXNIWC<,=>AQD'3R=/G)(B+&]Y4H
MD_Q'^'W%)R<9M=YMM*2SBJ]T%1*RZDB2(Q:/0(Y85+26"T.E 0M+?2.G@)3P
M!@XR+/:C/M/[+QK\.\%XKBA6<'C=SM6C28,R9.Q\UD3N*^&*-3[*,[RFE6ID
M4NX=B\.US7-MIT:Y!,$Q$C;8*\U#<P+N*BPK;6#;UTIIEZ%.KI;$V%)9="BE
MV-*C+<9?;7TGI<;6M)Z3PH\'BVU6Z'FF6/IO;(>U[7-(,VL=CU5ZHU!68VLR
MO0KTJ@ECJ#F/;'^LRQ!Y&3L54&J:K)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(OAS\!?)Z1P?K?+[?CZ:#
M<1U&Z@XP"22/,1(^-EACXU?$-%\/NS=G=19D9&<9,MW&\#BGZZ_IR8TOJMG&
M.2IR!010[:3$<!+RV8T4.(7);YRK@KA^OQ+GE+"T*+ZF#I'7CJK6WITFN:#!
M(TR7&#(N)B2%KWM+XQP?!?"^*QF*Q%*CF%5KJ66TG. -:L6FY;)<=(@DM-B6
MCFO,5-LU6,RPN+B<]<6U@X_,M+FU?,VRL)+Q\Q^5-GO];SBW%];BB2&T=2O*
M2VV.@=GY9@,-EE-N%ILHG+L+AVTVUZM&AWFFDS2TN<&-:20+D@GF;[?-C,>(
M,QSC'5<1B\5B:6:9CC*E:GAZ%>L:;CB*Q?9KJCG2 X$0ZPC:"I,O!=?N[0[<
MY%>T#\V#N9N?:0%UL&PAEW'J/!J1;BD7DFO8DLQF[VXDO.(=C34P)[S4ZJ6V
M'H<8/N<[<9&AQ5Q&:.#%/[#@V'#OJT&4VO-;47F0U@99KVS8S80%VAP!2Q_
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M)AQT@Z8)$6YW,67(%7$NQ52GA,43@,1EWCI]TT.E]/8$D@P3<G>W60J-\1V
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M2JE3D-O2VPIOWJ0^RVPA14&9*OJ#*N(^T_*1@74\LI#$8@M.D-#B&D@P2XM
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M7=<XKSDU<N4EMTQGF7>IR#+4VZRPXXXA;*FW#TYGP?Q<>&<2YM=AK8;$&F"
M2#3[MWB<(G[P>9'.!!%UKWCW@JMQ7AV/P-7#T,9AVU([]@>VLVH(#1&DZFD2
M"9$&"-B(WF?"#XG9\Q-:O;]NN2'F@+B1E%''@QG&G IJ:U)AS)TX.,.)2^RX
MW ><;<2TL,'RTI3N/']IG"=3!'O*1Q8J4R*N&+2YSM0LTM=3:T-F)D\C<%<_
M83LAX_9F--M1^#P]!E9I[^EX'M:QVH.8>\<9D"XY'DLCI.Q=#"\6FQ^>[A4E
M-?[O1,'Q"MO\FAL.)K[&V@1<SKTWC-?*<*'+9,>&PVJR>2J4A++:6?(2RVTW
MI7$<3YM3P.9Y/EN*=2R#,:U6,&7.U4*;W]Z #,$2[3L"07#8DGHK#\#9 <SR
MOBO-\M;C^+*5"C@AC*;6%F'-.D&'%5=8+ONL#09N=)M"O#XAN?W]L(!]/=ME
MB1\B-Y5)''KQZ\<#6+4Q%. 9#6D3N;!HDG\?FL[ZS!/4;$R)CRW4@R""GM\"
M0?OYU(' S!F+%07WJ*)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB*W6>[B8UMU43;W++)FKK8ZT-M*6M:Y,Q]: 6XD&
M*RE;TF6\?JM1V4EQ7'/ 0.L8_P 2<39#PKE[\RS['T\#AJ;7.#JFH%Y:)TL#
M02]QB-,0-R8!5UR3(\TXAQS,!EN%?5JO(&IL0&\WO<2&L:V;EQ\A<@+ W+?&
MKDLZ4XC!\3K*J"DJ#4_+'7IT^0@J^H[]$UKS#<4*"2KRI%DITA20ZVG@I/&/
M%_MD-H8NMAN%<JI5*.'<]K\5BW BN# INIL (&D-<7 F8<T#G&_,G["\'3I!
M^?XW$/K/ (HX&FTBF1<A]2JTN@S TMO!(<%;P^+'>HK*OI/#U(Y"BTK%2&RD
M=R@@6O7T_P GGSNH>O43W.L1[9':.^KKHY?ESJ37$Z32HP6])# 0/>#RLLJ_
MQ+\"]T0^AF!= $BM4UZC ! DM)!O<1S(BRN;AOC:N8;B(VX&)PIL112%6N(.
M/IDQT<CEURDLUN&0VVCZRTQ;%QX#\!E7IK;'!?MAY7CR,/QGE;J%0DA[\"QK
MP".?=N<S5SL#Z3$'%LZ[!WN;KX<S$4VEOAI9D&L<2 ?#WE-FEA<; O:&@@R[
M>,[,,SS&\YI(>28O9Q[:HF(ZFY,9Q2E-N)'#D>5'<2V[$E,K/2]'>0'6E<I<
M2@\<]CY%G>3\2952SK(L8,5A*U,5&%LR"&AQI/:3X7M! <TP0>JY^S?*LTR/
M%U,!G&$=A:]-VDZA9P)AKV'9['Q+7LEKA]TF)5=L_@J[D\K)^L>3Z#MJ^!P<
M X-TR+CSV5NTENYF;@^16]J*)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHBP6\;(_Q;@I)X'1N*">"?\ P%G'GMW/' / [^G'PU ZK!OWB8!GK]':]U2?
M+3KG^5MO?=8?>/?Q>83M=MOMIM14QDY3N9]"8[D4RD1+,:MI*:3B-A5L2;ZP
M:0\XQ(FKGEROKHS2Y4MEGS5*CL+2Z<RX8X-K9\]U6L[N\-3LVHZ1K>'!I#0)
MEK1J#G2+CG<CRU\6&Z6@PX'5$'F(N>6X($Q8&2"L4<&]M=N3C]K!B[@[0X7;
MXE%$:*^,/MKBKR*+#8:2V)#7TU(LJZ<\$-\!EXUC;R^$H>2KDC-\7V5T10=]
MFQ[W8LM/=4GM8ZF]_)M@TB;PZ3','9>=V8BDQ[R!I:TFWA,><S//S'H2IP-N
M_%GL3N;A.!9U0[BXO$J-R)'T9BT6[N(%+;R\A9;"IV,+K+&0Q*&05JPMN=6(
M;7(94DJ"7&BVXO5./RG&Y9BJV%Q="HRI1/C&DEI%X>QP)!:Z#I(C:XD. O&'
MI5,70;7H@N:1J) , 1>2V0"/AT,%9*-+"VFUCN%(2H'Y\@'X<C5N.YCJ5""+
M.W%CZC=;FH(FB)HB:(M%'I23V[ GN>!^4\'C[^#HBH'+MRL(PB300LORO'<:
ME91:L4>/1KNXA5CUU<25)3'K:QJ6\TN=-?60EJ-&#KBE*2A025#F=M'$5=1H
M4750P:JA:"13;?Q.@&! -[>^ZKT<+6Q#:KZ37.%%H<_2"8#I FQ V,3'DHLO
M&%[5_"MB<KL=KMJL:A[F[@T:_(R6QE6CD'#,5G=)6JKD283;TRYN&4\^^0H/
MD,UZQY,V6U()9&P.%^SZOGM+[?B\3]DPC8< "35J#8.#72P-O+=0DBX@6-IK
MXSNG]T0-0W-K6Z@_@1%R(%U@/AGM2LBRC>S"-PMY,#H(E+3N0($^3M\NU,R%
M71DY #.%7;29KE@IE=\E3K,>4TZXAGICM./O(:&19GV5M&%?]@Q;JKQXV=Z=
M)-ON$L:!!( F/"3,V"H#&W!/(@\R"/,2;B3(YCXB5C=K*Z#.MT-K\PQ6SB7>
M-9#4;&6--;07DO19T&9O$7V'VUC@@% *5H4$N)<ZDJ2DMN)&HZN&K8!U:E78
M6OI/?1JL>?$U[" 9.QGD02"#,P95V!D-=:'-#AZ&X/P^14E#?X)_Z2OZ]>41
MN.=T6YJ*)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB+:+S0/!6 >_U3R#]7CJ''KVY[_+1$+R %?6X(![$$'GC\'CCNH=N1P2"
M0"-!N.2@=C'1==+L(T**_-F/>[QHS+LJ0\ZI2$,M,-K==<6H\!*4-MJ6HD_5
M2#\N-3!A>X4VW+R&B())= $>:IOJ-IT*E>JX,IT6.J5'.(: UH)),["UYA0K
M>([>:KW9W--CC5RQ=X125$%C%I4-];]78/S(R9-G<,<D-KD+<D+K ^TCE#,!
M+:5A+SX/S3]L;BC-6\>83A%YQ5++\+DC=5/74;AZM6OW]<URV=#ZFE[*9J%L
M@4VMFPGKWL#PV4X[LYP?$N55,-C7<09Q5!QM'34JT*&'Q)R\4:=0MUTF,J4*
MM1S&D!SJKGNG2"+%"PZ@%CL%)!Z3V /*N3P3^$>W4?4\#GN-<95GL8]N&:UN
MBC1I.U:0-;JFH$DM;<C1S$WWZ[XI8<TC4H^)W=O)UNESG!P$ N-R&P8!)B3$
M77U[^>..W'RY'']>I&U2T$-=I!W#7. /J VZJ]T=[SUT^[\++03R/3@=P>Q'
MJ/0^OJ/@?AJ4.:UVIH:UW]H2'?$-E0=1UB'#4+V<W4+[V,[\UD)X:]Z<?VBR
MO*[+/,FBXUMM(QF=;Y+:6<ER-454VKG5L&NN'5)ZT-*EJLS!DO!/#KDF*MXD
M(;([K]C#BK.<?Q+GW#+JF+Q.$9AZ55F'?4JU*%-^A[@YE)[G,:71#](!<(DE
M:/[;^%J>:\+Y7C:36',<!CZ>"I@!@Q&)I9G5[ONW5(#W,PW=M?3+C%&2&EH)
M+9F:FRB6$1$N*ZEZ.^0Y'>0HN(?96TVXV\TH=06TXA:5)6D]*@00>_?Z)&F:
M8:TS.F3.X,FQVN(OYKCQQ<*E6F]NEU"HZBX$ 7IP#MYD@^:[/S$_$D'X @@D
M_BCD=U?8.3W'S&H*"^?.;YZ0225%/X)]1Z_#X<_V:(MW1$T1-$31$T1-$31$
MT1-$31$T1-$6V74#U)]>!]57<\<\#M^3Y$]AWT1:%]H$ K'*B$CUX)/H >..
M>_/'// )X['1%])<0HCI4%<@D$=P>/7N.W(Y'(YY[C1%@YXUP%5V! \@']\0
M$@@'C]PT[XGL/R]M5\,T.Q%$.V-1LD["ZD-R1O8V]S=O.Y^*\IGB3R"XL=[M
MTI.1.OFT;RZ; 4W)Y+C$"J8BUU+&:!Y*8K%+%K1"3Z!A06 D*'/4/"^'PU+(
M\$:!8\%IEP G>;F),DGU,GFK!BI[]XF!O F+0!;:8W_")U8PV=HD!1ZBD $?
M4)!2!V'!].?R^@/;GTOQTL(J!HU,\37 #4TC8@[@^87G>T/:6D2"""#>?C;I
MO_=>+PZ359U.S[9:T6F7191M]G&:XVQ* <8H=TMNL:FY7B^5URE *KIDEBHF
MXY=2(ZVOI"GLUM2O,,:*6\6XRP5 ?8,<</1>YM>BVJ74F$OI5JC*;VN):=1_
M>"HV;AS;$2LAX,S-^$X@P=%X-7#%S6F@_P =$^)H\5)TL._,?%>C'V4?B[O]
MWL?LMC]R[VRN\TP"F8OL/R&TE.OV>2[?OEJ&8UR^ZKS)UQB<UZ-!?GOE<B=7
MRZZ1(6N4B6XO2O&.1,P&)9C\,T4\+B'$.ILAM.G6<TN,,'A#7B2T  -@BU@-
MF<?<.?8<6,VPS&T<+C7]Z:-)H92IOJP\-:Q@#6M\4!H@#IL%,XTM*0>5E040
M4^JOY(YXX!X].>/D>?GK"A,N,F"1'2( MZF2M>+<+K8]5 =P._([D<CN?F/3
M\WKJ9%J'$GXGU /U5=B1SP3QP.WQYX^W1%]Z(K8[O;EXUL]MSFNYV727(^/8
M/C]ED-IY/*GGF:^&N0F+&:"DAV5,<2B+%:Y'G2'4-#DJXU7PF'J8W$TL+1$U
M:U1M-N\ GF8Y#<^A\UZ<%@JN/Q5'#4I+JCVLL8(DB3:\1<^G1>2S+-[=P-VA
MXD_&-N#+7,S?;/%<5I]I:MQTRZC:F_W<RTXQ1S\7CO\ 7'BS<'QZ/<2XELF(
M9DK))B+USF:VPEC<.#R/#8#$Y%@&AI;BZ]4XT:0#BJ= 47EE4B-;"^H)83IT
M:FP&D@["XYPM/A/A7 C#4VLKX[[2RK5IM#:KNZ93+=3V@/> :A@$D"XV)!C&
MK[AU]Q;\A]U^3)><DR7Y"W'GWY3ZBZ_(>=<4IUY]YY2G'77%K==6HK6LJ)4=
MPFA1I&K2HTJ=)I: YE.FUC3M TL !%NBT%2JOJTZ=2JYQ>Y]R]Q+N>Y-SUCT
MFZN!769Z4'K(3]7E7)X'/8 J^!5W">?4]OCJD*9;:X'("0".=M@8]?,PO2!<
MD'U'GU]5.AX#;6ZM-LMN&[-UYZ!49YAU7CBWU*4$TZ-]F9+D9@J!/NT>YEVK
M+0' 1Y#C7'#20.?>T;"889RYV'<P%W=OK,9X :G=MDN:V 2Z!J)N3O)5VRY[
MW-ASRX"1<D@03 $FVP@1L?)>D)+J$ A1Z?K*]?0GUX'S)[\#U/!X]-:\$7@1
M<C:-E<^OU%@OOSF^>.KCMU=P1]7MRKN.P'/<GC@\CU!U%$#[1/3U#J'8IX/(
M/;MQZ\\'GT]._IWT1;NB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB)HBQ>5F637&\.5T";7+JC%L/731 ] QRBD8B])>QU&0VAO\HL(K
M\R%(;:L826XL1UI*$+:!Y2\>2?7U]?DJ9KK7<Z7)HF&MQ;$U&<Y2_%QNQM,>
MQ8W$?%L<QJ^LK._;8CU<&$8]Y8HJG(+5A$4_'K0P^%HD6"0PYB\7\A/R*3I\
M5C%X.QBX!O,=;CW*NXUA=[D;&73LYUA5U;XME]>B?5LJC1K!V*Y<5$2TKV'7
M9!89M&8D:P:9ZWT!,M*67EH(7KUX=PH8[#N%V]\S[U[0TF-MIWB^^P*M>?T*
MF+R3-\)3<ZF[%99B>[-*S@^I0?&DN#OXC87GJO.)LCFC-M0U6V]E(BU.;X@F
M=1T<6UD-5\?+JE-A/F.4;,R4IMB-F-+;3;!%=!F/LL752XS#BNIL*X,2>??:
ML]GO%]IE.EQ5PC0Q-3B#!Y:<)B6/;3?A:U-IJ5&/IM;296-1K*ND'ORPZ8@.
M$'!/80]J7(>#:%;L8[1L?@\FP]#-\6_),SQ[WTWC$8G%5*CZ5=[ZAIM)K.#M
M(I-/=D.#G&0;P/3784A^'-C2X5C'7Y4BNGQW(DV.M )*'HCZ&Y#:D]7"NII/
M)'U4]("E?)?.>&LXX=Q3LKS[!8C 8W":J=6K6H5:5.N&P!W3:C&G4RY?XW":
MC8 _B^R&#J8/'4\/7PF9Y?C\'B!4JTL9@\30K4J[7:-)I5*56I3<T WTN?8C
M[I, ;)/2%)4GN>>X(!2>?LY!!X'H>X/PUCK:N'BJU]4MJ"!3(87M+M;00YK3
MJ/A+B(<"#%C$&H*1#ZS'U:0((%'214<X2)FF'ASG= TM@&3LMV'+D64MN#5Q
MI5M8O+\MFLJH[EA.<<_$0Q&2M94>Y/6&T(2%+<6E*2=97D?!G$W$V-P^"X?R
M'-,S?5TC51PU8AQ-R6 47$-W )G:9BZEQKL+E^%.*S'&87*L,T NQV:5F8'"
M-WNY^(?3 !V:&O<YQ(#9-CBUXI=RJ]K"\EV:Q:7!R7,\N7"K\[>I)0LZO&:V
M%/AV%1MW$L8JG(EME^090Q2/Y3[@Y+@TT&I:IS)D3I+Z(WV&]D;V=,7V2X7,
M.-^*P]F>YIAF!N J"F,+0HMI.+3W99WX>&N/>O[XM<\  >$SS_Q1Q31XEKTQ
MA*;AE>4-QGV>L_5&-KUV&F<:9#0VA18"[!>%KBZH7N&G2#ZC5R[?;K86._&4
MP,@QO Z>#$\]KS4KNFJN!6P@\VHH4ZE5@IL*22E2@"D<$@ZVMB:G>XG$5 (#
MZ]1P%HASR1$<KV_%<B8QP?C,4\1#\15=(YRXDDW,F>?2%1F^&Y-[B-I15M3.
MRJ"D8I=WUC-QC%JC(O\ #$6=#44C-PJW2J/44K\JQGJES065-%L*5+CQV'U:
MH_7U]?%>==!B.X&Y5YG0KUV-H]-J<MH\9R/&H>"2F\(B5\3&:M[,+=G.I%?&
M;][8O9$\5S$2\L%E4:+7O5?\(])8(LS-$31$T1-$31$T1-$31$T1-$31$T18
MU;KY;E<;.\*PS'7LNAQ+.GR*ZN9^'8W2Y%/C^[66/UE.W-3<LRF(%4XNRL7W
MI3<<OER#R@!M#B'(']-O7\/YHJ8R[),]KK/-;C&<ZG2**DB"@;9M*+&WZM.=
M9!/K*>J@5<N- CSY+>.R)J)=M[Q,E,JG26JW@JBS&V8HKQ;:W.0RK/-<>OKJ
M/DAQ6W@PHEZQ7QJYZ0B?40K)V!8L05F"J?6.2"A;T5F&E;#\=*XC;B%./$6.
M'C9_X,P7GN"G<,>@)X_<-/\ 3[?E]OV:G8+R"006N!'43\NJE(OZ@_\ X0HM
MO:5^ 2YR?$*KQ1;,UTJROV,+QU[=C"(+1D2[>!5X_!:7FM RV"Z_:5==&#5W
M6-H4_9P8@L(_7*BN-2=I\!\8,P5;]EYG4#<-4AN$J"SFU75)+'N+G-TD$Z8:
M+V+HA6K'X2H?WM"7/)\;3<!L&[0--P=[FPL(E>:^TMDEM10OK20HI]4D]B>.
M!U%*N>4GD'H/<@=QK?-?"&K18:!U"N!I,S!)M<#E!]?F;!6Q!I-/> !X$MY7
M!_L@R>?/8>]92^#^)*J8V_6]3X,>MPK:C(=M\8ENH0IN7NGO7%7AF-5\=2AT
MO2:W'W\IR.6VP7'&(<)IYP!+G2K$N.*T_LC+*;@:KZS*]5H)UBEA#3J/<8V:
M7BG3,@27M .ZS;@7+:F/XBP%6BPOI L=4=$Q#FNM$0+$3&P(M*SM]FK:SJ/Q
MK[+QZU2TMW,7.\7GI;)!>J'\&M+186>1RRW.HZ]\!7*4NI;402 1@G&-&F_(
M*X>72QU%["2)GO T;B?NN,;<MY(71G:)AZ3^'Z].H2TT*C!3N/X*FEO(S:P@
M\P03LO5;N'>R,3P3*\A@+0J=3T5G,@(>3YC2Y\>$OW)*V^4!Q"Y'EH+95]=Q
MP#G@C6EV@-  V'5<Y\@.@B>>Y@G<3?H!Y!60WFW(R/#483%8FY+#\['LCR++
M9^&XO5Y%-A1J2-00VE28]QYD6MIY%Q=J+LQ39*4,J0'6$M*<$45+4^XN[,_,
MTTIGSG\AH[?;RDO,:K\&ENX*Y&L*3'K7.K1_.%UQBP)<"+9RW*^+'R!2A+:B
M0O<)*7UOI(LV]$46'M>;J?4>$6VC0NOR<AW(VXH;/H)X77.W*+)YM8X(+;CM
M:PPM*^I"DNJ24@D'63\&TV/SVF7@G2RH\=-36,:+<Q#KW&UC*S/@*G2K<0X:
MG6):QTB01()TW&J0(\AOS7GTV:JG=P<0\1.PD=8-UO#LZ_8X!'Z@'+/<_9VW
M_?#QBA83U)4J1D%6S?060%=2EM]""5EMM6S\VJ5<)B<JS)D%N#Q9%<O'@ITL
M3W=,N=$$-;4#"XR( D66P>US*JN)RJFV@'5*>!;5>T1J,UV, U%L6EF\!19U
MMFXWPA8\IQLEMQ*T+2I"VB4K2IM70M"TD*2I*@E25\I4 01K;A::V%P^*PQ#
MZE<-UM-V"P)B"#:.9(M>ZY197!929B&BF^G4(#6>&3!%]1=[XZ&QV6;_ (/O
M#9N5XMMT(.WV!1G8E5$,>=G&9NQG7JC#,=4\A+TN2X.AJ1<3$DL4U.F0A^9*
M6EQ19B,R)#6/<4<18'AS =]4>Q^,,,9AW&>\J$$Z0UI#M(W<XN\+=^2]^$IU
M\35(: *>Y<0=@8DF2)(V@"8YKTWY#M)B&Q64[-[48+%=B8SB%)LG @B2IMR9
M)>.]#LB=8S76T-MO6%G.>D3IKR4)#DE]Q2 E!"=<OYCCZ^:8ROC<0X"I6J5:
MI:R0P:HAHU:G:6@@-O(@<Y624,,R@V&EQ@#<BYFYL!OJ)6<N^&776)4&/(QU
MRX:M<GS.DQ\.8_30KZ\;KW&;&TMWJNKGI7$E26JZKD#^':>;80LO*;6$%)MM
MA_(?HJZHJ789N]:X=!H\]R=$B)70,FS.)=8WB; B8XU)=DNHN6HM.E^OO<@2
MDU,&# D1?(8C2['N8:_/CT^OK^Y%S-ILSSFSM,3BY/?0KU.9[:-Y[*AIIH]?
M*Q2:].J&V:UMV&4^\ULYFV>1$-FTF<E=2^X)4E#CHC$63FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(O@K2"$]R2>.P) [<CJ/H.?ASHB(<2O\ !Y([]^.!
MV(';GN>>>Q (['OHB^]$31%\%:1SSR.#QW_KY]./R_KT1:!U!]"?0$=CW!^1
M]/U]OCHBW >1S\^^B)_I\M$5$VF$8Y:5.24DZI956Y@N0K)6F7GXSELN7 BU
MKZY$B,XU)2ZN##CQ2['=;=Z&&RA:..-$5$N;(;=2H4"OD4TR='J9<J5 1.R3
M)):XRYL)$&8P'I5L[)7 EQ&FV9%8Z\Y7/-) 7%<("S W!'4%0(D$=01\5<^+
M4(@Q8\&)&C1X<9A$9B*PE+3#3#;:6FV6FD(2VAM"!TH;0$I2D< <G4':B&01
MJ:X.).U@!:TVY;?I&&DM#@2P4C3<+7)!%O*.OI$"WFP]HAX1KK:/<J_W;QJM
M=D;79K9.6EBJ!'4\UB&33AYT]FR;:0X6*NXFJ=G1;)3:6&Y4A<)TA7NZCLG)
M\]J8O"T,O<QHT L>Z^M[ 29B8)$@ 3R]R^;WM&=C.-R'B''<;Y+1K8C*<TJ'
M%XL89NHY5BF4F4RVHVFPN90JFF:O> '2YVDB0''#?'-_MT<?C1*Q=S&RVJ@'
MKA4.>5-9FM7&8;Z>6H4^T97<U<-;8"0U4V490;4D,J'26S2XB[-^ ^*L/WV>
M\,Y-BW88$4J[FTN^<:\&IKUX=]P:+ (<+EP/EA79W[4';9V:"GA>&N.<VI8.
MB^BTX'$U:N(8VC3[S2* .) T4VN((#7.#7,T.!4U=Q%V+K_ _;^+6'LCC3N0
M0MNCE$;&9$JW13'(W)3-2U%<::G%8JD7+Z7G%H >5"2O@)601HIO85V;5L]H
M8&GPGE9[RN6M!:T,TZ7N,GN_[#2!X2-4$B++[']EG;IVE=H>3<+XM_&.;89N
M=X>F^L]C:3:K?W%1SPRHX.?=U(ANMSB 1))N8%LJW^W@S2NF4UIF?T'C=BI9
MEXKMY456W.-36GBIU<:9&QAB';W$) =+7DY!>78+:4F4M]WS'%=#<,=F?!?"
M=:A7X>R/#Y;6HM <6T*6F0+P6L9-[M,""-K!;Y&#;B2ZMF=2KC<:XESLSS%U
M3&UG//\ %#ZE-HF8 :&Q-ANLS/9J>#ZXWPW,Q_=K(*0P=E=L;1FXKWY4=<>)
MGN957$BFJ:=E82W+HL=L"FRO;-+2H[UG"AU<5U1<MFT5N,,[PV'PC\!2Q#ZF
M+JN(JA@ 93I$^(N>UTZG&P; F2XF!"P'C?C!N&RQV48&C1IXFH',J5*8@: =
M))<TR"X7#;@3&R].][BE;E=).QV_A(G5-CT)F,>\R8RW$M2&9+)0_#<CR&G&
M'6FW&'6G6W6EH2M*P>PU,'%P!( M  ,B.4;=5HN -B23=Q(CQ'?UY7MZ+IX.
MUV(0(<F"BI]ZCS*AZBE&TL+&WER*B1)=ENUSUA:2IDYR.I]Y9"%/E* >&^D
M#1%5U31U](TZS60V(C<F9)GR4M!74[-FN*>ERG%K4I2W7G%$J))Y*CQQP-$7
M<Z(FB)HBT)X'/W?U\:(MHOH!(^M\".!Z\CGL.>>/F2 /M]-$6]HB:(M%*"?7
MG\@Y/YOEHBV_.1QS];CYA)/YN/7\FB+Z2L*) !''S''Y@>_Y>./D=$7WHB:(
MJ;<J*U5L[="$P;5R FI7,Z>F4NM3(,I,/J4H%+*I"W'>4IYZE @DI3HBMNSL
M/MPU6VE4Q23/HVX=:D3H;N2Y,MCWEJY:R!,F&VY:J%9+3<--V")-;[LZAX'I
M6$E2%(V\MD5R<:QBGQ.O:J:*NC5M<T7'?(C]:E.27U!4B3(?=*Y$J1(6.MZ1
M)<6^XONXXYSV(L./&W_P9@O_ $=P_P#[#3]5*?/W?FH<QZ'\6K+7"64OX/B"
M%I2M"L4H I*@"E0-7'!"@4JY!'8@]B.QY';5!S02QU]5,ZFP8O$?70W4P,3Y
MB% )XY?8EW6[&Z,G<SPP7^&8/$RZ4N9FN"Y.N;"HZ^X?*C+O\6>K:Z<J.U8*
M<7*L*)3+#"IY>D1I*$2ELM[DX0[2VY7A_LV=C%8@4&#[-4HM;4<2T'2RH'/I
MP1#8>)\P3XE9\3E;:]37+0))(%M[D[=?.;[JSWC'\"5QX0_"[L+28DX[DV'X
M==Y+;;V9! 84E^UW/RZ/40:;-IM>"I\T55#C66+5 Z'54=?*BJD*_P *E2D^
M3*>*:>;9YC<1C2]CL0T,PC7 'NZ37N=HD& 27![HF2 (A@6V^RFIEN6UJ]#%
M.#<54:/L[](+)<27 O-P!$B)D7@0N?[(C::SSCQ%2-W4PG7L.VQQ2]CQ+[RU
MJK9^7Y4RFJC0($[NS+D0*0VK\\,+<]V1(A-O=*W4 0XZS"B,#3P5*H'5:U1K
MB!!BFR7 FYCQ:1M&\+*>T?.J%3+Q@65-==]4.JQ#F$-=XB' R03=ICS@+TMY
M#C-9EE+8X]?1$SJ>VBF)812^^P7V5*0X4(>BN,OLD*2A8>9>:=0M"%(4DIYU
MJH;"=^:TEN!Z=(^O?Z<E3\/:S#8,%^N14"=&E4UCC\GZ9GV5U*DTULZA^RK'
MI]M+FS'(DIUMM2FU.G@MI[]D\$57U='6TR)B:V(S#-A+,Z86@HE^68\>*7EE
M:E%2RQ%8:!Y 2VVA('U>=$7<:(L)/:"[17.]7A9W1Q+&ZURVR>OA0,PQFM91
MUR+*\PZ;&OXE;%3QS[U9MQ'ZY@@\^;)2GMSSJ[\.XQN7YMA\15,4C5+'D7BF
M]H:7$2+-(:>D F;+(.%\;3P.=8/$/>6-94:*A,0&N</G8?.Z\LGAYQ?-]P]]
M]J\4VP;G(SR/GN.VS$GRW8;V'-4%K'M[:VO52 RJO%55PYWG5DH-R[%9%2B,
MX[(=:3MK.LPPM+*\4][V/96H/IL;]XN)!!! -IU  ]3.ZWWQ1G&5NR/&][4[
MPXS#=W0#=+B'L8\'5+O #K9!N1<\A,B?BM]AQF>Y&_MON%X?\WP;#]O=P;0W
M&2XWD;=DA[#KB>LN7<O&V*Z*^Q95<^4N18QJA4BM<@2I,V,B8N*N*(_CX;[3
M*&6Y4["9@S%5L3181AWTFL>RJ0"&AY=4::9  :3#@Z9@&0.1\9DXKXAE2GH:
MP5"X@R#!!'A@&??! ZPIQ/"AX5MN?"/M-3[7[>0$*4RA,W)\FEH:5=Y?D;S:
M1/O+B2AM!6XZL>3"BI/N]= :CPHJ$-LIYUAGF<XS/<?4QF*<2U[G:*<VI,))
M#&B;^;MR;3%A=Z-!F'IAE,;  D\R(G^6W(F\JR_B)_X^L*Y]?(V9_P#\S*U;
M&[&.COP:JXV,]/S"SLGTM?:2*J9-A1Y4BEF+L:IYY/4Y!G.1)5>N3'/(\MY4
M&;+BE8[^5)<3\>TB@J*>VEPYW);++U5TOZ>N%)-L\B^OF(,_HKD5+9E5+-DW
M5/!NO0F.D+AJ*0"XE27%=0(N9A^WN)8%$7%Q>F9JVW1$9>=]XG3YKK,-D,0H
M[\^Q>E35LQ6?X.*PI]3,5(/E(3U$Z(K@I6E1('/8 \\$ @_+^_C[.1HB^]$3
M1%M%Y*>>0H<*"3V!]3QSPDD\<_/@_'CCOHBW H*YX^'Y/U'O^<#[-$6NB)HB
MV@\CGCZP]?5)^ Y)].X^1'8GL#WT1?94!P.Y)XX 'S^WT'S[D:(OK1$T1-$3
M1%H5)'J0.W/<@=OG]WVZ(J,SS-Z? <7L\HM7^8U:A'1%8Z'9EC+?<2S#K(+)
M6DO3I\E;<:,TD\EQP'@I2H:BT%VU_P /DHZ76\)\4EMC<#<CK'.-N:PCB93X
MA=[)DR;CLY_&Z*+(>CCZ'N(V/T$)QI90]6B_16W%SE%O%6A4>P?J6(E1%D(D
M,HF!;03J<Z&V)$GF?H6ZP9]4(($D$#J00/P7T]F&_P#L=:P%Y=)E9/13Y3<1
MI%G9,W]5:.+"E*@UN3FMJKBFO7FFU*KX^01'*ZPD-&(U(6](96FF@:X[ GT!
M*SBPS,*?-<7I\IJI/7 N8PD,ID)$:3'=#BV9$&7'4HJCS8,EMV'+CK/6S)8=
M:5R4DZA(%B1)V$[J!!$2")( !$&2) @Q<BX&ZYF29'68O2V606TQB)55$*3/
ML)+A"@U'C-^8LI0D]:W. ?+:2"IU92VD%:TZC!)  DG8<SZ)U\K'R/0K!)6X
MF^6]5_81,"3-Q>FAO-MNM0I4*E:K4/-B0PQDV5R8%G+?O'X[C3ZZ/&X)-8E:
M69[_ "XU(5$C20' @SL1!-^A3^];=K9>(W99<>YNK=V^HO.2W(D6-O\ NMQM
M*EJ 1'M);U14Y/C1?<XCQ[DF?6L//),M+;24MNSPUUA8\NO\_H]5$ N.EH+B
M3 :!J)/2!<GRA9G;<[A5NXV-P\BKT+AE2W8=K62U(]]I[:( B=72RW_!%4=X
M'RWD$M2F%LR6"6G 1(008OY6WZ'WJ+F.9.MKF$;A[2TCK(<!$<Y5:S9T>#'D
M3),EIF+%8<E2'7%I2AF.PA;C[SBSR VAM"EJ5ZCI^W4.<<SL.?PW4HOM>=HO
M*P,M]X]VMXKV51[3Q["JI&$&1'?K_<*^U?K5J6U$O,@OK6/*9QN+: &154E=
M DY _%XE.%E*'&4S1I=#P01_"1!MY&#ZI!Y@@>8(_%=9<M>)7:I@Y--R:?=5
M$3HD63JK=.<U$%M(ZB;JGL*BHR&+"">?,F4+SKL5M)=6V&4KXF)IQ.P.QV'N
M.TR8];=%"1XKCPB77^Z.KN@]867.T>Z<3<^A>GJCM5ES5.MP<@J@\'D1)JVD
M/QY4*3V3,J+2,XB95S E/FQUAMP)E-266)""-P1ZV_%3ECQIEKAK;J;+2-3?
M[39%V^8D*M;NMJ+J!95EO!@VE;8M/QI<">PS+@S67& AUB3&>2XR\A:>4+0X
MA74GZI!'J94?1J-J4WN#FD$:7$.89)MTV!@2#;I"\];#4<71K8>OAZ>(HU6N
M95H5*;*E.NQPAS:@(+2#.GQ<A\()=K/ %M)O-EMMUW&3857P*:!>S*K'I<40
MY;EAD^3P)##'O;,EVLB^171D,LP%L(9)*FTI5QK)?V_7;1 <T/<\7))L0-R.
MOB\_*5SEG/LM\ YIFCLS8[%Y95J5'/Q>58$=UAZ6IVM@IN8WNBUX%36*8\):
MV0-5YA++8';.UV-G[ 2Z)!VPG8@K"7J5E]QI1IGHZ8Q+<@#S43$*"9;<D=3H
MEH2^"MWCFQC'5Z>,IXYC]->F_O&/U0&F8$NGF"6WN0>2Z*X<PF'X3P>68+(Z
M?V6CE+*=/"L:-.@4V%D=3J#G%QM<E0D[J^S*VDV7M83L_+<TW&A3\7S:\@TV
M0R:ZM@-2:)RB^C46;=%#KI=]PBP>2^Q+DIA2E);7)KW5D@Y95XPS?&X8X6BV
MG1JEK6BLQT$G8N+C :#R Y<RMB9GVA9YCLN&#HD4JP:UO>!SA,;G5:">H,[R
MO0/C5%2X_1TU115U?35=;70XD"KJXS4&!"C-,(0U&BPHZ&H\9A"4@(99;2A/
M2/J\C6$5'5:CB^J\NJ%VISW.+I<=S))F_P#:F^Q6$5*M:L[77>Y]0W<YQDZC
MO?G=50CT/<'O\/N&@,\B/54U]ZBB:(FB)HBT) ]2!]Y _KU"1,2)Z<_@BPUW
M@WYR9O)7-N]L&5.VZ)JJJ;<1X+%G/>N0T)#M%C4"2H0G)=?%<:DW-W:J12U"
M%I;=<<>;E)8F$:@#SO&UNOI93]W4C5W;X.QT.@^AB#SVY@CDJ$=P_P 4M?$&
M0HR*]DRV^9#],QFE587"$M\J4%4L[&XF,2ND?55$AV+9=1PEE]7(.IR6;1[X
MMMY0?KWJ0=-S:W7EMZ[*\6Q&^\W/)CV(YBU&A95$BRI,26S&<KV;QFM?$6VC
MR*R0I4BDR&E?6TW<4\A1X2XB5"4[&\X1Z?G!@<XLA\)#7>%Q$AIL2.H!O"RA
M4X@ _70#Z#E0'?X#U'YM(/10D")(OM??TZK$_>_?RQQ"P3A6%MQIN4OM0USI
MRX9M$4YM24TU?"J67$*N,DMR"[ KU/LQ6(Z#83G$Q%MI5,ULF\Q^,?RGX*H*
M;SLQYL39I-AN=MAS/)6N:PGQ438AR 9+<M2P!(33/9Y5P[0H4 [T&IAXL_C#
M#O' $5V:ZE!(0J6 %*$2YEV@7C:T])N9'US5/K!V,$="-QY'K/P5>[.[]9!*
MR'][W<M@QKYR6Y6U=I(AM54QRWCM>\N8]D->VXY!C6\B'_AU385CZZN[A];K
M"&'D]#DH:Z-4.T]8,?&(]9,_E, 3L"0)D@$@1U/+^]9A)=0$@J<1R GJ)4D
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M$P9(Z#WKK+L([9,1VAY3FC,Z=1&?9'1-;%8BC+:>+PS:;GFN+F'%M/Q@$#Q
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MH.J'[P08O,1$ F!>\KOLHFX\G+?$"MQOE;6S*W02MP<+]]GI*N.H#ND\$<<
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MJ,4*^J?O26^&(M]PWD[BW)=M^R2PLX?[5W$S.3841Z4,S._2^T=5$>%*3U<
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M/.!&/PKH(BX)@6&RBBC]38:<Y(4L/(/?L$F.KGC[>./3X$\\ZN]5S:M1]*#
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M786W4R9>7;92:[/;^BB-&18"'-F9')M8C#$=*UORJ6'D:)$AEH%XF$YY8=Z
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MT3P>KI'*1\N-46TG,>:FN9O8[\K#:Q^C*R,MP[F"EAZ+>^L"VJ *,W)#2_\
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MPQ::NBUL8K^G;)/4IB"RPTI10$H)*2HH0E)/"!Q0K.QF(K.?B,0ZH9,DDN)
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M ZY2<QU0]X7B?NDEUSIDR+P?6=S8\EDE&G5RS#TJV'P^&H4I&';@\,*44Z3
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MIAF3'<2I#D=]M+K3J2""EU"PIMP'XA;2^Q*>XU _F/EY1^8A3!\<O</H^?I
MCG/7P,>I*I2U55/55JEIX*H%=#A+5SZAQ<5ADK3QP.D!(4  H=M$UWV/I/X6
MMS^/D%VOEH3WXY)[<$GN?L Y)/;T 4?D#H7&+DGRE2B20+? #]%@MN+X[=N,
M(W)K=L(6*9Y=WCUHF#=R4XK>1(U=#:+IF2JJO^CW;O)I*$,D,-UM>F(1RX9A
M21S2+I(Y"08].I^MA95 T 1N3(GH#/P_4^:K9SQ@;3.(*%8QO,I"@4K2YLOG
MZT*2?5*D&GX4#\02 1V((U5U [N!_P"\HAL<Q[@ 5OX=XA]F;C)JJDH,%W J
MK>^L(]?$GR=D\GH(3<B2X&T*G6[](Q'@QPHA3TF4ZAI*25O.!"21 &9V]QGX
MV"&8F=A/K']U[>0A95^2GXJ6KL!]91)Y'/*B?FKMR?L'RU-)&QCTLJ9=/(#W
M _CMZ>JU\E'V_GTD]3\2H2?+X#]%A]XM&PF!BG3S]:KW( 'J21B:CV^WM\>!
M]O/;4"23UVN3Z_A^:J,-O?R'IT'U[EE-C+:3C6.@C_D2G^P\_1D?\@_)H">5
MMQ\"I7<SSD"#?<3>1>#U_(+N_)1\C^?49/4_$J63Y? ?HK)[D[ZX3M9;PJ3)
M*C<"?,G5XLVG,4P+)LLA(CJDR(J42)M'!EQX\DN1G5>ZOK;?#1;=\OH<!#4?
M[1^/UY*II)YB/]4*W?\ JP]J#V&-;U GTXV9W YY^''^)_7G4I?8^*;&T[^7
MO32>H]S1/NB_P5L\L]H)MCB.4XQ53L+W*7CV1LOMFZEX9?4=E"LFI"$):C8_
M<U\)^\A/,.)?4]4R9,^.HI;>@DNMZI!\.-K&Y$]>8ZFVUMT+) ZBT^73^<+.
M''KRORBEK;^H$T5MK&1+B"QKI]5-#+G!'O%?8QH\J,O@\EM]M#@]%)!U5!D3
M_/J!^"D<V!O/N^>_I\5WH1QP>>2"%#X=P"._!]#SW'Q'(^T1^NOUY=% &#Y<
M_P ?Q 6!]FW;^'_<A^UBURIN+VJY<>&"^B'$NJ*RLGK<T7T@]_@=7E&+VTVQ
M>HVIRX\:XJ9RV&GBZJ48\.72(&TCEMY?#W*N+B>JRSP;<''MP8D^10(LH[E3
M*CPK.OMJYVMF0I,J,B:RDH4%1WVWHK@D(>A/RHRDGI0^I04E"8_']>5XL!S,
MJ1S9(O'+;GOUYS;ERGDJZ\OJ /(^9!!/8@\@=*T]^_8GD?-)U%2-,&?)4L]@
M&$2)PLY&(8P_8]9<58/4-2[.4X3SUJE*A!YQ?/<K6HJ)X/8C3U /QW^-N5AT
MYJ.L].?EMTV_&>=E5"([;:4H;2E"$)Z4)2 E#:?Q&T !*$>G"1V[>GQT4"Z;
M="??Z^?RZ0OOR_M_5_?HI5H6N>#R>W<#D@<A25 \I(4""D<*2H$=_7GL^OJ9
M_ J(=$_7T/Y75+V.!X7;RDS;7$\;LIB5%?OD^DJYDHJ"NM)]XDQ'GBH*[\EW
MCG@A((!"/H6^OTLIM?0<YN9_3U^*J*/#9B,HCQVV8[#0Z6F6&@RRV@>B4-I/
M2D#[ /NT4I))_#R6_P"7]OZO[]%!/+^W]7]^B*V&YZ]N<;QVRS3/<8B7=;3,
MAV0MO$#E5KTE0Z0S&BUMA-5]8 %?EHCM]B\X@<*$#;:?01[XV-_4F;JJUQ,C
MRW^N?R\EB/MIX]=I<I<R%BJV^W%I\8H;"/6TSM)@-WD+DU_RRY-7.K\7KID&
MA4PE;'N\-^:_.<#JWGFV&.E.J;C#C 'X^O\ /G\U&#U/X<_+R]WDKK_ZL7:O
M_FYO1_\ 4OG_ /V1J/>>7S_DI-!ZCY_HKJ[9;R8CNRJW;QNLS.O52IAJF'+L
M-OL1\X3U/)8$#Z<B1??E),=WWA,<*,<!!5SUCB(?)B(]_-"P@3,Q<V_7=4WX
MD$AO Z<I'/5N'@8/)[_5NT*[=NY/IQR/O^&IR2;$SO\ E[U,PS.WPC\/1=SX
M>TI5L[A8([^[6O/!![B^L^>"!W'/H>>"-0:>A.Y\CN?U^I4'G\3^ Y&1SZ"_
MSO+Y*/M_/J:3U/Q*DD^7P'Z)Y*/M_/I)ZGXE)/E\!^B>2C[?SZ2>I^)23Y?
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M1%PI]= M&4QK&%%GQT/,R4L3([,ID2([@<CO!J0AQL.,. .-.=)6TM*5MD+
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MB)HB:(FB)HB:(FB)HB:(FB)HBQO\5^T<[>?8O-\/HRZG*! =M\74P\8KCUU
M;6XW6J?0ILHC744OTLI*E%M4>:?,2H \D58["[;#:7:/!\%<?=F6-/213>3I
M#BGGYU_*;3)N9#CRU+6X/?W'F6BI1Z&&6FT<-H0 17?T1-$31$T1-$31$T1-
M$31$T1-$31$T1-$31$T1-$31$T1-$7)A_P :C_TJ/Z]$6DO^-2/Z9S_+.B+C
MZ(FB)HB:(FB)HB:(FB)HB:(FB)HB:(A/ )/P'/YM$5O+#='#ZNU8I9LY]JQE
M9K"P"*Q[F^OS\DL*-.0Q&4*0E0$1RL4EPSE],9#RDQU+#RTH+Z_G]7\D^:Y=
M=N1A=DSYK605<=11<R&XTZ;%ASGH%%)E1K"T9@OO)EN5B#$<D-S@SY#L13<E
MM:F5I5HA,?6_DMB9N3C#6.8YD]:_(R6OS)R$SB,?'6FK"9DCT^%(LXR*UM;S
M#)3]&Q)<]]^2_'CQ845^1(=;0@<D7(@;@XW,J47<F4:&M]Q9F27\F5'H?HU3
ML^96F%9HGOMF%,:FP)3"D.\,N.-@1GWPM)+Z^*A/Y^X>?U^$KM&,OQ63,A5T
M?)*)ZPLH[DNO@MVT!<J=%9+@=D0V$OER4RV&GBMQD+0$LNJ"E)0H@HKA_N[Q
M=V710Z^WA7"\AN;&@A.TLN+:1V;.IJ+"YL(\U^&^ZB(J+%K7VW@Z0IN2MAE:
M4J>1R3Z^OKT57_Z=^Q[CD<CX'@^A[C1$T1-$31$T1-$6#WCHP#%)^SF:[FV+
MF1M9;B&,(K<67495?TD)%C;W,*'%<?K:RPC19SS<R>VXU[RAWJ2V&>.GC1%3
M>1[4;<[#[8XE7LU&99%<[M9?M+M]=,2MR<KC27;:QL&92["+,=F2U5K4:0Q)
ME2H<!MA,QD&*ZM#*0=$^O3Z_-7#8\266WV?Y1BNWVW^/9-38%GC.!9)7R<]A
MU.XSYBN0F+>_I<1DP4M/T=:9+LB.]*L6W[)AB0ZPE9X!)_+^?/Z\UI;^)3*Y
MNX^;X/MYM]097^]Q?5M#D578YW"Q_/;MZ4S"D3YN(8O)A%$^MKXT]"S,E3F$
M3W6'6X8+?0ZI(^<?7U\T\E7M?ONW/R?Q 5#] B-4;%5%+.DVR[$K7<39^+RL
MJGP'H_NR6:]==':BL%T.R%++X46D!L=;\>GU*?7U\%:EOQ:3[BMVT@8[B^*1
ML_SG;B'NA;U>:9W&Q3&<6QNQE.1*MF1>R82I=C:6\CH1"A1*]'^#M.S'U-,=
M <*&]][?SY[3;=9 [(;JQ=YMO*O.8U7]#.R)UU3V=6F>S:,0KC'K:736;,.R
MC-LQ["#[U#6Y"F,MI1(C.-.?A$@%%7;T1-$31$T1-$31$T16[G;I8=76L&DF
M3GV;*RSC][R&PJ'(/FY,:%K) QUI0I*(1K'V%"P<*8OO$B/%+@>?;2HBWX.Y
M^!SX L49/31FC7V=QY$ZRA0YJ::I=EHDW"X+TA,I%868BIK,Q30:=@NM2DDM
MK!T^OKZY(OJSW%QR%1XY?0%RLCCY@[#9Q./CS34Z3D+DZ"_9Q_<"Z_&C>5]'
MQ9,U^1(DL1XT9A;K[J!P"1?<#</%IM*WD$F<**J5&BR'Y.2EF@,%<N9+@M0;
M!JR>8=B6(E0I#)C.H 6XE"67'2XCDB[:/EV*RY<2OB9)02K"='<EPX,:XKWI
MDJ*RGK<DQHJ)!D/QTIY47VFEM='"@LA2>2+AM9UB\N521*VVB6ZK^SLJF"]4
M2(]C%3,J($FQL6Y4F*\XS&,9F-T.-N*#Z7WV&5M)6LA)%5VB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(N3#_ (U'_I4?UZ(M)?\ &I'],Y_EG1%Q
M]$31$T1-$31$T1-$31$T1-$31$T1-$6A (((YY[<'T[^G/ /;Y]CHBQ@S[8S
M),IR'.\DI,GA4\^[C8<]B"I$:6\C'[RLLJ1W)[J6AM1$J5.J<=J8-0EM!]W4
MF6):5LR74J* ,^_Z'Q7,M-A@J-8,4S]/$=5=^^54I^$XY*C4T#:X[?TU3)E)
M07WD,35N6T@-K\MUM]]"4E]Q9)1^OJ;?7)55E>"V]MA&)XY#QS!;5%-&KV;'
M'[MVVAUC3L&"S%BRL=O:^";&KE5+[:E0I+=:U(D1''$)<@NK6O10Y^HD_E];
MCHK ;@;3;L5T+&D4MO87MK'1CJ9N0UM7$OIJ'</QVXK8U7+AY'8Q/-B9#)RN
MW*+Y]V;*K6JN&],0N?+4^R^OKZ"?7X?E]65Q&]C;C]S3;-8<=QJ]0]CTFH0W
M#,]G'8U!MTJ@ATHEK9<7*C,9;+G6;O)7'E0WUJ6A]UR0E;ZZ**YFU>R]_A-]
M#O+:76O\6]_:+@Q[&RL_HOZ0Q/&L7KT0Y\V'"$QR,S36B'A[A71DQ[8)BM)2
MUY:T?I\%"_,_E)^NGS63">>E/(X(2D$ \CLD#L3P3Z?$)/\ -'IHHK71$T1-
M$31$T161\0&U=EO'@<;":^VA5##V8X;=W3TYF2^B728Y?P[J=6LIC?73)G>Y
M-,-+7PTCE2EGCU(MW=;:^?N)DNS=DS9PX=1MKN.SGMO!?9?<>MU5=1.@5,:"
MIO\ @6G6)<X25JDA25):_@P".-/KZFWQ4/RW]%82;X:-Q<JS[&;S.+[;6SB8
MAGT7,ZW<6JQ612[Q65963W;&LQ"SL:]$:H17)*VZZQFM%U<^L0M!C)D.K<T^
MO@HKZS#PT;B;@9C&>S"^VTLZ*LSV'E]'GS&'NUV\U32UELU:PL/8N:\QJD1V
MPRW6.6JE./2*]3@>C+</5I];D_7T>JA\[?7Q\@M<O\.V[TJRW_K,,S?"*[#?
M$![U/M)5Y37,K+J"RD8TUCJZ^$[$>17/5;T9A 1)D(,B&AUY+;"GDMZ**XU[
MX5\FJ\EI,GP!S:RV?_>MQ+;.[JMU,5E9#6P%X@TIBMR;&?=TNNLR_*<4F17R
MBVQ+ 3YKS8]"+++;?#UX'A=%BKT]BUE5<0(G6D>HK*%FPGNN+>F2VJFGCQ:^
M$TXZX4LL,-$H90CS77GBXXHGUY^?Y*N-$31$T1-$31$T1-$6,.?;#WV67^=7
M];E$2IE74W![/$'/=Y2G,9LJB3CK67V*^@]+LV[J,9JX=<XPDF,6WP__  ;R
MTK(M;O8)V5#O6*=^BA.S[BVFUCCT%0=AU:=J)&V^.5+S[;+BU,PWWUV4Y*#Y
M;C2SY2%.@AQZ>]0Y\^OEZ*M<PPB]N\0Q2AAT6$VPJHT1NQI\@>M8,&+*C5R8
MD2QQR^J(IM*N;4R?,<9=;ALOSH:EM^?7R%A:WUNGU[O[OFL>]Q-H=U8[./BH
ML9U_/:=KY,S((M;#NY\E5!A3^+PZ*RB75E$6S'NI-[?2?I\FP?K6F8SKR$3W
MUR ^OKZYJ*N(O8FU:ID.T1QK'K[Z1K[&N28*Y[%)"K=JI6"UE$9+L=;\F-!M
M["78N* ++\9;BUQG'5J8=(N;M5LKDF#W\.\MK.MD->^W\Z16,S;*T5!798YB
M5%7(AV,N' 0^8;=%8(? @0XP:L@F"RTEIQ!(LF]$31$T1-$31$T1-$31$T1-
M$31$T1-$31$T1-$31$T1<F'_ !J/_2H_KT1:2_XU(_IG/\LZ(N/HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(L>]XMZL@V]RW;C!,
M,V_&X>6;CIRA^!7.9-$Q:/!A8K#AS9LN1/F0IS12ZB8$-H*&^5(XZR5 :*!,
M?GY>?UZK;VFWVGYWE^>[=9M@4W;3.MO(-%=7%;)OJO)*F70Y&U)56V<*\K$,
M,)2'8<EN2S*884R$)6EQT%8;**OC4W]'?,NR:*XJ;J,RZIAZ14V4.R99?0>[
M+KD)Y]#;H')+:E=22E04 0=$^OK^Y<)&98@X[)9;RK&W'(3B&9C;5[5N.1'7
M' TTU*;3*ZV''7BEEIMP)6XZI*$IY)X(N8O(J!JU11.W=.U>.MEUJE<LX*+=
MUL<$K;K5/B8M !'UPSTD]@2."2?7U\I]5MSLGQJL=<8LLAHJ]]EYB.ZS-MZ^
M*ZB1)3U1V%-OR&W$O/I(4PTI*7'D$+;0I)YT1;UK?T="PW*O;FII(CKB6FY5
MO90ZV.XZO\!IIZ8\RVXZOU2A*B"GN%<\))/KZ^NO-;DFXJ8;;#TNTK(K,M+B
MXC\FPB,,RD-,^\.+C.K="'T-L<ON+:4M#<=)>6I*..2&RX,O+<5@18$Z=DV/
M0H5J&S62Y=W5QH]CYI"4&"^]*0S,"B04^[..]22" 5$(T147F.\>$8/E6!X?
M<V;'TMN#93:^I#,J"EF&U!J95NNRME294=4.O?9C&/#>4A2I<IUIEA"U+&B+
MO:K*K:PS/+,>D4$>'08["I'H.4"^KI2[699,2'YT&11LJ,^E16-LLJ3)LO*1
M/2_UQT!ME:B^M_KW]%#G_(_C[OYW"[ROR;'+9F9)JK^FLXU>5B=(KK6OG,PB
MVA3B_?'(TEQ$;I2A15YA!2E*U\%*%E)16L/(Z"QF*KZ^\IITY+"91APK2#+E
MB*M(6B48T=]Q],925 I=4VD*!Z@"V4K44)^'7ZY+N001R.?B._8\@\']8T45
MKHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:
M(FB+DP_XU'_I4?UZ(M)?\:D?TSG^6=$7'T1-$31$T1-$31$T1-$31$T1-$31
M$T1-$31$T1-$31$T1-$31$T1/B/M('ISZGCG@?+UT18$[G8G=;K>,''J"ASG
M)-OGMN-CK*[5D6*,T[]BS/S/)HM2BO=3=U]E%;;EP8*U/>6RU)Z&VR'6^D#1
M0Y6Y_G[OQ6*4D7#'A^EW%G<27,XRKQ)1]O/$IG^92+2<PJBQ.YL8L"+DBJU=
M?(K,&<A)I6)4&O7 CMQITL^>E$Y;BBBJ_KV:6BQSQ1[@XYEF'1,?.T,;!'6M
MA,2L\=Q-W+9 DKKK;'IUA<NU6095&C3V8$Y%$^XZVPIEMQYZ4&VTD^OKZ^"Z
M386OP'<?.MJH-O0[;8QD.U.!W<FDP6%A.5UE[N9?MU<5M-WD$G,<5QZ-8"E?
MCFW$>(;F8U;/B6U-2QSYA0Y_W7V_3ZLJ(VZK5;AT^ 1K?+=KF=Y<HW;CW]R_
M%PS)[C?_ !_(JO*GYT^+>6C5VGZ!Q^%!C+K'W)$.-1M5+L=N,T^%=)?7U^7Y
M)\+_ $?R5R<UQ;"<LPOV@&\&6XO39%/@Y3?X7A\^UAHEN5#^(XK44D!^H=6I
MQ<*6BYFL],B&AA\*9Z$N=CP_GLHKJ<A??J-S12[I7FU4>CP787;F%A%;OG2W
M>255][_4%666N(P8EG"C666.3XS%?-Z6YUS[NF*W$'EN/$OKZ^OYE55%MK7Y
M'D_@OV8S$R,MH<>P?=K<FV@VU9:4J9-18R&8.-55E16$EZ?#KV&+ 5HKYS[J
MG(32F'T^42@$5-[Y76WDBSW\J&*7:3&$;0X8C;W',9S.ALLHR>]@-XNJXCJV
M[Q7Z2A56(4S<JP\AN[J8$U]U^(JPL'68[2$)*'7^[K]<O7959CF'X(G?/PDX
MSN)78W(F4_AD;6U(RJ'"D/93F$WZ"C5-8V_/;<%O94[$:R?KXH<>=AM)+[(;
MYY)171YQ:V;N'>*;-&I4Z#CN8^*G$\!S>ZK#($FKVKQ1%'CV33/-A\OM0TMF
M=&FNM$)CQ7GUGE*E#1%P-S)NW];8;^YIX?H5'%VSH/#'9X/DEKA;#4;$LASW
M*;EF%C<&/(@-MP+>ZI:N2XJ;-B%YQIN:TU)='2 "7^ND_I\U=:BVDPW;[?KP
M>8[A^/5]!?5>VV>W>;6U9#3%M+R#7XK2U26;R8@^?8-/7-BX\TF4ISI4A*$!
M*$-\% \^7Z?%22CX]N/K*_RCHHC]?D5KHB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+DP_XU'_I4?UZ(M)?\:D?TSG^6
M=$7'T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$7'3
M$C(D*F)88$M;2&5R@RV)"VFU%2&UOA/G*0@GEM"G"V@E12@$\@BV%5=<IN6P
MJ!!5'L%K<GQS%9+$QQP!#BY#126WU+0E*5EY+I7TCK*@ D$5NMQMG<.W*Q")
MAMFS+HJZKNJC(Z*1BKS5)+H[VBEIG55C7AAA<7JC2D]:HTB,_$?0I:'V'.KJ
M!/KZZ+H\:V1@5F:5FX>49GF6XN74-784V.666/4S4>@@VJF#:&NK:*IJ8?OL
M]$=IB182FY+YCI+39;2M743Z^K_717=8I:B--DV4:KKH]C,2E,N>Q!BM3)0"
M4HXD24-!Y])2D#I>6XD >FB?/\_5;QKJ]3,B.J#"5'EO+?E1S#C%B0\ZOK<=
M?9\KRW'EJ""IU22M90E2RH@$$6U,IZFP<BO3ZRNG/03UPWIL&)*=BN'U<C+?
M966%GUY9Z._KSHBY1BQS(1,\AD2VVBPW*#*/>$,E7664OD>;Y14$J4T5EM:D
MA2TJ/!!/KZ^O<N"]0TLB6[.?J*Q^8_&5#>EOP(KTIR*KUC+?6T7%Q_CY#A6T
M3ZIZ?J BWW:RO?=BOO0H;K\$\P7G8K+CL(\<$Q7%I+D<*Y5U!E3?((2"$C@D
M7W]'0?(?B^Y1#$E+=<EQ3%8$>4N1U>\KD,I0EMY;_4?-4ZE?F J#@7SV(MAB
MEIXT$5<:JK(U8.#]&QX$5B 5!:7.HPVVDQB2XA*_]Z[+Y4."=$7*,2*9#<HQ
MH_O+32F&Y'D-^>VRM74IIMXI+C;:SP%H0I*%@#J22 =$7)[? <?Z?Y_71$T1
M-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31
M%R8?\:C_ -*C^O1%I+_C4C^F<_RSHBX^B)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M+DP_XU'_ *5']>B+27_&I'],Y_EG1%Q]$31$T1-$31$T1-$31$T1-$31$T1-
M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
M7)A_QJ/_ $J/Z]$7.D5S[C[SB5M +<6H J7SP5$CGA!'/W$Z(MKZ+D?CL_I+
M_9Z(GT7(_'9_27^ST1/HN1^.S^DO]GHB?1<C\=G])?[/1$^BY'X[/Z2_V>B)
M]%R/QV?TE_L]$3Z+D?CL_I+_ &>B)]%R/QV?TE_L]$3Z+D?CL_I+_9Z(GT7(
M_'9_27^ST1/HN1^.S^DO]GHB?1<C\=G])?[/1$^BY'X[/Z2_V>B)]%R/QV?T
ME_L]$3Z+D?CL_I+_ &>B)]%R/QV?TE_L]$3Z+D?CL_I+_9Z(GT7(_'9_27^S
MT1/HN1^.S^DO]GHB?1<C\=G])?[/1$^BY'X[/Z2_V>B)]%R/QV?TE_L]$3Z+
MD?CL_I+_ &>B)]%R/QV?TE_L]$3Z+D?CL_I+_9Z(GT7(_'9_27^ST1/HN1^.
MS^DO]GHB?1<C\=G])?[/1$^BY'X[/Z2_V>B)]%R/QV?TE_L]$3Z+D?CL_I+_
M &>B)]%R/QV?TE_L]$3Z+D?CL_I+_9Z(GT7(_'9_27^ST1/HN1^.S^DO]GHB
M?1<C\=G])?[/1$^BY'X[/Z2_V>B)]%R/QV?TE_L]$3Z+D?CL_I+_ &>B)]%R
M/QV?TE_L]$3Z+D?CL_I+_9Z(GT7(_'9_27^ST1/HN1^.S^DO]GHB?1<C\=G]
M)?[/1$^BY'X[/Z2_V>B)]%R/QV?TE_L]$3Z+D?CL_I+_ &>B)]%R/QV?TE_L
M]$3Z+D?CL_I+_9Z(GT7(_'9_27^ST1/HN1^.S^DO]GHB?1<C\=G])?[/1$^B
MY'X[/Z2_V>B)]%R/QV?TE_L]$3Z+D?CL_I+_ &>B)]%R/QV?TE_L]$3Z+D?C
ML_I+_9Z(GT7(_'9_27^ST1/HN1^.S^DO]GHB?1<C\=G])?[/1$^BY'X[/Z2_
MV>B)]%R/QV?TE_L]$3Z+D?CL_I+_ &>B)]%R/QV?TE_L]$6]'KGVWVG%*:*4
1.)40%+YX!^'* .?O(T1?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g40894g21m31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g21m31.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1G24&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q :X            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      T$    &
M  -&   $N0    8 1 !3 %  ,@ T #     !
M  $             !+D   -&                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   -&     %)G:'1L;VYG   $N0    9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   #1@    !29VAT;&]N9P  !+D    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M 0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E
M9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '
M9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y
M<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T
M;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S
M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     0X0DE-! P     #UP    !    H    &\
M  '@  #0(   #T  &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( &\ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
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M.#A>XMJ<!!WP;-H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0'_P  1" %N A # 1$  A$! Q$!_\0 '@ !  $#!0$
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M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBXKA
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M5LG(L6S/=O'<GN**JHI>5R[?&J'%K6YE-1\?KV)<BS84[+@>>$LNI+*G%+'
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MW99?/KDV4)Y]#WHXHY^WT]._W:UQV9&,9G1_^8TH]>_8LVX^/]&P?*"\$_\
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M9;<IYL,. GDJ00E/Q62/0#U)Y]1J5Q>UCGL +FB1J,">4E#I+@QQC48^AO\
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M5<&##TGU@YWAA@;W@W!/A!#;<Q'D</PM:KF.;?L7#-<YYQ5.A3<SQ6J,IN=
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M=M'$5=1H4750P:JA:"13;?Q.@&! -[>^ZKT<+6Q#:KZ37.%%H<_2"8#I FQ
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M""#>?C;IO_=>+PZ359U.S[9:T6F7191M]G&:XVQ* <8H=TMNL:FY7B^5URE
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MFB)HB:(FB)HB:(FB)HB:(FB)HB:(O@K2"$]R2>.P) [<CJ/H.?ASHB(<2O\
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M3 ,%9P><SR4EYKJ Y*?,3R/3N1U<@=QZ_,?,:0=X,;3'/HI3X8U6U26S:0"
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M8-<=FN=8NL";"23;D!SV@7*S<P7-*G/<<KLHIGE*@6; <2P^@,S(,EIUUB9
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MOMM45PS/,:Q^XL[R;';FMT6.MOMP6UQ(#G0Q+GVCBI"&''EN1X<2))<>C/\
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MQ<.MPT': T  DBVPZ)RS@SAW+,,T9E@6XQT /<6&I))W@ <COTWY*3#V=?M
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M/J^:9?F RW"OK!]' 42'4&46_P!32J ZVN>VF0RK<ZJFJ!I"F]\)OC+C[Q;
MYKN+G\.#6Y!M&Q9NYPF T40Y4>MIC<1[B$R?,<9;L8S3P\DK<6S)9?;#BD=/
M.%YODXPV/9AZ8(94> )VN2"?0?SC>>U.R;MBI<;\ YCQ1G+64L;P]3K/S'0#
MW<X6B:XJT@=3FA[&N.F7>)I (! $)V]7C8WIWARZ9DZ;J/A=2RF9!IL>J*Z
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M?,;V]KLZ>U6@!  X7RI\VD$XG,!S$@0-I@&X ,DQ[5$CJN*=*^H*-M5\?66
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MAPKW&G6=-^^+9B#H:&@-$=)ZSO>]^1LU?&8XL2(&+Q3&@02)KUA/,GP@23>
M(D !2A>R5>2]XDLD5T@+_>JN^2 .23?4"2#Q\>A:D]^_20/0)XQGBASW9.0X
MD_9\:VC1)%V4W>,@&)=+W$R2XW@&! ZM]CLA_'V>U(;J/#[6N< !J[S%D/F+
M&6@-N)$6(49N223^Z3)P 5?[(L@2I7'/ %Q*(3V[)">I0 '';ZO<  9: *>%
MPS6>%N'IT74F@D:756N[QW5VLM;(<3 ;X8DSRKGM=SL_SACCJ+LSQP<XC?\
M? B;#:71<09-YE9\>RZ2W*\76.-.(Y;3A^<(2WR4CI-<P2D])"E#J0#]8G@C
ML1R0<:XJ<6Y>*H([RHRBZH^WB<*E(3>VQY ;KHSV17E_:I48?NC(\U+18 2[
M#L(M<^%[P 28#I@6*Q#WM?2C>G=YKR^4L;I[A!L=ST<93;+(^9X62?K$GN?4
M#@WK+Y&!PNGP][3I]Y%M>P.]FC3'W2V=[+1_:*_3Q]QLT@EM/BKB&G2W=I93
MS7%M:V=S&F!)= %Y$A9$>SN6U+\8.U3;B>09%XYQRM/*F\<N4I(X([!!3V';
MN2>23S:N)P:>1T:+012UU_#O$P?O&3N7"YYK:/LQ/[[MFR%SYU,HXUX(\/BI
MX.KI=X8! EN\B1<223:/Q5NEOQ)[XH0"I W+RD]/+JD!1L7>?JA70#\3]7GY
MZ]V5/<[+\,'1:DULZ6@QI!B0 =R>:PSMEJO_ ,:/'5.Y8WB3,"T!I('C !EH
MOX8%^4>2JWP/.ESQ8['(7R$G,DD()<""HUECZ(4HHYXY]$\C5+.WN;E>* ($
MTG-)AI<6P3&HC5N!S5W[ *KSVN\#TC.@YI6=!:8D8#%F07"1>]MOQU\<CZ(_
MBUWO0A(Y&7N$'J*B.NJKDJ3W)/!22.GT]#Q]4<.'P*F0MIODTQB:)TB6R06/
MF1!^]??D.1A/:&J&AVR\9]V+G$T3).LS5RW"N>(=)AQ<XP" )&F+12'A4>2O
MQ*;#,K;!0]NMA(6CN"2;MGKX/X0Z@$\@$<]/I\=>G-B'Y?BR27&DRH*9/\(T
M-@&#!ATGQ3OYPK#V.OGM/X":1#:O$^4,J-V+@<;2D'<AK@8\)%XLO9;';0TP
MVV@=*$)"4@<]@/O)/YR=::!+A),DR2?>5]H'$N))W/T/DM[45!-$7!E?[XW_
M .K_ )8T=]T?ZWYM4I,$^88/_;G\EXM/$<H_ZH/>[CCG]]O< <D\< 95:<G\
MWP_7K;N J@X*C3(@"B9=/2DP[1SG>;+XN]L8([4.-7 _>S[$M@#8:6WGTO$>
M0ZJ\OL]U*3XQ]CB0%*^GK_L#\/W(9 1WXX^'RX^TGU\V?/%;)C>(:UTV,Q%K
M1L=_2%FGLT'3VP\/@B268P=)/V=WKM ^(OS5'>-)Q0\5^_0 ')W$L@.3QV]U
MB$GT(]3Q]OWZKY*X#)Z#0?X&7ZR0!;>-E8NWML=KO&W.<Q)%INVC3 ^,?CN)
M7!\'RC_JJ=@%*''.YN.CUYX_PAP_E['_ #:AG%8,P&,H!LZJ4ZIC_H0[[L'S
M&_)2=A(([6.!B;SGN$&^W3U@ *X_M#EJ/C&WLX '^.Z8]U$ _P"Q6B[\]O3O
M^O7DX>JZ<KP[+6U.DG?4=@/*-Y]W-7[VFI';!Q*1UPK=R+##4ST\XB^T\U8W
MP\<_O^[+=A_QI8/SWY_\(H/I\?\ 0^HYU[LSJ#]GXKSI.BXO!!_E_/?!NR$$
M]I_!!)WX@P/7?6?C8_'DLG/:<K*/&1N*  >:/"3W/'_@_7D#_3UU:^%3_0*Q
MZ-'R:[U6R_:I/_ABSP&8=@\E%O\ [-I$7]W0K#;;=Q9W'V]! Z?W?X8.Q[C_
M &158'(X[_;QQ\]7/&5M> C3&IC!N#L\$W OL/T6GN!F'_#;@]I,Z>)^'_B<
MWPK8WZ7Y<@L\_:OJ(\6$@  _[6F%GGJX()D9"!VXYX^T?=QWU:N%7!N7UA_\
MZ>?7]U1L?KYK?7M?D_XUJ $7X5RG?E_2LRN/3=1STZU"YI>>"/IFJ]%I/?W^
M/\N3_FUD.(>!AL1SFB\1!!&J!,S%I]ZYCRB?VKEH(C^GX6\S/[YFTW4I'M>3
M_M^;??;M53CU].JYN3SW'PYUC/"3] K&)_K1O_U@\O-=>^V8-7%?"Y%B.'WG
MXXFESLHIBLA ![\.*([CXDCUX[\#[?\ -K)7N#FXX;>#2;R?NM.UHFP$V7(>
M&D8S $\J^',?]]H^,D]8]ZEK]JX1^Z'PW_,[*)/?T'^%0OC]G([]N_Y]8UPL
M_NCC^?\ 2'\XY V^NMEV-[7<O'9I(@GAH[7@S1_G]&%$B^\M*%I*0>65<DK]
M $G[/CSV^?;YZR5I#\,]P_BUF!?F/Q)Z;KC"'=ZP$_Q,%^6TF_7U]Z]"/CL)
M_P!;#VNY]3&\/A/V$.TW]NL)X:'_ "H8?^NK_.C5_1??CL,^YP/._P#@]AMM
MO\@IKSS-^GY_\M>MP'9OI^976:O?X6^_BC\.R?\ ^-6 GG[[9(_S\ZLW$IG)
M,<[_ *EXCU!'Y*Q<6&.$\6.@J'\/T7M9;'2"/M'^2G6A@(GS)/Q7+8,SY&%N
M:BHIHB:(FB*%CVTYZ=JMFE?#]\:Q2>_'KB]HKG_X=9=PA_ESO^[^#_[UQM[:
M%^!^&;Q_RF'_ /K,P_O7GG6XKJ (! \H>IY[-(^S]7PY]3K.M0IU,2?O#QP
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M5<$=IQ=!Q]PD^IOOS,KL7V0JGC[1FD6_P:=4!!Y&H6AONU7Z1$*)V2LATE(
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M/2H  'J^MP+;P^US<+7:"?#BG 1:1HIP=[&1'YK>_M=N_P#"M0!:#/"V4;W
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M:C#:>;3OZ02/[EV7[*>H9+VL#2#JX;HB)B-.'QP$$S_;WO!'-17L*/EMJ('
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MK+B<_43PATH3S.W [EP-]"O^BE74 1SK',)?,ZO.2T>Z8/P_GLNU>,Q_XHO
MW,_:GF(/+B3%GSW/*9@'W1EE8 =4._("AZ^@/'?\_P .=7LB=/D_I:=4\_Y\
M[V7$I(<:4<P=Q<6 V4F4MU*O9;X^V.KK3ND%G^#=*>^5W!'\($>6?M 5R/B!
MJT8C_/57_LM$#_U1?YGX%=KXFWLB,'_UEJC_ /NJOZ>?-1F-N EH#UZW>?\
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M"A_K77AO*CR#N$YZ]_\ E'<(]_N_MXYU9:)C&U/0#>]P(]TW_FNU^,)_X)'
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M!!.NEJ=+]V)W@[BXWV/X2)%A9=24H-$;7CW]/4?S/)'II<;4#SW '"BD@GD
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M?5@I>_8[@*W;W@!]$[;5BD]_7_9/$ Y_+]VK-G,&C0Z]X[G:(FWRG^:[-]C
M$\4<83%\EP M_P!O/X&?DI8?' E+7A \2*@3_P 3><\CGX&ED]7PY[?W:H\.
M?Y^RGE_3J'^^(7TWR)H9GF3N&XQM!TG;PN;$^5UXD6YR>AL=0[-M^IZ3^ /E
MS_5V^W73TFGW3;:7F'0+BPVFQY^JZ@<X4:5 DRUX&HBQV&T^O/U-[K<$U)4A
M(4#U.-C\+D\%:4^G;OW)/J.WIVXUYL6TC!8R1 T5.6X\0F;B_E>Q,7A4<;H_
M9N+(+OZNIO<Q?^77ELO?I0-]./8_R/6DJ2/7CCZ/C?K^?S]?CKE*L=6)Q)!/
M]:9(O-I&XWC=<G8R/M^.C_SAWQ@>07:]"?E^L_VZD@]3\OT5!.A/R_6?[=(/
M4_+]$3H3\OUG^W2#U/R_1%YG?;@."-OYLN?@YL[8J]>/P<VL$^O?\;N?U<$Z
MW+V7 .I9@#<BHVW_ '&#8;F(B/-;M[+'--+%-)\0!]PDWY38^L<]U"N9C9]5
M#U!X\P?($>H^0^''KQZG6T^Z<1'(& 8O?EN.?X=!"V@*KFR+%NH7GS]1OL/+
MU4U?L/71*W[WI )X;V@JE<<@^F:P>._Q[K6/\WKK5W:BQO<98-M56J.D#NS<
M>L#S\]EK+M/+#1P))\4OB^_@Z$ W@^\1=3S^+)A \,N^JOK$IVRRLI[CU^BY
M'R YUJ+ DC%,J_Q4RX-Z6:1)NN3^TOQ=G'%33L>%\RF/)@;^!*\? ]!]PUF+
M7AS0X[N <8#8DB3$@F.B^*I;!( L# \3MAMR4M_LT$!>V7C/"B0!MC (XX![
MT>=CY'X_,?VZM69.&O#@<G@B=R9Z".@'SYE=J>RJ0WACM780?Z1E>$8\R20U
MF'S M+3%C+S.J1MRE1*\K4D-*X"$$H!'8_6 5W/H?P4_#[#SJX-<!]F')U)K
MB2.;?" !_P!XSTM!7&-<CO:L<W/=!Z$D^EY_12S>R@2%Y?O\OOU'9]"C];GN
M;.43ZIYX';O\OM]?#FA;WE$;!N)H 6BP+8F]M[S_ #78OLA@A_:.X22>&:E,
MS?P]XRH>0O+/0"1"B@=Z5*4">/X*0. >._O,@C[B?7[3KV"H&/J$$6Q!C5>Q
MT_,<@/<.:Y%S:/VAF#>F98P;'E7>8!&QO<^:E#]DF$I\1^4H22I VHNB">_K
M?8]R/A_*X''''KKPYG7<ZFR0T20; \GF+S%[?5UU=[&P+>.<^TF8X=Q,3>^J
M_P M[R3YPHT,I4$Y+DR23R<@O ._8 V\DJ/Q[@DCX=N!KVX2HYS:<Z8EUH\@
M3:>?7XKEWB5I=Q'G0!,_M3%P03RJ.%CM\-P+;+/OV7R KQ:T1)YYQ#-E'@\<
M*%>CC@?B\'M\S\3P=>3,:H=2>PV_=4],;VJT8F9$R-AT(*W_ .R6XCM6IO!E
M[<AS  1:75,()(_U?. ;E8>[X#G>_>-1/^][G[@!/!XYXR>VXY^9Y^7!_-KU
M47AF#:&\[F>A>9\OC^2TQVDMT]H'&8),'BK/_>3F^+@1%[Z@+>4RLC/9Q)(\
M7VUP4>Y:R0CO\3C%N/M^(_5QSZ#5+,'AV$9) _K /.&@GKUYK:7LLO [9N'9
MY4\<# @R:+1'Q'G$_"T'BT_[YO?;[-SLI ^[Z0<X_MUZ,-H%"G$F6@[--R!.
M_G\KK!^VB_:IQR1_Z?QG\1'-L;#I"JOP,)"_%KL:#Z?NP!/_ %78C]?I^74N
M++30J;@Z'18"^D]!_=[U>_9W$]LG! =]W]H8HF'$GP99C7C?_2:V?*;KD^/'
MJ'BYWP*.X_=8D=^W'3352QW/ )*N>!P.WPYU2P3VLP3A>VEP(\P&GF>46M?D
M%6]HTAW;%Q@6B[JV!J&3;4_+\(2>I;),<Q GJJ.\*'3_ *IS84A1/F[H88>Y
M' )NV4JXX';L@?/O]FI\2\5,&YKH@$MD6) :US>O4[ >:QOL:!':EP&X G1Q
M1D[F"Y +,;1?MTDF0")*]?+C:4K6G@\!1]2>=8=$6!('+;]%]G&N+FAQW-S"
M[&E2!;5W '\;9_RQJ!^Z9,V.\?H.:F7.M ?I*?V/\;?^!_\ &JU$;#T'X(N&
ME)Y2>DGA1^8]0!\O]#V^^8"TR!Y<_*/JRGHN9WCV.,.>VB6^8IUQ4</>UI#?
M/INO)+XY=ILIVM\26Y;N00),:GS'*;?,\7N'6'1 N:[(9J[1\Q924>1[Q5R)
M+T*9$6MN2Q[L@EI25!1R/"U W#O:/^D#@'6 %@V'7U2=A (\[0OD7[0'!6>Y
M%VA\0YAC,'5."S7'''8+$4V/?1?2JM:W0YP;#*@<V"TV!= )NKK>S(VORW+O
M$MBN>UM9*7AVV[=S:Y!?*9<;K3(LZ.=35]4Q*=\MJ1.D/3_>5-1E..L184E;
MO02PA[RUZ@.%?2/@<18F0)GRDQ %XZV6<>RQP7Q%C>T3 <14LMQ)RW*\/7.(
MJ.8VFYSZK=%-E,/(!<722"YH#1J$V5)^T0VKRK;WQ-[@7]U7R(^-;B6Z<JQB
M\6VM5;-:DPXS,NO$EM"FTV%=)C.MO1%\22R6GPE3:@K4S*TX:E2:2\@-DC81
M!,R9L9@Q>!M*L?M'\%Y_E/:5GV<XG+ZYP&<UQB,)68WO &N;3UL?H!#7,<UP
M< 7$$:ITF5L^SSVHR[<CQ-;=7M# ?>QS;NZ9R_)KWR7DUE>S7>8J/!5*4T&7
M+*QE+81&B-J4\IE+CZ@AILKU6QE5K,-4J/D:V-#=I)%,,ZD6,"=^<&TO9LX&
MSK.NTC(,UHX9]+ Y)CZ6.Q=>NVK3::=-TAE*6$.JNNT-=H%S<%ITUU[4#:[+
M</\ $AD>=V%;)&(;ALU5C17H:4JO,VOIX5;/J9,I*?+8L&U1$2&VI"D*D,R$
MJ8+O2L(IX/$,;A6  NTAQ<1%A.US,CH/@%>O:EX)SO#]H>:<34L%6JY3FHIN
MIUJ;"\T7T&,94;7#9#9<Z6Z2XD2Z(@FR?@CVIR[='Q(;;LX_439-9B>3TV5Y
M/<MLDUE/5T<Q%CS,E=VD/S7&6H<2-U%]YY\I0CAITHJ5:[*F'J.8\  '[TB2
M'"PD"0.G0$%8'V$\&9QGW'_#>/P.&[[!93FF'QN958>UN'P]-KG$N+FAI<2-
M#&@RZH6MVDC)KVK6U63XUX@'-T7J^0K"LZQZBBLWS33KT"%>8[!9J957/?0A
M?NDA^+#BS(AD="9:7U!I2G0II-+#53W+?XG @$-(W(<+7']H$SM'-;3]K3@;
M-Z7'U3BC#X*K5RS.,/@6433IN=4HU<+@F4'TJH:' $FFQ[=)<2'F0(,8>>%?
M:K)MXM]MNL>Q*(_8-0<NH[_(;*,RXY"HJ"DLH]A86%E** Q$0IB(IF.AY:'9
M#[S+32%*6 8U,2 PM(<V-)+B1ID/U0/%,V@V@3:VVFNR'@7/^)>/^&*67Y=7
M<,!G.6YABZE6D]M.C0P..H8FL7.(!EU-A;3$ &HYK'%O+/+VNVT^7Q-W,8W@
MC54V9A%YB-5C4VV896[#IK^GGVKK<:R? )C(L8DYM^,M_I9<<2^RE8<2E*J6
M"Q+64GM<ZYJ.V$P T &WO%MK'E Z"]KW@C.L1Q3A^+<-A>]RAF28+ 5ZK6DN
MP^+PU3%.J4JC&R XTZE-[' D$:A,BT;FR.V&6[M[JXAA.'5DBRL;"XKG)K\9
M!<BTU7%FQW["ULGT<MPX<.."M3CY 4ZM##:5OJ"->U]5K\*]X=9WA$D@S,@D
M0# \C.T<XY=[/."\YXMXFRW 99AG$LQ-&M5JU*;VTJ=&G58:KW.#3 8#J/*
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M ;SS@2OG]F&48_*L;C<LQN#KT<6QQPYI.I$.%1E=A< !,MAITELV(!@RITO
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M<5&F-QWVU-IZ@R3.<OSG T*].LT%K6A[:CFM<U[0 ZTF(,@AQ!YP NE\GS?
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MBW'5^&<KHYI7?KKX^G0HZJP'C >]MB=08XDC5J:)\Y%4L(0 VAHH;2D=( 4
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MY<E8F9M70>)?<4919[;X=[JP4Q9N1)H:VR34UB'FGYC8R5R $9%F%T6$0U&
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M-IG$%"L8WF4A0*5I<V7S]:%)/JE2#3\*!^() ([$$:JZ@=W _P#>40V.8]P
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M/6%+7RH;4H*C/+7$4]YZ&@AQ20'$Z@70-_=,3?I\U*6DSL 2>0)WZ[W]?T%
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M %30.I^7Z)Y*_L_/IK/0?/\ 5- ZGY?HA961P0"#Z@GL?C_7J!>38@?/]4#
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F3Z+D?CL_I+_9Z(MZ/7/MOM.*4T4H<2H@*7SP#\.4 <_>1HB__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g40894g26z45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g26z45.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1RH4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '(R^<P@X0DE-! 0      "4< @   @  ' )0  ]!:V)A<FDL(%EA<VEN
M($4< @4 !5,M-"]! #A"24T$)0      $.>%(V2O)>J\*[A9O,GY';LX0DE-
M!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W13
M8F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX
M=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q :X            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      T$    &
M  /G   "N     8 1 !3 %  ,@ U #$    !
M  $              K@   /G                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   /G     %)G:'1L;VYG   "N     9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   #YP    !29VAT;&]N9P   K@    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     0X0DE-! P     $C$    !    ;P   )\
M  %0  #0L   $A4 &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( )\ ;P,!(@ "$0$#$0'_W0 $  ?_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
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M5W^B_,1,?-R+;&LLP;\>9E[]A8W1Q$N:[=[HV^UB2FY7;>:V&WV6%H+V-=N
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MXAV6W&EUC+*KF6^YU.\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M&&+!\"4S--+B\5-5HD-C&29$15AG<G>"DI.4I+*S_\0 '0$!  $% 0$!
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M1^:1J=*><.02DGI4HI!X4DI4 .A:5]:5)' ] DJX!5RH!04KE[2KJ*N5]1Z
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M%\ <*U^MO!K8M[*_23WQ5=,AE:TRD-)93G" I,:J)!T.NT "OBIZZ>=47GF
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M40/"9&4"4@$\Y) W@PJPY<M*6I"%^-OVAE4-8, 9D@$G7V2H::D0:E5M)C.
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M]1\1]:Y](_EC[OVZ564?U?E_ZJ^:BD*".I/)X'<GIY43^=TA9 '3^<1P.>_
M[ZN6KQ-XFU6T7&"R7E'*5 *E28]DC4)'G47[4JMOQB'<@#G<<A.@4?YMO'K6
MB-Q=XU8O9KH,8@P+:XC-LR9YF3#'BL-OJ7Y3)1'6EQ:UI2.%^84'J!!)/?AW
M:)VO-\/XB[AM@@!Q@DJ2E2TP4*5 (2W_ *#K.I\A77>$NS-6+8<UB+CA"7C
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M,:*(@:])W_+EOI65;5Y?:VS-SA^6"$SFF%2FZZS:@(>;BV%<MKBKN(B92UR
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M<.6F)"V9<N'&$.0EI!6K_P O8 $C4Z^X<ZO7B1;O8<5GNTNK0"I7A29[S25
M#EZ#<\S7G=;Y,WE]A875HAQZ;+?E)4W+"A(C,E]19:6R^&E,^6E*&PWY24\H
M"E#KZN?S;XNX@Q"^XFQ-C$S?V[J4KMFV5%QK(RE1<2X4!3>F<J3,&2(G01]U
M<-X(RSA6'6R+:W>PUVV3>N+4V'&W+LJ4T4I)0N3W:$'VQ URC<[)V3W?DX1:
MC&;ZP=>Q>6I3,93W -3-?!+3C:U!7EPW"%-OMKY2EQ8<;!2%=7O]@';)BG#'
M$M[P+Q/B%OBG"UXXH-*NW+=UNV!0XE*2MUE2@066AE[X02-1.O/^T_L\P_B4
M#B#!+-^VQ2P;5+%HV\A3V0E14&F'4I(/>+S?P_9&HT@8MN+7V64?NRRH#1[G
M3<C1#QEG&JYJO1D[<P)6XGV9J7.;L8<);B6H60^1#%D@N+"/R? ^O>,.Q;@/
MM1M&7K'#K6TL[<AQ&(H2I%NHE3:PH/LNH29#0)\6L](KB/#W:KQ'PI</X/=+
M?+BD=V;9X(*DY XB,CC94(.\\^<5.WPV^$"FP./$RO<&)'R#,_R<IBO?09%-
MCRY "U)BQUI4B7/20D.27$%"%@^6$A/.MQX3X5L^$<%L\#L'4NVU@CNFG$9L
MJ@D  @J4I4:<SITU(K4>(>(+SB+$G[V\S9BM:D!0 ,+,J.B4]!H)%3X;;3Y:
M1T!!3^:.D#I'IP. !Z=N1Q]7;UV6%*W)$=1_Q7AU"//?$CF>W>^[NW^0XCCC
M6WB,?I\I_&N)D5I)R)%9<Y%"P^ P<<53B#[6K(YJ6W0FW$9$!)F*>#A4R/>L
M\+8N\,4_WY3<AQ;2;8I22J&UO9M%%8 2F H ^/PQSJ8&GL^8.H.I $3$F?,;
M'EJ=6;F>/=6);GU./8GMMF.88BQ&<BY#-K:8&R7?/[EHVT;B5S[]HS":B1;=
MMT../,27)\AZ+$B".Y(3(1ZN'\)H7A9N[B]M[1U3H0VEYT)&0L=\DK"LJLRP
M0H $PB%D+ (J*E<O:/S$;P)VTC;4Z;Q4C<Y\3^W>W=I95^2MY8RFBPQ&<91/
MC4#\NEQ2ED,REUL?))S3@3 L+1464Q"A(;<<>?B+#[R&5-NK\*VP*YN74EI:
M%!QU338+A <4@PM3<QF2G51(DE(T3,I-#FU 2>1)C0#W<SL!IKZ5'2-X\&,Q
MSK!*W;2HBS\-RZ?@E:]*OH\J#=PIN19I=XI=M+C,RGXR36MU##T-33[[$I3Z
MRAU8&O<_Z4=M+2Z?NG0AQD.NI2E84%9$(7IFUE68 "!!!(G2:92HC3?*-003
M,CE'GL#->DAB,O*!>:;?1\$NMI< "O4>\% =C\./CK3TJ<"E@DE*COMI),;:
M[CG5 D @B9^]?7Y56)55D!I3,&N@PF5N+=6U$BL1VU.N'J<<4AEM"2XM0"EK
M(ZE'NHDZJN2.9UUY]:E79#+1'O-HY^/*1\]42D1J-?>*53V:/_\  :__ )$_
MLU7(GI\S]:K)VDQTFABQCZL,G]+:?V:9$]/F?K5*)C1T*"DL-)4D\A0;2"#\
MP>.Q^O3*D<OF?K2OOJ5*:4II2FE*:4JBB$@D^@^6E*B]F6^>5UF=WV'XG@<.
M];Q]%<F=9VN3HI6UOSX8EEN-%:K9SJTM(4E)<<=;ZE$\( '.D@;FE? ;Q;O+
M0H#:[&.P(2O\>UD#MV[?0//W\GY\Z4JE#OMF"\_Q'",OP*MIDY>JPCU]M3Y0
M+@LRX4-R<42XC]5"6EIQEMWA:'G>'$H24<*Z@I4A,B!&/7H)!XH[<'C@#J$)
MP*[ #CD]_C^KTTI75V^_@'AO]5Z+_+(VE*CQXJ=DE;AXH<OQR.EK<+"$"XHI
M4=*1)L(\/\O)IW%$<.%Y*5N1E.AQ"9"6PM!05@S2J-#L?/;?[Y4C[^_2O.G"
MKJNGU6,358G&OW)V0R#;8M&BS:[%ZFUCS8K#JWH-8P]%=L9E?(ESO:\D=%;'
M8KY*.@*6TR(ORVA5V5I::M$*<>><,,M(B<SNA !"3$@[':*ME^'[>R1;*??O
MU%IE24R6E)R^+>8.<<C[)K>&X'B,@X^XK&L!BPI\Z,V6S.ZDIIX"^H-^1%88
M4&WN@$#@=*4\>X1Z:^4^U#]HGAW ;IS#^$+C][<3M%:"&>[<PU#@"0 L=Z=
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M!)4/? Z:?VJ-?35VE-*4TI32E-*4TI32E-*4TI32E<%D=D'GW^0"!V!'?O\
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MVZ@455*KGV9:W,EK)\DM.-N(>5&4A*&/,Z"?+\U*6NKCE*0>-1<=O+X0C*E
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M[IJ5Q=[D^7ZGGU^??GU^/KJATJF=/7\_I_Q5/-_^[^__ -6E,Z>OR/TIYO\
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M,%)3J"0$Z&)J:7X/JI9BT6YLYM"QSED6L"UJ:6K]Q177%#J82EI7#LQT!3:
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M/D;N#)A-0ZB='G0ZZ##N)=;"99CL0X,GRT>>2F&M28G4RL@T $R )ZC?KO\
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MJJ%6-6]8FF#:ZEMQQ9>CW7LCS*%.IG,--2F_,9>;4RXI)QUWKBW$NE#8*<T
M),>,1)E4F.6NW+K*]X\O<0Q2SQ5^QPT/6B%H#"6GA;N!:,A#B"Z3, $*0I.H
M&E8K;^ ?%;K(IF46&=W<BTN,6<Q^\>--21VI,E5<JI3;UT6*W%AT_DQ%@^PQ
MHJXY4TIQ)#CBE*OMXH\V $M-0%!6H7K!S09629.Y,>6]9UMVD7]HVAJVL</;
M#;B%H(%R5D(7W@0MQ5PI2P2 DYE*D$ GG4MMFMJX&T>(R,4KK.;;19&1Y%D1
MF34-(D"1D-Q*MWF"EGW S&<E%EH\J6I#84I7*B!AW#ZKETNK"4DI0F$@A(#:
M$H$22=0F3KN36DXYB[^.8D]B5RAMMUYNV04M A 3;VS5NB HD^PTF9.\[#0;
M=X]/J_9QK&*03.LZ?*O(JNI4II2FE*:4II2FE*:4II2FE*:4II2L?RC]X+S^
M@[C_  3FE*M^WO\  /#/ZKT7^61M*5F&E*B)XX$E7A^R1 )ZEV- D)2I(4H_
M3$-0Z0HA)(4E)23^:H COQS<MPG\5;N./MV[+2\[SCSB6VPB1.9:U)0 (F5'
MTJT^,UN^TEM3KCK92TVA)6XIR1 0E(*B?(#7G41:K-,4HU5\BRR^C%3 @1VC
M3UZ6Y<I2A7M,B(_ 1!2M+T>6A<DRA/4IP/I:2A*$J S>+>V3@#A+#RA[%\'N
M;I*8+=OBMHZ^E:(*H0TXZ1*2E&0MZ%,P5;:W@O91QOCU\7D6>*V5LM4I<N;&
MY894E6@/>.]T@@'7,%;$ &NFGQ&8N_/#$?"K5VN\Q8?F'V%+[;1/9[V5#:D$
M< J2CSNLD=///?7S<Q^V=PS<XT,+M<*?5E=[M3@5<K(2%I2'219B$F0K-[)2
M9!Y5VA?[+_$B<.+]QB[9<+8=3;YVBI69)4$A/XE1)U3"8G63K5GQ>?"MK3+;
MJL0M%;:7C#\0N,*8<)3&90\'6E=/E.I/0@I">% >O;C7;W^+</XQPUC%+%QA
M84IM"DM/)=4@A"P0K*2H&$ZA0&QYZ#2+7AG$>%W7,/O6KA.0J_B.M+0E1S$B
M"KPZ@S )!B1MIH6[/'C8P+@\#_=DSP=C_P#K0Q$D?M&O*)W'F(]((^FOOWK/
M/+U_0U++J3\Q]HU&IC-RS1Y33D?,?:-*>/\ U?.G(^8^T:4\?^KYUQY!4?>]
M..W/;X?+CZ_7^X<:DRWG<=41.1&9(@DDA(,#0ZD@ 1.O*=:D@DJ(5($;JT&O
MF>GSVY"L(SYN,_CX8GI;7!<MJQ$U$@J2PJ,9J?-#_200QQ^?SR".WU:]S 'L
M#OA=M\4-6*\):;<_&,8MW*;-Y@0%)>3> -*;(,D+&0@:R*PKY6*Y%HP=ZYM;
MY22+6[M4O*>8>)&5;?<0LJ2>:%),F9%6UY_PVQ<@093%B\A33:'%0&;!6.)=
M;"6SY++3R%*YY7UJ"2PHI5R.OCCY<XE?_9</&:T8E;V]D6UC*S:X"ZK!R8$?
MXEK#%V1!E4E+Q3,]-.N8!8?M%GAY(LA;7EJ4%1O;R[91?D3J0V_B2;B9&@*,
M\ &"2*V&:C ')%7*PVJP6QQ]UMI4XH9A-RH:U/J3(58.2)34F(&H!4]%2U%>
M6]*X2\X$A''U;P&KL=N,/6.&+7A*UM^\5D_ '"VE+?#312M3"$!1=4G(A97"
MN[2G85\\<4?^UQJ_4;Z[QV\6"$NI?;OU=VG.HJ0V5.D%I,YDJ1F2%E0DD$#>
M'@7\IO"L^# :\A.XMGY 0.1Y?EL);+?8<@)*0E0 '2!P./7.QYRY-^6[=NT;
MLVS#19*"V49C[);<R$G+E$"=N8KT,.2^BS:7?*4N\6!WR5$EU"X3(4@E2D^(
MJ)S#:9V-3P"4@\@ 'N0>.".>.?T<\#[->;F7_3\C644_ZE::;C]!KZUR2E)^
M''''' _3\AZ=SV^LZDDD[B/='YG]/SIE/)2O>9^E<O+1\CZ\^A]?7Y:E5,JO
MZCTV_O\ />N 1QZ)(]/@?@"!]@)^TZAG'G]^^JY=/:5\?[3\ZJ$#DD@@JXY/
M!Y)'''/8_+[AJH4"8'SIE/)2OC/TJH;;'H%?/T/UCY?6?MU*F57]7RC\C3RV
M^_8]_7L?D!\OD .?JTJF57]1Z[?W^6U5* 1TCG@\#@@\$#Y]AI3*K?,?ORV]
MVGRKB603R0DGGGOS^S2F57]1^']Z^J1T@#Y?]?W:5(:#4SYURTJM-*4TI32E
M-*4TI32E-*4TI32E-*4TI6/Y1^\%Y_0=Q_@G-*5;]O?X!X9_5>B_RR-I2LPT
MI40_'"E1\/N2E!/F"PHTHZ0"KERVB)'2"0.0KI(/P^!!X.L/$;*ZQ2QNL+LF
MV';O$&'+9A+Y1D[Q:"D&' 02,VFT=1O6397#=E>6U^Y[-FZEX\CX2"8/+03/
MES&E>3<79K-PJ"F+'I;&=(A*<37U=@7;.0'D^V]4B/)4EAR4Q&6@K9;?#Q;(
M<#?1QKX%XX_9/[7TXK>8XU;8;>6*GWG V@,%24E95JGOEC<E 4$ $A0$F9^K
M^&/VB.#%V#.%8RZEI:$-('>*2I&5""@I">['M!.8@E4$G::[#$*^I9;-1/QJ
MZBSY"T1V8ZZV2R[)==0IE+;2/(Z7B%*"FBE:DJ5P4DCN.587P=Q]@^(O87?\
M 8A:8M>E5G:WR</="5IS!EIQ#@L1X8[M:2'2(B%&)KHCG&?!%ZR+]KB7#TMI
M0%I2J]924) !"0DO CPC+  (($@&(W+MT)K,6YKK*#*KI\&RC^;&DE/4EAYA
M*V M()(?2A)\Y1]Y1("N2-?=W91P-BW G!XL>(I1C%_=)O4LN2%IMB'0H@*6
MI1 4IM),)$DC>!7REQ_Q!AV-XTY^[\51?MH(.5#O>(&7*,XA:HU,#0#Q;UIV
MX(_WU=OU?Q1X9]P5<GMV;W,Q%:N/KX0K@>I/'SUT8C;X>NJMO[P?*M'.H(Z@
M@?"I5H!"0#Z]S]I)^WOW^1U>3M[S^9JM<M5I32E?-0//5Z?6>/@.W;_W^>J=
MX&I5_,=(]Q_7R]]7-5H#8/4F/4Z<^NWQK#-P'F8V)6RGD=;2U-#R$$K7(ZY2
M0&6RI+JO-60>E"4*42.$I/IK0./K'$L9X7QZTLL.O,3?N,.N&VK"R2ZN[O'"
M@!+# :;=<+BX(2$-K5IH#6U\&7]I8<1X*;VYM;2U3?,E^XO"V+9EK,<SC_>K
M0V&P(DK6D<R14=Y]C6N1DQ @I=0TT2PJ.0^PI:G%IZP8S+R1TK'*".%%0/!(
M&OSBXP8O5O)P"YM,3PV]00G]TW-A=&\F%>$%Q#3@))G_ "E;=#7V59DW(3?V
M&*V;N'IDBXM;]@6>5,"8:?6S$[@K T]QQXXYE,Y8=J<?R:2UPHMNP8LZ.@R5
MMJ]F?>E%"4F,VI"B6U!2'" GGD]MRX-[+>V>\;ME<(8!Q!@##5SG=-XW>V_X
MJ$)!NFP\W;'N5(RM )"DE3:QG)! UWB/C[LTLFW&L3Q? [_$%)"2JT59OE#6
M=6=A:V5NA+I.96JLZ4J!RP9KT^_!^(>3MOE*)1ZI3>8OHE%9ZEF0F)&#O*BD
M=1ZAP>!Z@CMSQK]*>'/WBWP_A>%8TI0QJRMVF\0*Y"U/-H;*U*S$J,J0L'4[
M'K7Q?Q*]@]SBUS?80$_AWUK4%(B"%*60?"D#90(C2/EZ%:V*O II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4K'\H_>"\_H.X_P
M3FE*M^WO\ \,_JO1?Y9&TI68:4J(OC@'/A]R;N04V%"M(3^<I2+>&L=/<<D!
M)('(Y (Y'KJ_9H0J]M5*"\R%DME#BVE)48A4H(F" 8.A^8Q[O6V>3_4DCW09
MJ)F-/9(V[5.UU#AJ;R35QGV8\K);%I]:DPVHKCYALQUPF)YKVV?=2GVORU$^
M8IL]^K*1WMD!<OONLE*4$=V (/B@N25E)),DC+FD[R:Y.\TVF]4K)*I41+S@
M(U.H (2#&VD\^1K8#TS=@M$_B_B'FI/*77[Z4HH*2> 5HA)7TH]"!WX'S[Z\
M5S#<&NF[:X?#3ETQ<!3;B[%E7=I;<7D2AR9S)2E )$9BF3"C%7'+R^:LUMI?
M>()4 G\4X/#XM" L#*!L#RY 5HO'7K)5YF:KIB/'N3<(5.:A.N/P#Y45)8,>
M0Z$NN)X*Q[R$ >O!/&M0[1S:C%,,6RHJ4G#RT 4I0<BG$*)4E,@$*   &VDB
MNB<(HM_W=WW<DW:E#/<%Y:RI )!1E5(B0F3,B !H34<;-QY7CQQ6(IPF.UX1
M,KE,(XX#4I_>:EBN/#O[Q4R&TE/8$('?OVT11RH"M#RB/,\]_A%;?.A/2?E/
MTJ7H>4  ?>/Q)]3HAPE(, 2-M3'ERJ0B-09YP=/RJOGG^2/M.I9ST'S^M-.A
M^(^E///\D?:=,YZ#Y_6FG0_$?2J>9R3[H[CY_(<]OT\:MJ25YU%491M&AA,]
M?N:DR8=.\: 2=I'I6&YC(:CTKDR6I#<2-<U4EY92ZZLI:GHZDL,M(4ZISI_B
MMI*B>W&MTX(>3<8A;MH80AU#N5MPG,<TD A.43N2-XTKP.)I%A>*!(AE:HVY
M C4$\Q,^=;DBY;MHZZU;JHGC9.QVTKL5X=8+EN(:2@)Z7%0%$('8A1!43Q]?
M.U7G9]P]<XBO$[SA[AZ]Q%1,WEQA6'/7(B(_C*8<6"(T5G!B1SBN?VW%F*VM
ML;1O$\;;9_\ <LXUB++&O6W0^EKGT(T%6:^SJCL;6OF5-QD41N(66'82<8R4
M((9D&4Z([<>.S'4N4T!%D+G),5#'2I!#B%!6SVEB[:,/VX;M1G)4RM#-LV&&
M2$I#.0IU2E86M*DD*E>H@)K7KI:[A(<3<W"%EU)<4IQQ:G#H3)*P"50 2J=O
M*MS^!5:).&;@2&U*\MS<*R<25H"5J"FF' 5 ]VSP>DH'8?JUS7&DMC$G%!I"
M7CG2ZZ  IPRJ20! G70$C6NJX5'[IMD09 2"K,3)A&IGTV_YJ>6O-KT*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*Q_*/W@O/
MZ#N/\$YI2K?M[_ /#/ZKT7^61M*5F&E*B)XX1SX><H)1U@6% #PL(*0JWBH*
MDJ(/!X44@\'CJYXY (R+/_O+?_X@_,5CW7^0[_L5^1^]QZ\C%/&G\F8<JY%=
MC>+&Z>KF'&H4C+)K+RU*AM1@\B$F&Y&:L#":;*EH0%AH$]0)//6(2;-.9;N2
M$S#8"( D@KU5DS$Z;2"-JY3<3^+5 3.8QXCF$Z3$P# D$>1Y&L\=M-UE-KZ,
M6Q,*(4$]>12RT%'T)/T?R0#SSP 3]7IK#0C#1;H*G7<W>JS("$Y4GO%R<Q5)
M5S(WDD<HJP\5FW,)!5F,$F/ZHYQ$1SC7GK6@J218.7N;*M8C,.W^EF_;&(DA
M<J$E'L0$9<9QU"%E+J>LJ/2GDI'(/.N?]I";5-_AW<*4M?X8!14 %99$RD&!
M!@;<O6NG<(__ *=J(E6H&HU49@^\G<ZG385&Z>M9\?>+\GM_N>9.?3X_[;J;
MC^[M^O6B.Z,Z= ??O6VJT2?O<Z_&I=]:OG]P_9JTU_EH_P!HJ9W,;28IUJ^?
MW#]FKE4IUJ^?W#]FE*J%J'U_J^![?\]20)#@\C_^%5:_S?>G\OOXUB>7RV&:
M<2I:T,Q8EQ5/2"0O@-MST\J:;"''''"D=DH0HJ)( YULW (<5BB$-GQ*>A&@
M]K-_<CW2*\/B;_\ 3KXZ_P#;N';7V=B/70U(.'NCABH4=;4BS4TEI""?H"X2
M!TMHY""81"D_\2"!W[#GTZX]97R7% )2-9/C2KF=X&\==XKC1621JHZ;Y2((
MCR(UZB/2L/O<]QZRN*V;6Y':0VX_D1WXJZ6_+2RB0N0^$1V8B6'W9<13L8JF
MH4TPA"7$*2L C(9MGVTN)>:"U%"E)A2-B"D$J7! 2H2,AS$[B-#=*AD20LB'
M!H9!Y=!K(G0^^-ZV[X$)(?Q+<M3:E%D[B2ULA2 VH(?C,*/4CN4D@_FDDI].
MW'&N78R/_$GB2?:4(Z>W^HKJ6&$_NVW &N1*O.=!Y]*GSKS*]&FE*:4II2FE
M*:4II2FE*:4II2FE*:4II2FE*H2$CDD ?,GC2E<4NMJ]%#X'Y<\^G'/'/ZN?
MKTI3S$<$\]@2">#Z@@'X?,C]/J.VE*HEUM7HH'Y>HY'S'('(^OT.E*Y)4E8Y
M2H*'S!Y^K2E5*D@D$CD#DCGN!\.1]?/;Y_#2E<0X@GCJ'(XY!Y!')X'(/<<G
MTY^'?T[Z4KGI2L?RC]X+S^@[C_!.:4JW[>_P#PS^J]%_ED;2E9AI2HB^. <^
M'S)P>./;Z,*)_-"56D9"B>X[@*Y3QWY';OK)L_\ N[?_ .(G7334=>ORBL>Z
M_P AS_:K\C44L8E9&AVI>BXM0NWLFNCRF(;^:.M/$>QM0ERTP RM$&<["99Z
ME=U%DD%*0L+/5O!^#E3BP$I2%?P1$#Q 9RDRD$DQMF,3FFN4W$B[,)!))/M]
M)$I&80J .>W+G6>N7>Z7EKZ<'HRYPHCJR4I;]2.217A03S\ KJ ]#SK :;8[
MA!#BN\+Z@4%(@)[Q7BGF8"=((DD\JQWBZ;>0@>V8,GD50(D& ><C;>H]5DNQ
M=N\Q=N(;5?:+N(Z)4:/(5+C)"8@#)C2"E)4V05<@@'XD#6F]H2&_QV']V2I/
MX/PJ4D D9Q,B.LZ<SSBNI<'D_@#F2)!@@:B9,Q[P =]N=1Z<ZE^-L*(Y4GPK
M,I2?B$JW6L5J /J OH"U < E()[@:YV(DZ0-.O\ 4)G?;;S]:W(Z@C3F!MO'
M+I^E2H;>(0D< \#UY]?CSV^>H*"LQ@@"3 ^Q3*D\OS%<_//\D?:=1A?4??NI
MD3T^9^M///\ )'VG2%]1]^ZF1/3YGZU3SE<_(?5\/V]^"/EHW.=X$R<@CIM^
M6HFKC0"5[:&//;7UZ]?AI6(9I9UU91)L;:1%A5L&TJY$B3(/*&T_23*02GI6
MI:BIQ"0A*5+42 $JY.MOX!25X@$@02X0(,<Q&LP"/<.AYUX7$C:W;&];:'\1
M=NI+8(YD"!$;:\IDG?2*WU&WSVJ;C1 YD\5H*::0A2J^:EI7*4)[+,$)'O<=
MR0._//QUU-^SN Z?"H29CO)/,ZZD?<:;5R;]V8C"90I1&F@3ECI!3Y>9\]!5
MINL_Q6RN*V?4YO B1FD,HE1 W(Z5(1**Y#Z8[;2&WW9,9Q4+IF@L(ZFUH'5U
M$30A]H+:4TI>9!4 2DSR'CGP@%,^$SY'22,+NA<-K=!3X8RC0$9B)@ 3,D&8
MY=!6VO >H.8QNFX@?DW-QI2VR!TCH5&9*5=/2D#J![#@#X < <\VQ915B#^;
M0YS^:IC?UF>?NKH>%LJ:MDH5.P(GR3Y\MOO>?>O.KT::4II2FE*:4II2FE*:
M4II2FE*:4II2FE*:4KISUE$9:DDA2?>2?>X'0E2U<E/YO*$J 4> %$=^>-14
M<HF)UBJ@28KRKVC\?>4V,K*;O<G&*Z7@%:;N.]:;>8YE3UEC>01MQ?Q"Q_%;
M9=N359#;Y(AUBSBKH9O0RVF0A]E)96H20"O;2=I,Z:=)UUVUJ*R&YG6#'3\X
MJ2&0^,C 8SMO055=F<"]1$LZB+97.*SHN-UF?Q\0EY1$PJWL@IT1[Y$-@/2(
MR&G(J7@8)EF8M#*JD02-XYC8^E4"I$[:3KR_X]U1D=\:VYKV.X)#B,5BL@RG
M-]FL=MKBEQ:=<MT5?F6V[.?9([/KI%I#AN/R076*A,.640X*9;[W[JAIC.50
MDK4$@@$SJ=M 3^E5.E;^H/P@WA]OJ^YG4DS+KY=-<8W0"/4XK+FR[F3E-K)I
M*.5418KLEU4>?90WVT1Y+D><T@MR'(8C/-R%36RI$R4F-R"3K\!/G&F_(354
M^*(Y]?[3_P :U;<U_"$[3XXSN/$JL=S6\R[;:H:N;;%6ZR'%GR8J;JNH[)3*
MU3UI:72RK!L6*)PB*CH'FI2XRH."*&U++<#1=[962E$@!M5\^&$.*UGNVU',
MY'BC8$U(IB9.L Z3UCW5V<4\;&+N7^9M9]6W.#U55<RJRC@W6/RX=W"=H\ A
MYS>1,D4)\JO;G38+S\RA3#D/(G0V%@!+R2C4(5W;;H$AQS$D"""!^[;HVKB@
M1HI+J@'&R/Y#K!! !,D)V),:\C,??.="!6?8!XU]D-R=S(VTV.3[TY=*BO/(
M8FU"XT=N;%KHMK-IWW/.<=CV<&',:,I#[#<9#R)$=$I;S#B!)*2MOO 1'0S/
MY??KH+2UA"R@@D]1M.__ #O'IK4D\C=#N/WI';II;E)'//"A#<!';Y:MA4SI
M$5<(B/,374V]_@'AG]5Z+_+(VI52LPTI41O'!S_N]Y. "0;&A"N "KCZ6BD=
M(40DJ*PD 'YGC639_P#>6_\ O!^!!K'NC##G^T\IY&HI8M+OFUULN/B%6]<2
M:V+,9A2<SCL]?M$)F*N8*UUEXQEOQ64)=0>$@)2X!RX.>L C\& 7%!*4@*AA
M6R1FR]XF)A1D$ P<P))!KE-P#^*)"025&)<'QR'J-(WT&VAK/',AW(X6IO;Z
MM2H]70M>31FP"5>ZI?1#ZD#ORH)'*3R..VL-IJV%NV3=>,O*E&112!WBQ[<'
M,K:9$;ZF-<9Y3@MC" /&HB%%,&5ZY=(,_#D(J.E?*FRK[+GK:"FNM#=I$R U
M)]NC1R(S09\F5TH#@4"H\= ]/AZ:T;M#4TB^P]+3@<3^#@&"E9E8))'\N\'U
MD=*ZIP=*K E4!4F>8F5"!.L>1Y""*CXR2YXU+-W^:>%ZA0 3R3[;NED;IZ?@
M $1"E7UJ3QVY.N=9TZZ'0$Z=#L-]8G7W[Z5N0VTWG4]8,'XQ4I.OCL!V'IW_
M --5.I)ZU6GF?5]_^FE*>9]7W_Z:4IYGU??J"-''CT0/_P 0?THE0SQT_7_D
M?.M0;YT]IE&W%E4TK;+EHY<8Z]%CR' TW+?B6T9TH,CA2F5/I:\M)*2@*4.K
M@#6W]G+Z!B[ 4,J>_3F48.5.8=).@$P.NHKRL7N$L-.O%)(:;*R- 3E&VL>F
M_6=M/A!P/?U;$:.K;"M0W[.T@O2LHC*;#8;0D@-L1G3PX#RCD!75TDD#OKM[
MSV']XHHO KQ$R4J3K.Y&7<$<_P ZU'_J1O\ _P =7O"3RC3Q0!S _.L3L]D=
MZ[#)JZ]E4%%5JCE*45;\Q$PO-,MS4+2VHN15!A\/M^UMB,^B1Y;06XT4<ZR4
M76'!M:,ZW3W:@7$CPB3(3)2->8V$1ON,9[B*U"TK<M75*T ""@:>([%6PDDG
MT\Z]&OP?$:1#P'/H<M"&Y,7-_(?0VA3;:'F:^,E:4(6I:D("@0E)6H@ #DZX
MOCI0<5?4A)2G,=#$ZE<;:<C\O=LEJ^A^W;>2DI2O5*3$C,!J8TF2-NAKT,UY
M=9%-*4TI32E-*4TI32E-*4TI32E-*4TI32E44>D%1!/ )X'<]OEI2M?9[N3@
M^W-.+K/LFI\7J')*8;4RUF(CID2G4+6B-%1W?DR"TE3I:CMK6&NISLE!5JH3
MF,0#SUJA5E$^>GKRK65#LML[;[2TN!T++D_;URZC9Q3F/<R'5OSSEB\Y8G,6
M'F+?4P;UQ4OR0?++*C'6$MDIU$GN_P M--]>4:?9UJH'>1SG77R^X^6U="T\
M+.SESFUGGL^IMG+2WF2K:96-9#;)QA[(IE*_CKN3G&T2OH@Y&Y2R7H#5G[*J
M4&5\\E0"M 9$]:$1ITZ5\JGPI;+4CE:N%2V!34WF*9)%;D7,Z0R+/#<05@U"
M^ZTZZMMQEJ@6Y$D-+0&Y#G$AT%[J49!60YIB.?KI^N_+>J*$@_\ &VM6^B\)
M&Q^)US4*JK;INGBY/C^6UM?-R>UE5E)8XM8O7=2U4LR)"FH-0Q/=<D+A@KCK
M4&FU?DFFT(J72LG4'K$Z^NOER-$ B!OK,1/RG\M/SJS,>#/PZS9.7WC-/8S$
M;BU>10+4(RNV?K%5^864:\N%438FJ;K_ &ZWBM6+$F"M+K,H*7'<2CI2D5K2
M E,)A^WN(()\5JX'FSU@*U.NLU<425><  =.4?3XC2*NE[X.MCLIH;.AR2JO
M+:';Y+C.6SYDW*+E5K*OL5IHN.ULM=D)(G*2]31?8+-I3BVK1F1($Q+Q6@MQ
M2M1"$2(2J\6$@>$&^>+SOIF49 T@ 3.LQ)B3TUGGUZQ/PK,,?\/VTV"Y_<[I
MT<6=36]DY+GV\1-]-:Q=,YZ*W$L+@4:GTUL><]"::9DS TD*0E3BP7''7'(E
MPH.4:#II/+X=/GZ@C/XCN8())^',?>NYC;EV\T_C-T\PZAYERAM5M.M.!UIQ
M"X"U)6TXDJ2MI0(+:DJ(*..-2B/?K]_":B%3/EIIT^YGSKY[>_P#PS^J]%_E
MD;2JUF&E*B+XX.K_ '>\G*5!/38X^HJ/'NA-Q$/(Y(')/"0._=7<:R;+_N[?
M7_S!I[Q]^4UCW7_;NZ3X3_\ B?STJ)F,2\CCKJK%C TN63M4EZ-%D9E7ME:#
M7QH2K!%6ME3K7FQV4(<"E*2%>^A@*473U>4JLT@O0!D!AE6I!S!!<G+H23H-
M)U/*N4W /XM9"),J(E2=M4Y@CKRU)!/*1-;$>R;<<(<#6W3'F *4@*R2(E(<
M[D=3@C'A)/R!(')X/!XPV[:Q_#H*KLYBZ<R,AA,K42K-J#H9 @'6)TK'N%NB
MWD-B>\('BU_FY0"!MKF@Z$"#4;H$R9*R'+W[:O5569N&A+KA);FH92(X\DMR
MD)1UES@E7N$'N01QWT'M$9MD8A8.,N]XHV9U(RYDR#.7<00-#[SJ .I<&_\
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M<QF-)5-82OS7')33:9 7YRXBFB^TI3*U* '%YEE# 6E%RRM!025$*A)4"DB
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MTE[,N$,O3)DN5[7(EP&:]JFF-EYR>_#4RM#3G28 0O,3"3&TDC;[F=*N$I*
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M_L<V)]?D+C<\?W< ZT1U2@SH>0Z5N\#T]-/R^73E4G@3PGN?S4_'_A&K#<%
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M*$B<[RX^MAZ1RE3*%'/<XSPE+;3#%H AO,I1#"0@O'\+WK[;164(#ZV5.=V
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MHJ6(OL6-/M]+R57T%UV3+24M.J2T5*-K!,9P.U6RO$K5-REM"DJ;[A*Y<*5
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MII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2L?RC]X+S^@[C_  3FE*M^WO\
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M1\]<1RBQG3)-?93:#+Z635MJ=66(D"U*8R7VI#CD(1K1"X[SGD&,N2&7"6W
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MB%%-THY0<I ).TUB<:>W@'BZMV+)2(=/X@=L<>71RU@--R]P-IW[.+:4H</
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MO"UV]J[*2V^6[<XBI2>\T"[COUDY!(5_-$ULJ7<(>96VN.EIYM(+S:R.O@@
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MN02D-OV[G9*AQ61%1X<A:@4LK5*1U#T3QWC2_?M;L6K;FCD#,) $YX]E6H(
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M]O9D.YR'+6'<*QZ6SD-_$=BY!>,R:F$ZW9W,-_RWXMK.;Z)4V,\A"V'W5H4
M00,5\=VO()<@A)4@2)UU.QCE.IVFMUPQU+F&VUSWF<N-I5W2I_$)! ,.-R0E
M6NH"R!H)K+LRW$PS;VHE9)FEW"QVHC,]:Y-D^W'2XH\]###97UOR%D\(9;2I
MQP\)0">VO+Q&_P /PQM=Y?W+=NTRB2XXM*41,Y05$2LD@ :3(J[=7MK86ZKB
M[?:MVMU!Q82L<AX3N20=B3N/7R*\0GX12XNE2Z#9".Y4UJTN,NY;<14"<XGJ
M*>JLJWD*\H+3PIN1./6$D$QDJ';YAXO[?777;FQX7M+G(A3C*[MYIH)4F% N
M,J27O"1J"H S&@FN<<0\<-ELMX6^WXM \I0[PZQX$DD"1S4"?(;UY49E>9-F
M5B_:Y7?6N1SWB5F1<2Y,Q:"HDK2T%N^2RV3^8RRTTT@^B#WUPYWB3&,7<[V[
MOW%:DE*WH49,@90@1ITD](WKD&,75Y?9EW-PXZI68'.M1S3MH")D>8 /(S6I
M;.)PKCA2B24#A/*R>0$M@) *NYZ6P!R2>!R2 ?9L'A<%+0+ZW"4)  *@HJ,"
M/%KUT ,<MXYOB5DXIP)"0XMTE*,TDI42!'/K&@Y>@KT4\(OX.7*MW9%=G>[$
M>5C&WB5-RXF/.J7#O<H;2HK:<>2D%VLJU$'K4XA$R6CA* TVH+5]"<&=F2+Q
MEN^Q=1[I24K2T,Z5D$F$D2B!">J@"=.==/X$[)'[PHO\?MV!:+2E330<>2\Y
M*I *<J$MZ:%PA9(T3(V_0C@>W6-[<4D#&\1I*ZCHZ^.B/&@P$%EEMI ' 2VD
M<%2B.7'%$N+/<DZ[O96%KA[26+1L--(2$I0D0 !I.YDF 23J3/K7T_AV&X?A
M5HW:6#";=II(2VVV@(0D#?94DDZR=2=3TK/D)4/S@.?J)]/[M9A"9D S$2=X
MF8TY5EB>>\_*OII5::4II2FE*:4II2FE*:4II2FE*:4II2FE*:4KKJ*_,4 .
MP2.%#UZB../N[=M4@3,ZQMY?3]?=%-<T$>'F?S^&FG3WQA&1YMB^+,/2LGNZ
MBCBLDER5:V#,)A"?Y2UNN(2D>G/603_%2>VL6ZQ"WLP!<.!M"M"I12E*0=R2
M2(T)/4QI-8]U=89:(+EW>-6Z$B5*=<#:1SU4HI!,[#R^,/=P_P (UX8\!4[#
MAYHWEM@UUI7#Q*'*NQUH"N4*E->7#0>K@=3DEM'<>\!Z:EBG'N 84A1-RFX4
MF? WXCL3_4@:'3VN?OK1,3[3.$,-44)Q)%PXF1DMQWA,28"B4MZ1OGC4":B?
MD7X7&G></XF[43Y+(!2B5DEM%KT.*!/!6Q!<L"@=/!($DJ'/! /)USN\[7G+
MIX-83PX]B*@(*U%T!*@20DAI>DB%2I0B><5K%YVVX6P)MK$.R/"X^\VW&I'L
MI*M]#H3$P36(_P#X4;<JQ(<C[9X6Q&4.5'Z4N'QW[#AU#1Y/3R.0.#SV^>M7
MQ?MFXBP%2%7.!X=9A1!#;KEZIQ6IT!4H 'PD:D"1!ZU:P_M4N<940SA]IEUU
M#BE:)W,A6PVVUYZ5TMMO&EMKBVZF4[S6OA^KH.Y><4M5CF5YWCES)?M+BCHD
M)14U\B/:/-1PS"#32&D,)8/"$]2U]/!R++]IC"[IQ*,2P9]D*("E,E"LHB?%
M-P9!/,3I /4>U8<:MVREK=LU!2S*E-KA*M(V65;   2G;034Y<-_")^'[))"
M8=O86V&R'$(Z3?UJVXWFJ)"D>V1G94=(0>GWG5-I//8JX/&_X1VR<%8FM*&'
MW;9:\@=%PE"1*I* "AU>QF9B)$3M6RVO'&#7 4NZ>-H&X_SA"25F#"D%0@$
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M?ZN>=2QG@K ,<20_:);6=<[(#:@=1IX5)$S)T)D#W:3BO9OPKBI)=L$,K/\
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M;,*LD%+U>W(0L(,^4WUH2%>3'6>%ZWKA?LBQ3%G47>)A%C8I=(6TYW;CSH"
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MR^IM'G*6$) OI#;8 ;0E*@ ) $QH-O=T%7,/X?PW#7N_M;=MI12$$H2 <H
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MKLY2%.,0&>LA*P[UK)4 $$@C7->*NU3AWA:V4XZHW;ZG0PW;M+25)6I*URL
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MC82E( "4) T !U DF0>==\L-E/3QPGIZ>!V'''']WK\SWU+7J3I&O05   0
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,4II2FE*:4II2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g40894g28q92.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g28q92.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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ME'7WP>M%A7/8-,U.TU;3X;ZRF66WE7<K#_/6D4<YXQ\?Z;X/58IU:XO)%W)
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MEC]37D2DY-MGT,(J$4D=Y\/$9=-NV(PIEX/KQ7T&7*U,^;S5KVJ1V5>D>2%
M&;K.AZ?KUB;/4;59X<Y /4'U'I0#.$F^"?A]Y2T=Q=1J?X=P.*=Q6.@\/?#S
M0/#<RW%K:&2Y7D32G<R_3TH!*QU;1K(A210RD8((R"*0S@=6^$'AO4KE[B))
M;-V.2(F^7\!VIW%8;I?P?\-Z?<+-,DMV5((65OE_$=Z+A9'?I&L2*D:A448
M P *0S-USP]IGB&R^RZE:I,G8GJOT/:@5CA9/@CH#S%DN;I$SG;N!Q^-.XK'
M4^'? VA^&&,EA:?OR,&:0[G_ #[4%)&KKFD0Z[HUSIEPS+#<+M8KU R#_2D!
MP0^"6@ ?\?5U^8IW%8OZ9\(O#6G7"RR0R794\"9LK^5%PL=['&D2*D:A448
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M$8['"Y.3NR6K$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
/4 % !0 4 % !0 4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g40894g40h04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g40h04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[12F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %(J^4E@X0DE-! 0      "4< @   @  ' )0  ]!:V)A<FDL(%EA<VEN
M($4< @4 !5,M-"]! #A"24T$)0      $.>%(V2O)>J\*[A9O,GY';LX0DE-
M!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W13
M8F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX
M=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q :X            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      T$    &
M  ('   %<0    8 1 !3 %  ,@ T #(    !
M  $             !7$   ('                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   ('     %)G:'1L;VYG   %<0    9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "!P    !29VAT;&]N9P  !7$    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     0X0DE-! P     "C     !    H    #P
M  '@  !P@   "A0 &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( #P H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
M 00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B
M,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8G
ME*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"
M! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M+MJ>6/3-(MR3Q+!-6@O:C;JU[6GW=,C4:O3%%+(*W)4$-F=%@15>S75\W?\
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MGDKK72JYIVOC1*]6!T>YIU5;#07;DRK<T"WK,C"E2;K%EEDJB%4KKQ)$[3R
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M!V(@HNBVF2ZII'1];&H#5M=T.34M-L<5;J'74I:CJ"TK,75S-%"]?39D-KK
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M..4DF!#E 3<8C6]2DTJI3L11)*UG6=+TQED+!5BOS-')*O"0>9&!N@)*[_I
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M-+:_I3;-2H2QQ+Z4CI-%C+2:M<+!RC99!8D.^%\W7:"NW* QMG^4.U#5I_\
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M6>%4Y;"9=MC4NAU..YTQTK2Y-1FU/HDFCS)UB2B:VL1ZM;IZ>E6LBI!-7O\
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M11,@CP YR$$0]D ,8 X_]W',D*"2:*,D@22(A([X#,%)&_9N >S+7/"K,/\
M=4GS G.])KZEEI,ZN)J7*3.NM$:I+Z*I0NHUN5H@5#5%WJ<6"4EJ[I[%A 1<
MNI.Q2,LZ69*).[$R*G&+C*]&YQ$%.8-TWU (9HZVG69!JVOZ>^D0"T=3@JZ.
MFHM'J4TG->%:TAI1&4/#%NE@"%V<=G2#T,H*)$ELWZZ)H>DZI'JDKU!IT]O4
M3IW%IBQ-"DO/!NR0P\%F1VE@+-$4#!8>_P#4RJ(2-;6&=6UTT0CHBU:J&G*[
MJRUJLC<;KI=I13Y"SS5\TP8,(*J*K%<.V24$F,O'KQ";M\BHG)N10<H)T/3N
M>&,2<.EZIS-&I76BTQK"-IVIZGJ='3=-HZG(\ME(XK4EQFYBA9U2M(_(*-&Q
MW&_D^@EL:A72?4-.2AKQTV"YJ0KR0:W1K5[]S4[.D110UI9+5&I2%AHF=X'6
M81";F*_#5.G.RS0;6'263W)5&ZZKUK1K38EZ#6*N61O4YS41LXK4,SEZXE1Y
M2+CX6!D4[4+Y!BY5?PH_<VJ"KAV1ZVYHZDGJ_2;5- MPZ=>IT+EO58:?P))4
M>Q7KFY/J,&GV(-069YW2&OUA;*V(F'.C1X4C$Q R'T+HQI?29;<NF7-0JQZ-
M)8GUN.XE>>3X)ATN_JJ6].>&.O&]N1-.EKFE,3P22QRF;EJ>*2:-;$="];]/
M7&M]4MFH\9IRRI.IKQ]5+E==)J186E]TXDZ60\:XU/M<?$:=LJG+0ET9O23<
MQ&12C.1;JQJA51,@LOCUKI1JFA6CIUJO0L6II.C\M.S6BN& TM9N7J%@241+
M+;EN5;%(M##6E<6HI %5904&30NB^E=((4N5K5^K!#'TD6Y7L-6DDZQHND0:
MO4:&ZE>*O#4MQ2M#9EL5R*3*9Y'Y"ECK3IYMNH&H^O5]I19J<JNEVE>G%NU2
MO,G'7;3G6&Q&KE&A$I26:5:U:>%2H%BD91VZ8Q\>M'F<LHX7"RK\RYF2Z.3%
MG6YZ&@2:K-$MFW);IT*%?J5_2%EMZEJ4&F4TLPZEQ6Z\:2S&6:=D"/$@,2_G
M$8PU/0X=2Z0TM'KS"M6FBFLV[9O4=9%>M2HVM1NRQ2Z6L<,TG5ZKK!54-,LQ
M"R]A[-F-#=B6@FX&DJ:Q4JVZGQ.G\5 :M)V&JW2W:4U*PL[KIS%5R?C&J>I5
MCCH?3]E5[##3XJNI>9CF)8-ZT%NZ<JD715&(UKI/JN@610NUM/GM6ZVEW=/G
MJQW3":]K68M&O)/4$DMF2>I/+')62O(6NHY5(DDC*F:T'HMI72-$M4K.I5JL
M&J7=,OQ66J23,5T+4=;TVQ5FB@2&))TTRQ#=6RC=4)219)(27&L=%VV4K4[<
MRII#"R\K5:- UJ?N%OF$K]IKK1*(05.J[NUV,:U:],"HT*POW+-J#6*;,5ET
MVKU0Z,BX,HW723F+&MS:?T<U'7;<8L-5(6O E#4-(:66>W%0JPS0:H6M1(UN
M3>2UP"-JY$T2,I5F@(='CU'7M,T6B_(%QXTLV'U&AJ\42"*:Y8GKSZ:D4$O+
MI1@+4XFGZTLD4DB$B..?T7;IM:U.I]TU=K5TUPA=/](Z/9;7J=3)R'KDA=5W
M+6>AX*FM*==6<-'4U=*S+SC526(^AEGM63;NCKMI%$[19QJ:EK.N:.]6O;J:
M99EU>YI6G:3/6FFAA2]=-IKD=ZO++-9,%*"I)/'9AX8[3-'7')FXPDAIVBZ'
MJZ6;%.YJ=:'28]4NZK#9AAGEETNC6BEKVJ$\,,-=+%FQ*E66E8+RP!C:!DA0
MJU^:5^IKZ3:]Z8K:JZ<ZLVBIQEMTUD9'2^!U*"N).#:R1%VBJ@.G-IL3%G&Q
M:\/9W,JS:5FS,F<.D65>M6\DBF *D")UOIAJN@6NH6-,KZC:2_I\A&G+9X[>
MAVZ.IW+,U6J\DLJZG072[4AK&29;<,>T(5W!$QT?Z':-TBTV768=5LZ9I\ O
M4+CZDU;@H:W')ID>G":PD,8FTJX=4KI/8B@66FW$SF11MD*U6V'Z4;<=/H;4
MS6^?U=.QE8726-4I%8;UB'MD;J#=X.6GK@WE'TY$R;2/@ZFVC :LF"D2I+R;
MY4Z2CM!-(ZA-BCTQEUC5GTG2HZ#B2_JO5M2D:::J='T^KI$L5GE12QM8M6Y]
M5552.:*)((^-CQ%5?6O=#$T?1Y-7U5[B]4JTH[>GQ-7CL?#-[5-:IBLL\D4D
M452"MHLTSS\%EWFD2-5$;<Q/W8=E&WR!T9KNKL)<KE=HFY3FI#>OJ676/;[M
MO?(PU/<MDHM4:;K."=GL\DY3<\B01JX.4CN$ *Q* /6A1#I+K(U5](LTZE2S
M6TS3[EAJM'5ND*M/<L7(&"1Z03)7@"UDECZP _YUXBS25Y3B7HUH8TRMJ]6[
M<M5+M^>M"EV[IG1^2.*"G0M$&?5(>KVYP]N2%C6_- 0QS[<NQ%O*]0_4^]&-
M-J5<;?9#:^PT%3-#].M8&=^FY6@1=%U'F+DUKKQWIC2Q=5))\%E!.9=H1KMN
MYL9$UHU161C4T#@(8QTNOM;ZO&FF/+W5S]'#IRI;;416AEL0MK!X;!5:T0A6
MS*CQ(G()46%DX2:=RM#J@L_]Z+"_15ND:7VGI"BECE+-'I4F]4,\LA85EDBD
M,C3LKK6,8D":@[KM(-#-'8[2-#34-6G<[J=I11=7U7-YL-.D(F*B+FA*C]SR
M;.OT^$>.9)@LP3XRQGR;5=-0Y0C4S 4V3NCZCJEW4^D-.W\'+!T?UFQHCM6@
MM)-;FBI:?=2TAEM2I#$5O<MH665R8^,2@'A$-K&G:50T[1+58:DUC7-)35HA
M/9JO#43X5U'3GKRK'2BDG8KIKRI*DD(5IE5HV"$MIAGI,\UFT.R#^^CM$_VG
M=!?]ZE5R'Z1?T?U[_DNJ_P"0L9,='OY_T/\ YQIG^=@SF;[O[[6[W_:9UR_W
MEV7+.C7]'-!_Y-IG^2@RO2/^D&N?\WU+_.39JEDWD-C&,8QC&,V4B-V>L\&Z
MI+V.F(=)QI]HW8]!ZR<]?CE.BZ=VH)X)ABX R?!W)J_=)*\Q+K<7C85$13-_
MDY,B;&B:?9;5&DCEXM8MZ7>NLD\B%K.C)0CH/$5(,0C73:O&B;"0JY;<NV3%
M'7]4TY=!6K-&J]&I]5LZ2'@BDY,NLSV+-\R\2_GUDELRF-9-Q$"%7L4#+0?>
MJ(;E'1!<L9*B5VSO9.AR]EOU8T\K<'?;N^TV?-).IJ7:RM&P.+$5I),6C]X1
MVF!9-VB59^"X\>.DO1315F5^3.U:.?4K$.F26I7TJ";5ZUBGJ#PT2>5'SZMN
MU %'Q8TGD$:J6WS*>DFK&M)!S:XDEIT*$FH+3KKJCU=+LU;="-KX03$U[%*K
M(KDF0F",,Q"[9[@]42W#M7L>M H:55*';R=QF)JF5/2RK0E'N\C?H8:_:W-[
MK#=L:/L_56)$&ATGI00;E*0S5)$Y"F#".AVB,C1SI<N+U"#3:YN7[-AZ%.O=
MBU"%-/=G#U'CN00SB6,\SCBCW8A0,VCTPUT2B>*:I6G;4QK%B:M0JP/>U#J=
MC3S/>X$"V@U.Y;@>.12C):GW4L^XXI_5 -<%X^8KC^ T:DJ#,5&LT<=+WVE%
M=4TWC*[4I]]:89M"U9+F6\<X)8I)W+NGB2IG+UZH"CA0_)* 9#T4TII!8:34
M6O#4/A,:BU^9KXM=0;2P18.Y$24':LD(4(B,Y XF).->E6K) M2(4(J IV*1
MTZ+3ZT=!XK=Z'4;+R5E4*\\URM7E><GF$01)OP(H&I%SM)[I8Y"QGKU3JQI
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M?1#I3Z'5][S3^ M+^F713T^?W7'K8=2_.*;#?.'?/L\QW7VOHATI]#J^]X^
MM+^F713T^?W7'K8=2_.*;#?.'?/L\QW7VOHATI]#J^]X^ M+^F713T^?W7'K
M8=2_.*;#?.'?/L\QW7VOHATI]#J^]X^ M+^F713T^?W7'K8=2_.*;#?.'?/L
M\QW7VOHATI]#J^]X^ M+^F713T^?W7'K8=2_.*;#?.'?/L\QW7VOHATI]#J^
M]X^ M+^F713T^?W7'K8=2_.*;#?.'?/L\QW7VOHATI]#J^]X^ M+^F713T^?
MW7'K8=2_.*;#?.'?/L\QW7VOHATI]#J^]X^ M+^F713T^?W7'K8=2_.*;#?.
M'?/L\QW7VOHATI]#J^]X^ M+^F713T^?W7'K8=2_.*;#?.'?/L\QW7VOHATI
M]#J^]X^ M+^F713T^?W7'K8=2_.*;#?.'?/L\QW7VOHATI]#J^]X^ M+^F71
M3T^?W7'K8=2_.*;#?.'?/L\QW7VOHATI]#J^]X^ M+^F713T^?W7'K8=2_.*
M;#?.'?/L\QW7VOHATI]#J^]X^ M+^F713T^?W7'K8=2_.*;#?.'?/L\QW7VO
MHATI]#J^]X^ M+^F713T^?W7+=TMV!:>T>#UMC)/U0K8XY7U*T><:>PQV6H%
MU.DSEEM2M-+F5W(BM0T3$8!'4N1;B=N5POTMRS*" I&652T;O2:[9?3V3HET
MG45-02W)Q5*^[1K4NURJ;6CNY>RA&^PX5;MWV!WZ.F:/5%_F=,>BY-K39Z<?
M!>F($DMBK*&<FNNR!8&!(#-N1L-MR*B];#J7YQ38;YP[Y]GF;W=?:^B'2GT.
MK[WFA\!:7],NBGI\_NN/6PZE^<4V&^<.^?9YCNOM?1#I3Z'5][Q\!:7],NBG
MI\_NN/6PZE^<4V&^<.^?9YCNOM?1#I3Z'5][Q\!:7],NBGI\_NN/6PZE^<4V
M&^<.^?9YCNOM?1#I3Z'5][Q\!:7],NBGI\_NN/6PZE^<4V&^<.^?9YCNOM?1
M#I3Z'5][Q\!:7],NBGI\_NN/6PZE^<4V&^<.^?9YCNOM?1#I3Z'5][Q\!:7]
M,NBGI\_NN/6PZE^<4V&^<.^?9YCNOM?1#I3Z'5][Q\!:7],NBGI\_NN/6PZE
M^<4V&^<.^?9YCNOM?1#I3Z'5][Q\!:7],NBGI\_NN/6PZE^<4V&^<.^?9YCN
MOM?1#I3Z'5][Q\!:7],NBGI\_NN2FF^I%*ZASB59HF^W95;["NW<NT82NW#4
M:7DU6K,G.NW!&3+3=9<R+9/^VLH!!*F7^T80#-2[T^73:[6K_1GI)4K*R(TT
MU6JD8>0\**6-O8%CV#PG-W3^B,6K65I:;THZ-7;3H\BUZ]RQ)*R1KQ2,%%7<
MA%[3X!EO^L%:Z^$GMK^6U>^RS(;\K^@^3=7^I2]\R?\ R4:[X]I7VEOW3'K!
M6NOA)[:_EM7OLLQ^5_0?)NK_ %*7OF/R4:[X]I7VEOW3'K!6NOA)[:_EM7OL
MLQ^5_0?)NK_4I>^8_)1KOCVE?:6_=,>L%:Z^$GMK^6U>^RS'Y7]!\FZO]2E[
MYC\E&N^/:5]I;]TQZP5KKX2>VOY;5[[+,?E?T'R;J_U*7OF/R4:[X]I7VEOW
M3'K!6NOA)[:_EM7OLLQ^5_0?)NK_ %*7OF/R4:[X]I7VEOW3+JVU^HB:RZ8;
MC- -1Y;</MVD8VA:UZ67-[&1[O5!*2E&U7O$'.+QD6:3TX81YI2028':1R3M
MZU05>*HIJ+I%,)PT-5_E6T2[I>I4H]/U5)+FGW:D;.E3@62S6EA1G*VF8(K.
M"Q"D[ [ G-_2OY,=:I:IIUV6[IC1T[]2U(J262[)7L1RLJ!JRJ794(4%@-R-
MR!VYW-:C"(:F:G=L0 -0[?\ ?X '_MIUG@]'/_=U;<]@CW_J'QGW.3W27^>;
M7_\ '_AKE4,+U2Y62&'B[E5I*7 ZR8Q3"Q1+R2 [?E X(+%L\4= = 2F!8HI
M<4A*8#@7@.2$4T,^_)ECEV7C/+=7V3<#B)4D<.Y'QN]VCM[<AY*\\*AI8)HE
M)"AI(W12Q[P!90-S\@WW/R9GW+YHS!$7CQNT!PNFV0%RX30!=RJ/!)NB*IR<
MXNH/:32)RE#CVBE$<O+*" 6 )#$ D D(I=B >^%0%F\"@L=@"<Q!6;?A4MPC
MB;8$[+N!N=N\-R!N>S<@?+GY8R+*3;$>1KYK(,U1.";MBZ1=ME!3.9-0$UVZ
MBB1Q(H4Q#@4X\DY3%'@("&5!!56':KJKHP[SHPW5U/>96':K#<$=H.&!5F1@
M59&*LK AE8=A5@>T,#WP0"/EP^D6,6V.\DW[2.9IB0JCM^Z19MDS*'!-,IUW
M"B:13**&*0@&. G.8I2@)A !M9E7A#,%+NL: D L[GA1%W_29B=E4;DGL RJ
MJS[A%9B%9B%!;95&[,=@=E4 EB>P ;D@9ZC3$61Z,:>5CRR)6@R!F!GS<KT&
M &$HO1:BJ"X- , E%R*?,@8!#E\0X90R(.9NZ#DJ'EW8#E(>+9Y.WXBGA;9F
MV!X6[>PY41R%48(Y61BB,%8J[@ E$.VS, RDJ"2 1N.T9[6$BQE6B$A%OVDD
MP=$YQL^8.D7C-PGQ$.<0<MU%$5B<0$.6F<Q>("''B&7_ " _(RJP_K5@&5AX
M0RD,#WB"".PY:RLK,K JRDJRL"&5@=BK [$$'L((!![^<OB/='QCC*9X$W !
M$3<  !$1$>   =L1$1'@  ';$1]C*$@ DD  $DD[  =I))[  .^< $G8#<GL
M '?)\&<5C(L9-L1[&OVDBS5$X).V+I%VU4%,YDU 3<-U%$CB10IB'Y)QY)RF
M*;@("& 055P04=%D1O\ =9&&ZNI[Q5AVAAV$=H.V5961F1E*NC%65@0RL#L5
M93L0P/800"#V'/VU>-GJ(.&;I!V@)U4P7:KIN$1405.@NF"B1CD$Z*R:B*I0
M-RDU2'3. '*8 J"" P((8!E([0RD;A@1V$$=H([".T8965BK JR]A5@0P) (
M!!V(["#V_(0?ESD<1[H^,<93'$>Z/C'&,<1[H^,<8QQ'NCXQQC'$>Z/C'&,K
M?5&R6"MP$<M6G$6TEI6S0,"D\F8]U+,&B<J[%%9RI'M)2&6<G3( BFF$DV#E
M" F,(!P'5L23":A!"T:&W;,#22QM*$1:MFP2J++%NQ, 4$OL.(G8YM54A86I
M)UD=*]1YPD<BQ,SB>"%07:*8!1SBQ' 2>$#<;[Y1BFO-T@+/,U.9;5>>=P;@
M\:,O')24!%R;Q9Q#&;N^9,]LKM@BR:2BJ4C'M0G'AG34#-C""HH)ZD>H.Q93
M&@*EHN)F98VDAFMK+,I5)7:%XZZHB)&S1V>:CR-'&9,D9-,AY4,Z/,JS()^6
M>7))'$T941,3R4,G-7F\UVA5JTB$1A]@V&0W5RZ#*8M,G5XM6H1S>*2,G&RC
MX]@1E7<3/O7!$6B[ I)*+Z3!'*5X8L8[;MERJJL%!(J"=3J)6%)VB!2T_#3'
M'LP=].KZA&EI55Q$@$KQ/.CNO&$V38[G-\"(\\52*=Q/QR+,7C'**#58M-1X
MV# AR)XY3"RD$*X67B 4^B<W*W)(S%]'1$ V:,&-B6G43+S#Y!T=@I4U&:L8
M9W$P;U7FV\ZJDLFJFT**X&.4ZR:20.+C=9)2SJO(5JT3@%BYD;5X:,SQ;JIX
M'@D+0M(BLK]LD)VV.%-,A>M.RO(9N.!H"0@"QS:;JEH),J/*H82TU+\#N.%5
M56',9DM5MJ]:WU!NUK/6H^'<PU?;V"MB62/.MY)F_;KJM.GLDBQ3QN\1.@)7
M+$B@)F$Y"-WQQY9B5M6IX=/DLB-4L1RPQF,;SH1/'4F1T*F)GV2URRAY;<Z)
MN'BC*LVO'3KMJ%>L)7DAD,JR.0*[*\$T\,B\3<Y%4F$.LOQARY 2H8,HK=ON
M1M,8M),I>+92+H'\7',#2-?L%#5;/3P$O/R[60B^EWB160Z(P9=1Y9NFDR?+
MOE6Z@(E8N%RVOJ'*60LG,,<U\_[T3FO0BK-*G*(D*6S+/P1QRR*DD968O''L
M[;:Z3',(6CD,8>"*20*\=E0;-M*U:1)MJZO$>*4V%5&D@,( 61Y@B<9AN/O2
MS\#IP$"]9SEM5AX&/<OGS%RV:.8BF.H\K]\FQ5! 4%; X7=<EB^46XF12,F5
M%,RF1)[ GIU66)Y+1U!0P=D5>K:M?J1LQ",2!!3*E @+-P2F0<;1KADHUECD
ME,DR+!6J2R[(DG$\L#/*J N 092@1RZ@*""G;Q9)6>Y*86;OWCFG1J+6#FW-
M4FR)V1PH\^Z)%Q8VI#1+<\*F#V#,K7CBH_749NDR.0,#$_,*@&"34^73ZZ(=
MXWK220H7(<SQ:/#J[QR[*5CA,<O)28%R77=HUX@,O.CJ+74^L-S *TQ;D_F^
MJV[-:"-@>9OU@"RCO%MP @J)3NI./?;GYF)C#N)*H0J;YK!,[2^3:V=Z\8=1
MG\4SE6S5FZ0KYG"TT9-T9$Z3AFVBDE4N*TJF10AAW)K!AL/795WAN+2G8,Q_
M.-9C@#P 1[2(!(7;F&'O!%XF892MI*VA7:*=P+BMU</$J,'3FJYL*9=XHPT:
M <'.D*R%C&. @XZ$W ZF=.F!>URKS,3'JQX "$M(Q\J!IV[2]6BTD0ZEKM7/
M(3:-3N$U2M3)B"R@.G)E2))ZT%NQU:&26)'DDL1U/S;D%IY4E9=D*;% Z(I8
M,I"ON(V*GBR2Z=1(#1SSQ<279]I(T=1#3I4[<FY#AE?AGD"CXX8A03& 2U_:
M5:FFU.CY:50BAC6$:^0B4U3NCK'<RB#!LK/-RD,W0Y"<3)K+1?.\3"NLU6.8
MB/ "COPR">!+"D<J9Y37(.Y>",B,2-\@+3+.@4<0X$20,>9PK%W*QIS]69MY
M4C#3*1MRW>24QI\H;CJBO8X@>SG\O;="3:O$>Z/C',F:N.(]T?&.,9\U^^3^
M]1JU_K]<_@RN9V/HS_,=#^Q-_F)LXMTH_G[4/[</^6AS4[)W(#&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,9W"^H6?_,(IOZ-M4?F%+.?_P IW]$K7_&4?\8Y
MTO\ DD_IM2_X+4?\N<^X//F?/K7&,8QC&,8QC&,95.L/M:A/\=0M../EI"C_
M /?*CO\ [F_@<H?_ )'\1G3UJ2 CJ5J@ =L1U!N( '^(S#OAG0=*!.F0@=I,
M+ #^LEP,Y/TD_GJS^V+_ *%SJ2KVANM$#+TR<- M3I1]FU3E8I*,BH>-L5:G
MY@TXG7).RS/3%EYNL/$W::AFZ',KMUCMQ7;+)IFX:%:GJ%>K4"*JVXNC4]:H
M\86):]V1626"[PD\Z0Q#:M-NR+*P)4$!LDK.H:98:\K2,89=4TZ2RLCR2BW3
M@>)V>DH""!UD4\V-OTHE8*W$P&8^-TSW&33"IO;Q&7^0:UG4ZESJD2>Y/7M@
M J$/)MK7,L7JTBV$(U:24CUV3%)<J4<071(Y))NH9,^W%7G$FGSNDWYI]5CC
M!E9Y*\-G3$BKBVS-Q3H;B2%F?C;ERM&08FX<MDM::OPE%!+55[.G<!D%=(Z\
MLJ:G%+#'$BH0CK2YBN?BK))%!*QYJ\0SD7ION-:1Z:[=?42+<P4+7'$+%L+4
M9I&N9H^I<NO-E?QR<ET1_P *FY1.X1=D,W5;&2 04701*DIPW8NJ/*9N*&7H
MQ"8FDXH15731%K&\7$4(2<?')!/,WDCW)+'!-:TQWG0+69+'=#(\IB_.B1^%
M]*"R\(D0LW$5*D$!>!F",RMB[Q1=R=IL]V;JP=Y<UB:5E0&)D+$65A#+,K;"
MO(!U%(N91..9I&BT'2J*<9#Q@MB<ML\6?J\%QUZD%XS5VL)-RTNZ9:*S/S3#
M+7U<O.RR%B2JTF#?FUBB9  (0\>YS-9TQ*@$4M83BK-#Q10\EI$GT9XRD@"
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MABL1&/G1<$HF",A?XV^\%B&"Q$1WI(@.\3FW!7U6O!:A33[?^DHJAS7FXH6
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M):E>C6.Z+H_Y>T7UK0]XQW+])_HWK_J;4O=L=AAO!\%3<=YDM2O1K'=%T?\
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MQC&,8QE4ZP^UJ$_2%IQ_&D+E1W_W-_ Y0][]Z_Q&5]1?^9V7X?W[^*Y3!_\
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MNT5T&:_I@H0P")K<5/>/F&+EKQU'A02FXTH4S#==W+#B]T5JINJ4J4ZY36U
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MFK]@:+(ORRJHRJ:38R:NII<VI0_ %,QR\A*,89)%(CD:;I%K/7NM,5$D<L-
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MPGQB_3C<>$><8Y$_S,OV;^S'.)]\)\8OTXW'A'G&.1/\S+]F_LSH\W7KH%W
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MVD^]CGS_ #TOVC^W.E7=''1ZFO.H)U&#)0XO(;B8[5 QAX5J% .)C)B(\
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MSC&P\ \PQN?"?.<8V'@'F&-SX3YSC&P\ \PQN?"?.<8V'@'F&-SX3YSC&P\
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M7'\VGU5]F=?NL<#!+:DVA5:%B%E3KL.4HK&,E%#<(B/*'*.= QC<"@ !Q$>
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MHO.KF1;(MTA/S=N(3^P@BDF')*']D@<>WQ$?/W>B^@V;,L\^G1O+(5+L)K*
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695D5"<LA1$H\.&-]OW]F-M_W=N?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g40894g45l12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g45l12.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1T64&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q :X            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      T,    &
M  (5   #ZP    < 1 !3 %  ,@ T #< 0@    $
M     0             #ZP   A4                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   A4     4F=H=&QO;F<   /K    !G-L:6-E
M<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO
M;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53
M;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53
M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   (5     %)G:'1L;VYG   #ZP    -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $    !CA"24T$#      2G0    $   "@
M50   >   )]@   2@0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ 50"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MUUVJM1AXN)];*V8U+*0>FN#MC0"[9;37
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M<2@0#%$NGU19$V?=UBS$+JE4W-=O@8+)4Y%1#VPQ5=%_.0]?5D3HM2OG[]-
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MRUII@JW6UPH78LW076;PO%1W+8VP9>IBM[-LR8FE""$4SR9=PB7==K8O'0M
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MB)HB:(FB)HB:(MIC"'/81X#GM\_L^G/^>VH)H7^B+:103^I1+]XA_1\QT:;
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MCXI2JE0?1[Y)L_;%71.FNU56;)I.D%"JH&4(/5HBB1\00.?%T\((>.2B[W&
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M[7#<'H1TM7+'MDC9*QP=&_=KP;:>G0]#U\UL<S$0BF<'$I'(@!1$16>MTP
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MXPJP;^>[1$2"9)JS<*&*H^>K@42HM&OG+JGX*0O(ZSNG\)^USB_(CT[#R\7
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MASV'5D[4\UP(,D@!\B1^@'3M:O&Z=AB_Z+3Y6 ?U_P J[#2-9LP*DV;-VY"
M!2D1231*4OR "IE+QQ\@*(=OVC;.FFD-N+C_ .SG'\R3O\?^%[MAAC $;0VA
MN &BOP'3SO\ NNR(3HY[^H!\AXY#GD>XF'OR'J(^GVZIKOW-7]%[>OU]?5;A
MXX[^FA%BO-#L"?)=-.0,'98]>)GXN.F8IT4".8R58MI"/<E 0, .&;M)9NL
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M)T%$>>DO/;OP'/80$/V" "'W:(M/+3[? 0./3@H!QZ?9]@?L#1%J!" /(%*
M_4"@ _MXT10*^($ !XO'A <  ?QW<7Z!Q_\ =&-U'<?(_J%/8_,?W4]*?Y@?
M>;^T.I4+?HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(NN45\LQB^88.!.;D3&$
MI0$WJ;OZ<B  4 'Z!QVU1SCG\/>R"; V Z];[?JI /W6#F<ZC1LD=SU/38[#
M;R"QKW#[BX3",&S;D:JV:_6@1CZ/3(\#+24Y*N!,F@"J)0,LWCTC""CIP8@
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MDSDB935(*+X3ORF<E.H02&6%JDD4HMG(*4<::[/PIIV1@Q21GB[BS_YVOY
M!PL.05%I\#F48RUK@T NL-\0GJ%[86.W,H2@#'Q_=AY37.YA]Z0[GF#=V,(
M%<YJR"O025J0@ 4H])0 I2E*4I0*!0      #T  ].P!P'&N#EC2&APYN4"N
M;?IO=&Q=[V=[WN]UGNG0!H\AL/7Y?DOH*)>./3OSV#Y_,?U_T:%I_P!+BTDV
M30)/_P!U[=O@.E*0:^GS_LMY2]/H(\<  !]/7_SJ0*W.YJB:HG\-E"I#(5D:
M4ZB7"UOS@FQKE<F)EVH8W2!&\<Q6=*F$PB !P1,1YY#C5OES"#%GF-?TXGNW
MZ;#O\+7AE3#'QIYS511/?OL/=:3N?*^JC.\(NJ.F^U!*\R!E%%\Q9"OF307/
MUE76C[+8I!:/\U0P]9S>RI("!P,/)1#@>G6O\+XY9I;VR<Q:_(=*+<6EU51/
M+571OS)-K <*X[68^7/(RG9,[W DNLML-VH@]0ZAT WZJ5-./1(!>!4X* <%
M,<Q@#CCC\XPB''''KV^_OK91&TM <.;N"[<C>Q1-U7;Y+90U@^ZVO_J=^A=7
MSVW7-*7I 0#Z\_T '_;58%"E*W:E$T1-$31$T1-$31$T1-$3Z?9_X$/^^B+P
MS?NDC &8+1OSP'>ZQ0;)/U:V5"ET>*FXJ,=O8TMG1N1Q+%O7B"*B#%987;?R
M/:5$_-\P ( B(")/7K;U^L=6\/:QGF+\6>-I0XULSJP7_*^*[A5FC6/67)+P
MC56NN)%XT7(7RC(QI&:Y7IA,((&2/U#Z $6?+O0^5=?Q^6WQV,]OIO\ CM^G
MQ_6OTFH1%1O#1*"Q!360C62*I!'D2*)-DR'*(\!W*8H@/8.X:E0NTT1-$31$
MT1-$31%'AX@$K(Q%6I#B.V.CO:44L+HAZR5"J.#5%/V,PC-"2U)G0*5P8 :<
MM0,H/?G@.^B**G F-\C9%\1';IE=KLFAO#TK6-JA?VUB.O,TR)G\Z!,M&S9M
M4FM<K/D%EV<&J(2BKI=(YVH%#A0G(!J._P O[_\ '?Z*>G<&_A^XV^G7O\?3
M('8 #[ ^O_?O^WO]=2H6NB)HB:(FB)HB:(H%/$#_ -KQX0'_ #NXO_I"-U'<
M?(_JU3V/S'Z.4]"?Y@?>;^T.I4+?HB:(FB)HB:(FB)HB:(FB)HB:(FB+01X
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M(" $4 IN0'D.PAJKE=W!'?<$?JCSR $B@ZJO;J:!Z&Q?ZCS7<:A2N.9P0@B
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ME2DBTXQ\:1,<WED*S!LH+GJ4* "4!2Z@Z@$!#GL.O.<L$,ID<&QB-Q>XF@&
M'FLV*VO>UXY+HF03/R*\!L3W2V2T>$&GGMP(('*#N*([;J';9UM0Q!E=O>LN
MV6FIGA9F].D<9Q0R$BD6)BX=\N(O# BX(HLHX5(GTG<F4*/0/'(B(ZX3P-P=
MHFM1YFKYN+,<"?4GMT2!V9F1OQ6Q/DD(D,4[7SBBR,-R72-;X?NM%D#A_ G
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M X?$(@!../ESWY-Z!ZATAW'U#L'S'CD3G/<]W/;/=8&U5/;S<[B:L\UM W(
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MA95[P#E^+)N5,ZZI0'I3 Y@'RTR_"F3@@=B@(7.9+]HD+Z /NBOBUH!Z;;_
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M2&JPL)BI)WBW%NA9>Y.C*_Z9<PLF@V8MT4S@DNSZQ$0$> BAZ];=.W3LIO\
MS\3O^M[_ %6>&S/8E9L5+9PO.Y>T4O,.3<^LJA7+HG#U@D?2PI]"@B5NOPI8
MAZ"@.?:6B(NY,5DP*HY5,!1,4 '4^BA/Y?\ /]U@1N_PUB?$GBZ>$@3&6.:9
M0AF'FX,)8U2KL9 ^\0:U%B+8'@1S=$%P0\PWE=?Y@G.//?O'?Z?I_P J*VOX
M_K?[+T9)_F!]YO[0ZE%OT1-$31$T1-$31$T1-$31$T1-$7'<&Z2E'CJ$.H0+
MSP)A .0 /M$=1W:+ +B +._QH=Z&Y [*#L"?($_/R%]K.PV.^U=U@]OEOTC
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MX3TO45(?B 2JE, E[\<=Q$W_ .D"@(CKRD:.>*2G.,;B !V\4>$7'X,#B[Y
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M=N]R>YVE82BC%DL>XB<,;OD=1)456+B8!5,\3#O  ?+6 ""DH9)03E*(J<E
M1$!Y+KKW\6<8X&B8Y,FF:$8LW4*<XQ33.?\ ]I[/N2!K0QE.#A;GUNTWROB%
MSN*>+-/X<@(ETO1G1:KJY !8_(!!QL9YWL<W]4LW +18!&TEB3<B2221"E(D
MBDFB1,H=)2 F42 4A0_- "](!QQ^;W'@ UUQK0W[NPY6M  H4+ JMNAJAVI=
M28T,IH Y0 &M["@:V^':OD* 46WB<Y:LJ-'I6UC$RYS9>W/3X4Q@#54Y5X6F
M)BF>WSJAB#RW13:'*T*)S)>8BL[,F(B@<-=']EVBXT.7F<3:NQK='X;A^W2.
M?7AS:A)8QX6!U@4\6T 4"6W]X%6&IS&1C<>)Q$LA,8#;!#:/,\U5M:!1 L\Q
M;WI9Z8&P_7<%8DH&*JNV31B*;76$20Q2%*9T[(B!Y"06$.YEW[Y1R[7/^<8Z
MWS#D TOB'5IM=U;.U/)<72Y.5),TDWX3++8V,)%M#(Z8*Z-%=%>8[/!@BB #
M0R-C2!TYF@63_N)=9)-DW:O.0H%#@I0* #\@ .?M[?;SK&-'* /7K]>J]5OU
M4B:(OFJ/23GOZAQQZ"//8#<=^D?F(>G'KHB\</CS;D]T%>W'-L4,+19\>XA;
MU)F\K:$!(N(ME='#Y( F'L@X;&(9RHQ5,5F5L=401(/5T?E1$><<19L[]0R<
M02S,BA$0,;9'LCD$D;7V]K2T2"R0 [F HU17*^+\W+;JPQYWSMPVQL,<4,LL
M3)&. )DD9&]HF_JA[*D! #10!(J8OP*[3?++L1J"-VA_=S> GIR'J;PS$6"D
MS747(*(2*B9BE%R<[A1<AGX\BZ,43"8W3SK8N&'.^P.C,98V.1Q8[E #@XDG
M< 7RG:S9KOV6S\'&5VDO#V@X[<N48SR0XN;RQF07N2UCW%K22=K'8DS+< 'H
M ?LULJVV@.@I:Z(FB)HB:(M#=@'[A_JT/0VGRW/8>:XH''U$1 /GR8W] CV'
M[O7MJCFC:+:22:)H'T?GTI4D2D] /ER[?$U9^O1=++V:#@&Z[V<FXV(9MR]:
MSJ2>I-$$B@'J=18Y"D^?/(_+D> UZQ0Y$Q'A1.>"+  -D=">AV![_BO.27&C
M!\61H>/O;]_Q LC< &_@L>+!O$PI%NS1D#.2>09H0'V:(Q_#2=G5=J@( "23
MV/0/&%.)O@'SGI"E'D3"  (ZR<>C9T@+^5D;&CWC(]H(!Z;'<'8GL1WZK'3:
MM@PD-YGN>XD,#&N-D=:VW^&^^_:E3:&7]R-\7;#0\$'J4(X6(16;RA8FD/(M
M$O,+UJDK<<5^Y7$4N3$*9TF'4(=75QTF]'8&F8\;C+FEV2 .6)@<6.-[V1S
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MGZEF0:?A1&2;*>R&%O*Y\CII'4">4@","B=A0!/, %N4TD<+#(\D<C>?<B@
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M%>J_]2:Y$(<'"C+=+PI+YY6R _UIV;4]@W8-P74ZQR-6@\.Z9J'%&J1<:Z]
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MP>[G?6F5<4E!  *4VB*^M9F5;% 0D\>.?1 R\6RD5(F41!"3CCO&Z;CV)^B
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M&PWPVYX2%M_B'N+8T;I']F;R68J68C58WJJW,9584%1( E%0@@;H$4Q Q#&
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M'*YI!V-@]#M:]=-RY-*U##U+3^7&SL#(AR\2?PFDPY$#Q)%(6%KKY'M!(+7
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M1MS&$3D.F8ARFR+6.#%/U%,7M(\\"03 /'UU$K89&F.9O.QP-CE)KR.W>_\
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3)HB:(FB)HB:(FB)HB:(FB+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g40894g53a53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g53a53.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[30B4&AO=&]S:&]P(#,N,  X0DE-! 0
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M @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M  #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M    $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M    !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G
M1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M      26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M   %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";"
M @9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"
M!5;G1&(U)L=                %)S;'15;G1&(U!X;$!I            "G
M9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M  3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M      4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V
M)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,96
M9T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296
M-T5&]P;&]N9P      .$))30/M       0 ,@    !  ( R     $  CA"24
MT$)@      #@             _@   .$))300-       $    >#A"24T$&0
M      !    !XX0DE- _,       D           $ .$))32<0       *
M$          CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0
M"AF9H !@       0 R     0!:    !@       0 U     0 M    !@
M   3A"24T#^       <   _____________________________P/H     /
M____________________________\#Z     #_______________________
M______ ^@     _____________________________P/H   X0DE-! @
M   !     !   "0    D      .$))300>       $     #A"24T$&@
M #-0    8              T    ->          $
M       0             #7@   T                       0
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M0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
M '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&
M]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=7
M1S971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$
M]U='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M       0$ .$))3004       $    !#A"24T$#      IA0    $   "@
M  F@   >   2#    I:0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &
M2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,#
MP1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A
M04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,#
MP,# P,_\  $0@ F@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
M        ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0
MH+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!
M52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>
M/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1
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M_H)8AP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &/ 9X# 1$  A$! Q$!_\0 '@
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M9"I,39+@=V15L*#8L,IL,"!V]1'?PX2+IDV=?"3" +=$-SO##D@@@"C7<V.
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MM*K#B<Y"6^S9>88V\GILFS)X&Z-FO[Z]P#5"ZY_$'2-&4GQX"0),U0T#?X&
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MU:Y$$&5GP9T3^6)X0<M'?<Z.H-^622%! I5!H$U^.FYG=$/I,N8_E2Y4=?\
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MI_7X_P!=]+K@YB_91B,1-TZNI%=NW[D^Y?Q_F\E DWR".WU';@\5^A]])1
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M']'71)KH;8TIR!Z'-CF5CV%.-6.:SKZOLE15<WI\=7A%553?VX+JN6/S[^Y
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MJ?+[_P!2;\!/-W1Y'L.WL+!X)YOZ\GMH_K^-_II)MMYVWW3S[?+S]Z[)\O\
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MCA21N06,8E!<W?EJ0: &K(](>9'4'5S17F[JLW'B(-1>7X^HVGL_.]*)-FF
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M^R<&D]^.3==CP10Y/?\ $^XN[H#2\[)^I47\/*[[^R*J;?J]O;@TO%GZ_J:
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MD7\=U]_EYX-+S0JJ_0&^W%\@W^H]^ ?K#^C-\<G6EZ?^$R7_ /N";P:7W/\
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M?AX7RJ>$_/MP:2[/'R1S_7TNN_X Z7CW1/9-U3VW^_;[MEW_ (MO?@T7];Y
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MRNG=/B=\O(QX%2-6B@C8-,Z @J(A7)!NRS6#[DZLLB7HO1Q&\HF#@LHO;N%
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MZJE0;%\T#P:!DM@>@NA]'<!?8Z>:.T=@.5(K6O#01@#,2,XW1'KP3HXE'9!
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M'+ V)(MH=<R+5T5=6 =6(:P086,%+>CK!$(9Y'=OZAU?H_AY5Q&RCB^5CO\
M9RYDG5G5MZQ/(7DFDD;S"$9B;4>CT@#6MZ?TXRPL^08"DC R&95#<?=V$ \D
M#T@?>% 77![O_HV-?@9M(JM(KK$-3!P)$2959'B>3T%D:-*>K'S WD*+:'-3
M2XA>\( Y$=8Y' ZF.*YSN*:#^T3HQQ%DZMCY>")$9)(,C'FC5U'W?)D:,"16
M%%Z?< Q''&HLF#A --#*,9E<[DR%?<O_ #C>"I#4-I7XN^!ILZ4\RFL6A^K1
MPWCSX_J706LFGNJ[(*>2D6QA#+$JTIY]1"BQ8];50HK)\T4B  1R3SH\BG"]
M[TE=6\/])ZSTI&A"38&1&KQ/CR*70E6E,BRN[-+([^4A1V(\L< 'C28[,'FC
M</-$L;D%S2.X-*RQFAM*@@-5 7SSS;)I[/7774W&M;)V'Q\MO03O6VV.K*L(
ML*'=X^R..3D^-P(4P\"3*@B%,ANE'C'ASA11B5C9*.5.99\!Z1@9'28\ML;'
M9 D4Y6-F>&8L5QYW9 Z*Y97"JP9";^YW>BRH(L<*P,)HH  #RQH#VX/ !!%
M@@^^@?\ 31ZQVLG(\ T[K[ L3'(&(T]L:F[EQ OE=ELDLH]N"*%@:\A8$>F9
M4RGV'6\0IJB%':Y'E9>_V3]*C$.9GM&K9#9,L:RA87@)QD5%B9R=].9?,781
M90$L10-+C1K'#*9-H>?)MQ[D*:%$D<=_235M]=5-&P3$LLTPLLWQ&4*D)BE\
MSZ^+E\XQ"V4ZZC14Q6GHR0XQ2#FS)U=:SQ(4W9>K9+2N:H_/1(^H9F+U./$S
M%:<94!^P_9$4"..)G^U33!V4%$CDC0TI8>@K=\:7(P<=XW2#:K?>W4:-JE@^
MXXJS=?GP;$.37Z0#5;1?%<>TOR'X9>X-4S(-386 [(+LQJHV569QQ+&EA&*Y
M;$U*Z:]QQHT0HD4#6SD_*"5,5XL\%=/ZOD3]2QC+CYDT<DD<?EL,5VQXU+K,
MP V"4)Z#R232$ &Z-L:#SSYT8:2)0@>R2%JCZ>>+ #7[COSQ=CJ!?:999@-]
M=:\Z?0!Q<)>:C-G&64U7&EW]>\,20^SQPPV&F*V:V:"O;&B&=*):C<&)]K\H
MO'L;%SX<V"+I&6S'*"S+A8\KLD4ELH6?L 4*M(2P"".F:AI[!DR,#(9L#.DC
M4G<T8!"Q\$$$_P"$@B^ MW7N=40ZE:^<JV,9#:U=1I=JG94DB.8$(I\SJ8+X
M@R39,>/-9"4%@O6O0T$>-8O&9SA=N2(343J[!A>&NNY<$<DN?TO'F5@9-N+*
MY8A S+OW)8KU$IZ3=K=G6@QO$G5X2%6?+S?4#Y;"5X1SR "VU03V]/!]NUG3
M0[1?!>:+&[J[T;U-)12,5KVK(QG40%=$RB%*%7B2RD0RU$E SJB.S[<:QC@(
MQI-FHP9FN8M#UC)S_#>5%'U#"\U<B3TSX32-CR*9"8PPF V2L>&C8@T>20;U
M8GQ-"\2Q]1PU;S6*W JDC<>-^WU*0QHW8[<\Z/FD6I.J>"8K)MM*<IQJT;27
M=G7EC8V8SY>;2*M#CESV54^!!K[N"-8\AIMXP)ZC8^1 L_W8W5G4\+#R9U3J
M>-.K2PQR!I@H3$22MJ-)'(S1.=P-64-@/&>#JLFQ.E=1D\@JD:.!7G;E*N0+
M4.?4INB.=MV![:L)Y=_I#<&U,GNQ;4"MD8-D<*%$<:U($GU4F2#$4)>N4K.]
M2$&9K4>RR1L1.\/HF.5=ER/5?!^5AQC+PY5RL=F91CC:,E *(;:/]K:DC]GS
MW)0:QO6/#&1@SO\ 90TT!%J+)(/)(4T=P [<@GXU8!7954VUK+J(!"R#0HD"
M>60R.9U>6-9.D)%?$L$8L*4_JBF0PP&(0'Y-2-:A6*N+=F6983$][2S,RD!:
MXJR/O#W'<6.WMF'C>+B12A[!6!![CV(L=_>M.7AS7C2X-&ND[5<WPJ)MO[_F
M_3P?Y_U_7;7AQV_3\S_VT.\(7HR'4E%^>40G>/\ OL=JEV\_=MY_/X\<*?Z_
M'W_K^&O"G;N- \@<'_Q5S6N>#.Z;+/\ ==FKG$]%]O=:VKZ?\O!5_ESW';XY
M'U^=.$D,!['W^O.@1S><W&"\J>GY[_()T:7EUH&2+#<4[K6S+N<-'#0YQ-8X
MH:>$=X5L)C48C.H8V/5Y&(Z[Z%T#,Z]EB&!'&-&5.5.!8B4D$K?8NRAMBV"U
M'X.M+X:\/3=?S5A+F#$C8'(R.*"GM&I/&]N /BP>>Q^9C-M9M6.9K)3YGJUE
M5A:0@R7S*2C,T(\<H&%7H8E541F@9#8(*,"0Q%-*F?9,\[U<J<=?7$P>B8\>
M)T['CC9E"32+?GS;;/[60D[S9L#:JH+6J&OHOPWX:Z;T<3#$1PR+:RM9%]]Q
M8J";Y-%N.W&O'()B&,02VN2$;6TL.22(>>[JEGE3BL.U8-;6]#&V%C* K-G&
M:6%$?T&D'Z6*B^\7'S^HRK#CCS&=0^P (JH-M-)(.8T4@W1#L. H)&F>N=<P
MNB0;K RE.Y""2X8D61RVX635@BOIM&@EF?,WJD:43",'L#Z58; 9#,D#%)9F
M6UT(A/R]E=9.TOQ2PDI%*PLF!&DBIX_2K85>-HRN=LL#PKTJ*-<O*B7J.6Q=
M=V0MQPD#A(X/N(A84KLK2,3ZW-J-<ES^NYF;D-))(93+ZR[JC@AB?2$961:!
M-$(&J[X-!G5MDMWDF25-KG]MD1+?'I$C"+Z=97H(CLA@ %;0X4U'%$]DXS8,
M^F<LM5 V6<!&@W,-Z6$D2PX^/,F!'!Y4X7-A5(G?R')B9T[VH+I+Z*.T,M\'
M58'E9F43*JE24"1I&NZ^ 0B+9/JXH@ZTYRRLAEQJV?<,JI6.4%E;UTEH)9)-
MF&1 )>XZLB3$DF3U@B'2"D@S(CT:(39"%5B[NJD>-&\J0>:,F>.*125"QE7$
M.12,H(4A2Y +]V*U[()YY)4C,SH(AZJH;B+]1(H?0@\$"J() (F)ZIQZ/#[G
M(XQC3,J*F?8+D)Y,5\Y+S%<\QN.>ODSIIT4KIV.Y#0/;$*SN25C2&]M$$U.J
MORNF&7,BQW4)C#[#G0*K[##DX60ZR*B [=D^/,&=32[@;YNG1,TBED8$@NK;
M0H)%  V%%468BJLW=\:8$'+*R75X>-8P9$['9EA!/%>R>M;9Q2/BRH<64$+^
M\XDJ1\1B.E,"\XTF#D#(A!A5E@^+('RF!*QY"(ZM^S\R-AN1F1BH V+L:BP!
MVE3W(++L8]J6=T;A6&YB.P-%;VD$GN0:/O9UT:X3(5_?T5]30BPIQXQ1LGFL
M8\B98Q!3W0ZJ+D%8@@I!R2I )*6P>5KC7H@0KEPT,<IB^^BH\,,\$SAT5A:!
M&5(V,>Z1H)=Q,D$UB6/:0(2SQ [0 &<HD;95(1P>  A!Y %<$7W/I )NV[6"
MURX:?YMJU89-I/3,&>/E>.9#:1F.D@964.38- 9D4<JK(D=N,.^@I+H)K3#&
MWU%A'<=Q&AV2A\09>'TT8_4FL209$,3-3F2>#+<PL.%MC P6="MTJ,%Y/&EB
MRS'C(^8J_951=P*A A<A Q95606S*:+@"Q5\V*;K [&387>,S,6MJ:9@8;1M
MOB#X)R6=8Z1'9-;+FG$- NAR938/2!#H(+ L8)RC5.NSBZAY,<,_VB.9,TQ"
M/+W(L;@'R]BCBF52_J(LV2>1PV</!S+EQAM\M2ZHI8B5J+ ^LGCM]T_D:Y;I
MEFMERJH8$M)YJ>."1!%'E ="+&K!-0"DB=HKVQ1QTE*4)'A>1[6]?;&1O#L8
M1@DK-Y:K.2CLRMN#2'D![7U%B@# -P?39&IN0ZP*8XT38RC<B@+9YX-4;[]N
MPXY'.N.&XYD<ZP9\+I+DHX$V&2;*"01H$&7+(PL9A9QC%A!*0CHZH.>9&#5W
M0HTZG(LG-FQXX6\S(B_:(^Q6M'=4%-Z %?: "+103WO@5G89-^3&$A:,QMWX
MD4%SW._>3V[$D#G@=S]4W+_IH;*.6BFQ;/K.!E5F"JC1ITW(0PY4"N8"0XLR
M/%D3AQF2!/&U(LJ2ANF-(Z)%>P@T<KOFSK&;%%UR7(Q83C1&5V1(7=6DW*H4
MLJ,:-\K8)925?X"]1R\W"ZI']D,R[E42&+AW)VD[J!*KR  *7Z>^HFZVZ2\H
M50LJ3/R]^.1)97=^3B\"WEH!SQKN*IG3>W#LF!6!/W95.**-TJYPF(C$2ZZ;
M+XBR-@CQ?.9: 6=XUOGO)$EM&3O2C(H9@11))O7=)\8=9Z<DBLA.U2VV<JA8
M597>0=H-@=U[UQ=F,+\%Y4)/4?&.:RB/*DE8*#$OJ&[1D-S%&,P),H"!1G<8
M(<DY7B1@D0B!>3=R-NI(O$24LWAZ= O+M$\0+W=,H;V!)50#SW8< :T6#X\S
MI TD_3Q*HL@)D1V.XKAK[\5R?<U5ZTN3:%Y#4U2WM3D>#Y]C8BG5;7!\FASR
MQWO3O,5U4CP6L4TA-D1KQ?;8UKE1R>[*98:00F'*QIB /)RL<KN X/[0[HVH
M_P"Z>":&M1T[QETK*VC)AR,21_4QECD5 ;-[9 OK YLVW<4= JRH9,.4\<ZN
ME02R!C,Z/:@.\@FRG-:PJBDN:43)(]_MM T:*C7*JIY2>DG -GTFMT9"*=H)
M(!4"]M?[YX) UI$S<?)B9<3(Q9XWKT@B5VO_  L)3(@//(V7V^@UH<-M,UTV
MOXN9Z;WUSA63Q9JM21 >(CIB1DZB-02(@90I#6.[P)+%$]"-1S7N0:I/R'Q\
MR$XV;%#FXQ3LY(\HM2KS>Y2I(H@@BB;')U19'0\#/26#(B?':2V,$L8VRK=N
MXI-BE021M[5P>P-XG*[]*'5Y..MQ?7Z#%Q.U<P,.'GD(<AE%8'5[1(EU7N:X
M]-)<1'*0RM?!15154;51>.9]9\'-"\DW2I6F #$XDA&]%)NT<?[0 ?= ()Y-
M$\CDOBC^RO-QHY.H]"5LK&!+O S)O6@2PC *,5[_ 'K/'!O5Q\*Q@6,:/,@3
M(TR++ .3&D13#. X"M1XS!*-7,((C7-5I&N5CD5-E\^<0RE6*L"K*2"I%$$&
MB"#R"#P?C7')$>*1HI5:.5"0\;@JZD<$,IHC\QKT!(PK.MC^XWJ>WJV1/+'N
M:J>$;^Y5%3V^7NOOQY!!Y'(Y_=QKPIL6+[GO^)%?EV_GKF_]P[_[EW\B\+I=
M,33'^P>B_P"*E>/N_;TGQYX-&G[P:-+@T:83?^R<;\<&C_I_T=E<&O/-_2S^
M7I%?ER?S_>_5_/MPALC@T?;M_F#KUKK<KD&[945Z-7;V3=?E[^$WX\ MMJ[<
M#FZ!//X =M'X#\O\KU4C])IKG?TVC62:>X=*=\1RJ</"KR+63X/Q<<>T8(TL
M9XK'EM!19D0K8\ D-@"2Y3W1BF&)RM)OO O2X!U&#-RF:H=V;C+,C-'N!8@*
MX01GRWLN)"VQ.19Y7>>#^AMU#*BGDQ[QXU#S9$@>.*)EH;8W)17)['U-7'OS
MJA?+L,=C-3%J)*-/DE/6I336B;(:''ID!@S1*N!']2T1K*M<3JL[!%>)"F9!
MBM*\<@B]2Q,I7>68,1%D.9:(1C,DC%7=V"$JD@'[-.&I=YV@H-=;F:3J4^/&
MD6W'PF5X&!91,8B )3[$*10#6#M)((NYE\B6F6,:9!A\P6N*5L4M_=1:;1>K
MR8\LY;Z]&=AK.]BT<)CI9!UP6*,$^4T,",5"2SO:,;"\9WQ3G2]08](Z6CE<
M>%Y.I38^Q1#$14<+2N0I\TM>T;G8>@ DUK-^(\O+<MTSI\LDK2!I.HE0@$*5
M4:D[0JF3U<(0:'/!YLQO=> 9-@&;3+3%<@BTTZNF(/(*&^AUMN_%9ZI6Q[*I
MQ\TYL\1726BC5Q421-E(594>,1A1[Y"'I!@S,../)@DF21&,$T$DD/VI!O:.
M6=4"%0A+. 51:VN01QA#T\^;'(96CV$H/2#Y;@$LQ])#$J&L,&'-\< 14#R^
M9;KIHM?:,<QJYP+'[DD;(=+,HE!M;.QQLG:#88D6'/C*T<HD58YA7C9[8,F7
M =+C'@]QHY'&D7K</1NKP]7Z$N(9X@V/U''1HXHYU)*9(>-NP<,/)*[U5]K*
MYY&I&8V$558)8PXXG52I9ZKEO2Q!%FJX!X!  &J3,QY0.8W3W4>3C^)CS9N)
MVH*,.39<-ED:@@UI?2&MID9V.BDGBTI9CAR'#8&1-5=XTAKRM4B=?QO$WAWJ
M'3UGS5POMD)G;%Q?0)Y)"6$0<3L TP7<.2J?XEH$#3&/EY4$C18F7(\$P3S1
M(8R5900-BE R[;JTHU[?+!7'\ET7R%V4Z=YO-9F%/+D9(^772IU-?TL:$1K$
M)D+Y3H>T^P$@942I&6<<,5Q&2Q-(JAXE&7&ZO ,;/Q(_LDT:XR*Z)+#*[7_L
M%7>"B$E7F(0%P-K?XM/1Y+J&)CEE9'>3(6525:)@JC=Z5 7T.5J[-]Z U.;4
M<HN??2S#LDQ:723.<#%&I-SZAB1Z_'Y^J^!U8'"*S'Y?[1BW5]5M[4P\$I4-
M*<64,37*..-N+Z=?@KJ>7CY:3CPS.3'A3.SS)TW,E-K),@WM%"YM P4JM G[
MS$S9%!AW02+%BRQ@HR 2>62W..Q?<41[(#$ (5 L L-1^Y:,VU4H]5<?P'&%
MR:'J)6S;>DH,7@0[>YDUTBKEVPK'#IE="FPX@*^SM#R'V:2QJ./+]1-G2QQ1
MJ)=#X@Q>F9'39\Z88[X4B0RY&2S1Q+()%B9,I'='<O'$H";.2FU40GG5>T<F
M.Z)D.#%1>,-L 5-NY%W@"[)6BQ)Y!OM17^D1R"QM=0,<-J 6SH,J?IQB3 8]
M'I1SF#8V;<BNHUC=P9PS,6)-$)H$?%EQR-*1X'D>TCW5G@.&.+ REP5BGQAG
MY.[(:;RR6V1&$QPR*5.]#ZJ96! W4* \9$*-) 260,0QC%T>3=F[[<\&B!V[
M:%>D>)YO;\LVM6/X_71LFGY!F^&S8JP QSG+'K(LVR95]R6)$!)^'NE2*M[4
MCFD6*GAB4A7]*R.I96(GB#I<\KMCIB8>2C[RP&Z201M+M4DE=^P2"W41@.0!
M>M0Z0128OFM0RMX%L0J@K'Y0'8_>N[[W]!J/9SY7563X-'4%HI%55EI >E/%
MK#3:[((@Y5G'R.;82'Q22),H+&QW#,,@1JH6JUR=/&AA^RSPB2>42K+,)B'5
MI C0,5C;'6-=X548AP0=QYY'(INI1G'G?R0)6$0#R CB1OO'XY"@BN/<5V$Z
M^;[67.-2M'M*ZA<HFUL(&#TM[95K[+M):Y'7P*>MGRK9RRA(U!2W0B5T:"*Q
M<]VQU&PH3+QCO"W2<7 ZMU.4P+,YS)H87\NS%CR/+(BPKM-DH'$C2%*Y%T1I
M)/*6* +&L(E8'*=B;(NQ;$E@;[E2NX\&P:U$+ Y. UPK"9'A79KNUPN=C^0&
MR<=78TV--LXB0K742N?!!(GS3UTDHS@KCLBR8?4Z:PA3O5.-%EQY^1(L<K0I
M#%EK/BC':6*;(9&W0X$@=E1%D565W&Y6X4[1JWR)X>F08\N&1(C,C3^DE?*[
MLY+)P*LDHW:R*()#:Q]^H>FUXW(ZNTRO%L.Q9U<*=FF--D5YIM.LR,2+,IIA
MBQ12RV90J^!726JQ1[.*I6M<[B?(V#GXPQ98L;(S\HR[<7(VR!)MK!HYD )0
M(.'D4@V* %C5+E8WFY4N6LH^QJJL%4C:"19!KGN=IYOO\ZO*Y*^;+"J.BNBY
MZ*LAVTE]3-NK&4TTELJJD,,R'?Q1R6)6>I>T0H.6AQU\48YX"38\62WN$;Q_
MQ9X;SI)HOL>]X09HXXUVK4BE-T#;29%4;B^,9E8E"%9E)&F<B"',VQ0RLDJ(
MDL6UBOJ8'G<"";(L*S'XX/>3.IG+M@V7QY?,)RYW]23+'0I=C:8E2$'.QS,8
MLD"@LH<.'(_:\F/.A/*V="8BQK$2(1!1Y+&OXRV)U?-QB.C]7BD7'5U2.>8;
M,B AMT98KZE9' *N?4A+<E21JWZ=UB4/'TSK6.[I6R'+!I8I!RKRLO*K0V@L
M5%D>]  /EKYB<^T7BCC81+FY70_$I$W*-$;RQ=8'Q:O=*>^=<8-;G:VU0<5H
MY!S4$EYW1%*P90JW]LI=]7Z7B=98'*V8LPC6/'ZG%&L;9#A0J1Y<0!B.X%5$
MRA=W-&_24Z_X<Q"C2/#.H?:\&;&Q,;DGB,@AE(9BH^E4"".;U]*]6,/UBP^M
MSG![8=K0VC'-"] DCR8LH3WBDPYL:0UA@2HQ6*,@7L1=VH]N[7)ORO.PLOIF
M5+AYL8CGC/I 8$.A4$,I!(8$$&Q57R/CFF7ASX4OESJ%!Y0\$,#=$$&C]17!
MXT3!JKF-5?=415VV7W_-XXBBR!8H^XNZ_/4;]VN:HB^%X72$ ]]#G#6I]9-2
M4V\?6:!\U^6/5G\_Z57SP?/T_D- 4#V_S_CKHPTJ!F:AO5&N1N<3E<U5\JGP
MVL3=/"^WOOMX_BX0FN2:';]?Z[>]Z&NC2EC[ =[L5^^OQU\I_/'K3+UXYL\[
MFR+&-=X3@DL^#X8T%>HP1*6F.HK,SU*1_K)$S(DES2RN@37Q6Q1H![(ZO+WK
MPYT_^ZO#^*D:M#DY(&5D@R6S2R+^S%@#8%@ 4*+Y8\[B=?2G@KH\71ND88RH
M@<C+B6>0E2M225(J,+)8HM*#:\CL+(T'%O*W'Z(MZA._2Q1" :.R,PDAX7M:
M\ 88W*+N/<KF;#W9VT(OC9NRRX<.3.R4Q2-DSEF5]Q !!IF<BZ ^>0:'R-:?
MK'57Z/BRYL9#!D8"%C2 @ KR.:[\5S=7R-1AUSL[[*,M2&*RIYE/$KHDJB;C
MDMQ*XT21%!8.E1!%52MEE')WEA(@3K(C&5!H[9J=%\/XN-T_")"2I(SLLYR$
MVR;E8IL8@UM!4[2"5VL#V.N ]:ZCD=8R5R9*W.S$+O+* 38/*CL"*%7]223K
MG@&A6HNHF27-+I3!74>;1TZ94<%7*C-D$B #'(6/ ;9)%/8FBC*9TVLBQCO5
M(TEH^YT*JIG]>Z?@P0R=28].$TIQD,@8^JV :3R]PB#&@DK,!ZE) O7O'Z;)
M&AE\]'A#H)-RE0A?A:?U@@GC:56V[-SPTI<A\>;.JI,9:N=C=W8DE2"Q_AAH
MDB6\;4@DC[L02!,+\CVQC>%Q58KD>BM1^(EDCG!$D>3"@5 WF JM^L, 22P)
MN[W "A5'4V7$A#20H:9 '63: "7'"[0>!SP0??\ (]</$KBVI[N\B-+#@4SZ
MK&CNKYCC,DV5D(Y*D;VG,YY)$I8QBH(*/$QP4:T7Y1K4<FSH(IH("5>2;S,@
M>8-I2*-E$I 4 !5W $L0QO[W%ZB8G2IR)I9-P(4I06[)6E]1:[)*C[M"_BAK
M41DMI5;*B-)#K&-'L:+*F+#<T\,A'AGH%2@ZI[RQ5$K'(K.D[V.5JO:JOM)
MLB,=TQ-D.B[@5<"XRQ5_0 U\'NHXX.HOV/)4/2- H(!#*390D[CRHL\#GXX/
M.MC15-ED,99J2@1H,=\4\Y%DI&>$RL*QLY[>MPA0WF"9SR(55'))'1SOM-16
MLC)AQB$*,7(=8_27!6Q:!J!+ ,.*%H"1=:?AZ?DY+%MRN7()X*MN[=K-7WY/
MX76C328;C^26 *"0"YRV;EM<V'6-K(]D>2'/A">*-+0%&RUF6,27&2/*<8K(
MX_VSW2]MH"N6AGZCD01M/$8L5<23=+YC1@-@NP9DN;RD1D;<H )(VTILKJU'
M3(D(^UT!5J#M ] ]1+L15GO= 57.K<N7_E>3E1Q1^J/-/E-/C&89./'L/CXQ
M"C20PL2Q2?.6! ]9<P5=6V]O=-;%D75>T/JW06/$:2PCW*[G?5.O#Q%E#!\.
M8\N1!C>?EG(D*[\C+"%GVQO4D,4-L(7W4&IJH@C/=4ZL,I9L*!5> !?.9'M6
M6)MRH*2SO*A=W&T_X37//7/56E)A>N%#AH<4NL\D1BX"?4R+-K:E]QC=WDD>
MH63>P8()8Z5L;TT^HKJZ6=#3Z](I7RP+)Z%:Z=TZ5,CI4V:<F/%$BYOV(I)*
M(IH<<R[(&<H9=Q=)'E2Q'(& 5MMZLND(9<O&,,@BA\D,F,4+F.3U*=TMJ&"G
MU &-?860+-)3X,?'9=K&L OOV-@-'6FBW38P(+0=3GNFQX[9+Y#886&&E%ZF
M)(CO5C3=#OR2]8CD;)CC=&$'K)=6@WLY.T#86*@;VHB<JRGDK?!$O-!BF9 "
MQ/WB6H]SR%"F^!P#0^:.C9B$_#X%0.305N8PVT_P^;?6>0Y)7Q\?M,HLC,#C
M[8V,#&![T<\/Y-CB64@42,21(].)J.6LS8\N1PDTF(YD+I#'!CR--%C1K<^[
M))8 @-R:1"S!5W$\1L(QK,SM9JMQL #N#0()!'8?-<4:U(?)N;_-IX8VD]G<
M/BUU.V3CM]=5UO,DER$I<C@#<W&A$)\/JA)%DJ&,5C91"A8\SF,ZNEN?Q?"F
M(@;J21;Y)2,B"&2)$$ &/(P.0:WRDLI+@E5#$ $]]2Y,L'*#1"-2H4.S*K>:
M%(44:!![$\\\T.^HN:DY7=6I(D4]WF%S2TI\LIZD]Y,?.C1X$6W[$,M3%8I&
MQ&A02J8@1!>3K-LBJ97+I.F8L,.YEBQ8II1BS2"%0C,YB!82N:))L$78  ^*
M#&7,<A6+ !6!7:!V!7YX+ DFJ(^ =,3#9]I4T^493$A2K"TR)@\4JI4(-0 4
MDME'?*R=RAF,(X2IC8VQFR6J'T+IRRE5'*B)/S526;'Q6=8XX"<F4.9&*K&P
M7'HIMO\ U@EBO)DV;0>.8N.D4:HY;=&Q8$)<=L!PMEFN^/;C^!ET)R.YA5V=
MY+BF89/BV5U4*JCXCBL!DFV#E-Q*]4IJ.RC]F1W*VLH8\N0V8HGB1&B5R(K4
M5U-UK$A>3"Q\K&Q\C&DDD.5E-MB;&B4I4T9L5)),RJ5L$60#JQBS'"^E&V@6
ML,TF]0H'92%0\<=B6[?6Y"Q.8;4BH=37-Y!Q_+*_)8$RPL:#+*>LN,;?&I#^
MCN95=&(>+DV.LCG:Y(X84T,6852/B5XG,<QV;F\/X,QFAB>6$X[JB28\DD63
M<PW0K(P5L>?<#;%T++0#.PJK;%SHTBW#S\*=G!2:"0[8SM7EEH*Y#"B#=@<L
M>=.N5<::9O(DN=1@TES%6!MJFC,Z;(QF?76+!EBVKJ^R"')\:BV4(@GBE$)9
MT[8Q6R'%8K'M2J?I^5B*"LLF=BM<<THV&9)4)!B#QDX\[1N#:A8Y2R[0""#K
M6=.\4]4B"QY,T74 @ 68D12+&.>542+(31!HJ?Q4 D;9ABTV$CSRNN- :!$(
MX1!3PN:4;GF)'D@"]E@%JHCHQXJJU[/W.Z^5;AD5&\L#=)NX+!D;@@ $-_LS
MWL,.*^G'0NF]17J$0R(W"UPR6"FX<&T[?CZOPKOJ:')-SYWF@IZS3;5JP+?Z
M5%D;4F0S6R4ML2C2]R.8BHLF1)J /5O[5.%A0-<J <C6():3Q#X;AZMOS<*(
M0]0C%R1*P*3L/R51(P'=;#'N/<<[\<_V=0]3KJ'3*_O)EMDCCVI*![,-U6;*
MAK'('<:^B/!L\Q74+&JW*\,N:O(,?MVD- M*B6*7"DL0I&.5I1-1$*TC7-,)
MS4((J.83[355>6SPSXLK8^3"\,Z$AXG!!7GW) '(]0KY_/7SQF8&7TV=\7-@
M?'GC-.C@@VW((X%A@017>^.VGDY=VO14V7H5=M]_&R^>&P2>XK\[_P AQ]=1
M=,73+^P>C_XJ5_SZ3]_GA=&G[P:-+@T:8+?^R>7\,&C[?X]E?C^*_P!-MS7G
MW[^_(_(>_P _Y7\:?J[_ "V]_G]W"&^*XYYOX]]>M1>YO-;X^@N@^H>>#L00
M;V'CM@+%D<CS%-D$@+HU:@X[ &5[12##*\CVH(?0G<^R[BX\.]-/5>LX6+Y?
MFX\LRG((;;MB4@L#VL, 0:93P:Y[6_1>E3=5S4@45&I#2R%2P5!5VMK9([ '
MZGC7SCXSDN049JK*["#<ZH<UVJL<=Y#6U4UK7:?5-N%9%7?V8C-' ^L<^$]\
MJK&=PX=%#%&<YK2D&QO7LF&*4RQ"2'!Z'@NT*K'M1LMXSMD@CVEG\A6M7(MY
M6+<E5.[N<<<,F.,."L3P_@HC9TA<0OD2I?*.0045A&2H%O>W< +TL3Y?K%\H
MF;ZE6"54>L;-636R[.*.(3(YSBR0AOLNGN94O<>1U3;-D*3-G.$9D9&@<HTX
M6?J5H<7$0,9"A#+&WF>2@"L8<9/VB@+2QEE5+4L2:.DRO$.+ 8X<!'E<*(TF
M4  1EB+$=-NM:/++ZK_(OY7I1J1.'6:J&=.YG,FQ"PJ#T6#X9;UNG6,8G&MZ
MSHJ&0*B64EY<8[!>T$1HHQX0)(&2%/%*=Q7NC8^=@*K=/39T#'R$E2;*R8WS
M\B=H9-TF^5%$,4[BV!978-MVN%[YA,[R<J:"4-B^=;F69"OG$,2UV6M^;)W$
M T".-'C ZW*^6W1J3G>M3\?'F>39:6WP+"RBEW$&KNZVU[KW2Y I4=ELI@RC
M+#DS+,U1!9"B)513D&H'UN9-C=<ZE'B=+6<X\&*L6;DADCDEA>,$;08V,6UD
M4LJ1B1R[^8Z@[M4I@3/SLJ#&G!Q(26><4%MK[+N'^[M-$$ [B>38FT;^DRU6
M)J3!KLOM?C>#1"VUD?ZQTA\?A9902+*15#E8M*;7G?+;!FHD2#7]+SE._ID-
M42/<.QZE_9_A# >?'3R\E_+C18)1,^+,L:R;<E#(*+IZG>E"BR#?=<S%Z/(K
M8L$2XV25'^L AB6'9A9% USZC7SS8'WTH_.]J+=YA2:/Z39S)P;# 4U/:V,K
M&QNB6%X^ZJ*RUCAL[<)!(" %TR17I31GB8\D8DF21[&L1EC_ &=>$\"#"GZM
MU7#_ +PRQ/+$BY#>B'RY9$)CBVON==JL)2*"L$"@DW5]/Z5-#+%!'*D4TWFG
MSY8_M'"%P"@WQ!0ZC=8)^]W(&J><DQ[4FOI:2^R^\F9#29)&-,E91#(#(*RK
ME%.D:0"U)!E&D!F5@4>[MN<AR#5CQ,(A'!;U+&RNDSY$T6'CKC3XS*L>*Y:"
M250-P:/>@4K*QY-  \<=S/FQ>IXL#Q/(KPY#%)9UCY5.!06Z HD_>/?N0196
MY3,1N,GYCL4QG [1E>5LRSG'OX17V-=58[55SY=G*CS'MAVR"E1HYI#0EC@)
MTF;#<C"M;Q6^*LE(.BR9.;&'#&!/(8>7++/))LC4H=\5H6"[PY!VE^02=>NG
MRX4.)U*,^:!'CS! Q!3> ")=UCD408P+):]]*0;<.;+5C37D^L#KH95Z91N;
MC43%*J'K3J0DX\?(<;LL@KHIBVU1BLB)8PXUK<O;\5GR1R6EAHBO)$D%/MQS
M3PWT[.\3,R=5EZ@_AG"RI&Z5T\1J<>:.*1AY,N4'0ND8/EQKMVL"!N 3F#%C
M9F?T^#*S_3C1@G$%<RB.MDCL2"44J?0%!(%!NU5Q\V&49[D^$:-9#97K,MD9
M'@,%^6725<-(626V.9CF5?5V[+J2 =G4MM81Y!(E:=L1U@\;I0P":%%XW?A?
M&PL?+ZS D!Q!CYT@Q(O-8MCQ3XN*\D1A4^7(8W5=TJWLNBS$UIV=G+X8!#*0
MA<*-H/M0;_#Q?8GZV>-//%\FLDT/Q65IW41\?P.#JI2,S.%8&-(R?)LPJ8<>
M;7Q V08L2(>AC0ILL3(D=[7@(O>D*4K4<Z*,2+^]LS^\)6GSWZ;/]EDC&W&@
MQ9F9'<Q,SL)BZ(2S [AVX/!XAR)&DQ%C)$,;1-'%_B'ED;E!L$ECSN':^QH7
M'[,\5J\)UZFX]'RV+58^6UI)\N^R&$.U/B\*^KB3)L:T@-@E4\JH#+,)T.(Q
MDB05 $$89%54N,#)DR^BK(^,\\Z131I%CN81DR0N%5HW+\)*4!#,:4;@0=3L
M\V!/&?(&1(CN&/F;0; 6R$[?('OV&WDP\P.#N+H?I--PO%I<F2MI,@K?GLG5
MB9#1NJ_2UMO\+M'QG]ZRDQG%B *U!C8AARW+)[2NK.@92IUGJ0RLE57RQ)Y
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M-K 5K6BPLL"",3T[!6>'(1DW>6OH0_?W59%BARU79X[\:\^G61Y-@60X+DV
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MQ9#+.:'E@,I*E=K,2RD"E)]R17'<:K]SO.](M)L/DV.F]''N\QRBW(RQ^(S
M6]FE]:C&5F190Y),0\JCCJI8M9C%=*BUXDA. ]CQHX3M?A]/ZCFY)CSI/*QH
M(QM:-3&/)C8CR(%(*K,U!Y9W#N=_#7SK4?:<SJ;P#)D80*#Y>.BD8TBT:V\,
MUU3%G3=NK@"J%4&!2V6*WV5ZCYQI9JEK(>YDQL>%J)<PHV&:8UA!3$JY(L%Q
MY!0A7A5C%<(J13RH,<<./)(TB*UL^:5X\B+&P<;/Z=TI8D.2<&)VRNH2 KYJ
MG,FMFBHK:[U5VWE17.G8()]Z1Q8^3'$"_D':JF2F&ZBS&D6F XMAMN@--#0:
ME?19YI'F0,1J<PQ[(LN@X+E&6Z51\CRJ#C-E\39.FIF\7(80+6AB3H\Q/33H
M,PM9 &7U GC5NRO]4R?.Q.IX@S&Q),?&?+@Q\\PXTF0@0(@Q'@)CF9"OJ5U$
MCD;2""#J=U3%C^SL<B+)^U>27BCG:)=RT5+Q?M6NBHW JC-7(/OH?I2>8? Q
M7M-'K!4.60M.\YJ*G+<)8Z,&3)CEH;%GP:WCOC22CI,6%)CD6P"XXW9$4;5V
M()J"M/[..@9DD<OF>;C-FX<LF'F42B%9XR)8B"H,N20R["%(QP?;@Y&)EP<,
M,"8O,(>:)B-Q5@R[B5)  ;:30["@.#JMS3ZPTNR7#,/-556<UF:4V6SSY/EE
MJHK33Y,!66Z?$QNKKB-/-H+&.H 0XEU!JHY%FR9$HLE%:CF]"SHNI8V7EK/)
MA2X4N,@Q\2*X\_[;L"-D2N"L<\; EFA>5AM 2O;4%?+E*>4'20FQ*X)2K-@"
MRX _\([\>VF+JU:5]_<7T^Y%:&H3VKI4E*6-/AP&,JC'^#"C4]HQTB,*$L@@
M8F[=U"C2B5!*J\>^DI+CB.& 1+,8PJ><R,]S*OG%I8SM);:&:_>P>0-7TT:M
MAXV:V05.-O1R@;_"[)ZAP>3[T>Y/L=:S33.:3&P3YD6/\=K,B;/QE,.MRDIZ
MFPBHT<UUW=2XIQ']? ]._P"',BL&II<A&$<;=P'IU7I>1D2JC-Y$N.(\C[7"
M!+-&Y)000J05,;;AYA8FE6Z% BSZ?UB%<2&U$B"5@VZBM *;((/+ C=PV[@<
M^UK_ -'A_P!3_8Z^T=S07!<0S%^,WE7)TN)%EV<>?/LVCKYLB/E$M\098T*L
MD%M)U44"S0!"14ZV#(J<T\9P]>3I4D&0OVG'$T<L?4K6-D2*Y$4XR[R&>10D
M<FX(3[@D7XZWGP_W/ERX^*AA9DB<H #'OOUD;02.=I !Y(XXU%/GOOZ"QYWM
M9KIE$]8<3/H5#8PZ.5'L+"^CTT2#6/D":4$QL)T]L8CE/V2=@JM$-CWL5$U'
M@J#(C\)=+B:?<QPI)TDG4QQ1/*SM7WEWA212V+ NP-0PH7IN! Q(E"0(R_XP
MI4NP>ZH*I.ZS=#ZUH;\W$*!1R='L!1M4 6'Z74OQ"LM)5C&NJ.PR&7:W42),
M'$C("<"+7V@DC/D[,@RGS'$$(C^+;PNTD\/5<_\ ;,V7U*4))&L;13) D<+L
MI=@Z,TD1WA>778 2 -0'95S4C# B--P4 GNQ(VA0:%5W[?35B7*7791"Y0\!
MRS):@I*_&,JUARK&TGQ!+#D/QG3_ -=16Q'N:!)M;66WJF.D."H6R!B4QNE&
M\83Q&\'^D75L;'D >>'I.-,8V.\+D9JI/$*+;9)(]IVAKHF@>^O>6\&3U#I!
M#HQ?%9Y(K(*$22A=WP10)[]^WOJI7&@W6HDW(LVR$EW>5LQQ;2?=,FT\.TFY
M/?1F1Z0GH[KM2)(73'^8]>PS7P6.*UPT:FW2IC!T^/'Q,;R(95/E+ 4F:-,:
M!MTP+0[D5MGN[+3<&[U)GW22[9O]F(T(D#*069;%#DKMVD<@7^>GUS-ZN$R.
MZQG3]:N67'-/*"'B+8L@$5:^+:QZV,*5+)80 *V<_8<9I)K2/(R4B?;>YZJZ
M/X;Z3Y$&3G^:HR<Z5LH,&;S6C,K$((W;T=VI#0*"P  1JMR\L;HD *Q@[)CR
M13< D$=@:% 6/GMJX+Z*70G&TT>RO6&CFV#968W_ -0KFHF08;.YCE;!BV5^
M+&YW=DDDQ[)2^C;):P17A%+'T-(JHO*_[1>KY+]7@Z9D*M8D1S8I8W8D3O(R
MP&>/:H4J%ME):BRD,!SI.LYD4&-C8F-80JDV^SZ]A8;/8C=R.;YH\^TZ,ETN
MM+@XXN*1Y,+N7(&3(T6$Z,@ZD3G2QD!:R"0PS(47]IQ"R1 "1"1I"*X@U179
MO%ZE%"C/DLK_ +%MI=PVZ1@%(,0#[7/K8(2P(9#P1>J,N)75'1D((82BVMCS
M0"W5'GM=T/;4"^>7E47-\>%EN8U5I@%WA'?G7&6XSA]=>U&IE5*;6U,:'<>C
MD >2VBF>T\>U,<_:B.E*9C5&Q5TOAGQ"G3Y&3!DBS(LW;''B393PS=.E3S)3
M)$&! A8#:8P%!;;1]AK_  ]G2YF7'TS*)GAC&Y/-++%3 V@+^YJ]M<W[GO13
MCEM:Z0:C-N:MTB 3$KB+81@-CMW@GK"G<J1F2AG Z4J.(1$4?6(B]3MW-;QV
M-XX^L]+$<^USEPM&TA8DN) OWMI5@O8=^1\76EZB!A=3E&-&R0(-S1K?E GC
MT^]\^P JQKZ(N7/Z0K!]0M/LPG7$V+:YY$IP17UN32*>AR.08[IE<MF@H8Z]
MMK5^G#%;)%!;+)'[)"$4+GJWCAW7O V=T_-Q8HHVCP7D9A+CB6?' 4)+Y>YC
M)Y<FYGVEM@:P!?O 48\\D4J2["L@9XU!8[17HLCBSVL\51.F1JUI-IUJ9@U+
MFV(DQV3EL>JB"ET%)-]8(A=GS[$=B!R 2:XTB4UE?81W(5T<SF((_2]!^<7+
MS<#+DQ<D3C':1BL\J;:'"1^6;(4!5)=2*W"[6^==T/K$ZS3PO*1""?*W59(L
M*%%'\2#0[:#/(OS.VW*_J^?&\J86%IAJ)+#!O:5CQ-#2Y$^:&OAY)7M(KB,0
M4=%!9!<C.Z"(KFH^0)46S\4=#A\0=-#0'=G82DPS<[I<=5+M"YKON.Z.AP7H
M[5.CQ5T0]1Z><V)"V2JF<;2-UE6+(QW*OJ_<2#1X&OJ6@RPS(XY 'L<(K&E$
MYCVO:01$ZA$8YJJUS",5'L5J]/0K>GQMQPT6NY64H4)5D84RD$]Z)[@77?YY
MUQ<$\@_>!8,/@J:(/U![_NXTQL0(Q,DU'W<G]DL!/FOE,>J_N3AP*Q 8#AKH
M_-&C^_YTF];(OD=^#_+5,GTMN72*_1T6"Q7M4V9:]R9)8Z(PA)$/'\9C2GC0
M#OMD;ZF5&559MT/1B[[KMQT+^SG'#]1S\MAZ<7"9=QX"M-(J AAP#M5^#W%C
MM==(_LU@23K,LY ,D4.R/BR/-)W$'BK" 'D?GJG3'(: HQRIXE5X&U\=BL<_
M]^4#F1^\PBL:G6V3N[<B(G8*Y556IQO<@E\E4B)]>]B*[C<I;:0">"OQ_B%]
MSKZ'7(6+"R)9B#Y4DG+ 6"%X^H%GCWY(H"] 354N0V-S(R +X,>EHYL>LKS
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M.3T?I/2A+]KAAR,"),?S-[--DK$&2-1&6!DDWNU*MLV_D_"KA9>'DH_4HO\
M4LG<X+*NV-=K$$GN2;% GDUS[Z^FY<,T]TVTUQS"*B1,PRNTZPVLKZ:+7V5<
ML;-[XD)TJ?)511&2%<.85"LL2R(K)D@"#>P8T<\G!X\K/SLV;,=$RYNH94DN
M0[QR%\2(.%5""VVB@HQA'**W>ZUFI9&FSI?,6\=6*P@T D8X4!;^.3\\T=0,
M^DLYFM3*_54.B=%>/P/3RLPG&Y]G<OKC,-ED^;$4\8$JTA[E6J8YS(S$A/:/
MO]YS^M&IQI/!/0L&;!_O.6(Y>;)ESI%"''^K*C4S+&U@RFMQWD^FAQ?.N\+X
M6/C]-;J+QK-,[R47()7:Y%!2:!(46>">>]ZKXJN<W6#E[J,=RS4^\@Z@Z*Y=
M,?@KL.DWZ%CY.:6\PP5T$#2GLXTZ!ULFLEC8(H$"WN.>UWC83^&>C]5FDQL'
M_P"[NK0,DXR6BIHV-!1RH23S2"GE\@@D\*"=6.2^,\0,T:PR2$?9)8=J2QS[
MA9/(+*UJ"+/IM@> P/NJ?*1RRZT:<7^=<K&;@FY,.0RYD4%SF?370DEE#ZG'
M;6'8PF7>.2^^L@E79SQEI3E3MEL ,>/IKNE>(_$/2LZ'%\08A6"VC1H</]JR
MH#LR(F5_*R%V[1-&A\P=U0T1JI;/F200]4A5(V38<Y6$B,0?2K'<P#$ ,>!>
MTU1JZS\LY=M6L! >7D.G&>X]W:Y:0<B7CAY5+:QS(27'AAOH@I5=+]5(1Y5L
MH4J5W&=?05&$1B= QO$G3\V18US,.4++YQ F"31,/0S^2Y1UVJ0!&RH+ /!6
M]/R=(Q#CR3]-S89I&1B4CD5GNOBR0.0+JA[=M:W',3UP!@TK,((+>DT_TN?%
M%,R:143J>O!/O)P*VJJJVUELCMNLCJ[)WJ1GC/DCA0HSPD&%',1SF3G=&?+&
M*ZQ9&9U)F*0K*DS%(E,DLLD498PP21^DH:9Y'!L^_J+ DCF0',6'(,&X1;P6
M9@A)9E!X4D'FA=^_L3,9R;*]08\ V4'DRYT&46!"R&3!8U+MT:&6>KW'Z@@D
M632KN5XQO:@2N5R,5%1*+JF'B]/<RX"*D3 220(Y_8[F50*]3+'7:Z-CBQSK
M3^&,UI5R>E]3:\F6)S%=51(6UH=J)(NJ(_$:^H3Z/#F1EZCXB;2C*94XV585
M0U=KCL^R>-\JYP:0,<*&,LAI5]=-H9D>14S92,:KQBC*YC7HY7<)\8]&7$RE
MZEC*@@S9'CG1.T>6OJ8[2/0LRD2(+[EJX( Y?XHZ+]@DDGB4*BS21RA;H2EB
MVZR> X(!!XO\QJ=V(%:S(M1E=Y1V2P%1-D_@[5>4\>$\_<F^Z*O&'G<DK'%Q
MY8]0'L6Y/[Q^7QSK*$HJ(U@%@2Q^>37^?'MKYZ/I8;F3/UTP/%.T!8M7*RJ^
M&0RJ17&M7TD621@>M$5P!5K=G;>-VHJKNB)USP%C_9^D=2R59BV3-&& :J"+
M)M4D<BV)XX]_>]=U_LDPH#CYF1-_M)9F,0XO:B@&B1?!8V.."3[G4##S:N#"
M3\E7R""8@9Q+-A8HXPD!T)8%9'W)W M[;F%:Q[D[A0,:XCN-9APRR92DLZJQ
M#*L1#ECN!V L:HDD5=&@3Q>M_P")<M$Z,\<8*ON< _=W;0P]5$7S9Y)[7[6(
M;61JN-?7T!D>#D$1;*;3P[9+:P2%*EC*YB7580AHZE@&?T2QCG!:C(S'L/T(
M[JXZ<BO]G@??)"WDI,\1BCWJM<PR* U2 6I*$DMRO.N!1A\B<LR(Q\\Q!BW)
M!8B^2">*KL=H^3H_@T\QVL#C-MF>O^E]!%HI,*W>'#&R-2<\"R8O<8]4Q"$"
M$P@GQN@8GWLA()7[.<W]RN;.;DR-D18_0^HS-D*\0;+*]/PR4X(_UMW<V&Y(
MA4N!8XUHR8A'_J=7$3OL BUX:GC9  6!%400>2=2(USUJQJ!D=1E]M>'U?R_
M((-+/Q&38"FU..5V'-$\-=.R,8GQ+D+PS6DC!Q5TCNED@.:S,Z.HP'KND].R
M?LDN%BPKTO&@\U,I4"RSMEEKD2"PT3 I1.1MI5*K&-UE<Y!TZ+*RAD]1)51D
M$(4;:C*A!!#<D5?8D"Z-4:U#FVU28MKJ2Q 6TVOST+U/&BS(YIJY"4L,@I$J
M88GJ754 CY#8\)5,]@3BC*QS?RR7N-TF1X>G,QBCEP7^\R,J'' D!4(!M\QZ
M4N_I!(+6!2ZT74.H8^+(Z8IWPM" FUMWJM1L+K7<78^>0#[M"OPC*Y-15V=6
M(KF7.23,1B4 ##5XK)(059WH\LJ.BRI,57Q8R.1&O<G2,?6K56UER\-)'BE(
MN''3+:<J?4GF'LR"F4-3-[\630).=B?()DELTS2+L:S096'^(V.>PO\ =K3_
M  \<F5+QRDIIQ)"3W1@=TJ@-7.]0C9[94='=,AR-3T[V(]$16N5J;MV:X9?+
M5<B:>,+LW&@")/3<95CRM\L..019TJPO*"J0MQR6 -5P23[-?8<\\]QSIZ0:
M6+0XSDE7D6+Y64T9]>.OO(.XZZJERI+Y,AMH]D,@YC)(FA%7P22A.:]._P!3
MW^.(;S//E8TV-E8H#B0O!)1DE55VIY8+ HRFR[A2"/3IY458BCQL"IVEK;W-
MBZOL-U@U7'<#1$P"LKR5VHE!& ;*(H\ )DEW65=Q8!A&MHYT6LEN&4TM<BEU
M)I0IA@GBPR1"BD""Y6 8XE7U*2;=@3DC&;^\!CQ2R0QEEA93YJ JB^2LH7:I
M5F#@@D<\66 ^,DLB-N</$:1F))8$5P:/%DW5\#D \6$_776O-M.M,<2T\RZ[
MM,4D:?XQG4\L^ D2'67$*IKZZU'DDR8XLVRA%$,D*EQR$(Y9MJYKVM5CV,XQ
MGV3I>)F9V5EXL$>6F=DX*K&Q9Y(6E=XV@C2DC<6'ER'*A(A5\7J$(<49L_G&
MDE0N'+<H0HV*K$$K;;00.XW*;%G7OYKM6]3(.2U>@59&F5T%]!1YMG%G@Q"5
MF1V$*)&D7,F@DSVV7>@>G$T,BQ$YXRUK N1[B&:[=GH73\*:!NL%TD<3RX>'
M'E@201R,XB6=5,>U]QW",T1(3Q2G3W2,7"QTFS,E00=]!@3Z 2-RJ0>Y!(X/
M!!['5:X-8,XJ*JVA1FW5</(ZNQA5M(_(\@F#&DZ0Z/&O8[ULRV4DL8B2$*(A
MG1"R-C.3[70F[/1,222)VECG^SRQR22B"",L40,T+!46-0PV\A=P45P1S*/5
MHVW$X*0FMB,%\PE:X/-W08&Z]N2;L^O$\MS^$*1E%7D6?-7&K>'&).9ERXY=
MXT2.+JF$A094_H,%]@%8L<<M#,,UA(QA->QRM\YF%AMM@:'"5LB&0[/LQR(9
MU=OV89U3TL$.YBA!'#*>1I<7.64F/(2.:#=&%!A"NQ4$&RH#%>P/ L<V*XMU
MLN;3.ZSE5HM2C A9+<ZI!BZ4"J9\^:(LZR$2V-F,HRI)<"MMA4U;%")61^F!
M83V2WHK4$Q>9IX>PFZ[+T[=+"O3G?J#Y"*K(D16(8J"UN2(S.Y-GUQH4'-ZB
M)TM9NKF552+&AC&1#%L4.KERMDT"RA>P^;LW>JLM5L8TXS.NI@:1OMK2;&A%
M2=5Y#+I(=UBQ#/AR4!7P0>@F7K"39DJ&\CXI7&>%A(ZE0I%3HG1Y\[">63J@
MCC21QY<L*RO%D@!EN1R'2$A%5Z# +=$@U;_59'G?R$()0$G:&!L'CL!1K_#_
M $&'C^/'QFBH\NS''YS:>NR=^,VZ0G!@3WSFQA+,!+$832]^?531EABE.&/O
MP&N:Y>EZ)8Y$XR9Y\7#R$,TF-]IB+ N@C+G:4(-4DBL&*V=K\\ZB1!D4&5&(
M$FPV2;-*![GZ<<]^#P1I3<=R3$[[";:_D6,VFMX=!ED.98M.:"*ML+%@U,0H
M3H2"9JUO0]'R$3HCJC5\)N@GQLK'RHH4C6:)Y\5E2@[2(EU14AU/F<<7Z_GG
M7N 2(\@W,$VL0 :*@"P!^?!YX/M[ZW]SJ%AK=2=8LC#&<_MQ;ZMQ$]4J,JVW
M,E8U6[( E>K9J-F@?,G++%*#T.D)VAE$Y[>(PZ9EMT_I,#$<O#)E*_WS$H:3
MR64!DM#M78RM84@E2-2,+J2J94\Q>!M)D-D\V0";)4$#GBS5^^M_A&IN=NC5
M>/V66XYEU'$I\MBOQ+4Z)59/2@I:JH66Y:V39)\:A!*1IQ0VU%B"262-J"8Y
M[F)Q"SNF8B^;D1XF3C2-/B,,CIQDQY3-)*%&]4!A<@%2_F(5"DV>]V\69CR2
M+&7C20Q.?-9B@^Z>#3!2QO;S?MWXTV8V-U.68W26U#.TOQ5SU=86>%7%O*JX
MXKX<\L"'<0["[+-'+JIZ/ !*J<:**#W"O.0HS(YCOVF;$S)H9TZI/51QYD42
MRDP;-[Q,D*J4E2F;S4#%B* %<R)(TDPOV;131D]@5!/ ;N) QHV;%V>.PK3<
MIJG6DN7WF &L6QK$]<Z?85=QE(*O&9%9!B&NR20'=,?CDJ,T<92U#4.B%.,#
MHG<1=EL9)NC_ &.+/5"8@_EH\6,9,D2.X@ =2BSJ;.V7TT%)W$'D9^1,A,J-
M=OFN7'[1+$8Y'9E[GN>6_3OHZ0I:0Z^)!=WK(5K"62\S!#E$ U&PMQEE;HJM
M8I55$8\B-&/9C$:U&<8/,C+Y4KKMB,+A52RH-[S86O?;[@63[G7??#DJ?W3C
MRRVY(999+]+".2118'!VJH7GV !-F]25^C]U7'I3S68>A+.8S&L[:?"+2,YZ
MM(\UZ=!TQ'!:Y$*,5L@2C)^^C:1Y%8N[MZKQ/T\]0Z%.'C'GX97+1@2.(1<O
MJ'()CL$=C0%U>LI_:-TN'J/0,F7&*RLA,T97:WEM$FYB&0':2H*GYNB0:U]1
MVF2=.$T+4\(T4MO3X\(DV2B)XWW1-MD7Y^Z^5XXBP ==IL"_>QZJ Y[>Q_HZ
M^8"P?U"J-<CZ<']3WO3_ ./>DTN#1J*.NN.5N09,CK*9)BI48<RSB=DMC'8D
MEMT:.IG'JA%FC<T17!&P;%:=QT8]S-FNXM^DSY$$C>6BM',5B;<L;&P"Q \T
MA.U$V;%6+Y!GX$@5R" 3?'S5#W/MW!'O?;0%J-((%'CU\&&27>6;(\[,$J(P
M9K:YT6]DN>)02T;\0%D 'MEOAH:,\;9IU/*$Y[W2&:";JC2RQ,RI!&73%\YB
MGF!X%IK7_9F!O1OHABHI2*"ZM5R-V2D>X@,.P)HU7^$_-GYOGBN-5-<P/+QD
MDS(HV1R"9K HK5DA<>Q 8"@NGVL%CPV< \V?8VI>\I$]2>R<.=)-',UB!&)4
M:W:=.ZO"JF-3B2RQD"?*+J81&]%&5$2)17*B/TJI4V202>H>'>JPCITV,JIO
MB:B44%E)/#-7.T$FP2/KP=,3 -1\QPW&28_3Z34>*4=$]L&VR;+:^QL'5$R?
M-CCFRX<BTB1'_6%ZM&]YC+(9&&U31(T2.JL5S+Q,?(G,\V9-D._JC@QBJB58
MU(02"-G'DCM0 +'@L[41>YG3\?(DQPG5S/E9:M(8X9DC92L=T%1A27]T7R17
M/8-J_I69QG&)XC2ZCI>Q<N]<S("A=84RLJAWTH\QUP0TV6"2$<4)WRK(Z+'=
M&:.,R'V6O$R1'.\$$N1)A>3Y)00*0DH#M$JCRAM4JVY@$1:(:SNL@DPHL;I^
M!U62:-C/C(\RN6#/+,L9VH&"AO456E!!-@@FP3-W*<RTNP[EJNL;+)C J["H
MMF07%GEK:E(6)5LD;I+F@BQIC(EC+9&BPS+$!&.L2+*BG*@Q(M-CX?4,GQ#!
M*NYWBDB5@L:R2%LIU.PDEU+(I9G <LNYU8"R-<YW2SF3+D3R"_F2-YA*MO;B
MP&8>I=I[V0#54=?.389G3W*Y1$L,7J\IR/)H5<ZOOTK)M+D.'7*!$65$JS.E
M^BLZQPAO%+=-C3(UA&5)41T6<XS7_046%/$N*Z9,F+CXS2"3'\U)H,R&R$:0
M!0\<ED%0K*T; HVY**Y>;(B\V2,IYC2_[-Z>XVL>H$DC[HHGDUP--ZT=0@DQ
MOA\B7W4JH9\A@R63:X4&V[[XYX0B[(-8]@(4>9&42(\<@:L>US'*BR8ADLCE
MT2O,<8[@I(7B W!R+O=&2R-=@J1R"+#<WV=7B#-(+ W ,PHWSV!'/L>W?O6M
MICAAI=5@ZOT\8,J3!;'A, D>%8SS6@3RHML411 6M@$8\L1YMB#*HF,&YR.5
MD;+4G'F:;<[".0LQ8,T:+$55H@06\QQ08**(LW1%R\1R,B$J67;(I+ TS(2I
MIF%$@*?S^#J4G,+IQ1X72OR&R@5EW'+!A,-/GWQJJ9#E&JH3YK:S%8\8/Q5X
MY"JEC(!:/$(PFHZ*,G<<3*^'>HSY<PQ8Y)86$C4B0+(C*)'">;DLQ\H$']FK
M1\AJW\ "^ZIB1A9,EEW"5&( J[KD@BC=\6!SP?IKR\BI,7FZSZ6HOUH7$L4C
M9R[4._:!TGIPJXQ.[AV_KI$ I497QX<E[$$]K3"5&/>UZ+X]>-H\M,#J08XH
MGS&PQT^ '8?MD61$\017 MV9?O"U:R >^O/3LW$_N<F!&.3C(=SR6PV*RFSN
M!._=L(]0- @4=>/6'3VKTJU"L],!W378[!O81,=R6&6I@0+G$9Y9,JHL 28X
M][-KX#8QT,6:  93"LD1'$1W2G1\V;J&$F<T)$[1R>?C.)9'BRHPJRH0YJ,;
M]R[50EE(*N/>;U"2"6"/-C";GQT+E:!/F$"FH7O%@;N_8DF]:[6-65N#:>7U
M#=2)&,VTR4DZ"DQMW!=;QGDJV289:Y7,#/=# V/9]:LAD*P2!(B;(DGHZG(S
MNI8\\"KD0Q@HY7R'$1J0HX>MR;CNC[OW)!YU7Y$QPX<2=) [&100WJ< _!O<
M #P.>YN]'ODYCY)J=FG[$E; )*J,XQ/*:"-:7\679UF/W,FI/*+'26PD:2R!
M8@@L;*B,(=\*0&-("CFM=U9[Q08.F8K9TSA6@S()FC@98Y9HUD51(%IDWQLQ
MVM2AP2K5QJXG>+)QX^HQT,G#QD/-'S$9V#*UWO90> ;H#ZZ9&2X[;5U]/TAP
MR+.=D[K1V'X]C3*\CK&RM;&:)ZV;W$W?(-(KPL02.C@'"C2QQHS4ZS%X7&R$
M:).IYI58=IR9YR])'#&I"Q #A0'8DTS%V4LW  .@,&.ZF:.6-H$QDD9CM*EV
M6WHV2 C#D=PW?VU]&G)1R>9GRT:294[);$^1ZDYMC];M7C:,\3'49'1L>N:L
M]A(I30#22=[]VCAB03&/>UJ\<7\1>)</KO6%,,/V;!Q)>9&21?M&Y@3(K*%W
M;PO^ @J3;$<USCQ%U^/JGV' AD8Q8DDA>:PH<%61?4&Y4%0%W#D]N*)\NK@5
MAQ<7@9;6FMRV(30;2T=!F04@#*56S#6$MR0P=@49YW*D)BOBL1I>AS&HB6'3
M'WOE28D@B6(AXH@Z/YA &Q8TMVW%@!Z^&[ WWJX85(^_?L;-GWY[FN./8_7G
M4$N:#4.D;A6;ULRFI-1ZS''XCA^*VQ&.G Q5TIBHRXL;N8!MA)C0(H61H:/E
MI6L=)<=S3.W<NHZ3@S&?!=9)>GS9'VK+R(Q2/D;23Y,<2-L5G8EGI"Y "\#6
MB\-@+E3,CEH-IW0LY*75;B&.T<D'@"R%LGN:I(MKHG;0,FQ[4MU/<3<<SZ/D
MN%.KX$JR?CUU#C2ZJ':5IHT3X3(AF!.?76,27VDFQFQY<<KI08RDZ V!U-GP
M,G$BD53BA9C*R1F0$;FL,_FK(H#,C*25+,C#:S4_U#)QT>2R"PD98P2*4\C<
MG-K8-!EOW'T(X!E]]IOJ%5Y!AK+6AN8LP+K2XQ96PQVX*\7K#(6N._KE G0F
MJR4.Q"D,T<CPD&TB$1+G['!GX,L.4T4T91A%%D$L8C(2@ D44K(_($9W @$$
MBM1)LYP4BDAN%E-[DW*2:LD50-$^J@:L7S6K(J;Z6"\SV9#P7)],L?Q*B96K
M!Q_*],Y5K4@KK<CFOC5<ZDL22*8D"8HU80]>UCX**9.KJ5.K R?V<)A7F)G2
MY<GF[LC&ZC'%*SPJ"&E250LN]";4.:<4:('#473>GQ03/TZ:9<AE8[%E8J2%
ML*%0DJ2>:^;/OIC9KSTW6/Z38)34=5B68SLEO\S#F-'J+4V620:QL>UBDQ^$
MZIDSOJ^5Q&#ESV2/ATDZ.$-R]CI7N3(O"4>1U3-\Q\C$AQ\?#?$FP'CQVD+1
ML)G$JH)E )5"N]0035WP_P!*P8QCKU3+:=LA9/+:Y'!503]X[@POTU9'=@#\
M>WE6Y=-4]?M6<?U:U%HI%SB,R$Z-)'54]9C6/4$237%^"-#50D9"] V"19?:
MC0HYMW@8]G61.&/$?6NG]%Z7/TGI\JQY2N'#2ROD33N' F+.]R;]R[0S,P%,
M0:!U..?#%+]M+>6T?[)%5G# *P_Q$[B2;LEC8/P-&'1'4NJY3.9ZKI<\),A2
M,-SBTPN7:QPJT$C!<MEC0S;$;QQE%$CR?0WM:]']ACCSW])&$&O&?ZCA3>(.
MAR_9%5ERL2/*2-CZOM>./28C;6VTO#(/O$*@!O5]UK BZSTF3-QS9R(]Q3=N
M"R(I"FK(LU][O1NSKZ1L$E1["USJP@&%,A3;RJE1)07L,$\8^-51 F"0;G,>
M,HU:]KV.<UR*BM<J>>.'LH1B'&R5/V,BMZ2#'VL>Q(//O?'%5KBWE&,M',NU
MT9@5;@BCQ8-<]Z/N-?.?]*B,T;FAQ \I!*"PJ[R#7HB+UH<)@DFJ_N*@5;L^
M.NWA=TV14541>P^!5:3PYGK&?5#/&TGO2[I M<6#S\]B;XH:[K_95FPQX^.L
MWWAD9,*A2 "SF,H'!Y-\\<'L?FX&Y1CLNXQVPDAE"C&)4R"-L)#W-8&+TN6P
MD()&O:T5>%C[!@R,<5&BZV*US$WUG2LF.#.@1PSKYBW&HLL25V*2:]3L50L/
M3S\DZV_BZ)Y^DY4D*(/)F>+@$U*=XYHV%(5A0(-D$\7J(%I&?37%E* &KFU?
MKGUE:6/*/(KWR 1"A+=AC2C,F,?/&0<X1#B4<5W210MW1B=,1Q/%&ER))Y8E
M<%0KA692(2RC80C H0++<BR.=<#C'V6G>R1.5 !I:O[VTF[/R:XOC6VQ:KFV
M3@J]IWP)\E:ILT2BZ50H>J0Q9+Q)&4L(2+,D%?VU037/1Z;HO$'.D2%2 5#H
MHFVT;X- [;W4[':JB^3S?-:+IDC9#L[LSHVY2'K:%YJMH6B!QR3_ )%UW.:Y
M)<S\.#;MQTD+&I2)B]S:UL"-'%!?)(1M5D#U8QMQ4H2,1\4\L9E9(*=C7HUR
M)Q%QL."-,N2)LD29"@94,3LY,@6O,@')BD(>G52 5"DJ>=>NH2I&4QBD7E*7
MD4F_O&@=UGDD*.Q["B/?6L -,A'3,)<U-!"DY.2<*J*"2"HQ\TDX3"FL,5)9
M3TG<C &8;C'Z&!<UPRHU=YS/]G:<^3+/(N,L;3*RM+,JJ0R[1M591N8@T++7
M>L\85D6,JY"E]RKV7=9('S7':A8[&]'C3/!-7M4C9'!2FKQNR7**ZX'DQXKX
M,2CMARU+"LJRQ)'BP8K+%Z;1D<T01C<+M,ZF*-V=ZGU'I73/L[B65OL^.\)@
M5@YFC90KQR(K,[>6.7Y))!L\WJ\Q<"6:)S*8HX@&<  [A2V:)/?B^1P0:OL#
MED^FAM&I;8]O51"9'/<]I@4$JQL+.S9, Y'33PXH1$>ZQL8ACR#1A?;.97 :
MD?K1N:Q^HR]9D(BF*P1FT,R)'%&$:@FYF(&R-E558BE%'U<'4?9^EXW2DGA6
M612H$N]D9A(%%["$!%6.#9LU0[B.UWB,::>LK](Y^?Y%3I7!N]28<P#1R::Z
MCN/(MA1($.>Z(85?&$JMG6,1KQ';MU)]IJ:R#+,:22=53!@F#^3T]T)V30L%
M6-F=T$@,C-RB,;4]B-8N13)+2#T.69D=_4HL5S1JNY%'CU?-,$@*VHQFXL:X
M<ZTO)-H;ZIY DP;BMJ[QKZ\-==5D27ZDAV#4TQQ^EL6ME(Q2%,)7-6:7EFR8
M87,<4 BO)@*&C+CU(9('=0J@G:@7EI$!H!JU(@AAB#3R;G:*18_1V1'4@AN^
MXW1!XJCP>")WZ1ZOY'CN(VHL%OJ&SNM/=/IM#05]['A*U^?9\5T'&HV,W3I8
M33K*MK03[9E;'8T8),<1&?:3NIB>I]-BEG1\V*6.'.STEF>)FXP\,A\A\B':
MP6-W98S(QM@QX(H"08<:>>*$1R$47?@;F5 TB$&C5R*BV0:!H 4#J(=#9:FT
M.:3*NNH[B9DSK:/C]W8&GVUG;R)V2UYJ>72VTTL@,QEU8FD2Q!BF,Z.I5C@8
MURQT7C520]-GQ%F>>./'$;9$*!(HXPN.XE2:%0K)Y4:JA+!0W#$GU::S)Y%=
M$\H,=NTJ5M=M_=*CG=1[CBF[:W-A\>R*AQ]^>V,3$J[%9-EI(>OC4T:/E$*#
M0.'=P&3ZP\V+(6<>UD2!2K60L?L>E*CV%>B([R#!CS3IA1OER9*1]4$IF9L9
MWF)A<I(JL-BQA2D8O=N'(O4.&)Y-DI*QH'9 K EJ]^37()J]M<[3H06U6YOP
MZ<*966<=$**[CK,EK8PQ%5(\&\OBH@N[(6;.60%H7G4L@HAD?N3=;**6Q*A2
M2)B+A.Q=CD#<\$ .XA=D94EMM*K$ 41I]-JO$ >TJ#<I'J4AE(-WP#[57TO4
MJ<_R@]5H3R\X@&V>E5 K=1-09+$B#-;V<_(LZE4DB;%C'*+N3(V/0!*%SW=G
M?OL(Y&<97!QQ+UCK>28@6EEP,-:?;'&D&$LH1F56I#.Y! !/:N0"+.U$TTV[
M;+#&8T+^I6C4L54@$&]QW$_0<#D: %#$P:'=0[.9:Y&E7,F,DSA!JX5=D%;(
M^SZ:55SQ39=<032N$9L::@D1XRAW&F[N-'-)EM"T*1XX>./8A:5Y()5YW+(F
MQ'!X*[DLD$'G5,$E=I9G)9G)(V@@*?SLT/?DCDU>IJ0L*R?7G(2):'AF;83Z
ME,C@ KWQZS*KFDANIZ;(+>N@MD"';.AGZB_#HP(!S;F*XQ'.5N$FZE#T9-F.
MK!HUE^SR,X:3&AF?S)8(I&()B#+Z?,;>H) H 7K8.CQ'$7*R&:.-T#MM=11[
MF@]BZ)%EA]!RVB3JIR>ZEX7C41,HEVI)@ZB2/#!!OH):ST%;8>NI(C*.^A&@
ME#US2N)4L1IF#5ZA8T2]'$;IOBO&RI[BAA"&56RR875_,>,)*_FPL'4D(/VA
M)%T#9-FI$'2II9UQLN5C9CVNMA/8V1ML@_XA[\GGO6]8:29:_/D99U(:ZOG7
M==)N[9]0-E56U]O+8"79-$UA!1&!+U/6. ;1Q0"<C&()O'0HNM8C87HE9I4A
M=88O-)DDDC4[(^:+$BN226)YLG4%NCR0L#&%F0N2WH(?:"37!-&^WI-:U69Z
M?69\JRVIAJ^YNFG- JW42%L!38=8<[Y=@O;1B("0) 2X$F.FTF,-[7*FR(C^
M#U*)<?%=ML<! DE$I",CR* B"[L@VLBL+5B*YU$R,)W5Y?+DC;A%+CT;+!)(
MH$GDB['/M7 T-+47=?91JB3!#>@BME$EQ8\QR&DU10,FR8)C1QD,"0U>U)8P
MZ.4#AN0;6+N[AW(DQI4>=6:!GVA791M64,460*Q"L#RK%?O WSV#N/-E0HN/
MO1T4DA=K!O8 &CV'X$_7FSO,:C91J?;8UA@HS3AIGOBPQ,JQ!GOJB-(V,6PL
M@0O72PP2;!2%/DN",+%8)K&N5O#.6V+TJ#*RRP#SKN8^8603 C>L<9?8A<6=
MZ*#9LDGG2XK3YN1 %618DE!(%C<O)YX;DU1^>2>-2CBPA4Y60WOF?"XA+. $
MWI4W,\1)("&BC?T,C-9)(SLC<G:08V-:B-1-N<Y+F>0RC89CY4C#=6T4K!6/
M):T!LCFRU@'OW[I1V=(..HVJZ, K&V6R;(JN3\UWY/-WUZ1QH>.Z]Z$E[S$>
MW5;"I$EAY7>.U5R*N:XR248UBO42H\HF(-C-NE%1%X<S)&RNG]7L,*Z?D*-B
MA5(\F05MLU\ \_.HO7H&PO"F0%VL)8\SU,+-"%F6Z84 ; ->U$:^PW3%ZNPV
MBW3;<$MRIO\ ZKXC-ZDW1[T5-_'AR^$3\W'SW&H51W/ '/?TEB/SY_AKX^10
M@""Z4&KJ_4239 'QQHA<.:]Z7!HT$LV$PV9F:\3'L?B-;'D$?,?#='CGR4CG
M&$YK"(0C"A$YHU9]O96]2;\3,9R %!(96=U 4,&)3:0;(X(7O[=Q6I.(H,MV
M;!X ]_2.#^/XC]#8TS2=^DOXT(5A9I/6#! (H2UP(DDC([&3H$P"@E@JRC*E
MB]Z%5YWCDCCJCFN:LBMDD+2,J;=SD@AV8 D&-T8,A<$%!:\;AN '::R2_:$,
M3 .EN=[>G8M%^%Y9N> " 3_B^*0-9-4;?4'5N9#GR,K9IE5V-E4EGPYZUUZ!
MT25(EEM*"P=T .\TUCG?"5(XY@*P9.PQ55.F86&F)T]*3%.6T22!?+\R,[E5
M!'/5D;5JI0NW==76NH=#Z='BXC3P,Z]1FV';/1QWW-Q4)4$)M?U$NP'/N!8C
MU4]9\ I$OLSEW(YUK.-C%Y.2/,MI6(B#"B"M[6++*\0I))A+:$&0<<IZM@$&
M9K]A2&2<"2FG$.,J+L030*"J+D%G8QHR!6*A/++!2@MP1W*ZT"8>+)GP,$2+
M*AA)R&B)$/G!2Q6%>2%(*D -[@7>HQU$U=-,6U#UVERX-8TMA,P;3B/D[8L9
M;#+)U;(E = _>@E])7HIDAP&%:.?)867VQ/Z^-9CXQZGDX/21')*5B7*SFQM
MS"+%6158O>YE+/8WOM] I0Q&L_XGZJ,2/[*DA3>^^4,P,C.*"J3=[&6CM*@G
M_>[ZK]RC5C-,B%&NQZG6^0&FUDNJOZPC2,DT-I(0T*[ISU$@)*DL(@!L (D%
MB-8)!JQ!N8BITO%Z5A8I,!Z;# (Y5E@E!M9XE(:&59E(E#@DE@_<DWW(/.\C
M,R9@T@F:F].Q> I'T()^/?YLFZU[Y]G+%5XPR02&UKXL"GDY39C$I*'T+&1+
M"AR(<57%*L:.:-949PK(G,K71EC$8WO"8P(X_-RF02$AY)5Q(BP$^\EDG@+"
M@&8,DRL%3S P>S1U*A622...0H#5+(RDL"!V:B+LT!6W@_(UX+W$;;&8>,S<
MACT!1Y'-LK:$<9)$[XFXPXKZX5[,*V/,?%<U!/KF.ZWC8=PG$:5=FMP=0BR7
MRDQGR5&,D<3@[4,:@L)# @++O'J\PB@Q&ZMO>WDZ<R_91*(6E:(G:48 RT2H
MJ[VE@..2W/SPX<,Q5ILQQZ):]L&%Y-(BP)#HA(1^HL."[(S4P&OZYD059.(R
MLDS(YD/6^LCAL55Q1O;XR\P# R'3U9F.'= P<>EW&.)6(.QS(G[148;9-C&+
M@$:@C%=,W8%V+2>:2;]04;MAKA0P-#O7'-@D]:_Y"_*[:GR&/-?(QBN^(TE0
M-M>X+XU_#0!"0J^9+9,KK8S!2A-F-/*BO.T9T:KW#:C*#P_"N.D^.\>S)E*3
M2LS@AL=[ 9E0J\0)4D$*P%K= ZL^IF11"ZRJR1 H$!Y+'BW4$^U "P0+()]M
M#RL1#FUMPZDC&?B.09')M:*;;S:PD6MCT^5T=G22V6$0 &>ID*2>PZECCE!$
MB]8_LHK>)'B4G^[ILBQF8\!A>*%)-\AGQIHIE,;,3L4",BF*DFK[ :3&R((>
MEY^+)#Y,GD29+2;0#)&"J%5)KEF92.#P#R3HN<V6)X1INW#N7DM8/4/*-.(8
M[K),UH),B16Y''M:VKM6QH"J5]B&HK3%4A98B,Z)LDJ,",>[4J?#^=FY^1E]
M>C?^[\?.=L>'$G11)!)$\L1=R*C,C@$!&'W!WNCI[IF AZ0JY+2MYD4>3 H.
MT^5N7:#:EK]Q5"O5P"->W5J5IKB_*EI-187C6/0+8\6PL[YN138MEDT65.L)
M3C0Z9TF8TA#S3%C2K=HXYF0:U@V(@I#GKP=)3J.5XGZG/FY,[QADCB.,ABQV
M5(T]<NU2 % 98K8%I.]K51LMDCA8)"SA:*>9ZJX]Z4 CXXN^:JCH<?1_Y1/I
M]>].Y:2;" K[^XJXX84&/&,.7-H)+8,UCRM'&6*%JG8I##22PJJ@!F>Y-Y_C
MK&BDZ7EIMCD/E0R,SNSKY:3+YBT+8.W!I24( L@#7K":=^E9K-M")$30!#EK
M)"DW6T$+[71))U]0.F$72O"=0\AK#U]%;Y%CK(=M)U RFNH7R,<A6+7D'_7
MT+)DPYEW#!$PO6&,QO>*QR]#> =37J&9B03!YH89R\2X.*TX&0\9%GR"61 H
M +L1RQ)4<;M9F3+S&Q$A2>58Y5N2(/ML&A0(J@:^[V( !) YG3CN;8IE$.1-
MQ_)J>\B1'#]7)K)T:4("D:KVL-V7J@.M$5S6/7V:J;KMXQN1BYF,\<>5 ^.\
MDKJB2(X,B .0 6">H !B0" 0*X.J62)T[H0*[FN2.3^/]?&H]<SNJ7+UB^&V
M>.ZVY9C..1[,3A5P[LK 6+IA$>.-858@O;-5K%>]HI8$Z5<PHNM=GIQ=>'L/
MK4F6DW2<;*G,)._REM:4^M7+ H5842K#GN.>=672^F]2SWW8T3^0&*O(X/ED
M42=K$D?%']2-?/5F62LQ#*=0(V-2J75G2@4ZM9=4]K'B3JVSIHYG2XC;*H.C
M9-;,C(P/I;(+PC$][HZ%:(O;X[EB1Q]1QL#SUEZ;U-HY/)FC8I-%.WH;RIEM
M9$;=ZHR"6 W42H.KEL7.Z4\N00X"[0X6_+*$#=8[F_FZXYN]0HUQPVAB2*7+
M,>L*B!I-;V=N/'96+P&-LJD9)P+R5CM]7L;#2?<5DDXQUH[649&C +ID+%")
M@])T7,R8QD8F0DTG5(TB,ZY+GRI0%:%)X7.\I'(BDR&-023>W<23=S18O54@
MR(6"QB). 07,J@%U)%V 3Z;!JN2Q&@M O:[+\DE4$ZJMJ6ND5C:L-N^R-/+#
MLHJ&$6[M;B6T@ /MI;@]^M T<%K".9'5SU>JW<N/)A8J9,<T4\@E\TQ"((&C
M;:PABA7:2(E#;9&)>ZN@!==!DC)FDQI(F18T*\$#<!Z:[<D_%=S7-6&JN-3:
M.J658$@0)D&>2#/(&='DSK::KS%K4QRN$T,IXA14V.81'!"5CB27N:X4='WR
M$RV")YDBR1AXPRE8XE 42')<[EO?>U2 2*  -MI[$V]/R6E"_L5(\P,-S,IJ
M@K"AR;%E>+NN+T?YN*5NH50[-,7O:R#<U8!7&4X):3&@LQV$)1J_(Z0H0/6;
M'M@QO4%CKYC3F&CC4C##1V<$\V!D?9LB%VCYAQLQ$+1F-QS#*"1M:(L5W6+0
MAC1!U?X\N(<182C-%G2%MZT2A%;5!-A&Y'-,6^-7!_1^\U]/GU9*P*V)!P;+
M:VE2:&NKY:$;<QZF*VNAQZV$=QD=:&:R38J8@%)+87L-&U6M5G-/&OAJ7#*9
MT?F9F/)*$WNI_9&5B[,[*%/EK82@]*1N)(/-'D1@Y+0A+B20DV*8AR>Q['BK
ML5?/;C47OI&P8SE6I/UGQ]LX$RVQ^ABYE(/%,QBV*1SR(CI!'HU$L'UK8R20
M;_DECHU&#\(EIX+.3BX028J1%-,^(H8&TWA& JSL\PMM-\AN2??9]!D48[]-
M*#R@[@-W<@HS#:;JE*T31!'')YU=G]%AE=ME_*UCTZXD%E2:^2W'@RC;J:3"
MQ^#$K()".>KE>]L4(1.>FS7*S=J(GA.9^.,6#%\19HA4+YQ6>116T/*BN0H'
M('-T>;)/TUR;Q1$L'7<R%!2J$(''=E!]OP[_ %^"-5V_2\XH1;K3O/V,W2LU
M)RW'Y)D5&L19%;C4V,!RKMU=]C)C6L5=G*G2JHBJ[C3?V;9)*=8P+_VT".H_
M#<I/Y6#8Y')H]M;3^S>6-1G^:36+DXN8H')HED:A8%V%NZX]^*U7EAA:RPZ*
M21$"&%:,EU!6R"C.R&7(8;X1')W7[,)7%G,,K/L(B(WI1[>K;33^;#-%D!V+
M1>6PVBF80N&%UW5PG')Y!Y% Z[QU'%^U=,ZKBQLID;SLQ=P.PE02*H$WZB!P
M.2>>"-0>R^O%57TB.2%$H;/$+$6.W]+9(Z:]UO3(2-=7$ATL"Q4CNL1.=&KM
MS(5BM'T*-O4O6,21GA5M[3QYD1R()HO344P#11#:V\MY9 :3TT>;/8?.$H68
MA!2-#D.KAP>2'*EEX/U-$#TU[\$K005V&8*K.X N4YE3-AUD&MBN;/KZNVM&
M'-9V2CZ(HY=N&.*#6!C[O@53I;R-&\K4XH6>7J'4!:O]EPYBTCR-:2211D".
M,&W*PL6>0MP\FT>H*;TC1PX&+:M'O=16TFP3S9! '!OM?L/KH>8?]3 6T<NH
M,2?-IX@KM\NTBN>0T:6ZGL(%/#!%,B161H>0R!2Y<AG6_H:@]PNW[MUE_;/)
M*].:..5S#MB< !E\V-Y6+J2Q9X%VJIH7R-P[9U#Y\Q?*MG'I5EL@T>!R*H6>
M?CXOB26@NEL^9 !D>:Q:VVQ2GI;L5;\=ITAQ:FUOV]466XVS33XL=PVRXVSR
M$&4KV0V->BH[+=>ZL@D?&PFDBRI986E,,N]I8H#M:.NT;$':W84!O/ U=X/3
M_*19)J,1)5 :M)+W GG@  B^2"1Q1U+^UU=Q'3#!R2\'L[>Y@U"Q:;(Y-11%
M)B[%:A6"K2&54'ZNP*[N_%[,_?\ 3"%VQBD-,TN3AZ7F]1SA'DPQ1O/NEA$\
MP7(HT3(@NZ0<>5'QN)LE2-3)Y,80EIY%7RK*B*R/,'"B2PC;68 -M5JW$D<B
MHI9+KQ7ZE0LOS^IR3,L%U9JI<-,:A5L\R4DW'HD84.;#=8HZ//6^'),^37O$
M$$$\!Q@]?6W[>LQ.@OTV7%PYL?%SNFRJYR))47S8YW)=6V$LGDE5"R EF#T:
ML\565G-DXZ1I(((Q8I-Q]?L57:HHV;:^] D<:CO27DZYA?"'0I$MB2I9%LPC
M?7VLTMP_>Q%*M B4MPV5/,_I!8,,T"H@VR6,>Y4OYX8HG,HDCC(1?V)(DC01
M#]F5C( BVHJ^I-I/<I?>-&)4\M#'/*KN%,P50&8T;-ON&T'GOVXYT:=-L=+
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M)&EN-(DNC%"C45%;QDWR,CJ&;-#TR-A)*H^TYWF&*)43<L:0*S>N5D+):[0
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M6S"ZJC][;S?O6JZ<ATZY?-<.8;(,5UFQ>+FN*#M,@Q^NU(I["3$R2#EL6<U
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M"Q<2AMX<(*+,M6O?P(TB8S2 *XB$2V-K,X+5=CM1'J[55MQ>K%=,\"P'5<V
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M2/$+\3L6NBDE!B-*<H$5R[L<9HV-*FW&C8HB>>[KO:C*[(Y-KN(")SM8T ;
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M3E"5Y9%6*69_VDH2]@^_>U6VW*X %;F-6=;+'@P>EPM'YL51+O';=Z/4. 0
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M5_\ >96+E/[GTPM,W:]M!;_&@-3[T6^BJU3>Y)^IVHU1A(264.<E-B-:F0Y
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MFFWR;Z.L\?I^)*NWY_OX4  5S0O\?Z^*_+1S7M^//Q\7QS^/XZXOS6<1'([
M\UV5-MDB5R+OO[HJ6B*GZ/"_/A"H((-\^]D$?0$$&OSTG-CL?GV_F?WC7B/E
M=D^'(C1L+S:.<PWM#))"K3>G,K501E8^U8A&C?L]6.>WJVZ=V[HJB*L;6J^X
M)LD[A[@DFZY^0?C2FCW'':@6Y_$@[OH:/;OW.A=FNGFFVI<*+&U(T-L,W-'B
MNC,L+G':<TT:%1O?)$EK9K.@H<B*111Y+6L\(FZ-3B=B=0S>GDG"R9\8%MQ2
M.5]K&R0&5F(8<U36*XXU8X76.I].0)@Y<V*H;=M1RP-]]PDWK?Q0H=A0 T!5
MY,] 07<C(*/2_67&+>5VU)+Q_-+JNV4(F@$K1IDSA(@PL:-HW,<QS=T<QR.5
M%MSXJZN\"X\LF/-$MTLN+ YY8L>2ECDW8Y'L>!JXA\8]:B?>SXLX/WEEPL:F
M![ABD:,;]R26^MZ;-CRPY?73"?5'+M1I=47LD;5ZG85A^>DCO"A6B%%NWN@W
M@H[4?X&6Q+VW=3AN;UO157Q'%Z5FZ;3@']I@S2XBD-5[D#21EN.2$6Q0[@'5
MFOC/&F#-F]+59SP'P9,N"/:.S&-<CR]]W9VV1[]J82<H&HB62V()T6O*M@>:
MBP].I721L@PR/:>(_/W5KC,:A%"@X@Q-*K'.&YJN19[^*<00A6P\MAM5#>1&
MS*0#RI7$,FTT-Q8DBJL$WKW'XQPP2K09OE[=NWS9A?;NRV]FOD][)L<OB+RA
MLL923,\R+6&[<0:1ID#',>PG$HDV"C_,&7(B#DV;XCV*K%&R>)[T<Y>XCMMH
MC>*) BKB8$$8#!U:9Y961@/O*KLB[NQ!*FR-1F\9+ 7^P],@]8*[LELJ5E+@
MC> \H4LO#6018[5I[U/)SRUUTL,R9H%FN2/"W9H\JFDO N<B,:PA&S;U[U<-
M!M0;$>@F(JH@]E3AE_%?7&0JN88039^SQ1Q$V2:M5]R3_&]54WBGK4PH9(A[
M<P1JA%  42&[ :/,'!=+:N"6NK>78,*&:*D(P8^%XH)#1$5'=@RI(5QA[^=B
M*]5=Y557=.*B3J/4965VS\S<K;E/GN:;M:[B0#^'%>U'5<>K=3<[GSLIF)LD
MS.1?T' 'X  ?3C6\J*S$:$1 5.BMA! 3?J!&Q?&ACW5')NB,DHOGJ7?[2HJ_
M)/;AE\G*E-S963,PJC)*YVU\5M!_^;=\BAII^H9[L';,R+%@U(5OMW*;2>1?
M?Y' )UOH]G7PS=^)I3>Q3*K54L>AH!$W:WI1W6.:UR+MOLNZ+Y5$7;=./#R2
M.M-)(0.WJ+=^_!L&_J#ILY64P8-D3N&^\&GF(/Q8WU^/')YK6T;E\MO5M@>:
M=+M_L+"JWM1=MD5$=9+Y3[MMO9-E3V;(!&TC<#WL \]OBAW[ 5WXXU'//MSQ
MR2QO\037Q\?NY['9G->YJK@>:HK41$VC5S6[)\E1+1&_HVX-H!#421P.37Q]
MVPO[OG01=7^XD>X^#[?U6NQ,XL&^/J'FB^=_]*UB[;_)%2S3Q_']_ H(NR39
M)Y X!YKTBC7M?/S[:7^O<_U]=+Z]3_X!9I_@==_^4^/6DY^GZ?3\?G]W'UTO
MKU/VW^H6:?X'7?R?$]^"_;_(_P >VCGY'Z?]==)\UL2L5&X%F:N1%V3TM8U%
M5?;]U9HB_G1?'S_ _K^KT<_C_+]]G]--6QR'()2(@]/\NVW7;<%6GONJ;K\6
M7Y^^_P"E//%A#/$@&YR&*BQL<T?<7V/X D:CM$"SFFMB;^*Y^G[[TPK"/EDK
MK46!Y2FZ*FQ&5;57==]T1MF[\-]_P3W]K&#/Q@?5*%/86C\\'G@>WOV[_32&
M(%=I#GFQMJ^Q!Y((_+\?PT0-&:N\IX&3/N:2;3$LL@]7'CSG1G%( =9 B]UJ
M13G:UCGA<G2]R.W3VV\)4]2R(YLDRQ[F!4*2 :I0 "."?FR?I\Z<A38&'-7Q
M??N?R_,5?P-&_B)I[2X-&EP:-+@T:7!HTN#1I<&C2X-&EP:-+@T:7!HTN#1I
M<&C2X-&EP:-+@T:7!HTN#1I<&C2X-&EP:-+@T:7!HTN#1I<&C2X-&EP:-+@T
M:7!HTN#1I<&C2X-&EP:-+@T:7!HTN#1K"I\T]]MO.VWZ?&_Z.#GV_A?^8T?U
M_7]?]>/2JKL[IV3RFR;>?N\JO\GGPOX<>*<GEAMKLJD&_P 23QI>/K^O_36%
M'NJ;N7PJ+^=$^2^WO_+YX7:+ODGOS_7MKSS\U^7_ %]QQKLX]:72X-&EP:-+
M@T:7!HTN#1I<&C2X-&EP:-+@T:7]%X\VW^[^\:-+Y>WYD_DX.:)H ^P)_B1[
M<G1K#>I?W2(B_@N_]/\ Y_AP*6-[@!\4;T:Z)4N+!"Z3,D!BQV;(\QR-$)JN
M79.I[U1K=U\)NJ;JO'L*S$!06)[  DG\ .=(2%%D@ =R>!^9/8?U=7K5_6?&
MU1%^/TNR^R_$X7^>X<\B?_@R_P#IO_+37VB#_C1_^=?YZS]9L<7_ &_IO\9P
MO\]^*<'D3_\ !E_]-_Y:7SX?^+'_ .8?S^H_4:Q]9L<_X?IOS?$X6_ZN]OP>
M1/\ \&7_ --_Y://ANO-CL_\P_GK/UFQS_A^F_QG"^7_ *;@\B?_ (,O_IO_
M "T>?#_Q8_\ S#^?_;2^LV.>?]'Z;Q[_ .B<+_/<'D3_ /!E_P#3?^6CSX?^
M*GQ]X?OYX[Z7UFQS_A^F_P 9POG]_P"6\<'DS=_)EH<$^6_!^.VCSX>WFQW\
M;A?\=83)L<7VOZ;[O^N<+_/<)Y,W_"D_\C?RTIFB'>1!?_,-9^LV.?\ #]-_
MC.%_G^%\B;_@R_\ IO\ RTGGPCO*@_\ F&L?6;'$\_'Z;;[_ (G"_P ]_'P>
M3,.\,H__ *;_ ,M GA/_ +V/M?WAV_727)\<3WOZ;_&</_/?BG!Y$_\ P9?_
M $W_ )://A_XL?/'WU_G\\?CQWTOK-CB^U_2_P"-(7^?X3R9O^%)WK[C=_CM
MW^FD^T0?\:/W/WQV'<]_;W^/?2^LV-K_ +?TWS_VSA?+W_U[@\J7_A2=K^XW
M:R+[=K!%]K!TOG0_\5/_ ##^>L_6;'/^'Z;_ !G"_P ]_1?'"^1/5^3+7SY;
MU_#1Y\/_ !4_\P_G]-8^L^-K_M_2^/\ QG"_SW]/T\'D3?\ !E_]-_Y:3[1!
M_P :/_SK_/2^LV.>?]'Z;Q[_ .B<+_/<)Y,W_"D_]-OY:]>=%Q^T3GMZA_/6
M?K+CG_#U-_C.%_GN#R9?^%)_Y&_EI//A_P"*G_F&L?6;&_;X_3>/'_7.%[_=
M^_<+Y$W_  9>U_[-^WSV[?71Y\/_ !8__,/QYYXXYY]N=9^LV.?\/TR_FLX2
M_P#X[A/)F_X4G_IM_+1Y\/\ Q4_\P_GI?67'/^'J;_&<+_/<+Y,Q[12G_P#I
MM_+1Y\/_ !4_\P_GI?6;'%_V_IO\9PO\]P>1/_P9?_3?^6CSX?\ BQ_^8>WY
MZQ]9L<_X?ION\V<)/_QW!Y$__!E_]-_Y:#/".\L?_F'X_.E]9L<_X?IO\9PO
M\]P>1/\ \&7_ --_Y://A_XL?/RZC^)UGZS8Y_P_3?XSA?Y[@\B?_@R_^F__
M -G2'(@'>:/_ ,Z_CQSSQS^&O=#LJZQ0BU\Z)-02HTCHD@4AHU7=41[A/>C5
M79=D5?.R[>W'AT=#3HR$\@.I4D?-$#7M)$D%HZN/E2&_@>->WCSKWI<&C6-T
M3W5$_3P:-9X-&EP:-+@T:7!HTN#1I<&C2X-&EP6!W-:-+=/;?S]W!8/8WHTN
M#1I<&C6-T^]/U\)8[6+^+T:2JB>ZHGYUVX+'R/UT:SPNC2X-&EP:-+@T:7!H
MTN#1I<&C2X-&EP:-+@T:QNB^RHOZ>#1H7ZQ_V!6O_'0/U>M"O^1/Z>>+3HW_
M .$L;BZ8G^OIJKZR^SIV0W_+1_K\N?IJ$[FHCE\;_:7RJ_TWW7[_ )K[<=6"
MV3? J[K]/R[_ /2]<H?)*@;>6LT!QS[W?O7L/WT-+9OW)^I.%\M/E?W::^UY
M'NA_*_K_ )^_M^ATMD^Y/U)P>6GRO[M+]JG_ -T_Q]_Q'M[>VELGW)^I.#8G
MROXT/Y_R[:/M>1?W6K\?GX_#D^_?FKXXN1%39$3=?94V1?OW1?Z>_ 8X^]@5
MS8H5[6?U[\?2M*N;.AW," #W_/Z?J ;_ !/%L#4K5'3C1S$I^>ZJ9ICV X=4
M$ "=D63V :VN&>4] Q8XR$7JD2Y9E[,:+'8608WV1C=TN5&BJ E:!L;FKM2V
M3=D#@ GZC\0-3D^T21,ZV&(+H:)-CD50)X('YW?%Z#4GG<Y2(6GM/JQ,Y@-,
M@:=9#=R<:I\M)D,=*F9D4*(DV91*3931[>'&<TLFODA#*$-['J-&O8Y?;Q(F
MRX]N_:4-J P<G;1O:;HUS8*T>>->(X^H9!4"9MQ%L+:U4"RU;;JJY^.W;3CP
M;FLY;M2BX6# ]:=/,J/J--O:[!0U&019#\NG8R(!;^'0M7H^(2:H<@2RXXEZ
MQH]J]+E7;ATXLBLT8B(D6%<ME4JQ3'9BGF>@L#&'%%A=<W0TVSY"23B4N8\5
MA"SE2 9F4.OW@*+*RLM]P?@C14PW/,+U#KYMK@V2TV5UU;>W6+SYU)+'.BQ,
MAQV>2KO*<Y1;L9/J[$1(<L";N&=BLV]]F98**LRU#)"94/%-1J^#P/T-@@@:
M8.3DK-]E<,'22%'ON//4L@/XCD?0\>VF=+U\T2@U>H]_.U5P6'1:0V ZC5"Y
ME9% #58);'C@D KLCFD*V/7S3"E1^W&>]3/*8049WB(/@>&H(99$*I.6,5@4
MXC-L1S5( &8M[4PX()G2)DQY7V0JQ*(DZ\&R(_V@JQ9LHR^D&C8N^-,RSYP>
M5BET_P <U8M^8'2BNTVR^PDU6,9E)S"L'27ME *HK"'7F[JD+)K7ITV0E$U]
M=Y=-0#?M*IQE12_E$ E<GFJ%&PX8FB#1HKWH@=B-1TBF>3[/ZMR-*"*-C[5=
MCW(K=R#W_'3CN^8_E_QK)\%PR\UFTWK<JU0CP[#3ZBDY55LL,N@6:-^%2Z,*
M'5)D2VZV)5R6O:"P(]HHA#$5&<(N&A=XQ UBX64J;]&YV0WR-NXDBCP>>^O#
M9<XQQ,$<JH\HFC0HD FAP#]:]R?<ZW.JFN>C6AE?2V6L.I>&Z;PLCM&TE%(R
M^[B4[+>W</N^AKVRB,?((P.Q2D8/L &J/.82*FZ(JR2O!&@9@.PH=S1'->UW
M^[B]/(V;)3*C^25#<;CW%DT+^15_RULM0]7-,=)\,=J)J5GN)X1@S5AM7*\C
MN8E=1F6Q8I*X<2:1ZLFEL6;/@@B=\LEJ]0VJWSP,HL(5MF;8%H [@18-U1!X
M-UR*TY'&\S2*MEHDWD#O1- UWOMP!?:ZUO\ #<PQ74/&:7,\'R"FRK$LC@BL
MJ#)*&='M*>V@'V[4R!-BN>$X7[JF[7(YKFN8]K7HK>/;P+%890IX+ @>_;CL
M;!N[(/\ ".,B8NR4Y()&WD&P>00>Q!]J!]S6G,X+V[]2*G2C554:G2U'JG2Y
MSD5&M:NZ[N5=F]#T<J*W;AJHKJDNZJEOZ\?P^1SISS)_^&W_ .57Z]M:N[MZ
MC&Z6TR#()T>FI**NGW%U:V!&QX=565<<LRPGS#N7I9&B0@DDG>WJZ0L<NRJU
M4X"L8+FQZ46B *.XUV]JL#FA]>!KTK9),3!& F:2, __ *,$COWX'L3[\:\^
M,9%C^:8W29AB5O!R#&,EK8=S07E88<NMN*F>$<B%90)+7*TT20 C"C(B)NU4
M79%7CWY<<3&)H[9*W!@#6X;O@CD$$$\'V.F"\[("9-@MU'.V]CE37(OD&S1^
MI.MVC?OV5/Q:B?G_ ,GR^[CWMC/&P*:[[0/UK_/^.FS)/&-PD,E$>G<2:]R!
M?[A?MK.R?)$V7S[?]'!Y:?*_NTGVO(_W3_/X/?C]_P".ELGW)^I.#RT^1^[1
M]KR+-J?IQ_'FNP_7]ZV3[D_4G!L3Y4\?3O\ /]?]@Y61[*>_ZC\?^GY_.=D3
MVV3]&W]/^GCRZJJDJ1W7XX_&OY:]Q322R*) 108B_<U[<GM\_P ]29Y>O]*Y
M/[_Z:K_?_P G)\_G[>>,!XM_]NA__4__ )Q^?W^W[M=!\(G_ .[W'Q*>/R%W
M]1Q^OZ2/XRNM7I<&C4,.=O(KW&].*2;C]Q9TDLF2 $^753#0CN%Z62Y1O(!S
M7N'U(B]"[MWW]E7C;?V?X>+G^(5Q\O$BR8CC.Q,B*X!&^AZN1\BK^HYYPG]H
M>9E8/03/B9,F/*LZ &)V1FNKY%=A^^OC56JZM:IIY343--U7SMDEKMONOW24
MWW_4GR]^.XCPCX;3>%Z-@4QW->/&>:Y[@US\? YXUQI?%WB.5(]_6LP;5('^
ML2*:OB_4.1VH\@=OKQ_9<U33_P"L3-4__"2V_P#BOQ_CX7_17PY_\&Z?_P#3
M1?\ V=+_ *4=?_\ C>;_ /4R?A_OZQ^RYJGMO^R)FNW]TEO_ /%<'^BOAS_X
M-T__ .FB_P#LZ/\ 2CK_ +=;S?\ ZF3_ .WK/[+>JGSU$S7QO_NCMD_7^VOE
M_3Y;'^BGAS_X-T__ .FB/X_X:_E[>]G^E'7_ /XYF_\ U,G_ /TTEU<U4^>H
MF:_IR2V]O;_?7Z.#_13PY_\ !NG\?_XT7[_3S^>C_2CK_P#\;S?_ *F3_P"W
MI?LN:I[[+J)FNZ^$3ZQV_E5]D_TU\U\;KX_';A1X4\.$B^B]/(YX.-%1'S]V
MCVOG]VO$GBGQ (V(ZYG6*[9,E]Q\.3S_ -=<TU:U2<C=M1,U1'(JHJY+;?::
MFZ.<C?4(JM394<J;HFWG9%3A?]$O#8;_ /!'3B?<?9X2*%>U$<_]^+J-_I=X
MEH7U?J '^]YTU<]C=V?I9K\ =835K5)>E/V0\U3J5%55R.X:B+LS==W'3=4<
M]&JB>=T7Y(B\>&\)>%Z/_P!R].)Y%'&@/N?;;P#5^W'!KG4@>*?%!4?_ 'MU
M)1M'J\Z=000!=@B[L631LG7)=5]4TWWU#S7=JKNGUBN/";JFZ+ZC9?.R[HNR
M]2;>_ /"/A@\CHN O'^&")0?BPJC\+(XKX'##^*O$B,-W6<YF XW3RD@<T 2
MW(_G^.DFK&J3OW&HF:N=\FIDEMNN[MO*^IV1-UWW5415V3]TJ(OO_1/PT+']
MT8!!!%''3B_C<" WU !')!%:5O&7BAU*'JN=L(^^DS@I[;^#9VCV]^W.N*:L
MZI*UJIJ)FNSEZ4_KEM5:GE$7=WJ=D5J;N<U539B=7LJ<*/"?AP *.C].M2&
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MCZ!AW_#GYTOV6]5/^Z'FO_*.V_\ BN$_T4\.=_[FZ?\ _31?PVUIS_2CK_\
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M')$9Q(:1T;!QA(<#!DS'C=LGP_C33#8JR2]0^UXX\P[558SY1D"K&$0+N9E
M75QU%<2#J&5! J1QQ]1(P A+&!:B,I)8EF#+O),I< E=O+7JQCZ)K!.9+2BD
MR'!.9VGU%7*6Z::/V6GMS.+=Q]+J33F/C$:!$TPK<=E(&KQK43"K*,8.:)T%
ML[DL@<Y92Q6(Q)^7)%*/-3RU;SIDF*CU2!7=8&7EK5854%A_M*#DL2:S?4A
M^5(((]D"%UCC&ZU8/NE=B39\R0V%)&T#:*')N.<GVVMW545'*JKNJK^/S7=?
MY???V6 6)-'M\6/RY'M_5^^F%C18C(H]8( )+$<FCPQ(^G;YURZ$^Y/X_P"?
MY)^O\.//Z_E_VXL_I]=>=[?(_P#*/Y=OZKVTNA-_;Q^=?Q]_/M^;SO\ AP<5
M]?\ MV^OX\5]=)O;Y_</Y?QTNAOW?RK_ "*G]/?[^#^N]?QO^NWQI?,;Z?\
ME7V_+];O7)$1/*)[_J_I]W'EONMQS8]OK_.N->XV)D6S[,.P'M]*[_F>#?SJ
M3?+VBI&R=53PLJO1%\_*.7YK^O[_ #Q@O%O_ +=#_P#J/_SC_'_O9UOO"/\
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M^%GD%C* 'SY0/X54O\:UW)HEG/OVJM?_ +_7Y^?[1YV3V7;S^=5X\?Z58?\
MP7';_$3S[\^6?KVXTO\ HGD\_M@>31V <>W&\Z7[".<_VNK^?^SU_P QY7Q_
ME^[@_P!*L+_A2?J;_P#[/?\ =H_T3RO>8>]>@=OC[_\ 5G7%VB&<JNW;JTV5
M%W]<J_=\^QX_#;=-_*_=PA\58G%12<'_ 'B+X/<>7[7\G7M/"N4F[]JIW+7W
M!8Y[_?\ W?OUV)HIG/3LH:Q%3=47X@OA47PO[Q\M]]D7S\E7;9/3^*\-A_L9
M 0+!!)-_%;!?TY%W1[WIN+PGFQEA]H4JX*D>77!X(OS".WO5Z;.1Z=99C/P5
M\RMD6/QW(*_'8RTHSVKX)[)LEXYMKVV(L&FC+'<DRQ(BBC.,%'IL7?CU#XFQ
MIUFJ-HV2)Y ) JV$H "@?6Q8;5%FA?M6GCX-E;=LGC#. KABP# #GGWXXYOW
M[:]J:8Y$EFE,Z=0MMW!4[:]UIO*4*+X*K$CN1&.\(G4_=>E?DO /$D'V=\AL
M2<*S>6S]X^002&VB^X])4?A\^?\ 13/\S' GC2+&E\P)18.. %W6*[&CM-W5
M #6T=HMG+EZ2,J_;QM/1VRK[KMV4]]]U7PB?G7AK_2W"#%1!,R!5 =?O71L!
M&"FB?^:OFQI9/">:SF43P@EW8JU_M QL D @;"/?OWH7K5V&FUY4L:EA98Y"
M(Y$Z&GN1,,]R*FZ,$HT>Y?ENQ'*BKNJ[(JHL?B>*0LL>#*Z^S!B3?/) C('!
M/&X]J' U(7P5U/)99'G5&2M@$;NI%5]^UH"P:KV]KUH%Q2XW>HD=,$UZL4\8
M%B8"*U>EZM,L15,UJHY%5B*JJS9NZ;+P^/$4/"F (>]-(BGW/;;Q?_,:^:]I
MI_L]ZE2M]MQ0S4'8WN937%;N/>N2?WZVL?3JWFC:^)<X[(1[QQE8RV&JMD*Q
M2H$HFB;VI"C7N(QZ,>YB(J(KMFIXE\2(DA#8<H4H#96F%,;<,0 RGL:'!'<@
M:JX?!>; =CY!D03RRA1&10D55V7O-5ML>GD&MNMA'TJR4Z26AF4)213%B2&"
MMTZ@RF-:10D:@VJAA-<C]G(B(U=E=PC>*,1028)R0 5](  8WM):QR*L\618
M [:]0>"LE8UA^VJ#M 93CMSL V-:R$\^_ [T:US_ &)\K>=D9LJD'(4CF#$M
MJUA7N&U'N8-$8TKMF;*Y&;NZ/*IMPT/%&.JJQPY*)W26ZB@>#(!Y; V3V[#O
MNO2+X5ZEY3DN R,8Z*-M\DDDR!]UVS7Z"%X).XU6O0NBN:_OJ?"^ENQ%>D_J
M395W5?WO[O"(BN541-U15X5O%N([B,02@4*8L.3?<*%ON. 2.W<:(O">1"&+
M3BFL2?LR"%YL >8=Q )JZL\6 =<W:,YLUKB.6JV<US%=\0:BHCT5FR?D"(J.
M3QLJ[>5ZFK]E4:?Q;A*@$D4B,Y.YBP.R0?=[H-Q:_P#EVU_BOCVWA3(:3'9<
MI8$CL2@1%B(_20HMTO<1ZCP!?8WIN8GRRS<%HQX_AF-XIB]"V;8VS*FB4$"
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M&%Z#CJP@UV>JB7J6_P"F^&L\N9LJ7RD*KLCX=@%X-"RBD6#R0010!(UNND^
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M.Q033N$@C>1CQ2AC7?O0('XGVU5)K_\ 2BXO1.ML>T)B4N;643N16Y=837?
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M4D T31L?CP%H6;.IE8IGU-5P+"QFV-58T1"3[F\')JVUX*YAD!&IV')*!%'
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M1'F0QR?XVE,8;:S<D(T8#* ; 4=N.UFZ?)P_M8(EBAG@/I,>2BJX(X)4A58
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MUWGI&$O3,.*<^4I0M%&@!L+O8$D4.;!(()[WWXUNH 6NG!G&D0R088IEKV$
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M,MAX^"TTX00Q!)F&$SE'+S?LWB8 H[LN[8R[>3V;9HEQF<,THAD$;7NOS*+
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MG>5';=]PD$FK[7S1Y-"K.B;:Z/:>801K\QS6MK;J6>1(FX;0,3)9E)%$@[*
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MCX[F9STF!QN$,3MN ^Y)2@QLW/J%_=)NE[42=76\<\U@-+@T:8F;_O\ A?\
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MS(F*TE,48LI8$7[2!!$=Y?RZQ_VJ  .2SFR:[ D(+)(KV/L8T8KKE*E0LGM
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M6=#62!4"V262 K2F4CEB%4T=7]]6,$09FF:Y=MG1)UJ1F*^4(ON2;2-Q3:P
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M=0).<Z@2=.,F)>QZO'I4? Y-96Y#4Q''9,DY=34L9CV6,AWIGS!H4#T(-AI
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M2HHN_(:X<K=ZR72U<Q=E>%C7$:O%KCX4,,"0I.TJPLZR%U!9E4E0K-2D%?\
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MA4 1V[2B0TQ#*#W'(#.2%!-4*(JM-0P11X16(;)F(6&(A1YC':)&=C3);[V
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M$VK$IO8*:%!E)')((T!-<=*]2N7/-<ER<^12;F!J-3RYV$9]@=H.RH<@E3I
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M2/ALF,KS*Z2UQ9!'M&YA$1%1J-:B(B9_QHAR<."!I!LS^K]-@<*?4NV4+(K
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MK V6\LEH_,')4>4PO=1JN#8U]'_V?^3G>'(ED(>18F$P8@[%#I&#N(IFW5N
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MY)1HHU[BLC39IBCW:KP$(KP/"XK7"<C>AR>.+?&<K!$7LHZ!0-H;L"52CS1
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M'(PDDNQZ220#0XH<\?0GZ4-QR3J1E8,NJX60:95P,CR'."SX@70Y=;1NLI5
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M;(X0B&B""Q7?91BD;1X,,19$> [E96W%0 @O[JK5$N!NW$CW')(U=YL&1'C
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M%F4(:#21Q;]I8*:][J]9K$Z@J,$FB+12!E+#LB-P=W!'8\BKJ^3W-@\7G T
MYL<YPG&.93ENJ:Z1DUN+'*O5_$.W L 73C(.,DLQ^I)\,1W1DF@4\Y(QBHYP
MU>J.3"GPOUOPUAY>3T7KTCC'C:>3I>02RF$]PBC[EC>4;8F\ C=[:]'%,*2)
MTK)DD63=(D>9MEQR\8LA2@1PPKCU$#@#WTQ-9,'Y7BY_J1RZZ>,R336ZI<G/
M.DZC7<V-+Q3)\AI8CBR,7M*HK!M92PT.^3%$!J*D[]LOC$$G2V1TS.\0IA]/
MZWG_ &?J$,D"HN#"I&5C0RM0R8I19\QR-C%N"E*&4FS9XB94V.F3D.(YI<=-
MZHA2 WML*26W,>*&X"A5DZ@%EN@VJ@=1,>QFDTORPLR2M'":R\%)?1Y%*8P9
M)]G6V$)S8J4]R1KC1U@RB**(YW2]IE5K-]@]?Z9_=V1D3]1QE"^<X\C;YV.I
M)\N.5'MO.B%!MZUNJP5[TV9TZ1\E#& T6X"0LW- TU<$!>]]^+N^+;6K&-6M
M''^!7D.J@974S9XQ8921ID.'AD(-MO*/(8I&MLY]W8>!AFED270P-(0I%4:#
MD]*S8IW,\3R-BR(A.5*RLV8[1>A5-7&D,?=D"KN:@!S?G(Z<Z1*(_40WI"V:
M/![]B!V_=>MK\.S/4VPK\2Q3(I4NKJ[ V27EU?2RQXQVQHT,4C+LA>1!PX$:
MD&,</'VF3K$(3!16K)*Y%:^TX?34ER<G'5))8U@@BA4,5+,Q&-!1+L922\]<
M$DL?2->TZ5+*D9EDV[22XXL]Z  ]R;)X[]]/K3#4:SN*G.L=R2X)>3:;(@V<
M:_>^25]G"F&^&V2![R*JQ9*UT:?!5-I$ASB=:IU;MJ^M],C63IN9!"N.)H"C
M0@*!&ZIOCNB0&7>4;_"NT4!5&U\/9K0/GX*/O,8*,31VVP*"Q?)Y^?:C[ZO3
M^BI&Z/DNL0NAJ '38HD3N$[[^T\LI[D<]W4U-D[2="-:YFVSE>OE.0>/98_L
M_2M];FDRSV"T5\H$"J[V"?J/;65\<"4RX1#?>$I/M9VQ<_OX^0?;D:N0S/\
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M+NKU#K)PU<O+3V\D--?UUA+?71V8A /AD*=; BR8IBT(CQI<F7!A%9 6PFM
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M6OIV#S\D-DM/8%L*VR5*^*CH-)+>T&0O.20B-(X->\[WHJ4N<0JQQ1X<D64
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M:10TVYR5+5M0LP)([J2-)TW)ESLZ>"+$")@QN5;S H51*JGS"Y .Y@E$[C[
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M: ^:[$C]*FLYF@IW&QVVBSXW::D2;%*B+)'D (T$###"P36 B2 C-'9'>C$
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M V!:DT"#$HA_8:C>AB-:FS6^$1&M141&M3[*-\>$3?SQB@ &+=P39!]S\WK
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M>QX(^1\'73( $X2A*(91D$0;QD8US'L>U6N8YKD5%:Y%5'(J;*B^4X]6>:+
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MDD[0>!9/ &N/3S2Y,KSY#F6:1MSR,22S'WL\U\#V  ]M.3H9OOT-W^_I3?\
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M<D\&_>OY\:]'GV'\_P!]?NUV?4;$?X/UG^#,3]?CS^GAV_PY_KCC^%:\T/\
MN2?X]N_MI?4;$?X/UG^##_FX-%#Z_J?YZ7U&Q'^#]9_@H_YN#1M'U_4_STOJ
M-B/\'ZS_  8?\W!HVCZ_J?YZ7U&Q'^#]9_@H_P";@T4/K^I_GI?4;$?X/UG^
M##_FX-%#Z_J?YZRN#8>OOCE1_@8OYN%!*_=X_#Z7_,Z6OZL_C_7Z=M=;L!PI
MW[K&*9?SP0_^[PN][O<P;Y!_K^&DVCX_K_/_ "]M=3M/,'5=_JM2>^Z_M /G
M\_V?Y=_?CV)YU-B5Q7;D\?Y?NUY,:&K';ZG^>MI58OCU&4AJ:EK:LIFM&<L*
M(*.4PV+U-81XV-<YK7;*C554_BX\2R2S,K22.Y4WZB3^7>AKT  *'8"AK?\
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*\J;O]1_7;\?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g40894g54a54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g54a54.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1O$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &ZB^<( X0DE-! 0      &$< 5H  QLE1QP"   "   < E  "')R-C T
M.#DP' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@4&5R<V5V97)A;F-E
M("T@1F]R;2!3+30@7T=0(#4N,3$N,C%?7S%? #A"24T$)0      $)%F[<T[
M^2P\;_QU'>MH61HX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q :0            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              (=   $UP         !
M      $             !-<   (=                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     $2@    !    H
M $8   '@  "#0   $0P &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( $8 H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MP]1CKOT>_8U]EN_TKK+6?X"U:^%UC$R+*L9A>ZQS)#GMB0$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MV[C]I[]HS2$]1)I!Y])P:DT?<K1J#3,=?<:2AO5EO])]YI*D4USI*V."G]O
ML'CD1*"RMN)JRI(JD[;5HT%[51ZS4\Q"7D1"AL.TD7^)A[DD<M=CZ<]0N#T"
MU%/I*X7"C[W:IM?J"N??<>HNK[S673UGMEKJ.X::9@T;'9JKMM!/^A*_MU)H
MRFI].5VG*VX37&MIXS<VU M[*5R8()(5B$,C HCHV\EUD$@]9=;6SP-O(VU]
M>B18I2^]0(V9"H6@PV7LY(/JY-D<M=&NB1VG],?<&V][4]17?SNQ8NZ/=.S]
MN+SVJT?'HCMS'VST;IG2FH[_ &74>H9Q;*G4VM+Y>+]>:[3=B2>KN6H&M]#3
M4)CMELIWJJF0[%J..546FF\LRM8IC$KK'M6O30<WZCWXH=>,-Y0M=1%S&-QH
M"0C?8(_Z154* Y-]757.T9\X'U_X\Y^N?GUBM@4?;^G]_P!WUEUSU[T=+HZ.
MET='2Z.CI='1TNCHZ71T=+HZ.ET='2Z.CI='1TNCHZ71T=+HZ.ET='2Z.CI=
M'1TB >#T='53?6_VTUOWE]*'?+MAVZMM#>-<ZOT956O2]JN-S@LM#<+HM915
MD%'4W:I#4UOCJ%I9(Q5SJ8HV*[@<]&U6*%@:#JW>N596[_H/Z?7I1@3B&8R,
M10BG3D7?F021CCW_ !?IW/SU5_7FA?5;ZL;1VZ[1=S>QNF_3YV>LFO>V>M.Y
M5_KN\%A[BZNU7;^UFI+1K?3^E-&V325G_1] +SJS35A%]O&H+E :2SK514%#
M65%0'I\T<QZB<Q^V.\LF)M;;ZY$9"911W"G)"D]Q^($#I)$QBQ41""TL/D2A
ME# )0'H)JF(4 ,.>.1U&N\?8CO[J>[]Q]$=Q/2UV$]:VBM3ZGOUX[1=P^Y&I
M=&Z,U%VPL6H(O=I]'ZOH+AH6X7=[?HZX-4Q6+46A[A6WROM!A%51PW.G:HF0
M+428\<:LD_FN\TB':)-T[R*7 /JVQL%HWPO!Z4!EWD$MY0B"JK>L7M - B@&
M-GE35_GTYIZ<O4[VJ[:=BM%R6G0WK/T'H_LI2=LN[_9SNG=;-:1?-6V^JBJ*
M'N/H_4^N=/ZBI+I414,U?I6NM&LJVF-;8HK;<!7BY15L4ZZ6GS,G(])CE2!8
MUV48VB\TN5%T/,\P77NH[5930@Q11J"Z,K-85J0JVW:I5>"%(-7\\]^C)Z%/
M3CJSL+_INO=\T=I3LWI[N[KZW:NT9Z>= W]]0Z,[0VVW:;H;-7QT-5%06NQ4
MUZU=<89KYJ*WZ2MU+IJDJ_86A-5,:JMG]9V8*&9GV@@%N37%"R2:_IUGM4$E
M5 +&R0 .?K\_GR3[]; .L.O>ET='2Z.CI='1TNCHZ71T=+HZ.ET='2Z.CI='
M1TNCHZ71T=+HZ.ET='2Z.CI='1TNCHZ71T=+HZ.D3@$_3KQNQ_(_TZ.M8_VL
M.B-.]S_3#I?MWJNGFJM,ZY]27IDTQ>X(*B2CJ7MMZ[TZ1H*K[M60/'/1U<<4
M[R4M7 ZS4U0D4T;*T8)U*2^=@1+PTDCLK$G:NU"QW5SSP!0)O\^O0."3V'?F
MCR:L?/S7\??JE<_=?6>F_4+Z,/2OWNJVO7>WTZ]^]<7#3][J3[%3WG[&S>F_
MO52]O>Z-N;(-3= E#)I+7T,&YK=JVV33506FO%"TBS#G1ILW-B1A-'X:SX,B
M)@MG(DR]-)>(61L)C9@6VL 6XX ZQFC55BC<G[MD:DJP,I)90%=@LIX%^KLE
MV +'4ZT9Z@_4?3=D/37ZU[OWTFOT/?3O1VRT9JCTZR:<TC%H&WZ/[I=S5[?4
MNG-#55';5UK2:ZT135]'>+S=*^_W87*HLU[CJ;534N(Z?6JAI<:!>'EPX9F8
MGT;_ +NLLU&MW+;MHKO0L<GKP,';*->F'*R(5L"RL<SQ(2!8HJ!R/8@5SU<3
MUV6^@O&M?0Y;+E04=RHJKU=6&*>CN-+!6T=0H[9]R)-DU-4)+#(OP%E5XV&Y
M5(PP!"."7_\ /M(4AM@CUX/VHE="S&C/?_/5<<$'VZW9/_\ #^LU_P QI= "
M>]!M>P5D[?\ 03=>W0A]0.G]!]KO79Z6;[H.AMVB[_K+MCZCK=WH;1=OCHJF
MM[-:1TC;M06V^7^TV6G$E8^FM:M0QZ;N$E'/5155TK:"B9S524[[T"&/599'
M98TT^$^F_,!\S*!:,BQN%CL+[<CVQD=_+QD4>J34HI%9N4VPHIF5^Q]09-H[
M6#?UI;1Z*U!V8],6A+]K'MQV.]37HVTW?M%]S=*^H_M+>[GVP]3=FLL^M:+4
M.G^YMTLMYL\L&JM:VZJK::HU-/9=86>^:B#7&F>U25-5);9/<6B8%R"8W?8,
M80V5E)V[/O ->EA6ZBPLWS?&,Q#^?Y!*4',HELDU881%=U&NVX+SP:(ZL)>-
M =P+[WX]5'<GTYV/TX^JO3>IKY9-(][>T??R&^:+[E=OM3Z;[?6:%]&Z1US4
MZ6U':Y='7?3ESM=]M]JN=G@MGZ7O=WJJ:^2K+5?=DBD[)I'#?=5SLXRRGB>-
M\?):&5,<7_RUD1O*)*[5Y%!K.UBICQDHK,8(S&;'E["MJ9:L[^>:!Y)JZXOW
MZ#M4:&U;Z5^U5Q[<6#5FE-(T%LK]-6_2VM;S_.*_:9J=*7BOTY==.R7\5-9%
M>J"QW6V5ELM%SIJF6DK;72T=12-]WDB =LN,QR*+#(T,$L3B[>.:))49[LB2
MGVN+/*\$BB4L8(:4,;<2'>1^'=0_#PO%5[?SOJW_ $FZV]+HZ.ET='2Z.CI=
M'1TNCHZ71T=+HZ.ET='2Z.CI='1TNCHZ71T=+HZ.ET='2Z.CKJ[!%+'P/\_/
MC_/'/'1T=5 U=Z\_2SH;7E3VZU)W*-'?;?J6W:+O5RATIK.OT1IS6%VJ*:DM
M^E=3=QZ#3U3H'3NH:FJKJ"G2T7G4E%7":NHT>%6J8@_L0,LBQ(+>1PD:^[N0
M2%6KMJ4\?ES\9,K*LC%3MCA:=C["-"H/UOU @5V[UVZPM5_: ^E#1FL-1Z"U
M#W2AH=2:.UE1:!UFL>F=85UHT3J:Y4MIK+72ZTU%;]/U5@TE1W6&]VQ;9=]0
M7*WVBOGJ?N]+6RS05,</J@&%<DLH@:22,.30:2*402(O'++*P0@=SP#VZ\=6
M!D0<ND,4Y4&SY<R&56!^D8+-_E /OT%K[]HEI0=S_5?VJIEI-'U?IL?LBD6M
M=<:5[DMI"^?Z3KE::&[BLK;7I=*:$PU-XH+/I@T5?6QWFKKH[NKM9J6MGI]$
M1;(CD=* 74(\#:Y"N9F>(%0MV13\'CFMU;AUG.@QV@4D2-/ITNHHT1#*8D$H
M!+#BP8[8 G@4.0:N[WB[O:4[%]I]==W]>3U%-I7M]I6XZKO<M'#]XJI:*VT[
M3FEH8-Z?>+A72[*.AI_<4S5=1!$&!8'KS(F3' )1Z,JPJ!1)=B *KFK/<B^Y
MKVZQQHVR&5 R@LAD)/I"J%+$V0+H"Z'/MW(ZI]%WI]>=OTY;.\%\]//:FN[<
MUT%HNM=V;TKK;5=W]05ATY<JBG>IK5JI-/0Z#U!JBT6NH-97Z0H):>.2IIYZ
M*WZ@J9%C>90RB*9X96$H,A1)( 2A[42) AVW?-#^AZPM9%#1$J-NX^8!=<\4
M+H_GVKGF^L?6'?OU9:L]3G<KLCV$M/I^L^G.VG;'M3KJXWGO1)W 6]W*O[FS
MZPC%#1TFD6^ZP0VR/2V)UJ=U0TM4&!*#K0A=ILE3MVX\D<14&V9I8S(".*X"
M$62+-T*!(R:E7&[DSPRRCZ+%(L9L7P;=30L4>3R.O'N'WL]9-E[E]A.PVD[3
MZ:ZGNKW#[:=TNXFN-07V;N0>W])#H&^:/M5-0Z6I[:/T_,U;#JN"66:[ *)*
M:6-'"E2VP'?/)$/V?DP).X?N5DE$0K;NHJYL[JH=B>W6,E)%%*02)<A\=0*L
M,D1F)-D#;2U0)-U8JZ)_IC]1?<3N#W)[Y=@.]&E=(6CNOV'?05;>K[VVNEUN
MG;_5-A[DV:JO6GJRU)?X*6^V>[4:T%91WBRW)9S"\5/64M944M9&(L8W$D+3
M $!<EL4J1ZMRJC%^"1L]8 NC8/%<]#CRYHX>YDQ%R]PL!5:::'RR31,EPESM
M!7:0=Q)-7:ZSZ]Z71T=+HZ.ET='2Z.CI='1TNCHZ71T=+HZ.ET='2Z.CI='1
MTNCHZ71T=+HZ.JM]]_4L>U&M-"]IM&=MM1]X.\G<>PZLU7IC0MAN^G=,TL.E
M-$362CU+J34&I]4U]#;+7;:.OU+8;;#'#%<;A5UUSA6&A:%)YHL-X+R1H"\D
M4<<KH*!"32-%$;8@$R2HR#FA1+E5YZR*A421V"+([QH39W-$BRR\ '_EQ$.;
MY(X6V-=1W1_JAU=W T1W+GTKZ?\ 6L7>GM/J:V:3U9V3U3J/2>FZR2NNE!;;
MQ37*P:\^^U^CKWIVKL]R6OM]WI*S,[TU30U%+25T#TXR[Q"8<KYLD$GL8IHA
M&TJ,#W,:RQL63<K!AM8T0-3$K*8CZ7,23Q@D$2P3&189%VV5\QH9 %?:ZE2'
M5=PZ %K^T.UC3]Q^\';77GIBU)H^Y=D.RE][U=PKG:NY_;_7=JTW1T%OJ*_3
MVDK]4V"=8[1JK6-)0UE;9J"<M*MMA%RJXXJ.2*63&:008V1E,"\4#1J-A&Z4
MR-M'EAJNB03=&O;XR$;&;'B1D5\@.Q#!JB" ,3)Q[[O3M!OL*H]3737VBO:O
M67HGK/6IIK3.I:W3MIHK.NH^W-9]RM^NM,Z@KM3V;2MRTK?:6IE6GH;O9ZZ\
M15#^Z4@K;>(J^B>:FJZ:23.<+%Y.ZF&1/!CH%[B:?(7&5&#$ %)6J06:"FBQ
M(!U0R!UE)W*L4,N02U>J".!\D.AOD/$A*$U98 @4:O\ 5-?245NDN%7/%345
M/2S5U553R)%!3TL$35%1--*Y6.*..)7>1V*QHJL6*J"1X!R :)O;8[V25'<7
M5]S^?TO8&WA*L;PI6^." 19%D<'VOJF/9/UV]HN^UQ]1C=OZ#5UYTMZ=TL4E
MRU73:>N$U/KZGN^E:S51N';JSQT_Z;U-:S3TLE#:+A1T+T^I:H*]@>NI7AJ)
M?#Z,%<YF]#YV5@A:);S<6.!V("WZ7\\!>Q])L %2=CHRY?W8 $MCP3J;  65
MYTIB30*^59HF@?>C4?T5ZZJ6LU=!ION]V1[E=B4U)VMUIWK[?5FL*C3EYJ-2
M=N^WT=FJ=4/>+%IBZ7.[Z.U;;:/4%LKI=+7:E>J,$S4_WEKC3S4<?A+!)G/+
M0(LDD((+K&\B1(U@[/QR*M!B>>1[]8FAL)8>7)/]V26FVF7RY):[!@!'$[60
M.U=<]N_70^H]8=M;)W&[#=Q>S&DN^-LNMT[+ZXUA=M(5]'JB*TZ<FUG^CM3V
M6RWBKO>@K[<-'4M;J*@M5\IY#]TH:RGJJBEN-/)1KD#<F3'V.)"9YR>R1BK)
MJSQ8)-5WZRD3:RB-A,'E6!'CNG=N %#@,23P+%DU?69VQ];DO<O5';Z:A[!]
MTJ'LWW@KZ^V=JN]8-BNUHOS4=-<JVCO.I-*6BNJ=3:%TKJ:BM514:5U'?J-*
M.Y++01U8MTMRHHYLU4EWB<K%D+&TJ0.?5+$L*Y!=&7<@N-A2NRMN!4@-QUJD
M81\J/,42I"[I6U)'F\@J=VTTL@]94$ <\\]7P1Q("1G@D$$8(. ?[B#^_K$?
M^>;H_''6?7?HZ.ET='2Z.CI='1TNCHZ71T=+HZ.ET='77>G^TO/CXAS_ &]8
M[E(!!%,:!^3].BC=5S\>_P##KG<I. P)^F1G^'7NY;VV+[U?/1USD?7QYZ 0
M>QOFOU'1TLCZCQG]WU_9U[T=<9&,Y&#X.1C^/1T=+(^H_CUX2!W('Y]'7/7O
M1TNCHZX8J 2Q 'C)X\\#]YSQUXW8US?'\>.CH?=P^V.A^ZUGM6G]>V*._P!I
MLNJ=+:WMM+)67"C%)JC1%]HM2:8NJRVRKHYY'M=ZM])6I332R4=281#64U33
MO)"XH"R1RC\<5[&^"11K\Q_WOKPV5:CW![>XYKO^GMS?''48UIV$[/\ <#N7
MVP[QZLT-:KUW/[,U%\J.VFLI)*V"[Z7&I[7+9M004[T=73P5E'<[?,\4]%<X
M*ZD20)4P0PU2),/87:!I9$4C[S$<=^"?0QW,#[ $JO-#M^G7C#S4CC+\0R"=
M1_UJ*L'Y(/\ OVZ&VGO1'Z6=+=QZ/NK8^TEKH=86[4%?JZSC].:KJ=*:>U==
MOO#775FFNWU7?I]!:;U1<GK*R6OU#8]-4%WJJBJJJB>L>:>1WP7D1R&PRQ[
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M%=J>.":2G6-86:/KR@5*CD$ROY9'H)F<R.74CDLQW-=62>.>@<;#[HH53R2
M![?S^3[&_>P6B](Z5[?Z9LVC-%V.UZ7TMIR@I;38M/6>EBH;9:+=1PI#345%
M2Q!8XX8T48V@EF)9BSLS-GYF\G<X+*%5@3^':H 47V50  .P' Z #RU?B-DT
M1=UR?K\]2G(^H_B.LNCI9'G(Q]<]'1UP70<EEY\<CG]G//[NO-R\<CD[1_\
MBYX_/@]>T?@]<AE/@@_O_+/]QST6.>1QWY[<7S\<$'GV-]>=+(/@@_OZ+%U[
M]'2W+_M#^(Z+%U8OXOGHZ61]1_'KWHZX#J20&4D>1D9'CS_$?Q'6.]2Q4,-P
M )%\@&J/ZV*^;'1[7[<\_EWZY#*3@$$XS@'Y?Y(_CUET?7V/8_/2W+G&Y<_3
M(S_#HZ*/QTMRX)W# \G(P/VGY?OZ.W1UP&4@$,I#?A.1AOV?7]W0.18Y'>QR
M*^;'7E@$"^3VZYW*?!!\_,?+S_#Y]'7O74R1J,LZ@?4L,>0/[R!^_KRQ\CCO
M].O0">P)_($_TZ1EC! +J"W@$CG]G^>.@LH(4D;CV%BSP3V[]@3UYTED1QE7
M5ASR"#X)!\?0@@_0CGH!!NO8D'\QWZ/:_;Y]OX]=)60H<L#@C@$$_O&?EYY^
MGUZ+''(Y) Y[D=Z^>O0"> .OSB>JCT[>LWNY:O4+I&Y=IN]?<+5=P[VTFLNV
MM;9.\&D=$>F2G[0VCN1IK4-@_1O;^QZAL]TU3W-CT_:ZN*[4FN+#6_I&]2-7
M5-Z%-3T,,.W <0ZAIN0];<#4(LM[-*Z!74H0!;  W7N:ZW3S(L&5&H]38$\:
MTA9FD;RU"6>SV#1LT+';GJUNN?35W@O?8C[5'2]%V\GJ=2^H3N;=[]VIH#4V
MA)]9VJ7M3VOLEOJHYS6F*E6"]V.\4<*72:DE26C:4!(YHI60S0LVDX>&DA+Q
M:IE93;39$>1KBZAR;/\ ]DE31L*M$< =8P,L&9DSL-Z/I20@'WF?29L4JH[E
MHY9!N%?C'M5]#7OYZ=._UYO_ *S=/:=[2Z@U#0]\]->BF^Z&U7;[CIR.R&M[
M)W_15#K[35W2LO5-=*&^TE+1U]XMRK;I;;66ZDGVURU;"!\W0&;*E$E1P^)<
M/.0 D^;%*<))2A%AA$8W+?'-^]XH=F'I2E6:6/PSJ.GS4IM,ACGRPJ17#/YT
M:J!?( '/:Z'?+T6ZU[U]N^_.BKMZF.[5XL_=S1EZLVG-#:GMG;230?;V_3UM
MOO>F[E:1IW05BUE6TUBNUKI(12W;5ER%3;9JV.I::IECJ(\U(5%'EB5L;,:=
M3(AN7U!@OL&13^$CGEN>U:\93$\+EF'[ QR D7Z@;# ]F]7-#DBN.JN>H337
MJ7]1?;:F[5WOTD]X-&^H2U:-N6D]-]YM$^IJ3078G2=^N=*EO_TC)7Z'[B6'
M4.K*.VUD<&HZ'26I.WEPN8BB%G;;[D\LGLI+S1/M-"4.VWD <78Y)'Y]KY]^
MC'79&%)!(B(-CL?CGLWZT/;GCHAV_P!!.B^Z/JQ[I:W]2W:&R=SM.)Z?O3=H
MG16L]13SU,5SU/HV'N!'KU:-*6ZP7*.5*BX6BKGGN$"B<UD9@D>03E?8SMFU
M!AZ3)E8\D1K@JN/*A9;L$*6*GX) /-=>N><"N\>+DHU?N,^1$X4\5;!=PX/
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M,[S._P"%8BB,X8D(1R#5=)\57&DP^8")\;2YX94()DGB;3YHUQU2[:4.44
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MMB]4NJ7M]NB666=]"]KU14? 4_\ J5RQ)PH(&X^//PUQG>(\#!G7'>7<[&@
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MD<5MX[@^]4!IK_YPS]L"!_UO]0MQD'^8?:XDY_9HL ?P^8XXY=*X'UOX^O\
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M.@>UN?BP3DC10)QCX<GX02!QT=9\_P!C_OUQ_P XA^V#_P#;!OW_ , ]K_\
MZ-Z.CI?\XA^V#_\ ;!OW_P !=K__ *,Z.CKD?RB#[8,D#_E@W[_X"[7_ /T9
M_CT=>'BS\<]>P_E#7VP9('_+!U /GQH+M=_]%GG&>/WGQT=:]Y^!US_SAG[8
M08_^^!J#Y^=!=KOW#/\ ,SG^_P#;T= D/N+_ )?Z?T^OZ+_G#/VPF>?6#J 8
MY_\ 4+M=R?E_^3/K^[HZ/,/Q_7Y_I_IS?63#_*%OM@'=%;U@:@YSG&A.UX/
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MQGK;=-;*8*&^\56Q$('@,-^X$@\<$X'[.KFTWP/KZ1.=9PQ@Q!?V9D"["O\
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MV.\4\@B0R1@$KY(4EY&O>30 H=:NJBS5<8,"T%0T,9W/-*KJ6?GXPS#@#.T
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M2\O(;)T@MF9.(GWA\9\5X=[J0(XYUG5&!95/"JQ-40;YMIJGM11Z.^QQ]?\
M1:9U33ZJL-V[S^F6>WWG%)'+.MNU541U2U*T\TK&8S5;"%)C[SJ@*@[N)'X
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M]"TG7!]UPW;,PXL<%954DWZN6:7:UAB";W 4:H#D>Z9I;82C=E2J"S.T999
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M!P //C'DD_N\\_OR?'GHZ.NS(RXW#&? )&?WCR/W]'1UV$3D CP?SQ]?[_\
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MM($9E=I(SEOB5F.WG@G('RR<\]5UX8\5ZI/K6",6?S(YD+3;C^%B02%(//-
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MDN%/!&\8GFF58_U22)(P@*M(/<'Q@(">HUK^EG2?O<-2/)"C,H\L@$)R+-D
M&OY@&O9BUWQI)@@1)CN6$;<M04OL(4#<!?KJ_D @<\];^-=>A?L6O8^P5]F@
MMM'2"UVJ2:_34U,9:*BJ*6%KM<YYX@:NYUH^,PPF90DAQ& 0!URCB^/]4E\4
MY^G!,A1"\C1+N??+**,4-$^7'&#89R"" #5=^<,?QQXMPLG'UR74YM1^_9$L
M9TP6L<<A,FR  RD!4=/+.R($@776L7OQV;O79BXZ0:U2U::%U%7I'IJ>"2:G
MM]SMP$8-?-B8%I9(O::6-L/$"^"?A8W'X1\39,QU,Z=/)#K@A>++:.2Y$&T%
ML=JH^EN5(L$4PHBNK&\+^),7Q-CYDV:D@SL6)_O".@$L4CM,K)$Q +1F572Q
M:[K4\FNJ]=V-5V'4%XMT%GIXY#9H4H:BME!E@JGI965/N<3[I8Z=5& )VDD+
M;B249<3/PEX:R\DY.3G93.9JD92)'<VW)<D ES]%  XKJ6^'\3,Q\68/N@CF
M9YHHE(W@2"RTC !6<BKVTI  H'HT)34U[TA8;Q51*]S$=+$R0TPIX_816_6,
MD<:HS")5&\K]<X\GJ?2O">C8FA:7E+C[\AIHXF\R*D"!'?S"2#ZO2*Y[61V'
M23%TM,34@DT8F@G8LTDK7M=UW[=I) 4,"H)^GR1T1-5]Q+KI'MY7730MPJK?
M5/!245SIJ::8)5)%.BHLJ1X$JKEG$3JH0_$"<#/OVK^#O"_C+P[A9^'!BIGZ
M9-'$5CBVSE+160E5&X@J=K6=VX#O?3+-X5T[6-=V3)'MB+[CL0!BQ6_+445*
M@]R#VX;MT.=&=S]?=P[S=C<[;;[Q47JTQT%1^E*+9%3TX01AH(Z4P"&4[228
MD&]N92QRW55Z3]C\6K:GB1X $8CB$F0LL9!"K1)]/"@"P3SR:%^ZO.\%8^"<
M:/%G,4<#K(6!906L4"+8L1V%GM8L>T0@IM<=MK[<]ERFM%AK6J;?*]!*JAH*
MGAH&5D=E0*3^"0-@8&#U.-1^S2/'SX#K"B7!P:QL7T7&"NT^DL!8'=>+[ CL
M#)SX=TS5HL;[SLG?&1+)W;BRV+/-+9%]V]O>NO&U:8U!I36EKN]EDI*\W035
M4;U]+#513QET=X:BEGCE#QR;PTK%0I"^3GKS4_LXQL_,P\*,LD63$[1QQJ?V
MJ!E"$J&["R.Q-<CGKW-TK3M1PVT\Y,V(N(M%4+;E%4K!PZ"Q^Z-Q()J@>>C]
M:^]&L+%='LM18[/#0J'-VNM#1FB%-3RR&20K# (4>-US$D:X"APHRH'57>,/
ML=BQLA1IKR)G02Q@*5D5*\P!R=K$<(6KTB^%XLU6VL?9[A^AH,[)RI95+X\,
MI)WR*IVBV:2B" Y[EMHJB>>FI;+H77=WTW604E-&MSK4_G!34]-+%%1T#;PT
MLA3W9%FE^$R,%W+(^T%E&XVCXA\%:7H7@G#RO">DKF>(Y,>$:B<9&,TA95\Y
MG7R[4(Y90>=X :A=!0F#JGA[16?(DF.3"0(RS JE%F55YIAMVD&E"GZ]ICJ;
MM'6=O])?I&IJJ6VT ME0]FI:4FIFN=/-5^\E/(\>TQ3PQNC,[9WA@"/D.7(M
M0C.IZABY*Y,0P)UQ=0C\MS]X:7?L4B^2A1@23].*(,,P_$46N9RP1QN\OFA9
M'>E,;**+<@ J6M>0!P:["M5/<QOOM[^^!9F=&D)CD&'09/PN449"D>2N?J2>
M3*Y=).&H$ 8P, \89&4JK@,%(-U0/\?IUTUX4++@&)F4* NT[CR:YKOSQR>;
M/MSU)>VUULD=DND=Q$"SBNM4D-+)$C32H9)!4F.;*[%B0J6'DYSC@]+/#>.S
M:SC2R!66&6 [6[$29$<4GN>5C=C55[7QTC\1X.5+G8+0DF-]T<U,=I7<" P[
M<[N3V-7WZO\ ::[DU36*MH>W%UHJF>DL\ULNUJJ6*4M5;ZRAEIYX)V1M^Q%E
M,B,BAO<B4 @G(ZQ\8:5I_COPBNDZ'DPC4?#WW?(@#BO)D6$#>"O(*@@\$7W)
M! N&:_X0T_/R(LK,AO)Q\B.;%E3O%-%*)$4J!MM@IVD6%/!H$U1[5MHJK6(I
M*UW-;[[)E69HQMSPFXME0,JN6R5'CGJM]2T2.+ Q(=17S<J-$A,M62P0*2#R
M>2"3S]>_>?1X\*8<$3^I]BINH$$D6+X!XXX('/Q[#U[%6U-1[2Q>R)I"V]PT
M<$:$G<\DS#:D:^&<GS]">H%J>@_X?!)(79(MQ( 0G8I)(LWP%^@J_GCI8V7]
MT79)9"#8*KFN.![\<\?KWZPJ>T5!JA#[;3)%,!(Z,WLE V&/OH"JJPY# \9/
M'R,=.)%/C.R7*8X_,4[2?4&H 7?T^A- U[>3:C N,\I(5]I"CC>#7!HD-=FO
M:^#R.MYGI^TJ:;[&'[2NGMU3#<'NG?CT="G2G]P*B"_7@+"#)&K/L:HV;@"I
M92RG(&<-,TW6\K,TV#*Q'BES2XQ!)0#(@&XW78+R./H.]]9Z+G-/BS-)&Z%*
M ,B@%CN-O5\ FZ^OTZHAI*VW[MQIRAM6H:=S'<(_>IU12RJDV6'X@.%SR<8R
M./J>NM'&?X2TZ/#U&,O#DQ[$5:-.%'?OM(!H_%7WZ;9ON^7-YB2!FA8C=78D
MW5^X(OGWJ^_5E-,WB/2>BY;U<V5!6QEX58XR5C;:3G''!S@8X'XL]3_%F7%T
MF#)S) BI$,B1C\/ZU7FO65(KVLGXZ8IXSDYAC060P''_ $\,3[@ GF^?BN =
M<'=34JZIU)65=./U$9=$\'<P9MQR/&6_X?NYA^T+55UK6 (A^S+N_>ZJP/I?
MI([#GMT_HB1K%$&XB4(2?<\@U_K5_G\0BP7R^6=:E+;,\9F"#;& 7#HY>-HS
ML8JR'=R /('5/3>&H]4R5L;G6=]H56:N ;(!^/?V/TZPS<3%R#%N%T3NXLT1
M16@0"":('\/H4=%U6LIX)0E$;I3!ZJ:2DN, J:7W*HDSS?=Y$V>Z?Q!\$;AD
M@>0_1?9MJ>HQ30P"1-B'RVV.=IKN*LBO8]QP.F'.T:-YXY(4:-DV^I&,1&VM
MJAKOD?P_,T,FOL.B;U,E#6VV32MV?\=9!&U;3/(TJ[Y'IQ[9IXV4LV(P$C5&
MR2 ,Q;,\(^(-"E"9.2V3%[1I'(7-<<]CS7O=\])1G:]IKL9JR,8 5&P"2!:.
MVF7\9!X]1+$^PZ"FH-+5-IJI87C%9%$S(*JG!DB(!.PY3=L>1<,$8AP",@8/
M2%\?(C!+Q-!V($J[2]]SR+%]_:ORZF.EZU%DHI:01EE!5)"%86H/ )LA>W''
M'QQU"YH$B8A58#&2#G(.2,>?H!Q_9U@"?WN3\WW^O;I]$C/ZB;]@0?;N.?UZ
MQI5)4  >0<<9R0>3_</^[K-._P"G^W62\D<\WP;/8>W;]>:XXXZ\-IYX.?E_
MGY\?3YX'SZV_W_?/^_6=4#W!KV'T/O7Q[T#S5^P\9CP>".3R<?\ $GG/U.?H
M,]>7SV/Y\?('S]?S^G0G8\WS9_EWZPL'ZX.?G]/IQ_?R1]3T<_W_ $[?^/K[
MY]+&?\_Y_P#$#KWHZ1\^/ S_  ^7Y^3QT='2&0#^_'GQ\OK_ &?EQQCHZ.EC
M]W_<?\\?($@='1UX2?B.>1CGQQQSC^P?+Y>>>M+_ (CT=+Y?Y_?^_P =8]'7
M=/QI_P#N7\OF/G\O\GCHZ!W'_C^?MTZ]:*/P>!_+_;K*OJ/;W'ZUW_OV]NLF
MGA)+;AP3],GY# /YD'Z_0#Z#"J_*C^G?O\?3C^?0S@+5<BA[=Q_?^OMT\QTA
M;9Q]0!C'!^GSS_W$G''6 >]WL/8?/?\ +_0#W[7TC=^?GG\N+_AS[\D_GTZ1
M4V"H Y^O[C\O)Q]?V'G'6EF/))X[US_*S_?Z\!/H-FAW^/U_4=_;V)XXS!2$
MY.TXP<^1_1;G./)_+G@YXXZQW =C^5?SY!XX^2._Z=)BX_OX^?Y_WQ?V3O2>
MI3TN^G)3Y7L9VI!Q^6AK'TXCD _(Z>@;%]?@>^W+KFMGVFWJ<EIXXY:J:X]K
MX1N91^J;L]H#( 8A2<;CGAN?ER>NL/L^U<8/@C0C L<F5Y>3 Q)!(B?-R9&7
MRR=JDF0L&"WZAS5=034)%?4LN,MZ4D)**2"#2'D@@CN.]W[6>#K$TM:::GEC
MN%>I]R1<2,[.[;"=Y1>3@9.,KSC/.!U</AW2Q&@U&=-L\B,J^822%8W8#$@7
M9 /!(/P>&K.RBY$4=]P2$NR![<'N?@W]>XZDT?W=J&X2P8^Z_>A%'#N+NY()
M92QW2*I4#!W ><8&>GV)L<P9(CN6#=*C"V8L][) +Y(9J  X4=N.DC@^9&7X
MD !)I?2#9_*P ;('/(LD=1]J"OCDDK*.TQ*L4P]Z.3!AJ:&4%'CE=B^ S.F"
M<,& ;@]5%XO\'3>(,;*BBTL838F0L^-*\GE@Q^6Z%MYD 9B7#,A) [D4!U'M
M7PX]4#1K)&)("'61CM(?:0 "G(%D?BM6(YY(/45[R=N]$4]MTG==(RS)>[K&
MZ7.V2F0"EJ\KEHRSLKQELA2HV;,$^,]4/D>#/&>F:YB:+JC/-IN;C&;%F4PE
M 23L EC(;T[>0S C<+'/4:\*Y7B"34LS2]2@1H4D9<>90H5HZY)9 .0.203]
M.AIKVAG.BUHG(,MMC@9Q@,<*5W>06_VCP>0!\NKA\38<O_"AP%($F'C)8I7(
M*J ;L-NL@?(%@@=7(J+'BNBBAY2@D>KB.B>]G@#\^_U! ,B"NMA@JW#QHI^[
MP,K-)%[AP)*?C:@D?&]01GG=SUR1J'G0:I(%M4DE9CZ5%DGGBK!/<  "CVZ9
M()%@E9HU96W\L#2D=RK@DDFK -'L/SZ%]1334<SP5,,D,B9&V16C.UB-KKG&
M0<CD<9Z=H9>X+$$%0 "17?X([GGW]J]QU+X9(Y(UDC<&ZYLFSW*D7Q7%@?G5
M4>L)U/(Y/!)R?H3QQ\AQXYY_=UO\R4-PQ8<<7?![5WNC_O\ 0K892>_O8L?(
M%_E7MR#W^:ZQF=T7A>3S_P ,<_N'Y#GZ=;7EF5;"]Q?X>?X5[]K]_:^EJA'Y
M//'!/ _GP>_'<=^O41CVED8DY_H@\X_=R!C&#G@](Q*3[$7].!Q?<_(^?Y#G
MK1YILBJ_W]ASQR/GO\#KS #;OI@^3@C]V?EXY^?Y]9B4>_S^7O\ 7X[?GQ=]
M9AQ0OYH\?G7\?Z_I>+-&)(G4CC;Q@G!)^AX)^7C]N.O+6166B10X!)//']CO
MW^;ZW12"[!K^ KO^GS\^PXKJ+30/$[! 0K$AP.<K\P"0?J?'/[<]-\D15CM'
MI)Y][']WV^>]]+0Q*FO<&^+Y'\?T]^O)$C$@WH2/ERV1^9 P>,<C\ND[BB:]
MQQUK#GW/]_/;_0_ETY*V)8CC]6$"K@;<KC S@ M^ULG(YY!(S@ #!FL\_)(_
M0$G@GL.W'7H]9.[D#^'/\#_'I_H9E>H@YPH8'Z'*G(.X<Y&1\_V^22IRWN.E
M[;>2!7([?D?J:L]-^6O[-N#Q8[GW%5VH"^W?G^'3E6SQ??-CN@,@)#DX;*@?
M09())S\OV=-T+.   W?D;CV]Q[D]OKWZ2QQ5"2JDE2!0_/WKN:KGZ\UT_:8U
M9J*T22QV*H=6F C98X(GW[3D8)B;!4Y.5/'U&>L,S!TW)0-.U,H+<R2<&O<;
MA?MQ575BNDFHZ=@Y"(V9&EISZ[ %FB20>QX')JZ-\<'[35Q@TK;9:JIJ)&U%
M<G$E6I97D1F.Z..19-YW.3O<H01P&^BM&'@)JN=BX8AEF@>18T6.-@J\@ [D
M4$@"QW( Y-@=0'6HVU+*6.-5&%CC9$J-0;G;Z-M%@+6E KD5U/\ 36C;G5SQ
MZFNU9% 6'OTD1; SG(+JV%#$KX)!!XX!&.N/!GV>)H6"-4DEA@58BV*97VL]
M$G9M)HG>IIF [=QS:[%Q<?38=[@&2.-F -KY?I))=NQ8 U[@59^>K)"Q]O;7
MIFDK;Q>I[OKBXE'H[7;TC>WVZ';G;4U<9RM0N06"<#@%F(.,].F\0:EXCE.=
M/AKIJ;1B1XLN%DRRE7/$OE&2;'M:(9C'9%62".JVAUCQ;KFN28^&BXVG0N3)
M*T<=[-_I9006(]N0"W%^PZ'4O<FUV)JV@ND\/M1J<I+AF(7PL;'+@C&!M8$G
M@XZL_&\90Z=YV)JDGF+ K>66(9N!^ DWN%?YB2 +ZL^+ ) MU24H"30!<56Z
M@/Q,>:7X_3JK]U[T5LFJIZRE9C;@YCAC*H2$& &&Y25R02#G(SY'/533_:0D
MVN94D<K;%=A&Y&Y57B@H96( (H$#V[^_4AQ\;R\>S'Z*H&J+4.;YH7P> .W(
ML=?IK_DQ^OJG5WKWU51O&R10>G[6,TF0@.XZETM$A)503E&SC)&3D@'D,OVC
M^,IM>\-083M<9RXIE(C"V83(@8MM!Y#GN>?Q<]9:5Y/W^,Q*RL/-#DGCE.!5
MD41SP.+K@CK6/Z@;G%9_M/\ UQ7*OHJ&X4C>H[NC0B&Z4\-91>W_ #BG9I)(
M9E=66+GX@0<97D ]<S:SIV)E&#&V,S3/%#$L,LJ2K-/*06]#J2.?FN2;!Y%>
M_;!)+D8<6'B330-M,Y;&D:.0O;* KJ0;8B]IL735?0P]3G?"RWJ\V>TZ2TII
M#35ZIC#;(+Q9+<D,MWIYMGO281(Z/(;D!5+$JI&0.K2\(Z/K'V/ZWY[SZA'@
M:QC)A-(RKDQPOE20D2M))YDB,JPDE0P])8A;'$%^SCPWK6FEM0U:34IL::!C
M(F06$:H&!1@'8[I+"D[.6Y])!(-%NZ"76XLC05-->I*BRP"JKH*2*&?VZ4^Y
M-3S!4 8HSJ6;\>  2!D=._C;P_IN+F3ZB-1;,FU.-,MPTQ-3-1)5"PKDA=H!
M&X\7QU;VE1X.G9:JD\BK),TZ1O(7KSK"M=D ,JVH-&@>.+Z$W;WME4:CI+E6
MI3S5#BNCH:-(W!'WAU:>2:9-Q)@@AV@$KM:1D7=R1TP>%_#F9KF?%CPQ3M&5
MW,RPED+4* 8+0/OMW \']9/JFKF+(@QL=@KR*9)&*V$C!-V:(6R"+%<D <D7
M:&W=K-0C32;(Y*RALR5#P6]G=%IZIRSS,T2L\1:7!'QCE?A/&<7?X>^RK,P)
M,_5J&1NLQP2.H>)HD4,JQEAN8@ D 'O7!OJ,Q10+JTD^7+&\DX0J-K,M[0J%
MK7: *H7P2+8V!T;M"6G2$6CZ*>\T,-+J61VBFIU@<S!(W( 9=GLJ"A))&"=Q
M))('5P^&\+28-/Q),R'%7,E\R*9'4M)O61P@$2AF0;"OJ"@'W/?K;GOEK+(D
M#MY>U2I4(%!(%D$@*2#=CO\ 3MU-=(Z1T?:M17JN$]#%<:JWYM\9MJUPJYW
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M)4>.&ZZB$$TW^KNAIG5EG]J5(4!4;U]K:P"EV P1QTUZ_J>C:GA:=,HC3/S
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M-O4Q@[&5BZK&Q.25"C/@=/7C?P-I.-B8?W3&D7)==V3(BLR,45?2 RE%%@@
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MC^O\.L"Y]OYC_OT[BESCX3X\_P#AG\^?/Y^.M%CCFK-6>./R_2ZZUF4CWOZ
M#^?673T[ \@@#\/!'^&?/DX^9Z&(VBP*'Y&^_P#KS7MW^*P:0D4#W// %>WM
M[_QZ?88&(&1X/'[^1CD?G^9S_!,S@=OX6:X_U%^_Y\6!UJ+#DL>?S /\/X?'
MY_+I3P.67C SX(&?!\?GGZ?V]:F8 'Y%^J_K]/:N+K]*ZT/)9KYXJOBC7O\
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M]ZA)20L%)+'X:CPPOV]^#7\.FG6BT]+!4U]HEI*VS&)A]RG;?$)6+9-.A)4
M <9!VGY8..MV7++!C22ND+I%"SRQ2+_S -NWU@D51((((;BB#WUXZ&22-&DD
MC+/6^,\@BR;'S8/(Y!N^/PC325UT7;$J:VILT-PNU2[?=XI 'HZ:0G(+A3A
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MTY2U^M"YN-166Z62FIRWQ4_MQ8!;)(;((R5"G/)XZZ%>!<1]2U;=).[XPD1
M:VQ11E]B]UMO2;YL"@/?J%[_ #S!A@;%CE*,Q)(8[B 0#1KO0)[GXZUCZMU-
M=K_=*F:X54TJ^](J1.QVJ-[X^'&/XY/Y_/KDKQ7KV9G9;ID3RO$TIA*%J:SN
MMN3R..!V^/CJ7+&@CI %V'@=A2T/PBN_;^ %=0](U61CD_$P.">1G!SCGSDD
MGQCSD>(/CQ0QY3Q\\RJM&P:X)8W[>_U/P176X2!H32^JJ)^3_"@/^W;WV5=F
MUMJ]J#=:&GBA>G18:R1_B>0@B-=F" I,N\G.XXP" >NS?!$N'C^&,?)@C";(
MY1(X[NT*^DL:/II@JJ?>^]\1/45>3*ACL%&5"JT0*)IZY[FK)HFKY^?2D[@W
MNT(M,:AHXJFJ6.F5H2V6<_"HR#DG_L\'SQC/2)/%&;CLJ3A&$DX2$RQ,6]79
M1M*7=V";(LUUE)AX[,&K9V! :K-<=[HD"O;]>W5BZ354MBTK^G=1;E 0R1R/
MA 5P=I((&/A!\_+QSCJ;2S110?><EH\=4A66<F]L? +59^2/3=V:Y[!E./YT
MYAB.[U[1P+8=[)% #ZUR!=]:Y^Z^N9NXVIYZBW0K-+-.E'31Q_B;VI?;B="3
ML_6D +NSD$9SSUS;]H_B0YZYF3BO'&L<+8V,'&\^6C, Y%@$OR]>VZO8#I^9
M(L#'$<DL:H 3(-O))L\$$VM#T^X !/<DX>F*EA(NFM:V^L%CL#W*>2FI4#&I
MO4D)-'35<ZDQB)S&$9E89BW@><]<QY&GY.H&-M-_;Y[YES*BDD*P0,XYI1Z5
M%43P:J^HYF%,<-DZ?(K394:QJ>S1QDTS*+LFS\>D\]^QQL-NUS=8+12TL-/:
M[>]7#-1I04=+3O39C,"2":&".4N('VG+GACG_:ZO_P )_8QG3?=<S5(DR(LL
M1LY\J1$@# 6[MN]03U75;OZ(ET2!29,[(:1Y &,6^I"Q.X AK]R"0!8N[%6>
MNN--1Z6G:U:JL5/?;<E+)"M<PD2LIDJI1,\M-6!C*7CD&Z-)&9<-)&"H8GI!
M]H_V4G2V$^CH%C2$2K*B.%DHTR@,[ .A'(9B"3P!?6AL;,Q9#D:9/+%&I#NI
M(=5(X&]: 92#^(K[\T0#U6+7O:VGI?;O6DJA[M8:P221*RDW&@2-E0172*,&
M."4NSB)E=DDC&XD.0O5'P9!Q)WQL[\2=W:DO\U8VIO@639KZ@2O1_%"MNQLY
M?*R$(!H[8W)!MDLEJ%+N%79&VU[0JF[6:PK8/O,-CJQ3L$"R31F .9/AC5/>
MV&3<3@&,,,C'3K#E1SD)CQNY]D4;B+/:_>^#Q\]/#^+-(@/EO.#(."%?=7.X
MWM!(XON1=FN#TWW'MMJ.VS"EK+9*M490B4\3&6:0A0[!%B!)*J03\Q\LX;"X
M8>7.&C7&FC<T=Y1BD=G]X\ !N0+/-$_7K?C>)]-RSMBF[ $LU@#FA9;L203Z
M?C\NH54VN2-94,+*T64<G(PX8?"0>00 PY'..1QD:<G&=$1 MF,@2R#E2!QW
M%CD_F*O\NGN/*BD>-0X.\6#\@ F_K??XX]CTQO3[LDY7'& Q^OY?\?\ N"0H
M1]?RZ5V/8@_EUY?=SQAOI\C\_P".?^/7E'X]B?X=^O+'S[U^O]_[]NO)X&+A
M0>,#XL?4GY9^76MU(-_D*][_ +KYZ]L$6#\W]*_O^[Z?;?2>VV]O!0C &/Z0
M."1^_(Z2R&QM!]^_^WZ'O_WK3))0('O_ -_XCYH\_E73RD29!P!E@/\ /(_9
MC]OY]:SV/Y'^_P"_].DQ8GO^G;_8=9XBSC@\GS_G]O'C/6K<37/Y\"O;X[_7
M^'S?A('Y?W_?>OGMUEQ4WQ# R<CC&< X^IS^[/6+-0Y/S5<?WWX^+X[]:F<
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MT#]/DUSP>.HSJJ_>HG:-2&0AE*D"BI/)X^O -_Z]6DL/=FOLI5K@ZU2)$K_
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MN-]O%RL\=K@MWM425,LT;I#M+RRK[;>[-M!90J_""> >/EA5BX+1R>>Q?:0
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M$.=H-^Q]R#S_  ZDVHNV=\FU-I,P5;3VM&@JIXX$/MLJ1L[ D/A?J2PP5&0
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M^6)_UXO][M-7:+;#L66JWLTWMD;B)9,G*_,!3O<^  2//66KZC@28D8+)/\
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M9XJ\,:/I_P!VCBRL32L5'G90/,VP1J69@I).[=R>:''!XSS3Y+S2S'S()96
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M:P!SW YH1>BTE8KMJ_\ 0!K9=-6ZVV6>KFN=-![LU;+@)#'#3*2&:IF8! _
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M@^><=5MX_P!<\G3\G3HT,C%%,LU\+)8*HIKN+]1%$77-<OFFPF&-LIB0=M*
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M'J+@#V(MN.]]";6FB_NPFO-B)GH:EM]396BD-5:V=O\ HVV95HU.X1'*RA
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MR(%LLL<=0E@*%^U5T[8T9>4+#&WD% KM98[6X/JJKY+\W0!//5=]):PK;S<
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M+Y_E1YK@]N>FVAK(KK/!';ZB(T='E9"CJS. C*H55.?./D1C^)R(V*2P+%K
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M..,8( ^?6N-(4$M?O!&YKCD'OW_[C@UTJP("F;"QYVQR=P>+0 \G^'\CS75
M?M >YELT?ZY_6[1UI9JP>I'N>:2%3SLGODSAP1D !F;/@G]O/767@#QKB:9X
M7,1IIA"$1MQ&RHE6S^+L!?'%V;^4.;C+FY05FI87+,.Y8AR1W[\]QUJ?U7JZ
M[7F62>:KF-.9'F]I7?"AB3@_%@\$CY<'Y=0/Q+XBSG GCF;R6)D8J2&J^Q;<
M.*//U(XZ70JK.%6E % ?'M9X[>_]+ZB--2R5%5!M5XVJ9(Q'NSR)&49!SSR1
MS@<]1;25CU/.&2DS>9),%(W7^(@'GFSS8[CWOXV_>(J,196(.PFO?V'('UOZ
M<B@>K=6C3.H=#V^V758C54LHIY:E4!8^T44GP/Z(S^_\_%^0:-JNAQX>HK$9
M<9VC:2_4"I /('8%>>1V[<4.F<M%-D/#$X9E+!U/!![ CY /Z?RZ,L%[AU3"
MK4%-^HIY(TDW(R;9%"MQ\B5;D_4#R,]3N7//B*&./$Q"(870.Q M30[<  #U
M?4BB3TC.,N'?F2$L^X#FK^>Y]Q0[_6NAYJG0]1%>!7BI6G2DC>502=N)57*D
M$C !4?TN<_LZANM^&Y\7/,OG!8X(F=2IX(E52WT!!7;V!_CUNAF&0(Y$9J17
M0* *MB-Q/8'@?7\QWZ<K/57K^;-2]#)[U5*TBHR-\?N$HJLB@D?JRI8'R<?7
MRGA3/ET;(3'8L\Q>,;31+DCD*.>*L<WQWYZ0YN&DX:*6K:-E!8>BF#<,0+H@
M]JNB/KUGUG;*_:ETI:+J*Y7J8ZE;<*.9V55>0M[F\,.-^3N/ W'\./*^'PMJ
M>3H6GRR93Y.9"#"F.X8*(C,\9MF8TV[EA0X]SVZT8N:FF1-CY +^0IN1!>XJ
MH** .654I5HV:H^YZG55V.LURT12P6IVI-24"LU='&$61)(S\8!"ARG(8?+!
MROT+]D>!,.?2H,=%&)J(CB<Y*L"'F(#2Q,54$(&+!"#P0-U@V$[9BR2EI%'E
MLUJZ*%D50;4K?<D<,#R0>*( ZC7;ZU45AN6H[;J.ZR/-#:':V*\K-[<L>1$1
MNSAF<$8 ^7GK5X<P5TC,S\3/R%,Z0((P[BE2V#21F^)#P5KFAP#[NTX,D,,F
M."ZNZEWJB0!P"!W!%[B>#0[<=1S5]YO5XL5KIZ2F4R4PFHJRHC+JS$G?"SLH
M\DQ[<L> ?)QTUZ]J>HZAIF"L49+1%X,F7<U,_IV,17%K&2UDVQOBZ.Z.'[NS
MM'1\QE8*W 6R2Y%<,!N/Z4.:ZB-VJ+O0V2DK;K7S-54=.8X:;>2T84'\&"26
M+ 8XY.#@>.FO*;+7$QILG(DD>&(K'&78L@ (% G@6+'UH].4441W^6@]7J8J
M -[5]*]^/RX^O5D[3KRCM%DTAJF.6&IIFMWW"2CD.V<5,@;+./B+,S$X.W)(
MP!C&;,36((](T[.>1ON\L,43H/\ F/,(U HD\LK1L&!Y]0-BZZC;:>7R,F*@
ML@;<']@MDU5<!@UWVX]^A/07#4]PU?=JB.*>WFXTSS&*1RJK#*WPMM_$N>1C
M)'/(.3U$<6;6,G7\N6""3%ER\9W\J0\1P';Y;D'MZ0.0 ;/L#TY/%B0XL9D*
MOY=#Y!D!(/ !ODW[CV^3U';IK:]:8T[+8J>^NU:UXEGFA56:GE@0DI\8< 2+
M(%7X@W'@#SU#)?$VO:7YNG)J$;1K-*=Z*3+NW@^6)=][:'J [GD\<=,/GRS:
MDP<021JC+&70BV]U*;SZEH"@.W/TZ<ZGN):-5:7$>H*6IJ[Q'2+$L8C::H+H
M%CWQ*R;U089AX55&=VWIVU'QMIF9H(CUK#:;4H@BQRH 6MW"%]NT6*9B_>ZW
M$WUK<C3LD/PJLP#XY/&TFK#,U 5V'8\ 43UBW72]EMNA;7J>"\5<5YMM7[U/
M1 %:F&J#$Q)G:H+!BF54@J1G]B'4M$T/(\))FC-E.0PWI"&0[G=C4(6@0RK3
M%KJC5"^5$KX^6N3BJ+@DB+J^X'N"3?R+)6AR"*LGMDW72UIK-+0ZOI]972CU
M54H$NMMKUG@F^\U.UM].X!:>,%BSEB=O&"<]5'I,'B?36A?8-(@RI!&R .M%
MR2&6BH)*G=?:NH3B9^LZ9J8P/N$<.',_[.6.@KHAKU^PJQ[79]^>O?MY8KGV
MJOL&KJR[4UPB@03?>JJ R>W+(NXR9=\@Q%FPV>,Y^$CJS9_L^6"+$R-7RGR<
M"1EGGD)#^9YJAW7E2 5O@$5\<7U)/$6BQ>(\(8,;/#*S,90.!M)Y(-GAB#R>
M]_2NK(:>]2E%J#4=#8K5+17.=A+"KTT0BC$U6PDDFJY0=\TBGX58L0HX'4K\
M+#PMI?B X/AU6;$SL9<9U0HH26,^>\K;5%D;"*H$^Q'?J":?]GV1H&0,R#(5
MI95:-UE+.HC'(50" @I ;^>]V.JU=ZM<4[ZYK(J^DGN%31*ZS0T[9I%>821[
M6X;'#KR<D!1QG)Z:?&NK(WBEL8I/-#@XT<2HG,*B0-Q)P:>VW-[V:]N9_HV'
ME1R;I7;81ND$?"EW-\*2;&VE'O07CIDM^J;9J/2513$O;:B(B !7:)5B39SN
M PPV\L?(XXX/6O&U3#R]!EB*RX^3'+0.^@(Q7%;>]>_^P/3V$:.YD+,%+;@6
M4N&%FPQYKGC]?SZ<1W/2PVNCTW!<&N%/1HGMQK*\JHB#X=_!4$*,9 YQ@@'I
M:OC5=/T^#35R8YML:!+-R^4""L;-?*CV'P.X'7CIAR1KER&F9$< GD6OXN.-
M]$V?;F^_4LU'JC2#:%J=0&21+Q)2A(*=$4 [6R"&\H2Y*,">0,\@C$EU/6M!
MS=!.=NA3-;%5$B7TR>:KK9KA2IHDL2#7I[\=>X:NTRP^;NQP6D#,0;5E)"CC
M=8(' Y!]_C:UZ.[K;]3?9+>NNLN%-1M(.\GI3'W26,.DM:;Y=A1+*@.6:02*
M5SD ;O((ZY3^W;5%U#1O#JPHD<V*V0,DIZ6,<A@56;V)_9_-$=N.R?73L\.^
M(#CY#H8EQE;:QW*!-)O -]J+'M7'R0.M('J,UI7-?)=#-:Z"FHM.U4L47MH&
MPTS^_*T9'&V5W#Y4@ < 'EC57@+1%SY1G/,P4<T;]B!1O\JKCYZ8O!&C8YQ(
M]3^^9#2YD(D<EJ!VDJBD=K7:5-\\\5T0NS>H;#:M 5,U#310W&>E:F?8 &:7
M=&QRP ))*KCC@X.>N]? ^I:5IOA99,=5CR(X@JJ%]4A6/;"H([*'))%CW[D6
M)AFP2S28X))A"@,+X!%AS7/)' OM?/':R&DKKJAK/;[I)#[U+*RTRK(6WA0V
MP8/D*, ?N'UZL32IY<W AFR55)9%9MHM3M5B Q'JLL 3W HW8NNF7*6))F2,
M$@<T:(OW"_"V:!YKXH===<ZUNEGJ$B*B.,(H(C+$@X#Y)R,#!^8^0\YSTEU?
M5%T>*&40^>)"]G=6T)M]MIL<_3Y[]LL:!)!)R5VT>!R>!SR>_8$>P'?GCOIS
M5EHU!;JRF$3S7>6&2&!,[HVE8-L0G'!XSD @X..<];=+UK%U>,28KA60?M(6
M)#*1?9@*9>+N@1\4;.IX9$ :RT9)IP.XNAP3P>15^GWXJ@T6GMG)75/WROI_
MNY:1S+N(+;N=OE<8SQDCY^,X/2%/#^ TGWG*7=D.S2/'&P,98FU.[:":]@?:
MN:'6YLQAZ$H*!P6%-QR3MYX_,@^]5QU(J&TQP7^.S.9DHT?D%OA=E'D@#:5=
MQ@Y&3SY'F2J?*B B0!%C%,#P/56VJ[@<_P +Z02TQ9F8$EKVUR1MN^]$>W:J
MX[]3NELMIANDZ5-"TA$<4M+.Y#)M\2%-R@+A@3@$D#'.,YU.[,J2 J&7<I-#
M>!QQ?>C?/MP?F@GCW!G ! +!@397Z*![,"!?Z$#L.FV[Z*TE=FJ*N11') #(
MA5D&"@+O\)0^2!D@_P .#TDGQ8,IHSDX\<S(5V2.ENHO@!AS5_N^_OTMAR,B
M(@*2%-V!^&VH;N?>K_@#T*ZF^T\[K;K%'[.]UI)W0X:38VP"0IM/.>1\\\\\
M=(9M77(E3#TPAI3/Y<LNRE@56 8)1LD $;CV6Z'?K8T+FWE/IVDU9.Z^>>*]
M^5[7W)]COI6Q4=HI(PY4UL@]Z5CC(.-V!\\+G'GR21YP'%J52D8I+/P"S.?4
MS$ 66//('  /:^D3V"37''-$71("]^U ]_K?)Z==0W:2UVIJN)@9(QA!CEB[
M8'[AD9\<#CY="A%\QY/P*K2,!SZ44L:X[FC^M7]=#,$5F(X4>]@ D@<GV NS
M^70EDK[QK.E^'$5/2N4=U9D,DDZ[5!RS9">VV ,  D9^(#K1BY$6I8[OCM-B
MHQ>,L0'=B 5(!]( 4FSWLT.*/6E)6<@H$9@%8#E5 O@G<2;-&OCF[L7,-"Z:
MGMLDLT]478D H"2"!GDGCY' &!C\\]9PP_<\?R?-><ERYDD !LU8 LD#CGDD
MGX '6T;BQ=J!( VJ20 /DD=^:[?-7S1/GA@F CF 88X5L<CQX.1UBK,O*_EV
M_P!1_3K.R/[_ +'/O^73)7VBP(@EJ*2BQ\R\<8P<$\DK@C]XY^?6]&D8[06)
M^O(KZ=B/RHD>_2>:2*-2TFT <DG@?G?\N?\ RTR5^EZ14:*EI2(B%)2)."Y^
M1"D'\.?F .>MX@R"3=B["W[55U5&B>]?J.]-[:GA4"K(PW!?3S1(XOVHT3?8
MU^=SBGHK=) B1TE.8FVN%]A NX@X8KMQD \GZ>/R1,SJQ]3 \]F/R15@]+3'
M&1M*(4)W;=JD?%U577%]^L&ITS;:AIVDI82)H7@V;$^$.N R#!7<I^(<$Y&>
MO7D,D?E2JLB'\2N-P8'NI!XHC@_3I!+IV))OWX\;;@57@>@L"-RBN&'L1[]N
M>@5?-(W*VK<('A-59WIJFG974.D23(Q>6-65E23Q@J% (\GP*.^T/['L#6XL
MK5=$CB3-6"21<<JH8NJL6\O:@YM0?8@GM0LQ+4=)EP67*A5B4=7WJ.*!%!^0
M?WJHGDCJH^M]"V^S5LE18VEJ[;*D)25H]KPS-$'ECF&<JPD+(&P PP>.N(-3
MTW5='F:'4T*,DKQL2>=RFBIOL01?O8YLWU-="\029<46-.!'D1J=POAAR !\
M\<@=#&%5$D@\.A <8YYW8R>.2!X(./(//2!R=JFO2XM3?Q5_Z=3)7W!;-]B2
M/T_7YY'?^N9M^'=G_.<?XGI.&YVU_ V.WM\?E[=;5[?GSR*/Z_/Y^_7<?#&Q
MQD_%Y\C"8/\ '=_9SUZ3; ?2_P"8/_\ S_==959 ^HY_7KZWGI;_ .K3Z?<?
M_P!%^V/G_P#PRS?LZL!/^7'_ .W'_P#!>IW#_P F+_VT_P#B.OQ,_:K=J]8]
MWOM5_4AI/1-!"U;-5=O:BHKJIQ!0TL%/VAT1OFJ)@&9GDDB]M(U5W+$$C:"3
MU3H?CY?!/V3:!G#%DGD/WT%HU%LHU;/BY)!)(VA?H. *ZHK[1_%.'X?U"4NG
MGY4\ODP8,)4/*X2.1C1DCC7]F2Q9F&ZC1!H'70EDU=H"[7;0^K8/NFI*.::)
M)'F+P.J* ##.3ET ^,! .", @=6MX)\7X'C?1,;6,9_6+3+@V;6BDOW2MIL<
M6.#WOD=(M#\2Z?XBP/.T_='-':38\H!>&5#M=21NL![Y%V.UCDC6W6ZHCNEU
M2XP;W =JEH\-[V6W MX,FX%F .<'/@YZFD:!/-=8H(VFE!$D2!6E4 @-(0 6
M93Q;7^(D?)?H%"E:W JAWCV+L02: Y#=^;/'(!%"+UETMUNO44U/3QR1H4(1
MXU+(5<?7('SQX(^GGI+F:ABXL\44^TRR*5+( 9$!- DUN"@6#1_2^ Y0HTL1
M=&(7AE4D@,*MJ%\'X//:_P W'5T6GKW4T5S:#X%IL3*D2;00.6*Y"EE&0<_,
M#GQUAEZ5A9J++GKO3'5V5MS &-AN+, "?319>+!)XOK2LN0O[.*0@R$@W9(-
MU0&X DD[1Z@*H@FZZ>],WRAAE6FH8JB>!8=A]Z95]L@D HI?8@^+.05/!)X&
M>MV+)BY""#%EWK BBZ9@J]E4LP#L0!0&T@ 5\=(,MSA*[.C.S66&X"CR25!]
M(!/>FN^>2+ZV2>E?L_:TDI.[NLXO:T];*BKJHXJE!*A>-3'33N7W+4PQS#WD
M&YE4;1%D 'KD?[;_ +1Y,GQ3B?9[H4^H+EA<E<R:$2F'S41',2F,D*%%'D#U
M7W)(',?BW6!J&?J+LDATC"RX5U!FDWRS9#&UQ(5#'?&&*"5; *$Q^KU41?7%
MJ[3.LNW=BL]C>2\5TEZI[HDE'3F2&FI&BE0BHF"EH)9%8 1*3E1AO&.HA_\
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M/ZB-Q&9"C<L0?A)89##&,<,/GQGIER=8T['C_82PY<H%LB3 !.] D*W)/>N
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M7B7*FDSADI*RLX"-&E[64=S0H6>WMS= =@PZUI^.F1CR?X@Y02@O $YF4<;
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MI>RV02$L@[:/-'@BAU#;C:KEJFYR 1S6R-G]P,I:(($(= 9&PP;<JG*8.[G
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M[(W,F]1NXR< @@Y! \C/4^\!G1LC0Y\'5?+3)@4N&D#;H^'_  ,#1-JO!!W
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M"^YY]NW%MEH;E[\<$AIUX,C(0H0LOPJV "<?,<X\GCIOT;0\;0X<R. -&LS
M)$W% ,Q!4$[J' JJX!'L.H[IN+(^>DR+(8XPVYFC8+=@ !R &]^Q-?3W/GNJ
MS<)YY .?WY^7\0/F>3TMKB@:XJ^IF ?\Q/<G_M\?E[]NH#KNT_>$I*Z.0)+
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M=_,E0-N"W5T01VXYXOGCBC9ZE4NJ*B.$UUPIXUID9D@94"C QGXSNSGP<#P
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M=3OPMI$NI-'FY$C1G$F"I%SM9557W=Q=ER!_^&^YZ1C BBQS--(%V.K-9YX
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M84!V%EN/EKB(FR!,/3RHW4NX=P;*W3;@U\V01=GCI:7J;=;;3<[S=;<(VHZ
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M 0-I (7G\KNSW%_0&(VFD?2D%#)2UI@DNL)CJE23#J\^58R;L<'@D!B>.0,
M]:,7#D\/8VGB%QOSGABRDE"E1,X!$BAO_P"6692U"CP+OC?DO/-'L6-6:$@J
M59E!0':PM1=L02*LT%/!XZ]NY5IKONJQ_I**LM=BIXJJ%HW!S-('=4 !.7)0
M^3G &>.EOB/$GRL=LDND6/A)]Y,9!\V6:,,"20M$;:"@L!;&KL]..C2I')M8
M,TDS%; I$!MJ(L;18/(W':!=<#H#Z6N.K-:7B".&WO-;]U?1A@0#MIRZH1CX
MB1L&>#\\\#J$:9D:OK>;&0C''19H SVJ(D8*+ZN2HW  <^X%<\268XN+"9-P
M0L=Q%>IF) )V@\DD_3L>W?J8Z9ME;+:KNZU2TK6*HF'W-V)DEF$SX"AER0.
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M)<H+C)&&<J9%B5HSD,J@*  IQGY\#Y\'IGQ<&'(<+.7(8AHU12Y=EYVT"!P
M/<#XZ4>=@S1;F*;E!)5N"";Y%^H^WY]J]^K@=ENV5;?XHKS74XC@HV8"2>,@
MQPY;,C'&[DK_ $06QD@')(Z#\ ^"HLT?XE+&N-C B*RI$T^T-P@[6#M+,64
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MJ73YX'>^WOS]..>>W6/J/2E/615,-/3Q/,K%XZE5+21E?Z64^(9. ?D,\C@
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MTU,BU&W[LF09E* ;8R?PR.@!4,V2!TU:%]I/C#1$?$T[4)X(G50DAFWM$Y(
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M   \DC)ZCFF!]0<M++YLTS;8HS^(N215W[$#L#Q[<4-4KQ8A$:TZFE#6:]N
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M)8[R.L/!WAG.TC,U//S\]-4AS,A9=.4H0((@3<A )46H&U;(JV^*K3[-]?\
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MCV)8]RQ^;H7P!VZ?9\AY'+NQ=S\^P]A5D  ?K7)/4Z!:&-ZRJD6*-%+OG"@
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MO[EB232*"&*QJB$+8"-5.3N0#V/()[;WR<2+'!D>/<J'S"X#'=S=$_'%<\_
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M]IDWAB'/@BC7='NQ\>3RPS1D !I'8LI53VL!F4D ?/2;Q $TK3!F1;VF90[
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M4C_TA:B=7,DC9*J% )SUS?I7A?7/$V7+JOGSPSY>2(YIQ&SD;F4,^. _8[:
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M:%)X5=Q/  X/\?8#N3[ $BZZK)>.YFH[V*BT6I*BKFK9$I(857$6Z9QAMX)
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M>)7BE;S<>;&V[Z.U9 5"0D\WN4.PJNW()YZ$?=._2Z=M:Z<M424J7:41QS(
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M,_EI$ODA@"JM9JY%)1[V_6P:ZG6?GXL$44&+$D8RLF..9I&]1JW 1:H#T$
MBA[#GJS=9/34LE%;THQ4RU<83[K'$NRFAQ@R.Q 4*>=NT$Y&!R1U-U5F#/N:
M@U;[')'JYY!XJCW-D7Q9Z029!CFBA$;,) 38L*H6@/Z@=N #] <VMJJ?3MG>
M9@H6+=[2!0&D=B2B #Z9 'RVC/&!C0S!F>1R0D:EG/)H*#9^3P.W<FAS[[I9
M4B0NYVJH'S[#L/S/Z#Z#JL^I_P"<>OO=F6JDH+?3-[M0QWK!#3"4(TCLI^ #
M(X 9I> !@<<[?:C]IT.%BSZ=@YHQ)(U!;'-B9_4*9RHYL*2J[CMHUSSU%\[Q
M,D$C8V.2S2 (&527NB2L8[\GAG%$@ 6!5-HL,5KM]3;8+M1:=%:\0@O=7%4/
M>JJFF$BLU-0*QFI89''Q.VUDCPQ(W'KC35?$VIZW,[R><Z1G?(X9K9 0#9!J
MB2/2#W_+IF26"2=<K+BES=BN6QXROE1RJP*&20T)" &-*2I)Z'W;CM=98=0Z
MOT[JJ6WUEXJ;4M19ZP;9H))*I&%,\,S#:K,[ N 0P/!P2 >GOL.71?%/ASQ1
M%J&/%]\A@E@1I0 R8[8LBF5#W+1-1H'< "1Q9ZG*ZOBR:2^7C!XXL==S"2.Y
M$*(24 IJMU9017.WGD=>FM;M9.WEKM^@Z>XPR3T2-!7S4S/)#4U;/))/)D9*
M*@9(1GAO;SG!ZI#0(X8_$N?FO&,G'&4V/CS$!J.*P3@'D!=B@6.1R.W40TS'
MRM9R9=3E@.V0^9"' !12+2N1>X6UCW8?3JQ/;AUMW;7$$RBJN"AZ;9(HV_>(
MT=-[YP&"LS<\XVD=?0CP?A28_A[2(QLLXOWBZ#!!,3* P HE01N^/P\\=2KF
M'$"2E@Y"QT!M<,>*!)%,+[]N+%W?6='J&GM]-44]?5[:FS@54WO.'268B0QK
M"P!X49WY)\KR,'$GERHU\[=*H7'B1LAJV!$=2X<\ $-L:E7D$=@:O;AZ1 LI
ME$5S.P.X^IF9+ Y)+':&HW_F)YZKJFI4UOKJ":MDG=DN,2PPQJ9(Q #^..,$
M!G(4;5') 49SQUQ)]NOC&;.&1BAYHH?*V84 8A AD57D>CM!D0&R1=D\B[Z;
M/$0G EA%K$D;#D@<[ 6>N>XX!Y(7O]2'W#NE!IJVZF[A7*:9+A?S<M-Z70$1
MR)34"1TU15S0Y)1(H6CIX(E 82RNP)*$=<I:7A2Y^2F#"M^6@FD[59]56:LD
M@DFOCY!Z9=-)G&EZ+CQB2#$:'+S#M!#RS'SE0'D^Y9F)&X"O:C]/_P!+SF3T
MU^G^0G)?LQVR<DG).[1MF.2?J<Y/Y]6N!M"KVVH@/Z*!UTUCC;!"M542"OCT
MCCKYO/V_=CAK_M@O5/)4PU$L4US[1J\=*H9Y%/9+MRN 1D;B<@ G) !QC!ZL
MS0<;3,72,+6,Z-Z@!.6P5V1461EW*H# 4*LJ+) '3#JN6,>?(=R[)&W().U4
MVK1!%5?'%CW YZI+%8.V6CU2RZ4KJ^?45=V^AJ+RM6A0TFH*B2I>>EHG1B0D
M2/3DG\9(YX48E'V):JN3+XY;+,JR9:RG0_-5MZQ,'"+%5E""4-\4;W,/> ^'
MM3U759LF?*C40C+40G@!H(6D!9K[WN0DDBZOGD]40K:>5*JICJI)6JTFD243
M,YE+!B&W,V2Q)!\DYQSD=1S.TPSF89LK?XC#DS!DD)=Y #2T7W$JP-A;HBJ[
M\V"97"*'I6'=1VL51XX/?MQ_3IUL5OJ[K<*>W1LT<;NGOONVE(@RJVTYXPK'
MQ]21TW:1X8.J:U&N3"J8Z!7ECV>0K!75;I1';'=5GFNW:NDZ(LC60IH\V5O:
M:[77<@6">X!]NK#T-"]BOM'8-&1+-]]IHTO%4TI>6*G<^W,RRO(&4I&S,-I_
M$%P!GJ]X,<Z;GXVG>'43;- L.4P--'"Z[)"A8EO2A/(L@B[OKR1@ H$24M%@
M2 54-P0";/)) ^>W/1>U-;]%7G3-/IBGNJ4UPBD1Z\Q5!69FC8-MD=#EN<[D
M<L"?D !U-=7P_#V;HW^#IFI#*AC,SQ2RQS.X'[7S)D*LW/860 :  8@H8ERQ
M/))+&YCD4@>H#;1&Q@ ;!([D@7VY'5<NX]LLVEX*6BH+E-4&H61V0R&81J2
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M8Y6&,<%,V?$"LJKM1@'D6-W ]):@0>#^&SW/3[A8<HQ,C%T^)1"JD(=W C*
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M9!5(8NSW;U2T4J$$!"HS@''('70'AO SV^S? R&T>/)QI8\OS7".7=4U3-@
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M SR>FK!\.:WE,%@QRNY@JHX+,PYY.VCR*]A5?'6_&1HVD 9MJ]BY KV_%0!
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M*S4[AAL4R@"(83:<XXS\7SZKSQ'XSTG4,*?3YGAP903([Y,@W!XR=IA'I]3
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MI%"CF"+,<"5.0J!3L)/Q>W=V[DV/?I?F8)G5)Y9V#L0 ECRUH>P][JR>.>*
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M""EM'L+7QEU3X2RYVX1M[(6!4,%SGY'GIQ,N-K2Q:I+@PHF*(GDC8*I'8@*
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MX%]6P[?ZK2S+_/6EL-'?!0&>XT='=*\4\8E*M+ ]3[*F22.!AN]J+ <G!(
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M'%GY4<5V)O;;L-ZB(+Q-2'L+WJMURCGG5ED[6ZZBM4E,) ,1SO8XZ<Y(4C)
M*<C(&.ICX3US2QJ31?XGBXF;$TF\294:8;XRN-ZF3>$)+;: OL"+(L:\_'7+
MA8/$\FW@*$8R%AV*6ION30-][ '5G[1V6[QUM)=+?+Z?^Z%+6012"2H;MIJU
M%GD"':8)7LQ+?$?@$9(R#MQQU9D6O:&\D@35-.B*2 2+]\Q$60E0?,!64"12
M#R["Z[_)CYTS(@"L8I"I!IMCG:;%!K7T-8H@$B^17( ZC]/'J!JZ>I5.T'>*
M/=.(?:;MSK5%"MYQFR;,?5O /@\Y"1=3T^>/('_$6%&SRLJ(VH8X5(A7I6Y+
MJK_""#Q9X(Z</*DB=&&&S@(&W+$6)<]KH#D5='GYL#H;=P_3IWSM:BQ0]B>\
M]5/</@DJ*#M?K:JIT?"G>\T5B=0IR/B)&23]#B$^)=0T/$CCPL;4<2:3,4L\
MZY,#*K[J-LCL$8T+%V/CCISPXLJ56EEC:-0Q4%E=?21P6) VGGBSR18XYZIW
M??2CZFX;C+1P^G?OA+!#(0LL?:?7TR2'R6WII_!SSP/!_(YZH#4H(H=1DC;.
MQYHU#%7$ZRK6[U658K8-@#L/Y=*8\9H"1*6=VHJ1P2K?A[\D7].>:L$=%+L]
MZ.?4)<KG)=;MV![R4M-0$(L5=VPUQ"9<X#E89["N0!G#>0?GD F:^ ]-T_*R
M!F3YNGPP1N=_GY<$6Z($!]HD86Q%D*+)KFATESO.Q@&4.6<$*H5C9(Y)(''<
M #BR3W/'5@]2^G[OC3U5+:](=@N\M%5NJ+5U:=K=;0P@98,PF6PA&)R#C).!
M]<=6-KVK:$&CT[PYEX>+D@D33QSQPIM[ [_,Y[$LU4;X-6>FU,?+GQ)UE+*0
MMK<;'R^Q8GTBO>KY'?CISH_3)W\T91?>*?M!WK%=6R":2>+MQKFH<LP!<'V[
M*Q13R"N!R>0,].&*VA>',+S8_$F(V9DNOFM#G0Y /&YE<!VH7S;"BPH71/1C
MPO*_EM!*(ULEI5<%G/&Y2UGD#YY!X'/(5[G=G/4;==3V*YTGI[[]5<EGEC-5
M,O:G7I695$?Q BP'W/@&"?J3]>H1XM\2X6I:OI.=B9\*+I\@$X7(0+. I6]H
M<[@2UT0*(XX!Z=L?3IEB0*3L61V8 '@-[#CMMW"N";[COU9[2797O3=K?3S7
M#L+WD1:B)?U<_;'6L4T; 9&Y7L@=/ R#AOI^=R:7XJT74,""274M,BD((*3Y
M>*+"US3R>GMQ8JQ5DCJ/9NGY6+E2>6DK(P_^V&)4VQOAA=CW[U?L:ZRNX?I[
M[]U%):*>#LIWCEIO>13#!VZUG(L5./A4&..REE;&-Q().!X'AK\2ZQI<V+C"
M'5M.>)<@G)2'/Q2S"O2U+*25%D+VVV>U]:-+Q<Z'*RI9D<0K #$'B?<.3O%L
MH%D;;Y-GFN#T(M7=DO4'IFSI3VSL#WLKY*H,BFF[6ZYJ'A4H296,=C)4Y. "
M/)XQU"?$_BW3O#NC/#AYN-E/EH2@AGAF=2RD -M<E2#^*^P'Z%U\O)E1W$;^
M9^&,>60-W)!;@#8!S[W0^; ^[<=E>^LQU FL?2YWNKSL'W-INTNN=S"IE$(#
M>[8%5R!N?(PPSNR",]<2^-9M7U7-^_-D.]NX*J['RSN8@#:>!?IL>W?OS&M7
M\.ZNF3ARX>3-'+D_M9WVN55@GF<D7RS$*%-41M' '65KW0WJ%HK.VD-#>F3O
M=0V:7<E>D/9[7L;U4DD9C9W>&PC>@&!C)7<H(!.#TPZ/H4N3E0SYK,"75@)&
MLD*P(+$W7/8W9'?K=I7A#4)\LZEJ\S3YD:K]W9B=L*JVZDL<$\U5?BKY/6=Z
M>O19W0JZFZWW6_83OA!+' SVJEJ.UFM06F;<6<I/8@>"  Q!*C/S/77WV2:'
MX<,V5DZKEZ<BI'2QY.7!!NLA1R[H10!-79-4#S>OQ+G^)?.@PM.@<0E@DL@@
M>0A5Y]((*D>Q-4+-D$ =+NWZ9?4G7&GLMD[%=Y%M#ETE6G[7ZX)0Y!0D0V!O
M@P,<_#GGC.>GG[0M8Q-+B:'3LS#FTT*1MQLF&23;M!]*1/;&S0-\4>*OIZ@?
M-P\6.23'=V=1YFR-G;=0X K@$D\CW !ZK56^C/U)1W"(4_87O@8\[3(W:G7N
M=WX6)9-/E=H^N<8\'Y=<Z:?-C9>H03>8Z1Y,@7]L2I4,0+;=POSWH#CM1Z<<
M;4\ORF#X<P8CFHG(_P#UC_WXXZ,6C_1/WPTQ6VS4&H>Q_>:KA<B1Z6D[6ZZG
MDAP_#M&FG]Y*JN>>,GD9P.KTT+0/#6@9F)K.HZEBRX\PN3'CRX9#& U$>6C[
MEL+="B;X'/6S(>:6/D2;U![QN5#UZ2  2P%UVJS?MUQW:[']\9Y*>#0?IR[]
ME1O-95OV=[@QGXA&(XTS8<DE@[,0/ ')^6OQQXJ\+220Q^%G!R&5Q.X#!%9>
M4*F0WW)OZV>U7ACZ<TA#SC<YHVL;I2@6 244W9)H=JN[)ZC^F.Q'JGCHDIZW
MTY]\+A=:R1(J":[=K.X<D%%&_P"K<"$V0(N&^))#\<?@-@;>N>O$>N>(M4;[
MGG9TSX:6&AC:U<"]HM#3*" ?59L <=(M5TE93YCOEF*%2YB57<NP[;";L$
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M-)ZK6[UOW4;Q!14,-E]\LV<1LR@M)D8(&3$/$WVC^"_#^;I,>9DKE963D&/
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MJO\ AT=>]+VX_P#=I_57_#HZ.E[<?^[3^JO^'1T=+VT'A$'_ /"/\.CH_O\
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9TNCHZ71T=+HZ.ET='2Z.CI='1TNCHZ__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g40894g55a55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g55a55.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2'84&AO=&]S:&]P(#,N,  X0DE-! 0
M    (;R^AC8X0DE-! 0      &$< 5H  QLE1QP"   "   < E  "')R-C T
M.#DP' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@4&5R<V5V97)A;F-E
M("T@1F]R;2!3+30@7T=0(#4N,3$N,C%?7S%? #A"24T$)0      $)%F[<T[
M^2P\;_QU'>MH61HX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q :0            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              /F   $H          !
M      $             !*    /F                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     %SP    !    H
M (<   '@  #](   %R  &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( (< H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M):8)XEJ?ZO666]-:^U[K';WC<\EQ@.\7*'UF_P"3/^N,_*H]!]7]CCTB&O\
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MW;O_ -+;Z?Z'_1_I&*5W3.D6Y%0KJPJJ&$.LBNIS[/\ @O<W]%7^=8[Z;_\
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M85=%
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ME*;@]D$=.1&WMW"+-;D'DB%)FORXQY4+3&B+#GOI?Q(MY<^?5U6,(""XU<I
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M^E0J._A;AT/AJK,**4HB411ZXK_Z775K;_K1G_G;]U0<N\?$)UUUXKK+A*5
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M_3:9!Z^GXC_KV_+6G/6C^>[-Y,Q)/811'Q71_J.!&S-K$BPK4 3S!Q!(GL4
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MIUH$D#1;20@=]-\,)/7?<X_!*MR>^ZNI^)KDK:.\=K[2+C)^TU0>T5'3\5]
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M?:L;&?FF)_45?W'*GBY_T3,W_P!$)O\ =#VWY_R"NJ\+^:83]FH_N!<&8_\
M.\5^V8K_ *OSU6W#^\KZ>Q[_ *?X\@9]SO@5B-NYN?WFGS%A%[\>>N2MST6_
M:OQ'T_E6GZ/QU]?K[US'Z3_IW'_K76_W>N]=M>@O]5-B_LC?WG+SU4PV\YSC
M*+)8-0;]IS.3=H$\W_&VX"[BN-$=4X];2+@R_'$>6"$.J#96 D*3NH]/"]G/
M]GG.7G:>R5]8VK39=Y:01%^-KB1GPX9Z+ V.\/&HUGO=@N4KBIU2OT6V7*V3
M)EDG,XPB%>6(,F3(D6^68UN0Z&+BV^W&E>60XEJ.V4+!40 ;%H(O,7[XG*PT
MM9'5&/,L   W9'&Y[9 <+3)!)'!3%;)*2#W22GZ=MN_QH@R&MEQ?-K;<[OBV
M06NRY*[B5WGVF7%MV1,L1Y+MDE.LK0U<T1Y)#3OLZU)7R+4A*E( 4H DU(F1
M DZ \>L^23!!.0(D0,N![9GNC,WA@YHYK8XD!OC:NB2IIUMLIQO$>8./0HD9
M"B4N@D>U1G9 ']=(+25 IYU7C2Q.7L(M_HS>./NWCQSO$JX<3AQ'NMX_V;Q'
M'Q\>-YV6MMYFVP&9,Q5PDLPXS<B<M*$+F/(:0EV4I""4(+ZPITI0>5/-LGH!
M5DR"0X09,@6@\AIV*C>#I<VP)D#A.G7=9?6Z%*;6A"RVM:%I0X "I"BD[+2E
M0(44G96Q!!VZU"@F/ F.*AA/T)XA)ET=D1N++(H,54Z6ZU;T85C;B&FG[J_/
M1$2ZL^:I$: [$MK:UE;BPPIU7SE%%.NO-!>) RGF,IT\>[BI-:<X[DV*XC:;
M'EV82L[OL!MUN=D\R#%M\FYJ4\M;;KD6(2PT4-*2WRH)W">8]3L":S<<1,R-
M+:?@<\USFBE*(E$2B*I'A=_JIGB+_O3X?_\ >E'HJ2+>/F#G.76BM:OC5T?L
MUT9LDN/ O#L"4W:YLMA4J+$GK96F+)D1DN-*?99>*''&@X@K2DIYAOO13I?7
MY^!^!4.4X)QN^2E/W\]+ XAAIMY7WMK@H&0+:A*W&OY>('EN7!2G -R6VT\F
MZA3OZX?Q^@42)UXYR(XYF 9MV3D%+S&&+Y%Q^SQ<DG1+G?X]OCM7FX0HZXD6
M9<4-I$B1&C+4XIAAU?,I#2G%J;&R2I1!-%(,]<>8MUK*KA\3_KIMI^-NV723
M]/\ *Y?0_#U_-13KX?/KN5)^_<=#T(V.VP[]=MB.G0=]QUWZ=012IX)]_P".
M7TV_LC<=_?\ K2Z/?W['?U]PIT/#^/<BOGUU_:IS#^QZ>W_T[7Z?EKZ?T-_K
M+LK]>?W'+XOUA?U.VY^R_P#>U5,I_G:B?<?MWZ_G_+72C!:H!F'OCE: N*G_
M )-N9]UFGSZFQDK<+!^O-H[[_*4#OW/ZJ:[_ )/7ZM^V-B9_D[$6_P#HZXSB
MYI.$7[^?.Z]79XG;.SAK]JP]K_Z5OA?X7L%<1>[NNRXE<+NVTE]RUV5Z<AE:
MBA+RXD13J6U*&Y"5% !(ZD$[5RK0I#$XVEAW/]F*^,% .C+>J%O/@;QIDNYZ
MU<X3!5,0&%YHX05-T:Q3L//RS,VH"S/Q/=0<C?+#F#0+/["Y,8879\IO-O6H
MAYYI#DA"&%)<4DC<I 0%; ;C;FKH_ >I_ 4*6]5VDXFJ6O@46O$%C;%T2+R
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ME^KW;VTL#2QH.'I4ZM@2YTWFX]V((X$]NJ\''>G6P]GXRM@JPK^VI@V#&QO
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M@J;66RE9!)Z;FOM#Z6^K;_4*9_\ \!^;.?;(Y KX@[%]8EOZ74U/Y<YR8_\
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MSU'U23B>/YOCFBUNQV?.QK+7V[A<K!C$=N\Q$&!9902];G"&7UJ4&E+ #:U
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M,,2SI"G5^:A02GFQUL;CE]5I&V_6O9]'L3AL)MG XG%U31HTJI<7!SFDG=<
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M5]2[;:DJ*C"A @;[&+& VVW_ '31 W]3O]=3.F?RZX9<E $'>#G \1 /PY*
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MS9K49.ZFD!266([;8?EONN*0E#$9MQY9(V22:FQB0")[?GIRA5M=5D@/J 0
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M6"QLN-042)N/VQ+<F9+/D18+:&H2UK<D+)0G9)"=RL[!.X9\.M.78JF-DQ<
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M8BMA$9U,>2IYJ0M3/.@/(;2L*%98*@.])W;B_;UWE9-*DQK'5(+7BF6  D"
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M/W 8AU '7'K6>@WZ=8I[^OT"IIL92)+&AI(@FY)'"\]RM.>]QDF8R$  'C
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M6*;'MK/<Z"PN,<=W@1D,AD>U7WU*;*88014;8YP7"V9CS UX6M?T7T=Q#0K
M;1IUA$1<6Q6</%DOO.2)3[TEY<F3(D/.'JX_(===*&TMLM<W(V@) K*>_?(,
M1 B.\_*.U8MY/"T?-<ZOV1V+&;5+O>072%9[1 0'9=QN$EN+#C)YTH!>?<6E
M"=UD)"2=U*^;L2=JH5QC'5'!K1+CIE;C?15+<3NKV5<5F8,\,/#Y>Y5KCIEN
M2LZRQAB4SR1K;(@RFS"G(:86+22LL7!UN0#*2\TRE$B(XZH%FTVLP\FI),>\
M6Z"0(S$P9,B"; <Y\<-G#O8.'S K-C,546[W^+"5&NN3&&VS-G>8Z9*HR%D+
M?:@,OJ48\54AQML;%.W8%BUJOM#:0WGGY&(Y>94BU+2G???H-_0?E) _+T]=
MJ*RH#ZX<0-XRZXZ@\/&DDJXX+K<]:GDX->\JM+L6QY:8RFEWZ-B=Q>0J.Y=8
MML,E49U12&9'DR$A:4+Y:7 N$"T'/H'/7+)7J>[3)>\$R-UN[>"=3<9 Z3F9
M%EL'";P(6K0S((.K-_RB\Y!J7=K/+:R),Z2]-MXFW)" ])C^T3)H9G!M/E2W
MX[JD2"5)0H,I;2+@,!PBY$?Q'CWJT]V\?<)W20;V,6-X^>F:L:JE0HX:MZ\X
M[@^5V32B1,=Q[,=0K!=7<(R6[VN4]A[5]03&MMON5S2R83,V3*6A4:&^^VN5
MR%"-UJ0E95L+&N#GR0#)  OW[PA0CT0\/B^W/+[7KAQ$YC=+]JM"R55Y$1B<
M\_:2B',4N/#DQ@_[ J&E;:'83<6.PEID-)=:4Z%J4654Q--P 8UV7]J&Q8VM
M)X3E&G 6S-M!OEVVZ-I1L!L.AWZ?#W=.U%@P)G6([E@O7K7G'- K)9LAR>RY
M)<[5=;I\FS9U@M3]T:QZ&&PN1>KP&6W#'MD4%)?6G9:M]DA1!%$U%XY<M8RO
MWVX75>+7!/F/%+J+DVIVNFI3]WP5]V+/TD1A\YR-:UV9Q!7;I#,9A<9#3:H:
MT,79J3&4[)=W2V\6774FE@+8DS>;=ROU*K'68"#J'6D=Q),G,SVJW&Q6B+8+
M-;++"0A$2UPF(,=#:/+0&H[8;1RHW(0"E(^:"4I_%2>4"JW&23Q\N7<K*Q=K
MAKGA.@^%7?,LOD./IMD%<]BQ6]QE=[NK;;S+#@M\13B5NI96^A4AX)+45OF?
M?6VRA;B853&.J$AND228%\K]>8FN/+])<I\0/-L>S%6>2F.&"39VW8%AM2Y=
MHN]NR")(0U>+==D1UL.JOT6276T2G''H;;24EML.H#IAPD$#59;2VBR'9V)
M(]XZ03?A<#(>%E.C>D-@T5T]QW3C''7W[/C<81XLF6>:;+5T!E3G25+?E.)"
M0\^M:G'EI+BB"L@2ZXC_ &8OW^'T6-5>*A!@B -<X,C+HG-9:J!8 < %;2I1
M*(MLO5L1>K/=+.Y(E1&[I;YEO7*@OKC3(Z)D=R.I^+(;(<8D-!PK9=00IMQ*
M5).XH@L0>"KAX:/#KQ;1C4+(M1<YRZ_:KY*Y>'Y>+S\QD+NZK8RB6)=NNP$P
M*\J_QQ^ ?E-;A]+++R@7D!=%?JU YC #E),G(P  1SF<YG6\*RM+:&D )'1
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M[J*VO*B+9[G8+/>VV6;Q;8-U8CR&I<=FX1&);;$EA8<8D,I?0X&WF7 %MNI
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M4J$/M_E1UV]*CPRX?CER\T6G\BURG_3 >-G_ -)<+W_V'^K^]4HM?Y%KE/\
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M>*S9;L&'D-GE2V4+6['9N$9;K:&W_9G%+0EPJ2&Y&S"]QN'/F[=MRB;?(_Q
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MD.EXVVVP#$1]EB@T4K)=$2B+B&H'[!LP_>U>OX/D41=5"2=I$CKT\YW<=O\
MGJ]R-OLW]?7K4#(=G62+<;#^OMD!]+Q:]M^G>:QUZ[[;^GN(VZ;[5*+M8XS^
MQRQ=?^D]NZ__ -&UUIV)UU"^.^79BUQGO;(,VXQ5LN><AF.W+9\G8AP/!3HY
MDE 5S)4%!0.Q22:OX?#/Q#@WVU)AF(<8)M:(;)DVD&?EAXO&-PC2XX?$5(%R
MP!PM,YN$9<,HOFE@NK$]E"(-KFV^(VTVJ.EZ.W%C>6I(V0PTTLI2$CKRI2!U
M42-SM5>)PKL-#75J-4R013)+FQ$;Q(',1F(C23&#Q0Q;#4;1K40;@50&SF#
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ML->LT78EJ42B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41:<J?ZT?8**(' >
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M.HK"41*(J[O$JW^\;:_=]UD'?_6U?F&]%&O=;YW\/!46^NY![JW))W_'('0
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MZ?6J]P%RFHLZS/BT0;K!8\I$9UYNX)CJ>GML(2RZ^$J4\$<YZ[DY=5P<06S
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M05(+>GMC=0I&X4E7W/L'FW3U"@K8[CJD@$'?OPWM1C:NW,<UXD?RKB;']JJ
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M_IV^RH/A<?%%V(*E$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B*M?@/\
MVW>/?_RHKR?_ %);O\?V&BC4=A[=.CW*RBBE*(E$77TX_P#IQ(9'N1^LF.=_
M_$W3MU/<?WJ*!V1G\?GFH4 ]03_7 CW C?<;]=]^WIOU(HI5W/AE@#23+]^P
MS%0]X.UNC[_^T-N_U;U&=C!Y(K"[D"ZRXRTIJ.7 H!?,WO\ .! (;>Y4$CUY
MARG;J:K8&[[7.I&JT.!<T-!!&HF003^,JS4>YM.HP>S!>TM!WH+9$2 8DB9
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M=); G'<8<N4J6[ 1!N5OWN,A0]I?,:Y@2 '%-C8[;;#F3T5N<6OAZF&J>SJ
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MPG/KPYKSQ]^GF/YUNF=^.G?"_0+X1?Z6'1/^UW91]D,5Q[Z1VVYM0?\ FG_
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MM/'MV'$)I7TV/WM%GKW&]ZE [#J>GV;;=:]7U0ACMC[2<][:;_;-C?!,&#G
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M3;\.Q'/QL\/0W*=LS]W?^55P'PW[_8>I.]?/^G/]4=M1_JS.W[]+M-LL]#8
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M/43/KE+AW"8E<=B8EJ',F.-+;>?"VWG(RV?-2A+NP.QS*6T<>VDVB,;B"QI
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M5]FXS<9,:.I"K9D$RT3WXZ(J0^77HUU#+2'64J45 5>^UXFP]O6@.<ZSX$N
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M@,: W<9:UA=I[A8QJ;*=4;PS>!9MPOM<-^ ,N).S;C4>8E83LV0L+;F@I40
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MAL,YFY6BYPU7),B#.C[^3(9*IRDAQO<\NZ2!N>E8S?=:&C(.+IUDF?!2I?\
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MR"E]PP\.=DX<-/8F'0Y46]W8/R9%WR<6]$&=>79!;(7*0E;FWEEL)0GG4$I
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M::BH<CO65]3GLMV<*%/0V'?:T?SD[E?I^SN7!I(N Z8B+Q.HN>/ Q=<>X9N
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M2J-'6HJ6PRM2MB5*:0I1V.XW*DD]#U'7H>U$6GLL;_.['^LM_P#!HB>RQ?\
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M+K3C:Y%DOF1J+=EA7!:T-H5+<\IU#6Z%+2TX\D,(=*"XI*1N-<G,QQ\ELP1
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MH:!;7/)::>?LZI\1RY1QNZVVZ%\@ 4:*W4I%@$C/B,M>,ZVRC12PUEXN=/\
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0(E$2B)1$HB41*(E$2B+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g40894g56a56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g56a56.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2G64&AO=&]S:&]P(#,N,  X0DE-! 0
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M @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M  #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M    $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M    !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G
M1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M      26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M   %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";"
M @9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"
M!5;G1&(U)L=                %)S;'15;G1&(U!X;$!F@           "G
M9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M  3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M      4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V
M)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,96
M9T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296
M-T5&]P;&]N9P      .$))30/M       0 +0    !  ( M     $  CA"24
MT$)@      #@             _@   .$))300-       $    >#A"24T$&0
M      !    !XX0DE- _,       D           $ .$))32<0       *
M$          CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0
M"AF9H !@       0 R     0!:    !@       0 U     0 M    !@
M   3A"24T#^       <   _____________________________P/H     /
M____________________________\#Z     #_______________________
M______ ^@     _____________________________P/H   X0DE-! @
M   !     !   "0    D      .$))300>       $     #A"24T$&@
M #-0    8              :8   &R          $
M       0             !L@   :8                      0
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M0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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M       0$ .$))3004       $    !#A"24T$#      ?.@    $   "@
M  G    >   22    ?'@ 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6
MYO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R
M!S4D="               !  #VU@ !     -,M2% @(
M                                              $6-P<G0   %0
M  ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H
M(8    %&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&
M0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&
MUE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\
M (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=V
MQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.3
M8V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                                    !865H@
M      \U$  0    $6S%A96B                      6%E:(        &
M^B   X]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X
M0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M     6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                   &1E<V,         +DE%0R V,3
MDV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M      +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("
MT@<U)'0@                            !D97-C         "Q2969E<F
M5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M     L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3
M(N,0                                  =FEE=P      $Z3^ !1?+@
M 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
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M $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2
M99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^
M4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1 ))0DZ"4\)9 EY"8\)I
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M+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
MX0#H P$1  (1 0,1 ?_$ !\  0 ! P4! 0             ) 0<( @4&"@L#
M!/_$ &\0   % @,#!@<%#!,*"PD   $" P0%!A$ !R$($C$)$T%187$4(C>!
MD;'P%3*AM<$6%Q@9-#A8<G-V=]$*(R0E)R@S-3E#175XEK*TU>'Q-D)$1E=T
M@X67LR925%5B9&:"E:34*4=399.4HJ.E_\0 ' $!  (" P$
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M5@BK@B8(F")@B@PY4WRG4%KQI-QI_K)/T]0!QO\ "6)VX$9TH.YW.#;5%O\
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MJNT#BIJLPN,U54C.E85Y-.V[]ZV9D%15M%M'$@^4 ;@!4&K8BBRAA'@4I;6
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MX OI@H.#=[>!S4<8\FQ)!'$CS[4F=92HY2JY5 <*GDR[P+2P285(!0D +[J
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M@@CC( %8222 30,**N^E.<CE38],:4LL,ZP>3E13)<H12H281!''##7R@:(
M0O0.0Y )"QR7Y73;84JYO6JM:P*E1-H-6GDW?S+Q@(EBUW2;U5 4@2W1,+A)
M,X''4-W3CCO(.;SDQ+LT,@Z/M)!/E"\RI)?'5I3(U;->;M'+[E2+1!.CMUFA
MB\C!27 -75(-:1$ES2^O2KT97<L%MQU1F7E]3<Q7]/N(J=K&G8B00+2,2B=1
MG(2;=JN0AR$ 4U!25-8Y1 0XA;'1Z4YM^3TBP6ZTRK+.DQRK/',@BF3"1K
M@ :HJ3B[FF-5WFA^<7E!:-(6&R3K5*GP3Y\,N*&7 88@(G\XD&X7'!ZYOW16
M1S*LVJJAMXZK9 YS 4"W,9(IC"!0"P7,(C8.'1IBM<<+13(10"**&%LG+4JY
M':K'P$F&$F\P@G>U5H=@J=NJ1LH5-P*:@(+JI L"2AB"!5!3T$X%.)3"73>
M-T1 ,80&&#5UA'$'!(:)R!>/-A+/LZ%ECX<5PI7M4<6=TAM<98*T8XCL[J+?
MHUKF/$T8BV<9; F:.:3GAJY'0G"8*#A1HFUYK>,  8P[PE"^OK]$'D]:S-E3
M]'6KRDFRQ3XHH9D8$R*!@ 2(#J")S>*$5N*XB3#$VM2*@&0)%:;2S[@&QR^R
MKIW->G_=4<T\Q(:N3+J(^Y01E*ITZ+$B/. N"MGCH7 J"*>ZH'-@ %&X#>V.
MAMT[1UH$$5@L<RSZIC$9FQF+6J& )#M"QKC1J+*$$.Y)KCTMB6N[-ZO20XF
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M,E?,MR<I?P32'P(^[CHJNG.7WH#U=WFTZ>F_PXO.+ADPW[54V*\[SWJH\0[
M'S:AYM>S\>,(_1WG=AUCIKV+.5ZS_P (\'R>FQ2#\F0/Z:NFOW@G@T^X!_9[
M6QJ[G7]C9OQ)&'_SR>'QKFO:<VOM-9_>M']":NS\I^IG^T-ZAQ4Q687G3;7=
MOHI]H$-=<U*LN'9[IN [_>;G:/B](@.+E\F#K\GM%ZQ),4J5#&Y-=67 &+8
M!J,&V4--.5('^(M+$!CY:.KXZ\=23F:]CU6/.Z ]%Q'3I_'QZ,=SJ0&*,D$Z
ML1A#DT J&K<'76";&9<L&)P((1<*-=@KJ9'>6G*6_#YXE)#Q#HF6MNT!O:W;
M;LQUNFH(/V1I&AI99I )B9V%:F_ &N-0NUT!$1IS11%YMDL4 KL I?L;:O2
MCM6#$!X"Q:C;M%$@W#6_P>C%+YGK9OQ(E<>$G5@VP@G>P72CY?#:SVF<E=M]
M&DLI<\<RLO*8^=?2DA[@TI4\A$Q?ASHSL7#KP1LH1(%U1 .<4 N\>P=!<6#Y
MMM!:(M_)N3:;9H^SVF>;7/@,V; 8HC##%2$U +.<.FY=5:K1.EV@0P3(H0,
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MMQ:[%VS$R<T \9Y0THW=98'*I1BY&AM^+5(X.\354NH/ARJ3TXODU'O/F(]
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,B8(F")@B8(F"+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g40894g57a57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g57a57.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2!D4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ($B^@F0X0DE-! 0      &$< 5H  QLE1QP"   "   < E  "')R-C T
M.#DP' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@4&5R<V5V97)A;F-E
M("T@1F]R;2!3+30@7T=0(#4N,3$N,C%?7S%? #A"24T$)0      $)%F[<T[
M^2P\;_QU'>MH61HX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q :0            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              *M   "V          !
M      $              M@   *M                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     %<@    !    H
M )<   '@  $;(   %:P &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( )< H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MW?[:DQBQ+;^49+)'4?RZQ>N25)W3&N)FUXDN((@%I<=WM=_F_33OZ<U[W/\
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M[/HF=E9/3:WFMKG-+JSM]HAL;?:?WEI5.M=/J,V#\W74KG_JNYUG2 X.
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$!_\  $0@!20%= P$1  (1 0,1 ?_$ !X   $#!0$!
M   !!P@"! 4&"0,*_\0 5A   0,"! 0#!00%!P@(!0,% 0(#! 41  8A,0<2
M05$($V$4(G&!D14RH;$)(S3!\!8D0E)RT>$756*"E++4\24S1%-4<Y+"&#4V
M9-(F=(0G0U>#P__$ !X! 0 " @,! 0$            ! @,'! 4&" D*_\0
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MWBHD4%44JB*/PI4ZUJ47!63J8,2#CP61=FLGEW$B\UG\_$["A%"H$IW28:4
M( 1"JM2=,$)"&"0^DAF?'>.(ZAYM+K3K;K+J$.-+:6EQ"D+',E2%(NE2% \Z
M5)*DJ"@0;$8T:RT_#$I$!(6D@@@@U!!K0T-+C&[-2550VE@Q#U]>C,U&;KBZ
M58))) %CJ=AB"'#,_2SX@D"IQ%#Q<9KX"Y?X8R:?QUSS3<DTJJ.'[%G/ 2JT
M*K&0I3;]&IK#4B9-=:25H=#4=380M27'4*4DX]-PD,[1F<*/D4HN9CPE KAC
M\A!(HHN!4@6+T-#CSG%&497G^61<KS0A,.9!$-8 U(6Q 4GHQ(+$!C<4QS"\
M,<SP0\6<S9>HF;N*<#.V<\N9XD9CX<Y=S'1Y^583-6@.^S0IL9V?9FIN5%GV
M1]VA.3%,2),*-*,)Q^.@C9/$N<<:E$S-2^4KRR%%E!+9E%A%<0E)&B)$ *$%
M))_KTJ*0L,JFK&M,G[(^#Y5>6'/%ISM659BC-,E@Q $_@!+*TI4H@JU#O4ZR
M 4#6 X9AB>F9:GGSA/Q,S%2>']!I-5D<15(KL5(AR$EMF,F:\XPPW"8D,LR3
M(=F>:9<4AQEII]IU]YQQIO2S1)J&418ZN[05)ANIR$%B0"3_ )W30;>N]XDU
MWZBF-&C1HJ$A2"M84GN_^6 Y4P3#TI;=J $MAMN(W&KC2Q1Y66\XTB!3V:PS
MY#D0L2A)<90ZAQ3A3$RR\\W'NVE7G%'ENI2I""DJ4I,=S @P]"%E:]7("EW-
M7W:S5L*''$0T0*BF,"4JT]R$C=_BU4)"=(9AR--G-R]XNLO9>H=$H:<G554*
MF0H=,]L5)J?F%$>,AOS?+.64-EQ925)0I]"3<!;B-5#'X^_I;%M_GYO[IZ/M
MN<;,.7N*?&C(U8R^V*Q1Z7EIR?+=FTY:&H#[S4MR.%MRV&EMOQY#\5I3@0%)
ME H05.,N*1G2M0A$(BD)+A24FB@;$UW8#KA#FH\!<1$*:BH1&&E4)"B$*Y@L
M0+$^ YNV)@( 2E( L+=/74_B<<<$&HQ/OUQ5B<,&&&###!AA@PPP888,,,&&
M&###!AA@PPP888,,,&&&###!AAC!9B^QE4>J)S"FG*HGL+Z:J*LN.BFK@+;6
MF2B>J6?9DQ2T5AX/@ME!/-H-;(,4+08.KO0I)AZ20K4#32174]FQ>&(IB($$
M+7%U-#0@%2RLV8 $D^'(N",<0>!_@_\ !IQ2X[5S,V1>(M+6_DO.+.8H_#K*
M>;*94J7,DPZK,GL*C-%Q^K1*9&EQH4A^/3WG(ANAKF;;<*,>RB9_G\/+E2\W
M++3#C(,%<9::A) #:M(2%*!+.02784Q[^/Q1Q?)9'%RW,Y;5#CI"84>/"[U,
M*&7NDI4$K(?XRQ2Y .))>.?PE\%L]36^->=*])RY6V&Z-1:FA-6C4N#7HL>0
M68J9#LIQ*X[K#:U@N0BTZM"N5:O>TZW+,YS*! ,C)PU1$:RL!G ?G0U'+D.;
M''Q_VH]C/9UQCG,EQ7QC.KD52L*'+10F93+09L);NDJ.I!%0E)*%/H!!!!(,
MV.#>6<@Y!X8Y1I?#^-0Z3E9F@T^8VW2UL+A.^9 9=ERWYS3BQ)DN+NN3,=<<
M6XK5U02"<=5-KF9B8B*F0LQBO3H+ZD'4P2E) </X.7.-M<,91D.0Y#EN6<+P
M).5R26ET&#^&*%RZX7=@]]$F02"5) *UJ<DL21AK*7Q-S-QES'F*F\*\Y9<I
M5 R[*>ARJBS+I-3G2I4=U3+BG&6DSGVPY9#B&DB,&F"R7I/GN*C(Q1I>/ 64
MS,!:0-+$V8C4&V'YF84!<U>O8Y7G>19K'F8&79G)SZI6(8<=,A,(C+2NR@H@
MBRG22'!9JW.2H/%FHY(XA4_AEQ3S-EV;,K@ R_/34*7%FR'7 ORF50FTPG%!
M2T!HI7#;?:<6RHN26WO,01)S$6#$B)@1##3I4% 4(JY=B"S7&Q--L5F,\R*3
MG8<A,YMELO.QU-+2<68"9HE])2I!!<Q#I"0['2?##S\4.)67>&63JEFROS(,
M2/#+#,1$^H1:<S,F2I#46,P),AQ+;:%.O(+KFI;9"G$A1"0<,*'&CE284&(M
M22Q #[L*];CF,9LQS++\J@)F<QGI60@*(2B/-1TP(*BJB?C4]]F#U%GPQM$>
MXT9WH+6=:9GB@1(,Y@U"ETR,FFR*>J(A2BV')(@S6T)D,)0X@OS93J4J"GW8
MSG,ALI$1$RF7C0(B==2-)!J2&Z=!T\,<J6G,OFI03$O,2\S*J2%IG8*Q'AL0
M^H+)2"$M4BEQ?&]\%^-%)XE0ZQ2I,^C2<UY6D&'7HE)J=/F>ZI3[34@QXTEU
M48J<CO,R&P5,H?:):<6VI*L65 F84%,>+ B(0M2@E3%CH4Q8L*[AV>O(MU\A
MG>2YM&FI?+,SD9^+**"(\&6F$QHJ20WQ(%0Y!#6=PYWQ?%OC(SEO,67>'66Z
MKEZ+GC-" 83%4J5,9>A17ENM)<1$E/\ ZQU?D/.**VG@U&8<<2R^Z6F7+PI2
M9BB)%AP%KAPT!:H@!(%7+-O0$D<N=HF.(,CD)R3R^<S&2@3TZLPY>6BS"(<=
M)9TJ,&JBF[6"BDBS8U3-N8>*O".EHSGFK.^7:SEZ/)835HU273Z8PS[2H)"&
M93T6"KE*N5I+K#I=0I8683C0<4E"1$FDZ(,!:HJ20H)!/P(H2;-LQ-":.;8Y
MDW.R.5RT::S&=E9:!#!6F+-1$2L,DV*8QU!1():&0Q<'51L23REF^AYRRY0\
MT4&9&G4NMQ8\F+(BOL/HL^ 5-%UAQ;:E,N%33H2;!:2+:XPQ N$K1$0M*G;2
M0U>?AL_VQ$E-RN82Z)R2F(,W+Q0Z(TNL181 )!(6DD%B"YV8C8C&W8C'+P88
M8TG.699%!13V:>Y35U&8\X[[)4%.)\VFPDI>J3[2FG6U-JC,$%*BEP*=6V@-
MJ))2Q!OTWOY,WGX7INV XPU60[!:BY?0EUMYJ+7$K5(>CP)G+3U.L+ECR6XK
M1$XJBS'&I"74)0DM)45!,>7MV]-\&/GTW/5_+D1SQ?CB=76D9;7-I<(.5U*U
MNTU27XM2BJDPW7Z6PIA3[R[2W6TM1WEM\LMQ:D\L8MIYSM<$WMY^/]]L16W3
MESY69N5:-N<</?TR*<^9RXZ^%?A%(JLG+V0<W4FN+1/C1GIL).:FIB!57Q$0
MZPJ=,@4F/&3 8<>;]V4H^8A+Z\;9X"S&4X?X:XSXFBP532<HRX3BY>$4".8,
MF%1U!(40=*[,*$BHHPXJ9"/G&<9#D,"95*1<WGH<DF* HI"UD $D,:$@O=B<
M<R<W>&;(L3*F:JKES/\ FLUO+67ZQ7HXKU'I@I=310H;E0EQI"J?4TSZ8I^+
M$>\ASS);:)09:>24NK>&A>R7^.'A[M<[4,K[/X'".8Y9&SN),2D"=F%2X2@2
MZE1U.4*40%)A+(8T%#1VWYQY_#/F7!/"\YQ7%XE3.Q,I@H7&AA,<'1$  #J+
M$LL!CL7Y8^FC]%SF7.^;/!+P;K.?ESG:N[3ZS&I\FI)6F9+RW"K]3AY>D.J=
M_6N#[-8::9=<NIUAMIP%25))VGQ\B0A\69JG+=0EDQ(:"DD$".F&E,=0:^N(
M"I]W??&@,MB&)*0U*<K45J*E74-9 .]&&_/ECH*K8]=#<6)N.HL-3?L,>.-
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MC_MSW^VR?^(P=W-3Y&OK<X8#69%OV]WII[9(Z?"0=K#6V /CY@_?#!]LR/\
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M BAWTV%6'R\E_#N4GMH[/BHLD9[ J2P^)$5)%>A9N9PU/&">?\J/$L**5?\
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M\?=/#'RVE- &K5PW4U_?%7VT_P#YP<_VZ1_Q&(>_(;T;WXXLVS>[_O@-:?\
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M?RIS\J$I*E+DS;J44H22;HOS'F42K?OPLNF/CCE[S:J>"B!SY,6 M6^-S_Q
MI;ASL-'_ /;++?"J98.>5NK4'A-_]#4TR[3./?G,M.%$G(905MMN%/.U7DFP
M=;< L23<6O?;MU/$\?4J$D[Q& J19)',6?\ 7GO[^!8-(<=/0F;RP<_^5'<
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MPO\ JV;V-M>0VO<C\[;>N&(']7C]AC7/+63L+#4&X)L.FIOL#?K<BVF&)?\
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M</?/$7H35B"!]?T?;;"6'8?0=-=K$]]]#UM;#$^]]RW,?*H/-ZJ4ITT!N+Z
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M2UL/-MM^>QYH6XJT28BQ(?=%9T DC8] 34-T;UQPY#(\FRN)&CY;E<CE\:-
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M:H2H:(RRZ] "PE&EW2?I;#*5K625>][YMW.FA/PV/IC]$E_#$4C2HZ0'B?\
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MG;D[;;;XY C)"0E,*&D @L"IGV+ZC4<SU\TCTV)#8;BQ&D1H[0/E1V$-LL-
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M<\%^QTR V ?,F3%(5R)(LEM*EFP!..1E$A-Y],0)&2UB.(H$921="72H%PH
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M/QW/\'%Q8=:_KROX7YXIZ^Q]OF.6"Q['Z'!_+V&K;]3:QPV]^_T\QA+$["^
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MC(AKC1%37=K(*4*5$:"SA2'4%;#K,ABZ$GG.HN=.^_4G?46/^&I@-#)#Z4N
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MK73_ $1^6+"PWJ!L:$EQTVKNX\J+_,?+Z#%E8]K_ %Z'?6^WY[G$B@+U)#V
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M"$/Q:F84EPOR6W%)6ZKS0VE:0!8((VN*VH?7ROS>F(U_(OR<5O?[^H?&-H/
M7*&5IL&IT.HYDIU1CRI4B9+8JJ&%UE-0DT9;M/J89BLH,+S*!2 VW";B.<B%
M,%Q2'G4JII8.X9_6C_4EVL=V?$Z^;6+[U]0/KR!KA)/A]R%-HE2H4TUZ7!J5
M,K5,(<JSK4F'$KF:F\YS6H,MAE#\9\UV.PXS)YW76F4--ATA!4)":%W=P '
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M-F++L2J5>F0V(,9^4[/+1B1IQJ+$67 :F-4Z='8G$SFA.C2&T2/UGE$BYJ0
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M2,B+!*=,34(E=(%@]C>W+]L>Z4$A?O(4M!/.E 4I5@;)LE-RLD>\0@K*$_>
MVQ!84K3QL[,>A-:NP-!C*8<1"4F(@HUU#T<5 -;6WQKV;YDZEY8K]2IB&WZE
M3Z34)M.8=2LL29L6&\_$8D!*2OV=]]MMMT@)/(HGF0 2.#FL2)#RO,8L"%W\
M>!(S<>#! I&BPH$1:(1#_$(BP$%+LMV!Y<_*8$M,YME<M.Q(L*5F<QDI:/$@
MIUQ$PXTQ#AKTC2JNE1=TEA<8XII\:?B<S_6J=EG*DVDT:K5NHQ:93H-#RW2'
MI3DJ8XEIJ,9-5C5-1#:E!3DE9;#;:%+4$(02?S;5_$MVT<6<3R_#/#LIELA,
M3^:"2EY6%)RL9<NF%$T*[U<TB(4,A05$4M1TD,DBB1]^*[!NR3A>1F<\SF!,
M3F70I0QXR\PGYF70R4E>K1*1I-6M;?##"5$DL 30=GLE4G,%+RIE^G9IKAS#
MF&#2(S%<K3C++#E2J26BJ5(*&4(;2D/E;* VGEY6TF]U&_Z,91*YC*93E,CF
M,T8^<HA#\3-G23$6Q[P_"-#%V# @BH#X^",\F\LGL[S2>RN4$EDT286)233K
M:$A],, K/>$@)U'47=1NSF/4[B12>%=;X]9KK<"OU*GCB/D^GJCY=IKM2FM&
M5P^RN@N.,I)\N(R2'GW $ !7O<RCCA<8<1RG">5)S::E,RGX:U*3%AY1(1\T
MFH>A>@K5+2\O-1$BCC^6D%+&KX[3A3A>?XJS3_"I2=E96+W06B)F$Q"@2RP4
M!24)7'4(:5$$(>CD%S<XR&6_&'X?LTRH=.9SV*35)<AF&S3*[1*Y3'E2WW P
MU'+TBFF(7G7EI:1RR3SJ4E([CQ/#_;7V<9Y&A24+.XTCF<RH0A(YIET_ETR5
M @!(1,2<NC5LR "17'MLW[%^T3(H$Q.Q^'X4U(0$=XJ?D,RDIB&M J5)3+3B
ME)2$U4#!2UFNTF.53B/=/OV! (5RD%-QSVW!'8BU[[8VM,#2B$82B#&($):8
M8B/J9BI92LH<. 5*3;^DC&IM94J,/B0J"Y7"F"(B"069)4"" S%B0J[[XU[-
M64J#GK+M6RGF:"S5J#782H4^F*6MH.,<R5J!<84T\TM+C2%LNMN>ZXE(L4W
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M&A(L;IU&FEO7'@6=6H&A(TI-   YK>EN7G7'T3&A+2SH"0@]V2*E:O\ .?\
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M(\.V&'>(7'T.(2I/\NLN :[I/#;*QM;F!()L2#>_7;&/ND1"K6D*U%R"Y=R
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MV^E2W2]/3EBV=*N>W,$IY=R+E1O<@C0: ;ZW!(W&L!*E%3G^EA<.1<6+ V<
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M^;.[%QRJ15T [FY!MUW^G76QN-R!>&_S<FWW\"78L-GNY(P<"WMFJY% ?-O
MX4; D=]+>]:^VI%M+'J"=]M#'>M 7>E*CQ<^#<ZN1Y<N=/D/W-/()<G?6P%C
MN+:$;6UTU ];[XBP+="&;E1P:EB=ZN0P&).S[DN]*O5C;EYBM, )Z7VO?36U
MS8D?(BW7YXLUJGDQ8E[=18E^8J<0?+R?[UZ5_3 03N3TO8GL0/W7%@!W.PBK
MT!)?>W5K  [$!S6F!\0W2]?JWB6L^#2Y_NZGU ZZ7]-=L!IWK1Q2H%W+>H)
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MY=-NHPQGB(XNQ>!O#"OY^D1VYTN.J'2Z'"<(2W(KE6>,: F4OF!1!:4%ORW
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M19]F7!O!<D>&Y271)JS_ (WG8:EIEI>9E8<RA&40UA,*-%,)7X>*I17H4I1
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M\7P>MR;7O>U]2-]!;N- /4#"U& #L/"Y=]J>?@QPWN=C1K[;W<^.]W&*C\]
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M U+#PL#Z4&!\.MWZO\_9?"?OL.EM";VWZ7.NFW73$ N"345N2!R^=+FEP27
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M>^NH.I/7%5+2"S@.S/UJ]=][%FH*EK)0I3,E1U LP<EG! :X9WJ/E4*@FQ)
M&A^\!KL+;7'Q/KTP"DJ_*02"S"H#AFVI7=G9N6((TAU?"DG2YI4%V-ZL-NF
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M]JTQQBY4J@!<NFE%;@"Y8V>]7J2#3J;:W&OQMO?:^][6(MN!;>:'>[7:M2*
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MG>K8ME7]T@7( L=E<J3<)N2+"^H%M#\<0H[@&IVHX>M2 !?=[5V)E+#5J#_
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M*+5,P2YE)IS+\PKD*1$@>QLK2M;B4NAX-GRRA*9 #L=Q8O>K6\O!SBIJ'(V
M<!Z;UL&JS>5+N(+ DVW)5J3I<WY0;WY1L!S$ :8NUJE[T(K>M=SZ,X?%7+&E
M.;> 8EMMK5K?%A%I=+@R9LZ#3H4674GO/J4J+&98?GOAIMI+TV0TE#DIQ+;2
M6T*?6HI1=(/+8"& 87-A05+U<$%FI7E;"K<A=G(H;&]:U%Z^A:SC;1,SYBRM
M1*/E2GJGRYN?<FO5=G[4D45C^3M.J[53JS<NI0S[=%BRVX;,!XQ$..."5R<J
MDJMB%;?.KVH"?+?%D;GIT\[_ -N>&/C^'OB%'IDQW^4#-0J24Y49IU)=S+F-
MFF(H#==K%;S9E5,[]8Y&BS&:C%H\6I*CJF/TRGM(<##3JD(HQ ?WY6=N8^M,
M7!JV_IRVOZ\O/%]E_@/Q#ILAI4^N4J:TEK+9?>54:L'9$:AY>SHRS0OU[9DO
M0(5>S/"$=]YU3JZ; ;+Y#Z0,2U-G-;VNX]_7%=0K6Q9N=145M?ZGKA('AOXA
M4-5*I^7LR1(-,HF1*=1J%[-6ZG$CTNO-Y1JU.K*/8C"<,F%7<Q55=?ER43F%
M.ML1TAI;[:'1#$^CTZ5J0]#:WBV)U#<V\O2O*O46K3&0KWA^SW+J@C4:K4V%
MERFY4JE#IID5VN+E5%RIY#JE&>;K++[3TDI>S14WJR_(3,\EZ.Q&"8ADM!0E
MCR-/U]VZXC4DO5G?;]N7Z8MJAX?N(SL:+3Z54Z3!H:*72*#&HC-?KL6'EU5-
MRE0J+$S#3U1D>;4)E#J;68)T"G!+#4Q<V+)?47$6,,S>'OWXO7%G%;T+6\/&
MAIAT^&7"3-&3L[2<T5[,BZH)]*SI&GI55*K*<GS:OG-%6H#CL22XJ$EBD9>B
MM1 IMEKDF3I*&U+!"S(<5Y7^E*]>=,5)<,/EN -O&WD16QD*-.Y)L>W87["U
M_CI;U&0T=F- >= U^;WMS(//&S_3ZL//G@_NTUN3U-KG;;_E; <@S,U^;N;"
M_*@.Q&'J_I:WF*^WP 6ZD][VT.H_>;ZW)[X6%>8%*!.]>5R*7&X=\37I8^=&
MWO44'/Y("-]!T.AN=+VZV/3K>P], +\R:!W9FIMYCD*6Q!>WG9J6'ER-*D\\
M%][]-QU.VPYK6UUWTWPY[%RXH20U'K0->O@03B6M\B'&YZ._+],*-]2-22;"
MQ&N]M!8@'YC?7$L 6K6M=R&-[TZC<X@E_)AY5I[V&]\9R!_U'?\ 6+W^7Q_C
M7KC$J_I] VYQE1;SY@_0#Y_1L8J7^U/?VDG7H+$'\[GKZ]#=(H"SW#>O.[T&
MUZV#8U?F5Y?;'@!;6YT^9/6_RN>Q/KB6&]6-]J4;U=@']",0_A6C<K<_ 5/C
M<4!H%$=[Z=1ZD=038=SVPK5]+DWY/85YV;85KA=F>@L>E_![G /6_P#'0']Y
MW^H#:S<@&-6H23]1S =\#>YK0GH[6^U,:MG3,$S*N5<Q9A@45^OS*/2950BT
M:)=,JK28;1<:A,*2VZOG6%$)2&G"HD!*%_=/59Q-+R_+YN=1"B3:X,,KARL'
M_BJ4E+:$DEB21=@-B^(F9I<"2F%I@F87 0M<*%NLD:B X/Q*L"Q-& KB&>2O
M'5DZI5]C+O$K)^8N%U1D.IC,2Z\%.4LNG57M3SL6#+A) <:2MUR,J.CS$%;C
M0-SJ[*>U^0BS,&2XGRS->%?Q*U0I&;G0\K-Q$$&*@K2 J&8:5H42I)!"KN&Q
MYB6XLA*$O_B.51,M7$B+1"C+ T*4R Q.A*DZ24OJ2WQ.[5,Y(TJ/*C(FP7VY
M;,MAJ2P^P?/8>8>2%LNM.M\Z'&W$J!0I)(5< ;@';D)4O-(1&@%$6$I*5P9F
M$H*$1)%"E0:Z3S8BM+8]=+H0&C+C(7+QQ5C_ $J 4""''( BCL :OB)G%OQC
M\/.'-8?RM1:=5.(6;HKI:F4C+)2XS3G0?+4S/J"&WV42$/*::7&80\^AQY"7
M$H4KEQKOB+M-R;))V/D^7P9OB7/(7Q3F5Y2-<22@ ?&M<0D(UI=)(25*=0<
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M,MN^8/*<5HK'F1VK9XB4D<V/9[G1RS,YN/!ES#7#5-P%P%)[Z9C0B@,8H6%
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M"E_Y,.!#$*$F&='=PDI("$Z6I85>F-C0@((AB$E,+NH0A([M*4$( 8 Z0Y(
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M6E<=MQ!20;D&^/59GQ-P]DLFJ>S3.LKDX AJB0M<]+%<=+/#$)(B.OO004Z
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MZ GKN+>.>'^%,IB3\6=@YA-?C$R4++9"8A1YF+,P]"^Y[J&8BTK_ )@)U)#
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M949E*+1W:I>,D+"W(5J)9TL15::I!<8M&EI6=1%ASR8<=&G4 P(UA@D@JU5
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M4"Q%AVV2I*X<)$*%"2E("4]PA&B6":. $V;:[L]SCT@A2T&7AR\J!#"'&H
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M=_RFC#^VS!Q3<4ZLQPK]N;"YJ.EVYFF#H.8#6UQ8@;Z::;Z;="+[:12F^P8
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M^)Q4/N)^?Y)Q0?G\U??$_P!!\!_Y*P@^X/BC%N7B?_-.(W_[?_DPJ>O]G_\
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MG$?Y?^S_ .;%C<^*_IBL;*^'[QBQ_,G_ +OIBNQ\1]%8\C]T_P!E'YG$JL?
M_3!-QXCZX7^F?B/]U6,9_(GQ_7&0?G5X?I@Z#_S3^2<7/]7^D?\ S8QIN/$?
I7"J_H_VA^_&(65X?<8R+N/!7TQG8'[/_ *ZOW8&_DGZ#!%CX_88__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g40894g57k72.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g57k72.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1\X4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q :X            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      T,    &
M  ,B   #30    < 1 !3 %  ,@ U #( 80    $
M     0             #30   R(                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   ,B     %)G:'1L;VYG   #30    -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $    !#A"24T$#      4OP    $   "@
MF    >   1T    4HP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ F "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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M:&F/T%FNGT.)4JK_ %'%OIO8 -"YL#31&23%
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MW1W"@1X<ROB6_3C2UV*9@Z,5:^FW,QO<VRR_$90):L\/U.@NH='?M U_F8,
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M&;)809&2))FB*Y&*C6Q1O:=[$E!:6$UC4/LK:6FU?SE^;RJ *4CL1R-Q((F
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MV*Q'.8U=YT76],NKA'\]G<B3X95))&8&(]>/4SZ5T70M4TZZNC<(<;5X8W*
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MK([B.DR9#WN(JL1A8SG)YW/C> 2#<=PU_A]\N>><<N75/)4"M:OO;<DR"4D
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M)"QYW,\R*@V,)<L7G4:DSM\S?\LE&94=R@0 $SD$=PF=L@]\;5+=M[3[[?Y
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MDR#&Q.AU50>[N*R$HV4]/3TTH\.*&EF#B3I9; @I4VPEB) " 9%>H'<]N/D
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MM+J4C:J"2%!)*0L$;3"1!!S&#U]/A6&XZ-HL?Q/&J88VHP;:NBK("<)Z1/\
M98PG<?IQRJK[Y^ZIJ&>U"^=4I3MU=/2,N//J6XK'"E3)C '8 #TFMA8L+%I*
M4LVC# $@-AM)2D'DR ,G[QCUBJ\V6X]_4[SR:YUA(3'V7-=0-K5<B1(XY<2
MT-B$7' I8)\D4Q9*<N(!WA5O8C59J+FH7#>O-AUQU;1<;"$J<) )2C,<@A1)
MY^9B*W5&C6MSTP\\AAI#R&75E:6TR86X"DX^["8 X$S/>MME5,;85E=/:O+9
ML&+*1?7VD &7]%5/Z_\ -?[]=P:7O:;7D;T(5!Y&Y(.?S^7I7S:\CPW76_\
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M./8GY?\ >JP;D[;RY>X-9DT6371J>?+J#WAID^-")7'JS1V'D]LDPU..1 C
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M01Y:3H8+ E9 I$\[#+'A,KXCY!&!1CWR)_E1S'*_OW'3],9<L/%=3*B@;#$
M>7>M1,2228&.$^\GZF^'G2]L>F$73S:?$?ME%!!(&]:?$*C(R94 1D""(XJ9
M#U6*3>2&H:YI'M1SC1A-@R55[$<B^:)X"(Y4<B*YRN7TGKTFH)=C;O*42V"0
M8G:8'?M\SP?7WG =T9"U;5)3+<I\O&25"/+,0<# F8@9/:8K(PS$9!F3\+H\
MLA6*C1P,DF2W.A>%4:YT&U)+58#7C>YYUD"E,5!J[R1D16EM*T:T=))04PD
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M:<ZIY>P!/H(^NW].)JBC')!$28 ''.8K%\%O9.5XE2Y!-CBC2K,!RFCQW$<
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M0UA&$0L9+(DF/]!'4RRQ!P9<84SRQ8AV!B@5JW7^FV#J2$(?=2V\%%"2LD@
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MJUW&L?46@_IH;!\P3< $GDR0B.XV\>N?*3%9/P4OVK/X\(N75K;9;U'J&Y>
M4 @MMB\>45$$ X!4H&8 GCC[$=L<\J=T=O,,W#HWM?5YCCM7?14:Y'^'Y\49
M317JBJGEB2%+%,WGEI0O:O"HNN=K24*4D\I)!_#]Z_5*RO&-0M+:^M7 [;7;
M#5PPXDR%M.H"T*!&#*2*SK7FLFFE*:4II2M8O7O@&T&YAZ*-N%'MHEA1L?51
M+''A09=M9QYS!6LBME5]HPU3,IJ]J#F(LT*2AS)!!5Y@K*(.9BH^(>H='7+K
M=DI :46EO)<R5.;9"D=A"%!*I(),8@2-DTSX<6?6-NEZ[2I3B0ZEE2"4AM"5
M$$+,$DJ6DE( (C/,BJ:2OP^X\F''E8ENN[X,B. \ =KBP2C^*0;7@[#5MK$&
MQGB5B,4<-J(SM_=IQVZVRT^-^H$)<N[1-PA0W?R]@.V(CSQDQ,3QSS6M7GP4
MTL.N(8N7&5)44G>I1\W!.)(B8]1&9S778]^'S=DM#CS7=>DHZ9@D)#L:;&[:
M[,:4PP^P,VND2H"@"YCE571W6*/5""(Q@W*YTW_QOLK@M,ITA;(#@4M3BF86
MK'^9&\@8!F)P0<Q4*[\$[ILI=8U W"@HD,M!?B #(/\ -V)(F1DXP>];ANE+
M:)=D-FZ7 19K^WE?"L;B=57/T=*5PH=C,?)? ?&>>1*(2/-66\A9I5E->9T9
MS6#CC8W5=7U5O6KUS4&F4LI> \B5%0\LB9A,0!!  X]:DK737M);^P/K6MQA
M12K>$A23W22DJ"LYF3SS%9'LN)9!MW,D5J?_ (GWCRLHR=R.<0&+0:/;\2N5
M%<G#%Q$C&M141K41%:CNY5BQ]8CZBLGZ^OG4VZK2FE*:4II2FE*:4II2JT9_
M"Q;]J;.87(C_ %Q/ K:D-7W-'(6&T4<))+I<"*9"-<USE<IC(TB#(YW[MJZ?
MK#6EINGG7;D-71"24!L&5!L!()W(*I$29, ]R(K?M">UA-A;H;L_$L96/'5<
M;0&RZ2M00$N%.T@@"$A1':2:BY5R)W_J4*KQ]VS9/"<>N/\ R3VB*GW_ %3[
M\>M:R5OK.YM;>P\$A?'?$)G,Y[UN2%6NQ,I<4<Y3L ,DSR3QQD<B>,&/LJR"
MBQG(,9D97-J6VLHA ULT&/J637Q%>(4DQ+$TV0:N@N(=H2&&URM4SWN8T33/
MUBNOABXMU7#S1E1&T(5N $@R5& .3C]ZS[>U?N[6[3:(=2E*"5%3D)(C$(2(
M4KDP8$B0?38+B$^+98U428<9L..V*D5D1CU(R,L%[X3PL>J(Y[&/CN0;WM:1
MS.UQ&,>KFIU:R>;N+5EUH0VI$)$S&PE!$R9@IYDSW,UP[4K=RVOKIEU6]Q+J
MBI<1NWPL&.!(4) P#(&*R3656#32E85N/EC,%P/+<N4:G+14<^;#C-3N?,LT
M"X55 &W^L2?9$B0QM_K$.U/?.A]N:J.1/K4:8/T_8918ACM9;0YTRZCUD8M[
M.^MW UGW\QJS;V>K!SFL:LZWDS9;FL1$[C+]U]ZR$W3Z$A*5PD" ('8 >GM6
M0B[?;@(7 & " 8 XS^)/SJE7XG6VF'XUT=;B6E5 EAF"M,-8,A;:UEL:C\IK
M.[D,F843E7CTJM56KPY%141=9UC?W2;EK:Y&Y: < 8WI[@2*X+_B<>7<_!?J
MT/G>&CH[B!Q"SKNFB3Z\\&1P8,"OG]J8, O1YN/>N$[ZC&ZBMJZ\1O*5.R,_
M;_<\SQH!")'<Y7A1R$<+R)RK4<B*_NG3=._;&$%7E6E:EB!YEJ"SND#=R94)
MB!,<$?G7I[+2_@1U*Z4'Q$_$KIN%@\!OI[J!M  $)A(O'9D3"B3D)CC9%"A"
MZ4-H;A@NV?+WNWBB',I3*U\>/B^U! L0*D4#7(XCN2,&CW)VHKN$1J7!<K5J
M-PC<=HMS &#);;!S$CDD=^9/%6M78;3\#.D'DHEU7Q ZI"C)\W_RC14G$QE+
M+8XX3 Y,^S>.)!@[,]*DZ.PC#VV 9W+EO>4A&/?$W;RR*Q&,>][ <L'RJ!:Q
MCU3R/:I'/<[PS<+65I4H$(4XV!Z>(D*!QS!P9)5/!JY\064(^'?P9=2"%+Z?
MZG2M6Y1)5_XCNMI@DI2 ,=LB<FN#U'18M8;95L5CQML.F_9:QE(I2$5\J9CY
MRR7M4I"^-'D55:P?8%B/X0:(QJI[LWU+\3<J2EQ]*3$0E+Q2)CG'MNP2<FJ?
M%U"&KSX?(0@C=\,^D7EF2J7'6[IUS)D@%:EJC=M$@    9UU&5E?5]6Q*2*!
MS("R]H443C'+S\S#\()(Y,0KI'YG/7L1I$1J*OWX:B>+2[<<LG%+42H/KDP!
MPMR('H(Y/?\ &IGXD-M-?'"P:;00DWO0V)41)T[1#R3.9/)@=AC&8X]4UQ/Q
M):W&WA>M.[JT=4OC+).A'15W-0'8DII$E-?X51$.A?/W(YWD1RJ1*/7;ATTK
MW?S%!*BJ!A10H%4<1/M[>]3VF,MI_P 53=N$GPT_$5Y"4@K\J4..*3YRHK*A
MCS;B21*L$UJGZESI7]1F_P!71FO9&A;S;H1 M<5Y')'#FMT!C5>17$>[QMX<
M\CG/>O#G.<[ER_0W3R?%T/2G,2JU9400!Y@@21&!DS^U?OKTVLKT/2BHRI33
M2B8 SL!/'S]!Z>]?=AL;M#@D_939^?)KI[Y$W:W;^4=R7ETQKBR<3J#$5HV3
MVL8WR/<K6,:UK47M:B-1$3Y:OKRX%[=PN-MT^!"4P(=6!B(,?\TSWFOFZ]O;
MDWER2Y.U]]*<# #B@!B.WKSWFOF'VWJZV3UYBH7"(M6F^&5PF@0QVO0,?(;9
M@D60A4.CVH+_ 'C2(]_KN5'.>Y9]=XH:<TLGSJ=!4<<J"DJ]H(/IZ?A^271K
M+0_Q,K8+9#0ZTZH0E()G^4WK"TG=(6?N#,R>,@DUA72Q7U]MN1G4.>)3AC;+
M[]3A-88H59(A[;9(\#E<-[7/:BHJJQR]KT]/[F\HOC5+IU#+>Q>U2U-)4K!!
M!2HD0?4CMZ&/2M5^#MNASK/J1#B I Z)Z]V@D_\ U- OF2)!!,M.+$S$*GDR
M./L%$ASL'ZI#R&J0M5L0RSB*TI1M$9VZ6V0/S(-[6&X81R=A4(-'=KD;W-:Y
MMZXN%!5J4JA+;:V5\'=!,D=Q,D3,Y@9I\*6&G.GOC&IQ.Y;?PTN_#4%*"4K.
MN:.J<&"-Z$&"#E/$0*\,!AQ)/3)U"6Q$>Z7 RW98,9Z%*UC1RYV<-.T@F.:,
MO<P;.%>U[F<<#5O<Y5]//K3>6385Y5)[1]X $1)) Y..2"?2O72UNTKX'_%)
M]:/YC74'1"4**E#:E=Y<[Y ,&8&2.V(FO>2%!;T>!O&B5;).HQ:IQU(3M6*7
M;8IVM\*$4'<TG<JD\2$<BHU7]OK5M%PM5VIO?_** X$@"=P40<Y(G'>  .*L
M+;;3\"4O!'\QWXEALKDSL;Z>=*4QN"9)4H;@,@P20<\;<>#"B],W33:A8X<Z
MSR/?X4POF.Y",K[? 61T:QY7,&K$,7\XD$K^YJ%[T:G;[1=+-TXA2MR&@TI
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MR*OVZG9"3*Y, ;)3X[$ .W(M>.28)K,E?*!%$XCXZ&JY>H7=6KAD>$(C)&1
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MX?6GUIU5=ZS=Z[7I]Z;]QMSZ&'#G9!5Q:BHH06(R&@,M<IOJS&HLR6 10$D
MKOJC[!T9IP_)6*D=2L0BN25T33T:GJ=K9N$AIQ9+T$!19;!6XE)/"EI24I,&
M"08,14QH&FIU?5[*P<44-/O /*$;@TGS.!,SYE)!2DP8)!@Q%:K-@/Q8L4VS
MP_9C;K=[$2L-,2V3-<XIIR"B8[5VV061\:N'8RZ-+EREEPI K*WBBL([HU2:
M'9U@I_S65X=U5\/+BZ:O[G374H;84$VEHXDJ<?4D#>@.@@))5(02DRN4*V@;
MJQ^IF['1M?>TFU<+K*1*'.R"$C<@\DD+W),<*21'%;9\:N:G(NH!;^ALH=O2
MW6R%?:U-I72!RX-C73LCK9$.;$DA<\1X\D!&%"4;G->Q[7(JIKG+C:FE+:=2
MIM]EQ2'&E@I4@C!"DG((4D@_]ZP 4E B9F09&W:1Z1,\09B)Q4C9MM-@FX$J
M+/R.G4MG#&H 6D&5)K;!8SD>BQ3R(9!.E1D0A/&&2AFA<0CP>)[W.6TH!0@R
M1Z28^<>M>D.*1P9'^E64\S(' ,CD9J.]QL1Q[ L:VOD8Q61J:LPK># 9C 1F
MN<][<JLB;=S"'D$<20<YPYDK3R3E(5XF(-Y/$G:E"D0F283D9]/7]?S-"M9)
ME142-OFE6)F!)QWB."<"K&:]5XII2FE*:4KYB^LC*;%G4Q>OBF*CZ#(9A*I@
MW+PV0N76DM2#3E?SDD(-'*G\2!$GV1>>@:4A(TI1VB2E$X&?Y21GF>.)C)K[
M+^']@RGH:S*@DJ?L4!9VR?.RG)[0),^OK5WDO7)]UX_3W_+CE$^WKCGW_+GC
M]-:\H;B3*ADQ!(_..]0!T]#1+:$$;29CN23)P1CMW[QBNFMKDKWQ%"\#3)YV
MC=(BK*&WR.CM<K1*]HU>C>7?G;^9&>G=K7C)[:3 5$GB25&0,@=B>3V]?QJP
M_;VZ&7A=*#3/A*)4H$P84,&9'MF,G@F:V]036$W;T)["'%KK"5B;GGA0"*6)
M$*6K<K0QG^("^(:*U&-03/'_ +MJ*C45=?6 %J )("C!/)SW]_7G/<U\Q7B6
MT75RAE:G6DO.I;<4(4M(60%$23)YDDD\GFNAV->,FS.U;Q<>-^W^)N9V\<=J
MTD+A$X]>OMKS6/4IZ4II2FE*:4II2FE*:4JD?5E;X\R?C56:)%/>BKK.4V2V
M4X,N+$D]H1#D1T@&25&.\)W!;\T"L>,Z.\3"JXL3JJTI;0%(*BHD2.P@\SC!
MS^D9J:T9)6ZX) $8D$PKUP>^ ?7U[&GOU=$5>7HUR^U1?ORJ(J\JJJJ\K[55
MX55]JB*NH87"D#8G[HXDSSGT]_[5L0MRH25 GB<B8,"!.,0(]J@S?&Z?].Q\
M+%1P"3YQ2I_5<4,1HA=R?JJ#F'5/?">E5/UU3Q2LDD=NWIB?["((]JOML;,D
MR"1CMW[GW$YX]Q6S+H+M36NS\@IWJ0H;4,97N=W$<R-6Q8HG$_3E1QV^T1$<
MJ*O]NI[35;FEB(VJ'ZSG](_#VK5-:0$W94,!<X]("9SWDDG]*N_J2J'II2H6
MA\'ZA[]ZHG-=L[C !JJJJM^IYEE)S]K?LB/^G1^]4^_C9S]DTI4TZ4II2FE*
MP6]V\QZ_?8R#I-A3[2;53IEG72&!L'K3,C-@0VG,&0C:T9(@)1*_QK%-+:Z0
M4;B/>KE5G\0.Q^OKY5T4O9O$YHK(4F5D1$M9-J:8YUT=RNBW<JSG6M4,;V.
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MS^55=67#N4XXX> 7%^(H#.-QR<]X ,S&8$T:O59II2FE*:4II2FE*@/J9_\
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MB;9U;8? * X4D$#89*3M6"?.K/&"*[/T1U5;=9]):%U%;LW%L-5LDW:K6Y0
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MVXO:X%P3_FE,E7$&0.V8^N_;J5<3MOL&FY" ,:_F8?C4J[CQQ-  %M(IH1K
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M>$D*F%)2D2D@E0$$F#*Z3I"]7><MY6V@LN$.^&5-[QM 0I4I"9"BHG=("2<
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M-B%"-T,L)[G%<:)*CC&4RF:O<I40;XY4EQ=<QU9%PK4;DWZ=A!;2&$^9K:E
M2DI*LD+"=Z@4DA2B 4D$5U?0ULMZ3;,VRU+2 Z%!:$I<2LN.%061,$*.T9C
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MMVMN).[N"PE+F.'1 %R*$%/_ #I25K9'Q;?QM8YSY5*&5+B37,12$I9CCO\
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M32E-*4TI32E-*4TI32E-*4TI32E-*4TI5<^KG&KO+^FK>3'<<KSVMU8878?
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M(-*>Q942*TD.<&,=KG+*BD_*(KC0Y:#$AAM1Z,)WA8HG]J*O/"I$7UFJT6E
M<0HJ259Y@$@ C!F,C)[U:=\A!*DA)X)]03(D9F/3\<&H<RCJ&LH%G-K:;'
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MD+(8P:HW0>H;/2]$UQGK_6>H[W2[#3-/&G.V2GEITQTONNI0MYI.[>M:WTP
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M:>&2%2H[QI(BS[))<<9$:Y0D<'M(K7=KW]KDUDO]/BV2/&#R%$;A*D04XR"
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M7#<[2H-.!0"0O8G?(41 VJ34!3.L+;JNSN?D<%N(5N2S1NKYLQ@\EO0"5J!
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8*4TI32E-*4TI32E-*4TI32E-*4TI7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g40894g58a58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g58a58.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1L*4&AO=&]S:&]P(#,N,  X0DE-! 0
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M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q :0            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              (8   $W@         !
M      $             !-X   (8                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     $&T    !    H
M $4   '@  "!8   $%$ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( $4 H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M^K?4'!@JZM=6YE7I>H6E]GTWV[VV6W/V.L;8RN_;[W^C5Z?HU_HEOI)*</\
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MZC=_I%K:MO\ ->W^=LM2OHIZE)8==_3GML->=EVM#-P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M$0$#$0'_Q  ?  $  00" P$             "0$'" H"!@,$!0O_Q !S$
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M1\G$U*UD<)-)[WK<IK@^48$5%,C9PL0JB1/&,2QB3DSA<LP,8<1@QYF&Y[J
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M'8?!#6^7-:23^$P9@@ZKXL$2](==[O"ES<S0DTJ;=T] C>-2NK+&$(.A\#2
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M[!D_'47EE*NX\Q19+78*5CB35(D2U9$A6R:3^JL&BHK$D/=:!W+,S-T"K</
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MI?DXOGZ2ZIEUQ'TJF0Q>/)QIN&Z6AM88<I \:?!8(4.-,D4B16PV4;JN(L*
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M]A]H_D[?%J"TD&IN;5W#<..;G4KAZ/DPG'CQ"7PAQSP CW$>/7]D';U\>>I
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MF >.P\\&$.0\Q#V=^70!6E[9W]UJ^Q06DDDDW-:;*%H!Z\SN%<LT]$)>0((
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MP%S]$4..W/ _[(1$ #V '/D'J ?5Z]<S792MLZTIU;2N(:T;-M>?\.9<O#W
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M[Z[E(%JN+.IHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBH//J
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M2 EQES6YJWRYLA^"L>QWAYRL=4?1GU#TVA93F]SLQ@.MM)!^YM\#6(J(BCV
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M:3D?>V<="KNJA*1SDPMUV$RDV7%8AR)E./ "3[^/?[%]R"WL[<+'$Y&EXZ_
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M\NG?SC,Y+T]G&=[C:>H!O*PY7<\H[D-OT15Z)DVMV%@O79J+P_>;;+3K2<Q
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M31$T1-$4%'7=^U-M4_"L@_T6Y/U2N48?Y$8\?ZF6_>X/N57TQMH[B?ZMN_\
MG-'%%'QTK>0ZD>/>_EMGSKW_ /U7BC@>_K]OJYUK;D8^48[_ '7NCJG\FGQ,
M5^E)[_\ B=G7F.BEEMNAY%^0/FUOY;85=$3Z?D\M$6%]GV [9K@ZR<^GJE-N
MG>7L@U#)]W<DN-G06>W&B^$M;D&!TI,HQ*#1 HME6$>"#1RB<Q5DC<@($7"?
MZ?\ MCLS7*C.7J,VNAF>W5.[WXJ=SM"!I.=I2;="OF:'2E"GBV;5JV2:J,F
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M*JR3I #AP4WB$0#1,NK<./4NM[-66R>*QP]CMCJ6%6^-FLP=&61PJ,&:)).
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M]//:>   !]:6"     . .YX#M[ ]7D'JUF]+O.3&/38O>O'HU\RR7T'?7<I
M]5Q9U-$31$T1-$01X 1]G?1%8?<W&T>>P-EBOY!9UN4K\OCZW(K1%J,R]ZI)
M=&"?.&R"B+X0174(X2363*4#*$.F50@<E =-A.P4!.P5-!4Y"^]02&C6)#0"
M!4D 5-2!??0JT/3\C<=5K:9@>MT%O5(E N-:U+2$+5U8X$BR<I'-W4C(.VK$
MYS \>NCG6=.%?LU5SG,J)E#&'4/+6/U"YI=KNAG4<UXUV5UAK-);5NJ0;V(I
MG9,R:%IU:@D$&FS9SY4-"+[EFMJ5*:(FB)HB:(FB)HB:(H0>NH'['W /'G\+
M''? ^SFG9"_'_FU1^43S.QW]7#[V*MZ9>:V*_JV_6"PKZ,';?;FS@0^Y I7?
MX_KQS?;OR'Q<_FYU3N1GYKQNM_Y3/7_%X/0>XJJ<F-/@Z?\ 3GU_PTIS[<\@
M+[5M(AYF^7^8-;HVGH'>Y;/5=2B:(H*.N[]J;:I^%9!_HMR?JE<HWF3CWZF6
M_>X.WV;>I5?3'S<Q/]6W9_O-XKNZ%'QTK_OD6/?7^QGSIY\^JUXH'_+VUK;D
M8^48[_=>Z.J?R:?%Q7Z<E_\ R;YT/97+9GMN!Y%_%\PZW\ML+EHB:(H'^NS^
MT/:%^$L\_0QE'6O^4_S,Q3Z4K^\0U4=-J_P=Q"NZ#3H\(/;58.=)#[XDQ_!4
MRM^DK%H^K^?U_BU2.1G\YCW1)_4*JG)A\3$OI0O;Q^-ML/6]UME-$31%#IUP
M_N-J_P!N?V16".?D^K9I_FU6M-/-#23]F1/KPU@])/F/$_0XO>Q1J](7[X;*
M_@F7;R_?3H/X_P O?6L^14?Q;'Z_ZQ)?91-W,:W[ZJE\F'R+$N:)"^LY;6NM
MXK:":(FB)HB:(FB)HB:(FB)HB:(FB)HBLCG/".*LW5N(89<KJ=C@:19(O(<6
MW4!<_N.PU0ZLA$R946P'6<J,'!2ND&Q2* LNDF'H3"!"Z*./?M_#K6%6(<.]
M/S=2PR)*XNKC:X1XYV8Y2O#A:#L4$V)F6M(I)).P)-Q4<0SN)=E(\?1C0#-2
M2H"J]1!8P@9ZDZSEP<L^**4!,H$3(0/(A"E#R\BE  \@ /5Z@ /B#12N>B)H
MB:(FB)HB:(FB)HB:(FB)HB:(H;NLQB+;59L&T7)N<\'P&8+!6<K8WHM$5LEL
M?T>O5YUD*XQT4J\N-G8E5/&TE$XE6G3^@\1DRIHD<-@5,J4>..]1>HW7KS[E
MUG8'7=LN#M[>X?;K@S!>%:8[1PMCW*#/)^'KB\NSV9JDM,E@'E*OZSUY)&K\
MO&6=JXDXADU<D:R4(="2%!-;TNFWJS]G/[$)-NG+CF%>JB[SU?H.GYLP)$X*
M^O[3,.SC;,6$+M>YASF&M8LN%+QFA<A1E;A%RDQ*,C,'2**3PT(HN46[Z0:^
MYB$7.44]%->*%8]=,5EEM]O:W#3>0=R6#MT]7K6!L:8VQQE[%62*I;+3:JK
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MJF55(JQ3E(</&4/$7D-?<I4U,2NB4U'E)B9DX_C,LS7@1'0GZKHM'U<VAV
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M1G3H&555SC4:;\8EXC T/DIZ&UH<?)JT-:2* U%3^E0;:U!6Z+TK0 .GOM6
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M)$ X#CCCX@^74M%L@*DFQKF>SL4JNN2)HBU^NN^'+;90'?[=]\_0_:OF#O\
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M V*L2SR&X.^8\I5<N\-/5V(0R+)Q,;%V25/"/718=JC+CZ!^]]$D*X-R)J*
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MN$\^G^&DZ^OKWK:1#U_+_,&MT[3T#O<MGJNI1-$4$_7=^U/M4_"L@_T69/\
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MR-E4C5;".1MMGOVK#(NF\0I*CF.B^[SQB#U5=XBP,Y](+1)TLJX(B)"+*'4
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M@]K?!1&AQK\<:P+C6E-F1J:$"JM<'%8,29B2YL1$B!AN+->&@$G.[A2FR^5
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M!L=:A)&;:#;L*O\ #Q*5B31E!$;X37<S-QH6MK0U:&[#8.L-YJMFX#]B]N_
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M&&WOG@/+CVAZP[:U5RNG_)66-K8M!WC:_*FW.AWW-32FN^4CS>9:GY>%??\
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M]J8WYH3?[-@_6AKKPOYWA^E3'5Y<6Z_7F'^Z+^/YM:$;D.@=RV#M'7V[/:M
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M\/SJ#@)C?9[HLWB<.1 3"$PJ8!/W-R8HF$1\P PFX]NOM'11^MH=&I4-\%B
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M(DEX@3,F4VM5<F^FF/:13^+0,2?*18<'"V16"%+.86/\(8>LSPD6)JOHX5>
MUSG4)>Z@"H.ANDN(XS-3,*;A ,A -:22;&H#C5M*FAJZZS5W2=>G"6%-U<-A
MRKYIQ,TH5/MMEI6X=:YXCSG/7*C3].>KIR[.O2=8=L*R_"4.@:$CEC,9!&-D
M/UQ='=L?U$=YRV#XG,P'3$"4B/EA5QBD.<105< :$!K1>E>A7J+,RL!VI%F8
M;(Q-H;W   GR32M;[P+C*^4]F(<ITK..,J'F+&TP-@Q_DRIPEUILT+9VQ"5K
MMA8HR45(%9/DD'C8KMFX25!%TBDNEX@(=,I@, 8\C5)!L0:$;B,QT@VXOWWK
MFT@@$$= ITV-SOJKD:A2HZ-W?3,P-NVR)3<ZR,G=L6;C<;1P1F/,X8WFQC[/
M7&I'*SM)JM&ODWD#,L2+N'!O<DBP.4WIS_9@/A$I%TCIS[1=T>RYSE'%N3LQ
MTO.F$[#9;/DZE74*TYJN5T[]=[(>2M#.XM&SEU R3!R@H=^22C_<@^^!S)$C
MDT.!*4;=OLV\=84I*R"3@@IKIIJIB("*:J9%""(#R B50IBB(>H>.0]6BE>-
M!FS;"8S9JV;F,'!C(H)I&,'// B0I1$.1Y !'@/5HB]G1%0WD/R#\VB*+;$?
MWVG=K^"KMW]?^$MT_P OT'5QQ'S.P+TV<^TFE4,/\Z\:]$D]G]7*?=P%=>9W
M]4"$W/+;<G-,MOO<QF4*/+Y=$T:2EP^3W5'D\F(4=\R.Y+.$_K#AY&=7L7N,
M(1$Z)&'N@S@X^&G*WJ'3JR]1O8GDYOL3:8_W781MSK'W44VYWRZHPEWC7QZS
M3:M)39K%99E-(QA9Q$."A ?NU1*DW$Q?$;N :)QQ3M^]:Y>]W<SM\NVZS?3:
M*IF*A3]>NN9;_-5&6BILKQE8XM]2(!BU?Q3I%$R3ELX=MEVZ*B7C*=5,Q?'P
M'(1JM<X:S@W5N"; D VKS\"]5S;34BU)KX,T&\U'LZ]RDNWE;W=HMQQ=TJXN
MK[B<6STABW;SD* R&SB[,S<N:;,O\=828-(^P)D4,,>Y<OH*6:HH+&*H92/<
M^?A 0UGRG8?/XEHU EY"4C3D<8E"B.A2[#$<&-<ZKM47H!4FQ&\4SH^G>&SV
M(8"V#)P#&C>%AN:QM*DZ["12NS5VD'J6.]#W>[86.&NJ5#N\[8U;R>3MAK>B
M8]8KV)H@ZN-P3DLB*EKL DJ<IY&6$)5D8S5N0YN'2(\AXN[DAPV>PR1FH>)2
M<SA[SB<.,P3<,P]:$8</6<!F0US +"]3:R\V@>'8CA>"S<*=EO 3+YGQ@0G_
M .[#;# %":@ZC2:&M:G*B@ZVJ91QY7=SNW*>G+;$0\%!99J$I-R\BX!HQC8]
M!10CATY66\ )I)>,H&YX^R,4H]QX'[#Q[&,'FI&'!@S\**7QX3V^#<'$G7AF
M@%*@7--:A)"XP929@Q8\40(NJV5G*O>PM90B&;5 -PTD'<#7FWZ>GAU,^G]B
MC99MVQWDK=]@6E7BJ8ZBXNR5:>OT2RF82315<BNPDF:JA5&SI$3 "B*A0.0?
M/D! 1U;I>0[23&'#;.QMM[.+;C,95H59-' T8-):I+FF&7 TH""XD$;P1M6I
M]NAW.;=[/NUW8VF S-09:M6S<9?K#7IMA-HN8^9@I!.&(SE8Q=,OA=LURH*@
MFL3@IE$S>'QE !U76D!S2; $'W>M9UIHX'<03U7[EDW<=WFV!]MKZ5=<:YUQ
MPYG,7[<\OUW(<4WL#=1_39V8L%/=1L38&Y0,K'O':#1P= BJ?*H(*> IA#6L
M>5"1Q#%-&Y:%A\C,S<88L2Z' A%[VL:Q[2_5'Z-P=8N#;W-+JG:=X?.XCA<*
M!)P3&=#F8<P-4YT&J01NWVJ,\JK)O8+OAVAX_D.H@K<=QF*:XE?]K&.ZO1S3
M-H:LBVFPQ[3/GNZ'AC+@F+^0:'GH@BR"*8'(,FS  ,*G.NKDIP[$<-P+$H>(
M2,Q(QOA6#&8R:AF&7L$,M+PT5<6_% ()N=@%!U:#8;.89A$:!-PG0HQC/BAC
MJ;12@OS5SJ1<+7.Z<.8L88\WL[';A?+O7ZE4:1G;&$W<++-O?<$/78B+<<O9
M"3>+IE2;M6GDZ6,82)B(<")?LM?6&DF*8=-:,2\HR<@Q(IEY6K8+JEKH4&S2
M'"WE#5?46)ML)[\-EYJ!BCXSH3@"8I+BTAE(CRV@-03Y+C382+E?I$AU=>F0
M7GC?+MP$!,/']D>&$.X\B <*B//?L %$?;[=:>!^,;  TSO7GXMDK;S7WUH;
MWKG2F?MW%:)VX#<G@">W+[N;%$9?HTA!V[='G6T5N5:3"*[&;KTU:WKN)EXQ
MPEX@<LI)L<JK-4I0!0O(]^PB%17G)S/0!V]/-S":TH=U#2U>?:I&<O[T=ITQ
MT^.DO0XS<'BU]=<5).RY(K+6SLUY>E&/B:T1@!86:0F7CN)1T@QX5*(BX623
M /LQ,%%Y3)6>Q/1B9A2$G'G(T29EB(4NPOB'4B-J0VM2 TEQ.0 -Q0JJZ82,
MSB&"3$K*PS%B/(< ,Z@ZP &VMP>KH7<]EV]_:)3:#U,H^U;BL4UUYDK;?4:U
M049>T,F9[9.-:?EEFYBX,BIRJ/GB#N4C&ZJ1"%$JKU @<^,#:QG)9AV(8;@$
MU Q"2CR49V*OB-AS+'0W%A<TAU-Q%:$$Y7YO/H/(3F%X/X";@F'%+_"EALX$
MMU=6F?&>=-6;".1*+ Y(P'(2MEC8]E"Y0Q#*6!Z\<>A:1$?"7BNR,D[<K"EX
M"(,V319PY4.8I4B)J" GX#GZ^Q;%,'BZ-"4;B$%\6/(P845C'M<Z$\:CM4
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M#IT;5,>.<ZXX1N]7WW[A+S8:O[_MC34-4)Z.RNC"6.18%,99M$RHR\;[D=G
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MR^Q#M\0>P-$OP/O7SY;95M+<QL@W:;8=OZ;MTP=M6ZOUHZ*GX%EFQTD1,H2
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M;-! %J4MMVG8I!#270QJ$@MR!H+T]6>72LY0V7[1@'MM?V_E\^_UH:(/'_\
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M=3RY]JW)/[@;M_)N1UZ)+Y3 ]*@?7;QWWJ5XI_Y'.^A3/V3UB)TK/O>>T_\
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MH6?)&1I6Z3%D!FH,^/4:6Z1O4J:>/CV44R:1L:T;,(]@V1:,F+)!-LT:-6Y
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MK.?%LMBG[^.#92L$(1,I2)D*0A2@4I2E I2E* %*4"@    4H   '    '8
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($T1-$31%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g40894g59a59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g59a59.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1GP4&AO=&]S:&]P(#,N,  X0DE-! 0
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M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q :6^^@         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              (<   % @         !
M      $             !0(   (<                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     #U0    !    H
M $,   '@  !]H   #S@ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( $, H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M07L+7-<$8D\0U.Z"!1T?_]#L:LW(?7U YF8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( /\"70,!$0 "$0$#$0'_Q  ?  $
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M>$_'L91DX_WXI^9>J,"8^K]88CEL(H4_7A3CUP/G7Q/Z(-F\#MW-]H$H'_\
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M\.>I=%NWTZ]ZHUFSN83&TD4\8,BI(H<;E;!!*LI&20<^F:A:OT0;.!(.YGM
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MI%VL^#N(!)8\U3.1^B K.&\N-)W(]H/'D-<I=8=W;VW;>0L'^?;5B(5Z>A(
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MSM'+$!?2OEZ.:8W(@$#"'RF99_,7W902 @49;C&6;&,8^/-6LKWCJ<BVSP7
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ML59P\7SFMK?E-K4M7<%#,B-*=9;<=4T'??1B5-R&W6G$K:6HI/84E*D^3NM
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M_=ZQZR^FK+L!@7:<>@=06S,3*9]0EYN :M[.Z3Y5%E+3\U2!'#CSR3R$H!)
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MB/5N_:JN[0;7HW+@YH\[EN.XR<6HG+D-WLI,=RS2UWDQX 5QWR#V$=J#W$D
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MK(S#\RVMRW ZV+-S:BOJ.9:=JL=%A"+,:P88<6W-'>MWO26.6!'2A)!0KN)
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MGOM++SWX/[,G*6?S+>#]"(I1N9\X+$Y;&[G P 0<'X9SSF7F5NK>92"5*+J
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MJ']X_6:Q'^R_\V_7I_7Q;L_[!4_F=25XHX]GZ%R3_P TK3L/_BO\2*CSH/\
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M6MI'>2BRGM56(B;:QD9,R*01C:Y]",< C@_=/Z]T\W5A,G;>)>6+>#B8;!%
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MBRRLBMM7<",MC&#SP<0 I6\M7O4$NCE![0HDJY^)[N>]1([O/J.!Y/.LE48
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M@! QX&.P' &,5/.);BW>&*O7Z6/6M*R2LF4M@R_7LRF68,Q 2X(J'@HQGDI
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M*:4II2FE*:4II2FE*T5^"?LTJA_>/V\5B0]E_P#NMUY_3^KBW9!^T,5(_/\
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MDXJ7\4]FKL7C>6T>4*ZI\ELU5%Q$MU09>QM:(\PQ9*)#C#ZANN06WRDI/S5
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M)/;C J.7'LSMB+./5QCU=YNZ*R&(H^4;'5'"%%7)3'2UNP26N ""KE?)4%>
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MW6F?GQ[5GC[>>*U_7W>DW_,7NW_K;B7_ #NU7^P=U9_AFD_#Z=YW^'\EJO\
M99Z?[^R:C_JVG[/:\T_7W>D[_,7NW_K=B7_.[^'5/[!W5G^&:3QG^=>=\9Q_
M)>^.V/GFJ?V6>G_\$U+_ %;3_P!53]?=Z3O\Q>[7^MV)?P??<?[G[^G]@_JO
MM[9I(/S:\^[^2X^7[\BG]EGI_P#P34?G[MI_ZKGZO]]/U]WI.\_QE[M?ZW8G
M_P [?[^G]@_JO(_MW2?AC?=]_P#^%S^/B1E_99T#_!-1^7%I^O\ MKCZZ?K[
MO2=_F+W:_P!;L2_?/WW'C3^P?U7R?;-)P./IWGI__B^OV^GK3^RST_Z6FI?:
MMH/_ /J_XT_7WND[_,7NW_K=B?\ SNT_L']5X_END?#.^\_]+3^RST__ ()J
M./\ -M,_=[5^.]/U]WI._P Q>[?H?_B[$O\ G=_T_4>=#X']5_X;I(/^?>9_
M_53^/A0^+/3X_P#PFH_ZMI^ZZ/WT_7W>D[_,7NU]7^%V)?O_ ,=WCX?O_1I_
M8/ZK.<7FE<<'WKSY_P#[)_7V^RG]EGI__!-1_P!6T_\ 5<?C[7Z^]TG?YB]V
M_P#6[$_^=NG]@[JO_#=)^/T[OM\?Y+Z4_LL]/]O9-1S]5I\!Z^U?/\'BGZ^[
MTG?YB]V^?/@UV)#_ /R[\_ASI_8/ZK[^V:3CU.^[QZ=R+7O]7'Q]*I_9:Z?/
M:TU$_P#TVOQ__>OV9]?AFGZ^[TG?YB]V^/I^YV)_\[?M^.G]@[JSO[;I/QQO
MN\?_ *KG]?K5?[+/3^<>R:C]UIG_ /6NWSS\N]/U]WI._P Q>[?'_F[$O^=W
MY\?;P_L']5CCVW2?]>\_]+CT.?\ A3^RST_G'LFI?ZMI\O\ ]J^?/PK:OV[G
M2BI)2C#-V@H\<'[G8GSSR.0!]]OQ'@'Q^( D>7\$>J44L][I(51N.TWC' YX
M'LO/;Y?6*H?%C0FPL=EJ+NV J_VJN>0#R+@D #D\9(].:F7V/^4P<]Q7JXW&
MJFI4:EW$ZLLZS6D8FJBJG-U.0U-)90D341'Y3+,I+,A*7VDO+"7 KM4M':LV
M/%JPGTN7I.PG,3RVW3D,;-"'5"5F9?\ I$1CRI.<'@]R:N>&MV-0BZCO%,JI
M-K;LJ2.K,N8E;!*LXS[P!Y[@US>O7V573UUE;AR,ZRK?[>O87<K.\(K=M,C7
MM9N="QZ#N/M_1O7$]G%KO";IB=49' 9E7,N8\M<-];)/)* I9,+QQHDDX@DS
M$V+NZB&&W'D0RY';:0X4DXP2/JEH7CI!;>:H$EN98;68$JT?M)7SHQZ'S-@.
M.&]W/.!5P'0MT^[N["MY_ R[K3R+JZVMLI%'$VJ;R^AP]K(]N8E+ ^Y]G3R\
MOPU<>MR)F0&H@;9^Y->J&N.M:PMQ]S6R\TM;1B5=TS%IA<<CS(WQM'/<=RK9
M(QV-:SRT6YD,1V1J!&\&,^7(,')R 0>X.0#SV%2-[3W:>^W:P#!:;#-BLTW;
MSZ'?HGX%DN,WU935.WF1P[6AL&Y.5/R\DH[6FJ,@A0I5:]F..1;.[QME+ZH2
M8SLT+<Q;<+'J^F7C#W(9<EN" "">00>#^OMS662?9;Q0P!:' 7U8YQP<'[L'
MX\8!KDL4^_L3VB.R,G/,RVSLL0=Z?.HA^EQ['<&R*KR&IJUYAL>A5?9Y18YM
M;1+F:S*7 [K)BDKFY*(DCNA)5*2IBZQRS$<@DG/;N>.  /V8JT,8';G [XY[
M=QZ\?NK)WJE>J:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE
M*:4II2FE*:4II2FE*QS^UU_F9/7-Z?RL^ZGK_I<D_OZN1?QD7_;1_M->3V?_
M +*3]GX_';RCA^"/_1^G^Y^?XN=3C%]%/\R'_P 2UP$1Y[X]]Q__ #$_'G]1
M^%7@>SY)'7=T:'Z.I[9(>2/0[A4?GQQQX^GSK2]2\:5?\?SX3CZG QZC\>O>
ML_21_P J#_,D^/\ >''W 5Z4'M:^LG<+H)Z'=R^IG:['L6RC,L-N\"K*VFS)
MJS>H)#65YA4XY,<EHJ)U=/*X\:Q<>8+4MH>^0@+Y22-1-&N^1(^<L1V^&<5V
M#MM1F] ,_P"^NE1F?Z)WZU,WSO:+<&TV=Z=6+79V\RC(*"-%JL\^1SI.58?:
M8;.:L@]ESCQ::K[:3(9,5QA:I(;]ZI;:>P[C\A,QSYH4]\9/&?LSWSW^? K6
M_E-<<(S#GG')QGU''R[XXS]6;7V,GMY.I[VBO62KITW;VTV8Q3%#M)G.?IM\
M"A9;&NQ:8O88S%B15*N\CM82H<AN[?\ ?I$7WH+;90XCSSA7EB;(Q@N'\P,>
MY/T2,YR!WW?#TK*MKD7(<A2NPJ#GYYS]V/AZ]_AVRQZ?G_?/\)^W6%6532E-
M*4TI32E-*4TI7GA>V5ZAMUNG'*MYLGV=NJK&LARKKIWBH+RUEX?A^43YM+48
MC13X-6T_E5!>&-%8G3)$Q+,3Y.@NNK+A4?(E[K+5[ZQT#H..POKJ!3T]'O\
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MJ%JL4S2!FEQ79+DEM%?CXC?)V\VB@IQZ08CB&W5QVMOREXMNN"0%]RE$@([
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MLF2E*@N(IQ'#PX6VKE!5RE8('E).YM=2T^\FN(+>\MY9;5MMRD<J,T##((E
M)VX*L,'&2#SG($=:OTAU'H-EIFH:UHFI:99:U'YVDW5Y:S107T.U7#6SL )
M4=6!4GA@<8XJ[7H8WHQ/I4ZN=G-X-V<)EY'B&#W,F3D%%)@AVP;B6%'/J&[>
M!"F>[:=FTSTV/;1&G>U*GHB0A06I"D\%XL]+ZEXA^&G572W3>M+INJ:Q8M!8
MZE!(0B/#+%(8GFB)*Q7"0M;R%/>"2$[NX.KEM9K*YM%U*S<I%+;W#6UY&8EG
MAW))RLH.Y2/>3C#87(*GF_SVMOM!^G;JCZA-G-P>G#"UO56U564V>3Y!2?<9
M[-)DJP:GMU<BL]\J2JMJ VZ&9$E2'%O3I0;;2VA+CL,_P:_!CK?PXZ#ZET#K
MG7))Y=>O7>TLK>]-TNDVX@\G=',VY5FF?+ND;O$$1/YY>NJT?J"PZ;ZZT3K+
M1=(LY/R5>6=Y+8W$&VWOY;1]VZXB5@&#H3%Y@PY54W$[%"XH-]]ZI.]V8MY7
M)QNDQU4>N:JVH=(VXAIY#3JW?E$P%PK=D$*[.]); 2E(*"1R?HKI#IE.E=+;
M3UOKB]$T[3M+<,"ZEE *K@ ! 5R0V_DDD]L=7XV>+=SXQ]51]2S:#I?3XM=/
MCT]+;38G03)'+)*)[AG=_,G)<KN4(-BJ-N02:3QVZ1%/9O3),U-\W\E75,M)
MC_<]YE9691F>]/RA#S:.WW'N>]"U$A8'H-_(9_.C$8C:W;?YS,7\T$?0"8&T
M@GZ6['&2#G-0W/[2L\*J(S Z%IF]\2 ^[Y>P#W>>=V[!QD@YR*E4/N)*B"/G
M?A>/7Z/K''PX(UD8!QQV^OGZ^<&@/.<MD 'U./5?B",?WU7#8INU"I=I\CVV
MF8-C-G+R9],B'ELIM\7E6\M3!3[IQ+_86TAM2&D!M("77"OWG(">5U#I^XO-
M?L-<CU6^@BL8]DNGIL]EG55;A@5R,[@6.XY 7&*FGIWQ1L-%\->H_#ZZZ+T/
M4KO7IO-L^IITF75;"25H1N2590FV(1XA5451O<N)/=Q3/(:>?A$NL#5K'7.D
MPHUHW(JYO"F$R5.)2VIYE86T\D,]KB I*DCCT/!&ZL[N#5;:?=;R!$N7MWCN
M8L!S&JDLJ.#N4EOI<KW^''!:YH=_T=>:>$U6VDNKC3X-3BN-*N]SVZ7/F*(7
MFB=2DR;&+KD$!ER,&MM5:T\E^REY0F?9R9$-98<1+4E?RWM_8G)2W4NJ=;2>
M4K *24]@"@>#KU<07");QV!MX55U\U3&2#"2=Z( P".?YI((SR5YQ5O3=0TF
M2?4+KJ5-0U*XGM9O994N<.M]M'D27#RI*\L0*D.H96((PPQ7'QQ85E>.$@N%
M=[3!"B>WM2+&*H@>>"$!("3QY'/))/.L[854-D@D@L._I]_[>_;-<V"IS[NP
M;F*J.#@GLQ.<XSP<?NKV\ZK]RZW_ $!$_P!KMZ50?O/?ZS^!\JY^E5II2FE*
M:4II2FE*:4II2FE*:4II2FE*VJ_!/Y_G_=]-*'^KY^OX^KO6)'V7_P"ZW7G]
M'ZN+=GCZ./<U/I]7YCQJ2?%'^(Z&[9_-.TS\<^8QY^?-1WT'_*>K_GU%/_X!
M5)O:M=3&SD^^Q3HIRK8'>?=;=+,V:7<O;"VP;-<1V3<I\@IILM51D.UN[>:9
M-009>YF*V$1,M.+50ESW8;X^61)-=(?8=BJ1'FGC>"46\UJ68SC/M*1NIWB!
M,>^C 8FRZ8&S ;/$F+L6$QS$/%?*T'E;2R.Z/&464Y"IN8YC;+=B<<<RS[%"
MES_,H6]74OG.+Y_(7NI;P\+H=TM[MZ*[<[?'):K:.[R;$GL2S2@QG#,4PW#X
M&)W3-RY4FA<N%6R[64_)FJ[&U';HT"Z1I_DLA%\D6J((5?:T%[ )H9I6ECB8
M3.K*)(U#[2?I,!DX$HD;4I0QRMA&VF;"01#<6TH6=(RK,&0D-ACM/';!-9,N
MJ?I+C=4,O::58[J9O@,;:3-6<_@4.-P<0M\;RK(8#7;2/YA29?CM_"N&J!\K
MGTK*FVFH-HINS#;DR+#=CX,<:I>VEZ5W26S$@ LN00<@,I!7.2,CD9X^(OR%
MGM;FV& +A-I8@'';T(/'J1@YP!VSFD4[9;:O$?:'[(Y9C^WN%5.7W73SU%VN
M0975XO35U]?6Z\TV/COVMI8PHC$B3/?3/FEU]:BI0FR4@I2LC5PG))QC))QW
MQD]OLKRH*J!G.,?\*R-?;X]?X?'Y1Y^K5*]4TI32E-*4TI32E4RW4W#M-MJ"
M-=U.V.X6ZLF18M0#CVV\7')=VPAQEYTSWV\FR3&("8+1:#;BT3UO!QUL)84"
MI25*I#TX=4S/4DS.LZ?93>?;S&XJ[J+%R?<JIQ"JJK2VQW()>-7=+!;HLSR*
MS^Z,"TKYR'/E4"-$=9C+=8E/)*0I5/AG]7V]^/P:NKTJM-*4TI4,N;JGQVKF
MW=_:5U)35K"I-C;6TV-75L",CCOD39TQUF+%81R.YUYU" 2 3R0-*5AWZY6.
MCS.LZZ;\PE;F8;,OLKZEMM,+SR90=05[11K';Q6,9Z_85UQ68MN'5U+%0J;"
MJ7)<E4%E;DF/!3)DKX;:6JGWC]WX^T5D3V9R/ILQ*IIMJMFMPMOYD1ER>[2X
MO4[G1\TNG5ONR+.Q4PNTR6^R":$E;\IQ*Y,A,=I*R@-,H2A*J_CZOG^/ZZN(
MTI32E-*4TI32E-4!SGY''X^5*@>19-CN(5,J^RN^I\:HX00J;<WUE#J:N('7
M4,MF383WF(C <=<;;1[UU/>XM*$\J(&JTS4EX[O=LYE]LQ0XGNIMWE%W);==
MC5&/9IC=S9R&F$]SSC,&NLI$IQ#2.5NJ2T0A()40 =5 )[#. 3]@[G]8JA('
M>JG)4% $>.>> >.?'V$ZI5:W:4II2L<WM=/YF3US?UL^ZG^]N5^?U>NKL7\9
M%_VT?[37EOY_/:*3]GX^[ZJ\H\>@^P?#\_S_ !:G"'Z"?YD/_B6N C ]<<NW
M&>_O$9^S]?WXO"]GQ_+W]&7/I^J>V2\>O/\ B@TG_2?I\:TG4W]R]0SG^,B[
M?YX^7)^'R^ZL[2/[IDC'T9>^>"$//U=_]U=^?]$G?S([?S_39LQ_PJ8O]1_/
MZ/7476G\HC^NNLN.(F^H_+T/PKS%&_P$_9KMAV'U"N;?AFP<'//[/4X]1D?4
M?2NQ]^A8_P":E_\ JU;P?[L8!^?Y?ASKGM=^G;?YLO[4K:Z9VF[?2C(///+\
M]\]^,_K(KTC=:&ML.P_'[::4II2FE*:4II2FE*\UK]$!H><LMPT,MEQ:O: [
MZ )2A2U*1]Y&-%1 ;2I?P_G4GTY/KXDSQ!(32O#]MZ^4.D8B[%@%5S*"RDD@
M9&3GX$"N Z&42Z_UM# OM$DFN^\B([OP)?<4*A)7Z6[ .&'J,&NO=MG VNL:
M;-T[F7=_5VL*F!PUBOC_ "IB38\N%3<Q+CS9;:2L- <I'""XOD%/"H0UQ]<A
MNM+.AV]G);O<9U-KARK^SG;M,11'R2-W=EYVXX)KZ;\.[+PSOM*ZO7Q$U?6;
M#5+'2P.DHK*#S86O\2[XIU>5"@1Q"NW;C#.201M-+L=J/N_;1JMJSK*WY8M[
M^++F2N% :++*I 5(D!MWL2L("&^&U$N*2CPGR=[<SK!$SE+AU 7=%;H)';+
M852RYQW], $^F*A^ZG6U@>XV2SE"!Y4"DSMN8*KA<@$8;)]XX )YP*KW%R#!
MLCVRQS:'%-J'+/>:YRF/ AY7#D&3)M9$R:8L*!7L);#LEV6ZXS$9B*2AL<H<
M0ZLK[1R<MAK-IKMSK]_U 8NFH+%Y/R?(FV.!8H]\DDS,=D:QJK2-)EB<8( [
M39J'7OAE'X-VG2L/026_7*7AO]0ZUFN%+K:*SNRIM0SRDH4B%LRI'&%+B1VP
M*@^_?2UOKTPWM-C&^F 7>!VV1U+=Y4)L#&=C6,!:E,K<C2(DA^*^Y&=3[N6T
MAXOQG"E+[;96CNN=)==]*=<V=S?=(ZY9:U:6=RUG=O9R%O(N%P3'(I 9=RD,
MA90''O*6%0G%.LY/F)<0':K;+BWE@D.0?+D"RJI:)L'# <D,, C%<;9_:"KW
M0BY@_/SVCPY>*TZK.,W<E2'+EU")/#$8(6.&TB*/>J'<M)=0 TOGG5WJ/J.?
M0I-,CATBZU07USY+O;8VP*&C 9\CD^^=N< A3DBII\*/"[3_ !&M^KI[WK31
MNE#TWIJ7]M%J>[S-3D:*YD*0<H B&W =AOD!E4+$W(J([7;N;=[>XIG&-95M
M;59Q=9!'5&JLCDR4!56 V^VD,-NQW5MMH<4B0AQEQMU:DI"N$DZQNH.G]9U;
M4M+OK#7[C2[:U827-E$IQ,"P;WF21 S$>X5<%0N<$YYV?AKXF]!]$]+]9:#U
M'X;Z9U?K&MQ/!INOSS1EK'"/&BJDMJ[Q1B0K.LL#"1G4*0!R+=6W$O+6AI):
M2M96  2E Y/8CYI)[0.WR$\\CZ-=FF>%RQ8CC:,[B ,GDJ!]_P#54$%E+,ZK
MP224Y90"P*@9QG;P.P(_57+8;?5W*<![.#VE:BGCC@>\3R@GCCE7:$<J\CU
M[J.6(!W>NPX(S@\X(]/@/MJJB0Y**&8 EFRI*@#( Y![C(]3\ZO5?W1GWVU>
M#YM?[O5EAF^U.25;^'[;3,?]]%<B5KL1#;MA(*%1I14U&:0674.(=82I*E(+
MA*8Q_-^"UUW5M'L^G+B+2^H;*:/4M;CNPLB/.KEEA7.Y=K2-A@ZD. 0& KZO
MUCK>7K'PFZ<U[J7Q3L[OJCH75+5.GN@GT>3]):0>5!ONKM&"2.T,*#&U@8]R
M%U+';+?5%U8W75'=8I=7>#8AA4W%ZEZL<>Q2.N.NY+SRWURK-UU(==7W+*&@
MM3I99[6$$I2#K*\/O#FT\/[34;.TUC4]4AOKE9U74G5S:E 5$<"J2H0CEL8W
M-EN<U&WBQXOW/BL^@FZT*STDZ1;RQ>8ERUXTYD2!<#S(;<P0(8 8[==ZH7?#
M$DDR)L?6;)W%ED2MY;NYI8;-,M6/&JCAU;MFA2^Y!4A:>T]I2IE!2AM9)"G$
M \G==53=40Q6+=-6EM=2O<[;T7#A D050"@P0P)Y8Y# XP*KX-Z9X0:C>=0)
MXLZOJ.EVZ:9OT0:9 [B:]#L'#E&R&";#&A 1R2&9  30^P3#;G3FX*Y#D-,M
MXPWE)2EQV,EU0:+OSU%*UM]I6GYWS@>.0>==1"9/)C69$2;:C3!6.U7"@.BG
M!) )(';( XJ(+U+5;V\2QDEELDNIQ:/(,2O:AG$+2#=@2E A=03R20W&3=+M
MWL'M[N/MT_>0]VJ;'LT@5UU8WF/WT9V.PU$@,NN1ODDIM;A=+P#:71[KWJ05
M%+2R %<'K'5NKZ+K'L<G3UQ=Z9<SVT-M>6C!Y"9642%HV"J"A+$#> <#+#)Q
M]']">"O1'7?0DNLVGB;IFB]7:?8ZK>ZKH>M1M! D5E%+):I#/&TCNL^U%E=8
MG<+N9(G*A3:?*I)T5M$A;2C#>>>9C3 V\B-*+*^U:X[KC24K1QVK]>0E0\<D
MC7=1S12 A9$\Q%5I(MP,L>X9 =1G!^WT-?.%QIUY;*DKPR"VEFEBMKSRI%M;
MGRF(9H)'1 Z9P02 0""0"<#(1[.[>79/:C<7(\>W:Z:JWJ3N=TJ1C;K;RGLK
M.-"9Q[*,@F-P8\ME,UAV*E=A(D1XZ[#A,J"TA2XRDJ6I28?\:NG.LM>T/3+O
MI?K^3H*VZ=O7UO6[B*R:[-]IEG$TLT!V.D@"JC2;""DIX96 VG:Z/!TY<1W5
MIKMIJ%W/*H73_860,ER,A1)NFAPI8Y5T<E2 =IKC==OL^-].A[*<3;W>@8Q%
M@;DLS[?&V\5N9-M75BF97?-QYQZ;%B2S)J$R&63(^3N1GVU-NM2%J*TIO^$/
MC'T?XO:9J5UTI<WMRVA3C3]0;4;/V.::>.%&%RB*SQE+@$.@# KG#*N*T<T-
MW:7WY-O8);:Y,,<\!E=)!+!)*\:2"1"0-KH5=6PRD X*D%I1W<Z3ZW;?9/%]
MTX6X%9;R[A-0NPIFVD([56L5<E*:^2B0\Y),9:"T_P"]CL=I(/GP#LNG?$.;
M6>I;[0'T>6V2W-P(;IB3GR) A,RE%"!P05VN^<8]./K/Q._@S6?0'A+T_P")
M-MUO9:M<ZDFF-?:2D:HHDU"V:?%A*L\CW#0,K1R^9#!MYP01MJT/&$*<RO&_
MG EO(*CGSW#]T(YY!(! /H!QX/GX:DTDD<\CTVX')[=\<?L&3FOD@9//O,3C
MOVQ\>_?'U_6,XKV_*KS5UO\ H")^]';&O)X)!&,=\_K^ZJCY_/\ ;Q^JN?I2
MFE*:4II2FE*:4II2FE*:4II2FE*:4K17H?L.E4/[Q^LBL2'LO_-MUYG_ .G%
MNSX]>.&:D?PC4D^*/\1T-Z_^R=KS\<R,?V']U1YT'GVGJ_\ TBG^_P M<UQ.
MO+*<MR',+3:/)^D/:_K+Z?5837WV88%B6X-(SU.X:[(FSVGLPH]M[Q,!^=6-
M&*RG&[3&,AIL@%M'?,64E<8 12HMY);F219LP +[3;J\@MU<-O67R\D-*%78
MA[B-N#@@23*3%!:M&54R&=O)EP&GD@\CRS;[L[C$7;S2A)7>F0H()E#V17Z3
M&)U>Y^TW3UO'N5;[/8A81;;'^F[?+;BSPW>'IUM\DM+^=D%5<7=[65>09/C.
M1V"G)U++OQ;3TR69CC=]91'V"C<%S/I>G,?+N!;116=M=Q%(\V=M$(XHIHH]
M@$J* =KQA@I^ &,-HTANY]JO;O<W%W<7,3EG\RX>8 RHS%R(V]XJ5?:W!R<U
MFI*DCCE0'/IR0.?'/CGU\>?LUB9!Q@YSV^?U5?\ C\N_R^OX=Q]]6;9I_+Y[
M _UM?49_O[V#TI5Y6E*:4II2FE*:4II2NOSN%[:W/\9W+W1P?&NE"KR*EVZW
M,SK;AK(;+>Z-0S+I_!,BG8Y-LS2IP.P5 :F38#CS$<SY"T,*2%J4KO 53GY?
M/\?C/RJU[9+VO.[^P&U$C$9O2;C60HI+S<K,GK&'ORF&'&,GS'*L[7#1&>VX
M=)>A1+=,#WI=*)+[!<Y2EP)2[4YSWX^&/W_K_?79@V?W 1NOM1MMN>W6KIV]
MQ,%Q3-FZAR0F6NK1E%%!NDUZY2&V4R50Q-^3J?2TV'2V5A"0K@*K51]*4TI6
M+OVU0Y]E5UQ?_4A;_C_PUI_!^D'T(/@CD$<:4KS ON14CO'W,KN"H\\PHQ\A
M7 (Y:\'P/*>">-4'8?4/QZ_M/UU="C S\2._SQZX^ [8)_567/V#T*%%]K%T
ME*BQ(T<N66Z"%JCL-LE:1L]G2PDJ;2GN2%(2K@\CN /@C0>@Q\?U''K\0:\-
MC/'XY(X_W5Z9VJUYII2G('J>-*5IW)_RP^GU'H/4_BU0D#N0/K.*5M]XW_ET
M?^TG^_\ 6/RZ9'Q'WBE:E0X/"D\_#DCCGX<\?BUY4@EL'US\\?U?"AX^WMGC
M-==GJ_ZNNJ5WJ6ZA=E,;S7:ZKVHV\N<"I*[$\OV-H]Q_NH+O;O%LUFR[B3?7
M\:/,4BUN7DQ637A$=J,PL**^%:E7H7H.PZKL+N[N[R]M6@N5@06PBV2*8ED+
M$RP2DX9L94@8'8GFHXZTZRN^FKNTM[6T@NA<6QFD+R1JT;B5T"@-+&2,+G."
M.3VJS39[</J'V2<E.;>9YL?23[',,SRTW;'2CM_&OHDW/LCL<ENX,"UK[^OE
MPZIN7:R8M97)=#$.L8AP5+6A/S>X/@SHPPWY5U)]N2580*IQGC]';1-VQV;D
M^F!SQW]EG53G.DVJEAMR9(F'I@D)*Y!R2>%V@<'UKL5= F\>>[_=)6T.[.YT
MZJL<[R:-EC626-)4"@J9\G'<\RG%6)L.H3*FHKTRH5)&D/1D2WTH><<[5D:@
M?6+"/2]6U+3XI6F2TN7A5V/]Z0"._IRI[C(J:=.N7O;"PO9$6-KFUCF9 00N
M]<^GISD? 'T' K!O!N=F&VU5 M,2V>S'>%#QFKM(V&7.$U,FEB0XR'Q,EG,L
MBQ]B2U(/O&VVZ]V0^A:/V1I*?G:UOR]3V'QK.R,$YX^/IC'?X8'W<<U)W3-U
M#7/4?AE=N"YLSG6U>)9%04&38=99M;X-/=RFIOF'I+3L:%B.37\BO=CL(8=D
M-6B(BP)3:4)4M#B4U((X((/J#\^?7% <C(.1GOZ??Z]CC'ZR,U0#VNA!]F3U
MS\$'CIHW4!X//G[W)/CQSY^W7N+^-B_[:/\ ?5">'QS^BD^KT^S[N>V:\HX'
MYH_]'X?D]?W_ /JU.,/*I\EA_:OW]_QQ7 1#[/??_P 1_ ]#]XJ\/V? /ZN_
MHR\\?MGMDOW]PJ7]\'\^3XTG4W]R[_![O$<_/> .WW\#ZJSM)Q^5">?HR#''
M]X0>_![?+O7?G_1)W\R/W\_TV;,_\*>+ZBZT_E$?UUUEQ_%/]1_8:\Q1O\!/
MV:[9>P^H?=C^O\>E<XX]\]P<DY].XS^H?+X$D&NQ]^A8_P":F?\ JU;P?[L8
M!KGM<&&MO\V7ZNZ>GI6TTPDK-GT>,>GIN_'[!FO2-UH:VH[#ZA32JTTI32E-
M*4TI32E><[[:S/W-K=Q\IS--35WZJKV@>_*G*JX90_7S$/X!CC*TN-J!(X"B
MM"D *0>..W7:>+>CC6ND.BM(:[GM/:^F(G%U:L5DC G#;0X(&3]%U))[Y&>!
MC?P?^M)/#;Q-UWK)-.T[7KC3-;NHWTC48%EL+J*Y250THVA1)&K85@0X8'G)
M)/5AR_(UY9E.0Y(J%$JA?V\^T-?5M?)H4+Y;(=?5%C,M)0D,,=Y0V@)X2A/'
M'C7 Z=9KI]C:6(EEN?9+:*!9IF9Y93%&$+.S,26;&>Y[\' %=1U1KQZIZDUK
M7Y;"STTZUJE]J9L;"%8+2S]JGDF\BVCC"H(8M^Q!VP.<D\PZKJIUI<0*>$RY
M)L;*5&A5[$=7:](D3'&V8C*.Q:$E;[CB&0%%*?G DC60\T$4,L]P?*BACEFF
ME/\ ,2)3(S8YX4 ]Q@8)[UH'=0&=CO1<GM@X ^'!/KZ'GTSBKIMZ^F+J6Z(=
MU,%KMP<;LL'W(8K:'<["I%3-:N'X\9F3\KK[>/(@*E,M2JZ=!*9++K8^3OMJ
M]XDM\:X/I;KSH7Q2Z>U2ZZ?U2#6M&6\NNG]2CG4Q1F5H_+GMW638&66*0;,?
MQB2 KW&/5S9RA!%=VLT23P>:(YHG3? ZYW!6P2H! ?\ O#D'!&*AO5%UC]0_
M6'<XA=[^YN_FECA% ,<QXIIZ2ACU\-3B7I*U1**!71WYTQX)<FS9#;DA\I;2
MISM0E(]=!^&'1'AE:ZC9=$:,-(@U:].H7\?FW$QEN&&U3NN)962)%.V*-2(T
M!]T<\Y-U=SWOLYF,3R0Q+$KJB@F*/.,LH&\CG/!)Y).22;7"N2V"VDOH/)20
M#[L+20DJ0L)[>Y)')(^<D\\GU)/>XSA2%(0D\X..3GGG&.W''RJP&:,,H,D4
MD@ 8*S)O3' 8#&05].>_/?F'2.2L$GE12DJY[>>X\^/F^!P. !Z@>/0#5,YY
MQCG\8^7PJPPVD# SC [8&2>Y'.?MR.?MY58T^])2U&96^\LI2AEMLNK=)6GY
MB6TA2EE7P2D<GTYX/FA<1@N2% !RQ. H((W$G@ 9[G 'QH#M5R[A%*^^6( "
MDD?2SW^?<#U K*3TT]*>\_M+,U1AN)5FUVUM=LEM_!BY%>.U+>*1D0&9KK3$
MZZ:90J;;7DMYUY4J:][J.RQ')>=9/;WPMU_XE]*>"&DQ:MK,NM:W+U%JQ2RL
MK43:E.]S(@)BMD0;8X5"J$50<NX5<LV*PM'T&^B:Z31HKW6);J=KIGFNV,$.
MY<+'Y[G9"&QB.,;G;D@%%)&/'<3$5;?9QE^!_=6IR)>*9);4"[RADJDU=F[4
M3WX#DVN?'"7X;RV"Y'=6D>\;4%#N!/,LZ3>C5]-T[5HX)[9-1LX+Q+>Y4QW,
M2W$2RK'-$QW)(JL Z-RK#! (.,Z&65T E1[9R0KVY"ETD[%2ZY#%3QN!(/!^
M53IL?>[:XEG3-ENYB<K+,4$.8V_5M%;+R9BXRQ%DEIM^,74)=4%*"EI3Z.=I
M[1K5]5:?KNHZ0\73NH)IU_Y\6)Y",-&'!DC#,K%&('< '@KGD@R]X.Z[X?=,
M=:Q:AXH=,S=2]."PNXS8Q[C)%<O;L(+AH%F@\X*_H[%02''*@B>L+S#IP8O]
MTI>8X);2*>Z;G*V[B0Y\SWF/.*+HBIE!,QHESE;!2XZJ0RD(4A:5D\C5:CI_
M6QM- CTS5K:.YMGC&KO)'%BZ&$+LFZ-L#Z0.P*QSN'<X[/I+JGP"CUOQ)NNJ
M^BM3DTC5DNVZ#M[2[N2VCNWF^2DPBNXW#Y,15Y3+"H5D8%0=UK4AX)7(]R0E
MEQ1" HH6H!*B4E2R5*"O3PE7/J4_'7<G=D;R"XQN(QC.#SQGX$?#[<"OG1BA
M:3RP5B,CO&IX88)VY/&2%.",G.>!V-;$2WVR%-.\=X4VL)6A'>E0X*2D$**5
M'@*^:2I(\]WC520Q7<JG80XR!W7L<GC(]!^JJ*[H2RN02"K&)BA=2,%&"D%@
MW(8$<Y.0151;;<>]R'&,5PVZ5!<H,2=FKKHT:)"C2G/E9:4^9$IAA$I]14VV
M&_>N*"0%<>FM1;Z-96FH:AJ5OY@NK\1"=FED*#8&*^7&S%$')+8 &<8P,BNX
MU3K[6]<Z=Z;Z2U3V0Z+TPUS)91P6EM;W,AN=I<374<2RS$;,*7<XW$D,W(V8
MUB&?O.UN48?C.4N--6C+=-<U%;9O)BV\=]$B$B+8QF%?X8176D+0&G/?MN-C
MM /)%^]U'1HA<6.H7>G_ *6U?VFTN[B!2;65-K"2*1PWELK;6++L(.T\'%86
MF='=7ZM#;:KH73.O7EA+>"VMKZRTJ^N[9KHL=ENEU##)$\ZX(**S-D'W>#52
MNHO?KJ/WMRBM/4CG^;9ADN&U$;'ZEG-GWVIM+5L_LJ(S<%]J,6U/!PONR%LJ
MD3%J"GWG2A)'/=$]']$=(:?,O0ND:/H^GZE>2WMPVCI&(;JZ<*CS.\+.'PJA
M  =B@;5  K7]2VFNZ?K,MCU+8WMAJ]H$@FM=1M)+*]@C(\R-989HXID7](9%
MWKR'+Y.[)H3*NK6PB-5[UE.FPF/GQX;LQYV.PI/(Y;CN.E ]1^"CS\U(^(UU
MBV]LDK3);P).V5:5(8T>3/)+NJC</K(&?D,5@SZMJMU:165WJ6H7-G:\06DU
MW/+;1<84QPM(R+M[95  #@>M7G]-/3KC\K+\3S+J-:SC:_96TE1FJ[.X&/3;
M&,<A4^TJBC3D-I>=B0[%](;;DO-H9<_G%A 4I/"=1=7NJ7&F])RZ;K/44+HT
MNEM>0Q3>RJZB[F@5OXV2VB8RE$#,,8[L*IKO2W7&DZ?I>IR=.ZKI^GZE-$R:
MIJ>F7UKILMF#N<P7DL45M))*F%A59F+E@45NU>QA6!*:^O#:BML0XX2X0H>\
M2EA 2L@@=O<.#QQSSSKMH&9HK8R!B[0JSEE*G=L4G<I *L3W4@$'C .<8%1
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M@+JZ9EYLBS78NY?4US;F;SFZ>11M0HD5B=*C6#+B[1I\1GDQU)=ROR1JI/\
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M*FH7:Z"\<9!73U\XQ7$C7"M;FX&5@5HF#DJ "#BK3<DOY%W,;DRF(3+C;26
MB RF,UVMH2@**$E22L]O)41XY^/Q[NUMTME94,C!G=R96+-ER6(!.#@9P!V
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M?=\L<00__/,^^5P5$*"DA0!'C@*\'C7#6=+;4_R*+V#\IB+SC;%SYNS'<*"
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MSA1QGCZOO_'PK8F2A05RA:5(Y!"@ 3Z$$$'@I4/(/CTX(!\:];U!(9E#!=[
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M_P 9^58D?9?_ +K]>GGG]O%NUZ_^1J?J'[WCZ-23XH_R?H7T_P#9*T_VC?\
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MMZ0\HIDAE#?N&6U.A?*ZSU=<ZEI<6BP:?:Z78KB6X-HI#75RD@96ER>-N V
M.6P68X4#H](Z;33M1@U2XOI]1N+1#%9I<$F.&%U(; R6+-D@'?L52P5 69C!
M8'LGML*38;8C9^GW-SBGR_IUW+?W+VVWC@5V.Q\QB6<VV>LK2IG,(@?<^726
M[3HB3X?:@O(8C.J6%-J[]BW7^JS:Y<:S)9VCI=Z8=+O[%@YMYX"JC/)R"3&N
M2,@KD'G!%B/I&RATR33([B;,VH-J4<V5WPW+$G*8 QLY*9;*L <GD&&;2;99
M?NM[4'=WJ R7'[N#@G3]M7C^P^W]Q?5$ZN3EV67 ^^+,<FHES&&VI=3%;E(J
M?ED%1BN2'7V&2?<+4O'COTT_HB>RBG'F=0ZM/?7-D&!-M!;21V\2D##)N6T@
M=0V Z'<%PM5NK.2]ZLT\/$S6_3NF*!>,N!/>W27#<GE69$N7R /=(4;N0*R]
M-CM6L=@2/FJ[@. LGNY^@<CQSQY\CGX:XT=@?CZ?#@5U8[D8/ !SZ$G.?M&!
MGZP/2OHK\$_9I53^\?M'X_;6)#V7_BVZ\_Z^+=G]]BI/CP/&I*\4<>1T-DG'
MYI6F#P3_ !K]^>_KGUS]\>=!_P IZO\ ](I_]F/L]/3_ (9<-1K4B4TI32E-
M*4TI3CG^'5" >_/K]U*<<?C\Z  9P.YR?F:4U6E?-2NSRI7 Y)Y/'D  \?#C
MT/I]OUZ\$D!V.<*=WU* ,]O3N?K..]4YW*.Y.1]9XQ_N_;\8/&R3'I=I+H8M
M_42KR TA^=4,6,-ZTALN$!MZ57H=5*8:65)"7'6DH42 DZ]CD!O1@&7YJ>Q'
MRQV^/?GO5 001GE3M/Q## ([\'Y'G/<5%5NH !]YQP>TC@\DG@<>@\CD*X]?
M3T"ARQG(S@D'G[">/G0Y '/8C.?7)"C[23Q\_C7&;FQG7G&$24^^82AUUKO2
M7$-/%:6U+2#W!"BVYVK("24J /S21Y ;;N]X[B5''9L $=NP/(]1GX8HQ&<9
M VJLAP<^X2X!^0)1ASCL>/2M9DZ) CN2ILQB)&95W/2)+J&&6D*!(+CKI0A"
M1X')4!SX)YU;8D; 6(WRE5X^D&# */M(QCDX'QKWQASZ(A9O^J!C)/P&/C7,
M;6E:$+20I*T)6E0/(4E0!!!^((((/QU>P5]TYRO!SWR.#GYYKR"& 8'(8 @_
M$$9!^ZM^E5II2FE*:4II2FE*:4II2FJ8&0?AV^VE-5I32E;''6V4*<=6EMM
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MUO\ D/0C"I'?9[7[4!D9!+]S6,6W)*",$Z#'&,*5(F75-7VA3QEFA,3DC/#
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MN74 >BAL#=S?)K&J_32E-*4TI32E-*4TI32E-*4TI32E>:E^B#/\>[A?U_\
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M622!R3SSY\#SX')]-*H2",<<>]G[\@X/')XQDGC)K:#P0?7@@\?3P?J\Z50
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M\QHYO/)W-[+<6:C&=L<]S;,0I[X/DCX\$\<5X*AXDC' 2:"8\8W>7#<1JI[
MC,N3\2/7TN@2 $I ]  !]G&K@[#UKT.PQ\*UTJM-*4TI32E-*4TI32E-*4TI
M32E-*5M42$DCX?W]4.>/K&?J_']54/8_4:IAO/M=1;V;5[@;3Y.MYN@W#Q.X
MQ6S=B]ORN-'MX;D4RHI)2!(BJ6'V"I0 >;1R0/(LW$2S1J",F.>WG7_.@FCF
M7[B@Y XY[XQ5R*5H7WKW:*:(@_":)HF]#CASW/W^MNF.]"VR=<_%N[ZNLK_,
MU9!29M>9,+.TKD7F;5&V+>TJ;U=4Q/=AQ4R,/"XCL!A2HGREU4M2%R4!8I<X
MG\V"1?T4D6K1X"@@)KMS=O=(>,$DW;\D<"K42>2(BF 8VTYQC'T]+EAGMCZ<
M"2%#CN0,<\527"/9?;"8GN?DN;/S,JN<3D5VUU3B&V<BZLV,6QC]*S$+/$:.
MPGM(FJ&56;$6TD3JRPMDK?IIBU.1E%92I&1#*RV\\,A#F74KS4@W/NK>6>FV
M1CP> 0FEQ^N2,$^E5?#R J L8TV+373^^$=W=WA?L.[7C!<9 (/.1Q.KGL[M
MB**#AE/MS L,#QK'LDVAO,BQZMDR)E;F<38]VRG8/$MH\J0IM%HW8R:]RVR-
M+#UQ:PZB%"ER'$MI4DLK">VNT/-M+<7$:D<!Y[6XMG8#N,^T%B!SGCX8\.@>
M&ZA8!C>*L<C>I"S1S#GG@>5@=^^!5_3("4A(21QQYXXX!0DCX CP>../4<:M
M1N7+$@C:0!D$=T5CC/S./CWJY@# SW_=Q^P#T%??5VE-*4TI32E-*4TI32E-
M*4TI32E-*5YJ7Z(,'\6[A'SXZ_\ ?3T_TC8SX/Y1X^L?5S)W7A T/P_^)Z9.
M.W/]L'GT]#C[1QSS'7163K/6N.0-;;/RR9L?5D_'YUU@BEQ2E$*('*^23P.
MKD@>I)/GZ/B.?4B,@NX9XQWYYS]7]=2.,DA02#V/ICU^_P"[Z\56W;[8[<C/
M\?O<NQ*@>N*7%6E2KEU$EJ.XEIN/\MD-1D+',ET1N2I*5!:05*"> .>;U7JK
M1]&N[/3M1NQ;SW[>7; QEQO=BD;28P54N<#/K\!VE+H?P<Z[\0-#UKJCIO1?
MRGHG31>;5/TZPRNEJGM,R6X9?TLHB#.54\#)R3@5+.XUKAEM.KY&#TMA11T5
M49NPB3I#<AU5HGO2^\RX@((; 2 .\=XYY(X\:S-&M]7MK>:+5KF&Z9KAY+9X
M5*@0'&P,#@;LY) !Q_?&M+UYJ/1FHZAI\O1>C7NAVJ:;"FH6UW+'*S:FK,)W
MC9&),>W:-SD,Q.XJAXJFQY1V^G>4]R"E(^=W'DA?SO!^T\'UY)UMN^<]OG\O
MW?7W^JN&PRL,'.['?')_=G')&<^F.:XI"B3R/)))X^D\^G[^JU9()9OK.>,C
M=CGX\$^H'P[<8B+((B#@))6M?!Y'<DI[!Z$_'N';\/!Y^G5 N2S?WJ@_?N&/
MG^W-7 ?= W,,8#*,8YRH/T@<G@GC@8P3FKA,1W^FXILYEFT;6+4]HQED]R<Y
M>3VR[,@J<9;84N.V4E'O6@URPZ5(4 I0X'=KDM0Z2BU+J33^H?;;N!["%8UM
M86VQR;'9_?(8>Z2Y#+@YQDD&IRZ5\;+KI?PIZD\+8^F]&OX>H;Z6Z.KW@,EU
M:&:&*)GBC*%?,C6+,4FY2NYL#G)A6QDW9B);Y"K>BMNK*K=QV8U0IHDMK=CW
M!4@1GEI<>8"0A/OBE?+@0LI*D+3R-7^J(>I9[>S_ #9EM8)TO8FN_:2P$ELO
MTP"JMD'C<I(W $ CDUK_  >O?"2SU/7CXMV&K7VGS:'=P:,-)1':'59,>3(1
M)+%M8#<J2 D(V&*X%4I^Y3MS;RXN/PY<AI3LEV%&2VX]*^2-*<=9+Z6DK*EI
M820ZH I!3^%P== 9?9K>)[V2-)0J"60N%BWD*&VLY P7SM!Y/K49+IYU35;F
MUT&TN[B&2:ZEL;81/-="S1G>/>L0D)98@I<K[H8%@Q%3HHW6&5,)ZPQZ=36L
MJ5#N<>OGX\B!+;,0MK4["6ZTDO-+3P"L*^8Y^"%HX)US>S:K<2B.]BNH4BDM
MKRU5TEC(<'W9 K':R\CD'*C'%=0LFL]':5 M]T]>Z3J=U=VFK].]1RQS6=W"
M8&5V]G,L:-+$00-R. K$,-W%0C(L_P QRYAT9%D5E:M/3EV3C4Z6\\S\O6VT
MR[*+*E%'>66&&RO@J('D>.-7K+2=-TUT:QLK:VD$0BW)&JDQAF;;N SM#9.&
MXS]0K7:]UOU9U1&8M?U_5-3@DO'OGBO+J6:%KQH8XGE\MG*[_*C1=X';(!SS
M50XM]LDYL_8U<['+UO=Q%FU]S;N"J,FF>@]O',T+=2XD\*6%-H;7W$I(= 2I
M*M1+:=5#J:*XBO;1M : K/:N&\]9.#F/"[2>.&+C )&/6N[MM;\'Y?"F[TR]
MZ<UB/Q.2]!T_5[5[<:7);8?^4[YEE"C(#QK Q8A6+ Y!HB\^L)2REQ265DE"
M ?P26BCD)Y*!RKSS\2.>/)UU& 6+E%'&W..<X[]L\#D>@^9SB'#)*R>4S,2-
MOZ,,PBSV!"Y W< Y [CN35V5MM?LG'Z=ZW,JS<AR1N=+?9:?Q)2$*<7*<E!E
M^ J,E:ELH894'TRU'W3H/"4A1/$>P:_U1)UE/IEQHJIH<2.5U#) $80-'*'(
M"L6;@H!E3@9XS7TWJGAMX-P^!>F]9V'7;3>(5S+"C]/LJ-(UXURL4]B;<-YL
M4<,1,BW18HXP50C(JV')\5N<:F(AW$94&4XRU)2PH)5PQ(1WMJ!3P .%)(3Y
M':003QKN+*_M]0C#VL@EC5FCWX*^\G##!&?3OW_;7S]U#T[K'3-ZECK=H;*Y
MFA2Z6(LK$1S#<N-IP?AP<<?*H=3U4NXL(E9%;]]+FRV(<-KWG:IZ3*=;CLI2
MI0\ K<1Q\$^O)/C5^>:*TCDGN&*PPPR32,N2%2,%V8CY ,3CGGYUK].L;O5;
MZRTRRC\^\U"\@L;6,N%W7%Q((H5W,0%W.ZKD^O?T-3/N5MEF&UEV,=S*M75V
M:F&):6"ZEU"V'@OW3C:D ((5P>?\J1QR>2!KM'UO3]>M#>:9-YUN)#&205*R
M+G*D'GMZ^HQ73]>>'_5/AQK*]/\ 5EA[!J+6\5W&@E$B/;R'W71U SDC'88(
MJ 8RVIO*,7)<[^[(*;P>21Q81C\2?3\7&MI\?WC\<5Q66/<D\^O;TSCM\>#Z
MX]*]P"J_<NM_T!#_ -KMZK51_7^VN?I2FE*:4II2FE*:4II2FE*:4II2FE*:
M4K17X)^S\_R^FE4/W\C]O[N]8C_9?=IMNO3M]/U<6[/U_P#:*GX\G4E>* 8P
M=#<$_P#LE:9P,X/FR? ?N^_FH\Z#S[3U<?3\XI\''?\ 1KZ^M9<=1K4B4TI3
M2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*
M4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E=9_JC]C7N[U!;E
M;MV%W0],FZ&W&:[T9+O#B]9NJ=QF;K&[7)H,>!+;0K$+"E;_ &2#'CL/H<DR
MV7%L(?0&E%23++=4=#ZQHN@6NO:9K'M>BV'L*/:31^64]T.PWN?IM'OP,!=V
M . !&AZ>ZKTS5=9N-$U"P%OJETMS,LL*@^8"[*&RF24$A7< <D;AR<U:W_@<
M^R4.3T]]"*AR%=JI._?!/@DI_CT(^GGDCZOCSK!=^%V$46/4GN@ 'SX<ECWW
M>_VSVQD^O':LOV?Q$/FN=0TH-N#QH(D*L<G*M^BX'/8]^P(R:J-B_L+]VL)I
M+/',5VIZ*Z2CN4.BQKJ^RW]88E%]"67E.\9N"%K93[A2DH[O=<)[E !(TVH:
M)X'ZK=Q7VH:)U!<WMOM$+RR0-Y>QBR!3NX ?D<8!RV.:D3IGQ4_A#=$Z-?=/
M=+=5V6F:/JXD;4K.!46.5[F(0SG!C)):$!-P8'!([<53ES]#HVBU$KZ>^A%2
ME+*B?E6_? *B2/\ NT!/ \%1X)/G6Y]K\,<A6T_J)43A0)X23QZG</B._P N
M/2HY>W\12QQ?Z2V6+&0Q)N8N<L3^C'KV[UL_P.;:?T/70@/I_BO?W_GIKW[7
MX5_X#U+_ $L'_FI[-XA\ 7VD]ASY2\>GJG/Z_MK7_ YUI_0]="'P_P#A>_OX
M_P#NT_)I[7X5_P" ]2_TT'V?SOO_ 'U7V;Q$_P .TCUY\H?NC'/Q(Q\A6G^!
MS;3S^UZZ$/J_BO?S]_\ CT^S5/:_"O\ P'J4?]]!^K+?CYU3V7Q#SGV[2.V!
M^B''U?H^?K/SQWXU_P #FVG]#UT(?_S>_O\ STU7VOPK_P !ZE_I8.W^M^K]
M=/9O$/M[=I..?^C'8_\ =\D?,8^&*?X'-LO'[7OH0'^6)E;^$ >?A]^A]!]1
M^S07?A7N']H]2XR.TT&<9]/>QGX<]_6JK;>(0=2U]I)7()!B4@X]#[F>W&1@
M_;4R8I^A_<RPFV;R#&=C^ABIMVV)$5J6R_OPM:6)*"T^D!>9*2.]M2D$\GP?
M3Z<*^M_!S5+/V74M-ZEEA,RNZB:+:=IW _QF[<#V]!W'?CH^D^IO&/HK5H]=
MZ>UO2+/4XK:YM8Y#9VTP$-PHCD&)8'!9D.#G'![]ZC>;>PAW-W&;J&,RV?Z(
M;YF@CF+3-RY>_"A#CJ".6FT_?B$!(#:!P.T<) 'H!K#TS2_!?1);EM%T7J"$
M7,I><M+$#*PR SYD;+>\3Z\\_&MSUMXC>/OB'#I,?5G5.F:HNA0&WTN.2RLX
MUMXF6-6C4Q6R87$:@#_J@]\&I /Z'.L_'[7OH1/@>LK?L?P9IQX]/Q>NMQ[5
MX6CZ6G]1J2.0L\)'PX][C@>G;]=<"MKXB@9:_P!*8\XS$O&<9 ]P KG) ^?I
MVI_@<VS^/3UT(^G_ .5[^>O]FGIH;OPKQ_(>I?Z: ?K#9JOLWB)ZWVD'_NEP
M>_\ \/UR,CY''H:#]#G6@\GI[Z$1QP>?E6_AXX^HYIY'VZ&[\+2"!8=2$G@
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MU_QK07GA;_@'4?VRP_ND]/QFGL?B&>^IZ8/^Y4?LCI][OMD/\\+HX_L9SO\
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/J';W57EL#OD@ =A@5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>g40894g60a60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g60a60.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1KP4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &M2^:&@X0DE-! 0      &$< 5H  QLE1QP"   "   < E  "')R-C T
M.#DP' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@4&5R<V5V97)A;F-E
M("T@1F]R;2!3+30@7T=0(#4N,3$N,C%?7S%? #A"24T$)0      $)%F[<T[
M^2P\;_QU'>MH61HX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q :0            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              (9   #Z0         !
M      $              ^D   (9                      $
M                $     $       !N=6QL     @    9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N
M9P          0G1O;6QO;F<   (9     %)G:'1L;VYG   #Z0    9S;&EC
M97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L
M;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%
M4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%
M4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   "&0    !29VAT;&]N9P   ^D    #=7)L5$585     $       !N
M=6QL5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     $%,    !    H
M %8   '@  "A0   $#< &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( %8 H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MZ&Z^JA+)Z;]9K,B]]%SZF.NL-0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" $" >$# 1$  A$! Q$!_\0 'P !  $$ @,!
M  @&!PD* 0(#!0L$_\0 <1    4# P$% P8%"0\,# \  0(#! 4&!Q$ ""$Q
M"1(305$487$5(H&1H? *%C*QP1<C,S4X.771X1@9)"4F)R@W0T52>+:W\39"
M1%-5969R=Y*6M1HI1D=98G-VA9.BUTA)5E>#AY2DI;.TPM/4UO_$ !P! 0$
M @,! 0             ! @,$!@@%!__$ %$1  $# @,%!04% P<*!0,%  $
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M NC OW<B<6WL:0I"8%!6/W@*4L1G>,]Y-C&_*3$? :JMOOZ:+)-$7B5*)B@
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MSYNXZ[1U.H^&7O45'.4T1-$0?O\ <.?JYT0]?HJ(I=+N3M<'\#P_%GFH^*+
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M9X#0HMIL</>J36I!QN;.V0[P@DWSBRY6&%-C\'5J@%E4GO&D^$?LW$$$2?>
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M"[IA=S+N*<IF96>*U#4QU%9(6+1X=RH49<$CG,ZRJ8HI D;/<$@D'&BJEF
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MHG4[G=$!,8"")Q*/=$N1$0'&.FL'O;3:7N,!K2XF"8 B;"^[BK$^'.=-_DN
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M"HKE(KLJABET3KH2LZL6]-)1S"0.T<,3/F35X9F[*4CIH+E$BPM7293& CE
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M.]UW(_)6>>?'UMQWQO4T+G^)^I97  (C_4)4HF  $1[IJ=D@' !D0'D/(1'
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M:(FB)HB:(FB)HB:(J"?VRHJ3>N9%]#$7=O%!5<JBY=E\10<9.)2+E* \?ZT
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MG3)9"V2KE9HV5>-R-':B"1W+5-;VDC=<Q %5$CCPT@7*D<3$!4$R H!>\!0
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M<H,VK1)1PZ=.EDF[9LW23%55=PNL<B2**293'454,4A"E$QC '.H2&EH.;S
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M2DI1R*CIPLIER]6$O>[I1 @ 4+;Z?HIP^ACUR5V"G*< ,0P&*8 ,!BB E$#
M!BB AP("40$!#("'.BJ[:(FB)G1$^_W^_P"8=$7 ]!^WX>?D/E[M$YJBV:.*
M[FE_9^Z)Z?ATQ<^PHD[X$=R(^%\H^UG77$!$#>SF8H)I ;Q"N%3'$I"@_.>)
MMUPRC=K>;X/W4MWOX9BA]W[01W'K]FBHR&G#<HH=/XNN/CQC[\Z(GIG&1'SS
M]ONY\L>_RT12LV0AG=-:( SQ+R0CGT^2'@_FQP'\NB+9[T1-$5/U+2M-UE&#
M"U7!1511 NF3X8Z89H/V8O(YTD]8N!;N$U$Q5:ND$ET3B41(H0HATT140M8N
MSJ[6.9*VRHA1K$HN&\8B>G8TR3!!W,I5"Z1:)B@(()+SB"4HHFGW2B\3*M^4
M&=$ZX=='176*4"@!0        P   8  #T#W8^&B@\O+KK+1!_3S\/I_-Q\<
M:*JQU5@NRI"_3QN"C)<8>H'*#M%H5BH"J-%)>&X2>MWRRSM5,Y"B1P=%@JB8
M *5,P$!4Q3@/2V4FXZ@#*XA:P(70N69,H_JBUV.1,.?QMG^<X'D!?\"'V<^_
M+KY=>BJ\"]PJ_=G;*.ZZK!RHR6%RS4<5+,KJ-''A'2!=H=1Z)D%^ZH=/Q2?.
M\)0Y [N1'1%Y_P!4^YO&;BUU_P!+9[CX?T=_%HBR]]EE5%3U(2\?XQ5'.SX,
MU*.!I\M2K^3%J"R4V94$#/G#@2>()0$P$[@< &,8P\_T3KKK19<A 1, @ 9
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M1G+14PS=T_44'5$*0B<]!R+063A=)LNCX2C8@FKP75W5@8<ZC4I'_$#LG*/
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MYX\P^GST12MV1!C=-:'(#^W#[CIUAY''NZ^?QR'710]6GX+9ZT57!@$0$ '
MB \XSCZ.-$4>+ORVYV.F8U*R%&6?J2GSQYC2;JXE8U53DFWDP6/W4&36 IN9
M;K,Q;]P157635!7)0(8O(?3P#>R"RJ>TJF.8\.'=#"=Q!;LN+MOOFN\4@ ;)
M%I)R7R>T7=KA]+^3:> >PM=WIQC:Y(=/AV.Z>WPQ,@WG510I/<!OFK.X-V+;
M1=GMMR,W:%S2#2H'+FZ-P2LG:U:4_P#C'&?)YB4.HL<B3/*;DRR*6%BB"??
M,Z^_BNR?9C#X#LS&NQ?:KV=ITZ]2G2:<,'TAAJQHN%0BF 9<"X;+C+1)LNOX
M;M3VGKXWM+!-PO9+7]FOPS*KS3Q&R\XK#4L2PTOVQ)V65 UVT -J8$*==J'E
MUGU*I+WBA:*@*P%VZ*M'T'-3$]!%9 </8U4Y";C(AZ=PHERX3%F5-,_S2*'
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M5$1\=+K^RIA]1BY\QY^'(CSUQHB^TQLM_<@[7/\ %^M#_D' Z(KW5R'>H^I
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MM0I:F9V&J.*<2^TLB,G RC&7CU#H64>I+$3>1Z[AN<R2A#)J@"F4U2F(8I3
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M' Z\8>UO[R]L[OY0JQSVCZ:7\LEZO]EOW>[+G_VC-PC.,YFT*Y%6J%-16X
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M(V&<Y  S[@SQY<] T3KKFLJV R \\9\Q\_IY#W#QGGJ&B+1Z_#+LE@]BH!G
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MK]D'SMT]HP-G]N'P@/Y/(PLD& $O(Y 1R'3UQ@,$6SMW2^GKT$0Z]<X'D.G
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M^41\E3-</',91E6R;)8S=]'4Q//6;@N!,@Y:1;I=!8H' Q!,FJF0^# (&[H
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M&.FB>G#^-_DKF#V=]S0Y#M']]8X_X:6WS\/[6W/TCIHX:N:6SN!S(X\5D"
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M0Y0,0Y#=X!*8I@$#%$!$!*(" @(@(:*:GD/FY=P        #  '   =  /(
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*$T1-$31$T1?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>g40894g60b60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g60b60.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1A&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &"J^888X0DE-! 0      &$< 5H  QLE1QP"   "   < E  "')R-C T
M.#DP' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@4&5R<V5V97)A;F-E
M("T@1F]R;2!3+30@7T=0(#4N,3$N,C%?7S%? #A"24T$)0      $)%F[<T[
M^2P\;_QU'>MH61HX0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q :0            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              &\   ":0         !
M      $              FD   &\                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     #:D    !    H
M ',   '@  #7H   #8T &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( ', H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M 'HMK8YOV:NWW[\WWT_H_P#A%V;;:G .:]I!.T$$$$_NJ:2E@G0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                  #_X4$6:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-
M<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D
M;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q
M,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @
M(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P
M,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R
M;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^
M:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z8W)E871O<CX*
M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^
M<G(V,#0X.3 \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @
M(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @
M(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA
M;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2!0<F]J96-T(%!E<G-E
M=F5R86YC92 M($9O<FT@4RTT(%]'4" U+C$Q+C(Q7U\Q7RYD;V-X/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L
M93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E
M871E1&%T93XR,#(Q+3 U+3$Q5#$U.C$R.C,S*S U.C,P/"]X;7 Z0W)E871E
M1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y04V-R:7!T-2YD;&P@
M5F5R<VEO;B U+C(N,CPO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP
M.DUO9&EF>41A=&4^,C R,2TP-2TQ,50Q-3HQ-SHU-BLP-3HS,#PO>&UP.DUO
M9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C$M,#4M
M,3%4,34Z,3<Z-38K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B
M92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%C<F]B
M870@1&ES=&EL;&5R(#$P+C$N,38@*%=I;F1O=W,I/"]P9&8Z4')O9'5C97(^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL
M;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B/@H@
M(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.CE%,D(S0D-",T1"
M,D5",3$X,C0P148W-$8U-CE&,T0Y/"]X;7!-33I$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.D$P,D(S0D-",T1",D5"
M,3$X,C0P148W-$8U-CE&,T0Y/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @
M(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R
M<SYF<F]M(&%P<&QI8V%T:6]N+W!D9B!T;R!A<'!L:6-A=&EO;B]V;F0N861O
M8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#HY13)",T)#0C-$0C)%0C$Q.#(T,$5&
M-S1&-38Y1C-$.3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.G=H96X^,C R,2TP-2TQ,50Q-3HQ-SHU,BLP-3HS,#PO<W1%
M=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E
M;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W
M87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\
M+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.CE&,D(S0D-",T1",D5",3$X,C0P148W-$8U-CE&,T0Y/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(Q+3 U+3$Q5#$U.C$W.C4V*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T
M:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z
M<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N
M=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T
M;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#I!,#)",T)#0C-$0C)%0C$Q.#(T,$5&
M-S1&-38Y1C-$.3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.G=H96X^,C R,2TP-2TQ,50Q-3HQ-SHU-BLP-3HS,#PO<W1%
M=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E
M;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W
M87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\
M+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*
M(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.F5E9#(T
M,3(X+6,W,V4M-#DS-2TX8F(P+31C93DY9F(Y,V(Q8SPO>&UP34TZ3W)I9VEN
M86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS
M=&%N8V5)1#YX;7 N:6ED.CE&,D(S0D-",T1",D5",3$X,C0P148W-$8U-CE&
M,T0Y/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C
M=6UE;G1)1#YX;7 N9&ED.CE%,D(S0D-",T1",D5",3$X,C0P148W-$8U-CE&
M,T0Y/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/G5U:60Z965D,C0Q,C@M8S<S92TT.3,U+3AB8C M
M-&-E.3EF8CDS8C%C/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @
M(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO
M<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D
M93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( -4!* ,!$0 "$0$#$0'_Q  ?  $  00# 0$!            "08'" H!
M @0% PO_Q !D$  ! @4"! ($!P8.# H+ 0 ! @, ! 4&$0<A"!(Q00E1$V%Q
M@105(I&AL? 6(S(U-W8*%R0E.$)R=+.TP='A\1@9)B<S-#8Y4G>RM4-&4U16
M8G6"A:0H1$5D969S@Y*4HL+_Q  < 0$! 0 " P$              0(#! 4&
M!PC_Q !$$0 " 0(#!0<"! ,%!@8#     1$"(0,Q001187'P!1*!D:&QP='A
M!@<3(C)"\10C-G)S%A<S0U)B-6."DK+"%28T_]H # ,!  (1 Q$ /P#?X@!
M" $ ( 0 @! " $ ( 0 @! " +?ZIW_1-+-/;NU#N.99E*+9] J=>J#\PXAMI
M#%/EEOX4I9"?OBTH;3E205+ SO'%BXBPTFXNXO\ U74:7-4J6UPZZ_J0<<"7
MBXW_ ,2<YQ 4*_=/6Z3=%F6U7[]TEH4BSB9O*U)$/JD'&6TO.+F'Y@-I/*SS
M;'8@D@=FG#JJP:\2F/VT]Z^Z-+;_ $\3%%/]]A+^5U)1S=^5OJ8_<'WBG\8'
M$/JLQ:3\GI(%7<[7J6Q9$ZZNC7=I_596:>8IYJ\K49IAZ9900A+J66UJ<7S<
MH( QEJ<%50IU>N7#GQRT4L[./2E#5*5XM=92KJ?756*@T[\0CC\E^)?5C2S4
M^BZ;KLSA]JU'?U)F+8EJC/5BH4:N3KS$BBBRK;KH=>;2EL/9;"4\WR#C"AG9
M7-#KB>_5^G>'W7397F4[7?U.KCI+N1:::?&5?QW1>8T1?GQ%?%HN+A;N712W
MM)+01=<S=<G)7MJ0Q4F5IG+8TY](PF?J;C1F6"PXRF8;<Y7$J7@*3RY3&,.%
MCU46:H?<>KWY/BX5M4V[&VH[O&E.VMW<OK9OB$5V^N.+2KA_MRE46>TXU&TA
M8U#E[B;*7)_G>I9GDI:6E_EY"\E3:QR$A(!_"&(Y>ZGC5+)4X6)6E_[7NRRC
M*QQ8E7=2<YUTTPW"_=IYK7?G$F+?$MQ=^)-IAQF6;PZ6C3=(IJD:M5*IS>GT
M].+FO3,6]3UA2OC0H>2E$VEO/R0D@D;YS'%LM7Z^-5ANRI;GA";TX*V6Z[.;
M:*5@X-.)_P!5K<TLGE>UN>5R2KB'XXK#X,M.M,*SQ%S$U]U5\S4C;34A:4B[
M4S4KJ5*!Z8EJ=+H!=<2XI*RVE()( V&=YBXBHVBG!5^\X7BWXK*TZ.;C#PZL
M39ZL;2E2EX3I%O'/70L15?&+X8J!?EJ:?UZ4O2BU*[1(R\C-U2A34I*(JE30
M%R%+=6XA.)Q\\Z/1@CE4 ,@@XY\2GN5NF9B+\TG\G%AU=^A5/6?1M?!B!I]X
MT=1U6O:6H4G0I#3^F4_7JJ:;3Z[CDWF5U*ATV95+F8E7%O\ (W,A*"ZZE1Z*
MV2,;X-)1TOA(SBTX\6KA6U,UDE](*'6*W*OU2M3UN6[=U4ISTI:=R5VEN+:J
M-/H]6<(E9QYAY/H^1I:B2"K<8$)O'!OKKS,]V\S>?ZZNVD6LHXDHR5!:0I)!
M!Z$="/,;G8]1ZH&UUU".T ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @
M! " $ 81>()P\7[Q3\-]T:'V'=S-EO7Q.TBFW'5G4J+CEJIJ,N_6Y"74GY3;
MT[*M*90M.X*NA$<>)A_J=W_M;?I\9^&\3&_PGCN]^)%U;?@?M:%ZIZ::C<->
MKMUVA5:;:\_9%_359K,Q4WIFB3\D[+J>H2)IMQ$J[*NJ2]+MMA"4D <N,F.>
MFONT.C-5)J[TA)VB_+??F57#=4G&3>YKGIEYE/:7^$1Q(SO$MI;JCKGJY:%9
MM_1.X'JM;=QVM;TI0;_N]E%13.235Z5:0EI;XT6I 4B:](GE5\G"U$DG%XC2
M]K1I%IW.,LYR#J;U;UO-W?>9CR7 SK+87$-Q7\0.F=]V](7#KFS:LM;4O6*4
MBI2M&31)HJGU3DO,(>:?$RPI7H^=*EMKPH*Y@#')LE2PJ<95)157753-X;;:
M:7./!+D:VKNXO]G5/\E%"J[MKTTI.6M>=VU<QHO_ ,%-KB>U=U4U@XG]2J]6
M:O=MGL6E:E/LZ>F*%3:,Q\$2F<3,2LLXVF8DWYIMMT2Q0A "2,8)CKT415B5
M-WKK=4WW4I74.(5\[G)M%=+_ $DH_;A).(5YJON>F<:7;L6$M3PD^/+1*^-+
MM1]&=>;0^ZO2ZTZG8=(G;GHB:FEVV7EK13I=:'5!2G9>4/H>;E*@<G(!(/(F
MZ:J*E:*Z9NKJ9<YN(5YMONH75K2K26:E7AN(FZY$C*>"77B_]<>%'B"U@OZW
M:G?.C5#J\E>XH]/^!25;GI]Q[D=DV&SR,I]$IM*AG\))STVE"6'VA5M*_P"'
M5AUT]VE0I=#I3[N7>R:>^\VMV-JJIQ=DP]GICOTNBKO-0W%2;4M[E#2L]-2[
M_&YP:5CB@OSAFNNG5Z1I<AHAJ:W>]3I\[+B8%48:E5M!EE)24I=R=B4X&.N3
MN[J;EI3O:4\YS\N)FG&5%+I3E-Y)J&O9+G$W\8P-9?!SX@-4N)=S4^<U8H=8
MLN6U9MG4:A(K4HZJJTB3H<XRX;>DFVE(EF91;7I,K4RH_).5 K(&G+EMSS:;
MT6^;<;^$&)3R7=3O"4)>D7SYG$OX,.KDWJ5/O5K4ZWUZ;'6VO:IRD@Q)!JL"
M5KY?#\BZ^D\OIF$/%*%#Y.0E1W Q(>?S.GIZ;];ZIK2F8::3O;EGF?>TD\'G
M6:V=3],+7OC56AU3AQT'U$K>I&F=*I='EY:[YJI5N=5.*EZU5D-!QUN74XM*
M<+RM&><J(&)]]WEUNOQM6+2Z6H2=LHEQG>T^;X0;&;+266D-)V2VA*$Y).$H
M&$@D]P,9]>8IA<MTZ2^6_>?K H@! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @
M! " $ ( 0!P0#C(SCIGZX X*02"1N.D9=*;3O8':- X(!()[?;> .8 X(SCU
M'(]L1J8X.0=0VE.0!@'.>G4G.=AUS!J5!(O,O*,[6'(,@Y.QR.G7YHOR1TIY
MMOKE]E+@[P-'52$J()&X]WEU^:'7F9=*<3IR^ASRCR[Y]_V^;M *A)S+GF<P
M-" $ ( 0 @! " $ ( 0 @! 'Y/O(EV77W" AIM3BR2 $I0"5*)) "0 222
M"89#EGH8'TCQ$>'RX;WURLJAUZ9GGM J,Q5;XJB).9%/9<=9==5)RCJVL33K
M2F5,K^#^D2%X.>4\T<=.+15AU8BF*6TTXEPXLLO7[\E6%7373AMI55Y1=+-?
MN;63>5M,S\>%7C[TUXHKPK%D4*DURVZ_3Z"BZ:9*5N45+IKEL.3WQ>W6))U8
M 4VJ:/)Z('T@ZJ3C$<E#[]/>2]YB^D1ZZ<3B=+3SBT/GHXR\=V1GRA86D*&<
M'/48.QQN.T1.9X-KR*NIZ1VB@0 @! '1:TMI4M6R4@J)VZ $GN.@'VWB55*E
M-N86Y25*6DLVTO,C"OKQ4]#+'OJ^K2F[;U"J=*TUK4I0KUO"CVM4ZC;] G9@
M*4M<_.,2SC3$O+(27'WB2EM&%*4$Y(S1B4XB;IF)B\?#9JK"J35+:EJ;7ROJ
MO'PWE5:@>)OPX6'4[:D4U.K7+(UVCTNXIVN6[3)NI4RW*%5UI:E*G79B794B
M29+BL.%SE*,'Y/3.P\.J,Z5QZ^;$@-%K=,N&D4VNT>:;G:75I-B?I\VR0IJ9
ME)EI+S+R%#8I6VM)'MBUIX=7<J5YBV6GI<XJ:E72JEKZ<SZL0T( 0 @#J5H2
MI*"H!2\E*2<%7+UQYX[CK DJ4M6=H%$ ?C,OHE9=^9<R&Y=EQYP@9(0T@K40
M.YY4G;O$;A-O))OR$3;?8BU=\6?0&6N&K24U;FH+%I42\G+&J>H2K:J*K1DZ
MXW-&4=1,5,2_H&66GTE#CJUAM!W4L9C.'B4XE"Q%*I?\+JM*M?5:[S5.%4ZZ
ML-.F:4YTNDMR>?*+(N+->)1P^RFJM(TR,S7IEBM5>D6])WLS19[[D55VN^B-
M*I8JQ9,LN8FDNI*.5?*<%60GINB:VTDU'_5"^7ZP1TM)-M7ZY19ZO//0D(0X
MEP93N,)4#MN%C((P3V@0[P @#HAUMPJ"%I64*Y5\I!Y5>1]<!*WG> ."<8]9
MQ#Y!;'6;5>U]#M,KPU5O-Y]BVK+I+M7JKDLTI^8+#2VVTML,I!+CSKCB&FT@
M'*UC8]#QXF+3A*:DX;241=NR5^)JFEUU*FG-M9[IOZ&#>G7BC:'7[<5(M><M
M^_;,JMSTA^KV@W=5O3M,:NIIA@S(EZ*[,2K:)F;=;&66$J*W3@(!.,\RI;KI
MP_YJJ>^GI'-:\I+^G6J'6W2Z55W;9S?P?A'!1E4>BGB.:3:SZV#0"0MF_K;U
M$3(/55RF7+;=1IH:IS:G^2:F'9F70EI+Z&/2L<Q2EQM:%)5ORQA-5)-3X\VO
MC+,Q52Z*FJFI4)Z+?/K;R>\D0B@0 @! " $ =5H0XA2'$I6A:2E:%)YDJ2=B
M"D@@@CJ"(CNFMZ8(0-;.&O5H:R\7,_I+8<I3:;?>C-OTFW9MB2EFI"MU9*Y@
MUUE8"4I<G7V7%I;6YSK#JP200G'6HI:P<97F:]+U2[0LW"C*;1D=JNNFO&P*
MI40F^#AYN8SSRW+*"*K37AFUBTLJ]:U@LEK5K1&G6%IM2J7=\]<4],J%Q78+
MCE5N4VE"80?14H_?74H:*9<\WR4;".WL\+"JEQ^V+YS%5KW2MDLYW0=9YNZF
M7'K?.8ZE&VWIC/3=3T^L^HS[RYF=G;?I<S-S#F"M]]V4:4ZZL@ *4XHE95WS
M&*)AS/\ %5FHM-GXK7X(5W&@( 0 @#\)E!<EWT#.5M.)&.N5(4D8^>./$3=%
M24MPX2S;CKQ@M,*JEO1KE$[C6]%]ZE:/53CET@5P]:B7M7M;+QFV+%FI:WYA
MZV*A+5REOTM$Y-SZV0RVU+NK"WU*7@( WR4QQ[.FJ&FFG.YIZ]?<[.-4GB4N
M5$;YTC25\%AZ7H;K?PY61J+I#7](;EO.X=>=)*);EO52BR+\Y*4*LSDVAR8I
M-0?##R)1BEI6I8^^(" TD@X!)[!E-7_<KIZK=XQO7%;[K97X>[+JVGNB>F5E
MUPK75[>M"ATVH\RBHMS<M3Y=I]KF423RN)5N>^?9&MIJ56+-+34\T^-E#7K?
M7,Z6"FJ%*ARR]49.40 @! %.57/QO0P"0%./YP<9P&P ?/\ "/4]<$ D0,O-
M??TY>46<*"HX&A 'SJPTM^DU-EI)4X[3YQMM*?PE+7+N)2!UW*B -NL9K4T5
MI9NFI>::*LUS7N:P]%N;5*E\/FOW"#(\.VH=8U#U'UAO(4FJSE#?3;,K2+BJ
MP<9N'XP=;2TI$HV@/(4"?EJ.YCJX6'5B;#L^SN:*\!4JIM1WNYGG$MZ1:(X,
M[6&TL;&;J4-5Q+33F,GPSA;N!^.H^G>KM6;X==#)31^_9#5G0S4*P)ZDU:7E
MGGM.[KITDXPNH5JO*0S\#==IZ7'.4O%9'+RH4"1CO8356+54UW*6J8[W[?X4
MDY5IF/7@<-37=I4Y-Y.=\.]XX::3)L]443HILB:DA#<^9&1^&I;R&TS?P5OX
M2A /1*7BL#<[>72,O-[IMNZ]/6.%:\WTK+TF<Y/JP*#T/\O3WP#R?QGX%+6X
M5>GK())3\.YAGS*=\>K;H-@?7F*_EY9>!FG)?Y5OX]=(JF(:.%?M?W0]?G$>
MG/X?5_L##3Q!;9N*[^#W7&WK4H\Y7Z_/VF!3J/(-EZ<GW9:J4^;4S+-)"E..
MEJ7<*$)25*(VQUCJ[734Z:>ZG4^]39)MPFY?)2<N"TL2ENW[E?S4<,Y\"(B6
MF]3N*RN\'^G=L:&WO9$KH74:+=-ZWS>%&=IB955 DE%VE4YY]EIQQ4TZA+("
M"L*2M1/+U/>5]HPZF[+"2;G]O>W6<3._AF<CJI_0Q%-,O&E*;N8RO=>:E*)@
MS]X!=&[N3>^OO$=J[0YZG:BZH:AU>2I<M5FBB8HUFV_-35*H4I)!S*T2DU)L
M(F4^C*$J#H^00H&.*B52M+<4[MZ/(X<:'BU*4UWM&FFDH6^<M^DZ02C1HP(
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MC;Y!Y<#S]T42M;63OG;?QX>.>7M0M#B0I"TK2>BD*"DGV$$@_/ J:>1V@40
M@#@]#[# %-6^/U15_7.9[>1\OI]?SD[?8E.7E[)QX3TRIH%$ ( 0 @! " $
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M[)QY=_8#']MUGF,XZE1Y:\<O+/BCUBDBE4P?&=/R9.62,33'4-)'9>PVQDX
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M+37PF34\DH0\TE:%D'E)QOI.5.\S=-KYESUQ)*='UI7I?89201]R]'SN,@_
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MU0-'AJOXLJ/[RFOX%<"/)ZV,"/#B&-%[E_UEWG_OF<\\^<!J^2]V2#0*( 0
M@! " $ ( IRJ*_7FB)[\TPH;X&R,')]XQC<;F*OA^QBI>L*8G7K2'99D&'B2
M?ESI_3_)]@_2DG[>?SQ#?777,CW3T'S^?L/?L-OJS@0 )V(W[]MMA]M^Y!QV
M@#8XX$_V-]E_NI_^,& ,PH Q[U0<URDI]^;T^E[(50):0>F9A-;<FFYE;S22
MXH<C#1 "TC=14HC&4X_;>3[/H[-Q*GA[>\==[$P5A/![VKJ6)WN[53:73W?&
MV_Q?:%?:&'2J]AHIJ[N'C?J)]W14]SNIZPJIR:B[2@LOHW?O$QJ71Y"Z'Z5I
MO)4=VL3LA/RS<Q/+F2S(3*V'5-J<:6A2B$DH2<C?J!T\MVWLG8>QXF)1LE>U
MO'_L^&\']5ON=YU*74E7"_:JHLWO:4GA^Q-I[9VO#PJ]KP\.G!6/6L2I.E5=
MU4.&DEI6Z9RROE+SG8;]&TA)2A*N4%8; 2@*.ZN4 #8'8$C..L>K'M:4)9>&
M1\&@G[]5D_Z,X?8?PAG[#?&8!:[]9Z=M<WF<7379NWJ6NH2=&GZXZA6/@=/1
MZ1\C!)(3D#MC)( /> ?-+?/AQ19UO7>;=K#U!1IW=7QJQ)M3SDKZ)@J$N\KE
M0L$.@8)R/:#Y&)/!]=:P)M,TQI>)]_?SFUZK>J[];I;%0F*;-TEYWFYI&=2$
MOM8) YP-MQ@[;>61N;UUS"?WY[C[D"B $ ( 0 @! " $ <9'F/G\NOS0!ACX
M@!3_ &*^HQR,?K(<Y&,?'$H3ZL8!SZ@?* ,B=(2#IA8>#G^Y>C_Q)F ,(M,/
M\X5KA^8U"^L_/_68$JTYKWZW_*DB3T'L'U0*>&J_BNH_O&:_@%^SZX$>3Z^'
M[&!'AQ?D7N7_ %EWF>W>LSF^WGZMLP&K>]+W?U)!H%$ ( 0 @! " $ 4Y5 /
MCFA'&_--#IVY$;;[=^^?FS%7'<_9QZF*GQW>$-7M???AO@@O\23\N=/_ #?9
M^M/M^W<=8ALCW&>_7 QM@#8_21U(&QV]4 =CGI[<D_R],YR>F,=( V.>!8!/
M#C9@'3GG_P",'[8\ND 9+W5>5M613EUJ[*Y3;?I#2T-+GZK-,R<JE;F>7G??
M4A"<D$#*@-CWS'+LVR;5MFT4X.RX=>-6Z6_TZ$VW$[O#/VN=?:-JP=EPJL7:
M*Z<.A5)=^IPKJRO&LMN_"2SM>XC=#'J#6D)U6L5QQ5/FTH1]TE,))6PM*2!Z
M?/4X.-NF>N_EL#L'MO#Q=GQ*^S-I[OZ]"EX==-+[M2E-K@[^QX['[9[*JP\:
MBC;\&JK]&IM48E/>2:J4J&HG+,L3PLZ\:-4?2IB4J>I=E24RFOW ^&7Z_3VE
MI9<J"RVYRN/!8YTD$8&_88WCRW;W8W:^-VA2Z.S-I7]Q0HHPZWEWM&VM9C.\
MGB.P>U^SL+8*OU-MPTEC5WQ,10K*R;=E;+[F7=I:LZ<7U-3,C9]ZV[<LY)M)
M>FI:C524GWI=I1(2XZF7<6I"20<%:0,C&<YCUG:]@V[8:55M6RXN!3=MXE#I
MMUKQ1['LW:.Q;95W=FVC#QJMU%2JWO3.R9]BF3:)1NX9Q0*D2SK\PH#\)26F
MW'"!T&58^<]<1TTY2:U4^9VTHF\W:\>.<-1&[*TD<]6\3>RJ95*C3%V56'54
M^=F9);B%IY%JEW5M%6%;X44YW&,&*:+<2_B*6@S?TY=WW&UCX/,T.7I88;4@
MJ"V)KTRE\JE(V4E1 (]@&,D-]L[>O7J2/>>?!\/L7:M+Q);,N>YZ!;+-E5IA
MVNU26IK,PXXV R9A2ASK2%+SR\IV!4H] ,D0Y^E_@>7EY>1)@TX'6VW4@A+B
M$K2",'"@%#(['!@$Y2Y>OTX^YW@40 @! " $ ( 0!0.IRKU;L6YE:=N4UF\E
M4UU- ?JX6:>Q/* 2EZ82D@$-#Y:$D@*6,*R-B,Q#F8EQZ9<Y6>YM;C6MOGC,
MU'E)[B(X9N(?4BGU^>DK2MVK4><FZ*Y1GG[N>NN2EYNC4,-I")RER\NM90^E
M"D@I'RSZ3:T+OT5564-VF6X;4Z;C4+R37G\64FR-HXXEW2RP'$#"5VI15 9S
MM\ 8P>W48/O[]8RG*F(&6LW?N83:8?YPK7#\QJ%_M&*9JT_S+WUZS@DB3T'L
M'U0-'AJOXLJ'[RFOX%<"59/E'G9&!'AP_D7N7_65>73I^.)OIW@-7R7N^EXS
MH2#0*?"J=SVY17D2]7KM)IDPXCTB&9Z?EI5Q:,XYPAYQ"BG.W,!B!)6E^4M>
M:3/(Q>UG33K3$O=% ?>?6EMEIJK2*W'EJ_!2VA+Y4M2N@"022"!O"5OX>.X3
M]^G%N)5 ((R""#T(W!]\"B $ ( 0!3M4_'%"'<KFL?\ X(]8_K@OK[>'6_(X
MZ\YBR2TSOE>W6X@N\23\N5/_ .P&/K3 Y"/@9P-]ML;9(_D\QT]9[P (V.-N
MF3ZN^_O)SOOGO &QWP+_ +'&S?W<_P#PY@OK[]? ,0_&OY_["ZXBAUYA?Q_2
M4H=86IIQ(*9GF^^((7@C; 4!WWS'T'\M**<3\28-%5-+55$)U*8_<K_7D>D?
MC^NK#[ Q:Z6TJ<6AM)Q-JO+/CZ&FDT].A 5\95,A:4$?J^:.$X *3EPC!P<C
M!SZX_2CP\/\ 36 \/"_N<5U*I4*^:B/#?H?"%M.*ZZL3#JKI[^&J*J75WIW/
M2RR?-G93LT,I:G9YILD$(1.3" E0&%*"4+2G*SNLD;G<8CEK>%5C/'JP<)Q0
MJ>ZZ,[K5/7=E-\S&%7BT8?Z56+753^I-4-TRHF%+:SYRIT9.]X"+C[VN^KB7
M9F9?+=G4TH,S,/3'*7)B<!Y ZM01D#]J!L0=^A^2?FQA8-'9NRXM&%12\?$2
M_:E2J5352[0KS.J6JN?3/RYKJQ=OVBF:E3@8:JAMM5S*M919V=]_ VAV3^M5
MWCKRLSN<=\RKIP![,8QM[(^ -)2M%*\$?9$YEY2Y663UYYYFK!= 5]U-S8Y1
M_=!5>J22,S;O?/;Z#CI I\;&-P!OMG&,G8GZ,GO]!@"X^CY4K5C3=(Y0!=E+
MP2G)W>)ZYV[^6,^V#R?QGX VJI3:5EAY2[/\&F!%9+D?LI82%$D )ZDG QC/
MD?7\T29<)-O<E?UZ>@;C<EO;CX/":I( E/PR4)&Q'PEH$'.",$C<#<YQC$:=
M-:J5+HJ4TNI6<PFE,-3$N)4J?3-.)17/=KIJC.&G'.]CM+5"5FEK0P\RX6S\
MH-NI60GLHA.2 3@;^>Q,*TZ%15595Y-V5LX;5X=GN<SD*,2G$[W=RI<3FF^>
M7N>SF3YCY]_FZQF4YB[76?MO-G:*! " $ 6]U3L5S4JP[ELENNU2V':_3ER;
M%>HSI9J-+?*@MJ;EEA23S-+0.9&4AQ"BA1QD0(YS5XT\&L],[Y_6#[7/P^YK
M2_3_ %)UTU?U'.M5\T>U*)9-DU"JV_(4Q=#HXK].?^%3)8"A.U-:F0%SCG,^
M"=E;Q<']E%=-5G4JHW+.WB\EIO92;O1[/Z5UA!6Q%JT5..4)P$R+*<8&W;/O
MC%":INH<OW<>D> >;,)-, ?[83K>?_D:AYWW'WQS'38_)Y>O08[B-&:M/\R\
M;]/P)(D]![!]4#1X:K^+*C^\IK^!7Y[0)5D\O'+TZDP(\.+\B]R[$?WR[S[Y
M_P#;,Y]O/<9@-?!?)07BU<=EV^'OPO3&NEF6E2[RJZ+BDJ*FEU:9=E94(F6'
MWB[Z1I*EE0]"1C'3.^<0*:8NK_Z(UN37.<76;^X6;4FJ\W2GZ9(U"G7W=%)$
MLEU"PA[X/(OH8<<:6OT@*VE!1 S@;"-I7;A6OX0OCR(E"A%EM'?'+F]*Y2G+
M?X<*5=-QTBL.5BFW#5M0[N<=9>"@N7:<E3-&6<99/,E(]'\H')&^!GOT/^9>
M%Y7EU/B4VB?!C\;/5;Q)M7;VTVO?2ZV++IUK6ZFJRL[1I^:F'WW$J2CD7Z9M
M 3D<W,-\D@YW,;)RW^^?U-EQ/-CY6,Y/3RR<>_&,^N!5UU+/PF9EJ5;]*\2E
M&<9"2K?V $P#M]CY"KEI*7%-%YSTJ4\Y;]"YS<OGGEY>XZ&'C[^67VXF>]PR
M;3RMQ=\ONC[+#[<PV'6B2A70E*DGYE &!4T_3UWGPJI^.:'ZE31/78%+8S[\
M8\_+O%Z]_?U@S5GGNA;X?'GQXK(@O\23\N=/_-YGY_2,X]6<<_L&8AI?+RYO
MI\2/CKT[$>73(SW.VV1T/EY0*"!@]C@[?5[1MMY=L'H!L<\"ASPWV63UYI_)
M[G]4'K$7R_<&(WC7?L+[@[YN"E#SQE$R.F/?CSW]4?1?RQG_ &HV:/\ I_\
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M?5K(NWTCJ+):'=$ ( 0 @###Q ?V*^HW_@@Q[:Q*#U0!D3I#^3"P_P UZ/\
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M:%15R4\J9]*"D!XO.@I+.0!C962<]O'+3U?ST_$\BVKQRN]=SRRUX9&9T"B
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M>J $ ( \::?((G%U%,G+)GW&@RN<2PV)E;0.0VI\)](4 [\I5C/: /9 " $
M>*=IM/J2$-U"2E9UMM:7$(FF&GT(<2<I6E+J5!*TG=*@ 0>A@2%Z1X'L  &
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'N .T:!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>g40894g66m96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g66m96.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1%04&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q :X            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      T,    &
M  #=   %<0    < 1 !3 %  ,@ T #$ 0@    $
M     0             %<0   -T                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   #=     %)G:'1L;VYG   %<0    -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $    !CA"24T$#      &V     $   ">
M&0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                          #_
MX3\3:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G
M:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX
M;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B
M92!835 @0V]R92 V+C M8S P,B W.2XQ-C0T-C L(#(P,C O,#4O,3(M,38Z
M,#0Z,3<@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM
M;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @
M(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O
M(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L
M96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS
M=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U
M<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @
M(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H
M;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C$M
M,#4M,3%4,30Z,S$Z,3$K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @
M(" \>&UP.D-R96%T;W)4;V]L/DUI8W)O<V]F=,*N(%=O<F0@,C Q-CPO>&UP
M.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,2TP
M-2TQ,50Q-3HU-SHU-RLP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @
M(#QX;7 Z365T861A=&%$871E/C(P,C$M,#4M,3%4,34Z-3<Z-3<K,#4Z,S \
M+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QP9&8Z4')O9'5C97(^36EC
M<F]S;V9TPJX@5V]R9" R,#$V/"]P9&8Z4')O9'5C97(^"B @(" @(" @(#QD
M8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:3Y!:V)A<FDL(%EA<VEN($4\+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @
M(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^4RTT+T$\+W)D9CIL
M:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE
M/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*
M(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HT.#@U9C@R,RUB
M8C1A+6(P-#8M83(Q-BTY9# Y,V-D8V8S,S<\+WAM<$U-.DEN<W1A;F-E240^
M"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O
M<VAO<#HY.#<S,6$U8BTW.65C+3,U-#<M8F)C,2TR8CEE-V)D-SDU,S,\+WAM
M<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^>&UP+F1I9#HR,#<P931D,2TQ8F8V+3,V-#,M.#0P,2UE-V9D8V0Y
M-&8S-3D\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM
M<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED
M.C(P-S!E-&0Q+3%B9C8M,S8T,RTX-# Q+64W9F1C9#DT9C,U.3PO<W1%=G0Z
M:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R
M,2TP-2TQ,50Q-3HU-SHT.2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P
M(#(Q+C(@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HS.3@P8V,R9"TV
M8CAD+34Y-#<M.&,S-RUD,S%C,S,P,C(X,V8\+W-T179T.FEN<W1A;F-E240^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#4M,3%4,34Z
M-3<Z-3<K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,2XR("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B
M92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@
M87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F
M/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E
M240^>&UP+FEI9#HT.#@U9C@R,RUB8C1A+6(P-#8M83(Q-BTY9# Y,V-D8V8S
M,S<\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C$M,#4M,3%4,34Z-3<Z-3<K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<" R,2XR("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @
M(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C,Y.#!C
M8S)D+39B.&0M-3DT-RTX8S,W+60S,6,S,S R,C@S9CPO<W12968Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HR
M,#<P931D,2TQ8F8V+3,V-#,M.#0P,2UE-V9D8V0Y-&8S-3D\+W-T4F5F.F1O
M8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT
M240^>&UP+F1I9#HR,#<P931D,2TQ8F8V+3,V-#,M.#0P,2UE-V9D8V0Y-&8S
M-3D\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-
M33I$97)I=F5D1G)O;3X*(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^
M-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1
M" !@ F # 1$  A$! Q$!_\0 'P !  (" P$! 0$           8'!0@#! D!
M @H+_\0 5Q   00" 0$"!PD+!PD%"0  ! (#!08!!P ($Y<1$A075=76"146
M&5-8DK;1&"$B-38W5E=VEM0C,6%WF+73.$%"47)UAK2W"B<T<;$D*#)&1W1X
MH;C_Q  < 0$  @,! 0$              04" P0&!PC_Q !5$0 " @$" @0)
M!@D)!@0%!0 ! @,$  41!A(3%"'2%B(Q4U5ADY31%R-!4521%3)Q=8&5L;33
M!S,T-59TL\'4)#92<[*U0G*"@R5#8J'$1&-EDO#_V@ , P$  A$#$0 _ *8Z
MQ^O'K2JG5OU0UBM=4^^(&N5SJ$W)!P,)%;,M847#PT3L.P@QD7'!#R2&! 0
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M4=]!TIG>M S,U* LS-$A9B2FY))))/E.1<XKXE2U91==U156>5547)@ H=@
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MX,?^][U#_P V/_JM</6O++P1X7] :3[C!W,K#Q9Q-N?_ (]JOE/_ .MG^O\
M\^??C$.NWYWO4/WK7#UIQX(\+^@-)]Q@[F1X6\3^GM5]]G[^/C$.NWYWO4/W
MK7#UIQX(\+^@-)]Q@[F/"WB?T]JOOL_?Q\8AUV_.]ZA^]:X>M./!'A?T!I/N
M,'<QX6\3^GM5]]G[^/C$.NWYWO4/WK7#UIQX(\+^@-)]Q@[F/"WB?T]JOOL_
M?Q\8AUV_.]ZA^]:X>M./!'A?T!I/N,'<QX6\3^GM5]]G[^/C$.NWYWO4/WK7
M#UIQX(\+^@-)]Q@[F/"WB?T]JOOL_?RT]8]?W6](";14=U8;^,5':JGI(!1.
MT+8]D.09G*RPR:-E<FKL26F27VT/(\"TH><3C.,*SSAN\*<-(U()H6EKSWHD
M?EI0#F0QS$JVR=JD@$@]FX&=U'BGB1Q=Y]<U-N2C-(G-<F/*ZR1 ,N[]C $@
M$=NQ/UY5GQB'7;\[WJ'[UKAZTYW>"/"_H#2?<8.YG#X6\3^GM5]]G[^/C$.N
MWYWO4/WK7#UIQX(\+^@-)]Q@[F/"WB?T]JOOL_?Q\8AUV_.]ZA^]:X>M./!'
MA?T!I/N,'<QX6\3^GM5]]G[^/C$.NWYWO4/WK7#UIQX(\+^@-)]Q@[F/"WB?
MT]JOOL_?Q\8AUV_.]ZA^]:X>M./!'A?T!I/N,'<QX6\3^GM5]]G[^/C$.NWY
MWO4/WK7#UIQX(\+^@-)]Q@[F/"WB?T]JOOL_?Q\8AUV_.]ZA^]:X>M./!'A?
MT!I/N,'<QX6\3^GM5]]G[^7/I7KZZVI<S92)3JMWY((C]*[/EP4E[/MC^!)2
M.@5/@2 ^')-79%AO?RH[Z/ XTO\ "0K&?O\ *K5N%N'(4HF+0]+C+ZI2B?EI
M0#FC>0AT;9.U6'8P/8<N-'XFXAF_"?2ZUJ<G1:5;ECY[DQY)%,7*Z[OV,NYV
M/E&_9E,?&(==OSO>H?O6N'K3EKX(\+^@-)]Q@[F4_A;Q/Z>U7WV?OX^,0Z[?
MG>]0_>M</6G'@CPOZ TGW&#N8\+>)_3VJ^^S]_'QB'7;\[WJ'[UKAZTX\$>%
M_0&D^XP=S'A;Q/Z>U7WV?OX^,0Z[?G>]0_>M</6G'@CPOZ TGW&#N8\+>)_3
MVJ^^S]_'QB'7;\[WJ'[UKAZTX\$>%_0&D^XP=S'A;Q/Z>U7WV?OX^,0Z[?G>
M]0_>M</6G'@CPOZ TGW&#N8\+>)_3VJ^^S]_'QB'7;\[WJ'[UKAZTX\$>%_0
M&D^XP=S'A;Q/Z>U7WV?OY;^L^OSK<D*AOTH[JNWZ63":CC)2(?(VA;'78R1<
MW9IZ(<."6N3RH8I<7*R4>IYK*7,B'%,95V;[B55U[A7AI+&E*FA:6JRZ@R2!
M:4 #H-/OR!6V3QEYT1]CV<RJ?*!EOIG$_$4M;66DUO4W:'3>DB+7)B8Y.N5$
MYT)?Q6Y69=QV[,1Y"<NW2-W]TSWSJZ+VI3NMK<B8LG>==TM+PI.UKZN>@6+"
MNI"9V*0(R>K!M/AI>[UN(F\A*6< 3*A/.,^3/]JBLU6OP7I&HQ:=9X:T_GGT
MRYJ$4ZT:W0F2K'/+'2=N3>.>W'5LFLS@1M)"8B1(\8>QTM^,]6TR;4ZO$E_E
MKVZM>6!KMGI>BL2/')939B)$JE4>:-?G!"[S*"D,I$CM-XZY:)':].O'NC/4
M-6A[Z'2Y)5A);WJ1KVM1]U*\F$*FM@#DJA/%C,?RLHR'@@EM*'&V&'GD=GGF
MJP\,WK%BM2X/TF:6 NBQ2/I<%B>==/COI%#6<&1ND$T<*R$"-7+.Y6-"V;)I
M>):M.O=N<7ZK%%8$C[PQZG:2&*+5;&ER23S1-T:%6JRV.CWYS&8T4&20+F1(
ML77A5=A6346U/=*-LT+:-,UI8MH7"J@W+:-W8KT-68B>M$A%%ST!+8C7I]RG
M1 %F%!#R^PX+8HH-9C1Z36!L%\%;&GG5:'!E2U0%ZIIXEDJTJ;O9MVJ&GA4A
MG7G*P:C>%&PQVY)JMHJ'C1'DZ)(N*JU]-+N\9V*]YZEK4%CBM6[D74J\%RXD
MQFA<*#:HTVNUTVYFKSUF;E:4JE3Z"W'[HQU'&[?9H'7%NEJ/U94Y&Q1\E/;/
MV!&^<"8\K<8JM$K(B9 AUJY7<<23,@HPYQ"<-Q1R'W?&:SGG?K5+A#0:-&YJ
M'"^GAKEF*O)7@IU)GJH*\UN_;E8*%:KIM:"6:S*@.ZA%0%Y$5J_1;/%NOZE<
MH:;Q1J,B5J\D\=J6Q;ACLN;-:E3@52Q,4U^[<K5X1(P"F0R2%8T=ELN4F_='
MZW4H#8UJZ^]OQFN9K1->WH1:XW8NR9[WE#F+%08*1I$E%AR#1+5R@1MC5VP$
M!9<2.?"$MD@/NY=PE/(PX-Z_;TR/A:@]VMJ\>DI$U2G&MDS5+5B.W#(Z\IK=
M+3FJ2$CGAF +J$9&;LKQ\9S:?2U1^*+T-*YI5[5'E-JW(U3J$W1RU9XT;<32
M1;6:Y!Y)H@X5N:*0+('BO= 9*[6&BTCW2/:UHD:<YKIRX2!UQVW6HF BMB5V
M2N;,TZ^68828!7J;$FS\VD,1PI*65  L%F92C.EFX3KTOPA>X.HUJIL:I61D
M@H6)'FTE;@LHL:*O;)9J"K6YF'2RSQ$\B<Q&:Q<63W(M/H\87+=N6CI6H<C3
MW:T:5]9DTQ:+/+(S*/F=2ZS8(!$$5:4,68J#&M=W?K?W!-Q@6J_=/-BW&'D)
M&A1)4FU=]OQDM!2%ZV _0&!9ZKGNHD0717VFY\7L72VY>#)'<$<09VPC.V]#
MPUI=9[&I<#UJO(USE45M/F2:.GP[JO$,C0RQDJ[B+2)Z<D>P:.S)"Q+1/SYS
M5I^(K]B.OIW&\]PR-2C8K9NQ-#)?XGT'AF'I8I"&$+3\05KB3 E9*\%I.5)X
M^C,WK</[I7>IJN!TGW0+<1D+:]<W:\P\S;+CMVA%+E:E; *%&4DF!GWDR#4S
M>KG,0T!33FEOQ4F^>MQ1#:0BDHY+%K@VG6OS6N$: EHG32U>K#I]UIHM1KW;
MIDB>'Q>>I1TW4+EF%^5UAK[C<.I%C6H\87+6GUZW%]OH[SZG$UFS/>IQUI-,
MFHUFZ1926:*Q;U.A5@EC+!II^3;F"J\!U;L3K7VI6M5RD=[I5N^(L>U-O(T?
M'U"2EMOK,A[^P-79"6"D9 :66*X#&1EE!)P8,A:C7VWP6!TOI3G/=J%;AJA8
MLQ^!NG6*U;1[.N];ACH<LNG5E?FDCB9 YD>1#'''_P"+<.6"'?*^A-Q+<AA>
M3C&_5LRZK7T4U)9+S/%J5EW2*&25',80<A:60=D8/D8CM_96Q^LV* NL_9_=
M)>I*E5:AIH[,U+7*'WY7CW)"_3=@A8=N/KIYS<L=&,+KAI!TP.VL=&%('8;?
M(0XA."0\-R-1BBX/T::QJ-J6M6B@FTJ9-X:,E^5IYHU9(-H8R%1MW9B#L%[<
MV2-Q-$^HK+QCJD<>DTNOW)94U&(=$=5I:0BUUDD5K#/:NQGG7:-8U8EBVRYU
M-)]4'7=0O="M):$V7U8[EMX<;U/:GI=E'1M&X2M3N%>D[]7&<O-CR!C2CJ_9
MX(YHEL<\-IQZ//PR6,VO+C6-EW2.&+W".J:K4X?H4YETK53R/2KI:I7:<5F"
MQ"[1AE6>I;@DB9HW9>>/F1B-CFFEJW$M/BS2--L\07;U:;4=&D26.Y8>M>T_
M434M59E5V#=%;IV(I.CD4.JR%)%# C//WKG_ ,M3J[__ "8WK_U-L_/7\,?[
MM\/_ )ETO]R@SR'$O^\>O?GG4_WV?-OO/[UN@#3-HBZ%6X"M6V U]J^(K48Q
MJP"08NTW2:' TB6F(<9H>[WNYS=7KPY41$; $GE-0$]+J$'8A\D.8\X=(X<D
ML)6DMS6+OX3U34 ["Y)$L4.NC4]6JP+XU*K7AN"M5U"Q7Z*0/%!UB7IRF_J8
MM;XAKP16(:,%>E6T;2J#A9*<4LS3\/W=%T2[<E)%RP9*L]^WI568O 6-CJJ&
M-)2)O:-M]5MBO;FQI+I4;1MZG(VUK2(RW;RGY.&39K$[!;6BQ]:/2Q$_.(A[
MA=[,#"EA-.0U09MX<1G$C'04%D7BH4>'ZL"PU=>'X,O/H]^4- &66&O?FM:2
MTFH,@6N\\=**G8GM$SW31>=REZ>S/+96]3XBDL1RVM <:GI(U*"$]8CC,5I]
M+IP:DT5!1\^E<&/4:]2H!7I-96%5?3T@K1X&Q;-W&S5[Q&3G3'58O3EWNMEO
MEY3+;P@ A)[95ZV!$7;!<)L9V>"B$+C9'33M=9J$(,<2U&Q4^S*>&;RB2&RI
MZ?I:2Z.8-=EFU'1JFFU-& TV9FAI:;1LUQ)/25#)92U7U]99+1:&'FEK/7:-
M.99.>UJ>IA-4>;04@I:O<U*;5Y)-4K@27+M^I.:T%MPM>F]2YHZJM1HIK1Y)
MDL%PP(I3J1VWL&]7".3N+25# WE:X"OC0%O&V:%F+"J<I?2MGUD]B'B[4_6(
MDV2C9UF"#G[)-9BSJ60/*MQ.9(E-@5:<.Z54T\L=)U2T]*E=BFOUY*+=+/J&
MFZ3%HD\32RP*ZANHQ36:E>(S)>AZ..2)'>NU?KVLW+71?A;2*R7)ZUF'3I5O
MQF.#3[^KMK<3=#'(Q?HFMSPT[=B58I:T[-(EB6%)H\W- ;[$OW49,;)T%#3,
M5U([#E8:UZ]#VA68N9'V&!?(;8356I9<58Y&=E;+7Y.9BX^1KX\1,'J G&F3
M ACGPR&=%)=&73>'=/I:O(TO#J5K=*X]&=XVACIW-+:S;C,4<2TYX9+<;3F:
M&))(I&6=3!)M-R36/PEKFHWM(C6#B&!JMFJ+]:)MI7J:C!'4G+R,UE&KU;44
M0AE>>-HMX'BG0-=43U!]5=,77:I7NEZH1-(*%(@=0U.I'QYP=>V"L;8\S(6N
MJ[)"E)NUSLLF'E]D!/14O<)6*CFVBV?%8EXY"L5-G2-"NPVI9^)K37E@FGN7
MYHS#)^"8-.HUI8I*0B@K"N.MZ7?Z<5Q(\LD#H[0.Z->T]=US3[% 5^%JPHB]
M7%2A'*LZRZS^%[%V.0WF,]@62VG6]->OTB!8(ITE43D29([+O#JZGY"I%77I
M)"C]A:,FI02*LY]@11:]%[3<I-.IY\_:HJ1, A#9R0*MU4M$=",S<9&3EBLC
M"0Q9>.(=CD:TT7AI7U#J.O,M;7J\]4TH8&N3?@VQ--5EI:>$5IAT<>AZA30]
M%/+6AKSMR*8$D$#7^(S!ILE[0'EEX=L:?9>]/:6I"VH00'4ZUS4G=1&8["Z_
M2N2D301V'G@4S%IVC,< ZD-ZN;5$F9?I'AR-FTC7AT<2)<+D97JS#Z\O=T'>
M,588Z9)AXX4Z?DRE5$1<W.)4M,BH02$S,>3E-]:Z1IIHVNI<2NE75-2@F$M6
MJEJ>34>EL<0:<E+E$AE,+V8-06.*"5I8:JEV$+3+G%)J]_KM1[_#+/-2TNU7
M$-FZU2L--KUH>$-5DN<T<9C#'3+-)I99XHXK4S<J2$0\U9W6P]8^T!9]RY:$
M;D-AV_5#.I;5+CAURI6Z:B8#<3%\AK =K>$S"+#.&E:<30 )!BNB@6#R=D(9
MPZ>\F03TTH^%M*:M/2U=8M.J:I1UZ"$-/:J1RU=!FA>(7).FY%GTV5-1E@,O
M200PM9") 9675=L<5:J]B*_H[2ZG;TK6>'GE;H*D\D&K:Q#%SK6'1=+U75#)
M2AL<K+/9MBO),\B1)FOG61;=F; N,=>]FZXM.O).UES<T,'.64:>BL+EFH6=
M)BX4)J"BSJ]D 29B#'X::-/F!PI:+<*2TEYMU^XX8I4-.CFHT;\%T5HTCD9(
M#'.1':NUNEEF$K16%%FM<K=)#&D8GK3IOSHZK3<5:CJ&JM!?O4+%(32'HU>>
M&2&-FI4)Q$L*UHK%>1ZEBE<5+4KR/7M03(.BD1VIB7_R?]>_UQ[E^I.AN7<?
M]:V_S?IW[SJF><?^K:O]_P!0_=M*RGN6&<6;&=(L/5+!U,:6A;R#"R51DKQ'
M"V "QH$<@BHY;9&7691!V<!K%5G"?'21GL_#A/A^_P"#E-Q')8AX>UV:HTJ6
MHM'U.2L\',)DG2E,T+Q%/&$JR!2A7Q@P!7MVRXX>CKR\0:!%;6)ZLNO:'%:2
M?E,+UI=7I1V4F#^(87@:190_B&,N&\7?/:6@:?Z-[3<HB:B:QI\2<JM;Z'Z3
M>J#--UTR(L,Y<0M0V8S9=?CI++L:KX2@R=MJ.T@F/ VW+1*399K*K(3A/S#4
MM1XIKUM1Y)M0>*WK?',FG2Q+*9J0TFMQ=5BTYR-W:J[PZ/J.E\X93,98H]DK
M5P?KD.E\*3ZJN\&EPBAH^@16H6: 5[PU36N$9UU"(;B,7*T#ZY0U$IXR4Y:K
M$[RV>6JJ[K+2<A6JD[U8Z_T]K781:4M[!CJK!T6@D ZK^Z:Z=X2!M4C7J-D&
M(JMA+JLSM&+<EHF/BIL^GL%'G8>0PV8NQEO:@E@#AVYJ-^OTNF&,69[MJ)M8
M?0.,9I*0GM%I'K335M%DMUVD:O#-U<@(\K[TQHZ7U>PVN5*%*RK:NL JP48'
M;14UKA2(76AK\D?6*\4^HKI]@J+$\3WQO,M<*F/JVMZ] 70G;W5AJ7I'H&O=
M,/;2E8"KQP<=$N;.C9@JO4K5\+:*5JP"P8M%$ G+ ]/5J\/0DE<+#[T3J921
M/BX])H,&_-)1AHZ3J/$5O5-9K:31MLW2,-.M2RS6M6M12VS$FG:FFF5M05*D
M,D%2*1:CE(W,73;3IU./4+=F]0X>KZ+I%_5+^G,K55DU'3ZT(ATFLXKF:74=
M/LZA-I2V;-B.Q:Z.>QR/)S2QBH[-'4K4,#U(ZWA8C0]RK%>WGI(#3UWE-8:I
MLELE-([KSL.T9-'M\S6"+600[555!#YQ)N)6GECY!$=AGDNL\M=.:[J5G@R2
M])JE>XTNMT>(J\=R[7K-J/#T=.$EX8)Q66":ZMB9"F\=V"9.9IHN493W$H43
MQ@*4.ERZ<]?0-5X<DEI5+$T5'B&S:>6!);=<V6FJ5.CJRQ2@S49X'($<N[M?
MM_UAI8:]VB,K6N-$*Z240W4@1MK9C,?1UW2E[0AK!L]-3AJ]:E%XN-8*B)6/
MUQ%:ZI556+6K3"G,))C)426DG\>?HZAJS:56EM7=77B'J?"QT"H7M+7U$3T-
M*:T]F(*8;ALVI-235Y;G/+1B225.@:")LOKFGZ&-3$5:II;:$U_B-.)K?)4,
MVFPPWKZ1=4D(,U,5=*6K8T@4^5;MMHXW:PTKP"J.M?7/2\/J?J!V)I:*UY6Y
M^,WUI_6!U&AWHMV3JTA7J[LE<_::(VRIQ]C7>SHARHRAS8"_)![G"6$)QML,
M>)\:TX>O:^=5T2KJ$EV:G;3B6_%9D$@1HNL5XDTV[S <T^FSK))3>0>-0NUD
M0F2&8FLUBEPX=#UFS2CHPZC3TOA2M-74QLYLRBI.^J4SOXO7X)I*UV*+MCL4
MII)#RV5&>-//I^?+,DU*_+.H_M17_P"]P^<]O^B6O[O-_AMG70_IU+^]UO\
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MI6JS3W--%J73["3L[SRQO*MI5KQGE:0LY&ZGRCY])SYMEV:H_(CJ3_J1A_\
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M"*]$//OONKRXZ\\\X&IQUUU:E+<<6I2UK5E2LYSG.>?C(6;   GF    $K@
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MU),*:.0SM,G6CK#AH^,--"EK'=MKCV6<)1"H;0IU;>4>.A['DJG_ !_P^3&
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M2G+ZY)1#KJUY=(Q;G.S,THGDW VEE,D,BR.!MV\U>, 1\BE0R\I#ON Y0H!
M5 %B':1$J+*O*G,3OLL\F_/SG=E).Z)MR1ND]?1,ZU80UDMF#3+LH$G#L0A
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M'&,<8QQC(W.?C2G?M$7]4K1QC))QC'&,<8QQC'&,<8QQC([)?E!6_P#9FO\
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MX+;[;?[#9C#?B&6)T+#D<KCNH21R>R*-96 !+%7:LJ\J@;EB+=>3E_&,4J2
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M((0>WF)^<(SDN5>VK"!6UZ%E=O>)YU)5F*0W)["M#95.8J(KT..RN(DY.T1
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MK^;;W[K+G\C_ #]2Y^<<<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8S^O/\
M[/5_DM;C_K[._P"GU%Y^5OY=O]Y=*_,D?[]=S].?R)_[MZE^>I?W*EGOKSXA
MGV3'&,<8R.V?\7A_M%4_K/$<8R1<8QQC'&,<8QQC'&,<8R/R_P"-:K_O8WZO
M3/&0?*OY?\CD@XR<<8QQC'&,<8QQC'&,C<Y^-*=^T1?U2M'&,DG&,<8QQC'&
M,<8QQC'&,CLE^4%;_P!F:_Y1GC&2+C&.,8XQCC&:>6G4^V[==;//RD;0D P\
MG&'ZGP+:Y@=@06)ME8MAK%C@VJ4E*)JZF5]#4[8D3,OB*&'CAHV*>Q[Y/'S
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1]1]>03OML#Y1]!^O?Z1G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>g40894g67p62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g67p62.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[19T4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q :X            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      T,    &
M  ).   %<0    < 1 !3 %  ,@ T #$ 80    $
M     0             %<0   DX                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   ).     %)G:'1L;VYG   %<0    -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $    !#A"24T$#      +^P    $   "@
M1    >   '^    +WP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ 1 "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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M!OW;OTEK9;J[U/=_A%MKENG&S$RL*W-VX]55+JW/
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( 0("8 ,!$0 "$0$#$0'_Q  >  $  00# 0$
M    " 4&!PD#! H! O_$ &@0  $$ @$"!  *!0,+#@H%#0,! @0%  8'"!$2
M$Q0A"14Q05%489&4TA8BH='A(U)5%Q@R-%-Q<H&RT_ 9)"4F)S,W0F)SDK;!
MPB@V1$568W>BL?$I975VM#4X0T979F>%AI.5I=3_Q  > 0$   <! 0$
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MSVC$$ 6.(4I7N5&L&-C7/>YRHC6HJJJ(F1:USG-:T%SG$-:T#)+B<  >)).
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M##8)'Q4@PJ!TX#NX; D0 CM4(CCDY#P?P[!74,M?5PBH;(^6"!A&6L#6EKY
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MXX:9ZN9D$6H[X;K>-1P<#.Q6D7D?FK<N6+0]EM5I(96%-YM;J,:6K-?IH_\
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MG/+61QF6)CW[NY-U..D$YQ@8RN\[3>()>&+7?[Q+3V]M5:Z2MJGS2,BBC=-
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MQ'B469?]'SZ6/#';U>JKARAL%?9+Q1T,EPE9.6.@$$;7G4Q[7S!X+F:"=;)
M]S,1.9J>W'^UGL)OO97;:6]SWNW7JSU=>RVLEIXIZ6LAJI8)JB)L]),PM:V2
M.GG+'PSSMS$X/=&YS _<9\ S?W]OT_<Q0YQ9!:"JY=$E#YJN\D,B;J-)(N@Q
M6N]FL\U(<@J,[HIY#W+V<KLV+VM111W6TO;COI+:_O<#<L95S-A+MSU>!RV;
MTPM0VESG1S9S@2C&?2P$_J6]7-3J[)A$PB816[L6WZKJ(!R=IV2CUX!E<T!+
MFTA5R2'-3Q.9'2483I#VHBJK M>]$15[=L8)Y#*@2!S('K7/1;-KNT1%GZU?
M4]_":[RWRJ:RAV0!D1.ZB(2&8S1E;_QA$5I&K[.:BXP1S&%'(/(Y5;PBM[8=
MMU;4HXY>T;'2:]',[RP%NK2%6M.1$5?+C^K,)3D[(J^6%'O[(J^'LBXP3R&5
M D#FN2AVC6MJBOFZS?TVP1!O\LLBFLX=D(1?G$9\,QD"5/G&3PO3YVICYWV4
M57<(K!W1W&]=635WR3J]766\R#+F/OIL*L'8V%7Z9]<?S)!HY),V%Z"(L11.
M?(%Z4/E=O+;V8)Y#*@<>)Q]^%UM-B<66DHFSZ-^B%O.;'# ->4DFOM9P ,C1
MXS8I9P2R9,5SXT2*(XGD$60R+'22A/3B\$2".8(]>R @\B#ZMU"3X0KHTG=2
M.L5.ZZ .,G*NB09D2)7G<..+<M;D%2677B2RN:(%A!E>=-HC2%2.II4Z$=X6
M3DD R+A^]"V2OAGR:2=S7.<,ET,C00)&@<P0</:-R TC=H7.7TA>QB7M.M%)
M=K&8H^*[!#.RDBD+617>@E<V26VRRG:.:.1KIJ&1WYMLLDT4A:R<R,T1<5;Q
MRKJW)VF<<VE;+V?TFYU6LS.,-XI [$B-=;AK+*AA1+B)+M:)&M:835H),!L8
M@O/$JL:_QW+BK@7@+C&BFJ.(>'.'[R/)Y'1UU;;Z2IE8-!<"V=\9?@N U-)R
M3LX!W+E;LC[;?I#]D?%UDX/X?XLXXM$!O5#05?!E555[Z26&6IC@GACH*D2]
MPP1%SXYJ,,8UK>\C<8RXNEU\*/<'Z?>4N/M+XCJJ3B35K/1#;.?8==I*N#>7
M=\Z]FU\J/&VVPBRK.K90P8<$BQ]?G5LCQ7/G3BE&Z(UF+=FO8]V64+:JX4?
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M-<',>!JP=L@MR,M<!@C(/(@[;ZA^I_BC9N&M_!J]C$MYU'0Z5QKK53N1:25
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MS9V#"RRR(!93)-0XMH:@LDK)\)8)63H4N>AL%PKZ<3L;''&X$Q&9Y89,;9:
MUWFYSASRUIP=U1\;?2&[.. [Z_AZY5=PKKG3O9'<8[11"LBMCWMU]W5ROG@9
MWS6EI?3P=]-%J:'L:<M6R6WZE^'*GA).H$FWPC\:GKFS:^V"TJR+&64SXD>D
MBU[F),=>$L&/KW5BA22"4,S3,&P!7LMS;=6/K#0"%PJ@XM=&<#3@9+G.SI#-
M)#M><$$$$Y"V!4]HO!U)P<./9;U3GA=].VHBN+ ]_?:WF)E/% &]\^L=.#!Y
M+H$S9FN8YK=+B-=72[SGPGU5\JWH>1+K86\A6OG&U;4KETFBK[*$".V9,!46
M559/>1M6%2Q8&M,F1$) @2+V9&L+&5(+$K[A8[A;H&S2-C?$,![X7%XC+B .
M\#FM(&HX#L$9.D.WPL)[/^WKL^[1[M)9+155]%=BV62EHKQ2LHWU\4(+I'43
MXYYXY7,C!E,#GQU'=-?(8L,>6]/J&ZBN$>E7FNKB<;W6QS]IIBQP[[JM1Y]U
M65H7^5*^*K&XL[)A3NGUSR!ET9#V1*>3(K+B D"2"3'F34-AN%PI_*&-CCB<
M"8G2N+#+@X.@!KO-R"-9 ;D.&<[+PXZ^D%V==G][=P_=*JX5UUA,8KX+11LK
M&VWO6]XQM9(^>G8V01EKW4\1EG:Q\9=&"X8V1&ZE^&@\))U!_IC#=QD^O68&
MX:,WJ"R_4/@_$;*Y6),6^2S8^K=5>4DEDUCQN:C6.>EN^KJSRTV_N7>5!VGN
M\CH':]6=.C20_7G&DY6>.[1N#F\&#C\WJG_)9U,:EMP >2XB1T!I1 &]\:T5
M+74II-'?"H:8BT$%:Y.FKG[A'JLY@N8_(UQL4?=[=QW:7J=NZ335EC%"-91X
M%9;54_Q^*MB-0$.@9(K_ (P'"G7DV//GR'-A5]?8J^W0=](V-\0($CX7:S&3
ML-66M."3C4 0#@9 P%@_ 7;]V>]H=Y-AM-37T5V>V5U'2W>D;2?6#(1KD\B>
MR>HC?(U@,G<2/BG=&U[A$=+UQ]2?4!PETJ<P5,?C:ZV*7NU.\3=VU.H=(NJV
MMC$$*<"LL[BUL&N5+2(]8L[7R2+-U8DVOO8(JV;"\JQC06&X7"G,[&QQQ.SW
M3YG%ADTDM)8 USB-0(U'2TD$9*EX]^D!V>=GEY%@NM3<*VZQZ#74UGHVU?U<
MV9K9&>6223T\3)#&YLGD\3IIVL<USHAJ&=D$;J6X8E<*+U!-W.$SB]D%TLMV
M09F2 R62DKWTKZU6>N2^2T5*M*A K+?.<T+&.1S7K;S;:T5OU?W#C5:M/=C&
M""-6L.^SW>CS]>=.G?*SJ/M&X-EX,_+]M[IAPJ*<U#KB[4W01+Y.:5T!'?"N
M%412^1Z._-21$&%Q&=?W1AU/\#<A<U;K3>!]7M^UVUE*T"3M-'"BRK-CMBW"
M\-#J+-I9CH4\M9<1R)7E/$D2E%*$)A5$B/N5?9+G04W>R%KX !WHAD<X,.P!
MD:0T$ X&H:F@XWY+7O _;OV8]H7$C+3;/**6^D2MMC[S;8*66N;&USI&6^J$
MD[@]T8?(*>1\$SV->1$<$*077;U,< \%:9'I.4Z,.[[QM=/L#M TZ%04]_=Q
MRI"?7%V9QKEX86MU<.5+!'?;EE!DG*KP5H)QPF$.6QV:Y76244+^XBC#6U$[
MY'QQ8=DB,Z 72.< 2(P#MN[ P5TYP]P_=[]+-';"8HF-#:FH?*^&%H?DM8\L
M!<]SL$A@:X^)P-UA#H$Z\N(>205'!]A#N]$Y$E3;V900K]8!Z79_/E2K-:ZD
MNH$E['7((2%.ZKGQ(!I 0&? =,\HJ#JKQPM<+7$ZJ<Z*IIFZ1))!K#HLX:'2
M1N:"&%Q#=;2X:B-6G(5;?>![QP_3^5S=S54C2!)/3%Y[DO. 96/:US6EQTAX
MU-R0'%I< MLV8NL/3")A$PB81,(F$3")A$PB81,(F$3")A$PB818XY:Y2U;A
MCC_8>1MP,8=-K\9A%CQ&-+/LY\DK(M945PGN8PDZSG%!$CH0@P#<1322AC"*
M5F/\4\2VK@^P7+B.]3F"W6NG=/,YHU22.R&100M) ?/42N9#$TD O>-3FMRX
M9/P;PE=^..([;PS9&1NKKE*6B29Q93TM/$QTU5653P'.93TM.R2:70U\C@S1
M$Q\KV,=HVF]?NVGYN'RU&X]UL=:!P8XM:D6EB2P?7AK)U2BDO1";''.?'GE.
MKAU!8S)#!C1"C1Q'<5R_3/J_K0B'@JE=91-AIDN$HNCH,C+RX1^3-D.,B/26
MCD7$C)[/C^B)PR+:(IN+[ZZ[=WO5Q4E"VV"<M.[;<_54N@#CC)N#)7-!=YI(
M8-V?!_,^J<]<>5/(6HK(!$FD/!LZF=Y:6-#=P58VQIYZ!<\3C1W/&4,@+G F
MPCQ9H%4,AF=D\%<8V;CSAR@XEL4KGT5<PZHI0&STE1'AL])4,!(;-"_8C.'-
M+7M\UP7'G'W UX[/.):SAJ]=U)/ V.HI:RGU&EN-OJ-1I:ZF+PUX9*&N9)&\
M"2"HCFIY!KB<L2['RGM\76]UN:S9JV/;Q+[:(&MT4A^JRTE@H)]W%APH"-:&
M1%LY@X$*<Z!>'EV%M!]=$I8PII0S(65K#%+"*XKXT=Y^WG/ )QO"QXD\UPVJ
M3L,BJ\:>-5[,>JO8GZKE545<(N?")A$PB81:@^93*G*F^(O=>VR6"=U]_9"=
MD3NJ_(B=D1/F1$1/9,O],X=Q%X^:.@^[<CEU7-G%;_\ &*[Y.?WY(-R=@, #
MD=@.2N^MFR/ZV_9!>:_R4Y/K1H+O^HC'4L4[VHG;Y'&:TBIW]WM1>^2.(\L8
M=OX@]/ZQ'/W<U>*>5WY!5PUG2+S$-/A@MA) V\7 .SC/+8+&O'DE[=\TUS'.
M8]-FI?"]BJUS5^,(Z=T5'=T_Q9ZS.!BD&.;'>(Z'H3\[+'K _P#ANU8(!\NI
ML$$_VC?[H_;R5P\V&7^JMO7=5<OQ]*15555>S48QJ=U7OV:QK6HGR(U$1.R=
MD26F($$0_N#Q;U/I'/G]_-5W&#\<277/]N.9/(,;CP/AX>'1=ZKM9J<';E!;
M((D)N]Z<_P!,BH@_%,@WRR57LGB5#+6P'N:YRM1T8:HB+XE=!VGRJ,Z=^ZDW
M..K<8WQ@ D9SXE55-42C@RZ1AY$8NE!YH/F_G>_[S.V<.[J/(W&6 @ JRM$.
MJ;QIO95:OZ5:]^LBJBIWMHB?*B]T]O;^]\OMGI*X=U+M_-O\6_U3Z3\[<RK)
M9),7FU$'?ZQHQL3G>HC!'(<P2#OR5Y\]&5.7=X155RI:C3NOOV3T,7LGR_(B
M=D3[,\Z4@4\7_=SS:/$]2"KIQF__ !EN@)Y2QC<G^QCQC8[87;I[.8/@C;8H
MY!&Q3\@ZX$P$5%&0;Z2YF.:J*B^'Q2JZ 9RM5JN=&$BKX?$U3PTU,;_$12;\
MR,.8!CF-]3@/#?*JJ2>1O!EQ8'D1NNM,US=])!IZB0C<9 ,D,+B0 <M .1D'
M&FJR'-V?7',5S'MO:AS'M56N:Y+".K7-<B]T<BHBHJ>_?Y,]9' QO'5CO%O]
M4]"5CMI?_"ENP<'RVFP07 C\\S<' P?3D+(_4"=W]5W<4<KG*DV.U%<JN[-;
M!C(UJ=W>S6M1$1$[(B)V1,\:1V*>/U'H/TCU(SZ_@KWQL_\ QDN.3R=$-R>0
MB9CP.P&PQTPI1='9%?J>UIW7PIL %1O?V1RUX4543NJ(JHUJ*ORJB)]"917#
M!DC/]P]/!QZ;>G[UL#LS=JM-=OL*\[;\^XBSSQX8Y <O%3!RWK9"81,(F$45
MTY4Y*J#6M]+U[XUU(WZ96L!UH^LJ'+0ZS)V&>"1KBT?QW935DT,.G$^+M4*F
MD'LI[I$22Z,,\<)%Q674'L=61[R:IK\V.\<&/%+7[)-?#DS26>]QSRPV,BB
MPM1,AZA&^)9"1V$FS;8;? D07JGD60M4Y*V&^V:-5&U;T])*L+RN=9R+ B6T
M67 ;93PD?6#J1P74SH,:%&9-9:DE.FV$5OD&#XI;R?.W+WXS[,\MEAWKIYLV
MG@_A/XXTDK8.S;5LD#3Z^Z\ 2DH1S*^TM)ME&"=A!$F)#J3Q(;B,>R/)E#EJ
M-_D(U;Q8Z**MK"V<:HX8G3NCW DTN8P,)&X&7AQZAI'BL][.>':/B7B..DN
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MI_XNB6AK,T742DSS]_XC]+W_ +!*W_KEM^4=+_'7/_ZP=_N(E@7!G^4N-_\
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MGUN7R)7Z:QC$\+&M8WNJ^%K4:G=RJYR]D1$[JY555^=555]UPB_6$3"+3_\
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M_P"@:K\ #\F//_O>]-#>GO/Q3]&M?_H&J_  _)CS_P"][TT-Z>\_%/T:U_\
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M#U*Z8 8SN K^Q4 5ECY KHK9*L:IFA= CN4+2JGC0:N5SE8B^%57OV]\E/\
M',Z=T=L_WR?5G;I]RO5.1^YW7G_MV'?^[W4)(/M5A: ]DC=]3 1@R#+L%6-[
M'=G->Q\L37-<U?96N:JHJ+[*B^^3OQH=@'.D^/H]06-\.N!OMI ._E]-U_M
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M+W78*=$3M\O>>!$3V7O[JO\ C^3Y\EUG?.^0?NVY[#P"Q>RM=];VS;^GTO\
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M)/O5&VV)":$PIA&3*^"V3Y!V]A2/)DJA2,=X2N8-SV>/Q.=+WN#I+2<8 ()
MW.=_0-\?C@+";]P#:;]6?6#YZBCJ9 /*# &/9.68 <YDGV)"W[3FN =L2W.2
M<PQ>&]+B\>%XT;!D$UX['.D/(7_9 TYQ62/C-TEK&^&:TXAO8YC&B:P;0(-0
M>(;HZSG.P/+;IC&-^8])W)WSE7:/AFTQ61U@;"XT#VD/U//?.D+FO[\R #\]
MK:UP(&D8#=.C+3@+1.#=-XTWWXQO9%M9%KB$E4!9(6^D [QO]/.*&*)2RO+
MYC4,S^2B3AE0P418Y%E,AY:2/ G43SY8'I]I&1C8JRV3L\M-GKF7!M14UDL3
MBZF9.&,9"[?#R& =X]@/FEQ#0?.P3IQV.7>(]*Y'V.+;T4BSC[!8J@;!U>!%
MAV+@B48">5+"URRD5!-E28[O3@AB)(E=B,:A8][U#CC.,'2<D[CD<X)SOC?
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MP22:BPCN6X(\CDE3;$WE$-8(=J(HCB.$+HBL:C0, %B-<UKD='4<@[#; '/
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M&MW7W#X)H;T]Y^*XG#1555[(J_2W/5K]AYV/1G'SU7F6D$X!QX;%?/*3[/\
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M4;&@ESWO<&M:T;G)<X ;'T+:DD(:'.)#&@$N<_9C6M&7.<3LT  ESLZ0T$G
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M]W@1/$]RJYSNW;Q.>Y5155WNKE55557NJ^^9)J:X[:1G;^K[LX ^[TKF<3R
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M /*7"+@PB81,(F$3")A$PB81,(H@6_2?3VO6;JW5B^ZF,?KW%=QI3]425+;
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MT,;(\8&-0&7DD$G)D+CMD')*^)/:)?#Q=QUQ5Q+K+FW:]U]1 79)\D;*:>B
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M98Z>IHZ*:>@K(WR$Q5,->U@I!%(PB1[YI8^YR6S"-P('H_XRXZY/X'Z?^.>
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MTA<2_43DDY&.?K\5R7])N>[R=K-ZI+A%)!0VNFMU#8*<,[NGBL[**%\/DK0
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MOR83 Z#V!/0POJ<7\.+\F$P.@]@3T,+ZG%_#B_)A,#H/8$]#"^IQ?PXOR83
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JPXOR83 Z#V!?L<.(Q['LBQV/:Y%:YH!-<U>_RHY&HJ+]J+A,#H/8%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>g40894g85t45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g85t45.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1K(4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q :X            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      T,    &
M  (5   #]@    < 1 !3 %  ,@ T #< 80    $
M     0             #]@   A4                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   (5     %)G:'1L;VYG   #]@    -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $    !#A"24T$#      03P    $   "@
M5    >   )V    0,P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ 5 "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
M      ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+
M$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52
MP6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S
M1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  ("
M 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A
M<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%
MM)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1
M #\ ]57-Y%_US%UPQJ&&GU+!5O%6[TP6BM[?T^UV[Z5'J;/T/K?:=E]=/J=(
MDDIYE]_UXEP;148+H(V01O;MV[KA_P!:W^G^I^I;=^N>GCJS5U+KN.,2O/QJ
MG79N3;0R'[-L579=+O8W);Z7ZM=5_I?1]"VROUO5J6ZLCKP)R^C /-9.<_\
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MZKZ=BTL:RRVBNRUGIO<)<S70_P!MK'_YS%/U*]_I[AOB=LB8_JJ22E))))(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 1$  A$! Q$!_\0 'P !   & P$!              (&!P@)"@,$!0$+_\0
M4Q    4$ 0(#!00$"@8'!@<  0(#! 4 !@<1"!(A"1,Q%!4B05$*,F%Q%B.!
ML1<8-#=T>9&AL_ D)5>6P=4G-D)2<M'Q&28I-56R,V)F=I6EXO_$ !X! 0 !
M!0$! 0$            ! @,$!08'" D*_\0 01$  00! @,%!@4# P,#! ,
M 0 " Q$$!2$2,4$&$U%A\ <B<8&1H10RL<'10N'Q%2-2"!8D,U-B)31R@E1C
MDO_:  P# 0 "$0,1 #\ W^*(E$4)C%( F,.@#8B/?L  (B(Z_ !HBIJUS/B5
M]>R^-F>2;*=7^V2,LO9S>XXM6XTDRB8IQ/$D<F> 8@E-UD\KK* ;,4 [T1=F
M&RUB^XIRX+9@<@6A+W#:G5^DL-'3\:[D8,"$*HH,FT1<'5:%3(8!5,L4I4AV
M502F*8 (H;;R[BV\8N9F[5R'9UPP]N+.6\_)Q%P1CYA#+,]BY))ND'!T60H@
M4W6+@Z9?A-H1Z3:(N")S1B2>M&0OZ%R19<I942+DLG=3&X8QS!,#-!,#@KN2
M2<&;-SI"0VRJJ%,8 V0# (")%"MFK$3>R"9*7R59*./U.@$[R4N.+);AS'."
M9$RRHN0:"L)Q OD@KYO4.A(%$4<_F7$UJV_$W7<F2++@[:GE&Z4).R=Q1;.*
MEU'0E!N6->K.2H/14$Y=>SG4  '9A  $0(JA-WC5VB@Y:KI.6[I(BS== P*H
MK(JE Z:R:A.HATE"F Q% $2'*.RB(411'4+U" &'0D 0$H]O4?3TV/IO\!#?
MI5#K)K<"K+KKQVYCR^">75=4SDB?Q&6 OQ: 3GT'KV =CT[$?QW].VZALK9;
M,8=)PN##P \SXV0#7CTVI"."@YP!.^Y\>@J_IT7."Q1'7F?(!'IV(:[=P$ U
M_P!H/GWWZ"-1WC>/N?>#^$G<=!5F[WY[@>?*DYBQRY<UVJNHN%9RW;AU+K)(
ME_[RIRIE^7_:.(!OOZ;W1%\*Y;G*!R+$.0P")3D,!BF N]])B[ =:'T$1[#1
M%R>830#U (#Z:[[W]-;V/X>M$3S$^_QE^$=#W]!#U_R%$0%"&'13 (^N@[Z#
MZC] 'Y"/K1$.HFGW.<I #U$P@4 WZ;$= '[1"B+C!TW%/S063%+75YH& 4]=
M^_F!\'R$1[]@[^@@-$7&#]D8IS%=MC%3#:ARK)F*F'U.8IA*4/Q,(!1%S$71
M4 IDU2*%, "4Q# <# (@&P$NP$-B&Q#L&^]$7$H^9HB *ND$A,&RE45(0Q@V
M  ( 80$0$3  " :V.O7=$7,"J9B]13 8NNH#%V8!#MW 0 0$.X>F^P[]*(HN
MLNM[[#\QV'[?R_'TWVWNB*$%DQ[ <#>OW=F#L.O4 $ []@V/?Y;T-$3S4]B7
MK*)@]2@.Q+L-AU '<.WUU1$%9,/4X!VZOGKI[]P'6A -=Q#L'SHB^^80?0P#
MV >P['0[[Z]==AW]-#O6J(OO476]]M";ML>P?E^[U'Y!1%Q@X0%3R@63%7I
MWE=0>9TCKXNC[^OB#8ZT&^^J(N-1ZS2.!%73=(YM"!%%DR&'8B : Q@$=ZHB
MB%VU!3RA<)>;H#>7UE$^AUH1* ]0;V ]P]._IWHBY153#N)P   !$1[  #W
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M!=;(KI*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B*!0!$H@
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MG"Z:@>4F)0*8A2&$1, @&BCO3ZQG9F%C\>'C?ZA*TVW3PX,?)Q6'/#W&@"&
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MD<?&1QZ]7$[#IS^?B0KWZPU>2B)1$HB41*(E$2B+C%9(# 054P..Q @G*!A
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M;W6V_!NUY2%C9!TS58KO6+5XHS7 2K-E%T"*';JE$>RB0FZ3E^1@'?:MZ"?
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MSOJNU-<1 Z!HKH*%?M_&U+O56H2B)1$HB41*(E$2B+JN%/+$!V4 Z!$1, B
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M3E-/X3 @995R5(O20QR%+\(>N=K41Q\G*CB=^$9'D1M;?O=V'.)>RY ZZ;8
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MX /<AQV?E :"W>JLGF1N-DT33CA8[I<EQERISQ22G8@D6&"R?='6CSOR5SZ
M"5%,HCL2D* CK6Q -".MCK8]];'7UKGP T -%-&P'.@.0OK7CU6Y;9 LV2!9
MJK/C2Y:E2E$2G-%:KR%Q?9US/<<9,OF]V=E06%+J5OQZ[DA9HQ3I)"-<M3(2
MCE\9-)%NFDN*O64PGZDR@4!&IQ7-QLF25K3(^3$DQ6@&JXRPA_4[<'Y>>XWL
M;Y#IN/3,_!<W@;F'%=WI(/=_AI \^Z=G=X"6V2 W>P>2LVG/%@\."\I&=PTW
MY-6/'OIR-?VV,FEUIP)%I=!5CU(2QTBQRBA5#F HB?RQ.71C=.QK'S,+)FQG
MQ/;(P.8P-E+'$-X'L=8&U@\- 6*Z$@4K.)EPQ9<$C9&/,+K,9=PE]@^Z"":V
MJMCOTLJ_?C58=O8UPQ8ED6G=2%Z6Y!P:"$1=#=9LNE,,U!,NB[(HT.HW,50J
MO8R9SAH #>PK.R\H9CPZZ>R''A<#N:AB9"''K[W=\5$;$D7M:H,;F2SR<' R
M>9\K1?Y>/>KH75<^M^2]C.MB1^2\2Y"L27G/T:CKHMB7B'<^ I;ATG+,Y!D-
MKF(@!6H_KC"J<"#T](_6M;F03SL8<:019$4C987%I>!(P@MMH+;%^?R*R\"?
M\-D12!G?.8YM,#@WB\ 33JNQOPGQI8$9+F/A#'D+)<;KJ\5&UMI6DOC^,F;3
MQW$I.K46:H!&HO'%S,2+LBO6:: )J*'/HZFS&$##NKVH2X^HMG9GY<,>1/-'
M*YC7B-_$TESQN;]XD;4V@/ T+&)!D8\OXT8.I9.'ALF;D218$[\=O'1:X3 .
MC(80:JKY[;!90N"&,)FP[$BGL!R!M/-F*7T,D>W7=L6O"1QW[U4WF.9V6N&+
M<+K3,D^4%11XH\_7^:8>H2[Z:V$TT#HFP0P4*'#.9+IM75!O"=B 3;;.]6L"
M/CF>,IN27PD'N8'0F-QB.T;C;RYKN"B6\)KJX@"\A:6QZA$-;Z?[B@ _(/RK
M#'A8/#MM^OK]EEM%"_$DUX7T/T7+4J4HB41*(E$2B)1%Y\D]!@S>.Q3.H#1J
MNX$B?<YP1145Z"%^9S= @4 WOT^E$6K% ^+5RBQQ/9_OKD),*V9&PT+E&1P1
MA&[L1/[5"^BV[-C$6\I&7XK(&]XN&Z)DY)TW]A1,[;&$$^X@-1?RH]>O/_/R
M\"IKE7SZ\ZZ<Q5U\>2F5]XG_ "^PBTR!B[(<]8N1LJ7GAK".6,-72UMIU!0M
MKR&:I1O&.(.XF!':YGT?:XO"K,U_,!9]Y)@4*!MZG^WKY)77I_;[7T_>E-4K
MXA7,*U)R_.%KN][+F>3K#D5BS#L!FO\ 0Y5M:S*W<H00SJTP^M<SX"KRD&1)
MRV:HIK%3=!Y*AQ XC4>NI]?M\$^_C^GG]UY]I>(WS)RS;%DX!M>X++MO-QL[
MYUQ#=N9'-N*NXQU%81B FTYJ/M,71?*>SX';-72 K"5NF98Y3&T BOY4>NWK
MPW^.^UB*^8!'7GX\ER6_XDO+OD=CS 4!B.ZK#QWD1[AO,^6\P7C(6NXFXR36
MPS,2D0G!6W$*/4102N)>*%1ZL8YCM"+F(CL$Q 0Z?I_G?;Y?!"!Y]*^?C\OO
MN.2R1XF\2G%\KQ*X^Y_S 6Y;?>YIM$SL65K67=EWI!,Q@*,IPP)6]%22K%JJ
M\0549E>F3+Y:@$ZQ$!$94'8D>"L<^SH34?<N$N9UQ1)G!XN=YY9EEXY1TV69
M.5&+]O$N6IUV;DJ;EHJ9%0OF-W"::R1]D.0# (4NTJO7R6Q51$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B+A6$"E 1WV, AKZZ'U^7^?SHH-]-R>0\5B
M'YWNSYWY)<3N(\.!WK%[>0YIR>FV4!0&EH8^(#B.:2#;[ID9*9<M1 JQ124*
M@;0&,4 KD]8K-U/!PHGAQCGAER& [B)CVN<7#D &@U[UWN!MOR&OG_4<K!TN
M%X=*S(AFR(V[N;$'@N>\;-H1L?0LFS=5LLMC)J5DW0:HI 1%LF1)$A2 0I$B
M#HA"E    *30:#L&M:] KJFM:QH:T4T<A^W3X=%UO &Q,C;5-H554-@*'+:O
MD-EZ)=Z#=5*M?:(E$2B)1%\$Q0WL=:]:7O77FH) W*D7(M^6UCBT)V]+JD$8
M^#MV.=R<@Y6.!"@BW;J'%(G4)?,77'22"11$YU3E*4HB(!63@X4VJYV/IF,P
MR394C8^$?TM<1[[O!@-<1Z#<[*QESLQ('Y3S_P"DUSHVV+DD V8T'8N/( T%
M9/QDLBXLO7Y(\M,K,U&TE/(*Q>'[.>D,)K*L05.E&452.'2E.7$5,CM=5,I5
M$6YRH"<2F&NN[0Y\6D8S>R."YA; >]S<B,^]-*=G,)'1KFD.%G<!M"BN9T?!
MESLR37LH/;))[D>,_<1-9M=60;WJ@/%9#2%#J$1*8-_,1_\ (?\ /T^G#!H!
M!LW^I76\1<.$@@5MMY?#_*Y0    #T -54@% #P7VBE*(@^@_E^=$6GO]I-Y
M&7RYOW#'$J"FY*"L>8@G60;[0CW#ED-S 1P9K%QSER@HD8[)!0ASK-1$P'ZN
MX:&NH[&Z0S5-4B:\AT8< 21L-][W]$=:I<]VHU1^!I\CHP6R.L-\]O,5UH';
MF1Y'6=5LRV3M3QWN=DH@5 #% C9,@%ZTP.(D'H\PAP$PCU!^L P;T!A&OI<]
MF-$;COPSC,D+(FW)PBW&1@?L:O8N(^V]!>(C6=1,K<H9,C7.DKA#G6"QU#K1
M!#?'K>]V=KO[-3R0ORYK:SMQ?NN7D[@@<.KPUQ6*_E'"KMU%P=R*JI*09'2H
MG,=!HL!%D$S'_5%,!2E*%?+_ &FTR'3-8RHX(RQCG  ;5MR #2>0/.@/HO=>
MSVH3ZCI<,F0[C<UH][?>S3@;\]QY?:XC[07GV^++PUAWCY9$_(VF;D7?)[?N
MVX(I19!^E:D:B1:1CFSM%1$[=1^*H(G,14#G)L '6PKA.T^I2Z3H&K:E"+FP
ML&;(B%U;HFEPNM]O$!>S>R+L1@]O.W'9KL[J,KH\/5M:P=/R',%O$.1(UKRT
M$BSPFQ^QY:Y,)B.PH*W6]LM;;B7,>")4WAWK1%=P_,!.D[ATJ=,QUUUC?&HH
MH83"81V(U\29G:;6,W.EU";.RFSN>YS.&1W"PN<3PUQ"@!L !\ %^Y&C>S;L
M;H>AXW9[#T#37:?! S'D;-BQ/DF:R/@XY'<!+I'$!Q-CF3S.^4;P)LMW9A_F
M+D/B6UEG\EBO(-BR>3+8@7"JJ[6SYF)<)^V(1H***%9LG:+LQ ;IE33$2$$"
MB8-A]4^ROM)DZ]V:G=F\3YL$QPB0DDR%@#"_XEO,WS/B-_R5_P"KKV;Z-[//
M:#ANT)D<.)KK\C,=B1M#&XXG$DQC8T$C@CD]QG*F4 *]T;AS83"4PF#0[+V'
MZ=(5Z7&;C8>5ML_$DG]U\JD4]^]@G;Z#S\?T79JM$HB41*(E$2B)1%TG[)-^
MT=-%3J)INFRS90R1A(H4BR2B1CIG*("10H*")#AW*(=O6B+$"^\(G'^09N5'
MD%F?)6>+*CHF]HG%UJ7PN@J..$[X.LK(/VDND(NY-_&F7Z(1R]$/8D4TDP*8
M$R@,5XU]/*OT^R6?A^OKEZ"\.SO!IQ6WQWE:U<K9<R/EN\,AVK;-A6]DJ?69
M-+EQ[:./E@=8_CK8%J0$R.H!TFDX4=F[OQ((+% #&VKGY^OI_?Q4DW6P%>"]
M=MX1=DK8GN>#N+-60I_/ESY!M_*1N2BH1[6^H^\[0:&C[3>-FZ91:@PB60E0
M49B(@Y^(3&#JI6U;_'JH]5Z_RI?DO!FL)'#F/;2LW-V3+,S78>0;LR@KGZ*.
MT&Z[ENW("!F5]+S<<(@R6:3L<)6H-1'RT"D*<.H=A4_?X_X_93?D/AT_G[_%
M3'?'A 8O=XZP?:6),K9 PS<^&+:N>R"7[;)V:\K>-G7\Y6=W]!W*@X*FV=!/
MNG;MR5T7]8R57$2 82EHE^0/Q_M2R48CPI8F"\0V9B*Q(U-M:./K8;0,&@X3
M276%%FV$#.ESG()3.7:XJ.G!BD*!UU3FUH=44+"A]GO,)L7\YM@ :\03.6@*
M % -A&#H #0 'T    #L :HBV%*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41>7,OF\9'.I!VJ1%JR06=N553 1)-!!(ZBAU#F^$A" '48QOA*!1$?2K
M<L@BBDD.P8QSC_\ J"51)(V)CY7$!L;2\D\F@<R?(>BL1'AYL%\Z9SY*<VYQ
M)==I>]UJXMQ"H^2,4[''%C.#QRZ\><1\OV.<F"K.@51+I;H PG,'<.9T!HS9
M\K5SOWKS%&:_I;;?T:!7P7(]GX_Q^I:AJ[@27E[([WH#9U$_\6!C30ZD=2LQ
M==4NQ2B)1$HB41*(N@Y4*F*AE%2II]MF,.@*'EB(['Z=A$1'Z 'I5K?O',XC
MQ34V( ;\0:; J]]N+Y?"YXFL!>\#A',FO$?#Z?'I96,ZYE'G-#-IK%C%E%^.
M^%)]N]O1\DH8&&1K^CE4EVMM('+HCV&A%PW+D_6HK+E*CZE'7HF-'#V.T%\V
M2UW_ ''J$;3A<?NNQX'M[QLNYL/<*KD1;1R!:N,R#DZWJK88B6Z?AN$KRWD\
M[L\J)!-5T!.]K)6Q:ILF[9JV0100;)HMTD42%32231T0I$R%  *1,H=)"AV
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MFN@J)R&3"9%L3VW0D 2;\W8G HB4I^HI1$ "MCG_ (?\9D?A*..)"(^&N'8
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M"?XC"0.K7<"B;XA !  Z@ 1  -_;]:\A#F$N##L"0210L;']-]^=UY>D^\&
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MN_Y(Z_HZW^&:B+7Q^SV_S7<Y_P"L$SC^Z,HBV%J(E$2B*$QP)W$!'?;L&_\
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MXU9^2K(KJ+-T+W(',CR!(!\R-E&=4A $QAT4H"81_  V/KW[!3B!%CGX=3Y
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MAY>C"( 8*(H$<FV(NM=[=*\+=57L(-WHD249&5M0 ;F=;GDRKB:-$S<AEO\
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MZ,4YLR!B6SF4ISFS88+#O&6AXALYM[S8ENS!"(>&33-& HW,DW*D3R0]E$A
MV00"-OWY^MOLG/X_J5FU7Y4>'HZ>VC).,Y\>57UAI&1LQV>[;:,O;*1VY&AB
M0YQ7 60"U3(AI/7ZL.@0U4J:/@?H5 CRD\/!!:\G">;^.R:^0]_IRJ2[;:*I
M=(>SG:?ZY,"P>V[;**(#YN_U9ND- (T2CX'Z%=8W)CPYS1-GP1LT<<C0^/WK
M22LF.-==LF:VP_8)J(LWD.D*PE9N&R2AP242Z1*)A - .Z)1\#]"O32Y:\ &
MMRS=XH9YX^I73<D8UAIV>3O"W0DY:*9>:+9@]<>T"==JW%93RDSF,!0.<H !
M>U#TY>CU\_[* "X/86^Z^P010<*JK-6/$777=8?^17#CPG\WY(3O^*Y7XPQR
MR?A(FN6U[5O"UR1DHZ=@=5-TTZENJ)/[6HJNZ\@#>U"8-]'07>-D8L&3P?F;
MF1N$N$YKZ:)HS?O D-/O%M [W>_-<'-V"TF+6<76YW9;,.');)EP8SBWO0YS
M2U@E8'.8*8X-YT22*W6/UWX<N D)92.AO$4XVI6D=PN=HM)W/'J70SC@<"4J
M2::;P&KI5-$HIG<F,0A3](B0=@%?06G^W+7&]G&P:AHE=I6Q]T<EKHAAA[:#
M<N>,.+FAW]36@@N(KGOZGFZ)[.Y.T\6I8\&O,T..,9.H:7*&/D>X@@LCG+@\
MPF9S#Q./'0Y TKHX_P -+PC!8LB3'-]!Q*&:H^]G3+-,<S;.GW0'M"S5JFOT
M-TE51$2([,4@:Z=>@^)YW:_V@:SJF7(?:#VFPILESC'I^D&/'Q(6G9K(0R$"
MFMH AP/AXKFM8T$9^H/S='<=/TDN/<898Q_!%_2'%QX[K<\C=W9JNI</AG>$
MXX:L$+6YU1\,Y0D$%Y%=_EN)E$W<<01\UDB4SU([954.D?:"@<2CL  0K81]
MLO:'CQ,T\=M]?=,P %TO<NG-5?&XQ$D[>]9W-DC<KF<OLIF2]V_%UV:#,9,7
M/>YC7,[GBO@#+ ]U@+6DDBN;32M[O'PY^,<?<DH7$OB!X&3LQX]!5FTON]FT
MG-1Z1D$DU!2>(.3D<%!0ACD04,F5,1-LX (UZ;V2]MV9HV%)I7:'\=V@U$S/
MD@SI6QQ'@>QC6XKRUC6GNWL>_BW<!*>=!>C:CHG837V:/)A#4M.S,+"BQ]<=
M R.2#,R8I'NDR(2[A#97Q.8UPX0-F_$W"XW\-_PHV]M,"9AYKPEW7J4IAD9:
M S$PMZ)%0YS'Z&C!NY-Y:6C@4H=9BZ( F^0UYOJ7M!]IFIZIESY7:G)T@2S2
M28&EZ5' R+&PVN( >X1%TCO>C!<]SG$C<WSU':;"[,Y6? .SAU32].Q,<8[A
MDO<794P#29I YKHP\EKJX":!=1 -*9[I\-_P<GT&_:VKS):6]/KII%93#S.#
M.:;LSE5*=03Q;AZFW7\U,!1$#B7I PCW$!IC]M_:!"YCG]M=:>&N;Q<8AHM!
MMUET0YBP3R W/ERN;V=;/$YL&KY<<KVEL;MMG.:6AU!H(():1OS Y72MYRMX
M=_#%M)1KC ?/?"L-$)0[1G*161,@LI)-U,$( .I1F\3<"9HFL/48K%,ITA$
M(0P"([[GLG[;>TFB9&=%VOD_UW"GE#M*R((H(\F)AX1W4KH8V]YN'#B?9!-V
M=@.S@T3L5G]F\#2YV:QC]I]/>6YNJ\!D@U"/F2]LI $H)(N.FUP[[JK>$/#V
M\,V)@9(>1',7&.1+O>OP79N;;RBWMV$B6($( -6K1%Z*IE!. B*J@D,(B/8!
MK2]J/:9VSUS4G9FE:GJF@Z4) ^/&Q1'Q1L#&@B5PC)>7%CG>]U>:JEEZQI_9
MR32])T;L[CSX^9AP.;GZA.(AE9V0^5[[HAS&QM8YC&@ 6&W0YFN$EP5\%!>V
MI&&B>05E1DRY 3M[D/FT7,@Q7$!%,4A4D?+40(;0F043,10  !U7-Z=[0>VK
M,Z;(C[;Z_E7PM[B4-? PVXCA8^+A!)'O5SKX+F,SL]-/C/Q,>4PYD8ITW#$3
MQ.!X;:6 'D3[M&^O16NY$\.S@4VL6T(W#G.;$<7>T2ZDW%TW%=]]1K]G=I7J
M@&8IG:(OA!@G&I"*:0-RF$X=)C@8X -=UV:]K/;K2<]LO:+\1JVC\<KWND9"
MR8L<QP9W;Z:1[Y8ZASH-!X20>ATG3.R\/9C4-%[2Q22:[,R)VGZWCM;Q02QR
MM?(R5KG5W<D37QBK<7.'Q53.(/$/@?BFXKAN'D;RJXT9F1DXE*-C;:3NIDC#
MQJQ5P44D$A<OD5E7)BB)>HQ  I0Z0#=6^U?MBUWM'F8A[.SRZ#IN'(YV2)2&
MY60\;6'@"F40*OAV)6RT[_M/2^SO^E:-IC]2[0YD[OQVH9T,4C(L4<0;#!&X
MD1APX7/>6M>.8=1"R"S&-O!4FXI_&GG>,D>+QDX9%>Q]Y1+5ZT]H2,D+AJX(
M_$Q'">^I)3XA*8"B%:%G;[MZQP?'K6I.JG-)+'MH66GA+2"-[JJ.RT<K(,B)
M^.S'QX7D%O$S&9&6NY&CP;UO6V_W6-K(GA[^&JK9\S'XCYJ8YM^^'MS!*1EP
M7%D6)E(QE BFH4+?]A,]*1<I5!(J=T;H<&-H"B!0,%9.#[5.W^G:QCYDVM.S
MX"Y@S](U&&+NY<9NX=B.9&U\&0[B-NC> X@=X#3:N=D=-[)8>5JV)VUAU3/@
MS,2L&; <Z-^GY!),<T;;$$FVTC'G<4=Z /A<8N$W#NQLJQ=ZYWYH<8<G6;$(
MNP&QXN[6"T;(.5T#MV[B167=HF$Z *"L5KT&*50 ZMZ+76]KO;+J>M8^-B]G
ML?+T5S9.\S'OX6YDH#'-#8Z<0R$/(<7#=Q#/'A.QT'#['=GM*U9\F/F:GK62
M##AS9F/$["Q<(R"1T@80Z\DED0XJ< TO'(F\JA++\%/2R@R7%?S%B"4P#=,0
M4@:[!I,K\"DV/S*4/7>][$>(9VZ[=FB=9U5P:?\ E9^ (%G]]ANM:1!+ 98L
M?%9&27<1QXVM !L\0>S\HJS8JK*I+FK#7A$7YC*Y;-Q_D7C'C^ZI2..C!W<S
MNB',\@Y#>TG:1@D#&/Y9NYDC@*:A1Z3%UNL%OM)[<X,L&I1=I,C(@@RFF3!U
M!S>XDIS.*-WN-F'$ 6[G:P=N:WG9_4] AUJ.76]+AS]/EQ7XF1'IT$<$CHY(
MY([BDA;&UDS"\.#PX%U .)V6+G'?A_<=HS(-N2F0.?/&:7L6%FV#^4A8RXFQ
M75QL6CI)9=@\%=V0C5)XDF9%7R3*!TG'1@T&O5-<]N.?J&DS:?H>G/P-9<.[
MDRIG!\,1+"']P/S.)+@6OLEM B[(%G0]*]G6AZSG9VH8VHZQ!W,S=+TC*:P/
M@R'BH),XL-O9":<[AV<=BLS+2Q/!8!%5)Q)<5@#S-EZ+MB>G0"(@)1]X"<H#
MVZBCT[']M>:8W;SMV(VB7M%G9&0QH;.8GCA:[H.$M'/?>A9!YU:U;PUWYL'#
MC87/,;ACP-[QA=>Y:T7PT&]>$V-BNE<F//!>D(63:1\[Q=8/W;%9BU?-[JA?
M-9'<D,B#M,IWX *C<3^:!@_6!T;)\0%"KCNW?;D-VUK40XN!87.);WMU$'!K
M2>#B(XA^7AOBL6LC GQL++@R9M+QLZ&.0&;$9CL<9H3M*VFM+A_MEQXP.)H!
M((*PLJ>'G@<ER+(M?$-XP_HR#X[E,%KF8EN%M'F<BHFS%H1X* E*@8J971Q)
MO93"F(]S>B1^W#7_ /M*>]&CR.T;8YL./4,=[#I(SG-+8)<BWMD:6%T;Y8@"
M31J@16Q.A^SB;M=BZW#I^O3=EFSQY.H:"\L9-QL<'38L.0'F08[Z+>,N$@!/
M";"V3K=Y*\ 8R'QFA+\@< 34]BN$8Q=K3SN[K=.^B5D(E.(=.HU4[@QF9W3<
MABJ>6.Q(;I-O05X3)D39LDL\WYII'32\(]TRO)+B-SMQ$D<^6ZU>86">1\,;
MHHR^0Q1\S'&7>XTT=RUG""2>E7U/O)<IO#S17N]TCG#CNFYO\ +>RY;MMLJM
MT%]F,S_UR85O]. &QS(Z6 0%/1-@'I0TM(]W<<K\58/&3[P-U7(\AR'(=*74
M5Y+>',I&6A"&S-QP-$6"^;R-FQY[IMDS6VWS0AB-7<0B*PD9.&X#^J41T)=B
M 54HH^!^A4_6'R,X57;E(%L=Y;PK<&6;]38P 'MNY8)[=5RHQ:3ARRC@*T6.
M[=E9HI.%4D V!"%4$ $ "BBCX>7S\%>+1$HB41*(E$2B*$_W3;].D?Q^0_*B
M+1-Y1\O^)UU^,*#T_$2RY(^+;LF;/O\ N:[IQ"&C[WN9$B35E<<PU626C2)1
M"^P3462.HY'H.J)= 88]?SY>'GS4@6-OT\*_GI\U43@G'7?QR\:.,;Y6XNXY
MM)GRD;3TQB*X[3>^^+;M^)*W4>>^[(D@(9JHK(-RD0DTD ;F0*H<$PZ1H/6U
M#F?OX^.Q0\A_._KE7*M^>Y6[<4=AOZ]M?(-"(=OIO52H45$2B)1$HB41*(E$
M2B)1$HB41*(E$2B*$Q"G^\ &#Z#Z?GKZ_CZT1<#HO^C*D+H!%,Q" (Z#J$HE
M*&]"(=Q#N =0>H=Z(L%WA.\!I?#=G<J4N46"K)+<E_<NLK9"LAU<L1;%SOY&
MP+@6C30D@F^Z) S=HX%-PHBS44270'J!1$@FT)%EI_BR\=?]AN*/]P[:_P"6
MA1$_BR\=?]AN*/\ <*VO^741/XLO'7_8;BC_ '"MK_EU$7W^+-QWUK^ [%(?
ME85L_P#+:?NA]X4=QZZC=/XL_'< U_ ?BG\?_<.V@W^>HT-Z^6_2G@>H((\B
M.1'K?JAWC=$2>[>6N<R]B67PD@\^&S7A:LGR)PFLR7YN\>\C0N!,8*XFM/%N
M6X.]'GZ*VNFV;W%/2-L*6TF>-%F!WBIT&#_R7/DG!IUK% Y14-NVZ,/EFF<Z
M0R9$0AF<99*?&'!_"6\7""'-!L $U5D6%<=+(^02N<3(&A@=0_(#8:6CW2 :
MH.::H55*]?\ BS<=A$=X/Q4(_P#[%ML/W1P>OX_LUH*NN)<T,)(   X3P.%<
MJ>VG[?\ Y*TX<3N(EU^3B ?D"!T\$_BR\=M@/\!V*=@.P$;#MH?[=QW?OW_.
MK;6!DPG!=WH:&AY>XF@*ZFKKF>953R7@!U&J - &AXD $^=G=0FXQ<=# (#@
M[%0;'?:Q;< 0'OW 0C]@([[_ %^=5$6US#9:]Q>X$[\1 !(/,&@!8(.RIE F
M:UC_ ,C#Q!K0(QQ4!9[OA)--&Y)Y*(.,W'<-?]!^*1T&N]AVUZ?_ ,;^[]^J
M-'  &WML"27.H=.-Q+JY;76P\ JG.+PUKJ<&?E!:T@;5X;[=3=6:YE?1XS<=
MA[#@[% ]M?\ 4*VO3T_^F^NOGZ_C1PX@0XD@BB+-5\+0N+A1#:JORM%;5M0!
M&W*JKF-PK-N>'">QLE\<YVT</X#QD_O5W=^-9!HU;6K;,4J:,A+]M^6G!(\,
MS1*F4L.S> H3S \](3I"!NL0J6^X UM -_*" :^'$#7ALDKG31,AD)=''7
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M5R:O8,3EW&YE1L#(I46J+A\:&*L)Q%U!.U#1L@HB=5 [@HF*<H@(44G]=_\
M*R?44)1$HB416:\[N2LIQ/XZW9ERWX-G<EU(2-MVM:,-).#M(YU<]X3+6!A_
M;W!"B9-FDZ= NN!-"<J?0)R=74 J0+/KEU5 /#PY;9ES9>G)' G(:,M)/+W&
MVZ;>BYR>L07!+8G8V\8GWY%BW;NA.J@\CT^IH[ #BDH<.M(1 1 "$<CX_P D
M+*310E$2B)1%PN3&*@J8A1.8I!$I WLPAZ%#0#W$=!Z"'U :(L(-O<U>9MJ<
MY<2X&S#8^+AMK.4U>S5ECBR)P9S(6++)M<%CPN2KS?-E%&P1%R$*D0K14B!T
MU% 2()CD,0">O7K^^<,/0/R"B+[1$HB41*(E$2B)1$HB41?!#8" ^@@(?V]J
M(K:[DX=\8;NRPQSG<N$<>3>6H[RO8[[D;=8NIY$4.GR3@[53,)E$ND/+.8!,
M7TV-$7HV'Q2XZXPR%<.5L?X>L*TLB748QK@NZ#MU@QFI/K,)E//>))@H7S3"
M(J@GT H(_$ ZHBN$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$5O>;N,&%N1
M3FRW.7;-"ZEL?37Z0VFJ>4DH\8V6*)1*X L>\:@OW(0.AP"J0@'W1W1%C/M'
MPAB6=G:(NB(R\NTP);'(-_R@MW%J%ML2W,WRE+,#,G[9U>_5[>O:@B=5P2+
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I41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>g40894g96k44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40894g96k44.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:Z4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q :X            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T#\@      "@  ________   X0DE-! T       0   !:
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         ".$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      -#    !@             !Y0  !7$    ' $0 4P!0 #( -0 R
M &(    !                          $             !7$   'E
M                  $                         $     $       !N
M=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   'E
M %)G:'1L;VYG   %<0    9S;&EC97-6;$QS     4]B:F,    !       %
M<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M       &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R
M871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   !Y0    !29VAT;&]N9P  !7$
M   #=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$58
M5     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,
M8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T
M   /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU
M;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP
M965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S
M971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T
M<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
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MUB?CN:?<A,;(_1A@()W6Q('\F7P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                              #_X3\A:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@
M:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM
M;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R
M92 V+C M8S P,B W.2XQ-C0T-C L(#(P,C O,#4O,3(M,38Z,#0Z,3<@(" @
M(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO
M<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL
M;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @(" @
M(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N
M,2\B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C
M(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C$M,#4M,3%4,30Z
M,S$Z,3$K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R
M96%T;W)4;V]L/DUI8W)O<V]F=,*N(%=O<F0@,C Q-CPO>&UP.D-R96%T;W)4
M;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,2TP-2TQ,50Q-CHQ
M,SHP."LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T
M861A=&%$871E/C(P,C$M,#4M,3%4,38Z,3,Z,#@K,#4Z,S \+WAM<#I-971A
M9&%T841A=&4^"B @(" @(" @(#QP9&8Z4')O9'5C97(^36EC<F]S;V9TPJX@
M5V]R9" R,#$V/"]P9&8Z4')O9'5C97(^"B @(" @(" @(#QD8SIC<F5A=&]R
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:3Y!:V)A<FDL(%EA<VEN($4\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^4RTT+T$\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @
M(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @(" @
M/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#IF9F(Y-C8X."TV9#0W+3(P-&0M
M.#@X92UF9CAB-V$S,#)E-C<\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @
M(#QX;7!-33I$;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#HW-SAD
M-F4Y82TV,# P+3<T-&0M.#@W.2TY9&$U.#0R,&4R-V4\+WAM<$U-.D1O8W5M
M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP
M+F1I9#HP-#$T-3DS-RTT8V)B+3,Y-#4M.#8Q82TW-38R-S@Y8V0R9#(\+WAM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O
M<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C T,30U.3,W
M+31C8F(M,SDT-2TX-C%A+3<U-C(W.#EC9#)D,CPO<W1%=G0Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP-2TQ,50Q
M-CHP.#HT."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(Q+C(@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#IF.&1D.3EF82UD93@V+3$Q-&0M
M.#,V92TV964U-&,U9C0S83@\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#4M,3%4,38Z,3,Z,#@K,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,2XR("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E
M<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H
M;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I
M;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP
M87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI
M9#IF9F(Y-C8X."TV9#0W+3(P-&0M.#@X92UF9CAB-V$S,#)E-C<\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,C$M,#4M,3%4,38Z,3,Z,#@K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO
M<" R,2XR("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ
M1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.F8X9&0Y.69A+61E.#8M
M,3$T9"TX,S9E+39E934T8S5F-#-A.#PO<W12968Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S
M:&]P.F1F-6%E86%A+69D-# M830T8RUA,S-B+3DW-34S-34R.#<X,SPO<W12
M968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C
M=6UE;G1)1#YX;7 N9&ED.C T,30U.3,W+31C8F(M,SDT-2TX-C%A+3<U-C(W
M.#EC9#)D,CPO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \
M+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R
M36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_;
M $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_  !$( -0"8 ,!$0 "$0$#$0'_Q  >   " @(# 0$            &!P4(
M  0! @,)"O_$ % 0  (" 0,$ 0($ P0&! H(!P$" P0%!A$2  <3(3$4(@@5
M(T$R46$D<8&1%D)2H;'1,Y+!\ D7)3=#8G*"TO$F4U158W63MC0V1G.4HN'_
MQ  ; 0 !!0$!               #  $"! 4&!__$ $H1  $# @4!!@0$!0(#
M!0<$ P$"$2$#,0 $$D%18043(G&!D3*AL? &P='A%"-"4O$5,P=BM20V<G2"
M%C0U0U-SDB5DHK)5=8/_V@ , P$  A$#$0 _ /W\=+"PH=0]]^U>E^XV)[39
MG4L\7<'-T\7D*6GZ6G-59AHZ&9NY#'XJ[D\EAL)D,/@ZEZYBLE!7LYO(8^&1
MJ5D\PD1;I86D@:V.E]+R0"&)^H?#(NY6C5A,\TQ6.-7=B%<[*D;R/]H!8D+&
MQV +;CT/>_3A)7X1<P/,EOL;X=(*E4TB356*:2[ J8EOD7PO=.=X^W.J-,=N
M-7XK4D!P/=RK@;?;^U=AN4)M1+J/3TNJ\1#6J6X(;,-JS@*]C(-5MQ03PQ5Y
MDE2.5.'3*IFDLT%EJE,%2DF2R"2I[N1I+\WD/B))*:JM( IU107P%J6*0',K
M4!&^&?\ 41 %5)8J=OX6V)]DC?;]MCO_ "V]_(W@L.'X\_O[O&$A)L?J\-Z6
M9VPF].?B&[.ZRN9BCI;6=?4%K 9:C@\FN*Q6?N1)?R.3;#5)*=B+%-7RN*;*
MQSX^7.XF6[A*MJO;CMY" U+)BB8"22P7 .H %0I*S%R0RE4T$@3 :3&)E"@5
M)(+I+$;C:>.KV.&/0S>$U'0K9C!9FAEL3;CL15<CB[L5ZA9:*>6I-X+=622"
M8PVHIJTGCD8QV(I(6 D1E5V(-%9<=V]0A0*7350"@D&XD*'1C:<#4DD+38U$
MA">A!)5#N&C8=2UI>J@$G(2%MXE7BVX.ZEMV /\ /EL2!^P]_'20DI"$$^)
M5J!,LMM+_P#XEGVLTX=W4I3_ !Z0GCP!6K_^V_OC?Z)A\9TL+$9+9B6:4,S!
MH$9F4;MNK MN%7<DCQ[ *"3N?70RI*45"J2>\4.@HZ2?_P"X?K%L0O5"?[=
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M'-8H9[PX\O)->5F$DE:4@*8I5$$,4I:7$:GD[D ?"+BZZU5Z55PA:UYNK4T
M@ YP_P VFF2>[TDI2"5$))!))?%[/PS=H\AV5T;F]&VQAH:%CNUWIU;IC&Z>
MC>OA\'H_7G<K5.L]+Z?J435I08PX7#9NGC9<=CZR8RG+5DCI.\#QD@54"@0
M!"19B2-SUN23SY8%F#JKH*0&"0"W1$[[EK7W,8LQT+$,9TL+&=+"QG2PL9TL
M+&=+"QG2PL9TL+&=+"QG2PL9TL+&=+"QG2PL9TL+&=+"QG2PL9TL+&=+"QG2
MPL9TL+&=+"QG2PL9TL+&=+"QG2PL9TL+&=+"QG2PL9TL+&=+"QG2PL9TL+&=
M+"QG2PL9TL+&=+"QG2PL9TL+&=+"QG2PL9TL+&=+"QG2PL9TL+&=+"QG2PL9
MTL+&=+"QG2PL9TL+&=+"QG2PL9TL+&=+"QG2PL9TL+&=+"Q7?\5'_F5U%_\
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M_P VP['>(<=?R]\9YD_];YV^/^SY_P /G^G4C[^6&QAE0?S_ ,-C_P #Z/\
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MV,P18[/OAL89D"L_LA2 0 -]S^WR!_OZ<EMB8> /:]\+'(D4[>FW(WX[#?\
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M;2UVU;^6-"CJS16+FKM0TG+9CBMK267(223K',YV$92(12MS/[>3X.[D[$=
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M_P"NP8LHZ)D*2U=KY2FMB2M0F0Q2]B6V)N\"=\6NPTZ^U,LEI544\F/">&!
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M3475*63(<^(W+O<;3=_<R"0DD$W<_(;?)YENN.:O=[63)6R>/P4R"NPL.\S
M5XT+/'-%,(X &1PDBJ4)(958*1[Z"OL*F3I-5)+O,N1L)XM;9MV)J5;40"SR
M?3JWWQ@,OYFQFX1<GOWK@LI:N15X'DJ481Y6\B2VT"RRR!OL:/;R2<2>.Q)Z
MLT<BC+@@!)8," Y!&\MZ;]7;#*6MCXE6/]1X\\>U2K9R5.C8Q^,CLS&@D5E)
MX1:Q_P!1!Q:U)7DE5IS(S@-+%.02X8,-B"2&JJB"^85<#XE>ESMRW2!BJ14
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M50 DL%,0YV.^[>WSBDNF-97-%0XNK!D;6/U+4O\ TLV$LPPW1+7-@<+-2TT
M"1P0*R$RJ7992%;<#;HZ^6I9NHI:DI[LTP'M(#%+#J27&TQ!Q97023WJ#W:M
M('A8$M<Q/Z[P<6M[QY7\]_#MD\P\*03W[7;ZS8BB!\*SRZYP/F\1))*-*)'
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MU$9V8,)E)8IXY4V+*W/;Q?=Q'H]"5ELPI":U4*"G!*6)>1YMJBQ<M?#I"0"
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M"6N=BT0.;/+VCZX=7;C6VHLU<O5L]3\>/C69ENVV>$Q[*G%PDZJVS$E1&26
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M4G5L"&=N-[$L<!36)II!8 6,O>X-A_G!CVELR9S462K9:M2;&VFACY9(UP$
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MMQ /4TBK*%"Z8*D*433*@5%!8LZ7D!_"1">!)Q2[3R/<K56"247 1)()>PM
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MDRQ14[%:2G*S3$12H\_%ZTTQW'HC2I9ONBE:@5RPAY^?SL6L,'2L4BZDN"&
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M G4RG9"ZXUU(!(/B'B/(((@;6WWL'$VGY[?I/SPE+N>R&H;]A+4=IS//S6$
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MD/D@>%8(H;DA>.6:L)'4R1N8^(L4<K1R^53J4GX!J*CI) 0'(N[P'(!DGJ3
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M5M("%@L>KAAO=X&.H_!%%>8_%W8])&E054J)*21XCW9(($NS%XC>#/Q?TO\
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M2O)'9C>&3RFP?'X6AF:5450J2,X^G8NWC8.-CRT <O2IA)8$$1T:_NW6SA\
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MZ>MCT8OM&(5JKEG9^G+=2+&]O<X%-03S000M<?(SS,L,5R*"Q%/+CZ]DL);
M\4CF66%!%(\"(90CA@IV]Z>6HBG(@!P.%$0P+6+&3%S!Q39F'Z.?IML?D^)#
M!UK./EQ\U3%WKM.Q"]^!;T,8DF@C"%78S>% ?N#_ *HB9@RE%;?J.8JA94@J
M 8D*:P,!N;B+_GB2*.I3SZ^UA(\GGY@]IW(LIE)8(L3?O+8FC)KQ$1XFH]5
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MHI34D*&D"Y4(9MQ#NTXO)>S&I]9W\3JC7&9F_-,'BC ,5"U;Z%HH9+,->?\
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MT4163%UH"3D!$50PP,[15Z4U=3-*H+R$GD>K0_BS4T@I_A^[#$&=1+! 9W
M)+V#8;2E+J 8D^+J&,CUNSN1-\'N@M(XC4LL>1_,[-C**1'1JR-*\7 RCF)9
M9"E:O''XRP21EM,X4[>-D+9/:69J9%)0E#:@%D@,7L_)@;,!(YQ+469X-N&Y
M(WD/>6E\60J832NDF&0S,HR%WP@04Z]F&PX<;*BV&5W$8YA0RH3+LP(/'F>N
M=55KYY**=/537K"BL02EF(L0/B#\D.XQ G2"1!W(NT>FUHGJV O+]P\UDI,E
M% E.OCH9X(:F.'CCK6&L!UEV;D(]X8T4NTH#RH?&NV_O33V6A/=KJ^)04%%1
M=QI(+L3P[7Y?$.\6?ZC]MTNYW]"8Q Z2T+=U1?>[=#Q8>G(TURW*5A@DGL5T
MBLQU_$JH84(_14^0D*>(!W)MYS.TZ%,IHD=ZH*2"B3&Y=S%WYC!*1U7DNVP@
MM>WEUFX@M:KDM)Z.1Z^#IG+7EF!2Q<5V"/L CAY%W8H "H#%1L#MZ]8"*6?S
M*BNI7J*IU"^E4) 4]V CBWUPBE(4H@ $ER1R/S'^(P :BU3GL[<BM6#8:K)(
MO."J[+6CJK(YEMM$SQJRHX1 "H63F=OX.M3*9'+9=*@::"I:M1)=RK2S[C;;
MCC#DDLY=H$[;?O@,+ZBR-[P_E42K'DYG-6(7(:D](Q\*I66Y((69'/FFF@W#
M1C9/6V]U*,NA/P)?29AWY+-.S!O5SB"[;>4^W,]#ZX8>4S^/IX.&G0\J9F.*
M1#%!$$JU9EF=4242)(CN\?*2&1I&"J%/$$]4,LE1K+%0N@E@[DB[!+%P'O9P
M[[8$)-G>VU^-K&/3R(T;F4RT1H8V2[E('IK#)%<@81RWGL/Y[4LBJC1>1 L*
M5W)@55#J=V]0S2TY+QA;+Y!#C9B6.S'TM@FE?,VWV<E_*UNEKW;TM0_*]!:-
MQYB6O]+CFB\*[<8V$LC,J\?MV&Y/KUUSQJJS%:O6)U*6O62?(.[^6!J=R\G<
MWO(_-O5L3( .V^Q'$#8['TP^X$?N"-MP?1Z!44L5O"2$@DJ9KLX?S88@@D)N
MT_?S?";U'HRU1R.5R5"Q6DQ^6EBLPT9JH:/%Y6-'"V5)#1NMJ1W=U(^V1E 5
M=]C>IU@JF$?U0"7N [^EG>+=,24Y%R79_)_T?\IPEM64I=18W,Z?OV(\=7K,
MF3B6A2$L5_)XZ"!ZU;ZFM'+)^:3Q(RF.W7$?&51$S,K!;^54::DJ0X)(!,6-
MS(LXV=^@Q9JTTIII4$@'>]Y%Y'0P8\YJF]Z73LV0CQ-U89\Q0EQ>0F\(#/3N
MOY)H9)'CA=9"3"I>)$' /&=E+#KL4BG7*%5$A92H+!),$0' ]3+SL2!BOI <
M:0YC;EO1RUV]CB<T5W%O:*U!#;IT*-DQI+4E_,:L=J"-K #2-%&DG"/Q1J&A
M<\0FX)V^>I=H=G)S>7<.EPZ=)(^$L!S+,SE^C8@(J%Q?GR=C#AP#QSU%A[W>
MJRN,@6C#C)KUFB$R&0N05X<@TRUY(6BBE61EAB2='2MXRKR*1RWXKURJ.Q:Q
M6OO%E2$D:4[ %W+!F,!W?@WP=1("6)W]68V:&W\_/"=NY2;4$L:Q1>>>9Y'E
MBE9'C;AL/&)O*S(Z.S\>*<VC!7X)VVZ5.EDJ)-@D D")*F#AG:0?.1UB5.&+
MMZ3-RWR ]3BPFG^W]+2^-KZPU6*_(PJU&!"1):*<G2MN/U1'%&WN1N04'93N
M03@Y[M%>:/<T=08L4@Q.^\L-O-H.(DOUF&GI^EYB9Q!9C4U'56:Y4C=3&V&K
M4<?4E62PM:U/ CM+*D)#QTXHG:RC2-!$.(1Y-W53*CE.YIG4D=XSZB)%[/S
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MRLNH[4B5!6024X8:M*0RR79)69H[<TQECA\YXA4C*KN2QZK4L[5J9Y222*#
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M*I@524DV5I&DLS@D.DA@7<[,)#7J=*FH+%-.A58A2E))=2DJU@DN6<B6@[Q
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M=Q5GFJO I$IL2;!1UN]BUBE6C4'22X6[%.W!F 6(=BV.R['*\[ETY1-4I*6
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M98WDWKQUHX;V_$K)(\OW'9&Y(2PY<0A ^>L="^U5TTH1K #OXC8M(;>_&'2
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M)8>YL_0@'$QE]#8.[:M9"2K:\MY$CM"">2$,\0VBM#QD#RHNZAQN[)LH/$;
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MI/+L[^A?RN"!: I/>)"QU/PPSMU^WPG,EIC*ZAM&/46D+N)JXJ:PV,R(;\S
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M-UX)Y;@N".*NGFEMS?5"Q7B$<J68Y@A+L#P=>G71VE2"AXC40IX8I.D AR6
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ME_$%:I&\* &P \\:5'M?M'*4*M+*UBG,4AWJE))=6OQ1(,).Q,#8OCYY]_\
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MV=[5M*]F32N.,TDLDSSM/<0/+*29''*WP/+FQV!];^MMNCISV< %,5:J4I#
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M5!V0#B/0ZG_%Y[_ZM;_\U_DK#N>2/D_Z^>/%^U_:V4D#0VCV"L!O^1XUHT/
MCV5K\%^S<>RI'\NI#/9U%LQF 2):HMF)Y?\ 8\X3GIZ@$_,.<3D.F-(5JT6/
M@PV"AIP,##4BJ4%K0O\ 'Z<(4H"!M_"H8[C^8/035S!4%ZJA)W)42>)L(MQ/
MEA=3UVC[?V^6-#_0#MPLCS_Z)Z32:0D/*V)Q@>5F/W<V\(9BQ)/]Y]_OU/\
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MEF<.-5(*)81&YOL/.(Q&35E:U:O37W>G5KUQ!/',:XAM6)8X$5H4E:1(Q''
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M%LR6I0DMV61EEBXR2*\2588XI(PL960R6"Y(C!'85<M16&32IMLR7+,8M?\
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MD7(E5O))%7'")TV!\0V0*-FX@$@GXZNY;,KRZ$H6G60"Q<I,N)A7GL2=\32
MH%RS/L[Q:XX/E]#3'Z5JXG3%JE3C)E@@D#1K[)C.Y14/^M[(.P]$ _( /5>O
MF%=X,QIU$%M!-W\+ZF+,[L07XX=24@.%6+,W4W+L(;[O6&Y+E*JR:?%!WEFL
MVX);')/T!,\4T/D5W+I$S#QM+$%=3]V[[<1T64IBI1%0U;SH*8'1WD>21TL'
M@+C[W]/.]M\-!]27)M"5X*%&.M;QYBIB:N$E>.;9D>6S>;BTD8)'/9/1 /\
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M5$85HRCL6'+GY0&"^/D_3)-Z I#NQXA5?XBOQD:&@I*BEG+Z7W;%):3K*7,
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MH -O=R6!;F8=^O39MZ@T/V]DS%UI9(TMW)6FG;RO)+)(^WD(C#A$7?[2 !Z
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MX/P1M^X]="J$!+DP"Y\IXQ!+ZAT?Z??K@1R461^LHFN]=:B26/S!)%/GD5H
M*XKD;JIBF#&1B1R4C;V.HTY+AF(<'H6-FY^I\L&^_OSWX^OCW6P\N>[.3XR)
M.<LMBA(%*A@PBR!D4$-]NVP7V?0'SZ!ZT,E7&7[035460D.526<#ASUCR&S0
MK)*T+2@.38"& +[L.GV,49TY@,72NW<=F:-CZN21&2)DE*H/:LW$,5\;*H8D
M!E9G^"0>NPS%>K633K4D!=,E(U!03!<V)"NKL&GDG%.DDTG2H,>OB^CCE_1H
M$;F/\.%SMB_IZ2:O]&=KF/DG#R-&TG%'C7;=5<KNJ>BNX] >^@YFFNO0*%(!
M=+*)TA@H2[EW V#R&%V!TD%0 .\^AY\_REL/>W7Q^O-/&TUIZMFM7,S_ $Z1
M-*;21[QOR]D1DE5E (X[@L-MCUSM.HK(53HFF()+LS\%B&VZ>3@E1"E" \7?
M=]['KN/8X1%2%K&2=+,D5;S1M!?2RX00^&,K6D6&8,9',X!5XVC],7!X[[]"
MA7\710M(U!202W!N9((V/HWD&FE05,2+GC]/?8;X?G;>W+=PE_%FZ'>K!?X,
MJ@)((0W #[F8C9201N#MNI.XWY[/4DTL]1) T:/'(,ZBX(#DQXCB\@@H5Q9V
M/ ?V>]F'GBN;P5[.:S<F2L/(M>0Q21PA.>Y#*RE3)(?"(V\B,3SYJ.2#UMU6
M6T&F@T90S.$D;;ZF+D6EXN(Q1S%B\!QM^W,6/R;$[VOI&/54,,,EUJ4AKSK%
M=D0VX^4Y;QM($YP1*-T$8 1E"?(/5'MFH!1EK%F!OI,0"UI/6T8:C:"UF!,[
M$7=W;D,PYQ/=S?H:6K;%FQ]95J%?'#%$0S>0ON&D=6C0*&W<MNXXD;@#Y'V'
M2_B,GJ" 5S#I=O4MS!][ EJ5>Y_W" !YG_\ JX^6(KMSK:.KF)XDRYN8V=YJ
MYGB<LJAG*>%Y(Y-O(22 =O8! _JW:79U8)0JC0>HG_<2Z4Z3YJ4D'HQ(VN,)
M&9IU$@Z]BT&6AR" 0_E]9[]Q=-38F\N0QTH2E<EKW_)$%DC&Q;9)@2Q!#$F6
M,F.4  -QWZGV75[Q)0H^.FR5)4[AW\IN7#\'$RD%B@\/M,-[#>2_R]NW;4Y[
M.52W>BG:W7:O E6-/!/8<%';B\PDAC!WW"I.206/$'ETW:RJE(I6E#D+2&)3
M8D W,DC@N;O$M2*>\ 46A7,D F"+[<X[]O,A8P>6RVF\BCR8RU9G"P69#89)
M99"B&N[*0BH"7*@>MQ[WVVK]IY;OLK2J98 U0Q4 R8#'Q:B 2&N"=\.E8"U"
MJ=*;)/NT![F\="!L']P:E?&ZF'C4P5)76*?QA >/,([* "&(1V<[;G<;;;[=
M:?9-2MFZ'A.J.0&:9<B;?H=ZZQ30#JAKL%%O8&[."8;ER,)[$9NS<OS4X*C4
MH:$]CZE)?&E@J"K1V(FB/T[1R1#R.'< G<*#+R4:*LMI;O$M4J?"'!U-%P[<
M7$[XHJJ!-4J#]VHC22&<:0Y:X (+.PW#X^A':C/K7_#IF\W+:BDCK7K[K:=3
M)"\*3XU%EX)NS(W/D NWW,Q(_BVX3M.@I':"LN$LL@,EQR7<NV\RS=&QITU@
M4]2C WDQY2?U)M(<"RMC!]P<?'0>SC_-*C?EU^I($DCE1#L&C=3)5,JL_CDV
MXC[59MC[LT4YWL[34-$A"0Y!53((+@$@*)W#, 19L$IJIU?A.H;P0-V@@/L8
MZ^>*YY[28[>N:4&)KVZM_/392_9H))'8M6;WZ5VP6E+"6:><);DJQQP1JK6)
M8E8JI;?[/SX[3)IK5I4D :5%A#\@#>99\5JRC3(TQ)BWG?<\B]R#AEZ#U-%4
MO+A\N3-IZQY!$MIY"L,B2^-ZHLH1(WJ3TZIQ6-64$*VQS>T\CWU09T>&HASH
M'U#..+G$J)-0^* [>0XZ#>=C=\%^C=%W,%J^_>JW8[^&OXF['1D3[4@=B[1U
M0>7-VBY*I5UY>MW4 ]9F=[25F,K234&FL7"PQLE12)^&4A)N/60+M%!1466\
M+.\<#8%[[%O;$)+W!N19;(X/*8Y)\=!],EHO)M.D=M1"MF*NZ,Y1=SY&0H &
M!)(/HU+LLT\M3SF5\=<:E:' ) 8W40EWY,<1@2*X%6LD,2H(!=W_ *FDQOL.
MA+W4?<[0533URKF,;"U_"VV6VAJ,T+02O":\,AM(P=8%+&.S!R**2&VV,9/1
M=D]J5<W35ELXCN<V!II4U:5!83\1U)*J:60"?$H<"6!%5RXFN#XTLH 2Y,&;
M. =]X?;#)[/:T%>>;3N;R-NC#:K3103LMJ20RR#A#%"P&S%)N313B3B(^0+*
M6.^;VWDDU02@#O")2(.[3 =[^K/AZ5?2)(%F>?\ &[<<NV%IJ?!2U<UJ>K+'
MX[336,K4MGBL\KJ-W#O)(FU:)58B"L?+(S!@/MW.KDZX4A*4@*0R4F>C$,[O
MU;@N9P-:JJ'U C5:W1K0[7GS@-AT]G-38.WA?RO/9)?K>,E6*L^YF\-A%+SL
MSGF*YV2-0>4HFC+ %=V&1VO07EZ_?TD$ :7("0((V_:68XL4U?R@DERY<<.7
M!#07 Z>N$KK#34FD]836:(:JT]M?I3"6:26969UK';[&@E3:19O;EBG'>)^7
M6YD\VGM#(_PJTC4$E*W(\+AM7GLP-A9[UZY52*2?#K+.XDQU,.7G;RP?(^G>
MXN#CK75DCU7725:VY5%L6(W,"AN6S&9(S_ "1)N0">(ZR:=#-]CUM-).O*55
M?SJFI/@1?4$ZM:I  TI)Y VGX#161*@(?EVN1$"YC%><K6SFG<Q6AMU)H6@D
MX1S,KUI?'%(3P ;8\%*@E2OMQN ?1ZZ:A6R&=IE JA2V'A*%@;?W):2['KP[
MTR:CVEIF7$\V!G\P;,#4[MK+2AS$MR>>[CC+#-5M6!%6!L<I3)2/CD,?U;(S
M7(PG+RH66:178"C2![.S(38+4"!>"202VS,V_0MAZ@40-(AO)[;/N2;#@@,,
M5R@TW^3"//>">C3R4UBM9LR0S-0LW:\*,L$*-+7\-_8Q".=(RIA $B./N7I*
MN>5F:M#*I2E1A98I$$$$N6)#RW0\Q3**E(A12R&(N&>=@7VZ;/MBQW;.S#;[
M.=]+$;+*\F5[,*TOWEC'%KMDC0NR@$1GDHC!WC]@A?@XV>IFE^).R$D ?R.U
M(C__ !M<FWG'(GC&#^,E%7X8SQ-OXSL3>)[:[/V&_6WRQ]..\.)?+8B**L56
M\D5N2HQ'II4:%OIW ()CLA!#(NXY<_9V)'7FV4;62=M,\7?K[;MCN\50Q[W<
M;;NPY&NN.KTZRM8LU#'XLA4VDALP9%1$\*I$)5B6)8BYYRR<56,=:F87W016
M%X&[AO$"^]P?N6-BW!XGT_*=_2M_<'3U33NH63&M/9H6:4=J#:9S QECD#1R
MSMRC*1)-7:$QHJNCJS@*"XZGL_-G-Y:F2;*'R2;"+L2>"?-Z1;7+!O6-@W4,
M#UP*:-P]+*9>E8>S5@*6FDAN79(Q]&)@ZS3 )NC!44QJ561AMO'(QV8W,]F%
M(I&FEY3I &Y9A?8DVCC>7'QH9I4DVZLT%F!%]_F+4T>X.E].)1P6.$>8N2BP
M);44!'*5 YAX!AR2+8\N855#$DC[AMSE3)U\Q*B0&D7L[N7:YY)9N,7FGHS@
MF8ZL_ETPL]2ZCS>=RYI\K'FA, 4HSD<Y)'<UHH%B"?9"T$\\I8A@S1;DHW*S
M0RE#*TBH@:BER^YAR9Y>.-YPA^1XM^1^QU=V*J4M)XQM3Y^:L+/Y>TU2*0JI
MEEV"D!&5#&D3LSD?<LA''<E3OS^8S"\[G$Y:F_=$>(3\14H$DB &9WX#X(BQ
M\_T^]L06F,=:U/?O:GS\_P#Y(K1M,K['QW)%!=:T;,5'%E9""ODC7A[;D5/4
M\XV6IHRE$$5%5$DD,#I 4"-]R'>\'R2[>H_/$9J?5*ZGLF.C*D-'&W4JO3B=
MC8#F-=BG .73C]O(%MG/,>QUIY/+TLO3%2HGQJ3JU& Y9K%I^9?I@?R(^[,[
M\DP.D8-],8Q=,8^QJG/0*EY:JI4J/]DE:M GCCW:PZRR<%*R$NQ><L2[%NL?
M,U1FLT*%%IAWN7;V]IB,-B 7/OF;DV9UA9FCJ$K4J000#Z<R+7>6.>4Q&0/+
M .'*%=^;;&7F!ZM)R1RZA#J29\X#[ON'_P X?V_QU_=CYXU<3IB#4.:CRE>D
MM7&TII)Y,AD$>!KZ! DWZ3%4CA8CDBK&A+?:I&P/4<YVBC+TC05\50.&9X@^
M]C;<V=EZ"QN.>'FS-]O.:ZR>&LT8=/4&C6E(I:Q'3=4+;""#;@&(9Y)9/)P'
MD2.-074,235R-"HZ\TH^$(7NP\5MM@&>''+8@K8<J'W]^1C&QK&G4I8/3&-@
M9J\?@5HX$8+SB6,"1W"LJRR*Q+!63^+^9V'4NRVS6:J:I%-SY%)<!]_/Z;%S
M#]VF1LU_, RQBY$\N+Z^@-/U:>4M5W\$DV.A:3S@#?:1?(A?8']1P1YCS(C?
M_5&W1>TZY+A[^=]@9-S$?0X'1%O4_+G<=>N#7N[BLME]*]MK.*JP7!7&9%F)
MPI9DL_2,@W8-]G.'Y()*>P=^A]B9JE0J55*CO D."Q!<OO?DF;/QAJKIJ$WC
M?R\A;W9W880EJ[F].5+&+S%*>O0L206"V(X?:Q;R<?4+<49PJRF3EN-]N/6\
MJE2S59-5#'2"YO.SMY3L^[X&00W( Z?+I <<3)QOU;6'L)+:IT,J,C<A%:;9
MV:NVVS(LD6RJX4;,I;<*P!'KT(U$_P#:13.EM"VV(9!O,'_'.'1=_-K;#RV%
MV8GR=FI/C;.9[<1T)Z2_F$$L4L=J12EB-(=Y51'0;1AGY,P4 ^SMQ^>N=R]3
MN<XL W48CD6+3L?7!3&XC[^7^,)W%7)*>8I0JN2XI)).\MB1)DKRQR*)XBS2
M+(L3\T\:@;*I/LD^NGJH_B,NH<B.CDOY2) GS;"H_P!/F=_/V^GOAO\ <6*+
M)Z3QN=Q-1CE*L@DL/),PA:*"-U=O&L;*SL"F[GBQ^.0 '6-V:#2SB\N[!!9O
M_$ K=I8Q?=GP9<)#CR^=]HF&G?%?\GF6*T9Z5IJ>-HV8K-NG$O%!9GK2?4I9
M'@EE^G,LJ^-PKL& /P68]53H@:X<J##JQ-AN3YMY,PIW),@/,Q+O(?J!&_H3
M;2.;J6=2T98Z?T\U8"K9D]&.TI#'E^F_C;B-AOL=VVX['8]9G:5%\M5W^ C9
MAWB.)V,7#V.)TOC'(>.((W<\<7X&)3N#C7HYE)Z^.AO59[\>2NF=I8YJBF!Y
M9;%*.-)?J)$>2'QUY!'"P:0!_)PC;.R"^]_D$LPD<78?0D3U><6_LXDM-:HR
MM#*5JMA*YQKQ[K,)VE'D+F,)P0CQR,2#(&=E7;C&BC?J-;(HS2.]HI"5)<QN
MW[VV]\1[Y3_6W6P('WZ8@NY>!:?+0YS&0_VAZZQ"TC,T@KR-*738ADC0$DAP
M-F/IMV)ZM]EU4]T,G6E5,K)<?W**@'N8(N">,5:JM2B3=A]!'7EXWOA)WI'E
ME2E/;GD>.H_CE8A29(%DEE9Y4"\66)'E9SNJJIW'L ;R4)*T)0 D)4ZQ!^)@
M(.[C8=+V!47H;KR#LS^SGSVQ&:)U_J/!9J60SQQXQI]E,@F=9*IB"M(OLA%E
M?8J0/N)5QQ4=&[1R.7KY=:$)'?E(T$.X((-V+1J$7\L-2K%2TIY)V#P"8GS/
MOY8=6N\/1SF!3-XV:1\K8B"RTF6%HC7"\F=9N4C-)]2L)4, Z@>MMP>N4R-8
M4,R:%8. 6D;?D&Z2V]A=MQ\B+@^6*U2YZ[CA)X;%BI)$D@DR'U/DBF?>2.**
M2*0!).$RKP"EI1L=E;Y'6)RN7KUZE4H"B:886@S!\KP;W:, L3%OK9O([BY#
MN]\?1#5N5RA[!]K9C9B%W)XS3"W;3R?3EFFTY8GGDB4CD[NR>DXE@I+?*]<'
MED4JG:59*DC0*E12?19TOT(#-S(V9'^DF06'H ';B7>1]<)C2>"P%%,AKC.4
MN4)6$X>O);*QRR0)XI9)(SXC95I&9S(NQ"[ $$$G1SV:4I5/*T"0$J.O2&<%
MFNY:+<[1AH^[1Y<V^LEQ"ZCSMS*33WK$=9:E0A^-FPM:.6*5?%# #$)651L9
M!$D+#QG<2<B3U<HTT4$I2 .^7\)%]3$B?3EY-\.6#]3;@;;&1YN'\\#&#QD>
MM\Q:;$(:U)K=!,@ZP+*(?'&T(IXYA!$?%,?ND\O-68 LNYWZGF*W\ COJTE@
M9C9R\_+RL^&+;<;[_?Y&<6=MW<;VYTA#CO-0K2U(RDWC16O;73]U9'39WL*=
MG,/&,Q(6V++\<ZHJS57OJKE).J3 2[@!F$@RT'G!]A[_ )_X]\0>DJ-J_:GR
M>5JS15(W#USXE,>4$L>Y9'5W,,"*P+O,40." 22>BYK,4%!%&F "P!9XV]RU
M^2_4&1;[]_V\SO@'[P=PHXZ&1CPT6R1Q*9)*ZQ6I$6%=N,TJ)Y(N(4^%68(Z
MJ6.[ ;:W9&26I2%U""% %/20[R=H^73 ZR]"09+EF'Y^W-S8XJM1S<:96?PP
M17'"4:=+(7X2[RY"Q'#;LI5Q\JM6KLAFB#7 C.\,:#D'Y$]DNDU)(4=*2%%2
M4J8:1 U$,3 ^%V!+&PQF&L]5($N0"X&Y+Q8;#JV]PXL=>J4\1F\ODED.8LM7
MI0-NEFOX*LK22OY&'.&>3G&8Q7W,D!$<L;*-UYXJ-;-"A1+)25/<&83N 1R\
MV+XMNYM)?8&=F=X^^&"JF8L9&"\)I5Q=F*S+=Q\E%8Y'-GZ>*LK7FD259998
M76M+$7D7PHB2QR,A)NU,MJ9!\3> O'PD@QZDW:YPE*[D!3B0^WQ<&'B_T=\-
M73N>?6E*+#)+1QU; U!2GI7&<2ZFR*HMMFIB9G\6)3S/#-:C6)H3 5<.JH!A
MYW)_P=3O0E2BI+NP 0!!#Q,1N2^PQ*E6[]&N(.C=X /R=IV:,&1J4\CE\'D:
MEV;RXJ2"&1\'E\>M%*E.N@FK2;M6$\<)D$B0NLS[(6"L+)ZS*M<FEK ^)9!>
M[J"B3+DO#G;I8V$$N?)O0-;C![!F)<=+<LQ7(,-*UVLDE_'B&,6XI68P37JK
M5YZ[(??D\J$K(K<65-EZS5([R9)!?R:SFYZ?G($U,Q?@W#C]/?#8P.L*65F?
M&3!ZN0KP><K+%PJW(FEEB62A:4_3V&D6 SM6B^^(2KR"AE!$NF.K6(-A/&W#
MOO[UBEY# C?R@#RF>@]IBYLSC8[J6.Q'[@D['^7QT&F!K;:WHX&'%AY#[G'M
MK/)Q8CM[5LS2"*$Y'%599'&Z1Q6[PA=WW_U0"2?Z>@?>_14TE5JQ0F#+-?PI
M'Y?GA%3$#G\W'[8K-K+13Y*Q^>Z9L&U-$H:*9/MBD4JK%&C'+<)NQ1BH^WEO
MOOUIY/M%>5K_ ,/5+T])(2190*0+F[/9W;ACB-:FU,5(<J2!Y%S.VT@]"=L)
M[*9#*8FV6R&,@DN$*P""O%'?6/=0OD\ 97 (8?<"" >0ZZ&D55P*B2>[#J58
M^$2IP00>O+N=L4P6(,00=]C;?U^4X(<3JAM/9".6&-!%.B/-5\A8I'N-G= %
M39CS5E//D5Y'UQVIYS)C.#^2-F<>=_J\]8C!^^M\XB]^?;]L-.YIW3>KTCRT
M"P(W!1*5D,:HI(=R7&ZE=_0# NNY52!N.L&IF,SV<KN H@H.AG#1$=/\<DV4
MHUI"X\0U&/+]/0/><$VBZF!Q_P!9!C[D!F>*?QN91LRQ[1M%&49V=B9!ZX\B
M/\B*I4J55(6MR5!P]F<AFOM(<N\#D@2$I4 >3;IY_8B&&*F:S@CHZMS#SB."
M.>R49?(L:3M/)]+P<?9[7G]VQ#[L-BIZ[/LW_P!U2!R#\CYW%S%O7&?FH!_\
M2>/*?K^V&SV>?\ES=FM7DC%B:."FYF\<QLU5<L4WF\I7;8?JQLLG$ <MMQUF
M]M@J0$AW-C,$@@%@6BPNX)DQB5$V]N>MY,7$"?,G$UW,TQ0[CXZTU*1DR%&R
M\=E5)KRR-#(VS+P*_I;?8' *<=N2G;W1[(SJ^RJ@IU"2EA>;\P?S]3@U2D*Q
M\7G;[X:?E.*O7J]'2KK"T(J_=NH6(\(ITV5BTBO$$24[.L95@S*7B"DD]=HA
MLZDU 04U!J'D0S,Q M&[-OB@$"E44C9!:.@\P6=GW?<8?.G=8MJ+ 4,%F(*D
M%:K XJVDC0V99&) L32*[%@X;_6!+  GXZY?.9&OE:QK4"0D$ZP##NS.1>#'
M,C@Z"6TQ+-#S(?\ ;[.(?"XQ,;FYHTY)]%+)82XLIDCE@L*)%D4$[1A K  *
M#ON"3U*HLYC*NL.H*0"UWU#[B/+ $?[H'2'CGH!SSU.%SD+DU341NF_9LSS2
ML50*6JR#R>165@O&*4 ;%@=V&P._KK510"LN PE+&)!+A[V>9 &%5+*O"22W
ME)ZN[[7+1;![F;ND];XJ.2U=GJY= T=F=JY6,NB\0(%4EY6B38-,J+'(Q=6'
M.([Y]"CF.S5]TDG2_)M:?6&GH<$1F*-:--S %FY /^=^N*QZGFH4+"+6LV+$
M,=EHULU'$4UF!H)8?UUX\G$2DR,O[.#QV]==;D::LRJ@5_$E)47<!]183'!M
M9L9N="158#PA0"3O9W9^;C_!O=VQGHP?A(U2V2MQTJ-*?)BW,\B 5X(+6'8I
MS50J.P"Q< NW.0[#KA^UT _B()%BI <;@ZK#KB\W_9F_Y2SL-R #L_YW8XK3
M E6?("TD%C3\HIKE,'-0R27%N*>+B2UCC+)8BA:+DNTFSAT=EA\0W&[F*"5Z
M4'Q!B% N &!AS! +0[&SO@675I0I0 AF#7=3 QM,NS<%GPU\7J?!Z_Q$&+S[
MP5KXC04;<AXI88@".5)-EDC83D$-* R;%'!B;@>6S.4S.1K*JT%*2";AP\O/
M$#\FP=*>_P#%O?S@[N[/^6 C/Z:U%@3A*^3JUK6'Q^8MR06FDG5+4-^(16H;
M4>Q+F?ER5P)4@/)D,;!.M?*=H4,Y34"!J4D AN'9A81=@";F,.I/<A^'X,&6
M)M[D/#3AA]KM6/C\Y+A;3.,7!.8J_P!;QF>E<1RQJ"8@F6+PHDD$I;F:KH)&
M8@CK-[4[/IIRZ,PA(#J) _\ 44](BQ%W."96OWBBDN!;R<-U<1Z;8$NYN*CC
MUE+/,S1I/1MF1XY)(.0QL_UT:+/&-SYX$6,(6 8G8?;N.M'LBH:M'NKA+1,$
MQZ6N]IY)#F4]S5!!^-W?A,N?=A;SG!CVYXZWTOE=-VF6Y8H+)-1>0B2:6,H?
MTXUE?^)H>!V"-O(H;<GWU3[2)[-SM*JD""7>&!!07:?ZKG$C5U4E![CAP[C?
M](]\+%TMTLHN$R$T<,V'5Y<?9GCD#9$JRFM$DIX%"Q9E6-?MY*6!^X]:R@,Q
MEA7W4EX\MKF7-W#[XK'R:;S/+[/RUL&NHZ5/7FGEU! (XLUC(;%*TJH1.UF)
M' <G=$4S&&>-XY(R?*B[,H)!RNSZR\IFTTJI\*B"Q,$<ASO:T7\[]-(K9=54
M'X03MM/4 AMN<5DP]^WC[D?U-IXK_P!59AK66JA9Y8Z\GG42/7?P0UOU/%"9
MT#F4.C&0; =GGZ%#-H*$A,(00Q,.AW=KGBQ>(QFT*[GR*A[*(@>3\.S^5II:
M^.[A:.222&W_ *3TY:5>O*[&*-8X?1L%/?*8*(HQS);QQJT7'=B>-0:G9F<4
M"KP5#I ,NQGY$P[.6VBY4 KH2X?27&S.&+M=N Y]6915JUC&9N>C):2.S&#(
MEV*2)8_/"0MAC(JH3*K ;,6V4^VW(ZW:JQF$I29U!F(_I9PP^P>6?%4U"E0I
M_P!WAL' #O=N)=F^F]J?4<&H:#)=H_69"!&I0Y VG;RLB%8I/M555E8<2V_&
M0$MMMN>HY&CW%:!$WLV\-Y%I/E?#AB?,L(L_2=H''.%EBLU#A<;E,+/7R-FU
ME8H8,=6IE&2*^L[\;!BDCEFE64R\(PGME^3N!UKULMW]1*R0!3,D@V%@2"W+
M[>[XKFKL=X$&&>V\GC?9W;4ARN+OX;_1/4^.;!9'&&Y-<L69+D]BSG)90(HY
M([0BBQRSTTCK&6K") 8R&D]^QK15IUZ.:0MTE24( ;2D)%DD2J7(+FXX.&K*
MUT1#$$O:2(,"[AQ%H;#MT#C,73_#OW3NU($@O9#4';07_'-*RN*G<2..L379
MFB@VC9MFC"^;<NP)V(J9FI4J?BGLY2RX_A^T6EP/_P!-S#_DX<[8YO\ &)'_
M +*YRX/\9V)_UO(?H2Q@0V/IYK0?_P  =@>)L?/OY9 /1]'V?@^O]H%=P?-Z
M>_I^>.[:0> ?FWZ8KIK' 5\;->RM7Z:-<X\1F@MV9HTES,-818\PM]R0QV*\
M#QWH8D*S3)%8X!F(ZO92HU4 DLX)%PQ)>_E/H6P^$9C=+^*OJ$9++''T9K-C
M$XVI8^GR#5[&01(:X,%ZH_+%+%::.G7I#=I(1(G(OPZTU5-=5(280RV'A+ V
M8'KT'H87IM._Z>6$5J;MKE]*&E9N3UZ-&.Q)2BKT)3%!9>9Y(U^^*.+Z>,>%
M[,)X\)>4<*QR\R>NHRG:-.NA%-G( $@6AH(O:0;S<'%6H?&&#,=HW]MN@.X&
M(#3VBM1V,S7&.LY*M9F-@/E[4TSQ;S3) )H"-W@AJE9$E\C'9 SPA5?D]NOG
MJ8IFGI!+?"$ARPX;R8#@%\$E_BF)<[]>!N[8MGVKTS!7U'-@,Y:QV7LP23<,
MW0M&6.<-L569G>8#@1Y%7?ZB-I#&_+;D>.[6S%17=$H4A!2&2H%)>6<'EN9?
M?$Z8\1=BQ ?8C](L]K](>WHW/ZR[EYFYK2Q+4T;AR#1KF1CCY:PFD@2GBZT;
MPA[$GB5>$HXE2)650_3U,SEZ/9H_AF5FE$A@!K?2"Y(F2X<OMM)M&F20K^T3
M];'I+S<--MG66I?J@N#PT<F/PE".1:S*&,!2L57PNR@Q)+)Z!YLIE92!NJ%@
MNR\IWE,YK-.*SLRB"0#.IB02=C)8<%G=:P4!,018!^7-B07%CSTQ/:/P.+AQ
M UCDXU1>8X4DB6)YK7 A/(P)#$[EB-R""-N6_0^T,RJHKN*4@D(40P<%DVEH
M.WS9\ Z?+Z6N9_+$=FL_-G,A!9U!7:.K%"6KT4F56EK3,:L,KH6^ED= -A"0
MTH'W*@/3TLC2HT-14"0\ON!<$VCK$%ML+Y;']_VX]R'2&F+6;M1WIZCTL3 T
M4].JQ8UHXEB6*22>!HUY3SG:8 $GFQ5N.PWSL]7%2G3H().A(0%/,'T(B+EH
M?!4(T,O8STVMQ8N=_3'IW"SUN3)KI;3U:-:Q5#::D/#,(PBF0Q1L8_J)G169
MXPS+Q4A4<C;HG9N10G^954+N'D,8N7W]!)?#5%!92P,!K;W/FW.![1^!K9>Y
M)-R#XJA/YW,WVLTW"%6C,EAMXHT>,!S%XE9V"\6^0;.BFE813+$A@!$/)N+O
MUDN<11\1\BT-YQY/;; WJN>746I+4L%J"M>QZ08L02*W)<?#8\QAAL\6BACE
MD*EI(I1Y">)Y>QU;R!&20JHJRDD@D![%O3:;$#@8%4)*@)8F0>"S08>/UZLL
M1R:5TC-8G0-D,D\G.6)N+\9V\<6S_L !Q!.WK;?;WUD*J#-9L5G<$@LT?I^?
M.V)??.&?=RU7 :%[<ID"62Q1MH9) NW)'AD;D75B"0VR\?;?.X'Q$H2O-YA2
M1.H$ ;N+-$LVWOAS]QTW\F]_.?%ETQGS$Z1TI9GB4!N<3.5;B_!5!Y<#]I=>
M).X)'Q[J5!F*:E+&H &P)&S1\]XQ-#,8_P '[.%]G=4Z2TSE)J]G%+S>3B)2
MZR0<]FY15X=F*I'&OD8'B#_ H._N]E*=7/)93A.ZO$1%NH<AF?=H?$E""VYX
MO(^>.U?N?C'D-<0Q^$ (B% BE#[;BB[E3Q(V!7?^OSO;_P!(2#JUR)WF"PY-
MO2+VP,O9BW#V=^ U]F$8E[6FM+YHO<J31U;\H,AXA64K('53)]HY*2 0NP_A
M!/L=!16KT>1R[FY<SU/SZX,P^GW^UOSG,7IV6EB#BFR4.4\C,((GX+P/L)&R
M'T$,94'<'WOZ(]]4<Q4K5*_>@."I))!80 ;N'L;_ %NO/Z?OQ[XK/K+M[/0S
M%N?'5YC#(WT]AE)#47+LWB !(C$;*)  H$@";[[';L^S^U45J(I5(53 W^(E
MPX-R?#!VYW-?,(*PD#;4?IB$POU&&RM"&7D(KEA;DD]@[RBTX ,57B7=H4D5
M3821E1-^:)Z ZN5^Z706H$.! $Q >P 9X9WW+L, 13T'47< \;Q$WM>_FSOO
M5SK?P^.R42GR^!:TDT6WDC6%&\1))^#M[ !(]';^7)Y%AGE!X<VYX_+]CC2J
MMW*?0/N+0X/U._D<5II6TQV=O16;^042O',!/6*U/)%&7D^G:/C KRI%+9E
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M8_)W'D#OZ8T9;F4SE(V:N3LV5F,LM>C!8L59#O)$!61XY(5C==BLJSKMR>,
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MM(XG$)%-G)'N91!"889AY)*O@//:,R%E@(.P8$"1MMS[(Z%6S=7-JT95TTC
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MJJ D+*4 )2^@%AJ 3!AW!@%^,7*.72X8$SR>L^HY MP[O"+MY^=18O3M%V3
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M 868%V!Z"I2J!-9"REP-7A"F8,0'+<DWV]\-I=#9C,PPO7Q]2S<JQQUK+7+
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M6'OBQ1@C4K47N/W-VV:YMA/:RHY/3^LG_LK7JM@M$JU6,D-)H@9/KI$=HA+
MRA8BT0?B[(=V!W&IV2JEF\F %"FM%, I47*B0S0S'CSZ8J5U=S64IBH*42&A
M@>2=Q9I^HP;ZM:OFM(T9WA7S2QR5KNTA#<((C&83#P9>3B0.'WY #;WMOU4R
M54T<Y7I:"1WL,0')AYDV Z;X55!6D5GTA+#3<L2\D,.EMGP+]OLA^4J((T6&
M&-$#0&3RN*Z#@GEB9$.Z\-F^X^-R%(;?<WNTZ KTO[3J"G9[/JM)>9X^34*H
M6T 2-Q<LYM=S9[DX=V1PVF4G:>S<%:Q-3BR$<:P!XW,X#*C.9%$7(@@DAA\
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MD&DB(\C>BI4*=Q9S)_PF8JYV@6IJ<=T 7&\DP;D !(;T!P0J357K 9BS78/
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M*G,D#@NXCGVCRP_<"<AKS1%^">:6Q;PLBVQ9DF:S(:\BA) K2NS11+QC:-%
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MB>H?VP@J]S*MJ&UD&,&3CB288U7B-FU+D(9$:'QX[ZA4>DQW7[UAE&W)GEW
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MM '_ (@68NQ\]O(L UF;!OKO*ZBKQH]CR/9H"C)(J2J0M?PA( >#!7'B</\
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M?))%=LP/&!;GY1@^#8RP11B9G>)O,QD !X;@]6.S\U010":Q%.HPT@@N180
M6)LQ,./4954W +[>T@F "6/^'PP] Z'U5J:E3@T]B5G$-*WDY9&8PK4M_F*\
M:OZBP5I+1C>P3M)O./([+PCW.3VAGLM2417JBFIPR5.3I/PEP#=GW#%@3<6:
M84M(+3,1L;;;3;;&YB=#PMJ/+G6E>=Y\-A)7;'12E<EDK<]MHJU:D&>2&;R6
M(FE^HCD:.IX@L3;,-Z]7M+N<M37EFJIK*4DD6 2$ER[&[!F&^Q83%-1(\)/D
M1ZO(YZRWGAO8.OGM./-3FBGUAE;V1DCQE,LSOAL?+$SU*;>2*1)*]>:=W7R
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M%\(,\B.+?/:;X^BNE,19R/X3=,XZ=G:=8S,Q;8R*M?45]PI#>,#C&JJ 0NP
M'H^SPF>J@=O5UI,&HEAYI#W$<ES[XM4O]O<"03;K_A^'Z"I$E&9,H&2W8\E=
M#"\4H BFFCE$D<O#B&+E08OT3P5?9!/L=/W@739CXA]1Q>[-'6<!2W>* X)Y
MG@>I;<OUP4VL\TM"FF1EKU17*5ZTEB5$#N'DF-<<OD@A_8!#*H(]$]5LOEOX
M>HI8!.O5T^*WD+;S@HDAF C=NK<^IW$&PP#T&LQ9$1\9IEBA81#R":1C]5*Z
M3\P1(XB(5XP%#$-Q! '6E4+98^HBSD=+3N]^+8IJ_P#>+W<MYF]KBS.9?83V
MUKF]58BQAQ2R#K]9 E[*/D(YXXY8Y8TD\+AR7=F#\HY8YV4%0'4[]+L_+4,Q
M345) *4C^EYF1L)< 3Q?!JGQJG<\Q$_8O:;8DLFU+4&FDH2XT19F2::])F4L
MB06*SP\8:'TX' *-UXOY%^XD$[_(J9%'.Z4$:0&T;.%'Q.-U)(#=!/Q8KK+&
M>#(;?RCD='M&%JUN?%T#-=,..-*&:S;KR)&+58H#:E=IE(-E$C41JX.Q?]/<
MD'K<U!9(<G4DN9;8<MY]=YF"G8.W :_0[\^6Y#$.Y\'E,5JK2]?',T+8K*U&
MF :"%/(N1AEB9I+7(.)G*HRAYHU!V"2K(%0\U56,C7-1Y<'=HGT!/R@C%RD'
M!!W> [@M;J]NK]8WM,=FM5:<J9W$S3_FF%6*C#I\^#Z*VTH@1++7;DEV=9BG
MID\5>/\ 3559F<G<>;[8H5Y@,[B8W(M,[QTC!*% S%]N6N8 ^0?G?#>Q7;_2
M6G\5-6>NT]I13R)EE624P6('XI-% XL@!W'N0O%[^Y54>^L)>?K@D4R= /A%
MF#DLYD7Z^NTUT1J5827-S8?/Y#;!?A,/:QD4L=.6G >*?3 1NMJ17 DD^ID#
MV&)EWW/H[C8<5V ZKU:]2N0:A)*01RQ(?R_Q%L20@(!;[AM][]=^N)C$8ZIF
MK4=2'!6[\U"96N9C("1L9#: /**)79!:6'DI4F)@FVP 8#:O5J&FA2@;$ =?
M$WI<P=YOB?,/U&WRL>(VXP>4=#8Z*>Q9REJ7,3S.65;"@5JX+$^.&(!24&_%
M>1&R@#;<;]51F@TJOL!U/6?U&(DEX#]7^_S_ "P61UX:\2PP(L,2+Q6.(<$W
MV_B*KMN=A^YVV_;?J'?@;$6 X'%IPVE1%P6F0.?7G@^V(>V8Q'Z'$@$\5_AW
M]D;;GEL=@3[W&YZ=*@I0+W?Y./I/KAP\O/'[_2PMCTU%?K8KM9J3(6Y(8Z]6
M&629Y@"B(MRLA9@3\$-L?ZD=3J(55J!"8*@ W5G:S\\>1P^*H]VI:6H=#T;>
M+X"K#3>-6A"*T<E.P+,'WLWVA1++)&-]S'M\[+O<[.-:AGZ&64[**G9_Z4*5
MY3IMY1AWT^(7 /79BWIY3RSX0VB-<&MKRG-:D9I0\ FF:=9!)5L<$E#&(-$Z
MJ65%^[< <6',$]==VOV<*N30I@6V#M^1$-#07L^*=&L>_.Q-P=_U#R&%S."O
MO+@+VB=48[*X^2G+#G:MA+"P2_4D57D+QP31O&JQ2M%)%)'(&V=T! /57L;,
M"O14@W#$$L>@DO W!V<1@U64L"T^]_.7(#"X)N<1O9CN$FGM2M2M!S6NV8#+
M9F=XHTAF$AEJ"$)N9XQ*I\G(H^P(V;UU/M[L[O\ *TEM8F'X6?66M/I@>7J.
MLT]A#]5!_6X+>6!'NVJ8W63L9+3/':4Q/!*Z>24.\M7ZAW;]>JT#QSF*8F,C
MB"1Z/5[L.D@Y3NE@%-,!G9O$2#\@SPW)88A5'<K4L!M;1%TCWWN_[ZV,U;+C
M,70R9R,.;Q-^SD*<U*"9X[U6-JX6&P5GYQ1P?42 K(NP9D91Z(/5Q66I]Z0E
M.E:?$E3#228T@N]@> Q?D :JFH:;ZH:Q# <FW6?H,)3*YJQC;&0N5(8I8\I;
MIFI+Y'@GKW@\96U#-7,L<C+%$8W*5U/ N"[!BJ[J**>X2Q^$;@6Z@@&>7N'O
M?/K.#;B7<6V:-V.WJ89VF9-1WL'?S-#&2YNBDC5\AXG^LCJS(JA/K*23H29'
M97@4%R^XDY;$Q)C9W^'HU4@J2")V<@N(+-!NWN[8M/X7;H/UV+EIC@/!!L]V
M7U-%IW14DM"E;U;JJ=TREVA#8%2M0NVWDJ<6@=%/TF*@L3I((YO)P,A0-)'U
MQW;0&9S*E)#(2E  ,@A*!,F']-@[XM4I0):\GVB+#RN]\3V'T_D,UE*%ES6:
MQ0G>KD<1' 9:J1Q3,*@%\QM+(E=(P]E@0D+L21(SD#*7FN[I)HRR22(@.S$V
M&WEY7Q809/ISM]_I;%G=,Z7K8%9+4_T]K*W)VGLVXXA%Q+#BD,2[EDACA"P@
M;[R*@=@"2.J!S(6L(#^(L?6Q8WF>K06Q)3L;,UIGGANF"$OQ.Y "@;$@[#Y)
M4!3Z'H[$\O9V/[]% T[N.2;-#=/V9L#)U6$O8#\]_;UQJV '5@?2*5,>W^N6
M_B+#]@I^/YG^8ZBJQ$  C2V[O^_'KAT"0;W?I:W7]<1TVXB()WV]#UMZ]^NH
M"Z?,?7!?SPJ.^'_F4UI_^=: _P#WYA>NC_#_ /\ &^S_ /[/:/\ TW,XX_\
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M8?ZN+[W26J\<@BA5^+K+!*$F/C=PK!QUH',G*4DA%!!*@$Z] !GPDDL"#/)
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M).J;\(4]*H(Y?  BK-)J!DZ0P;:/MB#_ )Q7))W/J7P?IH# >6&SD*L=ZU7
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MQ[5[<%S)Q,L$ILSPH_"LT^TTD=A91:4R2FO$.$@=VY[DC=MB-1>936"5.EB
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M\+&E.H 8+N1QW'[_ /#IB7"@[LQ'EO;8?YPL04VP9O?L[^M_?]/7S[_W]#
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;HTE!"]65S-'-4F44K !J44!8TRC4 02"/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345409085448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-4/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Consonance-HFW Acquisition Corp.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">AMENDMENT NO. 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001824893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345407522392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 774,931<span></span>
</td>
<td class="nump">$ 987,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">633,825<span></span>
</td>
<td class="nump">790,341<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">1,408,756<span></span>
</td>
<td class="nump">1,777,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Cash and marketable securities held in Trust Account</a></td>
<td class="nump">92,026,912<span></span>
</td>
<td class="nump">91,997,501<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">93,435,668<span></span>
</td>
<td class="nump">93,775,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">986,585<span></span>
</td>
<td class="nump">290,148<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">986,585<span></span>
</td>
<td class="nump">290,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">2,601,180<span></span>
</td>
<td class="nump">3,404,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_DeferredOfferingCostsNoncurrent', window );">Deferred underwriting fee payable</a></td>
<td class="nump">3,220,000<span></span>
</td>
<td class="nump">3,220,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">6,807,765<span></span>
</td>
<td class="nump">6,914,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A ordinary shares subject to possible redemption, 8,186,086 shares at redemption value</a></td>
<td class="nump">81,627,900<span></span>
</td>
<td class="nump">81,860,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholder's Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">7,354,918<span></span>
</td>
<td class="nump">7,121,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,355,292)<span></span>
</td>
<td class="num">(2,122,328)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholder's Equity</a></td>
<td class="nump">5,000,003<span></span>
</td>
<td class="nump">5,000,007<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">93,435,668<span></span>
</td>
<td class="nump">93,775,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent', window );">Current liabilities - accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholder's Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholder's Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered, excluding offering costs (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_AccruedLiabilitiesExcludingOfferingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_DeferredOfferingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_DeferredOfferingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345409130664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="nump">8,162,790<span></span>
</td>
<td class="nump">8,186,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value, (per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value, (per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">1,471,210<span></span>
</td>
<td class="nump">1,447,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">1,471,210<span></span>
</td>
<td class="nump">1,447,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value, (per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345410905272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENT OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Formation and operational costs</a></td>
<td class="nump">$ 1,065,209<span></span>
</td>
<td class="nump">$ 438,756<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,065,209)<span></span>
</td>
<td class="num">(438,756)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest earned on marketable securities held in Trust Account</a></td>
<td class="nump">23,112<span></span>
</td>
<td class="nump">5,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_TransactionCostsAssociatedWithInitialPublicOffering', window );">Transaction costs associated with initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(107,519)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value of warrant liability</a></td>
<td class="nump">802,834<span></span>
</td>
<td class="num">(1,573,554)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on marketable securities held in Trust Account</a></td>
<td class="nump">6,299<span></span>
</td>
<td class="num">(8,391)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">832,245<span></span>
</td>
<td class="num">(1,683,572)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(232,964)<span></span>
</td>
<td class="num">(2,122,328)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=chfw_ClassOrdinarySharesSubjectForRedemptionMember', window );">Class A ordinary shares subject to possible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest earned on marketable securities held in Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on marketable securities held in Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,466)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,181,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonredeemablePreferredStockMember', window );">Non-redeemable ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (232,964)<span></span>
</td>
<td class="num">$ (2,122,328)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average shares outstanding</a></td>
<td class="nump">3,747,914<span></span>
</td>
<td class="nump">2,461,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.86)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=chfw_ClassAOrdinarySharesSubjectForRedemptionMember', window );">Class A ordinary shares subject to redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest earned on marketable securities held in Trust Account</a></td>
<td class="nump">$ 20,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on marketable securities held in Trust Account</a></td>
<td class="nump">$ 5,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average shares outstanding</a></td>
<td class="nump">8,186,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_TransactionCostsAssociatedWithInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction costs associated with initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_TransactionCostsAssociatedWithInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=chfw_ClassOrdinarySharesSubjectForRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=chfw_ClassOrdinarySharesSubjectForRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonredeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonredeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=chfw_ClassAOrdinarySharesSubjectForRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=chfw_ClassAOrdinarySharesSubjectForRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345411977592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Class A ordinary </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Class B ordinary </div>
<div>Common Stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Aug. 20, 2020</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the beginning (in shares) at Aug. 20, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">24,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Class B ordinary shares to Sponsor(1) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodValueNewIssues', window );">Sale of Units, net of underwriting discounts, offering costs and warrant liability</a></td>
<td class="nump">$ 86,113,691<span></span>
</td>
<td class="nump">86,112,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of Units, net of underwriting discounts, offering costs and warrant liability (in shares)</a></td>
<td class="nump">9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_SaleOfPrivatePlacementUnitsValue', window );">Sale of Private Placement Units, net of warrant liability</a></td>
<td class="nump">$ 2,844,504<span></span>
</td>
<td class="nump">2,844,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_SaleOfPrivatePlacementUnitsShares', window );">Sale of Private Placement Units, net of warrant liability (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_CommonStockSubjectToPossibleRedemptionValue', window );">Class A ordinary shares subject to possible redemption</a></td>
<td class="num">(81,860,860)<span></span>
</td>
<td class="num">(81,860,042)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (818)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_CommonStockSubjectToPossibleRedemptionShares', window );">Class A ordinary shares subject to possible redemption (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,186,086)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,122,328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,122,328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2020</a></td>
<td class="nump">5,000,007<span></span>
</td>
<td class="nump">7,121,960<span></span>
</td>
<td class="num">(2,122,328)<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,447,914<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(232,964)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(232,964)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Mar. 31, 2021</a></td>
<td class="nump">5,000,003<span></span>
</td>
<td class="nump">7,354,918<span></span>
</td>
<td class="num">$ (2,355,292)<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,471,210<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption', window );">Change in value of Class A ordinary shares subject to redemption</a></td>
<td class="nump">$ 232,960<span></span>
</td>
<td class="nump">$ 232,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption', window );">Change in value of Class A ordinary shares subject to redemption (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_CommonStockSubjectToPossibleRedemptionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of the shares of common stock subject to possible redemption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_CommonStockSubjectToPossibleRedemptionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_CommonStockSubjectToPossibleRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of common stock subject to possible redemption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_CommonStockSubjectToPossibleRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_SaleOfPrivatePlacementUnitsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares sale of private placement units during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_SaleOfPrivatePlacementUnitsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_SaleOfPrivatePlacementUnitsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of sale of private placement units during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_SaleOfPrivatePlacementUnitsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value change in value of class a ordinary shares subject to redemption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_StockIssuedDuringPeriodSharesChangeInValueOfClassAOrdinarySharesSubjectToRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value change in value of class a ordinary shares subject to redemption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_StockIssuedDuringPeriodValueChangeInValueOfClassAOrdinarySharesSubjectToRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_UnitsIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new unit issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_UnitsIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345408930888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of Units, net of underwriting discounts, offering costs and warrant liability (in shares)</a></td>
<td class="nump">9,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Sale of Private Placement Units, net of warrant liability</a></td>
<td class="nump">434,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345411900200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENT OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (232,964)<span></span>
</td>
<td class="num">$ (2,122,328)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_FormationCosts', window );">Payment of formation costs through issuance of Class B ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest earned on marketable securities held in Trust Account</a></td>
<td class="num">(23,112)<span></span>
</td>
<td class="num">(5,892)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(802,834)<span></span>
</td>
<td class="nump">1,573,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_TransactionCostsAssociatedWithInitialPublicOffering', window );">Transaction costs in connection with the initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on marketable securities held in Trust Account</a></td>
<td class="num">(6,299)<span></span>
</td>
<td class="nump">8,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(790,341)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">696,437<span></span>
</td>
<td class="nump">290,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">156,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(212,256)<span></span>
</td>
<td class="num">(933,988)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_CashDepositedInTrustAccount', window );">Investment of cash in Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92,000,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_NetProceedsFromInitialPublicOffering', window );">Proceeds from sale of Units, net of underwriting discounts paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,160,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from sale of Private Placement Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,340,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from promissory note - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of promissory note - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(147,753)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(578,825)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,921,175<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Change in Cash</a></td>
<td class="num">(212,256)<span></span>
</td>
<td class="nump">987,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash &#8211; End of period</a></td>
<td class="nump">774,931<span></span>
</td>
<td class="nump">987,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-Cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption', window );">Initial classification of Class A ordinary shares subject to possible redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,522,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption', window );">Change in value of Class A ordinary shares subject to possible redemption</a></td>
<td class="num">$ (232,960)<span></span>
</td>
<td class="num">(2,429,850)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_InitialClassificationOfWarrantLiability', window );">Initial classification of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,830,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_OfferingCostsPaidBySponsorFromProceedsFromIssuanceOfCommonStockOrdinaryShares', window );">Offering costs paid directly by Sponsor from proceeds from issuance of Class B ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_DeferredUnderwritingFeePayable', window );">Deferred underwriting fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,220,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_CashDepositedInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from cash deposited in trust account.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_CashDepositedInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of change in value of common stock subject to possible redemption, classified as non-cash investing and financing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_DeferredUnderwritingFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of underwriting fee payable deferred during the period, classified as non-cash investing and financing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_DeferredUnderwritingFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_FormationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to formation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_FormationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of initial classification of common stock subject to possible redemption, classified as non-cash investing and financing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_InitialClassificationOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial classification of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_InitialClassificationOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_NetProceedsFromInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public, net of underwriting discounts paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_NetProceedsFromInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_OfferingCostsPaidBySponsorFromProceedsFromIssuanceOfCommonStockOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of offering costs paid directly by Sponsor from proceeds from issuance of common stock during the period, classified as non-cash investing and financing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_OfferingCostsPaidBySponsorFromProceedsFromIssuanceOfCommonStockOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_TransactionCostsAssociatedWithInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction costs associated with initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_TransactionCostsAssociatedWithInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345425423464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Consonance-HFW</div> Acquisition Corp. (the &#8220;Company&#8221;) is a blank check company incorporated as a Cayman Islands exempted company on August&#160;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (&#8220;Business Combination&#8221;). </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not limited to a particular industry or geographic region for purposes of completing a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2021, the Company had not commenced any operations. All activity through March&#160;31, 2021 relates to the Company&#8217;s formation, the initial public offering (&#8220;Initial Public Offering&#8221;), which is described below, and subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income from the proceeds derived from the Initial Public Offering. </div><br/></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration statement for the Company&#8217;s Initial Public Offering became effective on November&#160;18, 2020. On November&#160;23, 2020, the Company consummated the Initial Public Offering of 8,000,000 units (the &#8220;Units&#8221; and, with respect to the Class&#160;A ordinary shares included in the Units sold, the &#8220;Public Shares&#8221;), at $10.00 per Unit, generating gross proceeds of $80,000,000 which is described in Note 3. </div><br/></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the consummation of the Initial Public Offering, the Company consummated the sale of 410,000 units (the &#8220;Private Placement Units&#8221;) at a price of $10.00 per Private Placement Unit in a private placement to Consonance Life Sciences (the &#8220;Sponsor&#8221;), generating gross proceeds of $4,100,000, which is described in Note 4. </div><br/></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">Following the consummation of the Initial Public Offering on November&#160;23, 2020, an amount of $80,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Units was placed in a trust account (the &#8220;Trust Account&#8221;) and invested in U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;), with a maturity of 185&#160;days or less, or in any open-ended investment company that holds itself out as a money market fund meeting certain conditions of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;2a-7</div> of the Investment Company Act, as determined by the Company, until the earlier of: (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the funds in the Trust Account to the Company&#8217;s shareholders, as described below. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;1, 2020, the underwriters fully exercised their over-allotment option, resulting in an additional 1,200,000 Units issued for an aggregate amount of $12,000,000. In connection with the underwriters&#8217; full exercise of their over-allotment option, the Company also consummated the sale of an additional 24,000 Private Placement Units at $10.00 per Private Placement Unit, generating total proceeds of $12,240,000. A total of $12,000,000 was deposited into the Trust Account, bringing the aggregate proceeds held in the Trust Account to $92,000,000. </div><br/></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs amounted to $5,658,864, consisting of $1,840,000 of underwriting fees, $2,800,000 of deferred underwriting fees and $598,864 of other offering costs. </div><br/></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward completing a Business Combination. The Company must complete its initial Business Combination with one or more target businesses that together have a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding any deferred underwriting commissions held in the Trust Account and taxes payable on the interest earned on the Trust Account) at the time of the agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act. On April&#160;15, 2021, the Company has entered into a Business Combination Agreement with Surrozen, Inc., see Note 10. Subsequent Events &#8212; Business Combination Agreement and PIPE Financing, however, There is no assurance that the Company will be able to successfully effect a Business Combination. </div><br/></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will provide its shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a shareholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The shareholders will be entitled to redeem their shares for a pro&#160;rata portion of the amount held in the Trust Account (initially $10.00 per share), calculated as of two business days prior to the completion of a Business Combination, including any pro&#160;rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; page-break-before: always;"></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#8217;s financial position and/or effecting our Business Combination, the specific impact is not readily determinable as of the date of the financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Consonance-HFW</div> Acquisition Corp. (the &#8220;Company&#8221;) is a blank check company incorporated as a Cayman Islands exempted company on August&#160;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (&#8220;Business Combination&#8221;). </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not limited to a particular industry or geographic region for purposes of completing a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of December&#160;31, 2020, the Company had not commenced any operations. All activity for the period from August&#160;21, 2020 (inception) through December&#160;31, 2020 relates to the Company&#8217;s formation and the initial public offering (&#8220;Initial Public Offering&#8221;), which is described below. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income from the proceeds derived from the Initial Public Offering. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration statement for the Company&#8217;s Initial Public Offering became effective on November&#160;18, 2020. On November&#160;23, 2020, the Company consummated the Initial Public Offering of 8,000,000&#160;units (the &#8220;Units&#8221; and, with respect to the Class&#160;A ordinary shares included in the Units sold, the &#8220;Public Shares&#8221;), at $10.00 per Unit, generating gross proceeds of $80,000,000 which is described in </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4 </div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the consummation of the Initial Public Offering, the Company consummated the sale of 410,000&#160;units (the &#8220;Private Placement Units&#8221;) at a price of $10.00 per Private Placement Unit in a private placement to Consonance Life Sciences (the &#8220;Sponsor&#8221;), generating gross proceeds of $4,100,000, which is described in </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5. </div></div><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Following the consummation of the Initial Public Offering on November&#160;23, 2020, an amount of $80,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Units was placed in a trust account (the &#8220;Trust Account&#8221;) and invested in U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;), with a maturity of 185&#160;days or less, or in any open-ended investment company that holds itself out as a money market fund meeting certain conditions of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;2a-7</div> of the Investment Company Act, as determined by the Company, until the earlier of: (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the funds in the Trust Account to the Company&#8217;s shareholders, as described below. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;1, 2020, the underwriters fully exercised their over-allotment option, resulting in an additional 1,200,000&#160;Units issued for an aggregate amount of $12,000,000. In connection with the underwriters&#8217; full exercise of their over-allotment option, the Company also consummated the sale of an additional 24,000 Private Placement Units at $10.00 per Private Placement Unit, generating total proceeds of $12,240,000. A total of $12,000,000 was deposited into the Trust Account, bringing the aggregate proceeds held in the Trust Account to $92,000,000. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs amounted to $5,658,864, consisting of $1,840,000 of underwriting fees, $3,220,000 of deferred underwriting fees and $598,864 of other offering costs. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward completing a Business Combination. The Company must complete its initial Business Combination with one or more target businesses that together have a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding any deferred underwriting commissions held in the Trust Account and taxes payable on the interest earned on the Trust Account) at the time of the agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will provide its shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a shareholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The shareholders will be entitled to redeem their shares for a pro&#160;rata portion of the amount held in the Trust Account (initially $10.00 per share), calculated as of two business days prior to the completion of a Business Combination, including any pro&#160;rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#8217;s financial position and/or search for a target company, the specific impact is not readily determinable as of the date of the financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345409223016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 8 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited condensed financial statements should be read in conjunction with the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K/A</div> for the year ended December&#160;31, 2020 as filed with the SEC on May&#160;14, 2021. The interim results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2021 or for any future periods. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the condensed financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of March&#160;31, 2021 and December&#160;31, 2020. </div></div></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Marketable Securities Held in Trust Account </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2021 and December&#160;31, 2020, substantially all of the assets held in the Trust Account were held in U.S. Treasury Bills.</div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Warrant Liability </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification.</div></div> <div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital at the time of issuance or modification. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> gain or loss on the statements of operations. The fair value of the warrants was determined by using the publicly traded price on March&#160;31, 2021 (see Note 9). </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Class&#160;A Ordinary Shares Subject to Possible Redemption </div></div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class&#160;A ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221; Class&#160;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. The Company&#8217;s Class&#160;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, Class&#160;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders&#8217; equity section of the Company&#8217;s balance sheet. </div></div></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Income Taxes </div></div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the condensed financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</div></div><br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">ASC </div>740<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s condensed financial statements and prescribes a recognition threshold and measurement process for condensed financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be </div><div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were </div>no<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> unrecognized tax benefits and </div>no<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> amounts accrued for interest and penalties as of March&#160;</div>31<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> and December&#160;</div>31<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.</div><br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United&#160;States. As such, the Company&#8217;s tax provision was zero for the period presented. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Net Loss Per Ordinary Share </div></div></div></div></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"> </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period, excluding ordinary shares subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of</div></div><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> 3,211,334 shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s statement of operations includes a presentation of loss per share for ordinary shares subject to possible redemption in a manner similar to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method of loss per share. Net loss per ordinary share, basic and diluted, for Class&#160;A ordinary shares subject to possible redemption is calculated by dividing the proportionate share of income or loss on marketable securities held by the Trust Account by the weighted average number of Class&#160;A ordinary shares subject to possible redemption outstanding since original issuance. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Net loss per share, basic and diluted, for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> ordinary shares is calculated by dividing the net income (loss), adjusted for income or loss on marketable securities attributable to Class&#160;A ordinary shares subject to possible redemption, by the weighted average number of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> ordinary shares outstanding for the period. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> common stock includes Founder Shares and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> ordinary shares as these shares do not have any redemption features. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> ordinary shares participate in the income or loss on marketable securities based on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> shares&#8217; proportionate interest.</div> <div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="width:84%;"></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three&#160;Months</div><br/> <div style="font-weight:bold;display:inline;">Ended</div><br/> <div style="font-weight:bold;display:inline;">March&#160;31,</div><br/> <div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Class&#160;A ordinary Shares subject to possible redemption</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator: Earnings allocable to Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Interest earned on marketable securities held in Trust Account</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">20,507</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain on marketable securities held in Trust Account</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">5,589</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net income attributable</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">26,096</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator: Weighted Average Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1pt;"><td style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td><td colspan="4" style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Basic and diluted weighted average shares outstanding, Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">8,186,086</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income per share, Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">0.00</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-Redeemable</div> Ordinary Shares</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator: Net Loss minus Net Earnings</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net loss</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(232,964</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">)&#160;</div></td></tr><tr style="font-size: 1pt;"><td style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td><td colspan="4" style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Net income allocable to Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(26,096</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-Redeemable</div> Net Loss</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(259,060</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">)&#160;</div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Denominator: Weighted Average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> ordinary shares</div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted weighted average shares outstanding, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-redeemable</div> ordinary shares</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">3,747,914</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net loss per share, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> ordinary shares</div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(0.07</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">)&#160;</div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div>   <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Fair Value Measurements </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:9%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:9%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:9%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Derivative Financial Instruments </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &#8220;Derivatives and Hedging&#8221;. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-valued</div> at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> based on whether or not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">net-cash</div> settlement or conversion of the instrument could be required within 12 months of the balance sheet date.</div>  <div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s condensed financial statements. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In August 2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Debt &#8212; Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40)</div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;)</div> to simplify accounting for certain financial instruments. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#8217;s own equity. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> amends the diluted earnings per share guidance, including the requirement to use the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">if-converted</div> method for all instruments. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> is effective January&#160;1, 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January&#160;1, 2021. The Company is currently assessing the impact, if any, that ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> would have on its financial position, results of operations or cash flows. </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div></div>  <div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three&#160;months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December&#160;31, 2020. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Marketable Securities Held in Trust Account </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2020, substantially all of the assets held in the Trust Account were held in U.S. Treasury Bills. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Warrant Liability </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815,&#160;Derivatives and Hedging&#160;(&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> gain or loss on the statements of operations. The fair value of the warrants was estimated using a binomial lattice simulation methodology (see Note 9). </div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Class&#160;A Ordinary Shares Subject to Possible Redemption </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class&#160;A ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221; Class&#160;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. The Company&#8217;s Class&#160;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, Class&#160;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders&#8217; equity section of the Company&#8217;s balance sheet. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December&#160;31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. </div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the period presented. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Net Income (Loss) Per Share </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per share is computed by dividing net income by the weighted-average number of ordinary shares outstanding during the period, excluding ordinary shares subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 3,211,334 shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. </div></div> <div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company&#8217;s statement of operations includes a presentation of income (loss) per share for ordinary shares subject to possible redemption in a manner similar to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method of income (loss) per share. Net income (loss) per ordinary share, basic and diluted, for ordinary shares subject to possible redemption is calculated by dividing the proportionate share of income or loss on marketable securities held by the Trust Account by the weighted average number of ordinary shares subject to possible redemption outstanding since original issuance. </div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Net income (loss) per share, basic and diluted, for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> ordinary shares is calculated by dividing the net income (loss), adjusted for income or loss on marketable securities attributable to ordinary shares subject to possible redemption, by the weighted average number of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> ordinary shares outstanding for the period. </div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> ordinary shares include Founder Shares and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> ordinary shares as these shares do not have any redemption features. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> ordinary shares participate in the income or loss on marketable securities based on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> shares&#8217; proportionate interest. </div>  <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:85%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:8%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the&#160; Period</div></div></div><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">from</div></div></div><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">August&#160;21,&#160; 2020</div></div></div><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Inception)</div></div></div><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Through</div></div></div><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Ordinary shares subject to possible redemption</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator: Earnings allocable to Ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Interest earned on marketable securities held in Trust Account</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,243</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain (loss) on marketable securities held in Trust Account</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(7,466</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net income attributable to Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(2,223</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator: Weighted Average Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Basic and diluted weighted average shares outstanding, Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,181,335</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share, Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">0.00</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:84%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:5%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-Redeemable</div> Common Stock</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator: Net Loss minus Net Earnings</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net loss</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(2,122,328</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Add: Net loss allocable to Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">2,223</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-Redeemable</div> Net Loss</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(2,120,105</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Denominator: Weighted Average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> ordinary shares</div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"></td><td style="vertical-align:bottom;"></td><td style="vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted weighted average shares outstanding, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-redeemable</div> ordinary shares</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,461,095</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net loss per share, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> ordinary shares</div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(0.86</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</div>  <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div>  <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. </div></div>  <div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying financial statements. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345439176872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INITIAL PUBLIC OFFERING<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_InitialPublicOfferingAbstract', window );"><strong>INITIAL PUBLIC OFFERING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_InitialPublicOfferingTextBlock', window );">INITIAL PUBLIC OFFERING</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 3. INITIAL PUBLIC OFFERING </div></div></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;">Pursuant to the Initial Public Offering, the Company sold 9,200,000&#160;Units, inclusive of 1,200,000 Units sold to the underwriters on December&#160;1, 2020 upon the underwriters&#8217; election to fully exercise their over-allotment option, at a purchase price of $10.00 per Unit. Each Unit consists of one Class&#160;A ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of one redeemable warrant (&#8220;Public Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase one Class&#160;A ordinary share at an exercise price of $11.50 per share, subject to adjustment (see Note 8). <br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;1, 2020, the underwriters fully exercised their over-allotment option, resulting in an additional 1,200,000 Units issued for an aggregate amount of $12,000,000. In connection with the underwriters&#8217; full exercise of their over-allotment option, the Company also consummated the sale of an additional 24,000 Private Placement Units at $10.00 per Private Placement Unit, generating total proceeds of $12,240,000. A total of $12,000,000 was deposited into the Trust Account, bringing the aggregate proceeds held in the Trust Account to $92,000,000. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 4. INITIAL PUBLIC OFFERING </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the Initial Public Offering, the Company sold 8,000,000&#160;Units at a purchase price of $10.00 per Unit. Each Unit consists of one Class&#160;A ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of one redeemable warrant (&#8220;Public Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase one Class&#160;A ordinary share at an exercise price of $11.50 per share, subject to adjustment (see Note 8). </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;1, 2020, the underwriters fully exercised their over-allotment option, resulting in an additional 1,200,000&#160;Units issued for an aggregate amount of $12,000,000. In connection with the underwriters&#8217; full exercise of their over-allotment option, the Company also consummated the sale of an additional 24,000 Private Placement Units at $10.00 per Private Placement Unit, generating total proceeds of $12,240,000. A total of $12,000,000 was deposited into the Trust Account, bringing the aggregate proceeds held in the Trust Account to $92,000,000 (see Note 9). </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_InitialPublicOfferingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_InitialPublicOfferingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_InitialPublicOfferingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on information about initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_InitialPublicOfferingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345452859592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRIVATE PLACEMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PrivatePlacementAbstract', window );"><strong>PRIVATE PLACEMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PrivatePlacementTextBlock', window );">PRIVATE PLACEMENT</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 4. PRIVATE PLACEMENT </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">Simultaneously with the consummation of the Initial Public Offering, the Sponsor purchased an aggregate of 410,000 Private Placement Units at a price of $10.00 per Private Placement Unit, for an aggregate purchase price of $4,100,000. On December&#160;1, 2020, as a result of the underwriters&#8217; election to fully exercise their over-allotment option, the Sponsor purchased an additional 24,000 Private Placement Units, at a price of $10.00 per Private Placement Unit, or $240,000 in the aggregate (see Note 8). Each Private Placement Unit consists of one Class&#160;A ordinary share (&#8220;Private Placement Share&#8221; or, collectively, &#8220;Private Placement Shares&#8221;) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of one redeemable warrant (each, a &#8220;Private Placement Warrant&#8221;). Each whole Private Placement Warrant is exercisable for one Class&#160;A ordinary share at a price of $11.50 per share, subject to adjustment (see Note 8). The proceeds from the sale of the Private Placement Units were added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Units and all underlying securities will expire worthless. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 5. PRIVATE PLACEMENT </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Simultaneously with the consummation of the Initial Public Offering, the Sponsor purchased an aggregate of 410,000 Private Placement Units at a price of $10.00 per Private Placement Unit, for an aggregate purchase price of $4,100,000. On December&#160;1, 2020, as a result of the underwriters&#8217; election to fully exercise their over-allotment option, the Sponsor purchased an additional 24,000 Private Placement Units, at a price of $10.00 per Private Placement Unit, or $240,000 in the aggregate. Each Private Placement Unit consists of one Class&#160;A ordinary share (&#8220;Private Placement Share&#8221; or, collectively, &#8220;Private Placement Shares&#8221;) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of one redeemable warrant (each, a &#8220;Private Placement Warrant&#8221;). Each whole Private Placement Warrant is exercisable for one Class&#160;A ordinary share at a price of $11.50 per share, subject to adjustment (see Note 8). The proceeds from the sale of the Private Placement Units were added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Units and all underlying securities will expire worthless. </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_PrivatePlacementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_PrivatePlacementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_PrivatePlacementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on information about private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_PrivatePlacementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345426128712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 5. RELATED PARTY TRANSACTIONS </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Founder Shares </div></div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;4, 2020, the Sponsor<div style="display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;">paid $</div>25,000<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"> to cover certain offering and formation costs of the Company in consideration for </div>3,593,750<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"> Class&#160;B ordinary shares. On October&#160;</div>8<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"> and November&#160;</div>10<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;">, </div>718,750<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"> and </div>575,000<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"> Class&#160;B ordinary shares were contributed back to the Company for </div>no<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"> consideration, respectively, resulting in there being </div>2,300,000<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"> Class&#160;B ordinary shares (the &#8220;Founder Shares&#8221;) being issued and outstanding. The Founder Shares include an aggregate of up to </div>300,000<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;"> shares subject to forfeiture by the Sponsor to the extent that the underwriters&#8217; over-allotment is not exercised in full or in part, so that the number of Founder Shares will collectively represent </div>20<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;">% of the Company&#8217;s issued and outstanding shares upon the completion of the Initial Public Offering (not including the Private Placement Shares).&#160;On December&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%;;display:inline;">, the underwriters fully exercised their over-allotment option, therefore there are no Founder Shares subject to forfeiture.</div><br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;">The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of: (A)&#160;one year after the completion of a Business Combination; and (B)&#160;subsequent to a Business Combination, (x)&#160;if the closing price of the Class&#160;A ordinary shares equals or exceeds $12.00 per share (as adjusted for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share&#160;sub-divisions,&#160;share</div> capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">any&#160;30-trading&#160;day</div> period commencing at least 150&#160;days after a Business Combination, or (y)&#160;the date on which the Company completes a liquidation, merger, amalgamation, share exchange, reorganization or other similar transaction that results in all of the Company&#8217;s shareholders having the right to exchange their Class&#160;A ordinary shares for cash, securities or other property.</div> <div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Administrative Services Agreement </div></div></div><br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company entered into an agreement, commencing on November&#160;18, 2020 through the earlier of the Company&#8217;s consummation of a Business Combination and its liquidation, to pay the Sponsor a total of up to $55,000 per month for office space and administrative support services. For the period three months ended March&#160;31, 2021, the Company incurred and paid $165,000 of such fees. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Related Party Loans </div></div></div><br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company&#8217;s directors and officers may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into Private Placement Units of the post-Business Combination entity at a price of $10.00 per Private Placement Unit. The Private Placement Units would be identical to the Units. As of March&#160;31, 2021 and December&#160;31, 2020, the Company had no outstanding borrowings under the Working Capital Loans. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 6. RELATED PARTY TRANSACTIONS </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Founder Shares </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;4, 2020, the Sponsor paid $25,000 to cover certain offering and formation costs of the Company in consideration for 3,593,750 Class&#160;B ordinary shares. On October&#160;8, 2020 and November&#160;10, 2020, 718,750 and 575,000 Class&#160;B ordinary shares were contributed back to the Company for no consideration, respectively, resulting in there being 2,300,000 Class&#160;B ordinary shares (the &#8220;Founder Shares&#8221;) being issued and outstanding. The Founder Shares include an aggregate of up to 300,000 shares subject to forfeiture by the Sponsor to the extent that the underwriters&#8217; over-allotment is not exercised in full or in part, so that the number of Founder Shares will collectively represent 20% of the Company&#8217;s issued and outstanding shares upon the completion of the Initial Public Offering (not including the Private Placement Shares).&#160;On December&#160;1, 2020, the underwriters fully exercised their over-allotment option, therefore there are no Founder Shares subject to forfeiture. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until the earlier to occur of: (A)&#160;one year after the completion of a Business Combination; and (B)&#160;subsequent to a Business Combination, (x)&#160;if the closing price of the Class&#160;A ordinary shares equals or exceeds $12.00 per share (as adjusted for share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-divisions,</div> share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period commencing at least 150&#160;days after a Business Combination, or (y)&#160;the date on which the Company completes a liquidation, merger, amalgamation, share exchange, reorganization or other similar transaction that results in all of the Company&#8217;s shareholders having the right to exchange their Class&#160;A ordinary shares for cash, securities or other property. </div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Administrative Services Agreement </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company entered into an agreement, commencing on November&#160;18, 2020 through the earlier of the Company&#8217;s consummation of a Business Combination and its liquidation, to pay the Sponsor a total of up to $55,000 per month for office space and administrative support services. For the period from August&#160;21, 2020 (inception) through December&#160;31, 2020, the Company incurred and paid $55,000 of such fees. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Promissory Note&#160;&#8212;&#160;Related Party </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;4, 2020, the Company issued an unsecured promissory note to the Sponsor (the &#8220;Promissory Note&#8221;), pursuant to which the Company could borrow up to an aggregate principal amount of $300,000. The Promissory Note was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable on the earlier of (i)&#160;December&#160;31, 2021 or (i)&#160;the consummation of the Initial Public Offering. The outstanding balance under the Promissory Note of $147,753 was repaid at the closing of the Initial Public Offering on November&#160;23, 2020. </div><div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Related Party Loans </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company&#8217;s directors and officers may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into Private Placement Units of the post-Business Combination entity at a price of $10.00 per Private Placement Unit. The Private Placement Units would be identical to the Units. As of December&#160;31, 2020, the Company had no outstanding borrowings under the Working Capital Loans. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345410806552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 6. COMMITMENTS</div><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">&#160;</div></div><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Registration and Shareholder Rights </div></div></div><br/></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to a registration rights agreement entered into on November&#160;18, 2020, the holders of the Founder Shares, Private Placement Units (including securities contained therein) and warrants that may be issued upon conversion of the Working Capital Loans (and any Class&#160;A ordinary shares issuable upon the exercise of the Private Placement Units and warrants that may be issued upon conversion of Working Capital Loans and upon conversion of the Founder Shares) will be entitled to registration rights. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of a Business Combination. However, the registration and shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period. The registration rights agreement does not contain liquidating damages or other cash settlement provisions resulting from delays in registering the Company&#8217;s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.&#160; </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Underwriting Agreement </div></div></div><br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters are entitled to a deferred fee of $0.35 per Unit, or $3,220,000 in the aggregate (see Note 8). The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 7. COMMITMENTS </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Registration and Shareholder Rights </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to a registration rights agreement entered into on November&#160;18, 2020, the holders of the Founder Shares, Private Placement Units (including securities contained therein) and warrants that may be issued upon conversion of the Working Capital Loans (and any Class&#160;A ordinary shares issuable upon the exercise of the Private Placement Units and warrants that may be issued upon conversion of Working Capital Loans and upon conversion of the Founder Shares) will be entitled to registration rights. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of a Business Combination. However, the registration and shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period. The registration rights agreement does not contain liquidating damages or other cash settlement provisions resulting from delays in registering the Company&#8217;s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.&#160; </div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Underwriting Agreement </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters are entitled to a deferred fee of $0.35 per Unit, or $3,220,000 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345413065176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 7. STOCKHOLDERS&#8217; EQUITY </div></div><br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Preference Shares</div></div> <div style="font-weight:bold;display:inline;">&#8212;</div> The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. At March&#160;31, 2021 and December&#160;31, 2020, there were no preference shares issued or outstanding. </div><br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Class</div></div><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">&#160;A ordinary shares</div></div><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">&#8212;</div>The Company is authorized to issue 350,000,000 Class&#160;A ordinary shares, with a par value of $0.0001 per share. Holders of Class&#160;A ordinary shares are entitled to one vote for each share. At March&#160;31, 2021 and December&#160;31, 2020, there were 1,471,210 and 1,447,914 (excluding 8,162,790 and 8,186,086 shares subject to possible redemption) Class&#160;A ordinary shares issued and outstanding, respectively. </div><br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Class</div></div><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">&#160;B ordinary shares</div></div><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">&#8212;</div> The Company is authorized to issue 150,000,000 Class&#160;B ordinary shares, with a par value of $0.0001 per share. Holders of the Class&#160;B ordinary shares are entitled to one vote for each share. At March&#160;31, 2021 and December&#160;31, 2020, there were 2,300,000 Class&#160;B ordinary shares issued and outstanding. </div><br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Only holders of the Class&#160;B ordinary shares will have the right to vote on the election of directors prior to the Business Combination. Holders of Class&#160;A ordinary shares and holders of Class&#160;B ordinary shares will vote together as a single class on all other matters submitted to a vote of the Company&#8217;s shareholders except as otherwise required by law. </div><br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;">The Class&#160;B ordinary shares will automatically convert into Class&#160;A ordinary shares on the first business day following the consummation of a Business Combination at a ratio such that the number of Class&#160;A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, 20% of the sum of (i)&#160;the total number of ordinary shares issued and outstanding (excluding the Private Placement Shares underlying the Private Placement Units) upon completion of the Initial Public Offering, plus (ii)&#160;the sum of the total number of Class&#160;A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of a Business Combination, excluding any Class&#160;A ordinary shares or equity-linked securities exercisable for or convertible into Class&#160;A ordinary shares issued, deemed issued, or to be issued, to any seller in a Business Combination and any Private Placement Warrants issued to the Sponsor, members of the Company&#8217;s founding team or any of their affiliates upon conversion of Working Capital Loans. In no event will the Class&#160;B ordinary shares convert into Class&#160;A ordinary shares at a rate of less than one to one.&#160; </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 8. SHAREHOLDERS&#8217; EQUITY </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Preference shares &#8212;</div></div> The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. At December&#160;31, 2020, there were no preference shares issued or outstanding. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Class</div></div><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">&#160;A ordinary shares &#8212;</div></div> The Company is authorized to issue 350,000,000 Class&#160;A ordinary shares, with a par value of $0.0001 per share. Holders of Class&#160;A ordinary shares are entitled to one vote for each share. At December&#160;31, 2020, there were 1,447,914 Class&#160;A ordinary shares issued and outstanding, excluding 8,186,086 Class&#160;A ordinary shares subject to possible redemption. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Class</div></div><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">&#160;B ordinary shares &#8212;</div></div> The Company is authorized to issue 150,000,000 Class&#160;B ordinary shares, with a par value of $0.0001 per share. Holders of the Class&#160;B ordinary shares are entitled to one vote for each share. At December&#160;31, 2020, there were 2,300,000 Class&#160;B ordinary shares issued and outstanding. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Only holders of the Class&#160;B ordinary shares will have the right to vote on the election of directors prior to the Business Combination. Holders of Class&#160;A ordinary shares and holders of Class&#160;B ordinary shares will vote together as a single class on all other matters submitted to a vote of the Company&#8217;s shareholders except as otherwise required by law. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Class&#160;B ordinary shares will automatically convert into Class&#160;A ordinary shares on the first business day following the consummation of a Business Combination at a ratio such that the number of Class&#160;A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, 20% of the sum of (i)&#160;the total number of ordinary shares issued and outstanding (excluding the Private Placement Shares underlying the Private Placement Units) upon completion of the Initial Public Offering, plus (ii)&#160;the sum of the total number of Class&#160;A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of a Business Combination, excluding any Class&#160;A ordinary shares or equity-linked securities exercisable for or convertible into Class&#160;A ordinary shares issued, deemed issued, or to be issued, to any seller in a Business Combination and any Private Placement Warrants issued to the Sponsor, members of the Company&#8217;s founding team or any of their affiliates upon conversion of Working Capital Loans. In no event will the Class&#160;B ordinary shares convert into Class&#160;A ordinary shares at a rate of less than one to one.&#160; </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345418571448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantsTextBlock', window );">WARRANT LIABILITY</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 8. WARRANT LIABILITY </div></div><br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a)&#160;30&#160;days after the completion of a Business Combination and (b)&#160;one year from the closing of the Initial Public Offering. The Public Warrants will expire five&#160;years from the completion of a Business Combination or earlier upon redemption or liquidation. </div><br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will not be obligated to deliver any Class&#160;A ordinary shares pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the issuance of the Class&#160;A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating thereto is available, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption is available. </div><br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has agreed that as soon as practicable, but in no event later than 20 business days, after the closing of a Business Combination, it will use its commercially reasonable efforts to file with the SEC a registration statement covering the Class&#160;A ordinary shares issuable upon exercise of the warrants, and the Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of a Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class&#160;A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; if the Class&#160;A ordinary shares are, at the time of any exercise of a warrant, not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement. If a registration statement covering the Class&#160;A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act or another exemption, but will use its best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. </div><br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Redemption of warrants when the price per Class&#160;A ordinary share equals or exceeds $18.00</div>&#8212;Once the warrants become exercisable, the Company may redeem the outstanding Public Warrants (except with respect to the Private Placement Warrants): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $0.01 per Public Warrant; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon not less than 30&#160;days&#8217; prior written notice of redemption to each warrant holder; and </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;">if, and only if, the closing price of the Class&#160;A ordinary shares equals or exceeds $18.00 per share (as adjusted for share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-divisions,</div> share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period ending on the third trading day prior to the date on which notice of the redemption is given to the warrant holders (the &#8220;Reference Value&#8221;). </div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws. </div></div><br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Redemption of Warrants When the Price per Class</div><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">&#160;A Ordinary Share Equals or Exceeds $10.00</div>&#8212;Once the warrants become exercisable, the Company may redeem the outstanding warrants:&#160;</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at $0.10 per warrant upon a minimum of 30&#160;days&#8217; prior written notice of redemption; provided that during such 30 day period holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares, based on the redemption date and the fair market value of the Class&#160;A ordinary shares, that if the warrants are not exercised on a cashless basis or otherwise during such 30&#160;day period, the Company shall redeem such warrants for $0.10 per share; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted for share subdivisions, share dividends, reorganizations, recapitalizations and the like) on the trading day before the Company sends the notice of redemption to the warrant holders; and&#160;</div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 1px; margin-top: 6px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if the Reference Value is less than $18.00 per share (as adjusted for share splits, share dividends, reorganizations, recapitalizations and the like), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exercise price and number of ordinary shares issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with respect to such Public Warrants. Accordingly, the Public Warrants may expire worthless. </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">In addition, if (x)&#160;the Company issues additional Class&#160;A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per Class&#160;A ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y)&#160;the aggregate gross proceeds from such issuances represent more than </div>60<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its Class&#160;A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#8220;Market Value&#8221;) is below $</div>9.20<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to </div>115<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">% of the higher of the Market Value and the Newly Issued Price, and the $</div>10.00<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> and $</div>18.00<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"> per share redemption trigger price will be adjusted (to the nearest cent) to be equal to </div>100<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">% and </div>180<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">% of the higher of the Market Value and the Newly Issued Price, respectively.</div><br/></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the Class&#160;A ordinary shares issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30&#160;days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable,</div> except as described above, so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 9. Warrants </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Warrants &#8212;</div></div> Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a)&#160;30&#160;days after the completion of a Business Combination and (b)&#160;<div style="display:inline;">one</div> year from the closing of the Initial Public Offering. The Public Warrants will expire <div style="display:inline;">five</div>&#160;years from the completion of a Business Combination or earlier upon redemption or liquidation. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will not be obligated to deliver any Class&#160;A ordinary shares pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the issuance of the Class&#160;A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating thereto is available, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption is available. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has agreed that as soon as practicable, but in no event later than 20 business days, after the closing of a Business Combination, it will use its commercially reasonable efforts to file with the SEC a registration statement covering the Class&#160;A ordinary shares issuable upon exercise of the warrants, and the Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of a Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class&#160;A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; if the Class&#160;A ordinary shares are, at the time of any exercise of a warrant, not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement. If a registration statement covering the Class&#160;A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act or another exemption, but will use its best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Redemption of Warrants When the Price per Class</div></div><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">&#160;A Ordinary Share Equals or Exceeds $18.00</div></div>&#160;&#8212;&#160;Once the warrants become exercisable, the Company may redeem the outstanding Public Warrants: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $0.01 per Public Warrant; </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon not less than 30&#160;days&#8217; prior written notice of redemption to each warrant holder; and </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;">if, and only if, the closing price of the Class&#160;A ordinary shares equals or exceeds $18.00 per share (as adjusted for share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-divisions,</div> share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period ending on the third trading day prior to the date on which notice of the redemption is given to the warrant holders (the &#8220;Reference Value&#8221;). </div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if the Company are unable to register or qualify the underlying securities for sale under all applicable state securities laws. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Redemption of Warrants When the Price per Class</div></div><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">&#160;A Ordinary Share Equals or Exceeds $10.00</div></div>&#160;&#8212;&#160;Once the warrants become exercisable, the Company may redeem the outstanding warrants: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at $0.10 per warrant upon a minimum of 30&#160;days&#8217; prior written notice of redemption; provided that during such 30 day period holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares, based on the redemption date and the fair market value of the Class&#160;A ordinary shares, that if the warrants are not exercised on a cashless basis or otherwise during such 30 day period, the Company shall redeem such warrants for $0.10 per share; </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 1px; margin-top: 6px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted for share subdivisions, share dividends, reorganizations, recapitalizations and the like) on the trading day before the Company sends the notice of redemption to the warrant holders; and </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:5%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if the Reference Value is less than $18.00 per share (as adjusted for share splits, share dividends, reorganizations, recapitalizations and the like), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exercise price and number of ordinary shares issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with respect to such Public Warrants. Accordingly, the Public Warrants may expire worthless. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if (x)&#160;the Company issues additional Class&#160;A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per Class&#160;A ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y)&#160;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its Class&#160;A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#8220;Market Value&#8221;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $10.00 and $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 100% and 180% of the higher of the Market Value and the Newly Issued Price, respectively. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants and the Class&#160;A ordinary shares issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30&#160;days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable,</div> except as described above, so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_WarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants [Text Block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_WarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345414596008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 9. FAIR VALUE MEASUREMENTS</div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company follows the guidance in ASC 820 for its financial assets and liabilities that are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measured</div> and reported at fair value at each reporting period, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets and liabilities that are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measured</div> and reported at fair value at least annually.</div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="width:3%;"></td><td style="vertical-align:bottom;;width:1%;"></td><td style="width:6%;"></td><td style="vertical-align:bottom;;width:1%;"></td><td style="width:89%;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:top;">Level&#160;1:</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</td></tr><tr style="font-size: 1pt;"><td style="height:8;">&#160;</td><td colspan="2" style="height:8;">&#160;</td><td colspan="2" style="height:8;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:top;">Level&#160;2:</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</td></tr><tr style="font-size: 1pt;"><td style="height:8;">&#160;</td><td colspan="2" style="height:8;">&#160;</td><td colspan="2" style="height:8;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:top;">Level&#160;3:</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at March&#160;31, 2021 and December&#160;31, 2020, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:67%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 1pt;;vertical-align:bottom;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description</div></div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Assets:</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in Trust Account</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;">1</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">92,026,912</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">91,997,501</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1pt;"><td style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td><td colspan="4" style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td><td colspan="4" style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td><td colspan="4" style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Liabilities:</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant liability &#8211; Public Warrants</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;">1</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">2,484,000</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,250,667</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Warrant liability &#8211; Private Placement Warrants</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">3</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">117,180</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">153,347</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Warrants were accounted for as liabilities in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40</div> and are presented within warrant liabilities on our balance sheet. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the consolidated statement of operations. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Both the Private Placement Warrants and the Public Warrants were initially valued using a binomial lattice model, which is considered to be a Level&#160;3 fair value measurement. As of March&#160;31, 2021, the Public Warrants were valued using the instrument&#8217;s publicly listed trading notice as of the balance sheet date, which is considered to be a Level&#160;1 measurement due to the use of an observable market quote in an active market. The Private Warrants were valued using a binomial lattice model, which is considered to be a Level&#160;3 fair value measurement. The binomial lattice model&#8217;s primary unobservable input utilized in determining the fair value of the Private Placement Warrants is the expected volatility of the common stock. The expected volatility as of the IPO date was derived from observable public warrant pricing on comparable &#8216;blank-check&#8217; companies without an identified target. The expected volatility as of subsequent valuation dates will be implied from the Company&#8217;s own public warrant pricing. A binomial lattice model methodology was also used in estimating the fair value of the Public Warrants for periods where no observable traded price was available, using the same expected volatility as was used in measuring the fair value of the Private Placement Warrants. For periods subsequent to the detachment of the Warrants from the Units, the close price of the Public Warrant price will be used as the fair value as of each relevant date. </div></div></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the changes in the fair value of warrant liabilities: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"><tr style="font-size: 0px;"><td style="width:56%;"></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Private&#160;Placement</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Public</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Warrant&#160;Liabilities</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Fair value as of January&#160;1, 2021</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">153,347</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,250,667</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,404,014</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(36,167</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(766,667</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(802,834</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Fair value as of March&#160;31, 2021</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">117,180</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,484,000</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,601,180</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no transfers in or out of Level&#160;3 from other levels in the fair value hierarchy. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE <div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div>. FAIR VALUE MEASUREMENTS </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company follows the guidance in ASC Topic 820 for its financial assets and liabilities that are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measured</div> and reported at fair value at each reporting period, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets and liabilities that are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measured</div> and reported at fair value at least annually. </div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: </div></div><div style="text-indent: 2%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1: </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 13%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </div></div><div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 2%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2: </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 13%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. </div></div><div style="text-indent: 2%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3: </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 13%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s assets that are measured at fair value on a recurring basis at December&#160;31, 2020, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:80%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.7pt;;vertical-align:bottom;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description</div></div></div></td><td style="padding-bottom: 0.7pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level</div></td><td style="padding-bottom: 0.7pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.7pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December&#160;31,</div><br/> <div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.7pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Assets:</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in Trust Account</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">91,997,501</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Liabilities:</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability &#8211; Public Warrants</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,250,667</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Warrant Liability &#8211; Private Placement Warrants</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">153,347</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Warrants were accounted for as liabilities in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40</div> and are presented within warrant liabilities on our consolidated balance sheet. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the consolidated statement of operations. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Initial Measurement </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Both the Private Placement Warrants and the Public Warrants were initially valued using a binomial lattice model, which is considered to be a Level&#160;3 fair value measurement. The binomial lattice model&#8217;s primary unobservable input utilized in determining the fair value of the Private Placement Warrants is the expected volatility of the common stock. The expected volatility as of the IPO date was derived from observable public warrant pricing on comparable &#8216;blank-check&#8217; companies without an identified target. The expected volatility as of subsequent valuation dates will be implied from the Company&#8217;s own public warrant pricing. A binomial lattice model methodology was also used in estimating the fair value of the Public Warrants for periods where no observable traded price was available, using the same expected volatility as was used in measuring the fair value of the Private Placement Warrants. For periods subsequent to the detachment of the Warrants from the Units, the close price of the Public Warrant price will be used as the fair value as of each relevant date. </div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The key inputs into the binomial lattice simulation model for the Private Placement Warrants and Public Warrants were as follows at initial measurement: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:77%;"></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">Input</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;">November&#160;23,<br/> 2020 (Initial<br/> Measurement)</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;">December&#160;3<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div>, <br/>2020</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Risk-free interest rate</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.4</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">%</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.4</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Expected term (years)5</div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">5</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">5</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected volatility</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">12.0</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">%</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">11.50</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">11.50</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Fair value of Units</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9.81</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10.12</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;23, 2020, the Private Placement Warrants and Public Warrants were determined to be $.57 per warrant for aggregate values of $82,460 and $1,748,000, respectively (these values include the underwriters exercise of their overallotment option on December&#160;1, 2020). </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Subsequent Measurement </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Warrants are measured at fair value on a recurring basis. The subsequent measurement of the Public Warrants as of December&#160;31, 2020 is classified as Level&#160;1 due to the use of an observable market quote in an active market. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the aggregate values of the Private Placement Warrants and Public Warrants were $153,347 and $3,250,667&#160;million, respectively. </div></div> <div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the changes in the fair value of warrant liabilities: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"><tr style="font-size: 0px;"><td style="width:57%;"></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Private<br/>Placement</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Public</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Warrant<br/>Liabilities</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:top;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on November&#160;23, 2020</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">77,900</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,520,000</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,597,900</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Change in valuation inputs or other assumptions</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">75,447</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,730,667</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,806,114</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of December&#160;31, 2020</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">153,347</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,250,667</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,404,014</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to the use of quoted prices in an active market (Level 1) to measure the fair value of the Public Warrants, subsequent to initial measurement, the Company had transfers out of Level&#160;3 totaling $1,597,900 during the period from November&#160;23, 2020 through December&#160;31, 2020. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345413035496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 10. SUBSEQUENT EVENTS</div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed financial statements were issued. Based upon this review, except as set forth below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Business Combination Agreement and PIPE Financing </div></div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">On April&#160;15, 2021, the Company entered into a business combination agreement with Surrozen, Inc. (&#8220;Surrozen&#8221;), pursuant to which a wholly-owned subsidiary of the Company will merge with and into Surrozen, with Surrozen surviving as a wholly-owned subsidiary of the Company and the Company will redomicile as a Delaware corporation. In accordance with the terms and subject to the conditions of the Business Combination Agreement, each share and equity award (whether vested or unvested) of Surrozen outstanding as of closing will be exchanged for shares of the Company&#8217;s common stock or comparable equity awards that are settled or are exercisable for shares of the Company&#8217;s common stock, as applicable, based on an implied Surrozen equity value of $200,000,000 and a $10.00 per share value of the Company&#8217;s Common Stock. In connection with the foregoing and concurrently with the execution of the Business Combination Agreement, the Company entered into Subscription Agreements with certain investors (the &#8220;Subscription Agreements&#8221; and such investors, the &#8220;PIPE Investors&#8221;), pursuant to which the PIPE Investors have agreed to subscribe for and purchase, and the Company has agreed to issue and sell to the PIPE Investors, an aggregate of 12,020,000 units, each consisting of one share of the Company&#8217;s common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of one redeemable warrant for one share of the Company&#8217;s common stock (the &#8220;PIPE Warrants&#8221;), for a purchase price of $10.00 per unit (the &#8220;PIPE Units&#8221;), for aggregate gross proceeds of $120,200,000 (the &#8220;PIPE Financing&#8221;). Each whole PIPE Warrant entitles the holder thereof to purchase one share of the Company&#8217;s common stock at a price of $11.50 per share, subject to adjustment as described in the form of warrant agreement attached to the form of Subscription Agreement, and only whole PIPE Warrants will be exercisable. The PIPE Warrants have substantially the same provisions as the public warrants issued in connection with the Company&#8217;s initial public offering. The securities to be issued pursuant to the Subscription Agreements have not been registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) in reliance upon the exemption provided in Section&#160;4(a)(2) of the Securities Act. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="display:inline;">NOTE 11. SUBSEQUENT EVENTS&#160;<br/></div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, except as noted in footnote 2<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;and as set forth below</div></div><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements. </div><br/></div><div style="color: rgb(0, 0, 0); font-family: 'times new roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Business Combination Agreement and PIPE Financing</div></div></div></div></div><div style="color: rgb(0, 0, 0); font-family: 'times new roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 12pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April 15, 2021, the Company entered into a business combination agreement with Surrozen, Inc. (&#8220;Surrozen&#8221;), pursuant to which a wholly-owned subsidiary of the Company will merge with and into Surrozen, with Surrozen surviving as a wholly-owned subsidiary of the Company and the Company will redomicile as a Delaware corporation. In accordance with the terms and subject to the conditions of the Business Combination Agreement, each share and equity award (whether vested or unvested) of Surrozen outstanding as of closing will be exchanged for shares of the Company&#8217;s common stock or comparable equity awards that are settled or are exercisable for shares of the Company&#8217;s common stock, as applicable, based on an implied Surrozen equity value of $200,000,000 and a $10.00 per share value of the Company&#8217;s Common Stock. In connection with the foregoing and concurrently with the execution of the Business Combination Agreement, the Company entered into Subscription Agreements with certain investors (the &#8220;Subscription Agreements&#8221; and such investors, the &#8220;PIPE Investors&#8221;), pursuant to which the PIPE Investors have agreed to subscribe for and purchase, and the Company has agreed to issue and sell to the PIPE Investors, an aggregate of 12,020,000 units, each consisting of one share of the Company&#8217;s common stock and one-third of one redeemable warrant for one share of the Company&#8217;s common stock (the &#8220;PIPE Warrants&#8221;), for a purchase price of $10.00 per unit (the &#8220;PIPE Units&#8221;), for aggregate gross proceeds of $120,200,000 (the &#8220;PIPE Financing&#8221;). Each whole PIPE Warrant entitles the holder thereof to purchase one share of the Company&#8217;s common stock at a price of $11.50 per share, subject to adjustment as described in the form of warrant agreement attached to the form of Subscription Agreement, and only whole PIPE Warrants will be exercisable. The PIPE Warrants have substantially the same provisions as the public warrants issued in connection with the Company&#8217;s initial public offering. The securities to be issued pursuant to the Subscription Agreements have not been registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) in reliance upon the exemption provided in Section 4(a)(2) of the Securities Act.</div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(As of May 14, 2021)</div></div></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345418561432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS<br></strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_RestatementAbstract', window );"><strong>Restatement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock', window );">Restatement Of Previously Issued Financial Statements</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 2&#160;&#8212;&#160;RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company previously accounted for its outstanding Public Warrants (as defined in Note 4) and Private Placement Warrants issued in connection with its Initial Public Offering as components of equity instead of as derivative liabilities.&#160;The warrant agreement governing the warrants includes a provision that provides for potential changes to the settlement amounts dependent upon the characteristics of the holder of the warrant. In addition, the warrant agreement includes a provision that in the event of a tender or exchange offer made to and accepted by holders of more than 50% of the outstanding shares of a single class of ordinary shares, all holders of the warrants would be entitled to receive cash for their warrants (the &#8220;tender offer provision&#8221;). </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In connection with the audit of the Company&#8217;s financial statements for the period ended December&#160;31, 2020, the Company&#8217;s management further evaluated the warrants under Accounting Standards Codification (&#8220;ASC&#8221;) Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40,</div> Contracts in Entity&#8217;s Own Equity. ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;815-40-15</div></div> addresses equity versus liability treatment and classification of equity-linked financial instruments, including warrants, and states that a warrant may be classified as a component of equity only if, among other things, the warrant is indexed to the issuer&#8217;s common stock. Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;815-40-15,</div></div> a warrant is not indexed to the issuer&#8217;s common stock if the terms of the warrant require an adjustment to the exercise price upon a specified event and that event is not an input to the fair value of the warrant. Based on management&#8217;s evaluation, the Company&#8217;s audit committee, in consultation with management and after discussion with the Company&#8217;s independent registered public accounting firm, concluded that the Company&#8217;s Private Placement Warrants are not indexed to the Company&#8217;s ordinary shares in the manner contemplated by ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;815-40-15</div></div> because the holder of the instrument is not an input into the pricing of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fixed-for-fixed</div></div> option on equity shares. In addition, based on management&#8217;s evaluation, the Company&#8217;s audit committee, in consultation with management and after discussion with the Company&#8217;s independent registered public accounting firm, concluded the tender offer provision included in the warrant agreement fails the &#8220;classified in shareholders&#8217; equity&#8221; criteria as contemplated by ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;815-40-25.</div></div> </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result of the above, the Company should have classified the warrants as derivative liabilities in its previously issued financial statements. Under this accounting treatment, the Company is required to measure the fair value of the warrants at the end of each reporting period and recognize changes in the fair value from the prior period in the Company&#8217;s operating results for the current period.</div></div><br/></div> <div style="text-indent: 4%; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s accounting for the warrants as components of equity instead of as derivative liabilities did not have any effect on the Company&#8217;s previously reported operating expenses, cash or investments held in the trust account. </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"><tr style="font-size: 0px;"><td style="width: 63%;"></td><td style="width: 6%;;vertical-align:bottom;"></td><td></td><td></td><td></td><td style="width: 5%;;vertical-align:bottom;"></td><td></td><td></td><td></td><td style="width: 5%;;vertical-align:bottom;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;&#160;</div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">As</div></div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;&#160;</div></td><td colspan="2" style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;&#160;</div></td><td colspan="2" style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;&#160;</div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">Previously</div></div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;&#160;</div></td><td colspan="2" style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;&#160;</div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">As</div></div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="display:inline;">&#160;&#160;</div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="display:inline;">&#160;&#160;</div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="display:inline;">&#160;&#160;</div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Balance sheet as of November&#160;23, 2020 (audited)</div></div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">&#8212;&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,598,233</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,598,233</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total Liabilities</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">3,167,722</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">1,598,233</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">4,765,955</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary Shares Subject to Possible Redemption</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">74,121,170</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(1,598,233</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">72,522,937</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Class&#160;A Ordinary Shares</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">100</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">18</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">118</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div> Capital</div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">5,004,636</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">107,501</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">5,112,137</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Accumulated Deficit</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(4,961</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(107,519</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(112,480</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance sheet as of December&#160;31, 2020 (audited)</div></div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Warrant Liability</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">3,404,014</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">3,404,014</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">3,510,148</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">3,404,014</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">6,914,162</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Ordinary Shares Subject to Possible Redemption</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">85,264,880</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(3,404,020</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">81,860,860</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A Ordinary Shares</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">111</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">34</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">145</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Paid-in</div> Capital</div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">5,440,915</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">1,681,045</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">7,121,960</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated Deficit</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(441,255</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(1,681,073</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(2,122,328</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Shareholders&#8217; Equity</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">5,000,001</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">6</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">5,000,007</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Period from August&#160;20, 2020 (inception) to December&#160;31, 2020 (audited)</div></div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrant liability</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">&#8212;&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,573,554</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,573,554</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Allocation of initial public offering costs</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">107,519</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">107,519</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(441,255</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(1,681,073</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(2,122,328</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Weighted average shares outstanding of Class&#160;A redeemable ordinary shares</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">8,326,328</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(144,993</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">8,181,335</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">Weighted average shares outstanding of Class&#160;B <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> ordinary shares</div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">2,414,403</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">46,692</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">2,461,095</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Basic and diluted net loss per share, Class&#160;B</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(0.18</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(0.68</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(0.86</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash Flow Statement for the Period from August&#160;20, 2020 (inception) to December&#160;31, 2020 (audited)</div></div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net loss</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(441,255</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(1,681,073</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(2,122,328</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of initial public offering costs</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">&#8212;&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">107,519</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">107,519</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Change in fair value of warrant liability</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">1,573,554</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">1,573,554</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial classification of warrant liability</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">&#8212;&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,830,460</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,830,460</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Initial classification of common stock subject to possible redemption</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">74,121,170</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(1,598,233</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">72,522,937</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in value of common stock subject to possible redemption</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(436,290</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(1,993,560</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(2,429,850</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_RestatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_RestatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restatement of previously issued financial statements [Text block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_RestatementOfPreviouslyIssuedFinancialStatementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345410943560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 8 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited condensed financial statements should be read in conjunction with the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K/A</div> for the year ended December&#160;31, 2020 as filed with the SEC on May&#160;14, 2021. The interim results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2021 or for any future periods. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging Growth Company</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the condensed financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of March&#160;31, 2021 and December&#160;31, 2020. </div></div></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three&#160;months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December&#160;31, 2020. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_AssetsHeldInTrustAccountPolicyPolicyTextBlock', window );">Marketable Securities Held in Trust Account</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Marketable Securities Held in Trust Account </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2021 and December&#160;31, 2020, substantially all of the assets held in the Trust Account were held in U.S. Treasury Bills.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Marketable Securities Held in Trust Account </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2020, substantially all of the assets held in the Trust Account were held in U.S. Treasury Bills. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantLiabilityPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Warrant Liability </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification.</div></div> <div style="font-size: 1px; margin-top: 18px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital at the time of issuance or modification. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> gain or loss on the statements of operations. The fair value of the warrants was determined by using the publicly traded price on March&#160;31, 2021 (see Note 9). </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Warrant Liability </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815,&#160;Derivatives and Hedging&#160;(&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> gain or loss on the statements of operations. The fair value of the warrants was estimated using a binomial lattice simulation methodology (see Note 9). </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_TemporaryEquityPolicyPolicyTextBlock', window );">Class A Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Class&#160;A Ordinary Shares Subject to Possible Redemption </div></div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class&#160;A ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221; Class&#160;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. The Company&#8217;s Class&#160;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, Class&#160;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders&#8217; equity section of the Company&#8217;s balance sheet. </div></div></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Class&#160;A Ordinary Shares Subject to Possible Redemption </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class&#160;A ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221; Class&#160;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. The Company&#8217;s Class&#160;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, Class&#160;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders&#8217; equity section of the Company&#8217;s balance sheet. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Income Taxes </div></div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the condensed financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.</div></div><br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">ASC </div>740<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s condensed financial statements and prescribes a recognition threshold and measurement process for condensed financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be </div><div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were </div>no<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> unrecognized tax benefits and </div>no<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> amounts accrued for interest and penalties as of March&#160;</div>31<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> and December&#160;</div>31<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.</div><br/></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United&#160;States. As such, the Company&#8217;s tax provision was zero for the period presented. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December&#160;31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. </div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the period presented. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Ordinary Share</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Net Loss Per Ordinary Share </div></div></div></div></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"> </div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period, excluding ordinary shares subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of</div></div><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> 3,211,334 shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s statement of operations includes a presentation of loss per share for ordinary shares subject to possible redemption in a manner similar to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method of loss per share. Net loss per ordinary share, basic and diluted, for Class&#160;A ordinary shares subject to possible redemption is calculated by dividing the proportionate share of income or loss on marketable securities held by the Trust Account by the weighted average number of Class&#160;A ordinary shares subject to possible redemption outstanding since original issuance. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Net loss per share, basic and diluted, for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> ordinary shares is calculated by dividing the net income (loss), adjusted for income or loss on marketable securities attributable to Class&#160;A ordinary shares subject to possible redemption, by the weighted average number of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> ordinary shares outstanding for the period. </div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> common stock includes Founder Shares and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> ordinary shares as these shares do not have any redemption features. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> ordinary shares participate in the income or loss on marketable securities based on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> shares&#8217; proportionate interest.</div> <div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="width:84%;"></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three&#160;Months</div><br/> <div style="font-weight:bold;display:inline;">Ended</div><br/> <div style="font-weight:bold;display:inline;">March&#160;31,</div><br/> <div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Class&#160;A ordinary Shares subject to possible redemption</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator: Earnings allocable to Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Interest earned on marketable securities held in Trust Account</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">20,507</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain on marketable securities held in Trust Account</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">5,589</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net income attributable</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">26,096</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator: Weighted Average Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1pt;"><td style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td><td colspan="4" style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Basic and diluted weighted average shares outstanding, Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">8,186,086</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income per share, Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">0.00</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-Redeemable</div> Ordinary Shares</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator: Net Loss minus Net Earnings</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net loss</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(232,964</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">)&#160;</div></td></tr><tr style="font-size: 1pt;"><td style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td><td colspan="4" style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Net income allocable to Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(26,096</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-Redeemable</div> Net Loss</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(259,060</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">)&#160;</div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Denominator: Weighted Average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> ordinary shares</div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted weighted average shares outstanding, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-redeemable</div> ordinary shares</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">3,747,914</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net loss per share, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> ordinary shares</div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(0.07</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">)&#160;</div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Net Income (Loss) Per Share </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss) per share is computed by dividing net income by the weighted-average number of ordinary shares outstanding during the period, excluding ordinary shares subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and private placement to purchase an aggregate of 3,211,334 shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. </div></div> <div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px;"><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company&#8217;s statement of operations includes a presentation of income (loss) per share for ordinary shares subject to possible redemption in a manner similar to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method of income (loss) per share. Net income (loss) per ordinary share, basic and diluted, for ordinary shares subject to possible redemption is calculated by dividing the proportionate share of income or loss on marketable securities held by the Trust Account by the weighted average number of ordinary shares subject to possible redemption outstanding since original issuance. </div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Net income (loss) per share, basic and diluted, for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> ordinary shares is calculated by dividing the net income (loss), adjusted for income or loss on marketable securities attributable to ordinary shares subject to possible redemption, by the weighted average number of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> ordinary shares outstanding for the period. </div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> ordinary shares include Founder Shares and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> ordinary shares as these shares do not have any redemption features. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> ordinary shares participate in the income or loss on marketable securities based on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> shares&#8217; proportionate interest. </div>  <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:85%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:8%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the&#160; Period</div></div></div><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">from</div></div></div><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">August&#160;21,&#160; 2020</div></div></div><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Inception)</div></div></div><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Through</div></div></div><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Ordinary shares subject to possible redemption</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator: Earnings allocable to Ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Interest earned on marketable securities held in Trust Account</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,243</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain (loss) on marketable securities held in Trust Account</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(7,466</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net income attributable to Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(2,223</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator: Weighted Average Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Basic and diluted weighted average shares outstanding, Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,181,335</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share, Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">0.00</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:84%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:5%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-Redeemable</div> Common Stock</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator: Net Loss minus Net Earnings</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net loss</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(2,122,328</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Add: Net loss allocable to Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">2,223</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-Redeemable</div> Net Loss</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(2,120,105</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Denominator: Weighted Average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> ordinary shares</div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"></td><td style="vertical-align:bottom;"></td><td style="vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted weighted average shares outstanding, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-redeemable</div> ordinary shares</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,461,095</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net loss per share, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> ordinary shares</div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(0.86</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</div>  <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Fair Value Measurements </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:9%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:9%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:9%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:3%;">&#8226;</td><td style="vertical-align:top;;width:1%;">&#160;</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:left;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesReportingOfDerivativeActivity', window );">Derivative Financial Instruments</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Derivative Financial Instruments </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &#8220;Derivatives and Hedging&#8221;. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-valued</div> at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> based on whether or not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">net-cash</div> settlement or conversion of the instrument could be required within 12 months of the balance sheet date.</div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s condensed financial statements. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In August 2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Debt &#8212; Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40)</div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;)</div> to simplify accounting for certain financial instruments. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#8217;s own equity. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> amends the diluted earnings per share guidance, including the requirement to use the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">if-converted</div> method for all instruments. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> is effective January&#160;1, 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January&#160;1, 2021. The Company is currently assessing the impact, if any, that ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> would have on its financial position, results of operations or cash flows. </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div> <div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying financial statements. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_AssetsHeldInTrustAccountPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounting policy for assets held in trust.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_AssetsHeldInTrustAccountPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_EmergingGrowthCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the accounting policy on Emerging Growth Company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_EmergingGrowthCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_TemporaryEquityPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounting policy for temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_TemporaryEquityPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>warrant liability[Policy text block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesReportingOfDerivativeActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesReportingOfDerivativeActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345410782984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net income (loss) per ordinary share</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="width:84%;"></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three&#160;Months</div><br/> <div style="font-weight:bold;display:inline;">Ended</div><br/> <div style="font-weight:bold;display:inline;">March&#160;31,</div><br/> <div style="font-weight:bold;display:inline;">2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Class&#160;A ordinary Shares subject to possible redemption</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator: Earnings allocable to Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Interest earned on marketable securities held in Trust Account</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">20,507</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain on marketable securities held in Trust Account</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">5,589</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net income attributable</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">26,096</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator: Weighted Average Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1pt;"><td style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td><td colspan="4" style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Basic and diluted weighted average shares outstanding, Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">8,186,086</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income per share, Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">0.00</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-Redeemable</div> Ordinary Shares</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator: Net Loss minus Net Earnings</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net loss</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(232,964</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">)&#160;</div></td></tr><tr style="font-size: 1pt;"><td style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td><td colspan="4" style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Net income allocable to Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(26,096</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-Redeemable</div> Net Loss</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(259,060</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">)&#160;</div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Denominator: Weighted Average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> ordinary shares</div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted weighted average shares outstanding, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-redeemable</div> ordinary shares</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">3,747,914</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">&#160;</div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net loss per share, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> ordinary shares</div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">(0.07</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">)&#160;</div></td></tr><tr style="font-size: 1px;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:85%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:8%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the&#160; Period</div></div></div><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">from</div></div></div><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">August&#160;21,&#160; 2020</div></div></div><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Inception)</div></div></div><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Through</div></div></div><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;;text-align:center;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Ordinary shares subject to possible redemption</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator: Earnings allocable to Ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Interest earned on marketable securities held in Trust Account</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,243</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain (loss) on marketable securities held in Trust Account</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(7,466</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net income attributable to Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(2,223</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator: Weighted Average Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Basic and diluted weighted average shares outstanding, Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">8,181,335</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share, Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">0.00</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:84%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:5%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-Redeemable</div> Common Stock</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator: Net Loss minus Net Earnings</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net loss</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(2,122,328</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Add: Net loss allocable to Class&#160;A ordinary shares subject to possible redemption</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">2,223</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-Redeemable</div> Net Loss</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(2,120,105</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Denominator: Weighted Average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> ordinary shares</div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"></td><td style="vertical-align:bottom;"></td><td style="vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted weighted average shares outstanding, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Non-redeemable</div> ordinary shares</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,461,095</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net loss per share, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> ordinary shares</div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(0.86</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</div>  <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345414626552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_RestatementAbstract', window );"><strong>Restatement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Summary of restatement of previously issued financial statements</a></td>
<td class="text"><div style="text-indent: 4%; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s accounting for the warrants as components of equity instead of as derivative liabilities did not have any effect on the Company&#8217;s previously reported operating expenses, cash or investments held in the trust account. </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"><tr style="font-size: 0px;"><td style="width: 63%;"></td><td style="width: 6%;;vertical-align:bottom;"></td><td></td><td></td><td></td><td style="width: 5%;;vertical-align:bottom;"></td><td></td><td></td><td></td><td style="width: 5%;;vertical-align:bottom;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;&#160;</div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">As</div></div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;&#160;</div></td><td colspan="2" style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;&#160;</div></td><td colspan="2" style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;&#160;</div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">Previously</div></div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;&#160;</div></td><td colspan="2" style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;&#160;</div></td><td colspan="2" style="text-align:center;;vertical-align:bottom;;width:;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">As</div></div></td><td style="vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="display:inline;">&#160;&#160;</div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="display:inline;">&#160;&#160;</div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="display:inline;">&#160;&#160;</div></td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">Restated</div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;;width:;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Balance sheet as of November&#160;23, 2020 (audited)</div></div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">&#8212;&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,598,233</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,598,233</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total Liabilities</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">3,167,722</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">1,598,233</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">4,765,955</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary Shares Subject to Possible Redemption</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">74,121,170</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(1,598,233</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">72,522,937</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Class&#160;A Ordinary Shares</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">100</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">18</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">118</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div> Capital</div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">5,004,636</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">107,501</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">5,112,137</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Accumulated Deficit</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(4,961</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(107,519</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(112,480</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance sheet as of December&#160;31, 2020 (audited)</div></div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Warrant Liability</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">3,404,014</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">3,404,014</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">3,510,148</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">3,404,014</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">6,914,162</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Ordinary Shares Subject to Possible Redemption</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">85,264,880</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(3,404,020</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">81,860,860</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A Ordinary Shares</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">111</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">34</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">145</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Paid-in</div> Capital</div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">5,440,915</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">1,681,045</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">7,121,960</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated Deficit</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(441,255</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(1,681,073</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(2,122,328</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Shareholders&#8217; Equity</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">5,000,001</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">6</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">5,000,007</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Period from August&#160;20, 2020 (inception) to December&#160;31, 2020 (audited)</div></div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrant liability</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">&#8212;&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,573,554</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">$</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,573,554</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Allocation of initial public offering costs</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">107,519</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">107,519</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(441,255</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(1,681,073</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(2,122,328</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Weighted average shares outstanding of Class&#160;A redeemable ordinary shares</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">8,326,328</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(144,993</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">8,181,335</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;">Weighted average shares outstanding of Class&#160;B <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> ordinary shares</div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">2,414,403</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">46,692</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">2,461,095</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Basic and diluted net loss per share, Class&#160;B</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(0.18</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(0.68</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(0.86</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash Flow Statement for the Period from August&#160;20, 2020 (inception) to December&#160;31, 2020 (audited)</div></div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Net loss</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(441,255</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(1,681,073</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">$</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(2,122,328</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of initial public offering costs</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">&#8212;&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">107,519</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">107,519</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Change in fair value of warrant liability</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#8212;&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">1,573,554</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">1,573,554</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial classification of warrant liability</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">&#8212;&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,830,460</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">1,830,460</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="background-color: rgb(204, 238, 255);;display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Initial classification of common stock subject to possible redemption</div></div></div></td><td style="background-color: rgb(204, 238, 255); width: 6%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">74,121,170</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">(1,598,233</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">)&#160;</div></td><td style="background-color: rgb(204, 238, 255); width: 5%;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">72,522,937</div></td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255);;display:inline;">&#160;</div></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-size: 10pt; width: 63%;;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in value of common stock subject to possible redemption</div></div></div></td><td style="width: 6%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(436,290</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(1,993,560</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td><td style="width: 5%;;vertical-align:bottom;"><div style="display:inline;">&#160;&#160;</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">&#160;</div></td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"><div style="display:inline;">(2,429,850</div></td><td style="white-space: nowrap;;vertical-align:bottom;"><div style="display:inline;">)&#160;</div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_RestatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_RestatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345412957768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of company's assets that are measured at fair value on a recurring basis</a></td>
<td class="text">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at March&#160;31, 2021 and December&#160;31, 2020, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:<table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:67%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 1pt;;vertical-align:bottom;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description</div></div></div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 2021</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Assets:</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in Trust Account</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;">1</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">92,026,912</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">91,997,501</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1pt;"><td style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td><td colspan="4" style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td><td colspan="4" style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td><td colspan="4" style="font-family: &quot;times new roman&quot;;;height:8;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Liabilities:</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant liability &#8211; Public Warrants</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:center;;vertical-align:bottom;">1</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">2,484,000</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,250,667</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Warrant liability &#8211; Private Placement Warrants</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:center;;vertical-align:bottom;">3</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">117,180</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">153,347</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text">The following table presents information about the Company&#8217;s assets that are measured at fair value on a recurring basis at December&#160;31, 2020, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:<table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:80%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.7pt;;vertical-align:bottom;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description</div></div></div></td><td style="padding-bottom: 0.7pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Level</div></td><td style="padding-bottom: 0.7pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.7pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">December&#160;31,</div><br/> <div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.7pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"><div style="font-weight:bold;display:inline;">Assets:</div></div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in Trust Account</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">91,997,501</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Liabilities:</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability &#8211; Public Warrants</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,250,667</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Warrant Liability &#8211; Private Placement Warrants</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">153,347</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of key Inputs into the Binomial Lattice Simulation Model for the Private Placement Warrants and Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The key inputs into the binomial lattice simulation model for the Private Placement Warrants and Public Warrants were as follows at initial measurement: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:77%;"></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">Input</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;">November&#160;23,<br/> 2020 (Initial<br/> Measurement)</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;">December&#160;3<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div>, <br/>2020</td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Risk-free interest rate</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.4</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">%</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">0.4</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Expected term (years)5</div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">5</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">5</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Expected volatility</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">12.0</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"><div style="background-color: rgb(204, 238, 255); letter-spacing: 0px; top: 0px;;display:inline;">%</div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">16</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">11.50</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">11.50</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Fair value of Units</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9.81</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10.12</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Summary of fair value of the warrant liabilities</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the changes in the fair value of warrant liabilities: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"><tr style="font-size: 0px;"><td style="width:56%;"></td><td style="vertical-align:bottom;;width:7%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Private&#160;Placement</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Public</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Warrant&#160;Liabilities</div></td><td style="padding-bottom: 1pt;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Fair value as of January&#160;1, 2021</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">153,347</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,250,667</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">3,404,014</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(36,167</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(766,667</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">(802,834</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Fair value as of March&#160;31, 2021</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">117,180</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,484,000</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2,601,180</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td style="vertical-align:bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td><td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the changes in the fair value of warrant liabilities: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:84%;"><tr style="font-size: 0px;"><td style="width:57%;"></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:6%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Private<br/>Placement</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Public</div></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Warrant<br/>Liabilities</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:top;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on November&#160;23, 2020</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">77,900</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,520,000</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">1,597,900</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Change in valuation inputs or other assumptions</div></div></td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">75,447</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,730,667</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,806,114</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of December&#160;31, 2020</div></div></td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">153,347</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,250,667</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">3,404,014</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345405400488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 01, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 23, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum', window );">Condition for future business combination number of businesses minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of Units, net of underwriting discounts | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodValueNewIssues', window );">Proceeds from issuance of units</a></td>
<td class="nump">$ 12,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,113,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrust', window );">Assets Held-in-trust</a></td>
<td class="nump">92,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_AdditionsToAssetsHeldInTrust', window );">Additions to assets held in trust</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_TransactionCosts', window );">Transaction Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,658,864<span></span>
</td>
<td class="nump">5,658,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_SaleOfStockUnderwritingFees', window );">Underwriting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,840,000<span></span>
</td>
<td class="nump">1,840,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_DeferredOfferingCostsNoncurrent', window );">Deferred underwriting fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,220,000<span></span>
</td>
<td class="nump">3,220,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_SaleOfStockOtherOfferingCosts', window );">Other offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598,864<span></span>
</td>
<td class="nump">$ 598,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount', window );">Threshold minimum aggregate fair market value as a percentage of the assets held in the Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination', window );">Threshold percentage of outstanding voting securities of the target to be acquired by post-transaction company to complete business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of Units, net of underwriting discounts | shares</a></td>
<td class="nump">9,200,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodValueNewIssues', window );">Proceeds from issuance of units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrust', window );">Assets Held-in-trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of Units, net of underwriting discounts | shares</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodValueNewIssues', window );">Proceeds from issuance of units</a></td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-allotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of Units, net of underwriting discounts | shares</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodValueNewIssues', window );">Proceeds from issuance of units</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_AdditionsToAssetsHeldInTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of significant additions in the period in assets held in trust (current, noncurrent, or unclassified).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_AdditionsToAssetsHeldInTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum number of businesses which the reporting entity must acquire with the net proceeds of the offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_DeferredOfferingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_DeferredOfferingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_SaleOfStockOtherOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of other offering costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_SaleOfStockOtherOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_SaleOfStockUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of offering fees incurred and paid for underwriters.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_SaleOfStockUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold minimum aggregate fair market value as a percentage of the assets held in the Trust Account.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold percentage of outstanding voting securities of the target to be acquired by post-transaction company to complete business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of transaction costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_UnitsIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new unit issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_UnitsIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345414652712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_RestatementAbstract', window );"><strong>Restatement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PercentageOfMinimumAcceptanceOfShareholdersOfTenderOfferProvision', window );">Percentage of minimum acceptance of shareholders of tender offer provision</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_PercentageOfMinimumAcceptanceOfShareholdersOfTenderOfferProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of minimum acceptance of shareholders of tender offer provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_PercentageOfMinimumAcceptanceOfShareholdersOfTenderOfferProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_RestatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_RestatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345333878968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Summary of restatement of previously issued financial statements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">4 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 23, 2020</div></th>
<th class="th"><div>Aug. 20, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodRestatementOfBalanceSheetAbstract', window );"><strong>Prior Period Restatement Of Balance Sheet [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">$ 2,601,180<span></span>
</td>
<td class="nump">$ 3,404,014<span></span>
</td>
<td class="nump">$ 3,404,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">6,807,765<span></span>
</td>
<td class="nump">6,914,162<span></span>
</td>
<td class="nump">6,914,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ordinary Shares Subject to Possible Redemption</a></td>
<td class="nump">81,627,900<span></span>
</td>
<td class="nump">81,860,860<span></span>
</td>
<td class="nump">81,860,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">7,354,918<span></span>
</td>
<td class="nump">7,121,960<span></span>
</td>
<td class="nump">7,121,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,355,292)<span></span>
</td>
<td class="num">(2,122,328)<span></span>
</td>
<td class="num">(2,122,328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' Equity</a></td>
<td class="nump">5,000,003<span></span>
</td>
<td class="nump">5,000,007<span></span>
</td>
<td class="nump">5,000,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract', window );"><strong>Prior Period Adjustment Restatement of Statement Of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(802,834)<span></span>
</td>
<td class="nump">1,573,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(232,964)<span></span>
</td>
<td class="num">(2,122,328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract', window );"><strong>Prior Period Adjustment Restatement Of Statement Of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(232,964)<span></span>
</td>
<td class="num">(2,122,328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(802,834)<span></span>
</td>
<td class="nump">1,573,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_InitialClassificationOfWarrantLiability', window );">Initial classification of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,830,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption', window );">Initial classification of common stock subject to possible redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,522,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption', window );">Change in value of common stock subject to possible redemption</a></td>
<td class="num">(232,960)<span></span>
</td>
<td class="num">(2,429,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodRestatementOfBalanceSheetAbstract', window );"><strong>Prior Period Restatement Of Balance Sheet [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Class A Ordinary Shares</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=chfw_ClassOrdinarySharesSubjectForRedemptionMember', window );">Class A ordinary shares subject to possible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract', window );"><strong>Prior Period Adjustment Restatement of Statement Of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">weighted average shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,181,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonredeemablePreferredStockMember', window );">Non-redeemable ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract', window );"><strong>Prior Period Adjustment Restatement of Statement Of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (232,964)<span></span>
</td>
<td class="num">$ (2,122,328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">weighted average shares outstanding</a></td>
<td class="nump">3,747,914<span></span>
</td>
<td class="nump">2,461,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract', window );"><strong>Prior Period Adjustment Restatement Of Statement Of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (232,964)<span></span>
</td>
<td class="num">$ (2,122,328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodRestatementOfBalanceSheetAbstract', window );"><strong>Prior Period Restatement Of Balance Sheet [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,510,148<span></span>
</td>
<td class="nump">3,510,148<span></span>
</td>
<td class="nump">$ 3,167,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,264,880<span></span>
</td>
<td class="nump">85,264,880<span></span>
</td>
<td class="nump">74,121,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,440,915<span></span>
</td>
<td class="nump">5,440,915<span></span>
</td>
<td class="nump">5,004,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(441,255)<span></span>
</td>
<td class="num">(441,255)<span></span>
</td>
<td class="num">(4,961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,001<span></span>
</td>
<td class="nump">5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract', window );"><strong>Prior Period Adjustment Restatement of Statement Of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(441,255)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract', window );"><strong>Prior Period Adjustment Restatement Of Statement Of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(441,255)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption', window );">Initial classification of common stock subject to possible redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,121,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption', window );">Change in value of common stock subject to possible redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(436,290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported | Class A ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodRestatementOfBalanceSheetAbstract', window );"><strong>Prior Period Restatement Of Balance Sheet [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported | Class A ordinary shares subject to possible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract', window );"><strong>Prior Period Adjustment Restatement of Statement Of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">weighted average shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,326,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported | Non-redeemable ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract', window );"><strong>Prior Period Adjustment Restatement of Statement Of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">weighted average shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,414,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodRestatementOfBalanceSheetAbstract', window );"><strong>Prior Period Restatement Of Balance Sheet [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantLiability', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,404,014<span></span>
</td>
<td class="nump">$ 3,404,014<span></span>
</td>
<td class="nump">1,598,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,404,014<span></span>
</td>
<td class="nump">3,404,014<span></span>
</td>
<td class="nump">1,598,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,404,020)<span></span>
</td>
<td class="num">(3,404,020)<span></span>
</td>
<td class="num">(1,598,233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,681,045<span></span>
</td>
<td class="nump">1,681,045<span></span>
</td>
<td class="nump">107,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,681,073)<span></span>
</td>
<td class="num">(1,681,073)<span></span>
</td>
<td class="num">(107,519)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract', window );"><strong>Prior Period Adjustment Restatement of Statement Of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,573,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_AllocationOfInitialPublicOfferingCosts', window );">Allocation of initial public offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,681,073)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract', window );"><strong>Prior Period Adjustment Restatement Of Statement Of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,681,073)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_AllocationOfInitialPublicOfferingCosts', window );">Allocation of initial public offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,573,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_InitialClassificationOfWarrantLiability', window );">Initial classification of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,830,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption', window );">Initial classification of common stock subject to possible redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,598,233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption', window );">Change in value of common stock subject to possible redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,993,560)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments | Class A ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodRestatementOfBalanceSheetAbstract', window );"><strong>Prior Period Restatement Of Balance Sheet [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments | Class A ordinary shares subject to possible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract', window );"><strong>Prior Period Adjustment Restatement of Statement Of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">weighted average shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments | Non-redeemable ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract', window );"><strong>Prior Period Adjustment Restatement of Statement Of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">weighted average shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=chfw_RestatedMember', window );">As Restated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodRestatementOfBalanceSheetAbstract', window );"><strong>Prior Period Restatement Of Balance Sheet [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantLiability', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,404,014<span></span>
</td>
<td class="nump">$ 3,404,014<span></span>
</td>
<td class="nump">1,598,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,914,162<span></span>
</td>
<td class="nump">6,914,162<span></span>
</td>
<td class="nump">4,765,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,860,860<span></span>
</td>
<td class="nump">81,860,860<span></span>
</td>
<td class="nump">72,522,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,121,960<span></span>
</td>
<td class="nump">7,121,960<span></span>
</td>
<td class="nump">5,112,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,122,328)<span></span>
</td>
<td class="num">(2,122,328)<span></span>
</td>
<td class="num">(112,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,007<span></span>
</td>
<td class="nump">5,000,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract', window );"><strong>Prior Period Adjustment Restatement of Statement Of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,573,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_AllocationOfInitialPublicOfferingCosts', window );">Allocation of initial public offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,122,328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract', window );"><strong>Prior Period Adjustment Restatement Of Statement Of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,122,328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_AllocationOfInitialPublicOfferingCosts', window );">Allocation of initial public offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,573,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_InitialClassificationOfWarrantLiability', window );">Initial classification of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,830,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption', window );">Initial classification of common stock subject to possible redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,522,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption', window );">Change in value of common stock subject to possible redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,429,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=chfw_RestatedMember', window );">As Restated | Class A ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodRestatementOfBalanceSheetAbstract', window );"><strong>Prior Period Restatement Of Balance Sheet [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=chfw_RestatedMember', window );">As Restated | Class A ordinary shares subject to possible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract', window );"><strong>Prior Period Adjustment Restatement of Statement Of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">weighted average shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,181,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=chfw_RestatedMember', window );">As Restated | Non-redeemable ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract', window );"><strong>Prior Period Adjustment Restatement of Statement Of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">weighted average shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,461,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_AllocationOfInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allocation of initial public offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_AllocationOfInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of change in value of common stock subject to possible redemption, classified as non-cash investing and financing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_ChangeInValueOfCommonStockSubjectToPossibleRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of initial classification of common stock subject to possible redemption, classified as non-cash investing and financing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_InitialClassificationOfCommonStockSubjectToPossibleRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_InitialClassificationOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial classification of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_InitialClassificationOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prior period adjustment restatement of statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_PriorPeriodAdjustmentRestatementOfStatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prior period adjustment restatement of statement of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_PriorPeriodAdjustmentRestatementOfStatementOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_PriorPeriodRestatementOfBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prior period restatement of balance sheet [Abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_PriorPeriodRestatementOfBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=chfw_ClassOrdinarySharesSubjectForRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=chfw_ClassOrdinarySharesSubjectForRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonredeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonredeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=chfw_RestatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=chfw_RestatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345418462568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Amounts accrued for the payment of interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal Depository Insurance Coverage</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=chfw_InitialPublicOfferingAndPrivatePlacementMember', window );">Initial Public Offering and private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase shares issued</a></td>
<td class="nump">3,211,334<span></span>
</td>
<td class="nump">3,211,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=chfw_InitialPublicOfferingAndPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=chfw_InitialPublicOfferingAndPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345412228136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basic and diluted net income (loss) per ordinary share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (232,964)<span></span>
</td>
<td class="num">$ (2,122,328)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest earned on marketable securities held in Trust Account</a></td>
<td class="nump">23,112<span></span>
</td>
<td class="nump">5,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on marketable securities held in Trust Account</a></td>
<td class="nump">6,299<span></span>
</td>
<td class="num">(8,391)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=chfw_ClassAOrdinarySharesSubjectForRedemptionMember', window );">Class A ordinary Shares subject to possible redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest earned on marketable securities held in Trust Account</a></td>
<td class="nump">20,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on marketable securities held in Trust Account</a></td>
<td class="nump">5,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to holder</a></td>
<td class="nump">$ 26,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average shares outstanding</a></td>
<td class="nump">8,186,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonredeemablePreferredStockMember', window );">Non-redeemable ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (232,964)<span></span>
</td>
<td class="num">(2,122,328)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Less: Net income allocable to Class A ordinary shares subject to possible redemption</a></td>
<td class="num">(26,096)<span></span>
</td>
<td class="nump">2,223<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to holder</a></td>
<td class="num">$ (259,060)<span></span>
</td>
<td class="num">$ (2,120,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average shares outstanding</a></td>
<td class="nump">3,747,914<span></span>
</td>
<td class="nump">2,461,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.86)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=chfw_ClassOrdinarySharesSubjectForRedemptionMember', window );">Class A ordinary shares subject to possible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest earned on marketable securities held in Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on marketable securities held in Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,466)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to holder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,223)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,181,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=chfw_ClassAOrdinarySharesSubjectForRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=chfw_ClassAOrdinarySharesSubjectForRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonredeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonredeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=chfw_ClassOrdinarySharesSubjectForRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=chfw_ClassOrdinarySharesSubjectForRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345405495816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INITIAL PUBLIC OFFERING (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 01, 2020</div></th>
<th class="th"><div>Nov. 23, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of Units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodValueNewIssues', window );">Proceeds from issuance of units</a></td>
<td class="nump">$ 12,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,113,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_AdditionsToAssetsHeldInTrust', window );">Additions to assets held in trust</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrust', window );">Assets Held-in-trust</a></td>
<td class="nump">$ 92,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of Units (in shares)</a></td>
<td class="nump">9,200,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodValueNewIssues', window );">Proceeds from issuance of units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrust', window );">Assets Held-in-trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_NumberOfSharesIssuedPerUnit', window );">Shares per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_NumberOfWarrantsIssuedPerUnit', window );">Warrants per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Shares per warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-allotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of Units (in shares)</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodValueNewIssues', window );">Proceeds from issuance of units</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of Units (in shares)</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_NumberOfSharesIssuedPerUnit', window );">Shares per unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodValueNewIssues', window );">Proceeds from issuance of units</a></td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_AdditionsToAssetsHeldInTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of significant additions in the period in assets held in trust (current, noncurrent, or unclassified).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_AdditionsToAssetsHeldInTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_NumberOfSharesIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares in a unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_NumberOfSharesIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_NumberOfWarrantsIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants in a unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_NumberOfWarrantsIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_UnitsIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new unit issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_UnitsIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345405360408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRIVATE PLACEMENT (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 01, 2020</div></th>
<th class="th"><div>Nov. 23, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of Units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodValueNewIssues', window );">Proceeds from issuance of units</a></td>
<td class="nump">$ 12,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,113,691<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PrivatePlacementWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_NumberOfWarrantsIssuedPerUnit', window );">Warrants per unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodSharesNewIssues', window );">Sale of Units (in shares)</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_UnitsIssuedDuringPeriodValueNewIssues', window );">Proceeds from issuance of units</a></td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_NumberOfSharesIssuedPerUnit', window );">Shares per unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_NumberOfWarrantsIssuedPerUnit', window );">Warrants per unit</a></td>
<td class="nump">0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_NumberOfSharesIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares in a unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_NumberOfSharesIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_NumberOfWarrantsIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants in a unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_NumberOfWarrantsIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_UnitsIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new unit issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_UnitsIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chfw_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345405014872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS - Founder Shares (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 10, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 08, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 04, 2020 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,471,210<span></span>
</td>
<td class="nump">1,447,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,471,210<span></span>
</td>
<td class="nump">1,447,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=chfw_FounderSharesMember', window );">Founder Shares | Class B ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased during the period | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased during the period ( in shares)</a></td>
<td class="nump">575,000<span></span>
</td>
<td class="nump">718,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders', window );">Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=chfw_FounderSharesMember', window );">Founder Shares | Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_NumberOfSharesSubjectToForfeiture', window );">Shares subject to forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=chfw_FounderSharesMember', window );">Founder Shares | Sponsor | Class B ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,593,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays', window );">Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences', window );">Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">150 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=chfw_FounderSharesMember', window );">Founder Shares | Sponsor | Class A ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger', window );">Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_NumberOfSharesSubjectToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares owned by the founders subject to forfeiture if the underwriter overallotment option is not exercised in the proposed public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_NumberOfSharesSubjectToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected ownership percentage by the founders after completion of the proposed public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_PercentageOfIssuedAndOutstandingSharesAfterInitialPublicOfferingCollectivelyHeldByInitialStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The share price threshold that must be achieved in order to waive the restriction on transfer of shares during a restricted period after a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>When determining the condition for transfer of shares without restriction after a business combination, the number of consecutive trading days used to observe the share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>When determining the condition for transfer of shares without restriction after a business combination, the number of days in which the share price must exceed the specified amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=chfw_FounderSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=chfw_FounderSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chfw_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chfw_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345411788360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 18, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 23, 2020</div></th>
<th class="th"><div>Sep. 04, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of promissory note - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=chfw_PromissoryNoteWithRelatedPartyMember', window );">Promissory Note with Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote', window );">Maximum borrowing capacity of related party promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Outstanding balance of related party note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=chfw_AdministrativeSupportAgreementMember', window );">Administrative Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth', window );">Expenses per month</a></td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses incurred and paid</a></td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=chfw_RelatedPartyLoansMember', window );">Related Party Loans | Working capital loans warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_MaximumLoansConvertibleIntoWarrants', window );">Loan conversion agreement warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ClassOfWarrantOrRightPriceOfWarrantsOrRights', window );">Price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_ClassOfWarrantOrRightPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_ClassOfWarrantOrRightPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum borrowing capacity of related party promissory note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_MaximumLoansConvertibleIntoWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount which a potential loan could have repaid through issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_MaximumLoansConvertibleIntoWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The contractual monthly amount to be paid for support services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=chfw_PromissoryNoteWithRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=chfw_PromissoryNoteWithRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=chfw_AdministrativeSupportAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=chfw_AdministrativeSupportAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=chfw_RelatedPartyLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=chfw_RelatedPartyLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_WorkingCapitalLoansWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chfw_WorkingCapitalLoansWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345407489624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_DeferredFeePerUnit', window );">Deferred fee per unit</a></td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_DeferredOfferingCostsNoncurrent', window );">Deferred underwriting fee payable</a></td>
<td class="nump">$ 3,220,000<span></span>
</td>
<td class="nump">$ 3,220,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_DeferredFeePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the deferred fee per unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_DeferredFeePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_DeferredOfferingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_DeferredOfferingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345408282760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Preferred Stock Shares (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value, (per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345405365160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Common Stock Shares (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized (in shares)</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_CommonStockNumberOfVotesPerShare', window );">Common shares, votes per share | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="nump">1,471,210<span></span>
</td>
<td class="nump">1,447,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="nump">1,471,210<span></span>
</td>
<td class="nump">1,447,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Common stock subject to possible redemption, issued (in shares)</a></td>
<td class="nump">8,162,790<span></span>
</td>
<td class="nump">8,186,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_CommonStockNumberOfVotesPerShare', window );">Common shares, votes per share | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Common stock subject to possible redemption, issued (in shares)</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_CommonStockNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of votes that each common share is entitled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_CommonStockNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345405173976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>item </div>
<div>d </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>item </div>
<div>d </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders', window );">Threshold number of business days before sending notice of redemption to warrant holders | item</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant', window );">Trading period after business combination used to measure dilution of warrant | d</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement', window );">Maximum period after business combination in which to file registration statement</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective', window );">Period of time within which registration statement is expected to become effective</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">60 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PrivatePlacementWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion', window );">Restrictions on transfer period of time after business combination completion</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantExercisePeriodConditionOne', window );">Warrant exercise period condition one</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantExercisePeriodConditionTwo', window );">Warrant exercise period condition two</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Public Warrants expiration term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo', window );">Warrant redemption condition minimum share price scenario two</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant', window );">Share price trigger used to measure dilution of warrant</a></td>
<td class="nump">$ 9.20<span></span>
</td>
<td class="nump">$ 9.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant', window );">Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant', window );">Trading period after business combination used to measure dilution of warrant | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantExercisePriceAdjustmentMultiple', window );">Warrant exercise price adjustment multiple</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantRedemptionPriceAdjustmentMultiple', window );">Warrant redemption price adjustment multiple</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember', window );">Public Warrants | Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantRedemptionConditionMinimumSharePrice', window );">Warrant redemption condition minimum share price</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo', window );">Warrant redemption condition minimum share price scenario two</a></td>
<td class="nump">18.00<span></span>
</td>
<td class="nump">18.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights', window );">Redemption price per public warrant (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays', window );">Threshold trading days for redemption of public warrants | item</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days for redemption of public warrants | item</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders', window );">Threshold number of business days before sending notice of redemption to warrant holders | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_RedemptionPeriod', window );">Redemption period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantRedemptionPriceAdjustmentMultiple', window );">Warrant redemption price adjustment multiple</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember', window );">Public Warrants | Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $10.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantRedemptionConditionMinimumSharePrice', window );">Warrant redemption condition minimum share price</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo', window );">Warrant redemption condition minimum share price scenario two</a></td>
<td class="nump">18.00<span></span>
</td>
<td class="nump">18.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights', window );">Redemption price per public warrant (in dollars per share)</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays', window );">Threshold trading days for redemption of public warrants | item</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_RedemptionPeriod', window );">Redemption period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days for stock price trigger considered for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time after completion of a business combination in which the reporting entity is required to file a registration statement with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ratio of gross proceeds from a future offering to total equity proceeds which is used to measure whether dilution of the warrant has occurred. If aggregate gross proceeds from a new offering exceeds a specified percentage of total equity proceeds, the warrant exercise price will be adjusted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time after filing within which the registration statement filed with the SEC is expected to become effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_RedemptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_RedemptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time after completion of a business combination during which the shares or warrant may not be transferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cutoff price used to measure whether dilution of the warrant has occurred. Shares issued below this price will cause the exercise price of the warrant to be adjusted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of business days before sending notice of redemption to warrant holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of trading days after a business combination during which the share price is compared to the specified dilution trigger share price in order to determine whether the warrant exercise price should be adjusted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_WarrantExercisePeriodConditionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time after completion of a business combination before a warrant may be exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_WarrantExercisePeriodConditionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_WarrantExercisePeriodConditionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The alternate period of time after completion of an initial public offering before a warrant may be exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_WarrantExercisePeriodConditionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_WarrantExercisePriceAdjustmentMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_WarrantExercisePriceAdjustmentMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_WarrantRedemptionConditionMinimumSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum trading price for the reporting entity's stock which must be achieved as a condition for redemption of the warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_WarrantRedemptionConditionMinimumSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum trading price for the reporting entity's stock which must be achieved as a condition for redemption of the warrant under another scenario.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_WarrantRedemptionPriceAdjustmentMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted redemption price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_WarrantRedemptionPriceAdjustmentMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chfw_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345410947896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>item </div>
<div>d </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>item </div>
<div>d </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders', window );">Threshold number of business days before sending notice of redemption to warrant holders | item</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant', window );">Trading period after business combination used to measure dilution of warrant | d</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement', window );">Maximum period after business combination in which to file registration statement</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective', window );">Period of time within which registration statement is expected to become effective</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">60 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PrivatePlacementWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion', window );">Restrictions on transfer period of time after business combination completion</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantExercisePeriodConditionOne', window );">Warrant exercise period condition one</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantExercisePeriodConditionTwo', window );">Warrant exercise period condition two</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Public Warrants expiration term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo', window );">Warrant redemption condition minimum share price scenario two</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant', window );">Share price trigger used to measure dilution of warrant</a></td>
<td class="nump">$ 9.20<span></span>
</td>
<td class="nump">$ 9.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant', window );">Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant', window );">Trading period after business combination used to measure dilution of warrant | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantExercisePriceAdjustmentMultiple', window );">Warrant exercise price adjustment multiple</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantRedemptionPriceAdjustmentMultiple', window );">Warrant redemption price adjustment multiple</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember', window );">Public Warrants | Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantRedemptionConditionMinimumSharePrice', window );">Warrant redemption condition minimum share price</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo', window );">Warrant redemption condition minimum share price scenario two</a></td>
<td class="nump">18.00<span></span>
</td>
<td class="nump">18.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights', window );">Redemption price per public warrant (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays', window );">Threshold trading days for redemption of public warrants | item</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days for redemption of public warrants | item</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders', window );">Threshold number of business days before sending notice of redemption to warrant holders | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_RedemptionPeriod', window );">Redemption period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantRedemptionPriceAdjustmentMultiple', window );">Warrant redemption price adjustment multiple</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember', window );">Public Warrants | Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $10.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantRedemptionConditionMinimumSharePrice', window );">Warrant redemption condition minimum share price</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo', window );">Warrant redemption condition minimum share price scenario two</a></td>
<td class="nump">18.00<span></span>
</td>
<td class="nump">18.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights', window );">Redemption price per public warrant (in dollars per share)</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays', window );">Threshold trading days for redemption of public warrants | item</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_RedemptionPeriod', window );">Redemption period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days for stock price trigger considered for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time after completion of a business combination in which the reporting entity is required to file a registration statement with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ratio of gross proceeds from a future offering to total equity proceeds which is used to measure whether dilution of the warrant has occurred. If aggregate gross proceeds from a new offering exceeds a specified percentage of total equity proceeds, the warrant exercise price will be adjusted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time after filing within which the registration statement filed with the SEC is expected to become effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_RedemptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_RedemptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time after completion of a business combination during which the shares or warrant may not be transferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cutoff price used to measure whether dilution of the warrant has occurred. Shares issued below this price will cause the exercise price of the warrant to be adjusted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_SharePricetriggerUsedToMeasureDilutionOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of business days before sending notice of redemption to warrant holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_ThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of trading days after a business combination during which the share price is compared to the specified dilution trigger share price in order to determine whether the warrant exercise price should be adjusted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_WarrantExercisePeriodConditionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time after completion of a business combination before a warrant may be exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_WarrantExercisePeriodConditionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_WarrantExercisePeriodConditionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The alternate period of time after completion of an initial public offering before a warrant may be exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_WarrantExercisePeriodConditionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_WarrantExercisePriceAdjustmentMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_WarrantExercisePriceAdjustmentMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_WarrantRedemptionConditionMinimumSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum trading price for the reporting entity's stock which must be achieved as a condition for redemption of the warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_WarrantRedemptionConditionMinimumSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum trading price for the reporting entity's stock which must be achieved as a condition for redemption of the warrant under another scenario.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_WarrantRedemptionConditionMinimumSharePriceScenarioTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_WarrantRedemptionPriceAdjustmentMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In the event of dilution of the warrant, the multiple to be applied to the higher of the market price or the price of newly issued shares in order to obtain the adjusted redemption price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_WarrantRedemptionPriceAdjustmentMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chfw_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=chfw_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345405390840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Marketable securities held in Trust Account</a></td>
<td class="nump">$ 92,026,912<span></span>
</td>
<td class="nump">$ 91,997,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantLiability', window );">Warrant Liability</a></td>
<td class="nump">2,601,180<span></span>
</td>
<td class="nump">3,404,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Marketable securities held in Trust Account</a></td>
<td class="nump">92,026,912<span></span>
</td>
<td class="nump">91,997,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring | Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantLiability', window );">Warrant Liability</a></td>
<td class="nump">2,484,000<span></span>
</td>
<td class="nump">3,250,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Recurring | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantLiability', window );">Warrant Liability</a></td>
<td class="nump">$ 117,180<span></span>
</td>
<td class="nump">$ 153,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chfw_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345405470168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of key Inputs into the Binomial Lattice Simulation Model for the Private Placement Warrants and Public Warrants (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>yr</div>
</th>
<th class="th">
<div>Nov. 23, 2020 </div>
<div>yr</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, Measurement Input</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, Measurement Input</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, Measurement Input</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, Measurement Input</a></td>
<td class="nump">11.50<span></span>
</td>
<td class="nump">11.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=chfw_MeasurementInputFairValueOfUnitsMember', window );">Fair value of Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, Measurement Input</a></td>
<td class="nump">10.12<span></span>
</td>
<td class="nump">9.81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=chfw_MeasurementInputFairValueOfUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=chfw_MeasurementInputFairValueOfUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345411762680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of fair value of the  warrant liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=chfw_WarrantsLiabilitiesMember', window );">Warrants Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Initial measurement on November&#160;23, 2020</a></td>
<td class="nump">$ 1,597,900<span></span>
</td>
<td class="nump">$ 3,404,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in valuation inputs or other assumptions</a></td>
<td class="nump">1,806,114<span></span>
</td>
<td class="num">(802,834)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Fair value as of December&#160;31, 2020</a></td>
<td class="nump">3,404,014<span></span>
</td>
<td class="nump">2,601,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PrivatePlacementWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Initial measurement on November&#160;23, 2020</a></td>
<td class="nump">77,900<span></span>
</td>
<td class="nump">153,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in valuation inputs or other assumptions</a></td>
<td class="nump">75,447<span></span>
</td>
<td class="num">(36,167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Fair value as of December&#160;31, 2020</a></td>
<td class="nump">153,347<span></span>
</td>
<td class="nump">117,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Initial measurement on November&#160;23, 2020</a></td>
<td class="nump">1,520,000<span></span>
</td>
<td class="nump">3,250,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in valuation inputs or other assumptions</a></td>
<td class="nump">1,730,667<span></span>
</td>
<td class="num">(766,667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Fair value as of December&#160;31, 2020</a></td>
<td class="nump">$ 3,250,667<span></span>
</td>
<td class="nump">$ 2,484,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) recognized in income for derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3) and still held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=chfw_WarrantsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=chfw_WarrantsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chfw_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345404979608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Nov. 23, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=chfw_WarrantsLiabilitiesMember', window );">Warrants Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Transfers out of level 3</a></td>
<td class="nump">$ 1,597,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Transfers in or out of level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PrivatePlacementWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantLiabilityFairValueDisclosure', window );">Aggregate value of warrants</a></td>
<td class="nump">153,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantsPerShare', window );">Warrants per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantLiabilityFairValueDisclosure', window );">Aggregate value of warrants</a></td>
<td class="nump">$ 3,250,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,748,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chfw_WarrantsPerShare', window );">Warrants per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_WarrantLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant liability fair value disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_WarrantLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_WarrantsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_WarrantsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chfw_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=chfw_WarrantsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=chfw_WarrantsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chfw_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chfw_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140345411763768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 15, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,340,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chfw_SubscriptionAgreementMember', window );">Subscription Agreement [Member] | PIPE Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new shares</a></td>
<td class="nump">12,020,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=chfw_SubscriptionAgreementMember', window );">Subscription Agreement [Member] | PIPE Investors [Member] | PIPE Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="nump">$ 120,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subscription Agreement [Member] | PIPE Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant voting right per share</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right exercise price of warrants or rights</a></td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Business Combination Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Business Acquisition equity interest issued or issuable value assigned</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member] | Business Combination Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition share price</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chfw_SubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chfw_SubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chfw_InvestorAxis=chfw_PipeInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chfw_InvestorAxis=chfw_PipeInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chfw_PipeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chfw_PipeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=chfw_BusinessCombinationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=chfw_BusinessCombinationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M\+B3C@/7'VA0N.THV-Q2YE0!MQ9]/^'ION3><M"$!_H&O77#WM,$1FZE07"
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M@-_G$F2U>;$3M'?EI_\"4$L#!!0    ( (V)V%*>4 S52 H  '<O   8
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M8@%JM^91Y6.HTCL/V-@6=RMO^Z?A[7JX)0@I:B$X5[=[ANQQWNIVN_0'=M.
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MI)[3@YX _619 @37X'H3F/X.F G R?R,6UYJ*U&;B6*V6.W2UUBC5R#/!^R
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MZ&B'RU;U%YL7]*O9D]S:?$$?YTJ"E.  >#_-P2:X+[B!_]WU%_\#4$L#!!0
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MU5YE;@8GMA0QC@*J=HMF@<'XZOOM.7SLP@8R7&,JK3.B+K(B@9M,&,RT2M"
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M?!DTU[N;6%7Z/BE6E@[)#W/JBU$[ ]K?*[HK[<0YZ#OMY7]02P,$%     @
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M#O7XAV,-KH<U26O&+[(8XIA&2;U5V*A8FO\S(&1Q8<![,BNT:K5,J7'A2JL
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MMZR/ F\\F."EW8- T&@"0"ZH!<<@EZZHRA[/WD#@EJ+64(7Q%L]*J[A8!!N
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MU(9@"_[,E(0GB0#G=)MM%B2@?3\_^1-02P,$%     @ C8G84I\&NZ*2!P
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M*$F9L&"1!IN)@Y*SM_Z(?A_Z>;54B9NO;6(NL-E_ + $T:$7\QBB4J-(\4U
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M]&P51FS>-/Q<H;R!%%[S0:#WJ+C)%R 1YP,?10K(K!I3JWXTJOQ.IWA^ASM
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M$8#W:R'TTXWY%';\N#K\#U!+ P04    " "-B=A2-T U@48"  "_!   &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q]5-MJVT 0_95%4&BAM139:4NP
M#7+L4$,NQDI22NG#6AI92_:B[H[C].\[NY)5%Q*_2#NS<\Y<=$;CO;%/K@9
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M01)\.-;TAP'K ^B^,@8/AD_0_[.F?P%02P,$%     @ C8G84E>) \ >"P
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MLKOXY=]!Z9'(^YO&45K\'[V4MO@(35=I%L_+QGH&\W"Q_NG_5:Y$I8'NQ]Z
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M+:[!:G>X2C]X/PQ NS! '[H?3?CE4JJ6NZ&NP5X7QMY#E9:RVYK2(ELN7=?
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MAP.1ZH@G;"J12N.8RI<K%HGU90=W-@\>^#+4YH$S'*SHDLV8_K::2KAS"I2
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M\J;;G<J1HCEB_DKEDB<*16P!2NYI'[1E=FJ;W6BQLJ>,<Z&UB.UER"@T@A&
M]PLA].;&'%P69^?#_P!02P,$%     @ C8G84DV[=[.& P  ^PL  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&ULM59;C]HZ$/XK5G0>6JF'Q+G M@(D
MNK Z*VVW"&BKZJ@/)AG :A+GV 9VI?[XCIUL8$O(<AZ6!V([\\U\<\EX^GLA
M?ZH-@"8/69JK@;/1NOC@NBK>0,941Q20XYN5D!G3N)5K5Q426&)!6>KZGM=U
M,\9S9]BW9U,Y[(NM3GD.4TG4-LN8?/P(J=@/'.H\'<SX>J/-@3OL%VP-<]!?
MBJG$G5MK27@&N>(B)Q)6 V=$/]S0R "LQ%<.>W6T)L:5I1 _S>8V&3B>800I
MQ-JH8/C8P36DJ=&$//ZKE#JU30,\7C]IO['.HS-+IN!:I-]XHC<#Y\HA":S8
M-M4SL?\'*H<LP5BDROZ3?2G;\QT2;Y46605&!AG/RR=[J )Q!*#A&8!? ?Q+
M 4$%""X%A!4@O!0058#H4D"W G1M[,M@V4B/F6;#OA1[(HTT:C,+FRZ+Q@#S
MW%367$M\RQ&GA[/)W6@Q&9/I:+;X3A:ST?U\=+VX_7P_)W^349)PDW^6DMN\
MK&)3#6_&H!E/U5L4^3(?DS=_O>V[&LD8E6Y<&?Y8&O;/&+X7NPZA5^^([_E>
M _RZ'?Z)R0X)J(73!OBX'3Z&N(8W69]<0-X/SL)OVN%S*#K$"YO@+N:O3J)?
M)]&W^H)S2824:4C(E$G]2!:2Y8J5'^Z_=RA*;C5DZD>+H: V%%A#X5E#!7O$
MOJ*)6)%"BHPK)>0CR84&+ 99\2@,CZ:DE-HCJ]WTO-V0AKU>%/3=70.KL&85
MMK*:'HC<&R)[KC?D64Q:7(]J(]'KQKA;&^JV>O.)/?!LFY&ED(CD^9K$K& Q
M1ZL8]&<A_C,%3978/0EYX)E?<\A[-<E>*\G/6ZTTRQ-#;\E2EL=PRNX,I4GO
M?U7!54WIJI72*,'VR)66S-Q59 YRQV-09+26 *9F6W+SOK;Q_G6+@'J'ONRU
MNC-YP.%!(?\"),E$KC>-/=8[B644G<TN/;H5Z&76>1YOI427,=F85IXTLJ O
ML*@Z^JD8[;:P/;0_ZK_0EH[3<B<P+>07^88C3?7Y<(U76&K/]TQBVMJ*@1ZZ
M(0U>N1P.+8ZV]SCC%(E%O@-IASKV5-7-#E4!#T\#'CW_^JO+\F7!Y[P/79-&
M+_1F7K:&-IK1J?43AJTR)3GW: PR8S'."&N.*4]AA2"OTT.T+"?-<J-%82>C
MI= X9]GE!J=SD$8 WZ\$=K!J8X:M>MX?_@902P,$%     @ C8G84K@;S;4*
M @  \ 0  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULC91?;YLP%,6_
MBH7VT$I;3"#=JHH@K<FF]2%;U+3;LP.78-78S+Z$]MO/-@31*6GZ$OSGGA_G
M.!<GK=)/I@1 \EP):>9!B5C?4&JR$BIF)JH&:7<*I2N&=JIWU-0:6.Y%E:!1
M&'ZF%>,R2!._MM9IHAH47,):$]-4%=,OMR!4.P^FP6'AGN]*= LT36JV@PW@
M8[W6=D8'2LXKD(8K2304\^#K]&8Q<_6^X#>'UHS&Q"79*O7D)G?Y/ B=(1"0
MH2,P^]C# H1P(&OC;\\,AE<ZX7A\H'_WV6V6+3.P4.(/S[&<!]<!R:%@C<![
MU?Z /L^5XV5*&/]+VJXVG@4D:PRJJA=;!Q67W9,]]^<P$DQ/":)>$+U7$/>"
MV ?MG/E82X8L3;1JB7;5EN8&_FR\VJ;ATOV+&]1VEUL=IHM?J]7=P^K;SX<-
MN5@",B[,)?E$'C=+<O'A,J%H7^)*:=8#;SM@= *X8GI"XNE'$H71](A\\;9\
M"=D@#U_+J8TVY(N&?)'GQ>?SO4&+!UKL:;.3[@K0&G)2 ) :-&DDQV-GU&&N
M/<9]2/LTG,17"=V/3^),T2N'L\'A['T.&YF#;C5'+G>=7?;"M@*.N>V05R,C
M<62O@3#\S_#YNLXS'?6CNPML3^RX-$1 897AY(M%Z.[[ZB:H:M^B6X6VX?VP
MM%<2:%=@]PNE\#!Q73]<<ND_4$L#!!0    ( (V)V%(8V%79=P(  )<&   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;)U5:T_;,!3]*U8T:2!US:-M
MV% :"5HFT!YT%#9-TSZXR6UCX<3!=EK8K]^U$[*6M061#_7KGG///:EOHI60
MMRH#T.0^YX4:.IG6Y;'KJB2#G*JN**' D[F0.=6XE M7E1)H:D$Y=P//"]V<
MLL*)([LWD7$D*LU9 1-)5)7G5#Z< A>KH>,[CQM7;)%IL^'&44D7, 5]4TXD
MKMR6)64Y%(J)@DB8#YT3_W@4FG@;\)W!2JW-B:ED)L2M65RD0\<S@H!#H@T#
MQ6$)(^#<$*&,NX;3:5,:X/K\D?VCK1UKF5$%(\%_L%1G0^>]0U*8TXKK*[$Z
MAZ:>@>%+!%?VEZSJV/"#0Y)*:9$W8%20LZ(>Z7WCPQK [^\ ! T@>"F@UP!Z
MMM!:F2UK3#6-(RE61)IH9#,3ZXU%8S6L,&]QJB6>,L3I>'I].?IT?OEY?'8U
M?4O.OMU<7/\D[\@$S00I(253+9);,LVH!$4.QJ IX^H00]X0ERB[';D:E1@^
M-VFRGM99@QU9OU#9)3V_0P(O\+? 1_OA8TA:N+<)=['^UH2@-2&P?+U=)I@:
M,\%3D I-N*N8?B!?A0;RZV2FM,3_VN\]:7IMFIY-T]^1YI^IM6^=9B2TTIF0
M[ ^DVZRL24-+:B[E,O8]^T3N<MVSY^,V5/=;U?V7JC8V=4A))5E27D&'')0@
MZR(.MRFOB8_6%'E=U.,_$?YLV(;N0:M[\#JWF5+5=J<'_SGXU.-]$1LJPU9E
M^#J5V'&5ID7*BL4VJ>&S4O=%U%+=M;9A6C;>R@4K%.$P1XS7/<)J9=T&ZX46
MI>TD,Z&Q+]EIAE\.D"8 S^<"[TRS,,VI_1;%?P%02P,$%     @ C8G84N&E
MQ(YR P  &@X  !D   !X;"]W;W)K<VAE971S+W-H965T,S0N>&ULO5=M;YLP
M$/XK%IJT5NH*AA22*HG4IIU:K5.[IMTT3?O@!"?Q:C"SG:2;]N-G&TJ@(8%T
M+_D0,+Y[[GG.Y@YWEXP_B!G&$CQ&-!8]:R9E<FS;8CS#$1*'+,&QFIDP'B&I
MAGQJBX1C%!JGB-JNX_AVA$AL];OFV0WO=]E<4A+C&P[$/(H0_W&**5OV+&@]
M/;@ETYG4#^Q^-T%3/,3R/KGA:F3G*"&)<"P(BP''DYYU H\',- .QN(CP4M1
MN =:RHBQ!SVX#'N6HQEABL=20R!U6> !IE0C*1[?,U KCZD=B_=/Z&^->"5F
MA 0>,/J)A'+6L]H6"/$$S:F\9<L+G DZTGAC1H7Y!\O4UF]98#P7DD69LV(0
MD3B]HL<L$04';Y.#FSFX31V\S,$S0E-F1M89DJC?Y6P)N+96:/K&Y,9X*S4D
MULLXE%S-$N4G^\.[Z\&[B^NKL_/;X6MP_N'^\NXS> ,&+(I4DH>2C1_ <(8X
M%F#O#$M$J-COVE)%UO[V.(MRFD9Q-T1YC_@A\. !<!T7$HFC5\ &PL"F_Q60
M@^V09WB<0SKUD+;*2YX<-T^.:V*T-L084"0$. &,AR16FWP+I)=#>@;2VPK)
M)EEJOURI>7"IZ(NO6]!;.7IK.^%TV=($'&17@.9RQCCYB4.P1YYF*U<Q1?<-
MNBX B[YWY*2_KKTH+DX3RY*$HUS"T2X2$L3! M$Y-M1#1BGB B28IQ;[X!=8
M+7R5I#1:4"#J'"J2\)F>6K.2&#\7X^\B9L$D+I!7W/7&K6+MKZ7W.>%M%B6N
M0<XU>,'>(4+,Z_=-L$ZF%4 7/M\U57:MH -;U=3;.?7V"ZBKIB4DBM6K.ZWC
MWV[(O\IN"_].SK_3B+\I"6(^^J9Z') ,)$P(,J)8]<L01XGN>P<-5Z2SQK0-
M?3?H/%=49=?VG;9?K0@ZJ[[B-*B=ITUJ)RPT*_@/JB=<U7M84_#_L'YF\*4-
MLJ& -C(MRUCU&.C]UQJ:A:LMHO5V94&KM@9WZFO-ZRA<[U-KI+>9E/FN>AC<
MJ8GM5$LSZ"(?UZO<0?6&9?JKK@5W:EN[UU.XWITV:*@W+&M8=3/8K)W]Q9H*
MU]O7!E7UAJDJN_#AKD]-ZCMY2F(!*)XH3^<P4$O,TX-(.I L,=_R(R;5R<#<
MSM3A#7-MH.8G3+T:V4 ?#_+C8/\W4$L#!!0    ( (V)V%)[<X2X% 8  !(?
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;,U9VV[C-A#]%<+8ARU0
MQ)(8.\XB,9!DMVB!I@V2;?-0](&6QA:[DN@EJ3@!]N,[I&31LF7:,=9I\Q#K
M,K<S',XAQ8N%D%]4"J#)<YX5ZK*7:CW_T.^K.(6<J1,QAP+?3(7,F<9;.>NK
MN0266*4\ZT=!,.SGC!>]\85]=B?'%Z+4&2_@3A)5YCF3+]>0B<5E+^PM']SS
M6:K-@_[X8LYF\ #ZC_F=Q+M^8R7A.12*BX)(F%[VKL(/-Z>!4; 2?W)8J)5K
M8J!,A/AB;GY)+GN!B0@RB+4QP?#G"6X@RXPEC.-K;;37^#2*J]=+ZS]9\ AF
MPA3<B.R1)SJ][(UZ)($I*S-]+Q8_0PUH8.S%(E/V/UG4LD&/Q*72(J^5,8*<
M%]4O>ZX3L:(0G6]1B&J%:%\%6BM0"[2*S,+ZR#0;7TBQ(-)(HS5S87-CM1$-
M+\PP/FB);SGJZ?'CU?W]U6^?'\C[CZ 9S]0/%WV-=LW;?ES;N*YL1%ML4'(K
M"ITJ\JE((.G0O_'KGWKT^XBG 14M05U'7H.W3)X0&OY(HB *N88\>4?Z1*5,
M@NH*SV_M(\2-M<!KK14L;4: 6O-TB_F;C"E%Q)0\,BE9H8F0Q,XF\M>O*$I^
M08_J;X^CT\;1J75TNL71YQ0#3D66D*+,)R"-STFI4 K])^Q%D0E@7P"BH$AX
M,2.%T#P&(R8A@7QNYYT69%$':FR!5.0;,5GIJILJH*$-R#24IS&]Z#]U8!@T
M& 9^#)+9T.8@N4@(FVK$T8"(13[A!;-QE@H2$VP.3)4(*N%9:5\@G"6 ;Z2K
M6J\'&U%'07?8PR;LH3?L>FA]Y7+6F#H[;KF,&D<C;\RW[)GG9;Y'JGE!%BF/
M4Y/N*<\ RV7&E9;56Z49A@2%[DJU/X0HL'79-64/4&QEX;S)PKG7TEV%'O.M
MD;VP.>NT@=L-DW!%X'F.-%45X 0P5T!@.@5+65UI\,<PW)Z& Q1;:0@#QQ.!
M/Q&2/R%"<I>QN,*Y1U&'*S04'K>LP\BYBKQ([@$'C=M5!'K$CH;^U!2+>]X>
M:T_%X_4\ W/9R99^_W3[<!ZBV<Z"8YV0^L>SG&0\WFL0'<&$IT<>1,<#H9\(
MEA[@&63,%2P'+Q;(756?+SJGV@Z[OL$Y0+.-SM%%N!=?>-#IA>A$Y[<;DA=@
MLA/<ZQ7;V!Q_A6>O*3S3*WG=0W&^=2XC=E@<V."ZQ^P S38N1Y>AGW.68[:R
M5G+#A2MW2Z9VU4CFTJRK5 P%PV'=.I:5O\'*.B0<->N0&I]7IHW$45[HIXV'
ME2"Q4\YFV ;W6$YU8J@\C5;B.S\)SUM_ZY!>H]+>'C@RBW:0&4XKI##<IYKX
M9U)@VRIPRSF7(@9(E$&JA689@:\EUR_NQ8%YJ.-975,.@S7@?IDV4L>K4?B?
M+YAOZACV63%'CJ8C/]EM]D!;D"SY!W?%=@&2XU:=(P]W)CS:""D,!^L9]PNU
M W?,&OF9M:,1O"YTNAE5L%$L?J%VZ([ (_\6<;TW?R/W#H3C=44>4\!VG>)R
MT"+#ZB(5^5^1WR46'),OI&HCG[Z6+%-F)?#IN9I"[\+1B0EU^S;?K0*BP7$7
M')&CY&@_2MZWO7>.['"S6V\,K%>F';SCW,C/<]^=FVI_0Q\W^67:2!S+1GZ6
MO5^?5*;TYE79+KO4>]RA)2++D-GM:PNL\[M6[6R5:X*3(%P'LD.J#<71;.2G
M6?<]1M=-VGZ$F6(-R]:L:\/S?6^I/6YIQ#4:KTS[$Y8C5.HG5(<%ZTI!7)J=
M[O?#13>ID:[C\LNT<3GZI#OH\\V_F=W033+=\M&,.BZEN[:\;M;8A4!GD@_>
MMAZBV4:R\K'TN.1*.WASM%%*?J%VZ(Y<Z?^"7 ,_N5)'KO3(Y$H=N=+CDRO=
M@US],NW@';G2-R97N@>Y^F7:2!RYTK<D5]I%F^O<ND.H#<11*WUS:J6;M+E)
M05Z9]J&-H]93/[7NU;MWV/#T[D,T*R3]E5/''.3,'L::/659Z.H LGG:'/A>
MV6/.OA.O3HMOF9SQ0I$,IJ@:G)SA#)75 6QUH\7<GF%.A-8BMY<I,&12(X#O
MIT+HY8UQT!R#C_\%4$L#!!0    ( (V)V%( 3W;J'08  !L?   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;,U9;6_;-A#^*X31#QTPQ)(8.TGA&$C2
M#@O0=$':+1B&?:"EL\55$EV2BA.@/WY'2A8M6Z8=H\F6#[%>[NTY'N\AQ=%"
MR*\J!=#D,<\*==Y+M9Z_Z_=5G$+.U)&80X%OID+F3..MG/757 )+K%*>]:,@
M&/9SQHO>>&2?W<KQ2)0ZXP7<2J+*/&?RZ1(RL3COA;WE@SL^2[5YT!^/YFP&
MGT'_/K^5>-=OK"0\AT)Q41 )T_/>1?CNZC@P"E;B#PX+M7)-#)2)$%_-S75R
MW@M,1)!!K(T)AC\/< 599BQA'-]JH[W&IU%<O5Y:_\6"1S 3IN!*9/<\T>EY
M[[1'$IBR,M-W8O$KU( &QEXL,F7_DT4M&_1(7"HM\EH9(\AY4?VRQSH1*PK1
MV1:%J%:(]E6@M0*U0*O(+*SW3+/Q2(H%D48:K9D+FQNKC6AX88;QLY;XEJ.>
M'M]?W-U=?/I"/EY?7%Y_O/[R)WG['C3CF?IIU-?HP(CUX]K8964LVF*,DAM1
MZ%21#T4"28?^E5__V*/?1V -NFB)[C+R&KQA\HC0\&<2!5'(->3)&](G*F42
M5%=X?FOO(6ZL!5YKK6!I,Q34FJ=;S%]E3"DBIN2>2<D*380D=EJ1OSZB*+E&
MC^IOCZ/CQM&Q=72\Q=&7% -.19:0HLPG((W/2:E0"OTG[$F1"6"# **@2'@Q
M(X70/ 8C)B&!?&XGH!9D40=J;(%4Y#LQ6>FJFRJ@H0W(=):',1WU'SHP#!H,
M S\&R6QH<Y!<)(1-->)H0,0BG_""V3A+!8D)-@>F2@25\*RT+Q#.$L!WTE6M
MEX.-J*.@.^QA$_;0&W8]M+YR.6E,G;QLN9PVCDZ],=^P1YZ7^1ZIY@59I#Q.
M3;JG/ ,LEQE76E9OE688$A2Z*]7^$*+ UF77E#U L96%LR8+9UY+MQ5ZS+=&
M&L,NK=,&;C=,PA6!QSGR556 $\!< 8'I%"QW=:7!'\-P>QH.4&RE(0P<803^
M1$C^@ C);<;B"N<>11VN\%'XLF4=1LY5Y$5R!SAHW"XGT"-V-/2GIEC<\_98
M>RH>K^<9F,M.MO3[I]N'\Q#-=A8<ZX34/Y[E)./Q7H/H""8\?N%!=#P0^HE@
MZ0$>0<9<P7+P8H'<5?7YHG.J[;#K&YP#--OH'%V$>_&%!YU>B$YT?KLA>0(F
M.\$]7[&-S?%7>/*<PC.]DM<]%.=;YS)BA\6!#:Y[S [0;.-R=!GZ.6<Y9BMK
M)3=<N(2W9&I7C60NS;I*Q5 P'-:M8UGY&ZRL0\+39AU2X_/*M)$XR@O]M/%Y
M)4CLE+,9ML$]EE.=&"I/IROQG1V%9ZV_=4C/46EO#QR913O(#*<54AAN6$W\
M,RFP;16X]YQ+$0,DRB#50K.,P+>2ZR?WXL \U/&LKBF'P1IPOTP;J>/5*/S/
M%\Q7=0S[K)@C1].1G^PV>Z M2);\@]MCNP#)<<_.D8<[$QYMA!2&@_6,^X7:
M@3MFC?S,VM$(GA<ZW8PJV"@6OU [=$?@D7^+N-Z;OY,[!\+QNB+W*6"[3G$Y
M:)%A=9&*_"_(;Q(+CLDG4K61#]]*EBFS$OCP6$VA-^'ID0EU^S;?K0*BP<LN
M.")'R=%^E+QO>^\<V>%FM]X86*],.WC'N9&?YWXX-]7^ACYN\LNTD3B6C?PL
M>[<^J4SIS:NR77:IM[A#2T26(;/;UQ98YW>MVMDJUP1'0;@.9(=4&XJCV<A/
ML^Y[C*Z;M/T(,\4:EJU9UX;G^]Y2>]S2B&LT7IGV)RQ'J-1/J X+UI6"N#0[
MW1^'BVY2(UW'Y9=IXW+T27?0YZM_,[NBFV2ZY:,9=5Q*=VUYW:RQ"X'.)!^\
M;3U$LXUDY6/IRY(K[>#-TXU2\@NU0W?D2O\7Y!KXR94Z<J4O3*[4D2M]>7*E
M>Y"K7Z8=O"-7^LKD2O<@5[],&XDC5_J:Y$J[:'.=6W<(M8$X:J6O3JUTDS8W
M*<@KTSZT<=1Z[*?6O7KW#AN>WGV(9H6DOW+\F(.<V5-9LZ<L"UV=1#9/FY/?
M"WO>V7?BU;'Q#9,S7BB2P115@Z,3G*&R.HFM;K28V\/,B=!:Y/8R!89,:@3P
M_50(O;PQ#IKS\/&_4$L#!!0    ( (V)V%('C$5HXP(  (,)   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;+56T6[:,!3]%2O:0RMMC9V$ !4@4:!:
MI79"4-IG$RY@U8F9;:"5]O&SDQ HA*A3NY?$CN\YN>?XYCJMK9 O:@F@T6O,
M$]5VEEJOKEU714N(J;H2*TC,RES(F&HSE0M7K23060J*N>MA'+HQ98G3::7/
MAK+3$FO-60)#B=0ZCJE\NP$NMFV'.+L'([98:OO [;16= %CT)/54)J96[#,
M6 R)8B)!$N9MITNN>R2P@#3BB<%6'8R1E3(5XL5.[F9M!]N,@$.D+04UMPWT
M@'/+9/+XG9,ZQ3LM\'"\8[]-Q1LQ4ZJ@)_@SF^EEVVDX: 9SNN9Z)+8_(1=4
MLWR1X"J]HFT6&S0=%*V5%G$.-AG$+,GN]#4WX@!@A)8#O!S@?13@YP _%9IE
MELKJ4TT[+2FV2-IHPV8'J3<IVJAAB=W&L99FE1F<[MQV[T;HJ7L_&:"'07<\
M&0T>!K\>Q^BB#YHRKB[1#S09]]'%M\N6J\T++<R-<O*;C-P[0_Y Y17RR7?D
M88^4P'O5\#Y$!1R_A[M&9J'5*[1Z*9]_AJ^K%&AU7<'D%TQ^RA2<%_9B_)ER
M0 JBM62:@4)+X#/$$O0HS;ZA;A2)=:++7,O(:RFY_<XVG::1&#:)UW(WA_Z4
M!))FLU[#I A\EW]0Y!]4.G'/Z)3Q-.LJ.VH%7:W2CF<J)4TTVM&^E8G.*,(#
M+5Z("6G@(\VG<7Z  TR"<LEAD6-8F>,];( C@OZ@D=TQR9)%A?)ZP5K_9$DU
M"J;&_RRIQHEK9TJJ)+"RI)I%_LU_]=>,A^LI9Q'*"T15^$3POF/AKRA><M "
MR>?+-^=X5[]!(\#XN'Y+ GVOAL.P7FXPV;<OXGW 8O_88LDV5 ,:<AJ!.6#U
MA]S>=SKB?XG;^]9#@B]P.SCI?(343YM%65S-]X-CK]V#$]+^GIBO;<$2A3C,
M#1!?U0V#S$[\;*+%*CTTIT*;(S@=+LU?$D@;8-;G0NC=Q)[#Q7]7YR]02P,$
M%     @ C8G84HB3^"DM P  ;0L  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&ULQ59-;^(P$/TKHYQVI99\4"BM (E2JJU4*@3].*SV8,( 5ITXM1TH
M_WYM)PTII6D/2%Q(;,\\YKUGAFFON7B12T0%;Q&+9<=9*I5<NJX,EQ@16>,)
MQOIDSD5$E%Z*A2L3@61FDR+F!I[7="-"8Z?;MGLCT6WS5#$:XTB 3*.(B,T5
M,K[N.+[SOC&FBZ4R&VZWG9 %3E ])B.A5VZ!,J,1QI+R& 3..T[/O^S[39-@
M(YXHKF7I'0R5*><O9G$[ZSB>J0@9ALI $/U881\9,TBZCM<<U"F^TR26W]_1
M;RQY369*)/8Y>Z8SM>PX+0=F."<I4V.^_H,YH8;!"SF3]A/6>:SG0)A*Q:,\
M65<0T3A[DK=<B%*")KH_(<@3@I\FU/.$NB6:569I71-%NFW!UR!,M$8S+U8;
MFZW9T-C8.%%"GU*=I[HWO=LQ//7N'@<P'/0FC^/!<'#_,(%3F&3& I_#"V[@
M-DY2)8'&BH-:(ES1F$>4,+@C2M$084*CE!'KS9#/D(&^8S9R).B**/UD)$1]
M Q0\$R%(K-%(/(-1.F4TW.[]ND9%*)._VZ[2!$V9;IB3N<K(!%^0N<:P!G7_
M! (O\#9B#T"_&N">KVH0U/<#N%K:0M^@T#>PB&=?((ZI?#F="T2C' J4"H06
MHP*Y7B#7+7+]*^<(%?!$6(HP1")3D6F;^V24-8>9(0\8+F/ZFJ*$OW<:!VX5
M1O)?115G115GE?S>;3OY7,0^_S(PW[-HIL6LNE[MK.VNRAY]$_2ASD919Z.R
MSL%;HAL'SD";$,&O#1*Q>\,^X#8+W.8173@OJC@_I L96+.D;V/'@JJ(#Q6V
MB@I;/]-_Q4V38%1M*GA?%*@71U3?][9-U#ND_CE:65Z_N>/ OIA@OP=^J=G[
MW[B (J02(1&Z95=1W_8W/SBF!=MNZ-</:D&&=E&6UZ_M_@R^B_I8Z[9G^M5-
MTVJVLIKI?]?'F"I9I<&VQ_F-8WJQ[8E^\Z!>-#^K[-5*MSTWXW/81:WE[YCA
MEF8A,X@.B5C06 +#N4[S:N=:0I'-=ME"\<2.1U.N]+!E7Y=Z'D9A O3YG'/U
MOC 35S%A=_\#4$L#!!0    ( (V)V%)A $2 W ,  %@.   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;-5738_B.!#]*R5VM>J6NCMQ$A)Z%I#X:@U2
MTT(P]!Q6>S#!@#6)S=H.S/S[M9.0I(<0S87#7"!VJI[?JW*YXNZ)BV]R3XB"
M[W'$9*^U5^KPR;)DN"<QED_\0)A^L^4BQDH/Q<Z2!T'P)G6*(\NQ;=^*,66M
M?C>=FXM^ER<JHHS,!<@DCK'X,201/_5:J'6>6-#=7ID)J]\]X!U9$K4ZS(4>
M607*AL:$2<H9"++MM0;HTP@%QB&U>*?D)"O/8*2L.?]F!M--KV4;1B0BH3(0
M6/\=R8A$D4'2//[+05O%FL:Q^GQ&?TG%:S%K+,F(1U_I1NU[K4X+-F2+DT@M
M^.DSR06U#5[((YG^PBFWM5L0)E+Q.'?6#&+*LG_\/0]$Q4'CU#LXN8/SJPYN
M[N"F0C-FJ:PQ5KC?%?P$PEAK-/.0QB;UUFHH,VE<*J'?4NVG^B^#Z0+>!Z^K
M"<PF@^5J,9E-WKXLX1&666*!;V&+J8 CCA)B1FI/ $Y8",P41!2O:405)1+N
MQD1A&LE[[;U:CN'NS_NNI31)LY05YH2&&2'G"B$$,\[47L*$;<BFQG_4[.\V
M^%LZ.$6$G'.$ADXCX)B$3^"B!W!LQZ[CT^P^PZ)P1PUTW")A;HKG7<'[F@5>
MPFL9^098KX#U4ECWVCXP*7XW*7Z -WUZC(F@1VQ*# 92ZHF[\WH_[F%&L$P$
MV8"NPP4)$R$HV\$02RH?8,7X6A)QQ.N(P)0=$F5L. NU,TY+]Y]7O3A,%8GE
MOPW4VP7U=F-$IDP' 4<09ZST&:,,L3=^)/&:B+_^0+[]M^->3> P@V^G\.;8
M._91^SEXMK7QL9KH2SO7LST;>87=!_Y^P=]OY#_:8[8C0%E:8EF(J(F;!"Z
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M_8@P!OK]EG-U'I@%BLMD_W]02P,$%     @ C8G84FF"*LQ1 P   PL  !D
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M=VE?QQO5[$'J3RNS'6'GT&7T1M&2K>U\778",/8^SD[JFF\^<K80%76;?W'
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M:L_!@_,H:<^I9/L;T.074$L#!!0    ( (V)V%*7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ C8G84H"><6[< P
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M=?])YI]02P$"% ,4    " "-B=A2!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( (V)V%*[SW"C[@
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( (V)V%*97)PC$ 8  )PG   3              "  <P!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ C8G84G=>K_8! P  G D  !@
M             ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( (V)V%+'SE.&. 4  .83   8              " @40+  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "-B=A2FZG,N2\#   L
M#0  &               @(&R$   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ C8G84HP!U,[+!   <1,  !@              ("!%Q0
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( (V)V%(,\\C)
M/04  +H5   8              " @1@9  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " "-B=A2GS4QI6D"  !F!0  &
M@(&+'@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ C8G8
M4JR;-,L\!@  -Q<  !@              ("!*B$  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( (V)V%*>4 S52 H  '<O   8
M      " @9PG  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" "-B=A2\L<8YZX4  "#70  &               @($:,@  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ C8G84EL'D9NT P  !PP  !D
M             ("!_D8  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " "-B=A2'Q*B0"\#  "="@  &0              @('I2@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( (V)V%+T:>NA" @
M +@@   9              " @4].  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ C8G84G*(PXY[!   HQ   !D              ("!
MCE8  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "-B=A2
M? 3K\6L#  !U"P  &0              @(% 6P  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( (V)V%(&)^[X9 P  %U#   9
M      " @>)>  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ C8G84KMTB![6"0  7"D  !D              ("!?6L  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "-B=A2\E1YWT,&  !+%P
M&0              @(&*=0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( (V)V%*?!KNBD@<  $03   9              " @01\  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ C8G84ADY?]CG
M%0  $6@  !D              ("!S8,  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " "-B=A27/Y5[&X$   W#P  &0
M@('KF0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( (V)
MV%+34A(.<04  !X-   9              " @9">  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ C8G84JAQB'$7!0  UP\  !D
M         ("!.*0  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " "-B=A2MP!;:#H%  !H%0  &0              @(&&J0  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( (V)V%(W0#6!1@(  +\$
M   9              " @?>N  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ C8G84E>) \ >"P  6$H  !D              ("!=+$
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " "-B=A2MB.5
MCLT"  !&!P  &0              @(')O   >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( (V)V%*GX6L;=P0   (2   9
M  " @<V_  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
MC8G84BLIDAPK!   ^A$  !D              ("!>\0  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " "-B=A2UFG%.S$#  #0"P  &0
M            @('=R   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( (V)V%*\(W]E1P4  $<7   9              " @47,  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ C8G84DV[=[.& P
M^PL  !D              ("!P]$  'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " "-B=A2N!O-M0H"  #P!   &0              @(&
MU0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( (V)V%(8
MV%79=P(  )<&   9              " @<'7  !X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ C8G84N&EQ(YR P  &@X  !D
M     ("!;]H  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
M" "-B=A2>W.$N!0&   2'P  &0              @($8W@  >&PO=V]R:W-H
M965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( (V)V%( 3W;J'08  !L?   9
M              " @6/D  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L!
M A0#%     @ C8G84@>,16CC @  @PD  !D              ("!M^H  'AL
M+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " "-B=A2B)/X*2T#
M  !M"P  &0              @('1[0  >&PO=V]R:W-H965T<R]S:&5E=#,X
M+GAM;%!+ 0(4 Q0    ( (V)V%)A $2 W ,  %@.   9              "
M@37Q  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ C8G8
M4FF"*LQ1 P   PL  !D              ("!2/4  'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " "-B=A27%T0$E$#  #""@  &0
M        @('0^   >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( (V)V%)*>83^(@,  ! 2   -              "  5C\  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ C8G84I>*NQS     $P(   L
M ( !I?\  %]R96QS+RYR96QS4$L! A0#%     @ C8G84H"><6[< P  C!L
M  \              ( !C@ ! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M (V)V%(I78B@DP$  .(8   :              "  9<$ 0!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( (V)V%*(C*DWI0$  "\9   3
M              "  6(& 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     Q
- #$ 3@T  #@( 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>134</ContextCount>
  <ElementCount>265</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>40</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001002 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>001003 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>001004 - Statement - STATEMENT OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/StatementOfOperations</Role>
      <ShortName>STATEMENT OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>001005 - Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/StatementOfChangesInStockholdersEquity</Role>
      <ShortName>STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>001006 - Statement - STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/StatementOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>001007 - Statement - STATEMENT OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/StatementOfCashFlows</Role>
      <ShortName>STATEMENT OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100007 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/DescriptionOfOrganizationAndBusinessOperations</Role>
      <ShortName>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100009 - Disclosure - INITIAL PUBLIC OFFERING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/InitialPublicOffering</Role>
      <ShortName>INITIAL PUBLIC OFFERING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100010 - Disclosure - PRIVATE PLACEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/PrivatePlacement</Role>
      <ShortName>PRIVATE PLACEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100011 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100012 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/Commitments</Role>
      <ShortName>COMMITMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100013 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100014 - Disclosure - WARRANT LIABILITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/WarrantLiability</Role>
      <ShortName>WARRANT LIABILITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100015 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100016 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>102009 - Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatements</Role>
      <ShortName>RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>20000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>300018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Consonance.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>302020 - Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables</Role>
      <ShortName>RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>302022 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Consonance.com/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>400000 - Disclosure - DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails</Role>
      <ShortName>DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Consonance.com/role/DescriptionOfOrganizationAndBusinessOperations</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>400001 - Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatementsAdditionalInformationDetails</Role>
      <ShortName>RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>400002 - Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Summary of restatement of previously issued financial statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/RestatementOfPreviouslyIssuedFinancialStatementsSummaryOfRestatementOfPreviouslyIssuedFinancialStatementsDetails</Role>
      <ShortName>RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Summary of restatement of previously issued financial statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>400003 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>400004 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basic and diluted net income (loss) per ordinary share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedNetIncomeLossPerOrdinaryShareDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basic and diluted net income (loss) per ordinary share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>400013 - Disclosure - INITIAL PUBLIC OFFERING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/InitialPublicOfferingDetails</Role>
      <ShortName>INITIAL PUBLIC OFFERING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Consonance.com/role/InitialPublicOffering</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>400014 - Disclosure - PRIVATE PLACEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/PrivatePlacementDetails</Role>
      <ShortName>PRIVATE PLACEMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Consonance.com/role/PrivatePlacement</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>400015 - Disclosure - RELATED PARTY TRANSACTIONS - Founder Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/RelatedPartyTransactionsFounderSharesDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS - Founder Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>400016 - Disclosure - RELATED PARTY TRANSACTIONS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>400017 - Disclosure - COMMITMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/CommitmentsDetails</Role>
      <ShortName>COMMITMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Consonance.com/role/Commitments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>400018 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/StockholdersEquityPreferredStockSharesDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Preferred Stock Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>400019 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/StockholdersEquityCommonStockSharesDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Common Stock Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>400020 - Disclosure - WARRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/WarrantsDetails</Role>
      <ShortName>WARRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Consonance.com/role/WarrantLiability</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>400030 - Disclosure - WARRANT LIABILITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/WarrantLiabilityDetails</Role>
      <ShortName>WARRANT LIABILITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Consonance.com/role/WarrantLiability</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>402036 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Consonance.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>402037 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of key Inputs into the Binomial Lattice Simulation Model for the Private Placement Warrants and Public Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/FairValueMeasurementsSummaryOfKeyInputsIntoTheBinomialLatticeSimulationModelForThePrivatePlacementWarrantsAndPublicWarrantsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of key Inputs into the Binomial Lattice Simulation Model for the Private Placement Warrants and Public Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>402038 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of fair value of the  warrant liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/FairValueMeasurementsSummaryOfFairValueOfTheWarrantLiabilitiesDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of fair value of the  warrant liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>402039 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="chfw-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>402040 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/SubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Consonance.com/role/SubsequentEvents</ParentRole>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>chfw-20210331.xml</File>
    <File>chfw-20210331.xsd</File>
    <File>chfw-20210331_cal.xml</File>
    <File>chfw-20210331_def.xml</File>
    <File>chfw-20210331_lab.xml</File>
    <File>chfw-20210331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>97
<FILENAME>0001193125-21-198826-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-198826-xbrl.zip
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MZK1/ITT@GE O1+PY-,U)_,+ Y'UZ6/Y0,$<4!J7CG[^#7]6#/ CSX\*7^IA
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M3;R%2&8QQ-3$A,3T4GU@4Q:A'MFBRVE?J*%GCQW/X6%@ALX#NXLF$S\(>\.
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M<="_,."PH'P1K'<2!2QG(<=AG_4"6+!P_37-XOS#Q^V[PUK9I)3=#.[-8,A
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MJ?/-AR4 ]>%30V2&OQRS8 C;#(; 8SB2%\Z6FZ9PJ.QT3^3=(&DMC.'YYAK
MYJ<GRPV4F>D"MB\PW6O/9D__Q>9<DEXWMW2H>*(>D(A-)\ UAXOB+/5R!O:>
M;8,*Q$GFW014KL*;3\4&8ONG#GKQ2.NH;9LT>9E/IIQA]N@6:MLN"-?I>:M[
ME/;GKU;;=L'YVZ>GI\>=7$G7E6O;+KH][?/STV/=Y[IJ;=M% >@"'EJ=\RP
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MCG6=T!*^(YE0&5RHSF1?+*%#,A2)A&Q!5B&5RC9E5>4LV8A"VK*D<9J&/1P
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M8QZJN!,SD,%<&"NPR>P6=E7,/E WAT% 0^6:OPXOZT_"=(X+_$4,C+#8&[,
M&%$J\^[OO=YM*A!,[A+4TYVQ!JSCQ5E],E2< T]XMW@81*(D(*H-5Y@;MB$%
MH=UJ_G=JFQ&N'B:\@@ ZP_5^8T.T<13-; "&N^;_%(58[RXO#HT+&?K540>X
M'?A^Z*'[QH[%"<K^8$Q[J.<I%9+*- +!O=1H*2$Z]*B-'5B=W< T7QZ920 U
MB%P9-PAB='%M(24$ 6"@08K)>CT" SZZSZ3</.>4#=>5U)$F(H4*/'_H-,)\
M+6'^QF[*B7[P :B\YJ5"C01SDM9*<7W+Y"-CX/J/G,*&PE\"=K$8*W'N"YUL
MN;.K+U+3J+(A'E/N,4 K2Y08'N8G,)6-@R[Y+!K(R9U%05KY2]"@IYX*A"".
M$Q0D%PFH\ 17 S.[0(W;CS3HY3DN'Y'J3]Y@DPX3O/ O4&W30>4BY;_G>1AH
M^$8' *V$#3.Y_WK72VV/VL9G9H*]01&<?!1?YFNWT'@8.*[*F%=G&J#^8CYK
M#NLCX; 6!H0Z[8J.U(SA*& ,DUW"$9<SEZ6)$S4#"U 4[1!OLRD<]A#;,&H"
MX9=GLG!H;H6XLZ5+; NF&I!),XBH$Y>D\"G^EMHALB.53I7;,42]G=AQ5U6E
MKA+[I\<%Q%T;38,KN6;32"5.8V+(@!*[RO+S8I&?A.546MC8MZF+BG)R_S,:
M3X"7 O>[T9T<=_A5-.$JEZ_3:G=R^7O_O/EXE\_8(Y4RA$V "<R?P-3M!Y-J
MO=)E)*E(B=MTI)Z0<^(!"^I%/%%%5&1/<VD@'Y)Q>!F@$AD1\C)*?$,H>1JY
M5NE%HL3#W3#Z49BY<=6@O_M, X4<U*3-:"G,)*.08P$A<"G84Z##HG-[=-0Z
MBK?(#/HFH+QY\^0RF;T'4T68!)IHE;KS&W4[DW0TQ*)H8$1@@8B4@5^/G.:"
M<]+%,$2JT"$F@?_TK$E/L5_9[1 ,/;T*#'Z(Q '/]_J.8.6PN0[',F0/J ;[
M7AE(=*NG+%@#)V&(7WMXR<VT1A$JB^:SF#D3+) !)[L">7]748#TU\CO;[O5
M.>B_/6C'!U&=%(EH/H4J"?_3Z0[!!Y)#I*25(LVJI @]D(FZLZ12U).)#NB8
M.!P59KR+*G)BT>) E.-5,S/#0,INK=C,<LF.T>Z@!,IPD!Y9"V]U(#JT5 $5
ML%=I&82J2WGK%2=\2Z=XVO%;"!5"(XKW0@9D%;^(LP0LO/_HRCB0/PDI-UAN
M)'M2B39Q[3=YSH2&G@&O@(E-)I2.L\F;7HJX4J<B1VC(\W"Y>'53K!<7HRT9
MI),3 &9]XK?I+!3*?W"%BB>S,31,B2'+426L)!$&EKY^A@GO:J=H:I%PHFVN
M%"PX-<BP :.J/7IBEDW.$7'_5=Q/#/)TG\KC:,A<D3*Y2[1@VKBT FJ+P=53
M?/(';>;[B%J'D\0<H\2D5P/@J[&-.#UPD9Q$X5OR"N3B<W)1Q).Q__)UHWT[
M[6<Q%&Z$3TXJN>VH/ QG'1/<.KS'3+E!SC@.Y^ UMBC.Z@5;.&24^1;OM44B
MNX3'\9SE6UL%.[(*OHM-O.2P9#J0M3DPPQP0?L"44VBFHPJ?0 \<Y@HE#D,I
M;W@IT]"28(%E$[=A\48A@\7T,*4*"H$E(JA"FJ$>B9R8$E9$"H](Q,177:W.
M&_ZMJZ\#&8(>$L\N>2><*S :)],6@1/?U!9:K>CM9]C4 EU[B?SNQ(\JH$=6
M@@Z_F#_)HHB)(2:E-,G$MR]X$@LU_A790WS@T+@FM2'.VIT:MU=SQ;J5C-4/
M1'ZHK2J=.&&4%#5A](#E!%8T1OYO*?V-/3ETWVU.*E*NVG$J28*#/B@=\GBX
MR(6.&:JHL4MH&S+30&JI,C[CH7L+X_Q :\(TU=*@I2<+3ZR#F0" Y@<1XL^Z
MV[%V0T2.9>%,$U,)":AC'/ I[334W.--JYUDU1.'6%^8N!%]T"H-[XM<? D%
M==31YA3:X2,0 4TZK8Y6YDTJSW!L'< +G$+]TFG*7R[OFPJS1=5@4I<O*$K#
MDGU.&TZV8VMF,5F;Z<=EBE"I,]Z;%B)80W&<K>W/Q@)5-7M:@#U]H6LWY%#5
MG#W_D/F[Z=S=/6%8N]G37KCDF6V4W_.:><OI$;.@U<]TS?\^H+88S\9'QW7Y
M8:T/5.W J=9S287P^EC-*<6EZT>X^%0B/LI+Z=!B5(.V2:YF$>1"0:WPK'\O
M<IN$V.^3[/;%S7:\I,C%+7)Q!.4TZ9H$*N$750AI-B=Q*5.TO0U%='P8.2*K
M!PYHG(=J)-FC&&F33JR//OH2]82NJ][=QU1"5^%[%Q32DSY0_?7>W47J[:,S
M8#:?1!Y+Y/ 1#J,79R>30I9;SHR#[^9JC.#W9W@_[A,CIR>L5V#C'\P>9LO"
MR8?U081FI.$\4=/T:S_)3J,M!6I8?/M0SVE+-E3/BI*@-^CJDC ,,7;J)+=!
M8OHH?@^74P@,#:B7-=1=_4B@3-:MEE0G]T<$.F+,);=L2E?L8-.7W.V8%$'Z
MCUZV2E8#O2*8KD2#:B5+2D$KEQ6%G% <:SS &5GP5,!1GJ:PU&2@91A[+$ZW
MP"T72;3>7ZO)X=J15&Z2E&-1NNDG@3]@='L:#J!R 370_R,OV3$[>_E9$C8%
M=X@K"I<CU<$UK9%>^/&OR P >/0<B< !0Y<B>G7$Q9#<.=&N);^X&J%7&"N)
M V)Q#D>\?G'E(\.1+"J@XICE1[Z1QZ(>;*6,.G10J9+(&/_Q/2D=M9(I&XIE
M8ANDIN.E]LR2C10RA!435(P>R=2,N5 G8]4Q!M>/OE#>#%4%%"@=5!0[D)>3
ME,=2+45F9N"QZ)LN+8Z/$$!;WMT"31\+D1X:%^2*C&LK*7>@G9ID4 2LY0\]
MK$ OMG>#(6GT<J3#T9@%A.H9UK:3&-!\_*G\7WD5JGPQC[EZ5TDH4D1!,>8>
MF+@3LK:?5VJM'<27\L^GE;?>E0&UKX*E0B98KL+HC=*=Y%7ZNZ1P]:T*6R0M
M6Q<VV"I@O.TKU92:?QB2F5DI5BM 'H>?M(OB)1=?=)-M-8/KWI^ E0AVA)XU
M.9\!=JBG?"ZRT#%"&6)*GK92Y/::^4O</C%\$N-)Z&,!U8+$P"T)KH3Q'AIQ
MHVMR58F:!Z(D3@:B@\2RR?Y$$G? Z,9$P;W].'M36O5:A4I9-4;Q?YE+B&'!
M9/W:@'$% -\2?<E$4=?XTJL,PY'HY[[+9.:64WY96 +PM@"AH>J$(W6%0Z,G
MM3%AUN$Y:>1PD1]'+S2AS1V/>E\"VDP:41A7BY^">2T2*O08U*VQ=LF4="2U
M-[)^N]J.,M3+F&AA('35<TV=,=2%&*1@[3>A0!3L5R.[R.D;@7F,>L)&$4I2
M:EL=FJD5G6TK.J+EE7%/Q<MJK:4"6HO8$%%-+G$%GF*A9$U%T/=-UP.R_E1X
M+^U/E5^FW372S%/<*BZ%AT5U2E*Q$%;8G)%,YI1WN9):(7I.9I^%CWA%=6;:
MFBJDAQYW9U;RF+HWEEPD$P*#WF<>&SBJ!%RZ$P7\3":EFLN"E6)_0^R]B8,^
MBD1PA:C$B4'J3%R?3I1((6&"%<E%O31QLXUCM!24-V:+^+^H4$*)/J[S$Y4(
MD*.>R(HF@5I0OZMH#^(F).(B(W6&*_7)XN=%2ZPM1_YSN;D,I/WF2' Y\=@L
MAR^]AF4RFNC@]N"UH[\M%WB%K=1Q@(=B"]/*DL*N&:#JQN-;Q]):0/K5JJO0
MG1S]\&N^%U%4F:H)3@*'LZQ:-2T15%SID26QD7#UPXXY*QPU&'I,JO1T$JEX
M*!?G?/J9U<?+CB(JN $%QY5S\,(7N77B8RL.C?A>%+6'YP,&9UGZYD0*FSS2
M7/.;">PTLE-03=(^RXFSA?9[7:XM//5-<>J;>.J;<'Y7 FP90A0HXX 7:K@J
MS![V9(Y5;3.\ZF<^T74M&9ND/EJZE(H1SI&(L=%W4N"-:(P!BY27=D2I.9@U
M\C0JUA@SQ603:E=YN''5-OR7CB7/WPJ>IH +*]P!0"IO66$\KLZ0QWIA4I@.
M<K>]#9 ;*32ANW0[B"I,H*G \K<B:7+]^623=?>9U 7ST0R8ND=)D0ZE6N(]
M(Y#QI(6(3&)9#PP8L9Z^K>Y:-@0E@F"C4(E)X0\7E)4'1S 24K'H:JGDQCG0
M-,L\Q0!B9L21&XW-?R'GS_$D@$KXW;#X35%(>D]5GEU?,M?\.::7=#+-=#C5
M>CKB2]*#(JFL<&,9-U)&#9:GR-W=5NZT]&12O1=UC9(S+0H<@7Y>T%(RI1>1
M3H 7.*E6+ : _LT"/U,7I:PL2AW(>1G^C:\L-+!QMG$+W"X=Q-F<N^,U(OIE
M=ZO>S?8B\9*K(J[E+%CU>!*%(H@-(#H40?'4H[)HAZ "9C?-!Q9@90TO0M6(
MHN895[E>K%^[!B?X8\-(NB1,\;$#4QTP!]TO^4O@HAUM$BY(W>-*!>FQ0>,\
MW=(*F^FI2Q;IKD+^8!I=[GR'C6ZCTVXWNMVCI'6E<)/)BMW*&^2XM.5I:FA(
M;4AXP5(]C])I'-K-RI*(5RK8$M^?I @=ES#0E?TDH4)5U,*L]";!YSRP"MR5
M+(M^)0Z+5.:(JNC&J0Q[NO9:YNRAYK!$_!CCK1Y+NJW++,T-I=*$C[Y(8TXA
M?\Q @[;S:SHT4CPFO;H&N6$M>5.7"+!!2%@YJL[UBO0Z&R/&$_C2#XH'6*">
M&@Z+NL1)0M XN9BBE0RANPZ2"Z:O0F18HY%GC:LN3&>EXFC&-\54SM:.JN_E
M14GI[FXPQRO)!D@A(=>^=RI]H*B3Q'" 2\*"4E2),?:/S$<H9B@:$*I242MN
M?F,.^MH]:G4*35M"U2@+N2Z4?"U'";9THN)$6(@[YOY7OO"(R/PNY>_;[6Z9
M%#3@3/V=*ICDI?)W9.Z&O."]78QFP9Z86)?7F2#_=E0CK/D.97S59OO(YZD6
MX)C'D99$RN]Z./.<E-U\Z%3NYL..KC[LSN4U2-I'FX)_#[!&%2]2NG/R,;&R
M\LH2IK/!^71!P^-D-+%)J.F.TI'_]OUB"K)<<6=E9.L#;>X23:X=1*:M0Z[M
MP_KH04S:M' ')AR^5I_BGU+K_2"09]!?Z&#V/WP@3[SI.D/OO<L&,(OH8G%R
M]K<$KV%0@-;4&0[MF&?1ZV='VNM:[XKD.5 3@%V:KIQ;[*>:_;3L[96^U!IG
M9%8TS^$G'Z;6C\@AX_X]*#R^8Q=A0I) 3*IM&.!#\;*+R*T(:2L,.65P(!H@
M$^^W-YV8-B7UB+&0OOS@O1$,^P>MAH'_O(T)3#XB]HT ROPBG&@&]2%)D9M%
MH?WI\"_AZKO'BA3)<K]0:8J2@$DA^YDUP256<%OG@/D;%^L<744C4_QKS<2U
MSG/6SC;^FGG0^J;U<QB@*JM3:J>%!;^[9_"OX^.WN94 ZR^DL51DLMEF8PG<
M^D)GI<W.Y'?(AN$]G#D52Q/%]7>C6ACSX7B7EU7\S&65Z8;KW*&/HI.R%,$M
MSI>7WMQUPE=#M2Q4VV:#-8-;>R@J&J/''(GBT@P\>(T*9?G6FKQG"S.>G;&4
M;1_+O9BOUG/6P :ZE6(#*^@YU_G&OU-B-=DB8A7700H]D:N#L(0Y\\M<V%D!
M7LU"I?M_:U]!I]4X;IUN>AEK!GJ*+ZS6>/:2U15N\W=/7;&1E2@VR\0VR9YV
M<@)F@+1QWG+<.#X[7QZ^:C&-)!!4</:WK5*NBU3G1W&:P10'T92O583:)D_"
MS9KQU):SG,5(>@]!K_7W30NUXTH)M17T]Z])AHV>)%,KYJ]',3]IM,Y/7I=B
M7LO8Q015%P25[4?DQ]LW(;LQV"LE9?=,?NZ!&_P3\WRZIX@L[4^5Z-F3B9ZU
M#[Q*/NGJ^,"59 G7(UGDZ3B;O?XXG>5H^52K>:>K38@7QP)7,"$^YG(G<VGQ
M^8STE>NZU1;*]CQX53%5SAKM,[!6SFIKI;96:FNEME9>IZB>4PAK=^>TBX#[
M:K=L(W"SO"]O\Z*O==AJ+0]>+<]J>5;+L]I W;#46T.">V;8)>Z"KA(,\[WF
MM^(;HYFF$!6W/JN4$%Y#5=W<VA?/D;:NAVO)\W$]LK'C19S^5/GTM?M_K^>K
MU8L7EQ>Z8@H-5@JHN$Y0'7?H_N?,''2ZG<;YR=&>^:'?KLEPKX.;KU<'JQ;;
M+B3SSXQSH7ZIS,:7<'MQ8<?>DD,NQ#P/M.S!=0"=Y5"U.W%_LL[W&/1*"807
MJ>TOE#!?&:^?,N%K=?Z%J_/'YXW6R?(!MOU6YPL%YXL7@W54K>J"<,]$W'3O
M]/1T\M4%X(J%7+=JRFR#MZSS[5H#W/CQ6#*)>.>*XQI/UVO5'Q<4JU56)+N-
MTZ/3QGE[WQS#M2)9165LGV&OE#Q]X9+2*VCX\;H4RM>>'7S0.ERAME;MEZC%
M2<5AGU><O!/52X;YJN&6RTQ0I@#T$:[C*88F5=&_K$/#@F^OM8WH(CUU=A-P
M74KE+'AG#?G#%[Z'%?:#N+/'!8@K)S2^.?SGPEU =]3#<C>;> 72V[.P#R/H
M4V$0B7Z]U"YZXH?P!_SD/B?1<:WU8^ACV\$$[]2>W!*(#Q#QU!.24SL^R^0C
M["PMFIU3T[Q!:F8GC$2/+1!5V/,7YA<K'YO/U&Q%-I:\ C4D@'<^,>H_[8/F
M<>WQ*,#.:P"9=!K C+]TCEN-5JM5W*X2V]$'#O9&%"T7&74L$JV8%)@5[!?\
MZ@_ZE>D$QA^F&]$>)\1[K1%O?=YGM4A")#XH))9UUS;A5,A.H:YC]AV7BF'*
M VK\%<$>#9ZQ@=F@D(6(9FN]NPOCWI^ Z7+6 :5 3=!IZ3OYA9EP@JEU9R-^
MHOW!,">3P']RL F]:M\4!,_4(U8T6S("%G?W5GW(\/328O YX$!@UV'#L;[I
M$HO@(\:PR_TD@'$#P+UA1TQV['30CO*#L E('1N>*;K=UDR@PDQ (YWZX$\7
M],FA=[AA,SBUZ&7GLB.K0UV&0>K&;7\#9C'G0;;<Y*9+S );+R-?P#Y_$],1
M/X+\]_A -, T8V;QW" Y[QED*<!!H\=,BU2T/@L?&5,%=Y-^@M2;6*@9XV1K
M#1M8P*'Q]U[OUF <E7T'SC$V] VQ 5(3&%.@<[41_(U]AIX5MX+U^5C,]]^2
MD3C>)$(>Q07?$%-1Q\QX$*$WQ",90\"%>'D$1(^US^6@I A%7MRA%/>,V0*E
M0M6QL'&R7"H7'4S1VX36F.*RV#8Q8;+&P6?VP%RCK2.!OXV[-KO^8QX O\]9
M\$#YCG)Y<I1N>A1:&*@YB+2X.?)27>M.YG5TE3.#9)RZ9]V3Z@C7;K4*&](M
MXOP4(YW_K1!31?Z!7&^\ O>IA*^;&A5D]<G<;@=ME/9Z8=L0IYW+CUODY\@U
M&ZR.*""VD*"]W=#%09Z-4%MX^"7-V X2EO<VP]-T-3#'_SY,%]-5]N]L[VTM
M'H@$I>M3-5^N^7+-EU\#7^ZD^+)DQL N&#9U![UZEJ))ZCRV)F8.O60[H-*'
MH(@CL_:2OQ*&7\SI2?]W !=F,)VUX\#Y5Q.Y4#Y.#F3TT8G!/\2=VFN94<N,
M6F;4,J.6&>4RHYN2&45. >"VPB?B.F&(3IT 5JG\,+89F@9[<CBZ2%%H,.#@
MZ KZ*W+(/P)B![FY\#G8.+<_,1QD_8_D&8K$=4EX6\D2=*;(\!"<$>%0 DPD
MWQLALT:>\U?$-." ?2%D8YR= ]J= 9"(%\92,$A]*[P^-HX><)(?^LK+7;BU
M]%A9>JS779K.B#K_6X4.VK5G<+Q5;#F!%8TQ%]EBXI"DO(EP+*2W37=(CA'1
MZ%2US) -_8":CCV"6@8$;SN# 1PT(&,7SQ-7,9DB?^:A<8U1#I\STJ T&/3)
M-,>IPU-3PG1X6/$(!PP.L8R9%$T%!,%%9T?-XT@0BO4*70W&UP^BB*.4 %.'
M4JH72OF$+-DD)7Z_@JEZ4)\)68+R(RP+1Y*XPK@>+-UP!D(\Z0^@U+!C;)"(
ML0 Z; PX8!0*E.:)%OEDXSZS;3@E^HMD%EF@$5*\$0^Y'@5M'Z>BH)^T%]'.
M^0>S8;E#+0IZ:%P!*,D$9>M3EI/,7I!Q&P R%;S%TZF-E8R )]GQ')GN :8A
MJK0VQF((IUK$6#"$86#*N S![5!HQ-M4 FK FC2[G2(U$_O/PC8&;.*##@GJ
M"<+3$#BWP$0>BNW(L"3Q>!(Q!CX:R@@BL%Y_PF0ZBX@ 65@X@OB;RBTJQ!]O
MR% *@O$X8F1QYXB,C[3HFL1P:H<,L6>H;U$ C<?$;:NX& -T Q29E6,ZBV\?
M&MJ!UH=%RE K25:>"HKCO%84D"0"*#:TDZ!:-.4LJ;V,I8W"'>FEX<; 8&$3
M<Y)2,'"&&O%8(@!./ZJ3<M.%G(]/BY7L(ZK&B31O=T!I]<)1+,;3.*9 YFS1
ME^3"9F5;<3KF#*.<!MJ,4;Y&?K^PQ^$U"^YO#!/O5#-:Y !W>#W.#.SJRNQ*
M[.$7TS.',JO 9R(;L,]<!S1;*40]DG_P  A"!TQ:9C>,/BB\^.0SG&$&^CJY
M)AM*V"+ZN4)_ ]4+R>)@!-/V)R$.(1(K1B;,8QJ8TQ2@#!>#*:E:E(>5Y# E
MDC\165.4ZC7JU%.3D<$DZ45#;(W<:6&2%Z5IQJ 64NA''_YC'.CI8+V[CYK6
M\U9BOOCU[Q-2//3W>W??4Z]O2&[@"INMDT8*T9]8/XR5NG9'?D%:R$4B1%!-
MNB'1=B-\),;!7=0/22W<$+1'IZUFI_4VK30!&"5:9VH- 'D8F);P&%V2SR=%
MEC>/\#6I*9M?!VC-S:/,.C*;O^$-UVDK!0;8%=P93X1%D- JZMX6"X3Y4*2P
M'QI; %H'%%@<%2)0J912TQO[-OH<B/-)70;TH(F9I-+WF<= _47XK30U4U*W
M]EUL)Y&#3_P0.L+WJ!E:\*9$F2.!T31J;H$"3@G?=$B,8>0(0VHBL(G(!9P+
M!;E .;=TLHV]E2G*15>E>%]H^,@%%?<V3)?[\&H8^':$$2P,+>#8L'K M.7Z
M7*PP5A#% FT\\;BR0<"8NJA>;*#A5<,GX2DB5)#2:<\'[I9IQ@30;;E%\M8A
MD[6,DUN'\1;I%A"^(LF)1"UFJ&'.V6AC12^<05-N2,9*'(,]X4MKV-WM&41S
M3BD/QC]-+S*#YU0>#KS4$501&XKF!$Z*,(U,8Q"YKO"+V\*0"QA0*I_((<&(
M<KBT?V&CE/:!1V."KH\0=[#/@-?3.8*O2X!HIV]-.%Q7:/"V!%>;# <93AOI
M//!D0Y#YEM&J:5:^E_$!T2T1NE@"QS9RLS8^&7K(Q@:N_YA1IHH#CJF8'$7W
M#'JF"9#Z4?A^X,#A_I /1&8"E4E$, F1S1N2^/5=Q)M#TYR\QUO!_&9P*Y+@
M:4D]S[Y+/+*)^G3K@RD!#/>>/84?7=_Z^?O__H__]6MFH,SCS^+?\2O$7>&/
M;VSPVYO;5OL'_(/4<N^WNC^ZXO.;WU^3-5$ABY"V$*E;IX;*VH+WV:L:D6>"
MZ$ &-=W@$>>\C\GCDP 5%2D[,RY731>;!""7G(D+H ]!EPG(PPF_LXGF!/SN
MT=QW(6E(@,7>&)02RTSIF9B GK(R*+_%0U-NG%+S!A@W#I6>5 !>XDZR!!\"
M 7D%+VV*;;9;S?_.F0$]#+P#=SO#]7YCP\A-:&8#,-PU_R<%@G20W5U>'!H7
M4E?640>X'?A^"&8W2^E>(BB/QKG(72<$%Y+*- *ARP0)+25$!]/Z0E0VC$D4
M\$@+; 61*TVF($87UQ920A"QF_:0[%DLF3!T25BR9\/VR;,@%T,ZBJ".-!$I
M5.#Y \648\T%TFD,/$2P'7B+0SOX -3<4K"1%8/7XE" 3>?)L<:QVZ21OV8U
M]]G5%RFRAZ7O7%X5):T$+Y&(/48_#.@=^*VXC:7N<U"*6 8-Y.'/HH!<_P5H
MD&N'@15"8H.&4"#NM8R8]*MS([YG5J C;,/)DIEGR9M_R^V:'K4PZ3#!"_^*
M/'&5)^9G1<ZKG@?ZI0O,!0\ :F<;9G+_]:Z7VAZUC<^@#F/DA*'SP\*X7: E
MS0BEMR4N,[K2F1^?:8#ZBZFKR$>ZCJQ.NZ(C-2/=3%*Q #'S%PRLYZ9MQPF/
MBJ(=XFTV6;4/\1U--0&PHCZC"\R6BO+I*\2=+5UB6S#5@)R<@PB/E*+P&8[$
MO="#9ZBOI/%:H\'C^TL0[NCQ^GO@/X8C2;@[5G;KQ(5%M%VU@X;8PMA4K:J^
M6XG]R]CTIJ>G(C"%T:' J)04Z1O9R<U1D )WC"2 EK%^8+Z-M2$4W2+XW$,'
M ;P:>RWZS_3(/Z/Q!,0,"(:;*# ^1AP&YAQU\"",)O0>CM9IM3O& ;F.$FC_
M>?/Q#A_0U?&&T+9#JAD1FC]!WMD/H+W)BA#*'\N>9%,'KC(1@0%&7 NF:YXK
M/;,"/3%Q0PF1B#^)^O"=Q)7#,AGLQ2AU&$\\94EH"?VS(?D%&S(HI8%BBVH;
MH.@])\*)Q#<R<R $+G6>%.BPZ-P>';6.XBTR@[X)*&_>/+F@B-(VP501%L5(
M%&[#AR4.I:H+:J])ZBMBT8I(/B%8H#V(^66&F1 J@!F!5*%>X6W^9TVQ$/N5
MW8Z,ZY!6,0+N0NFGF)K8=X24@\UU.!8 >4 +P??*0!+^--@3' 7VC,H*/.!]
M!/)9&4/\VL,[R*8UBE"/-I_%S+@-H/@]('F@S4@O9E7 G:B#5U& ]-?([V^[
MU3GHOSUHQP=1G12):#Z%*@G_T^D.P0>20Z2D]<6B4*B!7[AH@#]@O"Z9Z$ F
M#S9D,B/]2<88HGP$2J:982!(>6 @R+!$3$/ CBR73+S$L8KI4KX<B(*M%"5
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M,[3O8J.,7*[BA] 1WF#-JH,W)<H<"8RFOG,+M'VZN$&'Q!A&CK#:)@*;B%S
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M-JX5N8E$G5Z@(ETGPCC J T&_P,XVD(P:LQ7WMYYNU1*=4JO7R4/0PQ4)V+
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M,%L-@^[R'L5;\67_UD1B<R8FMD.YBRNI"2$V1]N2'R!Q$H%S&[ !"^#ONQ"
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MI(YW/*>JO(B8[L%T7%&!/3GT5/2W!%_XD@)O6DF\Z71W:%QID&H;H+J4,*R
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MY+ 7:='(0&DW!Y:25=?.3\JKFA_*TT-[>8FF [@&+>VS/!F[Y$SL9>($S!@
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MQ4M6 2G'ZDV!--GJXKM(@0KOP/-]QNSP4^"/;V!A!Y0HRH67>9'K@VZC>:9
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MMP5!ZX 963;=+IP(Q&4?&0;R ^XA HYU;'0!6!8W>*8IT9.:;PQ@NX6<PS@
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MF#U,>O_A ]G/PNOJ9[GBH=Q"J@ZIQ3/IW:,!!>I.4O*66G/J%:OY#>(P)A4
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M_9@,7ASCE9V$S15?'!\UF0!V)Y, 84,!<&V:7LM![3#E:7*1Y=X(/L;GR5&
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M$ $WX,AU;(CQWI(;D]LU9[0QA\&!D\S43>"1.UE44>=2@PD84"!44&Z'B2/
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M"8NL5%4FB.094-=<1[@G,W].G=*%.J;M@.$?^0$W][GN!S^,K:EI].)(^+]
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M]@X:IH'_.<Q0WO_-P.W_2G!1$C <,OC_[;UKCYM(]CC\>E?:[X"BR:HCT3V
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M]UB0_&F/ )SHZF0R4@?: 2 I=?#.2;,*.OCO0GB15*1;KH(T?5627N2JFG=
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MGC9BFKA0-@*5[<.Z!(C5#ZZ(MU^*,TZSJ8)4T"$Y"DMGLHQ2\IWI4@(/9[A
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M/&>^G*,>6<T+B\_X#XX=AXKS$$ :1]C31"L]MISC7(;8L"F++2W(:4@M><&
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MD8%:3@<BH#P_VA)8@ +Z&"QUGC\UX'P 7,$)9>*)&1N'\< DTSZ;'<9P2"W
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MB#\E)S8>B\EZDN+2V[PM:'RX<?%LWVF\8[Z]PUYJU[R>"C2OIW5L4@-\*-W
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M(/67C"C_R&%P 4G]%=W5(%9<SL.+W\1E8C82YXB^8#'):-!TB3Q@-)GK!EE
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MBZ,42TZ0: V#D9HLY$PC6YZ#$U2BIE#-@U_^'WK>?[?"?_[IA_\!4$L#!!0
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M-/]G1@EW"O8<)P[*6LHC8"AGP#.0'&+ )G0,%)2HX+S9^([C]-L=DJDB_\T
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M #W\H-,H67N@+&Q&"V_YW+8(Z*M;ET&CUW@%8ND=[@>*I7?H*XRE=V@K\6V
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M.Z6RM8B2E[M(]+EQ_\(8S'^MHO(T?'Y&Z?<,GQY?49 M4T0:-U27"(]$S6F
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M.OK52T-- 34,M':TC%N6M9YA25AD=4-L:9\+T%8;YLEX;KZ^G6MO0U][T7Y
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MX78&\B QH@/1X%01)XN +J*$$5 V7$)<8FIDZ8+D&L/UV:<T/M;XD58^7/T
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MCW46I#F+*QF5C[ZF'@6D%Q(9;F<N(D,C.I21FNRD0D+Q#0E&XVN?PM"$<2P
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M^ RV\71 WHV%]#0P.Q[O'<J=<&L\0;""5E]P+1U\UY7EJHVVJ#'*(G#9HG;
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M"(GF/NR"#"PRWM;  DB.ZC9.-Z0@8'N_2<@+S[;,/HE*7+!0*EAVT(!#4S8
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M&K/6S B :-&:F8>CF>$H^>$6JG#.?F)T#L"LR8VI':6[ANR.[1WJ>BWW=*M
M33TOW?)0_Q.N"]AM0<^=FL41O5A0.\B)E>%,;*<UP@X-)V 4FU845"A15L/D
M1_Z-/]A&%FX3U%-_3CLEBI:2304'AVITJ $/,G\]-/]H7-Q)W$HZ, 6K<O-C
MSQ;T#SE[8S  7<L:G(XWE3D8ICPO>U!MP!W; _,YL6\0R)%!J#$Z,0BMJ3GG
MQ_X/6XP+2>V7[N]9U>5Q=NCU:&<[2JQ$9B*-/5+3\F(H!U@-@3314^ML&RCE
MD6L6:-##$;LZ!S:=9\ 3ED_LOIH_+2[BX85Z<VZ:R9HN\6/?M;M,%U\GGC+0
MB%Q[PQ-/R9%=*%53V-IYOH"ZH0*9,F.L/D>9NM"[]CVYL7]N)BF#2AY-AOOS
MH:CT\^./%? 1A4Y&_E=M>)>WRG&.=HP@8I$8.2L!=2QJ+,JN)6T:SM<^S\KV
MH9GK#P&&(S.AF_C%!7-Z]J+%X<L)A]/ZV'N\KZZ,)'VL3!=//E8*&I%K;^9C
M94>VKT,UY=-<FIH^U@HS)K>*%0!@2=?)3O-CZ>3%L,&=W!)";&2B_L5"=PL?
MRX(>)*3S:P-7WS^0.Z=>TE3VT69@52T)IZ7M<\W :FC2(B^WZM(QX\.* K_L
MT)'70#./*M,)A_2W,5>>OM&<"24SE^HGGYV+ICPK&@LF^M?Q8HE^U&*T.J+M
M-*.2K2>6#UE49+2IGK0H#.I":/CEN3C:J@[VSIK'[1I6SC)3.A:O(FEV.*>L
M Z<ILP9:>);UH\18'5_;D6GGZ:_ZY-A& BQ5">C,=378QJ\4G&:TZFQ@11*F
MR%O5+PN*F:O&5T W<8J7])^=[VJ&VGE> YWBZ5@$58WLK((ZAW.^D> .#&@C
M1EQWJ6[$@<%"3@:YLMBN-G<951)RR)-7N%O#D4@S$R3577J^QI^+<SKV;R.R
MK3>89P70!-VA)6HCV5$E?9K3Z!L[K2D!L@<PN'IJ%21U[$J.?@64Z!%@JM^)
M3S8C^OJ[ A=4S01'ABIH=>1*.1,,GHF-<CL16F=X&K-AS]2MX;WPB 5KM?%L
MF-I8.NP-:V#'C)P,-9$W9G1-A%P+N($3'@$L)Y0/08)!.UG\2!4^PJ)'^M]F
M2W?R(;;RX(AL#P/!5AK;G:3?'MB%=/EL(:\BA_8B<FA?10X=6,&.DZ?+RG[0
M.N=JJ@+DN6GO#(TZTWPB;)TK#>?U,!SU5:5H.2D#BM[$J1  TW(_ _/ ZK,H
MFHU6GYE9C38V":/!.KBQ&2=#NS,95_\X@,C$NWT0,G$"6U!5P/%J/[1F0<-\
M#.D8P^";IRF-A_O3RH<0IP&5E7HU?H_W).N[_U;IXN$L4QH:D6NO?]*I,K*+
M(+%J;U62U;V[L<V(WI5U!T/3!H$]A%L<'<"27&49R2Y(!BD_V .8-.I\.M-[
M;&9S2$]!9%:@$SOCF06AV:+LP!L*9. 8&#;4 ,>RK?0\BLK%-A7IG2/YF!D=
MGWK8[2!O#DNTIG'@J#,CS:=PE$OQ$)TOVB9,4?NP7JRO/E[=KM'J&EW\M+C]
M\>H!+6_1PT^+^ZN?5C>75_</7Z.KOWQ:KO^JQ:9(BX*C2[:BY+\SWVK=XA?V
MU11[KN5XOB1(?2HR+KWY\%9JKS7">.M'G>+';*0TH#\:(ZN!?8UWU"W2B>$C
M7-"5Y"ND4&:YUA9%D<6/AP*LPIK<!5/E16QG!D,/A\>_4Q,"O]D=R?,8;-0]
MCBCRPCQKPYJNG/. &2B>"*O*K@N![-(IE@V&\;&%-H%+],<PV&@;4G/XB*0&
M)G*['2=HCD7"89YGN4K>I+S+GF *U)8:3=9Y0L#%$>N6<BV[Y-PD>%[[MY_3
M!.@;ZE/V8_A'FO(%7YV>W-(LL%,/ZRN,"&\8/I+^>(@C6#@H']#(I-L^.TY;
M"DMQO6-?M>EAIU53KK_LSXK&PN93FN$@B?^)HQ^#.+VAZX:5J!#!EO&3)+FL
M,:"$ D!4)>C>XS?,%E0HQ^$AX^4PMCAAQ6#6&=T2068OF!O#A8UXZ'Y3SF%5
MCOV2SCV%<\@Z#_X5NOE8N*C (_)]#!8FBJ.[6XC\<F)+-A2*N :(*C"J5L4!
M?VJKC)*O"@$""/Q0'UW.B2^=,\JGIXRM/.KK&F'])LX(4>;%6*31??RT+?)&
M=OKC^K$]!Y,Z0W@ZB-2"2O3ZFQTTZE)RIH?<17,LJ 'F#)V4^]5PVR[9U5#/
M$HX*<TKN.:=K-+9^'?#%)VT\.MY3+*2G@;E+[1S*N?_,X1*<+\&5=^BFP#45
ML@*LHW 8U Q'"[K"#9XP#SX2J5T;NG<>Y'%(E?(R3@ZT]02J]R* H8 C*T]N
M20WJF-WFWS?T7W_^E_(3^G^/08[__"__!U!+ P04    " "-B=A2I#=N?]%!
M  "O2P0 %0   &-H9G<M,C R,3 S,S%?<')E+GAM;.U]6W/C.++F^XDX_\';
MYV4W8JO*LGSM.+TGY%N/8ZI*/K9J>O=)09.0S6F*=//B*O>OWP2H"RGA2H)"
MBM,5,3U5-@#BRR]Q2V0F_O._?LRC@S>29F$2__+3X./A3P<D]I,@C)]_^:G(
M9Q_.?_JO__/O__:?_^/#AX/KV[NO!Q\.7O+\-?OYTZ?OW[]_#&9AG"51D4/U
M[*.?S#\=?/BP+'\U^7;PC[+IGP].SSX>5W^7$H]6.@B\G,!O/QT-/QT='@T.
M!D<_#PY_'IP=C+X<W'A93M+X8!+.2;5N\OJ>AL\O^<'_]/_7 :MUG<0QB2+R
M?G ;QE[LAUYT\+CLU_\^N(O]CP>C*#IXH-6R@P>2D?2-!!\7K49A_/O/]#]/
M7D8.0"1QQO[YRT\4[ +KCZ<T^IBDS]#/P^&G9>F?%L5_9&&M]/?ALNS@T__]
M\OG1?R%S[P-(*X?NK6MM?651;W!Q<?&)_1:*9N'/&:O_.?&9U#3Z=2 L0?_U
M85GL _W1A\'1A^'@XX\L^&DEC32)R .9'; ^_)R_OY)??LK"^6M$^\Y^]I*2
MV2\_^2^S[Q\H!X?#LHG_N$I G^Z]9RA(&_GV<+?J[A6PD5!^"-,5^NM/E>*?
MK'P]#DB<D>#2B^B''E\(R3.]KFQ4Z:X[]UY*XOR%Y*'O10WZME'?1D>O2>:G
MX2O5KO%LG#Y[<?@GT[51'%P661B3+!N_DI3]3%.>IFW:P/%8S.=>^CZ>/8;/
M<3@# <7YR/>3(LYA3KM/HM /B6;_==NRT>^[.,QAUKHOGJ#5\6Q&4OB$7C<%
M56WTZCX-WV""OH\\G\Q!Y?0ZM%W+1E\>2 2-!J#[^?LD]>+,\PUT45S;SC"?
MS\.<8M7L3JV"%;W/$__WER0*8,&]^:,(\W=-'>?4L]&?W[P4I)Q_#KVG,-+N
MS78M&WVY]<+T'UY4D"_$RXJ4&/ DJ&IGIGK*R!\%-'CSIM^A[5J[FS6[F#WM
MSJ)ZWYQX3Y%=%,L6=[\27Y/<"Z-.%N15T[MCQ@B-89.[0W'I9:$/(KT.X01"
M@J\DAP-(,B>?DRR[)^DXA>,5M/+X MNX#A W^GQG>Q@C@/(6NMC1&'5/6+G+
M_<TMT NK,Z/+;("8M6AY'V344UZ];G9%]U"2I"D)V*\:"-6PR6Y04'DEL3T(
MXO:ZV L:=598N;.=H5'WY"UTUL?52K#Z[7@V>2$;PC)=42U]JHO=L>$Z*:B\
M[MDK*#G\BNUT/L,/:ETD/W(",V2P["1M5-.(M38G)GZMS8C:[I*TCGMI2V46
MNHSX'Y^3MT\!":DM])#^A0KE\,/A8&&?^P_XT91];/24Y2G,Y\OV(N^)1.PK
MTZTRTXOAQ6!X487?7>^N$[^@>G,7SY)TSN3+=L>"CHJ*LSX?#T24C=)Z_[W4
M7WX _EKC:]L"NBCQZ969T3[X+V&THGJ6)G.5&!<?3@Q0%!ET*&$[;VJQ2U*8
M>W_Y"7[QNEP\/I=R$7::]9@)KQ&/2QIG7O;$&BVR#\^>]UIR2:(\6_YDD]3%
MCZ>/('DV(UQ%'AP39FRU&/T(,PZSRCJE8(X<TZNDK<ZT/JH>T%W%=IW,O3"6
M\+Q=N!3%T"'!^FSQ699@XM,[W"MZV8Z/81Q](?,GDLKHW2I<BN(" ;T2F@2\
MBL'P>3TVY36'?37YC(/<2Q-R+ROR.'&Y]MH@=Q,,G]R3'9*[O<NE/YE^B\,\
MN_'\%[JS##-JRAG/QC%A)['QK)1!U6B3C>( ?C]Y"=-@/'L@ 2%SNFPMMN23
M9.3#J0[JQF2[LE ?G/6%,71ZO$_JYEY6?&T^=:_-"S!,,+^])"MT-S](ZH<9
MQ7N;I%R(HV4A<I^&/HAP,#@YE.MK-U]C4CYSN3MMII$=2X.O<V<[7AYMG$CA
MQ$_N8%?(.[NHJI0$N)RN&AQ=M$$)3BZ'[,^^,#V!=A7,TB*E8I_A8W*;%C&;
M-2!\]BYV=S!I3-D]2<,DN(F#:SBM*;BKE2VQG^\WB7Q$HK&(F,X1H G*J['5
M5;. 35[1$OJ.+)4W<1[F[P_D.:3VO3C_ZLU%FL<KRNGK_BB>5/@"O1M\/#QL
M;\+:'QE)21?)"/'8+/%<%2F5UP-Y35)Z9*'FL4*T#Y)58:(X1VC"U>=6 4S
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MW(\T8EH QE9DL/-SO&JCVN)F='J*P:/0KA%'#-16'/&61KB+.RW/FR\D#WV
MU->0P].ALTFU6<@ABM?#M$4KFE:W(/4@*LUNR.$I!@L7AR@%HUP</2"W;<CA
M*0XKA8PEP6F6C^6OD,,RN.L4PR%6P)',/+$%XJ^0PX4L,!Q+FQ):!?%7R&'I
M 7F*PY!HNI#6 ?0FY'#CPDLGJ:=NU>D9#CL#ET"MZS\^)$N!B@@N^^H7'G#
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MG?LT>0L#.D=]RTA049.1GX=O;!+3R69IW!@@QV"E49,C/)$W FQIH^'\U [
M9V&NL,JL"P%X#!O*IJSQ=6 37E?+^:ZY72?JRVA* #^)_3 B-1O4)+$W=W3Q
M.2 $@PG0KKYU)RCWH;:"P^[M\@DPEEQ4=*BMEP)(&(X8W;'%.>OR)-"76%N;
M>98'QQ@NB7>E&GKB:!N_B^>VJ+,LO*<G&.X8=JTV>F+AJP\"3T+WN;U/3_Z5
M9IO6DNI+T'%W": 'QQB\7'8]#VE)I6UT,YY53-]T)]T!F=G__N64RE1 ?8FB
M%IIUU:G)555A(&(PZ34W?9N#;1UXC7G:&?E^6D"G0N\IC-C ,E*.[>H@,PQ6
MF:X41 2X]3LG6.8.?7.6E:L"D!Z&E<FN$<\4OJWH;N<Y]07 RXV<I?LF26/
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M%!@N0M1L\5F68&J;'!0#O<Q;C&$<"2=D<>%2%"B<Q\4T"7@5@W&?E%/DZ\U
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M#+?D9CLB!9H]?]CR6YR]$C^<A220/DTJ+ ]2<'E_K6"'0Z4<"(*W>H37DLM
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M_/N__7]02P$"% ,4    " "-B=A2,&ADP"(D 0 =@0T $0
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M+3(P,C$P,S,Q7VQA8BYX;6Q02P$"% ,4    " "-B=A2I#=N?]%!  "O2P0
M%0              @ %DT0$ 8VAF=RTR,#(Q,#,S,5]P<F4N>&UL4$L%!@
0   &  8 B@$  &@3 @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
